ABILIFY MAINTENA	2281	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	19
Dosage adjustments for patients taking CYP2D6 inhibitors, CYP3A4 inhibitors, or CYP3A4 inducers for greater than 14 days
1	0	5	B-TRI	Dosage
2	7	17	L-TRI	adjustments
3	19	21	O	for
4	23	30	O	patients
5	32	37	O	taking
6	39	44	B-UNK	CYP2D6
7	46	55	L-UNK	inhibitors
8	56	56	O	,
9	58	63	B-UNK	CYP3A4
10	65	74	L-UNK	inhibitors
11	75	75	O	,
12	77	78	O	or
13	80	85	B-UNK	CYP3A4
14	87	94	L-UNK	inducers
15	96	98	O	for
16	100	106	O	greater
17	108	111	O	than
18	113	114	O	14
19	116	119	O	days
NULL

ABILIFY MAINTENA	2282	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	44
Patients Taking 400 mg of ABILIFY MAINTENA Strong CYP2D6 or CYP3A4 inhibitors 300 mg CYP2D6 and CYP3A4 inhibitors 200 mg CYP3A4 inducers Avoid use Patients Taking 300 mg of ABILIFY MAINTENA Strong CYP2D6 or CYP3A4 inhibitors 200 mg CYP2D6 and CYP3A4 inhibitors 160 mg CYP3A4 inducers
1	0	7	O	Patients
2	9	14	O	Taking
3	16	18	O	400
4	20	21	O	mg
5	23	24	O	of
6	26	41	O	XXXXXXXX
7	43	48	O	Strong
8	50	55	O	CYP2D6
9	57	58	O	or
10	60	65	B-UNK	CYP3A4
11	67	76	L-UNK	inhibitors
12	78	80	O	300
13	82	83	O	mg
14	85	90	O	CYP2D6
15	92	94	O	and
16	96	101	O	CYP3A4
17	103	112	O	inhibitors
18	114	116	O	200
19	118	119	O	mg
20	121	126	B-UNK	CYP3A4
21	128	135	L-UNK	inducers
22	137	141	U-TRI	Avoid
23	143	145	O	use
24	147	154	O	Patients
25	156	161	O	Taking
26	163	165	O	300
27	167	168	O	mg
28	170	171	O	of
29	173	188	O	XXXXXXXX
30	190	195	O	Strong
31	197	202	O	CYP2D6
32	204	205	O	or
33	207	212	O	CYP3A4
34	214	223	O	inhibitors
35	225	227	O	200
36	229	230	O	mg
37	232	237	O	CYP2D6
38	239	241	O	and
39	243	248	O	CYP3A4
40	250	259	O	inhibitors
41	261	263	O	160
42	265	266	O	mg
43	268	273	O	CYP3A4
44	275	282	O	inducers
NULL

ABILIFY MAINTENA	2283	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	23
With concomitant use of ABILIFY MAINTENA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 14 days, reduce the ABILIFY MAINTENA dosage.
1	0	3	O	With
2	5	15	O	concomitant
3	17	19	O	use
4	21	22	O	of
5	24	39	O	XXXXXXXX
6	41	44	O	with
7	46	46	O	a
8	48	53	B-KIN	strong
9	55	60	I-KIN	CYP3A4
10	62	70	L-KIN	inhibitor
11	72	73	O	or
12	75	80	B-KIN	CYP2D6
13	82	90	L-KIN	inhibitor
14	92	94	O	for
15	96	99	O	more
16	101	104	O	than
17	106	107	O	14
18	109	112	O	days
19	113	113	O	,
20	115	120	O	reduce
21	122	124	O	the
22	126	141	O	XXXXXXXX
23	143	148	O	dosage
K/12:C54355 K/8:C54355

ABILIFY MAINTENA	2284	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	19
Strong CYP3A4 Inducers (e.g., carbamazepine) The concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole.
1	0	5	O	Strong
2	7	12	O	CYP3A4
3	14	21	O	Inducers
4	24	26	O	e.g
5	28	28	O	,
6	30	42	U-KIN	carbamazepine
7	45	47	O	The
8	49	59	O	concomitant
9	61	63	O	use
10	65	66	O	of
11	68	71	O	oral
12	73	84	O	XXXXXXXX
13	86	88	O	and
14	90	102	O	carbamazepine
15	104	112	B-TRI	decreased
16	114	116	I-TRI	the
17	118	125	L-TRI	exposure
18	127	128	O	of
19	130	141	O	XXXXXXXX
K/6:C54356

ABILIFY MAINTENA	2285	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	17
Avoid use of ABILIFY MAINTENA in combination with carbamazepine and other inducers of CYP3A4 for greater than 14days.
1	0	4	B-TRI	Avoid
2	6	8	L-TRI	use
3	10	11	O	of
4	13	28	O	XXXXXXXX
5	30	31	O	in
6	33	43	O	combination
7	45	48	O	with
8	50	62	U-UNK	carbamazepine
9	64	66	O	and
10	68	72	O	other
11	74	81	B-UNK	inducers
12	83	84	I-UNK	of
13	86	91	L-UNK	CYP3A4
14	93	95	O	for
15	97	103	O	greater
16	105	108	O	than
17	110	115	O	14days
NULL

ABILIFY MAINTENA	2286	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	21
Antihypertensive Drugs Due to its alpha adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents.
1	0	15	O	Antihypertensive
2	17	21	O	Drugs
3	23	25	O	Due
4	27	28	O	to
5	30	32	O	its
6	34	38	O	alpha
7	40	49	O	adrenergic
8	51	60	O	antagonism
9	61	61	O	,
10	63	74	O	XXXXXXXX
11	76	78	O	has
12	80	82	O	the
13	84	92	O	potential
14	94	95	O	to
15	97	103	B-EFF	enhance
16	105	107	I-EFF	the
17	109	114	I-EFF	effect
18	116	117	I-EFF	of
19	119	125	I-EFF	certain
20	127	142	I-EFF	antihypertensive
21	144	149	L-EFF	agents
NULL

ABILIFY MAINTENA	2287	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	7
Monitor blood pressure and adjust dose accordingly.
1	0	6	O	Monitor
2	8	12	O	blood
3	14	21	O	pressure
4	23	25	O	and
5	27	32	O	adjust
6	34	37	O	dose
7	39	49	O	accordingly
NULL

ABILIFY MAINTENA	2288	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	26
Benzodiazepines (e.g., lorazepam) The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone.
1	0	14	U-DYN	Benzodiazepines
2	17	19	O	e.g
3	21	21	O	,
4	23	31	U-DYN	lorazepam
5	34	36	O	The
6	38	46	B-EFF	intensity
7	48	49	I-EFF	of
8	51	58	I-EFF	sedation
9	60	62	I-EFF	was
10	64	70	L-EFF	greater
11	72	75	O	with
12	77	79	O	the
13	81	91	O	combination
14	93	94	O	of
15	96	99	O	oral
16	101	112	O	XXXXXXXX
17	114	116	O	and
18	118	126	O	lorazepam
19	128	129	O	as
20	131	138	O	compared
21	140	141	O	to
22	143	146	O	that
23	148	155	O	observed
24	157	160	O	with
25	162	173	O	XXXXXXXX
26	175	179	O	alone
D/1:6:1 D/4:6:1

ABILIFY MAINTENA	2289	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	17
The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone.
1	0	2	O	The
2	4	14	O	orthostatic
3	16	26	O	hypotension
4	28	35	O	observed
5	37	39	O	was
6	41	47	O	greater
7	49	52	O	with
8	54	56	O	the
9	58	68	O	combination
10	70	71	O	as
11	73	80	O	compared
12	82	83	O	to
13	85	88	O	that
14	90	97	O	observed
15	99	102	O	with
16	104	112	U-DYN	lorazepam
17	114	118	O	alone
NULL

ABILIFY MAINTENA	2290	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	26
Based on pharmacokinetic studies with oral aripiprazole, no dosage adjustment of ABILIFY MAINTENA is required when administered concomitantly with famotidine, valproate, lithium, lorazepam.
1	0	4	O	Based
2	6	7	O	on
3	9	23	O	pharmacokinetic
4	25	31	O	studies
5	33	36	O	with
6	38	41	O	oral
7	43	54	O	XXXXXXXX
8	55	55	O	,
9	57	58	O	no
10	60	65	O	dosage
11	67	76	O	adjustment
12	78	79	O	of
13	81	96	O	XXXXXXXX
14	98	99	O	is
15	101	108	O	required
16	110	113	O	when
17	115	126	O	administered
18	128	140	O	concomitantly
19	142	145	O	with
20	147	156	O	famotidine
21	157	157	O	,
22	159	167	O	valproate
23	168	168	O	,
24	170	176	O	lithium
25	177	177	O	,
26	179	187	O	lorazepam
NULL

ABILIFY MAINTENA	2291	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	45
In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when co-administered with ABILIFY MAINTENA.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	no
5	16	21	O	dosage
6	23	32	O	adjustment
7	34	35	O	is
8	37	45	O	necessary
9	47	49	O	for
10	51	60	O	substrates
11	62	63	O	of
12	65	70	O	CYP2D6
13	73	75	O	e.g
14	77	77	O	,
15	79	94	O	dextromethorphan
16	95	95	O	,
17	97	106	O	fluoxetine
18	107	107	O	,
19	109	118	O	paroxetine
20	119	119	O	,
21	121	122	O	or
22	124	134	O	venlafaxine
23	136	136	O	,
24	138	143	O	CYP2C9
25	146	148	O	e.g
26	150	150	O	,
27	152	159	O	warfarin
28	161	161	O	,
29	163	169	O	CYP2C19
30	172	174	O	e.g
31	176	176	O	,
32	178	187	O	omeprazole
33	188	188	O	,
34	190	197	O	warfarin
35	199	199	O	,
36	201	202	O	or
37	204	209	O	CYP3A4
38	212	214	O	e.g
39	216	216	O	,
40	218	233	O	dextromethorphan
41	236	239	O	when
42	241	242	O	co
43	244	255	O	administered
44	257	260	O	with
45	262	277	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2292	34073-7	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	23
Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when co-administered with ABILIFY MAINTENA.
1	0	11	O	Additionally
2	12	12	O	,
3	14	15	O	no
4	17	22	O	dosage
5	24	33	O	adjustment
6	35	36	O	is
7	38	46	O	necessary
8	48	50	O	for
9	52	60	O	valproate
10	61	61	O	,
11	63	69	O	lithium
12	70	70	O	,
13	72	82	O	lamotrigine
14	83	83	O	,
15	85	93	O	lorazepam
16	94	94	O	,
17	96	97	O	or
18	99	108	O	sertraline
19	110	113	O	when
20	115	116	O	co
21	118	129	O	administered
22	131	134	O	with
23	136	151	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2293	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	17
The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	38	O	XXXXXXXX
7	40	41	O	in
8	43	45	O	the
9	47	55	O	treatment
10	57	58	O	of
11	60	72	O	schizophrenia
12	74	76	O	and
13	78	84	O	bipolar
14	86	86	O	I
15	88	95	O	disorder
16	97	98	O	is
17	100	106	O	unknown
NULL

ABILIFY MAINTENA	2294	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	29
The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors.
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	27	O	XXXXXXXX
5	29	33	O	could
6	35	36	O	be
7	38	45	O	mediated
8	47	53	O	through
9	55	55	O	a
10	57	67	O	combination
11	69	70	O	of
12	72	78	O	partial
13	80	86	O	agonist
14	88	95	O	activity
15	97	98	O	at
16	100	107	O	dopamine
17	109	110	O	D2
18	112	114	O	and
19	116	124	O	serotonin
20	126	126	O	5
21	128	131	O	HT1A
22	133	141	O	receptors
23	143	145	O	and
24	147	156	O	antagonist
25	158	165	O	activity
26	167	168	O	at
27	170	170	O	5
28	172	175	O	HT2A
29	177	185	O	receptors
NULL

ABILIFY MAINTENA	2295	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	79
Aripiprazole exhibits high affinity for dopamine D2 and D3 (Kis 0.34 and 0.8 nM respectively), serotonin 5-HT1A and 5-HT2A receptors (Kis 1.7 and 3.4 nM respectively), moderate affinity for dopamine D4, serotonin 5-HT2C and 5-HT7, alpha1-adrenergic and histamine H1 receptors (Kis 44 nM, 15 nM, 39 nM, 57 nM, and 61 nM, respectively), and moderate affinity for the serotonin reuptake site (Ki 98 nM).
1	0	11	O	XXXXXXXX
2	13	20	O	exhibits
3	22	25	O	high
4	27	34	O	affinity
5	36	38	O	for
6	40	47	O	dopamine
7	49	50	O	D2
8	52	54	O	and
9	56	57	O	D3
10	60	62	O	Kis
11	64	67	O	0.34
12	69	71	O	and
13	73	75	O	0.8
14	77	78	O	nM
15	80	91	O	respectively
16	93	93	O	,
17	95	103	O	serotonin
18	105	105	O	5
19	107	110	O	HT1A
20	112	114	O	and
21	116	116	O	5
22	118	121	O	HT2A
23	123	131	O	receptors
24	134	136	O	Kis
25	138	140	O	1.7
26	142	144	O	and
27	146	148	O	3.4
28	150	151	O	nM
29	153	164	O	respectively
30	166	166	O	,
31	168	175	O	moderate
32	177	184	O	affinity
33	186	188	O	for
34	190	197	O	dopamine
35	199	200	O	D4
36	201	201	O	,
37	203	211	O	serotonin
38	213	213	O	5
39	215	218	O	HT2C
40	220	222	O	and
41	224	224	O	5
42	226	228	O	HT7
43	229	229	O	,
44	231	236	O	alpha1
45	238	247	O	adrenergic
46	249	251	O	and
47	253	261	O	histamine
48	263	264	O	H1
49	266	274	O	receptors
50	277	279	O	Kis
51	281	282	O	44
52	284	285	O	nM
53	286	286	O	,
54	288	289	O	15
55	291	292	O	nM
56	293	293	O	,
57	295	296	O	39
58	298	299	O	nM
59	300	300	O	,
60	302	303	O	57
61	305	306	O	nM
62	307	307	O	,
63	309	311	O	and
64	313	314	O	61
65	316	317	O	nM
66	318	318	O	,
67	320	331	O	respectively
68	333	333	O	,
69	335	337	O	and
70	339	346	O	moderate
71	348	355	O	affinity
72	357	359	O	for
73	361	363	O	the
74	365	373	O	serotonin
75	375	382	O	reuptake
76	384	387	O	site
77	390	391	O	Ki
78	393	394	O	98
79	396	397	O	nM
NULL

ABILIFY MAINTENA	2296	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	10
Aripiprazole has no appreciable affinity for cholinergic muscarinic receptors (IC50>1000nM).
1	0	11	O	XXXXXXXX
2	13	15	O	has
3	17	18	O	no
4	20	30	O	appreciable
5	32	39	O	affinity
6	41	43	O	for
7	45	55	O	cholinergic
8	57	66	O	muscarinic
9	68	76	O	receptors
10	79	89	O	IC50>1000nM
NULL

ABILIFY MAINTENA	2297	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	42
Actions at receptors other than D2, 5-HT1A, and 5-HT2A may explain some of the other adverse reactions of aripiprazole (e.g., the orthostatic hypotension observed with aripiprazole may be explained by its antagonist activity at adrenergic alpha1 receptors).
1	0	6	O	Actions
2	8	9	O	at
3	11	19	O	receptors
4	21	25	O	other
5	27	30	O	than
6	32	33	O	D2
7	34	34	O	,
8	36	36	O	5
9	38	41	O	HT1A
10	42	42	O	,
11	44	46	O	and
12	48	48	O	5
13	50	53	O	HT2A
14	55	57	O	may
15	59	65	O	explain
16	67	70	O	some
17	72	73	O	of
18	75	77	O	the
19	79	83	O	other
20	85	91	O	adverse
21	93	101	O	reactions
22	103	104	O	of
23	106	117	O	XXXXXXXX
24	120	122	O	e.g
25	124	124	O	,
26	126	128	O	the
27	130	140	O	orthostatic
28	142	152	O	hypotension
29	154	161	O	observed
30	163	166	O	with
31	168	179	O	XXXXXXXX
32	181	183	O	may
33	185	186	O	be
34	188	196	O	explained
35	198	199	O	by
36	201	203	O	its
37	205	214	O	antagonist
38	216	223	O	activity
39	225	226	O	at
40	228	237	O	adrenergic
41	239	244	O	alpha1
42	246	254	O	receptors
NULL

ABILIFY MAINTENA	2298	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	31
Alcohol There was no significant difference between oral aripiprazole co-administered with ethanol and placebo co-administered with ethanol on performance of gross motor skills or stimulus response in healthy subjects.
1	0	6	O	Alcohol
2	8	12	O	There
3	14	16	O	was
4	18	19	O	no
5	21	31	O	significant
6	33	42	O	difference
7	44	50	O	between
8	52	55	O	oral
9	57	68	O	XXXXXXXX
10	70	71	O	co
11	73	84	O	administered
12	86	89	O	with
13	91	97	O	ethanol
14	99	101	O	and
15	103	109	O	placebo
16	111	112	O	co
17	114	125	O	administered
18	127	130	O	with
19	132	138	O	ethanol
20	140	141	O	on
21	143	153	O	performance
22	155	156	O	of
23	158	162	O	gross
24	164	168	O	motor
25	170	175	O	skills
26	177	178	O	or
27	180	187	O	stimulus
28	189	196	O	response
29	198	199	O	in
30	201	207	O	healthy
31	209	216	O	subjects
NULL

ABILIFY MAINTENA	2299	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	16
As with most psychoactive medications, patients should be advised to avoid alcohol while taking ABILIFY MAINTENA.
1	0	1	O	As
2	3	6	O	with
3	8	11	O	most
4	13	24	O	psychoactive
5	26	36	O	medications
6	37	37	O	,
7	39	46	O	patients
8	48	53	O	should
9	55	56	O	be
10	58	64	O	advised
11	66	67	O	to
12	69	73	U-TRI	avoid
13	75	81	U-UNK	alcohol
14	83	87	O	while
15	89	94	O	taking
16	96	111	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2300	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	53
ABILIFY MAINTENA activity is presumably primarily due to the parent drug, aripiprazole, and to a lesser extent, to its major metabolite, dehydro-aripiprazole, which has been shown to have affinities for D2 receptors similar to the parent drug and represents about 29% of the parent drug exposure in plasma.
1	0	15	O	XXXXXXXX
2	17	24	O	activity
3	26	27	O	is
4	29	38	O	presumably
5	40	48	O	primarily
6	50	52	O	due
7	54	55	O	to
8	57	59	O	the
9	61	66	O	parent
10	68	71	O	drug
11	72	72	O	,
12	74	85	O	XXXXXXXX
13	86	86	O	,
14	88	90	O	and
15	92	93	O	to
16	95	95	O	a
17	97	102	O	lesser
18	104	109	O	extent
19	110	110	O	,
20	112	113	O	to
21	115	117	O	its
22	119	123	O	major
23	125	134	O	metabolite
24	135	135	O	,
25	137	143	O	dehydro
26	145	156	O	XXXXXXXX
27	157	157	O	,
28	159	163	O	which
29	165	167	O	has
30	169	172	O	been
31	174	178	O	shown
32	180	181	O	to
33	183	186	O	have
34	188	197	O	affinities
35	199	201	O	for
36	203	204	O	D2
37	206	214	O	receptors
38	216	222	O	similar
39	224	225	O	to
40	227	229	O	the
41	231	236	O	parent
42	238	241	O	drug
43	243	245	O	and
44	247	256	O	represents
45	258	262	O	about
46	264	266	O	29%
47	268	269	O	of
48	271	273	O	the
49	275	280	O	parent
50	282	285	O	drug
51	287	294	O	exposure
52	296	297	O	in
53	299	304	O	plasma
NULL

ABILIFY MAINTENA	2301	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	20
Aripiprazole absorption into the systemic circulation is slow and prolonged following intramuscular injection due to low solubility of aripiprazole particles.
1	0	11	O	XXXXXXXX
2	13	22	O	absorption
3	24	27	O	into
4	29	31	O	the
5	33	40	O	systemic
6	42	52	O	circulation
7	54	55	O	is
8	57	60	O	slow
9	62	64	O	and
10	66	74	O	prolonged
11	76	84	O	following
12	86	98	O	intramuscular
13	100	108	O	injection
14	110	112	O	due
15	114	115	O	to
16	117	119	O	low
17	121	130	O	solubility
18	132	133	O	of
19	135	146	O	XXXXXXXX
20	148	156	O	particles
NULL

ABILIFY MAINTENA	2302	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	49
Following a single dose administration of ABILIFY MAINTENA in the deltoid and gluteal muscle, the extent of absorption (AUCt, AUC*) of aripiprazole was similar for both injection sites, but the rate of absorption (Cmax) was 31% higher following administration to the deltoid compared to the gluteal site.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	22	O	dose
5	24	37	O	administration
6	39	40	O	of
7	42	57	O	XXXXXXXX
8	59	60	O	in
9	62	64	O	the
10	66	72	O	deltoid
11	74	76	O	and
12	78	84	O	gluteal
13	86	91	O	muscle
14	92	92	O	,
15	94	96	O	the
16	98	103	O	extent
17	105	106	O	of
18	108	117	O	absorption
19	120	123	O	AUCt
20	124	124	O	,
21	126	129	O	AUC*
22	132	133	O	of
23	135	146	O	XXXXXXXX
24	148	150	O	was
25	152	158	O	similar
26	160	162	O	for
27	164	167	O	both
28	169	177	O	injection
29	179	183	O	sites
30	184	184	O	,
31	186	188	O	but
32	190	192	O	the
33	194	197	O	rate
34	199	200	O	of
35	202	211	O	absorption
36	214	217	O	Cmax
37	220	222	O	was
38	224	226	O	31%
39	228	233	O	higher
40	235	243	O	following
41	245	258	O	administration
42	260	261	O	to
43	263	265	O	the
44	267	273	O	deltoid
45	275	282	O	compared
46	284	285	O	to
47	287	289	O	the
48	291	297	O	gluteal
49	299	302	O	site
NULL

ABILIFY MAINTENA	2303	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	16
However, at steady state, AUC and Cmax were similar for both sites of injection.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	at
4	12	17	O	steady
5	19	23	O	state
6	24	24	O	,
7	26	28	O	AUC
8	30	32	O	and
9	34	37	O	Cmax
10	39	42	O	were
11	44	50	O	similar
12	52	54	O	for
13	56	59	O	both
14	61	65	O	sites
15	67	68	O	of
16	70	78	O	injection
NULL

ABILIFY MAINTENA	2304	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	35
Following multiple intramuscular doses, the plasma concentrations of aripiprazole gradually rise to maximum plasma concentrations at a median Tmax of 5 - 7 days for the gluteal muscle and 4 days for the deltoid muscle.
1	0	8	O	Following
2	10	17	O	multiple
3	19	31	O	intramuscular
4	33	37	O	doses
5	38	38	O	,
6	40	42	O	the
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	80	O	XXXXXXXX
11	82	90	O	gradually
12	92	95	O	rise
13	97	98	O	to
14	100	106	O	maximum
15	108	113	O	plasma
16	115	128	O	concentrations
17	130	131	O	at
18	133	133	O	a
19	135	140	O	median
20	142	145	O	Tmax
21	147	148	O	of
22	150	150	O	5
23	154	154	O	7
24	156	159	O	days
25	161	163	O	for
26	165	167	O	the
27	169	175	O	gluteal
28	177	182	O	muscle
29	184	186	O	and
30	188	188	O	4
31	190	193	O	days
32	195	197	O	for
33	199	201	O	the
34	203	209	O	deltoid
35	211	216	O	muscle
NULL

ABILIFY MAINTENA	2305	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	35
After gluteal administration, the mean apparent aripiprazole terminal elimination half-life was 29.9 days and 46.5 days after multiple injections for every 4-week injection of ABILIFY MAINTENA 300 mg and 400 mg, respectively.
1	0	4	O	After
2	6	12	O	gluteal
3	14	27	O	administration
4	28	28	O	,
5	30	32	O	the
6	34	37	O	mean
7	39	46	O	apparent
8	48	59	O	XXXXXXXX
9	61	68	O	terminal
10	70	80	O	elimination
11	82	85	O	half
12	87	90	O	life
13	92	94	O	was
14	96	99	O	29.9
15	101	104	O	days
16	106	108	O	and
17	110	113	O	46.5
18	115	118	O	days
19	120	124	O	after
20	126	133	O	multiple
21	135	144	O	injections
22	146	148	O	for
23	150	154	O	every
24	156	156	O	4
25	158	161	O	week
26	163	171	O	injection
27	173	174	O	of
28	176	191	O	XXXXXXXX
29	193	195	O	300
30	197	198	O	mg
31	200	202	O	and
32	204	206	O	400
33	208	209	O	mg
34	210	210	O	,
35	212	223	O	respectively
NULL

ABILIFY MAINTENA	2306	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	18
Steady state concentrations for the typical subject were attained by the fourth dose for both sites of administration.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	30	O	for
5	32	34	O	the
6	36	42	O	typical
7	44	50	O	subject
8	52	55	O	were
9	57	64	O	attained
10	66	67	O	by
11	69	71	O	the
12	73	78	O	fourth
13	80	83	O	dose
14	85	87	O	for
15	89	92	O	both
16	94	98	O	sites
17	100	101	O	of
18	103	116	O	administration
NULL

ABILIFY MAINTENA	2307	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	24
Approximate dose-proportional increases in aripiprazole and dehydro-aripiprazole exposure were observed after every four week ABILIFY MAINTENA injections of 300 mg and 400 mg.
1	0	10	O	Approximate
2	12	15	O	dose
3	17	28	O	proportional
4	30	38	O	increases
5	40	41	O	in
6	43	54	O	XXXXXXXX
7	56	58	O	and
8	60	66	O	dehydro
9	68	79	O	XXXXXXXX
10	81	88	O	exposure
11	90	93	O	were
12	95	102	O	observed
13	104	108	O	after
14	110	114	O	every
15	116	119	O	four
16	121	124	O	week
17	126	141	O	XXXXXXXX
18	143	152	O	injections
19	154	155	O	of
20	157	159	O	300
21	161	162	O	mg
22	164	166	O	and
23	168	170	O	400
24	172	173	O	mg
NULL

ABILIFY MAINTENA	2308	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	16
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
1	0	10	O	Elimination
2	12	13	O	of
3	15	26	O	XXXXXXXX
4	28	29	O	is
5	31	36	O	mainly
6	38	44	O	through
7	46	52	O	hepatic
8	54	63	O	metabolism
9	65	73	O	involving
10	75	77	O	two
11	79	82	O	P450
12	84	91	O	isozymes
13	92	92	O	,
14	94	99	O	CYP2D6
15	101	103	O	and
16	105	110	O	CYP3A4
NULL

ABILIFY MAINTENA	2309	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	23
Aripiprazole is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	18	O	not
4	20	20	O	a
5	22	30	O	substrate
6	32	33	O	of
7	35	40	O	CYP1A1
8	41	41	O	,
9	43	48	O	CYP1A2
10	49	49	O	,
11	51	56	O	CYP2A6
12	57	57	O	,
13	59	64	O	CYP2B6
14	65	65	O	,
15	67	72	O	CYP2C8
16	73	73	O	,
17	75	80	O	CYP2C9
18	81	81	O	,
19	83	89	O	CYP2C19
20	90	90	O	,
21	92	93	O	or
22	95	100	O	CYP2E1
23	102	108	O	enzymes
NULL

ABILIFY MAINTENA	2310	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	7
Aripiprazole also does not undergo direct glucuronidation.
1	0	11	O	XXXXXXXX
2	13	16	O	also
3	18	21	O	does
4	23	25	O	not
5	27	33	O	undergo
6	35	40	O	direct
7	42	56	O	glucuronidation
NULL

ABILIFY MAINTENA	2311	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	13
Drug Interaction Studies No specific drug interaction studies have been performed with ABILIFY MAINTENA.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	23	O	Studies
4	25	26	O	No
5	28	35	O	specific
6	37	40	O	drug
7	42	52	O	interaction
8	54	60	O	studies
9	62	65	O	have
10	67	70	O	been
11	72	80	O	performed
12	82	85	O	with
13	87	102	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2312	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	10
The information below is obtained from studies with oral aripiprazole.
1	0	2	O	The
2	4	14	O	information
3	16	20	O	below
4	22	23	O	is
5	25	32	O	obtained
6	34	37	O	from
7	39	45	O	studies
8	47	50	O	with
9	52	55	O	oral
10	57	68	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2313	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	22
Effects of other drugs on the exposures of aripiprazole and dehydro-aripiprazole are summarized in Figure 19 and Figure 20, respectively.
1	0	6	O	Effects
2	8	9	O	of
3	11	15	O	other
4	17	21	O	drugs
5	23	24	O	on
6	26	28	O	the
7	30	38	O	exposures
8	40	41	O	of
9	43	54	O	XXXXXXXX
10	56	58	O	and
11	60	66	O	dehydro
12	68	79	O	XXXXXXXX
13	81	83	O	are
14	85	94	O	summarized
15	96	97	O	in
16	99	104	O	Figure
17	106	107	O	19
18	109	111	O	and
19	113	118	O	Figure
20	120	121	O	20
21	122	122	O	,
22	124	135	O	respectively
NULL

ABILIFY MAINTENA	2314	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	33
Based on simulation, a 4.5-fold increase in mean Cmax and AUC values at steady-state is expected when extensive metabolizers of CYP2D6 are administered with both strong CYP2D6 and CYP3A4 inhibitors.
1	0	4	O	Based
2	6	7	O	on
3	9	18	O	simulation
4	19	19	O	,
5	21	21	O	a
6	23	25	O	4.5
7	27	30	O	fold
8	32	39	O	increase
9	41	42	O	in
10	44	47	O	mean
11	49	52	O	Cmax
12	54	56	O	and
13	58	60	O	AUC
14	62	67	O	values
15	69	70	O	at
16	72	77	O	steady
17	79	83	O	state
18	85	86	O	is
19	88	95	O	expected
20	97	100	O	when
21	102	110	O	extensive
22	112	123	O	metabolizers
23	125	126	O	of
24	128	133	O	CYP2D6
25	135	137	O	are
26	139	150	O	administered
27	152	155	O	with
28	157	160	O	both
29	162	167	O	strong
30	169	174	O	CYP2D6
31	176	178	O	and
32	180	185	O	CYP3A4
33	187	196	O	inhibitors
NULL

ABILIFY MAINTENA	2315	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	29
After oral administration, a 3-fold increase in mean Cmax and AUC values at steady-state is expected in poor metabolizers of CYP2D6 administered with strong CYP3A4 inhibitors.
1	0	4	O	After
2	6	9	O	oral
3	11	24	O	administration
4	25	25	O	,
5	27	27	O	a
6	29	29	O	3
7	31	34	O	fold
8	36	43	O	increase
9	45	46	O	in
10	48	51	O	mean
11	53	56	O	Cmax
12	58	60	O	and
13	62	64	O	AUC
14	66	71	O	values
15	73	74	O	at
16	76	81	O	steady
17	83	87	O	state
18	89	90	O	is
19	92	99	O	expected
20	101	102	O	in
21	104	107	O	poor
22	109	120	O	metabolizers
23	122	123	O	of
24	125	130	O	CYP2D6
25	132	143	O	administered
26	145	148	O	with
27	150	155	O	strong
28	157	162	O	CYP3A4
29	164	173	O	inhibitors
NULL

ABILIFY MAINTENA	2316	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	38
Figure 19: The effects of other drugs on aripiprazole pharmacokinetics Figure 20: The effects of other drugs on dehydro-aripiprazole pharmacokinetics The effects of ABILIFY on the exposures of other drugs are summarized in Figure 21.
1	0	5	O	Figure
2	7	8	O	19
3	9	9	O	:
4	11	13	O	The
5	15	21	O	effects
6	23	24	O	of
7	26	30	O	other
8	32	36	O	drugs
9	38	39	O	on
10	41	52	O	XXXXXXXX
11	54	69	O	pharmacokinetics
12	71	76	O	Figure
13	78	79	O	20
14	80	80	O	:
15	82	84	O	The
16	86	92	O	effects
17	94	95	O	of
18	97	101	O	other
19	103	107	O	drugs
20	109	110	O	on
21	112	118	O	dehydro
22	120	131	O	XXXXXXXX
23	133	148	O	pharmacokinetics
24	150	152	O	The
25	154	160	O	effects
26	162	163	O	of
27	165	171	O	ABILIFY
28	173	174	O	on
29	176	178	O	the
30	180	188	O	exposures
31	190	191	O	of
32	193	197	O	other
33	199	203	O	drugs
34	205	207	O	are
35	209	218	O	summarized
36	220	221	O	in
37	223	228	O	Figure
38	230	231	O	21
NULL

ABILIFY MAINTENA	2317	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	56
A population PK analysis in patients with major depressive disorder showed no substantial change in plasma concentrations of fluoxetine (20 mg/day or 40 mg/day), paroxetine CR (37.5 mg/day or 50 mg/day), or sertraline (100 mg/day or 150 mg/day) dosed to steady-state.
1	0	0	O	A
2	2	11	O	population
3	13	14	O	PK
4	16	23	O	analysis
5	25	26	O	in
6	28	35	O	patients
7	37	40	O	with
8	42	46	O	major
9	48	57	O	depressive
10	59	66	O	disorder
11	68	73	O	showed
12	75	76	O	no
13	78	88	O	substantial
14	90	95	O	change
15	97	98	O	in
16	100	105	O	plasma
17	107	120	O	concentrations
18	122	123	O	of
19	125	134	O	fluoxetine
20	137	138	O	20
21	140	141	O	mg
22	142	142	O	/
23	143	145	O	day
24	147	148	O	or
25	150	151	O	40
26	153	154	O	mg
27	155	155	O	/
28	156	158	O	day
29	160	160	O	,
30	162	171	O	paroxetine
31	173	174	O	CR
32	177	180	O	37.5
33	182	183	O	mg
34	184	184	O	/
35	185	187	O	day
36	189	190	O	or
37	192	193	O	50
38	195	196	O	mg
39	197	197	O	/
40	198	200	O	day
41	202	202	O	,
42	204	205	O	or
43	207	216	O	sertraline
44	219	221	O	100
45	223	224	O	mg
46	225	225	O	/
47	226	228	O	day
48	230	231	O	or
49	233	235	O	150
50	237	238	O	mg
51	239	239	O	/
52	240	242	O	day
53	245	249	O	dosed
54	251	252	O	to
55	254	259	O	steady
56	261	265	O	state
NULL

ABILIFY MAINTENA	2318	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	26
The steady-state plasma concentrations of fluoxetine and norfluoxetine increased by about 18% and 36%, respectively, and concentrations of paroxetine decreased by about 27%.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	22	O	plasma
5	24	37	O	concentrations
6	39	40	O	of
7	42	51	U-KIN	fluoxetine
8	53	55	O	and
9	57	69	U-KIN	norfluoxetine
10	71	79	O	increased
11	81	82	O	by
12	84	88	O	about
13	90	92	O	18%
14	94	96	O	and
15	98	100	O	36%
16	101	101	O	,
17	103	114	O	respectively
18	115	115	O	,
19	117	119	O	and
20	121	134	O	concentrations
21	136	137	O	of
22	139	148	U-KIN	paroxetine
23	150	158	O	decreased
24	160	161	O	by
25	163	167	O	about
26	169	171	O	27%
K/22:C54358 K/7:C54357 K/9:C54357

ABILIFY MAINTENA	2319	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	21
The steady-state plasma concentrations of sertraline and desmethylsertraline were not substantially changed when these antidepressant therapies were coadministered with aripiprazole.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	22	O	plasma
5	24	37	O	concentrations
6	39	40	O	of
7	42	51	O	sertraline
8	53	55	O	and
9	57	75	O	desmethylsertraline
10	77	80	O	were
11	82	84	O	not
12	86	98	O	substantially
13	100	106	O	changed
14	108	111	O	when
15	113	117	O	these
16	119	132	O	antidepressant
17	134	142	O	therapies
18	144	147	O	were
19	149	162	O	coadministered
20	164	167	O	with
21	169	180	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2320	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	34
Figure 21: The effects of oral aripiprazole on pharmacokinetics of other drugs Figure19 Figure 20 Figure 21 Studies in Specific Populations No specific pharmacokinetic studies have been performed with ABILIFY MAINTENA in specific populations.
1	0	5	O	Figure
2	7	8	O	21
3	9	9	O	:
4	11	13	O	The
5	15	21	O	effects
6	23	24	O	of
7	26	29	O	oral
8	31	42	O	XXXXXXXX
9	44	45	O	on
10	47	62	O	pharmacokinetics
11	64	65	O	of
12	67	71	O	other
13	73	77	O	drugs
14	79	86	O	Figure19
15	88	93	O	Figure
16	95	96	O	20
17	98	103	O	Figure
18	105	106	O	21
19	108	114	O	Studies
20	116	117	O	in
21	119	126	O	Specific
22	128	138	O	Populations
23	140	141	O	No
24	143	150	O	specific
25	152	166	O	pharmacokinetic
26	168	174	O	studies
27	176	179	O	have
28	181	184	O	been
29	186	194	O	performed
30	196	199	O	with
31	201	216	O	XXXXXXXX
32	218	219	O	in
33	221	228	O	specific
34	230	240	O	populations
NULL

ABILIFY MAINTENA	2321	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	10
All the information is obtained from studies with oral aripiprazole.
1	0	2	O	All
2	4	6	O	the
3	8	18	O	information
4	20	21	O	is
5	23	30	O	obtained
6	32	35	O	from
7	37	43	O	studies
8	45	48	O	with
9	50	53	O	oral
10	55	66	O	XXXXXXXX
NULL

ABILIFY MAINTENA	2322	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	19
Exposures of aripiprazole and dehydro-aripiprazole in specific populations are summarized in Figure 22 and Figure 23, respectively.
1	0	8	O	Exposures
2	10	11	O	of
3	13	24	O	XXXXXXXX
4	26	28	O	and
5	30	36	O	dehydro
6	38	49	O	XXXXXXXX
7	51	52	O	in
8	54	61	O	specific
9	63	73	O	populations
10	75	77	O	are
11	79	88	O	summarized
12	90	91	O	in
13	93	98	O	Figure
14	100	101	O	22
15	103	105	O	and
16	107	112	O	Figure
17	114	115	O	23
18	116	116	O	,
19	118	129	O	respectively
NULL

ABILIFY MAINTENA	2323	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	33
In addition, in pediatric patients (10 to 17 years of age) administered with oral aripiprazole (20 mg to 30 mg), the body weight corrected aripiprazole clearance was similar to the adults.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	in
5	16	24	O	pediatric
6	26	33	O	patients
7	36	37	O	10
8	39	40	O	to
9	42	43	O	17
10	45	49	O	years
11	51	52	O	of
12	54	56	O	age
13	59	70	O	administered
14	72	75	O	with
15	77	80	O	oral
16	82	93	O	XXXXXXXX
17	96	97	O	20
18	99	100	O	mg
19	102	103	O	to
20	105	106	O	30
21	108	109	O	mg
22	111	111	O	,
23	113	115	O	the
24	117	120	O	body
25	122	127	O	weight
26	129	137	O	corrected
27	139	150	O	XXXXXXXX
28	152	160	O	clearance
29	162	164	O	was
30	166	172	O	similar
31	174	175	O	to
32	177	179	O	the
33	181	186	O	adults
NULL

ABILIFY MAINTENA	2324	34090-1	ee49f3b1-1650-47ff-9fb1-ea53fe0b92b6	25
Figure 22 Effects of intrinsic factors on aripiprazole pharmacokinetics Figure 23: Effects of intrinsic factors on dehydro-aripiprazole pharmacokinetics: Figure 22 Figure 23
1	0	5	O	Figure
2	7	8	O	22
3	10	16	O	Effects
4	18	19	O	of
5	21	29	O	intrinsic
6	31	37	O	factors
7	39	40	O	on
8	42	53	O	XXXXXXXX
9	55	70	O	pharmacokinetics
10	72	77	O	Figure
11	79	80	O	23
12	81	81	O	:
13	83	89	O	Effects
14	91	92	O	of
15	94	102	O	intrinsic
16	104	110	O	factors
17	112	113	O	on
18	115	121	O	dehydro
19	123	134	O	XXXXXXXX
20	136	151	O	pharmacokinetics
21	152	152	O	:
22	154	159	O	Figure
23	161	162	O	22
24	164	169	O	Figure
25	171	172	O	23
NULL

Adasuve	2761	34073-7	b074f950-246a-41f0-aedf-32f38998a4b1	8
ADASUVE is a central nervous system (CNS) depressant.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	11	O	a
4	13	19	O	central
5	21	27	O	nervous
6	29	34	O	system
7	37	39	O	CNS
8	42	51	O	depressant
NULL

Adasuve	2762	34073-7	b074f950-246a-41f0-aedf-32f38998a4b1	54
The concurrent use of ADASUVE with other CNS depressants (e.g., alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, general anesthetics, phenothiazines, sedative/hypnotics, muscle relaxants, and/or illicit CNS depressants) can increase the risk of respiratory depression, hypotension, profound sedation, and syncope.
1	0	2	O	The
2	4	13	O	concurrent
3	15	17	O	use
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	33	O	with
7	35	39	O	other
8	41	43	B-DYN	CNS
9	45	55	L-DYN	depressants
10	58	60	O	e.g
11	62	62	O	,
12	64	70	U-DYN	alcohol
13	71	71	O	,
14	73	78	B-DYN	opioid
15	80	89	L-DYN	analgesics
16	90	90	O	,
17	92	106	U-DYN	benzodiazepines
18	107	107	O	,
19	109	117	B-DYN	tricyclic
20	119	133	L-DYN	antidepressants
21	134	134	O	,
22	136	142	B-DYN	general
23	144	154	L-DYN	anesthetics
24	155	155	O	,
25	157	170	U-DYN	phenothiazines
26	171	171	O	,
27	173	180	B-DYN	sedative
28	181	181	I-DYN	/
29	182	190	L-DYN	hypnotics
30	191	191	O	,
31	193	198	B-DYN	muscle
32	200	208	L-DYN	relaxants
33	209	209	O	,
34	211	213	O	and
35	214	214	O	/
36	215	216	O	or
37	218	224	B-DYN	illicit
38	226	228	I-DYN	CNS
39	230	240	L-DYN	depressants
40	243	245	O	can
41	247	254	O	increase
42	256	258	O	the
43	260	263	O	risk
44	265	266	O	of
45	268	278	B-EFF	respiratory
46	280	289	L-EFF	depression
47	290	290	O	,
48	292	302	U-EFF	hypotension
49	303	303	O	,
50	305	312	B-EFF	profound
51	314	321	L-EFF	sedation
52	322	322	O	,
53	324	326	O	and
54	328	334	U-EFF	syncope
D/12:45:1 D/12:48:1 D/12:50:1 D/12:54:1 D/14:45:1 D/14:48:1 D/14:50:1 D/14:54:1 D/17:45:1 D/17:48:1 D/17:50:1 D/17:54:1 D/19:45:1 D/19:48:1 D/19:50:1 D/19:54:1 D/22:45:1 D/22:48:1 D/22:50:1 D/22:54:1 D/25:45:1 D/25:48:1 D/25:50:1 D/25:54:1 D/27:45:1 D/27:48:1 D/27:50:1 D/27:54:1 D/31:45:1 D/31:48:1 D/31:50:1 D/31:54:1 D/37:45:1 D/37:48:1 D/37:50:1 D/37:54:1 D/8:45:1 D/8:48:1 D/8:50:1 D/8:54:1

Adasuve	2763	34073-7	b074f950-246a-41f0-aedf-32f38998a4b1	14
Therefore, consider reducing the dose of CNS depressants if used concomitantly with ADASUVE.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	consider
4	20	27	B-TRI	reducing
5	29	31	I-TRI	the
6	33	36	L-TRI	dose
7	38	39	O	of
8	41	43	B-KIN	CNS
9	45	55	L-KIN	depressants
10	57	58	O	if
11	60	63	O	used
12	65	77	O	concomitantly
13	79	82	O	with
14	84	90	O	XXXXXXXX
K/8:C54357

Adasuve	2764	34073-7	b074f950-246a-41f0-aedf-32f38998a4b1	24
The concomitant use of ADASUVE and other anticholinergic drugs can increase the risk of anticholinergic adverse reactions including exacerbation of glaucoma and urinary retention.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	O	XXXXXXXX
6	31	33	O	and
7	35	39	O	other
8	41	55	B-DYN	anticholinergic
9	57	61	L-DYN	drugs
10	63	65	O	can
11	67	74	O	increase
12	76	78	O	the
13	80	83	O	risk
14	85	86	O	of
15	88	102	B-EFF	anticholinergic
16	104	110	I-EFF	adverse
17	112	120	L-EFF	reactions
18	122	130	O	including
19	132	143	B-EFF	exacerbation
20	145	146	I-EFF	of
21	148	155	L-EFF	glaucoma
22	157	159	O	and
23	161	167	B-EFF	urinary
24	169	177	L-EFF	retention
D/8:15:1 D/8:19:1 D/8:23:1

Adasuve	2765	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	31
Mean Plasma Concentrations of Loxapine following Single-Dose Administration ADASUVE 10 mg in Healthy Subjects The mechanism of action of loxapine in the treatment of agitation associated with schizophrenia is unknown.
1	0	3	O	Mean
2	5	10	O	Plasma
3	12	25	O	Concentrations
4	27	28	O	of
5	30	37	O	XXXXXXXX
6	39	47	O	following
7	49	54	O	Single
8	56	59	O	Dose
9	61	74	O	Administration
10	76	82	O	XXXXXXXX
11	84	85	O	10
12	87	88	O	mg
13	90	91	O	in
14	93	99	O	Healthy
15	101	108	O	Subjects
16	110	112	O	The
17	114	122	O	mechanism
18	124	125	O	of
19	127	132	O	action
20	134	135	O	of
21	137	144	O	XXXXXXXX
22	146	147	O	in
23	149	151	O	the
24	153	161	O	treatment
25	163	164	O	of
26	166	174	O	agitation
27	176	185	O	associated
28	187	190	O	with
29	192	204	O	schizophrenia
30	206	207	O	is
31	209	215	O	unknown
NULL

Adasuve	2766	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	21
However, its efficacy could be mediated through a combination of antagonism of central dopamine D2 and serotonin 5-HT2A receptors.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	its
4	13	20	O	efficacy
5	22	26	O	could
6	28	29	O	be
7	31	38	O	mediated
8	40	46	O	through
9	48	48	O	a
10	50	60	O	combination
11	62	63	O	of
12	65	74	O	antagonism
13	76	77	O	of
14	79	85	O	central
15	87	94	O	dopamine
16	96	97	O	D2
17	99	101	O	and
18	103	111	O	serotonin
19	113	113	O	5
20	115	118	O	HT2A
21	120	128	O	receptors
NULL

Adasuve	2767	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	18
The mechanism of action of loxapine in the treatment of agitation associated with bipolar I disorder is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	34	O	XXXXXXXX
7	36	37	O	in
8	39	41	O	the
9	43	51	O	treatment
10	53	54	O	of
11	56	64	O	agitation
12	66	75	O	associated
13	77	80	O	with
14	82	88	O	bipolar
15	90	90	O	I
16	92	99	O	disorder
17	101	102	O	is
18	104	110	O	unknown
NULL

Adasuve	2768	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	49
Loxapine acts as an antagonist at central serotonin and dopamine receptors, with high affinity for serotonin 5-HT2A and dopamine D1, D2, D3, and D4 receptors (Ki values of 2 nM, 18 nM, 10 nM, 21 nM, 9 nM, respectively).
1	0	7	O	XXXXXXXX
2	9	12	O	acts
3	14	15	O	as
4	17	18	O	an
5	20	29	O	antagonist
6	31	32	O	at
7	34	40	O	central
8	42	50	O	serotonin
9	52	54	O	and
10	56	63	O	dopamine
11	65	73	O	receptors
12	74	74	O	,
13	76	79	O	with
14	81	84	O	high
15	86	93	O	affinity
16	95	97	O	for
17	99	107	O	serotonin
18	109	109	O	5
19	111	114	O	HT2A
20	116	118	O	and
21	120	127	O	dopamine
22	129	130	O	D1
23	131	131	O	,
24	133	134	O	D2
25	135	135	O	,
26	137	138	O	D3
27	139	139	O	,
28	141	143	O	and
29	145	146	O	D4
30	148	156	O	receptors
31	159	160	O	Ki
32	162	167	O	values
33	169	170	O	of
34	172	172	O	2
35	174	175	O	nM
36	176	176	O	,
37	178	179	O	18
38	181	182	O	nM
39	183	183	O	,
40	185	186	O	10
41	188	189	O	nM
42	190	190	O	,
43	192	193	O	21
44	195	196	O	nM
45	197	197	O	,
46	199	199	O	9
47	201	202	O	nM
48	203	203	O	,
49	205	216	O	respectively
NULL

Adasuve	2769	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	41
Some of the adverse effects of loxapine may be related to the antagonism of histamine H1 (somnolence), muscarinic M1 (anticholinergic), and adrenergic A2 (orthostatic hypotension) receptors (Ki values of 15 nM, 117 nM and 250 nM, respectively).
1	0	3	O	Some
2	5	6	O	of
3	8	10	O	the
4	12	18	O	adverse
5	20	26	O	effects
6	28	29	O	of
7	31	38	O	XXXXXXXX
8	40	42	O	may
9	44	45	O	be
10	47	53	O	related
11	55	56	O	to
12	58	60	O	the
13	62	71	O	antagonism
14	73	74	O	of
15	76	84	O	histamine
16	86	87	O	H1
17	90	99	O	somnolence
18	101	101	O	,
19	103	112	O	muscarinic
20	114	115	O	M1
21	118	132	O	anticholinergic
22	134	134	O	,
23	136	138	O	and
24	140	149	O	adrenergic
25	151	152	O	A2
26	155	165	O	orthostatic
27	167	177	O	hypotension
28	180	188	O	receptors
29	191	192	O	Ki
30	194	199	O	values
31	201	202	O	of
32	204	205	O	15
33	207	208	O	nM
34	209	209	O	,
35	211	213	O	117
36	215	216	O	nM
37	218	220	O	and
38	222	224	O	250
39	226	227	O	nM
40	228	228	O	,
41	230	241	O	respectively
NULL

Adasuve	2770	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	10
Thorough QTc Study ADASUVE did not prolong the QTc interval.
1	0	7	O	Thorough
2	9	11	O	QTc
3	13	17	O	Study
4	19	25	O	XXXXXXXX
5	27	29	O	did
6	31	33	O	not
7	35	41	O	prolong
8	43	45	O	the
9	47	49	O	QTc
10	51	58	O	interval
NULL

Adasuve	2771	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	28
The effect of ADASUVE on QTc prolongation was evaluated in a randomized, double-blinded, positive- (moxifloxacin 400 mg) and placebo-controlled parallel study in healthy subjects.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	O	XXXXXXXX
5	22	23	O	on
6	25	27	O	QTc
7	29	40	O	prolongation
8	42	44	O	was
9	46	54	O	evaluated
10	56	57	O	in
11	59	59	O	a
12	61	70	O	randomized
13	71	71	O	,
14	73	78	O	double
15	80	86	O	blinded
16	87	87	O	,
17	89	96	O	positive
18	100	111	O	moxifloxacin
19	113	115	O	400
20	117	118	O	mg
21	121	123	O	and
22	125	131	O	placebo
23	133	142	O	controlled
24	144	151	O	parallel
25	153	157	O	study
26	159	160	O	in
27	162	168	O	healthy
28	170	177	O	subjects
NULL

Adasuve	2772	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	11
A total of 48 healthy subjects were administered ADASUVE 10 mg.
1	0	0	O	A
2	2	6	O	total
3	8	9	O	of
4	11	12	O	48
5	14	20	O	healthy
6	22	29	O	subjects
7	31	34	O	were
8	36	47	O	administered
9	49	55	O	XXXXXXXX
10	57	58	O	10
11	60	61	O	mg
NULL

Adasuve	2773	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	45
In this study with a demonstrated ability to detect small effects, the upper bound of the 90% confidence interval (CI) for the largest placebo-adjusted, baseline-corrected QTc based on individual correction method was below 10 milliseconds, the threshold for regulatory concern.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	14	17	O	with
5	19	19	O	a
6	21	32	O	demonstrated
7	34	40	O	ability
8	42	43	O	to
9	45	50	O	detect
10	52	56	O	small
11	58	64	O	effects
12	65	65	O	,
13	67	69	O	the
14	71	75	O	upper
15	77	81	O	bound
16	83	84	O	of
17	86	88	O	the
18	90	92	O	90%
19	94	103	O	confidence
20	105	112	O	interval
21	115	116	O	CI
22	119	121	O	for
23	123	125	O	the
24	127	133	O	largest
25	135	141	O	placebo
26	143	150	O	adjusted
27	151	151	O	,
28	153	160	O	baseline
29	162	170	O	corrected
30	172	174	O	QTc
31	176	180	O	based
32	182	183	O	on
33	185	194	O	individual
34	196	205	O	correction
35	207	212	O	method
36	214	216	O	was
37	218	222	O	below
38	224	225	O	10
39	227	238	O	milliseconds
40	239	239	O	,
41	241	243	O	the
42	245	253	O	threshold
43	255	257	O	for
44	259	268	O	regulatory
45	270	276	O	concern
NULL

Adasuve	2774	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	30
Absorption: The single-dose pharmacokinetic parameters of loxapine following administration of single doses of ADASUVE 10 mg in healthy adult subjects are presented in Table 3 and Figure 8.
1	0	9	O	Absorption
2	10	10	O	:
3	12	14	O	The
4	16	21	O	single
5	23	26	O	dose
6	28	42	O	pharmacokinetic
7	44	53	O	parameters
8	55	56	O	of
9	58	65	O	XXXXXXXX
10	67	75	O	following
11	77	90	O	administration
12	92	93	O	of
13	95	100	O	single
14	102	106	O	doses
15	108	109	O	of
16	111	117	O	XXXXXXXX
17	119	120	O	10
18	122	123	O	mg
19	125	126	O	in
20	128	134	O	healthy
21	136	140	O	adult
22	142	149	O	subjects
23	151	153	O	are
24	155	163	O	presented
25	165	166	O	in
26	168	172	O	Table
27	174	174	O	3
28	176	178	O	and
29	180	185	O	Figure
30	187	187	O	8
NULL

Adasuve	2775	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	22
Administration of ADASUVE resulted in rapid absorption of loxapine, with a median time of maximum plasma concentration (Tmax) of 2 minutes.
1	0	13	O	Administration
2	15	16	O	of
3	18	24	O	XXXXXXXX
4	26	33	O	resulted
5	35	36	O	in
6	38	42	O	rapid
7	44	53	O	absorption
8	55	56	O	of
9	58	65	O	XXXXXXXX
10	66	66	O	,
11	68	71	O	with
12	73	73	O	a
13	75	80	O	median
14	82	85	O	time
15	87	88	O	of
16	90	96	O	maximum
17	98	103	O	plasma
18	105	117	O	concentration
19	120	123	O	Tmax
20	126	127	O	of
21	129	129	O	2
22	131	137	O	minutes
NULL

Adasuve	2776	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	21
Loxapine exposure in the first 2 hours after administration (AUC0-2h) was 66.7 ng*h/mL for the 10 mg dose.
1	0	7	O	XXXXXXXX
2	9	16	O	exposure
3	18	19	O	in
4	21	23	O	the
5	25	29	O	first
6	31	31	O	2
7	33	37	O	hours
8	39	43	O	after
9	45	58	O	administration
10	61	64	O	AUC0
11	66	67	O	2h
12	70	72	O	was
13	74	77	O	66.7
14	79	82	O	ng*h
15	83	83	O	/
16	84	85	O	mL
17	87	89	O	for
18	91	93	O	the
19	95	96	O	10
20	98	99	O	mg
21	101	104	O	dose
NULL

Adasuve	2777	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	25
As a consequence of the very rapid absorption of loxapine after oral inhalation, there is substantial variability in the early plasma concentrations of loxapine.
1	0	1	O	As
2	3	3	O	a
3	5	15	O	consequence
4	17	18	O	of
5	20	22	O	the
6	24	27	O	very
7	29	33	O	rapid
8	35	44	O	absorption
9	46	47	O	of
10	49	56	O	XXXXXXXX
11	58	62	O	after
12	64	67	O	oral
13	69	78	O	inhalation
14	79	79	O	,
15	81	85	O	there
16	87	88	O	is
17	90	100	O	substantial
18	102	112	O	variability
19	114	115	O	in
20	117	119	O	the
21	121	125	O	early
22	127	132	O	plasma
23	134	147	O	concentrations
24	149	150	O	of
25	152	159	O	XXXXXXXX
NULL

Adasuve	2778	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	16
The mean plasma loxapine concentrations following administration of ADASUVE were linear over the clinical dose range.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	plasma
4	16	23	O	XXXXXXXX
5	25	38	O	concentrations
6	40	48	O	following
7	50	63	O	administration
8	65	66	O	of
9	68	74	O	XXXXXXXX
10	76	79	O	were
11	81	86	O	linear
12	88	91	O	over
13	93	95	O	the
14	97	104	O	clinical
15	106	109	O	dose
16	111	115	O	range
NULL

Adasuve	2779	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	13
AUC0-2h, AUCinf, and Cmax increased in a dose-dependent manner.
1	0	3	O	AUC0
2	5	6	O	2h
3	7	7	O	,
4	9	14	O	AUCinf
5	15	15	O	,
6	17	19	O	and
7	21	24	O	Cmax
8	26	34	O	increased
9	36	37	O	in
10	39	39	O	a
11	41	44	O	dose
12	46	54	O	dependent
13	56	61	O	manner
NULL

Adasuve	2780	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	76
Pharmacokinetics in Healthy Adult Subjects Administered a Single Dose of ADASUVE 10 mg Parameter Healthy Subjects ADASUVE 10 mg (N=114) AUC0-2h (ng*h/mL), mean * SD 66.7 * 18.2 AUCinf (ng*h/mL), mean * SD 188 * 47 Cmax (ng/mL), mean * SD 257 * 219 Tmax (minutes), median (25%, 75%) 1.13 (1, 2) Half-life(h), mean * SD 7.61 * 1.87 Figure 8.
1	0	15	O	Pharmacokinetics
2	17	18	O	in
3	20	26	O	Healthy
4	28	32	O	Adult
5	34	41	O	Subjects
6	43	54	O	Administered
7	56	56	O	a
8	58	63	O	Single
9	65	68	O	Dose
10	70	71	O	of
11	73	79	O	XXXXXXXX
12	81	82	O	10
13	84	85	O	mg
14	87	95	O	Parameter
15	97	103	O	Healthy
16	105	112	O	Subjects
17	114	120	O	XXXXXXXX
18	122	123	O	10
19	125	126	O	mg
20	129	133	O	N=114
21	136	139	O	AUC0
22	141	142	O	2h
23	145	148	O	ng*h
24	149	149	O	/
25	150	151	O	mL
26	153	153	O	,
27	155	158	O	mean
28	160	160	O	*
29	162	163	O	SD
30	165	168	O	66.7
31	170	170	O	*
32	172	175	O	18.2
33	177	182	O	AUCinf
34	185	188	O	ng*h
35	189	189	O	/
36	190	191	O	mL
37	193	193	O	,
38	195	198	O	mean
39	200	200	O	*
40	202	203	O	SD
41	205	207	O	188
42	209	209	O	*
43	211	212	O	47
44	214	217	O	Cmax
45	220	221	O	ng
46	222	222	O	/
47	223	224	O	mL
48	226	226	O	,
49	228	231	O	mean
50	233	233	O	*
51	235	236	O	SD
52	238	240	O	257
53	242	242	O	*
54	244	246	O	219
55	248	251	O	Tmax
56	254	260	O	minutes
57	262	262	O	,
58	264	269	O	median
59	272	274	O	25%
60	275	275	O	,
61	277	279	O	75%
62	282	285	O	1.13
63	288	288	O	1
64	289	289	O	,
65	291	291	O	2
66	294	297	O	Half
67	299	304	O	life(h
68	306	306	O	,
69	308	311	O	mean
70	313	313	O	*
71	315	316	O	SD
72	318	321	O	7.61
73	323	323	O	*
74	325	328	O	1.87
75	330	335	O	Figure
76	337	337	O	8
NULL

Adasuve	2781	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	28
Mean Plasma Concentrations of Loxapine following Single-Dose Administration ADASUVE 10 mg in Healthy Subjects Distribution: Loxapine is removed rapidly from the plasma and distributed in tissues.
1	0	3	O	Mean
2	5	10	O	Plasma
3	12	25	O	Concentrations
4	27	28	O	of
5	30	37	O	XXXXXXXX
6	39	47	O	following
7	49	54	O	Single
8	56	59	O	Dose
9	61	74	O	Administration
10	76	82	O	XXXXXXXX
11	84	85	O	10
12	87	88	O	mg
13	90	91	O	in
14	93	99	O	Healthy
15	101	108	O	Subjects
16	110	121	O	Distribution
17	122	122	O	:
18	124	131	O	XXXXXXXX
19	133	134	O	is
20	136	142	O	removed
21	144	150	O	rapidly
22	152	155	O	from
23	157	159	O	the
24	161	166	O	plasma
25	168	170	O	and
26	172	182	O	distributed
27	184	185	O	in
28	187	193	O	tissues
NULL

Adasuve	2782	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	22
Animal studies following oral administration suggest an initial preferential distribution in the lungs, brain, spleen, heart, and kidney.
1	0	5	O	Animal
2	7	13	O	studies
3	15	23	O	following
4	25	28	O	oral
5	30	43	O	administration
6	45	51	O	suggest
7	53	54	O	an
8	56	62	O	initial
9	64	75	O	preferential
10	77	88	O	distribution
11	90	91	O	in
12	93	95	O	the
13	97	101	O	lungs
14	102	102	O	,
15	104	108	O	brain
16	109	109	O	,
17	111	116	O	spleen
18	117	117	O	,
19	119	123	O	heart
20	124	124	O	,
21	126	128	O	and
22	130	135	O	kidney
NULL

Adasuve	2783	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	8
Loxapine is 96.6% bound to human plasma proteins.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	16	O	96.6%
4	18	22	O	bound
5	24	25	O	to
6	27	31	O	human
7	33	38	O	plasma
8	40	47	O	proteins
NULL

Adasuve	2784	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	17
Metabolism: Loxapine is metabolized extensively in the liver following oral administration, with multiple metabolites formed.
1	0	9	O	Metabolism
2	10	10	O	:
3	12	19	O	XXXXXXXX
4	21	22	O	is
5	24	34	O	metabolized
6	36	46	O	extensively
7	48	49	O	in
8	51	53	O	the
9	55	59	O	liver
10	61	69	O	following
11	71	74	O	oral
12	76	89	O	administration
13	90	90	O	,
14	92	95	O	with
15	97	104	O	multiple
16	106	116	O	metabolites
17	118	123	O	formed
NULL

Adasuve	2785	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	45
The main metabolic pathways include: 1) hydroxylation to form 8-OH-loxapine by CYP1A2 and 7-OH-loxapine by CYP3A4 and CYP2D6, 2) N-oxidation to form loxapine N-oxide by flavanoid monoamine oxidases (FMOs), and 3) de-methylation to form amoxapine.
1	0	2	O	The
2	4	7	O	main
3	9	17	O	metabolic
4	19	26	O	pathways
5	28	34	O	include
6	35	35	O	:
7	37	37	O	1
8	40	52	O	hydroxylation
9	54	55	O	to
10	57	60	O	form
11	62	62	O	8
12	64	65	O	OH
13	67	74	O	XXXXXXXX
14	76	77	O	by
15	79	84	O	CYP1A2
16	86	88	O	and
17	90	90	O	7
18	92	93	O	OH
19	95	102	O	XXXXXXXX
20	104	105	O	by
21	107	112	O	CYP3A4
22	114	116	O	and
23	118	123	O	CYP2D6
24	124	124	O	,
25	126	126	O	2
26	129	129	O	N
27	131	139	O	oxidation
28	141	142	O	to
29	144	147	O	form
30	149	156	O	XXXXXXXX
31	158	158	O	N
32	160	164	O	oxide
33	166	167	O	by
34	169	177	O	flavanoid
35	179	187	O	monoamine
36	189	196	O	oxidases
37	199	202	O	FMOs
38	204	204	O	,
39	206	208	O	and
40	210	210	O	3
41	213	214	O	de
42	216	226	O	methylation
43	228	229	O	to
44	231	234	O	form
45	236	244	O	amoxapine
NULL

Adasuve	2786	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	22
Because there are multiple metabolic pathways, the risk of metabolic interactions caused by an effect on an individual isoform is minimal.
1	0	6	O	Because
2	8	12	O	there
3	14	16	O	are
4	18	25	O	multiple
5	27	35	O	metabolic
6	37	44	O	pathways
7	45	45	O	,
8	47	49	O	the
9	51	54	O	risk
10	56	57	O	of
11	59	67	O	metabolic
12	69	80	O	interactions
13	82	87	O	caused
14	89	90	O	by
15	92	93	O	an
16	95	100	O	effect
17	102	103	O	on
18	105	106	O	an
19	108	117	O	individual
20	119	125	O	isoform
21	127	128	O	is
22	130	136	O	minimal
NULL

Adasuve	2787	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	28
For ADASUVE, the order of metabolites observed in humans (based on systemic exposure) was 8-OH-loxapine >> loxapine N-oxide, 7-OH-loxapine > amoxapine.
1	0	2	O	For
2	4	10	O	XXXXXXXX
3	11	11	O	,
4	13	15	O	the
5	17	21	O	order
6	23	24	O	of
7	26	36	O	metabolites
8	38	45	O	observed
9	47	48	O	in
10	50	55	O	humans
11	58	62	O	based
12	64	65	O	on
13	67	74	O	systemic
14	76	83	O	exposure
15	86	88	O	was
16	90	90	O	8
17	92	93	O	OH
18	95	102	O	XXXXXXXX
19	104	105	O	>>
20	107	114	O	XXXXXXXX
21	116	116	O	N
22	118	122	O	oxide
23	123	123	O	,
24	125	125	O	7
25	127	128	O	OH
26	130	137	O	XXXXXXXX
27	139	139	O	>
28	141	149	O	amoxapine
NULL

Adasuve	2788	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	14
Plasma levels of 8-OH-loxapine are similar to those of the parent compound.
1	0	5	O	Plasma
2	7	12	O	levels
3	14	15	O	of
4	17	17	O	8
5	19	20	O	OH
6	22	29	O	XXXXXXXX
7	31	33	O	are
8	35	41	O	similar
9	43	44	O	to
10	46	50	O	those
11	52	53	O	of
12	55	57	O	the
13	59	64	O	parent
14	66	73	O	compound
NULL

Adasuve	2789	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	10
Excretion: Excretion occurs mainly in the first 24 hours.
1	0	8	O	Excretion
2	9	9	O	:
3	11	19	O	Excretion
4	21	26	O	occurs
5	28	33	O	mainly
6	35	36	O	in
7	38	40	O	the
8	42	46	O	first
9	48	49	O	24
10	51	55	O	hours
NULL

Adasuve	2790	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	16
Metabolites are excreted in the urine in the form of conjugates and in the feces unconjugated.
1	0	10	O	Metabolites
2	12	14	O	are
3	16	23	O	excreted
4	25	26	O	in
5	28	30	O	the
6	32	36	O	urine
7	38	39	O	in
8	41	43	O	the
9	45	48	O	form
10	50	51	O	of
11	53	62	O	conjugates
12	64	66	O	and
13	68	69	O	in
14	71	73	O	the
15	75	79	O	feces
16	81	92	O	unconjugated
NULL

Adasuve	2791	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	14
The terminal elimination half-life (T1/2) ranged from 6 to 8 hours.
1	0	2	O	The
2	4	11	O	terminal
3	13	23	O	elimination
4	25	28	O	half
5	30	33	O	life
6	36	37	O	T1
7	38	38	O	/
8	39	39	O	2
9	42	47	O	ranged
10	49	52	O	from
11	54	54	O	6
12	56	57	O	to
13	59	59	O	8
14	61	65	O	hours
NULL

Adasuve	2792	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	25
Transporter Interaction: In vitro studies indicated that loxapine was not a substrate for p-glycoprotein (P-gp): however, loxapine inhibited P-gp.
1	0	10	O	Transporter
2	12	22	O	Interaction
3	23	23	O	:
4	25	26	O	In
5	28	32	O	vitro
6	34	40	O	studies
7	42	50	O	indicated
8	52	55	O	that
9	57	64	O	XXXXXXXX
10	66	68	O	was
11	70	72	O	not
12	74	74	O	a
13	76	84	O	substrate
14	86	88	O	for
15	90	90	O	p
16	92	103	O	glycoprotein
17	106	106	O	P
18	108	109	O	gp
19	111	111	O	:
20	113	119	O	however
21	120	120	O	,
22	122	129	O	XXXXXXXX
23	131	139	O	inhibited
24	141	141	O	P
25	143	144	O	gp
NULL

Adasuve	2793	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	36
Special Populations: Pharmacokinetics in Smokers: Loxapine exposures in nonsmokers and smokers are similar, with geometric mean ratios of 92%, 85%, and 99% for AUC0-2h, AUCinf, and Cmax respectively.
1	0	6	O	Special
2	8	18	O	Populations
3	19	19	O	:
4	21	36	O	Pharmacokinetics
5	38	39	O	in
6	41	47	O	Smokers
7	48	48	O	:
8	50	57	O	XXXXXXXX
9	59	67	O	exposures
10	69	70	O	in
11	72	81	O	nonsmokers
12	83	85	O	and
13	87	93	O	smokers
14	95	97	O	are
15	99	105	O	similar
16	106	106	O	,
17	108	111	O	with
18	113	121	O	geometric
19	123	126	O	mean
20	128	133	O	ratios
21	135	136	O	of
22	138	140	O	92%
23	141	141	O	,
24	143	145	O	85%
25	146	146	O	,
26	148	150	O	and
27	152	154	O	99%
28	156	158	O	for
29	160	163	O	AUC0
30	165	166	O	2h
31	167	167	O	,
32	169	174	O	AUCinf
33	175	175	O	,
34	177	179	O	and
35	181	184	O	Cmax
36	186	197	O	respectively
NULL

Adasuve	2794	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	9
No dosage adjustment is recommended based on smoking status.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	34	O	recommended
6	36	40	O	based
7	42	43	O	on
8	45	51	O	smoking
9	53	58	O	status
NULL

Adasuve	2795	34090-1	b074f950-246a-41f0-aedf-32f38998a4b1	32
Demographic Effects : There were no clinically significant differences in loxapine pharmacokinetics following administration of ADASUVE in subgroups based on age, weight, body mass index, gender, or race.
1	0	10	O	Demographic
2	12	18	O	Effects
3	20	20	O	:
4	22	26	O	There
5	28	31	O	were
6	33	34	O	no
7	36	45	O	clinically
8	47	57	O	significant
9	59	69	O	differences
10	71	72	O	in
11	74	81	O	XXXXXXXX
12	83	98	O	pharmacokinetics
13	100	108	O	following
14	110	123	O	administration
15	125	126	O	of
16	128	134	O	XXXXXXXX
17	136	137	O	in
18	139	147	O	subgroups
19	149	153	O	based
20	155	156	O	on
21	158	160	O	age
22	161	161	O	,
23	163	168	O	weight
24	169	169	O	,
25	171	174	O	body
26	176	179	O	mass
27	181	185	O	index
28	186	186	O	,
29	188	193	O	gender
30	194	194	O	,
31	196	197	O	or
32	199	202	O	race
NULL

Amitriptyline Hydrochloride	1181	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	38
Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels.
1	0	3	O	Some
2	5	12	O	patients
3	14	16	O	may
4	18	27	O	experience
5	29	29	O	a
6	31	35	O	large
7	37	44	O	increase
8	46	47	O	in
9	49	61	O	XXXXXXXX
10	63	75	O	concentration
11	77	78	O	in
12	80	82	O	the
13	84	91	O	presence
14	93	94	O	of
15	96	105	U-KIN	topiramate
16	107	109	O	and
17	111	113	O	any
18	115	125	O	adjustments
19	127	128	O	in
20	130	142	O	XXXXXXXX
21	144	147	O	dose
22	149	154	O	should
23	156	157	O	be
24	159	162	O	made
25	164	172	O	according
26	174	175	O	to
27	177	179	O	the
28	181	189	O	patient's
29	191	198	O	clinical
30	200	207	O	response
31	209	211	O	and
32	213	215	O	not
33	217	218	O	on
34	220	222	O	the
35	224	228	O	basis
36	230	231	O	of
37	233	238	O	plasma
38	240	245	O	levels
K/15:C54355

Amitriptyline Hydrochloride	1182	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	56
The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available.
1	0	2	O	The
2	4	14	O	biochemical
3	16	23	O	activity
4	25	26	O	of
5	28	30	O	the
6	32	35	O	drug
7	37	48	O	metabolizing
8	50	56	O	isozyme
9	58	67	O	cytochrome
10	69	72	O	P450
11	74	76	O	2D6
12	79	89	O	debrisoquin
13	91	101	O	hydroxylase
14	104	105	O	is
15	107	113	O	reduced
16	115	116	O	in
17	118	118	O	a
18	120	125	O	subset
19	127	128	O	of
20	130	132	O	the
21	134	142	O	caucasian
22	144	153	O	population
23	156	160	O	about
24	162	163	O	7%
25	165	166	O	to
26	168	170	O	10%
27	172	173	O	of
28	175	184	O	Caucasians
29	186	188	O	are
30	190	191	O	so
31	193	198	O	called
32	200	204	O	"poor
33	206	218	O	metabolizers"
34	222	229	O	reliable
35	231	239	O	estimates
36	241	242	O	of
37	244	246	O	the
38	248	257	O	prevalence
39	259	260	O	of
40	262	268	O	reduced
41	270	273	O	P450
42	275	277	O	2D6
43	279	285	O	isozyme
44	287	294	O	activity
45	296	300	O	among
46	302	306	O	Asian
47	307	307	O	,
48	309	315	O	African
49	316	316	O	,
50	318	320	O	and
51	322	326	O	other
52	328	338	O	populations
53	340	342	O	are
54	344	346	O	not
55	348	350	O	yet
56	352	360	O	available
NULL

Amitriptyline Hydrochloride	1183	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	O	tricyclic
11	79	93	O	antidepressants
12	96	99	O	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Amitriptyline Hydrochloride	1184	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

Amitriptyline Hydrochloride	1185	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Amitriptyline Hydrochloride	1186	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	O	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Amitriptyline Hydrochloride	1187	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	40
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	O	quinidine
18	107	116	O	cimetidine
19	119	121	O	and
20	123	126	O	many
21	128	131	O	that
22	133	135	O	are
23	137	146	O	substrates
24	148	150	O	for
25	152	155	O	P450
26	157	159	O	2D6
27	162	165	O	many
28	167	171	O	other
29	173	187	O	antidepressants
30	188	188	O	,
31	190	203	O	phenothiazines
32	204	204	O	,
33	206	208	O	and
34	210	212	O	the
35	214	217	O	Type
36	219	220	O	1C
37	222	236	O	antiarrhythmics
38	238	248	O	propafenone
39	250	252	O	and
40	254	263	O	flecainide
NULL

Amitriptyline Hydrochloride	1188	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	32	O	serotonin
6	34	41	O	reuptake
7	43	52	O	inhibitors
8	55	59	O	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	O	fluoxetine
13	79	79	O	,
14	81	90	O	sertraline
15	91	91	O	,
16	93	95	O	and
17	97	106	O	paroxetine
18	107	107	O	,
19	109	115	O	inhibit
20	117	120	O	P450
21	122	124	O	2D6
22	125	125	O	,
23	127	130	O	they
24	132	134	O	may
25	136	139	O	vary
26	141	142	O	in
27	144	146	O	the
28	148	153	O	extent
29	155	156	O	of
30	158	167	O	inhibition
NULL

Amitriptyline Hydrochloride	1189	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	O	TCA
7	29	40	U-TRI	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	O	SSRI
25	146	153	O	involved
NULL

Amitriptyline Hydrochloride	1190	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	25
Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	57	O	coadministration
9	59	60	O	of
10	62	65	O	TCAs
11	67	70	O	with
12	72	74	O	any
13	76	77	O	of
14	79	81	O	the
15	83	87	O	SSRIs
16	89	91	O	and
17	93	96	O	also
18	98	99	O	in
19	101	109	O	switching
20	111	114	O	from
21	116	118	O	one
22	120	124	O	class
23	126	127	O	to
24	129	131	O	the
25	133	137	O	other
NULL

Amitriptyline Hydrochloride	1191	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	B-TRI	sufficient
6	37	40	I-TRI	time
7	42	45	I-TRI	must
8	47	52	I-TRI	elapse
9	54	59	I-TRI	before
10	61	70	L-TRI	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Amitriptyline Hydrochloride	1192	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	tricyclic
5	29	43	O	antidepressants
6	45	48	O	with
7	50	54	B-KIN	drugs
8	56	59	I-KIN	that
9	61	63	I-KIN	can
10	65	71	I-KIN	inhibit
11	73	82	I-KIN	cytochrome
12	84	87	I-KIN	P450
13	89	91	L-KIN	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	B-TRI	lower
17	111	115	L-TRI	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	O	tricyclic
25	166	179	O	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
K/7:C54355

Amitriptyline Hydrochloride	1193	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	22
Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	73	O	cotherapy
13	74	74	O	,
14	76	77	O	an
15	79	87	O	increased
16	89	92	O	dose
17	94	95	O	of
18	97	105	O	tricyclic
19	107	120	O	antidepressant
20	122	124	O	may
21	126	127	O	be
22	129	136	O	required
NULL

Amitriptyline Hydrochloride	1194	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	27
It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	U-TRI	monitor
6	27	29	O	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	O	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	88	O	coadministered
17	90	93	O	with
18	95	101	O	another
19	103	106	O	drug
20	108	112	O	known
21	114	115	O	to
22	117	118	O	be
23	120	121	O	an
24	123	131	B-UNK	inhibitor
25	133	134	I-UNK	of
26	136	139	I-UNK	P450
27	141	143	L-UNK	2D6
NULL

Amitriptyline Hydrochloride	1195	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	16
Guanethidine or similarly acting compounds; thyroid medication; alcohol, barbiturates and other CNS depressants; and disulfiram.
1	0	11	O	Guanethidine
2	13	14	O	or
3	16	24	O	similarly
4	26	31	O	acting
5	33	41	O	compounds
6	44	50	O	thyroid
7	52	61	O	medication
8	64	70	O	alcohol
9	71	71	O	,
10	73	84	O	barbiturates
11	86	88	O	and
12	90	94	O	other
13	96	98	O	CNS
14	100	110	O	depressants
15	113	115	O	and
16	117	126	O	disulfiram
NULL

Amitriptyline Hydrochloride	1196	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	27
When amitriptyline hydrochloride is given with anticholinergic agents or sympathomimetic drugs, including epinephrine combined with local anesthetics, close supervision and careful adjustment of dosages are required.
1	0	3	O	When
2	5	31	O	XXXXXXXX
3	33	34	O	is
4	36	40	O	given
5	42	45	O	with
6	47	61	B-UNK	anticholinergic
7	63	68	L-UNK	agents
8	70	71	O	or
9	73	87	B-UNK	sympathomimetic
10	89	93	L-UNK	drugs
11	94	94	O	,
12	96	104	O	including
13	106	116	B-UNK	epinephrine
14	118	125	I-UNK	combined
15	127	130	I-UNK	with
16	132	136	I-UNK	local
17	138	148	L-UNK	anesthetics
18	149	149	O	,
19	151	155	B-TRI	close
20	157	167	L-TRI	supervision
21	169	171	O	and
22	173	179	O	careful
23	181	190	O	adjustment
24	192	193	O	of
25	195	201	O	dosages
26	203	205	O	are
27	207	214	O	required
NULL

Amitriptyline Hydrochloride	1197	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	20
Hyperpyrexia has been reported when amitriptyline hydrochloride is administered with anticholinergic agents or with neuroleptic drugs, particularly during hot weather.
1	0	11	U-EFF	Hyperpyrexia
2	13	15	O	has
3	17	20	O	been
4	22	29	O	reported
5	31	34	O	when
6	36	62	O	XXXXXXXX
7	64	65	O	is
8	67	78	O	administered
9	80	83	O	with
10	85	99	B-DYN	anticholinergic
11	101	106	L-DYN	agents
12	108	109	O	or
13	111	114	O	with
14	116	126	B-DYN	neuroleptic
15	128	132	L-DYN	drugs
16	133	133	O	,
17	135	146	O	particularly
18	148	153	O	during
19	155	157	O	hot
20	159	165	O	weather
D/10:1:1 D/14:1:1

Amitriptyline Hydrochloride	1198	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	15
Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic type drugs.
1	0	8	B-EFF	Paralytic
2	10	14	L-EFF	ileus
3	16	18	O	may
4	20	24	O	occur
5	26	27	O	in
6	29	36	O	patients
7	38	43	O	taking
8	45	53	O	tricyclic
9	55	69	O	antidepressants
10	71	72	O	in
11	74	84	O	combination
12	86	89	O	with
13	91	105	U-DYN	anticholinergic
14	107	110	O	type
15	112	116	O	drugs
D/13:1:1

Amitriptyline Hydrochloride	1199	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	23
Cimetidine is reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs.
1	0	9	U-KIN	Cimetidine
2	11	12	O	is
3	14	21	O	reported
4	23	24	O	to
5	26	31	O	reduce
6	33	39	O	hepatic
7	41	50	O	metabolism
8	52	53	O	of
9	55	61	O	certain
10	63	71	O	tricyclic
11	73	87	O	antidepressants
12	88	88	O	,
13	90	96	O	thereby
14	98	105	O	delaying
15	107	117	O	elimination
16	119	121	O	and
17	123	132	O	increasing
18	134	139	O	steady
19	141	145	O	state
20	147	160	O	concentrations
21	162	163	O	of
22	165	169	O	these
23	171	175	O	drugs
K/1:C54355

Amitriptyline Hydrochloride	1200	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	15
Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine.
1	0	9	O	Clinically
2	11	21	O	significant
3	23	29	O	effects
4	31	34	O	have
5	36	39	O	been
6	41	48	O	reported
7	50	53	O	with
8	55	57	O	the
9	59	67	O	tricyclic
10	69	83	O	antidepressants
11	85	88	O	when
12	90	93	O	used
13	95	107	O	concomitantly
14	109	112	O	with
15	114	123	O	cimetidine
NULL

Amitriptyline Hydrochloride	1201	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	32
Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.
1	0	8	O	Increases
2	10	11	O	in
3	13	18	O	plasma
4	20	25	O	levels
5	27	28	O	of
6	30	38	O	tricyclic
7	40	54	O	antidepressants
8	55	55	O	,
9	57	59	O	and
10	61	62	O	in
11	64	66	O	the
12	68	76	O	frequency
13	78	80	O	and
14	82	89	O	severity
15	91	92	O	of
16	94	97	O	side
17	99	105	O	effects
18	106	106	O	,
19	108	119	O	particularly
20	121	135	O	anticholinergic
21	136	136	O	,
22	138	141	O	have
23	143	146	O	been
24	148	155	O	reported
25	157	160	O	when
26	162	171	U-KIN	cimetidine
27	173	175	O	was
28	177	181	O	added
29	183	184	O	to
30	186	188	O	the
31	190	193	O	drug
32	195	201	O	regimen
K/26:C54355

Amitriptyline Hydrochloride	1202	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	22
Discontinuation of cimetidine in well controlled patients receiving tricyclic antidepressants and cimetidine may decrease the plasma levels and efficacy of the antidepressants.
1	0	14	O	Discontinuation
2	16	17	O	of
3	19	28	U-KIN	cimetidine
4	30	31	O	in
5	33	36	O	well
6	38	47	O	controlled
7	49	56	O	patients
8	58	66	O	receiving
9	68	76	O	tricyclic
10	78	92	O	antidepressants
11	94	96	O	and
12	98	107	O	cimetidine
13	109	111	O	may
14	113	120	O	decrease
15	122	124	O	the
16	126	131	O	plasma
17	133	138	O	levels
18	140	142	O	and
19	144	151	O	efficacy
20	153	154	O	of
21	156	158	O	the
22	160	174	O	antidepressants
K/3:C54355

Amitriptyline Hydrochloride	1203	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	11
Caution is advised if patients receive large doses of ethchlorvynol concurrently.
1	0	6	U-TRI	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	if
5	22	29	O	patients
6	31	37	O	receive
7	39	43	O	large
8	45	49	O	doses
9	51	52	O	of
10	54	66	U-UNK	ethchlorvynol
11	68	79	O	concurrently
NULL

Amitriptyline Hydrochloride	1204	34073-7	ea35caf8-c8c8-481a-97a2-25f68cbc240b	23
Transient delirium has been reported in patients who were treated with one gram of ethchlorvynol and 75 mg to 150 mg of amitriptyline hydrochloride.
1	0	8	B-EFF	Transient
2	10	17	L-EFF	delirium
3	19	21	O	has
4	23	26	O	been
5	28	35	O	reported
6	37	38	O	in
7	40	47	O	patients
8	49	51	O	who
9	53	56	O	were
10	58	64	O	treated
11	66	69	O	with
12	71	73	O	one
13	75	78	O	gram
14	80	81	O	of
15	83	95	U-DYN	ethchlorvynol
16	97	99	O	and
17	101	102	O	75
18	104	105	O	mg
19	107	108	O	to
20	110	112	O	150
21	114	115	O	mg
22	117	118	O	of
23	120	146	O	XXXXXXXX
D/15:1:1

Amitriptyline Hydrochloride	1205	34090-1	ea35caf8-c8c8-481a-97a2-25f68cbc240b	7
Amitriptyline hydrochloride is an antidepressant with sedative effects.
1	0	26	O	XXXXXXXX
2	28	29	O	is
3	31	32	O	an
4	34	47	O	antidepressant
5	49	52	O	with
6	54	61	O	sedative
7	63	69	O	effects
NULL

Amitriptyline Hydrochloride	1206	34090-1	ea35caf8-c8c8-481a-97a2-25f68cbc240b	9
Its mechanism of action in man is not known.
1	0	2	O	Its
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	in
6	27	29	O	man
7	31	32	O	is
8	34	36	O	not
9	38	42	O	known
NULL

Amitriptyline Hydrochloride	1207	34090-1	ea35caf8-c8c8-481a-97a2-25f68cbc240b	20
It is not a monoamine oxidase inhibitor and it does not act primarily by stimulation of the central nervous system.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	10	O	a
5	12	20	O	monoamine
6	22	28	O	oxidase
7	30	38	O	inhibitor
8	40	42	O	and
9	44	45	O	it
10	47	50	O	does
11	52	54	O	not
12	56	58	O	act
13	60	68	O	primarily
14	70	71	O	by
15	73	83	O	stimulation
16	85	86	O	of
17	88	90	O	the
18	92	98	O	central
19	100	106	O	nervous
20	108	113	O	system
NULL

Amitriptyline Hydrochloride	1208	34090-1	ea35caf8-c8c8-481a-97a2-25f68cbc240b	18
Amitriptyline inhibits the membrane pump mechanism responsible for uptake of norepinephrine and serotonin in adrenergic and serotonergic neurons.
1	0	12	O	XXXXXXXX
2	14	21	O	inhibits
3	23	25	O	the
4	27	34	O	membrane
5	36	39	O	pump
6	41	49	O	mechanism
7	51	61	O	responsible
8	63	65	O	for
9	67	72	O	uptake
10	74	75	O	of
11	77	90	O	norepinephrine
12	92	94	O	and
13	96	104	O	serotonin
14	106	107	O	in
15	109	118	O	adrenergic
16	120	122	O	and
17	124	135	O	serotonergic
18	137	143	O	neurons
NULL

Amitriptyline Hydrochloride	1209	34090-1	ea35caf8-c8c8-481a-97a2-25f68cbc240b	22
Pharmacologically this action may potentiate or prolong neuronal activity since reuptake of these biogenic amines is important physiologically in terminating transmitting activity.
1	0	16	O	Pharmacologically
2	18	21	O	this
3	23	28	O	action
4	30	32	O	may
5	34	43	O	potentiate
6	45	46	O	or
7	48	54	O	prolong
8	56	63	O	neuronal
9	65	72	O	activity
10	74	78	O	since
11	80	87	O	reuptake
12	89	90	O	of
13	92	96	O	these
14	98	105	O	biogenic
15	107	112	O	amines
16	114	115	O	is
17	117	125	O	important
18	127	141	O	physiologically
19	143	144	O	in
20	146	156	O	terminating
21	158	169	O	transmitting
22	171	178	O	activity
NULL

Amitriptyline Hydrochloride	1210	34090-1	ea35caf8-c8c8-481a-97a2-25f68cbc240b	21
This interference with reuptake of norepinephrine and/or serotonin is believed by some to underlie the antidepressant activity of amitriptyline.
1	0	3	O	This
2	5	16	O	interference
3	18	21	O	with
4	23	30	O	reuptake
5	32	33	O	of
6	35	48	O	norepinephrine
7	50	52	O	and
8	53	53	O	/
9	54	55	O	or
10	57	65	O	serotonin
11	67	68	O	is
12	70	77	O	believed
13	79	80	O	by
14	82	85	O	some
15	87	88	O	to
16	90	97	O	underlie
17	99	101	O	the
18	103	116	O	antidepressant
19	118	125	O	activity
20	127	128	O	of
21	130	142	O	XXXXXXXX
NULL

Amoxapine	3401	34073-7	a16297df-3158-48db-85e5-5cd506885556	12
See CONTRAINDICATIONS about concurrent usage of tricyclic antidepressants and monoamine oxidase inhibitors.
1	0	2	O	See
2	4	20	U-TRI	CONTRAINDICATIONS
3	22	26	O	about
4	28	37	O	concurrent
5	39	43	O	usage
6	45	46	O	of
7	48	56	B-UNK	tricyclic
8	58	72	L-UNK	antidepressants
9	74	76	O	and
10	78	86	B-UNK	monoamine
11	88	94	I-UNK	oxidase
12	96	105	L-UNK	inhibitors
NULL

Amoxapine	3402	34073-7	a16297df-3158-48db-85e5-5cd506885556	14
Paralytic ileus may occur in patients taking tricyclic antidepressants in combination with anticholinergic drugs.
1	0	8	B-EFF	Paralytic
2	10	14	L-EFF	ileus
3	16	18	O	may
4	20	24	O	occur
5	26	27	O	in
6	29	36	O	patients
7	38	43	O	taking
8	45	53	O	tricyclic
9	55	69	O	antidepressants
10	71	72	O	in
11	74	84	O	combination
12	86	89	O	with
13	91	105	B-DYN	anticholinergic
14	107	111	L-DYN	drugs
D/13:1:1

Amoxapine	3403	34073-7	a16297df-3158-48db-85e5-5cd506885556	16
Amoxapine may enhance the response to alcohol and the effects of barbiturates and other CNS depressants.
1	0	8	O	XXXXXXXX
2	10	12	O	may
3	14	20	B-EFF	enhance
4	22	24	I-EFF	the
5	26	33	I-EFF	response
6	35	36	I-EFF	to
7	38	44	L-EFF	alcohol
8	46	48	O	and
9	50	52	O	the
10	54	60	O	effects
11	62	63	O	of
12	65	76	U-DYN	barbiturates
13	78	80	O	and
14	82	86	O	other
15	88	90	B-DYN	CNS
16	92	102	L-DYN	depressants
D/12:3:0 D/15:3:0

Amoxapine	3404	34073-7	a16297df-3158-48db-85e5-5cd506885556	18
Serum levels of several tricyclic antidepressants have been reported to be significantly increased when cimetidine is administered concurrently.
1	0	4	O	Serum
2	6	11	O	levels
3	13	14	O	of
4	16	22	O	several
5	24	32	O	tricyclic
6	34	48	O	antidepressants
7	50	53	O	have
8	55	58	O	been
9	60	67	O	reported
10	69	70	O	to
11	72	73	O	be
12	75	87	O	significantly
13	89	97	O	increased
14	99	102	O	when
15	104	113	U-KIN	cimetidine
16	115	116	O	is
17	118	129	O	administered
18	131	142	O	concurrently
K/15:C54355

Amoxapine	3405	34073-7	a16297df-3158-48db-85e5-5cd506885556	27
Although such an interaction has not been reported to date with amoxapine, specific interaction studies have not been done, and the possibility should be considered.
1	0	7	O	Although
2	9	12	O	such
3	14	15	O	an
4	17	27	O	interaction
5	29	31	O	has
6	33	35	O	not
7	37	40	O	been
8	42	49	O	reported
9	51	52	O	to
10	54	57	O	date
11	59	62	O	with
12	64	72	O	XXXXXXXX
13	73	73	O	,
14	75	82	O	specific
15	84	94	O	interaction
16	96	102	O	studies
17	104	107	O	have
18	109	111	O	not
19	113	116	O	been
20	118	121	O	done
21	122	122	O	,
22	124	126	O	and
23	128	130	O	the
24	132	142	O	possibility
25	144	149	O	should
26	151	152	O	be
27	154	163	O	considered
NULL

Amoxapine	3406	34073-7	a16297df-3158-48db-85e5-5cd506885556	60
Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	32	34	O	The
7	36	46	O	biochemical
8	48	55	O	activity
9	57	58	O	of
10	60	62	O	the
11	64	67	O	drug
12	69	80	O	metabolizing
13	82	88	O	isozyme
14	90	99	O	cytochrome
15	101	104	O	P450
16	106	108	O	2D6
17	111	121	O	debrisoquin
18	123	133	O	hydroxylase
19	136	137	O	is
20	139	145	O	reduced
21	147	148	O	in
22	150	150	O	a
23	152	157	O	subset
24	159	160	O	of
25	162	164	O	the
26	166	174	O	Caucasian
27	176	185	O	population
28	188	192	O	about
29	194	195	O	7%
30	197	198	O	to
31	200	202	O	10%
32	204	205	O	of
33	207	216	O	Caucasians
34	218	220	O	are
35	222	223	O	so
36	225	230	O	called
37	232	236	O	"poor
38	238	250	O	metabolizers"
39	254	261	O	reliable
40	263	271	O	estimates
41	273	274	O	of
42	276	278	O	the
43	280	289	O	prevalence
44	291	292	O	of
45	294	300	O	reduced
46	302	305	O	P450
47	307	309	O	2D6
48	311	317	O	isozyme
49	319	326	O	activity
50	328	332	O	among
51	334	338	O	Asian
52	339	339	O	,
53	341	347	O	African
54	349	351	O	and
55	353	357	O	other
56	359	369	O	populations
57	371	373	O	are
58	375	377	O	not
59	379	381	O	yet
60	383	391	O	available
NULL

Amoxapine	3407	34073-7	a16297df-3158-48db-85e5-5cd506885556	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	O	tricyclic
11	79	93	O	antidepressants
12	96	99	O	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Amoxapine	3408	34073-7	a16297df-3158-48db-85e5-5cd506885556	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

Amoxapine	3409	34073-7	a16297df-3158-48db-85e5-5cd506885556	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Amoxapine	3410	34073-7	a16297df-3158-48db-85e5-5cd506885556	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	O	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Amoxapine	3411	34073-7	a16297df-3158-48db-85e5-5cd506885556	40
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	O	quinidine
18	107	116	O	cimetidine
19	119	121	O	and
20	123	126	O	many
21	128	131	O	that
22	133	135	O	are
23	137	146	O	substrates
24	148	150	O	for
25	152	155	O	P450
26	157	159	O	2D6
27	162	165	O	many
28	167	171	O	other
29	173	187	O	antidepressants
30	188	188	O	,
31	190	203	O	phenothiazines
32	204	204	O	,
33	206	208	O	and
34	210	212	O	the
35	214	217	O	Type
36	219	220	O	1C
37	222	236	O	antiarrhythmics
38	238	248	O	propafenone
39	250	252	O	and
40	254	263	O	flecainide
NULL

Amoxapine	3412	34073-7	a16297df-3158-48db-85e5-5cd506885556	28
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	52	O	GGGGGGGG
6	55	59	O	SSRIs
7	61	61	O	,
8	63	65	O	e.g
9	67	67	O	,
10	69	78	O	fluoxetine
11	79	79	O	,
12	81	90	O	sertraline
13	91	91	O	,
14	93	95	O	and
15	97	106	O	paroxetine
16	107	107	O	,
17	109	115	O	inhibit
18	117	120	O	P450
19	122	124	O	2D6
20	125	125	O	,
21	127	130	O	they
22	132	134	O	may
23	136	139	O	vary
24	141	142	O	in
25	144	146	O	the
26	148	153	O	extent
27	155	156	O	of
28	158	167	O	inhibition
NULL

Amoxapine	3413	34073-7	a16297df-3158-48db-85e5-5cd506885556	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	O	TCA
7	29	40	U-TRI	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	O	SSRI
25	146	153	O	involved
NULL

Amoxapine	3414	34073-7	a16297df-3158-48db-85e5-5cd506885556	26
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

Amoxapine	3415	34073-7	a16297df-3158-48db-85e5-5cd506885556	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	B-TRI	sufficient
6	37	40	I-TRI	time
7	42	45	I-TRI	must
8	47	52	I-TRI	elapse
9	54	59	I-TRI	before
10	61	70	L-TRI	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Amoxapine	3416	34073-7	a16297df-3158-48db-85e5-5cd506885556	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	tricyclic
5	29	43	O	antidepressants
6	45	48	O	with
7	50	54	B-KIN	drugs
8	56	59	I-KIN	that
9	61	63	I-KIN	can
10	65	71	I-KIN	inhibit
11	73	82	I-KIN	cytochrome
12	84	87	I-KIN	P450
13	89	91	L-KIN	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	B-TRI	lower
17	111	115	L-TRI	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	O	tricyclic
25	166	179	O	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
K/7:C54357

Amoxapine	3417	34073-7	a16297df-3158-48db-85e5-5cd506885556	23
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	66	O	co
13	68	74	O	therapy
14	75	75	O	,
15	77	78	O	an
16	80	88	O	increased
17	90	93	O	dose
18	95	96	O	of
19	98	106	O	tricyclic
20	108	121	O	antidepressant
21	123	125	O	may
22	127	128	O	be
23	130	137	O	required
NULL

Amoxapine	3418	34073-7	a16297df-3158-48db-85e5-5cd506885556	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	U-TRI	monitor
6	27	29	O	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	O	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	B-UNK	inhibitor
26	134	135	I-UNK	of
27	137	140	I-UNK	P450
28	142	144	L-UNK	2D6
NULL

Amoxapine	3419	34090-1	a16297df-3158-48db-85e5-5cd506885556	12
Amoxapine is an antidepressant with a mild sedative component to its action.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	14	O	an
4	16	29	O	antidepressant
5	31	34	O	with
6	36	36	O	a
7	38	41	O	mild
8	43	50	O	sedative
9	52	60	O	component
10	62	63	O	to
11	65	67	O	its
12	69	74	O	action
NULL

Amoxapine	3420	34090-1	a16297df-3158-48db-85e5-5cd506885556	12
The mechanism of its clinical action in man is not well understood.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	19	O	its
5	21	28	O	clinical
6	30	35	O	action
7	37	38	O	in
8	40	42	O	man
9	44	45	O	is
10	47	49	O	not
11	51	54	O	well
12	56	65	O	understood
NULL

Amoxapine	3421	34090-1	a16297df-3158-48db-85e5-5cd506885556	20
In animals, amoxapine reduced the uptake of norepinephrine and serotonin and blocked the response of dopamine receptors to dopamine.
1	0	1	O	In
2	3	9	O	animals
3	10	10	O	,
4	12	20	O	XXXXXXXX
5	22	28	O	reduced
6	30	32	O	the
7	34	39	O	uptake
8	41	42	O	of
9	44	57	O	norepinephrine
10	59	61	O	and
11	63	71	O	serotonin
12	73	75	O	and
13	77	83	O	blocked
14	85	87	O	the
15	89	96	O	response
16	98	99	O	of
17	101	108	O	dopamine
18	110	118	O	receptors
19	120	121	O	to
20	123	130	O	dopamine
NULL

Amoxapine	3422	34090-1	a16297df-3158-48db-85e5-5cd506885556	7
Amoxapine is not a monoamine oxidase inhibitor.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	15	O	not
4	17	17	O	a
5	19	27	O	monoamine
6	29	35	O	oxidase
7	37	45	O	inhibitor
NULL

Amoxapine	3423	34090-1	a16297df-3158-48db-85e5-5cd506885556	14
Amoxapine is absorbed rapidly and reaches peak blood levels approximately 90 minutes after ingestion.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	20	O	absorbed
4	22	28	O	rapidly
5	30	32	O	and
6	34	40	O	reaches
7	42	45	O	peak
8	47	51	O	blood
9	53	58	O	levels
10	60	72	O	approximately
11	74	75	O	90
12	77	83	O	minutes
13	85	89	O	after
14	91	99	O	ingestion
NULL

Amoxapine	3424	34090-1	a16297df-3158-48db-85e5-5cd506885556	8
The main route of excretion is the kidney.
1	0	2	O	The
2	4	7	O	main
3	9	13	O	route
4	15	16	O	of
5	18	26	O	excretion
6	28	29	O	is
7	31	33	O	the
8	35	40	O	kidney
NULL

Amoxapine	3425	34090-1	a16297df-3158-48db-85e5-5cd506885556	13
In vitro tests show that amoxapine binding to human serum is approximately 90%.
1	0	1	O	In
2	3	7	O	vitro
3	9	13	O	tests
4	15	18	O	show
5	20	23	O	that
6	25	33	O	XXXXXXXX
7	35	41	O	binding
8	43	44	O	to
9	46	50	O	human
10	52	56	O	serum
11	58	59	O	is
12	61	73	O	approximately
13	75	77	O	90%
NULL

Amoxapine	3426	34090-1	a16297df-3158-48db-85e5-5cd506885556	14
In man, amoxapine serum concentration declines with a half-life of eight hours.
1	0	1	O	In
2	3	5	O	man
3	6	6	O	,
4	8	16	O	XXXXXXXX
5	18	22	O	serum
6	24	36	O	concentration
7	38	45	O	declines
8	47	50	O	with
9	52	52	O	a
10	54	57	O	half
11	59	62	O	life
12	64	65	O	of
13	67	71	O	eight
14	73	77	O	hours
NULL

Amoxapine	3427	34090-1	a16297df-3158-48db-85e5-5cd506885556	18
However, the major metabolite, 8-hydroxyamoxapine, has a biologic half-life of 30 hours.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	17	O	major
5	19	28	O	metabolite
6	29	29	O	,
7	31	31	O	8
8	33	39	O	hydroxy
9	40	48	O	XXXXXXXX
10	49	49	O	,
11	51	53	O	has
12	55	55	O	a
13	57	64	O	biologic
14	66	69	O	half
15	71	74	O	life
16	76	77	O	of
17	79	80	O	30
18	82	86	O	hours
NULL

Amoxapine	3428	34090-1	a16297df-3158-48db-85e5-5cd506885556	11
Metabolites are excreted in the urine in conjugated form as glucuronides.
1	0	10	O	Metabolites
2	12	14	O	are
3	16	23	O	excreted
4	25	26	O	in
5	28	30	O	the
6	32	36	O	urine
7	38	39	O	in
8	41	50	O	conjugated
9	52	55	O	form
10	57	58	O	as
11	60	71	O	glucuronides
NULL

Amoxapine	3429	34090-1	a16297df-3158-48db-85e5-5cd506885556	18
Clinical studies have demonstrated that amoxapine has a more rapid onset of action than either amitriptyline or imipramine.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	33	O	demonstrated
5	35	38	O	that
6	40	48	O	XXXXXXXX
7	50	52	O	has
8	54	54	O	a
9	56	59	O	more
10	61	65	O	rapid
11	67	71	O	onset
12	73	74	O	of
13	76	81	O	action
14	83	86	O	than
15	88	93	O	either
16	95	107	O	amitriptyline
17	109	110	O	or
18	112	121	O	imipramine
NULL

Amoxapine	3430	34090-1	a16297df-3158-48db-85e5-5cd506885556	21
The initial clinical effect may occur within four to seven days and occurs within two weeks in over 80% of responders.
1	0	2	O	The
2	4	10	O	initial
3	12	19	O	clinical
4	21	26	O	effect
5	28	30	O	may
6	32	36	O	occur
7	38	43	O	within
8	45	48	O	four
9	50	51	O	to
10	53	57	O	seven
11	59	62	O	days
12	64	66	O	and
13	68	73	O	occurs
14	75	80	O	within
15	82	84	O	two
16	86	90	O	weeks
17	92	93	O	in
18	95	98	O	over
19	100	102	O	80%
20	104	105	O	of
21	107	116	O	responders
NULL

Apixaban	1211	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	10
Apixaban is a substrate of both CYP3A4 and P-gp.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	12	O	a
4	14	22	O	substrate
5	24	25	O	of
6	27	30	O	both
7	32	37	O	CYP3A4
8	39	41	O	and
9	43	43	O	P
10	45	46	O	gp
NULL

Apixaban	1212	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	16
Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of bleeding.
1	0	9	B-DYN	Inhibitors
2	11	12	I-DYN	of
3	14	19	L-DYN	CYP3A4
4	21	23	O	and
5	25	25	O	P
6	27	28	O	gp
7	30	37	B-TRI	increase
8	39	46	L-TRI	exposure
9	48	49	O	to
10	51	58	O	XXXXXXXX
11	60	62	O	and
12	64	71	O	increase
13	73	75	O	the
14	77	80	O	risk
15	82	83	O	of
16	85	92	U-EFF	bleeding
D/1:16:1

Apixaban	1213	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	20
Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of stroke and other thromboembolic events.
1	0	7	B-DYN	Inducers
2	9	10	I-DYN	of
3	12	17	L-DYN	CYP3A4
4	19	21	O	and
5	23	23	O	P
6	25	26	O	gp
7	28	35	B-TRI	decrease
8	37	44	L-TRI	exposure
9	46	47	O	to
10	49	56	O	XXXXXXXX
11	58	60	O	and
12	62	69	O	increase
13	71	73	O	the
14	75	78	O	risk
15	80	81	O	of
16	83	88	U-EFF	stroke
17	90	92	O	and
18	94	98	O	other
19	100	113	B-EFF	thromboembolic
20	115	120	L-EFF	events
D/1:16:1 D/1:19:1

Apixaban	1214	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	12
*Combined P-gp and strong CYP3A4 inhibitors increase blood levels of apixaban.
1	0	8	O	Combined
2	10	10	B-KIN	P
3	12	13	I-KIN	gp
4	15	17	I-KIN	and
5	19	24	I-KIN	strong
6	26	31	I-KIN	CYP3A4
7	33	42	L-KIN	inhibitors
8	44	51	B-TRI	increase
9	53	57	I-TRI	blood
10	59	64	L-TRI	levels
11	66	67	O	of
12	69	76	O	XXXXXXXX
K/2:C54355

Apixaban	1215	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	6
Reduce ELIQUIS dose or avoid coadministration.
1	0	5	O	Reduce
2	7	13	O	ELIQUIS
3	15	18	O	dose
4	20	21	O	or
5	23	27	O	avoid
6	29	44	O	coadministration
NULL

Apixaban	1216	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	20
*Simultaneous use of strong dual inducers of CYP3A4 and P-gp reduces blood levels of apixaban: Avoid concomitant use.
1	0	12	O	Simultaneous
2	14	16	O	use
3	18	19	O	of
4	21	26	B-KIN	strong
5	28	31	I-KIN	dual
6	33	40	I-KIN	inducers
7	42	43	I-KIN	of
8	45	50	I-KIN	CYP3A4
9	52	54	I-KIN	and
10	56	56	I-KIN	P
11	58	59	L-KIN	gp
12	61	67	B-TRI	reduces
13	69	73	I-TRI	blood
14	75	80	L-TRI	levels
15	82	83	O	of
16	85	92	O	XXXXXXXX
17	93	93	O	:
18	95	99	O	Avoid
19	101	111	O	concomitant
20	113	115	O	use
K/4:C54356

Apixaban	1217	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	41
For patients receiving ELIQUIS 5 mg or 10 mg twice daily, the dose of ELIQUIS should be decreased by 50% when coadministered with drugs that are combined P-gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir).
1	0	2	O	For
2	4	11	O	patients
3	13	21	O	receiving
4	23	29	O	ELIQUIS
5	31	31	O	5
6	33	34	O	mg
7	36	37	O	or
8	39	40	O	10
9	42	43	O	mg
10	45	49	O	twice
11	51	55	O	daily
12	56	56	O	,
13	58	60	O	the
14	62	65	O	dose
15	67	68	O	of
16	70	76	O	ELIQUIS
17	78	83	O	should
18	85	86	O	be
19	88	96	O	decreased
20	98	99	O	by
21	101	103	O	50%
22	105	108	O	when
23	110	123	O	coadministered
24	125	128	O	with
25	130	134	O	drugs
26	136	139	O	that
27	141	143	O	are
28	145	152	B-KIN	combined
29	154	154	I-KIN	P
30	156	157	I-KIN	gp
31	159	161	I-KIN	and
32	163	168	I-KIN	strong
33	170	175	I-KIN	CYP3A4
34	177	186	L-KIN	inhibitors
35	189	191	O	e.g
36	193	193	O	,
37	195	206	U-KIN	ketoconazole
38	207	207	O	,
39	209	220	U-KIN	itraconazole
40	221	221	O	,
41	223	231	U-KIN	ritonavir
K/28:C54355 K/37:C54355 K/39:C54355 K/41:C54355

Apixaban	1218	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	23
For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with combined P-gp and strong CYP3A4 inhibitors.
1	0	2	O	For
2	4	11	O	patients
3	13	21	O	receiving
4	23	29	O	ELIQUIS
5	31	32	O	at
6	34	34	O	a
7	36	39	O	dose
8	41	42	O	of
9	44	46	O	2.5
10	48	49	O	mg
11	51	55	O	twice
12	57	61	O	daily
13	62	62	O	,
14	64	68	U-TRI	avoid
15	70	85	O	coadministration
16	87	90	O	with
17	92	99	B-UNK	combined
18	101	101	I-UNK	P
19	103	104	I-UNK	gp
20	106	108	I-UNK	and
21	110	115	I-UNK	strong
22	117	122	I-UNK	CYP3A4
23	124	133	L-UNK	inhibitors
NULL

Apixaban	1219	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	26
Although clarithromycin is a combined P-gp and strong CYP3A4 inhibitor, pharmacokinetic data suggest that no dose adjustment is necessary with concomitant administration with ELIQUIS.
1	0	7	O	Although
2	9	22	O	clarithromycin
3	24	25	O	is
4	27	27	O	a
5	29	36	O	combined
6	38	38	O	P
7	40	41	O	gp
8	43	45	O	and
9	47	52	O	strong
10	54	59	O	CYP3A4
11	61	69	O	inhibitor
12	70	70	O	,
13	72	86	O	pharmacokinetic
14	88	91	O	data
15	93	99	O	suggest
16	101	104	O	that
17	106	107	O	no
18	109	112	O	dose
19	114	123	O	adjustment
20	125	126	O	is
21	128	136	O	necessary
22	138	141	O	with
23	143	153	O	concomitant
24	155	168	O	administration
25	170	173	O	with
26	175	181	O	ELIQUIS
NULL

Apixaban	1220	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	33
Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. John's wort) because such drugs will decrease exposure to apixaban.
1	0	4	O	Avoid
2	6	16	O	concomitant
3	18	20	O	use
4	22	23	O	of
5	25	31	O	ELIQUIS
6	33	36	O	with
7	38	43	B-KIN	strong
8	45	48	I-KIN	dual
9	50	57	I-KIN	inducers
10	59	60	I-KIN	of
11	62	67	I-KIN	CYP3A4
12	69	71	I-KIN	and
13	73	73	I-KIN	P
14	75	76	L-KIN	gp
15	79	81	O	e.g
16	83	83	O	,
17	85	92	U-KIN	rifampin
18	93	93	O	,
19	95	107	U-KIN	carbamazepine
20	108	108	O	,
21	110	118	U-KIN	phenytoin
22	119	119	O	,
23	121	122	B-KIN	St
24	125	130	I-KIN	John's
25	132	135	L-KIN	wort
26	138	144	O	because
27	146	149	O	such
28	151	155	O	drugs
29	157	160	O	will
30	162	169	B-TRI	decrease
31	171	178	L-TRI	exposure
32	180	181	O	to
33	183	190	O	XXXXXXXX
K/17:C54356 K/19:C54356 K/21:C54356 K/23:C54356 K/7:C54356

Apixaban	1224	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	40
In ARISTOTLE, concomitant use of aspirin increased the bleeding risk on ELIQUIS from 1.8% per year to 3.4% per year and concomitant use of aspirin and warfarin increased the bleeding risk from 2.7% per year to 4.6% per year.
1	0	1	O	In
2	3	11	O	ARISTOTLE
3	12	12	O	,
4	14	24	O	concomitant
5	26	28	O	use
6	30	31	O	of
7	33	39	U-DYN	aspirin
8	41	49	O	increased
9	51	53	O	the
10	55	62	U-EFF	bleeding
11	64	67	O	risk
12	69	70	O	on
13	72	78	O	ELIQUIS
14	80	83	O	from
15	85	88	O	1.8%
16	90	92	O	per
17	94	97	O	year
18	99	100	O	to
19	102	105	O	3.4%
20	107	109	O	per
21	111	114	O	year
22	116	118	O	and
23	120	130	O	concomitant
24	132	134	O	use
25	136	137	O	of
26	139	145	B-DYN	aspirin
27	147	149	I-DYN	and
28	151	158	L-DYN	warfarin
29	160	168	O	increased
30	170	172	O	the
31	174	181	O	bleeding
32	183	186	O	risk
33	188	191	O	from
34	193	196	O	2.7%
35	198	200	O	per
36	202	205	O	year
37	207	208	O	to
38	210	213	O	4.6%
39	215	217	O	per
40	219	222	O	year
D/26:10:1 D/7:10:1

Apixaban	1225	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	16
In this clinical trial, there was limited (2.3%) use of dual antiplatelet therapy with ELIQUIS.
1	0	1	O	In
2	3	6	O	this
3	8	15	O	clinical
4	17	21	O	trial
5	22	22	O	,
6	24	28	O	there
7	30	32	O	was
8	34	40	O	limited
9	43	46	O	2.3%
10	49	51	O	use
11	53	54	O	of
12	56	59	O	dual
13	61	72	O	antiplatelet
14	74	80	O	therapy
15	82	85	O	with
16	87	93	O	ELIQUIS
NULL

Apixaban	1230	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	19
Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of bleeding.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	38	U-DYN	GGGGGGGG
4	39	39	O	,
5	41	53	U-DYN	fibrinolytics
6	54	54	O	,
7	56	62	U-DYN	heparin
8	63	63	O	,
9	65	71	U-DYN	aspirin
10	72	72	O	,
11	74	76	O	and
12	78	84	O	chronic
13	86	90	U-DYN	NSAID
14	92	94	O	use
15	96	104	O	increases
16	106	108	O	the
17	110	113	O	risk
18	115	116	O	of
19	118	125	U-EFF	bleeding
D/13:19:1 D/3:19:1 D/5:19:1 D/7:19:1 D/9:19:1

Apixaban	1231	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	45
APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk, post-acute coronary syndrome patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of bleeding with apixaban compared to placebo.
1	0	7	O	APPRAISE
2	9	9	O	2
3	10	10	O	,
4	12	12	O	a
5	14	20	O	placebo
6	22	31	O	controlled
7	33	40	O	clinical
8	42	46	O	trial
9	48	49	O	of
10	51	58	O	XXXXXXXX
11	60	61	O	in
12	63	66	O	high
13	68	71	O	risk
14	72	72	O	,
15	74	77	O	post
16	79	83	O	acute
17	85	92	O	coronary
18	94	101	O	syndrome
19	103	110	O	patients
20	112	118	O	treated
21	120	123	O	with
22	125	131	U-DYN	aspirin
23	133	134	O	or
24	136	138	O	the
25	140	150	B-DYN	combination
26	152	153	I-DYN	of
27	155	161	I-DYN	aspirin
28	163	165	I-DYN	and
29	167	177	L-DYN	clopidogrel
30	178	178	O	,
31	180	182	O	was
32	184	193	O	terminated
33	195	199	O	early
34	201	203	O	due
35	205	206	O	to
36	208	208	O	a
37	210	215	O	higher
38	217	220	O	rate
39	222	223	O	of
40	225	232	U-EFF	bleeding
41	234	237	O	with
42	239	246	O	XXXXXXXX
43	248	255	O	compared
44	257	258	O	to
45	260	266	O	placebo
D/22:40:1 D/25:40:1

Apixaban	1232	34073-7	e9481622-7cc6-418a-acb6-c5450daae9b0	43
The rate of ISTH major bleeding was 2.8% per year with apixaban versus 0.6% per year with placebo in patients receiving single antiplatelet therapy and was 5.9% per year with apixaban versus 2.5% per year with placebo in those receiving dual antiplatelet therapy.
1	0	2	O	The
2	4	7	O	rate
3	9	10	O	of
4	12	15	O	ISTH
5	17	21	B-EFF	major
6	23	30	L-EFF	bleeding
7	32	34	O	was
8	36	39	O	2.8%
9	41	43	O	per
10	45	48	O	year
11	50	53	O	with
12	55	62	O	XXXXXXXX
13	64	69	O	versus
14	71	74	O	0.6%
15	76	78	O	per
16	80	83	O	year
17	85	88	O	with
18	90	96	O	placebo
19	98	99	O	in
20	101	108	O	patients
21	110	118	O	receiving
22	120	125	O	single
23	127	138	B-DYN	antiplatelet
24	140	146	L-DYN	therapy
25	148	150	O	and
26	152	154	O	was
27	156	159	O	5.9%
28	161	163	O	per
29	165	168	O	year
30	170	173	O	with
31	175	182	O	XXXXXXXX
32	184	189	O	versus
33	191	194	O	2.5%
34	196	198	O	per
35	200	203	O	year
36	205	208	O	with
37	210	216	O	placebo
38	218	219	O	in
39	221	225	O	those
40	227	235	O	receiving
41	237	240	O	dual
42	242	253	O	antiplatelet
43	255	261	O	therapy
D/23:5:1

Apixaban	1235	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	7
Apixaban is a selective inhibitor of FXa.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	12	O	a
4	14	22	O	selective
5	24	32	O	inhibitor
6	34	35	O	of
7	37	39	O	FXa
NULL

Apixaban	1236	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	9
It does not require antithrombin III for antithrombotic activity.
1	0	1	O	It
2	3	6	O	does
3	8	10	O	not
4	12	18	O	require
5	20	31	O	antithrombin
6	33	35	O	III
7	37	39	O	for
8	41	54	O	antithrombotic
9	56	63	O	activity
NULL

Apixaban	1237	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	11
Apixaban inhibits free and clot-bound FXa, and prothrombinase activity.
1	0	7	O	XXXXXXXX
2	9	16	O	inhibits
3	18	21	O	free
4	23	25	O	and
5	27	30	O	clot
6	32	36	O	bound
7	38	40	O	FXa
8	41	41	O	,
9	43	45	O	and
10	47	60	O	prothrombinase
11	62	69	O	activity
NULL

Apixaban	1238	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	17
Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	14	O	no
4	16	21	O	direct
5	23	28	O	effect
6	30	31	O	on
7	33	40	O	platelet
8	42	52	O	aggregation
9	53	53	O	,
10	55	57	O	but
11	59	68	O	indirectly
12	70	77	O	inhibits
13	79	86	O	platelet
14	88	98	O	aggregation
15	100	106	O	induced
16	108	109	O	by
17	111	118	O	thrombin
NULL

Apixaban	1239	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	11
By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.
1	0	1	O	By
2	3	12	O	inhibiting
3	14	16	O	FXa
4	17	17	O	,
5	19	26	O	XXXXXXXX
6	28	36	O	decreases
7	38	45	O	thrombin
8	47	56	O	generation
9	58	60	O	and
10	62	69	O	thrombus
11	71	81	O	development
NULL

Apixaban	1240	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	25
As a result of FXa inhibition, apixaban prolongs clotting tests such as prothrombin time (PT), INR, and activated partial thromboplastin time (aPTT).
1	0	1	O	As
2	3	3	O	a
3	5	10	O	result
4	12	13	O	of
5	15	17	O	FXa
6	19	28	O	inhibition
7	29	29	O	,
8	31	38	O	XXXXXXXX
9	40	47	O	prolongs
10	49	56	O	clotting
11	58	62	O	tests
12	64	67	O	such
13	69	70	O	as
14	72	82	O	prothrombin
15	84	87	O	time
16	90	91	O	PT
17	93	93	O	,
18	95	97	O	INR
19	98	98	O	,
20	100	102	O	and
21	104	112	O	activated
22	114	120	O	partial
23	122	135	O	thromboplastin
24	137	140	O	time
25	143	146	O	aPTT
NULL

Apixaban	1241	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	35
Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban.
1	0	6	O	Changes
2	8	15	O	observed
3	17	18	O	in
4	20	24	O	these
5	26	33	O	clotting
6	35	39	O	tests
7	41	42	O	at
8	44	46	O	the
9	48	55	O	expected
10	57	67	O	therapeutic
11	69	72	O	dose
12	73	73	O	,
13	75	81	O	however
14	82	82	O	,
15	84	86	O	are
16	88	92	O	small
17	93	93	O	,
18	95	101	O	subject
19	103	104	O	to
20	106	106	O	a
21	108	111	O	high
22	113	118	O	degree
23	120	121	O	of
24	123	133	O	variability
25	134	134	O	,
26	136	138	O	and
27	140	142	O	not
28	144	149	O	useful
29	151	152	O	in
30	154	163	O	monitoring
31	165	167	O	the
32	169	183	O	anticoagulation
33	185	190	O	effect
34	192	193	O	of
35	195	202	O	XXXXXXXX
NULL

Apixaban	1242	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	23
The Rotachrom* Heparin chromogenic assay was used to measure the effect of apixaban on FXa activity in humans during the apixaban development program.
1	0	2	O	The
2	4	13	O	Rotachrom*
3	15	21	O	Heparin
4	23	33	O	chromogenic
5	35	39	O	assay
6	41	43	O	was
7	45	48	O	used
8	50	51	O	to
9	53	59	O	measure
10	61	63	O	the
11	65	70	O	effect
12	72	73	O	of
13	75	82	O	XXXXXXXX
14	84	85	O	on
15	87	89	O	FXa
16	91	98	O	activity
17	100	101	O	in
18	103	108	O	humans
19	110	115	O	during
20	117	119	O	the
21	121	128	O	XXXXXXXX
22	130	140	O	development
23	142	148	O	program
NULL

Apixaban	1243	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	25
A concentration-dependent increase in anti-FXa activity was observed in the dose range tested and was similar in healthy subjects and patients with AF.
1	0	0	O	A
2	2	14	O	concentration
3	16	24	O	dependent
4	26	33	O	increase
5	35	36	O	in
6	38	41	O	anti
7	43	45	O	FXa
8	47	54	O	activity
9	56	58	O	was
10	60	67	O	observed
11	69	70	O	in
12	72	74	O	the
13	76	79	O	dose
14	81	85	O	range
15	87	92	O	tested
16	94	96	O	and
17	98	100	O	was
18	102	108	O	similar
19	110	111	O	in
20	113	119	O	healthy
21	121	128	O	subjects
22	130	132	O	and
23	134	141	O	patients
24	143	146	O	with
25	148	149	O	AF
NULL

Apixaban	1244	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	12
This test is not recommended for assessing the anticoagulant effect of apixaban.
1	0	3	O	This
2	5	8	O	test
3	10	11	O	is
4	13	15	O	not
5	17	27	O	recommended
6	29	31	O	for
7	33	41	O	assessing
8	43	45	O	the
9	47	59	O	anticoagulant
10	61	66	O	effect
11	68	69	O	of
12	71	78	O	XXXXXXXX
NULL

Apixaban	1245	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	22
There is no clinical experience to reverse bleeding with the use of 4-factor PCC products in individuals who have received ELIQUIS.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	19	O	clinical
5	21	30	O	experience
6	32	33	O	to
7	35	41	O	reverse
8	43	50	O	bleeding
9	52	55	O	with
10	57	59	O	the
11	61	63	O	use
12	65	66	O	of
13	68	68	O	4
14	70	75	O	factor
15	77	79	O	PCC
16	81	88	O	products
17	90	91	O	in
18	93	103	O	individuals
19	105	107	O	who
20	109	112	O	have
21	114	121	O	received
22	123	129	O	ELIQUIS
NULL

Apixaban	1246	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	15
Effects of 4-factor PCCs on the pharmacodynamics of apixaban were studied in healthy subjects.
1	0	6	O	Effects
2	8	9	O	of
3	11	11	O	4
4	13	18	O	factor
5	20	23	O	PCCs
6	25	26	O	on
7	28	30	O	the
8	32	47	O	pharmacodynamics
9	49	50	O	of
10	52	59	O	XXXXXXXX
11	61	64	O	were
12	66	72	O	studied
13	74	75	O	in
14	77	83	O	healthy
15	85	92	O	subjects
NULL

Apixaban	1247	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	36
Following administration of apixaban dosed to steady state, endogenous thrombin potential (ETP) returned to pre-apixaban levels 4 hours after the initiation of a 30-minute PCC infusion, compared to 45 hours with placebo.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	35	O	XXXXXXXX
5	37	41	O	dosed
6	43	44	O	to
7	46	51	O	steady
8	53	57	O	state
9	58	58	O	,
10	60	69	B-EFF	endogenous
11	71	78	I-EFF	thrombin
12	80	88	L-EFF	potential
13	91	93	U-EFF	ETP
14	96	103	O	returned
15	105	106	O	to
16	108	110	O	pre
17	112	119	O	XXXXXXXX
18	121	126	O	levels
19	128	128	O	4
20	130	134	O	hours
21	136	140	O	after
22	142	144	O	the
23	146	155	O	initiation
24	157	158	O	of
25	160	160	O	a
26	162	163	O	30
27	165	170	O	minute
28	172	174	U-DYN	PCC
29	176	183	O	infusion
30	184	184	O	,
31	186	193	O	compared
32	195	196	O	to
33	198	199	O	45
34	201	205	O	hours
35	207	210	O	with
36	212	218	O	placebo
D/28:10:1 D/28:13:1

Apixaban	1248	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	45
Mean ETP levels continued to increase and exceeded pre-apixaban levels reaching a maximum (34%-51% increase over pre-apixaban levels) at 21 hours after initiating PCC and remained elevated (21%-27% increase) at the end of the study (69 hours after initiation of PCC).
1	0	3	O	Mean
2	5	7	O	ETP
3	9	14	O	levels
4	16	24	O	continued
5	26	27	O	to
6	29	36	O	increase
7	38	40	O	and
8	42	49	O	exceeded
9	51	53	O	pre
10	55	62	O	XXXXXXXX
11	64	69	O	levels
12	71	78	O	reaching
13	80	80	O	a
14	82	88	O	maximum
15	91	93	O	34%
16	95	97	O	51%
17	99	106	O	increase
18	108	111	O	over
19	113	115	O	pre
20	117	124	O	XXXXXXXX
21	126	131	O	levels
22	134	135	O	at
23	137	138	O	21
24	140	144	O	hours
25	146	150	O	after
26	152	161	O	initiating
27	163	165	U-DYN	PCC
28	167	169	O	and
29	171	178	O	remained
30	180	187	O	elevated
31	190	192	O	21%
32	194	196	O	27%
33	198	205	O	increase
34	208	209	O	at
35	211	213	O	the
36	215	217	O	end
37	219	220	O	of
38	222	224	O	the
39	226	230	O	study
40	233	234	O	69
41	236	240	O	hours
42	242	246	O	after
43	248	257	O	initiation
44	259	260	O	of
45	262	264	O	PCC
NULL

Apixaban	1249	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	10
The clinical relevance of this increase in ETP is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	29	O	this
6	31	38	O	increase
7	40	41	O	in
8	43	45	O	ETP
9	47	48	O	is
10	50	56	O	unknown
NULL

Apixaban	1250	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	21
Pharmacodynamic drug interaction studies with aspirin, clopidogrel, aspirin and clopidogrel, prasugrel, enoxaparin, and naproxen were conducted.
1	0	14	O	Pharmacodynamic
2	16	19	O	drug
3	21	31	O	interaction
4	33	39	O	studies
5	41	44	O	with
6	46	52	O	aspirin
7	53	53	O	,
8	55	65	O	clopidogrel
9	66	66	O	,
10	68	74	O	aspirin
11	76	78	O	and
12	80	90	O	clopidogrel
13	91	91	O	,
14	93	101	O	prasugrel
15	102	102	O	,
16	104	113	O	enoxaparin
17	114	114	O	,
18	116	118	O	and
19	120	127	O	naproxen
20	129	132	O	were
21	134	142	O	conducted
NULL

Apixaban	1251	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	12
No pharmacodynamic interactions were observed with aspirin, clopidogrel, or prasugrel.
1	0	1	O	No
2	3	17	O	pharmacodynamic
3	19	30	O	interactions
4	32	35	O	were
5	37	44	O	observed
6	46	49	O	with
7	51	57	O	aspirin
8	58	58	O	,
9	60	70	O	clopidogrel
10	71	71	O	,
11	73	74	O	or
12	76	84	O	prasugrel
NULL

Apixaban	1252	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	19
A 50% to 60% increase in anti-FXa activity was observed when apixaban was coadministered with enoxaparin or naproxen.
1	0	0	O	A
2	2	4	O	50%
3	6	7	O	to
4	9	11	O	60%
5	13	20	B-EFF	increase
6	22	23	I-EFF	in
7	25	28	I-EFF	anti
8	30	32	I-EFF	FXa
9	34	41	L-EFF	activity
10	43	45	O	was
11	47	54	O	observed
12	56	59	O	when
13	61	68	O	XXXXXXXX
14	70	72	O	was
15	74	87	O	coadministered
16	89	92	O	with
17	94	103	U-DYN	enoxaparin
18	105	106	O	or
19	108	115	U-DYN	naproxen
D/17:5:1 D/19:5:1

Apixaban	1253	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	17
Renal impairment: Anti-FXa activity adjusted for exposure to apixaban was similar across renal function categories.
1	0	4	O	Renal
2	6	15	O	impairment
3	16	16	O	:
4	18	21	O	Anti
5	23	25	O	FXa
6	27	34	O	activity
7	36	43	O	adjusted
8	45	47	O	for
9	49	56	O	exposure
10	58	59	O	to
11	61	68	O	XXXXXXXX
12	70	72	O	was
13	74	80	O	similar
14	82	87	O	across
15	89	93	O	renal
16	95	102	O	function
17	104	113	O	categories
NULL

Apixaban	1254	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	21
Hepatic impairment: Changes in anti-FXa activity were similar in patients with mild-to-moderate hepatic impairment and healthy subjects.
1	0	6	O	Hepatic
2	8	17	O	impairment
3	18	18	O	:
4	20	26	O	Changes
5	28	29	O	in
6	31	34	O	anti
7	36	38	O	FXa
8	40	47	O	activity
9	49	52	O	were
10	54	60	O	similar
11	62	63	O	in
12	65	72	O	patients
13	74	77	O	with
14	79	82	O	mild
15	84	85	O	to
16	87	94	O	moderate
17	96	102	O	hepatic
18	104	113	O	impairment
19	115	117	O	and
20	119	125	O	healthy
21	127	134	O	subjects
NULL

Apixaban	1255	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	35
However, in patients with moderate hepatic impairment, there is no clear understanding of the impact of this degree of hepatic function impairment on the coagulation cascade and its relationship to efficacy and bleeding.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	19	O	patients
5	21	24	O	with
6	26	33	O	moderate
7	35	41	O	hepatic
8	43	52	O	impairment
9	53	53	O	,
10	55	59	O	there
11	61	62	O	is
12	64	65	O	no
13	67	71	O	clear
14	73	85	O	understanding
15	87	88	O	of
16	90	92	O	the
17	94	99	O	impact
18	101	102	O	of
19	104	107	O	this
20	109	114	O	degree
21	116	117	O	of
22	119	125	O	hepatic
23	127	134	O	function
24	136	145	O	impairment
25	147	148	O	on
26	150	152	O	the
27	154	164	O	coagulation
28	166	172	O	cascade
29	174	176	O	and
30	178	180	O	its
31	182	193	O	relationship
32	195	196	O	to
33	198	205	O	efficacy
34	207	209	O	and
35	211	218	O	bleeding
NULL

Apixaban	1256	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	8
Patients with severe hepatic impairment were not studied.
1	0	7	O	Patients
2	9	12	O	with
3	14	19	O	severe
4	21	27	O	hepatic
5	29	38	O	impairment
6	40	43	O	were
7	45	47	O	not
8	49	55	O	studied
NULL

Apixaban	1257	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	33
Apixaban has no effect on the QTc interval in humans at doses up to 50 mg. Apixaban demonstrates linear pharmacokinetics with dose-proportional increases in exposure for oral doses up to 10 mg.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	14	O	no
4	16	21	O	effect
5	23	24	O	on
6	26	28	O	the
7	30	32	O	QTc
8	34	41	O	interval
9	43	44	O	in
10	46	51	O	humans
11	53	54	O	at
12	56	60	O	doses
13	62	63	O	up
14	65	66	O	to
15	68	69	O	50
16	71	72	O	mg
17	75	82	O	XXXXXXXX
18	84	95	O	demonstrates
19	97	102	O	linear
20	104	119	O	pharmacokinetics
21	121	124	O	with
22	126	129	O	dose
23	131	142	O	proportional
24	144	152	O	increases
25	154	155	O	in
26	157	164	O	exposure
27	166	168	O	for
28	170	173	O	oral
29	175	179	O	doses
30	181	182	O	up
31	184	185	O	to
32	187	188	O	10
33	190	191	O	mg
NULL

Apixaban	1258	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	16
The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	39	O	XXXXXXXX
6	41	42	O	is
7	44	56	O	approximately
8	58	60	O	50%
9	62	64	O	for
10	66	70	O	doses
11	72	73	O	up
12	75	76	O	to
13	78	79	O	10
14	81	82	O	mg
15	84	85	O	of
16	87	93	O	ELIQUIS
NULL

Apixaban	1259	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	8
Food does not affect the bioavailability of apixaban.
1	0	3	O	Food
2	5	8	O	does
3	10	12	O	not
4	14	19	O	affect
5	21	23	O	the
6	25	39	O	bioavailability
7	41	42	O	of
8	44	51	O	XXXXXXXX
NULL

Apixaban	1260	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	15
Maximum concentrations (Cmax) of apixaban appear 3 to 4 hours after oral administration of ELIQUIS.
1	0	6	O	Maximum
2	8	21	O	concentrations
3	24	27	O	Cmax
4	30	31	O	of
5	33	40	O	XXXXXXXX
6	42	47	O	appear
7	49	49	O	3
8	51	52	O	to
9	54	54	O	4
10	56	60	O	hours
11	62	66	O	after
12	68	71	O	oral
13	73	86	O	administration
14	88	89	O	of
15	91	97	O	ELIQUIS
NULL

Apixaban	1261	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	13
At doses >25 mg, apixaban displays dissolution-limited absorption with decreased bioavailability.
1	0	1	O	At
2	3	7	O	doses
3	9	11	O	>25
4	13	14	O	mg
5	15	15	O	,
6	17	24	O	XXXXXXXX
7	26	33	O	displays
8	35	45	O	dissolution
9	47	53	O	limited
10	55	64	O	absorption
11	66	69	O	with
12	71	79	O	decreased
13	81	95	O	bioavailability
NULL

Apixaban	1262	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	35
Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets suspended in 30 mL of water, exposure was similar to that after oral administration of 2 intact 5 mg tablets.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	34	O	10
6	36	37	O	mg
7	39	40	O	of
8	42	49	O	XXXXXXXX
9	51	52	O	as
10	54	54	O	2
11	56	62	O	crushed
12	64	64	O	5
13	66	67	O	mg
14	69	75	O	tablets
15	77	85	O	suspended
16	87	88	O	in
17	90	91	O	30
18	93	94	O	mL
19	96	97	O	of
20	99	103	O	water
21	104	104	O	,
22	106	113	O	exposure
23	115	117	O	was
24	119	125	O	similar
25	127	128	O	to
26	130	133	O	that
27	135	139	O	after
28	141	144	O	oral
29	146	159	O	administration
30	161	162	O	of
31	164	164	O	2
32	166	171	O	intact
33	173	173	O	5
34	175	176	O	mg
35	178	184	O	tablets
NULL

Apixaban	1263	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	43
Following oral administration of 10 mg of apixaban as 2 crushed 5 mg tablets mixed with 30 g of applesauce, the Cmax and AUC were 20% and 16% lower, respectively, when compared to administration of 2 intact 5 mg tablets.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	34	O	10
6	36	37	O	mg
7	39	40	O	of
8	42	49	O	XXXXXXXX
9	51	52	O	as
10	54	54	O	2
11	56	62	O	crushed
12	64	64	O	5
13	66	67	O	mg
14	69	75	O	tablets
15	77	81	O	mixed
16	83	86	O	with
17	88	89	O	30
18	91	91	O	g
19	93	94	O	of
20	96	105	O	applesauce
21	106	106	O	,
22	108	110	O	the
23	112	115	O	Cmax
24	117	119	O	and
25	121	123	O	AUC
26	125	128	O	were
27	130	132	O	20%
28	134	136	O	and
29	138	140	O	16%
30	142	146	O	lower
31	147	147	O	,
32	149	160	O	respectively
33	161	161	O	,
34	163	166	O	when
35	168	175	O	compared
36	177	178	O	to
37	180	193	O	administration
38	195	196	O	of
39	198	198	O	2
40	200	205	O	intact
41	207	207	O	5
42	209	210	O	mg
43	212	218	O	tablets
NULL

Apixaban	1264	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	45
Following administration of a crushed 5 mg ELIQUIS tablet that was suspended in 60 mL D5W and delivered through a nasogastric tube (NGT), exposure was similar to that seen in other clinical trials involving healthy volunteers receiving a single oral 5 mg tablet dose.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	28	O	a
5	30	36	O	crushed
6	38	38	O	5
7	40	41	O	mg
8	43	49	O	ELIQUIS
9	51	56	O	tablet
10	58	61	O	that
11	63	65	O	was
12	67	75	O	suspended
13	77	78	O	in
14	80	81	O	60
15	83	84	O	mL
16	86	88	O	D5W
17	90	92	O	and
18	94	102	O	delivered
19	104	110	O	through
20	112	112	O	a
21	114	124	O	nasogastric
22	126	129	O	tube
23	132	134	O	NGT
24	136	136	O	,
25	138	145	O	exposure
26	147	149	O	was
27	151	157	O	similar
28	159	160	O	to
29	162	165	O	that
30	167	170	O	seen
31	172	173	O	in
32	175	179	O	other
33	181	188	O	clinical
34	190	195	O	trials
35	197	205	O	involving
36	207	213	O	healthy
37	215	224	O	volunteers
38	226	234	O	receiving
39	236	236	O	a
40	238	243	O	single
41	245	248	O	oral
42	250	250	O	5
43	252	253	O	mg
44	255	260	O	tablet
45	262	265	O	dose
NULL

Apixaban	1265	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	8
Plasma protein binding in humans is approximately 87%.
1	0	5	O	Plasma
2	7	13	O	protein
3	15	21	O	binding
4	23	24	O	in
5	26	31	O	humans
6	33	34	O	is
7	36	48	O	approximately
8	50	52	O	87%
NULL

Apixaban	1266	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	9
The volume of distribution (Vss) is approximately 21 liters.
1	0	2	O	The
2	4	9	O	volume
3	11	12	O	of
4	14	25	O	distribution
5	28	30	O	Vss
6	33	34	O	is
7	36	48	O	approximately
8	50	51	O	21
9	53	58	O	liters
NULL

Apixaban	1267	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	16
Approximately 25% of an orally administered apixaban dose is recovered in urine and feces as metabolites.
1	0	12	O	Approximately
2	14	16	O	25%
3	18	19	O	of
4	21	22	O	an
5	24	29	O	orally
6	31	42	O	administered
7	44	51	O	XXXXXXXX
8	53	56	O	dose
9	58	59	O	is
10	61	69	O	recovered
11	71	72	O	in
12	74	78	O	urine
13	80	82	O	and
14	84	88	O	feces
15	90	91	O	as
16	93	103	O	metabolites
NULL

Apixaban	1268	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	20
Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	metabolized
4	24	29	O	mainly
5	31	33	O	via
6	35	40	O	CYP3A4
7	42	45	O	with
8	47	51	O	minor
9	53	65	O	contributions
10	67	70	O	from
11	72	77	O	CYP1A2
12	78	78	O	,
13	80	82	O	2C8
14	83	83	O	,
15	85	87	O	2C9
16	88	88	O	,
17	90	93	O	2C19
18	94	94	O	,
19	96	98	O	and
20	100	102	O	2J2
NULL

Apixaban	1269	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	15
O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation.
1	0	0	O	O
2	2	14	O	demethylation
3	16	18	O	and
4	20	32	O	hydroxylation
5	34	35	O	at
6	37	39	O	the
7	41	41	O	3
8	43	56	O	oxopiperidinyl
9	58	63	O	moiety
10	65	67	O	are
11	69	71	O	the
12	73	77	O	major
13	79	83	O	sites
14	85	86	O	of
15	88	104	O	biotransformation
NULL

Apixaban	1270	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	17
Unchanged apixaban is the major drug-related component in human plasma; there are no active circulating metabolites.
1	0	8	O	Unchanged
2	10	17	O	XXXXXXXX
3	19	20	O	is
4	22	24	O	the
5	26	30	O	major
6	32	35	O	drug
7	37	43	O	related
8	45	53	O	component
9	55	56	O	in
10	58	62	O	human
11	64	69	O	plasma
12	72	76	O	there
13	78	80	O	are
14	82	83	O	no
15	85	90	O	active
16	92	102	O	circulating
17	104	114	O	metabolites
NULL

Apixaban	1271	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	8
Apixaban is eliminated in both urine and feces.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	21	O	eliminated
4	23	24	O	in
5	26	29	O	both
6	31	35	O	urine
7	37	39	O	and
8	41	45	O	feces
NULL

Apixaban	1272	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	9
Renal excretion accounts for about 27% of total clearance.
1	0	4	O	Renal
2	6	14	O	excretion
3	16	23	O	accounts
4	25	27	O	for
5	29	33	O	about
6	35	37	O	27%
7	39	40	O	of
8	42	46	O	total
9	48	56	O	clearance
NULL

Apixaban	1273	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	13
Biliary and direct intestinal excretion contributes to elimination of apixaban in the feces.
1	0	6	O	Biliary
2	8	10	O	and
3	12	17	O	direct
4	19	28	O	intestinal
5	30	38	O	excretion
6	40	50	O	contributes
7	52	53	O	to
8	55	65	O	elimination
9	67	68	O	of
10	70	77	O	XXXXXXXX
11	79	80	O	in
12	82	84	O	the
13	86	90	O	feces
NULL

Apixaban	1274	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	23
Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	13	O	a
4	15	19	O	total
5	21	29	O	clearance
6	31	32	O	of
7	34	46	O	approximately
8	48	50	O	3.3
9	52	52	O	L
10	53	53	O	/
11	54	57	O	hour
12	59	61	O	and
13	63	64	O	an
14	66	73	O	apparent
15	75	78	O	half
16	80	83	O	life
17	85	86	O	of
18	88	100	O	approximately
19	102	103	O	12
20	105	109	O	hours
21	111	119	O	following
22	121	124	O	oral
23	126	139	O	administration
NULL

Apixaban	1275	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	15
Apixaban is a substrate of transport proteins: P-gp and breast cancer resistance protein.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	12	O	a
4	14	22	O	substrate
5	24	25	O	of
6	27	35	O	transport
7	37	44	O	proteins
8	45	45	O	:
9	47	47	O	P
10	49	50	O	gp
11	52	54	O	and
12	56	61	O	breast
13	63	68	O	cancer
14	70	79	O	resistance
15	81	87	O	protein
NULL

Apixaban	1276	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	55
In vitro apixaban studies at concentrations significantly greater than therapeutic exposures, no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4/5, or CYP2C19, nor induction effect on the activity of CYP1A2, CYP2B6, or CYP3A4/5 were observed.
1	0	1	O	In
2	3	7	O	vitro
3	9	16	O	XXXXXXXX
4	18	24	O	studies
5	26	27	O	at
6	29	42	O	concentrations
7	44	56	O	significantly
8	58	64	O	greater
9	66	69	O	than
10	71	81	O	therapeutic
11	83	91	O	exposures
12	92	92	O	,
13	94	95	O	no
14	97	106	O	inhibitory
15	108	113	O	effect
16	115	116	O	on
17	118	120	O	the
18	122	129	O	activity
19	131	132	O	of
20	134	139	O	CYP1A2
21	140	140	O	,
22	142	147	O	CYP2A6
23	148	148	O	,
24	150	155	O	CYP2B6
25	156	156	O	,
26	158	163	O	CYP2C8
27	164	164	O	,
28	166	171	O	CYP2C9
29	172	172	O	,
30	174	179	O	CYP2D6
31	180	180	O	,
32	182	187	O	CYP3A4
33	188	188	O	/
34	189	189	O	5
35	190	190	O	,
36	192	193	O	or
37	195	201	O	CYP2C19
38	202	202	O	,
39	204	206	O	nor
40	208	216	O	induction
41	218	223	O	effect
42	225	226	O	on
43	228	230	O	the
44	232	239	O	activity
45	241	242	O	of
46	244	249	O	CYP1A2
47	250	250	O	,
48	252	257	O	CYP2B6
49	258	258	O	,
50	260	261	O	or
51	263	268	O	CYP3A4
52	269	269	O	/
53	270	270	O	5
54	272	275	O	were
55	277	284	O	observed
NULL

Apixaban	1277	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	20
Therefore, apixaban is not expected to alter the metabolic clearance of coadministered drugs that are metabolized by these enzymes.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	XXXXXXXX
4	20	21	O	is
5	23	25	O	not
6	27	34	O	expected
7	36	37	O	to
8	39	43	O	alter
9	45	47	O	the
10	49	57	O	metabolic
11	59	67	O	clearance
12	69	70	O	of
13	72	85	O	coadministered
14	87	91	O	drugs
15	93	96	O	that
16	98	100	O	are
17	102	112	O	metabolized
18	114	115	O	by
19	117	121	O	these
20	123	129	O	enzymes
NULL

Apixaban	1278	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	9
Apixaban is not a significant inhibitor of P-gp.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	14	O	not
4	16	16	O	a
5	18	28	O	significant
6	30	38	O	inhibitor
7	40	41	O	of
8	43	43	O	P
9	45	46	O	gp
NULL

Apixaban	1279	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	15
The effects of coadministered drugs on the pharmacokinetics of apixaban are summarized in Figure 2.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	28	O	coadministered
5	30	34	O	drugs
6	36	37	O	on
7	39	41	O	the
8	43	58	O	pharmacokinetics
9	60	61	O	of
10	63	70	O	XXXXXXXX
11	72	74	O	are
12	76	85	O	summarized
13	87	88	O	in
14	90	95	O	Figure
15	97	97	O	2
NULL

Apixaban	1280	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	36
Figure 2: Effect of Coadministered Drugs on the Pharmacokinetics of Apixaban In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.
1	0	5	O	Figure
2	7	7	O	2
3	8	8	O	:
4	10	15	O	Effect
5	17	18	O	of
6	20	33	O	Coadministered
7	35	39	O	Drugs
8	41	42	O	on
9	44	46	O	the
10	48	63	O	Pharmacokinetics
11	65	66	O	of
12	68	75	O	XXXXXXXX
13	77	78	O	In
14	80	88	O	dedicated
15	90	96	O	studies
16	98	106	O	conducted
17	108	109	O	in
18	111	117	O	healthy
19	119	126	O	subjects
20	127	127	O	,
21	129	138	O	famotidine
22	139	139	O	,
23	141	148	O	atenolol
24	149	149	O	,
25	151	159	O	prasugrel
26	160	160	O	,
27	162	164	O	and
28	166	175	O	enoxaparin
29	177	179	O	did
30	181	183	O	not
31	185	196	O	meaningfully
32	198	202	O	alter
33	204	206	O	the
34	208	223	O	pharmacokinetics
35	225	226	O	of
36	228	235	O	XXXXXXXX
NULL

Apixaban	1281	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	26
In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.
1	0	1	O	In
2	3	9	O	studies
3	11	19	O	conducted
4	21	22	O	in
5	24	30	O	healthy
6	32	39	O	subjects
7	40	40	O	,
8	42	49	O	XXXXXXXX
9	51	53	O	did
10	55	57	O	not
11	59	70	O	meaningfully
12	72	76	O	alter
13	78	80	O	the
14	82	97	O	pharmacokinetics
15	99	100	O	of
16	102	108	O	digoxin
17	109	109	O	,
18	111	118	O	naproxen
19	119	119	O	,
20	121	128	O	atenolol
21	129	129	O	,
22	131	139	O	prasugrel
23	140	140	O	,
24	142	143	O	or
25	145	159	O	acetylsalicylic
26	161	164	O	acid
NULL

Apixaban	1282	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	36
Effect of Coadministered Drugs on Pharmacokinetics of Apixaban The effects of level of renal impairment, age, body weight, and level of hepatic impairment on the pharmacokinetics of apixaban are summarized in Figure 3.
1	0	5	O	Effect
2	7	8	O	of
3	10	23	O	Coadministered
4	25	29	O	Drugs
5	31	32	O	on
6	34	49	O	Pharmacokinetics
7	51	52	O	of
8	54	61	O	XXXXXXXX
9	63	65	O	The
10	67	73	O	effects
11	75	76	O	of
12	78	82	O	level
13	84	85	O	of
14	87	91	O	renal
15	93	102	O	impairment
16	103	103	O	,
17	105	107	O	age
18	108	108	O	,
19	110	113	O	body
20	115	120	O	weight
21	121	121	O	,
22	123	125	O	and
23	127	131	O	level
24	133	134	O	of
25	136	142	O	hepatic
26	144	153	O	impairment
27	155	156	O	on
28	158	160	O	the
29	162	177	O	pharmacokinetics
30	179	180	O	of
31	182	189	O	XXXXXXXX
32	191	193	O	are
33	195	204	O	summarized
34	206	207	O	in
35	209	214	O	Figure
36	216	216	O	3
NULL

Apixaban	1283	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	30
Figure 3: Effect of Specific Populations on the Pharmacokinetics of Apixaban * ESRD subjects treated with intermittent hemodialysis; reported PK findings are following single dose of apixaban post hemodialysis.
1	0	5	O	Figure
2	7	7	O	3
3	8	8	O	:
4	10	15	O	Effect
5	17	18	O	of
6	20	27	O	Specific
7	29	39	O	Populations
8	41	42	O	on
9	44	46	O	the
10	48	63	O	Pharmacokinetics
11	65	66	O	of
12	68	75	O	XXXXXXXX
13	77	77	O	*
14	79	82	O	ESRD
15	84	91	O	subjects
16	93	99	O	treated
17	101	104	O	with
18	106	117	O	intermittent
19	119	130	O	hemodialysis
20	133	140	O	reported
21	142	143	O	PK
22	145	152	O	findings
23	154	156	O	are
24	158	166	O	following
25	168	173	O	single
26	175	178	O	dose
27	180	181	O	of
28	183	190	O	XXXXXXXX
29	192	195	O	post
30	197	208	O	hemodialysis
NULL

Apixaban	1284	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	13
* Results reflect CrCl of 15 mL/min based on regression analysis.
1	0	0	O	*
2	2	8	O	Results
3	10	16	O	reflect
4	18	21	O	CrCl
5	23	24	O	of
6	26	27	O	15
7	29	30	O	mL
8	31	31	O	/
9	32	34	O	min
10	36	40	O	based
11	42	43	O	on
12	45	54	O	regression
13	56	63	O	analysis
NULL

Apixaban	1285	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	14
* Dashed vertical lines illustrate pharmacokinetic changes that were used to inform dosing recommendations.
1	0	0	O	*
2	2	7	O	Dashed
3	9	16	O	vertical
4	18	22	O	lines
5	24	33	O	illustrate
6	35	49	O	pharmacokinetic
7	51	57	O	changes
8	59	62	O	that
9	64	67	O	were
10	69	72	O	used
11	74	75	O	to
12	77	82	O	inform
13	84	89	O	dosing
14	91	105	O	recommendations
NULL

Apixaban	1286	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	41
No dose adjustment is recommended for nonvalvular atrial fibrillation patients unless at least 2 of the following patient characteristics are present: age > 79 years, body weight < 61 kg, or serum creatinine > 1.4 mg/dL.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	32	O	recommended
6	34	36	O	for
7	38	48	O	nonvalvular
8	50	55	O	atrial
9	57	68	O	fibrillation
10	70	77	O	patients
11	79	84	O	unless
12	86	87	O	at
13	89	93	O	least
14	95	95	O	2
15	97	98	O	of
16	100	102	O	the
17	104	112	O	following
18	114	120	O	patient
19	122	136	O	characteristics
20	138	140	O	are
21	142	148	O	present
22	149	149	O	:
23	151	153	O	age
24	155	155	O	>
25	157	158	O	79
26	160	164	O	years
27	165	165	O	,
28	167	170	O	body
29	172	177	O	weight
30	179	179	O	<
31	181	182	O	61
32	184	185	O	kg
33	186	186	O	,
34	188	189	O	or
35	191	195	O	serum
36	197	206	O	creatinine
37	208	208	O	>
38	210	212	O	1.4
39	214	215	O	mg
40	216	216	O	/
41	217	218	O	dL
NULL

Apixaban	1287	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	18
Gender: A study in healthy subjects comparing the pharmacokinetics in males and females showed no meaningful difference.
1	0	5	O	Gender
2	6	6	O	:
3	8	8	O	A
4	10	14	O	study
5	16	17	O	in
6	19	25	O	healthy
7	27	34	O	subjects
8	36	44	O	comparing
9	46	48	O	the
10	50	65	O	pharmacokinetics
11	67	68	O	in
12	70	74	O	males
13	76	78	O	and
14	80	86	O	females
15	88	93	O	showed
16	95	96	O	no
17	98	107	O	meaningful
18	109	118	O	difference
NULL

Apixaban	1288	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	29
Race: The results across pharmacokinetic studies in normal subjects showed no differences in apixaban pharmacokinetics among White/Caucasian, Asian, and Black/African American subjects.
1	0	3	O	Race
2	4	4	O	:
3	6	8	O	The
4	10	16	O	results
5	18	23	O	across
6	25	39	O	pharmacokinetic
7	41	47	O	studies
8	49	50	O	in
9	52	57	O	normal
10	59	66	O	subjects
11	68	73	O	showed
12	75	76	O	no
13	78	88	O	differences
14	90	91	O	in
15	93	100	O	XXXXXXXX
16	102	117	O	pharmacokinetics
17	119	123	O	among
18	125	129	O	White
19	130	130	O	/
20	131	139	O	Caucasian
21	140	140	O	,
22	142	146	O	Asian
23	147	147	O	,
24	149	151	O	and
25	153	157	O	Black
26	158	158	O	/
27	159	165	O	African
28	167	174	O	American
29	176	183	O	subjects
NULL

Apixaban	1289	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	10
No dose adjustment is required based on race/ethnicity.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	29	O	required
6	31	35	O	based
7	37	38	O	on
8	40	43	O	race
9	44	44	O	/
10	45	53	O	ethnicity
NULL

Apixaban	1290	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	43
Hemodialysis in ESRD subjects: Systemic exposure to apixaban administered as a single 5 mg dose in ESRD subjects dosed immediately after the completion of a 4-hour hemodialysis session (post-dialysis) is 36% higher when compared to subjects with normal renal function.
1	0	11	O	Hemodialysis
2	13	14	O	in
3	16	19	O	ESRD
4	21	28	O	subjects
5	29	29	O	:
6	31	38	O	Systemic
7	40	47	O	exposure
8	49	50	O	to
9	52	59	O	XXXXXXXX
10	61	72	O	administered
11	74	75	O	as
12	77	77	O	a
13	79	84	O	single
14	86	86	O	5
15	88	89	O	mg
16	91	94	O	dose
17	96	97	O	in
18	99	102	O	ESRD
19	104	111	O	subjects
20	113	117	O	dosed
21	119	129	O	immediately
22	131	135	O	after
23	137	139	O	the
24	141	150	O	completion
25	152	153	O	of
26	155	155	O	a
27	157	157	O	4
28	159	162	O	hour
29	164	175	O	hemodialysis
30	177	183	O	session
31	186	189	O	post
32	191	198	O	dialysis
33	201	202	O	is
34	204	206	O	36%
35	208	213	O	higher
36	215	218	O	when
37	220	227	O	compared
38	229	230	O	to
39	232	239	O	subjects
40	241	244	O	with
41	246	251	O	normal
42	253	257	O	renal
43	259	266	O	function
NULL

Apixaban	1291	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	50
The systemic exposure to apixaban administered 2 hours prior to a 4-hour hemodialysis session with a dialysate flow rate of 500 mL/min and a blood flow rate in the range of 350 to 500 mL/min is 17% higher compared to those with normal renal function.
1	0	2	O	The
2	4	11	O	systemic
3	13	20	O	exposure
4	22	23	O	to
5	25	32	O	XXXXXXXX
6	34	45	O	administered
7	47	47	O	2
8	49	53	O	hours
9	55	59	O	prior
10	61	62	O	to
11	64	64	O	a
12	66	66	O	4
13	68	71	O	hour
14	73	84	O	hemodialysis
15	86	92	O	session
16	94	97	O	with
17	99	99	O	a
18	101	109	O	dialysate
19	111	114	O	flow
20	116	119	O	rate
21	121	122	O	of
22	124	126	O	500
23	128	129	O	mL
24	130	130	O	/
25	131	133	O	min
26	135	137	O	and
27	139	139	O	a
28	141	145	O	blood
29	147	150	O	flow
30	152	155	O	rate
31	157	158	O	in
32	160	162	O	the
33	164	168	O	range
34	170	171	O	of
35	173	175	O	350
36	177	178	O	to
37	180	182	O	500
38	184	185	O	mL
39	186	186	O	/
40	187	189	O	min
41	191	192	O	is
42	194	196	O	17%
43	198	203	O	higher
44	205	212	O	compared
45	214	215	O	to
46	217	221	O	those
47	223	226	O	with
48	228	233	O	normal
49	235	239	O	renal
50	241	248	O	function
NULL

Apixaban	1292	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	11
The dialysis clearance of apixaban is approximately 18 mL/min.
1	0	2	O	The
2	4	11	O	dialysis
3	13	21	O	clearance
4	23	24	O	of
5	26	33	O	XXXXXXXX
6	35	36	O	is
7	38	50	O	approximately
8	52	53	O	18
9	55	56	O	mL
10	57	57	O	/
11	58	60	O	min
NULL

Apixaban	1293	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	16
The systemic exposure of apixaban is 14% lower on dialysis when compared to not on dialysis.
1	0	2	O	The
2	4	11	O	systemic
3	13	20	O	exposure
4	22	23	O	of
5	25	32	O	XXXXXXXX
6	34	35	O	is
7	37	39	O	14%
8	41	45	O	lower
9	47	48	O	on
10	50	57	O	dialysis
11	59	62	O	when
12	64	71	O	compared
13	73	74	O	to
14	76	78	O	not
15	80	81	O	on
16	83	90	O	dialysis
NULL

Apixaban	1294	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	20
Protein binding was similar (92%-94%) between healthy controls and ESRD subjects during the on-dialysis and off-dialysis periods.
1	0	6	O	Protein
2	8	14	O	binding
3	16	18	O	was
4	20	26	O	similar
5	29	31	O	92%
6	33	35	O	94%
7	38	44	O	between
8	46	52	O	healthy
9	54	61	O	controls
10	63	65	O	and
11	67	70	O	ESRD
12	72	79	O	subjects
13	81	86	O	during
14	88	90	O	the
15	92	93	O	on
16	95	102	O	dialysis
17	104	106	O	and
18	108	110	O	off
19	112	119	O	dialysis
20	121	127	O	periods
NULL

Apixaban	1295	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	3
O:\E-Submissions\PBO\PRODUCTS\Eliquis 202155\08.
1	0	3	O	O:\E
2	5	36	O	Submissions\PBO\PRODUCTS\Eliquis
3	38	46	O	202155\08
NULL

Apixaban	1296	34090-1	e9481622-7cc6-418a-acb6-c5450daae9b0	5
Orig Submission\Source\eliquis-pkplot-pop-fig3.jpg
1	0	3	O	Orig
2	5	29	O	Submission\Source\eliquis
3	31	36	O	pkplot
4	38	40	O	pop
5	42	49	O	fig3.jpg
NULL

Aubagio	3148	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	27
Drugs metabolized by CYP2C8 and OAT3 transporters: Monitor patients because teriflunomide may increase exposure of these drugs (7) Teriflunomide may increase exposure of ethinylestradiol and levonorgestrel.
1	0	4	B-KIN	Drugs
2	6	16	I-KIN	metabolized
3	18	19	I-KIN	by
4	21	26	L-KIN	CYP2C8
5	28	30	O	and
6	32	35	O	OAT3
7	37	48	O	transporters
8	49	49	O	:
9	51	57	O	Monitor
10	59	66	O	patients
11	68	74	O	because
12	76	88	O	XXXXXXXX
13	90	92	O	may
14	94	101	B-TRI	increase
15	103	110	L-TRI	exposure
16	112	113	O	of
17	115	119	O	these
18	121	125	O	drugs
19	128	128	O	7
20	131	143	O	XXXXXXXX
21	145	147	O	may
22	149	156	O	increase
23	158	165	O	exposure
24	167	168	O	of
25	170	185	U-KIN	ethinylestradiol
26	187	189	O	and
27	191	204	U-KIN	levonorgestrel
K/1:C54357 K/25:C54357 K/27:C54357

Aubagio	3149	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	85
Choose an appropriate oral contraceptive (7) Drugs metabolized by CYP1A2: Monitor patients because teriflunomide may decrease exposure of these drugs (7) Warfarin: Monitor INR as teriflunomide may decrease INR (7) Drugs metabolized by BCRP and OATP1B1/B3 transporters: Monitor patients because teriflunomide may increase exposure of these drugs (7) Rosuvastatin: The dose of rosuvastatin should not exceed 10 mg once daily in patients taking AUBAGIO (7) Effect of AUBAGIO on CYP2C8 substrates Teriflunomide is an inhibitor of CYP2C8 in vivo.
1	0	5	O	Choose
2	7	8	O	an
3	10	20	O	appropriate
4	22	25	O	oral
5	27	39	O	contraceptive
6	42	42	O	7
7	45	49	B-KIN	Drugs
8	51	61	I-KIN	metabolized
9	63	64	I-KIN	by
10	66	71	L-KIN	CYP1A2
11	72	72	O	:
12	74	80	O	Monitor
13	82	89	O	patients
14	91	97	O	because
15	99	111	O	XXXXXXXX
16	113	115	O	may
17	117	124	B-TRI	decrease
18	126	133	L-TRI	exposure
19	135	136	O	of
20	138	142	O	these
21	144	148	O	drugs
22	151	151	O	7
23	154	161	U-DYN	Warfarin
24	162	162	O	:
25	164	170	O	Monitor
26	172	174	O	INR
27	176	177	O	as
28	179	191	O	XXXXXXXX
29	193	195	O	may
30	197	204	B-EFF	decrease
31	206	208	L-EFF	INR
32	211	211	O	7
33	214	218	B-KIN	Drugs
34	220	230	I-KIN	metabolized
35	232	233	I-KIN	by
36	235	238	L-KIN	BCRP
37	240	242	O	and
38	244	250	O	OATP1B1
39	251	251	O	/
40	252	253	O	B3
41	255	266	O	transporters
42	267	267	O	:
43	269	275	O	Monitor
44	277	284	O	patients
45	286	292	O	because
46	294	306	O	XXXXXXXX
47	308	310	O	may
48	312	319	B-TRI	increase
49	321	328	L-TRI	exposure
50	330	331	O	of
51	333	337	O	these
52	339	343	O	drugs
53	346	346	O	7
54	349	360	O	Rosuvastatin
55	361	361	O	:
56	363	365	O	The
57	367	370	O	dose
58	372	373	O	of
59	375	386	U-KIN	rosuvastatin
60	388	393	O	should
61	395	397	O	not
62	399	404	O	exceed
63	406	407	O	10
64	409	410	O	mg
65	412	415	O	once
66	417	421	O	daily
67	423	424	O	in
68	426	433	O	patients
69	435	440	O	taking
70	442	448	O	XXXXXXXX
71	451	451	O	7
72	454	459	O	Effect
73	461	462	O	of
74	464	470	O	XXXXXXXX
75	472	473	O	on
76	475	480	B-DYN	CYP2C8
77	482	491	L-DYN	substrates
78	493	505	O	XXXXXXXX
79	507	508	O	is
80	510	511	O	an
81	513	521	O	inhibitor
82	523	524	O	of
83	526	531	O	CYP2C8
84	533	534	O	in
85	536	539	O	vivo
D/23:30:1 D/76:30:0K/33:C54357 K/59:C54357 K/7:C54358

Aubagio	3150	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	23
In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	25	O	XXXXXXXX
5	26	26	O	,
6	28	35	O	exposure
7	37	38	O	of
8	40	44	B-KIN	drugs
9	46	56	I-KIN	metabolized
10	58	59	I-KIN	by
11	61	66	L-KIN	CYP2C8
12	69	71	O	e.g
13	73	73	O	,
14	75	84	U-KIN	paclitaxel
15	85	85	O	,
16	87	98	U-KIN	pioglitazone
17	99	99	O	,
18	101	111	U-KIN	repaglinide
19	112	112	O	,
20	114	126	U-KIN	rosiglitazone
21	129	131	O	may
22	133	134	O	be
23	136	144	O	increased
K/14:C54357 K/16:C54357 K/18:C54357 K/20:C54357 K/8:C54357

Aubagio	3151	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	16
Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required.
1	0	6	U-TRI	Monitor
2	8	12	O	these
3	14	21	O	patients
4	23	25	O	and
5	27	32	O	adjust
6	34	36	O	the
7	38	41	O	dose
8	43	44	O	of
9	46	48	O	the
10	50	60	O	concomitant
11	62	67	B-UNK	drug(s
12	70	80	I-UNK	metabolized
13	82	83	I-UNK	by
14	85	90	L-UNK	CYP2C8
15	92	93	O	as
16	95	102	O	required
NULL

Aubagio	3152	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	28
Effect of AUBAGIO on warfarin Coadministration of AUBAGIO with warfarin requires close monitoring of the international normalized ratio (INR) because AUBAGIO may decrease peak INR by approximately 25%.
1	0	5	O	Effect
2	7	8	O	of
3	10	16	O	XXXXXXXX
4	18	19	O	on
5	21	28	U-DYN	warfarin
6	30	45	O	Coadministration
7	47	48	O	of
8	50	56	O	XXXXXXXX
9	58	61	O	with
10	63	70	O	warfarin
11	72	79	O	requires
12	81	85	O	close
13	87	96	O	monitoring
14	98	99	O	of
15	101	103	O	the
16	105	117	O	international
17	119	128	O	normalized
18	130	134	O	ratio
19	137	139	O	INR
20	142	148	O	because
21	150	156	O	XXXXXXXX
22	158	160	O	may
23	162	169	B-EFF	decrease
24	171	174	I-EFF	peak
25	176	178	L-EFF	INR
26	180	181	O	by
27	183	195	O	approximately
28	197	199	O	25%
D/5:23:1

Aubagio	3153	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	16
Effect of AUBAGIO on oral contraceptives AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel.
1	0	5	O	Effect
2	7	8	O	of
3	10	16	O	XXXXXXXX
4	18	19	O	on
5	21	24	B-KIN	oral
6	26	39	L-KIN	contraceptives
7	41	47	O	XXXXXXXX
8	49	51	O	may
9	53	60	B-TRI	increase
10	62	64	I-TRI	the
11	66	73	I-TRI	systemic
12	75	83	L-TRI	exposures
13	85	86	O	of
14	88	103	U-KIN	ethinylestradiol
15	105	107	O	and
16	109	122	U-KIN	levonorgestrel
K/14:C54357 K/16:C54357 K/5:C54357

Aubagio	3154	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	16
Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO.
1	0	12	O	Consideration
2	14	19	O	should
3	21	22	O	be
4	24	28	O	given
5	30	31	O	to
6	33	35	O	the
7	37	40	O	type
8	42	43	O	or
9	45	48	O	dose
10	50	51	O	of
11	53	66	U-UNK	contraceptives
12	68	71	O	used
13	73	74	O	in
14	76	86	O	combination
15	88	91	O	with
16	93	99	O	XXXXXXXX
NULL

Aubagio	3155	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	16
Effect of AUBAGIO on CYP1A2 substrates Teriflunomide may be a weak inducer of CYP1A2 in vivo.
1	0	5	O	Effect
2	7	8	O	of
3	10	16	O	XXXXXXXX
4	18	19	O	on
5	21	26	B-DYN	CYP1A2
6	28	37	L-DYN	substrates
7	39	51	O	XXXXXXXX
8	53	55	O	may
9	57	58	O	be
10	60	60	O	a
11	62	65	O	weak
12	67	73	O	inducer
13	75	76	O	of
14	78	83	O	CYP1A2
15	85	86	O	in
16	88	91	O	vivo
NULL

Aubagio	3156	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	23
In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	25	O	XXXXXXXX
5	26	26	O	,
6	28	35	O	exposure
7	37	38	O	of
8	40	44	B-KIN	drugs
9	46	56	I-KIN	metabolized
10	58	59	I-KIN	by
11	61	66	L-KIN	CYP1A2
12	69	71	O	e.g
13	73	73	O	,
14	75	83	U-KIN	alosetron
15	84	84	O	,
16	86	95	U-KIN	duloxetine
17	96	96	O	,
18	98	109	U-KIN	theophylline
19	110	110	O	,
20	112	121	U-KIN	tizanidine
21	124	126	O	may
22	128	129	O	be
23	131	137	O	reduced
K/14:C54358 K/16:C54358 K/18:C54358 K/20:C54358 K/8:C54358

Aubagio	3157	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	16
Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required.
1	0	6	U-TRI	Monitor
2	8	12	O	these
3	14	21	O	patients
4	23	25	O	and
5	27	32	O	adjust
6	34	36	O	the
7	38	41	O	dose
8	43	44	O	of
9	46	48	O	the
10	50	60	O	concomitant
11	62	67	B-UNK	drug(s
12	70	80	I-UNK	metabolized
13	82	83	I-UNK	by
14	85	90	L-UNK	CYP1A2
15	92	93	O	as
16	95	102	O	required
NULL

Aubagio	3158	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	18
Effect of AUBAGIO on organic anion transporter 3 (OAT3) substrates Teriflunomide inhibits the activity of OAT3 in vivo.
1	0	5	O	Effect
2	7	8	O	of
3	10	16	O	XXXXXXXX
4	18	19	O	on
5	21	27	B-DYN	organic
6	29	33	I-DYN	anion
7	35	45	I-DYN	transporter
8	47	47	I-DYN	3
9	50	53	I-DYN	OAT3
10	56	65	L-DYN	substrates
11	67	79	O	XXXXXXXX
12	81	88	O	inhibits
13	90	92	O	the
14	94	101	O	activity
15	103	104	O	of
16	106	109	O	OAT3
17	111	112	O	in
18	114	117	O	vivo
NULL

Aubagio	3159	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	33
In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	25	O	XXXXXXXX
5	26	26	O	,
6	28	35	O	exposure
7	37	38	O	of
8	40	44	O	drugs
9	46	50	O	which
10	52	54	O	are
11	56	59	B-KIN	OAT3
12	61	70	L-KIN	substrates
13	73	75	O	e.g
14	77	77	O	,
15	79	86	U-KIN	cefaclor
16	87	87	O	,
17	89	98	U-KIN	cimetidine
18	99	99	O	,
19	101	113	U-KIN	ciprofloxacin
20	114	114	O	,
21	116	125	B-KIN	penicillin
22	127	127	L-KIN	GGGGGGGG
23	128	128	O	,
24	130	139	U-KIN	ketoprofen
25	140	140	O	,
26	142	151	U-KIN	furosemide
27	152	152	O	,
28	154	165	U-KIN	methotrexate
29	166	166	O	,
30	168	177	U-KIN	zidovudine
31	180	182	O	may
32	184	185	O	be
33	187	195	O	increased
K/11:C54357 K/15:C54357 K/17:C54357 K/19:C54357 K/21:C54357 K/24:C54357 K/26:C54357 K/28:C54357 K/30:C54357

Aubagio	3160	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	17
Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required.
1	0	6	U-TRI	Monitor
2	8	12	O	these
3	14	21	O	patients
4	23	25	O	and
5	27	32	O	adjust
6	34	36	O	the
7	38	41	O	dose
8	43	44	O	of
9	46	48	O	the
10	50	60	O	concomitant
11	62	67	O	drug(s
12	70	74	O	which
13	76	78	O	are
14	80	83	B-UNK	OAT3
15	85	94	L-UNK	substrates
16	96	97	O	as
17	99	106	O	required
NULL

Aubagio	3161	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	29
Effect of AUBAGIO on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo.
1	0	5	O	Effect
2	7	8	O	of
3	10	16	O	XXXXXXXX
4	18	19	O	on
5	21	24	O	BCRP
6	26	28	O	and
7	30	36	B-DYN	organic
8	38	42	I-DYN	anion
9	44	55	I-DYN	transporting
10	57	67	I-DYN	polypeptide
11	69	70	I-DYN	B1
12	72	74	I-DYN	and
13	76	77	I-DYN	B3
14	80	86	I-DYN	OATP1B1
15	87	87	I-DYN	/
16	88	90	I-DYN	1B3
17	93	102	L-DYN	substrates
18	104	116	O	XXXXXXXX
19	118	125	O	inhibits
20	127	129	O	the
21	131	138	O	activity
22	140	141	O	of
23	143	146	O	BCRP
24	148	150	O	and
25	152	158	O	OATP1B1
26	159	159	O	/
27	160	162	O	1B3
28	164	165	O	in
29	167	170	O	vivo
NULL

Aubagio	3162	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	17
For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily.
1	0	2	O	For
2	4	4	O	a
3	6	12	O	patient
4	14	19	O	taking
5	21	27	O	XXXXXXXX
6	28	28	O	,
7	30	32	O	the
8	34	37	O	dose
9	39	40	O	of
10	42	53	U-KIN	rosuvastatin
11	55	60	O	should
12	62	64	O	not
13	66	71	O	exceed
14	73	74	O	10
15	76	77	O	mg
16	79	82	O	once
17	84	88	O	daily
K/10:C54357

Aubagio	3163	34073-7	4650d12c-b9c8-4525-b07f-a2d773eca155	64
For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO.
1	0	2	O	For
2	4	8	O	other
3	10	19	B-KIN	substrates
4	21	22	I-KIN	of
5	24	27	L-KIN	BCRP
6	30	32	O	e.g
7	34	34	O	,
8	36	47	U-KIN	mitoxantrone
9	50	52	O	and
10	54	58	B-KIN	drugs
11	60	61	I-KIN	in
12	63	65	I-KIN	the
13	67	70	I-KIN	OATP
14	72	77	L-KIN	family
15	80	82	O	e.g
16	84	84	O	,
17	86	97	U-KIN	methotrexate
18	98	98	O	,
19	100	107	U-KIN	rifampin
20	109	109	O	,
21	111	120	O	especially
22	122	124	B-KIN	HMG
23	126	127	I-KIN	Co
24	129	137	I-KIN	reductase
25	139	148	L-KIN	inhibitors
26	151	153	O	e.g
27	155	155	O	,
28	157	168	U-KIN	atorvastatin
29	169	169	O	,
30	171	181	U-KIN	nateglinide
31	182	182	O	,
32	184	194	U-KIN	pravastatin
33	195	195	O	,
34	197	207	U-KIN	repaglinide
35	208	208	O	,
36	210	212	O	and
37	214	224	U-KIN	simvastatin
38	226	226	O	,
39	228	235	O	consider
40	237	244	B-TRI	reducing
41	246	248	I-TRI	the
42	250	253	L-TRI	dose
43	255	256	O	of
44	258	262	O	these
45	264	268	O	drugs
46	270	272	O	and
47	274	280	O	monitor
48	282	289	O	patients
49	291	297	O	closely
50	299	301	O	for
51	303	307	O	signs
52	309	311	O	and
53	313	320	O	symptoms
54	322	323	O	of
55	325	333	O	increased
56	335	343	O	exposures
57	345	346	O	to
58	348	350	O	the
59	352	356	O	drugs
60	358	362	O	while
61	364	371	O	patients
62	373	375	O	are
63	377	382	O	taking
64	384	390	O	XXXXXXXX
K/10:C54357 K/17:C54357 K/19:C54357 K/22:C54357 K/28:C54357 K/3:C54357 K/30:C54357 K/32:C54357 K/34:C54357 K/37:C54357 K/8:C54357

Aubagio	3164	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	23
Teriflunomide, an immunomodulatory agent with anti-inflammatory properties, inhibits dihydroorotate dehydrogenase, a mitochondrial enzyme involved in de novo pyrimidine synthesis.
1	0	12	O	XXXXXXXX
2	13	13	O	,
3	15	16	O	an
4	18	33	O	immunomodulatory
5	35	39	O	agent
6	41	44	O	with
7	46	49	O	anti
8	51	62	O	inflammatory
9	64	73	O	properties
10	74	74	O	,
11	76	83	O	inhibits
12	85	98	O	dihydroorotate
13	100	112	O	dehydrogenase
14	113	113	O	,
15	115	115	O	a
16	117	129	O	mitochondrial
17	131	136	O	enzyme
18	138	145	O	involved
19	147	148	O	in
20	150	151	O	de
21	153	156	O	novo
22	158	167	O	pyrimidine
23	169	177	O	synthesis
NULL

Aubagio	3165	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	28
The exact mechanism by which teriflunomide exerts its therapeutic effect in multiple sclerosis is unknown but may involve a reduction in the number of activated lymphocytes in CNS.
1	0	2	O	The
2	4	8	O	exact
3	10	18	O	mechanism
4	20	21	O	by
5	23	27	O	which
6	29	41	O	XXXXXXXX
7	43	48	O	exerts
8	50	52	O	its
9	54	64	O	therapeutic
10	66	71	O	effect
11	73	74	O	in
12	76	83	O	multiple
13	85	93	O	sclerosis
14	95	96	O	is
15	98	104	O	unknown
16	106	108	O	but
17	110	112	O	may
18	114	120	O	involve
19	122	122	O	a
20	124	132	O	reduction
21	134	135	O	in
22	137	139	O	the
23	141	146	O	number
24	148	149	O	of
25	151	159	O	activated
26	161	171	O	lymphocytes
27	173	174	O	in
28	176	178	O	CNS
NULL

Aubagio	3166	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	54
Potential to prolong the QT interval In a placebo controlled thorough QT study performed in healthy subjects, there was no evidence that teriflunomide caused QT interval prolongation of clinical significance (i.e., the upper bound of the 90% confidence interval for the largest placebo-adjusted, baseline-corrected QTc was below 10 ms).
1	0	8	O	Potential
2	10	11	O	to
3	13	19	O	prolong
4	21	23	O	the
5	25	26	O	QT
6	28	35	O	interval
7	37	38	O	In
8	40	40	O	a
9	42	48	O	placebo
10	50	59	O	controlled
11	61	68	O	thorough
12	70	71	O	QT
13	73	77	O	study
14	79	87	O	performed
15	89	90	O	in
16	92	98	O	healthy
17	100	107	O	subjects
18	108	108	O	,
19	110	114	O	there
20	116	118	O	was
21	120	121	O	no
22	123	130	O	evidence
23	132	135	O	that
24	137	149	O	XXXXXXXX
25	151	156	O	caused
26	158	159	O	QT
27	161	168	O	interval
28	170	181	O	prolongation
29	183	184	O	of
30	186	193	O	clinical
31	195	206	O	significance
32	209	211	O	i.e
33	213	213	O	,
34	215	217	O	the
35	219	223	O	upper
36	225	229	O	bound
37	231	232	O	of
38	234	236	O	the
39	238	240	O	90%
40	242	251	O	confidence
41	253	260	O	interval
42	262	264	O	for
43	266	268	O	the
44	270	276	O	largest
45	278	284	O	placebo
46	286	293	O	adjusted
47	294	294	O	,
48	296	303	O	baseline
49	305	313	O	corrected
50	315	317	O	QTc
51	319	321	O	was
52	323	327	O	below
53	329	330	O	10
54	332	333	O	ms
NULL

Aubagio	3167	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	16
Teriflunomide is the principal active metabolite of leflunomide and is responsible for leflunomide's activity in vivo.
1	0	12	O	XXXXXXXX
2	14	15	O	is
3	17	19	O	the
4	21	29	O	principal
5	31	36	O	active
6	38	47	O	metabolite
7	49	50	O	of
8	52	62	O	leflunomide
9	64	66	O	and
10	68	69	O	is
11	71	81	O	responsible
12	83	85	O	for
13	87	99	O	leflunomide's
14	101	108	O	activity
15	110	111	O	in
16	113	116	O	vivo
NULL

Aubagio	3168	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	17
At recommended doses, teriflunomide and leflunomide result in a similar range of plasma concentrations of teriflunomide.
1	0	1	O	At
2	3	13	O	recommended
3	15	19	O	doses
4	20	20	O	,
5	22	34	O	XXXXXXXX
6	36	38	O	and
7	40	50	O	leflunomide
8	52	57	O	result
9	59	60	O	in
10	62	62	O	a
11	64	70	O	similar
12	72	76	O	range
13	78	79	O	of
14	81	86	O	plasma
15	88	101	O	concentrations
16	103	104	O	of
17	106	118	O	XXXXXXXX
NULL

Aubagio	3169	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	34
Based on a population analysis of teriflunomide in healthy volunteers and MS patients, median t1/2 was approximately 18 and 19 days after repeated doses of 7 mg and 14 mg respectively.
1	0	4	O	Based
2	6	7	O	on
3	9	9	O	a
4	11	20	O	population
5	22	29	O	analysis
6	31	32	O	of
7	34	46	O	XXXXXXXX
8	48	49	O	in
9	51	57	O	healthy
10	59	68	O	volunteers
11	70	72	O	and
12	74	75	O	MS
13	77	84	O	patients
14	85	85	O	,
15	87	92	O	median
16	94	95	O	t1
17	96	96	O	/
18	97	97	O	2
19	99	101	O	was
20	103	115	O	approximately
21	117	118	O	18
22	120	122	O	and
23	124	125	O	19
24	127	130	O	days
25	132	136	O	after
26	138	145	O	repeated
27	147	151	O	doses
28	153	154	O	of
29	156	156	O	7
30	158	159	O	mg
31	161	163	O	and
32	165	166	O	14
33	168	169	O	mg
34	171	182	O	respectively
NULL

Aubagio	3170	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	11
It takes approximately 3 months respectively to reach steady-state concentrations.
1	0	1	O	It
2	3	7	O	takes
3	9	21	O	approximately
4	23	23	O	3
5	25	30	O	months
6	32	43	O	respectively
7	45	46	O	to
8	48	52	O	reach
9	54	59	O	steady
10	61	65	O	state
11	67	80	O	concentrations
NULL

Aubagio	3171	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	37
The estimated AUC accumulation ratio is approximately 30 after repeated doses of 7 or 14 mg. Absorption Median time to reach maximum plasma concentrations is between 1 to 4 hours post dose following oral administration of teriflunomide.
1	0	2	O	The
2	4	12	O	estimated
3	14	16	O	AUC
4	18	29	O	accumulation
5	31	35	O	ratio
6	37	38	O	is
7	40	52	O	approximately
8	54	55	O	30
9	57	61	O	after
10	63	70	O	repeated
11	72	76	O	doses
12	78	79	O	of
13	81	81	O	7
14	83	84	O	or
15	86	87	O	14
16	89	90	O	mg
17	93	102	O	Absorption
18	104	109	O	Median
19	111	114	O	time
20	116	117	O	to
21	119	123	O	reach
22	125	131	O	maximum
23	133	138	O	plasma
24	140	153	O	concentrations
25	155	156	O	is
26	158	164	O	between
27	166	166	O	1
28	168	169	O	to
29	171	171	O	4
30	173	177	O	hours
31	179	182	O	post
32	184	187	O	dose
33	189	197	O	following
34	199	202	O	oral
35	204	217	O	administration
36	219	220	O	of
37	222	234	O	XXXXXXXX
NULL

Aubagio	3172	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	11
Food does not have a clinically relevant effect on teriflunomide pharmacokinetics.
1	0	3	O	Food
2	5	8	O	does
3	10	12	O	not
4	14	17	O	have
5	19	19	O	a
6	21	30	O	clinically
7	32	39	O	relevant
8	41	46	O	effect
9	48	49	O	on
10	51	63	O	XXXXXXXX
11	65	80	O	pharmacokinetics
NULL

Aubagio	3173	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	15
Distribution Teriflunomide is extensively bound to plasma protein (>99%) and is mainly distributed in plasma.
1	0	11	O	Distribution
2	13	25	O	XXXXXXXX
3	27	28	O	is
4	30	40	O	extensively
5	42	46	O	bound
6	48	49	O	to
7	51	56	O	plasma
8	58	64	O	protein
9	67	70	O	>99%
10	73	75	O	and
11	77	78	O	is
12	80	85	O	mainly
13	87	97	O	distributed
14	99	100	O	in
15	102	107	O	plasma
NULL

Aubagio	3174	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	13
The volume of distribution is 11 L after a single intravenous (IV) administration.
1	0	2	O	The
2	4	9	O	volume
3	11	12	O	of
4	14	25	O	distribution
5	27	28	O	is
6	30	31	O	11
7	33	33	O	L
8	35	39	O	after
9	41	41	O	a
10	43	48	O	single
11	50	60	O	intravenous
12	63	64	O	IV
13	67	80	O	administration
NULL

Aubagio	3175	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	10
Metabolism Teriflunomide is the major circulating moiety detected in plasma.
1	0	9	O	Metabolism
2	11	23	O	XXXXXXXX
3	25	26	O	is
4	28	30	O	the
5	32	36	O	major
6	38	48	O	circulating
7	50	55	O	moiety
8	57	64	O	detected
9	66	67	O	in
10	69	74	O	plasma
NULL

Aubagio	3176	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	18
The primary biotransformation pathway to minor metabolites of teriflunomide is hydrolysis, with oxidation being a minor pathway.
1	0	2	O	The
2	4	10	O	primary
3	12	28	O	biotransformation
4	30	36	O	pathway
5	38	39	O	to
6	41	45	O	minor
7	47	57	O	metabolites
8	59	60	O	of
9	62	74	O	XXXXXXXX
10	76	77	O	is
11	79	88	O	hydrolysis
12	89	89	O	,
13	91	94	O	with
14	96	104	O	oxidation
15	106	110	O	being
16	112	112	O	a
17	114	118	O	minor
18	120	126	O	pathway
NULL

Aubagio	3177	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	10
Secondary pathways involve oxidation, N-acetylation and sulfate conjugation.
1	0	8	O	Secondary
2	10	17	O	pathways
3	19	25	O	involve
4	27	35	O	oxidation
5	36	36	O	,
6	38	38	O	N
7	40	50	O	acetylation
8	52	54	O	and
9	56	62	O	sulfate
10	64	74	O	conjugation
NULL

Aubagio	3178	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	19
Elimination Teriflunomide is eliminated mainly through direct biliary excretion of unchanged drug as well as renal excretion of metabolites.
1	0	10	O	Elimination
2	12	24	O	XXXXXXXX
3	26	27	O	is
4	29	38	O	eliminated
5	40	45	O	mainly
6	47	53	O	through
7	55	60	O	direct
8	62	68	O	biliary
9	70	78	O	excretion
10	80	81	O	of
11	83	91	O	unchanged
12	93	96	O	drug
13	98	99	O	as
14	101	104	O	well
15	106	107	O	as
16	109	113	O	renal
17	115	123	O	excretion
18	125	126	O	of
19	128	138	O	metabolites
NULL

Aubagio	3179	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	17
Over 21 days, 60.1% of the administered dose is excreted via feces (37.5%) and urine (22.6%).
1	0	3	O	Over
2	5	6	O	21
3	8	11	O	days
4	12	12	O	,
5	14	18	O	60.1%
6	20	21	O	of
7	23	25	O	the
8	27	38	O	administered
9	40	43	O	dose
10	45	46	O	is
11	48	55	O	excreted
12	57	59	O	via
13	61	65	O	feces
14	68	72	O	37.5%
15	75	77	O	and
16	79	83	O	urine
17	86	90	O	22.6%
NULL

Aubagio	3180	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	16
After an accelerated elimination procedure with cholestyramine, an additional 23.1% was recovered (mostly in feces).
1	0	4	O	After
2	6	7	O	an
3	9	19	O	accelerated
4	21	31	O	elimination
5	33	41	O	procedure
6	43	46	O	with
7	48	61	O	cholestyramine
8	62	62	O	,
9	64	65	O	an
10	67	76	O	additional
11	78	82	O	23.1%
12	84	86	O	was
13	88	96	O	recovered
14	99	104	O	mostly
15	106	107	O	in
16	109	113	O	feces
NULL

Aubagio	3181	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	17
After a single IV administration, the total body clearance of teriflunomide is 30.5 mL/h.
1	0	4	O	After
2	6	6	O	a
3	8	13	O	single
4	15	16	O	IV
5	18	31	O	administration
6	32	32	O	,
7	34	36	O	the
8	38	42	O	total
9	44	47	O	body
10	49	57	O	clearance
11	59	60	O	of
12	62	74	O	XXXXXXXX
13	76	77	O	is
14	79	82	O	30.5
15	84	85	O	mL
16	86	86	O	/
17	87	87	O	h
NULL

Aubagio	3182	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	15
Drug Interaction Studies Teriflunomide is not metabolized by Cytochrome P450 or flavin monoamine oxidase enzymes.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	23	O	Studies
4	25	37	O	XXXXXXXX
5	39	40	O	is
6	42	44	O	not
7	46	56	O	metabolized
8	58	59	O	by
9	61	70	O	Cytochrome
10	72	75	O	P450
11	77	78	O	or
12	80	85	O	flavin
13	87	95	O	monoamine
14	97	103	O	oxidase
15	105	111	O	enzymes
NULL

Aubagio	3183	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	51
The Potential Effect of AUBAGIO on Other Drugs CYP2C8 Substrates There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo.
1	0	2	O	The
2	4	12	O	Potential
3	14	19	O	Effect
4	21	22	O	of
5	24	30	O	XXXXXXXX
6	32	33	O	on
7	35	39	O	Other
8	41	45	O	Drugs
9	47	52	U-KIN	CYP2C8
10	54	63	O	Substrates
11	65	69	O	There
12	71	73	O	was
13	75	76	O	an
14	78	85	O	increase
15	87	88	O	in
16	90	93	O	mean
17	95	105	U-KIN	repaglinide
18	107	110	O	Cmax
19	112	114	O	and
20	116	118	O	AUC
21	121	123	O	1.7
22	126	128	O	and
23	130	132	O	2.4
24	134	137	O	fold
25	138	138	O	,
26	140	151	O	respectively
27	153	153	O	,
28	155	163	O	following
29	165	172	O	repeated
30	174	178	O	doses
31	180	181	O	of
32	183	195	O	XXXXXXXX
33	197	199	O	and
34	201	201	O	a
35	203	208	O	single
36	210	213	O	dose
37	215	216	O	of
38	218	221	O	0.25
39	223	224	O	mg
40	226	236	O	repaglinide
41	237	237	O	,
42	239	248	O	suggesting
43	250	253	O	that
44	255	267	O	XXXXXXXX
45	269	270	O	is
46	272	273	O	an
47	275	283	O	inhibitor
48	285	286	O	of
49	288	293	O	CYP2C8
50	295	296	O	in
51	298	301	O	vivo
K/17:C54610 K/9:C54613

Aubagio	3184	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	12
The magnitude of interaction could be higher at the recommended repaglinide dose.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	27	U-TRI	interaction
5	29	33	O	could
6	35	36	O	be
7	38	43	O	higher
8	45	46	O	at
9	48	50	O	the
10	52	62	O	recommended
11	64	74	U-UNK	repaglinide
12	76	79	O	dose
NULL

Aubagio	3185	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	32
CYP1A2 Substrates Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo.
1	0	5	O	CYP1A2
2	7	16	O	Substrates
3	18	25	O	Repeated
4	27	31	O	doses
5	33	34	O	of
6	36	48	O	XXXXXXXX
7	50	58	O	decreased
8	60	63	O	mean
9	65	68	O	Cmax
10	70	72	O	and
11	74	76	O	AUC
12	78	79	O	of
13	81	88	U-KIN	caffeine
14	90	91	O	by
15	93	95	O	18%
16	97	99	O	and
17	101	103	O	55%
18	104	104	O	,
19	106	117	O	respectively
20	118	118	O	,
21	120	129	O	suggesting
22	131	134	O	that
23	136	148	O	XXXXXXXX
24	150	152	O	may
25	154	155	O	be
26	157	157	O	a
27	159	162	O	weak
28	164	170	O	inducer
29	172	173	O	of
30	175	180	O	CYP1A2
31	182	183	O	in
32	185	188	O	vivo
K/13:C54614

Aubagio	3186	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	39
OAT3 Substrates There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of organic anion transporter 3 (OAT3) in vivo.
1	0	3	B-KIN	OAT3
2	5	14	L-KIN	Substrates
3	16	20	O	There
4	22	24	O	was
5	26	27	O	an
6	29	36	O	increase
7	38	39	O	in
8	41	44	O	mean
9	46	53	U-KIN	cefaclor
10	55	58	O	Cmax
11	60	62	O	and
12	64	66	O	AUC
13	69	72	O	1.43
14	75	77	O	and
15	79	82	O	1.54
16	84	87	O	fold
17	88	88	O	,
18	90	101	O	respectively
19	103	103	O	,
20	105	113	O	following
21	115	122	O	repeated
22	124	128	O	doses
23	130	131	O	of
24	133	145	O	XXXXXXXX
25	146	146	O	,
26	148	157	O	suggesting
27	159	162	O	that
28	164	176	O	XXXXXXXX
29	178	179	O	is
30	181	182	O	an
31	184	192	O	inhibitor
32	194	195	O	of
33	197	203	O	organic
34	205	209	O	anion
35	211	221	O	transporter
36	223	223	O	3
37	226	229	O	OAT3
38	232	233	O	in
39	235	238	O	vivo
K/1:C54610 K/9:C54610

Aubagio	3187	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	49
BCRP and OATP1B1/1B3 Substrates There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide , suggesting that teriflunomide is an inhibitor of BCRP transporter and organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3).
1	0	3	O	BCRP
2	5	7	O	and
3	9	15	B-KIN	OATP1B1
4	16	16	I-KIN	/
5	17	19	I-KIN	1B3
6	21	30	L-KIN	Substrates
7	32	36	O	There
8	38	40	O	was
9	42	43	O	an
10	45	52	O	increase
11	54	55	O	in
12	57	60	O	mean
13	62	73	U-KIN	rosuvastatin
14	75	78	O	Cmax
15	80	82	O	and
16	84	86	O	AUC
17	89	92	O	2.65
18	95	97	O	and
19	99	102	O	2.51
20	104	107	O	fold
21	108	108	O	,
22	110	121	O	respectively
23	123	123	O	,
24	125	133	O	following
25	135	142	O	repeated
26	144	148	O	doses
27	150	151	O	of
28	153	165	O	XXXXXXXX
29	167	167	O	,
30	169	178	O	suggesting
31	180	183	O	that
32	185	197	O	XXXXXXXX
33	199	200	O	is
34	202	203	O	an
35	205	213	O	inhibitor
36	215	216	O	of
37	218	221	O	BCRP
38	223	233	O	transporter
39	235	237	O	and
40	239	245	O	organic
41	247	251	O	anion
42	253	264	O	transporting
43	266	276	O	polypeptide
44	278	280	O	1B1
45	282	284	O	and
46	286	288	O	1B3
47	291	297	O	OATP1B1
48	298	298	O	/
49	299	301	O	1B3
K/13:C54610 K/3:C54610

Aubagio	3188	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	36
Oral Contraceptives There was an increase in mean ethinylestradiol Cmax and AUC0-24 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC0-24 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide.
1	0	3	B-KIN	Oral
2	5	18	L-KIN	Contraceptives
3	20	24	O	There
4	26	28	O	was
5	30	31	O	an
6	33	40	O	increase
7	42	43	O	in
8	45	48	O	mean
9	50	65	U-KIN	ethinylestradiol
10	67	70	O	Cmax
11	72	74	O	and
12	76	79	O	AUC0
13	81	82	O	24
14	85	88	O	1.58
15	91	93	O	and
16	95	98	O	1.54
17	100	103	O	fold
18	104	104	O	,
19	106	117	O	respectively
20	120	122	O	and
21	124	137	U-KIN	levonorgestrel
22	139	142	O	Cmax
23	144	146	O	and
24	148	151	O	AUC0
25	153	154	O	24
26	157	160	O	1.33
27	163	165	O	and
28	167	170	O	1.41
29	172	175	O	fold
30	176	176	O	,
31	178	189	O	respectively
32	192	200	O	following
33	202	209	O	repeated
34	211	215	O	doses
35	217	218	O	of
36	220	232	O	XXXXXXXX
K/1:C54613 K/21:C54610 K/9:C54610

Aubagio	3189	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	33
Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).
1	0	12	O	XXXXXXXX
2	14	16	O	did
3	18	20	O	not
4	22	27	O	affect
5	29	31	O	the
6	33	48	O	pharmacokinetics
7	50	51	O	of
8	53	61	O	bupropion
9	64	64	O	a
10	66	71	O	CYP2B6
11	73	81	O	substrate
12	83	83	O	,
13	85	93	O	midazolam
14	96	96	O	a
15	98	103	O	CYP3A4
16	105	113	O	substrate
17	115	115	O	,
18	117	117	O	S
19	119	126	O	warfarin
20	129	129	O	a
21	131	136	O	CYP2C9
22	138	146	O	substrate
23	148	148	O	,
24	150	159	O	omeprazole
25	162	162	O	a
26	164	170	O	CYP2C19
27	172	180	O	substrate
28	182	182	O	,
29	184	186	O	and
30	188	197	O	metoprolol
31	200	200	O	a
32	202	207	O	CYP2D6
33	209	217	O	substrate
NULL

Aubagio	3190	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	22
The Potential Effect of Other Drugs on AUBAGIO Potent CYP and transporter inducers: Rifampin did not affect the pharmacokinetics of teriflunomide.
1	0	2	O	The
2	4	12	O	Potential
3	14	19	O	Effect
4	21	22	O	of
5	24	28	O	Other
6	30	34	O	Drugs
7	36	37	O	on
8	39	45	O	XXXXXXXX
9	47	52	O	Potent
10	54	56	O	CYP
11	58	60	O	and
12	62	72	O	transporter
13	74	81	O	inducers
14	82	82	O	:
15	84	91	O	Rifampin
16	93	95	O	did
17	97	99	O	not
18	101	106	O	affect
19	108	110	O	the
20	112	127	O	pharmacokinetics
21	129	130	O	of
22	132	144	O	XXXXXXXX
NULL

Aubagio	3191	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	17
Specific populations Hepatic Impairment Mild and moderate hepatic impairment had no impact on the pharmacokinetics of teriflunomide.
1	0	7	O	Specific
2	9	19	O	populations
3	21	27	O	Hepatic
4	29	38	O	Impairment
5	40	43	O	Mild
6	45	47	O	and
7	49	56	O	moderate
8	58	64	O	hepatic
9	66	75	O	impairment
10	77	79	O	had
11	81	82	O	no
12	84	89	O	impact
13	91	92	O	on
14	94	96	O	the
15	98	113	O	pharmacokinetics
16	115	116	O	of
17	118	130	O	XXXXXXXX
NULL

Aubagio	3192	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	12
The pharmacokinetics of teriflunomide in severe hepatic impairment have not been evaluated.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	36	O	XXXXXXXX
5	38	39	O	in
6	41	46	O	severe
7	48	54	O	hepatic
8	56	65	O	impairment
9	67	70	O	have
10	72	74	O	not
11	76	79	O	been
12	81	89	O	evaluated
NULL

Aubagio	3193	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	13
Renal Impairment Severe renal impairment had no impact on the pharmacokinetics of teriflunomide.
1	0	4	O	Renal
2	6	15	O	Impairment
3	17	22	O	Severe
4	24	28	O	renal
5	30	39	O	impairment
6	41	43	O	had
7	45	46	O	no
8	48	53	O	impact
9	55	56	O	on
10	58	60	O	the
11	62	77	O	pharmacokinetics
12	79	80	O	of
13	82	94	O	XXXXXXXX
NULL

Aubagio	3194	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	19
Gender In a population analysis, the clearance rate for teriflunomide is 23% less in females than in males.
1	0	5	O	Gender
2	7	8	O	In
3	10	10	O	a
4	12	21	O	population
5	23	30	O	analysis
6	31	31	O	,
7	33	35	O	the
8	37	45	O	clearance
9	47	50	O	rate
10	52	54	O	for
11	56	68	O	XXXXXXXX
12	70	71	O	is
13	73	75	O	23%
14	77	80	O	less
15	82	83	O	in
16	85	91	O	females
17	93	96	O	than
18	98	99	O	in
19	101	105	O	males
NULL

Aubagio	3195	34090-1	4650d12c-b9c8-4525-b07f-a2d773eca155	26
Race Effect of race on the pharmacokinetics of teriflunomide cannot be adequately assessed due to a low number of non-white patients in the clinical trials.
1	0	3	O	Race
2	5	10	O	Effect
3	12	13	O	of
4	15	18	O	race
5	20	21	O	on
6	23	25	O	the
7	27	42	O	pharmacokinetics
8	44	45	O	of
9	47	59	O	XXXXXXXX
10	61	66	O	cannot
11	68	69	O	be
12	71	80	O	adequately
13	82	89	O	assessed
14	91	93	O	due
15	95	96	O	to
16	98	98	O	a
17	100	102	O	low
18	104	109	O	number
19	111	112	O	of
20	114	116	O	non
21	118	122	O	white
22	124	131	O	patients
23	133	134	O	in
24	136	138	O	the
25	140	147	O	clinical
26	149	154	O	trials
NULL

Bicalutamide	4901	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	16
Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide).
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	24	O	not
5	26	30	O	shown
6	32	34	O	any
7	36	39	O	drug
8	41	52	O	interactions
9	54	60	O	between
10	62	73	O	XXXXXXXX
11	75	77	O	and
12	79	82	O	LHRH
13	84	90	O	analogs
14	93	101	O	goserelin
15	103	104	O	or
16	106	115	O	leuprolide
NULL

Bicalutamide	4902	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	9
There is no evidence that bicalutamide induces hepatic enzymes.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	19	O	evidence
5	21	24	O	that
6	26	37	O	XXXXXXXX
7	39	45	O	induces
8	47	53	O	hepatic
9	55	61	O	enzymes
NULL

Bicalutamide	4903	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	26
In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	33	O	R
8	35	46	O	XXXXXXXX
9	48	49	O	is
10	51	52	O	an
11	54	62	O	inhibitor
12	64	65	O	of
13	67	69	O	CYP
14	71	73	O	3A4
15	75	78	O	with
16	80	85	O	lesser
17	87	96	O	inhibitory
18	98	104	O	effects
19	106	107	O	on
20	109	111	O	CYP
21	113	115	O	2C9
22	116	116	O	,
23	118	121	O	2C19
24	123	125	O	and
25	127	129	O	2D6
26	131	138	O	activity
NULL

Bicalutamide	4904	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	31
Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5-fold (for C max) and 1.9-fold (for AUC).
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	26	O	shown
5	28	31	O	that
6	33	36	O	with
7	38	39	O	co
8	41	54	O	administration
9	56	57	O	of
10	59	70	O	XXXXXXXX
11	71	71	O	,
12	73	76	O	mean
13	78	86	U-KIN	midazolam
14	89	89	O	a
15	91	93	B-KIN	CYP
16	95	97	I-KIN	3A4
17	99	107	L-KIN	substrate
18	110	115	O	levels
19	117	119	O	may
20	121	122	O	be
21	124	132	O	increased
22	134	136	O	1.5
23	138	141	O	fold
24	144	146	O	for
25	148	148	O	C
26	150	152	O	max
27	155	157	O	and
28	159	161	O	1.9
29	163	166	O	fold
30	169	171	O	for
31	173	175	O	AUC
K/13:C54357 K/15:C54613

Bicalutamide	4905	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	15
Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.
1	0	4	O	Hence
2	5	5	O	,
3	7	13	U-TRI	caution
4	15	20	O	should
5	22	23	O	be
6	25	33	O	exercised
7	35	38	O	when
8	40	51	O	XXXXXXXX
9	53	54	O	is
10	56	57	O	co
11	59	70	O	administered
12	72	75	O	with
13	77	79	B-UNK	CYP
14	81	83	I-UNK	3A4
15	85	94	L-UNK	substrates
NULL

Bicalutamide	4906	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	16
In vitro protein-binding studies have shown that bicalutamide can displace coumarin anticoagulants from binding sites.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	protein
4	17	23	O	binding
5	25	31	O	studies
6	33	36	O	have
7	38	42	O	shown
8	44	47	O	that
9	49	60	O	XXXXXXXX
10	62	64	O	can
11	66	73	B-EFF	displace
12	75	82	I-EFF	coumarin
13	84	97	I-EFF	anticoagulants
14	99	102	I-EFF	from
15	104	110	I-EFF	binding
16	112	116	L-EFF	sites
NULL

Bicalutamide	4907	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	26
Prothrombin times should be closely monitored in patients already receiving coumarin anticoagulants who are started on bicalutamide and adjustment of the anticoagulant dose may be necessary.
1	0	10	O	Prothrombin
2	12	16	O	times
3	18	23	B-TRI	should
4	25	26	I-TRI	be
5	28	34	I-TRI	closely
6	36	44	L-TRI	monitored
7	46	47	O	in
8	49	56	O	patients
9	58	64	O	already
10	66	74	O	receiving
11	76	83	B-UNK	coumarin
12	85	98	L-UNK	anticoagulants
13	100	102	O	who
14	104	106	O	are
15	108	114	O	started
16	116	117	O	on
17	119	130	O	XXXXXXXX
18	132	134	O	and
19	136	145	O	adjustment
20	147	148	O	of
21	150	152	O	the
22	154	166	O	anticoagulant
23	168	171	O	dose
24	173	175	O	may
25	177	178	O	be
26	180	188	O	necessary
NULL

Bicalutamide	4908	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	23
R-bicalutamide is an inhibitor of CYP 3A4; therefore, caution should be used when bicalutamide is co-administered with CYP 3A4 substrates.
1	0	0	O	R
2	2	13	O	XXXXXXXX
3	15	16	O	is
4	18	19	O	an
5	21	29	O	inhibitor
6	31	32	O	of
7	34	36	O	CYP
8	38	40	O	3A4
9	43	51	O	therefore
10	52	52	O	,
11	54	60	U-TRI	caution
12	62	67	O	should
13	69	70	O	be
14	72	75	O	used
15	77	80	O	when
16	82	93	O	XXXXXXXX
17	95	96	O	is
18	98	99	O	co
19	101	112	O	administered
20	114	117	O	with
21	119	121	B-UNK	CYP
22	123	125	I-UNK	3A4
23	127	136	L-UNK	substrates
NULL

Bicalutamide	4909	34073-7	7c295b64-ec39-42ec-9f02-da5b42e775e1	17
Prothrombin times should be closely monitored in patient already receiving coumarin anticoagulants who are started on bicalutamide.
1	0	10	O	Prothrombin
2	12	16	O	times
3	18	23	B-TRI	should
4	25	26	I-TRI	be
5	28	34	I-TRI	closely
6	36	44	L-TRI	monitored
7	46	47	O	in
8	49	55	O	patient
9	57	63	O	already
10	65	73	O	receiving
11	75	82	B-UNK	coumarin
12	84	97	L-UNK	anticoagulants
13	99	101	O	who
14	103	105	O	are
15	107	113	O	started
16	115	116	O	on
17	118	129	O	XXXXXXXX
NULL

Bicalutamide	4910	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	8
Bicalutamide is a non-steroidal androgen receptor inhibitor.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	16	O	a
4	18	20	O	non
5	22	30	O	steroidal
6	32	39	O	androgen
7	41	48	O	receptor
8	50	58	O	inhibitor
NULL

Bicalutamide	4911	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	17
It competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue.
1	0	1	O	It
2	3	15	O	competitively
3	17	24	O	inhibits
4	26	28	O	the
5	30	35	O	action
6	37	38	O	of
7	40	48	O	androgens
8	50	51	O	by
9	53	59	O	binding
10	61	62	O	to
11	64	70	O	cytosol
12	72	79	O	androgen
13	81	89	O	receptors
14	91	92	O	in
15	94	96	O	the
16	98	103	O	target
17	105	110	O	tissue
NULL

Bicalutamide	4912	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	26
Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen.
1	0	8	O	Prostatic
2	10	18	O	carcinoma
3	20	21	O	is
4	23	27	O	known
5	29	30	O	to
6	32	33	O	be
7	35	42	O	androgen
8	44	52	O	sensitive
9	54	56	O	and
10	58	65	O	responds
11	67	68	O	to
12	70	78	O	treatment
13	80	83	O	that
14	85	95	O	counteracts
15	97	99	O	the
16	101	106	O	effect
17	108	109	O	of
18	111	118	O	androgen
19	120	122	O	and
20	123	123	O	/
21	124	125	O	or
22	127	133	O	removes
23	135	137	O	the
24	139	144	O	source
25	146	147	O	of
26	149	156	O	androgen
NULL

Bicalutamide	4913	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	22
When bicalutamide is combined with LHRH analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected.
1	0	3	O	When
2	5	16	O	XXXXXXXX
3	18	19	O	is
4	21	28	O	combined
5	30	33	O	with
6	35	38	O	LHRH
7	40	45	O	analog
8	47	53	O	therapy
9	54	54	O	,
10	56	58	O	the
11	60	70	O	suppression
12	72	73	O	of
13	75	79	O	serum
14	81	92	O	testosterone
15	94	100	O	induced
16	102	103	O	by
17	105	107	O	the
18	109	112	O	LHRH
19	114	119	O	analog
20	121	122	O	is
21	124	126	O	not
22	128	135	O	affected
NULL

Bicalutamide	4914	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	24
However, in clinical trials with bicalutamide as a single agent for prostate cancer, rises in serum testosterone and estradiol have been noted.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	19	O	clinical
5	21	26	O	trials
6	28	31	O	with
7	33	44	O	XXXXXXXX
8	46	47	O	as
9	49	49	O	a
10	51	56	O	single
11	58	62	O	agent
12	64	66	O	for
13	68	75	O	prostate
14	77	82	O	cancer
15	83	83	O	,
16	85	89	O	rises
17	91	92	O	in
18	94	98	O	serum
19	100	111	O	testosterone
20	113	115	O	and
21	117	125	O	estradiol
22	127	130	O	have
23	132	135	O	been
24	137	141	O	noted
NULL

Bicalutamide	4915	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	46
In a subset of patients who have been treated with bicalutamide and an LHRH agonist, and who discontinue bicalutamide therapy due to progressive advanced prostate cancer, a reduction in Prostate Specific Antigen (PSA) and/or clinical improvement (antiandrogen withdrawal phenomenon) may be observed.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	subset
4	12	13	O	of
5	15	22	O	patients
6	24	26	O	who
7	28	31	O	have
8	33	36	O	been
9	38	44	O	treated
10	46	49	O	with
11	51	62	O	XXXXXXXX
12	64	66	O	and
13	68	69	O	an
14	71	74	O	LHRH
15	76	82	O	agonist
16	83	83	O	,
17	85	87	O	and
18	89	91	O	who
19	93	103	O	discontinue
20	105	116	O	XXXXXXXX
21	118	124	O	therapy
22	126	128	O	due
23	130	131	O	to
24	133	143	O	progressive
25	145	152	O	advanced
26	154	161	O	prostate
27	163	168	O	cancer
28	169	169	O	,
29	171	171	O	a
30	173	181	O	reduction
31	183	184	O	in
32	186	193	O	Prostate
33	195	202	O	Specific
34	204	210	O	Antigen
35	213	215	O	PSA
36	218	220	O	and
37	221	221	O	/
38	222	223	O	or
39	225	232	O	clinical
40	234	244	O	improvement
41	247	258	O	antiandrogen
42	260	269	O	withdrawal
43	271	280	O	phenomenon
44	283	285	O	may
45	287	288	O	be
46	290	297	O	observed
NULL

Bicalutamide	4916	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	15
Absorption Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown.
1	0	9	O	Absorption
2	11	22	O	XXXXXXXX
3	24	25	O	is
4	27	30	O	well
5	32	39	O	absorbed
6	41	49	O	following
7	51	54	O	oral
8	56	69	O	administration
9	70	70	O	,
10	72	79	O	although
11	81	83	O	the
12	85	92	O	absolute
13	94	108	O	bioavailability
14	110	111	O	is
15	113	119	O	unknown
NULL

Bicalutamide	4917	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	17
Co-administration of bicalutamide with food has no clinically significant effect on rate or extent of absorption.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	32	O	XXXXXXXX
5	34	37	O	with
6	39	42	O	food
7	44	46	O	has
8	48	49	O	no
9	51	60	O	clinically
10	62	72	O	significant
11	74	79	O	effect
12	81	82	O	on
13	84	87	O	rate
14	89	90	O	or
15	92	97	O	extent
16	99	100	O	of
17	102	111	O	absorption
NULL

Bicalutamide	4918	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	7
Distribution Bicalutamide is highly protein-bound (96%).
1	0	11	O	Distribution
2	13	24	O	XXXXXXXX
3	26	27	O	is
4	29	34	O	highly
5	36	42	O	protein
6	44	48	O	bound
7	51	53	O	96%
NULL

Bicalutamide	4919	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	7
Metabolism/Elimination Bicalutamide undergoes stereospecific metabolism.
1	0	9	O	Metabolism
2	10	10	O	/
3	11	21	O	Elimination
4	23	34	O	XXXXXXXX
5	36	44	O	undergoes
6	46	59	O	stereospecific
7	61	70	O	metabolism
NULL

Bicalutamide	4920	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	9
The S (inactive) isomer is metabolized primarily by glucuronidation.
1	0	2	O	The
2	4	4	O	S
3	7	14	O	inactive
4	17	22	O	isomer
5	24	25	O	is
6	27	37	O	metabolized
7	39	47	O	primarily
8	49	50	O	by
9	52	66	O	glucuronidation
NULL

Bicalutamide	4921	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	18
The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation.
1	0	2	O	The
2	4	4	O	R
3	7	12	O	active
4	15	20	O	isomer
5	22	25	O	also
6	27	35	O	undergoes
7	37	51	O	glucuronidation
8	53	55	O	but
9	57	58	O	is
10	60	72	O	predominantly
11	74	81	O	oxidized
12	83	84	O	to
13	86	87	O	an
14	89	96	O	inactive
15	98	107	O	metabolite
16	109	116	O	followed
17	118	119	O	by
18	121	135	O	glucuronidation
NULL

Bicalutamide	4922	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	13
Both the parent and metabolite glucuronides are eliminated in the urine and feces.
1	0	3	O	Both
2	5	7	O	the
3	9	14	O	parent
4	16	18	O	and
5	20	29	O	metabolite
6	31	42	O	glucuronides
7	44	46	O	are
8	48	57	O	eliminated
9	59	60	O	in
10	62	64	O	the
11	66	70	O	urine
12	72	74	O	and
13	76	80	O	feces
NULL

Bicalutamide	4923	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	26
The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels.
1	0	2	O	The
2	4	4	O	S
3	6	15	O	enantiomer
4	17	18	O	is
5	20	26	O	rapidly
6	28	34	O	cleared
7	36	43	O	relative
8	45	46	O	to
9	48	50	O	the
10	52	52	O	R
11	54	63	O	enantiomer
12	64	64	O	,
13	66	69	O	with
14	71	73	O	the
15	75	75	O	R
16	77	86	O	enantiomer
17	88	97	O	accounting
18	99	101	O	for
19	103	107	O	about
20	109	111	O	99%
21	113	114	O	of
22	116	120	O	total
23	122	127	O	steady
24	129	133	O	state
25	135	140	O	plasma
26	142	147	O	levels
NULL

Bicalutamide	4924	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	20
Pharmacokinetics of the active enantiomer of bicalutamide in normal males and patients with prostate cancer are presented in Table 3.
1	0	15	O	Pharmacokinetics
2	17	18	O	of
3	20	22	O	the
4	24	29	O	active
5	31	40	O	enantiomer
6	42	43	O	of
7	45	56	O	XXXXXXXX
8	58	59	O	in
9	61	66	O	normal
10	68	72	O	males
11	74	76	O	and
12	78	85	O	patients
13	87	90	O	with
14	92	99	O	prostate
15	101	106	O	cancer
16	108	110	O	are
17	112	120	O	presented
18	122	123	O	in
19	125	129	O	Table
20	131	131	O	3
NULL

Bicalutamide	4925	34090-1	7c295b64-ec39-42ec-9f02-da5b42e775e1	18
Parameter Mean Standard Deviation Normal Males (n=30) Apparent Oral Clearance (L/hr) 0.320 0.103 Single Dose Peak
1	0	8	O	Parameter
2	10	13	O	Mean
3	15	22	O	Standard
4	24	32	O	Deviation
5	34	39	O	Normal
6	41	45	O	Males
7	48	51	O	n=30
8	54	61	O	Apparent
9	63	66	O	Oral
10	68	76	O	Clearance
11	79	79	O	L
12	80	80	O	/
13	81	82	O	hr
14	85	89	O	0.320
15	91	95	O	0.103
16	97	102	O	Single
17	104	107	O	Dose
18	109	112	O	Peak
NULL

Brintellix	5130	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	30
*Strong inhibitors of CYP2D6: Reduce BRINTELLIX dose by half when a strong CYP2D6 inhibitor (e.g., bupropion, fluoxetine, paroxetine, or quinidine) is coadministered (2.6 and 7.3).
1	0	6	O	Strong
2	8	17	B-KIN	inhibitors
3	19	20	I-KIN	of
4	22	27	L-KIN	CYP2D6
5	28	28	O	:
6	30	35	B-TRI	Reduce
7	37	46	I-TRI	XXXXXXXX
8	48	51	L-TRI	dose
9	53	54	O	by
10	56	59	O	half
11	61	64	O	when
12	66	66	O	a
13	68	73	B-KIN	strong
14	75	80	I-KIN	CYP2D6
15	82	90	L-KIN	inhibitor
16	93	95	O	e.g
17	97	97	O	,
18	99	107	U-KIN	bupropion
19	108	108	O	,
20	110	119	U-KIN	fluoxetine
21	120	120	O	,
22	122	131	U-KIN	paroxetine
23	132	132	O	,
24	134	135	O	or
25	137	145	U-KIN	quinidine
26	148	149	O	is
27	151	164	O	coadministered
28	167	169	O	2.6
29	171	173	O	and
30	175	177	O	7.3
K/13:C54355 K/18:C54355 K/2:C54355 K/20:C54355 K/22:C54355 K/25:C54355

Brintellix	5131	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	28
*Strong CYP Inducers: Consider increasing BRINTELLIX dose when a strong CYP inducer (e.g., rifampin, carbamazepine, or phenytoin) is coadministered for more than 14 days.
1	0	6	O	Strong
2	8	10	B-KIN	CYP
3	12	19	L-KIN	Inducers
4	20	20	O	:
5	22	29	O	Consider
6	31	40	B-TRI	increasing
7	42	51	I-TRI	XXXXXXXX
8	53	56	L-TRI	dose
9	58	61	O	when
10	63	63	O	a
11	65	70	B-KIN	strong
12	72	74	I-KIN	CYP
13	76	82	L-KIN	inducer
14	85	87	O	e.g
15	89	89	O	,
16	91	98	U-KIN	rifampin
17	99	99	O	,
18	101	113	U-KIN	carbamazepine
19	114	114	O	,
20	116	117	O	or
21	119	127	U-KIN	phenytoin
22	130	131	O	is
23	133	146	O	coadministered
24	148	150	O	for
25	152	155	O	more
26	157	160	O	than
27	162	163	O	14
28	165	168	O	days
K/11:C54356 K/16:C54356 K/18:C54356 K/2:C54356 K/21:C54356

Brintellix	5132	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	15
The maximum recommended dose should not exceed 3 times the original dose (2.7 and 7.3).
1	0	2	O	The
2	4	10	O	maximum
3	12	22	O	recommended
4	24	27	O	dose
5	29	34	O	should
6	36	38	O	not
7	40	45	O	exceed
8	47	47	O	3
9	49	53	O	times
10	55	57	O	the
11	59	66	O	original
12	68	71	O	dose
13	74	76	O	2.7
14	78	80	O	and
15	82	84	O	7.3
NULL

Brintellix	5133	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	52
Monoamine Oxidase Inhibitors Adverse reactions, some of which are serious or fatal, can develop in patients who use MAOIs or who have recently been discontinued from an MAOI and started on a serotonergic antidepressant(s) or who have recently had SSRI or SNRI therapy discontinued prior to initiation of an MAOI.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	29	35	B-TRI	Adverse
5	37	45	L-TRI	reactions
6	46	46	O	,
7	48	51	O	some
8	53	54	O	of
9	56	60	O	which
10	62	64	O	are
11	66	72	O	serious
12	74	75	O	or
13	77	81	O	fatal
14	82	82	O	,
15	84	86	O	can
16	88	94	O	develop
17	96	97	O	in
18	99	106	O	patients
19	108	110	O	who
20	112	114	O	use
21	116	120	U-UNK	MAOIs
22	122	123	O	or
23	125	127	O	who
24	129	132	O	have
25	134	141	O	recently
26	143	146	O	been
27	148	159	O	discontinued
28	161	164	O	from
29	166	167	O	an
30	169	172	O	MAOI
31	174	176	O	and
32	178	184	O	started
33	186	187	O	on
34	189	189	O	a
35	191	202	O	serotonergic
36	204	219	O	antidepressant(s
37	222	223	O	or
38	225	227	O	who
39	229	232	O	have
40	234	241	O	recently
41	243	245	O	had
42	247	250	O	SSRI
43	252	253	O	or
44	255	258	O	SNRI
45	260	266	O	therapy
46	268	279	O	discontinued
47	281	285	O	prior
48	287	288	O	to
49	290	299	O	initiation
50	301	302	O	of
51	304	305	O	an
52	307	310	O	MAOI
NULL

Brintellix	5134	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	51
Serotonergic Drugs Based on the mechanism of action of BRINTELLIX and the potential for serotonin toxicity, serotonin syndrome may occur when BRINTELLIX is coadministered with other drugs that may affect the serotonergic neurotransmitter systems (e.g., SSRIs, SNRIs, triptans, buspirone, tramadol, and tryptophan products etc.
1	0	11	B-DYN	Serotonergic
2	13	17	L-DYN	Drugs
3	19	23	O	Based
4	25	26	O	on
5	28	30	O	the
6	32	40	O	mechanism
7	42	43	O	of
8	45	50	O	action
9	52	53	O	of
10	55	64	O	XXXXXXXX
11	66	68	O	and
12	70	72	O	the
13	74	82	O	potential
14	84	86	O	for
15	88	96	B-EFF	serotonin
16	98	105	L-EFF	toxicity
17	106	106	O	,
18	108	116	B-EFF	serotonin
19	118	125	L-EFF	syndrome
20	127	129	O	may
21	131	135	O	occur
22	137	140	O	when
23	142	151	O	XXXXXXXX
24	153	154	O	is
25	156	169	O	coadministered
26	171	174	O	with
27	176	180	O	other
28	182	186	B-DYN	drugs
29	188	191	I-DYN	that
30	193	195	I-DYN	may
31	197	202	I-DYN	affect
32	204	206	I-DYN	the
33	208	219	I-DYN	serotonergic
34	221	236	I-DYN	neurotransmitter
35	238	244	L-DYN	systems
36	247	249	O	e.g
37	251	251	O	,
38	253	257	U-DYN	SSRIs
39	258	258	O	,
40	260	264	U-DYN	SNRIs
41	265	265	O	,
42	267	274	U-DYN	triptans
43	275	275	O	,
44	277	285	U-DYN	buspirone
45	286	286	O	,
46	288	295	U-DYN	tramadol
47	296	296	O	,
48	298	300	O	and
49	302	311	U-DYN	tryptophan
50	313	320	U-DYN	products
51	322	324	O	etc
D/1:15:1 D/1:18:1 D/28:15:1 D/28:18:1 D/38:15:1 D/38:18:1 D/40:15:1 D/40:18:1 D/42:15:1 D/42:18:1 D/44:15:1 D/44:18:1 D/46:15:1 D/46:18:1 D/49:15:1 D/49:18:1 D/50:15:1 D/50:18:1

Brintellix	5135	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	15
Closely monitor symptoms of serotonin syndrome if BRINTELLIX is co-administered with other serotonergic drugs.
1	0	6	O	Closely
2	8	14	O	monitor
3	16	23	O	symptoms
4	25	26	O	of
5	28	36	B-EFF	serotonin
6	38	45	L-EFF	syndrome
7	47	48	O	if
8	50	59	O	XXXXXXXX
9	61	62	O	is
10	64	65	O	co
11	67	78	O	administered
12	80	83	O	with
13	85	89	O	other
14	91	102	B-DYN	serotonergic
15	104	108	L-DYN	drugs
D/14:5:1

Brintellix	5136	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	16
Treatment with BRINTELLIX and any concomitant serotonergic agents should be discontinued immediately if serotonin syndrome occurs.
1	0	8	O	Treatment
2	10	13	O	with
3	15	24	O	XXXXXXXX
4	26	28	O	and
5	30	32	O	any
6	34	44	O	concomitant
7	46	57	B-DYN	serotonergic
8	59	64	L-DYN	agents
9	66	71	O	should
10	73	74	O	be
11	76	87	O	discontinued
12	89	99	O	immediately
13	101	102	O	if
14	104	112	B-EFF	serotonin
15	114	121	L-EFF	syndrome
16	123	128	O	occurs
D/7:14:1

Brintellix	5137	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	23
Other CNS Active Agents No clinically relevant effect was observed on steady state lithium exposure following coadministration with multiple daily doses of BRINTELLIX.
1	0	4	O	Other
2	6	8	O	CNS
3	10	15	O	Active
4	17	22	O	Agents
5	24	25	O	No
6	27	36	O	clinically
7	38	45	O	relevant
8	47	52	O	effect
9	54	56	O	was
10	58	65	O	observed
11	67	68	O	on
12	70	75	O	steady
13	77	81	O	state
14	83	89	O	lithium
15	91	98	O	exposure
16	100	108	O	following
17	110	125	O	coadministration
18	127	130	O	with
19	132	139	O	multiple
20	141	145	O	daily
21	147	151	O	doses
22	153	154	O	of
23	156	165	O	XXXXXXXX
NULL

Brintellix	5138	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	16
Multiple doses of BRINTELLIX did not affect the pharmacokinetics or pharmacodynamics (composite cognitive score) of diazepam.
1	0	7	O	Multiple
2	9	13	O	doses
3	15	16	O	of
4	18	27	O	XXXXXXXX
5	29	31	O	did
6	33	35	O	not
7	37	42	O	affect
8	44	46	O	the
9	48	63	O	pharmacokinetics
10	65	66	O	or
11	68	83	O	pharmacodynamics
12	86	94	O	composite
13	96	104	O	cognitive
14	106	110	O	score
15	113	114	O	of
16	116	123	O	diazepam
NULL

Brintellix	5139	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	34
A clinical study has shown that BRINTELLIX (single dose of 20 or 40 mg) did not increase the impairment of mental and motor skills caused by alcohol (single dose of 0.6 g/kg).
1	0	0	O	A
2	2	9	O	clinical
3	11	15	O	study
4	17	19	O	has
5	21	25	O	shown
6	27	30	O	that
7	32	41	O	XXXXXXXX
8	44	49	O	single
9	51	54	O	dose
10	56	57	O	of
11	59	60	O	20
12	62	63	O	or
13	65	66	O	40
14	68	69	O	mg
15	72	74	O	did
16	76	78	O	not
17	80	87	O	increase
18	89	91	O	the
19	93	102	O	impairment
20	104	105	O	of
21	107	112	O	mental
22	114	116	O	and
23	118	122	O	motor
24	124	129	O	skills
25	131	136	O	caused
26	138	139	O	by
27	141	147	O	alcohol
28	150	155	O	single
29	157	160	O	dose
30	162	163	O	of
31	165	167	O	0.6
32	169	169	O	g
33	170	170	O	/
34	171	172	O	kg
NULL

Brintellix	5140	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	16
Details on the potential pharmacokinetic interactions between BRINTELLIX and bupropion can be found in Section 7.3.
1	0	6	O	Details
2	8	9	O	on
3	11	13	O	the
4	15	23	O	potential
5	25	39	O	pharmacokinetic
6	41	52	O	interactions
7	54	60	O	between
8	62	71	O	XXXXXXXX
9	73	75	O	and
10	77	85	O	bupropion
11	87	89	O	can
12	91	92	O	be
13	94	98	O	found
14	100	101	O	in
15	103	109	O	Section
16	111	113	O	7.3
NULL

Brintellix	5141	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Brintellix	5142	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	29
Epidemiological studies of case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	30	O	case
5	32	38	O	control
6	40	42	O	and
7	44	49	O	cohort
8	51	56	O	design
9	58	61	O	have
10	63	74	O	demonstrated
11	76	77	O	an
12	79	89	O	association
13	91	97	O	between
14	99	101	O	use
15	103	104	O	of
16	106	117	O	psychotropic
17	119	123	O	drugs
18	125	128	O	that
19	130	138	O	interfere
20	140	143	O	with
21	145	153	O	serotonin
22	155	162	O	reuptake
23	164	166	O	and
24	168	170	O	the
25	172	181	O	occurrence
26	183	184	O	of
27	186	190	O	upper
28	192	207	O	gastrointestinal
29	209	216	O	bleeding
NULL

Brintellix	5143	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	19
These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	4	O	These
2	6	12	O	studies
3	14	17	O	have
4	19	22	O	also
5	24	28	O	shown
6	30	33	O	that
7	35	44	O	concurrent
8	46	48	O	use
9	50	51	O	of
10	53	54	O	an
11	56	60	U-DYN	NSAID
12	62	63	O	or
13	65	71	U-DYN	aspirin
14	73	75	O	may
15	77	86	O	potentiate
16	88	91	O	this
17	93	96	O	risk
18	98	99	O	of
19	101	108	U-EFF	bleeding
D/11:19:1 D/13:19:1

Brintellix	5144	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	19
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	93	O	and
15	95	99	O	SNRIs
16	101	103	O	are
17	105	118	O	coadministered
18	120	123	O	with
19	125	132	U-DYN	warfarin
D/19:1:1 D/19:6:1

Brintellix	5145	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	45
Following coadministration of stable doses of warfarin (1 to 10 mg/day) with multiple daily doses of BRINTELLIX, no significant effects were observed in INR, prothrombin values or total warfarin (protein bound plus free drug) pharmacokinetics for both R- and S-warfarin.
1	0	8	O	Following
2	10	25	O	coadministration
3	27	28	O	of
4	30	35	O	stable
5	37	41	O	doses
6	43	44	O	of
7	46	53	O	warfarin
8	56	56	O	1
9	58	59	O	to
10	61	62	O	10
11	64	65	O	mg
12	66	66	O	/
13	67	69	O	day
14	72	75	O	with
15	77	84	O	multiple
16	86	90	O	daily
17	92	96	O	doses
18	98	99	O	of
19	101	110	O	XXXXXXXX
20	111	111	O	,
21	113	114	O	no
22	116	126	O	significant
23	128	134	O	effects
24	136	139	O	were
25	141	148	O	observed
26	150	151	O	in
27	153	155	O	INR
28	156	156	O	,
29	158	168	O	prothrombin
30	170	175	O	values
31	177	178	O	or
32	180	184	O	total
33	186	193	O	warfarin
34	196	202	O	protein
35	204	208	O	bound
36	210	213	O	plus
37	215	218	O	free
38	220	223	O	drug
39	226	241	O	pharmacokinetics
40	243	245	O	for
41	247	250	O	both
42	252	252	O	R
43	255	257	O	and
44	259	259	O	S
45	261	268	O	warfarin
NULL

Brintellix	5146	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	28
Coadministration of aspirin 150 mg/day with multiple daily doses of BRINTELLIX had no significant inhibitory effect on platelet aggregation or pharmacokinetics of aspirin and salicylic acid.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	aspirin
4	28	30	O	150
5	32	33	O	mg
6	34	34	O	/
7	35	37	O	day
8	39	42	O	with
9	44	51	O	multiple
10	53	57	O	daily
11	59	63	O	doses
12	65	66	O	of
13	68	77	O	XXXXXXXX
14	79	81	O	had
15	83	84	O	no
16	86	96	O	significant
17	98	107	O	inhibitory
18	109	114	O	effect
19	116	117	O	on
20	119	126	O	platelet
21	128	138	O	aggregation
22	140	141	O	or
23	143	158	O	pharmacokinetics
24	160	161	O	of
25	163	169	O	aspirin
26	171	173	O	and
27	175	183	O	salicylic
28	185	188	O	acid
NULL

Brintellix	5147	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	18
Patients receiving other drugs that interfere with hemostasis should be carefully monitored when BRINTELLIX is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	other
4	25	29	B-UNK	drugs
5	31	34	I-UNK	that
6	36	44	I-UNK	interfere
7	46	49	I-UNK	with
8	51	60	L-UNK	hemostasis
9	62	67	B-TRI	should
10	69	70	I-TRI	be
11	72	80	I-TRI	carefully
12	82	90	L-TRI	monitored
13	92	95	O	when
14	97	106	O	XXXXXXXX
15	108	109	O	is
16	111	119	O	initiated
17	121	122	O	or
18	124	135	O	discontinued
NULL

Brintellix	5148	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	21
Reduce BRINTELLIX dose by half when a strong CYP2D6 inhibitor (e.g., bupropion, fluoxetine, paroxetine, quinidine) is coadministered.
1	0	5	B-TRI	Reduce
2	7	16	I-TRI	XXXXXXXX
3	18	21	L-TRI	dose
4	23	24	O	by
5	26	29	O	half
6	31	34	O	when
7	36	36	O	a
8	38	43	B-KIN	strong
9	45	50	I-KIN	CYP2D6
10	52	60	L-KIN	inhibitor
11	63	65	O	e.g
12	67	67	O	,
13	69	77	U-KIN	bupropion
14	78	78	O	,
15	80	89	U-KIN	fluoxetine
16	90	90	O	,
17	92	101	U-KIN	paroxetine
18	102	102	O	,
19	104	112	U-KIN	quinidine
20	115	116	O	is
21	118	131	O	coadministered
K/13:C54355 K/15:C54355 K/17:C54355 K/19:C54355 K/8:C54355

Brintellix	5149	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	19
Consider increasing the BRINTELLIX dose when a strong CYP inducer (e.g., rifampicin, carbamazepine, phenytoin) is coadministered.
1	0	7	O	Consider
2	9	18	O	increasing
3	20	22	O	the
4	24	33	O	XXXXXXXX
5	35	38	O	dose
6	40	43	O	when
7	45	45	O	a
8	47	52	B-KIN	strong
9	54	56	I-KIN	CYP
10	58	64	L-KIN	inducer
11	67	69	O	e.g
12	71	71	O	,
13	73	82	U-KIN	rifampicin
14	83	83	O	,
15	85	97	U-KIN	carbamazepine
16	98	98	O	,
17	100	108	U-KIN	phenytoin
18	111	112	O	is
19	114	127	O	coadministered
K/13:C54356 K/15:C54356 K/17:C54356 K/8:C54356

Brintellix	5150	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	13
The maximum dose is not recommended to exceed three times the original dose.
1	0	2	O	The
2	4	10	O	maximum
3	12	15	O	dose
4	17	18	O	is
5	20	22	O	not
6	24	34	O	recommended
7	36	37	O	to
8	39	44	O	exceed
9	46	50	O	three
10	52	56	O	times
11	58	60	O	the
12	62	69	O	original
13	71	74	O	dose
NULL

Brintellix	5151	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	70
Impact of Other Drugs on Vortioxetine PK Figure1.jpg No dose adjustment for the comedications is needed when BRINTELLIX is coadministered with a substrate of CYP1A2 (e.g., duloxetine), CYP2A6, CYP2B6 (e.g., bupropion), CYP2C8 (e.g., repaglinide), CYP2C9 (e.g., S-warfarin), CYP2C19 (e.g., diazepam), CYP2D6 (e.g., venlafaxine), CYP3A4/5 (e.g., budesonide), and P-gp (e.g., digoxin).
1	0	5	O	Impact
2	7	8	O	of
3	10	14	O	Other
4	16	20	O	Drugs
5	22	23	O	on
6	25	36	O	XXXXXXXX
7	38	39	O	PK
8	41	51	O	Figure1.jpg
9	53	54	O	No
10	56	59	O	dose
11	61	70	O	adjustment
12	72	74	O	for
13	76	78	O	the
14	80	92	O	comedications
15	94	95	O	is
16	97	102	O	needed
17	104	107	O	when
18	109	118	O	XXXXXXXX
19	120	121	O	is
20	123	136	O	coadministered
21	138	141	O	with
22	143	143	O	a
23	145	153	O	substrate
24	155	156	O	of
25	158	163	O	CYP1A2
26	166	168	O	e.g
27	170	170	O	,
28	172	181	O	duloxetine
29	183	183	O	,
30	185	190	O	CYP2A6
31	191	191	O	,
32	193	198	O	CYP2B6
33	201	203	O	e.g
34	205	205	O	,
35	207	215	O	bupropion
36	217	217	O	,
37	219	224	O	CYP2C8
38	227	229	O	e.g
39	231	231	O	,
40	233	243	O	repaglinide
41	245	245	O	,
42	247	252	O	CYP2C9
43	255	257	O	e.g
44	259	259	O	,
45	261	261	O	S
46	263	270	O	warfarin
47	272	272	O	,
48	274	280	O	CYP2C19
49	283	285	O	e.g
50	287	287	O	,
51	289	296	O	diazepam
52	298	298	O	,
53	300	305	O	CYP2D6
54	308	310	O	e.g
55	312	312	O	,
56	314	324	O	venlafaxine
57	326	326	O	,
58	328	333	O	CYP3A4
59	334	334	O	/
60	335	335	O	5
61	338	340	O	e.g
62	342	342	O	,
63	344	353	O	budesonide
64	355	355	O	,
65	357	359	O	and
66	361	361	O	P
67	363	364	O	gp
68	367	369	O	e.g
69	371	371	O	,
70	373	379	O	digoxin
NULL

Brintellix	5152	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	15
In addition, no dose adjustment for lithium, aspirin, and warfarin is necessary.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	no
5	16	19	O	dose
6	21	30	O	adjustment
7	32	34	O	for
8	36	42	O	lithium
9	43	43	O	,
10	45	51	O	aspirin
11	52	52	O	,
12	54	56	O	and
13	58	65	O	warfarin
14	67	68	O	is
15	70	78	O	necessary
NULL

Brintellix	5153	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	43
Vortioxetine and its metabolites are unlikely to inhibit the following CYP enzymes and transporter based on in vitro data: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, and P-gp.
1	0	11	O	XXXXXXXX
2	13	15	O	and
3	17	19	O	its
4	21	31	O	metabolites
5	33	35	O	are
6	37	44	O	unlikely
7	46	47	O	to
8	49	55	O	inhibit
9	57	59	O	the
10	61	69	O	following
11	71	73	O	CYP
12	75	81	O	enzymes
13	83	85	O	and
14	87	97	O	transporter
15	99	103	O	based
16	105	106	O	on
17	108	109	O	in
18	111	115	O	vitro
19	117	120	O	data
20	121	121	O	:
21	123	128	O	CYP1A2
22	129	129	O	,
23	131	136	O	CYP2A6
24	137	137	O	,
25	139	144	O	CYP2B6
26	145	145	O	,
27	147	152	O	CYP2C8
28	153	153	O	,
29	155	160	O	CYP2C9
30	161	161	O	,
31	163	169	O	CYP2C19
32	170	170	O	,
33	172	177	O	CYP2D6
34	178	178	O	,
35	180	185	O	CYP2E1
36	186	186	O	,
37	188	193	O	CYP3A4
38	194	194	O	/
39	195	195	O	5
40	196	196	O	,
41	198	200	O	and
42	202	202	O	P
43	204	205	O	gp
NULL

Brintellix	5154	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	17
As such, no clinically relevant interactions with drugs metabolized by these CYP enzymes would be expected.
1	0	1	O	As
2	3	6	O	such
3	7	7	O	,
4	9	10	O	no
5	12	21	O	clinically
6	23	30	O	relevant
7	32	43	O	interactions
8	45	48	O	with
9	50	54	O	drugs
10	56	66	O	metabolized
11	68	69	O	by
12	71	75	O	these
13	77	79	O	CYP
14	81	87	O	enzymes
15	89	93	O	would
16	95	96	O	be
17	98	105	O	expected
NULL

Brintellix	5155	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	32
In addition, vortioxetine did not induce CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP3A4/5 in an in vitro study in cultured human hepatocytes.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	24	O	XXXXXXXX
5	26	28	O	did
6	30	32	O	not
7	34	39	O	induce
8	41	46	O	CYP1A2
9	47	47	O	,
10	49	54	O	CYP2A6
11	55	55	O	,
12	57	62	O	CYP2B6
13	63	63	O	,
14	65	70	O	CYP2C8
15	71	71	O	,
16	73	78	O	CYP2C9
17	79	79	O	,
18	81	87	O	CYP2C19
19	88	88	O	,
20	90	92	O	and
21	94	99	O	CYP3A4
22	100	100	O	/
23	101	101	O	5
24	103	104	O	in
25	106	107	O	an
26	109	110	O	in
27	112	116	O	vitro
28	118	122	O	study
29	124	125	O	in
30	127	134	O	cultured
31	136	140	O	human
32	142	152	O	hepatocytes
NULL

Brintellix	5156	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	17
Chronic administration of BRINTELLIX is unlikely to induce the metabolism of drugs metabolized by these CYP isoforms.
1	0	6	O	Chronic
2	8	21	O	administration
3	23	24	O	of
4	26	35	O	XXXXXXXX
5	37	38	O	is
6	40	47	O	unlikely
7	49	50	O	to
8	52	57	O	induce
9	59	61	O	the
10	63	72	O	metabolism
11	74	75	O	of
12	77	81	O	drugs
13	83	93	O	metabolized
14	95	96	O	by
15	98	102	O	these
16	104	106	O	CYP
17	108	115	O	isoforms
NULL

Brintellix	5157	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	46
Furthermore, in a series of clinical drug interaction studies, coadministration of BRINTELLIX with substrates for CYP2B6 (e.g., bupropion), CYP2C9 (e.g., warfarin), and CYP2C19 (e.g., diazepam), had no clinical meaningful effect on the pharmacokinetics of these substrates (Figure 2).
1	0	10	O	Furthermore
2	11	11	O	,
3	13	14	O	in
4	16	16	O	a
5	18	23	O	series
6	25	26	O	of
7	28	35	O	clinical
8	37	40	O	drug
9	42	52	O	interaction
10	54	60	O	studies
11	61	61	O	,
12	63	78	O	coadministration
13	80	81	O	of
14	83	92	O	XXXXXXXX
15	94	97	O	with
16	99	108	O	substrates
17	110	112	O	for
18	114	119	O	CYP2B6
19	122	124	O	e.g
20	126	126	O	,
21	128	136	O	bupropion
22	138	138	O	,
23	140	145	O	CYP2C9
24	148	150	O	e.g
25	152	152	O	,
26	154	161	O	warfarin
27	163	163	O	,
28	165	167	O	and
29	169	175	O	CYP2C19
30	178	180	O	e.g
31	182	182	O	,
32	184	191	O	diazepam
33	193	193	O	,
34	195	197	O	had
35	199	200	O	no
36	202	209	O	clinical
37	211	220	O	meaningful
38	222	227	O	effect
39	229	230	O	on
40	232	234	O	the
41	236	251	O	pharmacokinetics
42	253	254	O	of
43	256	260	O	these
44	262	271	O	substrates
45	274	279	O	Figure
46	281	281	O	2
NULL

Brintellix	5158	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	28
Because vortioxetine is highly bound to plasma protein, coadministration of BRINTELLIX with another drug that is highly protein bound may increase free concentrations of the other drug.
1	0	6	O	Because
2	8	19	O	XXXXXXXX
3	21	22	O	is
4	24	29	O	highly
5	31	35	O	bound
6	37	38	O	to
7	40	45	O	plasma
8	47	53	O	protein
9	54	54	O	,
10	56	71	O	coadministration
11	73	74	O	of
12	76	85	O	XXXXXXXX
13	87	90	O	with
14	92	98	O	another
15	100	103	B-KIN	drug
16	105	108	I-KIN	that
17	110	111	I-KIN	is
18	113	118	I-KIN	highly
19	120	126	I-KIN	protein
20	128	132	L-KIN	bound
21	134	136	O	may
22	138	145	B-TRI	increase
23	147	150	I-TRI	free
24	152	165	I-TRI	concentrations
25	167	168	I-TRI	of
26	170	172	I-TRI	the
27	174	178	I-TRI	other
28	180	183	L-TRI	drug
K/15:C54357

Brintellix	5159	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	39
However, in a clinical study with coadministration of BRINTELLIX (10 mg/day) and warfarin (1 mg/day to 10 mg/day), a highly protein-bound drug, no significant change in INR was observed.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	12	O	a
5	14	21	O	clinical
6	23	27	O	study
7	29	32	O	with
8	34	49	O	coadministration
9	51	52	O	of
10	54	63	O	XXXXXXXX
11	66	67	O	10
12	69	70	O	mg
13	71	71	O	/
14	72	74	O	day
15	77	79	O	and
16	81	88	O	warfarin
17	91	91	O	1
18	93	94	O	mg
19	95	95	O	/
20	96	98	O	day
21	100	101	O	to
22	103	104	O	10
23	106	107	O	mg
24	108	108	O	/
25	109	111	O	day
26	113	113	O	,
27	115	115	O	a
28	117	122	O	highly
29	124	130	O	protein
30	132	136	O	bound
31	138	141	O	drug
32	142	142	O	,
33	144	145	O	no
34	147	157	O	significant
35	159	164	O	change
36	166	167	O	in
37	169	171	O	INR
38	173	175	O	was
39	177	184	O	observed
NULL

Brintellix	5160	34073-7	4b0700c9-b417-4c3a-b36f-de461e125bd3	9
Impact of Vortioxetine on PK of Other Drugs Figure2.jpg
1	0	5	O	Impact
2	7	8	O	of
3	10	21	O	XXXXXXXX
4	23	24	O	on
5	26	27	O	PK
6	29	30	O	of
7	32	36	O	Other
8	38	42	O	Drugs
9	44	54	O	Figure2.jpg
NULL

Brintellix	5161	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	37
The mechanism of the antidepressant effect of vortioxetine is not fully understood, but is thought to be related to its enhancement of serotonergic activity in the CNS through inhibition of the reuptake of serotonin (5-HT).
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	19	O	the
5	21	34	O	antidepressant
6	36	41	O	effect
7	43	44	O	of
8	46	57	O	XXXXXXXX
9	59	60	O	is
10	62	64	O	not
11	66	70	O	fully
12	72	81	O	understood
13	82	82	O	,
14	84	86	O	but
15	88	89	O	is
16	91	97	O	thought
17	99	100	O	to
18	102	103	O	be
19	105	111	O	related
20	113	114	O	to
21	116	118	O	its
22	120	130	O	enhancement
23	132	133	O	of
24	135	146	O	serotonergic
25	148	155	O	activity
26	157	158	O	in
27	160	162	O	the
28	164	166	O	CNS
29	168	174	O	through
30	176	185	O	inhibition
31	187	188	O	of
32	190	192	O	the
33	194	201	O	reuptake
34	203	204	O	of
35	206	214	O	serotonin
36	217	217	O	5
37	219	220	O	HT
NULL

Brintellix	5162	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	16
It also has several other activities including 5-HT3 receptor antagonism and 5-HT1A receptor agonism.
1	0	1	O	It
2	3	6	O	also
3	8	10	O	has
4	12	18	O	several
5	20	24	O	other
6	26	35	O	activities
7	37	45	O	including
8	47	47	O	5
9	49	51	O	HT3
10	53	60	O	receptor
11	62	71	O	antagonism
12	73	75	O	and
13	77	77	O	5
14	79	82	O	HT1A
15	84	91	O	receptor
16	93	99	O	agonism
NULL

Brintellix	5163	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	14
The contribution of these activities to vortioxetine's antidepressant effect has not been established.
1	0	2	O	The
2	4	15	O	contribution
3	17	18	O	of
4	20	24	O	these
5	26	35	O	activities
6	37	38	O	to
7	40	51	O	XXXXXXXX
8	52	53	O	's
9	55	68	O	antidepressant
10	70	75	O	effect
11	77	79	O	has
12	81	83	O	not
13	85	88	O	been
14	90	100	O	established
NULL

Brintellix	5164	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	25
Vortioxetine binds with high affinity to the human serotonin transporter (Ki=1.6 nM), but not to the norepinephrine (Ki=113 nM) or dopamine (Ki>1000 nM) transporters.
1	0	11	O	XXXXXXXX
2	13	17	O	binds
3	19	22	O	with
4	24	27	O	high
5	29	36	O	affinity
6	38	39	O	to
7	41	43	O	the
8	45	49	O	human
9	51	59	O	serotonin
10	61	71	O	transporter
11	74	79	O	Ki=1.6
12	81	82	O	nM
13	84	84	O	,
14	86	88	O	but
15	90	92	O	not
16	94	95	O	to
17	97	99	O	the
18	101	114	O	norepinephrine
19	117	122	O	Ki=113
20	124	125	O	nM
21	128	129	O	or
22	131	138	O	dopamine
23	141	147	O	Ki>1000
24	149	150	O	nM
25	153	164	O	transporters
NULL

Brintellix	5165	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	10
Vortioxetine potently and selectively inhibits reuptake of serotonin (IC50=5.4 nM).
1	0	11	O	XXXXXXXX
2	13	20	O	potently
3	22	24	O	and
4	26	36	O	selectively
5	38	45	O	inhibits
6	47	54	O	reuptake
7	56	57	O	of
8	59	67	O	serotonin
9	70	77	O	IC50=5.4
10	79	80	O	nM
NULL

Brintellix	5166	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	56
Vortioxetine binds to 5-HT3 (Ki=3.7 nM), 5-HT1A (Ki=15 nM), 5-HT7 (Ki=19 nM), 5-HT1D (Ki=54 nM), and 5-HT1B (Ki=33 nM), receptors and is a 5-HT3, 5-HT1D, and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor agonist.
1	0	11	O	XXXXXXXX
2	13	17	O	binds
3	19	20	O	to
4	22	22	O	5
5	24	26	O	HT3
6	29	34	O	Ki=3.7
7	36	37	O	nM
8	39	39	O	,
9	41	41	O	5
10	43	46	O	HT1A
11	49	53	O	Ki=15
12	55	56	O	nM
13	58	58	O	,
14	60	60	O	5
15	62	64	O	HT7
16	67	71	O	Ki=19
17	73	74	O	nM
18	76	76	O	,
19	78	78	O	5
20	80	83	O	HT1D
21	86	90	O	Ki=54
22	92	93	O	nM
23	95	95	O	,
24	97	99	O	and
25	101	101	O	5
26	103	106	O	HT1B
27	109	113	O	Ki=33
28	115	116	O	nM
29	118	118	O	,
30	120	128	O	receptors
31	130	132	O	and
32	134	135	O	is
33	137	137	O	a
34	139	139	O	5
35	141	143	O	HT3
36	144	144	O	,
37	146	146	O	5
38	148	151	O	HT1D
39	152	152	O	,
40	154	156	O	and
41	158	158	O	5
42	160	162	O	HT7
43	164	171	O	receptor
44	173	182	O	antagonist
45	183	183	O	,
46	185	185	O	5
47	187	190	O	HT1B
48	192	199	O	receptor
49	201	207	O	partial
50	209	215	O	agonist
51	216	216	O	,
52	218	220	O	and
53	222	222	O	5
54	224	227	O	HT1A
55	229	236	O	receptor
56	238	244	O	agonist
NULL

Brintellix	5167	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	57
In humans, the mean 5-HT transporter occupancy, based on the results from 2 clinical PET studies using 5-HTT ligands ([11C]-MADAM or [11C]-DASB), was approximately 50% at 5 mg/day, 65% at 10 mg/day and approximately 80% at 20 mg/day in the regions of interest.
1	0	1	O	In
2	3	8	O	humans
3	9	9	O	,
4	11	13	O	the
5	15	18	O	mean
6	20	20	O	5
7	22	23	O	HT
8	25	35	O	transporter
9	37	45	O	occupancy
10	46	46	O	,
11	48	52	O	based
12	54	55	O	on
13	57	59	O	the
14	61	67	O	results
15	69	72	O	from
16	74	74	O	2
17	76	83	O	clinical
18	85	87	O	PET
19	89	95	O	studies
20	97	101	O	using
21	103	103	O	5
22	105	107	O	HTT
23	109	115	O	ligands
24	119	121	O	11C
25	124	128	O	MADAM
26	130	131	O	or
27	134	136	O	11C
28	139	142	O	DASB
29	144	144	O	,
30	146	148	O	was
31	150	162	O	approximately
32	164	166	O	50%
33	168	169	O	at
34	171	171	O	5
35	173	174	O	mg
36	175	175	O	/
37	176	178	O	day
38	179	179	O	,
39	181	183	O	65%
40	185	186	O	at
41	188	189	O	10
42	191	192	O	mg
43	193	193	O	/
44	194	196	O	day
45	198	200	O	and
46	202	214	O	approximately
47	216	218	O	80%
48	220	221	O	at
49	223	224	O	20
50	226	227	O	mg
51	228	228	O	/
52	229	231	O	day
53	233	234	O	in
54	236	238	O	the
55	240	246	O	regions
56	248	249	O	of
57	251	258	O	interest
NULL

Brintellix	5168	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	46
Effect on Cardiac Repolarization The effect of vortioxetine 10 mg and 40 mg administered once daily on QTc interval was evaluated in a randomized, double-blind, placebo-, and active-controlled (moxifloxacin 400 mg), four-treatment-arm parallel study in 340 male subjects.
1	0	5	O	Effect
2	7	8	O	on
3	10	16	O	Cardiac
4	18	31	O	Repolarization
5	33	35	O	The
6	37	42	O	effect
7	44	45	O	of
8	47	58	O	XXXXXXXX
9	60	61	O	10
10	63	64	O	mg
11	66	68	O	and
12	70	71	O	40
13	73	74	O	mg
14	76	87	O	administered
15	89	92	O	once
16	94	98	O	daily
17	100	101	O	on
18	103	105	O	QTc
19	107	114	O	interval
20	116	118	O	was
21	120	128	O	evaluated
22	130	131	O	in
23	133	133	O	a
24	135	144	O	randomized
25	145	145	O	,
26	147	152	O	double
27	154	158	O	blind
28	159	159	O	,
29	161	167	O	placebo
30	169	169	O	,
31	171	173	O	and
32	175	180	O	active
33	182	191	O	controlled
34	194	205	O	moxifloxacin
35	207	209	O	400
36	211	212	O	mg
37	214	214	O	,
38	216	219	O	four
39	221	229	O	treatment
40	231	233	O	arm
41	235	242	O	parallel
42	244	248	O	study
43	250	251	O	in
44	253	255	O	340
45	257	260	O	male
46	262	269	O	subjects
NULL

Brintellix	5169	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	26
In the study the upper bound of the one-sided 95% confidence interval for the QTc was below 10 ms, the threshold for regulatory concern.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	study
4	13	15	O	the
5	17	21	O	upper
6	23	27	O	bound
7	29	30	O	of
8	32	34	O	the
9	36	38	O	one
10	40	44	O	sided
11	46	48	O	95%
12	50	59	O	confidence
13	61	68	O	interval
14	70	72	O	for
15	74	76	O	the
16	78	80	O	QTc
17	82	84	O	was
18	86	90	O	below
19	92	93	O	10
20	95	96	O	ms
21	97	97	O	,
22	99	101	O	the
23	103	111	O	threshold
24	113	115	O	for
25	117	126	O	regulatory
26	128	134	O	concern
NULL

Brintellix	5170	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	15
The oral dose of 40 mg is sufficient to assess the effect of metabolic inhibition.
1	0	2	O	The
2	4	7	O	oral
3	9	12	O	dose
4	14	15	O	of
5	17	18	O	40
6	20	21	O	mg
7	23	24	O	is
8	26	35	O	sufficient
9	37	38	O	to
10	40	45	O	assess
11	47	49	O	the
12	51	56	O	effect
13	58	59	O	of
14	61	69	O	metabolic
15	71	80	O	inhibition
NULL

Brintellix	5171	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	36
Effect on Driving Performance In a clinical study in healthy subjects, BRINTELLIX did not impair driving performance, or have adverse psychomotor or cognitive effects following single and multiple doses of 10 mg/day.
1	0	5	O	Effect
2	7	8	O	on
3	10	16	O	Driving
4	18	28	O	Performance
5	30	31	O	In
6	33	33	O	a
7	35	42	O	clinical
8	44	48	O	study
9	50	51	O	in
10	53	59	O	healthy
11	61	68	O	subjects
12	69	69	O	,
13	71	80	O	XXXXXXXX
14	82	84	O	did
15	86	88	O	not
16	90	95	O	impair
17	97	103	O	driving
18	105	115	O	performance
19	116	116	O	,
20	118	119	O	or
21	121	124	O	have
22	126	132	O	adverse
23	134	144	O	psychomotor
24	146	147	O	or
25	149	157	O	cognitive
26	159	165	O	effects
27	167	175	O	following
28	177	182	O	single
29	184	186	O	and
30	188	195	O	multiple
31	197	201	O	doses
32	203	204	O	of
33	206	207	O	10
34	209	210	O	mg
35	211	211	O	/
36	212	214	O	day
NULL

Brintellix	5172	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	46
Because any psychoactive drug may impair judgment, thinking, or motor skills, however, patients should be cautioned about operating hazardous machinery, including automobiles, until they are reasonably certain that BRINTELLIX therapy does not affect their ability to engage in such activities.
1	0	6	O	Because
2	8	10	O	any
3	12	23	O	psychoactive
4	25	28	O	drug
5	30	32	O	may
6	34	39	O	impair
7	41	48	O	judgment
8	49	49	O	,
9	51	58	O	thinking
10	59	59	O	,
11	61	62	O	or
12	64	68	O	motor
13	70	75	O	skills
14	76	76	O	,
15	78	84	O	however
16	85	85	O	,
17	87	94	O	patients
18	96	101	O	should
19	103	104	O	be
20	106	114	O	cautioned
21	116	120	O	about
22	122	130	O	operating
23	132	140	O	hazardous
24	142	150	O	machinery
25	151	151	O	,
26	153	161	O	including
27	163	173	O	automobiles
28	174	174	O	,
29	176	180	O	until
30	182	185	O	they
31	187	189	O	are
32	191	200	O	reasonably
33	202	208	O	certain
34	210	213	O	that
35	215	224	O	XXXXXXXX
36	226	232	O	therapy
37	234	237	O	does
38	239	241	O	not
39	243	248	O	affect
40	250	254	O	their
41	256	262	O	ability
42	264	265	O	to
43	267	272	O	engage
44	274	275	O	in
45	277	280	O	such
46	282	291	O	activities
NULL

Brintellix	5173	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	9
Vortioxetine pharmacological activity is due to the parent drug.
1	0	11	O	XXXXXXXX
2	13	27	O	pharmacological
3	29	36	O	activity
4	38	39	O	is
5	41	43	O	due
6	45	46	O	to
7	48	50	O	the
8	52	57	O	parent
9	59	62	O	drug
NULL

Brintellix	5174	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	20
The pharmacokinetics of vortioxetine (2.5 mg to 60 mg) are linear and dose-proportional when vortioxetine is administered once daily.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	35	O	XXXXXXXX
5	38	40	O	2.5
6	42	43	O	mg
7	45	46	O	to
8	48	49	O	60
9	51	52	O	mg
10	55	57	O	are
11	59	64	O	linear
12	66	68	O	and
13	70	73	O	dose
14	75	86	O	proportional
15	88	91	O	when
16	93	104	O	XXXXXXXX
17	106	107	O	is
18	109	120	O	administered
19	122	125	O	once
20	127	131	O	daily
NULL

Brintellix	5175	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	23
The mean terminal half-life is approximately 66 hours, and steady-state plasma concentrations are typically achieved within two weeks of dosing.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	terminal
4	18	21	O	half
5	23	26	O	life
6	28	29	O	is
7	31	43	O	approximately
8	45	46	O	66
9	48	52	O	hours
10	53	53	O	,
11	55	57	O	and
12	59	64	O	steady
13	66	70	O	state
14	72	77	O	plasma
15	79	92	O	concentrations
16	94	96	O	are
17	98	106	O	typically
18	108	115	O	achieved
19	117	122	O	within
20	124	126	O	two
21	128	132	O	weeks
22	134	135	O	of
23	137	142	O	dosing
NULL

Brintellix	5176	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	18
Absorption The maximal plasma vortioxetine concentration (Cmax) after dosing is reached within 7 to 11 hours postdose (Tmax).
1	0	9	O	Absorption
2	11	13	O	The
3	15	21	O	maximal
4	23	28	O	plasma
5	30	41	O	XXXXXXXX
6	43	55	O	concentration
7	58	61	O	Cmax
8	64	68	O	after
9	70	75	O	dosing
10	77	78	O	is
11	80	86	O	reached
12	88	93	O	within
13	95	95	O	7
14	97	98	O	to
15	100	101	O	11
16	103	107	O	hours
17	109	116	O	postdose
18	119	122	O	Tmax
NULL

Brintellix	5177	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	27
Steady-state mean Cmax values were 9, 18, and 33 ng/mL following doses of 5, 10, and 20 mg/day.
1	0	5	O	Steady
2	7	11	O	state
3	13	16	O	mean
4	18	21	O	Cmax
5	23	28	O	values
6	30	33	O	were
7	35	35	O	9
8	36	36	O	,
9	38	39	O	18
10	40	40	O	,
11	42	44	O	and
12	46	47	O	33
13	49	50	O	ng
14	51	51	O	/
15	52	53	O	mL
16	55	63	O	following
17	65	69	O	doses
18	71	72	O	of
19	74	74	O	5
20	75	75	O	,
21	77	78	O	10
22	79	79	O	,
23	81	83	O	and
24	85	86	O	20
25	88	89	O	mg
26	90	90	O	/
27	91	93	O	day
NULL

Brintellix	5178	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	9
No effect of food on the pharmacokinetics was observed.
1	0	1	O	No
2	3	8	O	effect
3	10	11	O	of
4	13	16	O	food
5	18	19	O	on
6	21	23	O	the
7	25	40	O	pharmacokinetics
8	42	44	O	was
9	46	53	O	observed
NULL

Brintellix	5179	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	16
Distribution The apparent volume of distribution of vortioxetine is approximately 2600L, indicating extensive extravascular distribution.
1	0	11	O	Distribution
2	13	15	O	The
3	17	24	O	apparent
4	26	31	O	volume
5	33	34	O	of
6	36	47	O	distribution
7	49	50	O	of
8	52	63	O	XXXXXXXX
9	65	66	O	is
10	68	80	O	approximately
11	82	86	O	2600L
12	87	87	O	,
13	89	98	O	indicating
14	100	108	O	extensive
15	110	122	O	extravascular
16	124	135	O	distribution
NULL

Brintellix	5180	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	15
The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations.
1	0	2	O	The
2	4	9	O	plasma
3	11	17	O	protein
4	19	25	O	binding
5	27	28	O	of
6	30	41	O	XXXXXXXX
7	43	44	O	in
8	46	51	O	humans
9	53	54	O	is
10	56	58	O	98%
11	59	59	O	,
12	61	71	O	independent
13	73	74	O	of
14	76	81	O	plasma
15	83	96	O	concentrations
NULL

Brintellix	5181	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	30
No apparent difference in the plasma protein binding between healthy subjects and subjects with hepatic (mild, moderate) or renal (mild, moderate, severe, ESRD) impairment is observed.
1	0	1	O	No
2	3	10	O	apparent
3	12	21	O	difference
4	23	24	O	in
5	26	28	O	the
6	30	35	O	plasma
7	37	43	O	protein
8	45	51	O	binding
9	53	59	O	between
10	61	67	O	healthy
11	69	76	O	subjects
12	78	80	O	and
13	82	89	O	subjects
14	91	94	O	with
15	96	102	O	hepatic
16	105	108	O	mild
17	109	109	O	,
18	111	118	O	moderate
19	121	122	O	or
20	124	128	O	renal
21	131	134	O	mild
22	135	135	O	,
23	137	144	O	moderate
24	145	145	O	,
25	147	152	O	severe
26	153	153	O	,
27	155	158	O	ESRD
28	161	170	O	impairment
29	172	173	O	is
30	175	182	O	observed
NULL

Brintellix	5182	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	32
Metabolism and Elimination Vortioxetine is extensively metabolized primarily through oxidation via cytochrome P450 isozymes CYP2D6, CYP3A4/5,CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 and subsequent glucuronic acid conjugation.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	27	38	O	XXXXXXXX
5	40	41	O	is
6	43	53	O	extensively
7	55	65	O	metabolized
8	67	75	O	primarily
9	77	83	O	through
10	85	93	O	oxidation
11	95	97	O	via
12	99	108	O	cytochrome
13	110	113	O	P450
14	115	122	O	isozymes
15	124	129	O	CYP2D6
16	130	130	O	,
17	132	137	O	CYP3A4
18	138	138	O	/
19	139	147	O	5,CYP2C19
20	148	148	O	,
21	150	155	O	CYP2C9
22	156	156	O	,
23	158	163	O	CYP2A6
24	164	164	O	,
25	166	171	O	CYP2C8
26	173	175	O	and
27	177	182	O	CYP2B6
28	184	186	O	and
29	188	197	O	subsequent
30	199	208	O	glucuronic
31	210	213	O	acid
32	215	225	O	conjugation
NULL

Brintellix	5183	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	36
CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine to its major, pharmacologically inactive, carboxylic acid metabolite, and poor metabolizers of CYP2D6 have approximately twice the vortioxetine plasma concentration of extensive metabolizers.
1	0	5	O	CYP2D6
2	7	8	O	is
3	10	12	O	the
4	14	20	O	primary
5	22	27	O	enzyme
6	29	38	O	catalyzing
7	40	42	O	the
8	44	53	O	metabolism
9	55	56	O	of
10	58	69	O	XXXXXXXX
11	71	72	O	to
12	74	76	O	its
13	78	82	O	major
14	83	83	O	,
15	85	101	O	pharmacologically
16	103	110	O	inactive
17	111	111	O	,
18	113	122	O	carboxylic
19	124	127	O	acid
20	129	138	O	metabolite
21	139	139	O	,
22	141	143	O	and
23	145	148	O	poor
24	150	161	O	metabolizers
25	163	164	O	of
26	166	171	O	CYP2D6
27	173	176	O	have
28	178	190	O	approximately
29	192	196	O	twice
30	198	200	O	the
31	202	213	O	XXXXXXXX
32	215	220	O	plasma
33	222	234	O	concentration
34	236	237	O	of
35	239	247	O	extensive
36	249	260	O	metabolizers
NULL

Brintellix	5184	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	29
Following a single oral dose of [14C]-labeled vortioxetine, approximately 59% and 26% of the administered radioactivity was recovered in the urine and feces, respectively as metabolites.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	22	O	oral
5	24	27	O	dose
6	29	30	O	of
7	33	35	O	14C
8	38	44	O	labeled
9	46	57	O	XXXXXXXX
10	58	58	O	,
11	60	72	O	approximately
12	74	76	O	59%
13	78	80	O	and
14	82	84	O	26%
15	86	87	O	of
16	89	91	O	the
17	93	104	O	administered
18	106	118	O	radioactivity
19	120	122	O	was
20	124	132	O	recovered
21	134	135	O	in
22	137	139	O	the
23	141	145	O	urine
24	147	149	O	and
25	151	155	O	feces
26	156	156	O	,
27	158	169	O	respectively
28	171	172	O	as
29	174	184	O	metabolites
NULL

Brintellix	5185	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	14
Negligible amounts of unchanged vortioxetine were excreted in the urine up to 48 hours.
1	0	9	O	Negligible
2	11	17	O	amounts
3	19	20	O	of
4	22	30	O	unchanged
5	32	43	O	XXXXXXXX
6	45	48	O	were
7	50	57	O	excreted
8	59	60	O	in
9	62	64	O	the
10	66	70	O	urine
11	72	73	O	up
12	75	76	O	to
13	78	79	O	48
14	81	85	O	hours
NULL

Brintellix	5186	34090-1	4b0700c9-b417-4c3a-b36f-de461e125bd3	25
The presence of hepatic (mild or moderate) or renal impairment (mild, moderate, severe and ESRD) did not affect the apparent clearance of vortioxetine.
1	0	2	O	The
2	4	11	O	presence
3	13	14	O	of
4	16	22	O	hepatic
5	25	28	O	mild
6	30	31	O	or
7	33	40	O	moderate
8	43	44	O	or
9	46	50	O	renal
10	52	61	O	impairment
11	64	67	O	mild
12	68	68	O	,
13	70	77	O	moderate
14	78	78	O	,
15	80	85	O	severe
16	87	89	O	and
17	91	94	O	ESRD
18	97	99	O	did
19	101	103	O	not
20	105	110	O	affect
21	112	114	O	the
22	116	123	O	apparent
23	125	133	O	clearance
24	135	136	O	of
25	138	149	O	XXXXXXXX
NULL

CLOMIPRAMINE HYDROCHLORIDE	2796	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	15
The risks of using clomipramine in combination with other drugs have not been systematically evaluated.
1	0	2	O	The
2	4	8	O	risks
3	10	11	O	of
4	13	17	O	using
5	19	30	O	XXXXXXXX
6	32	33	O	in
7	35	45	O	combination
8	47	50	O	with
9	52	56	O	other
10	58	62	O	drugs
11	64	67	O	have
12	69	71	O	not
13	73	76	O	been
14	78	91	O	systematically
15	93	101	O	evaluated
NULL

CLOMIPRAMINE HYDROCHLORIDE	2797	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	20
Given the primary CNS effects of clomipramine, caution is advised in using it concomitantly with other CNS-active drugs.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	44	O	XXXXXXXX
8	45	45	O	,
9	47	53	U-TRI	caution
10	55	56	O	is
11	58	64	O	advised
12	66	67	O	in
13	69	73	O	using
14	75	76	O	it
15	78	90	O	concomitantly
16	92	95	O	with
17	97	101	O	other
18	103	105	B-UNK	CNS
19	107	112	I-UNK	active
20	114	118	L-UNK	drugs
NULL

CLOMIPRAMINE HYDROCHLORIDE	2798	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	8
Clomipramine should not be used with MAO inhibitors.
1	0	11	O	XXXXXXXX
2	13	18	B-TRI	should
3	20	22	I-TRI	not
4	24	25	I-TRI	be
5	27	30	L-TRI	used
6	32	35	O	with
7	37	39	B-UNK	MAO
8	41	50	L-UNK	inhibitors
NULL

CLOMIPRAMINE HYDROCHLORIDE	2799	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	18
Close supervision and careful adjustment of dosage are required when clomipramine is administered with anticholinergic or sympathomimetic drugs.
1	0	4	B-TRI	Close
2	6	16	L-TRI	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	49	O	dosage
8	51	53	O	are
9	55	62	O	required
10	64	67	O	when
11	69	80	O	XXXXXXXX
12	82	83	O	is
13	85	96	O	administered
14	98	101	O	with
15	103	117	O	anticholinergic
16	119	120	O	or
17	122	136	B-UNK	sympathomimetic
18	138	142	L-UNK	drugs
NULL

CLOMIPRAMINE HYDROCHLORIDE	2800	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	38
Several tricyclic antidepressants have been reported to block the pharmacologic effects of guanethidine, clonidine, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.
1	0	6	O	Several
2	8	16	O	tricyclic
3	18	32	O	antidepressants
4	34	37	O	have
5	39	42	O	been
6	44	51	O	reported
7	53	54	O	to
8	56	60	B-EFF	block
9	62	64	I-EFF	the
10	66	78	I-EFF	pharmacologic
11	80	86	I-EFF	effects
12	88	89	I-EFF	of
13	91	102	L-EFF	guanethidine
14	103	103	O	,
15	105	113	U-DYN	clonidine
16	114	114	O	,
17	116	117	O	or
18	119	125	O	similar
19	127	132	O	agents
20	133	133	O	,
21	135	137	O	and
22	139	142	O	such
23	144	145	O	an
24	147	152	O	effect
25	154	156	O	may
26	158	159	O	be
27	161	171	O	anticipated
28	173	176	O	with
29	178	180	O	CMI
30	182	188	O	because
31	190	191	O	of
32	193	195	O	its
33	197	206	O	structural
34	208	217	O	similarity
35	219	220	O	to
36	222	226	O	other
37	228	236	O	tricyclic
38	238	252	O	antidepressants
D/15:8:0

CLOMIPRAMINE HYDROCHLORIDE	2801	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	73
The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.
1	0	2	O	The
2	4	9	O	plasma
3	11	23	O	concentration
4	25	26	O	of
5	28	30	O	CMI
6	32	34	O	has
7	36	39	O	been
8	41	48	O	reported
9	50	51	O	to
10	53	54	O	be
11	56	64	O	increased
12	66	67	O	by
13	69	71	O	the
14	73	83	O	concomitant
15	85	98	O	administration
16	100	101	O	of
17	103	113	U-KIN	haloperidol
18	116	121	O	plasma
19	123	128	O	levels
20	130	131	O	of
21	133	139	O	several
22	141	147	O	closely
23	149	155	O	related
24	157	165	O	tricyclic
25	167	181	O	antidepressants
26	183	186	O	have
27	188	191	O	been
28	193	200	O	reported
29	202	203	O	to
30	205	206	O	be
31	208	216	O	increased
32	218	219	O	by
33	221	223	O	the
34	225	235	O	concomitant
35	237	250	O	administration
36	252	253	O	of
37	255	269	U-KIN	methylphenidate
38	271	272	O	or
39	274	280	B-KIN	hepatic
40	282	287	I-KIN	enzyme
41	289	298	L-KIN	inhibitors
42	301	303	O	e.g
43	305	305	O	,
44	307	316	U-KIN	cimetidine
45	317	317	O	,
46	319	328	U-KIN	fluoxetine
47	331	333	O	and
48	335	343	O	decreased
49	345	346	O	by
50	348	350	O	the
51	352	362	O	concomitant
52	364	377	O	administration
53	379	380	O	of
54	382	388	B-KIN	hepatic
55	390	395	I-KIN	enzyme
56	397	404	L-KIN	inducers
57	407	409	O	e.g
58	411	411	O	,
59	413	424	U-KIN	barbiturates
60	425	425	O	,
61	427	435	U-KIN	phenytoin
62	437	437	O	,
63	439	441	O	and
64	443	446	O	such
65	448	449	O	an
66	451	456	O	effect
67	458	460	O	may
68	462	463	O	be
69	465	475	O	anticipated
70	477	480	O	with
71	482	484	O	CMI
72	486	487	O	as
73	489	492	O	well
K/17:C54355 K/37:C54355 K/39:C54355 K/44:C54355 K/46:C54355 K/54:C54356 K/59:C54356 K/61:C54356

CLOMIPRAMINE HYDROCHLORIDE	2802	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	17
Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly.
1	0	13	O	Administration
2	15	16	O	of
3	18	20	O	CMI
4	22	24	O	has
5	26	29	O	been
6	31	38	O	reported
7	40	41	O	to
8	43	50	B-TRI	increase
9	52	54	I-TRI	the
10	56	61	I-TRI	plasma
11	63	68	L-TRI	levels
12	70	71	O	of
13	73	85	U-KIN	phenobarbital
14	86	86	O	,
15	88	89	O	if
16	91	95	O	given
17	97	109	O	concomitantly
K/13:C54357

CLOMIPRAMINE HYDROCHLORIDE	2803	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	56
The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available.
1	0	2	O	The
2	4	14	O	biochemical
3	16	23	O	activity
4	25	26	O	of
5	28	30	O	the
6	32	35	O	drug
7	37	48	O	metabolizing
8	50	56	O	isozyme
9	58	67	O	cytochrome
10	69	72	O	P450
11	74	76	O	2D6
12	79	89	O	debrisoquin
13	91	101	O	hydroxylase
14	104	105	O	is
15	107	113	O	reduced
16	115	116	O	in
17	118	118	O	a
18	120	125	O	subset
19	127	128	O	of
20	130	132	O	the
21	134	142	O	caucasian
22	144	153	O	population
23	156	160	O	about
24	162	163	O	7%
25	165	166	O	to
26	168	170	O	10%
27	172	173	O	of
28	175	184	O	Caucasians
29	186	188	O	are
30	190	191	O	so
31	193	198	O	called
32	200	204	O	"poor
33	206	218	O	metabolizers"
34	222	229	O	reliable
35	231	239	O	estimates
36	241	242	O	of
37	244	246	O	the
38	248	257	O	prevalence
39	259	260	O	of
40	262	268	O	reduced
41	270	273	O	P450
42	275	277	O	2D6
43	279	285	O	isozyme
44	287	294	O	activity
45	296	300	O	among
46	302	306	O	Asian
47	307	307	O	,
48	309	315	O	African
49	316	316	O	,
50	318	320	O	and
51	322	326	O	other
52	328	338	O	populations
53	340	342	O	are
54	344	346	O	not
55	348	350	O	yet
56	352	360	O	available
NULL

CLOMIPRAMINE HYDROCHLORIDE	2804	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	O	tricyclic
11	79	93	O	antidepressants
12	96	99	O	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

CLOMIPRAMINE HYDROCHLORIDE	2805	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

CLOMIPRAMINE HYDROCHLORIDE	2806	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

CLOMIPRAMINE HYDROCHLORIDE	2807	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	O	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

CLOMIPRAMINE HYDROCHLORIDE	2808	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	40
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	O	quinidine
18	107	116	O	cimetidine
19	119	121	O	and
20	123	126	O	many
21	128	131	O	that
22	133	135	O	are
23	137	146	O	substrates
24	148	150	O	for
25	152	155	O	P450
26	157	159	O	2D6
27	162	165	O	many
28	167	171	O	other
29	173	187	O	antidepressants
30	188	188	O	,
31	190	203	O	phenothiazines
32	204	204	O	,
33	206	208	O	and
34	210	212	O	the
35	214	217	O	Type
36	219	220	O	1C
37	222	236	O	antiarrhythmics
38	238	248	O	propafenone
39	250	252	O	and
40	254	263	O	flecainide
NULL

CLOMIPRAMINE HYDROCHLORIDE	2809	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	52	O	GGGGGGGG
6	55	59	O	SSRIs
7	61	61	O	,
8	63	65	O	e.g
9	67	67	O	,
10	69	78	O	fluoxetine
11	79	79	O	,
12	81	90	O	sertraline
13	91	91	O	,
14	93	102	O	paroxetine
15	103	103	O	,
16	105	107	O	and
17	109	119	O	fluvoxamine
18	120	120	O	,
19	122	128	O	inhibit
20	130	133	O	P450
21	135	137	O	2D6
22	138	138	O	,
23	140	143	O	they
24	145	147	O	may
25	149	152	O	vary
26	154	155	O	in
27	157	159	O	the
28	161	166	O	extent
29	168	169	O	of
30	171	180	O	inhibition
NULL

CLOMIPRAMINE HYDROCHLORIDE	2810	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	17
Fluvoxamine has also been shown to inhibit P450 1A2, an isoform also involved in TCA metabolism.
1	0	10	O	Fluvoxamine
2	12	14	O	has
3	16	19	O	also
4	21	24	O	been
5	26	30	O	shown
6	32	33	O	to
7	35	41	O	inhibit
8	43	46	O	P450
9	48	50	O	1A2
10	51	51	O	,
11	53	54	O	an
12	56	62	O	isoform
13	64	67	O	also
14	69	76	O	involved
15	78	79	O	in
16	81	83	O	TCA
17	85	94	O	metabolism
NULL

CLOMIPRAMINE HYDROCHLORIDE	2811	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	O	SSRI
6	25	27	O	TCA
7	29	40	O	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	O	SSRI
25	146	153	O	involved
NULL

CLOMIPRAMINE HYDROCHLORIDE	2812	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	26
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

CLOMIPRAMINE HYDROCHLORIDE	2813	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	B-TRI	sufficient
6	37	40	I-TRI	time
7	42	45	I-TRI	must
8	47	52	I-TRI	elapse
9	54	59	I-TRI	before
10	61	70	L-TRI	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

CLOMIPRAMINE HYDROCHLORIDE	2814	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	36
Concomitant use of agents in tricyclic antidepressant class (which includes clomipramine) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	24	O	agents
5	26	27	O	in
6	29	37	O	tricyclic
7	39	52	O	antidepressant
8	54	58	O	class
9	61	65	O	which
10	67	74	O	includes
11	76	87	O	XXXXXXXX
12	90	93	O	with
13	95	99	B-KIN	drugs
14	101	104	I-KIN	that
15	106	108	I-KIN	can
16	110	116	I-KIN	inhibit
17	118	127	I-KIN	cytochrome
18	129	132	I-KIN	P450
19	134	136	L-KIN	2D6
20	138	140	O	may
21	142	148	O	require
22	150	154	B-TRI	lower
23	156	160	L-TRI	doses
24	162	165	O	than
25	167	173	O	usually
26	175	184	O	prescribed
27	186	188	O	for
28	190	195	O	either
29	197	199	O	the
30	201	209	O	tricyclic
31	211	224	O	antidepressant
32	226	230	O	agent
33	232	233	O	or
34	235	237	O	the
35	239	243	O	other
36	245	248	O	drug
K/13:C54355

CLOMIPRAMINE HYDROCHLORIDE	2815	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	23
Furthermore, whenever one of these drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant agent may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	drugs
8	41	42	O	is
9	44	52	O	withdrawn
10	54	57	O	from
11	59	60	O	co
12	62	68	O	therapy
13	69	69	O	,
14	71	72	O	an
15	74	82	O	increased
16	84	87	O	dose
17	89	90	O	of
18	92	100	O	tricyclic
19	102	115	O	antidepressant
20	117	121	O	agent
21	123	125	O	may
22	127	128	O	be
23	130	137	O	required
NULL

CLOMIPRAMINE HYDROCHLORIDE	2816	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	40
It is desirable to monitor TCA plasma levels whenever an agent of the tricyclic antidepressant class including clomipramine is going to be co-administered with another drug known to be an inhibitor of P450 2D6 (and/or P450 1A2).
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	U-TRI	monitor
6	27	29	O	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	55	O	an
11	57	61	O	agent
12	63	64	O	of
13	66	68	O	the
14	70	78	O	tricyclic
15	80	93	O	antidepressant
16	95	99	O	class
17	101	109	O	including
18	111	122	O	XXXXXXXX
19	124	125	O	is
20	127	131	O	going
21	133	134	O	to
22	136	137	O	be
23	139	140	O	co
24	142	153	O	administered
25	155	158	O	with
26	160	166	O	another
27	168	171	O	drug
28	173	177	O	known
29	179	180	O	to
30	182	183	O	be
31	185	186	O	an
32	188	196	B-UNK	inhibitor
33	198	199	I-UNK	of
34	201	204	I-UNK	P450
35	206	208	L-UNK	2D6
36	211	213	O	and
37	214	214	O	/
38	215	216	O	or
39	218	221	O	P450
40	223	225	O	1A2
NULL

CLOMIPRAMINE HYDROCHLORIDE	2817	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	45
Because clomipramine is highly bound to serum protein, the administration of clomipramine to patients taking other drugs that are highly bound to protein (e.g., warfarin, digoxin) may cause an increase in plasma concentrations of these drugs, potentially resulting in adverse effects.
1	0	6	O	Because
2	8	19	O	XXXXXXXX
3	21	22	O	is
4	24	29	O	highly
5	31	35	O	bound
6	37	38	O	to
7	40	44	O	serum
8	46	52	O	protein
9	53	53	O	,
10	55	57	O	the
11	59	72	O	administration
12	74	75	O	of
13	77	88	O	XXXXXXXX
14	90	91	O	to
15	93	100	O	patients
16	102	107	O	taking
17	109	113	O	other
18	115	119	B-KIN	drugs
19	121	124	I-KIN	that
20	126	128	I-KIN	are
21	130	135	I-KIN	highly
22	137	141	I-KIN	bound
23	143	144	I-KIN	to
24	146	152	L-KIN	protein
25	155	157	O	e.g
26	159	159	O	,
27	161	168	U-KIN	warfarin
28	169	169	O	,
29	171	177	U-KIN	digoxin
30	180	182	O	may
31	184	188	O	cause
32	190	191	O	an
33	193	200	B-TRI	increase
34	202	203	I-TRI	in
35	205	210	I-TRI	plasma
36	212	225	L-TRI	concentrations
37	227	228	O	of
38	230	234	O	these
39	236	240	O	drugs
40	241	241	O	,
41	243	253	O	potentially
42	255	263	O	resulting
43	265	266	O	in
44	268	274	O	adverse
45	276	282	O	effects
K/18:C54357 K/27:C54357 K/29:C54357

CLOMIPRAMINE HYDROCHLORIDE	2818	34073-7	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	17
Conversely, adverse effects may result from displacement of protein-bound clomipramine by other highly bound drugs.
1	0	9	O	Conversely
2	10	10	O	,
3	12	18	O	adverse
4	20	26	O	effects
5	28	30	O	may
6	32	37	O	result
7	39	42	O	from
8	44	55	B-EFF	displacement
9	57	58	I-EFF	of
10	60	66	I-EFF	protein
11	68	72	I-EFF	bound
12	74	85	L-EFF	XXXXXXXX
13	87	88	O	by
14	90	94	O	other
15	96	101	B-DYN	highly
16	103	107	I-DYN	bound
17	109	113	L-DYN	drugs
D/15:8:1

CLOMIPRAMINE HYDROCHLORIDE	2821	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	17
Clomipramine (CMI) is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission.
1	0	11	O	XXXXXXXX
2	14	16	O	CMI
3	19	20	O	is
4	22	29	O	presumed
5	31	32	O	to
6	34	42	O	influence
7	44	52	O	obsessive
8	54	56	O	and
9	58	67	O	compulsive
10	69	77	O	behaviors
11	79	85	O	through
12	87	89	O	its
13	91	97	O	effects
14	99	100	O	on
15	102	113	O	serotonergic
16	115	122	O	neuronal
17	124	135	O	transmission
NULL

CLOMIPRAMINE HYDROCHLORIDE	2822	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	23
The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of serotonin (5-HT) is thought to be important.
1	0	2	O	The
2	4	9	O	actual
3	11	23	O	neurochemical
4	25	33	O	mechanism
5	35	36	O	is
6	38	44	O	unknown
7	45	45	O	,
8	47	49	O	but
9	51	55	O	CMI's
10	57	64	O	capacity
11	66	67	O	to
12	69	75	O	inhibit
13	77	79	O	the
14	81	88	O	reuptake
15	90	91	O	of
16	93	101	O	serotonin
17	104	104	O	5
18	106	107	O	HT
19	110	111	O	is
20	113	119	O	thought
21	121	122	O	to
22	124	125	O	be
23	127	135	O	important
NULL

CLOMIPRAMINE HYDROCHLORIDE	2823	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	12
CMI from clomipramine hydrochloride capsules is as bioavailable as CMI from a solution.
1	0	2	O	CMI
2	4	7	O	from
3	9	34	O	XXXXXXXX
4	36	43	O	capsules
5	45	46	O	is
6	48	49	O	as
7	51	62	O	bioavailable
8	64	65	O	as
9	67	69	O	CMI
10	71	74	O	from
11	76	76	O	a
12	78	85	O	solution
NULL

CLOMIPRAMINE HYDROCHLORIDE	2824	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	12
The bioavailability of CMI from capsules is not significantly affected by food.
1	0	2	O	The
2	4	18	O	bioavailability
3	20	21	O	of
4	23	25	O	CMI
5	27	30	O	from
6	32	39	O	capsules
7	41	42	O	is
8	44	46	O	not
9	48	60	O	significantly
10	62	69	O	affected
11	71	72	O	by
12	74	77	O	food
NULL

CLOMIPRAMINE HYDROCHLORIDE	2825	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	80
In a dose proportionality study involving multiple CMI doses, steady-state plasma concentrations (Css) and area-under-plasma-concentration-time curves (AUC) of CMI and CMI's major active metabolite, desmethylclomipramine (DMI), were not proportional to dose over the ranges evaluated, i.e., between 25 to 100 mg/day and between 25 to 150 mg/day, although Css and AUC are approximately linearly related to dose between 100 to 150 mg/day.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	dose
4	10	24	O	proportionality
5	26	30	O	study
6	32	40	O	involving
7	42	49	O	multiple
8	51	53	O	CMI
9	55	59	O	doses
10	60	60	O	,
11	62	67	O	steady
12	69	73	O	state
13	75	80	O	plasma
14	82	95	O	concentrations
15	98	100	O	Css
16	103	105	O	and
17	107	110	O	area
18	112	116	O	under
19	118	123	O	plasma
20	125	137	O	concentration
21	139	142	O	time
22	144	149	O	curves
23	152	154	O	AUC
24	157	158	O	of
25	160	162	O	CMI
26	164	166	O	and
27	168	172	O	CMI's
28	174	178	O	major
29	180	185	O	active
30	187	196	O	metabolite
31	197	197	O	,
32	199	207	O	desmethyl
33	208	219	O	XXXXXXXX
34	222	224	O	DMI
35	226	226	O	,
36	228	231	O	were
37	233	235	O	not
38	237	248	O	proportional
39	250	251	O	to
40	253	256	O	dose
41	258	261	O	over
42	263	265	O	the
43	267	272	O	ranges
44	274	282	O	evaluated
45	283	283	O	,
46	285	287	O	i.e
47	289	289	O	,
48	291	297	O	between
49	299	300	O	25
50	302	303	O	to
51	305	307	O	100
52	309	310	O	mg
53	311	311	O	/
54	312	314	O	day
55	316	318	O	and
56	320	326	O	between
57	328	329	O	25
58	331	332	O	to
59	334	336	O	150
60	338	339	O	mg
61	340	340	O	/
62	341	343	O	day
63	344	344	O	,
64	346	353	O	although
65	355	357	O	Css
66	359	361	O	and
67	363	365	O	AUC
68	367	369	O	are
69	371	383	O	approximately
70	385	392	O	linearly
71	394	400	O	related
72	402	403	O	to
73	405	408	O	dose
74	410	416	O	between
75	418	420	O	100
76	422	423	O	to
77	425	427	O	150
78	429	430	O	mg
79	431	431	O	/
80	432	434	O	day
NULL

CLOMIPRAMINE HYDROCHLORIDE	2826	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	52
The relationship between dose and CMI/DMI concentrations at higher daily doses has not been systematically assessed, but if there is significant dose dependency at doses above 150 mg/day, there is the potential for dramatically higher Css and AUC even for patients dosed within the recommended range.
1	0	2	O	The
2	4	15	O	relationship
3	17	23	O	between
4	25	28	O	dose
5	30	32	O	and
6	34	36	O	CMI
7	37	37	O	/
8	38	40	O	DMI
9	42	55	O	concentrations
10	57	58	O	at
11	60	65	O	higher
12	67	71	O	daily
13	73	77	O	doses
14	79	81	O	has
15	83	85	O	not
16	87	90	O	been
17	92	105	O	systematically
18	107	114	O	assessed
19	115	115	O	,
20	117	119	O	but
21	121	122	O	if
22	124	128	O	there
23	130	131	O	is
24	133	143	O	significant
25	145	148	O	dose
26	150	159	O	dependency
27	161	162	O	at
28	164	168	O	doses
29	170	174	O	above
30	176	178	O	150
31	180	181	O	mg
32	182	182	O	/
33	183	185	O	day
34	186	186	O	,
35	188	192	O	there
36	194	195	O	is
37	197	199	O	the
38	201	209	O	potential
39	211	213	O	for
40	215	226	O	dramatically
41	228	233	O	higher
42	235	237	O	Css
43	239	241	O	and
44	243	245	O	AUC
45	247	250	O	even
46	252	254	O	for
47	256	263	O	patients
48	265	269	O	dosed
49	271	276	O	within
50	278	280	O	the
51	282	292	O	recommended
52	294	298	O	range
NULL

CLOMIPRAMINE HYDROCHLORIDE	2827	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	9
This may pose a potential risk to some patients.
1	0	3	O	This
2	5	7	O	may
3	9	12	O	pose
4	14	14	O	a
5	16	24	O	potential
6	26	29	O	risk
7	31	32	O	to
8	34	37	O	some
9	39	46	O	patients
NULL

CLOMIPRAMINE HYDROCHLORIDE	2828	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	41
After a single 50 mg oral dose, maximum plasma concentrations of CMI occur within 2 to 6 hours (mean, 4.7 hr) and range from 56 ng/mL to 154 ng/mL (mean, 92 ng/mL).
1	0	4	O	After
2	6	6	O	a
3	8	13	O	single
4	15	16	O	50
5	18	19	O	mg
6	21	24	O	oral
7	26	29	O	dose
8	30	30	O	,
9	32	38	O	maximum
10	40	45	O	plasma
11	47	60	O	concentrations
12	62	63	O	of
13	65	67	O	CMI
14	69	73	O	occur
15	75	80	O	within
16	82	82	O	2
17	84	85	O	to
18	87	87	O	6
19	89	93	O	hours
20	96	99	O	mean
21	100	100	O	,
22	102	104	O	4.7
23	106	107	O	hr
24	110	112	O	and
25	114	118	O	range
26	120	123	O	from
27	125	126	O	56
28	128	129	O	ng
29	130	130	O	/
30	131	132	O	mL
31	134	135	O	to
32	137	139	O	154
33	141	142	O	ng
34	143	143	O	/
35	144	145	O	mL
36	148	151	O	mean
37	152	152	O	,
38	154	155	O	92
39	157	158	O	ng
40	159	159	O	/
41	160	161	O	mL
NULL

CLOMIPRAMINE HYDROCHLORIDE	2829	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	53
After multiple daily doses of 150 mg of clomipramine hydrochloride, steady-state maximum plasma concentrations range from 94 ng/mL to 339 ng/mL (mean, 218 ng/mL) for CMI and from 134 ng/mL to 532 ng/mL (mean, 274 ng/mL) for DMI.
1	0	4	O	After
2	6	13	O	multiple
3	15	19	O	daily
4	21	25	O	doses
5	27	28	O	of
6	30	32	O	150
7	34	35	O	mg
8	37	38	O	of
9	40	65	O	XXXXXXXX
10	66	66	O	,
11	68	73	O	steady
12	75	79	O	state
13	81	87	O	maximum
14	89	94	O	plasma
15	96	109	O	concentrations
16	111	115	O	range
17	117	120	O	from
18	122	123	O	94
19	125	126	O	ng
20	127	127	O	/
21	128	129	O	mL
22	131	132	O	to
23	134	136	O	339
24	138	139	O	ng
25	140	140	O	/
26	141	142	O	mL
27	145	148	O	mean
28	149	149	O	,
29	151	153	O	218
30	155	156	O	ng
31	157	157	O	/
32	158	159	O	mL
33	162	164	O	for
34	166	168	O	CMI
35	170	172	O	and
36	174	177	O	from
37	179	181	O	134
38	183	184	O	ng
39	185	185	O	/
40	186	187	O	mL
41	189	190	O	to
42	192	194	O	532
43	196	197	O	ng
44	198	198	O	/
45	199	200	O	mL
46	203	206	O	mean
47	207	207	O	,
48	209	211	O	274
49	213	214	O	ng
50	215	215	O	/
51	216	217	O	mL
52	220	222	O	for
53	224	226	O	DMI
NULL

CLOMIPRAMINE HYDROCHLORIDE	2830	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	25
Additional information from a rising dose study of doses up to 250 mg suggests that DMI may exhibit nonlinear pharmacokinetics over the usual dosing range.
1	0	9	O	Additional
2	11	21	O	information
3	23	26	O	from
4	28	28	O	a
5	30	35	O	rising
6	37	40	O	dose
7	42	46	O	study
8	48	49	O	of
9	51	55	O	doses
10	57	58	O	up
11	60	61	O	to
12	63	65	O	250
13	67	68	O	mg
14	70	77	O	suggests
15	79	82	O	that
16	84	86	O	DMI
17	88	90	O	may
18	92	98	O	exhibit
19	100	108	O	nonlinear
20	110	125	O	pharmacokinetics
21	127	130	O	over
22	132	134	O	the
23	136	140	O	usual
24	142	147	O	dosing
25	149	153	O	range
NULL

CLOMIPRAMINE HYDROCHLORIDE	2831	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	58
At a dose of Clomipramine Hydrochloride Capsules, 200 mg, subjects who had a single blood sample taken approximately 9 to 22 hours, (median 16 hours), after the dose had plasma concentrations of up to 605 ng/mL for CMI, 781 ng/mL for DMI, and 1386 ng/mL for both.
1	0	1	O	At
2	3	3	O	a
3	5	8	O	dose
4	10	11	O	of
5	13	38	O	XXXXXXXX
6	40	47	O	Capsules
7	48	48	O	,
8	50	52	O	200
9	54	55	O	mg
10	56	56	O	,
11	58	65	O	subjects
12	67	69	O	who
13	71	73	O	had
14	75	75	O	a
15	77	82	O	single
16	84	88	O	blood
17	90	95	O	sample
18	97	101	O	taken
19	103	115	O	approximately
20	117	117	O	9
21	119	120	O	to
22	122	123	O	22
23	125	129	O	hours
24	130	130	O	,
25	133	138	O	median
26	140	141	O	16
27	143	147	O	hours
28	149	149	O	,
29	151	155	O	after
30	157	159	O	the
31	161	164	O	dose
32	166	168	O	had
33	170	175	O	plasma
34	177	190	O	concentrations
35	192	193	O	of
36	195	196	O	up
37	198	199	O	to
38	201	203	O	605
39	205	206	O	ng
40	207	207	O	/
41	208	209	O	mL
42	211	213	O	for
43	215	217	O	CMI
44	218	218	O	,
45	220	222	O	781
46	224	225	O	ng
47	226	226	O	/
48	227	228	O	mL
49	230	232	O	for
50	234	236	O	DMI
51	237	237	O	,
52	239	241	O	and
53	243	246	O	1386
54	248	249	O	ng
55	250	250	O	/
56	251	252	O	mL
57	254	256	O	for
58	258	261	O	both
NULL

CLOMIPRAMINE HYDROCHLORIDE	2832	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	12
CMI distributes into cerebrospinal fluid (CSF) and brain and into breast milk.
1	0	2	O	CMI
2	4	14	O	distributes
3	16	19	O	into
4	21	33	O	cerebrospinal
5	35	39	O	fluid
6	42	44	O	CSF
7	47	49	O	and
8	51	55	O	brain
9	57	59	O	and
10	61	64	O	into
11	66	71	O	breast
12	73	76	O	milk
NULL

CLOMIPRAMINE HYDROCHLORIDE	2833	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	15
DMI also distributes into CSF, with a mean CSF/plasma ratio of 2.6.
1	0	2	O	DMI
2	4	7	O	also
3	9	19	O	distributes
4	21	24	O	into
5	26	28	O	CSF
6	29	29	O	,
7	31	34	O	with
8	36	36	O	a
9	38	41	O	mean
10	43	45	O	CSF
11	46	46	O	/
12	47	52	O	plasma
13	54	58	O	ratio
14	60	61	O	of
15	63	65	O	2.6
NULL

CLOMIPRAMINE HYDROCHLORIDE	2834	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	19
The protein binding of CMI is approximately 97%, principally to albumin, and is independent of CMI concentration.
1	0	2	O	The
2	4	10	O	protein
3	12	18	O	binding
4	20	21	O	of
5	23	25	O	CMI
6	27	28	O	is
7	30	42	O	approximately
8	44	46	O	97%
9	47	47	O	,
10	49	59	O	principally
11	61	62	O	to
12	64	70	O	albumin
13	71	71	O	,
14	73	75	O	and
15	77	78	O	is
16	80	90	O	independent
17	92	93	O	of
18	95	97	O	CMI
19	99	111	O	concentration
NULL

CLOMIPRAMINE HYDROCHLORIDE	2835	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	20
The interaction between CMI and other highly protein-bound drugs has not been fully evaluated, but may be important.
1	0	2	O	The
2	4	14	U-TRI	interaction
3	16	22	O	between
4	24	26	O	CMI
5	28	30	O	and
6	32	36	O	other
7	38	43	B-UNK	highly
8	45	51	I-UNK	protein
9	53	57	I-UNK	bound
10	59	63	L-UNK	drugs
11	65	67	O	has
12	69	71	O	not
13	73	76	O	been
14	78	82	O	fully
15	84	92	O	evaluated
16	93	93	O	,
17	95	97	O	but
18	99	101	O	may
19	103	104	O	be
20	106	114	O	important
NULL

CLOMIPRAMINE HYDROCHLORIDE	2836	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	13
CMI is extensively biotransformed to DMI and other metabolites and their glucuronide conjugates.
1	0	2	O	CMI
2	4	5	O	is
3	7	17	O	extensively
4	19	32	O	biotransformed
5	34	35	O	to
6	37	39	O	DMI
7	41	43	O	and
8	45	49	O	other
9	51	61	O	metabolites
10	63	65	O	and
11	67	71	O	their
12	73	83	O	glucuronide
13	85	94	O	conjugates
NULL

CLOMIPRAMINE HYDROCHLORIDE	2837	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	13
DMI is pharmacologically active, but its effects on OCD behaviors are unknown.
1	0	2	O	DMI
2	4	5	O	is
3	7	23	O	pharmacologically
4	25	30	O	active
5	31	31	O	,
6	33	35	O	but
7	37	39	O	its
8	41	47	O	effects
9	49	50	O	on
10	52	54	O	OCD
11	56	64	O	behaviors
12	66	68	O	are
13	70	76	O	unknown
NULL

CLOMIPRAMINE HYDROCHLORIDE	2838	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	12
These metabolites are excreted in urine and feces, following biliary elimination.
1	0	4	O	These
2	6	16	O	metabolites
3	18	20	O	are
4	22	29	O	excreted
5	31	32	O	in
6	34	38	O	urine
7	40	42	O	and
8	44	48	O	feces
9	49	49	O	,
10	51	59	O	following
11	61	67	O	biliary
12	69	79	O	elimination
NULL

CLOMIPRAMINE HYDROCHLORIDE	2839	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	35
After a 25 mg radiolabeled dose of CMI in two subjects, 60% and 51%, respectively, of the dose were recovered in the urine and 32% and 24%, respectively, in feces.
1	0	4	O	After
2	6	6	O	a
3	8	9	O	25
4	11	12	O	mg
5	14	25	O	radiolabeled
6	27	30	O	dose
7	32	33	O	of
8	35	37	O	CMI
9	39	40	O	in
10	42	44	O	two
11	46	53	O	subjects
12	54	54	O	,
13	56	58	O	60%
14	60	62	O	and
15	64	66	O	51%
16	67	67	O	,
17	69	80	O	respectively
18	81	81	O	,
19	83	84	O	of
20	86	88	O	the
21	90	93	O	dose
22	95	98	O	were
23	100	108	O	recovered
24	110	111	O	in
25	113	115	O	the
26	117	121	O	urine
27	123	125	O	and
28	127	129	O	32%
29	131	133	O	and
30	135	137	O	24%
31	138	138	O	,
32	140	151	O	respectively
33	152	152	O	,
34	154	155	O	in
35	157	161	O	feces
NULL

CLOMIPRAMINE HYDROCHLORIDE	2840	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	23
In the same study, the combined urinary recoveries of CMI and DMI were only about 0.8% to 1.3% of the dose administered.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	same
4	12	16	O	study
5	17	17	O	,
6	19	21	O	the
7	23	30	O	combined
8	32	38	O	urinary
9	40	49	O	recoveries
10	51	52	O	of
11	54	56	O	CMI
12	58	60	O	and
13	62	64	O	DMI
14	66	69	O	were
15	71	74	O	only
16	76	80	O	about
17	82	85	O	0.8%
18	87	88	O	to
19	90	93	O	1.3%
20	95	96	O	of
21	98	100	O	the
22	102	105	O	dose
23	107	118	O	administered
NULL

CLOMIPRAMINE HYDROCHLORIDE	2841	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	14
CMI does not induce drug-metabolizing enzymes, as measured by antipyrine half-life.
1	0	2	O	CMI
2	4	7	O	does
3	9	11	O	not
4	13	18	O	induce
5	20	23	O	drug
6	25	36	O	metabolizing
7	38	44	O	enzymes
8	45	45	O	,
9	47	48	O	as
10	50	57	O	measured
11	59	60	O	by
12	62	71	O	antipyrine
13	73	76	O	half
14	78	81	O	life
NULL

CLOMIPRAMINE HYDROCHLORIDE	2842	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	30
Evidence that the C ss and AUC for CMI and DMI may increase disproportionately with increasing oral doses suggests that the metabolism of CMI and DMI may be capacity limited.
1	0	7	O	Evidence
2	9	12	O	that
3	14	16	O	the
4	18	18	O	C
5	20	21	O	ss
6	23	25	O	and
7	27	29	O	AUC
8	31	33	O	for
9	35	37	O	CMI
10	39	41	O	and
11	43	45	O	DMI
12	47	49	O	may
13	51	58	O	increase
14	60	77	O	disproportionately
15	79	82	O	with
16	84	93	O	increasing
17	95	98	O	oral
18	100	104	O	doses
19	106	113	O	suggests
20	115	118	O	that
21	120	122	O	the
22	124	133	O	metabolism
23	135	136	O	of
24	138	140	O	CMI
25	142	144	O	and
26	146	148	O	DMI
27	150	152	O	may
28	154	155	O	be
29	157	164	O	capacity
30	166	172	O	limited
NULL

CLOMIPRAMINE HYDROCHLORIDE	2843	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	28
This fact must be considered in assessing the estimates of the pharmacokinetic parameters presented below, as these were obtained in individuals exposed to doses of 150 mg.
1	0	3	O	This
2	5	8	O	fact
3	10	13	O	must
4	15	16	O	be
5	18	27	O	considered
6	29	30	O	in
7	32	40	O	assessing
8	42	44	O	the
9	46	54	O	estimates
10	56	57	O	of
11	59	61	O	the
12	63	77	O	pharmacokinetic
13	79	88	O	parameters
14	90	98	O	presented
15	100	104	O	below
16	105	105	O	,
17	107	108	O	as
18	110	114	O	these
19	116	119	O	were
20	121	128	O	obtained
21	130	131	O	in
22	133	143	O	individuals
23	145	151	O	exposed
24	153	154	O	to
25	156	160	O	doses
26	162	163	O	of
27	165	167	O	150
28	169	170	O	mg
NULL

CLOMIPRAMINE HYDROCHLORIDE	2844	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	45
If the pharmacokinetics of CMI and DMI are nonlinear at doses above 150 mg, their elimination half-lives may be considerably lengthened at doses near the upper end of the recommended dosing range (i.e., 200 mg/day to 250 mg/day).
1	0	1	O	If
2	3	5	O	the
3	7	22	O	pharmacokinetics
4	24	25	O	of
5	27	29	O	CMI
6	31	33	O	and
7	35	37	O	DMI
8	39	41	O	are
9	43	51	O	nonlinear
10	53	54	O	at
11	56	60	O	doses
12	62	66	O	above
13	68	70	O	150
14	72	73	O	mg
15	74	74	O	,
16	76	80	O	their
17	82	92	O	elimination
18	94	97	O	half
19	99	103	O	lives
20	105	107	O	may
21	109	110	O	be
22	112	123	O	considerably
23	125	134	O	lengthened
24	136	137	O	at
25	139	143	O	doses
26	145	148	O	near
27	150	152	O	the
28	154	158	O	upper
29	160	162	O	end
30	164	165	O	of
31	167	169	O	the
32	171	181	O	recommended
33	183	188	O	dosing
34	190	194	O	range
35	197	199	O	i.e
36	201	201	O	,
37	203	205	O	200
38	207	208	O	mg
39	209	209	O	/
40	210	212	O	day
41	214	215	O	to
42	217	219	O	250
43	221	222	O	mg
44	223	223	O	/
45	224	226	O	day
NULL

CLOMIPRAMINE HYDROCHLORIDE	2845	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	28
Consequently, CMI and DMI may accumulate, and this accumulation may increase the incidence of any dose- or plasma-concentration-dependent adverse reactions, in particular seizures.
1	0	11	O	Consequently
2	12	12	O	,
3	14	16	O	CMI
4	18	20	O	and
5	22	24	O	DMI
6	26	28	O	may
7	30	39	O	accumulate
8	40	40	O	,
9	42	44	O	and
10	46	49	O	this
11	51	62	O	accumulation
12	64	66	O	may
13	68	75	O	increase
14	77	79	O	the
15	81	89	O	incidence
16	91	92	O	of
17	94	96	O	any
18	98	101	O	dose
19	104	105	O	or
20	107	112	O	plasma
21	114	126	O	concentration
22	128	136	O	dependent
23	138	144	O	adverse
24	146	154	O	reactions
25	155	155	O	,
26	157	158	O	in
27	160	169	O	particular
28	171	178	O	seizures
NULL

CLOMIPRAMINE HYDROCHLORIDE	2846	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	37
After a 150 mg dose, the half-life of CMI ranges from 19 hours to 37 hours (mean, 32 hr) and that of DMI ranges from 54 hours to 77 hours (mean, 69 hr).
1	0	4	O	After
2	6	6	O	a
3	8	10	O	150
4	12	13	O	mg
5	15	18	O	dose
6	19	19	O	,
7	21	23	O	the
8	25	28	O	half
9	30	33	O	life
10	35	36	O	of
11	38	40	O	CMI
12	42	47	O	ranges
13	49	52	O	from
14	54	55	O	19
15	57	61	O	hours
16	63	64	O	to
17	66	67	O	37
18	69	73	O	hours
19	76	79	O	mean
20	80	80	O	,
21	82	83	O	32
22	85	86	O	hr
23	89	91	O	and
24	93	96	O	that
25	98	99	O	of
26	101	103	O	DMI
27	105	110	O	ranges
28	112	115	O	from
29	117	118	O	54
30	120	124	O	hours
31	126	127	O	to
32	129	130	O	77
33	132	136	O	hours
34	139	142	O	mean
35	143	143	O	,
36	145	146	O	69
37	148	149	O	hr
NULL

CLOMIPRAMINE HYDROCHLORIDE	2847	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	16
Steady-state levels after multiple dosing are typically reached within 7 to 14 days for CMI.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	levels
4	20	24	O	after
5	26	33	O	multiple
6	35	40	O	dosing
7	42	44	O	are
8	46	54	O	typically
9	56	62	O	reached
10	64	69	O	within
11	71	71	O	7
12	73	74	O	to
13	76	77	O	14
14	79	82	O	days
15	84	86	O	for
16	88	90	O	CMI
NULL

CLOMIPRAMINE HYDROCHLORIDE	2848	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	12
Plasma concentrations of the metabolite exceed the parent drug on multiple dosing.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	27	O	the
5	29	38	O	metabolite
6	40	45	O	exceed
7	47	49	O	the
8	51	56	O	parent
9	58	61	O	drug
10	63	64	O	on
11	66	73	O	multiple
12	75	80	O	dosing
NULL

CLOMIPRAMINE HYDROCHLORIDE	2849	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	22
After multiple dosing with 150 mg/day, the accumulation factor for CMI is approximately 2.5 and for DMI is 4.6.
1	0	4	O	After
2	6	13	O	multiple
3	15	20	O	dosing
4	22	25	O	with
5	27	29	O	150
6	31	32	O	mg
7	33	33	O	/
8	34	36	O	day
9	37	37	O	,
10	39	41	O	the
11	43	54	O	accumulation
12	56	61	O	factor
13	63	65	O	for
14	67	69	O	CMI
15	71	72	O	is
16	74	86	O	approximately
17	88	90	O	2.5
18	92	94	O	and
19	96	98	O	for
20	100	102	O	DMI
21	104	105	O	is
22	107	109	O	4.6
NULL

CLOMIPRAMINE HYDROCHLORIDE	2850	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	30
Importantly, it may take two weeks or longer to achieve this extent of accumulation at constant dosing because of the relatively long elimination half-lives of CMI and DMI.
1	0	10	O	Importantly
2	11	11	O	,
3	13	14	O	it
4	16	18	O	may
5	20	23	O	take
6	25	27	O	two
7	29	33	O	weeks
8	35	36	O	or
9	38	43	O	longer
10	45	46	O	to
11	48	54	O	achieve
12	56	59	O	this
13	61	66	O	extent
14	68	69	O	of
15	71	82	O	accumulation
16	84	85	O	at
17	87	94	O	constant
18	96	101	O	dosing
19	103	109	O	because
20	111	112	O	of
21	114	116	O	the
22	118	127	O	relatively
23	129	132	O	long
24	134	144	O	elimination
25	146	149	O	half
26	151	155	O	lives
27	157	158	O	of
28	160	162	O	CMI
29	164	166	O	and
30	168	170	O	DMI
NULL

CLOMIPRAMINE HYDROCHLORIDE	2851	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	16
The effects of hepatic and renal impairment on the disposition of clomipramine hydrochloride have not been determined.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	21	O	hepatic
5	23	25	O	and
6	27	31	O	renal
7	33	42	O	impairment
8	44	45	O	on
9	47	49	O	the
10	51	61	O	disposition
11	63	64	O	of
12	66	91	O	XXXXXXXX
13	93	96	O	have
14	98	100	O	not
15	102	105	O	been
16	107	116	O	determined
NULL

CLOMIPRAMINE HYDROCHLORIDE	2852	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	11
Co-administration of haloperidol with CMI increases plasma concentrations of CMI.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	31	U-KIN	haloperidol
5	33	36	O	with
6	38	40	O	CMI
7	42	50	B-TRI	increases
8	52	57	I-TRI	plasma
9	59	72	L-TRI	concentrations
10	74	75	O	of
11	77	79	O	CMI
K/4:C54355

CLOMIPRAMINE HYDROCHLORIDE	2853	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	11
Co-administration of CMI with phenobarbital increases plasma concentrations of phenobarbital.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	23	O	CMI
5	25	28	O	with
6	30	42	U-KIN	phenobarbital
7	44	52	B-TRI	increases
8	54	59	I-TRI	plasma
9	61	74	L-TRI	concentrations
10	76	77	O	of
11	79	91	O	phenobarbital
K/6:C54357

CLOMIPRAMINE HYDROCHLORIDE	2854	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	28
Younger subjects (18 to 40 years of age) tolerated CMI better and had significantly lower steady-state plasma concentrations, compared with subjects over 65 years of age.
1	0	6	O	Younger
2	8	15	O	subjects
3	18	19	O	18
4	21	22	O	to
5	24	25	O	40
6	27	31	O	years
7	33	34	O	of
8	36	38	O	age
9	41	49	O	tolerated
10	51	53	O	CMI
11	55	60	O	better
12	62	64	O	and
13	66	68	O	had
14	70	82	O	significantly
15	84	88	O	lower
16	90	95	O	steady
17	97	101	O	state
18	103	108	O	plasma
19	110	123	O	concentrations
20	124	124	O	,
21	126	133	O	compared
22	135	138	O	with
23	140	147	O	subjects
24	149	152	O	over
25	154	155	O	65
26	157	161	O	years
27	163	164	O	of
28	166	168	O	age
NULL

CLOMIPRAMINE HYDROCHLORIDE	2855	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	18
Children under 15 years of age had significantly lower plasma concentration/dose ratios, compared with adults.
1	0	7	O	Children
2	9	13	O	under
3	15	16	O	15
4	18	22	O	years
5	24	25	O	of
6	27	29	O	age
7	31	33	O	had
8	35	47	O	significantly
9	49	53	O	lower
10	55	60	O	plasma
11	62	74	O	concentration
12	75	75	O	/
13	76	79	O	dose
14	81	86	O	ratios
15	87	87	O	,
16	89	96	O	compared
17	98	101	O	with
18	103	108	O	adults
NULL

CLOMIPRAMINE HYDROCHLORIDE	2856	34090-1	1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e	12
Plasma concentrations of CMI were significantly lower in smokers than in nonsmokers.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	27	O	CMI
5	29	32	O	were
6	34	46	O	significantly
7	48	52	O	lower
8	54	55	O	in
9	57	63	O	smokers
10	65	68	O	than
11	70	71	O	in
12	73	82	O	nonsmokers
NULL

COUMADIN	2021	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	10
Drugs may interact with COUMADIN through pharmacodynamic or pharmacokinetic mechanisms.
1	0	4	O	Drugs
2	6	8	O	may
3	10	17	O	interact
4	19	22	O	with
5	24	31	O	XXXXXXXX
6	33	39	O	through
7	41	55	O	pharmacodynamic
8	57	58	O	or
9	60	74	O	pharmacokinetic
10	76	85	O	mechanisms
NULL

COUMADIN	2022	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	35
Pharmacodynamic mechanisms for drug interactions with COUMADIN are synergism (impaired hemostasis, reduced clotting factor synthesis), competitive antagonism (vitamin K), and alteration of the physiologic control loop for vitamin K metabolism (hereditary resistance).
1	0	14	O	Pharmacodynamic
2	16	25	O	mechanisms
3	27	29	O	for
4	31	34	O	drug
5	36	47	O	interactions
6	49	52	O	with
7	54	61	O	XXXXXXXX
8	63	65	O	are
9	67	75	O	synergism
10	78	85	O	impaired
11	87	96	O	hemostasis
12	97	97	O	,
13	99	105	O	reduced
14	107	114	O	clotting
15	116	121	O	factor
16	123	131	O	synthesis
17	133	133	O	,
18	135	145	O	competitive
19	147	156	O	antagonism
20	159	165	O	vitamin
21	167	167	O	K
22	169	169	O	,
23	171	173	O	and
24	175	184	O	alteration
25	186	187	O	of
26	189	191	O	the
27	193	203	O	physiologic
28	205	211	O	control
29	213	216	O	loop
30	218	220	O	for
31	222	228	O	vitamin
32	230	230	O	K
33	232	241	O	metabolism
34	244	253	O	hereditary
35	255	264	O	resistance
NULL

COUMADIN	2023	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	20
Pharmacokinetic mechanisms for drug interactions with COUMADIN are mainly enzyme induction, enzyme inhibition, and reduced plasma protein binding.
1	0	14	O	Pharmacokinetic
2	16	25	O	mechanisms
3	27	29	O	for
4	31	34	O	drug
5	36	47	O	interactions
6	49	52	O	with
7	54	61	O	XXXXXXXX
8	63	65	O	are
9	67	72	O	mainly
10	74	79	O	enzyme
11	81	89	O	induction
12	90	90	O	,
13	92	97	O	enzyme
14	99	108	O	inhibition
15	109	109	O	,
16	111	113	O	and
17	115	121	O	reduced
18	123	128	O	plasma
19	130	136	O	protein
20	138	144	O	binding
NULL

COUMADIN	2024	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	15
It is important to note that some drugs may interact by more than one mechanism.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	important
4	16	17	O	to
5	19	22	O	note
6	24	27	O	that
7	29	32	O	some
8	34	38	O	drugs
9	40	42	O	may
10	44	51	O	interact
11	53	54	O	by
12	56	59	O	more
13	61	64	O	than
14	66	68	O	one
15	70	78	O	mechanism
NULL

COUMADIN	2025	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	39
More frequent INR monitoring should be performed when starting or stopping other drugs, including botanicals, or when changing dosages of other drugs, including drugs intended for short-term use (e.g., antibiotics, antifungals, corticosteroids).
1	0	3	O	More
2	5	12	O	frequent
3	14	16	O	INR
4	18	27	O	monitoring
5	29	34	O	should
6	36	37	O	be
7	39	47	O	performed
8	49	52	O	when
9	54	61	O	starting
10	63	64	O	or
11	66	73	O	stopping
12	75	79	O	other
13	81	85	O	drugs
14	86	86	O	,
15	88	96	O	including
16	98	107	O	botanicals
17	108	108	O	,
18	110	111	O	or
19	113	116	O	when
20	118	125	O	changing
21	127	133	O	dosages
22	135	136	O	of
23	138	142	O	other
24	144	148	O	drugs
25	149	149	O	,
26	151	159	O	including
27	161	165	O	drugs
28	167	174	O	intended
29	176	178	O	for
30	180	184	O	short
31	186	189	O	term
32	191	193	O	use
33	196	198	O	e.g
34	200	200	O	,
35	202	212	O	antibiotics
36	213	213	O	,
37	215	225	O	antifungals
38	226	226	O	,
39	228	242	O	corticosteroids
NULL

COUMADIN	2026	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	22
Consult the labeling of all concurrently used drugs to obtain further information about interactions with COUMADIN or adverse reactions pertaining to bleeding.
1	0	6	O	Consult
2	8	10	O	the
3	12	19	O	labeling
4	21	22	O	of
5	24	26	O	all
6	28	39	O	concurrently
7	41	44	O	used
8	46	50	O	drugs
9	52	53	O	to
10	55	60	O	obtain
11	62	68	O	further
12	70	80	O	information
13	82	86	O	about
14	88	99	O	interactions
15	101	104	O	with
16	106	113	O	XXXXXXXX
17	115	116	O	or
18	118	124	O	adverse
19	126	134	O	reactions
20	136	145	O	pertaining
21	147	148	O	to
22	150	157	O	bleeding
NULL

COUMADIN	2027	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	29
Concomitant use of drugs that increase bleeding risk, antibiotics, antifungals, botanical (herbal) products, and inhibitors and inducers of CYP2C9, 1A2, or 3A4 (7).
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	23	O	drugs
5	25	28	O	that
6	30	37	O	increase
7	39	46	U-EFF	bleeding
8	48	51	O	risk
9	52	52	O	,
10	54	64	U-DYN	antibiotics
11	65	65	O	,
12	67	77	U-DYN	antifungals
13	78	78	O	,
14	80	88	O	botanical
15	91	96	O	herbal
16	99	106	O	products
17	107	107	O	,
18	109	111	O	and
19	113	122	O	inhibitors
20	124	126	O	and
21	128	135	B-DYN	inducers
22	137	138	I-DYN	of
23	140	145	L-DYN	CYP2C9
24	146	146	O	,
25	148	150	O	1A2
26	151	151	O	,
27	153	154	O	or
28	156	158	O	3A4
29	161	161	O	7
D/10:7:1 D/12:7:1 D/21:7:1

COUMADIN	2028	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Consult labeling of all concurrently used drugs for complete information about interactions with COUMADIN or increased risks for bleeding.
1	0	6	O	Consult
2	8	15	O	labeling
3	17	18	O	of
4	20	22	O	all
5	24	35	O	concurrently
6	37	40	O	used
7	42	46	O	drugs
8	48	50	O	for
9	52	59	O	complete
10	61	71	O	information
11	73	77	O	about
12	79	90	O	interactions
13	92	95	O	with
14	97	104	O	XXXXXXXX
15	106	107	O	or
16	109	117	O	increased
17	119	123	O	risks
18	125	127	O	for
19	129	136	O	bleeding
NULL

COUMADIN	2029	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	21
CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4.
1	0	5	O	CYP450
2	7	14	O	isozymes
3	16	23	O	involved
4	25	26	O	in
5	28	30	O	the
6	32	41	O	metabolism
7	43	44	O	of
8	46	53	O	XXXXXXXX
9	55	61	O	include
10	63	68	O	CYP2C9
11	69	69	O	,
12	71	74	O	2C19
13	75	75	O	,
14	77	79	O	2C8
15	80	80	O	,
16	82	85	O	2C18
17	86	86	O	,
18	88	90	O	1A2
19	91	91	O	,
20	93	95	O	and
21	97	99	O	3A4
NULL

COUMADIN	2030	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	20
The more potent warfarin S-enantiomer is metabolized by CYP2C9 while the R-enantiomer is metabolized by CYP1A2 and 3A4.
1	0	2	O	The
2	4	7	O	more
3	9	14	O	potent
4	16	23	O	XXXXXXXX
5	25	25	O	S
6	27	36	O	enantiomer
7	38	39	O	is
8	41	51	O	metabolized
9	53	54	O	by
10	56	61	O	CYP2C9
11	63	67	O	while
12	69	71	O	the
13	73	73	O	R
14	75	84	O	enantiomer
15	86	87	O	is
16	89	99	O	metabolized
17	101	102	O	by
18	104	109	O	CYP1A2
19	111	113	O	and
20	115	117	O	3A4
NULL

COUMADIN	2031	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	27
Inhibitors of CYP2C9, 1A2, and/or 3A4 have the potential to increase the effect (increase INR) of warfarin by increasing the exposure of warfarin.
1	0	9	B-DYN	Inhibitors
2	11	12	I-DYN	of
3	14	19	L-DYN	CYP2C9
4	20	20	O	,
5	22	24	O	1A2
6	25	25	O	,
7	27	29	O	and
8	30	30	O	/
9	31	32	O	or
10	34	36	O	3A4
11	38	41	O	have
12	43	45	O	the
13	47	55	O	potential
14	57	58	O	to
15	60	67	O	increase
16	69	71	O	the
17	73	78	O	effect
18	81	88	B-EFF	increase
19	90	92	L-EFF	INR
20	95	96	O	of
21	98	105	O	XXXXXXXX
22	107	108	O	by
23	110	119	B-TRI	increasing
24	121	123	I-TRI	the
25	125	132	L-TRI	exposure
26	134	135	O	of
27	137	144	O	XXXXXXXX
D/1:18:1

COUMADIN	2032	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	27
Inducers of CYP2C9, 1A2, and/or 3A4 have the potential to decrease the effect (decrease INR) of warfarin by decreasing the exposure of warfarin.
1	0	7	B-DYN	Inducers
2	9	10	I-DYN	of
3	12	17	L-DYN	CYP2C9
4	18	18	O	,
5	20	22	O	1A2
6	23	23	O	,
7	25	27	O	and
8	28	28	O	/
9	29	30	O	or
10	32	34	O	3A4
11	36	39	O	have
12	41	43	O	the
13	45	53	O	potential
14	55	56	O	to
15	58	65	O	decrease
16	67	69	O	the
17	71	76	O	effect
18	79	86	B-EFF	decrease
19	88	90	L-EFF	INR
20	93	94	O	of
21	96	103	O	XXXXXXXX
22	105	106	O	by
23	108	117	B-TRI	decreasing
24	119	121	I-TRI	the
25	123	130	L-TRI	exposure
26	132	133	O	of
27	135	142	O	XXXXXXXX
D/1:18:1

COUMADIN	2033	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	27
Examples of inhibitors and inducers of CYP2C9, 1A2, and 3A4 are below in Table 2; however, this list should not be considered all-inclusive.
1	0	7	O	Examples
2	9	10	O	of
3	12	21	O	inhibitors
4	23	25	O	and
5	27	34	O	inducers
6	36	37	O	of
7	39	44	O	CYP2C9
8	45	45	O	,
9	47	49	O	1A2
10	50	50	O	,
11	52	54	O	and
12	56	58	O	3A4
13	60	62	O	are
14	64	68	O	below
15	70	71	O	in
16	73	77	O	Table
17	79	79	O	2
18	82	88	O	however
19	89	89	O	,
20	91	94	O	this
21	96	99	O	list
22	101	106	O	should
23	108	110	O	not
24	112	113	O	be
25	115	124	O	considered
26	126	128	O	all
27	130	138	O	inclusive
NULL

COUMADIN	2034	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	16
Consult the labeling of all concurrently used drugs to obtain further information about CYP450 interaction potential.
1	0	6	O	Consult
2	8	10	O	the
3	12	19	O	labeling
4	21	22	O	of
5	24	26	O	all
6	28	39	O	concurrently
7	41	44	O	used
8	46	50	O	drugs
9	52	53	O	to
10	55	60	O	obtain
11	62	68	O	further
12	70	80	O	information
13	82	86	O	about
14	88	93	O	CYP450
15	95	105	O	interaction
16	107	115	O	potential
NULL

COUMADIN	2035	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	20
The CYP450 inhibition and induction potential should be considered when starting, stopping, or changing dose of concomitant medications.
1	0	2	O	The
2	4	9	O	CYP450
3	11	20	O	inhibition
4	22	24	O	and
5	26	34	O	induction
6	36	44	O	potential
7	46	51	O	should
8	53	54	O	be
9	56	65	O	considered
10	67	70	O	when
11	72	79	O	starting
12	80	80	O	,
13	82	89	O	stopping
14	90	90	O	,
15	92	93	O	or
16	95	102	O	changing
17	104	107	O	dose
18	109	110	O	of
19	112	122	O	concomitant
20	124	134	O	medications
NULL

COUMADIN	2036	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	20
Closely monitor INR if a concomitant drug is a CYP2C9, 1A2, and/or 3A4 inhibitor or inducer.
1	0	6	B-TRI	Closely
2	8	14	L-TRI	monitor
3	16	18	O	INR
4	20	21	O	if
5	23	23	O	a
6	25	35	O	concomitant
7	37	40	O	drug
8	42	43	O	is
9	45	45	O	a
10	47	52	O	CYP2C9
11	53	53	O	,
12	55	57	O	1A2
13	58	58	O	,
14	60	62	O	and
15	63	63	O	/
16	64	65	O	or
17	67	69	O	3A4
18	71	79	O	inhibitor
19	81	82	O	or
20	84	90	O	inducer
NULL

COUMADIN	2037	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	231
Table 2: Examples of CYP450 Interactions with Warfarin Enzyme Inhibitors Inducers CYP2C9 amiodarone, capecitabine, cotrimoxazole, etravirine, fluconazole, fluvastatin, fluvoxamine, metronidazole, miconazole, oxandrolone, sulfinpyrazone, tigecycline, voriconazole, zafirlukast aprepitant, bosentan, carbamazepine, phenobarbital, rifampin CYP1A2 acyclovir, allopurinol, caffeine, cimetidine, ciprofloxacin, disulfiram, enoxacin, famotidine, fluvoxamine, methoxsalen, mexiletine, norfloxacin, oral contraceptives, phenylpropanolamine, propafenone, propranolol, terbinafine, thiabendazole, ticlopidine, verapamil, zileuton montelukast, moricizine, omeprazole, phenobarbital, phenytoin, cigarette smoking CYP3A4 alprazolam, amiodarone, amlodipine, amprenavir, aprepitant, atorvastatin, atazanavir, bicalutamide, cilostazol, cimetidine, ciprofloxacin, clarithromycin, conivaptan, cyclosporine, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fluoxetine, fluvoxamine, fosamprenavir, imatinib, indinavir, isoniazid, itraconazole, ketoconazole, lopinavir/ritonavir, nefazodone, nelfinavir, nilotinib, oral contraceptives, posaconazole, ranitidine, ranolazine, ritonavir, saquinavir, telithromycin, tipranavir, voriconazole, zileuton armodafinil, amprenavir, aprepitant, bosentan, carbamazepine, efavirenz, etravirine, modafinil, nafcillin, phenytoin, pioglitazone, prednisone, rifampin, rufinamide Examples of drugs known to increase the risk of bleeding are presented in Table 3.
1	0	4	O	Table
2	6	6	O	2
3	7	7	O	:
4	9	16	O	Examples
5	18	19	O	of
6	21	26	O	CYP450
7	28	39	U-TRI	Interactions
8	41	44	O	with
9	46	53	O	XXXXXXXX
10	55	60	O	Enzyme
11	62	71	O	Inhibitors
12	73	80	O	Inducers
13	82	87	O	CYP2C9
14	89	98	U-UNK	amiodarone
15	99	99	O	,
16	101	112	U-UNK	capecitabine
17	113	113	O	,
18	115	127	U-UNK	cotrimoxazole
19	128	128	O	,
20	130	139	U-UNK	etravirine
21	140	140	O	,
22	142	152	U-UNK	fluconazole
23	153	153	O	,
24	155	165	U-UNK	fluvastatin
25	166	166	O	,
26	168	178	U-UNK	fluvoxamine
27	179	179	O	,
28	181	193	U-UNK	metronidazole
29	194	194	O	,
30	196	205	U-UNK	miconazole
31	206	206	O	,
32	208	218	U-UNK	oxandrolone
33	219	219	O	,
34	221	234	U-UNK	sulfinpyrazone
35	235	235	O	,
36	237	247	U-UNK	tigecycline
37	248	248	O	,
38	250	261	U-UNK	voriconazole
39	262	262	O	,
40	264	274	B-UNK	zafirlukast
41	276	285	L-UNK	aprepitant
42	286	286	O	,
43	288	295	U-UNK	bosentan
44	296	296	O	,
45	298	310	U-UNK	carbamazepine
46	311	311	O	,
47	313	325	U-UNK	phenobarbital
48	326	326	O	,
49	328	335	U-UNK	rifampin
50	337	342	O	CYP1A2
51	344	352	U-UNK	acyclovir
52	353	353	O	,
53	355	365	U-UNK	allopurinol
54	366	366	O	,
55	368	375	U-UNK	caffeine
56	376	376	O	,
57	378	387	U-UNK	cimetidine
58	388	388	O	,
59	390	402	U-UNK	ciprofloxacin
60	403	403	O	,
61	405	414	U-UNK	disulfiram
62	415	415	O	,
63	417	424	U-UNK	enoxacin
64	425	425	O	,
65	427	436	U-UNK	famotidine
66	437	437	O	,
67	439	449	O	fluvoxamine
68	450	450	O	,
69	452	462	U-UNK	methoxsalen
70	463	463	O	,
71	465	474	U-UNK	mexiletine
72	475	475	O	,
73	477	487	U-UNK	norfloxacin
74	488	488	O	,
75	490	493	B-UNK	oral
76	495	508	L-UNK	contraceptives
77	509	509	O	,
78	511	529	U-UNK	phenylpropanolamine
79	530	530	O	,
80	532	542	U-UNK	propafenone
81	543	543	O	,
82	545	555	U-UNK	propranolol
83	556	556	O	,
84	558	568	U-UNK	terbinafine
85	569	569	O	,
86	571	583	U-UNK	thiabendazole
87	584	584	O	,
88	586	596	U-UNK	ticlopidine
89	597	597	O	,
90	599	607	U-UNK	verapamil
91	608	608	O	,
92	610	617	B-UNK	zileuton
93	619	629	L-UNK	montelukast
94	630	630	O	,
95	632	641	U-UNK	moricizine
96	642	642	O	,
97	644	653	U-UNK	omeprazole
98	654	654	O	,
99	656	668	O	phenobarbital
100	669	669	O	,
101	671	679	U-UNK	phenytoin
102	680	680	O	,
103	682	690	B-UNK	cigarette
104	692	698	L-UNK	smoking
105	700	705	O	CYP3A4
106	707	716	U-UNK	alprazolam
107	717	717	O	,
108	719	728	O	amiodarone
109	729	729	O	,
110	731	740	U-UNK	amlodipine
111	741	741	O	,
112	743	752	U-UNK	amprenavir
113	753	753	O	,
114	755	764	O	aprepitant
115	765	765	O	,
116	767	778	U-UNK	atorvastatin
117	779	779	O	,
118	781	790	U-UNK	atazanavir
119	791	791	O	,
120	793	804	U-UNK	bicalutamide
121	805	805	O	,
122	807	816	U-UNK	cilostazol
123	817	817	O	,
124	819	828	O	cimetidine
125	829	829	O	,
126	831	843	O	ciprofloxacin
127	844	844	O	,
128	846	859	U-UNK	clarithromycin
129	860	860	O	,
130	862	871	U-UNK	conivaptan
131	872	872	O	,
132	874	885	U-UNK	cyclosporine
133	886	886	O	,
134	888	896	B-UNK	darunavir
135	897	897	I-UNK	/
136	898	906	L-UNK	ritonavir
137	907	907	O	,
138	909	917	U-UNK	diltiazem
139	918	918	O	,
140	920	931	U-UNK	erythromycin
141	932	932	O	,
142	934	944	O	fluconazole
143	945	945	O	,
144	947	956	U-UNK	fluoxetine
145	957	957	O	,
146	959	969	O	fluvoxamine
147	970	970	O	,
148	972	984	U-UNK	fosamprenavir
149	985	985	O	,
150	987	994	U-UNK	imatinib
151	995	995	O	,
152	997	1005	U-UNK	indinavir
153	1006	1006	O	,
154	1008	1016	U-UNK	isoniazid
155	1017	1017	O	,
156	1019	1030	U-UNK	itraconazole
157	1031	1031	O	,
158	1033	1044	U-UNK	ketoconazole
159	1045	1045	O	,
160	1047	1055	U-UNK	lopinavir
161	1056	1056	B-UNK	/
162	1057	1065	L-UNK	ritonavir
163	1066	1066	O	,
164	1068	1077	U-UNK	nefazodone
165	1078	1078	O	,
166	1080	1089	U-UNK	nelfinavir
167	1090	1090	O	,
168	1092	1100	U-UNK	nilotinib
169	1101	1101	O	,
170	1103	1106	O	oral
171	1108	1121	O	contraceptives
172	1122	1122	O	,
173	1124	1135	U-UNK	posaconazole
174	1136	1136	O	,
175	1138	1147	U-UNK	ranitidine
176	1148	1148	O	,
177	1150	1159	U-UNK	ranolazine
178	1160	1160	O	,
179	1162	1170	O	ritonavir
180	1171	1171	O	,
181	1173	1182	U-UNK	saquinavir
182	1183	1183	O	,
183	1185	1197	U-UNK	telithromycin
184	1198	1198	O	,
185	1200	1209	U-UNK	tipranavir
186	1210	1210	O	,
187	1212	1223	O	voriconazole
188	1224	1224	O	,
189	1226	1233	B-UNK	zileuton
190	1235	1245	L-UNK	armodafinil
191	1246	1246	O	,
192	1248	1257	O	amprenavir
193	1258	1258	O	,
194	1260	1269	O	aprepitant
195	1270	1270	O	,
196	1272	1279	O	bosentan
197	1280	1280	O	,
198	1282	1294	O	carbamazepine
199	1295	1295	O	,
200	1297	1305	U-UNK	efavirenz
201	1306	1306	O	,
202	1308	1317	O	etravirine
203	1318	1318	O	,
204	1320	1328	O	modafinil
205	1329	1329	O	,
206	1331	1339	U-UNK	nafcillin
207	1340	1340	O	,
208	1342	1350	O	phenytoin
209	1351	1351	O	,
210	1353	1364	U-UNK	pioglitazone
211	1365	1365	O	,
212	1367	1376	U-UNK	prednisone
213	1377	1377	O	,
214	1379	1386	O	rifampin
215	1387	1387	O	,
216	1389	1398	U-UNK	rufinamide
217	1400	1407	O	Examples
218	1409	1410	O	of
219	1412	1416	O	drugs
220	1418	1422	O	known
221	1424	1425	O	to
222	1427	1434	O	increase
223	1436	1438	O	the
224	1440	1443	O	risk
225	1445	1446	O	of
226	1448	1455	O	bleeding
227	1457	1459	O	are
228	1461	1469	O	presented
229	1471	1472	O	in
230	1474	1478	O	Table
231	1480	1480	O	3
NULL

COUMADIN	2038	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	23
Because bleeding risk is increased when these drugs are used concomitantly with warfarin, closely monitor patients receiving any such drug with warfarin.
1	0	6	O	Because
2	8	15	O	bleeding
3	17	20	O	risk
4	22	23	O	is
5	25	33	O	increased
6	35	38	O	when
7	40	44	O	these
8	46	50	O	drugs
9	52	54	O	are
10	56	59	O	used
11	61	73	O	concomitantly
12	75	78	O	with
13	80	87	O	XXXXXXXX
14	88	88	O	,
15	90	96	O	closely
16	98	104	O	monitor
17	106	113	O	patients
18	115	123	O	receiving
19	125	127	O	any
20	129	132	O	such
21	134	137	O	drug
22	139	142	O	with
23	144	151	O	XXXXXXXX
NULL

COUMADIN	2039	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	128
Table 3: Drugs that Can Increase the Risk of Bleeding Drug Class Specific Drugs Anticoagulants argatroban, dabigatran, bivalirudin, desirudin, heparin, lepirudin Antiplatelet Agents aspirin, cilostazol, clopidogrel, dipyridamole, prasugrel, ticlopidine Nonsteroidal Anti-Inflammatory Agents celecoxib, diclofenac, diflunisal, fenoprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, mefenamic acid, naproxen, oxaprozin, piroxicam, sulindac Serotonin Reuptake Inhibitors citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, paroxetine, sertraline, venlafaxine, vilazodone There have been reports of changes in INR in patients taking warfarin and antibiotics or antifungals, but clinical pharmacokinetic studies have not shown consistent effects of these agents on plasma concentrations of warfarin.
1	0	4	O	Table
2	6	6	O	3
3	7	7	O	:
4	9	13	O	Drugs
5	15	18	O	that
6	20	22	O	Can
7	24	31	O	Increase
8	33	35	O	the
9	37	40	O	Risk
10	42	43	O	of
11	45	52	U-EFF	Bleeding
12	54	57	O	Drug
13	59	63	O	Class
14	65	72	O	Specific
15	74	78	O	Drugs
16	80	93	U-DYN	GGGGGGGG
17	95	104	U-DYN	argatroban
18	105	105	O	,
19	107	116	U-DYN	dabigatran
20	117	117	O	,
21	119	129	U-DYN	bivalirudin
22	130	130	O	,
23	132	140	U-DYN	desirudin
24	141	141	O	,
25	143	149	U-DYN	heparin
26	150	150	O	,
27	152	160	U-DYN	lepirudin
28	162	173	B-DYN	Antiplatelet
29	175	180	L-DYN	Agents
30	182	188	U-DYN	aspirin
31	189	189	O	,
32	191	200	U-DYN	cilostazol
33	201	201	O	,
34	203	213	U-DYN	clopidogrel
35	214	214	O	,
36	216	227	U-DYN	dipyridamole
37	228	228	O	,
38	230	238	U-DYN	prasugrel
39	239	239	O	,
40	241	251	U-DYN	ticlopidine
41	253	264	B-DYN	Nonsteroidal
42	266	269	I-DYN	Anti
43	271	282	I-DYN	Inflammatory
44	284	289	L-DYN	Agents
45	291	299	U-DYN	celecoxib
46	300	300	O	,
47	302	311	U-DYN	diclofenac
48	312	312	O	,
49	314	323	U-DYN	diflunisal
50	324	324	O	,
51	326	335	U-DYN	fenoprofen
52	336	336	O	,
53	338	346	U-DYN	ibuprofen
54	347	347	O	,
55	349	360	U-DYN	indomethacin
56	361	361	O	,
57	363	372	U-DYN	ketoprofen
58	373	373	O	,
59	375	383	U-DYN	ketorolac
60	384	384	O	,
61	386	394	B-DYN	mefenamic
62	396	399	L-DYN	acid
63	400	400	O	,
64	402	409	U-DYN	naproxen
65	410	410	O	,
66	412	420	U-DYN	oxaprozin
67	421	421	O	,
68	423	431	U-DYN	piroxicam
69	432	432	O	,
70	434	441	U-DYN	sulindac
71	443	451	B-DYN	Serotonin
72	453	460	I-DYN	Reuptake
73	462	471	L-DYN	Inhibitors
74	473	482	U-DYN	citalopram
75	483	483	O	,
76	485	498	U-DYN	desvenlafaxine
77	499	499	O	,
78	501	510	U-DYN	duloxetine
79	511	511	O	,
80	513	524	U-DYN	escitalopram
81	525	525	O	,
82	527	536	U-DYN	fluoxetine
83	537	537	O	,
84	539	549	U-DYN	fluvoxamine
85	550	550	O	,
86	552	562	U-DYN	milnacipran
87	563	563	O	,
88	565	574	U-DYN	paroxetine
89	575	575	O	,
90	577	586	U-DYN	sertraline
91	587	587	O	,
92	589	599	O	venlafaxine
93	600	600	O	,
94	602	611	U-DYN	vilazodone
95	613	617	O	There
96	619	622	O	have
97	624	627	O	been
98	629	635	O	reports
99	637	638	O	of
100	640	646	B-EFF	changes
101	648	649	I-EFF	in
102	651	653	L-EFF	INR
103	655	656	O	in
104	658	665	O	patients
105	667	672	O	taking
106	674	681	O	XXXXXXXX
107	683	685	O	and
108	687	697	U-DYN	antibiotics
109	699	700	O	or
110	702	712	U-DYN	antifungals
111	713	713	O	,
112	715	717	O	but
113	719	726	O	clinical
114	728	742	O	pharmacokinetic
115	744	750	O	studies
116	752	755	O	have
117	757	759	O	not
118	761	765	O	shown
119	767	776	O	consistent
120	778	784	O	effects
121	786	787	O	of
122	789	793	O	these
123	795	800	O	agents
124	802	803	O	on
125	805	810	O	plasma
126	812	825	O	concentrations
127	827	828	O	of
128	830	837	O	XXXXXXXX
D/108:100:1 D/108:11:0 D/110:100:1 D/110:11:0 D/16:100:0 D/16:11:1 D/17:100:0 D/17:11:1 D/19:100:0 D/19:11:1 D/21:100:0 D/21:11:1 D/23:100:0 D/23:11:1 D/25:100:0 D/25:11:1 D/27:100:0 D/27:11:1 D/28:100:0 D/28:11:1 D/30:100:0 D/30:11:1 D/32:100:0 D/32:11:1 D/34:100:0 D/34:11:1 D/36:100:0 D/36:11:1 D/38:100:0 D/38:11:1 D/40:100:0 D/40:11:1 D/41:100:0 D/41:11:1 D/45:100:0 D/45:11:1 D/47:100:0 D/47:11:1 D/49:100:0 D/49:11:1 D/51:100:0 D/51:11:1 D/53:100:0 D/53:11:1 D/55:100:0 D/55:11:1 D/57:100:0 D/57:11:1 D/59:100:0 D/59:11:1 D/61:100:0 D/61:11:1 D/64:100:0 D/64:11:1 D/66:100:0 D/66:11:1 D/68:100:0 D/68:11:1 D/70:100:0 D/70:11:1 D/71:100:0 D/71:11:1 D/74:100:0 D/74:11:1 D/76:100:0 D/76:11:1 D/78:100:0 D/78:11:1 D/80:100:0 D/80:11:1 D/82:100:0 D/82:11:1 D/84:100:0 D/84:11:1 D/86:100:0 D/86:11:1 D/88:100:0 D/88:11:1 D/90:100:0 D/90:11:1 D/94:100:0 D/94:11:1

COUMADIN	2040	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	15
Closely monitor INR when starting or stopping any antibiotic or antifungal in patients taking warfarin.
1	0	6	B-TRI	Closely
2	8	14	L-TRI	monitor
3	16	18	O	INR
4	20	23	O	when
5	25	32	O	starting
6	34	35	O	or
7	37	44	O	stopping
8	46	48	O	any
9	50	59	U-UNK	antibiotic
10	61	62	O	or
11	64	73	U-UNK	antifungal
12	75	76	O	in
13	78	85	O	patients
14	87	92	O	taking
15	94	101	O	XXXXXXXX
NULL

COUMADIN	2041	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	12
More frequent INR monitoring should be performed when starting or stopping botanicals.
1	0	3	O	More
2	5	12	O	frequent
3	14	16	O	INR
4	18	27	U-TRI	monitoring
5	29	34	O	should
6	36	37	O	be
7	39	47	O	performed
8	49	52	O	when
9	54	61	O	starting
10	63	64	O	or
11	66	73	O	stopping
12	75	84	U-UNK	botanicals
NULL

COUMADIN	2042	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	21
Few adequate, well-controlled studies evaluating the potential for metabolic and/or pharmacologic interactions between botanicals and COUMADIN exist.
1	0	2	O	Few
2	4	11	O	adequate
3	12	12	O	,
4	14	17	O	well
5	19	28	O	controlled
6	30	36	O	studies
7	38	47	O	evaluating
8	49	51	O	the
9	53	61	O	potential
10	63	65	O	for
11	67	75	O	metabolic
12	77	79	O	and
13	80	80	O	/
14	81	82	O	or
15	84	96	O	pharmacologic
16	98	109	O	interactions
17	111	117	O	between
18	119	128	O	botanicals
19	130	132	O	and
20	134	141	O	XXXXXXXX
21	143	147	O	exist
NULL

COUMADIN	2043	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Due to a lack of manufacturing standardization with botanical medicinal preparations, the amount of active ingredients may vary.
1	0	2	O	Due
2	4	5	O	to
3	7	7	O	a
4	9	12	O	lack
5	14	15	O	of
6	17	29	O	manufacturing
7	31	45	O	standardization
8	47	50	O	with
9	52	60	O	botanical
10	62	70	O	medicinal
11	72	83	O	preparations
12	84	84	O	,
13	86	88	O	the
14	90	95	O	amount
15	97	98	O	of
16	100	105	O	active
17	107	117	O	ingredients
18	119	121	O	may
19	123	126	O	vary
NULL

COUMADIN	2044	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	14
This could further confound the ability to assess potential interactions and effects on anticoagulation.
1	0	3	O	This
2	5	9	O	could
3	11	17	O	further
4	19	26	O	confound
5	28	30	O	the
6	32	38	O	ability
7	40	41	O	to
8	43	48	O	assess
9	50	58	O	potential
10	60	71	O	interactions
11	73	75	O	and
12	77	83	O	effects
13	85	86	O	on
14	88	102	O	anticoagulation
NULL

COUMADIN	2045	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	27
Some botanicals may cause bleeding events when taken alone (e.g., garlic and Ginkgo biloba) and may have anticoagulant, antiplatelet, and/or fibrinolytic properties.
1	0	3	O	Some
2	5	14	O	botanicals
3	16	18	O	may
4	20	24	O	cause
5	26	33	O	bleeding
6	35	40	O	events
7	42	45	O	when
8	47	51	O	taken
9	53	57	O	alone
10	60	62	O	e.g
11	64	64	O	,
12	66	71	O	garlic
13	73	75	O	and
14	77	82	O	Ginkgo
15	84	89	O	biloba
16	92	94	O	and
17	96	98	O	may
18	100	103	O	have
19	105	117	O	anticoagulant
20	118	118	O	,
21	120	131	O	antiplatelet
22	132	132	O	,
23	134	136	O	and
24	137	137	O	/
25	138	139	O	or
26	141	152	O	fibrinolytic
27	154	163	O	properties
NULL

COUMADIN	2046	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	14
These effects would be expected to be additive to the anticoagulant effects of COUMADIN.
1	0	4	O	These
2	6	12	O	effects
3	14	18	O	would
4	20	21	O	be
5	23	30	O	expected
6	32	33	O	to
7	35	36	O	be
8	38	45	O	additive
9	47	48	O	to
10	50	52	O	the
11	54	66	O	anticoagulant
12	68	74	O	effects
13	76	77	O	of
14	79	86	O	XXXXXXXX
NULL

COUMADIN	2047	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	21
Conversely, some botanicals may decrease the effects of COUMADIN (e.g., co-enzyme Q10, St. John's wort, ginseng).
1	0	9	O	Conversely
2	10	10	O	,
3	12	15	O	some
4	17	26	U-DYN	botanicals
5	28	30	O	may
6	32	39	B-EFF	decrease
7	41	43	I-EFF	the
8	45	51	I-EFF	effects
9	53	54	I-EFF	of
10	56	63	L-EFF	XXXXXXXX
11	66	68	O	e.g
12	70	70	O	,
13	72	73	B-DYN	co
14	75	80	I-DYN	enzyme
15	82	84	L-DYN	Q10
16	85	85	O	,
17	87	88	B-DYN	St
18	91	96	I-DYN	John's
19	98	101	L-DYN	wort
20	102	102	O	,
21	104	110	U-DYN	ginseng
D/13:6:1 D/17:6:1 D/21:6:1 D/4:6:1

COUMADIN	2048	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	25
Some botanicals and foods can interact with COUMADIN through CYP450 interactions (e.g., echinacea, grapefruit juice, ginkgo, goldenseal, St. John's wort).
1	0	3	O	Some
2	5	14	U-UNK	botanicals
3	16	18	O	and
4	20	24	U-UNK	foods
5	26	28	O	can
6	30	37	B-TRI	interact
7	39	42	L-TRI	with
8	44	51	O	XXXXXXXX
9	53	59	O	through
10	61	66	O	CYP450
11	68	79	O	interactions
12	82	84	O	e.g
13	86	86	O	,
14	88	96	U-UNK	echinacea
15	97	97	O	,
16	99	108	B-UNK	grapefruit
17	110	114	L-UNK	juice
18	115	115	O	,
19	117	122	U-UNK	ginkgo
20	123	123	O	,
21	125	134	U-UNK	goldenseal
22	135	135	O	,
23	137	138	B-UNK	St
24	141	146	I-UNK	John's
25	148	151	L-UNK	wort
NULL

COUMADIN	2049	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	12
The amount of vitamin K in food may affect therapy with COUMADIN.
1	0	2	O	The
2	4	9	O	amount
3	11	12	O	of
4	14	20	B-DYN	vitamin
5	22	22	L-DYN	K
6	24	25	O	in
7	27	30	O	food
8	32	34	O	may
9	36	41	B-EFF	affect
10	43	49	I-EFF	therapy
11	51	54	I-EFF	with
12	56	63	L-EFF	XXXXXXXX
D/4:9:1

COUMADIN	2050	34073-7	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	38
Advise patients taking COUMADIN to eat a normal, balanced diet maintaining a consistent amount of vitamin K. Patients taking COUMADIN should avoid drastic changes in dietary habits, such as eating large amounts of green leafy vegetables.
1	0	5	U-TRI	Advise
2	7	14	O	patients
3	16	21	O	taking
4	23	30	O	XXXXXXXX
5	32	33	O	to
6	35	37	O	eat
7	39	39	O	a
8	41	46	O	normal
9	47	47	O	,
10	49	56	O	balanced
11	58	61	O	diet
12	63	73	O	maintaining
13	75	75	O	a
14	77	86	O	consistent
15	88	93	O	amount
16	95	96	O	of
17	98	104	B-UNK	vitamin
18	106	106	L-UNK	K
19	109	116	O	Patients
20	118	123	O	taking
21	125	132	O	XXXXXXXX
22	134	139	O	should
23	141	145	U-TRI	avoid
24	147	153	O	drastic
25	155	161	O	changes
26	163	164	O	in
27	166	172	O	dietary
28	174	179	O	habits
29	180	180	O	,
30	182	185	O	such
31	187	188	O	as
32	190	195	O	eating
33	197	201	O	large
34	203	209	O	amounts
35	211	212	O	of
36	214	218	B-UNK	green
37	220	224	I-UNK	leafy
38	226	235	L-UNK	vegetables
NULL

COUMADIN	2051	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	50
Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors, which include Factors II, VII, IX, and X, and the anticoagulant proteins C and S. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K-dependent clotting factors.
1	0	7	O	XXXXXXXX
2	9	12	O	acts
3	14	15	O	by
4	17	26	O	inhibiting
5	28	30	O	the
6	32	40	O	synthesis
7	42	43	O	of
8	45	51	O	vitamin
9	53	53	O	K
10	55	63	O	dependent
11	65	72	O	clotting
12	74	80	O	factors
13	81	81	O	,
14	83	87	O	which
15	89	95	O	include
16	97	103	O	Factors
17	105	106	O	II
18	107	107	O	,
19	109	111	O	VII
20	112	112	O	,
21	114	115	O	IX
22	116	116	O	,
23	118	120	O	and
24	122	122	O	XXXXXXXX
25	123	123	O	,
26	125	127	O	and
27	129	131	O	the
28	133	145	O	anticoagulant
29	147	154	O	proteins
30	156	156	O	C
31	158	160	O	and
32	162	162	O	S
33	165	171	O	Vitamin
34	173	173	O	K
35	175	176	O	is
36	178	179	O	an
37	181	189	O	essential
38	191	198	O	cofactor
39	200	202	O	for
40	204	206	O	the
41	208	211	O	post
42	213	221	O	ribosomal
43	223	231	O	synthesis
44	233	234	O	of
45	236	238	O	the
46	240	246	O	vitamin
47	248	248	O	K
48	250	258	O	dependent
49	260	267	O	clotting
50	269	275	O	factors
NULL

COUMADIN	2052	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Vitamin K promotes the biosynthesis of G-carboxyglutamic acid residues in the proteins that are essential for biological activity.
1	0	6	O	Vitamin
2	8	8	O	K
3	10	17	O	promotes
4	19	21	O	the
5	23	34	O	biosynthesis
6	36	37	O	of
7	39	39	O	GGGGGGGG
8	41	55	O	carboxyglutamic
9	57	60	O	acid
10	62	69	O	residues
11	71	72	O	in
12	74	76	O	the
13	78	85	O	proteins
14	87	90	O	that
15	92	94	O	are
16	96	104	O	essential
17	106	108	O	for
18	110	119	O	biological
19	121	128	O	activity
NULL

COUMADIN	2053	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	32
Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	18	O	thought
4	20	21	O	to
5	23	31	O	interfere
6	33	36	O	with
7	38	45	O	clotting
8	47	52	O	factor
9	54	62	O	synthesis
10	64	65	O	by
11	67	76	O	inhibition
12	78	79	O	of
13	81	83	O	the
14	85	86	O	C1
15	88	94	O	subunit
16	96	97	O	of
17	99	105	O	vitamin
18	107	107	O	K
19	109	115	O	epoxide
20	117	125	O	reductase
21	128	133	O	VKORC1
22	136	141	O	enzyme
23	143	149	O	complex
24	150	150	O	,
25	152	158	O	thereby
26	160	167	O	reducing
27	169	171	O	the
28	173	184	O	regeneration
29	186	187	O	of
30	189	195	O	vitamin
31	197	198	O	K1
32	200	206	O	epoxide
NULL

COUMADIN	2054	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	11
An anticoagulation effect generally occurs within 24 hours after warfarin administration.
1	0	1	O	An
2	3	17	O	anticoagulation
3	19	24	O	effect
4	26	34	O	generally
5	36	41	O	occurs
6	43	48	O	within
7	50	51	O	24
8	53	57	O	hours
9	59	63	O	after
10	65	72	O	XXXXXXXX
11	74	87	O	administration
NULL

COUMADIN	2055	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	12
However, peak anticoagulant effect may be delayed 72 to 96 hours.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	peak
4	14	26	O	anticoagulant
5	28	33	O	effect
6	35	37	O	may
7	39	40	O	be
8	42	48	O	delayed
9	50	51	O	72
10	53	54	O	to
11	56	57	O	96
12	59	63	O	hours
NULL

COUMADIN	2056	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	16
The duration of action of a single dose of racemic warfarin is 2 to 5 days.
1	0	2	O	The
2	4	11	O	duration
3	13	14	O	of
4	16	21	O	action
5	23	24	O	of
6	26	26	O	a
7	28	33	O	single
8	35	38	O	dose
9	40	41	O	of
10	43	49	O	racemic
11	51	58	O	XXXXXXXX
12	60	61	O	is
13	63	63	O	2
14	65	66	O	to
15	68	68	O	5
16	70	73	O	days
NULL

COUMADIN	2057	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	15
The effects of COUMADIN may become more pronounced as effects of daily maintenance doses overlap.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	22	O	XXXXXXXX
5	24	26	O	may
6	28	33	O	become
7	35	38	O	more
8	40	49	O	pronounced
9	51	52	O	as
10	54	60	O	effects
11	62	63	O	of
12	65	69	O	daily
13	71	81	O	maintenance
14	83	87	O	doses
15	89	95	O	overlap
NULL

COUMADIN	2058	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	54
This is consistent with the half-lives of the affected vitamin K-dependent clotting factors and anticoagulation proteins: Factor II - 60 hours, VII - 4 to 6 hours, IX - 24 hours, X - 48 to 72 hours, and proteins C and S are approximately 8 hours and 30 hours, respectively.
1	0	3	O	This
2	5	6	O	is
3	8	17	O	consistent
4	19	22	O	with
5	24	26	O	the
6	28	31	O	half
7	33	37	O	lives
8	39	40	O	of
9	42	44	O	the
10	46	53	O	affected
11	55	61	O	vitamin
12	63	63	O	K
13	65	73	O	dependent
14	75	82	O	clotting
15	84	90	O	factors
16	92	94	O	and
17	96	110	O	anticoagulation
18	112	119	O	proteins
19	120	120	O	:
20	122	127	O	Factor
21	129	130	O	II
22	134	135	O	60
23	137	141	O	hours
24	142	142	O	,
25	144	146	O	VII
26	150	150	O	4
27	152	153	O	to
28	155	155	O	6
29	157	161	O	hours
30	162	162	O	,
31	164	165	O	IX
32	169	170	O	24
33	172	176	O	hours
34	177	177	O	,
35	179	179	O	XXXXXXXX
36	183	184	O	48
37	186	187	O	to
38	189	190	O	72
39	192	196	O	hours
40	197	197	O	,
41	199	201	O	and
42	203	210	O	proteins
43	212	212	O	C
44	214	216	O	and
45	218	218	O	S
46	220	222	O	are
47	224	236	O	approximately
48	238	238	O	8
49	240	244	O	hours
50	246	248	O	and
51	250	251	O	30
52	253	257	O	hours
53	258	258	O	,
54	260	271	O	respectively
NULL

COUMADIN	2059	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	13
COUMADIN is a racemic mixture of the R- and S-enantiomers of warfarin.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	12	O	a
4	14	20	O	racemic
5	22	28	O	mixture
6	30	31	O	of
7	33	35	O	the
8	37	37	O	R
9	40	42	O	and
10	44	44	O	S
11	46	56	O	enantiomers
12	58	59	O	of
13	61	68	O	XXXXXXXX
NULL

COUMADIN	2060	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	25
The S-enantiomer exhibits 2 to 5 times more anticoagulant activity than the R-enantiomer in humans, but generally has a more rapid clearance.
1	0	2	O	The
2	4	4	O	S
3	6	15	O	enantiomer
4	17	24	O	exhibits
5	26	26	O	2
6	28	29	O	to
7	31	31	O	5
8	33	37	O	times
9	39	42	O	more
10	44	56	O	anticoagulant
11	58	65	O	activity
12	67	70	O	than
13	72	74	O	the
14	76	76	O	R
15	78	87	O	enantiomer
16	89	90	O	in
17	92	97	O	humans
18	98	98	O	,
19	100	102	O	but
20	104	112	O	generally
21	114	116	O	has
22	118	118	O	a
23	120	123	O	more
24	125	129	O	rapid
25	131	139	O	clearance
NULL

COUMADIN	2061	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Warfarin is essentially completely absorbed after oral administration, with peak concentration generally attained within the first 4 hours.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	essentially
4	24	33	O	completely
5	35	42	O	absorbed
6	44	48	O	after
7	50	53	O	oral
8	55	68	O	administration
9	69	69	O	,
10	71	74	O	with
11	76	79	O	peak
12	81	93	O	concentration
13	95	103	O	generally
14	105	112	O	attained
15	114	119	O	within
16	121	123	O	the
17	125	129	O	first
18	131	131	O	4
19	133	137	O	hours
NULL

COUMADIN	2062	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	12
Warfarin shows a volume of distribution of about 0.14 L/kg.
1	0	7	O	XXXXXXXX
2	9	13	O	shows
3	15	15	O	a
4	17	22	O	volume
5	24	25	O	of
6	27	38	O	distribution
7	40	41	O	of
8	43	47	O	about
9	49	52	O	0.14
10	54	54	O	L
11	55	55	O	/
12	56	57	O	kg
NULL

COUMADIN	2063	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	10
Approximately 99% of the drug is bound to plasma proteins.
1	0	12	O	Approximately
2	14	16	O	99%
3	18	19	O	of
4	21	23	O	the
5	25	28	O	drug
6	30	31	O	is
7	33	37	O	bound
8	39	40	O	to
9	42	47	O	plasma
10	49	56	O	proteins
NULL

COUMADIN	2064	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	9
The elimination of warfarin is almost entirely by metabolism.
1	0	2	O	The
2	4	14	O	elimination
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	29	O	is
6	31	36	O	almost
7	38	45	O	entirely
8	47	48	O	by
9	50	59	O	metabolism
NULL

COUMADIN	2065	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	30
Warfarin is stereoselectively metabolized by hepatic cytochrome P-450 (CYP450) microsomal enzymes to inactive hydroxylated metabolites (predominant route) and by reductases to reduced metabolites (warfarin alcohols) with minimal anticoagulant activity.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	28	O	stereoselectively
4	30	40	O	metabolized
5	42	43	O	by
6	45	51	O	hepatic
7	53	62	O	cytochrome
8	64	64	O	P
9	66	68	O	450
10	71	76	O	CYP450
11	79	88	O	microsomal
12	90	96	O	enzymes
13	98	99	O	to
14	101	108	O	inactive
15	110	121	O	hydroxylated
16	123	133	O	metabolites
17	136	146	O	predominant
18	148	152	O	route
19	155	157	O	and
20	159	160	O	by
21	162	171	O	reductases
22	173	174	O	to
23	176	182	O	reduced
24	184	194	O	metabolites
25	197	204	O	XXXXXXXX
26	206	213	O	alcohols
27	216	219	O	with
28	221	227	O	minimal
29	229	241	O	anticoagulant
30	243	250	O	activity
NULL

COUMADIN	2066	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	25
Identified metabolites of warfarin include dehydrowarfarin, two diastereoisomer alcohols, and 4'-, 6-, 7-, 8-, and 10-hydroxywarfarin.
1	0	9	O	Identified
2	11	21	O	metabolites
3	23	24	O	of
4	26	33	O	XXXXXXXX
5	35	41	O	include
6	43	49	O	dehydro
7	50	57	O	XXXXXXXX
8	58	58	O	,
9	60	62	O	two
10	64	78	O	diastereoisomer
11	80	87	O	alcohols
12	88	88	O	,
13	90	92	O	and
14	94	95	O	4'
15	97	97	O	,
16	99	99	O	6
17	101	101	O	,
18	103	103	O	7
19	105	105	O	,
20	107	107	O	8
21	109	109	O	,
22	111	113	O	and
23	115	116	O	10
24	118	124	O	hydroxy
25	125	132	O	XXXXXXXX
NULL

COUMADIN	2067	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	22
The CYP450 isozymes involved in the metabolism of warfarin include CYP2C9, 2C19, 2C8, 2C18, 1A2, and 3A4.
1	0	2	O	The
2	4	9	O	CYP450
3	11	18	O	isozymes
4	20	27	O	involved
5	29	30	O	in
6	32	34	O	the
7	36	45	O	metabolism
8	47	48	O	of
9	50	57	O	XXXXXXXX
10	59	65	O	include
11	67	72	O	CYP2C9
12	73	73	O	,
13	75	78	O	2C19
14	79	79	O	,
15	81	83	O	2C8
16	84	84	O	,
17	86	89	O	2C18
18	90	90	O	,
19	92	94	O	1A2
20	95	95	O	,
21	97	99	O	and
22	101	103	O	3A4
NULL

COUMADIN	2068	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	26
CYP2C9, a polymorphic enzyme, is likely to be the principal form of human liver CYP450 that modulates the in vivo anticoagulant activity of warfarin.
1	0	5	O	CYP2C9
2	6	6	O	,
3	8	8	O	a
4	10	20	O	polymorphic
5	22	27	O	enzyme
6	28	28	O	,
7	30	31	O	is
8	33	38	O	likely
9	40	41	O	to
10	43	44	O	be
11	46	48	O	the
12	50	58	O	principal
13	60	63	O	form
14	65	66	O	of
15	68	72	O	human
16	74	78	O	liver
17	80	85	O	CYP450
18	87	90	O	that
19	92	100	O	modulates
20	102	104	O	the
21	106	107	O	in
22	109	112	O	vivo
23	114	126	O	anticoagulant
24	128	135	O	activity
25	137	138	O	of
26	140	147	O	XXXXXXXX
NULL

COUMADIN	2069	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	13
Patients with one or more variant CYP2C9 alleles have decreased S-warfarin clearance.
1	0	7	O	Patients
2	9	12	O	with
3	14	16	O	one
4	18	19	O	or
5	21	24	O	more
6	26	32	O	variant
7	34	39	O	CYP2C9
8	41	47	O	alleles
9	49	52	O	have
10	54	62	O	decreased
11	64	64	O	S
12	66	73	O	XXXXXXXX
13	75	83	O	clearance
NULL

COUMADIN	2070	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	34
The terminal half-life of warfarin after a single dose is approximately 1 week; however, the effective half-life ranges from 20 to 60 hours, with a mean of about 40 hours.
1	0	2	O	The
2	4	11	O	terminal
3	13	16	O	half
4	18	21	O	life
5	23	24	O	of
6	26	33	O	XXXXXXXX
7	35	39	O	after
8	41	41	O	a
9	43	48	O	single
10	50	53	O	dose
11	55	56	O	is
12	58	70	O	approximately
13	72	72	O	1
14	74	77	O	week
15	80	86	O	however
16	87	87	O	,
17	89	91	O	the
18	93	101	O	effective
19	103	106	O	half
20	108	111	O	life
21	113	118	O	ranges
22	120	123	O	from
23	125	126	O	20
24	128	129	O	to
25	131	132	O	60
26	134	138	O	hours
27	139	139	O	,
28	141	144	O	with
29	146	146	O	a
30	148	151	O	mean
31	153	154	O	of
32	156	160	O	about
33	162	163	O	40
34	165	169	O	hours
NULL

COUMADIN	2071	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	35
The clearance of R-warfarin is generally half that of S-warfarin, thus as the volumes of distribution are similar, the half-life of R-warfarin is longer than that of S-warfarin.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	of
4	17	17	O	R
5	19	26	O	XXXXXXXX
6	28	29	O	is
7	31	39	O	generally
8	41	44	O	half
9	46	49	O	that
10	51	52	O	of
11	54	54	O	S
12	56	63	O	XXXXXXXX
13	64	64	O	,
14	66	69	O	thus
15	71	72	O	as
16	74	76	O	the
17	78	84	O	volumes
18	86	87	O	of
19	89	100	O	distribution
20	102	104	O	are
21	106	112	O	similar
22	113	113	O	,
23	115	117	O	the
24	119	122	O	half
25	124	127	O	life
26	129	130	O	of
27	132	132	O	R
28	134	141	O	XXXXXXXX
29	143	144	O	is
30	146	151	O	longer
31	153	156	O	than
32	158	161	O	that
33	163	164	O	of
34	166	166	O	S
35	168	175	O	XXXXXXXX
NULL

COUMADIN	2072	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	24
The half-life of R-warfarin ranges from 37 to 89 hours, while that of S-warfarin ranges from 21 to 43 hours.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	15	O	of
5	17	17	O	R
6	19	26	O	XXXXXXXX
7	28	33	O	ranges
8	35	38	O	from
9	40	41	O	37
10	43	44	O	to
11	46	47	O	89
12	49	53	O	hours
13	54	54	O	,
14	56	60	O	while
15	62	65	O	that
16	67	68	O	of
17	70	70	O	S
18	72	79	O	XXXXXXXX
19	81	86	O	ranges
20	88	91	O	from
21	93	94	O	21
22	96	97	O	to
23	99	100	O	43
24	102	106	O	hours
NULL

COUMADIN	2073	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Studies with radiolabeled drug have demonstrated that up to 92% of the orally administered dose is recovered in urine.
1	0	6	O	Studies
2	8	11	O	with
3	13	24	O	radiolabeled
4	26	29	O	drug
5	31	34	O	have
6	36	47	O	demonstrated
7	49	52	O	that
8	54	55	O	up
9	57	58	O	to
10	60	62	O	92%
11	64	65	O	of
12	67	69	O	the
13	71	76	O	orally
14	78	89	O	administered
15	91	94	O	dose
16	96	97	O	is
17	99	107	O	recovered
18	109	110	O	in
19	112	116	O	urine
NULL

COUMADIN	2074	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	8
Very little warfarin is excreted unchanged in urine.
1	0	3	O	Very
2	5	10	O	little
3	12	19	O	XXXXXXXX
4	21	22	O	is
5	24	31	O	excreted
6	33	41	O	unchanged
7	43	44	O	in
8	46	50	O	urine
NULL

COUMADIN	2075	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	8
Urinary excretion is in the form of metabolites.
1	0	6	O	Urinary
2	8	16	O	excretion
3	18	19	O	is
4	21	22	O	in
5	24	26	O	the
6	28	31	O	form
7	33	34	O	of
8	36	46	O	metabolites
NULL

COUMADIN	2076	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Patients 60 years or older appear to exhibit greater than expected INR response to the anticoagulant effects of warfarin.
1	0	7	O	Patients
2	9	10	O	60
3	12	16	O	years
4	18	19	O	or
5	21	25	O	older
6	27	32	O	appear
7	34	35	O	to
8	37	43	O	exhibit
9	45	51	O	greater
10	53	56	O	than
11	58	65	O	expected
12	67	69	O	INR
13	71	78	O	response
14	80	81	O	to
15	83	85	O	the
16	87	99	O	anticoagulant
17	101	107	O	effects
18	109	110	O	of
19	112	119	O	XXXXXXXX
NULL

COUMADIN	2077	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	30
The cause of the increased sensitivity to the anticoagulant effects of warfarin in this age group is unknown but may be due to a combination of pharmacokinetic and pharmacodynamic factors.
1	0	2	O	The
2	4	8	O	cause
3	10	11	O	of
4	13	15	O	the
5	17	25	O	increased
6	27	37	O	sensitivity
7	39	40	O	to
8	42	44	O	the
9	46	58	O	anticoagulant
10	60	66	O	effects
11	68	69	O	of
12	71	78	O	XXXXXXXX
13	80	81	O	in
14	83	86	O	this
15	88	90	O	age
16	92	96	O	group
17	98	99	O	is
18	101	107	O	unknown
19	109	111	O	but
20	113	115	O	may
21	117	118	O	be
22	120	122	O	due
23	124	125	O	to
24	127	127	O	a
25	129	139	O	combination
26	141	142	O	of
27	144	158	O	pharmacokinetic
28	160	162	O	and
29	164	178	O	pharmacodynamic
30	180	186	O	factors
NULL

COUMADIN	2078	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	35
Limited information suggests there is no difference in the clearance of S-warfarin; however, there may be a slight decrease in the clearance of R-warfarin in the elderly as compared to the young.
1	0	6	O	Limited
2	8	18	O	information
3	20	27	O	suggests
4	29	33	O	there
5	35	36	O	is
6	38	39	O	no
7	41	50	O	difference
8	52	53	O	in
9	55	57	O	the
10	59	67	O	clearance
11	69	70	O	of
12	72	72	O	S
13	74	81	O	XXXXXXXX
14	84	90	O	however
15	91	91	O	,
16	93	97	O	there
17	99	101	O	may
18	103	104	O	be
19	106	106	O	a
20	108	113	O	slight
21	115	122	O	decrease
22	124	125	O	in
23	127	129	O	the
24	131	139	O	clearance
25	141	142	O	of
26	144	144	O	R
27	146	153	O	XXXXXXXX
28	155	156	O	in
29	158	160	O	the
30	162	168	O	elderly
31	170	171	O	as
32	173	180	O	compared
33	182	183	O	to
34	185	187	O	the
35	189	193	O	young
NULL

COUMADIN	2079	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	22
Therefore, as patient age increases, a lower dose of warfarin is usually required to produce a therapeutic level of anticoagulation.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	as
4	14	20	O	patient
5	22	24	O	age
6	26	34	O	increases
7	35	35	O	,
8	37	37	O	a
9	39	43	O	lower
10	45	48	O	dose
11	50	51	O	of
12	53	60	O	XXXXXXXX
13	62	63	O	is
14	65	71	O	usually
15	73	80	O	required
16	82	83	O	to
17	85	91	O	produce
18	93	93	O	a
19	95	105	O	therapeutic
20	107	111	O	level
21	113	114	O	of
22	116	130	O	anticoagulation
NULL

COUMADIN	2080	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	11
Asian patients may require lower initiation and maintenance doses of warfarin.
1	0	4	O	Asian
2	6	13	O	patients
3	15	17	O	may
4	19	25	O	require
5	27	31	O	lower
6	33	42	O	initiation
7	44	46	O	and
8	48	58	O	maintenance
9	60	64	O	doses
10	66	67	O	of
11	69	76	O	XXXXXXXX
NULL

COUMADIN	2081	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	33
A non-controlled study of 151 Chinese outpatients stabilized on warfarin for various indications reported a mean daily warfarin requirement of 3.3 * 1.4 mg to achieve an INR of 2 to 2.5.
1	0	0	O	A
2	2	4	O	non
3	6	15	O	controlled
4	17	21	O	study
5	23	24	O	of
6	26	28	O	151
7	30	36	O	Chinese
8	38	48	O	outpatients
9	50	59	O	stabilized
10	61	62	O	on
11	64	71	O	XXXXXXXX
12	73	75	O	for
13	77	83	O	various
14	85	95	O	indications
15	97	104	O	reported
16	106	106	O	a
17	108	111	O	mean
18	113	117	O	daily
19	119	126	O	XXXXXXXX
20	128	138	O	requirement
21	140	141	O	of
22	143	145	O	3.3
23	147	147	O	*
24	149	151	O	1.4
25	153	154	O	mg
26	156	157	O	to
27	159	165	O	achieve
28	167	168	O	an
29	170	172	O	INR
30	174	175	O	of
31	177	177	O	2
32	179	180	O	to
33	182	184	O	2.5
NULL

COUMADIN	2082	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	23
Patient age was the most important determinant of warfarin requirement in these patients, with a progressively lower warfarin requirement with increasing age.
1	0	6	O	Patient
2	8	10	O	age
3	12	14	O	was
4	16	18	O	the
5	20	23	O	most
6	25	33	O	important
7	35	45	O	determinant
8	47	48	O	of
9	50	57	O	XXXXXXXX
10	59	69	O	requirement
11	71	72	O	in
12	74	78	O	these
13	80	87	O	patients
14	88	88	O	,
15	90	93	O	with
16	95	95	O	a
17	97	109	O	progressively
18	111	115	O	lower
19	117	124	O	XXXXXXXX
20	126	136	O	requirement
21	138	141	O	with
22	143	152	O	increasing
23	154	156	O	age
NULL

COUMADIN	2083	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	18
The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme.
1	0	2	O	The
2	4	4	O	S
3	6	15	O	enantiomer
4	17	18	O	of
5	20	27	O	XXXXXXXX
6	29	30	O	is
7	32	37	O	mainly
8	39	49	O	metabolized
9	51	52	O	to
10	54	54	O	7
11	56	62	O	hydroxy
12	63	70	O	XXXXXXXX
13	72	73	O	by
14	75	80	O	CYP2C9
15	81	81	O	,
16	83	83	O	a
17	85	95	O	polymorphic
18	97	102	O	enzyme
NULL

COUMADIN	2084	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	20
The variant alleles, CYP2C9*2 and CYP2C9*3, result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin.
1	0	2	O	The
2	4	10	O	variant
3	12	18	O	alleles
4	19	19	O	,
5	21	28	O	CYP2C9*2
6	30	32	O	and
7	34	41	O	CYP2C9*3
8	42	42	O	,
9	44	49	O	result
10	51	52	O	in
11	54	62	O	decreased
12	64	65	O	in
13	67	71	O	vitro
14	73	78	O	CYP2C9
15	80	88	O	enzymatic
16	90	90	O	7
17	92	104	O	hydroxylation
18	106	107	O	of
19	109	109	O	S
20	111	118	O	XXXXXXXX
NULL

COUMADIN	2085	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	18
The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively.
1	0	2	O	The
2	4	14	O	frequencies
3	16	17	O	of
4	19	23	O	these
5	25	31	O	alleles
6	33	34	O	in
7	36	45	O	Caucasians
8	47	49	O	are
9	51	63	O	approximately
10	65	67	O	11%
11	69	71	O	and
12	73	74	O	7%
13	76	78	O	for
14	80	87	O	CYP2C9*2
15	89	91	O	and
16	93	100	O	CYP2C9*3
17	101	101	O	,
18	103	114	O	respectively
NULL

COUMADIN	2086	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	36
Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9, and *11 alleles in Caucasians.
1	0	4	O	Other
2	6	11	O	CYP2C9
3	13	19	O	alleles
4	21	30	O	associated
5	32	35	O	with
6	37	43	O	reduced
7	45	53	O	enzymatic
8	55	62	O	activity
9	64	68	O	occur
10	70	71	O	at
11	73	77	O	lower
12	79	89	O	frequencies
13	90	90	O	,
14	92	100	O	including
15	102	103	O	5
16	104	104	O	,
17	106	107	O	6
18	108	108	O	,
19	110	112	O	and
20	114	116	O	11
21	118	124	O	alleles
22	126	127	O	in
23	129	139	O	populations
24	141	142	O	of
25	144	150	O	African
26	152	159	O	ancestry
27	161	163	O	and
28	165	166	O	5
29	167	167	O	,
30	169	170	O	9
31	171	171	O	,
32	173	175	O	and
33	177	179	O	11
34	181	187	O	alleles
35	189	190	O	in
36	192	201	O	Caucasians
NULL

COUMADIN	2087	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	25
Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle through inhibition of VKOR, a multiprotein enzyme complex.
1	0	7	O	XXXXXXXX
2	9	15	O	reduces
3	17	19	O	the
4	21	32	O	regeneration
5	34	35	O	of
6	37	43	O	vitamin
7	45	45	O	K
8	47	50	O	from
9	52	58	O	vitamin
10	60	60	O	K
11	62	68	O	epoxide
12	70	71	O	in
13	73	75	O	the
14	77	83	O	vitamin
15	85	85	O	K
16	87	91	O	cycle
17	93	99	O	through
18	101	110	O	inhibition
19	112	113	O	of
20	115	118	O	VKOR
21	119	119	O	,
22	121	121	O	a
23	123	134	O	multiprotein
24	136	141	O	enzyme
25	143	149	O	complex
NULL

COUMADIN	2088	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
Certain single nucleotide polymorphisms in the VKORC1 gene (e.g., -1639G>A) have been associated with variable warfarin dose requirements.
1	0	6	O	Certain
2	8	13	O	single
3	15	24	O	nucleotide
4	26	38	O	polymorphisms
5	40	41	O	in
6	43	45	O	the
7	47	52	O	VKORC1
8	54	57	O	gene
9	60	62	O	e.g
10	64	64	O	,
11	67	73	O	1639G>A
12	76	79	O	have
13	81	84	O	been
14	86	95	O	associated
15	97	100	O	with
16	102	109	O	variable
17	111	118	O	XXXXXXXX
18	120	123	O	dose
19	125	136	O	requirements
NULL

COUMADIN	2089	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	17
VKORC1 and CYP2C9 gene variants generally explain the largest proportion of known variability in warfarin dose requirements.
1	0	5	O	VKORC1
2	7	9	O	and
3	11	16	O	CYP2C9
4	18	21	O	gene
5	23	30	O	variants
6	32	40	O	generally
7	42	48	O	explain
8	50	52	O	the
9	54	60	O	largest
10	62	71	O	proportion
11	73	74	O	of
12	76	80	O	known
13	82	92	O	variability
14	94	95	O	in
15	97	104	O	XXXXXXXX
16	106	109	O	dose
17	111	122	O	requirements
NULL

COUMADIN	2090	34090-1	d2f6d2d0-1b32-4caf-9fce-6b798c94204b	19
CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the initial dose of warfarin.
1	0	5	O	CYP2C9
2	7	9	O	and
3	11	16	O	VKORC1
4	18	25	O	genotype
5	27	37	O	information
6	38	38	O	,
7	40	43	O	when
8	45	53	O	available
9	54	54	O	,
10	56	58	O	can
11	60	65	O	assist
12	67	68	O	in
13	70	78	O	selection
14	80	81	O	of
15	83	85	O	the
16	87	93	O	initial
17	95	98	O	dose
18	100	101	O	of
19	103	110	O	XXXXXXXX
NULL

CRESTOR	5995	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	7
* Cyclosporine: Combination increases rosuvastatin exposure.
1	0	0	O	*
2	2	13	U-KIN	Cyclosporine
3	14	14	O	:
4	16	26	O	Combination
5	28	36	B-TRI	increases
6	38	49	I-TRI	XXXXXXXX
7	51	58	L-TRI	exposure
K/2:C54355

CRESTOR	5996	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	7
* Gemfibrozil: Combination should be avoided.
1	0	0	O	*
2	2	12	U-UNK	Gemfibrozil
3	13	13	O	:
4	15	25	O	Combination
5	27	32	B-TRI	should
6	34	35	I-TRI	be
7	37	43	L-TRI	avoided
NULL

CRESTOR	5997	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	11
If used together, limit CRESTOR dose to 10mg once daily.
1	0	1	O	If
2	3	6	O	used
3	8	15	O	together
4	16	16	O	,
5	18	22	O	limit
6	24	30	O	XXXXXXXX
7	32	35	O	dose
8	37	38	O	to
9	40	43	O	10mg
10	45	48	O	once
11	50	54	O	daily
NULL

CRESTOR	5998	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	13
* Lopinavir/Ritonavir or atazanavir/ritonavir: Combination increases rosuvastatin exposure.
1	0	0	O	*
2	2	10	U-KIN	Lopinavir
3	11	11	B-KIN	/
4	12	20	L-KIN	Ritonavir
5	22	23	O	or
6	25	34	B-KIN	atazanavir
7	35	35	I-KIN	/
8	36	44	L-KIN	ritonavir
9	45	45	O	:
10	47	57	O	Combination
11	59	67	B-TRI	increases
12	69	80	I-TRI	XXXXXXXX
13	82	89	L-TRI	exposure
K/2:C54355 K/3:C54355 K/6:C54355

CRESTOR	5999	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	7
* Coumarin anticoagulants: Combination prolongs INR.
1	0	0	O	*
2	2	9	B-DYN	Coumarin
3	11	24	L-DYN	anticoagulants
4	25	25	O	:
5	27	37	O	Combination
6	39	46	B-EFF	prolongs
7	48	50	L-EFF	INR
D/2:6:1

CRESTOR	6000	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	7
Achieve stable INR prior to starting CRESTOR.
1	0	6	O	Achieve
2	8	13	O	stable
3	15	17	O	INR
4	19	23	O	prior
5	25	26	O	to
6	28	35	O	starting
7	37	43	O	XXXXXXXX
NULL

CRESTOR	6001	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	12
Monitor INR frequently until stable upon initiation or alteration of CRESTOR therapy.
1	0	6	O	Monitor
2	8	10	O	INR
3	12	21	O	frequently
4	23	27	O	until
5	29	34	O	stable
6	36	39	O	upon
7	41	50	O	initiation
8	52	53	O	or
9	55	64	O	alteration
10	66	67	O	of
11	69	75	O	XXXXXXXX
12	77	83	O	therapy
NULL

CRESTOR	6002	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	28
* Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (> 1 g/day) of niacin increases the risk of adverse skeletal muscle effects.
1	0	0	O	*
2	2	12	O	Concomitant
3	14	18	B-DYN	lipid
4	20	27	I-DYN	lowering
5	29	37	L-DYN	therapies
6	38	38	O	:
7	40	42	O	use
8	44	47	O	with
9	49	56	U-DYN	fibrates
10	58	59	O	or
11	61	65	O	lipid
12	67	75	O	modifying
13	77	81	O	doses
14	84	84	O	>
15	86	86	O	1
16	88	88	O	g
17	89	89	O	/
18	90	92	O	day
19	95	96	O	of
20	98	103	U-DYN	niacin
21	105	113	O	increases
22	115	117	O	the
23	119	122	O	risk
24	124	125	O	of
25	127	133	B-EFF	adverse
26	135	142	I-EFF	skeletal
27	144	149	I-EFF	muscle
28	151	157	L-EFF	effects
D/20:25:1 D/3:25:1 D/9:25:1

CRESTOR	6003	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	8
Caution should be used when prescribing with CRESTOR.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	38	O	prescribing
7	40	43	O	with
8	45	51	O	XXXXXXXX
NULL

CRESTOR	6004	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	7
Cyclosporine increased rosuvastatin exposure (AUC) 7-fold.
1	0	11	U-KIN	Cyclosporine
2	13	21	B-TRI	increased
3	23	34	I-TRI	XXXXXXXX
4	36	43	L-TRI	exposure
5	46	48	O	AUC
6	51	51	O	7
7	53	56	O	fold
K/1:C54605

CRESTOR	6005	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	17
Therefore, in patients taking cyclosporine, the dose of CRESTOR should not exceed 5mg once daily.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	41	U-KIN	cyclosporine
7	42	42	O	,
8	44	46	O	the
9	48	51	O	dose
10	53	54	O	of
11	56	62	O	XXXXXXXX
12	64	69	O	should
13	71	73	O	not
14	75	80	O	exceed
15	82	84	O	5mg
16	86	89	O	once
17	91	95	O	daily
K/6:C54355

CRESTOR	6006	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	5
Gemfibrozil significantly increased rosuvastatin exposure.
1	0	10	U-KIN	Gemfibrozil
2	12	24	O	significantly
3	26	34	B-TRI	increased
4	36	47	I-TRI	XXXXXXXX
5	49	56	L-TRI	exposure
K/1:C54355

CRESTOR	6007	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	20
Due to an observed increased risk of myopathy/rhabdomyolysis, combination therapy with CRESTOR and gemfibrozil should be avoided.
1	0	2	O	Due
2	4	5	O	to
3	7	8	O	an
4	10	17	O	observed
5	19	27	O	increased
6	29	32	O	risk
7	34	35	O	of
8	37	44	B-EFF	myopathy
9	45	45	I-EFF	/
10	46	59	L-EFF	rhabdomyolysis
11	60	60	O	,
12	62	72	O	combination
13	74	80	O	therapy
14	82	85	O	with
15	87	93	O	XXXXXXXX
16	95	97	O	and
17	99	109	U-DYN	gemfibrozil
18	111	116	O	should
19	118	119	O	be
20	121	127	O	avoided
D/17:8:1

CRESTOR	6008	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	14
If used together, the dose of CRESTOR should not exceed 10mg once daily.
1	0	1	O	If
2	3	6	O	used
3	8	15	O	together
4	16	16	O	,
5	18	20	O	the
6	22	25	O	dose
7	27	28	O	of
8	30	36	O	XXXXXXXX
9	38	43	O	should
10	45	47	O	not
11	49	54	O	exceed
12	56	59	O	10mg
13	61	64	O	once
14	66	70	O	daily
NULL

CRESTOR	6009	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	18
Coadministration of rosuvastatin with certain protease inhibitors given in combination with ritonavir has differing effects on rosuvastatin exposure.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	31	O	XXXXXXXX
4	33	36	O	with
5	38	44	O	certain
6	46	53	B-UNK	protease
7	55	64	L-UNK	inhibitors
8	66	70	O	given
9	72	73	O	in
10	75	85	O	combination
11	87	90	O	with
12	92	100	O	ritonavir
13	102	104	O	has
14	106	114	O	differing
15	116	122	B-TRI	effects
16	124	125	I-TRI	on
17	127	138	I-TRI	XXXXXXXX
18	140	147	L-TRI	exposure
NULL

CRESTOR	6010	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	18
The protease inhibitor combinations lopinavir/ritonavir and atazanavir/ritonavir increase rosuvastatin exposure (AUC) up to threefold.
1	0	2	O	The
2	4	11	O	protease
3	13	21	O	inhibitor
4	23	34	O	combinations
5	36	44	U-KIN	lopinavir
6	45	45	B-KIN	/
7	46	54	L-KIN	ritonavir
8	56	58	O	and
9	60	69	U-KIN	atazanavir
10	70	70	B-KIN	/
11	71	79	L-KIN	ritonavir
12	81	88	B-TRI	increase
13	90	101	I-TRI	XXXXXXXX
14	103	110	L-TRI	exposure
15	113	115	O	AUC
16	118	119	O	up
17	121	122	O	to
18	124	132	O	threefold
K/10:C54355 K/5:C54605 K/6:C54605 K/9:C54355

CRESTOR	6011	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	13
For these combinations the dose of CRESTOR should not exceed 10mg once daily.
1	0	2	O	For
2	4	8	O	these
3	10	21	O	combinations
4	23	25	O	the
5	27	30	O	dose
6	32	33	O	of
7	35	41	O	XXXXXXXX
8	43	48	O	should
9	50	52	O	not
10	54	59	O	exceed
11	61	64	O	10mg
12	66	69	O	once
13	71	75	O	daily
NULL

CRESTOR	6012	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	18
The combinations of tipranavir/ritonavir or fosamprenavir/ritonavir produce little or no change in rosuvastatin exposure.
1	0	2	O	The
2	4	15	O	combinations
3	17	18	O	of
4	20	29	O	tipranavir
5	30	30	O	/
6	31	39	O	ritonavir
7	41	42	O	or
8	44	56	O	fosamprenavir
9	57	57	O	/
10	58	66	O	ritonavir
11	68	74	O	produce
12	76	81	O	little
13	83	84	O	or
14	86	87	O	no
15	89	94	O	change
16	96	97	O	in
17	99	110	O	XXXXXXXX
18	112	119	O	exposure
NULL

CRESTOR	6013	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	16
Caution should be exercised when rosuvastatin is coadministered with protease inhibitors given in combination with ritonavir.
1	0	6	U-TRI	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	44	O	XXXXXXXX
7	46	47	O	is
8	49	62	O	coadministered
9	64	67	O	with
10	69	76	B-UNK	protease
11	78	87	I-UNK	inhibitors
12	89	93	I-UNK	given
13	95	96	I-UNK	in
14	98	108	I-UNK	combination
15	110	113	I-UNK	with
16	115	123	L-UNK	ritonavir
NULL

CRESTOR	6014	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	9
CRESTOR significantly increased INR in patients receiving coumarin anticoagulants.
1	0	6	O	XXXXXXXX
2	8	20	O	significantly
3	22	30	B-EFF	increased
4	32	34	L-EFF	INR
5	36	37	O	in
6	39	46	O	patients
7	48	56	O	receiving
8	58	65	B-DYN	coumarin
9	67	80	L-DYN	anticoagulants
D/8:3:1

CRESTOR	6015	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	15
Therefore, caution should be exercised when coumarin anticoagulants are given in conjunction with CRESTOR.
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	U-TRI	caution
4	19	24	O	should
5	26	27	O	be
6	29	37	O	exercised
7	39	42	O	when
8	44	51	B-UNK	coumarin
9	53	66	L-UNK	anticoagulants
10	68	70	O	are
11	72	76	O	given
12	78	79	O	in
13	81	91	O	conjunction
14	93	96	O	with
15	98	104	O	XXXXXXXX
NULL

CRESTOR	6016	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	31
In patients taking coumarin anticoagulants and CRESTOR concomitantly, INR should be determined before starting CRESTOR and frequently enough during early therapy to ensure that no significant alteration of INR occurs.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	26	B-UNK	coumarin
5	28	41	L-UNK	anticoagulants
6	43	45	O	and
7	47	53	O	XXXXXXXX
8	55	67	O	concomitantly
9	68	68	O	,
10	70	72	B-TRI	INR
11	74	79	I-TRI	should
12	81	82	I-TRI	be
13	84	93	L-TRI	determined
14	95	100	O	before
15	102	109	O	starting
16	111	117	O	XXXXXXXX
17	119	121	O	and
18	123	132	O	frequently
19	134	139	O	enough
20	141	146	O	during
21	148	152	O	early
22	154	160	O	therapy
23	162	163	O	to
24	165	170	O	ensure
25	172	175	O	that
26	177	178	O	no
27	180	190	O	significant
28	192	201	O	alteration
29	203	204	O	of
30	206	208	O	INR
31	210	215	O	occurs
NULL

CRESTOR	6017	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	32
The risk of skeletal muscle effects may be enhanced when CRESTOR is used in combination with lipid-modifying doses (>1g/day) of niacin; caution should be used when prescribing with CRESTOR.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	skeletal
5	21	26	I-EFF	muscle
6	28	34	L-EFF	effects
7	36	38	O	may
8	40	41	O	be
9	43	50	O	enhanced
10	52	55	O	when
11	57	63	O	XXXXXXXX
12	65	66	O	is
13	68	71	O	used
14	73	74	O	in
15	76	86	O	combination
16	88	91	O	with
17	93	97	O	lipid
18	99	107	O	modifying
19	109	113	O	doses
20	116	118	O	>1g
21	119	119	O	/
22	120	122	O	day
23	125	126	O	of
24	128	133	U-DYN	niacin
25	136	142	O	caution
26	144	149	O	should
27	151	152	O	be
28	154	157	O	used
29	159	162	O	when
30	164	174	O	prescribing
31	176	179	O	with
32	181	187	O	XXXXXXXX
D/24:4:1

CRESTOR	6018	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	20
When CRESTOR was coadministered with fenofibrate, no clinically significant increase in the AUC of rosuvastatin or fenofibrate was observed.
1	0	3	O	When
2	5	11	O	XXXXXXXX
3	13	15	O	was
4	17	30	O	coadministered
5	32	35	O	with
6	37	47	O	fenofibrate
7	48	48	O	,
8	50	51	O	no
9	53	62	O	clinically
10	64	74	O	significant
11	76	83	O	increase
12	85	86	O	in
13	88	90	O	the
14	92	94	O	AUC
15	96	97	O	of
16	99	110	O	XXXXXXXX
17	112	113	O	or
18	115	125	O	fenofibrate
19	127	129	O	was
20	131	138	O	observed
NULL

CRESTOR	6019	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	33
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concomitant use of fenofibrates, caution should be used when prescribing fenofibrates with CRESTOR.
1	0	6	O	Because
2	8	9	O	it
3	11	12	O	is
4	14	18	O	known
5	20	23	O	that
6	25	27	O	the
7	29	32	O	risk
8	34	35	O	of
9	37	44	U-EFF	myopathy
10	46	51	O	during
11	53	61	O	treatment
12	63	66	O	with
13	68	70	O	HMG
14	72	74	O	CoA
15	76	84	O	reductase
16	86	95	O	inhibitors
17	97	98	O	is
18	100	108	O	increased
19	110	113	O	with
20	115	125	O	concomitant
21	127	129	O	use
22	131	132	O	of
23	134	145	U-DYN	fenofibrates
24	146	146	O	,
25	148	154	O	caution
26	156	161	O	should
27	163	164	O	be
28	166	169	O	used
29	171	174	O	when
30	176	186	O	prescribing
31	188	199	O	fenofibrates
32	201	204	O	with
33	206	212	O	XXXXXXXX
D/23:9:1

CRESTOR	6020	34073-7	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	33
Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors, including rosuvastatin, coadministered with colchicine, and caution should be exercised when prescribing CRESTOR with colchicine.
1	0	4	O	Cases
2	6	7	O	of
3	9	16	U-EFF	myopathy
4	17	17	O	,
5	19	27	O	including
6	29	42	U-EFF	rhabdomyolysis
7	43	43	O	,
8	45	48	O	have
9	50	53	O	been
10	55	62	O	reported
11	64	67	O	with
12	69	71	O	HMG
13	73	75	O	CoA
14	77	85	O	reductase
15	87	96	O	inhibitors
16	97	97	O	,
17	99	107	O	including
18	109	120	O	XXXXXXXX
19	121	121	O	,
20	123	136	O	coadministered
21	138	141	O	with
22	143	152	U-DYN	colchicine
23	153	153	O	,
24	155	157	O	and
25	159	165	O	caution
26	167	172	O	should
27	174	175	O	be
28	177	185	O	exercised
29	187	190	O	when
30	192	202	O	prescribing
31	204	210	O	XXXXXXXX
32	212	215	O	with
33	217	226	O	colchicine
D/22:3:1 D/22:6:1

CRESTOR	6021	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	31
CRESTOR is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	11	O	a
4	13	21	O	selective
5	23	25	O	and
6	27	37	O	competitive
7	39	47	O	inhibitor
8	49	50	O	of
9	52	54	O	HMG
10	56	58	O	CoA
11	60	68	O	reductase
12	69	69	O	,
13	71	73	O	the
14	75	78	O	rate
15	80	87	O	limiting
16	89	94	O	enzyme
17	96	99	O	that
18	101	108	O	converts
19	110	110	O	3
20	112	118	O	hydroxy
21	120	120	O	3
22	122	135	O	methylglutaryl
23	137	144	O	coenzyme
24	146	146	O	A
25	148	149	O	to
26	151	160	O	mevalonate
27	161	161	O	,
28	163	163	O	a
29	165	173	O	precursor
30	175	176	O	of
31	178	188	O	cholesterol
NULL

CRESTOR	6022	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	41
In vivo studies in animals, and in vitro studies in cultured animal and human cells have shown rosuvastatin to have a high uptake into, and selectivity for, action in the liver, the target organ for cholesterol lowering.
1	0	1	O	In
2	3	6	O	vivo
3	8	14	O	studies
4	16	17	O	in
5	19	25	O	animals
6	26	26	O	,
7	28	30	O	and
8	32	33	O	in
9	35	39	O	vitro
10	41	47	O	studies
11	49	50	O	in
12	52	59	O	cultured
13	61	66	O	animal
14	68	70	O	and
15	72	76	O	human
16	78	82	O	cells
17	84	87	O	have
18	89	93	O	shown
19	95	106	O	XXXXXXXX
20	108	109	O	to
21	111	114	O	have
22	116	116	O	a
23	118	121	O	high
24	123	128	O	uptake
25	130	133	O	into
26	134	134	O	,
27	136	138	O	and
28	140	150	O	selectivity
29	152	154	O	for
30	155	155	O	,
31	157	162	O	action
32	164	165	O	in
33	167	169	O	the
34	171	175	O	liver
35	176	176	O	,
36	178	180	O	the
37	182	187	O	target
38	189	193	O	organ
39	195	197	O	for
40	199	209	O	cholesterol
41	211	218	O	lowering
NULL

CRESTOR	6023	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	17
In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways.
1	0	1	O	In
2	3	4	O	in
3	6	9	O	vivo
4	11	13	O	and
5	15	16	O	in
6	18	22	O	vitro
7	24	30	O	studies
8	31	31	O	,
9	33	44	O	XXXXXXXX
10	46	53	O	produces
11	55	57	O	its
12	59	63	O	lipid
13	65	73	O	modifying
14	75	81	O	effects
15	83	84	O	in
16	86	88	O	two
17	90	93	O	ways
NULL

CRESTOR	6024	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	21
First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL.
1	0	4	O	First
2	5	5	O	,
3	7	8	O	it
4	10	18	O	increases
5	20	22	O	the
6	24	29	O	number
7	31	32	O	of
8	34	40	O	hepatic
9	42	44	O	LDL
10	46	54	O	receptors
11	56	57	O	on
12	59	61	O	the
13	63	66	O	cell
14	68	74	O	surface
15	76	77	O	to
16	79	85	O	enhance
17	87	92	O	uptake
18	94	96	O	and
19	98	107	O	catabolism
20	109	110	O	of
21	112	114	O	LDL
NULL

CRESTOR	6025	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	19
Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.
1	0	5	O	Second
2	6	6	O	,
3	8	19	O	XXXXXXXX
4	21	28	O	inhibits
5	30	36	O	hepatic
6	38	46	O	synthesis
7	48	49	O	of
8	51	54	O	VLDL
9	55	55	O	,
10	57	61	O	which
11	63	69	O	reduces
12	71	73	O	the
13	75	79	O	total
14	81	86	O	number
15	88	89	O	of
16	91	94	O	VLDL
17	96	98	O	and
18	100	102	O	LDL
19	104	112	O	particles
NULL

CRESTOR	6026	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	23
* Absorption: In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5hours following oral dosing.
1	0	0	O	*
2	2	11	O	Absorption
3	12	12	O	:
4	14	15	O	In
5	17	24	O	clinical
6	26	37	O	pharmacology
7	39	45	O	studies
8	47	48	O	in
9	50	52	O	man
10	53	53	O	,
11	55	58	O	peak
12	60	65	O	plasma
13	67	80	O	concentrations
14	82	83	O	of
15	85	96	O	XXXXXXXX
16	98	101	O	were
17	103	109	O	reached
18	111	111	O	3
19	113	114	O	to
20	116	121	O	5hours
21	123	131	O	following
22	133	136	O	oral
23	138	143	O	dosing
NULL

CRESTOR	6027	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	11
Both Cmax and AUC increased in approximate proportion to CRESTOR dose.
1	0	3	O	Both
2	5	8	O	Cmax
3	10	12	O	and
4	14	16	O	AUC
5	18	26	O	increased
6	28	29	O	in
7	31	41	O	approximate
8	43	52	O	proportion
9	54	55	O	to
10	57	63	O	XXXXXXXX
11	65	68	O	dose
NULL

CRESTOR	6028	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	8
The absolute bioavailability of rosuvastatin is approximately 20%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	43	O	XXXXXXXX
6	45	46	O	is
7	48	60	O	approximately
8	62	64	O	20%
NULL

CRESTOR	6029	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	12
Administration of CRESTOR with food did not affect the AUC of rosuvastatin.
1	0	13	O	Administration
2	15	16	O	of
3	18	24	O	XXXXXXXX
4	26	29	O	with
5	31	34	O	food
6	36	38	O	did
7	40	42	O	not
8	44	49	O	affect
9	51	53	O	the
10	55	57	O	AUC
11	59	60	O	of
12	62	73	O	XXXXXXXX
NULL

CRESTOR	6030	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	13
The AUC of rosuvastatin does not differ following evening or morning drug administration.
1	0	2	O	The
2	4	6	O	AUC
3	8	9	O	of
4	11	22	O	XXXXXXXX
5	24	27	O	does
6	29	31	O	not
7	33	38	O	differ
8	40	48	O	following
9	50	56	O	evening
10	58	59	O	or
11	61	67	O	morning
12	69	72	O	drug
13	74	87	O	administration
NULL

CRESTOR	6031	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	16
* Distribution: Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters.
1	0	0	O	*
2	2	13	O	Distribution
3	14	14	O	:
4	16	19	O	Mean
5	21	26	O	volume
6	28	29	O	of
7	31	42	O	distribution
8	44	45	O	at
9	47	52	O	steady
10	54	58	O	state
11	60	61	O	of
12	63	74	O	XXXXXXXX
13	76	77	O	is
14	79	91	O	approximately
15	93	95	O	134
16	97	102	O	liters
NULL

CRESTOR	6032	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	10
Rosuvastatin is 88% bound to plasma proteins, mostly albumin.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	18	O	88%
4	20	24	O	bound
5	26	27	O	to
6	29	34	O	plasma
7	36	43	O	proteins
8	44	44	O	,
9	46	51	O	mostly
10	53	59	O	albumin
NULL

CRESTOR	6033	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	9
This binding is reversible and independent of plasma concentrations.
1	0	3	O	This
2	5	11	O	binding
3	13	14	O	is
4	16	25	O	reversible
5	27	29	O	and
6	31	41	O	independent
7	43	44	O	of
8	46	51	O	plasma
9	53	66	O	concentrations
NULL

CRESTOR	6034	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	18
* Metabolism: Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite.
1	0	0	O	*
2	2	11	O	Metabolism
3	12	12	O	:
4	14	25	O	XXXXXXXX
5	27	28	O	is
6	30	32	O	not
7	34	44	O	extensively
8	46	56	O	metabolized
9	59	71	O	approximately
10	73	75	O	10%
11	77	78	O	of
12	80	80	O	a
13	82	93	O	radiolabeled
14	95	98	O	dose
15	100	101	O	is
16	103	111	O	recovered
17	113	114	O	as
18	116	125	O	metabolite
NULL

CRESTOR	6035	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	44
The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound.
1	0	2	O	The
2	4	8	O	major
3	10	19	O	metabolite
4	21	22	O	is
5	24	24	O	N
6	26	34	O	desmethyl
7	36	47	O	XXXXXXXX
8	48	48	O	,
9	50	54	O	which
10	56	57	O	is
11	59	64	O	formed
12	66	76	O	principally
13	78	79	O	by
14	81	90	O	cytochrome
15	92	95	O	P450
16	97	100	O	\2C9
17	101	101	O	,
18	103	105	O	and
19	107	108	O	in
20	110	114	O	vitro
21	116	122	O	studies
22	124	127	O	have
23	129	140	O	demonstrated
24	142	145	O	that
25	147	147	O	N
26	149	157	O	desmethyl
27	159	170	O	XXXXXXXX
28	172	174	O	has
29	176	188	O	approximately
30	190	192	O	one
31	194	198	O	sixth
32	200	201	O	to
33	203	205	O	one
34	207	210	O	half
35	212	214	O	the
36	216	218	O	HMG
37	220	222	O	CoA
38	224	232	O	reductase
39	234	243	O	inhibitory
40	245	252	O	activity
41	254	255	O	of
42	257	259	O	the
43	261	266	O	parent
44	268	275	O	compound
NULL

CRESTOR	6036	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	20
Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound.
1	0	6	O	Overall
2	7	7	O	,
3	9	15	O	greater
4	17	20	O	than
5	22	24	O	90%
6	26	27	O	of
7	29	34	O	active
8	36	41	O	plasma
9	43	45	O	HMG
10	47	49	O	CoA
11	51	59	O	reductase
12	61	70	O	inhibitory
13	72	79	O	activity
14	81	82	O	is
15	84	92	O	accounted
16	94	96	O	for
17	98	99	O	by
18	101	103	O	the
19	105	110	O	parent
20	112	119	O	compound
NULL

CRESTOR	6037	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	18
* Excretion: Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%).
1	0	0	O	*
2	2	10	O	Excretion
3	11	11	O	:
4	13	21	O	Following
5	23	26	O	oral
6	28	41	O	administration
7	42	42	O	,
8	44	55	O	XXXXXXXX
9	57	59	O	and
10	61	63	O	its
11	65	75	O	metabolites
12	77	79	O	are
13	81	89	O	primarily
14	91	98	O	excreted
15	100	101	O	in
16	103	105	O	the
17	107	111	O	feces
18	114	116	O	90%
NULL

CRESTOR	6038	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	13
The elimination half-life (t1/2) of rosuvastatin is approximately 19 hours.
1	0	2	O	The
2	4	14	O	elimination
3	16	19	O	half
4	21	24	O	life
5	27	28	O	t1
6	29	29	O	/
7	30	30	O	2
8	33	34	O	of
9	36	47	O	XXXXXXXX
10	49	50	O	is
11	52	64	O	approximately
12	66	67	O	19
13	69	73	O	hours
NULL

CRESTOR	6039	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	23
After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route.
1	0	4	O	After
2	6	7	O	an
3	9	19	O	intravenous
4	21	24	O	dose
5	25	25	O	,
6	27	39	O	approximately
7	41	43	O	28%
8	45	46	O	of
9	48	52	O	total
10	54	57	O	body
11	59	67	O	clearance
12	69	71	O	was
13	73	75	O	via
14	77	79	O	the
15	81	85	O	renal
16	87	91	O	route
17	92	92	O	,
18	94	96	O	and
19	98	100	O	72%
20	102	103	O	by
21	105	107	O	the
22	109	115	O	hepatic
23	117	121	O	route
NULL

CRESTOR	6040	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	25
* Race: A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups.
1	0	0	O	*
2	2	5	O	Race
3	6	6	O	:
4	8	8	O	A
5	10	19	O	population
6	21	35	O	pharmacokinetic
7	37	44	O	analysis
8	46	53	O	revealed
9	55	56	O	no
10	58	67	O	clinically
11	69	76	O	relevant
12	78	88	O	differences
13	90	91	O	in
14	93	108	O	pharmacokinetics
15	110	114	O	among
16	116	124	O	Caucasian
17	125	125	O	,
18	127	134	O	Hispanic
19	135	135	O	,
20	137	139	O	and
21	141	145	O	Black
22	147	148	O	or
23	150	153	O	Afro
24	155	163	O	Caribbean
25	165	170	O	groups
NULL

CRESTOR	6041	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	35
However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and Cmax) in Asian subjects when compared with a Caucasian control group.
1	0	6	O	However
2	7	7	O	,
3	9	23	O	pharmacokinetic
4	25	31	O	studies
5	32	32	O	,
6	34	42	O	including
7	44	46	O	one
8	48	56	O	conducted
9	58	59	O	in
10	61	63	O	the
11	65	66	O	US
12	67	67	O	,
13	69	72	O	have
14	74	85	O	demonstrated
15	87	88	O	an
16	90	100	O	approximate
17	102	102	O	2
18	104	107	O	fold
19	109	117	O	elevation
20	119	120	O	in
21	122	127	O	median
22	129	136	O	exposure
23	139	141	O	AUC
24	143	145	O	and
25	147	150	O	Cmax
26	153	154	O	in
27	156	160	O	Asian
28	162	169	O	subjects
29	171	174	O	when
30	176	183	O	compared
31	185	188	O	with
32	190	190	O	a
33	192	200	O	Caucasian
34	202	208	O	control
35	210	214	O	group
NULL

CRESTOR	6042	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	16
* Gender: There were no differences in plasma concentrations of rosuvastatin between men and women.
1	0	0	O	*
2	2	7	O	Gender
3	8	8	O	:
4	10	14	O	There
5	16	19	O	were
6	21	22	O	no
7	24	34	O	differences
8	36	37	O	in
9	39	44	O	plasma
10	46	59	O	concentrations
11	61	62	O	of
12	64	75	O	XXXXXXXX
13	77	83	O	between
14	85	87	O	men
15	89	91	O	and
16	93	97	O	women
NULL

CRESTOR	6043	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	20
* Geriatric: There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age >65years).
1	0	0	O	*
2	2	10	O	Geriatric
3	11	11	O	:
4	13	17	O	There
5	19	22	O	were
6	24	25	O	no
7	27	37	O	differences
8	39	40	O	in
9	42	47	O	plasma
10	49	62	O	concentrations
11	64	65	O	of
12	67	78	O	XXXXXXXX
13	80	86	O	between
14	88	90	O	the
15	92	101	O	nonelderly
16	103	105	O	and
17	107	113	O	elderly
18	115	125	O	populations
19	128	130	O	age
20	132	139	O	>65years
NULL

CRESTOR	6044	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	23
* Renal Impairment: Mild to moderate renal impairment (CLcr>30mL/min/1.73 m2) had no influence on plasma concentrations of rosuvastatin.
1	0	0	O	*
2	2	6	O	Renal
3	8	17	O	Impairment
4	18	18	O	:
5	20	23	O	Mild
6	25	26	O	to
7	28	35	O	moderate
8	37	41	O	renal
9	43	52	O	impairment
10	55	63	O	CLcr>30mL
11	64	64	O	/
12	65	67	O	min
13	68	68	O	/
14	69	72	O	1.73
15	74	75	O	m2
16	78	80	O	had
17	82	83	O	no
18	85	93	O	influence
19	95	96	O	on
20	98	103	O	plasma
21	105	118	O	concentrations
22	120	121	O	of
23	123	134	O	XXXXXXXX
NULL

CRESTOR	6045	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	41
However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3-fold) in patients with severe renal impairment (CLcr<30 mL/min/1.73 m2) not receiving hemodialysis compared with healthy subjects (CLcr> 80mL/min/1.73m2).
1	0	6	O	However
2	7	7	O	,
3	9	14	O	plasma
4	16	29	O	concentrations
5	31	32	O	of
6	34	45	O	XXXXXXXX
7	47	55	O	increased
8	57	58	O	to
9	60	60	O	a
10	62	71	O	clinically
11	73	83	O	significant
12	85	90	O	extent
13	93	97	O	about
14	99	99	O	3
15	101	104	O	fold
16	107	108	O	in
17	110	117	O	patients
18	119	122	O	with
19	124	129	O	severe
20	131	135	O	renal
21	137	146	O	impairment
22	149	155	O	CLcr<30
23	157	158	O	mL
24	159	159	O	/
25	160	162	O	min
26	163	163	O	/
27	164	167	O	1.73
28	169	170	O	m2
29	173	175	O	not
30	177	185	O	receiving
31	187	198	O	hemodialysis
32	200	207	O	compared
33	209	212	O	with
34	214	220	O	healthy
35	222	229	O	subjects
36	232	236	O	CLcr>
37	238	241	O	80mL
38	242	242	O	/
39	243	245	O	min
40	246	246	O	/
41	247	252	O	1.73m2
NULL

CRESTOR	6046	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	27
* Hemodialysis: Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function.
1	0	0	O	*
2	2	13	O	Hemodialysis
3	14	14	O	:
4	16	21	O	Steady
5	23	27	O	state
6	29	34	O	plasma
7	36	49	O	concentrations
8	51	52	O	of
9	54	65	O	XXXXXXXX
10	67	68	O	in
11	70	77	O	patients
12	79	80	O	on
13	82	88	O	chronic
14	90	101	O	hemodialysis
15	103	106	O	were
16	108	120	O	approximately
17	122	124	O	50%
18	126	132	O	greater
19	134	141	O	compared
20	143	146	O	with
21	148	154	O	healthy
22	156	164	O	volunteer
23	166	173	O	subjects
24	175	178	O	with
25	180	185	O	normal
26	187	191	O	renal
27	193	200	O	function
NULL

CRESTOR	6047	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	19
* Hepatic Impairment: In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased.
1	0	0	O	*
2	2	8	O	Hepatic
3	10	19	O	Impairment
4	20	20	O	:
5	22	23	O	In
6	25	32	O	patients
7	34	37	O	with
8	39	45	O	chronic
9	47	53	O	alcohol
10	55	59	O	liver
11	61	67	O	disease
12	68	68	O	,
13	70	75	O	plasma
14	77	90	O	concentrations
15	92	93	O	of
16	95	106	O	XXXXXXXX
17	108	111	O	were
18	113	120	O	modestly
19	122	130	O	increased
NULL

CRESTOR	6048	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	28
In patients with Child-Pugh A disease, Cmax and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	21	O	Child
5	23	26	O	Pugh
6	28	28	O	A
7	30	36	O	disease
8	37	37	O	,
9	39	42	O	Cmax
10	44	46	O	and
11	48	50	O	AUC
12	52	55	O	were
13	57	65	O	increased
14	67	68	O	by
15	70	72	O	60%
16	74	76	O	and
17	78	79	O	5%
18	80	80	O	,
19	82	93	O	respectively
20	94	94	O	,
21	96	97	O	as
22	99	106	O	compared
23	108	111	O	with
24	113	120	O	patients
25	122	125	O	with
26	127	132	O	normal
27	134	138	O	liver
28	140	147	O	function
NULL

CRESTOR	6049	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	26
In patients with Child-Pugh B disease, Cmax and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	21	O	Child
5	23	26	O	Pugh
6	28	28	O	B
7	30	36	O	disease
8	37	37	O	,
9	39	42	O	Cmax
10	44	46	O	and
11	48	50	O	AUC
12	52	55	O	were
13	57	65	O	increased
14	67	70	O	100%
15	72	74	O	and
16	76	78	O	21%
17	79	79	O	,
18	81	92	O	respectively
19	93	93	O	,
20	95	102	O	compared
21	104	107	O	with
22	109	116	O	patients
23	118	121	O	with
24	123	128	O	normal
25	130	134	O	liver
26	136	143	O	function
NULL

CRESTOR	6050	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	20
Drug-Drug Interactions: Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	22	22	O	:
5	24	35	O	XXXXXXXX
6	37	45	O	clearance
7	47	48	O	is
8	50	52	O	not
9	54	62	O	dependent
10	64	65	O	on
11	67	76	O	metabolism
12	78	79	O	by
13	81	90	O	cytochrome
14	92	95	O	P450
15	97	99	O	3A4
16	101	102	O	to
17	104	104	O	a
18	106	115	O	clinically
19	117	127	O	significant
20	129	134	O	extent
NULL

CRESTOR	6051	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	27
Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP).
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	16	O	a
4	18	26	O	substrate
5	28	30	O	for
6	32	38	O	certain
7	40	50	O	transporter
8	52	59	O	proteins
9	61	69	O	including
10	71	73	O	the
11	75	81	O	hepatic
12	83	88	O	uptake
13	90	100	O	transporter
14	102	108	O	organic
15	110	114	O	anion
16	116	127	O	transporting
17	129	139	O	polyprotein
18	141	143	O	1B1
19	146	152	O	OATP1B1
20	155	157	O	and
21	159	164	O	efflux
22	166	176	O	transporter
23	178	183	O	breast
24	185	190	O	cancer
25	192	201	O	resistance
26	203	209	O	protein
27	212	215	O	BCRP
NULL

CRESTOR	6052	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	33
Concomitant administration of CRESTOR with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	41	O	with
6	43	53	O	medications
7	55	58	O	that
8	60	62	O	are
9	64	73	O	inhibitors
10	75	76	O	of
11	78	82	O	these
12	84	94	O	transporter
13	96	103	O	proteins
14	106	108	O	e.g
15	111	122	U-DYN	cyclosporine
16	123	123	O	,
17	125	131	O	certain
18	133	135	B-DYN	HIV
19	137	144	I-DYN	protease
20	146	155	L-DYN	inhibitors
21	158	160	O	may
22	162	167	O	result
23	169	170	O	in
24	172	180	B-TRI	increased
25	182	193	I-TRI	XXXXXXXX
26	195	200	I-TRI	plasma
27	202	215	L-TRI	concentrations
28	217	219	O	and
29	221	222	O	an
30	224	232	O	increased
31	234	237	O	risk
32	239	240	O	of
33	242	249	U-EFF	myopathy
D/15:33:1 D/18:33:1

CRESTOR	6053	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	21
Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure Coadministered drug and dosing regimen Rosuvastatin Dose (mg) Single dose unless otherwise noted.
1	0	5	O	Effect
2	7	8	O	of
3	10	23	O	Coadministered
4	25	29	O	Drugs
5	31	32	O	on
6	34	45	O	XXXXXXXX
7	47	54	O	Systemic
8	56	63	O	Exposure
9	65	78	O	Coadministered
10	80	83	O	drug
11	85	87	O	and
12	89	94	O	dosing
13	96	102	O	regimen
14	104	115	O	XXXXXXXX
15	117	120	O	Dose
16	123	124	O	mg
17	127	132	O	Single
18	134	137	O	dose
19	139	144	O	unless
20	146	154	O	otherwise
21	156	160	O	noted
NULL

CRESTOR	6054	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	41
Change in AUC Mean ratio (with/without coadministered drug and no change = 1fold) or % change (with/without coadministered drug and no change = 0%); symbols of * and * indicate the exposure increase and decrease, respectively.
1	0	5	O	Change
2	7	8	O	in
3	10	12	O	AUC
4	14	17	O	Mean
5	19	23	O	ratio
6	26	29	O	with
7	30	30	O	/
8	31	37	O	without
9	39	52	O	coadministered
10	54	57	O	drug
11	59	61	O	and
12	63	64	O	no
13	66	71	O	change
14	73	73	O	=
15	75	79	O	1fold
16	82	83	O	or
17	85	85	O	%
18	87	92	O	change
19	95	98	O	with
20	99	99	O	/
21	100	106	O	without
22	108	121	O	coadministered
23	123	126	O	drug
24	128	130	O	and
25	132	133	O	no
26	135	140	O	change
27	142	142	O	=
28	144	145	O	0%
29	149	155	O	symbols
30	157	158	O	of
31	160	160	O	*
32	162	164	O	and
33	166	166	O	*
34	168	175	O	indicate
35	177	179	O	the
36	181	188	O	exposure
37	190	197	O	increase
38	199	201	O	and
39	203	210	O	decrease
40	211	211	O	,
41	213	224	O	respectively
NULL

CRESTOR	6055	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	242
Change in Cmax Cyclosporine - stable dose required (75mg - 200mgBID) 10mg QD for 10days * 7.1-foldClinically significant * 11-fold Atazanavir/ritonavir combination 300mg/100mgQD for 8days 10mg * 3.1-fold * 7-fold Lopinavir/ritonavir combination 400mg/100mgBID for 17days 20mgQD for 7days * 2.1-fold * 5-fold Gemfibrozil 600mgBID for 7days 80mg * 1.9-fold * 2.2-fold Eltrombopag 75 mg QD, 5 days 10 mg * 1.6-fold * 2-fold Darunavir 600 mg/ritonavir 100 mg BID, 7 days 10 mg QD for 7 days * 1.5-fold * 2.4-fold Tipranavir/ritonavir combination 500mg/200mgBID for 11days 10mg * 26% * 2.2-fold Dronedarone 400 mg BID 10 mg * 1.4-fold Itraconazole 200 mg QD, 5 days 10 mg or 80mg * 39% * 28% * 36% * 15% Ezetimibe 10 mg QD, 14 days 10 mg QD for 14 days * 1.2-fold Fosamprenavir/ritonavir 700mg/100mgBID for 7days 10mg * 8% * 45% Fenofibrate 67mgTID for 7days 10mg * * 21% Rifampicin 450 mg QD, 7 days 20 mg * Aluminum & magnesium hydroxide combination antacid Administered simultaneouslyAdministered 2hours apart 40mg40mg * 54% * 22% * 50% * 16% Ketoconazole 200mgBID for 7days 80mg * 2% * 5% Fluconazole 200mg QD for 11days 80mg * 14% * 9% Erythromycin 500mgQID for 7days 80mg * 20% * 31% Table 5.
1	0	5	O	Change
2	7	8	O	in
3	10	13	O	Cmax
4	15	26	O	Cyclosporine
5	30	35	O	stable
6	37	40	O	dose
7	42	49	O	required
8	52	55	O	75mg
9	59	66	O	200mgBID
10	69	72	O	10mg
11	74	75	O	QD
12	77	79	O	for
13	81	86	O	10days
14	88	88	O	*
15	90	92	O	7.1
16	94	107	O	foldClinically
17	109	119	O	significant
18	121	121	O	*
19	123	124	O	11
20	126	129	O	fold
21	131	140	O	Atazanavir
22	141	141	O	/
23	142	150	O	ritonavir
24	152	162	O	combination
25	164	168	O	300mg
26	169	169	O	/
27	170	176	O	100mgQD
28	178	180	O	for
29	182	186	O	8days
30	188	191	O	10mg
31	193	193	O	*
32	195	197	O	3.1
33	199	202	O	fold
34	204	204	O	*
35	206	206	O	7
36	208	211	O	fold
37	213	221	O	Lopinavir
38	222	222	O	/
39	223	231	O	ritonavir
40	233	243	O	combination
41	245	249	O	400mg
42	250	250	O	/
43	251	258	O	100mgBID
44	260	262	O	for
45	264	269	O	17days
46	271	276	O	20mgQD
47	278	280	O	for
48	282	286	O	7days
49	288	288	O	*
50	290	292	O	2.1
51	294	297	O	fold
52	299	299	O	*
53	301	301	O	5
54	303	306	O	fold
55	308	318	O	Gemfibrozil
56	320	327	O	600mgBID
57	329	331	O	for
58	333	337	O	7days
59	339	342	O	80mg
60	344	344	O	*
61	346	348	O	1.9
62	350	353	O	fold
63	355	355	O	*
64	357	359	O	2.2
65	361	364	O	fold
66	366	376	O	Eltrombopag
67	378	379	O	75
68	381	382	O	mg
69	384	385	O	QD
70	386	386	O	,
71	388	388	O	5
72	390	393	O	days
73	395	396	O	10
74	398	399	O	mg
75	401	401	O	*
76	403	405	O	1.6
77	407	410	O	fold
78	412	412	O	*
79	414	414	O	2
80	416	419	O	fold
81	421	429	O	Darunavir
82	431	433	O	600
83	435	436	O	mg
84	437	437	O	/
85	438	446	O	ritonavir
86	448	450	O	100
87	452	453	O	mg
88	455	457	O	BID
89	458	458	O	,
90	460	460	O	7
91	462	465	O	days
92	467	468	O	10
93	470	471	O	mg
94	473	474	O	QD
95	476	478	O	for
96	480	480	O	7
97	482	485	O	days
98	487	487	O	*
99	489	491	O	1.5
100	493	496	O	fold
101	498	498	O	*
102	500	502	O	2.4
103	504	507	O	fold
104	509	518	O	Tipranavir
105	519	519	O	/
106	520	528	O	ritonavir
107	530	540	O	combination
108	542	546	O	500mg
109	547	547	O	/
110	548	555	O	200mgBID
111	557	559	O	for
112	561	566	O	11days
113	568	571	O	10mg
114	573	573	O	*
115	575	577	O	26%
116	579	579	O	*
117	581	583	O	2.2
118	585	588	O	fold
119	590	600	O	Dronedarone
120	602	604	O	400
121	606	607	O	mg
122	609	611	O	BID
123	613	614	O	10
124	616	617	O	mg
125	619	619	O	*
126	621	623	O	1.4
127	625	628	O	fold
128	630	641	O	Itraconazole
129	643	645	O	200
130	647	648	O	mg
131	650	651	O	QD
132	652	652	O	,
133	654	654	O	5
134	656	659	O	days
135	661	662	O	10
136	664	665	O	mg
137	667	668	O	or
138	670	673	O	80mg
139	675	675	O	*
140	677	679	O	39%
141	681	681	O	*
142	683	685	O	28%
143	687	687	O	*
144	689	691	O	36%
145	693	693	O	*
146	695	697	O	15%
147	699	707	O	Ezetimibe
148	709	710	O	10
149	712	713	O	mg
150	715	716	O	QD
151	717	717	O	,
152	719	720	O	14
153	722	725	O	days
154	727	728	O	10
155	730	731	O	mg
156	733	734	O	QD
157	736	738	O	for
158	740	741	O	14
159	743	746	O	days
160	748	748	O	*
161	750	752	O	1.2
162	754	757	O	fold
163	759	771	O	Fosamprenavir
164	772	772	O	/
165	773	781	O	ritonavir
166	783	787	O	700mg
167	788	788	O	/
168	789	796	O	100mgBID
169	798	800	O	for
170	802	806	O	7days
171	808	811	O	10mg
172	813	813	O	*
173	815	816	O	8%
174	818	818	O	*
175	820	822	O	45%
176	824	834	O	Fenofibrate
177	836	842	O	67mgTID
178	844	846	O	for
179	848	852	O	7days
180	854	857	O	10mg
181	859	859	O	*
182	861	861	O	*
183	863	865	O	21%
184	867	876	O	Rifampicin
185	878	880	O	450
186	882	883	O	mg
187	885	886	O	QD
188	887	887	O	,
189	889	889	O	7
190	891	894	O	days
191	896	897	O	20
192	899	900	O	mg
193	902	902	O	*
194	904	911	O	Aluminum
195	913	913	O	&
196	915	923	O	magnesium
197	925	933	O	hydroxide
198	935	945	O	combination
199	947	953	O	antacid
200	955	966	O	Administered
201	968	993	O	simultaneouslyAdministered
202	995	1000	O	2hours
203	1002	1006	O	apart
204	1008	1015	O	40mg40mg
205	1017	1017	O	*
206	1019	1021	O	54%
207	1023	1023	O	*
208	1025	1027	O	22%
209	1029	1029	O	*
210	1031	1033	O	50%
211	1035	1035	O	*
212	1037	1039	O	16%
213	1041	1052	O	Ketoconazole
214	1054	1061	O	200mgBID
215	1063	1065	O	for
216	1067	1071	O	7days
217	1073	1076	O	80mg
218	1078	1078	O	*
219	1080	1081	O	2%
220	1083	1083	O	*
221	1085	1086	O	5%
222	1088	1098	O	Fluconazole
223	1100	1104	O	200mg
224	1106	1107	O	QD
225	1109	1111	O	for
226	1113	1118	O	11days
227	1120	1123	O	80mg
228	1125	1125	O	*
229	1127	1129	O	14%
230	1131	1131	O	*
231	1133	1134	O	9%
232	1136	1147	O	Erythromycin
233	1149	1156	O	500mgQID
234	1158	1160	O	for
235	1162	1166	O	7days
236	1168	1171	O	80mg
237	1173	1173	O	*
238	1175	1177	O	20%
239	1179	1179	O	*
240	1181	1183	O	31%
241	1185	1189	O	Table
242	1191	1191	O	5
NULL

CRESTOR	6056	34090-1	1fd0ba23-962e-427f-8b9d-2cf8f64d0f95	57
Effect of Rosuvastatin Coadministration on Systemic Exposure To Other Drugs Rosuvastatin Dosage Regimen Coadministered Drug Name and Dose Change in AUC Change in Cmax 40mg QD for 10 days WarfarinClinically significant pharmacodynamic effects QD for 21 Days EE * 26% NG * 34% EE * 25% NG * 23% EE = ethinyl estradiol, NG = norgestrel
1	0	5	O	Effect
2	7	8	O	of
3	10	21	O	XXXXXXXX
4	23	38	O	Coadministration
5	40	41	O	on
6	43	50	O	Systemic
7	52	59	O	Exposure
8	61	62	O	To
9	64	68	O	Other
10	70	74	O	Drugs
11	76	87	O	XXXXXXXX
12	89	94	O	Dosage
13	96	102	O	Regimen
14	104	117	O	Coadministered
15	119	122	O	Drug
16	124	127	O	Name
17	129	131	O	and
18	133	136	O	Dose
19	138	143	O	Change
20	145	146	O	in
21	148	150	O	AUC
22	152	157	O	Change
23	159	160	O	in
24	162	165	O	Cmax
25	167	170	O	40mg
26	172	173	O	QD
27	175	177	O	for
28	179	180	O	10
29	182	185	O	days
30	187	204	O	WarfarinClinically
31	206	216	O	significant
32	218	232	B-EFF	pharmacodynamic
33	234	240	L-EFF	effects
34	242	243	O	QD
35	245	247	O	for
36	249	250	O	21
37	252	255	O	Days
38	257	258	O	EE
39	260	260	O	*
40	262	264	O	26%
41	266	267	O	NG
42	269	269	O	*
43	271	273	O	34%
44	275	276	O	EE
45	278	278	O	*
46	280	282	O	25%
47	284	285	O	NG
48	287	287	O	*
49	289	291	O	23%
50	293	294	O	EE
51	296	296	O	=
52	298	304	O	ethinyl
53	306	314	O	estradiol
54	315	315	O	,
55	317	318	O	NG
56	320	320	O	=
57	322	331	O	norgestrel
NULL

Celexa	807	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	12
Serotonergic Drugs: See CONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.
1	0	11	B-TRI	Serotonergic
2	13	17	L-TRI	Drugs
3	18	18	O	:
4	20	22	O	See
5	24	40	U-UNK	CONTRAINDICATIONS
6	41	41	O	,
7	43	50	O	WARNINGS
8	51	51	O	,
9	53	55	O	and
10	57	62	O	DOSAGE
11	64	66	O	AND
12	68	81	O	ADMINISTRATION
NULL

Celexa	808	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	19
Triptans: There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
1	0	7	O	Triptans
2	8	8	O	:
3	10	14	O	There
4	16	19	O	have
5	21	24	O	been
6	26	29	O	rare
7	31	43	O	postmarketing
8	45	51	O	reports
9	53	54	O	of
10	56	64	B-EFF	serotonin
11	66	73	L-EFF	syndrome
12	75	78	O	with
13	80	82	O	use
14	84	85	O	of
15	87	88	O	an
16	90	93	O	SSRI
17	95	97	O	and
18	99	99	O	a
19	101	107	U-DYN	triptan
D/19:10:1

Celexa	809	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	27
If concomitant treatment of Celexa with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	26	O	of
5	28	33	U-UNK	XXXXXXXX
6	35	38	O	with
7	40	40	O	a
8	42	48	O	triptan
9	50	51	O	is
10	53	62	O	clinically
11	64	72	O	warranted
12	73	73	O	,
13	75	81	B-TRI	careful
14	83	93	L-TRI	observation
15	95	96	O	of
16	98	100	O	the
17	102	108	O	patient
18	110	111	O	is
19	113	119	O	advised
20	120	120	O	,
21	122	133	O	particularly
22	135	140	O	during
23	142	150	O	treatment
24	152	161	O	initiation
25	163	165	O	and
26	167	170	O	dose
27	172	180	O	increases
NULL

Celexa	810	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	25
CNS Drugs - Given the primary CNS effects of citalopram, caution should be used when it is taken in combination with other centrally acting drugs.
1	0	2	O	CNS
2	4	8	O	Drugs
3	12	16	O	Given
4	18	20	O	the
5	22	28	O	primary
6	30	32	O	CNS
7	34	40	O	effects
8	42	43	O	of
9	45	54	O	XXXXXXXX
10	55	55	O	,
11	57	63	U-TRI	caution
12	65	70	O	should
13	72	73	O	be
14	75	78	O	used
15	80	83	O	when
16	85	86	O	it
17	88	89	O	is
18	91	95	O	taken
19	97	98	O	in
20	100	110	O	combination
21	112	115	O	with
22	117	121	O	other
23	123	131	B-UNK	centrally
24	133	138	I-UNK	acting
25	140	144	L-UNK	drugs
NULL

Celexa	811	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	36
Alcohol - Although citalopram did not potentiate the cognitive and motor effects of alcohol in a clinical trial, as with other psychotropic medications, the use of alcohol by depressed patients taking Celexa is not recommended.
1	0	6	O	Alcohol
2	10	17	O	Although
3	19	28	O	XXXXXXXX
4	30	32	O	did
5	34	36	O	not
6	38	47	O	potentiate
7	49	51	O	the
8	53	61	O	cognitive
9	63	65	O	and
10	67	71	O	motor
11	73	79	O	effects
12	81	82	O	of
13	84	90	U-UNK	alcohol
14	92	93	O	in
15	95	95	O	a
16	97	104	O	clinical
17	106	110	O	trial
18	111	111	O	,
19	113	114	O	as
20	116	119	O	with
21	121	125	O	other
22	127	138	O	psychotropic
23	140	150	O	medications
24	151	151	O	,
25	153	155	O	the
26	157	159	O	use
27	161	162	O	of
28	164	170	O	alcohol
29	172	173	O	by
30	175	183	O	depressed
31	185	192	O	patients
32	194	199	O	taking
33	201	206	O	XXXXXXXX
34	208	209	O	is
35	211	213	B-TRI	not
36	215	225	L-TRI	recommended
NULL

Celexa	812	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	12
Monoamine Oxidase Inhibitors (MAOIs) - See CONTRAINDICATIONS , WARNINGS and DOSAGE AND ADMINISTRATION.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	30	34	U-UNK	MAOIs
5	39	41	O	See
6	43	59	U-TRI	CONTRAINDICATIONS
7	61	61	O	,
8	63	70	O	WARNINGS
9	72	74	O	and
10	76	81	O	DOSAGE
11	83	85	O	AND
12	87	100	O	ADMINISTRATION
NULL

Celexa	813	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	12
Drugs That Interfere With Hemostasis (NSAIDs, Aspirin, Warfarin, etc.)
1	0	4	O	Drugs
2	6	9	O	That
3	11	19	O	Interfere
4	21	24	O	With
5	26	35	O	Hemostasis
6	38	43	O	NSAIDs
7	44	44	O	,
8	46	52	O	Aspirin
9	53	53	O	,
10	55	62	O	Warfarin
11	63	63	O	,
12	65	67	O	etc
NULL

Celexa	815	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	48
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	O	psychotropic
19	128	132	O	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	O	upper
30	201	216	O	gastrointestinal
31	218	225	U-EFF	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-DYN	NSAID
41	275	276	O	or
42	278	284	U-DYN	aspirin
43	286	288	O	may
44	290	299	O	potentiate
45	301	304	O	this
46	306	309	O	risk
47	311	312	O	of
48	314	321	O	bleeding
D/40:31:1 D/42:31:1

Celexa	816	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	19
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	93	O	and
15	95	99	O	SNRIs
16	101	103	O	are
17	105	118	O	coadministered
18	120	123	O	with
19	125	132	U-DYN	warfarin
D/19:1:1 D/19:6:1

Celexa	817	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	14
Patients receiving warfarin therapy should be carefully monitored when Celexa is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	O	should
6	43	44	O	be
7	46	54	B-TRI	carefully
8	56	64	L-TRI	monitored
9	66	69	O	when
10	71	76	O	XXXXXXXX
11	78	79	O	is
12	81	89	O	initiated
13	91	92	O	or
14	94	105	O	discontinued
NULL

Celexa	818	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	42
Cimetidine - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of 400 mg twice a day cimetidine for 8 days resulted in an increase in citalopram AUC and Cmax of 43% and 39%, respectively.
1	0	9	O	Cimetidine
2	13	14	O	In
3	16	23	O	subjects
4	25	27	O	who
5	29	31	O	had
6	33	40	O	received
7	42	43	O	21
8	45	48	O	days
9	50	51	O	of
10	53	54	O	40
11	56	57	O	mg
12	58	58	O	/
13	59	61	O	day
14	63	68	O	XXXXXXXX
15	69	69	O	,
16	71	78	O	combined
17	80	93	O	administration
18	95	96	O	of
19	98	100	O	400
20	102	103	O	mg
21	105	109	O	twice
22	111	111	O	a
23	113	115	O	day
24	117	126	U-KIN	cimetidine
25	128	130	O	for
26	132	132	O	8
27	134	137	O	days
28	139	146	O	resulted
29	148	149	O	in
30	151	152	O	an
31	154	161	O	increase
32	163	164	O	in
33	166	175	O	XXXXXXXX
34	177	179	O	AUC
35	181	183	O	and
36	185	188	O	Cmax
37	190	191	O	of
38	193	195	O	43%
39	197	199	O	and
40	201	203	O	39%
41	204	204	O	,
42	206	217	O	respectively
K/24:C54605

Celexa	819	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	22
Celexa 20 mg/day is the maximum recommended dose for patients taking concomitant cimetidine because of the risk of QT prolongation.
1	0	5	O	XXXXXXXX
2	7	8	O	20
3	10	11	O	mg
4	12	12	O	/
5	13	15	O	day
6	17	18	O	is
7	20	22	O	the
8	24	30	B-TRI	maximum
9	32	42	I-TRI	recommended
10	44	47	L-TRI	dose
11	49	51	O	for
12	53	60	O	patients
13	62	67	O	taking
14	69	79	O	concomitant
15	81	90	U-DYN	cimetidine
16	92	98	O	because
17	100	101	O	of
18	103	105	O	the
19	107	110	O	risk
20	112	113	O	of
21	115	116	B-EFF	QT
22	118	129	L-EFF	prolongation
D/15:21:1

Celexa	820	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	37
Digoxin - In subjects who had received 21 days of 40 mg/day Celexa, combined administration of Celexa and digoxin (single dose of 1 mg) did not significantly affect the pharmacokinetics of either citalopram or digoxin.
1	0	6	O	Digoxin
2	10	11	O	In
3	13	20	O	subjects
4	22	24	O	who
5	26	28	O	had
6	30	37	O	received
7	39	40	O	21
8	42	45	O	days
9	47	48	O	of
10	50	51	O	40
11	53	54	O	mg
12	55	55	O	/
13	56	58	O	day
14	60	65	O	XXXXXXXX
15	66	66	O	,
16	68	75	O	combined
17	77	90	O	administration
18	92	93	O	of
19	95	100	O	XXXXXXXX
20	102	104	O	and
21	106	112	O	digoxin
22	115	120	O	single
23	122	125	O	dose
24	127	128	O	of
25	130	130	O	1
26	132	133	O	mg
27	136	138	O	did
28	140	142	O	not
29	144	156	O	significantly
30	158	163	O	affect
31	165	167	O	the
32	169	184	O	pharmacokinetics
33	186	187	O	of
34	189	194	O	either
35	196	205	O	XXXXXXXX
36	207	208	O	or
37	210	216	O	digoxin
NULL

Celexa	821	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	31
Lithium - Coadministration of Celexa (40 mg/day for 10 days) and lithium (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of citalopram or lithium.
1	0	6	O	Lithium
2	10	25	O	Coadministration
3	27	28	O	of
4	30	35	O	XXXXXXXX
5	38	39	O	40
6	41	42	O	mg
7	43	43	O	/
8	44	46	O	day
9	48	50	O	for
10	52	53	O	10
11	55	58	O	days
12	61	63	O	and
13	65	71	O	lithium
14	74	75	O	30
15	77	80	O	mmol
16	81	81	O	/
17	82	84	O	day
18	86	88	O	for
19	90	90	O	5
20	92	95	O	days
21	98	100	O	had
22	102	103	O	no
23	105	115	O	significant
24	117	122	O	effect
25	124	125	O	on
26	127	129	O	the
27	131	146	O	pharmacokinetics
28	148	149	O	of
29	151	160	O	XXXXXXXX
30	162	163	O	or
31	165	171	O	lithium
NULL

Celexa	822	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	21
Nevertheless, plasma lithium levels should be monitored with appropriate adjustment to the lithium dose in accordance with standard clinical practice.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	19	O	plasma
4	21	27	U-UNK	lithium
5	29	34	O	levels
6	36	41	B-TRI	should
7	43	44	I-TRI	be
8	46	54	L-TRI	monitored
9	56	59	O	with
10	61	71	O	appropriate
11	73	82	O	adjustment
12	84	85	O	to
13	87	89	O	the
14	91	97	O	lithium
15	99	102	O	dose
16	104	105	O	in
17	107	116	O	accordance
18	118	121	O	with
19	123	130	O	standard
20	132	139	O	clinical
21	141	148	O	practice
NULL

Celexa	823	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	20
Because lithium may enhance the serotonergic effects of citalopram, caution should be exercised when Celexa and lithium are coadministered.
1	0	6	O	Because
2	8	14	U-DYN	lithium
3	16	18	O	may
4	20	26	B-EFF	enhance
5	28	30	I-EFF	the
6	32	43	I-EFF	serotonergic
7	45	51	I-EFF	effects
8	53	54	I-EFF	of
9	56	65	L-EFF	XXXXXXXX
10	66	66	O	,
11	68	74	O	caution
12	76	81	O	should
13	83	84	O	be
14	86	94	O	exercised
15	96	99	O	when
16	101	106	O	XXXXXXXX
17	108	110	O	and
18	112	118	O	lithium
19	120	122	O	are
20	124	137	O	coadministered
D/2:4:1

Celexa	824	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	43
Pimozide - In a controlled study, a single dose of pimozide 2 mg co-administered with citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
1	0	7	O	Pimozide
2	11	12	O	In
3	14	14	O	a
4	16	25	O	controlled
5	27	31	O	study
6	32	32	O	,
7	34	34	O	a
8	36	41	O	single
9	43	46	O	dose
10	48	49	O	of
11	51	58	U-DYN	pimozide
12	60	60	O	2
13	62	63	O	mg
14	65	66	O	co
15	68	79	O	administered
16	81	84	O	with
17	86	95	O	XXXXXXXX
18	97	98	O	40
19	100	101	O	mg
20	103	107	O	given
21	109	112	O	once
22	114	118	O	daily
23	120	122	O	for
24	124	125	O	11
25	127	130	O	days
26	132	134	O	was
27	136	145	O	associated
28	147	150	O	with
29	152	152	O	a
30	154	157	O	mean
31	159	166	B-EFF	increase
32	168	169	I-EFF	in
33	171	173	I-EFF	QTc
34	175	180	L-EFF	values
35	182	183	O	of
36	185	197	O	approximately
37	199	200	O	10
38	202	205	O	msec
39	207	214	O	compared
40	216	217	O	to
41	219	226	O	pimozide
42	228	232	O	given
43	234	238	O	alone
D/11:31:1

Celexa	825	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	11
Citalopram did not alter the mean AUC or Cmax of pimozide.
1	0	9	O	XXXXXXXX
2	11	13	O	did
3	15	17	O	not
4	19	23	O	alter
5	25	27	O	the
6	29	32	O	mean
7	34	36	O	AUC
8	38	39	O	or
9	41	44	O	Cmax
10	46	47	O	of
11	49	56	O	pimozide
NULL

Celexa	826	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	9
The mechanism of this pharmacodynamic interaction is not known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	20	O	this
5	22	36	O	pharmacodynamic
6	38	48	O	interaction
7	50	51	O	is
8	53	55	O	not
9	57	61	O	known
NULL

Celexa	827	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	29
Theophylline - Combined administration of Celexa (40 mg/day for 21 days) and the CYP1A2 substrate theophylline (single dose of 300 mg) did not affect the pharmacokinetics of theophylline.
1	0	11	O	Theophylline
2	15	22	O	Combined
3	24	37	O	administration
4	39	40	O	of
5	42	47	O	XXXXXXXX
6	50	51	O	40
7	53	54	O	mg
8	55	55	O	/
9	56	58	O	day
10	60	62	O	for
11	64	65	O	21
12	67	70	O	days
13	73	75	O	and
14	77	79	O	the
15	81	86	O	CYP1A2
16	88	96	O	substrate
17	98	109	O	theophylline
18	112	117	O	single
19	119	122	O	dose
20	124	125	O	of
21	127	129	O	300
22	131	132	O	mg
23	135	137	O	did
24	139	141	O	not
25	143	148	O	affect
26	150	152	O	the
27	154	169	O	pharmacokinetics
28	171	172	O	of
29	174	185	O	theophylline
NULL

Celexa	828	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	12
The effect of theophylline on the pharmacokinetics of citalopram was not evaluated.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	25	O	theophylline
5	27	28	O	on
6	30	32	O	the
7	34	49	O	pharmacokinetics
8	51	52	O	of
9	54	63	O	XXXXXXXX
10	65	67	O	was
11	69	71	O	not
12	73	81	O	evaluated
NULL

Celexa	829	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	24
Sumatriptan - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a SSRI and sumatriptan.
1	0	10	O	Sumatriptan
2	14	18	O	There
3	20	23	O	have
4	25	28	O	been
5	30	33	O	rare
6	35	47	O	postmarketing
7	49	55	O	reports
8	57	66	O	describing
9	68	75	O	patients
10	77	80	O	with
11	82	89	U-EFF	weakness
12	90	90	O	,
13	92	104	U-EFF	hyperreflexia
14	105	105	O	,
15	107	109	O	and
16	111	124	U-EFF	incoordination
17	126	134	O	following
18	136	138	O	the
19	140	142	O	use
20	144	145	O	of
21	147	147	O	a
22	149	152	O	SSRI
23	154	156	O	and
24	158	168	U-DYN	sumatriptan
D/24:11:1 D/24:13:1 D/24:16:1

Celexa	830	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	30
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	40	U-UNK	sumatriptan
6	42	44	O	and
7	46	47	O	an
8	49	52	O	SSRI
9	55	57	O	e.g
10	59	59	O	,
11	61	70	O	fluoxetine
12	71	71	O	,
13	73	83	O	fluvoxamine
14	84	84	O	,
15	86	95	O	paroxetine
16	96	96	O	,
17	98	107	O	sertraline
18	108	108	O	,
19	110	119	O	XXXXXXXX
20	122	123	O	is
21	125	134	O	clinically
22	136	144	O	warranted
23	145	145	O	,
24	147	157	O	appropriate
25	159	169	O	observation
26	171	172	O	of
27	174	176	O	the
28	178	184	O	patient
29	186	187	O	is
30	189	195	O	advised
NULL

Celexa	831	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	22
Warfarin - Administration of 40 mg/day Celexa for 21 days did not affect the pharmacokinetics of warfarin, a CYP3A4 substrate.
1	0	7	O	Warfarin
2	11	24	O	Administration
3	26	27	O	of
4	29	30	O	40
5	32	33	O	mg
6	34	34	O	/
7	35	37	O	day
8	39	44	O	XXXXXXXX
9	46	48	O	for
10	50	51	O	21
11	53	56	O	days
12	58	60	O	did
13	62	64	O	not
14	66	71	O	affect
15	73	75	O	the
16	77	92	O	pharmacokinetics
17	94	95	O	of
18	97	104	O	warfarin
19	105	105	O	,
20	107	107	O	a
21	109	114	O	CYP3A4
22	116	124	O	substrate
NULL

Celexa	832	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	14
Prothrombin time was increased by 5%, the clinical significance of which is unknown.
1	0	10	O	Prothrombin
2	12	15	O	time
3	17	19	O	was
4	21	29	O	increased
5	31	32	O	by
6	34	35	O	5%
7	36	36	O	,
8	38	40	O	the
9	42	49	O	clinical
10	51	62	O	significance
11	64	65	O	of
12	67	71	O	which
13	73	74	O	is
14	76	82	O	unknown
NULL

Celexa	833	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	35
Carbamazepine - Combined administration of Celexa (40 mg/day for 14 days) and carbamazepine (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of carbamazepine, a CYP3A4 substrate.
1	0	12	O	Carbamazepine
2	16	23	O	Combined
3	25	38	O	administration
4	40	41	O	of
5	43	48	O	XXXXXXXX
6	51	52	O	40
7	54	55	O	mg
8	56	56	O	/
9	57	59	O	day
10	61	63	O	for
11	65	66	O	14
12	68	71	O	days
13	74	76	O	and
14	78	90	O	carbamazepine
15	93	100	O	titrated
16	102	103	O	to
17	105	107	O	400
18	109	110	O	mg
19	111	111	O	/
20	112	114	O	day
21	116	118	O	for
22	120	121	O	35
23	123	126	O	days
24	129	131	O	did
25	133	135	O	not
26	137	149	O	significantly
27	151	156	O	affect
28	158	160	O	the
29	162	177	O	pharmacokinetics
30	179	180	O	of
31	182	194	O	carbamazepine
32	195	195	O	,
33	197	197	O	a
34	199	204	O	CYP3A4
35	206	214	O	substrate
NULL

Celexa	834	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	35
Although trough citalopram plasma levels were unaffected, given the enzyme-inducing properties of carbamazepine, the possibility that carbamazepine might increase the clearance of citalopram should be considered if the two drugs are coadministered.
1	0	7	O	Although
2	9	14	O	trough
3	16	25	O	XXXXXXXX
4	27	32	O	plasma
5	34	39	O	levels
6	41	44	O	were
7	46	55	O	unaffected
8	56	56	O	,
9	58	62	O	given
10	64	66	O	the
11	68	73	O	enzyme
12	75	82	O	inducing
13	84	93	O	properties
14	95	96	O	of
15	98	110	U-KIN	carbamazepine
16	111	111	O	,
17	113	115	O	the
18	117	127	O	possibility
19	129	132	O	that
20	134	146	O	carbamazepine
21	148	152	O	might
22	154	161	B-TRI	increase
23	163	165	I-TRI	the
24	167	175	L-TRI	clearance
25	177	178	O	of
26	180	189	O	XXXXXXXX
27	191	196	O	should
28	198	199	O	be
29	201	210	O	considered
30	212	213	O	if
31	215	217	O	the
32	219	221	O	two
33	223	227	O	drugs
34	229	231	O	are
35	233	246	O	coadministered
K/15:C54356

Celexa	835	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	35
Triazolam - Combined administration of Celexa (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate triazolam (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either citalopram or triazolam.
1	0	8	O	Triazolam
2	12	19	O	Combined
3	21	34	O	administration
4	36	37	O	of
5	39	44	O	XXXXXXXX
6	47	54	O	titrated
7	56	57	O	to
8	59	60	O	40
9	62	63	O	mg
10	64	64	O	/
11	65	67	O	day
12	69	71	O	for
13	73	74	O	28
14	76	79	O	days
15	82	84	O	and
16	86	88	O	the
17	90	95	O	CYP3A4
18	97	105	O	substrate
19	107	115	O	triazolam
20	118	123	O	single
21	125	128	O	dose
22	130	131	O	of
23	133	136	O	0.25
24	138	139	O	mg
25	142	144	O	did
26	146	148	O	not
27	150	162	O	significantly
28	164	169	O	affect
29	171	173	O	the
30	175	190	O	pharmacokinetics
31	192	193	O	of
32	195	200	O	either
33	202	211	O	XXXXXXXX
34	213	214	O	or
35	216	224	O	triazolam
NULL

Celexa	836	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	34
Ketoconazole - Combined administration of Celexa (40 mg) and ketoconazole (200 mg) decreased the Cmax and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram.
1	0	11	O	Ketoconazole
2	15	22	O	Combined
3	24	37	O	administration
4	39	40	O	of
5	42	47	O	XXXXXXXX
6	50	51	O	40
7	53	54	O	mg
8	57	59	O	and
9	61	72	U-KIN	ketoconazole
10	75	77	O	200
11	79	80	O	mg
12	83	91	O	decreased
13	93	95	O	the
14	97	100	O	Cmax
15	102	104	O	and
16	106	108	O	AUC
17	110	111	O	of
18	113	124	O	ketoconazole
19	126	127	O	by
20	129	131	O	21%
21	133	135	O	and
22	137	139	O	10%
23	140	140	O	,
24	142	153	O	respectively
25	154	154	O	,
26	156	158	O	and
27	160	162	O	did
28	164	166	O	not
29	168	180	O	significantly
30	182	187	O	affect
31	189	191	O	the
32	193	208	O	pharmacokinetics
33	210	211	O	of
34	213	222	O	XXXXXXXX
K/9:C54614

Celexa	837	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	25
CYP2C19 Inhibitors - Celexa 20 mg/day is the maximum recommended dose for patients taking concomitant CYP2C19 inhibitors because of the risk of QT prolongation.
1	0	6	B-DYN	CYP2C19
2	8	17	L-DYN	Inhibitors
3	21	26	O	XXXXXXXX
4	28	29	O	20
5	31	32	O	mg
6	33	33	O	/
7	34	36	O	day
8	38	39	O	is
9	41	43	O	the
10	45	51	B-TRI	maximum
11	53	63	I-TRI	recommended
12	65	68	L-TRI	dose
13	70	72	O	for
14	74	81	O	patients
15	83	88	O	taking
16	90	100	O	concomitant
17	102	108	O	CYP2C19
18	110	119	O	inhibitors
19	121	127	O	because
20	129	130	O	of
21	132	134	O	the
22	136	139	O	risk
23	141	142	O	of
24	144	145	B-EFF	QT
25	147	158	L-EFF	prolongation
D/1:24:1

Celexa	838	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	27
Metoprolol - Administration of 40 mg/day Celexa for 22 days resulted in a two-fold increase in the plasma levels of the beta-adrenergic blocker metoprolol.
1	0	9	O	Metoprolol
2	13	26	O	Administration
3	28	29	O	of
4	31	32	O	40
5	34	35	O	mg
6	36	36	O	/
7	37	39	O	day
8	41	46	O	XXXXXXXX
9	48	50	O	for
10	52	53	O	22
11	55	58	O	days
12	60	67	O	resulted
13	69	70	O	in
14	72	72	O	a
15	74	76	O	two
16	78	81	O	fold
17	83	90	O	increase
18	92	93	O	in
19	95	97	O	the
20	99	104	O	plasma
21	106	111	O	levels
22	113	114	O	of
23	116	118	O	the
24	120	123	O	beta
25	125	134	O	adrenergic
26	136	142	O	blocker
27	144	153	U-KIN	metoprolol
K/27:C54357

Celexa	839	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	10
Increased metoprolol plasma levels have been associated with decreased cardioselectivity.
1	0	8	O	Increased
2	10	19	U-DYN	metoprolol
3	21	26	O	plasma
4	28	33	O	levels
5	35	38	O	have
6	40	43	O	been
7	45	54	O	associated
8	56	59	O	with
9	61	69	B-EFF	decreased
10	71	87	L-EFF	cardioselectivity
D/2:9:1

Celexa	840	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	16
Coadministration of Celexa and metoprolol had no clinically significant effects on blood pressure or heart rate.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	25	O	XXXXXXXX
4	27	29	O	and
5	31	40	O	metoprolol
6	42	44	O	had
7	46	47	O	no
8	49	58	O	clinically
9	60	70	O	significant
10	72	78	O	effects
11	80	81	O	on
12	83	87	O	blood
13	89	96	O	pressure
14	98	99	O	or
15	101	105	O	heart
16	107	110	O	rate
NULL

Celexa	841	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	19
Imipramine and Other Tricyclic Antidepressants (TCAs) - In vitro studies suggest that citalopram is a relatively weak inhibitor of CYP2D6.
1	0	9	O	Imipramine
2	11	13	O	and
3	15	19	O	Other
4	21	29	O	Tricyclic
5	31	45	O	Antidepressants
6	48	51	O	TCAs
7	56	57	O	In
8	59	63	O	vitro
9	65	71	O	studies
10	73	79	O	suggest
11	81	84	O	that
12	86	95	O	XXXXXXXX
13	97	98	O	is
14	100	100	O	a
15	102	111	O	relatively
16	113	116	O	weak
17	118	126	O	inhibitor
18	128	129	O	of
19	131	136	O	CYP2D6
NULL

Celexa	842	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	36
Coadministration of Celexa (40 mg/day for 10 days) with the TCA imipramine (single dose of 100 mg), a substrate for CYP2D6, did not significantly affect the plasma concentrations of imipramine or citalopram.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	25	O	XXXXXXXX
4	28	29	O	40
5	31	32	O	mg
6	33	33	O	/
7	34	36	O	day
8	38	40	O	for
9	42	43	O	10
10	45	48	O	days
11	51	54	O	with
12	56	58	O	the
13	60	62	O	TCA
14	64	73	O	imipramine
15	76	81	O	single
16	83	86	O	dose
17	88	89	O	of
18	91	93	O	100
19	95	96	O	mg
20	98	98	O	,
21	100	100	O	a
22	102	110	O	substrate
23	112	114	O	for
24	116	121	O	CYP2D6
25	122	122	O	,
26	124	126	O	did
27	128	130	O	not
28	132	144	O	significantly
29	146	151	O	affect
30	153	155	O	the
31	157	162	O	plasma
32	164	177	O	concentrations
33	179	180	O	of
34	182	191	O	imipramine
35	193	194	O	or
36	196	205	O	XXXXXXXX
NULL

Celexa	843	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	14
However, the concentration of the imipramine metabolite desipramine was increased by approximately 50%.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	25	O	concentration
5	27	28	O	of
6	30	32	O	the
7	34	43	O	imipramine
8	45	54	O	metabolite
9	56	66	O	desipramine
10	68	70	O	was
11	72	80	O	increased
12	82	83	O	by
13	85	97	O	approximately
14	99	101	O	50%
NULL

Celexa	844	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	9
The clinical significance of the desipramine change is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	31	O	the
6	33	43	O	desipramine
7	45	50	O	change
8	52	53	O	is
9	55	61	O	unknown
NULL

Celexa	845	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	12
Nevertheless, caution is indicated in the coadministration of TCAs with Celexa.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	57	O	coadministration
9	59	60	O	of
10	62	65	U-UNK	TCAs
11	67	70	O	with
12	72	77	O	XXXXXXXX
NULL

Celexa	846	34073-7	4259d9b1-de34-43a4-85a8-41dd214e9177	18
Electroconvulsive Therapy (ECT) - There are no clinical studies of the combined use of electroconvulsive therapy (ECT) and Celexa.
1	0	16	O	Electroconvulsive
2	18	24	O	Therapy
3	27	29	O	ECT
4	34	38	O	There
5	40	42	O	are
6	44	45	O	no
7	47	54	O	clinical
8	56	62	O	studies
9	64	65	O	of
10	67	69	O	the
11	71	78	O	combined
12	80	82	O	use
13	84	85	O	of
14	87	103	O	electroconvulsive
15	105	111	O	therapy
16	114	116	O	ECT
17	119	121	O	and
18	123	128	O	XXXXXXXX
NULL

Celexa	847	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	38
The mechanism of action of citalopram HBr as an antidepressant is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	40	O	HBr
8	42	43	O	as
9	45	46	O	an
10	48	61	O	antidepressant
11	63	64	O	is
12	66	73	O	presumed
13	75	76	O	to
14	78	79	O	be
15	81	86	O	linked
16	88	89	O	to
17	91	102	O	potentiation
18	104	105	O	of
19	107	118	O	serotonergic
20	120	127	O	activity
21	129	130	O	in
22	132	134	O	the
23	136	142	O	central
24	144	150	O	nervous
25	152	157	O	system
26	160	162	O	CNS
27	165	173	O	resulting
28	175	178	O	from
29	180	182	O	its
30	184	193	O	inhibition
31	195	196	O	of
32	198	200	O	CNS
33	202	209	O	neuronal
34	211	218	O	reuptake
35	220	221	O	of
36	223	231	O	serotonin
37	234	234	O	5
38	236	237	O	HT
NULL

Celexa	848	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	30
In vitro and in vivo studies in animals suggest that citalopram is a highly selective serotonin reuptake inhibitor (SSRI) with minimal effects on norepinephrine (NE) and dopamine (DA) neuronal reuptake.
1	0	1	O	In
2	3	7	O	vitro
3	9	11	O	and
4	13	14	O	in
5	16	19	O	vivo
6	21	27	O	studies
7	29	30	O	in
8	32	38	O	animals
9	40	46	O	suggest
10	48	51	O	that
11	53	62	O	XXXXXXXX
12	64	65	O	is
13	67	67	O	a
14	69	74	O	highly
15	76	84	O	selective
16	86	94	O	serotonin
17	96	103	O	reuptake
18	105	113	O	inhibitor
19	116	119	O	SSRI
20	122	125	O	with
21	127	133	O	minimal
22	135	141	O	effects
23	143	144	O	on
24	146	159	O	norepinephrine
25	162	163	O	NE
26	166	168	O	and
27	170	177	O	dopamine
28	180	181	O	DA
29	184	191	O	neuronal
30	193	200	O	reuptake
NULL

Celexa	849	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	21
Tolerance to the inhibition of 5-HT uptake is not induced by long-term (14-day) treatment of rats with citalopram.
1	0	8	O	Tolerance
2	10	11	O	to
3	13	15	O	the
4	17	26	O	inhibition
5	28	29	O	of
6	31	31	O	5
7	33	34	O	HT
8	36	41	O	uptake
9	43	44	O	is
10	46	48	O	not
11	50	56	O	induced
12	58	59	O	by
13	61	64	O	long
14	66	69	O	term
15	72	73	O	14
16	75	77	O	day
17	80	88	O	treatment
18	90	91	O	of
19	93	96	O	rats
20	98	101	O	with
21	103	112	O	XXXXXXXX
NULL

Celexa	850	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	25
Citalopram is a racemic mixture (50/50), and the inhibition of 5-HT reuptake by citalopram is primarily due to the (S)-enantiomer.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	22	O	racemic
5	24	30	O	mixture
6	33	34	O	50
7	35	35	O	/
8	36	37	O	50
9	39	39	O	,
10	41	43	O	and
11	45	47	O	the
12	49	58	O	inhibition
13	60	61	O	of
14	63	63	O	5
15	65	66	O	HT
16	68	75	O	reuptake
17	77	78	O	by
18	80	89	O	XXXXXXXX
19	91	92	O	is
20	94	102	O	primarily
21	104	106	O	due
22	108	109	O	to
23	111	113	O	the
24	116	116	O	S
25	119	128	O	enantiomer
NULL

Celexa	851	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	41
Citalopram has no or very low affinity for 5-HT1A, 5-HT2A, dopamine D1 and D2, A1-, A2-, and B-adrenergic, histamine H1, gamma aminobutyric acid (GABA), muscarinic cholinergic, and benzodiazepine receptors.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	16	O	no
4	18	19	O	or
5	21	24	O	very
6	26	28	O	low
7	30	37	O	affinity
8	39	41	O	for
9	43	43	O	5
10	45	48	O	HT1A
11	49	49	O	,
12	51	51	O	5
13	53	56	O	HT2A
14	57	57	O	,
15	59	66	O	dopamine
16	68	69	O	D1
17	71	73	O	and
18	75	76	O	D2
19	77	77	O	,
20	79	80	O	A1
21	82	82	O	,
22	84	85	O	A2
23	87	87	O	,
24	89	91	O	and
25	93	93	O	B
26	95	104	O	adrenergic
27	105	105	O	,
28	107	115	O	histamine
29	117	118	O	H1
30	119	119	O	,
31	121	125	O	gamma
32	127	138	O	aminobutyric
33	140	143	O	acid
34	146	149	O	GABA
35	151	151	O	,
36	153	162	O	muscarinic
37	164	174	O	cholinergic
38	175	175	O	,
39	177	179	O	and
40	181	194	O	benzodiazepine
41	196	204	O	receptors
NULL

Celexa	852	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	28
Antagonism of muscarinic, histaminergic, and adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of other psychotropic drugs.
1	0	9	O	Antagonism
2	11	12	O	of
3	14	23	O	muscarinic
4	24	24	O	,
5	26	38	O	histaminergic
6	39	39	O	,
7	41	43	O	and
8	45	54	O	adrenergic
9	56	64	O	receptors
10	66	68	O	has
11	70	73	O	been
12	75	86	O	hypothesized
13	88	89	O	to
14	91	92	O	be
15	94	103	O	associated
16	105	108	O	with
17	110	116	O	various
18	118	132	O	anticholinergic
19	133	133	O	,
20	135	142	O	sedative
21	143	143	O	,
22	145	147	O	and
23	149	162	O	cardiovascular
24	164	170	O	effects
25	172	173	O	of
26	175	179	O	other
27	181	192	O	psychotropic
28	194	198	O	drugs
NULL

Celexa	853	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	23
The single- and multiple-dose pharmacokinetics of citalopram are linear and dose-proportional in a dose range of 10-60 mg/day.
1	0	2	O	The
2	4	9	O	single
3	12	14	O	and
4	16	23	O	multiple
5	25	28	O	dose
6	30	45	O	pharmacokinetics
7	47	48	O	of
8	50	59	O	XXXXXXXX
9	61	63	O	are
10	65	70	O	linear
11	72	74	O	and
12	76	79	O	dose
13	81	92	O	proportional
14	94	95	O	in
15	97	97	O	a
16	99	102	O	dose
17	104	108	O	range
18	110	111	O	of
19	113	114	O	10
20	116	117	O	60
21	119	120	O	mg
22	121	121	O	/
23	122	124	O	day
NULL

Celexa	854	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	17
Biotransformation of citalopram is mainly hepatic, with a mean terminal half-life of about 35 hours.
1	0	16	O	Biotransformation
2	18	19	O	of
3	21	30	O	XXXXXXXX
4	32	33	O	is
5	35	40	O	mainly
6	42	48	O	hepatic
7	49	49	O	,
8	51	54	O	with
9	56	56	O	a
10	58	61	O	mean
11	63	70	O	terminal
12	72	75	O	half
13	77	80	O	life
14	82	83	O	of
15	85	89	O	about
16	91	92	O	35
17	94	98	O	hours
NULL

Celexa	855	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	15
With once daily dosing, steady state plasma concentrations are achieved within approximately one week.
1	0	3	O	With
2	5	8	O	once
3	10	14	O	daily
4	16	21	O	dosing
5	22	22	O	,
6	24	29	O	steady
7	31	35	O	state
8	37	42	O	plasma
9	44	57	O	concentrations
10	59	61	O	are
11	63	70	O	achieved
12	72	77	O	within
13	79	91	O	approximately
14	93	95	O	one
15	97	100	O	week
NULL

Celexa	856	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	33
At steady state, the extent of accumulation of citalopram in plasma, based on the half-life, is expected to be 2.5 times the plasma concentrations observed after a single dose.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	19	O	the
6	21	26	O	extent
7	28	29	O	of
8	31	42	O	accumulation
9	44	45	O	of
10	47	56	O	XXXXXXXX
11	58	59	O	in
12	61	66	O	plasma
13	67	67	O	,
14	69	73	O	based
15	75	76	O	on
16	78	80	O	the
17	82	85	O	half
18	87	90	O	life
19	91	91	O	,
20	93	94	O	is
21	96	103	O	expected
22	105	106	O	to
23	108	109	O	be
24	111	113	O	2.5
25	115	119	O	times
26	121	123	O	the
27	125	130	O	plasma
28	132	145	O	concentrations
29	147	154	O	observed
30	156	160	O	after
31	162	162	O	a
32	164	169	O	single
33	171	174	O	dose
NULL

Celexa	857	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	19
Following a single oral dose (40 mg tablet) of citalopram, peak blood levels occur at about 4 hours.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	22	O	oral
5	24	27	O	dose
6	30	31	O	40
7	33	34	O	mg
8	36	41	O	tablet
9	44	45	O	of
10	47	56	O	XXXXXXXX
11	57	57	O	,
12	59	62	O	peak
13	64	68	O	blood
14	70	75	O	levels
15	77	81	O	occur
16	83	84	O	at
17	86	90	O	about
18	92	92	O	4
19	94	98	O	hours
NULL

Celexa	858	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	21
The absolute bioavailability of citalopram was about 80% relative to an intravenous dose, and absorption is not affected by food.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	41	O	XXXXXXXX
6	43	45	O	was
7	47	51	O	about
8	53	55	O	80%
9	57	64	O	relative
10	66	67	O	to
11	69	70	O	an
12	72	82	O	intravenous
13	84	87	O	dose
14	88	88	O	,
15	90	92	O	and
16	94	103	O	absorption
17	105	106	O	is
18	108	110	O	not
19	112	119	O	affected
20	121	122	O	by
21	124	127	O	food
NULL

Celexa	859	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	33
The volume of distribution of citalopram is about 12 L/kg and the binding of citalopram (CT), demethylcitalopram (DCT) and didemethylcitalopram (DDCT) to human plasma proteins is about 80%.
1	0	2	O	The
2	4	9	O	volume
3	11	12	O	of
4	14	25	O	distribution
5	27	28	O	of
6	30	39	O	XXXXXXXX
7	41	42	O	is
8	44	48	O	about
9	50	51	O	12
10	53	53	O	L
11	54	54	O	/
12	55	56	O	kg
13	58	60	O	and
14	62	64	O	the
15	66	72	O	binding
16	74	75	O	of
17	77	86	O	XXXXXXXX
18	89	90	O	CT
19	92	92	O	,
20	94	101	O	demethyl
21	102	111	O	XXXXXXXX
22	114	116	O	DCT
23	119	121	O	and
24	123	132	O	didemethyl
25	133	142	O	XXXXXXXX
26	145	148	O	DDCT
27	151	152	O	to
28	154	158	O	human
29	160	165	O	plasma
30	167	174	O	proteins
31	176	177	O	is
32	179	183	O	about
33	185	187	O	80%
NULL

Celexa	860	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	25
Following intravenous administrations of citalopram, the fraction of drug recovered in the urine as citalopram and DCT was about 10% and 5%, respectively.
1	0	8	O	Following
2	10	20	O	intravenous
3	22	36	O	administrations
4	38	39	O	of
5	41	50	O	XXXXXXXX
6	51	51	O	,
7	53	55	O	the
8	57	64	O	fraction
9	66	67	O	of
10	69	72	O	drug
11	74	82	O	recovered
12	84	85	O	in
13	87	89	O	the
14	91	95	O	urine
15	97	98	O	as
16	100	109	O	XXXXXXXX
17	111	113	O	and
18	115	117	O	DCT
19	119	121	O	was
20	123	127	O	about
21	129	131	O	10%
22	133	135	O	and
23	137	138	O	5%
24	139	139	O	,
25	141	152	O	respectively
NULL

Celexa	861	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	20
The systemic clearance of citalopram was 330 mL/min, with approximately 20% of that due to renal clearance.
1	0	2	O	The
2	4	11	O	systemic
3	13	21	O	clearance
4	23	24	O	of
5	26	35	O	XXXXXXXX
6	37	39	O	was
7	41	43	O	330
8	45	46	O	mL
9	47	47	O	/
10	48	50	O	min
11	51	51	O	,
12	53	56	O	with
13	58	70	O	approximately
14	72	74	O	20%
15	76	77	O	of
16	79	82	O	that
17	84	86	O	due
18	88	89	O	to
19	91	95	O	renal
20	97	105	O	clearance
NULL

Celexa	862	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	22
Citalopram is metabolized to demethylcitalopram (DCT), didemethylcitalopram (DDCT), citalopram-N-oxide, and a deaminated propionic acid derivative.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	to
5	29	36	O	demethyl
6	37	46	O	XXXXXXXX
7	49	51	O	DCT
8	53	53	O	,
9	55	64	O	didemethyl
10	65	74	O	XXXXXXXX
11	77	80	O	DDCT
12	82	82	O	,
13	84	93	O	XXXXXXXX
14	95	95	O	N
15	97	101	O	oxide
16	102	102	O	,
17	104	106	O	and
18	108	108	O	a
19	110	119	O	deaminated
20	121	129	O	propionic
21	131	134	O	acid
22	136	145	O	derivative
NULL

Celexa	863	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	11
In humans, unchanged citalopram is the predominant compound in plasma.
1	0	1	O	In
2	3	8	O	humans
3	9	9	O	,
4	11	19	O	unchanged
5	21	30	O	XXXXXXXX
6	32	33	O	is
7	35	37	O	the
8	39	49	O	predominant
9	51	58	O	compound
10	60	61	O	in
11	63	68	O	plasma
NULL

Celexa	864	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	32
At steady state, the concentrations of citalopram's metabolites, DCT and DDCT, in plasma are approximately one-half and one-tenth, respectively, that of the parent drug.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	19	O	the
6	21	34	O	concentrations
7	36	37	O	of
8	39	48	O	XXXXXXXX
9	49	50	O	's
10	52	62	O	metabolites
11	63	63	O	,
12	65	67	O	DCT
13	69	71	O	and
14	73	76	O	DDCT
15	77	77	O	,
16	79	80	O	in
17	82	87	O	plasma
18	89	91	O	are
19	93	105	O	approximately
20	107	109	O	one
21	111	114	O	half
22	116	118	O	and
23	120	122	O	one
24	124	128	O	tenth
25	129	129	O	,
26	131	142	O	respectively
27	143	143	O	,
28	145	148	O	that
29	150	151	O	of
30	153	155	O	the
31	157	162	O	parent
32	164	167	O	drug
NULL

Celexa	865	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	39
In vitro studies show that citalopram is at least 8 times more potent than its metabolites in the inhibition of serotonin reuptake, suggesting that the metabolites evaluated do not likely contribute significantly to the antidepressant actions of citalopram.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	show
5	22	25	O	that
6	27	36	O	XXXXXXXX
7	38	39	O	is
8	41	42	O	at
9	44	48	O	least
10	50	50	O	8
11	52	56	O	times
12	58	61	O	more
13	63	68	O	potent
14	70	73	O	than
15	75	77	O	its
16	79	89	O	metabolites
17	91	92	O	in
18	94	96	O	the
19	98	107	O	inhibition
20	109	110	O	of
21	112	120	O	serotonin
22	122	129	O	reuptake
23	130	130	O	,
24	132	141	O	suggesting
25	143	146	O	that
26	148	150	O	the
27	152	162	O	metabolites
28	164	172	O	evaluated
29	174	175	O	do
30	177	179	O	not
31	181	186	O	likely
32	188	197	O	contribute
33	199	211	O	significantly
34	213	214	O	to
35	216	218	O	the
36	220	233	O	antidepressant
37	235	241	O	actions
38	243	244	O	of
39	246	255	O	XXXXXXXX
NULL

Celexa	866	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	23
In vitro studies using human liver microsomes indicated that CYP3A4 and CYP2C19 are the primary isozymes involved in the N-demethylation of citalopram.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	21	O	using
5	23	27	O	human
6	29	33	O	liver
7	35	44	O	microsomes
8	46	54	O	indicated
9	56	59	O	that
10	61	66	O	CYP3A4
11	68	70	O	and
12	72	78	O	CYP2C19
13	80	82	O	are
14	84	86	O	the
15	88	94	O	primary
16	96	103	O	isozymes
17	105	112	O	involved
18	114	115	O	in
19	117	119	O	the
20	121	121	O	N
21	123	135	O	demethylation
22	137	138	O	of
23	140	149	O	XXXXXXXX
NULL

Celexa	867	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	20
Age - Citalopram pharmacokinetics in subjects > 60 years of age were compared to younger subjects in two normal volunteer studies.
1	0	2	O	Age
2	6	15	O	XXXXXXXX
3	17	32	O	pharmacokinetics
4	34	35	O	in
5	37	44	O	subjects
6	46	46	O	>
7	48	49	O	60
8	51	55	O	years
9	57	58	O	of
10	60	62	O	age
11	64	67	O	were
12	69	76	O	compared
13	78	79	O	to
14	81	87	O	younger
15	89	96	O	subjects
16	98	99	O	in
17	101	103	O	two
18	105	110	O	normal
19	112	120	O	volunteer
20	122	128	O	studies
NULL

Celexa	868	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	42
In a single-dose study, citalopram AUC and half-life were increased in the subjects > 60 years old by 30% and 50%, respectively, whereas in a multiple-dose study they were increased by 23% and 30%, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	15	O	dose
5	17	21	O	study
6	22	22	O	,
7	24	33	O	XXXXXXXX
8	35	37	O	AUC
9	39	41	O	and
10	43	46	O	half
11	48	51	O	life
12	53	56	O	were
13	58	66	O	increased
14	68	69	O	in
15	71	73	O	the
16	75	82	O	subjects
17	84	84	O	>
18	86	87	O	60
19	89	93	O	years
20	95	97	O	old
21	99	100	O	by
22	102	104	O	30%
23	106	108	O	and
24	110	112	O	50%
25	113	113	O	,
26	115	126	O	respectively
27	127	127	O	,
28	129	135	O	whereas
29	137	138	O	in
30	140	140	O	a
31	142	149	O	multiple
32	151	154	O	dose
33	156	160	O	study
34	162	165	O	they
35	167	170	O	were
36	172	180	O	increased
37	182	183	O	by
38	185	187	O	23%
39	189	191	O	and
40	193	195	O	30%
41	196	196	O	,
42	198	209	O	respectively
NULL

Celexa	869	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	27
20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age , due to the risk of QT prolongation.
1	0	1	O	20
2	3	4	O	mg
3	5	5	O	/
4	6	8	O	day
5	10	11	O	is
6	13	15	O	the
7	17	23	O	maximum
8	25	35	O	recommended
9	37	40	O	dose
10	42	44	O	for
11	46	53	O	patients
12	55	57	O	who
13	59	61	O	are
14	63	69	O	greater
15	71	74	O	than
16	76	77	O	60
17	79	83	O	years
18	85	86	O	of
19	88	90	O	age
20	92	92	O	,
21	94	96	O	due
22	98	99	O	to
23	101	103	O	the
24	105	108	O	risk
25	110	111	O	of
26	113	114	O	QT
27	116	127	O	prolongation
NULL

Celexa	870	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	23
Gender - In three pharmacokinetic studies (total N=32), citalopram AUC in women was one and a half to two times that in men.
1	0	5	O	Gender
2	9	10	O	In
3	12	16	O	three
4	18	32	O	pharmacokinetic
5	34	40	O	studies
6	43	47	O	total
7	49	52	O	N=32
8	54	54	O	,
9	56	65	O	XXXXXXXX
10	67	69	O	AUC
11	71	72	O	in
12	74	78	O	women
13	80	82	O	was
14	84	86	O	one
15	88	90	O	and
16	92	92	O	a
17	94	97	O	half
18	99	100	O	to
19	102	104	O	two
20	106	110	O	times
21	112	115	O	that
22	117	118	O	in
23	120	122	O	men
NULL

Celexa	871	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	12
This difference was not observed in five other pharmacokinetic studies (total N=114).
1	0	3	O	This
2	5	14	O	difference
3	16	18	O	was
4	20	22	O	not
5	24	31	O	observed
6	33	34	O	in
7	36	39	O	five
8	41	45	O	other
9	47	61	O	pharmacokinetic
10	63	69	O	studies
11	72	76	O	total
12	78	82	O	N=114
NULL

Celexa	872	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	20
In clinical studies, no differences in steady state serum citalopram levels were seen between men (N=237) and women (N=388).
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	22	O	no
6	24	34	O	differences
7	36	37	O	in
8	39	44	O	steady
9	46	50	O	state
10	52	56	O	serum
11	58	67	O	XXXXXXXX
12	69	74	O	levels
13	76	79	O	were
14	81	84	O	seen
15	86	92	O	between
16	94	96	O	men
17	99	103	O	N=237
18	106	108	O	and
19	110	114	O	women
20	117	121	O	N=388
NULL

Celexa	873	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	12
There were no gender differences in the pharmacokinetics of DCT and DDCT.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	19	O	gender
5	21	31	O	differences
6	33	34	O	in
7	36	38	O	the
8	40	55	O	pharmacokinetics
9	57	58	O	of
10	60	62	O	DCT
11	64	66	O	and
12	68	71	O	DDCT
NULL

Celexa	874	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	11
No adjustment of dosage on the basis of gender is recommended.
1	0	1	O	No
2	3	12	O	adjustment
3	14	15	O	of
4	17	22	O	dosage
5	24	25	O	on
6	27	29	O	the
7	31	35	O	basis
8	37	38	O	of
9	40	45	O	gender
10	47	48	O	is
11	50	60	O	recommended
NULL

Celexa	875	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	25
Reduced hepatic function - Citalopram oral clearance was reduced by 37% and half-life was doubled in patients with reduced hepatic function compared to normal subjects.
1	0	6	O	Reduced
2	8	14	O	hepatic
3	16	23	O	function
4	27	36	O	XXXXXXXX
5	38	41	O	oral
6	43	51	O	clearance
7	53	55	O	was
8	57	63	O	reduced
9	65	66	O	by
10	68	70	O	37%
11	72	74	O	and
12	76	79	O	half
13	81	84	O	life
14	86	88	O	was
15	90	96	O	doubled
16	98	99	O	in
17	101	108	O	patients
18	110	113	O	with
19	115	121	O	reduced
20	123	129	O	hepatic
21	131	138	O	function
22	140	147	O	compared
23	149	150	O	to
24	152	157	O	normal
25	159	166	O	subjects
NULL

Celexa	876	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	21
20 mg/day is the maximum recommended dose for hepatically impaired patients , due to the risk of QT prolongation.
1	0	1	O	20
2	3	4	O	mg
3	5	5	O	/
4	6	8	O	day
5	10	11	O	is
6	13	15	O	the
7	17	23	O	maximum
8	25	35	O	recommended
9	37	40	O	dose
10	42	44	O	for
11	46	56	O	hepatically
12	58	65	O	impaired
13	67	74	O	patients
14	76	76	O	,
15	78	80	O	due
16	82	83	O	to
17	85	87	O	the
18	89	92	O	risk
19	94	95	O	of
20	97	98	O	QT
21	100	111	O	prolongation
NULL

Celexa	877	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	22
CYP2C19 poor metabolizers -- In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively.
1	0	6	O	CYP2C19
2	8	11	O	poor
3	13	24	O	metabolizers
4	29	30	O	In
5	32	38	O	CYP2C19
6	40	43	O	poor
7	45	56	O	metabolizers
8	57	57	O	,
9	59	68	O	XXXXXXXX
10	70	75	O	steady
11	77	81	O	state
12	83	86	O	Cmax
13	88	90	O	and
14	92	94	O	AUC
15	96	98	O	was
16	100	108	O	increased
17	110	111	O	by
18	113	115	O	68%
19	117	119	O	and
20	121	124	O	107%
21	125	125	O	,
22	127	138	O	respectively
NULL

Celexa	878	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	21
Celexa 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation.
1	0	5	O	XXXXXXXX
2	7	8	O	20
3	10	11	O	mg
4	12	12	O	/
5	13	15	O	day
6	17	18	O	is
7	20	22	O	the
8	24	30	O	maximum
9	32	42	O	recommended
10	44	47	O	dose
11	49	50	O	in
12	52	58	O	CYP2C19
13	60	63	O	poor
14	65	76	O	metabolizers
15	78	80	O	due
16	82	83	O	to
17	85	87	O	the
18	89	92	O	risk
19	94	95	O	of
20	97	98	O	QT
21	100	111	O	prolongation
NULL

Celexa	879	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	19
CYP2D6 poor metabolizers - Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6.
1	0	5	O	CYP2D6
2	7	10	O	poor
3	12	23	O	metabolizers
4	27	36	O	XXXXXXXX
5	38	43	O	steady
6	45	49	O	state
7	51	56	O	levels
8	58	61	O	were
9	63	65	O	not
10	67	79	O	significantly
11	81	89	O	different
12	91	92	O	in
13	94	97	O	poor
14	99	110	O	metabolizers
15	112	114	O	and
16	116	124	O	extensive
17	126	137	O	metabolizers
18	139	140	O	of
19	142	147	O	CYP2D6
NULL

Celexa	880	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	25
Reduced renal function - In patients with mild to moderate renal function impairment, oral clearance of citalopram was reduced by 17% compared to normal subjects.
1	0	6	O	Reduced
2	8	12	O	renal
3	14	21	O	function
4	25	26	O	In
5	28	35	O	patients
6	37	40	O	with
7	42	45	O	mild
8	47	48	O	to
9	50	57	O	moderate
10	59	63	O	renal
11	65	72	O	function
12	74	83	O	impairment
13	84	84	O	,
14	86	89	O	oral
15	91	99	O	clearance
16	101	102	O	of
17	104	113	O	XXXXXXXX
18	115	117	O	was
19	119	125	O	reduced
20	127	128	O	by
21	130	132	O	17%
22	134	141	O	compared
23	143	144	O	to
24	146	151	O	normal
25	153	160	O	subjects
NULL

Celexa	881	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	9
No adjustment of dosage for such patients is recommended.
1	0	1	O	No
2	3	12	O	adjustment
3	14	15	O	of
4	17	22	O	dosage
5	24	26	O	for
6	28	31	O	such
7	33	40	O	patients
8	42	43	O	is
9	45	55	O	recommended
NULL

Celexa	882	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	23
No information is available about the pharmacokinetics of citalopram in patients with severely reduced renal function (creatinine clearance < 20 mL/min).
1	0	1	O	No
2	3	13	O	information
3	15	16	O	is
4	18	26	O	available
5	28	32	O	about
6	34	36	O	the
7	38	53	O	pharmacokinetics
8	55	56	O	of
9	58	67	O	XXXXXXXX
10	69	70	O	in
11	72	79	O	patients
12	81	84	O	with
13	86	93	O	severely
14	95	101	O	reduced
15	103	107	O	renal
16	109	116	O	function
17	119	128	O	creatinine
18	130	138	O	clearance
19	140	140	O	<
20	142	143	O	20
21	145	146	O	mL
22	147	147	O	/
23	148	150	O	min
NULL

Celexa	883	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	37
In vitro enzyme inhibition data did not reveal an inhibitory effect of citalopram on CYP3A4, -2C9, or -2E1, but did suggest that it is a weak inhibitor of CYP1A2, -2D6, and -2C19.
1	0	1	O	In
2	3	7	O	vitro
3	9	14	O	enzyme
4	16	25	O	inhibition
5	27	30	O	data
6	32	34	O	did
7	36	38	O	not
8	40	45	O	reveal
9	47	48	O	an
10	50	59	O	inhibitory
11	61	66	O	effect
12	68	69	O	of
13	71	80	O	XXXXXXXX
14	82	83	O	on
15	85	90	O	CYP3A4
16	91	91	O	,
17	94	96	O	2C9
18	97	97	O	,
19	99	100	O	or
20	103	105	O	2E1
21	106	106	O	,
22	108	110	O	but
23	112	114	O	did
24	116	122	O	suggest
25	124	127	O	that
26	129	130	O	it
27	132	133	O	is
28	135	135	O	a
29	137	140	O	weak
30	142	150	O	inhibitor
31	152	153	O	of
32	155	160	O	CYP1A2
33	161	161	O	,
34	164	166	O	2D6
35	167	167	O	,
36	169	171	O	and
37	174	177	O	2C19
NULL

Celexa	884	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	17
Citalopram would be expected to have little inhibitory effect on in vivo metabolism mediated by these enzymes.
1	0	9	O	XXXXXXXX
2	11	15	O	would
3	17	18	O	be
4	20	27	O	expected
5	29	30	O	to
6	32	35	O	have
7	37	42	O	little
8	44	53	O	inhibitory
9	55	60	O	effect
10	62	63	O	on
11	65	66	O	in
12	68	71	O	vivo
13	73	82	O	metabolism
14	84	91	O	mediated
15	93	94	O	by
16	96	100	O	these
17	102	108	O	enzymes
NULL

Celexa	885	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	11
However, in vivo data to address this question are limited.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	data
6	22	23	O	to
7	25	31	O	address
8	33	36	O	this
9	38	45	O	question
10	47	49	O	are
11	51	57	O	limited
NULL

Celexa	886	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	53
CYP3A4 and CYP 2C19 inhibitors: Since CYP3A4 and CYP 2C19 are the primary enzymes involved in the metabolism of citalopram, it is expected that potent inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, and macrolide antibiotics) and potent inhibitors of CYP2C19 (e.g., omeprazole) might decrease the clearance of citalopram.
1	0	5	O	CYP3A4
2	7	9	O	and
3	11	13	O	CYP
4	15	18	O	2C19
5	20	29	O	inhibitors
6	30	30	O	:
7	32	36	O	Since
8	38	43	O	CYP3A4
9	45	47	O	and
10	49	51	O	CYP
11	53	56	O	2C19
12	58	60	O	are
13	62	64	O	the
14	66	72	O	primary
15	74	80	O	enzymes
16	82	89	O	involved
17	91	92	O	in
18	94	96	O	the
19	98	107	O	metabolism
20	109	110	O	of
21	112	121	O	XXXXXXXX
22	122	122	O	,
23	124	125	O	it
24	127	128	O	is
25	130	137	O	expected
26	139	142	O	that
27	144	149	B-KIN	potent
28	151	160	I-KIN	inhibitors
29	162	163	I-KIN	of
30	165	170	L-KIN	CYP3A4
31	173	175	O	e.g
32	177	177	O	,
33	179	190	U-KIN	ketoconazole
34	191	191	O	,
35	193	204	U-KIN	itraconazole
36	205	205	O	,
37	207	209	O	and
38	211	219	B-KIN	macrolide
39	221	231	L-KIN	antibiotics
40	234	236	O	and
41	238	243	B-KIN	potent
42	245	254	I-KIN	inhibitors
43	256	257	I-KIN	of
44	259	265	L-KIN	CYP2C19
45	268	270	O	e.g
46	272	272	O	,
47	274	283	U-KIN	omeprazole
48	286	290	O	might
49	292	299	B-TRI	decrease
50	301	303	I-TRI	the
51	305	313	L-TRI	clearance
52	315	316	O	of
53	318	327	O	XXXXXXXX
K/27:C54355 K/33:C54355 K/35:C54355 K/38:C54355 K/41:C54355 K/47:C54355

Celexa	887	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	19
However, coadministration of citalopram and the potent CYP3A4 inhibitor ketoconazole did not significantly affect the pharmacokinetics of citalopram.
1	0	6	O	However
2	7	7	O	,
3	9	24	O	coadministration
4	26	27	O	of
5	29	38	O	XXXXXXXX
6	40	42	O	and
7	44	46	O	the
8	48	53	O	potent
9	55	60	O	CYP3A4
10	62	70	O	inhibitor
11	72	83	O	ketoconazole
12	85	87	O	did
13	89	91	O	not
14	93	105	O	significantly
15	107	112	O	affect
16	114	116	O	the
17	118	133	O	pharmacokinetics
18	135	136	O	of
19	138	147	O	XXXXXXXX
NULL

Celexa	888	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	27
Celexa 20 mg/day is the maximum recommended dose in patients taking concomitant cimetidine or another CYP2C19 inhibitor, because of the risk of QT prolongation.
1	0	5	O	XXXXXXXX
2	7	8	O	20
3	10	11	O	mg
4	12	12	O	/
5	13	15	O	day
6	17	18	O	is
7	20	22	O	the
8	24	30	B-TRI	maximum
9	32	42	I-TRI	recommended
10	44	47	L-TRI	dose
11	49	50	O	in
12	52	59	O	patients
13	61	66	O	taking
14	68	78	O	concomitant
15	80	89	O	cimetidine
16	91	92	O	or
17	94	100	O	another
18	102	108	B-DYN	CYP2C19
19	110	118	L-DYN	inhibitor
20	119	119	O	,
21	121	127	O	because
22	129	130	O	of
23	132	134	O	the
24	136	139	O	risk
25	141	142	O	of
26	144	145	B-EFF	QT
27	147	158	L-EFF	prolongation
D/18:26:1

Celexa	889	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	32
CYP2D6 Inhibitors: Coadministration of a drug that inhibits CYP2D6 with Celexa is unlikely to have clinically significant effects on citalopram metabolism, based on the study results in CYP2D6 poor metabolizers.
1	0	5	O	CYP2D6
2	7	16	O	Inhibitors
3	17	17	O	:
4	19	34	O	Coadministration
5	36	37	O	of
6	39	39	O	a
7	41	44	O	drug
8	46	49	O	that
9	51	58	O	inhibits
10	60	65	O	CYP2D6
11	67	70	O	with
12	72	77	O	XXXXXXXX
13	79	80	O	is
14	82	89	O	unlikely
15	91	92	O	to
16	94	97	O	have
17	99	108	O	clinically
18	110	120	O	significant
19	122	128	O	effects
20	130	131	O	on
21	133	142	O	XXXXXXXX
22	144	153	O	metabolism
23	154	154	O	,
24	156	160	O	based
25	162	163	O	on
26	165	167	O	the
27	169	173	O	study
28	175	181	O	results
29	183	184	O	in
30	186	191	O	CYP2D6
31	193	196	O	poor
32	198	209	O	metabolizers
NULL

Celexa	890	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	40
The efficacy of Celexa as a treatment for depression was established in two placebo-controlled studies (of 4 to 6 weeks in duration) in adult outpatients (ages 18-66) meeting DSM-III or DSM-III-R criteria for major depression.
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	21	O	XXXXXXXX
5	23	24	O	as
6	26	26	O	a
7	28	36	O	treatment
8	38	40	O	for
9	42	51	O	depression
10	53	55	O	was
11	57	67	O	established
12	69	70	O	in
13	72	74	O	two
14	76	82	O	placebo
15	84	93	O	controlled
16	95	101	O	studies
17	104	105	O	of
18	107	107	O	4
19	109	110	O	to
20	112	112	O	6
21	114	118	O	weeks
22	120	121	O	in
23	123	130	O	duration
24	133	134	O	in
25	136	140	O	adult
26	142	152	O	outpatients
27	155	158	O	ages
28	160	161	O	18
29	163	164	O	66
30	167	173	O	meeting
31	175	177	O	DSM
32	179	181	O	III
33	183	184	O	or
34	186	188	O	DSM
35	190	192	O	III
36	194	194	O	R
37	196	203	O	criteria
38	205	207	O	for
39	209	213	O	major
40	215	224	O	depression
NULL

Celexa	891	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	76
Study 1, a 6-week trial in which patients received fixed Celexa doses of 10, 20, 40, and 60 mg/day, showed that Celexa at doses of 40 and 60 mg/day was effective as measured by the Hamilton Depression Rating Scale (HAMD) total score, the HAMD depressed mood item (Item 1), the Montgomery Asberg Depression Rating Scale, and the Clinical Global Impression (CGI) Severity scale.
1	0	4	O	Study
2	6	6	O	1
3	7	7	O	,
4	9	9	O	a
5	11	11	O	6
6	13	16	O	week
7	18	22	O	trial
8	24	25	O	in
9	27	31	O	which
10	33	40	O	patients
11	42	49	O	received
12	51	55	O	fixed
13	57	62	O	XXXXXXXX
14	64	68	O	doses
15	70	71	O	of
16	73	74	O	10
17	75	75	O	,
18	77	78	O	20
19	79	79	O	,
20	81	82	O	40
21	83	83	O	,
22	85	87	O	and
23	89	90	O	60
24	92	93	O	mg
25	94	94	O	/
26	95	97	O	day
27	98	98	O	,
28	100	105	O	showed
29	107	110	O	that
30	112	117	O	XXXXXXXX
31	119	120	O	at
32	122	126	O	doses
33	128	129	O	of
34	131	132	O	40
35	134	136	O	and
36	138	139	O	60
37	141	142	O	mg
38	143	143	O	/
39	144	146	O	day
40	148	150	O	was
41	152	160	O	effective
42	162	163	O	as
43	165	172	O	measured
44	174	175	O	by
45	177	179	O	the
46	181	188	O	Hamilton
47	190	199	O	Depression
48	201	206	O	Rating
49	208	212	O	Scale
50	215	218	O	HAMD
51	221	225	O	total
52	227	231	O	score
53	232	232	O	,
54	234	236	O	the
55	238	241	O	HAMD
56	243	251	O	depressed
57	253	256	O	mood
58	258	261	O	item
59	264	267	O	Item
60	269	269	O	1
61	271	271	O	,
62	273	275	O	the
63	277	286	O	Montgomery
64	288	293	O	Asberg
65	295	304	O	Depression
66	306	311	O	Rating
67	313	317	O	Scale
68	318	318	O	,
69	320	322	O	and
70	324	326	O	the
71	328	335	O	Clinical
72	337	342	O	Global
73	344	353	O	Impression
74	356	358	O	CGI
75	361	368	O	Severity
76	370	374	O	scale
NULL

Celexa	892	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	34
This study showed no clear effect of the 10 and 20 mg/day doses, and the 60 mg/day dose was not more effective than the 40 mg/day dose.
1	0	3	O	This
2	5	9	O	study
3	11	16	O	showed
4	18	19	O	no
5	21	25	O	clear
6	27	32	O	effect
7	34	35	O	of
8	37	39	O	the
9	41	42	O	10
10	44	46	O	and
11	48	49	O	20
12	51	52	O	mg
13	53	53	O	/
14	54	56	O	day
15	58	62	O	doses
16	63	63	O	,
17	65	67	O	and
18	69	71	O	the
19	73	74	O	60
20	76	77	O	mg
21	78	78	O	/
22	79	81	O	day
23	83	86	O	dose
24	88	90	O	was
25	92	94	O	not
26	96	99	O	more
27	101	109	O	effective
28	111	114	O	than
29	116	118	O	the
30	120	121	O	40
31	123	124	O	mg
32	125	125	O	/
33	126	128	O	day
34	130	133	O	dose
NULL

Celexa	893	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	49
In study 2, a 4-week, placebo-controlled trial in depressed patients, of whom 85% met criteria for melancholia, the initial dose was 20 mg/day, followed by titration to the maximum tolerated dose or a maximum dose of 80 mg/day.
1	0	1	O	In
2	3	7	O	study
3	9	9	O	2
4	10	10	O	,
5	12	12	O	a
6	14	14	O	4
7	16	19	O	week
8	20	20	O	,
9	22	28	O	placebo
10	30	39	O	controlled
11	41	45	O	trial
12	47	48	O	in
13	50	58	O	depressed
14	60	67	O	patients
15	68	68	O	,
16	70	71	O	of
17	73	76	O	whom
18	78	80	O	85%
19	82	84	O	met
20	86	93	O	criteria
21	95	97	O	for
22	99	109	O	melancholia
23	110	110	O	,
24	112	114	O	the
25	116	122	O	initial
26	124	127	O	dose
27	129	131	O	was
28	133	134	O	20
29	136	137	O	mg
30	138	138	O	/
31	139	141	O	day
32	142	142	O	,
33	144	151	O	followed
34	153	154	O	by
35	156	164	O	titration
36	166	167	O	to
37	169	171	O	the
38	173	179	O	maximum
39	181	189	O	tolerated
40	191	194	O	dose
41	196	197	O	or
42	199	199	O	a
43	201	207	O	maximum
44	209	212	O	dose
45	214	215	O	of
46	217	218	O	80
47	220	221	O	mg
48	222	222	O	/
49	223	225	O	day
NULL

Celexa	894	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	26
Patients treated with Celexa showed significantly greater improvement than placebo patients on the HAMD total score, HAMD item 1, and the CGI Severity score.
1	0	7	O	Patients
2	9	15	O	treated
3	17	20	O	with
4	22	27	O	XXXXXXXX
5	29	34	O	showed
6	36	48	O	significantly
7	50	56	O	greater
8	58	68	O	improvement
9	70	73	O	than
10	75	81	O	placebo
11	83	90	O	patients
12	92	93	O	on
13	95	97	O	the
14	99	102	O	HAMD
15	104	108	O	total
16	110	114	O	score
17	115	115	O	,
18	117	120	O	HAMD
19	122	125	O	item
20	127	127	O	1
21	128	128	O	,
22	130	132	O	and
23	134	136	O	the
24	138	140	O	CGI
25	142	149	O	Severity
26	151	155	O	score
NULL

Celexa	895	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	52
In three additional placebo-controlled depression trials, the difference in response to treatment between patients receiving Celexa and patients receiving placebo was not statistically significant, possibly due to high spontaneous response rate, smaller sample size, or, in the case of one study, too low a dose.
1	0	1	O	In
2	3	7	O	three
3	9	18	O	additional
4	20	26	O	placebo
5	28	37	O	controlled
6	39	48	O	depression
7	50	55	O	trials
8	56	56	O	,
9	58	60	O	the
10	62	71	O	difference
11	73	74	O	in
12	76	83	O	response
13	85	86	O	to
14	88	96	O	treatment
15	98	104	O	between
16	106	113	O	patients
17	115	123	O	receiving
18	125	130	O	XXXXXXXX
19	132	134	O	and
20	136	143	O	patients
21	145	153	O	receiving
22	155	161	O	placebo
23	163	165	O	was
24	167	169	O	not
25	171	183	O	statistically
26	185	195	O	significant
27	196	196	O	,
28	198	205	O	possibly
29	207	209	O	due
30	211	212	O	to
31	214	217	O	high
32	219	229	O	spontaneous
33	231	238	O	response
34	240	243	O	rate
35	244	244	O	,
36	246	252	O	smaller
37	254	259	O	sample
38	261	264	O	size
39	265	265	O	,
40	267	268	O	or
41	269	269	O	,
42	271	272	O	in
43	274	276	O	the
44	278	281	O	case
45	283	284	O	of
46	286	288	O	one
47	290	294	O	study
48	295	295	O	,
49	297	299	O	too
50	301	303	O	low
51	305	305	O	a
52	307	310	O	dose
NULL

Celexa	896	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	57
In two long-term studies, depressed patients who had responded to Celexa during an initial 6 or 8 weeks of acute treatment (fixed doses of 20 or 40 mg/day in one study and flexible doses of 20-60 mg/day in the second study) were randomized to continuation of Celexa or to placebo.
1	0	1	O	In
2	3	5	O	two
3	7	10	O	long
4	12	15	O	term
5	17	23	O	studies
6	24	24	O	,
7	26	34	O	depressed
8	36	43	O	patients
9	45	47	O	who
10	49	51	O	had
11	53	61	O	responded
12	63	64	O	to
13	66	71	O	XXXXXXXX
14	73	78	O	during
15	80	81	O	an
16	83	89	O	initial
17	91	91	O	6
18	93	94	O	or
19	96	96	O	8
20	98	102	O	weeks
21	104	105	O	of
22	107	111	O	acute
23	113	121	O	treatment
24	124	128	O	fixed
25	130	134	O	doses
26	136	137	O	of
27	139	140	O	20
28	142	143	O	or
29	145	146	O	40
30	148	149	O	mg
31	150	150	O	/
32	151	153	O	day
33	155	156	O	in
34	158	160	O	one
35	162	166	O	study
36	168	170	O	and
37	172	179	O	flexible
38	181	185	O	doses
39	187	188	O	of
40	190	191	O	20
41	193	194	O	60
42	196	197	O	mg
43	198	198	O	/
44	199	201	O	day
45	203	204	O	in
46	206	208	O	the
47	210	215	O	second
48	217	221	O	study
49	224	227	O	were
50	229	238	O	randomized
51	240	241	O	to
52	243	254	O	continuation
53	256	257	O	of
54	259	264	O	XXXXXXXX
55	266	267	O	or
56	269	270	O	to
57	272	278	O	placebo
NULL

Celexa	897	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	24
In both studies, patients receiving continued Celexa treatment experienced significantly lower relapse rates over the subsequent 6 months compared to those receiving placebo.
1	0	1	O	In
2	3	6	O	both
3	8	14	O	studies
4	15	15	O	,
5	17	24	O	patients
6	26	34	O	receiving
7	36	44	O	continued
8	46	51	O	XXXXXXXX
9	53	61	O	treatment
10	63	73	O	experienced
11	75	87	O	significantly
12	89	93	O	lower
13	95	101	O	relapse
14	103	107	O	rates
15	109	112	O	over
16	114	116	O	the
17	118	127	O	subsequent
18	129	129	O	6
19	131	136	O	months
20	138	145	O	compared
21	147	148	O	to
22	150	154	O	those
23	156	164	O	receiving
24	166	172	O	placebo
NULL

Celexa	898	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	25
In the fixed-dose study, the decreased rate of depression relapse was similar in patients receiving 20 or 40 mg/day of Celexa.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	fixed
4	13	16	O	dose
5	18	22	O	study
6	23	23	O	,
7	25	27	O	the
8	29	37	O	decreased
9	39	42	O	rate
10	44	45	O	of
11	47	56	O	depression
12	58	64	O	relapse
13	66	68	O	was
14	70	76	O	similar
15	78	79	O	in
16	81	88	O	patients
17	90	98	O	receiving
18	100	101	O	20
19	103	104	O	or
20	106	107	O	40
21	109	110	O	mg
22	111	111	O	/
23	112	114	O	day
24	116	117	O	of
25	119	124	O	XXXXXXXX
NULL

Celexa	899	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	27
Analyses of the relationship between treatment outcome and age, gender, and race did not suggest any differential responsiveness on the basis of these patient characteristics.
1	0	7	O	Analyses
2	9	10	O	of
3	12	14	O	the
4	16	27	O	relationship
5	29	35	O	between
6	37	45	O	treatment
7	47	53	O	outcome
8	55	57	O	and
9	59	61	O	age
10	62	62	O	,
11	64	69	O	gender
12	70	70	O	,
13	72	74	O	and
14	76	79	O	race
15	81	83	O	did
16	85	87	O	not
17	89	95	O	suggest
18	97	99	O	any
19	101	112	O	differential
20	114	127	O	responsiveness
21	129	130	O	on
22	132	134	O	the
23	136	140	O	basis
24	142	143	O	of
25	145	149	O	these
26	151	157	O	patient
27	159	173	O	characteristics
NULL

Celexa	900	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	14
Highly variable results have been seen in the clinical development of all antidepressant drugs.
1	0	5	O	Highly
2	7	14	O	variable
3	16	22	O	results
4	24	27	O	have
5	29	32	O	been
6	34	37	O	seen
7	39	40	O	in
8	42	44	O	the
9	46	53	O	clinical
10	55	65	O	development
11	67	68	O	of
12	70	72	O	all
13	74	87	O	antidepressant
14	89	93	O	drugs
NULL

Celexa	901	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	36
Furthermore, in those circumstances when the drugs have not been studied in the same controlled clinical trial(s), comparisons among the results of studies evaluating the effectiveness of different antidepressant drug products are inherently unreliable.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	14	O	in
4	16	20	O	those
5	22	34	O	circumstances
6	36	39	O	when
7	41	43	O	the
8	45	49	O	drugs
9	51	54	O	have
10	56	58	O	not
11	60	63	O	been
12	65	71	O	studied
13	73	74	O	in
14	76	78	O	the
15	80	83	O	same
16	85	94	O	controlled
17	96	103	O	clinical
18	105	111	O	trial(s
19	113	113	O	,
20	115	125	O	comparisons
21	127	131	O	among
22	133	135	O	the
23	137	143	O	results
24	145	146	O	of
25	148	154	O	studies
26	156	165	O	evaluating
27	167	169	O	the
28	171	183	O	effectiveness
29	185	186	O	of
30	188	196	O	different
31	198	211	O	antidepressant
32	213	216	O	drug
33	218	225	O	products
34	227	229	O	are
35	231	240	O	inherently
36	242	251	O	unreliable
NULL

Celexa	902	34090-1	4259d9b1-de34-43a4-85a8-41dd214e9177	52
Because conditions of testing (e.g., patient samples, investigators, doses of the treatments administered and compared, outcome measures, etc.) vary among trials, it is virtually impossible to distinguish a difference in drug effect from a difference due to one or more of the confounding factors just enumerated.
1	0	6	O	Because
2	8	17	O	conditions
3	19	20	O	of
4	22	28	O	testing
5	31	33	O	e.g
6	35	35	O	,
7	37	43	O	patient
8	45	51	O	samples
9	52	52	O	,
10	54	66	O	investigators
11	67	67	O	,
12	69	73	O	doses
13	75	76	O	of
14	78	80	O	the
15	82	91	O	treatments
16	93	104	O	administered
17	106	108	O	and
18	110	117	O	compared
19	118	118	O	,
20	120	126	O	outcome
21	128	135	O	measures
22	136	136	O	,
23	138	140	O	etc
24	144	147	O	vary
25	149	153	O	among
26	155	160	O	trials
27	161	161	O	,
28	163	164	O	it
29	166	167	O	is
30	169	177	O	virtually
31	179	188	O	impossible
32	190	191	O	to
33	193	203	O	distinguish
34	205	205	O	a
35	207	216	O	difference
36	218	219	O	in
37	221	224	O	drug
38	226	231	O	effect
39	233	236	O	from
40	238	238	O	a
41	240	249	O	difference
42	251	253	O	due
43	255	256	O	to
44	258	260	O	one
45	262	263	O	or
46	265	268	O	more
47	270	271	O	of
48	273	275	O	the
49	277	287	O	confounding
50	289	295	O	factors
51	297	300	O	just
52	302	311	O	enumerated
NULL

Clozapine	2980	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	26
Concomitant use of Strong CYP1A2 Inhibitors: Reduce CLOZARIL dose to one-third when coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, enoxacin).
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	24	O	Strong
5	26	31	O	CYP1A2
6	33	42	O	Inhibitors
7	43	43	O	:
8	45	50	O	Reduce
9	52	59	O	CLOZARIL
10	61	64	O	dose
11	66	67	O	to
12	69	71	O	one
13	73	77	O	third
14	79	82	O	when
15	84	97	O	coadministered
16	99	102	O	with
17	104	109	B-KIN	strong
18	111	116	I-KIN	CYP1A2
19	118	127	L-KIN	inhibitors
20	130	132	O	e.g
21	134	134	O	,
22	136	146	U-KIN	fluvoxamine
23	147	147	O	,
24	149	161	U-KIN	ciprofloxacin
25	162	162	O	,
26	164	171	U-KIN	enoxacin
K/17:C54355 K/22:C54355 K/24:C54355 K/26:C54355

Clozapine	2981	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	9
Concomitant use of Strong CYP3A4 Inducers is not recommended.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	24	B-UNK	Strong
5	26	31	I-UNK	CYP3A4
6	33	40	L-UNK	Inducers
7	42	43	O	is
8	45	47	B-TRI	not
9	49	59	L-TRI	recommended
NULL

Clozapine	2982	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	26
Discontinuation of CYP1A2 or CYP3A4 Inducers: Consider reducing CLOZARIL dose when CYP1A2 inducers (e.g., tobacco smoke) or CYP3A4 inducers (e.g., carbamazepine) are discontinued.
1	0	14	O	Discontinuation
2	16	17	O	of
3	19	24	O	CYP1A2
4	26	27	O	or
5	29	34	O	CYP3A4
6	36	43	O	Inducers
7	44	44	O	:
8	46	53	O	Consider
9	55	62	O	reducing
10	64	71	O	CLOZARIL
11	73	76	O	dose
12	78	81	O	when
13	83	88	B-KIN	CYP1A2
14	90	97	L-KIN	inducers
15	100	102	O	e.g
16	104	104	O	,
17	106	112	B-KIN	tobacco
18	114	118	L-KIN	smoke
19	121	122	O	or
20	124	129	B-KIN	CYP3A4
21	131	138	L-KIN	inducers
22	141	143	O	e.g
23	145	145	O	,
24	147	159	U-KIN	carbamazepine
25	162	164	O	are
26	166	177	O	discontinued
K/13:C54356 K/17:C54356 K/20:C54356 K/24:C54356

Clozapine	2983	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	18
Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP3A4, and CYP2D6.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	13	O	a
4	15	23	O	substrate
5	25	27	O	for
6	29	32	O	many
7	34	43	O	cytochrome
8	45	48	O	P450
9	50	57	O	isozymes
10	58	58	O	,
11	60	61	O	in
12	63	72	O	particular
13	74	79	O	CYP1A2
14	80	80	O	,
15	82	87	O	CYP3A4
16	88	88	O	,
17	90	92	O	and
18	94	99	O	CYP2D6
NULL

Clozapine	2984	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	16
Use caution when administering CLOZARIL concomitantly with drugs that are inducers or inhibitors of these enzymes.
1	0	2	O	Use
2	4	10	O	caution
3	12	15	O	when
4	17	29	O	administering
5	31	38	O	CLOZARIL
6	40	52	O	concomitantly
7	54	57	O	with
8	59	63	O	drugs
9	65	68	O	that
10	70	72	O	are
11	74	81	O	inducers
12	83	84	O	or
13	86	95	O	inhibitors
14	97	98	O	of
15	100	104	O	these
16	106	112	O	enzymes
NULL

Clozapine	2985	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	21
CYP1A2 Inhibitors Concomitant use of CLOZARIL and CYP1A2 inhibitors can increase plasma levels of clozapine, potentially resulting in adverse reactions.
1	0	5	O	CYP1A2
2	7	16	O	Inhibitors
3	18	28	O	Concomitant
4	30	32	O	use
5	34	35	O	of
6	37	44	O	CLOZARIL
7	46	48	O	and
8	50	55	B-KIN	CYP1A2
9	57	66	L-KIN	inhibitors
10	68	70	O	can
11	72	79	B-TRI	increase
12	81	86	I-TRI	plasma
13	88	93	L-TRI	levels
14	95	96	O	of
15	98	106	O	XXXXXXXX
16	107	107	O	,
17	109	119	O	potentially
18	121	129	O	resulting
19	131	132	O	in
20	134	140	O	adverse
21	142	150	O	reactions
K/8:C54355

Clozapine	2986	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	27
Reduce the CLOZARIL dose to one-third of the original dose when CLOZARIL is coadministered with strong CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin, or enoxacin).
1	0	5	O	Reduce
2	7	9	O	the
3	11	18	O	CLOZARIL
4	20	23	O	dose
5	25	26	O	to
6	28	30	O	one
7	32	36	O	third
8	38	39	O	of
9	41	43	O	the
10	45	52	O	original
11	54	57	O	dose
12	59	62	O	when
13	64	71	O	CLOZARIL
14	73	74	O	is
15	76	89	O	coadministered
16	91	94	O	with
17	96	101	B-KIN	strong
18	103	108	I-KIN	CYP1A2
19	110	119	L-KIN	inhibitors
20	122	124	O	e.g
21	126	126	O	,
22	128	138	U-KIN	fluvoxamine
23	139	139	O	,
24	141	153	U-KIN	ciprofloxacin
25	154	154	O	,
26	156	157	O	or
27	159	166	U-KIN	enoxacin
K/17:C54355 K/22:C54355 K/24:C54355 K/27:C54355

Clozapine	2987	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	18
The CLOZARIL dose should be increased to the original dose when coadministration of strong CYP1A2 inhibitors is discontinued.
1	0	2	O	The
2	4	11	O	CLOZARIL
3	13	16	O	dose
4	18	23	O	should
5	25	26	O	be
6	28	36	O	increased
7	38	39	O	to
8	41	43	O	the
9	45	52	O	original
10	54	57	O	dose
11	59	62	O	when
12	64	79	O	coadministration
13	81	82	O	of
14	84	89	B-KIN	strong
15	91	96	I-KIN	CYP1A2
16	98	107	L-KIN	inhibitors
17	109	110	O	is
18	112	123	O	discontinued
K/14:C54355

Clozapine	2988	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	10
Moderate or weak CYP1A2 inhibitors include oral contraceptives and caffeine.
1	0	7	O	Moderate
2	9	10	O	or
3	12	15	O	weak
4	17	22	O	CYP1A2
5	24	33	O	inhibitors
6	35	41	O	include
7	43	46	O	oral
8	48	61	O	contraceptives
9	63	65	O	and
10	67	74	O	caffeine
NULL

Clozapine	2989	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	10
Monitor patients closely when CLOZARIL is coadministered with these inhibitors.
1	0	6	O	Monitor
2	8	15	O	patients
3	17	23	O	closely
4	25	28	O	when
5	30	37	O	CLOZARIL
6	39	40	O	is
7	42	55	O	coadministered
8	57	60	O	with
9	62	66	O	these
10	68	77	O	inhibitors
NULL

Clozapine	2990	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	7
Consider reducing the CLOZARIL dosage if necessary.
1	0	7	O	Consider
2	9	16	O	reducing
3	18	20	O	the
4	22	29	O	CLOZARIL
5	31	36	O	dosage
6	38	39	O	if
7	41	49	O	necessary
NULL

Clozapine	2991	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	44
CYP2D6 and CYP3A4 Inhibitors Concomitant treatment with CLOZARIL and CYP2D6 or CYP3A4 inhibitors (e.g., cimetidine, escitalopram, erythromycin, paroxetine, bupropion, fluoxetine, quinidine, duloxetine, terbinafine, or sertraline) can increase clozapine levels and lead to adverse reactions.
1	0	5	O	CYP2D6
2	7	9	O	and
3	11	16	O	CYP3A4
4	18	27	O	Inhibitors
5	29	39	O	Concomitant
6	41	49	O	treatment
7	51	54	O	with
8	56	63	O	CLOZARIL
9	65	67	O	and
10	69	74	O	CYP2D6
11	76	77	O	or
12	79	84	B-KIN	CYP3A4
13	86	95	L-KIN	inhibitors
14	98	100	O	e.g
15	102	102	O	,
16	104	113	U-KIN	cimetidine
17	114	114	O	,
18	116	127	U-KIN	escitalopram
19	128	128	O	,
20	130	141	U-KIN	erythromycin
21	142	142	O	,
22	144	153	U-KIN	paroxetine
23	154	154	O	,
24	156	164	U-KIN	bupropion
25	165	165	O	,
26	167	176	U-KIN	fluoxetine
27	177	177	O	,
28	179	187	U-KIN	quinidine
29	188	188	O	,
30	190	199	U-KIN	duloxetine
31	200	200	O	,
32	202	212	U-KIN	terbinafine
33	213	213	O	,
34	215	216	O	or
35	218	227	U-KIN	sertraline
36	230	232	O	can
37	234	241	B-TRI	increase
38	243	251	I-TRI	XXXXXXXX
39	253	258	L-TRI	levels
40	260	262	O	and
41	264	267	O	lead
42	269	270	O	to
43	272	278	O	adverse
44	280	288	O	reactions
K/12:C54355 K/16:C54355 K/18:C54355 K/20:C54355 K/22:C54355 K/24:C54355 K/26:C54355 K/28:C54355 K/30:C54355 K/32:C54355 K/35:C54355

Clozapine	2992	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	10
Use caution and monitor patients closely when using such inhibitors.
1	0	2	O	Use
2	4	10	O	caution
3	12	14	O	and
4	16	22	O	monitor
5	24	31	O	patients
6	33	39	O	closely
7	41	44	O	when
8	46	50	O	using
9	52	55	O	such
10	57	66	O	inhibitors
NULL

Clozapine	2993	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	5
Consider reducing the CLOZARIL dose.
1	0	7	O	Consider
2	9	16	O	reducing
3	18	20	O	the
4	22	29	O	CLOZARIL
5	31	34	O	dose
NULL

Clozapine	2994	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	27
CYP1A2 and CYP3A4 Inducers Concomitant treatment with drugs that induce CYP1A2 or CYP3A4 can decrease the plasma concentration of clozapine, resulting in decreased effectiveness of CLOZARIL.
1	0	5	O	CYP1A2
2	7	9	O	and
3	11	16	B-KIN	CYP3A4
4	18	25	L-KIN	Inducers
5	27	37	O	Concomitant
6	39	47	O	treatment
7	49	52	O	with
8	54	58	B-KIN	drugs
9	60	63	I-KIN	that
10	65	70	I-KIN	induce
11	72	77	L-KIN	CYP1A2
12	79	80	O	or
13	82	87	O	CYP3A4
14	89	91	O	can
15	93	100	B-TRI	decrease
16	102	104	I-TRI	the
17	106	111	I-TRI	plasma
18	113	125	L-TRI	concentration
19	127	128	O	of
20	130	138	O	XXXXXXXX
21	139	139	O	,
22	141	149	O	resulting
23	151	152	O	in
24	154	162	O	decreased
25	164	176	O	effectiveness
26	178	179	O	of
27	181	188	O	CLOZARIL
K/3:C54356 K/8:C54356

Clozapine	2995	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	8
Tobacco smoke is a moderate inducer of CYP1A2.
1	0	6	O	Tobacco
2	8	12	O	smoke
3	14	15	O	is
4	17	17	O	a
5	19	26	O	moderate
6	28	34	O	inducer
7	36	37	O	of
8	39	44	O	CYP1A2
NULL

Clozapine	2996	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	14
Strong CYP3A4 inducers include carbamazepine, phenytoin, St. John's wort, and rifampin.
1	0	5	O	Strong
2	7	12	O	CYP3A4
3	14	21	O	inducers
4	23	29	O	include
5	31	43	O	carbamazepine
6	44	44	O	,
7	46	54	O	phenytoin
8	55	55	O	,
9	57	58	O	St
10	61	66	O	John's
11	68	71	O	wort
12	72	72	O	,
13	74	76	O	and
14	78	85	O	rifampin
NULL

Clozapine	2997	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	17
It may be necessary to increase the CLOZARIL dose if used concomitantly with inducers of these enzymes.
1	0	1	O	It
2	3	5	O	may
3	7	8	O	be
4	10	18	O	necessary
5	20	21	O	to
6	23	30	O	increase
7	32	34	O	the
8	36	43	O	CLOZARIL
9	45	48	O	dose
10	50	51	O	if
11	53	56	O	used
12	58	70	O	concomitantly
13	72	75	O	with
14	77	84	O	inducers
15	86	87	O	of
16	89	93	O	these
17	95	101	O	enzymes
NULL

Clozapine	2998	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	13
However, concomitant use of CLOZARIL and strong CYP3A4 inducers is not recommended.
1	0	6	O	However
2	7	7	O	,
3	9	19	O	concomitant
4	21	23	O	use
5	25	26	O	of
6	28	35	O	CLOZARIL
7	37	39	O	and
8	41	46	B-UNK	strong
9	48	53	I-UNK	CYP3A4
10	55	62	L-UNK	inducers
11	64	65	O	is
12	67	69	B-TRI	not
13	71	81	L-TRI	recommended
NULL

Clozapine	2999	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	28
Consider reducing the CLOZARIL dosage when discontinuing coadministered enzyme inducers; because discontinuation of inducers can result in increased clozapine plasma levels and an increased risk of adverse reactions.
1	0	7	O	Consider
2	9	16	O	reducing
3	18	20	O	the
4	22	29	O	CLOZARIL
5	31	36	O	dosage
6	38	41	O	when
7	43	55	O	discontinuing
8	57	70	O	coadministered
9	72	77	O	enzyme
10	79	86	O	inducers
11	89	95	O	because
12	97	111	O	discontinuation
13	113	114	O	of
14	116	123	O	inducers
15	125	127	O	can
16	129	134	O	result
17	136	137	O	in
18	139	147	O	increased
19	149	157	O	XXXXXXXX
20	159	164	O	plasma
21	166	171	O	levels
22	173	175	O	and
23	177	178	O	an
24	180	188	O	increased
25	190	193	O	risk
26	195	196	O	of
27	198	204	O	adverse
28	206	214	O	reactions
NULL

Clozapine	3000	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	23
Drugs that Cause QT Interval Prolongation Use caution when administering concomitant medications that prolong the QT interval or inhibit the metabolism of clozapine.
1	0	4	B-UNK	Drugs
2	6	9	I-UNK	that
3	11	15	I-UNK	Cause
4	17	18	I-UNK	QT
5	20	27	I-UNK	Interval
6	29	40	L-UNK	Prolongation
7	42	44	B-TRI	Use
8	46	52	L-TRI	caution
9	54	57	O	when
10	59	71	O	administering
11	73	83	O	concomitant
12	85	95	B-UNK	medications
13	97	100	I-UNK	that
14	102	108	I-UNK	prolong
15	110	112	I-UNK	the
16	114	115	I-UNK	QT
17	117	124	L-UNK	interval
18	126	127	O	or
19	129	135	O	inhibit
20	137	139	O	the
21	141	150	O	metabolism
22	152	153	O	of
23	155	163	O	XXXXXXXX
NULL

Clozapine	3001	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	77
Drugs that cause QT prolongation include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, thioridazine, mesoridazine, droperidol, and pimozide), specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin), Class 1A antiarrhythmics (e.g., quinidine, procainamide) or Class III antiarrhythmics (e.g., amiodarone, sotalol), and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).
1	0	4	O	Drugs
2	6	9	O	that
3	11	15	O	cause
4	17	18	O	QT
5	20	31	O	prolongation
6	33	39	O	include
7	40	40	O	:
8	42	49	O	specific
9	51	64	O	antipsychotics
10	67	69	O	e.g
11	71	71	O	,
12	73	83	O	ziprasidone
13	84	84	O	,
14	86	96	O	iloperidone
15	97	97	O	,
16	99	112	O	chlorpromazine
17	113	113	O	,
18	115	126	O	thioridazine
19	127	127	O	,
20	129	140	O	mesoridazine
21	141	141	O	,
22	143	152	O	droperidol
23	153	153	O	,
24	155	157	O	and
25	159	166	O	pimozide
26	168	168	O	,
27	170	177	O	specific
28	179	189	O	antibiotics
29	192	194	O	e.g
30	196	196	O	,
31	198	209	O	erythromycin
32	210	210	O	,
33	212	223	O	gatifloxacin
34	224	224	O	,
35	226	237	O	moxifloxacin
36	238	238	O	,
37	240	251	O	sparfloxacin
38	253	253	O	,
39	255	259	O	Class
40	261	262	O	1A
41	264	278	O	antiarrhythmics
42	281	283	O	e.g
43	285	285	O	,
44	287	295	O	quinidine
45	296	296	O	,
46	298	309	O	procainamide
47	312	313	O	or
48	315	319	O	Class
49	321	323	O	III
50	325	339	O	antiarrhythmics
51	342	344	O	e.g
52	346	346	O	,
53	348	357	O	amiodarone
54	358	358	O	,
55	360	366	O	sotalol
56	368	368	O	,
57	370	372	O	and
58	374	379	O	others
59	382	384	O	e.g
60	386	386	O	,
61	388	398	O	pentamidine
62	399	399	O	,
63	401	412	O	levomethadyl
64	414	420	O	acetate
65	421	421	O	,
66	423	431	O	methadone
67	432	432	O	,
68	434	445	O	halofantrine
69	446	446	O	,
70	448	457	O	mefloquine
71	458	458	O	,
72	460	469	O	dolasetron
73	471	478	O	mesylate
74	479	479	O	,
75	481	488	O	probucol
76	490	491	O	or
77	493	502	O	tacrolimus
NULL

Clozapine	3002	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	17
Concomitant use of CLOZARIL with other drugs metabolized by CYP2D6 can increase levels of these CYP2D6 substrates.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	26	O	CLOZARIL
5	28	31	O	with
6	33	37	O	other
7	39	43	B-KIN	drugs
8	45	55	I-KIN	metabolized
9	57	58	I-KIN	by
10	60	65	L-KIN	CYP2D6
11	67	69	O	can
12	71	78	B-TRI	increase
13	80	85	L-TRI	levels
14	87	88	O	of
15	90	94	O	these
16	96	101	B-KIN	CYP2D6
17	103	112	L-KIN	substrates
K/16:C54357 K/7:C54357

Clozapine	3003	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	13
Use caution when coadministering CLOZARIL with other drugs that are metabolized by CYP2D6.
1	0	2	B-TRI	Use
2	4	10	L-TRI	caution
3	12	15	O	when
4	17	31	O	coadministering
5	33	40	O	CLOZARIL
6	42	45	O	with
7	47	51	O	other
8	53	57	B-UNK	drugs
9	59	62	I-UNK	that
10	64	66	I-UNK	are
11	68	78	I-UNK	metabolized
12	80	81	I-UNK	by
13	83	88	L-UNK	CYP2D6
NULL

Clozapine	3004	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	14
It may be necessary to use lower doses of such drugs than usually prescribed.
1	0	1	O	It
2	3	5	O	may
3	7	8	O	be
4	10	18	O	necessary
5	20	21	O	to
6	23	25	O	use
7	27	31	O	lower
8	33	37	O	doses
9	39	40	O	of
10	42	45	O	such
11	47	51	O	drugs
12	53	56	O	than
13	58	64	O	usually
14	66	75	O	prescribed
NULL

Clozapine	3005	34073-7	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	22
Such drugs include specific antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide).
1	0	3	O	Such
2	5	9	O	drugs
3	11	17	O	include
4	19	26	O	specific
5	28	42	O	antidepressants
6	43	43	O	,
7	45	58	O	phenothiazines
8	59	59	O	,
9	61	73	O	carbamazepine
10	74	74	O	,
11	76	78	O	and
12	80	83	O	Type
13	85	86	O	1C
14	88	102	O	antiarrhythmics
15	105	107	O	e.g
16	109	109	O	,
17	111	121	O	propafenone
18	122	122	O	,
19	124	133	O	flecainide
20	134	134	O	,
21	136	138	O	and
22	140	148	O	encainide
NULL

Clozapine	3006	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	8
The mechanism of action of clozapine is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	35	O	XXXXXXXX
7	37	38	O	is
8	40	46	O	unknown
NULL

Clozapine	3007	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	32
However, it has been proposed that the therapeutic efficacy of clozapine in schizophrenia is mediated through antagonism of the dopamine type 2 (D2) and the serotonin type 2A (5-HT2A) receptors.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	28	O	proposed
7	30	33	O	that
8	35	37	O	the
9	39	49	O	therapeutic
10	51	58	O	efficacy
11	60	61	O	of
12	63	71	O	XXXXXXXX
13	73	74	O	in
14	76	88	O	schizophrenia
15	90	91	O	is
16	93	100	O	mediated
17	102	108	O	through
18	110	119	O	antagonism
19	121	122	O	of
20	124	126	O	the
21	128	135	O	dopamine
22	137	140	O	type
23	142	142	O	2
24	145	146	O	D2
25	149	151	O	and
26	153	155	O	the
27	157	165	O	serotonin
28	167	170	O	type
29	172	173	O	2A
30	176	176	O	5
31	178	181	O	HT2A
32	184	192	O	receptors
NULL

Clozapine	3008	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	18
CLOZARIL also acts as an antagonist at adrenergic, cholinergic, histaminergic and other dopaminergic and serotonergic receptors.
1	0	7	O	CLOZARIL
2	9	12	O	also
3	14	17	O	acts
4	19	20	O	as
5	22	23	O	an
6	25	34	O	antagonist
7	36	37	O	at
8	39	48	O	adrenergic
9	49	49	O	,
10	51	61	O	cholinergic
11	62	62	O	,
12	64	76	O	histaminergic
13	78	80	O	and
14	82	86	O	other
15	88	99	O	dopaminergic
16	101	103	O	and
17	105	116	O	serotonergic
18	118	126	O	receptors
NULL

Clozapine	3009	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	105
Clozapine demonstrated binding affinity to the following receptors: histamine H1 (Ki 1.1 nM), adrenergic A1A (Ki 1.6 nM), serotonin 5-HT6 (Ki 4 nM), serotonin 5-HT2A (Ki 5.4 nM), muscarinic M1 (Ki 6.2 nM), serotonin 5-HT7 (Ki 6.3 nM), serotonin 5-HT2C (Ki 9.4 nM), dopamine D4 (Ki 24 nM), adrenergic A2A (Ki 90 nM), serotonin 5-HT3 (Ki 95 nM), serotonin 5-HT1A (Ki 120 nM), dopamine D2 (Ki 160 nM), dopamine D1 (Ki 270 nM), dopamine D5 (Ki 454 nM), and dopamine D3 (Ki 555 nM).
1	0	8	O	XXXXXXXX
2	10	21	O	demonstrated
3	23	29	O	binding
4	31	38	O	affinity
5	40	41	O	to
6	43	45	O	the
7	47	55	O	following
8	57	65	O	receptors
9	66	66	O	:
10	68	76	O	histamine
11	78	79	O	H1
12	82	83	O	Ki
13	85	87	O	1.1
14	89	90	O	nM
15	92	92	O	,
16	94	103	O	adrenergic
17	105	107	O	A1A
18	110	111	O	Ki
19	113	115	O	1.6
20	117	118	O	nM
21	120	120	O	,
22	122	130	O	serotonin
23	132	132	O	5
24	134	136	O	HT6
25	139	140	O	Ki
26	142	142	O	4
27	144	145	O	nM
28	147	147	O	,
29	149	157	O	serotonin
30	159	159	O	5
31	161	164	O	HT2A
32	167	168	O	Ki
33	170	172	O	5.4
34	174	175	O	nM
35	177	177	O	,
36	179	188	O	muscarinic
37	190	191	O	M1
38	194	195	O	Ki
39	197	199	O	6.2
40	201	202	O	nM
41	204	204	O	,
42	206	214	O	serotonin
43	216	216	O	5
44	218	220	O	HT7
45	223	224	O	Ki
46	226	228	O	6.3
47	230	231	O	nM
48	233	233	O	,
49	235	243	O	serotonin
50	245	245	O	5
51	247	250	O	HT2C
52	253	254	O	Ki
53	256	258	O	9.4
54	260	261	O	nM
55	263	263	O	,
56	265	272	O	dopamine
57	274	275	O	D4
58	278	279	O	Ki
59	281	282	O	24
60	284	285	O	nM
61	287	287	O	,
62	289	298	O	adrenergic
63	300	302	O	A2A
64	305	306	O	Ki
65	308	309	O	90
66	311	312	O	nM
67	314	314	O	,
68	316	324	O	serotonin
69	326	326	O	5
70	328	330	O	HT3
71	333	334	O	Ki
72	336	337	O	95
73	339	340	O	nM
74	342	342	O	,
75	344	352	O	serotonin
76	354	354	O	5
77	356	359	O	HT1A
78	362	363	O	Ki
79	365	367	O	120
80	369	370	O	nM
81	372	372	O	,
82	374	381	O	dopamine
83	383	384	O	D2
84	387	388	O	Ki
85	390	392	O	160
86	394	395	O	nM
87	397	397	O	,
88	399	406	O	dopamine
89	408	409	O	D1
90	412	413	O	Ki
91	415	417	O	270
92	419	420	O	nM
93	422	422	O	,
94	424	431	O	dopamine
95	433	434	O	D5
96	437	438	O	Ki
97	440	442	O	454
98	444	445	O	nM
99	447	447	O	,
100	449	451	O	and
101	453	460	O	dopamine
102	462	463	O	D3
103	466	467	O	Ki
104	469	471	O	555
105	473	474	O	nM
NULL

Clozapine	3010	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	7
Clozapine causes little or no prolactin elevation.
1	0	8	O	XXXXXXXX
2	10	15	O	causes
3	17	22	O	little
4	24	25	O	or
5	27	28	O	no
6	30	38	O	prolactin
7	40	48	O	elevation
NULL

Clozapine	3011	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	17
Clinical electroencephalogram (EEG) studies demonstrated that clozapine increases delta and theta activity and slows dominant alpha frequencies.
1	0	7	O	Clinical
2	9	28	O	electroencephalogram
3	31	33	O	EEG
4	36	42	O	studies
5	44	55	O	demonstrated
6	57	60	O	that
7	62	70	O	XXXXXXXX
8	72	80	O	increases
9	82	86	O	delta
10	88	90	O	and
11	92	96	O	theta
12	98	105	O	activity
13	107	109	O	and
14	111	115	O	slows
15	117	124	O	dominant
16	126	130	O	alpha
17	132	142	O	frequencies
NULL

Clozapine	3012	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	11
Sharp wave activity and spike and wave complexes may also develop.
1	0	4	O	Sharp
2	6	9	O	wave
3	11	18	O	activity
4	20	22	O	and
5	24	28	O	spike
6	30	32	O	and
7	34	37	O	wave
8	39	47	O	complexes
9	49	51	O	may
10	53	56	O	also
11	58	64	O	develop
NULL

Clozapine	3013	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	11
Patients have reported an intensification of dream activity during clozapine therapy.
1	0	7	O	Patients
2	9	12	O	have
3	14	21	O	reported
4	23	24	O	an
5	26	40	O	intensification
6	42	43	O	of
7	45	49	O	dream
8	51	58	O	activity
9	60	65	O	during
10	67	75	O	XXXXXXXX
11	77	83	O	therapy
NULL

Clozapine	3014	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	14
REM sleep was found to be increased to 85% of the total sleep time.
1	0	2	O	REM
2	4	8	O	sleep
3	10	12	O	was
4	14	18	O	found
5	20	21	O	to
6	23	24	O	be
7	26	34	O	increased
8	36	37	O	to
9	39	41	O	85%
10	43	44	O	of
11	46	48	O	the
12	50	54	O	total
13	56	60	O	sleep
14	62	65	O	time
NULL

Clozapine	3015	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	15
In these patients, the onset of REM sleep occurred almost immediately after falling asleep.
1	0	1	O	In
2	3	7	O	these
3	9	16	O	patients
4	17	17	O	,
5	19	21	O	the
6	23	27	O	onset
7	29	30	O	of
8	32	34	O	REM
9	36	40	O	sleep
10	42	49	O	occurred
11	51	56	O	almost
12	58	68	O	immediately
13	70	74	O	after
14	76	82	O	falling
15	84	89	O	asleep
NULL

Clozapine	3016	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	19
Absorption In humans, CLOZARIL tablets (25 mg and 100 mg) are equally bioavailable relative to a CLOZARIL solution.
1	0	9	O	Absorption
2	11	12	O	In
3	14	19	O	humans
4	20	20	O	,
5	22	29	O	CLOZARIL
6	31	37	O	tablets
7	40	41	O	25
8	43	44	O	mg
9	46	48	O	and
10	50	52	O	100
11	54	55	O	mg
12	58	60	O	are
13	62	68	O	equally
14	70	81	O	bioavailable
15	83	90	O	relative
16	92	93	O	to
17	95	95	O	a
18	97	104	O	CLOZARIL
19	106	113	O	solution
NULL

Clozapine	3017	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	46
Following oral administration of CLOZARIL 100 mg twice daily, the average steady-state peak plasma concentration was 319 ng/mL (range: 102 to 771 ng/mL), occurring at the average of 2.5 hours (range: 1 to 6 hours) after dosing.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	40	O	CLOZARIL
6	42	44	O	100
7	46	47	O	mg
8	49	53	O	twice
9	55	59	O	daily
10	60	60	O	,
11	62	64	O	the
12	66	72	O	average
13	74	79	O	steady
14	81	85	O	state
15	87	90	O	peak
16	92	97	O	plasma
17	99	111	O	concentration
18	113	115	O	was
19	117	119	O	319
20	121	122	O	ng
21	123	123	O	/
22	124	125	O	mL
23	128	132	O	range
24	133	133	O	:
25	135	137	O	102
26	139	140	O	to
27	142	144	O	771
28	146	147	O	ng
29	148	148	O	/
30	149	150	O	mL
31	152	152	O	,
32	154	162	O	occurring
33	164	165	O	at
34	167	169	O	the
35	171	177	O	average
36	179	180	O	of
37	182	184	O	2.5
38	186	190	O	hours
39	193	197	O	range
40	198	198	O	:
41	200	200	O	1
42	202	203	O	to
43	205	205	O	6
44	207	211	O	hours
45	214	218	O	after
46	220	225	O	dosing
NULL

Clozapine	3018	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	27
The average minimum concentration at steady state was 122 ng/mL (range: 41 to 343 ng/mL), after 100 mg twice daily dosing.
1	0	2	O	The
2	4	10	O	average
3	12	18	O	minimum
4	20	32	O	concentration
5	34	35	O	at
6	37	42	O	steady
7	44	48	O	state
8	50	52	O	was
9	54	56	O	122
10	58	59	O	ng
11	60	60	O	/
12	61	62	O	mL
13	65	69	O	range
14	70	70	O	:
15	72	73	O	41
16	75	76	O	to
17	78	80	O	343
18	82	83	O	ng
19	84	84	O	/
20	85	86	O	mL
21	88	88	O	,
22	90	94	O	after
23	96	98	O	100
24	100	101	O	mg
25	103	107	O	twice
26	109	113	O	daily
27	115	120	O	dosing
NULL

Clozapine	3019	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	11
Food does not appear to affect the systemic bioavailability of CLOZARIL.
1	0	3	O	Food
2	5	8	O	does
3	10	12	O	not
4	14	19	O	appear
5	21	22	O	to
6	24	29	O	affect
7	31	33	O	the
8	35	42	O	systemic
9	44	58	O	bioavailability
10	60	61	O	of
11	63	70	O	CLOZARIL
NULL

Clozapine	3020	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	10
Thus, CLOZARIL may be administered with or without food.
1	0	3	O	Thus
2	4	4	O	,
3	6	13	O	CLOZARIL
4	15	17	O	may
5	19	20	O	be
6	22	33	O	administered
7	35	38	O	with
8	40	41	O	or
9	43	49	O	without
10	51	54	O	food
NULL

Clozapine	3021	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	9
Distribution Clozapine is approximately 97% bound to serum proteins.
1	0	11	O	Distribution
2	13	21	O	XXXXXXXX
3	23	24	O	is
4	26	38	O	approximately
5	40	42	O	97%
6	44	48	O	bound
7	50	51	O	to
8	53	57	O	serum
9	59	66	O	proteins
NULL

Clozapine	3022	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	19
The interaction between clozapine and other highly protein-bound drugs has not been fully evaluated but may be important.
1	0	2	O	The
2	4	14	U-TRI	interaction
3	16	22	O	between
4	24	32	O	XXXXXXXX
5	34	36	O	and
6	38	42	O	other
7	44	49	B-UNK	highly
8	51	57	I-UNK	protein
9	59	63	I-UNK	bound
10	65	69	L-UNK	drugs
11	71	73	O	has
12	75	77	O	not
13	79	82	O	been
14	84	88	O	fully
15	90	98	O	evaluated
16	100	102	O	but
17	104	106	O	may
18	108	109	O	be
19	111	119	O	important
NULL

Clozapine	3023	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	26
Metabolism and Excretion Clozapine is almost completely metabolized prior to excretion, and only trace amounts of unchanged drug are detected in the urine and feces.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	23	O	Excretion
4	25	33	O	XXXXXXXX
5	35	36	O	is
6	38	43	O	almost
7	45	54	O	completely
8	56	66	O	metabolized
9	68	72	O	prior
10	74	75	O	to
11	77	85	O	excretion
12	86	86	O	,
13	88	90	O	and
14	92	95	O	only
15	97	101	O	trace
16	103	109	O	amounts
17	111	112	O	of
18	114	122	O	unchanged
19	124	127	O	drug
20	129	131	O	are
21	133	140	O	detected
22	142	143	O	in
23	145	147	O	the
24	149	153	O	urine
25	155	157	O	and
26	159	163	O	feces
NULL

Clozapine	3024	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	18
Clozapine is a substrate for many cytochrome P450 isozymes, in particular CYP1A2, CYP2D6, and CYP3A4.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	13	O	a
4	15	23	O	substrate
5	25	27	O	for
6	29	32	O	many
7	34	43	O	cytochrome
8	45	48	O	P450
9	50	57	O	isozymes
10	58	58	O	,
11	60	61	O	in
12	63	72	O	particular
13	74	79	O	CYP1A2
14	80	80	O	,
15	82	87	O	CYP2D6
16	88	88	O	,
17	90	92	O	and
18	94	99	O	CYP3A4
NULL

Clozapine	3025	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	16
Approximately 50% of the administered dose is excreted in the urine and 30% in the feces.
1	0	12	O	Approximately
2	14	16	O	50%
3	18	19	O	of
4	21	23	O	the
5	25	36	O	administered
6	38	41	O	dose
7	43	44	O	is
8	46	53	O	excreted
9	55	56	O	in
10	58	60	O	the
11	62	66	O	urine
12	68	70	O	and
13	72	74	O	30%
14	76	77	O	in
15	79	81	O	the
16	83	87	O	feces
NULL

Clozapine	3026	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	16
The demethylated, hydroxylated, and N-oxide derivatives are components in both urine and feces.
1	0	2	O	The
2	4	15	O	demethylated
3	16	16	O	,
4	18	29	O	hydroxylated
5	30	30	O	,
6	32	34	O	and
7	36	36	O	N
8	38	42	O	oxide
9	44	54	O	derivatives
10	56	58	O	are
11	60	69	O	components
12	71	72	O	in
13	74	77	O	both
14	79	83	O	urine
15	85	87	O	and
16	89	93	O	feces
NULL

Clozapine	3027	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	24
Pharmacological testing has shown the desmethyl metabolite (norclozapine) to have only limited activity, while the hydroxylated and N-oxide derivatives were inactive.
1	0	14	O	Pharmacological
2	16	22	O	testing
3	24	26	O	has
4	28	32	O	shown
5	34	36	O	the
6	38	46	O	desmethyl
7	48	57	O	metabolite
8	60	62	O	nor
9	63	71	O	XXXXXXXX
10	74	75	O	to
11	77	80	O	have
12	82	85	O	only
13	87	93	O	limited
14	95	102	O	activity
15	103	103	O	,
16	105	109	O	while
17	111	113	O	the
18	115	126	O	hydroxylated
19	128	130	O	and
20	132	132	O	N
21	134	138	O	oxide
22	140	150	O	derivatives
23	152	155	O	were
24	157	164	O	inactive
NULL

Clozapine	3028	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	49
The mean elimination half-life of clozapine after a single 75 mg dose was 8 hours (range: 4 to12 hours), compared to a mean elimination half-life of 12 hours (range: 4 to 66 hours), after achieving steady state with 100 mg twice daily dosing.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	of
7	34	42	O	XXXXXXXX
8	44	48	O	after
9	50	50	O	a
10	52	57	O	single
11	59	60	O	75
12	62	63	O	mg
13	65	68	O	dose
14	70	72	O	was
15	74	74	O	8
16	76	80	O	hours
17	83	87	O	range
18	88	88	O	:
19	90	90	O	4
20	92	95	O	to12
21	97	101	O	hours
22	103	103	O	,
23	105	112	O	compared
24	114	115	O	to
25	117	117	O	a
26	119	122	O	mean
27	124	134	O	elimination
28	136	139	O	half
29	141	144	O	life
30	146	147	O	of
31	149	150	O	12
32	152	156	O	hours
33	159	163	O	range
34	164	164	O	:
35	166	166	O	4
36	168	169	O	to
37	171	172	O	66
38	174	178	O	hours
39	180	180	O	,
40	182	186	O	after
41	188	196	O	achieving
42	198	203	O	steady
43	205	209	O	state
44	211	214	O	with
45	216	218	O	100
46	220	221	O	mg
47	223	227	O	twice
48	229	233	O	daily
49	235	240	O	dosing
NULL

Clozapine	3029	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	37
A comparison of single-dose and multiple-dose administration of clozapine demonstrated that the elimination half-life increased significantly after multiple dosing relative to that after single-dose administration, suggesting the possibility of concentration-dependent pharmacokinetics.
1	0	0	O	A
2	2	11	O	comparison
3	13	14	O	of
4	16	21	O	single
5	23	26	O	dose
6	28	30	O	and
7	32	39	O	multiple
8	41	44	O	dose
9	46	59	O	administration
10	61	62	O	of
11	64	72	O	XXXXXXXX
12	74	85	O	demonstrated
13	87	90	O	that
14	92	94	O	the
15	96	106	O	elimination
16	108	111	O	half
17	113	116	O	life
18	118	126	O	increased
19	128	140	O	significantly
20	142	146	O	after
21	148	155	O	multiple
22	157	162	O	dosing
23	164	171	O	relative
24	173	174	O	to
25	176	179	O	that
26	181	185	O	after
27	187	192	O	single
28	194	197	O	dose
29	199	212	O	administration
30	213	213	O	,
31	215	224	O	suggesting
32	226	228	O	the
33	230	240	O	possibility
34	242	243	O	of
35	245	257	O	concentration
36	259	267	O	dependent
37	269	284	O	pharmacokinetics
NULL

Clozapine	3030	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	40
However, at steady state, approximately dose-proportional changes with respect to AUC (area under the curve), peak, and minimum clozapine plasma concentrations were observed after administration of 37.5, 75, and 150 mg twice daily.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	at
4	12	17	O	steady
5	19	23	O	state
6	24	24	O	,
7	26	38	O	approximately
8	40	43	O	dose
9	45	56	O	proportional
10	58	64	O	changes
11	66	69	O	with
12	71	77	O	respect
13	79	80	O	to
14	82	84	O	AUC
15	87	90	O	area
16	92	96	O	under
17	98	100	O	the
18	102	106	O	curve
19	108	108	O	,
20	110	113	O	peak
21	114	114	O	,
22	116	118	O	and
23	120	126	O	minimum
24	128	136	O	XXXXXXXX
25	138	143	O	plasma
26	145	158	O	concentrations
27	160	163	O	were
28	165	172	O	observed
29	174	178	O	after
30	180	193	O	administration
31	195	196	O	of
32	198	201	O	37.5
33	202	202	O	,
34	204	205	O	75
35	206	206	O	,
36	208	210	O	and
37	212	214	O	150
38	216	217	O	mg
39	219	223	O	twice
40	225	229	O	daily
NULL

Clozapine	3031	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	21
Drug-Drug Interaction Studies Fluvoxamine A pharmacokinetic study was conducted in 16 schizophrenic patients who received clozapine under steady-state conditions.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	20	O	Interaction
4	22	28	O	Studies
5	30	40	O	Fluvoxamine
6	42	42	O	A
7	44	58	O	pharmacokinetic
8	60	64	O	study
9	66	68	O	was
10	70	78	O	conducted
11	80	81	O	in
12	83	84	O	16
13	86	98	O	schizophrenic
14	100	107	O	patients
15	109	111	O	who
16	113	120	O	received
17	122	130	O	XXXXXXXX
18	132	136	O	under
19	138	143	O	steady
20	145	149	O	state
21	151	160	O	conditions
NULL

Clozapine	3032	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	36
After coadministration of fluvoxamine for 14 days, mean trough concentrations of clozapine and its metabolites, N-desmethylclozapine and clozapine N-oxide, were elevated about 3-fold compared to baseline steady-state concentrations.
1	0	4	O	After
2	6	21	O	coadministration
3	23	24	O	of
4	26	36	U-KIN	fluvoxamine
5	38	40	O	for
6	42	43	O	14
7	45	48	O	days
8	49	49	O	,
9	51	54	O	mean
10	56	61	O	trough
11	63	76	O	concentrations
12	78	79	O	of
13	81	89	O	XXXXXXXX
14	91	93	O	and
15	95	97	O	its
16	99	109	O	metabolites
17	110	110	O	,
18	112	112	O	N
19	114	122	O	desmethyl
20	123	131	O	XXXXXXXX
21	133	135	O	and
22	137	145	O	XXXXXXXX
23	147	147	O	N
24	149	153	O	oxide
25	154	154	O	,
26	156	159	O	were
27	161	168	O	elevated
28	170	174	O	about
29	176	176	O	3
30	178	181	O	fold
31	183	190	O	compared
32	192	193	O	to
33	195	202	O	baseline
34	204	209	O	steady
35	211	215	O	state
36	217	230	O	concentrations
K/4:C54355

Clozapine	3033	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	36
Paroxetine, Fluoxetine, and Sertraline In a study of schizophrenic patients (n=14) who received clozapine under steady-state conditions, coadministration of paroxetine produced only minor changes in the levels of clozapine and its metabolites.
1	0	9	O	Paroxetine
2	10	10	O	,
3	12	21	O	Fluoxetine
4	22	22	O	,
5	24	26	O	and
6	28	37	O	Sertraline
7	39	40	O	In
8	42	42	O	a
9	44	48	O	study
10	50	51	O	of
11	53	65	O	schizophrenic
12	67	74	O	patients
13	77	80	O	n=14
14	83	85	O	who
15	87	94	O	received
16	96	104	O	XXXXXXXX
17	106	110	O	under
18	112	117	O	steady
19	119	123	O	state
20	125	134	O	conditions
21	135	135	O	,
22	137	152	O	coadministration
23	154	155	O	of
24	157	166	O	paroxetine
25	168	175	O	produced
26	177	180	O	only
27	182	186	O	minor
28	188	194	O	changes
29	196	197	O	in
30	199	201	O	the
31	203	208	O	levels
32	210	211	O	of
33	213	221	O	XXXXXXXX
34	223	225	O	and
35	227	229	O	its
36	231	241	O	metabolites
NULL

Clozapine	3034	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	28
However, other published reports describe modest elevations (less than 2-fold) of clozapine and metabolite concentrations when clozapine was taken with paroxetine, fluoxetine, and sertraline.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	other
4	15	23	O	published
5	25	31	O	reports
6	33	40	O	describe
7	42	47	O	modest
8	49	58	U-TRI	elevations
9	61	64	O	less
10	66	69	O	than
11	71	71	O	2
12	73	76	O	fold
13	79	80	O	of
14	82	90	O	XXXXXXXX
15	92	94	O	and
16	96	105	O	metabolite
17	107	120	O	concentrations
18	122	125	O	when
19	127	135	O	XXXXXXXX
20	137	139	O	was
21	141	145	O	taken
22	147	150	O	with
23	152	161	U-KIN	paroxetine
24	162	162	O	,
25	164	173	U-KIN	fluoxetine
26	174	174	O	,
27	176	178	O	and
28	180	189	U-KIN	sertraline
K/23:C54355 K/25:C54355 K/28:C54355

Clozapine	3035	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	27
Specific Population Studies Renal or Hepatic Impairment No specific pharmacokinetic studies were conducted to investigate the effects of renal or hepatic impairment on the pharmacokinetics of clozapine.
1	0	7	O	Specific
2	9	18	O	Population
3	20	26	O	Studies
4	28	32	O	Renal
5	34	35	O	or
6	37	43	O	Hepatic
7	45	54	O	Impairment
8	56	57	O	No
9	59	66	O	specific
10	68	82	O	pharmacokinetic
11	84	90	O	studies
12	92	95	O	were
13	97	105	O	conducted
14	107	108	O	to
15	110	120	O	investigate
16	122	124	O	the
17	126	132	O	effects
18	134	135	O	of
19	137	141	O	renal
20	143	144	O	or
21	146	152	O	hepatic
22	154	163	O	impairment
23	165	166	O	on
24	168	170	O	the
25	172	187	O	pharmacokinetics
26	189	190	O	of
27	192	200	O	XXXXXXXX
NULL

Clozapine	3036	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	18
Higher clozapine plasma concentrations are likely in patients with significant renal or hepatic impairment when given usual doses.
1	0	5	O	Higher
2	7	15	O	XXXXXXXX
3	17	22	O	plasma
4	24	37	O	concentrations
5	39	41	O	are
6	43	48	O	likely
7	50	51	O	in
8	53	60	O	patients
9	62	65	O	with
10	67	77	O	significant
11	79	83	O	renal
12	85	86	O	or
13	88	94	O	hepatic
14	96	105	O	impairment
15	107	110	O	when
16	112	116	O	given
17	118	122	O	usual
18	124	128	O	doses
NULL

Clozapine	3037	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	18
CYP2D6 Poor Metabolizers A subset (3%-10%) of the population has reduced activity of CYP2D6 (CYP2D6 poor metabolizers).
1	0	5	O	CYP2D6
2	7	10	O	Poor
3	12	23	O	Metabolizers
4	25	25	O	A
5	27	32	O	subset
6	35	36	O	3%
7	38	40	O	10%
8	43	44	O	of
9	46	48	O	the
10	50	59	O	population
11	61	63	O	has
12	65	71	O	reduced
13	73	80	O	activity
14	82	83	O	of
15	85	90	O	CYP2D6
16	93	98	O	CYP2D6
17	100	103	O	poor
18	105	116	O	metabolizers
NULL

Clozapine	3038	34090-1	5f0c6f5f-b906-4c8f-8580-3939a476a1c1	15
These individuals may develop higher than expected plasma concentrations of clozapine when given usual doses.
1	0	4	O	These
2	6	16	O	individuals
3	18	20	O	may
4	22	28	O	develop
5	30	35	O	higher
6	37	40	O	than
7	42	49	O	expected
8	51	56	O	plasma
9	58	71	O	concentrations
10	73	74	O	of
11	76	84	O	XXXXXXXX
12	86	89	O	when
13	91	95	O	given
14	97	101	O	usual
15	103	107	O	doses
NULL

Dabigatran	1911	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	64
P-gp inducers rifampin: Avoid coadministration with PRADAXA (5.5) P-gp inhibitors in patients with CrCl 30-50 mL/min: Reduce dose or avoid (7) P-gp inhibitors in patients with CrCl <30 mL/min: Not recommended (7) The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided.
1	0	0	B-KIN	P
2	2	3	I-KIN	gp
3	5	12	L-KIN	inducers
4	14	21	U-KIN	rifampin
5	22	22	O	:
6	24	28	O	Avoid
7	30	45	O	coadministration
8	47	50	O	with
9	52	58	O	PRADAXA
10	61	63	O	5.5
11	66	66	B-KIN	P
12	68	69	I-KIN	gp
13	71	80	L-KIN	inhibitors
14	82	83	O	in
15	85	92	O	patients
16	94	97	O	with
17	99	102	O	CrCl
18	104	105	O	30
19	107	108	O	50
20	110	111	O	mL
21	112	112	O	/
22	113	115	O	min
23	116	116	O	:
24	118	123	B-TRI	Reduce
25	125	128	L-TRI	dose
26	130	131	O	or
27	133	137	O	avoid
28	140	140	O	7
29	143	143	O	P
30	145	146	O	gp
31	148	157	O	inhibitors
32	159	160	O	in
33	162	169	O	patients
34	171	174	O	with
35	176	179	O	CrCl
36	181	183	O	<30
37	185	186	O	mL
38	187	187	O	/
39	188	190	O	min
40	191	191	O	:
41	193	195	O	Not
42	197	207	O	recommended
43	210	210	O	7
44	213	215	O	The
45	217	227	O	concomitant
46	229	231	O	use
47	233	234	O	of
48	236	242	O	PRADAXA
49	244	247	O	with
50	249	249	O	P
51	251	252	O	gp
52	254	261	O	inducers
53	264	266	O	e.g
54	268	268	O	,
55	270	277	O	rifampin
56	280	286	B-TRI	reduces
57	288	295	L-TRI	exposure
58	297	298	O	to
59	300	309	O	XXXXXXXX
60	311	313	O	and
61	315	320	O	should
62	322	330	O	generally
63	332	333	O	be
64	335	341	O	avoided
K/1:C54356 K/11:C54355 K/4:C54356

Dabigatran	1912	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	19
P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran.
1	0	0	O	P
2	2	3	O	gp
3	5	14	O	inhibition
4	16	18	O	and
5	20	27	O	impaired
6	29	33	O	renal
7	35	42	O	function
8	44	46	O	are
9	48	50	O	the
10	52	56	O	major
11	58	68	O	independent
12	70	76	O	factors
13	78	81	O	that
14	83	88	O	result
15	90	91	O	in
16	93	101	O	increased
17	103	110	O	exposure
18	112	113	O	to
19	115	124	O	XXXXXXXX
NULL

Dabigatran	1913	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	27
Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	19	B-KIN	P
5	21	22	I-KIN	gp
6	24	33	L-KIN	inhibitors
7	35	36	O	in
8	38	45	O	patients
9	47	50	O	with
10	52	56	O	renal
11	58	67	O	impairment
12	69	70	O	is
13	72	79	O	expected
14	81	82	O	to
15	84	90	O	produce
16	92	100	B-TRI	increased
17	102	109	L-TRI	exposure
18	111	112	O	of
19	114	123	O	XXXXXXXX
20	125	132	O	compared
21	134	135	O	to
22	137	140	O	that
23	142	145	O	seen
24	147	150	O	with
25	152	157	O	either
26	159	164	O	factor
27	166	170	O	alone
K/4:C54355

Dabigatran	1914	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	35
In patients with moderate renal impairment (CrCl 30-50 mL/min), reduce the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	24	O	moderate
5	26	30	O	renal
6	32	41	O	impairment
7	44	47	O	CrCl
8	49	50	O	30
9	52	53	O	50
10	55	56	O	mL
11	57	57	O	/
12	58	60	O	min
13	62	62	O	,
14	64	69	B-TRI	reduce
15	71	73	I-TRI	the
16	75	78	L-TRI	dose
17	80	81	O	of
18	83	89	O	PRADAXA
19	91	92	O	to
20	94	95	O	75
21	97	98	O	mg
22	100	104	O	twice
23	106	110	O	daily
24	112	115	O	when
25	117	128	O	administered
26	130	142	O	concomitantly
27	144	147	O	with
28	149	151	O	the
29	153	153	B-KIN	P
30	155	156	I-KIN	gp
31	158	167	L-KIN	inhibitors
32	169	179	U-KIN	dronedarone
33	181	182	O	or
34	184	191	B-KIN	systemic
35	193	204	L-KIN	ketoconazole
K/29:C54355 K/32:C54355 K/34:C54355

Dabigatran	1915	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	25
The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dose adjustment of PRADAXA.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	13	O	the
5	15	15	O	P
6	17	18	O	gp
7	20	29	O	inhibitors
8	31	39	O	verapamil
9	40	40	O	,
10	42	51	O	amiodarone
11	52	52	O	,
12	54	62	O	quinidine
13	63	63	O	,
14	65	78	O	clarithromycin
15	79	79	O	,
16	81	83	O	and
17	85	94	O	ticagrelor
18	96	99	O	does
19	101	103	O	not
20	105	111	O	require
21	113	113	O	a
22	115	118	O	dose
23	120	129	O	adjustment
24	131	132	O	of
25	134	140	O	PRADAXA
NULL

Dabigatran	1916	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	11
These results should not be extrapolated to other P-gp inhibitors.
1	0	4	O	These
2	6	12	O	results
3	14	19	O	should
4	21	23	O	not
5	25	26	O	be
6	28	39	O	extrapolated
7	41	42	O	to
8	44	48	O	other
9	50	50	O	P
10	52	53	O	gp
11	55	64	O	inhibitors
NULL

Dabigatran	1917	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	24
The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	O	PRADAXA
6	31	33	O	and
7	35	35	B-UNK	P
8	37	38	I-UNK	gp
9	40	49	L-UNK	inhibitors
10	51	52	O	in
11	54	61	O	patients
12	63	66	O	with
13	68	73	O	severe
14	75	79	O	renal
15	81	90	O	impairment
16	93	96	O	CrCl
17	98	99	O	15
18	101	102	O	30
19	104	105	O	mL
20	106	106	O	/
21	107	109	O	min
22	112	117	B-TRI	should
23	119	120	I-TRI	be
24	122	128	L-TRI	avoided
NULL

Dabigatran	1918	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	16
Avoid use of PRADAXA and P-gp inhibitors in patients with CrCl <50 mL/min.
1	0	4	B-TRI	Avoid
2	6	8	L-TRI	use
3	10	11	O	of
4	13	19	O	PRADAXA
5	21	23	O	and
6	25	25	B-UNK	P
7	27	28	I-UNK	gp
8	30	39	L-UNK	inhibitors
9	41	42	O	in
10	44	51	O	patients
11	53	56	O	with
12	58	61	O	CrCl
13	63	65	O	<50
14	67	68	O	mL
15	69	69	O	/
16	70	72	O	min
NULL

Dabigatran	1919	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	43
In patients with CrCl >50 mL/min who have concomitant administration of P-gp inhibitors such as dronedarone or systemic ketoconazole, it may be helpful to separate the timing of administration of dabigatran and the P-gp inhibitor by several hours.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	20	O	CrCl
5	22	24	O	>50
6	26	27	O	mL
7	28	28	O	/
8	29	31	O	min
9	33	35	O	who
10	37	40	O	have
11	42	52	O	concomitant
12	54	67	O	administration
13	69	70	O	of
14	72	72	B-UNK	P
15	74	75	I-UNK	gp
16	77	86	L-UNK	inhibitors
17	88	91	O	such
18	93	94	O	as
19	96	106	U-UNK	dronedarone
20	108	109	O	or
21	111	118	B-UNK	systemic
22	120	131	L-UNK	ketoconazole
23	132	132	O	,
24	134	135	O	it
25	137	139	O	may
26	141	142	O	be
27	144	150	O	helpful
28	152	153	O	to
29	155	162	B-TRI	separate
30	164	166	I-TRI	the
31	168	173	I-TRI	timing
32	175	176	I-TRI	of
33	178	191	L-TRI	administration
34	193	194	O	of
35	196	205	O	XXXXXXXX
36	207	209	O	and
37	211	213	O	the
38	215	215	O	P
39	217	218	O	gp
40	220	228	O	inhibitor
41	230	231	O	by
42	233	239	O	several
43	241	245	O	hours
NULL

Dabigatran	1920	34073-7	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	20
The concomitant use of PRADAXA and P-gp inhibitors in patients with CrCl <50 mL/min should be avoided.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	O	PRADAXA
6	31	33	O	and
7	35	35	O	P
8	37	38	O	gp
9	40	49	O	inhibitors
10	51	52	O	in
11	54	61	O	patients
12	63	66	O	with
13	68	71	O	CrCl
14	73	75	O	<50
15	77	78	O	mL
16	79	79	O	/
17	80	82	O	min
18	84	89	O	should
19	91	92	O	be
20	94	100	O	avoided
NULL

Dabigatran	1921	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	11
Dabigatran and its acyl glucuronides are competitive, direct thrombin inhibitors.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	17	O	its
4	19	22	O	acyl
5	24	35	O	glucuronides
6	37	39	O	are
7	41	51	O	competitive
8	52	52	O	,
9	54	59	O	direct
10	61	68	O	thrombin
11	70	79	O	inhibitors
NULL

Dabigatran	1922	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	24
Because thrombin (serine protease) enables the conversion of fibrinogen into fibrin during the coagulation cascade, its inhibition prevents the development of a thrombus.
1	0	6	O	Because
2	8	15	O	thrombin
3	18	23	O	serine
4	25	32	O	protease
5	35	41	O	enables
6	43	45	O	the
7	47	56	O	conversion
8	58	59	O	of
9	61	70	O	fibrinogen
10	72	75	O	into
11	77	82	O	fibrin
12	84	89	O	during
13	91	93	O	the
14	95	105	O	coagulation
15	107	113	O	cascade
16	114	114	O	,
17	116	118	O	its
18	120	129	O	inhibition
19	131	138	O	prevents
20	140	142	O	the
21	144	154	O	development
22	156	157	O	of
23	159	159	O	a
24	161	168	O	thrombus
NULL

Dabigatran	1923	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	18
Both free and clot-bound thrombin, and thrombin-induced platelet aggregation are inhibited by the active moieties.
1	0	3	O	Both
2	5	8	O	free
3	10	12	O	and
4	14	17	O	clot
5	19	23	O	bound
6	25	32	O	thrombin
7	33	33	O	,
8	35	37	O	and
9	39	46	O	thrombin
10	48	54	O	induced
11	56	63	O	platelet
12	65	75	O	aggregation
13	77	79	O	are
14	81	89	O	inhibited
15	91	92	O	by
16	94	96	O	the
17	98	103	O	active
18	105	112	O	moieties
NULL

Dabigatran	1924	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	19
At recommended therapeutic doses, dabigatran etexilate prolongs the coagulation markers such as aPTT, ECT, and TT.
1	0	1	O	At
2	3	13	O	recommended
3	15	25	O	therapeutic
4	27	31	O	doses
5	32	32	O	,
6	34	43	O	XXXXXXXX
7	45	53	O	etexilate
8	55	62	O	prolongs
9	64	66	O	the
10	68	78	O	coagulation
11	80	86	O	markers
12	88	91	O	such
13	93	94	O	as
14	96	99	O	aPTT
15	100	100	O	,
16	102	104	O	ECT
17	105	105	O	,
18	107	109	O	and
19	111	112	O	TT
NULL

Dabigatran	1925	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	21
INR is relatively insensitive to the exposure to dabigatran and cannot be interpreted the same way as used for warfarin monitoring.
1	0	2	O	INR
2	4	5	O	is
3	7	16	O	relatively
4	18	28	O	insensitive
5	30	31	O	to
6	33	35	O	the
7	37	44	O	exposure
8	46	47	O	to
9	49	58	O	XXXXXXXX
10	60	62	O	and
11	64	69	O	cannot
12	71	72	O	be
13	74	84	O	interpreted
14	86	88	O	the
15	90	93	O	same
16	95	97	O	way
17	99	100	O	as
18	102	105	O	used
19	107	109	O	for
20	111	118	O	warfarin
21	120	129	O	monitoring
NULL

Dabigatran	1926	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	10
The aPTT test provides an approximation of PRADAXA's anticoagulant effect.
1	0	2	O	The
2	4	7	O	aPTT
3	9	12	O	test
4	14	21	O	provides
5	23	24	O	an
6	26	38	O	approximation
7	40	41	O	of
8	43	51	O	PRADAXA's
9	53	65	O	anticoagulant
10	67	72	O	effect
NULL

Dabigatran	1927	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	26
The average time course for effects on aPTT, following approved dosing regimens in patients with various degrees of renal impairment is shown in Figure 2.
1	0	2	O	The
2	4	10	O	average
3	12	15	O	time
4	17	22	O	course
5	24	26	O	for
6	28	34	O	effects
7	36	37	O	on
8	39	42	O	aPTT
9	43	43	O	,
10	45	53	O	following
11	55	62	O	approved
12	64	69	O	dosing
13	71	78	O	regimens
14	80	81	O	in
15	83	90	O	patients
16	92	95	O	with
17	97	103	O	various
18	105	111	O	degrees
19	113	114	O	of
20	116	120	O	renal
21	122	131	O	impairment
22	133	134	O	is
23	136	140	O	shown
24	142	143	O	in
25	145	150	O	Figure
26	152	152	O	2
NULL

Dabigatran	1928	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	15
The curves represent mean levels without confidence intervals; variations should be expected when measuring aPTT.
1	0	2	O	The
2	4	9	O	curves
3	11	19	O	represent
4	21	24	O	mean
5	26	31	O	levels
6	33	39	O	without
7	41	50	O	confidence
8	52	60	O	intervals
9	63	72	O	variations
10	74	79	O	should
11	81	82	O	be
12	84	91	O	expected
13	93	96	O	when
14	98	106	O	measuring
15	108	111	O	aPTT
NULL

Dabigatran	1929	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	51
While advice cannot be provided on the level of recovery of aPTT needed in any particular clinical setting, the curves can be used to estimate the time to get to a particular level of recovery, even when the time since the last dose of PRADAXA is not precisely known.
1	0	4	O	While
2	6	11	O	advice
3	13	18	O	cannot
4	20	21	O	be
5	23	30	O	provided
6	32	33	O	on
7	35	37	O	the
8	39	43	O	level
9	45	46	O	of
10	48	55	O	recovery
11	57	58	O	of
12	60	63	O	aPTT
13	65	70	O	needed
14	72	73	O	in
15	75	77	O	any
16	79	88	O	particular
17	90	97	O	clinical
18	99	105	O	setting
19	106	106	O	,
20	108	110	O	the
21	112	117	O	curves
22	119	121	O	can
23	123	124	O	be
24	126	129	O	used
25	131	132	O	to
26	134	141	O	estimate
27	143	145	O	the
28	147	150	O	time
29	152	153	O	to
30	155	157	O	get
31	159	160	O	to
32	162	162	O	a
33	164	173	O	particular
34	175	179	O	level
35	181	182	O	of
36	184	191	O	recovery
37	192	192	O	,
38	194	197	O	even
39	199	202	O	when
40	204	206	O	the
41	208	211	O	time
42	213	217	O	since
43	219	221	O	the
44	223	226	O	last
45	228	231	O	dose
46	233	234	O	of
47	236	242	O	PRADAXA
48	244	245	O	is
49	247	249	O	not
50	251	259	O	precisely
51	261	265	O	known
NULL

Dabigatran	1930	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	27
In the RE-LY trial, the median (10th to 90th percentile) trough aPTT in patients receiving the 150 mg dose was 52 (40 to 76) seconds.
1	0	1	O	In
2	3	5	O	the
3	7	8	O	RE
4	10	11	O	LY
5	13	17	O	trial
6	18	18	O	,
7	20	22	O	the
8	24	29	O	median
9	32	35	O	10th
10	37	38	O	to
11	40	43	O	90th
12	45	54	O	percentile
13	57	62	O	trough
14	64	67	O	aPTT
15	69	70	O	in
16	72	79	O	patients
17	81	89	O	receiving
18	91	93	O	the
19	95	97	O	150
20	99	100	O	mg
21	102	105	O	dose
22	107	109	O	was
23	111	112	O	52
24	115	116	O	40
25	118	119	O	to
26	121	122	O	76
27	125	131	O	seconds
NULL

Dabigatran	1931	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	70
Figure 2 Average Time Course for Effects of Dabigatran on aPTT, Following Approved PRADAXA Dosing Regimens in Patients with Various Degrees of Renal Impairment* *Simulations based on PK data from a study in subjects with renal impairment and PK/aPTT relationships derived from the RE-LY study; aPTT prolongation in RE-LY was measured centrally in citrate plasma using PTT Reagent Roche Diagnostics GmbH, Mannheim, Germany.
1	0	5	O	Figure
2	7	7	O	2
3	9	15	O	Average
4	17	20	O	Time
5	22	27	O	Course
6	29	31	O	for
7	33	39	O	Effects
8	41	42	O	of
9	44	53	O	XXXXXXXX
10	55	56	O	on
11	58	61	O	aPTT
12	62	62	O	,
13	64	72	O	Following
14	74	81	O	Approved
15	83	89	O	PRADAXA
16	91	96	O	Dosing
17	98	105	O	Regimens
18	107	108	O	in
19	110	117	O	Patients
20	119	122	O	with
21	124	130	O	Various
22	132	138	O	Degrees
23	140	141	O	of
24	143	147	O	Renal
25	149	159	O	Impairment*
26	161	172	O	Simulations
27	174	178	O	based
28	180	181	O	on
29	183	184	O	PK
30	186	189	O	data
31	191	194	O	from
32	196	196	O	a
33	198	202	O	study
34	204	205	O	in
35	207	214	O	subjects
36	216	219	O	with
37	221	225	O	renal
38	227	236	O	impairment
39	238	240	O	and
40	242	243	O	PK
41	244	244	O	/
42	245	248	O	aPTT
43	250	262	O	relationships
44	264	270	O	derived
45	272	275	O	from
46	277	279	O	the
47	281	282	O	RE
48	284	285	O	LY
49	287	291	O	study
50	294	297	O	aPTT
51	299	310	O	prolongation
52	312	313	O	in
53	315	316	O	RE
54	318	319	O	LY
55	321	323	O	was
56	325	332	O	measured
57	334	342	O	centrally
58	344	345	O	in
59	347	353	O	citrate
60	355	360	O	plasma
61	362	366	O	using
62	368	370	O	PTT
63	372	378	O	Reagent
64	380	384	O	Roche
65	386	396	O	Diagnostics
66	398	401	O	GmbH
67	402	402	O	,
68	404	411	O	Mannheim
69	412	412	O	,
70	414	420	O	Germany
NULL

Dabigatran	1932	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	12
There may be quantitative differences between various established methods for aPTT assessment.
1	0	4	O	There
2	6	8	O	may
3	10	11	O	be
4	13	24	O	quantitative
5	26	36	O	differences
6	38	44	O	between
7	46	52	O	various
8	54	64	O	established
9	66	72	O	methods
10	74	76	O	for
11	78	81	O	aPTT
12	83	92	O	assessment
NULL

Dabigatran	1933	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	15
The degree of anticoagulant activity can also be assessed by the ecarin clotting time (ECT).
1	0	2	O	The
2	4	9	O	degree
3	11	12	O	of
4	14	26	O	anticoagulant
5	28	35	O	activity
6	37	39	O	can
7	41	44	O	also
8	46	47	O	be
9	49	56	O	assessed
10	58	59	O	by
11	61	63	O	the
12	65	70	O	ecarin
13	72	79	O	clotting
14	81	84	O	time
15	87	89	O	ECT
NULL

Dabigatran	1934	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	18
This test is a more specific measure of the effect of dabigatran than activated partial thromboplastin time (aPTT).
1	0	3	O	This
2	5	8	O	test
3	10	11	O	is
4	13	13	O	a
5	15	18	O	more
6	20	27	O	specific
7	29	35	O	measure
8	37	38	O	of
9	40	42	O	the
10	44	49	O	effect
11	51	52	O	of
12	54	63	O	XXXXXXXX
13	65	68	O	than
14	70	78	O	activated
15	80	86	O	partial
16	88	101	O	thromboplastin
17	103	106	O	time
18	109	112	O	aPTT
NULL

Dabigatran	1935	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	27
In the RE-LY trial, the median (10th to 90th percentile) trough ECT in patients receiving the 150 mg dose was 63 (44 to 103) seconds.
1	0	1	O	In
2	3	5	O	the
3	7	8	O	RE
4	10	11	O	LY
5	13	17	O	trial
6	18	18	O	,
7	20	22	O	the
8	24	29	O	median
9	32	35	O	10th
10	37	38	O	to
11	40	43	O	90th
12	45	54	O	percentile
13	57	62	O	trough
14	64	66	O	ECT
15	68	69	O	in
16	71	78	O	patients
17	80	88	O	receiving
18	90	92	O	the
19	94	96	O	150
20	98	99	O	mg
21	101	104	O	dose
22	106	108	O	was
23	110	111	O	63
24	114	115	O	44
25	117	118	O	to
26	120	122	O	103
27	125	131	O	seconds
NULL

Dabigatran	1936	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	26
In orthopedic hip surgery patients, maximum aPTT response (Emax) to dabigatran and baseline aPTT were higher shortly after surgery than at later time points (e.g.
1	0	1	O	In
2	3	12	O	orthopedic
3	14	16	O	hip
4	18	24	O	surgery
5	26	33	O	patients
6	34	34	O	,
7	36	42	O	maximum
8	44	47	O	aPTT
9	49	56	O	response
10	59	62	O	Emax
11	65	66	O	to
12	68	77	O	XXXXXXXX
13	79	81	O	and
14	83	90	O	baseline
15	92	95	O	aPTT
16	97	100	O	were
17	102	107	O	higher
18	109	115	O	shortly
19	117	121	O	after
20	123	129	O	surgery
21	131	134	O	than
22	136	137	O	at
23	139	143	O	later
24	145	148	O	time
25	150	155	O	points
26	158	160	O	e.g
NULL

Dabigatran	1937	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	19
Cardiac Electrophysiology No prolongation of the QTc interval was observed with dabigatran etexilate at doses up to 600 mg.
1	0	6	O	Cardiac
2	8	24	O	Electrophysiology
3	26	27	O	No
4	29	40	O	prolongation
5	42	43	O	of
6	45	47	O	the
7	49	51	O	QTc
8	53	60	O	interval
9	62	64	O	was
10	66	73	O	observed
11	75	78	O	with
12	80	89	O	XXXXXXXX
13	91	99	O	etexilate
14	101	102	O	at
15	104	108	O	doses
16	110	111	O	up
17	113	114	O	to
18	116	118	O	600
19	120	121	O	mg
NULL

Dabigatran	1938	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	12
Figure 2 Dabigatran etexilate mesylate is absorbed as the dabigatran etexilate ester.
1	0	5	O	Figure
2	7	7	O	2
3	9	18	O	XXXXXXXX
4	20	28	O	etexilate
5	30	37	O	mesylate
6	39	40	O	is
7	42	49	O	absorbed
8	51	52	O	as
9	54	56	O	the
10	58	67	O	XXXXXXXX
11	69	77	O	etexilate
12	79	83	O	ester
NULL

Dabigatran	1939	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	12
The ester is then hydrolyzed, forming dabigatran, the active moiety.
1	0	2	O	The
2	4	8	O	ester
3	10	11	O	is
4	13	16	O	then
5	18	27	O	hydrolyzed
6	28	28	O	,
7	30	36	O	forming
8	38	47	O	XXXXXXXX
9	48	48	O	,
10	50	52	O	the
11	54	59	O	active
12	61	66	O	moiety
NULL

Dabigatran	1940	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	18
Dabigatran is metabolized to four different acyl glucuronides and both the glucuronides and dabigatran have similar pharmacological activity.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	to
5	29	32	O	four
6	34	42	O	different
7	44	47	O	acyl
8	49	60	O	glucuronides
9	62	64	O	and
10	66	69	O	both
11	71	73	O	the
12	75	86	O	glucuronides
13	88	90	O	and
14	92	101	O	XXXXXXXX
15	103	106	O	have
16	108	114	O	similar
17	116	130	O	pharmacological
18	132	139	O	activity
NULL

Dabigatran	1941	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	12
Pharmacokinetics described here refer to the sum of dabigatran and its glucuronides.
1	0	15	O	Pharmacokinetics
2	17	25	O	described
3	27	30	O	here
4	32	36	O	refer
5	38	39	O	to
6	41	43	O	the
7	45	47	O	sum
8	49	50	O	of
9	52	61	O	XXXXXXXX
10	63	65	O	and
11	67	69	O	its
12	71	82	O	glucuronides
NULL

Dabigatran	1942	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	37
Dabigatran displays dose-proportional pharmacokinetics in healthy subjects and patients in the range of doses from 10 to 400 mg. Absorption The absolute bioavailability of dabigatran following oral administration of dabigatran etexilate is approximately 3 to 7%.
1	0	9	O	XXXXXXXX
2	11	18	O	displays
3	20	23	O	dose
4	25	36	O	proportional
5	38	53	O	pharmacokinetics
6	55	56	O	in
7	58	64	O	healthy
8	66	73	O	subjects
9	75	77	O	and
10	79	86	O	patients
11	88	89	O	in
12	91	93	O	the
13	95	99	O	range
14	101	102	O	of
15	104	108	O	doses
16	110	113	O	from
17	115	116	O	10
18	118	119	O	to
19	121	123	O	400
20	125	126	O	mg
21	129	138	O	Absorption
22	140	142	O	The
23	144	151	O	absolute
24	153	167	O	bioavailability
25	169	170	O	of
26	172	181	O	XXXXXXXX
27	183	191	O	following
28	193	196	O	oral
29	198	211	O	administration
30	213	214	O	of
31	216	225	O	XXXXXXXX
32	227	235	O	etexilate
33	237	238	O	is
34	240	252	O	approximately
35	254	254	O	3
36	256	257	O	to
37	259	260	O	7%
NULL

Dabigatran	1943	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	11
Dabigatran etexilate is a substrate of the efflux transporter P-gp.
1	0	9	O	XXXXXXXX
2	11	19	O	etexilate
3	21	22	O	is
4	24	24	O	a
5	26	34	O	substrate
6	36	37	O	of
7	39	41	O	the
8	43	48	O	efflux
9	50	60	O	transporter
10	62	62	O	P
11	64	65	O	gp
NULL

Dabigatran	1944	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	21
After oral administration of dabigatran etexilate in healthy volunteers, Cmax occurs at 1 hour post-administration in the fasted state.
1	0	4	O	After
2	6	9	O	oral
3	11	24	O	administration
4	26	27	O	of
5	29	38	O	XXXXXXXX
6	40	48	O	etexilate
7	50	51	O	in
8	53	59	O	healthy
9	61	70	O	volunteers
10	71	71	O	,
11	73	76	O	Cmax
12	78	83	O	occurs
13	85	86	O	at
14	88	88	O	1
15	90	93	O	hour
16	95	98	O	post
17	100	113	O	administration
18	115	116	O	in
19	118	120	O	the
20	122	127	O	fasted
21	129	133	O	state
NULL

Dabigatran	1945	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	34
Coadministration of PRADAXA with a high-fat meal delays the time to Cmax by approximately 2 hours but has no effect on the bioavailability of dabigatran; PRADAXA may be administered with or without food.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	PRADAXA
4	28	31	O	with
5	33	33	O	a
6	35	38	B-KIN	high
7	40	42	I-KIN	fat
8	44	47	L-KIN	meal
9	49	54	B-TRI	delays
10	56	58	I-TRI	the
11	60	63	I-TRI	time
12	65	66	I-TRI	to
13	68	71	L-TRI	Cmax
14	73	74	O	by
15	76	88	O	approximately
16	90	90	O	2
17	92	96	O	hours
18	98	100	O	but
19	102	104	O	has
20	106	107	O	no
21	109	114	O	effect
22	116	117	O	on
23	119	121	O	the
24	123	137	O	bioavailability
25	139	140	O	of
26	142	151	O	XXXXXXXX
27	154	160	O	PRADAXA
28	162	164	O	may
29	166	167	O	be
30	169	180	O	administered
31	182	185	O	with
32	187	188	O	or
33	190	196	O	without
34	198	201	O	food
K/6:C54604

Dabigatran	1946	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	24
The oral bioavailability of dabigatran etexilate increases by 75% when the pellets are taken without the capsule shell compared to the intact capsule formulation.
1	0	2	O	The
2	4	7	O	oral
3	9	23	O	bioavailability
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	47	O	etexilate
7	49	57	O	increases
8	59	60	O	by
9	62	64	O	75%
10	66	69	O	when
11	71	73	O	the
12	75	81	O	pellets
13	83	85	O	are
14	87	91	O	taken
15	93	99	O	without
16	101	103	O	the
17	105	111	O	capsule
18	113	117	O	shell
19	119	126	O	compared
20	128	129	O	to
21	131	133	O	the
22	135	140	O	intact
23	142	148	O	capsule
24	150	160	O	formulation
NULL

Dabigatran	1947	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	14
PRADAXA capsules should therefore not be broken, chewed, or opened before administration.
1	0	6	O	PRADAXA
2	8	15	O	capsules
3	17	22	O	should
4	24	32	O	therefore
5	34	36	O	not
6	38	39	O	be
7	41	46	O	broken
8	47	47	O	,
9	49	54	O	chewed
10	55	55	O	,
11	57	58	O	or
12	60	65	O	opened
13	67	72	O	before
14	74	87	O	administration
NULL

Dabigatran	1948	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	10
Distribution Dabigatran is approximately 35% bound to human plasma proteins.
1	0	11	O	Distribution
2	13	22	O	XXXXXXXX
3	24	25	O	is
4	27	39	O	approximately
5	41	43	O	35%
6	45	49	O	bound
7	51	52	O	to
8	54	58	O	human
9	60	65	O	plasma
10	67	74	O	proteins
NULL

Dabigatran	1949	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	17
The red blood cell to plasma partitioning of dabigatran measured as total radioactivity is less than 0.3.
1	0	2	O	The
2	4	6	O	red
3	8	12	O	blood
4	14	17	O	cell
5	19	20	O	to
6	22	27	O	plasma
7	29	40	O	partitioning
8	42	43	O	of
9	45	54	O	XXXXXXXX
10	56	63	O	measured
11	65	66	O	as
12	68	72	O	total
13	74	86	O	radioactivity
14	88	89	O	is
15	91	94	O	less
16	96	99	O	than
17	101	103	O	0.3
NULL

Dabigatran	1950	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	24
The volume of distribution of dabigatran is 50 to 70 L. Dabigatran pharmacokinetics are dose proportional after single doses of 10 to 400 mg.
1	0	2	O	The
2	4	9	O	volume
3	11	12	O	of
4	14	25	O	distribution
5	27	28	O	of
6	30	39	O	XXXXXXXX
7	41	42	O	is
8	44	45	O	50
9	47	48	O	to
10	50	51	O	70
11	53	53	O	L
12	56	65	O	XXXXXXXX
13	67	82	O	pharmacokinetics
14	84	86	O	are
15	88	91	O	dose
16	93	104	O	proportional
17	106	110	O	after
18	112	117	O	single
19	119	123	O	doses
20	125	126	O	of
21	128	129	O	10
22	131	132	O	to
23	134	136	O	400
24	138	139	O	mg
NULL

Dabigatran	1951	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	11
Given twice daily, dabigatran's accumulation factor is approximately two.
1	0	4	O	Given
2	6	10	O	twice
3	12	16	O	daily
4	17	17	O	,
5	19	28	O	XXXXXXXX
6	29	30	O	's
7	32	43	O	accumulation
8	45	50	O	factor
9	52	53	O	is
10	55	67	O	approximately
11	69	71	O	two
NULL

Dabigatran	1952	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	8
Elimination Dabigatran is eliminated primarily in the urine.
1	0	10	O	Elimination
2	12	21	O	XXXXXXXX
3	23	24	O	is
4	26	35	O	eliminated
5	37	45	O	primarily
6	47	48	O	in
7	50	52	O	the
8	54	58	O	urine
NULL

Dabigatran	1953	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	12
Renal clearance of dabigatran is 80% of total clearance after intravenous administration.
1	0	4	O	Renal
2	6	14	O	clearance
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	31	O	is
6	33	35	O	80%
7	37	38	O	of
8	40	44	O	total
9	46	54	O	clearance
10	56	60	O	after
11	62	72	O	intravenous
12	74	87	O	administration
NULL

Dabigatran	1954	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	18
After oral administration of radiolabeled dabigatran, 7% of radioactivity is recovered in urine and 86% in feces.
1	0	4	O	After
2	6	9	O	oral
3	11	24	O	administration
4	26	27	O	of
5	29	40	O	radiolabeled
6	42	51	O	XXXXXXXX
7	52	52	O	,
8	54	55	O	7%
9	57	58	O	of
10	60	72	O	radioactivity
11	74	75	O	is
12	77	85	O	recovered
13	87	88	O	in
14	90	94	O	urine
15	96	98	O	and
16	100	102	O	86%
17	104	105	O	in
18	107	111	O	feces
NULL

Dabigatran	1955	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	13
The half-life of dabigatran in healthy subjects is 12 to 17 hours.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	15	O	of
5	17	26	O	XXXXXXXX
6	28	29	O	in
7	31	37	O	healthy
8	39	46	O	subjects
9	48	49	O	is
10	51	52	O	12
11	54	55	O	to
12	57	58	O	17
13	60	64	O	hours
NULL

Dabigatran	1956	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	11
Metabolism After oral administration, dabigatran etexilate is converted to dabigatran.
1	0	9	O	Metabolism
2	11	15	O	After
3	17	20	O	oral
4	22	35	O	administration
5	36	36	O	,
6	38	47	O	XXXXXXXX
7	49	57	O	etexilate
8	59	60	O	is
9	62	70	O	converted
10	72	73	O	to
11	75	84	O	XXXXXXXX
NULL

Dabigatran	1957	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	20
The cleavage of the dabigatran etexilate by esterase-catalyzed hydrolysis to the active principal dabigatran is the predominant metabolic reaction.
1	0	2	O	The
2	4	11	O	cleavage
3	13	14	O	of
4	16	18	O	the
5	20	29	O	XXXXXXXX
6	31	39	O	etexilate
7	41	42	O	by
8	44	51	O	esterase
9	53	61	O	catalyzed
10	63	72	O	hydrolysis
11	74	75	O	to
12	77	79	O	the
13	81	86	O	active
14	88	96	O	principal
15	98	107	O	XXXXXXXX
16	109	110	O	is
17	112	114	O	the
18	116	126	O	predominant
19	128	136	O	metabolic
20	138	145	O	reaction
NULL

Dabigatran	1958	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	13
Dabigatran is not a substrate, inhibitor, or inducer of CYP450 enzymes.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	16	O	not
4	18	18	O	a
5	20	28	O	substrate
6	29	29	O	,
7	31	39	O	inhibitor
8	40	40	O	,
9	42	43	O	or
10	45	51	O	inducer
11	53	54	O	of
12	56	61	O	CYP450
13	63	69	O	enzymes
NULL

Dabigatran	1959	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	10
Dabigatran is subject to conjugation forming pharmacologically active acyl glucuronides.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	20	O	subject
4	22	23	O	to
5	25	35	O	conjugation
6	37	43	O	forming
7	45	61	O	pharmacologically
8	63	68	O	active
9	70	73	O	acyl
10	75	86	O	glucuronides
NULL

Dabigatran	1960	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	31
Four positional isomers, 1-O, 2-O, 3-O, and 4-O-acylglucuronide exist, and each accounts for less than 10% of total dabigatran in plasma.
1	0	3	O	Four
2	5	14	O	positional
3	16	22	O	isomers
4	23	23	O	,
5	25	25	O	1
6	27	27	O	O
7	28	28	O	,
8	30	30	O	2
9	32	32	O	O
10	33	33	O	,
11	35	35	O	3
12	37	37	O	O
13	38	38	O	,
14	40	42	O	and
15	44	44	O	4
16	46	46	O	O
17	48	62	O	acylglucuronide
18	64	68	O	exist
19	69	69	O	,
20	71	73	O	and
21	75	78	O	each
22	80	87	O	accounts
23	89	91	O	for
24	93	96	O	less
25	98	101	O	than
26	103	105	O	10%
27	107	108	O	of
28	110	114	O	total
29	116	125	O	XXXXXXXX
30	127	128	O	in
31	130	135	O	plasma
NULL

Dabigatran	1961	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	32
Renal Impairment An open, parallel-group single-center study compared dabigatran pharmacokinetics in healthy subjects and patients with mild to moderate renal impairment receiving a single dose of PRADAXA 150 mg.
1	0	4	O	Renal
2	6	15	O	Impairment
3	17	18	O	An
4	20	23	O	open
5	24	24	O	,
6	26	33	O	parallel
7	35	39	O	group
8	41	46	O	single
9	48	53	O	center
10	55	59	O	study
11	61	68	O	compared
12	70	79	O	XXXXXXXX
13	81	96	O	pharmacokinetics
14	98	99	O	in
15	101	107	O	healthy
16	109	116	O	subjects
17	118	120	O	and
18	122	129	O	patients
19	131	134	O	with
20	136	139	O	mild
21	141	142	O	to
22	144	151	O	moderate
23	153	157	O	renal
24	159	168	O	impairment
25	170	178	O	receiving
26	180	180	O	a
27	182	187	O	single
28	189	192	O	dose
29	194	195	O	of
30	197	203	O	PRADAXA
31	205	207	O	150
32	209	210	O	mg
NULL

Dabigatran	1962	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	12
Exposure to dabigatran increases with severity of renal function impairment (Table 8).
1	0	7	O	Exposure
2	9	10	O	to
3	12	21	O	XXXXXXXX
4	23	31	O	increases
5	33	36	O	with
6	38	45	O	severity
7	47	48	O	of
8	50	54	O	renal
9	56	63	O	function
10	65	74	O	impairment
11	77	81	O	Table
12	83	83	O	8
NULL

Dabigatran	1963	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	16
Similar findings were observed in the RE-LY, RE-COVER and RE-NOVATE II trials.
1	0	6	O	Similar
2	8	15	O	findings
3	17	20	O	were
4	22	29	O	observed
5	31	32	O	in
6	34	36	O	the
7	38	39	O	RE
8	41	42	O	LY
9	43	43	O	,
10	45	46	O	RE
11	48	52	O	COVER
12	54	56	O	and
13	58	59	O	RE
14	61	66	O	NOVATE
15	68	69	O	II
16	71	76	O	trials
NULL

Dabigatran	1964	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	23
Table 6 Impact of Renal Impairment on Dabigatran Pharmacokinetics +Patients with severe renal impairment were not studied in RE-LY and RE-COVER.
1	0	4	O	Table
2	6	6	O	6
3	8	13	O	Impact
4	15	16	O	of
5	18	22	O	Renal
6	24	33	O	Impairment
7	35	36	O	on
8	38	47	O	XXXXXXXX
9	49	64	O	Pharmacokinetics
10	66	74	O	+Patients
11	76	79	O	with
12	81	86	O	severe
13	88	92	O	renal
14	94	103	O	impairment
15	105	108	O	were
16	110	112	O	not
17	114	120	O	studied
18	122	123	O	in
19	125	126	O	RE
20	128	129	O	LY
21	131	133	O	and
22	135	136	O	RE
23	138	142	O	COVER
NULL

Dabigatran	1965	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	13
Dosing recommendations in subjects with severe renal impairment are based on pharmacokinetic modeling.
1	0	5	O	Dosing
2	7	21	O	recommendations
3	23	24	O	in
4	26	33	O	subjects
5	35	38	O	with
6	40	45	O	severe
7	47	51	O	renal
8	53	62	O	impairment
9	64	66	O	are
10	68	72	O	based
11	74	75	O	on
12	77	91	O	pharmacokinetic
13	93	100	O	modeling
NULL

Dabigatran	1966	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	72
Renal Function CrCl (mL/min) Increase in AUC Increase in Cmax t1/2 (h) Normal > 80 1x 1x 13 Mild 50-80 1.5x 1.1x 15 Moderate 30-50 3.2x 1.7x 18 Severe+ 15-30 6.3x 2.1x 27 Hepatic Impairment Administration of PRADAXA in patients with moderate hepatic impairment (Child-Pugh B) showed a large inter-subject variability, but no evidence of a consistent change in exposure or pharmacodynamics.
1	0	4	O	Renal
2	6	13	O	Function
3	15	18	O	CrCl
4	21	22	O	mL
5	23	23	O	/
6	24	26	O	min
7	29	36	O	Increase
8	38	39	O	in
9	41	43	O	AUC
10	45	52	O	Increase
11	54	55	O	in
12	57	60	O	Cmax
13	62	63	O	t1
14	64	64	O	/
15	65	65	O	2
16	68	68	O	h
17	71	76	O	Normal
18	78	78	O	>
19	80	81	O	80
20	83	84	O	1x
21	86	87	O	1x
22	89	90	O	13
23	92	95	O	Mild
24	97	98	O	50
25	100	101	O	80
26	103	106	O	1.5x
27	108	111	O	1.1x
28	113	114	O	15
29	116	123	O	Moderate
30	125	126	O	30
31	128	129	O	50
32	131	134	O	3.2x
33	136	139	O	1.7x
34	141	142	O	18
35	144	150	O	Severe+
36	152	153	O	15
37	155	156	O	30
38	158	161	O	6.3x
39	163	166	O	2.1x
40	168	169	O	27
41	171	177	O	Hepatic
42	179	188	O	Impairment
43	190	203	O	Administration
44	205	206	O	of
45	208	214	O	PRADAXA
46	216	217	O	in
47	219	226	O	patients
48	228	231	O	with
49	233	240	O	moderate
50	242	248	O	hepatic
51	250	259	O	impairment
52	262	266	O	Child
53	268	271	O	Pugh
54	273	273	O	B
55	276	281	O	showed
56	283	283	O	a
57	285	289	O	large
58	291	295	O	inter
59	297	303	O	subject
60	305	315	O	variability
61	316	316	O	,
62	318	320	O	but
63	322	323	O	no
64	325	332	O	evidence
65	334	335	O	of
66	337	337	O	a
67	339	348	O	consistent
68	350	355	O	change
69	357	358	O	in
70	360	367	O	exposure
71	369	370	O	or
72	372	387	O	pharmacodynamics
NULL

Dabigatran	1967	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	20
Drug Interactions A summary of the effect of coadministered drugs on dabigatran exposure is shown in Figures 3.1 and 3.2.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	18	O	A
4	20	26	O	summary
5	28	29	O	of
6	31	33	O	the
7	35	40	O	effect
8	42	43	O	of
9	45	58	O	coadministered
10	60	64	O	drugs
11	66	67	O	on
12	69	78	O	XXXXXXXX
13	80	87	O	exposure
14	89	90	O	is
15	92	96	O	shown
16	98	99	O	in
17	101	107	O	Figures
18	109	111	O	3.1
19	113	115	O	and
20	117	119	O	3.2
NULL

Dabigatran	1968	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	16
In the orthopedic hip surgery patients, limited clinical data with P-gp inhibitors is available.
1	0	1	O	In
2	3	5	O	the
3	7	16	O	orthopedic
4	18	20	O	hip
5	22	28	O	surgery
6	30	37	O	patients
7	38	38	O	,
8	40	46	O	limited
9	48	55	O	clinical
10	57	60	O	data
11	62	65	O	with
12	67	67	O	P
13	69	70	O	gp
14	72	81	O	inhibitors
15	83	84	O	is
16	86	94	O	available
NULL

Dabigatran	1969	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	21
Figure 3.1 Effect of P-gp Inhibitor or Inducer (rifampicin) Drugs on Peak and Total Exposure to Dabigatran (Cmax and AUC).
1	0	5	O	Figure
2	7	9	O	3.1
3	11	16	O	Effect
4	18	19	O	of
5	21	21	O	P
6	23	24	O	gp
7	26	34	O	Inhibitor
8	36	37	O	or
9	39	45	O	Inducer
10	48	57	O	rifampicin
11	60	64	O	Drugs
12	66	67	O	on
13	69	72	O	Peak
14	74	76	O	and
15	78	82	O	Total
16	84	91	O	Exposure
17	93	94	O	to
18	96	105	O	XXXXXXXX
19	108	111	O	Cmax
20	113	115	O	and
21	117	119	O	AUC
NULL

Dabigatran	1970	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	13
Shown are the Geometric Mean Ratios (Ratio) and 90% Confidence Interval (90% CI).
1	0	4	O	Shown
2	6	8	O	are
3	10	12	O	the
4	14	22	O	Geometric
5	24	27	O	Mean
6	29	34	O	Ratios
7	37	41	O	Ratio
8	44	46	O	and
9	48	50	O	90%
10	52	61	O	Confidence
11	63	70	O	Interval
12	73	75	O	90%
13	77	78	O	CI
NULL

Dabigatran	1971	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	51
The Perpetrator and Dabigatran Etexilate Dose and Dosing Frequency are given as well as the Time of Perpetrator Dosing in Relation to Dabigatran Etexilate Dose (Time Difference) Figure 3.2 Effect of Non-P-gp Inhibitor or Inducer, Other Drugs, on Peak and Total Exposure to Dabigatran (Cmax and AUC).
1	0	2	O	The
2	4	14	O	Perpetrator
3	16	18	O	and
4	20	29	O	XXXXXXXX
5	31	39	O	Etexilate
6	41	44	O	Dose
7	46	48	O	and
8	50	55	O	Dosing
9	57	65	O	Frequency
10	67	69	O	are
11	71	75	O	given
12	77	78	O	as
13	80	83	O	well
14	85	86	O	as
15	88	90	O	the
16	92	95	O	Time
17	97	98	O	of
18	100	110	O	Perpetrator
19	112	117	O	Dosing
20	119	120	O	in
21	122	129	O	Relation
22	131	132	O	to
23	134	143	O	XXXXXXXX
24	145	153	O	Etexilate
25	155	158	O	Dose
26	161	164	O	Time
27	166	175	O	Difference
28	178	183	O	Figure
29	185	187	O	3.2
30	189	194	O	Effect
31	196	197	O	of
32	199	201	O	Non
33	203	203	O	P
34	205	206	O	gp
35	208	216	O	Inhibitor
36	218	219	O	or
37	221	227	O	Inducer
38	228	228	O	,
39	230	234	O	Other
40	236	240	O	Drugs
41	241	241	O	,
42	243	244	O	on
43	246	249	O	Peak
44	251	253	O	and
45	255	259	O	Total
46	261	268	O	Exposure
47	270	271	O	to
48	273	282	O	XXXXXXXX
49	285	288	O	Cmax
50	290	292	O	and
51	294	296	O	AUC
NULL

Dabigatran	1973	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	41
The Perpetrator and Dabigatran Etexilate Dose and Dosing Frequency are given as well as the Time of Perpetrator Dosing in Relation to Dabigatran Etexilate Dose (Time Difference) Figure 3.1 Figure 3.2 In RE-LY, dabigatran plasma samples were also collected.
1	0	2	O	The
2	4	14	O	Perpetrator
3	16	18	O	and
4	20	29	O	XXXXXXXX
5	31	39	O	Etexilate
6	41	44	O	Dose
7	46	48	O	and
8	50	55	O	Dosing
9	57	65	O	Frequency
10	67	69	O	are
11	71	75	O	given
12	77	78	O	as
13	80	83	O	well
14	85	86	O	as
15	88	90	O	the
16	92	95	O	Time
17	97	98	O	of
18	100	110	O	Perpetrator
19	112	117	O	Dosing
20	119	120	O	in
21	122	129	O	Relation
22	131	132	O	to
23	134	143	O	XXXXXXXX
24	145	153	O	Etexilate
25	155	158	O	Dose
26	161	164	O	Time
27	166	175	O	Difference
28	178	183	O	Figure
29	185	187	O	3.1
30	189	194	O	Figure
31	196	198	O	3.2
32	200	201	O	In
33	203	204	O	RE
34	206	207	O	LY
35	208	208	O	,
36	210	219	O	XXXXXXXX
37	221	226	O	plasma
38	228	234	O	samples
39	236	239	O	were
40	241	244	O	also
41	246	254	O	collected
NULL

Dabigatran	1974	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	22
The concomitant use of proton pump inhibitors, H2 antagonists, and digoxin did not appreciably change the trough concentration of dabigatran.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	28	O	proton
6	30	33	O	pump
7	35	44	O	inhibitors
8	45	45	O	,
9	47	48	O	H2
10	50	60	O	antagonists
11	61	61	O	,
12	63	65	O	and
13	67	73	O	digoxin
14	75	77	O	did
15	79	81	O	not
16	83	93	O	appreciably
17	95	100	O	change
18	102	104	O	the
19	106	111	O	trough
20	113	125	O	concentration
21	127	128	O	of
22	130	139	O	XXXXXXXX
NULL

Dabigatran	1975	34090-1	ba74e3cd-b06f-4145-b284-5fd6b84ff3c9	44
Impact of Dabigatran on Other Drugs In clinical studies exploring CYP3A4, CYP2C9, P-gp and other pathways, dabigatran did not meaningfully alter the pharmacokinetics of amiodarone, atorvastatin, clarithromycin, diclofenac, clopidogrel, digoxin, pantoprazole, or ranitidine.
1	0	5	O	Impact
2	7	8	O	of
3	10	19	O	XXXXXXXX
4	21	22	O	on
5	24	28	O	Other
6	30	34	O	Drugs
7	36	37	O	In
8	39	46	O	clinical
9	48	54	O	studies
10	56	64	O	exploring
11	66	71	O	CYP3A4
12	72	72	O	,
13	74	79	O	CYP2C9
14	80	80	O	,
15	82	82	O	P
16	84	85	O	gp
17	87	89	O	and
18	91	95	O	other
19	97	104	O	pathways
20	105	105	O	,
21	107	116	O	XXXXXXXX
22	118	120	O	did
23	122	124	O	not
24	126	137	O	meaningfully
25	139	143	O	alter
26	145	147	O	the
27	149	164	O	pharmacokinetics
28	166	167	O	of
29	169	178	O	amiodarone
30	179	179	O	,
31	181	192	O	atorvastatin
32	193	193	O	,
33	195	208	O	clarithromycin
34	209	209	O	,
35	211	220	O	diclofenac
36	221	221	O	,
37	223	233	O	clopidogrel
38	234	234	O	,
39	236	242	O	digoxin
40	243	243	O	,
41	245	256	O	pantoprazole
42	257	257	O	,
43	259	260	O	or
44	262	271	O	ranitidine
NULL

Doxepin	119	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	11
Studies have not been performed examining drug interactions with PRUDOXIN Cream.
1	0	6	O	Studies
2	8	11	O	have
3	13	15	O	not
4	17	20	O	been
5	22	30	O	performed
6	32	40	O	examining
7	42	45	O	drug
8	47	58	O	interactions
9	60	63	O	with
10	65	72	O	PRUDOXIN
11	74	78	O	Cream
NULL

Doxepin	120	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	95
However, since plasma levels of doxepin following topical application of PRUDOXIN Cream can reach levels obtained with oral doxepin HCl therapy, the following drug interactions are possible following topical PRUDOXIN Cream application: Drugs Metabolized by P450 2D6: The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	since
4	15	20	O	plasma
5	22	27	O	levels
6	29	30	O	of
7	32	38	O	XXXXXXXX
8	40	48	O	following
9	50	56	O	topical
10	58	68	O	application
11	70	71	O	of
12	73	80	O	PRUDOXIN
13	82	86	O	Cream
14	88	90	O	can
15	92	96	O	reach
16	98	103	O	levels
17	105	112	O	obtained
18	114	117	O	with
19	119	122	O	oral
20	124	130	O	XXXXXXXX
21	132	134	O	HCl
22	136	142	O	therapy
23	143	143	O	,
24	145	147	O	the
25	149	157	O	following
26	159	162	B-TRI	drug
27	164	175	L-TRI	interactions
28	177	179	O	are
29	181	188	O	possible
30	190	198	O	following
31	200	206	O	topical
32	208	215	O	PRUDOXIN
33	217	221	O	Cream
34	223	233	O	application
35	234	234	O	:
36	236	240	B-UNK	Drugs
37	242	252	I-UNK	Metabolized
38	254	255	I-UNK	by
39	257	260	I-UNK	P450
40	262	264	L-UNK	2D6
41	265	265	O	:
42	267	269	O	The
43	271	281	O	biochemical
44	283	290	O	activity
45	292	293	O	of
46	295	297	O	the
47	299	302	O	drug
48	304	315	O	metabolizing
49	317	323	O	isozyme
50	325	334	O	cytochrome
51	336	339	O	P450
52	341	343	O	2D6
53	346	356	O	debrisoquin
54	358	368	O	hydroxylase
55	371	372	O	is
56	374	380	O	reduced
57	382	383	O	in
58	385	385	O	a
59	387	392	O	subset
60	394	395	O	of
61	397	399	O	the
62	401	409	O	Caucasian
63	411	420	O	population
64	423	427	O	about
65	429	429	O	7
66	431	433	O	10%
67	435	436	O	of
68	438	447	O	Caucasians
69	449	451	O	are
70	453	454	O	so
71	456	461	O	called
72	463	467	O	"poor
73	469	481	O	metabolizers"
74	485	492	O	reliable
75	494	502	O	estimates
76	504	505	O	of
77	507	509	O	the
78	511	520	O	prevalence
79	522	523	O	of
80	525	531	O	reduced
81	533	536	O	P450
82	538	540	O	2D6
83	542	548	O	isozyme
84	550	557	O	activity
85	559	563	O	among
86	565	569	O	Asian
87	570	570	O	,
88	572	578	O	African
89	580	582	O	and
90	584	588	O	other
91	590	600	O	populations
92	602	604	O	are
93	606	608	O	not
94	610	612	O	yet
95	614	622	O	available
NULL

Doxepin	121	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	16
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	67	O	of
10	69	77	O	tricyclic
11	79	93	O	GGGGGGGG
12	96	99	O	TCAs
13	102	105	O	when
14	107	111	O	given
15	113	117	O	usual
16	119	123	O	doses
NULL

Doxepin	122	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

Doxepin	123	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Doxepin	124	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	27
An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	44	O	dosage
10	46	52	O	regimen
11	54	55	O	of
12	57	57	O	a
13	59	61	O	TCA
14	63	65	O	may
15	67	72	O	become
16	74	81	O	abruptly
17	83	87	O	toxic
18	89	92	O	when
19	94	98	O	given
20	100	102	O	one
21	104	105	O	of
22	107	111	O	these
23	113	122	O	inhibiting
24	124	128	O	drugs
25	130	131	O	as
26	133	143	O	concomitant
27	145	151	O	therapy
NULL

Doxepin	125	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	40
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	O	quinidine
18	107	116	O	cimetidine
19	119	121	O	and
20	123	126	O	many
21	128	131	O	that
22	133	135	O	are
23	137	146	O	substrates
24	148	150	O	for
25	152	155	O	P450
26	157	159	O	2D6
27	162	165	O	many
28	167	171	O	other
29	173	187	O	GGGGGGGG
30	188	188	O	,
31	190	203	O	phenothiazines
32	204	204	O	,
33	206	208	O	and
34	210	212	O	the
35	214	217	O	Type
36	219	220	O	1C
37	222	236	O	antiarrhythmics
38	238	248	O	propafenone
39	250	252	O	and
40	254	263	O	flecainide
NULL

Doxepin	126	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	32	O	serotonin
6	34	41	O	reuptake
7	43	52	O	inhibitors
8	55	59	O	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	O	fluoxetine
13	79	79	O	,
14	81	90	O	sertraline
15	91	91	O	,
16	93	95	O	and
17	97	106	O	paroxetine
18	107	107	O	,
19	109	115	O	inhibit
20	117	120	O	P450
21	122	124	O	2D6
22	125	125	O	,
23	127	130	O	they
24	132	134	O	may
25	136	139	O	vary
26	141	142	O	in
27	144	146	O	the
28	148	153	O	extent
29	155	156	O	of
30	158	167	O	inhibition
NULL

Doxepin	127	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	O	TCA
7	29	40	U-TRI	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	O	SSRI
25	146	153	O	involved
NULL

Doxepin	128	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	16
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	O	SSRIs
NULL

Doxepin	129	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	B-TRI	sufficient
6	37	40	I-TRI	time
7	42	45	I-TRI	must
8	47	52	I-TRI	elapse
9	54	59	I-TRI	before
10	61	70	L-TRI	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Doxepin	130	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	29
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	tricyclic
5	29	43	O	GGGGGGGG
6	45	48	O	with
7	50	54	B-KIN	drugs
8	56	59	I-KIN	that
9	61	63	I-KIN	can
10	65	71	I-KIN	inhibit
11	73	82	I-KIN	cytochrome
12	84	87	I-KIN	P450
13	89	91	L-KIN	2D6
14	93	95	O	may
15	97	103	O	require
16	105	109	B-TRI	lower
17	111	115	L-TRI	doses
18	117	120	O	than
19	122	128	O	usually
20	130	139	O	prescribed
21	141	143	O	for
22	145	150	O	either
23	152	154	O	the
24	156	164	O	tricyclic
25	166	179	O	antidepressant
26	181	182	O	or
27	184	186	O	the
28	188	192	O	other
29	194	197	O	drug
K/7:C54355

Doxepin	131	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	U-TRI	monitor
6	27	29	O	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	O	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	B-UNK	inhibitor
26	134	135	I-UNK	of
27	137	140	I-UNK	P450
28	142	144	L-UNK	2D6
NULL

Doxepin	132	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	22
MAO Inhibitors: Serious side effects and even death have been reported following the concomitant use of certain drugs with MAO inhibitors.
1	0	2	O	MAO
2	4	13	O	Inhibitors
3	14	14	O	:
4	16	22	O	Serious
5	24	27	O	side
6	29	35	O	effects
7	37	39	O	and
8	41	44	O	even
9	46	50	U-EFF	death
10	52	55	O	have
11	57	60	O	been
12	62	69	O	reported
13	71	79	O	following
14	81	83	O	the
15	85	95	O	concomitant
16	97	99	O	use
17	101	102	O	of
18	104	110	O	certain
19	112	116	O	drugs
20	118	121	O	with
21	123	125	B-DYN	MAO
22	127	136	L-DYN	inhibitors
D/21:9:1

Doxepin	133	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	21
Therefore, MAO inhibitors should be discontinued at least two weeks prior to the cautious initiation of therapy with PRUDOXIN Cream.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	B-UNK	MAO
4	15	24	L-UNK	inhibitors
5	26	31	O	should
6	33	34	O	be
7	36	47	O	discontinued
8	49	50	O	at
9	52	56	O	least
10	58	60	O	two
11	62	66	O	weeks
12	68	72	O	prior
13	74	75	O	to
14	77	79	O	the
15	81	88	O	cautious
16	90	99	O	initiation
17	101	102	O	of
18	104	110	O	therapy
19	112	115	O	with
20	117	124	O	PRUDOXIN
21	126	130	O	Cream
NULL

Doxepin	134	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	31
The exact length of time may vary and is dependent upon the particular MAO inhibitor being used, the length of time it has been administered, and the dosage involved.
1	0	2	O	The
2	4	8	O	exact
3	10	15	O	length
4	17	18	O	of
5	20	23	O	time
6	25	27	O	may
7	29	32	O	vary
8	34	36	O	and
9	38	39	O	is
10	41	49	O	dependent
11	51	54	O	upon
12	56	58	O	the
13	60	69	O	particular
14	71	73	O	MAO
15	75	83	O	inhibitor
16	85	89	O	being
17	91	94	O	used
18	95	95	O	,
19	97	99	O	the
20	101	106	O	length
21	108	109	O	of
22	111	114	O	time
23	116	117	O	it
24	119	121	O	has
25	123	126	O	been
26	128	139	O	administered
27	140	140	O	,
28	142	144	O	and
29	146	148	O	the
30	150	155	O	dosage
31	157	164	O	involved
NULL

Doxepin	135	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	33
Cimetidine: Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of tricyclic antidepressant when cimetidine therapy is initiated.
1	0	9	O	Cimetidine
2	10	10	O	:
3	12	18	O	Serious
4	20	34	B-EFF	anticholinergic
5	36	43	L-EFF	symptoms
6	46	48	O	i.e
7	50	50	O	,
8	52	57	O	severe
9	59	61	B-EFF	dry
10	63	67	L-EFF	mouth
11	68	68	O	,
12	70	76	B-EFF	urinary
13	78	86	L-EFF	retention
14	88	90	O	and
15	92	98	B-EFF	blurred
16	100	105	L-EFF	vision
17	108	111	O	have
18	113	116	O	been
19	118	127	O	associated
20	129	132	O	with
21	134	143	B-TRI	elevations
22	145	146	I-TRI	in
23	148	150	I-TRI	the
24	152	156	I-TRI	serum
25	158	163	L-TRI	levels
26	165	166	O	of
27	168	176	O	tricyclic
28	178	191	O	antidepressant
29	193	196	O	when
30	198	207	U-DYN	cimetidine
31	209	215	O	therapy
32	217	218	O	is
33	220	228	O	initiated
D/30:12:1 D/30:15:1 D/30:4:1 D/30:9:1

Doxepin	136	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	20
Additionally, higher than expected tricyclic antidepressant levels have been observed when they are begun in patients already taking cimetidine.
1	0	11	O	Additionally
2	12	12	O	,
3	14	19	O	higher
4	21	24	O	than
5	26	33	O	expected
6	35	43	O	tricyclic
7	45	58	O	antidepressant
8	60	65	O	levels
9	67	70	O	have
10	72	75	O	been
11	77	84	O	observed
12	86	89	O	when
13	91	94	O	they
14	96	98	O	are
15	100	104	O	begun
16	106	107	O	in
17	109	116	O	patients
18	118	124	O	already
19	126	131	O	taking
20	133	142	U-KIN	cimetidine
K/20:C54355

Doxepin	137	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	13
Alcohol: Alcohol ingestion may exacerbate the potential sedative effects of PRUDOXIN Cream.
1	0	6	U-DYN	Alcohol
2	7	7	O	:
3	9	15	O	Alcohol
4	17	25	O	ingestion
5	27	29	O	may
6	31	40	O	exacerbate
7	42	44	O	the
8	46	54	O	potential
9	56	63	O	sedative
10	65	71	O	effects
11	73	74	O	of
12	76	83	O	PRUDOXIN
13	85	89	O	Cream
NULL

Doxepin	138	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	11
This is especially important in patients who may use alcohol excessively.
1	0	3	O	This
2	5	6	O	is
3	8	17	O	especially
4	19	27	O	important
5	29	30	O	in
6	32	39	O	patients
7	41	43	O	who
8	45	47	O	may
9	49	51	O	use
10	53	59	O	alcohol
11	61	71	O	excessively
NULL

Doxepin	139	34073-7	c66a11c1-3093-45ef-b348-3b196c05ba0c	35
Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of oral doxepin (75 mg/day).
1	0	9	U-DYN	Tolazamide
2	10	10	O	:
3	12	12	O	A
4	14	17	O	case
5	19	20	O	of
6	22	27	O	severe
7	29	40	U-EFF	hypoglycemia
8	42	44	O	has
9	46	49	O	been
10	51	58	O	reported
11	60	61	O	in
12	63	63	O	a
13	65	68	O	type
14	70	71	O	II
15	73	80	O	diabetic
16	82	88	O	patient
17	90	99	O	maintained
18	101	102	O	on
19	104	113	O	tolazamide
20	116	116	O	1
21	118	119	O	gm
22	120	120	O	/
23	121	123	O	day
24	126	127	O	11
25	129	132	O	days
26	134	138	O	after
27	140	142	O	the
28	144	151	O	addition
29	153	154	O	of
30	156	159	O	oral
31	161	167	O	XXXXXXXX
32	170	171	O	75
33	173	174	O	mg
34	175	175	O	/
35	176	178	O	day
D/1:7:1

Doxepin	140	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	25
Although doxepin HCl does have H1 and H2 histamine receptor blocking actions, the exact mechanism by which doxepin exerts its antipruritic effect is unknown.
1	0	7	O	Although
2	9	15	O	XXXXXXXX
3	17	19	O	HCl
4	21	24	O	does
5	26	29	O	have
6	31	32	O	H1
7	34	36	O	and
8	38	39	O	H2
9	41	49	O	histamine
10	51	58	O	receptor
11	60	67	O	blocking
12	69	75	O	actions
13	76	76	O	,
14	78	80	O	the
15	82	86	O	exact
16	88	96	O	mechanism
17	98	99	O	by
18	101	105	O	which
19	107	113	O	XXXXXXXX
20	115	120	O	exerts
21	122	124	O	its
22	126	137	O	antipruritic
23	139	144	O	effect
24	146	147	O	is
25	149	155	O	unknown
NULL

Doxepin	141	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	15
PRUDOXIN Cream can produce drowsiness which may reduce awareness, including awareness of pruritic symptoms.
1	0	7	O	PRUDOXIN
2	9	13	O	Cream
3	15	17	O	can
4	19	25	O	produce
5	27	36	O	drowsiness
6	38	42	O	which
7	44	46	O	may
8	48	53	O	reduce
9	55	63	O	awareness
10	64	64	O	,
11	66	74	O	including
12	76	84	O	awareness
13	86	87	O	of
14	89	96	O	pruritic
15	98	105	O	symptoms
NULL

Doxepin	142	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	24
In 19 pruritic eczema patients treated with PRUDOXIN Cream, plasma doxepin concentrations ranged from nondetectable to 47 ng/mL from percutaneous absorption.
1	0	1	O	In
2	3	4	O	19
3	6	13	O	pruritic
4	15	20	O	eczema
5	22	29	O	patients
6	31	37	O	treated
7	39	42	O	with
8	44	51	O	PRUDOXIN
9	53	57	O	Cream
10	58	58	O	,
11	60	65	O	plasma
12	67	73	O	XXXXXXXX
13	75	88	O	concentrations
14	90	95	O	ranged
15	97	100	O	from
16	102	114	O	nondetectable
17	116	117	O	to
18	119	120	O	47
19	122	123	O	ng
20	124	124	O	/
21	125	126	O	mL
22	128	131	O	from
23	133	144	O	percutaneous
24	146	155	O	absorption
NULL

Doxepin	143	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	17
Plasma levels from topical application of PRUDOXIN Cream can result in CNS and other systemic side effects.
1	0	5	O	Plasma
2	7	12	O	levels
3	14	17	O	from
4	19	25	O	topical
5	27	37	O	application
6	39	40	O	of
7	42	49	O	PRUDOXIN
8	51	55	O	Cream
9	57	59	O	can
10	61	66	O	result
11	68	69	O	in
12	71	73	O	CNS
13	75	77	O	and
14	79	83	O	other
15	85	92	O	systemic
16	94	97	O	side
17	99	105	O	effects
NULL

Doxepin	144	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	20
Once absorbed into the systemic circulation, doxepin undergoes hepatic metabolism that results in conversion to pharmacologically-active desmethyldoxepin.
1	0	3	O	Once
2	5	12	O	absorbed
3	14	17	O	into
4	19	21	O	the
5	23	30	O	systemic
6	32	42	O	circulation
7	43	43	O	,
8	45	51	O	XXXXXXXX
9	53	61	O	undergoes
10	63	69	O	hepatic
11	71	80	O	metabolism
12	82	85	O	that
13	87	93	O	results
14	95	96	O	in
15	98	107	O	conversion
16	109	110	O	to
17	112	128	O	pharmacologically
18	130	135	O	active
19	137	145	O	desmethyl
20	146	152	O	XXXXXXXX
NULL

Doxepin	145	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	13
Further glucuronidation results in urinary excretion of the parent drug and its metabolites.
1	0	6	O	Further
2	8	22	O	glucuronidation
3	24	30	O	results
4	32	33	O	in
5	35	41	O	urinary
6	43	51	O	excretion
7	53	54	O	of
8	56	58	O	the
9	60	65	O	parent
10	67	70	O	drug
11	72	74	O	and
12	76	78	O	its
13	80	90	O	metabolites
NULL

Doxepin	146	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	20
Desmethyldoxepin has a half-life that ranges from 28 to 52 hours and is not affected by multiple dosing.
1	0	8	O	Desmethyl
2	9	15	O	XXXXXXXX
3	17	19	O	has
4	21	21	O	a
5	23	26	O	half
6	28	31	O	life
7	33	36	O	that
8	38	43	O	ranges
9	45	48	O	from
10	50	51	O	28
11	53	54	O	to
12	56	57	O	52
13	59	63	O	hours
14	65	67	O	and
15	69	70	O	is
16	72	74	O	not
17	76	83	O	affected
18	85	86	O	by
19	88	95	O	multiple
20	97	102	O	dosing
NULL

Doxepin	147	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	17
Plasma levels of both doxepin and desmethyldoxepin are highly variable and are poorly correlated with dosage.
1	0	5	O	Plasma
2	7	12	O	levels
3	14	15	O	of
4	17	20	O	both
5	22	28	O	XXXXXXXX
6	30	32	O	and
7	34	42	O	desmethyl
8	43	49	O	XXXXXXXX
9	51	53	O	are
10	55	60	O	highly
11	62	69	O	variable
12	71	73	O	and
13	75	77	O	are
14	79	84	O	poorly
15	86	95	O	correlated
16	97	100	O	with
17	102	107	O	dosage
NULL

Doxepin	148	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	15
Wide distribution occurs in body tissues including lungs, heart, brain, and liver.
1	0	3	O	Wide
2	5	16	O	distribution
3	18	23	O	occurs
4	25	26	O	in
5	28	31	O	body
6	33	39	O	tissues
7	41	49	O	including
8	51	55	O	lungs
9	56	56	O	,
10	58	62	O	heart
11	63	63	O	,
12	65	69	O	brain
13	70	70	O	,
14	72	74	O	and
15	76	80	O	liver
NULL

Doxepin	149	34090-1	c66a11c1-3093-45ef-b348-3b196c05ba0c	19
Renal disease, genetic factors, age, and other medications affect the metabolism and subsequent elimination of doxepin.
1	0	4	O	Renal
2	6	12	O	disease
3	13	13	O	,
4	15	21	O	genetic
5	23	29	O	factors
6	30	30	O	,
7	32	34	O	age
8	35	35	O	,
9	37	39	O	and
10	41	45	O	other
11	47	57	O	medications
12	59	64	O	affect
13	66	68	O	the
14	70	79	O	metabolism
15	81	83	O	and
16	85	94	O	subsequent
17	96	106	O	elimination
18	108	109	O	of
19	111	117	O	XXXXXXXX
NULL

Duloxetine	328	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	8
Potent inhibitors of CYP1A2 should be avoided (7.1).
1	0	5	O	Potent
2	7	16	B-UNK	inhibitors
3	18	19	I-UNK	of
4	21	26	L-UNK	CYP1A2
5	28	33	B-TRI	should
6	35	36	I-TRI	be
7	38	44	L-TRI	avoided
8	47	49	O	7.1
NULL

Duloxetine	329	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	9
Potent inhibitors of CYP2D6 may increase duloxetine concentrations (7.2).
1	0	5	O	Potent
2	7	16	B-KIN	inhibitors
3	18	19	I-KIN	of
4	21	26	L-KIN	CYP2D6
5	28	30	O	may
6	32	39	B-TRI	increase
7	41	50	I-TRI	XXXXXXXX
8	52	65	L-TRI	concentrations
9	68	70	O	7.2
K/2:C54355

Duloxetine	330	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	8
Duloxetine is a moderate inhibitor of CYP2D6 (7.9).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	23	O	moderate
5	25	33	O	inhibitor
6	35	36	O	of
7	38	43	O	CYP2D6
8	46	48	O	7.9
NULL

Duloxetine	331	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	9
Both CYP1A2 and CYP2D6 are responsible for duloxetine metabolism.
1	0	3	O	Both
2	5	10	O	CYP1A2
3	12	14	O	and
4	16	21	O	CYP2D6
5	23	25	O	are
6	27	37	O	responsible
7	39	41	O	for
8	43	52	O	XXXXXXXX
9	54	63	O	metabolism
NULL

Duloxetine	332	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	45
When duloxetine 60mg was co-administered with fluvoxamine 100mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the Cmax was increased about 2.5-fold, and duloxetine t1/2 was increased approximately 3-fold.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	19	O	60mg
4	21	23	O	was
5	25	26	O	co
6	28	39	O	administered
7	41	44	O	with
8	46	56	U-KIN	fluvoxamine
9	58	62	O	100mg
10	63	63	O	,
11	65	65	O	a
12	67	72	B-KIN	potent
13	74	79	I-KIN	CYP1A2
14	81	89	L-KIN	inhibitor
15	90	90	O	,
16	92	93	O	to
17	95	98	O	male
18	100	107	O	subjects
19	110	113	O	n=14
20	116	125	O	XXXXXXXX
21	127	129	O	AUC
22	131	133	O	was
23	135	143	O	increased
24	145	157	O	approximately
25	159	159	O	6
26	161	164	O	fold
27	165	165	O	,
28	167	169	O	the
29	171	174	O	Cmax
30	176	178	O	was
31	180	188	O	increased
32	190	194	O	about
33	196	198	O	2.5
34	200	203	O	fold
35	204	204	O	,
36	206	208	O	and
37	210	219	O	XXXXXXXX
38	221	222	O	t1
39	223	223	O	/
40	224	224	O	2
41	226	228	O	was
42	230	238	O	increased
43	240	252	O	approximately
44	254	254	O	3
45	256	259	O	fold
K/12:C54603 K/8:C54605

Duloxetine	333	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	16
Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin.
1	0	4	O	Other
2	6	10	O	drugs
3	12	15	O	that
4	17	23	O	inhibit
5	25	30	O	CYP1A2
6	32	41	O	metabolism
7	43	49	O	include
8	51	60	O	cimetidine
9	62	64	O	and
10	66	74	O	quinolone
11	76	89	O	antimicrobials
12	91	94	O	such
13	96	97	O	as
14	99	111	O	ciprofloxacin
15	113	115	O	and
16	117	124	O	enoxacin
NULL

Duloxetine	334	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	36
Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	31	32	O	40
6	34	35	O	mg
7	37	40	O	once
8	42	46	O	daily
9	49	52	O	with
10	54	63	U-KIN	paroxetine
11	66	67	O	20
12	69	70	O	mg
13	72	75	O	once
14	77	81	O	daily
15	84	92	O	increased
16	94	96	O	the
17	98	110	O	concentration
18	112	113	O	of
19	115	124	O	XXXXXXXX
20	126	128	O	AUC
21	130	131	O	by
22	133	137	O	about
23	139	141	O	60%
24	142	142	O	,
25	144	146	O	and
26	148	154	O	greater
27	156	162	O	degrees
28	164	165	O	of
29	167	176	O	inhibition
30	178	180	O	are
31	182	189	O	expected
32	191	194	O	with
33	196	201	O	higher
34	203	207	O	doses
35	209	210	O	of
36	212	221	O	paroxetine
K/10:C54605

Duloxetine	335	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	15
Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine).
1	0	6	O	Similar
2	8	14	O	effects
3	16	20	O	would
4	22	23	O	be
5	25	32	O	expected
6	34	37	O	with
7	39	43	O	other
8	45	50	O	potent
9	52	57	O	CYP2D6
10	59	68	O	inhibitors
11	71	73	O	e.g
12	75	75	O	,
13	77	86	O	fluoxetine
14	87	87	O	,
15	89	97	O	quinidine
NULL

Duloxetine	336	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	35
Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and Cmax.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	39	O	XXXXXXXX
5	41	42	O	40
6	44	45	O	mg
7	47	51	O	twice
8	53	57	O	daily
9	59	62	O	with
10	64	74	U-KIN	fluvoxamine
11	76	78	O	100
12	80	81	O	mg
13	82	82	O	,
14	84	84	O	a
15	86	91	O	potent
16	93	98	O	CYP1A2
17	100	108	O	inhibitor
18	109	109	O	,
19	111	112	O	to
20	114	119	O	CYP2D6
21	121	124	O	poor
22	126	136	O	metabolizer
23	138	145	O	subjects
24	148	151	O	n=14
25	154	161	O	resulted
26	163	164	O	in
27	166	166	O	a
28	168	168	O	6
29	170	173	O	fold
30	175	182	O	increase
31	184	185	O	in
32	187	196	O	XXXXXXXX
33	198	200	O	AUC
34	202	204	O	and
35	206	209	O	Cmax
K/10:C54605

Duloxetine	337	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Duloxetine	338	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	48
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	O	psychotropic
19	128	132	O	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	B-EFF	upper
30	201	216	I-EFF	gastrointestinal
31	218	225	L-EFF	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-DYN	NSAID
41	275	276	O	or
42	278	284	U-DYN	aspirin
43	286	288	O	may
44	290	299	O	potentiate
45	301	304	O	this
46	306	309	O	risk
47	311	312	O	of
48	314	321	O	bleeding
D/40:29:1 D/42:29:1

Duloxetine	339	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	20
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	92	O	or
15	94	98	O	SNRIs
16	100	102	O	are
17	104	105	O	co
18	107	118	O	administered
19	120	123	O	with
20	125	132	U-DYN	warfarin
D/20:1:1 D/20:6:1

Duloxetine	340	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	46
Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07).
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	37	O	warfarin
5	40	40	O	2
6	42	43	O	to
7	45	45	O	9
8	47	48	O	mg
9	50	53	O	once
10	55	59	O	daily
11	62	66	O	under
12	68	73	O	steady
13	75	79	O	state
14	81	90	O	conditions
15	92	95	O	with
16	97	106	O	XXXXXXXX
17	108	109	O	60
18	111	112	O	or
19	114	116	O	120
20	118	119	O	mg
21	121	124	O	once
22	126	130	O	daily
23	132	134	O	for
24	136	137	O	up
25	139	140	O	to
26	142	143	O	14
27	145	148	O	days
28	150	151	O	in
29	153	159	O	healthy
30	161	168	O	subjects
31	171	174	O	n=15
32	177	179	O	did
33	181	183	O	not
34	185	197	O	significantly
35	199	204	O	change
36	206	208	O	INR
37	210	213	O	from
38	215	222	O	baseline
39	225	228	O	mean
40	230	232	O	INR
41	234	240	O	changes
42	242	247	O	ranged
43	249	252	O	from
44	254	257	O	0.05
45	259	260	O	to
46	262	266	O	+0.07
NULL

Duloxetine	341	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	25
The total warfarin (protein bound plus free drug) pharmacokinetics (AUCT,ss, Cmax,ss or tmax,ss) for both R- and S-warfarin were not altered by duloxetine.
1	0	2	O	The
2	4	8	O	total
3	10	17	O	warfarin
4	20	26	O	protein
5	28	32	O	bound
6	34	37	O	plus
7	39	42	O	free
8	44	47	O	drug
9	50	65	O	pharmacokinetics
10	68	74	O	AUCT,ss
11	75	75	O	,
12	77	83	O	Cmax,ss
13	85	86	O	or
14	88	94	O	tmax,ss
15	97	99	O	for
16	101	104	O	both
17	106	106	O	R
18	109	111	O	and
19	113	113	O	S
20	115	122	O	warfarin
21	124	127	O	were
22	129	131	O	not
23	133	139	O	altered
24	141	142	O	by
25	144	153	O	XXXXXXXX
NULL

Duloxetine	342	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	24
Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	23	O	potential
5	25	30	O	effect
6	32	33	O	of
7	35	44	O	XXXXXXXX
8	46	47	O	on
9	49	57	O	platelets
10	58	58	O	,
11	60	67	O	patients
12	69	77	O	receiving
13	79	86	U-DYN	warfarin
14	88	94	O	therapy
15	96	101	O	should
16	103	104	O	be
17	106	114	O	carefully
18	116	124	O	monitored
19	126	129	O	when
20	131	140	O	XXXXXXXX
21	142	143	O	is
22	145	153	O	initiated
23	155	156	O	or
24	158	169	O	discontinued
NULL

Duloxetine	343	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	29
Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration.
1	0	4	O	Under
2	6	11	O	steady
3	13	17	O	state
4	19	28	O	conditions
5	30	32	O	for
6	34	43	O	XXXXXXXX
7	46	47	O	60
8	49	50	O	mg
9	52	52	O	Q
10	54	55	O	12
11	57	61	O	hours
12	64	66	O	and
13	68	76	O	lorazepam
14	79	79	O	2
15	81	82	O	mg
16	84	84	O	Q
17	86	87	O	12
18	89	93	O	hours
19	95	95	O	,
20	97	99	O	the
21	101	116	O	pharmacokinetics
22	118	119	O	of
23	121	130	O	XXXXXXXX
24	132	135	O	were
25	137	139	O	not
26	141	148	O	affected
27	150	151	O	by
28	153	154	O	co
29	156	169	O	administration
NULL

Duloxetine	344	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	25
Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration.
1	0	4	O	Under
2	6	11	O	steady
3	13	17	O	state
4	19	28	O	conditions
5	30	32	O	for
6	34	43	O	XXXXXXXX
7	46	47	O	20
8	49	50	O	mg
9	52	54	O	qhs
10	57	59	O	and
11	61	69	O	temazepam
12	72	73	O	30
13	75	76	O	mg
14	78	80	O	qhs
15	82	82	O	,
16	84	86	O	the
17	88	103	O	pharmacokinetics
18	105	106	O	of
19	108	117	O	XXXXXXXX
20	119	122	O	were
21	124	126	O	not
22	128	135	O	affected
23	137	138	O	by
24	140	141	O	co
25	143	156	O	administration
NULL

Duloxetine	345	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	24
Duloxetine delayed-release capsules have an enteric coating that resists dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5.
1	0	9	O	XXXXXXXX
2	11	17	O	delayed
3	19	25	O	release
4	27	34	O	capsules
5	36	39	O	have
6	41	42	O	an
7	44	50	O	enteric
8	52	58	O	coating
9	60	63	O	that
10	65	71	O	resists
11	73	83	O	dissolution
12	85	89	O	until
13	91	98	O	reaching
14	100	100	O	a
15	102	108	O	segment
16	110	111	O	of
17	113	115	O	the
18	117	132	O	gastrointestinal
19	134	138	O	tract
20	140	144	O	where
21	146	148	O	the
22	150	151	O	pH
23	153	159	O	exceeds
24	161	163	O	5.5
NULL

Duloxetine	346	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	19
In extremely acidic conditions, duloxetine, unprotected by the enteric coating, may undergo hydrolysis to form naphthol.
1	0	1	O	In
2	3	11	O	extremely
3	13	18	O	acidic
4	20	29	O	conditions
5	30	30	O	,
6	32	41	O	XXXXXXXX
7	42	42	O	,
8	44	54	O	unprotected
9	56	57	O	by
10	59	61	O	the
11	63	69	O	enteric
12	71	77	O	coating
13	78	78	O	,
14	80	82	O	may
15	84	90	O	undergo
16	92	101	O	hydrolysis
17	103	104	O	to
18	106	109	O	form
19	111	118	O	naphthol
NULL

Duloxetine	347	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	19
Caution is advised in using duloxetine in patients with conditions that may slow gastric emptying (e.g., some diabetics).
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	in
5	22	26	O	using
6	28	37	O	XXXXXXXX
7	39	40	O	in
8	42	49	O	patients
9	51	54	O	with
10	56	65	O	conditions
11	67	70	O	that
12	72	74	O	may
13	76	79	O	slow
14	81	87	O	gastric
15	89	96	O	emptying
16	99	101	O	e.g
17	103	103	O	,
18	105	108	O	some
19	110	118	O	diabetics
NULL

Duloxetine	348	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	14
Drugs that raise the gastrointestinal pH may lead to an earlier release of duloxetine.
1	0	4	B-DYN	Drugs
2	6	9	I-DYN	that
3	11	15	I-DYN	raise
4	17	19	I-DYN	the
5	21	36	I-DYN	gastrointestinal
6	38	39	L-DYN	pH
7	41	43	O	may
8	45	48	O	lead
9	50	51	O	to
10	53	54	O	an
11	56	62	B-EFF	earlier
12	64	70	I-EFF	release
13	72	73	I-EFF	of
14	75	84	L-EFF	XXXXXXXX
D/1:11:1

Duloxetine	349	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	39
However, co-administration of duloxetine with aluminum- and magnesium-containing antacids (51 mEq) or duloxetine with famotidine, had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	co
4	12	25	O	administration
5	27	28	O	of
6	30	39	O	XXXXXXXX
7	41	44	O	with
8	46	53	O	aluminum
9	56	58	O	and
10	60	68	O	magnesium
11	70	79	O	containing
12	81	88	O	antacids
13	91	92	O	51
14	94	96	O	mEq
15	99	100	O	or
16	102	111	O	XXXXXXXX
17	113	116	O	with
18	118	127	O	famotidine
19	128	128	O	,
20	130	132	O	had
21	134	135	O	no
22	137	147	O	significant
23	149	154	O	effect
24	156	157	O	on
25	159	161	O	the
26	163	166	O	rate
27	168	169	O	or
28	171	176	O	extent
29	178	179	O	of
30	181	190	O	XXXXXXXX
31	192	201	O	absorption
32	203	207	O	after
33	209	222	O	administration
34	224	225	O	of
35	227	227	O	a
36	229	230	O	40
37	232	233	O	mg
38	235	238	O	oral
39	240	243	O	dose
NULL

Duloxetine	350	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	14
It is unknown whether the concomitant administration of proton pump inhibitors affects duloxetine absorption.
1	0	1	O	It
2	3	4	O	is
3	6	12	O	unknown
4	14	20	O	whether
5	22	24	O	the
6	26	36	O	concomitant
7	38	51	O	administration
8	53	54	O	of
9	56	61	O	proton
10	63	66	O	pump
11	68	77	O	inhibitors
12	79	85	O	affects
13	87	96	O	XXXXXXXX
14	98	107	O	absorption
NULL

Duloxetine	351	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	13
In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	drug
4	14	24	O	interaction
5	26	32	O	studies
6	34	44	O	demonstrate
7	46	49	O	that
8	51	60	O	XXXXXXXX
9	62	65	O	does
10	67	69	O	not
11	71	76	O	induce
12	78	83	O	CYP1A2
13	85	92	O	activity
NULL

Duloxetine	352	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	31
Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	an
4	14	21	O	increase
5	23	24	O	in
6	26	28	O	the
7	30	39	O	metabolism
8	41	42	O	of
9	44	49	O	CYP1A2
10	51	60	O	substrates
11	63	65	O	e.g
12	67	67	O	,
13	69	80	O	theophylline
14	81	81	O	,
15	83	90	O	caffeine
16	93	101	O	resulting
17	103	106	O	from
18	108	116	O	induction
19	118	119	O	is
20	121	123	O	not
21	125	135	O	anticipated
22	136	136	O	,
23	138	145	O	although
24	147	154	O	clinical
25	156	162	O	studies
26	164	165	O	of
27	167	175	O	induction
28	177	180	O	have
29	182	184	O	not
30	186	189	O	been
31	191	199	O	performed
NULL

Duloxetine	353	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	46
Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when co-administered with duloxetine (60 mg twice daily).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	32	O	the
7	34	39	O	CYP1A2
8	41	47	O	isoform
9	49	50	O	in
10	52	53	O	in
11	55	59	O	vitro
12	61	67	O	studies
13	68	68	O	,
14	70	72	O	and
15	74	75	O	in
16	77	79	O	two
17	81	88	O	clinical
18	90	96	O	studies
19	98	100	O	the
20	102	108	O	average
21	111	113	O	90%
22	115	124	O	confidence
23	126	133	O	interval
24	136	143	O	increase
25	145	146	O	in
26	148	159	U-KIN	theophylline
27	161	163	O	AUC
28	165	167	O	was
29	169	170	O	7%
30	173	174	O	1%
31	176	177	O	to
32	179	181	O	15%
33	184	186	O	and
34	188	190	O	20%
35	193	195	O	13%
36	197	198	O	to
37	200	202	O	27%
38	205	208	O	when
39	210	211	O	co
40	213	224	O	administered
41	226	229	O	with
42	231	240	O	XXXXXXXX
43	243	244	O	60
44	246	247	O	mg
45	249	253	O	twice
46	255	259	O	daily
K/26:C54613

Duloxetine	354	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	7
Duloxetine is a moderate inhibitor of CYP2D6.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	23	O	moderate
5	25	33	O	inhibitor
6	35	36	O	of
7	38	43	O	CYP2D6
NULL

Duloxetine	355	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	34
When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	18	O	was
4	20	31	O	administered
5	34	35	O	at
6	37	37	O	a
7	39	42	O	dose
8	44	45	O	of
9	47	48	O	60
10	50	51	O	mg
11	53	57	O	twice
12	59	63	O	daily
13	66	67	O	in
14	69	79	O	conjunction
15	81	84	O	with
16	86	86	O	a
17	88	93	O	single
18	95	96	O	50
19	98	99	O	mg
20	101	104	O	dose
21	106	107	O	of
22	109	119	U-KIN	desipramine
23	120	120	O	,
24	122	122	O	a
25	124	129	O	CYP2D6
26	131	139	O	substrate
27	140	140	O	,
28	142	144	O	the
29	146	148	O	AUC
30	150	151	O	of
31	153	163	O	desipramine
32	165	173	O	increased
33	175	175	O	3
34	177	180	O	fold
K/22:C54613

Duloxetine	356	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	12
Results of in vitro studies demonstrate that duloxetine does not inhibit activity.
1	0	6	O	Results
2	8	9	O	of
3	11	12	O	in
4	14	18	O	vitro
5	20	26	O	studies
6	28	38	O	demonstrate
7	40	43	O	that
8	45	54	O	XXXXXXXX
9	56	59	O	does
10	61	63	O	not
11	65	71	O	inhibit
12	73	80	O	activity
NULL

Duloxetine	357	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	21
In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	study
5	19	19	O	,
6	21	23	O	the
7	25	40	O	pharmacokinetics
8	42	43	O	of
9	45	45	O	S
10	47	54	O	warfarin
11	55	55	O	,
12	57	57	O	a
13	59	64	O	CYP2C9
14	66	74	O	substrate
15	75	75	O	,
16	77	80	O	were
17	82	84	O	not
18	86	98	O	significantly
19	100	107	O	affected
20	109	110	O	by
21	112	121	O	XXXXXXXX
NULL

Duloxetine	358	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	15
Results of in vitro studies demonstrate that duloxetine does not inhibit or induce CYP3A activity.
1	0	6	O	Results
2	8	9	O	of
3	11	12	O	in
4	14	18	O	vitro
5	20	26	O	studies
6	28	38	O	demonstrate
7	40	43	O	that
8	45	54	O	XXXXXXXX
9	56	59	O	does
10	61	63	O	not
11	65	71	O	inhibit
12	73	74	O	or
13	76	81	O	induce
14	83	87	O	CYP3A
15	89	96	O	activity
NULL

Duloxetine	359	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	36
Therefore, an increase or decrease in the metabolism of CYP3A substrates (e.g., oral contraceptives and other steroidal agents) resulting from induction or inhibition is not anticipated, although clinical studies have not been performed.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	an
4	14	21	O	increase
5	23	24	O	or
6	26	33	O	decrease
7	35	36	O	in
8	38	40	O	the
9	42	51	O	metabolism
10	53	54	O	of
11	56	60	O	CYP3A
12	62	71	O	substrates
13	74	76	O	e.g
14	78	78	O	,
15	80	83	O	oral
16	85	98	O	contraceptives
17	100	102	O	and
18	104	108	O	other
19	110	118	O	steroidal
20	120	125	O	agents
21	128	136	O	resulting
22	138	141	O	from
23	143	151	O	induction
24	153	154	O	or
25	156	165	O	inhibition
26	167	168	O	is
27	170	172	O	not
28	174	184	O	anticipated
29	185	185	O	,
30	187	194	O	although
31	196	203	O	clinical
32	205	211	O	studies
33	213	216	O	have
34	218	220	O	not
35	222	225	O	been
36	227	235	O	performed
NULL

Duloxetine	360	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	16
Results of in vitro studies demonstrate that duloxetine does not inhibit CYP2C19 activity at therapeutic concentrations.
1	0	6	O	Results
2	8	9	O	of
3	11	12	O	in
4	14	18	O	vitro
5	20	26	O	studies
6	28	38	O	demonstrate
7	40	43	O	that
8	45	54	O	XXXXXXXX
9	56	59	O	does
10	61	63	O	not
11	65	71	O	inhibit
12	73	79	O	CYP2C19
13	81	88	O	activity
14	90	91	O	at
15	93	103	O	therapeutic
16	105	118	O	concentrations
NULL

Duloxetine	361	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	19
Inhibition of the metabolism of CYP2C19 substrates is therefore not anticipated, although clinical studies have not been performed.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	16	O	the
4	18	27	O	metabolism
5	29	30	O	of
6	32	38	O	CYP2C19
7	40	49	O	substrates
8	51	52	O	is
9	54	62	O	therefore
10	64	66	O	not
11	68	78	O	anticipated
12	79	79	O	,
13	81	88	O	although
14	90	97	O	clinical
15	99	105	O	studies
16	107	110	O	have
17	112	114	O	not
18	116	119	O	been
19	121	129	O	performed
NULL

Duloxetine	364	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	32
When duloxetine and ethanol were administered several hours apart so that peak concentrations of each would coincide, duloxetine did not increase the impairment of mental and motor skills caused by alcohol.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	18	O	and
4	20	26	O	ethanol
5	28	31	O	were
6	33	44	O	administered
7	46	52	O	several
8	54	58	O	hours
9	60	64	O	apart
10	66	67	O	so
11	69	72	O	that
12	74	77	O	peak
13	79	92	O	concentrations
14	94	95	O	of
15	97	100	O	each
16	102	106	O	would
17	108	115	O	coincide
18	116	116	O	,
19	118	127	O	XXXXXXXX
20	129	131	O	did
21	133	135	O	not
22	137	144	O	increase
23	146	148	O	the
24	150	159	O	impairment
25	161	162	O	of
26	164	169	O	mental
27	171	173	O	and
28	175	179	O	motor
29	181	186	O	skills
30	188	193	O	caused
31	195	196	O	by
32	198	204	O	alcohol
NULL

Duloxetine	365	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	27
In the duloxetine clinical trials database, three duloxetine -treated patients had liver injury as manifested by ALT and total bilirubin elevations, with evidence of obstruction.
1	0	1	O	In
2	3	5	O	the
3	7	16	O	XXXXXXXX
4	18	25	O	clinical
5	27	32	O	trials
6	34	41	O	database
7	42	42	O	,
8	44	48	O	three
9	50	59	O	XXXXXXXX
10	62	68	O	treated
11	70	77	O	patients
12	79	81	O	had
13	83	87	O	liver
14	89	94	O	injury
15	96	97	O	as
16	99	108	O	manifested
17	110	111	O	by
18	113	115	O	ALT
19	117	119	O	and
20	121	125	O	total
21	127	135	O	bilirubin
22	137	146	O	elevations
23	147	147	O	,
24	149	152	O	with
25	154	161	O	evidence
26	163	164	O	of
27	166	176	O	obstruction
NULL

Duloxetine	366	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	21
Substantial intercurrent ethanol use was present in each of these cases, and this may have contributed to the abnormalities seen.
1	0	10	O	Substantial
2	12	23	O	intercurrent
3	25	31	O	ethanol
4	33	35	O	use
5	37	39	O	was
6	41	47	O	present
7	49	50	O	in
8	52	55	O	each
9	57	58	O	of
10	60	64	O	these
11	66	70	O	cases
12	71	71	O	,
13	73	75	O	and
14	77	80	O	this
15	82	84	O	may
16	86	89	O	have
17	91	101	O	contributed
18	103	104	O	to
19	106	108	O	the
20	110	122	O	abnormalities
21	124	127	O	seen
NULL

Duloxetine	367	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	38
Because duloxetine is highly bound to plasma protein, administration of duloxetine to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse reactions.
1	0	6	O	Because
2	8	17	O	XXXXXXXX
3	19	20	O	is
4	22	27	O	highly
5	29	33	O	bound
6	35	36	O	to
7	38	43	O	plasma
8	45	51	O	protein
9	52	52	O	,
10	54	67	O	administration
11	69	70	O	of
12	72	81	O	XXXXXXXX
13	83	84	O	to
14	86	86	O	a
15	88	94	O	patient
16	96	101	O	taking
17	103	109	O	another
18	111	114	B-KIN	drug
19	116	119	I-KIN	that
20	121	122	I-KIN	is
21	124	129	I-KIN	highly
22	131	137	I-KIN	protein
23	139	143	L-KIN	bound
24	145	147	O	may
25	149	153	O	cause
26	155	163	B-TRI	increased
27	165	168	I-TRI	free
28	170	183	I-TRI	concentrations
29	185	186	I-TRI	of
30	188	190	I-TRI	the
31	192	196	I-TRI	other
32	198	201	L-TRI	drug
33	202	202	O	,
34	204	214	O	potentially
35	216	224	O	resulting
36	226	227	O	in
37	229	235	O	adverse
38	237	245	O	reactions
K/18:C54357

Duloxetine	368	34073-7	829a4f51-c882-4b64-81f3-abfb03a52ebe	48
However, co-administration of duloxetine (60 or 120 mg) with warfarin (2 to 9 mg), a highly protein-bound drug, did not result in significant changes in INR and in the pharmacokinetics of either total S-or total R-warfarin (protein bound plus free drug).
1	0	6	O	However
2	7	7	O	,
3	9	10	O	co
4	12	25	O	administration
5	27	28	O	of
6	30	39	O	XXXXXXXX
7	42	43	O	60
8	45	46	O	or
9	48	50	O	120
10	52	53	O	mg
11	56	59	O	with
12	61	68	O	warfarin
13	71	71	O	2
14	73	74	O	to
15	76	76	O	9
16	78	79	O	mg
17	81	81	O	,
18	83	83	O	a
19	85	90	O	highly
20	92	98	O	protein
21	100	104	O	bound
22	106	109	O	drug
23	110	110	O	,
24	112	114	O	did
25	116	118	O	not
26	120	125	O	result
27	127	128	O	in
28	130	140	O	significant
29	142	148	O	changes
30	150	151	O	in
31	153	155	O	INR
32	157	159	O	and
33	161	162	O	in
34	164	166	O	the
35	168	183	O	pharmacokinetics
36	185	186	O	of
37	188	193	O	either
38	195	199	O	total
39	201	201	O	S
40	203	204	O	or
41	206	210	O	total
42	212	212	O	R
43	214	221	O	warfarin
44	224	230	O	protein
45	232	236	O	bound
46	238	241	O	plus
47	243	246	O	free
48	248	251	O	drug
NULL

Duloxetine	369	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	39
Although the exact mechanisms of the antidepressant, central pain inhibitory and anxiolytic actions of duloxetine in humans are unknown, these actions are believed to be related to its potentiation of serotonergic and noradrenergic activity in the CNS.
1	0	7	O	Although
2	9	11	O	the
3	13	17	O	exact
4	19	28	O	mechanisms
5	30	31	O	of
6	33	35	O	the
7	37	50	O	antidepressant
8	51	51	O	,
9	53	59	O	central
10	61	64	O	pain
11	66	75	O	inhibitory
12	77	79	O	and
13	81	90	O	anxiolytic
14	92	98	O	actions
15	100	101	O	of
16	103	112	O	XXXXXXXX
17	114	115	O	in
18	117	122	O	humans
19	124	126	O	are
20	128	134	O	unknown
21	135	135	O	,
22	137	141	O	these
23	143	149	O	actions
24	151	153	O	are
25	155	162	O	believed
26	164	165	O	to
27	167	168	O	be
28	170	176	O	related
29	178	179	O	to
30	181	183	O	its
31	185	196	O	potentiation
32	198	199	O	of
33	201	212	O	serotonergic
34	214	216	O	and
35	218	230	O	noradrenergic
36	232	239	O	activity
37	241	242	O	in
38	244	246	O	the
39	248	250	O	CNS
NULL

Duloxetine	370	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	24
Preclinical studies have shown that duloxetine is a potent inhibitor of neuronal serotonin and norepinephrine reuptake and a less potent inhibitor of dopamine reuptake.
1	0	10	O	Preclinical
2	12	18	O	studies
3	20	23	O	have
4	25	29	O	shown
5	31	34	O	that
6	36	45	O	XXXXXXXX
7	47	48	O	is
8	50	50	O	a
9	52	57	O	potent
10	59	67	O	inhibitor
11	69	70	O	of
12	72	79	O	neuronal
13	81	89	O	serotonin
14	91	93	O	and
15	95	108	O	norepinephrine
16	110	117	O	reuptake
17	119	121	O	and
18	123	123	O	a
19	125	128	O	less
20	130	135	O	potent
21	137	145	O	inhibitor
22	147	148	O	of
23	150	157	O	dopamine
24	159	166	O	reuptake
NULL

Duloxetine	371	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	23
Duloxetine has no significant affinity for dopaminergic, adrenergic, cholinergic, histaminergic, opioid, glutamate, and GABA receptors in vitro.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	16	O	no
4	18	28	O	significant
5	30	37	O	affinity
6	39	41	O	for
7	43	54	O	dopaminergic
8	55	55	O	,
9	57	66	O	adrenergic
10	67	67	O	,
11	69	79	O	cholinergic
12	80	80	O	,
13	82	94	O	histaminergic
14	95	95	O	,
15	97	102	O	opioid
16	103	103	O	,
17	105	113	O	glutamate
18	114	114	O	,
19	116	118	O	and
20	120	123	O	GABA
21	125	133	O	receptors
22	135	136	O	in
23	138	142	O	vitro
NULL

Duloxetine	372	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	7
Duloxetine does not inhibit monoamine oxidase (MAO).
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	26	O	inhibit
5	28	36	O	monoamine
6	38	44	O	oxidase
7	47	49	O	MAO
NULL

Duloxetine	373	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	12
Duloxetine is in a class of drugs known to affect urethral resistance.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	in
4	17	17	O	a
5	19	23	O	class
6	25	26	O	of
7	28	32	O	drugs
8	34	38	O	known
9	40	41	O	to
10	43	48	O	affect
11	50	57	O	urethral
12	59	68	O	resistance
NULL

Duloxetine	374	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	24
If symptoms of urinary hesitation develop during treatment with duloxetine, consideration should be given to the possibility that they might be drug-related.
1	0	1	O	If
2	3	10	O	symptoms
3	12	13	O	of
4	15	21	O	urinary
5	23	32	O	hesitation
6	34	40	O	develop
7	42	47	O	during
8	49	57	O	treatment
9	59	62	O	with
10	64	73	O	XXXXXXXX
11	74	74	O	,
12	76	88	O	consideration
13	90	95	O	should
14	97	98	O	be
15	100	104	O	given
16	106	107	O	to
17	109	111	O	the
18	113	123	O	possibility
19	125	128	O	that
20	130	133	O	they
21	135	139	O	might
22	141	142	O	be
23	144	147	O	drug
24	149	155	O	related
NULL

Duloxetine	375	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	25
Duloxetine has an elimination half-life of about 12 hours (range 8 to 17 hours) and its pharmacokinetics are dose proportional over the therapeutic range.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	16	O	an
4	18	28	O	elimination
5	30	33	O	half
6	35	38	O	life
7	40	41	O	of
8	43	47	O	about
9	49	50	O	12
10	52	56	O	hours
11	59	63	O	range
12	65	65	O	8
13	67	68	O	to
14	70	71	O	17
15	73	77	O	hours
16	80	82	O	and
17	84	86	O	its
18	88	103	O	pharmacokinetics
19	105	107	O	are
20	109	112	O	dose
21	114	125	O	proportional
22	127	130	O	over
23	132	134	O	the
24	136	146	O	therapeutic
25	148	152	O	range
NULL

Duloxetine	376	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	12
Steady-state plasma concentrations are typically achieved after 3 days of dosing.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	plasma
4	20	33	O	concentrations
5	35	37	O	are
6	39	47	O	typically
7	49	56	O	achieved
8	58	62	O	after
9	64	64	O	3
10	66	69	O	days
11	71	72	O	of
12	74	79	O	dosing
NULL

Duloxetine	377	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	16
Elimination of duloxetine is mainly through hepatic metabolism involving two P450 isozymes, CYP1A2 and CYP2D6.
1	0	10	O	Elimination
2	12	13	O	of
3	15	24	O	XXXXXXXX
4	26	27	O	is
5	29	34	O	mainly
6	36	42	O	through
7	44	50	O	hepatic
8	52	61	O	metabolism
9	63	71	O	involving
10	73	75	O	two
11	77	80	O	P450
12	82	89	O	isozymes
13	90	90	O	,
14	92	97	O	CYP1A2
15	99	101	O	and
16	103	108	O	CYP2D6
NULL

Duloxetine	378	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	10
Absorption and Distribution Orally administered duloxetine hydrochloride is well absorbed.
1	0	9	O	Absorption
2	11	13	O	and
3	15	26	O	Distribution
4	28	33	O	Orally
5	35	46	O	administered
6	48	57	O	XXXXXXXX
7	59	71	O	hydrochloride
8	73	74	O	is
9	76	79	O	well
10	81	88	O	absorbed
NULL

Duloxetine	379	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	24
There is a median 2 hour lag until absorption begins (Tlag), with maximal plasma concentrations (Cmax) of duloxetine occurring 6 hours post dose.
1	0	4	O	There
2	6	7	O	is
3	9	9	O	a
4	11	16	O	median
5	18	18	O	2
6	20	23	O	hour
7	25	27	O	lag
8	29	33	O	until
9	35	44	O	absorption
10	46	51	O	begins
11	54	57	O	Tlag
12	59	59	O	,
13	61	64	O	with
14	66	72	O	maximal
15	74	79	O	plasma
16	81	94	O	concentrations
17	97	100	O	Cmax
18	103	104	O	of
19	106	115	O	XXXXXXXX
20	117	125	O	occurring
21	127	127	O	6
22	129	133	O	hours
23	135	138	O	post
24	140	143	O	dose
NULL

Duloxetine	380	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	34
Food does not affect the Cmax of duloxetine, but delays the time to reach peak concentration from 6 to 10 hours and it marginally decreases the extent of absorption (AUC) by about 10%.
1	0	3	U-KIN	Food
2	5	8	O	does
3	10	12	O	not
4	14	19	O	affect
5	21	23	O	the
6	25	28	O	Cmax
7	30	31	O	of
8	33	42	O	XXXXXXXX
9	43	43	O	,
10	45	47	O	but
11	49	54	B-TRI	delays
12	56	58	I-TRI	the
13	60	63	I-TRI	time
14	65	66	I-TRI	to
15	68	72	I-TRI	reach
16	74	77	I-TRI	peak
17	79	91	L-TRI	concentration
18	93	96	O	from
19	98	98	O	6
20	100	101	O	to
21	103	104	O	10
22	106	110	O	hours
23	112	114	O	and
24	116	117	O	it
25	119	128	O	marginally
26	130	138	O	decreases
27	140	142	O	the
28	144	149	O	extent
29	151	152	O	of
30	154	163	O	absorption
31	166	168	O	AUC
32	171	172	O	by
33	174	178	O	about
34	180	182	O	10%
K/1:C54609

Duloxetine	381	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	28
There is a 3 hour delay in absorption and a one-third increase in apparent clearance of duloxetine after an evening dose as compared to a morning dose.
1	0	4	O	There
2	6	7	O	is
3	9	9	O	a
4	11	11	O	3
5	13	16	O	hour
6	18	22	O	delay
7	24	25	O	in
8	27	36	O	absorption
9	38	40	O	and
10	42	42	O	a
11	44	46	O	one
12	48	52	O	third
13	54	61	O	increase
14	63	64	O	in
15	66	73	O	apparent
16	75	83	O	clearance
17	85	86	O	of
18	88	97	O	XXXXXXXX
19	99	103	O	after
20	105	106	O	an
21	108	114	O	evening
22	116	119	O	dose
23	121	122	O	as
24	124	131	O	compared
25	133	134	O	to
26	136	136	O	a
27	138	144	O	morning
28	146	149	O	dose
NULL

Duloxetine	382	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	27
The apparent volume of distribution averages about 1640L. Duloxetine is highly bound (>90%) to proteins in human plasma, binding primarily to albumin and A1-acid glycoprotein.
1	0	2	O	The
2	4	11	O	apparent
3	13	18	O	volume
4	20	21	O	of
5	23	34	O	distribution
6	36	43	O	averages
7	45	49	O	about
8	51	55	O	1640L
9	58	67	O	XXXXXXXX
10	69	70	O	is
11	72	77	O	highly
12	79	83	O	bound
13	86	89	O	>90%
14	92	93	O	to
15	95	102	O	proteins
16	104	105	O	in
17	107	111	O	human
18	113	118	O	plasma
19	119	119	O	,
20	121	127	O	binding
21	129	137	O	primarily
22	139	140	O	to
23	142	148	O	albumin
24	150	152	O	and
25	154	155	O	A1
26	157	160	O	acid
27	162	173	O	glycoprotein
NULL

Duloxetine	383	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	15
The interaction between duloxetine and other highly protein bound drugs has not been fully evaluated.
1	0	2	O	The
2	4	14	O	interaction
3	16	22	O	between
4	24	33	O	XXXXXXXX
5	35	37	O	and
6	39	43	O	other
7	45	50	O	highly
8	52	58	O	protein
9	60	64	O	bound
10	66	70	O	drugs
11	72	74	O	has
12	76	78	O	not
13	80	83	O	been
14	85	89	O	fully
15	91	99	O	evaluated
NULL

Duloxetine	384	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	13
Plasma protein binding of duloxetine is not affected by renal or hepatic impairment.
1	0	5	O	Plasma
2	7	13	O	protein
3	15	21	O	binding
4	23	24	O	of
5	26	35	O	XXXXXXXX
6	37	38	O	is
7	40	42	O	not
8	44	51	O	affected
9	53	54	O	by
10	56	60	O	renal
11	62	63	O	or
12	65	71	O	hepatic
13	73	82	O	impairment
NULL

Duloxetine	385	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	20
Metabolism and Elimination Biotransformation and disposition of duloxetine in humans have been determined following oral administration of 14C-labeled duloxetine.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	27	43	O	Biotransformation
5	45	47	O	and
6	49	59	O	disposition
7	61	62	O	of
8	64	73	O	XXXXXXXX
9	75	76	O	in
10	78	83	O	humans
11	85	88	O	have
12	90	93	O	been
13	95	104	O	determined
14	106	114	O	following
15	116	119	O	oral
16	121	134	O	administration
17	136	137	O	of
18	139	141	O	14C
19	143	149	O	labeled
20	151	160	O	XXXXXXXX
NULL

Duloxetine	386	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	22
Duloxetine comprises about 3% of the total radiolabeled material in the plasma, indicating that it undergoes extensive metabolism to numerous metabolites.
1	0	9	O	XXXXXXXX
2	11	19	O	comprises
3	21	25	O	about
4	27	28	O	3%
5	30	31	O	of
6	33	35	O	the
7	37	41	O	total
8	43	54	O	radiolabeled
9	56	63	O	material
10	65	66	O	in
11	68	70	O	the
12	72	77	O	plasma
13	78	78	O	,
14	80	89	O	indicating
15	91	94	O	that
16	96	97	O	it
17	99	107	O	undergoes
18	109	117	O	extensive
19	119	128	O	metabolism
20	130	131	O	to
21	133	140	O	numerous
22	142	152	O	metabolites
NULL

Duloxetine	387	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	18
The major biotransformation pathways for duloxetine involve oxidation of the naphthyl ring followed by conjugation and further oxidation.
1	0	2	O	The
2	4	8	O	major
3	10	26	O	biotransformation
4	28	35	O	pathways
5	37	39	O	for
6	41	50	O	XXXXXXXX
7	52	58	O	involve
8	60	68	O	oxidation
9	70	71	O	of
10	73	75	O	the
11	77	84	O	naphthyl
12	86	89	O	ring
13	91	98	O	followed
14	100	101	O	by
15	103	113	O	conjugation
16	115	117	O	and
17	119	125	O	further
18	127	135	O	oxidation
NULL

Duloxetine	388	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	13
Both CYP1A2 and CYP2D6 catalyze the oxidation of the naphthyl ring in vitro.
1	0	3	O	Both
2	5	10	O	CYP1A2
3	12	14	O	and
4	16	21	O	CYP2D6
5	23	30	O	catalyze
6	32	34	O	the
7	36	44	O	oxidation
8	46	47	O	of
9	49	51	O	the
10	53	60	O	naphthyl
11	62	65	O	ring
12	67	68	O	in
13	70	74	O	vitro
NULL

Duloxetine	389	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	17
Metabolites found in plasma include 4-hydroxy duloxetine glucuronide and 5-hydroxy, 6-methoxy duloxetine sulfate.
1	0	10	O	Metabolites
2	12	16	O	found
3	18	19	O	in
4	21	26	O	plasma
5	28	34	O	include
6	36	36	O	4
7	38	44	O	hydroxy
8	46	55	O	XXXXXXXX
9	57	67	O	glucuronide
10	69	71	O	and
11	73	73	O	5
12	75	81	O	hydroxy
13	82	82	O	,
14	84	84	O	6
15	86	92	O	methoxy
16	94	103	O	XXXXXXXX
17	105	111	O	sulfate
NULL

Duloxetine	390	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	16
Many additional metabolites have been identified in urine, some representing only minor pathways of elimination.
1	0	3	O	Many
2	5	14	O	additional
3	16	26	O	metabolites
4	28	31	O	have
5	33	36	O	been
6	38	47	O	identified
7	49	50	O	in
8	52	56	O	urine
9	57	57	O	,
10	59	62	O	some
11	64	75	O	representing
12	77	80	O	only
13	82	86	O	minor
14	88	95	O	pathways
15	97	98	O	of
16	100	110	O	elimination
NULL

Duloxetine	391	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	15
Only trace (<1% of the dose) amounts of unchanged duloxetine are present in the urine.
1	0	3	O	Only
2	5	9	O	trace
3	12	14	O	<1%
4	16	17	O	of
5	19	21	O	the
6	23	26	O	dose
7	29	35	O	amounts
8	37	38	O	of
9	40	48	O	unchanged
10	50	59	O	XXXXXXXX
11	61	63	O	are
12	65	71	O	present
13	73	74	O	in
14	76	78	O	the
15	80	84	O	urine
NULL

Duloxetine	392	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	22
Most (about 70%) of the duloxetine dose appears in the urine as metabolites of duloxetine; about 20% is excreted in the feces.
1	0	3	O	Most
2	6	10	O	about
3	12	14	O	70%
4	17	18	O	of
5	20	22	O	the
6	24	33	O	XXXXXXXX
7	35	38	O	dose
8	40	46	O	appears
9	48	49	O	in
10	51	53	O	the
11	55	59	O	urine
12	61	62	O	as
13	64	74	O	metabolites
14	76	77	O	of
15	79	88	O	XXXXXXXX
16	91	95	O	about
17	97	99	O	20%
18	101	102	O	is
19	104	111	O	excreted
20	113	114	O	in
21	116	118	O	the
22	120	124	O	feces
NULL

Duloxetine	393	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	23
Duloxetine undergoes extensive metabolism, but the major circulating metabolites have not been shown to contribute significantly to the pharmacologic activity of duloxetine.
1	0	9	O	XXXXXXXX
2	11	19	O	undergoes
3	21	29	O	extensive
4	31	40	O	metabolism
5	41	41	O	,
6	43	45	O	but
7	47	49	O	the
8	51	55	O	major
9	57	67	O	circulating
10	69	79	O	metabolites
11	81	84	O	have
12	86	88	O	not
13	90	93	O	been
14	95	99	O	shown
15	101	102	O	to
16	104	113	O	contribute
17	115	127	O	significantly
18	129	130	O	to
19	132	134	O	the
20	136	148	O	pharmacologic
21	150	157	O	activity
22	159	160	O	of
23	162	171	O	XXXXXXXX
NULL

Duloxetine	394	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	25
Pediatric use information for patients ages 7 to 17 years is approved for Eli Lilly and Company, Inc.'s CYMBALTA * (duloxetine) delayed-release capsules.
1	0	8	O	Pediatric
2	10	12	O	use
3	14	24	O	information
4	26	28	O	for
5	30	37	O	patients
6	39	42	O	ages
7	44	44	O	7
8	46	47	O	to
9	49	50	O	17
10	52	56	O	years
11	58	59	O	is
12	61	68	O	approved
13	70	72	O	for
14	74	76	O	Eli
15	78	82	O	Lilly
16	84	86	O	and
17	88	94	O	Company
18	95	95	O	,
19	97	102	O	Inc.'s
20	104	111	O	CYMBALTA
21	113	113	O	*
22	116	125	O	XXXXXXXX
23	128	134	O	delayed
24	136	142	O	release
25	144	151	O	capsules
NULL

Duloxetine	395	34090-1	829a4f51-c882-4b64-81f3-abfb03a52ebe	24
However, due to Eli Lilly and Company, Inc.'s marketing exclusivity rights, this drug product is not labeled with that pediatric information.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	due
4	13	14	O	to
5	16	18	O	Eli
6	20	24	O	Lilly
7	26	28	O	and
8	30	36	O	Company
9	37	37	O	,
10	39	44	O	Inc.'s
11	46	54	O	marketing
12	56	66	O	exclusivity
13	68	73	O	rights
14	74	74	O	,
15	76	79	O	this
16	81	84	O	drug
17	86	92	O	product
18	94	95	O	is
19	97	99	O	not
20	101	107	O	labeled
21	109	112	O	with
22	114	117	O	that
23	119	127	O	pediatric
24	129	139	O	information
NULL

EMSAM	16	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
Serious, sometimes fatal, central nervous system (CNS) toxicity referred to as the "serotonin syndrome" has been reported with the combination of nonselective MAOIs and serotonergic drugs.
1	0	6	O	Serious
2	7	7	O	,
3	9	17	O	sometimes
4	19	23	O	fatal
5	24	24	O	,
6	26	32	B-EFF	central
7	34	40	I-EFF	nervous
8	42	47	I-EFF	system
9	50	52	I-EFF	CNS
10	55	62	L-EFF	toxicity
11	64	71	O	referred
12	73	74	O	to
13	76	77	O	as
14	79	81	O	the
15	83	92	O	"serotonin
16	94	102	O	syndrome"
17	104	106	O	has
18	108	111	O	been
19	113	120	O	reported
20	122	125	O	with
21	127	129	O	the
22	131	141	O	combination
23	143	144	O	of
24	146	157	O	nonselective
25	159	163	O	MAOIs
26	165	167	O	and
27	169	180	B-DYN	serotonergic
28	182	186	L-DYN	drugs
D/27:6:1

EMSAM	17	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	8
Use of EMSAM with these drugs is contraindicated.
1	0	2	O	Use
2	4	5	O	of
3	7	11	O	XXXXXXXX
4	13	16	O	with
5	18	22	O	these
6	24	28	O	drugs
7	30	31	O	is
8	33	47	O	contraindicated
NULL

EMSAM	18	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	21
EMSAM has the capacity to inhibit intestinal MAO, which is responsible for the catabolism of tyramine in food and beverages.
1	0	4	O	XXXXXXXX
2	6	8	O	has
3	10	12	O	the
4	14	21	O	capacity
5	23	24	O	to
6	26	32	O	inhibit
7	34	43	O	intestinal
8	45	47	O	MAO
9	48	48	O	,
10	50	54	O	which
11	56	57	O	is
12	59	69	O	responsible
13	71	73	O	for
14	75	77	O	the
15	79	88	O	catabolism
16	90	91	O	of
17	93	100	O	tyramine
18	102	103	O	in
19	105	108	O	food
20	110	112	O	and
21	114	122	O	beverages
NULL

EMSAM	19	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	29
As a result of this inhibition, large amounts of tyramine may enter the systemic circulation and precipitate a sudden, large rise in blood pressure or hypertensive crisis.
1	0	1	O	As
2	3	3	O	a
3	5	10	O	result
4	12	13	O	of
5	15	18	O	this
6	20	29	O	inhibition
7	30	30	O	,
8	32	36	O	large
9	38	44	O	amounts
10	46	47	O	of
11	49	56	O	tyramine
12	58	60	O	may
13	62	66	O	enter
14	68	70	O	the
15	72	79	O	systemic
16	81	91	O	circulation
17	93	95	O	and
18	97	107	O	precipitate
19	109	109	O	a
20	111	116	O	sudden
21	117	117	O	,
22	119	123	O	large
23	125	128	O	rise
24	130	131	O	in
25	133	137	O	blood
26	139	146	O	pressure
27	148	149	O	or
28	151	162	O	hypertensive
29	164	169	O	crisis
NULL

EMSAM	20	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	13
A diet low in tyramine content may be necessary to avoid this interaction.
1	0	0	O	A
2	2	5	O	diet
3	7	9	O	low
4	11	12	O	in
5	14	21	O	tyramine
6	23	29	O	content
7	31	33	O	may
8	35	36	O	be
9	38	46	O	necessary
10	48	49	O	to
11	51	55	O	avoid
12	57	60	O	this
13	62	72	O	interaction
NULL

EMSAM	21	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	39
Studies to evaluate the potential for EMSAM to inhibit tyramine metabolism have been conducted and, overall, the data for EMSAM 6mg per 24 hours support a recommendation that a modified diet is not required at this dose.
1	0	6	O	Studies
2	8	9	O	to
3	11	18	O	evaluate
4	20	22	O	the
5	24	32	O	potential
6	34	36	O	for
7	38	42	O	XXXXXXXX
8	44	45	O	to
9	47	53	O	inhibit
10	55	62	O	tyramine
11	64	73	O	metabolism
12	75	78	O	have
13	80	83	O	been
14	85	93	O	conducted
15	95	97	O	and
16	98	98	O	,
17	100	106	O	overall
18	107	107	O	,
19	109	111	O	the
20	113	116	O	data
21	118	120	O	for
22	122	126	O	XXXXXXXX
23	128	130	O	6mg
24	132	134	O	per
25	136	137	O	24
26	139	143	O	hours
27	145	151	O	support
28	153	153	O	a
29	155	168	O	recommendation
30	170	173	O	that
31	175	175	O	a
32	177	184	O	modified
33	186	189	O	diet
34	191	192	O	is
35	194	196	O	not
36	198	205	O	required
37	207	208	O	at
38	210	213	O	this
39	215	218	O	dose
NULL

EMSAM	22	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	56
Due to the more limited data available for EMSAM 9mg per 24 hours and the results from the Phase I tyramine challenge study in fed volunteers administered EMSAM 12mg per 24 hours, patients receiving these doses should follow Dietary Modifications Required for Patients Taking EMSAM 9mg per 24 hours and 12mg per 24 hours below.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	14	O	more
5	16	22	O	limited
6	24	27	O	data
7	29	37	O	available
8	39	41	O	for
9	43	47	O	XXXXXXXX
10	49	51	O	9mg
11	53	55	O	per
12	57	58	O	24
13	60	64	O	hours
14	66	68	O	and
15	70	72	O	the
16	74	80	O	results
17	82	85	O	from
18	87	89	O	the
19	91	95	O	Phase
20	97	97	O	I
21	99	106	O	tyramine
22	108	116	O	challenge
23	118	122	O	study
24	124	125	O	in
25	127	129	O	fed
26	131	140	O	volunteers
27	142	153	O	administered
28	155	159	O	XXXXXXXX
29	161	164	O	12mg
30	166	168	O	per
31	170	171	O	24
32	173	177	O	hours
33	178	178	O	,
34	180	187	O	patients
35	189	197	O	receiving
36	199	203	O	these
37	205	209	O	doses
38	211	216	O	should
39	218	223	O	follow
40	225	231	O	Dietary
41	233	245	O	Modifications
42	247	254	O	Required
43	256	258	O	for
44	260	267	O	Patients
45	269	274	O	Taking
46	276	280	O	XXXXXXXX
47	282	284	O	9mg
48	286	288	O	per
49	290	291	O	24
50	293	297	O	hours
51	299	301	O	and
52	303	306	O	12mg
53	308	310	O	per
54	312	313	O	24
55	315	319	O	hours
56	321	325	O	below
NULL

EMSAM	23	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	63
The foods and beverages listed in Table 5 should be avoided beginning on the first day of EMSAM 9mg per 24 hours or 12mg per 24 hours treatment, and should continue to be avoided for 2 weeks after a dose reduction to EMSAM 6mg per 24 hours or following the discontinuation of EMSAM 9mg per 24 hours or 12mg per 24 hours.
1	0	2	O	The
2	4	8	O	foods
3	10	12	O	and
4	14	22	O	beverages
5	24	29	O	listed
6	31	32	O	in
7	34	38	O	Table
8	40	40	O	5
9	42	47	O	should
10	49	50	O	be
11	52	58	O	avoided
12	60	68	O	beginning
13	70	71	O	on
14	73	75	O	the
15	77	81	O	first
16	83	85	O	day
17	87	88	O	of
18	90	94	O	XXXXXXXX
19	96	98	O	9mg
20	100	102	O	per
21	104	105	O	24
22	107	111	O	hours
23	113	114	O	or
24	116	119	O	12mg
25	121	123	O	per
26	125	126	O	24
27	128	132	O	hours
28	134	142	O	treatment
29	143	143	O	,
30	145	147	O	and
31	149	154	O	should
32	156	163	O	continue
33	165	166	O	to
34	168	169	O	be
35	171	177	O	avoided
36	179	181	O	for
37	183	183	O	2
38	185	189	O	weeks
39	191	195	O	after
40	197	197	O	a
41	199	202	O	dose
42	204	212	O	reduction
43	214	215	O	to
44	217	221	O	XXXXXXXX
45	223	225	O	6mg
46	227	229	O	per
47	231	232	O	24
48	234	238	O	hours
49	240	241	O	or
50	243	251	O	following
51	253	255	O	the
52	257	271	O	discontinuation
53	273	274	O	of
54	276	280	O	XXXXXXXX
55	282	284	O	9mg
56	286	288	O	per
57	290	291	O	24
58	293	297	O	hours
59	299	300	O	or
60	302	305	O	12mg
61	307	309	O	per
62	311	312	O	24
63	314	318	O	hours
NULL

EMSAM	24	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	58
Food and Beverages to Avoid and Those which are Acceptable All other vegetables Dairy Aged cheeses Processed cheeses, mozzarella, ricotta cheese, cottage cheese, and yogurt Beverages All varieties of tap beer and beers that have not been pasteurized so as to allow for ongoing fermentation Concomitant use of alcohol with EMSAM is not recommended.
1	0	3	O	Food
2	5	7	O	and
3	9	17	O	Beverages
4	19	20	O	to
5	22	26	O	Avoid
6	28	30	O	and
7	32	36	O	Those
8	38	42	O	which
9	44	46	O	are
10	48	57	O	Acceptable
11	59	61	O	All
12	63	67	O	other
13	69	78	O	vegetables
14	80	84	O	Dairy
15	86	89	O	Aged
16	91	97	O	cheeses
17	99	107	O	Processed
18	109	115	O	cheeses
19	116	116	O	,
20	118	127	O	mozzarella
21	128	128	O	,
22	130	136	O	ricotta
23	138	143	O	cheese
24	144	144	O	,
25	146	152	O	cottage
26	154	159	O	cheese
27	160	160	O	,
28	162	164	O	and
29	166	171	O	yogurt
30	173	181	O	Beverages
31	183	185	O	All
32	187	195	O	varieties
33	197	198	O	of
34	200	202	O	tap
35	204	207	O	beer
36	209	211	O	and
37	213	217	O	beers
38	219	222	O	that
39	224	227	O	have
40	229	231	O	not
41	233	236	O	been
42	238	248	O	pasteurized
43	250	251	O	so
44	253	254	O	as
45	256	257	O	to
46	259	263	O	allow
47	265	267	O	for
48	269	275	O	ongoing
49	277	288	O	fermentation
50	290	300	O	Concomitant
51	302	304	O	use
52	306	307	O	of
53	309	315	U-UNK	alcohol
54	317	320	O	with
55	322	326	O	XXXXXXXX
56	328	329	O	is
57	331	333	B-TRI	not
58	335	345	L-TRI	recommended
NULL

EMSAM	25	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	11
(Bottled and canned beers and wines contain little or no tyramine.)
1	1	7	O	Bottled
2	9	11	O	and
3	13	18	O	canned
4	20	24	O	beers
5	26	28	O	and
6	30	34	O	wines
7	36	42	O	contain
8	44	49	O	little
9	51	52	O	or
10	54	55	O	no
11	57	64	O	tyramine
NULL

EMSAM	26	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	58
Miscellaneous Concentrated yeast extract (e.g., Marmite), sauerkraut, most soybean products (including soy sauce and tofu), OTC supplements containing tyramine Brewer's yeast, baker's yeast, soy milk, commercial chain restaurant pizzas prepared with cheeses low in tyramine The use of EMSAM with sympathomimetic amines or buspirone may produce substantial elevations in blood pressure.
1	0	12	O	Miscellaneous
2	14	25	O	Concentrated
3	27	31	O	yeast
4	33	39	O	extract
5	42	44	O	e.g
6	46	46	O	,
7	48	54	O	Marmite
8	56	56	O	,
9	58	67	O	sauerkraut
10	68	68	O	,
11	70	73	O	most
12	75	81	O	soybean
13	83	90	O	products
14	93	101	O	including
15	103	105	O	soy
16	107	111	O	sauce
17	113	115	O	and
18	117	120	O	tofu
19	122	122	O	,
20	124	126	O	OTC
21	128	138	O	supplements
22	140	149	O	containing
23	151	158	O	tyramine
24	160	167	O	Brewer's
25	169	173	O	yeast
26	174	174	O	,
27	176	182	O	baker's
28	184	188	O	yeast
29	189	189	O	,
30	191	193	O	soy
31	195	198	O	milk
32	199	199	O	,
33	201	210	O	commercial
34	212	216	O	chain
35	218	227	O	restaurant
36	229	234	O	pizzas
37	236	243	O	prepared
38	245	248	O	with
39	250	256	O	cheeses
40	258	260	O	low
41	262	263	O	in
42	265	272	O	tyramine
43	274	276	O	The
44	278	280	O	use
45	282	283	O	of
46	285	289	O	XXXXXXXX
47	291	294	O	with
48	296	310	B-DYN	sympathomimetic
49	312	317	L-DYN	amines
50	319	320	O	or
51	322	330	U-DYN	buspirone
52	332	334	O	may
53	336	342	O	produce
54	344	354	O	substantial
55	356	365	B-EFF	elevations
56	367	368	I-EFF	in
57	370	374	I-EFF	blood
58	376	383	L-EFF	pressure
D/48:55:1 D/51:55:1

EMSAM	27	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	41
Therefore, monitor blood pressure if EMSAM is used with any of the following drugs: buspirone, amphetamines, and cold products or weight-reducing preparations that contain sympathomimetic amines (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine).
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	U-TRI	monitor
4	19	23	O	blood
5	25	32	O	pressure
6	34	35	O	if
7	37	41	O	XXXXXXXX
8	43	44	O	is
9	46	49	O	used
10	51	54	O	with
11	56	58	O	any
12	60	61	O	of
13	63	65	O	the
14	67	75	O	following
15	77	81	O	drugs
16	82	82	O	:
17	84	92	U-UNK	buspirone
18	93	93	O	,
19	95	106	U-UNK	amphetamines
20	107	107	O	,
21	109	111	O	and
22	113	116	B-UNK	cold
23	118	125	L-UNK	products
24	127	128	O	or
25	130	135	B-UNK	weight
26	137	144	I-UNK	reducing
27	146	157	L-UNK	preparations
28	159	162	O	that
29	164	170	O	contain
30	172	186	O	sympathomimetic
31	188	193	O	amines
32	196	198	O	e.g
33	200	200	O	,
34	202	216	U-UNK	pseudoephedrine
35	217	217	O	,
36	219	231	U-UNK	phenylephrine
37	232	232	O	,
38	234	252	U-UNK	phenylpropanolamine
39	253	253	O	,
40	255	257	O	and
41	259	267	O	ephedrine
NULL

EMSAM	28	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	8
Carbamazepine is contraindicated with MAOIs, including selegiline.
1	0	12	U-UNK	Carbamazepine
2	14	15	O	is
3	17	31	U-TRI	contraindicated
4	33	36	O	with
5	38	42	O	MAOIs
6	43	43	O	,
7	45	53	O	including
8	55	64	O	XXXXXXXX
NULL

EMSAM	29	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	31
No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole).
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	21	O	for
5	23	27	O	XXXXXXXX
6	29	30	O	is
7	32	37	O	needed
8	39	42	O	when
9	44	48	O	XXXXXXXX
10	50	51	O	is
11	53	56	O	used
12	58	70	O	concomitantly
13	72	75	O	with
14	77	83	O	alcohol
15	84	84	O	,
16	86	95	O	alprazolam
17	96	96	O	,
18	98	106	O	ibuprofen
19	107	107	O	,
20	109	118	O	olanzapine
21	119	119	O	,
22	121	131	O	risperidone
23	132	132	O	,
24	134	146	O	levothyroxine
25	147	147	O	,
26	149	151	O	and
27	153	158	O	CYP3A4
28	160	169	O	inhibitors
29	172	174	O	e.g
30	176	176	O	,
31	178	189	O	ketoconazole
NULL

EMSAM	30	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	29
No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole.
1	0	1	O	No
2	3	12	O	clinically
3	14	23	O	meaningful
4	25	30	O	change
5	32	33	O	in
6	35	44	O	XXXXXXXX
7	46	53	O	exposure
8	55	57	O	was
9	59	62	O	seen
10	64	67	O	when
11	69	73	O	XXXXXXXX
12	75	77	O	was
13	79	80	O	co
14	82	93	O	administered
15	95	98	O	with
16	100	106	O	alcohol
17	107	107	O	,
18	109	118	O	alprazolam
19	119	119	O	,
20	121	129	O	ibuprofen
21	130	130	O	,
22	132	141	O	olanzapine
23	142	142	O	,
24	144	154	O	risperidone
25	155	155	O	,
26	157	169	O	levothyroxine
27	170	170	O	,
28	172	174	O	and
29	176	187	O	ketoconazole
NULL

EMSAM	31	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	32
Use of alcohol while taking EMSAM is not recommended, even though EMSAM has not been shown to increase the impairment of mental and motor skills caused by alcohol (0.75mg per kg).
1	0	2	O	Use
2	4	5	O	of
3	7	13	U-UNK	alcohol
4	15	19	O	while
5	21	26	O	taking
6	28	32	O	XXXXXXXX
7	34	35	O	is
8	37	39	B-TRI	not
9	41	51	L-TRI	recommended
10	52	52	O	,
11	54	57	O	even
12	59	64	O	though
13	66	70	O	XXXXXXXX
14	72	74	O	has
15	76	78	O	not
16	80	83	O	been
17	85	89	O	shown
18	91	92	O	to
19	94	101	O	increase
20	103	105	O	the
21	107	116	O	impairment
22	118	119	O	of
23	121	126	O	mental
24	128	130	O	and
25	132	136	O	motor
26	138	143	O	skills
27	145	150	O	caused
28	152	153	O	by
29	155	161	O	alcohol
30	164	169	O	0.75mg
31	171	173	O	per
32	175	176	O	kg
NULL

EMSAM	32	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	31
Monitor blood pressure if sympathomimetic agents (e.g., phenylpropanolamine (PPA) or pseudoephedrine) are used with EMSAM, even though selegiline does not appear to affect the pharmacokinetics of PPA or pseudoephedrine.
1	0	6	U-TRI	Monitor
2	8	12	O	blood
3	14	21	O	pressure
4	23	24	O	if
5	26	40	B-UNK	sympathomimetic
6	42	47	L-UNK	agents
7	50	52	O	e.g
8	54	54	O	,
9	56	74	U-UNK	phenylpropanolamine
10	77	79	U-UNK	PPA
11	82	83	O	or
12	85	99	U-UNK	pseudoephedrine
13	102	104	O	are
14	106	109	O	used
15	111	114	O	with
16	116	120	O	XXXXXXXX
17	121	121	O	,
18	123	126	O	even
19	128	133	O	though
20	135	144	O	XXXXXXXX
21	146	149	O	does
22	151	153	O	not
23	155	160	O	appear
24	162	163	O	to
25	165	170	O	affect
26	172	174	O	the
27	176	191	O	pharmacokinetics
28	193	194	O	of
29	196	198	O	PPA
30	200	201	O	or
31	203	217	O	pseudoephedrine
NULL

EMSAM	33	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	34
No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	of
5	22	31	O	alprazolam
6	32	32	O	,
7	34	42	O	ibuprofen
8	43	43	O	,
9	45	57	O	levothyroxine
10	58	58	O	,
11	60	69	O	olanzapine
12	70	70	O	,
13	72	82	O	risperdione
14	83	83	O	,
15	85	92	O	warfarin
16	93	93	O	,
17	95	96	O	or
18	98	103	O	strong
19	105	110	O	CYP3A4
20	112	121	O	inhibitors
21	124	126	O	e.g
22	128	128	O	,
23	130	141	O	ketoconazole
24	144	145	O	is
25	147	155	O	necessary
26	157	160	O	when
27	162	166	O	these
28	168	172	O	drugs
29	174	176	O	are
30	178	181	O	used
31	183	184	O	in
32	186	196	O	combination
33	198	201	O	with
34	203	207	O	XXXXXXXX
NULL

EMSAM	34	34073-7	b891bd9f-fdb8-4862-89c5-ecdd700398a3	11
EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.
1	0	4	O	XXXXXXXX
2	6	8	O	had
3	10	11	O	no
4	13	22	O	clinically
5	24	31	O	relevant
6	33	38	O	effect
7	40	41	O	on
8	43	58	O	pharmacokinetics
9	60	61	O	of
10	63	67	O	these
11	69	73	O	drugs
NULL

EMSAM	35	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	48
The mechanism of action of selegiline (the drug substance of EMSAM) as an antidepressant is not fully understood, but is presumed to be linked to potentiation of monoamine neurotransmitter activity in the central nervous system (CNS) resulting from its irreversible inhibition of the enzyme monoamine oxidase (MAO).
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	39	41	O	the
8	43	46	O	drug
9	48	56	O	substance
10	58	59	O	of
11	61	65	O	XXXXXXXX
12	68	69	O	as
13	71	72	O	an
14	74	87	O	antidepressant
15	89	90	O	is
16	92	94	O	not
17	96	100	O	fully
18	102	111	O	understood
19	112	112	O	,
20	114	116	O	but
21	118	119	O	is
22	121	128	O	presumed
23	130	131	O	to
24	133	134	O	be
25	136	141	O	linked
26	143	144	O	to
27	146	157	O	potentiation
28	159	160	O	of
29	162	170	O	monoamine
30	172	187	O	neurotransmitter
31	189	196	O	activity
32	198	199	O	in
33	201	203	O	the
34	205	211	O	central
35	213	219	O	nervous
36	221	226	O	system
37	229	231	O	CNS
38	234	242	O	resulting
39	244	247	O	from
40	249	251	O	its
41	253	264	O	irreversible
42	266	275	O	inhibition
43	277	278	O	of
44	280	282	O	the
45	284	289	O	enzyme
46	291	299	O	monoamine
47	301	307	O	oxidase
48	310	312	O	MAO
NULL

EMSAM	36	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	14
MAO exists as two isoenzymes, referred to as MAO-A and MAO-B.
1	0	2	O	MAO
2	4	9	O	exists
3	11	12	O	as
4	14	16	O	two
5	18	27	O	isoenzymes
6	28	28	O	,
7	30	37	O	referred
8	39	40	O	to
9	42	43	O	as
10	45	47	O	MAO
11	49	49	O	A
12	51	53	O	and
13	55	57	O	MAO
14	59	59	O	B
NULL

EMSAM	37	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	13
Selegiline has a greater affinity for MAO-B, compared to MAO-A.
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	15	O	a
4	17	23	O	greater
5	25	32	O	affinity
6	34	36	O	for
7	38	40	O	MAO
8	42	42	O	B
9	43	43	O	,
10	45	52	O	compared
11	54	55	O	to
12	57	59	O	MAO
13	61	61	O	A
NULL

EMSAM	38	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	10
However, at antidepressant doses, selegiline inhibits both isoenzymes.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	at
4	12	25	O	antidepressant
5	27	31	O	doses
6	32	32	O	,
7	34	43	O	XXXXXXXX
8	45	52	O	inhibits
9	54	57	O	both
10	59	68	O	isoenzymes
NULL

EMSAM	39	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	39
In an in vivo animal model used to test for antidepressant activity (Forced Swim Test), selegiline administered by transdermal system exhibited antidepressant properties only at doses that inhibited both MAO-A and MAO-B activity in the brain.
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	12	O	vivo
5	14	19	O	animal
6	21	25	O	model
7	27	30	O	used
8	32	33	O	to
9	35	38	O	test
10	40	42	O	for
11	44	57	O	antidepressant
12	59	66	O	activity
13	69	74	O	Forced
14	76	79	O	Swim
15	81	84	O	Test
16	86	86	O	,
17	88	97	O	XXXXXXXX
18	99	110	O	administered
19	112	113	O	by
20	115	125	O	transdermal
21	127	132	O	system
22	134	142	O	exhibited
23	144	157	O	antidepressant
24	159	168	O	properties
25	170	173	O	only
26	175	176	O	at
27	178	182	O	doses
28	184	187	O	that
29	189	197	O	inhibited
30	199	202	O	both
31	204	206	O	MAO
32	208	208	O	A
33	210	212	O	and
34	214	216	O	MAO
35	218	218	O	B
36	220	227	O	activity
37	229	230	O	in
38	232	234	O	the
39	236	240	O	brain
NULL

EMSAM	40	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	34
In the CNS, MAO-A and MAO-B play important roles in the catabolism of neurotransmitter amines such as norepinephrine, dopamine, and serotonin, as well as neuromodulators such as phenylethylamine.
1	0	1	O	In
2	3	5	O	the
3	7	9	O	CNS
4	10	10	O	,
5	12	14	O	MAO
6	16	16	O	A
7	18	20	O	and
8	22	24	O	MAO
9	26	26	O	B
10	28	31	O	play
11	33	41	O	important
12	43	47	O	roles
13	49	50	O	in
14	52	54	O	the
15	56	65	O	catabolism
16	67	68	O	of
17	70	85	O	neurotransmitter
18	87	92	O	amines
19	94	97	O	such
20	99	100	O	as
21	102	115	O	norepinephrine
22	116	116	O	,
23	118	125	O	dopamine
24	126	126	O	,
25	128	130	O	and
26	132	140	O	serotonin
27	141	141	O	,
28	143	144	O	as
29	146	149	O	well
30	151	152	O	as
31	154	168	O	neuromodulators
32	170	173	O	such
33	175	176	O	as
34	178	193	O	phenylethylamine
NULL

EMSAM	41	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	21
In in vitro receptor binding assays, selegiline has demonstrated affinity for the human recombinant adrenergic A2B receptor (Ki = 0.3mcM).
1	0	1	O	In
2	3	4	O	in
3	6	10	O	vitro
4	12	19	O	receptor
5	21	27	O	binding
6	29	34	O	assays
7	35	35	O	,
8	37	46	O	XXXXXXXX
9	48	50	O	has
10	52	63	O	demonstrated
11	65	72	O	affinity
12	74	76	O	for
13	78	80	O	the
14	82	86	O	human
15	88	98	O	recombinant
16	100	109	O	adrenergic
17	111	113	O	A2B
18	115	122	O	receptor
19	125	126	O	Ki
20	128	128	O	=
21	130	135	O	0.3mcM
NULL

EMSAM	42	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
No affinity [Ki greater than 10mcM] was noted at dopamine receptors, adrenergic B3, glutamate, muscarinic M1-M5, nicotinic, or rolipram receptor/sites.
1	0	1	O	No
2	3	10	O	affinity
3	13	14	O	Ki
4	16	22	O	greater
5	24	27	O	than
6	29	33	O	10mcM
7	36	38	O	was
8	40	44	O	noted
9	46	47	O	at
10	49	56	O	dopamine
11	58	66	O	receptors
12	67	67	O	,
13	69	78	O	adrenergic
14	80	81	O	B3
15	82	82	O	,
16	84	92	O	glutamate
17	93	93	O	,
18	95	104	O	muscarinic
19	106	107	O	M1
20	109	110	O	M5
21	111	111	O	,
22	113	121	O	nicotinic
23	122	122	O	,
24	124	125	O	or
25	127	134	O	rolipram
26	136	143	O	receptor
27	144	144	O	/
28	145	149	O	sites
NULL

EMSAM	43	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	19
Selegiline (the drug substance of EMSAM) is an irreversible inhibitor of monoamine oxidase (MAO), a ubiquitous intracellular enzyme.
1	0	9	O	XXXXXXXX
2	12	14	O	the
3	16	19	O	drug
4	21	29	O	substance
5	31	32	O	of
6	34	38	O	XXXXXXXX
7	41	42	O	is
8	44	45	O	an
9	47	58	O	irreversible
10	60	68	O	inhibitor
11	70	71	O	of
12	73	81	O	monoamine
13	83	89	O	oxidase
14	92	94	O	MAO
15	96	96	O	,
16	98	98	O	a
17	100	109	O	ubiquitous
18	111	123	O	intracellular
19	125	130	O	enzyme
NULL

EMSAM	45	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	26
Selegiline shows greater affinity for MAO-B; however, as selegiline concentration increases, this selectivity is lost with resulting dose-related inhibition of MAO-A.
1	0	9	O	XXXXXXXX
2	11	15	O	shows
3	17	23	O	greater
4	25	32	O	affinity
5	34	36	O	for
6	38	40	O	MAO
7	42	42	O	B
8	45	51	O	however
9	52	52	O	,
10	54	55	O	as
11	57	66	O	XXXXXXXX
12	68	80	O	concentration
13	82	90	O	increases
14	91	91	O	,
15	93	96	O	this
16	98	108	O	selectivity
17	110	111	O	is
18	113	116	O	lost
19	118	121	O	with
20	123	131	O	resulting
21	133	136	O	dose
22	138	144	O	related
23	146	155	O	inhibition
24	157	158	O	of
25	160	162	O	MAO
26	164	164	O	A
NULL

EMSAM	46	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	14
Intestinal MAO is predominantly type A, while in the brain both isoenzymes exist.
1	0	9	O	Intestinal
2	11	13	O	MAO
3	15	16	O	is
4	18	30	O	predominantly
5	32	35	O	type
6	37	37	O	A
7	38	38	O	,
8	40	44	O	while
9	46	47	O	in
10	49	51	O	the
11	53	57	O	brain
12	59	62	O	both
13	64	73	O	isoenzymes
14	75	79	O	exist
NULL

EMSAM	47	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	17
MAO plays a vital physiological role in terminating the biological activity of both endogenous and exogenous amines.
1	0	2	O	MAO
2	4	8	O	plays
3	10	10	O	a
4	12	16	O	vital
5	18	30	O	physiological
6	32	35	O	role
7	37	38	O	in
8	40	50	O	terminating
9	52	54	O	the
10	56	65	O	biological
11	67	74	O	activity
12	76	77	O	of
13	79	82	O	both
14	84	93	O	endogenous
15	95	97	O	and
16	99	107	O	exogenous
17	109	114	O	amines
NULL

EMSAM	48	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	32
In addition to their role in the catabolism of monoamines in the CNS, MAOs are also important in the catabolism of exogenous amines found in a variety of foods and drugs.
1	0	1	O	In
2	3	10	O	addition
3	12	13	O	to
4	15	19	O	their
5	21	24	O	role
6	26	27	O	in
7	29	31	O	the
8	33	42	O	catabolism
9	44	45	O	of
10	47	56	O	monoamines
11	58	59	O	in
12	61	63	O	the
13	65	67	O	CNS
14	68	68	O	,
15	70	73	O	MAOs
16	75	77	O	are
17	79	82	O	also
18	84	92	O	important
19	94	95	O	in
20	97	99	O	the
21	101	110	O	catabolism
22	112	113	O	of
23	115	123	O	exogenous
24	125	130	O	amines
25	132	136	O	found
26	138	139	O	in
27	141	141	O	a
28	143	149	O	variety
29	151	152	O	of
30	154	158	O	foods
31	160	162	O	and
32	164	168	O	drugs
NULL

EMSAM	49	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	36
MAO in the gastrointestinal tract (primarily type A) provides protection from exogenous amines with vasopressor actions, such as tyramine, which if absorbed intact can cause a hypertensive crisis, the so-called "cheese reaction".
1	0	2	O	MAO
2	4	5	O	in
3	7	9	O	the
4	11	26	O	gastrointestinal
5	28	32	O	tract
6	35	43	O	primarily
7	45	48	O	type
8	50	50	O	A
9	53	60	O	provides
10	62	71	O	protection
11	73	76	O	from
12	78	86	O	exogenous
13	88	93	O	amines
14	95	98	O	with
15	100	110	O	vasopressor
16	112	118	O	actions
17	119	119	O	,
18	121	124	O	such
19	126	127	O	as
20	129	136	O	tyramine
21	137	137	O	,
22	139	143	O	which
23	145	146	O	if
24	148	155	O	absorbed
25	157	162	O	intact
26	164	166	O	can
27	168	172	O	cause
28	174	174	O	a
29	176	187	O	hypertensive
30	189	194	O	crisis
31	195	195	O	,
32	197	199	O	the
33	201	202	O	so
34	204	209	O	called
35	211	217	O	"cheese
36	219	227	O	reaction"
NULL

EMSAM	50	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	31
If a large amount of tyramine is absorbed systemically, it is taken up by adrenergic neurons and causes norepinephrine release from neuronal storage sites with resultant elevation of blood pressure.
1	0	1	O	If
2	3	3	O	a
3	5	9	O	large
4	11	16	O	amount
5	18	19	O	of
6	21	28	O	tyramine
7	30	31	O	is
8	33	40	O	absorbed
9	42	53	O	systemically
10	54	54	O	,
11	56	57	O	it
12	59	60	O	is
13	62	66	O	taken
14	68	69	O	up
15	71	72	O	by
16	74	83	O	adrenergic
17	85	91	O	neurons
18	93	95	O	and
19	97	102	O	causes
20	104	117	O	norepinephrine
21	119	125	O	release
22	127	130	O	from
23	132	139	O	neuronal
24	141	147	O	storage
25	149	153	O	sites
26	155	158	O	with
27	160	168	O	resultant
28	170	178	O	elevation
29	180	181	O	of
30	183	187	O	blood
31	189	196	O	pressure
NULL

EMSAM	51	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	27
While most foods contain negligible amounts or no tyramine, certain food products may contain large amounts of tyramine that represent a potential risk for hypertensive crisis.
1	0	4	O	While
2	6	9	O	most
3	11	15	O	foods
4	17	23	O	contain
5	25	34	O	negligible
6	36	42	O	amounts
7	44	45	O	or
8	47	48	O	no
9	50	57	O	tyramine
10	58	58	O	,
11	60	66	O	certain
12	68	71	O	food
13	73	80	O	products
14	82	84	O	may
15	86	92	O	contain
16	94	98	O	large
17	100	106	O	amounts
18	108	109	O	of
19	111	118	O	tyramine
20	120	123	O	that
21	125	133	O	represent
22	135	135	O	a
23	137	145	O	potential
24	147	150	O	risk
25	152	154	O	for
26	156	167	O	hypertensive
27	169	174	O	crisis
NULL

EMSAM	52	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	25
To define the risk of hypertensive crises with use of EMSAM, several Phase I tyramine challenge studies were conducted both with and without food.
1	0	1	O	To
2	3	8	O	define
3	10	12	O	the
4	14	17	O	risk
5	19	20	O	of
6	22	33	O	hypertensive
7	35	40	O	crises
8	42	45	O	with
9	47	49	O	use
10	51	52	O	of
11	54	58	O	XXXXXXXX
12	59	59	O	,
13	61	67	O	several
14	69	73	O	Phase
15	75	75	O	I
16	77	84	O	tyramine
17	86	94	O	challenge
18	96	102	O	studies
19	104	107	O	were
20	109	117	O	conducted
21	119	122	O	both
22	124	127	O	with
23	129	131	O	and
24	133	139	O	without
25	141	144	O	food
NULL

EMSAM	53	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	60
Fourteen tyramine challenge studies including 214 healthy subjects (age range 18 to 65; 31 subjects greater than 50 years of age) were conducted to determine the pressor effects of oral tyramine with concurrent EMSAM treatment (6mg per 24 hours to 12mg per 24 hours), measured as the dose of tyramine required to raise systolic blood pressure by 30mmHg (TYR30).
1	0	7	O	Fourteen
2	9	16	O	tyramine
3	18	26	O	challenge
4	28	34	O	studies
5	36	44	O	including
6	46	48	O	214
7	50	56	O	healthy
8	58	65	O	subjects
9	68	70	O	age
10	72	76	O	range
11	78	79	O	18
12	81	82	O	to
13	84	85	O	65
14	88	89	O	31
15	91	98	O	subjects
16	100	106	O	greater
17	108	111	O	than
18	113	114	O	50
19	116	120	O	years
20	122	123	O	of
21	125	127	O	age
22	130	133	O	were
23	135	143	O	conducted
24	145	146	O	to
25	148	156	O	determine
26	158	160	O	the
27	162	168	O	pressor
28	170	176	O	effects
29	178	179	O	of
30	181	184	O	oral
31	186	193	O	tyramine
32	195	198	O	with
33	200	209	O	concurrent
34	211	215	O	XXXXXXXX
35	217	225	O	treatment
36	228	230	O	6mg
37	232	234	O	per
38	236	237	O	24
39	239	243	O	hours
40	245	246	O	to
41	248	251	O	12mg
42	253	255	O	per
43	257	258	O	24
44	260	264	O	hours
45	266	266	O	,
46	268	275	O	measured
47	277	278	O	as
48	280	282	O	the
49	284	287	O	dose
50	289	290	O	of
51	292	299	O	tyramine
52	301	308	O	required
53	310	311	O	to
54	313	317	O	raise
55	319	326	O	systolic
56	328	332	O	blood
57	334	341	O	pressure
58	343	344	O	by
59	346	351	O	30mmHg
60	354	358	O	TYR30
NULL

EMSAM	54	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	10
Studies were conducted with and without concomitant administration of food.
1	0	6	O	Studies
2	8	11	O	were
3	13	21	O	conducted
4	23	26	O	with
5	28	30	O	and
6	32	38	O	without
7	40	50	O	concomitant
8	52	65	O	administration
9	67	68	O	of
10	70	73	O	food
NULL

EMSAM	55	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	18
Studies conducted with food are most relevant to clinical practice since tyramine typically will be consumed in food.
1	0	6	O	Studies
2	8	16	O	conducted
3	18	21	O	with
4	23	26	O	food
5	28	30	O	are
6	32	35	O	most
7	37	44	O	relevant
8	46	47	O	to
9	49	56	O	clinical
10	58	65	O	practice
11	67	71	O	since
12	73	80	O	tyramine
13	82	90	O	typically
14	92	95	O	will
15	97	98	O	be
16	100	107	O	consumed
17	109	110	O	in
18	112	115	O	food
NULL

EMSAM	56	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	13
A high-tyramine meal is considered to contain up to 40mg of tyramine.
1	0	0	O	A
2	2	5	O	high
3	7	14	O	tyramine
4	16	19	O	meal
5	21	22	O	is
6	24	33	O	considered
7	35	36	O	to
8	38	44	O	contain
9	46	47	O	up
10	49	50	O	to
11	52	55	O	40mg
12	57	58	O	of
13	60	67	O	tyramine
NULL

EMSAM	57	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	30
One study using a crossover design in 13 subjects investigated tyramine pressor doses (TYR30) after administration of EMSAM 6mg per 24 hours and oral selegiline (5mg twice daily) for 9days.
1	0	2	O	One
2	4	8	O	study
3	10	14	O	using
4	16	16	O	a
5	18	26	O	crossover
6	28	33	O	design
7	35	36	O	in
8	38	39	O	13
9	41	48	O	subjects
10	50	61	O	investigated
11	63	70	O	tyramine
12	72	78	O	pressor
13	80	84	O	doses
14	87	91	O	TYR30
15	94	98	O	after
16	100	113	O	administration
17	115	116	O	of
18	118	122	O	XXXXXXXX
19	124	126	O	6mg
20	128	130	O	per
21	132	133	O	24
22	135	139	O	hours
23	141	143	O	and
24	145	148	O	oral
25	150	159	O	XXXXXXXX
26	162	164	O	5mg
27	166	170	O	twice
28	172	176	O	daily
29	179	181	O	for
30	183	187	O	9days
NULL

EMSAM	58	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	24
Mean pressor doses (TYR30) of tyramine capsules administered without food were 338mg and 385mg in subjects treated with EMSAM and oral selegiline, respectively.
1	0	3	O	Mean
2	5	11	O	pressor
3	13	17	O	doses
4	20	24	O	TYR30
5	27	28	O	of
6	30	37	O	tyramine
7	39	46	O	capsules
8	48	59	O	administered
9	61	67	O	without
10	69	72	O	food
11	74	77	O	were
12	79	83	O	338mg
13	85	87	O	and
14	89	93	O	385mg
15	95	96	O	in
16	98	105	O	subjects
17	107	113	O	treated
18	115	118	O	with
19	120	124	O	XXXXXXXX
20	126	128	O	and
21	130	133	O	oral
22	135	144	O	XXXXXXXX
23	145	145	O	,
24	147	158	O	respectively
NULL

EMSAM	59	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	29
Another study using a crossover design in 10 subjects investigated tyramine pressor doses after administration of EMSAM 6mg per 24 hours or tranylcypromine 30mg per day for 10 days.
1	0	6	O	Another
2	8	12	O	study
3	14	18	O	using
4	20	20	O	a
5	22	30	O	crossover
6	32	37	O	design
7	39	40	O	in
8	42	43	O	10
9	45	52	O	subjects
10	54	65	O	investigated
11	67	74	O	tyramine
12	76	82	O	pressor
13	84	88	O	doses
14	90	94	O	after
15	96	109	O	administration
16	111	112	O	of
17	114	118	O	XXXXXXXX
18	120	122	O	6mg
19	124	126	O	per
20	128	129	O	24
21	131	135	O	hours
22	137	138	O	or
23	140	154	O	tranylcypromine
24	156	159	O	30mg
25	161	163	O	per
26	165	167	O	day
27	169	171	O	for
28	173	174	O	10
29	176	179	O	days
NULL

EMSAM	60	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
Mean pressor doses (TYR30) of tyramine capsules administered without food were 270mg in subjects treated with EMSAM 6mg per 24 hours and 10mg in subjects treated with tranylcypromine.
1	0	3	O	Mean
2	5	11	O	pressor
3	13	17	O	doses
4	20	24	O	TYR30
5	27	28	O	of
6	30	37	O	tyramine
7	39	46	O	capsules
8	48	59	O	administered
9	61	67	O	without
10	69	72	O	food
11	74	77	O	were
12	79	83	O	270mg
13	85	86	O	in
14	88	95	O	subjects
15	97	103	O	treated
16	105	108	O	with
17	110	114	O	XXXXXXXX
18	116	118	O	6mg
19	120	122	O	per
20	124	125	O	24
21	127	131	O	hours
22	133	135	O	and
23	137	140	O	10mg
24	142	143	O	in
25	145	152	O	subjects
26	154	160	O	treated
27	162	165	O	with
28	167	181	O	tranylcypromine
NULL

EMSAM	61	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	14
In a third crossover study, tyramine without food was administered to 12 subjects.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	third
4	11	19	O	crossover
5	21	25	O	study
6	26	26	O	,
7	28	35	O	tyramine
8	37	43	O	without
9	45	48	O	food
10	50	52	O	was
11	54	65	O	administered
12	67	68	O	to
13	70	71	O	12
14	73	80	O	subjects
NULL

EMSAM	62	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	25
The mean tyramine pressor doses (TYR30) after administration of EMSAM 6mg per 24 hours for 9 and 33 days were 292mg and 204mg, respectively.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	tyramine
4	18	24	O	pressor
5	26	30	O	doses
6	33	37	O	TYR30
7	40	44	O	after
8	46	59	O	administration
9	61	62	O	of
10	64	68	O	XXXXXXXX
11	70	72	O	6mg
12	74	76	O	per
13	78	79	O	24
14	81	85	O	hours
15	87	89	O	for
16	91	91	O	9
17	93	95	O	and
18	97	98	O	33
19	100	103	O	days
20	105	108	O	were
21	110	114	O	292mg
22	116	118	O	and
23	120	124	O	204mg
24	125	125	O	,
25	127	138	O	respectively
NULL

EMSAM	63	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	14
The lowest pressor dose was 50mg in one subject in the 33-day group.
1	0	2	O	The
2	4	9	O	lowest
3	11	17	O	pressor
4	19	22	O	dose
5	24	26	O	was
6	28	31	O	50mg
7	33	34	O	in
8	36	38	O	one
9	40	46	O	subject
10	48	49	O	in
11	51	53	O	the
12	55	56	O	33
13	58	60	O	day
14	62	66	O	group
NULL

EMSAM	64	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	18
Tyramine pressor doses were also studied in 11 subjects after extended treatment with EMSAM 12mg per 24 hours.
1	0	7	O	Tyramine
2	9	15	O	pressor
3	17	21	O	doses
4	23	26	O	were
5	28	31	O	also
6	33	39	O	studied
7	41	42	O	in
8	44	45	O	11
9	47	54	O	subjects
10	56	60	O	after
11	62	69	O	extended
12	71	79	O	treatment
13	81	84	O	with
14	86	90	O	XXXXXXXX
15	92	95	O	12mg
16	97	99	O	per
17	101	102	O	24
18	104	108	O	hours
NULL

EMSAM	65	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
At 30, 60, and 90 days, the mean pressor doses (TYR30) of tyramine administered without food were 95mg, 72mg, and 88mg, respectively.
1	0	1	O	At
2	3	4	O	30
3	5	5	O	,
4	7	8	O	60
5	9	9	O	,
6	11	13	O	and
7	15	16	O	90
8	18	21	O	days
9	22	22	O	,
10	24	26	O	the
11	28	31	O	mean
12	33	39	O	pressor
13	41	45	O	doses
14	48	52	O	TYR30
15	55	56	O	of
16	58	65	O	tyramine
17	67	78	O	administered
18	80	86	O	without
19	88	91	O	food
20	93	96	O	were
21	98	101	O	95mg
22	102	102	O	,
23	104	107	O	72mg
24	108	108	O	,
25	110	112	O	and
26	114	117	O	88mg
27	118	118	O	,
28	120	131	O	respectively
NULL

EMSAM	66	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	21
The lowest pressor dose without food was 25mg in three subjects at day 30 while on EMSAM 12mg per 24 hours.
1	0	2	O	The
2	4	9	O	lowest
3	11	17	O	pressor
4	19	22	O	dose
5	24	30	O	without
6	32	35	O	food
7	37	39	O	was
8	41	44	O	25mg
9	46	47	O	in
10	49	53	O	three
11	55	62	O	subjects
12	64	65	O	at
13	67	69	O	day
14	71	72	O	30
15	74	78	O	while
16	80	81	O	on
17	83	87	O	XXXXXXXX
18	89	92	O	12mg
19	94	96	O	per
20	98	99	O	24
21	101	105	O	hours
NULL

EMSAM	67	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	47
Eight subjects from this study, with a mean tyramine pressor dose of 64mg at 90 days, were subsequently administered tyramine with food, resulting in a mean pressor dose of 172mg (2.7 times the mean pressor dose observed without food, p less than 0.003).
1	0	4	O	Eight
2	6	13	O	subjects
3	15	18	O	from
4	20	23	O	this
5	25	29	O	study
6	30	30	O	,
7	32	35	O	with
8	37	37	O	a
9	39	42	O	mean
10	44	51	O	tyramine
11	53	59	O	pressor
12	61	64	O	dose
13	66	67	O	of
14	69	72	O	64mg
15	74	75	O	at
16	77	78	O	90
17	80	83	O	days
18	84	84	O	,
19	86	89	O	were
20	91	102	O	subsequently
21	104	115	O	administered
22	117	124	O	tyramine
23	126	129	O	with
24	131	134	O	food
25	135	135	O	,
26	137	145	O	resulting
27	147	148	O	in
28	150	150	O	a
29	152	155	O	mean
30	157	163	O	pressor
31	165	168	O	dose
32	170	171	O	of
33	173	177	O	172mg
34	180	182	O	2.7
35	184	188	O	times
36	190	192	O	the
37	194	197	O	mean
38	199	205	O	pressor
39	207	210	O	dose
40	212	219	O	observed
41	221	227	O	without
42	229	232	O	food
43	233	233	O	,
44	235	235	O	p
45	237	240	O	less
46	242	245	O	than
47	247	251	O	0.003
NULL

EMSAM	68	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	46
With the exception of one study (N = 153), the Phase III clinical development program was conducted without requiring a modified diet (N = 2,553, 1,606 at 6mg per 24 hours, and 947 at 9mg per 24 hours or 12mg per 24 hours).
1	0	3	O	With
2	5	7	O	the
3	9	17	O	exception
4	19	20	O	of
5	22	24	O	one
6	26	30	O	study
7	33	33	O	N
8	35	35	O	=
9	37	39	O	153
10	41	41	O	,
11	43	45	O	the
12	47	51	O	Phase
13	53	55	O	III
14	57	64	O	clinical
15	66	76	O	development
16	78	84	O	program
17	86	88	O	was
18	90	98	O	conducted
19	100	106	O	without
20	108	116	O	requiring
21	118	118	O	a
22	120	127	O	modified
23	129	132	O	diet
24	135	135	O	N
25	137	137	O	=
26	139	143	O	2,553
27	144	144	O	,
28	146	150	O	1,606
29	152	153	O	at
30	155	157	O	6mg
31	159	161	O	per
32	163	164	O	24
33	166	170	O	hours
34	171	171	O	,
35	173	175	O	and
36	177	179	O	947
37	181	182	O	at
38	184	186	O	9mg
39	188	190	O	per
40	192	193	O	24
41	195	199	O	hours
42	201	202	O	or
43	204	207	O	12mg
44	209	211	O	per
45	213	214	O	24
46	216	220	O	hours
NULL

EMSAM	69	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	10
No hypertensive crises were reported in any patient receiving EMSAM.
1	0	1	O	No
2	3	14	O	hypertensive
3	16	21	O	crises
4	23	26	O	were
5	28	35	O	reported
6	37	38	O	in
7	40	42	O	any
8	44	50	O	patient
9	52	60	O	receiving
10	62	66	O	XXXXXXXX
NULL

EMSAM	70	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	23
Overall, the data for EMSAM 6mg per 24 hours support a recommendation that a modified diet is not required at this dose.
1	0	6	O	Overall
2	7	7	O	,
3	9	11	O	the
4	13	16	O	data
5	18	20	O	for
6	22	26	O	XXXXXXXX
7	28	30	O	6mg
8	32	34	O	per
9	36	37	O	24
10	39	43	O	hours
11	45	51	O	support
12	53	53	O	a
13	55	68	O	recommendation
14	70	73	O	that
15	75	75	O	a
16	77	84	O	modified
17	86	89	O	diet
18	91	92	O	is
19	94	96	O	not
20	98	105	O	required
21	107	108	O	at
22	110	113	O	this
23	115	118	O	dose
NULL

EMSAM	72	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
Following dermal application of EMSAM to humans, 25% to 30% of theselegilinecontent on average is delivered systemically over 24 hours (range approximately 10% to 40%).
1	0	8	O	Following
2	10	15	O	dermal
3	17	27	O	application
4	29	30	O	of
5	32	36	O	XXXXXXXX
6	38	39	O	to
7	41	46	O	humans
8	47	47	O	,
9	49	51	O	25%
10	53	54	O	to
11	56	58	O	30%
12	60	61	O	of
13	63	65	O	the
14	66	75	O	XXXXXXXX
15	76	82	O	content
16	84	85	O	on
17	87	93	O	average
18	95	96	O	is
19	98	106	O	delivered
20	108	119	O	systemically
21	121	124	O	over
22	126	127	O	24
23	129	133	O	hours
24	136	140	O	range
25	142	154	O	approximately
26	156	158	O	10%
27	160	161	O	to
28	163	165	O	40%
NULL

EMSAM	73	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	24
Consequently, the degree of drug absorption may be 1/3 higher than the average amounts of 6mg to 12mg per 24 hours.
1	0	11	O	Consequently
2	12	12	O	,
3	14	16	O	the
4	18	23	O	degree
5	25	26	O	of
6	28	31	O	drug
7	33	42	O	absorption
8	44	46	O	may
9	48	49	O	be
10	51	51	O	1
11	52	52	O	/
12	53	53	O	3
13	55	60	O	higher
14	62	65	O	than
15	67	69	O	the
16	71	77	O	average
17	79	85	O	amounts
18	87	88	O	of
19	90	92	O	6mg
20	94	95	O	to
21	97	100	O	12mg
22	102	104	O	per
23	106	107	O	24
24	109	113	O	hours
NULL

EMSAM	74	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
Transdermal dosing results in significantly higher exposure to selegiline with significantly lower exposure for all metabolites when compared to oral dosing, due to extensive first-pass metabolism.
1	0	10	O	Transdermal
2	12	17	O	dosing
3	19	25	O	results
4	27	28	O	in
5	30	42	O	significantly
6	44	49	O	higher
7	51	58	O	exposure
8	60	61	O	to
9	63	72	O	XXXXXXXX
10	74	77	O	with
11	79	91	O	significantly
12	93	97	O	lower
13	99	106	O	exposure
14	108	110	O	for
15	112	114	O	all
16	116	126	O	metabolites
17	128	131	O	when
18	133	140	O	compared
19	142	143	O	to
20	145	148	O	oral
21	150	155	O	dosing
22	156	156	O	,
23	158	160	O	due
24	162	163	O	to
25	165	173	O	extensive
26	175	179	O	first
27	181	184	O	pass
28	186	195	O	metabolism
NULL

EMSAM	75	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	51
In a 10-day study with daily administration of EMSAM to healthy male and female volunteers, steady-state selegiline plasma concentrations indicated selegiline concentration-time profiles were comparable when EMSAM is applied to the upper torso or upper thigh, and absorption from these two sites of administration was equivalent.
1	0	1	O	In
2	3	3	O	a
3	5	6	O	10
4	8	10	O	day
5	12	16	O	study
6	18	21	O	with
7	23	27	O	daily
8	29	42	O	administration
9	44	45	O	of
10	47	51	O	XXXXXXXX
11	53	54	O	to
12	56	62	O	healthy
13	64	67	O	male
14	69	71	O	and
15	73	78	O	female
16	80	89	O	volunteers
17	90	90	O	,
18	92	97	O	steady
19	99	103	O	state
20	105	114	O	XXXXXXXX
21	116	121	O	plasma
22	123	136	O	concentrations
23	138	146	O	indicated
24	148	157	O	XXXXXXXX
25	159	171	O	concentration
26	173	176	O	time
27	178	185	O	profiles
28	187	190	O	were
29	192	201	O	comparable
30	203	206	O	when
31	208	212	O	XXXXXXXX
32	214	215	O	is
33	217	223	O	applied
34	225	226	O	to
35	228	230	O	the
36	232	236	O	upper
37	238	242	O	torso
38	244	245	O	or
39	247	251	O	upper
40	253	257	O	thigh
41	258	258	O	,
42	260	262	O	and
43	264	273	O	absorption
44	275	278	O	from
45	280	284	O	these
46	286	288	O	two
47	290	294	O	sites
48	296	297	O	of
49	299	312	O	administration
50	314	316	O	was
51	318	327	O	equivalent
NULL

EMSAM	76	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	18
Following dermal application of radiolabeled selegiline to laboratory animals, selegiline is rapidly distributed to all body tissues.
1	0	8	O	Following
2	10	15	O	dermal
3	17	27	O	application
4	29	30	O	of
5	32	43	O	radiolabeled
6	45	54	O	XXXXXXXX
7	56	57	O	to
8	59	68	O	laboratory
9	70	76	O	animals
10	77	77	O	,
11	79	88	O	XXXXXXXX
12	90	91	O	is
13	93	99	O	rapidly
14	101	111	O	distributed
15	113	114	O	to
16	116	118	O	all
17	120	123	O	body
18	125	131	O	tissues
NULL

EMSAM	77	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	7
Selegiline rapidly penetrates the blood-brain barrier.
1	0	9	O	XXXXXXXX
2	11	17	O	rapidly
3	19	28	O	penetrates
4	30	32	O	the
5	34	38	O	blood
6	40	44	O	brain
7	46	52	O	barrier
NULL

EMSAM	78	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	20
In humans, selegiline is approximately 90% bound to plasma protein over a 2 to 500ng per mL concentration range.
1	0	1	O	In
2	3	8	O	humans
3	9	9	O	,
4	11	20	O	XXXXXXXX
5	22	23	O	is
6	25	37	O	approximately
7	39	41	O	90%
8	43	47	O	bound
9	49	50	O	to
10	52	57	O	plasma
11	59	65	O	protein
12	67	70	O	over
13	72	72	O	a
14	74	74	O	2
15	76	77	O	to
16	79	83	O	500ng
17	85	87	O	per
18	89	90	O	mL
19	92	104	O	concentration
20	106	110	O	range
NULL

EMSAM	79	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	7
Selegiline does not accumulate in the skin.
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	29	O	accumulate
5	31	32	O	in
6	34	36	O	the
7	38	41	O	skin
NULL

EMSAM	80	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	19
Transdermally absorbed selegiline (via EMSAM) is not metabolized in human skin and does not undergo extensive first-pass metabolism.
1	0	12	O	Transdermally
2	14	21	O	absorbed
3	23	32	O	XXXXXXXX
4	35	37	O	via
5	39	43	O	XXXXXXXX
6	46	47	O	is
7	49	51	O	not
8	53	63	O	metabolized
9	65	66	O	in
10	68	72	O	human
11	74	77	O	skin
12	79	81	O	and
13	83	86	O	does
14	88	90	O	not
15	92	98	O	undergo
16	100	108	O	extensive
17	110	114	O	first
18	116	119	O	pass
19	121	130	O	metabolism
NULL

EMSAM	81	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	10
Selegiline is extensively metabolized by several CYP450-dependent enzyme systems.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	39	O	by
6	41	47	O	several
7	49	54	O	CYP450
8	56	64	O	dependent
9	66	71	O	enzyme
10	73	79	O	systems
NULL

EMSAM	82	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	20
Selegiline is metabolized initially via N-dealkylation or N-depropargylation to form N-desmethylselegiline or R(-)-methamphetamine, respectively.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	34	O	initially
5	36	38	O	via
6	40	40	O	N
7	42	53	O	dealkylation
8	55	56	O	or
9	58	58	O	N
10	60	75	O	depropargylation
11	77	78	O	to
12	80	83	O	form
13	85	85	O	N
14	87	95	O	desmethyl
15	96	105	O	XXXXXXXX
16	107	108	O	or
17	110	110	O	R
18	115	129	O	methamphetamine
19	130	130	O	,
20	132	143	O	respectively
NULL

EMSAM	83	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	11
Both of these metabolites can be further metabolized to R(-)-amphetamine.
1	0	3	O	Both
2	5	6	O	of
3	8	12	O	these
4	14	24	O	metabolites
5	26	28	O	can
6	30	31	O	be
7	33	39	O	further
8	41	51	O	metabolized
9	53	54	O	to
10	56	56	O	R
11	61	71	O	amphetamine
NULL

EMSAM	84	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	23
These metabolites are all levorotatory (l-)enantiomers and no racemic biotransformation to the dextrorotatory form (i.e., S(+)-amphetamine or S(+)-methamphetamine) occurs.
1	0	4	O	These
2	6	16	O	metabolites
3	18	20	O	are
4	22	24	O	all
5	26	37	O	levorotatory
6	40	40	O	l
7	43	53	O	enantiomers
8	55	57	O	and
9	59	60	O	no
10	62	68	O	racemic
11	70	86	O	biotransformation
12	88	89	O	to
13	91	93	O	the
14	95	108	O	dextrorotatory
15	110	113	O	form
16	116	118	O	i.e
17	120	120	O	,
18	122	124	O	S(+
19	127	137	O	amphetamine
20	139	140	O	or
21	142	144	O	S(+
22	147	161	O	methamphetamine
23	164	169	O	occurs
NULL

EMSAM	85	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	11
R(-)-methamphetamine and R(-)-amphetamine are mainly excreted unchanged in urine.
1	0	0	O	R
2	5	19	O	methamphetamine
3	21	23	O	and
4	25	25	O	R
5	30	40	O	amphetamine
6	42	44	O	are
7	46	51	O	mainly
8	53	60	O	excreted
9	62	70	O	unchanged
10	72	73	O	in
11	75	79	O	urine
NULL

EMSAM	86	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	23
In vitro studies utilizing human liver microsomes demonstrated that several CYP450-dependent enzymes are involved in the metabolism of selegiline and its metabolites.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	25	O	utilizing
5	27	31	O	human
6	33	37	O	liver
7	39	48	O	microsomes
8	50	61	O	demonstrated
9	63	66	O	that
10	68	74	O	several
11	76	81	O	CYP450
12	83	91	O	dependent
13	93	99	O	enzymes
14	101	103	O	are
15	105	112	O	involved
16	114	115	O	in
17	117	119	O	the
18	121	130	O	metabolism
19	132	133	O	of
20	135	144	O	XXXXXXXX
21	146	148	O	and
22	150	152	O	its
23	154	164	O	metabolites
NULL

EMSAM	87	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	29
CYP2B6, CYP2C9, CYP3A4 and CYP3A5 appeared to be the major contributing enzymes in the formation of R(-)-methamphetamine from selegiline, with CYP2A6 having a minor role.
1	0	5	O	CYP2B6
2	6	6	O	,
3	8	13	O	CYP2C9
4	14	14	O	,
5	16	21	O	CYP3A4
6	23	25	O	and
7	27	32	O	CYP3A5
8	34	41	O	appeared
9	43	44	O	to
10	46	47	O	be
11	49	51	O	the
12	53	57	O	major
13	59	70	O	contributing
14	72	78	O	enzymes
15	80	81	O	in
16	83	85	O	the
17	87	95	O	formation
18	97	98	O	of
19	100	100	O	R
20	105	119	O	methamphetamine
21	121	124	O	from
22	126	135	O	XXXXXXXX
23	136	136	O	,
24	138	141	O	with
25	143	148	O	CYP2A6
26	150	155	O	having
27	157	157	O	a
28	159	163	O	minor
29	165	168	O	role
NULL

EMSAM	88	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	20
CYP2A6, CYP2B6, CYP3A4 and CYP3A5 appeared to contribute to the formation of R(-)-amphetamine from N-desmethylselegiline.
1	0	5	O	CYP2A6
2	6	6	O	,
3	8	13	O	CYP2B6
4	14	14	O	,
5	16	21	O	CYP3A4
6	23	25	O	and
7	27	32	O	CYP3A5
8	34	41	O	appeared
9	43	44	O	to
10	46	55	O	contribute
11	57	58	O	to
12	60	62	O	the
13	64	72	O	formation
14	74	75	O	of
15	77	77	O	R
16	82	92	O	amphetamine
17	94	97	O	from
18	99	99	O	N
19	101	109	O	desmethyl
20	110	119	O	XXXXXXXX
NULL

EMSAM	89	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	24
The potential for selegiline or N-desmethylselegiline to inhibit individual CYP450-dependent enzyme pathways was also examined in vitro with human liver microsomes.
1	0	2	O	The
2	4	12	O	potential
3	14	16	O	for
4	18	27	O	XXXXXXXX
5	29	30	O	or
6	32	32	O	N
7	34	42	O	desmethyl
8	43	52	O	XXXXXXXX
9	54	55	O	to
10	57	63	O	inhibit
11	65	74	O	individual
12	76	81	O	CYP450
13	83	91	O	dependent
14	93	98	O	enzyme
15	100	107	O	pathways
16	109	111	O	was
17	113	116	O	also
18	118	125	O	examined
19	127	128	O	in
20	130	134	O	vitro
21	136	139	O	with
22	141	145	O	human
23	147	151	O	liver
24	153	162	O	microsomes
NULL

EMSAM	90	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	12
Each substrate was examined over a concentration range of 2.5 to 250mcM.
1	0	3	O	Each
2	5	13	O	substrate
3	15	17	O	was
4	19	26	O	examined
5	28	31	O	over
6	33	33	O	a
7	35	47	O	concentration
8	49	53	O	range
9	55	56	O	of
10	58	60	O	2.5
11	62	63	O	to
12	65	70	O	250mcM
NULL

EMSAM	91	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	30
Consistent with competitive inhibition, both selegiline and N-desmethylselegiline caused a concentration dependent inhibition of CYP2D6 at 10 to 250mcM and CYP3A4 and CYP3A5 at 25 to 250mcM.
1	0	9	O	Consistent
2	11	14	O	with
3	16	26	O	competitive
4	28	37	O	inhibition
5	38	38	O	,
6	40	43	O	both
7	45	54	O	XXXXXXXX
8	56	58	O	and
9	60	60	O	N
10	62	70	O	desmethyl
11	71	80	O	XXXXXXXX
12	82	87	O	caused
13	89	89	O	a
14	91	103	O	concentration
15	105	113	O	dependent
16	115	124	O	inhibition
17	126	127	O	of
18	129	134	O	CYP2D6
19	136	137	O	at
20	139	140	O	10
21	142	143	O	to
22	145	150	O	250mcM
23	152	154	O	and
24	156	161	O	CYP3A4
25	163	165	O	and
26	167	172	O	CYP3A5
27	174	175	O	at
28	177	178	O	25
29	180	181	O	to
30	183	188	O	250mcM
NULL

EMSAM	92	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	12
CYP2C19 and CYP2B6 were also inhibited at concentrations of 100mcM or greater.
1	0	6	O	CYP2C19
2	8	10	O	and
3	12	17	O	CYP2B6
4	19	22	O	were
5	24	27	O	also
6	29	37	O	inhibited
7	39	40	O	at
8	42	55	O	concentrations
9	57	58	O	of
10	60	65	O	100mcM
11	67	68	O	or
12	70	76	O	greater
NULL

EMSAM	93	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	40
All inhibitory effects of selegiline and N-desmethylselegiline occurred at concentrations that are several orders of magnitude higher than concentrations seen clinically (highest predose concentration observed at a dose of 12mg per 24 hours at steady-state was 0.046mcM).
1	0	2	O	All
2	4	13	O	inhibitory
3	15	21	O	effects
4	23	24	O	of
5	26	35	O	XXXXXXXX
6	37	39	O	and
7	41	41	O	N
8	43	51	O	desmethyl
9	52	61	O	XXXXXXXX
10	63	70	O	occurred
11	72	73	O	at
12	75	88	O	concentrations
13	90	93	O	that
14	95	97	O	are
15	99	105	O	several
16	107	112	O	orders
17	114	115	O	of
18	117	125	O	magnitude
19	127	132	O	higher
20	134	137	O	than
21	139	152	O	concentrations
22	154	157	O	seen
23	159	168	O	clinically
24	171	177	O	highest
25	179	185	O	predose
26	187	199	O	concentration
27	201	208	O	observed
28	210	211	O	at
29	213	213	O	a
30	215	218	O	dose
31	220	221	O	of
32	223	226	O	12mg
33	228	230	O	per
34	232	233	O	24
35	235	239	O	hours
36	241	242	O	at
37	244	249	O	steady
38	251	255	O	state
39	257	259	O	was
40	261	268	O	0.046mcM
NULL

EMSAM	94	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	33
Approximately 10% and 2% of a radiolabeled dose applied dermally, as a DMSO solution, was recovered in urine and feces respectively, with at least 63% of the dose remaining unabsorbed.
1	0	12	O	Approximately
2	14	16	O	10%
3	18	20	O	and
4	22	23	O	2%
5	25	26	O	of
6	28	28	O	a
7	30	41	O	radiolabeled
8	43	46	O	dose
9	48	54	O	applied
10	56	63	O	dermally
11	64	64	O	,
12	66	67	O	as
13	69	69	O	a
14	71	74	O	DMSO
15	76	83	O	solution
16	84	84	O	,
17	86	88	O	was
18	90	98	O	recovered
19	100	101	O	in
20	103	107	O	urine
21	109	111	O	and
22	113	117	O	feces
23	119	130	O	respectively
24	131	131	O	,
25	133	136	O	with
26	138	139	O	at
27	141	145	O	least
28	147	149	O	63%
29	151	152	O	of
30	154	156	O	the
31	158	161	O	dose
32	163	171	O	remaining
33	173	182	O	unabsorbed
NULL

EMSAM	95	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	9
The remaining 25% of the dose was unaccounted for.
1	0	2	O	The
2	4	12	O	remaining
3	14	16	O	25%
4	18	19	O	of
5	21	23	O	the
6	25	28	O	dose
7	30	32	O	was
8	34	44	O	unaccounted
9	46	48	O	for
NULL

EMSAM	96	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	23
Urinary excretion of unchanged selegiline accounted for 0.1% of the applied dose with the remainder of the dose recovered in urine being metabolites.
1	0	6	O	Urinary
2	8	16	O	excretion
3	18	19	O	of
4	21	29	O	unchanged
5	31	40	O	XXXXXXXX
6	42	50	O	accounted
7	52	54	O	for
8	56	59	O	0.1%
9	61	62	O	of
10	64	66	O	the
11	68	74	O	applied
12	76	79	O	dose
13	81	84	O	with
14	86	88	O	the
15	90	98	O	remainder
16	100	101	O	of
17	103	105	O	the
18	107	110	O	dose
19	112	120	O	recovered
20	122	123	O	in
21	125	129	O	urine
22	131	135	O	being
23	137	147	O	metabolites
NULL

EMSAM	97	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	44
The systemic clearance of selegiline after intravenous administration was 1.4 L per min, and the mean half-lives of selegiline and its three metabolites, R(-)-N-desmethylselegiline, R(-)-amphetamine, and R(-)-methamphetamine, ranged from 18 to 25 hours.
1	0	2	O	The
2	4	11	O	systemic
3	13	21	O	clearance
4	23	24	O	of
5	26	35	O	XXXXXXXX
6	37	41	O	after
7	43	53	O	intravenous
8	55	68	O	administration
9	70	72	O	was
10	74	76	O	1.4
11	78	78	O	L
12	80	82	O	per
13	84	86	O	min
14	87	87	O	,
15	89	91	O	and
16	93	95	O	the
17	97	100	O	mean
18	102	105	O	half
19	107	111	O	lives
20	113	114	O	of
21	116	125	O	XXXXXXXX
22	127	129	O	and
23	131	133	O	its
24	135	139	O	three
25	141	151	O	metabolites
26	152	152	O	,
27	154	154	O	R
28	159	159	O	N
29	161	169	O	desmethyl
30	170	179	O	XXXXXXXX
31	180	180	O	,
32	182	182	O	R
33	187	197	O	amphetamine
34	198	198	O	,
35	200	202	O	and
36	204	204	O	R
37	209	223	O	methamphetamine
38	224	224	O	,
39	226	231	O	ranged
40	233	236	O	from
41	238	239	O	18
42	241	242	O	to
43	244	245	O	25
44	247	251	O	hours
NULL

EMSAM	98	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	13
EMSAM should not be used in patients less than 18 years of age.
1	0	4	O	XXXXXXXX
2	6	11	O	should
3	13	15	O	not
4	17	18	O	be
5	20	23	O	used
6	25	26	O	in
7	28	35	O	patients
8	37	40	O	less
9	42	45	O	than
10	47	48	O	18
11	50	54	O	years
12	56	57	O	of
13	59	61	O	age
NULL

EMSAM	99	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	44
Stratification of exposure data following treatment with EMSAM indicated that pre-dose (trough) selegiline plasma concentrations at steady state appeared higher (p = 0.12) in children aged < 12 years old, compared to adolescents aged > 12 years as shown in Table 6.
1	0	13	O	Stratification
2	15	16	O	of
3	18	25	O	exposure
4	27	30	O	data
5	32	40	O	following
6	42	50	O	treatment
7	52	55	O	with
8	57	61	O	XXXXXXXX
9	63	71	O	indicated
10	73	76	O	that
11	78	80	O	pre
12	82	85	O	dose
13	88	93	O	trough
14	96	105	O	XXXXXXXX
15	107	112	O	plasma
16	114	127	O	concentrations
17	129	130	O	at
18	132	137	O	steady
19	139	143	O	state
20	145	152	O	appeared
21	154	159	O	higher
22	162	162	O	p
23	164	164	O	=
24	166	169	O	0.12
25	172	173	O	in
26	175	182	O	children
27	184	187	O	aged
28	189	189	O	<
29	191	192	O	12
30	194	198	O	years
31	200	202	O	old
32	203	203	O	,
33	205	212	O	compared
34	214	215	O	to
35	217	227	O	adolescents
36	229	232	O	aged
37	234	234	O	>
38	236	237	O	12
39	239	243	O	years
40	245	246	O	as
41	248	252	O	shown
42	254	255	O	in
43	257	261	O	Table
44	263	263	O	6
NULL

EMSAM	100	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	81
Steady State Selegiline Trough Concentrations Associated with Administration of EMSAM 15 mg/15 cm2 Daily for 7 Days Trough Concentration, pg/mL 6 to 11 year old age group 12 to 14 year old age group (N = 6) (N = 4) Mean (SD) 2,562 (974) 1,821 (146) The pharmacokinetics and pharmacodynamics of alcohol (0.75mg per kg) alone or in combination with EMSAM 6mg per 24 hours for 7 days of treatment was examined in 16 healthy volunteers.
1	0	5	O	Steady
2	7	11	O	State
3	13	22	O	XXXXXXXX
4	24	29	O	Trough
5	31	44	O	Concentrations
6	46	55	O	Associated
7	57	60	O	with
8	62	75	O	Administration
9	77	78	O	of
10	80	84	O	XXXXXXXX
11	86	87	O	15
12	89	90	O	mg
13	91	91	O	/
14	92	93	O	15
15	95	97	O	cm2
16	99	103	O	Daily
17	105	107	O	for
18	109	109	O	7
19	111	114	O	Days
20	116	121	O	Trough
21	123	135	O	Concentration
22	136	136	O	,
23	138	139	O	pg
24	140	140	O	/
25	141	142	O	mL
26	144	144	O	6
27	146	147	O	to
28	149	150	O	11
29	152	155	O	year
30	157	159	O	old
31	161	163	O	age
32	165	169	O	group
33	171	172	O	12
34	174	175	O	to
35	177	178	O	14
36	180	183	O	year
37	185	187	O	old
38	189	191	O	age
39	193	197	O	group
40	200	200	O	N
41	202	202	O	=
42	204	204	O	6
43	208	208	O	N
44	210	210	O	=
45	212	212	O	4
46	215	218	O	Mean
47	221	222	O	SD
48	225	229	O	2,562
49	232	234	O	974
50	237	241	O	1,821
51	244	246	O	146
52	249	251	O	The
53	253	268	O	pharmacokinetics
54	270	272	O	and
55	274	289	O	pharmacodynamics
56	291	292	O	of
57	294	300	O	alcohol
58	303	308	O	0.75mg
59	310	312	O	per
60	314	315	O	kg
61	318	322	O	alone
62	324	325	O	or
63	327	328	O	in
64	330	340	O	combination
65	342	345	O	with
66	347	351	O	XXXXXXXX
67	353	355	O	6mg
68	357	359	O	per
69	361	362	O	24
70	364	368	O	hours
71	370	372	O	for
72	374	374	O	7
73	376	379	O	days
74	381	382	O	of
75	384	392	O	treatment
76	394	396	O	was
77	398	405	O	examined
78	407	408	O	in
79	410	411	O	16
80	413	419	O	healthy
81	421	430	O	volunteers
NULL

EMSAM	101	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	21
No clinically significant differences were observed in the pharmacokinetics or pharmacodynamics of alcohol or the pharmacokinetics of selegiline during co-administration.
1	0	1	O	No
2	3	12	O	clinically
3	14	24	O	significant
4	26	36	O	differences
5	38	41	O	were
6	43	50	O	observed
7	52	53	O	in
8	55	57	O	the
9	59	74	O	pharmacokinetics
10	76	77	O	or
11	79	94	O	pharmacodynamics
12	96	97	O	of
13	99	105	O	alcohol
14	107	108	O	or
15	110	112	O	the
16	114	129	O	pharmacokinetics
17	131	132	O	of
18	134	143	O	XXXXXXXX
19	145	150	O	during
20	152	153	O	co
21	155	168	O	administration
NULL

EMSAM	102	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	46
Although EMSAM has not been shown to increase the impairment of mental and motor skills caused by alcohol (0.75mg per kg) and failed to alter the pharmacokinetic properties of alcohol, patients should be advised that the use of alcohol is not recommended while taking EMSAM.
1	0	7	O	Although
2	9	13	O	XXXXXXXX
3	15	17	O	has
4	19	21	O	not
5	23	26	O	been
6	28	32	O	shown
7	34	35	O	to
8	37	44	O	increase
9	46	48	O	the
10	50	59	O	impairment
11	61	62	O	of
12	64	69	O	mental
13	71	73	O	and
14	75	79	O	motor
15	81	86	O	skills
16	88	93	O	caused
17	95	96	O	by
18	98	104	U-UNK	alcohol
19	107	112	O	0.75mg
20	114	116	O	per
21	118	119	O	kg
22	122	124	O	and
23	126	131	O	failed
24	133	134	O	to
25	136	140	O	alter
26	142	144	O	the
27	146	160	O	pharmacokinetic
28	162	171	O	properties
29	173	174	O	of
30	176	182	O	alcohol
31	183	183	O	,
32	185	192	O	patients
33	194	199	O	should
34	201	202	O	be
35	204	210	O	advised
36	212	215	O	that
37	217	219	O	the
38	221	223	O	use
39	225	226	O	of
40	228	234	O	alcohol
41	236	237	O	is
42	239	241	B-TRI	not
43	243	253	L-TRI	recommended
44	255	259	O	while
45	261	266	O	taking
46	268	272	O	XXXXXXXX
NULL

EMSAM	103	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	39
In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline.
1	0	1	O	In
2	3	10	O	subjects
3	12	14	O	who
4	16	18	O	had
5	20	27	O	received
6	29	33	O	XXXXXXXX
7	35	35	O	6
8	37	38	O	mg
9	40	42	O	per
10	44	45	O	24
11	47	51	O	hours
12	53	55	O	for
13	57	57	O	7
14	59	62	O	days
15	63	63	O	,
16	65	66	O	co
17	68	81	O	administration
18	83	86	O	with
19	88	97	O	alprazolam
20	100	101	O	15
21	103	104	O	mg
22	106	108	O	per
23	110	112	O	day
24	114	114	O	,
25	116	116	O	a
26	118	123	O	CYP3A4
27	125	127	O	and
28	129	134	O	CYP3A5
29	136	144	O	substrate
30	145	145	O	,
31	147	149	O	did
32	151	153	O	not
33	155	160	O	affect
34	162	164	O	the
35	166	181	O	pharmacokinetics
36	183	184	O	of
37	186	195	O	alprazolam
38	197	198	O	or
39	200	209	O	XXXXXXXX
NULL

EMSAM	104	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	55
Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400mg per day) for 14 days.
1	0	12	U-KIN	Carbamazepine
2	14	15	O	is
3	17	18	O	an
4	20	25	O	enzyme
5	27	33	O	inducer
6	35	37	O	and
7	39	47	O	typically
8	49	54	O	causes
9	56	64	O	decreases
10	66	67	O	in
11	69	72	O	drug
12	74	81	O	exposure
13	84	90	O	however
14	91	91	O	,
15	93	105	O	approximately
16	107	107	O	2
17	109	112	O	fold
18	114	122	B-TRI	increased
19	124	131	I-TRI	systemic
20	133	140	L-TRI	exposure
21	142	143	O	of
22	145	154	O	XXXXXXXX
23	156	158	O	and
24	160	162	O	its
25	164	174	O	metabolites
26	175	175	O	,
27	177	177	O	L
28	179	189	O	amphetamine
29	191	193	O	and
30	195	195	O	L
31	197	211	O	methamphetamine
32	213	216	O	were
33	218	221	O	seen
34	223	227	O	after
35	229	234	O	single
36	236	246	O	application
37	248	249	O	of
38	251	255	O	XXXXXXXX
39	257	257	O	6
40	259	260	O	mg
41	262	264	O	per
42	266	267	O	24
43	269	273	O	hours
44	275	276	O	in
45	278	285	O	subjects
46	287	289	O	who
47	291	293	O	had
48	295	302	O	received
49	304	316	O	carbamazepine
50	319	323	O	400mg
51	325	327	O	per
52	329	331	O	day
53	334	336	O	for
54	338	339	O	14
55	341	344	O	days
K/1:C54355

EMSAM	105	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	15
Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population.
1	0	6	O	Changes
2	8	9	O	in
3	11	16	O	plasma
4	18	27	O	XXXXXXXX
5	29	42	O	concentrations
6	44	47	O	were
7	49	54	O	nearly
8	56	56	O	2
9	58	61	O	fold
10	63	65	O	and
11	67	74	O	variable
12	76	81	O	across
13	83	85	O	the
14	87	93	O	subject
15	95	104	O	population
NULL

EMSAM	106	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	19
Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose.
1	0	3	O	Such
2	5	13	O	increases
3	15	17	O	may
4	19	26	O	increase
5	28	30	O	the
6	32	35	O	risk
7	37	38	O	of
8	40	40	O	a
9	42	53	B-EFF	hypertensive
10	55	60	L-EFF	crisis
11	62	65	O	when
12	67	79	U-DYN	carbamazepine
13	81	82	O	is
14	84	87	O	used
15	89	92	O	with
16	94	98	O	XXXXXXXX
17	100	101	O	at
18	103	105	O	any
19	107	110	O	dose
D/12:9:1

EMSAM	107	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	34
In subjects who had received EMSAM 6mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen.
1	0	1	O	In
2	3	10	O	subjects
3	12	14	O	who
4	16	18	O	had
5	20	27	O	received
6	29	33	O	XXXXXXXX
7	35	37	O	6mg
8	39	41	O	per
9	43	44	O	24
10	46	50	O	hours
11	52	54	O	for
12	56	57	O	11
13	59	62	O	days
14	63	63	O	,
15	65	72	O	combined
16	74	87	O	administration
17	89	92	O	with
18	94	96	O	the
19	98	103	O	CYP2C9
20	105	113	O	substrate
21	115	123	O	ibuprofen
22	126	130	O	800mg
23	132	137	O	single
24	139	142	O	dose
25	145	147	O	did
26	149	151	O	not
27	153	158	O	affect
28	160	162	O	the
29	164	179	O	pharmacokinetics
30	181	182	O	of
31	184	189	O	either
32	191	200	O	XXXXXXXX
33	202	203	O	or
34	205	213	O	ibuprofen
NULL

EMSAM	108	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	46
Seven-day treatment with ketoconazole (200mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed.
1	0	4	O	Seven
2	6	8	O	day
3	10	18	O	treatment
4	20	23	O	with
5	25	36	O	ketoconazole
6	39	43	O	200mg
7	45	47	O	per
8	49	51	O	day
9	53	53	O	,
10	55	55	O	a
11	57	62	O	potent
12	64	72	O	inhibitor
13	74	75	O	of
14	77	82	O	CYP3A4
15	83	83	O	,
16	85	87	O	did
17	89	91	O	not
18	93	98	O	affect
19	100	102	O	the
20	104	109	O	steady
21	111	115	O	state
22	117	132	O	pharmacokinetics
23	134	135	O	of
24	137	146	O	XXXXXXXX
25	148	149	O	in
26	151	158	O	subjects
27	160	162	O	who
28	164	171	O	received
29	173	177	O	XXXXXXXX
30	179	181	O	6mg
31	183	185	O	per
32	187	188	O	24
33	190	194	O	hours
34	196	198	O	for
35	200	200	O	7
36	202	205	O	days
37	207	209	O	and
38	211	212	O	no
39	214	224	O	differences
40	226	227	O	in
41	229	231	O	the
42	233	248	O	pharmacokinetics
43	250	251	O	of
44	253	264	O	ketoconazole
45	266	269	O	were
46	271	278	O	observed
NULL

EMSAM	109	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	32
In healthy subjects who had received EMSAM 6mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	20	22	O	who
5	24	26	O	had
6	28	35	O	received
7	37	41	O	XXXXXXXX
8	43	45	O	6mg
9	47	49	O	per
10	51	52	O	24
11	54	58	O	hours
12	60	62	O	for
13	64	65	O	10
14	67	70	O	days
15	71	71	O	,
16	73	78	O	single
17	80	83	O	dose
18	85	98	O	administration
19	100	103	O	with
20	105	117	O	levothyroxine
21	120	122	O	150
22	124	126	O	mcg
23	129	131	O	did
24	133	135	O	not
25	137	141	O	alter
26	143	145	O	the
27	147	162	O	pharmacokinetics
28	164	165	O	of
29	167	172	O	either
30	174	183	O	XXXXXXXX
31	185	186	O	or
32	188	200	O	levothyroxine
NULL

EMSAM	110	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	39
In subjects who had received EMSAM 6mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine.
1	0	1	O	In
2	3	10	O	subjects
3	12	14	O	who
4	16	18	O	had
5	20	27	O	received
6	29	33	O	XXXXXXXX
7	35	37	O	6mg
8	39	41	O	per
9	43	44	O	24
10	46	50	O	hours
11	52	54	O	for
12	56	57	O	10
13	59	62	O	days
14	63	63	O	,
15	65	66	O	co
16	68	81	O	administration
17	83	86	O	with
18	88	97	O	olanzapine
19	98	98	O	,
20	100	100	O	a
21	102	110	O	substrate
22	112	114	O	for
23	116	121	O	CYP1A2
24	122	122	O	,
25	124	129	O	CYP2D6
26	130	130	O	,
27	132	134	O	and
28	136	143	O	possibly
29	145	150	O	CYP2A6
30	151	151	O	,
31	153	155	O	did
32	157	159	O	not
33	161	166	O	affect
34	168	170	O	the
35	172	187	O	pharmacokinetics
36	189	190	O	of
37	192	201	O	XXXXXXXX
38	203	204	O	or
39	206	215	O	olanzapine
NULL

EMSAM	111	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	32
In subjects who had received EMSAM 6mg per 24 hours for 9 days, co-administration with PPA (25mg every 4 hours for 24 hours) did not affect the pharmacokinetics of PPA.
1	0	1	O	In
2	3	10	O	subjects
3	12	14	O	who
4	16	18	O	had
5	20	27	O	received
6	29	33	O	XXXXXXXX
7	35	37	O	6mg
8	39	41	O	per
9	43	44	O	24
10	46	50	O	hours
11	52	54	O	for
12	56	56	O	9
13	58	61	O	days
14	62	62	O	,
15	64	65	O	co
16	67	80	O	administration
17	82	85	O	with
18	87	89	O	PPA
19	92	95	O	25mg
20	97	101	O	every
21	103	103	O	4
22	105	109	O	hours
23	111	113	O	for
24	115	116	O	24
25	118	122	O	hours
26	125	127	O	did
27	129	131	O	not
28	133	138	O	affect
29	140	142	O	the
30	144	159	O	pharmacokinetics
31	161	162	O	of
32	164	166	O	PPA
NULL

EMSAM	112	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	28
There was a higher incidence of significant blood pressure elevations with the co-administration of EMSAM and PPA than with PPA alone, suggesting a possible pharmacodynamic interaction.
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	17	O	higher
5	19	27	O	incidence
6	29	30	O	of
7	32	42	O	significant
8	44	48	B-EFF	blood
9	50	57	I-EFF	pressure
10	59	68	L-EFF	elevations
11	70	73	O	with
12	75	77	O	the
13	79	80	O	co
14	82	95	O	administration
15	97	98	O	of
16	100	104	O	XXXXXXXX
17	106	108	O	and
18	110	112	U-DYN	PPA
19	114	117	O	than
20	119	122	O	with
21	124	126	O	PPA
22	128	132	O	alone
23	133	133	O	,
24	135	144	O	suggesting
25	146	146	O	a
26	148	155	O	possible
27	157	171	O	pharmacodynamic
28	173	183	O	interaction
D/18:8:1

EMSAM	113	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	26
EMSAM 6mg per 24 hours for 10 days, co-administered with pseudoephedrine (60mg, 3 times a day) did not affect the pharmacokinetics of pseudoephedrine.
1	0	4	O	XXXXXXXX
2	6	8	O	6mg
3	10	12	O	per
4	14	15	O	24
5	17	21	O	hours
6	23	25	O	for
7	27	28	O	10
8	30	33	O	days
9	34	34	O	,
10	36	37	O	co
11	39	50	O	administered
12	52	55	O	with
13	57	71	O	pseudoephedrine
14	74	77	O	60mg
15	78	78	O	,
16	80	80	O	3
17	82	86	O	times
18	88	88	O	a
19	90	92	O	day
20	95	97	O	did
21	99	101	O	not
22	103	108	O	affect
23	110	112	O	the
24	114	129	O	pharmacokinetics
25	131	132	O	of
26	134	148	O	pseudoephedrine
NULL

EMSAM	114	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	19
There were no clinically significant changes in blood pressure during pseudoephedrine administration alone, or in combination with EMSAM.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	23	O	clinically
5	25	35	O	significant
6	37	43	O	changes
7	45	46	O	in
8	48	52	O	blood
9	54	61	O	pressure
10	63	68	O	during
11	70	84	O	pseudoephedrine
12	86	99	O	administration
13	101	105	O	alone
14	106	106	O	,
15	108	109	O	or
16	111	112	O	in
17	114	124	O	combination
18	126	129	O	with
19	131	135	O	XXXXXXXX
NULL

EMSAM	115	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	39
In subjects who had received EMSAM 6mg per 24 hours for 10 days, co-administration with risperidone (2mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone.
1	0	1	O	In
2	3	10	O	subjects
3	12	14	O	who
4	16	18	O	had
5	20	27	O	received
6	29	33	O	XXXXXXXX
7	35	37	O	6mg
8	39	41	O	per
9	43	44	O	24
10	46	50	O	hours
11	52	54	O	for
12	56	57	O	10
13	59	62	O	days
14	63	63	O	,
15	65	66	O	co
16	68	81	O	administration
17	83	86	O	with
18	88	98	O	risperidone
19	101	103	O	2mg
20	105	107	O	per
21	109	111	O	day
22	113	115	O	for
23	117	117	O	7
24	119	122	O	days
25	124	124	O	,
26	126	126	O	a
27	128	136	O	substrate
28	138	140	O	for
29	142	147	O	CYP2D6
30	148	148	O	,
31	150	152	O	did
32	154	156	O	not
33	158	163	O	affect
34	165	167	O	the
35	169	184	O	pharmacokinetics
36	186	187	O	of
37	189	198	O	XXXXXXXX
38	200	201	O	or
39	203	213	O	risperidone
NULL

EMSAM	116	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	10
Warfarin is a substrate for CYP2C9 and CYP3A4 metabolism pathways.
1	0	7	O	Warfarin
2	9	10	O	is
3	12	12	O	a
4	14	22	O	substrate
5	24	26	O	for
6	28	33	O	CYP2C9
7	35	37	O	and
8	39	44	O	CYP3A4
9	46	55	O	metabolism
10	57	64	O	pathways
NULL

EMSAM	117	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	40
In healthy volunteers titrated with Coumadin*# (warfarin sodium) to clinical levels of anticoagulation (INR of 1.5 to 2), co-administration with EMSAM 6mg per 24 hours for 7 days did not affect the pharmacokinetics of the individual warfarin enantiomers.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	22	29	O	titrated
5	31	34	O	with
6	36	45	O	Coumadin*#
7	48	55	O	warfarin
8	57	62	O	sodium
9	65	66	O	to
10	68	75	O	clinical
11	77	82	O	levels
12	84	85	O	of
13	87	101	O	anticoagulation
14	104	106	O	INR
15	108	109	O	of
16	111	113	O	1.5
17	115	116	O	to
18	118	118	O	2
19	120	120	O	,
20	122	123	O	co
21	125	138	O	administration
22	140	143	O	with
23	145	149	O	XXXXXXXX
24	151	153	O	6mg
25	155	157	O	per
26	159	160	O	24
27	162	166	O	hours
28	168	170	O	for
29	172	172	O	7
30	174	177	O	days
31	179	181	O	did
32	183	185	O	not
33	187	192	O	affect
34	194	196	O	the
35	198	213	O	pharmacokinetics
36	215	216	O	of
37	218	220	O	the
38	222	231	O	individual
39	233	240	O	warfarin
40	242	252	O	enantiomers
NULL

EMSAM	118	34090-1	b891bd9f-fdb8-4862-89c5-ecdd700398a3	21
EMSAM did not alter the clinical pharmacodynamic effects of warfarin as measured by INR, Factor VII or Factor X levels.
1	0	4	O	XXXXXXXX
2	6	8	O	did
3	10	12	O	not
4	14	18	O	alter
5	20	22	O	the
6	24	31	O	clinical
7	33	47	O	pharmacodynamic
8	49	55	O	effects
9	57	58	O	of
10	60	67	O	warfarin
11	69	70	O	as
12	72	79	O	measured
13	81	82	O	by
14	84	86	O	INR
15	87	87	O	,
16	89	94	O	Factor
17	96	98	O	VII
18	100	101	O	or
19	103	108	O	Factor
20	110	110	O	XXXXXXXX
21	112	117	O	levels
NULL

Estazolam	3201	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	26
If estazolam is given concomitantly with other drugs acting on the central nervous system, careful consideration should be given to the pharmacology of all agents.
1	0	1	O	If
2	3	11	O	XXXXXXXX
3	13	14	O	is
4	16	20	O	given
5	22	34	O	concomitantly
6	36	39	O	with
7	41	45	O	other
8	47	51	B-UNK	drugs
9	53	58	I-UNK	acting
10	60	61	I-UNK	on
11	63	65	I-UNK	the
12	67	73	I-UNK	central
13	75	81	I-UNK	nervous
14	83	88	L-UNK	system
15	89	89	O	,
16	91	97	B-TRI	careful
17	99	111	L-TRI	consideration
18	113	118	O	should
19	120	121	O	be
20	123	127	O	given
21	129	130	O	to
22	132	134	O	the
23	136	147	O	pharmacology
24	149	150	O	of
25	152	154	O	all
26	156	161	O	agents
NULL

Estazolam	3202	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	35
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
1	0	2	O	The
2	4	9	O	action
3	11	12	O	of
4	14	16	O	the
5	18	32	O	benzodiazepines
6	34	36	O	may
7	38	39	O	be
8	41	51	O	potentiated
9	53	54	O	by
10	56	70	U-DYN	GGGGGGGG
11	71	71	O	,
12	73	86	U-DYN	antihistamines
13	87	87	O	,
14	89	95	U-DYN	alcohol
15	96	96	O	,
16	98	109	U-DYN	barbiturates
17	110	110	O	,
18	112	120	B-DYN	monoamine
19	122	128	I-DYN	oxidase
20	130	139	L-DYN	inhibitors
21	140	140	O	,
22	142	150	U-DYN	narcotics
23	151	151	O	,
24	153	166	U-DYN	phenothiazines
25	167	167	O	,
26	169	180	B-DYN	psychotropic
27	182	192	L-DYN	medications
28	193	193	O	,
29	195	196	O	or
30	198	202	O	other
31	204	208	B-DYN	drugs
32	210	213	I-DYN	that
33	215	221	I-DYN	produce
34	223	225	I-DYN	CNS
35	227	236	L-DYN	depression
NULL

Estazolam	3203	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	18
Smokers have an increased clearance of benzodiazepines as compared to nonsmokers; this was seen in studies with estazolam.
1	0	6	O	Smokers
2	8	11	O	have
3	13	14	O	an
4	16	24	O	increased
5	26	34	O	clearance
6	36	37	O	of
7	39	53	O	benzodiazepines
8	55	56	O	as
9	58	65	O	compared
10	67	68	O	to
11	70	79	O	nonsmokers
12	82	85	O	this
13	87	89	O	was
14	91	94	O	seen
15	96	97	O	in
16	99	105	O	studies
17	107	110	O	with
18	112	120	O	XXXXXXXX
NULL

Estazolam	3204	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	40
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.
1	0	4	O	While
2	6	7	O	no
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	drug
6	22	25	O	drug
7	27	37	O	interaction
8	39	45	O	studies
9	47	50	O	were
10	52	60	O	conducted
11	62	68	O	between
12	70	78	O	XXXXXXXX
13	80	82	O	and
14	84	91	O	inducers
15	93	94	O	of
16	96	100	O	CYP3A
17	101	101	O	,
18	103	111	O	compounds
19	113	116	O	that
20	118	120	O	are
21	122	127	B-KIN	potent
22	129	133	I-KIN	CYP3A
23	135	144	L-KIN	inhibitors
24	147	150	O	such
25	152	153	O	as
26	155	167	U-KIN	carbamazepine
27	168	168	O	,
28	170	178	U-KIN	phenytoin
29	179	179	O	,
30	181	188	U-KIN	rifampin
31	189	189	O	,
32	191	193	O	and
33	195	206	U-KIN	barbiturates
34	209	213	O	would
35	215	216	O	be
36	218	225	O	expected
37	227	228	O	to
38	230	237	B-TRI	decrease
39	239	247	I-TRI	XXXXXXXX
40	249	262	L-TRI	concentrations
K/21:C54356 K/26:C54356 K/28:C54356 K/30:C54356 K/33:C54356

Estazolam	3205	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	22
The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam and the metabolism of other triazolobenzodiazepines is catalyzed by CYP3A.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	26	O	XXXXXXXX
5	28	29	O	to
6	31	33	O	the
7	35	39	O	major
8	41	51	O	circulating
9	53	62	O	metabolite
10	64	64	O	4
11	66	72	O	hydroxy
12	74	82	O	XXXXXXXX
13	84	86	O	and
14	88	90	O	the
15	92	101	O	metabolism
16	103	104	O	of
17	106	110	O	other
18	112	134	O	triazolobenzodiazepines
19	136	137	O	is
20	139	147	O	catalyzed
21	149	150	O	by
22	152	156	O	CYP3A
NULL

Estazolam	3206	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	20
Consequently, estazolam should be avoided in patients receiving ketoconazole and itraconazole, which are very potent inhibitors of CYP3A.
1	0	11	O	Consequently
2	12	12	O	,
3	14	22	O	XXXXXXXX
4	24	29	B-TRI	should
5	31	32	I-TRI	be
6	34	40	L-TRI	avoided
7	42	43	O	in
8	45	52	O	patients
9	54	62	O	receiving
10	64	75	U-UNK	ketoconazole
11	77	79	O	and
12	81	92	U-UNK	itraconazole
13	93	93	O	,
14	95	99	O	which
15	101	103	O	are
16	105	108	O	very
17	110	115	B-UNK	potent
18	117	126	I-UNK	inhibitors
19	128	129	I-UNK	of
20	131	135	L-UNK	CYP3A
NULL

Estazolam	3207	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	26
With drugs inhibiting CYP3A to a lesser, but still significant degree, estazolam should be used only with caution and consideration of appropriate dosage reduction.
1	0	3	O	With
2	5	9	B-KIN	drugs
3	11	20	I-KIN	inhibiting
4	22	26	L-KIN	CYP3A
5	28	29	O	to
6	31	31	O	a
7	33	38	O	lesser
8	39	39	O	,
9	41	43	O	but
10	45	49	O	still
11	51	61	O	significant
12	63	68	O	degree
13	69	69	O	,
14	71	79	O	XXXXXXXX
15	81	86	O	should
16	88	89	O	be
17	91	94	O	used
18	96	99	O	only
19	101	104	O	with
20	106	112	O	caution
21	114	116	O	and
22	118	130	O	consideration
23	132	133	O	of
24	135	145	O	appropriate
25	147	152	B-TRI	dosage
26	154	162	L-TRI	reduction
K/2:C54355

Estazolam	3208	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	36
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.
1	0	2	O	The
2	4	12	O	following
3	14	16	O	are
4	18	25	O	examples
5	27	28	O	of
6	30	34	O	drugs
7	36	40	O	known
8	42	43	O	to
9	45	51	B-TRI	inhibit
10	53	55	I-TRI	the
11	57	66	L-TRI	metabolism
12	68	69	O	of
13	71	75	O	other
14	77	83	O	related
15	85	99	O	benzodiazepines
16	100	100	O	,
17	102	111	O	presumably
18	113	119	O	through
19	121	130	O	inhibition
20	132	133	O	of
21	135	139	O	CYP3A
22	140	140	O	:
23	142	151	U-KIN	nefazodone
24	152	152	O	,
25	154	164	U-KIN	fluvoxamine
26	165	165	O	,
27	167	176	U-KIN	cimetidine
28	177	177	O	,
29	179	187	U-KIN	diltiazem
30	188	188	O	,
31	190	199	U-KIN	isoniazide
32	200	200	O	,
33	202	204	O	and
34	206	209	O	some
35	211	219	B-KIN	macrolide
36	221	231	L-KIN	antibiotics
K/23:C54355 K/25:C54355 K/27:C54355 K/29:C54355 K/31:C54355 K/35:C54355

Estazolam	3209	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	26
A multiple-dose study was conducted to assess the effect of fluoxetine 20 mg BID on the pharmacokinetics of estazolam 2 mg QHS after seven days.
1	0	0	O	A
2	2	9	O	multiple
3	11	14	O	dose
4	16	20	O	study
5	22	24	O	was
6	26	34	O	conducted
7	36	37	O	to
8	39	44	O	assess
9	46	48	O	the
10	50	55	O	effect
11	57	58	O	of
12	60	69	O	fluoxetine
13	71	72	O	20
14	74	75	O	mg
15	77	79	O	BID
16	81	82	O	on
17	84	86	O	the
18	88	103	O	pharmacokinetics
19	105	106	O	of
20	108	116	O	XXXXXXXX
21	118	118	O	2
22	120	121	O	mg
23	123	125	O	QHS
24	127	131	O	after
25	133	137	O	seven
26	139	142	O	days
NULL

Estazolam	3210	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	21
The pharmacokinetics of estazolam (Cmax and AUC) were not affected during multiple-dose fluoxetine, suggesting no clinically significant pharmacokinetic interaction.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	32	O	XXXXXXXX
5	35	38	O	Cmax
6	40	42	O	and
7	44	46	O	AUC
8	49	52	O	were
9	54	56	O	not
10	58	65	O	affected
11	67	72	O	during
12	74	81	O	multiple
13	83	86	O	dose
14	88	97	O	fluoxetine
15	98	98	O	,
16	100	109	O	suggesting
17	111	112	O	no
18	114	123	O	clinically
19	125	135	O	significant
20	137	151	O	pharmacokinetic
21	153	163	O	interaction
NULL

Estazolam	3211	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	35
At clinically relevant concentrations, in vitro studies indicate that estazolam (0.6uM) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.
1	0	1	O	At
2	3	12	O	clinically
3	14	21	O	relevant
4	23	36	O	concentrations
5	37	37	O	,
6	39	40	O	in
7	42	46	O	vitro
8	48	54	O	studies
9	56	63	O	indicate
10	65	68	O	that
11	70	78	O	XXXXXXXX
12	81	85	O	0.6uM
13	88	90	O	was
14	92	94	O	not
15	96	105	O	inhibitory
16	107	113	O	towards
17	115	117	O	the
18	119	123	O	major
19	125	134	O	cytochrome
20	136	139	O	P450
21	141	148	O	isoforms
22	150	155	O	CYP1A2
23	156	156	O	,
24	158	163	O	CYP2A6
25	164	164	O	,
26	166	171	O	CYP2C9
27	172	172	O	,
28	174	180	O	CYP2C19
29	181	181	O	,
30	183	188	O	CYP2D6
31	189	189	O	,
32	191	196	O	CYP2E1
33	197	197	O	,
34	199	201	O	and
35	203	207	O	CYP3A
NULL

Estazolam	3212	34073-7	50914a46-eab6-4c83-97cf-6ab0234c8126	25
Therefore, based on these in vitro data, estazolam is very unlikely to inhibit the biotransformation of other drugs metabolized by these CYP isoforms.
1	0	8	O	Therefore
2	9	9	O	,
3	11	15	O	based
4	17	18	O	on
5	20	24	O	these
6	26	27	O	in
7	29	33	O	vitro
8	35	38	O	data
9	39	39	O	,
10	41	49	O	XXXXXXXX
11	51	52	O	is
12	54	57	O	very
13	59	66	O	unlikely
14	68	69	O	to
15	71	77	O	inhibit
16	79	81	O	the
17	83	99	O	biotransformation
18	101	102	O	of
19	104	108	O	other
20	110	114	O	drugs
21	116	126	O	metabolized
22	128	129	O	by
23	131	135	O	these
24	137	139	O	CYP
25	141	148	O	isoforms
NULL

Estazolam	3213	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	17
Estazolam tablets have been found to be equivalent in absorption to an orally administered solution of estazolam.
1	0	8	O	XXXXXXXX
2	10	16	O	tablets
3	18	21	O	have
4	23	26	O	been
5	28	32	O	found
6	34	35	O	to
7	37	38	O	be
8	40	49	O	equivalent
9	51	52	O	in
10	54	63	O	absorption
11	65	66	O	to
12	68	69	O	an
13	71	76	O	orally
14	78	89	O	administered
15	91	98	O	solution
16	100	101	O	of
17	103	111	O	XXXXXXXX
NULL

Estazolam	3214	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	46
In healthy subjects who received up to three times the recommended dose of estazolam, peak estazolam plasma concentrations occurred within two hours after dosing (range 0.5 to 6.0 hours) and were proportional to the administered dose, suggesting linear pharmacokinetics over the dosage range tested.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	20	22	O	who
5	24	31	O	received
6	33	34	O	up
7	36	37	O	to
8	39	43	O	three
9	45	49	O	times
10	51	53	O	the
11	55	65	O	recommended
12	67	70	O	dose
13	72	73	O	of
14	75	83	O	XXXXXXXX
15	84	84	O	,
16	86	89	O	peak
17	91	99	O	XXXXXXXX
18	101	106	O	plasma
19	108	121	O	concentrations
20	123	130	O	occurred
21	132	137	O	within
22	139	141	O	two
23	143	147	O	hours
24	149	153	O	after
25	155	160	O	dosing
26	163	167	O	range
27	169	171	O	0.5
28	173	174	O	to
29	176	178	O	6.0
30	180	184	O	hours
31	187	189	O	and
32	191	194	O	were
33	196	207	O	proportional
34	209	210	O	to
35	212	214	O	the
36	216	227	O	administered
37	229	232	O	dose
38	233	233	O	,
39	235	244	O	suggesting
40	246	251	O	linear
41	253	268	O	pharmacokinetics
42	270	273	O	over
43	275	277	O	the
44	279	284	O	dosage
45	286	290	O	range
46	292	297	O	tested
NULL

Estazolam	3215	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	11
Independent of concentration, estazolam in plasma is 93% protein bound.
1	0	10	O	Independent
2	12	13	O	of
3	15	27	O	concentration
4	28	28	O	,
5	30	38	O	XXXXXXXX
6	40	41	O	in
7	43	48	O	plasma
8	50	51	O	is
9	53	55	O	93%
10	57	63	O	protein
11	65	69	O	bound
NULL

Estazolam	3216	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	19
Only two metabolites (1-oxo-estazolam & 4-hydroxy-estazolam) were detected in human plasma up to 18 hrs.
1	0	3	O	Only
2	5	7	O	two
3	9	19	O	metabolites
4	22	22	O	1
5	24	26	O	oxo
6	28	36	O	XXXXXXXX
7	38	38	O	&
8	40	40	O	4
9	42	48	O	hydroxy
10	50	58	O	XXXXXXXX
11	61	64	O	were
12	66	73	O	detected
13	75	76	O	in
14	78	82	O	human
15	84	89	O	plasma
16	91	92	O	up
17	94	95	O	to
18	97	98	O	18
19	100	102	O	hrs
NULL

Estazolam	3217	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	11
The pharmacologic activity of estazolam is primarily from the parent drug.
1	0	2	O	The
2	4	16	O	pharmacologic
3	18	25	O	activity
4	27	28	O	of
5	30	38	O	XXXXXXXX
6	40	41	O	is
7	43	51	O	primarily
8	53	56	O	from
9	58	60	O	the
10	62	67	O	parent
11	69	72	O	drug
NULL

Estazolam	3218	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	29
The elimination of the parent drug takes place via hepatic metabolism of estazolam to hydroxylated and other metabolites that are eliminated largely in the urine both free and conjugated.
1	0	2	O	The
2	4	14	O	elimination
3	16	17	O	of
4	19	21	O	the
5	23	28	O	parent
6	30	33	O	drug
7	35	39	O	takes
8	41	45	O	place
9	47	49	O	via
10	51	57	O	hepatic
11	59	68	O	metabolism
12	70	71	O	of
13	73	81	O	XXXXXXXX
14	83	84	O	to
15	86	97	O	hydroxylated
16	99	101	O	and
17	103	107	O	other
18	109	119	O	metabolites
19	121	124	O	that
20	126	128	O	are
21	130	139	O	eliminated
22	141	147	O	largely
23	149	150	O	in
24	152	154	O	the
25	156	160	O	urine
26	162	165	O	both
27	167	170	O	free
28	172	174	O	and
29	176	185	O	conjugated
NULL

Estazolam	3219	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	19
In humans, greater than 70% of a single dose of estazolam was recovered in the urine as metabolites.
1	0	1	O	In
2	3	8	O	humans
3	9	9	O	,
4	11	17	O	greater
5	19	22	O	than
6	24	26	O	70%
7	28	29	O	of
8	31	31	O	a
9	33	38	O	single
10	40	43	O	dose
11	45	46	O	of
12	48	56	O	XXXXXXXX
13	58	60	O	was
14	62	70	O	recovered
15	72	73	O	in
16	75	77	O	the
17	79	83	O	urine
18	85	86	O	as
19	88	98	O	metabolites
NULL

Estazolam	3220	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	27
Less than 5% of a 2 mg dose of estazolam was excreted unchanged in the urine, with only 4% of the dose appearing in the feces.
1	0	3	O	Less
2	5	8	O	than
3	10	11	O	5%
4	13	14	O	of
5	16	16	O	a
6	18	18	O	2
7	20	21	O	mg
8	23	26	O	dose
9	28	29	O	of
10	31	39	O	XXXXXXXX
11	41	43	O	was
12	45	52	O	excreted
13	54	62	O	unchanged
14	64	65	O	in
15	67	69	O	the
16	71	75	O	urine
17	76	76	O	,
18	78	81	O	with
19	83	86	O	only
20	88	89	O	4%
21	91	92	O	of
22	94	96	O	the
23	98	101	O	dose
24	103	111	O	appearing
25	113	114	O	in
26	116	118	O	the
27	120	124	O	feces
NULL

Estazolam	3221	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	30
The principal urinary excretion product is an unidentified metabolite, presumed to be a metabolic product of 4-hydroxy-estazolam, accounting for at least 27% of the administered dose.
1	0	2	O	The
2	4	12	O	principal
3	14	20	O	urinary
4	22	30	O	excretion
5	32	38	O	product
6	40	41	O	is
7	43	44	O	an
8	46	57	O	unidentified
9	59	68	O	metabolite
10	69	69	O	,
11	71	78	O	presumed
12	80	81	O	to
13	83	84	O	be
14	86	86	O	a
15	88	96	O	metabolic
16	98	104	O	product
17	106	107	O	of
18	109	109	O	4
19	111	117	O	hydroxy
20	119	127	O	XXXXXXXX
21	128	128	O	,
22	130	139	O	accounting
23	141	143	O	for
24	145	146	O	at
25	148	152	O	least
26	154	156	O	27%
27	158	159	O	of
28	161	163	O	the
29	165	176	O	administered
30	178	181	O	dose
NULL

Estazolam	3222	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	23
4-hydroxy-estazolam is the major metabolite in plasma, with concentrations approaching 12% of those of the parent eight hours after administration.
1	0	0	O	4
2	2	8	O	hydroxy
3	10	18	O	XXXXXXXX
4	20	21	O	is
5	23	25	O	the
6	27	31	O	major
7	33	42	O	metabolite
8	44	45	O	in
9	47	52	O	plasma
10	53	53	O	,
11	55	58	O	with
12	60	73	O	concentrations
13	75	85	O	approaching
14	87	89	O	12%
15	91	92	O	of
16	94	98	O	those
17	100	101	O	of
18	103	105	O	the
19	107	112	O	parent
20	114	118	O	eight
21	120	124	O	hours
22	126	130	O	after
23	132	145	O	administration
NULL

Estazolam	3223	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	17
Urinary 4-hydroxy-estazolam and 1-oxo-estazolam account for 11.9% and 4.4% of the dose respectively.
1	0	6	O	Urinary
2	8	8	O	4
3	10	16	O	hydroxy
4	18	26	O	XXXXXXXX
5	28	30	O	and
6	32	32	O	1
7	34	36	O	oxo
8	38	46	O	XXXXXXXX
9	48	54	O	account
10	56	58	O	for
11	60	64	O	11.9%
12	66	68	O	and
13	70	73	O	4.4%
14	75	76	O	of
15	78	80	O	the
16	82	85	O	dose
17	87	98	O	respectively
NULL

Estazolam	3224	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	28
In vitro studies with human liver microsomes indicate that the biotransformation of estazolam to the major circulating metabolite 4-hydroxy-estazolam is mediated by cytochrome P450 3A (CYP3A).
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	with
5	22	26	O	human
6	28	32	O	liver
7	34	43	O	microsomes
8	45	52	O	indicate
9	54	57	O	that
10	59	61	O	the
11	63	79	O	biotransformation
12	81	82	O	of
13	84	92	O	XXXXXXXX
14	94	95	O	to
15	97	99	O	the
16	101	105	O	major
17	107	117	O	circulating
18	119	128	O	metabolite
19	130	130	O	4
20	132	138	O	hydroxy
21	140	148	O	XXXXXXXX
22	150	151	O	is
23	153	160	O	mediated
24	162	163	O	by
25	165	174	O	cytochrome
26	176	179	O	P450
27	181	182	O	3A
28	185	189	O	CYP3A
NULL

Estazolam	3225	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	34
While 4-hydroxy-estazolam and the lesser metabolite, 1-oxo-estazolam, have some pharmacologic activity, their low potencies and low concentrations preclude any significant contribution to the hypnotic effect of estazolam.
1	0	4	O	While
2	6	6	O	4
3	8	14	O	hydroxy
4	16	24	O	XXXXXXXX
5	26	28	O	and
6	30	32	O	the
7	34	39	O	lesser
8	41	50	O	metabolite
9	51	51	O	,
10	53	53	O	1
11	55	57	O	oxo
12	59	67	O	XXXXXXXX
13	68	68	O	,
14	70	73	O	have
15	75	78	O	some
16	80	92	O	pharmacologic
17	94	101	O	activity
18	102	102	O	,
19	104	108	O	their
20	110	112	O	low
21	114	122	O	potencies
22	124	126	O	and
23	128	130	O	low
24	132	145	O	concentrations
25	147	154	O	preclude
26	156	158	O	any
27	160	170	O	significant
28	172	183	O	contribution
29	185	186	O	to
30	188	190	O	the
31	192	199	O	hypnotic
32	201	206	O	effect
33	208	209	O	of
34	211	219	O	XXXXXXXX
NULL

Estazolam	3226	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	18
The range of estimates for the mean elimination half-life of estazolam varied from 10 to 24 hours.
1	0	2	O	The
2	4	8	O	range
3	10	11	O	of
4	13	21	O	estimates
5	23	25	O	for
6	27	29	O	the
7	31	34	O	mean
8	36	46	O	elimination
9	48	51	O	half
10	53	56	O	life
11	58	59	O	of
12	61	69	O	XXXXXXXX
13	71	76	O	varied
14	78	81	O	from
15	83	84	O	10
16	86	87	O	to
17	89	90	O	24
18	92	96	O	hours
NULL

Estazolam	3227	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	15
Radiolabel mass balance studies indicate that the main route of excretion is via the kidneys.
1	0	9	O	Radiolabel
2	11	14	O	mass
3	16	22	O	balance
4	24	30	O	studies
5	32	39	O	indicate
6	41	44	O	that
7	46	48	O	the
8	50	53	O	main
9	55	59	O	route
10	61	62	O	of
11	64	72	O	excretion
12	74	75	O	is
13	77	79	O	via
14	81	83	O	the
15	85	91	O	kidneys
NULL

Estazolam	3228	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	14
After 5 days, 87% of the administered radioactivity was excreted in human urine.
1	0	4	O	After
2	6	6	O	5
3	8	11	O	days
4	12	12	O	,
5	14	16	O	87%
6	18	19	O	of
7	21	23	O	the
8	25	36	O	administered
9	38	50	O	radioactivity
10	52	54	O	was
11	56	63	O	excreted
12	65	66	O	in
13	68	72	O	human
14	74	78	O	urine
NULL

Estazolam	3229	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	9
Less than 4% of the dose was excreted unchanged.
1	0	3	O	Less
2	5	8	O	than
3	10	11	O	4%
4	13	14	O	of
5	16	18	O	the
6	20	23	O	dose
7	25	27	O	was
8	29	36	O	excreted
9	38	46	O	unchanged
NULL

Estazolam	3230	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	25
Four metabolites were identified as 1-oxo-estazolam, 4'-hydroxy-estazolam, 4-hydroxy-estazolam, and benzophenone, as free metabolites and glucuronides.
1	0	3	O	Four
2	5	15	O	metabolites
3	17	20	O	were
4	22	31	O	identified
5	33	34	O	as
6	36	36	O	1
7	38	40	O	oxo
8	42	50	O	XXXXXXXX
9	51	51	O	,
10	53	54	O	4'
11	56	62	O	hydroxy
12	64	72	O	XXXXXXXX
13	73	73	O	,
14	75	75	O	4
15	77	83	O	hydroxy
16	85	93	O	XXXXXXXX
17	94	94	O	,
18	96	98	O	and
19	100	111	O	benzophenone
20	112	112	O	,
21	114	115	O	as
22	117	120	O	free
23	122	132	O	metabolites
24	134	136	O	and
25	138	149	O	glucuronides
NULL

Estazolam	3231	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	26
The predominant metabolite in urine (17% of the administered dose) has not been identified, but is likely to be a metabolite of 4-hydroxy-estazolam.
1	0	2	O	The
2	4	14	O	predominant
3	16	25	O	metabolite
4	27	28	O	in
5	30	34	O	urine
6	37	39	O	17%
7	41	42	O	of
8	44	46	O	the
9	48	59	O	administered
10	61	64	O	dose
11	67	69	O	has
12	71	73	O	not
13	75	78	O	been
14	80	89	O	identified
15	90	90	O	,
16	92	94	O	but
17	96	97	O	is
18	99	104	O	likely
19	106	107	O	to
20	109	110	O	be
21	112	112	O	a
22	114	123	O	metabolite
23	125	126	O	of
24	128	128	O	4
25	130	136	O	hydroxy
26	138	146	O	XXXXXXXX
NULL

Estazolam	3232	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	46
In a small study (N = 8) using various doses in older subjects (59 to 68 years), peak estazolam concentrations were found to be similar to those observed in younger subjects with a mean elimination half-life of 18.4 hours (range 13.5 to 34.6 hours).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	small
4	11	15	O	study
5	18	18	O	N
6	20	20	O	=
7	22	22	O	8
8	25	29	O	using
9	31	37	O	various
10	39	43	O	doses
11	45	46	O	in
12	48	52	O	older
13	54	61	O	subjects
14	64	65	O	59
15	67	68	O	to
16	70	71	O	68
17	73	77	O	years
18	79	79	O	,
19	81	84	O	peak
20	86	94	O	XXXXXXXX
21	96	109	O	concentrations
22	111	114	O	were
23	116	120	O	found
24	122	123	O	to
25	125	126	O	be
26	128	134	O	similar
27	136	137	O	to
28	139	143	O	those
29	145	152	O	observed
30	154	155	O	in
31	157	163	O	younger
32	165	172	O	subjects
33	174	177	O	with
34	179	179	O	a
35	181	184	O	mean
36	186	196	O	elimination
37	198	201	O	half
38	203	206	O	life
39	208	209	O	of
40	211	214	O	18.4
41	216	220	O	hours
42	223	227	O	range
43	229	232	O	13.5
44	234	235	O	to
45	237	240	O	34.6
46	242	246	O	hours
NULL

Estazolam	3233	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	16
The influence of hepatic or renal impairment on the pharmacokinetics of estazolam has not been studied.
1	0	2	O	The
2	4	12	O	influence
3	14	15	O	of
4	17	23	O	hepatic
5	25	26	O	or
6	28	32	O	renal
7	34	43	O	impairment
8	45	46	O	on
9	48	50	O	the
10	52	67	O	pharmacokinetics
11	69	70	O	of
12	72	80	O	XXXXXXXX
13	82	84	O	has
14	86	88	O	not
15	90	93	O	been
16	95	101	O	studied
NULL

Estazolam	3234	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	11
The pharmacokinetics of estazolam have not been studied in pediatric patients.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	32	O	XXXXXXXX
5	34	37	O	have
6	39	41	O	not
7	43	46	O	been
8	48	54	O	studied
9	56	57	O	in
10	59	67	O	pediatric
11	69	76	O	patients
NULL

Estazolam	3235	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	13
The influence of race on the pharmacokinetics of estazolam has not been studied.
1	0	2	O	The
2	4	12	O	influence
3	14	15	O	of
4	17	20	O	race
5	22	23	O	on
6	25	27	O	the
7	29	44	O	pharmacokinetics
8	46	47	O	of
9	49	57	O	XXXXXXXX
10	59	61	O	has
11	63	65	O	not
12	67	70	O	been
13	72	78	O	studied
NULL

Estazolam	3236	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	12
The gender-effect on the pharmacokinetics of estazolam has not been investigated.
1	0	2	O	The
2	4	9	O	gender
3	11	16	O	effect
4	18	19	O	on
5	21	23	O	the
6	25	40	O	pharmacokinetics
7	42	43	O	of
8	45	53	O	XXXXXXXX
9	55	57	O	has
10	59	61	O	not
11	63	66	O	been
12	68	79	O	investigated
NULL

Estazolam	3237	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	21
The clearance of benzodiazepines is accelerated in smokers compared to nonsmokers, and there is evidence that this occurs with estazolam.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	of
4	17	31	O	benzodiazepines
5	33	34	O	is
6	36	46	O	accelerated
7	48	49	O	in
8	51	57	O	smokers
9	59	66	O	compared
10	68	69	O	to
11	71	80	O	nonsmokers
12	81	81	O	,
13	83	85	O	and
14	87	91	O	there
15	93	94	O	is
16	96	103	O	evidence
17	105	108	O	that
18	110	113	O	this
19	115	120	O	occurs
20	122	125	O	with
21	127	135	O	XXXXXXXX
NULL

Estazolam	3238	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	24
This decrease in half-life, presumably due to enzyme induction by smoking, is consistent with other drugs with similar hepatic clearance characteristics.
1	0	3	O	This
2	5	12	O	decrease
3	14	15	O	in
4	17	20	O	half
5	22	25	O	life
6	26	26	O	,
7	28	37	O	presumably
8	39	41	O	due
9	43	44	O	to
10	46	51	O	enzyme
11	53	61	O	induction
12	63	64	O	by
13	66	72	O	smoking
14	73	73	O	,
15	75	76	O	is
16	78	87	O	consistent
17	89	92	O	with
18	94	98	O	other
19	100	104	O	drugs
20	106	109	O	with
21	111	117	O	similar
22	119	125	O	hepatic
23	127	135	O	clearance
24	137	151	O	characteristics
NULL

Estazolam	3239	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	20
In all subjects and at all doses, the mean elimination half-life appeared to be independent of the dose.
1	0	1	O	In
2	3	5	O	all
3	7	14	O	subjects
4	16	18	O	and
5	20	21	O	at
6	23	25	O	all
7	27	31	O	doses
8	32	32	O	,
9	34	36	O	the
10	38	41	O	mean
11	43	53	O	elimination
12	55	58	O	half
13	60	63	O	life
14	65	72	O	appeared
15	74	75	O	to
16	77	78	O	be
17	80	90	O	independent
18	92	93	O	of
19	95	97	O	the
20	99	102	O	dose
NULL

Estazolam	3240	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	16
The metabolism of estazolam to the major circulating metabolite 4-hydroxy-estazolam is catalyzed by CYP3A.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	26	O	XXXXXXXX
5	28	29	O	to
6	31	33	O	the
7	35	39	O	major
8	41	51	O	circulating
9	53	62	O	metabolite
10	64	64	O	4
11	66	72	O	hydroxy
12	74	82	O	XXXXXXXX
13	84	85	O	is
14	87	95	O	catalyzed
15	97	98	O	by
16	100	104	O	CYP3A
NULL

Estazolam	3241	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	64
While no in vivo drug-drug interaction studies were conducted between estazolam and inhibitors/inducers of CYP3A, compounds that are potent CYP3A inhibitors (such as ketoconazole, itraconazole, nefazodone, fluvoxamine, and erythromycin) would be expected to increase plasma estazolam concentrations and CYP3A inducers (such as carbamazepine, phenytoin, rifampin and barbiturates) would be expected to decrease estazolam concentrations.
1	0	4	O	While
2	6	7	O	no
3	9	10	O	in
4	12	15	O	vivo
5	17	20	O	drug
6	22	25	O	drug
7	27	37	O	interaction
8	39	45	O	studies
9	47	50	O	were
10	52	60	O	conducted
11	62	68	O	between
12	70	78	O	XXXXXXXX
13	80	82	O	and
14	84	93	O	inhibitors
15	94	94	O	/
16	95	102	O	inducers
17	104	105	O	of
18	107	111	O	CYP3A
19	112	112	O	,
20	114	122	O	compounds
21	124	127	O	that
22	129	131	O	are
23	133	138	B-KIN	potent
24	140	144	I-KIN	CYP3A
25	146	155	L-KIN	inhibitors
26	158	161	O	such
27	163	164	O	as
28	166	177	U-KIN	ketoconazole
29	178	178	O	,
30	180	191	U-KIN	itraconazole
31	192	192	O	,
32	194	203	U-KIN	nefazodone
33	204	204	O	,
34	206	216	U-KIN	fluvoxamine
35	217	217	O	,
36	219	221	O	and
37	223	234	U-KIN	erythromycin
38	237	241	O	would
39	243	244	O	be
40	246	253	O	expected
41	255	256	O	to
42	258	265	B-TRI	increase
43	267	272	I-TRI	plasma
44	274	282	I-TRI	XXXXXXXX
45	284	297	L-TRI	concentrations
46	299	301	O	and
47	303	307	B-KIN	CYP3A
48	309	316	L-KIN	inducers
49	319	322	O	such
50	324	325	O	as
51	327	339	U-KIN	carbamazepine
52	340	340	O	,
53	342	350	U-KIN	phenytoin
54	351	351	O	,
55	353	360	U-KIN	rifampin
56	362	364	O	and
57	366	377	U-KIN	barbiturates
58	380	384	O	would
59	386	387	O	be
60	389	396	O	expected
61	398	399	O	to
62	401	408	O	decrease
63	410	418	O	XXXXXXXX
64	420	433	O	concentrations
K/23:C54355 K/28:C54355 K/30:C54355 K/32:C54355 K/34:C54355 K/37:C54355 K/47:C54356 K/51:C54356 K/53:C54356 K/55:C54356 K/57:C54356

Estazolam	3244	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	45
The results from in vitro human liver microsomal studies suggest that at therapeutic concentrations, estazolam has no significant inhibitory effect on the major human cytochrome P450 enzyme activities (i.e., CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A).
1	0	2	O	The
2	4	10	O	results
3	12	15	O	from
4	17	18	O	in
5	20	24	O	vitro
6	26	30	O	human
7	32	36	O	liver
8	38	47	O	microsomal
9	49	55	O	studies
10	57	63	O	suggest
11	65	68	O	that
12	70	71	O	at
13	73	83	O	therapeutic
14	85	98	O	concentrations
15	99	99	O	,
16	101	109	O	XXXXXXXX
17	111	113	O	has
18	115	116	O	no
19	118	128	O	significant
20	130	139	O	inhibitory
21	141	146	O	effect
22	148	149	O	on
23	151	153	O	the
24	155	159	O	major
25	161	165	O	human
26	167	176	O	cytochrome
27	178	181	O	P450
28	183	188	O	enzyme
29	190	199	O	activities
30	202	204	O	i.e
31	206	206	O	,
32	208	213	O	CYP1A2
33	214	214	O	,
34	216	221	O	CYP2A6
35	222	222	O	,
36	224	229	O	CYP2C9
37	230	230	O	,
38	232	238	O	CYP2C19
39	239	239	O	,
40	241	246	O	CYP2D6
41	247	247	O	,
42	249	254	O	CYP2E1
43	255	255	O	,
44	257	259	O	and
45	261	265	O	CYP3A
NULL

Estazolam	3245	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	14
The ability of estazolam to induce human hepatic enzyme systems has not been determined.
1	0	2	O	The
2	4	10	O	ability
3	12	13	O	of
4	15	23	O	XXXXXXXX
5	25	26	O	to
6	28	33	O	induce
7	35	39	O	human
8	41	47	O	hepatic
9	49	54	O	enzyme
10	56	62	O	systems
11	64	66	O	has
12	68	70	O	not
13	72	75	O	been
14	77	86	O	determined
NULL

Estazolam	3246	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	50
Postulated relationship between elimination rate of benzodiazepine hypnotics and their profile of common untoward effects: The type and duration of hypnotic effects and the profile of unwanted effects during administration of benzodiazepine drugs may be influenced by the biologic half-life of administered drug and any active metabolites formed.
1	0	9	O	Postulated
2	11	22	O	relationship
3	24	30	O	between
4	32	42	O	elimination
5	44	47	O	rate
6	49	50	O	of
7	52	65	O	benzodiazepine
8	67	75	O	hypnotics
9	77	79	O	and
10	81	85	O	their
11	87	93	O	profile
12	95	96	O	of
13	98	103	O	common
14	105	112	O	untoward
15	114	120	O	effects
16	121	121	O	:
17	123	125	O	The
18	127	130	O	type
19	132	134	O	and
20	136	143	O	duration
21	145	146	O	of
22	148	155	O	hypnotic
23	157	163	O	effects
24	165	167	O	and
25	169	171	O	the
26	173	179	O	profile
27	181	182	O	of
28	184	191	O	unwanted
29	193	199	O	effects
30	201	206	O	during
31	208	221	O	administration
32	223	224	O	of
33	226	239	O	benzodiazepine
34	241	245	O	drugs
35	247	249	O	may
36	251	252	O	be
37	254	263	O	influenced
38	265	266	O	by
39	268	270	O	the
40	272	279	O	biologic
41	281	284	O	half
42	286	289	O	life
43	291	292	O	of
44	294	305	O	administered
45	307	310	O	drug
46	312	314	O	and
47	316	318	O	any
48	320	325	O	active
49	327	337	O	metabolites
50	339	344	O	formed
NULL

Estazolam	3247	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	45
If half-lives are long, drug or metabolites may accumulate during periods of nightly administration and may be associated with impairments of cognitive and/or motor performance during waking hours; the possibility of interaction with other psychoactive drugs or alcohol will be increased.
1	0	1	O	If
2	3	6	O	half
3	8	12	O	lives
4	14	16	O	are
5	18	21	O	long
6	22	22	O	,
7	24	27	O	drug
8	29	30	O	or
9	32	42	O	metabolites
10	44	46	O	may
11	48	57	O	accumulate
12	59	64	O	during
13	66	72	O	periods
14	74	75	O	of
15	77	83	O	nightly
16	85	98	O	administration
17	100	102	O	and
18	104	106	O	may
19	108	109	O	be
20	111	120	O	associated
21	122	125	O	with
22	127	137	O	impairments
23	139	140	O	of
24	142	150	O	cognitive
25	152	154	O	and
26	155	155	O	/
27	156	157	O	or
28	159	163	O	motor
29	165	175	O	performance
30	177	182	O	during
31	184	189	O	waking
32	191	195	O	hours
33	198	200	O	the
34	202	212	O	possibility
35	214	215	O	of
36	217	227	U-TRI	interaction
37	229	232	O	with
38	234	238	O	other
39	240	251	B-UNK	psychoactive
40	253	257	L-UNK	drugs
41	259	260	O	or
42	262	268	U-UNK	alcohol
43	270	273	O	will
44	275	276	O	be
45	278	286	O	increased
NULL

Estazolam	3248	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	38
In contrast, if half-lives are short, drug and metabolites will be cleared before the next dose is ingested, and carry-over effects related to excessive sedation or CNS depression should be minimal or absent.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	14	O	if
5	16	19	O	half
6	21	25	O	lives
7	27	29	O	are
8	31	35	O	short
9	36	36	O	,
10	38	41	O	drug
11	43	45	O	and
12	47	57	O	metabolites
13	59	62	O	will
14	64	65	O	be
15	67	73	O	cleared
16	75	80	O	before
17	82	84	O	the
18	86	89	O	next
19	91	94	O	dose
20	96	97	O	is
21	99	106	O	ingested
22	107	107	O	,
23	109	111	O	and
24	113	117	O	carry
25	119	122	O	over
26	124	130	O	effects
27	132	138	O	related
28	140	141	O	to
29	143	151	O	excessive
30	153	160	O	sedation
31	162	163	O	or
32	165	167	O	CNS
33	169	178	O	depression
34	180	185	O	should
35	187	188	O	be
36	190	196	O	minimal
37	198	199	O	or
38	201	206	O	absent
NULL

Estazolam	3249	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	22
However, during nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of benzodiazepine hypnotics may develop.
1	0	6	O	However
2	7	7	O	,
3	9	14	O	during
4	16	22	O	nightly
5	24	26	O	use
6	28	30	O	for
7	32	33	O	an
8	35	42	O	extended
9	44	49	O	period
10	50	50	O	,
11	52	66	O	pharmacodynamic
12	68	76	O	tolerance
13	78	79	O	or
14	81	90	O	adaptation
15	92	93	O	to
16	95	98	O	some
17	100	106	O	effects
18	108	109	O	of
19	111	124	O	benzodiazepine
20	126	134	O	hypnotics
21	136	138	O	may
22	140	146	O	develop
NULL

Estazolam	3250	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	44
If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug or its active metabolites (i.e., in relationship to the receptor site) may occur at some point in the interval between each night's use.
1	0	1	O	If
2	3	5	O	the
3	7	10	O	drug
4	12	14	O	has
5	16	16	O	a
6	18	22	O	short
7	24	34	O	elimination
8	36	39	O	half
9	41	44	O	life
10	45	45	O	,
11	47	48	O	it
12	50	51	O	is
13	53	60	O	possible
14	62	65	O	that
15	67	67	O	a
16	69	76	O	relative
17	78	87	O	deficiency
18	89	90	O	of
19	92	94	O	the
20	96	99	O	drug
21	101	102	O	or
22	104	106	O	its
23	108	113	O	active
24	115	125	O	metabolites
25	128	130	O	i.e
26	132	132	O	,
27	134	135	O	in
28	137	148	O	relationship
29	150	151	O	to
30	153	155	O	the
31	157	164	O	receptor
32	166	169	O	site
33	172	174	O	may
34	176	180	O	occur
35	182	183	O	at
36	185	188	O	some
37	190	194	O	point
38	196	197	O	in
39	199	201	O	the
40	203	210	O	interval
41	212	218	O	between
42	220	223	O	each
43	225	231	O	night's
44	233	235	O	use
NULL

Estazolam	3251	34090-1	50914a46-eab6-4c83-97cf-6ab0234c8126	43
This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepine hypnotics, namely, increased wakefulness during the last third of the night and increased daytime anxiety in selected patients.
1	0	3	O	This
2	5	12	O	sequence
3	14	15	O	of
4	17	22	O	events
5	24	26	O	may
6	28	34	O	account
7	36	38	O	for
8	40	42	O	two
9	44	51	O	clinical
10	53	60	O	findings
11	62	69	O	reported
12	71	72	O	to
13	74	78	O	occur
14	80	84	O	after
15	86	92	O	several
16	94	98	O	weeks
17	100	101	O	of
18	103	109	O	nightly
19	111	113	O	use
20	115	116	O	of
21	118	124	O	rapidly
22	126	135	O	eliminated
23	137	150	O	benzodiazepine
24	152	160	O	hypnotics
25	161	161	O	,
26	163	168	O	namely
27	169	169	O	,
28	171	179	O	increased
29	181	191	O	wakefulness
30	193	198	O	during
31	200	202	O	the
32	204	207	O	last
33	209	213	O	third
34	215	216	O	of
35	218	220	O	the
36	222	226	O	night
37	228	230	O	and
38	232	240	O	increased
39	242	248	O	daytime
40	250	256	O	anxiety
41	258	259	O	in
42	261	268	O	selected
43	270	277	O	patients
NULL

Eszopiclone	268	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	10
CNS Depressants: Additive CNS-depressant effects with combination use.
1	0	2	B-DYN	CNS
2	4	14	L-DYN	Depressants
3	15	15	O	:
4	17	24	B-EFF	Additive
5	26	28	I-EFF	CNS
6	30	39	I-EFF	depressant
7	41	47	L-EFF	effects
8	49	52	O	with
9	54	64	O	combination
10	66	68	O	use
D/1:4:1

Eszopiclone	269	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	30
Use with ethanol causes additive psychomotor impairment (7.1) Rifampicin: Combination use may decrease exposure and effects of LUNESTA (7.2) Ketoconazole: Combination use increases exposure and effect of LUNESTA.
1	0	2	O	Use
2	4	7	O	with
3	9	15	U-DYN	ethanol
4	17	22	O	causes
5	24	31	B-EFF	additive
6	33	43	I-EFF	psychomotor
7	45	54	L-EFF	impairment
8	57	59	O	7.1
9	62	71	U-KIN	Rifampicin
10	72	72	O	:
11	74	84	O	Combination
12	86	88	O	use
13	90	92	O	may
14	94	101	B-TRI	decrease
15	103	110	L-TRI	exposure
16	112	114	O	and
17	116	122	O	effects
18	124	125	O	of
19	127	133	O	LUNESTA
20	136	138	O	7.2
21	141	152	U-KIN	Ketoconazole
22	153	153	O	:
23	155	165	O	Combination
24	167	169	O	use
25	171	179	B-TRI	increases
26	181	188	L-TRI	exposure
27	190	192	O	and
28	194	199	O	effect
29	201	202	O	of
30	204	210	O	LUNESTA
D/3:5:1K/21:C54355 K/9:C54356

Eszopiclone	270	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	23
Dose reduction of LUNESTA is needed (7.2) Ethanol: An additive effect on psychomotor performance was seen with coadministration of eszopiclone and ethanol.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	of
4	18	24	O	LUNESTA
5	26	27	O	is
6	29	34	O	needed
7	37	39	O	7.2
8	42	48	O	Ethanol
9	49	49	O	:
10	51	52	O	An
11	54	61	B-EFF	additive
12	63	68	I-EFF	effect
13	70	71	I-EFF	on
14	73	83	I-EFF	psychomotor
15	85	95	L-EFF	performance
16	97	99	O	was
17	101	104	O	seen
18	106	109	O	with
19	111	126	O	coadministration
20	128	129	O	of
21	131	141	O	XXXXXXXX
22	143	145	O	and
23	147	153	U-DYN	ethanol
D/23:11:1

Eszopiclone	271	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	13
Olanzapine: Coadministration of eszopiclone and olanzapine produced a decrease in DSST scores.
1	0	9	O	Olanzapine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	42	O	XXXXXXXX
6	44	46	O	and
7	48	57	U-DYN	olanzapine
8	59	66	O	produced
9	68	68	O	a
10	70	77	B-EFF	decrease
11	79	80	I-EFF	in
12	82	85	I-EFF	DSST
13	87	92	L-EFF	scores
D/7:10:1

Eszopiclone	272	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	14
The interaction was pharmacodynamic; there was no alteration in the pharmacokinetics of either drug.
1	0	2	O	The
2	4	14	O	interaction
3	16	18	O	was
4	20	34	O	pharmacodynamic
5	37	41	O	there
6	43	45	O	was
7	47	48	O	no
8	50	59	O	alteration
9	61	62	O	in
10	64	66	O	the
11	68	83	O	pharmacokinetics
12	85	86	O	of
13	88	93	O	either
14	95	98	O	drug
NULL

Eszopiclone	273	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	15
Drugs That Inhibit CYP3A4 (Ketoconazole) CYP3A4 is a major metabolic pathway for elimination of eszopiclone.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	24	O	CYP3A4
5	27	38	O	Ketoconazole
6	41	46	O	CYP3A4
7	48	49	O	is
8	51	51	O	a
9	53	57	O	major
10	59	67	O	metabolic
11	69	75	O	pathway
12	77	79	O	for
13	81	91	O	elimination
14	93	94	O	of
15	96	106	O	XXXXXXXX
NULL

Eszopiclone	274	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	16
The exposure of eszopiclone was increased by coadministration of ketoconazole, a potent inhibitor of CYP3A4.
1	0	2	O	The
2	4	11	O	exposure
3	13	14	O	of
4	16	26	O	XXXXXXXX
5	28	30	O	was
6	32	40	O	increased
7	42	43	O	by
8	45	60	O	coadministration
9	62	63	O	of
10	65	76	U-KIN	ketoconazole
11	77	77	O	,
12	79	79	O	a
13	81	86	O	potent
14	88	96	O	inhibitor
15	98	99	O	of
16	101	106	O	CYP3A4
K/10:C54355

Eszopiclone	275	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	24
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.
1	0	4	O	Other
2	6	11	O	strong
3	13	22	O	inhibitors
4	24	25	O	of
5	27	32	O	CYP3A4
6	35	37	O	e.g
7	39	39	O	,
8	41	52	O	itraconazole
9	53	53	O	,
10	55	68	O	clarithromycin
11	69	69	O	,
12	71	80	O	nefazodone
13	81	81	O	,
14	83	96	O	troleandomycin
15	97	97	O	,
16	99	107	O	ritonavir
17	108	108	O	,
18	110	119	O	nelfinavir
19	122	126	O	would
20	128	129	O	be
21	131	138	O	expected
22	140	141	O	to
23	143	148	O	behave
24	150	158	O	similarly
NULL

Eszopiclone	276	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	15
Dose reduction of LUNESTA is needed for patient co-administered LUNESTA with potent CYP3A4 inhibitors.
1	0	3	B-TRI	Dose
2	5	13	L-TRI	reduction
3	15	16	O	of
4	18	24	O	LUNESTA
5	26	27	O	is
6	29	34	O	needed
7	36	38	O	for
8	40	46	O	patient
9	48	49	O	co
10	51	62	O	administered
11	64	70	O	LUNESTA
12	72	75	O	with
13	77	82	O	potent
14	84	89	B-KIN	CYP3A4
15	91	100	L-KIN	inhibitors
K/14:C54355

Eszopiclone	277	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	22
Drugs that Induce CYP3A4 (Rifampicin) Racemic zopiclone exposure was decreased 80% by concomitant use of rifampicin, a potent inducer of CYP3A4.
1	0	4	O	Drugs
2	6	9	O	that
3	11	16	O	Induce
4	18	23	O	CYP3A4
5	26	35	O	Rifampicin
6	38	44	O	Racemic
7	46	54	O	zopiclone
8	56	63	O	exposure
9	65	67	O	was
10	69	77	O	decreased
11	79	81	O	80%
12	83	84	O	by
13	86	96	O	concomitant
14	98	100	O	use
15	102	103	O	of
16	105	114	U-KIN	rifampicin
17	115	115	O	,
18	117	117	O	a
19	119	124	O	potent
20	126	132	O	inducer
21	134	135	O	of
22	137	142	O	CYP3A4
K/16:C54356

Eszopiclone	278	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	8
A similar effect would be expected with eszopiclone.
1	0	0	O	A
2	2	8	O	similar
3	10	15	O	effect
4	17	21	O	would
5	23	24	O	be
6	26	33	O	expected
7	35	38	O	with
8	40	50	O	XXXXXXXX
NULL

Eszopiclone	279	34073-7	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	13
Combination use with CYP3A4 inducer may decrease the exposure and effects of LUNESTA.
1	0	10	O	Combination
2	12	14	O	use
3	16	19	O	with
4	21	26	B-DYN	CYP3A4
5	28	34	L-DYN	inducer
6	36	38	O	may
7	40	47	O	decrease
8	49	51	O	the
9	53	60	O	exposure
10	62	64	O	and
11	66	72	O	effects
12	74	75	O	of
13	77	83	O	LUNESTA
NULL

Eszopiclone	280	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	39
The precise mechanism of action of eszopiclone as a hypnotic is unknown, but its effect is believed to result from its interaction with GABA-receptor complexes at binding domains located close to or allosterically coupled to benzodiazepine receptors.
1	0	2	O	The
2	4	10	O	precise
3	12	20	O	mechanism
4	22	23	O	of
5	25	30	O	action
6	32	33	O	of
7	35	45	O	XXXXXXXX
8	47	48	O	as
9	50	50	O	a
10	52	59	O	hypnotic
11	61	62	O	is
12	64	70	O	unknown
13	71	71	O	,
14	73	75	O	but
15	77	79	O	its
16	81	86	O	effect
17	88	89	O	is
18	91	98	O	believed
19	100	101	O	to
20	103	108	O	result
21	110	113	O	from
22	115	117	O	its
23	119	129	O	interaction
24	131	134	O	with
25	136	139	O	GABA
26	141	148	O	receptor
27	150	158	O	complexes
28	160	161	O	at
29	163	169	O	binding
30	171	177	O	domains
31	179	185	O	located
32	187	191	O	close
33	193	194	O	to
34	196	197	O	or
35	199	212	O	allosterically
36	214	220	O	coupled
37	222	223	O	to
38	225	238	O	benzodiazepine
39	240	248	O	receptors
NULL

Eszopiclone	281	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	35
Eszopiclone is a nonbenzodiazepine hypnotic that is a pyrrolopyrazine derivative of the cyclopyrrolone class with a chemical structure unrelated to pyrazolopyrimidines, imidazopyridines, benzodiazepines, barbiturates, or other drugs with known hypnotic properties.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	33	O	nonbenzodiazepine
5	35	42	O	hypnotic
6	44	47	O	that
7	49	50	O	is
8	52	52	O	a
9	54	68	O	pyrrolopyrazine
10	70	79	O	derivative
11	81	82	O	of
12	84	86	O	the
13	88	101	O	cyclopyrrolone
14	103	107	O	class
15	109	112	O	with
16	114	114	O	a
17	116	123	O	chemical
18	125	133	O	structure
19	135	143	O	unrelated
20	145	146	O	to
21	148	166	O	pyrazolopyrimidines
22	167	167	O	,
23	169	184	O	imidazopyridines
24	185	185	O	,
25	187	201	O	benzodiazepines
26	202	202	O	,
27	204	215	O	barbiturates
28	216	216	O	,
29	218	219	O	or
30	221	225	O	other
31	227	231	O	drugs
32	233	236	O	with
33	238	242	O	known
34	244	251	O	hypnotic
35	253	262	O	properties
NULL

Eszopiclone	282	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	22
The pharmacokinetics of eszopiclone have been investigated in healthy subjects (adult and elderly) and in patients with hepatic disease or renal disease.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	O	XXXXXXXX
5	36	39	O	have
6	41	44	O	been
7	46	57	O	investigated
8	59	60	O	in
9	62	68	O	healthy
10	70	77	O	subjects
11	80	84	O	adult
12	86	88	O	and
13	90	96	O	elderly
14	99	101	O	and
15	103	104	O	in
16	106	113	O	patients
17	115	118	O	with
18	120	126	O	hepatic
19	128	134	O	disease
20	136	137	O	or
21	139	143	O	renal
22	145	151	O	disease
NULL

Eszopiclone	283	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	33
In healthy subjects, the pharmacokinetic profile was examined after single doses of up to 7.5 mg and after once-daily administration of 1, 3, and 6 mg for 7 days.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	19	19	O	,
5	21	23	O	the
6	25	39	O	pharmacokinetic
7	41	47	O	profile
8	49	51	O	was
9	53	60	O	examined
10	62	66	O	after
11	68	73	O	single
12	75	79	O	doses
13	81	82	O	of
14	84	85	O	up
15	87	88	O	to
16	90	92	O	7.5
17	94	95	O	mg
18	97	99	O	and
19	101	105	O	after
20	107	110	O	once
21	112	116	O	daily
22	118	131	O	administration
23	133	134	O	of
24	136	136	O	1
25	137	137	O	,
26	139	139	O	3
27	140	140	O	,
28	142	144	O	and
29	146	146	O	6
30	148	149	O	mg
31	151	153	O	for
32	155	155	O	7
33	157	160	O	days
NULL

Eszopiclone	284	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	30
Eszopiclone is rapidly absorbed, with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 6 hours.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	21	O	rapidly
4	23	30	O	absorbed
5	31	31	O	,
6	33	36	O	with
7	38	38	O	a
8	40	43	O	time
9	45	46	O	to
10	48	51	O	peak
11	53	65	O	concentration
12	68	71	O	tmax
13	74	75	O	of
14	77	89	O	approximately
15	91	91	O	1
16	93	96	O	hour
17	98	100	O	and
18	102	102	O	a
19	104	111	O	terminal
20	113	117	O	phase
21	119	129	O	elimination
22	131	134	O	half
23	136	139	O	life
24	142	143	O	t1
25	144	144	O	/
26	145	145	O	2
27	148	149	O	of
28	151	163	O	approximately
29	165	165	O	6
30	167	171	O	hours
NULL

Eszopiclone	285	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	37
In healthy adults, LUNESTA does not accumulate with once-daily administration, and its exposure is dose-proportional over the range of 1 to 6 mg. Absorption and Distribution Eszopiclone is rapidly absorbed following oral administration.
1	0	1	O	In
2	3	9	O	healthy
3	11	16	O	adults
4	17	17	O	,
5	19	25	O	LUNESTA
6	27	30	O	does
7	32	34	O	not
8	36	45	O	accumulate
9	47	50	O	with
10	52	55	O	once
11	57	61	O	daily
12	63	76	O	administration
13	77	77	O	,
14	79	81	O	and
15	83	85	O	its
16	87	94	O	exposure
17	96	97	O	is
18	99	102	O	dose
19	104	115	O	proportional
20	117	120	O	over
21	122	124	O	the
22	126	130	O	range
23	132	133	O	of
24	135	135	O	1
25	137	138	O	to
26	140	140	O	6
27	142	143	O	mg
28	146	155	O	Absorption
29	157	159	O	and
30	161	172	O	Distribution
31	174	184	O	XXXXXXXX
32	186	187	O	is
33	189	195	O	rapidly
34	197	204	O	absorbed
35	206	214	O	following
36	216	219	O	oral
37	221	234	O	administration
NULL

Eszopiclone	286	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	12
Peak plasma concentrations are achieved within approximately 1 hour after oral administration.
1	0	3	O	Peak
2	5	10	O	plasma
3	12	25	O	concentrations
4	27	29	O	are
5	31	38	O	achieved
6	40	45	O	within
7	47	59	O	approximately
8	61	61	O	1
9	63	66	O	hour
10	68	72	O	after
11	74	77	O	oral
12	79	92	O	administration
NULL

Eszopiclone	287	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	9
Eszopiclone is weakly bound to plasma protein (52-59%).
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	20	O	weakly
4	22	26	O	bound
5	28	29	O	to
6	31	36	O	plasma
7	38	44	O	protein
8	47	48	O	52
9	50	52	O	59%
NULL

Eszopiclone	288	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	20
The large free fraction suggests that eszopiclone disposition should not be affected by drug-drug interactions caused by protein binding.
1	0	2	O	The
2	4	8	O	large
3	10	13	O	free
4	15	22	O	fraction
5	24	31	O	suggests
6	33	36	O	that
7	38	48	O	XXXXXXXX
8	50	60	O	disposition
9	62	67	O	should
10	69	71	O	not
11	73	74	O	be
12	76	83	O	affected
13	85	86	O	by
14	88	91	O	drug
15	93	96	O	drug
16	98	109	O	interactions
17	111	116	O	caused
18	118	119	O	by
19	121	127	O	protein
20	129	135	O	binding
NULL

Eszopiclone	289	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	20
The blood-to-plasma ratio for eszopiclone is less than one, indicating no selective uptake by red blood cells.
1	0	2	O	The
2	4	8	O	blood
3	10	11	O	to
4	13	18	O	plasma
5	20	24	O	ratio
6	26	28	O	for
7	30	40	O	XXXXXXXX
8	42	43	O	is
9	45	48	O	less
10	50	53	O	than
11	55	57	O	one
12	58	58	O	,
13	60	69	O	indicating
14	71	72	O	no
15	74	82	O	selective
16	84	89	O	uptake
17	91	92	O	by
18	94	96	O	red
19	98	102	O	blood
20	104	108	O	cells
NULL

Eszopiclone	290	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	13
Metabolism Following oral administration, eszopiclone is extensively metabolized by oxidation and demethylation.
1	0	9	O	Metabolism
2	11	19	O	Following
3	21	24	O	oral
4	26	39	O	administration
5	40	40	O	,
6	42	52	O	XXXXXXXX
7	54	55	O	is
8	57	67	O	extensively
9	69	79	O	metabolized
10	81	82	O	by
11	84	92	O	oxidation
12	94	96	O	and
13	98	110	O	demethylation
NULL

Eszopiclone	291	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	39
The primary plasma metabolites are (S)-zopiclone-N-oxide and (S)-N-desmethyl zopiclone; the latter compound binds to GABA receptors with substantially lower potency than eszopiclone, and the former compound shows no significant binding to this receptor.
1	0	2	O	The
2	4	10	O	primary
3	12	17	O	plasma
4	19	29	O	metabolites
5	31	33	O	are
6	36	36	O	S
7	39	47	O	zopiclone
8	49	49	O	N
9	51	55	O	oxide
10	57	59	O	and
11	62	62	O	S
12	65	65	O	N
13	67	75	O	desmethyl
14	77	85	O	zopiclone
15	88	90	O	the
16	92	97	O	latter
17	99	106	O	compound
18	108	112	O	binds
19	114	115	O	to
20	117	120	O	GABA
21	122	130	O	receptors
22	132	135	O	with
23	137	149	O	substantially
24	151	155	O	lower
25	157	163	O	potency
26	165	168	O	than
27	170	180	O	XXXXXXXX
28	181	181	O	,
29	183	185	O	and
30	187	189	O	the
31	191	196	O	former
32	198	205	O	compound
33	207	211	O	shows
34	213	214	O	no
35	216	226	O	significant
36	228	234	O	binding
37	236	237	O	to
38	239	242	O	this
39	244	251	O	receptor
NULL

Eszopiclone	292	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	17
In vitro studies have shown that CYP3A4 and CYP2E1 enzymes are involved in the metabolism of eszopiclone.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	38	O	CYP3A4
8	40	42	O	and
9	44	49	O	CYP2E1
10	51	57	O	enzymes
11	59	61	O	are
12	63	70	O	involved
13	72	73	O	in
14	75	77	O	the
15	79	88	O	metabolism
16	90	91	O	of
17	93	103	O	XXXXXXXX
NULL

Eszopiclone	293	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	27
Eszopiclone did not show any inhibitory potential on CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes.
1	0	10	O	XXXXXXXX
2	12	14	O	did
3	16	18	O	not
4	20	23	O	show
5	25	27	O	any
6	29	38	O	inhibitory
7	40	48	O	potential
8	50	51	O	on
9	53	58	O	CYP450
10	60	62	O	1A2
11	63	63	O	,
12	65	67	O	2A6
13	68	68	O	,
14	70	72	O	2C9
15	73	73	O	,
16	75	78	O	2C19
17	79	79	O	,
18	81	83	O	2D6
19	84	84	O	,
20	86	88	O	2E1
21	89	89	O	,
22	91	93	O	and
23	95	97	O	3A4
24	99	100	O	in
25	102	114	O	cryopreserved
26	116	120	O	human
27	122	132	O	hepatocytes
NULL

Eszopiclone	294	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	18
Elimination After oral administration, eszopiclone is eliminated with a mean t1/2 of approximately 6 hours.
1	0	10	O	Elimination
2	12	16	O	After
3	18	21	O	oral
4	23	36	O	administration
5	37	37	O	,
6	39	49	O	XXXXXXXX
7	51	52	O	is
8	54	63	O	eliminated
9	65	68	O	with
10	70	70	O	a
11	72	75	O	mean
12	77	78	O	t1
13	79	79	O	/
14	80	80	O	2
15	82	83	O	of
16	85	97	O	approximately
17	99	99	O	6
18	101	105	O	hours
NULL

Eszopiclone	295	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	19
Up to 75% of an oral dose of racemic zopiclone is excreted in the urine, primarily as metabolites.
1	0	1	O	Up
2	3	4	O	to
3	6	8	O	75%
4	10	11	O	of
5	13	14	O	an
6	16	19	O	oral
7	21	24	O	dose
8	26	27	O	of
9	29	35	O	racemic
10	37	45	O	zopiclone
11	47	48	O	is
12	50	57	O	excreted
13	59	60	O	in
14	62	64	O	the
15	66	70	O	urine
16	71	71	O	,
17	73	81	O	primarily
18	83	84	O	as
19	86	96	O	metabolites
NULL

Eszopiclone	296	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	16
A similar excretion profile would be expected for eszopiclone, the S-isomer of racemic zopiclone.
1	0	0	O	A
2	2	8	O	similar
3	10	18	O	excretion
4	20	26	O	profile
5	28	32	O	would
6	34	35	O	be
7	37	44	O	expected
8	46	48	O	for
9	50	60	O	XXXXXXXX
10	61	61	O	,
11	63	65	O	the
12	67	67	O	S
13	69	74	O	isomer
14	76	77	O	of
15	79	85	O	racemic
16	87	95	O	zopiclone
NULL

Eszopiclone	297	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	17
Less than 10% of the orally administered eszopiclone dose is excreted in the urine as parent drug.
1	0	3	O	Less
2	5	8	O	than
3	10	12	O	10%
4	14	15	O	of
5	17	19	O	the
6	21	26	O	orally
7	28	39	O	administered
8	41	51	O	XXXXXXXX
9	53	56	O	dose
10	58	59	O	is
11	61	68	O	excreted
12	70	71	O	in
13	73	75	O	the
14	77	81	O	urine
15	83	84	O	as
16	86	91	O	parent
17	93	96	O	drug
NULL

Eszopiclone	298	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	42
Effect of Food In healthy adults, administration of a 3 mg dose of eszopiclone after a high-fat meal resulted in no change in AUC, a reduction in mean Cmax of 21%, and delayed tmax by approximately 1 hour.
1	0	5	O	Effect
2	7	8	O	of
3	10	13	O	Food
4	15	16	O	In
5	18	24	O	healthy
6	26	31	O	adults
7	32	32	O	,
8	34	47	O	administration
9	49	50	O	of
10	52	52	O	a
11	54	54	O	3
12	56	57	O	mg
13	59	62	O	dose
14	64	65	O	of
15	67	77	O	XXXXXXXX
16	79	83	O	after
17	85	85	O	a
18	87	90	B-KIN	high
19	92	94	I-KIN	fat
20	96	99	L-KIN	meal
21	101	108	O	resulted
22	110	111	O	in
23	113	114	O	no
24	116	121	O	change
25	123	124	O	in
26	126	128	O	AUC
27	129	129	O	,
28	131	131	O	a
29	133	141	O	reduction
30	143	144	O	in
31	146	149	O	mean
32	151	154	O	Cmax
33	156	157	O	of
34	159	161	O	21%
35	162	162	O	,
36	164	166	O	and
37	168	174	B-TRI	delayed
38	176	179	L-TRI	tmax
39	181	182	O	by
40	184	196	O	approximately
41	198	198	O	1
42	200	203	O	hour
K/18:C54606

Eszopiclone	299	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	9
The half-life remained unchanged, approximately 6 hours.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	21	O	remained
5	23	31	O	unchanged
6	32	32	O	,
7	34	46	O	approximately
8	48	48	O	6
9	50	54	O	hours
NULL

Eszopiclone	300	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	24
The effects of LUNESTA on sleep onset may be reduced if it is taken with or immediately after a high-fat/heavy meal.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	21	O	LUNESTA
5	23	24	O	on
6	26	30	O	sleep
7	32	36	O	onset
8	38	40	O	may
9	42	43	O	be
10	45	51	O	reduced
11	53	54	O	if
12	56	57	O	it
13	59	60	O	is
14	62	66	O	taken
15	68	71	O	with
16	73	74	O	or
17	76	86	O	immediately
18	88	92	O	after
19	94	94	O	a
20	96	99	B-DYN	high
21	101	103	I-DYN	fat
22	104	104	I-DYN	/
23	105	109	I-DYN	heavy
24	111	114	L-DYN	meal
NULL

Eszopiclone	301	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	35
Specific Populations Age Compared with non-elderly adults, subjects 65 years and older had an increase of 41% in total exposure (AUC) and a slightly prolonged elimination of eszopiclone (t1/2 approximately 9hours).
1	0	7	O	Specific
2	9	19	O	Populations
3	21	23	O	Age
4	25	32	O	Compared
5	34	37	O	with
6	39	41	O	non
7	43	49	O	elderly
8	51	56	O	adults
9	57	57	O	,
10	59	66	O	subjects
11	68	69	O	65
12	71	75	O	years
13	77	79	O	and
14	81	85	O	older
15	87	89	O	had
16	91	92	O	an
17	94	101	O	increase
18	103	104	O	of
19	106	108	O	41%
20	110	111	O	in
21	113	117	O	total
22	119	126	O	exposure
23	129	131	O	AUC
24	134	136	O	and
25	138	138	O	a
26	140	147	O	slightly
27	149	157	O	prolonged
28	159	169	O	elimination
29	171	172	O	of
30	174	184	O	XXXXXXXX
31	187	188	O	t1
32	189	189	O	/
33	190	190	O	2
34	192	204	O	approximately
35	206	211	O	9hours
NULL

Eszopiclone	302	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	12
Therefore, in elderly patients the dose should not exceed 2 mg.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	20	O	elderly
5	22	29	O	patients
6	31	33	O	the
7	35	38	O	dose
8	40	45	O	should
9	47	49	O	not
10	51	56	O	exceed
11	58	58	O	2
12	60	61	O	mg
NULL

Eszopiclone	303	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	11
Gender The pharmacokinetics of eszopiclone in men and women are similar.
1	0	5	O	Gender
2	7	9	O	The
3	11	26	O	pharmacokinetics
4	28	29	O	of
5	31	41	O	XXXXXXXX
6	43	44	O	in
7	46	48	O	men
8	50	52	O	and
9	54	58	O	women
10	60	62	O	are
11	64	70	O	similar
NULL

Eszopiclone	304	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	25
Race In an analysis of data on all subjects participating in Phase 1 studies of eszopiclone, the pharmacokinetics for all races studied appeared similar.
1	0	3	O	Race
2	5	6	O	In
3	8	9	O	an
4	11	18	O	analysis
5	20	21	O	of
6	23	26	O	data
7	28	29	O	on
8	31	33	O	all
9	35	42	O	subjects
10	44	56	O	participating
11	58	59	O	in
12	61	65	O	Phase
13	67	67	O	1
14	69	75	O	studies
15	77	78	O	of
16	80	90	O	XXXXXXXX
17	91	91	O	,
18	93	95	O	the
19	97	112	O	pharmacokinetics
20	114	116	O	for
21	118	120	O	all
22	122	126	O	races
23	128	134	O	studied
24	136	143	O	appeared
25	145	151	O	similar
NULL

Eszopiclone	305	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	27
Hepatic Impairment Pharmacokinetics of a 2 mg eszopiclone dose were assessed in 16 healthy volunteers and in 8subjects with mild, moderate, and severe liver disease.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	19	34	O	Pharmacokinetics
4	36	37	O	of
5	39	39	O	a
6	41	41	O	2
7	43	44	O	mg
8	46	56	O	XXXXXXXX
9	58	61	O	dose
10	63	66	O	were
11	68	75	O	assessed
12	77	78	O	in
13	80	81	O	16
14	83	89	O	healthy
15	91	100	O	volunteers
16	102	104	O	and
17	106	107	O	in
18	109	117	O	8subjects
19	119	122	O	with
20	124	127	O	mild
21	128	128	O	,
22	130	137	O	moderate
23	138	138	O	,
24	140	142	O	and
25	144	149	O	severe
26	151	155	O	liver
27	157	163	O	disease
NULL

Eszopiclone	306	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	14
Exposure was increased 2-fold in severely impaired patients compared with the healthy volunteers.
1	0	7	O	Exposure
2	9	11	O	was
3	13	21	O	increased
4	23	23	O	2
5	25	28	O	fold
6	30	31	O	in
7	33	40	O	severely
8	42	49	O	impaired
9	51	58	O	patients
10	60	67	O	compared
11	69	72	O	with
12	74	76	O	the
13	78	84	O	healthy
14	86	95	O	volunteers
NULL

Eszopiclone	307	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	13
No dose adjustment is necessary for patients with mild-to-moderate hepatic impairment.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	30	O	necessary
6	32	34	O	for
7	36	43	O	patients
8	45	48	O	with
9	50	53	O	mild
10	55	56	O	to
11	58	65	O	moderate
12	67	73	O	hepatic
13	75	84	O	impairment
NULL

Eszopiclone	308	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	10
Dose reduction is recommended for patients with severe hepatic impairment.
1	0	3	O	Dose
2	5	13	O	reduction
3	15	16	O	is
4	18	28	O	recommended
5	30	32	O	for
6	34	41	O	patients
7	43	46	O	with
8	48	53	O	severe
9	55	61	O	hepatic
10	63	72	O	impairment
NULL

Eszopiclone	309	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	11
LUNESTA should be used with caution in patients with hepatic impairment.
1	0	6	O	LUNESTA
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	with
6	28	34	O	caution
7	36	37	O	in
8	39	46	O	patients
9	48	51	O	with
10	53	59	O	hepatic
11	61	70	O	impairment
NULL

Eszopiclone	310	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	20
Renal Impairment The pharmacokinetics of eszopiclone were studied in 24 patients with mild, moderate, or severe renal impairment.
1	0	4	O	Renal
2	6	15	O	Impairment
3	17	19	O	The
4	21	36	O	pharmacokinetics
5	38	39	O	of
6	41	51	O	XXXXXXXX
7	53	56	O	were
8	58	64	O	studied
9	66	67	O	in
10	69	70	O	24
11	72	79	O	patients
12	81	84	O	with
13	86	89	O	mild
14	90	90	O	,
15	92	99	O	moderate
16	100	100	O	,
17	102	103	O	or
18	105	110	O	severe
19	112	116	O	renal
20	118	127	O	impairment
NULL

Eszopiclone	311	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	15
AUC and Cmax were similar in the patients compared with demographically matched healthy control subjects.
1	0	2	O	AUC
2	4	6	O	and
3	8	11	O	Cmax
4	13	16	O	were
5	18	24	O	similar
6	26	27	O	in
7	29	31	O	the
8	33	40	O	patients
9	42	49	O	compared
10	51	54	O	with
11	56	70	O	demographically
12	72	78	O	matched
13	80	86	O	healthy
14	88	94	O	control
15	96	103	O	subjects
NULL

Eszopiclone	312	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	29
No dose adjustment is necessary in patients with renal impairment, since less than 10% of the orally administered eszopiclone dose is excreted in the urine as parent drug.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	30	O	necessary
6	32	33	O	in
7	35	42	O	patients
8	44	47	O	with
9	49	53	O	renal
10	55	64	O	impairment
11	65	65	O	,
12	67	71	O	since
13	73	76	O	less
14	78	81	O	than
15	83	85	O	10%
16	87	88	O	of
17	90	92	O	the
18	94	99	O	orally
19	101	112	O	administered
20	114	124	O	XXXXXXXX
21	126	129	O	dose
22	131	132	O	is
23	134	141	O	excreted
24	143	144	O	in
25	146	148	O	the
26	150	154	O	urine
27	156	157	O	as
28	159	164	O	parent
29	166	169	O	drug
NULL

Eszopiclone	313	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	13
Drug Interactions Eszopiclone is metabolized by CYP3A4 and CYP2E1 via demethylation and oxidation.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	28	O	XXXXXXXX
4	30	31	O	is
5	33	43	O	metabolized
6	45	46	O	by
7	48	53	O	CYP3A4
8	55	57	O	and
9	59	64	O	CYP2E1
10	66	68	O	via
11	70	82	O	demethylation
12	84	86	O	and
13	88	96	O	oxidation
NULL

Eszopiclone	314	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	11
There were no pharmacokinetic or pharmacodynamic interactions between eszopiclone and paroxetine.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	28	O	pharmacokinetic
5	30	31	O	or
6	33	47	O	pharmacodynamic
7	49	60	O	interactions
8	62	68	O	between
9	70	80	O	XXXXXXXX
10	82	84	O	and
11	86	95	O	paroxetine
NULL

Eszopiclone	315	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	31
When eszopiclone was coadministered with olanzapine, no pharmacokinetic interaction was detected in levels of eszopiclone or olanzapine, but a pharmacodynamic interaction was seen on a measure of psychomotor function.
1	0	3	O	When
2	5	15	O	XXXXXXXX
3	17	19	O	was
4	21	34	O	coadministered
5	36	39	O	with
6	41	50	U-DYN	olanzapine
7	51	51	O	,
8	53	54	O	no
9	56	70	O	pharmacokinetic
10	72	82	O	interaction
11	84	86	O	was
12	88	95	O	detected
13	97	98	O	in
14	100	105	O	levels
15	107	108	O	of
16	110	120	O	XXXXXXXX
17	122	123	O	or
18	125	134	O	olanzapine
19	135	135	O	,
20	137	139	O	but
21	141	141	O	a
22	143	157	O	pharmacodynamic
23	159	169	O	interaction
24	171	173	O	was
25	175	178	O	seen
26	180	181	O	on
27	183	183	O	a
28	185	191	B-EFF	measure
29	193	194	I-EFF	of
30	196	206	I-EFF	psychomotor
31	208	215	L-EFF	function
D/6:28:1

Eszopiclone	316	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	9
Eszopiclone and lorazepam decreased each other's Cmax by 22%.
1	0	10	O	XXXXXXXX
2	12	14	O	and
3	16	24	U-KIN	lorazepam
4	26	34	O	decreased
5	36	39	O	each
6	41	47	O	other's
7	49	52	O	Cmax
8	54	55	O	by
9	57	59	O	22%
K/3:C54615

Eszopiclone	317	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	32
Coadministration of eszopiclone 3 mg to subjects receiving ketoconazole, a potent inhibitor of CYP3A4, 400mg daily for 5 days, resulted in a 2.2-fold increase in exposure to eszopiclone.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	30	O	XXXXXXXX
4	32	32	O	3
5	34	35	O	mg
6	37	38	O	to
7	40	47	O	subjects
8	49	57	O	receiving
9	59	70	U-KIN	ketoconazole
10	71	71	O	,
11	73	73	O	a
12	75	80	O	potent
13	82	90	O	inhibitor
14	92	93	O	of
15	95	100	O	CYP3A4
16	101	101	O	,
17	103	107	O	400mg
18	109	113	O	daily
19	115	117	O	for
20	119	119	O	5
21	121	124	O	days
22	125	125	O	,
23	127	134	O	resulted
24	136	137	O	in
25	139	139	O	a
26	141	143	O	2.2
27	145	148	O	fold
28	150	157	O	increase
29	159	160	O	in
30	162	169	O	exposure
31	171	172	O	to
32	174	184	O	XXXXXXXX
K/9:C54355

Eszopiclone	318	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	14
Cmax and t1/2 were increased 1.4-fold and 1.3-fold, respectively.
1	0	3	O	Cmax
2	5	7	O	and
3	9	10	O	t1
4	11	11	O	/
5	12	12	O	2
6	14	17	O	were
7	19	27	O	increased
8	29	31	O	1.4
9	33	36	O	fold
10	38	40	O	and
11	42	44	O	1.3
12	46	49	O	fold
13	50	50	O	,
14	52	63	O	respectively
NULL

Eszopiclone	319	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	16
LUNESTA would not be expected to alter the clearance of drugs metabolized by common CYP450 enzymes.
1	0	6	O	LUNESTA
2	8	12	O	would
3	14	16	O	not
4	18	19	O	be
5	21	28	O	expected
6	30	31	O	to
7	33	37	O	alter
8	39	41	O	the
9	43	51	O	clearance
10	53	54	O	of
11	56	60	O	drugs
12	62	72	O	metabolized
13	74	75	O	by
14	77	82	O	common
15	84	89	O	CYP450
16	91	97	O	enzymes
NULL

Eszopiclone	320	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	16
Paroxetine: Coadministration of single dose of eszopiclone and paroxetine produced no pharmacokinetic or pharmacodynamic interaction.
1	0	9	O	Paroxetine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	37	O	single
6	39	42	O	dose
7	44	45	O	of
8	47	57	O	XXXXXXXX
9	59	61	O	and
10	63	72	O	paroxetine
11	74	81	O	produced
12	83	84	O	no
13	86	100	O	pharmacokinetic
14	102	103	O	or
15	105	119	O	pharmacodynamic
16	121	131	O	interaction
NULL

Eszopiclone	321	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	23
The lack of a drug interaction following single-dose administration does not predict the complete absence of a pharmacodynamic effect following chronic administration.
1	0	2	O	The
2	4	7	O	lack
3	9	10	O	of
4	12	12	O	a
5	14	17	O	drug
6	19	29	O	interaction
7	31	39	O	following
8	41	46	O	single
9	48	51	O	dose
10	53	66	O	administration
11	68	71	O	does
12	73	75	O	not
13	77	83	O	predict
14	85	87	O	the
15	89	96	O	complete
16	98	104	O	absence
17	106	107	O	of
18	109	109	O	a
19	111	125	O	pharmacodynamic
20	127	132	O	effect
21	134	142	O	following
22	144	150	O	chronic
23	152	165	O	administration
NULL

Eszopiclone	322	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	24
Lorazepam: Coadministration of single doses of eszopiclone and lorazepam did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.
1	0	8	O	Lorazepam
2	9	9	O	:
3	11	26	O	Coadministration
4	28	29	O	of
5	31	36	O	single
6	38	42	O	doses
7	44	45	O	of
8	47	57	O	XXXXXXXX
9	59	61	O	and
10	63	71	O	lorazepam
11	73	75	O	did
12	77	79	O	not
13	81	84	O	have
14	86	95	O	clinically
15	97	104	O	relevant
16	106	112	O	effects
17	114	115	O	on
18	117	119	O	the
19	121	136	O	pharmacodynamics
20	138	139	O	or
21	141	156	O	pharmacokinetics
22	158	159	O	of
23	161	166	O	either
24	168	171	O	drug
NULL

Eszopiclone	324	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	45
Drugs with a Narrow Therapeutic Index Digoxin: A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.
1	0	4	O	Drugs
2	6	9	O	with
3	11	11	O	a
4	13	18	O	Narrow
5	20	30	O	Therapeutic
6	32	36	O	Index
7	38	44	O	Digoxin
8	45	45	O	:
9	47	47	O	A
10	49	54	O	single
11	56	59	O	dose
12	61	62	O	of
13	64	74	O	XXXXXXXX
14	76	76	O	3
15	78	79	O	mg
16	81	83	O	did
17	85	87	O	not
18	89	94	O	affect
19	96	98	O	the
20	100	115	O	pharmacokinetics
21	117	118	O	of
22	120	126	O	digoxin
23	128	135	O	measured
24	137	138	O	at
25	140	145	O	steady
26	147	151	O	state
27	153	161	O	following
28	163	168	O	dosing
29	170	171	O	of
30	173	175	O	0.5
31	177	178	O	mg
32	180	184	O	twice
33	186	190	O	daily
34	192	194	O	for
35	196	198	O	one
36	200	202	O	day
37	204	206	O	and
38	208	211	O	0.25
39	213	214	O	mg
40	216	220	O	daily
41	222	224	O	for
42	226	228	O	the
43	230	233	O	next
44	235	235	O	6
45	237	240	O	days
NULL

Eszopiclone	325	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	41
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin.
1	0	7	O	Warfarin
2	8	8	O	:
3	10	20	O	XXXXXXXX
4	22	22	O	3
5	24	25	O	mg
6	27	38	O	administered
7	40	44	O	daily
8	46	48	O	for
9	50	50	O	5
10	52	55	O	days
11	57	59	O	did
12	61	63	O	not
13	65	70	O	affect
14	72	74	O	the
15	76	91	O	pharmacokinetics
16	93	94	O	of
17	97	97	O	R
18	101	102	O	or
19	105	105	O	S
20	108	115	O	warfarin
21	116	116	O	,
22	118	120	O	nor
23	122	125	O	were
24	127	131	O	there
25	133	135	O	any
26	137	143	O	changes
27	145	146	O	in
28	148	150	O	the
29	152	166	O	pharmacodynamic
30	168	174	O	profile
31	177	187	O	prothrombin
32	189	192	O	time
33	195	203	O	following
34	205	205	O	a
35	207	212	O	single
36	214	215	O	25
37	217	218	O	mg
38	220	223	O	oral
39	225	228	O	dose
40	230	231	O	of
41	233	240	O	warfarin
NULL

Eszopiclone	326	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	34
Drugs Highly Bound to Plasma Protein Eszopiclone is not highly bound to plasma proteins (52-59% bound); therefore, the disposition of eszopiclone is not expected to be sensitive to alterations in protein binding.
1	0	4	O	Drugs
2	6	11	O	Highly
3	13	17	O	Bound
4	19	20	O	to
5	22	27	O	Plasma
6	29	35	O	Protein
7	37	47	O	XXXXXXXX
8	49	50	O	is
9	52	54	O	not
10	56	61	O	highly
11	63	67	O	bound
12	69	70	O	to
13	72	77	O	plasma
14	79	86	O	proteins
15	89	90	O	52
16	92	94	O	59%
17	96	100	O	bound
18	104	112	O	therefore
19	113	113	O	,
20	115	117	O	the
21	119	129	O	disposition
22	131	132	O	of
23	134	144	O	XXXXXXXX
24	146	147	O	is
25	149	151	O	not
26	153	160	O	expected
27	162	163	O	to
28	165	166	O	be
29	168	176	O	sensitive
30	178	179	O	to
31	181	191	O	alterations
32	193	194	O	in
33	196	202	O	protein
34	204	210	O	binding
NULL

Eszopiclone	327	34090-1	39a5dae2-49f7-4662-9eac-aa7b4c7807a4	31
Administration of eszopiclone 3 mg to a patient taking another drug that is highly protein-bound would not be expected to cause an alteration in the free concentration of either drug.
1	0	13	O	Administration
2	15	16	O	of
3	18	28	O	XXXXXXXX
4	30	30	O	3
5	32	33	O	mg
6	35	36	O	to
7	38	38	O	a
8	40	46	O	patient
9	48	53	O	taking
10	55	61	O	another
11	63	66	O	drug
12	68	71	O	that
13	73	74	O	is
14	76	81	O	highly
15	83	89	O	protein
16	91	95	O	bound
17	97	101	O	would
18	103	105	O	not
19	107	108	O	be
20	110	117	O	expected
21	119	120	O	to
22	122	126	O	cause
23	128	129	O	an
24	131	140	O	alteration
25	142	143	O	in
26	145	147	O	the
27	149	152	O	free
28	154	166	O	concentration
29	168	169	O	of
30	171	176	O	either
31	178	181	O	drug
NULL

Fanapt	3967	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	25
Given the primary CNS effects of FANAPT, caution should be used when it is taken in combination with other centrally acting drugs and alcohol.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	38	O	XXXXXXXX
8	39	39	O	,
9	41	47	U-TRI	caution
10	49	54	O	should
11	56	57	O	be
12	59	62	O	used
13	64	67	O	when
14	69	70	O	it
15	72	73	O	is
16	75	79	O	taken
17	81	82	O	in
18	84	94	O	combination
19	96	99	O	with
20	101	105	O	other
21	107	115	B-UNK	centrally
22	117	122	I-UNK	acting
23	124	128	L-UNK	drugs
24	130	132	O	and
25	134	140	U-UNK	alcohol
NULL

Fanapt	3968	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	20
Due to its - alpha1-adrenergic receptor antagonism, FANAPT has the potential to enhance the effect of certain antihypertensive agents.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	its
4	13	18	O	alpha1
5	20	29	O	adrenergic
6	31	38	O	receptor
7	40	49	O	antagonism
8	50	50	O	,
9	52	57	O	XXXXXXXX
10	59	61	O	has
11	63	65	O	the
12	67	75	O	potential
13	77	78	O	to
14	80	86	B-EFF	enhance
15	88	90	I-EFF	the
16	92	97	I-EFF	effect
17	99	100	I-EFF	of
18	102	108	I-EFF	certain
19	110	125	I-EFF	antihypertensive
20	127	132	L-EFF	agents
NULL

Fanapt	3969	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	17
The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor.
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	17	O	XXXXXXXX
5	19	24	O	should
6	26	27	O	be
7	29	35	O	reduced
8	37	38	O	in
9	40	47	O	patients
10	49	50	O	co
11	52	63	O	administered
12	65	65	O	a
13	67	72	O	strong
14	74	79	O	CYP2D6
15	81	82	O	or
16	84	89	O	CYP3A4
17	91	99	O	inhibitor
NULL

Fanapt	3970	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	23
Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	17	O	not
4	19	19	O	a
5	21	29	O	substrate
6	31	33	O	for
7	35	40	O	CYP1A1
8	41	41	O	,
9	43	48	O	CYP1A2
10	49	49	O	,
11	51	56	O	CYP2A6
12	57	57	O	,
13	59	64	O	CYP2B6
14	65	65	O	,
15	67	72	O	CYP2C8
16	73	73	O	,
17	75	80	O	CYP2C9
18	81	81	O	,
19	83	89	O	CYP2C19
20	90	90	O	,
21	92	93	O	or
22	95	100	O	CYP2E1
23	102	108	O	enzymes
NULL

Fanapt	3971	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	24
This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	20	O	an
5	22	32	O	interaction
6	34	35	O	of
7	37	47	O	XXXXXXXX
8	49	52	O	with
9	54	63	O	inhibitors
10	65	66	O	or
11	68	75	O	inducers
12	77	78	O	of
13	80	84	O	these
14	86	92	O	enzymes
15	93	93	O	,
16	95	96	O	or
17	98	102	O	other
18	104	110	O	factors
19	111	111	O	,
20	113	116	O	like
21	118	124	O	smoking
22	125	125	O	,
23	127	128	O	is
24	130	137	O	unlikely
NULL

Fanapt	3972	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	9
Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism.
1	0	3	O	Both
2	5	10	O	CYP3A4
3	12	14	O	and
4	16	21	O	CYP2D6
5	23	25	O	are
6	27	37	O	responsible
7	39	41	O	for
8	43	53	O	XXXXXXXX
9	55	64	O	metabolism
NULL

Fanapt	3973	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	22
Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels.
1	0	9	B-KIN	Inhibitors
2	11	12	I-KIN	of
3	14	19	L-KIN	CYP3A4
4	22	24	O	e.g
5	26	26	O	,
6	28	39	U-KIN	ketoconazole
7	42	43	O	or
8	45	50	O	CYP2D6
9	53	55	O	e.g
10	57	57	O	,
11	59	68	U-KIN	fluoxetine
12	69	69	O	,
13	71	80	U-KIN	paroxetine
14	83	85	O	can
15	87	93	B-TRI	inhibit
16	95	105	I-TRI	XXXXXXXX
17	107	117	L-TRI	elimination
18	119	121	O	and
19	123	127	O	cause
20	129	137	O	increased
21	139	143	O	blood
22	145	150	O	levels
K/1:C54355 K/11:C54355 K/13:C54355 K/6:C54355

Fanapt	3974	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	62
Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively.
1	0	11	O	Ketoconazole
2	12	12	O	:
3	14	15	O	Co
4	17	30	O	administration
5	32	33	O	of
6	35	46	U-KIN	ketoconazole
7	49	51	O	200
8	53	54	O	mg
9	56	60	O	twice
10	62	66	O	daily
11	68	70	O	for
12	72	72	O	4
13	74	77	O	days
14	79	79	O	,
15	81	81	O	a
16	83	88	O	potent
17	90	98	O	inhibitor
18	100	101	O	of
19	103	108	O	CYP3A4
20	109	109	O	,
21	111	114	O	with
22	116	116	O	a
23	118	118	O	3
24	120	121	O	mg
25	123	128	O	single
26	130	133	O	dose
27	135	136	O	of
28	138	148	O	XXXXXXXX
29	150	151	O	to
30	153	154	O	19
31	156	162	O	healthy
32	164	173	O	volunteers
33	174	174	O	,
34	176	179	O	ages
35	181	182	O	18
36	184	185	O	to
37	187	188	O	45
38	190	194	O	years
39	195	195	O	,
40	197	205	B-TRI	increased
41	207	209	I-TRI	the
42	211	214	I-TRI	area
43	216	220	I-TRI	under
44	222	224	I-TRI	the
45	226	230	I-TRI	curve
46	233	235	L-TRI	AUC
47	238	239	O	of
48	241	251	O	XXXXXXXX
49	253	255	O	and
50	257	259	O	its
51	261	271	O	metabolites
52	273	275	O	P88
53	277	279	O	and
54	281	283	O	P95
55	285	286	O	by
56	288	290	O	57%
57	291	291	O	,
58	293	295	O	55%
59	297	299	O	and
60	301	303	O	35%
61	304	304	O	,
62	306	317	O	respectively
K/6:C54605

Fanapt	3975	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	22
Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole).
1	0	10	O	XXXXXXXX
2	12	16	B-TRI	doses
3	18	23	I-TRI	should
4	25	26	I-TRI	be
5	28	34	L-TRI	reduced
6	36	37	O	by
7	39	43	O	about
8	45	47	O	one
9	49	52	O	half
10	54	57	O	when
11	59	70	O	administered
12	72	75	O	with
13	77	88	U-KIN	ketoconazole
14	90	91	O	or
15	93	97	O	other
16	99	104	B-KIN	strong
17	106	115	I-KIN	inhibitors
18	117	118	I-KIN	of
19	120	125	L-KIN	CYP3A4
20	128	130	O	e.g
21	132	132	O	,
22	134	145	U-KIN	itraconazole
K/13:C54355 K/16:C54355 K/22:C54355

Fanapt	3976	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	12
Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied.
1	0	5	O	Weaker
2	7	16	O	inhibitors
3	19	21	O	e.g
4	23	23	O	,
5	25	36	O	erythromycin
6	37	37	O	,
7	39	48	O	grapefruit
8	50	54	O	juice
9	57	60	O	have
10	62	64	O	not
11	66	69	O	been
12	71	77	O	studied
NULL

Fanapt	3977	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	21
When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-UNK	CYP3A4
4	16	24	L-UNK	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	71	O	the
13	73	83	O	XXXXXXXX
14	85	88	O	dose
15	90	95	O	should
16	97	98	O	be
17	100	107	O	returned
18	109	110	O	to
19	112	114	O	the
20	116	123	O	previous
21	125	129	O	level
NULL

Fanapt	3978	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	75
Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half.
1	0	9	O	Fluoxetine
2	10	10	O	:
3	12	13	O	Co
4	15	28	O	administration
5	30	31	O	of
6	33	42	U-KIN	fluoxetine
7	45	46	O	20
8	48	49	O	mg
9	51	55	O	twice
10	57	61	O	daily
11	63	65	O	for
12	67	68	O	21
13	70	73	O	days
14	75	75	O	,
15	77	77	O	a
16	79	84	O	potent
17	86	94	O	inhibitor
18	96	97	O	of
19	99	104	O	CYP2D6
20	105	105	O	,
21	107	110	O	with
22	112	112	O	a
23	114	119	O	single
24	121	121	O	3
25	123	124	O	mg
26	126	129	O	dose
27	131	132	O	of
28	134	144	O	XXXXXXXX
29	146	147	O	to
30	149	150	O	23
31	152	158	O	healthy
32	160	169	O	volunteers
33	170	170	O	,
34	172	175	O	ages
35	177	178	O	29
36	180	181	O	to
37	183	184	O	44
38	186	190	O	years
39	191	191	O	,
40	193	195	O	who
41	197	200	O	were
42	202	211	O	classified
43	213	214	O	as
44	216	221	O	CYP2D6
45	223	231	O	extensive
46	233	244	O	metabolizers
47	245	245	O	,
48	247	255	B-TRI	increased
49	257	259	I-TRI	the
50	261	263	L-TRI	AUC
51	265	266	O	of
52	268	278	O	XXXXXXXX
53	280	282	O	and
54	284	286	O	its
55	288	297	O	metabolite
56	299	301	O	P88
57	302	302	O	,
58	304	305	O	by
59	307	311	O	about
60	313	313	O	2
61	316	317	O	to
62	319	319	O	3
63	321	324	O	fold
64	325	325	O	,
65	327	329	O	and
66	331	339	O	decreased
67	341	343	O	the
68	345	347	O	AUC
69	349	350	O	of
70	352	354	O	its
71	356	365	O	metabolite
72	367	369	O	P95
73	371	372	O	by
74	374	376	O	one
75	378	381	O	half
K/6:C54605

Fanapt	3979	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	12
Iloperidone doses should be reduced by one-half when administered with fluoxetine.
1	0	10	O	XXXXXXXX
2	12	16	B-TRI	doses
3	18	23	I-TRI	should
4	25	26	I-TRI	be
5	28	34	L-TRI	reduced
6	36	37	O	by
7	39	41	O	one
8	43	46	O	half
9	48	51	O	when
10	53	64	O	administered
11	66	69	O	with
12	71	80	U-KIN	fluoxetine
K/12:C54355

Fanapt	3980	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	19
When fluoxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.
1	0	3	O	When
2	5	14	U-UNK	fluoxetine
3	16	17	O	is
4	19	27	O	withdrawn
5	29	32	O	from
6	34	36	O	the
7	38	48	O	combination
8	50	56	O	therapy
9	57	57	O	,
10	59	61	O	the
11	63	73	O	XXXXXXXX
12	75	78	O	dose
13	80	85	O	should
14	87	88	O	be
15	90	97	O	returned
16	99	100	O	to
17	102	104	O	the
18	106	113	O	previous
19	115	119	O	level
NULL

Fanapt	3981	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	18
Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions.
1	0	4	O	Other
2	6	11	B-KIN	strong
3	13	22	I-KIN	inhibitors
4	24	25	I-KIN	of
5	27	32	L-KIN	CYP2D6
6	34	38	O	would
7	40	41	O	be
8	43	50	O	expected
9	52	53	O	to
10	55	58	O	have
11	60	66	O	similar
12	68	74	O	effects
13	76	78	O	and
14	80	84	O	would
15	86	89	O	need
16	91	101	O	appropriate
17	103	106	B-TRI	dose
18	108	117	L-TRI	reductions
K/2:C54355

Fanapt	3982	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	21
When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to the previous level.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-KIN	CYP2D6
4	16	24	L-KIN	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	79	O	XXXXXXXX
13	81	84	O	dose
14	86	90	O	could
15	92	95	O	then
16	97	98	O	be
17	100	108	O	increased
18	110	111	O	to
19	113	115	O	the
20	117	124	O	previous
21	126	130	O	level
K/3:C54355

Fanapt	3983	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	73
Paroxetine: Co-administration of paroxetine (20 mg/day for 5-8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18-65 resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6 fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half.
1	0	9	O	Paroxetine
2	10	10	O	:
3	12	13	O	Co
4	15	28	O	administration
5	30	31	O	of
6	33	42	U-KIN	paroxetine
7	45	46	O	20
8	48	49	O	mg
9	50	50	O	/
10	51	53	O	day
11	55	57	O	for
12	59	59	O	5
13	61	61	O	8
14	63	66	O	days
15	68	68	O	,
16	70	70	O	a
17	72	77	O	potent
18	79	87	O	inhibitor
19	89	90	O	of
20	92	97	O	CYP2D6
21	98	98	O	,
22	100	103	O	with
23	105	112	O	multiple
24	114	118	O	doses
25	120	121	O	of
26	123	133	O	XXXXXXXX
27	136	136	O	8
28	138	139	O	or
29	141	142	O	12
30	144	145	O	mg
31	147	151	O	twice
32	153	157	O	daily
33	160	161	O	to
34	163	170	O	patients
35	172	175	O	with
36	177	189	O	schizophrenia
37	191	194	O	ages
38	196	197	O	18
39	199	200	O	65
40	202	209	O	resulted
41	211	212	O	in
42	214	222	O	increased
43	224	227	O	mean
44	229	234	O	steady
45	236	240	O	state
46	242	245	O	peak
47	247	260	O	concentrations
48	262	263	O	of
49	265	275	O	XXXXXXXX
50	277	279	O	and
51	281	283	O	its
52	285	294	O	metabolite
53	296	298	O	P88
54	299	299	O	,
55	301	302	O	by
56	304	308	O	about
57	310	312	O	1.6
58	314	317	O	fold
59	318	318	O	,
60	320	322	O	and
61	324	332	O	decreased
62	334	337	O	mean
63	339	344	O	steady
64	346	350	O	state
65	352	355	O	peak
66	357	370	O	concentrations
67	372	373	O	of
68	375	377	O	its
69	379	388	O	metabolite
70	390	392	O	P95
71	394	395	O	by
72	397	399	O	one
73	401	404	O	half
K/6:C54602

Fanapt	3984	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	12
Iloperidone doses should be reduced by one-half when administered with paroxetine.
1	0	10	O	XXXXXXXX
2	12	16	B-TRI	doses
3	18	23	I-TRI	should
4	25	26	I-TRI	be
5	28	34	L-TRI	reduced
6	36	37	O	by
7	39	41	O	one
8	43	46	O	half
9	48	51	O	when
10	53	64	O	administered
11	66	69	O	with
12	71	80	U-KIN	paroxetine
K/12:C54355

Fanapt	3985	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	19
When paroxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.
1	0	3	O	When
2	5	14	U-UNK	paroxetine
3	16	17	O	is
4	19	27	O	withdrawn
5	29	32	O	from
6	34	36	O	the
7	38	48	O	combination
8	50	56	O	therapy
9	57	57	O	,
10	59	61	O	the
11	63	73	O	XXXXXXXX
12	75	78	O	dose
13	80	85	O	should
14	87	88	O	be
15	90	97	O	returned
16	99	100	O	to
17	102	104	O	the
18	106	113	O	previous
19	115	119	O	level
NULL

Fanapt	3987	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	20
When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to previous levels.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-KIN	CYP2D6
4	16	24	L-KIN	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	79	O	XXXXXXXX
13	81	84	O	dose
14	86	90	O	could
15	92	95	O	then
16	97	98	O	be
17	100	108	O	increased
18	110	111	O	to
19	113	120	O	previous
20	122	127	O	levels
K/3:C54355

Fanapt	3988	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	73
Paroxetine and Ketoconazole: Co-administration of paroxetine (20 mg once daily for 10 days), a CYP2D6 inhibitor, and ketoconazole (200 mg twice daily) with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18-65 resulted in a 1.4 fold increase in steady-state concentrations of iloperidone and its metabolite P88 and a 1.4 fold decrease in the P95 in the presence of paroxetine.
1	0	9	O	Paroxetine
2	11	13	O	and
3	15	26	O	Ketoconazole
4	27	27	O	:
5	29	30	O	Co
6	32	45	O	administration
7	47	48	O	of
8	50	59	U-KIN	paroxetine
9	62	63	O	20
10	65	66	O	mg
11	68	71	O	once
12	73	77	O	daily
13	79	81	O	for
14	83	84	O	10
15	86	89	O	days
16	91	91	O	,
17	93	93	O	a
18	95	100	O	CYP2D6
19	102	110	O	inhibitor
20	111	111	O	,
21	113	115	O	and
22	117	128	U-KIN	ketoconazole
23	131	133	O	200
24	135	136	O	mg
25	138	142	O	twice
26	144	148	O	daily
27	151	154	O	with
28	156	163	O	multiple
29	165	169	O	doses
30	171	172	O	of
31	174	184	O	XXXXXXXX
32	187	187	O	8
33	189	190	O	or
34	192	193	O	12
35	195	196	O	mg
36	198	202	O	twice
37	204	208	O	daily
38	211	212	O	to
39	214	221	O	patients
40	223	226	O	with
41	228	240	O	schizophrenia
42	242	245	O	ages
43	247	248	O	18
44	250	251	O	65
45	253	260	O	resulted
46	262	263	O	in
47	265	265	O	a
48	267	269	O	1.4
49	271	274	O	fold
50	276	283	O	increase
51	285	286	O	in
52	288	293	O	steady
53	295	299	O	state
54	301	314	O	concentrations
55	316	317	O	of
56	319	329	O	XXXXXXXX
57	331	333	O	and
58	335	337	O	its
59	339	348	O	metabolite
60	350	352	O	P88
61	354	356	O	and
62	358	358	O	a
63	360	362	O	1.4
64	364	367	O	fold
65	369	376	O	decrease
66	378	379	O	in
67	381	383	O	the
68	385	387	O	P95
69	389	390	O	in
70	392	394	O	the
71	396	403	O	presence
72	405	406	O	of
73	408	417	O	paroxetine
K/22:C54355 K/8:C54355

Fanapt	3989	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	22
So giving iloperidone with inhibitors of both of its metabolic pathways did not add to the effect of either inhibitor given alone.
1	0	1	O	So
2	3	8	O	giving
3	10	20	O	XXXXXXXX
4	22	25	O	with
5	27	36	O	inhibitors
6	38	39	O	of
7	41	44	O	both
8	46	47	O	of
9	49	51	O	its
10	53	61	O	metabolic
11	63	70	O	pathways
12	72	74	O	did
13	76	78	O	not
14	80	82	O	add
15	84	85	O	to
16	87	89	O	the
17	91	96	O	effect
18	98	99	O	of
19	101	106	O	either
20	108	116	O	inhibitor
21	118	122	O	given
22	124	128	O	alone
NULL

Fanapt	3990	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	20
Iloperidone doses should therefore be reduced by about one-half if administered concomitantly with both a CYP2D6 and CYP3A4 inhibitor.
1	0	10	O	XXXXXXXX
2	12	16	O	doses
3	18	23	O	should
4	25	33	O	therefore
5	35	36	O	be
6	38	44	O	reduced
7	46	47	O	by
8	49	53	O	about
9	55	57	O	one
10	59	62	O	half
11	64	65	O	if
12	67	78	O	administered
13	80	92	O	concomitantly
14	94	97	O	with
15	99	102	O	both
16	104	104	O	a
17	106	111	B-KIN	CYP2D6
18	113	115	I-KIN	and
19	117	122	I-KIN	CYP3A4
20	124	132	L-KIN	inhibitor
K/17:C54355

Fanapt	3991	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	40
In vitro studies in human liver microsomes showed that iloperidone does not substantially inhibit the metabolism of drugs metabolized by the following cytochrome P450 isozymes: CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, or CYP2E1.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	24	O	human
6	26	30	O	liver
7	32	41	O	microsomes
8	43	48	O	showed
9	50	53	O	that
10	55	65	O	XXXXXXXX
11	67	70	O	does
12	72	74	O	not
13	76	88	O	substantially
14	90	96	O	inhibit
15	98	100	O	the
16	102	111	O	metabolism
17	113	114	O	of
18	116	120	O	drugs
19	122	132	O	metabolized
20	134	135	O	by
21	137	139	O	the
22	141	149	O	following
23	151	160	O	cytochrome
24	162	165	O	P450
25	167	174	O	isozymes
26	175	175	O	:
27	177	182	O	CYP1A1
28	183	183	O	,
29	185	190	O	CYP1A2
30	191	191	O	,
31	193	198	O	CYP2A6
32	199	199	O	,
33	201	206	O	CYP2B6
34	207	207	O	,
35	209	214	O	CYP2C8
36	215	215	O	,
37	217	222	O	CYP2C9
38	223	223	O	,
39	225	226	O	or
40	228	233	O	CYP2E1
NULL

Fanapt	3992	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	38
Furthermore, in vitro studies in human liver microsomes showed that iloperidone does not have enzyme inducing properties, specifically for the following cytochrome P450 isozymes: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	14	O	in
4	16	20	O	vitro
5	22	28	O	studies
6	30	31	O	in
7	33	37	O	human
8	39	43	O	liver
9	45	54	O	microsomes
10	56	61	O	showed
11	63	66	O	that
12	68	78	O	XXXXXXXX
13	80	83	O	does
14	85	87	O	not
15	89	92	O	have
16	94	99	O	enzyme
17	101	108	O	inducing
18	110	119	O	properties
19	120	120	O	,
20	122	133	O	specifically
21	135	137	O	for
22	139	141	O	the
23	143	151	O	following
24	153	162	O	cytochrome
25	164	167	O	P450
26	169	176	O	isozymes
27	177	177	O	:
28	179	184	O	CYP1A2
29	185	185	O	,
30	187	192	O	CYP2C8
31	193	193	O	,
32	195	200	O	CYP2C9
33	201	201	O	,
34	203	209	O	CYP2C19
35	210	210	O	,
36	212	217	O	CYP3A4
37	219	221	O	and
38	223	228	O	CYP3A5
NULL

Fanapt	3993	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	47
Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (Cmax)of dextromethorphan.
1	0	15	O	Dextromethorphan
2	16	16	O	:
3	18	18	O	A
4	20	24	O	study
5	26	27	O	in
6	29	35	O	healthy
7	37	46	O	volunteers
8	48	53	O	showed
9	55	58	O	that
10	60	66	O	changes
11	68	69	O	in
12	71	73	O	the
13	75	90	O	pharmacokinetics
14	92	93	O	of
15	95	110	U-KIN	dextromethorphan
16	113	114	O	80
17	116	117	O	mg
18	119	122	O	dose
19	125	128	O	when
20	130	130	O	a
21	132	132	O	3
22	134	135	O	mg
23	137	140	O	dose
24	142	143	O	of
25	145	155	O	XXXXXXXX
26	157	159	O	was
27	161	162	O	co
28	164	175	O	administered
29	177	184	O	resulted
30	186	187	O	in
31	189	189	O	a
32	191	193	O	17%
33	195	202	O	increase
34	204	205	O	in
35	207	211	O	total
36	213	220	O	exposure
37	222	224	O	and
38	226	226	O	a
39	228	230	O	26%
40	232	239	B-TRI	increase
41	241	242	I-TRI	in
42	244	246	I-TRI	the
43	248	254	I-TRI	maximum
44	256	261	I-TRI	plasma
45	263	276	L-TRI	concentrations
46	279	285	O	Cmax)of
47	287	302	O	dextromethorphan
K/15:C54610

Fanapt	3994	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	12
Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	an
4	9	19	O	interaction
5	21	27	O	between
6	29	39	O	XXXXXXXX
7	41	43	O	and
8	45	49	O	other
9	51	56	O	CYP2D6
10	58	67	O	substrates
11	69	70	O	is
12	72	79	O	unlikely
NULL

Fanapt	3995	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	21
Fluoxetine: A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20 mg twice daily).
1	0	9	O	Fluoxetine
2	10	10	O	:
3	12	12	O	A
4	14	19	O	single
5	21	21	O	3
6	23	24	O	mg
7	26	29	O	dose
8	31	32	O	of
9	34	44	O	XXXXXXXX
10	46	48	O	had
11	50	51	O	no
12	53	58	O	effect
13	60	61	O	on
14	63	65	O	the
15	67	82	O	pharmacokinetics
16	84	85	O	of
17	87	96	O	fluoxetine
18	99	100	O	20
19	102	103	O	mg
20	105	109	O	twice
21	111	115	O	daily
NULL

Fanapt	3996	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	44
Midazolam (a sensitive CYP 3A4 substrate):A study in patients with schizophrenia showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax.
1	0	8	O	Midazolam
2	11	11	O	a
3	13	21	O	sensitive
4	23	25	O	CYP
5	27	29	O	3A4
6	31	42	O	substrate):A
7	44	48	O	study
8	50	51	O	in
9	53	60	O	patients
10	62	65	O	with
11	67	79	O	schizophrenia
12	81	86	O	showed
13	88	88	O	a
14	90	93	O	less
15	95	98	O	than
16	100	102	O	50%
17	104	111	O	increase
18	113	114	O	in
19	116	124	U-KIN	midazolam
20	126	130	O	total
21	132	139	O	exposure
22	141	142	O	at
23	144	154	O	XXXXXXXX
24	156	161	O	steady
25	163	167	O	state
26	170	171	O	14
27	173	176	O	days
28	178	179	O	of
29	181	184	O	oral
30	186	191	O	dosing
31	193	194	O	at
32	196	197	O	up
33	199	200	O	to
34	202	203	O	10
35	205	206	O	mg
36	208	218	O	XXXXXXXX
37	220	224	O	twice
38	226	230	O	daily
39	233	235	O	and
40	237	238	O	no
41	240	245	O	effect
42	247	248	O	on
43	250	258	O	midazolam
44	260	263	O	Cmax
K/19:C54357

Fanapt	3997	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	12
Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	an
4	9	19	O	interaction
5	21	27	O	between
6	29	39	O	XXXXXXXX
7	41	43	O	and
8	45	49	O	other
9	51	56	O	CYP3A4
10	58	67	O	substrates
11	69	70	O	is
12	72	79	O	unlikely
NULL

Fanapt	3998	34073-7	33f60b40-3fca-11de-8f56-0002a5d5c51b	14
FANAPT should not be used with any other drugs that prolong the QT interval.
1	0	5	O	XXXXXXXX
2	7	12	B-TRI	should
3	14	16	I-TRI	not
4	18	19	I-TRI	be
5	21	24	L-TRI	used
6	26	29	O	with
7	31	33	O	any
8	35	39	O	other
9	41	45	B-UNK	drugs
10	47	50	I-UNK	that
11	52	58	I-UNK	prolong
12	60	62	I-UNK	the
13	64	65	I-UNK	QT
14	67	74	L-UNK	interval
NULL

Fanapt	3999	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	18
The mechanism of action of FANAPT, as with other drugs having efficacy in schizophrenia, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	32	O	XXXXXXXX
7	33	33	O	,
8	35	36	O	as
9	38	41	O	with
10	43	47	O	other
11	49	53	O	drugs
12	55	60	O	having
13	62	69	O	efficacy
14	71	72	O	in
15	74	86	O	schizophrenia
16	87	87	O	,
17	89	90	O	is
18	92	98	O	unknown
NULL

Fanapt	4000	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	26
However it is proposed that the efficacy of FANAPTis mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonisms.
1	0	6	O	However
2	8	9	O	it
3	11	12	O	is
4	14	21	O	proposed
5	23	26	O	that
6	28	30	O	the
7	32	39	O	efficacy
8	41	42	O	of
9	44	49	O	XXXXXXXX
10	50	51	O	is
11	53	60	O	mediated
12	62	68	O	through
13	70	70	O	a
14	72	82	O	combination
15	84	85	O	of
16	87	94	O	dopamine
17	96	99	O	type
18	101	101	O	2
19	104	105	O	D2
20	108	110	O	and
21	112	120	O	serotonin
22	122	125	O	type
23	127	127	O	2
24	130	130	O	5
25	132	134	O	HT2
26	137	147	O	antagonisms
NULL

Fanapt	4001	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	34
FANAPT exhibits high (nM) affinity binding to serotonin 5-HT2A dopamine D2 and D3 receptors, and norepinephrine NEA1 receptors (Ki values of 5.6, 6.3, 7.1, and 0.36 nM, respectively).
1	0	5	O	XXXXXXXX
2	7	14	O	exhibits
3	16	19	O	high
4	22	23	O	nM
5	26	33	O	affinity
6	35	41	O	binding
7	43	44	O	to
8	46	54	O	serotonin
9	56	56	O	5
10	58	61	O	HT2A
11	63	70	O	dopamine
12	72	73	O	D2
13	75	77	O	and
14	79	80	O	D3
15	82	90	O	receptors
16	91	91	O	,
17	93	95	O	and
18	97	110	O	norepinephrine
19	112	115	O	NEA1
20	117	125	O	receptors
21	128	129	O	Ki
22	131	136	O	values
23	138	139	O	of
24	141	143	O	5.6
25	144	144	O	,
26	146	148	O	6.3
27	149	149	O	,
28	151	153	O	7.1
29	154	154	O	,
30	156	158	O	and
31	160	163	O	0.36
32	165	166	O	nM
33	167	167	O	,
34	169	180	O	respectively
NULL

Fanapt	4002	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	56
FANAPT has moderate affinity for dopamine D4, and serotonin 5-HT6 and 5-HT7 receptors (Ki values of 25, 43, and 22, nM respectively), and low affinity for the serotonin 5-HT1A, dopamine D1, and histamine H1 receptors (Ki values of 168, 216 and 437 nM, respectively).
1	0	5	O	XXXXXXXX
2	7	9	O	has
3	11	18	O	moderate
4	20	27	O	affinity
5	29	31	O	for
6	33	40	O	dopamine
7	42	43	O	D4
8	44	44	O	,
9	46	48	O	and
10	50	58	O	serotonin
11	60	60	O	5
12	62	64	O	HT6
13	66	68	O	and
14	70	70	O	5
15	72	74	O	HT7
16	76	84	O	receptors
17	87	88	O	Ki
18	90	95	O	values
19	97	98	O	of
20	100	101	O	25
21	102	102	O	,
22	104	105	O	43
23	106	106	O	,
24	108	110	O	and
25	112	113	O	22
26	114	114	O	,
27	116	117	O	nM
28	119	130	O	respectively
29	132	132	O	,
30	134	136	O	and
31	138	140	O	low
32	142	149	O	affinity
33	151	153	O	for
34	155	157	O	the
35	159	167	O	serotonin
36	169	169	O	5
37	171	174	O	HT1A
38	175	175	O	,
39	177	184	O	dopamine
40	186	187	O	D1
41	188	188	O	,
42	190	192	O	and
43	194	202	O	histamine
44	204	205	O	H1
45	207	215	O	receptors
46	218	219	O	Ki
47	221	226	O	values
48	228	229	O	of
49	231	233	O	168
50	234	234	O	,
51	236	238	O	216
52	240	242	O	and
53	244	246	O	437
54	248	249	O	nM
55	250	250	O	,
56	252	263	O	respectively
NULL

Fanapt	4003	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	12
FANAPT has no appreciable affinity (Ki >1000 nM) for cholinergic muscarinic receptors.
1	0	5	O	XXXXXXXX
2	7	9	O	has
3	11	12	O	no
4	14	24	O	appreciable
5	26	33	O	affinity
6	36	37	O	Ki
7	39	43	O	>1000
8	45	46	O	nM
9	49	51	O	for
10	53	63	O	cholinergic
11	65	74	O	muscarinic
12	76	84	O	receptors
NULL

Fanapt	4004	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	21
FANAPT functions as an antagonist at the dopamine D2, D3, serotonin 5-HT1A and norepinephrine A1/A2C receptors.
1	0	5	O	XXXXXXXX
2	7	15	O	functions
3	17	18	O	as
4	20	21	O	an
5	23	32	O	antagonist
6	34	35	O	at
7	37	39	O	the
8	41	48	O	dopamine
9	50	51	O	D2
10	52	52	O	,
11	54	55	O	D3
12	56	56	O	,
13	58	66	O	serotonin
14	68	68	O	5
15	70	73	O	HT1A
16	75	77	O	and
17	79	92	O	norepinephrine
18	94	95	O	A1
19	96	96	O	/
20	97	99	O	A2C
21	101	109	O	receptors
NULL

Fanapt	4005	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	18
The affinity of the FANAPT metabolite P88 is generally equal or less than that of the parent compound.
1	0	2	O	The
2	4	11	O	affinity
3	13	14	O	of
4	16	18	O	the
5	20	25	O	XXXXXXXX
6	27	36	O	metabolite
7	38	40	O	P88
8	42	43	O	is
9	45	53	O	generally
10	55	59	O	equal
11	61	62	O	or
12	64	67	O	less
13	69	72	O	than
14	74	77	O	that
15	79	80	O	of
16	82	84	O	the
17	86	91	O	parent
18	93	100	O	compound
NULL

Fanapt	4006	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	41
In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NEA1A, NEA1B, NEA1D, and NEA2 C receptors (Ki values of 4.7, 2.7, 8.8, and 4.7 nM respectively).
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	15	O	the
5	17	26	O	metabolite
6	28	30	O	P95
7	32	35	O	only
8	37	41	O	shows
9	43	50	O	affinity
10	52	54	O	for
11	56	56	O	5
12	58	61	O	HT2A
13	64	65	O	Ki
14	67	71	O	value
15	73	74	O	of
16	76	79	O	3.91
17	82	84	O	and
18	86	88	O	the
19	90	94	O	NEA1A
20	95	95	O	,
21	97	101	O	NEA1B
22	102	102	O	,
23	104	108	O	NEA1D
24	109	109	O	,
25	111	113	O	and
26	115	118	O	NEA2
27	120	120	O	C
28	122	130	O	receptors
29	133	134	O	Ki
30	136	141	O	values
31	143	144	O	of
32	146	148	O	4.7
33	149	149	O	,
34	151	153	O	2.7
35	154	154	O	,
36	156	158	O	8.8
37	159	159	O	,
38	161	163	O	and
39	165	167	O	4.7
40	169	170	O	nM
41	172	183	O	respectively
NULL

Fanapt	4007	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	42
The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM)are 18, 26, and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37, and 31 hours, respectively.
1	0	2	O	The
2	4	11	O	observed
3	13	16	O	mean
4	18	28	O	elimination
5	30	33	O	half
6	35	39	O	lives
7	41	43	O	for
8	45	55	O	XXXXXXXX
9	56	56	O	,
10	58	60	O	P88
11	62	64	O	and
12	66	68	O	P95
13	70	71	O	in
14	73	78	O	CYP2D6
15	80	88	O	extensive
16	90	101	O	metabolizers
17	104	109	O	EM)are
18	111	112	O	18
19	113	113	O	,
20	115	116	O	26
21	117	117	O	,
22	119	121	O	and
23	123	124	O	23
24	126	130	O	hours
25	131	131	O	,
26	133	144	O	respectively
27	145	145	O	,
28	147	149	O	and
29	151	152	O	in
30	154	157	O	poor
31	159	170	O	metabolizers
32	173	174	O	PM
33	177	179	O	are
34	181	182	O	33
35	183	183	O	,
36	185	186	O	37
37	187	187	O	,
38	189	191	O	and
39	193	194	O	31
40	196	200	O	hours
41	201	201	O	,
42	203	214	O	respectively
NULL

Fanapt	4008	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	11
Steady-state concentrations are attained within 3-4 days of dosing.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	30	O	are
5	32	39	O	attained
6	41	46	O	within
7	48	48	O	3
8	50	50	O	4
9	52	55	O	days
10	57	58	O	of
11	60	65	O	dosing
NULL

Fanapt	4009	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	8
Iloperidone accumulation is predictable from single-dose pharmacokinetics.
1	0	10	O	XXXXXXXX
2	12	23	O	accumulation
3	25	26	O	is
4	28	38	O	predictable
5	40	43	O	from
6	45	50	O	single
7	52	55	O	dose
8	57	72	O	pharmacokinetics
NULL

Fanapt	4010	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	9
The pharmacokinetics of iloperidone is more than dose proportional.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	O	XXXXXXXX
5	36	37	O	is
6	39	42	O	more
7	44	47	O	than
8	49	52	O	dose
9	54	65	O	proportional
NULL

Fanapt	4011	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	16
Elimination of iloperidone is mainly through hepatic metabolism involving 2 P450 isozymes, CYP2D6 and CYP3A4.
1	0	10	O	Elimination
2	12	13	O	of
3	15	25	O	XXXXXXXX
4	27	28	O	is
5	30	35	O	mainly
6	37	43	O	through
7	45	51	O	hepatic
8	53	62	O	metabolism
9	64	72	O	involving
10	74	74	O	2
11	76	79	O	P450
12	81	88	O	isozymes
13	89	89	O	,
14	91	96	O	CYP2D6
15	98	100	O	and
16	102	107	O	CYP3A4
NULL

Fanapt	4012	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	35
Absorption:Iloperidone is well absorbed after administration of the tablet with peak plasma concentrations occurring within 2 to 4 hours; while the relative bioavailability of the tablet formulation compared to oral solution is 96%.
1	0	9	O	Absorption
2	10	10	O	:
3	11	21	O	XXXXXXXX
4	23	24	O	is
5	26	29	O	well
6	31	38	O	absorbed
7	40	44	O	after
8	46	59	O	administration
9	61	62	O	of
10	64	66	O	the
11	68	73	O	tablet
12	75	78	O	with
13	80	83	O	peak
14	85	90	O	plasma
15	92	105	O	concentrations
16	107	115	O	occurring
17	117	122	O	within
18	124	124	O	2
19	126	127	O	to
20	129	129	O	4
21	131	135	O	hours
22	138	142	O	while
23	144	146	O	the
24	148	155	O	relative
25	157	171	O	bioavailability
26	173	174	O	of
27	176	178	O	the
28	180	185	O	tablet
29	187	197	O	formulation
30	199	206	O	compared
31	208	209	O	to
32	211	214	O	oral
33	216	223	O	solution
34	225	226	O	is
35	228	230	O	96%
NULL

Fanapt	4013	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	43
Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95.
1	0	13	O	Administration
2	15	16	O	of
3	18	28	O	XXXXXXXX
4	30	33	O	with
5	35	35	O	a
6	37	44	O	standard
7	46	49	B-KIN	high
8	51	53	I-KIN	fat
9	55	58	L-KIN	meal
10	60	62	O	did
11	64	66	O	not
12	68	80	O	significantly
13	82	87	O	affect
14	89	91	O	the
15	93	96	O	Cmax
16	98	99	O	or
17	101	103	O	AUC
18	105	106	O	of
19	108	118	O	XXXXXXXX
20	119	119	O	,
21	121	123	O	P88
22	124	124	O	,
23	126	127	O	or
24	129	131	O	P95
25	132	132	O	,
26	134	136	O	but
27	138	144	B-TRI	delayed
28	146	149	L-TRI	Tmax
29	151	152	O	by
30	154	154	O	1
31	156	159	O	hour
32	161	163	O	for
33	165	175	O	XXXXXXXX
34	176	176	O	,
35	178	178	O	2
36	180	184	O	hours
37	186	188	O	for
38	190	192	O	P88
39	194	196	O	and
40	198	198	O	6
41	200	204	O	hours
42	206	208	O	for
43	210	212	O	P95
K/7:C54604

Fanapt	4014	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	8
FANAPT can be administered without regard to meals.
1	0	5	O	XXXXXXXX
2	7	9	O	can
3	11	12	O	be
4	14	25	O	administered
5	27	33	O	without
6	35	40	O	regard
7	42	43	O	to
8	45	49	O	meals
NULL

Fanapt	4015	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	52
Distribution:Iloperidone has an apparent clearance (clearance/bioavailability) of 47 to 102 L/h, with an apparent volume of distribution of 1340 to 2800 L. At therapeutic concentrations, the unbound fraction of iloperidone in plasma is ~3% and of each metabolite (P88 and P95) it is ~8%.
1	0	11	O	Distribution
2	12	12	O	:
3	13	23	O	XXXXXXXX
4	25	27	O	has
5	29	30	O	an
6	32	39	O	apparent
7	41	49	O	clearance
8	52	60	O	clearance
9	61	61	O	/
10	62	76	O	bioavailability
11	79	80	O	of
12	82	83	O	47
13	85	86	O	to
14	88	90	O	102
15	92	92	O	L
16	93	93	O	/
17	94	94	O	h
18	95	95	O	,
19	97	100	O	with
20	102	103	O	an
21	105	112	O	apparent
22	114	119	O	volume
23	121	122	O	of
24	124	135	O	distribution
25	137	138	O	of
26	140	143	O	1340
27	145	146	O	to
28	148	151	O	2800
29	153	153	O	L
30	156	157	O	At
31	159	169	O	therapeutic
32	171	184	O	concentrations
33	185	185	O	,
34	187	189	O	the
35	191	197	O	unbound
36	199	206	O	fraction
37	208	209	O	of
38	211	221	O	XXXXXXXX
39	223	224	O	in
40	226	231	O	plasma
41	233	234	O	is
42	236	238	O	~3%
43	240	242	O	and
44	244	245	O	of
45	247	250	O	each
46	252	261	O	metabolite
47	264	266	O	P88
48	268	270	O	and
49	272	274	O	P95
50	277	278	O	it
51	280	281	O	is
52	283	285	O	~8%
NULL

Fanapt	4016	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	26
Metabolism and Elimination: Iloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and O-demethylation (mediated by CYP3A4).
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	26	26	O	:
5	28	38	O	XXXXXXXX
6	40	41	O	is
7	43	53	O	metabolized
8	55	63	O	primarily
9	65	66	O	by
10	68	68	O	3
11	70	86	O	biotransformation
12	88	95	O	pathways
13	96	96	O	:
14	98	105	O	carbonyl
15	107	115	O	reduction
16	116	116	O	,
17	118	130	O	hydroxylation
18	133	140	O	mediated
19	142	143	O	by
20	145	150	O	CYP2D6
21	153	155	O	and
22	157	157	O	O
23	159	171	O	demethylation
24	174	181	O	mediated
25	183	184	O	by
26	186	191	O	CYP3A4
NULL

Fanapt	4017	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	10
There are 2 predominant iloperidone metabolites, P95 and P88.
1	0	4	O	There
2	6	8	O	are
3	10	10	O	2
4	12	22	O	predominant
5	24	34	O	XXXXXXXX
6	36	46	O	metabolites
7	47	47	O	,
8	49	51	O	P95
9	53	55	O	and
10	57	59	O	P88
NULL

Fanapt	4018	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	29
The iloperidone metabolite P95 represents 47.9% of the AUC of iloperidone and its metabolites in plasma at steady-state for extensive metabolizers (EM) and 25% for poor metabolizers (PM).
1	0	2	O	The
2	4	14	O	XXXXXXXX
3	16	25	O	metabolite
4	27	29	O	P95
5	31	40	O	represents
6	42	46	O	47.9%
7	48	49	O	of
8	51	53	O	the
9	55	57	O	AUC
10	59	60	O	of
11	62	72	O	XXXXXXXX
12	74	76	O	and
13	78	80	O	its
14	82	92	O	metabolites
15	94	95	O	in
16	97	102	O	plasma
17	104	105	O	at
18	107	112	O	steady
19	114	118	O	state
20	120	122	O	for
21	124	132	O	extensive
22	134	145	O	metabolizers
23	148	149	O	EM
24	152	154	O	and
25	156	158	O	25%
26	160	162	O	for
27	164	167	O	poor
28	169	180	O	metabolizers
29	183	184	O	PM
NULL

Fanapt	4019	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	19
The active metabolite P88 accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively.
1	0	2	O	The
2	4	9	O	active
3	11	20	O	metabolite
4	22	24	O	P88
5	26	33	O	accounts
6	35	37	O	for
7	39	43	O	19.5%
8	45	47	O	and
9	49	53	O	34.0%
10	55	56	O	of
11	58	62	O	total
12	64	69	O	plasma
13	71	78	O	exposure
14	80	81	O	in
15	83	84	O	EM
16	86	88	O	and
17	90	91	O	PM
18	92	92	O	,
19	94	105	O	respectively
NULL

Fanapt	4020	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	38
Approximately 7% - 10% of Caucasians and 3% - 8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers.
1	0	12	O	Approximately
2	14	15	O	7%
3	19	21	O	10%
4	23	24	O	of
5	26	35	O	Caucasians
6	37	39	O	and
7	41	42	O	3%
8	46	47	O	8%
9	49	50	O	of
10	52	56	O	black
11	57	57	O	/
12	58	64	O	African
13	66	74	O	Americans
14	76	79	O	lack
15	81	83	O	the
16	85	92	O	capacity
17	94	95	O	to
18	97	106	O	metabolize
19	108	113	O	CYP2D6
20	115	124	O	substrates
21	126	128	O	and
22	130	132	O	are
23	134	143	O	classified
24	145	146	O	as
25	148	151	O	poor
26	153	164	O	metabolizers
27	167	168	O	PM
28	170	170	O	,
29	172	178	O	whereas
30	180	182	O	the
31	184	187	O	rest
32	189	191	O	are
33	193	204	O	intermediate
34	205	205	O	,
35	207	215	O	extensive
36	217	218	O	or
37	220	229	O	ultrarapid
38	231	242	O	metabolizers
NULL

Fanapt	4021	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	33
Co-administration of FANAPT with known strong inhibitors of CYP2D6 like fluoxetine results in a 2.3-fold increase in iloperidone plasma exposure, andtherefore one-half of the FANAPT dose should be administered.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	28	31	O	with
6	33	37	O	known
7	39	44	B-KIN	strong
8	46	55	I-KIN	inhibitors
9	57	58	I-KIN	of
10	60	65	L-KIN	CYP2D6
11	67	70	O	like
12	72	81	U-KIN	fluoxetine
13	83	89	O	results
14	91	92	O	in
15	94	94	O	a
16	96	98	O	2.3
17	100	103	O	fold
18	105	112	O	increase
19	114	115	O	in
20	117	127	O	XXXXXXXX
21	129	134	O	plasma
22	136	143	O	exposure
23	144	144	O	,
24	146	157	O	andtherefore
25	159	161	O	one
26	163	166	O	half
27	168	169	O	of
28	171	173	O	the
29	175	180	O	XXXXXXXX
30	182	185	O	dose
31	187	192	O	should
32	194	195	O	be
33	197	208	O	administered
K/12:C54355 K/7:C54355

Fanapt	4022	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	22
Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with EMsand PMs should have their dose reduced by one-half.
1	0	8	O	Similarly
2	9	9	O	,
3	11	13	O	PMs
4	15	16	O	of
5	18	23	O	CYP2D6
6	25	28	O	have
7	30	35	O	higher
8	37	44	O	exposure
9	46	47	O	to
10	49	59	O	XXXXXXXX
11	61	68	O	compared
12	70	73	O	with
13	75	80	O	EMsand
14	82	84	O	PMs
15	86	91	O	should
16	93	96	O	have
17	98	102	O	their
18	104	107	O	dose
19	109	115	O	reduced
20	117	118	O	by
21	120	122	O	one
22	124	127	O	half
NULL

Fanapt	4023	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	8
Laboratory tests are available to identify CYP2D6 PMs.
1	0	9	O	Laboratory
2	11	15	O	tests
3	17	19	O	are
4	21	29	O	available
5	31	32	O	to
6	34	41	O	identify
7	43	48	O	CYP2D6
8	50	52	O	PMs
NULL

Fanapt	4024	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	35
The bulk of the radioactive materials were recovered in the urine (mean 58.2% and 45.1% in EM and PM, respectively), with feces accounting for 19.9% (EM) to 22.1% (PM) of the dosed radioactivity.
1	0	2	O	The
2	4	7	O	bulk
3	9	10	O	of
4	12	14	O	the
5	16	26	O	radioactive
6	28	36	O	materials
7	38	41	O	were
8	43	51	O	recovered
9	53	54	O	in
10	56	58	O	the
11	60	64	O	urine
12	67	70	O	mean
13	72	76	O	58.2%
14	78	80	O	and
15	82	86	O	45.1%
16	88	89	O	in
17	91	92	O	EM
18	94	96	O	and
19	98	99	O	PM
20	100	100	O	,
21	102	113	O	respectively
22	115	115	O	,
23	117	120	O	with
24	122	126	O	feces
25	128	137	O	accounting
26	139	141	O	for
27	143	147	O	19.9%
28	150	151	O	EM
29	154	155	O	to
30	157	161	O	22.1%
31	164	165	O	PM
32	168	169	O	of
33	171	173	O	the
34	175	179	O	dosed
35	181	193	O	radioactivity
NULL

Fanapt	4025	34090-1	33f60b40-3fca-11de-8f56-0002a5d5c51b	20
Transporter Interaction: Iloperidone and P88 are not substrates of P-gp and iloperidone is a weak P-gp inhibitor.
1	0	10	O	Transporter
2	12	22	O	Interaction
3	23	23	O	:
4	25	35	O	XXXXXXXX
5	37	39	O	and
6	41	43	O	P88
7	45	47	O	are
8	49	51	O	not
9	53	62	O	substrates
10	64	65	O	of
11	67	67	O	P
12	69	70	O	gp
13	72	74	O	and
14	76	86	O	XXXXXXXX
15	88	89	O	is
16	91	91	O	a
17	93	96	O	weak
18	98	98	O	P
19	100	101	O	gp
20	103	111	O	inhibitor
NULL

Fetzima	5338	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	30
Other than CYP3A4 drug interactions, FETZIMA is predicted, based on in vitro studies, to have a low potential to be involved in clinically significant pharmacokinetic drug interactions.
1	0	4	O	Other
2	6	9	O	than
3	11	16	O	CYP3A4
4	18	21	O	drug
5	23	34	O	interactions
6	35	35	O	,
7	37	43	O	XXXXXXXX
8	45	46	O	is
9	48	56	O	predicted
10	57	57	O	,
11	59	63	O	based
12	65	66	O	on
13	68	69	O	in
14	71	75	O	vitro
15	77	83	O	studies
16	84	84	O	,
17	86	87	O	to
18	89	92	O	have
19	94	94	O	a
20	96	98	O	low
21	100	108	O	potential
22	110	111	O	to
23	113	114	O	be
24	116	123	O	involved
25	125	126	O	in
26	128	137	O	clinically
27	139	149	O	significant
28	151	165	O	pharmacokinetic
29	167	170	O	drug
30	172	183	O	interactions
NULL

Fetzima	5339	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	15
Strong CYP3A4 inhibitors such as ketoconazole: Do not exceed 80 mg once daily (7).
1	0	5	B-KIN	Strong
2	7	12	I-KIN	CYP3A4
3	14	23	L-KIN	inhibitors
4	25	28	O	such
5	30	31	O	as
6	33	44	U-KIN	ketoconazole
7	45	45	O	:
8	47	48	B-TRI	Do
9	50	52	I-TRI	not
10	54	59	L-TRI	exceed
11	61	62	O	80
12	64	65	O	mg
13	67	70	O	once
14	72	76	O	daily
15	79	79	O	7
K/1:C54357 K/6:C54357

Fetzima	5340	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Fetzima	5341	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	29
Epidemiological studies of case-control and cohort design have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	30	O	case
5	32	38	O	control
6	40	42	O	and
7	44	49	O	cohort
8	51	56	O	design
9	58	61	O	have
10	63	74	O	demonstrated
11	76	77	O	an
12	79	89	O	association
13	91	97	O	between
14	99	101	O	use
15	103	104	O	of
16	106	117	O	psychotropic
17	119	123	O	drugs
18	125	128	O	that
19	130	138	O	interfere
20	140	143	O	with
21	145	153	O	serotonin
22	155	162	O	reuptake
23	164	166	O	and
24	168	170	O	the
25	172	181	O	occurrence
26	183	184	O	of
27	186	190	O	upper
28	192	207	O	gastrointestinal
29	209	216	O	bleeding
NULL

Fetzima	5342	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	19
These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	4	O	These
2	6	12	O	studies
3	14	17	O	have
4	19	22	O	also
5	24	28	O	shown
6	30	33	O	that
7	35	44	O	concurrent
8	46	48	O	use
9	50	51	O	of
10	53	54	O	an
11	56	60	U-DYN	NSAID
12	62	63	O	or
13	65	71	U-DYN	aspirin
14	73	75	O	may
15	77	86	O	potentiate
16	88	91	O	this
17	93	96	O	risk
18	98	99	O	of
19	101	108	U-EFF	bleeding
D/11:19:1 D/13:19:1

Fetzima	5343	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	20
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are co-administered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	93	O	and
15	95	99	O	SNRIs
16	101	103	O	are
17	105	106	O	co
18	108	119	O	administered
19	121	124	O	with
20	126	133	U-DYN	warfarin
D/20:1:1 D/20:6:1

Fetzima	5344	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	14
Patients receiving warfarin therapy should be carefully monitored when FETZIMA is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	B-TRI	should
6	43	44	I-TRI	be
7	46	54	I-TRI	carefully
8	56	64	L-TRI	monitored
9	66	69	O	when
10	71	77	O	XXXXXXXX
11	79	80	O	is
12	82	90	O	initiated
13	92	93	O	or
14	95	106	O	discontinued
NULL

Fetzima	5345	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	16
Dose adjustment is recommended when FETZIMA is co-administered with strong inhibitors of CYP3A4 (e.g. ketoconazole).
1	0	3	B-TRI	Dose
2	5	14	L-TRI	adjustment
3	16	17	O	is
4	19	29	O	recommended
5	31	34	O	when
6	36	42	O	XXXXXXXX
7	44	45	O	is
8	47	48	O	co
9	50	61	O	administered
10	63	66	O	with
11	68	73	B-UNK	strong
12	75	84	I-UNK	inhibitors
13	86	87	I-UNK	of
14	89	94	L-UNK	CYP3A4
15	97	99	O	e.g
16	102	113	U-UNK	ketoconazole
NULL

Fetzima	5346	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	22
An in vivo study showed a clinically meaningful increase in levomilnacipran exposure when FETZIMA was co-administered with the CYP3A4 inhibitor ketoconazole.
1	0	1	O	An
2	3	4	O	in
3	6	9	O	vivo
4	11	15	O	study
5	17	22	O	showed
6	24	24	O	a
7	26	35	O	clinically
8	37	46	O	meaningful
9	48	55	O	increase
10	57	58	O	in
11	60	74	O	XXXXXXXX
12	76	83	O	exposure
13	85	88	O	when
14	90	96	O	XXXXXXXX
15	98	100	O	was
16	102	103	O	co
17	105	116	O	administered
18	118	121	O	with
19	123	125	O	the
20	127	132	O	CYP3A4
21	134	142	O	inhibitor
22	144	155	U-KIN	ketoconazole
K/22:C54355

Fetzima	5347	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	16
No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	31	O	is
7	33	38	O	needed
8	40	43	O	when
9	45	46	O	co
10	48	59	O	administered
11	61	64	O	with
12	66	66	O	a
13	68	73	O	CYP3A4
14	75	81	O	inducer
15	83	84	O	or
16	86	94	O	substrate
NULL

Fetzima	5348	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	24
In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam.
1	0	1	O	In
2	3	6	O	vivo
3	8	14	O	studies
4	16	21	O	showed
5	23	24	O	no
6	26	35	O	clinically
7	37	46	O	meaningful
8	48	53	O	change
9	55	56	O	in
10	58	72	O	XXXXXXXX
11	74	81	O	exposure
12	83	86	O	when
13	88	89	O	co
14	91	102	O	administered
15	104	107	O	with
16	109	111	O	the
17	113	118	O	CYP3A4
18	120	126	O	inducer
19	128	140	O	carbamazepine
20	142	143	O	or
21	145	147	O	the
22	149	154	O	CYP3A4
23	156	164	O	substrate
24	166	175	O	alprazolam
NULL

Fetzima	5349	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	36
No dose adjustment of FETZIMA is needed when co-administered with inhibitors of CYP2C8 , CYP2C19, CYP2D6, CYP2J2, P-glycoprotein, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	31	O	is
7	33	38	O	needed
8	40	43	O	when
9	45	46	O	co
10	48	59	O	administered
11	61	64	O	with
12	66	75	O	inhibitors
13	77	78	O	of
14	80	85	O	CYP2C8
15	87	87	O	,
16	89	95	O	CYP2C19
17	96	96	O	,
18	98	103	O	CYP2D6
19	104	104	O	,
20	106	111	O	CYP2J2
21	112	112	O	,
22	114	114	O	P
23	116	127	O	glycoprotein
24	128	128	O	,
25	130	133	O	BCRP
26	134	134	O	,
27	136	142	O	OATP1B1
28	143	143	O	,
29	145	151	O	OATP1B3
30	152	152	O	,
31	154	157	O	OAT1
32	158	158	O	,
33	160	163	O	OAT3
34	164	164	O	,
35	166	167	O	or
36	169	172	O	OCT2
NULL

Fetzima	5350	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	20
In vitro studies suggested that CYP2C8, CYP2C19, CYP2D6, and CYP2J2 had minimal contributions to metabolism of levomilnacipran.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	25	O	suggested
5	27	30	O	that
6	32	37	O	CYP2C8
7	38	38	O	,
8	40	46	O	CYP2C19
9	47	47	O	,
10	49	54	O	CYP2D6
11	55	55	O	,
12	57	59	O	and
13	61	66	O	CYP2J2
14	68	70	O	had
15	72	78	O	minimal
16	80	92	O	contributions
17	94	95	O	to
18	97	106	O	metabolism
19	108	109	O	of
20	111	125	O	XXXXXXXX
NULL

Fetzima	5351	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	29
In addition, levomilnacipran is not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2 and is a weak substrate of P-gp.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	27	O	XXXXXXXX
5	29	30	O	is
6	32	34	O	not
7	36	36	O	a
8	38	46	O	substrate
9	48	49	O	of
10	51	54	O	BCRP
11	55	55	O	,
12	57	63	O	OATP1B1
13	64	64	O	,
14	66	72	O	OATP1B3
15	73	73	O	,
16	75	78	O	OAT1
17	79	79	O	,
18	81	84	O	OAT3
19	85	85	O	,
20	87	88	O	or
21	90	93	O	OCT2
22	95	97	O	and
23	99	100	O	is
24	102	102	O	a
25	104	107	O	weak
26	109	117	O	substrate
27	119	120	O	of
28	122	122	O	P
29	124	125	O	gp
NULL

Fetzima	5352	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	58
Figure 1 PK Interactions between Levomilnacipran (LVM) and Other Drugs Figure 1 No dose adjustment of the concomitant medication is recommended when FETZIMA is administered with a substrate of CYP3A4, CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2.
1	0	5	O	Figure
2	7	7	O	1
3	9	10	O	PK
4	12	23	O	Interactions
5	25	31	O	between
6	33	47	O	XXXXXXXX
7	50	52	O	LVM
8	55	57	O	and
9	59	63	O	Other
10	65	69	O	Drugs
11	71	76	O	Figure
12	78	78	O	1
13	80	81	O	No
14	83	86	O	dose
15	88	97	O	adjustment
16	99	100	O	of
17	102	104	O	the
18	106	116	O	concomitant
19	118	127	O	medication
20	129	130	O	is
21	132	142	O	recommended
22	144	147	O	when
23	149	155	O	XXXXXXXX
24	157	158	O	is
25	160	171	O	administered
26	173	176	O	with
27	178	178	O	a
28	180	188	O	substrate
29	190	191	O	of
30	193	198	O	CYP3A4
31	199	199	O	,
32	201	206	O	CYP1A2
33	207	207	O	,
34	209	214	O	CYP2A6
35	215	215	O	,
36	217	222	O	CYP2C8
37	223	223	O	,
38	225	230	O	CYP2C9
39	231	231	O	,
40	233	239	O	CYP2C19
41	240	240	O	,
42	242	247	O	CYP2D6
43	248	248	O	,
44	250	255	O	CYP2E1
45	256	256	O	,
46	258	258	O	P
47	260	261	O	gp
48	262	262	O	,
49	264	270	O	OATP1B1
50	271	271	O	,
51	273	279	O	OATP1B3
52	280	280	O	,
53	282	285	O	OAT1
54	286	286	O	,
55	288	291	O	OAT3
56	292	292	O	,
57	294	295	O	or
58	297	300	O	OCT2
NULL

Fetzima	5353	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	39
In vitro studies have shown that levomilnacipran is not an inhibitor of CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, P-gp, OATP1B1, OATP1B3, OAT1, OAT3, or OCT2.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	47	O	XXXXXXXX
8	49	50	O	is
9	52	54	O	not
10	56	57	O	an
11	59	67	O	inhibitor
12	69	70	O	of
13	72	77	O	CYP1A2
14	78	78	O	,
15	80	85	O	CYP2A6
16	86	86	O	,
17	88	93	O	CYP2C8
18	94	94	O	,
19	96	101	O	CYP2C9
20	102	102	O	,
21	104	110	O	CYP2C19
22	111	111	O	,
23	113	118	O	CYP2D6
24	119	119	O	,
25	121	126	O	CYP2E1
26	127	127	O	,
27	129	129	O	P
28	131	132	O	gp
29	133	133	O	,
30	135	141	O	OATP1B1
31	142	142	O	,
32	144	150	O	OATP1B3
33	151	151	O	,
34	153	156	O	OAT1
35	157	157	O	,
36	159	162	O	OAT3
37	163	163	O	,
38	165	166	O	or
39	168	171	O	OCT2
NULL

Fetzima	5354	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	23
Concomitant use of FETZIMA with alprazolam or carbamazepine, substrates of CYP3A4, had no significant effect on alprazolam or carbamazepine plasma concentrations.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	25	O	XXXXXXXX
5	27	30	O	with
6	32	41	O	alprazolam
7	43	44	O	or
8	46	58	O	carbamazepine
9	59	59	O	,
10	61	70	O	substrates
11	72	73	O	of
12	75	80	O	CYP3A4
13	81	81	O	,
14	83	85	O	had
15	87	88	O	no
16	90	100	O	significant
17	102	107	O	effect
18	109	110	O	on
19	112	121	O	alprazolam
20	123	124	O	or
21	126	138	O	carbamazepine
22	140	145	O	plasma
23	147	160	O	concentrations
NULL

Fetzima	5355	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	17
The risk of using FETZIMA in combination with other CNS-active drugs has not been systematically evaluated.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	16	O	using
5	18	24	O	XXXXXXXX
6	26	27	O	in
7	29	39	O	combination
8	41	44	O	with
9	46	50	O	other
10	52	54	O	CNS
11	56	61	O	active
12	63	67	O	drugs
13	69	71	O	has
14	73	75	O	not
15	77	80	O	been
16	82	95	O	systematically
17	97	105	O	evaluated
NULL

Fetzima	5356	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	25
Consequently, caution is advised when FETZIMA is prescribed in combination with other CNS-active drugs, including those with a similar mechanism of action.
1	0	11	O	Consequently
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	31	O	advised
6	33	36	O	when
7	38	44	O	XXXXXXXX
8	46	47	O	is
9	49	58	O	prescribed
10	60	61	O	in
11	63	73	O	combination
12	75	78	O	with
13	80	84	O	other
14	86	88	B-UNK	CNS
15	90	95	I-UNK	active
16	97	101	L-UNK	drugs
17	102	102	O	,
18	104	112	O	including
19	114	118	O	those
20	120	123	O	with
21	125	125	O	a
22	127	133	O	similar
23	135	143	O	mechanism
24	145	146	O	of
25	148	153	O	action
NULL

Fetzima	5357	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	16
Alcohol In an in vitro study, alcohol interacted with the extended-release properties of FETZIMA.
1	0	6	O	Alcohol
2	8	9	O	In
3	11	12	O	an
4	14	15	O	in
5	17	21	O	vitro
6	23	27	O	study
7	28	28	O	,
8	30	36	U-UNK	alcohol
9	38	47	U-TRI	interacted
10	49	52	O	with
11	54	56	O	the
12	58	65	O	extended
13	67	73	O	release
14	75	84	O	properties
15	86	87	O	of
16	89	95	O	XXXXXXXX
NULL

Fetzima	5358	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	14
If FETZIMA is taken with alcohol, a pronounced accelerated drug release may occur.
1	0	1	O	If
2	3	9	O	XXXXXXXX
3	11	12	O	is
4	14	18	O	taken
5	20	23	O	with
6	25	31	U-DYN	alcohol
7	32	32	O	,
8	34	34	O	a
9	36	45	O	pronounced
10	47	57	B-EFF	accelerated
11	59	62	I-EFF	drug
12	64	70	L-EFF	release
13	72	74	O	may
14	76	80	O	occur
D/6:10:1

Fetzima	5359	34073-7	f371258d-91b3-4b6a-ac99-434a1964c3af	13
It is recommended that FETZIMA extended-release capsules not be taken with alcohol.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	29	O	XXXXXXXX
6	31	38	O	extended
7	40	46	O	release
8	48	55	O	capsules
9	57	59	O	not
10	61	62	O	be
11	64	68	O	taken
12	70	73	O	with
13	75	81	U-UNK	alcohol
NULL

Fetzima	5360	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	40
The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters.
1	0	2	O	The
2	4	8	O	exact
3	10	18	O	mechanism
4	20	21	O	of
5	23	25	O	the
6	27	40	O	antidepressant
7	42	47	O	action
8	49	50	O	of
9	52	66	O	XXXXXXXX
10	68	69	O	is
11	71	77	O	unknown
12	78	78	O	,
13	80	82	O	but
14	84	85	O	is
15	87	93	O	thought
16	95	96	O	to
17	98	99	O	be
18	101	107	O	related
19	109	110	O	to
20	112	114	O	the
21	116	127	O	potentiation
22	129	130	O	of
23	132	140	O	serotonin
24	142	144	O	and
25	146	159	O	norepinephrine
26	161	162	O	in
27	164	166	O	the
28	168	174	O	central
29	176	182	O	nervous
30	184	189	O	system
31	190	190	O	,
32	192	198	O	through
33	200	209	O	inhibition
34	211	212	O	of
35	214	221	O	reuptake
36	223	224	O	at
37	226	234	O	serotonin
38	236	238	O	and
39	240	253	O	norepinephrine
40	255	266	O	transporters
NULL

Fetzima	5361	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	18
Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
1	0	2	O	Non
2	4	11	O	clinical
3	13	19	O	studies
4	21	24	O	have
5	26	30	O	shown
6	32	35	O	that
7	37	51	O	XXXXXXXX
8	53	54	O	is
9	56	56	O	a
10	58	63	O	potent
11	65	67	O	and
12	69	77	O	selective
13	79	87	O	serotonin
14	89	91	O	and
15	93	106	O	norepinephrine
16	108	115	O	reuptake
17	117	125	O	inhibitor
18	128	131	O	SNRI
NULL

Fetzima	5362	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	40
Levomilnacipran binds with high affinity to the human serotonin (5-HT) and norepinephrine (NE) transporters (Ki = 11 and 91 nM, respectively) and potently inhibits 5-HT and NE reuptake (IC50 = 16-19 and 11 nM, respectively).
1	0	14	O	XXXXXXXX
2	16	20	O	binds
3	22	25	O	with
4	27	30	O	high
5	32	39	O	affinity
6	41	42	O	to
7	44	46	O	the
8	48	52	O	human
9	54	62	O	serotonin
10	65	65	O	5
11	67	68	O	HT
12	71	73	O	and
13	75	88	O	norepinephrine
14	91	92	O	NE
15	95	106	O	transporters
16	109	110	O	Ki
17	112	112	O	=
18	114	115	O	11
19	117	119	O	and
20	121	122	O	91
21	124	125	O	nM
22	126	126	O	,
23	128	139	O	respectively
24	142	144	O	and
25	146	153	O	potently
26	155	162	O	inhibits
27	164	164	O	5
28	166	167	O	HT
29	169	171	O	and
30	173	174	O	NE
31	176	183	O	reuptake
32	186	189	O	IC50
33	191	191	O	=
34	193	194	O	16
35	196	197	O	19
36	199	201	O	and
37	203	204	O	11
38	206	207	O	nM
39	208	208	O	,
40	210	221	O	respectively
NULL

Fetzima	5363	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	41
Levomilnacipran lacks significant affinity for any other receptors, ion channels or transporters tested in vitro, including serotonergic (5HT1-7), A- and B- adrenergic, muscarinic, or histaminergic receptors and Ca2+, Na+, K+ or Cl- channels.
1	0	14	O	XXXXXXXX
2	16	20	O	lacks
3	22	32	O	significant
4	34	41	O	affinity
5	43	45	O	for
6	47	49	O	any
7	51	55	O	other
8	57	65	O	receptors
9	66	66	O	,
10	68	70	O	ion
11	72	79	O	channels
12	81	82	O	or
13	84	95	O	transporters
14	97	102	O	tested
15	104	105	O	in
16	107	111	O	vitro
17	112	112	O	,
18	114	122	O	including
19	124	135	O	serotonergic
20	138	141	O	5HT1
21	143	143	O	7
22	145	145	O	,
23	147	147	O	A
24	150	152	O	and
25	154	154	O	B
26	157	166	O	adrenergic
27	167	167	O	,
28	169	178	O	muscarinic
29	179	179	O	,
30	181	182	O	or
31	184	196	O	histaminergic
32	198	206	O	receptors
33	208	210	O	and
34	212	215	O	Ca2+
35	216	216	O	,
36	218	220	O	Na+
37	221	221	O	,
38	223	224	O	K+
39	226	227	O	or
40	229	230	O	Cl
41	233	240	O	channels
NULL

Fetzima	5364	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	7
Levomilnacipran did not inhibit monoamine oxidase (MAO).
1	0	14	O	XXXXXXXX
2	16	18	O	did
3	20	22	O	not
4	24	30	O	inhibit
5	32	40	O	monoamine
6	42	48	O	oxidase
7	51	53	O	MAO
NULL

Fetzima	5365	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	22
Cardiovascular Electrophysiology At a dose 2.5 times the maximum recommended dose, levomilnacipran does not prolong QTc to any clinically relevant extent.
1	0	13	O	Cardiovascular
2	15	31	O	Electrophysiology
3	33	34	O	At
4	36	36	O	a
5	38	41	O	dose
6	43	45	O	2.5
7	47	51	O	times
8	53	55	O	the
9	57	63	O	maximum
10	65	75	O	recommended
11	77	80	O	dose
12	81	81	O	,
13	83	97	O	XXXXXXXX
14	99	102	O	does
15	104	106	O	not
16	108	114	O	prolong
17	116	118	O	QTc
18	120	121	O	to
19	123	125	O	any
20	127	136	O	clinically
21	138	145	O	relevant
22	147	152	O	extent
NULL

Fetzima	5366	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	20
The concentration of levomilnacipran at steady state is proportional to dose when administered from 25 to 300 mg once daily.
1	0	2	O	The
2	4	16	O	concentration
3	18	19	O	of
4	21	35	O	XXXXXXXX
5	37	38	O	at
6	40	45	O	steady
7	47	51	O	state
8	53	54	O	is
9	56	67	O	proportional
10	69	70	O	to
11	72	75	O	dose
12	77	80	O	when
13	82	93	O	administered
14	95	98	O	from
15	100	101	O	25
16	103	104	O	to
17	106	108	O	300
18	110	111	O	mg
19	113	116	O	once
20	118	122	O	daily
NULL

Fetzima	5367	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	18
Following an oral administration, the mean apparent total clearance of levomilnacipran is 21-29 L/h.
1	0	8	O	Following
2	10	11	O	an
3	13	16	O	oral
4	18	31	O	administration
5	32	32	O	,
6	34	36	O	the
7	38	41	O	mean
8	43	50	O	apparent
9	52	56	O	total
10	58	66	O	clearance
11	68	69	O	of
12	71	85	O	XXXXXXXX
13	87	88	O	is
14	90	91	O	21
15	93	94	O	29
16	96	96	O	L
17	97	97	O	/
18	98	98	O	h
NULL

Fetzima	5368	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	11
Steady-state concentrations of levomilnacipran are predictable from single-dose data.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	29	O	of
5	31	45	O	XXXXXXXX
6	47	49	O	are
7	51	61	O	predictable
8	63	66	O	from
9	68	73	O	single
10	75	78	O	dose
11	80	83	O	data
NULL

Fetzima	5369	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	12
The apparent terminal elimination half-life of levomilnacipran is approximately 12 hours.
1	0	2	O	The
2	4	11	O	apparent
3	13	20	O	terminal
4	22	32	O	elimination
5	34	37	O	half
6	39	42	O	life
7	44	45	O	of
8	47	61	O	XXXXXXXX
9	63	64	O	is
10	66	78	O	approximately
11	80	81	O	12
12	83	87	O	hours
NULL

Fetzima	5370	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	30
After daily dosing of FETZIMA 120 mg, the mean Cmax value is 341 ng/mL, and the mean steady-state AUC value is 5196 ng*h/mL.
1	0	4	O	After
2	6	10	O	daily
3	12	17	O	dosing
4	19	20	O	of
5	22	28	O	XXXXXXXX
6	30	32	O	120
7	34	35	O	mg
8	36	36	O	,
9	38	40	O	the
10	42	45	O	mean
11	47	50	O	Cmax
12	52	56	O	value
13	58	59	O	is
14	61	63	O	341
15	65	66	O	ng
16	67	67	O	/
17	68	69	O	mL
18	70	70	O	,
19	72	74	O	and
20	76	78	O	the
21	80	83	O	mean
22	85	90	O	steady
23	92	96	O	state
24	98	100	O	AUC
25	102	106	O	value
26	108	109	O	is
27	111	114	O	5196
28	116	119	O	ng*h
29	120	120	O	/
30	121	122	O	mL
NULL

Fetzima	5371	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	11
Interconversion between levomilnacipran and its stereoisomer does not occur in humans.
1	0	14	O	Interconversion
2	16	22	O	between
3	24	38	O	XXXXXXXX
4	40	42	O	and
5	44	46	O	its
6	48	59	O	stereoisomer
7	61	64	O	does
8	66	68	O	not
9	70	74	O	occur
10	76	77	O	in
11	79	84	O	humans
NULL

Fetzima	5372	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	18
Absorption The relative bioavailability of levomilnacipran after administration of FETZIMA ER was 92% when compared to oral solution.
1	0	9	O	Absorption
2	11	13	O	The
3	15	22	O	relative
4	24	38	O	bioavailability
5	40	41	O	of
6	43	57	O	XXXXXXXX
7	59	63	O	after
8	65	78	O	administration
9	80	81	O	of
10	83	89	O	XXXXXXXX
11	91	92	O	ER
12	94	96	O	was
13	98	100	O	92%
14	102	105	O	when
15	107	114	O	compared
16	116	117	O	to
17	119	122	O	oral
18	124	131	O	solution
NULL

Fetzima	5373	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	12
Levomilnacipran concentration was not significantly affected when FETZIMA was administered with food.
1	0	14	O	XXXXXXXX
2	16	28	O	concentration
3	30	32	O	was
4	34	36	O	not
5	38	50	O	significantly
6	52	59	O	affected
7	61	64	O	when
8	66	72	O	XXXXXXXX
9	74	76	O	was
10	78	89	O	administered
11	91	94	O	with
12	96	99	O	food
NULL

Fetzima	5374	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	16
The median time to peak concentration (Tmax) of levomilnacipran is 6-8 hours after oral administration.
1	0	2	O	The
2	4	9	O	median
3	11	14	O	time
4	16	17	O	to
5	19	22	O	peak
6	24	36	O	concentration
7	39	42	O	Tmax
8	45	46	O	of
9	48	62	O	XXXXXXXX
10	64	65	O	is
11	67	67	O	6
12	69	69	O	8
13	71	75	O	hours
14	77	81	O	after
15	83	86	O	oral
16	88	101	O	administration
NULL

Fetzima	5375	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	30
Distribution Levomilnacipran is widely distributed with an apparent volume of distribution of 387-473 L; plasma protein binding is 22% over concentration range of 10 to 1000 ng/mL.
1	0	11	O	Distribution
2	13	27	O	XXXXXXXX
3	29	30	O	is
4	32	37	O	widely
5	39	49	O	distributed
6	51	54	O	with
7	56	57	O	an
8	59	66	O	apparent
9	68	73	O	volume
10	75	76	O	of
11	78	89	O	distribution
12	91	92	O	of
13	94	96	O	387
14	98	100	O	473
15	102	102	O	L
16	105	110	O	plasma
17	112	118	O	protein
18	120	126	O	binding
19	128	129	O	is
20	131	133	O	22%
21	135	138	O	over
22	140	152	O	concentration
23	154	158	O	range
24	160	161	O	of
25	163	164	O	10
26	166	167	O	to
27	169	172	O	1000
28	174	175	O	ng
29	176	176	O	/
30	177	178	O	mL
NULL

Fetzima	5376	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	15
Metabolism Levomilnacipran undergoes desethylation to form desethyl levomilnacipran and hydroxylation to form p-hydroxy-levomilnacipran.
1	0	9	O	Metabolism
2	11	25	O	XXXXXXXX
3	27	35	O	undergoes
4	37	49	O	desethylation
5	51	52	O	to
6	54	57	O	form
7	59	66	O	desethyl
8	68	82	O	XXXXXXXX
9	84	86	O	and
10	88	100	O	hydroxylation
11	102	103	O	to
12	105	108	O	form
13	110	110	O	p
14	112	118	O	hydroxy
15	120	134	O	XXXXXXXX
NULL

Fetzima	5377	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	11
Both oxidative metabolites undergo further conjugation with glucuronide to form conjugates.
1	0	3	O	Both
2	5	13	O	oxidative
3	15	25	O	metabolites
4	27	33	O	undergo
5	35	41	O	further
6	43	53	O	conjugation
7	55	58	O	with
8	60	70	O	glucuronide
9	72	73	O	to
10	75	78	O	form
11	80	89	O	conjugates
NULL

Fetzima	5378	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	19
The desethylation is catalyzed primarily by CYP3A4 with minor contribution by CYP2C8, 2C19, 2D6, and 2J2.
1	0	2	O	The
2	4	16	O	desethylation
3	18	19	O	is
4	21	29	O	catalyzed
5	31	39	O	primarily
6	41	42	O	by
7	44	49	O	CYP3A4
8	51	54	O	with
9	56	60	O	minor
10	62	73	O	contribution
11	75	76	O	by
12	78	83	O	CYP2C8
13	84	84	O	,
14	86	89	O	2C19
15	90	90	O	,
16	92	94	O	2D6
17	95	95	O	,
18	97	99	O	and
19	101	103	O	2J2
NULL

Fetzima	5379	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	13
Elimination/Excretion Levomilnacipran and its metabolites are eliminated primarily by renal excretion.
1	0	10	O	Elimination
2	11	11	O	/
3	12	20	O	Excretion
4	22	36	O	XXXXXXXX
5	38	40	O	and
6	42	44	O	its
7	46	56	O	metabolites
8	58	60	O	are
9	62	71	O	eliminated
10	73	81	O	primarily
11	83	84	O	by
12	86	90	O	renal
13	92	100	O	excretion
NULL

Fetzima	5380	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	20
Following oral administration of 14C-levomilnacipran solution, approximately 58% of the dose is excreted in urine as unchanged levomilnacipran.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	35	O	14C
6	37	51	O	XXXXXXXX
7	53	60	O	solution
8	61	61	O	,
9	63	75	O	approximately
10	77	79	O	58%
11	81	82	O	of
12	84	86	O	the
13	88	91	O	dose
14	93	94	O	is
15	96	103	O	excreted
16	105	106	O	in
17	108	112	O	urine
18	114	115	O	as
19	117	125	O	unchanged
20	127	141	O	XXXXXXXX
NULL

Fetzima	5381	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	19
N-desethyl levomilnacipran is the major metabolite excreted in the urine and accounted for approximately 18% of the dose.
1	0	0	O	N
2	2	9	O	desethyl
3	11	25	O	XXXXXXXX
4	27	28	O	is
5	30	32	O	the
6	34	38	O	major
7	40	49	O	metabolite
8	51	58	O	excreted
9	60	61	O	in
10	63	65	O	the
11	67	71	O	urine
12	73	75	O	and
13	77	85	O	accounted
14	87	89	O	for
15	91	103	O	approximately
16	105	107	O	18%
17	109	110	O	of
18	112	114	O	the
19	116	119	O	dose
NULL

Fetzima	5382	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	28
Other identifiable metabolites excreted in the urine are levomilnacipran glucuronide (4%), desethyl levomilnacipran glucuronide (3%), p-hydroxy levomilnacipran glucuronide (1%), and p-hydroxy levomilnacipran (1%).
1	0	4	O	Other
2	6	17	O	identifiable
3	19	29	O	metabolites
4	31	38	O	excreted
5	40	41	O	in
6	43	45	O	the
7	47	51	O	urine
8	53	55	O	are
9	57	71	O	XXXXXXXX
10	73	83	O	glucuronide
11	86	87	O	4%
12	89	89	O	,
13	91	98	O	desethyl
14	100	114	O	XXXXXXXX
15	116	126	O	glucuronide
16	129	130	O	3%
17	132	132	O	,
18	134	134	O	p
19	136	142	O	hydroxy
20	144	158	O	XXXXXXXX
21	160	170	O	glucuronide
22	173	174	O	1%
23	176	176	O	,
24	178	180	O	and
25	182	182	O	p
26	184	190	O	hydroxy
27	192	206	O	XXXXXXXX
28	209	210	O	1%
NULL

Fetzima	5383	34090-1	f371258d-91b3-4b6a-ac99-434a1964c3af	4
The metabolites are inactive.
1	0	2	O	The
2	4	14	O	metabolites
3	16	18	O	are
4	20	27	O	inactive
NULL

Fluphenazine	5721	34090-1	b580471f-44a1-4da0-96ad-2f537eabec3e	24
The basic effects of fluphenazine decanoate appear to be no different from those of fluphenazine hydrochloride, with the exception of duration of action.
1	0	2	O	The
2	4	8	O	basic
3	10	16	O	effects
4	18	19	O	of
5	21	32	O	XXXXXXXX
6	34	42	O	decanoate
7	44	49	O	appear
8	51	52	O	to
9	54	55	O	be
10	57	58	O	no
11	60	68	O	different
12	70	73	O	from
13	75	79	O	those
14	81	82	O	of
15	84	95	O	XXXXXXXX
16	97	109	O	hydrochloride
17	110	110	O	,
18	112	115	O	with
19	117	119	O	the
20	121	129	O	exception
21	131	132	O	of
22	134	141	O	duration
23	143	144	O	of
24	146	151	O	action
NULL

Fluphenazine	5722	34090-1	b580471f-44a1-4da0-96ad-2f537eabec3e	17
The esterification of fluphenazine markedly prolongs the drug's duration of effect without unduly attenuating its beneficial action.
1	0	2	O	The
2	4	17	O	esterification
3	19	20	O	of
4	22	33	O	XXXXXXXX
5	35	42	O	markedly
6	44	51	O	prolongs
7	53	55	O	the
8	57	62	O	drug's
9	64	71	O	duration
10	73	74	O	of
11	76	81	O	effect
12	83	89	O	without
13	91	96	O	unduly
14	98	108	O	attenuating
15	110	112	O	its
16	114	123	O	beneficial
17	125	130	O	action
NULL

Fluphenazine	5723	34090-1	b580471f-44a1-4da0-96ad-2f537eabec3e	20
Fluphenazine decanoate has activity at all levels of the central nervous system (CNS) as well as on multiple organ systems.
1	0	11	O	XXXXXXXX
2	13	21	O	decanoate
3	23	25	O	has
4	27	34	O	activity
5	36	37	O	at
6	39	41	O	all
7	43	48	O	levels
8	50	51	O	of
9	53	55	O	the
10	57	63	O	central
11	65	71	O	nervous
12	73	78	O	system
13	81	83	O	CNS
14	86	87	O	as
15	89	92	O	well
16	94	95	O	as
17	97	98	O	on
18	100	107	O	multiple
19	109	113	O	organ
20	115	121	O	systems
NULL

Fluphenazine	5724	34090-1	b580471f-44a1-4da0-96ad-2f537eabec3e	10
The mechanism whereby its therapeutic action is exerted is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	20	O	whereby
4	22	24	O	its
5	26	36	O	therapeutic
6	38	43	O	action
7	45	46	O	is
8	48	54	O	exerted
9	56	57	O	is
10	59	65	O	unknown
NULL

Fluphenazine	5725	34090-1	b580471f-44a1-4da0-96ad-2f537eabec3e	69
Fluphenazine differs from other phenothiazine derivatives in several respects: it is more potent on a milligram basis, it has less potentiating effect on CNS depressants and anesthetics than do some of the phenothiazines and appears to be less sedating, and it is less likely than some of the older phenothiazines to produce hypotension (nevertheless, appropriate cautions should be observed, see PRECAUTIONS and ADVERSE REACTIONS ).
1	0	11	O	XXXXXXXX
2	13	19	O	differs
3	21	24	O	from
4	26	30	O	other
5	32	44	O	phenothiazine
6	46	56	O	derivatives
7	58	59	O	in
8	61	67	O	several
9	69	76	O	respects
10	77	77	O	:
11	79	80	O	it
12	82	83	O	is
13	85	88	O	more
14	90	95	O	potent
15	97	98	O	on
16	100	100	O	a
17	102	110	O	milligram
18	112	116	O	basis
19	117	117	O	,
20	119	120	O	it
21	122	124	O	has
22	126	129	O	less
23	131	142	O	potentiating
24	144	149	O	effect
25	151	152	O	on
26	154	156	O	CNS
27	158	168	O	depressants
28	170	172	O	and
29	174	184	O	anesthetics
30	186	189	O	than
31	191	192	O	do
32	194	197	O	some
33	199	200	O	of
34	202	204	O	the
35	206	219	O	phenothiazines
36	221	223	O	and
37	225	231	O	appears
38	233	234	O	to
39	236	237	O	be
40	239	242	O	less
41	244	251	O	sedating
42	252	252	O	,
43	254	256	O	and
44	258	259	O	it
45	261	262	O	is
46	264	267	O	less
47	269	274	O	likely
48	276	279	O	than
49	281	284	O	some
50	286	287	O	of
51	289	291	O	the
52	293	297	O	older
53	299	312	O	phenothiazines
54	314	315	O	to
55	317	323	O	produce
56	325	335	O	hypotension
57	338	349	O	nevertheless
58	350	350	O	,
59	352	362	O	appropriate
60	364	371	O	cautions
61	373	378	O	should
62	380	381	O	be
63	383	390	O	observed
64	391	391	O	,
65	393	395	O	see
66	397	407	O	PRECAUTIONS
67	409	411	O	and
68	413	419	O	ADVERSE
69	421	429	O	REACTIONS
NULL

Flurazepam Hydrochloride	3039	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	27
Benzodiazepines, including flurazepam, produce additive CNS depressant effects when co-administered with ethanol or other CNS depressants (e.g., psychotropic medications, anticonvulsants, antihistamines).
1	0	14	O	Benzodiazepines
2	15	15	O	,
3	17	25	O	including
4	27	36	O	XXXXXXXX
5	37	37	O	,
6	39	45	O	produce
7	47	54	B-EFF	additive
8	56	58	I-EFF	CNS
9	60	69	I-EFF	depressant
10	71	77	L-EFF	effects
11	79	82	O	when
12	84	85	O	co
13	87	98	O	administered
14	100	103	O	with
15	105	111	U-DYN	ethanol
16	113	114	O	or
17	116	120	O	other
18	122	124	B-DYN	CNS
19	126	136	L-DYN	depressants
20	139	141	O	e.g
21	143	143	O	,
22	145	156	B-DYN	psychotropic
23	158	168	L-DYN	medications
24	169	169	O	,
25	171	185	U-DYN	anticonvulsants
26	186	186	O	,
27	188	201	U-DYN	antihistamines
D/15:7:1 D/18:7:1 D/22:7:1 D/25:7:1 D/27:7:1

Flurazepam Hydrochloride	3040	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	18
Downward dose adjustment of flurazepam and/or concomitant CNS depressants may be necessary because of additive effects.
1	0	7	B-TRI	Downward
2	9	12	I-TRI	dose
3	14	23	L-TRI	adjustment
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	41	O	and
7	42	42	O	/
8	43	44	O	or
9	46	56	O	concomitant
10	58	60	B-DYN	CNS
11	62	72	L-DYN	depressants
12	74	76	O	may
13	78	79	O	be
14	81	89	O	necessary
15	91	97	O	because
16	99	100	O	of
17	102	109	O	additive
18	111	117	O	effects
NULL

Flurazepam Hydrochloride	3041	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	13
*CNS Depressants: Downward dose adjustment may be necessary due to additive effects.
1	0	3	O	CNS
2	5	15	U-DYN	Depressants
3	16	16	O	:
4	18	25	B-TRI	Downward
5	27	30	I-TRI	dose
6	32	41	L-TRI	adjustment
7	43	45	O	may
8	47	48	O	be
9	50	58	O	necessary
10	60	62	O	due
11	64	65	O	to
12	67	74	O	additive
13	76	82	O	effects
NULL

Flurazepam Hydrochloride	3042	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	16
Opioids: Limit dosage and duration, and follow patients closely for respiratory depression and sedation.
1	0	6	U-DYN	Opioids
2	7	7	O	:
3	9	13	O	Limit
4	15	20	O	dosage
5	22	24	O	and
6	26	33	O	duration
7	34	34	O	,
8	36	38	O	and
9	40	45	O	follow
10	47	54	O	patients
11	56	62	O	closely
12	64	66	O	for
13	68	78	B-EFF	respiratory
14	80	89	L-EFF	depression
15	91	93	O	and
16	95	102	U-EFF	sedation
D/1:13:1 D/1:16:1

Flurazepam Hydrochloride	3043	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	26
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	37	O	benzodiazepines
6	39	41	O	and
7	43	49	U-DYN	opioids
8	51	59	O	increases
9	61	63	O	the
10	65	68	O	risk
11	70	71	O	of
12	73	83	B-EFF	respiratory
13	85	94	L-EFF	depression
14	96	102	O	because
15	104	105	O	of
16	107	113	O	actions
17	115	116	O	at
18	118	126	O	different
19	128	135	O	receptor
20	137	141	O	sites
21	143	144	O	in
22	146	148	O	the
23	150	152	O	CNS
24	154	157	O	that
25	159	165	O	control
26	167	177	O	respiration
D/7:12:1

Flurazepam Hydrochloride	3044	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	13
Benzodiazepines interact at GABAA sites, and opioids interact primarily at mu receptors.
1	0	14	O	Benzodiazepines
2	16	23	O	interact
3	25	26	O	at
4	28	32	O	GABAA
5	34	38	O	sites
6	39	39	O	,
7	41	43	O	and
8	45	51	O	opioids
9	53	60	O	interact
10	62	70	O	primarily
11	72	73	O	at
12	75	76	O	mu
13	78	86	O	receptors
NULL

Flurazepam Hydrochloride	3045	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	19
When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists.
1	0	3	O	When
2	5	19	O	benzodiazepines
3	21	23	O	and
4	25	31	U-DYN	opioids
5	33	35	O	are
6	37	44	O	combined
7	45	45	O	,
8	47	49	O	the
9	51	59	O	potential
10	61	63	O	for
11	65	79	O	benzodiazepines
12	81	82	O	to
13	84	96	O	significantly
14	98	103	O	worsen
15	105	110	B-EFF	opioid
16	112	118	I-EFF	related
17	120	130	I-EFF	respiratory
18	132	141	L-EFF	depression
19	143	148	O	exists
D/4:15:1

Flurazepam Hydrochloride	3046	34073-7	2f2db2f5-49d3-4d47-a08a-628df49d2120	21
Limit dosage and duration of concomitant use of benzodiazepines and opioids, and follow patients closely for respiratory depression and sedation.
1	0	4	O	Limit
2	6	11	O	dosage
3	13	15	O	and
4	17	24	O	duration
5	26	27	O	of
6	29	39	O	concomitant
7	41	43	O	use
8	45	46	O	of
9	48	62	O	benzodiazepines
10	64	66	O	and
11	68	74	U-DYN	opioids
12	75	75	O	,
13	77	79	O	and
14	81	86	O	follow
15	88	95	O	patients
16	97	103	O	closely
17	105	107	O	for
18	109	119	B-EFF	respiratory
19	121	130	L-EFF	depression
20	132	134	O	and
21	136	143	U-EFF	sedation
D/11:18:1 D/11:21:1

Flurazepam Hydrochloride	3047	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	33
Flurazepam, like other central nervous system agents of the 1,4-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS).
1	0	9	O	XXXXXXXX
2	10	10	O	,
3	12	15	O	like
4	17	21	O	other
5	23	29	O	central
6	31	37	O	nervous
7	39	44	O	system
8	46	51	O	agents
9	53	54	O	of
10	56	58	O	the
11	60	62	O	1,4
12	64	77	O	benzodiazepine
13	79	83	O	class
14	84	84	O	,
15	86	95	O	presumably
16	97	102	O	exerts
17	104	106	O	its
18	108	114	O	effects
19	116	117	O	by
20	119	125	O	binding
21	127	128	O	to
22	130	135	O	stereo
23	137	144	O	specific
24	146	154	O	receptors
25	156	157	O	at
26	159	165	O	several
27	167	171	O	sites
28	173	178	O	within
29	180	182	O	the
30	184	190	O	central
31	192	198	O	nervous
32	200	205	O	system
33	208	210	O	CNS
NULL

Flurazepam Hydrochloride	3048	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	7
The exact mechanism of action is unknown.
1	0	2	O	The
2	4	8	O	exact
3	10	18	O	mechanism
4	20	21	O	of
5	23	28	O	action
6	30	31	O	is
7	33	39	O	unknown
NULL

Flurazepam Hydrochloride	3049	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	9
Flurazepam hydrochloride is rapidly absorbed from the gastro-intestinal tract.
1	0	23	O	XXXXXXXX
2	25	26	O	is
3	28	34	O	rapidly
4	36	43	O	absorbed
5	45	48	O	from
6	50	52	O	the
7	54	59	O	gastro
8	61	70	O	intestinal
9	72	76	O	tract
NULL

Flurazepam Hydrochloride	3050	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	11
Flurazepam is rapidly metabolized and is excreted primarily in the urine.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	20	O	rapidly
4	22	32	O	metabolized
5	34	36	O	and
6	38	39	O	is
7	41	48	O	excreted
8	50	58	O	primarily
9	60	61	O	in
10	63	65	O	the
11	67	71	O	urine
NULL

Flurazepam Hydrochloride	3051	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	26
Following a single oral dose, peak flurazepam plasma concentrations ranging from 0.5 to 4.0 ng/mL occur at 30 to 60 minutes post-dosing.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	22	O	oral
5	24	27	O	dose
6	28	28	O	,
7	30	33	O	peak
8	35	44	O	XXXXXXXX
9	46	51	O	plasma
10	53	66	O	concentrations
11	68	74	O	ranging
12	76	79	O	from
13	81	83	O	0.5
14	85	86	O	to
15	88	90	O	4.0
16	92	93	O	ng
17	94	94	O	/
18	95	96	O	mL
19	98	102	O	occur
20	104	105	O	at
21	107	108	O	30
22	110	111	O	to
23	113	114	O	60
24	116	122	O	minutes
25	124	127	O	post
26	129	134	O	dosing
NULL

Flurazepam Hydrochloride	3052	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	11
The harmonic mean apparent half-life of flurazepam is 2.3 hours.
1	0	2	O	The
2	4	11	O	harmonic
3	13	16	O	mean
4	18	25	O	apparent
5	27	30	O	half
6	32	35	O	life
7	37	38	O	of
8	40	49	O	XXXXXXXX
9	51	52	O	is
10	54	56	O	2.3
11	58	62	O	hours
NULL

Flurazepam Hydrochloride	3053	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	25
The blood level profile of flurazepam and its major metabolites was determined in man following the oral administration of 30 mg daily for 2 weeks.
1	0	2	O	The
2	4	8	O	blood
3	10	14	O	level
4	16	22	O	profile
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	40	O	and
8	42	44	O	its
9	46	50	O	major
10	52	62	O	metabolites
11	64	66	O	was
12	68	77	O	determined
13	79	80	O	in
14	82	84	O	man
15	86	94	O	following
16	96	98	O	the
17	100	103	O	oral
18	105	118	O	administration
19	120	121	O	of
20	123	124	O	30
21	126	127	O	mg
22	129	133	O	daily
23	135	137	O	for
24	139	139	O	2
25	141	145	O	weeks
NULL

Flurazepam Hydrochloride	3054	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	23
The N1-hydroxyethyl-flurazepam was measurable only during the early hours after a 30 mg dose and was not detectable after 24 hours.
1	0	2	O	The
2	4	5	O	N1
3	7	18	O	hydroxyethyl
4	20	29	O	XXXXXXXX
5	31	33	O	was
6	35	44	O	measurable
7	46	49	O	only
8	51	56	O	during
9	58	60	O	the
10	62	66	O	early
11	68	72	O	hours
12	74	78	O	after
13	80	80	O	a
14	82	83	O	30
15	85	86	O	mg
16	88	91	O	dose
17	93	95	O	and
18	97	99	O	was
19	101	103	O	not
20	105	114	O	detectable
21	116	120	O	after
22	122	123	O	24
23	125	129	O	hours
NULL

Flurazepam Hydrochloride	3055	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	41
The major metabolite in blood was N1-desalkyl-flurazepam, which reached steady-state (plateau) levels after 7 to 10 days of dosing, at levels approximately 5- to 6-fold greater than the 24-hour levels observed on Day 1.
1	0	2	O	The
2	4	8	O	major
3	10	19	O	metabolite
4	21	22	O	in
5	24	28	O	blood
6	30	32	O	was
7	34	35	O	N1
8	37	44	O	desalkyl
9	46	55	O	XXXXXXXX
10	56	56	O	,
11	58	62	O	which
12	64	70	O	reached
13	72	77	O	steady
14	79	83	O	state
15	86	92	O	plateau
16	95	100	O	levels
17	102	106	O	after
18	108	108	O	7
19	110	111	O	to
20	113	114	O	10
21	116	119	O	days
22	121	122	O	of
23	124	129	O	dosing
24	130	130	O	,
25	132	133	O	at
26	135	140	O	levels
27	142	154	O	approximately
28	156	156	O	5
29	159	160	O	to
30	162	162	O	6
31	164	167	O	fold
32	169	175	O	greater
33	177	180	O	than
34	182	184	O	the
35	186	187	O	24
36	189	192	O	hour
37	194	199	O	levels
38	201	208	O	observed
39	210	211	O	on
40	213	215	O	Day
41	217	217	O	1
NULL

Flurazepam Hydrochloride	3056	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	15
The half-life of elimination of N1-desalkyl-flurazepam ranged from 47 to 100 hours.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	15	O	of
5	17	27	O	elimination
6	29	30	O	of
7	32	33	O	N1
8	35	42	O	desalkyl
9	44	53	O	XXXXXXXX
10	55	60	O	ranged
11	62	65	O	from
12	67	68	O	47
13	70	71	O	to
14	73	75	O	100
15	77	81	O	hours
NULL

Flurazepam Hydrochloride	3057	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	18
The major urinary metabolite is conjugated N1-hydroxyethyl-flurazepam which accounts for 22% to 55% of the dose.
1	0	2	O	The
2	4	8	O	major
3	10	16	O	urinary
4	18	27	O	metabolite
5	29	30	O	is
6	32	41	O	conjugated
7	43	44	O	N1
8	46	57	O	hydroxyethyl
9	59	68	O	XXXXXXXX
10	70	74	O	which
11	76	83	O	accounts
12	85	87	O	for
13	89	91	O	22%
14	93	94	O	to
15	96	98	O	55%
16	100	101	O	of
17	103	105	O	the
18	107	110	O	dose
NULL

Flurazepam Hydrochloride	3058	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	15
Less than 1% of the dose is excreted in the urine as N1-desalkyl-flurazepam.
1	0	3	O	Less
2	5	8	O	than
3	10	11	O	1%
4	13	14	O	of
5	16	18	O	the
6	20	23	O	dose
7	25	26	O	is
8	28	35	O	excreted
9	37	38	O	in
10	40	42	O	the
11	44	48	O	urine
12	50	51	O	as
13	53	54	O	N1
14	56	63	O	desalkyl
15	65	74	O	XXXXXXXX
NULL

Flurazepam Hydrochloride	3059	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	47
This pharmacokinetic profile may be responsible for the clinical observation that flurazepam is increasingly effective on the second or third night of consecutive use and that for 1 or 2 nights after the drug is discontinued both sleep latency and total wake time may still be decreased.
1	0	3	O	This
2	5	19	O	pharmacokinetic
3	21	27	O	profile
4	29	31	O	may
5	33	34	O	be
6	36	46	O	responsible
7	48	50	O	for
8	52	54	O	the
9	56	63	O	clinical
10	65	75	O	observation
11	77	80	O	that
12	82	91	O	XXXXXXXX
13	93	94	O	is
14	96	107	O	increasingly
15	109	117	O	effective
16	119	120	O	on
17	122	124	O	the
18	126	131	O	second
19	133	134	O	or
20	136	140	O	third
21	142	146	O	night
22	148	149	O	of
23	151	161	O	consecutive
24	163	165	O	use
25	167	169	O	and
26	171	174	O	that
27	176	178	O	for
28	180	180	O	1
29	182	183	O	or
30	185	185	O	2
31	187	192	O	nights
32	194	198	O	after
33	200	202	O	the
34	204	207	O	drug
35	209	210	O	is
36	212	223	O	discontinued
37	225	228	O	both
38	230	234	O	sleep
39	236	242	O	latency
40	244	246	O	and
41	248	252	O	total
42	254	257	O	wake
43	259	262	O	time
44	264	266	O	may
45	268	272	O	still
46	274	275	O	be
47	277	285	O	decreased
NULL

Flurazepam Hydrochloride	3060	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	18
The single dose pharmacokinetics of flurazepam were studied in 12 healthy geriatric subjects (aged 61 to 85 years).
1	0	2	O	The
2	4	9	O	single
3	11	14	O	dose
4	16	31	O	pharmacokinetics
5	33	34	O	of
6	36	45	O	XXXXXXXX
7	47	50	O	were
8	52	58	O	studied
9	60	61	O	in
10	63	64	O	12
11	66	72	O	healthy
12	74	82	O	geriatric
13	84	91	O	subjects
14	94	97	O	aged
15	99	100	O	61
16	102	103	O	to
17	105	106	O	85
18	108	112	O	years
NULL

Flurazepam Hydrochloride	3061	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	43
The mean elimination half-life of desalkyl-flurazepam was longer in elderly male subjects (160 hours) compared with younger male subjects (74 hours), while mean elimination half-life was similar in geriatric female subjects (120 hours) and younger female subjects (90 hours).
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	of
7	34	41	O	desalkyl
8	43	52	O	XXXXXXXX
9	54	56	O	was
10	58	63	O	longer
11	65	66	O	in
12	68	74	O	elderly
13	76	79	O	male
14	81	88	O	subjects
15	91	93	O	160
16	95	99	O	hours
17	102	109	O	compared
18	111	114	O	with
19	116	122	O	younger
20	124	127	O	male
21	129	136	O	subjects
22	139	140	O	74
23	142	146	O	hours
24	148	148	O	,
25	150	154	O	while
26	156	159	O	mean
27	161	171	O	elimination
28	173	176	O	half
29	178	181	O	life
30	183	185	O	was
31	187	193	O	similar
32	195	196	O	in
33	198	206	O	geriatric
34	208	213	O	female
35	215	222	O	subjects
36	225	227	O	120
37	229	233	O	hours
38	236	238	O	and
39	240	246	O	younger
40	248	253	O	female
41	255	262	O	subjects
42	265	266	O	90
43	268	272	O	hours
NULL

Flurazepam Hydrochloride	3062	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	52
After multiple dosing, mean steady-state plasma levels of desalkyl-flurazepam were higher in elderly male subjects (81 ng/mL) compared with younger male subjects (53 ng/mL), while values were similar between elderly female subjects (85 ng/mL) and younger female subjects (86 ng/mL).
1	0	4	O	After
2	6	13	O	multiple
3	15	20	O	dosing
4	21	21	O	,
5	23	26	O	mean
6	28	33	O	steady
7	35	39	O	state
8	41	46	O	plasma
9	48	53	O	levels
10	55	56	O	of
11	58	65	O	desalkyl
12	67	76	O	XXXXXXXX
13	78	81	O	were
14	83	88	O	higher
15	90	91	O	in
16	93	99	O	elderly
17	101	104	O	male
18	106	113	O	subjects
19	116	117	O	81
20	119	120	O	ng
21	121	121	O	/
22	122	123	O	mL
23	126	133	O	compared
24	135	138	O	with
25	140	146	O	younger
26	148	151	O	male
27	153	160	O	subjects
28	163	164	O	53
29	166	167	O	ng
30	168	168	O	/
31	169	170	O	mL
32	172	172	O	,
33	174	178	O	while
34	180	185	O	values
35	187	190	O	were
36	192	198	O	similar
37	200	206	O	between
38	208	214	O	elderly
39	216	221	O	female
40	223	230	O	subjects
41	233	234	O	85
42	236	237	O	ng
43	238	238	O	/
44	239	240	O	mL
45	243	245	O	and
46	247	253	O	younger
47	255	260	O	female
48	262	269	O	subjects
49	272	273	O	86
50	275	276	O	ng
51	277	277	O	/
52	278	279	O	mL
NULL

Flurazepam Hydrochloride	3063	34090-1	2f2db2f5-49d3-4d47-a08a-628df49d2120	62
The mean washout half-life of desalkyl-flurazepam was longer in elderly male and female subjects (126 and 158 hours, respectively) compared with younger male and female subjects (111 and 113 hours, respectively).1 1 Greenblatt DJ, Divoll M, Hammatz JS, MacLauglin DS, Shader RI: Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs.
1	0	2	O	The
2	4	7	O	mean
3	9	15	O	washout
4	17	20	O	half
5	22	25	O	life
6	27	28	O	of
7	30	37	O	desalkyl
8	39	48	O	XXXXXXXX
9	50	52	O	was
10	54	59	O	longer
11	61	62	O	in
12	64	70	O	elderly
13	72	75	O	male
14	77	79	O	and
15	81	86	O	female
16	88	95	O	subjects
17	98	100	O	126
18	102	104	O	and
19	106	108	O	158
20	110	114	O	hours
21	115	115	O	,
22	117	128	O	respectively
23	131	138	O	compared
24	140	143	O	with
25	145	151	O	younger
26	153	156	O	male
27	158	160	O	and
28	162	167	O	female
29	169	176	O	subjects
30	179	181	O	111
31	183	185	O	and
32	187	189	O	113
33	191	195	O	hours
34	196	196	O	,
35	198	212	O	respectively).1
36	214	214	O	1
37	216	225	O	Greenblatt
38	227	228	O	DJ
39	229	229	O	,
40	231	236	O	Divoll
41	238	238	O	M
42	239	239	O	,
43	241	247	O	Hammatz
44	249	250	O	JS
45	251	251	O	,
46	253	262	O	MacLauglin
47	264	265	O	DS
48	266	266	O	,
49	268	273	O	Shader
50	275	276	O	RI
51	277	277	O	:
52	279	286	O	Kinetics
53	288	290	O	and
54	292	299	O	clinical
55	301	307	O	effects
56	309	310	O	of
57	312	321	O	XXXXXXXX
58	323	324	O	in
59	326	330	O	young
60	332	334	O	and
61	336	342	O	elderly
62	344	356	O	noninsomniacs
NULL

Fluvastatin	150	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	6
Cyclosporine: Combination increases fluvastatin exposure.
1	0	11	U-KIN	Cyclosporine
2	12	12	O	:
3	14	24	O	Combination
4	26	34	B-TRI	increases
5	36	46	I-TRI	XXXXXXXX
6	48	55	L-TRI	exposure
K/1:C54355

Fluvastatin	151	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	15
Limit fluvastatin dose to 20 mg (2.4, 7.1) Fluconazole: Combination increases fluvastatin exposure.
1	0	4	O	Limit
2	6	16	O	XXXXXXXX
3	18	21	O	dose
4	23	24	O	to
5	26	27	O	20
6	29	30	O	mg
7	33	35	O	2.4
8	36	36	O	,
9	38	40	O	7.1
10	43	53	U-KIN	Fluconazole
11	54	54	O	:
12	56	66	O	Combination
13	68	76	B-TRI	increases
14	78	88	I-TRI	XXXXXXXX
15	90	97	L-TRI	exposure
K/10:C54355

Fluvastatin	152	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	36
Limit fluvastatin dose to 20 mg (2.5, 7.2) Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (> 1 g/day) of niacin increases the risk of adverse skeletal muscle effects.
1	0	4	O	Limit
2	6	16	O	XXXXXXXX
3	18	21	O	dose
4	23	24	O	to
5	26	27	O	20
6	29	30	O	mg
7	33	35	O	2.5
8	36	36	O	,
9	38	40	O	7.2
10	43	53	O	Concomitant
11	55	59	O	lipid
12	61	68	O	lowering
13	70	78	O	therapies
14	79	79	O	:
15	81	83	O	Use
16	85	88	O	with
17	90	97	U-DYN	fibrates
18	99	100	O	or
19	102	106	O	lipid
20	108	116	O	modifying
21	118	122	O	doses
22	125	125	O	>
23	127	127	O	1
24	129	129	O	g
25	130	130	O	/
26	131	133	O	day
27	136	137	O	of
28	139	144	U-DYN	niacin
29	146	154	O	increases
30	156	158	O	the
31	160	163	O	risk
32	165	166	O	of
33	168	174	B-EFF	adverse
34	176	183	I-EFF	skeletal
35	185	190	I-EFF	muscle
36	192	198	L-EFF	effects
D/17:33:1 D/28:33:1

Fluvastatin	153	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	69
Caution should be used when prescribing with fluvastatin (5.1, 7.3, 7.4) Glyburide: Monitor blood glucose levels when fluvastatin dose is changed (7) Phenytoin: Monitor plasma phenytoin levels when fluvastatin treatment is initiated or when the dosage is changed (7) Warfarin and coumarin derivates: Monitor prothrombin times when fluvastatin coadministration is initiated, discontinued, or the dosage changed (7) Cyclosporine coadministration increases fluvastatin exposure.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	38	O	prescribing
7	40	43	O	with
8	45	55	O	XXXXXXXX
9	58	60	O	5.1
10	61	61	O	,
11	63	65	O	7.3
12	66	66	O	,
13	68	70	O	7.4
14	73	81	U-UNK	Glyburide
15	82	82	O	:
16	84	90	U-TRI	Monitor
17	92	96	O	blood
18	98	104	O	glucose
19	106	111	O	levels
20	113	116	O	when
21	118	128	O	XXXXXXXX
22	130	133	O	dose
23	135	136	O	is
24	138	144	O	changed
25	147	147	O	7
26	150	158	O	Phenytoin
27	159	159	O	:
28	161	167	O	Monitor
29	169	174	O	plasma
30	176	184	U-UNK	phenytoin
31	186	191	O	levels
32	193	196	O	when
33	198	208	O	XXXXXXXX
34	210	218	O	treatment
35	220	221	O	is
36	223	231	O	initiated
37	233	234	O	or
38	236	239	O	when
39	241	243	O	the
40	245	250	O	dosage
41	252	253	O	is
42	255	261	O	changed
43	264	264	O	7
44	267	274	U-UNK	Warfarin
45	276	278	O	and
46	280	287	B-UNK	coumarin
47	289	297	L-UNK	derivates
48	298	298	O	:
49	300	306	O	Monitor
50	308	318	O	prothrombin
51	320	324	O	times
52	326	329	O	when
53	331	341	O	XXXXXXXX
54	343	358	O	coadministration
55	360	361	O	is
56	363	371	O	initiated
57	372	372	O	,
58	374	385	O	discontinued
59	386	386	O	,
60	388	389	O	or
61	391	393	O	the
62	395	400	O	dosage
63	402	408	O	changed
64	411	411	O	7
65	414	425	U-KIN	Cyclosporine
66	427	442	O	coadministration
67	444	452	B-TRI	increases
68	454	464	I-TRI	XXXXXXXX
69	466	473	L-TRI	exposure
K/65:C54355

Fluvastatin	154	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	17
Therefore, in patients taking cyclosporine, therapy should be limited to fluvastatin 20 mg twice daily.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	41	U-UNK	cyclosporine
7	42	42	O	,
8	44	50	B-TRI	therapy
9	52	57	I-TRI	should
10	59	60	I-TRI	be
11	62	68	L-TRI	limited
12	70	71	O	to
13	73	83	O	XXXXXXXX
14	85	86	O	20
15	88	89	O	mg
16	91	95	O	twice
17	97	101	O	daily
NULL

Fluvastatin	155	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	24
Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with fluconazole for 4 days results in an increase of fluvastatin exposure.
1	0	13	O	Administration
2	15	16	O	of
3	18	28	O	XXXXXXXX
4	30	31	O	40
5	33	34	O	mg
6	36	41	O	single
7	43	46	O	dose
8	48	49	O	to
9	51	57	O	healthy
10	59	68	O	volunteers
11	70	72	O	pre
12	74	80	O	treated
13	82	85	O	with
14	87	97	U-KIN	fluconazole
15	99	101	O	for
16	103	103	O	4
17	105	108	O	days
18	110	116	O	results
19	118	119	O	in
20	121	122	O	an
21	124	131	O	increase
22	133	134	O	of
23	136	146	O	XXXXXXXX
24	148	155	O	exposure
K/14:C54355

Fluvastatin	156	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	17
Therefore, in patients taking fluconazole, therapy should be limited to fluvastatin 20 mg twice daily.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	40	U-UNK	fluconazole
7	41	41	O	,
8	43	49	B-TRI	therapy
9	51	56	I-TRI	should
10	58	59	I-TRI	be
11	61	67	L-TRI	limited
12	69	70	O	to
13	72	82	O	XXXXXXXX
14	84	85	O	20
15	87	88	O	mg
16	90	94	O	twice
17	96	100	O	daily
NULL

Fluvastatin	157	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	29
Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of fluvastatin sodium with gemfibrozil should be avoided.
1	0	2	O	Due
2	4	5	O	to
3	7	8	O	an
4	10	18	O	increased
5	20	23	O	risk
6	25	26	O	of
7	28	35	U-EFF	myopathy
8	36	36	O	/
9	37	50	U-EFF	rhabdomyolysis
10	52	55	O	when
11	57	59	O	HMG
12	61	63	O	CoA
13	65	73	O	reductase
14	75	84	O	inhibitors
15	86	88	O	are
16	90	103	O	coadministered
17	105	108	O	with
18	110	120	U-DYN	gemfibrozil
19	121	121	O	,
20	123	133	O	concomitant
21	135	148	O	administration
22	150	151	O	of
23	153	163	O	XXXXXXXX
24	165	170	O	sodium
25	172	175	O	with
26	177	187	O	gemfibrozil
27	189	194	O	should
28	196	197	O	be
29	199	205	O	avoided
D/18:7:1 D/18:9:1

Fluvastatin	158	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	38
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, fluvastatin sodium should be administered with caution when used concomitantly with other fibrates.
1	0	6	O	Because
2	8	9	O	it
3	11	12	O	is
4	14	18	O	known
5	20	23	O	that
6	25	27	O	the
7	29	32	O	risk
8	34	35	O	of
9	37	44	U-EFF	myopathy
10	46	51	O	during
11	53	61	O	treatment
12	63	66	O	with
13	68	70	O	HMG
14	72	74	O	CoA
15	76	84	O	reductase
16	86	95	O	inhibitors
17	97	98	O	is
18	100	108	O	increased
19	110	113	O	with
20	115	124	O	concurrent
21	126	139	O	administration
22	141	142	O	of
23	144	148	O	other
24	150	157	U-DYN	fibrates
25	158	158	O	,
26	160	170	O	XXXXXXXX
27	172	177	O	sodium
28	179	184	O	should
29	186	187	O	be
30	189	200	O	administered
31	202	205	O	with
32	207	213	O	caution
33	215	218	O	when
34	220	223	O	used
35	225	237	O	concomitantly
36	239	242	O	with
37	244	248	O	other
38	250	257	O	fibrates
D/24:9:1

Fluvastatin	159	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	39
The risk of skeletal muscle effects may be enhanced when fluvastatin sodium is used in combination with lipid-modifying doses (> 1 g/day) of niacin; a reduction in fluvastatin sodium dosage should be considered in this setting.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	skeletal
5	21	26	I-EFF	muscle
6	28	34	L-EFF	effects
7	36	38	O	may
8	40	41	O	be
9	43	50	O	enhanced
10	52	55	O	when
11	57	67	O	XXXXXXXX
12	69	74	O	sodium
13	76	77	O	is
14	79	82	O	used
15	84	85	O	in
16	87	97	O	combination
17	99	102	O	with
18	104	108	O	lipid
19	110	118	O	modifying
20	120	124	O	doses
21	127	127	O	>
22	129	129	O	1
23	131	131	O	g
24	132	132	O	/
25	133	135	O	day
26	138	139	O	of
27	141	146	U-DYN	niacin
28	149	149	O	a
29	151	159	O	reduction
30	161	162	O	in
31	164	174	O	XXXXXXXX
32	176	181	O	sodium
33	183	188	O	dosage
34	190	195	O	should
35	197	198	O	be
36	200	209	O	considered
37	211	212	O	in
38	214	217	O	this
39	219	225	O	setting
D/27:4:1

Fluvastatin	160	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	9
Concomitant administration of fluvastatin and glyburide increased glyburide exposures.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	40	O	XXXXXXXX
5	42	44	O	and
6	46	54	U-KIN	glyburide
7	56	64	O	increased
8	66	74	O	glyburide
9	76	84	O	exposures
K/6:C54357

Fluvastatin	161	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	14
Patients on concomitant therapy of glyburide and fluvastatin should continue to be monitored appropriately.
1	0	7	O	Patients
2	9	10	O	on
3	12	22	O	concomitant
4	24	30	O	therapy
5	32	33	O	of
6	35	43	U-UNK	glyburide
7	45	47	O	and
8	49	59	O	XXXXXXXX
9	61	66	O	should
10	68	75	O	continue
11	77	78	O	to
12	80	81	O	be
13	83	91	U-TRI	monitored
14	93	105	O	appropriately
NULL

Fluvastatin	162	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	9
Concomitant administration of fluvastatin and phenytoin increased phenytoin exposures.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	40	O	XXXXXXXX
5	42	44	O	and
6	46	54	U-KIN	phenytoin
7	56	64	O	increased
8	66	74	O	phenytoin
9	76	84	O	exposures
K/6:C54357

Fluvastatin	163	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	18
Patients should continue to be monitored appropriately when fluvastatin therapy is initiated or when fluvastatin dose is changed.
1	0	7	O	Patients
2	9	14	O	should
3	16	23	O	continue
4	25	26	O	to
5	28	29	O	be
6	31	39	O	monitored
7	41	53	O	appropriately
8	55	58	O	when
9	60	70	O	XXXXXXXX
10	72	78	O	therapy
11	80	81	O	is
12	83	91	O	initiated
13	93	94	O	or
14	96	99	O	when
15	101	111	O	XXXXXXXX
16	113	116	O	dose
17	118	119	O	is
18	121	127	O	changed
NULL

Fluvastatin	164	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	22
Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors.
1	0	7	U-EFF	Bleeding
2	9	11	O	and
3	12	12	O	/
4	13	14	O	or
5	16	24	B-EFF	increased
6	26	36	I-EFF	prothrombin
7	38	42	L-EFF	times
8	44	47	O	have
9	49	52	O	been
10	54	61	O	reported
11	63	64	O	in
12	66	73	O	patients
13	75	80	O	taking
14	82	89	U-DYN	coumarin
15	91	104	O	anticoagulants
16	106	118	O	concomitantly
17	120	123	O	with
18	125	129	O	other
19	131	133	O	HMG
20	135	137	O	CoA
21	139	147	O	reductase
22	149	158	O	inhibitors
D/14:1:1 D/14:5:1

Fluvastatin	165	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	27
Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	28	O	receiving
5	30	37	B-UNK	warfarin
6	39	42	I-UNK	type
7	44	57	L-UNK	anticoagulants
8	59	64	O	should
9	66	69	O	have
10	71	75	O	their
11	77	87	O	prothrombin
12	89	93	O	times
13	95	101	O	closely
14	103	111	U-TRI	monitored
15	113	116	O	when
16	118	128	O	XXXXXXXX
17	130	135	O	sodium
18	137	138	O	is
19	140	148	O	initiated
20	150	151	O	or
21	153	155	O	the
22	157	162	O	dosage
23	164	165	O	of
24	167	177	O	XXXXXXXX
25	179	184	O	sodium
26	186	187	O	is
27	189	195	O	changed
NULL

Fluvastatin	166	34073-7	aad8b373-0aec-4efb-8e61-3d8114b31127	26
Cases of myopathy, including rhabdomyolysis, have been reported with fluvastatin coadministered with colchicine, and caution should be exercised when prescribing fluvastatin with colchicine.
1	0	4	O	Cases
2	6	7	O	of
3	9	16	U-EFF	myopathy
4	17	17	O	,
5	19	27	O	including
6	29	42	U-EFF	rhabdomyolysis
7	43	43	O	,
8	45	48	O	have
9	50	53	O	been
10	55	62	O	reported
11	64	67	O	with
12	69	79	O	XXXXXXXX
13	81	94	O	coadministered
14	96	99	O	with
15	101	110	U-DYN	colchicine
16	111	111	O	,
17	113	115	O	and
18	117	123	O	caution
19	125	130	O	should
20	132	133	O	be
21	135	143	O	exercised
22	145	148	O	when
23	150	160	O	prescribing
24	162	172	O	XXXXXXXX
25	174	177	O	with
26	179	188	O	colchicine
D/15:3:1 D/15:6:1

Fluvastatin	167	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	35
Fluvastatin sodium is a competitive inhibitor of HMG-CoA reductase, the rate limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) to mevalonate, a precursor of sterols, including cholesterol.
1	0	10	O	XXXXXXXX
2	12	17	O	sodium
3	19	20	O	is
4	22	22	O	a
5	24	34	O	competitive
6	36	44	O	inhibitor
7	46	47	O	of
8	49	51	O	HMG
9	53	55	O	CoA
10	57	65	O	reductase
11	66	66	O	,
12	68	70	O	the
13	72	75	O	rate
14	77	84	O	limiting
15	86	91	O	enzyme
16	93	96	O	that
17	98	105	O	converts
18	107	107	O	3
19	109	115	O	hydroxy
20	117	117	O	3
21	119	132	O	methylglutaryl
22	134	141	O	coenzyme
23	143	143	O	A
24	146	148	O	HMG
25	150	152	O	CoA
26	155	156	O	to
27	158	167	O	mevalonate
28	168	168	O	,
29	170	170	O	a
30	172	180	O	precursor
31	182	183	O	of
32	185	191	O	sterols
33	192	192	O	,
34	194	202	O	including
35	204	214	O	cholesterol
NULL

Fluvastatin	168	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	27
The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles.
1	0	2	O	The
2	4	13	O	inhibition
3	15	16	O	of
4	18	28	O	cholesterol
5	30	41	O	biosynthesis
6	43	49	O	reduces
7	51	53	O	the
8	55	65	O	cholesterol
9	67	68	O	in
10	70	76	O	hepatic
11	78	82	O	cells
12	83	83	O	,
13	85	89	O	which
14	91	100	O	stimulates
15	102	104	O	the
16	106	114	O	synthesis
17	116	117	O	of
18	119	121	O	LDL
19	123	131	O	receptors
20	133	135	O	and
21	137	143	O	thereby
22	145	153	O	increases
23	155	157	O	the
24	159	164	O	uptake
25	166	167	O	of
26	169	171	O	LDL
27	173	181	O	particles
NULL

Fluvastatin	169	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	15
The end result of these biochemical processes is a reduction of the plasma cholesterol concentration.
1	0	2	O	The
2	4	6	O	end
3	8	13	O	result
4	15	16	O	of
5	18	22	O	these
6	24	34	O	biochemical
7	36	44	O	processes
8	46	47	O	is
9	49	49	O	a
10	51	59	O	reduction
11	61	62	O	of
12	64	66	O	the
13	68	73	O	plasma
14	75	85	O	cholesterol
15	87	99	O	concentration
NULL

Fluvastatin	170	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	18
Absorption: Following oral administration of the capsule, fluvastatin reaches peak concentrations in less than 1 hour.
1	0	9	O	Absorption
2	10	10	O	:
3	12	20	O	Following
4	22	25	O	oral
5	27	40	O	administration
6	42	43	O	of
7	45	47	O	the
8	49	55	O	capsule
9	56	56	O	,
10	58	68	O	XXXXXXXX
11	70	76	O	reaches
12	78	81	O	peak
13	83	96	O	concentrations
14	98	99	O	in
15	101	104	O	less
16	106	109	O	than
17	111	111	O	1
18	113	116	O	hour
NULL

Fluvastatin	171	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	16
The absolute bioavailability is 24% (range 9% to 50%) after administration of a 10 mg dose.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	is
5	32	34	O	24%
6	37	41	O	range
7	43	44	O	9%
8	46	47	O	to
9	49	51	O	50%
10	54	58	O	after
11	60	73	O	administration
12	75	76	O	of
13	78	78	O	a
14	80	81	O	10
15	83	84	O	mg
16	86	89	O	dose
NULL

Fluvastatin	172	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	44
At steady state, administration of fluvastatin with the evening meal results in a 50% decrease in Cmax, an 11% decrease in AUC, and a more than two-fold increase in tmax as compared to administration 4 hours after the evening meal.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	30	O	administration
6	32	33	O	of
7	35	45	O	XXXXXXXX
8	47	50	O	with
9	52	54	O	the
10	56	62	O	evening
11	64	67	O	meal
12	69	75	O	results
13	77	78	O	in
14	80	80	O	a
15	82	84	O	50%
16	86	93	O	decrease
17	95	96	O	in
18	98	101	O	Cmax
19	102	102	O	,
20	104	105	O	an
21	107	109	O	11%
22	111	118	O	decrease
23	120	121	O	in
24	123	125	O	AUC
25	126	126	O	,
26	128	130	O	and
27	132	132	O	a
28	134	137	O	more
29	139	142	O	than
30	144	146	O	two
31	148	151	O	fold
32	153	160	O	increase
33	162	163	O	in
34	165	168	O	tmax
35	170	171	O	as
36	173	180	O	compared
37	182	183	O	to
38	185	198	O	administration
39	200	200	O	4
40	202	206	O	hours
41	208	212	O	after
42	214	216	O	the
43	218	224	O	evening
44	226	229	O	meal
NULL

Fluvastatin	173	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	14
No significant differences in the lipid-lowering effects were observed between the two administrations.
1	0	1	O	No
2	3	13	O	significant
3	15	25	O	differences
4	27	28	O	in
5	30	32	O	the
6	34	38	O	lipid
7	40	47	O	lowering
8	49	55	O	effects
9	57	60	O	were
10	62	69	O	observed
11	71	77	O	between
12	79	81	O	the
13	83	85	O	two
14	87	101	O	administrations
NULL

Fluvastatin	174	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	24
After single or multiple doses above 20 mg, fluvastatin exhibits saturable first-pass metabolism resulting in more than dose proportional plasma fluvastatin concentrations.
1	0	4	O	After
2	6	11	O	single
3	13	14	O	or
4	16	23	O	multiple
5	25	29	O	doses
6	31	35	O	above
7	37	38	O	20
8	40	41	O	mg
9	42	42	O	,
10	44	54	O	XXXXXXXX
11	56	63	O	exhibits
12	65	73	O	saturable
13	75	79	O	first
14	81	84	O	pass
15	86	95	O	metabolism
16	97	105	O	resulting
17	107	108	O	in
18	110	113	O	more
19	115	118	O	than
20	120	123	O	dose
21	125	136	O	proportional
22	138	143	O	plasma
23	145	155	O	XXXXXXXX
24	157	170	O	concentrations
NULL

Fluvastatin	175	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	35
Fluvastatin administered as fluvastatin sodium extended-release 80 mg tablets reaches peak concentration in approximately 3 hours under fasting conditions, after a low fat meal, or 2.5 hours after a low fat meal.
1	0	10	O	XXXXXXXX
2	12	23	O	administered
3	25	26	O	as
4	28	38	O	XXXXXXXX
5	40	45	O	sodium
6	47	54	O	extended
7	56	62	O	release
8	64	65	O	80
9	67	68	O	mg
10	70	76	O	tablets
11	78	84	O	reaches
12	86	89	O	peak
13	91	103	O	concentration
14	105	106	O	in
15	108	120	O	approximately
16	122	122	O	3
17	124	128	O	hours
18	130	134	O	under
19	136	142	O	fasting
20	144	153	O	conditions
21	154	154	O	,
22	156	160	O	after
23	162	162	O	a
24	164	166	O	low
25	168	170	O	fat
26	172	175	O	meal
27	176	176	O	,
28	178	179	O	or
29	181	183	O	2.5
30	185	189	O	hours
31	191	195	O	after
32	197	197	O	a
33	199	201	O	low
34	203	205	O	fat
35	207	210	O	meal
NULL

Fluvastatin	176	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	30
The mean relative bioavailability of the extended-release tablet is approximately 29% (range: 9% to 66%) compared to that of the fluvastatin immediate-release capsule administered under fasting conditions.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	relative
4	18	32	O	bioavailability
5	34	35	O	of
6	37	39	O	the
7	41	48	O	extended
8	50	56	O	release
9	58	63	O	tablet
10	65	66	O	is
11	68	80	O	approximately
12	82	84	O	29%
13	87	91	O	range
14	92	92	O	:
15	94	95	O	9%
16	97	98	O	to
17	100	102	O	66%
18	105	112	O	compared
19	114	115	O	to
20	117	120	O	that
21	122	123	O	of
22	125	127	O	the
23	129	139	O	XXXXXXXX
24	141	149	O	immediate
25	151	157	O	release
26	159	165	O	capsule
27	167	178	O	administered
28	180	184	O	under
29	186	192	O	fasting
30	194	203	O	conditions
NULL

Fluvastatin	177	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	24
Administration of a high fat meal delayed the absorption (Tmax: 6h) and increased the bioavailability of the extended-release tablet by approximately 50%.
1	0	13	O	Administration
2	15	16	O	of
3	18	18	O	a
4	20	23	O	high
5	25	27	O	fat
6	29	32	O	meal
7	34	40	O	delayed
8	42	44	O	the
9	46	55	O	absorption
10	58	61	O	Tmax
11	62	62	O	:
12	64	65	O	6h
13	68	70	O	and
14	72	80	O	increased
15	82	84	O	the
16	86	100	O	bioavailability
17	102	103	O	of
18	105	107	O	the
19	109	116	O	extended
20	118	124	O	release
21	126	131	O	tablet
22	133	134	O	by
23	136	148	O	approximately
24	150	152	O	50%
NULL

Fluvastatin	178	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	37
However, the maximum concentration of fluvastatin sodium extended-release tablets seen after a high fat meal is less than the peak concentration following a single dose or twice daily dose of the 40 mg fluvastatin capsule.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	19	O	maximum
5	21	33	O	concentration
6	35	36	O	of
7	38	48	O	XXXXXXXX
8	50	55	O	sodium
9	57	64	O	extended
10	66	72	O	release
11	74	80	O	tablets
12	82	85	O	seen
13	87	91	O	after
14	93	93	O	a
15	95	98	O	high
16	100	102	O	fat
17	104	107	O	meal
18	109	110	O	is
19	112	115	O	less
20	117	120	O	than
21	122	124	O	the
22	126	129	O	peak
23	131	143	O	concentration
24	145	153	O	following
25	155	155	O	a
26	157	162	O	single
27	164	167	O	dose
28	169	170	O	or
29	172	176	O	twice
30	178	182	O	daily
31	184	187	O	dose
32	189	190	O	of
33	192	194	O	the
34	196	197	O	40
35	199	200	O	mg
36	202	212	O	XXXXXXXX
37	214	220	O	capsule
NULL

Fluvastatin	179	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	9
Distribution: Fluvastatin is 98% bound to plasma proteins.
1	0	11	O	Distribution
2	12	12	O	:
3	14	24	O	XXXXXXXX
4	26	27	O	is
5	29	31	O	98%
6	33	37	O	bound
7	39	40	O	to
8	42	47	O	plasma
9	49	56	O	proteins
NULL

Fluvastatin	180	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	13
The mean volume of distribution (VDss) is estimated at 0.35 L/kg.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	volume
4	16	17	O	of
5	19	30	O	distribution
6	33	36	O	VDss
7	39	40	O	is
8	42	50	O	estimated
9	52	53	O	at
10	55	58	O	0.35
11	60	60	O	L
12	61	61	O	/
13	62	63	O	kg
NULL

Fluvastatin	181	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	19
At therapeutic concentrations, the protein binding of fluvastatin is not affected by warfarin, salicylic acid and glyburide.
1	0	1	O	At
2	3	13	O	therapeutic
3	15	28	O	concentrations
4	29	29	O	,
5	31	33	O	the
6	35	41	O	protein
7	43	49	O	binding
8	51	52	O	of
9	54	64	O	XXXXXXXX
10	66	67	O	is
11	69	71	O	not
12	73	80	O	affected
13	82	83	O	by
14	85	92	O	warfarin
15	93	93	O	,
16	95	103	O	salicylic
17	105	108	O	acid
18	110	112	O	and
19	114	122	O	glyburide
NULL

Fluvastatin	182	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	22
Metabolism: Fluvastatin is metabolized in the liver, primarily via hydroxylation of the indole ring at the 5 and 6 positions.
1	0	9	O	Metabolism
2	10	10	O	:
3	12	22	O	XXXXXXXX
4	24	25	O	is
5	27	37	O	metabolized
6	39	40	O	in
7	42	44	O	the
8	46	50	O	liver
9	51	51	O	,
10	53	61	O	primarily
11	63	65	O	via
12	67	79	O	hydroxylation
13	81	82	O	of
14	84	86	O	the
15	88	93	O	indole
16	95	98	O	ring
17	100	101	O	at
18	103	105	O	the
19	107	107	O	5
20	109	111	O	and
21	113	113	O	6
22	115	123	O	positions
NULL

Fluvastatin	183	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	11
N-dealkylation and beta-oxidation of the side-chain also occurs.
1	0	0	O	N
2	2	13	O	dealkylation
3	15	17	O	and
4	19	22	O	beta
5	24	32	O	oxidation
6	34	35	O	of
7	37	39	O	the
8	41	44	O	side
9	46	50	O	chain
10	52	55	O	also
11	57	62	O	occurs
NULL

Fluvastatin	184	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	15
The hydroxy metabolites have some pharmacologic activity, but do not circulate in the blood.
1	0	2	O	The
2	4	10	O	hydroxy
3	12	22	O	metabolites
4	24	27	O	have
5	29	32	O	some
6	34	46	O	pharmacologic
7	48	55	O	activity
8	56	56	O	,
9	58	60	O	but
10	62	63	O	do
11	65	67	O	not
12	69	77	O	circulate
13	79	80	O	in
14	82	84	O	the
15	86	90	O	blood
NULL

Fluvastatin	185	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	10
Both enantiomers of fluvastatin are metabolized in a similar manner.
1	0	3	O	Both
2	5	15	O	enantiomers
3	17	18	O	of
4	20	30	O	XXXXXXXX
5	32	34	O	are
6	36	46	O	metabolized
7	48	49	O	in
8	51	51	O	a
9	53	59	O	similar
10	61	66	O	manner
NULL

Fluvastatin	186	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	13
In vitro data indicate that fluvastatin metabolism involves multiple Cytochrome P450 (CYP) isozymes.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	data
4	14	21	O	indicate
5	23	26	O	that
6	28	38	O	XXXXXXXX
7	40	49	O	metabolism
8	51	58	O	involves
9	60	67	O	multiple
10	69	78	O	Cytochrome
11	80	83	O	P450
12	86	88	O	CYP
13	91	98	O	isozymes
NULL

Fluvastatin	187	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	35
CYP2C9 isoenzyme is primarily involved in the metabolism of fluvastatin (approximately 75%), while CYP2C8 and CYP3A4 isoenzymes are involved to a much less extent, i.e., approximately 5% and approximately 20%, respectively.
1	0	5	O	CYP2C9
2	7	15	O	isoenzyme
3	17	18	O	is
4	20	28	O	primarily
5	30	37	O	involved
6	39	40	O	in
7	42	44	O	the
8	46	55	O	metabolism
9	57	58	O	of
10	60	70	O	XXXXXXXX
11	73	85	O	approximately
12	87	89	O	75%
13	91	91	O	,
14	93	97	O	while
15	99	104	O	CYP2C8
16	106	108	O	and
17	110	115	O	CYP3A4
18	117	126	O	isoenzymes
19	128	130	O	are
20	132	139	O	involved
21	141	142	O	to
22	144	144	O	a
23	146	149	O	much
24	151	154	O	less
25	156	161	O	extent
26	162	162	O	,
27	164	166	O	i.e
28	168	168	O	,
29	170	182	O	approximately
30	184	185	O	5%
31	187	189	O	and
32	191	203	O	approximately
33	205	207	O	20%
34	208	208	O	,
35	210	221	O	respectively
NULL

Fluvastatin	188	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	26
Excretion: Following oral administration, fluvastatin is primarily (about 90%) excreted in the feces as metabolites, with less than 2% present as unchanged drug.
1	0	8	O	Excretion
2	9	9	O	:
3	11	19	O	Following
4	21	24	O	oral
5	26	39	O	administration
6	40	40	O	,
7	42	52	O	XXXXXXXX
8	54	55	O	is
9	57	65	O	primarily
10	68	72	O	about
11	74	76	O	90%
12	79	86	O	excreted
13	88	89	O	in
14	91	93	O	the
15	95	99	O	feces
16	101	102	O	as
17	104	114	O	metabolites
18	115	115	O	,
19	117	120	O	with
20	122	125	O	less
21	127	130	O	than
22	132	133	O	2%
23	135	141	O	present
24	143	144	O	as
25	146	154	O	unchanged
26	156	159	O	drug
NULL

Fluvastatin	189	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	11
Approximately 5% of a radiolabeled oral dose were recovered in urine.
1	0	12	O	Approximately
2	14	15	O	5%
3	17	18	O	of
4	20	20	O	a
5	22	33	O	radiolabeled
6	35	38	O	oral
7	40	43	O	dose
8	45	48	O	were
9	50	58	O	recovered
10	60	61	O	in
11	63	67	O	urine
NULL

Fluvastatin	190	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	13
The elimination half-life (t1/2) of fluvastatin is approximately 3 hours.
1	0	2	O	The
2	4	14	O	elimination
3	16	19	O	half
4	21	24	O	life
5	27	28	O	t1
6	29	29	O	/
7	30	30	O	2
8	33	34	O	of
9	36	46	O	XXXXXXXX
10	48	49	O	is
11	51	63	O	approximately
12	65	65	O	3
13	67	71	O	hours
NULL

Fluvastatin	191	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	42
Specific Populations Renal Impairment: In patients with moderate to severe renal impairment (CLCr 10 to 40 mL/min), AUC and Cmax increased approximately 1.2 fold after administration of a single dose of 40 mg fluvastatin compared to healthy volunteers.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	25	O	Renal
4	27	36	O	Impairment
5	37	37	O	:
6	39	40	O	In
7	42	49	O	patients
8	51	54	O	with
9	56	63	O	moderate
10	65	66	O	to
11	68	73	O	severe
12	75	79	O	renal
13	81	90	O	impairment
14	93	96	O	CLCr
15	98	99	O	10
16	101	102	O	to
17	104	105	O	40
18	107	108	O	mL
19	109	109	O	/
20	110	112	O	min
21	114	114	O	,
22	116	118	O	AUC
23	120	122	O	and
24	124	127	O	Cmax
25	129	137	O	increased
26	139	151	O	approximately
27	153	155	O	1.2
28	157	160	O	fold
29	162	166	O	after
30	168	181	O	administration
31	183	184	O	of
32	186	186	O	a
33	188	193	O	single
34	195	198	O	dose
35	200	201	O	of
36	203	204	O	40
37	206	207	O	mg
38	209	219	O	XXXXXXXX
39	221	228	O	compared
40	230	231	O	to
41	233	239	O	healthy
42	241	250	O	volunteers
NULL

Fluvastatin	192	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	17
In patients with end-stage renal disease on hemodialysis, the AUC increased by approximately 1.5 fold.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	19	O	end
5	21	25	O	stage
6	27	31	O	renal
7	33	39	O	disease
8	41	42	O	on
9	44	55	O	hemodialysis
10	56	56	O	,
11	58	60	O	the
12	62	64	O	AUC
13	66	74	O	increased
14	76	77	O	by
15	79	91	O	approximately
16	93	95	O	1.5
17	97	100	O	fold
NULL

Fluvastatin	193	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	13
Fluvastatin sodium extended-release tablets were not evaluated in patients with renal impairment.
1	0	10	O	XXXXXXXX
2	12	17	O	sodium
3	19	26	O	extended
4	28	34	O	release
5	36	42	O	tablets
6	44	47	O	were
7	49	51	O	not
8	53	61	O	evaluated
9	63	64	O	in
10	66	73	O	patients
11	75	78	O	with
12	80	84	O	renal
13	86	95	O	impairment
NULL

Fluvastatin	194	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	22
However, systemic exposures after administration of fluvastatin sodium extended-release tablets are lower than after the 40 mg immediate-release capsule.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	systemic
4	18	26	O	exposures
5	28	32	O	after
6	34	47	O	administration
7	49	50	O	of
8	52	62	O	XXXXXXXX
9	64	69	O	sodium
10	71	78	O	extended
11	80	86	O	release
12	88	94	O	tablets
13	96	98	O	are
14	100	104	O	lower
15	106	109	O	than
16	111	115	O	after
17	117	119	O	the
18	121	122	O	40
19	124	125	O	mg
20	127	135	O	immediate
21	137	143	O	release
22	145	151	O	capsule
NULL

Fluvastatin	195	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	33
Hepatic Impairment: In patients with hepatic impairment due to liver cirrhosis, fluvastatin AUC and Cmax increased approximately 2.5 fold compared to healthy subjects after administration of a single 40 mg dose.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	18	18	O	:
4	20	21	O	In
5	23	30	O	patients
6	32	35	O	with
7	37	43	O	hepatic
8	45	54	O	impairment
9	56	58	O	due
10	60	61	O	to
11	63	67	O	liver
12	69	77	O	cirrhosis
13	78	78	O	,
14	80	90	O	XXXXXXXX
15	92	94	O	AUC
16	96	98	O	and
17	100	103	O	Cmax
18	105	113	O	increased
19	115	127	O	approximately
20	129	131	O	2.5
21	133	136	O	fold
22	138	145	O	compared
23	147	148	O	to
24	150	156	O	healthy
25	158	165	O	subjects
26	167	171	O	after
27	173	186	O	administration
28	188	189	O	of
29	191	191	O	a
30	193	198	O	single
31	200	201	O	40
32	203	204	O	mg
33	206	209	O	dose
NULL

Fluvastatin	196	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	21
The enantiomer ratios of the two isomers of fluvastatin in hepatic impairment patients were comparable to those observed in healthy subjects.
1	0	2	O	The
2	4	13	O	enantiomer
3	15	20	O	ratios
4	22	23	O	of
5	25	27	O	the
6	29	31	O	two
7	33	39	O	isomers
8	41	42	O	of
9	44	54	O	XXXXXXXX
10	56	57	O	in
11	59	65	O	hepatic
12	67	76	O	impairment
13	78	85	O	patients
14	87	90	O	were
15	92	101	O	comparable
16	103	104	O	to
17	106	110	O	those
18	112	119	O	observed
19	121	122	O	in
20	124	130	O	healthy
21	132	139	O	subjects
NULL

Fluvastatin	197	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	24
Geriatric: Plasma levels of fluvastatin are not significantly different in patients age > 65 years compared to patients age 21 to 49 years.
1	0	8	O	Geriatric
2	9	9	O	:
3	11	16	O	Plasma
4	18	23	O	levels
5	25	26	O	of
6	28	38	O	XXXXXXXX
7	40	42	O	are
8	44	46	O	not
9	48	60	O	significantly
10	62	70	O	different
11	72	73	O	in
12	75	82	O	patients
13	84	86	O	age
14	88	88	O	>
15	90	91	O	65
16	93	97	O	years
17	99	106	O	compared
18	108	109	O	to
19	111	118	O	patients
20	120	122	O	age
21	124	125	O	21
22	127	128	O	to
23	130	131	O	49
24	133	137	O	years
NULL

Fluvastatin	198	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	54
Gender: In a study evaluating the effect of age and gender on fluvastatin pharmacokinetics, there were no significant differences in fluvastatin exposures between males and females, except between younger females and younger males (both ages 21 to 49 years), where there was an approximate 30% increase in AUC in females.
1	0	5	O	Gender
2	6	6	O	:
3	8	9	O	In
4	11	11	O	a
5	13	17	O	study
6	19	28	O	evaluating
7	30	32	O	the
8	34	39	O	effect
9	41	42	O	of
10	44	46	O	age
11	48	50	O	and
12	52	57	O	gender
13	59	60	O	on
14	62	72	O	XXXXXXXX
15	74	89	O	pharmacokinetics
16	90	90	O	,
17	92	96	O	there
18	98	101	O	were
19	103	104	O	no
20	106	116	O	significant
21	118	128	O	differences
22	130	131	O	in
23	133	143	O	XXXXXXXX
24	145	153	O	exposures
25	155	161	O	between
26	163	167	O	males
27	169	171	O	and
28	173	179	O	females
29	180	180	O	,
30	182	187	O	except
31	189	195	O	between
32	197	203	O	younger
33	205	211	O	females
34	213	215	O	and
35	217	223	O	younger
36	225	229	O	males
37	232	235	O	both
38	237	240	O	ages
39	242	243	O	21
40	245	246	O	to
41	248	249	O	49
42	251	255	O	years
43	257	257	O	,
44	259	263	O	where
45	265	269	O	there
46	271	273	O	was
47	275	276	O	an
48	278	288	O	approximate
49	290	292	O	30%
50	294	301	O	increase
51	303	304	O	in
52	306	308	O	AUC
53	310	311	O	in
54	313	319	O	females
NULL

Fluvastatin	199	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	11
Adjusting for body weight decreases the magnitude of the differences seen.
1	0	8	O	Adjusting
2	10	12	O	for
3	14	17	O	body
4	19	24	O	weight
5	26	34	O	decreases
6	36	38	O	the
7	40	48	O	magnitude
8	50	51	O	of
9	53	55	O	the
10	57	67	O	differences
11	69	72	O	seen
NULL

Fluvastatin	200	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	11
Pediatric: Pharmacokinetic data in the pediatric population are not available.
1	0	8	O	Pediatric
2	9	9	O	:
3	11	25	O	Pharmacokinetic
4	27	30	O	data
5	32	33	O	in
6	35	37	O	the
7	39	47	O	pediatric
8	49	58	O	population
9	60	62	O	are
10	64	66	O	not
11	68	76	O	available
NULL

Fluvastatin	201	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	44
Drug-Drug Interactions: Data from drug-drug interactions studies involving coadministration of gemfibrozil, niacin, itraconazole, erythromycin, tolbutamide or clopidogrel indicate that the PK disposition of fluvastatin is not significantly altered when fluvastatin is coadministered with any of these drugs.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	22	22	O	:
5	24	27	O	Data
6	29	32	O	from
7	34	37	O	drug
8	39	42	O	drug
9	44	55	O	interactions
10	57	63	O	studies
11	65	73	O	involving
12	75	90	O	coadministration
13	92	93	O	of
14	95	105	O	gemfibrozil
15	106	106	O	,
16	108	113	O	niacin
17	114	114	O	,
18	116	127	O	itraconazole
19	128	128	O	,
20	130	141	O	erythromycin
21	142	142	O	,
22	144	154	O	tolbutamide
23	156	157	O	or
24	159	169	O	clopidogrel
25	171	178	O	indicate
26	180	183	O	that
27	185	187	O	the
28	189	190	O	PK
29	192	202	O	disposition
30	204	205	O	of
31	207	217	O	XXXXXXXX
32	219	220	O	is
33	222	224	O	not
34	226	238	O	significantly
35	240	246	O	altered
36	248	251	O	when
37	253	263	O	XXXXXXXX
38	265	266	O	is
39	268	281	O	coadministered
40	283	286	O	with
41	288	290	O	any
42	292	293	O	of
43	295	299	O	these
44	301	305	O	drugs
NULL

Fluvastatin	202	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	13
The below listed drug interaction information is derived from studies using fluvastatin capsules.
1	0	2	O	The
2	4	8	O	below
3	10	15	O	listed
4	17	20	O	drug
5	22	32	O	interaction
6	34	44	O	information
7	46	47	O	is
8	49	55	O	derived
9	57	60	O	from
10	62	68	O	studies
11	70	74	O	using
12	76	86	O	XXXXXXXX
13	88	95	O	capsules
NULL

Fluvastatin	203	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	66
Table 3: Effect of Coadministered Drugs on Fluvastatin Systemic Exposure Coadministered drug and dosing regimen Fluvastatin Dose (mg) Single dose unless otherwise noted Change in AUC Mean ratio (with/without coadministered drug and no change = 1 fold) or % change (with/without coadministered drug and no change = 0%); symbols of * and * indicate the exposure increase and decrease, respectively.
1	0	4	O	Table
2	6	6	O	3
3	7	7	O	:
4	9	14	O	Effect
5	16	17	O	of
6	19	32	O	Coadministered
7	34	38	O	Drugs
8	40	41	O	on
9	43	53	O	XXXXXXXX
10	55	62	O	Systemic
11	64	71	O	Exposure
12	73	86	O	Coadministered
13	88	91	O	drug
14	93	95	O	and
15	97	102	O	dosing
16	104	110	O	regimen
17	112	122	O	XXXXXXXX
18	124	127	O	Dose
19	130	131	O	mg
20	134	139	O	Single
21	141	144	O	dose
22	146	151	O	unless
23	153	161	O	otherwise
24	163	167	O	noted
25	169	174	O	Change
26	176	177	O	in
27	179	181	O	AUC
28	183	186	O	Mean
29	188	192	O	ratio
30	195	198	O	with
31	199	199	O	/
32	200	206	O	without
33	208	221	O	coadministered
34	223	226	O	drug
35	228	230	O	and
36	232	233	O	no
37	235	240	O	change
38	242	242	O	=
39	244	244	O	1
40	246	249	O	fold
41	252	253	O	or
42	255	255	O	%
43	257	262	O	change
44	265	268	O	with
45	269	269	O	/
46	270	276	O	without
47	278	291	O	coadministered
48	293	296	O	drug
49	298	300	O	and
50	302	303	O	no
51	305	310	O	change
52	312	312	O	=
53	314	315	O	0%
54	319	325	O	symbols
55	327	328	O	of
56	330	330	O	*
57	332	334	O	and
58	336	336	O	*
59	338	345	O	indicate
60	347	349	O	the
61	351	358	O	exposure
62	360	367	O	increase
63	369	371	O	and
64	373	380	O	decrease
65	381	381	O	,
66	383	394	O	respectively
NULL

Fluvastatin	204	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	7
Change in Cmax Cyclosporine - stable dose (b.i.d.
1	0	5	O	Change
2	7	8	O	in
3	10	13	O	Cmax
4	15	26	O	Cyclosporine
5	30	35	O	stable
6	37	40	O	dose
7	43	47	O	b.i.d
NULL

Fluvastatin	205	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	252
)Considered clinically significant 20 mg QD for 14 weeks *90% *30% Fluconazole 400 mg QD day 1,200 mg b.i.d. day 2 to 4 40 mg QD *84% *44% Cholestyramine 8 g QD 20 mg QD administered 4 hrs after a meal plus cholestyramine *51% *83% Rifampicin 600 mg QD for 6 days 20 mg QD *53% *42% Cimetidine 400 mg b.i.d. for 5 days, QD on Day 6 20 mg QD *30% *40% Ranitidine 150 mg b.i.d. for 5 days, QD on Day 6 20 mg QD *10% *50% Omeprazole 40 mg QD for 6 days 20 mg QD *20% *37% Phenytoin 300 mg QD 40 mg b.i.d. for 5 days *40% *27% Propranolol 40 mg b.i.d. for 3.5 days 40 mg QD *5% No change Digoxin 0.1 to 0.5 mg QD for 3 weeks 40 mg QD No change *11% Diclofenac 25 mg QD 40 mg QD for 8 days *50% *80% Glyburide 5 to 20 mg QD for 22 days 40 mg b.i.d. for 14 days *51% *44% Warfarin 30 mg QD 40 mg QD for 8 days *30% *67% Clopidogrel 300 mg loading dose on day 10, 75 mg QD on days 11 to 19 fluvastatin sodium extended-release tablets, 80 mg QD for 19 days *2% *27% Data from drug-drug interaction studies involving fluvastatin and coadministration of either gemfibrozil, tolbutamide or losartan indicate that the PK disposition of either gemfibrozil, tolbutamide or losartan is not significantly altered when coadministered with fluvastatin.
1	1	10	O	Considered
2	12	21	O	clinically
3	23	33	O	significant
4	35	36	O	20
5	38	39	O	mg
6	41	42	O	QD
7	44	46	O	for
8	48	49	O	14
9	51	55	O	weeks
10	57	60	O	90%
11	62	65	O	30%
12	67	77	O	Fluconazole
13	79	81	O	400
14	83	84	O	mg
15	86	87	O	QD
16	89	91	O	day
17	93	97	O	1,200
18	99	100	O	mg
19	102	106	O	b.i.d
20	109	111	O	day
21	113	113	O	2
22	115	116	O	to
23	118	118	O	4
24	120	121	O	40
25	123	124	O	mg
26	126	127	O	QD
27	129	132	O	84%
28	134	137	O	44%
29	139	152	O	Cholestyramine
30	154	154	O	8
31	156	156	O	g
32	158	159	O	QD
33	161	162	O	20
34	164	165	O	mg
35	167	168	O	QD
36	170	181	O	administered
37	183	183	O	4
38	185	187	O	hrs
39	189	193	O	after
40	195	195	O	a
41	197	200	O	meal
42	202	205	O	plus
43	207	220	O	cholestyramine
44	222	225	O	51%
45	227	230	O	83%
46	232	241	O	Rifampicin
47	243	245	O	600
48	247	248	O	mg
49	250	251	O	QD
50	253	255	O	for
51	257	257	O	6
52	259	262	O	days
53	264	265	O	20
54	267	268	O	mg
55	270	271	O	QD
56	273	276	O	53%
57	278	281	O	42%
58	283	292	O	Cimetidine
59	294	296	O	400
60	298	299	O	mg
61	301	305	O	b.i.d
62	308	310	O	for
63	312	312	O	5
64	314	317	O	days
65	318	318	O	,
66	320	321	O	QD
67	323	324	O	on
68	326	328	O	Day
69	330	330	O	6
70	332	333	O	20
71	335	336	O	mg
72	338	339	O	QD
73	341	344	O	30%
74	346	349	O	40%
75	351	360	O	Ranitidine
76	362	364	O	150
77	366	367	O	mg
78	369	373	O	b.i.d
79	376	378	O	for
80	380	380	O	5
81	382	385	O	days
82	386	386	O	,
83	388	389	O	QD
84	391	392	O	on
85	394	396	O	Day
86	398	398	O	6
87	400	401	O	20
88	403	404	O	mg
89	406	407	O	QD
90	409	412	O	10%
91	414	417	O	50%
92	419	428	O	Omeprazole
93	430	431	O	40
94	433	434	O	mg
95	436	437	O	QD
96	439	441	O	for
97	443	443	O	6
98	445	448	O	days
99	450	451	O	20
100	453	454	O	mg
101	456	457	O	QD
102	459	462	O	20%
103	464	467	O	37%
104	469	477	O	Phenytoin
105	479	481	O	300
106	483	484	O	mg
107	486	487	O	QD
108	489	490	O	40
109	492	493	O	mg
110	495	499	O	b.i.d
111	502	504	O	for
112	506	506	O	5
113	508	511	O	days
114	513	516	O	40%
115	518	521	O	27%
116	523	533	O	Propranolol
117	535	536	O	40
118	538	539	O	mg
119	541	545	O	b.i.d
120	548	550	O	for
121	552	554	O	3.5
122	556	559	O	days
123	561	562	O	40
124	564	565	O	mg
125	567	568	O	QD
126	570	572	O	5%
127	574	575	O	No
128	577	582	O	change
129	584	590	O	Digoxin
130	592	594	O	0.1
131	596	597	O	to
132	599	601	O	0.5
133	603	604	O	mg
134	606	607	O	QD
135	609	611	O	for
136	613	613	O	3
137	615	619	O	weeks
138	621	622	O	40
139	624	625	O	mg
140	627	628	O	QD
141	630	631	O	No
142	633	638	O	change
143	640	643	O	11%
144	645	654	O	Diclofenac
145	656	657	O	25
146	659	660	O	mg
147	662	663	O	QD
148	665	666	O	40
149	668	669	O	mg
150	671	672	O	QD
151	674	676	O	for
152	678	678	O	8
153	680	683	O	days
154	685	688	O	50%
155	690	693	O	80%
156	695	703	O	Glyburide
157	705	705	O	5
158	707	708	O	to
159	710	711	O	20
160	713	714	O	mg
161	716	717	O	QD
162	719	721	O	for
163	723	724	O	22
164	726	729	O	days
165	731	732	O	40
166	734	735	O	mg
167	737	741	O	b.i.d
168	744	746	O	for
169	748	749	O	14
170	751	754	O	days
171	756	759	O	51%
172	761	764	O	44%
173	766	773	O	Warfarin
174	775	776	O	30
175	778	779	O	mg
176	781	782	O	QD
177	784	785	O	40
178	787	788	O	mg
179	790	791	O	QD
180	793	795	O	for
181	797	797	O	8
182	799	802	O	days
183	804	807	O	30%
184	809	812	O	67%
185	814	824	O	Clopidogrel
186	826	828	O	300
187	830	831	O	mg
188	833	839	O	loading
189	841	844	O	dose
190	846	847	O	on
191	849	851	O	day
192	853	854	O	10
193	855	855	O	,
194	857	858	O	75
195	860	861	O	mg
196	863	864	O	QD
197	866	867	O	on
198	869	872	O	days
199	874	875	O	11
200	877	878	O	to
201	880	881	O	19
202	883	893	O	XXXXXXXX
203	895	900	O	sodium
204	902	909	O	extended
205	911	917	O	release
206	919	925	O	tablets
207	926	926	O	,
208	928	929	O	80
209	931	932	O	mg
210	934	935	O	QD
211	937	939	O	for
212	941	942	O	19
213	944	947	O	days
214	949	951	O	2%
215	953	956	O	27%
216	958	961	O	Data
217	963	966	O	from
218	968	971	O	drug
219	973	976	O	drug
220	978	988	O	interaction
221	990	996	O	studies
222	998	1006	O	involving
223	1008	1018	O	XXXXXXXX
224	1020	1022	O	and
225	1024	1039	O	coadministration
226	1041	1042	O	of
227	1044	1049	O	either
228	1051	1061	O	gemfibrozil
229	1062	1062	O	,
230	1064	1074	O	tolbutamide
231	1076	1077	O	or
232	1079	1086	O	losartan
233	1088	1095	O	indicate
234	1097	1100	O	that
235	1102	1104	O	the
236	1106	1107	O	PK
237	1109	1119	O	disposition
238	1121	1122	O	of
239	1124	1129	O	either
240	1131	1141	O	gemfibrozil
241	1142	1142	O	,
242	1144	1154	O	tolbutamide
243	1156	1157	O	or
244	1159	1166	O	losartan
245	1168	1169	O	is
246	1171	1173	O	not
247	1175	1187	O	significantly
248	1189	1195	O	altered
249	1197	1200	O	when
250	1202	1215	O	coadministered
251	1217	1220	O	with
252	1222	1232	O	XXXXXXXX
NULL

Fluvastatin	206	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	69
Table 4: Effect of Fluvastatin Coadministration on Systemic Exposure of Other Drugs Fluvastatin dosage regimen Coadministered drug Name and Dose (mg) Single dose unless otherwise noted Change in AUC Mean ratio (with/without coadministered drug and no change = 1 fold) or % change (with/without coadministered drug and no change = 0%); symbols of * and * indicate the exposure increase and decrease, respectively.
1	0	4	O	Table
2	6	6	O	4
3	7	7	O	:
4	9	14	O	Effect
5	16	17	O	of
6	19	29	O	XXXXXXXX
7	31	46	O	Coadministration
8	48	49	O	on
9	51	58	O	Systemic
10	60	67	O	Exposure
11	69	70	O	of
12	72	76	O	Other
13	78	82	O	Drugs
14	84	94	O	XXXXXXXX
15	96	101	O	dosage
16	103	109	O	regimen
17	111	124	O	Coadministered
18	126	129	O	drug
19	131	134	O	Name
20	136	138	O	and
21	140	143	O	Dose
22	146	147	O	mg
23	150	155	O	Single
24	157	160	O	dose
25	162	167	O	unless
26	169	177	O	otherwise
27	179	183	O	noted
28	185	190	O	Change
29	192	193	O	in
30	195	197	O	AUC
31	199	202	O	Mean
32	204	208	O	ratio
33	211	214	O	with
34	215	215	O	/
35	216	222	O	without
36	224	237	O	coadministered
37	239	242	O	drug
38	244	246	O	and
39	248	249	O	no
40	251	256	O	change
41	258	258	O	=
42	260	260	O	1
43	262	265	O	fold
44	268	269	O	or
45	271	271	O	%
46	273	278	O	change
47	281	284	O	with
48	285	285	O	/
49	286	292	O	without
50	294	307	O	coadministered
51	309	312	O	drug
52	314	316	O	and
53	318	319	O	no
54	321	326	O	change
55	328	328	O	=
56	330	331	O	0%
57	335	341	O	symbols
58	343	344	O	of
59	346	346	O	*
60	348	350	O	and
61	352	352	O	*
62	354	361	O	indicate
63	363	365	O	the
64	367	374	O	exposure
65	376	383	O	increase
66	385	387	O	and
67	389	396	O	decrease
68	397	397	O	,
69	399	410	O	respectively
NULL

Fluvastatin	207	34090-1	aad8b373-0aec-4efb-8e61-3d8114b31127	73
Change in Cmax 40 mg QD for 5 days Phenytoin 300 mg QDConsidered clinically significant *20% *5% 40 mg b.i.d. for 21 days Glyburide 5 to 20 mg QD for 22 days *70% *50% 40 mg QD for 8 days Diclofenac 25 mg QD *25% *60% 40 mg QD for 8 days Warfarin 30 mg QD S-warfarin: *7% S-warfarin: *10% R-warfarin: no change R-warfarin: *6%
1	0	5	B-TRI	Change
2	7	8	I-TRI	in
3	10	13	L-TRI	Cmax
4	15	16	O	40
5	18	19	O	mg
6	21	22	O	QD
7	24	26	O	for
8	28	28	O	5
9	30	33	O	days
10	35	43	U-UNK	Phenytoin
11	45	47	O	300
12	49	50	O	mg
13	52	63	O	QDConsidered
14	65	74	O	clinically
15	76	86	O	significant
16	88	91	O	20%
17	93	95	O	5%
18	97	98	O	40
19	100	101	O	mg
20	103	107	O	b.i.d
21	110	112	O	for
22	114	115	O	21
23	117	120	O	days
24	122	130	U-UNK	Glyburide
25	132	132	O	5
26	134	135	O	to
27	137	138	O	20
28	140	141	O	mg
29	143	144	O	QD
30	146	148	O	for
31	150	151	O	22
32	153	156	O	days
33	158	161	O	70%
34	163	166	O	50%
35	168	169	O	40
36	171	172	O	mg
37	174	175	O	QD
38	177	179	O	for
39	181	181	O	8
40	183	186	O	days
41	188	197	U-UNK	Diclofenac
42	199	200	O	25
43	202	203	O	mg
44	205	206	O	QD
45	208	211	O	25%
46	213	216	O	60%
47	218	219	O	40
48	221	222	O	mg
49	224	225	O	QD
50	227	229	O	for
51	231	231	O	8
52	233	236	O	days
53	238	245	U-UNK	Warfarin
54	247	248	O	30
55	250	251	O	mg
56	253	254	O	QD
57	256	256	O	S
58	258	265	O	warfarin
59	266	266	O	:
60	268	270	O	7%
61	272	272	O	S
62	274	281	O	warfarin
63	282	282	O	:
64	284	287	O	10%
65	289	289	O	R
66	291	298	O	warfarin
67	299	299	O	:
68	301	302	O	no
69	304	309	O	change
70	311	311	O	R
71	313	320	O	warfarin
72	321	321	O	:
73	323	325	O	6%
NULL

Fluvoxamine Maleate	1394	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	36
Drug Interactions (not described in Contraindications or Warnings and Precautions) include the following: Drugs Inhibiting or Metabolized by Cytochrome P450: Fluvoxamine inhibits several cytochrome P450 isoenzymes (CYP1A2, CYP2C9, CYP3A4, and CYP2C19).
1	0	3	B-TRI	Drug
2	5	16	L-TRI	Interactions
3	19	21	O	not
4	23	31	O	described
5	33	34	O	in
6	36	52	O	Contraindications
7	54	55	O	or
8	57	64	O	Warnings
9	66	68	O	and
10	70	80	O	Precautions
11	83	89	O	include
12	91	93	O	the
13	95	103	O	following
14	104	104	O	:
15	106	110	B-UNK	Drugs
16	112	121	I-UNK	Inhibiting
17	123	124	I-UNK	or
18	126	136	I-UNK	Metabolized
19	138	139	I-UNK	by
20	141	150	I-UNK	Cytochrome
21	152	155	L-UNK	P450
22	156	156	O	:
23	158	168	U-UNK	XXXXXXXX
24	170	177	O	inhibits
25	179	185	O	several
26	187	196	O	cytochrome
27	198	201	O	P450
28	203	212	O	isoenzymes
29	215	220	O	CYP1A2
30	221	221	O	,
31	223	228	O	CYP2C9
32	229	229	O	,
33	231	236	O	CYP3A4
34	237	237	O	,
35	239	241	O	and
36	243	249	O	CYP2C19
NULL

Fluvoxamine Maleate	1395	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	12
Carbamazepine: Elevated carbamazepine levels and symptoms of toxicity with coadministration (7.2).
1	0	12	O	Carbamazepine
2	13	13	O	:
3	15	22	O	Elevated
4	24	36	U-DYN	carbamazepine
5	38	43	O	levels
6	45	47	O	and
7	49	56	B-EFF	symptoms
8	58	59	I-EFF	of
9	61	68	L-EFF	toxicity
10	70	73	O	with
11	75	90	O	coadministration
12	93	95	O	7.2
D/4:7:1

Fluvoxamine Maleate	1396	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	19
Sumatriptan: Rare postmarketing reports of weakness, hyperreflexia, and incoordination following use of an SSRI and sumatriptan.
1	0	10	O	Sumatriptan
2	11	11	O	:
3	13	16	O	Rare
4	18	30	O	postmarketing
5	32	38	O	reports
6	40	41	O	of
7	43	50	U-EFF	weakness
8	51	51	O	,
9	53	65	U-EFF	hyperreflexia
10	66	66	O	,
11	68	70	O	and
12	72	85	U-EFF	incoordination
13	87	95	O	following
14	97	99	O	use
15	101	102	O	of
16	104	105	O	an
17	107	110	O	SSRI
18	112	114	O	and
19	116	126	U-DYN	sumatriptan
D/19:12:1 D/19:7:1 D/19:9:1

Fluvoxamine Maleate	1397	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	9
Monitor appropriately if concomitant treatment is clinically warranted (7.2).
1	0	6	O	Monitor
2	8	20	O	appropriately
3	22	23	O	if
4	25	35	O	concomitant
5	37	45	O	treatment
6	47	48	O	is
7	50	59	O	clinically
8	61	69	O	warranted
9	72	74	O	7.2
NULL

Fluvoxamine Maleate	1398	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	23
Tacrine: Coadministration increased tacrine Cmax and AUC five- and eight-fold and caused nausea, vomiting, sweating, and diarrhea (7.2).
1	0	6	O	Tacrine
2	7	7	O	:
3	9	24	O	Coadministration
4	26	34	O	increased
5	36	42	U-DYN	tacrine
6	44	47	O	Cmax
7	49	51	O	and
8	53	55	O	AUC
9	57	60	O	five
10	63	65	O	and
11	67	71	O	eight
12	73	76	O	fold
13	78	80	O	and
14	82	87	O	caused
15	89	94	U-EFF	nausea
16	95	95	O	,
17	97	104	U-EFF	vomiting
18	105	105	O	,
19	107	114	U-EFF	sweating
20	115	115	O	,
21	117	119	O	and
22	121	128	U-EFF	diarrhea
23	131	133	O	7.2
D/5:15:1 D/5:17:1 D/5:19:1 D/5:22:1

Fluvoxamine Maleate	1399	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	10
Tricyclic Antidepressants (TCAs): Coadministration significantly increased plasma TCA levels.
1	0	8	B-KIN	Tricyclic
2	10	24	L-KIN	Antidepressants
3	27	30	U-KIN	TCAs
4	32	32	O	:
5	34	49	O	Coadministration
6	51	63	O	significantly
7	65	73	O	increased
8	75	80	O	plasma
9	82	84	O	TCA
10	86	91	O	levels
K/1:C54357 K/3:C54357

Fluvoxamine Maleate	1400	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	12
Use caution; monitor plasma TCA levels; reduce TCA dose if indicated (7.2).
1	0	2	O	Use
2	4	10	O	caution
3	13	19	O	monitor
4	21	26	O	plasma
5	28	30	U-KIN	TCA
6	32	37	O	levels
7	40	45	O	reduce
8	47	49	O	TCA
9	51	54	O	dose
10	56	57	O	if
11	59	67	O	indicated
12	70	72	O	7.2
K/5:C54357

Fluvoxamine Maleate	1401	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	7
Tryptophan: Severe vomiting with coadministration (7.2).
1	0	9	U-DYN	Tryptophan
2	10	10	O	:
3	12	17	B-EFF	Severe
4	19	26	L-EFF	vomiting
5	28	31	O	with
6	33	48	O	coadministration
7	51	53	O	7.2
D/1:3:1

Fluvoxamine Maleate	1402	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	6
Diltiazem: Bradycardia with coadministration (7.3).
1	0	8	U-DYN	Diltiazem
2	9	9	O	:
3	11	21	U-EFF	Bradycardia
4	23	26	O	with
5	28	43	O	coadministration
6	46	48	O	7.3
D/1:3:1

Fluvoxamine Maleate	1403	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	13
Propranolol or metoprolol: Reduce dose if coadministered and titrate more cautiously (7.3).
1	0	10	U-KIN	Propranolol
2	12	13	O	or
3	15	24	U-KIN	metoprolol
4	25	25	O	:
5	27	32	B-TRI	Reduce
6	34	37	L-TRI	dose
7	39	40	O	if
8	42	55	O	coadministered
9	57	59	O	and
10	61	67	O	titrate
11	69	72	O	more
12	74	83	O	cautiously
13	86	88	O	7.3
K/1:C54357 K/3:C54357

Fluvoxamine Maleate	1404	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	22
Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds.
1	0	7	O	Multiple
2	9	15	O	hepatic
3	17	26	O	cytochrome
4	28	31	O	P450
5	33	42	O	isoenzymes
6	44	46	O	are
7	48	55	O	involved
8	57	58	O	in
9	60	62	O	the
10	64	72	O	oxidative
11	74	90	O	biotransformation
12	92	93	O	of
13	95	95	O	a
14	97	101	O	large
15	103	108	O	number
16	110	111	O	of
17	113	124	O	structurally
18	126	134	O	different
19	136	140	O	drugs
20	142	144	O	and
21	146	155	O	endogenous
22	157	165	O	compounds
NULL

Fluvoxamine Maleate	1405	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	36
The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available.
1	0	2	O	The
2	4	12	O	available
3	14	22	O	knowledge
4	24	33	O	concerning
5	35	37	O	the
6	39	50	O	relationship
7	52	53	O	of
8	55	65	O	XXXXXXXX
9	67	69	O	and
10	71	73	O	the
11	75	84	O	cytochrome
12	86	89	O	P450
13	91	99	O	isoenzyme
14	101	106	O	system
15	108	110	O	has
16	112	115	O	been
17	117	124	O	obtained
18	126	131	O	mostly
19	133	136	O	from
20	138	152	O	pharmacokinetic
21	154	164	O	interaction
22	166	172	O	studies
23	174	182	O	conducted
24	184	185	O	in
25	187	193	O	healthy
26	195	204	O	volunteers
27	205	205	O	,
28	207	209	O	but
29	211	214	O	some
30	216	226	O	preliminary
31	228	229	O	in
32	231	235	O	vitro
33	237	240	O	data
34	242	244	O	are
35	246	249	O	also
36	251	259	O	available
NULL

Fluvoxamine Maleate	1406	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	14
Based on a finding of substantial interactions of fluvoxamine with certain of these drugs.
1	0	4	O	Based
2	6	7	O	on
3	9	9	O	a
4	11	17	O	finding
5	19	20	O	of
6	22	32	O	substantial
7	34	45	O	interactions
8	47	48	O	of
9	50	60	O	XXXXXXXX
10	62	65	O	with
11	67	73	O	certain
12	75	76	O	of
13	78	82	O	these
14	84	88	O	drugs
NULL

Fluvoxamine Maleate	1407	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	13
In vitro data suggest that fluvoxamine is a relatively weak inhibitor of CYP2D6.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	data
4	14	20	O	suggest
5	22	25	O	that
6	27	37	O	XXXXXXXX
7	39	40	O	is
8	42	42	O	a
9	44	53	O	relatively
10	55	58	O	weak
11	60	68	O	inhibitor
12	70	71	O	of
13	73	78	O	CYP2D6
NULL

Fluvoxamine Maleate	1408	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	19
Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6.
1	0	12	O	Approximately
2	14	15	O	7%
3	17	18	O	of
4	20	22	O	the
5	24	29	O	normal
6	31	40	O	population
7	42	44	O	has
8	46	46	O	a
9	48	54	O	genetic
10	56	59	O	code
11	61	64	O	that
12	66	70	O	leads
13	72	73	O	to
14	75	81	O	reduced
15	83	88	O	levels
16	90	91	O	of
17	93	100	O	activity
18	102	103	O	of
19	105	110	O	CYP2D6
NULL

Fluvoxamine Maleate	1409	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	21
Such individuals have been referred to as "poor metabolizers" (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants.
1	0	3	O	Such
2	5	15	O	individuals
3	17	20	O	have
4	22	25	O	been
5	27	34	O	referred
6	36	37	O	to
7	39	40	O	as
8	42	46	O	"poor
9	48	60	O	metabolizers"
10	63	64	O	PM
11	67	68	O	of
12	70	74	O	drugs
13	76	79	O	such
14	81	82	O	as
15	84	94	O	debrisoquin
16	95	95	O	,
17	97	112	O	dextromethorphan
18	113	113	O	,
19	115	117	O	and
20	119	127	O	tricyclic
21	129	143	O	antidepressants
NULL

Fluvoxamine Maleate	1410	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	68
While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 "extensive metabolizers" (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group.
1	0	4	O	While
2	6	9	O	none
3	11	12	O	of
4	14	16	O	the
5	18	22	O	drugs
6	24	30	O	studied
7	32	34	O	for
8	36	39	O	drug
9	41	52	O	interactions
10	54	66	O	significantly
11	68	75	O	affected
12	77	79	O	the
13	81	96	O	pharmacokinetics
14	98	99	O	of
15	101	111	O	XXXXXXXX
16	112	112	O	,
17	114	115	O	an
18	117	118	O	in
19	120	123	O	vivo
20	125	129	O	study
21	131	132	O	of
22	134	144	O	XXXXXXXX
23	146	151	O	single
24	153	156	O	dose
25	158	173	O	pharmacokinetics
26	175	176	O	in
27	178	179	O	13
28	181	182	O	PM
29	184	191	O	subjects
30	193	204	O	demonstrated
31	206	212	O	altered
32	214	228	O	pharmacokinetic
33	230	239	O	properties
34	241	248	O	compared
35	250	251	O	to
36	253	254	O	16
37	256	265	O	"extensive
38	267	279	O	metabolizers"
39	282	283	O	EM
40	285	285	O	:
41	287	290	O	mean
42	292	295	O	Cmax
43	296	296	O	,
44	298	300	O	AUC
45	301	301	O	,
46	303	305	O	and
47	307	310	O	half
48	312	315	O	life
49	317	320	O	were
50	322	330	O	increased
51	332	333	O	by
52	335	337	O	52%
53	338	338	O	,
54	340	343	O	200%
55	344	344	O	,
56	346	348	O	and
57	350	352	O	62%
58	353	353	O	,
59	355	366	O	respectively
60	367	367	O	,
61	369	370	O	in
62	372	374	O	the
63	376	377	O	PM
64	379	386	O	compared
65	388	389	O	to
66	391	393	O	the
67	395	396	O	EM
68	398	402	O	group
NULL

Fluvoxamine Maleate	1411	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	14
This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	29	O	XXXXXXXX
5	31	32	O	is
6	34	44	O	metabolized
7	45	45	O	,
8	47	48	O	at
9	50	54	O	least
10	56	57	O	in
11	59	62	O	part
12	63	63	O	,
13	65	66	O	by
14	68	73	O	CYP2D6
NULL

Fluvoxamine Maleate	1412	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	28
Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).
1	0	6	U-TRI	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	22	O	in
5	24	31	O	patients
6	33	37	O	known
7	39	40	O	to
8	42	45	O	have
9	47	53	O	reduced
10	55	60	O	levels
11	62	63	O	of
12	65	70	O	CYP2D6
13	72	79	O	activity
14	81	83	O	and
15	85	89	O	those
16	91	99	O	receiving
17	101	111	O	concomitant
18	113	117	O	drugs
19	119	123	O	known
20	125	126	O	to
21	128	134	O	inhibit
22	136	139	O	this
23	141	150	O	cytochrome
24	152	155	O	P450
25	157	165	O	isoenzyme
26	168	170	O	e.g
27	172	172	O	,
28	174	182	U-UNK	quinidine
NULL

Fluvoxamine Maleate	1413	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	34
The metabolism of fluvoxamine has not been fully characterized and the effects of potent cytochrome P450 isoenzyme inhibition, such as the ketoconazole inhibition of CYP3A4, on fluvoxamine metabolism have not been studied.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	28	O	XXXXXXXX
5	30	32	O	has
6	34	36	O	not
7	38	41	O	been
8	43	47	O	fully
9	49	61	O	characterized
10	63	65	O	and
11	67	69	O	the
12	71	77	O	effects
13	79	80	O	of
14	82	87	O	potent
15	89	98	O	cytochrome
16	100	103	O	P450
17	105	113	O	isoenzyme
18	115	124	O	inhibition
19	125	125	O	,
20	127	130	O	such
21	132	133	O	as
22	135	137	O	the
23	139	150	O	ketoconazole
24	152	161	O	inhibition
25	163	164	O	of
26	166	171	O	CYP3A4
27	172	172	O	,
28	174	175	O	on
29	177	187	O	XXXXXXXX
30	189	198	O	metabolism
31	200	203	O	have
32	205	207	O	not
33	209	212	O	been
34	214	220	O	studied
NULL

Fluvoxamine Maleate	1414	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	28
A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin.
1	0	0	O	A
2	2	11	O	clinically
3	13	23	O	significant
4	25	35	O	XXXXXXXX
5	37	47	U-TRI	interaction
6	49	50	O	is
7	52	59	O	possible
8	61	64	O	with
9	66	70	O	drugs
10	72	77	O	having
11	79	79	O	a
12	81	86	O	narrow
13	88	98	O	therapeutic
14	100	104	O	ratio
15	106	109	O	such
16	111	112	O	as
17	114	121	U-UNK	pimozide
18	122	122	O	,
19	124	131	U-UNK	warfarin
20	132	132	O	,
21	134	145	U-UNK	theophylline
22	146	146	O	,
23	148	154	O	certain
24	156	170	U-UNK	benzodiazepines
25	171	171	O	,
26	173	182	U-UNK	omeprazole
27	184	186	O	and
28	188	196	U-UNK	phenytoin
NULL

Fluvoxamine Maleate	1415	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	48
If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached.
1	0	1	O	If
2	3	21	O	XXXXXXXX
3	23	29	O	tablets
4	31	33	O	are
5	35	36	O	to
6	38	39	O	be
7	41	52	O	administered
8	54	61	O	together
9	63	66	O	with
10	68	68	O	a
11	70	73	O	drug
12	75	78	O	that
13	80	81	O	is
14	83	92	O	eliminated
15	94	96	O	via
16	98	106	O	oxidative
17	108	117	O	metabolism
18	119	121	O	and
19	123	125	O	has
20	127	127	O	a
21	129	134	O	narrow
22	136	146	O	therapeutic
23	148	153	O	window
24	154	154	O	,
25	156	161	O	plasma
26	163	168	O	levels
27	170	172	O	and
28	173	173	O	/
29	174	175	O	or
30	177	191	O	pharmacodynamic
31	193	199	O	effects
32	201	202	O	of
33	204	206	O	the
34	208	213	O	latter
35	215	218	O	drug
36	220	225	O	should
37	227	228	O	be
38	230	238	O	monitored
39	240	246	O	closely
40	247	247	O	,
41	249	250	O	at
42	252	256	O	least
43	258	262	O	until
44	264	269	O	steady
45	271	275	O	state
46	277	286	O	conditions
47	288	290	O	are
48	292	298	O	reached
NULL

Fluvoxamine Maleate	1416	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	32
A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	of
4	11	18	O	multiple
5	20	24	O	doses
6	26	27	O	of
7	29	47	O	XXXXXXXX
8	50	51	O	50
9	53	54	O	mg
10	56	60	O	b.i.d
11	64	65	O	in
12	67	73	O	healthy
13	75	78	O	male
14	80	89	O	volunteers
15	92	92	O	N
16	94	94	O	=
17	96	97	O	12
18	100	102	O	and
19	104	104	O	a
20	106	111	O	single
21	113	116	O	dose
22	118	119	O	of
23	121	129	O	lorazepam
24	132	132	O	4
25	134	135	O	mg
26	137	142	O	single
27	144	147	O	dose
28	150	158	O	indicated
29	160	161	O	no
30	163	173	O	significant
31	175	189	O	pharmacokinetic
32	191	201	O	interaction
NULL

Fluvoxamine Maleate	1417	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	34
On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone.
1	0	1	O	On
2	3	9	O	average
3	10	10	O	,
4	12	15	O	both
5	17	25	O	lorazepam
6	27	31	O	alone
7	33	35	O	and
8	37	45	O	lorazepam
9	47	50	O	with
10	52	62	O	XXXXXXXX
11	64	71	O	produced
12	73	83	O	substantial
13	85	94	O	decrements
14	96	97	O	in
15	99	107	O	cognitive
16	109	119	O	functioning
17	122	128	O	however
18	129	129	O	,
19	131	133	O	the
20	135	150	O	coadministration
21	152	153	O	of
22	155	165	O	XXXXXXXX
23	167	169	O	and
24	171	179	O	lorazepam
25	181	183	O	did
26	185	187	O	not
27	189	195	O	produce
28	197	202	O	larger
29	204	207	O	mean
30	209	218	O	decrements
31	220	227	O	compared
32	229	230	O	to
33	232	240	O	lorazepam
34	242	246	O	alone
NULL

Fluvoxamine Maleate	1418	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	40
Studies involving single 40 g doses of ethanol (oral administration in one study and intravenous in the other) and multiple dosing with fluvoxamine maleate (50 mg b.i.d.) revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of the other.
1	0	6	O	Studies
2	8	16	O	involving
3	18	23	O	single
4	25	26	O	40
5	28	28	O	g
6	30	34	O	doses
7	36	37	O	of
8	39	45	O	ethanol
9	48	51	O	oral
10	53	66	O	administration
11	68	69	O	in
12	71	73	O	one
13	75	79	O	study
14	81	83	O	and
15	85	95	O	intravenous
16	97	98	O	in
17	100	102	O	the
18	104	108	O	other
19	111	113	O	and
20	115	122	O	multiple
21	124	129	O	dosing
22	131	134	O	with
23	136	154	O	XXXXXXXX
24	157	158	O	50
25	160	161	O	mg
26	163	167	O	b.i.d
27	171	178	O	revealed
28	180	181	O	no
29	183	188	O	effect
30	190	191	O	of
31	193	198	O	either
32	200	203	O	drug
33	205	206	O	on
34	208	210	O	the
35	212	227	O	pharmacokinetics
36	229	230	O	or
37	232	247	O	pharmacodynamics
38	249	250	O	of
39	252	254	O	the
40	256	260	O	other
NULL

Fluvoxamine Maleate	1419	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	17
As with other psychotropic medications, patients should be advised to avoid alcohol while taking fluvoxamine maleate tablets.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	25	O	psychotropic
5	27	37	O	medications
6	38	38	O	,
7	40	47	O	patients
8	49	54	O	should
9	56	57	O	be
10	59	65	O	advised
11	67	68	O	to
12	70	74	U-TRI	avoid
13	76	82	U-UNK	alcohol
14	84	88	O	while
15	90	95	O	taking
16	97	115	O	XXXXXXXX
17	117	123	O	tablets
NULL

Fluvoxamine Maleate	1420	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	17
Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine.
1	0	7	O	Elevated
2	9	21	U-DYN	carbamazepine
3	23	28	O	levels
4	30	32	O	and
5	34	41	B-EFF	symptoms
6	43	44	I-EFF	of
7	46	53	L-EFF	toxicity
8	55	58	O	have
9	60	63	O	been
10	65	72	O	reported
11	74	77	O	with
12	79	81	O	the
13	83	98	O	coadministration
14	100	101	O	of
15	103	121	O	XXXXXXXX
16	123	125	O	and
17	127	139	O	carbamazepine
D/2:5:1

Fluvoxamine Maleate	1421	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	25
As with other serotonergic drugs, lithium may enhance the serotonergic effects of fluvoxamine and, therefore, the combination should be used with caution.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	25	O	serotonergic
5	27	31	O	drugs
6	32	32	O	,
7	34	40	U-DYN	lithium
8	42	44	O	may
9	46	52	B-EFF	enhance
10	54	56	I-EFF	the
11	58	69	I-EFF	serotonergic
12	71	77	L-EFF	effects
13	79	80	O	of
14	82	92	O	XXXXXXXX
15	94	96	O	and
16	97	97	O	,
17	99	107	O	therefore
18	108	108	O	,
19	110	112	O	the
20	114	124	O	combination
21	126	131	O	should
22	133	134	O	be
23	136	139	O	used
24	141	144	O	with
25	146	152	O	caution
D/7:9:1

Fluvoxamine Maleate	1422	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	11
Seizures have been reported with the coadministration of fluvoxamine maleate and lithium.
1	0	7	U-EFF	Seizures
2	9	12	O	have
3	14	17	O	been
4	19	26	O	reported
5	28	31	O	with
6	33	35	O	the
7	37	52	O	coadministration
8	54	55	O	of
9	57	75	O	XXXXXXXX
10	77	79	O	and
11	81	87	U-DYN	lithium
D/11:1:1

Fluvoxamine Maleate	1423	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	15
See Dosage and Administration (2.5 and 2.6), Contraindications (4.2) and Warnings and Precautions (5.2).
1	0	2	O	See
2	4	9	O	Dosage
3	11	13	O	and
4	15	28	O	Administration
5	31	33	O	2.5
6	35	37	O	and
7	39	41	O	2.6
8	43	43	O	,
9	45	61	O	Contraindications
10	64	66	O	4.2
11	69	71	O	and
12	73	80	O	Warnings
13	82	84	O	and
14	86	96	O	Precautions
15	99	101	O	5.2
NULL

Fluvoxamine Maleate	1424	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	8
See Contraindications (4.1) and Warnings and Precautions (5.6).
1	0	2	O	See
2	4	20	O	Contraindications
3	23	25	O	4.1
4	28	30	O	and
5	32	39	O	Warnings
6	41	43	O	and
7	45	55	O	Precautions
8	58	60	O	5.6
NULL

Fluvoxamine Maleate	1426	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	51
In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with 5- and 8-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	13
6	17	23	O	healthy
7	24	24	O	,
8	26	29	O	male
9	31	40	O	volunteers
10	41	41	O	,
11	43	43	O	a
12	45	50	O	single
13	52	53	O	40
14	55	56	O	mg
15	58	61	O	dose
16	63	64	O	of
17	66	72	U-KIN	tacrine
18	74	78	O	added
19	80	81	O	to
20	83	93	O	XXXXXXXX
21	95	97	O	100
22	99	100	O	mg
23	101	101	O	/
24	102	104	O	day
25	106	117	O	administered
26	119	120	O	at
27	122	127	O	steady
28	129	133	O	state
29	135	137	O	was
30	139	148	O	associated
31	150	153	O	with
32	155	155	O	5
33	158	160	O	and
34	162	162	O	8
35	164	167	O	fold
36	169	177	O	increases
37	179	180	O	in
38	182	188	O	tacrine
39	190	193	O	Cmax
40	195	197	O	and
41	199	201	O	AUC
42	202	202	O	,
43	204	215	O	respectively
44	216	216	O	,
45	218	225	O	compared
46	227	228	O	to
47	230	232	O	the
48	234	247	O	administration
49	249	250	O	of
50	252	258	O	tacrine
51	260	264	O	alone
K/17:C54613

Fluvoxamine Maleate	1427	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	21
Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine.
1	0	3	O	Five
2	5	12	O	subjects
3	14	24	O	experienced
4	26	31	U-EFF	nausea
5	32	32	O	,
6	34	41	U-EFF	vomiting
7	42	42	O	,
8	44	51	U-EFF	sweating
9	52	52	O	,
10	54	56	O	and
11	58	65	U-EFF	diarrhea
12	67	75	O	following
13	77	92	O	coadministration
14	93	93	O	,
15	95	104	O	consistent
16	106	109	O	with
17	111	113	O	the
18	115	125	O	cholinergic
19	127	133	O	effects
20	135	136	O	of
21	138	144	U-DYN	tacrine
D/21:11:1 D/21:4:1 D/21:6:1 D/21:8:1

Fluvoxamine Maleate	1428	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	8
See Contraindications (4.1) and Warnings and Precautions (5.4).
1	0	2	O	See
2	4	20	O	Contraindications
3	23	25	O	4.1
4	28	30	O	and
5	32	39	O	Warnings
6	41	43	O	and
7	45	55	O	Precautions
8	58	60	O	5.4
NULL

Fluvoxamine Maleate	1429	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	8
See Contraindications (4.1) and Warnings and Precautions (5.5).
1	0	2	O	See
2	4	20	O	Contraindications
3	23	25	O	4.1
4	28	30	O	and
5	32	39	O	Warnings
6	41	43	O	and
7	45	55	O	Precautions
8	58	60	O	5.5
NULL

Fluvoxamine Maleate	1430	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	19
Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine.
1	0	12	O	Significantly
2	14	22	O	increased
3	24	29	O	plasma
4	31	33	O	TCA
5	35	40	O	levels
6	42	45	O	have
7	47	50	O	been
8	52	59	O	reported
9	61	64	O	with
10	66	68	O	the
11	70	85	O	coadministration
12	87	88	O	of
13	90	108	O	XXXXXXXX
14	110	112	O	and
15	114	126	U-KIN	amitriptyline
16	127	127	O	,
17	129	140	U-KIN	clomipramine
18	142	143	O	or
19	145	154	U-KIN	imipramine
K/15:C54357 K/17:C54357 K/19:C54357

Fluvoxamine Maleate	1431	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	30
Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	24	O	with
5	26	28	O	the
6	30	45	O	coadministration
7	47	48	O	of
8	50	68	O	XXXXXXXX
9	70	76	O	tablets
10	78	80	O	and
11	82	85	O	TCAs
12	88	93	O	plasma
13	95	97	O	TCA
14	99	112	O	concentrations
15	114	116	O	may
16	118	121	O	need
17	123	124	O	to
18	126	127	O	be
19	129	137	O	monitored
20	138	138	O	,
21	140	142	O	and
22	144	146	O	the
23	148	151	O	dose
24	153	154	O	of
25	156	158	O	TCA
26	160	162	O	may
27	164	167	O	need
28	169	170	O	to
29	172	173	O	be
30	175	181	O	reduced
NULL

Fluvoxamine Maleate	1432	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	17
There have been rare postmarketing reports of serotonin syndrome with use of an SSRI and a triptan.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	33	O	postmarketing
6	35	41	O	reports
7	43	44	O	of
8	46	54	B-EFF	serotonin
9	56	63	L-EFF	syndrome
10	65	68	O	with
11	70	72	O	use
12	74	75	O	of
13	77	78	O	an
14	80	83	O	SSRI
15	85	87	O	and
16	89	89	O	a
17	91	97	U-DYN	triptan
D/17:8:1

Fluvoxamine Maleate	1433	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	27
If concomitant treatment of fluvoxamine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	26	O	of
5	28	38	O	XXXXXXXX
6	40	43	O	with
7	45	45	O	a
8	47	53	U-UNK	triptan
9	55	56	O	is
10	58	67	O	clinically
11	69	77	O	warranted
12	78	78	O	,
13	80	86	B-TRI	careful
14	88	98	L-TRI	observation
15	100	101	O	of
16	103	105	O	the
17	107	113	O	patient
18	115	116	O	is
19	118	124	O	advised
20	125	125	O	,
21	127	138	O	particularly
22	140	145	O	during
23	147	155	O	treatment
24	157	166	O	initiation
25	168	170	O	and
26	172	175	O	dose
27	177	185	O	increases
NULL

Fluvoxamine Maleate	1434	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	27
There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	33	O	postmarketing
6	35	41	O	reports
7	43	52	O	describing
8	54	61	O	patients
9	63	66	O	with
10	68	75	U-EFF	weakness
11	76	76	O	,
12	78	90	U-EFF	hyperreflexia
13	91	91	O	,
14	93	95	O	and
15	97	110	U-EFF	incoordination
16	112	120	O	following
17	122	124	O	the
18	126	128	O	use
19	130	131	O	of
20	133	133	O	a
21	135	143	O	selective
22	145	153	O	serotonin
23	155	162	O	reuptake
24	164	172	O	inhibitor
25	175	178	O	SSRI
26	181	183	O	and
27	185	195	U-DYN	sumatriptan
D/27:10:1 D/27:12:1 D/27:15:1

Fluvoxamine Maleate	1435	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	28
If concomitant treatment with sumatriptan and an SSRI (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	40	U-UNK	sumatriptan
6	42	44	O	and
7	46	47	O	an
8	49	52	O	SSRI
9	55	57	O	e.g
10	59	59	O	,
11	61	70	O	fluoxetine
12	71	71	O	,
13	73	83	O	XXXXXXXX
14	84	84	O	,
15	86	95	O	paroxetine
16	96	96	O	,
17	98	107	O	sertraline
18	110	111	O	is
19	113	122	O	clinically
20	124	132	O	warranted
21	133	133	O	,
22	135	145	O	appropriate
23	147	157	O	observation
24	159	160	O	of
25	162	164	O	the
26	166	172	O	patient
27	174	175	O	is
28	177	183	O	advised
NULL

Fluvoxamine Maleate	1436	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	20
Tryptophan may enhance the serotonergic effects of fluvoxamine, and the combination should, therefore, be used with caution.
1	0	9	U-DYN	Tryptophan
2	11	13	O	may
3	15	21	B-EFF	enhance
4	23	25	I-EFF	the
5	27	38	I-EFF	serotonergic
6	40	46	L-EFF	effects
7	48	49	O	of
8	51	61	O	XXXXXXXX
9	62	62	O	,
10	64	66	O	and
11	68	70	O	the
12	72	82	O	combination
13	84	89	O	should
14	90	90	O	,
15	92	100	O	therefore
16	101	101	O	,
17	103	104	O	be
18	106	109	O	used
19	111	114	O	with
20	116	122	O	caution
D/1:3:1

Fluvoxamine Maleate	1437	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	12
Severe vomiting has been reported with the coadministration of fluvoxamine maleate and tryptophan.
1	0	5	B-EFF	Severe
2	7	14	L-EFF	vomiting
3	16	18	O	has
4	20	23	O	been
5	25	32	O	reported
6	34	37	O	with
7	39	41	O	the
8	43	58	O	coadministration
9	60	61	O	of
10	63	81	O	XXXXXXXX
11	83	85	O	and
12	87	96	U-DYN	tryptophan
D/12:1:1

Fluvoxamine Maleate	1438	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	14
See Contraindications (4.1), Warnings and Precautions (5.7), and Lotronex** (alosetron) package insert.
1	0	2	O	See
2	4	20	U-TRI	Contraindications
3	23	25	O	4.1
4	27	27	O	,
5	29	36	O	Warnings
6	38	40	O	and
7	42	52	O	Precautions
8	55	57	O	5.7
9	59	59	O	,
10	61	63	O	and
11	65	74	O	Lotronex**
12	77	85	U-UNK	alosetron
13	88	94	O	package
14	96	101	O	insert
NULL

Fluvoxamine Maleate	1439	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	27
Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin.
1	0	13	O	Administration
2	15	16	O	of
3	18	36	O	XXXXXXXX
4	38	40	O	100
5	42	43	O	mg
6	45	49	O	daily
7	51	53	O	for
8	55	56	O	18
9	58	61	O	days
10	64	64	O	N
11	66	66	O	=
12	68	68	O	8
13	71	73	O	did
14	75	77	O	not
15	79	91	O	significantly
16	93	98	O	affect
17	100	102	O	the
18	104	119	O	pharmacokinetics
19	121	122	O	of
20	124	124	O	a
21	126	129	O	1.25
22	131	132	O	mg
23	134	139	O	single
24	141	151	O	intravenous
25	153	156	O	dose
26	158	159	O	of
27	161	167	O	digoxin
NULL

Fluvoxamine Maleate	1440	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	11
Bradycardia has been reported with the coadministration of fluvoxamine maleate and diltiazem.
1	0	10	U-EFF	Bradycardia
2	12	14	O	has
3	16	19	O	been
4	21	28	O	reported
5	30	33	O	with
6	35	37	O	the
7	39	54	O	coadministration
8	56	57	O	of
9	59	77	O	XXXXXXXX
10	79	81	O	and
11	83	91	U-DYN	diltiazem
D/11:1:1

Fluvoxamine Maleate	1441	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	32
Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean five-fold increase (range 2 to 17) in minimum propranolol plasma concentrations.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	38	O	XXXXXXXX
4	40	42	O	100
5	44	45	O	mg
6	47	49	O	per
7	51	53	O	day
8	55	57	O	and
9	59	69	U-KIN	propranolol
10	71	73	O	160
11	75	76	O	mg
12	78	80	O	per
13	82	84	O	day
14	86	87	O	in
15	89	94	O	normal
16	96	105	O	volunteers
17	107	114	O	resulted
18	116	117	O	in
19	119	119	O	a
20	121	124	O	mean
21	126	129	O	five
22	131	134	O	fold
23	136	143	O	increase
24	146	150	O	range
25	152	152	O	2
26	154	155	O	to
27	157	158	O	17
28	161	162	O	in
29	164	170	O	minimum
30	172	182	O	propranolol
31	184	189	O	plasma
32	191	204	O	concentrations
K/9:C54357

Fluvoxamine Maleate	1442	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	24
In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	19	O	there
6	21	23	O	was
7	25	25	O	a
8	27	32	O	slight
9	34	45	O	potentiation
10	47	48	O	of
11	50	52	O	the
12	54	64	U-DYN	propranolol
13	66	72	O	induced
14	74	82	B-EFF	reduction
15	84	85	I-EFF	in
16	87	91	I-EFF	heart
17	93	96	L-EFF	rate
18	98	100	O	and
19	102	110	B-EFF	reduction
20	112	113	I-EFF	in
21	115	117	I-EFF	the
22	119	126	I-EFF	exercise
23	128	136	I-EFF	diastolic
24	138	145	L-EFF	pressure
D/12:14:1 D/12:19:1

Fluvoxamine Maleate	1443	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	23
One case of bradycardia and hypotension and a second case of orthostatic hypotension have been reported with the coadministration of fluvoxamine maleate and metoprolol.
1	0	2	O	One
2	4	7	O	case
3	9	10	O	of
4	12	22	B-EFF	bradycardia
5	24	26	I-EFF	and
6	28	38	L-EFF	hypotension
7	40	42	O	and
8	44	44	O	a
9	46	51	O	second
10	53	56	O	case
11	58	59	O	of
12	61	71	B-EFF	orthostatic
13	73	83	L-EFF	hypotension
14	85	88	O	have
15	90	93	O	been
16	95	102	O	reported
17	104	107	O	with
18	109	111	O	the
19	113	128	O	coadministration
20	130	131	O	of
21	133	151	O	XXXXXXXX
22	153	155	O	and
23	157	166	U-DYN	metoprolol
D/23:12:1 D/23:4:1

Fluvoxamine Maleate	1444	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	25
If propranolol or metoprolol is coadministered with fluvoxamine maleate tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended.
1	0	1	O	If
2	3	13	U-KIN	propranolol
3	15	16	O	or
4	18	27	U-KIN	metoprolol
5	29	30	O	is
6	32	45	O	coadministered
7	47	50	O	with
8	52	70	O	XXXXXXXX
9	72	78	O	tablets
10	79	79	O	,
11	81	81	O	a
12	83	91	O	reduction
13	93	94	O	in
14	96	98	O	the
15	100	106	O	initial
16	108	111	O	beta
17	113	119	O	blocker
18	121	124	O	dose
19	126	128	O	and
20	130	133	O	more
21	135	142	O	cautious
22	144	147	O	dose
23	149	157	O	titration
24	159	161	O	are
25	163	173	O	recommended
K/2:C54357 K/4:C54357

Fluvoxamine Maleate	1445	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	8
No dosage adjustment is required for fluvoxamine maleate tablets.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	31	O	required
6	33	35	O	for
7	37	55	O	XXXXXXXX
8	57	63	O	tablets
NULL

Fluvoxamine Maleate	1446	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	24
Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	38	O	XXXXXXXX
4	40	42	O	100
5	44	45	O	mg
6	47	49	O	per
7	51	53	O	day
8	55	58	O	with
9	60	67	O	atenolol
10	69	71	O	100
11	73	74	O	mg
12	76	78	O	per
13	80	82	O	day
14	85	85	O	N
15	87	87	O	=
16	89	89	O	6
17	92	94	O	did
18	96	98	O	not
19	100	105	O	affect
20	107	109	O	the
21	111	116	O	plasma
22	118	131	O	concentrations
23	133	134	O	of
24	136	143	O	atenolol
NULL

Fluvoxamine Maleate	1447	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	16
Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion.
1	0	5	O	Unlike
2	7	17	O	propranolol
3	19	21	O	and
4	23	32	O	metoprolol
5	34	38	O	which
6	40	46	O	undergo
7	48	54	O	hepatic
8	56	65	O	metabolism
9	66	66	O	,
10	68	75	O	atenolol
11	77	78	O	is
12	80	89	O	eliminated
13	91	99	O	primarily
14	101	102	O	by
15	104	108	O	renal
16	110	118	O	excretion
NULL

Fluvoxamine Maleate	1448	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	7
See Warnings and Precautions (5.8 and 5.10).
1	0	2	O	See
2	4	11	O	Warnings
3	13	15	O	and
4	17	27	O	Precautions
5	30	32	O	5.8
6	34	36	O	and
7	38	41	O	5.10
NULL

Fluvoxamine Maleate	1449	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	13
Smokers had a 25% increase in the metabolism of fluvoxamine compared to nonsmokers.
1	0	6	O	Smokers
2	8	10	O	had
3	12	12	O	a
4	14	16	O	25%
5	18	25	O	increase
6	27	28	O	in
7	30	32	O	the
8	34	43	O	metabolism
9	45	46	O	of
10	48	58	O	XXXXXXXX
11	60	67	O	compared
12	69	70	O	to
13	72	81	O	nonsmokers
NULL

Fluvoxamine Maleate	1450	34073-7	53664f8d-3a93-9f2b-daee-380707e4062c	17
There are no clinical studies establishing the benefits or risks of combined use of ECT and fluvoxamine maleate.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	20	O	clinical
5	22	28	O	studies
6	30	41	O	establishing
7	43	45	O	the
8	47	54	O	benefits
9	56	57	O	or
10	59	63	O	risks
11	65	66	O	of
12	68	75	O	combined
13	77	79	O	use
14	81	82	O	of
15	84	86	O	ECT
16	88	90	O	and
17	92	110	O	XXXXXXXX
NULL

Fluvoxamine Maleate	1451	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	24
The mechanism of action of fluvoxamine maleate in obsessive compulsive disorder is presumed to be linked to its specific serotonin reuptake inhibition in brain neurons.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	45	O	XXXXXXXX
7	47	48	O	in
8	50	58	O	obsessive
9	60	69	O	compulsive
10	71	78	O	disorder
11	80	81	O	is
12	83	90	O	presumed
13	92	93	O	to
14	95	96	O	be
15	98	103	O	linked
16	105	106	O	to
17	108	110	O	its
18	112	119	O	specific
19	121	129	O	serotonin
20	131	138	O	reuptake
21	140	149	O	inhibition
22	151	152	O	in
23	154	158	O	brain
24	160	166	O	neurons
NULL

Fluvoxamine Maleate	1452	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	24
Fluvoxamine has been shown to be a potent inhibitor of the serotonin reuptake transporter in preclinical studies, both in vitro and in vivo.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	19	O	been
4	21	25	O	shown
5	27	28	O	to
6	30	31	O	be
7	33	33	O	a
8	35	40	O	potent
9	42	50	O	inhibitor
10	52	53	O	of
11	55	57	O	the
12	59	67	O	serotonin
13	69	76	O	reuptake
14	78	88	O	transporter
15	90	91	O	in
16	93	103	O	preclinical
17	105	111	O	studies
18	112	112	O	,
19	114	117	O	both
20	119	120	O	in
21	122	126	O	vitro
22	128	130	O	and
23	132	133	O	in
24	135	138	O	vivo
NULL

Fluvoxamine Maleate	1453	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	23
In in vitro studies, fluvoxamine maleate had no significant affinity for histaminergic, alpha or beta adrenergic, muscarinic, or dopaminergic receptors.
1	0	1	O	In
2	3	4	O	in
3	6	10	O	vitro
4	12	18	O	studies
5	19	19	O	,
6	21	39	O	XXXXXXXX
7	41	43	O	had
8	45	46	O	no
9	48	58	O	significant
10	60	67	O	affinity
11	69	71	O	for
12	73	85	O	histaminergic
13	86	86	O	,
14	88	92	O	alpha
15	94	95	O	or
16	97	100	O	beta
17	102	111	O	adrenergic
18	112	112	O	,
19	114	123	O	muscarinic
20	124	124	O	,
21	126	127	O	or
22	129	140	O	dopaminergic
23	142	150	O	receptors
NULL

Fluvoxamine Maleate	1454	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	26
Antagonism of some of these receptors is thought to be associated with various sedative, cardiovascular, anticholinergic, and extrapyramidal effects of some psychotropic drugs.
1	0	9	O	Antagonism
2	11	12	O	of
3	14	17	O	some
4	19	20	O	of
5	22	26	O	these
6	28	36	O	receptors
7	38	39	O	is
8	41	47	O	thought
9	49	50	O	to
10	52	53	O	be
11	55	64	O	associated
12	66	69	O	with
13	71	77	O	various
14	79	86	O	sedative
15	87	87	O	,
16	89	102	O	cardiovascular
17	103	103	O	,
18	105	119	O	anticholinergic
19	120	120	O	,
20	122	124	O	and
21	126	139	O	extrapyramidal
22	141	147	O	effects
23	149	150	O	of
24	152	155	O	some
25	157	168	O	psychotropic
26	170	174	O	drugs
NULL

Fluvoxamine Maleate	1455	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	7
The absolute bioavailability of fluvoxamine maleate is 53%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	50	O	XXXXXXXX
6	52	53	O	is
7	55	57	O	53%
NULL

Fluvoxamine Maleate	1456	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	8
Oral bioavailability is not significantly affected by food.
1	0	3	O	Oral
2	5	19	O	bioavailability
3	21	22	O	is
4	24	26	O	not
5	28	40	O	significantly
6	42	49	O	affected
7	51	52	O	by
8	54	57	O	food
NULL

Fluvoxamine Maleate	1457	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	35
In a dose proportionality study involving fluvoxamine maleate at 100, 200 and 300 mg/day for 10 consecutive days in 30 normal volunteers, steady state was achieved after about a week of dosing.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	dose
4	10	24	O	proportionality
5	26	30	O	study
6	32	40	O	involving
7	42	60	O	XXXXXXXX
8	62	63	O	at
9	65	67	O	100
10	68	68	O	,
11	70	72	O	200
12	74	76	O	and
13	78	80	O	300
14	82	83	O	mg
15	84	84	O	/
16	85	87	O	day
17	89	91	O	for
18	93	94	O	10
19	96	106	O	consecutive
20	108	111	O	days
21	113	114	O	in
22	116	117	O	30
23	119	124	O	normal
24	126	135	O	volunteers
25	136	136	O	,
26	138	143	O	steady
27	145	149	O	state
28	151	153	O	was
29	155	162	O	achieved
30	164	168	O	after
31	170	174	O	about
32	176	176	O	a
33	178	181	O	week
34	183	184	O	of
35	186	191	O	dosing
NULL

Fluvoxamine Maleate	1458	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	28
Maximum plasma concentrations at steady state occurred within 3 to 8 hours of dosing and reached concentrations averaging 88, 283 and 546 ng/mL, respectively.
1	0	6	O	Maximum
2	8	13	O	plasma
3	15	28	O	concentrations
4	30	31	O	at
5	33	38	O	steady
6	40	44	O	state
7	46	53	O	occurred
8	55	60	O	within
9	62	62	O	3
10	64	65	O	to
11	67	67	O	8
12	69	73	O	hours
13	75	76	O	of
14	78	83	O	dosing
15	85	87	O	and
16	89	95	O	reached
17	97	110	O	concentrations
18	112	120	O	averaging
19	122	123	O	88
20	124	124	O	,
21	126	128	O	283
22	130	132	O	and
23	134	136	O	546
24	138	139	O	ng
25	140	140	O	/
26	141	142	O	mL
27	143	143	O	,
28	145	156	O	respectively
NULL

Fluvoxamine Maleate	1459	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	27
Thus, fluvoxamine had nonlinear pharmacokinetics over this dose range, i.e., higher doses of fluvoxamine maleate produced disproportionately higher concentrations than predicted from the lower dose.
1	0	3	O	Thus
2	4	4	O	,
3	6	16	O	XXXXXXXX
4	18	20	O	had
5	22	30	O	nonlinear
6	32	47	O	pharmacokinetics
7	49	52	O	over
8	54	57	O	this
9	59	62	O	dose
10	64	68	O	range
11	69	69	O	,
12	71	73	O	i.e
13	75	75	O	,
14	77	82	O	higher
15	84	88	O	doses
16	90	91	O	of
17	93	111	O	XXXXXXXX
18	113	120	O	produced
19	122	139	O	disproportionately
20	141	146	O	higher
21	148	161	O	concentrations
22	163	166	O	than
23	168	176	O	predicted
24	178	181	O	from
25	183	185	O	the
26	187	191	O	lower
27	193	196	O	dose
NULL

Fluvoxamine Maleate	1460	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	19
The mean apparent volume of distribution for fluvoxamine is approximately 25 L/kg, suggesting extensive tissue distribution.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	apparent
4	18	23	O	volume
5	25	26	O	of
6	28	39	O	distribution
7	41	43	O	for
8	45	55	O	XXXXXXXX
9	57	58	O	is
10	60	72	O	approximately
11	74	75	O	25
12	77	77	O	L
13	78	78	O	/
14	79	80	O	kg
15	81	81	O	,
16	83	92	O	suggesting
17	94	102	O	extensive
18	104	109	O	tissue
19	111	122	O	distribution
NULL

Fluvoxamine Maleate	1461	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	24
Approximately 80% of fluvoxamine is bound to plasma protein, mostly albumin, over a concentration range of 20 to 2000 ng/mL.
1	0	12	O	Approximately
2	14	16	O	80%
3	18	19	O	of
4	21	31	O	XXXXXXXX
5	33	34	O	is
6	36	40	O	bound
7	42	43	O	to
8	45	50	O	plasma
9	52	58	O	protein
10	59	59	O	,
11	61	66	O	mostly
12	68	74	O	albumin
13	75	75	O	,
14	77	80	O	over
15	82	82	O	a
16	84	96	O	concentration
17	98	102	O	range
18	104	105	O	of
19	107	108	O	20
20	110	111	O	to
21	113	116	O	2000
22	118	119	O	ng
23	120	120	O	/
24	121	122	O	mL
NULL

Fluvoxamine Maleate	1462	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	16
Fluvoxamine maleate is extensively metabolized by the liver; the main metabolic routes are oxidative demethylation and deamination.
1	0	18	O	XXXXXXXX
2	20	21	O	is
3	23	33	O	extensively
4	35	45	O	metabolized
5	47	48	O	by
6	50	52	O	the
7	54	58	O	liver
8	61	63	O	the
9	65	68	O	main
10	70	78	O	metabolic
11	80	85	O	routes
12	87	89	O	are
13	91	99	O	oxidative
14	101	113	O	demethylation
15	115	117	O	and
16	119	129	O	deamination
NULL

Fluvoxamine Maleate	1463	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	23
Nine metabolites were identified following a 5 mg radiolabelled dose of fluvoxamine maleate, constituting approximately 85% of the urinary excretion products of fluvoxamine.
1	0	3	O	Nine
2	5	15	O	metabolites
3	17	20	O	were
4	22	31	O	identified
5	33	41	O	following
6	43	43	O	a
7	45	45	O	5
8	47	48	O	mg
9	50	62	O	radiolabelled
10	64	67	O	dose
11	69	70	O	of
12	72	90	O	XXXXXXXX
13	91	91	O	,
14	93	104	O	constituting
15	106	118	O	approximately
16	120	122	O	85%
17	124	125	O	of
18	127	129	O	the
19	131	137	O	urinary
20	139	147	O	excretion
21	149	156	O	products
22	158	159	O	of
23	161	171	O	XXXXXXXX
NULL

Fluvoxamine Maleate	1464	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	25
The main human metabolite was fluvoxamine acid which, together with its N-acetylated analog, accounted for about 60% of the urinary excretion products.
1	0	2	O	The
2	4	7	O	main
3	9	13	O	human
4	15	24	O	metabolite
5	26	28	O	was
6	30	40	O	XXXXXXXX
7	42	45	O	acid
8	47	51	O	which
9	52	52	O	,
10	54	61	O	together
11	63	66	O	with
12	68	70	O	its
13	72	72	O	N
14	74	83	O	acetylated
15	85	90	O	analog
16	91	91	O	,
17	93	101	O	accounted
18	103	105	O	for
19	107	111	O	about
20	113	115	O	60%
21	117	118	O	of
22	120	122	O	the
23	124	130	O	urinary
24	132	140	O	excretion
25	142	149	O	products
NULL

Fluvoxamine Maleate	1465	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	15
A third metabolite, fluvoxethanol, formed by oxidative deamination, accounted for about 10%.
1	0	0	O	A
2	2	6	O	third
3	8	17	O	metabolite
4	18	18	O	,
5	20	32	O	fluvoxethanol
6	33	33	O	,
7	35	40	O	formed
8	42	43	O	by
9	45	53	O	oxidative
10	55	65	O	deamination
11	66	66	O	,
12	68	76	O	accounted
13	78	80	O	for
14	82	86	O	about
15	88	90	O	10%
NULL

Fluvoxamine Maleate	1466	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	48
Fluvoxamine acid and fluvoxethanol were tested in an in vitro assay of serotonin and norepinephrine reuptake inhibition in rats; they were inactive except for a weak effect of the former metabolite on inhibition of serotonin uptake (1 to 2 orders of magnitude less potent than the parent compound).
1	0	10	O	XXXXXXXX
2	12	15	O	acid
3	17	19	O	and
4	21	33	O	fluvoxethanol
5	35	38	O	were
6	40	45	O	tested
7	47	48	O	in
8	50	51	O	an
9	53	54	O	in
10	56	60	O	vitro
11	62	66	O	assay
12	68	69	O	of
13	71	79	O	serotonin
14	81	83	O	and
15	85	98	O	norepinephrine
16	100	107	O	reuptake
17	109	118	O	inhibition
18	120	121	O	in
19	123	126	O	rats
20	129	132	O	they
21	134	137	O	were
22	139	146	O	inactive
23	148	153	O	except
24	155	157	O	for
25	159	159	O	a
26	161	164	O	weak
27	166	171	O	effect
28	173	174	O	of
29	176	178	O	the
30	180	185	O	former
31	187	196	O	metabolite
32	198	199	O	on
33	201	210	O	inhibition
34	212	213	O	of
35	215	223	O	serotonin
36	225	230	O	uptake
37	233	233	O	1
38	235	236	O	to
39	238	238	O	2
40	240	245	O	orders
41	247	248	O	of
42	250	258	O	magnitude
43	260	263	O	less
44	265	270	O	potent
45	272	275	O	than
46	277	279	O	the
47	281	286	O	parent
48	288	295	O	compound
NULL

Fluvoxamine Maleate	1467	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	9
Approximately 2% of fluvoxamine was excreted in urine unchanged.
1	0	12	O	Approximately
2	14	15	O	2%
3	17	18	O	of
4	20	30	O	XXXXXXXX
5	32	34	O	was
6	36	43	O	excreted
7	45	46	O	in
8	48	52	O	urine
9	54	62	O	unchanged
NULL

Fluvoxamine Maleate	1468	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	27
Following a 14C-labelled oral dose of fluvoxamine maleate (5 mg), an average of 94% of drug-related products was recovered in the urine within 71 hours.
1	0	8	O	Following
2	10	10	O	a
3	12	14	O	14C
4	16	23	O	labelled
5	25	28	O	oral
6	30	33	O	dose
7	35	36	O	of
8	38	56	O	XXXXXXXX
9	59	59	O	5
10	61	62	O	mg
11	64	64	O	,
12	66	67	O	an
13	69	75	O	average
14	77	78	O	of
15	80	82	O	94%
16	84	85	O	of
17	87	90	O	drug
18	92	98	O	related
19	100	107	O	products
20	109	111	O	was
21	113	121	O	recovered
22	123	124	O	in
23	126	128	O	the
24	130	134	O	urine
25	136	141	O	within
26	143	144	O	71
27	146	150	O	hours
NULL

Fluvoxamine Maleate	1469	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	27
The mean plasma half-life of fluvoxamine at steady state after multiple oral doses of 100 mg/day in healthy, young volunteers was 15.6 hours.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	plasma
4	16	19	O	half
5	21	24	O	life
6	26	27	O	of
7	29	39	O	XXXXXXXX
8	41	42	O	at
9	44	49	O	steady
10	51	55	O	state
11	57	61	O	after
12	63	70	O	multiple
13	72	75	O	oral
14	77	81	O	doses
15	83	84	O	of
16	86	88	O	100
17	90	91	O	mg
18	92	92	O	/
19	93	95	O	day
20	97	98	O	in
21	100	106	O	healthy
22	107	107	O	,
23	109	113	O	young
24	115	124	O	volunteers
25	126	128	O	was
26	130	133	O	15.6
27	135	139	O	hours
NULL

Fluvoxamine Maleate	1470	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	33
In a study of fluvoxamine maleate tablets at 50 and 100 mg comparing elderly (ages 66-73) and young subjects (ages 19-35), mean maximum plasma concentrations in the elderly were 40% higher.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	32	O	XXXXXXXX
6	34	40	O	tablets
7	42	43	O	at
8	45	46	O	50
9	48	50	O	and
10	52	54	O	100
11	56	57	O	mg
12	59	67	O	comparing
13	69	75	O	elderly
14	78	81	O	ages
15	83	84	O	66
16	86	87	O	73
17	90	92	O	and
18	94	98	O	young
19	100	107	O	subjects
20	110	113	O	ages
21	115	116	O	19
22	118	119	O	35
23	121	121	O	,
24	123	126	O	mean
25	128	134	O	maximum
26	136	141	O	plasma
27	143	156	O	concentrations
28	158	159	O	in
29	161	163	O	the
30	165	171	O	elderly
31	173	176	O	were
32	178	180	O	40%
33	182	187	O	higher
NULL

Fluvoxamine Maleate	1471	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	37
The multiple dose elimination half-life of fluvoxamine was 17.4 and 25.9 hours in the elderly compared to 13.6 and 15.6 hours in the young subjects at steady state for 50 and 100 mg doses, respectively.
1	0	2	O	The
2	4	11	O	multiple
3	13	16	O	dose
4	18	28	O	elimination
5	30	33	O	half
6	35	38	O	life
7	40	41	O	of
8	43	53	O	XXXXXXXX
9	55	57	O	was
10	59	62	O	17.4
11	64	66	O	and
12	68	71	O	25.9
13	73	77	O	hours
14	79	80	O	in
15	82	84	O	the
16	86	92	O	elderly
17	94	101	O	compared
18	103	104	O	to
19	106	109	O	13.6
20	111	113	O	and
21	115	118	O	15.6
22	120	124	O	hours
23	126	127	O	in
24	129	131	O	the
25	133	137	O	young
26	139	146	O	subjects
27	148	149	O	at
28	151	156	O	steady
29	158	162	O	state
30	164	166	O	for
31	168	169	O	50
32	171	173	O	and
33	175	177	O	100
34	179	180	O	mg
35	182	186	O	doses
36	187	187	O	,
37	189	200	O	respectively
NULL

Fluvoxamine Maleate	1472	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	27
In elderly patients, the clearance of fluvoxamine was reduced by about 50% and, therefore, fluvoxamine maleate tablets should be slowly titrated during initiation of therapy.
1	0	1	O	In
2	3	9	O	elderly
3	11	18	O	patients
4	19	19	O	,
5	21	23	O	the
6	25	33	O	clearance
7	35	36	O	of
8	38	48	O	XXXXXXXX
9	50	52	O	was
10	54	60	O	reduced
11	62	63	O	by
12	65	69	O	about
13	71	73	O	50%
14	75	77	O	and
15	78	78	O	,
16	80	88	O	therefore
17	89	89	O	,
18	91	109	O	XXXXXXXX
19	111	117	O	tablets
20	119	124	O	should
21	126	127	O	be
22	129	134	O	slowly
23	136	143	O	titrated
24	145	150	O	during
25	152	161	O	initiation
26	163	164	O	of
27	166	172	O	therapy
NULL

Fluvoxamine Maleate	1473	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	21
The multiple-dose pharmacokinetics of fluvoxamine were determined in male and female children (ages 6-11) and adolescents (ages 12-17).
1	0	2	O	The
2	4	11	O	multiple
3	13	16	O	dose
4	18	33	O	pharmacokinetics
5	35	36	O	of
6	38	48	O	XXXXXXXX
7	50	53	O	were
8	55	64	O	determined
9	66	67	O	in
10	69	72	O	male
11	74	76	O	and
12	78	83	O	female
13	85	92	O	children
14	95	98	O	ages
15	100	100	O	6
16	102	103	O	11
17	106	108	O	and
18	110	120	O	adolescents
19	123	126	O	ages
20	128	129	O	12
21	131	132	O	17
NULL

Fluvoxamine Maleate	1474	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	15
Steady-state plasma fluvoxamine concentrations were 2-3 fold higher in children than in adolescents.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	plasma
4	20	30	O	XXXXXXXX
5	32	45	O	concentrations
6	47	50	O	were
7	52	52	O	2
8	54	54	O	3
9	56	59	O	fold
10	61	66	O	higher
11	68	69	O	in
12	71	78	O	children
13	80	83	O	than
14	85	86	O	in
15	88	98	O	adolescents
NULL

Fluvoxamine Maleate	1475	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	15
AUC and Cmax in children were 1.5- to 2.7-fold higher than that in adolescents.
1	0	2	O	AUC
2	4	6	O	and
3	8	11	O	Cmax
4	13	14	O	in
5	16	23	O	children
6	25	28	O	were
7	30	32	O	1.5
8	35	36	O	to
9	38	40	O	2.7
10	42	45	O	fold
11	47	52	O	higher
12	54	57	O	than
13	59	62	O	that
14	64	65	O	in
15	67	77	O	adolescents
NULL

Fluvoxamine Maleate	1476	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	13
As in adults, both children and adolescents exhibited nonlinear multiple-dose pharmacokinetics.
1	0	1	O	As
2	3	4	O	in
3	6	11	O	adults
4	12	12	O	,
5	14	17	O	both
6	19	26	O	children
7	28	30	O	and
8	32	42	O	adolescents
9	44	52	O	exhibited
10	54	62	O	nonlinear
11	64	71	O	multiple
12	73	76	O	dose
13	78	93	O	pharmacokinetics
NULL

Fluvoxamine Maleate	1477	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	27
Female children showed significantly higher AUC (0-12) and Cmax compared to male children and, therefore, lower doses of fluvoxamine maleate tablets may produce therapeutic benefit.
1	0	5	O	Female
2	7	14	O	children
3	16	21	O	showed
4	23	35	O	significantly
5	37	42	O	higher
6	44	46	O	AUC
7	49	49	O	0
8	51	52	O	12
9	55	57	O	and
10	59	62	O	Cmax
11	64	71	O	compared
12	73	74	O	to
13	76	79	O	male
14	81	88	O	children
15	90	92	O	and
16	93	93	O	,
17	95	103	O	therefore
18	104	104	O	,
19	106	110	O	lower
20	112	116	O	doses
21	118	119	O	of
22	121	139	O	XXXXXXXX
23	141	147	O	tablets
24	149	151	O	may
25	153	159	O	produce
26	161	171	O	therapeutic
27	173	179	O	benefit
NULL

Fluvoxamine Maleate	1478	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	7
No gender differences were observed in adolescents.
1	0	1	O	No
2	3	8	O	gender
3	10	20	O	differences
4	22	25	O	were
5	27	34	O	observed
6	36	37	O	in
7	39	49	O	adolescents
NULL

Fluvoxamine Maleate	1479	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	30
Steady-state plasma fluvoxamine concentrations were similar in adults and adolescents at a dose of 300 mg/day, indicating that fluvoxamine exposure was similar in these two populations.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	plasma
4	20	30	O	XXXXXXXX
5	32	45	O	concentrations
6	47	50	O	were
7	52	58	O	similar
8	60	61	O	in
9	63	68	O	adults
10	70	72	O	and
11	74	84	O	adolescents
12	86	87	O	at
13	89	89	O	a
14	91	94	O	dose
15	96	97	O	of
16	99	101	O	300
17	103	104	O	mg
18	105	105	O	/
19	106	108	O	day
20	109	109	O	,
21	111	120	O	indicating
22	122	125	O	that
23	127	137	O	XXXXXXXX
24	139	146	O	exposure
25	148	150	O	was
26	152	158	O	similar
27	160	161	O	in
28	163	167	O	these
29	169	171	O	two
30	173	183	O	populations
NULL

Fluvoxamine Maleate	1480	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	20
Dose adjustment in adolescents (up to the adult maximum dose of 300 mg) may be indicated to achieve therapeutic benefit.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	17	O	in
4	19	29	O	adolescents
5	32	33	O	up
6	35	36	O	to
7	38	40	O	the
8	42	46	O	adult
9	48	54	O	maximum
10	56	59	O	dose
11	61	62	O	of
12	64	66	O	300
13	68	69	O	mg
14	72	74	O	may
15	76	77	O	be
16	79	87	O	indicated
17	89	90	O	to
18	92	98	O	achieve
19	100	110	O	therapeutic
20	112	118	O	benefit
NULL

Fluvoxamine Maleate	1481	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	31
TABLE 4: COMPARISON OF MEAN (SD) FLUVOXAMINE PHARMACOKINETIC PARAMETERS BETWEEN CHILDREN, ADOLESCENTS, AND ADULTS Pharmacokinetic Parameter (body weight corrected) Dose = 200 mg/day (100 mg b.i.d.)
1	0	4	O	TABLE
2	6	6	O	4
3	7	7	O	:
4	9	18	O	COMPARISON
5	20	21	O	OF
6	23	26	O	MEAN
7	29	30	O	SD
8	33	43	O	XXXXXXXX
9	45	59	O	PHARMACOKINETIC
10	61	70	O	PARAMETERS
11	72	78	O	BETWEEN
12	80	87	O	CHILDREN
13	88	88	O	,
14	90	100	O	ADOLESCENTS
15	101	101	O	,
16	103	105	O	AND
17	107	112	O	ADULTS
18	114	128	O	Pharmacokinetic
19	130	138	O	Parameter
20	141	144	O	body
21	146	151	O	weight
22	153	161	O	corrected
23	164	167	O	Dose
24	169	169	O	=
25	171	173	O	200
26	175	176	O	mg
27	177	177	O	/
28	178	180	O	day
29	183	185	O	100
30	187	188	O	mg
31	190	194	O	b.i.d
NULL

Fluvoxamine Maleate	1482	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	91
Children(N = 10) Adolescent (N = 17) Adolescent (N = 13) Adult (N = 16) AUC 0-12 (ng*h/mL/kg) 155.1 (160.9) 43.9 (27.9) 69.6 (46.6) 59.4 (40.9) Cmax (ng/mL/kg) 14.8 (14.9) 4.2 (2.6) 6.7 (4.2) 5.7 (3.9) Cmin (ng/mL/kg) 11 (11.9) 2.9 (2) 4.8 (3.8) 4.6 (3.2) TABLE 5 COMPARISON OF MEAN (SD) FLUVOXAMINE PHARMACOKINETIC PARAMETERS BETWEEN MALE AND FEMALE CHILDREN (6 TO 11 YEARS) Pharmacokinetic Parameter (body weight corrected) Dose = 200 mg/day (100 mg b.i.d.)
1	0	9	O	Children(N
2	11	11	O	=
3	13	14	O	10
4	17	26	O	Adolescent
5	29	29	O	N
6	31	31	O	=
7	33	34	O	17
8	37	46	O	Adolescent
9	49	49	O	N
10	51	51	O	=
11	53	54	O	13
12	57	61	O	Adult
13	64	64	O	N
14	66	66	O	=
15	68	69	O	16
16	72	74	O	AUC
17	76	76	O	0
18	78	79	O	12
19	82	85	O	ng*h
20	86	86	O	/
21	87	88	O	mL
22	89	89	O	/
23	90	91	O	kg
24	94	98	O	155.1
25	101	105	O	160.9
26	108	111	O	43.9
27	114	117	O	27.9
28	120	123	O	69.6
29	126	129	O	46.6
30	132	135	O	59.4
31	138	141	O	40.9
32	144	147	O	Cmax
33	150	151	O	ng
34	152	152	O	/
35	153	154	O	mL
36	155	155	O	/
37	156	157	O	kg
38	160	163	O	14.8
39	166	169	O	14.9
40	172	174	O	4.2
41	177	179	O	2.6
42	182	184	O	6.7
43	187	189	O	4.2
44	192	194	O	5.7
45	197	199	O	3.9
46	202	205	O	Cmin
47	208	209	O	ng
48	210	210	O	/
49	211	212	O	mL
50	213	213	O	/
51	214	215	O	kg
52	218	219	O	11
53	222	225	O	11.9
54	228	230	O	2.9
55	233	233	O	2
56	236	238	O	4.8
57	241	243	O	3.8
58	246	248	O	4.6
59	251	253	O	3.2
60	256	260	O	TABLE
61	262	262	O	5
62	264	273	O	COMPARISON
63	275	276	O	OF
64	278	281	O	MEAN
65	284	285	O	SD
66	288	298	O	XXXXXXXX
67	300	314	O	PHARMACOKINETIC
68	316	325	O	PARAMETERS
69	327	333	O	BETWEEN
70	335	338	O	MALE
71	340	342	O	AND
72	344	349	O	FEMALE
73	351	358	O	CHILDREN
74	361	361	O	6
75	363	364	O	TO
76	366	367	O	11
77	369	373	O	YEARS
78	376	390	O	Pharmacokinetic
79	392	400	O	Parameter
80	403	406	O	body
81	408	413	O	weight
82	415	423	O	corrected
83	426	429	O	Dose
84	431	431	O	=
85	433	435	O	200
86	437	438	O	mg
87	439	439	O	/
88	440	442	O	day
89	445	447	O	100
90	449	450	O	mg
91	452	456	O	b.i.d
NULL

Fluvoxamine Maleate	1483	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	63
Male Children(N = 7) Female Children(N = 3) AUC 0-12 (ng*h/mL/kg) 95.8 (83.9) 293.5 (233) Cmax (ng/mL/kg) 9.1 (7.6) 28.1 (21.1) Cmin (ng/mL/kg) 6.6 (6.1) 21.2 (17.6) A cross study comparison (healthy subjects vs. patients with hepatic dysfunction) suggested a 30% decrease in fluvoxamine clearance in association with hepatic dysfunction.
1	0	3	O	Male
2	5	14	O	Children(N
3	16	16	O	=
4	18	18	O	7
5	21	26	O	Female
6	28	37	O	Children(N
7	39	39	O	=
8	41	41	O	3
9	44	46	O	AUC
10	48	48	O	0
11	50	51	O	12
12	54	57	O	ng*h
13	58	58	O	/
14	59	60	O	mL
15	61	61	O	/
16	62	63	O	kg
17	66	69	O	95.8
18	72	75	O	83.9
19	78	82	O	293.5
20	85	87	O	233
21	90	93	O	Cmax
22	96	97	O	ng
23	98	98	O	/
24	99	100	O	mL
25	101	101	O	/
26	102	103	O	kg
27	106	108	O	9.1
28	111	113	O	7.6
29	116	119	O	28.1
30	122	125	O	21.1
31	128	131	O	Cmin
32	134	135	O	ng
33	136	136	O	/
34	137	138	O	mL
35	139	139	O	/
36	140	141	O	kg
37	144	146	O	6.6
38	149	151	O	6.1
39	154	157	O	21.2
40	160	163	O	17.6
41	166	166	O	A
42	168	172	O	cross
43	174	178	O	study
44	180	189	O	comparison
45	192	198	O	healthy
46	200	207	O	subjects
47	209	210	O	vs
48	213	220	O	patients
49	222	225	O	with
50	227	233	O	hepatic
51	235	245	O	dysfunction
52	248	256	O	suggested
53	258	258	O	a
54	260	262	O	30%
55	264	271	O	decrease
56	273	274	O	in
57	276	286	O	XXXXXXXX
58	288	296	O	clearance
59	298	299	O	in
60	301	311	O	association
61	313	316	O	with
62	318	324	O	hepatic
63	326	336	O	dysfunction
NULL

Fluvoxamine Maleate	1484	34090-1	53664f8d-3a93-9f2b-daee-380707e4062c	46
The mean minimum plasma concentrations in renally impaired patients (creatinine clearance of 5 to 45 mL/min) after 4 and 6 weeks of treatment (50 mg b.i.d., N = 13) were comparable to each other, suggesting no accumulation of fluvoxamine in these patients.
1	0	2	O	The
2	4	7	O	mean
3	9	15	O	minimum
4	17	22	O	plasma
5	24	37	O	concentrations
6	39	40	O	in
7	42	48	O	renally
8	50	57	O	impaired
9	59	66	O	patients
10	69	78	O	creatinine
11	80	88	O	clearance
12	90	91	O	of
13	93	93	O	5
14	95	96	O	to
15	98	99	O	45
16	101	102	O	mL
17	103	103	O	/
18	104	106	O	min
19	109	113	O	after
20	115	115	O	4
21	117	119	O	and
22	121	121	O	6
23	123	127	O	weeks
24	129	130	O	of
25	132	140	O	treatment
26	143	144	O	50
27	146	147	O	mg
28	149	153	O	b.i.d
29	155	155	O	,
30	157	157	O	N
31	159	159	O	=
32	161	162	O	13
33	165	168	O	were
34	170	179	O	comparable
35	181	182	O	to
36	184	187	O	each
37	189	193	O	other
38	194	194	O	,
39	196	205	O	suggesting
40	207	208	O	no
41	210	221	O	accumulation
42	223	224	O	of
43	226	236	O	XXXXXXXX
44	238	239	O	in
45	241	245	O	these
46	247	254	O	patients
NULL

Gilenya	2871	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	7
Systemic ketoconazole: Monitor during concomitant use.
1	0	7	B-UNK	Systemic
2	9	20	L-UNK	ketoconazole
3	21	21	O	:
4	23	29	U-TRI	Monitor
5	31	36	O	during
6	38	48	O	concomitant
7	50	52	O	use
NULL

Gilenya	2872	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	16
Vaccines: Avoid live attenuated vaccines during, and for 2 months after stopping GILENYA treatment.
1	0	7	O	Vaccines
2	8	8	O	:
3	10	14	U-TRI	Avoid
4	16	19	B-UNK	live
5	21	30	I-UNK	attenuated
6	32	39	L-UNK	vaccines
7	41	46	O	during
8	47	47	O	,
9	49	51	O	and
10	53	55	O	for
11	57	57	O	2
12	59	64	O	months
13	66	70	O	after
14	72	79	O	stopping
15	81	87	O	XXXXXXXX
16	89	97	O	treatment
NULL

Gilenya	2873	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	15
GILENYA has not been studied in patients treated with drugs that prolong the QT interval.
1	0	6	O	XXXXXXXX
2	8	10	O	has
3	12	14	O	not
4	16	19	O	been
5	21	27	O	studied
6	29	30	O	in
7	32	39	O	patients
8	41	47	O	treated
9	49	52	O	with
10	54	58	O	drugs
11	60	63	O	that
12	65	71	O	prolong
13	73	75	O	the
14	77	78	O	QT
15	80	87	O	interval
NULL

Gilenya	2874	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
Drugs that prolong the QT interval have been associated with cases of torsades de pointes in patients with bradycardia.
1	0	4	B-DYN	Drugs
2	6	9	I-DYN	that
3	11	17	I-DYN	prolong
4	19	21	I-DYN	the
5	23	24	I-DYN	QT
6	26	33	L-DYN	interval
7	35	38	O	have
8	40	43	O	been
9	45	54	O	associated
10	56	59	O	with
11	61	65	O	cases
12	67	68	O	of
13	70	77	B-EFF	torsades
14	79	80	I-EFF	de
15	82	88	L-EFF	pointes
16	90	91	O	in
17	93	100	O	patients
18	102	105	O	with
19	107	117	O	bradycardia
D/1:13:1

Gilenya	2875	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	52
Since initiation of GILENYA treatment results in decreased heart rate and may prolong the QT interval, patients on QT prolonging drugs with a known risk of torsades de pointes (e.g., citalopram, chlorpromazine, haloperidol, methadone, erythromycin) should be monitored overnight with continuous ECG in a medical facility.
1	0	4	O	Since
2	6	15	O	initiation
3	17	18	O	of
4	20	26	O	XXXXXXXX
5	28	36	O	treatment
6	38	44	O	results
7	46	47	O	in
8	49	57	O	decreased
9	59	63	O	heart
10	65	68	O	rate
11	70	72	O	and
12	74	76	O	may
13	78	84	O	prolong
14	86	88	O	the
15	90	91	O	QT
16	93	100	O	interval
17	101	101	O	,
18	103	110	O	patients
19	112	113	O	on
20	115	116	B-DYN	QT
21	118	127	I-DYN	prolonging
22	129	133	I-DYN	drugs
23	135	138	I-DYN	with
24	140	140	I-DYN	a
25	142	146	I-DYN	known
26	148	151	I-DYN	risk
27	153	154	I-DYN	of
28	156	163	I-DYN	torsades
29	165	166	I-DYN	de
30	168	174	L-DYN	pointes
31	177	179	O	e.g
32	181	181	O	,
33	183	192	U-DYN	citalopram
34	193	193	O	,
35	195	208	U-DYN	chlorpromazine
36	209	209	O	,
37	211	221	U-DYN	haloperidol
38	222	222	O	,
39	224	232	U-DYN	methadone
40	233	233	O	,
41	235	246	U-DYN	erythromycin
42	249	254	O	should
43	256	257	O	be
44	259	267	O	monitored
45	269	277	O	overnight
46	279	282	O	with
47	284	293	O	continuous
48	295	297	O	ECG
49	299	300	O	in
50	302	302	O	a
51	304	310	O	medical
52	312	319	O	facility
NULL

Gilenya	2876	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	18
The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole.
1	0	2	O	The
2	4	8	O	blood
3	10	15	O	levels
4	17	18	O	of
5	20	29	O	XXXXXXXX
6	31	33	O	and
7	35	44	O	XXXXXXXX
8	46	54	O	phosphate
9	56	58	O	are
10	60	68	O	increased
11	70	71	O	by
12	73	75	O	1.7
13	77	80	O	fold
14	82	85	O	when
15	87	90	O	used
16	92	104	O	concomitantly
17	106	109	O	with
18	111	122	U-KIN	ketoconazole
K/18:C54355

Gilenya	2878	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	7
GILENYA reduces the immune response to vaccination.
1	0	6	O	XXXXXXXX
2	8	14	B-EFF	reduces
3	16	18	I-EFF	the
4	20	25	I-EFF	immune
5	27	34	I-EFF	response
6	36	37	I-EFF	to
7	39	49	L-EFF	vaccination
NULL

Gilenya	2879	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	18
Vaccination may be less effective during and for up to 2 months after discontinuation of treatment with GILENYA.
1	0	10	U-DYN	Vaccination
2	12	14	B-EFF	may
3	16	17	I-EFF	be
4	19	22	I-EFF	less
5	24	32	L-EFF	effective
6	34	39	O	during
7	41	43	O	and
8	45	47	O	for
9	49	50	O	up
10	52	53	O	to
11	55	55	O	2
12	57	62	O	months
13	64	68	O	after
14	70	84	O	discontinuation
15	86	87	O	of
16	89	97	O	treatment
17	99	102	O	with
18	104	110	O	XXXXXXXX
D/1:2:1

Gilenya	2880	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	22
Avoid the use of live attenuated vaccines during and for 2 months after treatment with GILENYA because of the risk of infection.
1	0	4	O	Avoid
2	6	8	O	the
3	10	12	O	use
4	14	15	O	of
5	17	20	B-DYN	live
6	22	31	I-DYN	attenuated
7	33	40	L-DYN	vaccines
8	42	47	O	during
9	49	51	O	and
10	53	55	O	for
11	57	57	O	2
12	59	64	O	months
13	66	70	O	after
14	72	80	O	treatment
15	82	85	O	with
16	87	93	O	XXXXXXXX
17	95	101	O	because
18	103	104	O	of
19	106	108	O	the
20	110	113	O	risk
21	115	116	O	of
22	118	126	U-EFF	infection
D/5:22:1

Gilenya	2881	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	46
Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA.
1	0	13	U-DYN	Antineoplastic
2	14	14	O	,
3	16	32	O	Immunosuppressive
4	33	33	O	,
5	35	36	O	or
6	38	43	O	Immune
7	45	54	O	Modulating
8	56	64	O	Therapies
9	66	79	O	Antineoplastic
10	80	80	O	,
11	82	87	O	immune
12	89	98	O	modulating
13	99	99	O	,
14	101	102	O	or
15	104	120	B-DYN	immunosuppressive
16	122	130	L-DYN	therapies
17	131	131	O	,
18	134	142	O	including
19	144	158	U-DYN	corticosteroids
20	161	163	O	are
21	165	172	O	expected
22	174	175	O	to
23	177	184	O	increase
24	186	188	O	the
25	190	193	O	risk
26	195	196	O	of
27	198	214	U-EFF	immunosuppression
28	215	215	O	,
29	217	219	O	and
30	221	223	O	the
31	225	228	O	risk
32	230	231	O	of
33	233	240	B-EFF	additive
34	242	247	I-EFF	immune
35	249	254	I-EFF	system
36	256	262	L-EFF	effects
37	264	267	O	must
38	269	270	O	be
39	272	281	O	considered
40	283	284	O	if
41	286	290	O	these
42	292	300	O	therapies
43	302	304	O	are
44	306	319	O	coadministered
45	321	324	O	with
46	326	332	O	XXXXXXXX
D/1:27:1 D/1:33:1 D/15:27:1 D/15:33:1 D/19:27:1 D/19:33:1

Gilenya	2882	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	38
When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA.
1	0	3	O	When
2	5	13	O	switching
3	15	18	O	from
4	20	24	B-DYN	drugs
5	26	29	I-DYN	with
6	31	39	I-DYN	prolonged
7	41	46	I-DYN	immune
8	48	54	L-DYN	effects
9	55	55	O	,
10	57	60	O	such
11	62	63	O	as
12	65	75	U-DYN	natalizumab
13	76	76	O	,
14	78	90	U-DYN	teriflunomide
15	92	93	O	or
16	95	106	U-DYN	mitoxantrone
17	107	107	O	,
18	109	111	O	the
19	113	120	O	duration
20	122	124	O	and
21	126	129	O	mode
22	131	132	O	of
23	134	139	O	action
24	141	142	O	of
25	144	148	O	these
26	150	154	O	drugs
27	156	159	O	must
28	161	162	O	be
29	164	173	O	considered
30	175	176	O	to
31	178	182	O	avoid
32	184	193	O	unintended
33	195	202	B-EFF	additive
34	204	220	I-EFF	immunosuppressive
35	222	228	L-EFF	effects
36	230	233	O	when
37	235	244	O	initiating
38	246	252	O	XXXXXXXX
D/12:33:1 D/14:33:1 D/16:33:1 D/4:33:1

Gilenya	2883	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	39
Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited.
1	0	9	O	Experience
2	11	14	O	with
3	16	22	O	XXXXXXXX
4	24	25	O	in
5	27	34	O	patients
6	36	44	O	receiving
7	46	55	O	concurrent
8	57	63	O	therapy
9	65	68	O	with
10	70	74	O	drugs
11	76	79	O	that
12	81	84	O	slow
13	86	88	O	the
14	90	94	O	heart
15	96	99	O	rate
16	101	102	O	or
17	104	119	O	atrioventricular
18	121	130	O	conduction
19	133	135	O	e.g
20	137	137	O	,
21	139	142	O	beta
22	144	151	O	blockers
23	152	152	O	,
24	154	160	O	digoxin
25	161	161	O	,
26	163	164	O	or
27	166	170	O	heart
28	172	175	O	rate
29	177	183	O	slowing
30	185	191	O	calcium
31	193	199	O	channel
32	201	208	O	blockers
33	210	213	O	such
34	215	216	O	as
35	218	226	O	diltiazem
36	228	229	O	or
37	231	239	O	verapamil
38	242	243	O	is
39	245	251	O	limited
NULL

Gilenya	2884	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	32
Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block.
1	0	6	O	Because
2	8	17	O	initiation
3	19	20	O	of
4	22	28	O	XXXXXXXX
5	30	38	O	treatment
6	40	42	O	may
7	44	49	O	result
8	51	52	O	in
9	54	55	O	an
10	57	66	O	additional
11	68	75	O	decrease
12	77	78	O	in
13	80	84	O	heart
14	86	89	O	rate
15	90	90	O	,
16	92	102	O	concomitant
17	104	106	O	use
18	108	109	O	of
19	111	115	O	these
20	117	121	O	drugs
21	123	128	O	during
22	130	136	O	XXXXXXXX
23	138	147	O	initiation
24	149	151	O	may
25	153	154	O	be
26	156	165	O	associated
27	167	170	O	with
28	172	177	O	severe
29	179	189	O	bradycardia
30	191	192	O	or
31	194	198	O	heart
32	200	204	O	block
NULL

Gilenya	2885	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	26
Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA.
1	0	3	O	Seek
2	5	10	O	advice
3	12	15	O	from
4	17	19	O	the
5	21	31	O	prescribing
6	33	41	O	physician
7	43	51	O	regarding
8	53	55	O	the
9	57	67	O	possibility
10	69	70	O	to
11	72	77	O	switch
12	79	80	O	to
13	82	86	O	drugs
14	88	91	O	that
15	93	94	O	do
16	96	98	O	not
17	100	103	O	slow
18	105	107	O	the
19	109	113	O	heart
20	115	118	O	rate
21	120	121	O	or
22	123	138	O	atrioventricular
23	140	149	O	conduction
24	151	156	O	before
25	158	167	O	initiating
26	169	175	O	XXXXXXXX
NULL

Gilenya	2886	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	15
Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose.
1	0	7	O	Patients
2	9	11	O	who
3	13	18	O	cannot
4	20	25	O	switch
5	26	26	O	,
6	28	33	O	should
7	35	38	O	have
8	40	48	O	overnight
9	50	59	O	continuous
10	61	63	O	ECG
11	65	74	O	monitoring
12	76	80	O	after
13	82	84	O	the
14	86	90	O	first
15	92	95	O	dose
NULL

Gilenya	2887	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	32
Because GILENYA reduces blood lymphocyte counts via redistribution in secondary lymphoid organs, peripheral blood lymphocyte counts cannot be utilized to evaluate the lymphocyte subset status of a patient treated with GILENYA.
1	0	6	O	Because
2	8	14	O	XXXXXXXX
3	16	22	O	reduces
4	24	28	O	blood
5	30	39	O	lymphocyte
6	41	46	O	counts
7	48	50	O	via
8	52	65	O	redistribution
9	67	68	O	in
10	70	78	O	secondary
11	80	87	O	lymphoid
12	89	94	O	organs
13	95	95	O	,
14	97	106	O	peripheral
15	108	112	O	blood
16	114	123	O	lymphocyte
17	125	130	O	counts
18	132	137	O	cannot
19	139	140	O	be
20	142	149	O	utilized
21	151	152	O	to
22	154	161	O	evaluate
23	163	165	O	the
24	167	176	O	lymphocyte
25	178	183	O	subset
26	185	190	O	status
27	192	193	O	of
28	195	195	O	a
29	197	203	O	patient
30	205	211	O	treated
31	213	216	O	with
32	218	224	O	XXXXXXXX
NULL

Gilenya	2888	34073-7	cc9e1c8c-0e2b-44e2-878b-27057f786be9	11
A recent CBC should be available before initiating treatment with GILENYA.
1	0	0	O	A
2	2	7	O	recent
3	9	11	O	CBC
4	13	18	O	should
5	20	21	O	be
6	23	31	O	available
7	33	38	O	before
8	40	49	O	initiating
9	51	59	O	treatment
10	61	64	O	with
11	66	72	O	XXXXXXXX
NULL

Gilenya	2889	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	13
Fingolimod is metabolized by sphingosine kinase to the active metabolite, fingolimod-phosphate.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	by
5	29	39	O	sphingosine
6	41	46	O	kinase
7	48	49	O	to
8	51	53	O	the
9	55	60	O	active
10	62	71	O	metabolite
11	72	72	O	,
12	74	83	O	XXXXXXXX
13	85	93	O	phosphate
NULL

Gilenya	2890	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	28
Fingolimod-phosphate is a sphingosine 1-phosphate receptor modulator, and binds with high affinity to sphingosine 1-phosphate receptors 1, 3, 4, and 5.
1	0	9	O	XXXXXXXX
2	11	19	O	phosphate
3	21	22	O	is
4	24	24	O	a
5	26	36	O	sphingosine
6	38	38	O	1
7	40	48	O	phosphate
8	50	57	O	receptor
9	59	67	O	modulator
10	68	68	O	,
11	70	72	O	and
12	74	78	O	binds
13	80	83	O	with
14	85	88	O	high
15	90	97	O	affinity
16	99	100	O	to
17	102	112	O	sphingosine
18	114	114	O	1
19	116	124	O	phosphate
20	126	134	O	receptors
21	136	136	O	1
22	137	137	O	,
23	139	139	O	3
24	140	140	O	,
25	142	142	O	4
26	143	143	O	,
27	145	147	O	and
28	149	149	O	5
NULL

Gilenya	2891	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	21
Fingolimod-phosphate blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.
1	0	9	O	XXXXXXXX
2	11	19	O	phosphate
3	21	26	O	blocks
4	28	30	O	the
5	32	39	O	capacity
6	41	42	O	of
7	44	54	O	lymphocytes
8	56	57	O	to
9	59	64	O	egress
10	66	69	O	from
11	71	75	O	lymph
12	77	81	O	nodes
13	82	82	O	,
14	84	91	O	reducing
15	93	95	O	the
16	97	102	O	number
17	104	105	O	of
18	107	117	O	lymphocytes
19	119	120	O	in
20	122	131	O	peripheral
21	133	137	O	blood
NULL

Gilenya	2892	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	26
The mechanism by which fingolimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	by
4	17	21	O	which
5	23	32	O	XXXXXXXX
6	34	39	O	exerts
7	41	51	O	therapeutic
8	53	59	O	effects
9	61	62	O	in
10	64	71	O	multiple
11	73	81	O	sclerosis
12	83	84	O	is
13	86	92	O	unknown
14	93	93	O	,
15	95	97	O	but
16	99	101	O	may
17	103	109	O	involve
18	111	119	O	reduction
19	121	122	O	of
20	124	133	O	lymphocyte
21	135	143	O	migration
22	145	148	O	into
23	150	152	O	the
24	154	160	O	central
25	162	168	O	nervous
26	170	175	O	system
NULL

Gilenya	2893	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	18
Heart Rate and Rhythm Fingolimod causes a transient reduction in heart rate and AV conduction at treatment initiation.
1	0	4	O	Heart
2	6	9	O	Rate
3	11	13	O	and
4	15	20	O	Rhythm
5	22	31	O	XXXXXXXX
6	33	38	O	causes
7	40	40	O	a
8	42	50	O	transient
9	52	60	O	reduction
10	62	63	O	in
11	65	69	O	heart
12	71	74	O	rate
13	76	78	O	and
14	80	81	O	AV
15	83	92	O	conduction
16	94	95	O	at
17	97	105	O	treatment
18	107	116	O	initiation
NULL

Gilenya	2894	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	22
Heart rate progressively increases after the first day, returning to baseline values within 1 month of the start of chronic treatment.
1	0	4	O	Heart
2	6	9	O	rate
3	11	23	O	progressively
4	25	33	O	increases
5	35	39	O	after
6	41	43	O	the
7	45	49	O	first
8	51	53	O	day
9	54	54	O	,
10	56	64	O	returning
11	66	67	O	to
12	69	76	O	baseline
13	78	83	O	values
14	85	90	O	within
15	92	92	O	1
16	94	98	O	month
17	100	101	O	of
18	103	105	O	the
19	107	111	O	start
20	113	114	O	of
21	116	122	O	chronic
22	124	132	O	treatment
NULL

Gilenya	2895	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	23
Autonomic responses of the heart, including diurnal variation of heart rate and response to exercise, are not affected by fingolimod treatment.
1	0	8	O	Autonomic
2	10	18	O	responses
3	20	21	O	of
4	23	25	O	the
5	27	31	O	heart
6	32	32	O	,
7	34	42	O	including
8	44	50	O	diurnal
9	52	60	O	variation
10	62	63	O	of
11	65	69	O	heart
12	71	74	O	rate
13	76	78	O	and
14	80	87	O	response
15	89	90	O	to
16	92	99	O	exercise
17	100	100	O	,
18	102	104	O	are
19	106	108	O	not
20	110	117	O	affected
21	119	120	O	by
22	122	131	O	XXXXXXXX
23	133	141	O	treatment
NULL

Gilenya	2896	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	11
Fingolimod treatment is not associated with a decrease in cardiac output.
1	0	9	O	XXXXXXXX
2	11	19	O	treatment
3	21	22	O	is
4	24	26	O	not
5	28	37	O	associated
6	39	42	O	with
7	44	44	O	a
8	46	53	O	decrease
9	55	56	O	in
10	58	64	O	cardiac
11	66	71	O	output
NULL

Gilenya	2897	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	57
Potential to Prolong the QT Interval In a thorough QT interval study of doses of 1.25 or 2.5 mg fingolimod at steady-state, when a negative chronotropic effect of fingolimod was still present, fingolimod treatment resulted in a prolongation of QTc, with the upper boundary of the 90% confidence interval (CI) of 14.0 msec.
1	0	8	O	Potential
2	10	11	O	to
3	13	19	O	Prolong
4	21	23	O	the
5	25	26	O	QT
6	28	35	O	Interval
7	37	38	O	In
8	40	40	O	a
9	42	49	O	thorough
10	51	52	O	QT
11	54	61	O	interval
12	63	67	O	study
13	69	70	O	of
14	72	76	O	doses
15	78	79	O	of
16	81	84	O	1.25
17	86	87	O	or
18	89	91	O	2.5
19	93	94	O	mg
20	96	105	O	XXXXXXXX
21	107	108	O	at
22	110	115	O	steady
23	117	121	O	state
24	122	122	O	,
25	124	127	O	when
26	129	129	O	a
27	131	138	O	negative
28	140	151	O	chronotropic
29	153	158	O	effect
30	160	161	O	of
31	163	172	O	XXXXXXXX
32	174	176	O	was
33	178	182	O	still
34	184	190	O	present
35	191	191	O	,
36	193	202	O	XXXXXXXX
37	204	212	O	treatment
38	214	221	O	resulted
39	223	224	O	in
40	226	226	O	a
41	228	239	O	prolongation
42	241	242	O	of
43	244	246	O	QTc
44	247	247	O	,
45	249	252	O	with
46	254	256	O	the
47	258	262	O	upper
48	264	271	O	boundary
49	273	274	O	of
50	276	278	O	the
51	280	282	O	90%
52	284	293	O	confidence
53	295	302	O	interval
54	305	306	O	CI
55	309	310	O	of
56	312	315	O	14.0
57	317	320	O	msec
NULL

Gilenya	2898	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	23
There is no consistent signal of increased incidence of QTc outliers, either absolute or change from baseline, associated with fingolimod treatment.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	21	O	consistent
5	23	28	O	signal
6	30	31	O	of
7	33	41	O	increased
8	43	51	O	incidence
9	53	54	O	of
10	56	58	O	QTc
11	60	67	O	outliers
12	68	68	O	,
13	70	75	O	either
14	77	84	O	absolute
15	86	87	O	or
16	89	94	O	change
17	96	99	O	from
18	101	108	O	baseline
19	109	109	O	,
20	111	120	O	associated
21	122	125	O	with
22	127	136	O	XXXXXXXX
23	138	146	O	treatment
NULL

Gilenya	2899	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	28
In MS studies, there was no clinically relevant prolongation of the QT interval, but patients at risk for QT prolongation were not included in clinical studies.
1	0	1	O	In
2	3	4	O	MS
3	6	12	O	studies
4	13	13	O	,
5	15	19	O	there
6	21	23	O	was
7	25	26	O	no
8	28	37	O	clinically
9	39	46	O	relevant
10	48	59	O	prolongation
11	61	62	O	of
12	64	66	O	the
13	68	69	O	QT
14	71	78	O	interval
15	79	79	O	,
16	81	83	O	but
17	85	92	O	patients
18	94	95	O	at
19	97	100	O	risk
20	102	104	O	for
21	106	107	O	QT
22	109	120	O	prolongation
23	122	125	O	were
24	127	129	O	not
25	131	138	O	included
26	140	141	O	in
27	143	150	O	clinical
28	152	158	O	studies
NULL

Gilenya	2900	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	41
Immune System Effects on Immune Cell Numbers in the Blood In a study in which 12 subjects received GILENYA 0.5 mg daily, the lymphocyte count decreased to approximately 60% of baseline within 4 to 6 hours after the first dose.
1	0	5	O	Immune
2	7	12	O	System
3	14	20	O	Effects
4	22	23	O	on
5	25	30	O	Immune
6	32	35	O	Cell
7	37	43	O	Numbers
8	45	46	O	in
9	48	50	O	the
10	52	56	O	Blood
11	58	59	O	In
12	61	61	O	a
13	63	67	O	study
14	69	70	O	in
15	72	76	O	which
16	78	79	O	12
17	81	88	O	subjects
18	90	97	O	received
19	99	105	O	XXXXXXXX
20	107	109	O	0.5
21	111	112	O	mg
22	114	118	O	daily
23	119	119	O	,
24	121	123	O	the
25	125	134	O	lymphocyte
26	136	140	O	count
27	142	150	O	decreased
28	152	153	O	to
29	155	167	O	approximately
30	169	171	O	60%
31	173	174	O	of
32	176	183	O	baseline
33	185	190	O	within
34	192	192	O	4
35	194	195	O	to
36	197	197	O	6
37	199	203	O	hours
38	205	209	O	after
39	211	213	O	the
40	215	219	O	first
41	221	224	O	dose
NULL

Gilenya	2901	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	32
With continued daily dosing, the lymphocyte count continued to decrease over a 2-week period, reaching a nadir count of approximately 500 cells/mcL or approximately 30% of baseline.
1	0	3	O	With
2	5	13	O	continued
3	15	19	O	daily
4	21	26	O	dosing
5	27	27	O	,
6	29	31	O	the
7	33	42	O	lymphocyte
8	44	48	O	count
9	50	58	O	continued
10	60	61	O	to
11	63	70	O	decrease
12	72	75	O	over
13	77	77	O	a
14	79	79	O	2
15	81	84	O	week
16	86	91	O	period
17	92	92	O	,
18	94	101	O	reaching
19	103	103	O	a
20	105	109	O	nadir
21	111	115	O	count
22	117	118	O	of
23	120	132	O	approximately
24	134	136	O	500
25	138	142	O	cells
26	143	143	O	/
27	144	146	O	mcL
28	148	149	O	or
29	151	163	O	approximately
30	165	167	O	30%
31	169	170	O	of
32	172	179	O	baseline
NULL

Gilenya	2902	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	43
In a placebo-controlled study in 1272 MS patients (of whom 425 received fingolimod 0.5 mg daily and 418 received placebo), 18% (N=78) of patients on fingolimod 0.5 mg reached a nadir of <200 cells/mcL on at least 1 occasion.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	placebo
4	13	22	O	controlled
5	24	28	O	study
6	30	31	O	in
7	33	36	O	1272
8	38	39	O	MS
9	41	48	O	patients
10	51	52	O	of
11	54	57	O	whom
12	59	61	O	425
13	63	70	O	received
14	72	81	O	XXXXXXXX
15	83	85	O	0.5
16	87	88	O	mg
17	90	94	O	daily
18	96	98	O	and
19	100	102	O	418
20	104	111	O	received
21	113	119	O	placebo
22	121	121	O	,
23	123	125	O	18%
24	128	131	O	N=78
25	134	135	O	of
26	137	144	O	patients
27	146	147	O	on
28	149	158	O	XXXXXXXX
29	160	162	O	0.5
30	164	165	O	mg
31	167	173	O	reached
32	175	175	O	a
33	177	181	O	nadir
34	183	184	O	of
35	186	189	O	<200
36	191	195	O	cells
37	196	196	O	/
38	197	199	O	mcL
39	201	202	O	on
40	204	205	O	at
41	207	211	O	least
42	213	213	O	1
43	215	222	O	occasion
NULL

Gilenya	2903	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	12
No patient on placebo reached a nadir of <200 cells/mcL.
1	0	1	O	No
2	3	9	O	patient
3	11	12	O	on
4	14	20	O	placebo
5	22	28	O	reached
6	30	30	O	a
7	32	36	O	nadir
8	38	39	O	of
9	41	44	O	<200
10	46	50	O	cells
11	51	51	O	/
12	52	54	O	mcL
NULL

Gilenya	2904	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	14
Low lymphocyte counts are maintained with chronic daily dosing of GILENYA 0.5 mg daily.
1	0	2	O	Low
2	4	13	O	lymphocyte
3	15	20	O	counts
4	22	24	O	are
5	26	35	O	maintained
6	37	40	O	with
7	42	48	O	chronic
8	50	54	O	daily
9	56	61	O	dosing
10	63	64	O	of
11	66	72	O	XXXXXXXX
12	74	76	O	0.5
13	78	79	O	mg
14	81	85	O	daily
NULL

Gilenya	2905	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	17
Chronic fingolimod dosing leads to a mild decrease in the neutrophil count to approximately 80% of baseline.
1	0	6	O	Chronic
2	8	17	O	XXXXXXXX
3	19	24	O	dosing
4	26	30	O	leads
5	32	33	O	to
6	35	35	O	a
7	37	40	O	mild
8	42	49	O	decrease
9	51	52	O	in
10	54	56	O	the
11	58	67	O	neutrophil
12	69	73	O	count
13	75	76	O	to
14	78	90	O	approximately
15	92	94	O	80%
16	96	97	O	of
17	99	106	O	baseline
NULL

Gilenya	2906	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	23
Peripheral lymphocyte count increases are evident within days of stopping fingolimod treatment and typically normal counts are reached within 1 to 2 months.
1	0	9	O	Peripheral
2	11	20	O	lymphocyte
3	22	26	O	count
4	28	36	O	increases
5	38	40	O	are
6	42	48	O	evident
7	50	55	O	within
8	57	60	O	days
9	62	63	O	of
10	65	72	O	stopping
11	74	83	O	XXXXXXXX
12	85	93	O	treatment
13	95	97	O	and
14	99	107	O	typically
15	109	114	O	normal
16	116	121	O	counts
17	123	125	O	are
18	127	133	O	reached
19	135	140	O	within
20	142	142	O	1
21	144	145	O	to
22	147	147	O	2
23	149	154	O	months
NULL

Gilenya	2907	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	17
Effect on Antibody Response GILENYA reduces the immune response to vaccination, as evaluated in 2 studies.
1	0	5	O	Effect
2	7	8	O	on
3	10	17	O	Antibody
4	19	26	O	Response
5	28	34	O	XXXXXXXX
6	36	42	B-EFF	reduces
7	44	46	I-EFF	the
8	48	53	I-EFF	immune
9	55	62	I-EFF	response
10	64	65	I-EFF	to
11	67	77	L-EFF	vaccination
12	78	78	O	,
13	80	81	O	as
14	83	91	O	evaluated
15	93	94	O	in
16	96	96	O	2
17	98	104	O	studies
NULL

Gilenya	2908	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	39
In the first study, the immunogenicity of keyhole limpet hemocyanin (KLH) and pneumococcal polysaccharide vaccine (PPV-23) immunization were assessed by IgM and IgG titers in a steady-state, randomized, placebo-controlled study in healthy volunteers.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	first
4	13	17	O	study
5	18	18	O	,
6	20	22	O	the
7	24	37	O	immunogenicity
8	39	40	O	of
9	42	48	O	keyhole
10	50	55	O	limpet
11	57	66	O	hemocyanin
12	69	71	O	KLH
13	74	76	O	and
14	78	89	O	pneumococcal
15	91	104	O	polysaccharide
16	106	112	O	vaccine
17	115	117	O	PPV
18	119	120	O	23
19	123	134	O	immunization
20	136	139	O	were
21	141	148	O	assessed
22	150	151	O	by
23	153	155	O	IgM
24	157	159	O	and
25	161	163	O	IgG
26	165	170	O	titers
27	172	173	O	in
28	175	175	O	a
29	177	182	O	steady
30	184	188	O	state
31	189	189	O	,
32	191	200	O	randomized
33	201	201	O	,
34	203	209	O	placebo
35	211	220	O	controlled
36	222	226	O	study
37	228	229	O	in
38	231	237	O	healthy
39	239	248	O	volunteers
NULL

Gilenya	2909	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	30
Compared to placebo, antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV-23, respectively, in subjects on GILENYA 0.5 mg.
1	0	7	O	Compared
2	9	10	O	to
3	12	18	O	placebo
4	19	19	O	,
5	21	27	O	antigen
6	29	36	O	specific
7	38	40	O	IgM
8	42	47	O	titers
9	49	52	O	were
10	54	62	O	decreased
11	64	65	O	by
12	67	69	O	91%
13	71	73	O	and
14	75	77	O	25%
15	79	80	O	in
16	82	89	O	response
17	91	92	O	to
18	94	96	O	KLH
19	98	100	O	and
20	102	104	O	PPV
21	106	107	O	23
22	108	108	O	,
23	110	121	O	respectively
24	122	122	O	,
25	124	125	O	in
26	127	134	O	subjects
27	136	137	O	on
28	139	145	O	XXXXXXXX
29	147	149	O	0.5
30	151	152	O	mg
NULL

Gilenya	2910	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	31
Similarly, IgG titers were decreased by 45% and 50%, in response to KLH and PPV-23, respectively, in subjects on GILENYA 0.5 mg daily compared to placebo.
1	0	8	O	Similarly
2	9	9	O	,
3	11	13	O	IgG
4	15	20	O	titers
5	22	25	O	were
6	27	35	O	decreased
7	37	38	O	by
8	40	42	O	45%
9	44	46	O	and
10	48	50	O	50%
11	51	51	O	,
12	53	54	O	in
13	56	63	O	response
14	65	66	O	to
15	68	70	O	KLH
16	72	74	O	and
17	76	78	O	PPV
18	80	81	O	23
19	82	82	O	,
20	84	95	O	respectively
21	96	96	O	,
22	98	99	O	in
23	101	108	O	subjects
24	110	111	O	on
25	113	119	O	XXXXXXXX
26	121	123	O	0.5
27	125	126	O	mg
28	128	132	O	daily
29	134	141	O	compared
30	143	144	O	to
31	146	152	O	placebo
NULL

Gilenya	2911	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	61
The responder rate for GILENYA 0.5 mg as measured by the number of subjects with a >4-fold increase in KLH IgG was comparable to placebo and 25% lower for PPV-23 IgG, while the number of subjects with a >4 fold increase in KLH and PPV-23 IgM was 75% and 40% lower, respectively, compared to placebo.
1	0	2	O	The
2	4	12	O	responder
3	14	17	O	rate
4	19	21	O	for
5	23	29	O	XXXXXXXX
6	31	33	O	0.5
7	35	36	O	mg
8	38	39	O	as
9	41	48	O	measured
10	50	51	O	by
11	53	55	O	the
12	57	62	O	number
13	64	65	O	of
14	67	74	O	subjects
15	76	79	O	with
16	81	81	O	a
17	83	84	O	>4
18	86	89	O	fold
19	91	98	O	increase
20	100	101	O	in
21	103	105	O	KLH
22	107	109	O	IgG
23	111	113	O	was
24	115	124	O	comparable
25	126	127	O	to
26	129	135	O	placebo
27	137	139	O	and
28	141	143	O	25%
29	145	149	O	lower
30	151	153	O	for
31	155	157	O	PPV
32	159	160	O	23
33	162	164	O	IgG
34	165	165	O	,
35	167	171	O	while
36	173	175	O	the
37	177	182	O	number
38	184	185	O	of
39	187	194	O	subjects
40	196	199	O	with
41	201	201	O	a
42	203	204	O	>4
43	206	209	O	fold
44	211	218	O	increase
45	220	221	O	in
46	223	225	O	KLH
47	227	229	O	and
48	231	233	O	PPV
49	235	236	O	23
50	238	240	O	IgM
51	242	244	O	was
52	246	248	O	75%
53	250	252	O	and
54	254	256	O	40%
55	258	262	O	lower
56	263	263	O	,
57	265	276	O	respectively
58	277	277	O	,
59	279	286	O	compared
60	288	289	O	to
61	291	297	O	placebo
NULL

Gilenya	2912	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	31
The capacity to mount a skin delayed-type hypersensitivity reaction to Candida and tetanus toxoid was decreased by approximately 30% in subjects on GILENYA 0.5 mg daily, compared to placebo.
1	0	2	O	The
2	4	11	O	capacity
3	13	14	O	to
4	16	20	O	mount
5	22	22	O	a
6	24	27	O	skin
7	29	35	O	delayed
8	37	40	O	type
9	42	57	O	hypersensitivity
10	59	66	O	reaction
11	68	69	O	to
12	71	77	O	Candida
13	79	81	O	and
14	83	89	O	tetanus
15	91	96	O	toxoid
16	98	100	O	was
17	102	110	O	decreased
18	112	113	O	by
19	115	127	O	approximately
20	129	131	O	30%
21	133	134	O	in
22	136	143	O	subjects
23	145	146	O	on
24	148	154	O	XXXXXXXX
25	156	158	O	0.5
26	160	161	O	mg
27	163	167	O	daily
28	168	168	O	,
29	170	177	O	compared
30	179	180	O	to
31	182	188	O	placebo
NULL

Gilenya	2913	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	16
Immunologic responses were further decreased with fingolimod 1.25 mg (a dose higher than recommended in MS).
1	0	10	O	Immunologic
2	12	20	O	responses
3	22	25	O	were
4	27	33	O	further
5	35	43	O	decreased
6	45	48	O	with
7	50	59	O	XXXXXXXX
8	61	64	O	1.25
9	66	67	O	mg
10	70	70	O	a
11	72	75	O	dose
12	77	82	O	higher
13	84	87	O	than
14	89	99	O	recommended
15	101	102	O	in
16	104	105	O	MS
NULL

Gilenya	2914	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	39
In the second study, the immunogenicity of Northern hemisphere seasonal influenza and tetanus toxoid vaccination was assessed in a 12-week steady-state, randomized, placebo-controlled study of GILENYA 0.5 mg in multiple sclerosis patients (n=136).
1	0	1	O	In
2	3	5	O	the
3	7	12	O	second
4	14	18	O	study
5	19	19	O	,
6	21	23	O	the
7	25	38	O	immunogenicity
8	40	41	O	of
9	43	50	O	Northern
10	52	61	O	hemisphere
11	63	70	O	seasonal
12	72	80	O	influenza
13	82	84	O	and
14	86	92	O	tetanus
15	94	99	O	toxoid
16	101	111	O	vaccination
17	113	115	O	was
18	117	124	O	assessed
19	126	127	O	in
20	129	129	O	a
21	131	132	O	12
22	134	137	O	week
23	139	144	O	steady
24	146	150	O	state
25	151	151	O	,
26	153	162	O	randomized
27	163	163	O	,
28	165	171	O	placebo
29	173	182	O	controlled
30	184	188	O	study
31	190	191	O	of
32	193	199	O	XXXXXXXX
33	201	203	O	0.5
34	205	206	O	mg
35	208	209	O	in
36	211	218	O	multiple
37	220	228	O	sclerosis
38	230	237	O	patients
39	240	244	O	n=136
NULL

Gilenya	2915	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	41
The responder rate 3 weeks after vaccination, defined as seroconversion or a >4-fold increase in antibody directed against at least 1 of the 3 influenza strains, was 54% for GILENYA 0.5 mg and 85% in the placebo group.
1	0	2	O	The
2	4	12	O	responder
3	14	17	O	rate
4	19	19	O	3
5	21	25	O	weeks
6	27	31	O	after
7	33	43	O	vaccination
8	44	44	O	,
9	46	52	O	defined
10	54	55	O	as
11	57	70	O	seroconversion
12	72	73	O	or
13	75	75	O	a
14	77	78	O	>4
15	80	83	O	fold
16	85	92	O	increase
17	94	95	O	in
18	97	104	O	antibody
19	106	113	O	directed
20	115	121	O	against
21	123	124	O	at
22	126	130	O	least
23	132	132	O	1
24	134	135	O	of
25	137	139	O	the
26	141	141	O	3
27	143	151	O	influenza
28	153	159	O	strains
29	160	160	O	,
30	162	164	O	was
31	166	168	O	54%
32	170	172	O	for
33	174	180	O	XXXXXXXX
34	182	184	O	0.5
35	186	187	O	mg
36	189	191	O	and
37	193	195	O	85%
38	197	198	O	in
39	200	202	O	the
40	204	210	O	placebo
41	212	216	O	group
NULL

Gilenya	2916	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	34
The responder rate 3 weeks after vaccination, defined as seroconversion or a >4-fold increase in antibody directed against tetanus toxoid was 40% for GILENYA 0.5 mg and 61% in the placebo group.
1	0	2	O	The
2	4	12	O	responder
3	14	17	O	rate
4	19	19	O	3
5	21	25	O	weeks
6	27	31	O	after
7	33	43	O	vaccination
8	44	44	O	,
9	46	52	O	defined
10	54	55	O	as
11	57	70	O	seroconversion
12	72	73	O	or
13	75	75	O	a
14	77	78	O	>4
15	80	83	O	fold
16	85	92	O	increase
17	94	95	O	in
18	97	104	O	antibody
19	106	113	O	directed
20	115	121	O	against
21	123	129	O	tetanus
22	131	136	O	toxoid
23	138	140	O	was
24	142	144	O	40%
25	146	148	O	for
26	150	156	O	XXXXXXXX
27	158	160	O	0.5
28	162	163	O	mg
29	165	167	O	and
30	169	171	O	61%
31	173	174	O	in
32	176	178	O	the
33	180	186	O	placebo
34	188	192	O	group
NULL

Gilenya	2917	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	22
Pulmonary Function Single fingolimod doses >5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance.
1	0	8	O	Pulmonary
2	10	17	O	Function
3	19	24	O	Single
4	26	35	O	XXXXXXXX
5	37	41	O	doses
6	43	44	O	>5
7	46	47	O	mg
8	50	51	O	10
9	53	56	O	fold
10	58	60	O	the
11	62	72	O	recommended
12	74	77	O	dose
13	80	82	O	are
14	84	93	O	associated
15	95	98	O	with
16	100	100	O	a
17	102	105	O	dose
18	107	115	O	dependent
19	117	124	O	increase
20	126	127	O	in
21	129	134	O	airway
22	136	145	O	resistance
NULL

Gilenya	2918	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	35
In a14-day study of 0.5, 1.25, or 5 mg/day, fingolimodwas not associated with impaired oxygenation or oxygen desaturation with exercise or an increase in airway responsiveness to methacholine.
1	0	1	O	In
2	3	5	O	a14
3	7	9	O	day
4	11	15	O	study
5	17	18	O	of
6	20	22	O	0.5
7	23	23	O	,
8	25	28	O	1.25
9	29	29	O	,
10	31	32	O	or
11	34	34	O	5
12	36	37	O	mg
13	38	38	O	/
14	39	41	O	day
15	42	42	O	,
16	44	53	O	XXXXXXXX
17	54	56	O	was
18	58	60	O	not
19	62	71	O	associated
20	73	76	O	with
21	78	85	O	impaired
22	87	97	O	oxygenation
23	99	100	O	or
24	102	107	O	oxygen
25	109	120	O	desaturation
26	122	125	O	with
27	127	134	O	exercise
28	136	137	O	or
29	139	140	O	an
30	142	149	O	increase
31	151	152	O	in
32	154	159	O	airway
33	161	174	O	responsiveness
34	176	177	O	to
35	179	190	O	methacholine
NULL

Gilenya	2919	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	13
Subjects on fingolimod treatment had a normal bronchodilator response to inhaled beta-agonists.
1	0	7	O	Subjects
2	9	10	O	on
3	12	21	O	XXXXXXXX
4	23	31	O	treatment
5	33	35	O	had
6	37	37	O	a
7	39	44	O	normal
8	46	59	O	bronchodilator
9	61	68	O	response
10	70	71	O	to
11	73	79	O	inhaled
12	81	84	O	beta
13	86	93	O	agonists
NULL

Gilenya	2920	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	25
In a 14-day placebo-controlled study of patients with moderate asthma, no effect was seen for GILENYA 0.5 mg (recommended dose in MS).
1	0	1	O	In
2	3	3	O	a
3	5	6	O	14
4	8	10	O	day
5	12	18	O	placebo
6	20	29	O	controlled
7	31	35	O	study
8	37	38	O	of
9	40	47	O	patients
10	49	52	O	with
11	54	61	O	moderate
12	63	68	O	asthma
13	69	69	O	,
14	71	72	O	no
15	74	79	O	effect
16	81	83	O	was
17	85	88	O	seen
18	90	92	O	for
19	94	100	O	XXXXXXXX
20	102	104	O	0.5
21	106	107	O	mg
22	110	120	O	recommended
23	122	125	O	dose
24	127	128	O	in
25	130	131	O	MS
NULL

Gilenya	2921	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	33
A 10% reduction in mean FEV1 at 6 hours after dosing was observed in patients receiving fingolimod 1.25 mg (a dose higher than recommended for use in MS) on Day 10 of treatment.
1	0	0	O	A
2	2	4	O	10%
3	6	14	O	reduction
4	16	17	O	in
5	19	22	O	mean
6	24	27	O	FEV1
7	29	30	O	at
8	32	32	O	6
9	34	38	O	hours
10	40	44	O	after
11	46	51	O	dosing
12	53	55	O	was
13	57	64	O	observed
14	66	67	O	in
15	69	76	O	patients
16	78	86	O	receiving
17	88	97	O	XXXXXXXX
18	99	102	O	1.25
19	104	105	O	mg
20	108	108	O	a
21	110	113	O	dose
22	115	120	O	higher
23	122	125	O	than
24	127	137	O	recommended
25	139	141	O	for
26	143	145	O	use
27	147	148	O	in
28	150	151	O	MS
29	154	155	O	on
30	157	159	O	Day
31	161	162	O	10
32	164	165	O	of
33	167	175	O	treatment
NULL

Gilenya	2922	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
Fingolimod 1.25 mg was associated with a 5-fold increase in the use of rescue short acting beta-agonists.
1	0	9	O	XXXXXXXX
2	11	14	O	1.25
3	16	17	O	mg
4	19	21	O	was
5	23	32	O	associated
6	34	37	O	with
7	39	39	O	a
8	41	41	O	5
9	43	46	O	fold
10	48	55	O	increase
11	57	58	O	in
12	60	62	O	the
13	64	66	O	use
14	68	69	O	of
15	71	76	O	rescue
16	78	82	O	short
17	84	89	O	acting
18	91	94	O	beta
19	96	103	O	agonists
NULL

Gilenya	2923	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	8
Absorption The Tmaxof fingolimod is 12-16 hours.
1	0	9	O	Absorption
2	11	13	O	The
3	15	20	O	Tmaxof
4	22	31	O	XXXXXXXX
5	33	34	O	is
6	36	37	O	12
7	39	40	O	16
8	42	46	O	hours
NULL

Gilenya	2924	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	6
The apparent absolute oral bioavailabilityis 93%.
1	0	2	O	The
2	4	11	O	apparent
3	13	20	O	absolute
4	22	25	O	oral
5	27	43	O	bioavailabilityis
6	45	47	O	93%
NULL

Gilenya	2925	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	14
Food intake does not alter Cmax or exposure (AUC) of fingolimod or fingolimod-phosphate.
1	0	3	O	Food
2	5	10	O	intake
3	12	15	O	does
4	17	19	O	not
5	21	25	O	alter
6	27	30	O	Cmax
7	32	33	O	or
8	35	42	O	exposure
9	45	47	O	AUC
10	50	51	O	of
11	53	62	O	XXXXXXXX
12	64	65	O	or
13	67	76	O	XXXXXXXX
14	78	86	O	phosphate
NULL

Gilenya	2926	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	9
Therefore GILENYA may be taken without regard to meals.
1	0	8	O	Therefore
2	10	16	O	XXXXXXXX
3	18	20	O	may
4	22	23	O	be
5	25	29	O	taken
6	31	37	O	without
7	39	44	O	regard
8	46	47	O	to
9	49	53	O	meals
NULL

Gilenya	2927	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	27
Steady-stateblood concentrations are reached within 1 to 2months following once-daily administration and steady-state levels are approximately 10-fold greater than with the initial dose.
1	0	5	O	Steady
2	7	16	O	stateblood
3	18	31	O	concentrations
4	33	35	O	are
5	37	43	O	reached
6	45	50	O	within
7	52	52	O	1
8	54	55	O	to
9	57	63	O	2months
10	65	73	O	following
11	75	78	O	once
12	80	84	O	daily
13	86	99	O	administration
14	101	103	O	and
15	105	110	O	steady
16	112	116	O	state
17	118	123	O	levels
18	125	127	O	are
19	129	141	O	approximately
20	143	144	O	10
21	146	149	O	fold
22	151	157	O	greater
23	159	162	O	than
24	164	167	O	with
25	169	171	O	the
26	173	179	O	initial
27	181	184	O	dose
NULL

Gilenya	2928	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	9
Distribution Fingolimod highly (86%) distributes in red blood cells.
1	0	11	O	Distribution
2	13	22	O	XXXXXXXX
3	24	29	O	highly
4	32	34	O	86%
5	37	47	O	distributes
6	49	50	O	in
7	52	54	O	red
8	56	60	O	blood
9	62	66	O	cells
NULL

Gilenya	2929	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	11
Fingolimod-phosphate has a smaller uptake in blood cells of <17%.
1	0	9	O	XXXXXXXX
2	11	19	O	phosphate
3	21	23	O	has
4	25	25	O	a
5	27	33	O	smaller
6	35	40	O	uptake
7	42	43	O	in
8	45	49	O	blood
9	51	55	O	cells
10	57	58	O	of
11	60	63	O	<17%
NULL

Gilenya	2930	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	8
Fingolimod and fingolimod-phosphate are >99.7% protein bound.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	24	O	XXXXXXXX
4	26	34	O	phosphate
5	36	38	O	are
6	40	45	O	>99.7%
7	47	53	O	protein
8	55	59	O	bound
NULL

Gilenya	2931	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	14
Fingolimod and fingolimod-phosphate protein binding is not altered by renal or hepatic impairment.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	24	O	XXXXXXXX
4	26	34	O	phosphate
5	36	42	O	protein
6	44	50	O	binding
7	52	53	O	is
8	55	57	O	not
9	59	65	O	altered
10	67	68	O	by
11	70	74	O	renal
12	76	77	O	or
13	79	85	O	hepatic
14	87	96	O	impairment
NULL

Gilenya	2932	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	80
Fingolimod is extensively distributed to body tissueswith a volume of distribution of about 1200*260 L. Metabolism The biotransformation of fingolimod in humans occurs by 3 main pathways: by reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod-phosphate, by oxidative biotransformation catalyzed mainly by the cytochrome P450 4F2 (CYP4F2) and possibly other CYP4F isoenzymes with subsequent fatty acid-like degradation to inactive metabolites, and by formation of pharmacologically inactive non-polar ceramide analogs of fingolimod.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	distributed
5	38	39	O	to
6	41	44	O	body
7	46	56	O	tissueswith
8	58	58	O	a
9	60	65	O	volume
10	67	68	O	of
11	70	81	O	distribution
12	83	84	O	of
13	86	90	O	about
14	92	99	O	1200*260
15	101	101	O	L
16	104	113	O	Metabolism
17	115	117	O	The
18	119	135	O	biotransformation
19	137	138	O	of
20	140	149	O	XXXXXXXX
21	151	152	O	in
22	154	159	O	humans
23	161	166	O	occurs
24	168	169	O	by
25	171	171	O	3
26	173	176	O	main
27	178	185	O	pathways
28	186	186	O	:
29	188	189	O	by
30	191	200	O	reversible
31	202	216	O	stereoselective
32	218	232	O	phosphorylation
33	234	235	O	to
34	237	239	O	the
35	241	257	O	pharmacologically
36	259	264	O	active
37	267	267	O	S
38	270	279	O	enantiomer
39	281	282	O	of
40	284	293	O	XXXXXXXX
41	295	303	O	phosphate
42	304	304	O	,
43	306	307	O	by
44	309	317	O	oxidative
45	319	335	O	biotransformation
46	337	345	O	catalyzed
47	347	352	O	mainly
48	354	355	O	by
49	357	359	O	the
50	361	370	O	cytochrome
51	372	375	O	P450
52	377	379	O	4F2
53	382	387	O	CYP4F2
54	390	392	O	and
55	394	401	O	possibly
56	403	407	O	other
57	409	413	O	CYP4F
58	415	424	O	isoenzymes
59	426	429	O	with
60	431	440	O	subsequent
61	442	446	O	fatty
62	448	451	O	acid
63	453	456	O	like
64	458	468	O	degradation
65	470	471	O	to
66	473	480	O	inactive
67	482	492	O	metabolites
68	493	493	O	,
69	495	497	O	and
70	499	500	O	by
71	502	510	O	formation
72	512	513	O	of
73	515	531	O	pharmacologically
74	533	540	O	inactive
75	542	544	O	non
76	546	550	O	polar
77	552	559	O	ceramide
78	561	567	O	analogs
79	569	570	O	of
80	572	581	O	XXXXXXXX
NULL

Gilenya	2933	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
Inhibitors or inducers of CYP4F2 and possibly other CYP4F isozymes might alter the exposure of fingolimod or fingolimod-phosphate.
1	0	9	O	Inhibitors
2	11	12	O	or
3	14	21	B-UNK	inducers
4	23	24	I-UNK	of
5	26	31	L-UNK	CYP4F2
6	33	35	O	and
7	37	44	O	possibly
8	46	50	O	other
9	52	56	O	CYP4F
10	58	65	O	isozymes
11	67	71	O	might
12	73	77	B-TRI	alter
13	79	81	I-TRI	the
14	83	90	L-TRI	exposure
15	92	93	O	of
16	95	104	O	XXXXXXXX
17	106	107	O	or
18	109	118	O	XXXXXXXX
19	120	128	O	phosphate
NULL

Gilenya	2934	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	21
In vitro studies in hepatocytes indicated that CYP3A4 may contribute to fingolimod metabolism in the case of strong induction of CYP3A4.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	30	O	hepatocytes
6	32	40	O	indicated
7	42	45	O	that
8	47	52	O	CYP3A4
9	54	56	O	may
10	58	67	O	contribute
11	69	70	O	to
12	72	81	O	XXXXXXXX
13	83	92	O	metabolism
14	94	95	O	in
15	97	99	O	the
16	101	104	O	case
17	106	107	O	of
18	109	114	O	strong
19	116	124	O	induction
20	126	127	O	of
21	129	134	O	CYP3A4
NULL

Gilenya	2935	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	63
Following single oral administration of [14C] fingolimod, the major fingolimod-related components in blood, as judged from their contribution to the AUC up to 816 hours post-dose of total radiolabeled components, are fingolimod itself (23.3%), fingolimod-phosphate (10.3%), and inactive metabolites [M3 carboxylic acid metabolite (8.3%), M29 ceramide metabolite (8.9%), and M30 ceramide metabolite (7.3%)].
1	0	8	O	Following
2	10	15	O	single
3	17	20	O	oral
4	22	35	O	administration
5	37	38	O	of
6	41	43	O	14C
7	46	55	O	XXXXXXXX
8	56	56	O	,
9	58	60	O	the
10	62	66	O	major
11	68	77	O	XXXXXXXX
12	79	85	O	related
13	87	96	O	components
14	98	99	O	in
15	101	105	O	blood
16	106	106	O	,
17	108	109	O	as
18	111	116	O	judged
19	118	121	O	from
20	123	127	O	their
21	129	140	O	contribution
22	142	143	O	to
23	145	147	O	the
24	149	151	O	AUC
25	153	154	O	up
26	156	157	O	to
27	159	161	O	816
28	163	167	O	hours
29	169	172	O	post
30	174	177	O	dose
31	179	180	O	of
32	182	186	O	total
33	188	199	O	radiolabeled
34	201	210	O	components
35	211	211	O	,
36	213	215	O	are
37	217	226	O	XXXXXXXX
38	228	233	O	itself
39	236	240	O	23.3%
40	242	242	O	,
41	244	253	O	XXXXXXXX
42	255	263	O	phosphate
43	266	270	O	10.3%
44	272	272	O	,
45	274	276	O	and
46	278	285	O	inactive
47	287	297	O	metabolites
48	300	301	O	M3
49	303	312	O	carboxylic
50	314	317	O	acid
51	319	328	O	metabolite
52	331	334	O	8.3%
53	336	336	O	,
54	338	340	O	M29
55	342	349	O	ceramide
56	351	360	O	metabolite
57	363	366	O	8.9%
58	368	368	O	,
59	370	372	O	and
60	374	376	O	M30
61	378	385	O	ceramide
62	387	396	O	metabolite
63	399	402	O	7.3%
NULL

Gilenya	2936	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	25
Elimination Fingolimod blood clearance is 6.3*2.3 L/h, and the average apparent terminal half-life (t1/2) is 6 to 9 days.
1	0	10	O	Elimination
2	12	21	O	XXXXXXXX
3	23	27	O	blood
4	29	37	O	clearance
5	39	40	O	is
6	42	48	O	6.3*2.3
7	50	50	O	L
8	51	51	O	/
9	52	52	O	h
10	53	53	O	,
11	55	57	O	and
12	59	61	O	the
13	63	69	O	average
14	71	78	O	apparent
15	80	87	O	terminal
16	89	92	O	half
17	94	97	O	life
18	100	101	O	t1
19	102	102	O	/
20	103	103	O	2
21	106	107	O	is
22	109	109	O	6
23	111	112	O	to
24	114	114	O	9
25	116	119	O	days
NULL

Gilenya	2937	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	23
Blood levels of fingolimod-phosphate decline in parallel with those of fingolimod in the terminal phase, yielding similar half-lives for both.
1	0	4	O	Blood
2	6	11	O	levels
3	13	14	O	of
4	16	25	O	XXXXXXXX
5	27	35	O	phosphate
6	37	43	O	decline
7	45	46	O	in
8	48	55	O	parallel
9	57	60	O	with
10	62	66	O	those
11	68	69	O	of
12	71	80	O	XXXXXXXX
13	82	83	O	in
14	85	87	O	the
15	89	96	O	terminal
16	98	102	O	phase
17	103	103	O	,
18	105	112	O	yielding
19	114	120	O	similar
20	122	125	O	half
21	127	131	O	lives
22	133	135	O	for
23	137	140	O	both
NULL

Gilenya	2938	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	18
After oral administration, about 81% of the dose is slowly excreted in the urine as inactive metabolites.
1	0	4	O	After
2	6	9	O	oral
3	11	24	O	administration
4	25	25	O	,
5	27	31	O	about
6	33	35	O	81%
7	37	38	O	of
8	40	42	O	the
9	44	47	O	dose
10	49	50	O	is
11	52	57	O	slowly
12	59	66	O	excreted
13	68	69	O	in
14	71	73	O	the
15	75	79	O	urine
16	81	82	O	as
17	84	91	O	inactive
18	93	103	O	metabolites
NULL

Gilenya	2939	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	29
Fingolimod and fingolimod-phosphate are not excreted intact in urine but are the major components in the feces with amounts of each representing less than 2.5% of the dose.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	24	O	XXXXXXXX
4	26	34	O	phosphate
5	36	38	O	are
6	40	42	O	not
7	44	51	O	excreted
8	53	58	O	intact
9	60	61	O	in
10	63	67	O	urine
11	69	71	O	but
12	73	75	O	are
13	77	79	O	the
14	81	85	O	major
15	87	96	O	components
16	98	99	O	in
17	101	103	O	the
18	105	109	O	feces
19	111	114	O	with
20	116	122	O	amounts
21	124	125	O	of
22	127	130	O	each
23	132	143	O	representing
24	145	148	O	less
25	150	153	O	than
26	155	158	O	2.5%
27	160	161	O	of
28	163	165	O	the
29	167	170	O	dose
NULL

Gilenya	2940	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	24
Specific Populations Geriatric Patients The mechanism for elimination and results from population pharmacokinetics suggest that dose adjustment would not be necessary in elderly patients.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	29	O	Geriatric
4	31	38	O	Patients
5	40	42	O	The
6	44	52	O	mechanism
7	54	56	O	for
8	58	68	O	elimination
9	70	72	O	and
10	74	80	O	results
11	82	85	O	from
12	87	96	O	population
13	98	113	O	pharmacokinetics
14	115	121	O	suggest
15	123	126	O	that
16	128	131	O	dose
17	133	142	O	adjustment
18	144	148	O	would
19	150	152	O	not
20	154	155	O	be
21	157	165	O	necessary
22	167	168	O	in
23	170	176	O	elderly
24	178	185	O	patients
NULL

Gilenya	2941	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	12
However, clinical experience in patients aged above 65 years is limited.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	clinical
4	18	27	O	experience
5	29	30	O	in
6	32	39	O	patients
7	41	44	O	aged
8	46	50	O	above
9	52	53	O	65
10	55	59	O	years
11	61	62	O	is
12	64	70	O	limited
NULL

Gilenya	2942	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	13
Gender Gender has no clinically significant influence on fingolimod and fingolimod-phosphate pharmacokinetics.
1	0	5	O	Gender
2	7	12	O	Gender
3	14	16	O	has
4	18	19	O	no
5	21	30	O	clinically
6	32	42	O	significant
7	44	52	O	influence
8	54	55	O	on
9	57	66	O	XXXXXXXX
10	68	70	O	and
11	72	81	O	XXXXXXXX
12	83	91	O	phosphate
13	93	108	O	pharmacokinetics
NULL

Gilenya	2943	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	28
Race The effects of race on fingolimod and fingolimod-phosphate pharmacokinetics cannot be adequately assessed due to a low number of non-white patients in the clinical program.
1	0	3	O	Race
2	5	7	O	The
3	9	15	O	effects
4	17	18	O	of
5	20	23	O	race
6	25	26	O	on
7	28	37	O	XXXXXXXX
8	39	41	O	and
9	43	52	O	XXXXXXXX
10	54	62	O	phosphate
11	64	79	O	pharmacokinetics
12	81	86	O	cannot
13	88	89	O	be
14	91	100	O	adequately
15	102	109	O	assessed
16	111	113	O	due
17	115	116	O	to
18	118	118	O	a
19	120	122	O	low
20	124	129	O	number
21	131	132	O	of
22	134	136	O	non
23	138	142	O	white
24	144	151	O	patients
25	153	154	O	in
26	156	158	O	the
27	160	167	O	clinical
28	169	175	O	program
NULL

Gilenya	2944	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	45
Renal Impairment In patients with severe renal impairment, fingolimod Cmax and AUC are increased by 32% and 43%, respectively, and fingolimod-phosphate Cmax and AUC are increased by 25% and 14%, respectively, with no change in apparent elimination half-life.
1	0	4	O	Renal
2	6	15	O	Impairment
3	17	18	O	In
4	20	27	O	patients
5	29	32	O	with
6	34	39	O	severe
7	41	45	O	renal
8	47	56	O	impairment
9	57	57	O	,
10	59	68	O	XXXXXXXX
11	70	73	O	Cmax
12	75	77	O	and
13	79	81	O	AUC
14	83	85	O	are
15	87	95	O	increased
16	97	98	O	by
17	100	102	O	32%
18	104	106	O	and
19	108	110	O	43%
20	111	111	O	,
21	113	124	O	respectively
22	125	125	O	,
23	127	129	O	and
24	131	140	O	XXXXXXXX
25	142	150	O	phosphate
26	152	155	O	Cmax
27	157	159	O	and
28	161	163	O	AUC
29	165	167	O	are
30	169	177	O	increased
31	179	180	O	by
32	182	184	O	25%
33	186	188	O	and
34	190	192	O	14%
35	193	193	O	,
36	195	206	O	respectively
37	207	207	O	,
38	209	212	O	with
39	214	215	O	no
40	217	222	O	change
41	224	225	O	in
42	227	234	O	apparent
43	236	246	O	elimination
44	248	251	O	half
45	253	256	O	life
NULL

Gilenya	2945	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
Based on these findings, the GILENYA 0.5 mg dose is appropriate for use in patients with renal impairment.
1	0	4	O	Based
2	6	7	O	on
3	9	13	O	these
4	15	22	O	findings
5	23	23	O	,
6	25	27	O	the
7	29	35	O	XXXXXXXX
8	37	39	O	0.5
9	41	42	O	mg
10	44	47	O	dose
11	49	50	O	is
12	52	62	O	appropriate
13	64	66	O	for
14	68	70	O	use
15	72	73	O	in
16	75	82	O	patients
17	84	87	O	with
18	89	93	O	renal
19	95	104	O	impairment
NULL

Gilenya	2946	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	18
The systemic exposure of 2 metabolites (M2 and M3) is increased by 3- and 13-fold, respectively.
1	0	2	O	The
2	4	11	O	systemic
3	13	20	O	exposure
4	22	23	O	of
5	25	25	O	2
6	27	37	O	metabolites
7	40	41	O	M2
8	43	45	O	and
9	47	48	O	M3
10	51	52	O	is
11	54	62	O	increased
12	64	65	O	by
13	67	67	O	3
14	70	72	O	and
15	74	75	O	13
16	77	80	O	fold
17	81	81	O	,
18	83	94	O	respectively
NULL

Gilenya	2947	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	10
The toxicity of these metabolites has not been fully characterized.
1	0	2	O	The
2	4	11	O	toxicity
3	13	14	O	of
4	16	20	O	these
5	22	32	O	metabolites
6	34	36	O	has
7	38	40	O	not
8	42	45	O	been
9	47	51	O	fully
10	53	65	O	characterized
NULL

Gilenya	2948	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	14
A study in patients with mild or moderate renal impairment has not been conducted.
1	0	0	O	A
2	2	6	O	study
3	8	9	O	in
4	11	18	O	patients
5	20	23	O	with
6	25	28	O	mild
7	30	31	O	or
8	33	40	O	moderate
9	42	46	O	renal
10	48	57	O	impairment
11	59	61	O	has
12	63	65	O	not
13	67	70	O	been
14	72	80	O	conducted
NULL

Gilenya	2949	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	45
Hepatic Impairment In subjects with mild, moderate, or severe hepatic impairment (Child-Pugh class A, B, and C), no change in fingolimod Cmax was observed, but fingolimod AUC0-* was increased respectively by 12%, 44%, and 103%.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	19	20	O	In
4	22	29	O	subjects
5	31	34	O	with
6	36	39	O	mild
7	40	40	O	,
8	42	49	O	moderate
9	50	50	O	,
10	52	53	O	or
11	55	60	O	severe
12	62	68	O	hepatic
13	70	79	O	impairment
14	82	86	O	Child
15	88	91	O	Pugh
16	93	97	O	class
17	99	99	O	A
18	100	100	O	,
19	102	102	O	B
20	103	103	O	,
21	105	107	O	and
22	109	109	O	C
23	111	111	O	,
24	113	114	O	no
25	116	121	O	change
26	123	124	O	in
27	126	135	O	XXXXXXXX
28	137	140	O	Cmax
29	142	144	O	was
30	146	153	O	observed
31	154	154	O	,
32	156	158	O	but
33	160	169	O	XXXXXXXX
34	171	174	O	AUC0
35	176	176	O	*
36	178	180	O	was
37	182	190	O	increased
38	192	203	O	respectively
39	205	206	O	by
40	208	210	O	12%
41	211	211	O	,
42	213	215	O	44%
43	216	216	O	,
44	218	220	O	and
45	222	225	O	103%
NULL

Gilenya	2950	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	26
In patients with severe hepatic impairment (Child-Pugh class C), fingolimod-phosphate Cmax was decreased by 22% and AUC0-96 hours was decreased by 29%.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	22	O	severe
5	24	30	O	hepatic
6	32	41	O	impairment
7	44	48	O	Child
8	50	53	O	Pugh
9	55	59	O	class
10	61	61	O	C
11	63	63	O	,
12	65	74	O	XXXXXXXX
13	76	84	O	phosphate
14	86	89	O	Cmax
15	91	93	O	was
16	95	103	O	decreased
17	105	106	O	by
18	108	110	O	22%
19	112	114	O	and
20	116	119	O	AUC0
21	121	122	O	96
22	124	128	O	hours
23	130	132	O	was
24	134	142	O	decreased
25	144	145	O	by
26	147	149	O	29%
NULL

Gilenya	2951	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	16
The pharmacokinetics of fingolimod-phosphate was not evaluated in patients with mild or moderate hepatic impairment.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	O	XXXXXXXX
5	35	43	O	phosphate
6	45	47	O	was
7	49	51	O	not
8	53	61	O	evaluated
9	63	64	O	in
10	66	73	O	patients
11	75	78	O	with
12	80	83	O	mild
13	85	86	O	or
14	88	95	O	moderate
15	97	103	O	hepatic
16	105	114	O	impairment
NULL

Gilenya	2952	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	30
The apparent elimination half-life of fingolimod is unchanged in subjects with mild hepatic impairment, but is prolonged by about 50% in patients with moderate or severe hepatic impairment.
1	0	2	O	The
2	4	11	O	apparent
3	13	23	O	elimination
4	25	28	O	half
5	30	33	O	life
6	35	36	O	of
7	38	47	O	XXXXXXXX
8	49	50	O	is
9	52	60	O	unchanged
10	62	63	O	in
11	65	72	O	subjects
12	74	77	O	with
13	79	82	O	mild
14	84	90	O	hepatic
15	92	101	O	impairment
16	102	102	O	,
17	104	106	O	but
18	108	109	O	is
19	111	119	O	prolonged
20	121	122	O	by
21	124	128	O	about
22	130	132	O	50%
23	134	135	O	in
24	137	144	O	patients
25	146	149	O	with
26	151	158	O	moderate
27	160	161	O	or
28	163	168	O	severe
29	170	176	O	hepatic
30	178	187	O	impairment
NULL

Gilenya	2953	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	22
Patients with severe hepatic impairment (Child-Pugh class C) should be closely monitored, as the risk of adverse reactions is greater.
1	0	7	O	Patients
2	9	12	O	with
3	14	19	O	severe
4	21	27	O	hepatic
5	29	38	O	impairment
6	41	45	O	Child
7	47	50	O	Pugh
8	52	56	O	class
9	58	58	O	C
10	61	66	O	should
11	68	69	O	be
12	71	77	O	closely
13	79	87	O	monitored
14	88	88	O	,
15	90	91	O	as
16	93	95	O	the
17	97	100	O	risk
18	102	103	O	of
19	105	111	O	adverse
20	113	121	O	reactions
21	123	124	O	is
22	126	132	O	greater
NULL

Gilenya	2954	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
No dose adjustment is needed in patients with mild or moderate hepatic impairment (Child-Pugh class A and B).
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	27	O	needed
6	29	30	O	in
7	32	39	O	patients
8	41	44	O	with
9	46	49	O	mild
10	51	52	O	or
11	54	61	O	moderate
12	63	69	O	hepatic
13	71	80	O	impairment
14	83	87	O	Child
15	89	92	O	Pugh
16	94	98	O	class
17	100	100	O	A
18	102	104	O	and
19	106	106	O	B
NULL

Gilenya	2955	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	41
Drug Interactions Ketoconazole The coadministration of ketoconazole (a potent inhibitor of CYP3A and CYP4F) 200 mg twice-daily at steady-state and a single dose of fingolimod 5 mg led to a 70% increase in AUC of fingolimod and fingolimod-phosphate.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	29	O	Ketoconazole
4	31	33	O	The
5	35	50	O	coadministration
6	52	53	O	of
7	55	66	U-KIN	ketoconazole
8	69	69	O	a
9	71	76	O	potent
10	78	86	O	inhibitor
11	88	89	O	of
12	91	95	O	CYP3A
13	97	99	O	and
14	101	105	O	CYP4F
15	108	110	O	200
16	112	113	O	mg
17	115	119	O	twice
18	121	125	O	daily
19	127	128	O	at
20	130	135	O	steady
21	137	141	O	state
22	143	145	O	and
23	147	147	O	a
24	149	154	O	single
25	156	159	O	dose
26	161	162	O	of
27	164	173	O	XXXXXXXX
28	175	175	O	5
29	177	178	O	mg
30	180	182	O	led
31	184	185	O	to
32	187	187	O	a
33	189	191	O	70%
34	193	200	B-TRI	increase
35	202	203	I-TRI	in
36	205	207	L-TRI	AUC
37	209	210	O	of
38	212	221	O	XXXXXXXX
39	223	225	O	and
40	227	236	O	XXXXXXXX
41	238	246	O	phosphate
K/7:C54605

Gilenya	2956	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	21
Patients who use GILENYA and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.
1	0	7	O	Patients
2	9	11	O	who
3	13	15	O	use
4	17	23	O	XXXXXXXX
5	25	27	O	and
6	29	36	B-UNK	systemic
7	38	49	L-UNK	ketoconazole
8	51	63	O	concomitantly
9	65	70	O	should
10	72	73	O	be
11	75	81	O	closely
12	83	91	U-TRI	monitored
13	92	92	O	,
14	94	95	O	as
15	97	99	O	the
16	101	104	O	risk
17	106	107	O	of
18	109	115	O	adverse
19	117	125	O	reactions
20	127	128	O	is
21	130	136	O	greater
NULL

Gilenya	2957	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	37
Carbamazepine The coadministration of carbamazepine (a potent CYP450 enzyme inducer) 600 mg twice-daily at steady-state and a single dose of fingolimod 2 mg decreased blood concentrations (AUC) of fingolimod and fingolimod-phosphate by approximately 40%.
1	0	12	O	Carbamazepine
2	14	16	O	The
3	18	33	O	coadministration
4	35	36	O	of
5	38	50	U-KIN	carbamazepine
6	53	53	O	a
7	55	60	O	potent
8	62	67	O	CYP450
9	69	74	O	enzyme
10	76	82	O	inducer
11	85	87	O	600
12	89	90	O	mg
13	92	96	O	twice
14	98	102	O	daily
15	104	105	O	at
16	107	112	O	steady
17	114	118	O	state
18	120	122	O	and
19	124	124	O	a
20	126	131	O	single
21	133	136	O	dose
22	138	139	O	of
23	141	150	O	XXXXXXXX
24	152	152	O	2
25	154	155	O	mg
26	157	165	O	decreased
27	167	171	O	blood
28	173	186	O	concentrations
29	189	191	O	AUC
30	194	195	O	of
31	197	206	O	XXXXXXXX
32	208	210	O	and
33	212	221	O	XXXXXXXX
34	223	231	O	phosphate
35	233	234	O	by
36	236	248	O	approximately
37	250	252	O	40%
K/5:C54609

Gilenya	2958	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	8
The clinical impact of this decrease is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	18	O	impact
4	20	21	O	of
5	23	26	O	this
6	28	35	O	decrease
7	37	38	O	is
8	40	46	O	unknown
NULL

Gilenya	2959	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	28
Other strong CYP450 enzyme inducers, e.g., rifampicin, phenytoin, phenobarbital, and St. John's wort, may also reduce AUC of fingolimod and fingolimod-phosphate.
1	0	4	O	Other
2	6	11	B-KIN	strong
3	13	18	I-KIN	CYP450
4	20	25	I-KIN	enzyme
5	27	34	L-KIN	inducers
6	35	35	O	,
7	37	39	O	e.g
8	41	41	O	,
9	43	52	U-KIN	rifampicin
10	53	53	O	,
11	55	63	U-KIN	phenytoin
12	64	64	O	,
13	66	78	U-KIN	phenobarbital
14	79	79	O	,
15	81	83	O	and
16	85	86	B-KIN	St
17	89	94	I-KIN	John's
18	96	99	L-KIN	wort
19	100	100	O	,
20	102	104	O	may
21	106	109	O	also
22	111	116	B-TRI	reduce
23	118	120	L-TRI	AUC
24	122	123	O	of
25	125	134	O	XXXXXXXX
26	136	138	O	and
27	140	149	O	XXXXXXXX
28	151	159	O	phosphate
K/11:C54609 K/13:C54609 K/16:C54609 K/2:C54609 K/9:C54609

Gilenya	2960	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	9
The clinical impact of this potential decrease is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	18	O	impact
4	20	21	O	of
5	23	26	O	this
6	28	36	O	potential
7	38	45	O	decrease
8	47	48	O	is
9	50	56	O	unknown
NULL

Gilenya	2961	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	114
Potential of Fingolimod and Fingolimod-phosphate to Inhibit the Metabolism of Comedications In vitro inhibition studies using pooled human liver microsomes and specific metabolic probe substrates demonstrate that fingolimod has little or no capacity to inhibit the activity of the following CYP enzymes: CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4/5, or CYP4A9/11 (fingolimod only), and similarly fingolimod-phosphate has little or no capacity to inhibit the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 at concentrations up to 3 orders of magnitude of therapeutic concentrations.
1	0	8	O	Potential
2	10	11	O	of
3	13	22	O	XXXXXXXX
4	24	26	O	and
5	28	37	O	XXXXXXXX
6	39	47	O	phosphate
7	49	50	O	to
8	52	58	O	Inhibit
9	60	62	O	the
10	64	73	O	Metabolism
11	75	76	O	of
12	78	90	O	Comedications
13	92	93	O	In
14	95	99	O	vitro
15	101	110	O	inhibition
16	112	118	O	studies
17	120	124	O	using
18	126	131	O	pooled
19	133	137	O	human
20	139	143	O	liver
21	145	154	O	microsomes
22	156	158	O	and
23	160	167	O	specific
24	169	177	O	metabolic
25	179	183	O	probe
26	185	194	O	substrates
27	196	206	O	demonstrate
28	208	211	O	that
29	213	222	O	XXXXXXXX
30	224	226	O	has
31	228	233	O	little
32	235	236	O	or
33	238	239	O	no
34	241	248	O	capacity
35	250	251	O	to
36	253	259	O	inhibit
37	261	263	O	the
38	265	272	O	activity
39	274	275	O	of
40	277	279	O	the
41	281	289	O	following
42	291	293	O	CYP
43	295	301	O	enzymes
44	302	302	O	:
45	304	309	O	CYP1A2
46	310	310	O	,
47	312	317	O	CYP2A6
48	318	318	O	,
49	320	325	O	CYP2B6
50	326	326	O	,
51	328	333	O	CYP2C8
52	334	334	O	,
53	336	341	O	CYP2C9
54	342	342	O	,
55	344	350	O	CYP2C19
56	351	351	O	,
57	353	358	O	CYP2D6
58	359	359	O	,
59	361	366	O	CYP2E1
60	367	367	O	,
61	369	374	O	CYP3A4
62	375	375	O	/
63	376	376	O	5
64	377	377	O	,
65	379	380	O	or
66	382	387	O	CYP4A9
67	388	388	O	/
68	389	390	O	11
69	393	402	O	XXXXXXXX
70	404	407	O	only
71	409	409	O	,
72	411	413	O	and
73	415	423	O	similarly
74	425	434	O	XXXXXXXX
75	436	444	O	phosphate
76	446	448	O	has
77	450	455	O	little
78	457	458	O	or
79	460	461	O	no
80	463	470	O	capacity
81	472	473	O	to
82	475	481	O	inhibit
83	483	485	O	the
84	487	494	O	activity
85	496	497	O	of
86	499	504	O	CYP1A2
87	505	505	O	,
88	507	512	O	CYP2A6
89	513	513	O	,
90	515	520	O	CYP2B6
91	521	521	O	,
92	523	528	O	CYP2C8
93	529	529	O	,
94	531	536	O	CYP2C9
95	537	537	O	,
96	539	545	O	CYP2C19
97	546	546	O	,
98	548	553	O	CYP2D6
99	554	554	O	,
100	556	561	O	CYP2E1
101	562	562	O	,
102	564	565	O	or
103	567	572	O	CYP3A4
104	574	575	O	at
105	577	590	O	concentrations
106	592	593	O	up
107	595	596	O	to
108	598	598	O	3
109	600	605	O	orders
110	607	608	O	of
111	610	618	O	magnitude
112	620	621	O	of
113	623	633	O	therapeutic
114	635	648	O	concentrations
NULL

Gilenya	2962	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	27
Therefore, fingolimod and fingolimod-phosphate are unlikely to reduce the clearance of drugs that are mainly cleared through metabolism by the major CYP isoenzymes described above.
1	0	8	O	Therefore
2	9	9	O	,
3	11	20	O	XXXXXXXX
4	22	24	O	and
5	26	35	O	XXXXXXXX
6	37	45	O	phosphate
7	47	49	O	are
8	51	58	O	unlikely
9	60	61	O	to
10	63	68	O	reduce
11	70	72	O	the
12	74	82	O	clearance
13	84	85	O	of
14	87	91	O	drugs
15	93	96	O	that
16	98	100	O	are
17	102	107	O	mainly
18	109	115	O	cleared
19	117	123	O	through
20	125	134	O	metabolism
21	136	137	O	by
22	139	141	O	the
23	143	147	O	major
24	149	151	O	CYP
25	153	162	O	isoenzymes
26	164	172	O	described
27	174	178	O	above
NULL

Gilenya	2963	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	57
Potential of Fingolimod and Fingolimod-phosphate to Induce its Own and/or the Metabolism of Comedications Fingolimod was examined for its potential to induce human CYP3A4, CYP1A2, CYP4F2, and MDR1 (P-glycoprotein) mRNA and CYP3A, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP4F2 activity in primary human hepatocytes.
1	0	8	O	Potential
2	10	11	O	of
3	13	22	O	XXXXXXXX
4	24	26	O	and
5	28	37	O	XXXXXXXX
6	39	47	O	phosphate
7	49	50	O	to
8	52	57	O	Induce
9	59	61	O	its
10	63	65	O	Own
11	67	69	O	and
12	70	70	O	/
13	71	72	O	or
14	74	76	O	the
15	78	87	O	Metabolism
16	89	90	O	of
17	92	104	O	Comedications
18	106	115	O	XXXXXXXX
19	117	119	O	was
20	121	128	O	examined
21	130	132	O	for
22	134	136	O	its
23	138	146	O	potential
24	148	149	O	to
25	151	156	O	induce
26	158	162	O	human
27	164	169	O	CYP3A4
28	170	170	O	,
29	172	177	O	CYP1A2
30	178	178	O	,
31	180	185	O	CYP4F2
32	186	186	O	,
33	188	190	O	and
34	192	195	O	MDR1
35	198	198	O	P
36	200	211	O	glycoprotein
37	214	217	O	mRNA
38	219	221	O	and
39	223	227	O	CYP3A
40	228	228	O	,
41	230	235	O	CYP1A2
42	236	236	O	,
43	238	243	O	CYP2B6
44	244	244	O	,
45	246	251	O	CYP2C8
46	252	252	O	,
47	254	259	O	CYP2C9
48	260	260	O	,
49	262	268	O	CYP2C19
50	269	269	O	,
51	271	273	O	and
52	275	280	O	CYP4F2
53	282	289	O	activity
54	291	292	O	in
55	294	300	O	primary
56	302	306	O	human
57	308	318	O	hepatocytes
NULL

Gilenya	2964	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	40
Fingolimod did not induce mRNA or activity of the different CYP enzymes and MDR1 with respect to the vehicle control; therefore, no clinically relevant induction of the tested CYP enzymes or MDR1 by fingolimod are expected at therapeutic concentrations.
1	0	9	O	XXXXXXXX
2	11	13	O	did
3	15	17	O	not
4	19	24	O	induce
5	26	29	O	mRNA
6	31	32	O	or
7	34	41	O	activity
8	43	44	O	of
9	46	48	O	the
10	50	58	O	different
11	60	62	O	CYP
12	64	70	O	enzymes
13	72	74	O	and
14	76	79	O	MDR1
15	81	84	O	with
16	86	92	O	respect
17	94	95	O	to
18	97	99	O	the
19	101	107	O	vehicle
20	109	115	O	control
21	118	126	O	therefore
22	127	127	O	,
23	129	130	O	no
24	132	141	O	clinically
25	143	150	O	relevant
26	152	160	O	induction
27	162	163	O	of
28	165	167	O	the
29	169	174	O	tested
30	176	178	O	CYP
31	180	186	O	enzymes
32	188	189	O	or
33	191	194	O	MDR1
34	196	197	O	by
35	199	208	O	XXXXXXXX
36	210	212	O	are
37	214	221	O	expected
38	223	224	O	at
39	226	236	O	therapeutic
40	238	251	O	concentrations
NULL

Gilenya	2965	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	35
Fingolimod-phosphate was also examined for its potential to induce mRNA and/or activity of human CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A, CYP4F2, CYP4F3B, and CYP4F12.
1	0	9	O	XXXXXXXX
2	11	19	O	phosphate
3	21	23	O	was
4	25	28	O	also
5	30	37	O	examined
6	39	41	O	for
7	43	45	O	its
8	47	55	O	potential
9	57	58	O	to
10	60	65	O	induce
11	67	70	O	mRNA
12	72	74	O	and
13	75	75	O	/
14	76	77	O	or
15	79	86	O	activity
16	88	89	O	of
17	91	95	O	human
18	97	102	O	CYP1A2
19	103	103	O	,
20	105	110	O	CYP2B6
21	111	111	O	,
22	113	118	O	CYP2C8
23	119	119	O	,
24	121	126	O	CYP2C9
25	127	127	O	,
26	129	135	O	CYP2C19
27	136	136	O	,
28	138	142	O	CYP3A
29	143	143	O	,
30	145	150	O	CYP4F2
31	151	151	O	,
32	153	159	O	CYP4F3B
33	160	160	O	,
34	162	164	O	and
35	166	172	O	CYP4F12
NULL

Gilenya	2966	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
Fingolimod-phosphate is not expected to have clinically significant induction effects on these enzymes at therapeutic dose of fingolimod.
1	0	9	O	XXXXXXXX
2	11	19	O	phosphate
3	21	22	O	is
4	24	26	O	not
5	28	35	O	expected
6	37	38	O	to
7	40	43	O	have
8	45	54	O	clinically
9	56	66	O	significant
10	68	76	O	induction
11	78	84	O	effects
12	86	87	O	on
13	89	93	O	these
14	95	101	O	enzymes
15	103	104	O	at
16	106	116	O	therapeutic
17	118	121	O	dose
18	123	124	O	of
19	126	135	O	XXXXXXXX
NULL

Gilenya	2967	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	14
In vitro experiments did not provide an indication of CYP induction by fingolimod-phosphate.
1	0	1	O	In
2	3	7	O	vitro
3	9	19	O	experiments
4	21	23	O	did
5	25	27	O	not
6	29	35	O	provide
7	37	38	O	an
8	40	49	O	indication
9	51	52	O	of
10	54	56	O	CYP
11	58	66	O	induction
12	68	69	O	by
13	71	80	O	XXXXXXXX
14	82	90	O	phosphate
NULL

Gilenya	2968	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	45
Transporters Based on in vitro data, fingolimod as well as fingolimod-phosphate are not expected to inhibit the uptake of comedications and/or biologics transported by the organic anion transporting polypeptides OATP1B1, OATP1B3, or the sodium taurocholate co-transporting polypeptide (NTCP).
1	0	11	O	Transporters
2	13	17	O	Based
3	19	20	O	on
4	22	23	O	in
5	25	29	O	vitro
6	31	34	O	data
7	35	35	O	,
8	37	46	O	XXXXXXXX
9	48	49	O	as
10	51	54	O	well
11	56	57	O	as
12	59	68	O	XXXXXXXX
13	70	78	O	phosphate
14	80	82	O	are
15	84	86	O	not
16	88	95	O	expected
17	97	98	O	to
18	100	106	O	inhibit
19	108	110	O	the
20	112	117	O	uptake
21	119	120	O	of
22	122	134	O	comedications
23	136	138	O	and
24	139	139	O	/
25	140	141	O	or
26	143	151	O	biologics
27	153	163	O	transported
28	165	166	O	by
29	168	170	O	the
30	172	178	O	organic
31	180	184	O	anion
32	186	197	O	transporting
33	199	210	O	polypeptides
34	212	218	O	OATP1B1
35	219	219	O	,
36	221	227	O	OATP1B3
37	228	228	O	,
38	230	231	O	or
39	233	235	O	the
40	237	242	O	sodium
41	244	255	O	taurocholate
42	257	258	O	co
43	260	271	O	transporting
44	273	283	O	polypeptide
45	286	289	O	NTCP
NULL

Gilenya	2969	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	48
Similarly, they are not expected to inhibit the efflux of comedications and/or biologics transported by the breast cancer resistance protein (BCRP), the bile salt export pump (BSEP), the multidrug resistance-associated protein 2 (MRP2), or P-glycoprotein (P-gp) at therapeutic concentrations.
1	0	8	O	Similarly
2	9	9	O	,
3	11	14	O	they
4	16	18	O	are
5	20	22	O	not
6	24	31	O	expected
7	33	34	O	to
8	36	42	O	inhibit
9	44	46	O	the
10	48	53	O	efflux
11	55	56	O	of
12	58	70	O	comedications
13	72	74	O	and
14	75	75	O	/
15	76	77	O	or
16	79	87	O	biologics
17	89	99	O	transported
18	101	102	O	by
19	104	106	O	the
20	108	113	O	breast
21	115	120	O	cancer
22	122	131	O	resistance
23	133	139	O	protein
24	142	145	O	BCRP
25	147	147	O	,
26	149	151	O	the
27	153	156	O	bile
28	158	161	O	salt
29	163	168	O	export
30	170	173	O	pump
31	176	179	O	BSEP
32	181	181	O	,
33	183	185	O	the
34	187	195	O	multidrug
35	197	206	O	resistance
36	208	217	O	associated
37	219	225	O	protein
38	227	227	O	2
39	230	233	O	MRP2
40	235	235	O	,
41	237	238	O	or
42	240	240	O	P
43	242	253	O	glycoprotein
44	256	256	O	P
45	258	259	O	gp
46	262	263	O	at
47	265	275	O	therapeutic
48	277	290	O	concentrations
NULL

Gilenya	2970	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	26
Oral Contraceptives The coadministration of fingolimod 0.5 mg daily with oral contraceptives (ethinylestradiol and levonorgestrel) did not elicit any clinically significant change in oral contraceptives exposure.
1	0	3	O	Oral
2	5	18	O	Contraceptives
3	20	22	O	The
4	24	39	O	coadministration
5	41	42	O	of
6	44	53	O	XXXXXXXX
7	55	57	O	0.5
8	59	60	O	mg
9	62	66	O	daily
10	68	71	O	with
11	73	76	O	oral
12	78	91	O	contraceptives
13	94	109	O	ethinylestradiol
14	111	113	O	and
15	115	128	O	levonorgestrel
16	131	133	O	did
17	135	137	O	not
18	139	144	O	elicit
19	146	148	O	any
20	150	159	O	clinically
21	161	171	O	significant
22	173	178	O	change
23	180	181	O	in
24	183	186	O	oral
25	188	201	O	contraceptives
26	203	210	O	exposure
NULL

Gilenya	2971	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	12
Fingolimod and fingolimod-phosphate exposure were consistent with those from previous studies.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	24	O	XXXXXXXX
4	26	34	O	phosphate
5	36	43	O	exposure
6	45	48	O	were
7	50	59	O	consistent
8	61	64	O	with
9	66	70	O	those
10	72	75	O	from
11	77	84	O	previous
12	86	92	O	studies
NULL

Gilenya	2972	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	24
No interaction studies have been performed with oral contraceptives containing other progestagens; however, an effect of fingolimod on their exposure is not expected.
1	0	1	O	No
2	3	13	O	interaction
3	15	21	O	studies
4	23	26	O	have
5	28	31	O	been
6	33	41	O	performed
7	43	46	O	with
8	48	51	O	oral
9	53	66	O	contraceptives
10	68	77	O	containing
11	79	83	O	other
12	85	96	O	progestagens
13	99	105	O	however
14	106	106	O	,
15	108	109	O	an
16	111	116	O	effect
17	118	119	O	of
18	121	130	O	XXXXXXXX
19	132	133	O	on
20	135	139	O	their
21	141	148	O	exposure
22	150	151	O	is
23	153	155	O	not
24	157	164	O	expected
NULL

Gilenya	2973	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	27
Cyclosporine The pharmacokinetics of single-dose fingolimod was not altered during coadministration with cyclosporine at steady-state, nor was cyclosporine steady-state pharmacokinetics altered by fingolimod.
1	0	11	O	Cyclosporine
2	13	15	O	The
3	17	32	O	pharmacokinetics
4	34	35	O	of
5	37	42	O	single
6	44	47	O	dose
7	49	58	O	XXXXXXXX
8	60	62	O	was
9	64	66	O	not
10	68	74	O	altered
11	76	81	O	during
12	83	98	O	coadministration
13	100	103	O	with
14	105	116	O	cyclosporine
15	118	119	O	at
16	121	126	O	steady
17	128	132	O	state
18	133	133	O	,
19	135	137	O	nor
20	139	141	O	was
21	143	154	O	cyclosporine
22	156	161	O	steady
23	163	167	O	state
24	169	184	O	pharmacokinetics
25	186	192	O	altered
26	194	195	O	by
27	197	206	O	XXXXXXXX
NULL

Gilenya	2974	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	19
These data indicate that GILENYA is unlikely to reduce or increase the clearance of drugs cleared mainly by CYP3A4.
1	0	4	O	These
2	6	9	O	data
3	11	18	O	indicate
4	20	23	O	that
5	25	31	O	XXXXXXXX
6	33	34	O	is
7	36	43	O	unlikely
8	45	46	O	to
9	48	53	O	reduce
10	55	56	O	or
11	58	65	O	increase
12	67	69	O	the
13	71	79	O	clearance
14	81	82	O	of
15	84	88	O	drugs
16	90	96	O	cleared
17	98	103	O	mainly
18	105	106	O	by
19	108	113	O	CYP3A4
NULL

Gilenya	2975	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	18
Potent inhibition of transporters MDR1 (P-gp), MRP2, and OATP-1B1 does not influence fingolimod disposition.
1	0	5	O	Potent
2	7	16	O	inhibition
3	18	19	O	of
4	21	32	O	transporters
5	34	37	O	MDR1
6	40	40	O	P
7	42	43	O	gp
8	45	45	O	,
9	47	50	O	MRP2
10	51	51	O	,
11	53	55	O	and
12	57	60	O	OATP
13	62	64	O	1B1
14	66	69	O	does
15	71	73	O	not
16	75	83	O	influence
17	85	94	O	XXXXXXXX
18	96	106	O	disposition
NULL

Gilenya	2976	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	23
Isoproterenol, Atropine, Atenolol, and Diltiazem Single-dose fingolimod and fingolimod-phosphate exposure was not altered by coadministered isoproterenol or atropine.
1	0	12	O	Isoproterenol
2	13	13	O	,
3	15	22	O	Atropine
4	23	23	O	,
5	25	32	O	Atenolol
6	33	33	O	,
7	35	37	O	and
8	39	47	O	Diltiazem
9	49	54	O	Single
10	56	59	O	dose
11	61	70	O	XXXXXXXX
12	72	74	O	and
13	76	85	O	XXXXXXXX
14	87	95	O	phosphate
15	97	104	O	exposure
16	106	108	O	was
17	110	112	O	not
18	114	120	O	altered
19	122	123	O	by
20	125	138	O	coadministered
21	140	152	O	isoproterenol
22	154	155	O	or
23	157	164	O	atropine
NULL

Gilenya	2977	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	34
Likewise, the single-dose pharmacokinetics of fingolimod and fingolimod-phosphate and the steady-state pharmacokinetics of both atenolol and diltiazem were unchanged during the coadministration of the latter 2 drugs individually with fingolimod.
1	0	7	O	Likewise
2	8	8	O	,
3	10	12	O	the
4	14	19	O	single
5	21	24	O	dose
6	26	41	O	pharmacokinetics
7	43	44	O	of
8	46	55	O	XXXXXXXX
9	57	59	O	and
10	61	70	O	XXXXXXXX
11	72	80	O	phosphate
12	82	84	O	and
13	86	88	O	the
14	90	95	O	steady
15	97	101	O	state
16	103	118	O	pharmacokinetics
17	120	121	O	of
18	123	126	O	both
19	128	135	O	atenolol
20	137	139	O	and
21	141	149	O	diltiazem
22	151	154	O	were
23	156	164	O	unchanged
24	166	171	O	during
25	173	175	O	the
26	177	192	O	coadministration
27	194	195	O	of
28	197	199	O	the
29	201	206	O	latter
30	208	208	O	2
31	210	214	O	drugs
32	216	227	O	individually
33	229	232	O	with
34	234	243	O	XXXXXXXX
NULL

Gilenya	2978	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	33
Population Pharmacokinetics Analysis A population pharmacokinetics evaluation performed in MS patients did not provide evidence for a significant effect of fluoxetine and paroxetine (strong CYP2D6 inhibitors) on fingolimod or fingolimod-phosphate predose concentrations.
1	0	9	O	Population
2	11	26	O	Pharmacokinetics
3	28	35	O	Analysis
4	37	37	O	A
5	39	48	O	population
6	50	65	O	pharmacokinetics
7	67	76	O	evaluation
8	78	86	O	performed
9	88	89	O	in
10	91	92	O	MS
11	94	101	O	patients
12	103	105	O	did
13	107	109	O	not
14	111	117	O	provide
15	119	126	O	evidence
16	128	130	O	for
17	132	132	O	a
18	134	144	O	significant
19	146	151	O	effect
20	153	154	O	of
21	156	165	O	fluoxetine
22	167	169	O	and
23	171	180	O	paroxetine
24	183	188	O	strong
25	190	195	O	CYP2D6
26	197	206	O	inhibitors
27	209	210	O	on
28	212	221	O	XXXXXXXX
29	223	224	O	or
30	226	235	O	XXXXXXXX
31	237	245	O	phosphate
32	247	253	O	predose
33	255	268	O	concentrations
NULL

Gilenya	2979	34090-1	cc9e1c8c-0e2b-44e2-878b-27057f786be9	38
In addition, the following commonly coprescribed substances had no clinically relevant effect (<20%) on fingolimod or fingolimod-phosphate predose concentrations: baclofen, gabapentin, oxybutynin, amantadine, modafinil, amitriptyline, pregabalin, and corticosteroids.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	the
5	17	25	O	following
6	27	34	O	commonly
7	36	47	O	coprescribed
8	49	58	O	substances
9	60	62	O	had
10	64	65	O	no
11	67	76	O	clinically
12	78	85	O	relevant
13	87	92	O	effect
14	95	98	O	<20%
15	101	102	O	on
16	104	113	O	XXXXXXXX
17	115	116	O	or
18	118	127	O	XXXXXXXX
19	129	137	O	phosphate
20	139	145	O	predose
21	147	160	O	concentrations
22	161	161	O	:
23	163	170	O	baclofen
24	171	171	O	,
25	173	182	O	gabapentin
26	183	183	O	,
27	185	194	O	oxybutynin
28	195	195	O	,
29	197	206	O	amantadine
30	207	207	O	,
31	209	217	O	modafinil
32	218	218	O	,
33	220	232	O	amitriptyline
34	233	233	O	,
35	235	244	O	pregabalin
36	245	245	O	,
37	247	249	O	and
38	251	265	O	corticosteroids
NULL

Halcion	5013	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	26
The concomitant use of benzodiazepines and opioids increases the risk of respiratory depression because of actions at different receptor sites in the CNS that control respiration.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	37	O	benzodiazepines
6	39	41	O	and
7	43	49	U-DYN	opioids
8	51	59	O	increases
9	61	63	O	the
10	65	68	O	risk
11	70	71	O	of
12	73	83	B-EFF	respiratory
13	85	94	L-EFF	depression
14	96	102	O	because
15	104	105	O	of
16	107	113	O	actions
17	115	116	O	at
18	118	126	O	different
19	128	135	O	receptor
20	137	141	O	sites
21	143	144	O	in
22	146	148	O	the
23	150	152	O	CNS
24	154	157	O	that
25	159	165	O	control
26	167	177	O	respiration
D/7:12:1

Halcion	5014	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	12
Benzodiazepines interact at GABAA sites and opioids interact primarily at mu receptors.
1	0	14	O	Benzodiazepines
2	16	23	O	interact
3	25	26	O	at
4	28	32	O	GABAA
5	34	38	O	sites
6	40	42	O	and
7	44	50	O	opioids
8	52	59	O	interact
9	61	69	O	primarily
10	71	72	O	at
11	74	75	O	mu
12	77	85	O	receptors
NULL

Halcion	5015	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	19
When benzodiazepines and opioids are combined, the potential for benzodiazepines to significantly worsen opioid-related respiratory depression exists.
1	0	3	O	When
2	5	19	O	benzodiazepines
3	21	23	O	and
4	25	31	U-DYN	opioids
5	33	35	O	are
6	37	44	O	combined
7	45	45	O	,
8	47	49	O	the
9	51	59	O	potential
10	61	63	O	for
11	65	79	O	benzodiazepines
12	81	82	O	to
13	84	96	O	significantly
14	98	103	O	worsen
15	105	110	B-EFF	opioid
16	112	118	I-EFF	related
17	120	130	I-EFF	respiratory
18	132	141	L-EFF	depression
19	143	148	O	exists
D/4:15:1

Halcion	5016	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	21
Limit dosage and duration of concomitant use of benzodiazepines and opioids, and monitor patients closely for respiratory depression and sedation.
1	0	4	O	Limit
2	6	11	O	dosage
3	13	15	O	and
4	17	24	O	duration
5	26	27	O	of
6	29	39	O	concomitant
7	41	43	O	use
8	45	46	O	of
9	48	62	O	benzodiazepines
10	64	66	O	and
11	68	74	U-DYN	opioids
12	75	75	O	,
13	77	79	O	and
14	81	87	O	monitor
15	89	96	O	patients
16	98	104	O	closely
17	106	108	O	for
18	110	120	B-EFF	respiratory
19	122	131	L-EFF	depression
20	133	135	O	and
21	137	144	U-EFF	sedation
D/11:18:1 D/11:21:1

Halcion	5017	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	10
Both pharmacodynamic and pharmacokinetic interactions have been reported with benzodiazepines.
1	0	3	O	Both
2	5	19	B-TRI	pharmacodynamic
3	21	23	I-TRI	and
4	25	39	I-TRI	pharmacokinetic
5	41	52	L-TRI	interactions
6	54	57	O	have
7	59	62	O	been
8	64	71	O	reported
9	73	76	O	with
10	78	92	U-UNK	benzodiazepines
NULL

Halcion	5018	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	30
In particular, triazolam produces additive CNS depressant effects when coadministered with other psychotropic medications, anticonvulsants, antihistamines, ethanol, and other drugs which themselves produce CNS depression.
1	0	1	O	In
2	3	12	O	particular
3	13	13	O	,
4	15	23	O	XXXXXXXX
5	25	32	O	produces
6	34	41	B-EFF	additive
7	43	45	I-EFF	CNS
8	47	56	I-EFF	depressant
9	58	64	L-EFF	effects
10	66	69	O	when
11	71	84	O	coadministered
12	86	89	O	with
13	91	95	O	other
14	97	108	B-DYN	psychotropic
15	110	120	L-DYN	medications
16	121	121	O	,
17	123	137	U-DYN	anticonvulsants
18	138	138	O	,
19	140	153	U-DYN	antihistamines
20	154	154	O	,
21	156	162	U-DYN	ethanol
22	163	163	O	,
23	165	167	O	and
24	169	173	O	other
25	175	179	O	drugs
26	181	185	O	which
27	187	196	O	themselves
28	198	204	O	produce
29	206	208	O	CNS
30	210	219	O	depression
D/14:6:1 D/17:6:1 D/19:6:1 D/21:6:1

Halcion	5019	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	15
The initial step in triazolam metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).
1	0	2	O	The
2	4	10	O	initial
3	12	15	O	step
4	17	18	O	in
5	20	28	O	XXXXXXXX
6	30	39	O	metabolism
7	41	42	O	is
8	44	56	O	hydroxylation
9	58	66	O	catalyzed
10	68	69	O	by
11	71	80	O	cytochrome
12	82	85	O	P450
13	87	88	O	3A
14	91	93	O	CYP
15	95	96	O	3A
NULL

Halcion	5020	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	16
Drugs which inhibit this metabolic pathway may have a profound effect on the clearance of triazolam.
1	0	4	O	Drugs
2	6	10	O	which
3	12	18	O	inhibit
4	20	23	O	this
5	25	33	O	metabolic
6	35	41	O	pathway
7	43	45	O	may
8	47	50	O	have
9	52	52	O	a
10	54	61	O	profound
11	63	68	O	effect
12	70	71	O	on
13	73	75	O	the
14	77	85	O	clearance
15	87	88	O	of
16	90	98	O	XXXXXXXX
NULL

Halcion	5021	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	15
HALCION is contraindicated with ketoconzaole, itraconazole, nefazodone, and several HIV protease inhibitors.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	25	U-TRI	contraindicated
4	27	30	O	with
5	32	43	U-UNK	ketoconzaole
6	44	44	O	,
7	46	57	U-UNK	itraconazole
8	58	58	O	,
9	60	69	U-UNK	nefazodone
10	70	70	O	,
11	72	74	O	and
12	76	82	O	several
13	84	86	B-UNK	HIV
14	88	95	I-UNK	protease
15	97	106	L-UNK	inhibitors
NULL

Halcion	5022	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	24
Coadministration of isoniazid increased the maximum plasma concentration of triazolam by 20%, decreased clearance by 42%, and increased half-life by 31%.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	U-KIN	isoniazid
4	30	38	B-TRI	increased
5	40	42	I-TRI	the
6	44	50	I-TRI	maximum
7	52	57	I-TRI	plasma
8	59	71	L-TRI	concentration
9	73	74	O	of
10	76	84	O	XXXXXXXX
11	86	87	O	by
12	89	91	O	20%
13	92	92	O	,
14	94	102	B-TRI	decreased
15	104	112	L-TRI	clearance
16	114	115	O	by
17	117	119	O	42%
18	120	120	O	,
19	122	124	O	and
20	126	134	B-TRI	increased
21	136	139	I-TRI	half
22	141	144	L-TRI	life
23	146	147	O	by
24	149	151	O	31%
K/3:C54603

Halcion	5023	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	22
Coadministration of oral contraceptives increased maximum plasma concentration by 6%, decreased clearance by 32%, and increased half-life by 16%.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	23	B-KIN	oral
4	25	38	L-KIN	contraceptives
5	40	48	B-TRI	increased
6	50	56	I-TRI	maximum
7	58	63	I-TRI	plasma
8	65	77	L-TRI	concentration
9	79	80	O	by
10	82	83	O	6%
11	84	84	O	,
12	86	94	B-TRI	decreased
13	96	104	L-TRI	clearance
14	106	107	O	by
15	109	111	O	32%
16	112	112	O	,
17	114	116	O	and
18	118	126	B-TRI	increased
19	128	131	I-TRI	half
20	133	136	L-TRI	life
21	138	139	O	by
22	141	143	O	16%
K/3:C54602

Halcion	5024	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	30
Coadministration of grapefruit juice increased the maximum plasma concentration of triazolam by 25%, increased the area under the concentration curve by 48%, and increased half-life by 18%.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	B-KIN	grapefruit
4	31	35	L-KIN	juice
5	37	45	B-TRI	increased
6	47	49	I-TRI	the
7	51	57	I-TRI	maximum
8	59	64	I-TRI	plasma
9	66	78	L-TRI	concentration
10	80	81	O	of
11	83	91	O	XXXXXXXX
12	93	94	O	by
13	96	98	O	25%
14	99	99	O	,
15	101	109	B-TRI	increased
16	111	113	I-TRI	the
17	115	118	I-TRI	area
18	120	124	I-TRI	under
19	126	128	I-TRI	the
20	130	142	I-TRI	concentration
21	144	148	L-TRI	curve
22	150	151	O	by
23	153	155	O	48%
24	156	156	O	,
25	158	160	O	and
26	162	170	B-TRI	increased
27	172	175	I-TRI	half
28	177	180	L-TRI	life
29	182	183	O	by
30	185	187	O	18%
K/3:C54602

Halcion	5025	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	27
Available data from clinical studies of benzodiazepines other than triazolam suggest a possible drug interaction with triazolam for the following: fluvoxamine, diltiazem, and verapamil.
1	0	8	O	Available
2	10	13	O	data
3	15	18	O	from
4	20	27	O	clinical
5	29	35	O	studies
6	37	38	O	of
7	40	54	O	benzodiazepines
8	56	60	O	other
9	62	65	O	than
10	67	75	O	XXXXXXXX
11	77	83	O	suggest
12	85	85	O	a
13	87	94	O	possible
14	96	99	B-TRI	drug
15	101	111	L-TRI	interaction
16	113	116	O	with
17	118	126	O	XXXXXXXX
18	128	130	O	for
19	132	134	O	the
20	136	144	O	following
21	145	145	O	:
22	147	157	U-UNK	fluvoxamine
23	158	158	O	,
24	160	168	U-UNK	diltiazem
25	169	169	O	,
26	171	173	O	and
27	175	183	U-UNK	verapamil
NULL

Halcion	5026	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	21
Data from in vitro studies of triazolam suggest a possible drug interaction with triazolam for the following: sertraline and paroxetine.
1	0	3	O	Data
2	5	8	O	from
3	10	11	O	in
4	13	17	O	vitro
5	19	25	O	studies
6	27	28	O	of
7	30	38	O	XXXXXXXX
8	40	46	O	suggest
9	48	48	O	a
10	50	57	O	possible
11	59	62	B-TRI	drug
12	64	74	L-TRI	interaction
13	76	79	O	with
14	81	89	O	XXXXXXXX
15	91	93	O	for
16	95	97	O	the
17	99	107	O	following
18	108	108	O	:
19	110	119	U-UNK	sertraline
20	121	123	O	and
21	125	134	U-UNK	paroxetine
NULL

Halcion	5027	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	31
Data from in vitro studies of benzodiazepines other than triazolam suggest a possible drug interaction with triazolam for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
1	0	3	O	Data
2	5	8	O	from
3	10	11	O	in
4	13	17	O	vitro
5	19	25	O	studies
6	27	28	O	of
7	30	44	O	benzodiazepines
8	46	50	O	other
9	52	55	O	than
10	57	65	O	XXXXXXXX
11	67	73	O	suggest
12	75	75	O	a
13	77	84	O	possible
14	86	89	B-TRI	drug
15	91	101	L-TRI	interaction
16	103	106	O	with
17	108	116	O	XXXXXXXX
18	118	120	O	for
19	122	124	O	the
20	126	134	O	following
21	135	135	O	:
22	137	146	U-UNK	ergotamine
23	147	147	O	,
24	149	160	U-UNK	cyclosporine
25	161	161	O	,
26	163	172	U-UNK	amiodarone
27	173	173	O	,
28	175	185	U-UNK	nicardipine
29	186	186	O	,
30	188	190	O	and
31	192	201	U-UNK	nifedipine
NULL

Halcion	5028	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	12
Caution is recommended during coadministration of any of these drugs with triazolam.
1	0	6	O	Caution
2	8	9	O	is
3	11	21	O	recommended
4	23	28	O	during
5	30	45	O	coadministration
6	47	48	O	of
7	50	52	O	any
8	54	55	O	of
9	57	61	O	these
10	63	67	O	drugs
11	69	72	O	with
12	74	82	O	XXXXXXXX
NULL

Halcion	5029	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	29
Coadministration of ranitidine increased the maximum plasma concentration of triazolam by 30%, increased the area under the concentration curve by 27%, and increased half-life by 3.3%.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-KIN	ranitidine
4	31	39	B-TRI	increased
5	41	43	I-TRI	the
6	45	51	I-TRI	maximum
7	53	58	I-TRI	plasma
8	60	72	L-TRI	concentration
9	74	75	O	of
10	77	85	O	XXXXXXXX
11	87	88	O	by
12	90	92	O	30%
13	93	93	O	,
14	95	103	B-TRI	increased
15	105	107	I-TRI	the
16	109	112	I-TRI	area
17	114	118	I-TRI	under
18	120	122	I-TRI	the
19	124	136	I-TRI	concentration
20	138	142	L-TRI	curve
21	144	145	O	by
22	147	149	O	27%
23	150	150	O	,
24	152	154	O	and
25	156	164	B-TRI	increased
26	166	169	I-TRI	half
27	171	174	L-TRI	life
28	176	177	O	by
29	179	182	O	3.3%
K/3:C54605

Halcion	5030	34073-7	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	7
Caution is recommended during coadministration with triazolam.
1	0	6	O	Caution
2	8	9	O	is
3	11	21	O	recommended
4	23	28	O	during
5	30	45	O	coadministration
6	47	50	O	with
7	52	60	O	XXXXXXXX
NULL

Halcion	5031	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	22
Triazolam is a hypnotic with a short mean plasma half-life reported to be in the range of 1.5 to 5.5 hours.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	13	O	a
4	15	22	O	hypnotic
5	24	27	O	with
6	29	29	O	a
7	31	35	O	short
8	37	40	O	mean
9	42	47	O	plasma
10	49	52	O	half
11	54	57	O	life
12	59	66	O	reported
13	68	69	O	to
14	71	72	O	be
15	74	75	O	in
16	77	79	O	the
17	81	85	O	range
18	87	88	O	of
19	90	92	O	1.5
20	94	95	O	to
21	97	99	O	5.5
22	101	105	O	hours
NULL

Halcion	5032	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	29
In normal subjects treated for 7 days with four times the recommended dosage, there was no evidence of altered systemic bioavailability, rate of elimination, or accumulation.
1	0	1	O	In
2	3	8	O	normal
3	10	17	O	subjects
4	19	25	O	treated
5	27	29	O	for
6	31	31	O	7
7	33	36	O	days
8	38	41	O	with
9	43	46	O	four
10	48	52	O	times
11	54	56	O	the
12	58	68	O	recommended
13	70	75	O	dosage
14	76	76	O	,
15	78	82	O	there
16	84	86	O	was
17	88	89	O	no
18	91	98	O	evidence
19	100	101	O	of
20	103	109	O	altered
21	111	118	O	systemic
22	120	134	O	bioavailability
23	135	135	O	,
24	137	140	O	rate
25	142	143	O	of
26	145	155	O	elimination
27	156	156	O	,
28	158	159	O	or
29	161	172	O	accumulation
NULL

Halcion	5033	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	11
Peak plasma levels are reached within 2 hours following oral administration.
1	0	3	O	Peak
2	5	10	O	plasma
3	12	17	O	levels
4	19	21	O	are
5	23	29	O	reached
6	31	36	O	within
7	38	38	O	2
8	40	44	O	hours
9	46	54	O	following
10	56	59	O	oral
11	61	74	O	administration
NULL

Halcion	5034	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	22
Following recommended doses of HALCION, triazolam peak plasma levels in the range of 1 to 6 ng/mL are seen.
1	0	8	O	Following
2	10	20	O	recommended
3	22	26	O	doses
4	28	29	O	of
5	31	37	O	XXXXXXXX
6	38	38	O	,
7	40	48	O	XXXXXXXX
8	50	53	O	peak
9	55	60	O	plasma
10	62	67	O	levels
11	69	70	O	in
12	72	74	O	the
13	76	80	O	range
14	82	83	O	of
15	85	85	O	1
16	87	88	O	to
17	90	90	O	6
18	92	93	O	ng
19	94	94	O	/
20	95	96	O	mL
21	98	100	O	are
22	102	105	O	seen
NULL

Halcion	5035	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	10
The plasma levels achieved are proportional to the dose given.
1	0	2	O	The
2	4	9	O	plasma
3	11	16	O	levels
4	18	25	O	achieved
5	27	29	O	are
6	31	42	O	proportional
7	44	45	O	to
8	47	49	O	the
9	51	54	O	dose
10	56	60	O	given
NULL

Halcion	5036	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	21
Triazolam and its metabolites, principally as conjugated glucuronides, which are presumably inactive, are excreted primarily in the urine.
1	0	8	O	XXXXXXXX
2	10	12	O	and
3	14	16	O	its
4	18	28	O	metabolites
5	29	29	O	,
6	31	41	O	principally
7	43	44	O	as
8	46	55	O	conjugated
9	57	68	O	glucuronides
10	69	69	O	,
11	71	75	O	which
12	77	79	O	are
13	81	90	O	presumably
14	92	99	O	inactive
15	100	100	O	,
16	102	104	O	are
17	106	113	O	excreted
18	115	123	O	primarily
19	125	126	O	in
20	128	130	O	the
21	132	136	O	urine
NULL

Halcion	5037	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	10
Only small amounts of unmetabolized triazolam appear in the urine.
1	0	3	O	Only
2	5	9	O	small
3	11	17	O	amounts
4	19	20	O	of
5	22	34	O	unmetabolized
6	36	44	O	XXXXXXXX
7	46	51	O	appear
8	53	54	O	in
9	56	58	O	the
10	60	64	O	urine
NULL

Halcion	5038	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	10
The two primary metabolites accounted for 79.9% of urinary excretion.
1	0	2	O	The
2	4	6	O	two
3	8	14	O	primary
4	16	26	O	metabolites
5	28	36	O	accounted
6	38	40	O	for
7	42	46	O	79.9%
8	48	49	O	of
9	51	57	O	urinary
10	59	67	O	excretion
NULL

Halcion	5039	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	10
Urinary excretion appeared to be biphasic in its time course.
1	0	6	O	Urinary
2	8	16	O	excretion
3	18	25	O	appeared
4	27	28	O	to
5	30	31	O	be
6	33	40	O	biphasic
7	42	43	O	in
8	45	47	O	its
9	49	52	O	time
10	54	59	O	course
NULL

Halcion	5040	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	27
HALCION Tablets 0.5 mg, in two separate studies, did not affect the prothrombin times or plasma warfarin levels in male volunteers administered sodium warfarin orally.
1	0	6	O	XXXXXXXX
2	8	14	O	Tablets
3	16	18	O	0.5
4	20	21	O	mg
5	22	22	O	,
6	24	25	O	in
7	27	29	O	two
8	31	38	O	separate
9	40	46	O	studies
10	47	47	O	,
11	49	51	O	did
12	53	55	O	not
13	57	62	O	affect
14	64	66	O	the
15	68	78	O	prothrombin
16	80	84	O	times
17	86	87	O	or
18	89	94	O	plasma
19	96	103	O	warfarin
20	105	110	O	levels
21	112	113	O	in
22	115	118	O	male
23	120	129	O	volunteers
24	131	142	O	administered
25	144	149	O	sodium
26	151	158	O	warfarin
27	160	165	O	orally
NULL

Halcion	5041	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	16
Extremely high concentrations of triazolam do not displace bilirubin bound to human serum albumin in vitro.
1	0	8	O	Extremely
2	10	13	O	high
3	15	28	O	concentrations
4	30	31	O	of
5	33	41	O	XXXXXXXX
6	43	44	O	do
7	46	48	O	not
8	50	57	O	displace
9	59	67	O	bilirubin
10	69	73	O	bound
11	75	76	O	to
12	78	82	O	human
13	84	88	O	serum
14	90	96	O	albumin
15	98	99	O	in
16	101	105	O	vitro
NULL

Halcion	5042	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	8
Triazolam 14C was administered orally to pregnant mice.
1	0	8	O	XXXXXXXX
2	10	12	O	14C
3	14	16	O	was
4	18	29	O	administered
5	31	36	O	orally
6	38	39	O	to
7	41	48	O	pregnant
8	50	53	O	mice
NULL

Halcion	5043	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	22
Drug-related material appeared uniformly distributed in the fetus with 14C concentrations approximately the same as in the brain of the mother.
1	0	3	O	Drug
2	5	11	O	related
3	13	20	O	material
4	22	29	O	appeared
5	31	39	O	uniformly
6	41	51	O	distributed
7	53	54	O	in
8	56	58	O	the
9	60	64	O	fetus
10	66	69	O	with
11	71	73	O	14C
12	75	88	O	concentrations
13	90	102	O	approximately
14	104	106	O	the
15	108	111	O	same
16	113	114	O	as
17	116	117	O	in
18	119	121	O	the
19	123	127	O	brain
20	129	130	O	of
21	132	134	O	the
22	136	141	O	mother
NULL

Halcion	5044	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	25
In sleep laboratory studies, HALCION Tablets significantly decreased sleep latency, increased the duration of sleep, and decreased the number of nocturnal awakenings.
1	0	1	O	In
2	3	7	O	sleep
3	9	18	O	laboratory
4	20	26	O	studies
5	27	27	O	,
6	29	35	O	XXXXXXXX
7	37	43	O	Tablets
8	45	57	O	significantly
9	59	67	O	decreased
10	69	73	O	sleep
11	75	81	O	latency
12	82	82	O	,
13	84	92	O	increased
14	94	96	O	the
15	98	105	O	duration
16	107	108	O	of
17	110	114	O	sleep
18	115	115	O	,
19	117	119	O	and
20	121	129	O	decreased
21	131	133	O	the
22	135	140	O	number
23	142	143	O	of
24	145	153	O	nocturnal
25	155	164	O	awakenings
NULL

Halcion	5045	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	32
After 2 weeks of consecutive nightly administration, the drug's effect on total wake time is decreased, and the values recorded in the last third of the night approach baseline levels.
1	0	4	O	After
2	6	6	O	2
3	8	12	O	weeks
4	14	15	O	of
5	17	27	O	consecutive
6	29	35	O	nightly
7	37	50	O	administration
8	51	51	O	,
9	53	55	O	the
10	57	62	O	drug's
11	64	69	O	effect
12	71	72	O	on
13	74	78	O	total
14	80	83	O	wake
15	85	88	O	time
16	90	91	O	is
17	93	101	O	decreased
18	102	102	O	,
19	104	106	O	and
20	108	110	O	the
21	112	117	O	values
22	119	126	O	recorded
23	128	129	O	in
24	131	133	O	the
25	135	138	O	last
26	140	144	O	third
27	146	147	O	of
28	149	151	O	the
29	153	157	O	night
30	159	166	O	approach
31	168	175	O	baseline
32	177	182	O	levels
NULL

Halcion	5046	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	42
On the first and/or second night after drug discontinuance (first or second post-drug night), total time asleep, percentage of time spent sleeping, and rapidity of falling asleep frequently were significantly less than on baseline (predrug) nights.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	first
4	13	15	O	and
5	16	16	O	/
6	17	18	O	or
7	20	25	O	second
8	27	31	O	night
9	33	37	O	after
10	39	42	O	drug
11	44	57	O	discontinuance
12	60	64	O	first
13	66	67	O	or
14	69	74	O	second
15	76	79	O	post
16	81	84	O	drug
17	86	90	O	night
18	92	92	O	,
19	94	98	O	total
20	100	103	O	time
21	105	110	O	asleep
22	111	111	O	,
23	113	122	O	percentage
24	124	125	O	of
25	127	130	O	time
26	132	136	O	spent
27	138	145	O	sleeping
28	146	146	O	,
29	148	150	O	and
30	152	159	O	rapidity
31	161	162	O	of
32	164	170	O	falling
33	172	177	O	asleep
34	179	188	O	frequently
35	190	193	O	were
36	195	207	O	significantly
37	209	212	O	less
38	214	217	O	than
39	219	220	O	on
40	222	229	O	baseline
41	232	238	O	predrug
42	241	246	O	nights
NULL

Halcion	5047	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	7
This effect is often called "rebound" insomnia.
1	0	3	O	This
2	5	10	O	effect
3	12	13	O	is
4	15	19	O	often
5	21	26	O	called
6	28	36	O	"rebound"
7	38	45	O	insomnia
NULL

Halcion	5048	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	34
The type and duration of hypnotic effects and the profile of unwanted effects during administration of benzodiazepine drugs may be influenced by the biologic half-life of administered drug and any active metabolites formed.
1	0	2	O	The
2	4	7	O	type
3	9	11	O	and
4	13	20	O	duration
5	22	23	O	of
6	25	32	O	hypnotic
7	34	40	O	effects
8	42	44	O	and
9	46	48	O	the
10	50	56	O	profile
11	58	59	O	of
12	61	68	O	unwanted
13	70	76	O	effects
14	78	83	O	during
15	85	98	O	administration
16	100	101	O	of
17	103	116	O	benzodiazepine
18	118	122	O	drugs
19	124	126	O	may
20	128	129	O	be
21	131	140	O	influenced
22	142	143	O	by
23	145	147	O	the
24	149	156	O	biologic
25	158	161	O	half
26	163	166	O	life
27	168	169	O	of
28	171	182	O	administered
29	184	187	O	drug
30	189	191	O	and
31	193	195	O	any
32	197	202	O	active
33	204	214	O	metabolites
34	216	221	O	formed
NULL

Halcion	5049	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	43
When half-lives are long, the drug or metabolites may accumulate during periods of nightly administration and be associated with impairments of cognitive and motor performance during waking hours; the possibility of interaction with other psychoactive drugs or alcohol will be enhanced.
1	0	3	O	When
2	5	8	O	half
3	10	14	O	lives
4	16	18	O	are
5	20	23	O	long
6	24	24	O	,
7	26	28	O	the
8	30	33	O	drug
9	35	36	O	or
10	38	48	O	metabolites
11	50	52	O	may
12	54	63	O	accumulate
13	65	70	O	during
14	72	78	O	periods
15	80	81	O	of
16	83	89	O	nightly
17	91	104	O	administration
18	106	108	O	and
19	110	111	O	be
20	113	122	O	associated
21	124	127	O	with
22	129	139	O	impairments
23	141	142	O	of
24	144	152	O	cognitive
25	154	156	O	and
26	158	162	O	motor
27	164	174	O	performance
28	176	181	O	during
29	183	188	O	waking
30	190	194	O	hours
31	197	199	O	the
32	201	211	O	possibility
33	213	214	O	of
34	216	226	U-TRI	interaction
35	228	231	O	with
36	233	237	O	other
37	239	250	B-UNK	psychoactive
38	252	256	L-UNK	drugs
39	258	259	O	or
40	261	267	U-UNK	alcohol
41	269	272	O	will
42	274	275	O	be
43	277	284	O	enhanced
NULL

Halcion	5050	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	39
In contrast, if half-lives are short, the drug and metabolites will be cleared before the next dose is ingested, and carry-over effects related to excessive sedation or CNS depression should be minimal or absent.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	14	O	if
5	16	19	O	half
6	21	25	O	lives
7	27	29	O	are
8	31	35	O	short
9	36	36	O	,
10	38	40	O	the
11	42	45	O	drug
12	47	49	O	and
13	51	61	O	metabolites
14	63	66	O	will
15	68	69	O	be
16	71	77	O	cleared
17	79	84	O	before
18	86	88	O	the
19	90	93	O	next
20	95	98	O	dose
21	100	101	O	is
22	103	110	O	ingested
23	111	111	O	,
24	113	115	O	and
25	117	121	O	carry
26	123	126	O	over
27	128	134	O	effects
28	136	142	O	related
29	144	145	O	to
30	147	155	O	excessive
31	157	164	O	sedation
32	166	167	O	or
33	169	171	O	CNS
34	173	182	O	depression
35	184	189	O	should
36	191	192	O	be
37	194	200	O	minimal
38	202	203	O	or
39	205	210	O	absent
NULL

Halcion	5051	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	21
However, during nightly use for an extended period pharmacodynamic tolerance or adaptation to some effects of benzodiazepine hypnotics may develop.
1	0	6	O	However
2	7	7	O	,
3	9	14	O	during
4	16	22	O	nightly
5	24	26	O	use
6	28	30	O	for
7	32	33	O	an
8	35	42	O	extended
9	44	49	O	period
10	51	65	O	pharmacodynamic
11	67	75	O	tolerance
12	77	78	O	or
13	80	89	O	adaptation
14	91	92	O	to
15	94	97	O	some
16	99	105	O	effects
17	107	108	O	of
18	110	123	O	benzodiazepine
19	125	133	O	hypnotics
20	135	137	O	may
21	139	145	O	develop
NULL

Halcion	5052	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	45
If the drug has a short half-life of elimination, it is possible that a relative deficiency of the drug or its active metabolites (ie, in relationship to the receptor site) may occur at some point in the interval between each night's use.
1	0	1	O	If
2	3	5	O	the
3	7	10	O	drug
4	12	14	O	has
5	16	16	O	a
6	18	22	O	short
7	24	27	O	half
8	29	32	O	life
9	34	35	O	of
10	37	47	O	elimination
11	48	48	O	,
12	50	51	O	it
13	53	54	O	is
14	56	63	O	possible
15	65	68	O	that
16	70	70	O	a
17	72	79	O	relative
18	81	90	O	deficiency
19	92	93	O	of
20	95	97	O	the
21	99	102	O	drug
22	104	105	O	or
23	107	109	O	its
24	111	116	O	active
25	118	128	O	metabolites
26	131	132	O	ie
27	133	133	O	,
28	135	136	O	in
29	138	149	O	relationship
30	151	152	O	to
31	154	156	O	the
32	158	165	O	receptor
33	167	170	O	site
34	173	175	O	may
35	177	181	O	occur
36	183	184	O	at
37	186	189	O	some
38	191	195	O	point
39	197	198	O	in
40	200	202	O	the
41	204	211	O	interval
42	213	219	O	between
43	221	224	O	each
44	226	232	O	night's
45	234	236	O	use
NULL

Halcion	5053	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	49
This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepine hypnotics: 1) increased wakefulness during the last third of the night and 2) the appearance of increased daytime anxiety after 10 days of continuous treatment.
1	0	3	O	This
2	5	12	O	sequence
3	14	15	O	of
4	17	22	O	events
5	24	26	O	may
6	28	34	O	account
7	36	38	O	for
8	40	42	O	two
9	44	51	O	clinical
10	53	60	O	findings
11	62	69	O	reported
12	71	72	O	to
13	74	78	O	occur
14	80	84	O	after
15	86	92	O	several
16	94	98	O	weeks
17	100	101	O	of
18	103	109	O	nightly
19	111	113	O	use
20	115	116	O	of
21	118	124	O	rapidly
22	126	135	O	eliminated
23	137	150	O	benzodiazepine
24	152	160	O	hypnotics
25	161	161	O	:
26	163	163	O	1
27	166	174	O	increased
28	176	186	O	wakefulness
29	188	193	O	during
30	195	197	O	the
31	199	202	O	last
32	204	208	O	third
33	210	211	O	of
34	213	215	O	the
35	217	221	O	night
36	223	225	O	and
37	227	227	O	2
38	230	232	O	the
39	234	243	O	appearance
40	245	246	O	of
41	248	256	O	increased
42	258	264	O	daytime
43	266	272	O	anxiety
44	274	278	O	after
45	280	281	O	10
46	283	286	O	days
47	288	289	O	of
48	291	300	O	continuous
49	302	310	O	treatment
NULL

Halcion	5054	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	41
In a study of elderly (62-83 years old) versus younger subjects (21-41 years old) who received HALCION at the same dose levels (0.125 mg and 0.25 mg), the elderly experienced both greater sedation and impairment of psychomotor performance.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	20	O	elderly
6	23	24	O	62
7	26	27	O	83
8	29	33	O	years
9	35	37	O	old
10	40	45	O	versus
11	47	53	O	younger
12	55	62	O	subjects
13	65	66	O	21
14	68	69	O	41
15	71	75	O	years
16	77	79	O	old
17	82	84	O	who
18	86	93	O	received
19	95	101	O	XXXXXXXX
20	103	104	O	at
21	106	108	O	the
22	110	113	O	same
23	115	118	O	dose
24	120	125	O	levels
25	128	132	O	0.125
26	134	135	O	mg
27	137	139	O	and
28	141	144	O	0.25
29	146	147	O	mg
30	149	149	O	,
31	151	153	O	the
32	155	161	O	elderly
33	163	173	O	experienced
34	175	178	O	both
35	180	186	O	greater
36	188	195	O	sedation
37	197	199	O	and
38	201	210	O	impairment
39	212	213	O	of
40	215	225	O	psychomotor
41	227	237	O	performance
NULL

Halcion	5055	34090-1	a0da0dba-a56d-486b-a45b-e8a7cdfbeac6	13
These effects resulted largely from higher plasma concentrations of triazolam in the elderly.
1	0	4	O	These
2	6	12	O	effects
3	14	21	O	resulted
4	23	29	O	largely
5	31	34	O	from
6	36	41	O	higher
7	43	48	O	plasma
8	50	63	O	concentrations
9	65	66	O	of
10	68	76	O	XXXXXXXX
11	78	79	O	in
12	81	83	O	the
13	85	91	O	elderly
NULL

Haloperidol	5129	34090-1	7d1a9689-23c8-44ef-a474-8c607e13d794	10
The precise mechanism of action has not been clearly established.
1	0	2	O	The
2	4	10	O	precise
3	12	20	O	mechanism
4	22	23	O	of
5	25	30	O	action
6	32	34	O	has
7	36	38	O	not
8	40	43	O	been
9	45	51	O	clearly
10	53	63	O	established
NULL

Harvoni	4334	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	9
Coadministration with amiodarone may result in serious symptomatic bradycardia.
1	0	15	O	Coadministration
2	17	20	O	with
3	22	31	U-DYN	amiodarone
4	33	35	O	may
5	37	42	O	result
6	44	45	O	in
7	47	53	B-EFF	serious
8	55	65	I-EFF	symptomatic
9	67	77	L-EFF	bradycardia
D/3:7:1

Harvoni	4335	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	8
Use of HARVONI with amiodarone is not recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	13	O	XXXXXXXX
4	15	18	O	with
5	20	29	U-UNK	amiodarone
6	31	32	O	is
7	34	36	B-TRI	not
8	38	48	L-TRI	recommended
NULL

Harvoni	4336	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
P-gp inducers (e.g., rifampin, St. John's wort): May alter concentrations of ledipasvir and sofosbuvir.
1	0	0	B-UNK	P
2	2	3	I-UNK	gp
3	5	12	L-UNK	inducers
4	15	17	O	e.g
5	19	19	O	,
6	21	28	U-UNK	rifampin
7	29	29	O	,
8	31	32	B-UNK	St
9	35	40	I-UNK	John's
10	42	45	L-UNK	wort
11	47	47	O	:
12	49	51	O	May
13	53	57	B-TRI	alter
14	59	72	L-TRI	concentrations
15	74	75	O	of
16	77	86	O	XXXXXXXX
17	88	90	O	and
18	92	101	O	XXXXXXXX
NULL

Harvoni	4337	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	10
Use of HARVONI with P-gp inducers is not recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	13	O	XXXXXXXX
4	15	18	O	with
5	20	20	B-UNK	P
6	22	23	I-UNK	gp
7	25	32	L-UNK	inducers
8	34	35	O	is
9	37	39	B-TRI	not
10	41	51	L-TRI	recommended
NULL

Harvoni	4338	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	14
Frequent monitoring of international normalized ratio (INR) values is recommended in patients receiving warfarin.
1	0	7	O	Frequent
2	9	18	U-TRI	monitoring
3	20	21	O	of
4	23	35	O	international
5	37	46	O	normalized
6	48	52	O	ratio
7	55	57	O	INR
8	60	65	O	values
9	67	68	O	is
10	70	80	O	recommended
11	82	83	O	in
12	85	92	O	patients
13	94	102	O	receiving
14	104	111	U-UNK	warfarin
NULL

Harvoni	4339	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
Consult the full prescribing information prior to use for potential drug interactions.
1	0	6	O	Consult
2	8	10	O	the
3	12	15	O	full
4	17	27	O	prescribing
5	29	39	O	information
6	41	45	O	prior
7	47	48	O	to
8	50	52	O	use
9	54	56	O	for
10	58	66	O	potential
11	68	71	O	drug
12	73	84	O	interactions
NULL

Harvoni	4340	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
As HARVONI contains ledipasvir and sofosbuvir, any interactions that have been identified with these agents individually may occur with HARVONI.
1	0	1	O	As
2	3	9	O	XXXXXXXX
3	11	18	O	contains
4	20	29	O	XXXXXXXX
5	31	33	O	and
6	35	44	O	XXXXXXXX
7	45	45	O	,
8	47	49	O	any
9	51	62	O	interactions
10	64	67	O	that
11	69	72	O	have
12	74	77	O	been
13	79	88	O	identified
14	90	93	O	with
15	95	99	O	these
16	101	106	O	agents
17	108	119	O	individually
18	121	123	O	may
19	125	129	O	occur
20	131	134	O	with
21	136	142	O	XXXXXXXX
NULL

Harvoni	4341	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
After oral administration of HARVONI, sofosbuvir is rapidly absorbed and subject to extensive first-pass hepatic extraction.
1	0	4	O	After
2	6	9	O	oral
3	11	24	O	administration
4	26	27	O	of
5	29	35	O	XXXXXXXX
6	36	36	O	,
7	38	47	O	XXXXXXXX
8	49	50	O	is
9	52	58	O	rapidly
10	60	67	O	absorbed
11	69	71	O	and
12	73	79	O	subject
13	81	82	O	to
14	84	92	O	extensive
15	94	98	O	first
16	100	103	O	pass
17	105	111	O	hepatic
18	113	122	O	extraction
NULL

Harvoni	4342	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
In clinical pharmacology studies, both sofosbuvir and the inactive metabolite GS-331007 were monitored for purposes of pharmacokinetic analyses.
1	0	1	O	In
2	3	10	O	clinical
3	12	23	O	pharmacology
4	25	31	O	studies
5	32	32	O	,
6	34	37	O	both
7	39	48	O	XXXXXXXX
8	50	52	O	and
9	54	56	O	the
10	58	65	O	inactive
11	67	76	O	metabolite
12	78	79	O	GS
13	81	86	O	331007
14	88	91	O	were
15	93	101	O	monitored
16	103	105	O	for
17	107	114	O	purposes
18	116	117	O	of
19	119	133	O	pharmacokinetic
20	135	142	O	analyses
NULL

Harvoni	4343	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	27
Ledipasvir is an inhibitor of the drug transporters P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of coadministered substrates for these transporters.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	32	O	the
7	34	37	O	drug
8	39	50	O	transporters
9	52	52	O	P
10	54	55	O	gp
11	57	59	O	and
12	61	66	O	breast
13	68	73	O	cancer
14	75	84	O	resistance
15	86	92	O	protein
16	95	98	O	BCRP
17	101	103	O	and
18	105	107	O	may
19	109	116	O	increase
20	118	127	O	intestinal
21	129	138	O	absorption
22	140	141	O	of
23	143	156	O	coadministered
24	158	167	O	substrates
25	169	171	O	for
26	173	177	O	these
27	179	190	O	transporters
NULL

Harvoni	4344	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
Ledipasvir and sofosbuvir are substrates of drug transporters P-gp and BCRP while GS-331007 is not.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	24	O	XXXXXXXX
4	26	28	O	are
5	30	39	O	substrates
6	41	42	O	of
7	44	47	O	drug
8	49	60	O	transporters
9	62	62	O	P
10	64	65	O	gp
11	67	69	O	and
12	71	74	O	BCRP
13	76	80	O	while
14	82	83	O	GS
15	85	90	O	331007
16	92	93	O	is
17	95	97	O	not
NULL

Harvoni	4346	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Fluctuations in INR values may occur in patients receiving warfarin concomitant with HCV treatment, including treatment with HARVONI.
1	0	11	B-EFF	Fluctuations
2	13	14	I-EFF	in
3	16	18	I-EFF	INR
4	20	25	L-EFF	values
5	27	29	O	may
6	31	35	O	occur
7	37	38	O	in
8	40	47	O	patients
9	49	57	O	receiving
10	59	66	U-DYN	warfarin
11	68	78	O	concomitant
12	80	83	O	with
13	85	87	O	HCV
14	89	97	O	treatment
15	98	98	O	,
16	100	108	O	including
17	110	118	O	treatment
18	120	123	O	with
19	125	131	O	XXXXXXXX
D/10:1:1

Harvoni	4347	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	14
Frequent monitoring of INR values is recommended during treatment and post-treatment follow-up.
1	0	7	O	Frequent
2	9	18	O	monitoring
3	20	21	O	of
4	23	25	O	INR
5	27	32	O	values
6	34	35	O	is
7	37	47	O	recommended
8	49	54	O	during
9	56	64	O	treatment
10	66	68	O	and
11	70	73	O	post
12	75	83	O	treatment
13	85	90	O	follow
14	92	93	O	up
NULL

Harvoni	4348	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	13
Table 5 provides a listing of established or potentially clinically significant drug interactions.
1	0	4	O	Table
2	6	6	O	5
3	8	15	O	provides
4	17	17	O	a
5	19	25	O	listing
6	27	28	O	of
7	30	40	O	established
8	42	43	O	or
9	45	55	O	potentially
10	57	66	O	clinically
11	68	78	O	significant
12	80	83	O	drug
13	85	96	O	interactions
NULL

Harvoni	4349	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	34
The drug interactions described are based on studies conducted with either HARVONI, the components of HARVONI (ledipasvir and sofosbuvir) as individual agents, or are predicted drug interactions that may occur with HARVONI.
1	0	2	O	The
2	4	7	O	drug
3	9	20	O	interactions
4	22	30	O	described
5	32	34	O	are
6	36	40	O	based
7	42	43	O	on
8	45	51	O	studies
9	53	61	O	conducted
10	63	66	O	with
11	68	73	O	either
12	75	81	O	XXXXXXXX
13	82	82	O	,
14	84	86	O	the
15	88	97	O	components
16	99	100	O	of
17	102	108	O	XXXXXXXX
18	111	120	O	XXXXXXXX
19	122	124	O	and
20	126	135	O	XXXXXXXX
21	138	139	O	as
22	141	150	O	individual
23	152	157	O	agents
24	158	158	O	,
25	160	161	O	or
26	163	165	O	are
27	167	175	O	predicted
28	177	180	O	drug
29	182	193	O	interactions
30	195	198	O	that
31	200	202	O	may
32	204	208	O	occur
33	210	213	O	with
34	215	221	O	XXXXXXXX
NULL

Harvoni	4350	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	28
Table 5 Potentially Significant Drug Interactions: Alteration in Dose or Regimen May Be Recommended Based on Drug Interaction Studies or Predicted InteractionThis table is not all inclusive.
1	0	4	O	Table
2	6	6	O	5
3	8	18	O	Potentially
4	20	30	O	Significant
5	32	35	O	Drug
6	37	48	O	Interactions
7	49	49	O	:
8	51	60	O	Alteration
9	62	63	O	in
10	65	68	O	Dose
11	70	71	O	or
12	73	79	O	Regimen
13	81	83	O	May
14	85	86	O	Be
15	88	98	O	Recommended
16	100	104	O	Based
17	106	107	O	on
18	109	112	O	Drug
19	114	124	O	Interaction
20	126	132	O	Studies
21	134	135	O	or
22	137	145	O	Predicted
23	147	161	O	InteractionThis
24	163	167	O	table
25	169	170	O	is
26	172	174	O	not
27	176	178	O	all
28	180	188	O	inclusive
NULL

Harvoni	4351	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	29
Concomitant Drug Class: Drug Name Effect on Concentration* = decrease, * = increase Clinical Comment Acid Reducing Agents: * ledipasvir Ledipasvir solubility decreases as pH increases.
1	0	10	O	Concomitant
2	12	15	O	Drug
3	17	21	O	Class
4	22	22	O	:
5	24	27	O	Drug
6	29	32	O	Name
7	34	39	O	Effect
8	41	42	O	on
9	44	57	O	Concentration*
10	59	59	O	=
11	61	68	O	decrease
12	69	69	O	,
13	71	71	O	*
14	73	73	O	=
15	75	82	O	increase
16	84	91	O	Clinical
17	93	99	O	Comment
18	101	104	O	Acid
19	106	113	O	Reducing
20	115	120	O	Agents
21	121	121	O	:
22	123	123	O	*
23	125	134	O	XXXXXXXX
24	136	145	O	XXXXXXXX
25	147	156	O	solubility
26	158	166	O	decreases
27	168	169	O	as
28	171	172	O	pH
29	174	182	O	increases
NULL

Harvoni	4352	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
Drugs that increase gastric pH are expected to decrease concentration of ledipasvir.
1	0	4	B-KIN	Drugs
2	6	9	I-KIN	that
3	11	18	I-KIN	increase
4	20	26	I-KIN	gastric
5	28	29	L-KIN	pH
6	31	33	O	are
7	35	42	O	expected
8	44	45	O	to
9	47	54	B-TRI	decrease
10	56	68	L-TRI	concentration
11	70	71	O	of
12	73	82	O	XXXXXXXX
K/1:C54356

Harvoni	4353	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Antacids (e.g., aluminum and magnesium hydroxide) It is recommended to separate antacid and HARVONI administration by 4 hours.
1	0	7	U-UNK	Antacids
2	10	12	O	e.g
3	14	14	O	,
4	16	23	B-UNK	aluminum
5	25	27	I-UNK	and
6	29	37	I-UNK	magnesium
7	39	47	L-UNK	hydroxide
8	50	51	O	It
9	53	54	O	is
10	56	66	O	recommended
11	68	69	O	to
12	71	78	O	separate
13	80	86	O	antacid
14	88	90	O	and
15	92	98	O	XXXXXXXX
16	100	113	O	administration
17	115	116	O	by
18	118	118	O	4
19	120	124	O	hours
NULL

Harvoni	4354	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	10
H2-receptor antagonistsThese interactions have been studied in healthy adults.
1	0	1	B-UNK	H2
2	3	10	L-UNK	receptor
3	12	27	O	antagonistsThese
4	29	40	U-TRI	interactions
5	42	45	O	have
6	47	50	O	been
7	52	58	O	studied
8	60	61	O	in
9	63	69	O	healthy
10	71	76	O	adults
NULL

Harvoni	4355	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	32
(e.g., famotidine) H2-receptor antagonists may be administered simultaneously with or 12 hours apart from HARVONI at a dose that does not exceed doses comparable to famotidine 40 mg twice daily.
1	1	3	O	e.g
2	5	5	O	,
3	7	16	U-KIN	famotidine
4	19	20	B-KIN	H2
5	22	29	I-KIN	receptor
6	31	41	L-KIN	antagonists
7	43	45	O	may
8	47	48	O	be
9	50	61	O	administered
10	63	76	O	simultaneously
11	78	81	O	with
12	83	84	O	or
13	86	87	O	12
14	89	93	O	hours
15	95	99	O	apart
16	101	104	O	from
17	106	112	O	XXXXXXXX
18	114	115	O	at
19	117	117	O	a
20	119	122	B-TRI	dose
21	124	127	I-TRI	that
22	129	132	I-TRI	does
23	134	136	I-TRI	not
24	138	143	L-TRI	exceed
25	145	149	O	doses
26	151	160	O	comparable
27	162	163	O	to
28	165	174	O	famotidine
29	176	177	O	40
30	179	180	O	mg
31	182	186	O	twice
32	188	192	O	daily
K/3:C54355 K/4:C54355

Harvoni	4356	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
Proton-pump inhibitors (e.g., omeprazole) Proton-pump inhibitor doses comparable to omeprazole 20 mg or lower can be administered simultaneously with HARVONI under fasted conditions.
1	0	5	B-KIN	Proton
2	7	10	L-KIN	pump
3	12	21	U-KIN	inhibitors
4	24	26	O	e.g
5	28	28	O	,
6	30	39	U-KIN	omeprazole
7	42	47	O	Proton
8	49	52	O	pump
9	54	62	O	inhibitor
10	64	68	O	doses
11	70	79	O	comparable
12	81	82	O	to
13	84	93	O	omeprazole
14	95	96	O	20
15	98	99	O	mg
16	101	102	O	or
17	104	108	O	lower
18	110	112	O	can
19	114	115	O	be
20	117	128	O	administered
21	130	143	O	simultaneously
22	145	148	O	with
23	150	156	O	XXXXXXXX
24	158	162	O	under
25	164	169	O	fasted
26	171	180	O	conditions
K/1:C54355 K/3:C54355 K/6:C54355

Harvoni	4357	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	24
Antiarrhythmics: amiodarone Effect on amiodarone, ledipasvir, and sofosbuvir concentrations unknown Coadministration of amiodarone with HARVONI may result in serious symptomatic bradycardia.
1	0	14	O	Antiarrhythmics
2	15	15	O	:
3	17	26	U-DYN	amiodarone
4	28	33	O	Effect
5	35	36	O	on
6	38	47	O	amiodarone
7	48	48	O	,
8	50	59	O	XXXXXXXX
9	60	60	O	,
10	62	64	O	and
11	66	75	O	XXXXXXXX
12	77	90	O	concentrations
13	92	98	O	unknown
14	100	115	O	Coadministration
15	117	118	O	of
16	120	129	O	amiodarone
17	131	134	O	with
18	136	142	O	XXXXXXXX
19	144	146	O	may
20	148	153	O	result
21	155	156	O	in
22	158	164	B-EFF	serious
23	166	176	I-EFF	symptomatic
24	178	188	L-EFF	bradycardia
D/3:22:1

Harvoni	4358	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
Coadministration of amiodarone with HARVONI is not recommended; if coadministration is required, cardiac monitoring is recommended digoxin * digoxin Coadministration of HARVONI with digoxin may increase the concentration of digoxin.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-UNK	amiodarone
4	31	34	O	with
5	36	42	O	XXXXXXXX
6	44	45	O	is
7	47	49	B-TRI	not
8	51	61	L-TRI	recommended
9	64	65	O	if
10	67	82	O	coadministration
11	84	85	O	is
12	87	94	O	required
13	95	95	O	,
14	97	103	O	cardiac
15	105	114	O	monitoring
16	116	117	O	is
17	119	129	O	recommended
18	131	137	U-KIN	digoxin
19	139	139	O	*
20	141	147	O	digoxin
21	149	164	O	Coadministration
22	166	167	O	of
23	169	175	O	XXXXXXXX
24	177	180	O	with
25	182	188	O	digoxin
26	190	192	O	may
27	194	201	B-TRI	increase
28	203	205	I-TRI	the
29	207	219	L-TRI	concentration
30	221	222	O	of
31	224	230	O	digoxin
K/18:C54357

Harvoni	4359	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
Therapeutic concentration monitoring of digoxin is recommended when coadministered with HARVONI.
1	0	10	O	Therapeutic
2	12	24	O	concentration
3	26	35	O	monitoring
4	37	38	O	of
5	40	46	U-UNK	digoxin
6	48	49	O	is
7	51	61	O	recommended
8	63	66	O	when
9	68	81	O	coadministered
10	83	86	O	with
11	88	94	O	XXXXXXXX
NULL

Harvoni	4360	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	43
Anticonvulsants: carbamazepine phenytoin phenobarbital oxcarbazepine * ledipasvir* sofosbuvir* GS-331007 Coadministration of HARVONI with carbamazepine, phenytoin, phenobarbital, or oxcarbazepine is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI.
1	0	14	U-KIN	Anticonvulsants
2	15	15	O	:
3	17	29	U-KIN	carbamazepine
4	31	39	U-KIN	phenytoin
5	41	53	U-KIN	phenobarbital
6	55	67	U-KIN	oxcarbazepine
7	69	69	O	*
8	71	80	O	XXXXXXXX
9	81	81	O	*
10	83	92	O	XXXXXXXX
11	93	93	O	*
12	95	96	O	GS
13	98	103	O	331007
14	105	120	O	Coadministration
15	122	123	O	of
16	125	131	O	XXXXXXXX
17	133	136	O	with
18	138	150	O	carbamazepine
19	151	151	O	,
20	153	161	O	phenytoin
21	162	162	O	,
22	164	176	O	phenobarbital
23	177	177	O	,
24	179	180	O	or
25	182	194	O	oxcarbazepine
26	196	197	O	is
27	199	206	O	expected
28	208	209	O	to
29	211	218	B-TRI	decrease
30	220	222	I-TRI	the
31	224	236	L-TRI	concentration
32	238	239	O	of
33	241	250	O	XXXXXXXX
34	252	254	O	and
35	256	265	O	XXXXXXXX
36	266	266	O	,
37	268	274	O	leading
38	276	277	O	to
39	279	285	O	reduced
40	287	297	O	therapeutic
41	299	304	O	effect
42	306	307	O	of
43	309	315	O	XXXXXXXX
K/1:C54356 K/3:C54356 K/4:C54356 K/5:C54356 K/6:C54356

Harvoni	4361	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	37
Antimycobacterials: rifabutin rifampin rifapentine * ledipasvir* sofosbuvir* GS-331007 Coadministration of HARVONI with rifabutin or rifapentine is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI.
1	0	17	U-KIN	Antimycobacterials
2	18	18	O	:
3	20	28	U-KIN	rifabutin
4	30	37	U-KIN	rifampin
5	39	49	U-KIN	rifapentine
6	51	51	O	*
7	53	62	O	XXXXXXXX
8	63	63	O	*
9	65	74	O	XXXXXXXX
10	75	75	O	*
11	77	78	O	GS
12	80	85	O	331007
13	87	102	O	Coadministration
14	104	105	O	of
15	107	113	O	XXXXXXXX
16	115	118	O	with
17	120	128	O	rifabutin
18	130	131	O	or
19	133	143	O	rifapentine
20	145	146	O	is
21	148	155	O	expected
22	157	158	O	to
23	160	167	B-TRI	decrease
24	169	171	I-TRI	the
25	173	185	L-TRI	concentration
26	187	188	O	of
27	190	199	O	XXXXXXXX
28	201	203	O	and
29	205	214	O	XXXXXXXX
30	215	215	O	,
31	217	223	O	leading
32	225	226	O	to
33	228	234	O	reduced
34	236	246	O	therapeutic
35	248	253	O	effect
36	255	256	O	of
37	258	264	O	XXXXXXXX
K/1:C54356 K/3:C54356 K/4:C54356 K/5:C54356

Harvoni	4362	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
Coadministration is not recommended.Coadministration of HARVONI with rifampin, a P-gp inducer, is not recommended.
1	0	15	O	Coadministration
2	17	18	O	is
3	20	22	U-TRI	not
4	24	51	O	recommended.Coadministration
5	53	54	O	of
6	56	62	O	XXXXXXXX
7	64	67	O	with
8	69	76	U-UNK	rifampin
9	77	77	O	,
10	79	79	O	a
11	81	81	O	P
12	83	84	O	gp
13	86	92	O	inducer
14	93	93	O	,
15	95	96	O	is
16	98	100	O	not
17	102	112	O	recommended
NULL

Harvoni	4363	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	43
HIV Antiretrovirals: Regimens containing tenofovir DF without an HIV protease inhibitor/ritonavir or cobicistat tenofovir Monitor for tenofovir-associated adverse reactions in patients receiving HARVONI concomitantly with a regimen containing tenofovir DF without an HIV protease inhibitor/ritonavir or cobicistat.
1	0	2	O	HIV
2	4	18	O	Antiretrovirals
3	19	19	O	:
4	21	28	O	Regimens
5	30	39	O	containing
6	41	49	U-UNK	tenofovir
7	51	52	O	DF
8	54	60	O	without
9	62	63	O	an
10	65	67	O	HIV
11	69	76	O	protease
12	78	86	O	inhibitor
13	87	87	O	/
14	88	96	O	ritonavir
15	98	99	O	or
16	101	110	O	cobicistat
17	112	120	O	tenofovir
18	122	128	O	Monitor
19	130	132	O	for
20	134	142	O	tenofovir
21	144	153	B-TRI	associated
22	155	161	I-TRI	adverse
23	163	171	L-TRI	reactions
24	173	174	O	in
25	176	183	O	patients
26	185	193	O	receiving
27	195	201	O	XXXXXXXX
28	203	215	O	concomitantly
29	217	220	O	with
30	222	222	O	a
31	224	230	O	regimen
32	232	241	O	containing
33	243	251	O	tenofovir
34	253	254	O	DF
35	256	262	O	without
36	264	265	O	an
37	267	269	O	HIV
38	271	278	O	protease
39	280	288	O	inhibitor
40	289	289	O	/
41	290	298	O	ritonavir
42	300	301	O	or
43	303	312	O	cobicistat
NULL

Harvoni	4364	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
Refer to VIREAD or TRUVADA prescribing information for recommendations on renal monitoring.
1	0	4	O	Refer
2	6	7	O	to
3	9	14	O	VIREAD
4	16	17	O	or
5	19	25	O	TRUVADA
6	27	37	O	prescribing
7	39	49	O	information
8	51	53	O	for
9	55	69	O	recommendations
10	71	72	O	on
11	74	78	O	renal
12	80	89	O	monitoring
NULL

Harvoni	4365	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	13
Regimens containing tenofovir DF and an HIV protease inhibitor/ritonavir or cobicistat
1	0	7	O	Regimens
2	9	18	O	containing
3	20	28	O	tenofovir
4	30	31	O	DF
5	33	35	O	and
6	37	38	O	an
7	40	42	O	HIV
8	44	51	O	protease
9	53	61	O	inhibitor
10	62	62	O	/
11	63	71	O	ritonavir
12	73	74	O	or
13	76	85	O	cobicistat
NULL

Harvoni	4366	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
If coadministration is necessary, monitor for tenofovir-associated adverse reactions.
1	0	1	O	If
2	3	18	O	coadministration
3	20	21	O	is
4	23	31	O	necessary
5	32	32	O	,
6	34	40	U-TRI	monitor
7	42	44	O	for
8	46	54	U-UNK	tenofovir
9	56	65	O	associated
10	67	73	O	adverse
11	75	83	O	reactions
NULL

Harvoni	4367	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	84
Refer to VIREAD or TRUVADA prescribing information for recommendations on renal monitoring. elvitegravir, cobicistat, emtricitabine, tenofovir DF * tenofovir The safety of increased tenofovir concentrations in the setting of HARVONI and the combination of elvitegravir, cobicistat, emtricitabine and tenofovir DF has not been established. tipranavir/ritonavir * ledipasvir* sofosbuvir* GS-331007 Coadministration of HARVONI with tipranavir/ritonavir is expected to decrease the concentration of ledipasvir and sofosbuvir, leading to reduced therapeutic effect of HARVONI.
1	0	4	O	Refer
2	6	7	O	to
3	9	14	O	VIREAD
4	16	17	O	or
5	19	25	O	TRUVADA
6	27	37	O	prescribing
7	39	49	O	information
8	51	53	O	for
9	55	69	O	recommendations
10	71	72	O	on
11	74	78	O	renal
12	80	89	O	monitoring
13	92	103	O	elvitegravir
14	104	104	O	,
15	106	115	O	cobicistat
16	116	116	O	,
17	118	130	O	emtricitabine
18	131	131	O	,
19	133	141	U-KIN	tenofovir
20	143	144	O	DF
21	146	146	O	*
22	148	156	O	tenofovir
23	158	160	O	The
24	162	167	O	safety
25	169	170	O	of
26	172	180	O	increased
27	182	190	O	tenofovir
28	192	205	O	concentrations
29	207	208	O	in
30	210	212	O	the
31	214	220	O	setting
32	222	223	O	of
33	225	231	O	XXXXXXXX
34	233	235	O	and
35	237	239	O	the
36	241	251	O	combination
37	253	254	O	of
38	256	267	O	elvitegravir
39	268	268	O	,
40	270	279	O	cobicistat
41	280	280	O	,
42	282	294	O	emtricitabine
43	296	298	O	and
44	300	308	O	tenofovir
45	310	311	O	DF
46	313	315	O	has
47	317	319	O	not
48	321	324	O	been
49	326	336	O	established
50	339	348	U-KIN	tipranavir
51	349	349	B-KIN	/
52	350	358	L-KIN	ritonavir
53	360	360	O	*
54	362	371	O	XXXXXXXX
55	372	372	O	*
56	374	383	O	XXXXXXXX
57	384	384	O	*
58	386	387	O	GS
59	389	394	O	331007
60	396	411	O	Coadministration
61	413	414	O	of
62	416	422	O	XXXXXXXX
63	424	427	O	with
64	429	438	O	tipranavir
65	439	439	O	/
66	440	448	O	ritonavir
67	450	451	O	is
68	453	460	O	expected
69	462	463	O	to
70	465	472	B-TRI	decrease
71	474	476	I-TRI	the
72	478	490	L-TRI	concentration
73	492	493	O	of
74	495	504	O	XXXXXXXX
75	506	508	O	and
76	510	519	O	XXXXXXXX
77	520	520	O	,
78	522	528	O	leading
79	530	531	O	to
80	533	539	O	reduced
81	541	551	O	therapeutic
82	553	558	O	effect
83	560	561	O	of
84	563	569	O	XXXXXXXX
K/19:C54357 K/50:C54356 K/51:C54356

Harvoni	4368	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
HCV Products: simeprevir * ledipasvir* simeprevir Concentrations of ledipasvir and simeprevir are increased when simeprevir is coadministered with ledipasvir.
1	0	2	O	HCV
2	4	11	O	Products
3	12	12	O	:
4	14	23	U-KIN	simeprevir
5	25	25	O	*
6	27	36	O	XXXXXXXX
7	37	37	O	*
8	39	48	O	simeprevir
9	50	63	O	Concentrations
10	65	66	O	of
11	68	77	O	XXXXXXXX
12	79	81	O	and
13	83	92	O	simeprevir
14	94	96	O	are
15	98	106	O	increased
16	108	111	O	when
17	113	122	O	simeprevir
18	124	125	O	is
19	127	140	O	coadministered
20	142	145	O	with
21	147	156	O	XXXXXXXX
K/4:C54357

Harvoni	4369	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	8
Coadministration of HARVONI with simeprevir is not recommended.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	XXXXXXXX
4	28	31	O	with
5	33	42	U-UNK	simeprevir
6	44	45	O	is
7	47	49	B-TRI	not
8	51	61	L-TRI	recommended
NULL

Harvoni	4370	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
Herbal Supplements: St. John's wort (Hypericum perforatum) * ledipasvir* sofosbuvir* GS-331007 Coadministration of HARVONI with St. John's wort, a P-gp inducer is not recommended.
1	0	5	O	Herbal
2	7	17	O	Supplements
3	18	18	O	:
4	20	21	B-UNK	St
5	24	29	I-UNK	John's
6	31	34	I-UNK	wort
7	37	45	I-UNK	Hypericum
8	47	56	L-UNK	perforatum
9	59	59	O	*
10	61	70	O	XXXXXXXX
11	71	71	O	*
12	73	82	O	XXXXXXXX
13	83	83	O	*
14	85	86	O	GS
15	88	93	O	331007
16	95	110	O	Coadministration
17	112	113	O	of
18	115	121	O	XXXXXXXX
19	123	126	O	with
20	128	129	O	St
21	132	137	O	John's
22	139	142	O	wort
23	143	143	O	,
24	145	145	O	a
25	147	147	O	P
26	149	150	O	gp
27	152	158	O	inducer
28	160	161	O	is
29	163	165	B-TRI	not
30	167	177	L-TRI	recommended
NULL

Harvoni	4371	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
HMG-CoA Reductase Inhibitors: rosuvastatin * rosuvastatin Coadministration of HARVONI with rosuvastatin may significantly increase the concentration of rosuvastatin which is associated with increased risk of myopathy, including rhabdomyolysis.
1	0	2	O	HMG
2	4	6	O	CoA
3	8	16	O	Reductase
4	18	27	O	Inhibitors
5	28	28	O	:
6	30	41	U-DYN	rosuvastatin
7	43	43	O	*
8	45	56	O	rosuvastatin
9	58	73	O	Coadministration
10	75	76	O	of
11	78	84	O	XXXXXXXX
12	86	89	O	with
13	91	102	O	rosuvastatin
14	104	106	O	may
15	108	120	O	significantly
16	122	129	B-TRI	increase
17	131	133	I-TRI	the
18	135	147	L-TRI	concentration
19	149	150	O	of
20	152	163	O	rosuvastatin
21	165	169	O	which
22	171	172	O	is
23	174	183	O	associated
24	185	188	O	with
25	190	198	O	increased
26	200	203	O	risk
27	205	206	O	of
28	208	215	U-EFF	myopathy
29	216	216	O	,
30	218	226	O	including
31	228	241	U-EFF	rhabdomyolysis
D/6:28:1 D/6:31:1

Harvoni	4372	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	24
Coadministration of HARVONI with rosuvastatin is not recommended.atorvastatin* atorvastatinCoadministration of HARVONI with atorvastatin may be associated with increased risk of myopathy, including rhabdomyolysis.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	26	O	XXXXXXXX
4	28	31	O	with
5	33	44	U-UNK	rosuvastatin
6	46	47	O	is
7	49	51	U-TRI	not
8	53	77	O	recommended.atorvastatin*
9	79	106	O	atorvastatinCoadministration
10	108	109	O	of
11	111	117	O	XXXXXXXX
12	119	122	O	with
13	124	135	O	atorvastatin
14	137	139	O	may
15	141	142	O	be
16	144	153	O	associated
17	155	158	O	with
18	160	168	O	increased
19	170	173	O	risk
20	175	176	O	of
21	178	185	U-EFF	myopathy
22	186	186	O	,
23	188	196	O	including
24	198	211	U-EFF	rhabdomyolysis
NULL

Harvoni	4373	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	16
Monitor closely for HMG-CoA reductase inhibitor-associated adverse reactions, such as myopathy and rhabdomyolysis.
1	0	6	O	Monitor
2	8	14	O	closely
3	16	18	O	for
4	20	22	B-DYN	HMG
5	24	26	I-DYN	CoA
6	28	36	I-DYN	reductase
7	38	46	L-DYN	inhibitor
8	48	57	O	associated
9	59	65	O	adverse
10	67	75	O	reactions
11	76	76	O	,
12	78	81	O	such
13	83	84	O	as
14	86	93	U-EFF	myopathy
15	95	97	O	and
16	99	112	U-EFF	rhabdomyolysis
D/4:14:1 D/4:16:1

Harvoni	4374	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	76
Based on drug interaction studies conducted with the components of HARVONI (ledipasvir or sofosbuvir) or HARVONI, no clinically significant drug interactions have been either observed or are expected when HARVONI is used with the following drugs individually : abacavir, atazanavir/ritonavir, cyclosporine, darunavir/ritonavir, efavirenz, emtricitabine, lamivudine, methadone, oral contraceptives, pravastatin, raltegravir, rilpivirine, tacrolimus, tenofovir disoproxil fumarate, or verapamil.
1	0	4	O	Based
2	6	7	O	on
3	9	12	O	drug
4	14	24	O	interaction
5	26	32	O	studies
6	34	42	O	conducted
7	44	47	O	with
8	49	51	O	the
9	53	62	O	components
10	64	65	O	of
11	67	73	O	XXXXXXXX
12	76	85	O	XXXXXXXX
13	87	88	O	or
14	90	99	O	XXXXXXXX
15	102	103	O	or
16	105	111	O	XXXXXXXX
17	112	112	O	,
18	114	115	O	no
19	117	126	O	clinically
20	128	138	O	significant
21	140	143	O	drug
22	145	156	O	interactions
23	158	161	O	have
24	163	166	O	been
25	168	173	O	either
26	175	182	O	observed
27	184	185	O	or
28	187	189	O	are
29	191	198	O	expected
30	200	203	O	when
31	205	211	O	XXXXXXXX
32	213	214	O	is
33	216	219	O	used
34	221	224	O	with
35	226	228	O	the
36	230	238	O	following
37	240	244	O	drugs
38	246	257	O	individually
39	259	259	O	:
40	261	268	O	abacavir
41	269	269	O	,
42	271	280	O	atazanavir
43	281	281	O	/
44	282	290	O	ritonavir
45	291	291	O	,
46	293	304	O	cyclosporine
47	305	305	O	,
48	307	315	O	darunavir
49	316	316	O	/
50	317	325	O	ritonavir
51	326	326	O	,
52	328	336	O	efavirenz
53	337	337	O	,
54	339	351	O	emtricitabine
55	352	352	O	,
56	354	363	O	lamivudine
57	364	364	O	,
58	366	374	O	methadone
59	375	375	O	,
60	377	380	O	oral
61	382	395	O	contraceptives
62	396	396	O	,
63	398	408	O	pravastatin
64	409	409	O	,
65	411	421	O	raltegravir
66	422	422	O	,
67	424	434	O	rilpivirine
68	435	435	O	,
69	437	446	O	tacrolimus
70	447	447	O	,
71	449	457	O	tenofovir
72	459	468	O	disoproxil
73	470	477	O	fumarate
74	478	478	O	,
75	480	481	O	or
76	483	491	O	verapamil
NULL

Harvoni	4375	34073-7	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
See Table 5 for use of HARVONI with certain HIV antiretroviral regimens.
1	0	2	O	See
2	4	8	O	Table
3	10	10	O	5
4	12	14	O	for
5	16	18	O	use
6	20	21	O	of
7	23	29	O	XXXXXXXX
8	31	34	O	with
9	36	42	O	certain
10	44	46	O	HIV
11	48	61	O	antiretroviral
12	63	70	O	regimens
NULL

Harvoni	4376	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
HARVONI is a fixed-dose combination of ledipasvir and sofosbuvir which are direct-acting antiviral agents against the hepatitis C virus.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	11	O	a
4	13	17	O	fixed
5	19	22	O	dose
6	24	34	O	combination
7	36	37	O	of
8	39	48	O	XXXXXXXX
9	50	52	O	and
10	54	63	O	XXXXXXXX
11	65	69	O	which
12	71	73	O	are
13	75	80	O	direct
14	82	87	O	acting
15	89	104	O	GGGGGGGG
16	106	112	O	against
17	114	116	O	the
18	118	126	O	hepatitis
19	128	128	O	C
20	130	134	O	virus
NULL

Harvoni	4377	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
Cardiac Electrophysiology Thorough QT studies have been conducted for ledipasvir and sofosbuvir.
1	0	6	O	Cardiac
2	8	24	O	Electrophysiology
3	26	33	O	Thorough
4	35	36	O	QT
5	38	44	O	studies
6	46	49	O	have
7	51	54	O	been
8	56	64	O	conducted
9	66	68	O	for
10	70	79	O	XXXXXXXX
11	81	83	O	and
12	85	94	O	XXXXXXXX
NULL

Harvoni	4378	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	47
The effect of ledipasvir 120 mg twice daily (2.67 times the maximum recommended dosage) for 10 days on QTc interval was evaluated in a randomized, multiple-dose, placebo-, and active-controlled (moxifloxacin 400 mg) three period crossover thorough QT trial in 59 healthy subjects.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	27	O	120
6	29	30	O	mg
7	32	36	O	twice
8	38	42	O	daily
9	45	48	O	2.67
10	50	54	O	times
11	56	58	O	the
12	60	66	O	maximum
13	68	78	O	recommended
14	80	85	O	dosage
15	88	90	O	for
16	92	93	O	10
17	95	98	O	days
18	100	101	O	on
19	103	105	O	QTc
20	107	114	O	interval
21	116	118	O	was
22	120	128	O	evaluated
23	130	131	O	in
24	133	133	O	a
25	135	144	O	randomized
26	145	145	O	,
27	147	154	O	multiple
28	156	159	O	dose
29	160	160	O	,
30	162	168	O	placebo
31	170	170	O	,
32	172	174	O	and
33	176	181	O	active
34	183	192	O	controlled
35	195	206	O	moxifloxacin
36	208	210	O	400
37	212	213	O	mg
38	216	220	O	three
39	222	227	O	period
40	229	237	O	crossover
41	239	246	O	thorough
42	248	249	O	QT
43	251	255	O	trial
44	257	258	O	in
45	260	261	O	59
46	263	269	O	healthy
47	271	278	O	subjects
NULL

Harvoni	4379	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
At the dose of 120 mg twice daily (2.67 times the maximum recommended dosage), ledipasvir does not prolong QTc interval to any clinically relevant extent.
1	0	1	O	At
2	3	5	O	the
3	7	10	O	dose
4	12	13	O	of
5	15	17	O	120
6	19	20	O	mg
7	22	26	O	twice
8	28	32	O	daily
9	35	38	O	2.67
10	40	44	O	times
11	46	48	O	the
12	50	56	O	maximum
13	58	68	O	recommended
14	70	75	O	dosage
15	77	77	O	,
16	79	88	O	XXXXXXXX
17	90	93	O	does
18	95	97	O	not
19	99	105	O	prolong
20	107	109	O	QTc
21	111	118	O	interval
22	120	121	O	to
23	123	125	O	any
24	127	136	O	clinically
25	138	145	O	relevant
26	147	152	O	extent
NULL

Harvoni	4380	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	48
The effect of sofosbuvir 400 mg (maximum recommended dosage) and 1200 mg (three times the maximum recommended dosage) on QTc interval was evaluated in a randomized, single-dose, placebo-, and active-controlled (moxifloxacin 400 mg) four period crossover thorough QT trial in 59 healthy subjects.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	27	O	400
6	29	30	O	mg
7	33	39	O	maximum
8	41	51	O	recommended
9	53	58	O	dosage
10	61	63	O	and
11	65	68	O	1200
12	70	71	O	mg
13	74	78	O	three
14	80	84	O	times
15	86	88	O	the
16	90	96	O	maximum
17	98	108	O	recommended
18	110	115	O	dosage
19	118	119	O	on
20	121	123	O	QTc
21	125	132	O	interval
22	134	136	O	was
23	138	146	O	evaluated
24	148	149	O	in
25	151	151	O	a
26	153	162	O	randomized
27	163	163	O	,
28	165	170	O	single
29	172	175	O	dose
30	176	176	O	,
31	178	184	O	placebo
32	186	186	O	,
33	188	190	O	and
34	192	197	O	active
35	199	208	O	controlled
36	211	222	O	moxifloxacin
37	224	226	O	400
38	228	229	O	mg
39	232	235	O	four
40	237	242	O	period
41	244	252	O	crossover
42	254	261	O	thorough
43	263	264	O	QT
44	266	270	O	trial
45	272	273	O	in
46	275	276	O	59
47	278	284	O	healthy
48	286	293	O	subjects
NULL

Harvoni	4381	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
At a dose three times the maximum recommended dose, sofosbuvir does not prolong QTc to any clinically relevant extent.
1	0	1	O	At
2	3	3	O	a
3	5	8	O	dose
4	10	14	O	three
5	16	20	O	times
6	22	24	O	the
7	26	32	O	maximum
8	34	44	O	recommended
9	46	49	O	dose
10	50	50	O	,
11	52	61	O	XXXXXXXX
12	63	66	O	does
13	68	70	O	not
14	72	78	O	prolong
15	80	82	O	QTc
16	84	85	O	to
17	87	89	O	any
18	91	100	O	clinically
19	102	109	O	relevant
20	111	116	O	extent
NULL

Harvoni	4382	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	48
Absorption The pharmacokinetic properties of ledipasvir, sofosbuvir, and the predominant circulating metabolite GS-331007 have been evaluated in healthy adult subjects and in subjects with chronic hepatitis C. Following oral administration of HARVONI, ledipasvir median peak concentrations were observed 4 to 4.5 hours post-dose.
1	0	9	O	Absorption
2	11	13	O	The
3	15	29	O	pharmacokinetic
4	31	40	O	properties
5	42	43	O	of
6	45	54	O	XXXXXXXX
7	55	55	O	,
8	57	66	O	XXXXXXXX
9	67	67	O	,
10	69	71	O	and
11	73	75	O	the
12	77	87	O	predominant
13	89	99	O	circulating
14	101	110	O	metabolite
15	112	113	O	GS
16	115	120	O	331007
17	122	125	O	have
18	127	130	O	been
19	132	140	O	evaluated
20	142	143	O	in
21	145	151	O	healthy
22	153	157	O	adult
23	159	166	O	subjects
24	168	170	O	and
25	172	173	O	in
26	175	182	O	subjects
27	184	187	O	with
28	189	195	O	chronic
29	197	205	O	hepatitis
30	207	207	O	C
31	210	218	O	Following
32	220	223	O	oral
33	225	238	O	administration
34	240	241	O	of
35	243	249	O	XXXXXXXX
36	250	250	O	,
37	252	261	O	XXXXXXXX
38	263	268	O	median
39	270	273	O	peak
40	275	288	O	concentrations
41	290	293	O	were
42	295	302	O	observed
43	304	304	O	4
44	306	307	O	to
45	309	311	O	4.5
46	313	317	O	hours
47	319	322	O	post
48	324	327	O	dose
NULL

Harvoni	4383	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
Sofosbuvir was absorbed quickly and the peak median plasma concentration was observed ~0.8 to 1 hour post-dose.
1	0	9	O	XXXXXXXX
2	11	13	O	was
3	15	22	O	absorbed
4	24	30	O	quickly
5	32	34	O	and
6	36	38	O	the
7	40	43	O	peak
8	45	50	O	median
9	52	57	O	plasma
10	59	71	O	concentration
11	73	75	O	was
12	77	84	O	observed
13	86	89	O	~0.8
14	91	92	O	to
15	94	94	O	1
16	96	99	O	hour
17	101	104	O	post
18	106	109	O	dose
NULL

Harvoni	4384	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	16
Median peak plasma concentration of GS-331007 was observed between 3.5 to 4 hours post-dose.
1	0	5	O	Median
2	7	10	O	peak
3	12	17	O	plasma
4	19	31	O	concentration
5	33	34	O	of
6	36	37	O	GS
7	39	44	O	331007
8	46	48	O	was
9	50	57	O	observed
10	59	65	O	between
11	67	69	O	3.5
12	71	72	O	to
13	74	74	O	4
14	76	80	O	hours
15	82	85	O	post
16	87	90	O	dose
NULL

Harvoni	4385	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	40
Based on the population pharmacokinetic analysis in HCV-infected subjects, geometric mean steady-state AUC0-24 for ledipasvir (N=2113), sofosbuvir (N=1542), and GS-331007 (N=2113) were 7290, 1320, and 12,000 ng*hr/mL, respectively.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	22	O	population
5	24	38	O	pharmacokinetic
6	40	47	O	analysis
7	49	50	O	in
8	52	54	O	HCV
9	56	63	O	infected
10	65	72	O	subjects
11	73	73	O	,
12	75	83	O	geometric
13	85	88	O	mean
14	90	95	O	steady
15	97	101	O	state
16	103	106	O	AUC0
17	108	109	O	24
18	111	113	O	for
19	115	124	O	XXXXXXXX
20	127	132	O	N=2113
21	134	134	O	,
22	136	145	O	XXXXXXXX
23	148	153	O	N=1542
24	155	155	O	,
25	157	159	O	and
26	161	162	O	GS
27	164	169	O	331007
28	172	177	O	N=2113
29	180	183	O	were
30	185	188	O	7290
31	189	189	O	,
32	191	194	O	1320
33	195	195	O	,
34	197	199	O	and
35	201	206	O	12,000
36	208	212	O	ng*hr
37	213	213	O	/
38	214	215	O	mL
39	216	216	O	,
40	218	229	O	respectively
NULL

Harvoni	4386	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	23
Steady-state Cmax for ledipasvir, sofosbuvir, and GS-331007 were 323, 618, and 707 ng/mL, respectively.
1	0	5	O	Steady
2	7	11	O	state
3	13	16	O	Cmax
4	18	20	O	for
5	22	31	O	XXXXXXXX
6	32	32	O	,
7	34	43	O	XXXXXXXX
8	44	44	O	,
9	46	48	O	and
10	50	51	O	GS
11	53	58	O	331007
12	60	63	O	were
13	65	67	O	323
14	68	68	O	,
15	70	72	O	618
16	73	73	O	,
17	75	77	O	and
18	79	81	O	707
19	83	84	O	ng
20	85	85	O	/
21	86	87	O	mL
22	88	88	O	,
23	90	101	O	respectively
NULL

Harvoni	4387	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Sofosbuvir and GS-331007 AUC0-24 and Cmax were similar in healthy adult subjects and subjects with HCV infection.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	16	O	GS
4	18	23	O	331007
5	25	28	O	AUC0
6	30	31	O	24
7	33	35	O	and
8	37	40	O	Cmax
9	42	45	O	were
10	47	53	O	similar
11	55	56	O	in
12	58	64	O	healthy
13	66	70	O	adult
14	72	79	O	subjects
15	81	83	O	and
16	85	92	O	subjects
17	94	97	O	with
18	99	101	O	HCV
19	103	111	O	infection
NULL

Harvoni	4388	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	24
Relative to healthy subjects (N=191), ledipasvir AUC0-24 and Cmax were 24% lower and 32% lower, respectively, in HCV-infected subjects.
1	0	7	O	Relative
2	9	10	O	to
3	12	18	O	healthy
4	20	27	O	subjects
5	30	34	O	N=191
6	36	36	O	,
7	38	47	O	XXXXXXXX
8	49	52	O	AUC0
9	54	55	O	24
10	57	59	O	and
11	61	64	O	Cmax
12	66	69	O	were
13	71	73	O	24%
14	75	79	O	lower
15	81	83	O	and
16	85	87	O	32%
17	89	93	O	lower
18	94	94	O	,
19	96	107	O	respectively
20	108	108	O	,
21	110	111	O	in
22	113	115	O	HCV
23	117	124	O	infected
24	126	133	O	subjects
NULL

Harvoni	4389	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	52
Effect of Food Relative to fasting conditions, the administration of a single dose of HARVONI with a moderate fat (~600 kcal, 25% to 30% fat) or high fat (~1000 kcal, 50% fat) meal increased sofosbuvir AUC0-inf by approximately 2-fold, but did not significantly affect sofosbuvir Cmax.
1	0	5	O	Effect
2	7	8	O	of
3	10	13	U-KIN	Food
4	15	22	O	Relative
5	24	25	O	to
6	27	33	O	fasting
7	35	44	O	conditions
8	45	45	O	,
9	47	49	O	the
10	51	64	O	administration
11	66	67	O	of
12	69	69	O	a
13	71	76	O	single
14	78	81	O	dose
15	83	84	O	of
16	86	92	O	XXXXXXXX
17	94	97	O	with
18	99	99	O	a
19	101	108	O	moderate
20	110	112	O	fat
21	115	118	O	~600
22	120	123	O	kcal
23	124	124	O	,
24	126	128	O	25%
25	130	131	O	to
26	133	135	O	30%
27	137	139	O	fat
28	142	143	O	or
29	145	148	O	high
30	150	152	O	fat
31	155	159	O	~1000
32	161	164	O	kcal
33	165	165	O	,
34	167	169	O	50%
35	171	173	O	fat
36	176	179	O	meal
37	181	189	B-TRI	increased
38	191	200	L-TRI	XXXXXXXX
39	202	205	O	AUC0
40	207	209	O	inf
41	211	212	O	by
42	214	226	O	approximately
43	228	228	O	2
44	230	233	O	fold
45	234	234	O	,
46	236	238	O	but
47	240	242	O	did
48	244	246	O	not
49	248	260	O	significantly
50	262	267	O	affect
51	269	278	O	XXXXXXXX
52	280	283	O	Cmax
K/3:C54605

Harvoni	4390	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
The exposures of GS-331007 and ledipasvir were not altered in the presence of either meal type.
1	0	2	O	The
2	4	12	O	exposures
3	14	15	O	of
4	17	18	O	GS
5	20	25	O	331007
6	27	29	O	and
7	31	40	O	XXXXXXXX
8	42	45	O	were
9	47	49	O	not
10	51	57	O	altered
11	59	60	O	in
12	62	64	O	the
13	66	73	O	presence
14	75	76	O	of
15	78	83	O	either
16	85	88	O	meal
17	90	93	O	type
NULL

Harvoni	4391	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
The response rates in Phase 3 trials were similar in HCV-infected subjects who received HARVONI with food or without food.
1	0	2	O	The
2	4	11	O	response
3	13	17	O	rates
4	19	20	O	in
5	22	26	O	Phase
6	28	28	O	3
7	30	35	O	trials
8	37	40	O	were
9	42	48	O	similar
10	50	51	O	in
11	53	55	O	HCV
12	57	64	O	infected
13	66	73	O	subjects
14	75	77	O	who
15	79	86	O	received
16	88	94	O	XXXXXXXX
17	96	99	O	with
18	101	104	O	food
19	106	107	O	or
20	109	115	O	without
21	117	120	O	food
NULL

Harvoni	4392	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	8
HARVONI can be administered without regard to food.
1	0	6	O	XXXXXXXX
2	8	10	O	can
3	12	13	O	be
4	15	26	O	administered
5	28	34	O	without
6	36	41	O	regard
7	43	44	O	to
8	46	49	O	food
NULL

Harvoni	4393	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
Distribution Ledipasvir is greater than 99.8% bound to human plasma proteins.
1	0	11	O	Distribution
2	13	22	O	XXXXXXXX
3	24	25	O	is
4	27	33	O	greater
5	35	38	O	than
6	40	44	O	99.8%
7	46	50	O	bound
8	52	53	O	to
9	55	59	O	human
10	61	66	O	plasma
11	68	75	O	proteins
NULL

Harvoni	4394	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
After a single 90 mg dose of [14C]-ledipasvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity ranged between 0.51 and 0.66.
1	0	4	O	After
2	6	6	O	a
3	8	13	O	single
4	15	16	O	90
5	18	19	O	mg
6	21	24	O	dose
7	26	27	O	of
8	30	32	O	14C
9	35	44	O	XXXXXXXX
10	46	47	O	in
11	49	55	O	healthy
12	57	64	O	subjects
13	65	65	O	,
14	67	69	O	the
15	71	75	O	blood
16	77	78	O	to
17	80	85	O	plasma
18	87	91	O	ratio
19	93	94	O	of
20	96	98	O	14C
21	100	112	O	radioactivity
22	114	119	O	ranged
23	121	127	O	between
24	129	132	O	0.51
25	134	136	O	and
26	138	141	O	0.66
NULL

Harvoni	4395	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
Sofosbuvir is approximately 61-65% bound to human plasma proteins and the binding is independent of drug concentration over the range of 1 ug/mL to 20 ug/mL.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	26	O	approximately
4	28	29	O	61
5	31	33	O	65%
6	35	39	O	bound
7	41	42	O	to
8	44	48	O	human
9	50	55	O	plasma
10	57	64	O	proteins
11	66	68	O	and
12	70	72	O	the
13	74	80	O	binding
14	82	83	O	is
15	85	95	O	independent
16	97	98	O	of
17	100	103	O	drug
18	105	117	O	concentration
19	119	122	O	over
20	124	126	O	the
21	128	132	O	range
22	134	135	O	of
23	137	137	O	1
24	139	140	O	ug
25	141	141	O	/
26	142	143	O	mL
27	145	146	O	to
28	148	149	O	20
29	151	152	O	ug
30	153	153	O	/
31	154	155	O	mL
NULL

Harvoni	4396	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	10
Protein binding of GS-331007 was minimal in human plasma.
1	0	6	O	Protein
2	8	14	O	binding
3	16	17	O	of
4	19	20	O	GS
5	22	27	O	331007
6	29	31	O	was
7	33	39	O	minimal
8	41	42	O	in
9	44	48	O	human
10	50	55	O	plasma
NULL

Harvoni	4397	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	24
After a single 400 mg dose of [14C]-sofosbuvir in healthy subjects, the blood to plasma ratio of 14C-radioactivity was approximately 0.7.
1	0	4	O	After
2	6	6	O	a
3	8	13	O	single
4	15	17	O	400
5	19	20	O	mg
6	22	25	O	dose
7	27	28	O	of
8	31	33	O	14C
9	36	45	O	XXXXXXXX
10	47	48	O	in
11	50	56	O	healthy
12	58	65	O	subjects
13	66	66	O	,
14	68	70	O	the
15	72	76	O	blood
16	78	79	O	to
17	81	86	O	plasma
18	88	92	O	ratio
19	94	95	O	of
20	97	99	O	14C
21	101	113	O	radioactivity
22	115	117	O	was
23	119	131	O	approximately
24	133	135	O	0.7
NULL

Harvoni	4398	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
Metabolism In vitro, no detectable metabolism of ledipasvir was observed by human CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.
1	0	9	O	Metabolism
2	11	12	O	In
3	14	18	O	vitro
4	19	19	O	,
5	21	22	O	no
6	24	33	O	detectable
7	35	44	O	metabolism
8	46	47	O	of
9	49	58	O	XXXXXXXX
10	60	62	O	was
11	64	71	O	observed
12	73	74	O	by
13	76	80	O	human
14	82	87	O	CYP1A2
15	88	88	O	,
16	90	95	O	CYP2C8
17	96	96	O	,
18	98	103	O	CYP2C9
19	104	104	O	,
20	106	112	O	CYP2C19
21	113	113	O	,
22	115	120	O	CYP2D6
23	121	121	O	,
24	123	125	O	and
25	127	132	O	CYP3A4
NULL

Harvoni	4399	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
Evidence of slow oxidative metabolism via an unknown mechanism has been observed.
1	0	7	O	Evidence
2	9	10	O	of
3	12	15	O	slow
4	17	25	O	oxidative
5	27	36	O	metabolism
6	38	40	O	via
7	42	43	O	an
8	45	51	O	unknown
9	53	61	O	mechanism
10	63	65	O	has
11	67	70	O	been
12	72	79	O	observed
NULL

Harvoni	4400	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	22
Following a single dose of 90 mg [14C]-ledipasvir, systemic exposure was almost exclusively to the parent drug (greater than 98%).
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	22	O	dose
5	24	25	O	of
6	27	28	O	90
7	30	31	O	mg
8	34	36	O	14C
9	39	48	O	XXXXXXXX
10	49	49	O	,
11	51	58	O	systemic
12	60	67	O	exposure
13	69	71	O	was
14	73	78	O	almost
15	80	90	O	exclusively
16	92	93	O	to
17	95	97	O	the
18	99	104	O	parent
19	106	109	O	drug
20	112	118	O	greater
21	120	123	O	than
22	125	127	O	98%
NULL

Harvoni	4401	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	9
Unchanged ledipasvir is the major species present in feces.
1	0	8	O	Unchanged
2	10	19	O	XXXXXXXX
3	21	22	O	is
4	24	26	O	the
5	28	32	O	major
6	34	40	O	species
7	42	48	O	present
8	50	51	O	in
9	53	57	O	feces
NULL

Harvoni	4402	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
Sofosbuvir is extensively metabolized in the liver to form the pharmacologically active nucleoside analog triphosphate GS-461203.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	39	O	in
6	41	43	O	the
7	45	49	O	liver
8	51	52	O	to
9	54	57	O	form
10	59	61	O	the
11	63	79	O	pharmacologically
12	81	86	O	active
13	88	97	O	nucleoside
14	99	104	O	analog
15	106	117	O	triphosphate
16	119	120	O	GS
17	122	127	O	461203
NULL

Harvoni	4403	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	42
The metabolic activation pathway involves sequential hydrolysis of the carboxyl ester moiety catalyzed by human cathepsin A (CatA) or carboxylesterase 1 (CES1) and phosphoramidate cleavage by histidine triad nucleotide-binding protein 1 (HINT1) followed by phosphorylation by the pyrimidine nucleotide biosynthesis pathway.
1	0	2	O	The
2	4	12	O	metabolic
3	14	23	O	activation
4	25	31	O	pathway
5	33	40	O	involves
6	42	51	O	sequential
7	53	62	O	hydrolysis
8	64	65	O	of
9	67	69	O	the
10	71	78	O	carboxyl
11	80	84	O	ester
12	86	91	O	moiety
13	93	101	O	catalyzed
14	103	104	O	by
15	106	110	O	human
16	112	120	O	cathepsin
17	122	122	O	A
18	125	128	O	CatA
19	131	132	O	or
20	134	149	O	carboxylesterase
21	151	151	O	1
22	154	157	O	CES1
23	160	162	O	and
24	164	178	O	phosphoramidate
25	180	187	O	cleavage
26	189	190	O	by
27	192	200	O	histidine
28	202	206	O	triad
29	208	217	O	nucleotide
30	219	225	O	binding
31	227	233	O	protein
32	235	235	O	1
33	238	242	O	HINT1
34	245	252	O	followed
35	254	255	O	by
36	257	271	O	phosphorylation
37	273	274	O	by
38	276	278	O	the
39	280	289	O	pyrimidine
40	291	300	O	nucleotide
41	302	313	O	biosynthesis
42	315	321	O	pathway
NULL

Harvoni	4404	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	22
Dephosphorylation results in the formation of nucleoside metabolite GS-331007 that cannot be efficiently rephosphorylated and lacks anti-HCV activity in vitro.
1	0	16	O	Dephosphorylation
2	18	24	O	results
3	26	27	O	in
4	29	31	O	the
5	33	41	O	formation
6	43	44	O	of
7	46	55	O	nucleoside
8	57	66	O	metabolite
9	68	69	O	GS
10	71	76	O	331007
11	78	81	O	that
12	83	88	O	cannot
13	90	91	O	be
14	93	103	O	efficiently
15	105	120	O	rephosphorylated
16	122	124	O	and
17	126	130	O	lacks
18	132	135	O	anti
19	137	139	O	HCV
20	141	148	O	activity
21	150	151	O	in
22	153	157	O	vitro
NULL

Harvoni	4405	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	23
After a single 400 mg oral dose of [14C]-sofosbuvir, GS-331007 accounted for approximately greater than 90% of total systemic exposure.
1	0	4	O	After
2	6	6	O	a
3	8	13	O	single
4	15	17	O	400
5	19	20	O	mg
6	22	25	O	oral
7	27	30	O	dose
8	32	33	O	of
9	36	38	O	14C
10	41	50	O	XXXXXXXX
11	51	51	O	,
12	53	54	O	GS
13	56	61	O	331007
14	63	71	O	accounted
15	73	75	O	for
16	77	89	O	approximately
17	91	97	O	greater
18	99	102	O	than
19	104	106	O	90%
20	108	109	O	of
21	111	115	O	total
22	117	124	O	systemic
23	126	133	O	exposure
NULL

Harvoni	4406	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	38
Elimination Following a single 90 mg oral dose of [14C]-ledipasvir, mean total recovery of the [14C]-radioactivity in feces and urine was approximately 87%, with most of the radioactive dose recovered from feces (approximately 86%).
1	0	10	O	Elimination
2	12	20	O	Following
3	22	22	O	a
4	24	29	O	single
5	31	32	O	90
6	34	35	O	mg
7	37	40	O	oral
8	42	45	O	dose
9	47	48	O	of
10	51	53	O	14C
11	56	65	O	XXXXXXXX
12	66	66	O	,
13	68	71	O	mean
14	73	77	O	total
15	79	86	O	recovery
16	88	89	O	of
17	91	93	O	the
18	96	98	O	14C
19	101	113	O	radioactivity
20	115	116	O	in
21	118	122	O	feces
22	124	126	O	and
23	128	132	O	urine
24	134	136	O	was
25	138	150	O	approximately
26	152	154	O	87%
27	155	155	O	,
28	157	160	O	with
29	162	165	O	most
30	167	168	O	of
31	170	172	O	the
32	174	184	O	radioactive
33	186	189	O	dose
34	191	199	O	recovered
35	201	204	O	from
36	206	210	O	feces
37	213	225	O	approximately
38	227	229	O	86%
NULL

Harvoni	4407	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
Unchanged ledipasvir excreted in feces accounted for a mean of 70% of the administered dose and the oxidative metabolite M19 accounted for 2.2% of the dose.
1	0	8	O	Unchanged
2	10	19	O	XXXXXXXX
3	21	28	O	excreted
4	30	31	O	in
5	33	37	O	feces
6	39	47	O	accounted
7	49	51	O	for
8	53	53	O	a
9	55	58	O	mean
10	60	61	O	of
11	63	65	O	70%
12	67	68	O	of
13	70	72	O	the
14	74	85	O	administered
15	87	90	O	dose
16	92	94	O	and
17	96	98	O	the
18	100	108	O	oxidative
19	110	119	O	metabolite
20	121	123	O	M19
21	125	133	O	accounted
22	135	137	O	for
23	139	142	O	2.2%
24	144	145	O	of
25	147	149	O	the
26	151	154	O	dose
NULL

Harvoni	4408	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
These data indicate that biliary excretion of unchanged ledipasvir is a major route of elimination, with renal excretion being a minor pathway (approximately 1%).
1	0	4	O	These
2	6	9	O	data
3	11	18	O	indicate
4	20	23	O	that
5	25	31	O	biliary
6	33	41	O	excretion
7	43	44	O	of
8	46	54	O	unchanged
9	56	65	O	XXXXXXXX
10	67	68	O	is
11	70	70	O	a
12	72	76	O	major
13	78	82	O	route
14	84	85	O	of
15	87	97	O	elimination
16	98	98	O	,
17	100	103	O	with
18	105	109	O	renal
19	111	119	O	excretion
20	121	125	O	being
21	127	127	O	a
22	129	133	O	minor
23	135	141	O	pathway
24	144	156	O	approximately
25	158	159	O	1%
NULL

Harvoni	4409	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	14
The median terminal half-life of ledipasvir following administration of HARVONI was 47 hours.
1	0	2	O	The
2	4	9	O	median
3	11	18	O	terminal
4	20	23	O	half
5	25	28	O	life
6	30	31	O	of
7	33	42	O	XXXXXXXX
8	44	52	O	following
9	54	67	O	administration
10	69	70	O	of
11	72	78	O	XXXXXXXX
12	80	82	O	was
13	84	85	O	47
14	87	91	O	hours
NULL

Harvoni	4410	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	42
Following a single 400 mg oral dose of [14C]-sofosbuvir, mean total recovery of the dose was greater than 92%, consisting of approximately 80%, 14%, and 2.5% recovered in urine, feces, and expired air, respectively.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	21	O	400
5	23	24	O	mg
6	26	29	O	oral
7	31	34	O	dose
8	36	37	O	of
9	40	42	O	14C
10	45	54	O	XXXXXXXX
11	55	55	O	,
12	57	60	O	mean
13	62	66	O	total
14	68	75	O	recovery
15	77	78	O	of
16	80	82	O	the
17	84	87	O	dose
18	89	91	O	was
19	93	99	O	greater
20	101	104	O	than
21	106	108	O	92%
22	109	109	O	,
23	111	120	O	consisting
24	122	123	O	of
25	125	137	O	approximately
26	139	141	O	80%
27	142	142	O	,
28	144	146	O	14%
29	147	147	O	,
30	149	151	O	and
31	153	156	O	2.5%
32	158	166	O	recovered
33	168	169	O	in
34	171	175	O	urine
35	176	176	O	,
36	178	182	O	feces
37	183	183	O	,
38	185	187	O	and
39	189	195	O	expired
40	197	199	O	air
41	200	200	O	,
42	202	213	O	respectively
NULL

Harvoni	4411	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
The majority of the sofosbuvir dose recovered in urine was GS-331007 (78%) while 3.5% was recovered as sofosbuvir.
1	0	2	O	The
2	4	11	O	majority
3	13	14	O	of
4	16	18	O	the
5	20	29	O	XXXXXXXX
6	31	34	O	dose
7	36	44	O	recovered
8	46	47	O	in
9	49	53	O	urine
10	55	57	O	was
11	59	60	O	GS
12	62	67	O	331007
13	70	72	O	78%
14	75	79	O	while
15	81	84	O	3.5%
16	86	88	O	was
17	90	98	O	recovered
18	100	101	O	as
19	103	112	O	XXXXXXXX
NULL

Harvoni	4412	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	14
These data indicate that renal clearance is the major elimination pathway for GS-331007.
1	0	4	O	These
2	6	9	O	data
3	11	18	O	indicate
4	20	23	O	that
5	25	29	O	renal
6	31	39	O	clearance
7	41	42	O	is
8	44	46	O	the
9	48	52	O	major
10	54	64	O	elimination
11	66	72	O	pathway
12	74	76	O	for
13	78	79	O	GS
14	81	86	O	331007
NULL

Harvoni	4413	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
The median terminal half-lives of sofosbuvir and GS-331007 following administration of HARVONI were 0.5 and 27 hours, respectively.
1	0	2	O	The
2	4	9	O	median
3	11	18	O	terminal
4	20	23	O	half
5	25	29	O	lives
6	31	32	O	of
7	34	43	O	XXXXXXXX
8	45	47	O	and
9	49	50	O	GS
10	52	57	O	331007
11	59	67	O	following
12	69	82	O	administration
13	84	85	O	of
14	87	93	O	XXXXXXXX
15	95	98	O	were
16	100	102	O	0.5
17	104	106	O	and
18	108	109	O	27
19	111	115	O	hours
20	116	116	O	,
21	118	129	O	respectively
NULL

Harvoni	4414	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
Specific Populations Race: Population pharmacokinetics analysis in HCV-infected subjects indicated that race had no clinically relevant effect on the exposure of ledipasvir, sofosbuvir, and GS-331007.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	24	O	Race
4	25	25	O	:
5	27	36	O	Population
6	38	53	O	pharmacokinetics
7	55	62	O	analysis
8	64	65	O	in
9	67	69	O	HCV
10	71	78	O	infected
11	80	87	O	subjects
12	89	97	O	indicated
13	99	102	O	that
14	104	107	O	race
15	109	111	O	had
16	113	114	O	no
17	116	125	O	clinically
18	127	134	O	relevant
19	136	141	O	effect
20	143	144	O	on
21	146	148	O	the
22	150	157	O	exposure
23	159	160	O	of
24	162	171	O	XXXXXXXX
25	172	172	O	,
26	174	183	O	XXXXXXXX
27	184	184	O	,
28	186	188	O	and
29	190	191	O	GS
30	193	198	O	331007
NULL

Harvoni	4415	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
Gender: Population pharmacokinetics analysis in HCV-infected subjects indicated that gender had no clinically relevant effect on the exposure of sofosbuvir and GS-331007.
1	0	5	O	Gender
2	6	6	O	:
3	8	17	O	Population
4	19	34	O	pharmacokinetics
5	36	43	O	analysis
6	45	46	O	in
7	48	50	O	HCV
8	52	59	O	infected
9	61	68	O	subjects
10	70	78	O	indicated
11	80	83	O	that
12	85	90	O	gender
13	92	94	O	had
14	96	97	O	no
15	99	108	O	clinically
16	110	117	O	relevant
17	119	124	O	effect
18	126	127	O	on
19	129	131	O	the
20	133	140	O	exposure
21	142	143	O	of
22	145	154	O	XXXXXXXX
23	156	158	O	and
24	160	161	O	GS
25	163	168	O	331007
NULL

Harvoni	4416	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	60
AUC and Cmax of ledipasvir were 77% and 58% higher, respectively, in females than males; however, the relationship between gender and ledipasvir exposures was not considered clinically relevant, as high response rates (SVR >90%) were achieved in male and female subjects across the Phase 3 studies and the safety profiles are similar in females and males.
1	0	2	O	AUC
2	4	6	O	and
3	8	11	O	Cmax
4	13	14	O	of
5	16	25	O	XXXXXXXX
6	27	30	O	were
7	32	34	O	77%
8	36	38	O	and
9	40	42	O	58%
10	44	49	O	higher
11	50	50	O	,
12	52	63	O	respectively
13	64	64	O	,
14	66	67	O	in
15	69	75	O	females
16	77	80	O	than
17	82	86	O	males
18	89	95	O	however
19	96	96	O	,
20	98	100	O	the
21	102	113	O	relationship
22	115	121	O	between
23	123	128	O	gender
24	130	132	O	and
25	134	143	O	XXXXXXXX
26	145	153	O	exposures
27	155	157	O	was
28	159	161	O	not
29	163	172	O	considered
30	174	183	O	clinically
31	185	192	O	relevant
32	193	193	O	,
33	195	196	O	as
34	198	201	O	high
35	203	210	O	response
36	212	216	O	rates
37	219	221	O	SVR
38	223	226	O	>90%
39	229	232	O	were
40	234	241	O	achieved
41	243	244	O	in
42	246	249	O	male
43	251	253	O	and
44	255	260	O	female
45	262	269	O	subjects
46	271	276	O	across
47	278	280	O	the
48	282	286	O	Phase
49	288	288	O	3
50	290	296	O	studies
51	298	300	O	and
52	302	304	O	the
53	306	311	O	safety
54	313	320	O	profiles
55	322	324	O	are
56	326	332	O	similar
57	334	335	O	in
58	337	343	O	females
59	345	347	O	and
60	349	353	O	males
NULL

Harvoni	4417	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	43
Pediatric Patients: The pharmacokinetics of ledipasvir, sofosbuvir, and GS-331007 were determined in 100 pediatric subjects 12 years of age and older infected with HCV genotype 1 receiving a daily dose of HARVONI (90 mg ledipasvir and 400 mg sofosbuvir).
1	0	8	O	Pediatric
2	10	17	O	Patients
3	18	18	O	:
4	20	22	O	The
5	24	39	O	pharmacokinetics
6	41	42	O	of
7	44	53	O	XXXXXXXX
8	54	54	O	,
9	56	65	O	XXXXXXXX
10	66	66	O	,
11	68	70	O	and
12	72	73	O	GS
13	75	80	O	331007
14	82	85	O	were
15	87	96	O	determined
16	98	99	O	in
17	101	103	O	100
18	105	113	O	pediatric
19	115	122	O	subjects
20	124	125	O	12
21	127	131	O	years
22	133	134	O	of
23	136	138	O	age
24	140	142	O	and
25	144	148	O	older
26	150	157	O	infected
27	159	162	O	with
28	164	166	O	HCV
29	168	175	O	genotype
30	177	177	O	1
31	179	187	O	receiving
32	189	189	O	a
33	191	195	O	daily
34	197	200	O	dose
35	202	203	O	of
36	205	211	O	XXXXXXXX
37	214	215	O	90
38	217	218	O	mg
39	220	229	O	XXXXXXXX
40	231	233	O	and
41	235	237	O	400
42	239	240	O	mg
43	242	251	O	XXXXXXXX
NULL

Harvoni	4418	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
The pharmacokinetic properties of ledipasvir, sofosbuvir, and GS-331007 in pediatric subjects 12 years of age and older are provided in Table 6.
1	0	2	O	The
2	4	18	O	pharmacokinetic
3	20	29	O	properties
4	31	32	O	of
5	34	43	O	XXXXXXXX
6	44	44	O	,
7	46	55	O	XXXXXXXX
8	56	56	O	,
9	58	60	O	and
10	62	63	O	GS
11	65	70	O	331007
12	72	73	O	in
13	75	83	O	pediatric
14	85	92	O	subjects
15	94	95	O	12
16	97	101	O	years
17	103	104	O	of
18	106	108	O	age
19	110	112	O	and
20	114	118	O	older
21	120	122	O	are
22	124	131	O	provided
23	133	134	O	in
24	136	140	O	Table
25	142	142	O	6
NULL

Harvoni	4419	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
Exposures in pediatric subjects were similar to those observed in adults.
1	0	8	O	Exposures
2	10	11	O	in
3	13	21	O	pediatric
4	23	30	O	subjects
5	32	35	O	were
6	37	43	O	similar
7	45	46	O	to
8	48	52	O	those
9	54	61	O	observed
10	63	64	O	in
11	66	71	O	adults
NULL

Harvoni	4420	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
Table 6 Pharmacokinetic Properties of the Components of HARVONI in Pediatric Subjects 12 Years of Age and Older
1	0	4	O	Table
2	6	6	O	6
3	8	22	O	Pharmacokinetic
4	24	33	O	Properties
5	35	36	O	of
6	38	40	O	the
7	42	51	O	Components
8	53	54	O	of
9	56	62	O	XXXXXXXX
10	64	65	O	in
11	67	75	O	Pediatric
12	77	84	O	Subjects
13	86	87	O	12
14	89	93	O	Years
15	95	96	O	of
16	98	100	O	Age
17	102	104	O	and
18	106	110	O	Older
NULL

Harvoni	4421	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	41
Geriatric Patients: Population pharmacokinetic analysis in HCV-infected subjects showed that within the age range (18 to 80 years) analyzed, age did not have a clinically relevant effect on the exposure to ledipasvir, sofosbuvir, and GS-331007.
1	0	8	O	Geriatric
2	10	17	O	Patients
3	18	18	O	:
4	20	29	O	Population
5	31	45	O	pharmacokinetic
6	47	54	O	analysis
7	56	57	O	in
8	59	61	O	HCV
9	63	70	O	infected
10	72	79	O	subjects
11	81	86	O	showed
12	88	91	O	that
13	93	98	O	within
14	100	102	O	the
15	104	106	O	age
16	108	112	O	range
17	115	116	O	18
18	118	119	O	to
19	121	122	O	80
20	124	128	O	years
21	131	138	O	analyzed
22	139	139	O	,
23	141	143	O	age
24	145	147	O	did
25	149	151	O	not
26	153	156	O	have
27	158	158	O	a
28	160	169	O	clinically
29	171	178	O	relevant
30	180	185	O	effect
31	187	188	O	on
32	190	192	O	the
33	194	201	O	exposure
34	203	204	O	to
35	206	215	O	XXXXXXXX
36	216	216	O	,
37	218	227	O	XXXXXXXX
38	228	228	O	,
39	230	232	O	and
40	234	235	O	GS
41	237	242	O	331007
NULL

Harvoni	4422	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	37
Patients with Renal Impairment: The pharmacokinetics of ledipasvir were studied with a single dose of 90 mg ledipasvir in HCV negative subjects with severe renal impairment (eGFR less than 30 mL/min by Cockcroft-Gault).
1	0	7	O	Patients
2	9	12	O	with
3	14	18	O	Renal
4	20	29	O	Impairment
5	30	30	O	:
6	32	34	O	The
7	36	51	O	pharmacokinetics
8	53	54	O	of
9	56	65	O	XXXXXXXX
10	67	70	O	were
11	72	78	O	studied
12	80	83	O	with
13	85	85	O	a
14	87	92	O	single
15	94	97	O	dose
16	99	100	O	of
17	102	103	O	90
18	105	106	O	mg
19	108	117	O	XXXXXXXX
20	119	120	O	in
21	122	124	O	HCV
22	126	133	O	negative
23	135	142	O	subjects
24	144	147	O	with
25	149	154	O	severe
26	156	160	O	renal
27	162	171	O	impairment
28	174	177	O	eGFR
29	179	182	O	less
30	184	187	O	than
31	189	190	O	30
32	192	193	O	mL
33	194	194	O	/
34	195	197	O	min
35	199	200	O	by
36	202	210	O	Cockcroft
37	212	216	O	Gault
NULL

Harvoni	4423	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
No clinically relevant differences in ledipasvir pharmacokinetics were observed between healthy subjects and subjects with severe renal impairment.
1	0	1	O	No
2	3	12	O	clinically
3	14	21	O	relevant
4	23	33	O	differences
5	35	36	O	in
6	38	47	O	XXXXXXXX
7	49	64	O	pharmacokinetics
8	66	69	O	were
9	71	78	O	observed
10	80	86	O	between
11	88	94	O	healthy
12	96	103	O	subjects
13	105	107	O	and
14	109	116	O	subjects
15	118	121	O	with
16	123	128	O	severe
17	130	134	O	renal
18	136	145	O	impairment
NULL

Harvoni	4424	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	69
The pharmacokinetics of sofosbuvir were studied in HCV-negative subjects with mild (eGFR between 50 to less than 80 mL/min/1.73 m2), moderate (eGFR between 30 to less than 50 mL/min/1.73 m2), severe renal impairment (eGFR less than 30 mL/min/1.73 m2), and subjects with ESRD requiring hemodialysis following a single 400 mg dose of sofosbuvir.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	O	XXXXXXXX
5	35	38	O	were
6	40	46	O	studied
7	48	49	O	in
8	51	53	O	HCV
9	55	62	O	negative
10	64	71	O	subjects
11	73	76	O	with
12	78	81	O	mild
13	84	87	O	eGFR
14	89	95	O	between
15	97	98	O	50
16	100	101	O	to
17	103	106	O	less
18	108	111	O	than
19	113	114	O	80
20	116	117	O	mL
21	118	118	O	/
22	119	121	O	min
23	122	122	O	/
24	123	126	O	1.73
25	128	129	O	m2
26	131	131	O	,
27	133	140	O	moderate
28	143	146	O	eGFR
29	148	154	O	between
30	156	157	O	30
31	159	160	O	to
32	162	165	O	less
33	167	170	O	than
34	172	173	O	50
35	175	176	O	mL
36	177	177	O	/
37	178	180	O	min
38	181	181	O	/
39	182	185	O	1.73
40	187	188	O	m2
41	190	190	O	,
42	192	197	O	severe
43	199	203	O	renal
44	205	214	O	impairment
45	217	220	O	eGFR
46	222	225	O	less
47	227	230	O	than
48	232	233	O	30
49	235	236	O	mL
50	237	237	O	/
51	238	240	O	min
52	241	241	O	/
53	242	245	O	1.73
54	247	248	O	m2
55	250	250	O	,
56	252	254	O	and
57	256	263	O	subjects
58	265	268	O	with
59	270	273	O	ESRD
60	275	283	O	requiring
61	285	296	O	hemodialysis
62	298	306	O	following
63	308	308	O	a
64	310	315	O	single
65	317	319	O	400
66	321	322	O	mg
67	324	327	O	dose
68	329	330	O	of
69	332	341	O	XXXXXXXX
NULL

Harvoni	4425	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	53
Relative to subjects with normal renal function (eGFR >80 mL/min/1.73m2), the sofosbuvir AUC0-inf was 61%, 107%, and 171% higher in mild, moderate, and severe renal impairment, while the GS-331007 AUC0-inf was 55%, 88%, and 451% higher, respectively.
1	0	7	O	Relative
2	9	10	O	to
3	12	19	O	subjects
4	21	24	O	with
5	26	31	O	normal
6	33	37	O	renal
7	39	46	O	function
8	49	52	O	eGFR
9	54	56	O	>80
10	58	59	O	mL
11	60	60	O	/
12	61	63	O	min
13	64	64	O	/
14	65	70	O	1.73m2
15	72	72	O	,
16	74	76	O	the
17	78	87	O	XXXXXXXX
18	89	92	O	AUC0
19	94	96	O	inf
20	98	100	O	was
21	102	104	O	61%
22	105	105	O	,
23	107	110	O	107%
24	111	111	O	,
25	113	115	O	and
26	117	120	O	171%
27	122	127	O	higher
28	129	130	O	in
29	132	135	O	mild
30	136	136	O	,
31	138	145	O	moderate
32	146	146	O	,
33	148	150	O	and
34	152	157	O	severe
35	159	163	O	renal
36	165	174	O	impairment
37	175	175	O	,
38	177	181	O	while
39	183	185	O	the
40	187	188	O	GS
41	190	195	O	331007
42	197	200	O	AUC0
43	202	204	O	inf
44	206	208	O	was
45	210	212	O	55%
46	213	213	O	,
47	215	217	O	88%
48	218	218	O	,
49	220	222	O	and
50	224	227	O	451%
51	229	234	O	higher
52	235	235	O	,
53	237	248	O	respectively
NULL

Harvoni	4426	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	48
In subjects with ESRD, relative to subjects with normal renal function, sofosbuvir and GS-331007 AUC0-inf was 28% and 1280% higher when sofosbuvir was dosed 1 hour before hemodialysis compared with 60% and 2070% higher when sofosbuvir was dosed 1 hour after hemodialysis, respectively.
1	0	1	O	In
2	3	10	O	subjects
3	12	15	O	with
4	17	20	O	ESRD
5	21	21	O	,
6	23	30	O	relative
7	32	33	O	to
8	35	42	O	subjects
9	44	47	O	with
10	49	54	O	normal
11	56	60	O	renal
12	62	69	O	function
13	70	70	O	,
14	72	81	O	XXXXXXXX
15	83	85	O	and
16	87	88	O	GS
17	90	95	O	331007
18	97	100	O	AUC0
19	102	104	O	inf
20	106	108	O	was
21	110	112	O	28%
22	114	116	O	and
23	118	122	O	1280%
24	124	129	O	higher
25	131	134	O	when
26	136	145	O	XXXXXXXX
27	147	149	O	was
28	151	155	O	dosed
29	157	157	O	1
30	159	162	O	hour
31	164	169	O	before
32	171	182	O	hemodialysis
33	184	191	O	compared
34	193	196	O	with
35	198	200	O	60%
36	202	204	O	and
37	206	210	O	2070%
38	212	217	O	higher
39	219	222	O	when
40	224	233	O	XXXXXXXX
41	235	237	O	was
42	239	243	O	dosed
43	245	245	O	1
44	247	250	O	hour
45	252	256	O	after
46	258	269	O	hemodialysis
47	270	270	O	,
48	272	283	O	respectively
NULL

Harvoni	4427	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
A 4 hour hemodialysis session removed approximately 18% of administered dose.
1	0	0	O	A
2	2	2	O	4
3	4	7	O	hour
4	9	20	O	hemodialysis
5	22	28	O	session
6	30	36	O	removed
7	38	50	O	approximately
8	52	54	O	18%
9	56	57	O	of
10	59	70	O	administered
11	72	75	O	dose
NULL

Harvoni	4428	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
Patients with Hepatic Impairment: The pharmacokinetics of ledipasvir were studied with a single dose of 90 mg ledipasvir in HCV negative subjects with severe hepatic impairment (Child-Pugh Class C).
1	0	7	O	Patients
2	9	12	O	with
3	14	20	O	Hepatic
4	22	31	O	Impairment
5	32	32	O	:
6	34	36	O	The
7	38	53	O	pharmacokinetics
8	55	56	O	of
9	58	67	O	XXXXXXXX
10	69	72	O	were
11	74	80	O	studied
12	82	85	O	with
13	87	87	O	a
14	89	94	O	single
15	96	99	O	dose
16	101	102	O	of
17	104	105	O	90
18	107	108	O	mg
19	110	119	O	XXXXXXXX
20	121	122	O	in
21	124	126	O	HCV
22	128	135	O	negative
23	137	144	O	subjects
24	146	149	O	with
25	151	156	O	severe
26	158	164	O	hepatic
27	166	175	O	impairment
28	178	182	O	Child
29	184	187	O	Pugh
30	189	193	O	Class
31	195	195	O	C
NULL

Harvoni	4429	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
Ledipasvir plasma exposure (AUC0-inf) was similar in subjects with severe hepatic impairment and control subjects with normal hepatic function.
1	0	9	O	XXXXXXXX
2	11	16	O	plasma
3	18	25	O	exposure
4	28	31	O	AUC0
5	33	35	O	inf
6	38	40	O	was
7	42	48	O	similar
8	50	51	O	in
9	53	60	O	subjects
10	62	65	O	with
11	67	72	O	severe
12	74	80	O	hepatic
13	82	91	O	impairment
14	93	95	O	and
15	97	103	O	control
16	105	112	O	subjects
17	114	117	O	with
18	119	124	O	normal
19	126	132	O	hepatic
20	134	141	O	function
NULL

Harvoni	4430	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	23
Population pharmacokinetics analysis in HCV-infected subjects indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure of ledipasvir.
1	0	9	O	Population
2	11	26	O	pharmacokinetics
3	28	35	O	analysis
4	37	38	O	in
5	40	42	O	HCV
6	44	51	O	infected
7	53	60	O	subjects
8	62	70	O	indicated
9	72	75	O	that
10	77	85	O	cirrhosis
11	88	96	O	including
12	98	110	O	decompensated
13	112	120	O	cirrhosis
14	123	125	O	had
15	127	128	O	no
16	130	139	O	clinically
17	141	148	O	relevant
18	150	155	O	effect
19	157	158	O	on
20	160	162	O	the
21	164	171	O	exposure
22	173	174	O	of
23	176	185	O	XXXXXXXX
NULL

Harvoni	4431	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
The pharmacokinetics of sofosbuvir were studied following 7-day dosing of 400 mg sofosbuvir in HCV-infected subjects with moderate and severe hepatic impairment (Child-Pugh Class B and C).
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	33	O	XXXXXXXX
5	35	38	O	were
6	40	46	O	studied
7	48	56	O	following
8	58	58	O	7
9	60	62	O	day
10	64	69	O	dosing
11	71	72	O	of
12	74	76	O	400
13	78	79	O	mg
14	81	90	O	XXXXXXXX
15	92	93	O	in
16	95	97	O	HCV
17	99	106	O	infected
18	108	115	O	subjects
19	117	120	O	with
20	122	129	O	moderate
21	131	133	O	and
22	135	140	O	severe
23	142	148	O	hepatic
24	150	159	O	impairment
25	162	166	O	Child
26	168	171	O	Pugh
27	173	177	O	Class
28	179	179	O	B
29	181	183	O	and
30	185	185	O	C
NULL

Harvoni	4432	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	37
Relative to subjects with normal hepatic function, the sofosbuvir AUC0-24 were 126% and 143% higher in moderate and severe hepatic impairment, while the GS-331007 AUC0-24 were 18% and 9% higher, respectively.
1	0	7	O	Relative
2	9	10	O	to
3	12	19	O	subjects
4	21	24	O	with
5	26	31	O	normal
6	33	39	O	hepatic
7	41	48	O	function
8	49	49	O	,
9	51	53	O	the
10	55	64	O	XXXXXXXX
11	66	69	O	AUC0
12	71	72	O	24
13	74	77	O	were
14	79	82	O	126%
15	84	86	O	and
16	88	91	O	143%
17	93	98	O	higher
18	100	101	O	in
19	103	110	O	moderate
20	112	114	O	and
21	116	121	O	severe
22	123	129	O	hepatic
23	131	140	O	impairment
24	141	141	O	,
25	143	147	O	while
26	149	151	O	the
27	153	154	O	GS
28	156	161	O	331007
29	163	166	O	AUC0
30	168	169	O	24
31	171	174	O	were
32	176	178	O	18%
33	180	182	O	and
34	184	185	O	9%
35	187	192	O	higher
36	193	193	O	,
37	195	206	O	respectively
NULL

Harvoni	4433	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
Population pharmacokinetics analysis in HCV-infected subjects indicated that cirrhosis (including decompensated cirrhosis) had no clinically relevant effect on the exposure of sofosbuvir and GS-331007.
1	0	9	O	Population
2	11	26	O	pharmacokinetics
3	28	35	O	analysis
4	37	38	O	in
5	40	42	O	HCV
6	44	51	O	infected
7	53	60	O	subjects
8	62	70	O	indicated
9	72	75	O	that
10	77	85	O	cirrhosis
11	88	96	O	including
12	98	110	O	decompensated
13	112	120	O	cirrhosis
14	123	125	O	had
15	127	128	O	no
16	130	139	O	clinically
17	141	148	O	relevant
18	150	155	O	effect
19	157	158	O	on
20	160	162	O	the
21	164	171	O	exposure
22	173	174	O	of
23	176	185	O	XXXXXXXX
24	187	189	O	and
25	191	192	O	GS
26	194	199	O	331007
NULL

Harvoni	4434	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
Drug Interaction Studies Ledipasvir and sofosbuvir are substrates of drug transporters P-gp and BCRP while GS-331007 is not.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	23	O	Studies
4	25	34	O	XXXXXXXX
5	36	38	O	and
6	40	49	O	XXXXXXXX
7	51	53	O	are
8	55	64	O	substrates
9	66	67	O	of
10	69	72	O	drug
11	74	85	O	transporters
12	87	87	O	P
13	89	90	O	gp
14	92	94	O	and
15	96	99	O	BCRP
16	101	105	O	while
17	107	108	O	GS
18	110	115	O	331007
19	117	118	O	is
20	120	122	O	not
NULL

Harvoni	4435	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	38
P-gp inducers (e.g., rifampin or St. John's wort) may decrease ledipasvir and sofosbuvir plasma concentrations, leading to reduced therapeutic effect of HARVONI, and the use with P-gp inducers is not recommended with HARVONI.
1	0	0	B-DYN	P
2	2	3	I-DYN	gp
3	5	12	L-DYN	inducers
4	15	17	O	e.g
5	19	19	O	,
6	21	28	U-DYN	rifampin
7	30	31	O	or
8	33	34	B-DYN	St
9	37	42	I-DYN	John's
10	44	47	L-DYN	wort
11	50	52	O	may
12	54	61	O	decrease
13	63	72	O	XXXXXXXX
14	74	76	O	and
15	78	87	O	XXXXXXXX
16	89	94	O	plasma
17	96	109	O	concentrations
18	110	110	O	,
19	112	118	O	leading
20	120	121	O	to
21	123	129	B-EFF	reduced
22	131	141	I-EFF	therapeutic
23	143	148	I-EFF	effect
24	150	151	I-EFF	of
25	153	159	L-EFF	XXXXXXXX
26	160	160	O	,
27	162	164	O	and
28	166	168	O	the
29	170	172	O	use
30	174	177	O	with
31	179	179	O	P
32	181	182	O	gp
33	184	191	O	inducers
34	193	194	O	is
35	196	198	O	not
36	200	210	O	recommended
37	212	215	O	with
38	217	223	O	XXXXXXXX
D/1:21:1 D/6:21:1 D/8:21:1

Harvoni	4436	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	36
Coadministration with drugs that inhibit P-gp and/or BCRP may increase ledipasvir and sofosbuvir plasma concentrations without increasing GS-331007 plasma concentration; HARVONI may be coadministered with P-gp and/or BCRP inhibitors.
1	0	15	O	Coadministration
2	17	20	O	with
3	22	26	B-KIN	drugs
4	28	31	I-KIN	that
5	33	39	I-KIN	inhibit
6	41	41	I-KIN	P
7	43	44	I-KIN	gp
8	46	48	I-KIN	and
9	49	49	I-KIN	/
10	50	51	I-KIN	or
11	53	56	L-KIN	BCRP
12	58	60	O	may
13	62	69	O	increase
14	71	80	O	XXXXXXXX
15	82	84	O	and
16	86	95	O	XXXXXXXX
17	97	102	O	plasma
18	104	117	O	concentrations
19	119	125	O	without
20	127	136	O	increasing
21	138	139	O	GS
22	141	146	O	331007
23	148	153	O	plasma
24	155	167	O	concentration
25	170	176	O	XXXXXXXX
26	178	180	O	may
27	182	183	O	be
28	185	198	O	coadministered
29	200	203	O	with
30	205	205	O	P
31	207	208	O	gp
32	210	212	O	and
33	213	213	O	/
34	214	215	O	or
35	217	220	O	BCRP
36	222	231	O	inhibitors
K/3:C54355

Harvoni	4437	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
Neither ledipasvir nor sofosbuvir is a substrate for hepatic uptake transporters OCT1, OATP1B1, or OATP1B3.
1	0	6	O	Neither
2	8	17	O	XXXXXXXX
3	19	21	O	nor
4	23	32	O	XXXXXXXX
5	34	35	O	is
6	37	37	O	a
7	39	47	O	substrate
8	49	51	O	for
9	53	59	O	hepatic
10	61	66	O	uptake
11	68	79	O	transporters
12	81	84	O	OCT1
13	85	85	O	,
14	87	93	O	OATP1B1
15	94	94	O	,
16	96	97	O	or
17	99	105	O	OATP1B3
NULL

Harvoni	4438	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	23
GS-331007 is not a substrate for renal transporters, including organic anion transporter OAT1 or OAT3, or organic cation transporter OCT2.
1	0	1	O	GS
2	3	8	O	331007
3	10	11	O	is
4	13	15	O	not
5	17	17	O	a
6	19	27	O	substrate
7	29	31	O	for
8	33	37	O	renal
9	39	50	O	transporters
10	51	51	O	,
11	53	61	O	including
12	63	69	O	organic
13	71	75	O	anion
14	77	87	O	transporter
15	89	92	O	OAT1
16	94	95	O	or
17	97	100	O	OAT3
18	101	101	O	,
19	103	104	O	or
20	106	112	O	organic
21	114	119	O	cation
22	121	131	O	transporter
23	133	136	O	OCT2
NULL

Harvoni	4439	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
Ledipasvir is subject to slow oxidative metabolism via an unknown mechanism.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	20	O	subject
4	22	23	O	to
5	25	28	O	slow
6	30	38	O	oxidative
7	40	49	O	metabolism
8	51	53	O	via
9	55	56	O	an
10	58	64	O	unknown
11	66	74	O	mechanism
NULL

Harvoni	4440	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	14
In vitro, no detectable metabolism of ledipasvir by CYP enzymes has been observed.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	11	O	no
5	13	22	O	detectable
6	24	33	O	metabolism
7	35	36	O	of
8	38	47	O	XXXXXXXX
9	49	50	O	by
10	52	54	O	CYP
11	56	62	O	enzymes
12	64	66	O	has
13	68	71	O	been
14	73	80	O	observed
NULL

Harvoni	4441	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
Biliary excretion of unchanged ledipasvir is a major route of elimination.
1	0	6	O	Biliary
2	8	16	O	excretion
3	18	19	O	of
4	21	29	O	unchanged
5	31	40	O	XXXXXXXX
6	42	43	O	is
7	45	45	O	a
8	47	51	O	major
9	53	57	O	route
10	59	60	O	of
11	62	72	O	elimination
NULL

Harvoni	4442	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	10
Sofosbuvir is not a substrate for CYP and UGT1A1 enzymes.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	16	O	not
4	18	18	O	a
5	20	28	O	substrate
6	30	32	O	for
7	34	36	O	CYP
8	38	40	O	and
9	42	47	O	UGT1A1
10	49	55	O	enzymes
NULL

Harvoni	4443	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	15
Clinically significant drug interactions with HARVONI mediated by CYP or UGT1A1 enzymes are not expected.
1	0	9	O	Clinically
2	11	21	O	significant
3	23	26	O	drug
4	28	39	O	interactions
5	41	44	O	with
6	46	52	O	XXXXXXXX
7	54	61	O	mediated
8	63	64	O	by
9	66	68	O	CYP
10	70	71	O	or
11	73	78	O	UGT1A1
12	80	86	O	enzymes
13	88	90	O	are
14	92	94	O	not
15	96	103	O	expected
NULL

Harvoni	4444	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
The effects of coadministered drugs on the exposure of ledipasvir, sofosbuvir, and GS-331007 are shown in Table 7.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	28	O	coadministered
5	30	34	O	drugs
6	36	37	O	on
7	39	41	O	the
8	43	50	O	exposure
9	52	53	O	of
10	55	64	O	XXXXXXXX
11	65	65	O	,
12	67	76	O	XXXXXXXX
13	77	77	O	,
14	79	81	O	and
15	83	84	O	GS
16	86	91	O	331007
17	93	95	O	are
18	97	101	O	shown
19	103	104	O	in
20	106	110	O	Table
21	112	112	O	7
NULL

Harvoni	4445	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	34
Table 7 Drug Interactions: Changes in Pharmacokinetic Parameters for Ledipasvir, Sofosbuvir, and the Predominant Circulating Metabolite GS-331007 in the Presence of the Coadministered DrugAll interaction studies conducted in healthy volunteers.
1	0	4	O	Table
2	6	6	O	7
3	8	11	O	Drug
4	13	24	O	Interactions
5	25	25	O	:
6	27	33	O	Changes
7	35	36	O	in
8	38	52	O	Pharmacokinetic
9	54	63	O	Parameters
10	65	67	O	for
11	69	78	O	XXXXXXXX
12	79	79	O	,
13	81	90	O	XXXXXXXX
14	91	91	O	,
15	93	95	O	and
16	97	99	O	the
17	101	111	O	Predominant
18	113	123	O	Circulating
19	125	134	O	Metabolite
20	136	137	O	GS
21	139	144	O	331007
22	146	147	O	in
23	149	151	O	the
24	153	160	O	Presence
25	162	163	O	of
26	165	167	O	the
27	169	182	O	Coadministered
28	184	190	O	DrugAll
29	192	202	O	interaction
30	204	210	O	studies
31	212	220	O	conducted
32	222	223	O	in
33	225	231	O	healthy
34	233	242	O	volunteers
NULL

Harvoni	4446	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	48
Co-administered Drug Dose of Co-administered Drug (mg) Ledipasvir Dose(mg) Sofosbuvir Dose(mg) N Mean Ratio (90% CI) of Ledipasvir, Sofosbuvir, and GS-331007 PK With/Without Coadministered DrugNo Effect=1.00 Cmax AUC Cmin NA = not available/not applicable, ND = not dosed.
1	0	1	O	Co
2	3	14	O	administered
3	16	19	O	Drug
4	21	24	O	Dose
5	26	27	O	of
6	29	30	O	Co
7	32	43	O	administered
8	45	48	O	Drug
9	51	52	O	mg
10	55	64	O	XXXXXXXX
11	66	72	O	Dose(mg
12	75	84	O	XXXXXXXX
13	86	92	O	Dose(mg
14	95	95	O	N
15	97	100	O	Mean
16	102	106	O	Ratio
17	109	111	O	90%
18	113	114	O	CI
19	117	118	O	of
20	120	129	O	XXXXXXXX
21	130	130	O	,
22	132	141	O	XXXXXXXX
23	142	142	O	,
24	144	146	O	and
25	148	149	O	GS
26	151	156	O	331007
27	158	159	O	PK
28	161	164	O	With
29	165	165	O	/
30	166	172	O	Without
31	174	187	O	Coadministered
32	189	194	O	DrugNo
33	196	206	O	Effect=1.00
34	208	211	O	Cmax
35	213	215	O	AUC
36	217	220	O	Cmin
37	222	223	O	NA
38	225	225	O	=
39	227	229	O	not
40	231	239	O	available
41	240	240	O	/
42	241	243	O	not
43	245	254	O	applicable
44	255	255	O	,
45	257	258	O	ND
46	260	260	O	=
47	262	264	O	not
48	266	270	O	dosed
NULL

Harvoni	4447	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	28
Staggered administration (12 hours apart) of atazanavir/ritonavir + emtricitabine/tenofovir DF or darunavir/ritonavir + emtricitabine/tenofovir DF and HARVONI provided similar results.
1	0	8	O	Staggered
2	10	23	O	administration
3	26	27	O	12
4	29	33	O	hours
5	35	39	O	apart
6	42	43	O	of
7	45	54	O	atazanavir
8	55	55	O	/
9	56	64	O	ritonavir
10	66	66	O	+
11	68	80	O	emtricitabine
12	81	81	O	/
13	82	90	O	tenofovir
14	92	93	O	DF
15	95	96	O	or
16	98	106	O	darunavir
17	107	107	O	/
18	108	116	O	ritonavir
19	118	118	O	+
20	120	132	O	emtricitabine
21	133	133	O	/
22	134	142	O	tenofovir
23	144	145	O	DF
24	147	149	O	and
25	151	157	O	XXXXXXXX
26	159	166	O	provided
27	168	174	O	similar
28	176	182	O	results
NULL

Harvoni	4448	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	23
, The effects of atazanavir/ritonavir on ledipasvir and sofosbuvir are similar with or without the presence of emtricitabine/tenofovir DF.
1	0	0	O	,
2	2	4	O	The
3	6	12	O	effects
4	14	15	O	of
5	17	26	O	atazanavir
6	27	27	O	/
7	28	36	O	ritonavir
8	38	39	O	on
9	41	50	O	XXXXXXXX
10	52	54	O	and
11	56	65	O	XXXXXXXX
12	67	69	O	are
13	71	77	O	similar
14	79	82	O	with
15	84	85	O	or
16	87	93	O	without
17	95	97	O	the
18	99	106	O	presence
19	108	109	O	of
20	111	123	O	emtricitabine
21	124	124	O	/
22	125	133	O	tenofovir
23	135	136	O	DF
NULL

Harvoni	4449	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	9
300/100 + 200/300 once daily
1	0	2	O	300
2	3	3	O	/
3	4	6	O	100
4	8	8	O	+
5	10	12	O	200
6	13	13	O	/
7	14	16	O	300
8	18	21	O	once
9	23	27	O	daily
NULL

Harvoni	4450	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	296
600/200/300 once daily 90 once daily 400 once daily 14 ledipasvir 0.66 (0.59, 0.75) 0.66(0.59, 0.75) 0.66(0.57, 0.76) sofosbuvir 1.03 (0.87, 1.23) 0.94 (0.81, 1.10) NA GS-331007 0.86 (0.76, 0.96) 0.90 (0.83, 0.97) 1.07 (1.02, 1.13) Elvitegravir/ cobicistat 150/150 once daily 90 once daily 400 once daily 29 ledipasvir 1.63 (1.51, 1.75) 1.78 (1.64, 1.94) 1.91 (1.76, 2.08) sofosbuvir 1.33 (1.14, 1.56) 1.36 (1.21, 1.52) NA GS-331007 1.33 (1.22, 1.44) 1.44 (1.41, 1.48) 1.53 (1.47, 1.59) Famotidine 40 single dose simultaneously with HARVONI 90 single dose 400 single dose 12 ledipasvir 0.80 (0.69, 0.93) 0.89 (0.76, 1.06) NA sofosbuvir 1.15 (0.88, 1.50) 1.11 (1.00, 1.24) NA GS-331007 1.06 (0.97, 1.14) 1.06 (1.02, 1.11) NA 40 single dose 12 hours prior to HARVONI 12 ledipasvir 0.83 (0.69, 1.00) 0.98 (0.80, 1.20) NA sofosbuvir 1.00 (0.76, 1.32) 0.95 (0.82, 1.10) NA GS-331007 1.13 (1.07, 1.20) 1.06 (1.01, 1.12) NA Methadone 30 to 130 daily ND 400 once daily 14 sofosbuvir 0.95(0.68, 1.33) 1.30 (1.00, 1.69) NA GS-331007 0.73(0.65, 0.83) 1.04 (0.89, 1.22) NA Omeprazole 20 once daily simultaneously with HARVONI 90 single dose 400 single dose 16 ledipasvir 0.89 (0.61, 1.30) 0.96 (0.66, 1.39) NA sofosbuvir 1.12 (0.88, 1.42) 1.00 (0.80, 1.25) NA GS-331007 1.14 (1.01, 1.29) 1.03 (0.96, 1.12) NA 20 once daily 2 hours prior to ledipasvir 30 single dose ND 17 ledipasvir 0.52(0.41, 0.66) 0.58(0.48, 0.71) NA RifampinThis study was conducted in the presence of two other investigational HCV direct-acting agents.
1	0	2	O	600
2	3	3	O	/
3	4	6	O	200
4	7	7	O	/
5	8	10	O	300
6	12	15	O	once
7	17	21	O	daily
8	23	24	O	90
9	26	29	O	once
10	31	35	O	daily
11	37	39	O	400
12	41	44	O	once
13	46	50	O	daily
14	52	53	O	14
15	55	64	O	XXXXXXXX
16	66	69	O	0.66
17	72	75	O	0.59
18	76	76	O	,
19	78	81	O	0.75
20	84	92	O	0.66(0.59
21	93	93	O	,
22	95	98	O	0.75
23	101	109	O	0.66(0.57
24	110	110	O	,
25	112	115	O	0.76
26	118	127	O	XXXXXXXX
27	129	132	O	1.03
28	135	138	O	0.87
29	139	139	O	,
30	141	144	O	1.23
31	147	150	O	0.94
32	153	156	O	0.81
33	157	157	O	,
34	159	162	O	1.10
35	165	166	O	NA
36	168	169	O	GS
37	171	176	O	331007
38	178	181	O	0.86
39	184	187	O	0.76
40	188	188	O	,
41	190	193	O	0.96
42	196	199	O	0.90
43	202	205	O	0.83
44	206	206	O	,
45	208	211	O	0.97
46	214	217	O	1.07
47	220	223	O	1.02
48	224	224	O	,
49	226	229	O	1.13
50	232	243	O	Elvitegravir
51	244	244	O	/
52	246	255	O	cobicistat
53	257	259	O	150
54	260	260	O	/
55	261	263	O	150
56	265	268	O	once
57	270	274	O	daily
58	276	277	O	90
59	279	282	O	once
60	284	288	O	daily
61	290	292	O	400
62	294	297	O	once
63	299	303	O	daily
64	305	306	O	29
65	308	317	O	XXXXXXXX
66	319	322	O	1.63
67	325	328	O	1.51
68	329	329	O	,
69	331	334	O	1.75
70	337	340	O	1.78
71	343	346	O	1.64
72	347	347	O	,
73	349	352	O	1.94
74	355	358	O	1.91
75	361	364	O	1.76
76	365	365	O	,
77	367	370	O	2.08
78	373	382	O	XXXXXXXX
79	384	387	O	1.33
80	390	393	O	1.14
81	394	394	O	,
82	396	399	O	1.56
83	402	405	O	1.36
84	408	411	O	1.21
85	412	412	O	,
86	414	417	O	1.52
87	420	421	O	NA
88	423	424	O	GS
89	426	431	O	331007
90	433	436	O	1.33
91	439	442	O	1.22
92	443	443	O	,
93	445	448	O	1.44
94	451	454	O	1.44
95	457	460	O	1.41
96	461	461	O	,
97	463	466	O	1.48
98	469	472	O	1.53
99	475	478	O	1.47
100	479	479	O	,
101	481	484	O	1.59
102	487	496	O	Famotidine
103	498	499	O	40
104	501	506	O	single
105	508	511	O	dose
106	513	526	O	simultaneously
107	528	531	O	with
108	533	539	O	XXXXXXXX
109	541	542	O	90
110	544	549	O	single
111	551	554	O	dose
112	556	558	O	400
113	560	565	O	single
114	567	570	O	dose
115	572	573	O	12
116	575	584	O	XXXXXXXX
117	586	589	O	0.80
118	592	595	O	0.69
119	596	596	O	,
120	598	601	O	0.93
121	604	607	O	0.89
122	610	613	O	0.76
123	614	614	O	,
124	616	619	O	1.06
125	622	623	O	NA
126	625	634	O	XXXXXXXX
127	636	639	O	1.15
128	642	645	O	0.88
129	646	646	O	,
130	648	651	O	1.50
131	654	657	O	1.11
132	660	663	O	1.00
133	664	664	O	,
134	666	669	O	1.24
135	672	673	O	NA
136	675	676	O	GS
137	678	683	O	331007
138	685	688	O	1.06
139	691	694	O	0.97
140	695	695	O	,
141	697	700	O	1.14
142	703	706	O	1.06
143	709	712	O	1.02
144	713	713	O	,
145	715	718	O	1.11
146	721	722	O	NA
147	724	725	O	40
148	727	732	O	single
149	734	737	O	dose
150	739	740	O	12
151	742	746	O	hours
152	748	752	O	prior
153	754	755	O	to
154	757	763	O	XXXXXXXX
155	765	766	O	12
156	768	777	O	XXXXXXXX
157	779	782	O	0.83
158	785	788	O	0.69
159	789	789	O	,
160	791	794	O	1.00
161	797	800	O	0.98
162	803	806	O	0.80
163	807	807	O	,
164	809	812	O	1.20
165	815	816	O	NA
166	818	827	O	XXXXXXXX
167	829	832	O	1.00
168	835	838	O	0.76
169	839	839	O	,
170	841	844	O	1.32
171	847	850	O	0.95
172	853	856	O	0.82
173	857	857	O	,
174	859	862	O	1.10
175	865	866	O	NA
176	868	869	O	GS
177	871	876	O	331007
178	878	881	O	1.13
179	884	887	O	1.07
180	888	888	O	,
181	890	893	O	1.20
182	896	899	O	1.06
183	902	905	O	1.01
184	906	906	O	,
185	908	911	O	1.12
186	914	915	O	NA
187	917	925	O	Methadone
188	927	928	O	30
189	930	931	O	to
190	933	935	O	130
191	937	941	O	daily
192	943	944	O	ND
193	946	948	O	400
194	950	953	O	once
195	955	959	O	daily
196	961	962	O	14
197	964	973	O	XXXXXXXX
198	975	983	O	0.95(0.68
199	984	984	O	,
200	986	989	O	1.33
201	992	995	O	1.30
202	998	1001	O	1.00
203	1002	1002	O	,
204	1004	1007	O	1.69
205	1010	1011	O	NA
206	1013	1014	O	GS
207	1016	1021	O	331007
208	1023	1031	O	0.73(0.65
209	1032	1032	O	,
210	1034	1037	O	0.83
211	1040	1043	O	1.04
212	1046	1049	O	0.89
213	1050	1050	O	,
214	1052	1055	O	1.22
215	1058	1059	O	NA
216	1061	1070	O	Omeprazole
217	1072	1073	O	20
218	1075	1078	O	once
219	1080	1084	O	daily
220	1086	1099	O	simultaneously
221	1101	1104	O	with
222	1106	1112	O	XXXXXXXX
223	1114	1115	O	90
224	1117	1122	O	single
225	1124	1127	O	dose
226	1129	1131	O	400
227	1133	1138	O	single
228	1140	1143	O	dose
229	1145	1146	O	16
230	1148	1157	O	XXXXXXXX
231	1159	1162	O	0.89
232	1165	1168	O	0.61
233	1169	1169	O	,
234	1171	1174	O	1.30
235	1177	1180	O	0.96
236	1183	1186	O	0.66
237	1187	1187	O	,
238	1189	1192	O	1.39
239	1195	1196	O	NA
240	1198	1207	O	XXXXXXXX
241	1209	1212	O	1.12
242	1215	1218	O	0.88
243	1219	1219	O	,
244	1221	1224	O	1.42
245	1227	1230	O	1.00
246	1233	1236	O	0.80
247	1237	1237	O	,
248	1239	1242	O	1.25
249	1245	1246	O	NA
250	1248	1249	O	GS
251	1251	1256	O	331007
252	1258	1261	O	1.14
253	1264	1267	O	1.01
254	1268	1268	O	,
255	1270	1273	O	1.29
256	1276	1279	O	1.03
257	1282	1285	O	0.96
258	1286	1286	O	,
259	1288	1291	O	1.12
260	1294	1295	O	NA
261	1297	1298	O	20
262	1300	1303	O	once
263	1305	1309	O	daily
264	1311	1311	O	2
265	1313	1317	O	hours
266	1319	1323	O	prior
267	1325	1326	O	to
268	1328	1337	O	XXXXXXXX
269	1339	1340	O	30
270	1342	1347	O	single
271	1349	1352	O	dose
272	1354	1355	O	ND
273	1357	1358	O	17
274	1360	1369	O	XXXXXXXX
275	1371	1379	O	0.52(0.41
276	1380	1380	O	,
277	1382	1385	O	0.66
278	1388	1396	O	0.58(0.48
279	1397	1397	O	,
280	1399	1402	O	0.71
281	1405	1406	O	NA
282	1408	1419	O	RifampinThis
283	1421	1425	O	study
284	1427	1429	O	was
285	1431	1439	O	conducted
286	1441	1442	O	in
287	1444	1446	O	the
288	1448	1455	O	presence
289	1457	1458	O	of
290	1460	1462	O	two
291	1464	1468	O	other
292	1470	1484	O	investigational
293	1486	1488	O	HCV
294	1490	1495	O	direct
295	1497	1502	O	acting
296	1504	1509	O	agents
NULL

Harvoni	4451	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	86
ND 31 ledipasvir 0.65 (0.56, 0.76) 0.41 (0.36, 0.48) NA ND 400 single dose 17 sofosbuvir 0.23 (0.19, 0.29) 0.28 (0.24, 0.32) NA GS-331007 1.23 (1.14, 1.34) 0.95 (0.88, 1.03) NA Simeprevir 150 once daily 30 once daily ND 22 ledipasvir 1.81 (1.69, 2.94) 1.92 (1.77, 2.07) NA Tacrolimus 5 single dose ND 400 single dose 16 sofosbuvir 0.97 (0.65, 1.43) 1.13 (0.81, 1.57) NA GS-331007 0.97 (0.83, 1.14) 1.00 (0.87, 1.13)
1	0	1	O	ND
2	3	4	O	31
3	6	15	O	XXXXXXXX
4	17	20	O	0.65
5	23	26	O	0.56
6	27	27	O	,
7	29	32	O	0.76
8	35	38	O	0.41
9	41	44	O	0.36
10	45	45	O	,
11	47	50	O	0.48
12	53	54	O	NA
13	56	57	O	ND
14	59	61	O	400
15	63	68	O	single
16	70	73	O	dose
17	75	76	O	17
18	78	87	O	XXXXXXXX
19	89	92	O	0.23
20	95	98	O	0.19
21	99	99	O	,
22	101	104	O	0.29
23	107	110	O	0.28
24	113	116	O	0.24
25	117	117	O	,
26	119	122	O	0.32
27	125	126	O	NA
28	128	129	O	GS
29	131	136	O	331007
30	138	141	O	1.23
31	144	147	O	1.14
32	148	148	O	,
33	150	153	O	1.34
34	156	159	O	0.95
35	162	165	O	0.88
36	166	166	O	,
37	168	171	O	1.03
38	174	175	O	NA
39	177	186	O	Simeprevir
40	188	190	O	150
41	192	195	O	once
42	197	201	O	daily
43	203	204	O	30
44	206	209	O	once
45	211	215	O	daily
46	217	218	O	ND
47	220	221	O	22
48	223	232	O	XXXXXXXX
49	234	237	O	1.81
50	240	243	O	1.69
51	244	244	O	,
52	246	249	O	2.94
53	252	255	O	1.92
54	258	261	O	1.77
55	262	262	O	,
56	264	267	O	2.07
57	270	271	O	NA
58	273	282	O	Tacrolimus
59	284	284	O	5
60	286	291	O	single
61	293	296	O	dose
62	298	299	O	ND
63	301	303	O	400
64	305	310	O	single
65	312	315	O	dose
66	317	318	O	16
67	320	329	O	XXXXXXXX
68	331	334	O	0.97
69	337	340	O	0.65
70	341	341	O	,
71	343	346	O	1.43
72	349	352	O	1.13
73	355	358	O	0.81
74	359	359	O	,
75	361	364	O	1.57
76	367	368	O	NA
77	370	371	O	GS
78	373	378	O	331007
79	380	383	O	0.97
80	386	389	O	0.83
81	390	390	O	,
82	392	395	O	1.14
83	398	401	O	1.00
84	404	407	O	0.87
85	408	408	O	,
86	410	413	O	1.13
NULL

Harvoni	4452	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
Ledipasvir is an inhibitor of drug transporter P-gp and breast cancer resistance protein (BCRP) and may increase intestinal absorption of coadministered substrates for these transporters.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	33	O	drug
7	35	45	O	transporter
8	47	47	O	P
9	49	50	O	gp
10	52	54	O	and
11	56	61	O	breast
12	63	68	O	cancer
13	70	79	O	resistance
14	81	87	O	protein
15	90	93	O	BCRP
16	96	98	O	and
17	100	102	O	may
18	104	111	B-TRI	increase
19	113	122	I-TRI	intestinal
20	124	133	L-TRI	absorption
21	135	136	O	of
22	138	151	O	coadministered
23	153	162	O	substrates
24	164	166	O	for
25	168	172	O	these
26	174	185	O	transporters
NULL

Harvoni	4453	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
Ledipasvir is an inhibitor of transporters OATP1B1, OATP1B3, and BSEP only at concentrations exceeding those achieved in clinic.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	41	O	transporters
7	43	49	O	OATP1B1
8	50	50	O	,
9	52	58	O	OATP1B3
10	59	59	O	,
11	61	63	O	and
12	65	68	O	BSEP
13	70	73	O	only
14	75	76	O	at
15	78	91	O	concentrations
16	93	101	O	exceeding
17	103	107	O	those
18	109	116	O	achieved
19	118	119	O	in
20	121	126	O	clinic
NULL

Harvoni	4454	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
Ledipasvir is not an inhibitor of transporters MRP2, MRP4, OCT2, OAT1, OAT3, MATE1, and OCT1.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	16	O	not
4	18	19	O	an
5	21	29	O	inhibitor
6	31	32	O	of
7	34	45	O	transporters
8	47	50	O	MRP2
9	51	51	O	,
10	53	56	O	MRP4
11	57	57	O	,
12	59	62	O	OCT2
13	63	63	O	,
14	65	68	O	OAT1
15	69	69	O	,
16	71	74	O	OAT3
17	75	75	O	,
18	77	81	O	MATE1
19	82	82	O	,
20	84	86	O	and
21	88	91	O	OCT1
NULL

Harvoni	4455	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
The drug-drug interaction potential of ledipasvir is primarily limited to the intestinal inhibition of P-gp and BCRP.
1	0	2	O	The
2	4	7	O	drug
3	9	12	O	drug
4	14	24	O	interaction
5	26	34	O	potential
6	36	37	O	of
7	39	48	O	XXXXXXXX
8	50	51	O	is
9	53	61	O	primarily
10	63	69	O	limited
11	71	72	O	to
12	74	76	O	the
13	78	87	O	intestinal
14	89	98	O	inhibition
15	100	101	O	of
16	103	103	O	P
17	105	106	O	gp
18	108	110	O	and
19	112	115	O	BCRP
NULL

Harvoni	4456	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Clinically relevant transporter inhibition by ledipasvir in the systemic circulation is not expected due to its high protein binding.
1	0	9	O	Clinically
2	11	18	O	relevant
3	20	30	O	transporter
4	32	41	O	inhibition
5	43	44	O	by
6	46	55	O	XXXXXXXX
7	57	58	O	in
8	60	62	O	the
9	64	71	O	systemic
10	73	83	O	circulation
11	85	86	O	is
12	88	90	O	not
13	92	99	O	expected
14	101	103	O	due
15	105	106	O	to
16	108	110	O	its
17	112	115	O	high
18	117	123	O	protein
19	125	131	O	binding
NULL

Harvoni	4457	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	40
Sofosbuvir and GS-331007 are not inhibitors of drug transporters P-gp, BCRP, MRP2, BSEP, OATP1B1, OATP1B3, and OCT1, and GS-331007 is not an inhibitor of OAT1, OCT2, and MATE1.
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	16	O	GS
4	18	23	O	331007
5	25	27	O	are
6	29	31	O	not
7	33	42	O	inhibitors
8	44	45	O	of
9	47	50	O	drug
10	52	63	O	transporters
11	65	65	O	P
12	67	68	O	gp
13	69	69	O	,
14	71	74	O	BCRP
15	75	75	O	,
16	77	80	O	MRP2
17	81	81	O	,
18	83	86	O	BSEP
19	87	87	O	,
20	89	95	O	OATP1B1
21	96	96	O	,
22	98	104	O	OATP1B3
23	105	105	O	,
24	107	109	O	and
25	111	114	O	OCT1
26	115	115	O	,
27	117	119	O	and
28	121	122	O	GS
29	124	129	O	331007
30	131	132	O	is
31	134	136	O	not
32	138	139	O	an
33	141	149	O	inhibitor
34	151	152	O	of
35	154	157	O	OAT1
36	158	158	O	,
37	160	163	O	OCT2
38	164	164	O	,
39	166	168	O	and
40	170	174	O	MATE1
NULL

Harvoni	4458	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
Ledipasvir, sofosbuvir, and GS-331007 are not inhibitors or inducers of CYP or UGT1A1 enzymes.
1	0	9	O	XXXXXXXX
2	10	10	O	,
3	12	21	O	XXXXXXXX
4	22	22	O	,
5	24	26	O	and
6	28	29	O	GS
7	31	36	O	331007
8	38	40	O	are
9	42	44	O	not
10	46	55	O	inhibitors
11	57	58	O	or
12	60	67	O	inducers
13	69	70	O	of
14	72	74	O	CYP
15	76	77	O	or
16	79	84	O	UGT1A1
17	86	92	O	enzymes
NULL

Harvoni	4459	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
The effects of ledipasvir or sofosbuvir on the exposure of coadministered drugs are shown in Table 8.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	24	O	XXXXXXXX
5	26	27	O	or
6	29	38	O	XXXXXXXX
7	40	41	O	on
8	43	45	O	the
9	47	54	O	exposure
10	56	57	O	of
11	59	72	O	coadministered
12	74	78	O	drugs
13	80	82	O	are
14	84	88	O	shown
15	90	91	O	in
16	93	97	O	Table
17	99	99	O	8
NULL

Harvoni	4460	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	29
Table 8 Drug Interactions: Changes in Pharmacokinetic Parameters for Coadministered Drug in the Presence of Ledipasvir, Sofosbuvir, or HARVONIAll interaction studies conducted in healthy volunteers.
1	0	4	O	Table
2	6	6	O	8
3	8	11	O	Drug
4	13	24	O	Interactions
5	25	25	O	:
6	27	33	O	Changes
7	35	36	O	in
8	38	52	O	Pharmacokinetic
9	54	63	O	Parameters
10	65	67	O	for
11	69	82	O	Coadministered
12	84	87	O	Drug
13	89	90	O	in
14	92	94	O	the
15	96	103	O	Presence
16	105	106	O	of
17	108	117	O	XXXXXXXX
18	118	118	O	,
19	120	129	O	XXXXXXXX
20	130	130	O	,
21	132	133	O	or
22	135	141	O	XXXXXXXX
23	142	144	O	All
24	146	156	O	interaction
25	158	164	O	studies
26	166	174	O	conducted
27	176	177	O	in
28	179	185	O	healthy
29	187	196	O	volunteers
NULL

Harvoni	4461	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	48
Co-administered Drug Dose of Co-administered Drug (mg) Ledipasvir Dose(mg) Sofosbuvir Dose(mg) N Mean Ratio (90% CI) of Coadministered Drug PK With/Without Ledipasvir, Sofosbuvir, or HARVONINo Effect=1.00 Cmax AUC Cmin NA = not available/not applicable, ND = not dosed.
1	0	1	O	Co
2	3	14	O	administered
3	16	19	O	Drug
4	21	24	O	Dose
5	26	27	O	of
6	29	30	O	Co
7	32	43	O	administered
8	45	48	O	Drug
9	51	52	O	mg
10	55	64	O	XXXXXXXX
11	66	72	O	Dose(mg
12	75	84	O	XXXXXXXX
13	86	92	O	Dose(mg
14	95	95	O	N
15	97	100	O	Mean
16	102	106	O	Ratio
17	109	111	O	90%
18	113	114	O	CI
19	117	118	O	of
20	120	133	O	Coadministered
21	135	138	O	Drug
22	140	141	O	PK
23	143	146	O	With
24	147	147	O	/
25	148	154	O	Without
26	156	165	O	XXXXXXXX
27	166	166	O	,
28	168	177	O	XXXXXXXX
29	178	178	O	,
30	180	181	O	or
31	183	189	O	XXXXXXXX
32	190	191	O	No
33	193	203	O	Effect=1.00
34	205	208	O	Cmax
35	210	212	O	AUC
36	214	217	O	Cmin
37	219	220	O	NA
38	222	222	O	=
39	224	226	O	not
40	228	236	O	available
41	237	237	O	/
42	238	240	O	not
43	242	251	O	applicable
44	252	252	O	,
45	254	255	O	ND
46	257	257	O	=
47	259	261	O	not
48	263	267	O	dosed
NULL

Harvoni	4463	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
, The effects of HARVONI on atazanavir and ritonavir are similar with or without the presence of emtricitabine/tenofovir DF.
1	0	0	O	,
2	2	4	O	The
3	6	12	O	effects
4	14	15	O	of
5	17	23	O	XXXXXXXX
6	25	26	O	on
7	28	37	O	atazanavir
8	39	41	O	and
9	43	51	O	ritonavir
10	53	55	O	are
11	57	63	O	similar
12	65	68	O	with
13	70	71	O	or
14	73	79	O	without
15	81	83	O	the
16	85	92	O	presence
17	94	95	O	of
18	97	109	O	emtricitabine
19	110	110	O	/
20	111	119	O	tenofovir
21	121	122	O	DF
NULL

Harvoni	4464	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
This magnitude of change in tenofovir exposure does not reflect the approximately 60-80% increase caused by the effects of an HIV PI/ritonavir and the effect of food.
1	0	3	O	This
2	5	13	O	magnitude
3	15	16	O	of
4	18	23	O	change
5	25	26	O	in
6	28	36	U-UNK	tenofovir
7	38	45	O	exposure
8	47	50	O	does
9	52	54	O	not
10	56	62	O	reflect
11	64	66	O	the
12	68	80	O	approximately
13	82	83	O	60
14	85	87	O	80%
15	89	96	O	increase
16	98	103	O	caused
17	105	106	O	by
18	108	110	O	the
19	112	118	O	effects
20	120	121	O	of
21	123	124	O	an
22	126	128	O	HIV
23	130	131	O	PI
24	132	132	O	/
25	133	141	O	ritonavir
26	143	145	O	and
27	147	149	O	the
28	151	156	O	effect
29	158	159	O	of
30	161	164	O	food
NULL

Harvoni	4465	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	57
Therefore, tenofovir exposure is approximately 130% higher when administered as tenofovir DF + atazanavir/ritonavir + HARVONI or tenofovir DF + darunavir/ritonavir + HARVONI and with food as compared to the tenofovir exposure observed following fasted administration of tenofovir DF-based regimens that do not contain an HIV PI/ritonavir and HARVONI.
1	0	8	O	Therefore
2	9	9	O	,
3	11	19	U-KIN	tenofovir
4	21	28	O	exposure
5	30	31	O	is
6	33	45	O	approximately
7	47	50	O	130%
8	52	57	O	higher
9	59	62	O	when
10	64	75	O	administered
11	77	78	O	as
12	80	88	O	tenofovir
13	90	91	O	DF
14	93	93	O	+
15	95	104	O	atazanavir
16	105	105	O	/
17	106	114	O	ritonavir
18	116	116	O	+
19	118	124	O	XXXXXXXX
20	126	127	O	or
21	129	137	O	tenofovir
22	139	140	O	DF
23	142	142	O	+
24	144	152	O	darunavir
25	153	153	O	/
26	154	162	O	ritonavir
27	164	164	O	+
28	166	172	O	XXXXXXXX
29	174	176	O	and
30	178	181	O	with
31	183	186	O	food
32	188	189	O	as
33	191	198	O	compared
34	200	201	O	to
35	203	205	O	the
36	207	215	O	tenofovir
37	217	224	O	exposure
38	226	233	O	observed
39	235	243	O	following
40	245	250	O	fasted
41	252	265	O	administration
42	267	268	O	of
43	270	278	O	tenofovir
44	280	281	O	DF
45	283	287	O	based
46	289	296	O	regimens
47	298	301	O	that
48	303	304	O	do
49	306	308	O	not
50	310	316	O	contain
51	318	319	O	an
52	321	323	O	HIV
53	325	326	O	PI
54	327	327	O	/
55	328	336	O	ritonavir
56	338	340	O	and
57	342	348	O	XXXXXXXX
K/3:C54357

Harvoni	4466	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	22
The effects of HARVONI on tenofovir exposures are similar when tenofovir is administered as ATRIPLA, COMPLERA, or TRUVADA + dolutegravir.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	21	O	XXXXXXXX
5	23	24	O	on
6	26	34	U-UNK	tenofovir
7	36	44	O	exposures
8	46	48	O	are
9	50	56	O	similar
10	58	61	O	when
11	63	71	O	tenofovir
12	73	74	O	is
13	76	87	O	administered
14	89	90	O	as
15	92	98	O	ATRIPLA
16	99	99	O	,
17	101	108	O	COMPLERA
18	109	109	O	,
19	111	112	O	or
20	114	120	O	TRUVADA
21	122	122	O	+
22	124	135	O	dolutegravir
NULL

Harvoni	4467	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	57
90 once daily 400 once daily 15 1.79 (1.56, 2.04) 1.98 (1.77, 2.23) 2.63 (2.32, 2.97) No effect on the pharmacokinetic parameters of the following coadministered drugs was observed with ledipasvir or sofosbuvir: abacavir, cyclosporine, darunavir/ritonavir, dolutegravir, efavirenz, emtricitabine, lamivudine, methadone, or rilpivirine.
1	0	1	O	90
2	3	6	O	once
3	8	12	O	daily
4	14	16	O	400
5	18	21	O	once
6	23	27	O	daily
7	29	30	O	15
8	32	35	O	1.79
9	38	41	O	1.56
10	42	42	O	,
11	44	47	O	2.04
12	50	53	O	1.98
13	56	59	O	1.77
14	60	60	O	,
15	62	65	O	2.23
16	68	71	O	2.63
17	74	77	O	2.32
18	78	78	O	,
19	80	83	O	2.97
20	86	87	O	No
21	89	94	O	effect
22	96	97	O	on
23	99	101	O	the
24	103	117	O	pharmacokinetic
25	119	128	O	parameters
26	130	131	O	of
27	133	135	O	the
28	137	145	O	following
29	147	160	O	coadministered
30	162	166	O	drugs
31	168	170	O	was
32	172	179	O	observed
33	181	184	O	with
34	186	195	O	XXXXXXXX
35	197	198	O	or
36	200	209	O	XXXXXXXX
37	210	210	O	:
38	212	219	O	abacavir
39	220	220	O	,
40	222	233	O	cyclosporine
41	234	234	O	,
42	236	244	O	darunavir
43	245	245	O	/
44	246	254	O	ritonavir
45	255	255	O	,
46	257	268	O	dolutegravir
47	269	269	O	,
48	271	279	O	efavirenz
49	280	280	O	,
50	282	294	O	emtricitabine
51	295	295	O	,
52	297	306	O	lamivudine
53	307	307	O	,
54	309	317	O	methadone
55	318	318	O	,
56	320	321	O	or
57	323	333	O	rilpivirine
NULL

Harvoni	4468	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Mechanism of Action Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication.
1	0	8	O	Mechanism
2	10	11	O	of
3	13	18	O	Action
4	20	29	O	XXXXXXXX
5	31	32	O	is
6	34	35	O	an
7	37	45	O	inhibitor
8	47	48	O	of
9	50	52	O	the
10	54	56	O	HCV
11	58	61	O	NS5A
12	63	69	O	protein
13	70	70	O	,
14	72	76	O	which
15	78	79	O	is
16	81	88	O	required
17	90	92	O	for
18	94	98	O	viral
19	100	110	O	replication
NULL

Harvoni	4469	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
Resistance selection in cell culture and cross-resistance studies indicate ledipasvir targets NS5A as its mode of action.
1	0	9	O	Resistance
2	11	19	O	selection
3	21	22	O	in
4	24	27	O	cell
5	29	35	O	culture
6	37	39	O	and
7	41	45	O	cross
8	47	56	O	resistance
9	58	64	O	studies
10	66	73	O	indicate
11	75	84	O	XXXXXXXX
12	86	92	O	targets
13	94	97	O	NS5A
14	99	100	O	as
15	102	104	O	its
16	106	109	O	mode
17	111	112	O	of
18	114	119	O	action
NULL

Harvoni	4470	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	25	O	inhibitor
5	27	28	O	of
6	30	32	O	the
7	34	36	O	HCV
8	38	41	O	NS5B
9	43	45	O	RNA
10	47	55	O	dependent
11	57	59	O	RNA
12	61	70	O	polymerase
13	71	71	O	,
14	73	77	O	which
15	79	80	O	is
16	82	89	O	required
17	91	93	O	for
18	95	99	O	viral
19	101	111	O	replication
NULL

Harvoni	4471	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	37
Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	25	O	nucleotide
5	27	33	O	prodrug
6	35	38	O	that
7	40	48	O	undergoes
8	50	62	O	intracellular
9	64	73	O	metabolism
10	75	76	O	to
11	78	81	O	form
12	83	85	O	the
13	87	103	O	pharmacologically
14	105	110	O	active
15	112	118	O	uridine
16	120	125	O	analog
17	127	138	O	triphosphate
18	141	142	O	GS
19	144	149	O	461203
20	151	151	O	,
21	153	157	O	which
22	159	161	O	can
23	163	164	O	be
24	166	177	O	incorporated
25	179	182	O	into
26	184	186	O	HCV
27	188	190	O	RNA
28	192	193	O	by
29	195	197	O	the
30	199	202	O	NS5B
31	204	213	O	polymerase
32	215	217	O	and
33	219	222	O	acts
34	224	225	O	as
35	227	227	O	a
36	229	233	O	chain
37	235	244	O	terminator
NULL

Harvoni	4472	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
In a biochemical assay, GS-461203 inhibited the polymerase activity of the recombinant NS5B from HCV genotypes 1b and 4a with IC50 values of 3.3 and 2.7 microM, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	15	O	biochemical
4	17	21	O	assay
5	22	22	O	,
6	24	25	O	GS
7	27	32	O	461203
8	34	42	O	inhibited
9	44	46	O	the
10	48	57	O	polymerase
11	59	66	O	activity
12	68	69	O	of
13	71	73	O	the
14	75	85	O	recombinant
15	87	90	O	NS5B
16	92	95	O	from
17	97	99	O	HCV
18	101	109	O	genotypes
19	111	112	O	1b
20	114	116	O	and
21	118	119	O	4a
22	121	124	O	with
23	126	129	O	IC50
24	131	136	O	values
25	138	139	O	of
26	141	143	O	3.3
27	145	147	O	and
28	149	151	O	2.7
29	153	158	O	microM
30	159	159	O	,
31	161	172	O	respectively
NULL

Harvoni	4473	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
GS-461203 is neither an inhibitor of human DNA and RNA polymerases nor an inhibitor of mitochondrial RNA polymerase.
1	0	1	O	GS
2	3	8	O	461203
3	10	11	O	is
4	13	19	O	neither
5	21	22	O	an
6	24	32	O	inhibitor
7	34	35	O	of
8	37	41	O	human
9	43	45	O	DNA
10	47	49	O	and
11	51	53	O	RNA
12	55	65	O	polymerases
13	67	69	O	nor
14	71	72	O	an
15	74	82	O	inhibitor
16	84	85	O	of
17	87	99	O	mitochondrial
18	101	103	O	RNA
19	105	114	O	polymerase
NULL

Harvoni	4474	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	29
Antiviral Activity In HCV replicon assays, the EC50 values of ledipasvir against full-length replicons from genotypes 1a and 1b were 0.031 nM and 0.004 nM, respectively.
1	0	8	O	Antiviral
2	10	17	O	Activity
3	19	20	O	In
4	22	24	O	HCV
5	26	33	O	replicon
6	35	40	O	assays
7	41	41	O	,
8	43	45	O	the
9	47	50	O	EC50
10	52	57	O	values
11	59	60	O	of
12	62	71	O	XXXXXXXX
13	73	79	O	against
14	81	84	O	full
15	86	91	O	length
16	93	101	O	replicons
17	103	106	O	from
18	108	116	O	genotypes
19	118	119	O	1a
20	121	123	O	and
21	125	126	O	1b
22	128	131	O	were
23	133	137	O	0.031
24	139	140	O	nM
25	142	144	O	and
26	146	150	O	0.004
27	152	153	O	nM
28	154	154	O	,
29	156	167	O	respectively
NULL

Harvoni	4475	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	44
The median EC50 values of ledipasvir against chimeric replicons encoding NS5A sequences from clinical isolates from treatment-naA*ve HCV-infected subjects were 0. 02 nM for genotype 1a (range 0.007-1.0 nM; N=23) and 0.006 nM for genotype 1b (range 0.002-1.0 nM; N=34).
1	0	2	O	The
2	4	9	O	median
3	11	14	O	EC50
4	16	21	O	values
5	23	24	O	of
6	26	35	O	XXXXXXXX
7	37	43	O	against
8	45	52	O	chimeric
9	54	62	O	replicons
10	64	71	O	encoding
11	73	76	O	NS5A
12	78	86	O	sequences
13	88	91	O	from
14	93	100	O	clinical
15	102	109	O	isolates
16	111	114	O	from
17	116	124	O	treatment
18	126	131	O	naA*ve
19	133	135	O	HCV
20	137	144	O	infected
21	146	153	O	subjects
22	155	158	O	were
23	160	160	O	0
24	163	164	O	02
25	166	167	O	nM
26	169	171	O	for
27	173	180	O	genotype
28	182	183	O	1a
29	186	190	O	range
30	192	196	O	0.007
31	198	200	O	1.0
32	202	203	O	nM
33	206	209	O	N=23
34	212	214	O	and
35	216	220	O	0.006
36	222	223	O	nM
37	225	227	O	for
38	229	236	O	genotype
39	238	239	O	1b
40	242	246	O	range
41	248	252	O	0.002
42	254	256	O	1.0
43	258	259	O	nM
44	262	265	O	N=34
NULL

Harvoni	4476	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
02 nM for genotype 1a (range 0.007-1.0 nM; N=23) and 0.006 nM for genotype 1b (range 0.002-1.0 nM; N=34).
1	0	1	O	02
2	3	4	O	nM
3	6	8	O	for
4	10	17	O	genotype
5	19	20	O	1a
6	23	27	O	range
7	29	33	O	0.007
8	35	37	O	1.0
9	39	40	O	nM
10	43	46	O	N=23
11	49	51	O	and
12	53	57	O	0.006
13	59	60	O	nM
14	62	64	O	for
15	66	73	O	genotype
16	75	76	O	1b
17	79	83	O	range
18	85	89	O	0.002
19	91	93	O	1.0
20	95	96	O	nM
21	99	102	O	N=34
NULL

Harvoni	4477	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	38
Ledipasvir had median EC50 values ranging between 0.002 nM to 0.16 nM against 11 genotype 4 subtypes (4a, 4d, 4n, 4r, 4o, 4c, 4f, 4k, 4l, 4m and 4t).
1	0	9	O	XXXXXXXX
2	11	13	O	had
3	15	20	O	median
4	22	25	O	EC50
5	27	32	O	values
6	34	40	O	ranging
7	42	48	O	between
8	50	54	O	0.002
9	56	57	O	nM
10	59	60	O	to
11	62	65	O	0.16
12	67	68	O	nM
13	70	76	O	against
14	78	79	O	11
15	81	88	O	genotype
16	90	90	O	4
17	92	99	O	subtypes
18	102	103	O	4a
19	104	104	O	,
20	106	107	O	4d
21	108	108	O	,
22	110	111	O	4n
23	112	112	O	,
24	114	115	O	4r
25	116	116	O	,
26	118	119	O	4o
27	120	120	O	,
28	122	123	O	4c
29	124	124	O	,
30	126	127	O	4f
31	128	128	O	,
32	130	131	O	4k
33	132	132	O	,
34	134	135	O	4l
35	136	136	O	,
36	138	139	O	4m
37	141	143	O	and
38	145	146	O	4t
NULL

Harvoni	4478	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	32
The median EC50 value for subtype 4b was 199.6 nM (range 0.66-1799 nM; N=3); the two 4b isolates with EC50 values greater than 100 nM had NS5A resistance-associated polymorphisms L30S+M31M+P58S+Y93H.
1	0	2	O	The
2	4	9	O	median
3	11	14	O	EC50
4	16	20	O	value
5	22	24	O	for
6	26	32	O	subtype
7	34	35	O	4b
8	37	39	O	was
9	41	45	O	199.6
10	47	48	O	nM
11	51	55	O	range
12	57	60	O	0.66
13	62	65	O	1799
14	67	68	O	nM
15	71	73	O	N=3
16	77	79	O	the
17	81	83	O	two
18	85	86	O	4b
19	88	95	O	isolates
20	97	100	O	with
21	102	105	O	EC50
22	107	112	O	values
23	114	120	O	greater
24	122	125	O	than
25	127	129	O	100
26	131	132	O	nM
27	134	136	O	had
28	138	141	O	NS5A
29	143	152	O	resistance
30	154	163	O	associated
31	165	177	O	polymorphisms
32	179	197	O	L30S+M31M+P58S+Y93H
NULL

Harvoni	4479	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	18
The median EC50 value of ledipasvir was 0.03 nM against genotype 5a isolates (range 0.008-0.081 nM; N=35).
1	0	2	O	The
2	4	9	O	median
3	11	14	O	EC50
4	16	20	O	value
5	22	23	O	of
6	25	34	O	XXXXXXXX
7	36	38	O	was
8	40	43	O	0.03
9	45	46	O	nM
10	48	54	O	against
11	56	63	O	genotype
12	65	66	O	5a
13	68	75	O	isolates
14	78	82	O	range
15	84	88	O	0.008
16	90	94	O	0.081
17	96	97	O	nM
18	100	103	O	N=35
NULL

Harvoni	4480	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	12
For genotype 6, the EC50 values for ledipasvir varied by subtype.
1	0	2	O	For
2	4	11	O	genotype
3	13	13	O	6
4	14	14	O	,
5	16	18	O	the
6	20	23	O	EC50
7	25	30	O	values
8	32	34	O	for
9	36	45	O	XXXXXXXX
10	47	52	O	varied
11	54	55	O	by
12	57	63	O	subtype
NULL

Harvoni	4481	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	15
Subtypes 6a and 6h had median EC50 values of 0.55 and 0.17 nM, respectively.
1	0	7	O	Subtypes
2	9	10	O	6a
3	12	14	O	and
4	16	17	O	6h
5	19	21	O	had
6	23	28	O	median
7	30	33	O	EC50
8	35	40	O	values
9	42	43	O	of
10	45	48	O	0.55
11	50	52	O	and
12	54	57	O	0.17
13	59	60	O	nM
14	61	61	O	,
15	63	74	O	respectively
NULL

Harvoni	4482	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
For subtypes 6e, 6l, 6n, 6q, 6k and 6m, the median EC50 values ranged from 60.6 nM to 430.1 nM.
1	0	2	O	For
2	4	11	O	subtypes
3	13	14	O	6e
4	15	15	O	,
5	17	18	O	6l
6	19	19	O	,
7	21	22	O	6n
8	23	23	O	,
9	25	26	O	6q
10	27	27	O	,
11	29	30	O	6k
12	32	34	O	and
13	36	37	O	6m
14	38	38	O	,
15	40	42	O	the
16	44	49	O	median
17	51	54	O	EC50
18	56	61	O	values
19	63	68	O	ranged
20	70	73	O	from
21	75	78	O	60.6
22	80	81	O	nM
23	83	84	O	to
24	86	90	O	430.1
25	92	93	O	nM
NULL

Harvoni	4483	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	46
In HCV replicon assays, the EC50 values of sofosbuvir against full-length replicons from genotypes 1a, 1b, 2a, 3a, and 4a, and chimeric 1b replicons encoding NS5B from genotypes 2b, 5a, or 6a ranged from 14-110 nM.
1	0	1	O	In
2	3	5	O	HCV
3	7	14	O	replicon
4	16	21	O	assays
5	22	22	O	,
6	24	26	O	the
7	28	31	O	EC50
8	33	38	O	values
9	40	41	O	of
10	43	52	O	XXXXXXXX
11	54	60	O	against
12	62	65	O	full
13	67	72	O	length
14	74	82	O	replicons
15	84	87	O	from
16	89	97	O	genotypes
17	99	100	O	1a
18	101	101	O	,
19	103	104	O	1b
20	105	105	O	,
21	107	108	O	2a
22	109	109	O	,
23	111	112	O	3a
24	113	113	O	,
25	115	117	O	and
26	119	120	O	4a
27	121	121	O	,
28	123	125	O	and
29	127	134	O	chimeric
30	136	137	O	1b
31	139	147	O	replicons
32	149	156	O	encoding
33	158	161	O	NS5B
34	163	166	O	from
35	168	176	O	genotypes
36	178	179	O	2b
37	180	180	O	,
38	182	183	O	5a
39	184	184	O	,
40	186	187	O	or
41	189	190	O	6a
42	192	197	O	ranged
43	199	202	O	from
44	204	205	O	14
45	207	209	O	110
46	211	212	O	nM
NULL

Harvoni	4484	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	60
The median EC50 value of sofosbuvir against chimeric replicons encoding NS5B sequences from clinical isolates was 62 nM for genotype 1a (range 29-128 nM; N=67), 102 nM for genotype 1b (range 45-170 nM; N=29), 29 nM for genotype 2 (range 14-81 nM; N=15), and 81 nM for genotype 3a (range 24-181 nM; N=106).
1	0	2	O	The
2	4	9	O	median
3	11	14	O	EC50
4	16	20	O	value
5	22	23	O	of
6	25	34	O	XXXXXXXX
7	36	42	O	against
8	44	51	O	chimeric
9	53	61	O	replicons
10	63	70	O	encoding
11	72	75	O	NS5B
12	77	85	O	sequences
13	87	90	O	from
14	92	99	O	clinical
15	101	108	O	isolates
16	110	112	O	was
17	114	115	O	62
18	117	118	O	nM
19	120	122	O	for
20	124	131	O	genotype
21	133	134	O	1a
22	137	141	O	range
23	143	144	O	29
24	146	148	O	128
25	150	151	O	nM
26	154	157	O	N=67
27	159	159	O	,
28	161	163	O	102
29	165	166	O	nM
30	168	170	O	for
31	172	179	O	genotype
32	181	182	O	1b
33	185	189	O	range
34	191	192	O	45
35	194	196	O	170
36	198	199	O	nM
37	202	205	O	N=29
38	207	207	O	,
39	209	210	O	29
40	212	213	O	nM
41	215	217	O	for
42	219	226	O	genotype
43	228	228	O	2
44	231	235	O	range
45	237	238	O	14
46	240	241	O	81
47	243	244	O	nM
48	247	250	O	N=15
49	252	252	O	,
50	254	256	O	and
51	258	259	O	81
52	261	262	O	nM
53	264	266	O	for
54	268	275	O	genotype
55	277	278	O	3a
56	281	285	O	range
57	287	288	O	24
58	290	292	O	181
59	294	295	O	nM
60	298	302	O	N=106
NULL

Harvoni	4485	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
In replication competent virus assays, the EC50 value of sofosbuvir against genotype 1a was 30 nM.
1	0	1	O	In
2	3	13	O	replication
3	15	23	O	competent
4	25	29	O	virus
5	31	36	O	assays
6	37	37	O	,
7	39	41	O	the
8	43	46	O	EC50
9	48	52	O	value
10	54	55	O	of
11	57	66	O	XXXXXXXX
12	68	74	O	against
13	76	83	O	genotype
14	85	86	O	1a
15	88	90	O	was
16	92	93	O	30
17	95	96	O	nM
NULL

Harvoni	4486	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Evaluation of sofosbuvir in combination with ledipasvir showed no antagonistic effect in reducing HCV RNA levels in replicon cells.
1	0	9	O	Evaluation
2	11	12	O	of
3	14	23	O	XXXXXXXX
4	25	26	O	in
5	28	38	O	combination
6	40	43	O	with
7	45	54	O	XXXXXXXX
8	56	61	O	showed
9	63	64	O	no
10	66	77	O	antagonistic
11	79	84	O	effect
12	86	87	O	in
13	89	96	O	reducing
14	98	100	O	HCV
15	102	104	O	RNA
16	106	111	O	levels
17	113	114	O	in
18	116	123	O	replicon
19	125	129	O	cells
NULL

Harvoni	4487	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	22
Resistance In Cell Culture HCV replicons with reduced susceptibility to ledipasvir have been selected in cell culture for genotypes 1a and 1b.
1	0	9	O	Resistance
2	11	12	O	In
3	14	17	O	Cell
4	19	25	O	Culture
5	27	29	O	HCV
6	31	39	O	replicons
7	41	44	O	with
8	46	52	O	reduced
9	54	67	O	susceptibility
10	69	70	O	to
11	72	81	O	XXXXXXXX
12	83	86	O	have
13	88	91	O	been
14	93	100	O	selected
15	102	103	O	in
16	105	108	O	cell
17	110	116	O	culture
18	118	120	O	for
19	122	130	O	genotypes
20	132	133	O	1a
21	135	137	O	and
22	139	140	O	1b
NULL

Harvoni	4488	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
Reduced susceptibility to ledipasvir was associated with the primary NS5A amino acid substitution Y93H in both genotypes 1a and 1b.
1	0	6	O	Reduced
2	8	21	O	susceptibility
3	23	24	O	to
4	26	35	O	XXXXXXXX
5	37	39	O	was
6	41	50	O	associated
7	52	55	O	with
8	57	59	O	the
9	61	67	O	primary
10	69	72	O	NS5A
11	74	78	O	amino
12	80	83	O	acid
13	85	96	O	substitution
14	98	101	O	Y93H
15	103	104	O	in
16	106	109	O	both
17	111	119	O	genotypes
18	121	122	O	1a
19	124	126	O	and
20	128	129	O	1b
NULL

Harvoni	4489	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	10
Additionally, a Q30E substitution emerged in genotype 1a replicons.
1	0	11	O	Additionally
2	12	12	O	,
3	14	14	O	a
4	16	19	O	Q30E
5	21	32	O	substitution
6	34	40	O	emerged
7	42	43	O	in
8	45	52	O	genotype
9	54	55	O	1a
10	57	65	O	replicons
NULL

Harvoni	4490	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	39
Site-directed mutagenesis of the Y93H in both genotypes 1a and 1b, as well as the Q30E substitution in genotype 1a, conferred high levels of reduced susceptibility to ledipasvir (fold change in EC50 greater than 1000-fold).
1	0	3	O	Site
2	5	12	O	directed
3	14	24	O	mutagenesis
4	26	27	O	of
5	29	31	O	the
6	33	36	O	Y93H
7	38	39	O	in
8	41	44	O	both
9	46	54	O	genotypes
10	56	57	O	1a
11	59	61	O	and
12	63	64	O	1b
13	65	65	O	,
14	67	68	O	as
15	70	73	O	well
16	75	76	O	as
17	78	80	O	the
18	82	85	O	Q30E
19	87	98	O	substitution
20	100	101	O	in
21	103	110	O	genotype
22	112	113	O	1a
23	114	114	O	,
24	116	124	O	conferred
25	126	129	O	high
26	131	136	O	levels
27	138	139	O	of
28	141	147	O	reduced
29	149	162	O	susceptibility
30	164	165	O	to
31	167	176	O	XXXXXXXX
32	179	182	O	fold
33	184	189	O	change
34	191	192	O	in
35	194	197	O	EC50
36	199	205	O	greater
37	207	210	O	than
38	212	215	O	1000
39	217	220	O	fold
NULL

Harvoni	4491	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
HCV replicons with reduced susceptibility to sofosbuvir have been selected in cell culture for multiple genotypes including 1b, 4a, 5a, and 6a.
1	0	2	O	HCV
2	4	12	O	replicons
3	14	17	O	with
4	19	25	O	reduced
5	27	40	O	susceptibility
6	42	43	O	to
7	45	54	O	XXXXXXXX
8	56	59	O	have
9	61	64	O	been
10	66	73	O	selected
11	75	76	O	in
12	78	81	O	cell
13	83	89	O	culture
14	91	93	O	for
15	95	102	O	multiple
16	104	112	O	genotypes
17	114	122	O	including
18	124	125	O	1b
19	126	126	O	,
20	128	129	O	4a
21	130	130	O	,
22	132	133	O	5a
23	134	134	O	,
24	136	138	O	and
25	140	141	O	6a
NULL

Harvoni	4492	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	16
Reduced susceptibility to sofosbuvir was associated with the NS5B substitution S282T in all replicon genotypes examined.
1	0	6	O	Reduced
2	8	21	O	susceptibility
3	23	24	O	to
4	26	35	O	XXXXXXXX
5	37	39	O	was
6	41	50	O	associated
7	52	55	O	with
8	57	59	O	the
9	61	64	O	NS5B
10	66	77	O	substitution
11	79	83	O	S282T
12	85	86	O	in
13	88	90	O	all
14	92	99	O	replicon
15	101	109	O	genotypes
16	111	118	O	examined
NULL

Harvoni	4493	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	15
An M289L substitution developed along with the S282T substitution in genotype 5 and 6 replicons.
1	0	1	O	An
2	3	7	O	M289L
3	9	20	O	substitution
4	22	30	O	developed
5	32	36	O	along
6	38	41	O	with
7	43	45	O	the
8	47	51	O	S282T
9	53	64	O	substitution
10	66	67	O	in
11	69	76	O	genotype
12	78	78	O	5
13	80	82	O	and
14	84	84	O	6
15	86	94	O	replicons
NULL

Harvoni	4494	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
Site-directed mutagenesis of the S282T substitution in replicons of 8 genotypes conferred 2- to 18-fold reduced susceptibility to sofosbuvir.
1	0	3	O	Site
2	5	12	O	directed
3	14	24	O	mutagenesis
4	26	27	O	of
5	29	31	O	the
6	33	37	O	S282T
7	39	50	O	substitution
8	52	53	O	in
9	55	63	O	replicons
10	65	66	O	of
11	68	68	O	8
12	70	78	O	genotypes
13	80	88	O	conferred
14	90	90	O	2
15	93	94	O	to
16	96	97	O	18
17	99	102	O	fold
18	104	110	O	reduced
19	112	125	O	susceptibility
20	127	128	O	to
21	130	139	O	XXXXXXXX
NULL

Harvoni	4495	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	51
In Clinical Trials In a pooled analysis of subjects who received HARVONI in Phase 3 trials, 37 subjects (29 with genotype 1a and 8 with genotype 1b) qualified for resistance analysis due to virologic failure (35 with virologic relapse, 2 with breakthrough on-treatment due to documented non-adherence).
1	0	1	O	In
2	3	10	O	Clinical
3	12	17	O	Trials
4	19	20	O	In
5	22	22	O	a
6	24	29	O	pooled
7	31	38	O	analysis
8	40	41	O	of
9	43	50	O	subjects
10	52	54	O	who
11	56	63	O	received
12	65	71	O	XXXXXXXX
13	73	74	O	in
14	76	80	O	Phase
15	82	82	O	3
16	84	89	O	trials
17	90	90	O	,
18	92	93	O	37
19	95	102	O	subjects
20	105	106	O	29
21	108	111	O	with
22	113	120	O	genotype
23	122	123	O	1a
24	125	127	O	and
25	129	129	O	8
26	131	134	O	with
27	136	143	O	genotype
28	145	146	O	1b
29	149	157	O	qualified
30	159	161	O	for
31	163	172	O	resistance
32	174	181	O	analysis
33	183	185	O	due
34	187	188	O	to
35	190	198	O	virologic
36	200	206	O	failure
37	209	210	O	35
38	212	215	O	with
39	217	225	O	virologic
40	227	233	O	relapse
41	234	234	O	,
42	236	236	O	2
43	238	241	O	with
44	243	254	O	breakthrough
45	256	257	O	on
46	259	267	O	treatment
47	269	271	O	due
48	273	274	O	to
49	276	285	O	documented
50	287	289	O	non
51	291	299	O	adherence
NULL

Harvoni	4496	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	28
Post-baseline NS5A and NS5B deep nucleotide sequence analysis data (assay sensitivity of 1%) were available for 37/37 and 36/37 subjects' viruses, respectively.
1	0	3	O	Post
2	5	12	O	baseline
3	14	17	O	NS5A
4	19	21	O	and
5	23	26	O	NS5B
6	28	31	O	deep
7	33	42	O	nucleotide
8	44	51	O	sequence
9	53	60	O	analysis
10	62	65	O	data
11	68	72	O	assay
12	74	84	O	sensitivity
13	86	87	O	of
14	89	90	O	1%
15	93	96	O	were
16	98	106	O	available
17	108	110	O	for
18	112	113	O	37
19	114	114	O	/
20	115	116	O	37
21	118	120	O	and
22	122	123	O	36
23	124	124	O	/
24	125	126	O	37
25	128	136	O	subjects'
26	138	144	O	viruses
27	145	145	O	,
28	147	158	O	respectively
NULL

Harvoni	4497	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	45
Of the 29 genotype 1a virologic failure subjects, 55% (16/29) of subjects had virus with emergent NS5A resistance-associated substitutions K24R, M28T/V, Q30R/H/K/L, L31M, or Y93H/N at failure.
1	0	1	O	Of
2	3	5	O	the
3	7	8	O	29
4	10	17	O	genotype
5	19	20	O	1a
6	22	30	O	virologic
7	32	38	O	failure
8	40	47	O	subjects
9	48	48	O	,
10	50	52	O	55%
11	55	56	O	16
12	57	57	O	/
13	58	59	O	29
14	62	63	O	of
15	65	72	O	subjects
16	74	76	O	had
17	78	82	O	virus
18	84	87	O	with
19	89	96	O	emergent
20	98	101	O	NS5A
21	103	112	O	resistance
22	114	123	O	associated
23	125	137	O	substitutions
24	139	142	O	K24R
25	143	143	O	,
26	145	148	O	M28T
27	149	149	O	/
28	150	150	O	V
29	151	151	O	,
30	153	156	O	Q30R
31	157	157	O	/
32	158	158	O	H
33	159	159	O	/
34	160	160	O	K
35	161	161	O	/
36	162	162	O	L
37	163	163	O	,
38	165	168	O	L31M
39	169	169	O	,
40	171	172	O	or
41	174	177	O	Y93H
42	178	178	O	/
43	179	179	O	N
44	181	182	O	at
45	184	190	O	failure
NULL

Harvoni	4498	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	17
Five of these 16 subjects' viruses also had baseline NS5A polymorphisms at resistance-associated amino acid positions.
1	0	3	O	Five
2	5	6	O	of
3	8	12	O	these
4	14	15	O	16
5	17	25	O	subjects'
6	27	33	O	viruses
7	35	38	O	also
8	40	42	O	had
9	44	51	O	baseline
10	53	56	O	NS5A
11	58	70	O	polymorphisms
12	72	73	O	at
13	75	84	O	resistance
14	86	95	O	associated
15	97	101	O	amino
16	103	106	O	acid
17	108	116	O	positions
NULL

Harvoni	4499	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	16
The most common substitutions detected at failure were Q30R, Y93H or N, and L31M.
1	0	2	O	The
2	4	7	O	most
3	9	14	O	common
4	16	28	O	substitutions
5	30	37	O	detected
6	39	40	O	at
7	42	48	O	failure
8	50	53	O	were
9	55	58	O	Q30R
10	59	59	O	,
11	61	64	O	Y93H
12	66	67	O	or
13	69	69	O	N
14	70	70	O	,
15	72	74	O	and
16	76	79	O	L31M
NULL

Harvoni	4500	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
Of the 8 genotype 1b virologic failure subjects, 88% (7/8) had virus with emergent NS5A resistance-associated substitutions L31V/M/I or Y93H at failure.
1	0	1	O	Of
2	3	5	O	the
3	7	7	O	8
4	9	16	O	genotype
5	18	19	O	1b
6	21	29	O	virologic
7	31	37	O	failure
8	39	46	O	subjects
9	47	47	O	,
10	49	51	O	88%
11	54	54	O	7
12	55	55	O	/
13	56	56	O	8
14	59	61	O	had
15	63	67	O	virus
16	69	72	O	with
17	74	81	O	emergent
18	83	86	O	NS5A
19	88	97	O	resistance
20	99	108	O	associated
21	110	122	O	substitutions
22	124	127	O	L31V
23	128	128	O	/
24	129	129	O	M
25	130	130	O	/
26	131	131	O	I
27	133	134	O	or
28	136	139	O	Y93H
29	141	142	O	at
30	144	150	O	failure
NULL

Harvoni	4501	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	16
Virus from three of these 7 subjects also had baseline NS5A polymorphisms at resistance-associated positions.
1	0	4	O	Virus
2	6	9	O	from
3	11	15	O	three
4	17	18	O	of
5	20	24	O	these
6	26	26	O	7
7	28	35	O	subjects
8	37	40	O	also
9	42	44	O	had
10	46	53	O	baseline
11	55	58	O	NS5A
12	60	72	O	polymorphisms
13	74	75	O	at
14	77	86	O	resistance
15	88	97	O	associated
16	99	107	O	positions
NULL

Harvoni	4502	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	9
The most common substitution detected at failure was Y93H.
1	0	2	O	The
2	4	7	O	most
3	9	14	O	common
4	16	27	O	substitution
5	29	36	O	detected
6	38	39	O	at
7	41	47	O	failure
8	49	51	O	was
9	53	56	O	Y93H
NULL

Harvoni	4503	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	22
At failure, 38% (14/37) of virologic failure subjects' viruses had 2 or more NS5A substitutions at resistance-associated positions.
1	0	1	O	At
2	3	9	O	failure
3	10	10	O	,
4	12	14	O	38%
5	17	18	O	14
6	19	19	O	/
7	20	21	O	37
8	24	25	O	of
9	27	35	O	virologic
10	37	43	O	failure
11	45	53	O	subjects'
12	55	61	O	viruses
13	63	65	O	had
14	67	67	O	2
15	69	70	O	or
16	72	75	O	more
17	77	80	O	NS5A
18	82	94	O	substitutions
19	96	97	O	at
20	99	108	O	resistance
21	110	119	O	associated
22	121	129	O	positions
NULL

Harvoni	4504	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	42
In the SOLAR-1 and SOLAR-2 trials (liver transplant recipients or subjects with decompensated liver disease), there were 24 virologic failures with genotype 1 infection (20 relapsers and 4 subjects who discontinued treatment prior to achieving HCV RNA < LLOQ).
1	0	1	O	In
2	3	5	O	the
3	7	11	O	SOLAR
4	13	13	O	1
5	15	17	O	and
6	19	23	O	SOLAR
7	25	25	O	2
8	27	32	O	trials
9	35	39	O	liver
10	41	50	O	transplant
11	52	61	O	recipients
12	63	64	O	or
13	66	73	O	subjects
14	75	78	O	with
15	80	92	O	decompensated
16	94	98	O	liver
17	100	106	O	disease
18	108	108	O	,
19	110	114	O	there
20	116	119	O	were
21	121	122	O	24
22	124	132	O	virologic
23	134	141	O	failures
24	143	146	O	with
25	148	155	O	genotype
26	157	157	O	1
27	159	167	O	infection
28	170	171	O	20
29	173	181	O	relapsers
30	183	185	O	and
31	187	187	O	4
32	189	196	O	subjects
33	198	200	O	who
34	202	213	O	discontinued
35	215	223	O	treatment
36	225	229	O	prior
37	231	232	O	to
38	234	242	O	achieving
39	244	246	O	HCV
40	248	250	O	RNA
41	252	252	O	<
42	254	257	O	LLOQ
NULL

Harvoni	4505	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	64
Treatment-emergent NS5A resistance-associated substitutions K24R, M28T, Q30R/H/K, L31V, H58D/P, and/or Y93H/C were detected in 14/17 (82%) genotype 1a virologic failure subjects, and R30Q, L31M, and/or Y93H/N were detected in 6/7 (86%) genotype 1b virologic failure subjects.
1	0	8	O	Treatment
2	10	17	O	emergent
3	19	22	O	NS5A
4	24	33	O	resistance
5	35	44	O	associated
6	46	58	O	substitutions
7	60	63	O	K24R
8	64	64	O	,
9	66	69	O	M28T
10	70	70	O	,
11	72	75	O	Q30R
12	76	76	O	/
13	77	77	O	H
14	78	78	O	/
15	79	79	O	K
16	80	80	O	,
17	82	85	O	L31V
18	86	86	O	,
19	88	91	O	H58D
20	92	92	O	/
21	93	93	O	P
22	94	94	O	,
23	96	98	O	and
24	99	99	O	/
25	100	101	O	or
26	103	106	O	Y93H
27	107	107	O	/
28	108	108	O	C
29	110	113	O	were
30	115	122	O	detected
31	124	125	O	in
32	127	128	O	14
33	129	129	O	/
34	130	131	O	17
35	134	136	O	82%
36	139	146	O	genotype
37	148	149	O	1a
38	151	159	O	virologic
39	161	167	O	failure
40	169	176	O	subjects
41	177	177	O	,
42	179	181	O	and
43	183	186	O	R30Q
44	187	187	O	,
45	189	192	O	L31M
46	193	193	O	,
47	195	197	O	and
48	198	198	O	/
49	199	200	O	or
50	202	205	O	Y93H
51	206	206	O	/
52	207	207	O	N
53	209	212	O	were
54	214	221	O	detected
55	223	224	O	in
56	226	226	O	6
57	227	227	O	/
58	228	228	O	7
59	231	233	O	86%
60	236	243	O	genotype
61	245	246	O	1b
62	248	256	O	virologic
63	258	264	O	failure
64	266	273	O	subjects
NULL

Harvoni	4506	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	26
In phenotypic analyses, post-baseline isolates from subjects who harbored NS5A resistance-associated substitutions at failure showed 20- to >243-fold reduced susceptibility to ledipasvir.
1	0	1	O	In
2	3	12	O	phenotypic
3	14	21	O	analyses
4	22	22	O	,
5	24	27	O	post
6	29	36	O	baseline
7	38	45	O	isolates
8	47	50	O	from
9	52	59	O	subjects
10	61	63	O	who
11	65	72	O	harbored
12	74	77	O	NS5A
13	79	88	O	resistance
14	90	99	O	associated
15	101	113	O	substitutions
16	115	116	O	at
17	118	124	O	failure
18	126	131	O	showed
19	133	134	O	20
20	137	138	O	to
21	140	143	O	>243
22	145	148	O	fold
23	150	156	O	reduced
24	158	171	O	susceptibility
25	173	174	O	to
26	176	185	O	XXXXXXXX
NULL

Harvoni	4507	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
Treatment-emergent NS5B substitutions L159 (n=1) and V321 (n=2) previously associated with sofosbuvir failure were detected in the Phase 3 trials (ION-3, ION-1, and ION-2).
1	0	8	O	Treatment
2	10	17	O	emergent
3	19	22	O	NS5B
4	24	36	O	substitutions
5	38	41	O	L159
6	44	46	O	n=1
7	49	51	O	and
8	53	56	O	V321
9	59	61	O	n=2
10	64	73	O	previously
11	75	84	O	associated
12	86	89	O	with
13	91	100	O	XXXXXXXX
14	102	108	O	failure
15	110	113	O	were
16	115	122	O	detected
17	124	125	O	in
18	127	129	O	the
19	131	135	O	Phase
20	137	137	O	3
21	139	144	O	trials
22	147	149	O	ION
23	151	151	O	3
24	152	152	O	,
25	154	156	O	ION
26	158	158	O	1
27	159	159	O	,
28	161	163	O	and
29	165	167	O	ION
30	169	169	O	2
NULL

Harvoni	4508	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	38
In addition, NS5B substitutions at highly conserved positions D61G (n=3), A112T (n=2), E237G (n=2), and S473T (n=1) were detected at low frequency by next generation sequencing in treatment failure subjects infected with HCV GT1a.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	16	O	NS5B
5	18	30	O	substitutions
6	32	33	O	at
7	35	40	O	highly
8	42	50	O	conserved
9	52	60	O	positions
10	62	65	O	D61G
11	68	70	O	n=3
12	72	72	O	,
13	74	78	O	A112T
14	81	83	O	n=2
15	85	85	O	,
16	87	91	O	E237G
17	94	96	O	n=2
18	98	98	O	,
19	100	102	O	and
20	104	108	O	S473T
21	111	113	O	n=1
22	116	119	O	were
23	121	128	O	detected
24	130	131	O	at
25	133	135	O	low
26	137	145	O	frequency
27	147	148	O	by
28	150	153	O	next
29	155	164	O	generation
30	166	175	O	sequencing
31	177	178	O	in
32	180	188	O	treatment
33	190	196	O	failure
34	198	205	O	subjects
35	207	214	O	infected
36	216	219	O	with
37	221	223	O	HCV
38	225	228	O	GT1a
NULL

Harvoni	4509	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
The D61G substitution was previously described in subjects infected with HCV genotype 1a in a liver pre-transplant trial.
1	0	2	O	The
2	4	7	O	D61G
3	9	20	O	substitution
4	22	24	O	was
5	26	35	O	previously
6	37	45	O	described
7	47	48	O	in
8	50	57	O	subjects
9	59	66	O	infected
10	68	71	O	with
11	73	75	O	HCV
12	77	84	O	genotype
13	86	87	O	1a
14	89	90	O	in
15	92	92	O	a
16	94	98	O	liver
17	100	102	O	pre
18	104	113	O	transplant
19	115	119	O	trial
NULL

Harvoni	4510	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
The E237G substitution was detected in 3 subjects infected with HCV GT1a in the SOLAR-1 and SOLAR-2 trials.
1	0	2	O	The
2	4	8	O	E237G
3	10	21	O	substitution
4	23	25	O	was
5	27	34	O	detected
6	36	37	O	in
7	39	39	O	3
8	41	48	O	subjects
9	50	57	O	infected
10	59	62	O	with
11	64	66	O	HCV
12	68	71	O	GT1a
13	73	74	O	in
14	76	78	O	the
15	80	84	O	SOLAR
16	86	86	O	1
17	88	90	O	and
18	92	96	O	SOLAR
19	98	98	O	2
20	100	105	O	trials
NULL

Harvoni	4511	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	9
The clinical significance of these substitutions is currently unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	47	O	substitutions
7	49	50	O	is
8	52	60	O	currently
9	62	68	O	unknown
NULL

Harvoni	4512	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
The sofosbuvir-associated resistance substitution S282T in NS5B was not detected in any failure isolate from the Phase 3 trials.
1	0	2	O	The
2	4	13	O	XXXXXXXX
3	15	24	O	associated
4	26	35	O	resistance
5	37	48	O	substitution
6	50	54	O	S282T
7	56	57	O	in
8	59	62	O	NS5B
9	64	66	O	was
10	68	70	O	not
11	72	79	O	detected
12	81	82	O	in
13	84	86	O	any
14	88	94	O	failure
15	96	102	O	isolate
16	104	107	O	from
17	109	111	O	the
18	113	117	O	Phase
19	119	119	O	3
20	121	126	O	trials
NULL

Harvoni	4513	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	40
NS5B substitutions S282T, L320V/I, and V321I in combination with NS5A substitutions L31M, Y93H, and Q30L were detected in one subject at failure following 8 weeks of treatment with HARVONI in a Phase 2 trial.
1	0	3	O	NS5B
2	5	17	O	substitutions
3	19	23	O	S282T
4	24	24	O	,
5	26	30	O	L320V
6	31	31	O	/
7	32	32	O	I
8	33	33	O	,
9	35	37	O	and
10	39	43	O	V321I
11	45	46	O	in
12	48	58	O	combination
13	60	63	O	with
14	65	68	O	NS5A
15	70	82	O	substitutions
16	84	87	O	L31M
17	88	88	O	,
18	90	93	O	Y93H
19	94	94	O	,
20	96	98	O	and
21	100	103	O	Q30L
22	105	108	O	were
23	110	117	O	detected
24	119	120	O	in
25	122	124	O	one
26	126	132	O	subject
27	134	135	O	at
28	137	143	O	failure
29	145	153	O	following
30	155	155	O	8
31	157	161	O	weeks
32	163	164	O	of
33	166	174	O	treatment
34	176	179	O	with
35	181	187	O	XXXXXXXX
36	189	190	O	in
37	192	192	O	a
38	194	198	O	Phase
39	200	200	O	2
40	202	206	O	trial
NULL

Harvoni	4514	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	47
Genotype 4, 5 or 6 Resistance analysis was performed for 6 relapse subjects infected with HCV genotype 4 (Study 1119 and ION-4, N=3), genotype 5 (Study 1119, N=2) or genotype 6 (ELECTRON-2, N=1) and treated with HARVONI for 12 weeks.
1	0	7	O	Genotype
2	9	9	O	4
3	10	10	O	,
4	12	12	O	5
5	14	15	O	or
6	17	17	O	6
7	19	28	O	Resistance
8	30	37	O	analysis
9	39	41	O	was
10	43	51	O	performed
11	53	55	O	for
12	57	57	O	6
13	59	65	O	relapse
14	67	74	O	subjects
15	76	83	O	infected
16	85	88	O	with
17	90	92	O	HCV
18	94	101	O	genotype
19	103	103	O	4
20	106	110	O	Study
21	112	115	O	1119
22	117	119	O	and
23	121	123	O	ION
24	125	125	O	4
25	126	126	O	,
26	128	130	O	N=3
27	132	132	O	,
28	134	141	O	genotype
29	143	143	O	5
30	146	150	O	Study
31	152	155	O	1119
32	156	156	O	,
33	158	160	O	N=2
34	163	164	O	or
35	166	173	O	genotype
36	175	175	O	6
37	178	185	O	ELECTRON
38	187	187	O	2
39	188	188	O	,
40	190	192	O	N=1
41	195	197	O	and
42	199	205	O	treated
43	207	210	O	with
44	212	218	O	XXXXXXXX
45	220	222	O	for
46	224	225	O	12
47	227	231	O	weeks
NULL

Harvoni	4515	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	32
All the relapse subjects with NS5A sequencing data (5 of 6) had pretreatment NS5A resistance-associated polymorphisms (single or combinations at positions 24, 28, 30, 31, and 58).
1	0	2	O	All
2	4	6	O	the
3	8	14	O	relapse
4	16	23	O	subjects
5	25	28	O	with
6	30	33	O	NS5A
7	35	44	O	sequencing
8	46	49	O	data
9	52	52	O	5
10	54	55	O	of
11	57	57	O	6
12	60	62	O	had
13	64	75	O	pretreatment
14	77	80	O	NS5A
15	82	91	O	resistance
16	93	102	O	associated
17	104	116	O	polymorphisms
18	119	124	O	single
19	126	127	O	or
20	129	140	O	combinations
21	142	143	O	at
22	145	153	O	positions
23	155	156	O	24
24	157	157	O	,
25	159	160	O	28
26	161	161	O	,
27	163	164	O	30
28	165	165	O	,
29	167	168	O	31
30	169	169	O	,
31	171	173	O	and
32	175	176	O	58
NULL

Harvoni	4516	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	28
NS5A resistance substitutions (Y93C or L28V) emerged in two of the genotype 4 relapse subjects post-treatment who also had NS5A polymorphisms pretreatment that were retained post-treatment.
1	0	3	O	NS5A
2	5	14	O	resistance
3	16	28	O	substitutions
4	31	34	O	Y93C
5	36	37	O	or
6	39	42	O	L28V
7	45	51	O	emerged
8	53	54	O	in
9	56	58	O	two
10	60	61	O	of
11	63	65	O	the
12	67	74	O	genotype
13	76	76	O	4
14	78	84	O	relapse
15	86	93	O	subjects
16	95	98	O	post
17	100	108	O	treatment
18	110	112	O	who
19	114	117	O	also
20	119	121	O	had
21	123	126	O	NS5A
22	128	140	O	polymorphisms
23	142	153	O	pretreatment
24	155	158	O	that
25	160	163	O	were
26	165	172	O	retained
27	174	177	O	post
28	179	187	O	treatment
NULL

Harvoni	4517	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
Two of the relapsers with genotype 4 HCV infection had an NS5B V321I substitution pretreatment, which was retained post-treatment.
1	0	2	O	Two
2	4	5	O	of
3	7	9	O	the
4	11	19	O	relapsers
5	21	24	O	with
6	26	33	O	genotype
7	35	35	O	4
8	37	39	O	HCV
9	41	49	O	infection
10	51	53	O	had
11	55	56	O	an
12	58	61	O	NS5B
13	63	67	O	V321I
14	69	80	O	substitution
15	82	93	O	pretreatment
16	94	94	O	,
17	96	100	O	which
18	102	104	O	was
19	106	113	O	retained
20	115	118	O	post
21	120	128	O	treatment
NULL

Harvoni	4518	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	38
Three of the relapse subjects (1 each for genotype 4, 5, and 6) had virus with emergent sofosbuvir resistance-associated substitution S282T at relapse; the genotype 5 relapse subject also had emergent nucleotide inhibitor substitution M289I.
1	0	4	O	Three
2	6	7	O	of
3	9	11	O	the
4	13	19	O	relapse
5	21	28	O	subjects
6	31	31	O	1
7	33	36	O	each
8	38	40	O	for
9	42	49	O	genotype
10	51	51	O	4
11	52	52	O	,
12	54	54	O	5
13	55	55	O	,
14	57	59	O	and
15	61	61	O	6
16	64	66	O	had
17	68	72	O	virus
18	74	77	O	with
19	79	86	O	emergent
20	88	97	O	XXXXXXXX
21	99	108	O	resistance
22	110	119	O	associated
23	121	132	O	substitution
24	134	138	O	S282T
25	140	141	O	at
26	143	149	O	relapse
27	152	154	O	the
28	156	163	O	genotype
29	165	165	O	5
30	167	173	O	relapse
31	175	181	O	subject
32	183	186	O	also
33	188	190	O	had
34	192	199	O	emergent
35	201	210	O	nucleotide
36	212	220	O	inhibitor
37	222	233	O	substitution
38	235	239	O	M289I
NULL

Harvoni	4519	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
Persistence of Resistance-Associated Substitutions No data are available on the persistence of ledipasvir or sofosbuvir resistance-associated substitutions.
1	0	10	O	Persistence
2	12	13	O	of
3	15	24	O	Resistance
4	26	35	O	Associated
5	37	49	O	Substitutions
6	51	52	O	No
7	54	57	O	data
8	59	61	O	are
9	63	71	O	available
10	73	74	O	on
11	76	78	O	the
12	80	90	O	persistence
13	92	93	O	of
14	95	104	O	XXXXXXXX
15	106	107	O	or
16	109	118	O	XXXXXXXX
17	120	129	O	resistance
18	131	140	O	associated
19	142	154	O	substitutions
NULL

Harvoni	4520	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	19
NS5A resistance-associated substitutions for other NS5A inhibitors have been found to persist for >1 year in some patients.
1	0	3	O	NS5A
2	5	14	O	resistance
3	16	25	O	associated
4	27	39	O	substitutions
5	41	43	O	for
6	45	49	O	other
7	51	54	O	NS5A
8	56	65	O	inhibitors
9	67	70	O	have
10	72	75	O	been
11	77	81	O	found
12	83	84	O	to
13	86	92	O	persist
14	94	96	O	for
15	98	99	O	>1
16	101	104	O	year
17	106	107	O	in
18	109	112	O	some
19	114	121	O	patients
NULL

Harvoni	4521	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	21
The long-term clinical impact of the emergence or persistence of virus containing ledipasvir or sofosbuvir resistance-associated substitutions is unknown.
1	0	2	O	The
2	4	7	O	long
3	9	12	O	term
4	14	21	O	clinical
5	23	28	O	impact
6	30	31	O	of
7	33	35	O	the
8	37	45	O	emergence
9	47	48	O	or
10	50	60	O	persistence
11	62	63	O	of
12	65	69	O	virus
13	71	80	O	containing
14	82	91	O	XXXXXXXX
15	93	94	O	or
16	96	105	O	XXXXXXXX
17	107	116	O	resistance
18	118	127	O	associated
19	129	141	O	substitutions
20	143	144	O	is
21	146	152	O	unknown
NULL

Harvoni	4522	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
Effect of Baseline HCV Polymorphisms on Treatment Response Adults Genotype 1 Analyses were conducted to explore the association between pre-existing baseline NS5A polymorphisms at resistance-associated positions and relapse rates.
1	0	5	O	Effect
2	7	8	O	of
3	10	17	O	Baseline
4	19	21	O	HCV
5	23	35	O	Polymorphisms
6	37	38	O	on
7	40	48	O	Treatment
8	50	57	O	Response
9	59	64	O	Adults
10	66	73	O	Genotype
11	75	75	O	1
12	77	84	O	Analyses
13	86	89	O	were
14	91	99	O	conducted
15	101	102	O	to
16	104	110	O	explore
17	112	114	O	the
18	116	126	O	association
19	128	134	O	between
20	136	138	O	pre
21	140	147	O	existing
22	149	156	O	baseline
23	158	161	O	NS5A
24	163	175	O	polymorphisms
25	177	178	O	at
26	180	189	O	resistance
27	191	200	O	associated
28	202	210	O	positions
29	212	214	O	and
30	216	222	O	relapse
31	224	228	O	rates
NULL

Harvoni	4523	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	54
In the pooled analysis of the Phase 3 trials, 23% (370/1589) of subjects' virus had baseline NS5A polymorphisms at resistance-associated positions (any change from reference at NS5A amino acid positions 24, 28, 30, 31, 58, 92, or 93) identified by population or deep sequencing.
1	0	1	O	In
2	3	5	O	the
3	7	12	O	pooled
4	14	21	O	analysis
5	23	24	O	of
6	26	28	O	the
7	30	34	O	Phase
8	36	36	O	3
9	38	43	O	trials
10	44	44	O	,
11	46	48	O	23%
12	51	53	O	370
13	54	54	O	/
14	55	58	O	1589
15	61	62	O	of
16	64	72	O	subjects'
17	74	78	O	virus
18	80	82	O	had
19	84	91	O	baseline
20	93	96	O	NS5A
21	98	110	O	polymorphisms
22	112	113	O	at
23	115	124	O	resistance
24	126	135	O	associated
25	137	145	O	positions
26	148	150	O	any
27	152	157	O	change
28	159	162	O	from
29	164	172	O	reference
30	174	175	O	at
31	177	180	O	NS5A
32	182	186	O	amino
33	188	191	O	acid
34	193	201	O	positions
35	203	204	O	24
36	205	205	O	,
37	207	208	O	28
38	209	209	O	,
39	211	212	O	30
40	213	213	O	,
41	215	216	O	31
42	217	217	O	,
43	219	220	O	58
44	221	221	O	,
45	223	224	O	92
46	225	225	O	,
47	227	228	O	or
48	230	231	O	93
49	234	243	O	identified
50	245	246	O	by
51	248	257	O	population
52	259	260	O	or
53	262	265	O	deep
54	267	276	O	sequencing
NULL

Harvoni	4524	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	44
In treatment-naive subjects whose virus had baseline NS5A polymorphisms at resistance-associated positions in Studies ION-1 and ION-3, relapse rates were 6% (3/48) after 8 weeks and 1% (1/113) after 12 weeks of treatment with HARVONI.
1	0	1	O	In
2	3	11	O	treatment
3	13	17	O	naive
4	19	26	O	subjects
5	28	32	O	whose
6	34	38	O	virus
7	40	42	O	had
8	44	51	O	baseline
9	53	56	O	NS5A
10	58	70	O	polymorphisms
11	72	73	O	at
12	75	84	O	resistance
13	86	95	O	associated
14	97	105	O	positions
15	107	108	O	in
16	110	116	O	Studies
17	118	120	O	ION
18	122	122	O	1
19	124	126	O	and
20	128	130	O	ION
21	132	132	O	3
22	133	133	O	,
23	135	141	O	relapse
24	143	147	O	rates
25	149	152	O	were
26	154	155	O	6%
27	158	158	O	3
28	159	159	O	/
29	160	161	O	48
30	164	168	O	after
31	170	170	O	8
32	172	176	O	weeks
33	178	180	O	and
34	182	183	O	1%
35	186	186	O	1
36	187	187	O	/
37	188	190	O	113
38	193	197	O	after
39	199	200	O	12
40	202	206	O	weeks
41	208	209	O	of
42	211	219	O	treatment
43	221	224	O	with
44	226	232	O	XXXXXXXX
NULL

Harvoni	4525	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
Relapse rates among subjects without baseline NS5A polymorphisms at resistance-associated positions were 5% (8/167) after 8 weeks and 1% (3/306) after 12 weeks treatment with HARVONI.
1	0	6	O	Relapse
2	8	12	O	rates
3	14	18	O	among
4	20	27	O	subjects
5	29	35	O	without
6	37	44	O	baseline
7	46	49	O	NS5A
8	51	63	O	polymorphisms
9	65	66	O	at
10	68	77	O	resistance
11	79	88	O	associated
12	90	98	O	positions
13	100	103	O	were
14	105	106	O	5%
15	109	109	O	8
16	110	110	O	/
17	111	113	O	167
18	116	120	O	after
19	122	122	O	8
20	124	128	O	weeks
21	130	132	O	and
22	134	135	O	1%
23	138	138	O	3
24	139	139	O	/
25	140	142	O	306
26	145	149	O	after
27	151	152	O	12
28	154	158	O	weeks
29	160	168	O	treatment
30	170	173	O	with
31	175	181	O	XXXXXXXX
NULL

Harvoni	4526	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	41
In treatment-experienced subjects in Study ION-2 whose virus had baseline NS5A polymorphisms at resistance-associated positions, relapse rates were 22% (5/23) after 12 weeks and 0% (0/19) after 24 weeks of treatment with HARVONI.
1	0	1	O	In
2	3	11	O	treatment
3	13	23	O	experienced
4	25	32	O	subjects
5	34	35	O	in
6	37	41	O	Study
7	43	45	O	ION
8	47	47	O	2
9	49	53	O	whose
10	55	59	O	virus
11	61	63	O	had
12	65	72	O	baseline
13	74	77	O	NS5A
14	79	91	O	polymorphisms
15	93	94	O	at
16	96	105	O	resistance
17	107	116	O	associated
18	118	126	O	positions
19	127	127	O	,
20	129	135	O	relapse
21	137	141	O	rates
22	143	146	O	were
23	148	150	O	22%
24	153	153	O	5
25	154	154	O	/
26	155	156	O	23
27	159	163	O	after
28	165	166	O	12
29	168	172	O	weeks
30	174	176	O	and
31	178	179	O	0%
32	182	182	O	0
33	183	183	O	/
34	184	185	O	19
35	188	192	O	after
36	194	195	O	24
37	197	201	O	weeks
38	203	204	O	of
39	206	214	O	treatment
40	216	219	O	with
41	221	227	O	XXXXXXXX
NULL

Harvoni	4527	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	44
In another study in treatment-experienced subjects (SIRIUS), 0/15 (0%) subjects with NS5A polymorphisms at resistance-associated positions relapsed after 12 weeks of treatment with HARVONI + RBV compared to 2/15 (13%) subjects treated with 24 weeks of HARVONI.
1	0	1	O	In
2	3	9	O	another
3	11	15	O	study
4	17	18	O	in
5	20	28	O	treatment
6	30	40	O	experienced
7	42	49	O	subjects
8	52	57	O	SIRIUS
9	59	59	O	,
10	61	61	O	0
11	62	62	O	/
12	63	64	O	15
13	67	68	O	0%
14	71	78	O	subjects
15	80	83	O	with
16	85	88	O	NS5A
17	90	102	O	polymorphisms
18	104	105	O	at
19	107	116	O	resistance
20	118	127	O	associated
21	129	137	O	positions
22	139	146	O	relapsed
23	148	152	O	after
24	154	155	O	12
25	157	161	O	weeks
26	163	164	O	of
27	166	174	O	treatment
28	176	179	O	with
29	181	187	O	XXXXXXXX
30	189	189	O	+
31	191	193	O	RBV
32	195	202	O	compared
33	204	205	O	to
34	207	207	O	2
35	208	208	O	/
36	209	210	O	15
37	213	215	O	13%
38	218	225	O	subjects
39	227	233	O	treated
40	235	238	O	with
41	240	241	O	24
42	243	247	O	weeks
43	249	250	O	of
44	252	258	O	XXXXXXXX
NULL

Harvoni	4528	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	33
SVR was achieved in all 24 subjects (N=20 with L159F+C316N; N=1 with L159F; and N=3 with N142T) who had baseline polymorphisms associated with resistance to sofosbuvir and/or other NS5B nucleoside inhibitors.
1	0	2	O	SVR
2	4	6	O	was
3	8	15	O	achieved
4	17	18	O	in
5	20	22	O	all
6	24	25	O	24
7	27	34	O	subjects
8	37	40	O	N=20
9	42	45	O	with
10	47	57	O	L159F+C316N
11	60	62	O	N=1
12	64	67	O	with
13	69	73	O	L159F
14	76	78	O	and
15	80	82	O	N=3
16	84	87	O	with
17	89	93	O	N142T
18	96	98	O	who
19	100	102	O	had
20	104	111	O	baseline
21	113	125	O	polymorphisms
22	127	136	O	associated
23	138	141	O	with
24	143	152	O	resistance
25	154	155	O	to
26	157	166	O	XXXXXXXX
27	168	170	O	and
28	171	171	O	/
29	172	173	O	or
30	175	179	O	other
31	181	184	O	NS5B
32	186	195	O	nucleoside
33	197	206	O	inhibitors
NULL

Harvoni	4529	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	31
The NS5B S282T substitution associated with resistance to sofosbuvir was not detected in the baseline NS5B sequence of any subject in Phase 3 trials by population or deep nucleotide sequence analysis.
1	0	2	O	The
2	4	7	O	NS5B
3	9	13	O	S282T
4	15	26	O	substitution
5	28	37	O	associated
6	39	42	O	with
7	44	53	O	resistance
8	55	56	O	to
9	58	67	O	XXXXXXXX
10	69	71	O	was
11	73	75	O	not
12	77	84	O	detected
13	86	87	O	in
14	89	91	O	the
15	93	100	O	baseline
16	102	105	O	NS5B
17	107	114	O	sequence
18	116	117	O	of
19	119	121	O	any
20	123	129	O	subject
21	131	132	O	in
22	134	138	O	Phase
23	140	140	O	3
24	142	147	O	trials
25	149	150	O	by
26	152	161	O	population
27	163	164	O	or
28	166	169	O	deep
29	171	180	O	nucleotide
30	182	189	O	sequence
31	191	198	O	analysis
NULL

Harvoni	4530	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	56
In the SOLAR-1 and SOLAR-2 trials (liver transplant recipients or subjects with decompensated liver disease), after 12 weeks of treatment with HARVONI and RBV, relapse rates were 7% (5/71) and 5% (10/217) in genotype 1 subjects with and without baseline NS5A polymorphisms at resistance-associated positions, respectively.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	SOLAR
4	13	13	O	1
5	15	17	O	and
6	19	23	O	SOLAR
7	25	25	O	2
8	27	32	O	trials
9	35	39	O	liver
10	41	50	O	transplant
11	52	61	O	recipients
12	63	64	O	or
13	66	73	O	subjects
14	75	78	O	with
15	80	92	O	decompensated
16	94	98	O	liver
17	100	106	O	disease
18	108	108	O	,
19	110	114	O	after
20	116	117	O	12
21	119	123	O	weeks
22	125	126	O	of
23	128	136	O	treatment
24	138	141	O	with
25	143	149	O	XXXXXXXX
26	151	153	O	and
27	155	157	O	RBV
28	158	158	O	,
29	160	166	O	relapse
30	168	172	O	rates
31	174	177	O	were
32	179	180	O	7%
33	183	183	O	5
34	184	184	O	/
35	185	186	O	71
36	189	191	O	and
37	193	194	O	5%
38	197	198	O	10
39	199	199	O	/
40	200	202	O	217
41	205	206	O	in
42	208	215	O	genotype
43	217	217	O	1
44	219	226	O	subjects
45	228	231	O	with
46	233	235	O	and
47	237	243	O	without
48	245	252	O	baseline
49	254	257	O	NS5A
50	259	271	O	polymorphisms
51	273	274	O	at
52	276	285	O	resistance
53	287	296	O	associated
54	298	306	O	positions
55	307	307	O	,
56	309	320	O	respectively
NULL

Harvoni	4531	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	56
In the Phase 3 trials and SOLAR trials, the specific baseline NS5A resistance-associated polymorphisms observed among subjects who relapsed were M28T/V, Q30H/R, L31M, H58D/P, and Y93H/N in genotype 1a, and L28M, L31M, A92T, and Y93H in genotype 1b.
1	0	1	O	In
2	3	5	O	the
3	7	11	O	Phase
4	13	13	O	3
5	15	20	O	trials
6	22	24	O	and
7	26	30	O	SOLAR
8	32	37	O	trials
9	38	38	O	,
10	40	42	O	the
11	44	51	O	specific
12	53	60	O	baseline
13	62	65	O	NS5A
14	67	76	O	resistance
15	78	87	O	associated
16	89	101	O	polymorphisms
17	103	110	O	observed
18	112	116	O	among
19	118	125	O	subjects
20	127	129	O	who
21	131	138	O	relapsed
22	140	143	O	were
23	145	148	O	M28T
24	149	149	O	/
25	150	150	O	V
26	151	151	O	,
27	153	156	O	Q30H
28	157	157	O	/
29	158	158	O	R
30	159	159	O	,
31	161	164	O	L31M
32	165	165	O	,
33	167	170	O	H58D
34	171	171	O	/
35	172	172	O	P
36	173	173	O	,
37	175	177	O	and
38	179	182	O	Y93H
39	183	183	O	/
40	184	184	O	N
41	186	187	O	in
42	189	196	O	genotype
43	198	199	O	1a
44	200	200	O	,
45	202	204	O	and
46	206	209	O	L28M
47	210	210	O	,
48	212	215	O	L31M
49	216	216	O	,
50	218	221	O	A92T
51	222	222	O	,
52	224	226	O	and
53	228	231	O	Y93H
54	233	234	O	in
55	236	243	O	genotype
56	245	246	O	1b
NULL

Harvoni	4532	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	15
Subjects with multiple NS5A polymorphisms at resistance-associated positions appeared to have higher relapse rates.
1	0	7	O	Subjects
2	9	12	O	with
3	14	21	O	multiple
4	23	26	O	NS5A
5	28	40	O	polymorphisms
6	42	43	O	at
7	45	54	O	resistance
8	56	65	O	associated
9	67	75	O	positions
10	77	84	O	appeared
11	86	87	O	to
12	89	92	O	have
13	94	99	O	higher
14	101	107	O	relapse
15	109	113	O	rates
NULL

Harvoni	4533	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	44
Genotype 4, 5 or 6 Phylogenetic analysis of HCV sequences from genotype 4-infected subjects in Study 1119 (N=44) and ION-4 (N=8) identified 7 HCV genotype 4 subtypes (4a, 4b, 4d, 4f, 4m, 4o, and 4r).
1	0	7	O	Genotype
2	9	9	O	4
3	10	10	O	,
4	12	12	O	5
5	14	15	O	or
6	17	17	O	6
7	19	30	O	Phylogenetic
8	32	39	O	analysis
9	41	42	O	of
10	44	46	O	HCV
11	48	56	O	sequences
12	58	61	O	from
13	63	70	O	genotype
14	72	72	O	4
15	74	81	O	infected
16	83	90	O	subjects
17	92	93	O	in
18	95	99	O	Study
19	101	104	O	1119
20	107	110	O	N=44
21	113	115	O	and
22	117	119	O	ION
23	121	121	O	4
24	124	126	O	N=8
25	129	138	O	identified
26	140	140	O	7
27	142	144	O	HCV
28	146	153	O	genotype
29	155	155	O	4
30	157	164	O	subtypes
31	167	168	O	4a
32	169	169	O	,
33	171	172	O	4b
34	173	173	O	,
35	175	176	O	4d
36	177	177	O	,
37	179	180	O	4f
38	181	181	O	,
39	183	184	O	4m
40	185	185	O	,
41	187	188	O	4o
42	189	189	O	,
43	191	193	O	and
44	195	196	O	4r
NULL

Harvoni	4534	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	27
Most subjects were infected with subtype 4a (N=32; 62%) or 4d (N=11; 21%); 1 to 3 subjects were infected with each of the other genotype 4 subtypes.
1	0	3	O	Most
2	5	12	O	subjects
3	14	17	O	were
4	19	26	O	infected
5	28	31	O	with
6	33	39	O	subtype
7	41	42	O	4a
8	45	48	O	N=32
9	51	53	O	62%
10	56	57	O	or
11	59	60	O	4d
12	63	66	O	N=11
13	69	71	O	21%
14	75	75	O	1
15	77	78	O	to
16	80	80	O	3
17	82	89	O	subjects
18	91	94	O	were
19	96	103	O	infected
20	105	108	O	with
21	110	113	O	each
22	115	116	O	of
23	118	120	O	the
24	122	126	O	other
25	128	135	O	genotype
26	137	137	O	4
27	139	146	O	subtypes
NULL

Harvoni	4535	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	30
There were 3 subjects with subtype 4r, 2 of whom experienced virologic relapse, and both had a combination of 2 pretreatment NS5A resistance-associated polymorphisms (L28M/V+L30R).
1	0	4	O	There
2	6	9	O	were
3	11	11	O	3
4	13	20	O	subjects
5	22	25	O	with
6	27	33	O	subtype
7	35	36	O	4r
8	37	37	O	,
9	39	39	O	2
10	41	42	O	of
11	44	47	O	whom
12	49	59	O	experienced
13	61	69	O	virologic
14	71	77	O	relapse
15	78	78	O	,
16	80	82	O	and
17	84	87	O	both
18	89	91	O	had
19	93	93	O	a
20	95	105	O	combination
21	107	108	O	of
22	110	110	O	2
23	112	123	O	pretreatment
24	125	128	O	NS5A
25	130	139	O	resistance
26	141	150	O	associated
27	152	164	O	polymorphisms
28	167	170	O	L28M
29	171	171	O	/
30	172	177	O	V+L30R
NULL

Harvoni	4536	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	33
Phylogenetic analysis of HCV sequences from genotype 5-infected subjects in Study 1119 showed almost all were subtype 5a (N=39) with one subject not having a subtype identified at screening or by analysis.
1	0	11	O	Phylogenetic
2	13	20	O	analysis
3	22	23	O	of
4	25	27	O	HCV
5	29	37	O	sequences
6	39	42	O	from
7	44	51	O	genotype
8	53	53	O	5
9	55	62	O	infected
10	64	71	O	subjects
11	73	74	O	in
12	76	80	O	Study
13	82	85	O	1119
14	87	92	O	showed
15	94	99	O	almost
16	101	103	O	all
17	105	108	O	were
18	110	116	O	subtype
19	118	119	O	5a
20	122	125	O	N=39
21	128	131	O	with
22	133	135	O	one
23	137	143	O	subject
24	145	147	O	not
25	149	154	O	having
26	156	156	O	a
27	158	164	O	subtype
28	166	175	O	identified
29	177	178	O	at
30	180	188	O	screening
31	190	191	O	or
32	193	194	O	by
33	196	203	O	analysis
NULL

Harvoni	4537	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	33
Phylogenetic analysis of HCV sequences from genotype 6-infected subjects in ELECTRON-2 identified 7 HCV genotype 6 subtypes (6a, 6e, 6l, 6m, 6p, 6q, and 6r).
1	0	11	O	Phylogenetic
2	13	20	O	analysis
3	22	23	O	of
4	25	27	O	HCV
5	29	37	O	sequences
6	39	42	O	from
7	44	51	O	genotype
8	53	53	O	6
9	55	62	O	infected
10	64	71	O	subjects
11	73	74	O	in
12	76	83	O	ELECTRON
13	85	85	O	2
14	87	96	O	identified
15	98	98	O	7
16	100	102	O	HCV
17	104	111	O	genotype
18	113	113	O	6
19	115	122	O	subtypes
20	125	126	O	6a
21	127	127	O	,
22	129	130	O	6e
23	131	131	O	,
24	133	134	O	6l
25	135	135	O	,
26	137	138	O	6m
27	139	139	O	,
28	141	142	O	6p
29	143	143	O	,
30	145	146	O	6q
31	147	147	O	,
32	149	151	O	and
33	153	154	O	6r
NULL

Harvoni	4538	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	14
Thirty-two percent of the subjects had subtype 6a and 24% had subtype 6e.
1	0	5	O	Thirty
2	7	9	O	two
3	11	17	O	percent
4	19	20	O	of
5	22	24	O	the
6	26	33	O	subjects
7	35	37	O	had
8	39	45	O	subtype
9	47	48	O	6a
10	50	52	O	and
11	54	56	O	24%
12	58	60	O	had
13	62	68	O	subtype
14	70	71	O	6e
NULL

Harvoni	4539	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	20
One to three subjects were infected with the other subtypes 6l, 6m, 6p, 6q, or 6r.
1	0	2	O	One
2	4	5	O	to
3	7	11	O	three
4	13	20	O	subjects
5	22	25	O	were
6	27	34	O	infected
7	36	39	O	with
8	41	43	O	the
9	45	49	O	other
10	51	58	O	subtypes
11	60	61	O	6l
12	62	62	O	,
13	64	65	O	6m
14	66	66	O	,
15	68	69	O	6p
16	70	70	O	,
17	72	73	O	6q
18	74	74	O	,
19	76	77	O	or
20	79	80	O	6r
NULL

Harvoni	4540	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	11
The one subject who did not achieve SVR12 had subtype 6l.
1	0	2	O	The
2	4	6	O	one
3	8	14	O	subject
4	16	18	O	who
5	20	22	O	did
6	24	26	O	not
7	28	34	O	achieve
8	36	40	O	SVR12
9	42	44	O	had
10	46	52	O	subtype
11	54	55	O	6l
NULL

Harvoni	4541	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	55
Although the data are limited, baseline HCV NS5A resistance-associated polymorphisms are not expected to impact the likelihood of achieving SVR when HARVONI is used as recommended to treat HCV genotype 4, 5, or 6-infected patients, based on the low virologic failure rate observed in Study 1119 and ELECTRON-2.
1	0	7	O	Although
2	9	11	O	the
3	13	16	O	data
4	18	20	O	are
5	22	28	O	limited
6	29	29	O	,
7	31	38	O	baseline
8	40	42	O	HCV
9	44	47	O	NS5A
10	49	58	O	resistance
11	60	69	O	associated
12	71	83	O	polymorphisms
13	85	87	O	are
14	89	91	O	not
15	93	100	O	expected
16	102	103	O	to
17	105	110	O	impact
18	112	114	O	the
19	116	125	O	likelihood
20	127	128	O	of
21	130	138	O	achieving
22	140	142	O	SVR
23	144	147	O	when
24	149	155	O	XXXXXXXX
25	157	158	O	is
26	160	163	O	used
27	165	166	O	as
28	168	178	O	recommended
29	180	181	O	to
30	183	187	O	treat
31	189	191	O	HCV
32	193	200	O	genotype
33	202	202	O	4
34	203	203	O	,
35	205	205	O	5
36	206	206	O	,
37	208	209	O	or
38	211	211	O	6
39	213	220	O	infected
40	222	229	O	patients
41	230	230	O	,
42	232	236	O	based
43	238	239	O	on
44	241	243	O	the
45	245	247	O	low
46	249	257	O	virologic
47	259	265	O	failure
48	267	270	O	rate
49	272	279	O	observed
50	281	282	O	in
51	284	288	O	Study
52	290	293	O	1119
53	295	297	O	and
54	299	306	O	ELECTRON
55	308	308	O	2
NULL

Harvoni	4542	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	38
The specific baseline polymorphisms observed in subjects with virologic failure were L28M/V, L30R, and P58T for genotype 4; L31M for genotype 5; and Q24K, F28V, R30A, and T58P for genotype 6.
1	0	2	O	The
2	4	11	O	specific
3	13	20	O	baseline
4	22	34	O	polymorphisms
5	36	43	O	observed
6	45	46	O	in
7	48	55	O	subjects
8	57	60	O	with
9	62	70	O	virologic
10	72	78	O	failure
11	80	83	O	were
12	85	88	O	L28M
13	89	89	O	/
14	90	90	O	V
15	91	91	O	,
16	93	96	O	L30R
17	97	97	O	,
18	99	101	O	and
19	103	106	O	P58T
20	108	110	O	for
21	112	119	O	genotype
22	121	121	O	4
23	124	127	O	L31M
24	129	131	O	for
25	133	140	O	genotype
26	142	142	O	5
27	145	147	O	and
28	149	152	O	Q24K
29	153	153	O	,
30	155	158	O	F28V
31	159	159	O	,
32	161	164	O	R30A
33	165	165	O	,
34	167	169	O	and
35	171	174	O	T58P
36	176	178	O	for
37	180	187	O	genotype
38	189	189	O	6
NULL

Harvoni	4543	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	40
Relapse occurred in 2 of 3 genotype 4 subjects who had baseline NS5B V321I, a polymorphism at a position associated with treatment failure to sofosbuvir and other nucleoside inhibitors; these two subjects also had baseline NS5A resistance-associated polymorphisms.
1	0	6	O	Relapse
2	8	15	O	occurred
3	17	18	O	in
4	20	20	O	2
5	22	23	O	of
6	25	25	O	3
7	27	34	O	genotype
8	36	36	O	4
9	38	45	O	subjects
10	47	49	O	who
11	51	53	O	had
12	55	62	O	baseline
13	64	67	O	NS5B
14	69	73	O	V321I
15	74	74	O	,
16	76	76	O	a
17	78	89	O	polymorphism
18	91	92	O	at
19	94	94	O	a
20	96	103	O	position
21	105	114	O	associated
22	116	119	O	with
23	121	129	O	treatment
24	131	137	O	failure
25	139	140	O	to
26	142	151	O	XXXXXXXX
27	153	155	O	and
28	157	161	O	other
29	163	172	O	nucleoside
30	174	183	O	inhibitors
31	186	190	O	these
32	192	194	O	two
33	196	203	O	subjects
34	205	208	O	also
35	210	212	O	had
36	214	221	O	baseline
37	223	226	O	NS5A
38	228	237	O	resistance
39	239	248	O	associated
40	250	262	O	polymorphisms
NULL

Harvoni	4544	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	47
For genotype 5 and 6, SVR12 was achieved in subjects who had baseline NS5B polymorphisms at positions associated with resistance to sofosbuvir and other nucleoside inhibitors (N=1 with N142T in genotype 5; N=1 with M289I in genotype 5; N=15 with M289L/I in genotype 6).
1	0	2	O	For
2	4	11	O	genotype
3	13	13	O	5
4	15	17	O	and
5	19	19	O	6
6	20	20	O	,
7	22	26	O	SVR12
8	28	30	O	was
9	32	39	O	achieved
10	41	42	O	in
11	44	51	O	subjects
12	53	55	O	who
13	57	59	O	had
14	61	68	O	baseline
15	70	73	O	NS5B
16	75	87	O	polymorphisms
17	89	90	O	at
18	92	100	O	positions
19	102	111	O	associated
20	113	116	O	with
21	118	127	O	resistance
22	129	130	O	to
23	132	141	O	XXXXXXXX
24	143	145	O	and
25	147	151	O	other
26	153	162	O	nucleoside
27	164	173	O	inhibitors
28	176	178	O	N=1
29	180	183	O	with
30	185	189	O	N142T
31	191	192	O	in
32	194	201	O	genotype
33	203	203	O	5
34	206	208	O	N=1
35	210	213	O	with
36	215	219	O	M289I
37	221	222	O	in
38	224	231	O	genotype
39	233	233	O	5
40	236	239	O	N=15
41	241	244	O	with
42	246	250	O	M289L
43	251	251	O	/
44	252	252	O	I
45	254	255	O	in
46	257	264	O	genotype
47	266	266	O	6
NULL

Harvoni	4545	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	36
The sofosbuvir resistance-associated substitution S282T was not detected in the baseline NS5B sequence of any subject with genotype 4, 5, or 6 HCV in clinical trials by population or deep nucleotide sequence analysis.
1	0	2	O	The
2	4	13	O	XXXXXXXX
3	15	24	O	resistance
4	26	35	O	associated
5	37	48	O	substitution
6	50	54	O	S282T
7	56	58	O	was
8	60	62	O	not
9	64	71	O	detected
10	73	74	O	in
11	76	78	O	the
12	80	87	O	baseline
13	89	92	O	NS5B
14	94	101	O	sequence
15	103	104	O	of
16	106	108	O	any
17	110	116	O	subject
18	118	121	O	with
19	123	130	O	genotype
20	132	132	O	4
21	133	133	O	,
22	135	135	O	5
23	136	136	O	,
24	138	139	O	or
25	141	141	O	6
26	143	145	O	HCV
27	147	148	O	in
28	150	157	O	clinical
29	159	164	O	trials
30	166	167	O	by
31	169	178	O	population
32	180	181	O	or
33	183	186	O	deep
34	188	197	O	nucleotide
35	199	206	O	sequence
36	208	215	O	analysis
NULL

Harvoni	4546	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	50
Pediatrics In Study 1116, the presence of NS5A and NS5B resistance-associated polymorphisms did not impact treatment outcome; all pediatric subjects 12 years of age and older with baseline NS5A or NS5B nucleoside inhibitor resistance-associated polymorphisms (18%; 17/96) achieved SVR following 12 weeks treatment with HARVONI.
1	0	9	O	Pediatrics
2	11	12	O	In
3	14	18	O	Study
4	20	23	O	1116
5	24	24	O	,
6	26	28	O	the
7	30	37	O	presence
8	39	40	O	of
9	42	45	O	NS5A
10	47	49	O	and
11	51	54	O	NS5B
12	56	65	O	resistance
13	67	76	O	associated
14	78	90	O	polymorphisms
15	92	94	O	did
16	96	98	O	not
17	100	105	O	impact
18	107	115	O	treatment
19	117	123	O	outcome
20	126	128	O	all
21	130	138	O	pediatric
22	140	147	O	subjects
23	149	150	O	12
24	152	156	O	years
25	158	159	O	of
26	161	163	O	age
27	165	167	O	and
28	169	173	O	older
29	175	178	O	with
30	180	187	O	baseline
31	189	192	O	NS5A
32	194	195	O	or
33	197	200	O	NS5B
34	202	211	O	nucleoside
35	213	221	O	inhibitor
36	223	232	O	resistance
37	234	243	O	associated
38	245	257	O	polymorphisms
39	260	262	O	18%
40	265	266	O	17
41	267	267	O	/
42	268	269	O	96
43	272	279	O	achieved
44	281	283	O	SVR
45	285	293	O	following
46	295	296	O	12
47	298	302	O	weeks
48	304	312	O	treatment
49	314	317	O	with
50	319	325	O	XXXXXXXX
NULL

Harvoni	4547	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	27
Cross Resistance Based on resistance patterns observed in cell culture replicon studies and HCV-infected subjects, cross-resistance between ledipasvir and other NS5A inhibitors is expected.
1	0	4	O	Cross
2	6	15	O	Resistance
3	17	21	O	Based
4	23	24	O	on
5	26	35	O	resistance
6	37	44	O	patterns
7	46	53	O	observed
8	55	56	O	in
9	58	61	O	cell
10	63	69	O	culture
11	71	78	O	replicon
12	80	86	O	studies
13	88	90	O	and
14	92	94	O	HCV
15	96	103	O	infected
16	105	112	O	subjects
17	113	113	O	,
18	115	119	O	cross
19	121	130	O	resistance
20	132	138	O	between
21	140	149	O	XXXXXXXX
22	151	153	O	and
23	155	159	O	other
24	161	164	O	NS5A
25	166	175	O	inhibitors
26	177	178	O	is
27	180	187	O	expected
NULL

Harvoni	4548	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	35
Both sofosbuvir and ledipasvir were fully active against substitutions associated with resistance to other classes of direct-acting antivirals with different mechanisms of action, such as NS5B non-nucleoside inhibitors and NS3 protease inhibitors.
1	0	3	O	Both
2	5	14	O	XXXXXXXX
3	16	18	O	and
4	20	29	O	XXXXXXXX
5	31	34	O	were
6	36	40	O	fully
7	42	47	O	active
8	49	55	O	against
9	57	69	O	substitutions
10	71	80	O	associated
11	82	85	O	with
12	87	96	O	resistance
13	98	99	O	to
14	101	105	O	other
15	107	113	O	classes
16	115	116	O	of
17	118	123	O	direct
18	125	130	O	acting
19	132	141	O	antivirals
20	143	146	O	with
21	148	156	O	different
22	158	167	O	mechanisms
23	169	170	O	of
24	172	177	O	action
25	178	178	O	,
26	180	183	O	such
27	185	186	O	as
28	188	191	O	NS5B
29	193	195	O	non
30	197	206	O	nucleoside
31	208	217	O	inhibitors
32	219	221	O	and
33	223	225	O	NS3
34	227	234	O	protease
35	236	245	O	inhibitors
NULL

Harvoni	4549	34090-1	f4ec77e4-bae8-4db0-b3d5-bde09c5fa075	25
The efficacy of ledipasvir/sofosbuvir has not been established in patients who have previously failed treatment with other regimens that include an NS5A inhibitor.
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	25	O	XXXXXXXX
5	26	26	O	/
6	27	36	O	XXXXXXXX
7	38	40	O	has
8	42	44	O	not
9	46	49	O	been
10	51	61	O	established
11	63	64	O	in
12	66	73	O	patients
13	75	77	O	who
14	79	82	O	have
15	84	93	O	previously
16	95	100	O	failed
17	102	110	O	treatment
18	112	115	O	with
19	117	121	O	other
20	123	130	O	regimens
21	132	135	O	that
22	137	143	O	include
23	145	146	O	an
24	148	151	O	NS5A
25	153	161	O	inhibitor
NULL

INVEGA	4247	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	13
Centrally-acting drugs: Due to CNS effects, use caution in combination.
1	0	8	B-DYN	Centrally
2	10	15	I-DYN	acting
3	17	21	L-DYN	drugs
4	22	22	O	:
5	24	26	O	Due
6	28	29	O	to
7	31	33	B-EFF	CNS
8	35	41	L-EFF	effects
9	42	42	O	,
10	44	46	O	use
11	48	54	O	caution
12	56	57	O	in
13	59	69	O	combination
D/1:7:1

INVEGA	4248	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	19
Drugs that may cause orthostatic hypotension: An additive effect may be observed when co-administered with INVEGA*.
1	0	4	B-DYN	Drugs
2	6	9	I-DYN	that
3	11	13	I-DYN	may
4	15	19	I-DYN	cause
5	21	31	I-DYN	orthostatic
6	33	43	L-DYN	hypotension
7	44	44	O	:
8	46	47	O	An
9	49	56	O	additive
10	58	63	O	effect
11	65	67	O	may
12	69	70	O	be
13	72	79	O	observed
14	81	84	O	when
15	86	87	O	co
16	89	100	O	administered
17	102	105	O	with
18	107	112	O	XXXXXXXX
19	113	113	O	*
NULL

INVEGA	4249	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	36
Strong CYP3A4/P-glycoprotein (P-gp) inducers: It may be necessary to increase the dose of INVEGA* when a strong inducer of both CYP3A4 and P-gp (e.g., carbamazepine) is co-administered.
1	0	5	B-KIN	Strong
2	7	12	I-KIN	CYP3A4
3	13	13	I-KIN	/
4	14	14	I-KIN	P
5	16	27	I-KIN	glycoprotein
6	30	30	I-KIN	P
7	32	33	I-KIN	gp
8	36	43	L-KIN	inducers
9	44	44	O	:
10	46	47	O	It
11	49	51	O	may
12	53	54	O	be
13	56	64	O	necessary
14	66	67	O	to
15	69	76	B-TRI	increase
16	78	80	I-TRI	the
17	82	85	L-TRI	dose
18	87	88	O	of
19	90	95	O	XXXXXXXX
20	96	96	O	*
21	98	101	O	when
22	103	103	O	a
23	105	110	B-KIN	strong
24	112	118	I-KIN	inducer
25	120	121	I-KIN	of
26	123	126	I-KIN	both
27	128	133	I-KIN	CYP3A4
28	135	137	I-KIN	and
29	139	139	I-KIN	P
30	141	142	L-KIN	gp
31	145	147	O	e.g
32	149	149	O	,
33	151	163	U-KIN	carbamazepine
34	166	167	O	is
35	169	170	O	co
36	172	183	O	administered
K/1:C54356 K/23:C54356 K/33:C54356

INVEGA	4250	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	20
Conversely, on discontinuation of the strong inducer, it may be necessary to decrease the dose of INVEGA*.
1	0	9	O	Conversely
2	10	10	O	,
3	12	13	O	on
4	15	29	O	discontinuation
5	31	32	O	of
6	34	36	O	the
7	38	43	O	strong
8	45	51	O	inducer
9	52	52	O	,
10	54	55	O	it
11	57	59	O	may
12	61	62	O	be
13	64	72	O	necessary
14	74	75	O	to
15	77	84	O	decrease
16	86	88	O	the
17	90	93	O	dose
18	95	96	O	of
19	98	103	O	XXXXXXXX
20	104	104	O	*
NULL

INVEGA	4251	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	14
Co-administration of divalproex sodium increased Cmax and AUC of paliperidone by approximately 50%.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	30	B-KIN	divalproex
5	32	37	L-KIN	sodium
6	39	47	B-TRI	increased
7	49	52	L-TRI	Cmax
8	54	56	O	and
9	58	60	O	AUC
10	62	63	O	of
11	65	76	O	XXXXXXXX
12	78	79	O	by
13	81	93	O	approximately
14	95	97	O	50%
K/4:C54602

INVEGA	4252	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	11
Adjust dose of INVEGA* if necessary based on clinical assessment.
1	0	5	O	Adjust
2	7	10	O	dose
3	12	13	O	of
4	15	20	O	XXXXXXXX
5	21	21	O	*
6	23	24	O	if
7	26	34	O	necessary
8	36	40	O	based
9	42	43	O	on
10	45	52	O	clinical
11	54	63	O	assessment
NULL

INVEGA	4253	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	24
Given the primary CNS effects of paliperidone , INVEGA* should be used with caution in combination with other centrally acting drugs and alcohol.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	44	O	XXXXXXXX
8	46	46	O	,
9	48	53	O	XXXXXXXX
10	54	54	O	*
11	56	61	O	should
12	63	64	O	be
13	66	69	O	used
14	71	74	O	with
15	76	82	U-TRI	caution
16	84	85	O	in
17	87	97	O	combination
18	99	102	O	with
19	104	108	O	other
20	110	118	B-UNK	centrally
21	120	125	I-UNK	acting
22	127	131	L-UNK	drugs
23	133	135	O	and
24	137	143	U-UNK	alcohol
NULL

INVEGA	4254	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	11
Paliperidone may antagonize the effect of levodopa and other dopamine agonists.
1	0	11	O	XXXXXXXX
2	13	15	O	may
3	17	26	B-EFF	antagonize
4	28	30	I-EFF	the
5	32	37	I-EFF	effect
6	39	40	I-EFF	of
7	42	49	L-EFF	levodopa
8	51	53	O	and
9	55	59	O	other
10	61	68	B-DYN	dopamine
11	70	77	L-DYN	agonists
D/10:3:0

INVEGA	4255	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	28
Because of its potential for inducing orthostatic hypotension, an additive effect may be observed when INVEGA* is administered with other therapeutic agents that have this potential.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	23	O	potential
5	25	27	O	for
6	29	36	O	inducing
7	38	48	O	orthostatic
8	50	60	O	hypotension
9	61	61	O	,
10	63	64	O	an
11	66	73	O	additive
12	75	80	O	effect
13	82	84	O	may
14	86	87	O	be
15	89	96	O	observed
16	98	101	O	when
17	103	108	O	XXXXXXXX
18	109	109	O	*
19	111	112	O	is
20	114	125	O	administered
21	127	130	O	with
22	132	136	O	other
23	138	148	O	therapeutic
24	150	155	O	agents
25	157	160	O	that
26	162	165	O	have
27	167	170	O	this
28	172	180	O	potential
NULL

INVEGA	4256	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	19
Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	18	O	not
4	20	27	O	expected
5	29	30	O	to
6	32	36	O	cause
7	38	47	O	clinically
8	49	57	O	important
9	59	73	O	pharmacokinetic
10	75	86	O	interactions
11	88	91	O	with
12	93	97	O	drugs
13	99	102	O	that
14	104	106	O	are
15	108	118	O	metabolized
16	120	121	O	by
17	123	132	O	cytochrome
18	134	137	O	P450
19	139	146	O	isozymes
NULL

INVEGA	4257	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	43
In vitro studies in human liver microsomes showed that paliperidone does not substantially inhibit the metabolism of drugs metabolized by cytochrome P450 isozymes, including CYP1A2, CYP2A6, CYP2C8/9/10, CYP2D6, CYP2E1, CYP3A4, and CYP3A5.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	24	O	human
6	26	30	O	liver
7	32	41	O	microsomes
8	43	48	O	showed
9	50	53	O	that
10	55	66	O	XXXXXXXX
11	68	71	O	does
12	73	75	O	not
13	77	89	O	substantially
14	91	97	O	inhibit
15	99	101	O	the
16	103	112	O	metabolism
17	114	115	O	of
18	117	121	O	drugs
19	123	133	O	metabolized
20	135	136	O	by
21	138	147	O	cytochrome
22	149	152	O	P450
23	154	161	O	isozymes
24	162	162	O	,
25	164	172	O	including
26	174	179	O	CYP1A2
27	180	180	O	,
28	182	187	O	CYP2A6
29	188	188	O	,
30	190	195	O	CYP2C8
31	196	196	O	/
32	197	197	O	9
33	198	198	O	/
34	199	200	O	10
35	201	201	O	,
36	203	208	O	CYP2D6
37	209	209	O	,
38	211	216	O	CYP2E1
39	217	217	O	,
40	219	224	O	CYP3A4
41	225	225	O	,
42	227	229	O	and
43	231	236	O	CYP3A5
NULL

INVEGA	4258	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	23
Therefore, paliperidone is not expected to inhibit clearance of drugs that are metabolized by these metabolic pathways in a clinically relevant manner.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	O	XXXXXXXX
4	24	25	O	is
5	27	29	O	not
6	31	38	O	expected
7	40	41	O	to
8	43	49	O	inhibit
9	51	59	O	clearance
10	61	62	O	of
11	64	68	O	drugs
12	70	73	O	that
13	75	77	O	are
14	79	89	O	metabolized
15	91	92	O	by
16	94	98	O	these
17	100	108	O	metabolic
18	110	117	O	pathways
19	119	120	O	in
20	122	122	O	a
21	124	133	O	clinically
22	135	142	O	relevant
23	144	149	O	manner
NULL

INVEGA	4259	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	10
Paliperidone is also not expected to have enzyme inducing properties.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	19	O	also
4	21	23	O	not
5	25	32	O	expected
6	34	35	O	to
7	37	40	O	have
8	42	47	O	enzyme
9	49	56	O	inducing
10	58	67	O	properties
NULL

INVEGA	4260	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	13
Paliperidone is a weak inhibitor of P-glycoprotein (P-gp) at high concentrations.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	16	O	a
4	18	21	O	weak
5	23	31	O	inhibitor
6	33	34	O	of
7	36	36	O	P
8	38	49	O	glycoprotein
9	52	52	O	P
10	54	55	O	gp
11	58	59	O	at
12	61	64	O	high
13	66	79	O	concentrations
NULL

INVEGA	4261	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	12
No in vivo data are available and the clinical relevance is unknown.
1	0	1	O	No
2	3	4	O	in
3	6	9	O	vivo
4	11	14	O	data
5	16	18	O	are
6	20	28	O	available
7	30	32	O	and
8	34	36	O	the
9	38	45	O	clinical
10	47	55	O	relevance
11	57	58	O	is
12	60	66	O	unknown
NULL

INVEGA	4262	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	9
Pharmacokinetic interaction between lithium and INVEGA* is unlikely.
1	0	14	O	Pharmacokinetic
2	16	26	O	interaction
3	28	34	O	between
4	36	42	O	lithium
5	44	46	O	and
6	48	53	O	XXXXXXXX
7	54	54	O	*
8	56	57	O	is
9	59	66	O	unlikely
NULL

INVEGA	4263	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	49
In a drug interaction study, co-administration of INVEGA* (12 mg once daily for 5 days) with divalproex sodium extended-release tablets (500 mg to 2000 mg once daily) did not affect the steady-state pharmacokinetics (AUC24h and Cmax,ss) of valproate in 13 patients stabilized on valproate.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	drug
4	10	20	O	interaction
5	22	26	O	study
6	27	27	O	,
7	29	30	O	co
8	32	45	O	administration
9	47	48	O	of
10	50	55	O	XXXXXXXX
11	56	56	O	*
12	59	60	O	12
13	62	63	O	mg
14	65	68	O	once
15	70	74	O	daily
16	76	78	O	for
17	80	80	O	5
18	82	85	O	days
19	88	91	O	with
20	93	102	O	divalproex
21	104	109	O	sodium
22	111	118	O	extended
23	120	126	O	release
24	128	134	O	tablets
25	137	139	O	500
26	141	142	O	mg
27	144	145	O	to
28	147	150	O	2000
29	152	153	O	mg
30	155	158	O	once
31	160	164	O	daily
32	167	169	O	did
33	171	173	O	not
34	175	180	O	affect
35	182	184	O	the
36	186	191	O	steady
37	193	197	O	state
38	199	214	O	pharmacokinetics
39	217	222	O	AUC24h
40	224	226	O	and
41	228	234	O	Cmax,ss
42	237	238	O	of
43	240	248	O	valproate
44	250	251	O	in
45	253	254	O	13
46	256	263	O	patients
47	265	274	O	stabilized
48	276	277	O	on
49	279	287	O	valproate
NULL

INVEGA	4264	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	32
In a clinical study, subjects on stable doses of valproate had comparable valproate average plasma concentrations when INVEGA* 3-15 mg/day was added to their existing valproate treatment.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	study
5	19	19	O	,
6	21	28	O	subjects
7	30	31	O	on
8	33	38	O	stable
9	40	44	O	doses
10	46	47	O	of
11	49	57	O	valproate
12	59	61	O	had
13	63	72	O	comparable
14	74	82	O	valproate
15	84	90	O	average
16	92	97	O	plasma
17	99	112	O	concentrations
18	114	117	O	when
19	119	124	O	XXXXXXXX
20	125	125	O	*
21	127	127	O	3
22	129	130	O	15
23	132	133	O	mg
24	134	134	O	/
25	135	137	O	day
26	139	141	O	was
27	143	147	O	added
28	149	150	O	to
29	152	156	O	their
30	158	165	O	existing
31	167	175	O	valproate
32	177	185	O	treatment
NULL

INVEGA	4265	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	28
Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	18	O	not
4	20	20	O	a
5	22	30	O	substrate
6	32	33	O	of
7	35	40	O	CYP1A2
8	41	41	O	,
9	43	48	O	CYP2A6
10	49	49	O	,
11	51	56	O	CYP2C9
12	57	57	O	,
13	59	61	O	and
14	63	69	O	CYP2C19
15	70	70	O	,
16	72	73	O	so
17	75	78	O	that
18	80	81	O	an
19	83	93	O	interaction
20	95	98	O	with
21	100	109	O	inhibitors
22	111	112	O	or
23	114	121	O	inducers
24	123	124	O	of
25	126	130	O	these
26	132	139	O	isozymes
27	141	142	O	is
28	144	151	O	unlikely
NULL

INVEGA	4266	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	40
While in vitro studies indicate that CYP2D6 and CYP3A4 may be minimally involved in paliperidone metabolism, in vivo studies do not show decreased elimination by these isozymes and they contribute to only a small fraction of total body clearance.
1	0	4	O	While
2	6	7	O	in
3	9	13	O	vitro
4	15	21	O	studies
5	23	30	O	indicate
6	32	35	O	that
7	37	42	O	CYP2D6
8	44	46	O	and
9	48	53	O	CYP3A4
10	55	57	O	may
11	59	60	O	be
12	62	70	O	minimally
13	72	79	O	involved
14	81	82	O	in
15	84	95	O	XXXXXXXX
16	97	106	O	metabolism
17	107	107	O	,
18	109	110	O	in
19	112	115	O	vivo
20	117	123	O	studies
21	125	126	O	do
22	128	130	O	not
23	132	135	O	show
24	137	145	O	decreased
25	147	157	O	elimination
26	159	160	O	by
27	162	166	O	these
28	168	175	O	isozymes
29	177	179	O	and
30	181	184	O	they
31	186	195	O	contribute
32	197	198	O	to
33	200	203	O	only
34	205	205	O	a
35	207	211	O	small
36	213	220	O	fraction
37	222	223	O	of
38	225	229	O	total
39	231	234	O	body
40	236	244	O	clearance
NULL

INVEGA	4267	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	12
In vitro studies have shown that paliperidone is a P-gp substrate.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	44	O	XXXXXXXX
8	46	47	O	is
9	49	49	O	a
10	51	51	O	P
11	53	54	O	gp
12	56	64	O	substrate
NULL

INVEGA	4268	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	45
Co-administration of INVEGA* 6 mg once daily with carbamazepine, a strong inducer of both CYP3A4 and P-glycoprotein (P-gp), at 200 mg twice daily caused a decrease of approximately 37% in the mean steady-state Cmax and AUC of paliperidone.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	XXXXXXXX
5	27	27	O	*
6	29	29	O	6
7	31	32	O	mg
8	34	37	O	once
9	39	43	O	daily
10	45	48	O	with
11	50	62	U-KIN	carbamazepine
12	63	63	O	,
13	65	65	O	a
14	67	72	O	strong
15	74	80	O	inducer
16	82	83	O	of
17	85	88	O	both
18	90	95	O	CYP3A4
19	97	99	O	and
20	101	101	O	P
21	103	114	O	glycoprotein
22	117	117	O	P
23	119	120	O	gp
24	122	122	O	,
25	124	125	O	at
26	127	129	O	200
27	131	132	O	mg
28	134	138	O	twice
29	140	144	O	daily
30	146	151	O	caused
31	153	153	O	a
32	155	162	O	decrease
33	164	165	O	of
34	167	179	O	approximately
35	181	183	O	37%
36	185	186	O	in
37	188	190	O	the
38	192	195	O	mean
39	197	202	O	steady
40	204	208	O	state
41	210	213	O	Cmax
42	215	217	O	and
43	219	221	O	AUC
44	223	224	O	of
45	226	237	O	XXXXXXXX
K/11:C54606

INVEGA	4269	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	19
This decrease is caused, to a substantial degree, by a 35% increase in renal clearance of paliperidone.
1	0	3	O	This
2	5	12	O	decrease
3	14	15	O	is
4	17	22	O	caused
5	23	23	O	,
6	25	26	O	to
7	28	28	O	a
8	30	40	O	substantial
9	42	47	O	degree
10	48	48	O	,
11	50	51	O	by
12	53	53	O	a
13	55	57	O	35%
14	59	66	O	increase
15	68	69	O	in
16	71	75	O	renal
17	77	85	O	clearance
18	87	88	O	of
19	90	101	O	XXXXXXXX
NULL

INVEGA	4270	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	31
A minor decrease in the amount of drug excreted unchanged in the urine suggests that there was little effect on the CYP metabolism or bioavailability of paliperidone during carbamazepine co-administration.
1	0	0	O	A
2	2	6	O	minor
3	8	15	O	decrease
4	17	18	O	in
5	20	22	O	the
6	24	29	O	amount
7	31	32	O	of
8	34	37	O	drug
9	39	46	O	excreted
10	48	56	O	unchanged
11	58	59	O	in
12	61	63	O	the
13	65	69	O	urine
14	71	78	O	suggests
15	80	83	O	that
16	85	89	O	there
17	91	93	O	was
18	95	100	O	little
19	102	107	O	effect
20	109	110	O	on
21	112	114	O	the
22	116	118	O	CYP
23	120	129	O	metabolism
24	131	132	O	or
25	134	148	O	bioavailability
26	150	151	O	of
27	153	164	O	XXXXXXXX
28	166	171	O	during
29	173	185	O	carbamazepine
30	187	188	O	co
31	190	203	O	administration
NULL

INVEGA	4271	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	18
On initiation of carbamazepine, the dose of INVEGA* should be re-evaluated and increased if necessary.
1	0	1	O	On
2	3	12	O	initiation
3	14	15	O	of
4	17	29	U-KIN	carbamazepine
5	30	30	O	,
6	32	34	O	the
7	36	39	O	dose
8	41	42	O	of
9	44	49	O	XXXXXXXX
10	50	50	O	*
11	52	57	O	should
12	59	60	O	be
13	62	63	O	re
14	65	73	O	evaluated
15	75	77	O	and
16	79	87	O	increased
17	89	90	O	if
18	92	100	O	necessary
K/4:C54356

INVEGA	4272	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	20
Conversely, on discontinuation of carbamazepine, the dose of INVEGA* should be re-evaluated and decreased if necessary.
1	0	9	O	Conversely
2	10	10	O	,
3	12	13	O	on
4	15	29	O	discontinuation
5	31	32	O	of
6	34	46	U-KIN	carbamazepine
7	47	47	O	,
8	49	51	O	the
9	53	56	O	dose
10	58	59	O	of
11	61	66	O	XXXXXXXX
12	67	67	O	*
13	69	74	O	should
14	76	77	O	be
15	79	80	O	re
16	82	90	O	evaluated
17	92	94	O	and
18	96	104	O	decreased
19	106	107	O	if
20	109	117	O	necessary
K/6:C54356

INVEGA	4273	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	9
Paliperidone is metabolized to a limited extent by CYP2D6.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	26	O	metabolized
4	28	29	O	to
5	31	31	O	a
6	33	39	O	limited
7	41	46	O	extent
8	48	49	O	by
9	51	56	O	CYP2D6
NULL

INVEGA	4274	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	49
In an interaction study in healthy subjects in which a single 3 mg dose of INVEGA* was administered concomitantly with 20 mg per day of paroxetine (a potent CYP2D6 inhibitor), paliperidone exposures were on average 16% (90% CI: 4, 30) higher in CYP2D6 extensive metabolizers.
1	0	1	O	In
2	3	4	O	an
3	6	16	O	interaction
4	18	22	O	study
5	24	25	O	in
6	27	33	O	healthy
7	35	42	O	subjects
8	44	45	O	in
9	47	51	O	which
10	53	53	O	a
11	55	60	O	single
12	62	62	O	3
13	64	65	O	mg
14	67	70	O	dose
15	72	73	O	of
16	75	80	O	XXXXXXXX
17	81	81	O	*
18	83	85	O	was
19	87	98	O	administered
20	100	112	O	concomitantly
21	114	117	O	with
22	119	120	O	20
23	122	123	O	mg
24	125	127	O	per
25	129	131	O	day
26	133	134	O	of
27	136	145	U-KIN	paroxetine
28	148	148	O	a
29	150	155	O	potent
30	157	162	O	CYP2D6
31	164	172	O	inhibitor
32	174	174	O	,
33	176	187	O	XXXXXXXX
34	189	197	O	exposures
35	199	202	O	were
36	204	205	O	on
37	207	213	O	average
38	215	217	O	16%
39	220	222	O	90%
40	224	225	O	CI
41	226	226	O	:
42	228	228	O	4
43	229	229	O	,
44	231	232	O	30
45	235	240	O	higher
46	242	243	O	in
47	245	250	O	CYP2D6
48	252	260	O	extensive
49	262	273	O	metabolizers
K/27:C54355

INVEGA	4275	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	8
Higher doses of paroxetine have not been studied.
1	0	5	O	Higher
2	7	11	O	doses
3	13	14	O	of
4	16	25	O	paroxetine
5	27	30	O	have
6	32	34	O	not
7	36	39	O	been
8	41	47	O	studied
NULL

INVEGA	4276	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	37
Co-administration of a single dose of INVEGA* 12 mg with divalproex sodium extended-release tablets (two 500 mg tablets once daily) resulted in an increase of approximately 50% in the Cmax and AUC of paliperidone.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	21	O	a
5	23	28	O	single
6	30	33	O	dose
7	35	36	O	of
8	38	43	O	XXXXXXXX
9	44	44	O	*
10	46	47	O	12
11	49	50	O	mg
12	52	55	O	with
13	57	66	B-KIN	divalproex
14	68	73	L-KIN	sodium
15	75	82	O	extended
16	84	90	O	release
17	92	98	O	tablets
18	101	103	O	two
19	105	107	O	500
20	109	110	O	mg
21	112	118	O	tablets
22	120	123	O	once
23	125	129	O	daily
24	132	139	O	resulted
25	141	142	O	in
26	144	145	O	an
27	147	154	O	increase
28	156	157	O	of
29	159	171	O	approximately
30	173	175	O	50%
31	177	178	O	in
32	180	182	O	the
33	184	187	O	Cmax
34	189	191	O	and
35	193	195	O	AUC
36	197	198	O	of
37	200	211	O	XXXXXXXX
K/13:C54602

INVEGA	4277	34073-7	7b8e5b26-b9e4-4704-921b-3c3c0d159916	19
Dosage reduction for INVEGA* should be considered when INVEGA* is co-administered with valproate after clinical assessment.
1	0	5	B-TRI	Dosage
2	7	15	L-TRI	reduction
3	17	19	O	for
4	21	26	O	XXXXXXXX
5	27	27	O	*
6	29	34	O	should
7	36	37	O	be
8	39	48	O	considered
9	50	53	O	when
10	55	60	O	XXXXXXXX
11	61	61	O	*
12	63	64	O	is
13	66	67	O	co
14	69	80	O	administered
15	82	85	O	with
16	87	95	U-KIN	valproate
17	97	101	O	after
18	103	110	O	clinical
19	112	121	O	assessment
K/16:C54355

INVEGA	4279	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	8
Paliperidone is the major active metabolite of risperidone.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	18	O	the
4	20	24	O	major
5	26	31	O	active
6	33	42	O	metabolite
7	44	45	O	of
8	47	57	O	risperidone
NULL

INVEGA	4280	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	49
The mechanism of action of paliperidone, as with other drugs having efficacy in schizophrenia, is unknown, but it has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	38	O	XXXXXXXX
7	39	39	O	,
8	41	42	O	as
9	44	47	O	with
10	49	53	O	other
11	55	59	O	drugs
12	61	66	O	having
13	68	75	O	efficacy
14	77	78	O	in
15	80	92	O	schizophrenia
16	93	93	O	,
17	95	96	O	is
18	98	104	O	unknown
19	105	105	O	,
20	107	109	O	but
21	111	112	O	it
22	114	116	O	has
23	118	121	O	been
24	123	130	O	proposed
25	132	135	O	that
26	137	139	O	the
27	141	146	O	drug's
28	148	158	O	therapeutic
29	160	167	O	activity
30	169	170	O	in
31	172	184	O	schizophrenia
32	186	187	O	is
33	189	196	O	mediated
34	198	204	O	through
35	206	206	O	a
36	208	218	O	combination
37	220	221	O	of
38	223	229	O	central
39	231	238	O	dopamine
40	240	243	O	Type
41	245	245	O	2
42	248	249	O	D2
43	252	254	O	and
44	256	264	O	serotonin
45	266	269	O	Type
46	271	271	O	2
47	274	278	O	5HT2A
48	281	288	O	receptor
49	290	299	O	antagonism
NULL

INVEGA	4281	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	18
Paliperidone is a centrally active dopamine Type 2 (D2) antagonist and with predominant serotonin Type 2 (5HT2A) activity.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	16	O	a
4	18	26	O	centrally
5	28	33	O	active
6	35	42	O	dopamine
7	44	47	O	Type
8	49	49	O	2
9	52	53	O	D2
10	56	65	O	antagonist
11	67	69	O	and
12	71	74	O	with
13	76	86	O	predominant
14	88	96	O	serotonin
15	98	101	O	Type
16	103	103	O	2
17	106	110	O	5HT2A
18	113	120	O	activity
NULL

INVEGA	4282	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	29
Paliperidone is also active as an antagonist at A1 and A2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	19	O	also
4	21	26	O	active
5	28	29	O	as
6	31	32	O	an
7	34	43	O	antagonist
8	45	46	O	at
9	48	49	O	A1
10	51	53	O	and
11	55	56	O	A2
12	58	67	O	adrenergic
13	69	77	O	receptors
14	79	81	O	and
15	83	84	O	H1
16	86	98	O	histaminergic
17	100	108	O	receptors
18	109	109	O	,
19	111	115	O	which
20	117	119	O	may
21	121	127	O	explain
22	129	132	O	some
23	134	135	O	of
24	137	139	O	the
25	141	145	O	other
26	147	153	O	effects
27	155	156	O	of
28	158	160	O	the
29	162	165	O	drug
NULL

INVEGA	4283	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	13
Paliperidone has no affinity for cholinergic muscarinic or B1- and B2-adrenergic receptors.
1	0	11	O	XXXXXXXX
2	13	15	O	has
3	17	18	O	no
4	20	27	O	affinity
5	29	31	O	for
6	33	43	O	cholinergic
7	45	54	O	muscarinic
8	56	57	O	or
9	59	60	O	B1
10	63	65	O	and
11	67	68	O	B2
12	70	79	O	adrenergic
13	81	89	O	receptors
NULL

INVEGA	4284	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	16
The pharmacological activity of the (+)- and (-)- paliperidone enantiomers is qualitatively and quantitatively similar in vitro.
1	0	2	O	The
2	4	18	O	pharmacological
3	20	27	O	activity
4	29	30	O	of
5	32	34	O	the
6	37	37	O	+
7	41	43	O	and
8	50	61	O	XXXXXXXX
9	63	73	O	enantiomers
10	75	76	O	is
11	78	90	O	qualitatively
12	92	94	O	and
13	96	109	O	quantitatively
14	111	117	O	similar
15	119	120	O	in
16	122	126	O	vitro
NULL

INVEGA	4285	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	23
Following a single dose, the plasma concentrations of paliperidone gradually rise to reach peak plasma concentration (Cmax) approximately 24 hours after dosing.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	22	O	dose
5	23	23	O	,
6	25	27	O	the
7	29	34	O	plasma
8	36	49	O	concentrations
9	51	52	O	of
10	54	65	O	XXXXXXXX
11	67	75	O	gradually
12	77	80	O	rise
13	82	83	O	to
14	85	89	O	reach
15	91	94	O	peak
16	96	101	O	plasma
17	103	115	O	concentration
18	118	121	O	Cmax
19	124	136	O	approximately
20	138	139	O	24
21	141	145	O	hours
22	147	151	O	after
23	153	158	O	dosing
NULL

INVEGA	4286	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	16
The pharmacokinetics of paliperidone following INVEGA* administration are dose-proportional within the available dose range.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	35	O	XXXXXXXX
5	37	45	O	following
6	47	52	O	XXXXXXXX
7	53	53	O	*
8	55	68	O	administration
9	70	72	O	are
10	74	77	O	dose
11	79	90	O	proportional
12	92	97	O	within
13	99	101	O	the
14	103	111	O	available
15	113	116	O	dose
16	118	122	O	range
NULL

INVEGA	4287	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	11
The terminal elimination half-life of paliperidone is approximately 23 hours.
1	0	2	O	The
2	4	11	O	terminal
3	13	23	O	elimination
4	25	28	O	half
5	30	33	O	life
6	35	36	O	of
7	38	49	O	XXXXXXXX
8	51	52	O	is
9	54	66	O	approximately
10	68	69	O	23
11	71	75	O	hours
NULL

INVEGA	4288	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	19
Steady-state concentrations of paliperidone are attained within 4-5 days of dosing with INVEGA* in most subjects.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	29	O	of
5	31	42	O	XXXXXXXX
6	44	46	O	are
7	48	55	O	attained
8	57	62	O	within
9	64	64	O	4
10	66	66	O	5
11	68	71	O	days
12	73	74	O	of
13	76	81	O	dosing
14	83	86	O	with
15	88	93	O	XXXXXXXX
16	94	94	O	*
17	96	97	O	in
18	99	102	O	most
19	104	111	O	subjects
NULL

INVEGA	4289	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	22
The mean steady-state peak:trough ratio for an INVEGA* dose of 9 mg was 1.7 with a range of 1.2-3.1.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	steady
4	16	20	O	state
5	22	32	O	peak:trough
6	34	38	O	ratio
7	40	42	O	for
8	44	45	O	an
9	47	52	O	XXXXXXXX
10	53	53	O	*
11	55	58	O	dose
12	60	61	O	of
13	63	63	O	9
14	65	66	O	mg
15	68	70	O	was
16	72	74	O	1.7
17	76	79	O	with
18	81	81	O	a
19	83	87	O	range
20	89	90	O	of
21	92	94	O	1.2
22	96	98	O	3.1
NULL

INVEGA	4290	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	26
Following administration of INVEGA*, the (+) and (-) enantiomers of paliperidone interconvert, reaching an AUC (+) to (-) ratio of approximately 1.6 at steady state.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	33	O	XXXXXXXX
5	34	34	O	*
6	35	35	O	,
7	37	39	O	the
8	42	42	O	+
9	45	47	O	and
10	53	63	O	enantiomers
11	65	66	O	of
12	68	79	O	XXXXXXXX
13	81	92	O	interconvert
14	93	93	O	,
15	95	102	O	reaching
16	104	105	O	an
17	107	109	O	AUC
18	112	112	O	+
19	115	116	O	to
20	122	126	O	ratio
21	128	129	O	of
22	131	143	O	approximately
23	145	147	O	1.6
24	149	150	O	at
25	152	157	O	steady
26	159	163	O	state
NULL

INVEGA	4291	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	15
Absorption and Distribution The absolute oral bioavailability of paliperidone following INVEGA* administration is 28%.
1	0	9	O	Absorption
2	11	13	O	and
3	15	26	O	Distribution
4	28	30	O	The
5	32	39	O	absolute
6	41	44	O	oral
7	46	60	O	bioavailability
8	62	63	O	of
9	65	76	O	XXXXXXXX
10	78	86	O	following
11	88	93	O	XXXXXXXX
12	94	94	O	*
13	96	109	O	administration
14	111	112	O	is
15	114	116	O	28%
NULL

INVEGA	4292	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	46
Administration of a 12 mg paliperidone extended-release tablet to healthy ambulatory subjects with a standard high-fat/high-caloric meal gave mean Cmax and AUC values of paliperidone that were increased by 60% and 54%, respectively, compared with administration under fasting conditions.
1	0	13	O	Administration
2	15	16	O	of
3	18	18	O	a
4	20	21	O	12
5	23	24	O	mg
6	26	37	O	XXXXXXXX
7	39	46	O	extended
8	48	54	O	release
9	56	61	O	tablet
10	63	64	O	to
11	66	72	O	healthy
12	74	83	O	ambulatory
13	85	92	O	subjects
14	94	97	O	with
15	99	99	O	a
16	101	108	O	standard
17	110	113	B-KIN	high
18	115	117	I-KIN	fat
19	118	118	I-KIN	/
20	119	122	I-KIN	high
21	124	130	I-KIN	caloric
22	132	135	L-KIN	meal
23	137	140	O	gave
24	142	145	O	mean
25	147	150	O	Cmax
26	152	154	O	and
27	156	158	O	AUC
28	160	165	O	values
29	167	168	O	of
30	170	181	O	XXXXXXXX
31	183	186	O	that
32	188	191	O	were
33	193	201	O	increased
34	203	204	O	by
35	206	208	O	60%
36	210	212	O	and
37	214	216	O	54%
38	217	217	O	,
39	219	230	O	respectively
40	231	231	O	,
41	233	240	O	compared
42	242	245	O	with
43	247	260	O	administration
44	262	266	O	under
45	268	274	O	fasting
46	276	285	O	conditions
K/17:C54602

INVEGA	4293	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	22
Clinical trials establishing the safety and efficacy of INVEGA* were carried out in subjects without regard to the timing of meals.
1	0	7	O	Clinical
2	9	14	O	trials
3	16	27	O	establishing
4	29	31	O	the
5	33	38	O	safety
6	40	42	O	and
7	44	51	O	efficacy
8	53	54	O	of
9	56	61	O	XXXXXXXX
10	62	62	O	*
11	64	67	O	were
12	69	75	O	carried
13	77	79	O	out
14	81	82	O	in
15	84	91	O	subjects
16	93	99	O	without
17	101	106	O	regard
18	108	109	O	to
19	111	113	O	the
20	115	120	O	timing
21	122	123	O	of
22	125	129	O	meals
NULL

INVEGA	4294	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	27
While INVEGA* can be taken without regard to food, the presence of food at the time of INVEGA* administration may increase exposure to paliperidone.
1	0	4	O	While
2	6	11	O	XXXXXXXX
3	12	12	O	*
4	14	16	O	can
5	18	19	O	be
6	21	25	O	taken
7	27	33	O	without
8	35	40	O	regard
9	42	43	O	to
10	45	48	U-KIN	food
11	49	49	O	,
12	51	53	O	the
13	55	62	O	presence
14	64	65	O	of
15	67	70	O	food
16	72	73	O	at
17	75	77	O	the
18	79	82	O	time
19	84	85	O	of
20	87	92	O	XXXXXXXX
21	93	93	O	*
22	95	108	O	administration
23	110	112	O	may
24	114	121	B-TRI	increase
25	123	130	L-TRI	exposure
26	132	133	O	to
27	135	146	O	XXXXXXXX
K/10:C54355

INVEGA	4295	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	25
Based on a population analysis, the apparent volume of distribution of paliperidone is 487 L. The plasma protein binding of racemic paliperidone is 74%.
1	0	4	O	Based
2	6	7	O	on
3	9	9	O	a
4	11	20	O	population
5	22	29	O	analysis
6	30	30	O	,
7	32	34	O	the
8	36	43	O	apparent
9	45	50	O	volume
10	52	53	O	of
11	55	66	O	distribution
12	68	69	O	of
13	71	82	O	XXXXXXXX
14	84	85	O	is
15	87	89	O	487
16	91	91	O	L
17	94	96	O	The
18	98	103	O	plasma
19	105	111	O	protein
20	113	119	O	binding
21	121	122	O	of
22	124	130	O	racemic
23	132	143	O	XXXXXXXX
24	145	146	O	is
25	148	150	O	74%
NULL

INVEGA	4296	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	37
Metabolism and Elimination Although in vitro studies suggested a role for CYP2D6 and CYP3A4 in the metabolism of paliperidone, in vivo results indicate that these isozymes play a limited role in the overall elimination of paliperidone.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	27	34	O	Although
5	36	37	O	in
6	39	43	O	vitro
7	45	51	O	studies
8	53	61	O	suggested
9	63	63	O	a
10	65	68	O	role
11	70	72	O	for
12	74	79	O	CYP2D6
13	81	83	O	and
14	85	90	O	CYP3A4
15	92	93	O	in
16	95	97	O	the
17	99	108	O	metabolism
18	110	111	O	of
19	113	124	O	XXXXXXXX
20	125	125	O	,
21	127	128	O	in
22	130	133	O	vivo
23	135	141	O	results
24	143	150	O	indicate
25	152	155	O	that
26	157	161	O	these
27	163	170	O	isozymes
28	172	175	O	play
29	177	177	O	a
30	179	185	O	limited
31	187	190	O	role
32	192	193	O	in
33	195	197	O	the
34	199	205	O	overall
35	207	217	O	elimination
36	219	220	O	of
37	222	233	O	XXXXXXXX
NULL

INVEGA	4297	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	54
One week following administration of a single oral dose of 1 mg immediate-release 14C-paliperidone to 5 healthy volunteers, 59% (range 51% - 67%) of the dose was excreted unchanged into urine, 32% (26% - 41%) of the dose was recovered as metabolites, and 6% - 12% of the dose was not recovered.
1	0	2	O	One
2	4	7	O	week
3	9	17	O	following
4	19	32	O	administration
5	34	35	O	of
6	37	37	O	a
7	39	44	O	single
8	46	49	O	oral
9	51	54	O	dose
10	56	57	O	of
11	59	59	O	1
12	61	62	O	mg
13	64	72	O	immediate
14	74	80	O	release
15	82	84	O	14C
16	86	97	O	XXXXXXXX
17	99	100	O	to
18	102	102	O	5
19	104	110	O	healthy
20	112	121	O	volunteers
21	122	122	O	,
22	124	126	O	59%
23	129	133	O	range
24	135	137	O	51%
25	141	143	O	67%
26	146	147	O	of
27	149	151	O	the
28	153	156	O	dose
29	158	160	O	was
30	162	169	O	excreted
31	171	179	O	unchanged
32	181	184	O	into
33	186	190	O	urine
34	191	191	O	,
35	193	195	O	32%
36	198	200	O	26%
37	204	206	O	41%
38	209	210	O	of
39	212	214	O	the
40	216	219	O	dose
41	221	223	O	was
42	225	233	O	recovered
43	235	236	O	as
44	238	248	O	metabolites
45	249	249	O	,
46	251	253	O	and
47	255	256	O	6%
48	260	262	O	12%
49	264	265	O	of
50	267	269	O	the
51	271	274	O	dose
52	276	278	O	was
53	280	282	O	not
54	284	292	O	recovered
NULL

INVEGA	4298	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	15
Approximately 80% of the administered radioactivity was recovered in urine and 11% in the feces.
1	0	12	O	Approximately
2	14	16	O	80%
3	18	19	O	of
4	21	23	O	the
5	25	36	O	administered
6	38	50	O	radioactivity
7	52	54	O	was
8	56	64	O	recovered
9	66	67	O	in
10	69	73	O	urine
11	75	77	O	and
12	79	81	O	11%
13	83	84	O	in
14	86	88	O	the
15	90	94	O	feces
NULL

INVEGA	4299	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	35
Four primary metabolic pathways have been identified in vivo, none of which could be shown to account for more than 10% of the dose: dealkylation, hydroxylation, dehydrogenation, and benzisoxazole scission.
1	0	3	O	Four
2	5	11	O	primary
3	13	21	O	metabolic
4	23	30	O	pathways
5	32	35	O	have
6	37	40	O	been
7	42	51	O	identified
8	53	54	O	in
9	56	59	O	vivo
10	60	60	O	,
11	62	65	O	none
12	67	68	O	of
13	70	74	O	which
14	76	80	O	could
15	82	83	O	be
16	85	89	O	shown
17	91	92	O	to
18	94	100	O	account
19	102	104	O	for
20	106	109	O	more
21	111	114	O	than
22	116	118	O	10%
23	120	121	O	of
24	123	125	O	the
25	127	130	O	dose
26	131	131	O	:
27	133	144	O	dealkylation
28	145	145	O	,
29	147	159	O	hydroxylation
30	160	160	O	,
31	162	176	O	dehydrogenation
32	177	177	O	,
33	179	181	O	and
34	183	195	O	benzisoxazole
35	197	204	O	scission
NULL

INVEGA	4300	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	21
Population pharmacokinetic analyses found no difference in exposure or clearance of paliperidone between extensive metabolizers and poor metabolizers of CYP2D6 substrates.
1	0	9	O	Population
2	11	25	O	pharmacokinetic
3	27	34	O	analyses
4	36	40	O	found
5	42	43	O	no
6	45	54	O	difference
7	56	57	O	in
8	59	66	O	exposure
9	68	69	O	or
10	71	79	O	clearance
11	81	82	O	of
12	84	95	O	XXXXXXXX
13	97	103	O	between
14	105	113	O	extensive
15	115	126	O	metabolizers
16	128	130	O	and
17	132	135	O	poor
18	137	148	O	metabolizers
19	150	151	O	of
20	153	158	O	CYP2D6
21	160	169	O	substrates
NULL

INVEGA	4301	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	20
Special Populations Renal Impairment The dose of INVEGA* should be reduced in patients with moderate or severe renal impairment.
1	0	6	O	Special
2	8	18	O	Populations
3	20	24	O	Renal
4	26	35	O	Impairment
5	37	39	O	The
6	41	44	O	dose
7	46	47	O	of
8	49	54	O	XXXXXXXX
9	55	55	O	*
10	57	62	O	should
11	64	65	O	be
12	67	73	O	reduced
13	75	76	O	in
14	78	85	O	patients
15	87	90	O	with
16	92	99	O	moderate
17	101	102	O	or
18	104	109	O	severe
19	111	115	O	renal
20	117	126	O	impairment
NULL

INVEGA	4302	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	23
The disposition of a single dose paliperidone 3 mg extended-release tablet was studied in adult subjects with varying degrees of renal function.
1	0	2	O	The
2	4	14	O	disposition
3	16	17	O	of
4	19	19	O	a
5	21	26	O	single
6	28	31	O	dose
7	33	44	O	XXXXXXXX
8	46	46	O	3
9	48	49	O	mg
10	51	58	O	extended
11	60	66	O	release
12	68	73	O	tablet
13	75	77	O	was
14	79	85	O	studied
15	87	88	O	in
16	90	94	O	adult
17	96	103	O	subjects
18	105	108	O	with
19	110	116	O	varying
20	118	124	O	degrees
21	126	127	O	of
22	129	133	O	renal
23	135	142	O	function
NULL

INVEGA	4303	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	9
Elimination of paliperidone decreased with decreasing estimated creatinine clearance.
1	0	10	O	Elimination
2	12	13	O	of
3	15	26	O	XXXXXXXX
4	28	36	O	decreased
5	38	41	O	with
6	43	52	O	decreasing
7	54	62	O	estimated
8	64	73	O	creatinine
9	75	83	O	clearance
NULL

INVEGA	4304	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	91
Total clearance of paliperidone was reduced in subjects with impaired renal function by 32% on average in mild (CrCl = 50 mL/min to < 80 mL/min), 64% in moderate (CrCl = 30 mL/min to < 50 mL/min), and 71% in severe (CrCl = 10 mL/min to < 30 mL/min) renal impairment, corresponding to an average increase in exposure (AUCinf) of 1.5 fold, 2.6 fold, and 4.8 fold, respectively, compared to healthy subjects.
1	0	4	O	Total
2	6	14	O	clearance
3	16	17	O	of
4	19	30	O	XXXXXXXX
5	32	34	O	was
6	36	42	O	reduced
7	44	45	O	in
8	47	54	O	subjects
9	56	59	O	with
10	61	68	O	impaired
11	70	74	O	renal
12	76	83	O	function
13	85	86	O	by
14	88	90	O	32%
15	92	93	O	on
16	95	101	O	average
17	103	104	O	in
18	106	109	O	mild
19	112	115	O	CrCl
20	117	117	O	=
21	119	120	O	50
22	122	123	O	mL
23	124	124	O	/
24	125	127	O	min
25	129	130	O	to
26	132	132	O	<
27	134	135	O	80
28	137	138	O	mL
29	139	139	O	/
30	140	142	O	min
31	144	144	O	,
32	146	148	O	64%
33	150	151	O	in
34	153	160	O	moderate
35	163	166	O	CrCl
36	168	168	O	=
37	170	171	O	30
38	173	174	O	mL
39	175	175	O	/
40	176	178	O	min
41	180	181	O	to
42	183	183	O	<
43	185	186	O	50
44	188	189	O	mL
45	190	190	O	/
46	191	193	O	min
47	195	195	O	,
48	197	199	O	and
49	201	203	O	71%
50	205	206	O	in
51	208	213	O	severe
52	216	219	O	CrCl
53	221	221	O	=
54	223	224	O	10
55	226	227	O	mL
56	228	228	O	/
57	229	231	O	min
58	233	234	O	to
59	236	236	O	<
60	238	239	O	30
61	241	242	O	mL
62	243	243	O	/
63	244	246	O	min
64	249	253	O	renal
65	255	264	O	impairment
66	265	265	O	,
67	267	279	O	corresponding
68	281	282	O	to
69	284	285	O	an
70	287	293	O	average
71	295	302	O	increase
72	304	305	O	in
73	307	314	O	exposure
74	317	322	O	AUCinf
75	325	326	O	of
76	328	330	O	1.5
77	332	335	O	fold
78	336	336	O	,
79	338	340	O	2.6
80	342	345	O	fold
81	346	346	O	,
82	348	350	O	and
83	352	354	O	4.8
84	356	359	O	fold
85	360	360	O	,
86	362	373	O	respectively
87	374	374	O	,
88	376	383	O	compared
89	385	386	O	to
90	388	394	O	healthy
91	396	403	O	subjects
NULL

INVEGA	4305	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	48
The mean terminal elimination half-life of paliperidone was 24 hours, 40 hours, and 51 hours in subjects with mild, moderate, and severe renal impairment, respectively, compared with 23 hours in subjects with normal renal function (CrCl > 80 mL/min).
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	terminal
4	18	28	O	elimination
5	30	33	O	half
6	35	38	O	life
7	40	41	O	of
8	43	54	O	XXXXXXXX
9	56	58	O	was
10	60	61	O	24
11	63	67	O	hours
12	68	68	O	,
13	70	71	O	40
14	73	77	O	hours
15	78	78	O	,
16	80	82	O	and
17	84	85	O	51
18	87	91	O	hours
19	93	94	O	in
20	96	103	O	subjects
21	105	108	O	with
22	110	113	O	mild
23	114	114	O	,
24	116	123	O	moderate
25	124	124	O	,
26	126	128	O	and
27	130	135	O	severe
28	137	141	O	renal
29	143	152	O	impairment
30	153	153	O	,
31	155	166	O	respectively
32	167	167	O	,
33	169	176	O	compared
34	178	181	O	with
35	183	184	O	23
36	186	190	O	hours
37	192	193	O	in
38	195	202	O	subjects
39	204	207	O	with
40	209	214	O	normal
41	216	220	O	renal
42	222	229	O	function
43	232	235	O	CrCl
44	237	237	O	>
45	239	240	O	80
46	242	243	O	mL
47	244	244	O	/
48	245	247	O	min
NULL

INVEGA	4306	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	43
Hepatic Impairment In a study in adult subjects with moderate hepatic impairment (Child-Pugh class B), the plasma concentrations of free paliperidone were similar to those of healthy subjects, although total paliperidone exposure decreased because of a decrease in protein binding.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	19	20	O	In
4	22	22	O	a
5	24	28	O	study
6	30	31	O	in
7	33	37	O	adult
8	39	46	O	subjects
9	48	51	O	with
10	53	60	O	moderate
11	62	68	O	hepatic
12	70	79	O	impairment
13	82	86	O	Child
14	88	91	O	Pugh
15	93	97	O	class
16	99	99	O	B
17	101	101	O	,
18	103	105	O	the
19	107	112	O	plasma
20	114	127	O	concentrations
21	129	130	O	of
22	132	135	O	free
23	137	148	O	XXXXXXXX
24	150	153	O	were
25	155	161	O	similar
26	163	164	O	to
27	166	170	O	those
28	172	173	O	of
29	175	181	O	healthy
30	183	190	O	subjects
31	191	191	O	,
32	193	200	O	although
33	202	206	O	total
34	208	219	O	XXXXXXXX
35	221	228	O	exposure
36	230	238	O	decreased
37	240	246	O	because
38	248	249	O	of
39	251	251	O	a
40	253	260	O	decrease
41	262	263	O	in
42	265	271	O	protein
43	273	279	O	binding
NULL

INVEGA	4307	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	15
Consequently, no dose adjustment is required in patients with mild or moderate hepatic impairment.
1	0	11	O	Consequently
2	12	12	O	,
3	14	15	O	no
4	17	20	O	dose
5	22	31	O	adjustment
6	33	34	O	is
7	36	43	O	required
8	45	46	O	in
9	48	55	O	patients
10	57	60	O	with
11	62	65	O	mild
12	67	68	O	or
13	70	77	O	moderate
14	79	85	O	hepatic
15	87	96	O	impairment
NULL

INVEGA	4308	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	12
INVEGA* has not been studied in patients with severe hepatic impairment.
1	0	5	O	XXXXXXXX
2	6	6	O	*
3	8	10	O	has
4	12	14	O	not
5	16	19	O	been
6	21	27	O	studied
7	29	30	O	in
8	32	39	O	patients
9	41	44	O	with
10	46	51	O	severe
11	53	59	O	hepatic
12	61	70	O	impairment
NULL

INVEGA	4309	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	24
Adolescents (12-17 years of age) Paliperidone systemic exposure in adolescents weighing > 51 kg (> 112 lbs) was similar to that in adults.
1	0	10	O	Adolescents
2	13	14	O	12
3	16	17	O	17
4	19	23	O	years
5	25	26	O	of
6	28	30	O	age
7	33	44	O	XXXXXXXX
8	46	53	O	systemic
9	55	62	O	exposure
10	64	65	O	in
11	67	77	O	adolescents
12	79	86	O	weighing
13	88	88	O	>
14	90	91	O	51
15	93	94	O	kg
16	97	97	O	>
17	99	101	O	112
18	103	105	O	lbs
19	108	110	O	was
20	112	118	O	similar
21	120	121	O	to
22	123	126	O	that
23	128	129	O	in
24	131	136	O	adults
NULL

INVEGA	4310	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	24
In adolescents weighing < 51 kg (< 112 lbs), a 23% higher exposure was observed; this is considered not to be clinically significant.
1	0	1	O	In
2	3	13	O	adolescents
3	15	22	O	weighing
4	24	24	O	<
5	26	27	O	51
6	29	30	O	kg
7	33	33	O	<
8	35	37	O	112
9	39	41	O	lbs
10	43	43	O	,
11	45	45	O	a
12	47	49	O	23%
13	51	56	O	higher
14	58	65	O	exposure
15	67	69	O	was
16	71	78	O	observed
17	81	84	O	this
18	86	87	O	is
19	89	98	O	considered
20	100	102	O	not
21	104	105	O	to
22	107	108	O	be
23	110	119	O	clinically
24	121	131	O	significant
NULL

INVEGA	4311	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	7
Age did not influence the paliperidone exposure.
1	0	2	O	Age
2	4	6	O	did
3	8	10	O	not
4	12	20	O	influence
5	22	24	O	the
6	26	37	O	XXXXXXXX
7	39	46	O	exposure
NULL

INVEGA	4312	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	10
Elderly No dosage adjustment is recommended based on age alone.
1	0	6	O	Elderly
2	8	9	O	No
3	11	16	O	dosage
4	18	27	O	adjustment
5	29	30	O	is
6	32	42	O	recommended
7	44	48	O	based
8	50	51	O	on
9	53	55	O	age
10	57	61	O	alone
NULL

INVEGA	4313	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	15
However, dose adjustment may be required because of age-related decreases in creatinine clearance.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	dose
4	14	23	O	adjustment
5	25	27	O	may
6	29	30	O	be
7	32	39	O	required
8	41	47	O	because
9	49	50	O	of
10	52	54	O	age
11	56	62	O	related
12	64	72	O	decreases
13	74	75	O	in
14	77	86	O	creatinine
15	88	96	O	clearance
NULL

INVEGA	4314	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	9
Race No dosage adjustment is recommended based on race.
1	0	3	O	Race
2	5	6	O	No
3	8	13	O	dosage
4	15	24	O	adjustment
5	26	27	O	is
6	29	39	O	recommended
7	41	45	O	based
8	47	48	O	on
9	50	53	O	race
NULL

INVEGA	4315	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	15
No differences in pharmacokinetics were observed in a pharmacokinetic study conducted in Japanese and Caucasians.
1	0	1	O	No
2	3	13	O	differences
3	15	16	O	in
4	18	33	O	pharmacokinetics
5	35	38	O	were
6	40	47	O	observed
7	49	50	O	in
8	52	52	O	a
9	54	68	O	pharmacokinetic
10	70	74	O	study
11	76	84	O	conducted
12	86	87	O	in
13	89	96	O	Japanese
14	98	100	O	and
15	102	111	O	Caucasians
NULL

INVEGA	4316	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	9
Gender No dosage adjustment is recommended based on gender.
1	0	5	O	Gender
2	7	8	O	No
3	10	15	O	dosage
4	17	26	O	adjustment
5	28	29	O	is
6	31	41	O	recommended
7	43	47	O	based
8	49	50	O	on
9	52	57	O	gender
NULL

INVEGA	4317	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	15
No differences in pharmacokinetics were observed in a pharmacokinetic study conducted in men and women.
1	0	1	O	No
2	3	13	O	differences
3	15	16	O	in
4	18	33	O	pharmacokinetics
5	35	38	O	were
6	40	47	O	observed
7	49	50	O	in
8	52	52	O	a
9	54	68	O	pharmacokinetic
10	70	74	O	study
11	76	84	O	conducted
12	86	87	O	in
13	89	91	O	men
14	93	95	O	and
15	97	101	O	women
NULL

INVEGA	4318	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	10
Smoking No dosage adjustment is recommended based on smoking status.
1	0	6	O	Smoking
2	8	9	O	No
3	11	16	O	dosage
4	18	27	O	adjustment
5	29	30	O	is
6	32	42	O	recommended
7	44	48	O	based
8	50	51	O	on
9	53	59	O	smoking
10	61	66	O	status
NULL

INVEGA	4319	34090-1	7b8e5b26-b9e4-4704-921b-3c3c0d159916	31
Based on in vitro studies utilizing human liver enzymes, paliperidone is not a substrate for CYP1A2; smoking should, therefore, not have an effect on the pharmacokinetics of paliperidone.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	16	O	vitro
5	18	24	O	studies
6	26	34	O	utilizing
7	36	40	O	human
8	42	46	O	liver
9	48	54	O	enzymes
10	55	55	O	,
11	57	68	O	XXXXXXXX
12	70	71	O	is
13	73	75	O	not
14	77	77	O	a
15	79	87	O	substrate
16	89	91	O	for
17	93	98	O	CYP1A2
18	101	107	O	smoking
19	109	114	O	should
20	115	115	O	,
21	117	125	O	therefore
22	126	126	O	,
23	128	130	O	not
24	132	135	O	have
25	137	138	O	an
26	140	145	O	effect
27	147	148	O	on
28	150	152	O	the
29	154	169	O	pharmacokinetics
30	171	172	O	of
31	174	185	O	XXXXXXXX
NULL

Iloperidone	662	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	25
Given the primary CNS effects of FANAPT, caution should be used when it is taken in combination with other centrally acting drugs and alcohol.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	38	O	FANAPT
8	39	39	O	,
9	41	47	U-TRI	caution
10	49	54	O	should
11	56	57	O	be
12	59	62	O	used
13	64	67	O	when
14	69	70	O	it
15	72	73	O	is
16	75	79	O	taken
17	81	82	O	in
18	84	94	O	combination
19	96	99	O	with
20	101	105	B-UNK	other
21	107	115	I-UNK	centrally
22	117	122	I-UNK	acting
23	124	128	L-UNK	drugs
24	130	132	O	and
25	134	140	U-UNK	alcohol
NULL

Iloperidone	663	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	20
Due to its alpha1-adrenergic receptor antagonism, FANAPT has the potential to enhance the effect of certain antihypertensive agents.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	its
4	11	16	O	alpha1
5	18	27	O	adrenergic
6	29	36	O	receptor
7	38	47	O	antagonism
8	48	48	O	,
9	50	55	O	FANAPT
10	57	59	O	has
11	61	63	O	the
12	65	73	O	potential
13	75	76	O	to
14	78	84	B-EFF	enhance
15	86	88	I-EFF	the
16	90	95	I-EFF	effect
17	97	98	I-EFF	of
18	100	106	I-EFF	certain
19	108	123	I-EFF	antihypertensive
20	125	130	L-EFF	agents
NULL

Iloperidone	664	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	17
The dose of FANAPT should be reduced in patients co-administered a strong CYP2D6 or CYP3A4 inhibitor.
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	17	O	FANAPT
5	19	24	O	should
6	26	27	O	be
7	29	35	O	reduced
8	37	38	O	in
9	40	47	O	patients
10	49	50	O	co
11	52	63	O	administered
12	65	65	O	a
13	67	72	O	strong
14	74	79	O	CYP2D6
15	81	82	O	or
16	84	89	O	CYP3A4
17	91	99	O	inhibitor
NULL

Iloperidone	665	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	23
Iloperidone is not a substrate for CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, or CYP2E1 enzymes.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	17	O	not
4	19	19	O	a
5	21	29	O	substrate
6	31	33	O	for
7	35	40	O	CYP1A1
8	41	41	O	,
9	43	48	O	CYP1A2
10	49	49	O	,
11	51	56	O	CYP2A6
12	57	57	O	,
13	59	64	O	CYP2B6
14	65	65	O	,
15	67	72	O	CYP2C8
16	73	73	O	,
17	75	80	O	CYP2C9
18	81	81	O	,
19	83	89	O	CYP2C19
20	90	90	O	,
21	92	93	O	or
22	95	100	O	CYP2E1
23	102	108	O	enzymes
NULL

Iloperidone	666	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	24
This suggests that an interaction of iloperidone with inhibitors or inducers of these enzymes, or other factors, like smoking, is unlikely.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	20	O	an
5	22	32	O	interaction
6	34	35	O	of
7	37	47	O	XXXXXXXX
8	49	52	O	with
9	54	63	O	inhibitors
10	65	66	O	or
11	68	75	O	inducers
12	77	78	O	of
13	80	84	O	these
14	86	92	O	enzymes
15	93	93	O	,
16	95	96	O	or
17	98	102	O	other
18	104	110	O	factors
19	111	111	O	,
20	113	116	O	like
21	118	124	O	smoking
22	125	125	O	,
23	127	128	O	is
24	130	137	O	unlikely
NULL

Iloperidone	667	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	9
Both CYP3A4 and CYP2D6 are responsible for iloperidone metabolism.
1	0	3	O	Both
2	5	10	O	CYP3A4
3	12	14	O	and
4	16	21	O	CYP2D6
5	23	25	O	are
6	27	37	O	responsible
7	39	41	O	for
8	43	53	O	XXXXXXXX
9	55	64	O	metabolism
NULL

Iloperidone	668	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	22
Inhibitors of CYP3A4 (e.g., ketoconazole) or CYP2D6 (e.g., fluoxetine, paroxetine) can inhibit iloperidone elimination and cause increased blood levels.
1	0	9	B-KIN	Inhibitors
2	11	12	I-KIN	of
3	14	19	L-KIN	CYP3A4
4	22	24	O	e.g
5	26	26	O	,
6	28	39	U-KIN	ketoconazole
7	42	43	O	or
8	45	50	O	CYP2D6
9	53	55	O	e.g
10	57	57	O	,
11	59	68	U-KIN	fluoxetine
12	69	69	O	,
13	71	80	U-KIN	paroxetine
14	83	85	O	can
15	87	93	B-TRI	inhibit
16	95	105	I-TRI	XXXXXXXX
17	107	117	L-TRI	elimination
18	119	121	O	and
19	123	127	O	cause
20	129	137	O	increased
21	139	143	O	blood
22	145	150	O	levels
K/1:C54355 K/11:C54355 K/13:C54355 K/6:C54355

Iloperidone	669	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	62
Ketoconazole: Co-administration of ketoconazole (200 mg twice daily for 4 days), a potent inhibitor of CYP3A4, with a 3 mg single dose of iloperidone to 19 healthy volunteers, ages 18 to 45 years, increased the area under the curve (AUC) of iloperidone and its metabolites P88 and P95 by 57%, 55% and 35%, respectively.
1	0	11	O	Ketoconazole
2	12	12	O	:
3	14	15	O	Co
4	17	30	O	administration
5	32	33	O	of
6	35	46	U-KIN	ketoconazole
7	49	51	O	200
8	53	54	O	mg
9	56	60	O	twice
10	62	66	O	daily
11	68	70	O	for
12	72	72	O	4
13	74	77	O	days
14	79	79	O	,
15	81	81	O	a
16	83	88	O	potent
17	90	98	O	inhibitor
18	100	101	O	of
19	103	108	O	CYP3A4
20	109	109	O	,
21	111	114	O	with
22	116	116	O	a
23	118	118	O	3
24	120	121	O	mg
25	123	128	O	single
26	130	133	O	dose
27	135	136	O	of
28	138	148	O	XXXXXXXX
29	150	151	O	to
30	153	154	O	19
31	156	162	O	healthy
32	164	173	O	volunteers
33	174	174	O	,
34	176	179	O	ages
35	181	182	O	18
36	184	185	O	to
37	187	188	O	45
38	190	194	O	years
39	195	195	O	,
40	197	205	O	increased
41	207	209	O	the
42	211	214	O	area
43	216	220	O	under
44	222	224	O	the
45	226	230	O	curve
46	233	235	O	AUC
47	238	239	O	of
48	241	251	O	XXXXXXXX
49	253	255	O	and
50	257	259	O	its
51	261	271	O	metabolites
52	273	275	O	P88
53	277	279	O	and
54	281	283	O	P95
55	285	286	O	by
56	288	290	O	57%
57	291	291	O	,
58	293	295	O	55%
59	297	299	O	and
60	301	303	O	35%
61	304	304	O	,
62	306	317	O	respectively
K/6:C54605

Iloperidone	670	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	22
Iloperidone doses should be reduced by about one-half when administered with ketoconazole or other strong inhibitors of CYP3A4 (e.g., itraconazole).
1	0	10	O	XXXXXXXX
2	12	16	B-TRI	doses
3	18	23	I-TRI	should
4	25	26	I-TRI	be
5	28	34	L-TRI	reduced
6	36	37	O	by
7	39	43	O	about
8	45	47	O	one
9	49	52	O	half
10	54	57	O	when
11	59	70	O	administered
12	72	75	O	with
13	77	88	U-KIN	ketoconazole
14	90	91	O	or
15	93	97	O	other
16	99	104	B-KIN	strong
17	106	115	I-KIN	inhibitors
18	117	118	I-KIN	of
19	120	125	L-KIN	CYP3A4
20	128	130	O	e.g
21	132	132	O	,
22	134	145	O	itraconazole
K/13:C54355 K/16:C54355

Iloperidone	671	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	12
Weaker inhibitors (e.g., erythromycin, grapefruit juice) have not been studied.
1	0	5	O	Weaker
2	7	16	O	inhibitors
3	19	21	O	e.g
4	23	23	O	,
5	25	36	O	erythromycin
6	37	37	O	,
7	39	48	O	grapefruit
8	50	54	O	juice
9	57	60	O	have
10	62	64	O	not
11	66	69	O	been
12	71	77	O	studied
NULL

Iloperidone	672	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	21
When the CYP3A4 inhibitor is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-UNK	CYP3A4
4	16	24	L-UNK	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	71	O	the
13	73	83	O	XXXXXXXX
14	85	88	O	dose
15	90	95	O	should
16	97	98	O	be
17	100	107	O	returned
18	109	110	O	to
19	112	114	O	the
20	116	123	O	previous
21	125	129	O	level
NULL

Iloperidone	673	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	75
Fluoxetine: Co-administration of fluoxetine (20 mg twice daily for 21 days), a potent inhibitor of CYP2D6, with a single 3 mg dose of iloperidone to 23 healthy volunteers, ages 29 to 44 years, who were classified as CYP2D6 extensive metabolizers, increased the AUC of iloperidone and its metabolite P88, by about 2- to 3-fold, and decreased the AUC of its metabolite P95 by one-half.
1	0	9	O	Fluoxetine
2	10	10	O	:
3	12	13	O	Co
4	15	28	O	administration
5	30	31	O	of
6	33	42	U-KIN	fluoxetine
7	45	46	O	20
8	48	49	O	mg
9	51	55	O	twice
10	57	61	O	daily
11	63	65	O	for
12	67	68	O	21
13	70	73	O	days
14	75	75	O	,
15	77	77	O	a
16	79	84	O	potent
17	86	94	O	inhibitor
18	96	97	O	of
19	99	104	O	CYP2D6
20	105	105	O	,
21	107	110	O	with
22	112	112	O	a
23	114	119	O	single
24	121	121	O	3
25	123	124	O	mg
26	126	129	O	dose
27	131	132	O	of
28	134	144	O	XXXXXXXX
29	146	147	O	to
30	149	150	O	23
31	152	158	O	healthy
32	160	169	O	volunteers
33	170	170	O	,
34	172	175	O	ages
35	177	178	O	29
36	180	181	O	to
37	183	184	O	44
38	186	190	O	years
39	191	191	O	,
40	193	195	O	who
41	197	200	O	were
42	202	211	O	classified
43	213	214	O	as
44	216	221	O	CYP2D6
45	223	231	O	extensive
46	233	244	O	metabolizers
47	245	245	O	,
48	247	255	O	increased
49	257	259	O	the
50	261	263	O	AUC
51	265	266	O	of
52	268	278	O	XXXXXXXX
53	280	282	O	and
54	284	286	O	its
55	288	297	O	metabolite
56	299	301	O	P88
57	302	302	O	,
58	304	305	O	by
59	307	311	O	about
60	313	313	O	2
61	316	317	O	to
62	319	319	O	3
63	321	324	O	fold
64	325	325	O	,
65	327	329	O	and
66	331	339	O	decreased
67	341	343	O	the
68	345	347	O	AUC
69	349	350	O	of
70	352	354	O	its
71	356	365	O	metabolite
72	367	369	O	P95
73	371	372	O	by
74	374	376	O	one
75	378	381	O	half
K/6:C54605

Iloperidone	674	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	12
Iloperidone doses should be reduced by one-half when administered with fluoxetine.
1	0	10	O	XXXXXXXX
2	12	16	B-TRI	doses
3	18	23	I-TRI	should
4	25	26	I-TRI	be
5	28	34	L-TRI	reduced
6	36	37	O	by
7	39	41	O	one
8	43	46	O	half
9	48	51	O	when
10	53	64	O	administered
11	66	69	O	with
12	71	80	U-KIN	fluoxetine
K/12:C54355

Iloperidone	675	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	19
When fluoxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.
1	0	3	O	When
2	5	14	U-UNK	fluoxetine
3	16	17	O	is
4	19	27	O	withdrawn
5	29	32	O	from
6	34	36	O	the
7	38	48	O	combination
8	50	56	O	therapy
9	57	57	O	,
10	59	61	O	the
11	63	73	O	XXXXXXXX
12	75	78	O	dose
13	80	85	O	should
14	87	88	O	be
15	90	97	O	returned
16	99	100	O	to
17	102	104	O	the
18	106	113	O	previous
19	115	119	O	level
NULL

Iloperidone	676	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	18
Other strong inhibitors of CYP2D6 would be expected to have similar effects and would need appropriate dose reductions.
1	0	4	O	Other
2	6	11	B-KIN	strong
3	13	22	I-KIN	inhibitors
4	24	25	I-KIN	of
5	27	32	L-KIN	CYP2D6
6	34	38	O	would
7	40	41	O	be
8	43	50	O	expected
9	52	53	O	to
10	55	58	O	have
11	60	66	O	similar
12	68	74	O	effects
13	76	78	O	and
14	80	84	O	would
15	86	89	O	need
16	91	101	O	appropriate
17	103	106	B-TRI	dose
18	108	117	L-TRI	reductions
K/2:C54355

Iloperidone	677	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	21
When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to the previous level.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-KIN	CYP2D6
4	16	24	L-KIN	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	79	O	XXXXXXXX
13	81	84	O	dose
14	86	90	O	could
15	92	95	O	then
16	97	98	O	be
17	100	108	O	increased
18	110	111	O	to
19	113	115	O	the
20	117	124	O	previous
21	126	130	O	level
K/3:C54355

Iloperidone	678	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	76
Paroxetine: Co-administration of paroxetine (20 mg/day for 5 to 8 days), a potent inhibitor of CYP2D6, with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in increased mean steady-state peak concentrations of iloperidone and its metabolite P88, by about 1.6-fold, and decreased mean steady-state peak concentrations of its metabolite P95 by one-half.
1	0	9	O	Paroxetine
2	10	10	O	:
3	12	13	O	Co
4	15	28	O	administration
5	30	31	O	of
6	33	42	U-KIN	paroxetine
7	45	46	O	20
8	48	49	O	mg
9	50	50	O	/
10	51	53	O	day
11	55	57	O	for
12	59	59	O	5
13	61	62	O	to
14	64	64	O	8
15	66	69	O	days
16	71	71	O	,
17	73	73	O	a
18	75	80	O	potent
19	82	90	O	inhibitor
20	92	93	O	of
21	95	100	O	CYP2D6
22	101	101	O	,
23	103	106	O	with
24	108	115	O	multiple
25	117	121	O	doses
26	123	124	O	of
27	126	136	O	XXXXXXXX
28	139	139	O	8
29	141	142	O	or
30	144	145	O	12
31	147	148	O	mg
32	150	154	O	twice
33	156	160	O	daily
34	163	164	O	to
35	166	173	O	patients
36	175	178	O	with
37	180	192	O	schizophrenia
38	194	197	O	ages
39	199	200	O	18
40	202	203	O	to
41	205	206	O	65
42	208	212	O	years
43	214	221	O	resulted
44	223	224	O	in
45	226	234	O	increased
46	236	239	O	mean
47	241	246	O	steady
48	248	252	O	state
49	254	257	O	peak
50	259	272	O	concentrations
51	274	275	O	of
52	277	287	O	XXXXXXXX
53	289	291	O	and
54	293	295	O	its
55	297	306	O	metabolite
56	308	310	O	P88
57	311	311	O	,
58	313	314	O	by
59	316	320	O	about
60	322	324	O	1.6
61	326	329	O	fold
62	330	330	O	,
63	332	334	O	and
64	336	344	O	decreased
65	346	349	O	mean
66	351	356	O	steady
67	358	362	O	state
68	364	367	O	peak
69	369	382	O	concentrations
70	384	385	O	of
71	387	389	O	its
72	391	400	O	metabolite
73	402	404	O	P95
74	406	407	O	by
75	409	411	O	one
76	413	416	O	half
K/6:C54602

Iloperidone	679	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	12
Iloperidone doses should be reduced by one-half when administered with paroxetine.
1	0	10	O	XXXXXXXX
2	12	16	B-TRI	doses
3	18	23	I-TRI	should
4	25	26	I-TRI	be
5	28	34	L-TRI	reduced
6	36	37	O	by
7	39	41	O	one
8	43	46	O	half
9	48	51	O	when
10	53	64	O	administered
11	66	69	O	with
12	71	80	U-KIN	paroxetine
K/12:C54355

Iloperidone	680	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	19
When paroxetine is withdrawn from the combination therapy, the iloperidone dose should be returned to the previous level.
1	0	3	O	When
2	5	14	U-UNK	paroxetine
3	16	17	O	is
4	19	27	O	withdrawn
5	29	32	O	from
6	34	36	O	the
7	38	48	O	combination
8	50	56	O	therapy
9	57	57	O	,
10	59	61	O	the
11	63	73	O	XXXXXXXX
12	75	78	O	dose
13	80	85	O	should
14	87	88	O	be
15	90	97	O	returned
16	99	100	O	to
17	102	104	O	the
18	106	113	O	previous
19	115	119	O	level
NULL

Iloperidone	682	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	20
When the CYP2D6 inhibitor is withdrawn from the combination therapy, iloperidone dose could then be increased to previous levels.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-KIN	CYP2D6
4	16	24	L-KIN	inhibitor
5	26	27	O	is
6	29	37	O	withdrawn
7	39	42	O	from
8	44	46	O	the
9	48	58	O	combination
10	60	66	O	therapy
11	67	67	O	,
12	69	79	O	XXXXXXXX
13	81	84	O	dose
14	86	90	O	could
15	92	95	O	then
16	97	98	O	be
17	100	108	O	increased
18	110	111	O	to
19	113	120	O	previous
20	122	127	O	levels
K/3:C54355

Iloperidone	683	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	75
Paroxetine and Ketoconazole: Co-administration of paroxetine (20 mg once daily for 10 days), a CYP2D6 inhibitor, and ketoconazole (200 mg twice daily) with multiple doses of iloperidone (8 or 12 mg twice daily) to patients with schizophrenia ages 18 to 65 years resulted in a 1.4-fold increase in steady-state concentrations of iloperidone and its metabolite P88 and a 1.4-fold decrease in the P95 in the presence of paroxetine.
1	0	9	O	Paroxetine
2	11	13	O	and
3	15	26	O	Ketoconazole
4	27	27	O	:
5	29	30	O	Co
6	32	45	O	administration
7	47	48	O	of
8	50	59	U-KIN	paroxetine
9	62	63	O	20
10	65	66	O	mg
11	68	71	O	once
12	73	77	O	daily
13	79	81	O	for
14	83	84	O	10
15	86	89	O	days
16	91	91	O	,
17	93	93	O	a
18	95	100	O	CYP2D6
19	102	110	O	inhibitor
20	111	111	O	,
21	113	115	O	and
22	117	128	U-KIN	ketoconazole
23	131	133	O	200
24	135	136	O	mg
25	138	142	O	twice
26	144	148	O	daily
27	151	154	O	with
28	156	163	O	multiple
29	165	169	O	doses
30	171	172	O	of
31	174	184	O	XXXXXXXX
32	187	187	O	8
33	189	190	O	or
34	192	193	O	12
35	195	196	O	mg
36	198	202	O	twice
37	204	208	O	daily
38	211	212	O	to
39	214	221	O	patients
40	223	226	O	with
41	228	240	O	schizophrenia
42	242	245	O	ages
43	247	248	O	18
44	250	251	O	to
45	253	254	O	65
46	256	260	O	years
47	262	269	O	resulted
48	271	272	O	in
49	274	274	O	a
50	276	278	O	1.4
51	280	283	O	fold
52	285	292	O	increase
53	294	295	O	in
54	297	302	O	steady
55	304	308	O	state
56	310	323	O	concentrations
57	325	326	O	of
58	328	338	O	XXXXXXXX
59	340	342	O	and
60	344	346	O	its
61	348	357	O	metabolite
62	359	361	O	P88
63	363	365	O	and
64	367	367	O	a
65	369	371	O	1.4
66	373	376	O	fold
67	378	385	O	decrease
68	387	388	O	in
69	390	392	O	the
70	394	396	O	P95
71	398	399	O	in
72	401	403	O	the
73	405	412	O	presence
74	414	415	O	of
75	417	426	O	paroxetine
K/22:C54355 K/8:C54355

Iloperidone	684	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	22
So giving iloperidone with inhibitors of both of its metabolic pathways did not add to the effect of either inhibitor given alone.
1	0	1	O	So
2	3	8	O	giving
3	10	20	O	XXXXXXXX
4	22	25	O	with
5	27	36	O	inhibitors
6	38	39	O	of
7	41	44	O	both
8	46	47	O	of
9	49	51	O	its
10	53	61	O	metabolic
11	63	70	O	pathways
12	72	74	O	did
13	76	78	O	not
14	80	82	O	add
15	84	85	O	to
16	87	89	O	the
17	91	96	O	effect
18	98	99	O	of
19	101	106	O	either
20	108	116	O	inhibitor
21	118	122	O	given
22	124	128	O	alone
NULL

Iloperidone	685	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	20
Iloperidone doses should therefore be reduced by about one-half if administered concomitantly with both a CYP2D6 and CYP3A4 inhibitor.
1	0	10	O	XXXXXXXX
2	12	16	O	doses
3	18	23	O	should
4	25	33	O	therefore
5	35	36	O	be
6	38	44	O	reduced
7	46	47	O	by
8	49	53	O	about
9	55	57	O	one
10	59	62	O	half
11	64	65	O	if
12	67	78	O	administered
13	80	92	O	concomitantly
14	94	97	O	with
15	99	102	O	both
16	104	104	O	a
17	106	111	O	CYP2D6
18	113	115	O	and
19	117	122	B-KIN	CYP3A4
20	124	132	L-KIN	inhibitor
K/19:C54355

Iloperidone	686	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	40
In vitro studies in human liver microsomes showed that iloperidone does not substantially inhibit the metabolism of drugs metabolized by the following cytochrome P450 isozymes: CYP1A1, CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, or CYP2E1.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	24	O	human
6	26	30	O	liver
7	32	41	O	microsomes
8	43	48	O	showed
9	50	53	O	that
10	55	65	O	XXXXXXXX
11	67	70	O	does
12	72	74	O	not
13	76	88	O	substantially
14	90	96	O	inhibit
15	98	100	O	the
16	102	111	O	metabolism
17	113	114	O	of
18	116	120	O	drugs
19	122	132	O	metabolized
20	134	135	O	by
21	137	139	O	the
22	141	149	O	following
23	151	160	O	cytochrome
24	162	165	O	P450
25	167	174	O	isozymes
26	175	175	O	:
27	177	182	O	CYP1A1
28	183	183	O	,
29	185	190	O	CYP1A2
30	191	191	O	,
31	193	198	O	CYP2A6
32	199	199	O	,
33	201	206	O	CYP2B6
34	207	207	O	,
35	209	214	O	CYP2C8
36	215	215	O	,
37	217	222	O	CYP2C9
38	223	223	O	,
39	225	226	O	or
40	228	233	O	CYP2E1
NULL

Iloperidone	687	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	38
Furthermore, in vitro studies in human liver microsomes showed that iloperidone does not have enzyme inducing properties, specifically for the following cytochrome P450 isozymes: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP3A4 and CYP3A5.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	14	O	in
4	16	20	O	vitro
5	22	28	O	studies
6	30	31	O	in
7	33	37	O	human
8	39	43	O	liver
9	45	54	O	microsomes
10	56	61	O	showed
11	63	66	O	that
12	68	78	O	XXXXXXXX
13	80	83	O	does
14	85	87	O	not
15	89	92	O	have
16	94	99	O	enzyme
17	101	108	O	inducing
18	110	119	O	properties
19	120	120	O	,
20	122	133	O	specifically
21	135	137	O	for
22	139	141	O	the
23	143	151	O	following
24	153	162	O	cytochrome
25	164	167	O	P450
26	169	176	O	isozymes
27	177	177	O	:
28	179	184	O	CYP1A2
29	185	185	O	,
30	187	192	O	CYP2C8
31	193	193	O	,
32	195	200	O	CYP2C9
33	201	201	O	,
34	203	209	O	CYP2C19
35	210	210	O	,
36	212	217	O	CYP3A4
37	219	221	O	and
38	223	228	O	CYP3A5
NULL

Iloperidone	688	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	47
Dextromethorphan: A study in healthy volunteers showed that changes in the pharmacokinetics of dextromethorphan (80 mg dose) when a 3 mg dose of iloperidone was co-administered resulted in a 17% increase in total exposure and a 26% increase in the maximum plasma concentrations (Cmax)of dextromethorphan.
1	0	15	O	Dextromethorphan
2	16	16	O	:
3	18	18	O	A
4	20	24	O	study
5	26	27	O	in
6	29	35	O	healthy
7	37	46	O	volunteers
8	48	53	O	showed
9	55	58	O	that
10	60	66	O	changes
11	68	69	O	in
12	71	73	O	the
13	75	90	O	pharmacokinetics
14	92	93	O	of
15	95	110	U-KIN	dextromethorphan
16	113	114	O	80
17	116	117	O	mg
18	119	122	O	dose
19	125	128	O	when
20	130	130	O	a
21	132	132	O	3
22	134	135	O	mg
23	137	140	O	dose
24	142	143	O	of
25	145	155	O	XXXXXXXX
26	157	159	O	was
27	161	162	O	co
28	164	175	O	administered
29	177	184	O	resulted
30	186	187	O	in
31	189	189	O	a
32	191	193	O	17%
33	195	202	B-TRI	increase
34	204	205	I-TRI	in
35	207	211	I-TRI	total
36	213	220	L-TRI	exposure
37	222	224	O	and
38	226	226	O	a
39	228	230	O	26%
40	232	239	B-TRI	increase
41	241	242	I-TRI	in
42	244	246	I-TRI	the
43	248	254	I-TRI	maximum
44	256	261	I-TRI	plasma
45	263	276	L-TRI	concentrations
46	279	285	O	Cmax)of
47	287	302	O	dextromethorphan
K/15:C54610

Iloperidone	689	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	12
Thus, an interaction between iloperidone and other CYP2D6 substrates is unlikely.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	an
4	9	19	O	interaction
5	21	27	O	between
6	29	39	O	XXXXXXXX
7	41	43	O	and
8	45	49	O	other
9	51	56	O	CYP2D6
10	58	67	O	substrates
11	69	70	O	is
12	72	79	O	unlikely
NULL

Iloperidone	690	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	21
Fluoxetine: A single 3 mg dose of iloperidone had no effect on the pharmacokinetics of fluoxetine (20 mg twice daily).
1	0	9	O	Fluoxetine
2	10	10	O	:
3	12	12	O	A
4	14	19	O	single
5	21	21	O	3
6	23	24	O	mg
7	26	29	O	dose
8	31	32	O	of
9	34	44	O	XXXXXXXX
10	46	48	O	had
11	50	51	O	no
12	53	58	O	effect
13	60	61	O	on
14	63	65	O	the
15	67	82	O	pharmacokinetics
16	84	85	O	of
17	87	96	O	fluoxetine
18	99	100	O	20
19	102	103	O	mg
20	105	109	O	twice
21	111	115	O	daily
NULL

Iloperidone	691	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	44
Midazolam (a sensitive CYP 3A4 substrate):A study in patients with schizophrenia showed a less than 50% increase in midazolam total exposure at iloperidone steady state (14 days of oral dosing at up to 10 mg iloperidone twice daily) and no effect on midazolam Cmax.
1	0	8	O	Midazolam
2	11	11	O	a
3	13	21	O	sensitive
4	23	25	O	CYP
5	27	29	O	3A4
6	31	42	O	substrate):A
7	44	48	O	study
8	50	51	O	in
9	53	60	O	patients
10	62	65	O	with
11	67	79	O	schizophrenia
12	81	86	O	showed
13	88	88	O	a
14	90	93	O	less
15	95	98	O	than
16	100	102	O	50%
17	104	111	O	increase
18	113	114	O	in
19	116	124	U-KIN	midazolam
20	126	130	O	total
21	132	139	O	exposure
22	141	142	O	at
23	144	154	O	XXXXXXXX
24	156	161	O	steady
25	163	167	O	state
26	170	171	O	14
27	173	176	O	days
28	178	179	O	of
29	181	184	O	oral
30	186	191	O	dosing
31	193	194	O	at
32	196	197	O	up
33	199	200	O	to
34	202	203	O	10
35	205	206	O	mg
36	208	218	O	XXXXXXXX
37	220	224	O	twice
38	226	230	O	daily
39	233	235	O	and
40	237	238	O	no
41	240	245	O	effect
42	247	248	O	on
43	250	258	O	midazolam
44	260	263	O	Cmax
K/19:C54357

Iloperidone	692	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	12
Thus, an interaction between iloperidone and other CYP3A4 substrates is unlikely.
1	0	3	O	Thus
2	4	4	O	,
3	6	7	O	an
4	9	19	O	interaction
5	21	27	O	between
6	29	39	O	XXXXXXXX
7	41	43	O	and
8	45	49	O	other
9	51	56	O	CYP3A4
10	58	67	O	substrates
11	69	70	O	is
12	72	79	O	unlikely
NULL

Iloperidone	693	34073-7	43452bf8-76e7-47a9-a5d8-41fe84d061f0	14
FANAPT should not be used with any other drugs that prolong the QT interval.
1	0	5	O	FANAPT
2	7	12	B-TRI	should
3	14	16	I-TRI	not
4	18	19	I-TRI	be
5	21	24	L-TRI	used
6	26	29	O	with
7	31	33	O	any
8	35	39	O	other
9	41	45	B-UNK	drugs
10	47	50	I-UNK	that
11	52	58	I-UNK	prolong
12	60	62	I-UNK	the
13	64	65	I-UNK	QT
14	67	74	L-UNK	interval
NULL

Iloperidone	694	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	18
The mechanism of action of FANAPT, as with other drugs having efficacy in schizophrenia, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	32	O	FANAPT
7	33	33	O	,
8	35	36	O	as
9	38	41	O	with
10	43	47	O	other
11	49	53	O	drugs
12	55	60	O	having
13	62	69	O	efficacy
14	71	72	O	in
15	74	86	O	schizophrenia
16	87	87	O	,
17	89	90	O	is
18	92	98	O	unknown
NULL

Iloperidone	695	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	25
However it is proposed that the efficacy of FANAPTis mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5-HT2) antagonisms.
1	0	6	O	However
2	8	9	O	it
3	11	12	O	is
4	14	21	O	proposed
5	23	26	O	that
6	28	30	O	the
7	32	39	O	efficacy
8	41	42	O	of
9	44	51	O	FANAPTis
10	53	60	O	mediated
11	62	68	O	through
12	70	70	O	a
13	72	82	O	combination
14	84	85	O	of
15	87	94	O	dopamine
16	96	99	O	type
17	101	101	O	2
18	104	105	O	D2
19	108	110	O	and
20	112	120	O	serotonin
21	122	125	O	type
22	127	127	O	2
23	130	130	O	5
24	132	134	O	HT2
25	137	147	O	antagonisms
NULL

Iloperidone	696	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	34
FANAPT exhibits high (nM) affinity binding to serotonin 5-HT2A dopamine D2 and D3 receptors, and norepinephrine NEA1 receptors (Ki values of 5.6, 6.3, 7.1, and 0.36 nM, respectively).
1	0	5	O	FANAPT
2	7	14	O	exhibits
3	16	19	O	high
4	22	23	O	nM
5	26	33	O	affinity
6	35	41	O	binding
7	43	44	O	to
8	46	54	O	serotonin
9	56	56	O	5
10	58	61	O	HT2A
11	63	70	O	dopamine
12	72	73	O	D2
13	75	77	O	and
14	79	80	O	D3
15	82	90	O	receptors
16	91	91	O	,
17	93	95	O	and
18	97	110	O	norepinephrine
19	112	115	O	NEA1
20	117	125	O	receptors
21	128	129	O	Ki
22	131	136	O	values
23	138	139	O	of
24	141	143	O	5.6
25	144	144	O	,
26	146	148	O	6.3
27	149	149	O	,
28	151	153	O	7.1
29	154	154	O	,
30	156	158	O	and
31	160	163	O	0.36
32	165	166	O	nM
33	167	167	O	,
34	169	180	O	respectively
NULL

Iloperidone	697	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	56
FANAPT has moderate affinity for dopamine D4, and serotonin 5-HT6 and 5-HT7 receptors (Ki values of 25, 43, and 22, nM respectively), and low affinity for the serotonin 5-HT1A, dopamine D1, and histamine H1 receptors (Ki values of 168, 216 and 437 nM, respectively).
1	0	5	O	FANAPT
2	7	9	O	has
3	11	18	O	moderate
4	20	27	O	affinity
5	29	31	O	for
6	33	40	O	dopamine
7	42	43	O	D4
8	44	44	O	,
9	46	48	O	and
10	50	58	O	serotonin
11	60	60	O	5
12	62	64	O	HT6
13	66	68	O	and
14	70	70	O	5
15	72	74	O	HT7
16	76	84	O	receptors
17	87	88	O	Ki
18	90	95	O	values
19	97	98	O	of
20	100	101	O	25
21	102	102	O	,
22	104	105	O	43
23	106	106	O	,
24	108	110	O	and
25	112	113	O	22
26	114	114	O	,
27	116	117	O	nM
28	119	130	O	respectively
29	132	132	O	,
30	134	136	O	and
31	138	140	O	low
32	142	149	O	affinity
33	151	153	O	for
34	155	157	O	the
35	159	167	O	serotonin
36	169	169	O	5
37	171	174	O	HT1A
38	175	175	O	,
39	177	184	O	dopamine
40	186	187	O	D1
41	188	188	O	,
42	190	192	O	and
43	194	202	O	histamine
44	204	205	O	H1
45	207	215	O	receptors
46	218	219	O	Ki
47	221	226	O	values
48	228	229	O	of
49	231	233	O	168
50	234	234	O	,
51	236	238	O	216
52	240	242	O	and
53	244	246	O	437
54	248	249	O	nM
55	250	250	O	,
56	252	263	O	respectively
NULL

Iloperidone	698	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	12
FANAPT has no appreciable affinity (Ki >1000 nM) for cholinergic muscarinic receptors.
1	0	5	O	FANAPT
2	7	9	O	has
3	11	12	O	no
4	14	24	O	appreciable
5	26	33	O	affinity
6	36	37	O	Ki
7	39	43	O	>1000
8	45	46	O	nM
9	49	51	O	for
10	53	63	O	cholinergic
11	65	74	O	muscarinic
12	76	84	O	receptors
NULL

Iloperidone	699	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	21
FANAPT functions as an antagonist at the dopamine D2, D3, serotonin 5-HT1A and norepinephrine A1/A2C receptors.
1	0	5	O	FANAPT
2	7	15	O	functions
3	17	18	O	as
4	20	21	O	an
5	23	32	O	antagonist
6	34	35	O	at
7	37	39	O	the
8	41	48	O	dopamine
9	50	51	O	D2
10	52	52	O	,
11	54	55	O	D3
12	56	56	O	,
13	58	66	O	serotonin
14	68	68	O	5
15	70	73	O	HT1A
16	75	77	O	and
17	79	92	O	norepinephrine
18	94	95	O	A1
19	96	96	O	/
20	97	99	O	A2C
21	101	109	O	receptors
NULL

Iloperidone	700	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	18
The affinity of the FANAPT metabolite P88 is generally equal or less than that of the parent compound.
1	0	2	O	The
2	4	11	O	affinity
3	13	14	O	of
4	16	18	O	the
5	20	25	O	FANAPT
6	27	36	O	metabolite
7	38	40	O	P88
8	42	43	O	is
9	45	53	O	generally
10	55	59	O	equal
11	61	62	O	or
12	64	67	O	less
13	69	72	O	than
14	74	77	O	that
15	79	80	O	of
16	82	84	O	the
17	86	91	O	parent
18	93	100	O	compound
NULL

Iloperidone	701	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	41
In contrast, the metabolite P95 only shows affinity for 5-HT2A (Ki value of 3.91) and the NEA1A, NEA1B, NEA1D, and NEA2 C receptors (Ki values of 4.7, 2.7, 8.8, and 4.7 nM respectively).
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	15	O	the
5	17	26	O	metabolite
6	28	30	O	P95
7	32	35	O	only
8	37	41	O	shows
9	43	50	O	affinity
10	52	54	O	for
11	56	56	O	5
12	58	61	O	HT2A
13	64	65	O	Ki
14	67	71	O	value
15	73	74	O	of
16	76	79	O	3.91
17	82	84	O	and
18	86	88	O	the
19	90	94	O	NEA1A
20	95	95	O	,
21	97	101	O	NEA1B
22	102	102	O	,
23	104	108	O	NEA1D
24	109	109	O	,
25	111	113	O	and
26	115	118	O	NEA2
27	120	120	O	C
28	122	130	O	receptors
29	133	134	O	Ki
30	136	141	O	values
31	143	144	O	of
32	146	148	O	4.7
33	149	149	O	,
34	151	153	O	2.7
35	154	154	O	,
36	156	158	O	8.8
37	159	159	O	,
38	161	163	O	and
39	165	167	O	4.7
40	169	170	O	nM
41	172	183	O	respectively
NULL

Iloperidone	702	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	42
The observed mean elimination half-lives for iloperidone, P88 and P95 in CYP2D6 extensive metabolizers (EM)are 18, 26, and 23 hours, respectively, and in poor metabolizers (PM) are 33, 37, and 31 hours, respectively.
1	0	2	O	The
2	4	11	O	observed
3	13	16	O	mean
4	18	28	O	elimination
5	30	33	O	half
6	35	39	O	lives
7	41	43	O	for
8	45	55	O	XXXXXXXX
9	56	56	O	,
10	58	60	O	P88
11	62	64	O	and
12	66	68	O	P95
13	70	71	O	in
14	73	78	O	CYP2D6
15	80	88	O	extensive
16	90	101	O	metabolizers
17	104	109	O	EM)are
18	111	112	O	18
19	113	113	O	,
20	115	116	O	26
21	117	117	O	,
22	119	121	O	and
23	123	124	O	23
24	126	130	O	hours
25	131	131	O	,
26	133	144	O	respectively
27	145	145	O	,
28	147	149	O	and
29	151	152	O	in
30	154	157	O	poor
31	159	170	O	metabolizers
32	173	174	O	PM
33	177	179	O	are
34	181	182	O	33
35	183	183	O	,
36	185	186	O	37
37	187	187	O	,
38	189	191	O	and
39	193	194	O	31
40	196	200	O	hours
41	201	201	O	,
42	203	214	O	respectively
NULL

Iloperidone	703	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	11
Steady-state concentrations are attained within3 to 4 days of dosing.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	30	O	are
5	32	39	O	attained
6	41	47	O	within3
7	49	50	O	to
8	52	52	O	4
9	54	57	O	days
10	59	60	O	of
11	62	67	O	dosing
NULL

Iloperidone	704	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	8
Iloperidone accumulation is predictable from single-dose pharmacokinetics.
1	0	10	O	XXXXXXXX
2	12	23	O	accumulation
3	25	26	O	is
4	28	38	O	predictable
5	40	43	O	from
6	45	50	O	single
7	52	55	O	dose
8	57	72	O	pharmacokinetics
NULL

Iloperidone	705	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	9
The pharmacokinetics of iloperidone is more than dose proportional.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	O	XXXXXXXX
5	36	37	O	is
6	39	42	O	more
7	44	47	O	than
8	49	52	O	dose
9	54	65	O	proportional
NULL

Iloperidone	706	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	16
Elimination of iloperidone is mainly through hepatic metabolism involving 2 P450 isozymes, CYP2D6 and CYP3A4.
1	0	10	O	Elimination
2	12	13	O	of
3	15	25	O	XXXXXXXX
4	27	28	O	is
5	30	35	O	mainly
6	37	43	O	through
7	45	51	O	hepatic
8	53	62	O	metabolism
9	64	72	O	involving
10	74	74	O	2
11	76	79	O	P450
12	81	88	O	isozymes
13	89	89	O	,
14	91	96	O	CYP2D6
15	98	100	O	and
16	102	107	O	CYP3A4
NULL

Iloperidone	707	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	35
Absorption:Iloperidone is well absorbed after administration of the tablet with peak plasma concentrations occurring within 2 to 4 hours; while the relative bioavailability of the tablet formulation compared to oral solution is 96%.
1	0	9	O	Absorption
2	10	10	O	:
3	11	21	O	XXXXXXXX
4	23	24	O	is
5	26	29	O	well
6	31	38	O	absorbed
7	40	44	O	after
8	46	59	O	administration
9	61	62	O	of
10	64	66	O	the
11	68	73	O	tablet
12	75	78	O	with
13	80	83	O	peak
14	85	90	O	plasma
15	92	105	O	concentrations
16	107	115	O	occurring
17	117	122	O	within
18	124	124	O	2
19	126	127	O	to
20	129	129	O	4
21	131	135	O	hours
22	138	142	O	while
23	144	146	O	the
24	148	155	O	relative
25	157	171	O	bioavailability
26	173	174	O	of
27	176	178	O	the
28	180	185	O	tablet
29	187	197	O	formulation
30	199	206	O	compared
31	208	209	O	to
32	211	214	O	oral
33	216	223	O	solution
34	225	226	O	is
35	228	230	O	96%
NULL

Iloperidone	708	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	43
Administration of iloperidone with a standard high-fat meal did not significantly affect the Cmax or AUC of iloperidone, P88, or P95, but delayed Tmax by 1 hour for iloperidone, 2 hours for P88 and 6 hours for P95.
1	0	13	O	Administration
2	15	16	O	of
3	18	28	O	XXXXXXXX
4	30	33	O	with
5	35	35	O	a
6	37	44	O	standard
7	46	49	B-KIN	high
8	51	53	I-KIN	fat
9	55	58	L-KIN	meal
10	60	62	O	did
11	64	66	O	not
12	68	80	O	significantly
13	82	87	O	affect
14	89	91	O	the
15	93	96	O	Cmax
16	98	99	O	or
17	101	103	O	AUC
18	105	106	O	of
19	108	118	O	XXXXXXXX
20	119	119	O	,
21	121	123	O	P88
22	124	124	O	,
23	126	127	O	or
24	129	131	O	P95
25	132	132	O	,
26	134	136	O	but
27	138	144	B-TRI	delayed
28	146	149	L-TRI	Tmax
29	151	152	O	by
30	154	154	O	1
31	156	159	O	hour
32	161	163	O	for
33	165	175	O	XXXXXXXX
34	176	176	O	,
35	178	178	O	2
36	180	184	O	hours
37	186	188	O	for
38	190	192	O	P88
39	194	196	O	and
40	198	198	O	6
41	200	204	O	hours
42	206	208	O	for
43	210	212	O	P95
K/7:C54604

Iloperidone	709	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	8
FANAPT can be administered without regard to meals.
1	0	5	O	FANAPT
2	7	9	O	can
3	11	12	O	be
4	14	25	O	administered
5	27	33	O	without
6	35	40	O	regard
7	42	43	O	to
8	45	49	O	meals
NULL

Iloperidone	710	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	52
Distribution:Iloperidone has an apparent clearance (clearance/bioavailability) of 47 to 102 L/h, with an apparent volume of distribution of 1340 to 2800 L. At therapeutic concentrations, the unbound fraction of iloperidone in plasma is ~3% and of each metabolite (P88 and P95) it is ~8%.
1	0	11	O	Distribution
2	12	12	O	:
3	13	23	O	XXXXXXXX
4	25	27	O	has
5	29	30	O	an
6	32	39	O	apparent
7	41	49	O	clearance
8	52	60	O	clearance
9	61	61	O	/
10	62	76	O	bioavailability
11	79	80	O	of
12	82	83	O	47
13	85	86	O	to
14	88	90	O	102
15	92	92	O	L
16	93	93	O	/
17	94	94	O	h
18	95	95	O	,
19	97	100	O	with
20	102	103	O	an
21	105	112	O	apparent
22	114	119	O	volume
23	121	122	O	of
24	124	135	O	distribution
25	137	138	O	of
26	140	143	O	1340
27	145	146	O	to
28	148	151	O	2800
29	153	153	O	L
30	156	157	O	At
31	159	169	O	therapeutic
32	171	184	O	concentrations
33	185	185	O	,
34	187	189	O	the
35	191	197	O	unbound
36	199	206	O	fraction
37	208	209	O	of
38	211	221	O	XXXXXXXX
39	223	224	O	in
40	226	231	O	plasma
41	233	234	O	is
42	236	238	O	~3%
43	240	242	O	and
44	244	245	O	of
45	247	250	O	each
46	252	261	O	metabolite
47	264	266	O	P88
48	268	270	O	and
49	272	274	O	P95
50	277	278	O	it
51	280	281	O	is
52	283	285	O	~8%
NULL

Iloperidone	711	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	26
Metabolism and Elimination: Iloperidone is metabolized primarily by 3 biotransformation pathways: carbonyl reduction, hydroxylation (mediated by CYP2D6) and O-demethylation (mediated by CYP3A4).
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	26	26	O	:
5	28	38	O	XXXXXXXX
6	40	41	O	is
7	43	53	O	metabolized
8	55	63	O	primarily
9	65	66	O	by
10	68	68	O	3
11	70	86	O	biotransformation
12	88	95	O	pathways
13	96	96	O	:
14	98	105	O	carbonyl
15	107	115	O	reduction
16	116	116	O	,
17	118	130	O	hydroxylation
18	133	140	O	mediated
19	142	143	O	by
20	145	150	O	CYP2D6
21	153	155	O	and
22	157	157	O	O
23	159	171	O	demethylation
24	174	181	O	mediated
25	183	184	O	by
26	186	191	O	CYP3A4
NULL

Iloperidone	712	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	10
There are 2 predominant iloperidone metabolites, P95 and P88.
1	0	4	O	There
2	6	8	O	are
3	10	10	O	2
4	12	22	O	predominant
5	24	34	O	XXXXXXXX
6	36	46	O	metabolites
7	47	47	O	,
8	49	51	O	P95
9	53	55	O	and
10	57	59	O	P88
NULL

Iloperidone	713	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	29
The iloperidone metabolite P95 represents 47.9% of the AUC of iloperidone and its metabolites in plasma at steady-state for extensive metabolizers (EM) and 25% for poor metabolizers (PM).
1	0	2	O	The
2	4	14	O	XXXXXXXX
3	16	25	O	metabolite
4	27	29	O	P95
5	31	40	O	represents
6	42	46	O	47.9%
7	48	49	O	of
8	51	53	O	the
9	55	57	O	AUC
10	59	60	O	of
11	62	72	O	XXXXXXXX
12	74	76	O	and
13	78	80	O	its
14	82	92	O	metabolites
15	94	95	O	in
16	97	102	O	plasma
17	104	105	O	at
18	107	112	O	steady
19	114	118	O	state
20	120	122	O	for
21	124	132	O	extensive
22	134	145	O	metabolizers
23	148	149	O	EM
24	152	154	O	and
25	156	158	O	25%
26	160	162	O	for
27	164	167	O	poor
28	169	180	O	metabolizers
29	183	184	O	PM
NULL

Iloperidone	714	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	19
The active metabolite P88 accounts for 19.5% and 34.0% of total plasma exposure in EM and PM, respectively.
1	0	2	O	The
2	4	9	O	active
3	11	20	O	metabolite
4	22	24	O	P88
5	26	33	O	accounts
6	35	37	O	for
7	39	43	O	19.5%
8	45	47	O	and
9	49	53	O	34.0%
10	55	56	O	of
11	58	62	O	total
12	64	69	O	plasma
13	71	78	O	exposure
14	80	81	O	in
15	83	84	O	EM
16	86	88	O	and
17	90	91	O	PM
18	92	92	O	,
19	94	105	O	respectively
NULL

Iloperidone	715	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	40
Approximately 7% to 10% of Caucasians and 3% to 8% of black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers.
1	0	12	O	Approximately
2	14	15	O	7%
3	17	18	O	to
4	20	22	O	10%
5	24	25	O	of
6	27	36	O	Caucasians
7	38	40	O	and
8	42	43	O	3%
9	45	46	O	to
10	48	49	O	8%
11	51	52	O	of
12	54	58	O	black
13	59	59	O	/
14	60	66	O	African
15	68	76	O	Americans
16	78	81	O	lack
17	83	85	O	the
18	87	94	O	capacity
19	96	97	O	to
20	99	108	O	metabolize
21	110	115	O	CYP2D6
22	117	126	O	substrates
23	128	130	O	and
24	132	134	O	are
25	136	145	O	classified
26	147	148	O	as
27	150	153	O	poor
28	155	166	O	metabolizers
29	169	170	O	PM
30	172	172	O	,
31	174	180	O	whereas
32	182	184	O	the
33	186	189	O	rest
34	191	193	O	are
35	195	206	O	intermediate
36	207	207	O	,
37	209	217	O	extensive
38	219	220	O	or
39	222	231	O	ultrarapid
40	233	244	O	metabolizers
NULL

Iloperidone	716	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	33
Co-administration of FANAPT with known strong inhibitors of CYP2D6 like fluoxetine results in a 2.3-fold increase in iloperidone plasma exposure, andtherefore one-half of the FANAPT dose should be administered.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	26	O	FANAPT
5	28	31	O	with
6	33	37	O	known
7	39	44	B-KIN	strong
8	46	55	I-KIN	inhibitors
9	57	58	I-KIN	of
10	60	65	L-KIN	CYP2D6
11	67	70	O	like
12	72	81	U-KIN	fluoxetine
13	83	89	O	results
14	91	92	O	in
15	94	94	O	a
16	96	98	O	2.3
17	100	103	O	fold
18	105	112	O	increase
19	114	115	O	in
20	117	127	O	XXXXXXXX
21	129	134	O	plasma
22	136	143	O	exposure
23	144	144	O	,
24	146	157	O	andtherefore
25	159	161	O	one
26	163	166	O	half
27	168	169	O	of
28	171	173	O	the
29	175	180	O	FANAPT
30	182	185	O	dose
31	187	192	O	should
32	194	195	O	be
33	197	208	O	administered
K/12:C54355 K/7:C54355

Iloperidone	717	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	22
Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with EMsand PMs should have their dose reduced by one-half.
1	0	8	O	Similarly
2	9	9	O	,
3	11	13	O	PMs
4	15	16	O	of
5	18	23	O	CYP2D6
6	25	28	O	have
7	30	35	O	higher
8	37	44	O	exposure
9	46	47	O	to
10	49	59	O	XXXXXXXX
11	61	68	O	compared
12	70	73	O	with
13	75	80	O	EMsand
14	82	84	O	PMs
15	86	91	O	should
16	93	96	O	have
17	98	102	O	their
18	104	107	O	dose
19	109	115	O	reduced
20	117	118	O	by
21	120	122	O	one
22	124	127	O	half
NULL

Iloperidone	718	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	8
Laboratory tests are available to identify CYP2D6 PMs.
1	0	9	O	Laboratory
2	11	15	O	tests
3	17	19	O	are
4	21	29	O	available
5	31	32	O	to
6	34	41	O	identify
7	43	48	O	CYP2D6
8	50	52	O	PMs
NULL

Iloperidone	719	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	35
The bulk of the radioactive materials were recovered in the urine (mean 58.2% and 45.1% in EM and PM, respectively), with feces accounting for 19.9% (EM) to 22.1% (PM) of the dosed radioactivity.
1	0	2	O	The
2	4	7	O	bulk
3	9	10	O	of
4	12	14	O	the
5	16	26	O	radioactive
6	28	36	O	materials
7	38	41	O	were
8	43	51	O	recovered
9	53	54	O	in
10	56	58	O	the
11	60	64	O	urine
12	67	70	O	mean
13	72	76	O	58.2%
14	78	80	O	and
15	82	86	O	45.1%
16	88	89	O	in
17	91	92	O	EM
18	94	96	O	and
19	98	99	O	PM
20	100	100	O	,
21	102	113	O	respectively
22	115	115	O	,
23	117	120	O	with
24	122	126	O	feces
25	128	137	O	accounting
26	139	141	O	for
27	143	147	O	19.9%
28	150	151	O	EM
29	154	155	O	to
30	157	161	O	22.1%
31	164	165	O	PM
32	168	169	O	of
33	171	173	O	the
34	175	179	O	dosed
35	181	193	O	radioactivity
NULL

Iloperidone	720	34090-1	43452bf8-76e7-47a9-a5d8-41fe84d061f0	20
Transporter Interaction: Iloperidone and P88 are not substrates of P-gp and iloperidone is a weak P-gp inhibitor.
1	0	10	O	Transporter
2	12	22	O	Interaction
3	23	23	O	:
4	25	35	O	XXXXXXXX
5	37	39	O	and
6	41	43	O	P88
7	45	47	O	are
8	49	51	O	not
9	53	62	O	substrates
10	64	65	O	of
11	67	67	O	P
12	69	70	O	gp
13	72	74	O	and
14	76	86	O	XXXXXXXX
15	88	89	O	is
16	91	91	O	a
17	93	96	O	weak
18	98	98	O	P
19	100	101	O	gp
20	103	111	O	inhibitor
NULL

Imipramine	972	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	60
Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	32	34	O	The
7	36	46	O	biochemical
8	48	55	O	activity
9	57	58	O	of
10	60	62	O	the
11	64	67	O	drug
12	69	80	O	metabolizing
13	82	88	O	isozyme
14	90	99	O	cytochrome
15	101	104	O	P450
16	106	108	O	2D6
17	111	121	O	debrisoquin
18	123	133	O	hydroxylase
19	136	137	O	is
20	139	145	O	reduced
21	147	148	O	in
22	150	150	O	a
23	152	157	O	subset
24	159	160	O	of
25	162	164	O	the
26	166	174	O	Caucasian
27	176	185	O	population
28	188	192	O	about
29	194	195	O	7%
30	197	198	O	to
31	200	202	O	10%
32	204	205	O	of
33	207	216	O	Caucasians
34	218	220	O	are
35	222	223	O	so
36	225	230	O	called
37	232	236	O	"poor
38	238	250	O	metabolizers"
39	254	261	O	reliable
40	263	271	O	estimates
41	273	274	O	of
42	276	278	O	the
43	280	289	O	prevalence
44	291	292	O	of
45	294	300	O	reduced
46	302	305	O	P450
47	307	309	O	2D6
48	311	317	O	isozyme
49	319	326	O	activity
50	328	332	O	among
51	334	338	O	Asian
52	339	339	O	,
53	341	347	O	African
54	349	351	O	and
55	353	357	O	other
56	359	369	O	populations
57	371	373	O	are
58	375	377	O	not
59	379	381	O	yet
60	383	391	O	available
NULL

Imipramine	973	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	15
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	77	O	GGGGGGGG
10	79	93	O	antidepressants
11	96	99	O	TCAs
12	102	105	O	when
13	107	111	O	given
14	113	117	O	usual
15	119	123	O	doses
NULL

Imipramine	974	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

Imipramine	975	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

Imipramine	976	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	O	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

Imipramine	977	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	40
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	O	quinidine
18	107	116	O	cimetidine
19	119	121	O	and
20	123	126	O	many
21	128	131	O	that
22	133	135	O	are
23	137	146	O	substrates
24	148	150	O	for
25	152	155	O	P450
26	157	159	O	2D6
27	162	165	O	many
28	167	171	O	other
29	173	187	O	antidepressants
30	188	188	O	,
31	190	203	O	phenothiazines
32	204	204	O	,
33	206	208	O	and
34	210	212	O	the
35	214	217	O	Type
36	219	220	O	1C
37	222	236	O	antiarrhythmics
38	238	248	O	propafenone
39	250	252	O	and
40	254	263	O	flecainide
NULL

Imipramine	978	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	32	O	serotonin
6	34	41	O	reuptake
7	43	52	O	inhibitors
8	55	59	O	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	O	fluoxetine
13	79	79	O	,
14	81	90	O	sertraline
15	91	91	O	,
16	93	95	O	and
17	97	106	O	paroxetine
18	107	107	O	,
19	109	115	O	inhibit
20	117	120	O	P450
21	122	124	O	2D6
22	125	125	O	,
23	127	130	O	they
24	132	134	O	may
25	136	139	O	vary
26	141	142	O	in
27	144	146	O	the
28	148	153	O	extent
29	155	156	O	of
30	158	167	O	inhibition
NULL

Imipramine	979	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	25
The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	O	TCA
7	29	40	U-TRI	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	O	SSRI
25	146	153	O	involved
NULL

Imipramine	980	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	26
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

Imipramine	981	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	B-TRI	sufficient
6	37	40	I-TRI	time
7	42	45	I-TRI	must
8	47	52	I-TRI	elapse
9	54	59	I-TRI	before
10	61	70	L-TRI	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

Imipramine	982	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	27
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	27	O	GGGGGGGG
4	29	43	O	antidepressants
5	45	48	O	with
6	50	54	B-KIN	drugs
7	56	59	I-KIN	that
8	61	63	I-KIN	can
9	65	71	I-KIN	inhibit
10	73	82	I-KIN	cytochrome
11	84	87	I-KIN	P450
12	89	91	L-KIN	2D6
13	93	95	O	may
14	97	103	O	require
15	105	109	B-TRI	lower
16	111	115	L-TRI	doses
17	117	120	O	than
18	122	128	O	usually
19	130	139	O	prescribed
20	141	143	O	for
21	145	150	O	either
22	152	164	O	tGGGGGGGGGGGG
23	166	179	O	antidepressant
24	181	182	O	or
25	184	186	O	the
26	188	192	O	other
27	194	197	O	drug
K/6:C54357

Imipramine	983	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	22
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	66	O	co
13	68	74	O	therapy
14	75	75	O	,
15	77	78	O	an
16	80	88	O	increased
17	90	93	O	dose
18	95	106	O	GGGGGGGG
19	108	121	O	antidepressant
20	123	125	O	may
21	127	128	O	be
22	130	137	O	required
NULL

Imipramine	984	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	U-TRI	monitor
6	27	29	O	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	O	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	B-UNK	inhibitor
26	134	135	I-UNK	of
27	137	140	I-UNK	P450
28	142	144	L-UNK	2D6
NULL

Imipramine	985	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	48
The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.
1	0	2	O	The
2	4	9	O	plasma
3	11	23	O	concentration
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	41	O	may
7	43	50	O	increase
8	52	55	O	when
9	57	59	O	the
10	61	64	O	drug
11	66	67	O	is
12	69	73	O	given
13	75	87	O	concomitantly
14	89	92	O	with
15	94	100	B-KIN	hepatic
16	102	107	I-KIN	enzyme
17	109	118	L-KIN	inhibitors
18	121	123	O	e.g
19	125	125	O	,
20	127	136	U-KIN	cimetidine
21	137	137	O	,
22	139	148	U-KIN	fluoxetine
23	151	153	O	and
24	155	162	O	decrease
25	164	165	O	by
26	167	177	O	concomitant
27	179	192	O	administration
28	194	197	O	with
29	199	205	B-KIN	hepatic
30	207	212	I-KIN	enzyme
31	214	221	L-KIN	inducers
32	224	226	O	e.g
33	228	228	O	,
34	230	241	U-KIN	barbiturates
35	242	242	O	,
36	244	252	U-KIN	phenytoin
37	254	254	O	,
38	256	258	O	and
39	260	269	O	adjustment
40	271	272	O	of
41	274	276	O	the
42	278	283	O	dosage
43	285	286	O	of
44	288	297	O	XXXXXXXX
45	299	301	O	may
46	303	311	O	therefore
47	313	314	O	be
48	316	324	O	necessary
K/15:C54355 K/20:C54355 K/22:C54355 K/29:C54356 K/34:C54356 K/36:C54356

Imipramine	986	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	28
In occasional susceptible patients or in those receiving anticholinergic drugs (including antiparkinsonism agents) in addition, the atropine-like effects may become more pronounced (e.g., paralytic ileus).
1	0	1	O	In
2	3	12	O	occasional
3	14	24	O	susceptible
4	26	33	O	patients
5	35	36	O	or
6	38	39	O	in
7	41	45	O	those
8	47	55	O	receiving
9	57	71	B-DYN	anticholinergic
10	73	77	L-DYN	drugs
11	80	88	O	including
12	90	105	B-DYN	antiparkinsonism
13	107	112	L-DYN	agents
14	115	116	O	in
15	118	125	O	addition
16	126	126	O	,
17	128	130	O	the
18	132	139	B-EFF	atropine
19	141	144	I-EFF	like
20	146	152	L-EFF	effects
21	154	156	O	may
22	158	163	O	become
23	165	168	O	more
24	170	179	O	pronounced
25	182	184	O	e.g
26	186	186	O	,
27	188	196	B-EFF	paralytic
28	198	202	L-EFF	ileus
D/12:18:1 D/12:27:1 D/9:18:1 D/9:27:1

Imipramine	987	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	18
Close supervision and careful adjustment of dosage is required when imipramine pamoate is administered concomitantly with anticholinergic drugs.
1	0	4	B-TRI	Close
2	6	16	L-TRI	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	49	O	dosage
8	51	52	O	is
9	54	61	O	required
10	63	66	O	when
11	68	77	O	XXXXXXXX
12	79	85	O	pamoate
13	87	88	O	is
14	90	101	O	administered
15	103	115	O	concomitantly
16	117	120	O	with
17	122	136	B-UNK	anticholinergic
18	138	142	L-UNK	drugs
NULL

Imipramine	988	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	37
Avoid the use of preparations, such as decongestants and local anesthetics, that contain any sympathomimetic amine (e.g., epinephrine, norepinephrine), since it has been reported that tricyclic antidepressants can potentiate the effects of catecholamines.
1	0	4	O	Avoid
2	6	8	O	the
3	10	12	O	use
4	14	15	O	of
5	17	28	O	preparations
6	29	29	O	,
7	31	34	O	such
8	36	37	O	as
9	39	51	O	decongestants
10	53	55	O	and
11	57	61	O	local
12	63	73	O	anesthetics
13	74	74	O	,
14	76	79	O	that
15	81	87	O	contain
16	89	91	O	any
17	93	107	B-DYN	sympathomimetic
18	109	113	L-DYN	amine
19	116	118	O	e.g
20	120	120	O	,
21	122	132	U-DYN	epinephrine
22	133	133	O	,
23	135	148	U-DYN	norepinephrine
24	150	150	O	,
25	152	156	O	since
26	158	159	O	it
27	161	163	O	has
28	165	168	O	been
29	170	177	O	reported
30	179	192	O	thGGGGGGGGGGGG
31	194	208	O	antidepressants
32	210	212	O	can
33	214	223	B-EFF	potentiate
34	225	227	I-EFF	the
35	229	235	I-EFF	effects
36	237	238	I-EFF	of
37	240	253	L-EFF	catecholamines
D/17:33:1 D/21:33:1 D/23:33:1

Imipramine	989	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	15
Caution should be exercised when imipramine pamoate is used with agents that lower blood pressure.
1	0	6	U-TRI	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	42	O	XXXXXXXX
7	44	50	O	pamoate
8	52	53	O	is
9	55	58	O	used
10	60	63	O	with
11	65	70	B-UNK	agents
12	72	75	I-UNK	that
13	77	81	I-UNK	lower
14	83	87	I-UNK	blood
15	89	96	L-UNK	pressure
NULL

Imipramine	990	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	10
Imipramine pamoate may potentiate the effects of CNS depressant drugs.
1	0	9	O	XXXXXXXX
2	11	17	O	pamoate
3	19	21	O	may
4	23	32	B-EFF	potentiate
5	34	36	I-EFF	the
6	38	44	I-EFF	effects
7	46	47	I-EFF	of
8	49	51	I-EFF	CNS
9	53	62	I-EFF	depressant
10	64	68	L-EFF	drugs
NULL

Imipramine	991	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	15
Patients should be warned that imipramine pamoate may enhance the CNS depressant effects of alcohol.
1	0	7	O	Patients
2	9	14	O	should
3	16	17	O	be
4	19	24	O	warned
5	26	29	O	that
6	31	40	O	XXXXXXXX
7	42	48	O	pamoate
8	50	52	O	may
9	54	60	O	enhance
10	62	64	O	the
11	66	68	O	CNS
12	70	79	O	depressant
13	81	87	O	effects
14	89	90	O	of
15	92	98	U-DYN	alcohol
NULL

Imipramine	992	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	4
Monoamine Oxidase Inhibitors (MAOIs)
1	0	8	O	Monoamine
2	10	16	O	Oxidase
3	18	27	O	Inhibitors
4	30	34	O	MAOIs
NULL

Imipramine	993	34073-7	75bf3473-2d70-4d41-93cd-afa1015e45bb	2
Serotonergic Drugs
1	0	11	O	Serotonergic
2	13	17	O	Drugs
NULL

Imipramine	994	34090-1	75bf3473-2d70-4d41-93cd-afa1015e45bb	10
The mechanism of action of imipramine is not definitely known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	39	O	is
8	41	43	O	not
9	45	54	O	definitely
10	56	60	O	known
NULL

Imipramine	995	34090-1	75bf3473-2d70-4d41-93cd-afa1015e45bb	14
However, it does not act primarily by stimulation of the central nervous system.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	15	O	does
5	17	19	O	not
6	21	23	O	act
7	25	33	O	primarily
8	35	36	O	by
9	38	48	O	stimulation
10	50	51	O	of
11	53	55	O	the
12	57	63	O	central
13	65	71	O	nervous
14	73	78	O	system
NULL

Imipramine	996	34090-1	75bf3473-2d70-4d41-93cd-afa1015e45bb	21
The clinical effect is hypothesized as being due to potentiation of adrenergic synapses by blocking uptake of norepinephrine at nerve endings.
1	0	2	O	The
2	4	11	O	clinical
3	13	18	O	effect
4	20	21	O	is
5	23	34	O	hypothesized
6	36	37	O	as
7	39	43	O	being
8	45	47	O	due
9	49	50	O	to
10	52	63	O	potentiation
11	65	66	O	of
12	68	77	O	adrenergic
13	79	86	O	synapses
14	88	89	O	by
15	91	98	O	blocking
16	100	105	O	uptake
17	107	108	O	of
18	110	123	O	norepinephrine
19	125	126	O	at
20	128	132	O	nerve
21	134	140	O	endings
NULL

Lamisil	5726	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	16
Terbinafine is an inhibitor of CYP450 2D6 isozyme and has an effect on metabolism of desipramine.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	16	O	an
4	18	26	O	inhibitor
5	28	29	O	of
6	31	36	O	CYP450
7	38	40	O	2D6
8	42	48	O	isozyme
9	50	52	O	and
10	54	56	O	has
11	58	59	O	an
12	61	66	B-EFF	effect
13	68	69	I-EFF	on
14	71	80	L-EFF	metabolism
15	82	83	O	of
16	85	95	U-DYN	desipramine
D/16:12:1

Lamisil	5727	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	17
Drug interactions have also been noted with cimetidine, fluconazole, cyclosporine, rifampin, and caffeine.
1	0	3	B-TRI	Drug
2	5	16	L-TRI	interactions
3	18	21	O	have
4	23	26	O	also
5	28	31	O	been
6	33	37	O	noted
7	39	42	O	with
8	44	53	U-UNK	cimetidine
9	54	54	O	,
10	56	66	U-UNK	fluconazole
11	67	67	O	,
12	69	80	U-UNK	cyclosporine
13	81	81	O	,
14	83	90	U-UNK	rifampin
15	91	91	O	,
16	93	95	O	and
17	97	104	U-UNK	caffeine
NULL

Lamisil	5728	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	15
In vivo studies have shown that terbinafine is an inhibitor of the CYP450 2D6 isozyme.
1	0	1	O	In
2	3	6	O	vivo
3	8	14	O	studies
4	16	19	O	have
5	21	25	O	shown
6	27	30	O	that
7	32	42	O	XXXXXXXX
8	44	45	O	is
9	47	48	O	an
10	50	58	O	inhibitor
11	60	61	O	of
12	63	65	O	the
13	67	72	O	CYP450
14	74	76	O	2D6
15	78	84	O	isozyme
NULL

Lamisil	5729	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	61
Drugs predominantly metabolized by the CYP450 2D6 isozyme include the following drug classes: tricyclic antidepressants, selective serotonin reuptake inhibitors, beta-blockers, antiarrhythmics class 1C (e.g., flecainide and propafenone) and monoamine oxidase inhibitors Type B. Coadministration of Lamisil Tablets should be done with careful monitoring and may require a reduction in dose of the 2D6-metabolized drug.
1	0	4	O	Drugs
2	6	18	O	predominantly
3	20	30	O	metabolized
4	32	33	O	by
5	35	37	O	the
6	39	44	O	CYP450
7	46	48	O	2D6
8	50	56	O	isozyme
9	58	64	O	include
10	66	68	O	the
11	70	78	O	following
12	80	83	O	drug
13	85	91	O	classes
14	92	92	O	:
15	94	102	B-KIN	tricyclic
16	104	118	L-KIN	antidepressants
17	119	119	O	,
18	121	129	B-KIN	selective
19	131	139	I-KIN	serotonin
20	141	148	I-KIN	reuptake
21	150	159	L-KIN	inhibitors
22	160	160	O	,
23	162	165	B-KIN	beta
24	167	174	L-KIN	blockers
25	175	175	O	,
26	177	191	B-KIN	antiarrhythmics
27	193	197	I-KIN	class
28	199	200	L-KIN	1C
29	203	205	O	e.g
30	207	207	O	,
31	209	218	U-KIN	flecainide
32	220	222	O	and
33	224	234	U-KIN	propafenone
34	237	239	O	and
35	241	249	B-KIN	monoamine
36	251	257	I-KIN	oxidase
37	259	268	I-KIN	inhibitors
38	270	273	I-KIN	Type
39	275	275	L-KIN	B
40	278	293	O	Coadministration
41	295	296	O	of
42	298	304	O	XXXXXXXX
43	306	312	O	Tablets
44	314	319	O	should
45	321	322	O	be
46	324	327	O	done
47	329	332	O	with
48	334	340	O	careful
49	342	351	O	monitoring
50	353	355	O	and
51	357	359	O	may
52	361	367	O	require
53	369	369	O	a
54	371	379	B-TRI	reduction
55	381	382	I-TRI	in
56	384	387	L-TRI	dose
57	389	390	O	of
58	392	394	O	the
59	396	398	O	2D6
60	400	410	O	metabolized
61	412	415	O	drug
K/15:C54357 K/18:C54357 K/23:C54357 K/26:C54357 K/31:C54357 K/33:C54357 K/35:C54357

Lamisil	5730	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	42
In a study to assess the effects of terbinafine on desipramine in healthy volunteers characterized as normal metabolizers, the administration of terbinafine resulted in a 2-fold increase in Cmax and a 5-fold increase in area under the curve (AUC).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	to
5	14	19	O	assess
6	21	23	O	the
7	25	31	O	effects
8	33	34	O	of
9	36	46	O	XXXXXXXX
10	48	49	O	on
11	51	61	U-KIN	desipramine
12	63	64	O	in
13	66	72	O	healthy
14	74	83	O	volunteers
15	85	97	O	characterized
16	99	100	O	as
17	102	107	O	normal
18	109	120	O	metabolizers
19	121	121	O	,
20	123	125	O	the
21	127	140	O	administration
22	142	143	O	of
23	145	155	O	XXXXXXXX
24	157	164	O	resulted
25	166	167	O	in
26	169	169	O	a
27	171	171	O	2
28	173	176	O	fold
29	178	185	B-TRI	increase
30	187	188	I-TRI	in
31	190	193	L-TRI	Cmax
32	195	197	O	and
33	199	199	O	a
34	201	201	O	5
35	203	206	O	fold
36	208	215	B-TRI	increase
37	217	218	I-TRI	in
38	220	223	I-TRI	area
39	225	229	I-TRI	under
40	231	233	I-TRI	the
41	235	239	L-TRI	curve
42	242	244	O	AUC
K/11:C54613

Lamisil	5731	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	22
In this study, these effects were shown to persist at the last observation at 4 weeks after discontinuation of LAMISIL Tablets.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	19	O	these
6	21	27	O	effects
7	29	32	O	were
8	34	38	O	shown
9	40	41	O	to
10	43	49	O	persist
11	51	52	O	at
12	54	56	O	the
13	58	61	O	last
14	63	73	O	observation
15	75	76	O	at
16	78	78	O	4
17	80	84	O	weeks
18	86	90	O	after
19	92	106	O	discontinuation
20	108	109	O	of
21	111	117	O	XXXXXXXX
22	119	125	O	Tablets
NULL

Lamisil	5732	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	35
In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/dextrorphan metabolite ratio in urine by 16- to 97-fold on average.
1	0	1	O	In
2	3	9	O	studies
3	11	12	O	in
4	14	20	O	healthy
5	22	29	O	subjects
6	31	43	O	characterized
7	45	46	O	as
8	48	56	O	extensive
9	58	69	O	metabolizers
10	71	72	O	of
11	74	89	U-DYN	dextromethorphan
12	92	102	O	antitussive
13	104	107	O	drug
14	109	111	O	and
15	113	118	O	CYP2D6
16	120	124	O	probe
17	126	134	O	substrate
18	136	136	O	,
19	138	148	O	XXXXXXXX
20	150	158	B-EFF	increases
21	160	162	I-EFF	the
22	164	179	I-EFF	dextromethorphan
23	180	180	I-EFF	/
24	181	191	I-EFF	dextrorphan
25	193	202	I-EFF	metabolite
26	204	208	I-EFF	ratio
27	210	211	I-EFF	in
28	213	217	L-EFF	urine
29	219	220	O	by
30	222	223	O	16
31	226	227	O	to
32	229	230	O	97
33	232	235	O	fold
34	237	238	O	on
35	240	246	O	average
D/11:20:1

Lamisil	5733	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	12
Thus, terbinafine may convert extensive CYP2D6 metabolizers to poor metabolizer status.
1	0	3	O	Thus
2	4	4	O	,
3	6	16	O	XXXXXXXX
4	18	20	O	may
5	22	28	O	convert
6	30	38	O	extensive
7	40	45	O	CYP2D6
8	47	58	O	metabolizers
9	60	61	O	to
10	63	66	O	poor
11	68	78	O	metabolizer
12	80	85	O	status
NULL

Lamisil	5734	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	27
In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, cyclosporine, cisapride and fluvastatin.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	with
5	22	26	O	human
6	28	32	O	liver
7	34	43	O	microsomes
8	45	50	O	showed
9	52	55	O	that
10	57	67	O	XXXXXXXX
11	69	72	O	does
12	74	76	O	not
13	78	84	O	inhibit
14	86	88	O	the
15	90	99	O	metabolism
16	101	102	O	of
17	104	114	O	tolbutamide
18	115	115	O	,
19	117	132	O	ethinylestradiol
20	133	133	O	,
21	135	148	O	ethoxycoumarin
22	149	149	O	,
23	151	162	O	cyclosporine
24	163	163	O	,
25	165	173	O	cisapride
26	175	177	O	and
27	179	189	O	fluvastatin
NULL

Lamisil	5735	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	23
In vivo drug-drug interaction studies conducted in healthy volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin.
1	0	1	O	In
2	3	6	O	vivo
3	8	11	O	drug
4	13	16	O	drug
5	18	28	O	interaction
6	30	36	O	studies
7	38	46	O	conducted
8	48	49	O	in
9	51	57	O	healthy
10	59	67	O	volunteer
11	69	76	O	subjects
12	78	83	O	showed
13	85	88	O	that
14	90	100	O	XXXXXXXX
15	102	105	O	does
16	107	109	O	not
17	111	116	O	affect
18	118	120	O	the
19	122	130	O	clearance
20	132	133	O	of
21	135	144	O	antipyrine
22	146	147	O	or
23	149	155	O	digoxin
NULL

Lamisil	5736	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	8
Terbinafine decreases the clearance of caffeine by 19%.
1	0	10	O	XXXXXXXX
2	12	20	B-TRI	decreases
3	22	24	I-TRI	the
4	26	34	L-TRI	clearance
5	36	37	O	of
6	39	46	U-KIN	caffeine
7	48	49	O	by
8	51	53	O	19%
K/6:C54357

Lamisil	5737	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	8
Terbinafine increases the clearance of cyclosporine by 15%.
1	0	10	O	XXXXXXXX
2	12	20	B-TRI	increases
3	22	24	I-TRI	the
4	26	34	L-TRI	clearance
5	36	37	O	of
6	39	50	U-KIN	cyclosporine
7	52	53	O	by
8	55	57	O	15%
K/6:C54358

Lamisil	5738	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	25
The influence of terbinafine on the pharmacokinetics of fluconazole, cotrimoxazole (trimethoprim and sulfamethoxazole), zidovudine or theophylline was not considered to be clinically significant.
1	0	2	O	The
2	4	12	O	influence
3	14	15	O	of
4	17	27	O	XXXXXXXX
5	29	30	O	on
6	32	34	O	the
7	36	51	O	pharmacokinetics
8	53	54	O	of
9	56	66	O	fluconazole
10	67	67	O	,
11	69	81	O	cotrimoxazole
12	84	95	O	trimethoprim
13	97	99	O	and
14	101	116	O	sulfamethoxazole
15	118	118	O	,
16	120	129	O	zidovudine
17	131	132	O	or
18	134	145	O	theophylline
19	147	149	O	was
20	151	153	O	not
21	155	164	O	considered
22	166	167	O	to
23	169	170	O	be
24	172	181	O	clinically
25	183	193	O	significant
NULL

Lamisil	5739	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	29
Coadministration of a single dose of fluconazole (100 mg) with a single dose of terbinafine resulted in a 52% and 69% increase in terbinafine Cmax and AUC, respectively.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	20	O	a
4	22	27	O	single
5	29	32	O	dose
6	34	35	O	of
7	37	47	U-KIN	fluconazole
8	50	52	O	100
9	54	55	O	mg
10	58	61	O	with
11	63	63	O	a
12	65	70	O	single
13	72	75	O	dose
14	77	78	O	of
15	80	90	O	XXXXXXXX
16	92	99	O	resulted
17	101	102	O	in
18	104	104	O	a
19	106	108	O	52%
20	110	112	O	and
21	114	116	O	69%
22	118	125	O	increase
23	127	128	O	in
24	130	140	O	XXXXXXXX
25	142	145	O	Cmax
26	147	149	O	and
27	151	153	O	AUC
28	154	154	O	,
29	156	167	O	respectively
K/7:C54605

Lamisil	5740	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	9
Fluconazole is an inhibitor of CYP2C9 and CYP3A enzymes.
1	0	10	O	Fluconazole
2	12	13	O	is
3	15	16	O	an
4	18	26	O	inhibitor
5	28	29	O	of
6	31	36	O	CYP2C9
7	38	40	O	and
8	42	46	O	CYP3A
9	48	54	O	enzymes
NULL

Lamisil	5741	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	40
Based on this finding, it is likely that other inhibitors of both CYP2C9 and CYP3A4 (e.g., ketoconazole, amiodarone) may also lead to a substantial increase in the systemic exposure (Cmax and AUC) of terbinafine when concomitantly administered.
1	0	4	O	Based
2	6	7	O	on
3	9	12	O	this
4	14	20	O	finding
5	21	21	O	,
6	23	24	O	it
7	26	27	O	is
8	29	34	O	likely
9	36	39	O	that
10	41	45	O	other
11	47	56	O	inhibitors
12	58	59	O	of
13	61	64	O	both
14	66	71	O	CYP2C9
15	73	75	O	and
16	77	82	O	CYP3A4
17	85	87	O	e.g
18	89	89	O	,
19	91	102	U-KIN	ketoconazole
20	103	103	O	,
21	105	114	U-KIN	amiodarone
22	117	119	O	may
23	121	124	O	also
24	126	129	O	lead
25	131	132	O	to
26	134	134	O	a
27	136	146	O	substantial
28	148	155	B-TRI	increase
29	157	158	I-TRI	in
30	160	162	I-TRI	the
31	164	171	I-TRI	systemic
32	173	180	L-TRI	exposure
33	183	186	O	Cmax
34	188	190	O	and
35	192	194	O	AUC
36	197	198	O	of
37	200	210	O	XXXXXXXX
38	212	215	O	when
39	217	229	O	concomitantly
40	231	242	O	administered
K/19:C54355 K/21:C54602

Lamisil	5742	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	36
There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL Tablets and these changes has not been established.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	26	O	spontaneous
5	28	34	O	reports
6	36	37	O	of
7	39	46	B-EFF	increase
8	48	49	I-EFF	or
9	51	58	I-EFF	decrease
10	60	61	I-EFF	in
11	63	73	I-EFF	prothrombin
12	75	79	L-EFF	times
13	81	82	O	in
14	84	91	O	patients
15	93	105	O	concomitantly
16	107	112	O	taking
17	114	117	O	oral
18	119	129	O	XXXXXXXX
19	131	133	O	and
20	135	142	U-DYN	warfarin
21	143	143	O	,
22	145	151	O	however
23	152	152	O	,
24	154	154	O	a
25	156	161	O	causal
26	163	174	O	relationship
27	176	182	O	between
28	184	190	O	XXXXXXXX
29	192	198	O	Tablets
30	200	202	O	and
31	204	208	O	these
32	210	216	O	changes
33	218	220	O	has
34	222	224	O	not
35	226	229	O	been
36	231	241	O	established
D/20:7:1

Lamisil	5743	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	23
Terbinafine clearance is increased 100% by rifampin, a CYP450 enzyme inducer, and decreased 33% by cimetidine, a CYP450 enzyme inhibitor.
1	0	10	O	XXXXXXXX
2	12	20	B-TRI	clearance
3	22	23	I-TRI	is
4	25	33	L-TRI	increased
5	35	38	O	100%
6	40	41	O	by
7	43	50	U-KIN	rifampin
8	51	51	O	,
9	53	53	O	a
10	55	60	O	CYP450
11	62	67	O	enzyme
12	69	75	O	inducer
13	76	76	O	,
14	78	80	O	and
15	82	90	O	decreased
16	92	94	O	33%
17	96	97	O	by
18	99	108	U-KIN	cimetidine
19	109	109	O	,
20	111	111	O	a
21	113	118	O	CYP450
22	120	125	O	enzyme
23	127	135	O	inhibitor
K/18:C54355 K/7:C54356

Lamisil	5744	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	6
Terbinafine clearance is unaffected by cyclosporine.
1	0	10	O	XXXXXXXX
2	12	20	O	clearance
3	22	23	O	is
4	25	34	O	unaffected
5	36	37	O	by
6	39	50	O	cyclosporine
NULL

Lamisil	5745	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	36
There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, phenytoins, thiazide diuretics, and calcium channel blockers.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	22	O	information
5	24	32	O	available
6	34	37	O	from
7	39	46	O	adequate
8	48	51	O	drug
9	53	56	O	drug
10	58	68	O	interaction
11	70	76	O	studies
12	78	81	O	with
13	83	85	O	the
14	87	95	O	following
15	97	103	O	classes
16	105	106	O	of
17	108	112	O	drugs
18	113	113	O	:
19	115	118	O	oral
20	120	133	O	contraceptives
21	134	134	O	,
22	136	142	O	hormone
23	144	154	O	replacement
24	156	164	O	therapies
25	165	165	O	,
26	167	179	O	hypoglycemics
27	180	180	O	,
28	182	191	O	phenytoins
29	192	192	O	,
30	194	201	O	thiazide
31	203	211	O	diuretics
32	212	212	O	,
33	214	216	O	and
34	218	224	O	calcium
35	226	232	O	channel
36	234	241	O	blockers
NULL

Lamisil	5746	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	12
An evaluation of the effect of food on LamisilTablets was conducted.
1	0	1	O	An
2	3	12	O	evaluation
3	14	15	O	of
4	17	19	O	the
5	21	26	O	effect
6	28	29	O	of
7	31	34	O	food
8	36	37	O	on
9	39	45	O	XXXXXXXX
10	46	52	O	Tablets
11	54	56	O	was
12	58	66	O	conducted
NULL

Lamisil	5747	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	20
An increase of less than 20% of the AUC of terbinafine was observed when LAMISIL Tablets were administered with food.
1	0	1	O	An
2	3	10	O	increase
3	12	13	O	of
4	15	18	O	less
5	20	23	O	than
6	25	27	O	20%
7	29	30	O	of
8	32	34	O	the
9	36	38	O	AUC
10	40	41	O	of
11	43	53	O	XXXXXXXX
12	55	57	O	was
13	59	66	O	observed
14	68	71	O	when
15	73	79	O	XXXXXXXX
16	81	87	O	Tablets
17	89	92	O	were
18	94	105	O	administered
19	107	110	O	with
20	112	115	U-KIN	food
K/20:C54605

Lamisil	5748	34073-7	7c6c1494-fb92-4442-bcff-764b77397495	9
Lamisil Tablets can be taken with or without food.
1	0	6	O	XXXXXXXX
2	8	14	O	Tablets
3	16	18	O	can
4	20	21	O	be
5	23	27	O	taken
6	29	32	O	with
7	34	35	O	or
8	37	43	O	without
9	45	48	O	food
NULL

Lamisil	5749	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	5
Terbinafine is an allylamine antifungal.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	16	O	an
4	18	27	O	allylamine
5	29	38	O	antifungal
NULL

Lamisil	5750	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	7
The pharmacodynamics of Lamisil Tablets is unknown.
1	0	2	O	The
2	4	19	O	pharmacodynamics
3	21	22	O	of
4	24	30	O	XXXXXXXX
5	32	38	O	Tablets
6	40	41	O	is
7	43	49	O	unknown
NULL

Lamisil	5751	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	25
Following oral administration, terbinafine is well absorbed (>70%) and the bioavailability of Lamisil Tablets as a result of first-pass metabolism is approximately 40%.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	29	29	O	,
5	31	41	O	XXXXXXXX
6	43	44	O	is
7	46	49	O	well
8	51	58	O	absorbed
9	61	64	O	>70%
10	67	69	O	and
11	71	73	O	the
12	75	89	O	bioavailability
13	91	92	O	of
14	94	100	O	XXXXXXXX
15	102	108	O	Tablets
16	110	111	O	as
17	113	113	O	a
18	115	120	O	result
19	122	123	O	of
20	125	129	O	first
21	131	134	O	pass
22	136	145	O	metabolism
23	147	148	O	is
24	150	162	O	approximately
25	164	166	O	40%
NULL

Lamisil	5752	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	26
Peak plasma concentrations of 1 mcg/mL appear within 2 hours after a single 250 mg dose; the AUC is approximately 4.56 mcg.h/mL.
1	0	3	O	Peak
2	5	10	O	plasma
3	12	25	O	concentrations
4	27	28	O	of
5	30	30	O	1
6	32	34	O	mcg
7	35	35	O	/
8	36	37	O	mL
9	39	44	O	appear
10	46	51	O	within
11	53	53	O	2
12	55	59	O	hours
13	61	65	O	after
14	67	67	O	a
15	69	74	O	single
16	76	78	O	250
17	80	81	O	mg
18	83	86	O	dose
19	89	91	O	the
20	93	95	O	AUC
21	97	98	O	is
22	100	112	O	approximately
23	114	117	O	4.56
24	119	123	O	mcg.h
25	124	124	O	/
26	125	126	O	mL
NULL

Lamisil	5753	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	19
An increase in the AUC of terbinafine of less than 20% is observed when LamisilTablets areadministered with food.
1	0	1	O	An
2	3	10	O	increase
3	12	13	O	in
4	15	17	O	the
5	19	21	O	AUC
6	23	24	O	of
7	26	36	O	XXXXXXXX
8	38	39	O	of
9	41	44	O	less
10	46	49	O	than
11	51	53	O	20%
12	55	56	O	is
13	58	65	O	observed
14	67	70	O	when
15	72	78	O	XXXXXXXX
16	79	85	O	Tablets
17	87	101	O	areadministered
18	103	106	O	with
19	108	111	U-KIN	food
K/19:C54605

Lamisil	5754	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	19
In plasma, terbinafine is greater than 99% bound to plasma proteins and there are no specific binding sites.
1	0	1	O	In
2	3	8	O	plasma
3	9	9	O	,
4	11	21	O	XXXXXXXX
5	23	24	O	is
6	26	32	O	greater
7	34	37	O	than
8	39	41	O	99%
9	43	47	O	bound
10	49	50	O	to
11	52	57	O	plasma
12	59	66	O	proteins
13	68	70	O	and
14	72	76	O	there
15	78	80	O	are
16	82	83	O	no
17	85	92	O	specific
18	94	100	O	binding
19	102	106	O	sites
NULL

Lamisil	5755	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	43
At steady-state, in comparison to a single dose, the peak concentration of terbinafine is 25% higher and plasma AUC increases by a factor of 2.5; the increase in plasma AUC is consistent with an effective half-life of ~36 hours.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	18	O	in
6	20	29	O	comparison
7	31	32	O	to
8	34	34	O	a
9	36	41	O	single
10	43	46	O	dose
11	47	47	O	,
12	49	51	O	the
13	53	56	O	peak
14	58	70	O	concentration
15	72	73	O	of
16	75	85	O	XXXXXXXX
17	87	88	O	is
18	90	92	O	25%
19	94	99	O	higher
20	101	103	O	and
21	105	110	O	plasma
22	112	114	O	AUC
23	116	124	O	increases
24	126	127	O	by
25	129	129	O	a
26	131	136	O	factor
27	138	139	O	of
28	141	143	O	2.5
29	146	148	O	the
30	150	157	O	increase
31	159	160	O	in
32	162	167	O	plasma
33	169	171	O	AUC
34	173	174	O	is
35	176	185	O	consistent
36	187	190	O	with
37	192	193	O	an
38	195	203	O	effective
39	205	208	O	half
40	210	213	O	life
41	215	216	O	of
42	218	220	O	~36
43	222	226	O	hours
NULL

Lamisil	5756	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	8
Terbinafine is distributed to the sebum and skin.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	25	O	distributed
4	27	28	O	to
5	30	32	O	the
6	34	38	O	sebum
7	40	42	O	and
8	44	47	O	skin
NULL

Lamisil	5757	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	22
A terminal half-life of 200-400 hours may represent the slow elimination of terbinafine from tissues such as skin and adipose.
1	0	0	O	A
2	2	9	O	terminal
3	11	14	O	half
4	16	19	O	life
5	21	22	O	of
6	24	26	O	200
7	28	30	O	400
8	32	36	O	hours
9	38	40	O	may
10	42	50	O	represent
11	52	54	O	the
12	56	59	O	slow
13	61	71	O	elimination
14	73	74	O	of
15	76	86	O	XXXXXXXX
16	88	91	O	from
17	93	99	O	tissues
18	101	104	O	such
19	106	107	O	as
20	109	112	O	skin
21	114	116	O	and
22	118	124	O	adipose
NULL

Lamisil	5758	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	27
Prior to excretion, terbinafine is extensively metabolizedby at least 7 CYP isoenzymes with major contributions from CYP2C9, CYP1A2, CYP3A4, CYP2C8, and CYP2C19.
1	0	4	O	Prior
2	6	7	O	to
3	9	17	O	excretion
4	18	18	O	,
5	20	30	O	XXXXXXXX
6	32	33	O	is
7	35	45	O	extensively
8	47	59	O	metabolizedby
9	61	62	O	at
10	64	68	O	least
11	70	70	O	7
12	72	74	O	CYP
13	76	85	O	isoenzymes
14	87	90	O	with
15	92	96	O	major
16	98	110	O	contributions
17	112	115	O	from
18	117	122	O	CYP2C9
19	123	123	O	,
20	125	130	O	CYP1A2
21	131	131	O	,
22	133	138	O	CYP3A4
23	139	139	O	,
24	141	146	O	CYP2C8
25	147	147	O	,
26	149	151	O	and
27	153	159	O	CYP2C19
NULL

Lamisil	5759	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	12
No metabolites have been identified that have antifungal activity similar to terbinafine.
1	0	1	O	No
2	3	13	O	metabolites
3	15	18	O	have
4	20	23	O	been
5	25	34	O	identified
6	36	39	O	that
7	41	44	O	have
8	46	55	O	antifungal
9	57	64	O	activity
10	66	72	O	similar
11	74	75	O	to
12	77	87	O	XXXXXXXX
NULL

Lamisil	5760	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	11
Approximately 70% of the administered dose is eliminated in the urine.
1	0	12	O	Approximately
2	14	16	O	70%
3	18	19	O	of
4	21	23	O	the
5	25	36	O	administered
6	38	41	O	dose
7	43	44	O	is
8	46	55	O	eliminated
9	57	58	O	in
10	60	62	O	the
11	64	68	O	urine
NULL

Lamisil	5761	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	33
In patients with renal impairment (creatinine clearance less than or equal to 50 mL/min) or hepatic cirrhosis, the clearance of terbinafine is decreased by approximately 50% compared to normal volunteers.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	21	O	renal
5	23	32	O	impairment
6	35	44	O	creatinine
7	46	54	O	clearance
8	56	59	O	less
9	61	64	O	than
10	66	67	O	or
11	69	73	O	equal
12	75	76	O	to
13	78	79	O	50
14	81	82	O	mL
15	83	83	O	/
16	84	86	O	min
17	89	90	O	or
18	92	98	O	hepatic
19	100	108	O	cirrhosis
20	109	109	O	,
21	111	113	O	the
22	115	123	O	clearance
23	125	126	O	of
24	128	138	O	XXXXXXXX
25	140	141	O	is
26	143	151	O	decreased
27	153	154	O	by
28	156	168	O	approximately
29	170	172	O	50%
30	174	181	O	compared
31	183	184	O	to
32	186	191	O	normal
33	193	202	O	volunteers
NULL

Lamisil	5762	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	15
No effect of gender on the blood levels of terbinafine was detected in clinical trials.
1	0	1	O	No
2	3	8	O	effect
3	10	11	O	of
4	13	18	O	gender
5	20	21	O	on
6	23	25	O	the
7	27	31	O	blood
8	33	38	O	levels
9	40	41	O	of
10	43	53	O	XXXXXXXX
11	55	57	O	was
12	59	66	O	detected
13	68	69	O	in
14	71	78	O	clinical
15	80	85	O	trials
NULL

Lamisil	5763	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	16
No clinically relevant age-dependent changes in steady-state plasma concentrations of terbinafine have been reported.
1	0	1	O	No
2	3	12	O	clinically
3	14	21	O	relevant
4	23	25	O	age
5	27	35	O	dependent
6	37	43	O	changes
7	45	46	O	in
8	48	53	O	steady
9	55	59	O	state
10	61	66	O	plasma
11	68	81	O	concentrations
12	83	84	O	of
13	86	96	O	XXXXXXXX
14	98	101	O	have
15	103	106	O	been
16	108	115	O	reported
NULL

Lamisil	5764	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	22
Terbinafine,an allylamine antifungal, inhibits biosynthesis of ergosterol, an essential component of fungal cell membrane, via inhibition of squaleneepoxidaseenzyme.
1	0	10	O	XXXXXXXX
2	11	13	O	,an
3	15	24	O	allylamine
4	26	35	O	antifungal
5	36	36	O	,
6	38	45	O	inhibits
7	47	58	O	biosynthesis
8	60	61	O	of
9	63	72	O	ergosterol
10	73	73	O	,
11	75	76	O	an
12	78	86	O	essential
13	88	96	O	component
14	98	99	O	of
15	101	106	O	fungal
16	108	111	O	cell
17	113	120	O	membrane
18	121	121	O	,
19	123	125	O	via
20	127	136	O	inhibition
21	138	139	O	of
22	141	163	O	squaleneepoxidaseenzyme
NULL

Lamisil	5765	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	28
This results in fungal cell death primarily due to the increased membrane permeability mediated by the accumulation of high concentrations of squalene but not due to ergosterol deficiency.
1	0	3	O	This
2	5	11	O	results
3	13	14	O	in
4	16	21	O	fungal
5	23	26	O	cell
6	28	32	O	death
7	34	42	O	primarily
8	44	46	O	due
9	48	49	O	to
10	51	53	O	the
11	55	63	O	increased
12	65	72	O	membrane
13	74	85	O	permeability
14	87	94	O	mediated
15	96	97	O	by
16	99	101	O	the
17	103	114	O	accumulation
18	116	117	O	of
19	119	122	O	high
20	124	137	O	concentrations
21	139	140	O	of
22	142	149	O	squalene
23	151	153	O	but
24	155	157	O	not
25	159	161	O	due
26	163	164	O	to
27	166	175	O	ergosterol
28	177	186	O	deficiency
NULL

Lamisil	5766	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	20
Depending on the concentration of the drug and the fungal species test in vitro, terbinafine hydrochloride may be fungicidal.
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	29	O	concentration
5	31	32	O	of
6	34	36	O	the
7	38	41	O	drug
8	43	45	O	and
9	47	49	O	the
10	51	56	O	fungal
11	58	64	O	species
12	66	69	O	test
13	71	72	O	in
14	74	78	O	vitro
15	79	79	O	,
16	81	91	O	XXXXXXXX
17	93	105	O	hydrochloride
18	107	109	O	may
19	111	112	O	be
20	114	123	O	fungicidal
NULL

Lamisil	5767	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	11
However, the clinical significance of in vitro data is unknown.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	20	O	clinical
5	22	33	O	significance
6	35	36	O	of
7	38	39	O	in
8	41	45	O	vitro
9	47	50	O	data
10	52	53	O	is
11	55	61	O	unknown
NULL

Lamisil	5768	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	40
Terbinafine has been shown to be active against most strains of the following microorganisms both in vitro and in clinical infections: Trichophyton mentagrophytes Trichophyton rubrum The following in vitro data are available, but their clinical significance is unknown.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	19	O	been
4	21	25	O	shown
5	27	28	O	to
6	30	31	O	be
7	33	38	O	active
8	40	46	O	against
9	48	51	O	most
10	53	59	O	strains
11	61	62	O	of
12	64	66	O	the
13	68	76	O	following
14	78	91	O	microorganisms
15	93	96	O	both
16	98	99	O	in
17	101	105	O	vitro
18	107	109	O	and
19	111	112	O	in
20	114	121	O	clinical
21	123	132	O	infections
22	133	133	O	:
23	135	146	O	Trichophyton
24	148	161	O	mentagrophytes
25	163	174	O	Trichophyton
26	176	181	O	rubrum
27	183	185	O	The
28	187	195	O	following
29	197	198	O	in
30	200	204	O	vitro
31	206	209	O	data
32	211	213	O	are
33	215	223	O	available
34	224	224	O	,
35	226	228	O	but
36	230	234	O	their
37	236	243	O	clinical
38	245	256	O	significance
39	258	259	O	is
40	261	267	O	unknown
NULL

Lamisil	5769	34090-1	7c6c1494-fb92-4442-bcff-764b77397495	48
In vitro, terbinafine exhibits satisfactory MIC's against most strains of the following microorganisms; however, the safety and efficacy of terbinafine in treating clinical infections due to these microorganisms have not been established in adequate and well-controlled clinical trials: Candida albicans Epidermophyton floccosum Scopulariopsis brevicaulis
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	20	O	XXXXXXXX
5	22	29	O	exhibits
6	31	42	O	satisfactory
7	44	48	O	MIC's
8	50	56	O	against
9	58	61	O	most
10	63	69	O	strains
11	71	72	O	of
12	74	76	O	the
13	78	86	O	following
14	88	101	O	microorganisms
15	104	110	O	however
16	111	111	O	,
17	113	115	O	the
18	117	122	O	safety
19	124	126	O	and
20	128	135	O	efficacy
21	137	138	O	of
22	140	150	O	XXXXXXXX
23	152	153	O	in
24	155	162	O	treating
25	164	171	O	clinical
26	173	182	O	infections
27	184	186	O	due
28	188	189	O	to
29	191	195	O	these
30	197	210	O	microorganisms
31	212	215	O	have
32	217	219	O	not
33	221	224	O	been
34	226	236	O	established
35	238	239	O	in
36	241	248	O	adequate
37	250	252	O	and
38	254	257	O	well
39	259	268	O	controlled
40	270	277	O	clinical
41	279	284	O	trials
42	285	285	O	:
43	287	293	O	Candida
44	295	302	O	albicans
45	304	317	O	Epidermophyton
46	319	327	O	floccosum
47	329	342	O	Scopulariopsis
48	344	354	O	brevicaulis
NULL

Latuda	3677	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	35
Table 34: Clinically Important Drug Interactions with LATUDA Strong CYP3A4 Inhibitors Clinical Impact: Concomitant use of LATUDA with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone.
1	0	4	O	Table
2	6	7	O	34
3	8	8	O	:
4	10	19	O	Clinically
5	21	29	O	Important
6	31	34	O	Drug
7	36	47	O	Interactions
8	49	52	O	with
9	54	59	O	XXXXXXXX
10	61	66	O	Strong
11	68	73	O	CYP3A4
12	75	84	O	Inhibitors
13	86	93	O	Clinical
14	95	100	O	Impact
15	101	101	O	:
16	103	113	O	Concomitant
17	115	117	O	use
18	119	120	O	of
19	122	127	O	XXXXXXXX
20	129	132	O	with
21	134	139	B-KIN	strong
22	141	146	I-KIN	CYP3A4
23	148	157	L-KIN	inhibitors
24	159	167	B-TRI	increased
25	169	171	I-TRI	the
26	173	180	L-TRI	exposure
27	182	183	O	of
28	185	194	O	XXXXXXXX
29	196	203	O	compared
30	205	206	O	to
31	208	210	O	the
32	212	214	O	use
33	216	217	O	of
34	219	224	O	XXXXXXXX
35	226	230	O	alone
K/21:C54355

Latuda	3678	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	12
Intervention: LATUDA should not be used concomitantly with strong CYP3A4 inhibitors.
1	0	11	O	Intervention
2	12	12	O	:
3	14	19	O	XXXXXXXX
4	21	26	B-TRI	should
5	28	30	I-TRI	not
6	32	33	I-TRI	be
7	35	38	L-TRI	used
8	40	52	O	concomitantly
9	54	57	O	with
10	59	64	B-UNK	strong
11	66	71	I-UNK	CYP3A4
12	73	82	L-UNK	inhibitors
NULL

Latuda	3679	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	37
Examples: Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil Moderate CYP3A4 Inhibitors Clinical Impact: Concomitant use of LATUDA with moderate CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone.
1	0	7	O	Examples
2	8	8	O	:
3	10	21	O	Ketoconazole
4	22	22	O	,
5	24	37	O	clarithromycin
6	38	38	O	,
7	40	48	O	ritonavir
8	49	49	O	,
9	51	62	O	voriconazole
10	63	63	O	,
11	65	74	O	mibefradil
12	76	83	O	Moderate
13	85	90	O	CYP3A4
14	92	101	O	Inhibitors
15	103	110	O	Clinical
16	112	117	O	Impact
17	118	118	O	:
18	120	130	O	Concomitant
19	132	134	O	use
20	136	137	O	of
21	139	144	O	XXXXXXXX
22	146	149	O	with
23	151	158	B-KIN	moderate
24	160	165	I-KIN	CYP3A4
25	167	176	L-KIN	inhibitors
26	178	186	B-TRI	increased
27	188	190	I-TRI	the
28	192	199	L-TRI	exposure
29	201	202	O	of
30	204	213	O	XXXXXXXX
31	215	222	O	compared
32	224	225	O	to
33	227	229	O	the
34	231	233	O	use
35	235	236	O	of
36	238	243	O	XXXXXXXX
37	245	249	O	alone
K/23:C54355

Latuda	3680	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	21
Intervention: LATUDA dose should be reduced to half of the original level when used concomitantly with moderate inhibitors of CYP3A4.
1	0	11	O	Intervention
2	12	12	O	:
3	14	19	O	XXXXXXXX
4	21	24	B-TRI	dose
5	26	31	I-TRI	should
6	33	34	I-TRI	be
7	36	42	L-TRI	reduced
8	44	45	O	to
9	47	50	O	half
10	52	53	O	of
11	55	57	O	the
12	59	66	O	original
13	68	72	O	level
14	74	77	O	when
15	79	82	O	used
16	84	96	O	concomitantly
17	98	101	O	with
18	103	110	B-KIN	moderate
19	112	121	I-KIN	inhibitors
20	123	124	I-KIN	of
21	126	131	L-KIN	CYP3A4
K/18:C54355

Latuda	3681	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	37
Examples: Diltiazem, atazanavir, erythromycin, fluconazole, verapamil Strong CYP3A4 Inducers Clinical Impact: Concomitant use of LATUDA with strong CYP3A4 inducers decreased the exposure of lurasidone compared to the use of LATUDA alone.
1	0	7	O	Examples
2	8	8	O	:
3	10	18	O	Diltiazem
4	19	19	O	,
5	21	30	O	atazanavir
6	31	31	O	,
7	33	44	O	erythromycin
8	45	45	O	,
9	47	57	O	fluconazole
10	58	58	O	,
11	60	68	O	verapamil
12	70	75	O	Strong
13	77	82	O	CYP3A4
14	84	91	O	Inducers
15	93	100	O	Clinical
16	102	107	O	Impact
17	108	108	O	:
18	110	120	O	Concomitant
19	122	124	O	use
20	126	127	O	of
21	129	134	O	XXXXXXXX
22	136	139	O	with
23	141	146	B-KIN	strong
24	148	153	I-KIN	CYP3A4
25	155	162	L-KIN	inducers
26	164	172	B-TRI	decreased
27	174	176	I-TRI	the
28	178	185	L-TRI	exposure
29	187	188	O	of
30	190	199	O	XXXXXXXX
31	201	208	O	compared
32	210	211	O	to
33	213	215	O	the
34	217	219	O	use
35	221	222	O	of
36	224	229	O	XXXXXXXX
37	231	235	O	alone
K/23:C54356

Latuda	3682	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	12
Intervention: LATUDA should not be used concomitantly with strong CYP3A4 inducers.
1	0	11	O	Intervention
2	12	12	O	:
3	14	19	O	XXXXXXXX
4	21	26	B-TRI	should
5	28	30	I-TRI	not
6	32	33	I-TRI	be
7	35	38	L-TRI	used
8	40	52	O	concomitantly
9	54	57	O	with
10	59	64	B-UNK	strong
11	66	71	I-UNK	CYP3A4
12	73	80	L-UNK	inducers
NULL

Latuda	3683	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	39
Examples: Rifampin, avasimibe, St. John's wort, phenytoin, carbamazepine Moderate CYP3A4 Inducers Clinical Impact: Concomitant use of LATUDA with moderate CYP3A4 inducers decreased the exposure of lurasidone compared to the use of LATUDA alone.
1	0	7	O	Examples
2	8	8	O	:
3	10	17	O	Rifampin
4	18	18	O	,
5	20	28	O	avasimibe
6	29	29	O	,
7	31	32	O	St
8	35	40	O	John's
9	42	45	O	wort
10	46	46	O	,
11	48	56	O	phenytoin
12	57	57	O	,
13	59	71	O	carbamazepine
14	73	80	O	Moderate
15	82	87	O	CYP3A4
16	89	96	O	Inducers
17	98	105	O	Clinical
18	107	112	O	Impact
19	113	113	O	:
20	115	125	O	Concomitant
21	127	129	O	use
22	131	132	O	of
23	134	139	O	XXXXXXXX
24	141	144	O	with
25	146	153	B-KIN	moderate
26	155	160	I-KIN	CYP3A4
27	162	169	L-KIN	inducers
28	171	179	B-TRI	decreased
29	181	183	I-TRI	the
30	185	192	L-TRI	exposure
31	194	195	O	of
32	197	206	O	XXXXXXXX
33	208	215	O	compared
34	217	218	O	to
35	220	222	O	the
36	224	226	O	use
37	228	229	O	of
38	231	236	O	XXXXXXXX
39	238	242	O	alone
K/25:C54356

Latuda	3684	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	15
Intervention: LATUDA dose should be increased when used concomitantly with moderate inducers of CYP3A4.
1	0	11	O	Intervention
2	12	12	O	:
3	14	19	O	XXXXXXXX
4	21	24	B-TRI	dose
5	26	31	I-TRI	should
6	33	34	I-TRI	be
7	36	44	L-TRI	increased
8	46	49	O	when
9	51	54	O	used
10	56	68	O	concomitantly
11	70	73	O	with
12	75	82	B-KIN	moderate
13	84	91	I-KIN	inducers
14	93	94	I-KIN	of
15	96	101	L-KIN	CYP3A4
K/12:C54356

Latuda	3685	34073-7	afad3051-9df2-4c54-9684-e8262a133af8	38
Examples: Bosentan, efavirenz, etravirine, modafinil, nafcillin Based on pharmacokinetic studies, no dosage adjustment of LATUDA is required when administered concomitantly with lithium, valproate, or substrates of P-gp or CYP3A4.
1	0	7	O	Examples
2	8	8	O	:
3	10	17	O	Bosentan
4	18	18	O	,
5	20	28	O	efavirenz
6	29	29	O	,
7	31	40	O	etravirine
8	41	41	O	,
9	43	51	O	modafinil
10	52	52	O	,
11	54	62	O	nafcillin
12	64	68	O	Based
13	70	71	O	on
14	73	87	O	pharmacokinetic
15	89	95	O	studies
16	96	96	O	,
17	98	99	O	no
18	101	106	O	dosage
19	108	117	O	adjustment
20	119	120	O	of
21	122	127	O	XXXXXXXX
22	129	130	O	is
23	132	139	O	required
24	141	144	O	when
25	146	157	O	administered
26	159	171	O	concomitantly
27	173	176	O	with
28	178	184	O	lithium
29	185	185	O	,
30	187	195	O	valproate
31	196	196	O	,
32	198	199	O	or
33	201	210	O	substrates
34	212	213	O	of
35	215	215	O	P
36	217	218	O	gp
37	220	221	O	or
38	223	228	O	CYP3A4
NULL

Latuda	3686	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	16
The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	39	O	in
8	41	43	O	the
9	45	53	O	treatment
10	55	56	O	of
11	58	70	O	schizophrenia
12	72	74	O	and
13	76	82	O	bipolar
14	84	93	O	depression
15	95	96	O	is
16	98	104	O	unclear
NULL

Latuda	3687	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	26
However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D2 and serotonin Type 2 (5HT2A) receptor antagonism.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	its
4	13	20	O	efficacy
5	22	23	O	in
6	25	37	O	schizophrenia
7	39	41	O	and
8	43	49	O	bipolar
9	51	60	O	depression
10	62	66	O	could
11	68	69	O	be
12	71	78	O	mediated
13	80	86	O	through
14	88	88	O	a
15	90	100	O	combination
16	102	103	O	of
17	105	111	O	central
18	113	120	O	dopamine
19	122	123	O	D2
20	125	127	O	and
21	129	137	O	serotonin
22	139	142	O	Type
23	144	144	O	2
24	147	151	O	5HT2A
25	154	161	O	receptor
26	163	172	O	antagonism
NULL

Latuda	3688	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	34
Lurasidone is an antagonist with high affinity binding at the dopamine D2 receptors (Ki of 1 nM) and the serotonin 5-HT2A (Ki of 0.5 nM) and 5-HT7 (Ki of 0.5 nM) receptors.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	26	O	antagonist
5	28	31	O	with
6	33	36	O	high
7	38	45	O	affinity
8	47	53	O	binding
9	55	56	O	at
10	58	60	O	the
11	62	69	O	dopamine
12	71	72	O	D2
13	74	82	O	receptors
14	85	86	O	Ki
15	88	89	O	of
16	91	91	O	1
17	93	94	O	nM
18	97	99	O	and
19	101	103	O	the
20	105	113	O	serotonin
21	115	115	O	5
22	117	120	O	HT2A
23	123	124	O	Ki
24	126	127	O	of
25	129	131	O	0.5
26	133	134	O	nM
27	137	139	O	and
28	141	141	O	5
29	143	145	O	HT7
30	148	149	O	Ki
31	151	152	O	of
32	154	156	O	0.5
33	158	159	O	nM
34	162	170	O	receptors
NULL

Latuda	3689	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	38
It also binds with moderate affinity to the human A2C adrenergic receptors (Ki=11 nM), is a partial agonist at serotonin 5-HT1A (Ki=6.4 nM) receptors, and is an antagonist at the A2A adrenergic receptors (Ki=41 nM).
1	0	1	O	It
2	3	6	O	also
3	8	12	O	binds
4	14	17	O	with
5	19	26	O	moderate
6	28	35	O	affinity
7	37	38	O	to
8	40	42	O	the
9	44	48	O	human
10	50	52	O	A2C
11	54	63	O	adrenergic
12	65	73	O	receptors
13	76	80	O	Ki=11
14	82	83	O	nM
15	85	85	O	,
16	87	88	O	is
17	90	90	O	a
18	92	98	O	partial
19	100	106	O	agonist
20	108	109	O	at
21	111	119	O	serotonin
22	121	121	O	5
23	123	126	O	HT1A
24	129	134	O	Ki=6.4
25	136	137	O	nM
26	140	148	O	receptors
27	149	149	O	,
28	151	153	O	and
29	155	156	O	is
30	158	159	O	an
31	161	170	O	antagonist
32	172	173	O	at
33	175	177	O	the
34	179	181	O	A2A
35	183	192	O	adrenergic
36	194	202	O	receptors
37	205	209	O	Ki=41
38	211	212	O	nM
NULL

Latuda	3690	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	17
Lurasidone exhibits little or no affinity for histamine H1 and muscarinic M1 receptors (IC50 > 1,000 nM).
1	0	9	O	XXXXXXXX
2	11	18	O	exhibits
3	20	25	O	little
4	27	28	O	or
5	30	31	O	no
6	33	40	O	affinity
7	42	44	O	for
8	46	54	O	histamine
9	56	57	O	H1
10	59	61	O	and
11	63	72	O	muscarinic
12	74	75	O	M1
13	77	85	O	receptors
14	88	91	O	IC50
15	93	93	O	>
16	95	99	O	1,000
17	101	102	O	nM
NULL

Latuda	3691	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	54
ECG Changes The effects of LATUDA on the QTc interval were evaluated in a randomized, double-blind, multiple-dose, parallel-dedicated thorough QT study in 43 patients with schizophrenia or schizoaffective disorder, who were treated with LATUDA doses of 120 mg daily, 600 mg daily and completed the study.
1	0	2	O	ECG
2	4	10	O	Changes
3	12	14	O	The
4	16	22	O	effects
5	24	25	O	of
6	27	32	O	XXXXXXXX
7	34	35	O	on
8	37	39	O	the
9	41	43	O	QTc
10	45	52	O	interval
11	54	57	O	were
12	59	67	O	evaluated
13	69	70	O	in
14	72	72	O	a
15	74	83	O	randomized
16	84	84	O	,
17	86	91	O	double
18	93	97	O	blind
19	98	98	O	,
20	100	107	O	multiple
21	109	112	O	dose
22	113	113	O	,
23	115	122	O	parallel
24	124	132	O	dedicated
25	134	141	O	thorough
26	143	144	O	QT
27	146	150	O	study
28	152	153	O	in
29	155	156	O	43
30	158	165	O	patients
31	167	170	O	with
32	172	184	O	schizophrenia
33	186	187	O	or
34	189	203	O	schizoaffective
35	205	212	O	disorder
36	213	213	O	,
37	215	217	O	who
38	219	222	O	were
39	224	230	O	treated
40	232	235	O	with
41	237	242	O	XXXXXXXX
42	244	248	O	doses
43	250	251	O	of
44	253	255	O	120
45	257	258	O	mg
46	260	264	O	daily
47	265	265	O	,
48	267	269	O	600
49	271	272	O	mg
50	274	278	O	daily
51	280	282	O	and
52	284	292	O	completed
53	294	296	O	the
54	298	302	O	study
NULL

Latuda	3692	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	49
The maximum mean (upper 1-sided, 95% CI) increase in baseline-adjusted QTc intervals based on individual correction method (QTcI) was 7.5 (11.7) ms and 4.6 (9.5) ms, for the 120 mg and 600 mg dose groups respectively, observed at 2 to 4 hours after dosing.
1	0	2	O	The
2	4	10	O	maximum
3	12	15	O	mean
4	18	22	O	upper
5	24	24	O	1
6	26	30	O	sided
7	31	31	O	,
8	33	35	O	95%
9	37	38	O	CI
10	41	48	O	increase
11	50	51	O	in
12	53	60	O	baseline
13	62	69	O	adjusted
14	71	73	O	QTc
15	75	83	O	intervals
16	85	89	O	based
17	91	92	O	on
18	94	103	O	individual
19	105	114	O	correction
20	116	121	O	method
21	124	127	O	QTcI
22	130	132	O	was
23	134	136	O	7.5
24	139	142	O	11.7
25	145	146	O	ms
26	148	150	O	and
27	152	154	O	4.6
28	157	159	O	9.5
29	162	163	O	ms
30	164	164	O	,
31	166	168	O	for
32	170	172	O	the
33	174	176	O	120
34	178	179	O	mg
35	181	183	O	and
36	185	187	O	600
37	189	190	O	mg
38	192	195	O	dose
39	197	202	O	groups
40	204	215	O	respectively
41	216	216	O	,
42	218	225	O	observed
43	227	228	O	at
44	230	230	O	2
45	232	233	O	to
46	235	235	O	4
47	237	241	O	hours
48	243	247	O	after
49	249	254	O	dosing
NULL

Latuda	3693	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	12
In this study, there was no apparent dose (exposure)-response relationship.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	19	O	there
6	21	23	O	was
7	25	26	O	no
8	28	35	O	apparent
9	37	40	O	dose
10	43	50	O	exposure
11	53	60	O	response
12	62	73	O	relationship
NULL

Latuda	3694	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	30
In short-term, placebo-controlled studies in schizophrenia and bipolar depression, no post-baseline QT prolongations exceeding 500 msec were reported in patients treated with LATUDA or placebo.
1	0	1	O	In
2	3	7	O	short
3	9	12	O	term
4	13	13	O	,
5	15	21	O	placebo
6	23	32	O	controlled
7	34	40	O	studies
8	42	43	O	in
9	45	57	O	schizophrenia
10	59	61	O	and
11	63	69	O	bipolar
12	71	80	O	depression
13	81	81	O	,
14	83	84	O	no
15	86	89	O	post
16	91	98	O	baseline
17	100	101	O	QT
18	103	115	O	prolongations
19	117	125	O	exceeding
20	127	129	O	500
21	131	134	O	msec
22	136	139	O	were
23	141	148	O	reported
24	150	151	O	in
25	153	160	O	patients
26	162	168	O	treated
27	170	173	O	with
28	175	180	O	XXXXXXXX
29	182	183	O	or
30	185	191	O	placebo
NULL

Latuda	3695	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	12
Adults The activity of LATUDA is primarily due to the parent drug.
1	0	5	O	Adults
2	7	9	O	The
3	11	18	O	activity
4	20	21	O	of
5	23	28	O	XXXXXXXX
6	30	31	O	is
7	33	41	O	primarily
8	43	45	O	due
9	47	48	O	to
10	50	52	O	the
11	54	59	O	parent
12	61	64	O	drug
NULL

Latuda	3696	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	32
The pharmacokinetics of LATUDA is dose-proportional within a total daily dose range of 20 mg to 160 mg. Steady-state concentrations of LATUDA are reached within 7 days of starting LATUDA.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	29	O	XXXXXXXX
5	31	32	O	is
6	34	37	O	dose
7	39	50	O	proportional
8	52	57	O	within
9	59	59	O	a
10	61	65	O	total
11	67	71	O	daily
12	73	76	O	dose
13	78	82	O	range
14	84	85	O	of
15	87	88	O	20
16	90	91	O	mg
17	93	94	O	to
18	96	98	O	160
19	100	101	O	mg
20	104	109	O	Steady
21	111	115	O	state
22	117	130	O	concentrations
23	132	133	O	of
24	135	140	O	XXXXXXXX
25	142	144	O	are
26	146	152	O	reached
27	154	159	O	within
28	161	161	O	7
29	163	166	O	days
30	168	169	O	of
31	171	178	O	starting
32	180	185	O	XXXXXXXX
NULL

Latuda	3697	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	18
Following administration of 40 mg of LATUDA, the mean (%CV) elimination half-life was 18 (7) hours.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	29	O	40
5	31	32	O	mg
6	34	35	O	of
7	37	42	O	XXXXXXXX
8	43	43	O	,
9	45	47	O	the
10	49	52	O	mean
11	55	57	O	%CV
12	60	70	O	elimination
13	72	75	O	half
14	77	80	O	life
15	82	84	O	was
16	86	87	O	18
17	90	90	O	7
18	93	97	O	hours
NULL

Latuda	3698	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	17
Absorption and Distribution: LATUDA is absorbed and reaches peak serum concentrations in approximately 1-3 hours.
1	0	9	O	Absorption
2	11	13	O	and
3	15	26	O	Distribution
4	27	27	O	:
5	29	34	O	XXXXXXXX
6	36	37	O	is
7	39	46	O	absorbed
8	48	50	O	and
9	52	58	O	reaches
10	60	63	O	peak
11	65	69	O	serum
12	71	84	O	concentrations
13	86	87	O	in
14	89	101	O	approximately
15	103	103	O	1
16	105	105	O	3
17	107	111	O	hours
NULL

Latuda	3699	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	12
It is estimated that 9-19% of an administered dose is absorbed.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	estimated
4	16	19	O	that
5	21	21	O	9
6	23	25	O	19%
7	27	28	O	of
8	30	31	O	an
9	33	44	O	administered
10	46	49	O	dose
11	51	52	O	is
12	54	61	O	absorbed
NULL

Latuda	3700	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	27
Following administration of 40 mg of LATUDA, the mean (%CV) apparent volume of distribution was 6173 (17.2) L. LATUDA is highly bound (~99%) to serum proteins.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	29	O	40
5	31	32	O	mg
6	34	35	O	of
7	37	42	O	XXXXXXXX
8	43	43	O	,
9	45	47	O	the
10	49	52	O	mean
11	55	57	O	%CV
12	60	67	O	apparent
13	69	74	O	volume
14	76	77	O	of
15	79	90	O	distribution
16	92	94	O	was
17	96	99	O	6173
18	102	105	O	17.2
19	108	108	O	L
20	111	116	O	XXXXXXXX
21	118	119	O	is
22	121	126	O	highly
23	128	132	O	bound
24	135	138	O	~99%
25	141	142	O	to
26	144	148	O	serum
27	150	157	O	proteins
NULL

Latuda	3701	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	33
In a food effect study, LATUDA mean Cmax and AUC were about 3-times and 2-times, respectively, when administered with food compared to the levels observed under fasting conditions.
1	0	1	O	In
2	3	3	O	a
3	5	8	U-KIN	food
4	10	15	O	effect
5	17	21	O	study
6	22	22	O	,
7	24	29	O	XXXXXXXX
8	31	34	O	mean
9	36	39	O	Cmax
10	41	43	O	and
11	45	47	O	AUC
12	49	52	O	were
13	54	58	O	about
14	60	60	O	3
15	62	66	O	times
16	68	70	O	and
17	72	72	O	2
18	74	78	O	times
19	79	79	O	,
20	81	92	O	respectively
21	93	93	O	,
22	95	98	O	when
23	100	111	O	administered
24	113	116	O	with
25	118	121	O	food
26	123	130	O	compared
27	132	133	O	to
28	135	137	O	the
29	139	144	O	levels
30	146	153	O	observed
31	155	159	O	under
32	161	167	O	fasting
33	169	178	O	conditions
K/3:C54605

Latuda	3702	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	22
LATUDA exposure was not affected as meal size was increased from 350 to 1000 calories and was independent of meal fat content.
1	0	5	O	XXXXXXXX
2	7	14	O	exposure
3	16	18	O	was
4	20	22	O	not
5	24	31	O	affected
6	33	34	O	as
7	36	39	O	meal
8	41	44	O	size
9	46	48	O	was
10	50	58	O	increased
11	60	63	O	from
12	65	67	O	350
13	69	70	O	to
14	72	75	O	1000
15	77	84	O	calories
16	86	88	O	and
17	90	92	O	was
18	94	104	O	independent
19	106	107	O	of
20	109	112	O	meal
21	114	116	O	fat
22	118	124	O	content
NULL

Latuda	3703	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	22
In clinical studies, establishing the safety and efficacy of LATUDA, patients were instructed to take their daily dose with food.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	32	O	establishing
6	34	36	O	the
7	38	43	O	safety
8	45	47	O	and
9	49	56	O	efficacy
10	58	59	O	of
11	61	66	O	XXXXXXXX
12	67	67	O	,
13	69	76	O	patients
14	78	81	O	were
15	83	92	O	instructed
16	94	95	O	to
17	97	100	O	take
18	102	106	O	their
19	108	112	O	daily
20	114	117	O	dose
21	119	122	O	with
22	124	127	O	food
NULL

Latuda	3704	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	10
Metabolism and Elimination: LATUDA is metabolized mainly via CYP3A4.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	26	26	O	:
5	28	33	O	XXXXXXXX
6	35	36	O	is
7	38	48	O	metabolized
8	50	55	O	mainly
9	57	59	O	via
10	61	66	O	CYP3A4
NULL

Latuda	3705	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	17
The major biotransformation pathways are oxidative N-dealkylation, hydroxylation of norbornane ring, and S-oxidation.
1	0	2	O	The
2	4	8	O	major
3	10	26	O	biotransformation
4	28	35	O	pathways
5	37	39	O	are
6	41	49	O	oxidative
7	51	51	O	N
8	53	64	O	dealkylation
9	65	65	O	,
10	67	79	O	hydroxylation
11	81	82	O	of
12	84	93	O	norbornane
13	95	98	O	ring
14	99	99	O	,
15	101	103	O	and
16	105	105	O	S
17	107	115	O	oxidation
NULL

Latuda	3706	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	23
LATUDA is metabolized into two active metabolites (ID-14283 and ID-14326) and two major non-active metabolites (ID-20219 and ID-20220).
1	0	5	O	XXXXXXXX
2	7	8	O	is
3	10	20	O	metabolized
4	22	25	O	into
5	27	29	O	two
6	31	36	O	active
7	38	48	O	metabolites
8	51	52	O	ID
9	54	58	O	14283
10	60	62	O	and
11	64	65	O	ID
12	67	71	O	14326
13	74	76	O	and
14	78	80	O	two
15	82	86	O	major
16	88	90	O	non
17	92	97	O	active
18	99	109	O	metabolites
19	112	113	O	ID
20	115	119	O	20219
21	121	123	O	and
22	125	126	O	ID
23	128	132	O	20220
NULL

Latuda	3707	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	32
Based on in vitro studies, LATUDA is not a substrate of CYP1A1, CYP1A2, CYP2A6, CYP4A11, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 or CYP2E1 enzymes.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	16	O	vitro
5	18	24	O	studies
6	25	25	O	,
7	27	32	O	XXXXXXXX
8	34	35	O	is
9	37	39	O	not
10	41	41	O	a
11	43	51	O	substrate
12	53	54	O	of
13	56	61	O	CYP1A1
14	62	62	O	,
15	64	69	O	CYP1A2
16	70	70	O	,
17	72	77	O	CYP2A6
18	78	78	O	,
19	80	86	O	CYP4A11
20	87	87	O	,
21	89	94	O	CYP2B6
22	95	95	O	,
23	97	102	O	CYP2C8
24	103	103	O	,
25	105	110	O	CYP2C9
26	111	111	O	,
27	113	119	O	CYP2C19
28	120	120	O	,
29	122	127	O	CYP2D6
30	129	130	O	or
31	132	137	O	CYP2E1
32	139	145	O	enzymes
NULL

Latuda	3708	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	22
Because LATUDA is not a substrate for CYP1A2, smoking is not expected to have an effect on the pharmacokinetics of LATUDA.
1	0	6	O	Because
2	8	13	O	XXXXXXXX
3	15	16	O	is
4	18	20	O	not
5	22	22	O	a
6	24	32	O	substrate
7	34	36	O	for
8	38	43	O	CYP1A2
9	44	44	O	,
10	46	52	O	smoking
11	54	55	O	is
12	57	59	O	not
13	61	68	O	expected
14	70	71	O	to
15	73	76	O	have
16	78	79	O	an
17	81	86	O	effect
18	88	89	O	on
19	91	93	O	the
20	95	110	O	pharmacokinetics
21	112	113	O	of
22	115	120	O	XXXXXXXX
NULL

Latuda	3709	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	28
Transporter proteins: In vitro studies suggest LATUDA is not a substrate of OATP1B1 or OATP1B3, however, is probably a substrate of P-gp and BCRP.
1	0	10	O	Transporter
2	12	19	O	proteins
3	20	20	O	:
4	22	23	O	In
5	25	29	O	vitro
6	31	37	O	studies
7	39	45	O	suggest
8	47	52	O	XXXXXXXX
9	54	55	O	is
10	57	59	O	not
11	61	61	O	a
12	63	71	O	substrate
13	73	74	O	of
14	76	82	O	OATP1B1
15	84	85	O	or
16	87	93	O	OATP1B3
17	94	94	O	,
18	96	102	O	however
19	103	103	O	,
20	105	106	O	is
21	108	115	O	probably
22	117	117	O	a
23	119	127	O	substrate
24	129	130	O	of
25	132	132	O	P
26	134	135	O	gp
27	137	139	O	and
28	141	144	O	BCRP
NULL

Latuda	3710	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	34
In vitro studies indicate that LATUDA is not expected to inhibit transporters OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2-K and BSEP at clinically relevant concentrations.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	36	O	XXXXXXXX
7	38	39	O	is
8	41	43	O	not
9	45	52	O	expected
10	54	55	O	to
11	57	63	O	inhibit
12	65	76	O	transporters
13	78	84	O	OATP1B1
14	85	85	O	,
15	87	93	O	OATP1B3
16	94	94	O	,
17	96	99	O	OCT1
18	100	100	O	,
19	102	105	O	OCT2
20	106	106	O	,
21	108	111	O	OAT1
22	112	112	O	,
23	114	117	O	OAT3
24	118	118	O	,
25	120	124	O	MATE1
26	125	125	O	,
27	127	131	O	MATE2
28	133	133	O	K
29	135	137	O	and
30	139	142	O	BSEP
31	144	145	O	at
32	147	156	O	clinically
33	158	165	O	relevant
34	167	180	O	concentrations
NULL

Latuda	3711	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	10
LATUDA is not a clinically significant inhibitor of P-gp.
1	0	5	O	XXXXXXXX
2	7	8	O	is
3	10	12	O	not
4	14	14	O	a
5	16	25	O	clinically
6	27	37	O	significant
7	39	47	O	inhibitor
8	49	50	O	of
9	52	52	O	P
10	54	55	O	gp
NULL

Latuda	3712	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	33
Total excretion of radioactivity in urine and feces combined was approximately 89%, with about 80% recovered in feces and 9% recovered in urine, after a single dose of [14C]-labeled LATUDA.
1	0	4	O	Total
2	6	14	O	excretion
3	16	17	O	of
4	19	31	O	radioactivity
5	33	34	O	in
6	36	40	O	urine
7	42	44	O	and
8	46	50	O	feces
9	52	59	O	combined
10	61	63	O	was
11	65	77	O	approximately
12	79	81	O	89%
13	82	82	O	,
14	84	87	O	with
15	89	93	O	about
16	95	97	O	80%
17	99	107	O	recovered
18	109	110	O	in
19	112	116	O	feces
20	118	120	O	and
21	122	123	O	9%
22	125	133	O	recovered
23	135	136	O	in
24	138	142	O	urine
25	143	143	O	,
26	145	149	O	after
27	151	151	O	a
28	153	158	O	single
29	160	163	O	dose
30	165	166	O	of
31	169	171	O	14C
32	174	180	O	labeled
33	182	187	O	XXXXXXXX
NULL

Latuda	3713	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	19
Following administration of 40 mg of LATUDA, the mean (%CV) apparent clearance was 3902 (18.0) mL/min.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	29	O	40
5	31	32	O	mg
6	34	35	O	of
7	37	42	O	XXXXXXXX
8	43	43	O	,
9	45	47	O	the
10	49	52	O	mean
11	55	57	O	%CV
12	60	67	O	apparent
13	69	77	O	clearance
14	79	81	O	was
15	83	86	O	3902
16	89	92	O	18.0
17	95	96	O	mL
18	97	97	O	/
19	98	100	O	min
NULL

Latuda	3714	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	18
Drug Interaction Studies: Effects of other drugs on the exposure of asenapine are summarized in Figure 1.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	23	O	Studies
4	24	24	O	:
5	26	32	O	Effects
6	34	35	O	of
7	37	41	O	other
8	43	47	O	drugs
9	49	50	O	on
10	52	54	O	the
11	56	63	O	exposure
12	65	66	O	of
13	68	76	O	asenapine
14	78	80	O	are
15	82	91	O	summarized
16	93	94	O	in
17	96	101	O	Figure
18	103	103	O	1
NULL

Latuda	3715	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	34
A population PK analyses concluded that coadministration of lithium 300-2400 mg/day or valproate 300-2000 mg/day with lurasidone for up to 6 weeks has minimal effect on lurasidone exposure.
1	0	0	O	A
2	2	11	O	population
3	13	14	O	PK
4	16	23	O	analyses
5	25	33	O	concluded
6	35	38	O	that
7	40	55	O	coadministration
8	57	58	O	of
9	60	66	O	lithium
10	68	70	O	300
11	72	75	O	2400
12	77	78	O	mg
13	79	79	O	/
14	80	82	O	day
15	84	85	O	or
16	87	95	O	valproate
17	97	99	O	300
18	101	104	O	2000
19	106	107	O	mg
20	108	108	O	/
21	109	111	O	day
22	113	116	O	with
23	118	127	O	XXXXXXXX
24	129	131	O	for
25	133	134	O	up
26	136	137	O	to
27	139	139	O	6
28	141	145	O	weeks
29	147	149	O	has
30	151	157	O	minimal
31	159	164	O	effect
32	166	167	O	on
33	169	178	O	XXXXXXXX
34	180	187	O	exposure
NULL

Latuda	3716	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	15
And the effects of Latuda on the exposures of other drugs are summarized in Figure2.
1	0	2	O	And
2	4	6	O	the
3	8	14	O	effects
4	16	17	O	of
5	19	24	O	XXXXXXXX
6	26	27	O	on
7	29	31	O	the
8	33	41	O	exposures
9	43	44	O	of
10	46	50	O	other
11	52	56	O	drugs
12	58	60	O	are
13	62	71	O	summarized
14	73	74	O	in
15	76	82	O	Figure2
NULL

Latuda	3717	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	35
A population PK analyses concluded that coadministration of lurasidone has minimal effect on lithium and valproate exposure when it is coadministered with lithium 300-2400 mg/day or valproate 300-2000 mg/day.
1	0	0	O	A
2	2	11	O	population
3	13	14	O	PK
4	16	23	O	analyses
5	25	33	O	concluded
6	35	38	O	that
7	40	55	O	coadministration
8	57	58	O	of
9	60	69	O	XXXXXXXX
10	71	73	O	has
11	75	81	O	minimal
12	83	88	O	effect
13	90	91	O	on
14	93	99	O	lithium
15	101	103	O	and
16	105	113	O	valproate
17	115	122	O	exposure
18	124	127	O	when
19	129	130	O	it
20	132	133	O	is
21	135	148	O	coadministered
22	150	153	O	with
23	155	161	O	lithium
24	163	165	O	300
25	167	170	O	2400
26	172	173	O	mg
27	174	174	O	/
28	175	177	O	day
29	179	180	O	or
30	182	190	O	valproate
31	192	194	O	300
32	196	199	O	2000
33	201	202	O	mg
34	203	203	O	/
35	204	206	O	day
NULL

Latuda	3718	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	9
Figure1: Impact of Other Drugs on LATUDA Pharmacokinetics
1	0	6	O	Figure1
2	7	7	O	:
3	9	14	O	Impact
4	16	17	O	of
5	19	23	O	Other
6	25	29	O	Drugs
7	31	32	O	on
8	34	39	O	XXXXXXXX
9	41	56	O	Pharmacokinetics
NULL

Latuda	3719	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	44
Pediatric Patients LATUDA exposure (i.e., steady-state Cmax and AUC) in children and adolescent patients (10 to 17 years of age) was generally similar to that in adults across the dose range from 40 to 160 mg, without adjusting for body weight.
1	0	8	O	Pediatric
2	10	17	O	Patients
3	19	24	O	XXXXXXXX
4	26	33	O	exposure
5	36	38	O	i.e
6	40	40	O	,
7	42	47	O	steady
8	49	53	O	state
9	55	58	O	Cmax
10	60	62	O	and
11	64	66	O	AUC
12	69	70	O	in
13	72	79	O	children
14	81	83	O	and
15	85	94	O	adolescent
16	96	103	O	patients
17	106	107	O	10
18	109	110	O	to
19	112	113	O	17
20	115	119	O	years
21	121	122	O	of
22	124	126	O	age
23	129	131	O	was
24	133	141	O	generally
25	143	149	O	similar
26	151	152	O	to
27	154	157	O	that
28	159	160	O	in
29	162	167	O	adults
30	169	174	O	across
31	176	178	O	the
32	180	183	O	dose
33	185	189	O	range
34	191	194	O	from
35	196	197	O	40
36	199	200	O	to
37	202	204	O	160
38	206	207	O	mg
39	208	208	O	,
40	210	216	O	without
41	218	226	O	adjusting
42	228	230	O	for
43	232	235	O	body
44	237	242	O	weight
NULL

Latuda	3720	34090-1	afad3051-9df2-4c54-9684-e8262a133af8	11
Figure 3: Impact of Other Patient Factors on Latuda Pharmacokinetics
1	0	5	O	Figure
2	7	7	O	3
3	8	8	O	:
4	10	15	O	Impact
5	17	18	O	of
6	20	24	O	Other
7	26	32	O	Patient
8	34	40	O	Factors
9	42	43	O	on
10	45	50	O	XXXXXXXX
11	52	67	O	Pharmacokinetics
NULL

Lipitor	3069	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	41
The risk of myopathy during treatment with statins is increased with concurrent administration of fibric acid derivatives, lipid-modifying doses of niacin, cyclosporine, or strong CYP 3A4 inhibitors (e.g., clarithromycin, HIV protease inhibitors, and itraconazole).
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	U-EFF	myopathy
5	21	26	O	during
6	28	36	O	treatment
7	38	41	O	with
8	43	49	O	statins
9	51	52	O	is
10	54	62	O	increased
11	64	67	O	with
12	69	78	O	concurrent
13	80	93	O	administration
14	95	96	O	of
15	98	103	B-DYN	fibric
16	105	108	I-DYN	acid
17	110	120	L-DYN	derivatives
18	121	121	O	,
19	123	127	O	lipid
20	129	137	O	modifying
21	139	143	O	doses
22	145	146	O	of
23	148	153	U-DYN	niacin
24	154	154	O	,
25	156	167	U-DYN	cyclosporine
26	168	168	O	,
27	170	171	O	or
28	173	178	B-DYN	strong
29	180	182	I-DYN	CYP
30	184	186	I-DYN	3A4
31	188	197	L-DYN	inhibitors
32	200	202	O	e.g
33	204	204	O	,
34	206	219	U-DYN	clarithromycin
35	220	220	O	,
36	222	224	B-DYN	HIV
37	226	233	I-DYN	protease
38	235	244	L-DYN	inhibitors
39	245	245	O	,
40	247	249	O	and
41	251	262	U-DYN	itraconazole
D/15:4:1 D/23:4:1 D/25:4:1 D/28:4:1 D/34:4:1 D/36:4:1 D/41:4:1

Lipitor	3070	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	119
Drug Interactions Associated with Increased Risk of Myopathy/Rhabdomyolysis (2.6, 5.1, 7, 12.3) Interacting Agents Prescribing Recommendations Cyclosporine, HIV protease inhibitors (tipranavir plus ritonavir), hepatitis C protease inhibitor (telaprevir) Avoid atorvastatin HIV protease inhibitor (lopinavir plus ritonavir) Use with caution and lowest dose necessary Clarithromycin, itraconazole, HIV protease inhibitors (saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, fosamprenavir plus ritonavir) Do not exceed 20 mg atorvastatin daily HIV protease inhibitor (nelfinavir)Hepatitis C protease inhibitor (boceprevir) Do not exceed 40 mg atorvastatin daily Other Lipid-Lowering Medications: Use with fibrate products or lipid-modifying doses (>1 g/day) of niacin increases the risk of adverse skeletal muscle effects.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	27	O	Associated
4	29	32	O	with
5	34	42	O	Increased
6	44	47	O	Risk
7	49	50	O	of
8	52	59	B-EFF	Myopathy
9	60	60	I-EFF	/
10	61	74	L-EFF	Rhabdomyolysis
11	77	79	O	2.6
12	80	80	O	,
13	82	84	O	5.1
14	85	85	O	,
15	87	87	O	7
16	88	88	O	,
17	90	93	O	12.3
18	96	106	O	Interacting
19	108	113	O	Agents
20	115	125	O	Prescribing
21	127	141	O	Recommendations
22	143	154	U-DYN	Cyclosporine
23	155	155	O	,
24	157	159	B-DYN	HIV
25	161	168	I-DYN	protease
26	170	179	L-DYN	inhibitors
27	182	191	U-DYN	tipranavir
28	193	196	B-DYN	plus
29	198	206	L-DYN	ritonavir
30	208	208	O	,
31	210	218	B-DYN	hepatitis
32	220	220	I-DYN	C
33	222	229	I-DYN	protease
34	231	239	L-DYN	inhibitor
35	242	251	U-DYN	telaprevir
36	254	258	O	Avoid
37	260	271	O	XXXXXXXX
38	273	275	O	HIV
39	277	284	O	protease
40	286	294	O	inhibitor
41	297	305	U-DYN	lopinavir
42	307	310	B-DYN	plus
43	312	320	L-DYN	ritonavir
44	323	325	O	Use
45	327	330	O	with
46	332	338	O	caution
47	340	342	O	and
48	344	349	O	lowest
49	351	354	O	dose
50	356	364	O	necessary
51	366	379	U-DYN	Clarithromycin
52	380	380	O	,
53	382	393	U-DYN	itraconazole
54	394	394	O	,
55	396	398	O	HIV
56	400	407	O	protease
57	409	418	O	inhibitors
58	421	430	B-DYN	saquinavir
59	432	435	I-DYN	plus
60	437	445	L-DYN	ritonavir
61	446	446	O	,
62	448	456	U-DYN	darunavir
63	458	461	B-DYN	plus
64	463	471	L-DYN	ritonavir
65	472	472	O	,
66	474	486	U-DYN	fosamprenavir
67	487	487	O	,
68	489	501	B-DYN	fosamprenavir
69	503	506	I-DYN	plus
70	508	516	L-DYN	ritonavir
71	519	520	O	Do
72	522	524	O	not
73	526	531	O	exceed
74	533	534	O	20
75	536	537	O	mg
76	539	550	O	XXXXXXXX
77	552	556	O	daily
78	558	560	O	HIV
79	562	569	O	protease
80	571	579	O	inhibitor
81	582	601	O	nelfinavir)Hepatitis
82	603	603	O	C
83	605	612	O	protease
84	614	622	O	inhibitor
85	625	634	U-DYN	boceprevir
86	637	638	O	Do
87	640	642	O	not
88	644	649	O	exceed
89	651	652	O	40
90	654	655	O	mg
91	657	668	O	XXXXXXXX
92	670	674	O	daily
93	676	680	O	Other
94	682	686	B-DYN	Lipid
95	688	695	I-DYN	Lowering
96	697	707	L-DYN	Medications
97	708	708	O	:
98	710	712	O	Use
99	714	717	O	with
100	719	725	B-DYN	fibrate
101	727	734	L-DYN	products
102	736	737	O	or
103	739	743	O	lipid
104	745	753	O	modifying
105	755	759	O	doses
106	762	763	O	>1
107	765	765	O	g
108	766	766	O	/
109	767	769	O	day
110	772	773	O	of
111	775	780	U-DYN	niacin
112	782	790	O	increases
113	792	794	O	the
114	796	799	O	risk
115	801	802	O	of
116	804	810	B-EFF	adverse
117	812	819	I-EFF	skeletal
118	821	826	I-EFF	muscle
119	828	834	L-EFF	effects
D/100:116:1 D/100:8:0 D/111:116:1 D/111:8:0 D/22:116:0 D/22:8:1 D/24:116:0 D/24:8:1 D/27:116:0 D/27:8:1 D/28:116:0 D/28:8:1 D/31:116:0 D/31:8:1 D/35:116:0 D/35:8:1 D/41:116:0 D/41:8:1 D/42:116:0 D/42:8:1 D/51:116:0 D/51:8:1 D/53:116:0 D/53:8:1 D/58:116:0 D/58:8:1 D/62:116:0 D/62:8:1 D/63:116:0 D/63:8:1 D/66:116:0 D/66:8:1 D/68:116:0 D/68:8:1 D/85:116:0 D/85:8:1 D/94:116:1 D/94:8:0

Lipitor	3071	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	9
Caution should be used when prescribing with LIPITOR (7).
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	38	O	prescribing
7	40	43	O	with
8	45	51	O	XXXXXXXX
9	54	54	O	7
NULL

Lipitor	3072	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	8
Digoxin: Patients should be monitored appropriately (7.8).
1	0	6	U-UNK	Digoxin
2	7	7	O	:
3	9	16	O	Patients
4	18	23	B-TRI	should
5	25	26	I-TRI	be
6	28	36	L-TRI	monitored
7	38	50	O	appropriately
8	53	55	O	7.8
NULL

Lipitor	3073	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	13
Oral Contraceptives: Values for norethindrone and ethinyl estradiol may be increased (7.9).
1	0	3	B-KIN	Oral
2	5	18	L-KIN	Contraceptives
3	19	19	O	:
4	21	26	O	Values
5	28	30	O	for
6	32	44	U-KIN	norethindrone
7	46	48	O	and
8	50	56	B-KIN	ethinyl
9	58	66	L-KIN	estradiol
10	68	70	O	may
11	72	73	O	be
12	75	83	O	increased
13	86	88	O	7.9
K/1:C54357 K/6:C54357 K/8:C54357

Lipitor	3074	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	9
Rifampin should be simultaneously co-administered with LIPITOR (7.7).
1	0	7	O	Rifampin
2	9	14	O	should
3	16	17	O	be
4	19	32	O	simultaneously
5	34	35	O	co
6	37	48	O	administered
7	50	53	O	with
8	55	61	O	XXXXXXXX
9	64	66	O	7.7
NULL

Lipitor	3075	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	7
LIPITOR is metabolized by cytochrome P450 3A4.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	21	O	metabolized
4	23	24	O	by
5	26	35	O	cytochrome
6	37	40	O	P450
7	42	44	O	3A4
NULL

Lipitor	3076	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	19
Concomitant administration of LIPITOR with strong inhibitors of CYP 3A4 can lead to increases in plasma concentrations of atorvastatin.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	41	O	with
6	43	48	B-KIN	strong
7	50	59	I-KIN	inhibitors
8	61	62	I-KIN	of
9	64	66	I-KIN	CYP
10	68	70	L-KIN	3A4
11	72	74	O	can
12	76	79	O	lead
13	81	82	O	to
14	84	92	B-TRI	increases
15	94	95	I-TRI	in
16	97	102	I-TRI	plasma
17	104	117	L-TRI	concentrations
18	119	120	O	of
19	122	133	O	XXXXXXXX
K/6:C54355

Lipitor	3077	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	17
The extent of interaction and potentiation of effects depend on the variability of effect on CYP 3A4.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	of
4	14	24	O	interaction
5	26	28	O	and
6	30	41	O	potentiation
7	43	44	O	of
8	46	52	O	effects
9	54	59	O	depend
10	61	62	O	on
11	64	66	O	the
12	68	78	O	variability
13	80	81	O	of
14	83	88	O	effect
15	90	91	O	on
16	93	95	O	CYP
17	97	99	O	3A4
NULL

Lipitor	3078	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	25
Clarithromycin Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 80 mg with clarithromycin (500 mg twice daily) compared to that of LIPITOR alone.
1	0	13	O	Clarithromycin
2	15	26	O	XXXXXXXX
3	28	30	O	AUC
4	32	34	O	was
5	36	48	O	significantly
6	50	58	O	increased
7	60	63	O	with
8	65	75	O	concomitant
9	77	90	O	administration
10	92	93	O	of
11	95	101	O	XXXXXXXX
12	103	104	O	80
13	106	107	O	mg
14	109	112	O	with
15	114	127	U-KIN	clarithromycin
16	130	132	O	500
17	134	135	O	mg
18	137	141	O	twice
19	143	147	O	daily
20	150	157	O	compared
21	159	160	O	to
22	162	165	O	that
23	167	168	O	of
24	170	176	O	XXXXXXXX
25	178	182	O	alone
K/15:C54605

Lipitor	3079	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
Therefore, in patients taking clarithromycin, caution should be used when the LIPITOR dose exceeds 20 mg.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	43	U-KIN	clarithromycin
7	44	44	O	,
8	46	52	O	caution
9	54	59	O	should
10	61	62	O	be
11	64	67	O	used
12	69	72	O	when
13	74	76	O	the
14	78	84	O	XXXXXXXX
15	86	89	O	dose
16	91	97	O	exceeds
17	99	100	O	20
18	102	103	O	mg
K/6:C54355

Lipitor	3080	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	40
Combination of Protease Inhibitors: Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR with several combinations of HIV protease inhibitors, as well as with the hepatitis C protease inhibitor telaprevir, compared to that of LIPITOR alone.
1	0	10	B-KIN	Combination
2	12	13	I-KIN	of
3	15	22	I-KIN	Protease
4	24	33	L-KIN	Inhibitors
5	34	34	O	:
6	36	47	O	XXXXXXXX
7	49	51	O	AUC
8	53	55	O	was
9	57	69	O	significantly
10	71	79	O	increased
11	81	84	O	with
12	86	96	O	concomitant
13	98	111	O	administration
14	113	114	O	of
15	116	122	O	XXXXXXXX
16	124	127	O	with
17	129	135	O	several
18	137	148	B-KIN	combinations
19	150	151	I-KIN	of
20	153	155	I-KIN	HIV
21	157	164	I-KIN	protease
22	166	175	L-KIN	inhibitors
23	176	176	O	,
24	178	179	O	as
25	181	184	O	well
26	186	187	O	as
27	189	192	O	with
28	194	196	O	the
29	198	206	B-KIN	hepatitis
30	208	208	I-KIN	C
31	210	217	I-KIN	protease
32	219	227	I-KIN	inhibitor
33	229	238	L-KIN	telaprevir
34	239	239	O	,
35	241	248	O	compared
36	250	251	O	to
37	253	256	O	that
38	258	259	O	of
39	261	267	O	XXXXXXXX
40	269	273	O	alone
K/1:C54605 K/18:C54605 K/29:C54605

Lipitor	3081	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	28
Therefore, in patients taking the HIV protease inhibitor tipranavir plus ritonavir, or the hepatitis C protease inhibitor telaprevir, concomitant use of LIPITOR should be avoided.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	32	O	the
7	34	36	B-UNK	HIV
8	38	45	I-UNK	protease
9	47	55	I-UNK	inhibitor
10	57	66	I-UNK	tipranavir
11	68	71	I-UNK	plus
12	73	81	L-UNK	ritonavir
13	82	82	O	,
14	84	85	O	or
15	87	89	O	the
16	91	99	B-UNK	hepatitis
17	101	101	I-UNK	C
18	103	110	I-UNK	protease
19	112	120	I-UNK	inhibitor
20	122	131	L-UNK	telaprevir
21	132	132	O	,
22	134	144	O	concomitant
23	146	148	O	use
24	150	151	O	of
25	153	159	O	XXXXXXXX
26	161	166	B-TRI	should
27	168	169	I-TRI	be
28	171	177	L-TRI	avoided
NULL

Lipitor	3082	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	26
In patients taking the HIV protease inhibitor lopinavir plus ritonavir, caution should be used when prescribing LIPITOR and the lowest dose necessary should be used.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	21	O	the
5	23	25	B-KIN	HIV
6	27	34	I-KIN	protease
7	36	44	I-KIN	inhibitor
8	46	54	I-KIN	lopinavir
9	56	59	I-KIN	plus
10	61	69	L-KIN	ritonavir
11	70	70	O	,
12	72	78	O	caution
13	80	85	O	should
14	87	88	O	be
15	90	93	O	used
16	95	98	O	when
17	100	110	O	prescribing
18	112	118	O	XXXXXXXX
19	120	122	O	and
20	124	126	O	the
21	128	133	B-TRI	lowest
22	135	138	I-TRI	dose
23	140	148	L-TRI	necessary
24	150	155	O	should
25	157	158	O	be
26	160	163	O	used
K/5:C54355

Lipitor	3083	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	37
In patients taking the HIV protease inhibitors saquinavir plus ritonavir, darunavir plus ritonavir, fosamprenavir, or fosamprenavir plus ritonavir, the dose of LIPITOR should not exceed 20 mg and should be used with caution.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	21	O	the
5	23	25	B-KIN	HIV
6	27	34	I-KIN	protease
7	36	45	L-KIN	inhibitors
8	47	56	U-KIN	saquinavir
9	58	61	B-KIN	plus
10	63	71	L-KIN	ritonavir
11	72	72	O	,
12	74	82	U-KIN	darunavir
13	84	87	O	plus
14	89	97	O	ritonavir
15	98	98	O	,
16	100	112	U-KIN	fosamprenavir
17	113	113	O	,
18	115	116	O	or
19	118	130	O	fosamprenavir
20	132	135	O	plus
21	137	145	O	ritonavir
22	146	146	O	,
23	148	150	O	the
24	152	155	O	dose
25	157	158	O	of
26	160	166	O	XXXXXXXX
27	168	173	O	should
28	175	177	O	not
29	179	184	O	exceed
30	186	187	O	20
31	189	190	O	mg
32	192	194	O	and
33	196	201	O	should
34	203	204	O	be
35	206	209	O	used
36	211	214	O	with
37	216	222	O	caution
K/12:C54355 K/16:C54355 K/5:C54355 K/8:C54355 K/9:C54355

Lipitor	3084	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	31
In patients taking the HIV protease inhibitor nelfinavir or the hepatitis C protease inhibitor boceprevir, the dose of LIPITOR should not exceed 40 mg and close clinical monitoring is recommended.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	21	O	the
5	23	25	B-KIN	HIV
6	27	34	I-KIN	protease
7	36	44	I-KIN	inhibitor
8	46	55	L-KIN	nelfinavir
9	57	58	O	or
10	60	62	O	the
11	64	72	B-KIN	hepatitis
12	74	74	I-KIN	C
13	76	83	I-KIN	protease
14	85	93	I-KIN	inhibitor
15	95	104	L-KIN	boceprevir
16	105	105	O	,
17	107	109	O	the
18	111	114	O	dose
19	116	117	O	of
20	119	125	O	XXXXXXXX
21	127	132	O	should
22	134	136	O	not
23	138	143	O	exceed
24	145	146	O	40
25	148	149	O	mg
26	151	153	O	and
27	155	159	O	close
28	161	168	O	clinical
29	170	179	O	monitoring
30	181	182	O	is
31	184	194	O	recommended
K/11:C54355 K/5:C54355

Lipitor	3085	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	17
Itraconazole Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 40 mg and itraconazole 200 mg.
1	0	11	O	Itraconazole
2	13	24	O	XXXXXXXX
3	26	28	O	AUC
4	30	32	O	was
5	34	46	O	significantly
6	48	56	O	increased
7	58	61	O	with
8	63	73	O	concomitant
9	75	88	O	administration
10	90	91	O	of
11	93	99	O	XXXXXXXX
12	101	102	O	40
13	104	105	O	mg
14	107	109	O	and
15	111	122	U-KIN	itraconazole
16	124	126	O	200
17	128	129	O	mg
K/15:C54605

Lipitor	3086	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
Therefore, in patients taking itraconazole, caution should be used when the LIPITOR dose exceeds 20 mg.
1	0	8	O	Therefore
2	9	9	O	,
3	11	12	O	in
4	14	21	O	patients
5	23	28	O	taking
6	30	41	U-KIN	itraconazole
7	42	42	O	,
8	44	50	O	caution
9	52	57	O	should
10	59	60	O	be
11	62	65	O	used
12	67	70	O	when
13	72	74	O	the
14	76	82	O	XXXXXXXX
15	84	87	O	dose
16	89	95	O	exceeds
17	97	98	O	20
18	100	101	O	mg
K/6:C54355

Lipitor	3087	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	27
Contains one or more components that inhibit CYP 3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day).
1	0	7	O	Contains
2	9	11	O	one
3	13	14	O	or
4	16	19	O	more
5	21	30	O	components
6	32	35	O	that
7	37	43	O	inhibit
8	45	47	O	CYP
9	49	51	O	3A4
10	53	55	O	and
11	57	59	O	can
12	61	68	B-TRI	increase
13	70	75	I-TRI	plasma
14	77	90	L-TRI	concentrations
15	92	93	O	of
16	95	106	O	XXXXXXXX
17	107	107	O	,
18	109	118	O	especially
19	120	123	O	with
20	125	133	O	excessive
21	135	144	B-KIN	grapefruit
22	146	150	L-KIN	juice
23	152	162	O	consumption
24	165	168	O	>1.2
25	170	175	O	liters
26	177	179	O	per
27	181	183	O	day
K/21:C54355

Lipitor	3088	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	10
Atorvastatin and atorvastatin-metabolites are substrates of the OATP1B1 transporter.
1	0	11	O	XXXXXXXX
2	13	15	O	and
3	17	28	O	XXXXXXXX
4	30	40	O	metabolites
5	42	44	O	are
6	46	55	O	substrates
7	57	58	O	of
8	60	62	O	the
9	64	70	O	OATP1B1
10	72	82	O	transporter
NULL

Lipitor	3089	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	13
Inhibitors of the OATP1B1 (e.g., cyclosporine) can increase the bioavailability of atorvastatin.
1	0	9	B-KIN	Inhibitors
2	11	12	I-KIN	of
3	14	16	I-KIN	the
4	18	24	L-KIN	OATP1B1
5	27	29	O	e.g
6	31	31	O	,
7	33	44	U-KIN	cyclosporine
8	47	49	O	can
9	51	58	B-TRI	increase
10	60	62	I-TRI	the
11	64	78	L-TRI	bioavailability
12	80	81	O	of
13	83	94	O	XXXXXXXX
K/1:C54355 K/7:C54355

Lipitor	3090	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	26
Atorvastatin AUC was significantly increased with concomitant administration of LIPITOR 10 mg and cyclosporine 5.2 mg/kg/day compared to that of LIPITOR alone.
1	0	11	O	XXXXXXXX
2	13	15	O	AUC
3	17	19	O	was
4	21	33	O	significantly
5	35	43	O	increased
6	45	48	O	with
7	50	60	O	concomitant
8	62	75	O	administration
9	77	78	O	of
10	80	86	O	XXXXXXXX
11	88	89	O	10
12	91	92	O	mg
13	94	96	O	and
14	98	109	U-KIN	cyclosporine
15	111	113	O	5.2
16	115	116	O	mg
17	117	117	O	/
18	118	119	O	kg
19	120	120	O	/
20	121	123	O	day
21	125	132	O	compared
22	134	135	O	to
23	137	140	O	that
24	142	143	O	of
25	145	151	O	XXXXXXXX
26	153	157	O	alone
K/14:C54605

Lipitor	3091	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	10
The co-administration of LIPITOR with cyclosporine should be avoided.
1	0	2	O	The
2	4	5	O	co
3	7	20	O	administration
4	22	23	O	of
5	25	31	O	XXXXXXXX
6	33	36	O	with
7	38	49	U-UNK	cyclosporine
8	51	56	B-TRI	should
9	58	59	I-TRI	be
10	61	67	L-TRI	avoided
NULL

Lipitor	3092	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	29
Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are co-administered with gemfibrozil, concomitant administration of LIPITOR with gemfibrozil should be avoided.
1	0	2	O	Due
2	4	5	O	to
3	7	8	O	an
4	10	18	O	increased
5	20	23	O	risk
6	25	26	O	of
7	28	35	B-EFF	myopathy
8	36	36	I-EFF	/
9	37	50	L-EFF	rhabdomyolysis
10	52	55	O	when
11	57	59	O	HMG
12	61	63	O	CoA
13	65	73	O	reductase
14	75	84	O	inhibitors
15	86	88	O	are
16	90	91	O	co
17	93	104	O	administered
18	106	109	O	with
19	111	121	U-DYN	gemfibrozil
20	122	122	O	,
21	124	134	O	concomitant
22	136	149	O	administration
23	151	152	O	of
24	154	160	O	XXXXXXXX
25	162	165	O	with
26	167	177	O	gemfibrozil
27	179	184	O	should
28	186	187	O	be
29	189	195	O	avoided
D/19:7:1

Lipitor	3093	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	37
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIPITOR should be administered with caution when used concomitantly with other fibrates.
1	0	6	O	Because
2	8	9	O	it
3	11	12	O	is
4	14	18	O	known
5	20	23	O	that
6	25	27	O	the
7	29	32	O	risk
8	34	35	O	of
9	37	44	U-EFF	myopathy
10	46	51	O	during
11	53	61	O	treatment
12	63	66	O	with
13	68	70	O	HMG
14	72	74	O	CoA
15	76	84	O	reductase
16	86	95	O	inhibitors
17	97	98	O	is
18	100	108	O	increased
19	110	113	O	with
20	115	124	O	concurrent
21	126	139	O	administration
22	141	142	O	of
23	144	148	O	other
24	150	157	U-DYN	fibrates
25	158	158	O	,
26	160	166	O	XXXXXXXX
27	168	173	O	should
28	175	176	O	be
29	178	189	O	administered
30	191	194	O	with
31	196	202	O	caution
32	204	207	O	when
33	209	212	O	used
34	214	226	O	concomitantly
35	228	231	O	with
36	233	237	O	other
37	239	246	O	fibrates
D/24:9:1

Lipitor	3094	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	28
The risk of skeletal muscle effects may be enhanced when LIPITOR is used in combination with niacin; a reduction in LIPITOR dosage should be considered in this setting.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	skeletal
5	21	26	I-EFF	muscle
6	28	34	L-EFF	effects
7	36	38	O	may
8	40	41	O	be
9	43	50	O	enhanced
10	52	55	O	when
11	57	63	O	XXXXXXXX
12	65	66	O	is
13	68	71	O	used
14	73	74	O	in
15	76	86	O	combination
16	88	91	O	with
17	93	98	U-DYN	niacin
18	101	101	O	a
19	103	111	O	reduction
20	113	114	O	in
21	116	122	O	XXXXXXXX
22	124	129	O	dosage
23	131	136	O	should
24	138	139	O	be
25	141	150	O	considered
26	152	153	O	in
27	155	158	O	this
28	160	166	O	setting
D/17:4:1

Lipitor	3095	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	25
Concomitant administration of LIPITOR with inducers of cytochrome P450 3A4 (e.g., efavirenz, rifampin) can lead to variable reductions in plasma concentrations of atorvastatin.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	XXXXXXXX
5	38	41	O	with
6	43	50	B-KIN	inducers
7	52	53	I-KIN	of
8	55	64	I-KIN	cytochrome
9	66	69	I-KIN	P450
10	71	73	L-KIN	3A4
11	76	78	O	e.g
12	80	80	O	,
13	82	90	U-KIN	efavirenz
14	91	91	O	,
15	93	100	U-KIN	rifampin
16	103	105	O	can
17	107	110	O	lead
18	112	113	O	to
19	115	122	O	variable
20	124	133	B-TRI	reductions
21	135	136	I-TRI	in
22	138	143	I-TRI	plasma
23	145	158	L-TRI	concentrations
24	160	161	O	of
25	163	174	O	XXXXXXXX
K/13:C54356 K/15:C54356 K/6:C54356

Lipitor	3096	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	39
Due to the dual interaction mechanism of rifampin, simultaneous co-administration of LIPITOR with rifampin is recommended, as delayed administration of LIPITOR after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	14	O	dual
5	16	26	O	interaction
6	28	36	O	mechanism
7	38	39	O	of
8	41	48	U-KIN	rifampin
9	49	49	O	,
10	51	62	O	simultaneous
11	64	65	O	co
12	67	80	O	administration
13	82	83	O	of
14	85	91	O	XXXXXXXX
15	93	96	O	with
16	98	105	O	rifampin
17	107	108	O	is
18	110	120	O	recommended
19	121	121	O	,
20	123	124	O	as
21	126	132	O	delayed
22	134	147	O	administration
23	149	150	O	of
24	152	158	O	XXXXXXXX
25	160	164	O	after
26	166	179	O	administration
27	181	182	O	of
28	184	191	O	rifampin
29	193	195	O	has
30	197	200	O	been
31	202	211	O	associated
32	213	216	O	with
33	218	218	O	a
34	220	230	O	significant
35	232	240	O	reduction
36	242	243	O	in
37	245	256	O	XXXXXXXX
38	258	263	O	plasma
39	265	278	O	concentrations
K/8:C54356

Lipitor	3097	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	20
When multiple doses of LIPITOR and digoxin were co-administered, steady state plasma digoxin concentrations increased by approximately 20%.
1	0	3	O	When
2	5	12	O	multiple
3	14	18	O	doses
4	20	21	O	of
5	23	29	O	XXXXXXXX
6	31	33	O	and
7	35	41	U-KIN	digoxin
8	43	46	O	were
9	48	49	O	co
10	51	62	O	administered
11	63	63	O	,
12	65	70	O	steady
13	72	76	O	state
14	78	83	O	plasma
15	85	91	O	digoxin
16	93	106	O	concentrations
17	108	116	O	increased
18	118	119	O	by
19	121	133	O	approximately
20	135	137	O	20%
K/7:C54357

Lipitor	3098	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	7
Patients taking digoxin should be monitored appropriately.
1	0	7	O	Patients
2	9	14	O	taking
3	16	22	U-UNK	digoxin
4	24	29	B-TRI	should
5	31	32	I-TRI	be
6	34	42	L-TRI	monitored
7	44	56	O	appropriately
NULL

Lipitor	3099	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	16
Co-administration of LIPITOR and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	27	O	XXXXXXXX
5	29	31	O	and
6	33	34	O	an
7	36	39	B-KIN	oral
8	41	53	L-KIN	contraceptive
9	55	63	B-TRI	increased
10	65	67	L-TRI	AUC
11	69	74	O	values
12	76	78	O	for
13	80	92	U-KIN	norethindrone
14	94	96	O	and
15	98	104	B-KIN	ethinyl
16	106	114	L-KIN	estradiol
K/13:C54613 K/15:C54613 K/7:C54613

Lipitor	3100	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
These increases should be considered when selecting an oral contraceptive for a woman taking LIPITOR.
1	0	4	O	These
2	6	14	B-TRI	increases
3	16	21	I-TRI	should
4	23	24	I-TRI	be
5	26	35	L-TRI	considered
6	37	40	O	when
7	42	50	O	selecting
8	52	53	O	an
9	55	58	B-UNK	oral
10	60	72	L-UNK	contraceptive
11	74	76	O	for
12	78	78	O	a
13	80	84	O	woman
14	86	91	O	taking
15	93	99	O	XXXXXXXX
NULL

Lipitor	3101	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	17
LIPITOR had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.
1	0	6	O	XXXXXXXX
2	8	10	O	had
3	12	13	O	no
4	15	24	O	clinically
5	26	36	O	significant
6	38	43	O	effect
7	45	46	O	on
8	48	58	O	prothrombin
9	60	63	O	time
10	65	68	O	when
11	70	81	O	administered
12	83	84	O	to
13	86	93	O	patients
14	95	103	O	receiving
15	105	111	O	chronic
16	113	120	O	warfarin
17	122	130	O	treatment
NULL

Lipitor	3102	34073-7	c6e131fe-e7df-4876-83f7-9156fc4e8228	27
Cases of myopathy, including rhabdomyolysis, have been reported with atorvastatin co-administered with colchicine, and caution should be exercised when prescribing atorvastatin with colchicine.
1	0	4	O	Cases
2	6	7	O	of
3	9	16	U-EFF	myopathy
4	17	17	O	,
5	19	27	O	including
6	29	42	U-EFF	rhabdomyolysis
7	43	43	O	,
8	45	48	O	have
9	50	53	O	been
10	55	62	O	reported
11	64	67	O	with
12	69	80	O	XXXXXXXX
13	82	83	O	co
14	85	96	O	administered
15	98	101	O	with
16	103	112	U-DYN	colchicine
17	113	113	O	,
18	115	117	O	and
19	119	125	O	caution
20	127	132	O	should
21	134	135	O	be
22	137	145	O	exercised
23	147	150	O	when
24	152	162	O	prescribing
25	164	175	O	XXXXXXXX
26	177	180	O	with
27	182	191	O	colchicine
D/16:3:1 D/16:6:1

Lipitor	3103	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	34
LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, a precursor of sterols, including cholesterol.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	11	O	a
4	13	21	O	selective
5	22	22	O	,
6	24	34	O	competitive
7	36	44	O	inhibitor
8	46	47	O	of
9	49	51	O	HMG
10	53	55	O	CoA
11	57	65	O	reductase
12	66	66	O	,
13	68	70	O	the
14	72	75	O	rate
15	77	84	O	limiting
16	86	91	O	enzyme
17	93	96	O	that
18	98	105	O	converts
19	107	107	O	3
20	109	115	O	hydroxy
21	117	117	O	3
22	119	132	O	methylglutaryl
23	134	141	O	coenzyme
24	143	143	O	A
25	145	146	O	to
26	148	157	O	mevalonate
27	158	158	O	,
28	160	160	O	a
29	162	170	O	precursor
30	172	173	O	of
31	175	181	O	sterols
32	182	182	O	,
33	184	192	O	including
34	194	204	O	cholesterol
NULL

Lipitor	3104	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	53
In animal models, LIPITOR lowers plasma cholesterol and lipoprotein levels by inhibiting HMG-CoA reductase and cholesterol synthesis in the liver and by increasing the number of hepatic LDL receptors on the cell surface to enhance uptake and catabolism of LDL; LIPITOR also reduces LDL production and the number of LDL particles.
1	0	1	O	In
2	3	8	O	animal
3	10	15	O	models
4	16	16	O	,
5	18	24	O	XXXXXXXX
6	26	31	O	lowers
7	33	38	O	plasma
8	40	50	O	cholesterol
9	52	54	O	and
10	56	66	O	lipoprotein
11	68	73	O	levels
12	75	76	O	by
13	78	87	O	inhibiting
14	89	91	O	HMG
15	93	95	O	CoA
16	97	105	O	reductase
17	107	109	O	and
18	111	121	O	cholesterol
19	123	131	O	synthesis
20	133	134	O	in
21	136	138	O	the
22	140	144	O	liver
23	146	148	O	and
24	150	151	O	by
25	153	162	O	increasing
26	164	166	O	the
27	168	173	O	number
28	175	176	O	of
29	178	184	O	hepatic
30	186	188	O	LDL
31	190	198	O	receptors
32	200	201	O	on
33	203	205	O	the
34	207	210	O	cell
35	212	218	O	surface
36	220	221	O	to
37	223	229	O	enhance
38	231	236	O	uptake
39	238	240	O	and
40	242	251	O	catabolism
41	253	254	O	of
42	256	258	O	LDL
43	261	267	O	XXXXXXXX
44	269	272	O	also
45	274	280	O	reduces
46	282	284	O	LDL
47	286	295	O	production
48	297	299	O	and
49	301	303	O	the
50	305	310	O	number
51	312	313	O	of
52	315	317	O	LDL
53	319	327	O	particles
NULL

Lipitor	3105	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
LIPITOR, as well as some of its metabolites, are pharmacologically active in humans.
1	0	6	O	XXXXXXXX
2	7	7	O	,
3	9	10	O	as
4	12	15	O	well
5	17	18	O	as
6	20	23	O	some
7	25	26	O	of
8	28	30	O	its
9	32	42	O	metabolites
10	43	43	O	,
11	45	47	O	are
12	49	65	O	pharmacologically
13	67	72	O	active
14	74	75	O	in
15	77	82	O	humans
NULL

Lipitor	3106	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
The liver is the primary site of action and the principal site of cholesterol synthesis and LDL clearance.
1	0	2	O	The
2	4	8	O	liver
3	10	11	O	is
4	13	15	O	the
5	17	23	O	primary
6	25	28	O	site
7	30	31	O	of
8	33	38	O	action
9	40	42	O	and
10	44	46	O	the
11	48	56	O	principal
12	58	61	O	site
13	63	64	O	of
14	66	76	O	cholesterol
15	78	86	O	synthesis
16	88	90	O	and
17	92	94	O	LDL
18	96	104	O	clearance
NULL

Lipitor	3107	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
Drug dosage, rather than systemic drug concentration, correlates better with LDL-C reduction.
1	0	3	O	Drug
2	5	10	O	dosage
3	11	11	O	,
4	13	18	O	rather
5	20	23	O	than
6	25	32	O	systemic
7	34	37	O	drug
8	39	51	O	concentration
9	52	52	O	,
10	54	63	O	correlates
11	65	70	O	better
12	72	75	O	with
13	77	79	O	LDL
14	81	81	O	C
15	83	91	O	reduction
NULL

Lipitor	3108	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	10
Individualization of drug dosage should be based on therapeutic response.
1	0	16	O	Individualization
2	18	19	O	of
3	21	24	O	drug
4	26	31	O	dosage
5	33	38	O	should
6	40	41	O	be
7	43	47	O	based
8	49	50	O	on
9	52	62	O	therapeutic
10	64	71	O	response
NULL

Lipitor	3109	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
Absorption: LIPITOR is rapidly absorbed after oral administration; maximum plasma concentrations occur within 1 to 2 hours.
1	0	9	O	Absorption
2	10	10	O	:
3	12	18	O	XXXXXXXX
4	20	21	O	is
5	23	29	O	rapidly
6	31	38	O	absorbed
7	40	44	O	after
8	46	49	O	oral
9	51	64	O	administration
10	67	73	O	maximum
11	75	80	O	plasma
12	82	95	O	concentrations
13	97	101	O	occur
14	103	108	O	within
15	110	110	O	1
16	112	113	O	to
17	115	115	O	2
18	117	121	O	hours
NULL

Lipitor	3110	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	9
Extent of absorption increases in proportion to LIPITOR dose.
1	0	5	O	Extent
2	7	8	O	of
3	10	19	O	absorption
4	21	29	O	increases
5	31	32	O	in
6	34	43	O	proportion
7	45	46	O	to
8	48	54	O	XXXXXXXX
9	56	59	O	dose
NULL

Lipitor	3111	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	23
The absolute bioavailability of atorvastatin (parent drug) is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	43	O	XXXXXXXX
6	46	51	O	parent
7	53	56	O	drug
8	59	60	O	is
9	62	74	O	approximately
10	76	78	O	14%
11	80	82	O	and
12	84	86	O	the
13	88	95	O	systemic
14	97	108	O	availability
15	110	111	O	of
16	113	115	O	HMG
17	117	119	O	CoA
18	121	129	O	reductase
19	131	140	O	inhibitory
20	142	149	O	activity
21	151	152	O	is
22	154	166	O	approximately
23	168	170	O	30%
NULL

Lipitor	3112	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	19
The low systemic availability is attributed to presystemic clearance in gastrointestinal mucosa and/or hepatic first-pass metabolism.
1	0	2	O	The
2	4	6	O	low
3	8	15	O	systemic
4	17	28	O	availability
5	30	31	O	is
6	33	42	O	attributed
7	44	45	O	to
8	47	57	O	presystemic
9	59	67	O	clearance
10	69	70	O	in
11	72	87	O	gastrointestinal
12	89	94	O	mucosa
13	96	98	O	and
14	99	99	O	/
15	100	101	O	or
16	103	109	O	hepatic
17	111	115	O	first
18	117	120	O	pass
19	122	131	O	metabolism
NULL

Lipitor	3113	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	38
Although food decreases the rate and extent of drug absorption by approximately 25% and 9%, respectively, as assessed by Cmax and AUC, LDL-C reduction is similar whether LIPITOR is given with or without food.
1	0	7	O	Although
2	9	12	U-KIN	food
3	14	22	O	decreases
4	24	26	O	the
5	28	31	O	rate
6	33	35	O	and
7	37	42	O	extent
8	44	45	O	of
9	47	50	O	drug
10	52	61	O	absorption
11	63	64	O	by
12	66	78	O	approximately
13	80	82	O	25%
14	84	86	O	and
15	88	89	O	9%
16	90	90	O	,
17	92	103	O	respectively
18	104	104	O	,
19	106	107	O	as
20	109	116	O	assessed
21	118	119	O	by
22	121	124	O	Cmax
23	126	128	O	and
24	130	132	O	AUC
25	133	133	O	,
26	135	137	O	LDL
27	139	139	O	C
28	141	149	O	reduction
29	151	152	O	is
30	154	160	O	similar
31	162	168	O	whether
32	170	176	O	XXXXXXXX
33	178	179	O	is
34	181	185	O	given
35	187	190	O	with
36	192	193	O	or
37	195	201	O	without
38	203	206	O	food
K/2:C54606

Lipitor	3114	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
Plasma LIPITOR concentrations are lower (approximately 30% for Cmax and AUC) following evening drug administration compared with morning.
1	0	5	O	Plasma
2	7	13	O	XXXXXXXX
3	15	28	O	concentrations
4	30	32	O	are
5	34	38	O	lower
6	41	53	O	approximately
7	55	57	O	30%
8	59	61	O	for
9	63	66	O	Cmax
10	68	70	O	and
11	72	74	O	AUC
12	77	85	O	following
13	87	93	O	evening
14	95	98	O	drug
15	100	113	O	administration
16	115	122	O	compared
17	124	127	O	with
18	129	135	O	morning
NULL

Lipitor	3115	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	17
However, LDL-C reduction is the same regardless of the time of day of drug administration.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	LDL
4	13	13	O	C
5	15	23	O	reduction
6	25	26	O	is
7	28	30	O	the
8	32	35	O	same
9	37	46	O	regardless
10	48	49	O	of
11	51	53	O	the
12	55	58	O	time
13	60	61	O	of
14	63	65	O	day
15	67	68	O	of
16	70	73	O	drug
17	75	88	O	administration
NULL

Lipitor	3116	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	12
Distribution: Mean volume of distribution of LIPITOR is approximately 381 liters.
1	0	11	O	Distribution
2	12	12	O	:
3	14	17	O	Mean
4	19	24	O	volume
5	26	27	O	of
6	29	40	O	distribution
7	42	43	O	of
8	45	51	O	XXXXXXXX
9	53	54	O	is
10	56	68	O	approximately
11	70	72	O	381
12	74	79	O	liters
NULL

Lipitor	3117	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	7
LIPITOR is >98% bound to plasma proteins.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	14	O	>98%
4	16	20	O	bound
5	22	23	O	to
6	25	30	O	plasma
7	32	39	O	proteins
NULL

Lipitor	3118	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	16
A blood/plasma ratio of approximately 0.25 indicates poor drug penetration into red blood cells.
1	0	0	O	A
2	2	6	O	blood
3	7	7	O	/
4	8	13	O	plasma
5	15	19	O	ratio
6	21	22	O	of
7	24	36	O	approximately
8	38	41	O	0.25
9	43	51	O	indicates
10	53	56	O	poor
11	58	61	O	drug
12	63	73	O	penetration
13	75	78	O	into
14	80	82	O	red
15	84	88	O	blood
16	90	94	O	cells
NULL

Lipitor	3119	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
Based on observations in rats, LIPITOR is likely to be secreted in human milk.
1	0	4	O	Based
2	6	7	O	on
3	9	20	O	observations
4	22	23	O	in
5	25	28	O	rats
6	29	29	O	,
7	31	37	O	XXXXXXXX
8	39	40	O	is
9	42	47	O	likely
10	49	50	O	to
11	52	53	O	be
12	55	62	O	secreted
13	64	65	O	in
14	67	71	O	human
15	73	76	O	milk
NULL

Lipitor	3120	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	16
Metabolism: LIPITOR is extensively metabolized to ortho- and parahydroxylated derivatives and various beta-oxidation products.
1	0	9	O	Metabolism
2	10	10	O	:
3	12	18	O	XXXXXXXX
4	20	21	O	is
5	23	33	O	extensively
6	35	45	O	metabolized
7	47	48	O	to
8	50	54	O	ortho
9	57	59	O	and
10	61	76	O	parahydroxylated
11	78	88	O	derivatives
12	90	92	O	and
13	94	100	O	various
14	102	105	O	beta
15	107	115	O	oxidation
16	117	124	O	products
NULL

Lipitor	3121	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
In vitro inhibition of HMG-CoA reductase by ortho- and parahydroxylated metabolites is equivalent to that of LIPITOR.
1	0	1	O	In
2	3	7	O	vitro
3	9	18	O	inhibition
4	20	21	O	of
5	23	25	O	HMG
6	27	29	O	CoA
7	31	39	O	reductase
8	41	42	O	by
9	44	48	O	ortho
10	51	53	O	and
11	55	70	O	parahydroxylated
12	72	82	O	metabolites
13	84	85	O	is
14	87	96	O	equivalent
15	98	99	O	to
16	101	104	O	that
17	106	107	O	of
18	109	115	O	XXXXXXXX
NULL

Lipitor	3122	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
Approximately 70% of circulating inhibitory activity for HMG-CoA reductase is attributed to active metabolites.
1	0	12	O	Approximately
2	14	16	O	70%
3	18	19	O	of
4	21	31	O	circulating
5	33	42	O	inhibitory
6	44	51	O	activity
7	53	55	O	for
8	57	59	O	HMG
9	61	63	O	CoA
10	65	73	O	reductase
11	75	76	O	is
12	78	87	O	attributed
13	89	90	O	to
14	92	97	O	active
15	99	109	O	metabolites
NULL

Lipitor	3123	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	35
In vitro studies suggest the importance of LIPITOR metabolism by cytochrome P450 3A4, consistent with increased plasma concentrations of LIPITOR in humans following co-administration with erythromycin, a known inhibitor of this isozyme.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	23	O	suggest
5	25	27	O	the
6	29	38	O	importance
7	40	41	O	of
8	43	49	O	XXXXXXXX
9	51	60	O	metabolism
10	62	63	O	by
11	65	74	O	cytochrome
12	76	79	O	P450
13	81	83	O	3A4
14	84	84	O	,
15	86	95	O	consistent
16	97	100	O	with
17	102	110	B-TRI	increased
18	112	117	I-TRI	plasma
19	119	132	L-TRI	concentrations
20	134	135	O	of
21	137	143	O	XXXXXXXX
22	145	146	O	in
23	148	153	O	humans
24	155	163	O	following
25	165	166	O	co
26	168	181	O	administration
27	183	186	O	with
28	188	199	U-KIN	erythromycin
29	200	200	O	,
30	202	202	O	a
31	204	208	O	known
32	210	218	O	inhibitor
33	220	221	O	of
34	223	226	O	this
35	228	234	O	isozyme
K/28:C54355

Lipitor	3124	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	10
In animals, the ortho-hydroxy metabolite undergoes further glucuronidation.
1	0	1	O	In
2	3	9	O	animals
3	10	10	O	,
4	12	14	O	the
5	16	20	O	ortho
6	22	28	O	hydroxy
7	30	39	O	metabolite
8	41	49	O	undergoes
9	51	57	O	further
10	59	73	O	glucuronidation
NULL

Lipitor	3125	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	30
Excretion: LIPITOR and its metabolites are eliminated primarily in bile following hepatic and/or extra-hepatic metabolism; however, the drug does not appear to undergo enterohepatic recirculation.
1	0	8	O	Excretion
2	9	9	O	:
3	11	17	O	XXXXXXXX
4	19	21	O	and
5	23	25	O	its
6	27	37	O	metabolites
7	39	41	O	are
8	43	52	O	eliminated
9	54	62	O	primarily
10	64	65	O	in
11	67	70	O	bile
12	72	80	O	following
13	82	88	O	hepatic
14	90	92	O	and
15	93	93	O	/
16	94	95	O	or
17	97	101	O	extra
18	103	109	O	hepatic
19	111	120	O	metabolism
20	123	129	O	however
21	130	130	O	,
22	132	134	O	the
23	136	139	O	drug
24	141	144	O	does
25	146	148	O	not
26	150	155	O	appear
27	157	158	O	to
28	160	166	O	undergo
29	168	180	O	enterohepatic
30	182	194	O	recirculation
NULL

Lipitor	3126	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	37
Mean plasma elimination half-life of LIPITOR in humans is approximately 14 hours, but the half-life of inhibitory activity for HMG-CoA reductase is 20 to 30 hours due to the contribution of active metabolites.
1	0	3	O	Mean
2	5	10	O	plasma
3	12	22	O	elimination
4	24	27	O	half
5	29	32	O	life
6	34	35	O	of
7	37	43	O	XXXXXXXX
8	45	46	O	in
9	48	53	O	humans
10	55	56	O	is
11	58	70	O	approximately
12	72	73	O	14
13	75	79	O	hours
14	80	80	O	,
15	82	84	O	but
16	86	88	O	the
17	90	93	O	half
18	95	98	O	life
19	100	101	O	of
20	103	112	O	inhibitory
21	114	121	O	activity
22	123	125	O	for
23	127	129	O	HMG
24	131	133	O	CoA
25	135	143	O	reductase
26	145	146	O	is
27	148	149	O	20
28	151	152	O	to
29	154	155	O	30
30	157	161	O	hours
31	163	165	O	due
32	167	168	O	to
33	170	172	O	the
34	174	185	O	contribution
35	187	188	O	of
36	190	195	O	active
37	197	207	O	metabolites
NULL

Lipitor	3127	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
Less than 2% of a dose of LIPITOR is recovered in urine following oral administration.
1	0	3	O	Less
2	5	8	O	than
3	10	11	O	2%
4	13	14	O	of
5	16	16	O	a
6	18	21	O	dose
7	23	24	O	of
8	26	32	O	XXXXXXXX
9	34	35	O	is
10	37	45	O	recovered
11	47	48	O	in
12	50	54	O	urine
13	56	64	O	following
14	66	69	O	oral
15	71	84	O	administration
NULL

Lipitor	3128	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	29
Specific Populations Geriatric: Plasma concentrations of LIPITOR are higher (approximately 40% for Cmax and 30% for AUC) in healthy elderly subjects (age >65 years) than in young adults.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	29	O	Geriatric
4	30	30	O	:
5	32	37	O	Plasma
6	39	52	O	concentrations
7	54	55	O	of
8	57	63	O	XXXXXXXX
9	65	67	O	are
10	69	74	O	higher
11	77	89	O	approximately
12	91	93	O	40%
13	95	97	O	for
14	99	102	O	Cmax
15	104	106	O	and
16	108	110	O	30%
17	112	114	O	for
18	116	118	O	AUC
19	121	122	O	in
20	124	130	O	healthy
21	132	138	O	elderly
22	140	147	O	subjects
23	150	152	O	age
24	154	156	O	>65
25	158	162	O	years
26	165	168	O	than
27	170	171	O	in
28	173	177	O	young
29	179	184	O	adults
NULL

Lipitor	3129	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	23
Clinical data suggest a greater degree of LDL-lowering at any dose of drug in the elderly patient population compared to younger adults.
1	0	7	O	Clinical
2	9	12	O	data
3	14	20	O	suggest
4	22	22	O	a
5	24	30	O	greater
6	32	37	O	degree
7	39	40	O	of
8	42	44	O	LDL
9	46	53	O	lowering
10	55	56	O	at
11	58	60	O	any
12	62	65	O	dose
13	67	68	O	of
14	70	73	O	drug
15	75	76	O	in
16	78	80	O	the
17	82	88	O	elderly
18	90	96	O	patient
19	98	107	O	population
20	109	116	O	compared
21	118	119	O	to
22	121	127	O	younger
23	129	134	O	adults
NULL

Lipitor	3130	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	60
Pediatric: Apparent oral clearance of atorvastatin in pediatric subjects appeared similar to that of adults when scaled allometrically by body weight as the body weight was the only significant covariate in atorvastatin population PK model with data including pediatric HeFH patients (ages 10 years to 17 years of age, n=29) in an open-label, 8-week study.
1	0	8	O	Pediatric
2	9	9	O	:
3	11	18	O	Apparent
4	20	23	O	oral
5	25	33	O	clearance
6	35	36	O	of
7	38	49	O	XXXXXXXX
8	51	52	O	in
9	54	62	O	pediatric
10	64	71	O	subjects
11	73	80	O	appeared
12	82	88	O	similar
13	90	91	O	to
14	93	96	O	that
15	98	99	O	of
16	101	106	O	adults
17	108	111	O	when
18	113	118	O	scaled
19	120	133	O	allometrically
20	135	136	O	by
21	138	141	O	body
22	143	148	O	weight
23	150	151	O	as
24	153	155	O	the
25	157	160	O	body
26	162	167	O	weight
27	169	171	O	was
28	173	175	O	the
29	177	180	O	only
30	182	192	O	significant
31	194	202	O	covariate
32	204	205	O	in
33	207	218	O	XXXXXXXX
34	220	229	O	population
35	231	232	O	PK
36	234	238	O	model
37	240	243	O	with
38	245	248	O	data
39	250	258	O	including
40	260	268	O	pediatric
41	270	273	O	HeFH
42	275	282	O	patients
43	285	288	O	ages
44	290	291	O	10
45	293	297	O	years
46	299	300	O	to
47	302	303	O	17
48	305	309	O	years
49	311	312	O	of
50	314	316	O	age
51	317	317	O	,
52	319	322	O	n=29
53	325	326	O	in
54	328	329	O	an
55	331	334	O	open
56	336	340	O	label
57	341	341	O	,
58	343	343	O	8
59	345	348	O	week
60	350	354	O	study
NULL

Lipitor	3131	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	41
Gender: Plasma concentrations of LIPITOR in women differ from those in men (approximately 20% higher for Cmax and 10% lower for AUC); however, there is no clinically significant difference in LDL-C reduction with LIPITOR between men and women.
1	0	5	O	Gender
2	6	6	O	:
3	8	13	O	Plasma
4	15	28	O	concentrations
5	30	31	O	of
6	33	39	O	XXXXXXXX
7	41	42	O	in
8	44	48	O	women
9	50	55	O	differ
10	57	60	O	from
11	62	66	O	those
12	68	69	O	in
13	71	73	O	men
14	76	88	O	approximately
15	90	92	O	20%
16	94	99	O	higher
17	101	103	O	for
18	105	108	O	Cmax
19	110	112	O	and
20	114	116	O	10%
21	118	122	O	lower
22	124	126	O	for
23	128	130	O	AUC
24	134	140	O	however
25	141	141	O	,
26	143	147	O	there
27	149	150	O	is
28	152	153	O	no
29	155	164	O	clinically
30	166	176	O	significant
31	178	187	O	difference
32	189	190	O	in
33	192	194	O	LDL
34	196	196	O	C
35	198	206	O	reduction
36	208	211	O	with
37	213	219	O	XXXXXXXX
38	221	227	O	between
39	229	231	O	men
40	233	235	O	and
41	237	241	O	women
NULL

Lipitor	3132	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	30
Renal Impairment: Renal disease has no influence on the plasma concentrations or LDL-C reduction of LIPITOR; thus, dose adjustment in patients with renal dysfunction is not necessary.
1	0	4	O	Renal
2	6	15	O	Impairment
3	16	16	O	:
4	18	22	O	Renal
5	24	30	O	disease
6	32	34	O	has
7	36	37	O	no
8	39	47	O	influence
9	49	50	O	on
10	52	54	O	the
11	56	61	O	plasma
12	63	76	O	concentrations
13	78	79	O	or
14	81	83	O	LDL
15	85	85	O	C
16	87	95	O	reduction
17	97	98	O	of
18	100	106	O	XXXXXXXX
19	109	112	O	thus
20	113	113	O	,
21	115	118	O	dose
22	120	129	O	adjustment
23	131	132	O	in
24	134	141	O	patients
25	143	146	O	with
26	148	152	O	renal
27	154	164	O	dysfunction
28	166	167	O	is
29	169	171	O	not
30	173	181	O	necessary
NULL

Lipitor	3133	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	35
Hemodialysis: While studies have not been conducted in patients with end-stage renal disease, hemodialysis is not expected to significantly enhance clearance of LIPITOR since the drug is extensively bound to plasma proteins.
1	0	11	O	Hemodialysis
2	12	12	O	:
3	14	18	O	While
4	20	26	O	studies
5	28	31	O	have
6	33	35	O	not
7	37	40	O	been
8	42	50	O	conducted
9	52	53	O	in
10	55	62	O	patients
11	64	67	O	with
12	69	71	O	end
13	73	77	O	stage
14	79	83	O	renal
15	85	91	O	disease
16	92	92	O	,
17	94	105	O	hemodialysis
18	107	108	O	is
19	110	112	O	not
20	114	121	O	expected
21	123	124	O	to
22	126	138	O	significantly
23	140	146	O	enhance
24	148	156	O	clearance
25	158	159	O	of
26	161	167	O	XXXXXXXX
27	169	173	O	since
28	175	177	O	the
29	179	182	O	drug
30	184	185	O	is
31	187	197	O	extensively
32	199	203	O	bound
33	205	206	O	to
34	208	213	O	plasma
35	215	222	O	proteins
NULL

Lipitor	3134	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
Hepatic Impairment: In patients with chronic alcoholic liver disease, plasma concentrations of LIPITOR are markedly increased.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	18	18	O	:
4	20	21	O	In
5	23	30	O	patients
6	32	35	O	with
7	37	43	O	chronic
8	45	53	O	alcoholic
9	55	59	O	liver
10	61	67	O	disease
11	68	68	O	,
12	70	75	O	plasma
13	77	90	O	concentrations
14	92	93	O	of
15	95	101	O	XXXXXXXX
16	103	105	O	are
17	107	114	O	markedly
18	116	124	O	increased
NULL

Lipitor	3135	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	15
Cmax and AUC are each 4-fold greater in patients with Childs-Pugh A disease.
1	0	3	O	Cmax
2	5	7	O	and
3	9	11	O	AUC
4	13	15	O	are
5	17	20	O	each
6	22	22	O	4
7	24	27	O	fold
8	29	35	O	greater
9	37	38	O	in
10	40	47	O	patients
11	49	52	O	with
12	54	59	O	Childs
13	61	64	O	Pugh
14	66	66	O	A
15	68	74	O	disease
NULL

Lipitor	3136	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	21
Cmax and AUC are approximately 16-fold and 11-fold increased, respectively, in patients with Childs-Pugh B disease.
1	0	3	O	Cmax
2	5	7	O	and
3	9	11	O	AUC
4	13	15	O	are
5	17	29	O	approximately
6	31	32	O	16
7	34	37	O	fold
8	39	41	O	and
9	43	44	O	11
10	46	49	O	fold
11	51	59	O	increased
12	60	60	O	,
13	62	73	O	respectively
14	74	74	O	,
15	76	77	O	in
16	79	86	O	patients
17	88	91	O	with
18	93	98	O	Childs
19	100	103	O	Pugh
20	105	105	O	B
21	107	113	O	disease
NULL

Lipitor	3137	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	45
Effect of Co-administered Drugs on the Pharmacokinetics of Atorvastatin Co-administered drug and dosing regimen Atorvastatin Dose (mg) Change in AUC Data given as x-fold change represent a simple ratio between co-administration and atorvastatin alone (i.e., 1-fold = no change).
1	0	5	O	Effect
2	7	8	O	of
3	10	11	O	Co
4	13	24	O	administered
5	26	30	O	Drugs
6	32	33	O	on
7	35	37	O	the
8	39	54	O	Pharmacokinetics
9	56	57	O	of
10	59	70	O	XXXXXXXX
11	72	73	O	Co
12	75	86	O	administered
13	88	91	O	drug
14	93	95	O	and
15	97	102	O	dosing
16	104	110	O	regimen
17	112	123	O	XXXXXXXX
18	125	128	O	Dose
19	131	132	O	mg
20	135	140	O	Change
21	142	143	O	in
22	145	147	O	AUC
23	149	152	O	Data
24	154	158	O	given
25	160	161	O	as
26	163	163	O	x
27	165	168	O	fold
28	170	175	O	change
29	177	185	O	represent
30	187	187	O	a
31	189	194	O	simple
32	196	200	O	ratio
33	202	208	O	between
34	210	211	O	co
35	213	226	O	administration
36	228	230	O	and
37	232	243	O	XXXXXXXX
38	245	249	O	alone
39	252	254	O	i.e
40	256	256	O	,
41	258	258	O	1
42	260	263	O	fold
43	265	265	O	=
44	267	268	O	no
45	270	275	O	change
NULL

Lipitor	3138	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	18
Data given as % change represent % difference relative to atorvastatin alone (i.e., 0% = no change).
1	0	3	O	Data
2	5	9	O	given
3	11	12	O	as
4	14	14	O	%
5	16	21	O	change
6	23	31	O	represent
7	33	33	O	%
8	35	44	O	difference
9	46	53	O	relative
10	55	56	O	to
11	58	69	O	XXXXXXXX
12	71	75	O	alone
13	78	80	O	i.e
14	82	82	O	,
15	84	85	O	0%
16	87	87	O	=
17	89	90	O	no
18	92	97	O	change
NULL

Lipitor	3139	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	11
Change in Cmax See Sections 5.1 and 7 for clinical significance.
1	0	5	O	Change
2	7	8	O	in
3	10	13	O	Cmax
4	15	17	O	See
5	19	26	O	Sections
6	28	30	O	5.1
7	32	34	O	and
8	36	36	O	7
9	38	40	O	for
10	42	49	O	clinical
11	51	62	O	significance
NULL

Lipitor	3140	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	21
Cyclosporine 5.2 mg/kg/day, stable dose 10 mg QD for 28 days * 8.7 fold *10.7 fold
1	0	11	O	Cyclosporine
2	13	15	O	5.2
3	17	18	O	mg
4	19	19	O	/
5	20	21	O	kg
6	22	22	O	/
7	23	25	O	day
8	26	26	O	,
9	28	33	O	stable
10	35	38	O	dose
11	40	41	O	10
12	43	44	O	mg
13	46	47	O	QD
14	49	51	O	for
15	53	54	O	28
16	56	59	O	days
17	61	61	O	*
18	63	65	O	8.7
19	67	70	O	fold
20	72	76	O	10.7
21	78	81	O	fold
NULL

Lipitor	3141	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	20
The increase in atorvastatin exposure when used clinically is likely to be higher than what was observed in this study.
1	0	2	O	The
2	4	11	O	increase
3	13	14	O	in
4	16	27	O	XXXXXXXX
5	29	36	O	exposure
6	38	41	O	when
7	43	46	O	used
8	48	57	O	clinically
9	59	60	O	is
10	62	67	O	likely
11	69	70	O	to
12	72	73	O	be
13	75	80	O	higher
14	82	85	O	than
15	87	90	O	what
16	92	94	O	was
17	96	103	O	observed
18	105	106	O	in
19	108	111	O	this
20	113	117	O	study
NULL

Lipitor	3142	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	190
Therefore, caution should be applied and the lowest dose necessary should be used.Saquinavir 400 mg BID/ ritonavir 400mg BID, 15 days 40 mg QD for 4 days * 3.9 fold * 4.3 fold Clarithromycin 500 mg BID, 9 days 80 mg QD for 8 days * 4.4 fold * 5.4 fold Darunavir 300 mg BID/ritonavir 100 mg BID, 9 days 10 mg QD for 4 days * 3.4 fold * 2.25 fold Itraconazole 200 mg QD, 4 days 40 mg SD * 3.3 fold * 20% Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days 10 mg QD for 4 days * 2.53 fold * 2.84 fold Fosamprenavir 1400 mg BID, 14 days 10 mg QD for 4 days * 2.3 fold * 4.04 fold Nelfinavir 1250 mg BID, 14 days 10 mg QD for 28 days * 74% * 2.2 fold Grapefruit Juice, 240 mL QD Greater increases in AUC (up to 2.5 fold) and/or Cmax (up to 71%) have been reported with excessive grapefruit consumption (> 750 mL - 1.2 liters per day).
1	0	8	O	Therefore
2	9	9	O	,
3	11	17	O	caution
4	19	24	O	should
5	26	27	O	be
6	29	35	O	applied
7	37	39	O	and
8	41	43	O	the
9	45	50	O	lowest
10	52	55	O	dose
11	57	65	O	necessary
12	67	72	O	should
13	74	75	O	be
14	77	91	O	used.Saquinavir
15	93	95	O	400
16	97	98	O	mg
17	100	102	O	BID
18	103	103	O	/
19	105	113	O	ritonavir
20	115	119	O	400mg
21	121	123	O	BID
22	124	124	O	,
23	126	127	O	15
24	129	132	O	days
25	134	135	O	40
26	137	138	O	mg
27	140	141	O	QD
28	143	145	O	for
29	147	147	O	4
30	149	152	O	days
31	154	154	O	*
32	156	158	O	3.9
33	160	163	O	fold
34	165	165	O	*
35	167	169	O	4.3
36	171	174	O	fold
37	176	189	O	Clarithromycin
38	191	193	O	500
39	195	196	O	mg
40	198	200	O	BID
41	201	201	O	,
42	203	203	O	9
43	205	208	O	days
44	210	211	O	80
45	213	214	O	mg
46	216	217	O	QD
47	219	221	O	for
48	223	223	O	8
49	225	228	O	days
50	230	230	O	*
51	232	234	O	4.4
52	236	239	O	fold
53	241	241	O	*
54	243	245	O	5.4
55	247	250	O	fold
56	252	260	O	Darunavir
57	262	264	O	300
58	266	267	O	mg
59	269	271	O	BID
60	272	272	O	/
61	273	281	O	ritonavir
62	283	285	O	100
63	287	288	O	mg
64	290	292	O	BID
65	293	293	O	,
66	295	295	O	9
67	297	300	O	days
68	302	303	O	10
69	305	306	O	mg
70	308	309	O	QD
71	311	313	O	for
72	315	315	O	4
73	317	320	O	days
74	322	322	O	*
75	324	326	O	3.4
76	328	331	O	fold
77	333	333	O	*
78	335	338	O	2.25
79	340	343	O	fold
80	345	356	O	Itraconazole
81	358	360	O	200
82	362	363	O	mg
83	365	366	O	QD
84	367	367	O	,
85	369	369	O	4
86	371	374	O	days
87	376	377	O	40
88	379	380	O	mg
89	382	383	O	SD
90	385	385	O	*
91	387	389	O	3.3
92	391	394	O	fold
93	396	396	O	*
94	398	400	O	20%
95	402	414	O	Fosamprenavir
96	416	418	O	700
97	420	421	O	mg
98	423	425	O	BID
99	426	426	O	/
100	427	435	O	ritonavir
101	437	439	O	100
102	441	442	O	mg
103	444	446	O	BID
104	447	447	O	,
105	449	450	O	14
106	452	455	O	days
107	457	458	O	10
108	460	461	O	mg
109	463	464	O	QD
110	466	468	O	for
111	470	470	O	4
112	472	475	O	days
113	477	477	O	*
114	479	482	O	2.53
115	484	487	O	fold
116	489	489	O	*
117	491	494	O	2.84
118	496	499	O	fold
119	501	513	O	Fosamprenavir
120	515	518	O	1400
121	520	521	O	mg
122	523	525	O	BID
123	526	526	O	,
124	528	529	O	14
125	531	534	O	days
126	536	537	O	10
127	539	540	O	mg
128	542	543	O	QD
129	545	547	O	for
130	549	549	O	4
131	551	554	O	days
132	556	556	O	*
133	558	560	O	2.3
134	562	565	O	fold
135	567	567	O	*
136	569	572	O	4.04
137	574	577	O	fold
138	579	588	O	Nelfinavir
139	590	593	O	1250
140	595	596	O	mg
141	598	600	O	BID
142	601	601	O	,
143	603	604	O	14
144	606	609	O	days
145	611	612	O	10
146	614	615	O	mg
147	617	618	O	QD
148	620	622	O	for
149	624	625	O	28
150	627	630	O	days
151	632	632	O	*
152	634	636	O	74%
153	638	638	O	*
154	640	642	O	2.2
155	644	647	O	fold
156	649	658	O	Grapefruit
157	660	664	O	Juice
158	665	665	O	,
159	667	669	O	240
160	671	672	O	mL
161	674	675	O	QD
162	677	683	O	Greater
163	685	693	B-TRI	increases
164	695	696	I-TRI	in
165	698	700	L-TRI	AUC
166	703	704	O	up
167	706	707	O	to
168	709	711	O	2.5
169	713	716	O	fold
170	719	721	O	and
171	722	722	O	/
172	723	724	O	or
173	726	729	O	Cmax
174	732	733	O	up
175	735	736	O	to
176	738	740	O	71%
177	743	746	O	have
178	748	751	O	been
179	753	760	O	reported
180	762	765	O	with
181	767	775	O	excessive
182	777	786	U-KIN	grapefruit
183	788	798	O	consumption
184	801	801	O	>
185	803	805	O	750
186	807	808	O	mL
187	812	814	O	1.2
188	816	821	O	liters
189	823	825	O	per
190	827	829	O	day
K/182:C54602

Lipitor	3143	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	96
40 mg, SD * 37% * 16% Diltiazem 240 mg QD, 28 days 40 mg, SD * 51% No change Erythromycin 500 mg QID, 7 days 10 mg, SD * 33% * 38% Amlodipine 10 mg, single dose 80 mg, SD * 15% * 12 % Cimetidine 300 mg QID, 2 weeks 10 mg QD for 2 weeks * Less than 1% * 11% Colestipol 10 mg BID, 28 weeks 40 mg QD for 28 weeks Not determined * 26%Single sample taken 8-16 h post dose.
1	0	1	O	40
2	3	4	O	mg
3	5	5	O	,
4	7	8	O	SD
5	10	10	O	*
6	12	14	O	37%
7	16	16	O	*
8	18	20	O	16%
9	22	30	O	Diltiazem
10	32	34	O	240
11	36	37	O	mg
12	39	40	O	QD
13	41	41	O	,
14	43	44	O	28
15	46	49	O	days
16	51	52	O	40
17	54	55	O	mg
18	56	56	O	,
19	58	59	O	SD
20	61	61	O	*
21	63	65	O	51%
22	67	68	O	No
23	70	75	O	change
24	77	88	O	Erythromycin
25	90	92	O	500
26	94	95	O	mg
27	97	99	O	QID
28	100	100	O	,
29	102	102	O	7
30	104	107	O	days
31	109	110	O	10
32	112	113	O	mg
33	114	114	O	,
34	116	117	O	SD
35	119	119	O	*
36	121	123	O	33%
37	125	125	O	*
38	127	129	O	38%
39	131	140	O	Amlodipine
40	142	143	O	10
41	145	146	O	mg
42	147	147	O	,
43	149	154	O	single
44	156	159	O	dose
45	161	162	O	80
46	164	165	O	mg
47	166	166	O	,
48	168	169	O	SD
49	171	171	O	*
50	173	175	O	15%
51	177	177	O	*
52	179	180	O	12
53	182	182	O	%
54	184	193	O	Cimetidine
55	195	197	O	300
56	199	200	O	mg
57	202	204	O	QID
58	205	205	O	,
59	207	207	O	2
60	209	213	O	weeks
61	215	216	O	10
62	218	219	O	mg
63	221	222	O	QD
64	224	226	O	for
65	228	228	O	2
66	230	234	O	weeks
67	236	236	O	*
68	238	241	O	Less
69	243	246	O	than
70	248	249	O	1%
71	251	251	O	*
72	253	255	O	11%
73	257	266	O	Colestipol
74	268	269	O	10
75	271	272	O	mg
76	274	276	O	BID
77	277	277	O	,
78	279	280	O	28
79	282	286	O	weeks
80	288	289	O	40
81	291	292	O	mg
82	294	295	O	QD
83	297	299	O	for
84	301	302	O	28
85	304	308	O	weeks
86	310	312	O	Not
87	314	323	O	determined
88	325	325	O	*
89	327	335	O	26%Single
90	337	342	O	sample
91	344	348	O	taken
92	350	350	O	8
93	352	353	O	16
94	355	355	O	h
95	357	360	O	post
96	362	365	O	dose
NULL

Lipitor	3144	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	82
Maalox TC* 30 mL QD, 17 days 10 mg QD for 15 days * 33% * 34% Efavirenz 600 mg QD, 14 days 10 mg for 3 days * 41% * 1% Rifampin 600 mg QD, 7 days (co-administered) Due to the dual interaction mechanism of rifampin, simultaneous co-administration of atorvastatin with rifampin is recommended, as delayed administration of atorvastatin after administration of rifampin has been associated with a significant reduction in atorvastatin plasma concentrations.
1	0	5	O	Maalox
2	7	9	O	TC*
3	11	12	O	30
4	14	15	O	mL
5	17	18	O	QD
6	19	19	O	,
7	21	22	O	17
8	24	27	O	days
9	29	30	O	10
10	32	33	O	mg
11	35	36	O	QD
12	38	40	O	for
13	42	43	O	15
14	45	48	O	days
15	50	50	O	*
16	52	54	O	33%
17	56	56	O	*
18	58	60	O	34%
19	62	70	O	Efavirenz
20	72	74	O	600
21	76	77	O	mg
22	79	80	O	QD
23	81	81	O	,
24	83	84	O	14
25	86	89	O	days
26	91	92	O	10
27	94	95	O	mg
28	97	99	O	for
29	101	101	O	3
30	103	106	O	days
31	108	108	O	*
32	110	112	O	41%
33	114	114	O	*
34	116	117	O	1%
35	119	126	O	Rifampin
36	128	130	O	600
37	132	133	O	mg
38	135	136	O	QD
39	137	137	O	,
40	139	139	O	7
41	141	144	O	days
42	147	148	O	co
43	150	161	O	administered
44	164	166	O	Due
45	168	169	O	to
46	171	173	O	the
47	175	178	O	dual
48	180	190	O	interaction
49	192	200	O	mechanism
50	202	203	O	of
51	205	212	U-KIN	rifampin
52	213	213	O	,
53	215	226	O	simultaneous
54	228	229	O	co
55	231	244	O	administration
56	246	247	O	of
57	249	260	O	XXXXXXXX
58	262	265	O	with
59	267	274	O	rifampin
60	276	277	O	is
61	279	289	O	recommended
62	290	290	O	,
63	292	293	O	as
64	295	301	O	delayed
65	303	316	O	administration
66	318	319	O	of
67	321	332	O	XXXXXXXX
68	334	338	O	after
69	340	353	O	administration
70	355	356	O	of
71	358	365	O	rifampin
72	367	369	O	has
73	371	374	O	been
74	376	385	O	associated
75	387	390	O	with
76	392	392	O	a
77	394	404	O	significant
78	406	414	O	reduction
79	416	417	O	in
80	419	430	O	XXXXXXXX
81	432	437	O	plasma
82	439	452	O	concentrations
K/51:C54356

Lipitor	3145	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	66
40 mg SD * 30% * 2.7 fold Rifampin 600 mg QD, 5 days (doses separated) 40 mg SD * 80% * 40% Gemfibrozil 600mg BID, 7 days 40mg SD * 35% * Less than 1% Fenofibrate 160mg QD, 7 days 40mg SD * 3% * 2% Boceprevir 800 mg TID, 7 days 40 mg SD *2.30 fold *2.66 fold TABLE 4.
1	0	1	O	40
2	3	4	O	mg
3	6	7	O	SD
4	9	9	O	*
5	11	13	O	30%
6	15	15	O	*
7	17	19	O	2.7
8	21	24	O	fold
9	26	33	O	Rifampin
10	35	37	O	600
11	39	40	O	mg
12	42	43	O	QD
13	44	44	O	,
14	46	46	O	5
15	48	51	O	days
16	54	58	O	doses
17	60	68	O	separated
18	71	72	O	40
19	74	75	O	mg
20	77	78	O	SD
21	80	80	O	*
22	82	84	O	80%
23	86	86	O	*
24	88	90	O	40%
25	92	102	O	Gemfibrozil
26	104	108	O	600mg
27	110	112	O	BID
28	113	113	O	,
29	115	115	O	7
30	117	120	O	days
31	122	125	O	40mg
32	127	128	O	SD
33	130	130	O	*
34	132	134	O	35%
35	136	136	O	*
36	138	141	O	Less
37	143	146	O	than
38	148	149	O	1%
39	151	161	O	Fenofibrate
40	163	167	O	160mg
41	169	170	O	QD
42	171	171	O	,
43	173	173	O	7
44	175	178	O	days
45	180	183	O	40mg
46	185	186	O	SD
47	188	188	O	*
48	190	191	O	3%
49	193	193	O	*
50	195	196	O	2%
51	198	207	O	Boceprevir
52	209	211	O	800
53	213	214	O	mg
54	216	218	O	TID
55	219	219	O	,
56	221	221	O	7
57	223	226	O	days
58	228	229	O	40
59	231	232	O	mg
60	234	235	O	SD
61	237	241	O	2.30
62	243	246	O	fold
63	248	252	O	2.66
64	254	257	O	fold
65	259	263	O	TABLE
66	265	265	O	4
NULL

Lipitor	3146	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	54
Effect of Atorvastatin on the Pharmacokinetics of Co-administered Drugs Atorvastatin Co-administered drug and dosing regimen Drug/Dose (mg) Change in AUC Change in Cmax 80 mg QD for 15 days Antipyrine, 600 mg SD * 3% * 11% 80 mg QD for 14 days See Section 7 for clinical significance.
1	0	5	O	Effect
2	7	8	O	of
3	10	21	O	XXXXXXXX
4	23	24	O	on
5	26	28	O	the
6	30	45	O	Pharmacokinetics
7	47	48	O	of
8	50	51	O	Co
9	53	64	O	administered
10	66	70	O	Drugs
11	72	83	O	XXXXXXXX
12	85	86	O	Co
13	88	99	O	administered
14	101	104	O	drug
15	106	108	O	and
16	110	115	O	dosing
17	117	123	O	regimen
18	125	128	O	Drug
19	129	129	O	/
20	130	133	O	Dose
21	136	137	O	mg
22	140	145	O	Change
23	147	148	O	in
24	150	152	O	AUC
25	154	159	O	Change
26	161	162	O	in
27	164	167	O	Cmax
28	169	170	O	80
29	172	173	O	mg
30	175	176	O	QD
31	178	180	O	for
32	182	183	O	15
33	185	188	O	days
34	190	199	O	Antipyrine
35	200	200	O	,
36	202	204	O	600
37	206	207	O	mg
38	209	210	O	SD
39	212	212	O	*
40	214	215	O	3%
41	217	217	O	*
42	219	221	O	11%
43	223	224	O	80
44	226	227	O	mg
45	229	230	O	QD
46	232	234	O	for
47	236	237	O	14
48	239	242	O	days
49	244	246	O	See
50	248	254	O	Section
51	256	256	O	7
52	258	260	O	for
53	262	269	O	clinical
54	271	282	O	significance
NULL

Lipitor	3147	34090-1	c6e131fe-e7df-4876-83f7-9156fc4e8228	96
Digoxin 0.25 mg QD, 20 days * 15% * 20 % 40 mg QD for 22 days Oral contraceptive QD, 2 months - norethindrone 1mg - ethinyl estradiol 35ug * 28% * 19% * 23% * 30% 10 mg, SD Tipranavir 500 mg BID/ritonavir 200 mg BID, 7 days No change No change 10 mg QD for 4 days Fosamprenavir 1400 mg BID, 14 days * 27% * 18% 10 mg QD for 4 days Fosamprenavir 700 mg BID/ritonavir 100 mg BID, 14 days No change No change
1	0	6	O	Digoxin
2	8	11	O	0.25
3	13	14	O	mg
4	16	17	O	QD
5	18	18	O	,
6	20	21	O	20
7	23	26	O	days
8	28	28	O	*
9	30	32	O	15%
10	34	34	O	*
11	36	37	O	20
12	39	39	O	%
13	41	42	O	40
14	44	45	O	mg
15	47	48	O	QD
16	50	52	O	for
17	54	55	O	22
18	57	60	O	days
19	62	65	O	Oral
20	67	79	O	contraceptive
21	81	82	O	QD
22	83	83	O	,
23	85	85	O	2
24	87	92	O	months
25	96	108	O	norethindrone
26	110	112	O	1mg
27	116	122	O	ethinyl
28	124	132	O	estradiol
29	134	137	O	35ug
30	139	139	O	*
31	141	143	O	28%
32	145	145	O	*
33	147	149	O	19%
34	151	151	O	*
35	153	155	O	23%
36	157	157	O	*
37	159	161	O	30%
38	163	164	O	10
39	166	167	O	mg
40	168	168	O	,
41	170	171	O	SD
42	173	182	O	Tipranavir
43	184	186	O	500
44	188	189	O	mg
45	191	193	O	BID
46	194	194	O	/
47	195	203	O	ritonavir
48	205	207	O	200
49	209	210	O	mg
50	212	214	O	BID
51	215	215	O	,
52	217	217	O	7
53	219	222	O	days
54	224	225	O	No
55	227	232	O	change
56	234	235	O	No
57	237	242	O	change
58	244	245	O	10
59	247	248	O	mg
60	250	251	O	QD
61	253	255	O	for
62	257	257	O	4
63	259	262	O	days
64	264	276	O	Fosamprenavir
65	278	281	O	1400
66	283	284	O	mg
67	286	288	O	BID
68	289	289	O	,
69	291	292	O	14
70	294	297	O	days
71	299	299	O	*
72	301	303	O	27%
73	305	305	O	*
74	307	309	O	18%
75	311	312	O	10
76	314	315	O	mg
77	317	318	O	QD
78	320	322	O	for
79	324	324	O	4
80	326	329	O	days
81	331	343	O	Fosamprenavir
82	345	347	O	700
83	349	350	O	mg
84	352	354	O	BID
85	355	355	O	/
86	356	364	O	ritonavir
87	366	368	O	100
88	370	371	O	mg
89	373	375	O	BID
90	376	376	O	,
91	378	379	O	14
92	381	384	O	days
93	386	387	O	No
94	389	394	O	change
95	396	397	O	No
96	399	404	O	change
NULL

Livalo	551	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	6
Erythromycin: Combination increases pitavastatin exposure.
1	0	11	U-KIN	Erythromycin
2	12	12	O	:
3	14	24	O	Combination
4	26	34	B-TRI	increases
5	36	47	I-TRI	XXXXXXXX
6	49	56	L-TRI	exposure
K/1:C54355

Livalo	552	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	16
Limit LIVALO to 1 mg once daily (2.3, 7.2) Rifampin: Combination increases pitavastatin exposure.
1	0	4	O	Limit
2	6	11	O	XXXXXXXX
3	13	14	O	to
4	16	16	O	1
5	18	19	O	mg
6	21	24	O	once
7	26	30	O	daily
8	33	35	O	2.3
9	36	36	O	,
10	38	40	O	7.2
11	43	50	U-KIN	Rifampin
12	51	51	O	:
13	53	63	O	Combination
14	65	73	B-TRI	increases
15	75	86	I-TRI	XXXXXXXX
16	88	95	L-TRI	exposure
K/11:C54355

Livalo	553	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	36
Limit LIVALO to 2 mg once daily (2.4, 7.3) Concomitant lipid-lowering therapies: Use with fibrates or lipid-modifying doses (>1 g/day) of niacin increases the risk of adverse skeletal muscle effects.
1	0	4	O	Limit
2	6	11	O	XXXXXXXX
3	13	14	O	to
4	16	16	O	2
5	18	19	O	mg
6	21	24	O	once
7	26	30	O	daily
8	33	35	O	2.4
9	36	36	O	,
10	38	40	O	7.3
11	43	53	O	Concomitant
12	55	59	O	lipid
13	61	68	O	lowering
14	70	78	O	therapies
15	79	79	O	:
16	81	83	O	Use
17	85	88	O	with
18	90	97	U-DYN	fibrates
19	99	100	O	or
20	102	106	O	lipid
21	108	116	O	modifying
22	118	122	O	doses
23	125	126	O	>1
24	128	128	O	g
25	129	129	O	/
26	130	132	O	day
27	135	136	O	of
28	138	143	U-DYN	niacin
29	145	153	O	increases
30	155	157	O	the
31	159	162	O	risk
32	164	165	O	of
33	167	173	B-EFF	adverse
34	175	182	I-EFF	skeletal
35	184	189	I-EFF	muscle
36	191	197	L-EFF	effects
D/18:33:1 D/28:33:1

Livalo	554	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	8
Caution should be used when prescribing with LIVALO.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	38	O	prescribing
7	40	43	O	with
8	45	50	O	XXXXXXXX
NULL

Livalo	555	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	5
Cyclosporine significantly increased pitavastatin exposure.
1	0	11	U-KIN	Cyclosporine
2	13	25	O	significantly
3	27	35	B-TRI	increased
4	37	48	I-TRI	XXXXXXXX
5	50	57	L-TRI	exposure
K/1:C54355

Livalo	556	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	8
Co-administration of cyclosporine with LIVALO is contraindicated.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	32	U-UNK	cyclosporine
5	34	37	O	with
6	39	44	O	XXXXXXXX
7	46	47	O	is
8	49	63	U-TRI	contraindicated
NULL

Livalo	557	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	5
Erythromycin significantly increased pitavastatin exposure.
1	0	11	U-KIN	Erythromycin
2	13	25	O	significantly
3	27	35	B-TRI	increased
4	37	48	I-TRI	XXXXXXXX
5	50	57	L-TRI	exposure
K/1:C54355

Livalo	558	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	17
In patients taking erythromycin, a dose of LIVALO 1 mg once daily should not be exceeded.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	30	U-KIN	erythromycin
5	31	31	O	,
6	33	33	O	a
7	35	38	O	dose
8	40	41	O	of
9	43	48	O	XXXXXXXX
10	50	50	O	1
11	52	53	O	mg
12	55	58	O	once
13	60	64	O	daily
14	66	71	O	should
15	73	75	O	not
16	77	78	O	be
17	80	87	O	exceeded
K/4:C54355

Livalo	559	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	5
Rifampin significantly increased pitavastatin exposure.
1	0	7	U-KIN	Rifampin
2	9	21	O	significantly
3	23	31	B-TRI	increased
4	33	44	I-TRI	XXXXXXXX
5	46	53	L-TRI	exposure
K/1:C54355

Livalo	560	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	17
In patients taking rifampin, a dose of LIVALO 2 mg once daily should not be exceeded.
1	0	1	O	In
2	3	10	O	patients
3	12	17	O	taking
4	19	26	U-KIN	rifampin
5	27	27	O	,
6	29	29	O	a
7	31	34	O	dose
8	36	37	O	of
9	39	44	O	XXXXXXXX
10	46	46	O	2
11	48	49	O	mg
12	51	54	O	once
13	56	60	O	daily
14	62	67	O	should
15	69	71	O	not
16	73	74	O	be
17	76	83	O	exceeded
K/4:C54355

Livalo	561	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	28
Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of LIVALO with gemfibrozil should be avoided.
1	0	2	O	Due
2	4	5	O	to
3	7	8	O	an
4	10	18	O	increased
5	20	23	O	risk
6	25	26	O	of
7	28	35	B-EFF	myopathy
8	36	36	I-EFF	/
9	37	50	L-EFF	rhabdomyolysis
10	52	55	O	when
11	57	59	O	HMG
12	61	63	O	CoA
13	65	73	O	reductase
14	75	84	O	inhibitors
15	86	88	O	are
16	90	103	O	coadministered
17	105	108	O	with
18	110	120	U-DYN	gemfibrozil
19	121	121	O	,
20	123	133	O	concomitant
21	135	148	O	administration
22	150	151	O	of
23	153	158	O	XXXXXXXX
24	160	163	O	with
25	165	175	O	gemfibrozil
26	177	182	O	should
27	184	185	O	be
28	187	193	O	avoided
D/18:7:1

Livalo	562	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	37
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LIVALO should be administered with caution when used concomitantly with other fibrates.
1	0	6	O	Because
2	8	9	O	it
3	11	12	O	is
4	14	18	O	known
5	20	23	O	that
6	25	27	O	the
7	29	32	O	risk
8	34	35	O	of
9	37	44	U-EFF	myopathy
10	46	51	O	during
11	53	61	O	treatment
12	63	66	O	with
13	68	70	O	HMG
14	72	74	O	CoA
15	76	84	O	reductase
16	86	95	O	inhibitors
17	97	98	O	is
18	100	108	O	increased
19	110	113	O	with
20	115	124	O	concurrent
21	126	139	O	administration
22	141	142	O	of
23	144	148	O	other
24	150	157	U-DYN	fibrates
25	158	158	O	,
26	160	165	O	XXXXXXXX
27	167	172	O	should
28	174	175	O	be
29	177	188	O	administered
30	190	193	O	with
31	195	201	O	caution
32	203	206	O	when
33	208	211	O	used
34	213	225	O	concomitantly
35	227	230	O	with
36	232	236	O	other
37	238	245	O	fibrates
D/24:9:1

Livalo	563	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	28
The risk of skeletal muscle effects may be enhanced when LIVALO is used in combination with niacin; a reduction in LIVALO dosage should be considered in this setting.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	skeletal
5	21	26	I-EFF	muscle
6	28	34	L-EFF	effects
7	36	38	O	may
8	40	41	O	be
9	43	50	O	enhanced
10	52	55	O	when
11	57	62	O	XXXXXXXX
12	64	65	O	is
13	67	70	O	used
14	72	73	O	in
15	75	85	O	combination
16	87	90	O	with
17	92	97	U-DYN	niacin
18	100	100	O	a
19	102	110	O	reduction
20	112	113	O	in
21	115	120	O	XXXXXXXX
22	122	127	O	dosage
23	129	134	O	should
24	136	137	O	be
25	139	148	O	considered
26	150	151	O	in
27	153	156	O	this
28	158	164	O	setting
D/17:4:1

Livalo	564	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	29
Cases of myopathy, including rhabdomyolysis, have been reported with HMG-CoA reductase inhibitors coadministered with colchicine, and caution should be exercised when prescribing LIVALO with colchicine.
1	0	4	O	Cases
2	6	7	O	of
3	9	16	U-EFF	myopathy
4	17	17	O	,
5	19	27	O	including
6	29	42	U-EFF	rhabdomyolysis
7	43	43	O	,
8	45	48	O	have
9	50	53	O	been
10	55	62	O	reported
11	64	67	O	with
12	69	71	O	HMG
13	73	75	O	CoA
14	77	85	O	reductase
15	87	96	O	inhibitors
16	98	111	O	coadministered
17	113	116	O	with
18	118	127	U-DYN	colchicine
19	128	128	O	,
20	130	132	O	and
21	134	140	O	caution
22	142	147	O	should
23	149	150	O	be
24	152	160	O	exercised
25	162	165	O	when
26	167	177	O	prescribing
27	179	184	O	XXXXXXXX
28	186	189	O	with
29	191	200	O	colchicine
D/18:3:1 D/18:6:1

Livalo	565	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	11
LIVALO had no significant pharmacokinetic interaction with R- and S- warfarin.
1	0	5	O	XXXXXXXX
2	7	9	O	had
3	11	12	O	no
4	14	24	O	significant
5	26	40	O	pharmacokinetic
6	42	52	O	interaction
7	54	57	O	with
8	59	59	O	R
9	62	64	O	and
10	66	66	O	S
11	69	76	O	warfarin
NULL

Livalo	566	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	22
LIVALO had no significant effect on prothrombin time (PT) and international normalized ratio (INR) when administered to patients receiving chronic warfarin treatment.
1	0	5	O	XXXXXXXX
2	7	9	O	had
3	11	12	O	no
4	14	24	O	significant
5	26	31	O	effect
6	33	34	O	on
7	36	46	O	prothrombin
8	48	51	O	time
9	54	55	O	PT
10	58	60	O	and
11	62	74	O	international
12	76	85	O	normalized
13	87	91	O	ratio
14	94	96	O	INR
15	99	102	O	when
16	104	115	O	administered
17	117	118	O	to
18	120	127	O	patients
19	129	137	O	receiving
20	139	145	O	chronic
21	147	154	O	warfarin
22	156	164	O	treatment
NULL

Livalo	567	34073-7	44dcbf97-99ec-427c-ba50-207e0069d6d2	19
However, patients receiving warfarin should have their PT and INR monitored when pitavastatin is added to their therapy.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	patients
4	18	26	O	receiving
5	28	35	U-DYN	warfarin
6	37	42	O	should
7	44	47	O	have
8	49	53	O	their
9	55	56	U-EFF	PT
10	58	60	O	and
11	62	64	U-EFF	INR
12	66	74	O	monitored
13	76	79	O	when
14	81	92	O	XXXXXXXX
15	94	95	O	is
16	97	101	O	added
17	103	104	O	to
18	106	110	O	their
19	112	118	O	therapy
D/5:11:1 D/5:9:1

Livalo	568	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	36
Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-determining enzyme involved with biosynthesis of cholesterol, in a manner of competition with the substrate so that it inhibits cholesterol synthesis in the liver.
1	0	11	O	XXXXXXXX
2	13	25	O	competitively
3	27	34	O	inhibits
4	36	38	O	HMG
5	40	42	O	CoA
6	44	52	O	reductase
7	53	53	O	,
8	55	59	O	which
9	61	62	O	is
10	64	64	O	a
11	66	69	O	rate
12	71	81	O	determining
13	83	88	O	enzyme
14	90	97	O	involved
15	99	102	O	with
16	104	115	O	biosynthesis
17	117	118	O	of
18	120	130	O	cholesterol
19	131	131	O	,
20	133	134	O	in
21	136	136	O	a
22	138	143	O	manner
23	145	146	O	of
24	148	158	O	competition
25	160	163	O	with
26	165	167	O	the
27	169	177	O	substrate
28	179	180	O	so
29	182	185	O	that
30	187	188	O	it
31	190	197	O	inhibits
32	199	209	O	cholesterol
33	211	219	O	synthesis
34	221	222	O	in
35	224	226	O	the
36	228	232	O	liver
NULL

Livalo	569	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	27
As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases.
1	0	1	O	As
2	3	3	O	a
3	5	10	O	result
4	11	11	O	,
5	13	15	O	the
6	17	26	O	expression
7	28	29	O	of
8	31	33	O	LDL
9	35	43	O	receptors
10	45	52	O	followed
11	54	55	O	by
12	57	59	O	the
13	61	66	O	uptake
14	68	69	O	of
15	71	73	O	LDL
16	75	78	O	from
17	80	84	O	blood
18	86	87	O	to
19	89	93	O	liver
20	95	96	O	is
21	98	108	O	accelerated
22	110	112	O	and
23	114	117	O	then
24	119	121	O	the
25	123	128	O	plasma
26	130	131	O	TC
27	133	141	O	decreases
NULL

Livalo	570	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	18
Further, the sustained inhibition of cholesterol synthesis in the liver decreases levels of very low density lipoproteins.
1	0	6	O	Further
2	7	7	O	,
3	9	11	O	the
4	13	21	O	sustained
5	23	32	O	inhibition
6	34	35	O	of
7	37	47	O	cholesterol
8	49	57	O	synthesis
9	59	60	O	in
10	62	64	O	the
11	66	70	O	liver
12	72	80	O	decreases
13	82	87	O	levels
14	89	90	O	of
15	92	95	O	very
16	97	99	O	low
17	101	107	O	density
18	109	120	O	lipoproteins
NULL

Livalo	571	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	53
In a randomized, double-blind, placebo-controlled, 4-way parallel, active-comparator study with moxifloxacin in 174 healthy participants, LIVALO was not associated with clinically meaningful prolongation of the QTc interval or heart rate at daily doses up to 16 mg (4 times the recommended maximum daily dose).
1	0	1	O	In
2	3	3	O	a
3	5	14	O	randomized
4	15	15	O	,
5	17	22	O	double
6	24	28	O	blind
7	29	29	O	,
8	31	37	O	placebo
9	39	48	O	controlled
10	49	49	O	,
11	51	51	O	4
12	53	55	O	way
13	57	64	O	parallel
14	65	65	O	,
15	67	72	O	active
16	74	83	O	comparator
17	85	89	O	study
18	91	94	O	with
19	96	107	O	moxifloxacin
20	109	110	O	in
21	112	114	O	174
22	116	122	O	healthy
23	124	135	O	participants
24	136	136	O	,
25	138	143	O	XXXXXXXX
26	145	147	O	was
27	149	151	O	not
28	153	162	O	associated
29	164	167	O	with
30	169	178	O	clinically
31	180	189	O	meaningful
32	191	202	O	prolongation
33	204	205	O	of
34	207	209	O	the
35	211	213	O	QTc
36	215	222	O	interval
37	224	225	O	or
38	227	231	O	heart
39	233	236	O	rate
40	238	239	O	at
41	241	245	O	daily
42	247	251	O	doses
43	253	254	O	up
44	256	257	O	to
45	259	260	O	16
46	262	263	O	mg
47	266	266	O	4
48	268	272	O	times
49	274	276	O	the
50	278	288	O	recommended
51	290	296	O	maximum
52	298	302	O	daily
53	304	307	O	dose
NULL

Livalo	572	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	14
Absorption: Pitavastatin peak plasma concentrations are achieved about 1 hour after oral administration.
1	0	9	O	Absorption
2	10	10	O	:
3	12	23	O	XXXXXXXX
4	25	28	O	peak
5	30	35	O	plasma
6	37	50	O	concentrations
7	52	54	O	are
8	56	63	O	achieved
9	65	69	O	about
10	71	71	O	1
11	73	76	O	hour
12	78	82	O	after
13	84	87	O	oral
14	89	102	O	administration
NULL

Livalo	573	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	23
Both Cmax and AUC0-inf increased in an approximately dose-proportional manner for single LIVALO doses from 1 to 24 mg once daily.
1	0	3	O	Both
2	5	8	O	Cmax
3	10	12	O	and
4	14	17	O	AUC0
5	19	21	O	inf
6	23	31	O	increased
7	33	34	O	in
8	36	37	O	an
9	39	51	O	approximately
10	53	56	O	dose
11	58	69	O	proportional
12	71	76	O	manner
13	78	80	O	for
14	82	87	O	single
15	89	94	O	XXXXXXXX
16	96	100	O	doses
17	102	105	O	from
18	107	107	O	1
19	109	110	O	to
20	112	113	O	24
21	115	116	O	mg
22	118	121	O	once
23	123	127	O	daily
NULL

Livalo	574	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	9
The absolute bioavailability of pitavastatin oral solution is 51%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	43	O	XXXXXXXX
6	45	48	O	oral
7	50	57	O	solution
8	59	60	O	is
9	62	64	O	51%
NULL

Livalo	575	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	23
Administration of LIVALO with a high fat meal (50% fat content) decreases pitavastatin Cmax by 43% but does not significantly reduce pitavastatin AUC.
1	0	13	O	Administration
2	15	16	O	of
3	18	23	O	XXXXXXXX
4	25	28	O	with
5	30	30	O	a
6	32	35	B-KIN	high
7	37	39	I-KIN	fat
8	41	44	L-KIN	meal
9	47	49	O	50%
10	51	53	O	fat
11	55	61	O	content
12	64	72	B-TRI	decreases
13	74	85	I-TRI	XXXXXXXX
14	87	90	L-TRI	Cmax
15	92	93	O	by
16	95	97	O	43%
17	99	101	O	but
18	103	106	O	does
19	108	110	O	not
20	112	124	O	significantly
21	126	131	O	reduce
22	133	144	O	XXXXXXXX
23	146	148	O	AUC
K/6:C54606

Livalo	576	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	15
The Cmax and AUC of pitavastatin did not differ following evening or morning drug administration.
1	0	2	O	The
2	4	7	O	Cmax
3	9	11	O	and
4	13	15	O	AUC
5	17	18	O	of
6	20	31	O	XXXXXXXX
7	33	35	O	did
8	37	39	O	not
9	41	46	O	differ
10	48	56	O	following
11	58	64	O	evening
12	66	67	O	or
13	69	75	O	morning
14	77	80	O	drug
15	82	95	O	administration
NULL

Livalo	577	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	27
In healthy volunteers receiving 4 mg pitavastatin, the percent change from baseline for LDL-C following evening dosing was slightly greater than that following morning dosing.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	22	30	O	receiving
5	32	32	O	4
6	34	35	O	mg
7	37	48	O	XXXXXXXX
8	49	49	O	,
9	51	53	O	the
10	55	61	O	percent
11	63	68	O	change
12	70	73	O	from
13	75	82	O	baseline
14	84	86	O	for
15	88	90	O	LDL
16	92	92	O	C
17	94	102	O	following
18	104	110	O	evening
19	112	117	O	dosing
20	119	121	O	was
21	123	130	O	slightly
22	132	138	O	greater
23	140	143	O	than
24	145	148	O	that
25	150	158	O	following
26	160	166	O	morning
27	168	173	O	dosing
NULL

Livalo	578	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	13
Pitavastatin was absorbed in the small intestine but very little in the colon.
1	0	11	O	XXXXXXXX
2	13	15	O	was
3	17	24	O	absorbed
4	26	27	O	in
5	29	31	O	the
6	33	37	O	small
7	39	47	O	intestine
8	49	51	O	but
9	53	56	O	very
10	58	63	O	little
11	65	66	O	in
12	68	70	O	the
13	72	76	O	colon
NULL

Livalo	579	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	46
Distribution: Pitavastatin is more than 99% protein bound in human plasma, mainly to albumin and alpha 1-acid glycoprotein, and the mean volume of distribution is approximately 148 L. Association of pitavastatin and/or its metabolites with the blood cells is minimal.
1	0	11	O	Distribution
2	12	12	O	:
3	14	25	O	XXXXXXXX
4	27	28	O	is
5	30	33	O	more
6	35	38	O	than
7	40	42	O	99%
8	44	50	O	protein
9	52	56	O	bound
10	58	59	O	in
11	61	65	O	human
12	67	72	O	plasma
13	73	73	O	,
14	75	80	O	mainly
15	82	83	O	to
16	85	91	O	albumin
17	93	95	O	and
18	97	101	O	alpha
19	103	103	O	1
20	105	108	O	acid
21	110	121	O	glycoprotein
22	122	122	O	,
23	124	126	O	and
24	128	130	O	the
25	132	135	O	mean
26	137	142	O	volume
27	144	145	O	of
28	147	158	O	distribution
29	160	161	O	is
30	163	175	O	approximately
31	177	179	O	148
32	181	181	O	L
33	184	194	O	Association
34	196	197	O	of
35	199	210	O	XXXXXXXX
36	212	214	O	and
37	215	215	O	/
38	216	217	O	or
39	219	221	O	its
40	223	233	O	metabolites
41	235	238	O	with
42	240	242	O	the
43	244	248	O	blood
44	250	254	O	cells
45	256	257	O	is
46	259	265	O	minimal
NULL

Livalo	580	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	15
Metabolism: Pitavastatin is marginally metabolized by CYP2C9 and to a lesser extent by CYP2C8.
1	0	9	O	Metabolism
2	10	10	O	:
3	12	23	O	XXXXXXXX
4	25	26	O	is
5	28	37	O	marginally
6	39	49	O	metabolized
7	51	52	O	by
8	54	59	O	CYP2C9
9	61	63	O	and
10	65	66	O	to
11	68	68	O	a
12	70	75	O	lesser
13	77	82	O	extent
14	84	85	O	by
15	87	92	O	CYP2C8
NULL

Livalo	581	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	28
The major metabolite in human plasma is the lactone which is formed via an ester-type pitavastatin glucuronide conjugate by uridine 5'-diphosphate (UDP) glucuronosyltransferase (UGT1A3 and UGT2B7).
1	0	2	O	The
2	4	8	O	major
3	10	19	O	metabolite
4	21	22	O	in
5	24	28	O	human
6	30	35	O	plasma
7	37	38	O	is
8	40	42	O	the
9	44	50	O	lactone
10	52	56	O	which
11	58	59	O	is
12	61	66	O	formed
13	68	70	O	via
14	72	73	O	an
15	75	79	O	ester
16	81	84	O	type
17	86	97	O	XXXXXXXX
18	99	109	O	glucuronide
19	111	119	O	conjugate
20	121	122	O	by
21	124	130	O	uridine
22	132	133	O	5'
23	135	145	O	diphosphate
24	148	150	O	UDP
25	153	175	O	glucuronosyltransferase
26	178	183	O	UGT1A3
27	185	187	O	and
28	189	194	O	UGT2B7
NULL

Livalo	582	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	39
Excretion: A mean of 15% of radioactivity of orally administered, single 32 mg 14C-labeled pitavastatin dose was excreted in urine, whereas a mean of 79% of the dose was excreted in feces within 7 days.
1	0	8	O	Excretion
2	9	9	O	:
3	11	11	O	A
4	13	16	O	mean
5	18	19	O	of
6	21	23	O	15%
7	25	26	O	of
8	28	40	O	radioactivity
9	42	43	O	of
10	45	50	O	orally
11	52	63	O	administered
12	64	64	O	,
13	66	71	O	single
14	73	74	O	32
15	76	77	O	mg
16	79	81	O	14C
17	83	89	O	labeled
18	91	102	O	XXXXXXXX
19	104	107	O	dose
20	109	111	O	was
21	113	120	O	excreted
22	122	123	O	in
23	125	129	O	urine
24	130	130	O	,
25	132	138	O	whereas
26	140	140	O	a
27	142	145	O	mean
28	147	148	O	of
29	150	152	O	79%
30	154	155	O	of
31	157	159	O	the
32	161	164	O	dose
33	166	168	O	was
34	170	177	O	excreted
35	179	180	O	in
36	182	186	O	feces
37	188	193	O	within
38	195	195	O	7
39	197	200	O	days
NULL

Livalo	583	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	10
The mean plasma elimination half-life is approximately 12 hours.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	plasma
4	16	26	O	elimination
5	28	31	O	half
6	33	36	O	life
7	38	39	O	is
8	41	53	O	approximately
9	55	56	O	12
10	58	62	O	hours
NULL

Livalo	584	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	30
Race: In pharmacokinetic studies pitavastatin Cmax and AUC were 21 and 5% lower, respectively in Black or African American healthy volunteers compared with those of Caucasian healthy volunteers.
1	0	3	O	Race
2	4	4	O	:
3	6	7	O	In
4	9	23	O	pharmacokinetic
5	25	31	O	studies
6	33	44	O	XXXXXXXX
7	46	49	O	Cmax
8	51	53	O	and
9	55	57	O	AUC
10	59	62	O	were
11	64	65	O	21
12	67	69	O	and
13	71	72	O	5%
14	74	78	O	lower
15	79	79	O	,
16	81	92	O	respectively
17	94	95	O	in
18	97	101	O	Black
19	103	104	O	or
20	106	112	O	African
21	114	121	O	American
22	123	129	O	healthy
23	131	140	O	volunteers
24	142	149	O	compared
25	151	154	O	with
26	156	160	O	those
27	162	163	O	of
28	165	173	O	Caucasian
29	175	181	O	healthy
30	183	192	O	volunteers
NULL

Livalo	585	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	19
In pharmacokinetic comparison between Caucasian volunteers and Japanese volunteers, there were no significant differences in Cmax and AUC.
1	0	1	O	In
2	3	17	O	pharmacokinetic
3	19	28	O	comparison
4	30	36	O	between
5	38	46	O	Caucasian
6	48	57	O	volunteers
7	59	61	O	and
8	63	70	O	Japanese
9	72	81	O	volunteers
10	82	82	O	,
11	84	88	O	there
12	90	93	O	were
13	95	96	O	no
14	98	108	O	significant
15	110	120	O	differences
16	122	123	O	in
17	125	128	O	Cmax
18	130	132	O	and
19	134	136	O	AUC
NULL

Livalo	586	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	27
Gender: In a pharmacokinetic study which compared healthy male and female volunteers, pitavastatin Cmax and AUC were 60 and 54% higher, respectively in females.
1	0	5	O	Gender
2	6	6	O	:
3	8	9	O	In
4	11	11	O	a
5	13	27	O	pharmacokinetic
6	29	33	O	study
7	35	39	O	which
8	41	48	O	compared
9	50	56	O	healthy
10	58	61	O	male
11	63	65	O	and
12	67	72	O	female
13	74	83	O	volunteers
14	84	84	O	,
15	86	97	O	XXXXXXXX
16	99	102	O	Cmax
17	104	106	O	and
18	108	110	O	AUC
19	112	115	O	were
20	117	118	O	60
21	120	122	O	and
22	124	126	O	54%
23	128	133	O	higher
24	134	134	O	,
25	136	147	O	respectively
26	149	150	O	in
27	152	158	O	females
NULL

Livalo	587	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	16
This had no effect on the efficacy or safety of LIVALO in women in clinical studies.
1	0	3	O	This
2	5	7	O	had
3	9	10	O	no
4	12	17	O	effect
5	19	20	O	on
6	22	24	O	the
7	26	33	O	efficacy
8	35	36	O	or
9	38	43	O	safety
10	45	46	O	of
11	48	53	O	XXXXXXXX
12	55	56	O	in
13	58	62	O	women
14	64	65	O	in
15	67	74	O	clinical
16	76	82	O	studies
NULL

Livalo	588	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	30
Geriatric: In a pharmacokinetic study which compared healthy young and elderly (>65years) volunteers, pitavastatin Cmax and AUC were 10 and 30% higher, respectively, in the elderly.
1	0	8	O	Geriatric
2	9	9	O	:
3	11	12	O	In
4	14	14	O	a
5	16	30	O	pharmacokinetic
6	32	36	O	study
7	38	42	O	which
8	44	51	O	compared
9	53	59	O	healthy
10	61	65	O	young
11	67	69	O	and
12	71	77	O	elderly
13	80	87	O	>65years
14	90	99	O	volunteers
15	100	100	O	,
16	102	113	O	XXXXXXXX
17	115	118	O	Cmax
18	120	122	O	and
19	124	126	O	AUC
20	128	131	O	were
21	133	134	O	10
22	136	138	O	and
23	140	142	O	30%
24	144	149	O	higher
25	150	150	O	,
26	152	163	O	respectively
27	164	164	O	,
28	166	167	O	in
29	169	171	O	the
30	173	179	O	elderly
NULL

Livalo	589	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	17
This had no effect on the efficacy or safety of LIVALO in elderly subjects in clinical studies.
1	0	3	O	This
2	5	7	O	had
3	9	10	O	no
4	12	17	O	effect
5	19	20	O	on
6	22	24	O	the
7	26	33	O	efficacy
8	35	36	O	or
9	38	43	O	safety
10	45	46	O	of
11	48	53	O	XXXXXXXX
12	55	56	O	in
13	58	64	O	elderly
14	66	73	O	subjects
15	75	76	O	in
16	78	85	O	clinical
17	87	93	O	studies
NULL

Livalo	590	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	60
Renal Impairment: In patients with moderate renal impairment (glomerular filtration rate of 30 - 59 mL/min/1.73 m2) and end stage renal disease receiving hemodialysis, pitavastatin AUC0-inf is 102 and 86% higher than those of healthy volunteers, respectively, while pitavastatin Cmax is 60 and 40% higher than those of healthy volunteers, respectively.
1	0	4	O	Renal
2	6	15	O	Impairment
3	16	16	O	:
4	18	19	O	In
5	21	28	O	patients
6	30	33	O	with
7	35	42	O	moderate
8	44	48	O	renal
9	50	59	O	impairment
10	62	71	O	glomerular
11	73	82	O	filtration
12	84	87	O	rate
13	89	90	O	of
14	92	93	O	30
15	97	98	O	59
16	100	101	O	mL
17	102	102	O	/
18	103	105	O	min
19	106	106	O	/
20	107	110	O	1.73
21	112	113	O	m2
22	116	118	O	and
23	120	122	O	end
24	124	128	O	stage
25	130	134	O	renal
26	136	142	O	disease
27	144	152	O	receiving
28	154	165	O	hemodialysis
29	166	166	O	,
30	168	179	O	XXXXXXXX
31	181	184	O	AUC0
32	186	188	O	inf
33	190	191	O	is
34	193	195	O	102
35	197	199	O	and
36	201	203	O	86%
37	205	210	O	higher
38	212	215	O	than
39	217	221	O	those
40	223	224	O	of
41	226	232	O	healthy
42	234	243	O	volunteers
43	244	244	O	,
44	246	257	O	respectively
45	258	258	O	,
46	260	264	O	while
47	266	277	O	XXXXXXXX
48	279	282	O	Cmax
49	284	285	O	is
50	287	288	O	60
51	290	292	O	and
52	294	296	O	40%
53	298	303	O	higher
54	305	308	O	than
55	310	314	O	those
56	316	317	O	of
57	319	325	O	healthy
58	327	336	O	volunteers
59	337	337	O	,
60	339	350	O	respectively
NULL

Livalo	591	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	16
Patients received hemodialysis immediately before pitavastatin dosing and did not undergo hemodialysis during the pharmacokinetic study.
1	0	7	O	Patients
2	9	16	O	received
3	18	29	O	hemodialysis
4	31	41	O	immediately
5	43	48	O	before
6	50	61	O	XXXXXXXX
7	63	68	O	dosing
8	70	72	O	and
9	74	76	O	did
10	78	80	O	not
11	82	88	O	undergo
12	90	101	O	hemodialysis
13	103	108	O	during
14	110	112	O	the
15	114	128	O	pharmacokinetic
16	130	134	O	study
NULL

Livalo	592	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	27
Hemodialysis patients have 33 and 36% increases in the mean unbound fraction of pitavastatin as compared to healthy volunteers and patients with moderate renal impairment, respectively.
1	0	11	O	Hemodialysis
2	13	20	O	patients
3	22	25	O	have
4	27	28	O	33
5	30	32	O	and
6	34	36	O	36%
7	38	46	O	increases
8	48	49	O	in
9	51	53	O	the
10	55	58	O	mean
11	60	66	O	unbound
12	68	75	O	fraction
13	77	78	O	of
14	80	91	O	XXXXXXXX
15	93	94	O	as
16	96	103	O	compared
17	105	106	O	to
18	108	114	O	healthy
19	116	125	O	volunteers
20	127	129	O	and
21	131	138	O	patients
22	140	143	O	with
23	145	152	O	moderate
24	154	158	O	renal
25	160	169	O	impairment
26	170	170	O	,
27	172	183	O	respectively
NULL

Livalo	593	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	33
In another pharmacokinetic study, patients with severe renal impairment (glomerular filtration rate 15 - 29 mL/min/1.73 m2) not receiving hemodialysis were administered a single dose of LIVALO 4 mg.
1	0	1	O	In
2	3	9	O	another
3	11	25	O	pharmacokinetic
4	27	31	O	study
5	32	32	O	,
6	34	41	O	patients
7	43	46	O	with
8	48	53	O	severe
9	55	59	O	renal
10	61	70	O	impairment
11	73	82	O	glomerular
12	84	93	O	filtration
13	95	98	O	rate
14	100	101	O	15
15	105	106	O	29
16	108	109	O	mL
17	110	110	O	/
18	111	113	O	min
19	114	114	O	/
20	115	118	O	1.73
21	120	121	O	m2
22	124	126	O	not
23	128	136	O	receiving
24	138	149	O	hemodialysis
25	151	154	O	were
26	156	167	O	administered
27	169	169	O	a
28	171	176	O	single
29	178	181	O	dose
30	183	184	O	of
31	186	191	O	XXXXXXXX
32	193	193	O	4
33	195	196	O	mg
NULL

Livalo	594	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	20
The AUC0-inf and the Cmax were 36 and 18% higher, respectively, compared with those of healthy volunteers.
1	0	2	O	The
2	4	7	O	AUC0
3	9	11	O	inf
4	13	15	O	and
5	17	19	O	the
6	21	24	O	Cmax
7	26	29	O	were
8	31	32	O	36
9	34	36	O	and
10	38	40	O	18%
11	42	47	O	higher
12	48	48	O	,
13	50	61	O	respectively
14	62	62	O	,
15	64	71	O	compared
16	73	76	O	with
17	78	82	O	those
18	84	85	O	of
19	87	93	O	healthy
20	95	104	O	volunteers
NULL

Livalo	595	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	21
For both patients with severe renal impairment and healthy volunteers, the mean percentage of protein-unbound pitavastatin was approximately 0.6%.
1	0	2	O	For
2	4	7	O	both
3	9	16	O	patients
4	18	21	O	with
5	23	28	O	severe
6	30	34	O	renal
7	36	45	O	impairment
8	47	49	O	and
9	51	57	O	healthy
10	59	68	O	volunteers
11	69	69	O	,
12	71	73	O	the
13	75	78	O	mean
14	80	89	O	percentage
15	91	92	O	of
16	94	100	O	protein
17	102	108	O	unbound
18	110	121	O	XXXXXXXX
19	123	125	O	was
20	127	139	O	approximately
21	141	144	O	0.6%
NULL

Livalo	596	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	13
The effect of mild renal impairment on pitavastatin exposure has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	17	O	mild
5	19	23	O	renal
6	25	34	O	impairment
7	36	37	O	on
8	39	50	O	XXXXXXXX
9	52	59	O	exposure
10	61	63	O	has
11	65	67	O	not
12	69	72	O	been
13	74	80	O	studied
NULL

Livalo	597	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	20
Hepatic Impairment: The disposition of pitavastatin was compared in healthy volunteers and patients with various degrees of hepatic impairment.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	18	18	O	:
4	20	22	O	The
5	24	34	O	disposition
6	36	37	O	of
7	39	50	O	XXXXXXXX
8	52	54	O	was
9	56	63	O	compared
10	65	66	O	in
11	68	74	O	healthy
12	76	85	O	volunteers
13	87	89	O	and
14	91	98	O	patients
15	100	103	O	with
16	105	111	O	various
17	113	119	O	degrees
18	121	122	O	of
19	124	130	O	hepatic
20	132	141	O	impairment
NULL

Livalo	598	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	20
The ratio of pitavastatin Cmax between patients with moderate hepatic impairment (Child-Pugh B disease) and healthy volunteers was 2.7.
1	0	2	O	The
2	4	8	O	ratio
3	10	11	O	of
4	13	24	O	XXXXXXXX
5	26	29	O	Cmax
6	31	37	O	between
7	39	46	O	patients
8	48	51	O	with
9	53	60	O	moderate
10	62	68	O	hepatic
11	70	79	O	impairment
12	82	86	O	Child
13	88	91	O	Pugh
14	93	93	O	B
15	95	101	O	disease
16	104	106	O	and
17	108	114	O	healthy
18	116	125	O	volunteers
19	127	129	O	was
20	131	133	O	2.7
NULL

Livalo	599	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	16
The ratio of pitavastatin AUCinf between patients with moderate hepatic impairment and healthy volunteers was 3.8.
1	0	2	O	The
2	4	8	O	ratio
3	10	11	O	of
4	13	24	O	XXXXXXXX
5	26	31	O	AUCinf
6	33	39	O	between
7	41	48	O	patients
8	50	53	O	with
9	55	62	O	moderate
10	64	70	O	hepatic
11	72	81	O	impairment
12	83	85	O	and
13	87	93	O	healthy
14	95	104	O	volunteers
15	106	108	O	was
16	110	112	O	3.8
NULL

Livalo	600	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	20
The ratio of pitavastatin Cmax between patients with mild hepatic impairment (Child-Pugh A disease) and healthy volunteers was 1.3.
1	0	2	O	The
2	4	8	O	ratio
3	10	11	O	of
4	13	24	O	XXXXXXXX
5	26	29	O	Cmax
6	31	37	O	between
7	39	46	O	patients
8	48	51	O	with
9	53	56	O	mild
10	58	64	O	hepatic
11	66	75	O	impairment
12	78	82	O	Child
13	84	87	O	Pugh
14	89	89	O	A
15	91	97	O	disease
16	100	102	O	and
17	104	110	O	healthy
18	112	121	O	volunteers
19	123	125	O	was
20	127	129	O	1.3
NULL

Livalo	601	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	16
The ratio of pitavastatin AUCinf between patients with mild hepatic impairment and healthy volunteers was 1.6.
1	0	2	O	The
2	4	8	O	ratio
3	10	11	O	of
4	13	24	O	XXXXXXXX
5	26	31	O	AUCinf
6	33	39	O	between
7	41	48	O	patients
8	50	53	O	with
9	55	58	O	mild
10	60	66	O	hepatic
11	68	77	O	impairment
12	79	81	O	and
13	83	89	O	healthy
14	91	100	O	volunteers
15	102	104	O	was
16	106	108	O	1.6
NULL

Livalo	602	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	24
Mean pitavastatin t% for moderate hepatic impairment, mild hepatic impairment, and healthy were 15, 10, and 8 hours, respectively.
1	0	3	O	Mean
2	5	16	O	XXXXXXXX
3	18	19	O	t%
4	21	23	O	for
5	25	32	O	moderate
6	34	40	O	hepatic
7	42	51	O	impairment
8	52	52	O	,
9	54	57	O	mild
10	59	65	O	hepatic
11	67	76	O	impairment
12	77	77	O	,
13	79	81	O	and
14	83	89	O	healthy
15	91	94	O	were
16	96	97	O	15
17	98	98	O	,
18	100	101	O	10
19	102	102	O	,
20	104	106	O	and
21	108	108	O	8
22	110	114	O	hours
23	115	115	O	,
24	117	128	O	respectively
NULL

Livalo	603	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	21
Drug-Drug Interactions: The principal route of pitavastatin metabolism is glucuronidation via liver UGTs with subsequent formation of pitavastatin lactone.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	22	22	O	:
5	24	26	O	The
6	28	36	O	principal
7	38	42	O	route
8	44	45	O	of
9	47	58	O	XXXXXXXX
10	60	69	O	metabolism
11	71	72	O	is
12	74	88	O	glucuronidation
13	90	92	O	via
14	94	98	O	liver
15	100	103	O	UGTs
16	105	108	O	with
17	110	119	O	subsequent
18	121	129	O	formation
19	131	132	O	of
20	134	145	O	XXXXXXXX
21	147	153	O	lactone
NULL

Livalo	604	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	10
There is only minimal metabolism by the cytochrome P450 system.
1	0	4	O	There
2	6	7	O	is
3	9	12	O	only
4	14	20	O	minimal
5	22	31	O	metabolism
6	33	34	O	by
7	36	38	O	the
8	40	49	O	cytochrome
9	51	54	O	P450
10	56	61	O	system
NULL

Livalo	605	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	32
Warfarin: The steady-state pharmacodynamics (international normalized ratio [INR] and prothrombin time [PT]) and pharmacokinetics of warfarin in healthy volunteers were unaffected by the co-administration of LIVALO 4 mg daily.
1	0	7	O	Warfarin
2	8	8	O	:
3	10	12	O	The
4	14	19	O	steady
5	21	25	O	state
6	27	42	O	pharmacodynamics
7	45	57	O	international
8	59	68	O	normalized
9	70	74	O	ratio
10	77	79	O	INR
11	82	84	O	and
12	86	96	O	prothrombin
13	98	101	O	time
14	104	105	O	PT
15	109	111	O	and
16	113	128	O	pharmacokinetics
17	130	131	O	of
18	133	140	O	warfarin
19	142	143	O	in
20	145	151	O	healthy
21	153	162	O	volunteers
22	164	167	O	were
23	169	178	O	unaffected
24	180	181	O	by
25	183	185	O	the
26	187	188	O	co
27	190	203	O	administration
28	205	206	O	of
29	208	213	O	XXXXXXXX
30	215	215	O	4
31	217	218	O	mg
32	220	224	O	daily
NULL

Livalo	606	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	20
However, patients receiving warfarin should have their PT time or INR monitored when pitavastatin is added to their therapy.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	patients
4	18	26	O	receiving
5	28	35	U-DYN	warfarin
6	37	42	O	should
7	44	47	O	have
8	49	53	O	their
9	55	56	B-EFF	PT
10	58	61	L-EFF	time
11	63	64	O	or
12	66	68	U-EFF	INR
13	70	78	O	monitored
14	80	83	O	when
15	85	96	O	XXXXXXXX
16	98	99	O	is
17	101	105	O	added
18	107	108	O	to
19	110	114	O	their
20	116	122	O	therapy
D/5:12:1 D/5:9:1

Livalo	607	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	32
Effect of Co-Administered Drugs on Pitavastatin Systemic Exposure * Data presented as x-fold change represent the ratio between co-administration and pitavastatin alone (i.e., 1-fold = no change).
1	0	5	O	Effect
2	7	8	O	of
3	10	11	O	Co
4	13	24	O	Administered
5	26	30	O	Drugs
6	32	33	O	on
7	35	46	O	XXXXXXXX
8	48	55	O	Systemic
9	57	64	O	Exposure
10	66	66	O	*
11	68	71	O	Data
12	73	81	O	presented
13	83	84	O	as
14	86	86	O	x
15	88	91	O	fold
16	93	98	O	change
17	100	108	O	represent
18	110	112	O	the
19	114	118	O	ratio
20	120	126	O	between
21	128	129	O	co
22	131	144	O	administration
23	146	148	O	and
24	150	161	O	XXXXXXXX
25	163	167	O	alone
26	170	172	O	i.e
27	174	174	O	,
28	176	176	O	1
29	178	181	O	fold
30	183	183	O	=
31	185	186	O	no
32	188	193	O	change
NULL

Livalo	608	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	18
Data presented as % change represent % difference relative to pitavastatin alone (i.e., 0% = no change).
1	0	3	O	Data
2	5	13	O	presented
3	15	16	O	as
4	18	18	O	%
5	20	25	O	change
6	27	35	O	represent
7	37	37	O	%
8	39	48	O	difference
9	50	57	O	relative
10	59	60	O	to
11	62	73	O	XXXXXXXX
12	75	79	O	alone
13	82	84	O	i.e
14	86	86	O	,
15	88	89	O	0%
16	91	91	O	=
17	93	94	O	no
18	96	101	O	change
NULL

Livalo	609	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	322
* Considered clinically significant BID = twice daily; QD = once daily; LA = Long Acting Co-administered drug Dose regimen Change inAUC* Change in Cmax* Cyclosporine Pitavastatin 2 mg QD for 6 days + cyclosporine 2 mg/kg on Day 6 * 4.6 fold* * 6.6 fold * Erythromycin Pitavastatin 4 mg single dose on Day 4 + erythromycin 500 mg 4 times daily for 6 days * 2.8 fold * * 3.6 fold * Rifampin Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days * 29% * 2.0 fold Atazanavir Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days * 31% * 60% Darunavir/Ritonavir Pitavastatin 4mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800mg/100 mg QD on Days 6-16 * 26% * 4% Lopinavir/Ritonavir Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9 - 24 * 20% *4 % Gemfibrozil Pitavastatin 4 mg QD + gemfibrozil 600 mg BID for 7 days * 45% * 31% Fenofibrate Pitavastatin 4 mg QD + fenofibrate 160 mg QD for 7 days *18% * 11% Ezetimibe Pitavastatin 2 mg QD + ezetimibe 10 mg for 7 days * 2% *0.2% Enalapril Pitavastatin 4 mg QD + enalapril 20 mg daily for 5 days * 6% * 7% Digoxin Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days * 4% * 9% Diltiazem LA Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15 *10% *15% Grapefruit Juice Pitavastatin 2 mg single dose on Day 3 + grapefruit juice for 4 days * 15% * 12% Itraconazole Pitavastatin 4 mg single dose on Day 4 + itraconazole 200 mg daily for 5 days * 23% * 22% Table 3.
1	0	0	O	*
2	2	11	O	Considered
3	13	22	O	clinically
4	24	34	O	significant
5	36	38	O	BID
6	40	40	O	=
7	42	46	O	twice
8	48	52	O	daily
9	55	56	O	QD
10	58	58	O	=
11	60	63	O	once
12	65	69	O	daily
13	72	73	O	LA
14	75	75	O	=
15	77	80	O	Long
16	82	87	O	Acting
17	89	90	O	Co
18	92	103	O	administered
19	105	108	O	drug
20	110	113	O	Dose
21	115	121	O	regimen
22	123	128	O	Change
23	130	135	O	inAUC*
24	137	142	O	Change
25	144	145	O	in
26	147	151	O	Cmax*
27	153	164	O	Cyclosporine
28	166	177	O	XXXXXXXX
29	179	179	O	2
30	181	182	O	mg
31	184	185	O	QD
32	187	189	O	for
33	191	191	O	6
34	193	196	O	days
35	198	198	O	+
36	200	211	O	cyclosporine
37	213	213	O	2
38	215	216	O	mg
39	217	217	O	/
40	218	219	O	kg
41	221	222	O	on
42	224	226	O	Day
43	228	228	O	6
44	230	230	O	*
45	232	234	O	4.6
46	236	240	O	fold*
47	242	242	O	*
48	244	246	O	6.6
49	248	251	O	fold
50	253	253	O	*
51	255	266	O	Erythromycin
52	268	279	O	XXXXXXXX
53	281	281	O	4
54	283	284	O	mg
55	286	291	O	single
56	293	296	O	dose
57	298	299	O	on
58	301	303	O	Day
59	305	305	O	4
60	307	307	O	+
61	309	320	O	erythromycin
62	322	324	O	500
63	326	327	O	mg
64	329	329	O	4
65	331	335	O	times
66	337	341	O	daily
67	343	345	O	for
68	347	347	O	6
69	349	352	O	days
70	354	354	O	*
71	356	358	O	2.8
72	360	363	O	fold
73	365	365	O	*
74	367	367	O	*
75	369	371	O	3.6
76	373	376	O	fold
77	378	378	O	*
78	380	387	O	Rifampin
79	389	400	O	XXXXXXXX
80	402	402	O	4
81	404	405	O	mg
82	407	408	O	QD
83	410	410	O	+
84	412	419	O	rifampin
85	421	423	O	600
86	425	426	O	mg
87	428	429	O	QD
88	431	433	O	for
89	435	435	O	5
90	437	440	O	days
91	442	442	O	*
92	444	446	O	29%
93	448	448	O	*
94	450	452	O	2.0
95	454	457	O	fold
96	459	468	O	Atazanavir
97	470	481	O	XXXXXXXX
98	483	483	O	4
99	485	486	O	mg
100	488	489	O	QD
101	491	491	O	+
102	493	502	O	atazanavir
103	504	506	O	300
104	508	509	O	mg
105	511	515	O	daily
106	517	519	O	for
107	521	521	O	5
108	523	526	O	days
109	528	528	O	*
110	530	532	O	31%
111	534	534	O	*
112	536	538	O	60%
113	540	548	O	Darunavir
114	549	549	O	/
115	550	558	O	Ritonavir
116	560	571	O	XXXXXXXX
117	573	575	O	4mg
118	577	578	O	QD
119	580	581	O	on
120	583	586	O	Days
121	588	588	O	1
122	590	590	O	5
123	592	594	O	and
124	596	597	O	12
125	599	600	O	16
126	602	602	O	+
127	604	612	O	darunavir
128	613	613	O	/
129	614	622	O	ritonavir
130	624	628	O	800mg
131	629	629	O	/
132	630	632	O	100
133	634	635	O	mg
134	637	638	O	QD
135	640	641	O	on
136	643	646	O	Days
137	648	648	O	6
138	650	651	O	16
139	653	653	O	*
140	655	657	O	26%
141	659	659	O	*
142	661	662	O	4%
143	664	672	O	Lopinavir
144	673	673	O	/
145	674	682	O	Ritonavir
146	684	695	O	XXXXXXXX
147	697	697	O	4
148	699	700	O	mg
149	702	703	O	QD
150	705	706	O	on
151	708	711	O	Days
152	713	713	O	1
153	715	715	O	5
154	717	719	O	and
155	721	722	O	20
156	724	725	O	24
157	727	727	O	+
158	729	737	O	lopinavir
159	738	738	O	/
160	739	747	O	ritonavir
161	749	751	O	400
162	753	754	O	mg
163	755	755	O	/
164	756	758	O	100
165	760	761	O	mg
166	763	765	O	BID
167	767	768	O	on
168	770	773	O	Days
169	775	775	O	9
170	779	780	O	24
171	782	782	O	*
172	784	786	O	20%
173	788	789	O	4
174	791	791	O	%
175	793	803	O	Gemfibrozil
176	805	816	O	XXXXXXXX
177	818	818	O	4
178	820	821	O	mg
179	823	824	O	QD
180	826	826	O	+
181	828	838	O	gemfibrozil
182	840	842	O	600
183	844	845	O	mg
184	847	849	O	BID
185	851	853	O	for
186	855	855	O	7
187	857	860	O	days
188	862	862	O	*
189	864	866	O	45%
190	868	868	O	*
191	870	872	O	31%
192	874	884	O	Fenofibrate
193	886	897	O	XXXXXXXX
194	899	899	O	4
195	901	902	O	mg
196	904	905	O	QD
197	907	907	O	+
198	909	919	O	fenofibrate
199	921	923	O	160
200	925	926	O	mg
201	928	929	O	QD
202	931	933	O	for
203	935	935	O	7
204	937	940	O	days
205	942	945	O	18%
206	947	947	O	*
207	949	951	O	11%
208	953	961	O	Ezetimibe
209	963	974	O	XXXXXXXX
210	976	976	O	2
211	978	979	O	mg
212	981	982	O	QD
213	984	984	O	+
214	986	994	O	ezetimibe
215	996	997	O	10
216	999	1000	O	mg
217	1002	1004	O	for
218	1006	1006	O	7
219	1008	1011	O	days
220	1013	1013	O	*
221	1015	1016	O	2%
222	1018	1022	O	0.2%
223	1024	1032	O	Enalapril
224	1034	1045	O	XXXXXXXX
225	1047	1047	O	4
226	1049	1050	O	mg
227	1052	1053	O	QD
228	1055	1055	O	+
229	1057	1065	O	enalapril
230	1067	1068	O	20
231	1070	1071	O	mg
232	1073	1077	O	daily
233	1079	1081	O	for
234	1083	1083	O	5
235	1085	1088	O	days
236	1090	1090	O	*
237	1092	1093	O	6%
238	1095	1095	O	*
239	1097	1098	O	7%
240	1100	1106	O	Digoxin
241	1108	1119	O	XXXXXXXX
242	1121	1121	O	4
243	1123	1124	O	mg
244	1126	1127	O	QD
245	1129	1129	O	+
246	1131	1137	O	digoxin
247	1139	1142	O	0.25
248	1144	1145	O	mg
249	1147	1149	O	for
250	1151	1151	O	7
251	1153	1156	O	days
252	1158	1158	O	*
253	1160	1161	O	4%
254	1163	1163	O	*
255	1165	1166	O	9%
256	1168	1176	O	Diltiazem
257	1178	1179	O	LA
258	1181	1192	O	XXXXXXXX
259	1194	1194	O	4
260	1196	1197	O	mg
261	1199	1200	O	QD
262	1202	1203	O	on
263	1205	1208	O	Days
264	1210	1210	O	1
265	1212	1212	O	5
266	1214	1216	O	and
267	1218	1219	O	11
268	1221	1222	O	15
269	1224	1226	O	and
270	1228	1236	O	diltiazem
271	1238	1239	O	LA
272	1241	1243	O	240
273	1245	1246	O	mg
274	1248	1249	O	on
275	1251	1254	O	Days
276	1256	1256	O	6
277	1258	1259	O	15
278	1261	1264	O	10%
279	1266	1269	O	15%
280	1271	1280	O	Grapefruit
281	1282	1286	O	Juice
282	1288	1299	O	XXXXXXXX
283	1301	1301	O	2
284	1303	1304	O	mg
285	1306	1311	O	single
286	1313	1316	O	dose
287	1318	1319	O	on
288	1321	1323	O	Day
289	1325	1325	O	3
290	1327	1327	O	+
291	1329	1338	O	grapefruit
292	1340	1344	O	juice
293	1346	1348	O	for
294	1350	1350	O	4
295	1352	1355	O	days
296	1357	1357	O	*
297	1359	1361	O	15%
298	1363	1363	O	*
299	1365	1367	O	12%
300	1369	1380	O	Itraconazole
301	1382	1393	O	XXXXXXXX
302	1395	1395	O	4
303	1397	1398	O	mg
304	1400	1405	O	single
305	1407	1410	O	dose
306	1412	1413	O	on
307	1415	1417	O	Day
308	1419	1419	O	4
309	1421	1421	O	+
310	1423	1434	O	itraconazole
311	1436	1438	O	200
312	1440	1441	O	mg
313	1443	1447	O	daily
314	1449	1451	O	for
315	1453	1453	O	5
316	1455	1458	O	days
317	1460	1460	O	*
318	1462	1464	O	23%
319	1466	1466	O	*
320	1468	1470	O	22%
321	1472	1476	O	Table
322	1478	1478	O	3
NULL

Livalo	610	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	31
Effect of Pitavastatin Co-Administration on Systemic Exposure to Other Drugs *Data presented as % change represent % difference relative to the investigated drug alone (i.e., 0% = no change).
1	0	5	O	Effect
2	7	8	O	of
3	10	21	O	XXXXXXXX
4	23	24	O	Co
5	26	39	O	Administration
6	41	42	O	on
7	44	51	O	Systemic
8	53	60	O	Exposure
9	62	63	O	to
10	65	69	O	Other
11	71	75	O	Drugs
12	77	81	O	Data
13	83	91	O	presented
14	93	94	O	as
15	96	96	O	%
16	98	103	O	change
17	105	113	O	represent
18	115	115	O	%
19	117	126	O	difference
20	128	135	O	relative
21	137	138	O	to
22	140	142	O	the
23	144	155	O	investigated
24	157	160	O	drug
25	162	166	O	alone
26	169	171	O	i.e
27	173	173	O	,
28	175	176	O	0%
29	178	178	O	=
30	180	181	O	no
31	183	188	O	change
NULL

Livalo	611	34090-1	44dcbf97-99ec-427c-ba50-207e0069d6d2	284
BID = twice daily; QD = once daily; LA = Long Acting Co-administered drug Dose regimen Change inAUC* Change in Cmax* Atazanavir Pitavastatin 4 mg QD + atazanavir 300 mg daily for 5 days * 6% * 13% Darunavir Pitavastatin 4mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800mg/100 mg QD on Days 6-16 * 3% * 6% Lopinavir Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9 - 24 * 9% * 7% Ritonavir Pitavastatin 4 mg QD on Days 1-5 and 20-24 + lopinavir/ritonavir 400 mg/100 mg BID on Days 9 - 24 * 11% * 11% Ritonavir Pitavastatin 4mg QD on Days 1-5 and 12-16 + darunavir/ritonavir 800mg/100 mg QD on Days 6-16 * 8% * 2% Enalapril Pitavastatin 4 mg QD + enalapril 20 mgdaily for 5 days Enalapril * 12% * 12% Enalaprilat * 1% * 1% Warfarin Individualized maintenance dose of warfarin (2 - 7 mg) for 8 days + pitavastatin 4 mg QD for 9 days R-warfarin * 7% * 3% S-warfarin * 6% * 3% Ezetimibe Pitavastatin 2 mg QD + ezetimibe 10 mg for 7 days * 9% * 2% Digoxin Pitavastatin 4 mg QD + digoxin 0.25 mg for 7 days * 3% * 4% Diltiazem LA Pitavastatin 4 mg QD on Days 1-5 and 11-15 and diltiazem LA 240 mg on Days 6-15 * 2% * 7% Rifampin Pitavastatin 4 mg QD + rifampin 600 mg QD for 5 days * 15% * 18%
1	0	2	O	BID
2	4	4	O	=
3	6	10	O	twice
4	12	16	O	daily
5	19	20	O	QD
6	22	22	O	=
7	24	27	O	once
8	29	33	O	daily
9	36	37	O	LA
10	39	39	O	=
11	41	44	O	Long
12	46	51	O	Acting
13	53	54	O	Co
14	56	67	O	administered
15	69	72	O	drug
16	74	77	O	Dose
17	79	85	O	regimen
18	87	92	O	Change
19	94	99	O	inAUC*
20	101	106	O	Change
21	108	109	O	in
22	111	115	O	Cmax*
23	117	126	O	Atazanavir
24	128	139	O	XXXXXXXX
25	141	141	O	4
26	143	144	O	mg
27	146	147	O	QD
28	149	149	O	+
29	151	160	O	atazanavir
30	162	164	O	300
31	166	167	O	mg
32	169	173	O	daily
33	175	177	O	for
34	179	179	O	5
35	181	184	O	days
36	186	186	O	*
37	188	189	O	6%
38	191	191	O	*
39	193	195	O	13%
40	197	205	O	Darunavir
41	207	218	O	XXXXXXXX
42	220	222	O	4mg
43	224	225	O	QD
44	227	228	O	on
45	230	233	O	Days
46	235	235	O	1
47	237	237	O	5
48	239	241	O	and
49	243	244	O	12
50	246	247	O	16
51	249	249	O	+
52	251	259	O	darunavir
53	260	260	O	/
54	261	269	O	ritonavir
55	271	275	O	800mg
56	276	276	O	/
57	277	279	O	100
58	281	282	O	mg
59	284	285	O	QD
60	287	288	O	on
61	290	293	O	Days
62	295	295	O	6
63	297	298	O	16
64	300	300	O	*
65	302	303	O	3%
66	305	305	O	*
67	307	308	O	6%
68	310	318	O	Lopinavir
69	320	331	O	XXXXXXXX
70	333	333	O	4
71	335	336	O	mg
72	338	339	O	QD
73	341	342	O	on
74	344	347	O	Days
75	349	349	O	1
76	351	351	O	5
77	353	355	O	and
78	357	358	O	20
79	360	361	O	24
80	363	363	O	+
81	365	373	O	lopinavir
82	374	374	O	/
83	375	383	O	ritonavir
84	385	387	O	400
85	389	390	O	mg
86	391	391	O	/
87	392	394	O	100
88	396	397	O	mg
89	399	401	O	BID
90	403	404	O	on
91	406	409	O	Days
92	411	411	O	9
93	415	416	O	24
94	418	418	O	*
95	420	421	O	9%
96	423	423	O	*
97	425	426	O	7%
98	428	436	O	Ritonavir
99	438	449	O	XXXXXXXX
100	451	451	O	4
101	453	454	O	mg
102	456	457	O	QD
103	459	460	O	on
104	462	465	O	Days
105	467	467	O	1
106	469	469	O	5
107	471	473	O	and
108	475	476	O	20
109	478	479	O	24
110	481	481	O	+
111	483	491	O	lopinavir
112	492	492	O	/
113	493	501	O	ritonavir
114	503	505	O	400
115	507	508	O	mg
116	509	509	O	/
117	510	512	O	100
118	514	515	O	mg
119	517	519	O	BID
120	521	522	O	on
121	524	527	O	Days
122	529	529	O	9
123	533	534	O	24
124	536	536	O	*
125	538	540	O	11%
126	542	542	O	*
127	544	546	O	11%
128	548	556	O	Ritonavir
129	558	569	O	XXXXXXXX
130	571	573	O	4mg
131	575	576	O	QD
132	578	579	O	on
133	581	584	O	Days
134	586	586	O	1
135	588	588	O	5
136	590	592	O	and
137	594	595	O	12
138	597	598	O	16
139	600	600	O	+
140	602	610	O	darunavir
141	611	611	O	/
142	612	620	O	ritonavir
143	622	626	O	800mg
144	627	627	O	/
145	628	630	O	100
146	632	633	O	mg
147	635	636	O	QD
148	638	639	O	on
149	641	644	O	Days
150	646	646	O	6
151	648	649	O	16
152	651	651	O	*
153	653	654	O	8%
154	656	656	O	*
155	658	659	O	2%
156	661	669	O	Enalapril
157	671	682	O	XXXXXXXX
158	684	684	O	4
159	686	687	O	mg
160	689	690	O	QD
161	692	692	O	+
162	694	702	O	enalapril
163	704	705	O	20
164	707	713	O	mgdaily
165	715	717	O	for
166	719	719	O	5
167	721	724	O	days
168	726	734	O	Enalapril
169	736	736	O	*
170	738	740	O	12%
171	742	742	O	*
172	744	746	O	12%
173	748	758	O	Enalaprilat
174	760	760	O	*
175	762	763	O	1%
176	765	765	O	*
177	767	768	O	1%
178	770	777	O	Warfarin
179	779	792	O	Individualized
180	794	804	O	maintenance
181	806	809	O	dose
182	811	812	O	of
183	814	821	O	warfarin
184	824	824	O	2
185	828	828	O	7
186	830	831	O	mg
187	834	836	O	for
188	838	838	O	8
189	840	843	O	days
190	845	845	O	+
191	847	858	O	XXXXXXXX
192	860	860	O	4
193	862	863	O	mg
194	865	866	O	QD
195	868	870	O	for
196	872	872	O	9
197	874	877	O	days
198	879	879	O	R
199	881	888	O	warfarin
200	890	890	O	*
201	892	893	O	7%
202	895	895	O	*
203	897	898	O	3%
204	900	900	O	S
205	902	909	O	warfarin
206	911	911	O	*
207	913	914	O	6%
208	916	916	O	*
209	918	919	O	3%
210	921	929	O	Ezetimibe
211	931	942	O	XXXXXXXX
212	944	944	O	2
213	946	947	O	mg
214	949	950	O	QD
215	952	952	O	+
216	954	962	O	ezetimibe
217	964	965	O	10
218	967	968	O	mg
219	970	972	O	for
220	974	974	O	7
221	976	979	O	days
222	981	981	O	*
223	983	984	O	9%
224	986	986	O	*
225	988	989	O	2%
226	991	997	O	Digoxin
227	999	1010	O	XXXXXXXX
228	1012	1012	O	4
229	1014	1015	O	mg
230	1017	1018	O	QD
231	1020	1020	O	+
232	1022	1028	O	digoxin
233	1030	1033	O	0.25
234	1035	1036	O	mg
235	1038	1040	O	for
236	1042	1042	O	7
237	1044	1047	O	days
238	1049	1049	O	*
239	1051	1052	O	3%
240	1054	1054	O	*
241	1056	1057	O	4%
242	1059	1067	O	Diltiazem
243	1069	1070	O	LA
244	1072	1083	O	XXXXXXXX
245	1085	1085	O	4
246	1087	1088	O	mg
247	1090	1091	O	QD
248	1093	1094	O	on
249	1096	1099	O	Days
250	1101	1101	O	1
251	1103	1103	O	5
252	1105	1107	O	and
253	1109	1110	O	11
254	1112	1113	O	15
255	1115	1117	O	and
256	1119	1127	O	diltiazem
257	1129	1130	O	LA
258	1132	1134	O	240
259	1136	1137	O	mg
260	1139	1140	O	on
261	1142	1145	O	Days
262	1147	1147	O	6
263	1149	1150	O	15
264	1152	1152	O	*
265	1154	1155	O	2%
266	1157	1157	O	*
267	1159	1160	O	7%
268	1162	1169	O	Rifampin
269	1171	1182	O	XXXXXXXX
270	1184	1184	O	4
271	1186	1187	O	mg
272	1189	1190	O	QD
273	1192	1192	O	+
274	1194	1201	O	rifampin
275	1203	1205	O	600
276	1207	1208	O	mg
277	1210	1211	O	QD
278	1213	1215	O	for
279	1217	1217	O	5
280	1219	1222	O	days
281	1224	1224	O	*
282	1226	1228	O	15%
283	1230	1230	O	*
284	1232	1234	O	18%
NULL

Lovastatin	5187	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	27
Lovastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	metabolized
4	26	27	O	by
5	29	34	O	CYP3A4
6	36	38	O	but
7	40	42	O	has
8	44	45	O	no
9	47	52	O	CYP3A4
10	54	63	O	inhibitory
11	65	72	O	activity
12	75	83	O	therefore
13	85	86	O	it
14	88	89	O	is
15	91	93	O	not
16	95	102	O	expected
17	104	105	O	to
18	107	112	O	affect
19	114	116	O	the
20	118	123	O	plasma
21	125	138	O	concentrations
22	140	141	O	of
23	143	147	O	other
24	149	153	O	drugs
25	155	165	O	metabolized
26	167	168	O	by
27	170	175	O	CYP3A4
NULL

Lovastatin	5188	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	49
Strong inhibitors of CYP3A4 (e.g., itraconazole, ketoconazole, posaconazole, voriconazole, clarithromycin, telithromycin, HIV protease inhibitors, boceprevir, telaprevir, nefazodone, erythromycin, and cobicistat-containing products), and grapefruit juice increase the risk of myopathy by reducing the elimination of lovastatin.
1	0	5	B-DYN	Strong
2	7	16	I-DYN	inhibitors
3	18	19	I-DYN	of
4	21	26	L-DYN	CYP3A4
5	29	31	O	e.g
6	33	33	O	,
7	35	46	U-DYN	itraconazole
8	47	47	O	,
9	49	60	U-DYN	ketoconazole
10	61	61	O	,
11	63	74	U-DYN	posaconazole
12	75	75	O	,
13	77	88	U-DYN	voriconazole
14	89	89	O	,
15	91	104	U-DYN	clarithromycin
16	105	105	O	,
17	107	119	U-DYN	telithromycin
18	120	120	O	,
19	122	124	B-DYN	HIV
20	126	133	I-DYN	protease
21	135	144	L-DYN	inhibitors
22	145	145	O	,
23	147	156	U-DYN	boceprevir
24	157	157	O	,
25	159	168	U-DYN	telaprevir
26	169	169	O	,
27	171	180	U-DYN	nefazodone
28	181	181	O	,
29	183	194	U-DYN	erythromycin
30	195	195	O	,
31	197	199	O	and
32	201	210	U-DYN	cobicistat
33	212	221	B-DYN	containing
34	223	230	L-DYN	products
35	232	232	O	,
36	234	236	O	and
37	238	247	B-DYN	grapefruit
38	249	253	L-DYN	juice
39	255	262	O	increase
40	264	266	O	the
41	268	271	O	risk
42	273	274	O	of
43	276	283	U-EFF	myopathy
44	285	286	O	by
45	288	295	B-TRI	reducing
46	297	299	I-TRI	the
47	301	311	L-TRI	elimination
48	313	314	O	of
49	316	325	O	XXXXXXXX
D/1:43:1 D/11:43:1 D/13:43:1 D/15:43:1 D/17:43:1 D/19:43:1 D/23:43:1 D/25:43:1 D/27:43:1 D/29:43:1 D/32:43:1 D/33:43:1 D/37:43:1 D/7:43:1 D/9:43:1

Lovastatin	5190	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	28
The risk of myopathy is also increased by the following lipid-lowering drugs that are not strong CYP3A4 inhibitors, but which can cause myopathy when given alone.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	U-EFF	myopathy
5	21	22	O	is
6	24	27	O	also
7	29	37	O	increased
8	39	40	O	by
9	42	44	O	the
10	46	54	O	following
11	56	60	B-DYN	lipid
12	62	69	I-DYN	lowering
13	71	75	L-DYN	drugs
14	77	80	O	that
15	82	84	O	are
16	86	88	O	not
17	90	95	O	strong
18	97	102	O	CYP3A4
19	104	113	O	inhibitors
20	114	114	O	,
21	116	118	O	but
22	120	124	O	which
23	126	128	O	can
24	130	134	O	cause
25	136	143	O	myopathy
26	145	148	O	when
27	150	154	O	given
28	156	160	O	alone
D/11:4:1

Lovastatin	5191	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	25
Gemfibrozil Other fibrates Niacin (nicotinic acid) (>1 g/day) Cyclosporine: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine.
1	0	10	O	Gemfibrozil
2	12	16	O	Other
3	18	25	O	fibrates
4	27	32	O	Niacin
5	35	43	O	nicotinic
6	45	48	O	acid
7	52	53	O	>1
8	55	55	O	g
9	56	56	O	/
10	57	59	O	day
11	62	73	O	Cyclosporine
12	74	74	O	:
13	76	78	O	The
14	80	83	O	risk
15	85	86	O	of
16	88	95	B-EFF	myopathy
17	96	96	I-EFF	/
18	97	110	L-EFF	rhabdomyolysis
19	112	113	O	is
20	115	123	O	increased
21	125	126	O	by
22	128	138	O	concomitant
23	140	153	O	administration
24	155	156	O	of
25	158	169	U-DYN	cyclosporine
D/25:16:1

Lovastatin	5192	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	33
Danazol, Diltiazem, Dronedarone or Verapamil: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of danazol, diltiazem, dronedarone or verapamil particularly with higher doses of lovastatin.
1	0	6	O	Danazol
2	7	7	O	,
3	9	17	O	Diltiazem
4	18	18	O	,
5	20	30	O	Dronedarone
6	32	33	O	or
7	35	43	O	Verapamil
8	44	44	O	:
9	46	48	O	The
10	50	53	O	risk
11	55	56	O	of
12	58	65	B-EFF	myopathy
13	66	66	I-EFF	/
14	67	80	L-EFF	rhabdomyolysis
15	82	83	O	is
16	85	93	O	increased
17	95	96	O	by
18	98	108	O	concomitant
19	110	123	O	administration
20	125	126	O	of
21	128	134	U-DYN	danazol
22	135	135	O	,
23	137	145	U-DYN	diltiazem
24	146	146	O	,
25	148	158	U-DYN	dronedarone
26	160	161	O	or
27	163	171	U-DYN	verapamil
28	173	184	O	particularly
29	186	189	O	with
30	191	196	O	higher
31	198	202	O	doses
32	204	205	O	of
33	207	216	O	XXXXXXXX
D/21:12:1 D/23:12:1 D/25:12:1 D/27:12:1

Lovastatin	5193	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	27
Amiodarone: The risk of myopathy/rhabdomyolysis is increased when amiodarone is used concomitantly with a closely related member of the HMG-CoA reductase inhibitor class.
1	0	9	O	Amiodarone
2	10	10	O	:
3	12	14	O	The
4	16	19	O	risk
5	21	22	O	of
6	24	31	B-EFF	myopathy
7	32	32	I-EFF	/
8	33	46	L-EFF	rhabdomyolysis
9	48	49	O	is
10	51	59	O	increased
11	61	64	O	when
12	66	75	U-DYN	amiodarone
13	77	78	O	is
14	80	83	O	used
15	85	97	O	concomitantly
16	99	102	O	with
17	104	104	O	a
18	106	112	O	closely
19	114	120	O	related
20	122	127	O	member
21	129	130	O	of
22	132	134	O	the
23	136	138	O	HMG
24	140	142	O	CoA
25	144	152	O	reductase
26	154	162	O	inhibitor
27	164	168	O	class
D/12:6:1

Lovastatin	5194	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	25
Coumarin Anticoagulants: In a small clinical trial in which lovastatin was administered to warfarin treated patients, no effect on prothrombin time was detected.
1	0	7	O	Coumarin
2	9	22	O	Anticoagulants
3	23	23	O	:
4	25	26	O	In
5	28	28	O	a
6	30	34	O	small
7	36	43	O	clinical
8	45	49	O	trial
9	51	52	O	in
10	54	58	O	which
11	60	69	O	XXXXXXXX
12	71	73	O	was
13	75	86	O	administered
14	88	89	O	to
15	91	98	O	warfarin
16	100	106	O	treated
17	108	115	O	patients
18	116	116	O	,
19	118	119	O	no
20	121	126	O	effect
21	128	129	O	on
22	131	141	O	prothrombin
23	143	146	O	time
24	148	150	O	was
25	152	159	O	detected
NULL

Lovastatin	5195	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	29
However, another HMG-CoA reductase inhibitor has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of warfarin.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	another
4	17	19	O	HMG
5	21	23	O	CoA
6	25	33	O	reductase
7	35	43	O	inhibitor
8	45	47	O	has
9	49	52	O	been
10	54	58	O	found
11	60	61	O	to
12	63	69	O	produce
13	71	71	O	a
14	73	76	O	less
15	78	81	O	than
16	83	85	O	two
17	87	92	O	second
18	94	101	O	increase
19	103	104	O	in
20	106	116	O	prothrombin
21	118	121	O	time
22	123	124	O	in
23	126	132	O	healthy
24	134	143	O	volunteers
25	145	153	O	receiving
26	155	157	O	low
27	159	163	O	doses
28	165	166	O	of
29	168	175	O	warfarin
NULL

Lovastatin	5196	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	22
Also, bleeding and/or increased prothrombin time have been reported in a few patients taking coumarin anticoagulants concomitantly with lovastatin.
1	0	3	O	Also
2	4	4	O	,
3	6	13	U-EFF	bleeding
4	15	17	O	and
5	18	18	O	/
6	19	20	O	or
7	22	30	B-EFF	increased
8	32	42	I-EFF	prothrombin
9	44	47	L-EFF	time
10	49	52	O	have
11	54	57	O	been
12	59	66	O	reported
13	68	69	O	in
14	71	71	O	a
15	73	75	O	few
16	77	84	O	patients
17	86	91	O	taking
18	93	100	B-DYN	coumarin
19	102	115	L-DYN	anticoagulants
20	117	129	O	concomitantly
21	131	134	O	with
22	136	145	O	XXXXXXXX
D/18:3:1 D/18:7:1

Lovastatin	5197	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	32
It is recommended that in patients taking anticoagulants, prothrombin time be determined before starting lovastatin and frequently enough during early therapy to insure that no significant alteration of prothrombin time occurs.
1	0	1	O	It
2	3	4	O	is
3	6	16	O	recommended
4	18	21	O	that
5	23	24	O	in
6	26	33	O	patients
7	35	40	O	taking
8	42	55	U-UNK	anticoagulants
9	56	56	O	,
10	58	68	O	prothrombin
11	70	73	O	time
12	75	76	O	be
13	78	87	O	determined
14	89	94	B-TRI	before
15	96	103	L-TRI	starting
16	105	114	O	XXXXXXXX
17	116	118	O	and
18	120	129	O	frequently
19	131	136	O	enough
20	138	143	O	during
21	145	149	O	early
22	151	157	O	therapy
23	159	160	O	to
24	162	167	O	insure
25	169	172	O	that
26	174	175	O	no
27	177	187	O	significant
28	189	198	O	alteration
29	200	201	O	of
30	203	213	O	prothrombin
31	215	218	O	time
32	220	225	O	occurs
NULL

Lovastatin	5198	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	24
Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.
1	0	3	O	Once
2	5	5	O	a
3	7	12	O	stable
4	14	24	O	prothrombin
5	26	29	O	time
6	31	33	O	has
7	35	38	O	been
8	40	49	O	documented
9	50	50	O	,
10	52	62	O	prothrombin
11	64	68	O	times
12	70	72	O	can
13	74	75	O	be
14	77	85	U-TRI	monitored
15	87	88	O	at
16	90	92	O	the
17	94	102	O	intervals
18	104	110	O	usually
19	112	122	O	recommended
20	124	126	O	for
21	128	135	O	patients
22	137	138	O	on
23	140	147	B-UNK	coumarin
24	149	162	L-UNK	anticoagulants
NULL

Lovastatin	5199	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	14
If the dose of lovastatin is changed, the same procedure should be repeated.
1	0	1	O	If
2	3	5	O	the
3	7	10	O	dose
4	12	13	O	of
5	15	24	O	XXXXXXXX
6	26	27	O	is
7	29	35	O	changed
8	36	36	O	,
9	38	40	O	the
10	42	45	O	same
11	47	55	O	procedure
12	57	62	O	should
13	64	65	O	be
14	67	74	O	repeated
NULL

Lovastatin	5200	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	19
Lovastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.
1	0	9	O	XXXXXXXX
2	11	17	O	therapy
3	19	21	O	has
4	23	25	O	not
5	27	30	O	been
6	32	41	O	associated
7	43	46	O	with
8	48	55	O	bleeding
9	57	58	O	or
10	60	63	O	with
11	65	71	O	changes
12	73	74	O	in
13	76	86	O	prothrombin
14	88	91	O	time
15	93	94	O	in
16	96	103	O	patients
17	105	107	O	not
18	109	114	O	taking
19	116	129	O	anticoagulants
NULL

Lovastatin	5201	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	17
Colchicine: Cases of myopathy, including rhabdomyolysis, have been reported with lovastatin coadministered with colchicine.
1	0	9	O	Colchicine
2	10	10	O	:
3	12	16	O	Cases
4	18	19	O	of
5	21	28	U-EFF	myopathy
6	29	29	O	,
7	31	39	O	including
8	41	54	U-EFF	rhabdomyolysis
9	55	55	O	,
10	57	60	O	have
11	62	65	O	been
12	67	74	O	reported
13	76	79	O	with
14	81	90	O	XXXXXXXX
15	92	105	O	coadministered
16	107	110	O	with
17	112	121	U-DYN	colchicine
D/17:5:1 D/17:8:1

Lovastatin	5202	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	18
Ranolazine: The risk of myopathy, including rhabdomyolysis, may be increased by concomitant administration of ranolazine.
1	0	9	O	Ranolazine
2	10	10	O	:
3	12	14	O	The
4	16	19	O	risk
5	21	22	O	of
6	24	31	U-EFF	myopathy
7	32	32	O	,
8	34	42	O	including
9	44	57	U-EFF	rhabdomyolysis
10	58	58	O	,
11	60	62	O	may
12	64	65	O	be
13	67	75	O	increased
14	77	78	O	by
15	80	90	O	concomitant
16	92	105	O	administration
17	107	108	O	of
18	110	119	U-DYN	ranolazine
D/18:6:1 D/18:9:1

Lovastatin	5203	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	25
Propranolol: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of lovastatin and propranolol.
1	0	10	O	Propranolol
2	11	11	O	:
3	13	14	O	In
4	16	21	O	normal
5	23	32	O	volunteers
6	33	33	O	,
7	35	39	O	there
8	41	43	O	was
9	45	46	O	no
10	48	57	O	clinically
11	59	69	O	significant
12	71	85	O	pharmacokinetic
13	87	88	O	or
14	90	104	O	pharmacodynamic
15	106	116	O	interaction
16	118	121	O	with
17	123	133	O	concomitant
18	135	148	O	administration
19	150	151	O	of
20	153	158	O	single
21	160	164	O	doses
22	166	167	O	of
23	169	178	O	XXXXXXXX
24	180	182	O	and
25	184	194	O	propranolol
NULL

Lovastatin	5204	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	21
Digoxin: In patients with hypercholesterolemia, concomitant administration of lovastatin and digoxin resulted in no effect on digoxin plasma concentrations.
1	0	6	O	Digoxin
2	7	7	O	:
3	9	10	O	In
4	12	19	O	patients
5	21	24	O	with
6	26	45	O	hypercholesterolemia
7	46	46	O	,
8	48	58	O	concomitant
9	60	73	O	administration
10	75	76	O	of
11	78	87	O	XXXXXXXX
12	89	91	O	and
13	93	99	O	digoxin
14	101	108	O	resulted
15	110	111	O	in
16	113	114	O	no
17	116	121	O	effect
18	123	124	O	on
19	126	132	O	digoxin
20	134	139	O	plasma
21	141	154	O	concentrations
NULL

Lovastatin	5205	34073-7	520428f1-2cd5-447f-8782-c8505ce65b72	27
Oral Hypoglycemic Agents: In pharmacokinetic studies of MEVACOR in hypercholesterolemic non-insulin dependent diabetic patients, there was no drug interaction with glipizide or with chlorpropamide.
1	0	3	O	Oral
2	5	16	O	Hypoglycemic
3	18	23	O	Agents
4	24	24	O	:
5	26	27	O	In
6	29	43	O	pharmacokinetic
7	45	51	O	studies
8	53	54	O	of
9	56	62	O	MEVACOR
10	64	65	O	in
11	67	86	O	hypercholesterolemic
12	88	90	O	non
13	92	98	O	insulin
14	100	108	O	dependent
15	110	117	O	diabetic
16	119	126	O	patients
17	127	127	O	,
18	129	133	O	there
19	135	137	O	was
20	139	140	O	no
21	142	145	O	drug
22	147	157	O	interaction
23	159	162	O	with
24	164	172	O	glipizide
25	174	175	O	or
26	177	180	O	with
27	182	195	O	chlorpropamide
NULL

Lovastatin	5206	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	28
The involvement of low-density lipoprotein cholesterol (LDL-C) in atherogenesis has been well-documented in clinical and pathological studies, as well as in many animal experiments.
1	0	2	O	The
2	4	14	O	involvement
3	16	17	O	of
4	19	21	O	low
5	23	29	O	density
6	31	41	O	lipoprotein
7	43	53	O	cholesterol
8	56	58	O	LDL
9	60	60	O	C
10	63	64	O	in
11	66	78	O	atherogenesis
12	80	82	O	has
13	84	87	O	been
14	89	92	O	well
15	94	103	O	documented
16	105	106	O	in
17	108	115	O	clinical
18	117	119	O	and
19	121	132	O	pathological
20	134	140	O	studies
21	141	141	O	,
22	143	144	O	as
23	146	149	O	well
24	151	152	O	as
25	154	155	O	in
26	157	160	O	many
27	162	167	O	animal
28	169	179	O	experiments
NULL

Lovastatin	5207	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	25
Epidemiological and clinical studies have established that high LDL-C and low high-density lipoprotein cholesterol (HDL-C) are both associated with coronary heart disease.
1	0	14	O	Epidemiological
2	16	18	O	and
3	20	27	O	clinical
4	29	35	O	studies
5	37	40	O	have
6	42	52	O	established
7	54	57	O	that
8	59	62	O	high
9	64	66	O	LDL
10	68	68	O	C
11	70	72	O	and
12	74	76	O	low
13	78	81	O	high
14	83	89	O	density
15	91	101	O	lipoprotein
16	103	113	O	cholesterol
17	116	118	O	HDL
18	120	120	O	C
19	123	125	O	are
20	127	130	O	both
21	132	141	O	associated
22	143	146	O	with
23	148	155	O	coronary
24	157	161	O	heart
25	163	169	O	disease
NULL

Lovastatin	5208	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	42
However, the risk of developing coronary heart disease is continuous and graded over the range of cholesterol levels and many coronary events do occur in patients with total cholesterol (total-C) and LDL-C in the lower end of this range.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	16	O	risk
5	18	19	O	of
6	21	30	O	developing
7	32	39	O	coronary
8	41	45	O	heart
9	47	53	O	disease
10	55	56	O	is
11	58	67	O	continuous
12	69	71	O	and
13	73	78	O	graded
14	80	83	O	over
15	85	87	O	the
16	89	93	O	range
17	95	96	O	of
18	98	108	O	cholesterol
19	110	115	O	levels
20	117	119	O	and
21	121	124	O	many
22	126	133	O	coronary
23	135	140	O	events
24	142	143	O	do
25	145	149	O	occur
26	151	152	O	in
27	154	161	O	patients
28	163	166	O	with
29	168	172	O	total
30	174	184	O	cholesterol
31	187	191	O	total
32	193	193	O	C
33	196	198	O	and
34	200	202	O	LDL
35	204	204	O	C
36	206	207	O	in
37	209	211	O	the
38	213	217	O	lower
39	219	221	O	end
40	223	224	O	of
41	226	229	O	this
42	231	235	O	range
NULL

Lovastatin	5209	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
MEVACOR has been shown to reduce elevated LDL-C concentrations.
1	0	6	O	MEVACOR
2	8	10	O	has
3	12	15	O	been
4	17	21	O	shown
5	23	24	O	to
6	26	31	O	reduce
7	33	40	O	elevated
8	42	44	O	LDL
9	46	46	O	C
10	48	61	O	concentrations
NULL

Lovastatin	5210	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	19
LDL is formed from very low-density lipoprotein (VLDL) and is catabolized predominantly by the high affinity LDL receptor.
1	0	2	O	LDL
2	4	5	O	is
3	7	12	O	formed
4	14	17	O	from
5	19	22	O	very
6	24	26	O	low
7	28	34	O	density
8	36	46	O	lipoprotein
9	49	52	O	VLDL
10	55	57	O	and
11	59	60	O	is
12	62	72	O	catabolized
13	74	86	O	predominantly
14	88	89	O	by
15	91	93	O	the
16	95	98	O	high
17	100	107	O	affinity
18	109	111	O	LDL
19	113	120	O	receptor
NULL

Lovastatin	5211	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	37
The mechanism of the LDL-lowering effect of MEVACOR may involve both reduction of VLDL-C concentration, and induction of the LDL receptor, leading to reduced production and/or increased catabolism of LDL-C.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	19	O	the
5	21	23	O	LDL
6	25	32	O	lowering
7	34	39	O	effect
8	41	42	O	of
9	44	50	O	MEVACOR
10	52	54	O	may
11	56	62	O	involve
12	64	67	O	both
13	69	77	O	reduction
14	79	80	O	of
15	82	85	O	VLDL
16	87	87	O	C
17	89	101	O	concentration
18	102	102	O	,
19	104	106	O	and
20	108	116	O	induction
21	118	119	O	of
22	121	123	O	the
23	125	127	O	LDL
24	129	136	O	receptor
25	137	137	O	,
26	139	145	O	leading
27	147	148	O	to
28	150	156	O	reduced
29	158	167	O	production
30	169	171	O	and
31	172	172	O	/
32	173	174	O	or
33	176	184	O	increased
34	186	195	O	catabolism
35	197	198	O	of
36	200	202	O	LDL
37	204	204	O	C
NULL

Lovastatin	5212	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	7
ApolipoproteinB also falls during treatment with MEVACOR.
1	0	14	O	ApolipoproteinB
2	16	19	O	also
3	21	25	O	falls
4	27	32	O	during
5	34	42	O	treatment
6	44	47	O	with
7	49	55	O	MEVACOR
NULL

Lovastatin	5213	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
MEVACOR is a specific inhibitor of HMG-CoA reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate.
1	0	6	O	MEVACOR
2	8	9	O	is
3	11	11	O	a
4	13	20	O	specific
5	22	30	O	inhibitor
6	32	33	O	of
7	35	37	O	HMG
8	39	41	O	CoA
9	43	51	O	reductase
10	52	52	O	,
11	54	56	O	the
12	58	63	O	enzyme
13	65	69	O	which
14	71	79	O	catalyzes
15	81	83	O	the
16	85	94	O	conversion
17	96	97	O	of
18	99	101	O	HMG
19	103	105	O	CoA
20	107	108	O	to
21	110	119	O	mevalonate
NULL

Lovastatin	5214	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	17
The conversion of HMG-CoA to mevalonate is an early step in the biosynthetic pathway for cholesterol.
1	0	2	O	The
2	4	13	O	conversion
3	15	16	O	of
4	18	20	O	HMG
5	22	24	O	CoA
6	26	27	O	to
7	29	38	O	mevalonate
8	40	41	O	is
9	43	44	O	an
10	46	50	O	early
11	52	55	O	step
12	57	58	O	in
13	60	62	O	the
14	64	75	O	biosynthetic
15	77	83	O	pathway
16	85	87	O	for
17	89	99	O	cholesterol
NULL

Lovastatin	5215	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	23
Lovastatin is a lactone which is readily hydrolyzed in vivo to the corresponding B-hydroxyacid, a strong inhibitor of HMG-CoA reductase.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	22	O	lactone
5	24	28	O	which
6	30	31	O	is
7	33	39	O	readily
8	41	50	O	hydrolyzed
9	52	53	O	in
10	55	58	O	vivo
11	60	61	O	to
12	63	65	O	the
13	67	79	O	corresponding
14	81	81	O	B
15	83	93	O	hydroxyacid
16	94	94	O	,
17	96	96	O	a
18	98	103	O	strong
19	105	113	O	inhibitor
20	115	116	O	of
21	118	120	O	HMG
22	122	124	O	CoA
23	126	134	O	reductase
NULL

Lovastatin	5216	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	39
Inhibition of HMG-CoA reductase is the basis for an assay in pharmacokinetic studies of the B-hydroxyacid metabolites (active inhibitors) and, following base hydrolysis, active plus latent inhibitors (total inhibitors) in plasma following administration of lovastatin.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	16	O	HMG
4	18	20	O	CoA
5	22	30	O	reductase
6	32	33	O	is
7	35	37	O	the
8	39	43	O	basis
9	45	47	O	for
10	49	50	O	an
11	52	56	O	assay
12	58	59	O	in
13	61	75	O	pharmacokinetic
14	77	83	O	studies
15	85	86	O	of
16	88	90	O	the
17	92	92	O	B
18	94	104	O	hydroxyacid
19	106	116	O	metabolites
20	119	124	O	active
21	126	135	O	inhibitors
22	138	140	O	and
23	141	141	O	,
24	143	151	O	following
25	153	156	O	base
26	158	167	O	hydrolysis
27	168	168	O	,
28	170	175	O	active
29	177	180	O	plus
30	182	187	O	latent
31	189	198	O	inhibitors
32	201	205	O	total
33	207	216	O	inhibitors
34	219	220	O	in
35	222	227	O	plasma
36	229	237	O	following
37	239	252	O	administration
38	254	255	O	of
39	257	266	O	XXXXXXXX
NULL

Lovastatin	5217	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	23
Following an oral dose of 14C-labeled lovastatin in man, 10% of the dose was excreted in urine and 83% in feces.
1	0	8	O	Following
2	10	11	O	an
3	13	16	O	oral
4	18	21	O	dose
5	23	24	O	of
6	26	28	O	14C
7	30	36	O	labeled
8	38	47	O	XXXXXXXX
9	49	50	O	in
10	52	54	O	man
11	55	55	O	,
12	57	59	O	10%
13	61	62	O	of
14	64	66	O	the
15	68	71	O	dose
16	73	75	O	was
17	77	84	O	excreted
18	86	87	O	in
19	89	93	O	urine
20	95	97	O	and
21	99	101	O	83%
22	103	104	O	in
23	106	110	O	feces
NULL

Lovastatin	5218	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	16
The latter represents absorbed drug equivalents excreted in bile, as well as any unabsorbed drug.
1	0	2	O	The
2	4	9	O	latter
3	11	20	O	represents
4	22	29	O	absorbed
5	31	34	O	drug
6	36	46	O	equivalents
7	48	55	O	excreted
8	57	58	O	in
9	60	63	O	bile
10	64	64	O	,
11	66	67	O	as
12	69	72	O	well
13	74	75	O	as
14	77	79	O	any
15	81	90	O	unabsorbed
16	92	95	O	drug
NULL

Lovastatin	5219	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	23
Plasma concentrations of total radioactivity (lovastatin plus 14C-metabolites) peaked at 2hours and declined rapidly to about 10% of peak by 24hours postdose.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	29	O	total
5	31	43	O	radioactivity
6	46	55	O	XXXXXXXX
7	57	60	O	plus
8	62	64	O	14C
9	66	76	O	metabolites
10	79	84	O	peaked
11	86	87	O	at
12	89	94	O	2hours
13	96	98	O	and
14	100	107	O	declined
15	109	115	O	rapidly
16	117	118	O	to
17	120	124	O	about
18	126	128	O	10%
19	130	131	O	of
20	133	136	O	peak
21	138	139	O	by
22	141	147	O	24hours
23	149	156	O	postdose
NULL

Lovastatin	5220	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	27
Absorption of lovastatin, estimated relative to an intravenous reference dose, in each of four animal species tested, averaged about 30% of an oral dose.
1	0	9	O	Absorption
2	11	12	O	of
3	14	23	O	XXXXXXXX
4	24	24	O	,
5	26	34	O	estimated
6	36	43	O	relative
7	45	46	O	to
8	48	49	O	an
9	51	61	O	intravenous
10	63	71	O	reference
11	73	76	O	dose
12	77	77	O	,
13	79	80	O	in
14	82	85	O	each
15	87	88	O	of
16	90	93	O	four
17	95	100	O	animal
18	102	108	O	species
19	110	115	O	tested
20	116	116	O	,
21	118	125	O	averaged
22	127	131	O	about
23	133	135	O	30%
24	137	138	O	of
25	140	141	O	an
26	143	146	O	oral
27	148	151	O	dose
NULL

Lovastatin	5221	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	27
In animal studies, after oral dosing, lovastatin had high selectivity for the liver, where it achieved substantially higher concentrations than in non-target tissues.
1	0	1	O	In
2	3	8	O	animal
3	10	16	O	studies
4	17	17	O	,
5	19	23	O	after
6	25	28	O	oral
7	30	35	O	dosing
8	36	36	O	,
9	38	47	O	XXXXXXXX
10	49	51	O	had
11	53	56	O	high
12	58	68	O	selectivity
13	70	72	O	for
14	74	76	O	the
15	78	82	O	liver
16	83	83	O	,
17	85	89	O	where
18	91	92	O	it
19	94	101	O	achieved
20	103	115	O	substantially
21	117	122	O	higher
22	124	137	O	concentrations
23	139	142	O	than
24	144	145	O	in
25	147	149	O	non
26	151	156	O	target
27	158	164	O	tissues
NULL

Lovastatin	5222	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	25
Lovastatin undergoes extensive first-pass extraction in the liver, its primary site of action, with subsequent excretion of drug equivalents in the bile.
1	0	9	O	XXXXXXXX
2	11	19	O	undergoes
3	21	29	O	extensive
4	31	35	O	first
5	37	40	O	pass
6	42	51	O	extraction
7	53	54	O	in
8	56	58	O	the
9	60	64	O	liver
10	65	65	O	,
11	67	69	O	its
12	71	77	O	primary
13	79	82	O	site
14	84	85	O	of
15	87	92	O	action
16	93	93	O	,
17	95	98	O	with
18	100	109	O	subsequent
19	111	119	O	excretion
20	121	122	O	of
21	124	127	O	drug
22	129	139	O	equivalents
23	141	142	O	in
24	144	146	O	the
25	148	151	O	bile
NULL

Lovastatin	5223	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	22
As a consequence of extensive hepatic extraction of lovastatin, the availability of drug to the general circulation is low and variable.
1	0	1	O	As
2	3	3	O	a
3	5	15	O	consequence
4	17	18	O	of
5	20	28	O	extensive
6	30	36	O	hepatic
7	38	47	O	extraction
8	49	50	O	of
9	52	61	O	XXXXXXXX
10	62	62	O	,
11	64	66	O	the
12	68	79	O	availability
13	81	82	O	of
14	84	87	O	drug
15	89	90	O	to
16	92	94	O	the
17	96	102	O	general
18	104	114	O	circulation
19	116	117	O	is
20	119	121	O	low
21	123	125	O	and
22	127	134	O	variable
NULL

Lovastatin	5224	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	30
In a single dose study in four hypercholesterolemic patients, it was estimated that less than 5% of an oral dose of lovastatin reaches the general circulation as active inhibitors.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	15	O	dose
5	17	21	O	study
6	23	24	O	in
7	26	29	O	four
8	31	50	O	hypercholesterolemic
9	52	59	O	patients
10	60	60	O	,
11	62	63	O	it
12	65	67	O	was
13	69	77	O	estimated
14	79	82	O	that
15	84	87	O	less
16	89	92	O	than
17	94	95	O	5%
18	97	98	O	of
19	100	101	O	an
20	103	106	O	oral
21	108	111	O	dose
22	113	114	O	of
23	116	125	O	XXXXXXXX
24	127	133	O	reaches
25	135	137	O	the
26	139	145	O	general
27	147	157	O	circulation
28	159	160	O	as
29	162	167	O	active
30	169	178	O	inhibitors
NULL

Lovastatin	5225	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	34
Following administration of lovastatin tablets the coefficient of variation, based on between-subject variability, was approximately 40% for the area under the curve (AUC) of total inhibitory activity in the general circulation.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	37	O	XXXXXXXX
5	39	45	O	tablets
6	47	49	O	the
7	51	61	O	coefficient
8	63	64	O	of
9	66	74	O	variation
10	75	75	O	,
11	77	81	O	based
12	83	84	O	on
13	86	92	O	between
14	94	100	O	subject
15	102	112	O	variability
16	113	113	O	,
17	115	117	O	was
18	119	131	O	approximately
19	133	135	O	40%
20	137	139	O	for
21	141	143	O	the
22	145	148	O	area
23	150	154	O	under
24	156	158	O	the
25	160	164	O	curve
26	167	169	O	AUC
27	172	173	O	of
28	175	179	O	total
29	181	190	O	inhibitory
30	192	199	O	activity
31	201	202	O	in
32	204	206	O	the
33	208	214	O	general
34	216	226	O	circulation
NULL

Lovastatin	5226	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	15
Both lovastatin and its B-hydroxyacid metabolite are highly bound (>95%) to human plasma proteins.
1	0	3	O	Both
2	5	14	O	XXXXXXXX
3	16	18	O	and
4	20	22	O	its
5	24	24	O	B
6	26	36	O	hydroxyacid
7	38	47	O	metabolite
8	49	51	O	are
9	53	58	O	highly
10	60	64	O	bound
11	67	70	O	>95%
12	73	74	O	to
13	76	80	O	human
14	82	87	O	plasma
15	89	96	O	proteins
NULL

Lovastatin	5227	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	12
Animal studies demonstrated that lovastatin crosses the blood-brain and placental barriers.
1	0	5	O	Animal
2	7	13	O	studies
3	15	26	O	demonstrated
4	28	31	O	that
5	33	42	O	XXXXXXXX
6	44	50	O	crosses
7	52	54	O	the
8	56	60	O	blood
9	62	66	O	brain
10	68	70	O	and
11	72	80	O	placental
12	82	89	O	barriers
NULL

Lovastatin	5228	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	24
The major active metabolites present in human plasma are the B-hydroxyacid of lovastatin, its 6*-hydroxy derivative, and two additional metabolites.
1	0	2	O	The
2	4	8	O	major
3	10	15	O	active
4	17	27	O	metabolites
5	29	35	O	present
6	37	38	O	in
7	40	44	O	human
8	46	51	O	plasma
9	53	55	O	are
10	57	59	O	the
11	61	61	O	B
12	63	73	O	hydroxyacid
13	75	76	O	of
14	78	87	O	XXXXXXXX
15	88	88	O	,
16	90	92	O	its
17	94	95	O	6*
18	97	103	O	hydroxy
19	105	114	O	derivative
20	115	115	O	,
21	117	119	O	and
22	121	123	O	two
23	125	134	O	additional
24	136	146	O	metabolites
NULL

Lovastatin	5229	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	18
Peak plasma concentrations of both active and total inhibitors were attained within 2 to 4hours of dose administration.
1	0	3	O	Peak
2	5	10	O	plasma
3	12	25	O	concentrations
4	27	28	O	of
5	30	33	O	both
6	35	40	O	active
7	42	44	O	and
8	46	50	O	total
9	52	61	O	inhibitors
10	63	66	O	were
11	68	75	O	attained
12	77	82	O	within
13	84	84	O	2
14	86	87	O	to
15	89	94	O	4hours
16	96	97	O	of
17	99	102	O	dose
18	104	117	O	administration
NULL

Lovastatin	5230	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	78
While the recommended therapeutic dose range is 10 to 80mg/day, linearity of inhibitory activity in the general circulation was established by a single dose study employing lovastatin tablet dosages from 60 to as high as 120mg. With a once-a-day dosing regimen, plasma concentrations of total inhibitors over a dosing interval achieved a steady state between the second and third days of therapy and were about 1.5 times those following a single dose.
1	0	4	O	While
2	6	8	O	the
3	10	20	O	recommended
4	22	32	O	therapeutic
5	34	37	O	dose
6	39	43	O	range
7	45	46	O	is
8	48	49	O	10
9	51	52	O	to
10	54	57	O	80mg
11	58	58	O	/
12	59	61	O	day
13	62	62	O	,
14	64	72	O	linearity
15	74	75	O	of
16	77	86	O	inhibitory
17	88	95	O	activity
18	97	98	O	in
19	100	102	O	the
20	104	110	O	general
21	112	122	O	circulation
22	124	126	O	was
23	128	138	O	established
24	140	141	O	by
25	143	143	O	a
26	145	150	O	single
27	152	155	O	dose
28	157	161	O	study
29	163	171	O	employing
30	173	182	O	XXXXXXXX
31	184	189	O	tablet
32	191	197	O	dosages
33	199	202	O	from
34	204	205	O	60
35	207	208	O	to
36	210	211	O	as
37	213	216	O	high
38	218	219	O	as
39	221	225	O	120mg
40	228	231	O	With
41	233	233	O	a
42	235	238	O	once
43	240	240	O	a
44	242	244	O	day
45	246	251	O	dosing
46	253	259	O	regimen
47	260	260	O	,
48	262	267	O	plasma
49	269	282	O	concentrations
50	284	285	O	of
51	287	291	O	total
52	293	302	O	inhibitors
53	304	307	O	over
54	309	309	O	a
55	311	316	O	dosing
56	318	325	O	interval
57	327	334	O	achieved
58	336	336	O	a
59	338	343	O	steady
60	345	349	O	state
61	351	357	O	between
62	359	361	O	the
63	363	368	O	second
64	370	372	O	and
65	374	378	O	third
66	380	383	O	days
67	385	386	O	of
68	388	394	O	therapy
69	396	398	O	and
70	400	403	O	were
71	405	409	O	about
72	411	413	O	1.5
73	415	419	O	times
74	421	425	O	those
75	427	435	O	following
76	437	437	O	a
77	439	444	O	single
78	446	449	O	dose
NULL

Lovastatin	5231	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	31
When lovastatin was given under fasting conditions, plasma concentrations of total inhibitors were on average about two-thirds those found when lovastatin was administered immediately after a standard test meal.
1	0	3	O	When
2	5	14	O	XXXXXXXX
3	16	18	O	was
4	20	24	O	given
5	26	30	O	under
6	32	38	O	fasting
7	40	49	O	conditions
8	50	50	O	,
9	52	57	O	plasma
10	59	72	O	concentrations
11	74	75	O	of
12	77	81	O	total
13	83	92	O	inhibitors
14	94	97	O	were
15	99	100	O	on
16	102	108	O	average
17	110	114	O	about
18	116	118	O	two
19	120	125	O	thirds
20	127	131	O	those
21	133	137	O	found
22	139	142	O	when
23	144	153	O	XXXXXXXX
24	155	157	O	was
25	159	170	O	administered
26	172	182	O	immediately
27	184	188	O	after
28	190	190	O	a
29	192	199	O	standard
30	201	204	O	test
31	206	209	O	meal
NULL

Lovastatin	5232	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	38
In a study of patients with severe renal insufficiency (creatinine clearance 10-30mL/min), the plasma concentrations of total inhibitors after a single dose of lovastatin were approximately two-fold higher than those in healthy volunteers.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	21	O	patients
6	23	26	O	with
7	28	33	O	severe
8	35	39	O	renal
9	41	53	O	insufficiency
10	56	65	O	creatinine
11	67	75	O	clearance
12	77	78	O	10
13	80	83	O	30mL
14	84	84	O	/
15	85	87	O	min
16	89	89	O	,
17	91	93	O	the
18	95	100	O	plasma
19	102	115	O	concentrations
20	117	118	O	of
21	120	124	O	total
22	126	135	O	inhibitors
23	137	141	O	after
24	143	143	O	a
25	145	150	O	single
26	152	155	O	dose
27	157	158	O	of
28	160	169	O	XXXXXXXX
29	171	174	O	were
30	176	188	O	approximately
31	190	192	O	two
32	194	197	O	fold
33	199	204	O	higher
34	206	209	O	than
35	211	215	O	those
36	217	218	O	in
37	220	226	O	healthy
38	228	237	O	volunteers
NULL

Lovastatin	5233	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	42
In a study including 16 elderly patients between 70-78years of age who received MEVACOR 80mg/day, the mean plasma level of HMG-CoA reductase inhibitory activity was increased approximately 45% compared with 18 patients between 18-30years of age.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	19	O	including
5	21	22	O	16
6	24	30	O	elderly
7	32	39	O	patients
8	41	47	O	between
9	49	50	O	70
10	52	58	O	78years
11	60	61	O	of
12	63	65	O	age
13	67	69	O	who
14	71	78	O	received
15	80	86	O	MEVACOR
16	88	91	O	80mg
17	92	92	O	/
18	93	95	O	day
19	96	96	O	,
20	98	100	O	the
21	102	105	O	mean
22	107	112	O	plasma
23	114	118	O	level
24	120	121	O	of
25	123	125	O	HMG
26	127	129	O	CoA
27	131	139	O	reductase
28	141	150	O	inhibitory
29	152	159	O	activity
30	161	163	O	was
31	165	173	O	increased
32	175	187	O	approximately
33	189	191	O	45%
34	193	200	O	compared
35	202	205	O	with
36	207	208	O	18
37	210	217	O	patients
38	219	225	O	between
39	227	228	O	18
40	230	236	O	30years
41	238	239	O	of
42	241	243	O	age
NULL

Lovastatin	5234	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
Although the mechanism is not fully understood, cyclosporine has been shown to increase the AUC of HMG-CoA reductase inhibitors.
1	0	7	O	Although
2	9	11	O	the
3	13	21	O	mechanism
4	23	24	O	is
5	26	28	O	not
6	30	34	O	fully
7	36	45	O	understood
8	46	46	O	,
9	48	59	U-KIN	cyclosporine
10	61	63	O	has
11	65	68	O	been
12	70	74	O	shown
13	76	77	O	to
14	79	86	B-TRI	increase
15	88	90	I-TRI	the
16	92	94	L-TRI	AUC
17	96	97	O	of
18	99	101	O	HMG
19	103	105	O	CoA
20	107	115	O	reductase
21	117	126	O	inhibitors
K/9:C54605

Lovastatin	5235	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	20
The increase in AUC for lovastatin and lovastatin acid is presumably due, in part, to inhibition of CYP3A4.
1	0	2	O	The
2	4	11	O	increase
3	13	14	O	in
4	16	18	O	AUC
5	20	22	O	for
6	24	33	O	XXXXXXXX
7	35	37	O	and
8	39	48	O	XXXXXXXX
9	50	53	O	acid
10	55	56	O	is
11	58	67	O	presumably
12	69	71	O	due
13	72	72	O	,
14	74	75	O	in
15	77	80	O	part
16	81	81	O	,
17	83	84	O	to
18	86	95	O	inhibition
19	97	98	O	of
20	100	105	O	CYP3A4
NULL

Lovastatin	5236	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	17
The risk of myopathy is increased by high levels of HMG-CoA reductase inhibitory activity in plasma.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	O	myopathy
5	21	22	O	is
6	24	32	O	increased
7	34	35	O	by
8	37	40	O	high
9	42	47	O	levels
10	49	50	O	of
11	52	54	O	HMG
12	56	58	O	CoA
13	60	68	O	reductase
14	70	79	O	inhibitory
15	81	88	O	activity
16	90	91	O	in
17	93	98	O	plasma
NULL

Lovastatin	5237	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
Strong inhibitors of CYP3A4 can raise the plasma levels of HMG-CoA reductase inhibitory activity and increase the risk of myopathy.
1	0	5	B-DYN	Strong
2	7	16	I-DYN	inhibitors
3	18	19	I-DYN	of
4	21	26	L-DYN	CYP3A4
5	28	30	O	can
6	32	36	B-TRI	raise
7	38	40	I-TRI	the
8	42	47	I-TRI	plasma
9	49	54	L-TRI	levels
10	56	57	O	of
11	59	61	O	HMG
12	63	65	O	CoA
13	67	75	O	reductase
14	77	86	O	inhibitory
15	88	95	O	activity
16	97	99	O	and
17	101	108	O	increase
18	110	112	O	the
19	114	117	O	risk
20	119	120	O	of
21	122	129	U-EFF	myopathy
D/1:21:1

Lovastatin	5238	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	9
Lovastatin is a substrate for cytochrome P450 isoform3A4 (CYP3A4).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	14	O	a
4	16	24	O	substrate
5	26	28	O	for
6	30	39	O	cytochrome
7	41	44	O	P450
8	46	55	O	isoform3A4
9	58	63	O	CYP3A4
NULL

Lovastatin	5239	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
Grapefruit juice contains one or more components that inhibit CYP3A4 and can increase the plasma concentrations of drugs metabolized by CYP3A4.
1	0	9	B-KIN	Grapefruit
2	11	15	L-KIN	juice
3	17	24	O	contains
4	26	28	O	one
5	30	31	O	or
6	33	36	O	more
7	38	47	O	components
8	49	52	O	that
9	54	60	O	inhibit
10	62	67	O	CYP3A4
11	69	71	O	and
12	73	75	O	can
13	77	84	B-TRI	increase
14	86	88	I-TRI	the
15	90	95	I-TRI	plasma
16	97	110	L-TRI	concentrations
17	112	113	O	of
18	115	119	O	drugs
19	121	131	O	metabolized
20	133	134	O	by
21	136	141	O	CYP3A4
K/1:C54355

Lovastatin	5240	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	16
In one study Kantola, T, et al., Clin Pharmacol Ther 1998; 63(4):397-402.
1	0	1	O	In
2	3	5	O	one
3	7	11	O	study
4	13	19	O	Kantola
5	20	20	O	,
6	22	22	O	T
7	23	23	O	,
8	25	26	O	et
9	28	29	O	al
10	31	31	O	,
11	33	36	O	Clin
12	38	46	O	Pharmacol
13	48	51	O	Ther
14	53	56	O	1998
15	59	67	O	63(4):397
16	69	71	O	402
NULL

Lovastatin	5241	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	55
, 10 subjects consumed 200mL of double-strength grapefruit juice (one can of frozen concentrate diluted with one rather than 3 cans of water) three times daily for 2 days and an additional 200mL double-strength grapefruit juice together with and 30 and 90minutes following a single dose of 80mg lovastatin on the third day.
1	0	0	O	,
2	2	3	O	10
3	5	12	O	subjects
4	14	21	O	consumed
5	23	27	O	200mL
6	29	30	O	of
7	32	37	O	double
8	39	46	O	strength
9	48	57	O	grapefruit
10	59	63	O	juice
11	66	68	O	one
12	70	72	O	can
13	74	75	O	of
14	77	82	O	frozen
15	84	94	O	concentrate
16	96	102	O	diluted
17	104	107	O	with
18	109	111	O	one
19	113	118	O	rather
20	120	123	O	than
21	125	125	O	3
22	127	130	O	cans
23	132	133	O	of
24	135	139	O	water
25	142	146	O	three
26	148	152	O	times
27	154	158	O	daily
28	160	162	O	for
29	164	164	O	2
30	166	169	O	days
31	171	173	O	and
32	175	176	O	an
33	178	187	O	additional
34	189	193	O	200mL
35	195	200	O	double
36	202	209	O	strength
37	211	220	O	grapefruit
38	222	226	O	juice
39	228	235	O	together
40	237	240	O	with
41	242	244	O	and
42	246	247	O	30
43	249	251	O	and
44	253	261	O	90minutes
45	263	271	O	following
46	273	273	O	a
47	275	280	O	single
48	282	285	O	dose
49	287	288	O	of
50	290	293	O	80mg
51	295	304	O	XXXXXXXX
52	306	307	O	on
53	309	311	O	the
54	313	317	O	third
55	319	321	O	day
NULL

Lovastatin	5242	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	49
This regimen of grapefruit juice resulted in a mean increase in the serum concentration of lovastatin and its B-hydroxyacid metabolite (as measured by the area under the concentration-time curve) of 15-fold and 5-fold, respectively [as measured using a chemical assay - high performance liquid chromatography].
1	0	3	O	This
2	5	11	O	regimen
3	13	14	O	of
4	16	25	B-KIN	grapefruit
5	27	31	L-KIN	juice
6	33	40	O	resulted
7	42	43	O	in
8	45	45	O	a
9	47	50	O	mean
10	52	59	B-TRI	increase
11	61	62	I-TRI	in
12	64	66	I-TRI	the
13	68	72	I-TRI	serum
14	74	86	L-TRI	concentration
15	88	89	O	of
16	91	100	O	XXXXXXXX
17	102	104	O	and
18	106	108	O	its
19	110	110	O	B
20	112	122	O	hydroxyacid
21	124	133	O	metabolite
22	136	137	O	as
23	139	146	O	measured
24	148	149	O	by
25	151	153	O	the
26	155	158	O	area
27	160	164	O	under
28	166	168	O	the
29	170	182	O	concentration
30	184	187	O	time
31	189	193	O	curve
32	196	197	O	of
33	199	200	O	15
34	202	205	O	fold
35	207	209	O	and
36	211	211	O	5
37	213	216	O	fold
38	217	217	O	,
39	219	230	O	respectively
40	233	234	O	as
41	236	243	O	measured
42	245	249	O	using
43	251	251	O	a
44	253	260	O	chemical
45	262	266	O	assay
46	270	273	O	high
47	275	285	O	performance
48	287	292	O	liquid
49	294	307	O	chromatography
K/4:C54355

Lovastatin	5243	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	46
In a second study, 15 subjects consumed one 8oz glass of single-strength grapefruit juice (one can of frozen concentrate diluted with 3cans of water) with breakfast for 3 consecutive days and a single dose of 40mg lovastatin in the evening of the third day.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	second
4	12	16	O	study
5	17	17	O	,
6	19	20	O	15
7	22	29	O	subjects
8	31	38	O	consumed
9	40	42	O	one
10	44	46	O	8oz
11	48	52	O	glass
12	54	55	O	of
13	57	62	O	single
14	64	71	O	strength
15	73	82	O	grapefruit
16	84	88	O	juice
17	91	93	O	one
18	95	97	O	can
19	99	100	O	of
20	102	107	O	frozen
21	109	119	O	concentrate
22	121	127	O	diluted
23	129	132	O	with
24	134	138	O	3cans
25	140	141	O	of
26	143	147	O	water
27	150	153	O	with
28	155	163	O	breakfast
29	165	167	O	for
30	169	169	O	3
31	171	181	O	consecutive
32	183	186	O	days
33	188	190	O	and
34	192	192	O	a
35	194	199	O	single
36	201	204	O	dose
37	206	207	O	of
38	209	212	O	40mg
39	214	223	O	XXXXXXXX
40	225	226	O	in
41	228	230	O	the
42	232	238	O	evening
43	240	241	O	of
44	243	245	O	the
45	247	251	O	third
46	253	255	O	day
NULL

Lovastatin	5244	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	94
This regimen of grapefruit juice resulted in a mean increase in the plasma concentration (as measured by the area under the concentration-time curve) of active and total HMG-CoA reductase inhibitory activity [using an enzyme inhibition assay both before (for active inhibitors) and after (for total inhibitors) base hydrolysis] of 1.34-fold and 1.36-fold, respectively, and of lovastatin and its B-hydroxyacid metabolite [measured using a chemical assay - liquid chromatography/tandem mass spectrometry - different from that used in the first study] of 1.94-fold and 1.57-fold, respectively.
1	0	3	O	This
2	5	11	O	regimen
3	13	14	O	of
4	16	25	B-KIN	grapefruit
5	27	31	L-KIN	juice
6	33	40	O	resulted
7	42	43	O	in
8	45	45	O	a
9	47	50	O	mean
10	52	59	B-TRI	increase
11	61	62	I-TRI	in
12	64	66	I-TRI	the
13	68	73	I-TRI	plasma
14	75	87	L-TRI	concentration
15	90	91	O	as
16	93	100	O	measured
17	102	103	O	by
18	105	107	O	the
19	109	112	O	area
20	114	118	O	under
21	120	122	O	the
22	124	136	O	concentration
23	138	141	O	time
24	143	147	O	curve
25	150	151	O	of
26	153	158	O	active
27	160	162	O	and
28	164	168	O	total
29	170	172	O	HMG
30	174	176	O	CoA
31	178	186	O	reductase
32	188	197	O	inhibitory
33	199	206	O	activity
34	209	213	O	using
35	215	216	O	an
36	218	223	O	enzyme
37	225	234	O	inhibition
38	236	240	O	assay
39	242	245	O	both
40	247	252	O	before
41	255	257	O	for
42	259	264	O	active
43	266	275	O	inhibitors
44	278	280	O	and
45	282	286	O	after
46	289	291	O	for
47	293	297	O	total
48	299	308	O	inhibitors
49	311	314	O	base
50	316	325	O	hydrolysis
51	328	329	O	of
52	331	334	O	1.34
53	336	339	O	fold
54	341	343	O	and
55	345	348	O	1.36
56	350	353	O	fold
57	354	354	O	,
58	356	367	O	respectively
59	368	368	O	,
60	370	372	O	and
61	374	375	O	of
62	377	386	O	XXXXXXXX
63	388	390	O	and
64	392	394	O	its
65	396	396	O	B
66	398	408	O	hydroxyacid
67	410	419	O	metabolite
68	422	429	O	measured
69	431	435	O	using
70	437	437	O	a
71	439	446	O	chemical
72	448	452	O	assay
73	456	461	O	liquid
74	463	476	O	chromatography
75	477	477	O	/
76	478	483	O	tandem
77	485	488	O	mass
78	490	501	O	spectrometry
79	505	513	O	different
80	515	518	O	from
81	520	523	O	that
82	525	528	O	used
83	530	531	O	in
84	533	535	O	the
85	537	541	O	first
86	543	547	O	study
87	550	551	O	of
88	553	556	O	1.94
89	558	561	O	fold
90	563	565	O	and
91	567	570	O	1.57
92	572	575	O	fold
93	576	576	O	,
94	578	589	O	respectively
K/4:C54605

Lovastatin	5245	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
The effect of amounts of grapefruit juice between those used in these two studies on lovastatin pharmacokinetics has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	O	amounts
5	22	23	O	of
6	25	34	O	grapefruit
7	36	40	O	juice
8	42	48	O	between
9	50	54	O	those
10	56	59	O	used
11	61	62	O	in
12	64	68	O	these
13	70	72	O	two
14	74	80	O	studies
15	82	83	O	on
16	85	94	O	XXXXXXXX
17	96	111	O	pharmacokinetics
18	113	115	O	has
19	117	119	O	not
20	121	124	O	been
21	126	132	O	studied
NULL

Lovastatin	5246	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	36
TABLE I: The Effect of Other Drugs on Lovastatin Exposure When Both Were Co-administered Number of Subjects Dosing of Coadministered Drug or Grapefruit Juice Dosing of Lovastatin AUC RatioResults based on a chemical assay.
1	0	4	O	TABLE
2	6	6	O	I
3	7	7	O	:
4	9	11	O	The
5	13	18	O	Effect
6	20	21	O	of
7	23	27	O	Other
8	29	33	O	Drugs
9	35	36	O	on
10	38	47	O	XXXXXXXX
11	49	56	O	Exposure
12	58	61	O	When
13	63	66	O	Both
14	68	71	O	Were
15	73	74	O	Co
16	76	87	O	administered
17	89	94	O	Number
18	96	97	O	of
19	99	106	O	Subjects
20	108	113	O	Dosing
21	115	116	O	of
22	118	131	O	Coadministered
23	133	136	O	Drug
24	138	139	O	or
25	141	150	O	Grapefruit
26	152	156	O	Juice
27	158	163	O	Dosing
28	165	166	O	of
29	168	177	O	XXXXXXXX
30	179	181	O	AUC
31	183	194	O	RatioResults
32	196	200	O	based
33	202	203	O	on
34	205	205	O	a
35	207	214	O	chemical
36	216	220	O	assay
NULL

Lovastatin	5247	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	20
(with / without coadministered drug)No Effect = 1.00 Lovastatin Lovastatin acid Lovastatin acid refers to the B-hydroxyacid of lovastatin.
1	1	4	O	with
2	6	6	O	/
3	8	14	O	without
4	16	29	O	coadministered
5	31	37	O	drug)No
6	39	44	O	Effect
7	46	46	O	=
8	48	51	O	1.00
9	53	62	O	XXXXXXXX
10	64	73	O	XXXXXXXX
11	75	78	O	acid
12	80	89	O	XXXXXXXX
13	91	94	O	acid
14	96	101	O	refers
15	103	104	O	to
16	106	108	O	the
17	110	110	O	B
18	112	122	O	hydroxyacid
19	124	125	O	of
20	127	136	O	XXXXXXXX
NULL

Lovastatin	5248	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	26
Gemfibrozil 11 600 mg BID for 3 days 40 mg 0.96 2.80 ItraconazoleThe mean total AUC of lovastatin without itraconazole phase could not be determined accurately.
1	0	10	O	Gemfibrozil
2	12	13	O	11
3	15	17	O	600
4	19	20	O	mg
5	22	24	O	BID
6	26	28	O	for
7	30	30	O	3
8	32	35	O	days
9	37	38	O	40
10	40	41	O	mg
11	43	46	O	0.96
12	48	51	O	2.80
13	53	67	O	ItraconazoleThe
14	69	72	O	mean
15	74	78	O	total
16	80	82	O	AUC
17	84	85	O	of
18	87	96	O	XXXXXXXX
19	98	104	O	without
20	106	117	O	itraconazole
21	119	123	O	phase
22	125	129	O	could
23	131	133	O	not
24	135	136	O	be
25	138	147	O	determined
26	149	158	O	accurately
NULL

Lovastatin	5249	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	24
Results could be representative of strong CYP3A4 inhibitors such as ketoconazole, posaconazole, clarithromycin, telithromycin, HIV protease inhibitors, and nefazodone.
1	0	6	O	Results
2	8	12	O	could
3	14	15	O	be
4	17	30	O	representative
5	32	33	O	of
6	35	40	O	strong
7	42	47	O	CYP3A4
8	49	58	O	inhibitors
9	60	63	O	such
10	65	66	O	as
11	68	79	O	ketoconazole
12	80	80	O	,
13	82	93	O	posaconazole
14	94	94	O	,
15	96	109	O	clarithromycin
16	110	110	O	,
17	112	124	O	telithromycin
18	125	125	O	,
19	127	129	O	HIV
20	131	138	O	protease
21	140	149	O	inhibitors
22	150	150	O	,
23	152	154	O	and
24	156	165	O	nefazodone
NULL

Lovastatin	5250	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	16
12 200 mg QD for 4 days 40 mg on Day 4 > 36Estimated minimum change.
1	0	1	O	12
2	3	5	O	200
3	7	8	O	mg
4	10	11	O	QD
5	13	15	O	for
6	17	17	O	4
7	19	22	O	days
8	24	25	O	40
9	27	28	O	mg
10	30	31	O	on
11	33	35	O	Day
12	37	37	O	4
13	39	39	O	>
14	41	51	O	36Estimated
15	53	59	O	minimum
16	61	66	O	change
NULL

Lovastatin	5251	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	38
22 10 100 mg QD for 4 days 40 mg on Day 4 > 14.8 15.4 Grapefruit JuiceThe effect of amounts of grapefruit juice between those used in these two studies on lovastatin pharmacokinetics has not been studied.
1	0	1	O	22
2	3	4	O	10
3	6	8	O	100
4	10	11	O	mg
5	13	14	O	QD
6	16	18	O	for
7	20	20	O	4
8	22	25	O	days
9	27	28	O	40
10	30	31	O	mg
11	33	34	O	on
12	36	38	O	Day
13	40	40	O	4
14	42	42	O	>
15	44	47	O	14.8
16	49	52	O	15.4
17	54	63	O	Grapefruit
18	65	72	O	JuiceThe
19	74	79	O	effect
20	81	82	O	of
21	84	90	O	amounts
22	92	93	O	of
23	95	104	O	grapefruit
24	106	110	O	juice
25	112	118	O	between
26	120	124	O	those
27	126	129	O	used
28	131	132	O	in
29	134	138	O	these
30	140	142	O	two
31	144	150	O	studies
32	152	153	O	on
33	155	164	O	XXXXXXXX
34	166	181	O	pharmacokinetics
35	183	185	O	has
36	187	189	O	not
37	191	194	O	been
38	196	202	O	studied
NULL

Lovastatin	5252	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	22
(high dose) 10 200 mL of double-strength TIDDouble-strength: one can of frozen concentrate diluted with one can of water.
1	1	4	O	high
2	6	9	O	dose
3	12	13	O	10
4	15	17	O	200
5	19	20	O	mL
6	22	23	O	of
7	25	30	O	double
8	32	39	O	strength
9	41	49	O	TIDDouble
10	51	58	O	strength
11	59	59	O	:
12	61	63	O	one
13	65	67	O	can
14	69	70	O	of
15	72	77	O	frozen
16	79	89	O	concentrate
17	91	97	O	diluted
18	99	102	O	with
19	104	106	O	one
20	108	110	O	can
21	112	113	O	of
22	115	119	O	water
NULL

Lovastatin	5253	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	29
Grapefruit juice was administered TID for 2 days, and 200 mL together with single dose lovastatin and 30 and 90 minutes following single dose lovastatin on Day 3.
1	0	9	O	Grapefruit
2	11	15	O	juice
3	17	19	O	was
4	21	32	O	administered
5	34	36	O	TID
6	38	40	O	for
7	42	42	O	2
8	44	47	O	days
9	48	48	O	,
10	50	52	O	and
11	54	56	O	200
12	58	59	O	mL
13	61	68	O	together
14	70	73	O	with
15	75	80	O	single
16	82	85	O	dose
17	87	96	O	XXXXXXXX
18	98	100	O	and
19	102	103	O	30
20	105	107	O	and
21	109	110	O	90
22	112	118	O	minutes
23	120	128	O	following
24	130	135	O	single
25	137	140	O	dose
26	142	151	O	XXXXXXXX
27	153	154	O	on
28	156	158	O	Day
29	160	160	O	3
NULL

Lovastatin	5254	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	32
80 mg single dose 15.3 5.0 Grapefruit Juice (low dose) 16 8 oz (about 250 mL) of single-strengthSingle-strength: one can of frozen concentrate diluted with 3 cans of water.
1	0	1	O	80
2	3	4	O	mg
3	6	11	O	single
4	13	16	O	dose
5	18	21	O	15.3
6	23	25	O	5.0
7	27	36	O	Grapefruit
8	38	42	O	Juice
9	45	47	O	low
10	49	52	O	dose
11	55	56	O	16
12	58	58	O	8
13	60	61	O	oz
14	64	68	O	about
15	70	72	O	250
16	74	75	O	mL
17	78	79	O	of
18	81	86	O	single
19	88	101	O	strengthSingle
20	103	110	O	strength
21	111	111	O	:
22	113	115	O	one
23	117	119	O	can
24	121	122	O	of
25	124	129	O	frozen
26	131	141	O	concentrate
27	143	149	O	diluted
28	151	154	O	with
29	156	156	O	3
30	158	161	O	cans
31	163	164	O	of
32	166	170	O	water
NULL

Lovastatin	5255	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	57
Grapefruit juice was administered with breakfast for 3 days, and lovastatin was administered in the evening on Day 3. for 4 days 40 mg single dose 1.94 1.57 Cyclosporine 16 Not describedCyclosporine-treated patients with psoriasis or post kidney or heart transplant patients with stable graft function, transplanted at least 9 months prior to study.
1	0	9	O	Grapefruit
2	11	15	O	juice
3	17	19	O	was
4	21	32	O	administered
5	34	37	O	with
6	39	47	O	breakfast
7	49	51	O	for
8	53	53	O	3
9	55	58	O	days
10	59	59	O	,
11	61	63	O	and
12	65	74	O	XXXXXXXX
13	76	78	O	was
14	80	91	O	administered
15	93	94	O	in
16	96	98	O	the
17	100	106	O	evening
18	108	109	O	on
19	111	113	O	Day
20	115	115	O	3
21	118	120	O	for
22	122	122	O	4
23	124	127	O	days
24	129	130	O	40
25	132	133	O	mg
26	135	140	O	single
27	142	145	O	dose
28	147	150	O	1.94
29	152	155	O	1.57
30	157	168	O	Cyclosporine
31	170	171	O	16
32	173	175	O	Not
33	177	197	O	describedCyclosporine
34	199	205	O	treated
35	207	214	O	patients
36	216	219	O	with
37	221	229	O	psoriasis
38	231	232	O	or
39	234	237	O	post
40	239	244	O	kidney
41	246	247	O	or
42	249	253	O	heart
43	255	264	O	transplant
44	266	273	O	patients
45	275	278	O	with
46	280	285	O	stable
47	287	291	O	graft
48	293	300	O	function
49	301	301	O	,
50	303	314	O	transplanted
51	316	317	O	at
52	319	323	O	least
53	325	325	O	9
54	327	332	O	months
55	334	338	O	prior
56	340	341	O	to
57	343	347	O	study
NULL

Lovastatin	5256	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	15
10 mg QD for 10 days 5- to 8-fold NDND = Analyte not determined.
1	0	1	O	10
2	3	4	O	mg
3	6	7	O	QD
4	9	11	O	for
5	13	14	O	10
6	16	19	O	days
7	21	21	O	5
8	24	25	O	to
9	27	27	O	8
10	29	32	O	fold
11	34	37	O	NDND
12	39	39	O	=
13	41	47	O	Analyte
14	49	51	O	not
15	53	62	O	determined
NULL

Lovastatin	5257	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	34
Number of Subjects Dosing of Coadministered Drug or Grapefruit Juice Dosing of Lovastatin AUC Ratio (with / without coadministered drug)No Effect = 1.00 Total Lovastatin acidLactone converted to acid by hydrolysis prior to analysis.
1	0	5	O	Number
2	7	8	O	of
3	10	17	O	Subjects
4	19	24	O	Dosing
5	26	27	O	of
6	29	42	O	Coadministered
7	44	47	O	Drug
8	49	50	O	or
9	52	61	O	Grapefruit
10	63	67	O	Juice
11	69	74	O	Dosing
12	76	77	O	of
13	79	88	O	XXXXXXXX
14	90	92	O	AUC
15	94	98	O	Ratio
16	101	104	O	with
17	106	106	O	/
18	108	114	O	without
19	116	129	O	coadministered
20	131	137	O	drug)No
21	139	144	O	Effect
22	146	146	O	=
23	148	151	O	1.00
24	153	157	O	Total
25	159	168	O	XXXXXXXX
26	170	180	O	acidLactone
27	182	190	O	converted
28	192	193	O	to
29	195	198	O	acid
30	200	201	O	by
31	203	212	O	hydrolysis
32	214	218	O	prior
33	220	221	O	to
34	223	230	O	analysis
NULL

Lovastatin	5258	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	7
Figure represents total unmetabolized acid and lactone.
1	0	5	O	Figure
2	7	16	O	represents
3	18	22	O	total
4	24	36	O	unmetabolized
5	38	41	O	acid
6	43	45	O	and
7	47	53	O	lactone
NULL

Lovastatin	5259	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	36
Diltiazem 10 120 mg BID for 14 days 20 mg 3.57 MEVACOR has been shown to reduce total-C and LDL-C in heterozygous familial and non-familial forms of primary hypercholesterolemia and in mixed hyperlipidemia.
1	0	8	O	Diltiazem
2	10	11	O	10
3	13	15	O	120
4	17	18	O	mg
5	20	22	O	BID
6	24	26	O	for
7	28	29	O	14
8	31	34	O	days
9	36	37	O	20
10	39	40	O	mg
11	42	45	O	3.57
12	47	53	O	MEVACOR
13	55	57	O	has
14	59	62	O	been
15	64	68	O	shown
16	70	71	O	to
17	73	78	O	reduce
18	80	84	O	total
19	86	86	O	C
20	88	90	O	and
21	92	94	O	LDL
22	96	96	O	C
23	98	99	O	in
24	101	112	O	heterozygous
25	114	121	O	familial
26	123	125	O	and
27	127	129	O	non
28	131	138	O	familial
29	140	144	O	forms
30	146	147	O	of
31	149	155	O	primary
32	157	176	O	hypercholesterolemia
33	178	180	O	and
34	182	183	O	in
35	185	189	O	mixed
36	191	204	O	hyperlipidemia
NULL

Lovastatin	5260	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	17
A marked response was seen within 2weeks, and the maximum therapeutic response occurred within 4-6weeks.
1	0	0	O	A
2	2	7	O	marked
3	9	16	O	response
4	18	20	O	was
5	22	25	O	seen
6	27	32	O	within
7	34	39	O	2weeks
8	40	40	O	,
9	42	44	O	and
10	46	48	O	the
11	50	56	O	maximum
12	58	68	O	therapeutic
13	70	77	O	response
14	79	86	O	occurred
15	88	93	O	within
16	95	95	O	4
17	97	102	O	6weeks
NULL

Lovastatin	5261	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	8
The response was maintained during continuation of therapy.
1	0	2	O	The
2	4	11	O	response
3	13	15	O	was
4	17	26	O	maintained
5	28	33	O	during
6	35	46	O	continuation
7	48	49	O	of
8	51	57	O	therapy
NULL

Lovastatin	5262	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	27
Single daily doses given in the evening were more effective than the same dose given in the morning, perhaps because cholesterol is synthesized mainly at night.
1	0	5	O	Single
2	7	11	O	daily
3	13	17	O	doses
4	19	23	O	given
5	25	26	O	in
6	28	30	O	the
7	32	38	O	evening
8	40	43	O	were
9	45	48	O	more
10	50	58	O	effective
11	60	63	O	than
12	65	67	O	the
13	69	72	O	same
14	74	77	O	dose
15	79	83	O	given
16	85	86	O	in
17	88	90	O	the
18	92	98	O	morning
19	99	99	O	,
20	101	107	O	perhaps
21	109	115	O	because
22	117	127	O	cholesterol
23	129	130	O	is
24	132	142	O	synthesized
25	144	149	O	mainly
26	151	152	O	at
27	154	158	O	night
NULL

Lovastatin	5263	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	32
In multicenter, double-blind studies in patients with familial or non-familial hypercholesterolemia, MEVACOR, administered in doses ranging from 10mg q.p.m. to 40mg b.i.d., was compared to placebo.
1	0	1	O	In
2	3	13	O	multicenter
3	14	14	O	,
4	16	21	O	double
5	23	27	O	blind
6	29	35	O	studies
7	37	38	O	in
8	40	47	O	patients
9	49	52	O	with
10	54	61	O	familial
11	63	64	O	or
12	66	68	O	non
13	70	77	O	familial
14	79	98	O	hypercholesterolemia
15	99	99	O	,
16	101	107	O	MEVACOR
17	108	108	O	,
18	110	121	O	administered
19	123	124	O	in
20	126	130	O	doses
21	132	138	O	ranging
22	140	143	O	from
23	145	148	O	10mg
24	150	154	O	q.p.m
25	157	158	O	to
26	160	163	O	40mg
27	165	169	O	b.i.d
28	171	171	O	,
29	173	175	O	was
30	177	184	O	compared
31	186	187	O	to
32	189	195	O	placebo
NULL

Lovastatin	5264	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	23
MEVACOR significantly decreased plasma total-C, LDL-C, total-C/HDL-C ratio and LDL-C/HDL-C ratio.
1	0	6	O	MEVACOR
2	8	20	O	significantly
3	22	30	O	decreased
4	32	37	O	plasma
5	39	43	O	total
6	45	45	O	C
7	46	46	O	,
8	48	50	O	LDL
9	52	52	O	C
10	53	53	O	,
11	55	59	O	total
12	61	61	O	C
13	62	62	O	/
14	63	65	O	HDL
15	67	67	O	C
16	69	73	O	ratio
17	75	77	O	and
18	79	81	O	LDL
19	83	83	O	C
20	84	84	O	/
21	85	87	O	HDL
22	89	89	O	C
23	91	95	O	ratio
NULL

Lovastatin	5265	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
In addition, MEVACOR produced increases of variable magnitude in HDL-C, and modestly decreased VLDL-C and plasma TG.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	MEVACOR
5	21	28	O	produced
6	30	38	O	increases
7	40	41	O	of
8	43	50	O	variable
9	52	60	O	magnitude
10	62	63	O	in
11	65	67	O	HDL
12	69	69	O	C
13	70	70	O	,
14	72	74	O	and
15	76	83	O	modestly
16	85	93	O	decreased
17	95	98	O	VLDL
18	100	100	O	C
19	102	104	O	and
20	106	111	O	plasma
21	113	114	O	TG
NULL

Lovastatin	5266	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	14
The results of a study in patients with primary hypercholesterolemia are presented in TableII.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	of
4	15	15	O	a
5	17	21	O	study
6	23	24	O	in
7	26	33	O	patients
8	35	38	O	with
9	40	46	O	primary
10	48	67	O	hypercholesterolemia
11	69	71	O	are
12	73	81	O	presented
13	83	84	O	in
14	86	92	O	TableII
NULL

Lovastatin	5267	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	27
Placebo (Mean Percent Change from Baseline After 6Weeks) DOSAGE N TOTAL-C LDL-C HDL-C LDL-C/HDL-C TOTAL-C/ HDL-C TG.
1	0	6	O	Placebo
2	9	12	O	Mean
3	14	20	O	Percent
4	22	27	O	Change
5	29	32	O	from
6	34	41	O	Baseline
7	43	47	O	After
8	49	54	O	6Weeks
9	57	62	O	DOSAGE
10	64	64	O	N
11	66	70	O	TOTAL
12	72	72	O	C
13	74	76	O	LDL
14	78	78	O	C
15	80	82	O	HDL
16	84	84	O	C
17	86	88	O	LDL
18	90	90	O	C
19	91	91	O	/
20	92	94	O	HDL
21	96	96	O	C
22	98	102	O	TOTAL
23	104	104	O	C
24	105	105	O	/
25	107	109	O	HDL
26	111	111	O	C
27	113	114	O	TG
NULL

Lovastatin	5268	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	12
Placebo 33 -2 -1 -1 0 +1 +9 MEVACOR 10 mg q.p.m.
1	0	6	O	Placebo
2	8	9	O	33
3	12	12	O	2
4	15	15	O	1
5	18	18	O	1
6	20	20	O	0
7	22	23	O	+1
8	25	26	O	+9
9	28	34	O	MEVACOR
10	36	37	O	10
11	39	40	O	mg
12	42	46	O	q.p.m
NULL

Lovastatin	5269	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
33 -16 -21 +5 -24 -19 -10 20 mg q.p.m.
1	0	1	O	33
2	4	5	O	16
3	8	9	O	21
4	11	12	O	+5
5	15	16	O	24
6	19	20	O	19
7	23	24	O	10
8	26	27	O	20
9	29	30	O	mg
10	32	36	O	q.p.m
NULL

Lovastatin	5270	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
33 -19 -27 +6 -30 -23 +9 10 mg b.i.d.
1	0	1	O	33
2	4	5	O	19
3	8	9	O	27
4	11	12	O	+6
5	15	16	O	30
6	19	20	O	23
7	22	23	O	+9
8	25	26	O	10
9	28	29	O	mg
10	31	35	O	b.i.d
NULL

Lovastatin	5271	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
32 -19 -28 +8 -33 -25 -7 40 mg q.p.m.
1	0	1	O	32
2	4	5	O	19
3	8	9	O	28
4	11	12	O	+8
5	15	16	O	33
6	19	20	O	25
7	23	23	O	7
8	25	26	O	40
9	28	29	O	mg
10	31	35	O	q.p.m
NULL

Lovastatin	5272	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
33 -22 -31 +5 -33 -25 -8 20 mg b.i.d.
1	0	1	O	33
2	4	5	O	22
3	8	9	O	31
4	11	12	O	+5
5	15	16	O	33
6	19	20	O	25
7	23	23	O	8
8	25	26	O	20
9	28	29	O	mg
10	31	35	O	b.i.d
NULL

Lovastatin	5273	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	18
36 -24 -32 +2 -32 -24 -6 MEVACOR was compared to cholestyramine in a randomized open parallel study.
1	0	1	O	36
2	4	5	O	24
3	8	9	O	32
4	11	12	O	+2
5	15	16	O	32
6	19	20	O	24
7	23	23	O	6
8	25	31	O	MEVACOR
9	33	35	O	was
10	37	44	O	compared
11	46	47	O	to
12	49	62	O	cholestyramine
13	64	65	O	in
14	67	67	O	a
15	69	78	O	randomized
16	80	83	O	open
17	85	92	O	parallel
18	94	98	O	study
NULL

Lovastatin	5274	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	16
The study was performed with patients with hypercholesterolemia who were at high risk of myocardial infarction.
1	0	2	O	The
2	4	8	O	study
3	10	12	O	was
4	14	22	O	performed
5	24	27	O	with
6	29	36	O	patients
7	38	41	O	with
8	43	62	O	hypercholesterolemia
9	64	66	O	who
10	68	71	O	were
11	73	74	O	at
12	76	79	O	high
13	81	84	O	risk
14	86	87	O	of
15	89	98	O	myocardial
16	100	109	O	infarction
NULL

Lovastatin	5275	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	6
Summary results are presented in TableIII.
1	0	6	O	Summary
2	8	14	O	results
3	16	18	O	are
4	20	28	O	presented
5	30	31	O	in
6	33	40	O	TableIII
NULL

Lovastatin	5276	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	33
TABLE III: MEVACOR vs. Cholestyramine (Percent Change from Baseline After 12Weeks) TREATMENT N TOTAL-C(mean) LDL-C(mean) HDL-C(mean) LDL-C/HDL-C(mean) TOTAL-C/HDL-C(mean) VLDL-C(median) TG.
1	0	4	O	TABLE
2	6	8	O	III
3	9	9	O	:
4	11	17	O	MEVACOR
5	19	20	O	vs
6	23	36	O	Cholestyramine
7	39	45	O	Percent
8	47	52	O	Change
9	54	57	O	from
10	59	66	O	Baseline
11	68	72	O	After
12	74	80	O	12Weeks
13	83	91	O	TREATMENT
14	93	93	O	N
15	95	99	O	TOTAL
16	101	106	O	C(mean
17	109	111	O	LDL
18	113	118	O	C(mean
19	121	123	O	HDL
20	125	130	O	C(mean
21	133	135	O	LDL
22	137	137	O	C
23	138	138	O	/
24	139	141	O	HDL
25	143	148	O	C(mean
26	151	155	O	TOTAL
27	157	157	O	C
28	158	158	O	/
29	159	161	O	HDL
30	163	168	O	C(mean
31	171	174	O	VLDL
32	176	183	O	C(median
33	186	187	O	TG
NULL

Lovastatin	5277	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	5
(mean) MEVACOR 20 mg b.i.d.
1	1	4	O	mean
2	7	13	O	MEVACOR
3	15	16	O	20
4	18	19	O	mg
5	21	25	O	b.i.d
NULL

Lovastatin	5278	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	11
85 -27 -32 +9 -36 -31 -34 -21 40 mg b.i.d.
1	0	1	O	85
2	4	5	O	27
3	8	9	O	32
4	11	12	O	+9
5	15	16	O	36
6	19	20	O	31
7	23	24	O	34
8	27	28	O	21
9	30	31	O	40
10	33	34	O	mg
11	36	40	O	b.i.d
NULL

Lovastatin	5279	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	12
88 -34 -42 +8 -44 -37 -31 -27 Cholestyramine 12 g b.i.d.
1	0	1	O	88
2	4	5	O	34
3	8	9	O	42
4	11	12	O	+8
5	15	16	O	44
6	19	20	O	37
7	23	24	O	31
8	27	28	O	27
9	30	43	O	Cholestyramine
10	45	46	O	12
11	48	48	O	g
12	50	54	O	b.i.d
NULL

Lovastatin	5280	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	29
88 -17 -23 +8 -27 -21 +2 +11 MEVACOR was studied in controlled trials in hypercholesterolemic patients with well-controlled non-insulin dependent diabetes mellitus with normal renal function.
1	0	1	O	88
2	4	5	O	17
3	8	9	O	23
4	11	12	O	+8
5	15	16	O	27
6	19	20	O	21
7	22	23	O	+2
8	25	27	O	+11
9	29	35	O	MEVACOR
10	37	39	O	was
11	41	47	O	studied
12	49	50	O	in
13	52	61	O	controlled
14	63	68	O	trials
15	70	71	O	in
16	73	92	O	hypercholesterolemic
17	94	101	O	patients
18	103	106	O	with
19	108	111	O	well
20	113	122	O	controlled
21	124	126	O	non
22	128	134	O	insulin
23	136	144	O	dependent
24	146	153	O	diabetes
25	155	162	O	mellitus
26	164	167	O	with
27	169	174	O	normal
28	176	180	O	renal
29	182	189	O	function
NULL

Lovastatin	5281	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	23
The effect of MEVACOR on lipids and lipoproteins and the safety profile of MEVACOR were similar to that demonstrated in studies in nondiabetics.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	20	O	MEVACOR
5	22	23	O	on
6	25	30	O	lipids
7	32	34	O	and
8	36	47	O	lipoproteins
9	49	51	O	and
10	53	55	O	the
11	57	62	O	safety
12	64	70	O	profile
13	72	73	O	of
14	75	81	O	MEVACOR
15	83	86	O	were
16	88	94	O	similar
17	96	97	O	to
18	99	102	O	that
19	104	115	O	demonstrated
20	117	118	O	in
21	120	126	O	studies
22	128	129	O	in
23	131	142	O	nondiabetics
NULL

Lovastatin	5282	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	18
MEVACOR had no clinically important effect on glycemic control or on the dose requirement of oral hypoglycemic agents.
1	0	6	O	MEVACOR
2	8	10	O	had
3	12	13	O	no
4	15	24	O	clinically
5	26	34	O	important
6	36	41	O	effect
7	43	44	O	on
8	46	53	O	glycemic
9	55	61	O	control
10	63	64	O	or
11	66	67	O	on
12	69	71	O	the
13	73	76	O	dose
14	78	88	O	requirement
15	90	91	O	of
16	93	96	O	oral
17	98	109	O	hypoglycemic
18	111	116	O	agents
NULL

Lovastatin	5283	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	44
MEVACOR was compared to placebo in 8,245 patients with hypercholesterolemia (total-C 240-300mg/dL [6.2mmol/L - 7.6mmol/L], LDL-C >160mg/dL [4.1mmol/L]) in the randomized, double-blind, parallel, 48-week EXCEL study.
1	0	6	O	MEVACOR
2	8	10	O	was
3	12	19	O	compared
4	21	22	O	to
5	24	30	O	placebo
6	32	33	O	in
7	35	39	O	8,245
8	41	48	O	patients
9	50	53	O	with
10	55	74	O	hypercholesterolemia
11	77	81	O	total
12	83	83	O	C
13	85	87	O	240
14	89	93	O	300mg
15	94	94	O	/
16	95	96	O	dL
17	99	105	O	6.2mmol
18	106	106	O	/
19	107	107	O	L
20	111	117	O	7.6mmol
21	118	118	O	/
22	119	119	O	L
23	121	121	O	,
24	123	125	O	LDL
25	127	127	O	C
26	129	134	O	>160mg
27	135	135	O	/
28	136	137	O	dL
29	140	146	O	4.1mmol
30	147	147	O	/
31	148	148	O	L
32	152	153	O	in
33	155	157	O	the
34	159	168	O	randomized
35	169	169	O	,
36	171	176	O	double
37	178	182	O	blind
38	183	183	O	,
39	185	192	O	parallel
40	193	193	O	,
41	195	196	O	48
42	198	201	O	week
43	203	207	O	EXCEL
44	209	213	O	study
NULL

Lovastatin	5284	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	20
All changes in the lipid measurements (TableIV) in MEVACOR treated patients were dose-related and significantly different from placebo (p<0.001).
1	0	2	O	All
2	4	10	O	changes
3	12	13	O	in
4	15	17	O	the
5	19	23	O	lipid
6	25	36	O	measurements
7	39	45	O	TableIV
8	48	49	O	in
9	51	57	O	MEVACOR
10	59	65	O	treated
11	67	74	O	patients
12	76	79	O	were
13	81	84	O	dose
14	86	92	O	related
15	94	96	O	and
16	98	110	O	significantly
17	112	120	O	different
18	122	125	O	from
19	127	133	O	placebo
20	136	142	O	p<0.001
NULL

Lovastatin	5285	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	7
These results were sustained throughout the study.
1	0	4	O	These
2	6	12	O	results
3	14	17	O	were
4	19	27	O	sustained
5	29	38	O	throughout
6	40	42	O	the
7	44	48	O	study
NULL

Lovastatin	5286	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	31
Placebo (Percent Change from Baseline - Average Values Between Weeks12 and48) DOSAGE NPatients enrolled TOTAL-C(mean) LDL-C(mean) HDL-C(mean) LDL-C/HDL-C (mean) TOTAL-C/HDL-C(mean) TG.
1	0	6	O	Placebo
2	9	15	O	Percent
3	17	22	O	Change
4	24	27	O	from
5	29	36	O	Baseline
6	40	46	O	Average
7	48	53	O	Values
8	55	61	O	Between
9	63	69	O	Weeks12
10	71	75	O	and48
11	78	83	O	DOSAGE
12	85	93	O	NPatients
13	95	102	O	enrolled
14	104	108	O	TOTAL
15	110	115	O	C(mean
16	118	120	O	LDL
17	122	127	O	C(mean
18	130	132	O	HDL
19	134	139	O	C(mean
20	142	144	O	LDL
21	146	146	O	C
22	147	147	O	/
23	148	150	O	HDL
24	152	152	O	C
25	155	158	O	mean
26	161	165	O	TOTAL
27	167	167	O	C
28	168	168	O	/
29	169	171	O	HDL
30	173	178	O	C(mean
31	181	182	O	TG
NULL

Lovastatin	5287	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	13
(median) Placebo 1663 +0.7 +0.4 +2.0 +0.2 +0.6 +4 MEVACOR 20 mg q.p.m.
1	1	6	O	median
2	9	15	O	Placebo
3	17	20	O	1663
4	22	25	O	+0.7
5	27	30	O	+0.4
6	32	35	O	+2.0
7	37	40	O	+0.2
8	42	45	O	+0.6
9	47	48	O	+4
10	50	56	O	MEVACOR
11	58	59	O	20
12	61	62	O	mg
13	64	68	O	q.p.m
NULL

Lovastatin	5288	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
1642 -17 -24 +6.6 -27 -21 -10 40 mg q.p.m.
1	0	3	O	1642
2	6	7	O	17
3	10	11	O	24
4	13	16	O	+6.6
5	19	20	O	27
6	23	24	O	21
7	27	28	O	10
8	30	31	O	40
9	33	34	O	mg
10	36	40	O	q.p.m
NULL

Lovastatin	5289	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
1645 -22 -30 +7.2 -34 -26 -14 20 mg b.i.d.
1	0	3	O	1645
2	6	7	O	22
3	10	11	O	30
4	13	16	O	+7.2
5	19	20	O	34
6	23	24	O	26
7	27	28	O	14
8	30	31	O	20
9	33	34	O	mg
10	36	40	O	b.i.d
NULL

Lovastatin	5290	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	10
1646 -24 -34 +8.6 -38 -29 -16 40 mg b.i.d.
1	0	3	O	1646
2	6	7	O	24
3	10	11	O	34
4	13	16	O	+8.6
5	19	20	O	38
6	23	24	O	29
7	27	28	O	16
8	30	31	O	40
9	33	34	O	mg
10	36	40	O	b.i.d
NULL

Lovastatin	5291	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	70
1649 -29 -40 +9.5 -44 -34 -19 The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS), a double-blind, randomized, placebo-controlled, primary prevention study, demonstrated that treatment with MEVACOR decreased the rate of acute major coronary events (composite endpoint of myocardial infarction, unstable angina, and sudden cardiac death) compared with placebo during a median of 5.1years of follow-up.
1	0	3	O	1649
2	6	7	O	29
3	10	11	O	40
4	13	16	O	+9.5
5	19	20	O	44
6	23	24	O	34
7	27	28	O	19
8	30	32	O	The
9	34	36	O	Air
10	38	42	O	Force
11	43	43	O	/
12	44	48	O	Texas
13	50	57	O	Coronary
14	59	73	O	Atherosclerosis
15	75	84	O	Prevention
16	86	90	O	Study
17	93	98	O	AFCAPS
18	99	99	O	/
19	100	106	O	TexCAPS
20	108	108	O	,
21	110	110	O	a
22	112	117	O	double
23	119	123	O	blind
24	124	124	O	,
25	126	135	O	randomized
26	136	136	O	,
27	138	144	O	placebo
28	146	155	O	controlled
29	156	156	O	,
30	158	164	O	primary
31	166	175	O	prevention
32	177	181	O	study
33	182	182	O	,
34	184	195	O	demonstrated
35	197	200	O	that
36	202	210	O	treatment
37	212	215	O	with
38	217	223	O	MEVACOR
39	225	233	O	decreased
40	235	237	O	the
41	239	242	O	rate
42	244	245	O	of
43	247	251	O	acute
44	253	257	O	major
45	259	266	O	coronary
46	268	273	O	events
47	276	284	O	composite
48	286	293	O	endpoint
49	295	296	O	of
50	298	307	O	myocardial
51	309	318	O	infarction
52	319	319	O	,
53	321	328	O	unstable
54	330	335	O	angina
55	336	336	O	,
56	338	340	O	and
57	342	347	O	sudden
58	349	355	O	cardiac
59	357	361	O	death
60	364	371	O	compared
61	373	376	O	with
62	378	384	O	placebo
63	386	391	O	during
64	393	393	O	a
65	395	400	O	median
66	402	403	O	of
67	405	412	O	5.1years
68	414	415	O	of
69	417	422	O	follow
70	424	425	O	up
NULL

Lovastatin	5292	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	49
Participants were middle-aged and elderly men (ages 45-73) and women (ages 55-73) without symptomatic cardiovascular disease with average to moderately elevated total-C and LDL-C, below average HDL-C, and who were at high risk based on elevated total-C/HDL-C.
1	0	11	O	Participants
2	13	16	O	were
3	18	23	O	middle
4	25	28	O	aged
5	30	32	O	and
6	34	40	O	elderly
7	42	44	O	men
8	47	50	O	ages
9	52	53	O	45
10	55	56	O	73
11	59	61	O	and
12	63	67	O	women
13	70	73	O	ages
14	75	76	O	55
15	78	79	O	73
16	82	88	O	without
17	90	100	O	symptomatic
18	102	115	O	cardiovascular
19	117	123	O	disease
20	125	128	O	with
21	130	136	O	average
22	138	139	O	to
23	141	150	O	moderately
24	152	159	O	elevated
25	161	165	O	total
26	167	167	O	C
27	169	171	O	and
28	173	175	O	LDL
29	177	177	O	C
30	178	178	O	,
31	180	184	O	below
32	186	192	O	average
33	194	196	O	HDL
34	198	198	O	C
35	199	199	O	,
36	201	203	O	and
37	205	207	O	who
38	209	212	O	were
39	214	215	O	at
40	217	220	O	high
41	222	225	O	risk
42	227	231	O	based
43	233	234	O	on
44	236	243	O	elevated
45	245	249	O	total
46	251	251	O	C
47	252	252	O	/
48	253	255	O	HDL
49	257	257	O	C
NULL

Lovastatin	5293	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	31
In addition to age, 63% of the participants had at least one other risk factor (baseline HDL-C <35mg/dL, hypertension, family history, smoking and diabetes).
1	0	1	O	In
2	3	10	O	addition
3	12	13	O	to
4	15	17	O	age
5	18	18	O	,
6	20	22	O	63%
7	24	25	O	of
8	27	29	O	the
9	31	42	O	participants
10	44	46	O	had
11	48	49	O	at
12	51	55	O	least
13	57	59	O	one
14	61	65	O	other
15	67	70	O	risk
16	72	77	O	factor
17	80	87	O	baseline
18	89	91	O	HDL
19	93	93	O	C
20	95	99	O	<35mg
21	100	100	O	/
22	101	102	O	dL
23	103	103	O	,
24	105	116	O	hypertension
25	117	117	O	,
26	119	124	O	family
27	126	132	O	history
28	133	133	O	,
29	135	141	O	smoking
30	143	145	O	and
31	147	154	O	diabetes
NULL

Lovastatin	5294	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	58
AFCAPS/TexCAPS enrolled 6,605 participants (5,608 men, 997 women) based on the following lipid entry criteria: total-C range of 180-264mg/dL, LDL-C range of 130-190mg/dL, HDL-C of <45mg/dL for men and <47mg/dL for women, and TG of <400mg/dL.
1	0	5	O	AFCAPS
2	6	6	O	/
3	7	13	O	TexCAPS
4	15	22	O	enrolled
5	24	28	O	6,605
6	30	41	O	participants
7	44	48	O	5,608
8	50	52	O	men
9	53	53	O	,
10	55	57	O	997
11	59	63	O	women
12	66	70	O	based
13	72	73	O	on
14	75	77	O	the
15	79	87	O	following
16	89	93	O	lipid
17	95	99	O	entry
18	101	108	O	criteria
19	109	109	O	:
20	111	115	O	total
21	117	117	O	C
22	119	123	O	range
23	125	126	O	of
24	128	130	O	180
25	132	136	O	264mg
26	137	137	O	/
27	138	139	O	dL
28	140	140	O	,
29	142	144	O	LDL
30	146	146	O	C
31	148	152	O	range
32	154	155	O	of
33	157	159	O	130
34	161	165	O	190mg
35	166	166	O	/
36	167	168	O	dL
37	169	169	O	,
38	171	173	O	HDL
39	175	175	O	C
40	177	178	O	of
41	180	184	O	<45mg
42	185	185	O	/
43	186	187	O	dL
44	189	191	O	for
45	193	195	O	men
46	197	199	O	and
47	201	205	O	<47mg
48	206	206	O	/
49	207	208	O	dL
50	210	212	O	for
51	214	218	O	women
52	219	219	O	,
53	221	223	O	and
54	225	226	O	TG
55	228	229	O	of
56	231	236	O	<400mg
57	237	237	O	/
58	238	239	O	dL
NULL

Lovastatin	5295	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	20
Participants were treated with standard care, including diet, and either MEVACOR 20-40mg daily (n=3,304) or placebo (n=3,301).
1	0	11	O	Participants
2	13	16	O	were
3	18	24	O	treated
4	26	29	O	with
5	31	38	O	standard
6	40	43	O	care
7	44	44	O	,
8	46	54	O	including
9	56	59	O	diet
10	60	60	O	,
11	62	64	O	and
12	66	71	O	either
13	73	79	O	MEVACOR
14	81	82	O	20
15	84	87	O	40mg
16	89	93	O	daily
17	96	102	O	n=3,304
18	105	106	O	or
19	108	114	O	placebo
20	117	123	O	n=3,301
NULL

Lovastatin	5296	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	27
Approximately 50% of the participants treated with MEVACOR were titrated to 40mg daily when their LDL-C remained >110mg/dL at the 20-mg starting dose.
1	0	12	O	Approximately
2	14	16	O	50%
3	18	19	O	of
4	21	23	O	the
5	25	36	O	participants
6	38	44	O	treated
7	46	49	O	with
8	51	57	O	MEVACOR
9	59	62	O	were
10	64	71	O	titrated
11	73	74	O	to
12	76	79	O	40mg
13	81	85	O	daily
14	87	90	O	when
15	92	96	O	their
16	98	100	O	LDL
17	102	102	O	C
18	104	111	O	remained
19	113	118	O	>110mg
20	119	119	O	/
21	120	121	O	dL
22	123	124	O	at
23	126	128	O	the
24	130	131	O	20
25	133	134	O	mg
26	136	143	O	starting
27	145	148	O	dose
NULL

Lovastatin	5297	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	26
MEVACOR reduced the risk of a first acute major coronary event, the primary efficacy endpoint, by 37% (MEVACOR 3.5%, placebo 5.5%; p<0.001; Figure1).
1	0	6	O	MEVACOR
2	8	14	O	reduced
3	16	18	O	the
4	20	23	O	risk
5	25	26	O	of
6	28	28	O	a
7	30	34	O	first
8	36	40	O	acute
9	42	46	O	major
10	48	55	O	coronary
11	57	61	O	event
12	62	62	O	,
13	64	66	O	the
14	68	74	O	primary
15	76	83	O	efficacy
16	85	92	O	endpoint
17	93	93	O	,
18	95	96	O	by
19	98	100	O	37%
20	103	109	O	MEVACOR
21	111	114	O	3.5%
22	115	115	O	,
23	117	123	O	placebo
24	125	128	O	5.5%
25	131	137	O	p<0.001
26	140	146	O	Figure1
NULL

Lovastatin	5298	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	32
A first acute major coronary event was defined as myocardial infarction (54 participants on MEVACOR, 94 on placebo) or unstable angina (54 vs. 80) or sudden cardiac death (8 vs. 9).
1	0	0	O	A
2	2	6	O	first
3	8	12	O	acute
4	14	18	O	major
5	20	27	O	coronary
6	29	33	O	event
7	35	37	O	was
8	39	45	O	defined
9	47	48	O	as
10	50	59	O	myocardial
11	61	70	O	infarction
12	73	74	O	54
13	76	87	O	participants
14	89	90	O	on
15	92	98	O	MEVACOR
16	99	99	O	,
17	101	102	O	94
18	104	105	O	on
19	107	113	O	placebo
20	116	117	O	or
21	119	126	O	unstable
22	128	133	O	angina
23	136	137	O	54
24	139	140	O	vs
25	143	144	O	80
26	147	148	O	or
27	150	155	O	sudden
28	157	163	O	cardiac
29	165	169	O	death
30	172	172	O	8
31	174	175	O	vs
32	178	178	O	9
NULL

Lovastatin	5299	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	54
Furthermore, among the secondary endpoints, MEVACOR reduced the risk of unstable angina by 32% (1.8 vs. 2.6%; p=0.023), of myocardial infarction by 40% (1.7 vs. 2.9%; p=0.002), and of undergoing coronary revascularization procedures (e.g., coronary artery bypass grafting or percutaneous transluminal coronary angioplasty) by 33% (3.2 vs. 4.8%; p=0.001).
1	0	10	O	Furthermore
2	11	11	O	,
3	13	17	O	among
4	19	21	O	the
5	23	31	O	secondary
6	33	41	O	endpoints
7	42	42	O	,
8	44	50	O	MEVACOR
9	52	58	O	reduced
10	60	62	O	the
11	64	67	O	risk
12	69	70	O	of
13	72	79	O	unstable
14	81	86	O	angina
15	88	89	O	by
16	91	93	O	32%
17	96	98	O	1.8
18	100	101	O	vs
19	104	107	O	2.6%
20	110	116	O	p=0.023
21	118	118	O	,
22	120	121	O	of
23	123	132	O	myocardial
24	134	143	O	infarction
25	145	146	O	by
26	148	150	O	40%
27	153	155	O	1.7
28	157	158	O	vs
29	161	164	O	2.9%
30	167	173	O	p=0.002
31	175	175	O	,
32	177	179	O	and
33	181	182	O	of
34	184	193	O	undergoing
35	195	202	O	coronary
36	204	220	O	revascularization
37	222	231	O	procedures
38	234	236	O	e.g
39	238	238	O	,
40	240	247	O	coronary
41	249	254	O	artery
42	256	261	O	bypass
43	263	270	O	grafting
44	272	273	O	or
45	275	286	O	percutaneous
46	288	299	O	transluminal
47	301	308	O	coronary
48	310	320	O	angioplasty
49	323	324	O	by
50	326	328	O	33%
51	331	333	O	3.2
52	335	336	O	vs
53	339	342	O	4.8%
54	345	351	O	p=0.001
NULL

Lovastatin	5300	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	31
Trends in risk reduction associated with treatment with MEVACOR were consistent across men and women, smokers and non-smokers, hypertensives and non-hypertensives, and older and younger participants.
1	0	5	O	Trends
2	7	8	O	in
3	10	13	O	risk
4	15	23	O	reduction
5	25	34	O	associated
6	36	39	O	with
7	41	49	O	treatment
8	51	54	O	with
9	56	62	O	MEVACOR
10	64	67	O	were
11	69	78	O	consistent
12	80	85	O	across
13	87	89	O	men
14	91	93	O	and
15	95	99	O	women
16	100	100	O	,
17	102	108	O	smokers
18	110	112	O	and
19	114	116	O	non
20	118	124	O	smokers
21	125	125	O	,
22	127	139	O	hypertensives
23	141	143	O	and
24	145	147	O	non
25	149	161	O	hypertensives
26	162	162	O	,
27	164	166	O	and
28	168	172	O	older
29	174	176	O	and
30	178	184	O	younger
31	186	197	O	participants
NULL

Lovastatin	5301	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
Participants with >2 risk factors had risk reductions (RR) in both acute major coronary events (RR43%) and coronary revascularization procedures (RR37%).
1	0	11	O	Participants
2	13	16	O	with
3	18	19	O	>2
4	21	24	O	risk
5	26	32	O	factors
6	34	36	O	had
7	38	41	O	risk
8	43	52	O	reductions
9	55	56	O	RR
10	59	60	O	in
11	62	65	O	both
12	67	71	O	acute
13	73	77	O	major
14	79	86	O	coronary
15	88	93	O	events
16	96	100	O	RR43%
17	103	105	O	and
18	107	114	O	coronary
19	116	132	O	revascularization
20	134	143	O	procedures
21	146	150	O	RR37%
NULL

Lovastatin	5302	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	34
Because there were too few events among those participants with age as their only risk factor in this study, the effect of MEVACOR on outcomes could not be adequately assessed in this subgroup.
1	0	6	O	Because
2	8	12	O	there
3	14	17	O	were
4	19	21	O	too
5	23	25	O	few
6	27	32	O	events
7	34	38	O	among
8	40	44	O	those
9	46	57	O	participants
10	59	62	O	with
11	64	66	O	age
12	68	69	O	as
13	71	75	O	their
14	77	80	O	only
15	82	85	O	risk
16	87	92	O	factor
17	94	95	O	in
18	97	100	O	this
19	102	106	O	study
20	107	107	O	,
21	109	111	O	the
22	113	118	O	effect
23	120	121	O	of
24	123	129	O	MEVACOR
25	131	132	O	on
26	134	141	O	outcomes
27	143	147	O	could
28	149	151	O	not
29	153	154	O	be
30	156	165	O	adequately
31	167	174	O	assessed
32	176	177	O	in
33	179	182	O	this
34	184	191	O	subgroup
NULL

Lovastatin	5303	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	35
Figure 1: Acute Major Coronary Events (Primary Endpoint) In the Canadian Coronary Atherosclerosis Intervention Trial (CCAIT), the effect of therapy with lovastatin on coronary atherosclerosis was assessed by coronary angiography in hyperlipidemic patients.
1	0	5	O	Figure
2	7	7	O	1
3	8	8	O	:
4	10	14	O	Acute
5	16	20	O	Major
6	22	29	O	Coronary
7	31	36	O	Events
8	39	45	O	Primary
9	47	54	O	Endpoint
10	57	58	O	In
11	60	62	O	the
12	64	71	O	Canadian
13	73	80	O	Coronary
14	82	96	O	Atherosclerosis
15	98	109	O	Intervention
16	111	115	O	Trial
17	118	122	O	CCAIT
18	124	124	O	,
19	126	128	O	the
20	130	135	O	effect
21	137	138	O	of
22	140	146	O	therapy
23	148	151	O	with
24	153	162	O	XXXXXXXX
25	164	165	O	on
26	167	174	O	coronary
27	176	190	O	atherosclerosis
28	192	194	O	was
29	196	203	O	assessed
30	205	206	O	by
31	208	215	O	coronary
32	217	227	O	angiography
33	229	230	O	in
34	232	245	O	hyperlipidemic
35	247	254	O	patients
NULL

Lovastatin	5304	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	34
In the randomized, double-blind, controlled clinical trial, patients were treated with conventional measures (usually diet and 325mg of aspirin every other day) and either lovastatin 20-80mg daily or placebo.
1	0	1	O	In
2	3	5	O	the
3	7	16	O	randomized
4	17	17	O	,
5	19	24	O	double
6	26	30	O	blind
7	31	31	O	,
8	33	42	O	controlled
9	44	51	O	clinical
10	53	57	O	trial
11	58	58	O	,
12	60	67	O	patients
13	69	72	O	were
14	74	80	O	treated
15	82	85	O	with
16	87	98	O	conventional
17	100	107	O	measures
18	110	116	O	usually
19	118	121	O	diet
20	123	125	O	and
21	127	131	O	325mg
22	133	134	O	of
23	136	142	O	aspirin
24	144	148	O	every
25	150	154	O	other
26	156	158	O	day
27	161	163	O	and
28	165	170	O	either
29	172	181	O	XXXXXXXX
30	183	184	O	20
31	186	189	O	80mg
32	191	195	O	daily
33	197	198	O	or
34	200	206	O	placebo
NULL

Lovastatin	5305	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	15
Angiograms were evaluated at baseline and at two years by computerized quantitative coronary angiography (QCA).
1	0	9	O	Angiograms
2	11	14	O	were
3	16	24	O	evaluated
4	26	27	O	at
5	29	36	O	baseline
6	38	40	O	and
7	42	43	O	at
8	45	47	O	two
9	49	53	O	years
10	55	56	O	by
11	58	69	O	computerized
12	71	82	O	quantitative
13	84	91	O	coronary
14	93	103	O	angiography
15	106	108	O	QCA
NULL

Lovastatin	5306	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	47
Lovastatin significantly slowed the progression of lesions as measured by the mean change per-patient in minimum lumen diameter (the primary endpoint) and percent diameter stenosis, and decreased the proportions of patients categorized with disease progression (33% vs. 50%) and with new lesions (16% vs. 32%).
1	0	9	O	XXXXXXXX
2	11	23	O	significantly
3	25	30	O	slowed
4	32	34	O	the
5	36	46	O	progression
6	48	49	O	of
7	51	57	O	lesions
8	59	60	O	as
9	62	69	O	measured
10	71	72	O	by
11	74	76	O	the
12	78	81	O	mean
13	83	88	O	change
14	90	92	O	per
15	94	100	O	patient
16	102	103	O	in
17	105	111	O	minimum
18	113	117	O	lumen
19	119	126	O	diameter
20	129	131	O	the
21	133	139	O	primary
22	141	148	O	endpoint
23	151	153	O	and
24	155	161	O	percent
25	163	170	O	diameter
26	172	179	O	stenosis
27	180	180	O	,
28	182	184	O	and
29	186	194	O	decreased
30	196	198	O	the
31	200	210	O	proportions
32	212	213	O	of
33	215	222	O	patients
34	224	234	O	categorized
35	236	239	O	with
36	241	247	O	disease
37	249	259	O	progression
38	262	264	O	33%
39	266	267	O	vs
40	270	272	O	50%
41	275	277	O	and
42	279	282	O	with
43	284	286	O	new
44	288	294	O	lesions
45	297	299	O	16%
46	301	302	O	vs
47	305	307	O	32%
NULL

Lovastatin	5307	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	25
In a similarly designed trial, the Monitored Atherosclerosis Regression Study (MARS), patients were treated with diet and either lovastatin 80mg daily or placebo.
1	0	1	O	In
2	3	3	O	a
3	5	13	O	similarly
4	15	22	O	designed
5	24	28	O	trial
6	29	29	O	,
7	31	33	O	the
8	35	43	O	Monitored
9	45	59	O	Atherosclerosis
10	61	70	O	Regression
11	72	76	O	Study
12	79	82	O	MARS
13	84	84	O	,
14	86	93	O	patients
15	95	98	O	were
16	100	106	O	treated
17	108	111	O	with
18	113	116	O	diet
19	118	120	O	and
20	122	127	O	either
21	129	138	O	XXXXXXXX
22	140	143	O	80mg
23	145	149	O	daily
24	151	152	O	or
25	154	160	O	placebo
NULL

Lovastatin	5308	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	32
No statistically significant difference between lovastatin and placebo was seen for the primary endpoint (mean change per patient in percent diameter stenosis of all lesions), or for most secondary QCA endpoints.
1	0	1	O	No
2	3	15	O	statistically
3	17	27	O	significant
4	29	38	O	difference
5	40	46	O	between
6	48	57	O	XXXXXXXX
7	59	61	O	and
8	63	69	O	placebo
9	71	73	O	was
10	75	78	O	seen
11	80	82	O	for
12	84	86	O	the
13	88	94	O	primary
14	96	103	O	endpoint
15	106	109	O	mean
16	111	116	O	change
17	118	120	O	per
18	122	128	O	patient
19	130	131	O	in
20	133	139	O	percent
21	141	148	O	diameter
22	150	157	O	stenosis
23	159	160	O	of
24	162	164	O	all
25	166	172	O	lesions
26	174	174	O	,
27	176	177	O	or
28	179	181	O	for
29	183	186	O	most
30	188	196	O	secondary
31	198	200	O	QCA
32	202	210	O	endpoints
NULL

Lovastatin	5309	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
Visual assessment by angiographers who formed a consensus opinion of overall angiographic change (Global Change Score) was also a secondary endpoint.
1	0	5	O	Visual
2	7	16	O	assessment
3	18	19	O	by
4	21	33	O	angiographers
5	35	37	O	who
6	39	44	O	formed
7	46	46	O	a
8	48	56	O	consensus
9	58	64	O	opinion
10	66	67	O	of
11	69	75	O	overall
12	77	88	O	angiographic
13	90	95	O	change
14	98	103	O	Global
15	105	110	O	Change
16	112	116	O	Score
17	119	121	O	was
18	123	126	O	also
19	128	128	O	a
20	130	138	O	secondary
21	140	147	O	endpoint
NULL

Lovastatin	5310	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	26
By this endpoint, significant slowing of disease was seen, with regression in 23% of patients treated with lovastatin compared to 11% of placebo patients.
1	0	1	O	By
2	3	6	O	this
3	8	15	O	endpoint
4	16	16	O	,
5	18	28	O	significant
6	30	36	O	slowing
7	38	39	O	of
8	41	47	O	disease
9	49	51	O	was
10	53	56	O	seen
11	57	57	O	,
12	59	62	O	with
13	64	73	O	regression
14	75	76	O	in
15	78	80	O	23%
16	82	83	O	of
17	85	92	O	patients
18	94	100	O	treated
19	102	105	O	with
20	107	116	O	XXXXXXXX
21	118	125	O	compared
22	127	128	O	to
23	130	132	O	11%
24	134	135	O	of
25	137	143	O	placebo
26	145	152	O	patients
NULL

Lovastatin	5311	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	54
In the Familial Atherosclerosis Treatment Study (FATS), either lovastatin or niacin in combination with a bile acid sequestrant for 2.5years in hyperlipidemic subjects significantly reduced the frequency of progression and increased the frequency of regression of coronary atherosclerotic lesions by QCA compared to diet and, in some cases, low-dose resin.
1	0	1	O	In
2	3	5	O	the
3	7	14	O	Familial
4	16	30	O	Atherosclerosis
5	32	40	O	Treatment
6	42	46	O	Study
7	49	52	O	FATS
8	54	54	O	,
9	56	61	O	either
10	63	72	O	XXXXXXXX
11	74	75	O	or
12	77	82	O	niacin
13	84	85	O	in
14	87	97	O	combination
15	99	102	O	with
16	104	104	O	a
17	106	109	O	bile
18	111	114	O	acid
19	116	126	O	sequestrant
20	128	130	O	for
21	132	139	O	2.5years
22	141	142	O	in
23	144	157	O	hyperlipidemic
24	159	166	O	subjects
25	168	180	O	significantly
26	182	188	O	reduced
27	190	192	O	the
28	194	202	O	frequency
29	204	205	O	of
30	207	217	O	progression
31	219	221	O	and
32	223	231	O	increased
33	233	235	O	the
34	237	245	O	frequency
35	247	248	O	of
36	250	259	O	regression
37	261	262	O	of
38	264	271	O	coronary
39	273	287	O	atherosclerotic
40	289	295	O	lesions
41	297	298	O	by
42	300	302	O	QCA
43	304	311	O	compared
44	313	314	O	to
45	316	319	O	diet
46	321	323	O	and
47	324	324	O	,
48	326	327	O	in
49	329	332	O	some
50	334	338	O	cases
51	339	339	O	,
52	341	343	O	low
53	345	348	O	dose
54	350	354	O	resin
NULL

Lovastatin	5312	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	22
The effect of lovastatin on the progression of atherosclerosis in the coronary arteries has been corroborated by similar findings in another vasculature.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	30	O	the
7	32	42	O	progression
8	44	45	O	of
9	47	61	O	atherosclerosis
10	63	64	O	in
11	66	68	O	the
12	70	77	O	coronary
13	79	86	O	arteries
14	88	90	O	has
15	92	95	O	been
16	97	108	O	corroborated
17	110	111	O	by
18	113	119	O	similar
19	121	128	O	findings
20	130	131	O	in
21	133	139	O	another
22	141	151	O	vasculature
NULL

Lovastatin	5313	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	39
In the Asymptomatic Carotid Artery Progression Study (ACAPS), the effect of therapy with lovastatin on carotid atherosclerosis was assessed by B-mode ultrasonography in hyperlipidemic patients with early carotid lesions and without known coronary heart disease at baseline.
1	0	1	O	In
2	3	5	O	the
3	7	18	O	Asymptomatic
4	20	26	O	Carotid
5	28	33	O	Artery
6	35	45	O	Progression
7	47	51	O	Study
8	54	58	O	ACAPS
9	60	60	O	,
10	62	64	O	the
11	66	71	O	effect
12	73	74	O	of
13	76	82	O	therapy
14	84	87	O	with
15	89	98	O	XXXXXXXX
16	100	101	O	on
17	103	109	O	carotid
18	111	125	O	atherosclerosis
19	127	129	O	was
20	131	138	O	assessed
21	140	141	O	by
22	143	143	O	B
23	145	148	O	mode
24	150	164	O	ultrasonography
25	166	167	O	in
26	169	182	O	hyperlipidemic
27	184	191	O	patients
28	193	196	O	with
29	198	202	O	early
30	204	210	O	carotid
31	212	218	O	lesions
32	220	222	O	and
33	224	230	O	without
34	232	236	O	known
35	238	245	O	coronary
36	247	251	O	heart
37	253	259	O	disease
38	261	262	O	at
39	264	271	O	baseline
NULL

Lovastatin	5314	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	29
In this double-blind, controlled clinical trial, 919 patients were randomized in a 2x2 factorial design to placebo, lovastatin 10-40mg daily and/or warfarin.
1	0	1	O	In
2	3	6	O	this
3	8	13	O	double
4	15	19	O	blind
5	20	20	O	,
6	22	31	O	controlled
7	33	40	O	clinical
8	42	46	O	trial
9	47	47	O	,
10	49	51	O	919
11	53	60	O	patients
12	62	65	O	were
13	67	76	O	randomized
14	78	79	O	in
15	81	81	O	a
16	83	85	O	2x2
17	87	95	O	factorial
18	97	102	O	design
19	104	105	O	to
20	107	113	O	placebo
21	114	114	O	,
22	116	125	O	XXXXXXXX
23	127	128	O	10
24	130	133	O	40mg
25	135	139	O	daily
26	141	143	O	and
27	144	144	O	/
28	145	146	O	or
29	148	155	O	warfarin
NULL

Lovastatin	5315	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	29
Ultrasonograms of the carotid walls were used to determine the change per patient from baseline to three years in mean maximum intimal-medial thickness (IMT) of 12 measured segments.
1	0	13	O	Ultrasonograms
2	15	16	O	of
3	18	20	O	the
4	22	28	O	carotid
5	30	34	O	walls
6	36	39	O	were
7	41	44	O	used
8	46	47	O	to
9	49	57	O	determine
10	59	61	O	the
11	63	68	O	change
12	70	72	O	per
13	74	80	O	patient
14	82	85	O	from
15	87	94	O	baseline
16	96	97	O	to
17	99	103	O	three
18	105	109	O	years
19	111	112	O	in
20	114	117	O	mean
21	119	125	O	maximum
22	127	133	O	intimal
23	135	140	O	medial
24	142	150	O	thickness
25	153	155	O	IMT
26	158	159	O	of
27	161	162	O	12
28	164	171	O	measured
29	173	180	O	segments
NULL

Lovastatin	5316	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	20
There was a significant regression of carotid lesions in patients receiving lovastatin alone compared to those receiving placebo alone (p=0.001).
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	22	O	significant
5	24	33	O	regression
6	35	36	O	of
7	38	44	O	carotid
8	46	52	O	lesions
9	54	55	O	in
10	57	64	O	patients
11	66	74	O	receiving
12	76	85	O	XXXXXXXX
13	87	91	O	alone
14	93	100	O	compared
15	102	103	O	to
16	105	109	O	those
17	111	119	O	receiving
18	121	127	O	placebo
19	129	133	O	alone
20	136	142	O	p=0.001
NULL

Lovastatin	5317	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	14
The predictive value of changes in IMT for stroke has not yet been established.
1	0	2	O	The
2	4	13	O	predictive
3	15	19	O	value
4	21	22	O	of
5	24	30	O	changes
6	32	33	O	in
7	35	37	O	IMT
8	39	41	O	for
9	43	48	O	stroke
10	50	52	O	has
11	54	56	O	not
12	58	60	O	yet
13	62	65	O	been
14	67	77	O	established
NULL

Lovastatin	5318	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	37
In the lovastatin group there was a significant reduction in the number of patients with major cardiovascular events relative to the placebo group (5 vs. 14) and a significant reduction in all-cause mortality (1 vs. 8).
1	0	1	O	In
2	3	5	O	the
3	7	16	O	XXXXXXXX
4	18	22	O	group
5	24	28	O	there
6	30	32	O	was
7	34	34	O	a
8	36	46	O	significant
9	48	56	O	reduction
10	58	59	O	in
11	61	63	O	the
12	65	70	O	number
13	72	73	O	of
14	75	82	O	patients
15	84	87	O	with
16	89	93	O	major
17	95	108	O	cardiovascular
18	110	115	O	events
19	117	124	O	relative
20	126	127	O	to
21	129	131	O	the
22	133	139	O	placebo
23	141	145	O	group
24	148	148	O	5
25	150	151	O	vs
26	154	155	O	14
27	158	160	O	and
28	162	162	O	a
29	164	174	O	significant
30	176	184	O	reduction
31	186	187	O	in
32	189	191	O	all
33	193	197	O	cause
34	199	207	O	mortality
35	210	210	O	1
36	212	213	O	vs
37	216	216	O	8
NULL

Lovastatin	5319	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	21
There was a high prevalence of baseline lenticular opacities in the patient population included in the early clinical trials with lovastatin.
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	15	O	high
5	17	26	O	prevalence
6	28	29	O	of
7	31	38	O	baseline
8	40	49	O	lenticular
9	51	59	O	opacities
10	61	62	O	in
11	64	66	O	the
12	68	74	O	patient
13	76	85	O	population
14	87	94	O	included
15	96	97	O	in
16	99	101	O	the
17	103	107	O	early
18	109	116	O	clinical
19	118	123	O	trials
20	125	128	O	with
21	130	139	O	XXXXXXXX
NULL

Lovastatin	5320	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	17
During these trials the appearance of new opacities was noted in both the lovastatin and placebo groups.
1	0	5	O	During
2	7	11	O	these
3	13	18	O	trials
4	20	22	O	the
5	24	33	O	appearance
6	35	36	O	of
7	38	40	O	new
8	42	50	O	opacities
9	52	54	O	was
10	56	60	O	noted
11	62	63	O	in
12	65	68	O	both
13	70	72	O	the
14	74	83	O	XXXXXXXX
15	85	87	O	and
16	89	95	O	placebo
17	97	102	O	groups
NULL

Lovastatin	5321	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	40
There was no clinically significant change in visual acuity in the patients who had new opacities reported nor was any patient, including those with opacities noted at baseline, discontinued from therapy because of a decrease in visual acuity.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	22	O	clinically
5	24	34	O	significant
6	36	41	O	change
7	43	44	O	in
8	46	51	O	visual
9	53	58	O	acuity
10	60	61	O	in
11	63	65	O	the
12	67	74	O	patients
13	76	78	O	who
14	80	82	O	had
15	84	86	O	new
16	88	96	O	opacities
17	98	105	O	reported
18	107	109	O	nor
19	111	113	O	was
20	115	117	O	any
21	119	125	O	patient
22	126	126	O	,
23	128	136	O	including
24	138	142	O	those
25	144	147	O	with
26	149	157	O	opacities
27	159	163	O	noted
28	165	166	O	at
29	168	175	O	baseline
30	176	176	O	,
31	178	189	O	discontinued
32	191	194	O	from
33	196	202	O	therapy
34	204	210	O	because
35	212	213	O	of
36	215	215	O	a
37	217	224	O	decrease
38	226	227	O	in
39	229	234	O	visual
40	236	241	O	acuity
NULL

Lovastatin	5322	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	49
A three-year, double-blind, placebo-controlled study in hypercholesterolemic patients to assess the effect of lovastatin on the human lens demonstrated that there were no clinically or statistically significant differences between the lovastatin and placebo groups in the incidence, type or progression of lenticular opacities.
1	0	0	O	A
2	2	6	O	three
3	8	11	O	year
4	12	12	O	,
5	14	19	O	double
6	21	25	O	blind
7	26	26	O	,
8	28	34	O	placebo
9	36	45	O	controlled
10	47	51	O	study
11	53	54	O	in
12	56	75	O	hypercholesterolemic
13	77	84	O	patients
14	86	87	O	to
15	89	94	O	assess
16	96	98	O	the
17	100	105	O	effect
18	107	108	O	of
19	110	119	O	XXXXXXXX
20	121	122	O	on
21	124	126	O	the
22	128	132	O	human
23	134	137	O	lens
24	139	150	O	demonstrated
25	152	155	O	that
26	157	161	O	there
27	163	166	O	were
28	168	169	O	no
29	171	180	O	clinically
30	182	183	O	or
31	185	197	O	statistically
32	199	209	O	significant
33	211	221	O	differences
34	223	229	O	between
35	231	233	O	the
36	235	244	O	XXXXXXXX
37	246	248	O	and
38	250	256	O	placebo
39	258	263	O	groups
40	265	266	O	in
41	268	270	O	the
42	272	280	O	incidence
43	281	281	O	,
44	283	286	O	type
45	288	289	O	or
46	291	301	O	progression
47	303	304	O	of
48	306	315	O	lenticular
49	317	325	O	opacities
NULL

Lovastatin	5323	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	15
There are no controlled clinical data assessing the lens available for treatment beyond three years.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	22	O	controlled
5	24	31	O	clinical
6	33	36	O	data
7	38	46	O	assessing
8	48	50	O	the
9	52	55	O	lens
10	57	65	O	available
11	67	69	O	for
12	71	79	O	treatment
13	81	86	O	beyond
14	88	92	O	three
15	94	98	O	years
NULL

Lovastatin	5324	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	33
In a double-blind, placebo-controlled study, 132 boys 10-17years of age (mean age 12.7yrs) with heterozygous familial hypercholesterolemia (heFH) were randomized to lovastatin (n=67) or placebo (n=65) for 48weeks.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	double
4	12	16	O	blind
5	17	17	O	,
6	19	25	O	placebo
7	27	36	O	controlled
8	38	42	O	study
9	43	43	O	,
10	45	47	O	132
11	49	52	O	boys
12	54	55	O	10
13	57	63	O	17years
14	65	66	O	of
15	68	70	O	age
16	73	76	O	mean
17	78	80	O	age
18	82	88	O	12.7yrs
19	91	94	O	with
20	96	107	O	heterozygous
21	109	116	O	familial
22	118	137	O	hypercholesterolemia
23	140	143	O	heFH
24	146	149	O	were
25	151	160	O	randomized
26	162	163	O	to
27	165	174	O	XXXXXXXX
28	177	180	O	n=67
29	183	184	O	or
30	186	192	O	placebo
31	195	198	O	n=65
32	201	203	O	for
33	205	211	O	48weeks
NULL

Lovastatin	5325	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	29
Inclusion in the study required a baseline LDL-C level between 189 and 500mg/dL and at least one parent with an LDL-C level >189mg/dL.
1	0	8	O	Inclusion
2	10	11	O	in
3	13	15	O	the
4	17	21	O	study
5	23	30	O	required
6	32	32	O	a
7	34	41	O	baseline
8	43	45	O	LDL
9	47	47	O	C
10	49	53	O	level
11	55	61	O	between
12	63	65	O	189
13	67	69	O	and
14	71	75	O	500mg
15	76	76	O	/
16	77	78	O	dL
17	80	82	O	and
18	84	85	O	at
19	87	91	O	least
20	93	95	O	one
21	97	102	O	parent
22	104	107	O	with
23	109	110	O	an
24	112	114	O	LDL
25	116	116	O	C
26	118	122	O	level
27	124	129	O	>189mg
28	130	130	O	/
29	131	132	O	dL
NULL

Lovastatin	5326	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	35
The mean baseline LDL-C value was 253.1mg/dL (range: 171-379mg/dL) in the MEVACOR group compared to 248.2mg/dL (range: 158.5-413.5mg/dL) in the placebo group.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	baseline
4	18	20	O	LDL
5	22	22	O	C
6	24	28	O	value
7	30	32	O	was
8	34	40	O	253.1mg
9	41	41	O	/
10	42	43	O	dL
11	46	50	O	range
12	51	51	O	:
13	53	55	O	171
14	57	61	O	379mg
15	62	62	O	/
16	63	64	O	dL
17	67	68	O	in
18	70	72	O	the
19	74	80	O	MEVACOR
20	82	86	O	group
21	88	95	O	compared
22	97	98	O	to
23	100	106	O	248.2mg
24	107	107	O	/
25	108	109	O	dL
26	112	116	O	range
27	117	117	O	:
28	119	123	O	158.5
29	125	131	O	413.5mg
30	132	132	O	/
31	133	134	O	dL
32	137	138	O	in
33	140	142	O	the
34	144	150	O	placebo
35	152	156	O	group
NULL

Lovastatin	5327	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	25
The dosage of lovastatin (once daily in the evening) was 10mg for the first 8weeks, 20mg for the second 8weeks, and 40mg thereafter.
1	0	2	O	The
2	4	9	O	dosage
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	26	29	O	once
6	31	35	O	daily
7	37	38	O	in
8	40	42	O	the
9	44	50	O	evening
10	53	55	O	was
11	57	60	O	10mg
12	62	64	O	for
13	66	68	O	the
14	70	74	O	first
15	76	81	O	8weeks
16	82	82	O	,
17	84	87	O	20mg
18	89	91	O	for
19	93	95	O	the
20	97	102	O	second
21	104	109	O	8weeks
22	110	110	O	,
23	112	114	O	and
24	116	119	O	40mg
25	121	130	O	thereafter
NULL

Lovastatin	5328	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	13
MEVACOR significantly decreased plasma levels of total-C, LDL-C and apolipoproteinB.
1	0	6	O	MEVACOR
2	8	20	O	significantly
3	22	30	O	decreased
4	32	37	O	plasma
5	39	44	O	levels
6	46	47	O	of
7	49	53	O	total
8	55	55	O	C
9	56	56	O	,
10	58	60	O	LDL
11	62	62	O	C
12	64	66	O	and
13	68	82	O	apolipoproteinB
NULL

Lovastatin	5329	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	92
TABLE V: Lipid-lowering Effects of Lovastatin in Adolescent Boys with Heterozygous Familial Hypercholesterolemia (Mean Percent Change from Baseline at Week48 in Intention-to-Treat Population) DOSAGE N TOTAL-C LDL-C HDL-C TG.data presented as median percent changes Apolipoprotein B Placebo 61 -1.1 -1.4 -2.2 -1.4 -4.4 MEVACOR 64 -19.3 -24.2 +1.1 -1.9 -21 The mean achieved LDL-C value was 190.9mg/dL (range: 108-336mg/dL) in the MEVACOR group compared to 244.8mg/dL (range: 135-404mg/dL) in the placebo group.
1	0	4	O	TABLE
2	6	6	O	V
3	7	7	O	:
4	9	13	O	Lipid
5	15	22	O	lowering
6	24	30	O	Effects
7	32	33	O	of
8	35	44	O	XXXXXXXX
9	46	47	O	in
10	49	58	O	Adolescent
11	60	63	O	Boys
12	65	68	O	with
13	70	81	O	Heterozygous
14	83	90	O	Familial
15	92	111	O	Hypercholesterolemia
16	114	117	O	Mean
17	119	125	O	Percent
18	127	132	O	Change
19	134	137	O	from
20	139	146	O	Baseline
21	148	149	O	at
22	151	156	O	Week48
23	158	159	O	in
24	161	169	O	Intention
25	171	172	O	to
26	174	178	O	Treat
27	180	189	O	Population
28	192	197	O	DOSAGE
29	199	199	O	N
30	201	205	O	TOTAL
31	207	207	O	C
32	209	211	O	LDL
33	213	213	O	C
34	215	217	O	HDL
35	219	219	O	C
36	221	227	O	TG.data
37	229	237	O	presented
38	239	240	O	as
39	242	247	O	median
40	249	255	O	percent
41	257	263	O	changes
42	265	278	O	Apolipoprotein
43	280	280	O	B
44	282	288	O	Placebo
45	290	291	O	61
46	294	296	O	1.1
47	299	301	O	1.4
48	304	306	O	2.2
49	309	311	O	1.4
50	314	316	O	4.4
51	318	324	O	MEVACOR
52	326	327	O	64
53	330	333	O	19.3
54	336	339	O	24.2
55	341	344	O	+1.1
56	347	349	O	1.9
57	352	353	O	21
58	355	357	O	The
59	359	362	O	mean
60	364	371	O	achieved
61	373	375	O	LDL
62	377	377	O	C
63	379	383	O	value
64	385	387	O	was
65	389	395	O	190.9mg
66	396	396	O	/
67	397	398	O	dL
68	401	405	O	range
69	406	406	O	:
70	408	410	O	108
71	412	416	O	336mg
72	417	417	O	/
73	418	419	O	dL
74	422	423	O	in
75	425	427	O	the
76	429	435	O	MEVACOR
77	437	441	O	group
78	443	450	O	compared
79	452	453	O	to
80	455	461	O	244.8mg
81	462	462	O	/
82	463	464	O	dL
83	467	471	O	range
84	472	472	O	:
85	474	476	O	135
86	478	482	O	404mg
87	483	483	O	/
88	484	485	O	dL
89	488	489	O	in
90	491	493	O	the
91	495	501	O	placebo
92	503	507	O	group
NULL

Lovastatin	5330	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	34
In a double-blind, placebo-controlled study, 54 girls 10-17years of age who were at least 1year post-menarche with heFH were randomized to lovastatin (n=35) or placebo (n=19) for 24weeks.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	double
4	12	16	O	blind
5	17	17	O	,
6	19	25	O	placebo
7	27	36	O	controlled
8	38	42	O	study
9	43	43	O	,
10	45	46	O	54
11	48	52	O	girls
12	54	55	O	10
13	57	63	O	17years
14	65	66	O	of
15	68	70	O	age
16	72	74	O	who
17	76	79	O	were
18	81	82	O	at
19	84	88	O	least
20	90	94	O	1year
21	96	99	O	post
22	101	108	O	menarche
23	110	113	O	with
24	115	118	O	heFH
25	120	123	O	were
26	125	134	O	randomized
27	136	137	O	to
28	139	148	O	XXXXXXXX
29	151	154	O	n=35
30	157	158	O	or
31	160	166	O	placebo
32	169	172	O	n=19
33	175	177	O	for
34	179	185	O	24weeks
NULL

Lovastatin	5331	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	22
Inclusion in the study required a baseline LDL-C level of 160-400mg/dL and a parental history of familial hypercholesterolemia.
1	0	8	O	Inclusion
2	10	11	O	in
3	13	15	O	the
4	17	21	O	study
5	23	30	O	required
6	32	32	O	a
7	34	41	O	baseline
8	43	45	O	LDL
9	47	47	O	C
10	49	53	O	level
11	55	56	O	of
12	58	60	O	160
13	62	66	O	400mg
14	67	67	O	/
15	68	69	O	dL
16	71	73	O	and
17	75	75	O	a
18	77	84	O	parental
19	86	92	O	history
20	94	95	O	of
21	97	104	O	familial
22	106	125	O	hypercholesterolemia
NULL

Lovastatin	5332	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	35
The mean baseline LDL-C value was 218.3mg/dL (range: 136.3-363.7mg/dL) in the MEVACOR group compared to 198.8mg/dL (range: 151.1-283.1mg/dL) in the placebo group.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	baseline
4	18	20	O	LDL
5	22	22	O	C
6	24	28	O	value
7	30	32	O	was
8	34	40	O	218.3mg
9	41	41	O	/
10	42	43	O	dL
11	46	50	O	range
12	51	51	O	:
13	53	57	O	136.3
14	59	65	O	363.7mg
15	66	66	O	/
16	67	68	O	dL
17	71	72	O	in
18	74	76	O	the
19	78	84	O	MEVACOR
20	86	90	O	group
21	92	99	O	compared
22	101	102	O	to
23	104	110	O	198.8mg
24	111	111	O	/
25	112	113	O	dL
26	116	120	O	range
27	121	121	O	:
28	123	127	O	151.1
29	129	135	O	283.1mg
30	136	136	O	/
31	137	138	O	dL
32	141	142	O	in
33	144	146	O	the
34	148	154	O	placebo
35	156	160	O	group
NULL

Lovastatin	5333	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	19
The dosage of lovastatin (once daily in the evening) was 20mg for the first 4weeks, and 40mg thereafter.
1	0	2	O	The
2	4	9	O	dosage
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	26	29	O	once
6	31	35	O	daily
7	37	38	O	in
8	40	42	O	the
9	44	50	O	evening
10	53	55	O	was
11	57	60	O	20mg
12	62	64	O	for
13	66	68	O	the
14	70	74	O	first
15	76	81	O	4weeks
16	82	82	O	,
17	84	86	O	and
18	88	91	O	40mg
19	93	102	O	thereafter
NULL

Lovastatin	5335	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	93
TABLE VI: Lipid-lowering Effects of Lovastatin in Post-Menarchal Girls with Heterozygous Familial Hypercholesterolemia (Mean Percent Change from Baseline at Week24 in Intention-to-Treat Population) DOSAGE N TOTAL-C LDL-C HDL-C TG.data presented as median percent changes Apolipoprotein B Placebo 18 +3.6 +2.5 +4.8 -3.0 +6.4 MEVACOR 35 -22.4 -29.2 +2.4 -22.7 -24.4 The mean achieved LDL-C value was 154.5mg/dL (range: 82-286mg/dL) in the MEVACOR group compared to 203.5mg/dL (range: 135-304mg/dL) in the placebo group.
1	0	4	O	TABLE
2	6	7	O	VI
3	8	8	O	:
4	10	14	O	Lipid
5	16	23	O	lowering
6	25	31	O	Effects
7	33	34	O	of
8	36	45	O	XXXXXXXX
9	47	48	O	in
10	50	53	O	Post
11	55	63	O	Menarchal
12	65	69	O	Girls
13	71	74	O	with
14	76	87	O	Heterozygous
15	89	96	O	Familial
16	98	117	O	Hypercholesterolemia
17	120	123	O	Mean
18	125	131	O	Percent
19	133	138	O	Change
20	140	143	O	from
21	145	152	O	Baseline
22	154	155	O	at
23	157	162	O	Week24
24	164	165	O	in
25	167	175	O	Intention
26	177	178	O	to
27	180	184	O	Treat
28	186	195	O	Population
29	198	203	O	DOSAGE
30	205	205	O	N
31	207	211	O	TOTAL
32	213	213	O	C
33	215	217	O	LDL
34	219	219	O	C
35	221	223	O	HDL
36	225	225	O	C
37	227	233	O	TG.data
38	235	243	O	presented
39	245	246	O	as
40	248	253	O	median
41	255	261	O	percent
42	263	269	O	changes
43	271	284	O	Apolipoprotein
44	286	286	O	B
45	288	294	O	Placebo
46	296	297	O	18
47	299	302	O	+3.6
48	304	307	O	+2.5
49	309	312	O	+4.8
50	315	317	O	3.0
51	319	322	O	+6.4
52	324	330	O	MEVACOR
53	332	333	O	35
54	336	339	O	22.4
55	342	345	O	29.2
56	347	350	O	+2.4
57	353	356	O	22.7
58	359	362	O	24.4
59	364	366	O	The
60	368	371	O	mean
61	373	380	O	achieved
62	382	384	O	LDL
63	386	386	O	C
64	388	392	O	value
65	394	396	O	was
66	398	404	O	154.5mg
67	405	405	O	/
68	406	407	O	dL
69	410	414	O	range
70	415	415	O	:
71	417	418	O	82
72	420	424	O	286mg
73	425	425	O	/
74	426	427	O	dL
75	430	431	O	in
76	433	435	O	the
77	437	443	O	MEVACOR
78	445	449	O	group
79	451	458	O	compared
80	460	461	O	to
81	463	469	O	203.5mg
82	470	470	O	/
83	471	472	O	dL
84	475	479	O	range
85	480	480	O	:
86	482	484	O	135
87	486	490	O	304mg
88	491	491	O	/
89	492	493	O	dL
90	496	497	O	in
91	499	501	O	the
92	503	509	O	placebo
93	511	515	O	group
NULL

Lovastatin	5336	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	15
The safety and efficacy of doses above 40mg daily have not been studied in children.
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	31	O	doses
7	33	37	O	above
8	39	42	O	40mg
9	44	48	O	daily
10	50	53	O	have
11	55	57	O	not
12	59	62	O	been
13	64	70	O	studied
14	72	73	O	in
15	75	82	O	children
NULL

Lovastatin	5337	34090-1	520428f1-2cd5-447f-8782-c8505ce65b72	20
The long-term efficacy of lovastatin therapy in childhood to reduce morbidity and mortality in adulthood has not been established.
1	0	2	O	The
2	4	7	O	long
3	9	12	O	term
4	14	21	O	efficacy
5	23	24	O	of
6	26	35	O	XXXXXXXX
7	37	43	O	therapy
8	45	46	O	in
9	48	56	O	childhood
10	58	59	O	to
11	61	66	O	reduce
12	68	76	O	morbidity
13	78	80	O	and
14	82	90	O	mortality
15	92	93	O	in
16	95	103	O	adulthood
17	105	107	O	has
18	109	111	O	not
19	113	116	O	been
20	118	128	O	established
NULL

Maprotiline Hydrochloride	4320	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	27
Close supervision and careful adjustment of dosage are required when administering maprotiline concomitantly with anticholinergic or sympathomimetic drugs because of the possibility of additive atropine like effects.
1	0	4	O	Close
2	6	16	O	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	49	O	dosage
8	51	53	O	are
9	55	62	O	required
10	64	67	O	when
11	69	81	O	administering
12	83	93	O	XXXXXXXX
13	95	107	O	concomitantly
14	109	112	O	with
15	114	128	O	anticholinergic
16	130	131	O	or
17	133	147	B-DYN	sympathomimetic
18	149	153	L-DYN	drugs
19	155	161	O	because
20	163	164	O	of
21	166	168	O	the
22	170	180	O	possibility
23	182	183	O	of
24	185	192	B-EFF	additive
25	194	201	I-EFF	atropine
26	203	206	I-EFF	like
27	208	214	L-EFF	effects
D/17:24:1

Maprotiline Hydrochloride	4321	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	19
Concurrent administration of maprotiline with electroshock therapy should be avoided because of the lack of experience in this area.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	39	O	XXXXXXXX
5	41	44	O	with
6	46	57	O	electroshock
7	59	65	O	therapy
8	67	72	O	should
9	74	75	O	be
10	77	83	O	avoided
11	85	91	O	because
12	93	94	O	of
13	96	98	O	the
14	100	103	O	lack
15	105	106	O	of
16	108	117	O	experience
17	119	120	O	in
18	122	125	O	this
19	127	130	O	area
NULL

Maprotiline Hydrochloride	4322	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	27
Caution should be exercised when administering maprotiline to hyperthyroid patients or those on thyroid medication because of the possibility of enhanced potential for cardiovascular toxicity of maprotiline.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	45	O	administering
7	47	57	O	XXXXXXXX
8	59	60	O	to
9	62	73	O	hyperthyroid
10	75	82	O	patients
11	84	85	O	or
12	87	91	O	those
13	93	94	O	on
14	96	102	B-DYN	thyroid
15	104	113	L-DYN	medication
16	115	121	O	because
17	123	124	O	of
18	126	128	O	the
19	130	140	O	possibility
20	142	143	O	of
21	145	152	O	enhanced
22	154	162	O	potential
23	164	166	O	for
24	168	181	B-EFF	cardiovascular
25	183	190	L-EFF	toxicity
26	192	193	O	of
27	195	205	O	XXXXXXXX
D/14:24:1

Maprotiline Hydrochloride	4323	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	23
Maprotiline should be used with caution in patients receiving guanethidine or similar agents since it may block the pharmacologic effects of these drugs.
1	0	10	O	XXXXXXXX
2	12	17	O	should
3	19	20	O	be
4	22	25	O	used
5	27	30	O	with
6	32	38	O	caution
7	40	41	O	in
8	43	50	O	patients
9	52	60	O	receiving
10	62	73	U-DYN	guanethidine
11	75	76	O	or
12	78	84	O	similar
13	86	91	O	agents
14	93	97	O	since
15	99	100	O	it
16	102	104	O	may
17	106	110	O	block
18	112	114	O	the
19	116	128	O	pharmacologic
20	130	136	O	effects
21	138	139	O	of
22	141	145	O	these
23	147	151	O	drugs
NULL

Maprotiline Hydrochloride	4324	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	27
The risk of seizures may be increased when maprotiline is taken concomitantly with phenothiazines or when the dosage of benzodiazepines is rapidly tapered in patients receiving maprotiline.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	U-EFF	seizures
5	21	23	O	may
6	25	26	O	be
7	28	36	O	increased
8	38	41	O	when
9	43	53	O	XXXXXXXX
10	55	56	O	is
11	58	62	O	taken
12	64	76	O	concomitantly
13	78	81	O	with
14	83	96	U-DYN	phenothiazines
15	98	99	O	or
16	101	104	O	when
17	106	108	O	the
18	110	115	O	dosage
19	117	118	O	of
20	120	134	U-DYN	benzodiazepines
21	136	137	O	is
22	139	145	O	rapidly
23	147	153	O	tapered
24	155	156	O	in
25	158	165	O	patients
26	167	175	O	receiving
27	177	187	O	XXXXXXXX
D/14:4:1 D/20:4:0

Maprotiline Hydrochloride	4325	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	56
Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	the
4	15	27	O	pharmacologic
5	29	38	O	similarity
6	40	41	O	of
7	43	67	O	XXXXXXXX
8	69	70	O	to
9	72	74	O	the
10	76	84	O	tricyclic
11	86	100	O	antidepressants
12	101	101	O	,
13	103	105	O	the
14	107	112	O	plasma
15	114	126	O	concentration
16	128	129	O	of
17	131	141	O	XXXXXXXX
18	143	145	O	may
19	147	148	O	be
20	150	158	O	increased
21	160	163	O	when
22	165	167	O	the
23	169	172	O	drug
24	174	175	O	is
25	177	181	O	given
26	183	195	O	concomitantly
27	197	200	O	with
28	202	208	B-KIN	hepatic
29	210	215	I-KIN	enzyme
30	217	226	L-KIN	inhibitors
31	229	231	O	e.g
32	233	233	O	,
33	235	244	U-KIN	cimetidine
34	245	245	O	,
35	247	256	U-KIN	fluoxetine
36	259	261	O	and
37	263	271	O	decreased
38	273	274	O	by
39	276	286	O	concomitant
40	288	301	O	administration
41	303	306	O	with
42	308	314	B-KIN	hepatic
43	316	321	I-KIN	enzyme
44	323	330	L-KIN	inducers
45	333	335	O	e.g
46	337	337	O	,
47	339	350	U-KIN	barbiturates
48	351	351	O	,
49	353	361	U-KIN	phenytoin
50	363	363	O	,
51	365	366	O	as
52	368	370	O	has
53	372	379	O	occurred
54	381	384	O	with
55	386	394	O	tricyclic
56	396	410	O	antidepressants
K/28:C54355 K/33:C54355 K/35:C54355 K/42:C54356 K/47:C54356 K/49:C54356

Maprotiline Hydrochloride	4326	34073-7	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	13
Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.
1	0	9	O	Adjustment
2	11	12	O	of
3	14	16	O	the
4	18	23	O	dosage
5	25	26	O	of
6	28	52	O	XXXXXXXX
7	54	56	O	may
8	58	66	O	therefore
9	68	69	O	be
10	71	79	O	necessary
11	81	82	O	in
12	84	87	O	such
13	89	93	O	cases
NULL

Maprotiline Hydrochloride	4328	34090-1	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	10
The mechanism of action of maprotiline is not precisely known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	37	O	XXXXXXXX
7	39	40	O	is
8	42	44	O	not
9	46	54	O	precisely
10	56	60	O	known
NULL

Maprotiline Hydrochloride	4329	34090-1	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	19
It does not act primarily by stimulation of the central nervous system and is not a monoamine oxidase inhibitor.
1	0	1	O	It
2	3	6	O	does
3	8	10	O	not
4	12	14	O	act
5	16	24	O	primarily
6	26	27	O	by
7	29	39	O	stimulation
8	41	42	O	of
9	44	46	O	the
10	48	54	O	central
11	56	62	O	nervous
12	64	69	O	system
13	71	73	O	and
14	75	76	O	is
15	78	80	O	not
16	82	82	O	a
17	84	92	O	monoamine
18	94	100	O	oxidase
19	102	110	O	inhibitor
NULL

Maprotiline Hydrochloride	4330	34090-1	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	24
The postulated mechanism of maprotiline is that it acts primarily by potentiation of central adrenergic synapses by blocking reuptake of norepinephrine at nerve endings.
1	0	2	O	The
2	4	13	O	postulated
3	15	23	O	mechanism
4	25	26	O	of
5	28	38	O	XXXXXXXX
6	40	41	O	is
7	43	46	O	that
8	48	49	O	it
9	51	54	O	acts
10	56	64	O	primarily
11	66	67	O	by
12	69	80	O	potentiation
13	82	83	O	of
14	85	91	O	central
15	93	102	O	adrenergic
16	104	111	O	synapses
17	113	114	O	by
18	116	123	O	blocking
19	125	132	O	reuptake
20	134	135	O	of
21	137	150	O	norepinephrine
22	152	153	O	at
23	155	159	O	nerve
24	161	167	O	endings
NULL

Maprotiline Hydrochloride	4331	34090-1	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	15
This pharmacologic action is thought to be responsible for the drug's antidepressant and anxiolytic effects.
1	0	3	O	This
2	5	17	O	pharmacologic
3	19	24	O	action
4	26	27	O	is
5	29	35	O	thought
6	37	38	O	to
7	40	41	O	be
8	43	53	O	responsible
9	55	57	O	for
10	59	61	O	the
11	63	68	O	drug's
12	70	83	O	antidepressant
13	85	87	O	and
14	89	98	O	anxiolytic
15	100	106	O	effects
NULL

Maprotiline Hydrochloride	4332	34090-1	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	8
The half-life of elimination averages 51 hours.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	15	O	of
5	17	27	O	elimination
6	29	36	O	averages
7	38	39	O	51
8	41	45	O	hours
NULL

Maprotiline Hydrochloride	4333	34090-1	c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87	40
Steady-state levels measured prior to the morning dose on a one dosage regimen are summarized as follows: Average Minimum Concentration 95% Confidence Limits Regimen ng/mL ng/mL 50 mg * 3 daily 238 181-295
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	levels
4	20	27	O	measured
5	29	33	O	prior
6	35	36	O	to
7	38	40	O	the
8	42	48	O	morning
9	50	53	O	dose
10	55	56	O	on
11	58	58	O	a
12	60	62	O	one
13	64	69	O	dosage
14	71	77	O	regimen
15	79	81	O	are
16	83	92	O	summarized
17	94	95	O	as
18	97	103	O	follows
19	104	104	O	:
20	106	112	O	Average
21	114	120	O	Minimum
22	122	134	O	Concentration
23	136	138	O	95%
24	140	149	O	Confidence
25	151	156	O	Limits
26	158	164	O	Regimen
27	166	167	O	ng
28	168	168	O	/
29	169	170	O	mL
30	172	173	O	ng
31	174	174	O	/
32	175	176	O	mL
33	178	179	O	50
34	181	182	O	mg
35	184	184	O	*
36	186	186	O	3
37	188	192	O	daily
38	194	196	O	238
39	198	200	O	181
40	202	204	O	295
NULL

ONDANSETRON	5522	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	7
Apomorphine - profound hypotension and loss of consciousness.
1	0	10	U-DYN	Apomorphine
2	14	21	B-EFF	profound
3	23	33	L-EFF	hypotension
4	35	37	O	and
5	39	42	B-EFF	loss
6	44	45	I-EFF	of
7	47	59	L-EFF	consciousness
D/1:2:1 D/1:5:1

ONDANSETRON	5523	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	6
Concomitant use with ondansetron is contraindicated.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	19	O	with
4	21	31	O	XXXXXXXX
5	33	34	O	is
6	36	50	O	contraindicated
NULL

ONDANSETRON	5524	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	19
Ondansetron does not appear to induce or inhibit the cytochrome P-450 drug-metabolizing enzyme system of the liver.
1	0	10	O	XXXXXXXX
2	12	15	O	does
3	17	19	O	not
4	21	26	O	appear
5	28	29	O	to
6	31	36	O	induce
7	38	39	O	or
8	41	47	O	inhibit
9	49	51	O	the
10	53	62	O	cytochrome
11	64	64	O	P
12	66	68	O	450
13	70	73	O	drug
14	75	86	O	metabolizing
15	88	93	O	enzyme
16	95	100	O	system
17	102	103	O	of
18	105	107	O	the
19	109	113	O	liver
NULL

ONDANSETRON	5525	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	37
Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron.
1	0	6	O	Because
2	8	18	O	XXXXXXXX
3	20	21	O	is
4	23	33	O	metabolized
5	35	36	O	by
6	38	44	O	hepatic
7	46	55	O	cytochrome
8	57	57	O	P
9	59	61	O	450
10	63	66	O	drug
11	68	79	O	metabolizing
12	81	87	O	enzymes
13	90	95	O	CYP3A4
14	96	96	O	,
15	98	103	O	CYP2D6
16	104	104	O	,
17	106	111	O	CYP1A2
18	113	113	O	,
19	115	122	O	inducers
20	124	125	O	or
21	127	136	O	inhibitors
22	138	139	O	of
23	141	145	O	these
24	147	153	O	enzymes
25	155	157	O	may
26	159	164	B-TRI	change
27	166	168	I-TRI	the
28	170	178	L-TRI	clearance
29	180	182	O	and
30	183	183	O	,
31	185	189	O	hence
32	190	190	O	,
33	192	194	O	the
34	196	199	O	half
35	201	204	O	life
36	206	207	O	of
37	209	219	O	XXXXXXXX
NULL

ONDANSETRON	5526	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	18
On the basis of limited available data, no dosage adjustment is recommended for patients on these drugs.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	basis
4	13	14	O	of
5	16	22	O	limited
6	24	32	O	available
7	34	37	O	data
8	38	38	O	,
9	40	41	O	no
10	43	48	O	dosage
11	50	59	O	adjustment
12	61	62	O	is
13	64	74	O	recommended
14	76	78	O	for
15	80	87	O	patients
16	89	90	O	on
17	92	96	O	these
18	98	102	O	drugs
NULL

ONDANSETRON	5527	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	25
Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, concomitant use of apomorphine with ondansetron is contraindicated.
1	0	4	O	Based
2	6	7	O	on
3	9	15	O	reports
4	17	18	O	of
5	20	27	B-EFF	profound
6	29	39	L-EFF	hypotension
7	41	43	O	and
8	45	48	B-EFF	loss
9	50	51	I-EFF	of
10	53	65	L-EFF	consciousness
11	67	70	O	when
12	72	82	U-DYN	apomorphine
13	84	86	O	was
14	88	99	O	administered
15	101	104	O	with
16	106	116	O	XXXXXXXX
17	117	117	O	,
18	119	129	O	concomitant
19	131	133	O	use
20	135	136	O	of
21	138	148	O	apomorphine
22	150	153	O	with
23	155	165	O	XXXXXXXX
24	167	168	O	is
25	170	184	O	contraindicated
D/12:5:1 D/12:8:1

ONDANSETRON	5528	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	30
In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased.
1	0	1	O	In
2	3	10	O	patients
3	12	18	O	treated
4	20	23	O	with
5	25	30	B-KIN	potent
6	32	39	I-KIN	inducers
7	41	42	I-KIN	of
8	44	49	L-KIN	CYP3A4
9	52	54	O	i.e
10	56	56	O	,
11	58	66	U-KIN	phenytoin
12	67	67	O	,
13	69	81	U-KIN	carbamazepine
14	82	82	O	,
15	84	86	O	and
16	88	95	U-KIN	rifampin
17	97	97	O	,
18	99	101	O	the
19	103	111	O	clearance
20	113	114	O	of
21	116	126	O	XXXXXXXX
22	128	130	O	was
23	132	144	O	significantly
24	146	154	O	increased
25	156	158	O	and
26	160	170	O	XXXXXXXX
27	172	176	O	blood
28	178	191	O	concentrations
29	193	196	O	were
30	198	206	O	decreased
K/11:C54356 K/13:C54356 K/16:C54356 K/5:C54356

ONDANSETRON	5529	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	21
However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	on
4	12	14	O	the
5	16	20	O	basis
6	22	23	O	of
7	25	33	O	available
8	35	38	O	data
9	39	39	O	,
10	41	42	O	no
11	44	49	O	dosage
12	51	60	O	adjustment
13	62	64	O	for
14	66	76	O	XXXXXXXX
15	78	79	O	is
16	81	91	O	recommended
17	93	95	O	for
18	97	104	O	patients
19	106	107	O	on
20	109	113	O	these
21	115	119	O	drugs
NULL

ONDANSETRON	5530	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	33
Although there are no data on pharmacokinetic drug interactions between ondansetron and tramadol, data from two small studies indicate that concomitant use of ondansetron may result in reduced analgesic activity of tramadol.
1	0	7	O	Although
2	9	13	O	there
3	15	17	O	are
4	19	20	O	no
5	22	25	O	data
6	27	28	O	on
7	30	44	O	pharmacokinetic
8	46	49	O	drug
9	51	62	O	interactions
10	64	70	O	between
11	72	82	O	XXXXXXXX
12	84	86	O	and
13	88	95	U-DYN	tramadol
14	96	96	O	,
15	98	101	O	data
16	103	106	O	from
17	108	110	O	two
18	112	116	O	small
19	118	124	O	studies
20	126	133	O	indicate
21	135	138	O	that
22	140	150	O	concomitant
23	152	154	O	use
24	156	157	O	of
25	159	169	O	XXXXXXXX
26	171	173	O	may
27	175	180	O	result
28	182	183	O	in
29	185	191	B-EFF	reduced
30	193	201	I-EFF	analgesic
31	203	210	L-EFF	activity
32	212	213	O	of
33	215	222	O	tramadol
D/13:29:1

ONDANSETRON	5531	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	26
Patients on concomitant ondansetron self administered tramadol more frequently in these studies, leading to an increased cumulative dose in patient controlled administration (PCA) of tramadol.
1	0	7	O	Patients
2	9	10	O	on
3	12	22	O	concomitant
4	24	34	O	XXXXXXXX
5	36	39	O	self
6	41	52	O	administered
7	54	61	U-KIN	tramadol
8	63	66	O	more
9	68	77	O	frequently
10	79	80	O	in
11	82	86	O	these
12	88	94	O	studies
13	95	95	O	,
14	97	103	O	leading
15	105	106	O	to
16	108	109	O	an
17	111	119	O	increased
18	121	130	O	cumulative
19	132	135	O	dose
20	137	138	O	in
21	140	146	O	patient
22	148	157	O	controlled
23	159	172	O	administration
24	175	177	O	PCA
25	180	181	O	of
26	183	190	O	tramadol
K/7:C54358

ONDANSETRON	5532	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	43
Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs).
1	0	8	B-EFF	Serotonin
2	10	17	L-EFF	syndrome
3	20	28	O	including
4	30	36	B-EFF	altered
5	38	43	I-EFF	mental
6	45	50	L-EFF	status
7	51	51	O	,
8	53	61	B-EFF	autonomic
9	63	73	L-EFF	instability
10	74	74	O	,
11	76	78	O	and
12	80	92	B-EFF	neuromuscular
13	94	101	L-EFF	symptoms
14	104	106	O	has
15	108	111	O	been
16	113	121	O	described
17	123	131	O	following
18	133	135	O	the
19	137	147	O	concomitant
20	149	151	O	use
21	153	154	O	of
22	156	156	O	5
23	158	160	O	HT3
24	162	169	O	receptor
25	171	181	O	antagonists
26	183	185	O	and
27	187	191	O	other
28	193	204	B-DYN	serotonergic
29	206	210	L-DYN	drugs
30	211	211	O	,
31	213	221	O	including
32	223	231	B-DYN	selective
33	233	241	I-DYN	serotonin
34	243	250	I-DYN	reuptake
35	252	261	L-DYN	inhibitors
36	264	268	U-DYN	SSRIs
37	271	273	O	and
38	275	283	B-DYN	serotonin
39	285	287	I-DYN	and
40	289	301	I-DYN	noradrenaline
41	303	310	I-DYN	reuptake
42	312	321	L-DYN	inhibitors
43	324	328	U-DYN	SNRIs
D/28:1:1 D/28:12:1 D/28:4:1 D/28:8:1 D/32:1:1 D/32:12:1 D/32:4:1 D/32:8:1 D/36:1:1 D/36:12:1 D/36:4:1 D/36:8:1 D/38:1:1 D/38:12:1 D/38:4:1 D/38:8:1 D/43:1:1 D/43:12:1 D/43:4:1 D/43:8:1

ONDANSETRON	5533	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	16
In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.
1	0	1	O	In
2	3	8	O	humans
3	9	9	O	,
4	11	20	O	carmustine
5	21	21	O	,
6	23	31	O	etoposide
7	32	32	O	,
8	34	36	O	and
9	38	46	O	cisplatin
10	48	49	O	do
11	51	53	O	not
12	55	60	O	affect
13	62	64	O	the
14	66	81	O	pharmacokinetics
15	83	84	O	of
16	86	96	O	XXXXXXXX
NULL

ONDANSETRON	5534	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	20
In a crossover study in 76 pediatric patients, intravenous ondansetron did not increase blood levels of high-dose methotrexate.
1	0	1	O	In
2	3	3	O	a
3	5	13	O	crossover
4	15	19	O	study
5	21	22	O	in
6	24	25	O	76
7	27	35	O	pediatric
8	37	44	O	patients
9	45	45	O	,
10	47	57	O	intravenous
11	59	69	O	XXXXXXXX
12	71	73	O	did
13	75	77	O	not
14	79	86	O	increase
15	88	92	O	blood
16	94	99	O	levels
17	101	102	O	of
18	104	107	O	high
19	109	112	O	dose
20	114	125	O	methotrexate
NULL

ONDANSETRON	5535	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	14
The coadministration of ondansetron had no effect on the pharmacokinetics and pharmacodynamics of temazepam.
1	0	2	O	The
2	4	19	O	coadministration
3	21	22	O	of
4	24	34	O	XXXXXXXX
5	36	38	O	had
6	40	41	O	no
7	43	48	O	effect
8	50	51	O	on
9	53	55	O	the
10	57	72	O	pharmacokinetics
11	74	76	O	and
12	78	93	O	pharmacodynamics
13	95	96	O	of
14	98	106	O	temazepam
NULL

ONDANSETRON	5536	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	20
Ondansetron does not alter the respiratory depressant effects produced by alfentanil or the degree of neuromuscular blockade produced by atracurium.
1	0	10	O	XXXXXXXX
2	12	15	O	does
3	17	19	O	not
4	21	25	O	alter
5	27	29	O	the
6	31	41	O	respiratory
7	43	52	O	depressant
8	54	60	O	effects
9	62	69	O	produced
10	71	72	O	by
11	74	83	O	alfentanil
12	85	86	O	or
13	88	90	O	the
14	92	97	O	degree
15	99	100	O	of
16	102	114	O	neuromuscular
17	116	123	O	blockade
18	125	132	O	produced
19	134	135	O	by
20	137	146	O	atracurium
NULL

ONDANSETRON	5537	34073-7	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	10
Interactions with general or local anesthetics have not been studied.
1	0	11	O	Interactions
2	13	16	O	with
3	18	24	O	general
4	26	27	O	or
5	29	33	O	local
6	35	45	O	anesthetics
7	47	50	O	have
8	52	54	O	not
9	56	59	O	been
10	61	67	O	studied
NULL

ONDANSETRON	5538	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	8
Ondansetron is a selective 5-HT3 receptor antagonist.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	25	O	selective
5	27	27	O	5
6	29	31	O	HT3
7	33	40	O	receptor
8	42	51	O	antagonist
NULL

ONDANSETRON	5539	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	19
While ondansetron's mechanism of action has not been fully characterized, it is not a dopamine-receptor antagonist.
1	0	4	O	While
2	6	16	O	XXXXXXXX
3	17	18	O	's
4	20	28	O	mechanism
5	30	31	O	of
6	33	38	O	action
7	40	42	O	has
8	44	46	O	not
9	48	51	O	been
10	53	57	O	fully
11	59	71	O	characterized
12	72	72	O	,
13	74	75	O	it
14	77	78	O	is
15	80	82	O	not
16	84	84	O	a
17	86	93	O	dopamine
18	95	102	O	receptor
19	104	113	O	antagonist
NULL

ONDANSETRON	5540	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	25
QTc interval prolongation was studied in a double blind, single intravenous dose, placebo- and positive-controlled, crossover study in 58 healthy subjects.
1	0	2	O	QTc
2	4	11	O	interval
3	13	24	O	prolongation
4	26	28	O	was
5	30	36	O	studied
6	38	39	O	in
7	41	41	O	a
8	43	48	O	double
9	50	54	O	blind
10	55	55	O	,
11	57	62	O	single
12	64	74	O	intravenous
13	76	79	O	dose
14	80	80	O	,
15	82	88	O	placebo
16	91	93	O	and
17	95	102	O	positive
18	104	113	O	controlled
19	114	114	O	,
20	116	124	O	crossover
21	126	130	O	study
22	132	133	O	in
23	135	136	O	58
24	138	144	O	healthy
25	146	153	O	subjects
NULL

ONDANSETRON	5541	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	37
The maximum mean (95% upper confidence bound) difference in QTcF from placebo after baseline-correction was 19.5 (21.8) ms and 5.6 (7.4) ms after 15 minute intravenous infusions of 32 mg and 8 mg Ondansetron, respectively.
1	0	2	O	The
2	4	10	O	maximum
3	12	15	O	mean
4	18	20	O	95%
5	22	26	O	upper
6	28	37	O	confidence
7	39	43	O	bound
8	46	55	O	difference
9	57	58	O	in
10	60	63	O	QTcF
11	65	68	O	from
12	70	76	O	placebo
13	78	82	O	after
14	84	91	O	baseline
15	93	102	O	correction
16	104	106	O	was
17	108	111	O	19.5
18	114	117	O	21.8
19	120	121	O	ms
20	123	125	O	and
21	127	129	O	5.6
22	132	134	O	7.4
23	137	138	O	ms
24	140	144	O	after
25	146	147	O	15
26	149	154	O	minute
27	156	166	O	intravenous
28	168	176	O	infusions
29	178	179	O	of
30	181	182	O	32
31	184	185	O	mg
32	187	189	O	and
33	191	191	O	8
34	193	194	O	mg
35	196	206	O	XXXXXXXX
36	207	207	O	,
37	209	220	O	respectively
NULL

ONDANSETRON	5542	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	12
A significant exposure-response relationship was identified between ondansetron concentration and DDQTcF.
1	0	0	O	A
2	2	12	O	significant
3	14	21	O	exposure
4	23	30	O	response
5	32	43	O	relationship
6	45	47	O	was
7	49	58	O	identified
8	60	66	O	between
9	68	78	O	XXXXXXXX
10	80	92	O	concentration
11	94	96	O	and
12	98	103	O	DDQTcF
NULL

ONDANSETRON	5543	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	27
Using the established exposure-response relationship, 24 mg infused intravenously over 15 min had a mean predicted (95% upper prediction interval) DDQTcF of 14.0 (16.3) ms.
1	0	4	O	Using
2	6	8	O	the
3	10	20	O	established
4	22	29	O	exposure
5	31	38	O	response
6	40	51	O	relationship
7	52	52	O	,
8	54	55	O	24
9	57	58	O	mg
10	60	66	O	infused
11	68	80	O	intravenously
12	82	85	O	over
13	87	88	O	15
14	90	92	O	min
15	94	96	O	had
16	98	98	O	a
17	100	103	O	mean
18	105	113	O	predicted
19	116	118	O	95%
20	120	124	O	upper
21	126	135	O	prediction
22	137	144	O	interval
23	147	152	O	DDQTcF
24	154	155	O	of
25	157	160	O	14.0
26	163	166	O	16.3
27	169	170	O	ms
NULL

ONDANSETRON	5544	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	27
In contrast, 16 mg infused intravenously over 15 min using the same model had a mean predicted (95% upper prediction interval) DDQTcF of 9.1 (11.2) ms.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	14	O	16
5	16	17	O	mg
6	19	25	O	infused
7	27	39	O	intravenously
8	41	44	O	over
9	46	47	O	15
10	49	51	O	min
11	53	57	O	using
12	59	61	O	the
13	63	66	O	same
14	68	72	O	model
15	74	76	O	had
16	78	78	O	a
17	80	83	O	mean
18	85	93	O	predicted
19	96	98	O	95%
20	100	104	O	upper
21	106	115	O	prediction
22	117	124	O	interval
23	127	132	O	DDQTcF
24	134	135	O	of
25	137	139	O	9.1
26	142	145	O	11.2
27	148	149	O	ms
NULL

ONDANSETRON	5545	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	34
In normal volunteers, single intravenous doses of 0.15 mg/kg of ondansetron had no effect on esophageal motility, gastric motility, lower esophageal sphincter pressure, or small intestinal transit time.
1	0	1	O	In
2	3	8	O	normal
3	10	19	O	volunteers
4	20	20	O	,
5	22	27	O	single
6	29	39	O	intravenous
7	41	45	O	doses
8	47	48	O	of
9	50	53	O	0.15
10	55	56	O	mg
11	57	57	O	/
12	58	59	O	kg
13	61	62	O	of
14	64	74	O	XXXXXXXX
15	76	78	O	had
16	80	81	O	no
17	83	88	O	effect
18	90	91	O	on
19	93	102	O	esophageal
20	104	111	O	motility
21	112	112	O	,
22	114	120	O	gastric
23	122	129	O	motility
24	130	130	O	,
25	132	136	O	lower
26	138	147	O	esophageal
27	149	157	O	sphincter
28	159	166	O	pressure
29	167	167	O	,
30	169	170	O	or
31	172	176	O	small
32	178	187	O	intestinal
33	189	195	O	transit
34	197	200	O	time
NULL

ONDANSETRON	5546	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	39
In another study in six normal male volunteers, a 16-mg dose infused over 5 minutes showed no effect of the drug on cardiac output, heart rate, stroke volume, blood pressure, or electrocardiogram (ECG).
1	0	1	O	In
2	3	9	O	another
3	11	15	O	study
4	17	18	O	in
5	20	22	O	six
6	24	29	O	normal
7	31	34	O	male
8	36	45	O	volunteers
9	46	46	O	,
10	48	48	O	a
11	50	51	O	16
12	53	54	O	mg
13	56	59	O	dose
14	61	67	O	infused
15	69	72	O	over
16	74	74	O	5
17	76	82	O	minutes
18	84	89	O	showed
19	91	92	O	no
20	94	99	O	effect
21	101	102	O	of
22	104	106	O	the
23	108	111	O	drug
24	113	114	O	on
25	116	122	O	cardiac
26	124	129	O	output
27	130	130	O	,
28	132	136	O	heart
29	138	141	O	rate
30	142	142	O	,
31	144	149	O	stroke
32	151	156	O	volume
33	157	157	O	,
34	159	163	O	blood
35	165	172	O	pressure
36	173	173	O	,
37	175	176	O	or
38	178	194	O	electrocardiogram
39	197	199	O	ECG
NULL

ONDANSETRON	5547	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	14
Multiday administration of ondansetron has been shown to slow colonic transit in normal volunteers.
1	0	7	O	Multiday
2	9	22	O	administration
3	24	25	O	of
4	27	37	O	XXXXXXXX
5	39	41	O	has
6	43	46	O	been
7	48	52	O	shown
8	54	55	O	to
9	57	60	O	slow
10	62	68	O	colonic
11	70	76	O	transit
12	78	79	O	in
13	81	86	O	normal
14	88	97	O	volunteers
NULL

ONDANSETRON	5548	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	8
Ondansetron has no effect on plasma prolactin concentrations.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	17	O	no
4	19	24	O	effect
5	26	27	O	on
6	29	34	O	plasma
7	36	44	O	prolactin
8	46	59	O	concentrations
NULL

ONDANSETRON	5549	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	33
In a gender-balanced pharmacodynamic study (n = 56), ondansetron 4 mg administered intravenously or intramuscularly was dynamically similar in the prevention of nausea and vomiting using the ipecacuanha model of emesis.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	gender
4	12	19	O	balanced
5	21	35	O	pharmacodynamic
6	37	41	O	study
7	44	44	O	n
8	46	46	O	=
9	48	49	O	56
10	51	51	O	,
11	53	63	O	XXXXXXXX
12	65	65	O	4
13	67	68	O	mg
14	70	81	O	administered
15	83	95	O	intravenously
16	97	98	O	or
17	100	114	O	intramuscularly
18	116	118	O	was
19	120	130	O	dynamically
20	132	138	O	similar
21	140	141	O	in
22	143	145	O	the
23	147	156	O	prevention
24	158	159	O	of
25	161	166	O	nausea
26	168	170	O	and
27	172	179	O	vomiting
28	181	185	O	using
29	187	189	O	the
30	191	201	O	ipecacuanha
31	203	207	O	model
32	209	210	O	of
33	212	217	O	emesis
NULL

ONDANSETRON	5550	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	22
In normal adult volunteers, the following mean pharmacokinetic data have been determined following a single 0.15-mg/kg intravenous dose.
1	0	1	O	In
2	3	8	O	normal
3	10	14	O	adult
4	16	25	O	volunteers
5	26	26	O	,
6	28	30	O	the
7	32	40	O	following
8	42	45	O	mean
9	47	61	O	pharmacokinetic
10	63	66	O	data
11	68	71	O	have
12	73	76	O	been
13	78	87	O	determined
14	89	97	O	following
15	99	99	O	a
16	101	106	O	single
17	108	111	O	0.15
18	113	114	O	mg
19	115	115	O	/
20	116	117	O	kg
21	119	129	O	intravenous
22	131	134	O	dose
NULL

ONDANSETRON	5551	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	76
Pharmacokinetics in Normal Adult Volunteers Age-group(years) n Peak Plasma Concentration (ng/mL) Mean EliminationHalf-life (h) Plasma Clearance(L/h/kg) 19-40 11 102 3.5 0.381 61-74 12 106 4.7 0.319 > 75 11 170 5.5 0.262 Absorption: A study was performed in normal volunteers (n = 56) to evaluate the pharmacokinetics of a single 4-mg dose administered as a 5-minute infusion compared to a single intramuscular injection.
1	0	15	O	Pharmacokinetics
2	17	18	O	in
3	20	25	O	Normal
4	27	31	O	Adult
5	33	42	O	Volunteers
6	44	46	O	Age
7	48	58	O	group(years
8	61	61	O	n
9	63	66	O	Peak
10	68	73	O	Plasma
11	75	87	O	Concentration
12	90	91	O	ng
13	92	92	O	/
14	93	94	O	mL
15	97	100	O	Mean
16	102	116	O	EliminationHalf
17	118	121	O	life
18	124	124	O	h
19	127	132	O	Plasma
20	134	144	O	Clearance(L
21	145	145	O	/
22	146	146	O	h
23	147	147	O	/
24	148	149	O	kg
25	152	153	O	19
26	155	156	O	40
27	158	159	O	11
28	161	163	O	102
29	165	167	O	3.5
30	169	173	O	0.381
31	175	176	O	61
32	178	179	O	74
33	181	182	O	12
34	184	186	O	106
35	188	190	O	4.7
36	192	196	O	0.319
37	198	198	O	>
38	200	201	O	75
39	203	204	O	11
40	206	208	O	170
41	210	212	O	5.5
42	214	218	O	0.262
43	220	229	O	Absorption
44	230	230	O	:
45	232	232	O	A
46	234	238	O	study
47	240	242	O	was
48	244	252	O	performed
49	254	255	O	in
50	257	262	O	normal
51	264	273	O	volunteers
52	276	276	O	n
53	278	278	O	=
54	280	281	O	56
55	284	285	O	to
56	287	294	O	evaluate
57	296	298	O	the
58	300	315	O	pharmacokinetics
59	317	318	O	of
60	320	320	O	a
61	322	327	O	single
62	329	329	O	4
63	331	332	O	mg
64	334	337	O	dose
65	339	350	O	administered
66	352	353	O	as
67	355	355	O	a
68	357	357	O	5
69	359	364	O	minute
70	366	373	O	infusion
71	375	382	O	compared
72	384	385	O	to
73	387	387	O	a
74	389	394	O	single
75	396	408	O	intramuscular
76	410	418	O	injection
NULL

ONDANSETRON	5552	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	36
Systemic exposure as measured by mean AUC were equivalent, with values of 156 [95% CI 136, 180] and 161 [95% CI 137, 190] ng*h/mL for intravenous and intramuscular groups, respectively.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	as
4	21	28	O	measured
5	30	31	O	by
6	33	36	O	mean
7	38	40	O	AUC
8	42	45	O	were
9	47	56	O	equivalent
10	57	57	O	,
11	59	62	O	with
12	64	69	O	values
13	71	72	O	of
14	74	76	O	156
15	79	81	O	95%
16	83	84	O	CI
17	86	88	O	136
18	89	89	O	,
19	91	93	O	180
20	96	98	O	and
21	100	102	O	161
22	105	107	O	95%
23	109	110	O	CI
24	112	114	O	137
25	115	115	O	,
26	117	119	O	190
27	122	125	O	ng*h
28	126	126	O	/
29	127	128	O	mL
30	130	132	O	for
31	134	144	O	intravenous
32	146	148	O	and
33	150	162	O	intramuscular
34	164	169	O	groups
35	170	170	O	,
36	172	183	O	respectively
NULL

ONDANSETRON	5553	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	36
Mean peak plasma concentrations were 42.9 [95% CI 33.8, 54.4] ng/mL at 10 minutes after intravenous infusion and 31.9 [95% CI 26.3, 38.6] ng/mL at 41 minutes after intramuscular injection.
1	0	3	O	Mean
2	5	8	O	peak
3	10	15	O	plasma
4	17	30	O	concentrations
5	32	35	O	were
6	37	40	O	42.9
7	43	45	O	95%
8	47	48	O	CI
9	50	53	O	33.8
10	54	54	O	,
11	56	59	O	54.4
12	62	63	O	ng
13	64	64	O	/
14	65	66	O	mL
15	68	69	O	at
16	71	72	O	10
17	74	80	O	minutes
18	82	86	O	after
19	88	98	O	intravenous
20	100	107	O	infusion
21	109	111	O	and
22	113	116	O	31.9
23	119	121	O	95%
24	123	124	O	CI
25	126	129	O	26.3
26	130	130	O	,
27	132	135	O	38.6
28	138	139	O	ng
29	140	140	O	/
30	141	142	O	mL
31	144	145	O	at
32	147	148	O	41
33	150	156	O	minutes
34	158	162	O	after
35	164	176	O	intramuscular
36	178	186	O	injection
NULL

ONDANSETRON	5554	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	28
Distribution: Plasma protein binding of ondansetron as measured in vitro was 70% to 76%, over the pharmacologic concentration range of 10 to 500 ng/mL.
1	0	11	O	Distribution
2	12	12	O	:
3	14	19	O	Plasma
4	21	27	O	protein
5	29	35	O	binding
6	37	38	O	of
7	40	50	O	XXXXXXXX
8	52	53	O	as
9	55	62	O	measured
10	64	65	O	in
11	67	71	O	vitro
12	73	75	O	was
13	77	79	O	70%
14	81	82	O	to
15	84	86	O	76%
16	87	87	O	,
17	89	92	O	over
18	94	96	O	the
19	98	110	O	pharmacologic
20	112	124	O	concentration
21	126	130	O	range
22	132	133	O	of
23	135	136	O	10
24	138	139	O	to
25	141	143	O	500
26	145	146	O	ng
27	147	147	O	/
28	148	149	O	mL
NULL

ONDANSETRON	5555	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	6
Circulating drug also distributes into erythrocytes.
1	0	10	O	Circulating
2	12	15	O	drug
3	17	20	O	also
4	22	32	O	distributes
5	34	37	O	into
6	39	50	O	erythrocytes
NULL

ONDANSETRON	5556	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	24
Metabolism: Ondansetron is extensively metabolized in humans, with approximately 5% of a radiolabeled dose recovered as the parent compound from the urine.
1	0	9	O	Metabolism
2	10	10	O	:
3	12	22	O	XXXXXXXX
4	24	25	O	is
5	27	37	O	extensively
6	39	49	O	metabolized
7	51	52	O	in
8	54	59	O	humans
9	60	60	O	,
10	62	65	O	with
11	67	79	O	approximately
12	81	82	O	5%
13	84	85	O	of
14	87	87	O	a
15	89	100	O	radiolabeled
16	102	105	O	dose
17	107	115	O	recovered
18	117	118	O	as
19	120	122	O	the
20	124	129	O	parent
21	131	138	O	compound
22	140	143	O	from
23	145	147	O	the
24	149	153	O	urine
NULL

ONDANSETRON	5557	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	17
The primary metabolic pathway is hydroxylation on the indole ring followed by subsequent glucuronide or sulfate conjugation.
1	0	2	O	The
2	4	10	O	primary
3	12	20	O	metabolic
4	22	28	O	pathway
5	30	31	O	is
6	33	45	O	hydroxylation
7	47	48	O	on
8	50	52	O	the
9	54	59	O	indole
10	61	64	O	ring
11	66	73	O	followed
12	75	76	O	by
13	78	87	O	subsequent
14	89	99	O	glucuronide
15	101	102	O	or
16	104	110	O	sulfate
17	112	122	O	conjugation
NULL

ONDANSETRON	5558	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	26
Although some nonconjugated metabolites have pharmacologic activity, these are not found in plasma at concentrations likely to significantly contribute to the biological activity of ondansetron.
1	0	7	O	Although
2	9	12	O	some
3	14	26	O	nonconjugated
4	28	38	O	metabolites
5	40	43	O	have
6	45	57	O	pharmacologic
7	59	66	O	activity
8	67	67	O	,
9	69	73	O	these
10	75	77	O	are
11	79	81	O	not
12	83	87	O	found
13	89	90	O	in
14	92	97	O	plasma
15	99	100	O	at
16	102	115	O	concentrations
17	117	122	O	likely
18	124	125	O	to
19	127	139	O	significantly
20	141	150	O	contribute
21	152	153	O	to
22	155	157	O	the
23	159	168	O	biological
24	170	177	O	activity
25	179	180	O	of
26	182	192	O	XXXXXXXX
NULL

ONDANSETRON	5559	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	7
The metabolites are observed in the urine.
1	0	2	O	The
2	4	14	O	metabolites
3	16	18	O	are
4	20	27	O	observed
5	29	30	O	in
6	32	34	O	the
7	36	40	O	urine
NULL

ONDANSETRON	5560	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	27
In vitro metabolism studies have shown that ondansetron is a substrate for multiple human hepatic cytochrome P-450 enzymes, including CYP1A2, CYP2D6, and CYP3A4.
1	0	1	O	In
2	3	7	O	vitro
3	9	18	O	metabolism
4	20	26	O	studies
5	28	31	O	have
6	33	37	O	shown
7	39	42	O	that
8	44	54	O	XXXXXXXX
9	56	57	O	is
10	59	59	O	a
11	61	69	O	substrate
12	71	73	O	for
13	75	82	O	multiple
14	84	88	O	human
15	90	96	O	hepatic
16	98	107	O	cytochrome
17	109	109	O	P
18	111	113	O	450
19	115	121	O	enzymes
20	122	122	O	,
21	124	132	O	including
22	134	139	O	CYP1A2
23	140	140	O	,
24	142	147	O	CYP2D6
25	148	148	O	,
26	150	152	O	and
27	154	159	O	CYP3A4
NULL

ONDANSETRON	5561	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	25
In terms of overall ondansetron turnover, CYP3A4 plays a predominant role while formation of the major in vivo metabolites is apparently mediated by CYP1A2.
1	0	1	O	In
2	3	7	O	terms
3	9	10	O	of
4	12	18	O	overall
5	20	30	O	XXXXXXXX
6	32	39	O	turnover
7	40	40	O	,
8	42	47	O	CYP3A4
9	49	53	O	plays
10	55	55	O	a
11	57	67	O	predominant
12	69	72	O	role
13	74	78	O	while
14	80	88	O	formation
15	90	91	O	of
16	93	95	O	the
17	97	101	O	major
18	103	104	O	in
19	106	109	O	vivo
20	111	121	O	metabolites
21	123	124	O	is
22	126	135	O	apparently
23	137	144	O	mediated
24	146	147	O	by
25	149	154	O	CYP1A2
NULL

ONDANSETRON	5562	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	12
The role of CYP2D6 in ondansetron in vivo metabolism is relatively minor.
1	0	2	O	The
2	4	7	O	role
3	9	10	O	of
4	12	17	O	CYP2D6
5	19	20	O	in
6	22	32	O	XXXXXXXX
7	34	35	O	in
8	37	40	O	vivo
9	42	51	O	metabolism
10	53	54	O	is
11	56	65	O	relatively
12	67	71	O	minor
NULL

ONDANSETRON	5563	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	37
The pharmacokinetics of intravenous ondansetron did not differ between subjects who were poor metabolisers of CYP2D6 and those who were extensive metabolisers of CYP2D6, further supporting the limited role of CYP2D6 in ondansetron disposition in vivo.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	O	intravenous
5	36	46	O	XXXXXXXX
6	48	50	O	did
7	52	54	O	not
8	56	61	O	differ
9	63	69	O	between
10	71	78	O	subjects
11	80	82	O	who
12	84	87	O	were
13	89	92	O	poor
14	94	105	O	metabolisers
15	107	108	O	of
16	110	115	O	CYP2D6
17	117	119	O	and
18	121	125	O	those
19	127	129	O	who
20	131	134	O	were
21	136	144	O	extensive
22	146	157	O	metabolisers
23	159	160	O	of
24	162	167	O	CYP2D6
25	168	168	O	,
26	170	176	O	further
27	178	187	O	supporting
28	189	191	O	the
29	193	199	O	limited
30	201	204	O	role
31	206	207	O	of
32	209	214	O	CYP2D6
33	216	217	O	in
34	219	229	O	XXXXXXXX
35	231	241	O	disposition
36	243	244	O	in
37	246	249	O	vivo
NULL

ONDANSETRON	5564	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	31
Elimination: In adult cancer patients, the mean ondansetron elimination half-life was 4.0 hours, and there was no difference in the multidose pharmacokinetics over a 4-day period.
1	0	10	O	Elimination
2	11	11	O	:
3	13	14	O	In
4	16	20	O	adult
5	22	27	O	cancer
6	29	36	O	patients
7	37	37	O	,
8	39	41	O	the
9	43	46	O	mean
10	48	58	O	XXXXXXXX
11	60	70	O	elimination
12	72	75	O	half
13	77	80	O	life
14	82	84	O	was
15	86	88	O	4.0
16	90	94	O	hours
17	95	95	O	,
18	97	99	O	and
19	101	105	O	there
20	107	109	O	was
21	111	112	O	no
22	114	123	O	difference
23	125	126	O	in
24	128	130	O	the
25	132	140	O	multidose
26	142	157	O	pharmacokinetics
27	159	162	O	over
28	164	164	O	a
29	166	166	O	4
30	168	170	O	day
31	172	177	O	period
NULL

ONDANSETRON	5565	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	31
In a dose proportionality study, systemic exposure to 32 mg of ondansetron was not proportional to dose as measured by comparing dose-normalized AUC values to an 8-mg dose.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	dose
4	10	24	O	proportionality
5	26	30	O	study
6	31	31	O	,
7	33	40	O	systemic
8	42	49	O	exposure
9	51	52	O	to
10	54	55	O	32
11	57	58	O	mg
12	60	61	O	of
13	63	73	O	XXXXXXXX
14	75	77	O	was
15	79	81	O	not
16	83	94	O	proportional
17	96	97	O	to
18	99	102	O	dose
19	104	105	O	as
20	107	114	O	measured
21	116	117	O	by
22	119	127	O	comparing
23	129	132	O	dose
24	134	143	O	normalized
25	145	147	O	AUC
26	149	154	O	values
27	156	157	O	to
28	159	160	O	an
29	162	162	O	8
30	164	165	O	mg
31	167	170	O	dose
NULL

ONDANSETRON	5566	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	14
This is consistent with a small decrease in systemic clearance with increasing plasma concentrations.
1	0	3	O	This
2	5	6	O	is
3	8	17	O	consistent
4	19	22	O	with
5	24	24	O	a
6	26	30	O	small
7	32	39	O	decrease
8	41	42	O	in
9	44	51	O	systemic
10	53	61	O	clearance
11	63	66	O	with
12	68	77	O	increasing
13	79	84	O	plasma
14	86	99	O	concentrations
NULL

ONDANSETRON	5567	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	21
Geriatrics: A reduction in clearance and increase in elimination half-life are seen in patients over 75 years of age.
1	0	9	O	Geriatrics
2	10	10	O	:
3	12	12	O	A
4	14	22	O	reduction
5	24	25	O	in
6	27	35	O	clearance
7	37	39	O	and
8	41	48	O	increase
9	50	51	O	in
10	53	63	O	elimination
11	65	68	O	half
12	70	73	O	life
13	75	77	O	are
14	79	82	O	seen
15	84	85	O	in
16	87	94	O	patients
17	96	99	O	over
18	101	102	O	75
19	104	108	O	years
20	110	111	O	of
21	113	115	O	age
NULL

ONDANSETRON	5568	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	45
In clinical trials with cancer patients, safety and efficacy were similar in patients over 65 years of age and those under 65 years of age; there was an insufficient number of patients over 75 years of age to permit conclusions in that age-group.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	19	22	O	with
5	24	29	O	cancer
6	31	38	O	patients
7	39	39	O	,
8	41	46	O	safety
9	48	50	O	and
10	52	59	O	efficacy
11	61	64	O	were
12	66	72	O	similar
13	74	75	O	in
14	77	84	O	patients
15	86	89	O	over
16	91	92	O	65
17	94	98	O	years
18	100	101	O	of
19	103	105	O	age
20	107	109	O	and
21	111	115	O	those
22	117	121	O	under
23	123	124	O	65
24	126	130	O	years
25	132	133	O	of
26	135	137	O	age
27	140	144	O	there
28	146	148	O	was
29	150	151	O	an
30	153	164	O	insufficient
31	166	171	O	number
32	173	174	O	of
33	176	183	O	patients
34	185	188	O	over
35	190	191	O	75
36	193	197	O	years
37	199	200	O	of
38	202	204	O	age
39	206	207	O	to
40	209	214	O	permit
41	216	226	O	conclusions
42	228	229	O	in
43	231	234	O	that
44	236	238	O	age
45	240	244	O	group
NULL

ONDANSETRON	5569	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	8
No dosage adjustment is recommended in the elderly.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	34	O	recommended
6	36	37	O	in
7	39	41	O	the
8	43	49	O	elderly
NULL

ONDANSETRON	5570	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	41
Pediatrics: Pharmacokinetic samples were collected from 74 cancer patients 6 to 48 months of age, who received a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses during a safety and efficacy trial.
1	0	9	O	Pediatrics
2	10	10	O	:
3	12	26	O	Pharmacokinetic
4	28	34	O	samples
5	36	39	O	were
6	41	49	O	collected
7	51	54	O	from
8	56	57	O	74
9	59	64	O	cancer
10	66	73	O	patients
11	75	75	O	6
12	77	78	O	to
13	80	81	O	48
14	83	88	O	months
15	90	91	O	of
16	93	95	O	age
17	96	96	O	,
18	98	100	O	who
19	102	109	O	received
20	111	111	O	a
21	113	116	O	dose
22	118	119	O	of
23	121	124	O	0.15
24	126	127	O	mg
25	128	128	O	/
26	129	130	O	kg
27	132	133	O	of
28	135	145	O	intravenous
29	147	157	O	XXXXXXXX
30	159	163	O	every
31	165	165	O	4
32	167	171	O	hours
33	173	175	O	for
34	177	177	O	3
35	179	183	O	doses
36	185	190	O	during
37	192	192	O	a
38	194	199	O	safety
39	201	203	O	and
40	205	212	O	efficacy
41	214	218	O	trial
NULL

ONDANSETRON	5571	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	52
These data were combined with sequential pharmacokinetics data from 41 surgery patients 1 month to 24 months of age, who received a single dose of 0.1 mg/kg of intravenous ondansetron prior to surgery with general anesthesia, and a population pharmacokinetic analysis was performed on the combined data set.
1	0	4	O	These
2	6	9	O	data
3	11	14	O	were
4	16	23	O	combined
5	25	28	O	with
6	30	39	O	sequential
7	41	56	O	pharmacokinetics
8	58	61	O	data
9	63	66	O	from
10	68	69	O	41
11	71	77	O	surgery
12	79	86	O	patients
13	88	88	O	1
14	90	94	O	month
15	96	97	O	to
16	99	100	O	24
17	102	107	O	months
18	109	110	O	of
19	112	114	O	age
20	115	115	O	,
21	117	119	O	who
22	121	128	O	received
23	130	130	O	a
24	132	137	O	single
25	139	142	O	dose
26	144	145	O	of
27	147	149	O	0.1
28	151	152	O	mg
29	153	153	O	/
30	154	155	O	kg
31	157	158	O	of
32	160	170	O	intravenous
33	172	182	O	XXXXXXXX
34	184	188	O	prior
35	190	191	O	to
36	193	199	O	surgery
37	201	204	O	with
38	206	212	O	general
39	214	223	O	anesthesia
40	224	224	O	,
41	226	228	O	and
42	230	230	O	a
43	232	241	O	population
44	243	257	O	pharmacokinetic
45	259	266	O	analysis
46	268	270	O	was
47	272	280	O	performed
48	282	283	O	on
49	285	287	O	the
50	289	296	O	combined
51	298	301	O	data
52	303	305	O	set
NULL

ONDANSETRON	5572	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	26
The results of this analysis are included in Table 4 and are compared to the pharmacokinetic results in cancer patients 4 to 18 years of age.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	of
4	15	18	O	this
5	20	27	O	analysis
6	29	31	O	are
7	33	40	O	included
8	42	43	O	in
9	45	49	O	Table
10	51	51	O	4
11	53	55	O	and
12	57	59	O	are
13	61	68	O	compared
14	70	71	O	to
15	73	75	O	the
16	77	91	O	pharmacokinetic
17	93	99	O	results
18	101	102	O	in
19	104	109	O	cancer
20	111	118	O	patients
21	120	120	O	4
22	122	123	O	to
23	125	126	O	18
24	128	132	O	years
25	134	135	O	of
26	137	139	O	age
NULL

ONDANSETRON	5573	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	25
Pharmacokinetics in Pediatric Cancer Patients 1 Month to 18 Years of Age a Population PK (Pharmacokinetic) Patients: 64% cancer patients and 36% surgery patients.
1	0	15	O	Pharmacokinetics
2	17	18	O	in
3	20	28	O	Pediatric
4	30	35	O	Cancer
5	37	44	O	Patients
6	46	46	O	1
7	48	52	O	Month
8	54	55	O	to
9	57	58	O	18
10	60	64	O	Years
11	66	67	O	of
12	69	71	O	Age
13	73	73	O	a
14	75	84	O	Population
15	86	87	O	PK
16	90	104	O	Pharmacokinetic
17	107	114	O	Patients
18	115	115	O	:
19	117	119	O	64%
20	121	126	O	cancer
21	128	135	O	patients
22	137	139	O	and
23	141	143	O	36%
24	145	151	O	surgery
25	153	160	O	patients
NULL

ONDANSETRON	5574	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	112
Subjects and Age Group N CL(L/h/kg) Vdss (L/kg) T% (h) Geometric Mean Mean Pediatric Cancer Patients4 to 18 years of age N = 21 0.599 1.9 2.8 Population PK Patientsa 1 month to 48 months of age N = 115 0.582 3.65 4.9 Based on the population pharmacokinetic analysis, cancer patients 6 to 48 months of age who receive a dose of 0.15 mg/kg of intravenous ondansetron every 4 hours for 3 doses would be expected to achieve a systemic exposure (AUC) consistent with the exposure achieved in previous pediatric studies in cancer patients (4 to 18 years of age) at similar doses.
1	0	7	O	Subjects
2	9	11	O	and
3	13	15	O	Age
4	17	21	O	Group
5	23	23	O	N
6	25	28	O	CL(L
7	29	29	O	/
8	30	30	O	h
9	31	31	O	/
10	32	33	O	kg
11	36	39	O	Vdss
12	42	42	O	L
13	43	43	O	/
14	44	45	O	kg
15	48	49	O	T%
16	52	52	O	h
17	55	63	O	Geometric
18	65	68	O	Mean
19	70	73	O	Mean
20	75	83	O	Pediatric
21	85	90	O	Cancer
22	92	100	O	Patients4
23	102	103	O	to
24	105	106	O	18
25	108	112	O	years
26	114	115	O	of
27	117	119	O	age
28	121	121	O	N
29	123	123	O	=
30	125	126	O	21
31	128	132	O	0.599
32	134	136	O	1.9
33	138	140	O	2.8
34	142	151	O	Population
35	153	154	O	PK
36	156	164	O	Patientsa
37	166	166	O	1
38	168	172	O	month
39	174	175	O	to
40	177	178	O	48
41	180	185	O	months
42	187	188	O	of
43	190	192	O	age
44	194	194	O	N
45	196	196	O	=
46	198	200	O	115
47	202	206	O	0.582
48	208	211	O	3.65
49	213	215	O	4.9
50	217	221	O	Based
51	223	224	O	on
52	226	228	O	the
53	230	239	O	population
54	241	255	O	pharmacokinetic
55	257	264	O	analysis
56	265	265	O	,
57	267	272	O	cancer
58	274	281	O	patients
59	283	283	O	6
60	285	286	O	to
61	288	289	O	48
62	291	296	O	months
63	298	299	O	of
64	301	303	O	age
65	305	307	O	who
66	309	315	O	receive
67	317	317	O	a
68	319	322	O	dose
69	324	325	O	of
70	327	330	O	0.15
71	332	333	O	mg
72	334	334	O	/
73	335	336	O	kg
74	338	339	O	of
75	341	351	O	intravenous
76	353	363	O	XXXXXXXX
77	365	369	O	every
78	371	371	O	4
79	373	377	O	hours
80	379	381	O	for
81	383	383	O	3
82	385	389	O	doses
83	391	395	O	would
84	397	398	O	be
85	400	407	O	expected
86	409	410	O	to
87	412	418	O	achieve
88	420	420	O	a
89	422	429	O	systemic
90	431	438	O	exposure
91	441	443	O	AUC
92	446	455	O	consistent
93	457	460	O	with
94	462	464	O	the
95	466	473	O	exposure
96	475	482	O	achieved
97	484	485	O	in
98	487	494	O	previous
99	496	504	O	pediatric
100	506	512	O	studies
101	514	515	O	in
102	517	522	O	cancer
103	524	531	O	patients
104	534	534	O	4
105	536	537	O	to
106	539	540	O	18
107	542	546	O	years
108	548	549	O	of
109	551	553	O	age
110	556	557	O	at
111	559	565	O	similar
112	567	571	O	doses
NULL

ONDANSETRON	5575	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	57
In a study of 21 pediatric patients (3 to 12 years of age) who were undergoing surgery requiring anesthesia for a duration of 45 minutes to 2 hours, a single intravenous dose of ondansetron, 2 mg (3 to 7 years) or 4 mg (8 to 12 years), was administered immediately prior to anesthesia induction.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	21
6	17	25	O	pediatric
7	27	34	O	patients
8	37	37	O	3
9	39	40	O	to
10	42	43	O	12
11	45	49	O	years
12	51	52	O	of
13	54	56	O	age
14	59	61	O	who
15	63	66	O	were
16	68	77	O	undergoing
17	79	85	O	surgery
18	87	95	O	requiring
19	97	106	O	anesthesia
20	108	110	O	for
21	112	112	O	a
22	114	121	O	duration
23	123	124	O	of
24	126	127	O	45
25	129	135	O	minutes
26	137	138	O	to
27	140	140	O	2
28	142	146	O	hours
29	147	147	O	,
30	149	149	O	a
31	151	156	O	single
32	158	168	O	intravenous
33	170	173	O	dose
34	175	176	O	of
35	178	188	O	XXXXXXXX
36	189	189	O	,
37	191	191	O	2
38	193	194	O	mg
39	197	197	O	3
40	199	200	O	to
41	202	202	O	7
42	204	208	O	years
43	211	212	O	or
44	214	214	O	4
45	216	217	O	mg
46	220	220	O	8
47	222	223	O	to
48	225	226	O	12
49	228	232	O	years
50	234	234	O	,
51	236	238	O	was
52	240	251	O	administered
53	253	263	O	immediately
54	265	269	O	prior
55	271	272	O	to
56	274	283	O	anesthesia
57	285	293	O	induction
NULL

ONDANSETRON	5576	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	23
Mean weight-normalized clearance and volume of distribution values in these pediatric surgical patients were similar to those previously reported for young adults.
1	0	3	O	Mean
2	5	10	O	weight
3	12	21	O	normalized
4	23	31	O	clearance
5	33	35	O	and
6	37	42	O	volume
7	44	45	O	of
8	47	58	O	distribution
9	60	65	O	values
10	67	68	O	in
11	70	74	O	these
12	76	84	O	pediatric
13	86	93	O	surgical
14	95	102	O	patients
15	104	107	O	were
16	109	115	O	similar
17	117	118	O	to
18	120	124	O	those
19	126	135	O	previously
20	137	144	O	reported
21	146	148	O	for
22	150	154	O	young
23	156	161	O	adults
NULL

ONDANSETRON	5577	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	26
Mean terminal half-life was slightly reduced in pediatric patients (range, 2.5 to 3 hours) in comparison with adults (range, 3 to 3.5 hours).
1	0	3	O	Mean
2	5	12	O	terminal
3	14	17	O	half
4	19	22	O	life
5	24	26	O	was
6	28	35	O	slightly
7	37	43	O	reduced
8	45	46	O	in
9	48	56	O	pediatric
10	58	65	O	patients
11	68	72	O	range
12	73	73	O	,
13	75	77	O	2.5
14	79	80	O	to
15	82	82	O	3
16	84	88	O	hours
17	91	92	O	in
18	94	103	O	comparison
19	105	108	O	with
20	110	115	O	adults
21	118	122	O	range
22	123	123	O	,
23	125	125	O	3
24	127	128	O	to
25	130	132	O	3.5
26	134	138	O	hours
NULL

ONDANSETRON	5578	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	41
In a study of 51 pediatric patients (1 month to 24 months of age) who were undergoing surgery requiring general anesthesia, a single intravenous dose of ondansetron, 0.1 or 0.2 mg/kg, was administered prior to surgery.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	51
6	17	25	O	pediatric
7	27	34	O	patients
8	37	37	O	1
9	39	43	O	month
10	45	46	O	to
11	48	49	O	24
12	51	56	O	months
13	58	59	O	of
14	61	63	O	age
15	66	68	O	who
16	70	73	O	were
17	75	84	O	undergoing
18	86	92	O	surgery
19	94	102	O	requiring
20	104	110	O	general
21	112	121	O	anesthesia
22	122	122	O	,
23	124	124	O	a
24	126	131	O	single
25	133	143	O	intravenous
26	145	148	O	dose
27	150	151	O	of
28	153	163	O	XXXXXXXX
29	164	164	O	,
30	166	168	O	0.1
31	170	171	O	or
32	173	175	O	0.2
33	177	178	O	mg
34	179	179	O	/
35	180	181	O	kg
36	182	182	O	,
37	184	186	O	was
38	188	199	O	administered
39	201	205	O	prior
40	207	208	O	to
41	210	216	O	surgery
NULL

ONDANSETRON	5579	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	47
As shown in Table 5, the 41 patients with pharmacokinetic data were divided into 2 groups, patients 1 month to 4 months of age and patients 5 to 24 months of age, and are compared to pediatric patients 3 to 12 years of age.
1	0	1	O	As
2	3	7	O	shown
3	9	10	O	in
4	12	16	O	Table
5	18	18	O	5
6	19	19	O	,
7	21	23	O	the
8	25	26	O	41
9	28	35	O	patients
10	37	40	O	with
11	42	56	O	pharmacokinetic
12	58	61	O	data
13	63	66	O	were
14	68	74	O	divided
15	76	79	O	into
16	81	81	O	2
17	83	88	O	groups
18	89	89	O	,
19	91	98	O	patients
20	100	100	O	1
21	102	106	O	month
22	108	109	O	to
23	111	111	O	4
24	113	118	O	months
25	120	121	O	of
26	123	125	O	age
27	127	129	O	and
28	131	138	O	patients
29	140	140	O	5
30	142	143	O	to
31	145	146	O	24
32	148	153	O	months
33	155	156	O	of
34	158	160	O	age
35	161	161	O	,
36	163	165	O	and
37	167	169	O	are
38	171	178	O	compared
39	180	181	O	to
40	183	191	O	pediatric
41	193	200	O	patients
42	202	202	O	3
43	204	205	O	to
44	207	208	O	12
45	210	214	O	years
46	216	217	O	of
47	219	221	O	age
NULL

ONDANSETRON	5580	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	106
Pharmacokinetics in Pediatric Surgery Patients 1 Month to 12 Years of Age Subjects and Age Group N CL(L/h/kg) Vdss (L/kg) T% (h) Geometric Mean Mean Pediatric Surgery Patients3 to 12 years of age N = 21 0.439 1.65 2.9 Pediatric Surgery Patients5 to 24 months of age N = 22 0.581 2.3 2.9 Pediatric Surgery Patients1 month to 4 months of age N = 19 0.401 3.5 6.7 In general, surgical and cancer pediatric patients younger than 18 years tend to have a higher ondansetron clearance compared to adults leading to a shorter half-life in most pediatric patients.
1	0	15	O	Pharmacokinetics
2	17	18	O	in
3	20	28	O	Pediatric
4	30	36	O	Surgery
5	38	45	O	Patients
6	47	47	O	1
7	49	53	O	Month
8	55	56	O	to
9	58	59	O	12
10	61	65	O	Years
11	67	68	O	of
12	70	72	O	Age
13	74	81	O	Subjects
14	83	85	O	and
15	87	89	O	Age
16	91	95	O	Group
17	97	97	O	N
18	99	102	O	CL(L
19	103	103	O	/
20	104	104	O	h
21	105	105	O	/
22	106	107	O	kg
23	110	113	O	Vdss
24	116	116	O	L
25	117	117	O	/
26	118	119	O	kg
27	122	123	O	T%
28	126	126	O	h
29	129	137	O	Geometric
30	139	142	O	Mean
31	144	147	O	Mean
32	149	157	O	Pediatric
33	159	165	O	Surgery
34	167	175	O	Patients3
35	177	178	O	to
36	180	181	O	12
37	183	187	O	years
38	189	190	O	of
39	192	194	O	age
40	196	196	O	N
41	198	198	O	=
42	200	201	O	21
43	203	207	O	0.439
44	209	212	O	1.65
45	214	216	O	2.9
46	218	226	O	Pediatric
47	228	234	O	Surgery
48	236	244	O	Patients5
49	246	247	O	to
50	249	250	O	24
51	252	257	O	months
52	259	260	O	of
53	262	264	O	age
54	266	266	O	N
55	268	268	O	=
56	270	271	O	22
57	273	277	O	0.581
58	279	281	O	2.3
59	283	285	O	2.9
60	287	295	O	Pediatric
61	297	303	O	Surgery
62	305	313	O	Patients1
63	315	319	O	month
64	321	322	O	to
65	324	324	O	4
66	326	331	O	months
67	333	334	O	of
68	336	338	O	age
69	340	340	O	N
70	342	342	O	=
71	344	345	O	19
72	347	351	O	0.401
73	353	355	O	3.5
74	357	359	O	6.7
75	361	362	O	In
76	364	370	O	general
77	371	371	O	,
78	373	380	O	surgical
79	382	384	O	and
80	386	391	O	cancer
81	393	401	O	pediatric
82	403	410	O	patients
83	412	418	O	younger
84	420	423	O	than
85	425	426	O	18
86	428	432	O	years
87	434	437	O	tend
88	439	440	O	to
89	442	445	O	have
90	447	447	O	a
91	449	454	O	higher
92	456	466	O	XXXXXXXX
93	468	476	O	clearance
94	478	485	O	compared
95	487	488	O	to
96	490	495	O	adults
97	497	503	O	leading
98	505	506	O	to
99	508	508	O	a
100	510	516	O	shorter
101	518	521	O	half
102	523	526	O	life
103	528	529	O	in
104	531	534	O	most
105	536	544	O	pediatric
106	546	553	O	patients
NULL

ONDANSETRON	5581	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	27
In patients 1 month to 4 months of age, a longer half-life was observed due to the higher volume of distribution in this age group.
1	0	1	O	In
2	3	10	O	patients
3	12	12	O	1
4	14	18	O	month
5	20	21	O	to
6	23	23	O	4
7	25	30	O	months
8	32	33	O	of
9	35	37	O	age
10	38	38	O	,
11	40	40	O	a
12	42	47	O	longer
13	49	52	O	half
14	54	57	O	life
15	59	61	O	was
16	63	70	O	observed
17	72	74	O	due
18	76	77	O	to
19	79	81	O	the
20	83	88	O	higher
21	90	95	O	volume
22	97	98	O	of
23	100	111	O	distribution
24	113	114	O	in
25	116	119	O	this
26	121	123	O	age
27	125	129	O	group
NULL

ONDANSETRON	5582	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	47
In a study of 21 pediatric cancer patients (4 to 18 years of age) who received three intravenous doses of 0.15 mg/kg of ondansetron at 4-hour intervals, patients older than 15 years of age exhibited ondansetron pharmacokinetic parameters similar to those of adults.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	21
6	17	25	O	pediatric
7	27	32	O	cancer
8	34	41	O	patients
9	44	44	O	4
10	46	47	O	to
11	49	50	O	18
12	52	56	O	years
13	58	59	O	of
14	61	63	O	age
15	66	68	O	who
16	70	77	O	received
17	79	83	O	three
18	85	95	O	intravenous
19	97	101	O	doses
20	103	104	O	of
21	106	109	O	0.15
22	111	112	O	mg
23	113	113	O	/
24	114	115	O	kg
25	117	118	O	of
26	120	130	O	XXXXXXXX
27	132	133	O	at
28	135	135	O	4
29	137	140	O	hour
30	142	150	O	intervals
31	151	151	O	,
32	153	160	O	patients
33	162	166	O	older
34	168	171	O	than
35	173	174	O	15
36	176	180	O	years
37	182	183	O	of
38	185	187	O	age
39	189	197	O	exhibited
40	199	209	O	XXXXXXXX
41	211	225	O	pharmacokinetic
42	227	236	O	parameters
43	238	244	O	similar
44	246	247	O	to
45	249	253	O	those
46	255	256	O	of
47	258	263	O	adults
NULL

ONDANSETRON	5583	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	31
Renal Impairment: Due to the very small contribution (5%) of renal clearance to the overall clearance, renal impairment was not expected to significantly influence the total clearance of ondansetron.
1	0	4	O	Renal
2	6	15	O	Impairment
3	16	16	O	:
4	18	20	O	Due
5	22	23	O	to
6	25	27	O	the
7	29	32	O	very
8	34	38	O	small
9	40	51	O	contribution
10	54	55	O	5%
11	58	59	O	of
12	61	65	O	renal
13	67	75	O	clearance
14	77	78	O	to
15	80	82	O	the
16	84	90	O	overall
17	92	100	O	clearance
18	101	101	O	,
19	103	107	O	renal
20	109	118	O	impairment
21	120	122	O	was
22	124	126	O	not
23	128	135	O	expected
24	137	138	O	to
25	140	152	O	significantly
26	154	162	O	influence
27	164	166	O	the
28	168	172	O	total
29	174	182	O	clearance
30	184	185	O	of
31	187	197	O	XXXXXXXX
NULL

ONDANSETRON	5584	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	24
However, ondansetron mean plasma clearance was reduced by about 41% in patients with severe renal impairment (creatinine clearance < 30 mL/min).
1	0	6	O	However
2	7	7	O	,
3	9	19	O	XXXXXXXX
4	21	24	O	mean
5	26	31	O	plasma
6	33	41	O	clearance
7	43	45	O	was
8	47	53	O	reduced
9	55	56	O	by
10	58	62	O	about
11	64	66	O	41%
12	68	69	O	in
13	71	78	O	patients
14	80	83	O	with
15	85	90	O	severe
16	92	96	O	renal
17	98	107	O	impairment
18	110	119	O	creatinine
19	121	129	O	clearance
20	131	131	O	<
21	133	134	O	30
22	136	137	O	mL
23	138	138	O	/
24	139	141	O	min
NULL

ONDANSETRON	5585	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	16
This reduction in clearance is variable and was not consistent with an increase in half-life.
1	0	3	O	This
2	5	13	O	reduction
3	15	16	O	in
4	18	26	O	clearance
5	28	29	O	is
6	31	38	O	variable
7	40	42	O	and
8	44	46	O	was
9	48	50	O	not
10	52	61	O	consistent
11	63	66	O	with
12	68	69	O	an
13	71	78	O	increase
14	80	81	O	in
15	83	86	O	half
16	88	91	O	life
NULL

ONDANSETRON	5586	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	12
No reduction in dose or dosing frequency in these patients is warranted.
1	0	1	O	No
2	3	11	O	reduction
3	13	14	O	in
4	16	19	O	dose
5	21	22	O	or
6	24	29	O	dosing
7	31	39	O	frequency
8	41	42	O	in
9	44	48	O	these
10	50	57	O	patients
11	59	60	O	is
12	62	70	O	warranted
NULL

ONDANSETRON	5587	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	35
Hepatic Impairment: In patients with mild-to-moderate hepatic impairment, clearance is reduced 2-fold and mean half-life is increased to 11.6 hours compared to 5.7 hours in those without hepatic impairment.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	18	18	O	:
4	20	21	O	In
5	23	30	O	patients
6	32	35	O	with
7	37	40	O	mild
8	42	43	O	to
9	45	52	O	moderate
10	54	60	O	hepatic
11	62	71	O	impairment
12	72	72	O	,
13	74	82	O	clearance
14	84	85	O	is
15	87	93	O	reduced
16	95	95	O	2
17	97	100	O	fold
18	102	104	O	and
19	106	109	O	mean
20	111	114	O	half
21	116	119	O	life
22	121	122	O	is
23	124	132	O	increased
24	134	135	O	to
25	137	140	O	11.6
26	142	146	O	hours
27	148	155	O	compared
28	157	158	O	to
29	160	162	O	5.7
30	164	168	O	hours
31	170	171	O	in
32	173	177	O	those
33	179	185	O	without
34	187	193	O	hepatic
35	195	204	O	impairment
NULL

ONDANSETRON	5588	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	39
In patients with severe hepatic impairment (Child-Pugh score of 10 or greater), clearance is reduced 2-fold to 3-fold and apparent volume of distribution is increased with a resultant increase in half-life to 20 hours.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	22	O	severe
5	24	30	O	hepatic
6	32	41	O	impairment
7	44	48	O	Child
8	50	53	O	Pugh
9	55	59	O	score
10	61	62	O	of
11	64	65	O	10
12	67	68	O	or
13	70	76	O	greater
14	78	78	O	,
15	80	88	O	clearance
16	90	91	O	is
17	93	99	O	reduced
18	101	101	O	2
19	103	106	O	fold
20	108	109	O	to
21	111	111	O	3
22	113	116	O	fold
23	118	120	O	and
24	122	129	O	apparent
25	131	136	O	volume
26	138	139	O	of
27	141	152	O	distribution
28	154	155	O	is
29	157	165	O	increased
30	167	170	O	with
31	172	172	O	a
32	174	182	O	resultant
33	184	191	O	increase
34	193	194	O	in
35	196	199	O	half
36	201	204	O	life
37	206	207	O	to
38	209	210	O	20
39	212	216	O	hours
NULL

ONDANSETRON	5589	34090-1	d89017aa-b8c3-4fd2-8e68-44e2cfd6f290	18
In patients with severe hepatic impairment, a total daily dose of 8 mg should not be exceeded.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	22	O	severe
5	24	30	O	hepatic
6	32	41	O	impairment
7	42	42	O	,
8	44	44	O	a
9	46	50	O	total
10	52	56	O	daily
11	58	61	O	dose
12	63	64	O	of
13	66	66	O	8
14	68	69	O	mg
15	71	76	O	should
16	78	80	O	not
17	82	83	O	be
18	85	92	O	exceeded
NULL

PAMELOR	6132	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	19
Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a "stimulating" effect in some depressed patients.
1	0	13	O	Administration
2	15	16	O	of
3	18	26	U-DYN	reserpine
4	28	33	O	during
5	35	41	O	therapy
6	43	58	O	withGGGGGGGGGGGG
7	60	73	O	antidepressant
8	75	77	O	has
9	79	82	O	been
10	84	88	O	shown
11	90	91	O	to
12	93	99	O	produce
13	101	101	O	a
14	103	115	O	"stimulating"
15	117	122	O	effect
16	124	125	O	in
17	127	130	O	some
18	132	140	O	depressed
19	142	149	O	patients
NULL

PAMELOR	6133	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	21
Close supervision and careful adjustment of the dosage are required when Pamelor is used with other anticholinergic drugs and sympathomimetic drugs.
1	0	4	B-TRI	Close
2	6	16	L-TRI	supervision
3	18	20	O	and
4	22	28	O	careful
5	30	39	O	adjustment
6	41	42	O	of
7	44	46	O	the
8	48	53	O	dosage
9	55	57	O	are
10	59	66	O	required
11	68	71	O	when
12	73	79	O	XXXXXXXX
13	81	82	O	is
14	84	87	O	used
15	89	92	O	with
16	94	98	O	other
17	100	114	B-UNK	anticholinergic
18	116	120	L-UNK	drugs
19	122	124	O	and
20	126	140	B-UNK	sympathomimetic
21	142	146	L-UNK	drugs
NULL

PAMELOR	6134	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	18
Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressant.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	38	U-KIN	cimetidine
5	40	52	O	aGGGGGGGGGGGG
6	54	68	O	antidepressants
7	70	72	O	can
8	74	80	O	produce
9	82	91	O	clinically
10	93	103	O	significant
11	105	113	B-TRI	increases
12	115	116	I-TRI	in
13	118	120	I-TRI	the
14	122	127	I-TRI	plasma
15	129	142	L-TRI	concentrations
16	144	145	O	of
17	147	159	O	tGGGGGGGGGGGG
18	161	174	O	antidepressant
K/4:C54355

PAMELOR	6135	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	13
The patient should be informed that the response to alcohol may be exaggerated.
1	0	2	O	The
2	4	10	O	patient
3	12	17	O	should
4	19	20	O	be
5	22	29	O	informed
6	31	34	O	that
7	36	38	O	the
8	40	47	B-EFF	response
9	49	50	I-EFF	to
10	52	58	I-EFF	alcohol
11	60	62	I-EFF	may
12	64	65	I-EFF	be
13	67	77	L-EFF	exaggerated
NULL

PAMELOR	6136	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	31
A case of significant hypoglycemia has been reported in a type II diabetic patient maintained on chlorpropamide (250 mg/day), after the addition of nortriptyline (125 mg/day).
1	0	0	O	A
2	2	5	O	case
3	7	8	O	of
4	10	20	O	significant
5	22	33	U-EFF	hypoglycemia
6	35	37	O	has
7	39	42	O	been
8	44	51	O	reported
9	53	54	O	in
10	56	56	O	a
11	58	61	O	type
12	63	64	O	II
13	66	73	O	diabetic
14	75	81	O	patient
15	83	92	O	maintained
16	94	95	O	on
17	97	110	U-DYN	chlorpropamide
18	113	115	O	250
19	117	118	O	mg
20	119	119	O	/
21	120	122	O	day
22	124	124	O	,
23	126	130	O	after
24	132	134	O	the
25	136	143	O	addition
26	145	146	O	of
27	148	160	O	XXXXXXXX
28	163	165	O	125
29	167	168	O	mg
30	169	169	O	/
31	170	172	O	day
D/17:5:1

PAMELOR	6137	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	60
Drugs Metabolized by P450 2D6 - The biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	2D6
6	32	34	O	The
7	36	46	O	biochemical
8	48	55	O	activity
9	57	58	O	of
10	60	62	O	the
11	64	67	O	drug
12	69	80	O	metabolizing
13	82	88	O	isozyme
14	90	99	O	cytochrome
15	101	104	O	P450
16	106	108	O	2D6
17	111	121	O	debrisoquin
18	123	133	O	hydroxylase
19	136	137	O	is
20	139	145	O	reduced
21	147	148	O	in
22	150	150	O	a
23	152	157	O	subset
24	159	160	O	of
25	162	164	O	the
26	166	174	O	Caucasian
27	176	185	O	population
28	188	192	O	about
29	194	195	O	7%
30	197	198	O	to
31	200	202	O	10%
32	204	205	O	of
33	207	216	O	Caucasians
34	218	220	O	are
35	222	223	O	so
36	225	230	O	called
37	232	236	O	"poor
38	238	250	O	metabolizers"
39	254	261	O	reliable
40	263	271	O	estimates
41	273	274	O	of
42	276	278	O	the
43	280	289	O	prevalence
44	291	292	O	of
45	294	300	O	reduced
46	302	305	O	P450
47	307	309	O	2D6
48	311	317	O	isozyme
49	319	326	O	activity
50	328	332	O	among
51	334	338	O	Asian
52	339	339	O	,
53	341	347	O	African
54	349	351	O	and
55	353	357	O	other
56	359	369	O	populations
57	371	373	O	are
58	375	377	O	not
59	379	381	O	yet
60	383	391	O	available
NULL

PAMELOR	6138	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	15
Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	21	O	have
4	23	28	O	higher
5	30	33	O	than
6	35	42	O	expected
7	44	49	O	plasma
8	51	64	O	concentrations
9	66	77	O	GGGGGGGG
10	79	93	O	antidepressants
11	96	99	O	TCAs
12	102	105	O	when
13	107	111	O	given
14	113	117	O	usual
15	119	123	O	doses
NULL

PAMELOR	6139	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	32
Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).
1	0	8	O	Depending
2	10	11	O	on
3	13	15	O	the
4	17	24	O	fraction
5	26	27	O	of
6	29	32	O	drug
7	34	44	O	metabolized
8	46	47	O	by
9	49	52	O	P450
10	54	56	O	2D6
11	57	57	O	,
12	59	61	O	the
13	63	70	O	increase
14	72	73	O	in
15	75	80	O	plasma
16	82	94	O	concentration
17	96	98	O	may
18	100	101	O	be
19	103	107	O	small
20	108	108	O	,
21	110	111	O	or
22	113	117	O	quite
23	119	123	O	large
24	126	126	O	8
25	128	131	O	fold
26	133	140	O	increase
27	142	143	O	in
28	145	150	O	plasma
29	152	154	O	AUC
30	156	157	O	of
31	159	161	O	the
32	163	165	O	TCA
NULL

PAMELOR	6140	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	18
In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	19	O	certain
5	21	25	O	drugs
6	27	33	O	inhibit
7	35	37	O	the
8	39	46	O	activity
9	48	49	O	of
10	51	54	O	this
11	56	62	O	isozyme
12	64	66	O	and
13	68	71	O	make
14	73	78	O	normal
15	80	91	O	metabolizers
16	93	100	O	resemble
17	102	105	O	poor
18	107	118	O	metabolizers
NULL

PAMELOR	6141	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	25
An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy.
1	0	1	O	An
2	3	12	O	individual
3	14	16	O	who
4	18	19	O	is
5	21	26	O	stable
6	28	29	O	on
7	31	31	O	a
8	33	37	O	given
9	39	42	O	dose
10	44	45	O	of
11	47	49	O	TCA
12	51	53	O	may
13	55	60	O	become
14	62	69	O	abruptly
15	71	75	O	toxic
16	77	80	O	when
17	82	86	O	given
18	88	90	O	one
19	92	93	O	of
20	95	99	O	these
21	101	110	O	inhibiting
22	112	116	O	drugs
23	118	119	O	as
24	121	131	O	concomitant
25	133	139	O	therapy
NULL

PAMELOR	6142	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	40
The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).
1	0	2	O	The
2	4	8	O	drugs
3	10	13	O	that
4	15	21	O	inhibit
5	23	32	O	cytochrome
6	34	37	O	P450
7	39	41	O	2D6
8	43	49	O	include
9	51	54	O	some
10	56	59	O	that
11	61	63	O	are
12	65	67	O	not
13	69	79	O	metabolized
14	81	82	O	by
15	84	86	O	the
16	88	93	O	enzyme
17	96	104	O	quinidine
18	107	116	O	cimetidine
19	119	121	O	and
20	123	126	O	many
21	128	131	O	that
22	133	135	O	are
23	137	146	O	substrates
24	148	150	O	for
25	152	155	O	P450
26	157	159	O	2D6
27	162	165	O	many
28	167	171	O	other
29	173	187	O	antidepressants
30	188	188	O	,
31	190	203	O	phenothiazines
32	204	204	O	,
33	206	208	O	and
34	210	212	O	the
35	214	217	O	Type
36	219	220	O	1C
37	222	236	O	antiarrhythmics
38	238	248	O	propafenone
39	250	252	O	and
40	254	263	O	flecainide
NULL

PAMELOR	6143	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	30
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.
1	0	4	O	While
2	6	8	O	all
3	10	12	O	the
4	14	22	O	selective
5	24	32	O	serotonin
6	34	41	O	reuptake
7	43	52	O	inhibitors
8	55	59	O	SSRIs
9	61	61	O	,
10	63	65	O	e.g
11	67	67	O	,
12	69	78	O	fluoxetine
13	79	79	O	,
14	81	90	O	sertraline
15	91	91	O	,
16	93	95	O	and
17	97	106	O	paroxetine
18	107	107	O	,
19	109	115	O	inhibit
20	117	120	O	P450
21	122	124	O	2D6
22	125	125	O	,
23	127	130	O	they
24	132	134	O	may
25	136	139	O	vary
26	141	142	O	in
27	144	146	O	the
28	148	153	O	extent
29	155	156	O	of
30	158	167	O	inhibition
NULL

PAMELOR	6144	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	25
The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	U-UNK	SSRI
6	25	27	O	TCA
7	29	40	U-TRI	interactions
8	42	44	O	may
9	46	49	O	pose
10	51	58	O	clinical
11	60	67	O	problems
12	69	72	O	will
13	74	79	O	depend
14	81	82	O	on
15	84	86	O	the
16	88	93	O	degree
17	95	96	O	of
18	98	107	O	inhibition
19	109	111	O	and
20	113	115	O	the
21	117	132	O	pharmacokinetics
22	134	135	O	of
23	137	139	O	the
24	141	144	O	SSRI
25	146	153	O	involved
NULL

PAMELOR	6145	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	26
Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCAs
12	68	71	O	with
13	73	75	O	any
14	77	78	O	of
15	80	82	O	the
16	84	88	U-UNK	SSRIs
17	90	92	O	and
18	94	97	O	also
19	99	100	O	in
20	102	110	O	switching
21	112	115	O	from
22	117	119	O	one
23	121	125	O	class
24	127	128	O	to
25	130	132	O	the
26	134	138	O	other
NULL

PAMELOR	6146	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	38
Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).
1	0	1	O	Of
2	3	12	O	particular
3	14	23	O	importance
4	24	24	O	,
5	26	35	B-TRI	sufficient
6	37	40	I-TRI	time
7	42	45	I-TRI	must
8	47	52	I-TRI	elapse
9	54	59	I-TRI	before
10	61	70	L-TRI	initiating
11	72	74	O	TCA
12	76	84	O	treatment
13	86	87	O	in
14	89	89	O	a
15	91	97	O	patient
16	99	103	O	being
17	105	113	O	withdrawn
18	115	118	O	from
19	120	129	U-UNK	fluoxetine
20	130	130	O	,
21	132	136	O	given
22	138	140	O	the
23	142	145	O	long
24	147	150	O	half
25	152	155	O	life
26	157	158	O	of
27	160	162	O	the
28	164	169	O	parent
29	171	173	O	and
30	175	180	O	active
31	182	191	O	metabolite
32	194	195	O	at
33	197	201	O	least
34	203	203	O	5
35	205	209	O	weeks
36	211	213	O	may
37	215	216	O	be
38	218	226	O	necessary
NULL

PAMELOR	6147	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	27
Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	27	O	GGGGGGGG
4	29	43	O	antidepressants
5	45	48	O	with
6	50	54	B-KIN	drugs
7	56	59	I-KIN	that
8	61	63	I-KIN	can
9	65	71	I-KIN	inhibit
10	73	82	I-KIN	cytochrome
11	84	87	I-KIN	P450
12	89	91	L-KIN	2D6
13	93	95	O	may
14	97	103	O	require
15	105	109	B-TRI	lower
16	111	115	L-TRI	doses
17	117	120	O	than
18	122	128	O	usually
19	130	139	O	prescribed
20	141	143	O	for
21	145	150	O	either
22	152	164	O	tGGGGGGGGGGGG
23	166	179	O	antidepressant
24	181	182	O	or
25	184	186	O	the
26	188	192	O	other
27	194	197	O	drug
K/6:C54355

PAMELOR	6148	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	22
Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	24	O	one
5	26	27	O	of
6	29	33	O	these
7	35	39	O	other
8	41	45	O	drugs
9	47	48	O	is
10	50	58	O	withdrawn
11	60	63	O	from
12	65	66	O	co
13	68	74	O	therapy
14	75	75	O	,
15	77	78	O	an
16	80	88	O	increased
17	90	93	O	dose
18	95	106	O	GGGGGGGG
19	108	121	O	antidepressant
20	123	125	O	may
21	127	128	O	be
22	130	137	O	required
NULL

PAMELOR	6149	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	28
It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.
1	0	1	O	It
2	3	4	O	is
3	6	14	O	desirable
4	16	17	O	to
5	19	25	U-TRI	monitor
6	27	29	O	TCA
7	31	36	O	plasma
8	38	43	O	levels
9	45	52	O	whenever
10	54	54	O	a
11	56	58	O	TCA
12	60	61	O	is
13	63	67	O	going
14	69	70	O	to
15	72	73	O	be
16	75	76	O	co
17	78	89	O	administered
18	91	94	O	with
19	96	102	O	another
20	104	107	O	drug
21	109	113	O	known
22	115	116	O	to
23	118	119	O	be
24	121	122	O	an
25	124	132	B-UNK	inhibitor
26	134	135	I-UNK	of
27	137	140	I-UNK	P450
28	142	144	L-UNK	2D6
NULL

PAMELOR	6150	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	4
Monoamine Oxidase Inhibitors (MAOIs)
1	0	8	O	Monoamine
2	10	16	O	Oxidase
3	18	27	O	Inhibitors
4	30	34	O	MAOIs
NULL

PAMELOR	6151	34073-7	e17dc299-f52d-414d-ab6e-e809bd6f8acb	2
Serotonergic Drugs
1	0	11	O	Serotonergic
2	13	17	O	Drugs
NULL

PAMELOR	6152	34090-1	e17dc299-f52d-414d-ab6e-e809bd6f8acb	11
The mechanism of mood elevation by tricyclic antidepressants is at present unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	20	O	mood
5	22	30	O	elevation
6	32	43	O	GGGGGGGG
7	45	59	O	antidepressants
8	61	62	O	is
9	64	65	O	at
10	67	73	O	present
11	75	81	O	unknown
NULL

PAMELOR	6153	34090-1	e17dc299-f52d-414d-ab6e-e809bd6f8acb	7
Pamelor is not a monoamine oxidase inhibitor.
1	0	6	O	XXXXXXXX
2	8	9	O	is
3	11	13	O	not
4	15	15	O	a
5	17	25	O	monoamine
6	27	33	O	oxidase
7	35	43	O	inhibitor
NULL

PAMELOR	6154	34090-1	e17dc299-f52d-414d-ab6e-e809bd6f8acb	16
It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine.
1	0	1	O	It
2	3	10	O	inhibits
3	12	14	O	the
4	16	23	O	activity
5	25	26	O	of
6	28	31	O	such
7	33	39	O	diverse
8	41	46	O	agents
9	48	49	O	as
10	51	59	U-DYN	histamine
11	60	60	O	,
12	62	62	B-DYN	5
13	64	80	L-DYN	hydroxytryptamine
14	81	81	O	,
15	83	85	O	and
16	87	99	U-DYN	acetylcholine
NULL

PAMELOR	6155	34090-1	e17dc299-f52d-414d-ab6e-e809bd6f8acb	14
It increases the pressor effect of norepinephrine but blocks the pressor response of phenethylamine.
1	0	1	O	It
2	3	11	B-EFF	increases
3	13	15	I-EFF	the
4	17	23	I-EFF	pressor
5	25	30	L-EFF	effect
6	32	33	O	of
7	35	48	U-DYN	norepinephrine
8	50	52	O	but
9	54	59	B-EFF	blocks
10	61	63	I-EFF	the
11	65	71	I-EFF	pressor
12	73	80	L-EFF	response
13	82	83	O	of
14	85	98	U-DYN	phenethylamine
D/14:2:0 D/14:9:1 D/7:2:1 D/7:9:0

PAMELOR	6156	34090-1	e17dc299-f52d-414d-ab6e-e809bd6f8acb	15
Studies suggest that Pamelor interferes with the transport, release, and storage of catecholamines.
1	0	6	O	Studies
2	8	14	O	suggest
3	16	19	O	that
4	21	27	O	XXXXXXXX
5	29	38	B-EFF	interferes
6	40	43	I-EFF	with
7	45	47	I-EFF	the
8	49	57	I-EFF	transport
9	58	58	I-EFF	,
10	60	66	I-EFF	release
11	67	67	I-EFF	,
12	69	71	I-EFF	and
13	73	79	I-EFF	storage
14	81	82	I-EFF	of
15	84	97	L-EFF	catecholamines
NULL

PAMELOR	6157	34090-1	e17dc299-f52d-414d-ab6e-e809bd6f8acb	18
Operant conditioning techniques in rats and pigeons suggest that Pamelor has a combination of stimulant and depressant properties.
1	0	6	O	Operant
2	8	19	O	conditioning
3	21	30	O	techniques
4	32	33	O	in
5	35	38	O	rats
6	40	42	O	and
7	44	50	O	pigeons
8	52	58	O	suggest
9	60	63	O	that
10	65	71	O	XXXXXXXX
11	73	75	O	has
12	77	77	O	a
13	79	89	O	combination
14	91	92	O	of
15	94	102	O	stimulant
16	104	106	O	and
17	108	117	O	depressant
18	119	128	O	properties
NULL

PAROXETINE	3504	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
As with other serotonin reuptake inhibitors, an interaction between paroxetine and tryptophan may occur when they are coadministered.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	42	U-UNK	GGGGGGGG
5	43	43	O	,
6	45	46	O	an
7	48	58	U-TRI	interaction
8	60	66	O	between
9	68	77	O	XXXXXXXX
10	79	81	O	and
11	83	92	U-UNK	tryptophan
12	94	96	O	may
13	98	102	O	occur
14	104	107	O	when
15	109	112	O	they
16	114	116	O	are
17	118	131	O	coadministered
NULL

PAROXETINE	3505	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	26
Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking paroxetine.
1	0	6	O	Adverse
2	8	18	O	experiences
3	19	19	O	,
4	21	30	O	consisting
5	32	40	O	primarily
6	42	43	O	of
7	45	52	U-EFF	headache
8	53	53	O	,
9	55	60	U-EFF	nausea
10	61	61	O	,
11	63	70	U-EFF	sweating
12	71	71	O	,
13	73	75	O	and
14	77	85	U-EFF	dizziness
15	86	86	O	,
16	88	91	O	have
17	93	96	O	been
18	98	105	O	reported
19	107	110	O	when
20	112	121	U-DYN	tryptophan
21	123	125	O	was
22	127	138	O	administered
23	140	141	O	to
24	143	150	O	patients
25	152	157	O	taking
26	159	168	O	XXXXXXXX
D/20:11:1 D/20:14:1 D/20:7:1 D/20:9:1

PAROXETINE	3506	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	11
Consequently, concomitant use of paroxetine with tryptophan is not recommended.
1	0	11	O	Consequently
2	12	12	O	,
3	14	24	O	concomitant
4	26	28	O	use
5	30	31	O	of
6	33	42	O	XXXXXXXX
7	44	47	O	with
8	49	58	U-UNK	tryptophan
9	60	61	O	is
10	63	65	B-TRI	not
11	67	77	L-TRI	recommended
NULL

PAROXETINE	3507	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	4
See CONTRAINDICATIONS and WARNINGS.
1	0	2	O	See
2	4	20	O	CONTRAINDICATIONS
3	22	24	O	and
4	26	33	O	WARNINGS
NULL

PAROXETINE	3508	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	47
In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, co-administration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.
1	0	1	O	In
2	3	3	O	a
3	5	14	O	controlled
4	16	20	O	study
5	22	23	O	of
6	25	31	O	healthy
7	33	42	O	volunteers
8	43	43	O	,
9	45	49	O	after
10	51	60	O	XXXXXXXX
11	62	64	O	was
12	66	73	O	titrated
13	75	76	O	to
14	78	79	O	60
15	81	82	O	mg
16	84	88	O	daily
17	89	89	O	,
18	91	92	O	co
19	94	107	O	administration
20	109	110	O	of
21	112	112	O	a
22	114	119	O	single
23	121	124	O	dose
24	126	127	O	of
25	129	129	O	2
26	131	132	O	mg
27	134	141	U-KIN	pimozide
28	143	145	O	was
29	147	156	O	associated
30	158	161	O	with
31	163	166	O	mean
32	168	176	O	increases
33	178	179	O	in
34	181	188	O	pimozide
35	190	192	O	AUC
36	194	195	O	of
37	197	200	O	151%
38	202	204	O	and
39	206	209	O	Cmax
40	211	212	O	of
41	214	216	O	62%
42	217	217	O	,
43	219	226	O	compared
44	228	229	O	to
45	231	238	O	pimozide
46	240	251	O	administered
47	253	257	O	alone
K/27:C54610

PAROXETINE	3509	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	16
The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine.
1	0	2	O	The
2	4	11	O	increase
3	13	14	O	in
4	16	23	U-KIN	pimozide
5	25	27	O	AUC
6	29	31	O	and
7	33	36	O	Cmax
8	38	39	O	is
9	41	43	O	due
10	45	46	O	to
11	48	50	O	the
12	52	57	O	CYP2D6
13	59	68	O	inhibitory
14	70	79	O	properties
15	81	82	O	of
16	84	93	O	XXXXXXXX
K/4:C54610

PAROXETINE	3510	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	26
Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine is contraindicated.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	16	O	narrow
5	18	28	O	therapeutic
6	30	34	O	index
7	36	37	O	of
8	39	46	U-DYN	pimozide
9	48	50	O	and
10	52	54	O	its
11	56	60	O	known
12	62	68	O	ability
13	70	71	O	to
14	73	79	B-EFF	prolong
15	81	83	I-EFF	the
16	85	86	I-EFF	QT
17	88	95	L-EFF	interval
18	96	96	O	,
19	98	108	O	concomitant
20	110	112	O	use
21	114	115	O	of
22	117	124	O	pimozide
23	126	128	O	and
24	130	139	O	XXXXXXXX
25	141	142	O	is
26	144	158	O	contraindicated
D/8:14:1

PAROXETINE	3511	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	54
Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, or St. John's wort.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	21	O	mechanism
5	23	24	O	of
6	26	31	O	action
7	33	34	O	of
8	36	40	O	SNRIs
9	42	44	O	and
10	46	50	O	SSRIs
11	51	51	O	,
12	53	61	O	including
13	63	72	O	XXXXXXXX
14	74	86	O	hydrochloride
15	87	87	O	,
16	89	91	O	and
17	93	95	O	the
18	97	105	O	potential
19	107	109	O	for
20	111	119	B-EFF	serotonin
21	121	128	L-EFF	syndrome
22	129	129	O	,
23	131	137	O	caution
24	139	140	O	is
25	142	148	O	advised
26	150	153	O	when
27	155	164	O	XXXXXXXX
28	166	167	O	is
29	169	182	O	coadministered
30	184	187	O	with
31	189	193	O	other
32	195	199	B-DYN	drugs
33	201	204	I-DYN	that
34	206	208	I-DYN	may
35	210	215	I-DYN	affect
36	217	219	I-DYN	the
37	221	232	I-DYN	serotonergic
38	234	249	I-DYN	neurotransmitter
39	251	257	L-DYN	systems
40	258	258	O	,
41	260	263	O	such
42	265	266	O	as
43	268	275	U-DYN	triptans
44	276	276	O	,
45	278	284	U-DYN	lithium
46	285	285	O	,
47	287	294	U-DYN	fentanyl
48	295	295	O	,
49	297	304	U-DYN	tramadol
50	305	305	O	,
51	307	308	O	or
52	310	311	B-DYN	St
53	314	319	I-DYN	John's
54	321	324	L-DYN	wort
D/32:20:1 D/43:20:1 D/45:20:1 D/47:20:1 D/49:20:1 D/52:20:1

PAROXETINE	3512	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
The concomitant use of paroxetine with MAOIs (including linezolid and intravenous methylene blue) is contraindicated.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	32	O	XXXXXXXX
6	34	37	O	with
7	39	43	U-UNK	MAOIs
8	46	54	O	including
9	56	64	U-UNK	linezolid
10	66	68	O	and
11	70	80	B-UNK	intravenous
12	82	90	I-UNK	methylene
13	92	95	L-UNK	blue
14	98	99	O	is
15	101	115	U-TRI	contraindicated
NULL

PAROXETINE	3513	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
The concomitant use of paroxetine with other SSRIs, SNRIs or tryptophan is not recommended.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	32	O	XXXXXXXX
6	34	37	O	with
7	39	43	O	other
8	45	49	U-UNK	SSRIs
9	50	50	O	,
10	52	56	U-UNK	SNRIs
11	58	59	O	or
12	61	70	U-UNK	tryptophan
13	72	73	O	is
14	75	77	B-TRI	not
15	79	89	L-TRI	recommended
NULL

PAROXETINE	3515	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	27
Preliminary data suggest that there may be a pharmacodynamic interaction (that causes an increased bleeding diathesis in the face of unaltered prothrombin time) between paroxetine and warfarin.
1	0	10	O	Preliminary
2	12	15	O	data
3	17	23	O	suggest
4	25	28	O	that
5	30	34	O	there
6	36	38	O	may
7	40	41	O	be
8	43	43	O	a
9	45	59	O	pharmacodynamic
10	61	71	O	interaction
11	74	77	O	that
12	79	84	O	causes
13	86	87	O	an
14	89	97	B-EFF	increased
15	99	106	I-EFF	bleeding
16	108	116	L-EFF	diathesis
17	118	119	O	in
18	121	123	O	the
19	125	128	O	face
20	130	131	O	of
21	133	141	O	unaltered
22	143	153	O	prothrombin
23	155	158	O	time
24	161	167	O	between
25	169	178	O	XXXXXXXX
26	180	182	O	and
27	184	191	U-DYN	warfarin
D/27:14:1

PAROXETINE	3516	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
Since there is little clinical experience, the concomitant administration of paroxetine and warfarin should be undertaken with caution.
1	0	4	O	Since
2	6	10	O	there
3	12	13	O	is
4	15	20	O	little
5	22	29	O	clinical
6	31	40	O	experience
7	41	41	O	,
8	43	45	O	the
9	47	57	O	concomitant
10	59	72	O	administration
11	74	75	O	of
12	77	86	O	XXXXXXXX
13	88	90	O	and
14	92	99	U-UNK	warfarin
15	101	106	O	should
16	108	109	O	be
17	111	120	O	undertaken
18	122	125	O	with
19	127	133	U-TRI	caution
NULL

PAROXETINE	3517	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	18
There have been rare postmarketing reports of serotonin syndrome with the use of an SSRI and a triptan.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	33	O	postmarketing
6	35	41	O	reports
7	43	44	O	of
8	46	54	B-EFF	serotonin
9	56	63	L-EFF	syndrome
10	65	68	O	with
11	70	72	O	the
12	74	76	O	use
13	78	79	O	of
14	81	82	O	an
15	84	87	U-DYN	SSRI
16	89	91	O	and
17	93	93	O	a
18	95	101	O	triptan
D/15:8:1

PAROXETINE	3518	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	27
If concomitant use of paroxetine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
1	0	1	O	If
2	3	13	O	concomitant
3	15	17	O	use
4	19	20	O	of
5	22	31	O	XXXXXXXX
6	33	36	O	with
7	38	38	O	a
8	40	46	U-UNK	triptan
9	48	49	O	is
10	51	60	O	clinically
11	62	70	O	warranted
12	71	71	O	,
13	73	79	B-TRI	careful
14	81	91	L-TRI	observation
15	93	94	O	of
16	96	98	O	the
17	100	106	O	patient
18	108	109	O	is
19	111	117	O	advised
20	118	118	O	,
21	120	131	O	particularly
22	133	138	O	during
23	140	148	O	treatment
24	150	159	O	initiation
25	161	163	O	and
26	165	168	O	dose
27	170	178	O	increases
NULL

PAROXETINE	3519	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	18
The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug-metabolizing enzymes.
1	0	2	O	The
2	4	13	O	metabolism
3	15	17	O	and
4	19	34	O	pharmacokinetics
5	36	37	O	of
6	39	48	O	XXXXXXXX
7	50	52	O	may
8	54	55	O	be
9	57	64	O	affected
10	66	67	O	by
11	69	71	O	the
12	73	81	O	induction
13	83	84	O	or
14	86	95	O	inhibition
15	97	98	O	of
16	100	103	O	drug
17	105	116	O	metabolizing
18	118	124	O	enzymes
NULL

PAROXETINE	3520	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	7
Cimetidine inhibits many cytochrome P450 (oxidative) enzymes.
1	0	9	O	Cimetidine
2	11	18	O	inhibits
3	20	23	O	many
4	25	34	O	cytochrome
5	36	39	O	P450
6	42	50	O	oxidative
7	53	59	O	enzymes
NULL

PAROXETINE	3521	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	41
In a study where paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	15	O	where
5	17	26	O	XXXXXXXX
6	29	30	O	30
7	32	33	O	mg
8	35	38	O	once
9	40	44	O	daily
10	47	49	O	was
11	51	55	O	dosed
12	57	62	O	orally
13	64	66	O	for
14	68	68	O	4
15	70	74	O	weeks
16	75	75	O	,
17	77	82	O	steady
18	84	88	O	state
19	90	95	O	plasma
20	97	110	O	concentrations
21	112	113	O	of
22	115	124	O	XXXXXXXX
23	126	129	O	were
24	131	139	O	increased
25	141	142	O	by
26	144	156	O	approximately
27	158	160	O	50%
28	162	167	O	during
29	169	184	O	coadministration
30	186	189	O	with
31	191	194	O	oral
32	196	205	U-KIN	cimetidine
33	208	210	O	300
34	212	213	O	mg
35	215	219	O	three
36	221	225	O	times
37	227	231	O	daily
38	234	236	O	for
39	238	240	O	the
40	242	246	O	final
41	248	251	O	week
K/32:C54355

PAROXETINE	3522	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
Therefore, when these drugs are administered concurrently, dosage adjustment of paroxetine after the 20-mg starting dose should be guided by clinical effect.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	20	O	these
5	22	26	O	drugs
6	28	30	O	are
7	32	43	O	administered
8	45	56	O	concurrently
9	57	57	O	,
10	59	64	O	dosage
11	66	75	O	adjustment
12	77	78	O	of
13	80	89	O	XXXXXXXX
14	91	95	O	after
15	97	99	O	the
16	101	102	O	20
17	104	105	O	mg
18	107	114	O	starting
19	116	119	O	dose
20	121	126	O	should
21	128	129	O	be
22	131	136	O	guided
23	138	139	O	by
24	141	148	O	clinical
25	150	155	O	effect
NULL

PAROXETINE	3523	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
The effect of paroxetine on cimetidine's pharmacokinetics was not studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	39	O	cimetidine's
7	41	56	O	pharmacokinetics
8	58	60	O	was
9	62	64	O	not
10	66	72	O	studied
NULL

PAROXETINE	3524	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	7
Phenobarbital induces many cytochrome P450 (oxidative) enzymes.
1	0	12	O	Phenobarbital
2	14	20	O	induces
3	22	25	O	many
4	27	36	O	cytochrome
5	38	41	O	P450
6	44	52	O	oxidative
7	55	61	O	enzymes
NULL

PAROXETINE	3525	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	43
When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T% were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.
1	0	3	O	When
2	5	5	O	a
3	7	12	O	single
4	14	17	O	oral
5	19	20	O	30
6	22	23	O	mg
7	25	28	O	dose
8	30	31	O	of
9	33	42	O	XXXXXXXX
10	44	46	O	was
11	48	59	O	administered
12	61	62	O	at
13	64	76	U-KIN	phenobarbital
14	78	83	O	steady
15	85	89	O	state
16	92	94	O	100
17	96	97	O	mg
18	99	102	O	once
19	104	108	O	daily
20	110	112	O	for
21	114	115	O	14
22	117	120	O	days
23	122	122	O	,
24	124	133	O	XXXXXXXX
25	135	137	O	AUC
26	139	141	O	and
27	143	144	O	T%
28	146	149	O	were
29	151	157	O	reduced
30	160	161	O	by
31	163	164	O	an
32	166	172	O	average
33	174	175	O	of
34	177	179	O	25%
35	181	183	O	and
36	185	187	O	38%
37	188	188	O	,
38	190	201	O	respectively
39	204	211	O	compared
40	213	214	O	to
41	216	225	O	XXXXXXXX
42	227	238	O	administered
43	240	244	O	alone
K/13:C54607

PAROXETINE	3526	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
The effect of paroxetine on phenobarbital pharmacokinetics was not studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	40	O	phenobarbital
7	42	57	O	pharmacokinetics
8	59	61	O	was
9	63	65	O	not
10	67	73	O	studied
NULL

PAROXETINE	3527	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed.
1	0	4	O	Since
2	6	15	O	XXXXXXXX
3	17	24	O	exhibits
4	26	34	O	nonlinear
5	36	51	O	pharmacokinetics
6	52	52	O	,
7	54	56	O	the
8	58	64	O	results
9	66	67	O	of
10	69	72	O	this
11	74	78	O	study
12	80	82	O	may
13	84	86	O	not
14	88	94	O	address
15	96	98	O	the
16	100	103	O	case
17	105	109	O	where
18	111	113	O	the
19	115	115	O	2
20	117	121	O	drugs
21	123	125	O	are
22	127	130	O	both
23	132	136	O	being
24	138	148	O	chronically
25	150	154	O	dosed
NULL

PAROXETINE	3528	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	22
No initial dosage adjustment of paroxetine is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.
1	0	1	O	No
2	3	9	O	initial
3	11	16	O	dosage
4	18	27	O	adjustment
5	29	30	O	of
6	32	41	O	XXXXXXXX
7	43	44	O	is
8	46	55	O	considered
9	57	65	O	necessary
10	67	70	O	when
11	72	85	O	coadministered
12	87	90	O	with
13	92	104	O	phenobarbital
14	107	109	O	any
15	111	120	O	subsequent
16	122	131	O	adjustment
17	133	138	O	should
18	140	141	O	be
19	143	148	O	guided
20	150	151	O	by
21	153	160	O	clinical
22	162	167	O	effect
NULL

PAROXETINE	3529	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	41
When a single oral 30-mg dose of paroxetine was administered at phenytoin steady state (300mg once daily for 14days), paroxetine AUC and T% were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone.
1	0	3	O	When
2	5	5	O	a
3	7	12	O	single
4	14	17	O	oral
5	19	20	O	30
6	22	23	O	mg
7	25	28	O	dose
8	30	31	O	of
9	33	42	O	XXXXXXXX
10	44	46	O	was
11	48	59	O	administered
12	61	62	O	at
13	64	72	U-KIN	phenytoin
14	74	79	O	steady
15	81	85	O	state
16	88	92	O	300mg
17	94	97	O	once
18	99	103	O	daily
19	105	107	O	for
20	109	114	O	14days
21	116	116	O	,
22	118	127	O	XXXXXXXX
23	129	131	O	AUC
24	133	135	O	and
25	137	138	O	T%
26	140	143	O	were
27	145	151	O	reduced
28	154	155	O	by
29	157	158	O	an
30	160	166	O	average
31	168	169	O	of
32	171	173	O	50%
33	175	177	O	and
34	179	181	O	35%
35	182	182	O	,
36	184	195	O	respectively
37	198	205	O	compared
38	207	208	O	to
39	210	219	O	XXXXXXXX
40	221	232	O	administered
41	234	238	O	alone
K/13:C54609

PAROXETINE	3530	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	41
In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	separate
4	14	18	O	study
5	19	19	O	,
6	21	24	O	when
7	26	26	O	a
8	28	33	O	single
9	35	38	O	oral
10	40	42	O	300
11	44	45	O	mg
12	47	50	O	dose
13	52	53	O	of
14	55	63	U-KIN	phenytoin
15	65	67	O	was
16	69	80	O	administered
17	82	83	O	at
18	85	94	O	XXXXXXXX
19	96	101	O	steady
20	103	107	O	state
21	110	111	O	30
22	113	114	O	mg
23	116	119	O	once
24	121	125	O	daily
25	127	129	O	for
26	131	132	O	14
27	134	137	O	days
28	139	139	O	,
29	141	149	O	phenytoin
30	151	153	O	AUC
31	155	157	O	was
32	159	166	O	slightly
33	168	174	O	reduced
34	177	179	O	12%
35	181	182	O	on
36	184	190	O	average
37	193	200	O	compared
38	202	203	O	to
39	205	213	O	phenytoin
40	215	226	O	administered
41	228	232	O	alone
K/14:C54614

PAROXETINE	3531	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.
1	0	4	O	Since
2	6	9	O	both
3	11	15	O	drugs
4	17	23	O	exhibit
5	25	33	O	nonlinear
6	35	50	O	pharmacokinetics
7	51	51	O	,
8	53	55	O	the
9	57	61	O	above
10	63	69	O	studies
11	71	73	O	may
12	75	77	O	not
13	79	85	O	address
14	87	89	O	the
15	91	94	O	case
16	96	100	O	where
17	102	104	O	the
18	106	106	O	2
19	108	112	O	drugs
20	114	116	O	are
21	118	121	O	both
22	123	127	O	being
23	129	139	O	chronically
24	141	145	O	dosed
NULL

PAROXETINE	3532	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect.
1	0	1	O	No
2	3	9	O	initial
3	11	16	O	dosage
4	18	28	O	adjustments
5	30	32	O	are
6	34	43	O	considered
7	45	53	O	necessary
8	55	58	O	when
9	60	64	O	these
10	66	70	O	drugs
11	72	74	O	are
12	76	89	O	coadministered
13	92	94	O	any
14	96	105	O	subsequent
15	107	117	O	adjustments
16	119	124	O	should
17	126	127	O	be
18	129	134	O	guided
19	136	137	O	by
20	139	146	O	clinical
21	148	153	O	effect
NULL

PAROXETINE	3533	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	30
Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.
1	0	3	O	Many
2	5	9	O	drugs
3	10	10	O	,
4	12	20	O	including
5	22	25	O	most
6	27	31	O	drugs
7	33	41	O	effective
8	43	44	O	in
9	46	48	O	the
10	50	58	O	treatment
11	60	61	O	of
12	63	67	O	major
13	69	78	O	depressive
14	80	87	O	disorder
15	90	99	O	XXXXXXXX
16	100	100	O	,
17	102	106	O	other
18	108	112	O	SSRIs
19	114	116	O	and
20	118	121	O	many
21	123	132	O	tricyclics
22	134	134	O	,
23	136	138	O	are
24	140	150	O	metabolized
25	152	153	O	by
26	155	157	O	the
27	159	168	O	cytochrome
28	170	173	O	P450
29	175	181	O	isozyme
30	183	188	O	CYP2D6
NULL

PAROXETINE	3534	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	18
Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.
1	0	3	O	Like
2	5	9	O	other
3	11	16	O	agents
4	18	21	O	that
5	23	25	O	are
6	27	37	O	metabolized
7	39	40	O	by
8	42	47	O	CYP2D6
9	48	48	O	,
10	50	59	O	XXXXXXXX
11	61	63	O	may
12	65	77	O	significantly
13	79	85	O	inhibit
14	87	89	O	the
15	91	98	O	activity
16	100	101	O	of
17	103	106	O	this
18	108	114	O	isozyme
NULL

PAROXETINE	3535	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
In most patients (>90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine.
1	0	1	O	In
2	3	6	O	most
3	8	15	O	patients
4	18	21	O	>90%
5	23	23	O	,
6	25	28	O	this
7	30	35	O	CYP2D6
8	37	43	O	isozyme
9	45	46	O	is
10	48	56	O	saturated
11	58	62	O	early
12	64	69	O	during
13	71	76	O	dosing
14	78	81	O	with
15	83	92	O	XXXXXXXX
NULL

PAROXETINE	3536	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	42
In 1 study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T% by an average of approximately 2-, 5-, and 3-fold, respectively.
1	0	1	O	In
2	3	3	O	1
3	5	9	O	study
4	10	10	O	,
5	12	16	O	daily
6	18	23	O	dosing
7	25	26	O	of
8	28	37	O	XXXXXXXX
9	40	41	O	20
10	43	44	O	mg
11	46	49	O	once
12	51	55	O	daily
13	58	62	O	under
14	64	69	O	steady
15	71	75	O	state
16	77	86	O	conditions
17	88	96	O	increased
18	98	103	O	single
19	105	108	O	dose
20	110	120	U-KIN	desipramine
21	123	125	O	100
22	127	128	O	mg
23	131	134	O	Cmax
24	135	135	O	,
25	137	139	O	AUC
26	140	140	O	,
27	142	144	O	and
28	146	147	O	T%
29	149	150	O	by
30	152	153	O	an
31	155	161	O	average
32	163	164	O	of
33	166	178	O	approximately
34	180	180	O	2
35	182	182	O	,
36	184	184	O	5
37	186	186	O	,
38	188	190	O	and
39	192	192	O	3
40	194	197	O	fold
41	198	198	O	,
42	200	211	O	respectively
K/20:C54613

PAROXETINE	3537	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	33	O	with
6	35	45	O	risperidone
7	46	46	O	,
8	48	48	O	a
9	50	55	O	CYP2D6
10	57	65	O	substrate
11	67	69	O	has
12	71	74	O	also
13	76	79	O	been
14	81	89	O	evaluated
NULL

PAROXETINE	3538	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	55
In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.
1	0	1	O	In
2	3	3	O	1
3	5	9	O	study
4	10	10	O	,
5	12	16	O	daily
6	18	23	O	dosing
7	25	26	O	of
8	28	37	O	XXXXXXXX
9	39	40	O	20
10	42	43	O	mg
11	45	46	O	in
12	48	55	O	patients
13	57	66	O	stabilized
14	68	69	O	on
15	71	81	U-KIN	risperidone
16	84	84	O	4
17	86	87	O	to
18	89	89	O	8
19	91	92	O	mg
20	93	93	O	/
21	94	96	O	day
22	99	107	O	increased
23	109	112	O	mean
24	114	119	O	plasma
25	121	134	O	concentrations
26	136	137	O	of
27	139	149	O	risperidone
28	151	163	O	approximately
29	165	165	O	4
30	167	170	O	fold
31	171	171	O	,
32	173	181	O	decreased
33	183	183	O	9
34	185	202	O	hydroxyrisperidone
35	204	217	O	concentrations
36	219	231	O	approximately
37	233	235	O	10%
38	236	236	O	,
39	238	240	O	and
40	242	250	O	increased
41	252	265	O	concentrations
42	267	268	O	of
43	270	272	O	the
44	274	279	O	active
45	281	286	O	moiety
46	289	291	O	the
47	293	295	O	sum
48	297	298	O	of
49	300	310	O	risperidone
50	312	315	O	plus
51	317	317	O	9
52	319	336	O	hydroxyrisperidone
53	339	351	O	approximately
54	353	355	O	1.4
55	357	360	O	fold
K/15:C54357

PAROXETINE	3539	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	30	O	the
7	32	47	O	pharmacokinetics
8	49	50	O	of
9	52	62	O	atomoxetine
10	64	66	O	has
11	68	71	O	been
12	73	81	O	evaluated
13	83	86	O	when
14	88	91	O	both
15	93	97	O	drugs
16	99	102	O	were
17	104	105	O	at
18	107	112	O	steady
19	114	118	O	state
NULL

PAROXETINE	3540	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	22	24	O	who
5	26	29	O	were
6	31	39	O	extensive
7	41	52	O	metabolizers
8	54	55	O	of
9	57	62	O	CYP2D6
10	63	63	O	,
11	65	74	O	XXXXXXXX
12	76	77	O	20
13	79	80	O	mg
14	82	86	O	daily
15	88	90	O	was
16	92	96	O	given
17	98	99	O	in
18	101	111	O	combination
19	113	116	O	with
20	118	119	O	20
21	121	122	O	mg
22	124	134	O	atomoxetine
23	136	140	O	every
24	142	143	O	12
25	145	149	O	hours
NULL

PAROXETINE	3541	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	35
This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.
1	0	3	O	This
2	5	12	O	resulted
3	14	15	O	in
4	17	25	O	increases
5	27	28	O	in
6	30	35	O	steady
7	37	41	O	state
8	43	53	U-KIN	atomoxetine
9	55	57	O	AUC
10	59	64	O	values
11	66	69	O	that
12	71	74	O	were
13	76	76	O	6
14	79	80	O	to
15	82	82	O	8
16	84	87	O	fold
17	89	95	O	greater
18	97	99	O	and
19	101	102	O	in
20	104	114	O	atomoxetine
21	116	119	O	Cmax
22	121	126	O	values
23	128	131	O	that
24	133	136	O	were
25	138	138	O	3
26	141	142	O	to
27	144	144	O	4
28	146	149	O	fold
29	151	157	O	greater
30	159	162	O	than
31	164	167	O	when
32	169	179	O	atomoxetine
33	181	183	O	was
34	185	189	O	given
35	191	195	O	alone
K/8:C54610

PAROXETINE	3542	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	19	O	of
4	21	31	U-KIN	atomoxetine
5	33	35	O	may
6	37	38	O	be
7	40	48	O	necessary
8	50	52	O	and
9	54	55	O	it
10	57	58	O	is
11	60	70	O	recommended
12	72	75	O	that
13	77	87	O	atomoxetine
14	89	90	O	be
15	92	100	O	initiated
16	102	103	O	at
17	105	105	O	a
18	107	113	B-TRI	reduced
19	115	118	L-TRI	dose
20	120	123	O	when
21	125	126	O	it
22	128	129	O	is
23	131	135	O	given
24	137	140	O	with
25	142	151	O	XXXXXXXX
K/4:C54357

PAROXETINE	3543	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	31
Concomitant use of paroxetine with other drugs metabolized by cytochrome CYP2D6 has not been formally studied but may require lower doses than usually prescribed for either paroxetine or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	33	O	with
6	35	39	O	other
7	41	45	B-KIN	drugs
8	47	57	I-KIN	metabolized
9	59	60	I-KIN	by
10	62	71	I-KIN	cytochrome
11	73	78	L-KIN	CYP2D6
12	80	82	O	has
13	84	86	O	not
14	88	91	O	been
15	93	100	O	formally
16	102	108	O	studied
17	110	112	O	but
18	114	116	O	may
19	118	124	O	require
20	126	130	B-TRI	lower
21	132	136	L-TRI	doses
22	138	141	O	than
23	143	149	O	usually
24	151	160	O	prescribed
25	162	164	O	for
26	166	171	O	either
27	173	182	O	XXXXXXXX
28	184	185	O	or
29	187	189	O	the
30	191	195	O	other
31	197	200	O	drug
K/7:C54357

PAROXETINE	3544	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	68
Therefore, coadministration of paroxetine with other drugs that are metabolized by this isozyme, including certain drugs effective in the treatment of major depressive disorder (e.g., nortriptyline, amitriptyline, imipramine, desipramine, and fluoxetine), phenothiazines, risperidone,and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
1	0	8	O	Therefore
2	9	9	O	,
3	11	26	O	coadministration
4	28	29	O	of
5	31	40	O	XXXXXXXX
6	42	45	O	with
7	47	51	O	other
8	53	57	O	drugs
9	59	62	O	that
10	64	66	O	are
11	68	78	O	metabolized
12	80	81	O	by
13	83	86	O	this
14	88	94	O	isozyme
15	95	95	O	,
16	97	105	O	including
17	107	113	O	certain
18	115	119	O	drugs
19	121	129	O	effective
20	131	132	O	in
21	134	136	O	the
22	138	146	O	treatment
23	148	149	O	of
24	151	155	O	major
25	157	166	O	depressive
26	168	175	O	disorder
27	178	180	O	e.g
28	182	182	O	,
29	184	196	U-UNK	nortriptyline
30	197	197	O	,
31	199	211	U-UNK	amitriptyline
32	212	212	O	,
33	214	223	U-UNK	imipramine
34	224	224	O	,
35	226	236	U-UNK	desipramine
36	237	237	O	,
37	239	241	O	and
38	243	252	U-UNK	fluoxetine
39	254	254	O	,
40	256	269	U-UNK	phenothiazines
41	270	270	O	,
42	272	286	O	risperidone,and
43	288	291	B-UNK	Type
44	293	294	I-UNK	1C
45	296	310	L-UNK	antiarrhythmics
46	313	315	O	e.g
47	317	317	O	,
48	319	329	U-UNK	propafenone
49	330	330	O	,
50	332	341	U-UNK	flecainide
51	342	342	O	,
52	344	346	O	and
53	348	356	U-UNK	encainide
54	358	358	O	,
55	360	361	O	or
56	363	366	O	that
57	368	374	O	inhibit
58	376	379	O	this
59	381	386	O	enzyme
60	389	391	O	e.g
61	393	393	O	,
62	395	403	U-UNK	quinidine
63	405	405	O	,
64	407	412	O	should
65	414	415	O	be
66	417	426	O	approached
67	428	431	O	with
68	433	439	U-TRI	caution
NULL

PAROXETINE	3545	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	29
However, due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, paroxetine and thioridazine should not be coadministered.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	due
4	13	14	O	to
5	16	18	O	the
6	20	23	O	risk
7	25	26	O	of
8	28	34	B-EFF	serious
9	36	46	I-EFF	ventricular
10	48	58	L-EFF	arrhythmias
11	60	62	O	and
12	64	69	B-EFF	sudden
13	71	75	L-EFF	death
14	77	87	O	potentially
15	89	98	O	associated
16	100	103	O	with
17	105	112	B-TRI	elevated
18	114	119	I-TRI	plasma
19	121	126	L-TRI	levels
20	128	129	O	of
21	131	142	U-DYN	thioridazine
22	143	143	O	,
23	145	154	O	XXXXXXXX
24	156	158	O	and
25	160	171	O	thioridazine
26	173	178	O	should
27	180	182	O	not
28	184	185	O	be
29	187	200	O	coadministered
D/21:12:1 D/21:8:1

PAROXETINE	3546	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
Tamoxifen is a pro-drug requiring metabolic activation by CYP2D6.
1	0	8	O	Tamoxifen
2	10	11	O	is
3	13	13	O	a
4	15	17	O	pro
5	19	22	O	drug
6	24	32	O	requiring
7	34	42	O	metabolic
8	44	53	O	activation
9	55	56	O	by
10	58	63	O	CYP2D6
NULL

PAROXETINE	3547	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	22
Inhibition of CYP2D6 by paroxetine may lead to reduced plasma concentrations of an active metabolite (endoxifen) and hence reduced efficacy of tamoxifen.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	19	O	CYP2D6
4	21	22	O	by
5	24	33	O	XXXXXXXX
6	35	37	O	may
7	39	42	O	lead
8	44	45	O	to
9	47	53	B-TRI	reduced
10	55	60	I-TRI	plasma
11	62	75	L-TRI	concentrations
12	77	78	O	of
13	80	81	O	an
14	83	88	O	active
15	90	99	O	metabolite
16	102	110	O	endoxifen
17	113	115	O	and
18	117	121	O	hence
19	123	129	O	reduced
20	131	138	O	efficacy
21	140	141	O	of
22	143	151	U-KIN	tamoxifen
K/22:C54358

PAROXETINE	3548	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	30
At steady state, when the CYP2D6 pathway is essentially saturated, paroxetine clearance is governed by alternative P450 isozymes that, unlike CYP2D6, show no evidence of saturation.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	20	O	when
6	22	24	O	the
7	26	31	O	CYP2D6
8	33	39	O	pathway
9	41	42	O	is
10	44	54	O	essentially
11	56	64	O	saturated
12	65	65	O	,
13	67	76	O	XXXXXXXX
14	78	86	O	clearance
15	88	89	O	is
16	91	98	O	governed
17	100	101	O	by
18	103	113	O	alternative
19	115	118	O	P450
20	120	127	O	isozymes
21	129	132	O	that
22	133	133	O	,
23	135	140	O	unlike
24	142	147	O	CYP2D6
25	148	148	O	,
26	150	153	O	show
27	155	156	O	no
28	158	165	O	evidence
29	167	168	O	of
30	170	179	O	saturation
NULL

PAROXETINE	3549	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	31
An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.
1	0	1	O	An
2	3	4	O	in
3	6	9	O	vivo
4	11	21	O	interaction
5	23	27	O	study
6	29	37	O	involving
7	39	41	O	the
8	43	58	O	coadministration
9	60	64	O	under
10	66	71	O	steady
11	73	77	O	state
12	79	88	O	conditions
13	90	91	O	of
14	93	102	O	XXXXXXXX
15	104	106	O	and
16	108	118	O	terfenadine
17	119	119	O	,
18	121	121	O	a
19	123	131	O	substrate
20	133	135	O	for
21	137	146	O	cytochrome
22	148	153	O	CYP3A4
23	154	154	O	,
24	156	163	O	revealed
25	165	166	O	no
26	168	173	O	effect
27	175	176	O	of
28	178	187	O	XXXXXXXX
29	189	190	O	on
30	192	202	O	terfenadine
31	204	219	O	pharmacokinetics
NULL

PAROXETINE	3550	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	51
In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	in
5	16	20	O	vitro
6	22	28	O	studies
7	30	33	O	have
8	35	39	O	shown
9	41	52	O	ketoconazole
10	53	53	O	,
11	55	55	O	a
12	57	62	O	potent
13	64	72	O	inhibitor
14	74	75	O	of
15	77	82	O	CYP3A4
16	84	91	O	activity
17	92	92	O	,
18	94	95	O	to
19	97	98	O	be
20	100	101	O	at
21	103	107	O	least
22	109	111	O	100
23	113	117	O	times
24	119	122	O	more
25	124	129	O	potent
26	131	134	O	than
27	136	145	O	XXXXXXXX
28	147	148	O	as
29	150	151	O	an
30	153	161	O	inhibitor
31	163	164	O	of
32	166	168	O	the
33	170	179	O	metabolism
34	181	182	O	of
35	184	190	O	several
36	192	201	O	substrates
37	203	205	O	for
38	207	210	O	this
39	212	217	O	enzyme
40	218	218	O	,
41	220	228	O	including
42	230	240	O	terfenadine
43	241	241	O	,
44	243	252	O	astemizole
45	253	253	O	,
46	255	263	O	cisapride
47	264	264	O	,
48	266	274	O	triazolam
49	275	275	O	,
50	277	279	O	and
51	281	292	O	cyclosporine
NULL

PAROXETINE	3551	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	47
Based on the assumption that the relationship between paroxetine's in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine's extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	22	O	assumption
5	24	27	O	that
6	29	31	O	the
7	33	44	O	relationship
8	46	52	O	between
9	54	63	O	XXXXXXXX
10	64	65	O	's
11	67	68	O	in
12	70	74	O	vitro
13	76	77	O	Ki
14	79	81	O	and
15	83	85	O	its
16	87	90	O	lack
17	92	93	O	of
18	95	100	O	effect
19	102	103	O	on
20	105	117	O	terfenadine's
21	119	120	O	in
22	122	125	O	vivo
23	127	135	O	clearance
24	137	144	O	predicts
25	146	148	O	its
26	150	155	O	effect
27	157	158	O	on
28	160	164	O	other
29	166	171	O	CYP3A4
30	173	182	O	substrates
31	183	183	O	,
32	185	194	O	XXXXXXXX
33	195	196	O	's
34	198	203	O	extent
35	205	206	O	of
36	208	217	O	inhibition
37	219	220	O	of
38	222	227	O	CYP3A4
39	229	236	O	activity
40	238	239	O	is
41	241	243	O	not
42	245	250	O	likely
43	252	253	O	to
44	255	256	O	be
45	258	259	O	of
46	261	268	O	clinical
47	270	281	O	significance
NULL

PAROXETINE	3552	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
Caution is indicated in the coadministration of tricyclic antidepressants (TCAs) with paroxetine, because paroxetine may inhibit TCA metabolism.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	22	O	in
5	24	26	O	the
6	28	43	O	coadministration
7	45	46	O	of
8	48	56	B-KIN	tricyclic
9	58	72	L-KIN	antidepressants
10	75	78	U-KIN	TCAs
11	81	84	O	with
12	86	95	O	XXXXXXXX
13	96	96	O	,
14	98	104	O	because
15	106	115	O	XXXXXXXX
16	117	119	O	may
17	121	127	O	inhibit
18	129	131	O	TCA
19	133	142	O	metabolism
K/10:C54357 K/8:C54357

PAROXETINE	3553	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	27
Plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced, if a TCA is coadministered with paroxetine.
1	0	5	O	Plasma
2	7	9	U-KIN	TCA
3	11	24	O	concentrations
4	26	28	O	may
5	30	33	O	need
6	35	36	O	to
7	38	39	O	be
8	41	49	O	monitored
9	50	50	O	,
10	52	54	O	and
11	56	58	O	the
12	60	63	O	dose
13	65	66	O	of
14	68	70	O	TCA
15	72	74	O	may
16	76	79	O	need
17	81	82	O	to
18	84	85	O	be
19	87	93	O	reduced
20	94	94	O	,
21	96	97	O	if
22	99	99	O	a
23	101	103	O	TCA
24	105	106	O	is
25	108	121	O	coadministered
26	123	126	O	with
27	128	137	O	XXXXXXXX
K/2:C54357

PAROXETINE	3554	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	38
Because paroxetine is highly bound to plasma protein, administration of paroxetine to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse events.
1	0	6	O	Because
2	8	17	O	XXXXXXXX
3	19	20	O	is
4	22	27	O	highly
5	29	33	O	bound
6	35	36	O	to
7	38	43	O	plasma
8	45	51	O	protein
9	52	52	O	,
10	54	67	O	administration
11	69	70	O	of
12	72	81	O	XXXXXXXX
13	83	84	O	to
14	86	86	O	a
15	88	94	O	patient
16	96	101	O	taking
17	103	109	O	another
18	111	114	B-KIN	drug
19	116	119	I-KIN	that
20	121	122	I-KIN	is
21	124	129	I-KIN	highly
22	131	137	I-KIN	protein
23	139	143	L-KIN	bound
24	145	147	O	may
25	149	153	O	cause
26	155	163	B-TRI	increased
27	165	168	I-TRI	free
28	170	183	I-TRI	concentrations
29	185	186	I-TRI	of
30	188	190	I-TRI	the
31	192	196	I-TRI	other
32	198	201	L-TRI	drug
33	202	202	O	,
34	204	214	O	potentially
35	216	224	O	resulting
36	226	227	O	in
37	229	235	O	adverse
38	237	242	O	events
K/18:C54357

PAROXETINE	3555	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
Conversely, adverse effects could result from displacement of paroxetine by other highly bound drugs.
1	0	9	O	Conversely
2	10	10	O	,
3	12	18	B-TRI	adverse
4	20	26	L-TRI	effects
5	28	32	O	could
6	34	39	O	result
7	41	44	O	from
8	46	57	O	displacement
9	59	60	O	of
10	62	71	O	XXXXXXXX
11	73	74	O	by
12	76	80	O	other
13	82	87	B-UNK	highly
14	89	93	I-UNK	bound
15	95	99	L-UNK	drugs
NULL

PAROXETINE	3556	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

PAROXETINE	3557	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	48
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	O	psychotropic
19	128	132	O	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	B-EFF	upper
30	201	216	I-EFF	gastrointestinal
31	218	225	L-EFF	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-DYN	NSAID
41	275	276	O	or
42	278	284	U-DYN	aspirin
43	286	288	O	may
44	290	299	O	potentiate
45	301	304	O	this
46	306	309	O	risk
47	311	312	O	of
48	314	321	O	bleeding
D/40:29:1 D/42:29:1

PAROXETINE	3558	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	92	O	or
15	94	98	O	SNRIs
16	100	102	O	are
17	104	117	O	coadministered
18	119	122	O	with
19	124	131	U-DYN	warfarin
D/19:1:1 D/19:6:1

PAROXETINE	3559	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
Patients receiving warfarin therapy should be carefully monitored when paroxetine is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	B-TRI	should
6	43	44	I-TRI	be
7	46	54	I-TRI	carefully
8	56	64	L-TRI	monitored
9	66	69	O	when
10	71	80	O	XXXXXXXX
11	82	83	O	is
12	85	93	O	initiated
13	95	96	O	or
14	98	109	O	discontinued
NULL

PAROXETINE	3560	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	26
Although paroxetine does not increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking paroxetine.
1	0	7	O	Although
2	9	18	O	XXXXXXXX
3	20	23	O	does
4	25	27	O	not
5	29	36	O	increase
6	38	40	O	the
7	42	51	O	impairment
8	53	54	O	of
9	56	61	O	mental
10	63	65	O	and
11	67	71	O	motor
12	73	78	O	skills
13	80	85	O	caused
14	87	88	O	by
15	90	96	U-UNK	alcohol
16	97	97	O	,
17	99	106	O	patients
18	108	113	O	should
19	115	116	O	be
20	118	124	O	advised
21	126	127	O	to
22	129	133	U-TRI	avoid
23	135	141	O	alcohol
24	143	147	O	while
25	149	154	O	taking
26	156	165	O	XXXXXXXX
NULL

PAROXETINE	3561	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
A multiple-dose study has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.
1	0	0	O	A
2	2	9	O	multiple
3	11	14	O	dose
4	16	20	O	study
5	22	24	O	has
6	26	30	O	shown
7	32	35	O	that
8	37	41	O	there
9	43	44	O	is
10	46	47	O	no
11	49	63	O	pharmacokinetic
12	65	75	O	interaction
13	77	83	O	between
14	85	94	O	XXXXXXXX
15	96	98	O	and
16	100	106	O	lithium
17	108	116	O	carbonate
NULL

PAROXETINE	3562	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
However, due to the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with lithium.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	due
4	13	14	O	to
5	16	18	O	the
6	20	28	O	potential
7	30	32	O	for
8	34	42	B-EFF	serotonin
9	44	51	L-EFF	syndrome
10	52	52	O	,
11	54	60	O	caution
12	62	63	O	is
13	65	71	O	advised
14	73	76	O	when
15	78	87	O	XXXXXXXX
16	89	90	O	is
17	92	105	O	coadministered
18	107	110	O	with
19	112	118	U-DYN	lithium
D/19:8:1

PAROXETINE	3563	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	16
The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	32	O	pharmacokinetics
5	34	35	O	of
6	37	46	O	XXXXXXXX
7	48	50	O	was
8	52	54	O	not
9	56	62	O	altered
10	64	67	O	when
11	69	80	O	administered
12	82	85	O	with
13	87	93	O	digoxin
14	95	96	O	at
15	98	103	O	steady
16	105	109	O	state
NULL

PAROXETINE	3564	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine.
1	0	3	O	Mean
2	5	11	U-KIN	digoxin
3	13	15	O	AUC
4	17	18	O	at
5	20	25	O	steady
6	27	31	O	state
7	33	41	O	decreased
8	43	44	O	by
9	46	48	O	15%
10	50	51	O	in
11	53	55	O	the
12	57	64	O	presence
13	66	67	O	of
14	69	78	O	XXXXXXXX
K/2:C54614

PAROXETINE	3565	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.
1	0	4	O	Since
2	6	10	O	there
3	12	13	O	is
4	15	20	O	little
5	22	29	O	clinical
6	31	40	O	experience
7	41	41	O	,
8	43	45	O	the
9	47	56	O	concurrent
10	58	71	O	administration
11	73	74	O	of
12	76	85	O	XXXXXXXX
13	87	89	O	and
14	91	97	U-UNK	digoxin
15	99	104	O	should
16	106	107	O	be
17	109	118	O	undertaken
18	120	123	O	with
19	125	131	U-TRI	caution
NULL

PAROXETINE	3566	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	13
Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics.
1	0	4	O	Under
2	6	11	O	steady
3	13	17	O	state
4	19	28	O	conditions
5	29	29	O	,
6	31	38	O	diazepam
7	40	43	O	does
8	45	47	O	not
9	49	54	O	appear
10	56	57	O	to
11	59	64	O	affect
12	66	75	O	XXXXXXXX
13	77	84	O	kinetics
NULL

PAROXETINE	3567	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	9
The effects of paroxetine on diazepam were not evaluated.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	24	O	XXXXXXXX
5	26	27	O	on
6	29	36	O	diazepam
7	38	41	O	were
8	43	45	O	not
9	47	55	O	evaluated
NULL

PAROXETINE	3568	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	41
Daily oral dosing of paroxetine (30mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5mg oral once daily) by 35%, 37% and 67%, respectively, compared to procyclidine alone at steady state.
1	0	4	O	Daily
2	6	9	O	oral
3	11	16	O	dosing
4	18	19	O	of
5	21	30	O	XXXXXXXX
6	33	36	O	30mg
7	38	41	O	once
8	43	47	O	daily
9	50	58	O	increased
10	60	65	O	steady
11	67	71	O	state
12	73	76	O	AUC0
13	78	79	O	24
14	80	80	O	,
15	82	85	O	Cmax
16	86	86	O	,
17	88	90	O	and
18	92	95	O	Cmin
19	97	102	O	values
20	104	105	O	of
21	107	118	U-KIN	procyclidine
22	121	123	O	5mg
23	125	128	O	oral
24	130	133	O	once
25	135	139	O	daily
26	142	143	O	by
27	145	147	O	35%
28	148	148	O	,
29	150	152	O	37%
30	154	156	O	and
31	158	160	O	67%
32	161	161	O	,
33	163	174	O	respectively
34	175	175	O	,
35	177	184	O	compared
36	186	187	O	to
37	189	200	O	procyclidine
38	202	206	O	alone
39	208	209	O	at
40	211	216	O	steady
41	218	222	O	state
K/21:C54610

PAROXETINE	3569	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	13
If anticholinergic effects are seen, the dose of procyclidine should be reduced.
1	0	1	O	If
2	3	17	B-EFF	anticholinergic
3	19	25	L-EFF	effects
4	27	29	O	are
5	31	34	O	seen
6	35	35	O	,
7	37	39	O	the
8	41	44	O	dose
9	46	47	O	of
10	49	60	U-DYN	procyclidine
11	62	67	O	should
12	69	70	O	be
13	72	78	O	reduced
D/10:2:1

PAROXETINE	3570	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	35
In a study where propranolol (80mg twice daily) was dosed orally for 18days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with paroxetine (30mg once daily) for the final 10days.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	15	O	where
5	17	27	O	propranolol
6	30	33	O	80mg
7	35	39	O	twice
8	41	45	O	daily
9	48	50	O	was
10	52	56	O	dosed
11	58	63	O	orally
12	65	67	O	for
13	69	74	O	18days
14	75	75	O	,
15	77	79	O	the
16	81	91	O	established
17	93	98	O	steady
18	100	104	O	state
19	106	111	O	plasma
20	113	126	O	concentrations
21	128	129	O	of
22	131	141	O	propranolol
23	143	146	O	were
24	148	156	O	unaltered
25	158	163	O	during
26	165	180	O	coadministration
27	182	185	O	with
28	187	196	O	XXXXXXXX
29	199	202	O	30mg
30	204	207	O	once
31	209	213	O	daily
32	216	218	O	for
33	220	222	O	the
34	224	228	O	final
35	230	235	O	10days
NULL

PAROXETINE	3571	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
The effects of propranolol on paroxetine have not been evaluated.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	O	propranolol
5	27	28	O	on
6	30	39	O	XXXXXXXX
7	41	44	O	have
8	46	48	O	not
9	50	53	O	been
10	55	63	O	evaluated
NULL

PAROXETINE	3572	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	13
Reports of elevated theophylline levels associated with treatment with paroxetine have been reported.
1	0	6	O	Reports
2	8	9	O	of
3	11	18	O	elevated
4	20	31	U-KIN	theophylline
5	33	38	O	levels
6	40	49	O	associated
7	51	54	O	with
8	56	64	O	treatment
9	66	69	O	with
10	71	80	O	XXXXXXXX
11	82	85	O	have
12	87	90	O	been
13	92	99	O	reported
K/4:C54357

PAROXETINE	3573	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	23
While this interaction has not been formally studied, it is recommended that theophylline levels be monitored when these drugs are concurrently administered.
1	0	4	O	While
2	6	9	O	this
3	11	21	U-TRI	interaction
4	23	25	O	has
5	27	29	O	not
6	31	34	O	been
7	36	43	O	formally
8	45	51	O	studied
9	52	52	O	,
10	54	55	O	it
11	57	58	O	is
12	60	70	O	recommended
13	72	75	O	that
14	77	88	U-UNK	theophylline
15	90	95	O	levels
16	97	98	O	be
17	100	108	O	monitored
18	110	113	O	when
19	115	119	O	these
20	121	125	O	drugs
21	127	129	O	are
22	131	142	O	concurrently
23	144	155	O	administered
NULL

PAROXETINE	3574	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
Co-administration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.
1	0	1	O	Co
2	3	16	O	administration
3	18	19	O	of
4	21	33	B-KIN	fosamprenavir
5	34	34	I-KIN	/
6	35	43	L-KIN	ritonavir
7	45	48	O	with
8	50	59	O	XXXXXXXX
9	61	73	O	significantly
10	75	83	B-TRI	decreased
11	85	90	I-TRI	plasma
12	92	97	L-TRI	levels
13	99	100	O	of
14	102	111	O	XXXXXXXX
K/4:C54356

PAROXETINE	3575	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	12
Any dose adjustment should be guided by clinical effect (tolerability and efficacy).
1	0	2	O	Any
2	4	7	O	dose
3	9	18	O	adjustment
4	20	25	O	should
5	27	28	O	be
6	30	35	O	guided
7	37	38	O	by
8	40	47	O	clinical
9	49	54	O	effect
10	57	68	O	tolerability
11	70	72	O	and
12	74	81	O	efficacy
NULL

PAROXETINE	3576	34073-7	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	13
There are no clinical studies of the combined use of ECT and paroxetine.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	20	O	clinical
5	22	28	O	studies
6	30	31	O	of
7	33	35	O	the
8	37	44	O	combined
9	46	48	O	use
10	50	51	O	of
11	53	55	O	ECT
12	57	59	O	and
13	61	70	O	XXXXXXXX
NULL

PAROXETINE	3577	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	58
The efficacy of paroxetine in the treatment of major depressive disorder, social anxiety disorder, obsessive compulsive disorder (OCD), panic disorder (PD), generalized anxiety disorder (GAD) is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-hydroxy-tryptamine, 5-HT).
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	25	O	XXXXXXXX
5	27	28	O	in
6	30	32	O	the
7	34	42	O	treatment
8	44	45	O	of
9	47	51	O	major
10	53	62	O	depressive
11	64	71	O	disorder
12	72	72	O	,
13	74	79	O	social
14	81	87	O	anxiety
15	89	96	O	disorder
16	97	97	O	,
17	99	107	O	obsessive
18	109	118	O	compulsive
19	120	127	O	disorder
20	130	132	O	OCD
21	134	134	O	,
22	136	140	O	panic
23	142	149	O	disorder
24	152	153	O	PD
25	155	155	O	,
26	157	167	O	generalized
27	169	175	O	anxiety
28	177	184	O	disorder
29	187	189	O	GAD
30	192	193	O	is
31	195	202	O	presumed
32	204	205	O	to
33	207	208	O	be
34	210	215	O	linked
35	217	218	O	to
36	220	231	O	potentiation
37	233	234	O	of
38	236	247	O	serotonergic
39	249	256	O	activity
40	258	259	O	in
41	261	263	O	the
42	265	271	O	central
43	273	279	O	nervous
44	281	286	O	system
45	288	296	O	resulting
46	298	301	O	from
47	303	312	O	inhibition
48	314	315	O	of
49	317	324	O	neuronal
50	326	333	O	reuptake
51	335	336	O	of
52	338	346	O	serotonin
53	349	349	O	5
54	351	357	O	hydroxy
55	359	368	O	tryptamine
56	369	369	O	,
57	371	371	O	5
58	373	374	O	HT
NULL

PAROXETINE	3578	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
Studies at clinically relevant doses in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets.
1	0	6	O	Studies
2	8	9	O	at
3	11	20	O	clinically
4	22	29	O	relevant
5	31	35	O	doses
6	37	38	O	in
7	40	45	O	humans
8	47	50	O	have
9	52	63	O	demonstrated
10	65	68	O	that
11	70	79	O	XXXXXXXX
12	81	86	O	blocks
13	88	90	O	the
14	92	97	O	uptake
15	99	100	O	of
16	102	110	O	serotonin
17	112	115	O	into
18	117	121	O	human
19	123	131	O	platelets
NULL

PAROXETINE	3579	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	32
In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	26	O	animals
6	28	31	O	also
7	33	39	O	suggest
8	41	44	O	that
9	46	55	O	XXXXXXXX
10	57	58	O	is
11	60	60	O	a
12	62	67	O	potent
13	69	71	O	and
14	73	78	O	highly
15	80	88	O	selective
16	90	98	O	inhibitor
17	100	101	O	of
18	103	110	O	neuronal
19	112	120	O	serotonin
20	122	129	O	reuptake
21	131	133	O	and
22	135	137	O	has
23	139	142	O	only
24	144	147	O	very
25	149	152	O	weak
26	154	160	O	effects
27	162	163	O	on
28	165	178	O	norepinephrine
29	180	182	O	and
30	184	191	O	dopamine
31	193	200	O	neuronal
32	202	209	O	reuptake
NULL

PAROXETINE	3580	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	60
In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic, alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors; antagonism of muscarinic, histaminergic, and alpha1-adrenergic receptors has been associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs.
1	0	1	O	In
2	3	7	O	vitro
3	9	19	O	radioligand
4	21	27	O	binding
5	29	35	O	studies
6	37	44	O	indicate
7	46	49	O	that
8	51	60	O	XXXXXXXX
9	62	64	O	has
10	66	71	O	little
11	73	80	O	affinity
12	82	84	O	for
13	86	95	O	muscarinic
14	96	96	O	,
15	98	103	O	alpha1
16	105	105	O	,
17	107	112	O	alpha2
18	114	114	O	,
19	116	119	O	beta
20	121	130	O	adrenergic
21	132	132	O	,
22	134	141	O	dopamine
23	144	145	O	D2
24	148	148	O	,
25	150	150	O	5
26	152	154	O	HT1
27	156	156	O	,
28	158	158	O	5
29	160	162	O	HT2
30	164	164	O	,
31	166	168	O	and
32	170	178	O	histamine
33	181	182	O	H1
34	185	193	O	receptors
35	196	205	O	antagonism
36	207	208	O	of
37	210	219	O	muscarinic
38	220	220	O	,
39	222	234	O	histaminergic
40	235	235	O	,
41	237	239	O	and
42	241	246	O	alpha1
43	248	257	O	adrenergic
44	259	267	O	receptors
45	269	271	O	has
46	273	276	O	been
47	278	287	O	associated
48	289	292	O	with
49	294	300	O	various
50	302	316	O	anticholinergic
51	317	317	O	,
52	319	326	O	sedative
53	327	327	O	,
54	329	331	O	and
55	333	346	O	cardiovascular
56	348	354	O	effects
57	356	358	O	for
58	360	364	O	other
59	366	377	O	psychotropic
60	379	383	O	drugs
NULL

PAROXETINE	3581	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
Because the relative potencies of paroxetine's major metabolites are at most 1/50 of the parent compound, they are essentially inactive.
1	0	6	O	Because
2	8	10	O	the
3	12	19	O	relative
4	21	29	O	potencies
5	31	32	O	of
6	34	43	O	XXXXXXXX
7	44	45	O	's
8	47	51	O	major
9	53	63	O	metabolites
10	65	67	O	are
11	69	70	O	at
12	72	75	O	most
13	77	77	O	1
14	78	78	O	/
15	79	80	O	50
16	82	83	O	of
17	85	87	O	the
18	89	94	O	parent
19	96	103	O	compound
20	104	104	O	,
21	106	109	O	they
22	111	113	O	are
23	115	125	O	essentially
24	127	134	O	inactive
NULL

PAROXETINE	3582	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
Paroxetine hydrochloride is completely absorbed after oral dosing of a solution of the hydrochloride salt.
1	0	9	O	XXXXXXXX
2	11	23	O	hydrochloride
3	25	26	O	is
4	28	37	O	completely
5	39	46	O	absorbed
6	48	52	O	after
7	54	57	O	oral
8	59	64	O	dosing
9	66	67	O	of
10	69	69	O	a
11	71	78	O	solution
12	80	81	O	of
13	83	85	O	the
14	87	99	O	hydrochloride
15	101	104	O	salt
NULL

PAROXETINE	3583	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	is
7	34	46	O	approximately
8	48	49	O	21
9	51	55	O	hours
10	58	59	O	CV
11	61	63	O	32%
12	66	70	O	after
13	72	75	O	oral
14	77	82	O	dosing
15	84	85	O	of
16	87	88	O	30
17	90	91	O	mg
18	93	99	O	tablets
19	101	102	O	of
20	104	113	O	XXXXXXXX
21	115	119	O	daily
22	121	123	O	for
23	125	126	O	30
24	128	131	O	days
NULL

PAROXETINE	3584	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	12
Paroxetine is extensively metabolized and the metabolites are considered to be inactive.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	40	O	and
6	42	44	O	the
7	46	56	O	metabolites
8	58	60	O	are
9	62	71	O	considered
10	73	74	O	to
11	76	77	O	be
12	79	86	O	inactive
NULL

PAROXETINE	3585	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	8
Nonlinearity in pharmacokinetics is observed with increasing doses.
1	0	11	O	Nonlinearity
2	13	14	O	in
3	16	31	O	pharmacokinetics
4	33	34	O	is
5	36	43	O	observed
6	45	48	O	with
7	50	59	O	increasing
8	61	65	O	doses
NULL

PAROXETINE	3586	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
Paroxetine metabolism is mediated in part by CYP2D6, and the metabolites are primarily excreted in the urine and to some extent in the feces.
1	0	9	O	XXXXXXXX
2	11	20	O	metabolism
3	22	23	O	is
4	25	32	O	mediated
5	34	35	O	in
6	37	40	O	part
7	42	43	O	by
8	45	50	O	CYP2D6
9	51	51	O	,
10	53	55	O	and
11	57	59	O	the
12	61	71	O	metabolites
13	73	75	O	are
14	77	85	O	primarily
15	87	94	O	excreted
16	96	97	O	in
17	99	101	O	the
18	103	107	O	urine
19	109	111	O	and
20	113	114	O	to
21	116	119	O	some
22	121	126	O	extent
23	128	129	O	in
24	131	133	O	the
25	135	139	O	feces
NULL

PAROXETINE	3587	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
Pharmacokinetic behavior of paroxetine has not been evaluated in subjects who are deficient in CYP2D6 (poor metabolizers).
1	0	14	O	Pharmacokinetic
2	16	23	O	behavior
3	25	26	O	of
4	28	37	O	XXXXXXXX
5	39	41	O	has
6	43	45	O	not
7	47	50	O	been
8	52	60	O	evaluated
9	62	63	O	in
10	65	72	O	subjects
11	74	76	O	who
12	78	80	O	are
13	82	90	O	deficient
14	92	93	O	in
15	95	100	O	CYP2D6
16	103	106	O	poor
17	108	119	O	metabolizers
NULL

PAROXETINE	3588	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	39
In a meta-analysis of paroxetine from 4 studies done in healthy volunteers following multiple dosing of 20 mg/day to 40 mg/day, males did not exhibit a significantly lower Cmax or AUC than females.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	meta
4	10	17	O	analysis
5	19	20	O	of
6	22	31	O	XXXXXXXX
7	33	36	O	from
8	38	38	O	4
9	40	46	O	studies
10	48	51	O	done
11	53	54	O	in
12	56	62	O	healthy
13	64	73	O	volunteers
14	75	83	O	following
15	85	92	O	multiple
16	94	99	O	dosing
17	101	102	O	of
18	104	105	O	20
19	107	108	O	mg
20	109	109	O	/
21	110	112	O	day
22	114	115	O	to
23	117	118	O	40
24	120	121	O	mg
25	122	122	O	/
26	123	125	O	day
27	126	126	O	,
28	128	132	O	males
29	134	136	O	did
30	138	140	O	not
31	142	148	O	exhibit
32	150	150	O	a
33	152	164	O	significantly
34	166	170	O	lower
35	172	175	O	Cmax
36	177	178	O	or
37	180	182	O	AUC
38	184	187	O	than
39	189	195	O	females
NULL

PAROXETINE	3589	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
Paroxetine is equally bioavailable from the oral suspension and tablet.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	20	O	equally
4	22	33	O	bioavailable
5	35	38	O	from
6	40	42	O	the
7	44	47	O	oral
8	49	58	O	suspension
9	60	62	O	and
10	64	69	O	tablet
NULL

PAROXETINE	3591	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	44
In a study in which normal male subjects (n = 15) received 30 mg tablets daily for 30 days, steady-state paroxetine concentrations were achieved by approximately 10 days for most subjects, although it may take substantially longer in an occasional patient.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	18	O	which
6	20	25	O	normal
7	27	30	O	male
8	32	39	O	subjects
9	42	42	O	n
10	44	44	O	=
11	46	47	O	15
12	50	57	O	received
13	59	60	O	30
14	62	63	O	mg
15	65	71	O	tablets
16	73	77	O	daily
17	79	81	O	for
18	83	84	O	30
19	86	89	O	days
20	90	90	O	,
21	92	97	O	steady
22	99	103	O	state
23	105	114	O	XXXXXXXX
24	116	129	O	concentrations
25	131	134	O	were
26	136	143	O	achieved
27	145	146	O	by
28	148	160	O	approximately
29	162	163	O	10
30	165	168	O	days
31	170	172	O	for
32	174	177	O	most
33	179	186	O	subjects
34	187	187	O	,
35	189	196	O	although
36	198	199	O	it
37	201	203	O	may
38	205	208	O	take
39	210	222	O	substantially
40	224	229	O	longer
41	231	232	O	in
42	234	235	O	an
43	237	246	O	occasional
44	248	254	O	patient
NULL

PAROXETINE	3592	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
At steady state, mean values of Cmax, Tmax, Cmin, and T% were 61.7 ng/mL (CV 45%), 5.2 hr.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	20	O	mean
6	22	27	O	values
7	29	30	O	of
8	32	35	O	Cmax
9	36	36	O	,
10	38	41	O	Tmax
11	42	42	O	,
12	44	47	O	Cmin
13	48	48	O	,
14	50	52	O	and
15	54	55	O	T%
16	57	60	O	were
17	62	65	O	61.7
18	67	68	O	ng
19	69	69	O	/
20	70	71	O	mL
21	74	75	O	CV
22	77	79	O	45%
23	81	81	O	,
24	83	85	O	5.2
25	87	88	O	hr
NULL

PAROXETINE	3593	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
(CV 10%), 30.7 ng/mL (CV 67%), and 21 hours (CV 32%), respectively.
1	1	2	O	CV
2	4	6	O	10%
3	8	8	O	,
4	10	13	O	30.7
5	15	16	O	ng
6	17	17	O	/
7	18	19	O	mL
8	22	23	O	CV
9	25	27	O	67%
10	29	29	O	,
11	31	33	O	and
12	35	36	O	21
13	38	42	O	hours
14	45	46	O	CV
15	48	50	O	32%
16	52	52	O	,
17	54	65	O	respectively
NULL

PAROXETINE	3594	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
The steady-state Cmax and Cmin values were about 6 and 14 times what would be predicted from single-dose studies.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	20	O	Cmax
5	22	24	O	and
6	26	29	O	Cmin
7	31	36	O	values
8	38	41	O	were
9	43	47	O	about
10	49	49	O	6
11	51	53	O	and
12	55	56	O	14
13	58	62	O	times
14	64	67	O	what
15	69	73	O	would
16	75	76	O	be
17	78	86	O	predicted
18	88	91	O	from
19	93	98	O	single
20	100	103	O	dose
21	105	111	O	studies
NULL

PAROXETINE	3595	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
Steady-state drug exposure based on AUC0-24 was about 8 times greater than would have been predicted from single-dose data in these subjects.
1	0	5	O	Steady
2	7	11	O	state
3	13	16	O	drug
4	18	25	O	exposure
5	27	31	O	based
6	33	34	O	on
7	36	39	O	AUC0
8	41	42	O	24
9	44	46	O	was
10	48	52	O	about
11	54	54	O	8
12	56	60	O	times
13	62	68	O	greater
14	70	73	O	than
15	75	79	O	would
16	81	84	O	have
17	86	89	O	been
18	91	99	O	predicted
19	101	104	O	from
20	106	111	O	single
21	113	116	O	dose
22	118	121	O	data
23	123	124	O	in
24	126	130	O	these
25	132	139	O	subjects
NULL

PAROXETINE	3596	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	20
The excess accumulation is a consequence of the fact that 1 of the enzymes that metabolizes paroxetine is readily saturable.
1	0	2	O	The
2	4	9	O	excess
3	11	22	O	accumulation
4	24	25	O	is
5	27	27	O	a
6	29	39	O	consequence
7	41	42	O	of
8	44	46	O	the
9	48	51	O	fact
10	53	56	O	that
11	58	58	O	1
12	60	61	O	of
13	63	65	O	the
14	67	73	O	enzymes
15	75	78	O	that
16	80	90	O	metabolizes
17	92	101	O	XXXXXXXX
18	103	104	O	is
19	106	112	O	readily
20	114	122	O	saturable
NULL

PAROXETINE	3597	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
The effects of food on the bioavailability of paroxetine were studied in subjects administered a single dose with and without food.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	18	O	food
5	20	21	O	on
6	23	25	O	the
7	27	41	O	bioavailability
8	43	44	O	of
9	46	55	O	XXXXXXXX
10	57	60	O	were
11	62	68	O	studied
12	70	71	O	in
13	73	80	O	subjects
14	82	93	O	administered
15	95	95	O	a
16	97	102	O	single
17	104	107	O	dose
18	109	112	O	with
19	114	116	O	and
20	118	124	O	without
21	126	129	O	food
NULL

PAROXETINE	3598	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	36
AUC was only slightly increased (6%) when drug was administered with food but the Cmax was 29% greater, while the time to reach peak plasma concentration decreased from 6.4 hours post-dosing to 4.9 hours.
1	0	2	O	AUC
2	4	6	O	was
3	8	11	O	only
4	13	20	O	slightly
5	22	30	O	increased
6	33	34	O	6%
7	37	40	O	when
8	42	45	O	drug
9	47	49	O	was
10	51	62	O	administered
11	64	67	O	with
12	69	72	U-KIN	food
13	74	76	O	but
14	78	80	O	the
15	82	85	O	Cmax
16	87	89	O	was
17	91	93	O	29%
18	95	101	O	greater
19	102	102	O	,
20	104	108	O	while
21	110	112	O	the
22	114	117	B-TRI	time
23	119	120	I-TRI	to
24	122	126	I-TRI	reach
25	128	131	I-TRI	peak
26	133	138	I-TRI	plasma
27	140	152	I-TRI	concentration
28	154	162	L-TRI	decreased
29	164	167	O	from
30	169	171	O	6.4
31	173	177	O	hours
32	179	182	O	post
33	184	189	O	dosing
34	191	192	O	to
35	194	196	O	4.9
36	198	202	O	hours
K/12:C54608

PAROXETINE	3599	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
Paroxetine distributes throughout the body, including the CNS, with only 1% remaining in the plasma.
1	0	9	O	XXXXXXXX
2	11	21	O	distributes
3	23	32	O	throughout
4	34	36	O	the
5	38	41	O	body
6	42	42	O	,
7	44	52	O	including
8	54	56	O	the
9	58	60	O	CNS
10	61	61	O	,
11	63	66	O	with
12	68	71	O	only
13	73	74	O	1%
14	76	84	O	remaining
15	86	87	O	in
16	89	91	O	the
17	93	98	O	plasma
NULL

PAROXETINE	3600	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	23
Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively.
1	0	12	O	Approximately
2	14	16	O	95%
3	18	20	O	and
4	22	24	O	93%
5	26	27	O	of
6	29	38	O	XXXXXXXX
7	40	41	O	is
8	43	47	O	bound
9	49	50	O	to
10	52	57	O	plasma
11	59	65	O	protein
12	67	68	O	at
13	70	72	O	100
14	74	75	O	ng
15	76	76	O	/
16	77	78	O	mL
17	80	82	O	and
18	84	86	O	400
19	88	89	O	ng
20	90	90	O	/
21	91	92	O	mL
22	93	93	O	,
23	95	106	O	respectively
NULL

PAROXETINE	3601	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL.
1	0	4	O	Under
2	6	13	O	clinical
3	15	24	O	conditions
4	25	25	O	,
5	27	36	O	XXXXXXXX
6	38	51	O	concentrations
7	53	57	O	would
8	59	66	O	normally
9	68	69	O	be
10	71	74	O	less
11	76	79	O	than
12	81	83	O	400
13	85	86	O	ng
14	87	87	O	/
15	88	89	O	mL
NULL

PAROXETINE	3602	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	13
Paroxetine does not alter the in vitro protein binding of phenytoin or warfarin.
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	24	O	alter
5	26	28	O	the
6	30	31	O	in
7	33	37	O	vitro
8	39	45	O	protein
9	47	53	O	binding
10	55	56	O	of
11	58	66	O	phenytoin
12	68	69	O	or
13	71	78	O	warfarin
NULL

PAROXETINE	3603	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
The mean elimination half-life is approximately 21hours (CV32%) after oral dosing of 30mg tablets daily for 30days of Paroxetinehydrochloride.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	is
7	34	46	O	approximately
8	48	54	O	21hours
9	57	61	O	CV32%
10	64	68	O	after
11	70	73	O	oral
12	75	80	O	dosing
13	82	83	O	of
14	85	88	O	30mg
15	90	96	O	tablets
16	98	102	O	daily
17	104	106	O	for
18	108	113	O	30days
19	115	116	O	of
20	118	127	O	XXXXXXXX
21	128	140	O	hydrochloride
NULL

PAROXETINE	3604	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	49
In steady-state dose proportionality studies involving elderly and nonelderly patients, at doses of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, again reflecting a saturable metabolic pathway.
1	0	1	O	In
2	3	8	O	steady
3	10	14	O	state
4	16	19	O	dose
5	21	35	O	proportionality
6	37	43	O	studies
7	45	53	O	involving
8	55	61	O	elderly
9	63	65	O	and
10	67	76	O	nonelderly
11	78	85	O	patients
12	86	86	O	,
13	88	89	O	at
14	91	95	O	doses
15	97	98	O	of
16	100	101	O	20
17	103	104	O	mg
18	106	107	O	to
19	109	110	O	40
20	112	113	O	mg
21	115	119	O	daily
22	121	123	O	for
23	125	127	O	the
24	129	135	O	elderly
25	137	139	O	and
26	141	142	O	20
27	144	145	O	mg
28	147	148	O	to
29	150	151	O	50
30	153	154	O	mg
31	156	160	O	daily
32	162	164	O	for
33	166	168	O	the
34	170	179	O	nonelderly
35	180	180	O	,
36	182	185	O	some
37	187	198	O	nonlinearity
38	200	202	O	was
39	204	211	O	observed
40	213	214	O	in
41	216	219	O	both
42	221	231	O	populations
43	232	232	O	,
44	234	238	O	again
45	240	249	O	reflecting
46	251	251	O	a
47	253	261	O	saturable
48	263	271	O	metabolic
49	273	279	O	pathway
NULL

PAROXETINE	3605	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
In comparison to Cmin values after 20 mg daily, values after 40 mg daily were only about 2 to 3 times greater than doubled.
1	0	1	O	In
2	3	12	O	comparison
3	14	15	O	to
4	17	20	O	Cmin
5	22	27	O	values
6	29	33	O	after
7	35	36	O	20
8	38	39	O	mg
9	41	45	O	daily
10	46	46	O	,
11	48	53	O	values
12	55	59	O	after
13	61	62	O	40
14	64	65	O	mg
15	67	71	O	daily
16	73	76	O	were
17	78	81	O	only
18	83	87	O	about
19	89	89	O	2
20	91	92	O	to
21	94	94	O	3
22	96	100	O	times
23	102	108	O	greater
24	110	113	O	than
25	115	121	O	doubled
NULL

PAROXETINE	3606	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	7
Paroxetine is extensively metabolized after oral administration.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	42	O	after
6	44	47	O	oral
7	49	62	O	administration
NULL

PAROXETINE	3607	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared.
1	0	2	O	The
2	4	12	O	principal
3	14	24	O	metabolites
4	26	28	O	are
5	30	34	O	polar
6	36	38	O	and
7	40	49	O	conjugated
8	51	58	O	products
9	60	61	O	of
10	63	71	O	oxidation
11	73	75	O	and
12	77	87	O	methylation
13	88	88	O	,
14	90	94	O	which
15	96	98	O	are
16	100	106	O	readily
17	108	114	O	cleared
NULL

PAROXETINE	3608	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	16
Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified.
1	0	9	O	Conjugates
2	11	14	O	with
3	16	25	O	glucuronic
4	27	30	O	acid
5	32	34	O	and
6	36	42	O	sulfate
7	44	54	O	predominate
8	55	55	O	,
9	57	59	O	and
10	61	65	O	major
11	67	77	O	metabolites
12	79	82	O	have
13	84	87	O	been
14	89	96	O	isolated
15	98	100	O	and
16	102	111	O	identified
NULL

PAROXETINE	3609	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	22
Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake.
1	0	3	O	Data
2	5	12	O	indicate
3	14	17	O	that
4	19	21	O	the
5	23	33	O	metabolites
6	35	38	O	have
7	40	41	O	no
8	43	46	O	more
9	48	51	O	than
10	53	53	O	1
11	54	54	O	/
12	55	56	O	50
13	58	60	O	the
14	62	68	O	potency
15	70	71	O	of
16	73	75	O	the
17	77	82	O	parent
18	84	91	O	compound
19	93	94	O	at
20	96	105	O	inhibiting
21	107	115	O	serotonin
22	117	122	O	uptake
NULL

PAROXETINE	3610	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
The metabolism of paroxetine is accomplished in part by CYP2D6.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	27	O	XXXXXXXX
5	29	30	O	is
6	32	43	O	accomplished
7	45	46	O	in
8	48	51	O	part
9	53	54	O	by
10	56	61	O	CYP2D6
NULL

PAROXETINE	3611	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment.
1	0	9	O	Saturation
2	11	12	O	of
3	14	17	O	this
4	19	24	O	enzyme
5	26	27	O	at
6	29	36	O	clinical
7	38	42	O	doses
8	44	50	O	appears
9	52	53	O	to
10	55	61	O	account
11	63	65	O	for
12	67	69	O	the
13	71	82	O	nonlinearity
14	84	85	O	of
15	87	96	O	XXXXXXXX
16	98	105	O	kinetics
17	107	110	O	with
18	112	121	O	increasing
19	123	126	O	dose
20	128	130	O	and
21	132	141	O	increasing
22	143	150	O	duration
23	152	153	O	of
24	155	163	O	treatment
NULL

PAROXETINE	3612	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions.
1	0	2	O	The
2	4	7	O	role
3	9	10	O	of
4	12	15	O	this
5	17	22	O	enzyme
6	24	25	O	in
7	27	36	O	XXXXXXXX
8	38	47	O	metabolism
9	49	52	O	also
10	54	61	O	suggests
11	63	71	O	potential
12	73	76	O	drug
13	78	81	O	drug
14	83	94	O	interactions
NULL

PAROXETINE	3613	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	33
Approximately 64% of a 30-mg oral solution dose of paroxetine was excreted in the urine with 2% as the parent compound and 62% as metabolites over a 10-day post-dosing period.
1	0	12	O	Approximately
2	14	16	O	64%
3	18	19	O	of
4	21	21	O	a
5	23	24	O	30
6	26	27	O	mg
7	29	32	O	oral
8	34	41	O	solution
9	43	46	O	dose
10	48	49	O	of
11	51	60	O	XXXXXXXX
12	62	64	O	was
13	66	73	O	excreted
14	75	76	O	in
15	78	80	O	the
16	82	86	O	urine
17	88	91	O	with
18	93	94	O	2%
19	96	97	O	as
20	99	101	O	the
21	103	108	O	parent
22	110	117	O	compound
23	119	121	O	and
24	123	125	O	62%
25	127	128	O	as
26	130	140	O	metabolites
27	142	145	O	over
28	147	147	O	a
29	149	150	O	10
30	152	154	O	day
31	156	159	O	post
32	161	166	O	dosing
33	168	173	O	period
NULL

PAROXETINE	3614	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	30
About 36% was excreted in the feces (probably via the bile), mostly as metabolites and less than 1% as the parent compound over the 10-day post-dosing period.
1	0	4	O	About
2	6	8	O	36%
3	10	12	O	was
4	14	21	O	excreted
5	23	24	O	in
6	26	28	O	the
7	30	34	O	feces
8	37	44	O	probably
9	46	48	O	via
10	50	52	O	the
11	54	57	O	bile
12	59	59	O	,
13	61	66	O	mostly
14	68	69	O	as
15	71	81	O	metabolites
16	83	85	O	and
17	87	90	O	less
18	92	95	O	than
19	97	98	O	1%
20	100	101	O	as
21	103	105	O	the
22	107	112	O	parent
23	114	121	O	compound
24	123	126	O	over
25	128	130	O	the
26	132	133	O	10
27	135	137	O	day
28	139	142	O	post
29	144	149	O	dosing
30	151	156	O	period
NULL

PAROXETINE	3615	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	13
Increased plasma concentrations of paroxetine occur in subjects with renal and hepatic impairment.
1	0	8	O	Increased
2	10	15	O	plasma
3	17	30	O	concentrations
4	32	33	O	of
5	35	44	O	XXXXXXXX
6	46	50	O	occur
7	52	53	O	in
8	55	62	O	subjects
9	64	67	O	with
10	69	73	O	renal
11	75	77	O	and
12	79	85	O	hepatic
13	87	96	O	impairment
NULL

PAROXETINE	3616	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
The mean plasma concentrations in patients with creatinine clearance below 30 mL/min. were approximately 4 times greater than seen in normal volunteers.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	plasma
4	16	29	O	concentrations
5	31	32	O	in
6	34	41	O	patients
7	43	46	O	with
8	48	57	O	creatinine
9	59	67	O	clearance
10	69	73	O	below
11	75	76	O	30
12	78	79	O	mL
13	80	80	O	/
14	81	83	O	min
15	86	89	O	were
16	91	103	O	approximately
17	105	105	O	4
18	107	111	O	times
19	113	119	O	greater
20	121	124	O	than
21	126	129	O	seen
22	131	132	O	in
23	134	139	O	normal
24	141	150	O	volunteers
NULL

PAROXETINE	3617	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	29
Patients with creatinine clearance of 30 to 60 mL/min. and patients with hepatic functional impairment had about a 2-fold increase in plasma concentrations (AUC, Cmax).
1	0	7	O	Patients
2	9	12	O	with
3	14	23	O	creatinine
4	25	33	O	clearance
5	35	36	O	of
6	38	39	O	30
7	41	42	O	to
8	44	45	O	60
9	47	48	O	mL
10	49	49	O	/
11	50	52	O	min
12	55	57	O	and
13	59	66	O	patients
14	68	71	O	with
15	73	79	O	hepatic
16	81	90	O	functional
17	92	101	O	impairment
18	103	105	O	had
19	107	111	O	about
20	113	113	O	a
21	115	115	O	2
22	117	120	O	fold
23	122	129	O	increase
24	131	132	O	in
25	134	139	O	plasma
26	141	154	O	concentrations
27	157	159	O	AUC
28	160	160	O	,
29	162	165	O	Cmax
NULL

PAROXETINE	3618	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	28
The initial dosage should therefore be reduced in patients with severe renal or hepatic impairment, and upward titration, if necessary, should be at increased intervals.
1	0	2	O	The
2	4	10	O	initial
3	12	17	O	dosage
4	19	24	O	should
5	26	34	O	therefore
6	36	37	O	be
7	39	45	O	reduced
8	47	48	O	in
9	50	57	O	patients
10	59	62	O	with
11	64	69	O	severe
12	71	75	O	renal
13	77	78	O	or
14	80	86	O	hepatic
15	88	97	O	impairment
16	98	98	O	,
17	100	102	O	and
18	104	109	O	upward
19	111	119	O	titration
20	120	120	O	,
21	122	123	O	if
22	125	133	O	necessary
23	134	134	O	,
24	136	141	O	should
25	143	144	O	be
26	146	147	O	at
27	149	157	O	increased
28	159	167	O	intervals
NULL

PAROXETINE	3619	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	36
In a multiple-dose study in the elderly at daily paroxetine doses of 20, 30, and 40mg, Cmin concentrations were about 70% to 80% greater than the respective Cmin concentrations in nonelderly subjects.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	multiple
4	14	17	O	dose
5	19	23	O	study
6	25	26	O	in
7	28	30	O	the
8	32	38	O	elderly
9	40	41	O	at
10	43	47	O	daily
11	49	58	O	XXXXXXXX
12	60	64	O	doses
13	66	67	O	of
14	69	70	O	20
15	71	71	O	,
16	73	74	O	30
17	75	75	O	,
18	77	79	O	and
19	81	84	O	40mg
20	85	85	O	,
21	87	90	O	Cmin
22	92	105	O	concentrations
23	107	110	O	were
24	112	116	O	about
25	118	120	O	70%
26	122	123	O	to
27	125	127	O	80%
28	129	135	O	greater
29	137	140	O	than
30	142	144	O	the
31	146	155	O	respective
32	157	160	O	Cmin
33	162	175	O	concentrations
34	177	178	O	in
35	180	189	O	nonelderly
36	191	198	O	subjects
NULL

PAROXETINE	3620	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
Therefore the initial dosage in the elderly should be reduced.
1	0	8	O	Therefore
2	10	12	O	the
3	14	20	O	initial
4	22	27	O	dosage
5	29	30	O	in
6	32	34	O	the
7	36	42	O	elderly
8	44	49	O	should
9	51	52	O	be
10	54	60	O	reduced
NULL

PAROXETINE	3621	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	10
In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	drug
4	14	24	O	interaction
5	26	32	O	studies
6	34	39	O	reveal
7	41	44	O	that
8	46	55	O	XXXXXXXX
9	57	64	O	inhibits
10	66	71	O	CYP2D6
NULL

PAROXETINE	3622	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	31
Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine.
1	0	7	O	Clinical
2	9	12	O	drug
3	14	24	O	interaction
4	26	32	O	studies
5	34	37	O	have
6	39	42	O	been
7	44	52	O	performed
8	54	57	O	with
9	59	68	O	substrates
10	70	71	O	of
11	73	78	O	CYP2D6
12	80	82	O	and
13	84	87	O	show
14	89	92	O	that
15	94	103	O	XXXXXXXX
16	105	107	O	can
17	109	115	B-TRI	inhibit
18	117	119	I-TRI	the
19	121	130	L-TRI	metabolism
20	132	133	O	of
21	135	139	B-KIN	drugs
22	141	151	I-KIN	metabolized
23	153	154	I-KIN	by
24	156	161	L-KIN	CYP2D6
25	163	171	O	including
26	173	183	U-KIN	desipramine
27	184	184	O	,
28	186	196	U-KIN	risperidone
29	197	197	O	,
30	199	201	O	and
31	203	213	U-KIN	atomoxetine
K/21:C54357 K/26:C54357 K/28:C54357 K/31:C54357

PAROXETINE	3623	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	29
The efficacy of paroxetine as a treatment for major depressive disorder has been established in 6 placebo-controlled studies of patients with major depressive disorder (aged 18 to 73).
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	25	O	XXXXXXXX
5	27	28	O	as
6	30	30	O	a
7	32	40	O	treatment
8	42	44	O	for
9	46	50	O	major
10	52	61	O	depressive
11	63	70	O	disorder
12	72	74	O	has
13	76	79	O	been
14	81	91	O	established
15	93	94	O	in
16	96	96	O	6
17	98	104	O	placebo
18	106	115	O	controlled
19	117	123	O	studies
20	125	126	O	of
21	128	135	O	patients
22	137	140	O	with
23	142	146	O	major
24	148	157	O	depressive
25	159	166	O	disorder
26	169	172	O	aged
27	174	175	O	18
28	177	178	O	to
29	180	181	O	73
NULL

PAROXETINE	3624	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	49
In these studies, paroxetine was shown to be significantly more effective than placebo in treating major depressive disorder by at least 2 of the following measures: Hamilton Depression Rating Scale (HDRS), the Hamilton depressed mood item, and the Clinical Global Impression (CGI)-Severity of Illness.
1	0	1	O	In
2	3	7	O	these
3	9	15	O	studies
4	16	16	O	,
5	18	27	O	XXXXXXXX
6	29	31	O	was
7	33	37	O	shown
8	39	40	O	to
9	42	43	O	be
10	45	57	O	significantly
11	59	62	O	more
12	64	72	O	effective
13	74	77	O	than
14	79	85	O	placebo
15	87	88	O	in
16	90	97	O	treating
17	99	103	O	major
18	105	114	O	depressive
19	116	123	O	disorder
20	125	126	O	by
21	128	129	O	at
22	131	135	O	least
23	137	137	O	2
24	139	140	O	of
25	142	144	O	the
26	146	154	O	following
27	156	163	O	measures
28	164	164	O	:
29	166	173	O	Hamilton
30	175	184	O	Depression
31	186	191	O	Rating
32	193	197	O	Scale
33	200	203	O	HDRS
34	205	205	O	,
35	207	209	O	the
36	211	218	O	Hamilton
37	220	228	O	depressed
38	230	233	O	mood
39	235	238	O	item
40	239	239	O	,
41	241	243	O	and
42	245	247	O	the
43	249	256	O	Clinical
44	258	263	O	Global
45	265	274	O	Impression
46	277	279	O	CGI
47	282	289	O	Severity
48	291	292	O	of
49	294	300	O	Illness
NULL

PAROXETINE	3625	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	28
Paroxetine was significantly better than placebo in improvement of the HDRS sub-factor scores, including the depressed mood item, sleep disturbance factor, and anxiety factor.
1	0	9	O	XXXXXXXX
2	11	13	O	was
3	15	27	O	significantly
4	29	34	O	better
5	36	39	O	than
6	41	47	O	placebo
7	49	50	O	in
8	52	62	O	improvement
9	64	65	O	of
10	67	69	O	the
11	71	74	O	HDRS
12	76	78	O	sub
13	80	85	O	factor
14	87	92	O	scores
15	93	93	O	,
16	95	103	O	including
17	105	107	O	the
18	109	117	O	depressed
19	119	122	O	mood
20	124	127	O	item
21	128	128	O	,
22	130	134	O	sleep
23	136	146	O	disturbance
24	148	153	O	factor
25	154	154	O	,
26	156	158	O	and
27	160	166	O	anxiety
28	168	173	O	factor
NULL

PAROXETINE	3626	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	55
A study of outpatients with major depressive disorder who had responded to paroxetine (HDRS total score <8) during an initial 8-week open-treatment phase and were then randomized to continuation on paroxetine or placebo for 1 year demonstrated a significantly lower relapse rate for patients taking paroxetine (15%) compared to those on placebo (39%).
1	0	0	O	A
2	2	6	O	study
3	8	9	O	of
4	11	21	O	outpatients
5	23	26	O	with
6	28	32	O	major
7	34	43	O	depressive
8	45	52	O	disorder
9	54	56	O	who
10	58	60	O	had
11	62	70	O	responded
12	72	73	O	to
13	75	84	O	XXXXXXXX
14	87	90	O	HDRS
15	92	96	O	total
16	98	102	O	score
17	104	105	O	<8
18	108	113	O	during
19	115	116	O	an
20	118	124	O	initial
21	126	126	O	8
22	128	131	O	week
23	133	136	O	open
24	138	146	O	treatment
25	148	152	O	phase
26	154	156	O	and
27	158	161	O	were
28	163	166	O	then
29	168	177	O	randomized
30	179	180	O	to
31	182	193	O	continuation
32	195	196	O	on
33	198	207	O	XXXXXXXX
34	209	210	O	or
35	212	218	O	placebo
36	220	222	O	for
37	224	224	O	1
38	226	229	O	year
39	231	242	O	demonstrated
40	244	244	O	a
41	246	258	O	significantly
42	260	264	O	lower
43	266	272	O	relapse
44	274	277	O	rate
45	279	281	O	for
46	283	290	O	patients
47	292	297	O	taking
48	299	308	O	XXXXXXXX
49	311	313	O	15%
50	316	323	O	compared
51	325	326	O	to
52	328	332	O	those
53	334	335	O	on
54	337	343	O	placebo
55	346	348	O	39%
NULL

PAROXETINE	3627	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	8
Effectiveness was similar for male and female patients.
1	0	12	O	Effectiveness
2	14	16	O	was
3	18	24	O	similar
4	26	28	O	for
5	30	33	O	male
6	35	37	O	and
7	39	44	O	female
8	46	53	O	patients
NULL

PAROXETINE	3628	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	29
The effectiveness of paroxetine in the treatment of obsessive compulsive disorder (OCD) was demonstrated in two 12-week multicenter placebo-controlled studies of adult outpatients (Studies 1 and 2).
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	30	O	XXXXXXXX
5	32	33	O	in
6	35	37	O	the
7	39	47	O	treatment
8	49	50	O	of
9	52	60	O	obsessive
10	62	71	O	compulsive
11	73	80	O	disorder
12	83	85	O	OCD
13	88	90	O	was
14	92	103	O	demonstrated
15	105	106	O	in
16	108	110	O	two
17	112	113	O	12
18	115	118	O	week
19	120	130	O	multicenter
20	132	138	O	placebo
21	140	149	O	controlled
22	151	157	O	studies
23	159	160	O	of
24	162	166	O	adult
25	168	178	O	outpatients
26	181	187	O	Studies
27	189	189	O	1
28	191	193	O	and
29	195	195	O	2
NULL

PAROXETINE	3629	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	30
Patients in all studies had moderate to severe OCD (DSM-IIIR) with mean baseline ratings on the Yale Brown Obsessive Compulsive Scale (YBOCS) total score ranging from 23 to 26.
1	0	7	O	Patients
2	9	10	O	in
3	12	14	O	all
4	16	22	O	studies
5	24	26	O	had
6	28	35	O	moderate
7	37	38	O	to
8	40	45	O	severe
9	47	49	O	OCD
10	52	54	O	DSM
11	56	59	O	IIIR
12	62	65	O	with
13	67	70	O	mean
14	72	79	O	baseline
15	81	87	O	ratings
16	89	90	O	on
17	92	94	O	the
18	96	99	O	Yale
19	101	105	O	Brown
20	107	115	O	Obsessive
21	117	126	O	Compulsive
22	128	132	O	Scale
23	135	139	O	YBOCS
24	142	146	O	total
25	148	152	O	score
26	154	160	O	ranging
27	162	165	O	from
28	167	168	O	23
29	170	171	O	to
30	173	174	O	26
NULL

PAROXETINE	3630	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	44
Study 1, a dose-range finding study where patients were treated with fixed doses of 20, 40, or 60 mg of paroxetine/day demonstrated that daily doses of paroxetine 40 and 60 mg are effective in the treatment of OCD.
1	0	4	O	Study
2	6	6	O	1
3	7	7	O	,
4	9	9	O	a
5	11	14	O	dose
6	16	20	O	range
7	22	28	O	finding
8	30	34	O	study
9	36	40	O	where
10	42	49	O	patients
11	51	54	O	were
12	56	62	O	treated
13	64	67	O	with
14	69	73	O	fixed
15	75	79	O	doses
16	81	82	O	of
17	84	85	O	20
18	86	86	O	,
19	88	89	O	40
20	90	90	O	,
21	92	93	O	or
22	95	96	O	60
23	98	99	O	mg
24	101	102	O	of
25	104	113	O	XXXXXXXX
26	114	114	O	/
27	115	117	O	day
28	119	130	O	demonstrated
29	132	135	O	that
30	137	141	O	daily
31	143	147	O	doses
32	149	150	O	of
33	152	161	O	XXXXXXXX
34	163	164	O	40
35	166	168	O	and
36	170	171	O	60
37	173	174	O	mg
38	176	178	O	are
39	180	188	O	effective
40	190	191	O	in
41	193	195	O	the
42	197	205	O	treatment
43	207	208	O	of
44	210	212	O	OCD
NULL

PAROXETINE	3631	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	50
Patients receiving doses of 40 and 60 mg paroxetine experienced a mean reduction of approximately 6 and 7 points, respectively, on the YBOCS total score which was significantly greater than the approximate 4-point reduction at 20 mg and a 3-point reduction in the placebo-treated patients.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	doses
4	25	26	O	of
5	28	29	O	40
6	31	33	O	and
7	35	36	O	60
8	38	39	O	mg
9	41	50	O	XXXXXXXX
10	52	62	O	experienced
11	64	64	O	a
12	66	69	O	mean
13	71	79	O	reduction
14	81	82	O	of
15	84	96	O	approximately
16	98	98	O	6
17	100	102	O	and
18	104	104	O	7
19	106	111	O	points
20	112	112	O	,
21	114	125	O	respectively
22	126	126	O	,
23	128	129	O	on
24	131	133	O	the
25	135	139	O	YBOCS
26	141	145	O	total
27	147	151	O	score
28	153	157	O	which
29	159	161	O	was
30	163	175	O	significantly
31	177	183	O	greater
32	185	188	O	than
33	190	192	O	the
34	194	204	O	approximate
35	206	206	O	4
36	208	212	O	point
37	214	222	O	reduction
38	224	225	O	at
39	227	228	O	20
40	230	231	O	mg
41	233	235	O	and
42	237	237	O	a
43	239	239	O	3
44	241	245	O	point
45	247	255	O	reduction
46	257	258	O	in
47	260	262	O	the
48	264	270	O	placebo
49	272	278	O	treated
50	280	287	O	patients
NULL

PAROXETINE	3632	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
Study 2 was a flexible-dose study comparing paroxetine (20 to 60 mg daily) with clomipramine (25 to 250 mg daily).
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	21	O	flexible
6	23	26	O	dose
7	28	32	O	study
8	34	42	O	comparing
9	44	53	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	to
12	62	63	O	60
13	65	66	O	mg
14	68	72	O	daily
15	75	78	O	with
16	80	91	O	clomipramine
17	94	95	O	25
18	97	98	O	to
19	100	102	O	250
20	104	105	O	mg
21	107	111	O	daily
NULL

PAROXETINE	3633	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	37
In this study, patients receiving paroxetine experienced a mean reduction of approximately 7 points on the YBOCS total score, which was significantly greater than the mean reduction of approximately 4 points in placebo-treated patients.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	22	O	patients
6	24	32	O	receiving
7	34	43	O	XXXXXXXX
8	45	55	O	experienced
9	57	57	O	a
10	59	62	O	mean
11	64	72	O	reduction
12	74	75	O	of
13	77	89	O	approximately
14	91	91	O	7
15	93	98	O	points
16	100	101	O	on
17	103	105	O	the
18	107	111	O	YBOCS
19	113	117	O	total
20	119	123	O	score
21	124	124	O	,
22	126	130	O	which
23	132	134	O	was
24	136	148	O	significantly
25	150	156	O	greater
26	158	161	O	than
27	163	165	O	the
28	167	170	O	mean
29	172	180	O	reduction
30	182	183	O	of
31	185	197	O	approximately
32	199	199	O	4
33	201	206	O	points
34	208	209	O	in
35	211	217	O	placebo
36	219	225	O	treated
37	227	234	O	patients
NULL

PAROXETINE	3634	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
The following table provides the outcome classification by treatment group on Global Improvement items of the Clinical Global Impression (CGI) scale for Study 1.
1	0	2	O	The
2	4	12	O	following
3	14	18	O	table
4	20	27	O	provides
5	29	31	O	the
6	33	39	O	outcome
7	41	54	O	classification
8	56	57	O	by
9	59	67	O	treatment
10	69	73	O	group
11	75	76	O	on
12	78	83	O	Global
13	85	95	O	Improvement
14	97	101	O	items
15	103	104	O	of
16	106	108	O	the
17	110	117	O	Clinical
18	119	124	O	Global
19	126	135	O	Impression
20	138	140	O	CGI
21	143	147	O	scale
22	149	151	O	for
23	153	157	O	Study
24	159	159	O	1
NULL

PAROXETINE	3635	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	79
Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 Outcome Classification Placebo (n=74) Paroxetine 20 mg Paroxetine 40 mg Paroxetine 60 mg (n=75) (n=66) (n=66) Worse 14% 7% 7% 3% No Change 44% 35% 22% 19% Minimally Improved 24% 33% 29% 34% Much Improved 11% 18% 22% 24% Very Much Improved 7% 7% 20% 20% Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.
1	0	6	O	Outcome
2	8	21	O	Classification
3	24	24	O	%
4	27	28	O	on
5	30	32	O	CGI
6	34	39	O	Global
7	41	51	O	Improvement
8	53	56	O	Item
9	58	60	O	for
10	62	71	O	Completers
11	73	74	O	in
12	76	80	O	Study
13	82	82	O	1
14	84	90	O	Outcome
15	92	105	O	Classification
16	107	113	O	Placebo
17	116	119	O	n=74
18	122	131	O	XXXXXXXX
19	133	134	O	20
20	136	137	O	mg
21	139	148	O	XXXXXXXX
22	150	151	O	40
23	153	154	O	mg
24	156	165	O	XXXXXXXX
25	167	168	O	60
26	170	171	O	mg
27	174	177	O	n=75
28	181	184	O	n=66
29	188	191	O	n=66
30	194	198	O	Worse
31	200	202	O	14%
32	204	205	O	7%
33	207	208	O	7%
34	210	211	O	3%
35	213	214	O	No
36	216	221	O	Change
37	223	225	O	44%
38	227	229	O	35%
39	231	233	O	22%
40	235	237	O	19%
41	239	247	O	Minimally
42	249	256	O	Improved
43	258	260	O	24%
44	262	264	O	33%
45	266	268	O	29%
46	270	272	O	34%
47	274	277	O	Much
48	279	286	O	Improved
49	288	290	O	11%
50	292	294	O	18%
51	296	298	O	22%
52	300	302	O	24%
53	304	307	O	Very
54	309	312	O	Much
55	314	321	O	Improved
56	323	324	O	7%
57	326	327	O	7%
58	329	331	O	20%
59	333	335	O	20%
60	337	344	O	Subgroup
61	346	353	O	analyses
62	355	357	O	did
63	359	361	O	not
64	363	370	O	indicate
65	372	375	O	that
66	377	381	O	there
67	383	386	O	were
68	388	390	O	any
69	392	402	O	differences
70	404	405	O	in
71	407	415	O	treatment
72	417	424	O	outcomes
73	426	427	O	as
74	429	429	O	a
75	431	438	O	function
76	440	441	O	of
77	443	445	O	age
78	447	448	O	or
79	450	455	O	gender
NULL

PAROXETINE	3636	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
The long-term maintenance effects of paroxetine in OCD were demonstrated in a long-term extension to Study 1.
1	0	2	O	The
2	4	7	O	long
3	9	12	O	term
4	14	24	O	maintenance
5	26	32	O	effects
6	34	35	O	of
7	37	46	O	XXXXXXXX
8	48	49	O	in
9	51	53	O	OCD
10	55	58	O	were
11	60	71	O	demonstrated
12	73	74	O	in
13	76	76	O	a
14	78	81	O	long
15	83	86	O	term
16	88	96	O	extension
17	98	99	O	to
18	101	105	O	Study
19	107	107	O	1
NULL

PAROXETINE	3637	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	44
Patients who were responders on paroxetine during the 3-month double-blind phase and a 6-month extension on open-label paroxetine (20 to 60 mg/day) were randomized to either paroxetine or placebo in a 6-month double-blind relapse prevention phase.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	were
4	18	27	O	responders
5	29	30	O	on
6	32	41	O	XXXXXXXX
7	43	48	O	during
8	50	52	O	the
9	54	54	O	3
10	56	60	O	month
11	62	67	O	double
12	69	73	O	blind
13	75	79	O	phase
14	81	83	O	and
15	85	85	O	a
16	87	87	O	6
17	89	93	O	month
18	95	103	O	extension
19	105	106	O	on
20	108	111	O	open
21	113	117	O	label
22	119	128	O	XXXXXXXX
23	131	132	O	20
24	134	135	O	to
25	137	138	O	60
26	140	141	O	mg
27	142	142	O	/
28	143	145	O	day
29	148	151	O	were
30	153	162	O	randomized
31	164	165	O	to
32	167	172	O	either
33	174	183	O	XXXXXXXX
34	185	186	O	or
35	188	194	O	placebo
36	196	197	O	in
37	199	199	O	a
38	201	201	O	6
39	203	207	O	month
40	209	214	O	double
41	216	220	O	blind
42	222	228	O	relapse
43	230	239	O	prevention
44	241	245	O	phase
NULL

PAROXETINE	3638	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
Patients randomized to paroxetine were significantly less likely to relapse than comparably treated patients who were randomized to placebo.
1	0	7	O	Patients
2	9	18	O	randomized
3	20	21	O	to
4	23	32	O	XXXXXXXX
5	34	37	O	were
6	39	51	O	significantly
7	53	56	O	less
8	58	63	O	likely
9	65	66	O	to
10	68	74	O	relapse
11	76	79	O	than
12	81	90	O	comparably
13	92	98	O	treated
14	100	107	O	patients
15	109	111	O	who
16	113	116	O	were
17	118	127	O	randomized
18	129	130	O	to
19	132	138	O	placebo
NULL

PAROXETINE	3639	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	30
The effectiveness of paroxetine in the treatment of panic disorder was demonstrated in three 10- to 12-week multicenter, placebo-controlled studies of adult outpatients (Studies 1 to 3).
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	30	O	XXXXXXXX
5	32	33	O	in
6	35	37	O	the
7	39	47	O	treatment
8	49	50	O	of
9	52	56	O	panic
10	58	65	O	disorder
11	67	69	O	was
12	71	82	O	demonstrated
13	84	85	O	in
14	87	91	O	three
15	93	94	O	10
16	97	98	O	to
17	100	101	O	12
18	103	106	O	week
19	108	118	O	multicenter
20	119	119	O	,
21	121	127	O	placebo
22	129	138	O	controlled
23	140	146	O	studies
24	148	149	O	of
25	151	155	O	adult
26	157	167	O	outpatients
27	170	176	O	Studies
28	178	178	O	1
29	180	181	O	to
30	183	183	O	3
NULL

PAROXETINE	3640	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
Patients in all studies had panic disorder (DSM-IIIR), with or without agoraphobia.
1	0	7	O	Patients
2	9	10	O	in
3	12	14	O	all
4	16	22	O	studies
5	24	26	O	had
6	28	32	O	panic
7	34	41	O	disorder
8	44	46	O	DSM
9	48	51	O	IIIR
10	53	53	O	,
11	55	58	O	with
12	60	61	O	or
13	63	69	O	without
14	71	81	O	agoraphobia
NULL

PAROXETINE	3641	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	40
In these studies, paroxetine was shown to be significantly more effective than placebo in treating panic disorder by at least 2 out of 3 measures of panic attack frequency and on the Clinical Global Impression Severity of Illness score.
1	0	1	O	In
2	3	7	O	these
3	9	15	O	studies
4	16	16	O	,
5	18	27	O	XXXXXXXX
6	29	31	O	was
7	33	37	O	shown
8	39	40	O	to
9	42	43	O	be
10	45	57	O	significantly
11	59	62	O	more
12	64	72	O	effective
13	74	77	O	than
14	79	85	O	placebo
15	87	88	O	in
16	90	97	O	treating
17	99	103	O	panic
18	105	112	O	disorder
19	114	115	O	by
20	117	118	O	at
21	120	124	O	least
22	126	126	O	2
23	128	130	O	out
24	132	133	O	of
25	135	135	O	3
26	137	144	O	measures
27	146	147	O	of
28	149	153	O	panic
29	155	160	O	attack
30	162	170	O	frequency
31	172	174	O	and
32	176	177	O	on
33	179	181	O	the
34	183	190	O	Clinical
35	192	197	O	Global
36	199	208	O	Impression
37	210	217	O	Severity
38	219	220	O	of
39	222	228	O	Illness
40	230	234	O	score
NULL

PAROXETINE	3642	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	29
Study 1 was a 10-week dose-range finding study; patients were treated with fixed paroxetine doses of 10, 20, or 40 mg/day or placebo.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	12	O	a
5	14	15	O	10
6	17	20	O	week
7	22	25	O	dose
8	27	31	O	range
9	33	39	O	finding
10	41	45	O	study
11	48	55	O	patients
12	57	60	O	were
13	62	68	O	treated
14	70	73	O	with
15	75	79	O	fixed
16	81	90	O	XXXXXXXX
17	92	96	O	doses
18	98	99	O	of
19	101	102	O	10
20	103	103	O	,
21	105	106	O	20
22	107	107	O	,
23	109	110	O	or
24	112	113	O	40
25	115	116	O	mg
26	117	117	O	/
27	118	120	O	day
28	122	123	O	or
29	125	131	O	placebo
NULL

PAROXETINE	3643	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	15
A significant difference from placebo was observed only for the 40 mg/day group.
1	0	0	O	A
2	2	12	O	significant
3	14	23	O	difference
4	25	28	O	from
5	30	36	O	placebo
6	38	40	O	was
7	42	49	O	observed
8	51	54	O	only
9	56	58	O	for
10	60	62	O	the
11	64	65	O	40
12	67	68	O	mg
13	69	69	O	/
14	70	72	O	day
15	74	78	O	group
NULL

PAROXETINE	3644	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	25
At endpoint, 76% of patients receiving paroxetine 40 mg/day were free of panic attacks, compared to 44% of placebo-treated patients.
1	0	1	O	At
2	3	10	O	endpoint
3	11	11	O	,
4	13	15	O	76%
5	17	18	O	of
6	20	27	O	patients
7	29	37	O	receiving
8	39	48	O	XXXXXXXX
9	50	51	O	40
10	53	54	O	mg
11	55	55	O	/
12	56	58	O	day
13	60	63	O	were
14	65	68	O	free
15	70	71	O	of
16	73	77	O	panic
17	79	85	O	attacks
18	86	86	O	,
19	88	95	O	compared
20	97	98	O	to
21	100	102	O	44%
22	104	105	O	of
23	107	113	O	placebo
24	115	121	O	treated
25	123	130	O	patients
NULL

PAROXETINE	3645	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	18
Study 2 was a 12-week flexible-dose study comparing paroxetine (10 to 60 mg daily) and placebo.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	29	O	flexible
8	31	34	O	dose
9	36	40	O	study
10	42	50	O	comparing
11	52	61	O	XXXXXXXX
12	64	65	O	10
13	67	68	O	to
14	70	71	O	60
15	73	74	O	mg
16	76	80	O	daily
17	83	85	O	and
18	87	93	O	placebo
NULL

PAROXETINE	3646	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	19
At endpoint, 51% of paroxetine patients were free of panic attacks compared to 32% of placebo-treated patients.
1	0	1	O	At
2	3	10	O	endpoint
3	11	11	O	,
4	13	15	O	51%
5	17	18	O	of
6	20	29	O	XXXXXXXX
7	31	38	O	patients
8	40	43	O	were
9	45	48	O	free
10	50	51	O	of
11	53	57	O	panic
12	59	65	O	attacks
13	67	74	O	compared
14	76	77	O	to
15	79	81	O	32%
16	83	84	O	of
17	86	92	O	placebo
18	94	100	O	treated
19	102	109	O	patients
NULL

PAROXETINE	3647	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	26
Study 3 was a 12-week flexible-dose study comparing paroxetine (10 to 60 mg daily) to placebo in patients concurrently receiving standardized cognitive behavioral therapy.
1	0	4	O	Study
2	6	6	O	3
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	29	O	flexible
8	31	34	O	dose
9	36	40	O	study
10	42	50	O	comparing
11	52	61	O	XXXXXXXX
12	64	65	O	10
13	67	68	O	to
14	70	71	O	60
15	73	74	O	mg
16	76	80	O	daily
17	83	84	O	to
18	86	92	O	placebo
19	94	95	O	in
20	97	104	O	patients
21	106	117	O	concurrently
22	119	127	O	receiving
23	129	140	O	standardized
24	142	150	O	cognitive
25	152	161	O	behavioral
26	163	169	O	therapy
NULL

PAROXETINE	3648	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	24
At endpoint, 33% of the paroxetine-treated patients showed a reduction to 0 or 1 panic attacks compared to 14% of placebo patients.
1	0	1	O	At
2	3	10	O	endpoint
3	11	11	O	,
4	13	15	O	33%
5	17	18	O	of
6	20	22	O	the
7	24	33	O	XXXXXXXX
8	35	41	O	treated
9	43	50	O	patients
10	52	57	O	showed
11	59	59	O	a
12	61	69	O	reduction
13	71	72	O	to
14	74	74	O	0
15	76	77	O	or
16	79	79	O	1
17	81	85	O	panic
18	87	93	O	attacks
19	95	102	O	compared
20	104	105	O	to
21	107	109	O	14%
22	111	112	O	of
23	114	120	O	placebo
24	122	129	O	patients
NULL

PAROXETINE	3649	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	23
In both Studies 2 and 3, the mean paroxetine dose for completers at endpoint was approximately 40 mg/day of paroxetine.
1	0	1	O	In
2	3	6	O	both
3	8	14	O	Studies
4	16	16	O	2
5	18	20	O	and
6	22	22	O	3
7	23	23	O	,
8	25	27	O	the
9	29	32	O	mean
10	34	43	O	XXXXXXXX
11	45	48	O	dose
12	50	52	O	for
13	54	63	O	completers
14	65	66	O	at
15	68	75	O	endpoint
16	77	79	O	was
17	81	93	O	approximately
18	95	96	O	40
19	98	99	O	mg
20	100	100	O	/
21	101	103	O	day
22	105	106	O	of
23	108	117	O	XXXXXXXX
NULL

PAROXETINE	3650	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
Long-term maintenance effects of paroxetine in panic disorder were demonstrated in an extension to Study 1.
1	0	3	O	Long
2	5	8	O	term
3	10	20	O	maintenance
4	22	28	O	effects
5	30	31	O	of
6	33	42	O	XXXXXXXX
7	44	45	O	in
8	47	51	O	panic
9	53	60	O	disorder
10	62	65	O	were
11	67	78	O	demonstrated
12	80	81	O	in
13	83	84	O	an
14	86	94	O	extension
15	96	97	O	to
16	99	103	O	Study
17	105	105	O	1
NULL

PAROXETINE	3651	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	45
Patients who were responders during the 10-week double-blind phase and during a 3-month double-blind extension phase were randomized to either paroxetine (10, 20, or 40 mg/day) or placebo in a 3-month double-blind relapse prevention phase.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	were
4	18	27	O	responders
5	29	34	O	during
6	36	38	O	the
7	40	41	O	10
8	43	46	O	week
9	48	53	O	double
10	55	59	O	blind
11	61	65	O	phase
12	67	69	O	and
13	71	76	O	during
14	78	78	O	a
15	80	80	O	3
16	82	86	O	month
17	88	93	O	double
18	95	99	O	blind
19	101	109	O	extension
20	111	115	O	phase
21	117	120	O	were
22	122	131	O	randomized
23	133	134	O	to
24	136	141	O	either
25	143	152	O	XXXXXXXX
26	155	156	O	10
27	157	157	O	,
28	159	160	O	20
29	161	161	O	,
30	163	164	O	or
31	166	167	O	40
32	169	170	O	mg
33	171	171	O	/
34	172	174	O	day
35	177	178	O	or
36	180	186	O	placebo
37	188	189	O	in
38	191	191	O	a
39	193	193	O	3
40	195	199	O	month
41	201	206	O	double
42	208	212	O	blind
43	214	220	O	relapse
44	222	231	O	prevention
45	233	237	O	phase
NULL

PAROXETINE	3653	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	20
Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	20	O	did
4	22	24	O	not
5	26	33	O	indicate
6	35	38	O	that
7	40	44	O	there
8	46	49	O	were
9	51	53	O	any
10	55	65	O	differences
11	67	68	O	in
12	70	78	O	treatment
13	80	87	O	outcomes
14	89	90	O	as
15	92	92	O	a
16	94	101	O	function
17	103	104	O	of
18	106	108	O	age
19	110	111	O	or
20	113	118	O	gender
NULL

PAROXETINE	3654	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	39
The effectiveness of paroxetine in the treatment of social anxiety disorder was demonstrated in three 12-week, multicenter, placebo-controlled studies (Studies 1, 2, and 3) of adult outpatients with social anxiety disorder (DSM-IV).
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	30	O	XXXXXXXX
5	32	33	O	in
6	35	37	O	the
7	39	47	O	treatment
8	49	50	O	of
9	52	57	O	social
10	59	65	O	anxiety
11	67	74	O	disorder
12	76	78	O	was
13	80	91	O	demonstrated
14	93	94	O	in
15	96	100	O	three
16	102	103	O	12
17	105	108	O	week
18	109	109	O	,
19	111	121	O	multicenter
20	122	122	O	,
21	124	130	O	placebo
22	132	141	O	controlled
23	143	149	O	studies
24	152	158	O	Studies
25	160	160	O	1
26	161	161	O	,
27	163	163	O	2
28	164	164	O	,
29	166	168	O	and
30	170	170	O	3
31	173	174	O	of
32	176	180	O	adult
33	182	192	O	outpatients
34	194	197	O	with
35	199	204	O	social
36	206	212	O	anxiety
37	214	221	O	disorder
38	224	226	O	DSM
39	228	229	O	IV
NULL

PAROXETINE	3655	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	55
In these studies, the effectiveness of paroxetine compared to placebo was evaluated on the basis of (1) the proportion of responders, as defined by a Clinical Global Impression (CGI) Improvement score of 1 (very much improved) or 2 (much improved), and (2) change from baseline in the Liebowitz Social Anxiety Scale (LSAS).
1	0	1	O	In
2	3	7	O	these
3	9	15	O	studies
4	16	16	O	,
5	18	20	O	the
6	22	34	O	effectiveness
7	36	37	O	of
8	39	48	O	XXXXXXXX
9	50	57	O	compared
10	59	60	O	to
11	62	68	O	placebo
12	70	72	O	was
13	74	82	O	evaluated
14	84	85	O	on
15	87	89	O	the
16	91	95	O	basis
17	97	98	O	of
18	101	101	O	1
19	104	106	O	the
20	108	117	O	proportion
21	119	120	O	of
22	122	131	O	responders
23	132	132	O	,
24	134	135	O	as
25	137	143	O	defined
26	145	146	O	by
27	148	148	O	a
28	150	157	O	Clinical
29	159	164	O	Global
30	166	175	O	Impression
31	178	180	O	CGI
32	183	193	O	Improvement
33	195	199	O	score
34	201	202	O	of
35	204	204	O	1
36	207	210	O	very
37	212	215	O	much
38	217	224	O	improved
39	227	228	O	or
40	230	230	O	2
41	233	236	O	much
42	238	245	O	improved
43	247	247	O	,
44	249	251	O	and
45	254	254	O	2
46	257	262	O	change
47	264	267	O	from
48	269	276	O	baseline
49	278	279	O	in
50	281	283	O	the
51	285	293	O	Liebowitz
52	295	300	O	Social
53	302	308	O	Anxiety
54	310	314	O	Scale
55	317	320	O	LSAS
NULL

PAROXETINE	3656	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	16
Studies 1 and 2 were flexible-dose studies comparing paroxetine (20 to 50mg daily) and placebo.
1	0	6	O	Studies
2	8	8	O	1
3	10	12	O	and
4	14	14	O	2
5	16	19	O	were
6	21	28	O	flexible
7	30	33	O	dose
8	35	41	O	studies
9	43	51	O	comparing
10	53	62	O	XXXXXXXX
11	65	66	O	20
12	68	69	O	to
13	71	74	O	50mg
14	76	80	O	daily
15	83	85	O	and
16	87	93	O	placebo
NULL

PAROXETINE	3657	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
Paroxetine demonstrated statistically significant superiority over placebo on both the CGI Improvement responder criterion and the Liebowitz Social Anxiety Scale (LSAS).
1	0	9	O	XXXXXXXX
2	11	22	O	demonstrated
3	24	36	O	statistically
4	38	48	O	significant
5	50	60	O	superiority
6	62	65	O	over
7	67	73	O	placebo
8	75	76	O	on
9	78	81	O	both
10	83	85	O	the
11	87	89	O	CGI
12	91	101	O	Improvement
13	103	111	O	responder
14	113	121	O	criterion
15	123	125	O	and
16	127	129	O	the
17	131	139	O	Liebowitz
18	141	146	O	Social
19	148	154	O	Anxiety
20	156	160	O	Scale
21	163	166	O	LSAS
NULL

PAROXETINE	3658	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	26
In Study1, for patients who completed to week12, 69% of paroxetine-treated patients compared to 29% of placebo-treated patients were CGI Improvement responders.
1	0	1	O	In
2	3	8	O	Study1
3	9	9	O	,
4	11	13	O	for
5	15	22	O	patients
6	24	26	O	who
7	28	36	O	completed
8	38	39	O	to
9	41	46	O	week12
10	47	47	O	,
11	49	51	O	69%
12	53	54	O	of
13	56	65	O	XXXXXXXX
14	67	73	O	treated
15	75	82	O	patients
16	84	91	O	compared
17	93	94	O	to
18	96	98	O	29%
19	100	101	O	of
20	103	109	O	placebo
21	111	117	O	treated
22	119	126	O	patients
23	128	131	O	were
24	133	135	O	CGI
25	137	147	O	Improvement
26	149	158	O	responders
NULL

PAROXETINE	3659	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	20
In Study 2, CGI Improvement responders were 77% and 42% for the paroxetine- and placebo-treated patients, respectively.
1	0	1	O	In
2	3	7	O	Study
3	9	9	O	2
4	10	10	O	,
5	12	14	O	CGI
6	16	26	O	Improvement
7	28	37	O	responders
8	39	42	O	were
9	44	46	O	77%
10	48	50	O	and
11	52	54	O	42%
12	56	58	O	for
13	60	62	O	the
14	64	73	O	XXXXXXXX
15	76	78	O	and
16	80	86	O	placebo
17	88	94	O	treated
18	96	103	O	patients
19	104	104	O	,
20	106	117	O	respectively
NULL

PAROXETINE	3660	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	22
Study 3 was a 12-week study comparing fixed paroxetine doses of 20, 40, or 60mg/day with placebo.
1	0	4	O	Study
2	6	6	O	3
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	26	O	study
8	28	36	O	comparing
9	38	42	O	fixed
10	44	53	O	XXXXXXXX
11	55	59	O	doses
12	61	62	O	of
13	64	65	O	20
14	66	66	O	,
15	68	69	O	40
16	70	70	O	,
17	72	73	O	or
18	75	78	O	60mg
19	79	79	O	/
20	80	82	O	day
21	84	87	O	with
22	89	95	O	placebo
NULL

PAROXETINE	3661	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	38
Paroxetine 20mg was demonstrated to be significantly superior to placebo on both the LSAS Total Score and the CGI Improvement responder criterion; there were trends for superiority over placebo for the 40mg and 60mg/day dose groups.
1	0	9	O	XXXXXXXX
2	11	14	O	20mg
3	16	18	O	was
4	20	31	O	demonstrated
5	33	34	O	to
6	36	37	O	be
7	39	51	O	significantly
8	53	60	O	superior
9	62	63	O	to
10	65	71	O	placebo
11	73	74	O	on
12	76	79	O	both
13	81	83	O	the
14	85	88	O	LSAS
15	90	94	O	Total
16	96	100	O	Score
17	102	104	O	and
18	106	108	O	the
19	110	112	O	CGI
20	114	124	O	Improvement
21	126	134	O	responder
22	136	144	O	criterion
23	147	151	O	there
24	153	156	O	were
25	158	163	O	trends
26	165	167	O	for
27	169	179	O	superiority
28	181	184	O	over
29	186	192	O	placebo
30	194	196	O	for
31	198	200	O	the
32	202	205	O	40mg
33	207	209	O	and
34	211	214	O	60mg
35	215	215	O	/
36	216	218	O	day
37	220	223	O	dose
38	225	230	O	groups
NULL

PAROXETINE	3662	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	18
There was no indication in this study of any additional benefit for doses higher than 20mg/day.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	22	O	indication
5	24	25	O	in
6	27	30	O	this
7	32	36	O	study
8	38	39	O	of
9	41	43	O	any
10	45	54	O	additional
11	56	62	O	benefit
12	64	66	O	for
13	68	72	O	doses
14	74	79	O	higher
15	81	84	O	than
16	86	89	O	20mg
17	90	90	O	/
18	91	93	O	day
NULL

PAROXETINE	3663	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	20
Subgroup analyses generally did not indicate differences in treatment outcomes as a function of age, race, or gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	26	O	generally
4	28	30	O	did
5	32	34	O	not
6	36	43	O	indicate
7	45	55	O	differences
8	57	58	O	in
9	60	68	O	treatment
10	70	77	O	outcomes
11	79	80	O	as
12	82	82	O	a
13	84	91	O	function
14	93	94	O	of
15	96	98	O	age
16	99	99	O	,
17	101	104	O	race
18	105	105	O	,
19	107	108	O	or
20	110	115	O	gender
NULL

PAROXETINE	3664	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	37
The effectiveness of paroxetine in the treatment of Generalized Anxiety Disorder (GAD) was demonstrated in two 8-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adult outpatients with Generalized Anxiety Disorder (DSM-IV).
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	30	O	XXXXXXXX
5	32	33	O	in
6	35	37	O	the
7	39	47	O	treatment
8	49	50	O	of
9	52	62	O	Generalized
10	64	70	O	Anxiety
11	72	79	O	Disorder
12	82	84	O	GAD
13	87	89	O	was
14	91	102	O	demonstrated
15	104	105	O	in
16	107	109	O	two
17	111	111	O	8
18	113	116	O	week
19	117	117	O	,
20	119	129	O	multicenter
21	130	130	O	,
22	132	138	O	placebo
23	140	149	O	controlled
24	151	157	O	studies
25	160	166	O	Studies
26	168	168	O	1
27	170	172	O	and
28	174	174	O	2
29	177	178	O	of
30	180	184	O	adult
31	186	196	O	outpatients
32	198	201	O	with
33	203	213	O	Generalized
34	215	221	O	Anxiety
35	223	230	O	Disorder
36	233	235	O	DSM
37	237	238	O	IV
NULL

PAROXETINE	3665	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	21
Study 1 was an 8-week study comparing fixed paroxetine doses of 20 mg or 40 mg/day with placebo.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	13	O	an
5	15	15	O	8
6	17	20	O	week
7	22	26	O	study
8	28	36	O	comparing
9	38	42	O	fixed
10	44	53	O	XXXXXXXX
11	55	59	O	doses
12	61	62	O	of
13	64	65	O	20
14	67	68	O	mg
15	70	71	O	or
16	73	74	O	40
17	76	77	O	mg
18	78	78	O	/
19	79	81	O	day
20	83	86	O	with
21	88	94	O	placebo
NULL

PAROXETINE	3666	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	29
Doses of 20 mg or 40 mg of paroxetine were both demonstrated to be significantly superior to placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score.
1	0	4	O	Doses
2	6	7	O	of
3	9	10	O	20
4	12	13	O	mg
5	15	16	O	or
6	18	19	O	40
7	21	22	O	mg
8	24	25	O	of
9	27	36	O	XXXXXXXX
10	38	41	O	were
11	43	46	O	both
12	48	59	O	demonstrated
13	61	62	O	to
14	64	65	O	be
15	67	79	O	significantly
16	81	88	O	superior
17	90	91	O	to
18	93	99	O	placebo
19	101	102	O	on
20	104	106	O	the
21	108	115	O	Hamilton
22	117	122	O	Rating
23	124	128	O	Scale
24	130	132	O	for
25	134	140	O	Anxiety
26	143	145	O	HAM
27	147	147	O	A
28	150	154	O	total
29	156	160	O	score
NULL

PAROXETINE	3667	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	28
There was not sufficient evidence in this study to suggest a greater benefit for the 40 mg/day dose compared to the 20 mg/day dose.
1	0	4	O	There
2	6	8	O	was
3	10	12	O	not
4	14	23	O	sufficient
5	25	32	O	evidence
6	34	35	O	in
7	37	40	O	this
8	42	46	O	study
9	48	49	O	to
10	51	57	O	suggest
11	59	59	O	a
12	61	67	O	greater
13	69	75	O	benefit
14	77	79	O	for
15	81	83	O	the
16	85	86	O	40
17	88	89	O	mg
18	90	90	O	/
19	91	93	O	day
20	95	98	O	dose
21	100	107	O	compared
22	109	110	O	to
23	112	114	O	the
24	116	117	O	20
25	119	120	O	mg
26	121	121	O	/
27	122	124	O	day
28	126	129	O	dose
NULL

PAROXETINE	3668	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	17
Study 2 was a flexible-dose study comparing paroxetine (20 mg to 50 mg daily) and placebo.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	21	O	flexible
6	23	26	O	dose
7	28	32	O	study
8	34	42	O	comparing
9	44	53	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	mg
12	62	63	O	to
13	65	66	O	50
14	68	69	O	mg
15	71	75	O	daily
16	78	80	O	and
17	82	88	O	placebo
NULL

PAROXETINE	3669	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	18
Paroxetine demonstrated statistically significant superiority over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score.
1	0	9	O	XXXXXXXX
2	11	22	O	demonstrated
3	24	36	O	statistically
4	38	48	O	significant
5	50	60	O	superiority
6	62	65	O	over
7	67	73	O	placebo
8	75	76	O	on
9	78	80	O	the
10	82	89	O	Hamilton
11	91	96	O	Rating
12	98	102	O	Scale
13	104	106	O	for
14	108	114	O	Anxiety
15	117	119	O	HAM
16	121	121	O	A
17	124	128	O	total
18	130	134	O	score
NULL

PAROXETINE	3670	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	41
A third study, also flexible-dose comparing paroxetine (20 mg to 50 mg daily), did not demonstrate statistically significant superiority of paroxetine over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score, the primary outcome.
1	0	0	O	A
2	2	6	O	third
3	8	12	O	study
4	13	13	O	,
5	15	18	O	also
6	20	27	O	flexible
7	29	32	O	dose
8	34	42	O	comparing
9	44	53	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	mg
12	62	63	O	to
13	65	66	O	50
14	68	69	O	mg
15	71	75	O	daily
16	77	77	O	,
17	79	81	O	did
18	83	85	O	not
19	87	97	O	demonstrate
20	99	111	O	statistically
21	113	123	O	significant
22	125	135	O	superiority
23	137	138	O	of
24	140	149	O	XXXXXXXX
25	151	154	O	over
26	156	162	O	placebo
27	164	165	O	on
28	167	169	O	the
29	171	178	O	Hamilton
30	180	185	O	Rating
31	187	191	O	Scale
32	193	195	O	for
33	197	203	O	Anxiety
34	206	208	O	HAM
35	210	210	O	A
36	213	217	O	total
37	219	223	O	score
38	224	224	O	,
39	226	228	O	the
40	230	236	O	primary
41	238	244	O	outcome
NULL

PAROXETINE	3671	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	16
Subgroup analyses did not indicate differences in treatment outcomes as a function of race or gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	20	O	did
4	22	24	O	not
5	26	33	O	indicate
6	35	45	O	differences
7	47	48	O	in
8	50	58	O	treatment
9	60	67	O	outcomes
10	69	70	O	as
11	72	72	O	a
12	74	81	O	function
13	83	84	O	of
14	86	89	O	race
15	91	92	O	or
16	94	99	O	gender
NULL

PAROXETINE	3672	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	14
There were insufficient elderly patients to conduct subgroup analyses on the basis of age.
1	0	4	O	There
2	6	9	O	were
3	11	22	O	insufficient
4	24	30	O	elderly
5	32	39	O	patients
6	41	42	O	to
7	44	50	O	conduct
8	52	59	O	subgroup
9	61	68	O	analyses
10	70	71	O	on
11	73	75	O	the
12	77	81	O	basis
13	83	84	O	of
14	86	88	O	age
NULL

PAROXETINE	3673	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	64
In a longer-term trial, 566 patients meeting DSM-IV criteria for Generalized Anxiety Disorder, who had responded during a single-blind, 8-week acute treatment phase with 20 to 50 mg/day of paroxetine, were randomized to continuation of paroxetine at their same dose, or to placebo, for up to 24 weeks of observation for relapse.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	trial
6	22	22	O	,
7	24	26	O	566
8	28	35	O	patients
9	37	43	O	meeting
10	45	47	O	DSM
11	49	50	O	IV
12	52	59	O	criteria
13	61	63	O	for
14	65	75	O	Generalized
15	77	83	O	Anxiety
16	85	92	O	Disorder
17	93	93	O	,
18	95	97	O	who
19	99	101	O	had
20	103	111	O	responded
21	113	118	O	during
22	120	120	O	a
23	122	127	O	single
24	129	133	O	blind
25	134	134	O	,
26	136	136	O	8
27	138	141	O	week
28	143	147	O	acute
29	149	157	O	treatment
30	159	163	O	phase
31	165	168	O	with
32	170	171	O	20
33	173	174	O	to
34	176	177	O	50
35	179	180	O	mg
36	181	181	O	/
37	182	184	O	day
38	186	187	O	of
39	189	198	O	XXXXXXXX
40	199	199	O	,
41	201	204	O	were
42	206	215	O	randomized
43	217	218	O	to
44	220	231	O	continuation
45	233	234	O	of
46	236	245	O	XXXXXXXX
47	247	248	O	at
48	250	254	O	their
49	256	259	O	same
50	261	264	O	dose
51	265	265	O	,
52	267	268	O	or
53	270	271	O	to
54	273	279	O	placebo
55	280	280	O	,
56	282	284	O	for
57	286	287	O	up
58	289	290	O	to
59	292	293	O	24
60	295	299	O	weeks
61	301	302	O	of
62	304	314	O	observation
63	316	318	O	for
64	320	326	O	relapse
NULL

PAROXETINE	3674	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	31
Response during the single-blind phase was defined by having a decrease of >2 points compared to baseline on the CGI-Severity of Illness scale, to a score of <3.
1	0	7	O	Response
2	9	14	O	during
3	16	18	O	the
4	20	25	O	single
5	27	31	O	blind
6	33	37	O	phase
7	39	41	O	was
8	43	49	O	defined
9	51	52	O	by
10	54	59	O	having
11	61	61	O	a
12	63	70	O	decrease
13	72	73	O	of
14	75	76	O	>2
15	78	83	O	points
16	85	92	O	compared
17	94	95	O	to
18	97	104	O	baseline
19	106	107	O	on
20	109	111	O	the
21	113	115	O	CGI
22	117	124	O	Severity
23	126	127	O	of
24	129	135	O	Illness
25	137	141	O	scale
26	142	142	O	,
27	144	145	O	to
28	147	147	O	a
29	149	153	O	score
30	155	156	O	of
31	158	159	O	<3
NULL

PAROXETINE	3675	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	39
Relapse during the double-blind phase was defined as an increase of > 2 points compared to baseline on the CGI-Severity of Illness scale to a score of > 4, or withdrawal due to lack of efficacy.
1	0	6	O	Relapse
2	8	13	O	during
3	15	17	O	the
4	19	24	O	double
5	26	30	O	blind
6	32	36	O	phase
7	38	40	O	was
8	42	48	O	defined
9	50	51	O	as
10	53	54	O	an
11	56	63	O	increase
12	65	66	O	of
13	68	68	O	>
14	70	70	O	2
15	72	77	O	points
16	79	86	O	compared
17	88	89	O	to
18	91	98	O	baseline
19	100	101	O	on
20	103	105	O	the
21	107	109	O	CGI
22	111	118	O	Severity
23	120	121	O	of
24	123	129	O	Illness
25	131	135	O	scale
26	137	138	O	to
27	140	140	O	a
28	142	146	O	score
29	148	149	O	of
30	151	151	O	>
31	153	153	O	4
32	154	154	O	,
33	156	157	O	or
34	159	168	O	withdrawal
35	170	172	O	due
36	174	175	O	to
37	177	180	O	lack
38	182	183	O	of
39	185	192	O	efficacy
NULL

PAROXETINE	3676	34090-1	08320ea3-8f93-6f04-5d1c-f69af3eb5a81	20
Patients receiving continued paroxetine experienced a significantly lower relapse rate over the subsequent 24 weeks compared to those receiving placebo.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	27	O	continued
4	29	38	O	XXXXXXXX
5	40	50	O	experienced
6	52	52	O	a
7	54	66	O	significantly
8	68	72	O	lower
9	74	80	O	relapse
10	82	85	O	rate
11	87	90	O	over
12	92	94	O	the
13	96	105	O	subsequent
14	107	108	O	24
15	110	114	O	weeks
16	116	123	O	compared
17	125	126	O	to
18	128	132	O	those
19	134	142	O	receiving
20	144	150	O	placebo
NULL

Paroxetine	4087	34073-7	326e8ab0-6886-4749-9544-885b37070051	17
As with other serotonin reuptake inhibitors, an interaction between paroxetine and tryptophan may occur when they are coadministered.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	42	O	GGGGGGGG
5	43	43	O	,
6	45	46	O	an
7	48	58	U-TRI	interaction
8	60	66	O	between
9	68	77	O	XXXXXXXX
10	79	81	O	and
11	83	92	U-UNK	tryptophan
12	94	96	O	may
13	98	102	O	occur
14	104	107	O	when
15	109	112	O	they
16	114	116	O	are
17	118	131	O	coadministered
NULL

Paroxetine	4088	34073-7	326e8ab0-6886-4749-9544-885b37070051	26
Adverse experiences, consisting primarily of headache, nausea, sweating, and dizziness, have been reported when tryptophan was administered to patients taking paroxetine.
1	0	6	O	Adverse
2	8	18	O	experiences
3	19	19	O	,
4	21	30	O	consisting
5	32	40	O	primarily
6	42	43	O	of
7	45	52	U-EFF	headache
8	53	53	O	,
9	55	60	U-EFF	nausea
10	61	61	O	,
11	63	70	U-EFF	sweating
12	71	71	O	,
13	73	75	O	and
14	77	85	U-EFF	dizziness
15	86	86	O	,
16	88	91	O	have
17	93	96	O	been
18	98	105	O	reported
19	107	110	O	when
20	112	121	U-DYN	tryptophan
21	123	125	O	was
22	127	138	O	administered
23	140	141	O	to
24	143	150	O	patients
25	152	157	O	taking
26	159	168	O	XXXXXXXX
D/20:11:1 D/20:14:1 D/20:7:1 D/20:9:1

Paroxetine	4089	34073-7	326e8ab0-6886-4749-9544-885b37070051	11
Consequently, concomitant use of paroxetine with tryptophan is not recommended.
1	0	11	O	Consequently
2	12	12	O	,
3	14	24	O	concomitant
4	26	28	O	use
5	30	31	O	of
6	33	42	O	XXXXXXXX
7	44	47	O	with
8	49	58	U-UNK	tryptophan
9	60	61	O	is
10	63	65	B-TRI	not
11	67	77	L-TRI	recommended
NULL

Paroxetine	4090	34073-7	326e8ab0-6886-4749-9544-885b37070051	7
Monoamine Oxidase Inhibitors See CONTRAINDICATIONS and WARNINGS.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	29	31	O	See
5	33	49	U-TRI	CONTRAINDICATIONS
6	51	53	O	and
7	55	62	O	WARNINGS
NULL

Paroxetine	4091	34073-7	326e8ab0-6886-4749-9544-885b37070051	47
Pimozide In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, coadministration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone.
1	0	7	O	Pimozide
2	9	10	O	In
3	12	12	O	a
4	14	23	O	controlled
5	25	29	O	study
6	31	32	O	of
7	34	40	O	healthy
8	42	51	O	volunteers
9	52	52	O	,
10	54	58	O	after
11	60	69	O	XXXXXXXX
12	71	73	O	was
13	75	82	O	titrated
14	84	85	O	to
15	87	88	O	60
16	90	91	O	mg
17	93	97	O	daily
18	98	98	O	,
19	100	115	O	coadministration
20	117	118	O	of
21	120	120	O	a
22	122	127	O	single
23	129	132	O	dose
24	134	135	O	of
25	137	137	O	2
26	139	140	O	mg
27	142	149	U-KIN	pimozide
28	151	153	O	was
29	155	164	O	associated
30	166	169	O	with
31	171	174	O	mean
32	176	184	O	increases
33	186	187	O	in
34	189	196	O	pimozide
35	198	200	O	AUC
36	202	203	O	of
37	205	208	O	151%
38	210	212	O	and
39	214	217	O	Cmax
40	219	220	O	of
41	222	224	O	62%
42	225	225	O	,
43	227	234	O	compared
44	236	237	O	to
45	239	246	O	pimozide
46	248	259	O	administered
47	261	265	O	alone
K/27:C54613

Paroxetine	4092	34073-7	326e8ab0-6886-4749-9544-885b37070051	16
The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine.
1	0	2	O	The
2	4	11	O	increase
3	13	14	O	in
4	16	23	U-KIN	pimozide
5	25	27	O	AUC
6	29	31	O	and
7	33	36	O	Cmax
8	38	39	O	is
9	41	43	O	due
10	45	46	O	to
11	48	50	O	the
12	52	57	O	CYP2D6
13	59	68	O	inhibitory
14	70	79	O	properties
15	81	82	O	of
16	84	93	O	XXXXXXXX
K/4:C54610

Paroxetine	4093	34073-7	326e8ab0-6886-4749-9544-885b37070051	26
Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine is contraindicated.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	16	O	narrow
5	18	28	O	therapeutic
6	30	34	O	index
7	36	37	O	of
8	39	46	U-UNK	pimozide
9	48	50	O	and
10	52	54	O	its
11	56	60	O	known
12	62	68	O	ability
13	70	71	O	to
14	73	79	O	prolong
15	81	83	O	the
16	85	86	O	QT
17	88	95	O	interval
18	96	96	O	,
19	98	108	O	concomitant
20	110	112	O	use
21	114	115	O	of
22	117	124	O	pimozide
23	126	128	O	and
24	130	139	O	XXXXXXXX
25	141	142	O	is
26	144	158	U-TRI	contraindicated
NULL

Paroxetine	4094	34073-7	326e8ab0-6886-4749-9544-885b37070051	56
Serotonergic Drugs Based on the mechanism of action of SNRIs and SSRIs, including paroxetine hydrochloride, and the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, lithium, fentanyl, tramadol, or St. John's Wort.
1	0	11	O	Serotonergic
2	13	17	O	Drugs
3	19	23	O	Based
4	25	26	O	on
5	28	30	O	the
6	32	40	O	mechanism
7	42	43	O	of
8	45	50	O	action
9	52	53	O	of
10	55	59	O	SNRIs
11	61	63	O	and
12	65	69	O	SSRIs
13	70	70	O	,
14	72	80	O	including
15	82	91	O	XXXXXXXX
16	93	105	O	hydrochloride
17	106	106	O	,
18	108	110	O	and
19	112	114	O	the
20	116	124	O	potential
21	126	128	O	for
22	130	138	B-EFF	serotonin
23	140	147	L-EFF	syndrome
24	148	148	O	,
25	150	156	O	caution
26	158	159	O	is
27	161	167	O	advised
28	169	172	O	when
29	174	183	O	XXXXXXXX
30	185	186	O	is
31	188	201	O	coadministered
32	203	206	O	with
33	208	212	O	other
34	214	218	B-DYN	drugs
35	220	223	I-DYN	that
36	225	227	I-DYN	may
37	229	234	I-DYN	affect
38	236	238	I-DYN	the
39	240	251	I-DYN	serotonergic
40	253	268	I-DYN	neurotransmitter
41	270	276	L-DYN	systems
42	277	277	O	,
43	279	282	O	such
44	284	285	O	as
45	287	294	U-DYN	triptans
46	295	295	O	,
47	297	303	U-DYN	lithium
48	304	304	O	,
49	306	313	U-DYN	fentanyl
50	314	314	O	,
51	316	323	U-DYN	tramadol
52	324	324	O	,
53	326	327	O	or
54	329	330	B-DYN	St
55	333	338	I-DYN	John's
56	340	343	L-DYN	Wort
D/34:22:1 D/45:22:1 D/47:22:1 D/49:22:1 D/51:22:1 D/54:22:1

Paroxetine	4095	34073-7	326e8ab0-6886-4749-9544-885b37070051	15
The concomitant use of paroxetine with MAOIs (including linezolid and intravenous methylene blue) is contraindicated.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	32	O	XXXXXXXX
6	34	37	O	with
7	39	43	U-UNK	MAOIs
8	46	54	O	including
9	56	64	U-UNK	linezolid
10	66	68	O	and
11	70	80	B-UNK	intravenous
12	82	90	I-UNK	methylene
13	92	95	L-UNK	blue
14	98	99	O	is
15	101	115	U-TRI	contraindicated
NULL

Paroxetine	4096	34073-7	326e8ab0-6886-4749-9544-885b37070051	15
The concomitant use of paroxetine with other SSRIs, SNRIs or tryptophan is not recommended.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	32	O	XXXXXXXX
6	34	37	O	with
7	39	43	O	other
8	45	49	U-UNK	SSRIs
9	50	50	O	,
10	52	56	U-UNK	SNRIs
11	58	59	O	or
12	61	70	U-UNK	tryptophan
13	72	73	O	is
14	75	77	B-TRI	not
15	79	89	L-TRI	recommended
NULL

Paroxetine	4097	34073-7	326e8ab0-6886-4749-9544-885b37070051	5
Thioridazine See CONTRAINDICATIONS and WARNINGS.
1	0	11	U-UNK	Thioridazine
2	13	15	O	See
3	17	33	U-TRI	CONTRAINDICATIONS
4	35	37	O	and
5	39	46	O	WARNINGS
NULL

Paroxetine	4098	34073-7	326e8ab0-6886-4749-9544-885b37070051	28
Warfarin Preliminary data suggest that there may be a pharmacodynamic interaction (that causes an increased bleeding diathesis in the face of unaltered prothrombin time) between paroxetine and warfarin.
1	0	7	O	Warfarin
2	9	19	O	Preliminary
3	21	24	O	data
4	26	32	O	suggest
5	34	37	O	that
6	39	43	O	there
7	45	47	O	may
8	49	50	O	be
9	52	52	O	a
10	54	68	O	pharmacodynamic
11	70	80	O	interaction
12	83	86	O	that
13	88	93	O	causes
14	95	96	O	an
15	98	106	B-EFF	increased
16	108	115	I-EFF	bleeding
17	117	125	L-EFF	diathesis
18	127	128	O	in
19	130	132	O	the
20	134	137	O	face
21	139	140	O	of
22	142	150	O	unaltered
23	152	162	O	prothrombin
24	164	167	O	time
25	170	176	O	between
26	178	187	O	XXXXXXXX
27	189	191	O	and
28	193	200	U-DYN	warfarin
D/28:15:1

Paroxetine	4099	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
Since there is little clinical experience, the concomitant administration of paroxetine and warfarin should be undertaken with caution.
1	0	4	O	Since
2	6	10	O	there
3	12	13	O	is
4	15	20	O	little
5	22	29	O	clinical
6	31	40	O	experience
7	41	41	O	,
8	43	45	O	the
9	47	57	O	concomitant
10	59	72	O	administration
11	74	75	O	of
12	77	86	O	XXXXXXXX
13	88	90	O	and
14	92	99	U-UNK	warfarin
15	101	106	O	should
16	108	109	O	be
17	111	120	O	undertaken
18	122	125	O	with
19	127	133	U-TRI	caution
NULL

Paroxetine	4100	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
Triptans There have been rare postmarketing reports of serotonin syndrome with the use of an SSRI and a triptan.
1	0	7	U-DYN	Triptans
2	9	13	O	There
3	15	18	O	have
4	20	23	O	been
5	25	28	O	rare
6	30	42	O	postmarketing
7	44	50	O	reports
8	52	53	O	of
9	55	63	B-EFF	serotonin
10	65	72	L-EFF	syndrome
11	74	77	O	with
12	79	81	O	the
13	83	85	O	use
14	87	88	O	of
15	90	91	O	an
16	93	96	O	SSRI
17	98	100	O	and
18	102	102	O	a
19	104	110	U-DYN	triptan
D/1:9:1 D/19:9:1

Paroxetine	4101	34073-7	326e8ab0-6886-4749-9544-885b37070051	27
If concomitant use of paroxetine with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
1	0	1	O	If
2	3	13	O	concomitant
3	15	17	O	use
4	19	20	O	of
5	22	31	O	XXXXXXXX
6	33	36	O	with
7	38	38	O	a
8	40	46	U-UNK	triptan
9	48	49	O	is
10	51	60	O	clinically
11	62	70	O	warranted
12	71	71	O	,
13	73	79	B-TRI	careful
14	81	91	L-TRI	observation
15	93	94	O	of
16	96	98	O	the
17	100	106	O	patient
18	108	109	O	is
19	111	117	O	advised
20	118	118	O	,
21	120	131	O	particularly
22	133	138	O	during
23	140	148	O	treatment
24	150	159	O	initiation
25	161	163	O	and
26	165	168	O	dose
27	170	178	O	increases
NULL

Paroxetine	4102	34073-7	326e8ab0-6886-4749-9544-885b37070051	22
Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of paroxetine may be affected by the induction or inhibition of drug-metabolizing enzymes.
1	0	4	O	Drugs
2	6	14	O	Affecting
3	16	22	O	Hepatic
4	24	33	O	Metabolism
5	35	37	O	The
6	39	48	O	metabolism
7	50	52	O	and
8	54	69	O	pharmacokinetics
9	71	72	O	of
10	74	83	O	XXXXXXXX
11	85	87	O	may
12	89	90	O	be
13	92	99	O	affected
14	101	102	O	by
15	104	106	O	the
16	108	116	O	induction
17	118	119	O	or
18	121	130	O	inhibition
19	132	133	O	of
20	135	138	O	drug
21	140	151	O	metabolizing
22	153	159	O	enzymes
NULL

Paroxetine	4103	34073-7	326e8ab0-6886-4749-9544-885b37070051	8
Cimetidine Cimetidine inhibits many cytochrome P450 (oxidative) enzymes.
1	0	9	O	Cimetidine
2	11	20	O	Cimetidine
3	22	29	O	inhibits
4	31	34	O	many
5	36	45	O	cytochrome
6	47	50	O	P450
7	53	61	O	oxidative
8	64	70	O	enzymes
NULL

Paroxetine	4104	34073-7	326e8ab0-6886-4749-9544-885b37070051	41
In a study where paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	15	O	where
5	17	26	O	XXXXXXXX
6	29	30	O	30
7	32	33	O	mg
8	35	38	O	once
9	40	44	O	daily
10	47	49	O	was
11	51	55	O	dosed
12	57	62	O	orally
13	64	66	O	for
14	68	68	O	4
15	70	74	O	weeks
16	75	75	O	,
17	77	82	O	steady
18	84	88	O	state
19	90	95	O	plasma
20	97	110	O	concentrations
21	112	113	O	of
22	115	124	O	XXXXXXXX
23	126	129	O	were
24	131	139	O	increased
25	141	142	O	by
26	144	156	O	approximately
27	158	160	O	50%
28	162	167	O	during
29	169	184	O	coadministration
30	186	189	O	with
31	191	194	O	oral
32	196	205	U-KIN	cimetidine
33	208	210	O	300
34	212	213	O	mg
35	215	219	O	three
36	221	225	O	times
37	227	231	O	daily
38	234	236	O	for
39	238	240	O	the
40	242	246	O	final
41	248	251	O	week
K/32:C54355

Paroxetine	4105	34073-7	326e8ab0-6886-4749-9544-885b37070051	25
Therefore, when these drugs are administered concurrently, dosage adjustment of paroxetine after the 20 mg starting dose should be guided by clinical effect.
1	0	8	O	Therefore
2	9	9	O	,
3	11	14	O	when
4	16	20	O	these
5	22	26	O	drugs
6	28	30	O	are
7	32	43	O	administered
8	45	56	O	concurrently
9	57	57	O	,
10	59	64	O	dosage
11	66	75	O	adjustment
12	77	78	O	of
13	80	89	O	XXXXXXXX
14	91	95	O	after
15	97	99	O	the
16	101	102	O	20
17	104	105	O	mg
18	107	114	O	starting
19	116	119	O	dose
20	121	126	O	should
21	128	129	O	be
22	131	136	O	guided
23	138	139	O	by
24	141	148	O	clinical
25	150	155	O	effect
NULL

Paroxetine	4106	34073-7	326e8ab0-6886-4749-9544-885b37070051	10
The effect of paroxetine on cimetidine's pharmacokinetics was not studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	39	O	cimetidine's
7	41	56	O	pharmacokinetics
8	58	60	O	was
9	62	64	O	not
10	66	72	O	studied
NULL

Paroxetine	4107	34073-7	326e8ab0-6886-4749-9544-885b37070051	8
Phenobarbital Phenobarbital induces many cytochrome P450 (oxidative) enzymes.
1	0	12	O	Phenobarbital
2	14	26	O	Phenobarbital
3	28	34	O	induces
4	36	39	O	many
5	41	50	O	cytochrome
6	52	55	O	P450
7	58	66	O	oxidative
8	69	75	O	enzymes
NULL

Paroxetine	4108	34073-7	326e8ab0-6886-4749-9544-885b37070051	43
When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T% were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone.
1	0	3	O	When
2	5	5	O	a
3	7	12	O	single
4	14	17	O	oral
5	19	20	O	30
6	22	23	O	mg
7	25	28	O	dose
8	30	31	O	of
9	33	42	O	XXXXXXXX
10	44	46	O	was
11	48	59	O	administered
12	61	62	O	at
13	64	76	U-KIN	phenobarbital
14	78	83	O	steady
15	85	89	O	state
16	92	94	O	100
17	96	97	O	mg
18	99	102	O	once
19	104	108	O	daily
20	110	112	O	for
21	114	115	O	14
22	117	120	O	days
23	122	122	O	,
24	124	133	O	XXXXXXXX
25	135	137	O	AUC
26	139	141	O	and
27	143	144	O	T%
28	146	149	O	were
29	151	157	O	reduced
30	160	161	O	by
31	163	164	O	an
32	166	172	O	average
33	174	175	O	of
34	177	179	O	25%
35	181	183	O	and
36	185	187	O	38%
37	188	188	O	,
38	190	201	O	respectively
39	204	211	O	compared
40	213	214	O	to
41	216	225	O	XXXXXXXX
42	227	238	O	administered
43	240	244	O	alone
K/13:C54607

Paroxetine	4109	34073-7	326e8ab0-6886-4749-9544-885b37070051	10
The effect of paroxetine on phenobarbital pharmacokinetics was not studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	40	O	phenobarbital
7	42	57	O	pharmacokinetics
8	59	61	O	was
9	63	65	O	not
10	67	73	O	studied
NULL

Paroxetine	4110	34073-7	326e8ab0-6886-4749-9544-885b37070051	25
Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed.
1	0	4	O	Since
2	6	15	O	XXXXXXXX
3	17	24	O	exhibits
4	26	34	O	nonlinear
5	36	51	O	pharmacokinetics
6	52	52	O	,
7	54	56	O	the
8	58	64	O	results
9	66	67	O	of
10	69	72	O	this
11	74	78	O	study
12	80	82	O	may
13	84	86	O	not
14	88	94	O	address
15	96	98	O	the
16	100	103	O	case
17	105	109	O	where
18	111	113	O	the
19	115	115	O	2
20	117	121	O	drugs
21	123	125	O	are
22	127	130	O	both
23	132	136	O	being
24	138	148	O	chronically
25	150	154	O	dosed
NULL

Paroxetine	4111	34073-7	326e8ab0-6886-4749-9544-885b37070051	22
No initial dosage adjustment of paroxetine is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.
1	0	1	O	No
2	3	9	O	initial
3	11	16	O	dosage
4	18	27	O	adjustment
5	29	30	O	of
6	32	41	O	XXXXXXXX
7	43	44	O	is
8	46	55	O	considered
9	57	65	O	necessary
10	67	70	O	when
11	72	85	O	coadministered
12	87	90	O	with
13	92	104	O	phenobarbital
14	107	109	O	any
15	111	120	O	subsequent
16	122	131	O	adjustment
17	133	138	O	should
18	140	141	O	be
19	143	148	O	guided
20	150	151	O	by
21	153	160	O	clinical
22	162	167	O	effect
NULL

Paroxetine	4112	34073-7	326e8ab0-6886-4749-9544-885b37070051	44
Phenytoin When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T% were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone.
1	0	8	O	Phenytoin
2	10	13	O	When
3	15	15	O	a
4	17	22	O	single
5	24	27	O	oral
6	29	30	O	30
7	32	33	O	mg
8	35	38	O	dose
9	40	41	O	of
10	43	52	O	XXXXXXXX
11	54	56	O	was
12	58	69	O	administered
13	71	72	O	at
14	74	82	U-KIN	phenytoin
15	84	89	O	steady
16	91	95	O	state
17	98	100	O	300
18	102	103	O	mg
19	105	108	O	once
20	110	114	O	daily
21	116	118	O	for
22	120	121	O	14
23	123	126	O	days
24	128	128	O	,
25	130	139	O	XXXXXXXX
26	141	143	O	AUC
27	145	147	O	and
28	149	150	O	T%
29	152	155	O	were
30	157	163	O	reduced
31	166	167	O	by
32	169	170	O	an
33	172	178	O	average
34	180	181	O	of
35	183	185	O	50%
36	187	189	O	and
37	191	193	O	35%
38	194	194	O	,
39	196	207	O	respectively
40	210	217	O	compared
41	219	220	O	to
42	222	231	O	XXXXXXXX
43	233	244	O	administered
44	246	250	O	alone
K/14:C54609

Paroxetine	4113	34073-7	326e8ab0-6886-4749-9544-885b37070051	41
In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	separate
4	14	18	O	study
5	19	19	O	,
6	21	24	O	when
7	26	26	O	a
8	28	33	O	single
9	35	38	O	oral
10	40	42	O	300
11	44	45	O	mg
12	47	50	O	dose
13	52	53	O	of
14	55	63	U-KIN	phenytoin
15	65	67	O	was
16	69	80	O	administered
17	82	83	O	at
18	85	94	O	XXXXXXXX
19	96	101	O	steady
20	103	107	O	state
21	110	111	O	30
22	113	114	O	mg
23	116	119	O	once
24	121	125	O	daily
25	127	129	O	for
26	131	132	O	14
27	134	137	O	days
28	139	139	O	,
29	141	149	O	phenytoin
30	151	153	O	AUC
31	155	157	O	was
32	159	166	O	slightly
33	168	174	O	reduced
34	177	179	O	12%
35	181	182	O	on
36	184	190	O	average
37	193	200	O	compared
38	202	203	O	to
39	205	213	O	phenytoin
40	215	226	O	administered
41	228	232	O	alone
K/14:C54614

Paroxetine	4114	34073-7	326e8ab0-6886-4749-9544-885b37070051	24
Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed.
1	0	4	O	Since
2	6	9	O	both
3	11	15	O	drugs
4	17	23	O	exhibit
5	25	33	O	nonlinear
6	35	50	O	pharmacokinetics
7	51	51	O	,
8	53	55	O	the
9	57	61	O	above
10	63	69	O	studies
11	71	73	O	may
12	75	77	O	not
13	79	85	O	address
14	87	89	O	the
15	91	94	O	case
16	96	100	O	where
17	102	104	O	the
18	106	106	O	2
19	108	112	O	drugs
20	114	116	O	are
21	118	121	O	both
22	123	127	O	being
23	129	139	O	chronically
24	141	145	O	dosed
NULL

Paroxetine	4115	34073-7	326e8ab0-6886-4749-9544-885b37070051	21
No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect.
1	0	1	O	No
2	3	9	O	initial
3	11	16	O	dosage
4	18	28	O	adjustments
5	30	32	O	are
6	34	43	O	considered
7	45	53	O	necessary
8	55	58	O	when
9	60	64	O	these
10	66	70	O	drugs
11	72	74	O	are
12	76	89	O	coadministered
13	92	94	O	any
14	96	105	O	subsequent
15	107	117	O	adjustments
16	119	124	O	should
17	126	127	O	be
18	129	134	O	guided
19	136	137	O	by
20	139	146	O	clinical
21	148	153	O	effect
NULL

Paroxetine	4116	34073-7	326e8ab0-6886-4749-9544-885b37070051	30
Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6.
1	0	3	O	Many
2	5	9	O	drugs
3	10	10	O	,
4	12	20	O	including
5	22	25	O	most
6	27	31	O	drugs
7	33	41	O	effective
8	43	44	O	in
9	46	48	O	the
10	50	58	O	treatment
11	60	61	O	of
12	63	67	O	major
13	69	78	O	depressive
14	80	87	O	disorder
15	90	99	O	XXXXXXXX
16	100	100	O	,
17	102	106	O	other
18	108	112	O	SSRIs
19	114	116	O	and
20	118	121	O	many
21	123	132	O	tricyclics
22	134	134	O	,
23	136	138	O	are
24	140	150	O	metabolized
25	152	153	O	by
26	155	157	O	the
27	159	168	O	cytochrome
28	170	173	O	P450
29	175	181	O	isozyme
30	183	188	O	CYP2D6
NULL

Paroxetine	4117	34073-7	326e8ab0-6886-4749-9544-885b37070051	18
Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme.
1	0	3	O	Like
2	5	9	O	other
3	11	16	O	agents
4	18	21	O	that
5	23	25	O	are
6	27	37	O	metabolized
7	39	40	O	by
8	42	47	O	CYP2D6
9	48	48	O	,
10	50	59	O	XXXXXXXX
11	61	63	O	may
12	65	77	O	significantly
13	79	85	O	inhibit
14	87	89	O	the
15	91	98	O	activity
16	100	101	O	of
17	103	106	O	this
18	108	114	O	isozyme
NULL

Paroxetine	4118	34073-7	326e8ab0-6886-4749-9544-885b37070051	15
In most patients (>90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine.
1	0	1	O	In
2	3	6	O	most
3	8	15	O	patients
4	18	21	O	>90%
5	23	23	O	,
6	25	28	O	this
7	30	35	O	CYP2D6
8	37	43	O	isozyme
9	45	46	O	is
10	48	56	O	saturated
11	58	62	O	early
12	64	69	O	during
13	71	76	O	dosing
14	78	81	O	with
15	83	92	O	XXXXXXXX
NULL

Paroxetine	4119	34073-7	326e8ab0-6886-4749-9544-885b37070051	42
In 1 study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T% by an average of approximately 2-, 5-, and 3-fold, respectively.
1	0	1	O	In
2	3	3	O	1
3	5	9	O	study
4	10	10	O	,
5	12	16	O	daily
6	18	23	O	dosing
7	25	26	O	of
8	28	37	O	XXXXXXXX
9	40	41	O	20
10	43	44	O	mg
11	46	49	O	once
12	51	55	O	daily
13	58	62	O	under
14	64	69	O	steady
15	71	75	O	state
16	77	86	O	conditions
17	88	96	O	increased
18	98	103	O	single
19	105	108	O	dose
20	110	120	U-KIN	desipramine
21	123	125	O	100
22	127	128	O	mg
23	131	134	O	Cmax
24	135	135	O	,
25	137	139	O	AUC
26	140	140	O	,
27	142	144	O	and
28	146	147	O	T%
29	149	150	O	by
30	152	153	O	an
31	155	161	O	average
32	163	164	O	of
33	166	178	O	approximately
34	180	180	O	2
35	182	182	O	,
36	184	184	O	5
37	186	186	O	,
38	188	190	O	and
39	192	192	O	3
40	194	197	O	fold
41	198	198	O	,
42	200	211	O	respectively
K/20:C54613

Paroxetine	4120	34073-7	326e8ab0-6886-4749-9544-885b37070051	14
Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	33	O	with
6	35	45	O	risperidone
7	46	46	O	,
8	48	48	O	a
9	50	55	O	CYP2D6
10	57	65	O	substrate
11	67	69	O	has
12	71	74	O	also
13	76	79	O	been
14	81	89	O	evaluated
NULL

Paroxetine	4121	34073-7	326e8ab0-6886-4749-9544-885b37070051	55
In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.
1	0	1	O	In
2	3	3	O	1
3	5	9	O	study
4	10	10	O	,
5	12	16	O	daily
6	18	23	O	dosing
7	25	26	O	of
8	28	37	O	XXXXXXXX
9	39	40	O	20
10	42	43	O	mg
11	45	46	O	in
12	48	55	O	patients
13	57	66	O	stabilized
14	68	69	O	on
15	71	81	U-KIN	risperidone
16	84	84	O	4
17	86	87	O	to
18	89	89	O	8
19	91	92	O	mg
20	93	93	O	/
21	94	96	O	day
22	99	107	O	increased
23	109	112	O	mean
24	114	119	O	plasma
25	121	134	O	concentrations
26	136	137	O	of
27	139	149	O	risperidone
28	151	163	O	approximately
29	165	165	O	4
30	167	170	O	fold
31	171	171	O	,
32	173	181	O	decreased
33	183	183	O	9
34	185	202	O	hydroxyrisperidone
35	204	217	O	concentrations
36	219	231	O	approximately
37	233	235	O	10%
38	236	236	O	,
39	238	240	O	and
40	242	250	O	increased
41	252	265	O	concentrations
42	267	268	O	of
43	270	272	O	the
44	274	279	O	active
45	281	286	O	moiety
46	289	291	O	the
47	293	295	O	sum
48	297	298	O	of
49	300	310	O	risperidone
50	312	315	O	plus
51	317	317	O	9
52	319	336	O	hydroxyrisperidone
53	339	351	O	approximately
54	353	355	O	1.4
55	357	360	O	fold
K/15:C54357

Paroxetine	4122	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	XXXXXXXX
5	25	26	O	on
6	28	30	O	the
7	32	47	O	pharmacokinetics
8	49	50	O	of
9	52	62	O	atomoxetine
10	64	66	O	has
11	68	71	O	been
12	73	81	O	evaluated
13	83	86	O	when
14	88	91	O	both
15	93	97	O	drugs
16	99	102	O	were
17	104	105	O	at
18	107	112	O	steady
19	114	118	O	state
NULL

Paroxetine	4123	34073-7	326e8ab0-6886-4749-9544-885b37070051	25
In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours.
1	0	1	O	In
2	3	9	O	healthy
3	11	20	O	volunteers
4	22	24	O	who
5	26	29	O	were
6	31	39	O	extensive
7	41	52	O	metabolizers
8	54	55	O	of
9	57	62	O	CYP2D6
10	63	63	O	,
11	65	74	O	XXXXXXXX
12	76	77	O	20
13	79	80	O	mg
14	82	86	O	daily
15	88	90	O	was
16	92	96	O	given
17	98	99	O	in
18	101	111	O	combination
19	113	116	O	with
20	118	119	O	20
21	121	122	O	mg
22	124	134	O	atomoxetine
23	136	140	O	every
24	142	143	O	12
25	145	149	O	hours
NULL

Paroxetine	4124	34073-7	326e8ab0-6886-4749-9544-885b37070051	35
This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone.
1	0	3	O	This
2	5	12	O	resulted
3	14	15	O	in
4	17	25	O	increases
5	27	28	O	in
6	30	35	O	steady
7	37	41	O	state
8	43	53	U-KIN	atomoxetine
9	55	57	O	AUC
10	59	64	O	values
11	66	69	O	that
12	71	74	O	were
13	76	76	O	6
14	79	80	O	to
15	82	82	O	8
16	84	87	O	fold
17	89	95	O	greater
18	97	99	O	and
19	101	102	O	in
20	104	114	O	atomoxetine
21	116	119	O	Cmax
22	121	126	O	values
23	128	131	O	that
24	133	136	O	were
25	138	138	O	3
26	141	142	O	to
27	144	144	O	4
28	146	149	O	fold
29	151	157	O	greater
30	159	162	O	than
31	164	167	O	when
32	169	179	O	atomoxetine
33	181	183	O	was
34	185	189	O	given
35	191	195	O	alone
K/8:C54613

Paroxetine	4125	34073-7	326e8ab0-6886-4749-9544-885b37070051	25
Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	19	O	of
4	21	31	U-KIN	atomoxetine
5	33	35	O	may
6	37	38	O	be
7	40	48	O	necessary
8	50	52	O	and
9	54	55	O	it
10	57	58	O	is
11	60	70	O	recommended
12	72	75	O	that
13	77	87	O	atomoxetine
14	89	90	O	be
15	92	100	O	initiated
16	102	103	O	at
17	105	105	O	a
18	107	113	B-TRI	reduced
19	115	118	L-TRI	dose
20	120	123	O	when
21	125	126	O	it
22	128	129	O	is
23	131	135	O	given
24	137	140	O	with
25	142	151	O	XXXXXXXX
K/4:C54357

Paroxetine	4126	34073-7	326e8ab0-6886-4749-9544-885b37070051	31
Concomitant use of paroxetine with other drugs metabolized by cytochrome CYP2D6 has not been formally studied but may require lower doses than usually prescribed for either paroxetine or the other drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	33	O	with
6	35	39	O	other
7	41	45	B-KIN	drugs
8	47	57	I-KIN	metabolized
9	59	60	I-KIN	by
10	62	71	I-KIN	cytochrome
11	73	78	L-KIN	CYP2D6
12	80	82	O	has
13	84	86	O	not
14	88	91	O	been
15	93	100	O	formally
16	102	108	O	studied
17	110	112	O	but
18	114	116	O	may
19	118	124	O	require
20	126	130	B-TRI	lower
21	132	136	L-TRI	doses
22	138	141	O	than
23	143	149	O	usually
24	151	160	O	prescribed
25	162	164	O	for
26	166	171	O	either
27	173	182	O	XXXXXXXX
28	184	185	O	or
29	187	189	O	the
30	191	195	O	other
31	197	200	O	drug
K/7:C54355

Paroxetine	4127	34073-7	326e8ab0-6886-4749-9544-885b37070051	68
Therefore, coadministration of paroxetine with other drugs that are metabolized by this isozyme, including certain drugs effective in the treatment of major depressive disorder (e.g., nortriptyline, amitriptyline, imipramine, desipramine, and fluoxetine), phenothiazines, risperidone,and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide), or that inhibit this enzyme (e.g., quinidine), should be approached with caution.
1	0	8	O	Therefore
2	9	9	O	,
3	11	26	O	coadministration
4	28	29	O	of
5	31	40	O	XXXXXXXX
6	42	45	O	with
7	47	51	O	other
8	53	57	O	drugs
9	59	62	O	that
10	64	66	O	are
11	68	78	O	metabolized
12	80	81	O	by
13	83	86	O	this
14	88	94	O	isozyme
15	95	95	O	,
16	97	105	O	including
17	107	113	O	certain
18	115	119	B-UNK	drugs
19	121	129	I-UNK	effective
20	131	132	I-UNK	in
21	134	136	I-UNK	the
22	138	146	I-UNK	treatment
23	148	149	I-UNK	of
24	151	155	I-UNK	major
25	157	166	I-UNK	depressive
26	168	175	L-UNK	disorder
27	178	180	O	e.g
28	182	182	O	,
29	184	196	U-UNK	nortriptyline
30	197	197	O	,
31	199	211	U-UNK	amitriptyline
32	212	212	O	,
33	214	223	U-UNK	imipramine
34	224	224	O	,
35	226	236	U-UNK	desipramine
36	237	237	O	,
37	239	241	O	and
38	243	252	U-UNK	fluoxetine
39	254	254	O	,
40	256	269	U-UNK	phenothiazines
41	270	270	O	,
42	272	286	O	risperidone,and
43	288	291	B-UNK	Type
44	293	294	I-UNK	1C
45	296	310	L-UNK	antiarrhythmics
46	313	315	O	e.g
47	317	317	O	,
48	319	329	U-UNK	propafenone
49	330	330	O	,
50	332	341	U-UNK	flecainide
51	342	342	O	,
52	344	346	O	and
53	348	356	U-UNK	encainide
54	358	358	O	,
55	360	361	O	or
56	363	366	O	that
57	368	374	O	inhibit
58	376	379	O	this
59	381	386	O	enzyme
60	389	391	O	e.g
61	393	393	O	,
62	395	403	U-UNK	quinidine
63	405	405	O	,
64	407	412	O	should
65	414	415	O	be
66	417	426	O	approached
67	428	431	O	with
68	433	439	U-TRI	caution
NULL

Paroxetine	4128	34073-7	326e8ab0-6886-4749-9544-885b37070051	29
However, due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, paroxetine and thioridazine should not be coadministered.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	due
4	13	14	O	to
5	16	18	O	the
6	20	23	O	risk
7	25	26	O	of
8	28	34	B-EFF	serious
9	36	46	I-EFF	ventricular
10	48	58	L-EFF	arrhythmias
11	60	62	O	and
12	64	69	B-EFF	sudden
13	71	75	L-EFF	death
14	77	87	O	potentially
15	89	98	O	associated
16	100	103	O	with
17	105	112	B-TRI	elevated
18	114	119	I-TRI	plasma
19	121	126	L-TRI	levels
20	128	129	O	of
21	131	142	U-DYN	thioridazine
22	143	143	O	,
23	145	154	O	XXXXXXXX
24	156	158	O	and
25	160	171	O	thioridazine
26	173	178	O	should
27	180	182	O	not
28	184	185	O	be
29	187	200	O	coadministered
D/21:12:1 D/21:8:1

Paroxetine	4129	34073-7	326e8ab0-6886-4749-9544-885b37070051	10
Tamoxifen is a pro-drug requiring metabolic activation by CYP2D6.
1	0	8	O	Tamoxifen
2	10	11	O	is
3	13	13	O	a
4	15	17	O	pro
5	19	22	O	drug
6	24	32	O	requiring
7	34	42	O	metabolic
8	44	53	O	activation
9	55	56	O	by
10	58	63	O	CYP2D6
NULL

Paroxetine	4130	34073-7	326e8ab0-6886-4749-9544-885b37070051	22
Inhibition of CYP2D6 by paroxetine may lead to reduced plasma concentrations of an active metabolite (endoxifen) and hence reduced efficacy of tamoxifen.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	19	O	CYP2D6
4	21	22	O	by
5	24	33	O	XXXXXXXX
6	35	37	O	may
7	39	42	O	lead
8	44	45	O	to
9	47	53	B-EFF	reduced
10	55	60	I-EFF	plasma
11	62	75	I-EFF	concentrations
12	77	78	I-EFF	of
13	80	81	I-EFF	an
14	83	88	I-EFF	active
15	90	99	L-EFF	metabolite
16	102	110	O	endoxifen
17	113	115	O	and
18	117	121	O	hence
19	123	129	B-EFF	reduced
20	131	138	I-EFF	efficacy
21	140	141	I-EFF	of
22	143	151	L-EFF	tamoxifen
NULL

Paroxetine	4131	34073-7	326e8ab0-6886-4749-9544-885b37070051	30
At steady state, when the CYP2D6 pathway is essentially saturated, paroxetine clearance is governed by alternative P450 isozymes that, unlike CYP2D6, show no evidence of saturation.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	20	O	when
6	22	24	O	the
7	26	31	O	CYP2D6
8	33	39	O	pathway
9	41	42	O	is
10	44	54	O	essentially
11	56	64	O	saturated
12	65	65	O	,
13	67	76	O	XXXXXXXX
14	78	86	O	clearance
15	88	89	O	is
16	91	98	O	governed
17	100	101	O	by
18	103	113	O	alternative
19	115	118	O	P450
20	120	127	O	isozymes
21	129	132	O	that
22	133	133	O	,
23	135	140	O	unlike
24	142	147	O	CYP2D6
25	148	148	O	,
26	150	153	O	show
27	155	156	O	no
28	158	165	O	evidence
29	167	168	O	of
30	170	179	O	saturation
NULL

Paroxetine	4132	34073-7	326e8ab0-6886-4749-9544-885b37070051	36
Drugs Metabolized by Cytochrome CYP3A4 An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	30	O	Cytochrome
5	32	37	O	CYP3A4
6	39	40	O	An
7	42	43	O	in
8	45	48	O	vivo
9	50	60	O	interaction
10	62	66	O	study
11	68	76	O	involving
12	78	80	O	the
13	82	97	O	coadministration
14	99	103	O	under
15	105	110	O	steady
16	112	116	O	state
17	118	127	O	conditions
18	129	130	O	of
19	132	141	O	XXXXXXXX
20	143	145	O	and
21	147	157	O	terfenadine
22	158	158	O	,
23	160	160	O	a
24	162	170	O	substrate
25	172	174	O	for
26	176	185	O	cytochrome
27	187	192	O	CYP3A4
28	193	193	O	,
29	195	202	O	revealed
30	204	205	O	no
31	207	212	O	effect
32	214	215	O	of
33	217	226	O	XXXXXXXX
34	228	229	O	on
35	231	241	O	terfenadine
36	243	258	O	pharmacokinetics
NULL

Paroxetine	4133	34073-7	326e8ab0-6886-4749-9544-885b37070051	51
In addition, in vitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100 times more potent than paroxetine as an inhibitor of the metabolism of several substrates for this enzyme, including terfenadine, astemizole, cisapride, triazolam, and cyclosporine.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	in
5	16	20	O	vitro
6	22	28	O	studies
7	30	33	O	have
8	35	39	O	shown
9	41	52	O	ketoconazole
10	53	53	O	,
11	55	55	O	a
12	57	62	O	potent
13	64	72	O	inhibitor
14	74	75	O	of
15	77	82	O	CYP3A4
16	84	91	O	activity
17	92	92	O	,
18	94	95	O	to
19	97	98	O	be
20	100	101	O	at
21	103	107	O	least
22	109	111	O	100
23	113	117	O	times
24	119	122	O	more
25	124	129	O	potent
26	131	134	O	than
27	136	145	O	XXXXXXXX
28	147	148	O	as
29	150	151	O	an
30	153	161	O	inhibitor
31	163	164	O	of
32	166	168	O	the
33	170	179	O	metabolism
34	181	182	O	of
35	184	190	O	several
36	192	201	O	substrates
37	203	205	O	for
38	207	210	O	this
39	212	217	O	enzyme
40	218	218	O	,
41	220	228	O	including
42	230	240	O	terfenadine
43	241	241	O	,
44	243	252	O	astemizole
45	253	253	O	,
46	255	263	O	cisapride
47	264	264	O	,
48	266	274	O	triazolam
49	275	275	O	,
50	277	279	O	and
51	281	292	O	cyclosporine
NULL

Paroxetine	4134	34073-7	326e8ab0-6886-4749-9544-885b37070051	47
Based on the assumption that the relationship between paroxetine's in vitro Ki and its lack of effect on terfenadine's in vivo clearance predicts its effect on other CYP3A4 substrates, paroxetine's extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	22	O	assumption
5	24	27	O	that
6	29	31	O	the
7	33	44	O	relationship
8	46	52	O	between
9	54	63	O	XXXXXXXX
10	64	65	O	's
11	67	68	O	in
12	70	74	O	vitro
13	76	77	O	Ki
14	79	81	O	and
15	83	85	O	its
16	87	90	O	lack
17	92	93	O	of
18	95	100	O	effect
19	102	103	O	on
20	105	117	O	terfenadine's
21	119	120	O	in
22	122	125	O	vivo
23	127	135	O	clearance
24	137	144	O	predicts
25	146	148	O	its
26	150	155	O	effect
27	157	158	O	on
28	160	164	O	other
29	166	171	O	CYP3A4
30	173	182	O	substrates
31	183	183	O	,
32	185	194	O	XXXXXXXX
33	195	196	O	's
34	198	203	O	extent
35	205	206	O	of
36	208	217	O	inhibition
37	219	220	O	of
38	222	227	O	CYP3A4
39	229	236	O	activity
40	238	239	O	is
41	241	243	O	not
42	245	250	O	likely
43	252	253	O	to
44	255	256	O	be
45	258	259	O	of
46	261	268	O	clinical
47	270	281	O	significance
NULL

Paroxetine	4135	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
Caution is indicated in the coadministration of tricyclic antidepressants (TCAs) with paroxetine, because paroxetine may inhibit TCA metabolism.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	22	O	in
5	24	26	O	the
6	28	43	O	coadministration
7	45	46	O	of
8	48	56	B-KIN	tricyclic
9	58	72	I-KIN	antidepressants
10	75	78	L-KIN	TCAs
11	81	84	O	with
12	86	95	O	XXXXXXXX
13	96	96	O	,
14	98	104	O	because
15	106	115	O	XXXXXXXX
16	117	119	O	may
17	121	127	O	inhibit
18	129	131	O	TCA
19	133	142	O	metabolism
K/8:C54357

Paroxetine	4136	34073-7	326e8ab0-6886-4749-9544-885b37070051	27
Plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced, if a TCA is coadministered with paroxetine.
1	0	5	O	Plasma
2	7	9	U-KIN	TCA
3	11	24	O	concentrations
4	26	28	O	may
5	30	33	O	need
6	35	36	O	to
7	38	39	O	be
8	41	49	O	monitored
9	50	50	O	,
10	52	54	O	and
11	56	58	O	the
12	60	63	O	dose
13	65	66	O	of
14	68	70	O	TCA
15	72	74	O	may
16	76	79	O	need
17	81	82	O	to
18	84	85	O	be
19	87	93	O	reduced
20	94	94	O	,
21	96	97	O	if
22	99	99	O	a
23	101	103	O	TCA
24	105	106	O	is
25	108	121	O	coadministered
26	123	126	O	with
27	128	137	O	XXXXXXXX
K/2:C54357

Paroxetine	4137	34073-7	326e8ab0-6886-4749-9544-885b37070051	44
Drugs Highly Bound to Plasma Protein Because paroxetine is highly bound to plasma protein, administration of paroxetine to a patient taking another drug that is highly protein bound may cause increased free concentrations of the other drug, potentially resulting in adverse events.
1	0	4	B-KIN	Drugs
2	6	11	I-KIN	Highly
3	13	17	I-KIN	Bound
4	19	20	I-KIN	to
5	22	27	I-KIN	Plasma
6	29	35	L-KIN	Protein
7	37	43	O	Because
8	45	54	O	XXXXXXXX
9	56	57	O	is
10	59	64	O	highly
11	66	70	O	bound
12	72	73	O	to
13	75	80	O	plasma
14	82	88	O	protein
15	89	89	O	,
16	91	104	O	administration
17	106	107	O	of
18	109	118	O	XXXXXXXX
19	120	121	O	to
20	123	123	O	a
21	125	131	O	patient
22	133	138	O	taking
23	140	146	O	another
24	148	151	B-KIN	drug
25	153	156	I-KIN	that
26	158	159	I-KIN	is
27	161	166	I-KIN	highly
28	168	174	I-KIN	protein
29	176	180	L-KIN	bound
30	182	184	O	may
31	186	190	O	cause
32	192	200	B-TRI	increased
33	202	205	I-TRI	free
34	207	220	I-TRI	concentrations
35	222	223	I-TRI	of
36	225	227	I-TRI	the
37	229	233	I-TRI	other
38	235	238	L-TRI	drug
39	239	239	O	,
40	241	251	O	potentially
41	253	261	O	resulting
42	263	264	O	in
43	266	272	O	adverse
44	274	279	O	events
K/1:C54357 K/24:C54357

Paroxetine	4138	34073-7	326e8ab0-6886-4749-9544-885b37070051	15
Conversely, adverse effects could result from displacement of paroxetine by other highly bound drugs.
1	0	9	O	Conversely
2	10	10	O	,
3	12	18	B-TRI	adverse
4	20	26	L-TRI	effects
5	28	32	O	could
6	34	39	O	result
7	41	44	O	from
8	46	57	O	displacement
9	59	60	O	of
10	62	71	O	XXXXXXXX
11	73	74	O	by
12	76	80	O	other
13	82	87	B-UNK	highly
14	89	93	I-UNK	bound
15	95	99	L-UNK	drugs
NULL

Paroxetine	4139	34073-7	326e8ab0-6886-4749-9544-885b37070051	23
Drugs That Interfere With Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin) Serotonin release by platelets plays an important role in hemostasis.
1	0	4	O	Drugs
2	6	9	O	That
3	11	19	O	Interfere
4	21	24	O	With
5	26	35	O	Hemostasis
6	38	40	O	e.g
7	42	42	O	,
8	44	49	O	NSAIDs
9	50	50	O	,
10	52	58	O	Aspirin
11	59	59	O	,
12	61	63	O	and
13	65	72	O	Warfarin
14	75	83	O	Serotonin
15	85	91	O	release
16	93	94	O	by
17	96	104	O	platelets
18	106	110	O	plays
19	112	113	O	an
20	115	123	O	important
21	125	128	O	role
22	130	131	O	in
23	133	142	O	hemostasis
NULL

Paroxetine	4140	34073-7	326e8ab0-6886-4749-9544-885b37070051	48
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	O	psychotropic
19	128	132	O	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	O	upper
30	201	216	O	gastrointestinal
31	218	225	U-EFF	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-DYN	NSAID
41	275	276	O	or
42	278	284	U-DYN	aspirin
43	286	288	O	may
44	290	299	O	potentiate
45	301	304	O	this
46	306	309	O	risk
47	311	312	O	of
48	314	321	O	bleeding
D/40:31:1 D/42:31:1

Paroxetine	4141	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	92	O	or
15	94	98	O	SNRIs
16	100	102	O	are
17	104	117	O	coadministered
18	119	122	O	with
19	124	131	U-DYN	warfarin
D/19:1:1 D/19:6:1

Paroxetine	4142	34073-7	326e8ab0-6886-4749-9544-885b37070051	14
Patients receiving warfarin therapy should be carefully monitored when paroxetine is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	B-TRI	should
6	43	44	I-TRI	be
7	46	54	I-TRI	carefully
8	56	64	L-TRI	monitored
9	66	69	O	when
10	71	80	O	XXXXXXXX
11	82	83	O	is
12	85	93	O	initiated
13	95	96	O	or
14	98	109	O	discontinued
NULL

Paroxetine	4143	34073-7	326e8ab0-6886-4749-9544-885b37070051	27
Alcohol Although paroxetine does not increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking paroxetine.
1	0	6	O	Alcohol
2	8	15	O	Although
3	17	26	O	XXXXXXXX
4	28	31	O	does
5	33	35	O	not
6	37	44	O	increase
7	46	48	O	the
8	50	59	O	impairment
9	61	62	O	of
10	64	69	O	mental
11	71	73	O	and
12	75	79	O	motor
13	81	86	O	skills
14	88	93	O	caused
15	95	96	O	by
16	98	104	U-UNK	alcohol
17	105	105	O	,
18	107	114	O	patients
19	116	121	O	should
20	123	124	O	be
21	126	132	O	advised
22	134	135	O	to
23	137	141	U-TRI	avoid
24	143	149	O	alcohol
25	151	155	O	while
26	157	162	O	taking
27	164	173	O	XXXXXXXX
NULL

Paroxetine	4144	34073-7	326e8ab0-6886-4749-9544-885b37070051	18
Lithium A multiple-dose study has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate.
1	0	6	O	Lithium
2	8	8	O	A
3	10	17	O	multiple
4	19	22	O	dose
5	24	28	O	study
6	30	32	O	has
7	34	38	O	shown
8	40	43	O	that
9	45	49	O	there
10	51	52	O	is
11	54	55	O	no
12	57	71	O	pharmacokinetic
13	73	83	O	interaction
14	85	91	O	between
15	93	102	O	XXXXXXXX
16	104	106	O	and
17	108	114	O	lithium
18	116	124	O	carbonate
NULL

Paroxetine	4145	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
However, due to the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with lithium.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	due
4	13	14	O	to
5	16	18	O	the
6	20	28	O	potential
7	30	32	O	for
8	34	42	B-EFF	serotonin
9	44	51	L-EFF	syndrome
10	52	52	O	,
11	54	60	O	caution
12	62	63	O	is
13	65	71	O	advised
14	73	76	O	when
15	78	87	O	XXXXXXXX
16	89	90	O	is
17	92	105	O	coadministered
18	107	110	O	with
19	112	118	U-DYN	lithium
D/19:8:1

Paroxetine	4146	34073-7	326e8ab0-6886-4749-9544-885b37070051	17
Digoxin The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state.
1	0	6	O	Digoxin
2	8	10	O	The
3	12	17	O	steady
4	19	23	O	state
5	25	40	O	pharmacokinetics
6	42	43	O	of
7	45	54	O	XXXXXXXX
8	56	58	O	was
9	60	62	O	not
10	64	70	O	altered
11	72	75	O	when
12	77	88	O	administered
13	90	93	O	with
14	95	101	O	digoxin
15	103	104	O	at
16	106	111	O	steady
17	113	117	O	state
NULL

Paroxetine	4147	34073-7	326e8ab0-6886-4749-9544-885b37070051	14
Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine.
1	0	3	O	Mean
2	5	11	U-KIN	digoxin
3	13	15	O	AUC
4	17	18	O	at
5	20	25	O	steady
6	27	31	O	state
7	33	41	O	decreased
8	43	44	O	by
9	46	48	O	15%
10	50	51	O	in
11	53	55	O	the
12	57	64	O	presence
13	66	67	O	of
14	69	78	O	XXXXXXXX
K/2:C54614

Paroxetine	4148	34073-7	326e8ab0-6886-4749-9544-885b37070051	19
Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.
1	0	4	O	Since
2	6	10	O	there
3	12	13	O	is
4	15	20	O	little
5	22	29	O	clinical
6	31	40	O	experience
7	41	41	O	,
8	43	45	O	the
9	47	56	O	concurrent
10	58	71	O	administration
11	73	74	O	of
12	76	85	O	XXXXXXXX
13	87	89	O	and
14	91	97	U-UNK	digoxin
15	99	104	O	should
16	106	107	O	be
17	109	118	O	undertaken
18	120	123	O	with
19	125	131	U-TRI	caution
NULL

Paroxetine	4149	34073-7	326e8ab0-6886-4749-9544-885b37070051	14
Diazepam Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics.
1	0	7	O	Diazepam
2	9	13	O	Under
3	15	20	O	steady
4	22	26	O	state
5	28	37	O	conditions
6	38	38	O	,
7	40	47	O	diazepam
8	49	52	O	does
9	54	56	O	not
10	58	63	O	appear
11	65	66	O	to
12	68	73	O	affect
13	75	84	O	XXXXXXXX
14	86	93	O	kinetics
NULL

Paroxetine	4150	34073-7	326e8ab0-6886-4749-9544-885b37070051	9
The effects of paroxetine on diazepam were not evaluated.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	24	O	XXXXXXXX
5	26	27	O	on
6	29	36	O	diazepam
7	38	41	O	were
8	43	45	O	not
9	47	55	O	evaluated
NULL

Paroxetine	4151	34073-7	326e8ab0-6886-4749-9544-885b37070051	45
Procyclidine Daily oral dosing of paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state.
1	0	11	O	Procyclidine
2	13	17	O	Daily
3	19	22	O	oral
4	24	29	O	dosing
5	31	32	O	of
6	34	43	O	XXXXXXXX
7	46	47	O	30
8	49	50	O	mg
9	52	55	O	once
10	57	61	O	daily
11	64	72	O	increased
12	74	79	O	steady
13	81	85	O	state
14	87	90	O	AUC0
15	92	93	O	24
16	94	94	O	,
17	96	99	O	Cmax
18	100	100	O	,
19	102	104	O	and
20	106	109	O	Cmin
21	111	116	O	values
22	118	119	O	of
23	121	132	U-KIN	procyclidine
24	135	135	O	5
25	137	138	O	mg
26	140	143	O	oral
27	145	148	O	once
28	150	154	O	daily
29	157	158	O	by
30	160	162	O	35%
31	163	163	O	,
32	165	167	O	37%
33	168	168	O	,
34	170	172	O	and
35	174	176	O	67%
36	177	177	O	,
37	179	190	O	respectively
38	191	191	O	,
39	193	200	O	compared
40	202	203	O	to
41	205	216	O	procyclidine
42	218	222	O	alone
43	224	225	O	at
44	227	232	O	steady
45	234	238	O	state
K/23:C54357

Paroxetine	4152	34073-7	326e8ab0-6886-4749-9544-885b37070051	13
If anticholinergic effects are seen, the dose of procyclidine should be reduced.
1	0	1	O	If
2	3	17	B-EFF	anticholinergic
3	19	25	L-EFF	effects
4	27	29	O	are
5	31	34	O	seen
6	35	35	O	,
7	37	39	O	the
8	41	44	O	dose
9	46	47	O	of
10	49	60	U-DYN	procyclidine
11	62	67	O	should
12	69	70	O	be
13	72	78	O	reduced
D/10:2:1

Paroxetine	4153	34073-7	326e8ab0-6886-4749-9544-885b37070051	41
Beta-Blockers In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with paroxetine (30 mg once daily) for the final 10 days.
1	0	3	O	Beta
2	5	12	O	Blockers
3	14	15	O	In
4	17	17	O	a
5	19	23	O	study
6	25	29	O	where
7	31	41	O	propranolol
8	44	45	O	80
9	47	48	O	mg
10	50	54	O	twice
11	56	60	O	daily
12	63	65	O	was
13	67	71	O	dosed
14	73	78	O	orally
15	80	82	O	for
16	84	85	O	18
17	87	90	O	days
18	91	91	O	,
19	93	95	O	the
20	97	107	O	established
21	109	114	O	steady
22	116	120	O	state
23	122	127	O	plasma
24	129	142	O	concentrations
25	144	145	O	of
26	147	157	O	propranolol
27	159	162	O	were
28	164	172	O	unaltered
29	174	179	O	during
30	181	196	O	coadministration
31	198	201	O	with
32	203	212	O	XXXXXXXX
33	215	216	O	30
34	218	219	O	mg
35	221	224	O	once
36	226	230	O	daily
37	233	235	O	for
38	237	239	O	the
39	241	245	O	final
40	247	248	O	10
41	250	253	O	days
NULL

Paroxetine	4154	34073-7	326e8ab0-6886-4749-9544-885b37070051	10
The effects of propranolol on paroxetine have not been evaluated.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	25	O	propranolol
5	27	28	O	on
6	30	39	O	XXXXXXXX
7	41	44	O	have
8	46	48	O	not
9	50	53	O	been
10	55	63	O	evaluated
NULL

Paroxetine	4155	34073-7	326e8ab0-6886-4749-9544-885b37070051	14
Theophylline Reports of elevated theophylline levels associated with treatment with paroxetine have been reported.
1	0	11	O	Theophylline
2	13	19	O	Reports
3	21	22	O	of
4	24	31	O	elevated
5	33	44	U-KIN	theophylline
6	46	51	O	levels
7	53	62	O	associated
8	64	67	O	with
9	69	77	O	treatment
10	79	82	O	with
11	84	93	O	XXXXXXXX
12	95	98	O	have
13	100	103	O	been
14	105	112	O	reported
K/5:C54357

Paroxetine	4156	34073-7	326e8ab0-6886-4749-9544-885b37070051	23
While this interaction has not been formally studied, it is recommended that theophylline levels be monitored when these drugs are concurrently administered.
1	0	4	O	While
2	6	9	O	this
3	11	21	O	interaction
4	23	25	O	has
5	27	29	O	not
6	31	34	O	been
7	36	43	O	formally
8	45	51	O	studied
9	52	52	O	,
10	54	55	O	it
11	57	58	O	is
12	60	70	O	recommended
13	72	75	O	that
14	77	88	U-UNK	theophylline
15	90	95	O	levels
16	97	98	O	be
17	100	108	O	monitored
18	110	113	O	when
19	115	119	O	these
20	121	125	O	drugs
21	127	129	O	are
22	131	142	O	concurrently
23	144	155	O	administered
NULL

Paroxetine	4157	34073-7	326e8ab0-6886-4749-9544-885b37070051	16
Fosamprenavir/Ritonavir Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine.
1	0	12	O	Fosamprenavir
2	13	13	O	/
3	14	22	O	Ritonavir
4	24	39	O	Coadministration
5	41	42	O	of
6	44	56	U-KIN	fosamprenavir
7	57	57	B-KIN	/
8	58	66	L-KIN	ritonavir
9	68	71	O	with
10	73	82	O	XXXXXXXX
11	84	96	O	significantly
12	98	106	B-TRI	decreased
13	108	113	I-TRI	plasma
14	115	120	L-TRI	levels
15	122	123	O	of
16	125	134	O	XXXXXXXX
K/6:C54356 K/7:C54356

Paroxetine	4158	34073-7	326e8ab0-6886-4749-9544-885b37070051	12
Any dose adjustment should be guided by clinical effect (tolerability and efficacy).
1	0	2	O	Any
2	4	7	O	dose
3	9	18	O	adjustment
4	20	25	O	should
5	27	28	O	be
6	30	35	O	guided
7	37	38	O	by
8	40	47	O	clinical
9	49	54	O	effect
10	57	68	O	tolerability
11	70	72	O	and
12	74	81	O	efficacy
NULL

Paroxetine	4159	34073-7	326e8ab0-6886-4749-9544-885b37070051	16
Electroconvulsive Therapy (ECT) There are no clinical studies of the combined use of ECT and paroxetine.
1	0	16	O	Electroconvulsive
2	18	24	O	Therapy
3	27	29	O	ECT
4	32	36	O	There
5	38	40	O	are
6	42	43	O	no
7	45	52	O	clinical
8	54	60	O	studies
9	62	63	O	of
10	65	67	O	the
11	69	76	O	combined
12	78	80	O	use
13	82	83	O	of
14	85	87	O	ECT
15	89	91	O	and
16	93	102	O	XXXXXXXX
NULL

Paroxetine	4160	34090-1	326e8ab0-6886-4749-9544-885b37070051	55
The efficacy of paroxetine in the treatment of major depressive disorder, obsessive compulsive disorder (OCD), panic disorder (PD), and generalized anxiety disorder (GAD) is presumed to be linked to potentiation of serotonergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-hydroxy-tryptamine, 5-HT).
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	25	O	XXXXXXXX
5	27	28	O	in
6	30	32	O	the
7	34	42	O	treatment
8	44	45	O	of
9	47	51	O	major
10	53	62	O	depressive
11	64	71	O	disorder
12	72	72	O	,
13	74	82	O	obsessive
14	84	93	O	compulsive
15	95	102	O	disorder
16	105	107	O	OCD
17	109	109	O	,
18	111	115	O	panic
19	117	124	O	disorder
20	127	128	O	PD
21	130	130	O	,
22	132	134	O	and
23	136	146	O	generalized
24	148	154	O	anxiety
25	156	163	O	disorder
26	166	168	O	GAD
27	171	172	O	is
28	174	181	O	presumed
29	183	184	O	to
30	186	187	O	be
31	189	194	O	linked
32	196	197	O	to
33	199	210	O	potentiation
34	212	213	O	of
35	215	226	O	serotonergic
36	228	235	O	activity
37	237	238	O	in
38	240	242	O	the
39	244	250	O	central
40	252	258	O	nervous
41	260	265	O	system
42	267	275	O	resulting
43	277	280	O	from
44	282	291	O	inhibition
45	293	294	O	of
46	296	303	O	neuronal
47	305	312	O	reuptake
48	314	315	O	of
49	317	325	O	serotonin
50	328	328	O	5
51	330	336	O	hydroxy
52	338	347	O	tryptamine
53	348	348	O	,
54	350	350	O	5
55	352	353	O	HT
NULL

Paroxetine	4161	34090-1	326e8ab0-6886-4749-9544-885b37070051	19
Studies at clinically relevant doses in humans have demonstrated that paroxetine blocks the uptake of serotonin into human platelets.
1	0	6	O	Studies
2	8	9	O	at
3	11	20	O	clinically
4	22	29	O	relevant
5	31	35	O	doses
6	37	38	O	in
7	40	45	O	humans
8	47	50	O	have
9	52	63	O	demonstrated
10	65	68	O	that
11	70	79	O	XXXXXXXX
12	81	86	O	blocks
13	88	90	O	the
14	92	97	O	uptake
15	99	100	O	of
16	102	110	O	serotonin
17	112	115	O	into
18	117	121	O	human
19	123	131	O	platelets
NULL

Paroxetine	4162	34090-1	326e8ab0-6886-4749-9544-885b37070051	32
In vitro studies in animals also suggest that paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	26	O	animals
6	28	31	O	also
7	33	39	O	suggest
8	41	44	O	that
9	46	55	O	XXXXXXXX
10	57	58	O	is
11	60	60	O	a
12	62	67	O	potent
13	69	71	O	and
14	73	78	O	highly
15	80	88	O	selective
16	90	98	O	inhibitor
17	100	101	O	of
18	103	110	O	neuronal
19	112	120	O	serotonin
20	122	129	O	reuptake
21	131	133	O	and
22	135	137	O	has
23	139	142	O	only
24	144	147	O	very
25	149	152	O	weak
26	154	160	O	effects
27	162	163	O	on
28	165	178	O	norepinephrine
29	180	182	O	and
30	184	191	O	dopamine
31	193	200	O	neuronal
32	202	209	O	reuptake
NULL

Paroxetine	4163	34090-1	326e8ab0-6886-4749-9544-885b37070051	60
In vitro radioligand binding studies indicate that paroxetine has little affinity for muscarinic, alpha1-, alpha2-, beta-adrenergic-, dopamine (D2)-, 5-HT1-, 5-HT2-, and histamine (H1)-receptors; antagonism of muscarinic, histaminergic, and alpha1-adrenergic receptors has been associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs.
1	0	1	O	In
2	3	7	O	vitro
3	9	19	O	radioligand
4	21	27	O	binding
5	29	35	O	studies
6	37	44	O	indicate
7	46	49	O	that
8	51	60	O	XXXXXXXX
9	62	64	O	has
10	66	71	O	little
11	73	80	O	affinity
12	82	84	O	for
13	86	95	O	muscarinic
14	96	96	O	,
15	98	103	O	alpha1
16	105	105	O	,
17	107	112	O	alpha2
18	114	114	O	,
19	116	119	O	beta
20	121	130	O	adrenergic
21	132	132	O	,
22	134	141	O	dopamine
23	144	145	O	D2
24	148	148	O	,
25	150	150	O	5
26	152	154	O	HT1
27	156	156	O	,
28	158	158	O	5
29	160	162	O	HT2
30	164	164	O	,
31	166	168	O	and
32	170	178	O	histamine
33	181	182	O	H1
34	185	193	O	receptors
35	196	205	O	antagonism
36	207	208	O	of
37	210	219	O	muscarinic
38	220	220	O	,
39	222	234	O	histaminergic
40	235	235	O	,
41	237	239	O	and
42	241	246	O	alpha1
43	248	257	O	adrenergic
44	259	267	O	receptors
45	269	271	O	has
46	273	276	O	been
47	278	287	O	associated
48	289	292	O	with
49	294	300	O	various
50	302	316	O	anticholinergic
51	317	317	O	,
52	319	326	O	sedative
53	327	327	O	,
54	329	331	O	and
55	333	346	O	cardiovascular
56	348	354	O	effects
57	356	358	O	for
58	360	364	O	other
59	366	377	O	psychotropic
60	379	383	O	drugs
NULL

Paroxetine	4164	34090-1	326e8ab0-6886-4749-9544-885b37070051	24
Because the relative potencies of paroxetine's major metabolites are at most 1/50 of the parent compound, they are essentially inactive.
1	0	6	O	Because
2	8	10	O	the
3	12	19	O	relative
4	21	29	O	potencies
5	31	32	O	of
6	34	43	O	XXXXXXXX
7	44	45	O	's
8	47	51	O	major
9	53	63	O	metabolites
10	65	67	O	are
11	69	70	O	at
12	72	75	O	most
13	77	77	O	1
14	78	78	O	/
15	79	80	O	50
16	82	83	O	of
17	85	87	O	the
18	89	94	O	parent
19	96	103	O	compound
20	104	104	O	,
21	106	109	O	they
22	111	113	O	are
23	115	125	O	essentially
24	127	134	O	inactive
NULL

Paroxetine	4165	34090-1	326e8ab0-6886-4749-9544-885b37070051	15
Paroxetine hydrochloride is completely absorbed after oral dosing of a solution of the hydrochloride salt.
1	0	9	O	XXXXXXXX
2	11	23	O	hydrochloride
3	25	26	O	is
4	28	37	O	completely
5	39	46	O	absorbed
6	48	52	O	after
7	54	57	O	oral
8	59	64	O	dosing
9	66	67	O	of
10	69	69	O	a
11	71	78	O	solution
12	80	81	O	of
13	83	85	O	the
14	87	99	O	hydrochloride
15	101	104	O	salt
NULL

Paroxetine	4166	34090-1	326e8ab0-6886-4749-9544-885b37070051	24
The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets of paroxetine daily for 30 days.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	is
7	34	46	O	approximately
8	48	49	O	21
9	51	55	O	hours
10	58	59	O	CV
11	61	63	O	32%
12	66	70	O	after
13	72	75	O	oral
14	77	82	O	dosing
15	84	85	O	of
16	87	88	O	30
17	90	91	O	mg
18	93	99	O	tablets
19	101	102	O	of
20	104	113	O	XXXXXXXX
21	115	119	O	daily
22	121	123	O	for
23	125	126	O	30
24	128	131	O	days
NULL

Paroxetine	4167	34090-1	326e8ab0-6886-4749-9544-885b37070051	12
Paroxetine is extensively metabolized and the metabolites are considered to be inactive.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	40	O	and
6	42	44	O	the
7	46	56	O	metabolites
8	58	60	O	are
9	62	71	O	considered
10	73	74	O	to
11	76	77	O	be
12	79	86	O	inactive
NULL

Paroxetine	4168	34090-1	326e8ab0-6886-4749-9544-885b37070051	8
Nonlinearity in pharmacokinetics is observed with increasing doses.
1	0	11	O	Nonlinearity
2	13	14	O	in
3	16	31	O	pharmacokinetics
4	33	34	O	is
5	36	43	O	observed
6	45	48	O	with
7	50	59	O	increasing
8	61	65	O	doses
NULL

Paroxetine	4169	34090-1	326e8ab0-6886-4749-9544-885b37070051	25
Paroxetine metabolism is mediated in part by CYP2D6, and the metabolites are primarily excreted in the urine and to some extent in the feces.
1	0	9	O	XXXXXXXX
2	11	20	O	metabolism
3	22	23	O	is
4	25	32	O	mediated
5	34	35	O	in
6	37	40	O	part
7	42	43	O	by
8	45	50	O	CYP2D6
9	51	51	O	,
10	53	55	O	and
11	57	59	O	the
12	61	71	O	metabolites
13	73	75	O	are
14	77	85	O	primarily
15	87	94	O	excreted
16	96	97	O	in
17	99	101	O	the
18	103	107	O	urine
19	109	111	O	and
20	113	114	O	to
21	116	119	O	some
22	121	126	O	extent
23	128	129	O	in
24	131	133	O	the
25	135	139	O	feces
NULL

Paroxetine	4170	34090-1	326e8ab0-6886-4749-9544-885b37070051	17
Pharmacokinetic behavior of paroxetine has not been evaluated in subjects who are deficient in CYP2D6 (poor metabolizers).
1	0	14	O	Pharmacokinetic
2	16	23	O	behavior
3	25	26	O	of
4	28	37	O	XXXXXXXX
5	39	41	O	has
6	43	45	O	not
7	47	50	O	been
8	52	60	O	evaluated
9	62	63	O	in
10	65	72	O	subjects
11	74	76	O	who
12	78	80	O	are
13	82	90	O	deficient
14	92	93	O	in
15	95	100	O	CYP2D6
16	103	106	O	poor
17	108	119	O	metabolizers
NULL

Paroxetine	4171	34090-1	326e8ab0-6886-4749-9544-885b37070051	39
In a meta-analysis of paroxetine from 4 studies done in healthy volunteers following multiple dosing of 20 mg/day to 40 mg/day, males did not exhibit a significantly lower Cmax or AUC than females.
1	0	1	O	In
2	3	3	O	a
3	5	8	O	meta
4	10	17	O	analysis
5	19	20	O	of
6	22	31	O	XXXXXXXX
7	33	36	O	from
8	38	38	O	4
9	40	46	O	studies
10	48	51	O	done
11	53	54	O	in
12	56	62	O	healthy
13	64	73	O	volunteers
14	75	83	O	following
15	85	92	O	multiple
16	94	99	O	dosing
17	101	102	O	of
18	104	105	O	20
19	107	108	O	mg
20	109	109	O	/
21	110	112	O	day
22	114	115	O	to
23	117	118	O	40
24	120	121	O	mg
25	122	122	O	/
26	123	125	O	day
27	126	126	O	,
28	128	132	O	males
29	134	136	O	did
30	138	140	O	not
31	142	148	O	exhibit
32	150	150	O	a
33	152	164	O	significantly
34	166	170	O	lower
35	172	175	O	Cmax
36	177	178	O	or
37	180	182	O	AUC
38	184	187	O	than
39	189	195	O	females
NULL

Paroxetine	4172	34090-1	326e8ab0-6886-4749-9544-885b37070051	18
Absorption and Distribution Paroxetine hydrochloride is completely absorbed after oral dosing of a solution of the hydrochloride salt.
1	0	9	O	Absorption
2	11	13	O	and
3	15	26	O	Distribution
4	28	37	O	XXXXXXXX
5	39	51	O	hydrochloride
6	53	54	O	is
7	56	65	O	completely
8	67	74	O	absorbed
9	76	80	O	after
10	82	85	O	oral
11	87	92	O	dosing
12	94	95	O	of
13	97	97	O	a
14	99	106	O	solution
15	108	109	O	of
16	111	113	O	the
17	115	127	O	hydrochloride
18	129	132	O	salt
NULL

Paroxetine	4173	34090-1	326e8ab0-6886-4749-9544-885b37070051	44
In a study in which normal male subjects (n = 15) received 30 mg tablets daily for 30 days, steady-state paroxetine concentrations were achieved by approximately 10 days for most subjects, although it may take substantially longer in an occasional patient.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	18	O	which
6	20	25	O	normal
7	27	30	O	male
8	32	39	O	subjects
9	42	42	O	n
10	44	44	O	=
11	46	47	O	15
12	50	57	O	received
13	59	60	O	30
14	62	63	O	mg
15	65	71	O	tablets
16	73	77	O	daily
17	79	81	O	for
18	83	84	O	30
19	86	89	O	days
20	90	90	O	,
21	92	97	O	steady
22	99	103	O	state
23	105	114	O	XXXXXXXX
24	116	129	O	concentrations
25	131	134	O	were
26	136	143	O	achieved
27	145	146	O	by
28	148	160	O	approximately
29	162	163	O	10
30	165	168	O	days
31	170	172	O	for
32	174	177	O	most
33	179	186	O	subjects
34	187	187	O	,
35	189	196	O	although
36	198	199	O	it
37	201	203	O	may
38	205	208	O	take
39	210	222	O	substantially
40	224	229	O	longer
41	231	232	O	in
42	234	235	O	an
43	237	246	O	occasional
44	248	254	O	patient
NULL

Paroxetine	4174	34090-1	326e8ab0-6886-4749-9544-885b37070051	25
At steady state, mean values of Cmax, Tmax, Cmin, and T% were 61.7 ng/mL (CV 45%), 5.2 hr.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	20	O	mean
6	22	27	O	values
7	29	30	O	of
8	32	35	O	Cmax
9	36	36	O	,
10	38	41	O	Tmax
11	42	42	O	,
12	44	47	O	Cmin
13	48	48	O	,
14	50	52	O	and
15	54	55	O	T%
16	57	60	O	were
17	62	65	O	61.7
18	67	68	O	ng
19	69	69	O	/
20	70	71	O	mL
21	74	75	O	CV
22	77	79	O	45%
23	81	81	O	,
24	83	85	O	5.2
25	87	88	O	hr
NULL

Paroxetine	4175	34090-1	326e8ab0-6886-4749-9544-885b37070051	17
(CV 10%), 30.7 ng/mL (CV 67%), and 21 hours (CV 32%), respectively.
1	1	2	O	CV
2	4	6	O	10%
3	8	8	O	,
4	10	13	O	30.7
5	15	16	O	ng
6	17	17	O	/
7	18	19	O	mL
8	22	23	O	CV
9	25	27	O	67%
10	29	29	O	,
11	31	33	O	and
12	35	36	O	21
13	38	42	O	hours
14	45	46	O	CV
15	48	50	O	32%
16	52	52	O	,
17	54	65	O	respectively
NULL

Paroxetine	4176	34090-1	326e8ab0-6886-4749-9544-885b37070051	21
The steady-state Cmax and Cmin values were about 6 and 14 times what would be predicted from single-dose studies.
1	0	2	O	The
2	4	9	O	steady
3	11	15	O	state
4	17	20	O	Cmax
5	22	24	O	and
6	26	29	O	Cmin
7	31	36	O	values
8	38	41	O	were
9	43	47	O	about
10	49	49	O	6
11	51	53	O	and
12	55	56	O	14
13	58	62	O	times
14	64	67	O	what
15	69	73	O	would
16	75	76	O	be
17	78	86	O	predicted
18	88	91	O	from
19	93	98	O	single
20	100	103	O	dose
21	105	111	O	studies
NULL

Paroxetine	4177	34090-1	326e8ab0-6886-4749-9544-885b37070051	25
Steady-state drug exposure based on AUC0-24 was about 8 times greater than would have been predicted from single-dose data in these subjects.
1	0	5	O	Steady
2	7	11	O	state
3	13	16	O	drug
4	18	25	O	exposure
5	27	31	O	based
6	33	34	O	on
7	36	39	O	AUC0
8	41	42	O	24
9	44	46	O	was
10	48	52	O	about
11	54	54	O	8
12	56	60	O	times
13	62	68	O	greater
14	70	73	O	than
15	75	79	O	would
16	81	84	O	have
17	86	89	O	been
18	91	99	O	predicted
19	101	104	O	from
20	106	111	O	single
21	113	116	O	dose
22	118	121	O	data
23	123	124	O	in
24	126	130	O	these
25	132	139	O	subjects
NULL

Paroxetine	4178	34090-1	326e8ab0-6886-4749-9544-885b37070051	20
The excess accumulation is a consequence of the fact that 1 of the enzymes that metabolizes paroxetine is readily saturable.
1	0	2	O	The
2	4	9	O	excess
3	11	22	O	accumulation
4	24	25	O	is
5	27	27	O	a
6	29	39	O	consequence
7	41	42	O	of
8	44	46	O	the
9	48	51	O	fact
10	53	56	O	that
11	58	58	O	1
12	60	61	O	of
13	63	65	O	the
14	67	73	O	enzymes
15	75	78	O	that
16	80	90	O	metabolizes
17	92	101	O	XXXXXXXX
18	103	104	O	is
19	106	112	O	readily
20	114	122	O	saturable
NULL

Paroxetine	4179	34090-1	326e8ab0-6886-4749-9544-885b37070051	21
The effects of food on the bioavailability of paroxetine were studied in subjects administered a single dose with and without food.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	18	O	food
5	20	21	O	on
6	23	25	O	the
7	27	41	O	bioavailability
8	43	44	O	of
9	46	55	O	XXXXXXXX
10	57	60	O	were
11	62	68	O	studied
12	70	71	O	in
13	73	80	O	subjects
14	82	93	O	administered
15	95	95	O	a
16	97	102	O	single
17	104	107	O	dose
18	109	112	O	with
19	114	116	O	and
20	118	124	O	without
21	126	129	O	food
NULL

Paroxetine	4180	34090-1	326e8ab0-6886-4749-9544-885b37070051	36
AUC was only slightly increased (6%) when drug was administered with food but the Cmax was 29% greater, while the time to reach peak plasma concentration decreased from 6.4 hours post-dosing to 4.9 hours.
1	0	2	O	AUC
2	4	6	O	was
3	8	11	O	only
4	13	20	O	slightly
5	22	30	O	increased
6	33	34	O	6%
7	37	40	O	when
8	42	45	O	drug
9	47	49	O	was
10	51	62	O	administered
11	64	67	O	with
12	69	72	U-KIN	food
13	74	76	O	but
14	78	80	O	the
15	82	85	O	Cmax
16	87	89	O	was
17	91	93	O	29%
18	95	101	O	greater
19	102	102	O	,
20	104	108	O	while
21	110	112	O	the
22	114	117	B-TRI	time
23	119	120	I-TRI	to
24	122	126	I-TRI	reach
25	128	131	I-TRI	peak
26	133	138	I-TRI	plasma
27	140	152	I-TRI	concentration
28	154	162	L-TRI	decreased
29	164	167	O	from
30	169	171	O	6.4
31	173	177	O	hours
32	179	182	O	post
33	184	189	O	dosing
34	191	192	O	to
35	194	196	O	4.9
36	198	202	O	hours
K/12:C54608

Paroxetine	4181	34090-1	326e8ab0-6886-4749-9544-885b37070051	17
Paroxetine distributes throughout the body, including the CNS, with only 1% remaining in the plasma.
1	0	9	O	XXXXXXXX
2	11	21	O	distributes
3	23	32	O	throughout
4	34	36	O	the
5	38	41	O	body
6	42	42	O	,
7	44	52	O	including
8	54	56	O	the
9	58	60	O	CNS
10	61	61	O	,
11	63	66	O	with
12	68	71	O	only
13	73	74	O	1%
14	76	84	O	remaining
15	86	87	O	in
16	89	91	O	the
17	93	98	O	plasma
NULL

Paroxetine	4182	34090-1	326e8ab0-6886-4749-9544-885b37070051	23
Approximately 95% and 93% of paroxetine is bound to plasma protein at 100 ng/mL and 400 ng/mL, respectively.
1	0	12	O	Approximately
2	14	16	O	95%
3	18	20	O	and
4	22	24	O	93%
5	26	27	O	of
6	29	38	O	XXXXXXXX
7	40	41	O	is
8	43	47	O	bound
9	49	50	O	to
10	52	57	O	plasma
11	59	65	O	protein
12	67	68	O	at
13	70	72	O	100
14	74	75	O	ng
15	76	76	O	/
16	77	78	O	mL
17	80	82	O	and
18	84	86	O	400
19	88	89	O	ng
20	90	90	O	/
21	91	92	O	mL
22	93	93	O	,
23	95	106	O	respectively
NULL

Paroxetine	4183	34090-1	326e8ab0-6886-4749-9544-885b37070051	15
Under clinical conditions, paroxetine concentrations would normally be less than 400 ng/mL.
1	0	4	O	Under
2	6	13	O	clinical
3	15	24	O	conditions
4	25	25	O	,
5	27	36	O	XXXXXXXX
6	38	51	O	concentrations
7	53	57	O	would
8	59	66	O	normally
9	68	69	O	be
10	71	74	O	less
11	76	79	O	than
12	81	83	O	400
13	85	86	O	ng
14	87	87	O	/
15	88	89	O	mL
NULL

Paroxetine	4184	34090-1	326e8ab0-6886-4749-9544-885b37070051	13
Paroxetine does not alter the in vitro protein binding of phenytoin or warfarin.
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	24	O	alter
5	26	28	O	the
6	30	31	O	in
7	33	37	O	vitro
8	39	45	O	protein
9	47	53	O	binding
10	55	56	O	of
11	58	66	O	phenytoin
12	68	69	O	or
13	71	78	O	warfarin
NULL

Paroxetine	4185	34090-1	326e8ab0-6886-4749-9544-885b37070051	27
Metabolism and Excretion The mean elimination half-life is approximately 21 hours (CV 32%) after oral dosing of 30 mg tablets daily for 30 days of paroxetine.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	23	O	Excretion
4	25	27	O	The
5	29	32	O	mean
6	34	44	O	elimination
7	46	49	O	half
8	51	54	O	life
9	56	57	O	is
10	59	71	O	approximately
11	73	74	O	21
12	76	80	O	hours
13	83	84	O	CV
14	86	88	O	32%
15	91	95	O	after
16	97	100	O	oral
17	102	107	O	dosing
18	109	110	O	of
19	112	113	O	30
20	115	116	O	mg
21	118	124	O	tablets
22	126	130	O	daily
23	132	134	O	for
24	136	137	O	30
25	139	142	O	days
26	144	145	O	of
27	147	156	O	XXXXXXXX
NULL

Paroxetine	4186	34090-1	326e8ab0-6886-4749-9544-885b37070051	49
In steady-state dose proportionality studies involving elderly and nonelderly patients, at doses of 20 mg to 40 mg daily for the elderly and 20 mg to 50 mg daily for the nonelderly, some nonlinearity was observed in both populations, again reflecting a saturable metabolic pathway.
1	0	1	O	In
2	3	8	O	steady
3	10	14	O	state
4	16	19	O	dose
5	21	35	O	proportionality
6	37	43	O	studies
7	45	53	O	involving
8	55	61	O	elderly
9	63	65	O	and
10	67	76	O	nonelderly
11	78	85	O	patients
12	86	86	O	,
13	88	89	O	at
14	91	95	O	doses
15	97	98	O	of
16	100	101	O	20
17	103	104	O	mg
18	106	107	O	to
19	109	110	O	40
20	112	113	O	mg
21	115	119	O	daily
22	121	123	O	for
23	125	127	O	the
24	129	135	O	elderly
25	137	139	O	and
26	141	142	O	20
27	144	145	O	mg
28	147	148	O	to
29	150	151	O	50
30	153	154	O	mg
31	156	160	O	daily
32	162	164	O	for
33	166	168	O	the
34	170	179	O	nonelderly
35	180	180	O	,
36	182	185	O	some
37	187	198	O	nonlinearity
38	200	202	O	was
39	204	211	O	observed
40	213	214	O	in
41	216	219	O	both
42	221	231	O	populations
43	232	232	O	,
44	234	238	O	again
45	240	249	O	reflecting
46	251	251	O	a
47	253	261	O	saturable
48	263	271	O	metabolic
49	273	279	O	pathway
NULL

Paroxetine	4187	34090-1	326e8ab0-6886-4749-9544-885b37070051	25
In comparison to Cmin values after 20 mg daily, values after 40 mg daily were only about 2 to 3 times greater than doubled.
1	0	1	O	In
2	3	12	O	comparison
3	14	15	O	to
4	17	20	O	Cmin
5	22	27	O	values
6	29	33	O	after
7	35	36	O	20
8	38	39	O	mg
9	41	45	O	daily
10	46	46	O	,
11	48	53	O	values
12	55	59	O	after
13	61	62	O	40
14	64	65	O	mg
15	67	71	O	daily
16	73	76	O	were
17	78	81	O	only
18	83	87	O	about
19	89	89	O	2
20	91	92	O	to
21	94	94	O	3
22	96	100	O	times
23	102	108	O	greater
24	110	113	O	than
25	115	121	O	doubled
NULL

Paroxetine	4188	34090-1	326e8ab0-6886-4749-9544-885b37070051	7
Paroxetine is extensively metabolized after oral administration.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	42	O	after
6	44	47	O	oral
7	49	62	O	administration
NULL

Paroxetine	4189	34090-1	326e8ab0-6886-4749-9544-885b37070051	17
The principal metabolites are polar and conjugated products of oxidation and methylation, which are readily cleared.
1	0	2	O	The
2	4	12	O	principal
3	14	24	O	metabolites
4	26	28	O	are
5	30	34	O	polar
6	36	38	O	and
7	40	49	O	conjugated
8	51	58	O	products
9	60	61	O	of
10	63	71	O	oxidation
11	73	75	O	and
12	77	87	O	methylation
13	88	88	O	,
14	90	94	O	which
15	96	98	O	are
16	100	106	O	readily
17	108	114	O	cleared
NULL

Paroxetine	4190	34090-1	326e8ab0-6886-4749-9544-885b37070051	16
Conjugates with glucuronic acid and sulfate predominate, and major metabolites have been isolated and identified.
1	0	9	O	Conjugates
2	11	14	O	with
3	16	25	O	glucuronic
4	27	30	O	acid
5	32	34	O	and
6	36	42	O	sulfate
7	44	54	O	predominate
8	55	55	O	,
9	57	59	O	and
10	61	65	O	major
11	67	77	O	metabolites
12	79	82	O	have
13	84	87	O	been
14	89	96	O	isolated
15	98	100	O	and
16	102	111	O	identified
NULL

Paroxetine	4191	34090-1	326e8ab0-6886-4749-9544-885b37070051	22
Data indicate that the metabolites have no more than 1/50 the potency of the parent compound at inhibiting serotonin uptake.
1	0	3	O	Data
2	5	12	O	indicate
3	14	17	O	that
4	19	21	O	the
5	23	33	O	metabolites
6	35	38	O	have
7	40	41	O	no
8	43	46	O	more
9	48	51	O	than
10	53	53	O	1
11	54	54	O	/
12	55	56	O	50
13	58	60	O	the
14	62	68	O	potency
15	70	71	O	of
16	73	75	O	the
17	77	82	O	parent
18	84	91	O	compound
19	93	94	O	at
20	96	105	O	inhibiting
21	107	115	O	serotonin
22	117	122	O	uptake
NULL

Paroxetine	4192	34090-1	326e8ab0-6886-4749-9544-885b37070051	10
The metabolism of paroxetine is accomplished in part by CYP2D6.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	27	O	XXXXXXXX
5	29	30	O	is
6	32	43	O	accomplished
7	45	46	O	in
8	48	51	O	part
9	53	54	O	by
10	56	61	O	CYP2D6
NULL

Paroxetine	4193	34090-1	326e8ab0-6886-4749-9544-885b37070051	24
Saturation of this enzyme at clinical doses appears to account for the nonlinearity of paroxetine kinetics with increasing dose and increasing duration of treatment.
1	0	9	O	Saturation
2	11	12	O	of
3	14	17	O	this
4	19	24	O	enzyme
5	26	27	O	at
6	29	36	O	clinical
7	38	42	O	doses
8	44	50	O	appears
9	52	53	O	to
10	55	61	O	account
11	63	65	O	for
12	67	69	O	the
13	71	82	O	nonlinearity
14	84	85	O	of
15	87	96	O	XXXXXXXX
16	98	105	O	kinetics
17	107	110	O	with
18	112	121	O	increasing
19	123	126	O	dose
20	128	130	O	and
21	132	141	O	increasing
22	143	150	O	duration
23	152	153	O	of
24	155	163	O	treatment
NULL

Paroxetine	4194	34090-1	326e8ab0-6886-4749-9544-885b37070051	14
The role of this enzyme in paroxetine metabolism also suggests potential drug-drug interactions.
1	0	2	O	The
2	4	7	O	role
3	9	10	O	of
4	12	15	O	this
5	17	22	O	enzyme
6	24	25	O	in
7	27	36	O	XXXXXXXX
8	38	47	O	metabolism
9	49	52	O	also
10	54	61	O	suggests
11	63	71	O	potential
12	73	76	O	drug
13	78	81	O	drug
14	83	94	O	interactions
NULL

Paroxetine	4195	34090-1	326e8ab0-6886-4749-9544-885b37070051	20
Specific Populations Renal and Liver Disease: Increased plasma concentrations of paroxetine occur in subjects with renal and hepatic impairment.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	25	O	Renal
4	27	29	O	and
5	31	35	O	Liver
6	37	43	O	Disease
7	44	44	O	:
8	46	54	O	Increased
9	56	61	O	plasma
10	63	76	O	concentrations
11	78	79	O	of
12	81	90	O	XXXXXXXX
13	92	96	O	occur
14	98	99	O	in
15	101	108	O	subjects
16	110	113	O	with
17	115	119	O	renal
18	121	123	O	and
19	125	131	O	hepatic
20	133	142	O	impairment
NULL

Paroxetine	4196	34090-1	326e8ab0-6886-4749-9544-885b37070051	24
The mean plasma concentrations in patients with creatinine clearance below 30 mL/min. were approximately 4 times greater than seen in normal volunteers.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	plasma
4	16	29	O	concentrations
5	31	32	O	in
6	34	41	O	patients
7	43	46	O	with
8	48	57	O	creatinine
9	59	67	O	clearance
10	69	73	O	below
11	75	76	O	30
12	78	79	O	mL
13	80	80	O	/
14	81	83	O	min
15	86	89	O	were
16	91	103	O	approximately
17	105	105	O	4
18	107	111	O	times
19	113	119	O	greater
20	121	124	O	than
21	126	129	O	seen
22	131	132	O	in
23	134	139	O	normal
24	141	150	O	volunteers
NULL

Paroxetine	4197	34090-1	326e8ab0-6886-4749-9544-885b37070051	29
Patients with creatinine clearance of 30 to 60 mL/min. and patients with hepatic functional impairment had about a 2-fold increase in plasma concentrations (AUC, Cmax).
1	0	7	O	Patients
2	9	12	O	with
3	14	23	O	creatinine
4	25	33	O	clearance
5	35	36	O	of
6	38	39	O	30
7	41	42	O	to
8	44	45	O	60
9	47	48	O	mL
10	49	49	O	/
11	50	52	O	min
12	55	57	O	and
13	59	66	O	patients
14	68	71	O	with
15	73	79	O	hepatic
16	81	90	O	functional
17	92	101	O	impairment
18	103	105	O	had
19	107	111	O	about
20	113	113	O	a
21	115	115	O	2
22	117	120	O	fold
23	122	129	O	increase
24	131	132	O	in
25	134	139	O	plasma
26	141	154	O	concentrations
27	157	159	O	AUC
28	160	160	O	,
29	162	165	O	Cmax
NULL

Paroxetine	4198	34090-1	326e8ab0-6886-4749-9544-885b37070051	28
The initial dosage should therefore be reduced in patients with severe renal or hepatic impairment, and upward titration, if necessary, should be at increased intervals.
1	0	2	O	The
2	4	10	O	initial
3	12	17	O	dosage
4	19	24	O	should
5	26	34	O	therefore
6	36	37	O	be
7	39	45	O	reduced
8	47	48	O	in
9	50	57	O	patients
10	59	62	O	with
11	64	69	O	severe
12	71	75	O	renal
13	77	78	O	or
14	80	86	O	hepatic
15	88	97	O	impairment
16	98	98	O	,
17	100	102	O	and
18	104	109	O	upward
19	111	119	O	titration
20	120	120	O	,
21	122	123	O	if
22	125	133	O	necessary
23	134	134	O	,
24	136	141	O	should
25	143	144	O	be
26	146	147	O	at
27	149	157	O	increased
28	159	167	O	intervals
NULL

Paroxetine	4199	34090-1	326e8ab0-6886-4749-9544-885b37070051	40
Elderly Patients: In a multiple-dose study in the elderly at daily paroxetine doses of 20, 30, and 40 mg, Cmin concentrations were about 70% to 80% greater than the respective Cmin concentrations in nonelderly subjects.
1	0	6	O	Elderly
2	8	15	O	Patients
3	16	16	O	:
4	18	19	O	In
5	21	21	O	a
6	23	30	O	multiple
7	32	35	O	dose
8	37	41	O	study
9	43	44	O	in
10	46	48	O	the
11	50	56	O	elderly
12	58	59	O	at
13	61	65	O	daily
14	67	76	O	XXXXXXXX
15	78	82	O	doses
16	84	85	O	of
17	87	88	O	20
18	89	89	O	,
19	91	92	O	30
20	93	93	O	,
21	95	97	O	and
22	99	100	O	40
23	102	103	O	mg
24	104	104	O	,
25	106	109	O	Cmin
26	111	124	O	concentrations
27	126	129	O	were
28	131	135	O	about
29	137	139	O	70%
30	141	142	O	to
31	144	146	O	80%
32	148	154	O	greater
33	156	159	O	than
34	161	163	O	the
35	165	174	O	respective
36	176	179	O	Cmin
37	181	194	O	concentrations
38	196	197	O	in
39	199	208	O	nonelderly
40	210	217	O	subjects
NULL

Paroxetine	4200	34090-1	326e8ab0-6886-4749-9544-885b37070051	10
Therefore the initial dosage in the elderly should be reduced.
1	0	8	O	Therefore
2	10	12	O	the
3	14	20	O	initial
4	22	27	O	dosage
5	29	30	O	in
6	32	34	O	the
7	36	42	O	elderly
8	44	49	O	should
9	51	52	O	be
10	54	60	O	reduced
NULL

Paroxetine	4201	34090-1	326e8ab0-6886-4749-9544-885b37070051	13
Drug-Drug Interactions In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	24	O	In
5	26	30	O	vitro
6	32	35	O	drug
7	37	47	O	interaction
8	49	55	O	studies
9	57	62	O	reveal
10	64	67	O	that
11	69	78	O	XXXXXXXX
12	80	87	O	inhibits
13	89	94	O	CYP2D6
NULL

Paroxetine	4202	34090-1	326e8ab0-6886-4749-9544-885b37070051	31
Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine.
1	0	7	O	Clinical
2	9	12	O	drug
3	14	24	O	interaction
4	26	32	O	studies
5	34	37	O	have
6	39	42	O	been
7	44	52	O	performed
8	54	57	O	with
9	59	68	O	substrates
10	70	71	O	of
11	73	78	O	CYP2D6
12	80	82	O	and
13	84	87	O	show
14	89	92	O	that
15	94	103	O	XXXXXXXX
16	105	107	O	can
17	109	115	B-TRI	inhibit
18	117	119	I-TRI	the
19	121	130	L-TRI	metabolism
20	132	133	O	of
21	135	139	B-KIN	drugs
22	141	151	I-KIN	metabolized
23	153	154	I-KIN	by
24	156	161	L-KIN	CYP2D6
25	163	171	O	including
26	173	183	U-KIN	desipramine
27	184	184	O	,
28	186	196	U-KIN	risperidone
29	197	197	O	,
30	199	201	O	and
31	203	213	U-KIN	atomoxetine
K/21:C54357 K/26:C54357 K/28:C54357 K/31:C54357

Paroxetine	4203	34090-1	326e8ab0-6886-4749-9544-885b37070051	32
Major Depressive Disorder The efficacy of paroxetine as a treatment for major depressive disorder has been established in 6 placebo-controlled studies of patients with major depressive disorder (aged 18 to 73).
1	0	4	O	Major
2	6	15	O	Depressive
3	17	24	O	Disorder
4	26	28	O	The
5	30	37	O	efficacy
6	39	40	O	of
7	42	51	O	XXXXXXXX
8	53	54	O	as
9	56	56	O	a
10	58	66	O	treatment
11	68	70	O	for
12	72	76	O	major
13	78	87	O	depressive
14	89	96	O	disorder
15	98	100	O	has
16	102	105	O	been
17	107	117	O	established
18	119	120	O	in
19	122	122	O	6
20	124	130	O	placebo
21	132	141	O	controlled
22	143	149	O	studies
23	151	152	O	of
24	154	161	O	patients
25	163	166	O	with
26	168	172	O	major
27	174	183	O	depressive
28	185	192	O	disorder
29	195	198	O	aged
30	200	201	O	18
31	203	204	O	to
32	206	207	O	73
NULL

Paroxetine	4204	34090-1	326e8ab0-6886-4749-9544-885b37070051	49
In these studies, paroxetine was shown to be significantly more effective than placebo in treating major depressive disorder by at least 2 of the following measures: Hamilton Depression Rating Scale (HDRS), the Hamilton depressed mood item, and the Clinical Global Impression (CGI)-Severity of Illness.
1	0	1	O	In
2	3	7	O	these
3	9	15	O	studies
4	16	16	O	,
5	18	27	O	XXXXXXXX
6	29	31	O	was
7	33	37	O	shown
8	39	40	O	to
9	42	43	O	be
10	45	57	O	significantly
11	59	62	O	more
12	64	72	O	effective
13	74	77	O	than
14	79	85	O	placebo
15	87	88	O	in
16	90	97	O	treating
17	99	103	O	major
18	105	114	O	depressive
19	116	123	O	disorder
20	125	126	O	by
21	128	129	O	at
22	131	135	O	least
23	137	137	O	2
24	139	140	O	of
25	142	144	O	the
26	146	154	O	following
27	156	163	O	measures
28	164	164	O	:
29	166	173	O	Hamilton
30	175	184	O	Depression
31	186	191	O	Rating
32	193	197	O	Scale
33	200	203	O	HDRS
34	205	205	O	,
35	207	209	O	the
36	211	218	O	Hamilton
37	220	228	O	depressed
38	230	233	O	mood
39	235	238	O	item
40	239	239	O	,
41	241	243	O	and
42	245	247	O	the
43	249	256	O	Clinical
44	258	263	O	Global
45	265	274	O	Impression
46	277	279	O	CGI
47	282	289	O	Severity
48	291	292	O	of
49	294	300	O	Illness
NULL

Paroxetine	4205	34090-1	326e8ab0-6886-4749-9544-885b37070051	28
Paroxetine was significantly better than placebo in improvement of the HDRS sub-factor scores, including the depressed mood item, sleep disturbance factor, and anxiety factor.
1	0	9	O	XXXXXXXX
2	11	13	O	was
3	15	27	O	significantly
4	29	34	O	better
5	36	39	O	than
6	41	47	O	placebo
7	49	50	O	in
8	52	62	O	improvement
9	64	65	O	of
10	67	69	O	the
11	71	74	O	HDRS
12	76	78	O	sub
13	80	85	O	factor
14	87	92	O	scores
15	93	93	O	,
16	95	103	O	including
17	105	107	O	the
18	109	117	O	depressed
19	119	122	O	mood
20	124	127	O	item
21	128	128	O	,
22	130	134	O	sleep
23	136	146	O	disturbance
24	148	153	O	factor
25	154	154	O	,
26	156	158	O	and
27	160	166	O	anxiety
28	168	173	O	factor
NULL

Paroxetine	4206	34090-1	326e8ab0-6886-4749-9544-885b37070051	55
A study of outpatients with major depressive disorder who had responded to paroxetine (HDRS total score <8) during an initial 8-week open-treatment phase and were then randomized to continuation on paroxetine or placebo for 1 year demonstrated a significantly lower relapse rate for patients taking paroxetine (15%) compared to those on placebo (39%).
1	0	0	O	A
2	2	6	O	study
3	8	9	O	of
4	11	21	O	outpatients
5	23	26	O	with
6	28	32	O	major
7	34	43	O	depressive
8	45	52	O	disorder
9	54	56	O	who
10	58	60	O	had
11	62	70	O	responded
12	72	73	O	to
13	75	84	O	XXXXXXXX
14	87	90	O	HDRS
15	92	96	O	total
16	98	102	O	score
17	104	105	O	<8
18	108	113	O	during
19	115	116	O	an
20	118	124	O	initial
21	126	126	O	8
22	128	131	O	week
23	133	136	O	open
24	138	146	O	treatment
25	148	152	O	phase
26	154	156	O	and
27	158	161	O	were
28	163	166	O	then
29	168	177	O	randomized
30	179	180	O	to
31	182	193	O	continuation
32	195	196	O	on
33	198	207	O	XXXXXXXX
34	209	210	O	or
35	212	218	O	placebo
36	220	222	O	for
37	224	224	O	1
38	226	229	O	year
39	231	242	O	demonstrated
40	244	244	O	a
41	246	258	O	significantly
42	260	264	O	lower
43	266	272	O	relapse
44	274	277	O	rate
45	279	281	O	for
46	283	290	O	patients
47	292	297	O	taking
48	299	308	O	XXXXXXXX
49	311	313	O	15%
50	316	323	O	compared
51	325	326	O	to
52	328	332	O	those
53	334	335	O	on
54	337	343	O	placebo
55	346	348	O	39%
NULL

Paroxetine	4207	34090-1	326e8ab0-6886-4749-9544-885b37070051	8
Effectiveness was similar for male and female patients.
1	0	12	O	Effectiveness
2	14	16	O	was
3	18	24	O	similar
4	26	28	O	for
5	30	33	O	male
6	35	37	O	and
7	39	44	O	female
8	46	53	O	patients
NULL

Paroxetine	4208	34090-1	326e8ab0-6886-4749-9544-885b37070051	32
Obsessive Compulsive Disorder The effectiveness of paroxetine in the treatment of obsessive compulsive disorder (OCD) was demonstrated in two 12-week multicenter placebo-controlled studies of adult outpatients (Studies 1 and 2).
1	0	8	O	Obsessive
2	10	19	O	Compulsive
3	21	28	O	Disorder
4	30	32	O	The
5	34	46	O	effectiveness
6	48	49	O	of
7	51	60	O	XXXXXXXX
8	62	63	O	in
9	65	67	O	the
10	69	77	O	treatment
11	79	80	O	of
12	82	90	O	obsessive
13	92	101	O	compulsive
14	103	110	O	disorder
15	113	115	O	OCD
16	118	120	O	was
17	122	133	O	demonstrated
18	135	136	O	in
19	138	140	O	two
20	142	143	O	12
21	145	148	O	week
22	150	160	O	multicenter
23	162	168	O	placebo
24	170	179	O	controlled
25	181	187	O	studies
26	189	190	O	of
27	192	196	O	adult
28	198	208	O	outpatients
29	211	217	O	Studies
30	219	219	O	1
31	221	223	O	and
32	225	225	O	2
NULL

Paroxetine	4209	34090-1	326e8ab0-6886-4749-9544-885b37070051	30
Patients in all studies had moderate to severe OCD (DSM-IIIR) with mean baseline ratings on the Yale Brown Obsessive Compulsive Scale (YBOCS) total score ranging from 23 to 26.
1	0	7	O	Patients
2	9	10	O	in
3	12	14	O	all
4	16	22	O	studies
5	24	26	O	had
6	28	35	O	moderate
7	37	38	O	to
8	40	45	O	severe
9	47	49	O	OCD
10	52	54	O	DSM
11	56	59	O	IIIR
12	62	65	O	with
13	67	70	O	mean
14	72	79	O	baseline
15	81	87	O	ratings
16	89	90	O	on
17	92	94	O	the
18	96	99	O	Yale
19	101	105	O	Brown
20	107	115	O	Obsessive
21	117	126	O	Compulsive
22	128	132	O	Scale
23	135	139	O	YBOCS
24	142	146	O	total
25	148	152	O	score
26	154	160	O	ranging
27	162	165	O	from
28	167	168	O	23
29	170	171	O	to
30	173	174	O	26
NULL

Paroxetine	4210	34090-1	326e8ab0-6886-4749-9544-885b37070051	44
Study 1, a dose-range finding study where patients were treated with fixed doses of 20, 40, or 60 mg of paroxetine/day demonstrated that daily doses of paroxetine 40 and 60 mg are effective in the treatment of OCD.
1	0	4	O	Study
2	6	6	O	1
3	7	7	O	,
4	9	9	O	a
5	11	14	O	dose
6	16	20	O	range
7	22	28	O	finding
8	30	34	O	study
9	36	40	O	where
10	42	49	O	patients
11	51	54	O	were
12	56	62	O	treated
13	64	67	O	with
14	69	73	O	fixed
15	75	79	O	doses
16	81	82	O	of
17	84	85	O	20
18	86	86	O	,
19	88	89	O	40
20	90	90	O	,
21	92	93	O	or
22	95	96	O	60
23	98	99	O	mg
24	101	102	O	of
25	104	113	O	XXXXXXXX
26	114	114	O	/
27	115	117	O	day
28	119	130	O	demonstrated
29	132	135	O	that
30	137	141	O	daily
31	143	147	O	doses
32	149	150	O	of
33	152	161	O	XXXXXXXX
34	163	164	O	40
35	166	168	O	and
36	170	171	O	60
37	173	174	O	mg
38	176	178	O	are
39	180	188	O	effective
40	190	191	O	in
41	193	195	O	the
42	197	205	O	treatment
43	207	208	O	of
44	210	212	O	OCD
NULL

Paroxetine	4211	34090-1	326e8ab0-6886-4749-9544-885b37070051	50
Patients receiving doses of 40 and 60 mg paroxetine experienced a mean reduction of approximately 6 and 7 points, respectively, on the YBOCS total score which was significantly greater than the approximate 4-point reduction at 20 mg and a 3-point reduction in the placebo-treated patients.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	doses
4	25	26	O	of
5	28	29	O	40
6	31	33	O	and
7	35	36	O	60
8	38	39	O	mg
9	41	50	O	XXXXXXXX
10	52	62	O	experienced
11	64	64	O	a
12	66	69	O	mean
13	71	79	O	reduction
14	81	82	O	of
15	84	96	O	approximately
16	98	98	O	6
17	100	102	O	and
18	104	104	O	7
19	106	111	O	points
20	112	112	O	,
21	114	125	O	respectively
22	126	126	O	,
23	128	129	O	on
24	131	133	O	the
25	135	139	O	YBOCS
26	141	145	O	total
27	147	151	O	score
28	153	157	O	which
29	159	161	O	was
30	163	175	O	significantly
31	177	183	O	greater
32	185	188	O	than
33	190	192	O	the
34	194	204	O	approximate
35	206	206	O	4
36	208	212	O	point
37	214	222	O	reduction
38	224	225	O	at
39	227	228	O	20
40	230	231	O	mg
41	233	235	O	and
42	237	237	O	a
43	239	239	O	3
44	241	245	O	point
45	247	255	O	reduction
46	257	258	O	in
47	260	262	O	the
48	264	270	O	placebo
49	272	278	O	treated
50	280	287	O	patients
NULL

Paroxetine	4212	34090-1	326e8ab0-6886-4749-9544-885b37070051	21
Study 2 was a flexible-dose study comparing paroxetine (20 to 60 mg daily) with clomipramine (25 to 250 mg daily).
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	21	O	flexible
6	23	26	O	dose
7	28	32	O	study
8	34	42	O	comparing
9	44	53	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	to
12	62	63	O	60
13	65	66	O	mg
14	68	72	O	daily
15	75	78	O	with
16	80	91	O	clomipramine
17	94	95	O	25
18	97	98	O	to
19	100	102	O	250
20	104	105	O	mg
21	107	111	O	daily
NULL

Paroxetine	4213	34090-1	326e8ab0-6886-4749-9544-885b37070051	37
In this study, patients receiving paroxetine experienced a mean reduction of approximately 7 points on the YBOCS total score, which was significantly greater than the mean reduction of approximately 4 points in placebo-treated patients.
1	0	1	O	In
2	3	6	O	this
3	8	12	O	study
4	13	13	O	,
5	15	22	O	patients
6	24	32	O	receiving
7	34	43	O	XXXXXXXX
8	45	55	O	experienced
9	57	57	O	a
10	59	62	O	mean
11	64	72	O	reduction
12	74	75	O	of
13	77	89	O	approximately
14	91	91	O	7
15	93	98	O	points
16	100	101	O	on
17	103	105	O	the
18	107	111	O	YBOCS
19	113	117	O	total
20	119	123	O	score
21	124	124	O	,
22	126	130	O	which
23	132	134	O	was
24	136	148	O	significantly
25	150	156	O	greater
26	158	161	O	than
27	163	165	O	the
28	167	170	O	mean
29	172	180	O	reduction
30	182	183	O	of
31	185	197	O	approximately
32	199	199	O	4
33	201	206	O	points
34	208	209	O	in
35	211	217	O	placebo
36	219	225	O	treated
37	227	234	O	patients
NULL

Paroxetine	4214	34090-1	326e8ab0-6886-4749-9544-885b37070051	24
The following table provides the outcome classification by treatment group on Global Improvement items of the Clinical Global Impression (CGI) scale for Study 1.
1	0	2	O	The
2	4	12	O	following
3	14	18	O	table
4	20	27	O	provides
5	29	31	O	the
6	33	39	O	outcome
7	41	54	O	classification
8	56	57	O	by
9	59	67	O	treatment
10	69	73	O	group
11	75	76	O	on
12	78	83	O	Global
13	85	95	O	Improvement
14	97	101	O	items
15	103	104	O	of
16	106	108	O	the
17	110	117	O	Clinical
18	119	124	O	Global
19	126	135	O	Impression
20	138	140	O	CGI
21	143	147	O	scale
22	149	151	O	for
23	153	157	O	Study
24	159	159	O	1
NULL

Paroxetine	4215	34090-1	326e8ab0-6886-4749-9544-885b37070051	83
Outcome Classification (%) on CGI-Global Improvement Item for Completers in Study 1 Outcome Classification Placebo(n = 74) Paroxetine20 mg(n = 75) Paroxetine40 mg(n = 66) Paroxetine60 mg(n = 66) Worse 14% 7% 7% 3% No Change 44% 35% 22% 19% Minimally Improved 24% 33% 29% 34% Much Improved 11% 18% 22% 24% Very Much Improved 7% 7% 20% 20% Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.
1	0	6	O	Outcome
2	8	21	O	Classification
3	24	24	O	%
4	27	28	O	on
5	30	32	O	CGI
6	34	39	O	Global
7	41	51	O	Improvement
8	53	56	O	Item
9	58	60	O	for
10	62	71	O	Completers
11	73	74	O	in
12	76	80	O	Study
13	82	82	O	1
14	84	90	O	Outcome
15	92	105	O	Classification
16	107	115	O	Placebo(n
17	117	117	O	=
18	119	120	O	74
19	123	132	O	XXXXXXXX
20	133	134	O	20
21	136	139	O	mg(n
22	141	141	O	=
23	143	144	O	75
24	147	156	O	XXXXXXXX
25	157	158	O	40
26	160	163	O	mg(n
27	165	165	O	=
28	167	168	O	66
29	171	180	O	XXXXXXXX
30	181	182	O	60
31	184	187	O	mg(n
32	189	189	O	=
33	191	192	O	66
34	195	199	O	Worse
35	201	203	O	14%
36	205	206	O	7%
37	208	209	O	7%
38	211	212	O	3%
39	214	215	O	No
40	217	222	O	Change
41	224	226	O	44%
42	228	230	O	35%
43	232	234	O	22%
44	236	238	O	19%
45	240	248	O	Minimally
46	250	257	O	Improved
47	259	261	O	24%
48	263	265	O	33%
49	267	269	O	29%
50	271	273	O	34%
51	275	278	O	Much
52	280	287	O	Improved
53	289	291	O	11%
54	293	295	O	18%
55	297	299	O	22%
56	301	303	O	24%
57	305	308	O	Very
58	310	313	O	Much
59	315	322	O	Improved
60	324	325	O	7%
61	327	328	O	7%
62	330	332	O	20%
63	334	336	O	20%
64	338	345	O	Subgroup
65	347	354	O	analyses
66	356	358	O	did
67	360	362	O	not
68	364	371	O	indicate
69	373	376	O	that
70	378	382	O	there
71	384	387	O	were
72	389	391	O	any
73	393	403	O	differences
74	405	406	O	in
75	408	416	O	treatment
76	418	425	O	outcomes
77	427	428	O	as
78	430	430	O	a
79	432	439	O	function
80	441	442	O	of
81	444	446	O	age
82	448	449	O	or
83	451	456	O	gender
NULL

Paroxetine	4216	34090-1	326e8ab0-6886-4749-9544-885b37070051	19
The long-term maintenance effects of paroxetine in OCD were demonstrated in a long-term extension to Study 1.
1	0	2	O	The
2	4	7	O	long
3	9	12	O	term
4	14	24	O	maintenance
5	26	32	O	effects
6	34	35	O	of
7	37	46	O	XXXXXXXX
8	48	49	O	in
9	51	53	O	OCD
10	55	58	O	were
11	60	71	O	demonstrated
12	73	74	O	in
13	76	76	O	a
14	78	81	O	long
15	83	86	O	term
16	88	96	O	extension
17	98	99	O	to
18	101	105	O	Study
19	107	107	O	1
NULL

Paroxetine	4217	34090-1	326e8ab0-6886-4749-9544-885b37070051	44
Patients who were responders on paroxetine during the 3-month double-blind phase and a 6-month extension on open-label paroxetine (20 to 60 mg/day) were randomized to either paroxetine or placebo in a 6-month double-blind relapse prevention phase.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	were
4	18	27	O	responders
5	29	30	O	on
6	32	41	O	XXXXXXXX
7	43	48	O	during
8	50	52	O	the
9	54	54	O	3
10	56	60	O	month
11	62	67	O	double
12	69	73	O	blind
13	75	79	O	phase
14	81	83	O	and
15	85	85	O	a
16	87	87	O	6
17	89	93	O	month
18	95	103	O	extension
19	105	106	O	on
20	108	111	O	open
21	113	117	O	label
22	119	128	O	XXXXXXXX
23	131	132	O	20
24	134	135	O	to
25	137	138	O	60
26	140	141	O	mg
27	142	142	O	/
28	143	145	O	day
29	148	151	O	were
30	153	162	O	randomized
31	164	165	O	to
32	167	172	O	either
33	174	183	O	XXXXXXXX
34	185	186	O	or
35	188	194	O	placebo
36	196	197	O	in
37	199	199	O	a
38	201	201	O	6
39	203	207	O	month
40	209	214	O	double
41	216	220	O	blind
42	222	228	O	relapse
43	230	239	O	prevention
44	241	245	O	phase
NULL

Paroxetine	4218	34090-1	326e8ab0-6886-4749-9544-885b37070051	19
Patients randomized to paroxetine were significantly less likely to relapse than comparably treated patients who were randomized to placebo.
1	0	7	O	Patients
2	9	18	O	randomized
3	20	21	O	to
4	23	32	O	XXXXXXXX
5	34	37	O	were
6	39	51	O	significantly
7	53	56	O	less
8	58	63	O	likely
9	65	66	O	to
10	68	74	O	relapse
11	76	79	O	than
12	81	90	O	comparably
13	92	98	O	treated
14	100	107	O	patients
15	109	111	O	who
16	113	116	O	were
17	118	127	O	randomized
18	129	130	O	to
19	132	138	O	placebo
NULL

Paroxetine	4219	34090-1	326e8ab0-6886-4749-9544-885b37070051	32
Panic Disorder The effectiveness of paroxetine in the treatment of panic disorder was demonstrated in three 10- to 12-week multicenter, placebo-controlled studies of adult outpatients (Studies 1 to 3).
1	0	4	O	Panic
2	6	13	O	Disorder
3	15	17	O	The
4	19	31	O	effectiveness
5	33	34	O	of
6	36	45	O	XXXXXXXX
7	47	48	O	in
8	50	52	O	the
9	54	62	O	treatment
10	64	65	O	of
11	67	71	O	panic
12	73	80	O	disorder
13	82	84	O	was
14	86	97	O	demonstrated
15	99	100	O	in
16	102	106	O	three
17	108	109	O	10
18	112	113	O	to
19	115	116	O	12
20	118	121	O	week
21	123	133	O	multicenter
22	134	134	O	,
23	136	142	O	placebo
24	144	153	O	controlled
25	155	161	O	studies
26	163	164	O	of
27	166	170	O	adult
28	172	182	O	outpatients
29	185	191	O	Studies
30	193	193	O	1
31	195	196	O	to
32	198	198	O	3
NULL

Paroxetine	4220	34090-1	326e8ab0-6886-4749-9544-885b37070051	14
Patients in all studies had panic disorder (DSM-IIIR), with or without agoraphobia.
1	0	7	O	Patients
2	9	10	O	in
3	12	14	O	all
4	16	22	O	studies
5	24	26	O	had
6	28	32	O	panic
7	34	41	O	disorder
8	44	46	O	DSM
9	48	51	O	IIIR
10	53	53	O	,
11	55	58	O	with
12	60	61	O	or
13	63	69	O	without
14	71	81	O	agoraphobia
NULL

Paroxetine	4221	34090-1	326e8ab0-6886-4749-9544-885b37070051	40
In these studies, paroxetine was shown to be significantly more effective than placebo in treating panic disorder by at least 2 out of 3 measures of panic attack frequency and on the Clinical Global Impression Severity of Illness score.
1	0	1	O	In
2	3	7	O	these
3	9	15	O	studies
4	16	16	O	,
5	18	27	O	XXXXXXXX
6	29	31	O	was
7	33	37	O	shown
8	39	40	O	to
9	42	43	O	be
10	45	57	O	significantly
11	59	62	O	more
12	64	72	O	effective
13	74	77	O	than
14	79	85	O	placebo
15	87	88	O	in
16	90	97	O	treating
17	99	103	O	panic
18	105	112	O	disorder
19	114	115	O	by
20	117	118	O	at
21	120	124	O	least
22	126	126	O	2
23	128	130	O	out
24	132	133	O	of
25	135	135	O	3
26	137	144	O	measures
27	146	147	O	of
28	149	153	O	panic
29	155	160	O	attack
30	162	170	O	frequency
31	172	174	O	and
32	176	177	O	on
33	179	181	O	the
34	183	190	O	Clinical
35	192	197	O	Global
36	199	208	O	Impression
37	210	217	O	Severity
38	219	220	O	of
39	222	228	O	Illness
40	230	234	O	score
NULL

Paroxetine	4222	34090-1	326e8ab0-6886-4749-9544-885b37070051	29
Study 1 was a 10-week dose-range finding study; patients were treated with fixed paroxetine doses of 10, 20, or 40 mg/day or placebo.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	12	O	a
5	14	15	O	10
6	17	20	O	week
7	22	25	O	dose
8	27	31	O	range
9	33	39	O	finding
10	41	45	O	study
11	48	55	O	patients
12	57	60	O	were
13	62	68	O	treated
14	70	73	O	with
15	75	79	O	fixed
16	81	90	O	XXXXXXXX
17	92	96	O	doses
18	98	99	O	of
19	101	102	O	10
20	103	103	O	,
21	105	106	O	20
22	107	107	O	,
23	109	110	O	or
24	112	113	O	40
25	115	116	O	mg
26	117	117	O	/
27	118	120	O	day
28	122	123	O	or
29	125	131	O	placebo
NULL

Paroxetine	4223	34090-1	326e8ab0-6886-4749-9544-885b37070051	15
A significant difference from placebo was observed only for the 40 mg/day group.
1	0	0	O	A
2	2	12	O	significant
3	14	23	O	difference
4	25	28	O	from
5	30	36	O	placebo
6	38	40	O	was
7	42	49	O	observed
8	51	54	O	only
9	56	58	O	for
10	60	62	O	the
11	64	65	O	40
12	67	68	O	mg
13	69	69	O	/
14	70	72	O	day
15	74	78	O	group
NULL

Paroxetine	4224	34090-1	326e8ab0-6886-4749-9544-885b37070051	25
At endpoint, 76% of patients receiving paroxetine 40 mg/day were free of panic attacks, compared to 44% of placebo-treated patients.
1	0	1	O	At
2	3	10	O	endpoint
3	11	11	O	,
4	13	15	O	76%
5	17	18	O	of
6	20	27	O	patients
7	29	37	O	receiving
8	39	48	O	XXXXXXXX
9	50	51	O	40
10	53	54	O	mg
11	55	55	O	/
12	56	58	O	day
13	60	63	O	were
14	65	68	O	free
15	70	71	O	of
16	73	77	O	panic
17	79	85	O	attacks
18	86	86	O	,
19	88	95	O	compared
20	97	98	O	to
21	100	102	O	44%
22	104	105	O	of
23	107	113	O	placebo
24	115	121	O	treated
25	123	130	O	patients
NULL

Paroxetine	4225	34090-1	326e8ab0-6886-4749-9544-885b37070051	18
Study 2 was a 12-week flexible-dose study comparing paroxetine (10 to 60 mg daily) and placebo.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	29	O	flexible
8	31	34	O	dose
9	36	40	O	study
10	42	50	O	comparing
11	52	61	O	XXXXXXXX
12	64	65	O	10
13	67	68	O	to
14	70	71	O	60
15	73	74	O	mg
16	76	80	O	daily
17	83	85	O	and
18	87	93	O	placebo
NULL

Paroxetine	4226	34090-1	326e8ab0-6886-4749-9544-885b37070051	19
At endpoint, 51% of paroxetine patients were free of panic attacks compared to 32% of placebo-treated patients.
1	0	1	O	At
2	3	10	O	endpoint
3	11	11	O	,
4	13	15	O	51%
5	17	18	O	of
6	20	29	O	XXXXXXXX
7	31	38	O	patients
8	40	43	O	were
9	45	48	O	free
10	50	51	O	of
11	53	57	O	panic
12	59	65	O	attacks
13	67	74	O	compared
14	76	77	O	to
15	79	81	O	32%
16	83	84	O	of
17	86	92	O	placebo
18	94	100	O	treated
19	102	109	O	patients
NULL

Paroxetine	4227	34090-1	326e8ab0-6886-4749-9544-885b37070051	26
Study 3 was a 12-week flexible-dose study comparing paroxetine (10 to 60 mg daily) to placebo in patients concurrently receiving standardized cognitive behavioral therapy.
1	0	4	O	Study
2	6	6	O	3
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	29	O	flexible
8	31	34	O	dose
9	36	40	O	study
10	42	50	O	comparing
11	52	61	O	XXXXXXXX
12	64	65	O	10
13	67	68	O	to
14	70	71	O	60
15	73	74	O	mg
16	76	80	O	daily
17	83	84	O	to
18	86	92	O	placebo
19	94	95	O	in
20	97	104	O	patients
21	106	117	O	concurrently
22	119	127	O	receiving
23	129	140	O	standardized
24	142	150	O	cognitive
25	152	161	O	behavioral
26	163	169	O	therapy
NULL

Paroxetine	4228	34090-1	326e8ab0-6886-4749-9544-885b37070051	24
At endpoint, 33% of the paroxetine-treated patients showed a reduction to 0 or 1 panic attacks compared to 14% of placebo patients.
1	0	1	O	At
2	3	10	O	endpoint
3	11	11	O	,
4	13	15	O	33%
5	17	18	O	of
6	20	22	O	the
7	24	33	O	XXXXXXXX
8	35	41	O	treated
9	43	50	O	patients
10	52	57	O	showed
11	59	59	O	a
12	61	69	O	reduction
13	71	72	O	to
14	74	74	O	0
15	76	77	O	or
16	79	79	O	1
17	81	85	O	panic
18	87	93	O	attacks
19	95	102	O	compared
20	104	105	O	to
21	107	109	O	14%
22	111	112	O	of
23	114	120	O	placebo
24	122	129	O	patients
NULL

Paroxetine	4229	34090-1	326e8ab0-6886-4749-9544-885b37070051	23
In both Studies 2 and 3, the mean paroxetine dose for completers at endpoint was approximately 40 mg/day of paroxetine.
1	0	1	O	In
2	3	6	O	both
3	8	14	O	Studies
4	16	16	O	2
5	18	20	O	and
6	22	22	O	3
7	23	23	O	,
8	25	27	O	the
9	29	32	O	mean
10	34	43	O	XXXXXXXX
11	45	48	O	dose
12	50	52	O	for
13	54	63	O	completers
14	65	66	O	at
15	68	75	O	endpoint
16	77	79	O	was
17	81	93	O	approximately
18	95	96	O	40
19	98	99	O	mg
20	100	100	O	/
21	101	103	O	day
22	105	106	O	of
23	108	117	O	XXXXXXXX
NULL

Paroxetine	4230	34090-1	326e8ab0-6886-4749-9544-885b37070051	17
Long-term maintenance effects of paroxetine in panic disorder were demonstrated in an extension to Study 1.
1	0	3	O	Long
2	5	8	O	term
3	10	20	O	maintenance
4	22	28	O	effects
5	30	31	O	of
6	33	42	O	XXXXXXXX
7	44	45	O	in
8	47	51	O	panic
9	53	60	O	disorder
10	62	65	O	were
11	67	78	O	demonstrated
12	80	81	O	in
13	83	84	O	an
14	86	94	O	extension
15	96	97	O	to
16	99	103	O	Study
17	105	105	O	1
NULL

Paroxetine	4231	34090-1	326e8ab0-6886-4749-9544-885b37070051	45
Patients who were responders during the 10-week double-blind phase and during a 3-month double-blind extension phase were randomized to either paroxetine (10, 20, or 40 mg/day) or placebo in a 3-month double-blind relapse prevention phase.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	were
4	18	27	O	responders
5	29	34	O	during
6	36	38	O	the
7	40	41	O	10
8	43	46	O	week
9	48	53	O	double
10	55	59	O	blind
11	61	65	O	phase
12	67	69	O	and
13	71	76	O	during
14	78	78	O	a
15	80	80	O	3
16	82	86	O	month
17	88	93	O	double
18	95	99	O	blind
19	101	109	O	extension
20	111	115	O	phase
21	117	120	O	were
22	122	131	O	randomized
23	133	134	O	to
24	136	141	O	either
25	143	152	O	XXXXXXXX
26	155	156	O	10
27	157	157	O	,
28	159	160	O	20
29	161	161	O	,
30	163	164	O	or
31	166	167	O	40
32	169	170	O	mg
33	171	171	O	/
34	172	174	O	day
35	177	178	O	or
36	180	186	O	placebo
37	188	189	O	in
38	191	191	O	a
39	193	193	O	3
40	195	199	O	month
41	201	206	O	double
42	208	212	O	blind
43	214	220	O	relapse
44	222	231	O	prevention
45	233	237	O	phase
NULL

Paroxetine	4233	34090-1	326e8ab0-6886-4749-9544-885b37070051	20
Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age or gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	20	O	did
4	22	24	O	not
5	26	33	O	indicate
6	35	38	O	that
7	40	44	O	there
8	46	49	O	were
9	51	53	O	any
10	55	65	O	differences
11	67	68	O	in
12	70	78	O	treatment
13	80	87	O	outcomes
14	89	90	O	as
15	92	92	O	a
16	94	101	O	function
17	103	104	O	of
18	106	108	O	age
19	110	111	O	or
20	113	118	O	gender
NULL

Paroxetine	4234	34090-1	326e8ab0-6886-4749-9544-885b37070051	40
Generalized Anxiety Disorder The effectiveness of paroxetine in the treatment of Generalized Anxiety Disorder (GAD) was demonstrated in two 8-week, multicenter, placebo-controlled studies (Studies 1 and 2) of adult outpatients with Generalized Anxiety Disorder (DSM-IV).
1	0	10	O	Generalized
2	12	18	O	Anxiety
3	20	27	O	Disorder
4	29	31	O	The
5	33	45	O	effectiveness
6	47	48	O	of
7	50	59	O	XXXXXXXX
8	61	62	O	in
9	64	66	O	the
10	68	76	O	treatment
11	78	79	O	of
12	81	91	O	Generalized
13	93	99	O	Anxiety
14	101	108	O	Disorder
15	111	113	O	GAD
16	116	118	O	was
17	120	131	O	demonstrated
18	133	134	O	in
19	136	138	O	two
20	140	140	O	8
21	142	145	O	week
22	146	146	O	,
23	148	158	O	multicenter
24	159	159	O	,
25	161	167	O	placebo
26	169	178	O	controlled
27	180	186	O	studies
28	189	195	O	Studies
29	197	197	O	1
30	199	201	O	and
31	203	203	O	2
32	206	207	O	of
33	209	213	O	adult
34	215	225	O	outpatients
35	227	230	O	with
36	232	242	O	Generalized
37	244	250	O	Anxiety
38	252	259	O	Disorder
39	262	264	O	DSM
40	266	267	O	IV
NULL

Paroxetine	4235	34090-1	326e8ab0-6886-4749-9544-885b37070051	21
Study 1 was an 8-week study comparing fixed paroxetine doses of 20 mg or 40 mg/day with placebo.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	13	O	an
5	15	15	O	8
6	17	20	O	week
7	22	26	O	study
8	28	36	O	comparing
9	38	42	O	fixed
10	44	53	O	XXXXXXXX
11	55	59	O	doses
12	61	62	O	of
13	64	65	O	20
14	67	68	O	mg
15	70	71	O	or
16	73	74	O	40
17	76	77	O	mg
18	78	78	O	/
19	79	81	O	day
20	83	86	O	with
21	88	94	O	placebo
NULL

Paroxetine	4236	34090-1	326e8ab0-6886-4749-9544-885b37070051	29
Doses of 20 mg or 40 mg of paroxetine were both demonstrated to be significantly superior to placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score.
1	0	4	O	Doses
2	6	7	O	of
3	9	10	O	20
4	12	13	O	mg
5	15	16	O	or
6	18	19	O	40
7	21	22	O	mg
8	24	25	O	of
9	27	36	O	XXXXXXXX
10	38	41	O	were
11	43	46	O	both
12	48	59	O	demonstrated
13	61	62	O	to
14	64	65	O	be
15	67	79	O	significantly
16	81	88	O	superior
17	90	91	O	to
18	93	99	O	placebo
19	101	102	O	on
20	104	106	O	the
21	108	115	O	Hamilton
22	117	122	O	Rating
23	124	128	O	Scale
24	130	132	O	for
25	134	140	O	Anxiety
26	143	145	O	HAM
27	147	147	O	A
28	150	154	O	total
29	156	160	O	score
NULL

Paroxetine	4237	34090-1	326e8ab0-6886-4749-9544-885b37070051	28
There was not sufficient evidence in this study to suggest a greater benefit for the 40 mg/day dose compared to the 20 mg/day dose.
1	0	4	O	There
2	6	8	O	was
3	10	12	O	not
4	14	23	O	sufficient
5	25	32	O	evidence
6	34	35	O	in
7	37	40	O	this
8	42	46	O	study
9	48	49	O	to
10	51	57	O	suggest
11	59	59	O	a
12	61	67	O	greater
13	69	75	O	benefit
14	77	79	O	for
15	81	83	O	the
16	85	86	O	40
17	88	89	O	mg
18	90	90	O	/
19	91	93	O	day
20	95	98	O	dose
21	100	107	O	compared
22	109	110	O	to
23	112	114	O	the
24	116	117	O	20
25	119	120	O	mg
26	121	121	O	/
27	122	124	O	day
28	126	129	O	dose
NULL

Paroxetine	4238	34090-1	326e8ab0-6886-4749-9544-885b37070051	17
Study 2 was a flexible-dose study comparing paroxetine (20 mg to 50 mg daily) and placebo.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	21	O	flexible
6	23	26	O	dose
7	28	32	O	study
8	34	42	O	comparing
9	44	53	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	mg
12	62	63	O	to
13	65	66	O	50
14	68	69	O	mg
15	71	75	O	daily
16	78	80	O	and
17	82	88	O	placebo
NULL

Paroxetine	4239	34090-1	326e8ab0-6886-4749-9544-885b37070051	18
Paroxetine demonstrated statistically significant superiority over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score.
1	0	9	O	XXXXXXXX
2	11	22	O	demonstrated
3	24	36	O	statistically
4	38	48	O	significant
5	50	60	O	superiority
6	62	65	O	over
7	67	73	O	placebo
8	75	76	O	on
9	78	80	O	the
10	82	89	O	Hamilton
11	91	96	O	Rating
12	98	102	O	Scale
13	104	106	O	for
14	108	114	O	Anxiety
15	117	119	O	HAM
16	121	121	O	A
17	124	128	O	total
18	130	134	O	score
NULL

Paroxetine	4240	34090-1	326e8ab0-6886-4749-9544-885b37070051	41
A third study, also flexible-dose comparing paroxetine (20 mg to 50 mg daily), did not demonstrate statistically significant superiority of paroxetine over placebo on the Hamilton Rating Scale for Anxiety (HAM-A) total score, the primary outcome.
1	0	0	O	A
2	2	6	O	third
3	8	12	O	study
4	13	13	O	,
5	15	18	O	also
6	20	27	O	flexible
7	29	32	O	dose
8	34	42	O	comparing
9	44	53	O	XXXXXXXX
10	56	57	O	20
11	59	60	O	mg
12	62	63	O	to
13	65	66	O	50
14	68	69	O	mg
15	71	75	O	daily
16	77	77	O	,
17	79	81	O	did
18	83	85	O	not
19	87	97	O	demonstrate
20	99	111	O	statistically
21	113	123	O	significant
22	125	135	O	superiority
23	137	138	O	of
24	140	149	O	XXXXXXXX
25	151	154	O	over
26	156	162	O	placebo
27	164	165	O	on
28	167	169	O	the
29	171	178	O	Hamilton
30	180	185	O	Rating
31	187	191	O	Scale
32	193	195	O	for
33	197	203	O	Anxiety
34	206	208	O	HAM
35	210	210	O	A
36	213	217	O	total
37	219	223	O	score
38	224	224	O	,
39	226	228	O	the
40	230	236	O	primary
41	238	244	O	outcome
NULL

Paroxetine	4241	34090-1	326e8ab0-6886-4749-9544-885b37070051	16
Subgroup analyses did not indicate differences in treatment outcomes as a function of race or gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	20	O	did
4	22	24	O	not
5	26	33	O	indicate
6	35	45	O	differences
7	47	48	O	in
8	50	58	O	treatment
9	60	67	O	outcomes
10	69	70	O	as
11	72	72	O	a
12	74	81	O	function
13	83	84	O	of
14	86	89	O	race
15	91	92	O	or
16	94	99	O	gender
NULL

Paroxetine	4242	34090-1	326e8ab0-6886-4749-9544-885b37070051	14
There were insufficient elderly patients to conduct subgroup analyses on the basis of age.
1	0	4	O	There
2	6	9	O	were
3	11	22	O	insufficient
4	24	30	O	elderly
5	32	39	O	patients
6	41	42	O	to
7	44	50	O	conduct
8	52	59	O	subgroup
9	61	68	O	analyses
10	70	71	O	on
11	73	75	O	the
12	77	81	O	basis
13	83	84	O	of
14	86	88	O	age
NULL

Paroxetine	4243	34090-1	326e8ab0-6886-4749-9544-885b37070051	64
In a longer-term trial, 566 patients meeting DSM-IV criteria for Generalized Anxiety Disorder, who had responded during a single-blind, 8-week acute treatment phase with 20 to 50 mg/day of paroxetine, were randomized to continuation of paroxetine at their same dose, or to placebo, for up to 24 weeks of observation for relapse.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	trial
6	22	22	O	,
7	24	26	O	566
8	28	35	O	patients
9	37	43	O	meeting
10	45	47	O	DSM
11	49	50	O	IV
12	52	59	O	criteria
13	61	63	O	for
14	65	75	O	Generalized
15	77	83	O	Anxiety
16	85	92	O	Disorder
17	93	93	O	,
18	95	97	O	who
19	99	101	O	had
20	103	111	O	responded
21	113	118	O	during
22	120	120	O	a
23	122	127	O	single
24	129	133	O	blind
25	134	134	O	,
26	136	136	O	8
27	138	141	O	week
28	143	147	O	acute
29	149	157	O	treatment
30	159	163	O	phase
31	165	168	O	with
32	170	171	O	20
33	173	174	O	to
34	176	177	O	50
35	179	180	O	mg
36	181	181	O	/
37	182	184	O	day
38	186	187	O	of
39	189	198	O	XXXXXXXX
40	199	199	O	,
41	201	204	O	were
42	206	215	O	randomized
43	217	218	O	to
44	220	231	O	continuation
45	233	234	O	of
46	236	245	O	XXXXXXXX
47	247	248	O	at
48	250	254	O	their
49	256	259	O	same
50	261	264	O	dose
51	265	265	O	,
52	267	268	O	or
53	270	271	O	to
54	273	279	O	placebo
55	280	280	O	,
56	282	284	O	for
57	286	287	O	up
58	289	290	O	to
59	292	293	O	24
60	295	299	O	weeks
61	301	302	O	of
62	304	314	O	observation
63	316	318	O	for
64	320	326	O	relapse
NULL

Paroxetine	4244	34090-1	326e8ab0-6886-4749-9544-885b37070051	31
Response during the single-blind phase was defined by having a decrease of >2 points compared to baseline on the CGI-Severity of Illness scale, to a score of <3.
1	0	7	O	Response
2	9	14	O	during
3	16	18	O	the
4	20	25	O	single
5	27	31	O	blind
6	33	37	O	phase
7	39	41	O	was
8	43	49	O	defined
9	51	52	O	by
10	54	59	O	having
11	61	61	O	a
12	63	70	O	decrease
13	72	73	O	of
14	75	76	O	>2
15	78	83	O	points
16	85	92	O	compared
17	94	95	O	to
18	97	104	O	baseline
19	106	107	O	on
20	109	111	O	the
21	113	115	O	CGI
22	117	124	O	Severity
23	126	127	O	of
24	129	135	O	Illness
25	137	141	O	scale
26	142	142	O	,
27	144	145	O	to
28	147	147	O	a
29	149	153	O	score
30	155	156	O	of
31	158	159	O	<3
NULL

Paroxetine	4245	34090-1	326e8ab0-6886-4749-9544-885b37070051	39
Relapse during the double-blind phase was defined as an increase of > 2 points compared to baseline on the CGI-Severity of Illness scale to a score of > 4, or withdrawal due to lack of efficacy.
1	0	6	O	Relapse
2	8	13	O	during
3	15	17	O	the
4	19	24	O	double
5	26	30	O	blind
6	32	36	O	phase
7	38	40	O	was
8	42	48	O	defined
9	50	51	O	as
10	53	54	O	an
11	56	63	O	increase
12	65	66	O	of
13	68	68	O	>
14	70	70	O	2
15	72	77	O	points
16	79	86	O	compared
17	88	89	O	to
18	91	98	O	baseline
19	100	101	O	on
20	103	105	O	the
21	107	109	O	CGI
22	111	118	O	Severity
23	120	121	O	of
24	123	129	O	Illness
25	131	135	O	scale
26	137	138	O	to
27	140	140	O	a
28	142	146	O	score
29	148	149	O	of
30	151	151	O	>
31	153	153	O	4
32	154	154	O	,
33	156	157	O	or
34	159	168	O	withdrawal
35	170	172	O	due
36	174	175	O	to
37	177	180	O	lack
38	182	183	O	of
39	185	192	O	efficacy
NULL

Paroxetine	4246	34090-1	326e8ab0-6886-4749-9544-885b37070051	20
Patients receiving continued paroxetine experienced a significantly lower relapse rate over the subsequent 24 weeks compared to those receiving placebo.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	27	O	continued
4	29	38	O	XXXXXXXX
5	40	50	O	experienced
6	52	52	O	a
7	54	66	O	significantly
8	68	72	O	lower
9	74	80	O	relapse
10	82	85	O	rate
11	87	90	O	over
12	92	94	O	the
13	96	105	O	subsequent
14	107	108	O	24
15	110	114	O	weeks
16	116	123	O	compared
17	125	126	O	to
18	128	132	O	those
19	134	142	O	receiving
20	144	150	O	placebo
NULL

Perphenazine	4550	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	27
Metabolism of a number of medications, including antipsychotics, antidepressants, B-blockers, and antiarrhythmics, occurs through the cytochrome P450 2D6 isoenzyme (debrisoquine hydroxylase).
1	0	9	O	Metabolism
2	11	12	O	of
3	14	14	O	a
4	16	21	O	number
5	23	24	O	of
6	26	36	O	medications
7	37	37	O	,
8	39	47	O	including
9	49	62	O	antipsychotics
10	63	63	O	,
11	65	79	O	antidepressants
12	80	80	O	,
13	82	82	O	B
14	84	91	O	blockers
15	92	92	O	,
16	94	96	O	and
17	98	112	O	antiarrhythmics
18	113	113	O	,
19	115	120	O	occurs
20	122	128	O	through
21	130	132	O	the
22	134	143	O	cytochrome
23	145	148	O	P450
24	150	152	O	2D6
25	154	162	O	isoenzyme
26	165	176	O	debrisoquine
27	178	188	O	hydroxylase
NULL

Perphenazine	4551	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	17
Approximately 10% of the Caucasian population has reduced activity of this enzyme, so-called "poor" metabolizers.
1	0	12	O	Approximately
2	14	16	O	10%
3	18	19	O	of
4	21	23	O	the
5	25	33	O	Caucasian
6	35	44	O	population
7	46	48	O	has
8	50	56	O	reduced
9	58	65	O	activity
10	67	68	O	of
11	70	73	O	this
12	75	80	O	enzyme
13	81	81	O	,
14	83	84	O	so
15	86	91	O	called
16	93	98	O	"poor"
17	100	111	O	metabolizers
NULL

Perphenazine	4552	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	8
Among other populations the prevalence is not known.
1	0	4	O	Among
2	6	10	O	other
3	12	22	O	populations
4	24	26	O	the
5	28	37	O	prevalence
6	39	40	O	is
7	42	44	O	not
8	46	50	O	known
NULL

Perphenazine	4553	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	20
Poor metabolizers demonstrate higher plasma concentrations of antipsychotic drugs at usual doses, which may correlate with emergence of side effects.
1	0	3	O	Poor
2	5	16	O	metabolizers
3	18	28	O	demonstrate
4	30	35	O	higher
5	37	42	O	plasma
6	44	57	O	concentrations
7	59	60	O	of
8	62	80	O	GGGGGGGG
9	82	83	O	at
10	85	89	O	usual
11	91	95	O	doses
12	96	96	O	,
13	98	102	O	which
14	104	106	O	may
15	108	116	O	correlate
16	118	121	O	with
17	123	131	O	emergence
18	133	134	O	of
19	136	139	O	side
20	141	147	O	effects
NULL

Perphenazine	4554	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	52
In one study of 45 elderly patients suffering from dementia treated with perphenazine, the 5 patients who were prospectively identified as poor P450 2D6 metabolizers had reported significantly greater side effects during the first 10 days of treatment than the 40 extensive metabolizers, following which the groups tended to converge.
1	0	1	O	In
2	3	5	O	one
3	7	11	O	study
4	13	14	O	of
5	16	17	O	45
6	19	25	O	elderly
7	27	34	O	patients
8	36	44	O	suffering
9	46	49	O	from
10	51	58	O	dementia
11	60	66	O	treated
12	68	71	O	with
13	73	84	O	XXXXXXXX
14	85	85	O	,
15	87	89	O	the
16	91	91	O	5
17	93	100	O	patients
18	102	104	O	who
19	106	109	O	were
20	111	123	O	prospectively
21	125	134	O	identified
22	136	137	O	as
23	139	142	O	poor
24	144	147	O	P450
25	149	151	O	2D6
26	153	164	O	metabolizers
27	166	168	O	had
28	170	177	O	reported
29	179	191	O	significantly
30	193	199	O	greater
31	201	204	O	side
32	206	212	O	effects
33	214	219	O	during
34	221	223	O	the
35	225	229	O	first
36	231	232	O	10
37	234	237	O	days
38	239	240	O	of
39	242	250	O	treatment
40	252	255	O	than
41	257	259	O	the
42	261	262	O	40
43	264	272	O	extensive
44	274	285	O	metabolizers
45	286	286	O	,
46	288	296	O	following
47	298	302	O	which
48	304	306	O	the
49	308	313	O	groups
50	315	320	O	tended
51	322	323	O	to
52	325	332	O	converge
NULL

Perphenazine	4555	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	17
Prospective phenotyping of elderly patients prior to antipsychotic treatment may identify those at risk for adverse events.
1	0	10	O	Prospective
2	12	22	O	phenotyping
3	24	25	O	of
4	27	33	O	elderly
5	35	42	O	patients
6	44	48	O	prior
7	50	51	O	to
8	53	65	O	antipsychotic
9	67	75	O	treatment
10	77	79	O	may
11	81	88	O	identify
12	90	94	O	those
13	96	97	O	at
14	99	102	O	risk
15	104	106	O	for
16	108	114	O	adverse
17	116	121	O	events
NULL

Perphenazine	4556	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	20
The concomitant administration of other drugs that inhibit the activity of P450 2D6 may acutely increase plasma concentrations of antipsychotics.
1	0	2	O	The
2	4	14	O	concomitant
3	16	29	O	administration
4	31	32	O	of
5	34	38	O	other
6	40	44	O	drugs
7	46	49	O	that
8	51	57	O	inhibit
9	59	61	O	the
10	63	70	O	activity
11	72	73	O	of
12	75	78	O	P450
13	80	82	O	2D6
14	84	86	O	may
15	88	94	O	acutely
16	96	103	B-TRI	increase
17	105	110	I-TRI	plasma
18	112	125	L-TRI	concentrations
19	127	128	O	of
20	130	143	O	antipsychotics
NULL

Perphenazine	4557	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	18
Among these are tricyclic antidepressants and selective serotonin reuptake inhibitors, e.g., fluoxetine, sertraline and paroxetine.
1	0	4	O	Among
2	6	10	O	these
3	12	14	O	are
4	16	24	O	tricyclic
5	26	40	O	antidepressants
6	42	44	O	and
7	46	54	O	selective
8	56	64	O	serotonin
9	66	73	O	reuptake
10	75	84	O	inhibitors
11	85	85	O	,
12	87	89	O	e.g
13	91	91	O	,
14	93	102	O	fluoxetine
15	103	103	O	,
16	105	114	O	sertraline
17	116	118	O	and
18	120	129	O	paroxetine
NULL

Perphenazine	4558	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	24
When prescribing these drugs to patients already receiving antipsychotic therapy, close monitoring is essential and dose reduction may become necessary to avoid toxicity.
1	0	3	O	When
2	5	15	O	prescribing
3	17	21	O	these
4	23	27	O	drugs
5	29	30	O	to
6	32	39	O	patients
7	41	47	O	already
8	49	57	O	receiving
9	59	71	O	antipsychotic
10	73	79	O	therapy
11	80	80	O	,
12	82	86	O	close
13	88	97	O	monitoring
14	99	100	O	is
15	102	110	O	essential
16	112	114	O	and
17	116	119	O	dose
18	121	129	O	reduction
19	131	133	O	may
20	135	140	O	become
21	142	150	O	necessary
22	152	153	O	to
23	155	159	O	avoid
24	161	168	O	toxicity
NULL

Perphenazine	4559	34073-7	d78e9639-6fab-4a78-8b29-6991a18ae6c6	16
Lower doses than usually prescribed for either the antipsychotic or the other drug may be required.
1	0	4	O	Lower
2	6	10	O	doses
3	12	15	O	than
4	17	23	O	usually
5	25	34	O	prescribed
6	36	38	O	for
7	40	45	O	either
8	47	49	O	the
9	51	63	O	antipsychotic
10	65	66	O	or
11	68	70	O	the
12	72	76	O	other
13	78	81	O	drug
14	83	85	O	may
15	87	88	O	be
16	90	97	O	required
NULL

Perphenazine	4560	34090-1	d78e9639-6fab-4a78-8b29-6991a18ae6c6	19
Following oral administration of perphenazine tablets, mean peak plasma perphenazine concentrations were observed between 1 to 3 hours.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	44	O	XXXXXXXX
6	46	52	O	tablets
7	53	53	O	,
8	55	58	O	mean
9	60	63	O	peak
10	65	70	O	plasma
11	72	83	O	XXXXXXXX
12	85	98	O	concentrations
13	100	103	O	were
14	105	112	O	observed
15	114	120	O	between
16	122	122	O	1
17	124	125	O	to
18	127	127	O	3
19	129	133	O	hours
NULL

Perphenazine	4561	34090-1	d78e9639-6fab-4a78-8b29-6991a18ae6c6	18
The plasma elimination half-life of perphenazine was independent of dose and ranged between 9 and 12 hours.
1	0	2	O	The
2	4	9	O	plasma
3	11	21	O	elimination
4	23	26	O	half
5	28	31	O	life
6	33	34	O	of
7	36	47	O	XXXXXXXX
8	49	51	O	was
9	53	63	O	independent
10	65	66	O	of
11	68	71	O	dose
12	73	75	O	and
13	77	82	O	ranged
14	84	90	O	between
15	92	92	O	9
16	94	96	O	and
17	98	99	O	12
18	101	105	O	hours
NULL

Perphenazine	4562	34090-1	d78e9639-6fab-4a78-8b29-6991a18ae6c6	27
In a study in which normal volunteers (n=12) received perphenazine 4 mg q8h for 5 days, steady-state concentrations of perphenazine were reached within 72 hours.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	in
5	14	18	O	which
6	20	25	O	normal
7	27	36	O	volunteers
8	39	42	O	n=12
9	45	52	O	received
10	54	65	O	XXXXXXXX
11	67	67	O	4
12	69	70	O	mg
13	72	74	O	q8h
14	76	78	O	for
15	80	80	O	5
16	82	85	O	days
17	86	86	O	,
18	88	93	O	steady
19	95	99	O	state
20	101	114	O	concentrations
21	116	117	O	of
22	119	130	O	XXXXXXXX
23	132	135	O	were
24	137	143	O	reached
25	145	150	O	within
26	152	153	O	72
27	155	159	O	hours
NULL

Perphenazine	4563	34090-1	d78e9639-6fab-4a78-8b29-6991a18ae6c6	64
Mean (%CV) Cmax and Cmin values for perphenazine and 7-hydroxyperphenazine at steady-state are listed below: Parameter Perphenazine 7-Hydroxyperphenazine Cmax (pg/mL) 984 (43) 509 (25) Cmin (pg/mL) 442 (76) 350 (56) Peak 7-hydroxyperphenazine concentrations were observed between 2 to 4 hours with a terminal phase half-life ranging between 9.9 to 18.8 hours.
1	0	3	O	Mean
2	6	8	O	%CV
3	11	14	O	Cmax
4	16	18	O	and
5	20	23	O	Cmin
6	25	30	O	values
7	32	34	O	for
8	36	47	O	XXXXXXXX
9	49	51	O	and
10	53	53	O	7
11	55	61	O	hydroxy
12	62	73	O	XXXXXXXX
13	75	76	O	at
14	78	83	O	steady
15	85	89	O	state
16	91	93	O	are
17	95	100	O	listed
18	102	106	O	below
19	107	107	O	:
20	109	117	O	Parameter
21	119	130	O	XXXXXXXX
22	132	132	O	7
23	134	140	O	Hydroxy
24	141	152	O	XXXXXXXX
25	154	157	O	Cmax
26	160	161	O	pg
27	162	162	O	/
28	163	164	O	mL
29	167	169	O	984
30	172	173	O	43
31	176	178	O	509
32	181	182	O	25
33	185	188	O	Cmin
34	191	192	O	pg
35	193	193	O	/
36	194	195	O	mL
37	198	200	O	442
38	203	204	O	76
39	207	209	O	350
40	212	213	O	56
41	216	219	O	Peak
42	221	221	O	7
43	223	229	O	hydroxy
44	230	241	O	XXXXXXXX
45	243	256	O	concentrations
46	258	261	O	were
47	263	270	O	observed
48	272	278	O	between
49	280	280	O	2
50	282	283	O	to
51	285	285	O	4
52	287	291	O	hours
53	293	296	O	with
54	298	298	O	a
55	300	307	O	terminal
56	309	313	O	phase
57	315	318	O	half
58	320	323	O	life
59	325	331	O	ranging
60	333	339	O	between
61	341	343	O	9.9
62	345	346	O	to
63	348	351	O	18.8
64	353	357	O	hours
NULL

Perphenazine	4564	34090-1	d78e9639-6fab-4a78-8b29-6991a18ae6c6	21
Perphenazine is extensively metabolized in the liver to a number of metabolites by sulfoxidation, hydroxylation, dealkylation, and glucuronidation.
1	0	11	O	XXXXXXXX
2	13	14	O	is
3	16	26	O	extensively
4	28	38	O	metabolized
5	40	41	O	in
6	43	45	O	the
7	47	51	O	liver
8	53	54	O	to
9	56	56	O	a
10	58	63	O	number
11	65	66	O	of
12	68	78	O	metabolites
13	80	81	O	by
14	83	95	O	sulfoxidation
15	96	96	O	,
16	98	110	O	hydroxylation
17	111	111	O	,
18	113	124	O	dealkylation
19	125	125	O	,
20	127	129	O	and
21	131	145	O	glucuronidation
NULL

Perphenazine	4565	34090-1	d78e9639-6fab-4a78-8b29-6991a18ae6c6	70
The pharmacokinetics of perphenazine covary with the hydroxylation of debrisoquine which is mediated by cytochrome P450 2D6 (CYP 2D6) and thus is subject to genetic polymorphism-i.e., 7% to 10% of Caucasians and a low percentage of Asians have little or no activity and are called "poor metabolizers." Poor metabolizers of CYP 2D6 will metabolize perphenazine more slowly and will experience higher concentrations compared with normal or "extensive" metabolizers.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	35	O	XXXXXXXX
5	37	42	O	covary
6	44	47	O	with
7	49	51	O	the
8	53	65	O	hydroxylation
9	67	68	O	of
10	70	81	O	debrisoquine
11	83	87	O	which
12	89	90	O	is
13	92	99	O	mediated
14	101	102	O	by
15	104	113	O	cytochrome
16	115	118	O	P450
17	120	122	O	2D6
18	125	127	O	CYP
19	129	131	O	2D6
20	134	136	O	and
21	138	141	O	thus
22	143	144	O	is
23	146	152	O	subject
24	154	155	O	to
25	157	163	O	genetic
26	165	176	O	polymorphism
27	178	180	O	i.e
28	182	182	O	,
29	184	185	O	7%
30	187	188	O	to
31	190	192	O	10%
32	194	195	O	of
33	197	206	O	Caucasians
34	208	210	O	and
35	212	212	O	a
36	214	216	O	low
37	218	227	O	percentage
38	229	230	O	of
39	232	237	O	Asians
40	239	242	O	have
41	244	249	O	little
42	251	252	O	or
43	254	255	O	no
44	257	264	O	activity
45	266	268	O	and
46	270	272	O	are
47	274	279	O	called
48	281	285	O	"poor
49	287	300	O	metabolizers."
50	302	305	O	Poor
51	307	318	O	metabolizers
52	320	321	O	of
53	323	325	O	CYP
54	327	329	O	2D6
55	331	334	O	will
56	336	345	O	metabolize
57	347	358	O	XXXXXXXX
58	360	363	O	more
59	365	370	O	slowly
60	372	374	O	and
61	376	379	O	will
62	381	390	O	experience
63	392	397	O	higher
64	399	412	O	concentrations
65	414	421	O	compared
66	423	426	O	with
67	428	433	O	normal
68	435	436	O	or
69	438	448	O	"extensive"
70	450	461	O	metabolizers
NULL

Pfizerpen	6476	34073-7	efef4846-9497-41af-8dd6-518f86eca7f2	28
Bacteriostatic antibacterials (i.e., chloramphenicol, erythromycins, sulfonamides or tetracyclines) may antagonize the bactericidal effect of penicillin, and concurrent use of these drugs should be avoided.
1	0	13	B-DYN	Bacteriostatic
2	15	28	L-DYN	antibacterials
3	31	33	O	i.e
4	35	35	O	,
5	37	51	U-DYN	chloramphenicol
6	52	52	O	,
7	54	66	U-DYN	erythromycins
8	67	67	O	,
9	69	80	U-DYN	sulfonamides
10	82	83	O	or
11	85	97	U-DYN	tetracyclines
12	100	102	O	may
13	104	113	B-EFF	antagonize
14	115	117	I-EFF	the
15	119	130	I-EFF	bactericidal
16	132	137	L-EFF	effect
17	139	140	O	of
18	142	151	O	penicillin
19	152	152	O	,
20	154	156	O	and
21	158	167	O	concurrent
22	169	171	O	use
23	173	174	O	of
24	176	180	O	these
25	182	186	O	drugs
26	188	193	O	should
27	195	196	O	be
28	198	204	O	avoided
D/1:13:1 D/11:13:1 D/5:13:1 D/7:13:1 D/9:13:1

Pfizerpen	6477	34073-7	efef4846-9497-41af-8dd6-518f86eca7f2	18
This has been documented in vitro; however, the clinical significance of this interaction is not well-documented.
1	0	3	O	This
2	5	7	O	has
3	9	12	O	been
4	14	23	O	documented
5	25	26	O	in
6	28	32	O	vitro
7	35	41	O	however
8	42	42	O	,
9	44	46	O	the
10	48	55	O	clinical
11	57	68	O	significance
12	70	71	O	of
13	73	76	O	this
14	78	88	O	interaction
15	90	91	O	is
16	93	95	O	not
17	97	100	O	well
18	102	111	O	documented
NULL

Pfizerpen	6478	34073-7	efef4846-9497-41af-8dd6-518f86eca7f2	19
Penicillin blood levels may be prolonged by concurrent administration of probenecid which blocks the renal tubular secretion of penicillins.
1	0	9	O	Penicillin
2	11	15	O	blood
3	17	22	O	levels
4	24	26	O	may
5	28	29	O	be
6	31	39	O	prolonged
7	41	42	O	by
8	44	53	O	concurrent
9	55	68	O	administration
10	70	71	O	of
11	73	82	U-KIN	probenecid
12	84	88	O	which
13	90	95	O	blocks
14	97	99	O	the
15	101	105	O	renal
16	107	113	O	tubular
17	115	123	O	secretion
18	125	126	O	of
19	128	138	O	penicillins
K/11:C54355

Pfizerpen	6479	34073-7	efef4846-9497-41af-8dd6-518f86eca7f2	20
Other drugs may compete with penicillin G for renal tubular secretion and thus prolong the serum half-life of penicillin.
1	0	4	O	Other
2	6	10	O	drugs
3	12	14	O	may
4	16	22	O	compete
5	24	27	O	with
6	29	38	O	penicillin
7	40	40	O	GGGGGGGG
8	42	44	O	for
9	46	50	O	renal
10	52	58	O	tubular
11	60	68	O	secretion
12	70	72	O	and
13	74	77	O	thus
14	79	85	O	prolong
15	87	89	O	the
16	91	95	O	serum
17	97	100	O	half
18	102	105	O	life
19	107	108	O	of
20	110	119	O	penicillin
NULL

Pfizerpen	6480	34073-7	efef4846-9497-41af-8dd6-518f86eca7f2	19
These drugs include: aspirin, phenylbutazone, sulfonamides, indomethacin, thiazide diuretics, furosemide and ethacrynic acid.
1	0	4	O	These
2	6	10	O	drugs
3	12	18	O	include
4	19	19	O	:
5	21	27	O	aspirin
6	28	28	O	,
7	30	43	O	phenylbutazone
8	44	44	O	,
9	46	57	O	sulfonamides
10	58	58	O	,
11	60	71	O	indomethacin
12	72	72	O	,
13	74	81	O	thiazide
14	83	91	O	diuretics
15	92	92	O	,
16	94	103	O	furosemide
17	105	107	O	and
18	109	118	O	ethacrynic
19	120	123	O	acid
NULL

Pfizerpen	6481	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	12
Aqueous penicillin G is rapidly absorbed following both intramuscular and subcutaneous injection.
1	0	6	O	Aqueous
2	8	17	O	penicillin
3	19	19	O	GGGGGGGG
4	21	22	O	is
5	24	30	O	rapidly
6	32	39	O	absorbed
7	41	49	O	following
8	51	54	O	both
9	56	68	O	intramuscular
10	70	72	O	and
11	74	85	O	subcutaneous
12	87	95	O	injection
NULL

Pfizerpen	6482	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	10
Initial blood levels following parenteral administration are high but transient.
1	0	6	O	Initial
2	8	12	O	blood
3	14	19	O	levels
4	21	29	O	following
5	31	40	O	parenteral
6	42	55	O	administration
7	57	59	O	are
8	61	64	O	high
9	66	68	O	but
10	70	78	O	transient
NULL

Pfizerpen	6483	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	8
Penicillins bind to serum proteins, mainly albumin.
1	0	10	O	Penicillins
2	12	15	O	bind
3	17	18	O	to
4	20	24	O	serum
5	26	33	O	proteins
6	34	34	O	,
7	36	41	O	mainly
8	43	49	O	albumin
NULL

Pfizerpen	6484	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	19
Therapeutic levels of the penicillins are easily achieved under normal circumstances in extracellular fluid and most other body tissues.
1	0	10	O	Therapeutic
2	12	17	O	levels
3	19	20	O	of
4	22	24	O	the
5	26	36	O	penicillins
6	38	40	O	are
7	42	47	O	easily
8	49	56	O	achieved
9	58	62	O	under
10	64	69	O	normal
11	71	83	O	circumstances
12	85	86	O	in
13	88	100	O	extracellular
14	102	106	O	fluid
15	108	110	O	and
16	112	115	O	most
17	117	121	O	other
18	123	126	O	body
19	128	134	O	tissues
NULL

Pfizerpen	6485	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	20
Penicillins are distributed in varying degrees into pleural, pericardial, peritoneal, ascitic, synovial, and interstitial fluids.
1	0	10	O	Penicillins
2	12	14	O	are
3	16	26	O	distributed
4	28	29	O	in
5	31	37	O	varying
6	39	45	O	degrees
7	47	50	O	into
8	52	58	O	pleural
9	59	59	O	,
10	61	71	O	pericardial
11	72	72	O	,
12	74	83	O	peritoneal
13	84	84	O	,
14	86	92	O	ascitic
15	93	93	O	,
16	95	102	O	synovial
17	103	103	O	,
18	105	107	O	and
19	109	120	O	interstitial
20	122	127	O	fluids
NULL

Pfizerpen	6486	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	12
Penetration into the cerebrospinal fluid, eyes, and prostate is poor.
1	0	10	O	Penetration
2	12	15	O	into
3	17	19	O	the
4	21	33	O	cerebrospinal
5	35	39	O	fluid
6	40	40	O	,
7	42	45	O	eyes
8	46	46	O	,
9	48	50	O	and
10	52	59	O	prostate
11	61	62	O	is
12	64	67	O	poor
NULL

Pfizerpen	6487	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	19
Penicillins are rapidly excreted in the urine by glomerular filtration and active tubular secretion, primarily as unchanged drug.
1	0	10	O	Penicillins
2	12	14	O	are
3	16	22	O	rapidly
4	24	31	O	excreted
5	33	34	O	in
6	36	38	O	the
7	40	44	O	urine
8	46	47	O	by
9	49	58	O	glomerular
10	60	69	O	filtration
11	71	73	O	and
12	75	80	O	active
13	82	88	O	tubular
14	90	98	O	secretion
15	99	99	O	,
16	101	109	O	primarily
17	111	112	O	as
18	114	122	O	unchanged
19	124	127	O	drug
NULL

Pfizerpen	6488	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	20
Approximately 60 percent of the total dose of 300,000 units is excreted in the urine within this 5-hour period.
1	0	12	O	Approximately
2	14	15	O	60
3	17	23	O	percent
4	25	26	O	of
5	28	30	O	the
6	32	36	O	total
7	38	41	O	dose
8	43	44	O	of
9	46	52	O	300,000
10	54	58	O	units
11	60	61	O	is
12	63	70	O	excreted
13	72	73	O	in
14	75	77	O	the
15	79	83	O	urine
16	85	90	O	within
17	92	95	O	this
18	97	97	O	5
19	99	102	O	hour
20	104	109	O	period
NULL

Pfizerpen	6489	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	28
For this reason, high and frequent doses are required to maintain the elevated serum levels desirable in treating certain severe infections in individuals with normal kidney function.
1	0	2	O	For
2	4	7	O	this
3	9	14	O	reason
4	15	15	O	,
5	17	20	O	high
6	22	24	O	and
7	26	33	O	frequent
8	35	39	O	doses
9	41	43	O	are
10	45	52	O	required
11	54	55	O	to
12	57	64	O	maintain
13	66	68	O	the
14	70	77	O	elevated
15	79	83	O	serum
16	85	90	O	levels
17	92	100	O	desirable
18	102	103	O	in
19	105	112	O	treating
20	114	120	O	certain
21	122	127	O	severe
22	129	138	O	infections
23	140	141	O	in
24	143	153	O	individuals
25	155	158	O	with
26	160	165	O	normal
27	167	172	O	kidney
28	174	181	O	function
NULL

Pfizerpen	6490	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	18
In neonates and young infants, and in individuals with impaired kidney function, excretion is considerably delayed.
1	0	1	O	In
2	3	10	O	neonates
3	12	14	O	and
4	16	20	O	young
5	22	28	O	infants
6	29	29	O	,
7	31	33	O	and
8	35	36	O	in
9	38	48	O	individuals
10	50	53	O	with
11	55	62	O	impaired
12	64	69	O	kidney
13	71	78	O	function
14	79	79	O	,
15	81	89	O	excretion
16	91	92	O	is
17	94	105	O	considerably
18	107	113	O	delayed
NULL

Pfizerpen	6491	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	19
After an intravenous infusion of penicillin G, peak serum concentrations are attained immediately after completion of the infusion.
1	0	4	O	After
2	6	7	O	an
3	9	19	O	intravenous
4	21	28	O	infusion
5	30	31	O	of
6	33	42	O	penicillin
7	44	44	O	GGGGGGGG
8	45	45	O	,
9	47	50	O	peak
10	52	56	O	serum
11	58	71	O	concentrations
12	73	75	O	are
13	77	84	O	attained
14	86	96	O	immediately
15	98	102	O	after
16	104	113	O	completion
17	115	116	O	of
18	118	120	O	the
19	122	129	O	infusion
NULL

Pfizerpen	6492	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	58
In a study of ten patients administered a single 5 million unit dose of penicillin G intravenously over 3-5 minutes, the mean serum concentrations were 400 mcg/mL, 273 mcg/mL and 3.0 mcg/mL at 5-6 minutes, 10 minutes and 4 hours after completion of the injection, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	16	O	ten
6	18	25	O	patients
7	27	38	O	administered
8	40	40	O	a
9	42	47	O	single
10	49	49	O	5
11	51	57	O	million
12	59	62	O	unit
13	64	67	O	dose
14	69	70	O	of
15	72	81	O	penicillin
16	83	83	O	GGGGGGGG
17	85	97	O	intravenously
18	99	102	O	over
19	104	104	O	3
20	106	106	O	5
21	108	114	O	minutes
22	115	115	O	,
23	117	119	O	the
24	121	124	O	mean
25	126	130	O	serum
26	132	145	O	concentrations
27	147	150	O	were
28	152	154	O	400
29	156	158	O	mcg
30	159	159	O	/
31	160	161	O	mL
32	162	162	O	,
33	164	166	O	273
34	168	170	O	mcg
35	171	171	O	/
36	172	173	O	mL
37	175	177	O	and
38	179	181	O	3.0
39	183	185	O	mcg
40	186	186	O	/
41	187	188	O	mL
42	190	191	O	at
43	193	193	O	5
44	195	195	O	6
45	197	203	O	minutes
46	204	204	O	,
47	206	207	O	10
48	209	215	O	minutes
49	217	219	O	and
50	221	221	O	4
51	223	227	O	hours
52	229	233	O	after
53	235	244	O	completion
54	246	247	O	of
55	249	251	O	the
56	253	261	O	injection
57	262	262	O	,
58	264	275	O	respectively
NULL

Pfizerpen	6493	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	32
In a separate study, five healthy adults were administered one million units of penicillin G intravenously, either as a bolus over 4 minutes or as an infusion over 60 minutes.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	separate
4	14	18	O	study
5	19	19	O	,
6	21	24	O	five
7	26	32	O	healthy
8	34	39	O	adults
9	41	44	O	were
10	46	57	O	administered
11	59	61	O	one
12	63	69	O	million
13	71	75	O	units
14	77	78	O	of
15	80	89	O	penicillin
16	91	91	O	GGGGGGGG
17	93	105	O	intravenously
18	106	106	O	,
19	108	113	O	either
20	115	116	O	as
21	118	118	O	a
22	120	124	O	bolus
23	126	129	O	over
24	131	131	O	4
25	133	139	O	minutes
26	141	142	O	or
27	144	145	O	as
28	147	148	O	an
29	150	157	O	infusion
30	159	162	O	over
31	164	165	O	60
32	167	173	O	minutes
NULL

Pfizerpen	6494	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	29
The mean serum concentration eight minutes after completion of the bolus was 45 mcg/mL and eight minutes after completion of the infusion was 14.4 mcg/mL.
1	0	2	O	The
2	4	7	O	mean
3	9	13	O	serum
4	15	27	O	concentration
5	29	33	O	eight
6	35	41	O	minutes
7	43	47	O	after
8	49	58	O	completion
9	60	61	O	of
10	63	65	O	the
11	67	71	O	bolus
12	73	75	O	was
13	77	78	O	45
14	80	82	O	mcg
15	83	83	O	/
16	84	85	O	mL
17	87	89	O	and
18	91	95	O	eight
19	97	103	O	minutes
20	105	109	O	after
21	111	120	O	completion
22	122	123	O	of
23	125	127	O	the
24	129	136	O	infusion
25	138	140	O	was
26	142	145	O	14.4
27	147	149	O	mcg
28	150	150	O	/
29	151	152	O	mL
NULL

Pfizerpen	6495	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	33
The mean B-phase serum half-life of penicillin G administered by the intravenous route in ten patients with normal renal function was 42 minutes, with a range of 31-50 minutes.
1	0	2	O	The
2	4	7	O	mean
3	9	9	O	B
4	11	15	O	phase
5	17	21	O	serum
6	23	26	O	half
7	28	31	O	life
8	33	34	O	of
9	36	45	O	penicillin
10	47	47	O	GGGGGGGG
11	49	60	O	administered
12	62	63	O	by
13	65	67	O	the
14	69	79	O	intravenous
15	81	85	O	route
16	87	88	O	in
17	90	92	O	ten
18	94	101	O	patients
19	103	106	O	with
20	108	113	O	normal
21	115	119	O	renal
22	121	128	O	function
23	130	132	O	was
24	134	135	O	42
25	137	143	O	minutes
26	144	144	O	,
27	146	149	O	with
28	151	151	O	a
29	153	157	O	range
30	159	160	O	of
31	162	163	O	31
32	165	166	O	50
33	168	174	O	minutes
NULL

Pfizerpen	6496	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	13
The clearance of penicillin G in normal individuals is predominantly via the kidney.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	of
4	17	26	O	penicillin
5	28	28	O	GGGGGGGG
6	30	31	O	in
7	33	38	O	normal
8	40	50	O	individuals
9	52	53	O	is
10	55	67	O	predominantly
11	69	71	O	via
12	73	75	O	the
13	77	82	O	kidney
NULL

Pfizerpen	6497	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	25
The renal clearance, which is extremely rapid, is the result of glomerular filtration and active tubular transport, with the latter route predominating.
1	0	2	O	The
2	4	8	O	renal
3	10	18	O	clearance
4	19	19	O	,
5	21	25	O	which
6	27	28	O	is
7	30	38	O	extremely
8	40	44	O	rapid
9	45	45	O	,
10	47	48	O	is
11	50	52	O	the
12	54	59	O	result
13	61	62	O	of
14	64	73	O	glomerular
15	75	84	O	filtration
16	86	88	O	and
17	90	95	O	active
18	97	103	O	tubular
19	105	113	O	transport
20	114	114	O	,
21	116	119	O	with
22	121	123	O	the
23	125	130	O	latter
24	132	136	O	route
25	138	150	O	predominating
NULL

Pfizerpen	6498	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	12
Urinary recovery is reported to be 58-85% of the administered dose.
1	0	6	O	Urinary
2	8	15	O	recovery
3	17	18	O	is
4	20	27	O	reported
5	29	30	O	to
6	32	33	O	be
7	35	36	O	58
8	38	40	O	85%
9	42	43	O	of
10	45	47	O	the
11	49	60	O	administered
12	62	65	O	dose
NULL

Pfizerpen	6499	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	20
Renal clearance of penicillin is delayed in premature infants, neonates and in the elderly due to decreased renal function.
1	0	4	O	Renal
2	6	14	O	clearance
3	16	17	O	of
4	19	28	O	penicillin
5	30	31	O	is
6	33	39	O	delayed
7	41	42	O	in
8	44	52	O	premature
9	54	60	O	infants
10	61	61	O	,
11	63	70	O	neonates
12	72	74	O	and
13	76	77	O	in
14	79	81	O	the
15	83	89	O	elderly
16	91	93	O	due
17	95	96	O	to
18	98	106	O	decreased
19	108	112	O	renal
20	114	121	O	function
NULL

Pfizerpen	6500	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	39
The serum half-life of penicillin G correlates inversely with age and clearance of creatinine and ranges from 3.2 hours in infants 0 to 6 days of age to 1.4 hours in infants 14 days of age or older.
1	0	2	O	The
2	4	8	O	serum
3	10	13	O	half
4	15	18	O	life
5	20	21	O	of
6	23	32	O	penicillin
7	34	34	O	GGGGGGGG
8	36	45	O	correlates
9	47	55	O	inversely
10	57	60	O	with
11	62	64	O	age
12	66	68	O	and
13	70	78	O	clearance
14	80	81	O	of
15	83	92	O	creatinine
16	94	96	O	and
17	98	103	O	ranges
18	105	108	O	from
19	110	112	O	3.2
20	114	118	O	hours
21	120	121	O	in
22	123	129	O	infants
23	131	131	O	0
24	133	134	O	to
25	136	136	O	6
26	138	141	O	days
27	143	144	O	of
28	146	148	O	age
29	150	151	O	to
30	153	155	O	1.4
31	157	161	O	hours
32	163	164	O	in
33	166	172	O	infants
34	174	175	O	14
35	177	180	O	days
36	182	183	O	of
37	185	187	O	age
38	189	190	O	or
39	192	196	O	older
NULL

Pfizerpen	6501	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	14
Nonrenal clearance includes hepatic metabolism and, to a lesser extent, biliary excretion.
1	0	7	O	Nonrenal
2	9	17	O	clearance
3	19	26	O	includes
4	28	34	O	hepatic
5	36	45	O	metabolism
6	47	49	O	and
7	50	50	O	,
8	52	53	O	to
9	55	55	O	a
10	57	62	O	lesser
11	64	69	O	extent
12	70	70	O	,
13	72	78	O	biliary
14	80	88	O	excretion
NULL

Pfizerpen	6502	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	9
The latter routes become more important with renal impairment.
1	0	2	O	The
2	4	9	O	latter
3	11	16	O	routes
4	18	23	O	become
5	25	28	O	more
6	30	38	O	important
7	40	43	O	with
8	45	49	O	renal
9	51	60	O	impairment
NULL

Pfizerpen	6503	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	8
Probenecid blocks the renal tubular secretion of penicillin.
1	0	9	U-KIN	Probenecid
2	11	16	B-TRI	blocks
3	18	20	I-TRI	the
4	22	26	I-TRI	renal
5	28	34	I-TRI	tubular
6	36	44	L-TRI	secretion
7	46	47	O	of
8	49	58	O	penicillin
K/1:C54355

Pfizerpen	6504	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	21
Therefore, the concurrent administration of probenecid prolongs the elimination of penicillin G and, consequently, increases the serum concentrations.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	24	O	concurrent
5	26	39	O	administration
6	41	42	O	of
7	44	53	U-KIN	probenecid
8	55	62	B-TRI	prolongs
9	64	66	I-TRI	the
10	68	78	L-TRI	elimination
11	80	81	O	of
12	83	92	O	penicillin
13	94	94	O	GGGGGGGG
14	96	98	O	and
15	99	99	O	,
16	101	112	O	consequently
17	113	113	O	,
18	115	123	O	increases
19	125	127	O	the
20	129	133	O	serum
21	135	148	O	concentrations
K/7:C54355

Pfizerpen	6505	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	22
Penicillin G is distributed to most areas of the body including lung, liver, kidney, muscle, bone and placenta.
1	0	9	O	Penicillin
2	11	11	O	GGGGGGGG
3	13	14	O	is
4	16	26	O	distributed
5	28	29	O	to
6	31	34	O	most
7	36	40	O	areas
8	42	43	O	of
9	45	47	O	the
10	49	52	O	body
11	54	62	O	including
12	64	67	O	lung
13	68	68	O	,
14	70	74	O	liver
15	75	75	O	,
16	77	82	O	kidney
17	83	83	O	,
18	85	90	O	muscle
19	91	91	O	,
20	93	96	O	bone
21	98	100	O	and
22	102	109	O	placenta
NULL

Pfizerpen	6506	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	28
In the presence of inflammation, levels of penicillin in abscesses, middle ear, pleural, peritoneal and synovial fluids are sufficient to inhibit most susceptible bacteria.
1	0	1	O	In
2	3	5	O	the
3	7	14	O	presence
4	16	17	O	of
5	19	30	O	inflammation
6	31	31	O	,
7	33	38	O	levels
8	40	41	O	of
9	43	52	O	penicillin
10	54	55	O	in
11	57	65	O	abscesses
12	66	66	O	,
13	68	73	O	middle
14	75	77	O	ear
15	78	78	O	,
16	80	86	O	pleural
17	87	87	O	,
18	89	98	O	peritoneal
19	100	102	O	and
20	104	111	O	synovial
21	113	118	O	fluids
22	120	122	O	are
23	124	133	O	sufficient
24	135	136	O	to
25	138	144	O	inhibit
26	146	149	O	most
27	151	161	O	susceptible
28	163	170	O	bacteria
NULL

Pfizerpen	6507	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	19
Penetration in the eye, brain, cerebrospinal fluid (CSF) or prostate is poor in the absence of inflammation.
1	0	10	O	Penetration
2	12	13	O	in
3	15	17	O	the
4	19	21	O	eye
5	22	22	O	,
6	24	28	O	brain
7	29	29	O	,
8	31	43	O	cerebrospinal
9	45	49	O	fluid
10	52	54	O	CSF
11	57	58	O	or
12	60	67	O	prostate
13	69	70	O	is
14	72	75	O	poor
15	77	78	O	in
16	80	82	O	the
17	84	90	O	absence
18	92	93	O	of
19	95	106	O	inflammation
NULL

Pfizerpen	6508	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	24
With inflamed meninges, the penetration of penicillin G into the CSF improves, such that the CSF/serum ratio is 2-6%.
1	0	3	O	With
2	5	12	O	inflamed
3	14	21	O	meninges
4	22	22	O	,
5	24	26	O	the
6	28	38	O	penetration
7	40	41	O	of
8	43	52	O	penicillin
9	54	54	O	GGGGGGGG
10	56	59	O	into
11	61	63	O	the
12	65	67	O	CSF
13	69	76	O	improves
14	77	77	O	,
15	79	82	O	such
16	84	87	O	that
17	89	91	O	the
18	93	95	O	CSF
19	96	96	O	/
20	97	101	O	serum
21	103	107	O	ratio
22	109	110	O	is
23	112	112	O	2
24	114	115	O	6%
NULL

Pfizerpen	6509	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	9
Inflammation also enhances its penetration into the pericardial fluid.
1	0	11	O	Inflammation
2	13	16	O	also
3	18	25	O	enhances
4	27	29	O	its
5	31	41	O	penetration
6	43	46	O	into
7	48	50	O	the
8	52	62	O	pericardial
9	64	68	O	fluid
NULL

Pfizerpen	6510	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	20
Penicillin G is actively secreted into the bile resulting in levels at least 10 times those achieved simultaneously in serum.
1	0	9	O	Penicillin
2	11	11	O	GGGGGGGG
3	13	14	O	is
4	16	23	O	actively
5	25	32	O	secreted
6	34	37	O	into
7	39	41	O	the
8	43	46	O	bile
9	48	56	O	resulting
10	58	59	O	in
11	61	66	O	levels
12	68	69	O	at
13	71	75	O	least
14	77	78	O	10
15	80	84	O	times
16	86	90	O	those
17	92	99	O	achieved
18	101	114	O	simultaneously
19	116	117	O	in
20	119	123	O	serum
NULL

Pfizerpen	6511	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	8
Penicillin G penetrates poorly into human polymorphonuclear leukocytes.
1	0	9	O	Penicillin
2	11	11	O	GGGGGGGG
3	13	22	O	penetrates
4	24	29	O	poorly
5	31	34	O	into
6	36	40	O	human
7	42	58	O	polymorphonuclear
8	60	69	O	leukocytes
NULL

Pfizerpen	6512	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	19
In the presence of impaired renal function, the B-phase serum half-life of penicillin G is prolonged.
1	0	1	O	In
2	3	5	O	the
3	7	14	O	presence
4	16	17	O	of
5	19	26	O	impaired
6	28	32	O	renal
7	34	41	O	function
8	42	42	O	,
9	44	46	O	the
10	48	48	O	B
11	50	54	O	phase
12	56	60	O	serum
13	62	65	O	half
14	67	70	O	life
15	72	73	O	of
16	75	84	O	penicillin
17	86	86	O	GGGGGGGG
18	88	89	O	is
19	91	99	O	prolonged
NULL

Pfizerpen	6513	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	34
B-phase serum half-lives of one to two hours were observed in azotemic patients with serum creatinine concentrations <3 mg/100 mL and ranged as high as 20 hours in anuric patients.
1	0	0	O	B
2	2	6	O	phase
3	8	12	O	serum
4	14	17	O	half
5	19	23	O	lives
6	25	26	O	of
7	28	30	O	one
8	32	33	O	to
9	35	37	O	two
10	39	43	O	hours
11	45	48	O	were
12	50	57	O	observed
13	59	60	O	in
14	62	69	O	azotemic
15	71	78	O	patients
16	80	83	O	with
17	85	89	O	serum
18	91	100	O	creatinine
19	102	115	O	concentrations
20	117	118	O	<3
21	120	121	O	mg
22	122	122	O	/
23	123	125	O	100
24	127	128	O	mL
25	130	132	O	and
26	134	139	O	ranged
27	141	142	O	as
28	144	147	O	high
29	149	150	O	as
30	152	153	O	20
31	155	159	O	hours
32	161	162	O	in
33	164	169	O	anuric
34	171	178	O	patients
NULL

Pfizerpen	6514	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	28
A linear relationship, including the lowest range of renal function, is found between the serum elimination rate constant and renal function as measured by creatinine clearance.
1	0	0	O	A
2	2	7	O	linear
3	9	20	O	relationship
4	21	21	O	,
5	23	31	O	including
6	33	35	O	the
7	37	42	O	lowest
8	44	48	O	range
9	50	51	O	of
10	53	57	O	renal
11	59	66	O	function
12	67	67	O	,
13	69	70	O	is
14	72	76	O	found
15	78	84	O	between
16	86	88	O	the
17	90	94	O	serum
18	96	106	O	elimination
19	108	111	O	rate
20	113	120	O	constant
21	122	124	O	and
22	126	130	O	renal
23	132	139	O	function
24	141	142	O	as
25	144	151	O	measured
26	153	154	O	by
27	156	165	O	creatinine
28	167	175	O	clearance
NULL

Pfizerpen	6515	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	42
In patients with altered renal function, the presence of hepatic insufficiency further alters the elimination of penicillin G. In one study, the serum half-lives in two anuric patients (excreting <400 mL urine/day) were 7.2 and 10.1 hours.
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	23	O	altered
5	25	29	O	renal
6	31	38	O	function
7	39	39	O	,
8	41	43	O	the
9	45	52	O	presence
10	54	55	O	of
11	57	63	O	hepatic
12	65	77	O	insufficiency
13	79	85	O	further
14	87	92	O	alters
15	94	96	O	the
16	98	108	O	elimination
17	110	111	O	of
18	113	122	O	penicillin
19	124	124	O	GGGGGGGG
20	127	128	O	In
21	130	132	O	one
22	134	138	O	study
23	139	139	O	,
24	141	143	O	the
25	145	149	O	serum
26	151	154	O	half
27	156	160	O	lives
28	162	163	O	in
29	165	167	O	two
30	169	174	O	anuric
31	176	183	O	patients
32	186	194	O	excreting
33	196	199	O	<400
34	201	202	O	mL
35	204	208	O	urine
36	209	209	O	/
37	210	212	O	day
38	215	218	O	were
39	220	222	O	7.2
40	224	226	O	and
41	228	231	O	10.1
42	233	237	O	hours
NULL

Pfizerpen	6516	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	33
A totally anuric patient with terminal hepatic cirrhosis had a penicillin half-life of 30.5 hours, while another patient with anuria and liver disease had a serum half-life of 16.4 hours.
1	0	0	O	A
2	2	8	O	totally
3	10	15	O	anuric
4	17	23	O	patient
5	25	28	O	with
6	30	37	O	terminal
7	39	45	O	hepatic
8	47	55	O	cirrhosis
9	57	59	O	had
10	61	61	O	a
11	63	72	O	penicillin
12	74	77	O	half
13	79	82	O	life
14	84	85	O	of
15	87	90	O	30.5
16	92	96	O	hours
17	97	97	O	,
18	99	103	O	while
19	105	111	O	another
20	113	119	O	patient
21	121	124	O	with
22	126	131	O	anuria
23	133	135	O	and
24	137	141	O	liver
25	143	149	O	disease
26	151	153	O	had
27	155	155	O	a
28	157	161	O	serum
29	163	166	O	half
30	168	171	O	life
31	173	174	O	of
32	176	179	O	16.4
33	181	185	O	hours
NULL

Pfizerpen	6517	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	25
The dosage of penicillin G should be reduced in patients with severe renal impairment, with additional modifications when hepatic disease accompanies the renal impairment.
1	0	2	O	The
2	4	9	O	dosage
3	11	12	O	of
4	14	23	O	penicillin
5	25	25	O	GGGGGGGG
6	27	32	O	should
7	34	35	O	be
8	37	43	O	reduced
9	45	46	O	in
10	48	55	O	patients
11	57	60	O	with
12	62	67	O	severe
13	69	73	O	renal
14	75	84	O	impairment
15	85	85	O	,
16	87	90	O	with
17	92	101	O	additional
18	103	115	O	modifications
19	117	120	O	when
20	122	128	O	hepatic
21	130	136	O	disease
22	138	148	O	accompanies
23	150	152	O	the
24	154	158	O	renal
25	160	169	O	impairment
NULL

Pfizerpen	6518	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	10
Hemodialysis has been shown to reduce penicillin G serum levels.
1	0	11	O	Hemodialysis
2	13	15	O	has
3	17	20	O	been
4	22	26	O	shown
5	28	29	O	to
6	31	36	O	reduce
7	38	47	O	penicillin
8	49	49	O	GGGGGGGG
9	51	55	O	serum
10	57	62	O	levels
NULL

Pfizerpen	6519	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	16
Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication.
1	0	9	O	Penicillin
2	11	11	O	GGGGGGGG
3	13	18	O	exerts
4	20	20	O	a
5	22	33	O	bactericidal
6	35	40	O	action
7	42	48	O	against
8	50	59	O	penicillin
9	61	71	O	susceptible
10	73	86	O	microorganisms
11	88	93	O	during
12	95	97	O	the
13	99	103	O	stage
14	105	106	O	of
15	108	113	O	active
16	115	128	O	multiplication
NULL

Pfizerpen	6520	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	17
It acts through the inhibition of biosynthesis of cell wall peptidoglycan rendering the cell wall osmotically unstable.
1	0	1	O	It
2	3	6	O	acts
3	8	14	O	through
4	16	18	O	the
5	20	29	O	inhibition
6	31	32	O	of
7	34	45	O	biosynthesis
8	47	48	O	of
9	50	53	O	cell
10	55	58	O	wall
11	60	72	O	peptidoglycan
12	74	82	O	rendering
13	84	86	O	the
14	88	91	O	cell
15	93	96	O	wall
16	98	108	O	osmotically
17	110	117	O	unstable
NULL

Pfizerpen	6521	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	37
It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci or against organisms resistant to beta-lactams because of alterations in the penicillin-binding proteins, such as methicillin-resistant staphylococci.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	15	O	active
5	17	23	O	against
6	25	27	O	the
7	29	41	O	penicillinase
8	43	51	O	producing
9	53	60	O	bacteria
10	61	61	O	,
11	63	67	O	which
12	69	75	O	include
13	77	80	O	many
14	82	88	O	strains
15	90	91	O	of
16	93	105	O	staphylococci
17	107	108	O	or
18	110	116	O	against
19	118	126	O	organisms
20	128	136	O	resistant
21	138	139	O	to
22	141	144	O	beta
23	146	152	O	lactams
24	154	160	O	because
25	162	163	O	of
26	165	175	O	alterations
27	177	178	O	in
28	180	182	O	the
29	184	193	O	penicillin
30	195	201	O	binding
31	203	210	O	proteins
32	211	211	O	,
33	213	216	O	such
34	218	219	O	as
35	221	231	O	methicillin
36	233	241	O	resistant
37	243	255	O	staphylococci
NULL

Pfizerpen	6522	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	28
Penicillin G is highly active in vitro against streptococci (groups A, B, C, G, H, L, and M), and Neisseria meningitidis.
1	0	9	O	Penicillin
2	11	11	O	GGGGGGGG
3	13	14	O	is
4	16	21	O	highly
5	23	28	O	active
6	30	31	O	in
7	33	37	O	vitro
8	39	45	O	against
9	47	58	O	streptococci
10	61	66	O	groups
11	68	68	O	A
12	69	69	O	,
13	71	71	O	B
14	72	72	O	,
15	74	74	O	C
16	75	75	O	,
17	77	77	O	GGGGGGGG
18	78	78	O	,
19	80	80	O	H
20	81	81	O	,
21	83	83	O	L
22	84	84	O	,
23	86	88	O	and
24	90	90	O	M
25	92	92	O	,
26	94	96	O	and
27	98	106	O	Neisseria
28	108	119	O	meningitidis
NULL

Pfizerpen	6523	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	82
Other organisms susceptible to penicillin G are N. gonorrhoeae, Corynebacterium diphtheriae, Bacillus anthracis, Clostridium spp, Actinomyces species, "Spirillum minus", Streptobacillus moniliformis, Listeria monocytogenes and Leptospira spp; Treponema pallidum is extremely sensitive to the bactericidal action of penicillin G. Some species of gram-negative bacilli were previously considered susceptible to very high intravenous doses of penicillin G (up to 80 million units/day) including some strains of Escherichia coli, Proteus mirabilis, Salmonella spp.
1	0	4	O	Other
2	6	14	O	organisms
3	16	26	O	susceptible
4	28	29	O	to
5	31	40	O	penicillin
6	42	42	O	GGGGGGGG
7	44	46	O	are
8	48	48	O	N
9	51	61	O	gonorrhoeae
10	62	62	O	,
11	64	78	O	Corynebacterium
12	80	90	O	diphtheriae
13	91	91	O	,
14	93	100	O	Bacillus
15	102	110	O	anthracis
16	111	111	O	,
17	113	123	O	Clostridium
18	125	127	O	spp
19	128	128	O	,
20	130	140	O	Actinomyces
21	142	148	O	species
22	149	149	O	,
23	151	160	O	"Spirillum
24	162	167	O	minus"
25	168	168	O	,
26	170	184	O	Streptobacillus
27	186	197	O	moniliformis
28	198	198	O	,
29	200	207	O	Listeria
30	209	221	O	monocytogenes
31	223	225	O	and
32	227	236	O	Leptospira
33	238	240	O	spp
34	243	251	O	Treponema
35	253	260	O	pallidum
36	262	263	O	is
37	265	273	O	extremely
38	275	283	O	sensitive
39	285	286	O	to
40	288	290	O	the
41	292	303	O	bactericidal
42	305	310	O	action
43	312	313	O	of
44	315	324	O	penicillin
45	326	326	O	GGGGGGGG
46	329	332	O	Some
47	334	340	O	species
48	342	343	O	of
49	345	348	O	gram
50	350	357	O	negative
51	359	365	O	bacilli
52	367	370	O	were
53	372	381	O	previously
54	383	392	O	considered
55	394	404	O	susceptible
56	406	407	O	to
57	409	412	O	very
58	414	417	O	high
59	419	429	O	intravenous
60	431	435	O	doses
61	437	438	O	of
62	440	449	O	penicillin
63	451	451	O	GGGGGGGG
64	454	455	O	up
65	457	458	O	to
66	460	461	O	80
67	463	469	O	million
68	471	475	O	units
69	476	476	O	/
70	477	479	O	day
71	482	490	O	including
72	492	495	O	some
73	497	503	O	strains
74	505	506	O	of
75	508	518	O	Escherichia
76	520	523	O	coli
77	524	524	O	,
78	526	532	O	Proteus
79	534	542	O	mirabilis
80	543	543	O	,
81	545	554	O	Salmonella
82	556	558	O	spp
NULL

Pfizerpen	6524	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	8
; Enterobacter aerogenes (formerly Aerobacter aerogenes) and Alcaligenes faecalis.
1	2	13	O	Enterobacter
2	15	23	O	aerogenes
3	26	33	O	formerly
4	35	44	O	Aerobacter
5	46	54	O	aerogenes
6	57	59	O	and
7	61	71	O	Alcaligenes
8	73	80	O	faecalis
NULL

Pfizerpen	6525	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	16
Penicillin G is no longer considered a drug of choice for infections caused by these organisms.
1	0	9	O	Penicillin
2	11	11	O	GGGGGGGG
3	13	14	O	is
4	16	17	O	no
5	19	24	O	longer
6	26	35	O	considered
7	37	37	O	a
8	39	42	O	drug
9	44	45	O	of
10	47	52	O	choice
11	54	56	O	for
12	58	67	O	infections
13	69	74	O	caused
14	76	77	O	by
15	79	83	O	these
16	85	93	O	organisms
NULL

Pfizerpen	6526	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	44
When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.
1	0	3	O	When
2	5	13	O	available
3	14	14	O	,
4	16	18	O	the
5	20	27	O	clinical
6	29	40	O	microbiology
7	42	51	O	laboratory
8	53	58	O	should
9	60	66	O	provide
10	68	70	O	the
11	72	78	O	results
12	80	81	O	of
13	83	84	O	in
14	86	90	O	vitro
15	92	105	O	susceptibility
16	107	110	O	test
17	112	118	O	results
18	120	122	O	for
19	124	136	O	antimicrobial
20	138	142	O	drugs
21	144	147	O	used
22	149	150	O	in
23	152	156	O	local
24	158	166	O	hospitals
25	168	170	O	and
26	172	179	O	practice
27	181	185	O	areas
28	187	188	O	to
29	190	192	O	the
30	194	202	O	physician
31	204	205	O	as
32	207	214	O	periodic
33	216	222	O	reports
34	224	227	O	that
35	229	236	O	describe
36	238	240	O	the
37	242	255	O	susceptibility
38	257	263	O	profile
39	265	266	O	of
40	268	277	O	nosocomial
41	279	281	O	and
42	283	291	O	community
43	293	300	O	acquired
44	302	310	O	pathogens
NULL

Pfizerpen	6527	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	12
These reports should aid the physician in selecting the most effective antimicrobial.
1	0	4	O	These
2	6	12	O	reports
3	14	19	O	should
4	21	23	O	aid
5	25	27	O	the
6	29	37	O	physician
7	39	40	O	in
8	42	50	O	selecting
9	52	54	O	the
10	56	59	O	most
11	61	69	O	effective
12	71	83	O	antimicrobial
NULL

Pfizerpen	6528	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	11
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs).
1	0	11	O	Quantitative
2	13	19	O	methods
3	21	23	O	are
4	25	28	O	used
5	30	31	O	to
6	33	41	O	determine
7	43	55	O	antimicrobial
8	57	63	O	minimum
9	65	74	O	inhibitory
10	76	89	O	concentrations
11	92	95	O	MICs
NULL

Pfizerpen	6529	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	12
These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.
1	0	4	O	These
2	6	9	O	MICs
3	11	17	O	provide
4	19	27	O	estimates
5	29	30	O	of
6	32	34	O	the
7	36	49	O	susceptibility
8	51	52	O	of
9	54	61	O	bacteria
10	63	64	O	to
11	66	78	O	antimicrobial
12	80	88	O	compounds
NULL

Pfizerpen	6530	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	9
The MICs should be determined using a standardized procedure.
1	0	2	O	The
2	4	7	O	MICs
3	9	14	O	should
4	16	17	O	be
5	19	28	O	determined
6	30	34	O	using
7	36	36	O	a
8	38	49	O	standardized
9	51	59	O	procedure
NULL

Pfizerpen	6531	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	25
Standardized procedures are based on dilution method 1, 2, 3 (broth or agar dilution) or equivalent using standardized inoculum and concentrations of penicillin.
1	0	11	O	Standardized
2	13	22	O	procedures
3	24	26	O	are
4	28	32	O	based
5	34	35	O	on
6	37	44	O	dilution
7	46	51	O	method
8	53	53	O	1
9	54	54	O	,
10	56	56	O	2
11	57	57	O	,
12	59	59	O	3
13	62	66	O	broth
14	68	69	O	or
15	71	74	O	agar
16	76	83	O	dilution
17	86	87	O	or
18	89	98	O	equivalent
19	100	104	O	using
20	106	117	O	standardized
21	119	126	O	inoculum
22	128	130	O	and
23	132	145	O	concentrations
24	147	148	O	of
25	150	159	O	penicillin
NULL

Pfizerpen	6532	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	13
The MIC values should be interpreted according to the criteria in Table 1.
1	0	2	O	The
2	4	6	O	MIC
3	8	13	O	values
4	15	20	O	should
5	22	23	O	be
6	25	35	O	interpreted
7	37	45	O	according
8	47	48	O	to
9	50	52	O	the
10	54	61	O	criteria
11	63	64	O	in
12	66	70	O	Table
13	72	72	O	1
NULL

Pfizerpen	6533	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	20
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.
1	0	11	O	Quantitative
2	13	19	O	methods
3	21	24	O	that
4	26	32	O	require
5	34	44	O	measurement
6	46	47	O	of
7	49	52	O	zone
8	54	62	O	diameters
9	64	67	O	also
10	69	75	O	provide
11	77	88	O	reproducible
12	90	98	O	estimates
13	100	101	O	of
14	103	105	O	the
15	107	120	O	susceptibility
16	122	123	O	of
17	125	132	O	bacteria
18	134	135	O	to
19	137	149	O	antimicrobial
20	151	159	O	compounds
NULL

Pfizerpen	6534	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	14
One such standardized procedure 2, 4 requires the use of standardized inoculum concentrations.
1	0	2	O	One
2	4	7	O	such
3	9	20	O	standardized
4	22	30	O	procedure
5	32	32	O	2
6	33	33	O	,
7	35	35	O	4
8	37	44	O	requires
9	46	48	O	the
10	50	52	O	use
11	54	55	O	of
12	57	68	O	standardized
13	70	77	O	inoculum
14	79	92	O	concentrations
NULL

Pfizerpen	6535	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	19
This procedure uses paper disks impregnated with 10 units of penicillin to test the susceptibility of microorganisms to penicillin.
1	0	3	O	This
2	5	13	O	procedure
3	15	18	O	uses
4	20	24	O	paper
5	26	30	O	disks
6	32	42	O	impregnated
7	44	47	O	with
8	49	50	O	10
9	52	56	O	units
10	58	59	O	of
11	61	70	O	penicillin
12	72	73	O	to
13	75	78	O	test
14	80	82	O	the
15	84	97	O	susceptibility
16	99	100	O	of
17	102	115	O	microorganisms
18	117	118	O	to
19	120	129	O	penicillin
NULL

Pfizerpen	6536	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	16
Interpretation involves correlation of the diameter obtained in the disk test with the MIC for penicillin.
1	0	13	O	Interpretation
2	15	22	O	involves
3	24	34	O	correlation
4	36	37	O	of
5	39	41	O	the
6	43	50	O	diameter
7	52	59	O	obtained
8	61	62	O	in
9	64	66	O	the
10	68	71	O	disk
11	73	76	O	test
12	78	81	O	with
13	83	85	O	the
14	87	89	O	MIC
15	91	93	O	for
16	95	104	O	penicillin
NULL

Pfizerpen	6537	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	30
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 10 unit penicillin disk should be interpreted according to the following criteria in Table 1.
1	0	6	O	Reports
2	8	11	O	from
3	13	15	O	the
4	17	26	O	laboratory
5	28	36	O	providing
6	38	44	O	results
7	46	47	O	of
8	49	51	O	the
9	53	60	O	standard
10	62	67	O	single
11	69	72	O	disk
12	74	87	O	susceptibility
13	89	92	O	test
14	94	97	O	with
15	99	99	O	a
16	101	102	O	10
17	104	107	O	unit
18	109	118	O	penicillin
19	120	123	O	disk
20	125	130	O	should
21	132	133	O	be
22	135	145	O	interpreted
23	147	155	O	according
24	157	158	O	to
25	160	162	O	the
26	164	172	O	following
27	174	181	O	criteria
28	183	184	O	in
29	186	190	O	Table
30	192	192	O	1
NULL

Pfizerpen	6538	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	34
Table 1: Susceptibility Test Interpretive Criteria for Penicillin MIC (mcg/mL) Disk Diffusion (zone diameter in mm)Organisms for which no values for disk susceptibility appear cannot be reliably tested with this method.
1	0	4	O	Table
2	6	6	O	1
3	7	7	O	:
4	9	22	O	Susceptibility
5	24	27	O	Test
6	29	40	O	Interpretive
7	42	49	O	Criteria
8	51	53	O	for
9	55	64	O	Penicillin
10	66	68	O	MIC
11	71	73	O	mcg
12	74	74	O	/
13	75	76	O	mL
14	79	82	O	Disk
15	84	92	O	Diffusion
16	95	98	O	zone
17	100	107	O	diameter
18	109	110	O	in
19	112	123	O	mm)Organisms
20	125	127	O	for
21	129	133	O	which
22	135	136	O	no
23	138	143	O	values
24	145	147	O	for
25	149	152	O	disk
26	154	167	O	susceptibility
27	169	174	O	appear
28	176	181	O	cannot
29	183	184	O	be
30	186	193	O	reliably
31	195	200	O	tested
32	202	205	O	with
33	207	210	O	this
34	212	217	O	method
NULL

Pfizerpen	6539	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	9
Pathogen Susceptible(S) Intermediate(I) Resistant(R) Susceptible(S) Intermediate(I) Resistant(R) Staphylococcus spp.
1	0	7	O	Pathogen
2	9	21	O	Susceptible(S
3	24	37	O	Intermediate(I
4	40	50	O	Resistant(R
5	53	65	O	Susceptible(S
6	68	81	O	Intermediate(I
7	84	94	O	Resistant(R
8	97	110	O	Staphylococcus
9	112	114	O	spp
NULL

Pfizerpen	6540	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	8
<0.12Penicillin-resistant strains of staphylococci produce B-lactamase.
1	0	14	O	<0.12Penicillin
2	16	24	O	resistant
3	26	32	O	strains
4	34	35	O	of
5	37	49	O	staphylococci
6	51	57	O	produce
7	59	59	O	B
8	61	69	O	lactamase
NULL

Pfizerpen	6541	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	34
An induced B-lactamase test should be performed on all S. aureus isolates for which the penicillin MIC is <0.12 mcg/mL or zone diameter is >29 mm before reporting as penicillin susceptible.
1	0	1	O	An
2	3	9	O	induced
3	11	11	O	B
4	13	21	O	lactamase
5	23	26	O	test
6	28	33	O	should
7	35	36	O	be
8	38	46	O	performed
9	48	49	O	on
10	51	53	O	all
11	55	55	O	S
12	58	63	O	aureus
13	65	72	O	isolates
14	74	76	O	for
15	78	82	O	which
16	84	86	O	the
17	88	97	O	penicillin
18	99	101	O	MIC
19	103	104	O	is
20	106	110	O	<0.12
21	112	114	O	mcg
22	115	115	O	/
23	116	117	O	mL
24	119	120	O	or
25	122	125	O	zone
26	127	134	O	diameter
27	136	137	O	is
28	139	141	O	>29
29	143	144	O	mm
30	146	151	O	before
31	153	161	O	reporting
32	163	164	O	as
33	166	175	O	penicillin
34	177	187	O	susceptible
NULL

Pfizerpen	6542	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	20
Rare isolates of staphylococci that contains genes for B-lactamase production may not produce a positive induced B-lactamase test.
1	0	3	O	Rare
2	5	12	O	isolates
3	14	15	O	of
4	17	29	O	staphylococci
5	31	34	O	that
6	36	43	O	contains
7	45	49	O	genes
8	51	53	O	for
9	55	55	O	B
10	57	65	O	lactamase
11	67	76	O	production
12	78	80	O	may
13	82	84	O	not
14	86	92	O	produce
15	94	94	O	a
16	96	103	O	positive
17	105	111	O	induced
18	113	113	O	B
19	115	123	O	lactamase
20	125	128	O	test
NULL

Pfizerpen	6543	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	44
For serious infections requiring penicillin therapy, laboratories should perform MIC tests and induced B-lactamase testing on all subsequent isolates from the same patient.2 - >0.25 >29 - <28 Neisseria Gonorrhoeae A positive N. gonorrhoeae B-lactamase test predicts one form of resistance to penicillin.
1	0	2	O	For
2	4	10	O	serious
3	12	21	O	infections
4	23	31	O	requiring
5	33	42	O	penicillin
6	44	50	O	therapy
7	51	51	O	,
8	53	64	O	laboratories
9	66	71	O	should
10	73	79	O	perform
11	81	83	O	MIC
12	85	89	O	tests
13	91	93	O	and
14	95	101	O	induced
15	103	103	O	B
16	105	113	O	lactamase
17	115	121	O	testing
18	123	124	O	on
19	126	128	O	all
20	130	139	O	subsequent
21	141	148	O	isolates
22	150	153	O	from
23	155	157	O	the
24	159	162	O	same
25	164	172	O	patient.2
26	176	180	O	>0.25
27	182	184	O	>29
28	188	190	O	<28
29	192	200	O	Neisseria
30	202	212	O	Gonorrhoeae
31	214	214	O	A
32	216	223	O	positive
33	225	225	O	N
34	228	238	O	gonorrhoeae
35	240	240	O	B
36	242	250	O	lactamase
37	252	255	O	test
38	257	264	O	predicts
39	266	268	O	one
40	270	273	O	form
41	275	276	O	of
42	278	287	O	resistance
43	289	290	O	to
44	292	301	O	penicillin
NULL

Pfizerpen	6544	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	50
Strains with chromosomally mediated resistance can be detected only by agar dilution or disk diffusion susceptibility test methods.2 Isolates with zone diameters <19 mm generally produced B-lactamase.2,4 <0.06 0.12 - 1 >2 >47 27 - 46 <26 Listeria Monocytogenes <2The current absence of resistant isolates precludes defining results other than "Susceptible".
1	0	6	O	Strains
2	8	11	O	with
3	13	25	O	chromosomally
4	27	34	O	mediated
5	36	45	O	resistance
6	47	49	O	can
7	51	52	O	be
8	54	61	O	detected
9	63	66	O	only
10	68	69	O	by
11	71	74	O	agar
12	76	83	O	dilution
13	85	86	O	or
14	88	91	O	disk
15	93	101	O	diffusion
16	103	116	O	susceptibility
17	118	121	O	test
18	123	131	O	methods.2
19	133	140	O	Isolates
20	142	145	O	with
21	147	150	O	zone
22	152	160	O	diameters
23	162	164	O	<19
24	166	167	O	mm
25	169	177	O	generally
26	179	186	O	produced
27	188	188	O	B
28	190	202	O	lactamase.2,4
29	204	208	O	<0.06
30	210	213	O	0.12
31	217	217	O	1
32	219	220	O	>2
33	222	224	O	>47
34	226	227	O	27
35	231	232	O	46
36	234	236	O	<26
37	238	245	O	Listeria
38	247	259	O	Monocytogenes
39	261	265	O	<2The
40	267	273	O	current
41	275	281	O	absence
42	283	284	O	of
43	286	294	O	resistant
44	296	303	O	isolates
45	305	313	O	precludes
46	315	322	O	defining
47	324	330	O	results
48	332	336	O	other
49	338	341	O	than
50	343	355	O	"Susceptible"
NULL

Pfizerpen	6545	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	17
Isolates yielding results suggestive of "Non-susceptible" should be submitted to a reference laboratory for further testing.
1	0	7	O	Isolates
2	9	16	O	yielding
3	18	24	O	results
4	26	35	O	suggestive
5	37	38	O	of
6	40	43	O	"Non
7	45	56	O	susceptible"
8	58	63	O	should
9	65	66	O	be
10	68	76	O	submitted
11	78	79	O	to
12	81	81	O	a
13	83	91	O	reference
14	93	102	O	laboratory
15	104	106	O	for
16	108	114	O	further
17	116	122	O	testing
NULL

Pfizerpen	6546	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	54
- - - - - Streptococcus pneumoniae (meningitis) <0.06 - >0.12 - - - Streptococcus pneumoniae (non-meningitis) <2 4 >8 - - - Streptococcus spp., Beta-hemolytic GroupSusceptibility testing of penicillins for treatment of B-hemolytic streptococcal infections need not be performed routinely, because non-susceptible isolates are extremely rare in any B-hemolytic streptococcus and have not been reported from Streptococcus pyogenes.
1	10	22	O	Streptococcus
2	24	33	O	pneumoniae
3	36	45	O	meningitis
4	48	52	O	<0.06
5	56	60	O	>0.12
6	68	80	O	Streptococcus
7	82	91	O	pneumoniae
8	94	96	O	non
9	98	107	O	meningitis
10	110	111	O	<2
11	113	113	O	4
12	115	116	O	>8
13	124	136	O	Streptococcus
14	138	140	O	spp
15	142	142	O	,
16	144	147	O	Beta
17	149	157	O	hemolytic
18	159	177	O	GroupSusceptibility
19	179	185	O	testing
20	187	188	O	of
21	190	200	O	penicillins
22	202	204	O	for
23	206	214	O	treatment
24	216	217	O	of
25	219	219	O	B
26	221	229	O	hemolytic
27	231	243	O	streptococcal
28	245	254	O	infections
29	256	259	O	need
30	261	263	O	not
31	265	266	O	be
32	268	276	O	performed
33	278	286	O	routinely
34	287	287	O	,
35	289	295	O	because
36	297	299	O	non
37	301	311	O	susceptible
38	313	320	O	isolates
39	322	324	O	are
40	326	334	O	extremely
41	336	339	O	rare
42	341	342	O	in
43	344	346	O	any
44	348	348	O	B
45	350	358	O	hemolytic
46	360	372	O	streptococcus
47	374	376	O	and
48	378	381	O	have
49	383	385	O	not
50	387	390	O	been
51	392	399	O	reported
52	401	404	O	from
53	406	418	O	Streptococcus
54	420	427	O	pyogenes
NULL

Pfizerpen	6547	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	51
Any B-hemolytic streptococcal isolate found to be non-susceptible to penicillin should be re-identified, retested, and, if confirmed, submitted to a public health authority.2,4 <0.12 - - >24 - - Streptococcus spp., Viridans Group <0.12 0.25-2 >4 - - - Bacillus anthracis B. anthracis strains may contain inducible B-lactamases.
1	0	2	O	Any
2	4	4	O	B
3	6	14	O	hemolytic
4	16	28	O	streptococcal
5	30	36	O	isolate
6	38	42	O	found
7	44	45	O	to
8	47	48	O	be
9	50	52	O	non
10	54	64	O	susceptible
11	66	67	O	to
12	69	78	O	penicillin
13	80	85	O	should
14	87	88	O	be
15	90	91	O	re
16	93	102	O	identified
17	103	103	O	,
18	105	112	O	retested
19	113	113	O	,
20	115	117	O	and
21	118	118	O	,
22	120	121	O	if
23	123	131	O	confirmed
24	132	132	O	,
25	134	142	O	submitted
26	144	145	O	to
27	147	147	O	a
28	149	154	O	public
29	156	161	O	health
30	163	175	O	authority.2,4
31	177	181	O	<0.12
32	187	189	O	>24
33	195	207	O	Streptococcus
34	209	211	O	spp
35	213	213	O	,
36	215	222	O	Viridans
37	224	228	O	Group
38	230	234	O	<0.12
39	236	239	O	0.25
40	241	241	O	2
41	243	244	O	>4
42	252	259	O	Bacillus
43	261	269	O	anthracis
44	271	271	O	B
45	274	282	O	anthracis
46	284	290	O	strains
47	292	294	O	may
48	296	302	O	contain
49	304	312	O	inducible
50	314	314	O	B
51	316	325	O	lactamases
NULL

Pfizerpen	6548	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	13
In vitro penicillinase induction studies suggest that penicillin MICs may increase during therapy.
1	0	1	O	In
2	3	7	O	vitro
3	9	21	O	penicillinase
4	23	31	O	induction
5	33	39	O	studies
6	41	47	O	suggest
7	49	52	O	that
8	54	63	O	penicillin
9	65	68	O	MICs
10	70	72	O	may
11	74	81	O	increase
12	83	88	O	during
13	90	96	O	therapy
NULL

Pfizerpen	6549	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	58
However, B-lactamase testing of clinical isolates of B. anthracis is unreliable and should not be performed.3 <0.12 - >0.25 - - - Standardized susceptibility test procedures require the use of laboratory control microorganisms to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test.
1	0	6	O	However
2	7	7	O	,
3	9	9	O	B
4	11	19	O	lactamase
5	21	27	O	testing
6	29	30	O	of
7	32	39	O	clinical
8	41	48	O	isolates
9	50	51	O	of
10	53	53	O	B
11	56	64	O	anthracis
12	66	67	O	is
13	69	78	O	unreliable
14	80	82	O	and
15	84	89	O	should
16	91	93	O	not
17	95	96	O	be
18	98	108	O	performed.3
19	110	114	O	<0.12
20	118	122	O	>0.25
21	130	141	O	Standardized
22	143	156	O	susceptibility
23	158	161	O	test
24	163	172	O	procedures
25	174	180	O	require
26	182	184	O	the
27	186	188	O	use
28	190	191	O	of
29	193	202	O	laboratory
30	204	210	O	control
31	212	225	O	microorganisms
32	227	228	O	to
33	230	236	O	monitor
34	238	240	O	and
35	242	247	O	ensure
36	249	251	O	the
37	253	260	O	accuracy
38	262	264	O	and
39	266	274	O	precision
40	276	277	O	of
41	279	281	O	the
42	283	290	O	supplies
43	292	294	O	and
44	296	303	O	reagents
45	305	308	O	used
46	310	311	O	in
47	313	315	O	the
48	317	321	O	assay
49	322	322	O	,
50	324	326	O	and
51	328	330	O	the
52	332	341	O	techniques
53	343	344	O	of
54	346	348	O	the
55	350	360	O	individuals
56	362	371	O	performing
57	373	375	O	the
58	377	380	O	test
NULL

Pfizerpen	6550	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	9
Standard penicillin powder should provide MIC values provided below.
1	0	7	O	Standard
2	9	18	O	penicillin
3	20	25	O	powder
4	27	32	O	should
5	34	40	O	provide
6	42	44	O	MIC
7	46	51	O	values
8	53	60	O	provided
9	62	66	O	below
NULL

Pfizerpen	6551	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	24
For the diffusion technique, the 10 unit penicillin disk should provide the following zone diameters with the quality control strains: Table 2.
1	0	2	O	For
2	4	6	O	the
3	8	16	O	diffusion
4	18	26	O	technique
5	27	27	O	,
6	29	31	O	the
7	33	34	O	10
8	36	39	O	unit
9	41	50	O	penicillin
10	52	55	O	disk
11	57	62	O	should
12	64	70	O	provide
13	72	74	O	the
14	76	84	O	following
15	86	89	O	zone
16	91	99	O	diameters
17	101	104	O	with
18	106	108	O	the
19	110	116	O	quality
20	118	124	O	control
21	126	132	O	strains
22	133	133	O	:
23	135	139	O	Table
24	141	141	O	2
NULL

Pfizerpen	6552	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	50
In Vitro Susceptibility Test Quality Control Ranges for Penicillin Organism(ATTC #) MIC range mcg/mL Disk Diffusion range (mm) Staphylococcus aureus (29213) 0.25 - 2 Not applicable Staphylococcus aureus (25923) Not applicable 26 - 37 Streptococcus pneumoniae (49619) 0.25 - 1 24 - 30 Neisseria gonorrhoeae (49226) 0.25 - 1Using agar dilution method only.
1	0	1	O	In
2	3	7	O	Vitro
3	9	22	O	Susceptibility
4	24	27	O	Test
5	29	35	O	Quality
6	37	43	O	Control
7	45	50	O	Ranges
8	52	54	O	for
9	56	65	O	Penicillin
10	67	79	O	Organism(ATTC
11	81	81	O	#
12	84	86	O	MIC
13	88	92	O	range
14	94	96	O	mcg
15	97	97	O	/
16	98	99	O	mL
17	101	104	O	Disk
18	106	114	O	Diffusion
19	116	120	O	range
20	123	124	O	mm
21	127	140	O	Staphylococcus
22	142	147	O	aureus
23	150	154	O	29213
24	157	160	O	0.25
25	164	164	O	2
26	166	168	O	Not
27	170	179	O	applicable
28	181	194	O	Staphylococcus
29	196	201	O	aureus
30	204	208	O	25923
31	211	213	O	Not
32	215	224	O	applicable
33	226	227	O	26
34	231	232	O	37
35	234	246	O	Streptococcus
36	248	257	O	pneumoniae
37	260	264	O	49619
38	267	270	O	0.25
39	274	274	O	1
40	276	277	O	24
41	281	282	O	30
42	284	292	O	Neisseria
43	294	304	O	gonorrhoeae
44	307	311	O	49226
45	314	317	O	0.25
46	321	326	O	1Using
47	328	331	O	agar
48	333	340	O	dilution
49	342	347	O	method
50	349	352	O	only
NULL

Pfizerpen	6553	34090-1	efef4846-9497-41af-8dd6-518f86eca7f2	9
No criteria for broth microdilution are available.2 26 - 34
1	0	1	O	No
2	3	10	O	criteria
3	12	14	O	for
4	16	20	O	broth
5	22	34	O	microdilution
6	36	38	O	are
7	40	50	O	available.2
8	52	53	O	26
9	57	58	O	34
NULL

Pimozide	2723	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	40
Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval.
1	0	6	O	Because
2	8	15	O	XXXXXXXX
3	17	24	O	prolongs
4	26	28	O	the
5	30	31	O	QT
6	33	40	O	interval
7	42	43	O	of
8	45	47	O	the
9	49	65	O	electrocardiogram
10	66	66	O	,
11	68	69	O	an
12	71	78	B-EFF	additive
13	80	85	I-EFF	effect
14	87	88	I-EFF	on
15	90	91	I-EFF	QT
16	93	100	L-EFF	interval
17	102	106	O	would
18	108	109	O	be
19	111	121	O	anticipated
20	123	124	O	if
21	126	137	O	administered
22	139	142	O	with
23	144	148	O	other
24	150	154	O	drugs
25	155	155	O	,
26	157	160	O	such
27	162	163	O	as
28	165	178	U-DYN	phenothiazines
29	179	179	O	,
30	181	189	B-DYN	tricyclic
31	191	205	L-DYN	antidepressants
32	207	208	O	or
33	210	223	B-DYN	antiarrhythmic
34	225	230	L-DYN	agents
35	231	231	O	,
36	233	237	O	which
37	239	245	O	prolong
38	247	249	O	the
39	251	252	O	QT
40	254	261	O	interval
D/28:12:1 D/30:12:1 D/33:12:1

Pimozide	2724	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	71
Accordingly, pimozide should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	20	O	XXXXXXXX
4	22	27	O	should
5	29	31	O	not
6	33	34	O	be
7	36	40	O	given
8	42	45	O	with
9	47	56	U-DYN	dofetilide
10	57	57	O	,
11	59	65	U-DYN	sotalol
12	66	66	O	,
13	68	76	U-DYN	quinidine
14	77	77	O	,
15	79	83	O	other
16	85	89	O	Class
17	91	92	O	Ia
18	94	96	O	and
19	98	100	O	III
20	102	105	O	anti
21	107	117	O	arrhythmics
22	118	118	O	,
23	120	131	U-DYN	mesoridazine
24	132	132	O	,
25	134	145	U-DYN	thioridazine
26	146	146	O	,
27	148	161	U-DYN	chlorpromazine
28	162	162	O	,
29	164	173	U-DYN	droperidol
30	174	174	O	,
31	176	187	U-DYN	sparfloxacin
32	188	188	O	,
33	190	201	U-DYN	gatifloxacin
34	202	202	O	,
35	204	215	U-DYN	moxifloxacin
36	216	216	O	,
37	218	229	U-DYN	halofantrine
38	230	230	O	,
39	232	241	U-DYN	mefloquine
40	242	242	O	,
41	244	254	U-DYN	pentamidine
42	255	255	O	,
43	257	263	B-DYN	arsenic
44	265	272	L-DYN	trioxide
45	273	273	O	,
46	275	286	B-DYN	levomethadyl
47	288	294	L-DYN	acetate
48	295	295	O	,
49	297	306	B-DYN	dolasetron
50	308	315	L-DYN	mesylate
51	316	316	O	,
52	318	325	U-DYN	probucol
53	326	326	O	,
54	328	337	U-DYN	tacrolimus
55	338	338	O	,
56	340	350	U-DYN	ziprasidone
57	351	351	O	,
58	353	354	O	or
59	356	360	O	other
60	362	366	B-DYN	drugs
61	368	371	I-DYN	that
62	373	376	I-DYN	have
63	378	389	I-DYN	demonstrated
64	391	392	I-DYN	QT
65	394	405	I-DYN	prolongation
66	407	408	I-DYN	as
67	410	412	I-DYN	one
68	414	415	I-DYN	of
69	417	421	I-DYN	their
70	423	437	I-DYN	pharmacodynamic
71	439	445	L-DYN	effects
NULL

Pimozide	2725	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	20
Also, the use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias.
1	0	3	O	Also
2	4	4	O	,
3	6	8	O	the
4	10	12	O	use
5	14	15	O	of
6	17	25	B-DYN	macrolide
7	27	37	L-DYN	antibiotics
8	39	40	O	in
9	42	49	O	patients
10	51	54	O	with
11	56	64	O	prolonged
12	66	67	O	QT
13	69	77	O	intervals
14	79	81	O	has
15	83	86	O	been
16	88	93	O	rarely
17	95	104	O	associated
18	106	109	O	with
19	111	121	B-EFF	ventricular
20	123	133	L-EFF	arrhythmias
D/6:19:1

Pimozide	2726	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	7
Such concomitant administration should not be undertaken.
1	0	3	O	Such
2	5	15	O	concomitant
3	17	30	O	administration
4	32	37	O	should
5	39	41	O	not
6	43	44	O	be
7	46	55	O	undertaken
NULL

Pimozide	2727	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	31
Since pimozide is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as azole antifungal agents and protease inhibitor drugs.
1	0	4	O	Since
2	6	13	O	XXXXXXXX
3	15	16	O	is
4	18	23	O	partly
5	25	35	O	metabolized
6	37	39	O	via
7	41	43	O	CYP
8	45	47	O	3A4
9	48	48	O	,
10	50	51	O	it
11	53	58	B-TRI	should
12	60	62	I-TRI	not
13	64	65	I-TRI	be
14	67	78	L-TRI	administered
15	80	92	O	concomitantly
16	94	97	O	with
17	99	108	O	inhibitors
18	110	111	O	of
19	113	116	O	this
20	118	126	O	metabolic
21	128	133	O	system
22	134	134	O	,
23	136	139	O	such
24	141	142	O	as
25	144	148	B-UNK	azole
26	150	159	I-UNK	antifungal
27	161	166	L-UNK	agents
28	168	170	O	and
29	172	179	B-UNK	protease
30	181	189	I-UNK	inhibitor
31	191	195	L-UNK	drugs
NULL

Pimozide	2728	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	46
Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone.
1	0	7	O	XXXXXXXX
2	9	11	O	and
3	13	18	U-DYN	Celexa
4	19	19	O	:
5	21	22	O	In
6	24	24	O	a
7	26	35	O	controlled
8	37	41	O	study
9	42	42	O	,
10	44	44	O	a
11	46	51	O	single
12	53	56	O	dose
13	58	59	O	of
14	61	68	O	XXXXXXXX
15	70	70	O	2
16	72	73	O	mg
17	75	88	O	coadministered
18	90	93	O	with
19	95	101	O	racemic
20	103	112	U-DYN	citalopram
21	114	115	O	40
22	117	118	O	mg
23	120	124	O	given
24	126	129	O	once
25	131	135	O	daily
26	137	139	O	for
27	141	142	O	11
28	144	147	O	days
29	149	151	O	was
30	153	162	O	associated
31	164	167	O	with
32	169	169	O	a
33	171	174	O	mean
34	176	183	B-EFF	increase
35	185	186	I-EFF	in
36	188	190	L-EFF	QTc
37	192	197	O	values
38	199	200	O	of
39	202	214	O	approximately
40	216	217	O	10
41	219	222	O	msec
42	224	231	O	compared
43	233	234	O	to
44	236	243	O	XXXXXXXX
45	245	249	O	given
46	251	255	O	alone
D/20:34:1 D/3:34:1

Pimozide	2729	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	12
Racemic citalopram did not alter the mean AUC or Cmax of pimozide.
1	0	6	O	Racemic
2	8	17	O	citalopram
3	19	21	O	did
4	23	25	O	not
5	27	31	O	alter
6	33	35	O	the
7	37	40	O	mean
8	42	44	O	AUC
9	46	47	O	or
10	49	52	O	Cmax
11	54	55	O	of
12	57	64	O	XXXXXXXX
NULL

Pimozide	2730	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	9
The mechanism of this pharmacodynamic interaction is not known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	20	O	this
5	22	36	O	pharmacodynamic
6	38	48	O	interaction
7	50	51	O	is
8	53	55	O	not
9	57	61	O	known
NULL

Pimozide	2731	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	10
Concomitant use of Pimozide and Celexa or Lexapro is contraindicated.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	30	O	and
6	32	37	U-UNK	Celexa
7	39	40	O	or
8	42	48	U-UNK	Lexapro
9	50	51	O	is
10	53	67	U-TRI	contraindicated
NULL

Pimozide	2732	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	40
CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone.
1	0	2	B-KIN	CYP
2	4	6	I-KIN	2D6
3	8	17	L-KIN	inhibitors
4	18	18	O	:
5	20	21	O	In
6	23	29	O	healthy
7	31	38	O	subjects
8	39	39	O	,
9	41	42	O	co
10	44	57	O	administration
11	59	60	O	of
12	62	69	O	XXXXXXXX
13	71	71	O	2
14	73	74	O	mg
15	77	82	O	single
16	84	87	O	dose
17	90	92	O	and
18	94	103	U-KIN	paroxetine
19	105	106	O	60
20	108	109	O	mg
21	111	118	O	resulted
22	120	121	O	in
23	123	123	O	a
24	125	128	O	151%
25	130	137	O	increase
26	139	140	O	in
27	142	149	O	XXXXXXXX
28	151	153	O	AUC
29	155	157	O	and
30	159	159	O	a
31	161	163	O	62%
32	165	172	O	increase
33	174	175	O	in
34	177	184	O	XXXXXXXX
35	186	189	O	Cmax
36	191	198	O	compared
37	200	201	O	to
38	203	210	O	XXXXXXXX
39	212	223	O	administered
40	225	229	O	alone
K/1:C54602 K/18:C54602

Pimozide	2733	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	17
The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine.
1	0	2	O	The
2	4	11	O	increase
3	13	14	O	in
4	16	23	O	XXXXXXXX
5	25	27	O	AUC
6	29	31	O	and
7	33	36	O	Cmax
8	38	39	O	is
9	41	47	O	related
10	49	50	O	to
11	52	54	O	the
12	56	58	O	CYP
13	60	62	O	2D6
14	64	73	O	inhibitory
15	75	84	O	properties
16	86	87	O	of
17	89	98	U-KIN	paroxetine
K/17:C54602

Pimozide	2734	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	14
Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	30	O	and
6	32	41	U-UNK	paroxetine
7	43	44	O	or
8	46	50	O	other
9	52	57	B-UNK	strong
10	59	61	I-UNK	CYP
11	63	65	I-UNK	2D6
12	67	76	L-UNK	inhibitors
13	78	80	O	are
14	82	96	U-TRI	contraindicated
NULL

Pimozide	2735	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	29
As CYP 1A2 may also contribute to the metabolism of pimozide, prescribers should be aware of the theoretical potential for drug interactions with inhibitors of this enzymatic system.
1	0	1	O	As
2	3	5	O	CYP
3	7	9	O	1A2
4	11	13	O	may
5	15	18	O	also
6	20	29	O	contribute
7	31	32	O	to
8	34	36	O	the
9	38	47	O	metabolism
10	49	50	O	of
11	52	59	O	XXXXXXXX
12	60	60	O	,
13	62	72	O	prescribers
14	74	79	O	should
15	81	82	O	be
16	84	88	O	aware
17	90	91	O	of
18	93	95	O	the
19	97	107	O	theoretical
20	109	117	O	potential
21	119	121	O	for
22	123	126	B-TRI	drug
23	128	139	L-TRI	interactions
24	141	144	O	with
25	146	155	O	inhibitors
26	157	158	O	of
27	160	163	O	this
28	165	173	O	enzymatic
29	175	180	O	system
NULL

Pimozide	2736	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	18
Pimozide may be capable of potentiating CNS depressants, including analgesics, sedatives, anxiolytics, and alcohol.
1	0	7	O	XXXXXXXX
2	9	11	O	may
3	13	14	O	be
4	16	22	O	capable
5	24	25	O	of
6	27	38	B-EFF	potentiating
7	40	42	I-EFF	CNS
8	44	54	L-EFF	depressants
9	55	55	O	,
10	57	65	O	including
11	67	76	U-DYN	analgesics
12	77	77	O	,
13	79	87	U-DYN	sedatives
14	88	88	O	,
15	90	100	U-DYN	anxiolytics
16	101	101	O	,
17	103	105	O	and
18	107	113	U-DYN	alcohol
D/11:6:0 D/13:6:0 D/15:6:0 D/18:6:0

Pimozide	2737	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	15
Rare case reports have suggested possible additive effects of pimozide and fluoxetine leading to bradycardia.
1	0	3	O	Rare
2	5	8	O	case
3	10	16	O	reports
4	18	21	O	have
5	23	31	O	suggested
6	33	40	O	possible
7	42	49	O	additive
8	51	57	O	effects
9	59	60	O	of
10	62	69	O	XXXXXXXX
11	71	73	O	and
12	75	84	U-DYN	fluoxetine
13	86	92	O	leading
14	94	95	O	to
15	97	107	U-EFF	bradycardia
D/12:15:1

Pimozide	2738	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	9
Concomitant administration of pimozide and sertraline should be contraindicated.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	37	O	XXXXXXXX
5	39	41	O	and
6	43	52	U-UNK	sertraline
7	54	59	O	should
8	61	62	O	be
9	64	78	U-TRI	contraindicated
NULL

Pimozide	2739	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	27
Pharmacogenomics Individuals with genetic variations resulting in poor CYP 2D6 metabolism (approximately 5 to 10% of the population) exhibit higher pimozide concentrations than extensive CYP 2D6 metabolizers.
1	0	15	O	Pharmacogenomics
2	17	27	O	Individuals
3	29	32	O	with
4	34	40	O	genetic
5	42	51	O	variations
6	53	61	O	resulting
7	63	64	O	in
8	66	69	O	poor
9	71	73	O	CYP
10	75	77	O	2D6
11	79	88	O	metabolism
12	91	103	O	approximately
13	105	105	O	5
14	107	108	O	to
15	110	112	O	10%
16	114	115	O	of
17	117	119	O	the
18	121	130	O	population
19	133	139	O	exhibit
20	141	146	O	higher
21	148	155	O	XXXXXXXX
22	157	170	O	concentrations
23	172	175	O	than
24	177	185	O	extensive
25	187	189	O	CYP
26	191	193	O	2D6
27	195	206	O	metabolizers
NULL

Pimozide	2740	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	21
The concentrations observed in poor CYP 2D6 metabolizers are similar to those seen with strong CYP 2D6 inhibitors such as paroxetine.
1	0	2	O	The
2	4	17	O	concentrations
3	19	26	O	observed
4	28	29	O	in
5	31	34	O	poor
6	36	38	O	CYP
7	40	42	O	2D6
8	44	55	O	metabolizers
9	57	59	O	are
10	61	67	O	similar
11	69	70	O	to
12	72	76	O	those
13	78	81	O	seen
14	83	86	O	with
15	88	93	O	strong
16	95	97	O	CYP
17	99	101	O	2D6
18	103	112	O	inhibitors
19	114	117	O	such
20	119	120	O	as
21	122	131	O	paroxetine
NULL

Pimozide	2741	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	27
The time to achieve steady state Pimozide concentrations is expected to be longer (approximately 2 weeks) in poor CYP 2D6 metabolizers because of the prolonged half-life.
1	0	2	O	The
2	4	7	O	time
3	9	10	O	to
4	12	18	O	achieve
5	20	25	O	steady
6	27	31	O	state
7	33	40	O	XXXXXXXX
8	42	55	O	concentrations
9	57	58	O	is
10	60	67	O	expected
11	69	70	O	to
12	72	73	O	be
13	75	80	O	longer
14	83	95	O	approximately
15	97	97	O	2
16	99	103	O	weeks
17	106	107	O	in
18	109	112	O	poor
19	114	116	O	CYP
20	118	120	O	2D6
21	122	133	O	metabolizers
22	135	141	O	because
23	143	144	O	of
24	146	148	O	the
25	150	158	O	prolonged
26	160	163	O	half
27	165	168	O	life
NULL

Pimozide	2742	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	14
Alternative dosing strategies are recommended in patients who are genetically poor CYP 2D6 metabolizers.
1	0	10	O	Alternative
2	12	17	O	dosing
3	19	28	O	strategies
4	30	32	O	are
5	34	44	O	recommended
6	46	47	O	in
7	49	56	O	patients
8	58	60	O	who
9	62	64	O	are
10	66	76	O	genetically
11	78	81	O	poor
12	83	85	O	CYP
13	87	89	O	2D6
14	91	102	O	metabolizers
NULL

Pimozide	2743	34073-7	70b079e2-a1f7-4a93-8685-d60a4d7c1280	19
Interaction with Food Patients should avoid grapefruit juice because it may inhibit the metabolism of pimozide by CYP 3A4.
1	0	10	O	Interaction
2	12	15	O	with
3	17	20	O	Food
4	22	29	O	Patients
5	31	36	O	should
6	38	42	O	avoid
7	44	53	B-KIN	grapefruit
8	55	59	L-KIN	juice
9	61	67	O	because
10	69	70	O	it
11	72	74	O	may
12	76	82	B-TRI	inhibit
13	84	86	I-TRI	the
14	88	97	L-TRI	metabolism
15	99	100	O	of
16	102	109	O	XXXXXXXX
17	111	112	O	by
18	114	116	O	CYP
19	118	120	O	3A4
K/7:C54355

Pimozide	2744	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	31
Pharmacodynamic Actions Pimozide tablets, USP is an orally active antipsychotic drug product which shares with other antipsychotics the ability to blockade dopaminergic receptors on neurons in the central nervous system.
1	0	14	O	Pharmacodynamic
2	16	22	O	Actions
3	24	31	O	XXXXXXXX
4	33	39	O	tablets
5	40	40	O	,
6	42	44	O	USP
7	46	47	O	is
8	49	50	O	an
9	52	57	O	orally
10	59	64	O	active
11	66	78	O	antipsychotic
12	80	83	O	drug
13	85	91	O	product
14	93	97	O	which
15	99	104	O	shares
16	106	109	O	with
17	111	115	O	other
18	117	130	O	antipsychotics
19	132	134	O	the
20	136	142	O	ability
21	144	145	O	to
22	147	154	O	blockade
23	156	167	O	dopaminergic
24	169	177	O	receptors
25	179	180	O	on
26	182	188	O	neurons
27	190	191	O	in
28	193	195	O	the
29	197	203	O	central
30	205	211	O	nervous
31	213	218	O	system
NULL

Pimozide	2745	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	35
Although its exact mode of action has not been established, the ability of pimozide to suppress motor and phonic tics in Tourette's Disorder is thought to be a function of its dopaminergic blocking activity.
1	0	7	O	Although
2	9	11	O	its
3	13	17	O	exact
4	19	22	O	mode
5	24	25	O	of
6	27	32	O	action
7	34	36	O	has
8	38	40	O	not
9	42	45	O	been
10	47	57	O	established
11	58	58	O	,
12	60	62	O	the
13	64	70	O	ability
14	72	73	O	of
15	75	82	O	XXXXXXXX
16	84	85	O	to
17	87	94	O	suppress
18	96	100	O	motor
19	102	104	O	and
20	106	111	O	phonic
21	113	116	O	tics
22	118	119	O	in
23	121	130	O	Tourette's
24	132	139	O	Disorder
25	141	142	O	is
26	144	150	O	thought
27	152	153	O	to
28	155	156	O	be
29	158	158	O	a
30	160	167	O	function
31	169	170	O	of
32	172	174	O	its
33	176	187	O	dopaminergic
34	189	196	O	blocking
35	198	205	O	activity
NULL

Pimozide	2746	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	30
However, receptor blockade is often accompanied by a series of secondary alterations in central dopamine metabolism and function which may contribute to both pimozide's therapeutic and untoward effects.
1	0	6	O	However
2	7	7	O	,
3	9	16	O	receptor
4	18	25	O	blockade
5	27	28	O	is
6	30	34	O	often
7	36	46	O	accompanied
8	48	49	O	by
9	51	51	O	a
10	53	58	O	series
11	60	61	O	of
12	63	71	O	secondary
13	73	83	O	alterations
14	85	86	O	in
15	88	94	O	central
16	96	103	O	dopamine
17	105	114	O	metabolism
18	116	118	O	and
19	120	127	O	function
20	129	133	O	which
21	135	137	O	may
22	139	148	O	contribute
23	150	151	O	to
24	153	156	O	both
25	158	165	O	XXXXXXXX
26	166	167	O	's
27	169	179	O	therapeutic
28	181	183	O	and
29	185	192	O	untoward
30	194	200	O	effects
NULL

Pimozide	2747	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	28
In addition, pimozide tablets, USP in common with other antipsychotic drugs, has various effects on other central nervous system receptor systems which are not fully characterized.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	20	O	XXXXXXXX
5	22	28	O	tablets
6	29	29	O	,
7	31	33	O	USP
8	35	36	O	in
9	38	43	O	common
10	45	48	O	with
11	50	54	O	other
12	56	74	O	GGGGGGGG
13	75	75	O	,
14	77	79	O	has
15	81	87	O	various
16	89	95	O	effects
17	97	98	O	on
18	100	104	O	other
19	106	112	O	central
20	114	120	O	nervous
21	122	127	O	system
22	129	136	O	receptor
23	138	144	O	systems
24	146	150	O	which
25	152	154	O	are
26	156	158	O	not
27	160	164	O	fully
28	166	178	O	characterized
NULL

Pimozide	2748	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	16
Metabolism and Pharmacokinetics More than 50% of a dose of pimozide is absorbed after oral administration.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	30	O	Pharmacokinetics
4	32	35	O	More
5	37	40	O	than
6	42	44	O	50%
7	46	47	O	of
8	49	49	O	a
9	51	54	O	dose
10	56	57	O	of
11	59	66	O	XXXXXXXX
12	68	69	O	is
13	71	78	O	absorbed
14	80	84	O	after
15	86	89	O	oral
16	91	104	O	administration
NULL

Pimozide	2749	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	16
Based on the pharmacokinetic and metabolic profile, pimozide appears to undergo significant first pass metabolism.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	27	O	pharmacokinetic
5	29	31	O	and
6	33	41	O	metabolic
7	43	49	O	profile
8	50	50	O	,
9	52	59	O	XXXXXXXX
10	61	67	O	appears
11	69	70	O	to
12	72	78	O	undergo
13	80	90	O	significant
14	92	96	O	first
15	98	101	O	pass
16	103	112	O	metabolism
NULL

Pimozide	2750	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	16
Peak serum levels occur generally six to eight hours (range 4 to 12 hours) after dosing.
1	0	3	O	Peak
2	5	9	O	serum
3	11	16	O	levels
4	18	22	O	occur
5	24	32	O	generally
6	34	36	O	six
7	38	39	O	to
8	41	45	O	eight
9	47	51	O	hours
10	54	58	O	range
11	60	60	O	4
12	62	63	O	to
13	65	66	O	12
14	68	72	O	hours
15	75	79	O	after
16	81	86	O	dosing
NULL

Pimozide	2751	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	12
Pimozide is extensively metabolized, primarily by N-dealkylation in the liver.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	extensively
4	24	34	O	metabolized
5	35	35	O	,
6	37	45	O	primarily
7	47	48	O	by
8	50	50	O	N
9	52	63	O	dealkylation
10	65	66	O	in
11	68	70	O	the
12	72	76	O	liver
NULL

Pimozide	2752	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	32
This metabolism is catalyzed mainly by the cytochrome P450 3A4 (CYP 3A4) enzymatic system and to a lesser extent, by cytochrome P450 1A2 (CYP 1A2) and cytochrome P450 2D6 (CYP 2D6).
1	0	3	O	This
2	5	14	O	metabolism
3	16	17	O	is
4	19	27	O	catalyzed
5	29	34	O	mainly
6	36	37	O	by
7	39	41	O	the
8	43	52	O	cytochrome
9	54	57	O	P450
10	59	61	O	3A4
11	64	66	O	CYP
12	68	70	O	3A4
13	73	81	O	enzymatic
14	83	88	O	system
15	90	92	O	and
16	94	95	O	to
17	97	97	O	a
18	99	104	O	lesser
19	106	111	O	extent
20	112	112	O	,
21	114	115	O	by
22	117	126	O	cytochrome
23	128	131	O	P450
24	133	135	O	1A2
25	138	140	O	CYP
26	142	144	O	1A2
27	147	149	O	and
28	151	160	O	cytochrome
29	162	165	O	P450
30	167	169	O	2D6
31	172	174	O	CYP
32	176	178	O	2D6
NULL

Pimozide	2753	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	18
Two major metabolites have been identified, 1-(4-piperidyl)-2-benzimidazolinone and 4,4-bis(4-fluorophenyl) butyric acid.
1	0	2	O	Two
2	4	8	O	major
3	10	20	O	metabolites
4	22	25	O	have
5	27	30	O	been
6	32	41	O	identified
7	42	42	O	,
8	44	44	O	1
9	47	47	O	4
10	49	57	O	piperidyl
11	60	60	O	2
12	62	78	O	benzimidazolinone
13	80	82	O	and
14	84	86	O	4,4
15	88	92	O	bis(4
16	94	105	O	fluorophenyl
17	108	114	O	butyric
18	116	119	O	acid
NULL

Pimozide	2754	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	8
The antipsychotic activity of these metabolites is undetermined.
1	0	2	O	The
2	4	16	O	antipsychotic
3	18	25	O	activity
4	27	28	O	of
5	30	34	O	these
6	36	46	O	metabolites
7	48	49	O	is
8	51	62	O	undetermined
NULL

Pimozide	2755	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	14
The major route of elimination of pimozide and its metabolites is through the kidney.
1	0	2	O	The
2	4	8	O	major
3	10	14	O	route
4	16	17	O	of
5	19	29	O	elimination
6	31	32	O	of
7	34	41	O	XXXXXXXX
8	43	45	O	and
9	47	49	O	its
10	51	61	O	metabolites
11	63	64	O	is
12	66	72	O	through
13	74	76	O	the
14	78	83	O	kidney
NULL

Pimozide	2756	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	15
The mean serum elimination half-life of pimozide in schizophrenic patients was approximately 55 hours.
1	0	2	O	The
2	4	7	O	mean
3	9	13	O	serum
4	15	25	O	elimination
5	27	30	O	half
6	32	35	O	life
7	37	38	O	of
8	40	47	O	XXXXXXXX
9	49	50	O	in
10	52	64	O	schizophrenic
11	66	73	O	patients
12	75	77	O	was
13	79	91	O	approximately
14	93	94	O	55
15	96	100	O	hours
NULL

Pimozide	2757	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	30
There was a 13-fold interindividual difference in the area under the serum pimozide level-time curve and an equivalent degree of variation in peak serum levels among patients studied.
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	13	O	13
5	15	18	O	fold
6	20	34	O	interindividual
7	36	45	O	difference
8	47	48	O	in
9	50	52	O	the
10	54	57	O	area
11	59	63	O	under
12	65	67	O	the
13	69	73	O	serum
14	75	82	O	XXXXXXXX
15	84	88	O	level
16	90	93	O	time
17	95	99	O	curve
18	101	103	O	and
19	105	106	O	an
20	108	117	O	equivalent
21	119	124	O	degree
22	126	127	O	of
23	129	137	O	variation
24	139	140	O	in
25	142	145	O	peak
26	147	151	O	serum
27	153	158	O	levels
28	160	164	O	among
29	166	173	O	patients
30	175	181	O	studied
NULL

Pimozide	2758	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	17
The significance of this is unclear since there are few correlations between plasma levels and clinical findings.
1	0	2	O	The
2	4	15	O	significance
3	17	18	O	of
4	20	23	O	this
5	25	26	O	is
6	28	34	O	unclear
7	36	40	O	since
8	42	46	O	there
9	48	50	O	are
10	52	54	O	few
11	56	67	O	correlations
12	69	75	O	between
13	77	82	O	plasma
14	84	89	O	levels
15	91	93	O	and
16	95	102	O	clinical
17	104	111	O	findings
NULL

Pimozide	2759	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	19
Effects of food and disease upon the absorption, distribution, metabolism and elimination of pimozide are not known.
1	0	6	O	Effects
2	8	9	O	of
3	11	14	O	food
4	16	18	O	and
5	20	26	O	disease
6	28	31	O	upon
7	33	35	O	the
8	37	46	O	absorption
9	47	47	O	,
10	49	60	O	distribution
11	61	61	O	,
12	63	72	O	metabolism
13	74	76	O	and
14	78	88	O	elimination
15	90	91	O	of
16	93	100	O	XXXXXXXX
17	102	104	O	are
18	106	108	O	not
19	110	114	O	known
NULL

Pimozide	2760	34090-1	70b079e2-a1f7-4a93-8685-d60a4d7c1280	18
Effects of concomitant medication and genetic variations on pimozide metabolism are described in the CONTRAINDICATIONS and PRECAUTIONS sections.
1	0	6	O	Effects
2	8	9	O	of
3	11	21	O	concomitant
4	23	32	O	medication
5	34	36	O	and
6	38	44	O	genetic
7	46	55	O	variations
8	57	58	O	on
9	60	67	O	XXXXXXXX
10	69	78	O	metabolism
11	80	82	O	are
12	84	92	O	described
13	94	95	O	in
14	97	99	O	the
15	101	117	O	CONTRAINDICATIONS
16	119	121	O	and
17	123	133	O	PRECAUTIONS
18	135	142	O	sections
NULL

Pravastatin Sodium	1976	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	22
For the concurrent therapy of either cyclosporine, fibrates, niacin (nicotinic acid), or erythromycin, the risk of myopathy increases.
1	0	2	O	For
2	4	6	O	the
3	8	17	O	concurrent
4	19	25	O	therapy
5	27	28	O	of
6	30	35	O	either
7	37	48	U-DYN	cyclosporine
8	49	49	O	,
9	51	58	U-DYN	fibrates
10	59	59	O	,
11	61	66	U-DYN	niacin
12	69	77	B-DYN	nicotinic
13	79	82	L-DYN	acid
14	84	84	O	,
15	86	87	O	or
16	89	100	U-DYN	erythromycin
17	101	101	O	,
18	103	105	O	the
19	107	110	O	risk
20	112	113	O	of
21	115	122	U-EFF	myopathy
22	124	132	O	increases
D/11:21:1 D/12:21:1 D/16:21:1 D/7:21:1 D/9:21:1

Pravastatin Sodium	1977	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	28
* Concomitant lipid-lowering therapies: use with fibrates or lipid-modifying doses (> 1 g/day) of niacin increases the risk of adverse skeletal muscle effects.
1	0	0	O	*
2	2	12	O	Concomitant
3	14	18	B-DYN	lipid
4	20	27	I-DYN	lowering
5	29	37	L-DYN	therapies
6	38	38	O	:
7	40	42	O	use
8	44	47	O	with
9	49	56	U-DYN	fibrates
10	58	59	O	or
11	61	65	O	lipid
12	67	75	O	modifying
13	77	81	O	doses
14	84	84	O	>
15	86	86	O	1
16	88	88	O	g
17	89	89	O	/
18	90	92	O	day
19	95	96	O	of
20	98	103	U-DYN	niacin
21	105	113	O	increases
22	115	117	O	the
23	119	122	O	risk
24	124	125	O	of
25	127	133	B-EFF	adverse
26	135	142	I-EFF	skeletal
27	144	149	I-EFF	muscle
28	151	157	L-EFF	effects
D/20:25:1 D/3:25:1 D/9:25:1

Pravastatin Sodium	1978	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	8
Caution should be used when prescribing with pravastatin sodium.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	26	O	when
6	28	38	O	prescribing
7	40	43	O	with
8	45	62	O	XXXXXXXX
NULL

Pravastatin Sodium	1979	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	5
Cyclosporine: combination increases exposure.
1	0	11	U-KIN	Cyclosporine
2	12	12	O	:
3	14	24	O	combination
4	26	34	B-TRI	increases
5	36	43	L-TRI	exposure
K/1:C54355

Pravastatin Sodium	1980	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	5
Clarithromycin: combination increases exposure.
1	0	13	U-KIN	Clarithromycin
2	14	14	O	:
3	16	26	O	combination
4	28	36	B-TRI	increases
5	38	45	L-TRI	exposure
K/1:C54355

Pravastatin Sodium	1981	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	13
The risk of myopathy/rhabdomyolysis is increased with concomitant administration of cyclosporine.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	myopathy
5	20	20	I-EFF	/
6	21	34	L-EFF	rhabdomyolysis
7	36	37	O	is
8	39	47	O	increased
9	49	52	O	with
10	54	64	O	concomitant
11	66	79	O	administration
12	81	82	O	of
13	84	95	U-DYN	cyclosporine
D/13:4:1

Pravastatin Sodium	1982	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	12
Limit pravastatin to 20 mg once daily for concomitant use with cyclosporine.
1	0	4	O	Limit
2	6	16	O	XXXXXXXX
3	18	19	O	to
4	21	22	O	20
5	24	25	O	mg
6	27	30	O	once
7	32	36	O	daily
8	38	40	O	for
9	42	52	O	concomitant
10	54	56	O	use
11	58	61	O	with
12	63	74	U-KIN	cyclosporine
K/12:C54355

Pravastatin Sodium	1983	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	13
The risk of myopathy/rhabdomyolysis is increased with concomitant administration of clarithromycin.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	myopathy
5	20	20	I-EFF	/
6	21	34	L-EFF	rhabdomyolysis
7	36	37	O	is
8	39	47	O	increased
9	49	52	O	with
10	54	64	O	concomitant
11	66	79	O	administration
12	81	82	O	of
13	84	97	U-DYN	clarithromycin
D/13:4:1

Pravastatin Sodium	1984	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	12
Limit pravastatin to 40 mg once daily for concomitant use with clarithromycin.
1	0	4	O	Limit
2	6	16	O	XXXXXXXX
3	18	19	O	to
4	21	22	O	40
5	24	25	O	mg
6	27	30	O	once
7	32	36	O	daily
8	38	40	O	for
9	42	52	O	concomitant
10	54	56	O	use
11	58	61	O	with
12	63	76	U-KIN	clarithromycin
K/12:C54355

Pravastatin Sodium	1985	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	18
Other macrolides (e.g., erythromycin and azithromycin) have the potential to increase statin exposures while used in combination.
1	0	4	O	Other
2	6	15	U-KIN	macrolides
3	18	20	O	e.g
4	22	22	O	,
5	24	35	U-KIN	erythromycin
6	37	39	O	and
7	41	52	U-KIN	azithromycin
8	55	58	O	have
9	60	62	O	the
10	64	72	O	potential
11	74	75	O	to
12	77	84	O	increase
13	86	91	O	statin
14	93	101	O	exposures
15	103	107	O	while
16	109	112	O	used
17	114	115	O	in
18	117	127	O	combination
K/2:C54355 K/5:C54355 K/7:C54355

Pravastatin Sodium	1986	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	16
Pravastatin should be used cautiously with macrolide antibiotics due to a potential increased risk of myopathies.
1	0	10	O	XXXXXXXX
2	12	17	O	should
3	19	20	O	be
4	22	25	O	used
5	27	36	O	cautiously
6	38	41	O	with
7	43	51	B-DYN	macrolide
8	53	63	L-DYN	antibiotics
9	65	67	O	due
10	69	70	O	to
11	72	72	O	a
12	74	82	O	potential
13	84	92	O	increased
14	94	97	O	risk
15	99	100	O	of
16	102	111	U-EFF	myopathies
D/7:16:1

Pravastatin Sodium	1987	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	13
The risk of myopathy/rhabdomyolysis is increased with concomitant administration of colchicine.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	myopathy
5	20	20	I-EFF	/
6	21	34	L-EFF	rhabdomyolysis
7	36	37	O	is
8	39	47	O	increased
9	49	52	O	with
10	54	64	O	concomitant
11	66	79	O	administration
12	81	82	O	of
13	84	93	U-DYN	colchicine
D/13:4:1

Pravastatin Sodium	1988	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	28
Due to an increased risk of myopathy/rhabdomyolysis when HMG-CoA reductase inhibitors are coadministered with gemfibrozil, concomitant administration of pravastatin sodium with gemfibrozil should be avoided.
1	0	2	O	Due
2	4	5	O	to
3	7	8	O	an
4	10	18	O	increased
5	20	23	O	risk
6	25	26	O	of
7	28	35	B-EFF	myopathy
8	36	36	I-EFF	/
9	37	50	L-EFF	rhabdomyolysis
10	52	55	O	when
11	57	59	O	HMG
12	61	63	O	CoA
13	65	73	O	reductase
14	75	84	O	inhibitors
15	86	88	O	are
16	90	103	O	coadministered
17	105	108	O	with
18	110	120	U-DYN	gemfibrozil
19	121	121	O	,
20	123	133	O	concomitant
21	135	148	O	administration
22	150	151	O	of
23	153	170	O	XXXXXXXX
24	172	175	O	with
25	177	187	O	gemfibrozil
26	189	194	O	should
27	196	197	O	be
28	199	205	O	avoided
D/18:7:1

Pravastatin Sodium	1989	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	37
Because it is known that the risk of myopathy during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, pravastatin sodium should be administered with caution when used concomitantly with other fibrates.
1	0	6	O	Because
2	8	9	O	it
3	11	12	O	is
4	14	18	O	known
5	20	23	O	that
6	25	27	O	the
7	29	32	O	risk
8	34	35	O	of
9	37	44	U-EFF	myopathy
10	46	51	O	during
11	53	61	O	treatment
12	63	66	O	with
13	68	70	O	HMG
14	72	74	O	CoA
15	76	84	O	reductase
16	86	95	O	inhibitors
17	97	98	O	is
18	100	108	O	increased
19	110	113	O	with
20	115	124	O	concurrent
21	126	139	O	administration
22	141	142	O	of
23	144	148	O	other
24	150	157	U-DYN	fibrates
25	158	158	O	,
26	160	177	O	XXXXXXXX
27	179	184	O	should
28	186	187	O	be
29	189	200	O	administered
30	202	205	O	with
31	207	213	O	caution
32	215	218	O	when
33	220	223	O	used
34	225	237	O	concomitantly
35	239	242	O	with
36	244	248	O	other
37	250	257	O	fibrates
D/24:9:1

Pravastatin Sodium	1990	34073-7	ad386ed4-a284-4da5-b79a-3c0f4165057a	28
The risk of skeletal muscle effects may be enhanced when pravastatin is used in combination with niacin; a reduction in pravastatin sodium dosage should be considered in this setting.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	19	B-EFF	skeletal
5	21	26	I-EFF	muscle
6	28	34	L-EFF	effects
7	36	38	O	may
8	40	41	O	be
9	43	50	O	enhanced
10	52	55	O	when
11	57	67	O	XXXXXXXX
12	69	70	O	is
13	72	75	O	used
14	77	78	O	in
15	80	90	O	combination
16	92	95	O	with
17	97	102	U-DYN	niacin
18	105	105	O	a
19	107	115	O	reduction
20	117	118	O	in
21	120	137	O	XXXXXXXX
22	139	144	O	dosage
23	146	151	O	should
24	153	154	O	be
25	156	165	O	considered
26	167	168	O	in
27	170	173	O	this
28	175	181	O	setting
D/17:4:1

Pravastatin Sodium	1991	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	40
Pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonate, an early and rate limiting step in the biosynthetic pathway for cholesterol.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	26	O	reversible
5	28	36	O	inhibitor
6	38	39	O	of
7	41	41	O	3
8	43	49	O	hydroxy
9	51	51	O	3
10	53	66	O	methylglutaryl
11	68	75	O	coenzyme
12	77	77	O	A
13	80	82	O	HMG
14	84	86	O	CoA
15	89	97	O	reductase
16	98	98	O	,
17	100	102	O	the
18	104	109	O	enzyme
19	111	114	O	that
20	116	124	O	catalyzes
21	126	128	O	the
22	130	139	O	conversion
23	141	142	O	of
24	144	146	O	HMG
25	148	150	O	CoA
26	152	153	O	to
27	155	164	O	mevalonate
28	165	165	O	,
29	167	168	O	an
30	170	174	O	early
31	176	178	O	and
32	180	183	O	rate
33	185	192	O	limiting
34	194	197	O	step
35	199	200	O	in
36	202	204	O	the
37	206	217	O	biosynthetic
38	219	225	O	pathway
39	227	229	O	for
40	231	241	O	cholesterol
NULL

Pravastatin Sodium	1992	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	23
In addition, pravastatin reduces VLDL and TG and increases HDL-C. General Absorption:Pravastatin sodiumis administered orally in the active form.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	23	O	XXXXXXXX
5	25	31	O	reduces
6	33	36	O	VLDL
7	38	40	O	and
8	42	43	O	TG
9	45	47	O	and
10	49	57	O	increases
11	59	61	O	HDL
12	63	63	O	C
13	66	72	O	General
14	74	83	O	Absorption
15	84	84	O	:
16	85	102	O	XXXXXXXX
17	103	104	O	is
18	106	117	O	administered
19	119	124	O	orally
20	126	127	O	in
21	129	131	O	the
22	133	138	O	active
23	140	143	O	form
NULL

Pravastatin Sodium	1993	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	17
In studies in man, peak plasma pravastatin concentrations occurred 1 to 1.5 hours upon oral administration.
1	0	1	O	In
2	3	9	O	studies
3	11	12	O	in
4	14	16	O	man
5	17	17	O	,
6	19	22	O	peak
7	24	29	O	plasma
8	31	41	O	XXXXXXXX
9	43	56	O	concentrations
10	58	65	O	occurred
11	67	67	O	1
12	69	70	O	to
13	72	74	O	1.5
14	76	80	O	hours
15	82	85	O	upon
16	87	90	O	oral
17	92	105	O	administration
NULL

Pravastatin Sodium	1994	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	22
Based on urinary recovery of total radiolabeled drug, the average oral absorption of pravastatin is 34% and absolute bioavailability is 17%.
1	0	4	O	Based
2	6	7	O	on
3	9	15	O	urinary
4	17	24	O	recovery
5	26	27	O	of
6	29	33	O	total
7	35	46	O	radiolabeled
8	48	51	O	drug
9	52	52	O	,
10	54	56	O	the
11	58	64	O	average
12	66	69	O	oral
13	71	80	O	absorption
14	82	83	O	of
15	85	95	O	XXXXXXXX
16	97	98	O	is
17	100	102	O	34%
18	104	106	O	and
19	108	115	O	absolute
20	117	131	O	bioavailability
21	133	134	O	is
22	136	138	O	17%
NULL

Pravastatin Sodium	1995	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	31
While the presence of food in the gastrointestinal tract reduces systemic bioavailability, the lipid-lowering effects of the drug are similar whether taken with or 1 hour prior to meals.
1	0	4	O	While
2	6	8	O	the
3	10	17	O	presence
4	19	20	O	of
5	22	25	U-KIN	food
6	27	28	O	in
7	30	32	O	the
8	34	49	O	gastrointestinal
9	51	55	O	tract
10	57	63	B-TRI	reduces
11	65	72	I-TRI	systemic
12	74	88	L-TRI	bioavailability
13	89	89	O	,
14	91	93	O	the
15	95	99	O	lipid
16	101	108	O	lowering
17	110	116	O	effects
18	118	119	O	of
19	121	123	O	the
20	125	128	O	drug
21	130	132	O	are
22	134	140	O	similar
23	142	148	O	whether
24	150	154	O	taken
25	156	159	O	with
26	161	162	O	or
27	164	164	O	1
28	166	169	O	hour
29	171	175	O	prior
30	177	178	O	to
31	180	184	O	meals
K/5:C54356

Pravastatin Sodium	1996	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	27
Pravastatin plasma concentrations, including area under the concentration-time curve (AUC), Cmax, and steady-state minimum (Cmin), are directly proportional to administered dose.
1	0	10	O	XXXXXXXX
2	12	17	O	plasma
3	19	32	O	concentrations
4	33	33	O	,
5	35	43	O	including
6	45	48	O	area
7	50	54	O	under
8	56	58	O	the
9	60	72	O	concentration
10	74	77	O	time
11	79	83	O	curve
12	86	88	O	AUC
13	90	90	O	,
14	92	95	O	Cmax
15	96	96	O	,
16	98	100	O	and
17	102	107	O	steady
18	109	113	O	state
19	115	121	O	minimum
20	124	127	O	Cmin
21	129	129	O	,
22	131	133	O	are
23	135	142	O	directly
24	144	155	O	proportional
25	157	158	O	to
26	160	171	O	administered
27	173	176	O	dose
NULL

Pravastatin Sodium	1997	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	19
Systemic bioavailability of pravastatin administered following a bedtime dose was decreased 60% compared to that following an AM dose.
1	0	7	O	Systemic
2	9	23	O	bioavailability
3	25	26	O	of
4	28	38	O	XXXXXXXX
5	40	51	O	administered
6	53	61	O	following
7	63	63	O	a
8	65	71	O	bedtime
9	73	76	O	dose
10	78	80	O	was
11	82	90	O	decreased
12	92	94	O	60%
13	96	103	O	compared
14	105	106	O	to
15	108	111	O	that
16	113	121	O	following
17	123	124	O	an
18	126	127	O	AM
19	129	132	O	dose
NULL

Pravastatin Sodium	1998	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	33
Despite this decrease in systemic bioavailability, the efficacy of pravastatin administered once daily in the evening, although not statistically significant, was marginally more effective than that after a morning dose.
1	0	6	O	Despite
2	8	11	O	this
3	13	20	O	decrease
4	22	23	O	in
5	25	32	O	systemic
6	34	48	O	bioavailability
7	49	49	O	,
8	51	53	O	the
9	55	62	O	efficacy
10	64	65	O	of
11	67	77	O	XXXXXXXX
12	79	90	O	administered
13	92	95	O	once
14	97	101	O	daily
15	103	104	O	in
16	106	108	O	the
17	110	116	O	evening
18	117	117	O	,
19	119	126	O	although
20	128	130	O	not
21	132	144	O	statistically
22	146	156	O	significant
23	157	157	O	,
24	159	161	O	was
25	163	172	O	marginally
26	174	177	O	more
27	179	187	O	effective
28	189	192	O	than
29	194	197	O	that
30	199	203	O	after
31	205	205	O	a
32	207	213	O	morning
33	215	218	O	dose
NULL

Pravastatin Sodium	1999	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	18
The coefficient of variation (CV), based on between-subject variability, was 50% to 60% for AUC.
1	0	2	O	The
2	4	14	O	coefficient
3	16	17	O	of
4	19	27	O	variation
5	30	31	O	CV
6	33	33	O	,
7	35	39	O	based
8	41	42	O	on
9	44	50	O	between
10	52	58	O	subject
11	60	70	O	variability
12	71	71	O	,
13	73	75	O	was
14	77	79	O	50%
15	81	82	O	to
16	84	86	O	60%
17	88	90	O	for
18	92	94	O	AUC
NULL

Pravastatin Sodium	2000	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	29
The geometric means of pravastatin Cma xand AUC following a 20 mg dose in the fasted state were 26.5 ng/mL and 59.8 ng*hr/mL, respectively.
1	0	2	O	The
2	4	12	O	geometric
3	14	18	O	means
4	20	21	O	of
5	23	33	O	XXXXXXXX
6	35	37	O	Cma
7	39	42	O	xand
8	44	46	O	AUC
9	48	56	O	following
10	58	58	O	a
11	60	61	O	20
12	63	64	O	mg
13	66	69	O	dose
14	71	72	O	in
15	74	76	O	the
16	78	83	O	fasted
17	85	89	O	state
18	91	94	O	were
19	96	99	O	26.5
20	101	102	O	ng
21	103	103	O	/
22	104	105	O	mL
23	107	109	O	and
24	111	114	O	59.8
25	116	120	O	ng*hr
26	121	121	O	/
27	122	123	O	mL
28	124	124	O	,
29	126	137	O	respectively
NULL

Pravastatin Sodium	2001	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	24
Steady-state AUCs, Cmax, and Cminplasma concentrations showed no evidence of pravastatin accumulation following once or twice daily administration of pravastatin sodium tablets.
1	0	5	O	Steady
2	7	11	O	state
3	13	16	O	AUCs
4	17	17	O	,
5	19	22	O	Cmax
6	23	23	O	,
7	25	27	O	and
8	29	38	O	Cminplasma
9	40	53	O	concentrations
10	55	60	O	showed
11	62	63	O	no
12	65	72	O	evidence
13	74	75	O	of
14	77	87	O	XXXXXXXX
15	89	100	O	accumulation
16	102	110	O	following
17	112	115	O	once
18	117	118	O	or
19	120	124	O	twice
20	126	130	O	daily
21	132	145	O	administration
22	147	148	O	of
23	150	167	O	XXXXXXXX
24	169	175	O	tablets
NULL

Pravastatin Sodium	2002	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	11
Distribution:Approximately 50% of the circulating drug is bound to plasma proteins.
1	0	25	O	Distribution:Approximately
2	27	29	O	50%
3	31	32	O	of
4	34	36	O	the
5	38	48	O	circulating
6	50	53	O	drug
7	55	56	O	is
8	58	62	O	bound
9	64	65	O	to
10	67	72	O	plasma
11	74	81	O	proteins
NULL

Pravastatin Sodium	2003	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	30
Metabolism:The major biotransformation pathways for pravastatin are: (a) isomerization to 6-epi pravastatin and the 3A-hydroxyisomer of pravastatin (SQ 31,906) and (b) enzymatic ring hydroxylation to SQ 31,945.
1	0	13	O	Metabolism:The
2	15	19	O	major
3	21	37	O	biotransformation
4	39	46	O	pathways
5	48	50	O	for
6	52	62	O	XXXXXXXX
7	64	66	O	are
8	67	67	O	:
9	70	70	O	a
10	73	85	O	isomerization
11	87	88	O	to
12	90	90	O	6
13	92	94	O	epi
14	96	106	O	XXXXXXXX
15	108	110	O	and
16	112	114	O	the
17	116	117	O	3A
18	119	131	O	hydroxyisomer
19	133	134	O	of
20	136	146	O	XXXXXXXX
21	149	150	O	SQ
22	152	157	O	31,906
23	160	162	O	and
24	165	165	O	b
25	168	176	O	enzymatic
26	178	181	O	ring
27	183	195	O	hydroxylation
28	197	198	O	to
29	200	201	O	SQ
30	203	208	O	31,945
NULL

Pravastatin Sodium	2004	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	24
The 3A-hydroxyisomeric metabolite (SQ 31,906) has 1/10 to 1/40 the HMG-CoA reductase inhibitory activity of the parent compound.
1	0	2	O	The
2	4	5	O	3A
3	7	21	O	hydroxyisomeric
4	23	32	O	metabolite
5	35	36	O	SQ
6	38	43	O	31,906
7	46	48	O	has
8	50	50	O	1
9	51	51	O	/
10	52	53	O	10
11	55	56	O	to
12	58	58	O	1
13	59	59	O	/
14	60	61	O	40
15	63	65	O	the
16	67	69	O	HMG
17	71	73	O	CoA
18	75	83	O	reductase
19	85	94	O	inhibitory
20	96	103	O	activity
21	105	106	O	of
22	108	110	O	the
23	112	117	O	parent
24	119	126	O	compound
NULL

Pravastatin Sodium	2005	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	12
Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66).
1	0	10	O	XXXXXXXX
2	12	20	O	undergoes
3	22	30	O	extensive
4	32	36	O	first
5	38	41	O	pass
6	43	52	O	extraction
7	54	55	O	in
8	57	59	O	the
9	61	65	O	liver
10	68	77	O	extraction
11	79	83	O	ratio
12	85	88	O	0.66
NULL

Pravastatin Sodium	2006	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	16
Excretion:Approximately 20% of a radiolabeled oral dose is excreted in urine and 70% in the feces.
1	0	22	O	Excretion:Approximately
2	24	26	O	20%
3	28	29	O	of
4	31	31	O	a
5	33	44	O	radiolabeled
6	46	49	O	oral
7	51	54	O	dose
8	56	57	O	is
9	59	66	O	excreted
10	68	69	O	in
11	71	75	O	urine
12	77	79	O	and
13	81	83	O	70%
14	85	86	O	in
15	88	90	O	the
16	92	96	O	feces
NULL

Pravastatin Sodium	2007	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	32
After intravenous administration of radiolabeled pravastatin to normal volunteers, approximately 47% of total body clearance was via renal excretion and 53% by non-renal routes (i.e., biliary excretion and biotransformation).
1	0	4	O	After
2	6	16	O	intravenous
3	18	31	O	administration
4	33	34	O	of
5	36	47	O	radiolabeled
6	49	59	O	XXXXXXXX
7	61	62	O	to
8	64	69	O	normal
9	71	80	O	volunteers
10	81	81	O	,
11	83	95	O	approximately
12	97	99	O	47%
13	101	102	O	of
14	104	108	O	total
15	110	113	O	body
16	115	123	O	clearance
17	125	127	O	was
18	129	131	O	via
19	133	137	O	renal
20	139	147	O	excretion
21	149	151	O	and
22	153	155	O	53%
23	157	158	O	by
24	160	162	O	non
25	164	168	O	renal
26	170	175	O	routes
27	178	180	O	i.e
28	182	182	O	,
29	184	190	O	biliary
30	192	200	O	excretion
31	202	204	O	and
32	206	222	O	biotransformation
NULL

Pravastatin Sodium	2008	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	18
Following single dose oral administration of14C-pravastatin, the radioactive elimination t%for pravastatin is 1.8 hours in humans.
1	0	8	O	Following
2	10	15	O	single
3	17	20	O	dose
4	22	25	O	oral
5	27	40	O	administration
6	42	46	O	of14C
7	48	58	O	XXXXXXXX
8	59	59	O	,
9	61	63	O	the
10	65	75	O	radioactive
11	77	87	O	elimination
12	89	93	O	t%for
13	95	105	O	XXXXXXXX
14	107	108	O	is
15	110	112	O	1.8
16	114	118	O	hours
17	120	121	O	in
18	123	128	O	humans
NULL

Pravastatin Sodium	2009	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	27
Specific Populations Renal Impairment:A single 20 mg oral dose of pravastatin was administered to 24 patients with varying degrees of renal impairment (as determined by creatinine clearance).
1	0	7	O	Specific
2	9	19	O	Populations
3	21	25	O	Renal
4	27	38	O	Impairment:A
5	40	45	O	single
6	47	48	O	20
7	50	51	O	mg
8	53	56	O	oral
9	58	61	O	dose
10	63	64	O	of
11	66	76	O	XXXXXXXX
12	78	80	O	was
13	82	93	O	administered
14	95	96	O	to
15	98	99	O	24
16	101	108	O	patients
17	110	113	O	with
18	115	121	O	varying
19	123	129	O	degrees
20	131	132	O	of
21	134	138	O	renal
22	140	149	O	impairment
23	152	153	O	as
24	155	164	O	determined
25	166	167	O	by
26	169	178	O	creatinine
27	180	188	O	clearance
NULL

Pravastatin Sodium	2010	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	17
No effect was observed on the pharmacokinetics of pravastatin or its 3A-hydroxy isomeric metabolite (SQ 31,906).
1	0	1	O	No
2	3	8	O	effect
3	10	12	O	was
4	14	21	O	observed
5	23	24	O	on
6	26	28	O	the
7	30	45	O	pharmacokinetics
8	47	48	O	of
9	50	60	O	XXXXXXXX
10	62	63	O	or
11	65	67	O	its
12	69	70	O	3A
13	72	78	O	hydroxy
14	80	87	O	isomeric
15	89	98	O	metabolite
16	101	102	O	SQ
17	104	109	O	31,906
NULL

Pravastatin Sodium	2011	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	40
Compared to healthy subjects with normal renal function, patients with severe renal impairment had 69% and 37% higher mean AUC and Cmaxvalues, respectively, and a 0.61 hour shorter t%for the inactive enzymatic ring hydroxylation metabolite (SQ 31,945).
1	0	7	O	Compared
2	9	10	O	to
3	12	18	O	healthy
4	20	27	O	subjects
5	29	32	O	with
6	34	39	O	normal
7	41	45	O	renal
8	47	54	O	function
9	55	55	O	,
10	57	64	O	patients
11	66	69	O	with
12	71	76	O	severe
13	78	82	O	renal
14	84	93	O	impairment
15	95	97	O	had
16	99	101	O	69%
17	103	105	O	and
18	107	109	O	37%
19	111	116	O	higher
20	118	121	O	mean
21	123	125	O	AUC
22	127	129	O	and
23	131	140	O	Cmaxvalues
24	141	141	O	,
25	143	154	O	respectively
26	155	155	O	,
27	157	159	O	and
28	161	161	O	a
29	163	166	O	0.61
30	168	171	O	hour
31	173	179	O	shorter
32	181	185	O	t%for
33	187	189	O	the
34	191	198	O	inactive
35	200	208	O	enzymatic
36	210	213	O	ring
37	215	227	O	hydroxylation
38	229	238	O	metabolite
39	241	242	O	SQ
40	244	249	O	31,945
NULL

Pravastatin Sodium	2012	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	40
Hepatic Impairment:In a study comparing the kinetics of pravastatin in patients with biopsy confirmed cirrhosis (N = 7) and normal subjects (N = 7), the mean AUC varied 18 fold in cirrhotic patients and 5 fold in healthy subjects.
1	0	6	O	Hepatic
2	8	20	O	Impairment:In
3	22	22	O	a
4	24	28	O	study
5	30	38	O	comparing
6	40	42	O	the
7	44	51	O	kinetics
8	53	54	O	of
9	56	66	O	XXXXXXXX
10	68	69	O	in
11	71	78	O	patients
12	80	83	O	with
13	85	90	O	biopsy
14	92	100	O	confirmed
15	102	110	O	cirrhosis
16	113	113	O	N
17	115	115	O	=
18	117	117	O	7
19	120	122	O	and
20	124	129	O	normal
21	131	138	O	subjects
22	141	141	O	N
23	143	143	O	=
24	145	145	O	7
25	147	147	O	,
26	149	151	O	the
27	153	156	O	mean
28	158	160	O	AUC
29	162	167	O	varied
30	169	170	O	18
31	172	175	O	fold
32	177	178	O	in
33	180	188	O	cirrhotic
34	190	197	O	patients
35	199	201	O	and
36	203	203	O	5
37	205	208	O	fold
38	210	211	O	in
39	213	219	O	healthy
40	221	228	O	subjects
NULL

Pravastatin Sodium	2013	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	19
Similarly, the peak pravastatin values varied 47 fold for cirrhotic patients compared to 6 fold for healthy subjects.
1	0	8	O	Similarly
2	9	9	O	,
3	11	13	O	the
4	15	18	O	peak
5	20	30	O	XXXXXXXX
6	32	37	O	values
7	39	44	O	varied
8	46	47	O	47
9	49	52	O	fold
10	54	56	O	for
11	58	66	O	cirrhotic
12	68	75	O	patients
13	77	84	O	compared
14	86	87	O	to
15	89	89	O	6
16	91	94	O	fold
17	96	98	O	for
18	100	106	O	healthy
19	108	115	O	subjects
NULL

Pravastatin Sodium	2014	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	47
Geriatric:In a single oral dose study using pravastatin 20 mg, the mean AUC for pravastatin was approximately 27% greater and the mean cumulative urinary excretion (CUE) approximately 19% lower in elderly men (65 to 75 years old) compared with younger men (19 to 31 years old).
1	0	11	O	Geriatric:In
2	13	13	O	a
3	15	20	O	single
4	22	25	O	oral
5	27	30	O	dose
6	32	36	O	study
7	38	42	O	using
8	44	54	O	XXXXXXXX
9	56	57	O	20
10	59	60	O	mg
11	61	61	O	,
12	63	65	O	the
13	67	70	O	mean
14	72	74	O	AUC
15	76	78	O	for
16	80	90	O	XXXXXXXX
17	92	94	O	was
18	96	108	O	approximately
19	110	112	O	27%
20	114	120	O	greater
21	122	124	O	and
22	126	128	O	the
23	130	133	O	mean
24	135	144	O	cumulative
25	146	152	O	urinary
26	154	162	O	excretion
27	165	167	O	CUE
28	170	182	O	approximately
29	184	186	O	19%
30	188	192	O	lower
31	194	195	O	in
32	197	203	O	elderly
33	205	207	O	men
34	210	211	O	65
35	213	214	O	to
36	216	217	O	75
37	219	223	O	years
38	225	227	O	old
39	230	237	O	compared
40	239	242	O	with
41	244	250	O	younger
42	252	254	O	men
43	257	258	O	19
44	260	261	O	to
45	263	264	O	31
46	266	270	O	years
47	272	274	O	old
NULL

Pravastatin Sodium	2015	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	41
In a similar study conducted in women, the mean AUC for pravastatin was approximately 46% higher and the mean CUE approximately 18% lower in elderly women (65 to 78 years old) compared with younger women (18 to 38 years old).
1	0	1	O	In
2	3	3	O	a
3	5	11	O	similar
4	13	17	O	study
5	19	27	O	conducted
6	29	30	O	in
7	32	36	O	women
8	37	37	O	,
9	39	41	O	the
10	43	46	O	mean
11	48	50	O	AUC
12	52	54	O	for
13	56	66	O	XXXXXXXX
14	68	70	O	was
15	72	84	O	approximately
16	86	88	O	46%
17	90	95	O	higher
18	97	99	O	and
19	101	103	O	the
20	105	108	O	mean
21	110	112	O	CUE
22	114	126	O	approximately
23	128	130	O	18%
24	132	136	O	lower
25	138	139	O	in
26	141	147	O	elderly
27	149	153	O	women
28	156	157	O	65
29	159	160	O	to
30	162	163	O	78
31	165	169	O	years
32	171	173	O	old
33	176	183	O	compared
34	185	188	O	with
35	190	196	O	younger
36	198	202	O	women
37	205	206	O	18
38	208	209	O	to
39	211	212	O	38
40	214	218	O	years
41	220	222	O	old
NULL

Pravastatin Sodium	2016	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	17
In both studies, Cmax, Tmax, and t%values were similar in older and younger subjects.
1	0	1	O	In
2	3	6	O	both
3	8	14	O	studies
4	15	15	O	,
5	17	20	O	Cmax
6	21	21	O	,
7	23	26	O	Tmax
8	27	27	O	,
9	29	31	O	and
10	33	40	O	t%values
11	42	45	O	were
12	47	53	O	similar
13	55	56	O	in
14	58	62	O	older
15	64	66	O	and
16	68	74	O	younger
17	76	83	O	subjects
NULL

Pravastatin Sodium	2017	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	50
Pediatric:After 2 weeks of once-daily 20 mg oral pravastatin administration, the geometric means of AUC were 80.7 (CV 44%) and 44.8 (CV 89%) ng*hr/mL for children (8 to 11 years, N = 14) and adolescents (12 to 16 years, N = 10), respectively.
1	0	14	O	Pediatric:After
2	16	16	O	2
3	18	22	O	weeks
4	24	25	O	of
5	27	30	O	once
6	32	36	O	daily
7	38	39	O	20
8	41	42	O	mg
9	44	47	O	oral
10	49	59	O	XXXXXXXX
11	61	74	O	administration
12	75	75	O	,
13	77	79	O	the
14	81	89	O	geometric
15	91	95	O	means
16	97	98	O	of
17	100	102	O	AUC
18	104	107	O	were
19	109	112	O	80.7
20	115	116	O	CV
21	118	120	O	44%
22	123	125	O	and
23	127	130	O	44.8
24	133	134	O	CV
25	136	138	O	89%
26	141	145	O	ng*hr
27	146	146	O	/
28	147	148	O	mL
29	150	152	O	for
30	154	161	O	children
31	164	164	O	8
32	166	167	O	to
33	169	170	O	11
34	172	176	O	years
35	177	177	O	,
36	179	179	O	N
37	181	181	O	=
38	183	184	O	14
39	187	189	O	and
40	191	201	O	adolescents
41	204	205	O	12
42	207	208	O	to
43	210	211	O	16
44	213	217	O	years
45	218	218	O	,
46	220	220	O	N
47	222	222	O	=
48	224	225	O	10
49	227	227	O	,
50	229	240	O	respectively
NULL

Pravastatin Sodium	2018	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	21
The corresponding values for Cmaxwere 42.4 (CV 54%) and 18.6 ng/mL (CV 100%) for children and adolescents, respectively.
1	0	2	O	The
2	4	16	O	corresponding
3	18	23	O	values
4	25	27	O	for
5	29	36	O	Cmaxwere
6	38	41	O	42.4
7	44	45	O	CV
8	47	49	O	54%
9	52	54	O	and
10	56	59	O	18.6
11	61	62	O	ng
12	63	63	O	/
13	64	65	O	mL
14	68	69	O	CV
15	71	74	O	100%
16	77	79	O	for
17	81	88	O	children
18	90	92	O	and
19	94	104	O	adolescents
20	105	105	O	,
21	107	118	O	respectively
NULL

Pravastatin Sodium	2019	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	19
No conclusion can be made based on these findings due to the small number of samples and large variability.
1	0	1	O	No
2	3	12	O	conclusion
3	14	16	O	can
4	18	19	O	be
5	21	24	O	made
6	26	30	O	based
7	32	33	O	on
8	35	39	O	these
9	41	48	O	findings
10	50	52	O	due
11	54	55	O	to
12	57	59	O	the
13	61	65	O	small
14	67	72	O	number
15	74	75	O	of
16	77	83	O	samples
17	85	87	O	and
18	89	93	O	large
19	95	105	O	variability
NULL

Pravastatin Sodium	2020	34090-1	ad386ed4-a284-4da5-b79a-3c0f4165057a	495
Drug-Drug Interactions Table 3: Effect of Coadministered Drugs on the Pharmacokinetics of Pravastatin Coadministered Drug and Dosing Regimen Pravastatin Dose (mg) Change in AUC Change in Cmax Cyclosporine 5 mg/kg single dose 40 mg single dose *282% *327% Clarithromycin 500 mg BID for 9 days 40 mg OD for 8 days *110% *128% Boceprevir 800 mg TID for 6 days 40 mg single dose *63% *49% Darunavir 600 mg BID/Ritonavir 100 mg BID for 7 days 40 mg single dose *81% *63% Colestipol 10 g single dose 20 mg single dose *47% *53% Cholestyramine 4 g single dose 20 mg single dose Administered simultaneously *40% *39% Administered 1 hour prior tocholestyramine *12% *30% Administered 4 hours aftercholestyramine *12% *6.8% Cholestyramine 24 g OD for 4 weeks 20 mg BID for 8 weeks *51% *4.9% 5 mg BID for 8 weeks *38% *23% 10 mg BID for 8 weeks *18% *33% Fluconazole 200 mg IV for 6 days 20 mg PO + 10 mg IV *34% *33% 200 mg PO for 6 days 20 mg PO + 10 mg IV *16% *16% Kaletra 400 mg/100 mg BID for 14 days 20 mg OD for 4 days *33% *26% Verapamil IR 120 mg for 1 day and Verapamil ER 480 mg for 3 days 40 mg single dose *31% *42% Cimetidine 300 mg QID for 3 days 20 mg single dose *30% *9.8% Antacids 15 mL QID for 3 days 20 mg single dose *28% *24% Digoxin 0.2 mg OD for 9 days 20 mg OD for 9 days *23% *26% Probucol 500 mg single dose 20 mg single dose *14% *24% Warfarin 5 mg OD for 6 days 20 mg BID for 6 days *13% *6.7% Itraconazole 200 mg OD for 30 days 40 mg OD for 30 days *11% (compared to Day 1) *17% (compared to Day 1) Gemfibrozil 600 mg single dose 20 mg single dose *7.0% *20% Aspirin 324 mg single dose 20 mg single dose *4.7% *8.9% Niacin 1 g single dose 20 mg single dose *3.6% *8.2% Diltiazem 20 mg single dose *2.7% *30% Grapefruit juice 40 mg single dose *1.8% *3.7% BID = twice daily; OD = once daily; QID = four times daily Table 4: Effect of Pravastatin on the Pharmacokinetics of Coadministered Drugs Pravastatin Dosing Regimen Name and Dose Change in AUC Change in Cmax 20 mg BID for 6 days Warfarin 5 mg OD for 6 days *17% *15% Change in mean prothrombin time *0.4 sec 20 mg OD for 9 days Digoxin 0.2 mg OD for 9 days *4.6% *5.3% 20 mg BID for 4 weeks Antipyrine 1.2 g single dose *3.0% Not Reported 10 mg BID for 4 weeks *1.6% 5 mg BID for 4 weeks *Less than1% 20 mg OD for 4 days Kaletra 400 mg/100 mg BID for 14 days No change No change BID = twice daily; OD = once daily
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	27	O	Table
5	29	29	O	3
6	30	30	O	:
7	32	37	O	Effect
8	39	40	O	of
9	42	55	O	Coadministered
10	57	61	O	Drugs
11	63	64	O	on
12	66	68	O	the
13	70	85	O	Pharmacokinetics
14	87	88	O	of
15	90	100	O	XXXXXXXX
16	102	115	O	Coadministered
17	117	120	O	Drug
18	122	124	O	and
19	126	131	O	Dosing
20	133	139	O	Regimen
21	141	151	O	XXXXXXXX
22	153	156	O	Dose
23	159	160	O	mg
24	163	168	O	Change
25	170	171	O	in
26	173	175	O	AUC
27	177	182	O	Change
28	184	185	O	in
29	187	190	O	Cmax
30	192	203	O	Cyclosporine
31	205	205	O	5
32	207	208	O	mg
33	209	209	O	/
34	210	211	O	kg
35	213	218	O	single
36	220	223	O	dose
37	225	226	O	40
38	228	229	O	mg
39	231	236	O	single
40	238	241	O	dose
41	243	247	O	282%
42	249	253	O	327%
43	255	268	O	Clarithromycin
44	270	272	O	500
45	274	275	O	mg
46	277	279	O	BID
47	281	283	O	for
48	285	285	O	9
49	287	290	O	days
50	292	293	O	40
51	295	296	O	mg
52	298	299	O	OD
53	301	303	O	for
54	305	305	O	8
55	307	310	O	days
56	312	316	O	110%
57	318	322	O	128%
58	324	333	O	Boceprevir
59	335	337	O	800
60	339	340	O	mg
61	342	344	O	TID
62	346	348	O	for
63	350	350	O	6
64	352	355	O	days
65	357	358	O	40
66	360	361	O	mg
67	363	368	O	single
68	370	373	O	dose
69	375	378	O	63%
70	380	383	O	49%
71	385	393	O	Darunavir
72	395	397	O	600
73	399	400	O	mg
74	402	404	O	BID
75	405	405	O	/
76	406	414	O	Ritonavir
77	416	418	O	100
78	420	421	O	mg
79	423	425	O	BID
80	427	429	O	for
81	431	431	O	7
82	433	436	O	days
83	438	439	O	40
84	441	442	O	mg
85	444	449	O	single
86	451	454	O	dose
87	456	459	O	81%
88	461	464	O	63%
89	466	475	O	Colestipol
90	477	478	O	10
91	480	480	O	g
92	482	487	O	single
93	489	492	O	dose
94	494	495	O	20
95	497	498	O	mg
96	500	505	O	single
97	507	510	O	dose
98	512	515	O	47%
99	517	520	O	53%
100	522	535	O	Cholestyramine
101	537	537	O	4
102	539	539	O	g
103	541	546	O	single
104	548	551	O	dose
105	553	554	O	20
106	556	557	O	mg
107	559	564	O	single
108	566	569	O	dose
109	571	582	O	Administered
110	584	597	O	simultaneously
111	599	602	O	40%
112	604	607	O	39%
113	609	620	O	Administered
114	622	622	O	1
115	624	627	O	hour
116	629	633	O	prior
117	635	650	O	tocholestyramine
118	652	655	O	12%
119	657	660	O	30%
120	662	673	O	Administered
121	675	675	O	4
122	677	681	O	hours
123	683	701	O	aftercholestyramine
124	703	706	O	12%
125	708	712	O	6.8%
126	714	727	O	Cholestyramine
127	729	730	O	24
128	732	732	O	g
129	734	735	O	OD
130	737	739	O	for
131	741	741	O	4
132	743	747	O	weeks
133	749	750	O	20
134	752	753	O	mg
135	755	757	O	BID
136	759	761	O	for
137	763	763	O	8
138	765	769	O	weeks
139	771	774	O	51%
140	776	780	O	4.9%
141	782	782	O	5
142	784	785	O	mg
143	787	789	O	BID
144	791	793	O	for
145	795	795	O	8
146	797	801	O	weeks
147	803	806	O	38%
148	808	811	O	23%
149	813	814	O	10
150	816	817	O	mg
151	819	821	O	BID
152	823	825	O	for
153	827	827	O	8
154	829	833	O	weeks
155	835	838	O	18%
156	840	843	O	33%
157	845	855	O	Fluconazole
158	857	859	O	200
159	861	862	O	mg
160	864	865	O	IV
161	867	869	O	for
162	871	871	O	6
163	873	876	O	days
164	878	879	O	20
165	881	882	O	mg
166	884	885	O	PO
167	887	887	O	+
168	889	890	O	10
169	892	893	O	mg
170	895	896	O	IV
171	898	901	O	34%
172	903	906	O	33%
173	908	910	O	200
174	912	913	O	mg
175	915	916	O	PO
176	918	920	O	for
177	922	922	O	6
178	924	927	O	days
179	929	930	O	20
180	932	933	O	mg
181	935	936	O	PO
182	938	938	O	+
183	940	941	O	10
184	943	944	O	mg
185	946	947	O	IV
186	949	952	O	16%
187	954	957	O	16%
188	959	965	O	Kaletra
189	967	969	O	400
190	971	972	O	mg
191	973	973	O	/
192	974	976	O	100
193	978	979	O	mg
194	981	983	O	BID
195	985	987	O	for
196	989	990	O	14
197	992	995	O	days
198	997	998	O	20
199	1000	1001	O	mg
200	1003	1004	O	OD
201	1006	1008	O	for
202	1010	1010	O	4
203	1012	1015	O	days
204	1017	1020	O	33%
205	1022	1025	O	26%
206	1027	1035	O	Verapamil
207	1037	1038	O	IR
208	1040	1042	O	120
209	1044	1045	O	mg
210	1047	1049	O	for
211	1051	1051	O	1
212	1053	1055	O	day
213	1057	1059	O	and
214	1061	1069	O	Verapamil
215	1071	1072	O	ER
216	1074	1076	O	480
217	1078	1079	O	mg
218	1081	1083	O	for
219	1085	1085	O	3
220	1087	1090	O	days
221	1092	1093	O	40
222	1095	1096	O	mg
223	1098	1103	O	single
224	1105	1108	O	dose
225	1110	1113	O	31%
226	1115	1118	O	42%
227	1120	1129	O	Cimetidine
228	1131	1133	O	300
229	1135	1136	O	mg
230	1138	1140	O	QID
231	1142	1144	O	for
232	1146	1146	O	3
233	1148	1151	O	days
234	1153	1154	O	20
235	1156	1157	O	mg
236	1159	1164	O	single
237	1166	1169	O	dose
238	1171	1174	O	30%
239	1176	1180	O	9.8%
240	1182	1189	O	Antacids
241	1191	1192	O	15
242	1194	1195	O	mL
243	1197	1199	O	QID
244	1201	1203	O	for
245	1205	1205	O	3
246	1207	1210	O	days
247	1212	1213	O	20
248	1215	1216	O	mg
249	1218	1223	O	single
250	1225	1228	O	dose
251	1230	1233	O	28%
252	1235	1238	O	24%
253	1240	1246	O	Digoxin
254	1248	1250	O	0.2
255	1252	1253	O	mg
256	1255	1256	O	OD
257	1258	1260	O	for
258	1262	1262	O	9
259	1264	1267	O	days
260	1269	1270	O	20
261	1272	1273	O	mg
262	1275	1276	O	OD
263	1278	1280	O	for
264	1282	1282	O	9
265	1284	1287	O	days
266	1289	1292	O	23%
267	1294	1297	O	26%
268	1299	1306	O	Probucol
269	1308	1310	O	500
270	1312	1313	O	mg
271	1315	1320	O	single
272	1322	1325	O	dose
273	1327	1328	O	20
274	1330	1331	O	mg
275	1333	1338	O	single
276	1340	1343	O	dose
277	1345	1348	O	14%
278	1350	1353	O	24%
279	1355	1362	O	Warfarin
280	1364	1364	O	5
281	1366	1367	O	mg
282	1369	1370	O	OD
283	1372	1374	O	for
284	1376	1376	O	6
285	1378	1381	O	days
286	1383	1384	O	20
287	1386	1387	O	mg
288	1389	1391	O	BID
289	1393	1395	O	for
290	1397	1397	O	6
291	1399	1402	O	days
292	1404	1407	O	13%
293	1409	1413	O	6.7%
294	1415	1426	O	Itraconazole
295	1428	1430	O	200
296	1432	1433	O	mg
297	1435	1436	O	OD
298	1438	1440	O	for
299	1442	1443	O	30
300	1445	1448	O	days
301	1450	1451	O	40
302	1453	1454	O	mg
303	1456	1457	O	OD
304	1459	1461	O	for
305	1463	1464	O	30
306	1466	1469	O	days
307	1471	1474	O	11%
308	1477	1484	O	compared
309	1486	1487	O	to
310	1489	1491	O	Day
311	1493	1493	O	1
312	1496	1499	O	17%
313	1502	1509	O	compared
314	1511	1512	O	to
315	1514	1516	O	Day
316	1518	1518	O	1
317	1521	1531	O	Gemfibrozil
318	1533	1535	O	600
319	1537	1538	O	mg
320	1540	1545	O	single
321	1547	1550	O	dose
322	1552	1553	O	20
323	1555	1556	O	mg
324	1558	1563	O	single
325	1565	1568	O	dose
326	1570	1574	O	7.0%
327	1576	1579	O	20%
328	1581	1587	O	Aspirin
329	1589	1591	O	324
330	1593	1594	O	mg
331	1596	1601	O	single
332	1603	1606	O	dose
333	1608	1609	O	20
334	1611	1612	O	mg
335	1614	1619	O	single
336	1621	1624	O	dose
337	1626	1630	O	4.7%
338	1632	1636	O	8.9%
339	1638	1643	O	Niacin
340	1645	1645	O	1
341	1647	1647	O	g
342	1649	1654	O	single
343	1656	1659	O	dose
344	1661	1662	O	20
345	1664	1665	O	mg
346	1667	1672	O	single
347	1674	1677	O	dose
348	1679	1683	O	3.6%
349	1685	1689	O	8.2%
350	1691	1699	O	Diltiazem
351	1701	1702	O	20
352	1704	1705	O	mg
353	1707	1712	O	single
354	1714	1717	O	dose
355	1719	1723	O	2.7%
356	1725	1728	O	30%
357	1730	1739	O	Grapefruit
358	1741	1745	O	juice
359	1747	1748	O	40
360	1750	1751	O	mg
361	1753	1758	O	single
362	1760	1763	O	dose
363	1765	1769	O	1.8%
364	1771	1775	O	3.7%
365	1777	1779	O	BID
366	1781	1781	O	=
367	1783	1787	O	twice
368	1789	1793	O	daily
369	1796	1797	O	OD
370	1799	1799	O	=
371	1801	1804	O	once
372	1806	1810	O	daily
373	1813	1815	O	QID
374	1817	1817	O	=
375	1819	1822	O	four
376	1824	1828	O	times
377	1830	1834	O	daily
378	1836	1840	O	Table
379	1842	1842	O	4
380	1843	1843	O	:
381	1845	1850	O	Effect
382	1852	1853	O	of
383	1855	1865	O	XXXXXXXX
384	1867	1868	O	on
385	1870	1872	O	the
386	1874	1889	O	Pharmacokinetics
387	1891	1892	O	of
388	1894	1907	O	Coadministered
389	1909	1913	O	Drugs
390	1915	1925	O	XXXXXXXX
391	1927	1932	O	Dosing
392	1934	1940	O	Regimen
393	1942	1945	O	Name
394	1947	1949	O	and
395	1951	1954	O	Dose
396	1956	1961	O	Change
397	1963	1964	O	in
398	1966	1968	O	AUC
399	1970	1975	O	Change
400	1977	1978	O	in
401	1980	1983	O	Cmax
402	1985	1986	O	20
403	1988	1989	O	mg
404	1991	1993	O	BID
405	1995	1997	O	for
406	1999	1999	O	6
407	2001	2004	O	days
408	2006	2013	O	Warfarin
409	2015	2015	O	5
410	2017	2018	O	mg
411	2020	2021	O	OD
412	2023	2025	O	for
413	2027	2027	O	6
414	2029	2032	O	days
415	2034	2037	O	17%
416	2039	2042	O	15%
417	2044	2049	O	Change
418	2051	2052	O	in
419	2054	2057	O	mean
420	2059	2069	O	prothrombin
421	2071	2074	O	time
422	2076	2079	O	0.4
423	2081	2083	O	sec
424	2085	2086	O	20
425	2088	2089	O	mg
426	2091	2092	O	OD
427	2094	2096	O	for
428	2098	2098	O	9
429	2100	2103	O	days
430	2105	2111	O	Digoxin
431	2113	2115	O	0.2
432	2117	2118	O	mg
433	2120	2121	O	OD
434	2123	2125	O	for
435	2127	2127	O	9
436	2129	2132	O	days
437	2134	2138	O	4.6%
438	2140	2144	O	5.3%
439	2146	2147	O	20
440	2149	2150	O	mg
441	2152	2154	O	BID
442	2156	2158	O	for
443	2160	2160	O	4
444	2162	2166	O	weeks
445	2168	2177	O	Antipyrine
446	2179	2181	O	1.2
447	2183	2183	O	g
448	2185	2190	O	single
449	2192	2195	O	dose
450	2197	2201	O	3.0%
451	2203	2205	O	Not
452	2207	2214	O	Reported
453	2216	2217	O	10
454	2219	2220	O	mg
455	2222	2224	O	BID
456	2226	2228	O	for
457	2230	2230	O	4
458	2232	2236	O	weeks
459	2238	2242	O	1.6%
460	2244	2244	O	5
461	2246	2247	O	mg
462	2249	2251	O	BID
463	2253	2255	O	for
464	2257	2257	O	4
465	2259	2263	O	weeks
466	2265	2269	O	Less
467	2271	2276	O	than1%
468	2278	2279	O	20
469	2281	2282	O	mg
470	2284	2285	O	OD
471	2287	2289	O	for
472	2291	2291	O	4
473	2293	2296	O	days
474	2298	2304	O	Kaletra
475	2306	2308	O	400
476	2310	2311	O	mg
477	2312	2312	O	/
478	2313	2315	O	100
479	2317	2318	O	mg
480	2320	2322	O	BID
481	2324	2326	O	for
482	2328	2329	O	14
483	2331	2334	O	days
484	2336	2337	O	No
485	2339	2344	O	change
486	2346	2347	O	No
487	2349	2354	O	change
488	2356	2358	O	BID
489	2360	2360	O	=
490	2362	2366	O	twice
491	2368	2372	O	daily
492	2375	2376	O	OD
493	2378	2378	O	=
494	2380	2383	O	once
495	2385	2389	O	daily
NULL

Pristiq	721	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	20
Do not use MAOIs intended to treat psychiatric disorders with desvenlafaxine or within 7 days of stopping treatment with desvenlafaxine.
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	9	L-TRI	use
4	11	15	U-UNK	MAOIs
5	17	24	O	intended
6	26	27	O	to
7	29	33	O	treat
8	35	45	O	psychiatric
9	47	55	O	disorders
10	57	60	O	with
11	62	75	O	XXXXXXXX
12	77	78	O	or
13	80	85	O	within
14	87	87	O	7
15	89	92	O	days
16	94	95	O	of
17	97	104	O	stopping
18	106	114	O	treatment
19	116	119	O	with
20	121	134	O	XXXXXXXX
NULL

Pristiq	722	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	16
Do not use desvenlafaxine within 14 days of stopping an MAOI intended to treat psychiatric disorders.
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	9	L-TRI	use
4	11	24	O	XXXXXXXX
5	26	31	O	within
6	33	34	O	14
7	36	39	O	days
8	41	42	O	of
9	44	51	O	stopping
10	53	54	O	an
11	56	59	U-UNK	MAOI
12	61	68	O	intended
13	70	71	O	to
14	73	77	O	treat
15	79	89	O	psychiatric
16	91	99	O	disorders
NULL

Pristiq	723	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	20
In addition, do not start desvenlafaxine in a patient who is being treated with linezolid or intravenous methylene blue.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	B-TRI	do
5	16	18	I-TRI	not
6	20	24	L-TRI	start
7	26	39	O	XXXXXXXX
8	41	42	O	in
9	44	44	O	a
10	46	52	O	patient
11	54	56	O	who
12	58	59	O	is
13	61	65	O	being
14	67	73	O	treated
15	75	78	O	with
16	80	88	U-UNK	linezolid
17	90	91	O	or
18	93	103	B-UNK	intravenous
19	105	113	I-UNK	methylene
20	115	118	L-UNK	blue
NULL

Pristiq	724	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	33
Based on the mechanism of action of desvenlafaxine and the potential for serotonin syndrome, caution is advised when desvenlafaxine is co-administered with other drugs that may affect the serotonergic neurotransmitter systems.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	21	O	mechanism
5	23	24	O	of
6	26	31	O	action
7	33	34	O	of
8	36	49	O	XXXXXXXX
9	51	53	O	and
10	55	57	O	the
11	59	67	O	potential
12	69	71	O	for
13	73	81	B-EFF	serotonin
14	83	90	L-EFF	syndrome
15	91	91	O	,
16	93	99	O	caution
17	101	102	O	is
18	104	110	O	advised
19	112	115	O	when
20	117	130	O	XXXXXXXX
21	132	133	O	is
22	135	136	O	co
23	138	149	O	administered
24	151	154	O	with
25	156	160	O	other
26	162	166	B-DYN	drugs
27	168	171	I-DYN	that
28	173	175	I-DYN	may
29	177	182	I-DYN	affect
30	184	186	I-DYN	the
31	188	199	I-DYN	serotonergic
32	201	216	I-DYN	neurotransmitter
33	218	224	L-DYN	systems
D/26:13:1

Pristiq	725	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Pristiq	726	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	30
Epidemiological studies of case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	30	O	case
5	32	38	O	control
6	40	42	O	and
7	44	49	O	cohort
8	51	56	O	design
9	58	61	O	that
10	63	66	O	have
11	68	79	O	demonstrated
12	81	82	O	an
13	84	94	O	association
14	96	102	O	between
15	104	106	O	use
16	108	109	O	of
17	111	122	O	psychotropic
18	124	128	O	drugs
19	130	133	O	that
20	135	143	O	interfere
21	145	148	O	with
22	150	158	O	serotonin
23	160	167	O	reuptake
24	169	171	O	and
25	173	175	O	the
26	177	186	O	occurrence
27	188	189	O	of
28	191	195	O	upper
29	197	212	O	gastrointestinal
30	214	221	O	bleeding
NULL

Pristiq	727	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	19
These studies have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	4	O	These
2	6	12	O	studies
3	14	17	O	have
4	19	22	O	also
5	24	28	O	shown
6	30	33	O	that
7	35	44	O	concurrent
8	46	48	O	use
9	50	51	O	of
10	53	54	O	an
11	56	60	U-DYN	NSAID
12	62	63	O	or
13	65	71	U-DYN	aspirin
14	73	75	O	may
15	77	86	O	potentiate
16	88	91	O	this
17	93	96	O	risk
18	98	99	O	of
19	101	108	U-EFF	bleeding
D/11:19:1 D/13:19:1

Pristiq	728	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	20
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are co-administered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	93	O	and
15	95	99	O	SNRIs
16	101	103	O	are
17	105	106	O	co
18	108	119	O	administered
19	121	124	O	with
20	126	133	U-DYN	warfarin
D/20:1:1 D/20:6:1

Pristiq	729	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	14
Patients receiving warfarin therapy should be carefully monitored when PRISTIQ is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	O	should
6	43	44	O	be
7	46	54	O	carefully
8	56	64	U-TRI	monitored
9	66	69	O	when
10	71	77	O	XXXXXXXX
11	79	80	O	is
12	82	90	O	initiated
13	92	93	O	or
14	95	106	O	discontinued
NULL

Pristiq	730	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	42
Based on in vitro data, no dose adjustment is required for PRISTIQ when used concomitantly with inhibitors of CYP3A4 and CYP1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, 2E1, and the P-glycoprotein transporter.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	16	O	vitro
5	18	21	O	data
6	22	22	O	,
7	24	25	O	no
8	27	30	O	dose
9	32	41	O	adjustment
10	43	44	O	is
11	46	53	O	required
12	55	57	O	for
13	59	65	O	XXXXXXXX
14	67	70	O	when
15	72	75	O	used
16	77	89	O	concomitantly
17	91	94	O	with
18	96	105	O	inhibitors
19	107	108	O	of
20	110	115	O	CYP3A4
21	117	119	O	and
22	121	126	O	CYP1A1
23	127	127	O	,
24	129	131	O	1A2
25	132	132	O	,
26	134	136	O	2A6
27	137	137	O	,
28	139	141	O	2D6
29	142	142	O	,
30	144	146	O	2C8
31	147	147	O	,
32	149	151	O	2C9
33	152	152	O	,
34	154	157	O	2C19
35	158	158	O	,
36	160	162	O	2E1
37	163	163	O	,
38	165	167	O	and
39	169	171	O	the
40	173	173	O	P
41	175	186	O	glycoprotein
42	188	198	O	transporter
NULL

Pristiq	731	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between PRISTIQ and strong CYP 3A4 inhibitors (Figure 1).
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	33	O	demonstrated
5	35	36	O	no
6	38	47	O	clinically
7	49	59	O	significant
8	61	75	O	pharmacokinetic
9	77	87	O	interaction
10	89	95	O	between
11	97	103	O	XXXXXXXX
12	105	107	O	and
13	109	114	O	strong
14	116	118	O	CYP
15	120	122	O	3A4
16	124	133	O	inhibitors
17	136	141	O	Figure
18	143	143	O	1
NULL

Pristiq	732	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	27
Figure 1 Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily (Figure 2).
1	0	5	O	Figure
2	7	7	O	1
3	9	16	O	Clinical
4	18	24	O	studies
5	26	29	O	have
6	31	35	O	shown
7	37	40	O	that
8	42	55	O	XXXXXXXX
9	57	60	O	does
10	62	64	O	not
11	66	69	O	have
12	71	71	O	a
13	73	82	O	clinically
14	84	91	O	relevant
15	93	98	O	effect
16	100	101	O	on
17	103	108	O	CYP2D6
18	110	119	O	metabolism
19	121	122	O	at
20	124	126	O	the
21	128	131	O	dose
22	133	134	O	of
23	136	138	O	100
24	140	141	O	mg
25	143	147	O	daily
26	150	155	O	Figure
27	157	157	O	2
NULL

Pristiq	733	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	41
Substrates primarily metabolized by CYP2D6 (e.g., desipramine , atomoxetine, dextromethorphan, metoprolol, nebivolol, perphenazine, tolterodine) should be dosed at the original level when co-administered with PRISTIQ 100 mg or lower or when PRISTIQ is discontinued.
1	0	9	B-KIN	Substrates
2	11	19	I-KIN	primarily
3	21	31	I-KIN	metabolized
4	33	34	I-KIN	by
5	36	41	L-KIN	CYP2D6
6	44	46	O	e.g
7	48	48	O	,
8	50	60	U-KIN	desipramine
9	62	62	O	,
10	64	74	U-KIN	atomoxetine
11	75	75	O	,
12	77	92	U-KIN	dextromethorphan
13	93	93	O	,
14	95	104	U-KIN	metoprolol
15	105	105	O	,
16	107	115	U-KIN	nebivolol
17	116	116	O	,
18	118	129	U-KIN	perphenazine
19	130	130	O	,
20	132	142	U-KIN	tolterodine
21	145	150	O	should
22	152	153	O	be
23	155	159	O	dosed
24	161	162	O	at
25	164	166	O	the
26	168	175	O	original
27	177	181	O	level
28	183	186	O	when
29	188	189	O	co
30	191	202	O	administered
31	204	207	O	with
32	209	215	O	XXXXXXXX
33	217	219	O	100
34	221	222	O	mg
35	224	225	O	or
36	227	231	O	lower
37	233	234	O	or
38	236	239	O	when
39	241	247	O	XXXXXXXX
40	249	250	O	is
41	252	263	O	discontinued
K/1:C54357 K/10:C54357 K/12:C54357 K/14:C54357 K/16:C54357 K/18:C54357 K/20:C54357 K/8:C54357

Pristiq	734	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	19
Reduce the dose of these substrates by up to one-half if co-administered with 400 mg of PRISTIQ.
1	0	5	O	Reduce
2	7	9	O	the
3	11	14	O	dose
4	16	17	O	of
5	19	23	O	these
6	25	34	O	substrates
7	36	37	O	by
8	39	40	O	up
9	42	43	O	to
10	45	47	O	one
11	49	52	O	half
12	54	55	O	if
13	57	58	O	co
14	60	71	O	administered
15	73	76	O	with
16	78	80	O	400
17	82	83	O	mg
18	85	86	O	of
19	88	94	O	XXXXXXXX
NULL

Pristiq	735	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	30
No additional dose adjustment is required for concomitant use of substrates of CYP3A4, 1A2, 2A6, 2C8, 2C9, and 2C19 isozymes, and P-glycoprotein transporter.
1	0	1	O	No
2	3	12	O	additional
3	14	17	O	dose
4	19	28	O	adjustment
5	30	31	O	is
6	33	40	O	required
7	42	44	O	for
8	46	56	O	concomitant
9	58	60	O	use
10	62	63	O	of
11	65	74	O	substrates
12	76	77	O	of
13	79	84	O	CYP3A4
14	85	85	O	,
15	87	89	O	1A2
16	90	90	O	,
17	92	94	O	2A6
18	95	95	O	,
19	97	99	O	2C8
20	100	100	O	,
21	102	104	O	2C9
22	105	105	O	,
23	107	109	O	and
24	111	114	O	2C19
25	116	123	O	isozymes
26	124	124	O	,
27	126	128	O	and
28	130	130	O	P
29	132	143	O	glycoprotein
30	145	155	O	transporter
NULL

Pristiq	736	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	16
Clinical studies have demonstrated no clinically significant pharmacokinetic interaction between PRISTIQ and CYP3A4 substrates (Figure 2).
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	33	O	demonstrated
5	35	36	O	no
6	38	47	O	clinically
7	49	59	O	significant
8	61	75	O	pharmacokinetic
9	77	87	O	interaction
10	89	95	O	between
11	97	103	O	XXXXXXXX
12	105	107	O	and
13	109	114	O	CYP3A4
14	116	125	O	substrates
15	128	133	O	Figure
16	135	135	O	2
NULL

Pristiq	737	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	36
Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	26	O	shown
5	28	31	O	that
6	33	46	O	XXXXXXXX
7	49	51	O	100
8	53	54	O	mg
9	56	60	O	daily
10	63	66	O	does
11	68	70	O	not
12	72	75	O	have
13	77	77	O	a
14	79	88	O	clinically
15	90	97	O	relevant
16	99	104	O	effect
17	106	107	O	on
18	109	117	O	tamoxifen
19	119	121	O	and
20	123	134	O	aripiprazole
21	135	135	O	,
22	137	145	O	compounds
23	147	150	O	that
24	152	154	O	are
25	156	166	O	metabolized
26	168	169	O	by
27	171	171	O	a
28	173	183	O	combination
29	185	186	O	of
30	188	191	O	both
31	193	198	O	CYP2D6
32	200	202	O	and
33	204	209	O	CYP3A4
34	211	217	O	enzymes
35	220	225	O	Figure
36	227	227	O	2
NULL

Pristiq	738	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	13
In vitro studies showed minimal inhibitory effect of desvenlafaxine on the CYP2D6 isoenzyme.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	22	O	showed
5	24	30	O	minimal
6	32	41	O	inhibitory
7	43	48	O	effect
8	50	51	O	of
9	53	66	O	XXXXXXXX
10	68	69	O	on
11	71	73	O	the
12	75	80	O	CYP2D6
13	82	90	O	isoenzyme
NULL

Pristiq	739	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	12
In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	23	O	XXXXXXXX
5	25	28	O	does
6	30	32	O	not
7	34	40	O	inhibit
8	42	43	O	or
9	45	50	O	induce
10	52	54	O	the
11	56	61	O	CYP3A4
12	63	69	O	isozyme
NULL

Pristiq	740	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	44
In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19, isozymes, and P-glycoprotein transporter and would not be expected to affect the pharmacokinetics of drugs that are substrates of these CYP isozymes and transporter.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	23	O	XXXXXXXX
5	25	28	O	does
6	30	32	O	not
7	34	40	O	inhibit
8	42	47	O	CYP1A2
9	48	48	O	,
10	50	52	O	2A6
11	53	53	O	,
12	55	57	O	2C8
13	58	58	O	,
14	60	62	O	2C9
15	63	63	O	,
16	65	67	O	and
17	69	72	O	2C19
18	73	73	O	,
19	75	82	O	isozymes
20	83	83	O	,
21	85	87	O	and
22	89	89	O	P
23	91	102	O	glycoprotein
24	104	114	O	transporter
25	116	118	O	and
26	120	124	O	would
27	126	128	O	not
28	130	131	O	be
29	133	140	O	expected
30	142	143	O	to
31	145	150	O	affect
32	152	154	O	the
33	156	171	O	pharmacokinetics
34	173	174	O	of
35	176	180	O	drugs
36	182	185	O	that
37	187	189	O	are
38	191	200	O	substrates
39	202	203	O	of
40	205	209	O	these
41	211	213	O	CYP
42	215	222	O	isozymes
43	224	226	O	and
44	228	238	O	transporter
NULL

Pristiq	741	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	14
Figure 2 Avoid use of PRISTIQ with other desvenlafaxine-containing products or venlafaxine products.
1	0	5	O	Figure
2	7	7	O	2
3	9	13	B-TRI	Avoid
4	15	17	L-TRI	use
5	19	20	O	of
6	22	28	O	XXXXXXXX
7	30	33	O	with
8	35	39	O	other
9	41	54	B-UNK	XXXXXXXX
10	56	65	I-UNK	containing
11	67	74	L-UNK	products
12	76	77	O	or
13	79	89	O	venlafaxine
14	91	98	O	products
NULL

Pristiq	742	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	23
The concomitant use of PRISTIQ with other desvenlafaxine-containing products or venlafaxine will increase desvenlafaxine blood levels and increase dose-related adverse reactions.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	29	O	XXXXXXXX
6	31	34	O	with
7	36	40	O	other
8	42	55	B-KIN	XXXXXXXX
9	57	66	I-KIN	containing
10	68	75	L-KIN	products
11	77	78	O	or
12	80	90	O	venlafaxine
13	92	95	O	will
14	97	104	B-TRI	increase
15	106	119	I-TRI	XXXXXXXX
16	121	125	I-TRI	blood
17	127	132	L-TRI	levels
18	134	136	O	and
19	138	145	O	increase
20	147	150	O	dose
21	152	158	O	related
22	160	166	O	adverse
23	168	176	O	reactions
K/8:C54355

Pristiq	743	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	20
A clinical study has shown that PRISTIQ does not increase the impairment of mental and motor skills caused by ethanol.
1	0	0	O	A
2	2	9	O	clinical
3	11	15	O	study
4	17	19	O	has
5	21	25	O	shown
6	27	30	O	that
7	32	38	O	XXXXXXXX
8	40	43	O	does
9	45	47	O	not
10	49	56	O	increase
11	58	60	O	the
12	62	71	O	impairment
13	73	74	O	of
14	76	81	O	mental
15	83	85	O	and
16	87	91	O	motor
17	93	98	O	skills
18	100	105	O	caused
19	107	108	O	by
20	110	116	O	ethanol
NULL

Pristiq	744	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	20
However, as with all CNS-active drugs, patients should be advised to avoid alcohol consumption while taking PRISTIQ.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	as
4	12	15	O	with
5	17	19	O	all
6	21	23	O	CNS
7	25	30	O	active
8	32	36	O	drugs
9	37	37	O	,
10	39	46	O	patients
11	48	53	O	should
12	55	56	O	be
13	58	64	O	advised
14	66	67	O	to
15	69	73	U-TRI	avoid
16	75	81	U-UNK	alcohol
17	83	93	O	consumption
18	95	99	O	while
19	101	106	O	taking
20	108	114	O	XXXXXXXX
NULL

Pristiq	745	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking desvenlafaxine.
1	0	4	O	False
2	6	13	O	positive
3	15	19	O	urine
4	21	31	O	immunoassay
5	33	41	O	screening
6	43	47	O	tests
7	49	51	O	for
8	53	65	O	phencyclidine
9	68	70	O	PCP
10	73	75	O	and
11	77	87	O	amphetamine
12	89	92	O	have
13	94	97	O	been
14	99	106	O	reported
15	108	109	O	in
16	111	118	O	patients
17	120	125	O	taking
18	127	140	O	XXXXXXXX
NULL

Pristiq	746	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	11
This is due to lack of specificity of the screening tests.
1	0	3	O	This
2	5	6	O	is
3	8	10	O	due
4	12	13	O	to
5	15	18	O	lack
6	20	21	O	of
7	23	33	O	specificity
8	35	36	O	of
9	38	40	O	the
10	42	50	O	screening
11	52	56	O	tests
NULL

Pristiq	747	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	15
False positive test results may be expected for several days following discontinuation of desvenlafaxine therapy.
1	0	4	O	False
2	6	13	O	positive
3	15	18	O	test
4	20	26	O	results
5	28	30	O	may
6	32	33	O	be
7	35	42	O	expected
8	44	46	O	for
9	48	54	O	several
10	56	59	O	days
11	61	69	O	following
12	71	85	O	discontinuation
13	87	88	O	of
14	90	103	O	XXXXXXXX
15	105	111	O	therapy
NULL

Pristiq	748	34073-7	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish desvenlafaxine from PCP and amphetamine.
1	0	11	O	Confirmatory
2	13	17	O	tests
3	18	18	O	,
4	20	23	O	such
5	25	26	O	as
6	28	30	O	gas
7	32	45	O	chromatography
8	46	46	O	/
9	47	50	O	mass
10	52	63	O	spectrometry
11	64	64	O	,
12	66	69	O	will
13	71	81	O	distinguish
14	83	96	O	XXXXXXXX
15	98	101	O	from
16	103	105	O	PCP
17	107	109	O	and
18	111	121	O	amphetamine
NULL

Pristiq	749	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	36
The exact mechanism of the antidepressant action of desvenlafaxine is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.
1	0	2	O	The
2	4	8	O	exact
3	10	18	O	mechanism
4	20	21	O	of
5	23	25	O	the
6	27	40	O	antidepressant
7	42	47	O	action
8	49	50	O	of
9	52	65	O	XXXXXXXX
10	67	68	O	is
11	70	76	O	unknown
12	77	77	O	,
13	79	81	O	but
14	83	84	O	is
15	86	92	O	thought
16	94	95	O	to
17	97	98	O	be
18	100	106	O	related
19	108	109	O	to
20	111	113	O	the
21	115	126	O	potentiation
22	128	129	O	of
23	131	139	O	serotonin
24	141	143	O	and
25	145	158	O	norepinephrine
26	160	161	O	in
27	163	165	O	the
28	167	173	O	central
29	175	181	O	nervous
30	183	188	O	system
31	189	189	O	,
32	191	197	O	through
33	199	208	O	inhibition
34	210	211	O	of
35	213	217	O	their
36	219	226	O	reuptake
NULL

Pristiq	750	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Non-clinical studies have shown that desvenlafaxine is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).
1	0	2	O	Non
2	4	11	O	clinical
3	13	19	O	studies
4	21	24	O	have
5	26	30	O	shown
6	32	35	O	that
7	37	50	O	XXXXXXXX
8	52	53	O	is
9	55	55	O	a
10	57	62	O	potent
11	64	66	O	and
12	68	76	O	selective
13	78	86	O	serotonin
14	88	90	O	and
15	92	105	O	norepinephrine
16	107	114	O	reuptake
17	116	124	O	inhibitor
18	127	130	O	SNRI
NULL

Pristiq	751	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	21
Desvenlafaxine lacked significant affinity for numerous receptors, including muscarinic-cholinergic, H1-histaminergic, or A1-adrenergic receptors in vitro.
1	0	13	O	XXXXXXXX
2	15	20	O	lacked
3	22	32	O	significant
4	34	41	O	affinity
5	43	45	O	for
6	47	54	O	numerous
7	56	64	O	receptors
8	65	65	O	,
9	67	75	O	including
10	77	86	O	muscarinic
11	88	98	O	cholinergic
12	99	99	O	,
13	101	102	O	H1
14	104	116	O	histaminergic
15	117	117	O	,
16	119	120	O	or
17	122	123	O	A1
18	125	134	O	adrenergic
19	136	144	O	receptors
20	146	147	O	in
21	149	153	O	vitro
NULL

Pristiq	752	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	8
Desvenlafaxine also lacked monoamine oxidase (MAO) inhibitory activity.
1	0	13	O	XXXXXXXX
2	15	18	O	also
3	20	25	O	lacked
4	27	35	O	monoamine
5	37	43	O	oxidase
6	46	48	O	MAO
7	51	60	O	inhibitory
8	62	69	O	activity
NULL

Pristiq	753	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	27
ECG changes Electrocardiograms were obtained from 1,492 desvenlafaxine treated patients with major depressive disorder and 984 placebo-treated patients in clinical studies lasting up to 8 weeks.
1	0	2	O	ECG
2	4	10	O	changes
3	12	29	O	Electrocardiograms
4	31	34	O	were
5	36	43	O	obtained
6	45	48	O	from
7	50	54	O	1,492
8	56	69	O	XXXXXXXX
9	71	77	O	treated
10	79	86	O	patients
11	88	91	O	with
12	93	97	O	major
13	99	108	O	depressive
14	110	117	O	disorder
15	119	121	O	and
16	123	125	O	984
17	127	133	O	placebo
18	135	141	O	treated
19	143	150	O	patients
20	152	153	O	in
21	155	162	O	clinical
22	164	170	O	studies
23	172	178	O	lasting
24	180	181	O	up
25	183	184	O	to
26	186	186	O	8
27	188	192	O	weeks
NULL

Pristiq	754	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	23
No clinically relevant differences were observed between desvenlafaxine treated and placebo-treated patients for QT, QTc, PR, and QRS intervals.
1	0	1	O	No
2	3	12	O	clinically
3	14	21	O	relevant
4	23	33	O	differences
5	35	38	O	were
6	40	47	O	observed
7	49	55	O	between
8	57	70	O	XXXXXXXX
9	72	78	O	treated
10	80	82	O	and
11	84	90	O	placebo
12	92	98	O	treated
13	100	107	O	patients
14	109	111	O	for
15	113	114	O	QT
16	115	115	O	,
17	117	119	O	QTc
18	120	120	O	,
19	122	123	O	PR
20	124	124	O	,
21	126	128	O	and
22	130	132	O	QRS
23	134	142	O	intervals
NULL

Pristiq	755	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	16
In a thorough QTc study with prospectively determined criteria, desvenlafaxine did not cause QT prolongation.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	thorough
4	14	16	O	QTc
5	18	22	O	study
6	24	27	O	with
7	29	41	O	prospectively
8	43	52	O	determined
9	54	61	O	criteria
10	62	62	O	,
11	64	77	O	XXXXXXXX
12	79	81	O	did
13	83	85	O	not
14	87	91	O	cause
15	93	94	O	QT
16	96	107	O	prolongation
NULL

Pristiq	756	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	13
No difference was observed between placebo and desvenlafaxine treatments for the QRS interval.
1	0	1	O	No
2	3	12	O	difference
3	14	16	O	was
4	18	25	O	observed
5	27	33	O	between
6	35	41	O	placebo
7	43	45	O	and
8	47	60	O	XXXXXXXX
9	62	71	O	treatments
10	73	75	O	for
11	77	79	O	the
12	81	83	O	QRS
13	85	92	O	interval
NULL

Pristiq	757	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	22
The single-dose pharmacokinetics of desvenlafaxine are linear and dose-proportional in a dose range of 50 to 600 mg per day.
1	0	2	O	The
2	4	9	O	single
3	11	14	O	dose
4	16	31	O	pharmacokinetics
5	33	34	O	of
6	36	49	O	XXXXXXXX
7	51	53	O	are
8	55	60	O	linear
9	62	64	O	and
10	66	69	O	dose
11	71	82	O	proportional
12	84	85	O	in
13	87	87	O	a
14	89	92	O	dose
15	94	98	O	range
16	100	101	O	of
17	103	104	O	50
18	106	107	O	to
19	109	111	O	600
20	113	114	O	mg
21	116	118	O	per
22	120	122	O	day
NULL

Pristiq	758	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	17
With once-daily dosing, steady-state plasma concentrations are achieved within approximately 4 to 5 days.
1	0	3	O	With
2	5	8	O	once
3	10	14	O	daily
4	16	21	O	dosing
5	22	22	O	,
6	24	29	O	steady
7	31	35	O	state
8	37	42	O	plasma
9	44	57	O	concentrations
10	59	61	O	are
11	63	70	O	achieved
12	72	77	O	within
13	79	91	O	approximately
14	93	93	O	4
15	95	96	O	to
16	98	98	O	5
17	100	103	O	days
NULL

Pristiq	759	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	19
At steady-state, multiple-dose accumulation of desvenlafaxine is linear and predictable from the single-dose pharmacokinetic profile.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	24	O	multiple
6	26	29	O	dose
7	31	42	O	accumulation
8	44	45	O	of
9	47	60	O	XXXXXXXX
10	62	63	O	is
11	65	70	O	linear
12	72	74	O	and
13	76	86	O	predictable
14	88	91	O	from
15	93	95	O	the
16	97	102	O	single
17	104	107	O	dose
18	109	123	O	pharmacokinetic
19	125	131	O	profile
NULL

Pristiq	760	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	15
Absorption and distribution The absolute oral bioavailability of PRISTIQ after oral administration is about 80%.
1	0	9	O	Absorption
2	11	13	O	and
3	15	26	O	distribution
4	28	30	O	The
5	32	39	O	absolute
6	41	44	O	oral
7	46	60	O	bioavailability
8	62	63	O	of
9	65	71	O	XXXXXXXX
10	73	77	O	after
11	79	82	O	oral
12	84	97	O	administration
13	99	100	O	is
14	102	106	O	about
15	108	110	O	80%
NULL

Pristiq	761	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	42
A food-effect study involving administration of PRISTIQ to healthy subjects under fasting and fed conditions (high-fat meal, 800 to 1000 calories) indicated that desvenlafaxine Cmax was increased about 16% in the fed state, while the AUCs were similar.
1	0	0	O	A
2	2	5	O	food
3	7	12	O	effect
4	14	18	O	study
5	20	28	O	involving
6	30	43	O	administration
7	45	46	O	of
8	48	54	O	XXXXXXXX
9	56	57	O	to
10	59	65	O	healthy
11	67	74	O	subjects
12	76	80	O	under
13	82	88	O	fasting
14	90	92	O	and
15	94	96	O	fed
16	98	107	O	conditions
17	110	113	B-KIN	high
18	115	117	I-KIN	fat
19	119	122	L-KIN	meal
20	123	123	O	,
21	125	127	O	800
22	129	130	O	to
23	132	135	O	1000
24	137	144	O	calories
25	147	155	O	indicated
26	157	160	O	that
27	162	175	O	XXXXXXXX
28	177	180	B-TRI	Cmax
29	182	184	I-TRI	was
30	186	194	L-TRI	increased
31	196	200	O	about
32	202	204	O	16%
33	206	207	O	in
34	209	211	O	the
35	213	215	O	fed
36	217	221	O	state
37	222	222	O	,
38	224	228	O	while
39	230	232	O	the
40	234	237	O	AUCs
41	239	242	O	were
42	244	250	O	similar
K/17:C54602

Pristiq	762	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	19
This difference is not expected to be clinically significant; therefore, PRISTIQ can be taken without regard to meals.
1	0	3	O	This
2	5	14	O	difference
3	16	17	O	is
4	19	21	O	not
5	23	30	O	expected
6	32	33	O	to
7	35	36	O	be
8	38	47	O	clinically
9	49	59	O	significant
10	62	70	O	therefore
11	71	71	O	,
12	73	79	O	XXXXXXXX
13	81	83	O	can
14	85	86	O	be
15	88	92	O	taken
16	94	100	O	without
17	102	107	O	regard
18	109	110	O	to
19	112	116	O	meals
NULL

Pristiq	763	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	15
The plasma protein binding of desvenlafaxine is low (30%) and is independent of drug concentration.
1	0	2	O	The
2	4	9	O	plasma
3	11	17	O	protein
4	19	25	O	binding
5	27	28	O	of
6	30	43	O	XXXXXXXX
7	45	46	O	is
8	48	50	O	low
9	53	55	O	30%
10	58	60	O	and
11	62	63	O	is
12	65	75	O	independent
13	77	78	O	of
14	80	83	O	drug
15	85	97	O	concentration
NULL

Pristiq	764	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	22
The desvenlafaxine volume of distribution at steady-state following intravenous administration is 3.4 L/kg, indicating distribution into nonvascular compartments.
1	0	2	O	The
2	4	17	O	XXXXXXXX
3	19	24	O	volume
4	26	27	O	of
5	29	40	O	distribution
6	42	43	O	at
7	45	50	O	steady
8	52	56	O	state
9	58	66	O	following
10	68	78	O	intravenous
11	80	93	O	administration
12	95	96	O	is
13	98	100	O	3.4
14	102	102	O	L
15	103	103	O	/
16	104	105	O	kg
17	106	106	O	,
18	108	117	O	indicating
19	119	130	O	distribution
20	132	135	O	into
21	137	147	O	nonvascular
22	149	160	O	compartments
NULL

Pristiq	765	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	23
Metabolism and elimination Desvenlafaxine is primarily metabolized by conjugation (mediated by UGT isoforms) and, to a minor extent, through oxidative metabolism.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	elimination
4	27	40	O	XXXXXXXX
5	42	43	O	is
6	45	53	O	primarily
7	55	65	O	metabolized
8	67	68	O	by
9	70	80	O	conjugation
10	83	90	O	mediated
11	92	93	O	by
12	95	97	O	UGT
13	99	106	O	isoforms
14	109	111	O	and
15	112	112	O	,
16	114	115	O	to
17	117	117	O	a
18	119	123	O	minor
19	125	130	O	extent
20	131	131	O	,
21	133	139	O	through
22	141	149	O	oxidative
23	151	160	O	metabolism
NULL

Pristiq	766	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	14
CYP3A4 is the cytochrome P450 isozyme mediating the oxidative metabolism (N-demethylation) of desvenlafaxine.
1	0	5	O	CYP3A4
2	7	8	O	is
3	10	12	O	the
4	14	23	O	cytochrome
5	25	28	O	P450
6	30	36	O	isozyme
7	38	46	O	mediating
8	48	50	O	the
9	52	60	O	oxidative
10	62	71	O	metabolism
11	74	74	O	N
12	76	88	O	demethylation
13	91	92	O	of
14	94	107	O	XXXXXXXX
NULL

Pristiq	767	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	30
The CYP2D6 metabolic pathway is not involved, and after administration of 100 mg, the pharmacokinetics of desvenlafaxine was similar in subjects with CYP2D6 poor and extensive metabolizer phenotype.
1	0	2	O	The
2	4	9	O	CYP2D6
3	11	19	O	metabolic
4	21	27	O	pathway
5	29	30	O	is
6	32	34	O	not
7	36	43	O	involved
8	44	44	O	,
9	46	48	O	and
10	50	54	O	after
11	56	69	O	administration
12	71	72	O	of
13	74	76	O	100
14	78	79	O	mg
15	80	80	O	,
16	82	84	O	the
17	86	101	O	pharmacokinetics
18	103	104	O	of
19	106	119	O	XXXXXXXX
20	121	123	O	was
21	125	131	O	similar
22	133	134	O	in
23	136	143	O	subjects
24	145	148	O	with
25	150	155	O	CYP2D6
26	157	160	O	poor
27	162	164	O	and
28	166	174	O	extensive
29	176	186	O	metabolizer
30	188	196	O	phenotype
NULL

Pristiq	768	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	15
Approximately 45% of desvenlafaxine is excreted unchanged in urine at 72 hours after oral administration.
1	0	12	O	Approximately
2	14	16	O	45%
3	18	19	O	of
4	21	34	O	XXXXXXXX
5	36	37	O	is
6	39	46	O	excreted
7	48	56	O	unchanged
8	58	59	O	in
9	61	65	O	urine
10	67	68	O	at
11	70	71	O	72
12	73	77	O	hours
13	79	83	O	after
14	85	88	O	oral
15	90	103	O	administration
NULL

Pristiq	769	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	22
Approximately 19% of the administered dose is excreted as the glucuronide metabolite and <5% as the oxidative metabolite (N,O-didesmethylvenlafaxine) in urine.
1	0	12	O	Approximately
2	14	16	O	19%
3	18	19	O	of
4	21	23	O	the
5	25	36	O	administered
6	38	41	O	dose
7	43	44	O	is
8	46	53	O	excreted
9	55	56	O	as
10	58	60	O	the
11	62	72	O	glucuronide
12	74	83	O	metabolite
13	85	87	O	and
14	89	91	O	<5%
15	93	94	O	as
16	96	98	O	the
17	100	108	O	oxidative
18	110	119	O	metabolite
19	122	124	O	N,O
20	126	147	O	didesmethylvenlafaxine
21	150	151	O	in
22	153	157	O	urine
NULL

Pristiq	770	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	17
Drug interaction studies Inhibitors of CYP3A4 (ketoconazole) CYP3A4 is a minor pathway for the metabolism of desvenlafaxine.
1	0	3	O	Drug
2	5	15	O	interaction
3	17	23	O	studies
4	25	34	O	Inhibitors
5	36	37	O	of
6	39	44	O	CYP3A4
7	47	58	O	ketoconazole
8	61	66	O	CYP3A4
9	68	69	O	is
10	71	71	O	a
11	73	77	O	minor
12	79	85	O	pathway
13	87	89	O	for
14	91	93	O	the
15	95	104	O	metabolism
16	106	107	O	of
17	109	122	O	XXXXXXXX
NULL

Pristiq	771	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	33
In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of desvenlafaxine (400 mg single dose) by about 43% and Cmax by about 8%.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	study
5	19	19	O	,
6	21	32	U-KIN	ketoconazole
7	35	37	O	200
8	39	40	O	mg
9	42	44	O	BID
10	47	55	O	increased
11	57	59	O	the
12	61	64	O	area
13	66	70	O	under
14	72	74	O	the
15	76	88	O	concentration
16	90	91	O	vs
17	94	97	O	time
18	99	103	O	curve
19	106	108	O	AUC
20	111	112	O	of
21	114	127	O	XXXXXXXX
22	130	132	O	400
23	134	135	O	mg
24	137	142	O	single
25	144	147	O	dose
26	150	151	O	by
27	153	157	O	about
28	159	161	O	43%
29	163	165	O	and
30	167	170	O	Cmax
31	172	173	O	by
32	175	179	O	about
33	181	182	O	8%
K/6:C54605

Pristiq	772	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	16
Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher concentrations of desvenlafaxine.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	32	O	XXXXXXXX
5	34	37	O	with
6	39	44	B-KIN	potent
7	46	55	I-KIN	inhibitors
8	57	58	I-KIN	of
9	60	65	L-KIN	CYP3A4
10	67	69	O	may
11	71	76	O	result
12	78	79	O	in
13	81	86	B-TRI	higher
14	88	101	L-TRI	concentrations
15	103	104	O	of
16	106	119	O	XXXXXXXX
K/6:C54355

Pristiq	773	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	63
Inhibitors of other CYP enzymes Based on in vitro data, drugs that inhibit CYP isozymes 1A1, 1A2, 2A6, 2D6, 2C8, 2C9, 2C19, and 2E1 are not expected to have significant impact on the pharmacokinetic profile of desvenlafaxine. desipramine, dextromethorphan, metoprolol, atomoxetine) In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	18	O	other
4	20	22	O	CYP
5	24	30	O	enzymes
6	32	36	O	Based
7	38	39	O	on
8	41	42	O	in
9	44	48	O	vitro
10	50	53	O	data
11	54	54	O	,
12	56	60	O	drugs
13	62	65	O	that
14	67	73	O	inhibit
15	75	77	O	CYP
16	79	86	O	isozymes
17	88	90	O	1A1
18	91	91	O	,
19	93	95	O	1A2
20	96	96	O	,
21	98	100	O	2A6
22	101	101	O	,
23	103	105	O	2D6
24	106	106	O	,
25	108	110	O	2C8
26	111	111	O	,
27	113	115	O	2C9
28	116	116	O	,
29	118	121	O	2C19
30	122	122	O	,
31	124	126	O	and
32	128	130	O	2E1
33	132	134	O	are
34	136	138	O	not
35	140	147	O	expected
36	149	150	O	to
37	152	155	O	have
38	157	167	O	significant
39	169	174	O	impact
40	176	177	O	on
41	179	181	O	the
42	183	197	O	pharmacokinetic
43	199	205	O	profile
44	207	208	O	of
45	210	223	O	XXXXXXXX
46	226	236	O	desipramine
47	237	237	O	,
48	239	254	O	dextromethorphan
49	255	255	O	,
50	257	266	O	metoprolol
51	267	267	O	,
52	269	279	O	atomoxetine
53	282	283	O	In
54	285	289	O	vitro
55	291	297	O	studies
56	299	304	O	showed
57	306	312	O	minimal
58	314	323	O	inhibitory
59	325	330	O	effect
60	332	333	O	of
61	335	348	O	XXXXXXXX
62	350	351	O	on
63	353	358	O	CYP2D6
NULL

Pristiq	774	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	23
Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	20	O	have
4	22	26	O	shown
5	28	31	O	that
6	33	46	O	XXXXXXXX
7	48	51	O	does
8	53	55	O	not
9	57	60	O	have
10	62	62	O	a
11	64	73	O	clinically
12	75	82	O	relevant
13	84	89	O	effect
14	91	92	O	on
15	94	99	O	CYP2D6
16	101	110	O	metabolism
17	112	113	O	at
18	115	117	O	the
19	119	122	O	dose
20	124	125	O	of
21	127	129	O	100
22	131	132	O	mg
23	134	138	O	daily
NULL

Pristiq	775	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	40
When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively.
1	0	3	O	When
2	5	18	O	XXXXXXXX
3	20	28	O	succinate
4	30	32	O	was
5	34	45	O	administered
6	47	48	O	at
7	50	50	O	a
8	52	55	O	dose
9	57	58	O	of
10	60	62	O	100
11	64	65	O	mg
12	67	71	O	daily
13	73	74	O	in
14	76	86	O	conjunction
15	88	91	O	with
16	93	93	O	a
17	95	100	O	single
18	102	103	O	50
19	105	106	O	mg
20	108	111	O	dose
21	113	114	O	of
22	116	126	U-KIN	desipramine
23	127	127	O	,
24	129	129	O	a
25	131	136	O	CYP2D6
26	138	146	O	substrate
27	147	147	O	,
28	149	151	O	the
29	153	156	O	Cmax
30	158	160	O	and
31	162	164	O	AUC
32	166	167	O	of
33	169	179	O	desipramine
34	181	189	O	increased
35	191	203	O	approximately
36	205	207	O	25%
37	209	211	O	and
38	213	215	O	17%
39	216	216	O	,
40	218	229	O	respectively
K/22:C54610

Pristiq	776	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	26
When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively.
1	0	3	O	When
2	5	7	O	400
3	9	10	O	mg
4	13	13	O	8
5	15	19	O	times
6	21	23	O	the
7	25	35	O	recommended
8	37	38	O	50
9	40	41	O	mg
10	43	46	O	dose
11	49	51	O	was
12	53	64	O	administered
13	65	65	O	,
14	67	69	O	the
15	71	74	O	Cmax
16	76	78	O	and
17	80	82	O	AUC
18	84	85	O	of
19	87	97	U-KIN	desipramine
20	99	107	O	increased
21	109	121	O	approximately
22	123	125	O	50%
23	127	129	O	and
24	131	133	O	90%
25	134	134	O	,
26	136	147	O	respectively
K/19:C54613

Pristiq	777	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	32	O	XXXXXXXX
5	34	37	O	with
6	39	39	O	a
7	41	44	B-KIN	drug
8	46	56	I-KIN	metabolized
9	58	59	I-KIN	by
10	61	66	L-KIN	CYP2D6
11	68	70	O	can
12	72	77	O	result
13	79	80	O	in
14	82	87	B-TRI	higher
15	89	102	I-TRI	concentrations
16	104	105	I-TRI	of
17	107	110	I-TRI	that
18	112	115	L-TRI	drug
K/7:C54357

Pristiq	778	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	17
Drugs metabolized by CYP3A4 (midazolam) In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme.
1	0	4	O	Drugs
2	6	16	O	metabolized
3	18	19	O	by
4	21	26	O	CYP3A4
5	29	37	O	midazolam
6	40	41	O	In
7	43	47	O	vitro
8	48	48	O	,
9	50	63	O	XXXXXXXX
10	65	68	O	does
11	70	72	O	not
12	74	80	O	inhibit
13	82	83	O	or
14	85	90	O	induce
15	92	94	O	the
16	96	101	O	CYP3A4
17	103	109	O	isozyme
NULL

Pristiq	779	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	30
In a clinical study, desvenlafaxine 400 mg daily (8 times the recommended 50 mg dose) was co-administered with a single 4 mg dose of midazolam (a CYP3A4 substrate).
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	study
5	19	19	O	,
6	21	34	O	XXXXXXXX
7	36	38	O	400
8	40	41	O	mg
9	43	47	O	daily
10	50	50	O	8
11	52	56	O	times
12	58	60	O	the
13	62	72	O	recommended
14	74	75	O	50
15	77	78	O	mg
16	80	83	O	dose
17	86	88	O	was
18	90	91	O	co
19	93	104	O	administered
20	106	109	O	with
21	111	111	O	a
22	113	118	O	single
23	120	120	O	4
24	122	123	O	mg
25	125	128	O	dose
26	130	131	O	of
27	133	141	O	midazolam
28	144	144	O	a
29	146	151	O	CYP3A4
30	153	161	O	substrate
NULL

Pristiq	780	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	14
The AUC and Cmax of midazolam decreased by approximately 31% and 16%, respectively.
1	0	2	O	The
2	4	6	O	AUC
3	8	10	O	and
4	12	15	O	Cmax
5	17	18	O	of
6	20	28	U-KIN	midazolam
7	30	38	O	decreased
8	40	41	O	by
9	43	55	O	approximately
10	57	59	O	31%
11	61	63	O	and
12	65	67	O	16%
13	68	68	O	,
14	70	81	O	respectively
K/6:C54614

Pristiq	781	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 can result in lower exposures to that drug.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	32	O	XXXXXXXX
5	34	37	O	with
6	39	39	O	a
7	41	44	B-KIN	drug
8	46	56	I-KIN	metabolized
9	58	59	I-KIN	by
10	61	66	L-KIN	CYP3A4
11	68	70	O	can
12	72	77	O	result
13	79	80	O	in
14	82	86	B-TRI	lower
15	88	96	I-TRI	exposures
16	98	99	I-TRI	to
17	101	104	I-TRI	that
18	106	109	L-TRI	drug
K/7:C54358

Pristiq	782	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	48
Drugs metabolized by CYP1A2, 2A6, 2C8, 2C9 and 2C19 In vitro, desvenlafaxine does not inhibit CYP1A2, 2A6, 2C8, 2C9, and 2C19 isozymes and would not be expected to affect the pharmacokinetics of drugs that are metabolized by these CYP isozymes.
1	0	4	O	Drugs
2	6	16	O	metabolized
3	18	19	O	by
4	21	26	O	CYP1A2
5	27	27	O	,
6	29	31	O	2A6
7	32	32	O	,
8	34	36	O	2C8
9	37	37	O	,
10	39	41	O	2C9
11	43	45	O	and
12	47	50	O	2C19
13	52	53	O	In
14	55	59	O	vitro
15	60	60	O	,
16	62	75	O	XXXXXXXX
17	77	80	O	does
18	82	84	O	not
19	86	92	O	inhibit
20	94	99	O	CYP1A2
21	100	100	O	,
22	102	104	O	2A6
23	105	105	O	,
24	107	109	O	2C8
25	110	110	O	,
26	112	114	O	2C9
27	115	115	O	,
28	117	119	O	and
29	121	124	O	2C19
30	126	133	O	isozymes
31	135	137	O	and
32	139	143	O	would
33	145	147	O	not
34	149	150	O	be
35	152	159	O	expected
36	161	162	O	to
37	164	169	O	affect
38	171	173	O	the
39	175	190	O	pharmacokinetics
40	192	193	O	of
41	195	199	O	drugs
42	201	204	O	that
43	206	208	O	are
44	210	220	O	metabolized
45	222	223	O	by
46	225	229	O	these
47	231	233	O	CYP
48	235	242	O	isozymes
NULL

Pristiq	783	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	16
In vitro, desvenlafaxine is not a substrate or an inhibitor for the P-glycoprotein transporter.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	23	O	XXXXXXXX
5	25	26	O	is
6	28	30	O	not
7	32	32	O	a
8	34	42	O	substrate
9	44	45	O	or
10	47	48	O	an
11	50	58	O	inhibitor
12	60	62	O	for
13	64	66	O	the
14	68	68	O	P
15	70	81	O	glycoprotein
16	83	93	O	transporter
NULL

Pristiq	784	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	37
The pharmacokinetics of desvenlafaxine are unlikely to be affected by drugs that inhibit the P-glycoprotein transporter, and desvenlafaxine is not likely to affect the pharmacokinetics of drugs that are substrates of the P-glycoprotein transporter.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	37	O	XXXXXXXX
5	39	41	O	are
6	43	50	O	unlikely
7	52	53	O	to
8	55	56	O	be
9	58	65	O	affected
10	67	68	O	by
11	70	74	O	drugs
12	76	79	O	that
13	81	87	O	inhibit
14	89	91	O	the
15	93	93	O	P
16	95	106	O	glycoprotein
17	108	118	O	transporter
18	119	119	O	,
19	121	123	O	and
20	125	138	O	XXXXXXXX
21	140	141	O	is
22	143	145	O	not
23	147	152	O	likely
24	154	155	O	to
25	157	162	O	affect
26	164	166	O	the
27	168	183	O	pharmacokinetics
28	185	186	O	of
29	188	192	O	drugs
30	194	197	O	that
31	199	201	O	are
32	203	212	O	substrates
33	214	215	O	of
34	217	219	O	the
35	221	221	O	P
36	223	234	O	glycoprotein
37	236	246	O	transporter
NULL

Pristiq	785	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	55
Special populations Age In a study of healthy subjects administered doses of up to 300 mg, there was an approximate 32% increase in Cmax and a 55% increase in AUC in subjects older than 75 years of age (n = 17), compared with subjects 18 to 45 years of age (n = 16).
1	0	6	O	Special
2	8	18	O	populations
3	20	22	O	Age
4	24	25	O	In
5	27	27	O	a
6	29	33	O	study
7	35	36	O	of
8	38	44	O	healthy
9	46	53	O	subjects
10	55	66	O	administered
11	68	72	O	doses
12	74	75	O	of
13	77	78	O	up
14	80	81	O	to
15	83	85	O	300
16	87	88	O	mg
17	89	89	O	,
18	91	95	O	there
19	97	99	O	was
20	101	102	O	an
21	104	114	O	approximate
22	116	118	O	32%
23	120	127	O	increase
24	129	130	O	in
25	132	135	O	Cmax
26	137	139	O	and
27	141	141	O	a
28	143	145	O	55%
29	147	154	O	increase
30	156	157	O	in
31	159	161	O	AUC
32	163	164	O	in
33	166	173	O	subjects
34	175	179	O	older
35	181	184	O	than
36	186	187	O	75
37	189	193	O	years
38	195	196	O	of
39	198	200	O	age
40	203	203	O	n
41	205	205	O	=
42	207	208	O	17
43	210	210	O	,
44	212	219	O	compared
45	221	224	O	with
46	226	233	O	subjects
47	235	236	O	18
48	238	239	O	to
49	241	242	O	45
50	244	248	O	years
51	250	251	O	of
52	253	255	O	age
53	258	258	O	n
54	260	260	O	=
55	262	263	O	16
NULL

Pristiq	786	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	33
Subjects 65 to 75 years of age (n = 15) had no change in Cmax, but an approximately 32% increase in AUC, compared to subjects 18 to 45 years of age.
1	0	7	O	Subjects
2	9	10	O	65
3	12	13	O	to
4	15	16	O	75
5	18	22	O	years
6	24	25	O	of
7	27	29	O	age
8	32	32	O	n
9	34	34	O	=
10	36	37	O	15
11	40	42	O	had
12	44	45	O	no
13	47	52	O	change
14	54	55	O	in
15	57	60	O	Cmax
16	61	61	O	,
17	63	65	O	but
18	67	68	O	an
19	70	82	O	approximately
20	84	86	O	32%
21	88	95	O	increase
22	97	98	O	in
23	100	102	O	AUC
24	103	103	O	,
25	105	112	O	compared
26	114	115	O	to
27	117	124	O	subjects
28	126	127	O	18
29	129	130	O	to
30	132	133	O	45
31	135	139	O	years
32	141	142	O	of
33	144	146	O	age
NULL

Pristiq	787	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	32
Gender In a study of healthy subjects administered doses of up to 300 mg, women had an approximately 25% higher Cmax and an approximately 10% higher AUC than age-matched men.
1	0	5	O	Gender
2	7	8	O	In
3	10	10	O	a
4	12	16	O	study
5	18	19	O	of
6	21	27	O	healthy
7	29	36	O	subjects
8	38	49	O	administered
9	51	55	O	doses
10	57	58	O	of
11	60	61	O	up
12	63	64	O	to
13	66	68	O	300
14	70	71	O	mg
15	72	72	O	,
16	74	78	O	women
17	80	82	O	had
18	84	85	O	an
19	87	99	O	approximately
20	101	103	O	25%
21	105	110	O	higher
22	112	115	O	Cmax
23	117	119	O	and
24	121	122	O	an
25	124	136	O	approximately
26	138	140	O	10%
27	142	147	O	higher
28	149	151	O	AUC
29	153	156	O	than
30	158	160	O	age
31	162	168	O	matched
32	170	172	O	men
NULL

Pristiq	788	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	11
No adjustment of dosage on the basis of gender is needed.
1	0	1	O	No
2	3	12	O	adjustment
3	14	15	O	of
4	17	22	O	dosage
5	24	25	O	on
6	27	29	O	the
7	31	35	O	basis
8	37	38	O	of
9	40	45	O	gender
10	47	48	O	is
11	50	55	O	needed
NULL

Pristiq	789	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	35
Race Pharmacokinetic analysis showed that race (White, n = 466; Black, n = 97; Hispanic, n = 39; Other, n = 33) had no apparent effect on the pharmacokinetics of PRISTIQ.
1	0	3	O	Race
2	5	19	O	Pharmacokinetic
3	21	28	O	analysis
4	30	35	O	showed
5	37	40	O	that
6	42	45	O	race
7	48	52	O	White
8	53	53	O	,
9	55	55	O	n
10	57	57	O	=
11	59	61	O	466
12	64	68	O	Black
13	69	69	O	,
14	71	71	O	n
15	73	73	O	=
16	75	76	O	97
17	79	86	O	Hispanic
18	87	87	O	,
19	89	89	O	n
20	91	91	O	=
21	93	94	O	39
22	97	101	O	Other
23	102	102	O	,
24	104	104	O	n
25	106	106	O	=
26	108	109	O	33
27	112	114	O	had
28	116	117	O	no
29	119	126	O	apparent
30	128	133	O	effect
31	135	136	O	on
32	138	140	O	the
33	142	157	O	pharmacokinetics
34	159	160	O	of
35	162	168	O	XXXXXXXX
NULL

Pristiq	790	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	11
No adjustment of dosage on the basis of race is needed.
1	0	1	O	No
2	3	12	O	adjustment
3	14	15	O	of
4	17	22	O	dosage
5	24	25	O	on
6	27	29	O	the
7	31	35	O	basis
8	37	38	O	of
9	40	43	O	race
10	45	46	O	is
11	48	53	O	needed
NULL

Pristiq	791	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	53
Hepatic insufficiency The disposition of desvenlafaxine succinate after administration of 100 mg was studied in subjects with mild (Child-Pugh A, n = 8), moderate (Child-Pugh B, n = 8), and severe (Child-Pugh C, n = 8) hepatic impairment and to healthy subjects (n = 12).
1	0	6	O	Hepatic
2	8	20	O	insufficiency
3	22	24	O	The
4	26	36	O	disposition
5	38	39	O	of
6	41	54	O	XXXXXXXX
7	56	64	O	succinate
8	66	70	O	after
9	72	85	O	administration
10	87	88	O	of
11	90	92	O	100
12	94	95	O	mg
13	97	99	O	was
14	101	107	O	studied
15	109	110	O	in
16	112	119	O	subjects
17	121	124	O	with
18	126	129	O	mild
19	132	136	O	Child
20	138	141	O	Pugh
21	143	143	O	A
22	144	144	O	,
23	146	146	O	n
24	148	148	O	=
25	150	150	O	8
26	152	152	O	,
27	154	161	O	moderate
28	164	168	O	Child
29	170	173	O	Pugh
30	175	175	O	B
31	176	176	O	,
32	178	178	O	n
33	180	180	O	=
34	182	182	O	8
35	184	184	O	,
36	186	188	O	and
37	190	195	O	severe
38	198	202	O	Child
39	204	207	O	Pugh
40	209	209	O	C
41	210	210	O	,
42	212	212	O	n
43	214	214	O	=
44	216	216	O	8
45	219	225	O	hepatic
46	227	236	O	impairment
47	238	240	O	and
48	242	243	O	to
49	245	251	O	healthy
50	253	260	O	subjects
51	263	263	O	n
52	265	265	O	=
53	267	268	O	12
NULL

Pristiq	792	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	25
Average AUC was increased by approximately 31% and 35% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects.
1	0	6	O	Average
2	8	10	O	AUC
3	12	14	O	was
4	16	24	O	increased
5	26	27	O	by
6	29	41	O	approximately
7	43	45	O	31%
8	47	49	O	and
9	51	53	O	35%
10	55	56	O	in
11	58	65	O	patients
12	67	70	O	with
13	72	79	O	moderate
14	81	83	O	and
15	85	90	O	severe
16	92	98	O	hepatic
17	100	109	O	impairment
18	110	110	O	,
19	112	123	O	respectively
20	124	124	O	,
21	126	127	O	as
22	129	136	O	compared
23	138	139	O	to
24	141	147	O	healthy
25	149	156	O	subjects
NULL

Pristiq	793	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	17
Average AUC values were similar in subjects with mild hepatic impairment and healthy subjects (< 5% difference).
1	0	6	O	Average
2	8	10	O	AUC
3	12	17	O	values
4	19	22	O	were
5	24	30	O	similar
6	32	33	O	in
7	35	42	O	subjects
8	44	47	O	with
9	49	52	O	mild
10	54	60	O	hepatic
11	62	71	O	impairment
12	73	75	O	and
13	77	83	O	healthy
14	85	92	O	subjects
15	95	95	O	<
16	97	98	O	5%
17	100	109	O	difference
NULL

Pristiq	794	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	28
Systemic clearance (CL/F) was decreased by approximately 20% and 36% in patients with moderate and severe hepatic impairment, respectively, as compared to healthy subjects.
1	0	7	O	Systemic
2	9	17	O	clearance
3	20	21	O	CL
4	22	22	O	/
5	23	23	O	F
6	26	28	O	was
7	30	38	O	decreased
8	40	41	O	by
9	43	55	O	approximately
10	57	59	O	20%
11	61	63	O	and
12	65	67	O	36%
13	69	70	O	in
14	72	79	O	patients
15	81	84	O	with
16	86	93	O	moderate
17	95	97	O	and
18	99	104	O	severe
19	106	112	O	hepatic
20	114	123	O	impairment
21	124	124	O	,
22	126	137	O	respectively
23	138	138	O	,
24	140	141	O	as
25	143	150	O	compared
26	152	153	O	to
27	155	161	O	healthy
28	163	170	O	subjects
NULL

Pristiq	795	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	16
CL/F values were comparable in mild hepatic impairment and healthy subjects (< 5% difference).
1	0	1	O	CL
2	2	2	O	/
3	3	3	O	F
4	5	10	O	values
5	12	15	O	were
6	17	26	O	comparable
7	28	29	O	in
8	31	34	O	mild
9	36	42	O	hepatic
10	44	53	O	impairment
11	55	57	O	and
12	59	65	O	healthy
13	67	74	O	subjects
14	77	77	O	<
15	79	80	O	5%
16	82	91	O	difference
NULL

Pristiq	796	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	32
The mean t1/2 changed from approximately 10 hours in healthy subjects and subjects with mild hepatic impairment to 13 and 14 hours in moderate and severe hepatic impairment, respectively.
1	0	2	O	The
2	4	7	O	mean
3	9	10	O	t1
4	11	11	O	/
5	12	12	O	2
6	14	20	O	changed
7	22	25	O	from
8	27	39	O	approximately
9	41	42	O	10
10	44	48	O	hours
11	50	51	O	in
12	53	59	O	healthy
13	61	68	O	subjects
14	70	72	O	and
15	74	81	O	subjects
16	83	86	O	with
17	88	91	O	mild
18	93	99	O	hepatic
19	101	110	O	impairment
20	112	113	O	to
21	115	116	O	13
22	118	120	O	and
23	122	123	O	14
24	125	129	O	hours
25	131	132	O	in
26	134	141	O	moderate
27	143	145	O	and
28	147	152	O	severe
29	154	160	O	hepatic
30	162	171	O	impairment
31	172	172	O	,
32	174	185	O	respectively
NULL

Pristiq	797	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	13
The recommended dose in patients with hepatic impairment is 50 mg per day.
1	0	2	O	The
2	4	14	O	recommended
3	16	19	O	dose
4	21	22	O	in
5	24	31	O	patients
6	33	36	O	with
7	38	44	O	hepatic
8	46	55	O	impairment
9	57	58	O	is
10	60	61	O	50
11	63	64	O	mg
12	66	68	O	per
13	70	72	O	day
NULL

Pristiq	798	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	10
Dose escalation above 100 mg per day is not recommended.
1	0	3	O	Dose
2	5	14	O	escalation
3	16	20	O	above
4	22	24	O	100
5	26	27	O	mg
6	29	31	O	per
7	33	35	O	day
8	37	38	O	is
9	40	42	O	not
10	44	54	O	recommended
NULL

Pristiq	799	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	52
Renal insufficiency The disposition of desvenlafaxine after administration of 100 mg was studied in subjects with mild (n = 9), moderate (n = 8), severe (n = 7) and end-stage renal disease (ESRD) (n = 9) requiring dialysis and in healthy, age-matched control subjects (n = 8).
1	0	4	O	Renal
2	6	18	O	insufficiency
3	20	22	O	The
4	24	34	O	disposition
5	36	37	O	of
6	39	52	O	XXXXXXXX
7	54	58	O	after
8	60	73	O	administration
9	75	76	O	of
10	78	80	O	100
11	82	83	O	mg
12	85	87	O	was
13	89	95	O	studied
14	97	98	O	in
15	100	107	O	subjects
16	109	112	O	with
17	114	117	O	mild
18	120	120	O	n
19	122	122	O	=
20	124	124	O	9
21	126	126	O	,
22	128	135	O	moderate
23	138	138	O	n
24	140	140	O	=
25	142	142	O	8
26	144	144	O	,
27	146	151	O	severe
28	154	154	O	n
29	156	156	O	=
30	158	158	O	7
31	161	163	O	and
32	165	167	O	end
33	169	173	O	stage
34	175	179	O	renal
35	181	187	O	disease
36	190	193	O	ESRD
37	197	197	O	n
38	199	199	O	=
39	201	201	O	9
40	204	212	O	requiring
41	214	221	O	dialysis
42	223	225	O	and
43	227	228	O	in
44	230	236	O	healthy
45	237	237	O	,
46	239	241	O	age
47	243	249	O	matched
48	251	257	O	control
49	259	266	O	subjects
50	269	269	O	n
51	271	271	O	=
52	273	273	O	8
NULL

Pristiq	800	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	7
Elimination was significantly correlated with creatinine clearance.
1	0	10	O	Elimination
2	12	14	O	was
3	16	28	O	significantly
4	30	39	O	correlated
5	41	44	O	with
6	46	55	O	creatinine
7	57	65	O	clearance
NULL

Pristiq	801	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	80
Increases in AUCs of about 42% in mild renal impairment (24-hr CrCl = 50 to 80 mL/min, Cockcroft-Gault [C-G]), about 56% in moderate renal impairment (24-hr CrCl = 30 to 50 mL/min, C-G), about 108% in severe renal impairment (24-hr CrCl <30 mL/min, C-G), and about 116% in ESRD subjects were observed, compared with healthy, age-matched control subjects.
1	0	8	O	Increases
2	10	11	O	in
3	13	16	O	AUCs
4	18	19	O	of
5	21	25	O	about
6	27	29	O	42%
7	31	32	O	in
8	34	37	O	mild
9	39	43	O	renal
10	45	54	O	impairment
11	57	58	O	24
12	60	61	O	hr
13	63	66	O	CrCl
14	68	68	O	=
15	70	71	O	50
16	73	74	O	to
17	76	77	O	80
18	79	80	O	mL
19	81	81	O	/
20	82	84	O	min
21	85	85	O	,
22	87	95	O	Cockcroft
23	97	101	O	Gault
24	104	104	O	C
25	106	106	O	GGGGGGGG
26	109	109	O	,
27	111	115	O	about
28	117	119	O	56%
29	121	122	O	in
30	124	131	O	moderate
31	133	137	O	renal
32	139	148	O	impairment
33	151	152	O	24
34	154	155	O	hr
35	157	160	O	CrCl
36	162	162	O	=
37	164	165	O	30
38	167	168	O	to
39	170	171	O	50
40	173	174	O	mL
41	175	175	O	/
42	176	178	O	min
43	179	179	O	,
44	181	181	O	C
45	183	183	O	GGGGGGGG
46	185	185	O	,
47	187	191	O	about
48	193	196	O	108%
49	198	199	O	in
50	201	206	O	severe
51	208	212	O	renal
52	214	223	O	impairment
53	226	227	O	24
54	229	230	O	hr
55	232	235	O	CrCl
56	237	239	O	<30
57	241	242	O	mL
58	243	243	O	/
59	244	246	O	min
60	247	247	O	,
61	249	249	O	C
62	251	251	O	GGGGGGGG
63	253	253	O	,
64	255	257	O	and
65	259	263	O	about
66	265	268	O	116%
67	270	271	O	in
68	273	276	O	ESRD
69	278	285	O	subjects
70	287	290	O	were
71	292	299	O	observed
72	300	300	O	,
73	302	309	O	compared
74	311	314	O	with
75	316	322	O	healthy
76	323	323	O	,
77	325	327	O	age
78	329	335	O	matched
79	337	343	O	control
80	345	352	O	subjects
NULL

Pristiq	802	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	41
The mean terminal half-life (t1/2) was prolonged from 11.1 hours in the control subjects to approximately 13.5, 15.5, 17.6, and 22.8 hours in mild, moderate, severe renal impairment and ESRD subjects, respectively.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	terminal
4	18	21	O	half
5	23	26	O	life
6	29	30	O	t1
7	31	31	O	/
8	32	32	O	2
9	35	37	O	was
10	39	47	O	prolonged
11	49	52	O	from
12	54	57	O	11.1
13	59	63	O	hours
14	65	66	O	in
15	68	70	O	the
16	72	78	O	control
17	80	87	O	subjects
18	89	90	O	to
19	92	104	O	approximately
20	106	109	O	13.5
21	110	110	O	,
22	112	115	O	15.5
23	116	116	O	,
24	118	121	O	17.6
25	122	122	O	,
26	124	126	O	and
27	128	131	O	22.8
28	133	137	O	hours
29	139	140	O	in
30	142	145	O	mild
31	146	146	O	,
32	148	155	O	moderate
33	156	156	O	,
34	158	163	O	severe
35	165	169	O	renal
36	171	180	O	impairment
37	182	184	O	and
38	186	189	O	ESRD
39	191	198	O	subjects
40	199	199	O	,
41	201	212	O	respectively
NULL

Pristiq	803	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Less than 5% of the drug in the body was cleared during a standard 4-hour hemodialysis procedure.
1	0	3	O	Less
2	5	8	O	than
3	10	11	O	5%
4	13	14	O	of
5	16	18	O	the
6	20	23	O	drug
7	25	26	O	in
8	28	30	O	the
9	32	35	O	body
10	37	39	O	was
11	41	47	O	cleared
12	49	54	O	during
13	56	56	O	a
14	58	65	O	standard
15	67	67	O	4
16	69	72	O	hour
17	74	85	O	hemodialysis
18	87	95	O	procedure
NULL

Pristiq	804	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	15
The maximum recommended dose in patients with moderate renal impairment is 50 mg per day.
1	0	2	O	The
2	4	10	O	maximum
3	12	22	O	recommended
4	24	27	O	dose
5	29	30	O	in
6	32	39	O	patients
7	41	44	O	with
8	46	53	O	moderate
9	55	59	O	renal
10	61	70	O	impairment
11	72	73	O	is
12	75	76	O	50
13	78	79	O	mg
14	81	83	O	per
15	85	87	O	day
NULL

Pristiq	805	34090-1	a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35	18
Dosage adjustment of 50 mg every other day is recommended in patients with severe renal impairment or ESRD.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	19	O	of
4	21	22	O	50
5	24	25	O	mg
6	27	31	O	every
7	33	37	O	other
8	39	41	O	day
9	43	44	O	is
10	46	56	O	recommended
11	58	59	O	in
12	61	68	O	patients
13	70	73	O	with
14	75	80	O	severe
15	82	86	O	renal
16	88	97	O	impairment
17	99	100	O	or
18	102	105	O	ESRD
NULL

Protriptyline Hydrochloride	903	34090-1	b8881a81-75d7-43e8-825f-37c352c146dc	5
Protriptyline hydrochloride is an antidepressant agent.
1	0	26	O	XXXXXXXX
2	28	29	O	is
3	31	32	O	an
4	34	47	O	antidepressant
5	49	53	O	agent
NULL

Protriptyline Hydrochloride	904	34090-1	b8881a81-75d7-43e8-825f-37c352c146dc	11
The mechanism of its antidepressant action in man is not known.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	19	O	its
5	21	34	O	antidepressant
6	36	41	O	action
7	43	44	O	in
8	46	48	O	man
9	50	51	O	is
10	53	55	O	not
11	57	61	O	known
NULL

Protriptyline Hydrochloride	905	34090-1	b8881a81-75d7-43e8-825f-37c352c146dc	21
It is not a monoamine oxidase inhibitor, and it does not act primarily by stimulation of the central nervous system.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	10	O	a
5	12	20	O	monoamine
6	22	28	O	oxidase
7	30	38	O	inhibitor
8	39	39	O	,
9	41	43	O	and
10	45	46	O	it
11	48	51	O	does
12	53	55	O	not
13	57	59	O	act
14	61	69	O	primarily
15	71	72	O	by
16	74	84	O	stimulation
17	86	87	O	of
18	89	91	O	the
19	93	99	O	central
20	101	107	O	nervous
21	109	114	O	system
NULL

Protriptyline Hydrochloride	906	34090-1	b8881a81-75d7-43e8-825f-37c352c146dc	19
Protriptyline has been found in some studies to have a more rapid onset of action than imipramine or amitriptyline.
1	0	12	O	XXXXXXXX
2	14	16	O	has
3	18	21	O	been
4	23	27	O	found
5	29	30	O	in
6	32	35	O	some
7	37	43	O	studies
8	45	46	O	to
9	48	51	O	have
10	53	53	O	a
11	55	58	O	more
12	60	64	O	rapid
13	66	70	O	onset
14	72	73	O	of
15	75	80	O	action
16	82	85	O	than
17	87	96	O	imipramine
18	98	99	O	or
19	101	113	O	amitriptyline
NULL

Protriptyline Hydrochloride	907	34090-1	b8881a81-75d7-43e8-825f-37c352c146dc	9
The initial clinical effect may occur within one week.
1	0	2	O	The
2	4	10	O	initial
3	12	19	O	clinical
4	21	26	O	effect
5	28	30	O	may
6	32	36	O	occur
7	38	43	O	within
8	45	47	O	one
9	49	52	O	week
NULL

Protriptyline Hydrochloride	908	34090-1	b8881a81-75d7-43e8-825f-37c352c146dc	6
Sedative and tranquilizing properties are lacking.
1	0	7	O	Sedative
2	9	11	O	and
3	13	25	O	tranquilizing
4	27	36	O	properties
5	38	40	O	are
6	42	48	O	lacking
NULL

Prozac	3721	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	25
As with all drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic drug inhibition or enhancement, etc.)
1	0	1	O	As
2	3	6	O	with
3	8	10	O	all
4	12	16	O	drugs
5	17	17	O	,
6	19	21	O	the
7	23	31	O	potential
8	33	35	O	for
9	37	47	O	interaction
10	49	50	O	by
11	52	52	O	a
12	54	60	O	variety
13	62	63	O	of
14	65	74	O	mechanisms
15	77	79	O	e.g
16	81	81	O	,
17	83	97	O	pharmacodynamic
18	98	98	O	,
19	100	114	O	pharmacokinetic
20	116	119	O	drug
21	121	130	O	inhibition
22	132	133	O	or
23	135	145	O	enhancement
24	146	146	O	,
25	148	150	O	etc
NULL

Prozac	3722	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	122
Monoamine Oxidase Inhibitors (MAOIs): (2.9, 2.10, 4.1, 5.2) Drugs Metabolized by CYP2D6: Fluoxetine is a potent inhibitor of CYP2D6 enzyme pathway (7.7) Tricyclic Antidepressants (TCAs): Monitor TCA levels during coadministration with PROZAC or when PROZAC has been recently discontinued (5.2, 7.7) CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs (7.2) Benzodiazepines: Diazepam - increased t%, alprazolam - further psychomotor performance decrement due to increased levels (7.7) Antipsychotics: Potential for elevation of haloperidol and clozapine levels (7.7) Anticonvulsants: Potential for elevated phenytoin and carbamazepine levels and clinical anticonvulsant toxicity (7.7) Serotonergic Drugs: (2.9, 2.10, 4.1, 5.2) Drugs that Interfere with Hemostasis(e.g.
1	0	8	O	Monoamine
2	10	16	O	Oxidase
3	18	27	O	Inhibitors
4	30	34	O	MAOIs
5	36	36	O	:
6	39	41	O	2.9
7	42	42	O	,
8	44	47	O	2.10
9	48	48	O	,
10	50	52	O	4.1
11	53	53	O	,
12	55	57	O	5.2
13	60	64	O	Drugs
14	66	76	O	Metabolized
15	78	79	O	by
16	81	86	O	CYP2D6
17	87	87	O	:
18	89	98	O	XXXXXXXX
19	100	101	O	is
20	103	103	O	a
21	105	110	O	potent
22	112	120	O	inhibitor
23	122	123	O	of
24	125	130	O	CYP2D6
25	132	137	O	enzyme
26	139	145	O	pathway
27	148	150	O	7.7
28	153	161	B-UNK	Tricyclic
29	163	177	L-UNK	Antidepressants
30	180	183	U-UNK	TCAs
31	185	185	O	:
32	187	193	U-TRI	Monitor
33	195	197	O	TCA
34	199	204	O	levels
35	206	211	O	during
36	213	228	O	coadministration
37	230	233	O	with
38	235	240	O	XXXXXXXX
39	242	243	O	or
40	245	248	O	when
41	250	255	O	XXXXXXXX
42	257	259	O	has
43	261	264	O	been
44	266	273	O	recently
45	275	286	O	discontinued
46	289	291	O	5.2
47	292	292	O	,
48	294	296	O	7.7
49	299	301	B-UNK	CNS
50	303	308	I-UNK	Acting
51	310	314	L-UNK	Drugs
52	315	315	O	:
53	317	323	U-TRI	Caution
54	325	330	O	should
55	332	333	O	be
56	335	338	O	used
57	340	343	O	when
58	345	349	O	taken
59	351	352	O	in
60	354	364	O	combination
61	366	369	O	with
62	371	375	O	other
63	377	385	B-UNK	centrally
64	387	392	I-UNK	acting
65	394	398	L-UNK	drugs
66	401	403	O	7.2
67	406	420	O	Benzodiazepines
68	421	421	O	:
69	423	430	U-KIN	Diazepam
70	434	442	B-TRI	increased
71	444	445	L-TRI	t%
72	446	446	O	,
73	448	457	U-DYN	alprazolam
74	461	467	B-EFF	further
75	469	479	I-EFF	psychomotor
76	481	491	I-EFF	performance
77	493	501	L-EFF	decrement
78	503	505	O	due
79	507	508	O	to
80	510	518	B-TRI	increased
81	520	525	L-TRI	levels
82	528	530	O	7.7
83	533	546	O	Antipsychotics
84	547	547	O	:
85	549	557	O	Potential
86	559	561	O	for
87	563	571	O	elevation
88	573	574	O	of
89	576	586	U-KIN	haloperidol
90	588	590	O	and
91	592	600	U-KIN	clozapine
92	602	607	O	levels
93	610	612	O	7.7
94	615	629	U-DYN	Anticonvulsants
95	630	630	O	:
96	632	640	O	Potential
97	642	644	O	for
98	646	653	O	elevated
99	655	663	U-KIN	phenytoin
100	665	667	O	and
101	669	681	U-KIN	carbamazepine
102	683	688	O	levels
103	690	692	O	and
104	694	701	B-EFF	clinical
105	703	716	I-EFF	anticonvulsant
106	718	725	L-EFF	toxicity
107	728	730	O	7.7
108	733	744	O	Serotonergic
109	746	750	O	Drugs
110	751	751	O	:
111	754	756	O	2.9
112	757	757	O	,
113	759	762	O	2.10
114	763	763	O	,
115	765	767	O	4.1
116	768	768	O	,
117	770	772	O	5.2
118	775	779	O	Drugs
119	781	784	O	that
120	786	794	O	Interfere
121	796	799	O	with
122	801	814	O	Hemostasis(e.g
D/73:104:0 D/73:74:1 D/94:104:1 D/94:74:0K/101:C54357 K/69:C54611 K/89:C54357 K/91:C54357 K/99:C54357

Prozac	3723	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	68
NSAIDs, Aspirin, Warfarin): May potentiate the risk of bleeding (7.4) Drugs Tightly Bound to Plasma Proteins: May cause a shift in plasma concentrations (7.6, 7.7) Olanzapine: When used in combination with PROZAC, also refer to the Drug Interactions section of the package insert for Symbyax (7.7) Drugs that Prolong the QT Interval: Do not use Prozac with thioridazine or pimozide.
1	0	5	U-DYN	NSAIDs
2	6	6	O	,
3	8	14	U-DYN	Aspirin
4	15	15	O	,
5	17	24	U-DYN	Warfarin
6	26	26	O	:
7	28	30	O	May
8	32	41	O	potentiate
9	43	45	O	the
10	47	50	O	risk
11	52	53	O	of
12	55	62	U-EFF	bleeding
13	65	67	O	7.4
14	70	74	B-UNK	Drugs
15	76	82	I-UNK	Tightly
16	84	88	I-UNK	Bound
17	90	91	I-UNK	to
18	93	98	I-UNK	Plasma
19	100	107	L-UNK	Proteins
20	108	108	O	:
21	110	112	O	May
22	114	118	O	cause
23	120	120	O	a
24	122	126	B-TRI	shift
25	128	129	I-TRI	in
26	131	136	I-TRI	plasma
27	138	151	L-TRI	concentrations
28	154	156	O	7.6
29	157	157	O	,
30	159	161	O	7.7
31	164	173	U-UNK	Olanzapine
32	174	174	O	:
33	176	179	O	When
34	181	184	O	used
35	186	187	O	in
36	189	199	O	combination
37	201	204	O	with
38	206	211	O	XXXXXXXX
39	212	212	O	,
40	214	217	O	also
41	219	223	O	refer
42	225	226	O	to
43	228	230	O	the
44	232	235	B-TRI	Drug
45	237	248	L-TRI	Interactions
46	250	256	O	section
47	258	259	O	of
48	261	263	O	the
49	265	271	O	package
50	273	278	O	insert
51	280	282	O	for
52	284	290	O	Symbyax
53	293	295	O	7.7
54	298	302	B-UNK	Drugs
55	304	307	I-UNK	that
56	309	315	I-UNK	Prolong
57	317	319	I-UNK	the
58	321	322	I-UNK	QT
59	324	331	L-UNK	Interval
60	332	332	O	:
61	334	335	B-TRI	Do
62	337	339	I-TRI	not
63	341	343	L-TRI	use
64	345	350	O	XXXXXXXX
65	352	355	O	with
66	357	368	U-UNK	thioridazine
67	370	371	O	or
68	373	380	U-UNK	pimozide
D/1:12:1 D/3:12:1 D/5:12:1

Prozac	3724	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	20
Use with caution in combination with other drugs that prolong the QT interval (4.2, 5.11, 7.7, 7.8).
1	0	2	O	Use
2	4	7	O	with
3	9	15	U-TRI	caution
4	17	18	O	in
5	20	30	O	combination
6	32	35	O	with
7	37	41	O	other
8	43	47	B-UNK	drugs
9	49	52	I-UNK	that
10	54	60	I-UNK	prolong
11	62	64	I-UNK	the
12	66	67	I-UNK	QT
13	69	76	L-UNK	interval
14	79	81	O	4.2
15	82	82	O	,
16	84	87	O	5.11
17	88	88	O	,
18	90	92	O	7.7
19	93	93	O	,
20	95	97	O	7.8
NULL

Prozac	3725	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
Caution is advised if the concomitant administration of PROZAC and such drugs is required.
1	0	6	O	Caution
2	8	9	O	is
3	11	17	O	advised
4	19	20	O	if
5	22	24	O	the
6	26	36	O	concomitant
7	38	51	O	administration
8	53	54	O	of
9	56	61	O	XXXXXXXX
10	63	65	O	and
11	67	70	O	such
12	72	76	O	drugs
13	78	79	O	is
14	81	88	O	required
NULL

Prozac	3726	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	30
In evaluating individual cases, consideration should be given to using lower initial doses of the concomitantly administered drugs, using conservative titration schedules, and monitoring of clinical status.
1	0	1	O	In
2	3	12	O	evaluating
3	14	23	O	individual
4	25	29	O	cases
5	30	30	O	,
6	32	44	O	consideration
7	46	51	O	should
8	53	54	O	be
9	56	60	O	given
10	62	63	O	to
11	65	69	O	using
12	71	75	O	lower
13	77	83	O	initial
14	85	89	O	doses
15	91	92	O	of
16	94	96	O	the
17	98	110	O	concomitantly
18	112	123	O	administered
19	125	129	O	drugs
20	130	130	O	,
21	132	136	O	using
22	138	149	O	conservative
23	151	159	O	titration
24	161	169	O	schedules
25	170	170	O	,
26	172	174	O	and
27	176	185	O	monitoring
28	187	188	O	of
29	190	197	O	clinical
30	199	204	O	status
NULL

Prozac	3728	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Prozac	3729	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	48
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	O	psychotropic
19	128	132	O	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	O	upper
30	201	216	O	gastrointestinal
31	218	225	U-EFF	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-DYN	NSAID
41	275	276	O	or
42	278	284	U-DYN	aspirin
43	286	288	O	may
44	290	299	O	potentiate
45	301	304	O	this
46	306	309	O	risk
47	311	312	O	of
48	314	321	O	bleeding
D/40:31:1 D/42:31:1

Prozac	3730	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Altered anticoagulant effects, including increased bleeding, have been reported when SNRIs or SSRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SNRIs
14	91	92	O	or
15	94	98	O	SSRIs
16	100	102	O	are
17	104	117	O	coadministered
18	119	122	O	with
19	124	131	U-DYN	warfarin
D/19:1:1 D/19:6:1

Prozac	3731	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
Patients receiving warfarin therapy should be carefully monitored when fluoxetine is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	B-TRI	should
6	43	44	I-TRI	be
7	46	54	I-TRI	carefully
8	56	64	L-TRI	monitored
9	66	69	O	when
10	71	80	O	XXXXXXXX
11	82	83	O	is
12	85	93	O	initiated
13	95	96	O	or
14	98	109	O	discontinued
NULL

Prozac	3732	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	16
There are no clinical studies establishing the benefit of the combined use of ECT and fluoxetine.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	20	O	clinical
5	22	28	O	studies
6	30	41	O	establishing
7	43	45	O	the
8	47	53	O	benefit
9	55	56	O	of
10	58	60	O	the
11	62	69	O	combined
12	71	73	O	use
13	75	76	O	of
14	78	80	O	ECT
15	82	84	O	and
16	86	95	O	XXXXXXXX
NULL

Prozac	3733	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	15
There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	19	O	rare
5	21	27	O	reports
6	29	30	O	of
7	32	40	B-EFF	prolonged
8	42	49	L-EFF	seizures
9	51	52	O	in
10	54	61	O	patients
11	63	64	O	on
12	66	75	O	XXXXXXXX
13	77	85	O	receiving
14	87	89	U-DYN	ECT
15	91	99	O	treatment
D/14:7:1

Prozac	3734	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	30
Drugs Tightly Bound to Plasma Proteins - Because fluoxetine is tightly bound to plasma proteins, adverse effects may result from displacement of protein-bound fluoxetine by other tightly-bound drugs.
1	0	4	B-UNK	Drugs
2	6	12	I-UNK	Tightly
3	14	18	I-UNK	Bound
4	20	21	I-UNK	to
5	23	28	I-UNK	Plasma
6	30	37	L-UNK	Proteins
7	41	47	O	Because
8	49	58	O	XXXXXXXX
9	60	61	O	is
10	63	69	O	tightly
11	71	75	O	bound
12	77	78	O	to
13	80	85	O	plasma
14	87	94	O	proteins
15	95	95	O	,
16	97	103	B-TRI	adverse
17	105	111	L-TRI	effects
18	113	115	O	may
19	117	122	O	result
20	124	127	O	from
21	129	140	B-EFF	displacement
22	142	143	I-EFF	of
23	145	151	I-EFF	protein
24	153	157	I-EFF	bound
25	159	168	L-EFF	XXXXXXXX
26	170	171	O	by
27	173	177	O	other
28	179	185	B-DYN	tightly
29	187	191	I-DYN	bound
30	193	197	L-DYN	drugs
D/28:21:1

Prozac	3735	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	9
Pimozide - Concomitant use in patients taking pimozide is contraindicated.
1	0	7	O	Pimozide
2	11	21	O	Concomitant
3	23	25	O	use
4	27	28	O	in
5	30	37	O	patients
6	39	44	O	taking
7	46	53	U-UNK	pimozide
8	55	56	O	is
9	58	72	U-TRI	contraindicated
NULL

Prozac	3736	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	11
Fluoxetine can increase the level of pimozide through inhibition of CYP2D6.
1	0	9	O	XXXXXXXX
2	11	13	O	can
3	15	22	B-TRI	increase
4	24	26	I-TRI	the
5	28	32	L-TRI	level
6	34	35	O	of
7	37	44	U-KIN	pimozide
8	46	52	O	through
9	54	63	O	inhibition
10	65	66	O	of
11	68	73	O	CYP2D6
K/7:C54357

Prozac	3737	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	7
Fluoxetine can also prolong the QT interval.
1	0	9	O	XXXXXXXX
2	11	13	O	can
3	15	18	O	also
4	20	26	O	prolong
5	28	30	O	the
6	32	33	O	QT
7	35	42	O	interval
NULL

Prozac	3738	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	15
Clinical studies of pimozide with other antidepressants demonstrate an increase in drug interaction or QTprolongation.
1	0	7	O	Clinical
2	9	15	O	studies
3	17	18	O	of
4	20	27	U-DYN	pimozide
5	29	32	O	with
6	34	38	O	other
7	40	54	O	antidepressants
8	56	66	O	demonstrate
9	68	69	O	an
10	71	78	O	increase
11	80	81	O	in
12	83	86	O	drug
13	88	98	O	interaction
14	100	101	O	or
15	103	116	U-EFF	QTprolongation
D/4:15:1

Prozac	3739	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	29
While a specific study with pimozide and fluoxetine has not been conducted, the potential for drug interactions or QTprolongation warrants restricting the concurrent use of pimozide and PROZAC.
1	0	4	O	While
2	6	6	O	a
3	8	15	O	specific
4	17	21	O	study
5	23	26	O	with
6	28	35	U-DYN	pimozide
7	37	39	O	and
8	41	50	O	XXXXXXXX
9	52	54	O	has
10	56	58	O	not
11	60	63	O	been
12	65	73	O	conducted
13	74	74	O	,
14	76	78	O	the
15	80	88	O	potential
16	90	92	O	for
17	94	97	O	drug
18	99	110	O	interactions
19	112	113	O	or
20	115	128	U-EFF	QTprolongation
21	130	137	O	warrants
22	139	149	O	restricting
23	151	153	O	the
24	155	164	O	concurrent
25	166	168	O	use
26	170	171	O	of
27	173	180	O	pimozide
28	182	184	O	and
29	186	191	O	XXXXXXXX
D/6:20:1

Prozac	3740	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	27
Thioridazine - Thioridazine should not be administered with PROZAC or within a minimum of 5weeks after PROZAC has been discontinued, because of the risk of QT Prolongation.
1	0	11	U-DYN	Thioridazine
2	15	26	O	Thioridazine
3	28	33	O	should
4	35	37	O	not
5	39	40	O	be
6	42	53	O	administered
7	55	58	O	with
8	60	65	O	XXXXXXXX
9	67	68	O	or
10	70	75	O	within
11	77	77	O	a
12	79	85	O	minimum
13	87	88	O	of
14	90	95	O	5weeks
15	97	101	O	after
16	103	108	O	XXXXXXXX
17	110	112	O	has
18	114	117	O	been
19	119	130	O	discontinued
20	131	131	O	,
21	133	139	O	because
22	141	142	O	of
23	144	146	O	the
24	148	151	O	risk
25	153	154	O	of
26	156	157	B-EFF	QT
27	159	170	L-EFF	Prolongation
D/1:26:1

Prozac	3741	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	50
In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	19
6	17	23	O	healthy
7	25	28	O	male
8	30	37	O	subjects
9	38	38	O	,
10	40	44	O	which
11	46	53	O	included
12	55	55	O	6
13	57	60	O	slow
14	62	64	O	and
15	66	67	O	13
16	69	73	O	rapid
17	75	87	O	hydroxylators
18	89	90	O	of
19	92	102	O	debrisoquin
20	103	103	O	,
21	105	105	O	a
22	107	112	O	single
23	114	115	O	25
24	117	118	O	mg
25	120	123	O	oral
26	125	128	O	dose
27	130	131	O	of
28	133	144	U-KIN	thioridazine
29	146	153	O	produced
30	155	155	O	a
31	157	159	O	2.4
32	161	164	O	fold
33	166	171	B-TRI	higher
34	173	176	L-TRI	Cmax
35	178	180	O	and
36	182	182	O	a
37	184	186	O	4.5
38	188	191	O	fold
39	193	198	B-TRI	higher
40	200	202	L-TRI	AUC
41	204	206	O	for
42	208	219	O	thioridazine
43	221	222	O	in
44	224	226	O	the
45	228	231	O	slow
46	233	245	O	hydroxylators
47	247	254	O	compared
48	256	257	O	to
49	259	263	O	rapid
50	265	277	O	hydroxylators
K/28:C54610

Prozac	3742	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	16
The rate of debrisoquin hydroxylation is felt to depend on the level of CYP2D6 isozyme activity.
1	0	2	O	The
2	4	7	O	rate
3	9	10	O	of
4	12	22	O	debrisoquin
5	24	36	O	hydroxylation
6	38	39	O	is
7	41	44	O	felt
8	46	47	O	to
9	49	54	O	depend
10	56	57	O	on
11	59	61	O	the
12	63	67	O	level
13	69	70	O	of
14	72	77	O	CYP2D6
15	79	85	O	isozyme
16	87	94	O	activity
NULL

Prozac	3743	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	26
Thus, this study suggests that drugs which inhibit CYP2D6, such as certain SSRIs, including fluoxetine, will produce elevated plasma levels of thioridazine.
1	0	3	O	Thus
2	4	4	O	,
3	6	9	O	this
4	11	15	O	study
5	17	24	O	suggests
6	26	29	O	that
7	31	35	O	drugs
8	37	41	O	which
9	43	49	O	inhibit
10	51	56	O	CYP2D6
11	57	57	O	,
12	59	62	O	such
13	64	65	O	as
14	67	73	O	certain
15	75	79	O	SSRIs
16	80	80	O	,
17	82	90	O	including
18	92	101	O	XXXXXXXX
19	102	102	O	,
20	104	107	O	will
21	109	115	O	produce
22	117	124	B-TRI	elevated
23	126	131	I-TRI	plasma
24	133	138	L-TRI	levels
25	140	141	O	of
26	143	154	U-KIN	thioridazine
K/26:C54357

Prozac	3744	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	29
Thioridazine administration produces a dose-related prolongation of the QT interval, which is associated with serious ventricular arrhythmias, such as TorsadesdePointes-type arrhythmias, and sudden death.
1	0	11	U-DYN	Thioridazine
2	13	26	O	administration
3	28	35	O	produces
4	37	37	O	a
5	39	42	O	dose
6	44	50	O	related
7	52	63	B-EFF	prolongation
8	65	66	I-EFF	of
9	68	70	I-EFF	the
10	72	73	I-EFF	QT
11	75	82	L-EFF	interval
12	83	83	O	,
13	85	89	O	which
14	91	92	O	is
15	94	103	O	associated
16	105	108	O	with
17	110	116	B-EFF	serious
18	118	128	I-EFF	ventricular
19	130	140	L-EFF	arrhythmias
20	141	141	O	,
21	143	146	O	such
22	148	149	O	as
23	151	167	B-EFF	TorsadesdePointes
24	169	172	I-EFF	type
25	174	184	L-EFF	arrhythmias
26	185	185	O	,
27	187	189	O	and
28	191	196	B-EFF	sudden
29	198	202	L-EFF	death
D/1:17:1 D/1:23:1 D/1:28:1 D/1:7:1

Prozac	3745	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	13
This risk is expected to increase with fluoxetine-induced inhibition of thioridazine metabolism.
1	0	3	O	This
2	5	8	O	risk
3	10	11	O	is
4	13	20	O	expected
5	22	23	O	to
6	25	32	O	increase
7	34	37	O	with
8	39	48	O	XXXXXXXX
9	50	56	O	induced
10	58	67	O	inhibition
11	69	70	O	of
12	72	83	U-KIN	thioridazine
13	85	94	O	metabolism
K/12:C54357

Prozac	3746	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	24
Drugs Metabolized by CYP2D6 - Fluoxetine inhibits the activity of CYP2D6, and may make individuals with normal CYP2D6 metabolic activity resemble a poor metabolizer.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	26	O	CYP2D6
5	30	39	O	XXXXXXXX
6	41	48	O	inhibits
7	50	52	O	the
8	54	61	O	activity
9	63	64	O	of
10	66	71	O	CYP2D6
11	72	72	O	,
12	74	76	O	and
13	78	80	O	may
14	82	85	O	make
15	87	97	O	individuals
16	99	102	O	with
17	104	109	O	normal
18	111	116	O	CYP2D6
19	118	126	O	metabolic
20	128	135	O	activity
21	137	144	O	resemble
22	146	146	O	a
23	148	151	O	poor
24	153	163	O	metabolizer
NULL

Prozac	3747	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	42
Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	O	XXXXXXXX
4	31	34	O	with
5	36	40	O	other
6	42	46	B-UNK	drugs
7	48	51	I-UNK	that
8	53	55	I-UNK	are
9	57	67	I-UNK	metabolized
10	69	70	I-UNK	by
11	72	77	L-UNK	CYP2D6
12	78	78	O	,
13	80	88	O	including
14	90	96	B-UNK	certain
15	98	112	L-UNK	antidepressants
16	115	117	O	e.g
17	119	119	O	,
18	121	124	U-UNK	TCAs
19	126	126	O	,
20	128	141	U-UNK	antipsychotics
21	144	146	O	e.g
22	148	148	O	,
23	150	163	U-UNK	phenothiazines
24	165	167	O	and
25	169	172	O	most
26	174	182	O	atypicals
27	184	184	O	,
28	186	188	O	and
29	190	204	U-UNK	antiarrhythmics
30	207	209	O	e.g
31	211	211	O	,
32	213	223	U-UNK	propafenone
33	224	224	O	,
34	226	235	U-UNK	flecainide
35	236	236	O	,
36	238	240	O	and
37	242	247	O	others
38	250	255	O	should
39	257	258	O	be
40	260	269	O	approached
41	271	274	O	with
42	276	282	U-TRI	caution
NULL

Prozac	3748	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	45
Therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5weeks.
1	0	6	O	Therapy
2	8	11	O	with
3	13	23	B-KIN	medications
4	25	28	I-KIN	that
5	30	32	I-KIN	are
6	34	46	I-KIN	predominantly
7	48	58	I-KIN	metabolized
8	60	61	I-KIN	by
9	63	65	I-KIN	the
10	67	72	I-KIN	CYP2D6
11	74	79	I-KIN	system
12	81	83	I-KIN	and
13	85	88	I-KIN	that
14	90	93	I-KIN	have
15	95	95	I-KIN	a
16	97	106	I-KIN	relatively
17	108	113	I-KIN	narrow
18	115	125	I-KIN	therapeutic
19	127	131	L-KIN	index
20	133	138	O	should
21	140	141	O	be
22	143	151	O	initiated
23	153	154	O	at
24	156	158	O	the
25	160	162	O	low
26	164	166	O	end
27	168	169	O	of
28	171	173	O	the
29	175	178	O	dose
30	180	184	O	range
31	186	187	O	if
32	189	189	O	a
33	191	197	O	patient
34	199	200	O	is
35	202	210	O	receiving
36	212	221	O	XXXXXXXX
37	223	234	O	concurrently
38	236	237	O	or
39	239	241	O	has
40	243	247	O	taken
41	249	250	O	it
42	252	253	O	in
43	255	257	O	the
44	259	266	O	previous
45	268	273	O	5weeks
K/3:C54357

Prozac	3749	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	12
Thus, his/her dosing requirements resemble those of poor metabolizers.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	his
4	9	9	O	/
5	10	12	O	her
6	14	19	O	dosing
7	21	32	O	requirements
8	34	41	O	resemble
9	43	47	O	those
10	49	50	O	of
11	52	55	O	poor
12	57	68	O	metabolizers
NULL

Prozac	3750	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	31
If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered.
1	0	1	O	If
2	3	12	O	XXXXXXXX
3	14	15	O	is
4	17	21	O	added
5	23	24	O	to
6	26	28	O	the
7	30	38	O	treatment
8	40	46	O	regimen
9	48	49	O	of
10	51	51	O	a
11	53	59	O	patient
12	61	67	O	already
13	69	77	O	receiving
14	79	79	O	a
15	81	84	B-KIN	drug
16	86	96	I-KIN	metabolized
17	98	99	I-KIN	by
18	101	106	L-KIN	CYP2D6
19	107	107	O	,
20	109	111	O	the
21	113	116	O	need
22	118	120	O	for
23	122	130	B-TRI	decreased
24	132	135	L-TRI	dose
25	137	138	O	of
26	140	142	O	the
27	144	151	O	original
28	153	162	O	medication
29	164	169	O	should
30	171	172	O	be
31	174	183	O	considered
K/15:C54357

Prozac	3751	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	20
Drugs with a narrow therapeutic index represent the greatest concern (e.g., flecainide, propafenone, vinblastine, and TCAs).
1	0	4	B-UNK	Drugs
2	6	9	I-UNK	with
3	11	11	I-UNK	a
4	13	18	I-UNK	narrow
5	20	30	I-UNK	therapeutic
6	32	36	L-UNK	index
7	38	46	O	represent
8	48	50	O	the
9	52	59	O	greatest
10	61	67	U-TRI	concern
11	70	72	O	e.g
12	74	74	O	,
13	76	85	U-UNK	flecainide
14	86	86	O	,
15	88	98	U-UNK	propafenone
16	99	99	O	,
17	101	111	U-UNK	vinblastine
18	112	112	O	,
19	114	116	O	and
20	118	121	U-UNK	TCAs
NULL

Prozac	3752	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	38
Due to the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of thioridazine, thioridazine should not be administered with fluoxetine or within a minimum of 5weeks after fluoxetine has been discontinued.
1	0	2	O	Due
2	4	5	O	to
3	7	9	O	the
4	11	14	O	risk
5	16	17	O	of
6	19	25	B-EFF	serious
7	27	37	I-EFF	ventricular
8	39	49	L-EFF	arrhythmias
9	51	53	O	and
10	55	60	B-EFF	sudden
11	62	66	L-EFF	death
12	68	78	O	potentially
13	80	89	O	associated
14	91	94	O	with
15	96	103	B-TRI	elevated
16	105	110	I-TRI	plasma
17	112	117	L-TRI	levels
18	119	120	O	of
19	122	133	U-DYN	thioridazine
20	134	134	O	,
21	136	147	O	thioridazine
22	149	154	O	should
23	156	158	O	not
24	160	161	O	be
25	163	174	O	administered
26	176	179	O	with
27	181	190	O	XXXXXXXX
28	192	193	O	or
29	195	200	O	within
30	202	202	O	a
31	204	210	O	minimum
32	212	213	O	of
33	215	220	O	5weeks
34	222	226	O	after
35	228	237	O	XXXXXXXX
36	239	241	O	has
37	243	246	O	been
38	248	259	O	discontinued
D/19:10:1 D/19:6:1

Prozac	3753	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	29
Tricyclic Antidepressants (TCAs) - In 2studies, previously stable plasma levels of imipramine and desipramine have increased greater than 2- to 10-fold when fluoxetine has been administered in combination.
1	0	8	B-KIN	Tricyclic
2	10	24	L-KIN	Antidepressants
3	27	30	U-KIN	TCAs
4	35	36	O	In
5	38	45	O	2studies
6	46	46	O	,
7	48	57	O	previously
8	59	64	O	stable
9	66	71	O	plasma
10	73	78	O	levels
11	80	81	O	of
12	83	92	U-KIN	imipramine
13	94	96	O	and
14	98	108	U-KIN	desipramine
15	110	113	O	have
16	115	123	O	increased
17	125	131	O	greater
18	133	136	O	than
19	138	138	O	2
20	141	142	O	to
21	144	145	O	10
22	147	150	O	fold
23	152	155	O	when
24	157	166	O	XXXXXXXX
25	168	170	O	has
26	172	175	O	been
27	177	188	O	administered
28	190	191	O	in
29	193	203	O	combination
K/1:C54357 K/12:C54357 K/14:C54357 K/3:C54357

Prozac	3754	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	12
This influence may persist for 3weeks or longer after fluoxetine is discontinued.
1	0	3	O	This
2	5	13	O	influence
3	15	17	O	may
4	19	25	O	persist
5	27	29	O	for
6	31	36	O	3weeks
7	38	39	O	or
8	41	46	O	longer
9	48	52	O	after
10	54	63	O	XXXXXXXX
11	65	66	O	is
12	68	79	O	discontinued
NULL

Prozac	3755	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	30
Thus, the dose of TCAs may need to be reduced and plasma TCA concentrations may need to be monitored temporarily when fluoxetine is coadministered or has been recently discontinued.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	13	O	dose
5	15	16	O	of
6	18	21	U-KIN	TCAs
7	23	25	O	may
8	27	30	O	need
9	32	33	O	to
10	35	36	O	be
11	38	44	O	reduced
12	46	48	O	and
13	50	55	O	plasma
14	57	59	O	TCA
15	61	74	O	concentrations
16	76	78	O	may
17	80	83	O	need
18	85	86	O	to
19	88	89	O	be
20	91	99	O	monitored
21	101	111	O	temporarily
22	113	116	O	when
23	118	127	O	XXXXXXXX
24	129	130	O	is
25	132	145	O	coadministered
26	147	148	O	or
27	150	152	O	has
28	154	157	O	been
29	159	166	O	recently
30	168	179	O	discontinued
K/6:C54357

Prozac	3756	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
Benzodiazepines - The half-life of concurrently administered diazepam may be prolonged in some patients.
1	0	14	O	Benzodiazepines
2	18	20	O	The
3	22	25	O	half
4	27	30	O	life
5	32	33	O	of
6	35	46	O	concurrently
7	48	59	O	administered
8	61	68	U-KIN	diazepam
9	70	72	O	may
10	74	75	O	be
11	77	85	O	prolonged
12	87	88	O	in
13	90	93	O	some
14	95	102	O	patients
K/8:C54611

Prozac	3757	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	23
Coadministration of alprazolam and fluoxetine has resulted in increased alprazolam plasma concentrations and in further psychomotor performance decrement due to increased alprazolam levels.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-DYN	alprazolam
4	31	33	O	and
5	35	44	O	XXXXXXXX
6	46	48	O	has
7	50	57	O	resulted
8	59	60	O	in
9	62	70	O	increased
10	72	81	O	alprazolam
11	83	88	O	plasma
12	90	103	O	concentrations
13	105	107	O	and
14	109	110	O	in
15	112	118	B-EFF	further
16	120	130	I-EFF	psychomotor
17	132	142	I-EFF	performance
18	144	152	L-EFF	decrement
19	154	156	O	due
20	158	159	O	to
21	161	169	O	increased
22	171	180	O	alprazolam
23	182	187	O	levels
D/3:15:1

Prozac	3758	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	17
Antipsychotics - Some clinical data suggests a possible pharmacodynamic and/or pharmacokinetic interaction between SSRIs and antipsychotics.
1	0	13	O	Antipsychotics
2	17	20	O	Some
3	22	29	O	clinical
4	31	34	O	data
5	36	43	O	suggests
6	45	45	O	a
7	47	54	O	possible
8	56	70	B-TRI	pharmacodynamic
9	72	74	I-TRI	and
10	75	75	I-TRI	/
11	76	77	I-TRI	or
12	79	93	I-TRI	pharmacokinetic
13	95	105	L-TRI	interaction
14	107	113	O	between
15	115	119	O	SSRIs
16	121	123	O	and
17	125	138	U-UNK	antipsychotics
NULL

Prozac	3759	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	16
Elevation of blood levels of haloperidol and clozapine has been observed in patients receiving concomitant fluoxetine.
1	0	8	B-TRI	Elevation
2	10	11	I-TRI	of
3	13	17	I-TRI	blood
4	19	24	L-TRI	levels
5	26	27	O	of
6	29	39	U-KIN	haloperidol
7	41	43	O	and
8	45	53	U-KIN	clozapine
9	55	57	O	has
10	59	62	O	been
11	64	71	O	observed
12	73	74	O	in
13	76	83	O	patients
14	85	93	O	receiving
15	95	105	O	concomitant
16	107	116	O	XXXXXXXX
K/6:C54357 K/8:C54357

Prozac	3760	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	25
Anticonvulsants - Patients on stable doses of phenytoin and carbamazepine have developed elevated plasma anticonvulsant concentrations and clinical anticonvulsant toxicity following initiation of concomitant fluoxetine treatment.
1	0	14	U-DYN	Anticonvulsants
2	18	25	O	Patients
3	27	28	O	on
4	30	35	O	stable
5	37	41	O	doses
6	43	44	O	of
7	46	54	U-DYN	phenytoin
8	56	58	O	and
9	60	72	U-DYN	carbamazepine
10	74	77	O	have
11	79	87	O	developed
12	89	96	O	elevated
13	98	103	O	plasma
14	105	118	U-DYN	anticonvulsant
15	120	133	O	concentrations
16	135	137	O	and
17	139	146	B-EFF	clinical
18	148	161	I-EFF	anticonvulsant
19	163	170	L-EFF	toxicity
20	172	180	O	following
21	182	191	O	initiation
22	193	194	O	of
23	196	206	O	concomitant
24	208	217	O	XXXXXXXX
25	219	227	O	treatment
D/1:17:1 D/14:17:1 D/7:17:1 D/9:17:1

Prozac	3761	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Lithium - There have been reports of both increased and decreased lithium levels when lithium was used concomitantly with fluoxetine.
1	0	6	O	Lithium
2	10	14	O	There
3	16	19	O	have
4	21	24	O	been
5	26	32	O	reports
6	34	35	O	of
7	37	40	O	both
8	42	50	O	increased
9	52	54	O	and
10	56	64	O	decreased
11	66	72	U-KIN	lithium
12	74	79	O	levels
13	81	84	O	when
14	86	92	O	lithium
15	94	96	O	was
16	98	101	O	used
17	103	115	O	concomitantly
18	117	120	O	with
19	122	131	O	XXXXXXXX
K/11:C54357

Prozac	3762	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	11
Cases of lithium toxicity and increased serotonergic effects have been reported.
1	0	4	O	Cases
2	6	7	O	of
3	9	15	U-DYN	lithium
4	17	24	U-EFF	toxicity
5	26	28	O	and
6	30	38	B-EFF	increased
7	40	51	I-EFF	serotonergic
8	53	59	L-EFF	effects
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
D/3:4:1 D/3:6:1

Prozac	3763	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	11
Lithium levels should be monitored when these drugs are administered concomitantly.
1	0	6	U-UNK	Lithium
2	8	13	O	levels
3	15	20	B-TRI	should
4	22	23	I-TRI	be
5	25	33	L-TRI	monitored
6	35	38	O	when
7	40	44	O	these
8	46	50	O	drugs
9	52	54	O	are
10	56	67	O	administered
11	69	81	O	concomitantly
NULL

Prozac	3764	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	49
Drugs Tightly Bound to Plasma Proteins - Because fluoxetine is tightly bound to plasma proteins, the administration of fluoxetine to a patient taking another drug that is tightly bound to protein (e.g., Coumadin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect.
1	0	4	B-UNK	Drugs
2	6	12	I-UNK	Tightly
3	14	18	I-UNK	Bound
4	20	21	I-UNK	to
5	23	28	I-UNK	Plasma
6	30	37	L-UNK	Proteins
7	41	47	O	Because
8	49	58	O	XXXXXXXX
9	60	61	O	is
10	63	69	O	tightly
11	71	75	O	bound
12	77	78	O	to
13	80	85	O	plasma
14	87	94	O	proteins
15	95	95	O	,
16	97	99	O	the
17	101	114	O	administration
18	116	117	O	of
19	119	128	O	XXXXXXXX
20	130	131	O	to
21	133	133	O	a
22	135	141	O	patient
23	143	148	O	taking
24	150	156	O	another
25	158	161	B-UNK	drug
26	163	166	I-UNK	that
27	168	169	I-UNK	is
28	171	177	I-UNK	tightly
29	179	183	I-UNK	bound
30	185	186	I-UNK	to
31	188	194	L-UNK	protein
32	197	199	O	e.g
33	201	201	O	,
34	203	210	U-UNK	Coumadin
35	211	211	O	,
36	213	221	U-UNK	digitoxin
37	224	226	O	may
38	228	232	O	cause
39	234	234	O	a
40	236	240	B-TRI	shift
41	242	243	I-TRI	in
42	245	250	I-TRI	plasma
43	252	265	L-TRI	concentrations
44	267	277	O	potentially
45	279	287	O	resulting
46	289	290	O	in
47	292	293	O	an
48	295	301	O	adverse
49	303	308	O	effect
NULL

Prozac	3765	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	32
Drugs Metabolized by CYP3A4 - In an invivo interaction study involving coadministration of fluoxetine with single doses of terfenadine (a CYP3A4 substrate), no increase in plasma terfenadine concentrations occurred with concomitant fluoxetine.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	26	O	CYP3A4
5	30	31	O	In
6	33	34	O	an
7	36	41	O	invivo
8	43	53	O	interaction
9	55	59	O	study
10	61	69	O	involving
11	71	86	O	coadministration
12	88	89	O	of
13	91	100	O	XXXXXXXX
14	102	105	O	with
15	107	112	O	single
16	114	118	O	doses
17	120	121	O	of
18	123	133	O	terfenadine
19	136	136	O	a
20	138	143	O	CYP3A4
21	145	153	O	substrate
22	155	155	O	,
23	157	158	O	no
24	160	167	O	increase
25	169	170	O	in
26	172	177	O	plasma
27	179	189	O	terfenadine
28	191	204	O	concentrations
29	206	213	O	occurred
30	215	218	O	with
31	220	230	O	concomitant
32	232	241	O	XXXXXXXX
NULL

Prozac	3766	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	47
Additionally, invitro studies have shown ketoconazole, a potent inhibitor of CYP3A4 activity, to be at least 100times more potent than fluoxetine or norfluoxetine as an inhibitor of the metabolism of several substrates for this enzyme, including astemizole, cisapride, and midazolam.
1	0	11	O	Additionally
2	12	12	O	,
3	14	20	O	invitro
4	22	28	O	studies
5	30	33	O	have
6	35	39	O	shown
7	41	52	O	ketoconazole
8	53	53	O	,
9	55	55	O	a
10	57	62	O	potent
11	64	72	O	inhibitor
12	74	75	O	of
13	77	82	O	CYP3A4
14	84	91	O	activity
15	92	92	O	,
16	94	95	O	to
17	97	98	O	be
18	100	101	O	at
19	103	107	O	least
20	109	116	O	100times
21	118	121	O	more
22	123	128	O	potent
23	130	133	O	than
24	135	144	O	XXXXXXXX
25	146	147	O	or
26	149	151	O	nor
27	152	161	O	XXXXXXXX
28	163	164	O	as
29	166	167	O	an
30	169	177	O	inhibitor
31	179	180	O	of
32	182	184	O	the
33	186	195	O	metabolism
34	197	198	O	of
35	200	206	O	several
36	208	217	O	substrates
37	219	221	O	for
38	223	226	O	this
39	228	233	O	enzyme
40	234	234	O	,
41	236	244	O	including
42	246	255	O	astemizole
43	256	256	O	,
44	258	266	O	cisapride
45	267	267	O	,
46	269	271	O	and
47	273	281	O	midazolam
NULL

Prozac	3767	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	20
These data indicate that fluoxetine's extent of inhibition of CYP3A4 activity is not likely to be of clinical significance.
1	0	4	O	These
2	6	9	O	data
3	11	18	O	indicate
4	20	23	O	that
5	25	34	O	XXXXXXXX
6	35	36	O	's
7	38	43	O	extent
8	45	46	O	of
9	48	57	O	inhibition
10	59	60	O	of
11	62	67	O	CYP3A4
12	69	76	O	activity
13	78	79	O	is
14	81	83	O	not
15	85	90	O	likely
16	92	93	O	to
17	95	96	O	be
18	98	99	O	of
19	101	108	O	clinical
20	110	121	O	significance
NULL

Prozac	3768	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	34
Olanzapine - Fluoxetine (60mg single dose or 60 mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.
1	0	9	O	Olanzapine
2	13	22	O	XXXXXXXX
3	25	28	O	60mg
4	30	35	O	single
5	37	40	O	dose
6	42	43	O	or
7	45	46	O	60
8	48	49	O	mg
9	51	55	O	daily
10	57	60	O	dose
11	62	64	O	for
12	66	66	O	8
13	68	71	O	days
14	74	79	O	causes
15	81	81	O	a
16	83	87	O	small
17	90	93	O	mean
18	95	97	O	16%
19	100	107	B-TRI	increase
20	109	110	I-TRI	in
21	112	114	I-TRI	the
22	116	122	I-TRI	maximum
23	124	136	L-TRI	concentration
24	138	139	O	of
25	141	150	U-KIN	olanzapine
26	152	154	O	and
27	156	156	O	a
28	158	162	O	small
29	165	168	O	mean
30	170	172	O	16%
31	175	182	O	decrease
32	184	185	O	in
33	187	196	O	olanzapine
34	198	206	O	clearance
K/25:C54357

Prozac	3769	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	27
The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	19	O	the
5	21	26	O	impact
6	28	29	O	of
7	31	34	O	this
8	36	41	O	factor
9	43	44	O	is
10	46	50	O	small
11	52	53	O	in
12	55	64	O	comparison
13	66	67	O	to
14	69	71	O	the
15	73	79	O	overall
16	81	91	O	variability
17	93	99	O	between
18	101	111	O	individuals
19	112	112	O	,
20	114	116	O	and
21	118	126	O	therefore
22	128	131	O	dose
23	133	144	O	modification
24	146	147	O	is
25	149	151	O	not
26	153	161	O	routinely
27	163	173	O	recommended
NULL

Prozac	3770	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	22
When using PROZAC and olanzapine and in combination, also refer to the Drug Interactions section of the package insert for Symbyax.
1	0	3	O	When
2	5	9	O	using
3	11	16	O	XXXXXXXX
4	18	20	O	and
5	22	31	U-UNK	olanzapine
6	33	35	O	and
7	37	38	O	in
8	40	50	O	combination
9	51	51	O	,
10	53	56	O	also
11	58	62	O	refer
12	64	65	O	to
13	67	69	O	the
14	71	74	B-TRI	Drug
15	76	87	L-TRI	Interactions
16	89	95	O	section
17	97	98	O	of
18	100	102	O	the
19	104	110	O	package
20	112	117	O	insert
21	119	121	O	for
22	123	129	O	Symbyax
NULL

Prozac	3771	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Do not use PROZAC in combination with thioridazine or pimozide.
1	0	1	B-TRI	Do
2	3	5	I-TRI	not
3	7	9	L-TRI	use
4	11	16	O	XXXXXXXX
5	18	19	O	in
6	21	31	O	combination
7	33	36	O	with
8	38	49	U-UNK	thioridazine
9	51	52	O	or
10	54	61	U-UNK	pimozide
NULL

Prozac	3772	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	13
Use PROZAC with caution in combination with other drugs that cause QT prolongation.
1	0	2	O	Use
2	4	9	O	XXXXXXXX
3	11	14	O	with
4	16	22	U-TRI	caution
5	24	25	O	in
6	27	37	O	combination
7	39	42	O	with
8	44	48	O	other
9	50	54	B-UNK	drugs
10	56	59	I-UNK	that
11	61	65	I-UNK	cause
12	67	68	I-UNK	QT
13	70	81	L-UNK	prolongation
NULL

Prozac	3773	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	65
These include: specific antipsychotics (e.g., ziprasidone, iloperidone, chlorpromazine, mesoridazine, droperidol); specific antibiotics (e.g., erythromycin, gatifloxacin, moxifloxacin, sparfloxacin); Class 1A antiarrhythmic medications (e.g., quinidine, procainamide); Class III antiarrhythmics (e.g., amiodarone, sotalol); and others (e.g., pentamidine, levomethadyl acetate, methadone, halofantrine, mefloquine, dolasetron mesylate, probucol or tacrolimus).
1	0	4	O	These
2	6	12	O	include
3	13	13	O	:
4	15	22	O	specific
5	24	37	O	antipsychotics
6	40	42	O	e.g
7	44	44	O	,
8	46	56	O	ziprasidone
9	57	57	O	,
10	59	69	O	iloperidone
11	70	70	O	,
12	72	85	O	chlorpromazine
13	86	86	O	,
14	88	99	O	mesoridazine
15	100	100	O	,
16	102	111	O	droperidol
17	115	122	O	specific
18	124	134	O	antibiotics
19	137	139	O	e.g
20	141	141	O	,
21	143	154	O	erythromycin
22	155	155	O	,
23	157	168	O	gatifloxacin
24	169	169	O	,
25	171	182	O	moxifloxacin
26	183	183	O	,
27	185	196	O	sparfloxacin
28	200	204	O	Class
29	206	207	O	1A
30	209	222	O	antiarrhythmic
31	224	234	O	medications
32	237	239	O	e.g
33	241	241	O	,
34	243	251	O	quinidine
35	252	252	O	,
36	254	265	O	procainamide
37	269	273	O	Class
38	275	277	O	III
39	279	293	O	antiarrhythmics
40	296	298	O	e.g
41	300	300	O	,
42	302	311	O	amiodarone
43	312	312	O	,
44	314	320	O	sotalol
45	324	326	O	and
46	328	333	O	others
47	336	338	O	e.g
48	340	340	O	,
49	342	352	O	pentamidine
50	353	353	O	,
51	355	366	O	levomethadyl
52	368	374	O	acetate
53	375	375	O	,
54	377	385	O	methadone
55	386	386	O	,
56	388	399	O	halofantrine
57	400	400	O	,
58	402	411	O	mefloquine
59	412	412	O	,
60	414	423	O	dolasetron
61	425	432	O	mesylate
62	433	433	O	,
63	435	442	O	probucol
64	444	445	O	or
65	447	456	O	tacrolimus
NULL

Prozac	3774	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	6
PROZAC is primarily metabolized by CYP2D6.
1	0	5	O	XXXXXXXX
2	7	8	O	is
3	10	18	O	primarily
4	20	30	O	metabolized
5	32	33	O	by
6	35	40	O	CYP2D6
NULL

Prozac	3775	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	11
Concomitant treatment with CYP2D6 inhibitors can increase the concentration of PROZAC.
1	0	10	O	Concomitant
2	12	20	O	treatment
3	22	25	O	with
4	27	32	B-KIN	CYP2D6
5	34	43	L-KIN	inhibitors
6	45	47	O	can
7	49	56	B-TRI	increase
8	58	60	I-TRI	the
9	62	74	L-TRI	concentration
10	76	77	O	of
11	79	84	O	XXXXXXXX
K/4:C54355

Prozac	3776	34073-7	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
Concomitant use of other highly protein-bound drugs can increase the concentration of PROZAC.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	23	O	other
5	25	30	B-KIN	highly
6	32	38	I-KIN	protein
7	40	44	I-KIN	bound
8	46	50	L-KIN	drugs
9	52	54	O	can
10	56	63	B-TRI	increase
11	65	67	I-TRI	the
12	69	81	L-TRI	concentration
13	83	84	O	of
14	86	91	O	XXXXXXXX
K/5:C54355

Prozac	3777	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	24
Although the exact mechanism of PROZAC is unknown, it is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin.
1	0	7	O	Although
2	9	11	O	the
3	13	17	O	exact
4	19	27	O	mechanism
5	29	30	O	of
6	32	37	O	XXXXXXXX
7	39	40	O	is
8	42	48	O	unknown
9	49	49	O	,
10	51	52	O	it
11	54	55	O	is
12	57	64	O	presumed
13	66	67	O	to
14	69	70	O	be
15	72	77	O	linked
16	79	80	O	to
17	82	84	O	its
18	86	95	O	inhibition
19	97	98	O	of
20	100	102	O	CNS
21	104	111	O	neuronal
22	113	118	O	uptake
23	120	121	O	of
24	123	131	O	serotonin
NULL

Prozac	3778	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets.
1	0	6	O	Studies
2	8	9	O	at
3	11	20	O	clinically
4	22	29	O	relevant
5	31	35	O	doses
6	37	38	O	in
7	40	42	O	man
8	44	47	O	have
9	49	60	O	demonstrated
10	62	65	O	that
11	67	76	O	XXXXXXXX
12	78	83	O	blocks
13	85	87	O	the
14	89	94	O	uptake
15	96	97	O	of
16	99	107	O	serotonin
17	109	112	O	into
18	114	118	O	human
19	120	128	O	platelets
NULL

Prozac	3779	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine.
1	0	6	O	Studies
2	8	9	O	in
3	11	17	O	animals
4	19	22	O	also
5	24	30	O	suggest
6	32	35	O	that
7	37	46	O	XXXXXXXX
8	48	49	O	is
9	51	51	O	a
10	53	56	O	much
11	58	61	O	more
12	63	68	O	potent
13	70	75	O	uptake
14	77	85	O	inhibitor
15	87	88	O	of
16	90	98	O	serotonin
17	100	103	O	than
18	105	106	O	of
19	108	121	O	norepinephrine
NULL

Prozac	3780	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	30
Antagonism of muscarinic, histaminergic, and A1-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant(TCA) drugs.
1	0	9	O	Antagonism
2	11	12	O	of
3	14	23	O	muscarinic
4	24	24	O	,
5	26	38	O	histaminergic
6	39	39	O	,
7	41	43	O	and
8	45	46	O	A1
9	48	57	O	adrenergic
10	59	67	O	receptors
11	69	71	O	has
12	73	76	O	been
13	78	89	O	hypothesized
14	91	92	O	to
15	94	95	O	be
16	97	106	O	associated
17	108	111	O	with
18	113	119	O	various
19	121	135	O	anticholinergic
20	136	136	O	,
21	138	145	O	sedative
22	146	146	O	,
23	148	150	O	and
24	152	165	O	cardiovascular
25	167	173	O	effects
26	175	176	O	of
27	178	186	O	classical
28	188	196	O	tricyclic
29	198	215	O	antidepressant(TCA
30	218	222	O	drugs
NULL

Prozac	3781	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	20
Fluoxetine binds to these and other membrane receptors from brain tissue much less potently invitro than do the tricyclic drugs.
1	0	9	O	XXXXXXXX
2	11	15	O	binds
3	17	18	O	to
4	20	24	O	these
5	26	28	O	and
6	30	34	O	other
7	36	43	O	membrane
8	45	53	O	receptors
9	55	58	O	from
10	60	64	O	brain
11	66	71	O	tissue
12	73	76	O	much
13	78	81	O	less
14	83	90	O	potently
15	92	98	O	invitro
16	100	103	O	than
17	105	106	O	do
18	108	110	O	the
19	112	120	O	tricyclic
20	122	126	O	drugs
NULL

Prozac	3782	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	27
Systemic Bioavailability - In man, following a single oral 40 mgdose, peak plasma concentrations of fluoxetine from 15to 55ng/mL are observed after 6to 8hours.
1	0	7	O	Systemic
2	9	23	O	Bioavailability
3	27	28	O	In
4	30	32	O	man
5	33	33	O	,
6	35	43	O	following
7	45	45	O	a
8	47	52	O	single
9	54	57	O	oral
10	59	60	O	40
11	62	67	O	mgdose
12	68	68	O	,
13	70	73	O	peak
14	75	80	O	plasma
15	82	95	O	concentrations
16	97	98	O	of
17	100	109	O	XXXXXXXX
18	111	114	O	from
19	116	119	O	15to
20	121	124	O	55ng
21	125	125	O	/
22	126	127	O	mL
23	129	131	O	are
24	133	140	O	observed
25	142	146	O	after
26	148	150	O	6to
27	152	157	O	8hours
NULL

Prozac	3783	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	12
The Pulvule and PROZACWeekly capsule dosage forms of fluoxetine are bioequivalent.
1	0	2	O	The
2	4	10	O	Pulvule
3	12	14	O	and
4	16	21	O	XXXXXXXX
5	22	27	O	Weekly
6	29	35	O	capsule
7	37	42	O	dosage
8	44	48	O	forms
9	50	51	O	of
10	53	62	O	XXXXXXXX
11	64	66	O	are
12	68	80	O	bioequivalent
NULL

Prozac	3784	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	28
Food does not appear to affect the systemic bioavailability of fluoxetine, although it may delay its absorption by 1to 2hours, which is probably not clinically significant.
1	0	3	U-KIN	Food
2	5	8	O	does
3	10	12	O	not
4	14	19	O	appear
5	21	22	O	to
6	24	29	O	affect
7	31	33	O	the
8	35	42	O	systemic
9	44	58	O	bioavailability
10	60	61	O	of
11	63	72	O	XXXXXXXX
12	73	73	O	,
13	75	82	O	although
14	84	85	O	it
15	87	89	O	may
16	91	95	O	delay
17	97	99	O	its
18	101	110	O	absorption
19	112	113	O	by
20	115	117	O	1to
21	119	124	O	2hours
22	125	125	O	,
23	127	131	O	which
24	133	134	O	is
25	136	143	O	probably
26	145	147	O	not
27	149	158	O	clinically
28	160	170	O	significant
K/1:C54356

Prozac	3785	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Thus, fluoxetine may be administered with or without food.
1	0	3	O	Thus
2	4	4	O	,
3	6	15	O	XXXXXXXX
4	17	19	O	may
5	21	22	O	be
6	24	35	O	administered
7	37	40	O	with
8	42	43	O	or
9	45	51	O	without
10	53	56	O	food
NULL

Prozac	3786	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	27
PROZACWeekly capsules, a delayed-release formulation, contain enteric-coated pellets that resist dissolution until reaching a segment of the gastrointestinal tract where the pHexceeds5.5.
1	0	5	O	XXXXXXXX
2	6	11	O	Weekly
3	13	20	O	capsules
4	21	21	O	,
5	23	23	O	a
6	25	31	O	delayed
7	33	39	O	release
8	41	51	O	formulation
9	52	52	O	,
10	54	60	O	contain
11	62	68	O	enteric
12	70	75	O	coated
13	77	83	O	pellets
14	85	88	O	that
15	90	95	O	resist
16	97	107	O	dissolution
17	109	113	O	until
18	115	122	O	reaching
19	124	124	O	a
20	126	132	O	segment
21	134	135	O	of
22	137	139	O	the
23	141	156	O	gastrointestinal
24	158	162	O	tract
25	164	168	O	where
26	170	172	O	the
27	174	185	O	pHexceeds5.5
NULL

Prozac	3787	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	18
The enteric coating delays the onset of absorption of fluoxetine 1to 2hours relative to the immediate-release formulations.
1	0	2	O	The
2	4	10	O	enteric
3	12	18	O	coating
4	20	25	O	delays
5	27	29	O	the
6	31	35	O	onset
7	37	38	O	of
8	40	49	O	absorption
9	51	52	O	of
10	54	63	O	XXXXXXXX
11	65	67	O	1to
12	69	74	O	2hours
13	76	83	O	relative
14	85	86	O	to
15	88	90	O	the
16	92	100	O	immediate
17	102	108	O	release
18	110	121	O	formulations
NULL

Prozac	3788	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	28
Protein Binding - Over the concentration range from 200to 1000ng/mL, approximately94.5% of fluoxetine is bound invitro to human serum proteins, including albumin and A1-glycoprotein.
1	0	6	O	Protein
2	8	14	O	Binding
3	18	21	O	Over
4	23	25	O	the
5	27	39	O	concentration
6	41	45	O	range
7	47	50	O	from
8	52	56	O	200to
9	58	63	O	1000ng
10	64	64	O	/
11	65	66	O	mL
12	67	67	O	,
13	69	86	O	approximately94.5%
14	88	89	O	of
15	91	100	O	XXXXXXXX
16	102	103	O	is
17	105	109	O	bound
18	111	117	O	invitro
19	119	120	O	to
20	122	126	O	human
21	128	132	O	serum
22	134	141	O	proteins
23	142	142	O	,
24	144	152	O	including
25	154	160	O	albumin
26	162	164	O	and
27	166	167	O	A1
28	169	180	O	glycoprotein
NULL

Prozac	3789	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	20
The interaction between fluoxetine and other highly protein-bound drugs has not been fully evaluated, but may be important.
1	0	2	O	The
2	4	14	U-TRI	interaction
3	16	22	O	between
4	24	33	O	XXXXXXXX
5	35	37	O	and
6	39	43	O	other
7	45	50	B-UNK	highly
8	52	58	I-UNK	protein
9	60	64	I-UNK	bound
10	66	70	L-UNK	drugs
11	72	74	O	has
12	76	78	O	not
13	80	83	O	been
14	85	89	O	fully
15	91	99	O	evaluated
16	100	100	O	,
17	102	104	O	but
18	106	108	O	may
19	110	111	O	be
20	113	121	O	important
NULL

Prozac	3790	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	15
Enantiomers - Fluoxetine is a racemic mixture(50/50) of R-fluoxetine and S-fluoxetine enantiomers.
1	0	10	O	Enantiomers
2	14	23	O	XXXXXXXX
3	25	26	O	is
4	28	28	O	a
5	30	36	O	racemic
6	38	47	O	mixture(50
7	48	48	O	/
8	49	50	O	50
9	53	54	O	of
10	56	56	O	R
11	58	67	O	XXXXXXXX
12	69	71	O	and
13	73	73	O	S
14	75	84	O	XXXXXXXX
15	86	96	O	enantiomers
NULL

Prozac	3791	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	16
In animal models, both enantiomers are specific and potent serotonin uptake inhibitors with essentially equivalent pharmacologic activity.
1	0	1	O	In
2	3	8	O	animal
3	10	15	O	models
4	16	16	O	,
5	18	21	O	both
6	23	33	O	enantiomers
7	35	37	O	are
8	39	46	O	specific
9	48	50	O	and
10	52	57	O	potent
11	59	85	O	GGGGGGGG
12	87	90	O	with
13	92	102	O	essentially
14	104	113	O	equivalent
15	115	127	O	pharmacologic
16	129	136	O	activity
NULL

Prozac	3792	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
The S-fluoxetine enantiomer is eliminated more slowly and is the predominant enantiomer present in plasma at steady state.
1	0	2	O	The
2	4	4	O	S
3	6	15	O	XXXXXXXX
4	17	26	O	enantiomer
5	28	29	O	is
6	31	40	O	eliminated
7	42	45	O	more
8	47	52	O	slowly
9	54	56	O	and
10	58	59	O	is
11	61	63	O	the
12	65	75	O	predominant
13	77	86	O	enantiomer
14	88	94	O	present
15	96	97	O	in
16	99	104	O	plasma
17	106	107	O	at
18	109	114	O	steady
19	116	120	O	state
NULL

Prozac	3793	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	18
Metabolism - Fluoxetine is extensively metabolized in the liver to norfluoxetine and a number of other unidentified metabolites.
1	0	9	O	Metabolism
2	13	22	O	XXXXXXXX
3	24	25	O	is
4	27	37	O	extensively
5	39	49	O	metabolized
6	51	52	O	in
7	54	56	O	the
8	58	62	O	liver
9	64	65	O	to
10	67	69	O	nor
11	70	79	O	XXXXXXXX
12	81	83	O	and
13	85	85	O	a
14	87	92	O	number
15	94	95	O	of
16	97	101	O	other
17	103	114	O	unidentified
18	116	126	O	metabolites
NULL

Prozac	3794	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	15
The only identified active metabolite, norfluoxetine, is formed by demethylation of fluoxetine.
1	0	2	O	The
2	4	7	O	only
3	9	18	O	identified
4	20	25	O	active
5	27	36	O	metabolite
6	37	37	O	,
7	39	41	O	nor
8	42	51	O	XXXXXXXX
9	52	52	O	,
10	54	55	O	is
11	57	62	O	formed
12	64	65	O	by
13	67	79	O	demethylation
14	81	82	O	of
15	84	93	O	XXXXXXXX
NULL

Prozac	3795	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	26
In animal models, S-norfluoxetine is a potent and selective inhibitor of serotonin uptake and has activity essentially equivalent to R- or S-fluoxetine.
1	0	1	O	In
2	3	8	O	animal
3	10	15	O	models
4	16	16	O	,
5	18	18	O	S
6	20	22	O	nor
7	23	32	O	XXXXXXXX
8	34	35	O	is
9	37	37	O	a
10	39	44	O	potent
11	46	48	O	and
12	50	58	O	selective
13	60	68	O	inhibitor
14	70	71	O	of
15	73	81	O	serotonin
16	83	88	O	uptake
17	90	92	O	and
18	94	96	O	has
19	98	105	O	activity
20	107	117	O	essentially
21	119	128	O	equivalent
22	130	131	O	to
23	133	133	O	R
24	136	137	O	or
25	139	139	O	S
26	141	150	O	XXXXXXXX
NULL

Prozac	3796	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	17
R-norfluoxetine is significantly less potent than the parent drug in the inhibition of serotonin uptake.
1	0	0	O	R
2	2	4	O	nor
3	5	14	O	XXXXXXXX
4	16	17	O	is
5	19	31	O	significantly
6	33	36	O	less
7	38	43	O	potent
8	45	48	O	than
9	50	52	O	the
10	54	59	O	parent
11	61	64	O	drug
12	66	67	O	in
13	69	71	O	the
14	73	82	O	inhibition
15	84	85	O	of
16	87	95	O	serotonin
17	97	102	O	uptake
NULL

Prozac	3797	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	17
The primary route of elimination appears to be hepatic metabolism to inactive metabolites excreted by the kidney.
1	0	2	O	The
2	4	10	O	primary
3	12	16	O	route
4	18	19	O	of
5	21	31	O	elimination
6	33	39	O	appears
7	41	42	O	to
8	44	45	O	be
9	47	53	O	hepatic
10	55	64	O	metabolism
11	66	67	O	to
12	69	76	O	inactive
13	78	88	O	metabolites
14	90	97	O	excreted
15	99	100	O	by
16	102	104	O	the
17	106	111	O	kidney
NULL

Prozac	3798	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Variability in Metabolism - A subset (about7%) of the population has reduced activity of the drug metabolizing enzyme cytochrome P4502D6(CYP2D6).
1	0	10	O	Variability
2	12	13	O	in
3	15	24	O	Metabolism
4	28	28	O	A
5	30	35	O	subset
6	38	44	O	about7%
7	47	48	O	of
8	50	52	O	the
9	54	63	O	population
10	65	67	O	has
11	69	75	O	reduced
12	77	84	O	activity
13	86	87	O	of
14	89	91	O	the
15	93	96	O	drug
16	98	109	O	metabolizing
17	111	116	O	enzyme
18	118	127	O	cytochrome
19	129	142	O	P4502D6(CYP2D6
NULL

Prozac	3799	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan, and the TCAs.
1	0	3	O	Such
2	5	15	O	individuals
3	17	19	O	are
4	21	28	O	referred
5	30	31	O	to
6	33	34	O	as
7	36	40	O	"poor
8	42	54	O	metabolizers"
9	56	57	O	of
10	59	63	O	drugs
11	65	68	O	such
12	70	71	O	as
13	73	83	O	debrisoquin
14	84	84	O	,
15	86	101	O	dextromethorphan
16	102	102	O	,
17	104	106	O	and
18	108	110	O	the
19	112	115	O	TCAs
NULL

Prozac	3800	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	30
In a study involving labeled and unlabeled enantiomers administered as a racemate, these individuals metabolized S-fluoxetine at a slower rate and thus achieved higher concentrations of S-fluoxetine.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	19	O	involving
5	21	27	O	labeled
6	29	31	O	and
7	33	41	O	unlabeled
8	43	53	O	enantiomers
9	55	66	O	administered
10	68	69	O	as
11	71	71	O	a
12	73	80	O	racemate
13	81	81	O	,
14	83	87	O	these
15	89	99	O	individuals
16	101	111	O	metabolized
17	113	113	O	S
18	115	124	O	XXXXXXXX
19	126	127	O	at
20	129	129	O	a
21	131	136	O	slower
22	138	141	O	rate
23	143	145	O	and
24	147	150	O	thus
25	152	159	O	achieved
26	161	166	O	higher
27	168	181	O	concentrations
28	183	184	O	of
29	186	186	O	S
30	188	197	O	XXXXXXXX
NULL

Prozac	3801	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	12
Consequently, concentrations of S-norfluoxetine at steady state were lower.
1	0	11	O	Consequently
2	12	12	O	,
3	14	27	O	concentrations
4	29	30	O	of
5	32	32	O	S
6	34	36	O	nor
7	37	46	O	XXXXXXXX
8	48	49	O	at
9	51	56	O	steady
10	58	62	O	state
11	64	67	O	were
12	69	73	O	lower
NULL

Prozac	3802	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	11
The metabolism of R-fluoxetine in these poor metabolizers appears normal.
1	0	2	O	The
2	4	13	O	metabolism
3	15	16	O	of
4	18	18	O	R
5	20	29	O	XXXXXXXX
6	31	32	O	in
7	34	38	O	these
8	40	43	O	poor
9	45	56	O	metabolizers
10	58	64	O	appears
11	66	71	O	normal
NULL

Prozac	3803	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	27
When compared with normal metabolizers, the total sum at steady state of the plasma concentrations of the 4active enantiomers was not significantly greater among poor metabolizers.
1	0	3	O	When
2	5	12	O	compared
3	14	17	O	with
4	19	24	O	normal
5	26	37	O	metabolizers
6	38	38	O	,
7	40	42	O	the
8	44	48	O	total
9	50	52	O	sum
10	54	55	O	at
11	57	62	O	steady
12	64	68	O	state
13	70	71	O	of
14	73	75	O	the
15	77	82	O	plasma
16	84	97	O	concentrations
17	99	100	O	of
18	102	104	O	the
19	106	112	O	4active
20	114	124	O	enantiomers
21	126	128	O	was
22	130	132	O	not
23	134	146	O	significantly
24	148	154	O	greater
25	156	160	O	among
26	162	165	O	poor
27	167	178	O	metabolizers
NULL

Prozac	3804	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Thus, the net pharmacodynamic activities were essentially the same.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	12	O	net
5	14	28	O	pharmacodynamic
6	30	39	O	activities
7	41	44	O	were
8	46	56	O	essentially
9	58	60	O	the
10	62	65	O	same
NULL

Prozac	3805	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	13
Alternative, nonsaturable pathways (non-2D6) also contribute to the metabolism of fluoxetine.
1	0	10	O	Alternative
2	11	11	O	,
3	13	24	O	nonsaturable
4	26	33	O	pathways
5	36	38	O	non
6	40	42	O	2D6
7	45	48	O	also
8	50	59	O	contribute
9	61	62	O	to
10	64	66	O	the
11	68	77	O	metabolism
12	79	80	O	of
13	82	91	O	XXXXXXXX
NULL

Prozac	3806	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
This explains how fluoxetine achieves a steady-state concentration rather than increasing without limit.
1	0	3	O	This
2	5	12	O	explains
3	14	16	O	how
4	18	27	O	XXXXXXXX
5	29	36	O	achieves
6	38	38	O	a
7	40	45	O	steady
8	47	51	O	state
9	53	65	O	concentration
10	67	72	O	rather
11	74	77	O	than
12	79	88	O	increasing
13	90	96	O	without
14	98	102	O	limit
NULL

Prozac	3807	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	44
Because fluoxetine's metabolism, like that of a number of other compounds including TCAs and other selective serotonin reuptake inhibitors(SSRIs), involves the CYP2D6 system, concomitant therapy with drugs also metabolized by this enzyme system (such as the TCAs) may lead to drug interactions.
1	0	6	O	Because
2	8	17	O	XXXXXXXX
3	18	19	O	's
4	21	30	O	metabolism
5	31	31	O	,
6	33	36	O	like
7	38	41	O	that
8	43	44	O	of
9	46	46	O	a
10	48	53	O	number
11	55	56	O	of
12	58	62	O	other
13	64	72	O	compounds
14	74	82	O	including
15	84	87	U-UNK	TCAs
16	89	91	O	and
17	93	97	O	other
18	99	107	U-UNK	selective
19	109	143	O	GGGGGGGGGGGGGGGGGGGGGGGGGGGGG(SSRIs
20	145	145	O	,
21	147	154	O	involves
22	156	158	O	the
23	160	165	O	CYP2D6
24	167	172	O	system
25	173	173	O	,
26	175	185	O	concomitant
27	187	193	O	therapy
28	195	198	O	with
29	200	204	O	drugs
30	206	209	O	also
31	211	221	O	metabolized
32	223	224	O	by
33	226	229	O	this
34	231	236	O	enzyme
35	238	243	O	system
36	246	249	O	such
37	251	252	O	as
38	254	256	O	the
39	258	261	O	TCAs
40	264	266	O	may
41	268	271	O	lead
42	273	274	O	to
43	276	279	B-TRI	drug
44	281	292	L-TRI	interactions
NULL

Prozac	3808	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	69
Accumulation and Slow Elimination - The relatively slow elimination of fluoxetine (elimination half-life of 1to 3days after acute administration and 4to 6days after chronic administration) and its active metabolite, norfluoxetine (elimination half-life of 4to 16days after acute and chronic administration), leads to significant accumulation of these active species in chronic use and delayed attainment of steady state, even when a fixed dose is used.
1	0	11	O	Accumulation
2	13	15	O	and
3	17	20	O	Slow
4	22	32	O	Elimination
5	36	38	O	The
6	40	49	O	relatively
7	51	54	O	slow
8	56	66	O	elimination
9	68	69	O	of
10	71	80	O	XXXXXXXX
11	83	93	O	elimination
12	95	98	O	half
13	100	103	O	life
14	105	106	O	of
15	108	110	O	1to
16	112	116	O	3days
17	118	122	O	after
18	124	128	O	acute
19	130	143	O	administration
20	145	147	O	and
21	149	151	O	4to
22	153	157	O	6days
23	159	163	O	after
24	165	171	O	chronic
25	173	186	O	administration
26	189	191	O	and
27	193	195	O	its
28	197	202	O	active
29	204	213	O	metabolite
30	214	214	O	,
31	216	218	O	nor
32	219	228	O	XXXXXXXX
33	231	241	O	elimination
34	243	246	O	half
35	248	251	O	life
36	253	254	O	of
37	256	258	O	4to
38	260	265	O	16days
39	267	271	O	after
40	273	277	O	acute
41	279	281	O	and
42	283	289	O	chronic
43	291	304	O	administration
44	306	306	O	,
45	308	312	O	leads
46	314	315	O	to
47	317	327	O	significant
48	329	340	O	accumulation
49	342	343	O	of
50	345	349	O	these
51	351	356	O	active
52	358	364	O	species
53	366	367	O	in
54	369	375	O	chronic
55	377	379	O	use
56	381	383	O	and
57	385	391	O	delayed
58	393	402	O	attainment
59	404	405	O	of
60	407	412	O	steady
61	414	418	O	state
62	419	419	O	,
63	421	424	O	even
64	426	429	O	when
65	431	431	O	a
66	433	437	O	fixed
67	439	442	O	dose
68	444	445	O	is
69	447	450	O	used
NULL

Prozac	3809	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	35
After 30days of dosing at 40mg/day, plasma concentrations of fluoxetine in the range of 91to 302ng/mL and norfluoxetine in the range of 72to 258ng/mL have been observed.
1	0	4	O	After
2	6	11	O	30days
3	13	14	O	of
4	16	21	O	dosing
5	23	24	O	at
6	26	29	O	40mg
7	30	30	O	/
8	31	33	O	day
9	34	34	O	,
10	36	41	O	plasma
11	43	56	O	concentrations
12	58	59	O	of
13	61	70	O	XXXXXXXX
14	72	73	O	in
15	75	77	O	the
16	79	83	O	range
17	85	86	O	of
18	88	91	O	91to
19	93	97	O	302ng
20	98	98	O	/
21	99	100	O	mL
22	102	104	O	and
23	106	108	O	nor
24	109	118	O	XXXXXXXX
25	120	121	O	in
26	123	125	O	the
27	127	131	O	range
28	133	134	O	of
29	136	139	O	72to
30	141	145	O	258ng
31	146	146	O	/
32	147	148	O	mL
33	150	153	O	have
34	155	158	O	been
35	160	167	O	observed
NULL

Prozac	3810	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	23
Plasma concentrations of fluoxetine were higher than those predicted by single-dose studies, because fluoxetine's metabolism is not proportional to dose.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	34	O	XXXXXXXX
5	36	39	O	were
6	41	46	O	higher
7	48	51	O	than
8	53	57	O	those
9	59	67	O	predicted
10	69	70	O	by
11	72	77	O	single
12	79	82	O	dose
13	84	90	O	studies
14	91	91	O	,
15	93	99	O	because
16	101	110	O	XXXXXXXX
17	111	112	O	's
18	114	123	O	metabolism
19	125	126	O	is
20	128	130	O	not
21	132	143	O	proportional
22	145	146	O	to
23	148	151	O	dose
NULL

Prozac	3811	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Norfluoxetine, however, appears to have linear pharmacokinetics.
1	0	2	O	Nor
2	3	12	O	XXXXXXXX
3	13	13	O	,
4	15	21	O	however
5	22	22	O	,
6	24	30	O	appears
7	32	33	O	to
8	35	38	O	have
9	40	45	O	linear
10	47	62	O	pharmacokinetics
NULL

Prozac	3812	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	17
Its mean terminal half-life after a single dose was 8.6days and after multiple dosing was 9.3days.
1	0	2	O	Its
2	4	7	O	mean
3	9	16	O	terminal
4	18	21	O	half
5	23	26	O	life
6	28	32	O	after
7	34	34	O	a
8	36	41	O	single
9	43	46	O	dose
10	48	50	O	was
11	52	58	O	8.6days
12	60	62	O	and
13	64	68	O	after
14	70	77	O	multiple
15	79	84	O	dosing
16	86	88	O	was
17	90	96	O	9.3days
NULL

Prozac	3813	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
Steady-state levels after prolonged dosing are similar to levels seen at 4to 5weeks.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	levels
4	20	24	O	after
5	26	34	O	prolonged
6	36	41	O	dosing
7	43	45	O	are
8	47	53	O	similar
9	55	56	O	to
10	58	63	O	levels
11	65	68	O	seen
12	70	71	O	at
13	73	75	O	4to
14	77	82	O	5weeks
NULL

Prozac	3814	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	47
The long elimination half-lives of fluoxetine and norfluoxetine assure that, even when dosing is stopped, active drug substance will persist in the body for weeks (primarily depending on individual patient characteristics, previous dosing regimen, and length of previous therapy at discontinuation).
1	0	2	O	The
2	4	7	O	long
3	9	19	O	elimination
4	21	24	O	half
5	26	30	O	lives
6	32	33	O	of
7	35	44	O	XXXXXXXX
8	46	48	O	and
9	50	52	O	nor
10	53	62	O	XXXXXXXX
11	64	69	O	assure
12	71	74	O	that
13	75	75	O	,
14	77	80	O	even
15	82	85	O	when
16	87	92	O	dosing
17	94	95	O	is
18	97	103	O	stopped
19	104	104	O	,
20	106	111	O	active
21	113	116	O	drug
22	118	126	O	substance
23	128	131	O	will
24	133	139	O	persist
25	141	142	O	in
26	144	146	O	the
27	148	151	O	body
28	153	155	O	for
29	157	161	O	weeks
30	164	172	O	primarily
31	174	182	O	depending
32	184	185	O	on
33	187	196	O	individual
34	198	204	O	patient
35	206	220	O	characteristics
36	221	221	O	,
37	223	230	O	previous
38	232	237	O	dosing
39	239	245	O	regimen
40	246	246	O	,
41	248	250	O	and
42	252	257	O	length
43	259	260	O	of
44	262	269	O	previous
45	271	277	O	therapy
46	279	280	O	at
47	282	296	O	discontinuation
NULL

Prozac	3815	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	28
This is of potential consequence when drug discontinuation is required or when drugs are prescribed that might interact with fluoxetine and norfluoxetine following the discontinuation of PROZAC.
1	0	3	O	This
2	5	6	O	is
3	8	9	O	of
4	11	19	O	potential
5	21	31	O	consequence
6	33	36	O	when
7	38	41	O	drug
8	43	57	O	discontinuation
9	59	60	O	is
10	62	69	O	required
11	71	72	O	or
12	74	77	O	when
13	79	83	O	drugs
14	85	87	O	are
15	89	98	O	prescribed
16	100	103	O	that
17	105	109	O	might
18	111	118	O	interact
19	120	123	O	with
20	125	134	O	XXXXXXXX
21	136	138	O	and
22	140	142	O	nor
23	143	152	O	XXXXXXXX
24	154	162	O	following
25	164	166	O	the
26	168	182	O	discontinuation
27	184	185	O	of
28	187	192	O	XXXXXXXX
NULL

Prozac	3816	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	39
Weekly Dosing - Administration of PROZACWeekly once weekly results in increased fluctuation between peak and trough concentrations of fluoxetine and norfluoxetine compared with once-daily dosing [for fluoxetine:24%(daily) to 164%(weekly) and for norfluoxetine:17%(daily) to 43%(weekly)].
1	0	5	O	Weekly
2	7	12	O	Dosing
3	16	29	O	Administration
4	31	32	O	of
5	34	39	O	XXXXXXXX
6	40	45	O	Weekly
7	47	50	O	once
8	52	57	O	weekly
9	59	65	O	results
10	67	68	O	in
11	70	78	O	increased
12	80	90	O	fluctuation
13	92	98	O	between
14	100	103	O	peak
15	105	107	O	and
16	109	114	O	trough
17	116	129	O	concentrations
18	131	132	O	of
19	134	143	O	XXXXXXXX
20	145	147	O	and
21	149	151	O	nor
22	152	161	O	XXXXXXXX
23	163	170	O	compared
24	172	175	O	with
25	177	180	O	once
26	182	186	O	daily
27	188	193	O	dosing
28	196	198	O	for
29	200	209	O	XXXXXXXX
30	210	219	O	:24%(daily
31	222	223	O	to
32	225	235	O	164%(weekly
33	238	240	O	and
34	242	244	O	for
35	246	248	O	nor
36	249	258	O	XXXXXXXX
37	259	268	O	:17%(daily
38	271	272	O	to
39	274	283	O	43%(weekly
NULL

Prozac	3817	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Plasma concentrations may not necessarily be predictive of clinical response.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	24	O	may
4	26	28	O	not
5	30	40	O	necessarily
6	42	43	O	be
7	45	54	O	predictive
8	56	57	O	of
9	59	66	O	clinical
10	68	75	O	response
NULL

Prozac	3818	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	26
Peak concentrations from once-weekly doses of PROZACWeekly capsules of fluoxetine are in the range of the average concentration for 20 mg once-daily dosing.
1	0	3	O	Peak
2	5	18	O	concentrations
3	20	23	O	from
4	25	28	O	once
5	30	35	O	weekly
6	37	41	O	doses
7	43	44	O	of
8	46	51	O	XXXXXXXX
9	52	57	O	Weekly
10	59	66	O	capsules
11	68	69	O	of
12	71	80	O	XXXXXXXX
13	82	84	O	are
14	86	87	O	in
15	89	91	O	the
16	93	97	O	range
17	99	100	O	of
18	102	104	O	the
19	106	112	O	average
20	114	126	O	concentration
21	128	130	O	for
22	132	133	O	20
23	135	136	O	mg
24	138	141	O	once
25	143	147	O	daily
26	149	154	O	dosing
NULL

Prozac	3819	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	22
Average trough concentrations are 76%lower for fluoxetine and 47%lower for norfluoxetine than the concentrations maintained by 20 mg once-daily dosing.
1	0	6	O	Average
2	8	13	O	trough
3	15	28	O	concentrations
4	30	32	O	are
5	34	41	O	76%lower
6	43	45	O	for
7	47	56	O	XXXXXXXX
8	58	60	O	and
9	62	69	O	47%lower
10	71	73	O	for
11	75	77	O	nor
12	78	87	O	XXXXXXXX
13	89	92	O	than
14	94	96	O	the
15	98	111	O	concentrations
16	113	122	O	maintained
17	124	125	O	by
18	127	128	O	20
19	130	131	O	mg
20	133	136	O	once
21	138	142	O	daily
22	144	149	O	dosing
NULL

Prozac	3820	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	21
Average steady-state concentrations of either once-daily or once-weekly dosing are in relative proportion to the total dose administered.
1	0	6	O	Average
2	8	13	O	steady
3	15	19	O	state
4	21	34	O	concentrations
5	36	37	O	of
6	39	44	O	either
7	46	49	O	once
8	51	55	O	daily
9	57	58	O	or
10	60	63	O	once
11	65	70	O	weekly
12	72	77	O	dosing
13	79	81	O	are
14	83	84	O	in
15	86	93	O	relative
16	95	104	O	proportion
17	106	107	O	to
18	109	111	O	the
19	113	117	O	total
20	119	122	O	dose
21	124	135	O	administered
NULL

Prozac	3821	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
Average steady-state fluoxetine concentrations are approximately 50%lower following the once-weekly regimen compared with the once-daily regimen.
1	0	6	O	Average
2	8	13	O	steady
3	15	19	O	state
4	21	30	O	XXXXXXXX
5	32	45	O	concentrations
6	47	49	O	are
7	51	63	O	approximately
8	65	72	O	50%lower
9	74	82	O	following
10	84	86	O	the
11	88	91	O	once
12	93	98	O	weekly
13	100	106	O	regimen
14	108	115	O	compared
15	117	120	O	with
16	122	124	O	the
17	126	129	O	once
18	131	135	O	daily
19	137	143	O	regimen
NULL

Prozac	3822	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	35
Cmax for fluoxetine following the 90 mg dose was approximately 1.7-fold higher than the Cmax value for the established 20 mg once-daily regimen following transition the next day to the once-weekly regimen.
1	0	3	O	Cmax
2	5	7	O	for
3	9	18	O	XXXXXXXX
4	20	28	O	following
5	30	32	O	the
6	34	35	O	90
7	37	38	O	mg
8	40	43	O	dose
9	45	47	O	was
10	49	61	O	approximately
11	63	65	O	1.7
12	67	70	O	fold
13	72	77	O	higher
14	79	82	O	than
15	84	86	O	the
16	88	91	O	Cmax
17	93	97	O	value
18	99	101	O	for
19	103	105	O	the
20	107	117	O	established
21	119	120	O	20
22	122	123	O	mg
23	125	128	O	once
24	130	134	O	daily
25	136	142	O	regimen
26	144	152	O	following
27	154	163	O	transition
28	165	167	O	the
29	169	172	O	next
30	174	176	O	day
31	178	179	O	to
32	181	183	O	the
33	185	188	O	once
34	190	195	O	weekly
35	197	203	O	regimen
NULL

Prozac	3823	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	25
In contrast, when the first90 mgonce-weekly dose and the last 20 mgonce-daily dose were separated by 1week, Cmax values were similar.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	16	O	when
5	18	20	O	the
6	22	28	O	first90
7	30	35	O	mgonce
8	37	42	O	weekly
9	44	47	O	dose
10	49	51	O	and
11	53	55	O	the
12	57	60	O	last
13	62	63	O	20
14	65	70	O	mgonce
15	72	76	O	daily
16	78	81	O	dose
17	83	86	O	were
18	88	96	O	separated
19	98	99	O	by
20	101	105	O	1week
21	106	106	O	,
22	108	111	O	Cmax
23	113	118	O	values
24	120	123	O	were
25	125	131	O	similar
NULL

Prozac	3824	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	26
Also, there was a transient increase in the average steady-state concentrations of fluoxetine observed following transition the next day to the once-weekly regimen.
1	0	3	O	Also
2	4	4	O	,
3	6	10	O	there
4	12	14	O	was
5	16	16	O	a
6	18	26	O	transient
7	28	35	O	increase
8	37	38	O	in
9	40	42	O	the
10	44	50	O	average
11	52	57	O	steady
12	59	63	O	state
13	65	78	O	concentrations
14	80	81	O	of
15	83	92	O	XXXXXXXX
16	94	101	O	observed
17	103	111	O	following
18	113	122	O	transition
19	124	126	O	the
20	128	131	O	next
21	133	135	O	day
22	137	138	O	to
23	140	142	O	the
24	144	147	O	once
25	149	154	O	weekly
26	156	162	O	regimen
NULL

Prozac	3825	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	24
From a pharmacokinetic perspective, it may be better to separate the first90 mgweekly dose and the last 20 mgonce-daily dose by 1week.
1	0	3	O	From
2	5	5	O	a
3	7	21	O	pharmacokinetic
4	23	33	O	perspective
5	34	34	O	,
6	36	37	O	it
7	39	41	O	may
8	43	44	O	be
9	46	51	O	better
10	53	54	O	to
11	56	63	O	separate
12	65	67	O	the
13	69	75	O	first90
14	77	84	O	mgweekly
15	86	89	O	dose
16	91	93	O	and
17	95	97	O	the
18	99	102	O	last
19	104	105	O	20
20	107	112	O	mgonce
21	114	118	O	daily
22	120	123	O	dose
23	125	126	O	by
24	128	132	O	1week
NULL

Prozac	3826	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	21
Liver Disease - As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of fluoxetine.
1	0	4	O	Liver
2	6	12	O	Disease
3	16	17	O	As
4	19	23	O	might
5	25	26	O	be
6	28	36	O	predicted
7	38	41	O	from
8	43	45	O	its
9	47	53	O	primary
10	55	58	O	site
11	60	61	O	of
12	63	72	O	metabolism
13	73	73	O	,
14	75	79	O	liver
15	81	90	O	impairment
16	92	94	O	can
17	96	101	O	affect
18	103	105	O	the
19	107	117	O	elimination
20	119	120	O	of
21	122	131	O	XXXXXXXX
NULL

Prozac	3827	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	59
The elimination half-life of fluoxetine was prolonged in a study of cirrhotic patients, with a mean of 7.6days compared with the range of 2to 3days seen in subjects without liver disease; norfluoxetine elimination was also delayed, with a mean duration of 12days for cirrhotic patients compared with the range of 7to 9days in normal subjects.
1	0	2	O	The
2	4	14	O	elimination
3	16	19	O	half
4	21	24	O	life
5	26	27	O	of
6	29	38	O	XXXXXXXX
7	40	42	O	was
8	44	52	O	prolonged
9	54	55	O	in
10	57	57	O	a
11	59	63	O	study
12	65	66	O	of
13	68	76	O	cirrhotic
14	78	85	O	patients
15	86	86	O	,
16	88	91	O	with
17	93	93	O	a
18	95	98	O	mean
19	100	101	O	of
20	103	109	O	7.6days
21	111	118	O	compared
22	120	123	O	with
23	125	127	O	the
24	129	133	O	range
25	135	136	O	of
26	138	140	O	2to
27	142	146	O	3days
28	148	151	O	seen
29	153	154	O	in
30	156	163	O	subjects
31	165	171	O	without
32	173	177	O	liver
33	179	185	O	disease
34	188	190	O	nor
35	191	200	O	XXXXXXXX
36	202	212	O	elimination
37	214	216	O	was
38	218	221	O	also
39	223	229	O	delayed
40	230	230	O	,
41	232	235	O	with
42	237	237	O	a
43	239	242	O	mean
44	244	251	O	duration
45	253	254	O	of
46	256	261	O	12days
47	263	265	O	for
48	267	275	O	cirrhotic
49	277	284	O	patients
50	286	293	O	compared
51	295	298	O	with
52	300	302	O	the
53	304	308	O	range
54	310	311	O	of
55	313	315	O	7to
56	317	321	O	9days
57	323	324	O	in
58	326	331	O	normal
59	333	340	O	subjects
NULL

Prozac	3828	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	17
This suggests that the use of fluoxetine in patients with liver disease must be approached with caution.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	21	O	the
5	23	25	O	use
6	27	28	O	of
7	30	39	O	XXXXXXXX
8	41	42	O	in
9	44	51	O	patients
10	53	56	O	with
11	58	62	O	liver
12	64	70	O	disease
13	72	75	O	must
14	77	78	O	be
15	80	89	O	approached
16	91	94	O	with
17	96	102	O	caution
NULL

Prozac	3829	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	19
If fluoxetine is administered to patients with liver disease, a lower or less frequent dose should be used.
1	0	1	O	If
2	3	12	O	XXXXXXXX
3	14	15	O	is
4	17	28	O	administered
5	30	31	O	to
6	33	40	O	patients
7	42	45	O	with
8	47	51	O	liver
9	53	59	O	disease
10	60	60	O	,
11	62	62	O	a
12	64	68	O	lower
13	70	71	O	or
14	73	76	O	less
15	78	85	O	frequent
16	87	90	O	dose
17	92	97	O	should
18	99	100	O	be
19	102	105	O	used
NULL

Prozac	3830	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	35
Renal Disease - In depressed patients on dialysis(N=12), fluoxetine administered as 20mg once daily for 2months produced steady-state fluoxetine and norfluoxetine plasma concentrations comparable with those seen in patients with normal renal function.
1	0	4	O	Renal
2	6	12	O	Disease
3	16	17	O	In
4	19	27	O	depressed
5	29	36	O	patients
6	38	39	O	on
7	41	53	O	dialysis(N=12
8	55	55	O	,
9	57	66	O	XXXXXXXX
10	68	79	O	administered
11	81	82	O	as
12	84	87	O	20mg
13	89	92	O	once
14	94	98	O	daily
15	100	102	O	for
16	104	110	O	2months
17	112	119	O	produced
18	121	126	O	steady
19	128	132	O	state
20	134	143	O	XXXXXXXX
21	145	147	O	and
22	149	151	O	nor
23	152	161	O	XXXXXXXX
24	163	168	O	plasma
25	170	183	O	concentrations
26	185	194	O	comparable
27	196	199	O	with
28	201	205	O	those
29	207	210	O	seen
30	212	213	O	in
31	215	222	O	patients
32	224	227	O	with
33	229	234	O	normal
34	236	240	O	renal
35	242	249	O	function
NULL

Prozac	3831	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	38
While the possibility exists that renally excreted metabolites of fluoxetine may accumulate to higher levels in patients with severe renal dysfunction, use of a lower or less frequent dose is not routinely necessary in renally impaired patients.
1	0	4	O	While
2	6	8	O	the
3	10	20	O	possibility
4	22	27	O	exists
5	29	32	O	that
6	34	40	O	renally
7	42	49	O	excreted
8	51	61	O	metabolites
9	63	64	O	of
10	66	75	O	XXXXXXXX
11	77	79	O	may
12	81	90	O	accumulate
13	92	93	O	to
14	95	100	O	higher
15	102	107	O	levels
16	109	110	O	in
17	112	119	O	patients
18	121	124	O	with
19	126	131	O	severe
20	133	137	O	renal
21	139	149	O	dysfunction
22	150	150	O	,
23	152	154	O	use
24	156	157	O	of
25	159	159	O	a
26	161	165	O	lower
27	167	168	O	or
28	170	173	O	less
29	175	182	O	frequent
30	184	187	O	dose
31	189	190	O	is
32	192	194	O	not
33	196	204	O	routinely
34	206	214	O	necessary
35	216	217	O	in
36	219	225	O	renally
37	227	234	O	impaired
38	236	243	O	patients
NULL

Prozac	3832	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	26
Geriatric Pharmacokinetics - The disposition of single doses of fluoxetine in healthy elderly subjects (>65years of age) did not differ significantly from that in younger normal subjects.
1	0	8	O	Geriatric
2	10	25	O	Pharmacokinetics
3	29	31	O	The
4	33	43	O	disposition
5	45	46	O	of
6	48	53	O	single
7	55	59	O	doses
8	61	62	O	of
9	64	73	O	XXXXXXXX
10	75	76	O	in
11	78	84	O	healthy
12	86	92	O	elderly
13	94	101	O	subjects
14	104	111	O	>65years
15	113	114	O	of
16	116	118	O	age
17	121	123	O	did
18	125	127	O	not
19	129	134	O	differ
20	136	148	O	significantly
21	150	153	O	from
22	155	158	O	that
23	160	161	O	in
24	163	169	O	younger
25	171	176	O	normal
26	178	185	O	subjects
NULL

Prozac	3833	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	47
However, given the long half-life and nonlinear disposition of the drug, a single-dose study is not adequate to rule out the possibility of altered pharmacokinetics in the elderly, particularly if they have systemic illness or are receiving multiple drugs for concomitant diseases.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	given
4	15	17	O	the
5	19	22	O	long
6	24	27	O	half
7	29	32	O	life
8	34	36	O	and
9	38	46	O	nonlinear
10	48	58	O	disposition
11	60	61	O	of
12	63	65	O	the
13	67	70	O	drug
14	71	71	O	,
15	73	73	O	a
16	75	80	O	single
17	82	85	O	dose
18	87	91	O	study
19	93	94	O	is
20	96	98	O	not
21	100	107	O	adequate
22	109	110	O	to
23	112	115	O	rule
24	117	119	O	out
25	121	123	O	the
26	125	135	O	possibility
27	137	138	O	of
28	140	146	O	altered
29	148	163	O	pharmacokinetics
30	165	166	O	in
31	168	170	O	the
32	172	178	O	elderly
33	179	179	O	,
34	181	192	O	particularly
35	194	195	O	if
36	197	200	O	they
37	202	205	O	have
38	207	214	O	systemic
39	216	222	O	illness
40	224	225	O	or
41	227	229	O	are
42	231	239	O	receiving
43	241	248	O	multiple
44	250	254	O	drugs
45	256	258	O	for
46	260	270	O	concomitant
47	272	279	O	diseases
NULL

Prozac	3834	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	28
The effects of age upon the metabolism of fluoxetine have been investigated in 260elderly but otherwise healthy depressed patients (>60years of age) who received 20mg fluoxetine for 6weeks.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	17	O	age
5	19	22	O	upon
6	24	26	O	the
7	28	37	O	metabolism
8	39	40	O	of
9	42	51	O	XXXXXXXX
10	53	56	O	have
11	58	61	O	been
12	63	74	O	investigated
13	76	77	O	in
14	79	88	O	260elderly
15	90	92	O	but
16	94	102	O	otherwise
17	104	110	O	healthy
18	112	120	O	depressed
19	122	129	O	patients
20	132	139	O	>60years
21	141	142	O	of
22	144	146	O	age
23	149	151	O	who
24	153	160	O	received
25	162	165	O	20mg
26	167	176	O	XXXXXXXX
27	178	180	O	for
28	182	187	O	6weeks
NULL

Prozac	3835	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	16
Combined fluoxetine plus norfluoxetine plasma concentrations were 209.3*85.7ng/mL at the end of 6weeks.
1	0	7	O	Combined
2	9	18	O	XXXXXXXX
3	20	23	O	plus
4	25	27	O	nor
5	28	37	O	XXXXXXXX
6	39	44	O	plasma
7	46	59	O	concentrations
8	61	64	O	were
9	66	77	O	209.3*85.7ng
10	78	78	O	/
11	79	80	O	mL
12	82	83	O	at
13	85	87	O	the
14	89	91	O	end
15	93	94	O	of
16	96	101	O	6weeks
NULL

Prozac	3836	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	14
No unusual age-associated pattern of adverse reactions was observed in those elderly patients.
1	0	1	O	No
2	3	9	O	unusual
3	11	13	O	age
4	15	24	O	associated
5	26	32	O	pattern
6	34	35	O	of
7	37	43	O	adverse
8	45	53	O	reactions
9	55	57	O	was
10	59	66	O	observed
11	68	69	O	in
12	71	75	O	those
13	77	83	O	elderly
14	85	92	O	patients
NULL

Prozac	3837	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	30
Pediatric Pharmacokinetics (children and adolescents) - Fluoxetine pharmacokinetics were evaluated in 21pediatric patients (10children ages6 to <13, 11adolescents ages13 to <18) diagnosed with Major Depressive Disorder or Obsessive Compulsive Disorder(OCD).
1	0	8	O	Pediatric
2	10	25	O	Pharmacokinetics
3	28	35	O	children
4	37	39	O	and
5	41	51	O	adolescents
6	56	65	O	XXXXXXXX
7	67	82	O	pharmacokinetics
8	84	87	O	were
9	89	97	O	evaluated
10	99	100	O	in
11	102	112	O	21pediatric
12	114	121	O	patients
13	124	133	O	10children
14	135	139	O	ages6
15	141	142	O	to
16	144	146	O	<13
17	147	147	O	,
18	149	161	O	11adolescents
19	163	168	O	ages13
20	170	171	O	to
21	173	175	O	<18
22	178	186	O	diagnosed
23	188	191	O	with
24	193	197	O	Major
25	199	208	O	Depressive
26	210	217	O	Disorder
27	219	220	O	or
28	222	230	O	Obsessive
29	232	241	O	Compulsive
30	243	254	O	Disorder(OCD
NULL

Prozac	3838	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	10
Fluoxetine 20mg/day was administered for up to 62days.
1	0	9	O	XXXXXXXX
2	11	14	O	20mg
3	15	15	O	/
4	16	18	O	day
5	20	22	O	was
6	24	35	O	administered
7	37	39	O	for
8	41	42	O	up
9	44	45	O	to
10	47	52	O	62days
NULL

Prozac	3839	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	23
The average steady-state concentrations of fluoxetine in these children were 2-fold higher than in adolescents (171and 86ng/mL, respectively).
1	0	2	O	The
2	4	10	O	average
3	12	17	O	steady
4	19	23	O	state
5	25	38	O	concentrations
6	40	41	O	of
7	43	52	O	XXXXXXXX
8	54	55	O	in
9	57	61	O	these
10	63	70	O	children
11	72	75	O	were
12	77	77	O	2
13	79	82	O	fold
14	84	89	O	higher
15	91	94	O	than
16	96	97	O	in
17	99	109	O	adolescents
18	112	117	O	171and
19	119	122	O	86ng
20	123	123	O	/
21	124	125	O	mL
22	126	126	O	,
23	128	139	O	respectively
NULL

Prozac	3840	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	23
The average norfluoxetine steady-state concentrations in these children were 1.5-fold higher than in adolescents (195and 113ng/mL, respectively).
1	0	2	O	The
2	4	10	O	average
3	12	14	O	nor
4	15	24	O	XXXXXXXX
5	26	31	O	steady
6	33	37	O	state
7	39	52	O	concentrations
8	54	55	O	in
9	57	61	O	these
10	63	70	O	children
11	72	75	O	were
12	77	79	O	1.5
13	81	84	O	fold
14	86	91	O	higher
15	93	96	O	than
16	98	99	O	in
17	101	111	O	adolescents
18	114	119	O	195and
19	121	125	O	113ng
20	126	126	O	/
21	127	128	O	mL
22	129	129	O	,
23	131	142	O	respectively
NULL

Prozac	3841	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	11
These differences can be almost entirely explained by differences in weight.
1	0	4	O	These
2	6	16	O	differences
3	18	20	O	can
4	22	23	O	be
5	25	30	O	almost
6	32	39	O	entirely
7	41	49	O	explained
8	51	52	O	by
9	54	64	O	differences
10	66	67	O	in
11	69	74	O	weight
NULL

Prozac	3842	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	9
No gender-associated difference in fluoxetine pharmacokinetics was observed.
1	0	1	O	No
2	3	8	O	gender
3	10	19	O	associated
4	21	30	O	difference
5	32	33	O	in
6	35	44	O	XXXXXXXX
7	46	61	O	pharmacokinetics
8	63	65	O	was
9	67	74	O	observed
NULL

Prozac	3843	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	24
Similar ranges of fluoxetine and norfluoxetine plasma concentrations were observed in another study in 94pediatric patients (ages8 to<18) diagnosed with Major Depressive Disorder.
1	0	6	O	Similar
2	8	13	O	ranges
3	15	16	O	of
4	18	27	O	XXXXXXXX
5	29	31	O	and
6	33	35	O	nor
7	36	45	O	XXXXXXXX
8	47	52	O	plasma
9	54	67	O	concentrations
10	69	72	O	were
11	74	81	O	observed
12	83	84	O	in
13	86	92	O	another
14	94	98	O	study
15	100	101	O	in
16	103	113	O	94pediatric
17	115	122	O	patients
18	125	129	O	ages8
19	131	135	O	to<18
20	138	146	O	diagnosed
21	148	151	O	with
22	153	157	O	Major
23	159	168	O	Depressive
24	170	177	O	Disorder
NULL

Prozac	3844	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	31
Higher average steady-state fluoxetine and norfluoxetine concentrations were observed in children relative to adults; however, these concentrations were within the range of concentrations observed in the adult population.
1	0	5	O	Higher
2	7	13	O	average
3	15	20	O	steady
4	22	26	O	state
5	28	37	O	XXXXXXXX
6	39	41	O	and
7	43	45	O	nor
8	46	55	O	XXXXXXXX
9	57	70	O	concentrations
10	72	75	O	were
11	77	84	O	observed
12	86	87	O	in
13	89	96	O	children
14	98	105	O	relative
15	107	108	O	to
16	110	115	O	adults
17	118	124	O	however
18	125	125	O	,
19	127	131	O	these
20	133	146	O	concentrations
21	148	151	O	were
22	153	158	O	within
23	160	162	O	the
24	164	168	O	range
25	170	171	O	of
26	173	186	O	concentrations
27	188	195	O	observed
28	197	198	O	in
29	200	202	O	the
30	204	208	O	adult
31	210	219	O	population
NULL

Prozac	3845	34090-1	5f356c1b-96bd-4ef1-960c-91cf4905e6b1	24
As in adults, fluoxetine and norfluoxetine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3to4weeks of daily dosing.
1	0	1	O	As
2	3	4	O	in
3	6	11	O	adults
4	12	12	O	,
5	14	23	O	XXXXXXXX
6	25	27	O	and
7	29	31	O	nor
8	32	41	O	XXXXXXXX
9	43	53	O	accumulated
10	55	65	O	extensively
11	67	75	O	following
12	77	84	O	multiple
13	86	89	O	oral
14	91	96	O	dosing
15	99	104	O	steady
16	106	110	O	state
17	112	125	O	concentrations
18	127	130	O	were
19	132	139	O	achieved
20	141	146	O	within
21	148	156	O	3to4weeks
22	158	159	O	of
23	161	165	O	daily
24	167	172	O	dosing
NULL

Quazepam	1	34073-7	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	26
Benzodiazepines, including QUAZEPAM, produce additive CNS depressant effects when co-administered with ethanol or other CNS depressants (e.g. psychotropic medications, anticonvulsants, antihistamines).
1	0	14	O	Benzodiazepines
2	15	15	O	,
3	17	25	O	including
4	27	34	O	XXXXXXXX
5	35	35	O	,
6	37	43	O	produce
7	45	52	B-EFF	additive
8	54	56	I-EFF	CNS
9	58	67	I-EFF	depressant
10	69	75	L-EFF	effects
11	77	80	O	when
12	82	83	O	co
13	85	96	O	administered
14	98	101	O	with
15	103	109	U-DYN	ethanol
16	111	112	O	or
17	114	118	O	other
18	120	122	B-DYN	CNS
19	124	134	L-DYN	depressants
20	137	139	O	e.g
21	142	153	B-DYN	psychotropic
22	155	165	L-DYN	medications
23	166	166	O	,
24	168	182	U-DYN	anticonvulsants
25	183	183	O	,
26	185	198	U-DYN	antihistamines
D/15:7:1 D/18:7:1 D/21:7:1 D/24:7:1 D/26:7:1

Quazepam	2	34073-7	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	18
Downward dose adjustment of QUAZEPAM and/or concomitant CNS depressants may be necessary because of additive effects.
1	0	7	B-TRI	Downward
2	9	12	I-TRI	dose
3	14	23	L-TRI	adjustment
4	25	26	O	of
5	28	35	O	XXXXXXXX
6	37	39	O	and
7	40	40	O	/
8	41	42	O	or
9	44	54	O	concomitant
10	56	58	B-DYN	CNS
11	60	70	L-DYN	depressants
12	72	74	O	may
13	76	77	O	be
14	79	87	O	necessary
15	89	95	O	because
16	97	98	O	of
17	100	107	O	additive
18	109	115	O	effects
NULL

Quazepam	3	34073-7	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	14
CNS Depressants: downward dose adjustment may be necessary due to additive effects (7)
1	0	2	B-DYN	CNS
2	4	14	L-DYN	Depressants
3	15	15	O	:
4	17	24	B-TRI	downward
5	26	29	I-TRI	dose
6	31	40	L-TRI	adjustment
7	42	44	O	may
8	46	47	O	be
9	49	57	O	necessary
10	59	61	O	due
11	63	64	O	to
12	66	73	O	additive
13	75	81	O	effects
14	84	84	O	7
NULL

Quazepam	4	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	33
Quazepam, like other central nervous system agents of the 1,4-benzodiazepine class, presumably exerts its effects by binding to stereo-specific receptors at several sites within the central nervous system (CNS).
1	0	7	O	XXXXXXXX
2	8	8	O	,
3	10	13	O	like
4	15	19	O	other
5	21	27	O	central
6	29	35	O	nervous
7	37	42	O	system
8	44	49	O	agents
9	51	52	O	of
10	54	56	O	the
11	58	60	O	1,4
12	62	75	O	benzodiazepine
13	77	81	O	class
14	82	82	O	,
15	84	93	O	presumably
16	95	100	O	exerts
17	102	104	O	its
18	106	112	O	effects
19	114	115	O	by
20	117	123	O	binding
21	125	126	O	to
22	128	133	O	stereo
23	135	142	O	specific
24	144	152	O	receptors
25	154	155	O	at
26	157	163	O	several
27	165	169	O	sites
28	171	176	O	within
29	178	180	O	the
30	182	188	O	central
31	190	196	O	nervous
32	198	203	O	system
33	206	208	O	CNS
NULL

Quazepam	5	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	7
The exact mechanism of action is unknown.
1	0	2	O	The
2	4	8	O	exact
3	10	18	O	mechanism
4	20	21	O	of
5	23	28	O	action
6	30	31	O	is
7	33	39	O	unknown
NULL

Quazepam	6	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	19
Absorption: Quazepam is rapidly (absorption half-life of about 30 minutes) and well absorbed from the gastrointestinal tract.
1	0	9	O	Absorption
2	10	10	O	:
3	12	19	O	XXXXXXXX
4	21	22	O	is
5	24	30	O	rapidly
6	33	42	O	absorption
7	44	47	O	half
8	49	52	O	life
9	54	55	O	of
10	57	61	O	about
11	63	64	O	30
12	66	72	O	minutes
13	75	77	O	and
14	79	82	O	well
15	84	91	O	absorbed
16	93	96	O	from
17	98	100	O	the
18	102	117	O	gastrointestinal
19	119	123	O	tract
NULL

Quazepam	7	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	23
The peak plasma concentration of quazepam is approximately 20 ng/mL after a 15 mg dose and occurs at about 2 hours.
1	0	2	O	The
2	4	7	O	peak
3	9	14	O	plasma
4	16	28	O	concentration
5	30	31	O	of
6	33	40	O	XXXXXXXX
7	42	43	O	is
8	45	57	O	approximately
9	59	60	O	20
10	62	63	O	ng
11	64	64	O	/
12	65	66	O	mL
13	68	72	O	after
14	74	74	O	a
15	76	77	O	15
16	79	80	O	mg
17	82	85	O	dose
18	87	89	O	and
19	91	96	O	occurs
20	98	99	O	at
21	101	105	O	about
22	107	107	O	2
23	109	113	O	hours
NULL

Quazepam	8	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	30
Metabolism: Quazepam, the active parent compound, is extensively metabolized in the liver; two of the plasma metabolites are 2-oxoquazepam and N-desalkyl-2-oxoquazepam.
1	0	9	O	Metabolism
2	10	10	O	:
3	12	19	O	XXXXXXXX
4	20	20	O	,
5	22	24	O	the
6	26	31	O	active
7	33	38	O	parent
8	40	47	O	compound
9	48	48	O	,
10	50	51	O	is
11	53	63	O	extensively
12	65	75	O	metabolized
13	77	78	O	in
14	80	82	O	the
15	84	88	O	liver
16	91	93	O	two
17	95	96	O	of
18	98	100	O	the
19	102	107	O	plasma
20	109	119	O	metabolites
21	121	123	O	are
22	125	125	O	2
23	127	129	O	oxo
24	130	137	O	XXXXXXXX
25	139	141	O	and
26	143	143	O	N
27	145	152	O	desalkyl
28	154	154	O	2
29	156	158	O	oxo
30	159	166	O	XXXXXXXX
NULL

Quazepam	9	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	7
All three compounds show CNS depressant activity.
1	0	2	O	All
2	4	8	O	three
3	10	18	O	compounds
4	20	23	O	show
5	25	27	O	CNS
6	29	38	O	depressant
7	40	47	O	activity
NULL

Quazepam	10	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	19
Distribution: The degree of plasma protein binding for quazepam and its two major metabolites is greater than 95%.
1	0	11	O	Distribution
2	12	12	O	:
3	14	16	O	The
4	18	23	O	degree
5	25	26	O	of
6	28	33	O	plasma
7	35	41	O	protein
8	43	49	O	binding
9	51	53	O	for
10	55	62	O	XXXXXXXX
11	64	66	O	and
12	68	70	O	its
13	72	74	O	two
14	76	80	O	major
15	82	92	O	metabolites
16	94	95	O	is
17	97	103	O	greater
18	105	108	O	than
19	110	112	O	95%
NULL

Quazepam	11	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	35
Elimination: Following administration of 14C-quazepam, 31% of the dose appeared in the urine and 23% in the feces over five days; only trace amounts of unchanged drug were present in the urine.
1	0	10	O	Elimination
2	11	11	O	:
3	13	21	O	Following
4	23	36	O	administration
5	38	39	O	of
6	41	43	O	14C
7	45	52	O	XXXXXXXX
8	53	53	O	,
9	55	57	O	31%
10	59	60	O	of
11	62	64	O	the
12	66	69	O	dose
13	71	78	O	appeared
14	80	81	O	in
15	83	85	O	the
16	87	91	O	urine
17	93	95	O	and
18	97	99	O	23%
19	101	102	O	in
20	104	106	O	the
21	108	112	O	feces
22	114	117	O	over
23	119	122	O	five
24	124	127	O	days
25	130	133	O	only
26	135	139	O	trace
27	141	147	O	amounts
28	149	150	O	of
29	152	160	O	unchanged
30	162	165	O	drug
31	167	170	O	were
32	172	178	O	present
33	180	181	O	in
34	183	185	O	the
35	187	191	O	urine
NULL

Quazepam	12	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	25
The mean elimination half-life of quazepam and 2-oxoquazepam is 39 hours and that of N-desalkyl-2-oxoquazepam is 73 hours.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	of
7	34	41	O	XXXXXXXX
8	43	45	O	and
9	47	47	O	2
10	49	51	O	oxo
11	52	59	O	XXXXXXXX
12	61	62	O	is
13	64	65	O	39
14	67	71	O	hours
15	73	75	O	and
16	77	80	O	that
17	82	83	O	of
18	85	85	O	N
19	87	94	O	desalkyl
20	96	96	O	2
21	98	100	O	oxo
22	101	108	O	XXXXXXXX
23	110	111	O	is
24	113	114	O	73
25	116	120	O	hours
NULL

Quazepam	13	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	29
Steady-state levels of quazepam and 2-oxoquazepam are attained by the seventh daily dose and that of N-desalkyl-2-oxoquazepam by the thirteenth daily dose.
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	levels
4	20	21	O	of
5	23	30	O	XXXXXXXX
6	32	34	O	and
7	36	36	O	2
8	38	40	O	oxo
9	41	48	O	XXXXXXXX
10	50	52	O	are
11	54	61	O	attained
12	63	64	O	by
13	66	68	O	the
14	70	76	O	seventh
15	78	82	O	daily
16	84	87	O	dose
17	89	91	O	and
18	93	96	O	that
19	98	99	O	of
20	101	101	O	N
21	103	110	O	desalkyl
22	112	112	O	2
23	114	116	O	oxo
24	117	124	O	XXXXXXXX
25	126	127	O	by
26	129	131	O	the
27	133	142	O	thirteenth
28	144	148	O	daily
29	150	153	O	dose
NULL

Quazepam	14	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	52
Special Populations: Geriatrics: The pharmacokinetics of quazepam and 2-oxoquazepam in geriatric subjects are comparable to those seen in young adults; as with desalkyl metabolites of other benzodiazepines, the elimination half-life of N-desalkyl-2-oxoquazepam in geriatric patients is about twice that of young adults.
1	0	6	O	Special
2	8	18	O	Populations
3	19	19	O	:
4	21	30	O	Geriatrics
5	31	31	O	:
6	33	35	O	The
7	37	52	O	pharmacokinetics
8	54	55	O	of
9	57	64	O	XXXXXXXX
10	66	68	O	and
11	70	70	O	2
12	72	74	O	oxo
13	75	82	O	XXXXXXXX
14	84	85	O	in
15	87	95	O	geriatric
16	97	104	O	subjects
17	106	108	O	are
18	110	119	O	comparable
19	121	122	O	to
20	124	128	O	those
21	130	133	O	seen
22	135	136	O	in
23	138	142	O	young
24	144	149	O	adults
25	152	153	O	as
26	155	158	O	with
27	160	167	O	desalkyl
28	169	179	O	metabolites
29	181	182	O	of
30	184	188	O	other
31	190	204	O	benzodiazepines
32	205	205	O	,
33	207	209	O	the
34	211	221	O	elimination
35	223	226	O	half
36	228	231	O	life
37	233	234	O	of
38	236	236	O	N
39	238	245	O	desalkyl
40	247	247	O	2
41	249	251	O	oxo
42	252	259	O	XXXXXXXX
43	261	262	O	in
44	264	272	O	geriatric
45	274	281	O	patients
46	283	284	O	is
47	286	290	O	about
48	292	296	O	twice
49	298	301	O	that
50	303	304	O	of
51	306	310	O	young
52	312	317	O	adults
NULL

Quazepam	15	34090-1	309f8ac3-a3fd-4313-96aa-7f21fa9cd646	37
Bupropion (a CYP2B6 substrate): Co-administration of a single dose of 150 mg Bupropion Hydrochloride XL with steady state quazepam did not significantly affect the AUC and Cmax of bupropion or its primary metabolite, hydroxybupropion.
1	0	8	O	Bupropion
2	11	11	O	a
3	13	18	O	CYP2B6
4	20	28	O	substrate
5	30	30	O	:
6	32	33	O	Co
7	35	48	O	administration
8	50	51	O	of
9	53	53	O	a
10	55	60	O	single
11	62	65	O	dose
12	67	68	O	of
13	70	72	O	150
14	74	75	O	mg
15	77	85	O	Bupropion
16	87	99	O	Hydrochloride
17	101	102	O	XL
18	104	107	O	with
19	109	114	O	steady
20	116	120	O	state
21	122	129	O	XXXXXXXX
22	131	133	O	did
23	135	137	O	not
24	139	151	O	significantly
25	153	158	O	affect
26	160	162	O	the
27	164	166	O	AUC
28	168	170	O	and
29	172	175	O	Cmax
30	177	178	O	of
31	180	188	O	bupropion
32	190	191	O	or
33	193	195	O	its
34	197	203	O	primary
35	205	214	O	metabolite
36	215	215	O	,
37	217	232	O	hydroxybupropion
NULL

Quetiapine fumarate	208	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	118
Concomitant use of strong CYP3A4 inhibitors: Reduce quetiapine dose to one sixth when coadministered with strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir) (2.5, 7.1, 12.3) Concomitant use of strong CYP3A4 inducers: Increase quetiapine dose up to 5 fold when used in combination with a chronic treatment (more than 7 to 14 days) of potent CYP3A4 inducers (e.g. phenytoin, rifampin, St. John's wort) (2.6, 7.1, 12.3) Discontinuation of strong CYP3A4 inducers: Reduce quetiapine dose by 5 fold within 7 to 14 days of discontinuation of CYP3A4 inducers (2.6, 7.1, 12.3) The risks of using quetiapine in combination with other drugs have not been extensively evaluated in systematic studies.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	24	B-KIN	strong
5	26	31	I-KIN	CYP3A4
6	33	42	L-KIN	inhibitors
7	43	43	O	:
8	45	50	B-TRI	Reduce
9	52	61	I-TRI	XXXXXXXX
10	63	66	L-TRI	dose
11	68	69	O	to
12	71	73	O	one
13	75	79	O	sixth
14	81	84	O	when
15	86	99	O	coadministered
16	101	104	O	with
17	106	111	O	strong
18	113	118	O	CYP3A4
19	120	129	O	inhibitors
20	132	134	O	e.g
21	137	148	O	ketoconazole
22	149	149	O	,
23	151	159	O	ritonavir
24	163	165	O	2.5
25	166	166	O	,
26	168	170	O	7.1
27	171	171	O	,
28	173	176	O	12.3
29	179	189	O	Concomitant
30	191	193	O	use
31	195	196	O	of
32	198	203	B-KIN	strong
33	205	210	I-KIN	CYP3A4
34	212	219	L-KIN	inducers
35	220	220	O	:
36	222	229	O	Increase
37	231	240	O	XXXXXXXX
38	242	245	O	dose
39	247	248	O	up
40	250	251	O	to
41	253	253	O	5
42	255	258	O	fold
43	260	263	O	when
44	265	268	O	used
45	270	271	O	in
46	273	283	O	combination
47	285	288	O	with
48	290	290	O	a
49	292	298	O	chronic
50	300	308	O	treatment
51	311	314	O	more
52	316	319	O	than
53	321	321	O	7
54	323	324	O	to
55	326	327	O	14
56	329	332	O	days
57	335	336	O	of
58	338	343	O	potent
59	345	350	O	CYP3A4
60	352	359	O	inducers
61	362	364	O	e.g
62	367	375	O	phenytoin
63	376	376	O	,
64	378	385	O	rifampin
65	386	386	O	,
66	388	389	O	St
67	392	397	O	John's
68	399	402	O	wort
69	406	408	O	2.6
70	409	409	O	,
71	411	413	O	7.1
72	414	414	O	,
73	416	419	O	12.3
74	422	436	O	Discontinuation
75	438	439	O	of
76	441	446	O	strong
77	448	453	O	CYP3A4
78	455	462	O	inducers
79	463	463	O	:
80	465	470	O	Reduce
81	472	481	O	XXXXXXXX
82	483	486	O	dose
83	488	489	O	by
84	491	491	O	5
85	493	496	O	fold
86	498	503	O	within
87	505	505	O	7
88	507	508	O	to
89	510	511	O	14
90	513	516	O	days
91	518	519	O	of
92	521	535	O	discontinuation
93	537	538	O	of
94	540	545	O	CYP3A4
95	547	554	O	inducers
96	557	559	O	2.6
97	560	560	O	,
98	562	564	O	7.1
99	565	565	O	,
100	567	570	O	12.3
101	573	575	O	The
102	577	581	O	risks
103	583	584	O	of
104	586	590	O	using
105	592	601	O	XXXXXXXX
106	603	604	O	in
107	606	616	O	combination
108	618	621	O	with
109	623	627	O	other
110	629	633	O	drugs
111	635	638	O	have
112	640	642	O	not
113	644	647	O	been
114	649	659	O	extensively
115	661	669	O	evaluated
116	671	672	O	in
117	674	683	O	systematic
118	685	691	O	studies
K/32:C54356 K/4:C54355

Quetiapine fumarate	209	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	23
Given the primary CNS effects of quetiapine, caution should be used when it is taken in combination with other centrally acting drugs.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	42	O	XXXXXXXX
8	43	43	O	,
9	45	51	U-TRI	caution
10	53	58	O	should
11	60	61	O	be
12	63	66	O	used
13	68	71	O	when
14	73	74	O	it
15	76	77	O	is
16	79	83	O	taken
17	85	86	O	in
18	88	98	O	combination
19	100	103	O	with
20	105	109	O	other
21	111	119	B-UNK	centrally
22	121	126	I-UNK	acting
23	128	132	L-UNK	drugs
NULL

Quetiapine fumarate	210	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	29
Quetiapine potentiated the cognitive and motor effects of alcohol in a clinical trial in subjects with selected psychotic disorders, and alcoholic beverages should be limited while taking quetiapine.
1	0	9	O	XXXXXXXX
2	11	21	B-EFF	potentiated
3	23	25	I-EFF	the
4	27	35	I-EFF	cognitive
5	37	39	I-EFF	and
6	41	45	I-EFF	motor
7	47	53	L-EFF	effects
8	55	56	O	of
9	58	64	U-DYN	alcohol
10	66	67	O	in
11	69	69	O	a
12	71	78	O	clinical
13	80	84	O	trial
14	86	87	O	in
15	89	96	O	subjects
16	98	101	O	with
17	103	110	O	selected
18	112	120	O	psychotic
19	122	130	O	disorders
20	131	131	O	,
21	133	135	O	and
22	137	145	B-UNK	alcoholic
23	147	155	L-UNK	beverages
24	157	162	B-TRI	should
25	164	165	I-TRI	be
26	167	173	L-TRI	limited
27	175	179	O	while
28	181	186	O	taking
29	188	197	O	XXXXXXXX
D/9:2:1

Quetiapine fumarate	211	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	43
Quetiapine exposure is increased by the prototype CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, indinavir, ritonavir, nefazodone, etc. and decreased by the prototype CYP3A4 inducers (e..g, phenytoin, carbamazepine, rifampin, avasimibe, St. John's wort etc.
1	0	9	O	XXXXXXXX
2	11	18	O	exposure
3	20	21	O	is
4	23	31	O	increased
5	33	34	O	by
6	36	38	O	the
7	40	48	O	prototype
8	50	55	B-KIN	CYP3A4
9	57	66	L-KIN	inhibitors
10	69	71	O	e.g
11	73	73	O	,
12	75	86	U-KIN	ketoconazole
13	87	87	O	,
14	89	100	U-KIN	itraconazole
15	101	101	O	,
16	103	111	U-KIN	indinavir
17	112	112	O	,
18	114	122	U-KIN	ritonavir
19	123	123	O	,
20	125	134	U-KIN	nefazodone
21	135	135	O	,
22	137	139	O	etc
23	142	144	O	and
24	146	154	O	decreased
25	156	157	O	by
26	159	161	O	the
27	163	171	O	prototype
28	173	178	B-KIN	CYP3A4
29	180	187	L-KIN	inducers
30	190	193	O	e..g
31	194	194	O	,
32	196	204	U-KIN	phenytoin
33	205	205	O	,
34	207	219	U-KIN	carbamazepine
35	220	220	O	,
36	222	229	U-KIN	rifampin
37	230	230	O	,
38	232	240	U-KIN	avasimibe
39	241	241	O	,
40	243	244	B-KIN	St
41	247	252	I-KIN	John's
42	254	257	L-KIN	wort
43	259	261	O	etc
K/12:C54355 K/14:C54355 K/16:C54355 K/18:C54355 K/20:C54355 K/28:C54356 K/32:C54356 K/34:C54356 K/36:C54356 K/38:C54356 K/40:C54356 K/8:C54355

Quetiapine fumarate	212	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	18
Dose adjustment of quetiapine will be necessary if it is co-administered with potent CYP3A4 inducers or inhibitors.
1	0	3	B-TRI	Dose
2	5	14	L-TRI	adjustment
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	33	O	will
6	35	36	O	be
7	38	46	O	necessary
8	48	49	O	if
9	51	52	O	it
10	54	55	O	is
11	57	58	O	co
12	60	71	O	administered
13	73	76	O	with
14	78	83	O	potent
15	85	90	B-UNK	CYP3A4
16	92	99	L-UNK	inducers
17	101	102	O	or
18	104	113	O	inhibitors
NULL

Quetiapine fumarate	213	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	19
CYP3A4 inhibitors:Coadministration of ketoconazole, a potent inhibitor of cytochrome CYP3A4, resulted in significant increase in quetiapine exposure.
1	0	5	U-KIN	CYP3A4
2	7	33	O	inhibitors:Coadministration
3	35	36	O	of
4	38	49	U-KIN	ketoconazole
5	50	50	O	,
6	52	52	O	a
7	54	59	O	potent
8	61	69	O	inhibitor
9	71	72	O	of
10	74	83	O	cytochrome
11	85	90	O	CYP3A4
12	91	91	O	,
13	93	100	O	resulted
14	102	103	O	in
15	105	115	O	significant
16	117	124	O	increase
17	126	127	O	in
18	129	138	O	XXXXXXXX
19	140	147	O	exposure
K/1:C54355 K/4:C54355

Quetiapine fumarate	214	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	21
The dose of quetiapine should be reduced to one sixth of the original dose if coadministered with a strong CYP3A4 inhibitor.
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	21	O	XXXXXXXX
5	23	28	O	should
6	30	31	O	be
7	33	39	O	reduced
8	41	42	O	to
9	44	46	O	one
10	48	52	O	sixth
11	54	55	O	of
12	57	59	O	the
13	61	68	O	original
14	70	73	O	dose
15	75	76	O	if
16	78	91	O	coadministered
17	93	96	O	with
18	98	98	O	a
19	100	105	O	strong
20	107	112	B-KIN	CYP3A4
21	114	122	L-KIN	inhibitor
K/20:C54355

Quetiapine fumarate	215	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	20
CYP3A4 inducers:Coadministration of quetiapine and phenytoin, a CYP3A4 inducer increased the mean oral clearance of quetiapine by 5-fold.
1	0	5	U-KIN	CYP3A4
2	7	31	O	inducers:Coadministration
3	33	34	O	of
4	36	45	O	XXXXXXXX
5	47	49	O	and
6	51	59	U-KIN	phenytoin
7	60	60	O	,
8	62	62	O	a
9	64	69	O	CYP3A4
10	71	77	O	inducer
11	79	87	O	increased
12	89	91	O	the
13	93	96	O	mean
14	98	101	O	oral
15	103	111	O	clearance
16	113	114	O	of
17	116	125	O	XXXXXXXX
18	127	128	O	by
19	130	130	O	5
20	132	135	O	fold
K/1:C54356 K/6:C54356

Quetiapine fumarate	216	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	31
Increased doses of quetiapine up to 5 fold may be required to maintain control of symptoms of schizophrenia in patients receiving quetiapine and phenytoin, or other known potent CYP3A4 inducers.
1	0	8	B-TRI	Increased
2	10	14	L-TRI	doses
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	31	O	up
6	33	34	O	to
7	36	36	O	5
8	38	41	O	fold
9	43	45	O	may
10	47	48	O	be
11	50	57	O	required
12	59	60	O	to
13	62	69	O	maintain
14	71	77	O	control
15	79	80	O	of
16	82	89	O	symptoms
17	91	92	O	of
18	94	106	O	schizophrenia
19	108	109	O	in
20	111	118	O	patients
21	120	128	O	receiving
22	130	139	O	XXXXXXXX
23	141	143	O	and
24	145	153	U-KIN	phenytoin
25	154	154	O	,
26	156	157	O	or
27	159	163	O	other
28	165	169	O	known
29	171	176	O	potent
30	178	183	B-KIN	CYP3A4
31	185	192	L-KIN	inducers
K/24:C54356 K/30:C54356

Quetiapine fumarate	217	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	23
When the CYP3A4 inducer is discontinued, the dose of quetiapine should be reduced to the original level within 7 to 14 days.
1	0	3	O	When
2	5	7	O	the
3	9	14	B-KIN	CYP3A4
4	16	22	L-KIN	inducer
5	24	25	O	is
6	27	38	O	discontinued
7	39	39	O	,
8	41	43	O	the
9	45	48	O	dose
10	50	51	O	of
11	53	62	O	XXXXXXXX
12	64	69	O	should
13	71	72	O	be
14	74	80	O	reduced
15	82	83	O	to
16	85	87	O	the
17	89	96	O	original
18	98	102	O	level
19	104	109	O	within
20	111	111	O	7
21	113	114	O	to
22	116	117	O	14
23	119	122	O	days
K/3:C54355

Quetiapine fumarate	218	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	29
The potential effects of several concomitant medications on quetiapine pharmacokinetics were studied Because of its potential for inducing hypotension, quetiapine may enhance the effects of certain antihypertensive agents.
1	0	2	O	The
2	4	12	O	potential
3	14	20	O	effects
4	22	23	O	of
5	25	31	O	several
6	33	43	O	concomitant
7	45	55	O	medications
8	57	58	O	on
9	60	69	O	XXXXXXXX
10	71	86	O	pharmacokinetics
11	88	91	O	were
12	93	99	O	studied
13	101	107	O	Because
14	109	110	O	of
15	112	114	O	its
16	116	124	O	potential
17	126	128	O	for
18	130	137	O	inducing
19	139	149	U-EFF	hypotension
20	150	150	O	,
21	152	161	O	XXXXXXXX
22	163	165	O	may
23	167	173	O	enhance
24	175	177	O	the
25	179	185	O	effects
26	187	188	O	of
27	190	196	O	certain
28	198	213	B-DYN	antihypertensive
29	215	220	L-DYN	agents
D/28:19:1

Quetiapine fumarate	219	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	10
Quetiapine may antagonize the effects of levodopa and dopamine agonists.
1	0	9	O	XXXXXXXX
2	11	13	O	may
3	15	24	B-EFF	antagonize
4	26	28	I-EFF	the
5	30	36	I-EFF	effects
6	38	39	I-EFF	of
7	41	48	L-EFF	levodopa
8	50	52	O	and
9	54	61	U-DYN	dopamine
10	63	70	O	agonists
D/9:3:0

Quetiapine fumarate	220	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	17
There are no clinically relevant pharmacokinetic interactions of quetiapine on other drugs based on the CYP pathway.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	22	O	clinically
5	24	31	O	relevant
6	33	47	O	pharmacokinetic
7	49	60	O	interactions
8	62	63	O	of
9	65	74	O	XXXXXXXX
10	76	77	O	on
11	79	83	O	other
12	85	89	O	drugs
13	91	95	O	based
14	97	98	O	on
15	100	102	O	the
16	104	106	O	CYP
17	108	114	O	pathway
NULL

Quetiapine fumarate	221	34073-7	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	20
Quetiapine and its metabolites are non-inhibitors of major metabolizing CYP's (1A2, 2C9, 2C19, 2D6 and 3A4).
1	0	9	O	XXXXXXXX
2	11	13	O	and
3	15	17	O	its
4	19	29	O	metabolites
5	31	33	O	are
6	35	37	O	non
7	39	48	O	inhibitors
8	50	51	O	of
9	53	57	O	major
10	59	70	O	metabolizing
11	72	76	O	CYP's
12	79	81	O	1A2
13	82	82	O	,
14	84	86	O	2C9
15	87	87	O	,
16	89	92	O	2C19
17	93	93	O	,
18	95	97	O	2D6
19	99	101	O	and
20	103	105	O	3A4
NULL

Quetiapine fumarate	222	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	8
The mechanism of action of quetiapine is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	39	O	is
8	41	47	O	unknown
NULL

Quetiapine fumarate	223	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	39
However, it has been proposed that the efficacy of quetiapine in schizophrenia and its mood stabilizing properties in bipolar depression and mania are mediated through a combination of dopamine type 2 (D2) and serotonin type 2 (5HT2) antagonism.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	28	O	proposed
7	30	33	O	that
8	35	37	O	the
9	39	46	O	efficacy
10	48	49	O	of
11	51	60	O	XXXXXXXX
12	62	63	O	in
13	65	77	O	schizophrenia
14	79	81	O	and
15	83	85	O	its
16	87	90	O	mood
17	92	102	O	stabilizing
18	104	113	O	properties
19	115	116	O	in
20	118	124	O	bipolar
21	126	135	O	depression
22	137	139	O	and
23	141	145	O	mania
24	147	149	O	are
25	151	158	O	mediated
26	160	166	O	through
27	168	168	O	a
28	170	180	O	combination
29	182	183	O	of
30	185	192	O	dopamine
31	194	197	O	type
32	199	199	O	2
33	202	203	O	D2
34	206	208	O	and
35	210	218	O	serotonin
36	220	223	O	type
37	225	225	O	2
38	228	231	O	5HT2
39	234	243	O	antagonism
NULL

Quetiapine fumarate	224	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	21
Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other effects of quetiapine.
1	0	9	O	Antagonism
2	11	12	O	at
3	14	22	O	receptors
4	24	28	O	other
5	30	33	O	than
6	35	42	O	dopamine
7	44	46	O	and
8	48	51	O	5HT2
9	53	56	O	with
10	58	64	O	similar
11	66	73	O	receptor
12	75	84	O	affinities
13	86	88	O	may
14	90	96	O	explain
15	98	101	O	some
16	103	104	O	of
17	106	108	O	the
18	110	114	O	other
19	116	122	O	effects
20	124	125	O	of
21	127	136	O	XXXXXXXX
NULL

Quetiapine fumarate	225	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	15
Quetiapine's antagonism of histamine H1 receptors may explain the somnolence observed with this drug.
1	0	9	O	XXXXXXXX
2	10	11	O	's
3	13	22	O	antagonism
4	24	25	O	of
5	27	35	O	histamine
6	37	38	O	H1
7	40	48	O	receptors
8	50	52	O	may
9	54	60	O	explain
10	62	64	O	the
11	66	75	O	somnolence
12	77	84	O	observed
13	86	89	O	with
14	91	94	O	this
15	96	99	O	drug
NULL

Quetiapine fumarate	226	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	16
Quetiapine's antagonism of adrenergic A1 receptors may explain the orthostatic hypotension observed with this drug.
1	0	9	O	XXXXXXXX
2	10	11	O	's
3	13	22	O	antagonism
4	24	25	O	of
5	27	36	O	adrenergic
6	38	39	O	A1
7	41	49	O	receptors
8	51	53	O	may
9	55	61	O	explain
10	63	65	O	the
11	67	77	O	orthostatic
12	79	89	O	hypotension
13	91	98	O	observed
14	100	103	O	with
15	105	108	O	this
16	110	113	O	drug
NULL

Quetiapine fumarate	227	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	46
Quetiapine is an antagonist at multiple neurotransmitter receptors in the brain: serotonin 5HT1A and 5HT2 (IC50s=717 & 148nM, respectively), dopamine D1 and D2 (IC50s=1268 & 329nM, respectively), histamine H1 (IC50=30nM), and adrenergic A1 and A2receptors (IC50s=94 & 271nM, respectively).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	26	O	antagonist
5	28	29	O	at
6	31	38	O	multiple
7	40	55	O	neurotransmitter
8	57	65	O	receptors
9	67	68	O	in
10	70	72	O	the
11	74	78	O	brain
12	79	79	O	:
13	81	89	O	serotonin
14	91	95	O	5HT1A
15	97	99	O	and
16	101	104	O	5HT2
17	107	115	O	IC50s=717
18	117	117	O	&
19	119	123	O	148nM
20	124	124	O	,
21	126	137	O	respectively
22	139	139	O	,
23	141	148	O	dopamine
24	150	151	O	D1
25	153	155	O	and
26	157	158	O	D2
27	161	170	O	IC50s=1268
28	172	172	O	&
29	174	178	O	329nM
30	179	179	O	,
31	181	192	O	respectively
32	194	194	O	,
33	196	204	O	histamine
34	206	207	O	H1
35	210	218	O	IC50=30nM
36	220	220	O	,
37	222	224	O	and
38	226	235	O	adrenergic
39	237	238	O	A1
40	240	242	O	and
41	244	254	O	A2receptors
42	257	264	O	IC50s=94
43	266	266	O	&
44	268	272	O	271nM
45	273	273	O	,
46	275	286	O	respectively
NULL

Quetiapine fumarate	228	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	15
Quetiapine has no appreciable affinity at cholinergic muscarinic and benzodiazepine receptors (IC50s > 5000 nM).
1	0	9	O	XXXXXXXX
2	11	13	O	has
3	15	16	O	no
4	18	28	O	appreciable
5	30	37	O	affinity
6	39	40	O	at
7	42	52	O	cholinergic
8	54	63	O	muscarinic
9	65	67	O	and
10	69	82	O	benzodiazepine
11	84	92	O	receptors
12	95	99	O	IC50s
13	101	101	O	>
14	103	106	O	5000
15	108	109	O	nM
NULL

Quetiapine fumarate	229	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	18
Effect on QT Interval In clinical trials quetiapine was not associated with a persistent increase in QT intervals.
1	0	5	O	Effect
2	7	8	O	on
3	10	11	O	QT
4	13	20	O	Interval
5	22	23	O	In
6	25	32	O	clinical
7	34	39	O	trials
8	41	50	O	XXXXXXXX
9	52	54	O	was
10	56	58	O	not
11	60	69	O	associated
12	71	74	O	with
13	76	76	O	a
14	78	87	O	persistent
15	89	96	O	increase
16	98	99	O	in
17	101	102	O	QT
18	104	112	O	intervals
NULL

Quetiapine fumarate	230	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	14
However, the QT effect was not systematically evaluated in a thorough QT study.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	14	O	QT
5	16	21	O	effect
6	23	25	O	was
7	27	29	O	not
8	31	44	O	systematically
9	46	54	O	evaluated
10	56	57	O	in
11	59	59	O	a
12	61	68	O	thorough
13	70	71	O	QT
14	73	77	O	study
NULL

Quetiapine fumarate	231	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	38
In post marketing experience there were cases reported of QT prolongation in patients who overdosed on quetiapine , in patients with concomitant illness, and in patients taking medicines known to cause electrolyte imbalance or increase QT interval.
1	0	1	O	In
2	3	6	O	post
3	8	16	O	marketing
4	18	27	O	experience
5	29	33	O	there
6	35	38	O	were
7	40	44	O	cases
8	46	53	O	reported
9	55	56	O	of
10	58	59	B-EFF	QT
11	61	72	L-EFF	prolongation
12	74	75	O	in
13	77	84	O	patients
14	86	88	O	who
15	90	98	O	overdosed
16	100	101	O	on
17	103	112	O	XXXXXXXX
18	114	114	O	,
19	116	117	O	in
20	119	126	O	patients
21	128	131	O	with
22	133	143	O	concomitant
23	145	151	O	illness
24	152	152	O	,
25	154	156	O	and
26	158	159	O	in
27	161	168	O	patients
28	170	175	O	taking
29	177	185	B-DYN	medicines
30	187	191	I-DYN	known
31	193	194	I-DYN	to
32	196	200	I-DYN	cause
33	202	212	I-DYN	electrolyte
34	214	222	L-DYN	imbalance
35	224	225	O	or
36	227	234	O	increase
37	236	237	O	QT
38	239	246	O	interval
D/29:10:1

Quetiapine fumarate	232	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	10
Adults Quetiapine fumarate activity is primarily due to the parent drug.
1	0	5	O	Adults
2	7	25	O	XXXXXXXX
3	27	34	O	activity
4	36	37	O	is
5	39	47	O	primarily
6	49	51	O	due
7	53	54	O	to
8	56	58	O	the
9	60	65	O	parent
10	67	70	O	drug
NULL

Quetiapine fumarate	233	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	24
The multiple-dose pharmacokinetics of quetiapine are dose-proportional within the proposed clinical dose range, and quetiapine accumulation is predictable upon multiple dosing.
1	0	2	O	The
2	4	11	O	multiple
3	13	16	O	dose
4	18	33	O	pharmacokinetics
5	35	36	O	of
6	38	47	O	XXXXXXXX
7	49	51	O	are
8	53	56	O	dose
9	58	69	O	proportional
10	71	76	O	within
11	78	80	O	the
12	82	89	O	proposed
13	91	98	O	clinical
14	100	103	O	dose
15	105	109	O	range
16	110	110	O	,
17	112	114	O	and
18	116	125	O	XXXXXXXX
19	127	138	O	accumulation
20	140	141	O	is
21	143	153	O	predictable
22	155	158	O	upon
23	160	167	O	multiple
24	169	174	O	dosing
NULL

Quetiapine fumarate	234	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	24
Elimination of quetiapine is mainly via hepatic metabolism with a mean terminal half-life of about 6 hours within the proposed clinical dose range.
1	0	10	O	Elimination
2	12	13	O	of
3	15	24	O	XXXXXXXX
4	26	27	O	is
5	29	34	O	mainly
6	36	38	O	via
7	40	46	O	hepatic
8	48	57	O	metabolism
9	59	62	O	with
10	64	64	O	a
11	66	69	O	mean
12	71	78	O	terminal
13	80	83	O	half
14	85	88	O	life
15	90	91	O	of
16	93	97	O	about
17	99	99	O	6
18	101	105	O	hours
19	107	112	O	within
20	114	116	O	the
21	118	125	O	proposed
22	127	134	O	clinical
23	136	139	O	dose
24	141	145	O	range
NULL

Quetiapine fumarate	235	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	13
Steady-state concentrations are expected to be achieved within two days of dosing.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	30	O	are
5	32	39	O	expected
6	41	42	O	to
7	44	45	O	be
8	47	54	O	achieved
9	56	61	O	within
10	63	65	O	two
11	67	70	O	days
12	72	73	O	of
13	75	80	O	dosing
NULL

Quetiapine fumarate	236	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	15
Quetiapine is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	21	O	unlikely
4	23	24	O	to
5	26	34	O	interfere
6	36	39	O	with
7	41	43	O	the
8	45	54	O	metabolism
9	56	57	O	of
10	59	63	O	drugs
11	65	75	O	metabolized
12	77	78	O	by
13	80	89	O	cytochrome
14	91	94	O	P450
15	96	102	O	enzymes
NULL

Quetiapine fumarate	237	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	28
Children and Adolescents At steady-state the pharmacokinetics of the parent compound, in children and adolescents (10 to 17 years of age), were similar to adults.
1	0	7	O	Children
2	9	11	O	and
3	13	23	O	Adolescents
4	25	26	O	At
5	28	33	O	steady
6	35	39	O	state
7	41	43	O	the
8	45	60	O	pharmacokinetics
9	62	63	O	of
10	65	67	O	the
11	69	74	O	parent
12	76	83	O	compound
13	84	84	O	,
14	86	87	O	in
15	89	96	O	children
16	98	100	O	and
17	102	112	O	adolescents
18	115	116	O	10
19	118	119	O	to
20	121	122	O	17
21	124	128	O	years
22	130	131	O	of
23	133	135	O	age
24	137	137	O	,
25	139	142	O	were
26	144	150	O	similar
27	152	153	O	to
28	155	160	O	adults
NULL

Quetiapine fumarate	238	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	31
However, when adjusted for dose and weight, AUC and Cmax of the parent compound were 41% and 39% lower, respectively, in children and adolescents than in adults.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	when
4	14	21	O	adjusted
5	23	25	O	for
6	27	30	O	dose
7	32	34	O	and
8	36	41	O	weight
9	42	42	O	,
10	44	46	O	AUC
11	48	50	O	and
12	52	55	O	Cmax
13	57	58	O	of
14	60	62	O	the
15	64	69	O	parent
16	71	78	O	compound
17	80	83	O	were
18	85	87	O	41%
19	89	91	O	and
20	93	95	O	39%
21	97	101	O	lower
22	102	102	O	,
23	104	115	O	respectively
24	116	116	O	,
25	118	119	O	in
26	121	128	O	children
27	130	132	O	and
28	134	144	O	adolescents
29	146	149	O	than
30	151	152	O	in
31	154	159	O	adults
NULL

Quetiapine fumarate	239	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	26
For the active metabolite, norquetiapine, AUC and Cmax were 45% and 31% higher, respectively, in children and adolescents than in adults.
1	0	2	O	For
2	4	6	O	the
3	8	13	O	active
4	15	24	O	metabolite
5	25	25	O	,
6	27	29	O	nor
7	30	39	O	XXXXXXXX
8	40	40	O	,
9	42	44	O	AUC
10	46	48	O	and
11	50	53	O	Cmax
12	55	58	O	were
13	60	62	O	45%
14	64	66	O	and
15	68	70	O	31%
16	72	77	O	higher
17	78	78	O	,
18	80	91	O	respectively
19	92	92	O	,
20	94	95	O	in
21	97	104	O	children
22	106	108	O	and
23	110	120	O	adolescents
24	122	125	O	than
25	127	128	O	in
26	130	135	O	adults
NULL

Quetiapine fumarate	240	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	24
When adjusted for dose and weight, the pharmacokinetics of the metabolite, norquetiapine, was similar between children and adolescents and adults.
1	0	3	O	When
2	5	12	O	adjusted
3	14	16	O	for
4	18	21	O	dose
5	23	25	O	and
6	27	32	O	weight
7	33	33	O	,
8	35	37	O	the
9	39	54	O	pharmacokinetics
10	56	57	O	of
11	59	61	O	the
12	63	72	O	metabolite
13	73	73	O	,
14	75	77	O	nor
15	78	87	O	XXXXXXXX
16	88	88	O	,
17	90	92	O	was
18	94	100	O	similar
19	102	108	O	between
20	110	117	O	children
21	119	121	O	and
22	123	133	O	adolescents
23	135	137	O	and
24	139	144	O	adults
NULL

Quetiapine fumarate	241	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	16
Absorption Quetiapine fumarate is rapidly absorbed after oral administration, reaching peak plasma concentrations in 1.5 hours.
1	0	9	O	Absorption
2	11	29	O	XXXXXXXX
3	31	32	O	is
4	34	40	O	rapidly
5	42	49	O	absorbed
6	51	55	O	after
7	57	60	O	oral
8	62	75	O	administration
9	76	76	O	,
10	78	85	O	reaching
11	87	90	O	peak
12	92	97	O	plasma
13	99	112	O	concentrations
14	114	115	O	in
15	117	119	O	1.5
16	121	125	O	hours
NULL

Quetiapine fumarate	242	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	9
The tablet formulation is 100% bioavailable relative to solution.
1	0	2	O	The
2	4	9	O	tablet
3	11	21	O	formulation
4	23	24	O	is
5	26	29	O	100%
6	31	42	O	bioavailable
7	44	51	O	relative
8	53	54	O	to
9	56	63	O	solution
NULL

Quetiapine fumarate	243	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	24
The bioavailability of quetiapine is marginally affected by administration with food, with Cmax and AUC values increased by 25% and 15%, respectively.
1	0	2	O	The
2	4	18	O	bioavailability
3	20	21	O	of
4	23	32	O	XXXXXXXX
5	34	35	O	is
6	37	46	O	marginally
7	48	55	O	affected
8	57	58	O	by
9	60	73	O	administration
10	75	78	O	with
11	80	83	U-KIN	food
12	84	84	O	,
13	86	89	O	with
14	91	94	O	Cmax
15	96	98	O	and
16	100	102	O	AUC
17	104	109	O	values
18	111	119	O	increased
19	121	122	O	by
20	124	126	O	25%
21	128	130	O	and
22	132	134	O	15%
23	135	135	O	,
24	137	148	O	respectively
K/11:C54602

Quetiapine fumarate	244	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	19
Distribution Quetiapine is widely distributed throughout the body with an apparent volume of distribution of 10*4 L/kg.
1	0	11	O	Distribution
2	13	22	O	XXXXXXXX
3	24	25	O	is
4	27	32	O	widely
5	34	44	O	distributed
6	46	55	O	throughout
7	57	59	O	the
8	61	64	O	body
9	66	69	O	with
10	71	72	O	an
11	74	81	O	apparent
12	83	88	O	volume
13	90	91	O	of
14	93	104	O	distribution
15	106	107	O	of
16	109	112	O	10*4
17	114	114	O	L
18	115	115	O	/
19	116	117	O	kg
NULL

Quetiapine fumarate	245	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	10
It is 83% bound to plasma proteins at therapeutic concentrations.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	83%
4	10	14	O	bound
5	16	17	O	to
6	19	24	O	plasma
7	26	33	O	proteins
8	35	36	O	at
9	38	48	O	therapeutic
10	50	63	O	concentrations
NULL

Quetiapine fumarate	246	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	17
In vitro, quetiapine did not affect the binding of warfarin or diazepam to human serum albumin.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	19	O	XXXXXXXX
5	21	23	O	did
6	25	27	O	not
7	29	34	O	affect
8	36	38	O	the
9	40	46	O	binding
10	48	49	O	of
11	51	58	O	warfarin
12	60	61	O	or
13	63	70	O	diazepam
14	72	73	O	to
15	75	79	O	human
16	81	85	O	serum
17	87	93	O	albumin
NULL

Quetiapine fumarate	247	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	12
In turn, neither warfarin nor diazepam altered the binding of quetiapine.
1	0	1	O	In
2	3	6	O	turn
3	7	7	O	,
4	9	15	O	neither
5	17	24	O	warfarin
6	26	28	O	nor
7	30	37	O	diazepam
8	39	45	O	altered
9	47	49	O	the
10	51	57	O	binding
11	59	60	O	of
12	62	71	O	XXXXXXXX
NULL

Quetiapine fumarate	248	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	31
Metabolism and Elimination Following a single oral dose of 14C-quetiapine, less than 1% of the administered dose was excreted as unchanged drug, indicating that quetiapine is highly metabolized.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	27	35	O	Following
5	37	37	O	a
6	39	44	O	single
7	46	49	O	oral
8	51	54	O	dose
9	56	57	O	of
10	59	61	O	14C
11	63	72	O	XXXXXXXX
12	73	73	O	,
13	75	78	O	less
14	80	83	O	than
15	85	86	O	1%
16	88	89	O	of
17	91	93	O	the
18	95	106	O	administered
19	108	111	O	dose
20	113	115	O	was
21	117	124	O	excreted
22	126	127	O	as
23	129	137	O	unchanged
24	139	142	O	drug
25	143	143	O	,
26	145	154	O	indicating
27	156	159	O	that
28	161	170	O	XXXXXXXX
29	172	173	O	is
30	175	180	O	highly
31	182	192	O	metabolized
NULL

Quetiapine fumarate	249	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	16
Approximately 73% and 20% of the dose was recovered in the urine and feces, respectively.
1	0	12	O	Approximately
2	14	16	O	73%
3	18	20	O	and
4	22	24	O	20%
5	26	27	O	of
6	29	31	O	the
7	33	36	O	dose
8	38	40	O	was
9	42	50	O	recovered
10	52	53	O	in
11	55	57	O	the
12	59	63	O	urine
13	65	67	O	and
14	69	73	O	feces
15	74	74	O	,
16	76	87	O	respectively
NULL

Quetiapine fumarate	250	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	7
Quetiapine is extensively metabolized by the liver.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	metabolized
5	38	39	O	by
6	41	43	O	the
7	45	49	O	liver
NULL

Quetiapine fumarate	251	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	22
The major metabolic pathways are sulfoxidation to the sulfoxide metabolite and oxidation to the parent acid metabolite; both metabolites are pharmacologically inactive.
1	0	2	O	The
2	4	8	O	major
3	10	18	O	metabolic
4	20	27	O	pathways
5	29	31	O	are
6	33	45	O	sulfoxidation
7	47	48	O	to
8	50	52	O	the
9	54	62	O	sulfoxide
10	64	73	O	metabolite
11	75	77	O	and
12	79	87	O	oxidation
13	89	90	O	to
14	92	94	O	the
15	96	101	O	parent
16	103	106	O	acid
17	108	117	O	metabolite
18	120	123	O	both
19	125	135	O	metabolites
20	137	139	O	are
21	141	157	O	pharmacologically
22	159	166	O	inactive
NULL

Quetiapine fumarate	252	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	41
In vitro studies using human liver microsomes revealed that the cytochrome P450 3A4 isoenzyme is involved in the metabolism of quetiapine to its major, but inactive, sulfoxide metabolite and in the metabolism of its active metabolite N-desalkyl quetiapine.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	21	O	using
5	23	27	O	human
6	29	33	O	liver
7	35	44	O	microsomes
8	46	53	O	revealed
9	55	58	O	that
10	60	62	O	the
11	64	73	O	cytochrome
12	75	78	O	P450
13	80	82	O	3A4
14	84	92	O	isoenzyme
15	94	95	O	is
16	97	104	O	involved
17	106	107	O	in
18	109	111	O	the
19	113	122	O	metabolism
20	124	125	O	of
21	127	136	O	XXXXXXXX
22	138	139	O	to
23	141	143	O	its
24	145	149	O	major
25	150	150	O	,
26	152	154	O	but
27	156	163	O	inactive
28	164	164	O	,
29	166	174	O	sulfoxide
30	176	185	O	metabolite
31	187	189	O	and
32	191	192	O	in
33	194	196	O	the
34	198	207	O	metabolism
35	209	210	O	of
36	212	214	O	its
37	216	221	O	active
38	223	232	O	metabolite
39	234	234	O	N
40	236	243	O	desalkyl
41	245	254	O	XXXXXXXX
NULL

Quetiapine fumarate	253	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	29
Age Oral clearance of quetiapine was reduced by 40% in elderly patients (> 65 years, n=9) compared to young patients (n=12), and dosing adjustment may be necessary.
1	0	2	O	Age
2	4	7	O	Oral
3	9	17	O	clearance
4	19	20	O	of
5	22	31	O	XXXXXXXX
6	33	35	O	was
7	37	43	O	reduced
8	45	46	O	by
9	48	50	O	40%
10	52	53	O	in
11	55	61	O	elderly
12	63	70	O	patients
13	73	73	O	>
14	75	76	O	65
15	78	82	O	years
16	83	83	O	,
17	85	87	O	n=9
18	90	97	O	compared
19	99	100	O	to
20	102	106	O	young
21	108	115	O	patients
22	118	121	O	n=12
23	123	123	O	,
24	125	127	O	and
25	129	134	O	dosing
26	136	145	O	adjustment
27	147	149	O	may
28	151	152	O	be
29	154	162	O	necessary
NULL

Quetiapine fumarate	254	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	11
Gender There is no gender effect on the pharmacokinetics of quetiapine.
1	0	5	O	Gender
2	7	11	O	There
3	13	14	O	is
4	16	17	O	no
5	19	24	O	gender
6	26	31	O	effect
7	33	34	O	on
8	36	38	O	the
9	40	55	O	pharmacokinetics
10	57	58	O	of
11	60	69	O	XXXXXXXX
NULL

Quetiapine fumarate	255	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	11
Race There is no race effect on the pharmacokinetics of quetiapine.
1	0	3	O	Race
2	5	9	O	There
3	11	12	O	is
4	14	15	O	no
5	17	20	O	race
6	22	27	O	effect
7	29	30	O	on
8	32	34	O	the
9	36	51	O	pharmacokinetics
10	53	54	O	of
11	56	65	O	XXXXXXXX
NULL

Quetiapine fumarate	256	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	11
Smoking Smoking has no effect on the oral clearance of quetiapine.
1	0	6	O	Smoking
2	8	14	O	Smoking
3	16	18	O	has
4	20	21	O	no
5	23	28	O	effect
6	30	31	O	on
7	33	35	O	the
8	37	40	O	oral
9	42	50	O	clearance
10	52	53	O	of
11	55	64	O	XXXXXXXX
NULL

Quetiapine fumarate	257	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	64
Renal Insufficiency Patients with severe renal impairment (Clcr=10 to 30 mL/min/1.73 m2, n=8) had a 25% lower mean oral clearance than normal subjects (Clcr > 80 mL/min/1.73 m2, n=8), but plasma quetiapine concentrations in the subjects with renal insufficiency were within the range of concentrations seen in normal subjects receiving the same dose.
1	0	4	O	Renal
2	6	18	O	Insufficiency
3	20	27	O	Patients
4	29	32	O	with
5	34	39	O	severe
6	41	45	O	renal
7	47	56	O	impairment
8	59	65	O	Clcr=10
9	67	68	O	to
10	70	71	O	30
11	73	74	O	mL
12	75	75	O	/
13	76	78	O	min
14	79	79	O	/
15	80	83	O	1.73
16	85	86	O	m2
17	87	87	O	,
18	89	91	O	n=8
19	94	96	O	had
20	98	98	O	a
21	100	102	O	25%
22	104	108	O	lower
23	110	113	O	mean
24	115	118	O	oral
25	120	128	O	clearance
26	130	133	O	than
27	135	140	O	normal
28	142	149	O	subjects
29	152	155	O	Clcr
30	157	157	O	>
31	159	160	O	80
32	162	163	O	mL
33	164	164	O	/
34	165	167	O	min
35	168	168	O	/
36	169	172	O	1.73
37	174	175	O	m2
38	176	176	O	,
39	178	180	O	n=8
40	182	182	O	,
41	184	186	O	but
42	188	193	O	plasma
43	195	204	O	XXXXXXXX
44	206	219	O	concentrations
45	221	222	O	in
46	224	226	O	the
47	228	235	O	subjects
48	237	240	O	with
49	242	246	O	renal
50	248	260	O	insufficiency
51	262	265	O	were
52	267	272	O	within
53	274	276	O	the
54	278	282	O	range
55	284	285	O	of
56	287	300	O	concentrations
57	302	305	O	seen
58	307	308	O	in
59	310	315	O	normal
60	317	324	O	subjects
61	326	334	O	receiving
62	336	338	O	the
63	340	343	O	same
64	345	348	O	dose
NULL

Quetiapine fumarate	258	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	9
Dosage adjustment is therefore not needed in these patients.
1	0	5	O	Dosage
2	7	16	O	adjustment
3	18	19	O	is
4	21	29	O	therefore
5	31	33	O	not
6	35	40	O	needed
7	42	43	O	in
8	45	49	O	these
9	51	58	O	patients
NULL

Quetiapine fumarate	260	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	18
Hepatic Insufficiency Hepatically impaired patients (n=8) had a 30% lower mean oral clearance of quetiapine than normal subjects.
1	0	6	O	Hepatic
2	8	20	O	Insufficiency
3	22	32	O	Hepatically
4	34	41	O	impaired
5	43	50	O	patients
6	53	55	O	n=8
7	58	60	O	had
8	62	62	O	a
9	64	66	O	30%
10	68	72	O	lower
11	74	77	O	mean
12	79	82	O	oral
13	84	92	O	clearance
14	94	95	O	of
15	97	106	O	XXXXXXXX
16	108	111	O	than
17	113	118	O	normal
18	120	127	O	subjects
NULL

Quetiapine fumarate	261	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	23
In two of the 8 hepatically impaired patients, AUC and Cmax were 3 times higher than those observed typically in healthy subjects.
1	0	1	O	In
2	3	5	O	two
3	7	8	O	of
4	10	12	O	the
5	14	14	O	8
6	16	26	O	hepatically
7	28	35	O	impaired
8	37	44	O	patients
9	45	45	O	,
10	47	49	O	AUC
11	51	53	O	and
12	55	58	O	Cmax
13	60	63	O	were
14	65	65	O	3
15	67	71	O	times
16	73	78	O	higher
17	80	83	O	than
18	85	89	O	those
19	91	98	O	observed
20	100	108	O	typically
21	110	111	O	in
22	113	119	O	healthy
23	121	128	O	subjects
NULL

Quetiapine fumarate	262	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	26
Since quetiapine is extensively metabolized by the liver, higher plasma levels are expected in the hepatically impaired population, and dosage adjustment may be needed.
1	0	4	O	Since
2	6	15	O	XXXXXXXX
3	17	18	O	is
4	20	30	O	extensively
5	32	42	O	metabolized
6	44	45	O	by
7	47	49	O	the
8	51	55	O	liver
9	56	56	O	,
10	58	63	O	higher
11	65	70	O	plasma
12	72	77	O	levels
13	79	81	O	are
14	83	90	O	expected
15	92	93	O	in
16	95	97	O	the
17	99	109	O	hepatically
18	111	118	O	impaired
19	120	129	O	population
20	130	130	O	,
21	132	134	O	and
22	136	141	O	dosage
23	143	152	O	adjustment
24	154	156	O	may
25	158	159	O	be
26	161	166	O	needed
NULL

Quetiapine fumarate	263	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	23
Drug-Drug Interaction Studies The in vivo assessments of effect of other drugs on the pharmacokinetics of quetiapine are summarized in Table 17.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	20	O	Interaction
4	22	28	O	Studies
5	30	32	O	The
6	34	35	O	in
7	37	40	O	vivo
8	42	52	O	assessments
9	54	55	O	of
10	57	62	O	effect
11	64	65	O	of
12	67	71	O	other
13	73	77	O	drugs
14	79	80	O	on
15	82	84	O	the
16	86	101	O	pharmacokinetics
17	103	104	O	of
18	106	115	O	XXXXXXXX
19	117	119	O	are
20	121	130	O	summarized
21	132	133	O	in
22	135	139	O	Table
23	141	142	O	17
NULL

Quetiapine fumarate	264	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	59
Table 17: The Effect of Other Drugs on the Pharmacokinetics of Quetiapine Coadministered drug Dose schedules Effect on quetiapine pharmacokinetics Coadministered drug Quetiapine Phenytoin 100 mg three times daily 250 mg three times daily 5 fold Increase in oral clearance Divalproex 500 mg twice daily 150 mg twice daily 17% increase mean max plasma concentration at steady state.
1	0	4	O	Table
2	6	7	O	17
3	8	8	O	:
4	10	12	O	The
5	14	19	O	Effect
6	21	22	O	of
7	24	28	O	Other
8	30	34	O	Drugs
9	36	37	O	on
10	39	41	O	the
11	43	58	O	Pharmacokinetics
12	60	61	O	of
13	63	72	O	XXXXXXXX
14	74	87	O	Coadministered
15	89	92	O	drug
16	94	97	O	Dose
17	99	107	O	schedules
18	109	114	O	Effect
19	116	117	O	on
20	119	128	O	XXXXXXXX
21	130	145	O	pharmacokinetics
22	147	160	O	Coadministered
23	162	165	O	drug
24	167	176	O	XXXXXXXX
25	178	186	U-KIN	Phenytoin
26	188	190	O	100
27	192	193	O	mg
28	195	199	O	three
29	201	205	O	times
30	207	211	O	daily
31	213	215	O	250
32	217	218	O	mg
33	220	224	O	three
34	226	230	O	times
35	232	236	O	daily
36	238	238	O	5
37	240	243	O	fold
38	245	252	O	Increase
39	254	255	O	in
40	257	260	O	oral
41	262	270	O	clearance
42	272	281	U-KIN	Divalproex
43	283	285	O	500
44	287	288	O	mg
45	290	294	O	twice
46	296	300	O	daily
47	302	304	O	150
48	306	307	O	mg
49	309	313	O	twice
50	315	319	O	daily
51	321	323	O	17%
52	325	332	B-TRI	increase
53	334	337	I-TRI	mean
54	339	341	I-TRI	max
55	343	348	I-TRI	plasma
56	350	362	L-TRI	concentration
57	364	365	O	at
58	367	372	O	steady
59	374	378	O	state
K/25:C54356 K/42:C54602

Quetiapine fumarate	265	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	168
No effect on absorption or mean oral clearance Thioridazine 200 mg twice daily 300 mg twice daily 65% increase in oral clearance Cimetidine 400 mg three times daily for 4 days 150 mg three times daily 20% decrease in mean oral clearance Ketoconazole (potent CYP 3A4 inhibitor) 200 mg once daily for 4 days 25 mg single dose 84% decrease in oral clearance resulting in a 6.2 fold increase in AUC of quetiapine Fluoxetine 60 mg once daily 300 mg twice daily No change in steady state PK Imipramine 75 mg twice daily 300 mg twice daily No change in steady state PK Haloperidol 7.5 mg twice daily 300 mg twice daily No change in steady state PK Risperidone 3 mg twice daily 300 mg twice daily No change in steady state PK In vitro enzyme inhibition data suggest that quetiapine and 9 of its metabolites would have little inhibitory effect on in vivo metabolism mediated by cytochromes CYP 1A2, 2C9, 2C19, 2D6 and 3A4.
1	0	1	O	No
2	3	8	O	effect
3	10	11	O	on
4	13	22	O	absorption
5	24	25	O	or
6	27	30	O	mean
7	32	35	O	oral
8	37	45	O	clearance
9	47	58	O	Thioridazine
10	60	62	O	200
11	64	65	O	mg
12	67	71	O	twice
13	73	77	O	daily
14	79	81	O	300
15	83	84	O	mg
16	86	90	O	twice
17	92	96	O	daily
18	98	100	O	65%
19	102	109	O	increase
20	111	112	O	in
21	114	117	O	oral
22	119	127	O	clearance
23	129	138	U-KIN	Cimetidine
24	140	142	O	400
25	144	145	O	mg
26	147	151	O	three
27	153	157	O	times
28	159	163	O	daily
29	165	167	O	for
30	169	169	O	4
31	171	174	O	days
32	176	178	O	150
33	180	181	O	mg
34	183	187	O	three
35	189	193	O	times
36	195	199	O	daily
37	201	203	O	20%
38	205	212	O	decrease
39	214	215	O	in
40	217	220	O	mean
41	222	225	O	oral
42	227	235	O	clearance
43	237	248	U-KIN	Ketoconazole
44	251	256	O	potent
45	258	260	O	CYP
46	262	264	O	3A4
47	266	274	O	inhibitor
48	277	279	O	200
49	281	282	O	mg
50	284	287	O	once
51	289	293	O	daily
52	295	297	O	for
53	299	299	O	4
54	301	304	O	days
55	306	307	O	25
56	309	310	O	mg
57	312	317	O	single
58	319	322	O	dose
59	324	326	O	84%
60	328	335	O	decrease
61	337	338	O	in
62	340	343	O	oral
63	345	353	O	clearance
64	355	363	O	resulting
65	365	366	O	in
66	368	368	O	a
67	370	372	O	6.2
68	374	377	O	fold
69	379	386	O	increase
70	388	389	O	in
71	391	393	O	AUC
72	395	396	O	of
73	398	407	O	XXXXXXXX
74	409	418	U-KIN	Fluoxetine
75	420	421	O	60
76	423	424	O	mg
77	426	429	O	once
78	431	435	O	daily
79	437	439	O	300
80	441	442	O	mg
81	444	448	O	twice
82	450	454	O	daily
83	456	457	O	No
84	459	464	O	change
85	466	467	O	in
86	469	474	O	steady
87	476	480	O	state
88	482	483	O	PK
89	485	494	O	Imipramine
90	496	497	O	75
91	499	500	O	mg
92	502	506	O	twice
93	508	512	O	daily
94	514	516	O	300
95	518	519	O	mg
96	521	525	O	twice
97	527	531	O	daily
98	533	534	O	No
99	536	541	O	change
100	543	544	O	in
101	546	551	O	steady
102	553	557	O	state
103	559	560	O	PK
104	562	572	O	Haloperidol
105	574	576	O	7.5
106	578	579	O	mg
107	581	585	O	twice
108	587	591	O	daily
109	593	595	O	300
110	597	598	O	mg
111	600	604	O	twice
112	606	610	O	daily
113	612	613	O	No
114	615	620	O	change
115	622	623	O	in
116	625	630	O	steady
117	632	636	O	state
118	638	639	O	PK
119	641	651	O	Risperidone
120	653	653	O	3
121	655	656	O	mg
122	658	662	O	twice
123	664	668	O	daily
124	670	672	O	300
125	674	675	O	mg
126	677	681	O	twice
127	683	687	O	daily
128	689	690	O	No
129	692	697	O	change
130	699	700	O	in
131	702	707	O	steady
132	709	713	O	state
133	715	716	O	PK
134	718	719	O	In
135	721	725	O	vitro
136	727	732	O	enzyme
137	734	743	O	inhibition
138	745	748	O	data
139	750	756	O	suggest
140	758	761	O	that
141	763	772	O	XXXXXXXX
142	774	776	O	and
143	778	778	O	9
144	780	781	O	of
145	783	785	O	its
146	787	797	O	metabolites
147	799	803	O	would
148	805	808	O	have
149	810	815	O	little
150	817	826	O	inhibitory
151	828	833	O	effect
152	835	836	O	on
153	838	839	O	in
154	841	844	O	vivo
155	846	855	O	metabolism
156	857	864	O	mediated
157	866	867	O	by
158	869	879	O	cytochromes
159	881	883	O	CYP
160	885	887	O	1A2
161	888	888	O	,
162	890	892	O	2C9
163	893	893	O	,
164	895	898	O	2C19
165	899	899	O	,
166	901	903	O	2D6
167	905	907	O	and
168	909	911	O	3A4
K/23:C54356 K/43:C54355 K/74:C54605

Quetiapine fumarate	266	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	23
Quetiapine at doses of 750 mg/day did not affect the single dose pharmacokinetics of antipyrine, lithium or lorazepam (Table 18).
1	0	9	O	XXXXXXXX
2	11	12	O	at
3	14	18	O	doses
4	20	21	O	of
5	23	25	O	750
6	27	28	O	mg
7	29	29	O	/
8	30	32	O	day
9	34	36	O	did
10	38	40	O	not
11	42	47	O	affect
12	49	51	O	the
13	53	58	O	single
14	60	63	O	dose
15	65	80	O	pharmacokinetics
16	82	83	O	of
17	85	94	O	antipyrine
18	95	95	O	,
19	97	103	O	lithium
20	105	106	O	or
21	108	116	O	lorazepam
22	119	123	O	Table
23	125	126	O	18
NULL

Quetiapine fumarate	267	34090-1	4e1e5249-1cb7-4cc2-ad5a-cdeeee2f494f	116
Table 18: The Effect of Quetiapine on the Pharmacokinetics of Other Drugs Coadministered drug Dose schedules Effect on other drugs pharmacokinetics Coadministered drug Quetiapine Lorazepam 2 mg, single dose 250 mg three times daily Oral clearance of lorazepam reduced by 20% Divalproex 500 mg twice daily 150 mg twice daily Cmax and AUC of free valproic acid at steady-state was decreased by 10 to 12% Lithium Up to 2400 mg/day given in twice daily doses 250 mg three times daily No effect on steady-state pharmacokinetics of lithium Antipyrine 1 g, single dose 250 mg three times daily No effect on clearance of antipyrine or urinary recovery of its metabolites
1	0	4	O	Table
2	6	7	O	18
3	8	8	O	:
4	10	12	O	The
5	14	19	O	Effect
6	21	22	O	of
7	24	33	O	XXXXXXXX
8	35	36	O	on
9	38	40	O	the
10	42	57	O	Pharmacokinetics
11	59	60	O	of
12	62	66	O	Other
13	68	72	O	Drugs
14	74	87	O	Coadministered
15	89	92	O	drug
16	94	97	O	Dose
17	99	107	O	schedules
18	109	114	O	Effect
19	116	117	O	on
20	119	123	O	other
21	125	129	O	drugs
22	131	146	O	pharmacokinetics
23	148	161	O	Coadministered
24	163	166	O	drug
25	168	177	O	XXXXXXXX
26	179	187	O	Lorazepam
27	189	189	O	2
28	191	192	O	mg
29	193	193	O	,
30	195	200	O	single
31	202	205	O	dose
32	207	209	O	250
33	211	212	O	mg
34	214	218	O	three
35	220	224	O	times
36	226	230	O	daily
37	232	235	O	Oral
38	237	245	O	clearance
39	247	248	O	of
40	250	258	U-KIN	lorazepam
41	260	266	O	reduced
42	268	269	O	by
43	271	273	O	20%
44	275	284	U-KIN	Divalproex
45	286	288	O	500
46	290	291	O	mg
47	293	297	O	twice
48	299	303	O	daily
49	305	307	O	150
50	309	310	O	mg
51	312	316	O	twice
52	318	322	O	daily
53	324	327	O	Cmax
54	329	331	O	and
55	333	335	O	AUC
56	337	338	O	of
57	340	343	O	free
58	345	352	O	valproic
59	354	357	O	acid
60	359	360	O	at
61	362	367	O	steady
62	369	373	O	state
63	375	377	O	was
64	379	387	O	decreased
65	389	390	O	by
66	392	393	O	10
67	395	396	O	to
68	398	400	O	12%
69	402	408	O	Lithium
70	410	411	O	Up
71	413	414	O	to
72	416	419	O	2400
73	421	422	O	mg
74	423	423	O	/
75	424	426	O	day
76	428	432	O	given
77	434	435	O	in
78	437	441	O	twice
79	443	447	O	daily
80	449	453	O	doses
81	455	457	O	250
82	459	460	O	mg
83	462	466	O	three
84	468	472	O	times
85	474	478	O	daily
86	480	481	O	No
87	483	488	O	effect
88	490	491	O	on
89	493	498	O	steady
90	500	504	O	state
91	506	521	O	pharmacokinetics
92	523	524	O	of
93	526	532	O	lithium
94	534	543	O	Antipyrine
95	545	545	O	1
96	547	547	O	g
97	548	548	O	,
98	550	555	O	single
99	557	560	O	dose
100	562	564	O	250
101	566	567	O	mg
102	569	573	O	three
103	575	579	O	times
104	581	585	O	daily
105	587	588	O	No
106	590	595	O	effect
107	597	598	O	on
108	600	608	O	clearance
109	610	611	O	of
110	613	622	O	antipyrine
111	624	625	O	or
112	627	633	O	urinary
113	635	642	O	recovery
114	644	645	O	of
115	647	649	O	its
116	651	661	O	metabolites
K/40:C54357 K/44:C54615

REMERON	3431	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	27
As with other drugs, the potential for interaction by a variety of mechanisms (e.g., pharmacodynamic, pharmacokinetic inhibition or enhancement, etc.) is a possibility.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	18	O	drugs
5	19	19	O	,
6	21	23	O	the
7	25	33	O	potential
8	35	37	O	for
9	39	49	O	interaction
10	51	52	O	by
11	54	54	O	a
12	56	62	O	variety
13	64	65	O	of
14	67	76	O	mechanisms
15	79	81	O	e.g
16	83	83	O	,
17	85	99	O	pharmacodynamic
18	100	100	O	,
19	102	116	O	pharmacokinetic
20	118	127	O	inhibition
21	129	130	O	or
22	132	142	O	enhancement
23	143	143	O	,
24	145	147	O	etc
25	151	152	O	is
26	154	154	O	a
27	156	166	O	possibility
NULL

REMERON	3433	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	20
The metabolism and pharmacokinetics of REMERON (mirtazapine) Tablets may be affected by the induction or inhibition of drug-metabolizing enzymes.
1	0	2	O	The
2	4	13	O	metabolism
3	15	17	O	and
4	19	34	O	pharmacokinetics
5	36	37	O	of
6	39	45	O	XXXXXXXX
7	48	58	O	XXXXXXXX
8	61	67	O	Tablets
9	69	71	O	may
10	73	74	O	be
11	76	83	O	affected
12	85	86	O	by
13	88	90	O	the
14	92	100	O	induction
15	102	103	O	or
16	105	114	O	inhibition
17	116	117	O	of
18	119	122	O	drug
19	124	135	O	metabolizing
20	137	143	O	enzymes
NULL

REMERON	3434	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	39
(these studies used both drugs at steady state) In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%.
1	1	5	O	these
2	7	13	O	studies
3	15	18	O	used
4	20	23	O	both
5	25	29	O	drugs
6	31	32	O	at
7	34	39	O	steady
8	41	45	O	state
9	48	49	O	In
10	51	57	O	healthy
11	59	62	O	male
12	64	71	O	patients
13	74	77	O	n=18
14	79	79	O	,
15	81	89	O	phenytoin
16	92	94	O	200
17	96	97	O	mg
18	99	103	O	daily
19	106	114	O	increased
20	116	126	O	XXXXXXXX
21	129	130	O	30
22	132	133	O	mg
23	135	139	O	daily
24	142	150	O	clearance
25	152	156	O	about
26	158	158	O	2
27	160	163	O	fold
28	164	164	O	,
29	166	174	O	resulting
30	176	177	O	in
31	179	179	O	a
32	181	188	O	decrease
33	190	191	O	in
34	193	199	O	average
35	201	206	O	plasma
36	208	218	O	XXXXXXXX
37	220	233	O	concentrations
38	235	236	O	of
39	238	240	O	45%
NULL

REMERON	3435	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	9
Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.
1	0	10	O	XXXXXXXX
2	12	14	O	did
3	16	18	O	not
4	20	32	O	significantly
5	34	39	O	affect
6	41	43	O	the
7	45	60	O	pharmacokinetics
8	62	63	O	of
9	65	73	O	phenytoin
NULL

REMERON	3436	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	26
In healthy male patients (n=24), carbamazepine (400 mg b.i.d.) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 60%.
1	0	1	O	In
2	3	9	O	healthy
3	11	14	O	male
4	16	23	O	patients
5	26	29	O	n=24
6	31	31	O	,
7	33	45	U-KIN	carbamazepine
8	48	50	O	400
9	52	53	O	mg
10	55	59	O	b.i.d
11	63	71	O	clearance
12	73	77	O	about
13	79	79	O	2
14	81	84	O	fold
15	85	85	O	,
16	87	95	O	resulting
17	97	98	O	in
18	100	100	O	a
19	102	109	O	decrease
20	111	112	O	in
21	114	120	O	average
22	122	127	O	plasma
23	129	139	O	XXXXXXXX
24	141	154	O	concentrations
25	156	157	O	of
26	159	161	O	60%
K/7:C54356

REMERON	3437	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	28
When phenytoin, carbamazepine, or another inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased.
1	0	3	O	When
2	5	13	U-KIN	phenytoin
3	14	14	O	,
4	16	28	U-KIN	carbamazepine
5	29	29	O	,
6	31	32	O	or
7	34	40	O	another
8	42	48	B-KIN	inducer
9	50	51	I-KIN	of
10	53	59	I-KIN	hepatic
11	61	70	L-KIN	metabolism
12	73	76	O	such
13	78	79	O	as
14	81	90	U-KIN	rifampicin
15	93	94	O	is
16	96	100	O	added
17	102	103	O	to
18	105	115	O	XXXXXXXX
19	117	123	O	therapy
20	124	124	O	,
21	126	128	O	the
22	130	140	O	XXXXXXXX
23	142	145	O	dose
24	147	149	O	may
25	151	154	O	have
26	156	157	O	to
27	159	160	O	be
28	162	170	O	increased
K/14:C54356 K/2:C54356 K/4:C54356 K/8:C54356

REMERON	3438	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	19
If treatment with such a medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.
1	0	1	O	If
2	3	11	O	treatment
3	13	16	O	with
4	18	21	O	such
5	23	23	O	a
6	25	33	O	medicinal
7	35	41	O	product
8	43	44	O	is
9	46	57	O	discontinued
10	58	58	O	,
11	60	61	O	it
12	63	65	O	may
13	67	68	O	be
14	70	78	O	necessary
15	80	81	O	to
16	83	88	O	reduce
17	90	92	O	the
18	94	104	O	XXXXXXXX
19	106	109	O	dose
NULL

REMERON	3439	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	51
In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%.
1	0	1	O	In
2	3	9	O	healthy
3	11	14	O	male
4	16	23	O	patients
5	26	29	O	n=12
6	31	31	O	,
7	33	36	O	when
8	38	47	U-KIN	cimetidine
9	48	48	O	,
10	50	50	O	a
11	52	55	O	weak
12	57	65	O	inhibitor
13	67	68	O	of
14	70	75	O	CYP1A2
15	76	76	O	,
16	78	83	O	CYP2D6
17	84	84	O	,
18	86	88	O	and
19	90	95	O	CYP3A4
20	96	96	O	,
21	98	102	O	given
22	104	105	O	at
23	107	109	O	800
24	111	112	O	mg
25	114	118	O	b.i.d
26	121	122	O	at
27	124	129	O	steady
28	131	135	O	state
29	137	139	O	was
30	141	154	O	coadministered
31	156	159	O	with
32	161	171	O	XXXXXXXX
33	174	175	O	30
34	177	178	O	mg
35	180	184	O	daily
36	187	188	O	at
37	190	195	O	steady
38	197	201	O	state
39	202	202	O	,
40	204	206	O	the
41	208	211	O	Area
42	213	217	O	Under
43	219	221	O	the
44	223	227	O	Curve
45	230	232	O	AUC
46	235	236	O	of
47	238	248	O	XXXXXXXX
48	250	258	O	increased
49	260	263	O	more
50	265	268	O	than
51	270	272	O	50%
K/8:C54605

REMERON	3440	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	11
Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine.
1	0	10	O	XXXXXXXX
2	12	14	O	did
3	16	18	O	not
4	20	24	O	cause
5	26	33	O	relevant
6	35	41	O	changes
7	43	44	O	in
8	46	48	O	the
9	50	65	O	pharmacokinetics
10	67	68	O	of
11	70	79	O	cimetidine
NULL

REMERON	3441	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	23
The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.
1	0	2	O	The
2	4	14	O	XXXXXXXX
3	16	19	O	dose
4	21	23	O	may
5	25	28	O	have
6	30	31	O	to
7	33	34	O	be
8	36	44	O	decreased
9	46	49	O	when
10	51	61	O	concomitant
11	63	71	O	treatment
12	73	76	O	with
13	78	87	U-KIN	cimetidine
14	89	90	O	is
15	92	98	O	started
16	99	99	O	,
17	101	102	O	or
18	104	112	O	increased
19	114	117	O	when
20	119	128	O	cimetidine
21	130	138	O	treatment
22	140	141	O	is
23	143	154	O	discontinued
K/13:C54355

REMERON	3442	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	45
In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.
1	0	1	O	In
2	3	9	O	healthy
3	10	10	O	,
4	12	15	O	male
5	16	16	O	,
6	18	26	O	Caucasian
7	28	35	O	patients
8	38	41	O	n=24
9	43	43	O	,
10	45	60	O	coadministration
11	62	63	O	of
12	65	67	O	the
13	69	74	B-KIN	potent
14	76	81	I-KIN	CYP3A4
15	83	91	L-KIN	inhibitor
16	93	104	U-KIN	ketoconazole
17	107	109	O	200
18	111	112	O	mg
19	114	118	O	b.i.d
20	121	123	O	for
21	125	127	O	6.5
22	129	132	O	days
23	135	143	B-TRI	increased
24	145	147	I-TRI	the
25	149	152	I-TRI	peak
26	154	159	I-TRI	plasma
27	161	166	L-TRI	levels
28	168	170	O	and
29	172	174	O	the
30	176	178	O	AUC
31	180	181	O	of
32	183	183	O	a
33	185	190	O	single
34	192	193	O	30
35	195	196	O	mg
36	198	201	O	dose
37	203	204	O	of
38	206	216	O	XXXXXXXX
39	218	219	O	by
40	221	233	O	approximately
41	235	237	O	40%
42	239	241	O	and
43	243	245	O	50%
44	246	246	O	,
45	248	259	O	respectively
K/13:C54602 K/16:C54602

REMERON	3443	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	23
Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.
1	0	6	U-TRI	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	47	O	coadministering
7	49	59	O	XXXXXXXX
8	61	64	O	with
9	66	71	B-UNK	potent
10	73	78	I-UNK	CYP3A4
11	80	89	L-UNK	inhibitors
12	90	90	O	,
13	92	94	B-UNK	HIV
14	96	103	I-UNK	protease
15	105	114	L-UNK	inhibitors
16	115	115	O	,
17	117	121	B-UNK	azole
18	123	133	L-UNK	antifungals
19	134	134	O	,
20	136	147	U-UNK	erythromycin
21	148	148	O	,
22	150	151	O	or
23	153	162	U-UNK	nefazodone
NULL

REMERON	3444	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	45
In an in vivo interaction study in healthy, CYP2D6 extensive metabolizer patients (n=24), mirtazapine (30 mg/day), at steady state, did not cause relevant changes in the pharmacokinetics of steady state paroxetine (40 mg/day), a CYP2D6 inhibitor.
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	12	O	vivo
5	14	24	O	interaction
6	26	30	O	study
7	32	33	O	in
8	35	41	O	healthy
9	42	42	O	,
10	44	49	O	CYP2D6
11	51	59	O	extensive
12	61	71	O	metabolizer
13	73	80	O	patients
14	83	86	O	n=24
15	88	88	O	,
16	90	100	O	XXXXXXXX
17	103	104	O	30
18	106	107	O	mg
19	108	108	O	/
20	109	111	O	day
21	113	113	O	,
22	115	116	O	at
23	118	123	O	steady
24	125	129	O	state
25	130	130	O	,
26	132	134	O	did
27	136	138	O	not
28	140	144	O	cause
29	146	153	O	relevant
30	155	161	O	changes
31	163	164	O	in
32	166	168	O	the
33	170	185	O	pharmacokinetics
34	187	188	O	of
35	190	195	O	steady
36	197	201	O	state
37	203	212	O	paroxetine
38	215	216	O	40
39	218	219	O	mg
40	220	220	O	/
41	221	223	O	day
42	225	225	O	,
43	227	227	O	a
44	229	234	O	CYP2D6
45	236	244	O	inhibitor
NULL

REMERON	3445	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	45
In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.
1	0	1	O	In
2	3	9	O	healthy
3	10	10	O	,
4	12	17	O	CYP2D6
5	19	27	O	extensive
6	29	39	O	metabolizer
7	41	48	O	patients
8	51	54	O	n=32
9	56	56	O	,
10	58	70	O	amitriptyline
11	73	74	O	75
12	76	77	O	mg
13	79	83	O	daily
14	85	85	O	,
15	87	88	O	at
16	90	95	O	steady
17	97	101	O	state
18	102	102	O	,
19	104	106	O	did
20	108	110	O	not
21	112	116	O	cause
22	118	125	O	relevant
23	127	133	O	changes
24	135	136	O	in
25	138	140	O	the
26	142	157	O	pharmacokinetics
27	159	160	O	of
28	162	167	O	steady
29	169	173	O	state
30	175	185	O	XXXXXXXX
31	188	189	O	30
32	191	192	O	mg
33	194	198	O	daily
34	202	212	O	XXXXXXXX
35	214	217	O	also
36	219	221	O	did
37	223	225	O	not
38	227	231	O	cause
39	233	240	O	relevant
40	242	248	O	changes
41	250	251	O	to
42	253	255	O	the
43	257	272	O	pharmacokinetics
44	274	275	O	of
45	277	289	O	amitriptyline
NULL

REMERON	3446	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	34
In healthy male subjects (n=16), mirtazapine (30 mg daily), at steady state, caused a small (0.2) but statistically significant increase in the International Normalized Ratio (INR) in subjects treated with warfarin.
1	0	1	O	In
2	3	9	O	healthy
3	11	14	O	male
4	16	23	O	subjects
5	26	29	O	n=16
6	31	31	O	,
7	33	43	O	XXXXXXXX
8	46	47	O	30
9	49	50	O	mg
10	52	56	O	daily
11	58	58	O	,
12	60	61	O	at
13	63	68	O	steady
14	70	74	O	state
15	75	75	O	,
16	77	82	O	caused
17	84	84	O	a
18	86	90	O	small
19	93	95	O	0.2
20	98	100	O	but
21	102	114	O	statistically
22	116	126	O	significant
23	128	135	B-EFF	increase
24	137	138	I-EFF	in
25	140	142	I-EFF	the
26	144	156	I-EFF	International
27	158	167	I-EFF	Normalized
28	169	173	I-EFF	Ratio
29	176	178	L-EFF	INR
30	181	182	O	in
31	184	191	O	subjects
32	193	199	O	treated
33	201	204	O	with
34	206	213	U-DYN	warfarin
D/34:23:1

REMERON	3447	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	33
As at a higher dose of mirtazapine, a more pronounced effect can not be excluded, it is advisable to monitor the INR in case of concomitant treatment of warfarin with mirtazapine.
1	0	1	O	As
2	3	4	O	at
3	6	6	O	a
4	8	13	O	higher
5	15	18	O	dose
6	20	21	O	of
7	23	33	O	XXXXXXXX
8	34	34	O	,
9	36	36	O	a
10	38	41	O	more
11	43	52	O	pronounced
12	54	59	O	effect
13	61	63	O	can
14	65	67	O	not
15	69	70	O	be
16	72	79	O	excluded
17	80	80	O	,
18	82	83	O	it
19	85	86	O	is
20	88	96	O	advisable
21	98	99	O	to
22	101	107	U-TRI	monitor
23	109	111	O	the
24	113	115	O	INR
25	117	118	O	in
26	120	123	O	case
27	125	126	O	of
28	128	138	O	concomitant
29	140	148	O	treatment
30	150	151	O	of
31	153	160	U-UNK	warfarin
32	162	165	O	with
33	167	177	O	XXXXXXXX
NULL

REMERON	3448	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	42
No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of lithium (600 mg/day for 10 days) at steady state and a single 30-mg dose of mirtazapine.
1	0	1	O	No
2	3	10	O	relevant
3	12	19	O	clinical
4	21	27	O	effects
5	29	30	O	or
6	32	42	O	significant
7	44	50	O	changes
8	52	53	O	in
9	55	70	O	pharmacokinetics
10	72	75	O	have
11	77	80	O	been
12	82	89	O	observed
13	91	92	O	in
14	94	100	O	healthy
15	102	105	O	male
16	107	114	O	subjects
17	116	117	O	on
18	119	128	O	concurrent
19	130	138	O	treatment
20	140	143	O	with
21	145	158	O	subtherapeutic
22	160	165	O	levels
23	167	168	O	of
24	170	176	O	lithium
25	179	181	O	600
26	183	184	O	mg
27	185	185	O	/
28	186	188	O	day
29	190	192	O	for
30	194	195	O	10
31	197	200	O	days
32	203	204	O	at
33	206	211	O	steady
34	213	217	O	state
35	219	221	O	and
36	223	223	O	a
37	225	230	O	single
38	232	233	O	30
39	235	236	O	mg
40	238	241	O	dose
41	243	244	O	of
42	246	256	O	XXXXXXXX
NULL

REMERON	3449	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	14
The effects of higher doses of lithium on the pharmacokinetics of mirtazapine are unknown.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	20	O	higher
5	22	26	O	doses
6	28	29	O	of
7	31	37	O	lithium
8	39	40	O	on
9	42	44	O	the
10	46	61	O	pharmacokinetics
11	63	64	O	of
12	66	76	O	XXXXXXXX
13	78	80	O	are
14	82	88	O	unknown
NULL

REMERON	3450	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	44
In an in vivo, nonrandomized, interaction study, subjects (n=6) in need of treatment with an antipsychotic and antidepressant drug, showed that mirtazapine (30 mg daily) at steady state did not influence the pharmacokinetics of risperidone (up to 3 mg b.i.d.
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	12	O	vivo
5	13	13	O	,
6	15	27	O	nonrandomized
7	28	28	O	,
8	30	40	O	interaction
9	42	46	O	study
10	47	47	O	,
11	49	56	O	subjects
12	59	61	O	n=6
13	64	65	O	in
14	67	70	O	need
15	72	73	O	of
16	75	83	O	treatment
17	85	88	O	with
18	90	91	O	an
19	93	105	O	antipsychotic
20	107	109	O	and
21	111	124	O	antidepressant
22	126	129	O	drug
23	130	130	O	,
24	132	137	O	showed
25	139	142	O	that
26	144	154	O	XXXXXXXX
27	157	158	O	30
28	160	161	O	mg
29	163	167	O	daily
30	170	171	O	at
31	173	178	O	steady
32	180	184	O	state
33	186	188	O	did
34	190	192	O	not
35	194	202	O	influence
36	204	206	O	the
37	208	223	O	pharmacokinetics
38	225	226	O	of
39	228	238	O	risperidone
40	241	242	O	up
41	244	245	O	to
42	247	247	O	3
43	249	250	O	mg
44	252	256	O	b.i.d
NULL

REMERON	3451	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	24
Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	36	O	alcohol
5	39	48	O	equivalent
6	50	51	O	to
7	53	54	O	60
8	56	56	O	g
9	59	61	O	had
10	63	63	O	a
11	65	71	O	minimal
12	73	78	O	effect
13	80	81	O	on
14	83	88	O	plasma
15	90	95	O	levels
16	97	98	O	of
17	100	110	O	XXXXXXXX
18	113	114	O	15
19	116	117	O	mg
20	120	121	O	in
21	123	123	O	6
22	125	131	O	healthy
23	133	136	O	male
24	138	145	O	subjects
NULL

REMERON	3452	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	22
However, the impairment of cognitive and motor skills produced by REMERON were shown to be additive with those produced by alcohol.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	22	O	impairment
5	24	25	O	of
6	27	35	O	cognitive
7	37	39	O	and
8	41	45	O	motor
9	47	52	O	skills
10	54	61	O	produced
11	63	64	O	by
12	66	72	O	XXXXXXXX
13	74	77	O	were
14	79	83	O	shown
15	85	86	O	to
16	88	89	O	be
17	91	98	O	additive
18	100	103	O	with
19	105	109	O	those
20	111	118	O	produced
21	120	121	O	by
22	123	129	U-DYN	alcohol
NULL

REMERON	3453	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	12
Accordingly, patients should be advised to avoid alcohol while taking REMERON.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	20	O	patients
4	22	27	O	should
5	29	30	O	be
6	32	38	O	advised
7	40	41	O	to
8	43	47	U-TRI	avoid
9	49	55	U-UNK	alcohol
10	57	61	O	while
11	63	68	O	taking
12	70	76	O	XXXXXXXX
NULL

REMERON	3454	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	21
Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	37	O	diazepam
5	40	41	O	15
6	43	44	O	mg
7	47	49	O	had
8	51	51	O	a
9	53	59	O	minimal
10	61	66	O	effect
11	68	69	O	on
12	71	76	O	plasma
13	78	83	O	levels
14	85	86	O	of
15	88	98	O	XXXXXXXX
16	101	102	O	15
17	104	105	O	mg
18	108	109	O	in
19	111	112	O	12
20	114	120	O	healthy
21	122	129	O	subjects
NULL

REMERON	3455	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	21
However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	22	B-EFF	impairment
5	24	25	I-EFF	of
6	27	31	I-EFF	motor
7	33	38	L-EFF	skills
8	40	47	O	produced
9	49	50	O	by
10	52	58	O	XXXXXXXX
11	60	62	O	has
12	64	67	O	been
13	69	73	O	shown
14	75	76	O	to
15	78	79	O	be
16	81	88	O	additive
17	90	93	O	with
18	95	99	O	those
19	101	106	O	caused
20	108	109	O	by
21	111	118	U-DYN	diazepam
D/21:4:1

REMERON	3456	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	16
Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	20	O	patients
4	22	27	O	should
5	29	30	O	be
6	32	38	O	advised
7	40	41	O	to
8	43	47	U-TRI	avoid
9	49	56	U-UNK	diazepam
10	58	60	O	and
11	62	66	O	other
12	68	74	O	similar
13	76	80	O	drugs
14	82	86	O	while
15	88	93	O	taking
16	95	101	O	XXXXXXXX
NULL

REMERON	3457	34073-7	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	40
The risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes) may be increased with concomitant use of medicines which prolong the QTc interval (e.g., some antipsychotics and antibiotics) and in case of mirtazapine overdose.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	13	B-EFF	QT
5	15	26	L-EFF	prolongation
6	28	30	O	and
7	31	31	O	/
8	32	33	O	or
9	35	45	B-EFF	ventricular
10	47	57	L-EFF	arrhythmias
11	60	62	O	e.g
12	64	64	O	,
13	66	73	B-EFF	Torsades
14	75	76	I-EFF	de
15	78	84	L-EFF	Pointes
16	87	89	O	may
17	91	92	O	be
18	94	102	O	increased
19	104	107	O	with
20	109	119	O	concomitant
21	121	123	O	use
22	125	126	O	of
23	128	136	B-DYN	medicines
24	138	142	I-DYN	which
25	144	150	I-DYN	prolong
26	152	154	I-DYN	the
27	156	158	I-DYN	QTc
28	160	167	L-DYN	interval
29	170	172	O	e.g
30	174	174	O	,
31	176	179	O	some
32	181	194	U-DYN	antipsychotics
33	196	198	O	and
34	200	210	U-DYN	antibiotics
35	213	215	O	and
36	217	218	O	in
37	220	223	O	case
38	225	226	O	of
39	228	238	O	XXXXXXXX
40	240	247	O	overdose
D/23:13:1 D/23:4:1 D/23:9:1 D/32:13:1 D/32:4:1 D/32:9:1 D/34:13:1 D/34:4:1 D/34:9:1

REMERON	3458	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	24
The mechanism of action of REMERON (mirtazapine) Tablets, as with other drugs effective in the treatment of major depressive disorder, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	33	O	XXXXXXXX
7	36	46	O	XXXXXXXX
8	49	55	O	Tablets
9	56	56	O	,
10	58	59	O	as
11	61	64	O	with
12	66	70	O	other
13	72	76	O	drugs
14	78	86	O	effective
15	88	89	O	in
16	91	93	O	the
17	95	103	O	treatment
18	105	106	O	of
19	108	112	O	major
20	114	123	O	depressive
21	125	132	O	disorder
22	133	133	O	,
23	135	136	O	is
24	138	144	O	unknown
NULL

REMERON	3459	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	14
Evidence gathered in preclinical studies suggests that mirtazapine enhances central noradrenergic and serotonergic activity.
1	0	7	O	Evidence
2	9	16	O	gathered
3	18	19	O	in
4	21	31	O	preclinical
5	33	39	O	studies
6	41	48	O	suggests
7	50	53	O	that
8	55	65	O	XXXXXXXX
9	67	74	O	enhances
10	76	82	O	central
11	84	96	O	noradrenergic
12	98	100	O	and
13	102	113	O	serotonergic
14	115	122	O	activity
NULL

REMERON	3460	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	36
These studies have shown that mirtazapine acts as an antagonist at central presynaptic A2-adrenergic inhibitory autoreceptors and heteroreceptors, an action that is postulated to result in an increase in central noradrenergic and serotonergic activity.
1	0	4	O	These
2	6	12	O	studies
3	14	17	O	have
4	19	23	O	shown
5	25	28	O	that
6	30	40	O	XXXXXXXX
7	42	45	O	acts
8	47	48	O	as
9	50	51	O	an
10	53	62	O	antagonist
11	64	65	O	at
12	67	73	O	central
13	75	85	O	presynaptic
14	87	88	O	A2
15	90	99	O	adrenergic
16	101	110	O	inhibitory
17	112	124	O	autoreceptors
18	126	128	O	and
19	130	144	O	heteroreceptors
20	145	145	O	,
21	147	148	O	an
22	150	155	O	action
23	157	160	O	that
24	162	163	O	is
25	165	174	O	postulated
26	176	177	O	to
27	179	184	O	result
28	186	187	O	in
29	189	190	O	an
30	192	199	O	increase
31	201	202	O	in
32	204	210	O	central
33	212	224	O	noradrenergic
34	226	228	O	and
35	230	241	O	serotonergic
36	243	250	O	activity
NULL

REMERON	3461	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	12
Mirtazapine is a potent antagonist of 5-HT2 and 5-HT3 receptors.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	22	O	potent
5	24	33	O	antagonist
6	35	36	O	of
7	38	38	O	5
8	40	42	O	HT2
9	44	46	O	and
10	48	48	O	5
11	50	52	O	HT3
12	54	62	O	receptors
NULL

REMERON	3462	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	13
Mirtazapine has no significant affinity for the 5-HT1A and 5-HT1B receptors.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	17	O	no
4	19	29	O	significant
5	31	38	O	affinity
6	40	42	O	for
7	44	46	O	the
8	48	48	O	5
9	50	53	O	HT1A
10	55	57	O	and
11	59	59	O	5
12	61	64	O	HT1B
13	66	74	O	receptors
NULL

REMERON	3463	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	19
Mirtazapine is a potent antagonist of histamine (H1) receptors, a property that may explain its prominent sedative effects.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	22	O	potent
5	24	33	O	antagonist
6	35	36	O	of
7	38	46	O	histamine
8	49	50	O	H1
9	53	61	O	receptors
10	62	62	O	,
11	64	64	O	a
12	66	73	O	property
13	75	78	O	that
14	80	82	O	may
15	84	90	O	explain
16	92	94	O	its
17	96	104	O	prominent
18	106	113	O	sedative
19	115	121	O	effects
NULL

REMERON	3464	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	24
Mirtazapine is a moderate peripheral A1-adrenergic antagonist, a property that may explain the occasional orthostatic hypotension reported in association with its use.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	24	O	moderate
5	26	35	O	peripheral
6	37	38	O	A1
7	40	49	O	adrenergic
8	51	60	O	antagonist
9	61	61	O	,
10	63	63	O	a
11	65	72	O	property
12	74	77	O	that
13	79	81	O	may
14	83	89	O	explain
15	91	93	O	the
16	95	104	O	occasional
17	106	116	O	orthostatic
18	118	128	O	hypotension
19	130	137	O	reported
20	139	140	O	in
21	142	152	O	association
22	154	157	O	with
23	159	161	O	its
24	163	165	O	use
NULL

REMERON	3465	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	26
Mirtazapine is a moderate antagonist at muscarinic receptors, a property that may explain the relatively low incidence of anticholinergic side effects associated with its use.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	24	O	moderate
5	26	35	O	antagonist
6	37	38	O	at
7	40	49	O	muscarinic
8	51	59	O	receptors
9	60	60	O	,
10	62	62	O	a
11	64	71	O	property
12	73	76	O	that
13	78	80	O	may
14	82	88	O	explain
15	90	92	O	the
16	94	103	O	relatively
17	105	107	O	low
18	109	117	O	incidence
19	119	120	O	of
20	122	136	O	anticholinergic
21	138	141	O	side
22	143	149	O	effects
23	151	160	O	associated
24	162	165	O	with
25	167	169	O	its
26	171	173	O	use
NULL

REMERON	3466	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	22
REMERON (mirtazapine) Tablets are rapidly and completely absorbed following oral administration and have a half-life of about 20 to 40 hours.
1	0	6	O	XXXXXXXX
2	9	19	O	XXXXXXXX
3	22	28	O	Tablets
4	30	32	O	are
5	34	40	O	rapidly
6	42	44	O	and
7	46	55	O	completely
8	57	64	O	absorbed
9	66	74	O	following
10	76	79	O	oral
11	81	94	O	administration
12	96	98	O	and
13	100	103	O	have
14	105	105	O	a
15	107	110	O	half
16	112	115	O	life
17	117	118	O	of
18	120	124	O	about
19	126	127	O	20
20	129	130	O	to
21	132	133	O	40
22	135	139	O	hours
NULL

REMERON	3467	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	13
Peak plasma concentrations are reached within about 2 hours following an oral dose.
1	0	3	O	Peak
2	5	10	O	plasma
3	12	25	O	concentrations
4	27	29	O	are
5	31	37	O	reached
6	39	44	O	within
7	46	50	O	about
8	52	52	O	2
9	54	58	O	hours
10	60	68	O	following
11	70	71	O	an
12	73	76	O	oral
13	78	81	O	dose
NULL

REMERON	3468	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	26
The presence of food in the stomach has a minimal effect on both the rate and extent of absorption and does not require a dosage adjustment.
1	0	2	O	The
2	4	11	O	presence
3	13	14	O	of
4	16	19	O	food
5	21	22	O	in
6	24	26	O	the
7	28	34	O	stomach
8	36	38	O	has
9	40	40	O	a
10	42	48	O	minimal
11	50	55	O	effect
12	57	58	O	on
13	60	63	O	both
14	65	67	O	the
15	69	72	O	rate
16	74	76	O	and
17	78	83	O	extent
18	85	86	O	of
19	88	97	O	absorption
20	99	101	O	and
21	103	106	O	does
22	108	110	O	not
23	112	118	O	require
24	120	120	O	a
25	122	127	O	dosage
26	129	138	O	adjustment
NULL

REMERON	3469	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	7
Mirtazapine is extensively metabolized after oral administration.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	25	O	extensively
4	27	37	O	metabolized
5	39	43	O	after
6	45	48	O	oral
7	50	63	O	administration
NULL

REMERON	3470	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	12
Major pathways of biotransformation are demethylation and hydroxylation followed by glucuronide conjugation.
1	0	4	O	Major
2	6	13	O	pathways
3	15	16	O	of
4	18	34	O	biotransformation
5	36	38	O	are
6	40	52	O	demethylation
7	54	56	O	and
8	58	70	O	hydroxylation
9	72	79	O	followed
10	81	82	O	by
11	84	94	O	glucuronide
12	96	106	O	conjugation
NULL

REMERON	3471	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	45
In vitro data from human liver microsomes indicate that cytochrome 2D6 and 1A2 are involved in the formation of the 8-hydroxy metabolite of mirtazapine, whereas cytochrome 3A is considered to be responsible for the formation of the N-desmethyl and N-oxide metabolite.
1	0	1	O	In
2	3	7	O	vitro
3	9	12	O	data
4	14	17	O	from
5	19	23	O	human
6	25	29	O	liver
7	31	40	O	microsomes
8	42	49	O	indicate
9	51	54	O	that
10	56	65	O	cytochrome
11	67	69	O	2D6
12	71	73	O	and
13	75	77	O	1A2
14	79	81	O	are
15	83	90	O	involved
16	92	93	O	in
17	95	97	O	the
18	99	107	O	formation
19	109	110	O	of
20	112	114	O	the
21	116	116	O	8
22	118	124	O	hydroxy
23	126	135	O	metabolite
24	137	138	O	of
25	140	150	O	XXXXXXXX
26	151	151	O	,
27	153	159	O	whereas
28	161	170	O	cytochrome
29	172	173	O	3A
30	175	176	O	is
31	178	187	O	considered
32	189	190	O	to
33	192	193	O	be
34	195	205	O	responsible
35	207	209	O	for
36	211	213	O	the
37	215	223	O	formation
38	225	226	O	of
39	228	230	O	the
40	232	232	O	N
41	234	242	O	desmethyl
42	244	246	O	and
43	248	248	O	N
44	250	254	O	oxide
45	256	265	O	metabolite
NULL

REMERON	3472	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	8
Mirtazapine has an absolute bioavailability of about 50%.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	17	O	an
4	19	26	O	absolute
5	28	42	O	bioavailability
6	44	45	O	of
7	47	51	O	about
8	53	55	O	50%
NULL

REMERON	3473	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	11
It is eliminated predominantly via urine (75%) with 15% in feces.
1	0	1	O	It
2	3	4	O	is
3	6	15	O	eliminated
4	17	29	O	predominantly
5	31	33	O	via
6	35	39	O	urine
7	42	44	O	75%
8	47	50	O	with
9	52	54	O	15%
10	56	57	O	in
11	59	63	O	feces
NULL

REMERON	3474	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	16
Several unconjugated metabolites possess pharmacological activity but are present in the plasma at very low levels.
1	0	6	O	Several
2	8	19	O	unconjugated
3	21	31	O	metabolites
4	33	39	O	possess
5	41	55	O	pharmacological
6	57	64	O	activity
7	66	68	O	but
8	70	72	O	are
9	74	80	O	present
10	82	83	O	in
11	85	87	O	the
12	89	94	O	plasma
13	96	97	O	at
14	99	102	O	very
15	104	106	O	low
16	108	113	O	levels
NULL

REMERON	3475	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	35
The (-) enantiomer has an elimination half-life that is approximately twice as long as the (+) enantiomer and therefore achieves plasma levels that are about 3 times as high as that of the (+) enantiomer.
1	0	2	O	The
2	8	17	O	enantiomer
3	19	21	O	has
4	23	24	O	an
5	26	36	O	elimination
6	38	41	O	half
7	43	46	O	life
8	48	51	O	that
9	53	54	O	is
10	56	68	O	approximately
11	70	74	O	twice
12	76	77	O	as
13	79	82	O	long
14	84	85	O	as
15	87	89	O	the
16	92	92	O	+
17	95	104	O	enantiomer
18	106	108	O	and
19	110	118	O	therefore
20	120	127	O	achieves
21	129	134	O	plasma
22	136	141	O	levels
23	143	146	O	that
24	148	150	O	are
25	152	156	O	about
26	158	158	O	3
27	160	164	O	times
28	166	167	O	as
29	169	172	O	high
30	174	175	O	as
31	177	180	O	that
32	182	183	O	of
33	185	187	O	the
34	190	190	O	+
35	193	202	O	enantiomer
NULL

REMERON	3476	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	16
Plasma levels are linearly related to dose over a dose range of 15 to 80 mg.
1	0	5	O	Plasma
2	7	12	O	levels
3	14	16	O	are
4	18	25	O	linearly
5	27	33	O	related
6	35	36	O	to
7	38	41	O	dose
8	43	46	O	over
9	48	48	O	a
10	50	53	O	dose
11	55	59	O	range
12	61	62	O	of
13	64	65	O	15
14	67	68	O	to
15	70	71	O	80
16	73	74	O	mg
NULL

REMERON	3477	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	49
The mean elimination half-life of mirtazapine after oral administration ranges from approximately 20 to 40 hours across age and gender subgroups, with females of all ages exhibiting significantly longer elimination half-lives than males (mean half-life of 37 hours for females vs. 26 hours for males).
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	31	32	O	of
7	34	44	O	XXXXXXXX
8	46	50	O	after
9	52	55	O	oral
10	57	70	O	administration
11	72	77	O	ranges
12	79	82	O	from
13	84	96	O	approximately
14	98	99	O	20
15	101	102	O	to
16	104	105	O	40
17	107	111	O	hours
18	113	118	O	across
19	120	122	O	age
20	124	126	O	and
21	128	133	O	gender
22	135	143	O	subgroups
23	144	144	O	,
24	146	149	O	with
25	151	157	O	females
26	159	160	O	of
27	162	164	O	all
28	166	169	O	ages
29	171	180	O	exhibiting
30	182	194	O	significantly
31	196	201	O	longer
32	203	213	O	elimination
33	215	218	O	half
34	220	224	O	lives
35	226	229	O	than
36	231	235	O	males
37	238	241	O	mean
38	243	246	O	half
39	248	251	O	life
40	253	254	O	of
41	256	257	O	37
42	259	263	O	hours
43	265	267	O	for
44	269	275	O	females
45	277	278	O	vs
46	281	282	O	26
47	284	288	O	hours
48	290	292	O	for
49	294	298	O	males
NULL

REMERON	3478	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	20
Steady state plasma levels of mirtazapine are attained within 5 days, with about 50% accumulation (accumulation ratio = 1.5).
1	0	5	O	Steady
2	7	11	O	state
3	13	18	O	plasma
4	20	25	O	levels
5	27	28	O	of
6	30	40	O	XXXXXXXX
7	42	44	O	are
8	46	53	O	attained
9	55	60	O	within
10	62	62	O	5
11	64	67	O	days
12	68	68	O	,
13	70	73	O	with
14	75	79	O	about
15	81	83	O	50%
16	85	96	O	accumulation
17	99	110	O	accumulation
18	112	116	O	ratio
19	118	118	O	=
20	120	122	O	1.5
NULL

REMERON	3479	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	19
Mirtazapine is approximately 85% bound to plasma proteins over a concentration range of 0.01 to 10 mcg/mL.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	27	O	approximately
4	29	31	O	85%
5	33	37	O	bound
6	39	40	O	to
7	42	47	O	plasma
8	49	56	O	proteins
9	58	61	O	over
10	63	63	O	a
11	65	77	O	concentration
12	79	83	O	range
13	85	86	O	of
14	88	91	O	0.01
15	93	94	O	to
16	96	97	O	10
17	99	101	O	mcg
18	102	102	O	/
19	103	104	O	mL
NULL

REMERON	3480	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	38
Following oral administration of REMERON (mirtazapine) Tablets 20 mg/day for 7 days to subjects of varying ages (range, 25-74), oral clearance of mirtazapine was reduced in the elderly compared to the younger subjects.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	39	O	XXXXXXXX
6	42	52	O	XXXXXXXX
7	55	61	O	Tablets
8	63	64	O	20
9	66	67	O	mg
10	68	68	O	/
11	69	71	O	day
12	73	75	O	for
13	77	77	O	7
14	79	82	O	days
15	84	85	O	to
16	87	94	O	subjects
17	96	97	O	of
18	99	105	O	varying
19	107	110	O	ages
20	113	117	O	range
21	118	118	O	,
22	120	121	O	25
23	123	124	O	74
24	126	126	O	,
25	128	131	O	oral
26	133	141	O	clearance
27	143	144	O	of
28	146	156	O	XXXXXXXX
29	158	160	O	was
30	162	168	O	reduced
31	170	171	O	in
32	173	175	O	the
33	177	183	O	elderly
34	185	192	O	compared
35	194	195	O	to
36	197	199	O	the
37	201	207	O	younger
38	209	216	O	subjects
NULL

REMERON	3481	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	35
The differences were most striking in males, with a 40% lower clearance in elderly males compared to younger males, while the clearance in elderly females was only 10% lower compared to younger females.
1	0	2	O	The
2	4	14	O	differences
3	16	19	O	were
4	21	24	O	most
5	26	33	O	striking
6	35	36	O	in
7	38	42	O	males
8	43	43	O	,
9	45	48	O	with
10	50	50	O	a
11	52	54	O	40%
12	56	60	O	lower
13	62	70	O	clearance
14	72	73	O	in
15	75	81	O	elderly
16	83	87	O	males
17	89	96	O	compared
18	98	99	O	to
19	101	107	O	younger
20	109	113	O	males
21	114	114	O	,
22	116	120	O	while
23	122	124	O	the
24	126	134	O	clearance
25	136	137	O	in
26	139	145	O	elderly
27	147	153	O	females
28	155	157	O	was
29	159	162	O	only
30	164	166	O	10%
31	168	172	O	lower
32	174	181	O	compared
33	183	184	O	to
34	186	192	O	younger
35	194	200	O	females
NULL

REMERON	3482	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	9
Caution is indicated in administering REMERON to elderly patients.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	22	O	in
5	24	36	O	administering
6	38	44	O	XXXXXXXX
7	46	47	O	to
8	49	55	O	elderly
9	57	64	O	patients
NULL

REMERON	3483	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	13
Safety and effectiveness of mirtazapine in the pediatric population have not been established.
1	0	5	O	Safety
2	7	9	O	and
3	11	23	O	effectiveness
4	25	26	O	of
5	28	38	O	XXXXXXXX
6	40	41	O	in
7	43	45	O	the
8	47	55	O	pediatric
9	57	66	O	population
10	68	71	O	have
11	73	75	O	not
12	77	80	O	been
13	82	92	O	established
NULL

REMERON	3485	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	17
There have been no clinical studies to evaluate the effect of race on the pharmacokinetics of REMERON.
1	0	4	O	There
2	6	9	O	have
3	11	14	O	been
4	16	17	O	no
5	19	26	O	clinical
6	28	34	O	studies
7	36	37	O	to
8	39	46	O	evaluate
9	48	50	O	the
10	52	57	O	effect
11	59	60	O	of
12	62	65	O	race
13	67	68	O	on
14	70	72	O	the
15	74	89	O	pharmacokinetics
16	91	92	O	of
17	94	100	O	XXXXXXXX
NULL

REMERON	3486	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	14
The disposition of mirtazapine was studied in patients with varying degrees of renal function.
1	0	2	O	The
2	4	14	O	disposition
3	16	17	O	of
4	19	29	O	XXXXXXXX
5	31	33	O	was
6	35	41	O	studied
7	43	44	O	in
8	46	53	O	patients
9	55	58	O	with
10	60	66	O	varying
11	68	74	O	degrees
12	76	77	O	of
13	79	83	O	renal
14	85	92	O	function
NULL

REMERON	3487	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	8
Elimination of mirtazapine is correlated with creatinine clearance.
1	0	10	O	Elimination
2	12	13	O	of
3	15	25	O	XXXXXXXX
4	27	28	O	is
5	30	39	O	correlated
6	41	44	O	with
7	46	55	O	creatinine
8	57	65	O	clearance
NULL

REMERON	3488	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	42
Total body clearance of mirtazapine was reduced approximately 30% in patients with moderate (Clcr=11-39 mL/min/1.73 m2) and approximately 50% in patients with severe (Clcr=<10 mL/min/1.73 m2) renal impairment when compared to normal subjects.
1	0	4	O	Total
2	6	9	O	body
3	11	19	O	clearance
4	21	22	O	of
5	24	34	O	XXXXXXXX
6	36	38	O	was
7	40	46	O	reduced
8	48	60	O	approximately
9	62	64	O	30%
10	66	67	O	in
11	69	76	O	patients
12	78	81	O	with
13	83	90	O	moderate
14	93	99	O	Clcr=11
15	101	102	O	39
16	104	105	O	mL
17	106	106	O	/
18	107	109	O	min
19	110	110	O	/
20	111	114	O	1.73
21	116	117	O	m2
22	120	122	O	and
23	124	136	O	approximately
24	138	140	O	50%
25	142	143	O	in
26	145	152	O	patients
27	154	157	O	with
28	159	164	O	severe
29	167	174	O	Clcr=<10
30	176	177	O	mL
31	178	178	O	/
32	179	181	O	min
33	182	182	O	/
34	183	186	O	1.73
35	188	189	O	m2
36	192	196	O	renal
37	198	207	O	impairment
38	209	212	O	when
39	214	221	O	compared
40	223	224	O	to
41	226	231	O	normal
42	233	240	O	subjects
NULL

REMERON	3489	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	12
Caution is indicated in administering REMERON to patients with compromised renal function.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	22	O	in
5	24	36	O	administering
6	38	44	O	XXXXXXXX
7	46	47	O	to
8	49	56	O	patients
9	58	61	O	with
10	63	73	O	compromised
11	75	79	O	renal
12	81	88	O	function
NULL

REMERON	3490	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	31
Following a single 15-mg oral dose of REMERON, the oral clearance of mirtazapine was decreased by approximately 30% in hepatically impaired patients compared to subjects with normal hepatic function.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	20	O	15
5	22	23	O	mg
6	25	28	O	oral
7	30	33	O	dose
8	35	36	O	of
9	38	44	O	XXXXXXXX
10	45	45	O	,
11	47	49	O	the
12	51	54	O	oral
13	56	64	O	clearance
14	66	67	O	of
15	69	79	O	XXXXXXXX
16	81	83	O	was
17	85	93	O	decreased
18	95	96	O	by
19	98	110	O	approximately
20	112	114	O	30%
21	116	117	O	in
22	119	129	O	hepatically
23	131	138	O	impaired
24	140	147	O	patients
25	149	156	O	compared
26	158	159	O	to
27	161	168	O	subjects
28	170	173	O	with
29	175	180	O	normal
30	182	188	O	hepatic
31	190	197	O	function
NULL

REMERON	3491	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	12
Caution is indicated in administering REMERON to patients with compromised hepatic function.
1	0	6	O	Caution
2	8	9	O	is
3	11	19	O	indicated
4	21	22	O	in
5	24	36	O	administering
6	38	44	O	XXXXXXXX
7	46	47	O	to
8	49	56	O	patients
9	58	61	O	with
10	63	73	O	compromised
11	75	81	O	hepatic
12	83	90	O	function
NULL

REMERON	3492	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	34
The efficacy of REMERON (mirtazapine) Tablets as a treatment for major depressive disorder was established in 4 placebo-controlled, 6-week trials in adult outpatients meeting DSM-III criteria for major depressive disorder.
1	0	2	O	The
2	4	11	O	efficacy
3	13	14	O	of
4	16	22	O	XXXXXXXX
5	25	35	O	XXXXXXXX
6	38	44	O	Tablets
7	46	47	O	as
8	49	49	O	a
9	51	59	O	treatment
10	61	63	O	for
11	65	69	O	major
12	71	80	O	depressive
13	82	89	O	disorder
14	91	93	O	was
15	95	105	O	established
16	107	108	O	in
17	110	110	O	4
18	112	118	O	placebo
19	120	129	O	controlled
20	130	130	O	,
21	132	132	O	6
22	134	137	O	week
23	139	144	O	trials
24	146	147	O	in
25	149	153	O	adult
26	155	165	O	outpatients
27	167	173	O	meeting
28	175	177	O	DSM
29	179	181	O	III
30	183	190	O	criteria
31	192	194	O	for
32	196	200	O	major
33	202	211	O	depressive
34	213	220	O	disorder
NULL

REMERON	3493	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	18
Patients were titrated with mirtazapine from a dose range of 5 mg up to 35 mg/day.
1	0	7	O	Patients
2	9	12	O	were
3	14	21	O	titrated
4	23	26	O	with
5	28	38	O	XXXXXXXX
6	40	43	O	from
7	45	45	O	a
8	47	50	O	dose
9	52	56	O	range
10	58	59	O	of
11	61	61	O	5
12	63	64	O	mg
13	66	67	O	up
14	69	70	O	to
15	72	73	O	35
16	75	76	O	mg
17	77	77	O	/
18	78	80	O	day
NULL

REMERON	3494	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	45
Overall, these studies demonstrated mirtazapine to be superior to placebo on at least 3 of the following 4 measures: 21-Item Hamilton Depression Rating Scale (HDRS) total score; HDRS Depressed Mood Item; CGI Severity score; and Montgomery and Asberg Depression Rating Scale (MADRS).
1	0	6	O	Overall
2	7	7	O	,
3	9	13	O	these
4	15	21	O	studies
5	23	34	O	demonstrated
6	36	46	O	XXXXXXXX
7	48	49	O	to
8	51	52	O	be
9	54	61	O	superior
10	63	64	O	to
11	66	72	O	placebo
12	74	75	O	on
13	77	78	O	at
14	80	84	O	least
15	86	86	O	3
16	88	89	O	of
17	91	93	O	the
18	95	103	O	following
19	105	105	O	4
20	107	114	O	measures
21	115	115	O	:
22	117	118	O	21
23	120	123	O	Item
24	125	132	O	Hamilton
25	134	143	O	Depression
26	145	150	O	Rating
27	152	156	O	Scale
28	159	162	O	HDRS
29	165	169	O	total
30	171	175	O	score
31	178	181	O	HDRS
32	183	191	O	Depressed
33	193	196	O	Mood
34	198	201	O	Item
35	204	206	O	CGI
36	208	215	O	Severity
37	217	221	O	score
38	224	226	O	and
39	228	237	O	Montgomery
40	239	241	O	and
41	243	248	O	Asberg
42	250	259	O	Depression
43	261	266	O	Rating
44	268	272	O	Scale
45	275	279	O	MADRS
NULL

REMERON	3495	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	24
Superiority of mirtazapine over placebo was also found for certain factors of the HDRS, including anxiety/somatization factor and sleep disturbance factor.
1	0	10	O	Superiority
2	12	13	O	of
3	15	25	O	XXXXXXXX
4	27	30	O	over
5	32	38	O	placebo
6	40	42	O	was
7	44	47	O	also
8	49	53	O	found
9	55	57	O	for
10	59	65	O	certain
11	67	73	O	factors
12	75	76	O	of
13	78	80	O	the
14	82	85	O	HDRS
15	86	86	O	,
16	88	96	O	including
17	98	104	O	anxiety
18	105	105	O	/
19	106	117	O	somatization
20	119	124	O	factor
21	126	128	O	and
22	130	134	O	sleep
23	136	146	O	disturbance
24	148	153	O	factor
NULL

REMERON	3496	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	19
The mean mirtazapine dose for patients who completed these 4 studies ranged from 21 to 32 mg/day.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	XXXXXXXX
4	21	24	O	dose
5	26	28	O	for
6	30	37	O	patients
7	39	41	O	who
8	43	51	O	completed
9	53	57	O	these
10	59	59	O	4
11	61	67	O	studies
12	69	74	O	ranged
13	76	79	O	from
14	81	82	O	21
15	84	85	O	to
16	87	88	O	32
17	90	91	O	mg
18	92	92	O	/
19	93	95	O	day
NULL

REMERON	3497	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	20
A fifth study of similar design utilized a higher dose (up to 50 mg) per day and also showed effectiveness.
1	0	0	O	A
2	2	6	O	fifth
3	8	12	O	study
4	14	15	O	of
5	17	23	O	similar
6	25	30	O	design
7	32	39	O	utilized
8	41	41	O	a
9	43	48	O	higher
10	50	53	O	dose
11	56	57	O	up
12	59	60	O	to
13	62	63	O	50
14	65	66	O	mg
15	69	71	O	per
16	73	75	O	day
17	77	79	O	and
18	81	84	O	also
19	86	91	O	showed
20	93	105	O	effectiveness
NULL

REMERON	3498	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	21
Examination of age and gender subsets of the population did not reveal any differential responsiveness on the basis of these subgroupings.
1	0	10	O	Examination
2	12	13	O	of
3	15	17	O	age
4	19	21	O	and
5	23	28	O	gender
6	30	36	O	subsets
7	38	39	O	of
8	41	43	O	the
9	45	54	O	population
10	56	58	O	did
11	60	62	O	not
12	64	69	O	reveal
13	71	73	O	any
14	75	86	O	differential
15	88	101	O	responsiveness
16	103	104	O	on
17	106	108	O	the
18	110	114	O	basis
19	116	117	O	of
20	119	123	O	these
21	125	136	O	subgroupings
NULL

REMERON	3499	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	47
In a longer-term study, patients meeting (DSM-IV) criteria for major depressive disorder who had responded during an initial 8 to 12 weeks of acute treatment on REMERON were randomized to continuation of REMERON or placebo for up to 40 weeks of observation for relapse.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	study
6	22	22	O	,
7	24	31	O	patients
8	33	39	O	meeting
9	42	44	O	DSM
10	46	47	O	IV
11	50	57	O	criteria
12	59	61	O	for
13	63	67	O	major
14	69	78	O	depressive
15	80	87	O	disorder
16	89	91	O	who
17	93	95	O	had
18	97	105	O	responded
19	107	112	O	during
20	114	115	O	an
21	117	123	O	initial
22	125	125	O	8
23	127	128	O	to
24	130	131	O	12
25	133	137	O	weeks
26	139	140	O	of
27	142	146	O	acute
28	148	156	O	treatment
29	158	159	O	on
30	161	167	O	XXXXXXXX
31	169	172	O	were
32	174	183	O	randomized
33	185	186	O	to
34	188	199	O	continuation
35	201	202	O	of
36	204	210	O	XXXXXXXX
37	212	213	O	or
38	215	221	O	placebo
39	223	225	O	for
40	227	228	O	up
41	230	231	O	to
42	233	234	O	40
43	236	240	O	weeks
44	242	243	O	of
45	245	255	O	observation
46	257	259	O	for
47	261	267	O	relapse
NULL

REMERON	3500	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	49
Response during the open phase was defined as having achieved a HAM-D 17 total score of <8 and a CGI-Improvement score of 1 or 2 at 2 consecutive visits beginning with week 6 of the 8 to 12 weeks in the open-label phase of the study.
1	0	7	O	Response
2	9	14	O	during
3	16	18	O	the
4	20	23	O	open
5	25	29	O	phase
6	31	33	O	was
7	35	41	O	defined
8	43	44	O	as
9	46	51	O	having
10	53	60	O	achieved
11	62	62	O	a
12	64	66	O	HAM
13	68	68	O	D
14	70	71	O	17
15	73	77	O	total
16	79	83	O	score
17	85	86	O	of
18	88	89	O	<8
19	91	93	O	and
20	95	95	O	a
21	97	99	O	CGI
22	101	111	O	Improvement
23	113	117	O	score
24	119	120	O	of
25	122	122	O	1
26	124	125	O	or
27	127	127	O	2
28	129	130	O	at
29	132	132	O	2
30	134	144	O	consecutive
31	146	151	O	visits
32	153	161	O	beginning
33	163	166	O	with
34	168	171	O	week
35	173	173	O	6
36	175	176	O	of
37	178	180	O	the
38	182	182	O	8
39	184	185	O	to
40	187	188	O	12
41	190	194	O	weeks
42	196	197	O	in
43	199	201	O	the
44	203	206	O	open
45	208	212	O	label
46	214	218	O	phase
47	220	221	O	of
48	223	225	O	the
49	227	231	O	study
NULL

REMERON	3501	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	12
Relapse during the double-blind phase was determined by the individual investigators.
1	0	6	O	Relapse
2	8	13	O	during
3	15	17	O	the
4	19	24	O	double
5	26	30	O	blind
6	32	36	O	phase
7	38	40	O	was
8	42	51	O	determined
9	53	54	O	by
10	56	58	O	the
11	60	69	O	individual
12	71	83	O	investigators
NULL

REMERON	3502	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	20
Patients receiving continued REMERON treatment experienced significantly lower relapse rates over the subsequent 40 weeks compared to those receiving placebo.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	27	O	continued
4	29	35	O	XXXXXXXX
5	37	45	O	treatment
6	47	57	O	experienced
7	59	71	O	significantly
8	73	77	O	lower
9	79	85	O	relapse
10	87	91	O	rates
11	93	96	O	over
12	98	100	O	the
13	102	111	O	subsequent
14	113	114	O	40
15	116	120	O	weeks
16	122	129	O	compared
17	131	132	O	to
18	134	138	O	those
19	140	148	O	receiving
20	150	156	O	placebo
NULL

REMERON	3503	34090-1	010f9162-9f7f-4b6d-a6e4-4f832f26f38e	10
This pattern was demonstrated in both male and female patients.
1	0	3	O	This
2	5	11	O	pattern
3	13	15	O	was
4	17	28	O	demonstrated
5	30	31	O	in
6	33	36	O	both
7	38	41	O	male
8	43	45	O	and
9	47	52	O	female
10	54	61	O	patients
NULL

Rifampin	997	34090-1	55816042-946d-4bec-9461-bd998628ff45	8
Rifampin is readily absorbed from the gastrointestinal tract.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	18	O	readily
4	20	27	O	absorbed
5	29	32	O	from
6	34	36	O	the
7	38	53	O	gastrointestinal
8	55	59	O	tract
NULL

Rifampin	998	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
Peak serum concentrations in healthy adults and pediatric populations vary widely from individual to individual.
1	0	3	O	Peak
2	5	9	O	serum
3	11	24	O	concentrations
4	26	27	O	in
5	29	35	O	healthy
6	37	42	O	adults
7	44	46	O	and
8	48	56	O	pediatric
9	58	68	O	populations
10	70	73	O	vary
11	75	80	O	widely
12	82	85	O	from
13	87	96	O	individual
14	98	99	O	to
15	101	110	O	individual
NULL

Rifampin	999	34090-1	55816042-946d-4bec-9461-bd998628ff45	32
Following a single 600 mg oral dose of rifampin in healthy adults, the peak serum concentration averages 7 mcg/mL but may vary from 4 to 32 mcg/mL.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	21	O	600
5	23	24	O	mg
6	26	29	O	oral
7	31	34	O	dose
8	36	37	O	of
9	39	46	O	XXXXXXXX
10	48	49	O	in
11	51	57	O	healthy
12	59	64	O	adults
13	65	65	O	,
14	67	69	O	the
15	71	74	O	peak
16	76	80	O	serum
17	82	94	O	concentration
18	96	103	O	averages
19	105	105	O	7
20	107	109	O	mcg
21	110	110	O	/
22	111	112	O	mL
23	114	116	O	but
24	118	120	O	may
25	122	125	O	vary
26	127	130	O	from
27	132	132	O	4
28	134	135	O	to
29	137	138	O	32
30	140	142	O	mcg
31	143	143	O	/
32	144	145	O	mL
NULL

Rifampin	1000	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
Absorption of rifampin is reduced by about 30% when the drug is ingested with food.
1	0	9	O	Absorption
2	11	12	O	of
3	14	21	O	XXXXXXXX
4	23	24	O	is
5	26	32	O	reduced
6	34	35	O	by
7	37	41	O	about
8	43	45	O	30%
9	47	50	O	when
10	52	54	O	the
11	56	59	O	drug
12	61	62	O	is
13	64	71	O	ingested
14	73	76	O	with
15	78	81	U-KIN	food
K/15:C54355

Rifampin	1001	34090-1	55816042-946d-4bec-9461-bd998628ff45	7
Rifampin is widely distributed throughout the body.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	17	O	widely
4	19	29	O	distributed
5	31	40	O	throughout
6	42	44	O	the
7	46	49	O	body
NULL

Rifampin	1002	34090-1	55816042-946d-4bec-9461-bd998628ff45	16
It is present in effective concentrations in many organs and body fluids, including cerebrospinal fluid.
1	0	1	O	It
2	3	4	O	is
3	6	12	O	present
4	14	15	O	in
5	17	25	O	effective
6	27	40	O	concentrations
7	42	43	O	in
8	45	48	O	many
9	50	55	O	organs
10	57	59	O	and
11	61	64	O	body
12	66	71	O	fluids
13	72	72	O	,
14	74	82	O	including
15	84	96	O	cerebrospinal
16	98	102	O	fluid
NULL

Rifampin	1003	34090-1	55816042-946d-4bec-9461-bd998628ff45	16
Most of the unbound fraction is not ionized and, therefore, diffuses freely into tissues.
1	0	3	O	Most
2	5	6	O	of
3	8	10	O	the
4	12	18	O	unbound
5	20	27	O	fraction
6	29	30	O	is
7	32	34	O	not
8	36	42	O	ionized
9	44	46	O	and
10	47	47	O	,
11	49	57	O	therefore
12	58	58	O	,
13	60	67	O	diffuses
14	69	74	O	freely
15	76	79	O	into
16	81	87	O	tissues
NULL

Rifampin	1004	34090-1	55816042-946d-4bec-9461-bd998628ff45	39
In healthy adults, the mean biological half-life of rifampin in serum averages 3.35 * 0.66 hours after a 600 mg oral dose, with increases up to 5.08 * 2.45 hours reported after a 900 mg dose.
1	0	1	O	In
2	3	9	O	healthy
3	11	16	O	adults
4	17	17	O	,
5	19	21	O	the
6	23	26	O	mean
7	28	37	O	biological
8	39	42	O	half
9	44	47	O	life
10	49	50	O	of
11	52	59	O	XXXXXXXX
12	61	62	O	in
13	64	68	O	serum
14	70	77	O	averages
15	79	82	O	3.35
16	84	84	O	*
17	86	89	O	0.66
18	91	95	O	hours
19	97	101	O	after
20	103	103	O	a
21	105	107	O	600
22	109	110	O	mg
23	112	115	O	oral
24	117	120	O	dose
25	121	121	O	,
26	123	126	O	with
27	128	136	O	increases
28	138	139	O	up
29	141	142	O	to
30	144	147	O	5.08
31	149	149	O	*
32	151	154	O	2.45
33	156	160	O	hours
34	162	169	O	reported
35	171	175	O	after
36	177	177	O	a
37	179	181	O	900
38	183	184	O	mg
39	186	189	O	dose
NULL

Rifampin	1005	34090-1	55816042-946d-4bec-9461-bd998628ff45	18
With repeated administration, the half-life decreases and reaches average values of approximately 2 to 3 hours.
1	0	3	O	With
2	5	12	O	repeated
3	14	27	O	administration
4	28	28	O	,
5	30	32	O	the
6	34	37	O	half
7	39	42	O	life
8	44	52	O	decreases
9	54	56	O	and
10	58	64	O	reaches
11	66	72	O	average
12	74	79	O	values
13	81	82	O	of
14	84	96	O	approximately
15	98	98	O	2
16	100	101	O	to
17	103	103	O	3
18	105	109	O	hours
NULL

Rifampin	1006	34090-1	55816042-946d-4bec-9461-bd998628ff45	27
The half-life does not differ in patients with renal failure at doses not exceeding 600 mg daily, and consequently, no dosage adjustment is required.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	17	O	does
5	19	21	O	not
6	23	28	O	differ
7	30	31	O	in
8	33	40	O	patients
9	42	45	O	with
10	47	51	O	renal
11	53	59	O	failure
12	61	62	O	at
13	64	68	O	doses
14	70	72	O	not
15	74	82	O	exceeding
16	84	86	O	600
17	88	89	O	mg
18	91	95	O	daily
19	96	96	O	,
20	98	100	O	and
21	102	113	O	consequently
22	114	114	O	,
23	116	117	O	no
24	119	124	O	dosage
25	126	135	O	adjustment
26	137	138	O	is
27	140	147	O	required
NULL

Rifampin	1007	34090-1	55816042-946d-4bec-9461-bd998628ff45	21
The half-life of rifampin at a dose of 720 mg daily has not been established in patients with renal failure.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	15	O	of
5	17	24	O	XXXXXXXX
6	26	27	O	at
7	29	29	O	a
8	31	34	O	dose
9	36	37	O	of
10	39	41	O	720
11	43	44	O	mg
12	46	50	O	daily
13	52	54	O	has
14	56	58	O	not
15	60	63	O	been
16	65	75	O	established
17	77	78	O	in
18	80	87	O	patients
19	89	92	O	with
20	94	98	O	renal
21	100	106	O	failure
NULL

Rifampin	1008	34090-1	55816042-946d-4bec-9461-bd998628ff45	64
Following a single 900 mg oral dose of rifampin in patients with varying degrees of renal insufficiency, the mean half-life increased from 3.6 hours in healthy adults to 5, 7.3, and 11 hours in patients with glomerular filtration rates of 30 to 50 mL/min, less than 30 mL/min, and in anuric patients, respectively.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	21	O	900
5	23	24	O	mg
6	26	29	O	oral
7	31	34	O	dose
8	36	37	O	of
9	39	46	O	XXXXXXXX
10	48	49	O	in
11	51	58	O	patients
12	60	63	O	with
13	65	71	O	varying
14	73	79	O	degrees
15	81	82	O	of
16	84	88	O	renal
17	90	102	O	insufficiency
18	103	103	O	,
19	105	107	O	the
20	109	112	O	mean
21	114	117	O	half
22	119	122	O	life
23	124	132	O	increased
24	134	137	O	from
25	139	141	O	3.6
26	143	147	O	hours
27	149	150	O	in
28	152	158	O	healthy
29	160	165	O	adults
30	167	168	O	to
31	170	170	O	5
32	171	171	O	,
33	173	175	O	7.3
34	176	176	O	,
35	178	180	O	and
36	182	183	O	11
37	185	189	O	hours
38	191	192	O	in
39	194	201	O	patients
40	203	206	O	with
41	208	217	O	glomerular
42	219	228	O	filtration
43	230	234	O	rates
44	236	237	O	of
45	239	240	O	30
46	242	243	O	to
47	245	246	O	50
48	248	249	O	mL
49	250	250	O	/
50	251	253	O	min
51	254	254	O	,
52	256	259	O	less
53	261	264	O	than
54	266	267	O	30
55	269	270	O	mL
56	271	271	O	/
57	272	274	O	min
58	275	275	O	,
59	277	279	O	and
60	281	282	O	in
61	284	289	O	anuric
62	291	298	O	patients
63	299	299	O	,
64	301	312	O	respectively
NULL

Rifampin	1009	34090-1	55816042-946d-4bec-9461-bd998628ff45	12
Refer to the WARNINGS section for information regarding patients with hepatic insufficiency.
1	0	4	O	Refer
2	6	7	O	to
3	9	11	O	the
4	13	20	O	WARNINGS
5	22	28	O	section
6	30	32	O	for
7	34	44	O	information
8	46	54	O	regarding
9	56	63	O	patients
10	65	68	O	with
11	70	76	O	hepatic
12	78	90	O	insufficiency
NULL

Rifampin	1010	34090-1	55816042-946d-4bec-9461-bd998628ff45	16
After absorption, rifampin is rapidly eliminated in the bile, and an enterohepatic circulation ensues.
1	0	4	O	After
2	6	15	O	absorption
3	16	16	O	,
4	18	25	O	XXXXXXXX
5	27	28	O	is
6	30	36	O	rapidly
7	38	47	O	eliminated
8	49	50	O	in
9	52	54	O	the
10	56	59	O	bile
11	60	60	O	,
12	62	64	O	and
13	66	67	O	an
14	69	81	O	enterohepatic
15	83	93	O	circulation
16	95	100	O	ensues
NULL

Rifampin	1011	34090-1	55816042-946d-4bec-9461-bd998628ff45	25
During this process, rifampin undergoes progressive deacetylation so that nearly all the drug in the bile is in this form in about 6 hours.
1	0	5	O	During
2	7	10	O	this
3	12	18	O	process
4	19	19	O	,
5	21	28	O	XXXXXXXX
6	30	38	O	undergoes
7	40	50	O	progressive
8	52	64	O	deacetylation
9	66	67	O	so
10	69	72	O	that
11	74	79	O	nearly
12	81	83	O	all
13	85	87	O	the
14	89	92	O	drug
15	94	95	O	in
16	97	99	O	the
17	101	104	O	bile
18	106	107	O	is
19	109	110	O	in
20	112	115	O	this
21	117	120	O	form
22	122	123	O	in
23	125	129	O	about
24	131	131	O	6
25	133	137	O	hours
NULL

Rifampin	1012	34090-1	55816042-946d-4bec-9461-bd998628ff45	5
This metabolite has antibacterial activity.
1	0	3	O	This
2	5	14	O	metabolite
3	16	18	O	has
4	20	32	O	antibacterial
5	34	41	O	activity
NULL

Rifampin	1013	34090-1	55816042-946d-4bec-9461-bd998628ff45	11
Intestinal reabsorption is reduced by deacetylation, and elimination is facilitated.
1	0	9	O	Intestinal
2	11	22	O	reabsorption
3	24	25	O	is
4	27	33	O	reduced
5	35	36	O	by
6	38	50	O	deacetylation
7	51	51	O	,
8	53	55	O	and
9	57	67	O	elimination
10	69	70	O	is
11	72	82	O	facilitated
NULL

Rifampin	1014	34090-1	55816042-946d-4bec-9461-bd998628ff45	20
Up to 30% of a dose is excreted in the urine, with about half of this being unchanged drug.
1	0	1	O	Up
2	3	4	O	to
3	6	8	O	30%
4	10	11	O	of
5	13	13	O	a
6	15	18	O	dose
7	20	21	O	is
8	23	30	O	excreted
9	32	33	O	in
10	35	37	O	the
11	39	43	O	urine
12	44	44	O	,
13	46	49	O	with
14	51	55	O	about
15	57	60	O	half
16	62	63	O	of
17	65	68	O	this
18	70	74	O	being
19	76	84	O	unchanged
20	86	89	O	drug
NULL

Rifampin	1015	34090-1	55816042-946d-4bec-9461-bd998628ff45	35
In one study, pediatric patients 6 to 58 months old were given rifampin suspended in simple syrup or as dry powder mixed with applesauce at a dose of 10 mg/kg body weight.
1	0	1	O	In
2	3	5	O	one
3	7	11	O	study
4	12	12	O	,
5	14	22	O	pediatric
6	24	31	O	patients
7	33	33	O	6
8	35	36	O	to
9	38	39	O	58
10	41	46	O	months
11	48	50	O	old
12	52	55	O	were
13	57	61	O	given
14	63	70	O	XXXXXXXX
15	72	80	O	suspended
16	82	83	O	in
17	85	90	O	simple
18	92	96	O	syrup
19	98	99	O	or
20	101	102	O	as
21	104	106	O	dry
22	108	113	O	powder
23	115	119	O	mixed
24	121	124	O	with
25	126	135	O	applesauce
26	137	138	O	at
27	140	140	O	a
28	142	145	O	dose
29	147	148	O	of
30	150	151	O	10
31	153	154	O	mg
32	155	155	O	/
33	156	157	O	kg
34	159	162	O	body
35	164	169	O	weight
NULL

Rifampin	1016	34090-1	55816042-946d-4bec-9461-bd998628ff45	31
Peak serum concentrations of 10.7 * 3.7 and 11.5 * 5.1 mcg/mL were obtained 1 hour after preprandial ingestion of the drug suspension and the applesauce mixture, respectively.
1	0	3	O	Peak
2	5	9	O	serum
3	11	24	O	concentrations
4	26	27	O	of
5	29	32	O	10.7
6	34	34	O	*
7	36	38	O	3.7
8	40	42	O	and
9	44	47	O	11.5
10	49	49	O	*
11	51	53	O	5.1
12	55	57	O	mcg
13	58	58	O	/
14	59	60	O	mL
15	62	65	O	were
16	67	74	O	obtained
17	76	76	O	1
18	78	81	O	hour
19	83	87	O	after
20	89	99	O	preprandial
21	101	109	O	ingestion
22	111	112	O	of
23	114	116	O	the
24	118	121	O	drug
25	123	132	O	suspension
26	134	136	O	and
27	138	140	O	the
28	142	151	O	applesauce
29	153	159	O	mixture
30	160	160	O	,
31	162	173	O	respectively
NULL

Rifampin	1017	34090-1	55816042-946d-4bec-9461-bd998628ff45	16
After the administration of either preparation, the t1/2 of rifampin averaged 2.9 hours.
1	0	4	O	After
2	6	8	O	the
3	10	23	O	administration
4	25	26	O	of
5	28	33	O	either
6	35	45	O	preparation
7	46	46	O	,
8	48	50	O	the
9	52	53	O	t1
10	54	54	O	/
11	55	55	O	2
12	57	58	O	of
13	60	67	O	XXXXXXXX
14	69	76	O	averaged
15	78	80	O	2.9
16	82	86	O	hours
NULL

Rifampin	1018	34090-1	55816042-946d-4bec-9461-bd998628ff45	39
It should be noted that in other studies in pediatric populations, at doses of 10 mg/kg body weight, mean peak serum concentrations of 3.5 mcg/mL to 15 mcg/mL have been reported.
1	0	1	O	It
2	3	8	O	should
3	10	11	O	be
4	13	17	O	noted
5	19	22	O	that
6	24	25	O	in
7	27	31	O	other
8	33	39	O	studies
9	41	42	O	in
10	44	52	O	pediatric
11	54	64	O	populations
12	65	65	O	,
13	67	68	O	at
14	70	74	O	doses
15	76	77	O	of
16	79	80	O	10
17	82	83	O	mg
18	84	84	O	/
19	85	86	O	kg
20	88	91	O	body
21	93	98	O	weight
22	99	99	O	,
23	101	104	O	mean
24	106	109	O	peak
25	111	115	O	serum
26	117	130	O	concentrations
27	132	133	O	of
28	135	137	O	3.5
29	139	141	O	mcg
30	142	142	O	/
31	143	144	O	mL
32	146	147	O	to
33	149	150	O	15
34	152	154	O	mcg
35	155	155	O	/
36	156	157	O	mL
37	159	162	O	have
38	164	167	O	been
39	169	176	O	reported
NULL

Rifampin	1019	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
Mechanism of Action Rifampin inhibits DNA-dependent RNA polymerase activity in susceptible Mycobacterium tuberculosis organisms.
1	0	8	O	Mechanism
2	10	11	O	of
3	13	18	O	Action
4	20	27	O	XXXXXXXX
5	29	36	O	inhibits
6	38	40	O	DNA
7	42	50	O	dependent
8	52	54	O	RNA
9	56	65	O	polymerase
10	67	74	O	activity
11	76	77	O	in
12	79	89	O	susceptible
13	91	103	O	Mycobacterium
14	105	116	O	tuberculosis
15	118	126	O	organisms
NULL

Rifampin	1020	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
1	0	11	O	Specifically
2	12	12	O	,
3	14	15	O	it
4	17	25	O	interacts
5	27	30	O	with
6	32	40	O	bacterial
7	42	44	O	RNA
8	46	55	O	polymerase
9	57	59	O	but
10	61	64	O	does
11	66	68	O	not
12	70	76	O	inhibit
13	78	80	O	the
14	82	90	O	mammalian
15	92	97	O	enzyme
NULL

Rifampin	1021	34090-1	55816042-946d-4bec-9461-bd998628ff45	14
Drug Resistance Organisms resistant to rifampin are likely to be resistant to other rifamycins.
1	0	3	O	Drug
2	5	14	O	Resistance
3	16	24	O	Organisms
4	26	34	O	resistant
5	36	37	O	to
6	39	46	O	XXXXXXXX
7	48	50	O	are
8	52	57	O	likely
9	59	60	O	to
10	62	63	O	be
11	65	73	O	resistant
12	75	76	O	to
13	78	82	O	other
14	84	93	O	rifamycins
NULL

Rifampin	1022	34090-1	55816042-946d-4bec-9461-bd998628ff45	29
In the treatment of both tuberculosis and the meningococcal carrier state , the small number of resistant cells present within large populations of susceptible cells can rapidly become predominant.
1	0	1	O	In
2	3	5	O	the
3	7	15	O	treatment
4	17	18	O	of
5	20	23	O	both
6	25	36	O	tuberculosis
7	38	40	O	and
8	42	44	O	the
9	46	58	O	meningococcal
10	60	66	O	carrier
11	68	72	O	state
12	74	74	O	,
13	76	78	O	the
14	80	84	O	small
15	86	91	O	number
16	93	94	O	of
17	96	104	O	resistant
18	106	110	O	cells
19	112	118	O	present
20	120	125	O	within
21	127	131	O	large
22	133	143	O	populations
23	145	146	O	of
24	148	158	O	susceptible
25	160	164	O	cells
26	166	168	O	can
27	170	176	O	rapidly
28	178	183	O	become
29	185	195	O	predominant
NULL

Rifampin	1023	34090-1	55816042-946d-4bec-9461-bd998628ff45	21
In addition, resistance to rifampin has been determined to occur as single-step mutations of the DNA-dependent RNA polymerase.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	22	O	resistance
5	24	25	O	to
6	27	34	O	XXXXXXXX
7	36	38	O	has
8	40	43	O	been
9	45	54	O	determined
10	56	57	O	to
11	59	63	O	occur
12	65	66	O	as
13	68	73	O	single
14	75	78	O	step
15	80	88	O	mutations
16	90	91	O	of
17	93	95	O	the
18	97	99	O	DNA
19	101	109	O	dependent
20	111	113	O	RNA
21	115	124	O	polymerase
NULL

Rifampin	1024	34090-1	55816042-946d-4bec-9461-bd998628ff45	19
Since resistance can emerge rapidly, appropriate susceptibility tests should be performed in the event of persistent positive cultures.
1	0	4	O	Since
2	6	15	O	resistance
3	17	19	O	can
4	21	26	O	emerge
5	28	34	O	rapidly
6	35	35	O	,
7	37	47	O	appropriate
8	49	62	O	susceptibility
9	64	68	O	tests
10	70	75	O	should
11	77	78	O	be
12	80	88	O	performed
13	90	91	O	in
14	93	95	O	the
15	97	101	O	event
16	103	104	O	of
17	106	115	O	persistent
18	117	124	O	positive
19	126	133	O	cultures
NULL

Rifampin	1025	34090-1	55816042-946d-4bec-9461-bd998628ff45	20
Activity in vitro and in vivo Rifampin has bactericidal activity in vitro against slow and intermittently growing M tuberculosis organisms.
1	0	7	O	Activity
2	9	10	O	in
3	12	16	O	vitro
4	18	20	O	and
5	22	23	O	in
6	25	28	O	vivo
7	30	37	O	XXXXXXXX
8	39	41	O	has
9	43	54	O	bactericidal
10	56	63	O	activity
11	65	66	O	in
12	68	72	O	vitro
13	74	80	O	against
14	82	85	O	slow
15	87	89	O	and
16	91	104	O	intermittently
17	106	112	O	growing
18	114	114	O	M
19	116	127	O	tuberculosis
20	129	137	O	organisms
NULL

Rifampin	1026	34090-1	55816042-946d-4bec-9461-bd998628ff45	30
Rifampin has been shown to be active against most strains of the following microorganisms, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	22	O	shown
5	24	25	O	to
6	27	28	O	be
7	30	35	O	active
8	37	43	O	against
9	45	48	O	most
10	50	56	O	strains
11	58	59	O	of
12	61	63	O	the
13	65	73	O	following
14	75	88	O	microorganisms
15	89	89	O	,
16	91	94	O	both
17	96	97	O	in
18	99	103	O	vitro
19	105	107	O	and
20	109	110	O	in
21	112	119	O	clinical
22	121	130	O	infections
23	132	133	O	as
24	135	143	O	described
25	145	146	O	in
26	148	150	O	the
27	152	162	O	INDICATIONS
28	164	166	O	AND
29	168	172	O	USAGE
30	174	180	O	section
NULL

Rifampin	1027	34090-1	55816042-946d-4bec-9461-bd998628ff45	26
Aerobic Gram-Negative Microorganisms: Neisseria meningitidis "Other" Microorganisms: Mycobacterium tuberculosis The following in vitro data are available, but their clinical significance is unknown.
1	0	6	O	Aerobic
2	8	11	O	Gram
3	13	20	O	Negative
4	22	35	O	Microorganisms
5	36	36	O	:
6	38	46	O	Neisseria
7	48	59	O	meningitidis
8	61	67	O	"Other"
9	69	82	O	Microorganisms
10	83	83	O	:
11	85	97	O	Mycobacterium
12	99	110	O	tuberculosis
13	112	114	O	The
14	116	124	O	following
15	126	127	O	in
16	129	133	O	vitro
17	135	138	O	data
18	140	142	O	are
19	144	152	O	available
20	153	153	O	,
21	155	157	O	but
22	159	163	O	their
23	165	172	O	clinical
24	174	185	O	significance
25	187	188	O	is
26	190	196	O	unknown
NULL

Rifampin	1028	34090-1	55816042-946d-4bec-9461-bd998628ff45	38
Rifampin exhibits in vitro activity against most strains of the following microorganisms; however, the safety and effectiveness of rifampin in treating clinical infections due to these microorganisms have not been established in adequate and well controlled trials.
1	0	7	O	XXXXXXXX
2	9	16	O	exhibits
3	18	19	O	in
4	21	25	O	vitro
5	27	34	O	activity
6	36	42	O	against
7	44	47	O	most
8	49	55	O	strains
9	57	58	O	of
10	60	62	O	the
11	64	72	O	following
12	74	87	O	microorganisms
13	90	96	O	however
14	97	97	O	,
15	99	101	O	the
16	103	108	O	safety
17	110	112	O	and
18	114	126	O	effectiveness
19	128	129	O	of
20	131	138	O	XXXXXXXX
21	140	141	O	in
22	143	150	O	treating
23	152	159	O	clinical
24	161	170	O	infections
25	172	174	O	due
26	176	177	O	to
27	179	183	O	these
28	185	198	O	microorganisms
29	200	203	O	have
30	205	207	O	not
31	209	212	O	been
32	214	224	O	established
33	226	227	O	in
34	229	236	O	adequate
35	238	240	O	and
36	242	245	O	well
37	247	256	O	controlled
38	258	263	O	trials
NULL

Rifampin	1029	34090-1	55816042-946d-4bec-9461-bd998628ff45	38
Aerobic Gram-Positive Microorganisms: Staphylococcus aureus (including Methicillin-Resistant S. aureus/MRSA) Staphylococcus epidermis Aerobic Gram-Negative Microorganisms: Haemophilus influenzae "Other" Microorganisms: Mycobacterium leprae *-lactamase production should have no effect on rifampin activity.
1	0	6	O	Aerobic
2	8	11	O	Gram
3	13	20	O	Positive
4	22	35	O	Microorganisms
5	36	36	O	:
6	38	51	O	Staphylococcus
7	53	58	O	aureus
8	61	69	O	including
9	71	81	O	Methicillin
10	83	91	O	Resistant
11	93	93	O	S
12	96	101	O	aureus
13	102	102	O	/
14	103	106	O	MRSA
15	109	122	O	Staphylococcus
16	124	132	O	epidermis
17	134	140	O	Aerobic
18	142	145	O	Gram
19	147	154	O	Negative
20	156	169	O	Microorganisms
21	170	170	O	:
22	172	182	O	Haemophilus
23	184	193	O	influenzae
24	195	201	O	"Other"
25	203	216	O	Microorganisms
26	217	217	O	:
27	219	231	O	Mycobacterium
28	233	238	O	leprae
29	240	240	O	*
30	242	250	O	lactamase
31	252	261	O	production
32	263	268	O	should
33	270	273	O	have
34	275	276	O	no
35	278	283	O	effect
36	285	286	O	on
37	288	295	O	XXXXXXXX
38	297	304	O	activity
NULL

Rifampin	1030	34090-1	55816042-946d-4bec-9461-bd998628ff45	22
Prior to initiation of therapy, appropriate specimens should be collected for identification of the infecting organism and in vitro susceptibility tests.
1	0	4	O	Prior
2	6	7	O	to
3	9	18	O	initiation
4	20	21	O	of
5	23	29	O	therapy
6	30	30	O	,
7	32	42	O	appropriate
8	44	52	O	specimens
9	54	59	O	should
10	61	62	O	be
11	64	72	O	collected
12	74	76	O	for
13	78	91	O	identification
14	93	94	O	of
15	96	98	O	the
16	100	108	O	infecting
17	110	117	O	organism
18	119	121	O	and
19	123	124	O	in
20	126	130	O	vitro
21	132	145	O	susceptibility
22	147	151	O	tests
NULL

Rifampin	1031	34090-1	55816042-946d-4bec-9461-bd998628ff45	23
In vitro testing for Mycobacterium tuberculosis isolates: Two standardized in vitro susceptibility methods are available for testing rifampin against M tuberculosis organisms.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	testing
4	17	19	O	for
5	21	33	O	Mycobacterium
6	35	46	O	tuberculosis
7	48	55	O	isolates
8	56	56	O	:
9	58	60	O	Two
10	62	73	O	standardized
11	75	76	O	in
12	78	82	O	vitro
13	84	97	O	susceptibility
14	99	105	O	methods
15	107	109	O	are
16	111	119	O	available
17	121	123	O	for
18	125	131	O	testing
19	133	140	O	XXXXXXXX
20	142	148	O	against
21	150	150	O	M
22	152	163	O	tuberculosis
23	165	173	O	organisms
NULL

Rifampin	1032	34090-1	55816042-946d-4bec-9461-bd998628ff45	29
The agar proportion method (CDC or CLSI(1) M24-A) utilizes Middlebrook 7H10 medium impregnated with rifampin at a final concentration of 1.0 mcg/mL to determine drug resistance.
1	0	2	O	The
2	4	7	O	agar
3	9	18	O	proportion
4	20	25	O	method
5	28	30	O	CDC
6	32	33	O	or
7	35	40	O	CLSI(1
8	43	45	O	M24
9	47	47	O	A
10	50	57	O	utilizes
11	59	69	O	Middlebrook
12	71	74	O	7H10
13	76	81	O	medium
14	83	93	O	impregnated
15	95	98	O	with
16	100	107	O	XXXXXXXX
17	109	110	O	at
18	112	112	O	a
19	114	118	O	final
20	120	132	O	concentration
21	134	135	O	of
22	137	139	O	1.0
23	141	143	O	mcg
24	144	144	O	/
25	145	146	O	mL
26	148	149	O	to
27	151	159	O	determine
28	161	164	O	drug
29	166	175	O	resistance
NULL

Rifampin	1033	34090-1	55816042-946d-4bec-9461-bd998628ff45	25
After three weeks of incubation MIC99 values are calculated by comparing the quantity of organisms growing in the medium containing drug to the control cultures.
1	0	4	O	After
2	6	10	O	three
3	12	16	O	weeks
4	18	19	O	of
5	21	30	O	incubation
6	32	36	O	MIC99
7	38	43	O	values
8	45	47	O	are
9	49	58	O	calculated
10	60	61	O	by
11	63	71	O	comparing
12	73	75	O	the
13	77	84	O	quantity
14	86	87	O	of
15	89	97	O	organisms
16	99	105	O	growing
17	107	108	O	in
18	110	112	O	the
19	114	119	O	medium
20	121	130	O	containing
21	132	135	O	drug
22	137	138	O	to
23	140	142	O	the
24	144	150	O	control
25	152	159	O	cultures
NULL

Rifampin	1034	34090-1	55816042-946d-4bec-9461-bd998628ff45	22
Mycobacterial growth in the presence of drug, of at least 1% of the growth in the control culture, indicates resistance.
1	0	12	O	Mycobacterial
2	14	19	O	growth
3	21	22	O	in
4	24	26	O	the
5	28	35	O	presence
6	37	38	O	of
7	40	43	O	drug
8	44	44	O	,
9	46	47	O	of
10	49	50	O	at
11	52	56	O	least
12	58	59	O	1%
13	61	62	O	of
14	64	66	O	the
15	68	73	O	growth
16	75	76	O	in
17	78	80	O	the
18	82	88	O	control
19	90	96	O	culture
20	97	97	O	,
21	99	107	O	indicates
22	109	118	O	resistance
NULL

Rifampin	1035	34090-1	55816042-946d-4bec-9461-bd998628ff45	31
The radiometric broth method employs the BACTEC 460 machine to compare the growth index from untreated control cultures to cultures grown in the presence of 2.0 mcg/mL of rifampin.
1	0	2	O	The
2	4	14	O	radiometric
3	16	20	O	broth
4	22	27	O	method
5	29	35	O	employs
6	37	39	O	the
7	41	46	O	BACTEC
8	48	50	O	460
9	52	58	O	machine
10	60	61	O	to
11	63	69	O	compare
12	71	73	O	the
13	75	80	O	growth
14	82	86	O	index
15	88	91	O	from
16	93	101	O	untreated
17	103	109	O	control
18	111	118	O	cultures
19	120	121	O	to
20	123	130	O	cultures
21	132	136	O	grown
22	138	139	O	in
23	141	143	O	the
24	145	152	O	presence
25	154	155	O	of
26	157	159	O	2.0
27	161	163	O	mcg
28	164	164	O	/
29	165	166	O	mL
30	168	169	O	of
31	171	178	O	XXXXXXXX
NULL

Rifampin	1036	34090-1	55816042-946d-4bec-9461-bd998628ff45	17
Strict adherence to the manufacturer's instructions for sample processing and data interpretation is required for this assay.
1	0	5	O	Strict
2	7	15	O	adherence
3	17	18	O	to
4	20	22	O	the
5	24	37	O	manufacturer's
6	39	50	O	instructions
7	52	54	O	for
8	56	61	O	sample
9	63	72	O	processing
10	74	76	O	and
11	78	81	O	data
12	83	96	O	interpretation
13	98	99	O	is
14	101	108	O	required
15	110	112	O	for
16	114	117	O	this
17	119	123	O	assay
NULL

Rifampin	1037	34090-1	55816042-946d-4bec-9461-bd998628ff45	27
Susceptibility test results obtained by the two different methods can only be compared if the appropriate rifampin concentration is used for each test method as indicated above.
1	0	13	O	Susceptibility
2	15	18	O	test
3	20	26	O	results
4	28	35	O	obtained
5	37	38	O	by
6	40	42	O	the
7	44	46	O	two
8	48	56	O	different
9	58	64	O	methods
10	66	68	O	can
11	70	73	O	only
12	75	76	O	be
13	78	85	O	compared
14	87	88	O	if
15	90	92	O	the
16	94	104	O	appropriate
17	106	113	O	XXXXXXXX
18	115	127	O	concentration
19	129	130	O	is
20	132	135	O	used
21	137	139	O	for
22	141	144	O	each
23	146	149	O	test
24	151	156	O	method
25	158	159	O	as
26	161	169	O	indicated
27	171	175	O	above
NULL

Rifampin	1038	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
Both procedures require the use of M tuberculosis H37Rv ATCC 27294 as a control organism.
1	0	3	O	Both
2	5	14	O	procedures
3	16	22	O	require
4	24	26	O	the
5	28	30	O	use
6	32	33	O	of
7	35	35	O	M
8	37	48	O	tuberculosis
9	50	54	O	H37Rv
10	56	59	O	ATCC
11	61	65	O	27294
12	67	68	O	as
13	70	70	O	a
14	72	78	O	control
15	80	87	O	organism
NULL

Rifampin	1039	34090-1	55816042-946d-4bec-9461-bd998628ff45	28
The clinical relevance of in vitro susceptibility test results for mycobacterial species other than M tuberculosis using either the radiometric or the proportion method has not been determined.
1	0	2	O	The
2	4	11	O	clinical
3	13	21	O	relevance
4	23	24	O	of
5	26	27	O	in
6	29	33	O	vitro
7	35	48	O	susceptibility
8	50	53	O	test
9	55	61	O	results
10	63	65	O	for
11	67	79	O	mycobacterial
12	81	87	O	species
13	89	93	O	other
14	95	98	O	than
15	100	100	O	M
16	102	113	O	tuberculosis
17	115	119	O	using
18	121	126	O	either
19	128	130	O	the
20	132	142	O	radiometric
21	144	145	O	or
22	147	149	O	the
23	151	160	O	proportion
24	162	167	O	method
25	169	171	O	has
26	173	175	O	not
27	177	180	O	been
28	182	191	O	determined
NULL

Rifampin	1040	34090-1	55816042-946d-4bec-9461-bd998628ff45	32
In vitro testing for Neisseria meningitidis isolates: Dilution Techniques: Quantitative methods that are used to determine minimum inhibitory concentrations provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	testing
4	17	19	O	for
5	21	29	O	Neisseria
6	31	42	O	meningitidis
7	44	51	O	isolates
8	52	52	O	:
9	54	61	O	Dilution
10	63	72	O	Techniques
11	73	73	O	:
12	75	86	O	Quantitative
13	88	94	O	methods
14	96	99	O	that
15	101	103	O	are
16	105	108	O	used
17	110	111	O	to
18	113	121	O	determine
19	123	129	O	minimum
20	131	140	O	inhibitory
21	142	155	O	concentrations
22	157	163	O	provide
23	165	176	O	reproducible
24	178	186	O	estimates
25	188	189	O	of
26	191	193	O	the
27	195	208	O	susceptibility
28	210	211	O	of
29	213	220	O	bacteria
30	222	223	O	to
31	225	237	O	antimicrobial
32	239	247	O	compounds
NULL

Rifampin	1041	34090-1	55816042-946d-4bec-9461-bd998628ff45	20
One such standardized procedure uses a standardized dilution method2,4 (broth, agar, or microdilution) or equivalent with rifampin powder.
1	0	2	O	One
2	4	7	O	such
3	9	20	O	standardized
4	22	30	O	procedure
5	32	35	O	uses
6	37	37	O	a
7	39	50	O	standardized
8	52	59	O	dilution
9	61	69	O	method2,4
10	72	76	O	broth
11	77	77	O	,
12	79	82	O	agar
13	83	83	O	,
14	85	86	O	or
15	88	100	O	microdilution
16	103	104	O	or
17	106	115	O	equivalent
18	117	120	O	with
19	122	129	O	XXXXXXXX
20	131	136	O	powder
NULL

Rifampin	1042	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
The MIC values obtained should be interpreted according to the following criteria for Neisseria meningitidis
1	0	2	O	The
2	4	6	O	MIC
3	8	13	O	values
4	15	22	O	obtained
5	24	29	O	should
6	31	32	O	be
7	34	44	O	interpreted
8	46	54	O	according
9	56	57	O	to
10	59	61	O	the
11	63	71	O	following
12	73	80	O	criteria
13	82	84	O	for
14	86	94	O	Neisseria
15	96	107	O	meningitidis
NULL

Rifampin	1043	34090-1	55816042-946d-4bec-9461-bd998628ff45	33
A report of "intermediate" indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.
1	0	0	O	A
2	2	7	O	report
3	9	10	O	of
4	12	25	O	"intermediate"
5	27	35	O	indicates
6	37	40	O	that
7	42	44	O	the
8	46	51	O	result
9	53	58	O	should
10	60	61	O	be
11	63	72	O	considered
12	74	82	O	equivocal
13	83	83	O	,
14	85	87	O	and
15	89	90	O	if
16	92	94	O	the
17	96	108	O	microorganism
18	110	111	O	is
19	113	115	O	not
20	117	121	O	fully
21	123	133	O	susceptible
22	135	136	O	to
23	138	148	O	alternative
24	149	149	O	,
25	151	160	O	clinically
26	162	169	O	feasible
27	171	175	O	drugs
28	176	176	O	,
29	178	180	O	the
30	182	185	O	test
31	187	192	O	should
32	194	195	O	be
33	197	204	O	repeated
NULL

Rifampin	1044	34090-1	55816042-946d-4bec-9461-bd998628ff45	28
This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where the maximum acceptable dose of drug can be used.
1	0	3	O	This
2	5	12	O	category
3	14	20	O	implies
4	22	29	O	possible
5	31	38	O	clinical
6	40	52	O	applicability
7	54	55	O	in
8	57	60	O	body
9	62	66	O	sites
10	68	72	O	where
11	74	76	O	the
12	78	81	O	drug
13	83	84	O	is
14	86	100	O	physiologically
15	102	113	O	concentrated
16	115	116	O	or
17	118	119	O	in
18	121	130	O	situations
19	132	136	O	where
20	138	140	O	the
21	142	148	O	maximum
22	150	159	O	acceptable
23	161	164	O	dose
24	166	167	O	of
25	169	172	O	drug
26	174	176	O	can
27	178	179	O	be
28	181	184	O	used
NULL

Rifampin	1045	34090-1	55816042-946d-4bec-9461-bd998628ff45	19
This category also provides a buffer zone that prevents small-uncontrolled technical factors from causing major discrepancies in interpretation.
1	0	3	O	This
2	5	12	O	category
3	14	17	O	also
4	19	26	O	provides
5	28	28	O	a
6	30	35	O	buffer
7	37	40	O	zone
8	42	45	O	that
9	47	54	O	prevents
10	56	60	O	small
11	62	73	O	uncontrolled
12	75	83	O	technical
13	85	91	O	factors
14	93	96	O	from
15	98	104	O	causing
16	106	110	O	major
17	112	124	O	discrepancies
18	126	127	O	in
19	129	142	O	interpretation
NULL

Rifampin	1046	34090-1	55816042-946d-4bec-9461-bd998628ff45	28
A report of "resistant" indicates that usually achievable concentrations of the antimicrobial compound in the blood are unlikely to be inhibitory and that other therapy should be selected.
1	0	0	O	A
2	2	7	O	report
3	9	10	O	of
4	12	22	O	"resistant"
5	24	32	O	indicates
6	34	37	O	that
7	39	45	O	usually
8	47	56	O	achievable
9	58	71	O	concentrations
10	73	74	O	of
11	76	78	O	the
12	80	92	O	antimicrobial
13	94	101	O	compound
14	103	104	O	in
15	106	108	O	the
16	110	114	O	blood
17	116	118	O	are
18	120	127	O	unlikely
19	129	130	O	to
20	132	133	O	be
21	135	144	O	inhibitory
22	146	148	O	and
23	150	153	O	that
24	155	159	O	other
25	161	167	O	therapy
26	169	174	O	should
27	176	177	O	be
28	179	186	O	selected
NULL

Rifampin	1047	34090-1	55816042-946d-4bec-9461-bd998628ff45	22
Measurement of MIC or minimum bactericidal concentrations (MBC) and achieved antimicrobial compound concentrations may be appropriate to guide therapy in some infections.
1	0	10	O	Measurement
2	12	13	O	of
3	15	17	O	MIC
4	19	20	O	or
5	22	28	O	minimum
6	30	41	O	bactericidal
7	43	56	O	concentrations
8	59	61	O	MBC
9	64	66	O	and
10	68	75	O	achieved
11	77	89	O	antimicrobial
12	91	98	O	compound
13	100	113	O	concentrations
14	115	117	O	may
15	119	120	O	be
16	122	132	O	appropriate
17	134	135	O	to
18	137	141	O	guide
19	143	149	O	therapy
20	151	152	O	in
21	154	157	O	some
22	159	168	O	infections
NULL

Rifampin	1049	34090-1	55816042-946d-4bec-9461-bd998628ff45	11
Standardized susceptibility test procedures require the use of laboratory control microorganisms.
1	0	11	O	Standardized
2	13	26	O	susceptibility
3	28	31	O	test
4	33	42	O	procedures
5	44	50	O	require
6	52	54	O	the
7	56	58	O	use
8	60	61	O	of
9	63	72	O	laboratory
10	74	80	O	control
11	82	95	O	microorganisms
NULL

Rifampin	1050	34090-1	55816042-946d-4bec-9461-bd998628ff45	22
The use of these microorganisms does not imply clinical efficacy ; they are used to control the technical aspects of the laboratory procedures.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	15	O	these
5	17	30	O	microorganisms
6	32	35	O	does
7	37	39	O	not
8	41	45	O	imply
9	47	54	O	clinical
10	56	63	O	efficacy
11	67	70	O	they
12	72	74	O	are
13	76	79	O	used
14	81	82	O	to
15	84	90	O	control
16	92	94	O	the
17	96	104	O	technical
18	106	112	O	aspects
19	114	115	O	of
20	117	119	O	the
21	121	130	O	laboratory
22	132	141	O	procedures
NULL

Rifampin	1051	34090-1	55816042-946d-4bec-9461-bd998628ff45	67
Standard rifampin powder should give the following MIC values: Microorganism MIC (mcg/mL) Staphylococcus aureus ATCC 29213 0.008 - 0.06 Enterococcus faecalis ATCC 29212 1 - 4 Escherichia coli ATCC 25922 8 - 32 Pseudomonas aeruginosa ATCC 27853 32 - 64 Haemophilus influenzae ATCC 49247 0.25 - 1 Diffusion Techniques: Quantitative methods that require measurement of zone diameters provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.
1	0	7	O	Standard
2	9	16	O	XXXXXXXX
3	18	23	O	powder
4	25	30	O	should
5	32	35	O	give
6	37	39	O	the
7	41	49	O	following
8	51	53	O	MIC
9	55	60	O	values
10	61	61	O	:
11	63	75	O	Microorganism
12	77	79	O	MIC
13	82	84	O	mcg
14	85	85	O	/
15	86	87	O	mL
16	90	103	O	Staphylococcus
17	105	110	O	aureus
18	112	115	O	ATCC
19	117	121	O	29213
20	123	127	O	0.008
21	131	134	O	0.06
22	136	147	O	Enterococcus
23	149	156	O	faecalis
24	158	161	O	ATCC
25	163	167	O	29212
26	169	169	O	1
27	173	173	O	4
28	175	185	O	Escherichia
29	187	190	O	coli
30	192	195	O	ATCC
31	197	201	O	25922
32	203	203	O	8
33	207	208	O	32
34	210	220	O	Pseudomonas
35	222	231	O	aeruginosa
36	233	236	O	ATCC
37	238	242	O	27853
38	244	245	O	32
39	249	250	O	64
40	252	262	O	Haemophilus
41	264	273	O	influenzae
42	275	278	O	ATCC
43	280	284	O	49247
44	286	289	O	0.25
45	293	293	O	1
46	295	303	O	Diffusion
47	305	314	O	Techniques
48	315	315	O	:
49	317	328	O	Quantitative
50	330	336	O	methods
51	338	341	O	that
52	343	349	O	require
53	351	361	O	measurement
54	363	364	O	of
55	366	369	O	zone
56	371	379	O	diameters
57	381	387	O	provide
58	389	400	O	reproducible
59	402	410	O	estimates
60	412	413	O	of
61	415	417	O	the
62	419	432	O	susceptibility
63	434	435	O	of
64	437	444	O	bacteria
65	446	447	O	to
66	449	461	O	antimicrobial
67	463	471	O	compounds
NULL

Rifampin	1052	34090-1	55816042-946d-4bec-9461-bd998628ff45	26
One such standardized procedure3,4 that has been recommended for use with disks to test the susceptibility of microorganisms to rifampin uses the 5 mcg rifampin disk.
1	0	2	O	One
2	4	7	O	such
3	9	20	O	standardized
4	22	33	O	procedure3,4
5	35	38	O	that
6	40	42	O	has
7	44	47	O	been
8	49	59	O	recommended
9	61	63	O	for
10	65	67	O	use
11	69	72	O	with
12	74	78	O	disks
13	80	81	O	to
14	83	86	O	test
15	88	90	O	the
16	92	105	O	susceptibility
17	107	108	O	of
18	110	123	O	microorganisms
19	125	126	O	to
20	128	135	O	XXXXXXXX
21	137	140	O	uses
22	142	144	O	the
23	146	146	O	5
24	148	150	O	mcg
25	152	159	O	XXXXXXXX
26	161	164	O	disk
NULL

Rifampin	1053	34090-1	55816042-946d-4bec-9461-bd998628ff45	16
Interpretation involves correlation of the diameter obtained in the disk test with the MIC for rifampin.
1	0	13	O	Interpretation
2	15	22	O	involves
3	24	34	O	correlation
4	36	37	O	of
5	39	41	O	the
6	43	50	O	diameter
7	52	59	O	obtained
8	61	62	O	in
9	64	66	O	the
10	68	71	O	disk
11	73	76	O	test
12	78	81	O	with
13	83	85	O	the
14	87	89	O	MIC
15	91	93	O	for
16	95	102	O	XXXXXXXX
NULL

Rifampin	1054	34090-1	55816042-946d-4bec-9461-bd998628ff45	58
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg rifampin disk should be interpreted according to the following criteria for Neisseria meningitides: Zone Diameter (mm) Interpretation > 20 (S) Susceptible 17 - 19 (I) Intermediate < 16 (R) Resistant Interpretation should be as stated above for results using dilution techniques.
1	0	6	O	Reports
2	8	11	O	from
3	13	15	O	the
4	17	26	O	laboratory
5	28	36	O	providing
6	38	44	O	results
7	46	47	O	of
8	49	51	O	the
9	53	60	O	standard
10	62	67	O	single
11	69	72	O	disk
12	74	87	O	susceptibility
13	89	92	O	test
14	94	97	O	with
15	99	99	O	a
16	101	101	O	5
17	103	105	O	mcg
18	107	114	O	XXXXXXXX
19	116	119	O	disk
20	121	126	O	should
21	128	129	O	be
22	131	141	O	interpreted
23	143	151	O	according
24	153	154	O	to
25	156	158	O	the
26	160	168	O	following
27	170	177	O	criteria
28	179	181	O	for
29	183	191	O	Neisseria
30	193	204	O	meningitides
31	205	205	O	:
32	207	210	O	Zone
33	212	219	O	Diameter
34	222	223	O	mm
35	226	239	O	Interpretation
36	241	241	O	>
37	243	244	O	20
38	247	247	O	S
39	250	260	O	Susceptible
40	262	263	O	17
41	267	268	O	19
42	271	271	O	I
43	274	285	O	Intermediate
44	287	287	O	<
45	289	290	O	16
46	293	293	O	R
47	296	304	O	Resistant
48	306	319	O	Interpretation
49	321	326	O	should
50	328	329	O	be
51	331	332	O	as
52	334	339	O	stated
53	341	345	O	above
54	347	349	O	for
55	351	357	O	results
56	359	363	O	using
57	365	372	O	dilution
58	374	383	O	techniques
NULL

Rifampin	1055	34090-1	55816042-946d-4bec-9461-bd998628ff45	15
As with standard dilution techniques, diffusion methods require the use of laboratory control microorganisms.
1	0	1	O	As
2	3	6	O	with
3	8	15	O	standard
4	17	24	O	dilution
5	26	35	O	techniques
6	36	36	O	,
7	38	46	O	diffusion
8	48	54	O	methods
9	56	62	O	require
10	64	66	O	the
11	68	70	O	use
12	72	73	O	of
13	75	84	O	laboratory
14	86	92	O	control
15	94	107	O	microorganisms
NULL

Rifampin	1057	34090-1	55816042-946d-4bec-9461-bd998628ff45	39
The 5 mcg rifampin disk should provide the following zone diameters in these quality control strains: Microorganism Zone Diameter (mm) S. aureus ATCC 25923 26 - 34 E. coli ATCC 25922 8 - 10 H. influenzae ATCC 49247 22 - 30
1	0	2	O	The
2	4	4	O	5
3	6	8	O	mcg
4	10	17	O	XXXXXXXX
5	19	22	O	disk
6	24	29	O	should
7	31	37	O	provide
8	39	41	O	the
9	43	51	O	following
10	53	56	O	zone
11	58	66	O	diameters
12	68	69	O	in
13	71	75	O	these
14	77	83	O	quality
15	85	91	O	control
16	93	99	O	strains
17	100	100	O	:
18	102	114	O	Microorganism
19	116	119	O	Zone
20	121	128	O	Diameter
21	131	132	O	mm
22	135	135	O	S
23	138	143	O	aureus
24	145	148	O	ATCC
25	150	154	O	25923
26	156	157	O	26
27	161	162	O	34
28	164	164	O	E
29	167	170	O	coli
30	172	175	O	ATCC
31	177	181	O	25922
32	183	183	O	8
33	187	188	O	10
34	190	190	O	H
35	193	202	O	influenzae
36	204	207	O	ATCC
37	209	213	O	49247
38	215	216	O	22
39	220	221	O	30
NULL

Risperidone	5056	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	10
*Carbamazepine and other enzyme inducers decrease plasma concentrations of risperidone.
1	0	13	O	Carbamazepine
2	15	17	O	and
3	19	23	O	other
4	25	30	B-KIN	enzyme
5	32	39	L-KIN	inducers
6	41	48	B-TRI	decrease
7	50	55	I-TRI	plasma
8	57	70	L-TRI	concentrations
9	72	73	O	of
10	75	85	O	XXXXXXXX
K/4:C54356

Risperidone	5057	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	11
Increase the respiridone dose up to double the patient's usual dose.
1	0	7	O	Increase
2	9	11	O	the
3	13	23	O	respiridone
4	25	28	O	dose
5	30	31	O	up
6	33	34	O	to
7	36	41	O	double
8	43	45	O	the
9	47	55	O	patient's
10	57	61	O	usual
11	63	66	O	dose
NULL

Risperidone	5058	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	15
*Fluoxetine, paroxetine, and other CYP 2D6 enzyme inhibitors increase plasma concentrations of risperidone.
1	0	10	O	Fluoxetine
2	11	11	O	,
3	13	22	U-KIN	paroxetine
4	23	23	O	,
5	25	27	O	and
6	29	33	O	other
7	35	37	B-KIN	CYP
8	39	41	I-KIN	2D6
9	43	48	I-KIN	enzyme
10	50	59	L-KIN	inhibitors
11	61	68	B-TRI	increase
12	70	75	I-TRI	plasma
13	77	90	L-TRI	concentrations
14	92	93	O	of
15	95	105	O	XXXXXXXX
K/3:C54355 K/7:C54355

Risperidone	5059	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	13
Do not exceed a final dose of 8 mg per day of respiridone.
1	0	1	O	Do
2	3	5	O	not
3	7	12	O	exceed
4	14	14	O	a
5	16	20	O	final
6	22	25	O	dose
7	27	28	O	of
8	30	30	O	8
9	32	33	O	mg
10	35	37	O	per
11	39	41	O	day
12	43	44	O	of
13	46	56	O	respiridone
NULL

Risperidone	5060	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	27
The dose of risperidone should be adjusted when used in combination with CYP2D6 enzyme inhibitors (e.g., fluoxetine, and paroxetine) and enzyme inducers (e.g., carbamazepine).
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	22	O	XXXXXXXX
5	24	29	O	should
6	31	32	O	be
7	34	41	O	adjusted
8	43	46	O	when
9	48	51	O	used
10	53	54	O	in
11	56	66	O	combination
12	68	71	O	with
13	73	78	B-UNK	CYP2D6
14	80	85	I-UNK	enzyme
15	87	96	L-UNK	inhibitors
16	99	101	O	e.g
17	103	103	O	,
18	105	114	U-UNK	fluoxetine
19	115	115	O	,
20	117	119	O	and
21	121	130	U-UNK	paroxetine
22	133	135	O	and
23	137	142	O	enzyme
24	144	151	O	inducers
25	154	156	O	e.g
26	158	158	O	,
27	160	172	U-UNK	carbamazepine
NULL

Risperidone	5061	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	19
Dose adjustment is not recommended for risperidone when co-administered with ranitidine, cimetidine, amitriptyline, or erythromycin.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	17	O	is
4	19	21	O	not
5	23	33	O	recommended
6	35	37	O	for
7	39	49	O	XXXXXXXX
8	51	54	O	when
9	56	57	O	co
10	59	70	O	administered
11	72	75	O	with
12	77	86	O	ranitidine
13	87	87	O	,
14	89	98	O	cimetidine
15	99	99	O	,
16	101	113	O	amitriptyline
17	114	114	O	,
18	116	117	O	or
19	119	130	O	erythromycin
NULL

Risperidone	5062	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	49
Table 18 Summary of Effect of Coadministered Drugs on Exposure to Active Moiety (Risperidone + 9-Hydroxy-Risperidone) in Healthy Subjects or Patients with Schizophrenia CoadministeredDrug DosingSchedule EffectonActiveMoiety(Risperidone+9-Hydroxy-Risperidone(Ratio*) RisperidoneDoseRecommendation CoadministeredDrug Risperidone AUC Cmax Enzyme(CYP2D6)Inhibitors Fluoxetine 20mg/day 2or3mgtwicedaily 1.4 1.5 Re-evaluatedosing.
1	0	4	O	Table
2	6	7	O	18
3	9	15	O	Summary
4	17	18	O	of
5	20	25	O	Effect
6	27	28	O	of
7	30	43	O	Coadministered
8	45	49	O	Drugs
9	51	52	O	on
10	54	61	O	Exposure
11	63	64	O	to
12	66	71	O	Active
13	73	78	O	Moiety
14	81	91	O	XXXXXXXX
15	93	93	O	+
16	95	95	O	9
17	97	103	O	Hydroxy
18	105	115	O	XXXXXXXX
19	118	119	O	in
20	121	127	O	Healthy
21	129	136	O	Subjects
22	138	139	O	or
23	141	148	O	Patients
24	150	153	O	with
25	155	167	O	Schizophrenia
26	169	186	O	CoadministeredDrug
27	188	201	O	DosingSchedule
28	203	222	O	EffectonActiveMoiety
29	224	234	O	XXXXXXXX
30	235	236	O	+9
31	238	244	O	Hydroxy
32	246	256	O	XXXXXXXX
33	258	263	O	Ratio*
34	266	276	O	XXXXXXXX
35	277	294	O	DoseRecommendation
36	296	313	O	CoadministeredDrug
37	315	325	O	XXXXXXXX
38	327	329	O	AUC
39	331	334	O	Cmax
40	336	359	O	Enzyme(CYP2D6)Inhibitors
41	361	370	U-UNK	Fluoxetine
42	372	375	O	20mg
43	376	376	O	/
44	377	379	O	day
45	381	396	O	2or3mgtwicedaily
46	398	400	O	1.4
47	402	404	O	1.5
48	406	407	O	Re
49	409	422	O	evaluatedosing
NULL

Risperidone	5063	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	13
Donotexceed8mg/day Paroxetine 10mg/day 4mg/day 1.3 - Re-evaluatedosing.
1	0	13	O	Donotexceed8mg
2	14	14	O	/
3	15	17	O	day
4	19	28	U-KIN	Paroxetine
5	30	33	O	10mg
6	34	34	O	/
7	35	37	O	day
8	39	41	O	4mg
9	42	42	O	/
10	43	45	O	day
11	47	49	O	1.3
12	53	54	O	Re
13	56	69	O	evaluatedosing
K/4:C54357

Risperidone	5064	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	28
Do not exceed 8 mg/day Enzyme (CYP3A/PgP inducers)Inducers Carbamazepine 573 * 168 mg/day 3 mg twice daily 0.51 0.55 Titrate dose upwards.
1	0	1	O	Do
2	3	5	O	not
3	7	12	O	exceed
4	14	14	O	8
5	16	17	O	mg
6	18	18	O	/
7	19	21	O	day
8	23	28	O	Enzyme
9	31	35	B-KIN	CYP3A
10	36	36	I-KIN	/
11	37	39	L-KIN	PgP
12	41	57	O	inducers)Inducers
13	59	71	U-KIN	Carbamazepine
14	73	75	O	573
15	77	77	O	*
16	79	81	O	168
17	83	84	O	mg
18	85	85	O	/
19	86	88	O	day
20	90	90	O	3
21	92	93	O	mg
22	95	99	O	twice
23	101	105	O	daily
24	107	110	O	0.51
25	112	115	O	0.55
26	117	123	B-TRI	Titrate
27	125	128	I-TRI	dose
28	130	136	L-TRI	upwards
K/13:C54356 K/9:C54356

Risperidone	5065	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	7
Dose adjustment for lithium is not recommended.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	18	O	for
4	20	26	O	lithium
5	28	29	O	is
6	31	33	O	not
7	35	45	O	recommended
NULL

Risperidone	5066	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	37
Valproate Repeated oral doses of risperidone (4 mg once daily) did not affect the pre-dose or average plasma concentrations and exposure (AUC) of valproate (1000 mg/day in three divided doses) compared to placebo (n=21).
1	0	8	O	Valproate
2	10	17	O	Repeated
3	19	22	O	oral
4	24	28	O	doses
5	30	31	O	of
6	33	43	O	XXXXXXXX
7	46	46	O	4
8	48	49	O	mg
9	51	54	O	once
10	56	60	O	daily
11	63	65	O	did
12	67	69	O	not
13	71	76	O	affect
14	78	80	O	the
15	82	84	O	pre
16	86	89	O	dose
17	91	92	O	or
18	94	100	O	average
19	102	107	O	plasma
20	109	122	O	concentrations
21	124	126	O	and
22	128	135	O	exposure
23	138	140	O	AUC
24	143	144	O	of
25	146	154	O	valproate
26	157	160	O	1000
27	162	163	O	mg
28	164	164	O	/
29	165	167	O	day
30	169	170	O	in
31	172	176	O	three
32	178	184	O	divided
33	186	190	O	doses
34	193	200	O	compared
35	202	203	O	to
36	205	211	O	placebo
37	214	217	O	n=21
NULL

Risperidone	5067	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	18
However, there was a 20% increase in valproate peak plasma concentration (Cmax) after concomitant administration of risperidone.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	there
4	15	17	O	was
5	19	19	O	a
6	21	23	O	20%
7	25	32	O	increase
8	34	35	O	in
9	37	45	U-KIN	valproate
10	47	50	O	peak
11	52	57	O	plasma
12	59	71	O	concentration
13	74	77	O	Cmax
14	80	84	O	after
15	86	96	O	concomitant
16	98	111	O	administration
17	113	114	O	of
18	116	126	O	XXXXXXXX
K/9:C54610

Risperidone	5068	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	7
Dose adjustment for valproate is not recommended.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	18	O	for
4	20	28	O	valproate
5	30	31	O	is
6	33	35	O	not
7	37	47	O	recommended
NULL

Risperidone	5069	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	18
Digoxin Risperidone (0.25 mg twice daily) did not show a clinically relevant effect on the pharmacokinetics of digoxin.
1	0	6	O	Digoxin
2	8	18	O	XXXXXXXX
3	21	24	O	0.25
4	26	27	O	mg
5	29	33	O	twice
6	35	39	O	daily
7	42	44	O	did
8	46	48	O	not
9	50	53	O	show
10	55	55	O	a
11	57	66	O	clinically
12	68	75	O	relevant
13	77	82	O	effect
14	84	85	O	on
15	87	89	O	the
16	91	106	O	pharmacokinetics
17	108	109	O	of
18	111	117	O	digoxin
NULL

Risperidone	5070	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	7
Dose adjustment for digoxin is not recommended.
1	0	3	O	Dose
2	5	14	O	adjustment
3	16	18	O	for
4	20	26	O	digoxin
5	28	29	O	is
6	31	33	O	not
7	35	45	O	recommended
NULL

Risperidone	5071	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	30
Centrally-Acting Drugs and Alcohol Given the primary CNS effects of risperidone, caution should be used when risperidone is taken in combination with other centrally-acting drugs and alcohol.
1	0	8	O	Centrally
2	10	15	O	Acting
3	17	21	O	Drugs
4	23	25	O	and
5	27	33	O	Alcohol
6	35	39	O	Given
7	41	43	O	the
8	45	51	O	primary
9	53	55	O	CNS
10	57	63	O	effects
11	65	66	O	of
12	68	78	O	XXXXXXXX
13	79	79	O	,
14	81	87	U-TRI	caution
15	89	94	O	should
16	96	97	O	be
17	99	102	O	used
18	104	107	O	when
19	109	119	O	XXXXXXXX
20	121	122	O	is
21	124	128	O	taken
22	130	131	O	in
23	133	143	O	combination
24	145	148	O	with
25	150	154	O	other
26	156	164	B-UNK	centrally
27	166	171	I-UNK	acting
28	173	177	L-UNK	drugs
29	179	181	O	and
30	183	189	U-UNK	alcohol
NULL

Risperidone	5072	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	25
Drugs with Hypotensive Effects Because of its potential for inducing hypotension, risperidone may enhance the hypotensive effects of other therapeutic agents with this potential.
1	0	4	B-DYN	Drugs
2	6	9	I-DYN	with
3	11	21	I-DYN	Hypotensive
4	23	29	L-DYN	Effects
5	31	37	O	Because
6	39	40	O	of
7	42	44	O	its
8	46	54	O	potential
9	56	58	O	for
10	60	67	O	inducing
11	69	79	O	hypotension
12	80	80	O	,
13	82	92	O	XXXXXXXX
14	94	96	O	may
15	98	104	B-EFF	enhance
16	106	108	I-EFF	the
17	110	120	I-EFF	hypotensive
18	122	128	L-EFF	effects
19	130	131	O	of
20	133	137	O	other
21	139	149	O	therapeutic
22	151	156	O	agents
23	158	161	O	with
24	163	166	O	this
25	168	176	O	potential
D/1:15:1

Risperidone	5073	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	14
Levodopa and Dopamine Agonists Risperidone may antagonize the effects of levodopa and dopamine agonists.
1	0	7	O	Levodopa
2	9	11	O	and
3	13	20	O	Dopamine
4	22	29	O	Agonists
5	31	41	O	XXXXXXXX
6	43	45	O	may
7	47	56	B-EFF	antagonize
8	58	60	I-EFF	the
9	62	68	I-EFF	effects
10	70	71	I-EFF	of
11	73	80	L-EFF	levodopa
12	82	84	O	and
13	86	93	B-DYN	dopamine
14	95	102	L-DYN	agonists
D/13:7:0

Risperidone	5074	34073-7	49c4105b-e518-481c-a248-6684135f5bc1	13
Clozapine Chronic administration of clozapine with risperidone may decrease the clearance of risperidone.
1	0	8	O	Clozapine
2	10	16	O	Chronic
3	18	31	O	administration
4	33	34	O	of
5	36	44	U-KIN	clozapine
6	46	49	O	with
7	51	61	O	XXXXXXXX
8	63	65	O	may
9	67	74	B-TRI	decrease
10	76	78	I-TRI	the
11	80	88	L-TRI	clearance
12	90	91	O	of
13	93	103	O	XXXXXXXX
K/5:C54355

Risperidone	5075	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	12
The mechanism of action of risperidone, in schizophrenia, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	37	O	XXXXXXXX
7	38	38	O	,
8	40	41	O	in
9	43	55	O	schizophrenia
10	56	56	O	,
11	58	59	O	is
12	61	67	O	unknown
NULL

Risperidone	5076	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	31
However, it has been proposed that the drug's therapeutic activity in schizophrenia could be mediated through a combination of dopamine Type 2 (D2) and serotonin Type 2 (5HT2) receptor antagonism.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	28	O	proposed
7	30	33	O	that
8	35	37	O	the
9	39	44	O	drug's
10	46	56	O	therapeutic
11	58	65	O	activity
12	67	68	O	in
13	70	82	O	schizophrenia
14	84	88	O	could
15	90	91	O	be
16	93	100	O	mediated
17	102	108	O	through
18	110	110	O	a
19	112	122	O	combination
20	124	125	O	of
21	127	134	O	dopamine
22	136	139	O	Type
23	141	141	O	2
24	144	145	O	D2
25	148	150	O	and
26	152	160	O	serotonin
27	162	165	O	Type
28	167	167	O	2
29	170	173	O	5HT2
30	176	183	O	receptor
31	185	194	O	antagonism
NULL

Risperidone	5077	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	20
The clinical effect from risperidone results from the combined concentrations of risperidone and its major metabolite, 9-hydroxyrisperidone.
1	0	2	O	The
2	4	11	O	clinical
3	13	18	O	effect
4	20	23	O	from
5	25	35	O	XXXXXXXX
6	37	43	O	results
7	45	48	O	from
8	50	52	O	the
9	54	61	O	combined
10	63	76	O	concentrations
11	78	79	O	of
12	81	91	O	XXXXXXXX
13	93	95	O	and
14	97	99	O	its
15	101	105	O	major
16	107	116	O	metabolite
17	117	117	O	,
18	119	119	O	9
19	121	127	O	hydroxy
20	128	138	O	XXXXXXXX
NULL

Risperidone	5078	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	17
Antagonism at receptors other than D2 and 5HT2 may explain some of the other effects of risperidone.
1	0	9	O	Antagonism
2	11	12	O	at
3	14	22	O	receptors
4	24	28	O	other
5	30	33	O	than
6	35	36	O	D2
7	38	40	O	and
8	42	45	O	5HT2
9	47	49	O	may
10	51	57	O	explain
11	59	62	O	some
12	64	65	O	of
13	67	69	O	the
14	71	75	O	other
15	77	83	O	effects
16	85	86	O	of
17	88	98	O	XXXXXXXX
NULL

Risperidone	5079	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	36
Risperidone is a selective monoaminergic antagonist with high affinity (Ki of 0.12 to 7.3 nM) for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), A1 and A2 adrenergic, and H1 histaminergic receptors.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	25	O	selective
5	27	39	O	monoaminergic
6	41	50	O	antagonist
7	52	55	O	with
8	57	60	O	high
9	62	69	O	affinity
10	72	73	O	Ki
11	75	76	O	of
12	78	81	O	0.12
13	83	84	O	to
14	86	88	O	7.3
15	90	91	O	nM
16	94	96	O	for
17	98	100	O	the
18	102	110	O	serotonin
19	112	115	O	Type
20	117	117	O	2
21	120	123	O	5HT2
22	125	125	O	,
23	127	134	O	dopamine
24	136	139	O	Type
25	141	141	O	2
26	144	145	O	D2
27	147	147	O	,
28	149	150	O	A1
29	152	154	O	and
30	156	157	O	A2
31	159	168	O	adrenergic
32	169	169	O	,
33	171	173	O	and
34	175	176	O	H1
35	178	190	O	histaminergic
36	192	200	O	receptors
NULL

Risperidone	5080	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	13
Risperidone acts as an antagonist at other receptors, but with lower potency.
1	0	10	O	XXXXXXXX
2	12	15	O	acts
3	17	18	O	as
4	20	21	O	an
5	23	32	O	antagonist
6	34	35	O	at
7	37	41	O	other
8	43	51	O	receptors
9	52	52	O	,
10	54	56	O	but
11	58	61	O	with
12	63	67	O	lower
13	69	75	O	potency
NULL

Risperidone	5081	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	60
Risperidone has low to moderate affinity (Ki of 47 to 253 nM) for the serotonin 5HT1C, 5HT1D, and 5HT1A receptors, weak affinity (Ki of 620 to 800 nM) for the dopamine D1 and haloperidol-sensitive sigma site, and no affinity (when tested at concentrations >10-5 M) for cholinergic muscarinic or B1 and B2 adrenergic receptors.
1	0	10	O	XXXXXXXX
2	12	14	O	has
3	16	18	O	low
4	20	21	O	to
5	23	30	O	moderate
6	32	39	O	affinity
7	42	43	O	Ki
8	45	46	O	of
9	48	49	O	47
10	51	52	O	to
11	54	56	O	253
12	58	59	O	nM
13	62	64	O	for
14	66	68	O	the
15	70	78	O	serotonin
16	80	84	O	5HT1C
17	85	85	O	,
18	87	91	O	5HT1D
19	92	92	O	,
20	94	96	O	and
21	98	102	O	5HT1A
22	104	112	O	receptors
23	113	113	O	,
24	115	118	O	weak
25	120	127	O	affinity
26	130	131	O	Ki
27	133	134	O	of
28	136	138	O	620
29	140	141	O	to
30	143	145	O	800
31	147	148	O	nM
32	151	153	O	for
33	155	157	O	the
34	159	166	O	dopamine
35	168	169	O	D1
36	171	173	O	and
37	175	185	O	haloperidol
38	187	195	O	sensitive
39	197	201	O	sigma
40	203	206	O	site
41	207	207	O	,
42	209	211	O	and
43	213	214	O	no
44	216	223	O	affinity
45	226	229	O	when
46	231	236	O	tested
47	238	239	O	at
48	241	254	O	concentrations
49	256	258	O	>10
50	260	260	O	5
51	262	262	O	M
52	265	267	O	for
53	269	279	O	cholinergic
54	281	290	O	muscarinic
55	292	293	O	or
56	295	296	O	B1
57	298	300	O	and
58	302	303	O	B2
59	305	314	O	adrenergic
60	316	324	O	receptors
NULL

Risperidone	5082	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	5
Absorption Risperidone is well absorbed.
1	0	9	O	Absorption
2	11	21	O	XXXXXXXX
3	23	24	O	is
4	26	29	O	well
5	31	38	O	absorbed
NULL

Risperidone	5083	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	9
The absolute oral bioavailability of risperidone is 70% (CV=25%).
1	0	2	O	The
2	4	11	O	absolute
3	13	16	O	oral
4	18	32	O	bioavailability
5	34	35	O	of
6	37	47	O	XXXXXXXX
7	49	50	O	is
8	52	54	O	70%
9	57	62	O	CV=25%
NULL

Risperidone	5084	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	17
The relative oral bioavailability of risperidone from a tablet is 94% (CV=10%) when compared to a solution.
1	0	2	O	The
2	4	11	O	relative
3	13	16	O	oral
4	18	32	O	bioavailability
5	34	35	O	of
6	37	47	O	XXXXXXXX
7	49	52	O	from
8	54	54	O	a
9	56	61	O	tablet
10	63	64	O	is
11	66	68	O	94%
12	71	76	O	CV=10%
13	79	82	O	when
14	84	91	O	compared
15	93	94	O	to
16	96	96	O	a
17	98	105	O	solution
NULL

Risperidone	5085	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	17
Pharmacokinetic studies showed that Risperidone Orally Disintegrating Tablets and Risperidone Oral Solution are bioequivalent to Risperidone Tablets.
1	0	14	O	Pharmacokinetic
2	16	22	O	studies
3	24	29	O	showed
4	31	34	O	that
5	36	46	O	XXXXXXXX
6	48	53	O	Orally
7	55	68	O	Disintegrating
8	70	76	O	Tablets
9	78	80	O	and
10	82	92	O	XXXXXXXX
11	94	97	O	Oral
12	99	106	O	Solution
13	108	110	O	are
14	112	124	O	bioequivalent
15	126	127	O	to
16	129	139	O	XXXXXXXX
17	141	147	O	Tablets
NULL

Risperidone	5086	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	38
Plasma concentrations of risperidone, its major metabolite, 9-hydroxyrisperidone, and risperidone plus 9-hydroxyrisperidone are dose proportional over the dosing range of 1 to 16 mg daily (0.5 to 8 mg twice daily).
1	0	5	O	Plasma
2	7	20	O	concentrations
3	22	23	O	of
4	25	35	O	XXXXXXXX
5	36	36	O	,
6	38	40	O	its
7	42	46	O	major
8	48	57	O	metabolite
9	58	58	O	,
10	60	60	O	9
11	62	68	O	hydroxy
12	69	79	O	XXXXXXXX
13	80	80	O	,
14	82	84	O	and
15	86	96	O	XXXXXXXX
16	98	101	O	plus
17	103	103	O	9
18	105	111	O	hydroxy
19	112	122	O	XXXXXXXX
20	124	126	O	are
21	128	131	O	dose
22	133	144	O	proportional
23	146	149	O	over
24	151	153	O	the
25	155	160	O	dosing
26	162	166	O	range
27	168	169	O	of
28	171	171	O	1
29	173	174	O	to
30	176	177	O	16
31	179	180	O	mg
32	182	186	O	daily
33	189	191	O	0.5
34	193	194	O	to
35	196	196	O	8
36	198	199	O	mg
37	201	205	O	twice
38	207	211	O	daily
NULL

Risperidone	5087	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	19
Following oral administration of solution or tablet, mean peak plasma concentrations of risperidone occurred at about 1 hour.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	40	O	solution
6	42	43	O	or
7	45	50	O	tablet
8	51	51	O	,
9	53	56	O	mean
10	58	61	O	peak
11	63	68	O	plasma
12	70	83	O	concentrations
13	85	86	O	of
14	88	98	O	XXXXXXXX
15	100	107	O	occurred
16	109	110	O	at
17	112	116	O	about
18	118	118	O	1
19	120	123	O	hour
NULL

Risperidone	5088	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	21
Peak concentrations of 9-hydroxyrisperidone occurred at about 3 hours in extensive metabolizers, and 17 hours in poor metabolizers.
1	0	3	O	Peak
2	5	18	O	concentrations
3	20	21	O	of
4	23	23	O	9
5	25	31	O	hydroxy
6	32	42	O	XXXXXXXX
7	44	51	O	occurred
8	53	54	O	at
9	56	60	O	about
10	62	62	O	3
11	64	68	O	hours
12	70	71	O	in
13	73	81	O	extensive
14	83	94	O	metabolizers
15	95	95	O	,
16	97	99	O	and
17	101	102	O	17
18	104	108	O	hours
19	110	111	O	in
20	113	116	O	poor
21	118	129	O	metabolizers
NULL

Risperidone	5089	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	28
Steady-state concentrations of risperidone are reached in 1 day in extensive metabolizers and would be expected to reach steady-state in about 5 days in poor metabolizers.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	29	O	of
5	31	41	O	XXXXXXXX
6	43	45	O	are
7	47	53	O	reached
8	55	56	O	in
9	58	58	O	1
10	60	62	O	day
11	64	65	O	in
12	67	75	O	extensive
13	77	88	O	metabolizers
14	90	92	O	and
15	94	98	O	would
16	100	101	O	be
17	103	110	O	expected
18	112	113	O	to
19	115	119	O	reach
20	121	126	O	steady
21	128	132	O	state
22	134	135	O	in
23	137	141	O	about
24	143	143	O	5
25	145	148	O	days
26	150	151	O	in
27	153	156	O	poor
28	158	169	O	metabolizers
NULL

Risperidone	5090	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	17
Steady-state concentrations of 9-hydroxyrisperidone are reached in 5-6 days (measured in extensive metabolizers).
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	29	O	of
5	31	31	O	9
6	33	39	O	hydroxy
7	40	50	O	XXXXXXXX
8	52	54	O	are
9	56	62	O	reached
10	64	65	O	in
11	67	67	O	5
12	69	69	O	6
13	71	74	O	days
14	77	84	O	measured
15	86	87	O	in
16	89	97	O	extensive
17	99	110	O	metabolizers
NULL

Risperidone	5091	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	15
Food Effect Food does not affect either the rate or extent of absorption of risperidone.
1	0	3	O	Food
2	5	10	O	Effect
3	12	15	O	Food
4	17	20	O	does
5	22	24	O	not
6	26	31	O	affect
7	33	38	O	either
8	40	42	O	the
9	44	47	O	rate
10	49	50	O	or
11	52	57	O	extent
12	59	60	O	of
13	62	71	O	absorption
14	73	74	O	of
15	76	86	O	XXXXXXXX
NULL

Risperidone	5092	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	10
Thus, risperidone can be given with or without meals.
1	0	3	O	Thus
2	4	4	O	,
3	6	16	O	XXXXXXXX
4	18	20	O	can
5	22	23	O	be
6	25	29	O	given
7	31	34	O	with
8	36	37	O	or
9	39	45	O	without
10	47	51	O	meals
NULL

Risperidone	5093	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	5
Distribution Risperidone is rapidly distributed.
1	0	11	O	Distribution
2	13	23	O	XXXXXXXX
3	25	26	O	is
4	28	34	O	rapidly
5	36	46	O	distributed
NULL

Risperidone	5094	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	12
In plasma, risperidone is bound to albumin and A1-acid glycoprotein.
1	0	1	O	In
2	3	8	O	plasma
3	9	9	O	,
4	11	21	O	XXXXXXXX
5	23	24	O	is
6	26	30	O	bound
7	32	33	O	to
8	35	41	O	albumin
9	43	45	O	and
10	47	48	O	A1
11	50	53	O	acid
12	55	66	O	glycoprotein
NULL

Risperidone	5095	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	22
The plasma protein binding of risperidone is 90%, and that of its major metabolite, 9-hydroxyrisperidone, is 77%.
1	0	2	O	The
2	4	9	O	plasma
3	11	17	O	protein
4	19	25	O	binding
5	27	28	O	of
6	30	40	O	XXXXXXXX
7	42	43	O	is
8	45	47	O	90%
9	48	48	O	,
10	50	52	O	and
11	54	57	O	that
12	59	60	O	of
13	62	64	O	its
14	66	70	O	major
15	72	81	O	metabolite
16	82	82	O	,
17	84	84	O	9
18	86	92	O	hydroxy
19	93	103	O	XXXXXXXX
20	104	104	O	,
21	106	107	O	is
22	109	111	O	77%
NULL

Risperidone	5096	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	13
Neither risperidone nor 9-hydroxyrisperidone displaces each other from plasma binding sites.
1	0	6	O	Neither
2	8	18	O	XXXXXXXX
3	20	22	O	nor
4	24	24	O	9
5	26	32	O	hydroxy
6	33	43	O	XXXXXXXX
7	45	53	O	displaces
8	55	58	O	each
9	60	64	O	other
10	66	69	O	from
11	71	76	O	plasma
12	78	84	O	binding
13	86	90	O	sites
NULL

Risperidone	5097	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	52
High therapeutic concentrations of sulfamethazine (100 mcg/mL), warfarin (10 mcg/mL), and carbamazepine (10mcg/mL) caused only a slight increase in the free fraction of risperidone at 10 ng/mL and 9-hydroxyrisperidone at 50 ng/mL, changes of unknown clinical significance.
1	0	3	O	High
2	5	15	O	therapeutic
3	17	30	O	concentrations
4	32	33	O	of
5	35	48	O	sulfamethazine
6	51	53	O	100
7	55	57	O	mcg
8	58	58	O	/
9	59	60	O	mL
10	62	62	O	,
11	64	71	O	warfarin
12	74	75	O	10
13	77	79	O	mcg
14	80	80	O	/
15	81	82	O	mL
16	84	84	O	,
17	86	88	O	and
18	90	102	O	carbamazepine
19	105	109	O	10mcg
20	110	110	O	/
21	111	112	O	mL
22	115	120	O	caused
23	122	125	O	only
24	127	127	O	a
25	129	134	O	slight
26	136	143	O	increase
27	145	146	O	in
28	148	150	O	the
29	152	155	O	free
30	157	164	O	fraction
31	166	167	O	of
32	169	179	O	XXXXXXXX
33	181	182	O	at
34	184	185	O	10
35	187	188	O	ng
36	189	189	O	/
37	190	191	O	mL
38	193	195	O	and
39	197	197	O	9
40	199	205	O	hydroxy
41	206	216	O	XXXXXXXX
42	218	219	O	at
43	221	222	O	50
44	224	225	O	ng
45	226	226	O	/
46	227	228	O	mL
47	229	229	O	,
48	231	237	O	changes
49	239	240	O	of
50	242	248	O	unknown
51	250	257	O	clinical
52	259	270	O	significance
NULL

Risperidone	5098	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	8
Metabolism Risperidone is extensively metabolized in the liver.
1	0	9	O	Metabolism
2	11	21	O	XXXXXXXX
3	23	24	O	is
4	26	36	O	extensively
5	38	48	O	metabolized
6	50	51	O	in
7	53	55	O	the
8	57	61	O	liver
NULL

Risperidone	5099	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	19
The main metabolic pathway is through hydroxylation of risperidone to 9-hydroxyrisperidone by the enzyme, CYP 2D6.
1	0	2	O	The
2	4	7	O	main
3	9	17	O	metabolic
4	19	25	O	pathway
5	27	28	O	is
6	30	36	O	through
7	38	50	O	hydroxylation
8	52	53	O	of
9	55	65	O	XXXXXXXX
10	67	68	O	to
11	70	70	O	9
12	72	78	O	hydroxy
13	79	89	O	XXXXXXXX
14	91	92	O	by
15	94	96	O	the
16	98	103	O	enzyme
17	104	104	O	,
18	106	108	O	CYP
19	110	112	O	2D6
NULL

Risperidone	5100	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	8
A minor metabolic pathway is through N-dealkylation.
1	0	0	O	A
2	2	6	O	minor
3	8	16	O	metabolic
4	18	24	O	pathway
5	26	27	O	is
6	29	35	O	through
7	37	37	O	N
8	39	50	O	dealkylation
NULL

Risperidone	5101	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	14
The main metabolite, 9-hydroxyrisperidone, has similar pharmacological activity as risperidone.
1	0	2	O	The
2	4	7	O	main
3	9	18	O	metabolite
4	19	19	O	,
5	21	21	O	9
6	23	29	O	hydroxy
7	30	40	O	XXXXXXXX
8	41	41	O	,
9	43	45	O	has
10	47	53	O	similar
11	55	69	O	pharmacological
12	71	78	O	activity
13	80	81	O	as
14	83	93	O	XXXXXXXX
NULL

Risperidone	5102	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	19
Consequently, the clinical effect of the drug results from the combined concentrations of risperidone plus 9-hydroxyrisperidone.
1	0	11	O	Consequently
2	12	12	O	,
3	14	16	O	the
4	18	25	O	clinical
5	27	32	O	effect
6	34	35	O	of
7	37	39	O	the
8	41	44	O	drug
9	46	52	O	results
10	54	57	O	from
11	59	61	O	the
12	63	70	O	combined
13	72	85	O	concentrations
14	87	88	O	of
15	90	100	O	XXXXXXXX
16	102	105	O	plus
17	107	107	O	9
18	109	115	O	hydroxy
19	116	126	O	XXXXXXXX
NULL

Risperidone	5103	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	25
CYP 2D6, also called debrisoquin hydroxylase, is the enzyme responsible for metabolism of many neuroleptics, antidepressants, antiarrhythmics, and other drugs.
1	0	2	O	CYP
2	4	6	O	2D6
3	7	7	O	,
4	9	12	O	also
5	14	19	O	called
6	21	31	O	debrisoquin
7	33	43	O	hydroxylase
8	44	44	O	,
9	46	47	O	is
10	49	51	O	the
11	53	58	O	enzyme
12	60	70	O	responsible
13	72	74	O	for
14	76	85	O	metabolism
15	87	88	O	of
16	90	93	O	many
17	95	106	O	neuroleptics
18	107	107	O	,
19	109	123	O	antidepressants
20	124	124	O	,
21	126	140	O	antiarrhythmics
22	141	141	O	,
23	143	145	O	and
24	147	151	O	other
25	153	157	O	drugs
NULL

Risperidone	5104	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	45
CYP 2D6 is subject to genetic polymorphism (about 6%-8% of Caucasians, and a very low percentage of Asians, have little or no activity and are "poor metabolizers") and to inhibition by a variety of substrates and some non-substrates, notably quinidine.
1	0	2	O	CYP
2	4	6	O	2D6
3	8	9	O	is
4	11	17	O	subject
5	19	20	O	to
6	22	28	O	genetic
7	30	41	O	polymorphism
8	44	48	O	about
9	50	51	O	6%
10	53	54	O	8%
11	56	57	O	of
12	59	68	O	Caucasians
13	69	69	O	,
14	71	73	O	and
15	75	75	O	a
16	77	80	O	very
17	82	84	O	low
18	86	95	O	percentage
19	97	98	O	of
20	100	105	O	Asians
21	106	106	O	,
22	108	111	O	have
23	113	118	O	little
24	120	121	O	or
25	123	124	O	no
26	126	133	O	activity
27	135	137	O	and
28	139	141	O	are
29	143	147	O	"poor
30	149	161	O	metabolizers"
31	164	166	O	and
32	168	169	O	to
33	171	180	O	inhibition
34	182	183	O	by
35	185	185	O	a
36	187	193	O	variety
37	195	196	O	of
38	198	207	O	substrates
39	209	211	O	and
40	213	216	O	some
41	218	220	O	non
42	222	231	O	substrates
43	232	232	O	,
44	234	240	O	notably
45	242	250	O	quinidine
NULL

Risperidone	5105	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	22
Extensive CYP 2D6 metabolizers convert risperidone rapidly into 9-hydroxyrisperidone, whereas poor CYP 2D6 metabolizers convert it much more slowly.
1	0	8	O	Extensive
2	10	12	O	CYP
3	14	16	O	2D6
4	18	29	O	metabolizers
5	31	37	O	convert
6	39	49	O	XXXXXXXX
7	51	57	O	rapidly
8	59	62	O	into
9	64	64	O	9
10	66	72	O	hydroxy
11	73	83	O	XXXXXXXX
12	84	84	O	,
13	86	92	O	whereas
14	94	97	O	poor
15	99	101	O	CYP
16	103	105	O	2D6
17	107	118	O	metabolizers
18	120	126	O	convert
19	128	129	O	it
20	131	134	O	much
21	136	139	O	more
22	141	146	O	slowly
NULL

Risperidone	5106	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	39
Although extensive metabolizers have lower risperidone and higher 9-hydroxyrisperidone concentrations than poor metabolizers, the pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, are similar in extensive and poor metabolizers.
1	0	7	O	Although
2	9	17	O	extensive
3	19	30	O	metabolizers
4	32	35	O	have
5	37	41	O	lower
6	43	53	O	XXXXXXXX
7	55	57	O	and
8	59	64	O	higher
9	66	66	O	9
10	68	74	O	hydroxy
11	75	85	O	XXXXXXXX
12	87	100	O	concentrations
13	102	105	O	than
14	107	110	O	poor
15	112	123	O	metabolizers
16	124	124	O	,
17	126	128	O	the
18	130	145	O	pharmacokinetics
19	147	148	O	of
20	150	160	O	XXXXXXXX
21	162	164	O	and
22	166	166	O	9
23	168	174	O	hydroxy
24	175	185	O	XXXXXXXX
25	187	194	O	combined
26	195	195	O	,
27	197	201	O	after
28	203	208	O	single
29	210	212	O	and
30	214	221	O	multiple
31	223	227	O	doses
32	228	228	O	,
33	230	232	O	are
34	234	240	O	similar
35	242	243	O	in
36	245	253	O	extensive
37	255	257	O	and
38	259	262	O	poor
39	264	275	O	metabolizers
NULL

Risperidone	5107	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	11
Risperidone could be subject to two kinds of drug-drug interactions.
1	0	10	O	XXXXXXXX
2	12	16	O	could
3	18	19	O	be
4	21	27	O	subject
5	29	30	O	to
6	32	34	O	two
7	36	40	O	kinds
8	42	43	O	of
9	45	48	O	drug
10	50	53	O	drug
11	55	66	O	interactions
NULL

Risperidone	5108	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	15
First, inhibitors of CYP 2D6 interfere with conversion of risperidone to 9-hydroxyrisperidone.
1	0	4	O	First
2	5	5	O	,
3	7	16	B-DYN	inhibitors
4	18	19	I-DYN	of
5	21	23	I-DYN	CYP
6	25	27	L-DYN	2D6
7	29	37	B-EFF	interfere
8	39	42	I-EFF	with
9	44	53	I-EFF	conversion
10	55	56	I-EFF	of
11	58	68	L-EFF	XXXXXXXX
12	70	71	O	to
13	73	73	O	9
14	75	81	O	hydroxy
15	82	92	O	XXXXXXXX
D/3:7:1

Risperidone	5109	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	17
This occurs with quinidine, giving essentially all recipients a risperidone pharmacokinetic profile typical of poor metabolizers.
1	0	3	O	This
2	5	10	O	occurs
3	12	15	O	with
4	17	25	U-KIN	quinidine
5	26	26	O	,
6	28	33	O	giving
7	35	45	O	essentially
8	47	49	O	all
9	51	60	O	recipients
10	62	62	O	a
11	64	74	O	XXXXXXXX
12	76	90	B-TRI	pharmacokinetic
13	92	98	I-TRI	profile
14	100	106	I-TRI	typical
15	108	109	I-TRI	of
16	111	114	I-TRI	poor
17	116	127	L-TRI	metabolizers
K/4:C54355

Risperidone	5110	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	39
The therapeutic benefits and adverse effects of risperidone in patients receiving quinidine have not been evaluated, but observations in a modest number (n=70) of poor metabolizers given risperidone do not suggest important differences between poor and extensive metabolizers.
1	0	2	O	The
2	4	14	O	therapeutic
3	16	23	O	benefits
4	25	27	O	and
5	29	35	O	adverse
6	37	43	O	effects
7	45	46	O	of
8	48	58	O	XXXXXXXX
9	60	61	O	in
10	63	70	O	patients
11	72	80	O	receiving
12	82	90	O	quinidine
13	92	95	O	have
14	97	99	O	not
15	101	104	O	been
16	106	114	O	evaluated
17	115	115	O	,
18	117	119	O	but
19	121	132	O	observations
20	134	135	O	in
21	137	137	O	a
22	139	144	O	modest
23	146	151	O	number
24	154	157	O	n=70
25	160	161	O	of
26	163	166	O	poor
27	168	179	O	metabolizers
28	181	185	O	given
29	187	197	O	XXXXXXXX
30	199	200	O	do
31	202	204	O	not
32	206	212	O	suggest
33	214	222	O	important
34	224	234	O	differences
35	236	242	O	between
36	244	247	O	poor
37	249	251	O	and
38	253	261	O	extensive
39	263	274	O	metabolizers
NULL

Risperidone	5111	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	35
Second, co-administration of known enzyme inducers (e.g., carbamazepine, phenytoin, rifampin, and phenobarbital) with risperidone may cause a decrease in the combined plasma concentrations of risperidone and 9-hydroxyrisperidone.
1	0	5	O	Second
2	6	6	O	,
3	8	9	O	co
4	11	24	O	administration
5	26	27	O	of
6	29	33	O	known
7	35	40	B-KIN	enzyme
8	42	49	L-KIN	inducers
9	52	54	O	e.g
10	56	56	O	,
11	58	70	U-KIN	carbamazepine
12	71	71	O	,
13	73	81	U-KIN	phenytoin
14	82	82	O	,
15	84	91	U-KIN	rifampin
16	92	92	O	,
17	94	96	O	and
18	98	110	U-KIN	phenobarbital
19	113	116	O	with
20	118	128	O	XXXXXXXX
21	130	132	O	may
22	134	138	O	cause
23	140	140	O	a
24	142	149	O	decrease
25	151	152	O	in
26	154	156	O	the
27	158	165	O	combined
28	167	172	O	plasma
29	174	187	O	concentrations
30	189	190	O	of
31	192	202	O	XXXXXXXX
32	204	206	O	and
33	208	208	O	9
34	210	216	O	hydroxy
35	217	227	O	XXXXXXXX
K/11:C54356 K/13:C54356 K/15:C54356 K/18:C54356 K/7:C54356

Risperidone	5112	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	18
It would also be possible for risperidone to interfere with metabolism of other drugs metabolized by CYP 2D6.
1	0	1	O	It
2	3	7	O	would
3	9	12	O	also
4	14	15	O	be
5	17	24	O	possible
6	26	28	O	for
7	30	40	O	XXXXXXXX
8	42	43	O	to
9	45	53	B-TRI	interfere
10	55	58	I-TRI	with
11	60	69	L-TRI	metabolism
12	71	72	O	of
13	74	78	O	other
14	80	84	B-KIN	drugs
15	86	96	I-KIN	metabolized
16	98	99	I-KIN	by
17	101	103	I-KIN	CYP
18	105	107	L-KIN	2D6
K/14:C54357

Risperidone	5113	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	12
Relatively weak binding of risperidone to the enzyme suggests this is unlikely.
1	0	9	O	Relatively
2	11	14	O	weak
3	16	22	O	binding
4	24	25	O	of
5	27	37	O	XXXXXXXX
6	39	40	O	to
7	42	44	O	the
8	46	51	O	enzyme
9	53	60	O	suggests
10	62	65	O	this
11	67	68	O	is
12	70	77	O	unlikely
NULL

Risperidone	5114	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	14
In vitro studies indicate that risperidone is a relatively weak inhibitor of CYP 2D6.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	41	O	XXXXXXXX
7	43	44	O	is
8	46	46	O	a
9	48	57	O	relatively
10	59	62	O	weak
11	64	72	O	inhibitor
12	74	75	O	of
13	77	79	O	CYP
14	81	83	O	2D6
NULL

Risperidone	5115	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	20
Therefore, risperidone is not expected to substantially inhibit the clearance of drugs that are metabolized by this enzymatic pathway.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	XXXXXXXX
4	23	24	O	is
5	26	28	O	not
6	30	37	O	expected
7	39	40	O	to
8	42	54	O	substantially
9	56	62	O	inhibit
10	64	66	O	the
11	68	76	O	clearance
12	78	79	O	of
13	81	85	O	drugs
14	87	90	O	that
15	92	94	O	are
16	96	106	O	metabolized
17	108	109	O	by
18	111	114	O	this
19	116	124	O	enzymatic
20	126	132	O	pathway
NULL

Risperidone	5116	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	23
In drug interaction studies, risperidone did not significantly affect the pharmacokinetics of donepezil and galantamine, which are metabolized by CYP 2D6.
1	0	1	O	In
2	3	6	O	drug
3	8	18	O	interaction
4	20	26	O	studies
5	27	27	O	,
6	29	39	O	XXXXXXXX
7	41	43	O	did
8	45	47	O	not
9	49	61	O	significantly
10	63	68	O	affect
11	70	72	O	the
12	74	89	O	pharmacokinetics
13	91	92	O	of
14	94	102	O	donepezil
15	104	106	O	and
16	108	118	O	galantamine
17	119	119	O	,
18	121	125	O	which
19	127	129	O	are
20	131	141	O	metabolized
21	143	144	O	by
22	146	148	O	CYP
23	150	152	O	2D6
NULL

Risperidone	5117	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	31
In vitro studies demonstrated that drugs metabolized by other CYP isozymes, including 1A1, 1A2, 2C9, 2C19, and 3A4, are only weak inhibitors of risperidone metabolism.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	28	O	demonstrated
5	30	33	O	that
6	35	39	O	drugs
7	41	51	O	metabolized
8	53	54	O	by
9	56	60	O	other
10	62	64	O	CYP
11	66	73	O	isozymes
12	74	74	O	,
13	76	84	O	including
14	86	88	O	1A1
15	89	89	O	,
16	91	93	O	1A2
17	94	94	O	,
18	96	98	O	2C9
19	99	99	O	,
20	101	104	O	2C19
21	105	105	O	,
22	107	109	O	and
23	111	113	O	3A4
24	114	114	O	,
25	116	118	O	are
26	120	123	O	only
27	125	128	O	weak
28	130	139	O	inhibitors
29	141	142	O	of
30	144	154	O	XXXXXXXX
31	156	165	O	metabolism
NULL

Risperidone	5118	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	21
Excretion Risperidone and its metabolites are eliminated via the urine and, to a much lesser extent, via the feces.
1	0	8	O	Excretion
2	10	20	O	XXXXXXXX
3	22	24	O	and
4	26	28	O	its
5	30	40	O	metabolites
6	42	44	O	are
7	46	55	O	eliminated
8	57	59	O	via
9	61	63	O	the
10	65	69	O	urine
11	71	73	O	and
12	74	74	O	,
13	76	77	O	to
14	79	79	O	a
15	81	84	O	much
16	86	91	O	lesser
17	93	98	O	extent
18	99	99	O	,
19	101	103	O	via
20	105	107	O	the
21	109	113	O	feces
NULL

Risperidone	5119	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	46
As illustrated by a mass balance study of a single 1 mg oral dose of 14C-risperidone administered as solution to three healthy male volunteers, total recovery of radioactivity at 1 week was 84%, including 70% in the urine and 14% in the feces.
1	0	1	O	As
2	3	13	O	illustrated
3	15	16	O	by
4	18	18	O	a
5	20	23	O	mass
6	25	31	O	balance
7	33	37	O	study
8	39	40	O	of
9	42	42	O	a
10	44	49	O	single
11	51	51	O	1
12	53	54	O	mg
13	56	59	O	oral
14	61	64	O	dose
15	66	67	O	of
16	69	71	O	14C
17	73	83	O	XXXXXXXX
18	85	96	O	administered
19	98	99	O	as
20	101	108	O	solution
21	110	111	O	to
22	113	117	O	three
23	119	125	O	healthy
24	127	130	O	male
25	132	141	O	volunteers
26	142	142	O	,
27	144	148	O	total
28	150	157	O	recovery
29	159	160	O	of
30	162	174	O	radioactivity
31	176	177	O	at
32	179	179	O	1
33	181	184	O	week
34	186	188	O	was
35	190	192	O	84%
36	193	193	O	,
37	195	203	O	including
38	205	207	O	70%
39	209	210	O	in
40	212	214	O	the
41	216	220	O	urine
42	222	224	O	and
43	226	228	O	14%
44	230	231	O	in
45	233	235	O	the
46	237	241	O	feces
NULL

Risperidone	5120	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	20
The apparent half-life of risperidone was 3 hours (CV=30%) in extensive metabolizers and 20 hours (CV=40%) in poor metabolizers.
1	0	2	O	The
2	4	11	O	apparent
3	13	16	O	half
4	18	21	O	life
5	23	24	O	of
6	26	36	O	XXXXXXXX
7	38	40	O	was
8	42	42	O	3
9	44	48	O	hours
10	51	56	O	CV=30%
11	59	60	O	in
12	62	70	O	extensive
13	72	83	O	metabolizers
14	85	87	O	and
15	89	90	O	20
16	92	96	O	hours
17	99	104	O	CV=40%
18	107	108	O	in
19	110	113	O	poor
20	115	126	O	metabolizers
NULL

Risperidone	5121	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	23
The apparent half-life of 9-hydroxyrisperidone was about 21 hours (CV=20%) in extensive metabolizers and 30 hours (CV=25%) in poor metabolizers.
1	0	2	O	The
2	4	11	O	apparent
3	13	16	O	half
4	18	21	O	life
5	23	24	O	of
6	26	26	O	9
7	28	34	O	hydroxy
8	35	45	O	XXXXXXXX
9	47	49	O	was
10	51	55	O	about
11	57	58	O	21
12	60	64	O	hours
13	67	72	O	CV=20%
14	75	76	O	in
15	78	86	O	extensive
16	88	99	O	metabolizers
17	101	103	O	and
18	105	106	O	30
19	108	112	O	hours
20	115	120	O	CV=25%
21	123	124	O	in
22	126	129	O	poor
23	131	142	O	metabolizers
NULL

Risperidone	5122	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	35
The pharmacokinetics of risperidone and 9-hydroxyrisperidone combined, after single and multiple doses, were similar in extensive and poor metabolizers, with an overall mean elimination half-life of about 20 hours.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	34	O	XXXXXXXX
5	36	38	O	and
6	40	40	O	9
7	42	48	O	hydroxy
8	49	59	O	XXXXXXXX
9	61	68	O	combined
10	69	69	O	,
11	71	75	O	after
12	77	82	O	single
13	84	86	O	and
14	88	95	O	multiple
15	97	101	O	doses
16	102	102	O	,
17	104	107	O	were
18	109	115	O	similar
19	117	118	O	in
20	120	128	O	extensive
21	130	132	O	and
22	134	137	O	poor
23	139	150	O	metabolizers
24	151	151	O	,
25	153	156	O	with
26	158	159	O	an
27	161	167	O	overall
28	169	172	O	mean
29	174	184	O	elimination
30	186	189	O	half
31	191	194	O	life
32	196	197	O	of
33	199	203	O	about
34	205	206	O	20
35	208	212	O	hours
NULL

Risperidone	5123	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	4
Drug-Drug Interaction Studies.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	20	O	Interaction
4	22	28	O	Studies
NULL

Risperidone	5124	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	6
Specific Populations Renal and Hepatic Impairment.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	25	O	Renal
4	27	29	O	and
5	31	37	O	Hepatic
6	39	48	O	Impairment
NULL

Risperidone	5125	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	29
Elderly In healthy elderly subjects, renal clearance of both risperidone and 9-hydroxyrisperidone was decreased, and elimination half-lives were prolonged compared to young healthy subjects.
1	0	6	O	Elderly
2	8	9	O	In
3	11	17	O	healthy
4	19	25	O	elderly
5	27	34	O	subjects
6	35	35	O	,
7	37	41	O	renal
8	43	51	O	clearance
9	53	54	O	of
10	56	59	O	both
11	61	71	O	XXXXXXXX
12	73	75	O	and
13	77	77	O	9
14	79	85	O	hydroxy
15	86	96	O	XXXXXXXX
16	98	100	O	was
17	102	110	O	decreased
18	111	111	O	,
19	113	115	O	and
20	117	127	O	elimination
21	129	132	O	half
22	134	138	O	lives
23	140	143	O	were
24	145	153	O	prolonged
25	155	162	O	compared
26	164	165	O	to
27	167	171	O	young
28	173	179	O	healthy
29	181	188	O	subjects
NULL

Risperidone	5126	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	9
Dosing should be modified accordingly in the elderly patients.
1	0	5	O	Dosing
2	7	12	O	should
3	14	15	O	be
4	17	24	O	modified
5	26	36	O	accordingly
6	38	39	O	in
7	41	43	O	the
8	45	51	O	elderly
9	53	60	O	patients
NULL

Risperidone	5127	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	25
Pediatric The pharmacokinetics of risperidone and 9-hydroxyrisperidone in children were similar to those in adults after correcting for the difference in body weight.
1	0	8	O	Pediatric
2	10	12	O	The
3	14	29	O	pharmacokinetics
4	31	32	O	of
5	34	44	O	XXXXXXXX
6	46	48	O	and
7	50	50	O	9
8	52	58	O	hydroxy
9	59	69	O	XXXXXXXX
10	71	72	O	in
11	74	81	O	children
12	83	86	O	were
13	88	94	O	similar
14	96	97	O	to
15	99	103	O	those
16	105	106	O	in
17	108	113	O	adults
18	115	119	O	after
19	121	130	O	correcting
20	132	134	O	for
21	136	138	O	the
22	140	149	O	difference
23	151	152	O	in
24	154	157	O	body
25	159	164	O	weight
NULL

Risperidone	5128	34090-1	49c4105b-e518-481c-a248-6684135f5bc1	44
Race and Gender Effects No specific pharmacokinetic study was conducted to investigate race and gender effects, but a population pharmacokinetic analysis did not identify important differences in the disposition of risperidone due to gender (whether corrected for body weight or not) or race.
1	0	3	O	Race
2	5	7	O	and
3	9	14	O	Gender
4	16	22	O	Effects
5	24	25	O	No
6	27	34	O	specific
7	36	50	O	pharmacokinetic
8	52	56	O	study
9	58	60	O	was
10	62	70	O	conducted
11	72	73	O	to
12	75	85	O	investigate
13	87	90	O	race
14	92	94	O	and
15	96	101	O	gender
16	103	109	O	effects
17	110	110	O	,
18	112	114	O	but
19	116	116	O	a
20	118	127	O	population
21	129	143	O	pharmacokinetic
22	145	152	O	analysis
23	154	156	O	did
24	158	160	O	not
25	162	169	O	identify
26	171	179	O	important
27	181	191	O	differences
28	193	194	O	in
29	196	198	O	the
30	200	210	O	disposition
31	212	213	O	of
32	215	225	O	XXXXXXXX
33	227	229	O	due
34	231	232	O	to
35	234	239	O	gender
36	242	248	O	whether
37	250	258	O	corrected
38	260	262	O	for
39	264	267	O	body
40	269	274	O	weight
41	276	277	O	or
42	279	281	O	not
43	284	285	O	or
44	287	290	O	race
NULL

SAPHRIS	5933	34073-7	5429f134-839f-4ffc-9944-55f51238def8	7
Antihypertensive Drugs: SAPHRIS may cause hypotension.
1	0	15	B-DYN	Antihypertensive
2	17	21	L-DYN	Drugs
3	22	22	O	:
4	24	30	O	XXXXXXXX
5	32	34	O	may
6	36	40	O	cause
7	42	52	U-EFF	hypotension
D/1:7:1

SAPHRIS	5934	34073-7	5429f134-839f-4ffc-9944-55f51238def8	16
Paroxetine (CYP2D6 substrate and inhibitor): Reduce paroxetine by half when used in combination with SAPHRIS.
1	0	9	O	Paroxetine
2	12	17	O	CYP2D6
3	19	27	O	substrate
4	29	31	O	and
5	33	41	O	inhibitor
6	43	43	O	:
7	45	50	O	Reduce
8	52	61	U-KIN	paroxetine
9	63	64	O	by
10	66	69	O	half
11	71	74	O	when
12	76	79	O	used
13	81	82	O	in
14	84	94	O	combination
15	96	99	O	with
16	101	107	O	XXXXXXXX
K/8:C54357

SAPHRIS	5935	34073-7	5429f134-839f-4ffc-9944-55f51238def8	42
Table 12: Clinically Important Drug Interactions with SAPHRIS Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Antihypertensive Drugs Because of its A1-adrenergic antagonism with potential for inducing hypotension, SAPHRIS may enhance the effects of certain antihypertensive agents.
1	0	4	O	Table
2	6	7	O	12
3	8	8	O	:
4	10	19	O	Clinically
5	21	29	O	Important
6	31	34	O	Drug
7	36	47	O	Interactions
8	49	52	O	with
9	54	60	O	XXXXXXXX
10	62	72	O	Concomitant
11	74	77	O	Drug
12	79	82	O	Name
13	84	85	O	or
14	87	90	O	Drug
15	92	96	O	Class
16	98	105	O	Clinical
17	107	115	O	Rationale
18	117	124	O	Clinical
19	126	139	O	Recommendation
20	141	156	O	Antihypertensive
21	158	162	O	Drugs
22	164	170	O	Because
23	172	173	O	of
24	175	177	O	its
25	179	180	O	A1
26	182	191	O	adrenergic
27	193	202	O	antagonism
28	204	207	O	with
29	209	217	O	potential
30	219	221	O	for
31	223	230	O	inducing
32	232	242	O	hypotension
33	243	243	O	,
34	245	251	O	XXXXXXXX
35	253	255	O	may
36	257	263	O	enhance
37	265	267	O	the
38	269	275	O	effects
39	277	278	O	of
40	280	286	O	certain
41	288	303	B-DYN	antihypertensive
42	305	310	L-DYN	agents
NULL

SAPHRIS	5936	34073-7	5429f134-839f-4ffc-9944-55f51238def8	10
Monitor blood pressure and adjust dosage of antihypertensive drug accordingly.
1	0	6	U-TRI	Monitor
2	8	12	O	blood
3	14	21	O	pressure
4	23	25	O	and
5	27	32	O	adjust
6	34	39	O	dosage
7	41	42	O	of
8	44	59	B-UNK	antihypertensive
9	61	64	L-UNK	drug
10	66	76	O	accordingly
NULL

SAPHRIS	5937	34073-7	5429f134-839f-4ffc-9944-55f51238def8	11
Strong CYP1A2 Inhibitors (e.g., Fluvoxamine) SAPHRIS is metabolized by CYP1A2.
1	0	5	O	Strong
2	7	12	O	CYP1A2
3	14	23	O	Inhibitors
4	26	28	O	e.g
5	30	30	O	,
6	32	42	O	Fluvoxamine
7	45	51	O	XXXXXXXX
8	53	54	O	is
9	56	66	O	metabolized
10	68	69	O	by
11	71	76	O	CYP1A2
NULL

SAPHRIS	5938	34073-7	5429f134-839f-4ffc-9944-55f51238def8	19
Marginal increase of asenapine exposure was observed when SAPHRIS is used with fluvoxamine at 25 mg administered twice daily.
1	0	7	O	Marginal
2	9	16	O	increase
3	18	19	O	of
4	21	29	O	XXXXXXXX
5	31	38	O	exposure
6	40	42	O	was
7	44	51	O	observed
8	53	56	O	when
9	58	64	O	XXXXXXXX
10	66	67	O	is
11	69	72	O	used
12	74	77	O	with
13	79	89	O	fluvoxamine
14	91	92	O	at
15	94	95	O	25
16	97	98	O	mg
17	100	111	O	administered
18	113	117	O	twice
19	119	123	O	daily
NULL

SAPHRIS	5939	34073-7	5429f134-839f-4ffc-9944-55f51238def8	8
However, the tested fluvoxamine dose was suboptimal.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	18	O	tested
5	20	30	O	fluvoxamine
6	32	35	O	dose
7	37	39	O	was
8	41	50	O	suboptimal
NULL

SAPHRIS	5940	34073-7	5429f134-839f-4ffc-9944-55f51238def8	15
Full therapeutic dose of fluvoxamine is expected to cause a greater increase in asenapine exposure.
1	0	3	O	Full
2	5	15	O	therapeutic
3	17	20	O	dose
4	22	23	O	of
5	25	35	U-KIN	fluvoxamine
6	37	38	O	is
7	40	47	O	expected
8	49	50	O	to
9	52	56	O	cause
10	58	58	O	a
11	60	66	O	greater
12	68	75	O	increase
13	77	78	O	in
14	80	88	O	XXXXXXXX
15	90	97	O	exposure
K/5:C54355

SAPHRIS	5941	34073-7	5429f134-839f-4ffc-9944-55f51238def8	11
Dosage reduction for SAPHRIS based on clinical response may be necessary.
1	0	5	O	Dosage
2	7	15	O	reduction
3	17	19	O	for
4	21	27	O	XXXXXXXX
5	29	33	O	based
6	35	36	O	on
7	38	45	O	clinical
8	47	54	O	response
9	56	58	O	may
10	60	61	O	be
11	63	71	O	necessary
NULL

SAPHRIS	5942	34073-7	5429f134-839f-4ffc-9944-55f51238def8	19
CYP2D6 substrates and inhibitors (e.g., paroxetine) SAPHRIS may enhance the inhibitory effects of paroxetine on its own metabolism.
1	0	5	O	CYP2D6
2	7	16	O	substrates
3	18	20	O	and
4	22	31	O	inhibitors
5	34	36	O	e.g
6	38	38	O	,
7	40	49	U-KIN	paroxetine
8	52	58	O	XXXXXXXX
9	60	62	O	may
10	64	70	O	enhance
11	72	74	O	the
12	76	85	O	inhibitory
13	87	93	O	effects
14	95	96	O	of
15	98	107	O	paroxetine
16	109	110	O	on
17	112	114	O	its
18	116	118	O	own
19	120	129	O	metabolism
K/7:C54357

SAPHRIS	5943	34073-7	5429f134-839f-4ffc-9944-55f51238def8	19
Concomitant use of paroxetine with SAPHRIS increased the paroxetine exposure by 2-fold as compared to use paroxetine alone.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	28	U-KIN	paroxetine
5	30	33	O	with
6	35	41	O	XXXXXXXX
7	43	51	O	increased
8	53	55	O	the
9	57	66	O	paroxetine
10	68	75	O	exposure
11	77	78	O	by
12	80	80	O	2
13	82	85	O	fold
14	87	88	O	as
15	90	97	O	compared
16	99	100	O	to
17	102	104	O	use
18	106	115	O	paroxetine
19	117	121	O	alone
K/4:C54357

SAPHRIS	5944	34073-7	5429f134-839f-4ffc-9944-55f51238def8	13
Reduce paroxetine dose by half when paroxetine is used in combination with SAPHRIS.
1	0	5	O	Reduce
2	7	16	U-KIN	paroxetine
3	18	21	O	dose
4	23	24	O	by
5	26	29	O	half
6	31	34	O	when
7	36	45	O	paroxetine
8	47	48	O	is
9	50	53	O	used
10	55	56	O	in
11	58	68	O	combination
12	70	73	O	with
13	75	81	O	XXXXXXXX
K/2:C54357

SAPHRIS	5945	34073-7	5429f134-839f-4ffc-9944-55f51238def8	12
No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	of
5	24	30	O	XXXXXXXX
6	32	33	O	is
7	35	43	O	necessary
8	45	48	O	when
9	50	61	O	administered
10	63	75	O	concomitantly
11	77	80	O	with
12	82	91	O	paroxetine
NULL

SAPHRIS	5946	34073-7	5429f134-839f-4ffc-9944-55f51238def8	40
In addition, valproic acid and lithium pre-dose serum concentrations collected from an adjunctive therapy study were comparable between asenapine-treated patients and placebo-treated patients indicating a lack of effect of asenapine on valproic and lithium plasma levels.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	20	O	valproic
5	22	25	O	acid
6	27	29	O	and
7	31	37	O	lithium
8	39	41	O	pre
9	43	46	O	dose
10	48	52	O	serum
11	54	67	O	concentrations
12	69	77	O	collected
13	79	82	O	from
14	84	85	O	an
15	87	96	O	adjunctive
16	98	104	O	therapy
17	106	110	O	study
18	112	115	O	were
19	117	126	O	comparable
20	128	134	O	between
21	136	144	O	XXXXXXXX
22	146	152	O	treated
23	154	161	O	patients
24	163	165	O	and
25	167	173	O	placebo
26	175	181	O	treated
27	183	190	O	patients
28	192	201	O	indicating
29	203	203	O	a
30	205	208	O	lack
31	210	211	O	of
32	213	218	O	effect
33	220	221	O	of
34	223	231	O	XXXXXXXX
35	233	234	O	on
36	236	243	O	valproic
37	245	247	O	and
38	249	255	O	lithium
39	257	262	O	plasma
40	264	269	O	levels
NULL

SAPHRIS	5947	34090-1	5429f134-839f-4ffc-9944-55f51238def8	16
The mechanism of action of asenapine, in schizophrenia and bipolar I disorder, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	35	O	XXXXXXXX
7	36	36	O	,
8	38	39	O	in
9	41	53	O	schizophrenia
10	55	57	O	and
11	59	65	O	bipolar
12	67	67	O	I
13	69	76	O	disorder
14	77	77	O	,
15	79	80	O	is
16	82	88	O	unknown
NULL

SAPHRIS	5948	34090-1	5429f134-839f-4ffc-9944-55f51238def8	26
It has been suggested that the efficacy of asenapine in schizophrenia could be mediated through a combination of antagonist activity at D2 and 5-HT2A receptors.
1	0	1	O	It
2	3	5	O	has
3	7	10	O	been
4	12	20	O	suggested
5	22	25	O	that
6	27	29	O	the
7	31	38	O	efficacy
8	40	41	O	of
9	43	51	O	XXXXXXXX
10	53	54	O	in
11	56	68	O	schizophrenia
12	70	74	O	could
13	76	77	O	be
14	79	86	O	mediated
15	88	94	O	through
16	96	96	O	a
17	98	108	O	combination
18	110	111	O	of
19	113	122	O	antagonist
20	124	131	O	activity
21	133	134	O	at
22	136	137	O	D2
23	139	141	O	and
24	143	143	O	5
25	145	148	O	HT2A
26	150	158	O	receptors
NULL

SAPHRIS	5949	34090-1	5429f134-839f-4ffc-9944-55f51238def8	126
Asenapine exhibits high affinity for serotonin 5-HT1A, 5-HT1B, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT5A, 5-HT6, and 5-HT7 receptors (Ki values of 2.5, 2.7, 0.07, 0.18, 0.03, 1.6, 0.25, and 0.11nM, respectively), dopamine D2A, D2B, D3, D4, and D1 receptors (Ki values of 1.3, 1.4, 0.42, 1.1, and 1.4 nM, respectively), A1A, A2A, A2B, and A2C -adrenergic receptors (Ki values of 1.2, 1.2, 0.33 and 1.2 nM, respectively), and histamine H1 receptors (Ki value 1.0 nM), and moderate affinity for H2 receptors (Ki value of 6.2 nM).
1	0	8	O	XXXXXXXX
2	10	17	O	exhibits
3	19	22	O	high
4	24	31	O	affinity
5	33	35	O	for
6	37	45	O	serotonin
7	47	47	O	5
8	49	52	O	HT1A
9	53	53	O	,
10	55	55	O	5
11	57	60	O	HT1B
12	61	61	O	,
13	63	63	O	5
14	65	68	O	HT2A
15	69	69	O	,
16	71	71	O	5
17	73	76	O	HT2B
18	77	77	O	,
19	79	79	O	5
20	81	84	O	HT2C
21	85	85	O	,
22	87	87	O	5
23	89	92	O	HT5A
24	93	93	O	,
25	95	95	O	5
26	97	99	O	HT6
27	100	100	O	,
28	102	104	O	and
29	106	106	O	5
30	108	110	O	HT7
31	112	120	O	receptors
32	123	124	O	Ki
33	126	131	O	values
34	133	134	O	of
35	136	138	O	2.5
36	139	139	O	,
37	141	143	O	2.7
38	144	144	O	,
39	146	149	O	0.07
40	150	150	O	,
41	152	155	O	0.18
42	156	156	O	,
43	158	161	O	0.03
44	162	162	O	,
45	164	166	O	1.6
46	167	167	O	,
47	169	172	O	0.25
48	173	173	O	,
49	175	177	O	and
50	179	184	O	0.11nM
51	185	185	O	,
52	187	198	O	respectively
53	200	200	O	,
54	202	209	O	dopamine
55	211	213	O	D2A
56	214	214	O	,
57	216	218	O	D2B
58	219	219	O	,
59	221	222	O	D3
60	223	223	O	,
61	225	226	O	D4
62	227	227	O	,
63	229	231	O	and
64	233	234	O	D1
65	236	244	O	receptors
66	247	248	O	Ki
67	250	255	O	values
68	257	258	O	of
69	260	262	O	1.3
70	263	263	O	,
71	265	267	O	1.4
72	268	268	O	,
73	270	273	O	0.42
74	274	274	O	,
75	276	278	O	1.1
76	279	279	O	,
77	281	283	O	and
78	285	287	O	1.4
79	289	290	O	nM
80	291	291	O	,
81	293	304	O	respectively
82	306	306	O	,
83	308	310	O	A1A
84	311	311	O	,
85	313	315	O	A2A
86	316	316	O	,
87	318	320	O	A2B
88	321	321	O	,
89	323	325	O	and
90	327	329	O	A2C
91	332	341	O	adrenergic
92	343	351	O	receptors
93	354	355	O	Ki
94	357	362	O	values
95	364	365	O	of
96	367	369	O	1.2
97	370	370	O	,
98	372	374	O	1.2
99	375	375	O	,
100	377	380	O	0.33
101	382	384	O	and
102	386	388	O	1.2
103	390	391	O	nM
104	392	392	O	,
105	394	405	O	respectively
106	407	407	O	,
107	409	411	O	and
108	413	421	O	histamine
109	423	424	O	H1
110	426	434	O	receptors
111	437	438	O	Ki
112	440	444	O	value
113	446	448	O	1.0
114	450	451	O	nM
115	453	453	O	,
116	455	457	O	and
117	459	466	O	moderate
118	468	475	O	affinity
119	477	479	O	for
120	481	482	O	H2
121	484	492	O	receptors
122	495	496	O	Ki
123	498	502	O	value
124	504	505	O	of
125	507	509	O	6.2
126	511	512	O	nM
NULL

SAPHRIS	5950	34090-1	5429f134-839f-4ffc-9944-55f51238def8	12
In in vitro assays asenapine acts as an antagonist at these receptors.
1	0	1	O	In
2	3	4	O	in
3	6	10	O	vitro
4	12	17	O	assays
5	19	27	O	XXXXXXXX
6	29	32	O	acts
7	34	35	O	as
8	37	38	O	an
9	40	49	O	antagonist
10	51	52	O	at
11	54	58	O	these
12	60	68	O	receptors
NULL

SAPHRIS	5951	34090-1	5429f134-839f-4ffc-9944-55f51238def8	18
Asenapine has no appreciable affinity for muscarinic cholinergic receptors (e.g., Ki value of 8128 nM for M1).
1	0	8	O	XXXXXXXX
2	10	12	O	has
3	14	15	O	no
4	17	27	O	appreciable
5	29	36	O	affinity
6	38	40	O	for
7	42	51	O	muscarinic
8	53	63	O	cholinergic
9	65	73	O	receptors
10	76	78	O	e.g
11	80	80	O	,
12	82	83	O	Ki
13	85	89	O	value
14	91	92	O	of
15	94	97	O	8128
16	99	100	O	nM
17	102	104	O	for
18	106	107	O	M1
NULL

SAPHRIS	5952	34090-1	5429f134-839f-4ffc-9944-55f51238def8	28
Following a single 5 mg dose of SAPHRIS, the mean Cmax was approximately 4 ng/mL and was observed at a mean tmax of 1 hour.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	19	O	5
5	21	22	O	mg
6	24	27	O	dose
7	29	30	O	of
8	32	38	O	XXXXXXXX
9	39	39	O	,
10	41	43	O	the
11	45	48	O	mean
12	50	53	O	Cmax
13	55	57	O	was
14	59	71	O	approximately
15	73	73	O	4
16	75	76	O	ng
17	77	77	O	/
18	78	79	O	mL
19	81	83	O	and
20	85	87	O	was
21	89	96	O	observed
22	98	99	O	at
23	101	101	O	a
24	103	106	O	mean
25	108	111	O	tmax
26	113	114	O	of
27	116	116	O	1
28	118	121	O	hour
NULL

SAPHRIS	5953	34090-1	5429f134-839f-4ffc-9944-55f51238def8	19
Elimination of asenapine is primarily through direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2).
1	0	10	O	Elimination
2	12	13	O	of
3	15	23	O	XXXXXXXX
4	25	26	O	is
5	28	36	O	primarily
6	38	44	O	through
7	46	51	O	direct
8	53	67	O	glucuronidation
9	69	70	O	by
10	72	77	O	UGT1A4
11	79	81	O	and
12	83	91	O	oxidative
13	93	102	O	metabolism
14	104	105	O	by
15	107	116	O	cytochrome
16	118	121	O	P450
17	123	132	O	isoenzymes
18	135	147	O	predominantly
19	149	154	O	CYP1A2
NULL

SAPHRIS	5954	34090-1	5429f134-839f-4ffc-9944-55f51238def8	17
Following an initial more rapid distribution phase, the mean terminal half-life is approximately 24 hrs.
1	0	8	O	Following
2	10	11	O	an
3	13	19	O	initial
4	21	24	O	more
5	26	30	O	rapid
6	32	43	O	distribution
7	45	49	O	phase
8	50	50	O	,
9	52	54	O	the
10	56	59	O	mean
11	61	68	O	terminal
12	70	73	O	half
13	75	78	O	life
14	80	81	O	is
15	83	95	O	approximately
16	97	98	O	24
17	100	102	O	hrs
NULL

SAPHRIS	5955	34090-1	5429f134-839f-4ffc-9944-55f51238def8	14
With multiple-dose twice-daily dosing, steady-state is attained within 3 days.
1	0	3	O	With
2	5	12	O	multiple
3	14	17	O	dose
4	19	23	O	twice
5	25	29	O	daily
6	31	36	O	dosing
7	37	37	O	,
8	39	44	O	steady
9	46	50	O	state
10	52	53	O	is
11	55	62	O	attained
12	64	69	O	within
13	71	71	O	3
14	73	76	O	days
NULL

SAPHRIS	5956	34090-1	5429f134-839f-4ffc-9944-55f51238def8	12
Overall, steady-state asenapine pharmacokinetics are similar to single-dose pharmacokinetics.
1	0	6	O	Overall
2	7	7	O	,
3	9	14	O	steady
4	16	20	O	state
5	22	30	O	XXXXXXXX
6	32	47	O	pharmacokinetics
7	49	51	O	are
8	53	59	O	similar
9	61	62	O	to
10	64	69	O	single
11	71	74	O	dose
12	76	91	O	pharmacokinetics
NULL

SAPHRIS	5957	34090-1	5429f134-839f-4ffc-9944-55f51238def8	20
Absorption: Following sublingual administration, asenapine is rapidly absorbed with peak plasma concentrations occurring within 0.5 to 1.5 hours.
1	0	9	O	Absorption
2	10	10	O	:
3	12	20	O	Following
4	22	31	O	sublingual
5	33	46	O	administration
6	47	47	O	,
7	49	57	O	XXXXXXXX
8	59	60	O	is
9	62	68	O	rapidly
10	70	77	O	absorbed
11	79	82	O	with
12	84	87	O	peak
13	89	94	O	plasma
14	96	109	O	concentrations
15	111	119	O	occurring
16	121	126	O	within
17	128	130	O	0.5
18	132	133	O	to
19	135	137	O	1.5
20	139	143	O	hours
NULL

SAPHRIS	5958	34090-1	5429f134-839f-4ffc-9944-55f51238def8	11
The absolute bioavailability of sublingual asenapine at 5 mg is 35%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	41	O	sublingual
6	43	51	O	XXXXXXXX
7	53	54	O	at
8	56	56	O	5
9	58	59	O	mg
10	61	62	O	is
11	64	66	O	35%
NULL

SAPHRIS	5959	34090-1	5429f134-839f-4ffc-9944-55f51238def8	32
Increasing the dose from 5 mg to 10 mg twice daily (a two-fold increase) results in less than linear (1.7 times) increases in both the extent of exposure and maximum concentration.
1	0	9	O	Increasing
2	11	13	O	the
3	15	18	O	dose
4	20	23	O	from
5	25	25	O	5
6	27	28	O	mg
7	30	31	O	to
8	33	34	O	10
9	36	37	O	mg
10	39	43	O	twice
11	45	49	O	daily
12	52	52	O	a
13	54	56	O	two
14	58	61	O	fold
15	63	70	O	increase
16	73	79	O	results
17	81	82	O	in
18	84	87	O	less
19	89	92	O	than
20	94	99	O	linear
21	102	104	O	1.7
22	106	110	O	times
23	113	121	O	increases
24	123	124	O	in
25	126	129	O	both
26	131	133	O	the
27	135	140	O	extent
28	142	143	O	of
29	145	152	O	exposure
30	154	156	O	and
31	158	164	O	maximum
32	166	178	O	concentration
NULL

SAPHRIS	5960	34090-1	5429f134-839f-4ffc-9944-55f51238def8	15
The absolute bioavailability of asenapine when swallowed is low (<2% with an oral tablet formulation).
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	40	O	XXXXXXXX
6	42	45	O	when
7	47	55	O	swallowed
8	57	58	O	is
9	60	62	O	low
10	65	67	O	<2%
11	69	72	O	with
12	74	75	O	an
13	77	80	O	oral
14	82	87	O	tablet
15	89	99	O	formulation
NULL

SAPHRIS	5961	34090-1	5429f134-839f-4ffc-9944-55f51238def8	17
The intake of water several (2 or 5) minutes after asenapine administration resulted in decreased asenapine exposure.
1	0	2	O	The
2	4	9	O	intake
3	11	12	O	of
4	14	18	U-KIN	water
5	20	26	O	several
6	29	29	O	2
7	31	32	O	or
8	34	34	O	5
9	37	43	O	minutes
10	45	49	O	after
11	51	59	O	XXXXXXXX
12	61	74	O	administration
13	76	83	O	resulted
14	85	86	O	in
15	88	96	B-TRI	decreased
16	98	106	I-TRI	XXXXXXXX
17	108	115	L-TRI	exposure
K/4:C54356

SAPHRIS	5962	34090-1	5429f134-839f-4ffc-9944-55f51238def8	13
Therefore, eating and drinking should be avoided for 10 minutes after administration.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	eating
4	18	20	O	and
5	22	29	O	drinking
6	31	36	O	should
7	38	39	O	be
8	41	47	O	avoided
9	49	51	O	for
10	53	54	O	10
11	56	62	O	minutes
12	64	68	O	after
13	70	83	O	administration
NULL

SAPHRIS	5963	34090-1	5429f134-839f-4ffc-9944-55f51238def8	24
Distribution: Asenapine is rapidly distributed and has a large volume of distribution (approximately 20 - 25 L/kg), indicating extensive extravascular distribution.
1	0	11	O	Distribution
2	12	12	O	:
3	14	22	O	XXXXXXXX
4	24	25	O	is
5	27	33	O	rapidly
6	35	45	O	distributed
7	47	49	O	and
8	51	53	O	has
9	55	55	O	a
10	57	61	O	large
11	63	68	O	volume
12	70	71	O	of
13	73	84	O	distribution
14	87	99	O	approximately
15	101	102	O	20
16	106	107	O	25
17	109	109	O	L
18	110	110	O	/
19	111	112	O	kg
20	114	114	O	,
21	116	125	O	indicating
22	127	135	O	extensive
23	137	149	O	extravascular
24	151	162	O	distribution
NULL

SAPHRIS	5964	34090-1	5429f134-839f-4ffc-9944-55f51238def8	15
Asenapine is highly bound (95%) to plasma proteins, including albumin and A1-acid glycoprotein.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	18	O	highly
4	20	24	O	bound
5	27	29	O	95%
6	32	33	O	to
7	35	40	O	plasma
8	42	49	O	proteins
9	50	50	O	,
10	52	60	O	including
11	62	68	O	albumin
12	70	72	O	and
13	74	75	O	A1
14	77	80	O	acid
15	82	93	O	glycoprotein
NULL

SAPHRIS	5965	34090-1	5429f134-839f-4ffc-9944-55f51238def8	24
Metabolism and Elimination: Direct glucuronidation by UGT1A4 and oxidative metabolism by cytochrome P450 isoenzymes (predominantly CYP1A2) are the primary metabolic pathways for asenapine.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	26	26	O	:
5	28	33	O	Direct
6	35	49	O	glucuronidation
7	51	52	O	by
8	54	59	O	UGT1A4
9	61	63	O	and
10	65	73	O	oxidative
11	75	84	O	metabolism
12	86	87	O	by
13	89	98	O	cytochrome
14	100	103	O	P450
15	105	114	O	isoenzymes
16	117	129	O	predominantly
17	131	136	O	CYP1A2
18	139	141	O	are
19	143	145	O	the
20	147	153	O	primary
21	155	163	O	metabolic
22	165	172	O	pathways
23	174	176	O	for
24	178	186	O	XXXXXXXX
NULL

SAPHRIS	5966	34090-1	5429f134-839f-4ffc-9944-55f51238def8	17
Asenapine is a high clearance drug with a clearance after intravenous administration of 52 L/h.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	13	O	a
4	15	18	O	high
5	20	28	O	clearance
6	30	33	O	drug
7	35	38	O	with
8	40	40	O	a
9	42	50	O	clearance
10	52	56	O	after
11	58	68	O	intravenous
12	70	83	O	administration
13	85	86	O	of
14	88	89	O	52
15	91	91	O	L
16	92	92	O	/
17	93	93	O	h
NULL

SAPHRIS	5967	34090-1	5429f134-839f-4ffc-9944-55f51238def8	30
In this circumstance, hepatic clearance is influenced primarily by changes in liver blood flow rather than by changes in the intrinsic clearance, i.e., the metabolizing enzymatic activity.
1	0	1	O	In
2	3	6	O	this
3	8	19	O	circumstance
4	20	20	O	,
5	22	28	O	hepatic
6	30	38	O	clearance
7	40	41	O	is
8	43	52	O	influenced
9	54	62	O	primarily
10	64	65	O	by
11	67	73	O	changes
12	75	76	O	in
13	78	82	O	liver
14	84	88	O	blood
15	90	93	O	flow
16	95	100	O	rather
17	102	105	O	than
18	107	108	O	by
19	110	116	O	changes
20	118	119	O	in
21	121	123	O	the
22	125	133	O	intrinsic
23	135	143	O	clearance
24	144	144	O	,
25	146	148	O	i.e
26	150	150	O	,
27	152	154	O	the
28	156	167	O	metabolizing
29	169	177	O	enzymatic
30	179	186	O	activity
NULL

SAPHRIS	5968	34090-1	5429f134-839f-4ffc-9944-55f51238def8	18
Following an initial more rapid distribution phase, the terminal half-life of asenapine is approximately 24 hours.
1	0	8	O	Following
2	10	11	O	an
3	13	19	O	initial
4	21	24	O	more
5	26	30	O	rapid
6	32	43	O	distribution
7	45	49	O	phase
8	50	50	O	,
9	52	54	O	the
10	56	63	O	terminal
11	65	68	O	half
12	70	73	O	life
13	75	76	O	of
14	78	86	O	XXXXXXXX
15	88	89	O	is
16	91	103	O	approximately
17	105	106	O	24
18	108	112	O	hours
NULL

SAPHRIS	5969	34090-1	5429f134-839f-4ffc-9944-55f51238def8	14
Steady-state concentrations of asenapine are reached within 3 days of twice daily dosing.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	29	O	of
5	31	39	O	XXXXXXXX
6	41	43	O	are
7	45	51	O	reached
8	53	58	O	within
9	60	60	O	3
10	62	65	O	days
11	67	68	O	of
12	70	74	O	twice
13	76	80	O	daily
14	82	87	O	dosing
NULL

SAPHRIS	5970	34090-1	5429f134-839f-4ffc-9944-55f51238def8	30
After administration of a single dose of [14C]-labeled asenapine, about 90% of the dose was recovered; approximately 50% was recovered in urine, and 40% recovered in feces.
1	0	4	O	After
2	6	19	O	administration
3	21	22	O	of
4	24	24	O	a
5	26	31	O	single
6	33	36	O	dose
7	38	39	O	of
8	42	44	O	14C
9	47	53	O	labeled
10	55	63	O	XXXXXXXX
11	64	64	O	,
12	66	70	O	about
13	72	74	O	90%
14	76	77	O	of
15	79	81	O	the
16	83	86	O	dose
17	88	90	O	was
18	92	100	O	recovered
19	103	115	O	approximately
20	117	119	O	50%
21	121	123	O	was
22	125	133	O	recovered
23	135	136	O	in
24	138	142	O	urine
25	143	143	O	,
26	145	147	O	and
27	149	151	O	40%
28	153	161	O	recovered
29	163	164	O	in
30	166	170	O	feces
NULL

SAPHRIS	5971	34090-1	5429f134-839f-4ffc-9944-55f51238def8	11
About 50% of the circulating species in plasma have been identified.
1	0	4	O	About
2	6	8	O	50%
3	10	11	O	of
4	13	15	O	the
5	17	27	O	circulating
6	29	35	O	species
7	37	38	O	in
8	40	45	O	plasma
9	47	50	O	have
10	52	55	O	been
11	57	66	O	identified
NULL

SAPHRIS	5972	34090-1	5429f134-839f-4ffc-9944-55f51238def8	26
The predominant species was asenapine N+-glucuronide; others included N-desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and unchanged asenapine in smaller amounts.
1	0	2	O	The
2	4	14	O	predominant
3	16	22	O	species
4	24	26	O	was
5	28	36	O	XXXXXXXX
6	38	39	O	N+
7	41	51	O	glucuronide
8	54	59	O	others
9	61	68	O	included
10	70	70	O	N
11	72	80	O	desmethyl
12	81	89	O	XXXXXXXX
13	90	90	O	,
14	92	92	O	N
15	94	102	O	desmethyl
16	103	111	O	XXXXXXXX
17	113	113	O	N
18	115	123	O	carbamoyl
19	125	135	O	glucuronide
20	136	136	O	,
21	138	140	O	and
22	142	150	O	unchanged
23	152	160	O	XXXXXXXX
24	162	163	O	in
25	165	171	O	smaller
26	173	179	O	amounts
NULL

SAPHRIS	5973	34090-1	5429f134-839f-4ffc-9944-55f51238def8	9
SAPHRIS activity is primarily due to the parent drug.
1	0	6	O	XXXXXXXX
2	8	15	O	activity
3	17	18	O	is
4	20	28	O	primarily
5	30	32	O	due
6	34	35	O	to
7	37	39	O	the
8	41	46	O	parent
9	48	51	O	drug
NULL

SAPHRIS	5974	34090-1	5429f134-839f-4ffc-9944-55f51238def8	21
In vitro studies indicate that asenapine is a substrate for UGT1A4, CYP1A2 and to a lesser extent CYP3A4 and CYP2D6.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	39	O	XXXXXXXX
7	41	42	O	is
8	44	44	O	a
9	46	54	O	substrate
10	56	58	O	for
11	60	65	O	UGT1A4
12	66	66	O	,
13	68	73	O	CYP1A2
14	75	77	O	and
15	79	80	O	to
16	82	82	O	a
17	84	89	O	lesser
18	91	96	O	extent
19	98	103	O	CYP3A4
20	105	107	O	and
21	109	114	O	CYP2D6
NULL

SAPHRIS	5975	34090-1	5429f134-839f-4ffc-9944-55f51238def8	14
Asenapine does not cause induction of CYP1A2 or CYP3A4 activities in cultured human hepatocytes.
1	0	8	O	XXXXXXXX
2	10	13	O	does
3	15	17	O	not
4	19	23	O	cause
5	25	33	O	induction
6	35	36	O	of
7	38	43	O	CYP1A2
8	45	46	O	or
9	48	53	O	CYP3A4
10	55	64	O	activities
11	66	67	O	in
12	69	76	O	cultured
13	78	82	O	human
14	84	94	O	hepatocytes
NULL

SAPHRIS	5976	34090-1	5429f134-839f-4ffc-9944-55f51238def8	25
Coadministration of asenapine with known inhibitors, inducers or substrates of these metabolic pathways has been studied in a number of drug-drug interaction studies.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	28	O	XXXXXXXX
4	30	33	O	with
5	35	39	O	known
6	41	50	O	inhibitors
7	51	51	O	,
8	53	60	O	inducers
9	62	63	O	or
10	65	74	O	substrates
11	76	77	O	of
12	79	83	O	these
13	85	93	O	metabolic
14	95	102	O	pathways
15	104	106	O	has
16	108	111	O	been
17	113	119	O	studied
18	121	122	O	in
19	124	124	O	a
20	126	131	O	number
21	133	134	O	of
22	136	139	O	drug
23	141	144	O	drug
24	146	156	O	interaction
25	158	164	O	studies
NULL

SAPHRIS	5977	34090-1	5429f134-839f-4ffc-9944-55f51238def8	30
Food: A crossover study in 26 healthy adult male subjects was performed to evaluate the effect of food on the pharmacokinetics of a single 5 mg dose of asenapine.
1	0	3	O	Food
2	4	4	O	:
3	6	6	O	A
4	8	16	O	crossover
5	18	22	O	study
6	24	25	O	in
7	27	28	O	26
8	30	36	O	healthy
9	38	42	O	adult
10	44	47	O	male
11	49	56	O	subjects
12	58	60	O	was
13	62	70	O	performed
14	72	73	O	to
15	75	82	O	evaluate
16	84	86	O	the
17	88	93	O	effect
18	95	96	O	of
19	98	101	O	food
20	103	104	O	on
21	106	108	O	the
22	110	125	O	pharmacokinetics
23	127	128	O	of
24	130	130	O	a
25	132	137	O	single
26	139	139	O	5
27	141	142	O	mg
28	144	147	O	dose
29	149	150	O	of
30	152	160	O	XXXXXXXX
NULL

SAPHRIS	5978	34090-1	5429f134-839f-4ffc-9944-55f51238def8	27
Consumption of food immediately prior to sublingual administration decreased asenapine exposure by 20%; consumption of food 4 hours after sublingual administration decreased asenapine exposure by about 10%.
1	0	10	O	Consumption
2	12	13	O	of
3	15	18	U-KIN	food
4	20	30	O	immediately
5	32	36	O	prior
6	38	39	O	to
7	41	50	O	sublingual
8	52	65	O	administration
9	67	75	B-TRI	decreased
10	77	85	I-TRI	XXXXXXXX
11	87	94	L-TRI	exposure
12	96	97	O	by
13	99	101	O	20%
14	104	114	O	consumption
15	116	117	O	of
16	119	122	O	food
17	124	124	O	4
18	126	130	O	hours
19	132	136	O	after
20	138	147	O	sublingual
21	149	162	O	administration
22	164	172	O	decreased
23	174	182	O	XXXXXXXX
24	184	191	O	exposure
25	193	194	O	by
26	196	200	O	about
27	202	204	O	10%
K/3:C54356

SAPHRIS	5979	34090-1	5429f134-839f-4ffc-9944-55f51238def8	10
These effects are probably due to increased hepatic blood flow.
1	0	4	O	These
2	6	12	O	effects
3	14	16	O	are
4	18	25	O	probably
5	27	29	O	due
6	31	32	O	to
7	34	42	O	increased
8	44	50	O	hepatic
9	52	56	O	blood
10	58	61	O	flow
NULL

SAPHRIS	5980	34090-1	5429f134-839f-4ffc-9944-55f51238def8	23
In clinical trials establishing the efficacy and safety of SAPHRIS, patients were instructed to avoid eating for 10 minutes following sublingual dosing.
1	0	1	O	In
2	3	10	O	clinical
3	12	17	O	trials
4	19	30	O	establishing
5	32	34	O	the
6	36	43	O	efficacy
7	45	47	O	and
8	49	54	O	safety
9	56	57	O	of
10	59	65	O	XXXXXXXX
11	66	66	O	,
12	68	75	O	patients
13	77	80	O	were
14	82	91	O	instructed
15	93	94	O	to
16	96	100	O	avoid
17	102	107	O	eating
18	109	111	O	for
19	113	114	O	10
20	116	122	O	minutes
21	124	132	O	following
22	134	143	O	sublingual
23	145	150	O	dosing
NULL

SAPHRIS	5981	34090-1	5429f134-839f-4ffc-9944-55f51238def8	15
There were no other restrictions with regard to the timing of meals in these trials.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	18	O	other
5	20	31	O	restrictions
6	33	36	O	with
7	38	43	O	regard
8	45	46	O	to
9	48	50	O	the
10	52	57	O	timing
11	59	60	O	of
12	62	66	O	meals
13	68	69	O	in
14	71	75	O	these
15	77	82	O	trials
NULL

SAPHRIS	5982	34090-1	5429f134-839f-4ffc-9944-55f51238def8	25
Water: In clinical trials establishing the efficacy and safety of SAPHRIS, patients were instructed to avoid drinking for 10 minutes following sublingual dosing.
1	0	4	O	Water
2	5	5	O	:
3	7	8	O	In
4	10	17	O	clinical
5	19	24	O	trials
6	26	37	O	establishing
7	39	41	O	the
8	43	50	O	efficacy
9	52	54	O	and
10	56	61	O	safety
11	63	64	O	of
12	66	72	O	XXXXXXXX
13	73	73	O	,
14	75	82	O	patients
15	84	87	O	were
16	89	98	O	instructed
17	100	101	O	to
18	103	107	O	avoid
19	109	116	O	drinking
20	118	120	O	for
21	122	123	O	10
22	125	131	O	minutes
23	133	141	O	following
24	143	152	O	sublingual
25	154	159	O	dosing
NULL

SAPHRIS	5983	34090-1	5429f134-839f-4ffc-9944-55f51238def8	33
The effect of water administration following 10 mg sublingual SAPHRIS dosing was studied at different time points of 2, 5, 10, and 30 minutes in 15 healthy adult male subjects.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	18	O	water
5	20	33	O	administration
6	35	43	O	following
7	45	46	O	10
8	48	49	O	mg
9	51	60	O	sublingual
10	62	68	O	XXXXXXXX
11	70	75	O	dosing
12	77	79	O	was
13	81	87	O	studied
14	89	90	O	at
15	92	100	O	different
16	102	105	O	time
17	107	112	O	points
18	114	115	O	of
19	117	117	O	2
20	118	118	O	,
21	120	120	O	5
22	121	121	O	,
23	123	124	O	10
24	125	125	O	,
25	127	129	O	and
26	131	132	O	30
27	134	140	O	minutes
28	142	143	O	in
29	145	146	O	15
30	148	154	O	healthy
31	156	160	O	adult
32	162	165	O	male
33	167	174	O	subjects
NULL

SAPHRIS	5984	34090-1	5429f134-839f-4ffc-9944-55f51238def8	25
The exposure of asenapine following administration of water 10 minutes after sublingual dosing was equivalent to that when water was administered 30 minutes after dosing.
1	0	2	O	The
2	4	11	O	exposure
3	13	14	O	of
4	16	24	O	XXXXXXXX
5	26	34	O	following
6	36	49	O	administration
7	51	52	O	of
8	54	58	O	water
9	60	61	O	10
10	63	69	O	minutes
11	71	75	O	after
12	77	86	O	sublingual
13	88	93	O	dosing
14	95	97	O	was
15	99	108	O	equivalent
16	110	111	O	to
17	113	116	O	that
18	118	121	O	when
19	123	127	O	water
20	129	131	O	was
21	133	144	O	administered
22	146	147	O	30
23	149	155	O	minutes
24	157	161	O	after
25	163	168	O	dosing
NULL

SAPHRIS	5985	34090-1	5429f134-839f-4ffc-9944-55f51238def8	19
Reduced exposure to asenapine was observed following water administration at 2 minutes (19% decrease) and 5 minutes (10% decrease).
1	0	6	B-TRI	Reduced
2	8	15	L-TRI	exposure
3	17	18	O	to
4	20	28	O	XXXXXXXX
5	30	32	O	was
6	34	41	O	observed
7	43	51	O	following
8	53	57	U-KIN	water
9	59	72	O	administration
10	74	75	O	at
11	77	77	O	2
12	79	85	O	minutes
13	88	90	O	19%
14	92	99	O	decrease
15	102	104	O	and
16	106	106	O	5
17	108	114	O	minutes
18	117	119	O	10%
19	121	128	O	decrease
K/8:C54356

SAPHRIS	5986	34090-1	5429f134-839f-4ffc-9944-55f51238def8	18
Drug Interaction Studies: Effects of other drugs on the exposure of asenapine are summarized in Figure 1.
1	0	3	O	Drug
2	5	15	O	Interaction
3	17	23	O	Studies
4	24	24	O	:
5	26	32	O	Effects
6	34	35	O	of
7	37	41	O	other
8	43	47	O	drugs
9	49	50	O	on
10	52	54	O	the
11	56	63	O	exposure
12	65	66	O	of
13	68	76	O	XXXXXXXX
14	78	80	O	are
15	82	91	O	summarized
16	93	94	O	in
17	96	101	O	Figure
18	103	103	O	1
NULL

SAPHRIS	5987	34090-1	5429f134-839f-4ffc-9944-55f51238def8	22
In addition, a population pharmacokinetic analysis indicated that the concomitant administration of lithium had no effect on the pharmacokinetics of asenapine.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	13	O	a
5	15	24	O	population
6	26	40	O	pharmacokinetic
7	42	49	O	analysis
8	51	59	O	indicated
9	61	64	O	that
10	66	68	O	the
11	70	80	O	concomitant
12	82	95	O	administration
13	97	98	O	of
14	100	106	O	lithium
15	108	110	O	had
16	112	113	O	no
17	115	120	O	effect
18	122	123	O	on
19	125	127	O	the
20	129	144	O	pharmacokinetics
21	146	147	O	of
22	149	157	O	XXXXXXXX
NULL

SAPHRIS	5988	34090-1	5429f134-839f-4ffc-9944-55f51238def8	27
Figure 1: Effect of Other Drugs on Asenapine Pharmacokinetics The effects of asenapine on the pharmacokinetics of other co-administered drugs are summarized in Figure 2.
1	0	5	O	Figure
2	7	7	O	1
3	8	8	O	:
4	10	15	O	Effect
5	17	18	O	of
6	20	24	O	Other
7	26	30	O	Drugs
8	32	33	O	on
9	35	43	O	XXXXXXXX
10	45	60	O	Pharmacokinetics
11	62	64	O	The
12	66	72	O	effects
13	74	75	O	of
14	77	85	O	XXXXXXXX
15	87	88	O	on
16	90	92	O	the
17	94	109	O	pharmacokinetics
18	111	112	O	of
19	114	118	O	other
20	120	121	O	co
21	123	134	O	administered
22	136	140	O	drugs
23	142	144	O	are
24	146	155	O	summarized
25	157	158	O	in
26	160	165	O	Figure
27	167	167	O	2
NULL

SAPHRIS	5989	34090-1	5429f134-839f-4ffc-9944-55f51238def8	20
Coadministration of paroxetine with SAPHRIS caused a two-fold increase in the maximum plasma concentrations and systemic exposure of paroxetine.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	29	U-KIN	paroxetine
4	31	34	O	with
5	36	42	O	XXXXXXXX
6	44	49	O	caused
7	51	51	O	a
8	53	55	O	two
9	57	60	O	fold
10	62	69	B-TRI	increase
11	71	72	I-TRI	in
12	74	76	I-TRI	the
13	78	84	I-TRI	maximum
14	86	91	I-TRI	plasma
15	93	106	L-TRI	concentrations
16	108	110	O	and
17	112	119	O	systemic
18	121	128	O	exposure
19	130	131	O	of
20	133	142	O	paroxetine
K/3:C54357

SAPHRIS	5990	34090-1	5429f134-839f-4ffc-9944-55f51238def8	13
Asenapine enhances the inhibitory effects of paroxetine on its own metabolism by CYP2D6.
1	0	8	O	XXXXXXXX
2	10	17	O	enhances
3	19	21	O	the
4	23	32	O	inhibitory
5	34	40	O	effects
6	42	43	O	of
7	45	54	U-KIN	paroxetine
8	56	57	O	on
9	59	61	O	its
10	63	65	O	own
11	67	76	O	metabolism
12	78	79	O	by
13	81	86	O	CYP2D6
K/7:C54357

SAPHRIS	5991	34090-1	5429f134-839f-4ffc-9944-55f51238def8	30
Figure 2: Effect of Asenapine on Other Drug Pharmacokinetics Figure 1 Figure 2 Studies in Special Populations: Exposures of asenapine in special populations are summarized in Figure 3.
1	0	5	O	Figure
2	7	7	O	2
3	8	8	O	:
4	10	15	O	Effect
5	17	18	O	of
6	20	28	O	XXXXXXXX
7	30	31	O	on
8	33	37	O	Other
9	39	42	O	Drug
10	44	59	O	Pharmacokinetics
11	61	66	O	Figure
12	68	68	O	1
13	70	75	O	Figure
14	77	77	O	2
15	79	85	O	Studies
16	87	88	O	in
17	90	96	O	Special
18	98	108	O	Populations
19	109	109	O	:
20	111	119	O	Exposures
21	121	122	O	of
22	124	132	O	XXXXXXXX
23	134	135	O	in
24	137	143	O	special
25	145	155	O	populations
26	157	159	O	are
27	161	170	O	summarized
28	172	173	O	in
29	175	180	O	Figure
30	182	182	O	3
NULL

SAPHRIS	5992	34090-1	5429f134-839f-4ffc-9944-55f51238def8	25
Additionally, based on population pharmacokinetic analysis, no effects of sex, race, BMI, and smoking status on asenapine exposure were observed.
1	0	11	O	Additionally
2	12	12	O	,
3	14	18	O	based
4	20	21	O	on
5	23	32	O	population
6	34	48	O	pharmacokinetic
7	50	57	O	analysis
8	58	58	O	,
9	60	61	O	no
10	63	69	O	effects
11	71	72	O	of
12	74	76	O	sex
13	77	77	O	,
14	79	82	O	race
15	83	83	O	,
16	85	87	O	BMI
17	88	88	O	,
18	90	92	O	and
19	94	100	O	smoking
20	102	107	O	status
21	109	110	O	on
22	112	120	O	XXXXXXXX
23	122	129	O	exposure
24	131	134	O	were
25	136	143	O	observed
NULL

SAPHRIS	5993	34090-1	5429f134-839f-4ffc-9944-55f51238def8	12
Exposure in elderly patients is 30-40% higher as compared to adults.
1	0	7	O	Exposure
2	9	10	O	in
3	12	18	O	elderly
4	20	27	O	patients
5	29	30	O	is
6	32	33	O	30
7	35	37	O	40%
8	39	44	O	higher
9	46	47	O	as
10	49	56	O	compared
11	58	59	O	to
12	61	66	O	adults
NULL

SAPHRIS	5994	34090-1	5429f134-839f-4ffc-9944-55f51238def8	12
Figure 3: Effect of Intrinsic Factors on Asenapine Pharmacokinetics Figure 3
1	0	5	O	Figure
2	7	7	O	3
3	8	8	O	:
4	10	15	O	Effect
5	17	18	O	of
6	20	28	O	Intrinsic
7	30	36	O	Factors
8	38	39	O	on
9	41	49	O	XXXXXXXX
10	51	66	O	Pharmacokinetics
11	68	73	O	Figure
12	75	75	O	3
NULL

Sertraline Hydrochloride	1485	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	54
Potential Effects of Coadministration of Drugs Highly Bound to Plasma Proteins-Because sertraline is tightly bound to plasma protein, the administration of sertraline hydrochloride to a patient taking another drug which is tightly bound to protein (e.g., warfarin, digitoxin) may cause a shift in plasma concentrations potentially resulting in an adverse effect.
1	0	8	O	Potential
2	10	16	O	Effects
3	18	19	O	of
4	21	36	O	Coadministration
5	38	39	O	of
6	41	45	O	Drugs
7	47	52	O	Highly
8	54	58	O	Bound
9	60	61	O	to
10	63	68	O	Plasma
11	70	77	O	Proteins
12	79	85	O	Because
13	87	96	O	XXXXXXXX
14	98	99	O	is
15	101	107	O	tightly
16	109	113	O	bound
17	115	116	O	to
18	118	123	O	plasma
19	125	131	O	protein
20	132	132	O	,
21	134	136	O	the
22	138	151	O	administration
23	153	154	O	of
24	156	179	O	XXXXXXXX
25	181	182	O	to
26	184	184	O	a
27	186	192	O	patient
28	194	199	O	taking
29	201	207	O	another
30	209	212	O	drug
31	214	218	O	which
32	220	221	O	is
33	223	229	O	tightly
34	231	235	O	bound
35	237	238	O	to
36	240	246	O	protein
37	249	251	O	e.g
38	253	253	O	,
39	255	262	U-UNK	warfarin
40	263	263	O	,
41	265	273	U-UNK	digitoxin
42	276	278	O	may
43	280	284	O	cause
44	286	286	O	a
45	288	292	B-TRI	shift
46	294	295	I-TRI	in
47	297	302	I-TRI	plasma
48	304	317	L-TRI	concentrations
49	319	329	O	potentially
50	331	339	O	resulting
51	341	342	O	in
52	344	345	O	an
53	347	353	O	adverse
54	355	360	O	effect
NULL

Sertraline Hydrochloride	1486	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	17
Conversely, adverse effects may result from displacement of protein bound sertraline hydrochloride by other tightly bound drugs.
1	0	9	O	Conversely
2	10	10	O	,
3	12	18	B-TRI	adverse
4	20	26	L-TRI	effects
5	28	30	O	may
6	32	37	O	result
7	39	42	O	from
8	44	55	O	displacement
9	57	58	O	of
10	60	66	O	protein
11	68	72	O	bound
12	74	97	O	XXXXXXXX
13	99	100	O	by
14	102	106	O	other
15	108	114	B-UNK	tightly
16	116	120	I-UNK	bound
17	122	126	L-UNK	drugs
NULL

Sertraline Hydrochloride	1487	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	63
In a study comparing prothrombin time AUC (0 to 120 hr) following dosing with warfarin (0.75 mg/kg) before and after 21 days of dosing with either sertraline (50 to 200 mg/day) or placebo, there was a mean increase in prothrombin time of 8% relative to baseline for sertraline compared to a 1% decrease for placebo (p < 0.02).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	19	O	comparing
5	21	31	O	prothrombin
6	33	36	O	time
7	38	40	O	AUC
8	43	43	O	0
9	45	46	O	to
10	48	50	O	120
11	52	53	O	hr
12	56	64	O	following
13	66	71	O	dosing
14	73	76	O	with
15	78	85	U-DYN	warfarin
16	88	91	O	0.75
17	93	94	O	mg
18	95	95	O	/
19	96	97	O	kg
20	100	105	O	before
21	107	109	O	and
22	111	115	O	after
23	117	118	O	21
24	120	123	O	days
25	125	126	O	of
26	128	133	O	dosing
27	135	138	O	with
28	140	145	O	either
29	147	156	O	XXXXXXXX
30	159	160	O	50
31	162	163	O	to
32	165	167	O	200
33	169	170	O	mg
34	171	171	O	/
35	172	174	O	day
36	177	178	O	or
37	180	186	O	placebo
38	187	187	O	,
39	189	193	O	there
40	195	197	O	was
41	199	199	O	a
42	201	204	O	mean
43	206	213	B-EFF	increase
44	215	216	I-EFF	in
45	218	228	I-EFF	prothrombin
46	230	233	L-EFF	time
47	235	236	O	of
48	238	239	O	8%
49	241	248	O	relative
50	250	251	O	to
51	253	260	O	baseline
52	262	264	O	for
53	266	275	O	XXXXXXXX
54	277	284	O	compared
55	286	287	O	to
56	289	289	O	a
57	291	292	O	1%
58	294	301	O	decrease
59	303	305	O	for
60	307	313	O	placebo
61	316	316	O	p
62	318	318	O	<
63	320	323	O	0.02
D/15:43:1

Sertraline Hydrochloride	1488	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	16
The normalization of prothrombin time for the sertraline hydrochloride group was delayed compared to the placebo group.
1	0	2	O	The
2	4	16	O	normalization
3	18	19	O	of
4	21	31	O	prothrombin
5	33	36	O	time
6	38	40	O	for
7	42	44	O	the
8	46	69	O	XXXXXXXX
9	71	75	O	group
10	77	79	O	was
11	81	87	O	delayed
12	89	96	O	compared
13	98	99	O	to
14	101	103	O	the
15	105	111	O	placebo
16	113	117	O	group
NULL

Sertraline Hydrochloride	1489	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	8
The clinical significance of this change is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	39	O	change
7	41	42	O	is
8	44	50	O	unknown
NULL

Sertraline Hydrochloride	1490	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	15
Accordingly, prothrombin time should be carefully monitored when sertraline hydrochloride therapy is initiated or stopped.
1	0	10	O	Accordingly
2	11	11	O	,
3	13	23	O	prothrombin
4	25	28	O	time
5	30	35	O	should
6	37	38	O	be
7	40	48	O	carefully
8	50	58	O	monitored
9	60	63	O	when
10	65	88	O	XXXXXXXX
11	90	96	O	therapy
12	98	99	O	is
13	101	109	O	initiated
14	111	112	O	or
15	114	120	O	stopped
NULL

Sertraline Hydrochloride	1491	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	43
Cimetidine In a study assessing disposition of Sertraline hydrochloride (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were increases in Sertraline hydrochloride mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo group.
1	0	9	O	Cimetidine
2	11	12	O	In
3	14	14	O	a
4	16	20	O	study
5	22	30	O	assessing
6	32	42	O	disposition
7	44	45	O	of
8	47	70	O	XXXXXXXX
9	73	75	O	100
10	77	78	O	mg
11	81	82	O	on
12	84	86	O	the
13	88	93	O	second
14	95	96	O	of
15	98	98	O	8
16	100	103	O	days
17	105	106	O	of
18	108	117	U-KIN	cimetidine
19	119	132	O	administration
20	135	137	O	800
21	139	140	O	mg
22	142	146	O	daily
23	148	148	O	,
24	150	154	O	there
25	156	159	O	were
26	161	169	O	increases
27	171	172	O	in
28	174	197	O	XXXXXXXX
29	199	202	O	mean
30	204	206	O	AUC
31	209	211	O	50%
32	213	213	O	,
33	215	218	O	Cmax
34	221	223	O	24%
35	226	228	O	and
36	230	233	O	half
37	235	238	O	life
38	241	243	O	26%
39	246	253	O	compared
40	255	256	O	to
41	258	260	O	the
42	262	268	O	placebo
43	270	274	O	group
K/18:C54605

Sertraline Hydrochloride	1492	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	8
The clinical significance of these changes is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	33	O	these
6	35	41	O	changes
7	43	44	O	is
8	46	52	O	unknown
NULL

Sertraline Hydrochloride	1493	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	64
CNS Active Drugs-In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p < 0.03).
1	0	2	O	CNS
2	4	9	O	Active
3	11	15	O	Drugs
4	17	18	O	In
5	20	20	O	a
6	22	26	O	study
7	28	36	O	comparing
8	38	40	O	the
9	42	52	O	disposition
10	54	55	O	of
11	57	69	O	intravenously
12	71	82	O	administered
13	84	91	U-KIN	diazepam
14	93	98	O	before
15	100	102	O	and
16	104	108	O	after
17	110	111	O	21
18	113	116	O	days
19	118	119	O	of
20	121	126	O	dosing
21	128	131	O	with
22	133	138	O	either
23	140	149	O	XXXXXXXX
24	152	153	O	50
25	155	156	O	to
26	158	160	O	200
27	162	163	O	mg
28	164	164	O	/
29	165	167	O	day
30	169	178	O	escalating
31	180	183	O	dose
32	186	187	O	or
33	189	195	O	placebo
34	196	196	O	,
35	198	202	O	there
36	204	206	O	was
37	208	208	O	a
38	210	212	O	32%
39	214	221	O	decrease
40	223	230	O	relative
41	232	233	O	to
42	235	242	O	baseline
43	244	245	O	in
44	247	254	O	diazepam
45	256	264	O	clearance
46	266	268	O	for
47	270	272	O	the
48	274	283	O	XXXXXXXX
49	285	289	O	group
50	291	298	O	compared
51	300	301	O	to
52	303	303	O	a
53	305	307	O	19%
54	309	316	O	decrease
55	318	325	O	relative
56	327	328	O	to
57	330	337	O	baseline
58	339	341	O	for
59	343	345	O	the
60	347	353	O	placebo
61	355	359	O	group
62	362	362	O	p
63	364	364	O	<
64	366	369	O	0.03
K/13:C54357

Sertraline Hydrochloride	1494	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	25
There was a 23% increase in Tmax for desmethyldiazepam in the sertraline hydrochloride group compared to a 20% decrease in the placebo group (p < 0.03).
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	14	O	23%
5	16	23	B-TRI	increase
6	25	26	I-TRI	in
7	28	31	L-TRI	Tmax
8	33	35	O	for
9	37	53	U-KIN	desmethyldiazepam
10	55	56	O	in
11	58	60	O	the
12	62	85	O	XXXXXXXX
13	87	91	O	group
14	93	100	O	compared
15	102	103	O	to
16	105	105	O	a
17	107	109	O	20%
18	111	118	O	decrease
19	120	121	O	in
20	123	125	O	the
21	127	133	O	placebo
22	135	139	O	group
23	142	142	O	p
24	144	144	O	<
25	146	149	O	0.03
K/9:C54612

Sertraline Hydrochloride	1496	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	30
In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline hydrochloride did not significantly alter steady-state lithium levels or the renal clearance of lithium.
1	0	1	O	In
2	3	3	O	a
3	5	11	O	placebo
4	13	22	O	controlled
5	24	28	O	trial
6	30	31	O	in
7	33	38	O	normal
8	40	49	O	volunteers
9	50	50	O	,
10	52	54	O	the
11	56	69	O	administration
12	71	72	O	of
13	74	76	O	two
14	78	82	O	doses
15	84	85	O	of
16	87	110	O	XXXXXXXX
17	112	114	O	did
18	116	118	O	not
19	120	132	O	significantly
20	134	138	O	alter
21	140	145	O	steady
22	147	151	O	state
23	153	159	O	lithium
24	161	166	O	levels
25	168	169	O	or
26	171	173	O	the
27	175	179	O	renal
28	181	189	O	clearance
29	191	192	O	of
30	194	200	O	lithium
NULL

Sertraline Hydrochloride	1497	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	27
Nonetheless, at this time, it is recommended that plasma lithium levels be monitored following initiation of sertraline hydrochloride therapy with appropriate adjustments to the lithium dose.
1	0	10	O	Nonetheless
2	11	11	O	,
3	13	14	O	at
4	16	19	O	this
5	21	24	O	time
6	25	25	O	,
7	27	28	O	it
8	30	31	O	is
9	33	43	O	recommended
10	45	48	O	that
11	50	55	O	plasma
12	57	63	U-UNK	lithium
13	65	70	O	levels
14	72	73	O	be
15	75	83	U-TRI	monitored
16	85	93	O	following
17	95	104	O	initiation
18	106	107	O	of
19	109	132	O	XXXXXXXX
20	134	140	O	therapy
21	142	145	O	with
22	147	157	O	appropriate
23	159	169	O	adjustments
24	171	172	O	to
25	174	176	O	the
26	178	184	O	lithium
27	186	189	O	dose
NULL

Sertraline Hydrochloride	1498	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	46
In a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and Cmax of about 40%, but was not associated with any changes in EKG.
1	0	1	O	In
2	3	3	O	a
3	5	14	O	controlled
4	16	20	O	study
5	22	23	O	of
6	25	25	O	a
7	27	32	O	single
8	34	37	O	dose
9	40	40	O	2
10	42	43	O	mg
11	46	47	O	of
12	49	56	U-KIN	pimozide
13	57	57	O	,
14	59	61	O	200
15	63	64	O	mg
16	66	75	O	XXXXXXXX
17	78	80	O	q.d
18	84	85	O	co
19	87	100	O	administration
20	102	103	O	to
21	105	110	O	steady
22	112	116	O	state
23	118	120	O	was
24	122	131	O	associated
25	133	136	O	with
26	138	138	O	a
27	140	143	O	mean
28	145	152	O	increase
29	154	155	O	in
30	157	164	O	pimozide
31	166	168	O	AUC
32	170	172	O	and
33	174	177	O	Cmax
34	179	180	O	of
35	182	186	O	about
36	188	190	O	40%
37	191	191	O	,
38	193	195	O	but
39	197	199	O	was
40	201	203	O	not
41	205	214	O	associated
42	216	219	O	with
43	221	223	O	any
44	225	231	O	changes
45	233	234	O	in
46	236	238	O	EKG
K/12:C54610

Sertraline Hydrochloride	1499	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	37
Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known.
1	0	4	O	Since
2	6	8	O	the
3	10	16	O	highest
4	18	28	O	recommended
5	30	37	O	pimozide
6	39	42	O	dose
7	45	46	O	10
8	48	49	O	mg
9	52	54	O	has
10	56	58	O	not
11	60	63	O	been
12	65	73	O	evaluated
13	75	76	O	in
14	78	88	O	combination
15	90	93	O	with
16	95	104	O	XXXXXXXX
17	105	105	O	,
18	107	109	O	the
19	111	116	O	effect
20	118	119	O	on
21	121	122	O	QT
22	124	131	O	interval
23	133	135	O	and
24	137	138	O	PK
25	140	149	O	parameters
26	151	152	O	at
27	154	158	O	doses
28	160	165	O	higher
29	167	170	O	than
30	172	172	O	2
31	174	175	O	mg
32	177	178	O	at
33	180	183	O	this
34	185	188	O	time
35	190	192	O	are
36	194	196	O	not
37	198	202	O	known
NULL

Sertraline Hydrochloride	1500	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	39
While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline hydrochloride and pimozide should be contraindicated.
1	0	4	O	While
2	6	8	O	the
3	10	18	O	mechanism
4	20	21	O	of
5	23	26	O	this
6	28	38	U-TRI	interaction
7	40	41	O	is
8	43	49	O	unknown
9	50	50	O	,
10	52	54	O	due
11	56	57	O	to
12	59	61	O	the
13	63	68	O	narrow
14	70	80	O	therapeutic
15	82	86	O	index
16	88	89	O	of
17	91	98	U-UNK	pimozide
18	100	102	O	and
19	104	106	O	due
20	108	109	O	to
21	111	113	O	the
22	115	125	O	interaction
23	127	131	O	noted
24	133	134	O	at
25	136	136	O	a
26	138	140	O	low
27	142	145	O	dose
28	147	148	O	of
29	150	157	O	pimozide
30	158	158	O	,
31	160	170	O	concomitant
32	172	185	O	administration
33	187	188	O	of
34	190	213	O	XXXXXXXX
35	215	217	O	and
36	219	226	O	pimozide
37	228	233	O	should
38	235	236	O	be
39	238	252	O	contraindicated
NULL

Sertraline Hydrochloride	1501	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	28
Results of a placebo-controlled trial in normal volunteers suggest that chronic administration of sertraline 200 mg/day does not produce clinically important inhibition of phenytoin metabolism.
1	0	6	O	Results
2	8	9	O	of
3	11	11	O	a
4	13	19	O	placebo
5	21	30	O	controlled
6	32	36	O	trial
7	38	39	O	in
8	41	46	O	normal
9	48	57	O	volunteers
10	59	65	O	suggest
11	67	70	O	that
12	72	78	O	chronic
13	80	93	O	administration
14	95	96	O	of
15	98	107	O	XXXXXXXX
16	109	111	O	200
17	113	114	O	mg
18	115	115	O	/
19	116	118	O	day
20	120	123	O	does
21	125	127	O	not
22	129	135	O	produce
23	137	146	O	clinically
24	148	156	O	important
25	158	167	O	inhibition
26	169	170	O	of
27	172	180	O	phenytoin
28	182	191	O	metabolism
NULL

Sertraline Hydrochloride	1502	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	44
Nonetheless, at this time, it is recommended that plasma phenytoin concentrations be monitored following initiation of sertraline therapy with appropriate adjustments to the phenytoin dose, particularly in patients with multiple underlying medical conditions and/or those receiving multiple concomitant medications.
1	0	10	O	Nonetheless
2	11	11	O	,
3	13	14	O	at
4	16	19	O	this
5	21	24	O	time
6	25	25	O	,
7	27	28	O	it
8	30	31	O	is
9	33	43	O	recommended
10	45	48	O	that
11	50	55	O	plasma
12	57	65	U-UNK	phenytoin
13	67	80	O	concentrations
14	82	83	O	be
15	85	93	O	monitored
16	95	103	O	following
17	105	114	O	initiation
18	116	117	O	of
19	119	128	O	XXXXXXXX
20	130	136	O	therapy
21	138	141	O	with
22	143	153	O	appropriate
23	155	165	O	adjustments
24	167	168	O	to
25	170	172	O	the
26	174	182	O	phenytoin
27	184	187	O	dose
28	188	188	O	,
29	190	201	O	particularly
30	203	204	O	in
31	206	213	O	patients
32	215	218	O	with
33	220	227	O	multiple
34	229	238	O	underlying
35	240	246	O	medical
36	248	257	O	conditions
37	259	261	O	and
38	262	262	O	/
39	263	264	O	or
40	266	270	O	those
41	272	280	O	receiving
42	282	289	O	multiple
43	291	301	O	concomitant
44	303	313	O	medications
NULL

Sertraline Hydrochloride	1503	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	14
The effect of sertraline hydrochloride on valproate levels has not been evaluated in clinical trials.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	37	O	XXXXXXXX
5	39	40	O	on
6	42	50	O	valproate
7	52	57	O	levels
8	59	61	O	has
9	63	65	O	not
10	67	70	O	been
11	72	80	O	evaluated
12	82	83	O	in
13	85	92	O	clinical
14	94	99	O	trials
NULL

Sertraline Hydrochloride	1504	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	28
In the absence of such data, it is recommended that plasma valproate levels be monitored following initiation of sertraline hydrochloride therapy with appropriate adjustments to the valproate dose.
1	0	1	O	In
2	3	5	O	the
3	7	13	O	absence
4	15	16	O	of
5	18	21	O	such
6	23	26	O	data
7	27	27	O	,
8	29	30	O	it
9	32	33	O	is
10	35	45	O	recommended
11	47	50	O	that
12	52	57	O	plasma
13	59	67	U-UNK	valproate
14	69	74	O	levels
15	76	77	O	be
16	79	87	U-TRI	monitored
17	89	97	O	following
18	99	108	O	initiation
19	110	111	O	of
20	113	136	O	XXXXXXXX
21	138	144	O	therapy
22	146	149	O	with
23	151	161	O	appropriate
24	163	173	O	adjustments
25	175	176	O	to
26	178	180	O	the
27	182	190	O	valproate
28	192	195	O	dose
NULL

Sertraline Hydrochloride	1505	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	17
The risk of using sertraline hydrochloride in combination with other CNS active drugs has not been systematically evaluated.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	16	O	using
5	18	41	O	XXXXXXXX
6	43	44	O	in
7	46	56	O	combination
8	58	61	O	with
9	63	67	O	other
10	69	71	O	CNS
11	73	78	O	active
12	80	84	O	drugs
13	86	88	O	has
14	90	92	O	not
15	94	97	O	been
16	99	112	O	systematically
17	114	122	O	evaluated
NULL

Sertraline Hydrochloride	1506	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	16
Consequently, caution is advised if the concomitant administration of sertraline hydrochloride and such drugs is required.
1	0	11	O	Consequently
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	31	O	advised
6	33	34	O	if
7	36	38	O	the
8	40	50	O	concomitant
9	52	65	O	administration
10	67	68	O	of
11	70	93	O	XXXXXXXX
12	95	97	O	and
13	99	102	O	such
14	104	108	O	drugs
15	110	111	O	is
16	113	120	O	required
NULL

Sertraline Hydrochloride	1507	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	43
There is limited controlled experience regarding the optimal timing of switching from other drugs effective in the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, posttraumatic stress disorder, premenstrual dysphoric disorder and social anxiety disorder to sertraline.
1	0	4	O	There
2	6	7	O	is
3	9	15	O	limited
4	17	26	O	controlled
5	28	37	O	experience
6	39	47	O	regarding
7	49	51	O	the
8	53	59	O	optimal
9	61	66	O	timing
10	68	69	O	of
11	71	79	O	switching
12	81	84	O	from
13	86	90	O	other
14	92	96	O	drugs
15	98	106	O	effective
16	108	109	O	in
17	111	113	O	the
18	115	123	O	treatment
19	125	126	O	of
20	128	132	O	major
21	134	143	O	depressive
22	145	152	O	disorder
23	153	153	O	,
24	155	163	O	obsessive
25	165	174	O	compulsive
26	176	183	O	disorder
27	184	184	O	,
28	186	190	O	panic
29	192	199	O	disorder
30	200	200	O	,
31	202	214	O	posttraumatic
32	216	221	O	stress
33	223	230	O	disorder
34	231	231	O	,
35	233	244	O	premenstrual
36	246	254	O	dysphoric
37	256	263	O	disorder
38	265	267	O	and
39	269	274	O	social
40	276	282	O	anxiety
41	284	291	O	disorder
42	293	294	O	to
43	296	305	O	XXXXXXXX
NULL

Sertraline Hydrochloride	1508	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	16
Care and prudent medical judgment should be exercised when switching, particularly from long-acting agents.
1	0	3	O	Care
2	5	7	O	and
3	9	15	O	prudent
4	17	23	O	medical
5	25	32	O	judgment
6	34	39	O	should
7	41	42	O	be
8	44	52	O	exercised
9	54	57	O	when
10	59	67	O	switching
11	68	68	O	,
12	70	81	O	particularly
13	83	86	O	from
14	88	91	O	long
15	93	98	O	acting
16	100	105	O	agents
NULL

Sertraline Hydrochloride	1509	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	25
The duration of an appropriate washout period which should intervene before switching from one selective serotonin reuptake inhibitor (SSRI) to another has not been established.
1	0	2	O	The
2	4	11	O	duration
3	13	14	O	of
4	16	17	O	an
5	19	29	O	appropriate
6	31	37	O	washout
7	39	44	O	period
8	46	50	O	which
9	52	57	O	should
10	59	67	O	intervene
11	69	74	O	before
12	76	84	O	switching
13	86	89	O	from
14	91	93	O	one
15	95	103	O	selective
16	105	113	O	serotonin
17	115	122	O	reuptake
18	124	132	O	inhibitor
19	135	138	O	SSRI
20	141	142	O	to
21	144	150	O	another
22	152	154	O	has
23	156	158	O	not
24	160	163	O	been
25	165	175	O	established
NULL

Sertraline Hydrochloride	1510	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	11
Monoamine Oxidase Inhibitors- See CONTRAINDICATIONS, WARNINGS, andDOSAGE AND ADMINISTRATION.
1	0	8	B-UNK	Monoamine
2	10	16	I-UNK	Oxidase
3	18	27	L-UNK	Inhibitors
4	30	32	O	See
5	34	50	U-TRI	CONTRAINDICATIONS
6	51	51	O	,
7	53	60	O	WARNINGS
8	61	61	O	,
9	63	71	O	andDOSAGE
10	73	75	O	AND
11	77	90	O	ADMINISTRATION
NULL

Sertraline Hydrochloride	1511	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	33
Drugs Metabolized by P450 3A4-In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	24	O	P450
5	26	28	O	3A4
6	30	31	O	In
7	33	37	O	three
8	39	46	O	separate
9	48	49	O	in
10	51	54	O	vivo
11	56	66	O	interaction
12	68	74	O	studies
13	75	75	O	,
14	77	86	O	XXXXXXXX
15	88	90	O	was
16	92	93	O	co
17	95	106	O	administered
18	108	111	O	with
19	113	122	O	cytochrome
20	124	127	O	P450
21	129	131	O	3A4
22	133	142	O	substrates
23	143	143	O	,
24	145	155	O	terfenadine
25	156	156	O	,
26	158	170	O	carbamazepine
27	171	171	O	,
28	173	174	O	or
29	176	184	O	cisapride
30	186	190	O	under
31	192	197	O	steady
32	199	203	O	state
33	205	214	O	conditions
NULL

Sertraline Hydrochloride	1512	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	20
The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride.
1	0	2	O	The
2	4	10	O	results
3	12	13	O	of
4	15	19	O	these
5	21	27	O	studies
6	29	37	O	indicated
7	39	42	O	that
8	44	53	O	XXXXXXXX
9	55	57	O	did
10	59	61	O	not
11	63	70	O	increase
12	72	77	O	plasma
13	79	92	O	concentrations
14	94	95	O	of
15	97	107	O	terfenadine
16	108	108	O	,
17	110	122	O	carbamazepine
18	123	123	O	,
19	125	126	O	or
20	128	136	O	cisapride
NULL

Sertraline Hydrochloride	1513	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	21
These data indicate that sertraline's extent of inhibition of P450 3A4 activity is not likely to be of clinical significance.
1	0	4	O	These
2	6	9	O	data
3	11	18	O	indicate
4	20	23	O	that
5	25	34	O	XXXXXXXX
6	35	36	O	's
7	38	43	O	extent
8	45	46	O	of
9	48	57	O	inhibition
10	59	60	O	of
11	62	65	O	P450
12	67	69	O	3A4
13	71	78	O	activity
14	80	81	O	is
15	83	85	O	not
16	87	92	O	likely
17	94	95	O	to
18	97	98	O	be
19	100	101	O	of
20	103	110	O	clinical
21	112	123	O	significance
NULL

Sertraline Hydrochloride	1514	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	27
Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).
1	0	6	O	Results
2	8	9	O	of
3	11	13	O	the
4	15	25	O	interaction
5	27	31	O	study
6	33	36	O	with
7	38	46	U-KIN	cisapride
8	48	55	O	indicate
9	57	60	O	that
10	62	71	O	XXXXXXXX
11	73	75	O	200
12	77	78	O	mg
13	81	83	O	q.d
14	87	93	B-TRI	induces
15	95	97	I-TRI	the
16	99	108	L-TRI	metabolism
17	110	111	O	of
18	113	121	O	cisapride
19	124	132	O	cisapride
20	134	136	O	AUC
21	138	140	O	and
22	142	145	O	Cmax
23	147	150	O	were
24	152	158	O	reduced
25	160	161	O	by
26	163	167	O	about
27	169	171	O	35%
K/7:C54614

Sertraline Hydrochloride	1515	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	71
Drugs Metabolized by P450 2D6-Many drugs effective in the treatment of major depressive disorder, e.g., the SSRIs, including sertraline, and most tricyclic antidepressant drugs effective in the treatment of major depressive disorder inhibit the biochemical activity of the drug metabolizing isozyme cytochrome P450 2D6 (debrisoquin hydroxylase), and, thus, may increase the plasma concentrations of co-administered drugs that are metabolized by P450 2D6.
1	0	4	B-KIN	Drugs
2	6	16	I-KIN	Metabolized
3	18	19	I-KIN	by
4	21	24	I-KIN	P450
5	26	28	L-KIN	2D6
6	30	33	O	Many
7	35	39	O	drugs
8	41	49	O	effective
9	51	52	O	in
10	54	56	O	the
11	58	66	O	treatment
12	68	69	O	of
13	71	75	O	major
14	77	86	O	depressive
15	88	95	O	disorder
16	96	96	O	,
17	98	100	O	e.g
18	102	102	O	,
19	104	106	O	the
20	108	112	O	SSRIs
21	113	113	O	,
22	115	123	O	including
23	125	134	O	XXXXXXXX
24	135	135	O	,
25	137	139	O	and
26	141	144	O	most
27	146	154	O	tricyclic
28	156	169	O	antidepressant
29	171	175	O	drugs
30	177	185	O	effective
31	187	188	O	in
32	190	192	O	the
33	194	202	O	treatment
34	204	205	O	of
35	207	211	O	major
36	213	222	O	depressive
37	224	231	O	disorder
38	233	239	O	inhibit
39	241	243	O	the
40	245	255	O	biochemical
41	257	264	O	activity
42	266	267	O	of
43	269	271	O	the
44	273	276	O	drug
45	278	289	O	metabolizing
46	291	297	O	isozyme
47	299	308	O	cytochrome
48	310	313	O	P450
49	315	317	O	2D6
50	320	330	O	debrisoquin
51	332	342	O	hydroxylase
52	344	344	O	,
53	346	348	O	and
54	349	349	O	,
55	351	354	O	thus
56	355	355	O	,
57	357	359	O	may
58	361	368	B-TRI	increase
59	370	372	I-TRI	the
60	374	379	I-TRI	plasma
61	381	394	L-TRI	concentrations
62	396	397	O	of
63	399	400	O	co
64	402	413	O	administered
65	415	419	O	drugs
66	421	424	O	that
67	426	428	O	are
68	430	440	O	metabolized
69	442	443	O	by
70	445	448	O	P450
71	450	452	O	2D6
K/1:C54357

Sertraline Hydrochloride	1516	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	47
The drugs for which this potential interaction is of greatest concern are those metabolized primarily by 2D6 and which have a narrow therapeutic index, e.g., the tricyclic antidepressant drugs effective in the treatment of major depressive disorder and the Type 1C antiarrhythmics propafenone and flecainide.
1	0	2	O	The
2	4	8	O	drugs
3	10	12	O	for
4	14	18	O	which
5	20	23	O	this
6	25	33	O	potential
7	35	45	O	interaction
8	47	48	O	is
9	50	51	O	of
10	53	60	O	greatest
11	62	68	O	concern
12	70	72	O	are
13	74	78	O	those
14	80	90	O	metabolized
15	92	100	O	primarily
16	102	103	O	by
17	105	107	O	2D6
18	109	111	O	and
19	113	117	O	which
20	119	122	O	have
21	124	124	O	a
22	126	131	O	narrow
23	133	143	O	therapeutic
24	145	149	O	index
25	150	150	O	,
26	152	154	O	e.g
27	156	156	O	,
28	158	160	O	the
29	162	170	O	tricyclic
30	172	185	O	antidepressant
31	187	191	O	drugs
32	193	201	O	effective
33	203	204	O	in
34	206	208	O	the
35	210	218	O	treatment
36	220	221	O	of
37	223	227	O	major
38	229	238	O	depressive
39	240	247	O	disorder
40	249	251	O	and
41	253	255	O	the
42	257	260	O	Type
43	262	263	O	1C
44	265	279	O	antiarrhythmics
45	281	291	O	propafenone
46	293	295	O	and
47	297	306	O	flecainide
NULL

Sertraline Hydrochloride	1517	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	33
The extent to which this interaction is an important clinical problem depends on the extent of the inhibition of P450 2D6 by the antidepressant and the therapeutic index of the co-administered drug.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	to
4	14	18	O	which
5	20	23	O	this
6	25	35	O	interaction
7	37	38	O	is
8	40	41	O	an
9	43	51	O	important
10	53	60	O	clinical
11	62	68	O	problem
12	70	76	O	depends
13	78	79	O	on
14	81	83	O	the
15	85	90	O	extent
16	92	93	O	of
17	95	97	O	the
18	99	108	O	inhibition
19	110	111	O	of
20	113	116	O	P450
21	118	120	O	2D6
22	122	123	O	by
23	125	127	O	the
24	129	142	O	antidepressant
25	144	146	O	and
26	148	150	O	the
27	152	162	O	therapeutic
28	164	168	O	index
29	170	171	O	of
30	173	175	O	the
31	177	178	O	co
32	180	191	O	administered
33	193	196	O	drug
NULL

Sertraline Hydrochloride	1518	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	44
There is variability among the drugs effective in the treatment of major depressive disorder in the extent of clinically important 2D6 inhibition, and in fact sertraline at lower doses has a less prominent inhibitory effect on 2D6 than some others in the class.
1	0	4	O	There
2	6	7	O	is
3	9	19	O	variability
4	21	25	O	among
5	27	29	O	the
6	31	35	O	drugs
7	37	45	O	effective
8	47	48	O	in
9	50	52	O	the
10	54	62	O	treatment
11	64	65	O	of
12	67	71	O	major
13	73	82	O	depressive
14	84	91	O	disorder
15	93	94	O	in
16	96	98	O	the
17	100	105	O	extent
18	107	108	O	of
19	110	119	O	clinically
20	121	129	O	important
21	131	133	O	2D6
22	135	144	O	inhibition
23	145	145	O	,
24	147	149	O	and
25	151	152	O	in
26	154	157	O	fact
27	159	168	O	XXXXXXXX
28	170	171	O	at
29	173	177	O	lower
30	179	183	O	doses
31	185	187	O	has
32	189	189	O	a
33	191	194	O	less
34	196	204	O	prominent
35	206	215	O	inhibitory
36	217	222	O	effect
37	224	225	O	on
38	227	229	O	2D6
39	231	234	O	than
40	236	239	O	some
41	241	246	O	others
42	248	249	O	in
43	251	253	O	the
44	255	259	O	class
NULL

Sertraline Hydrochloride	1519	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	12
Nevertheless, even sertraline has the potential for clinically important 2D6 inhibition.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	17	O	even
4	19	28	O	XXXXXXXX
5	30	32	O	has
6	34	36	O	the
7	38	46	O	potential
8	48	50	O	for
9	52	61	O	clinically
10	63	71	O	important
11	73	75	O	2D6
12	77	86	O	inhibition
NULL

Sertraline Hydrochloride	1520	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	24
Consequently, concomitant use of a drug metabolized by P450 2D6 with sertraline hydrochloride may require lower doses than usually prescribed for the other drug.
1	0	11	O	Consequently
2	12	12	O	,
3	14	24	O	concomitant
4	26	28	O	use
5	30	31	O	of
6	33	33	O	a
7	35	38	B-KIN	drug
8	40	50	I-KIN	metabolized
9	52	53	I-KIN	by
10	55	58	I-KIN	P450
11	60	62	L-KIN	2D6
12	64	67	O	with
13	69	92	O	XXXXXXXX
14	94	96	O	may
15	98	104	O	require
16	106	110	O	lower
17	112	116	O	doses
18	118	121	O	than
19	123	129	O	usually
20	131	140	O	prescribed
21	142	144	O	for
22	146	148	O	the
23	150	154	O	other
24	156	159	O	drug
K/7:C54357

Sertraline Hydrochloride	1521	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	21
Furthermore, whenever sertraline hydrochloride is withdrawn from co-therapy, an increased dose of the co-administered drug may be required.
1	0	10	O	Furthermore
2	11	11	O	,
3	13	20	O	whenever
4	22	45	O	XXXXXXXX
5	47	48	O	is
6	50	58	O	withdrawn
7	60	63	O	from
8	65	66	O	co
9	68	74	O	therapy
10	75	75	O	,
11	77	78	O	an
12	80	88	O	increased
13	90	93	O	dose
14	95	96	O	of
15	98	100	O	the
16	102	103	O	co
17	105	116	O	administered
18	118	121	O	drug
19	123	125	O	may
20	127	128	O	be
21	130	137	O	required
NULL

Sertraline Hydrochloride	1522	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	10
Serotonergic Drugs-SeeCONTRAINDICATIONS, WARNINGS, and DOSAGE AND ADMINISTRATION.
1	0	11	B-UNK	Serotonergic
2	13	17	L-UNK	Drugs
3	19	38	O	SeeCONTRAINDICATIONS
4	39	39	O	,
5	41	48	O	WARNINGS
6	49	49	O	,
7	51	53	O	and
8	55	60	O	DOSAGE
9	62	64	O	AND
10	66	79	O	ADMINISTRATION
NULL

Sertraline Hydrochloride	1523	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Triptans - There have been rare post marketing reports of serotonin hydrochloride syndrome with use of an SNRI or an SSRI and a triptan.
1	0	7	U-DYN	Triptans
2	11	15	O	There
3	17	20	O	have
4	22	25	O	been
5	27	30	O	rare
6	32	35	O	post
7	37	45	O	marketing
8	47	53	O	reports
9	55	56	O	of
10	58	66	B-EFF	serotonin
11	68	80	I-EFF	hydrochloride
12	82	89	L-EFF	syndrome
13	91	94	O	with
14	96	98	O	use
15	100	101	O	of
16	103	104	O	an
17	106	109	O	SNRI
18	111	112	O	or
19	114	115	O	an
20	117	120	O	SSRI
21	122	124	O	and
22	126	126	O	a
23	128	134	U-DYN	triptan
D/1:10:1 D/23:10:1

Sertraline Hydrochloride	1524	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	33
If concomitant treatment of SNRIs and SSRIs, including sertraline hydrochloride, with a triptan is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	26	O	of
5	28	32	O	SNRIs
6	34	36	O	and
7	38	42	O	SSRIs
8	43	43	O	,
9	45	53	O	including
10	55	78	O	XXXXXXXX
11	79	79	O	,
12	81	84	O	with
13	86	86	O	a
14	88	94	U-UNK	triptan
15	96	97	O	is
16	99	108	O	clinically
17	110	118	O	warranted
18	119	119	O	,
19	121	127	B-TRI	careful
20	129	139	L-TRI	observation
21	141	142	O	of
22	144	146	O	the
23	148	154	O	patient
24	156	157	O	is
25	159	165	O	advised
26	166	166	O	,
27	168	179	O	particularly
28	181	186	O	during
29	188	196	O	treatment
30	198	207	O	initiation
31	209	211	O	and
32	213	216	O	dose
33	218	226	O	increases
NULL

Sertraline Hydrochloride	1525	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	29
Sumatriptan-There have been rare post marketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a selective serotonin reuptake inhibitor (SSRI) and sumatriptan.
1	0	10	O	Sumatriptan
2	12	16	O	There
3	18	21	O	have
4	23	26	O	been
5	28	31	O	rare
6	33	36	O	post
7	38	46	O	marketing
8	48	54	O	reports
9	56	65	O	describing
10	67	74	O	patients
11	76	79	O	with
12	81	88	U-EFF	weakness
13	89	89	O	,
14	91	103	U-EFF	hyperreflexia
15	104	104	O	,
16	106	108	O	and
17	110	123	U-EFF	incoordination
18	125	133	O	following
19	135	137	O	the
20	139	141	O	use
21	143	144	O	of
22	146	146	O	a
23	148	156	O	selective
24	158	166	O	serotonin
25	168	175	O	reuptake
26	177	185	O	inhibitor
27	188	191	O	SSRI
28	194	196	O	and
29	198	208	U-DYN	sumatriptan
D/29:12:1 D/29:14:1 D/29:17:1

Sertraline Hydrochloride	1526	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	30
If concomitant treatment with sumatriptan and an SSRI (e.g., citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) is clinically warranted, appropriate observation of the patient is advised.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	40	O	sumatriptan
6	42	44	O	and
7	46	47	O	an
8	49	52	O	SSRI
9	55	57	O	e.g
10	59	59	O	,
11	61	70	O	citalopram
12	71	71	O	,
13	73	82	O	fluoxetine
14	83	83	O	,
15	85	95	O	fluvoxamine
16	96	96	O	,
17	98	107	O	paroxetine
18	108	108	O	,
19	110	119	O	XXXXXXXX
20	122	123	O	is
21	125	134	O	clinically
22	136	144	O	warranted
23	145	145	O	,
24	147	157	O	appropriate
25	159	169	O	observation
26	171	172	O	of
27	174	176	O	the
28	178	184	O	patient
29	186	187	O	is
30	189	195	O	advised
NULL

Sertraline Hydrochloride	1527	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	36
Tricyclic Antidepressant Drugs Effective in the Treatment of Major Depressive Disorder(TCAs)-The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.
1	0	8	O	Tricyclic
2	10	23	O	Antidepressant
3	25	29	O	Drugs
4	31	39	O	Effective
5	41	42	O	in
6	44	46	O	the
7	48	56	O	Treatment
8	58	59	O	of
9	61	65	O	Major
10	67	76	O	Depressive
11	78	90	O	Disorder(TCAs
12	93	95	O	The
13	97	102	O	extent
14	104	105	O	to
15	107	111	O	which
16	113	116	O	SSRI
17	118	120	O	TCA
18	122	133	U-TRI	interactions
19	135	137	O	may
20	139	142	O	pose
21	144	151	O	clinical
22	153	160	O	problems
23	162	165	O	will
24	167	172	O	depend
25	174	175	O	on
26	177	179	O	the
27	181	186	O	degree
28	188	189	O	of
29	191	200	O	inhibition
30	202	204	O	and
31	206	208	O	the
32	210	225	O	pharmacokinetics
33	227	228	O	of
34	230	232	O	the
35	234	237	O	SSRI
36	239	246	O	involved
NULL

Sertraline Hydrochloride	1528	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	20
Nevertheless, caution is indicated in the co-administration of TCAs with sertraline hydrochloride, because sertraline may inhibit TCA metabolism.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	20	O	caution
4	22	23	O	is
5	25	33	O	indicated
6	35	36	O	in
7	38	40	O	the
8	42	43	O	co
9	45	58	O	administration
10	60	61	O	of
11	63	66	O	TCAs
12	68	71	O	with
13	73	96	O	XXXXXXXX
14	97	97	O	,
15	99	105	O	because
16	107	116	O	XXXXXXXX
17	118	120	O	may
18	122	128	O	inhibit
19	130	132	O	TCA
20	134	143	O	metabolism
NULL

Sertraline Hydrochloride	1529	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	28
Plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced, if a TCA is co-administered with sertraline hydrochloride.
1	0	5	O	Plasma
2	7	9	U-KIN	TCA
3	11	24	O	concentrations
4	26	28	O	may
5	30	33	O	need
6	35	36	O	to
7	38	39	O	be
8	41	49	O	monitored
9	50	50	O	,
10	52	54	O	and
11	56	58	O	the
12	60	63	O	dose
13	65	66	O	of
14	68	70	O	TCA
15	72	74	O	may
16	76	79	O	need
17	81	82	O	to
18	84	85	O	be
19	87	93	O	reduced
20	94	94	O	,
21	96	97	O	if
22	99	99	O	a
23	101	103	O	TCA
24	105	106	O	is
25	108	109	O	co
26	111	122	O	administered
27	124	127	O	with
28	129	152	O	XXXXXXXX
K/2:C54357

Sertraline Hydrochloride	1530	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	46
Hypoglycemic Drugs-In a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose.
1	0	11	O	Hypoglycemic
2	13	17	O	Drugs
3	19	20	O	In
4	22	22	O	a
5	24	30	O	placebo
6	32	41	O	controlled
7	43	47	O	trial
8	49	50	O	in
9	52	57	O	normal
10	59	68	O	volunteers
11	69	69	O	,
12	71	84	O	administration
13	86	87	O	of
14	89	98	O	XXXXXXXX
15	100	102	O	for
16	104	105	O	22
17	107	110	O	days
18	113	121	O	including
19	123	125	O	200
20	127	128	O	mg
21	129	129	O	/
22	130	132	O	day
23	134	136	O	for
24	138	140	O	the
25	142	146	O	final
26	148	149	O	13
27	151	154	O	days
28	157	162	O	caused
29	164	164	O	a
30	166	178	O	statistically
31	180	190	O	significant
32	192	194	O	16%
33	196	203	O	decrease
34	205	208	O	from
35	210	217	O	baseline
36	219	220	O	in
37	222	224	O	the
38	226	234	O	clearance
39	236	237	O	of
40	239	249	U-KIN	tolbutamide
41	251	259	O	following
42	261	262	O	an
43	264	274	O	intravenous
44	276	279	O	1000
45	281	282	O	mg
46	284	287	O	dose
K/40:C54357

Sertraline Hydrochloride	1531	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	36
Sertraline hydrochloride administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug.
1	0	23	O	XXXXXXXX
2	25	38	O	administration
3	40	42	O	did
4	44	46	O	not
5	48	57	O	noticeably
6	59	64	O	change
7	66	71	O	either
8	73	75	O	the
9	77	82	O	plasma
10	84	90	O	protein
11	92	98	O	binding
12	100	101	O	or
13	103	105	O	the
14	107	114	O	apparent
15	116	121	O	volume
16	123	124	O	of
17	126	137	O	distribution
18	139	140	O	of
19	142	152	U-KIN	tolbutamide
20	153	153	O	,
21	155	164	O	suggesting
22	166	169	O	that
23	171	173	O	the
24	175	183	B-TRI	decreased
25	185	193	L-TRI	clearance
26	195	197	O	was
27	199	201	O	due
28	203	204	O	to
29	206	206	O	a
30	208	213	O	change
31	215	216	O	in
32	218	220	O	the
33	222	231	O	metabolism
34	233	234	O	of
35	236	238	O	the
36	240	243	O	drug
K/19:C54357

Sertraline Hydrochloride	1532	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	11
The clinical significance of this decrease in tolbutamide clearance is unknown.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	41	O	decrease
7	43	44	O	in
8	46	56	U-KIN	tolbutamide
9	58	66	O	clearance
10	68	69	O	is
11	71	77	O	unknown
K/8:C54357

Sertraline Hydrochloride	1533	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	22
Atenolol-Sertraline (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol.
1	0	7	O	Atenolol
2	9	18	O	XXXXXXXX
3	21	23	O	100
4	25	26	O	mg
5	29	32	O	when
6	34	45	O	administered
7	47	48	O	to
8	50	51	O	10
9	53	59	O	healthy
10	61	64	O	male
11	66	73	O	subjects
12	75	77	O	had
13	79	80	O	no
14	82	87	O	effect
15	89	90	O	on
16	92	94	O	the
17	96	99	O	beta
18	101	110	O	adrenergic
19	112	119	O	blocking
20	121	127	O	ability
21	129	130	O	of
22	132	139	O	atenolol
NULL

Sertraline Hydrochloride	1534	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	36
Digoxin-In a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.
1	0	6	O	Digoxin
2	8	9	O	In
3	11	11	O	a
4	13	19	O	placebo
5	21	30	O	controlled
6	32	36	O	trial
7	38	39	O	in
8	41	46	O	normal
9	48	57	O	volunteers
10	58	58	O	,
11	60	73	O	administration
12	75	76	O	of
13	78	87	O	XXXXXXXX
14	89	91	O	for
15	93	94	O	17
16	96	99	O	days
17	102	110	O	including
18	112	114	O	200
19	116	117	O	mg
20	118	118	O	/
21	119	121	O	day
22	123	125	O	for
23	127	129	O	the
24	131	134	O	last
25	136	137	O	10
26	139	142	O	days
27	145	147	O	did
28	149	151	O	not
29	153	158	O	change
30	160	164	O	serum
31	166	172	O	digoxin
32	174	179	O	levels
33	181	182	O	or
34	184	190	O	digoxin
35	192	196	O	renal
36	198	206	O	clearance
NULL

Sertraline Hydrochloride	1535	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	13
Microsomal Enzyme Induction-Preclinical studies have shown sertraline to induce hepatic microsomal enzymes.
1	0	9	O	Microsomal
2	11	16	O	Enzyme
3	18	26	O	Induction
4	28	38	O	Preclinical
5	40	46	O	studies
6	48	51	O	have
7	53	57	O	shown
8	59	68	O	XXXXXXXX
9	70	71	O	to
10	73	78	O	induce
11	80	86	O	hepatic
12	88	97	O	microsomal
13	99	105	O	enzymes
NULL

Sertraline Hydrochloride	1536	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	36
In clinical studies, sertraline hydrochloride was shown to induce hepatic enzymes minimally as determined by a small (5%) but statistically significant decrease in antipyrine half-life following administration of 200 mg/day for 21 days.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	44	O	XXXXXXXX
6	46	48	O	was
7	50	54	O	shown
8	56	57	O	to
9	59	64	O	induce
10	66	72	O	hepatic
11	74	80	O	enzymes
12	82	90	O	minimally
13	92	93	O	as
14	95	104	O	determined
15	106	107	O	by
16	109	109	O	a
17	111	115	O	small
18	118	119	O	5%
19	122	124	O	but
20	126	138	O	statistically
21	140	150	O	significant
22	152	159	O	decrease
23	161	162	O	in
24	164	173	U-KIN	antipyrine
25	175	178	O	half
26	180	183	O	life
27	185	193	O	following
28	195	208	O	administration
29	210	211	O	of
30	213	215	O	200
31	217	218	O	mg
32	219	219	O	/
33	220	222	O	day
34	224	226	O	for
35	228	229	O	21
36	231	234	O	days
K/24:C54616

Sertraline Hydrochloride	1537	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	15
This small change in antipyrine half-life reflects a clinically insignificant change in hepatic metabolism.
1	0	3	O	This
2	5	9	O	small
3	11	16	O	change
4	18	19	O	in
5	21	30	O	antipyrine
6	32	35	O	half
7	37	40	O	life
8	42	49	O	reflects
9	51	51	O	a
10	53	62	O	clinically
11	64	76	O	insignificant
12	78	83	O	change
13	85	86	O	in
14	88	94	O	hepatic
15	96	105	O	metabolism
NULL

Sertraline Hydrochloride	1538	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	14
Drugs That Interfere With Hemostasis (Non-selective NSAIDs, Aspirin, Warfarin, etc.
1	0	4	O	Drugs
2	6	9	O	That
3	11	19	O	Interfere
4	21	24	O	With
5	26	35	O	Hemostasis
6	38	40	O	Non
7	42	50	O	selective
8	52	57	O	NSAIDs
9	58	58	O	,
10	60	66	O	Aspirin
11	67	67	O	,
12	69	76	O	Warfarin
13	77	77	O	,
14	79	81	O	etc
NULL

Sertraline Hydrochloride	1539	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	10
)-Serotonin release by platelets plays an important role in hemostasis.
1	2	10	O	Serotonin
2	12	18	O	release
3	20	21	O	by
4	23	31	O	platelets
5	33	37	O	plays
6	39	40	O	an
7	42	50	O	important
8	52	55	O	role
9	57	58	O	in
10	60	69	O	hemostasis
NULL

Sertraline Hydrochloride	1540	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	48
Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	14	O	Epidemiological
2	16	22	O	studies
3	24	25	O	of
4	27	29	O	the
5	31	34	O	case
6	36	42	O	control
7	44	46	O	and
8	48	53	O	cohort
9	55	60	O	design
10	62	65	O	that
11	67	70	O	have
12	72	83	O	demonstrated
13	85	86	O	an
14	88	98	O	association
15	100	106	O	between
16	108	110	O	use
17	112	113	O	of
18	115	126	O	psychotropic
19	128	132	O	drugs
20	134	137	O	that
21	139	147	O	interfere
22	149	152	O	with
23	154	162	O	serotonin
24	164	171	O	reuptake
25	173	175	O	and
26	177	179	O	the
27	181	190	O	occurrence
28	192	193	O	of
29	195	199	O	upper
30	201	216	O	gastrointestinal
31	218	225	U-EFF	bleeding
32	227	230	O	have
33	232	235	O	also
34	237	241	O	shown
35	243	246	O	that
36	248	257	O	concurrent
37	259	261	O	use
38	263	264	O	of
39	266	267	O	an
40	269	273	U-DYN	NSAID
41	275	276	O	or
42	278	284	U-DYN	aspirin
43	286	288	O	may
44	290	299	O	potentiate
45	301	304	O	this
46	306	309	O	risk
47	311	312	O	of
48	314	321	O	bleeding
D/40:31:1 D/42:31:1

Sertraline Hydrochloride	1541	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	19
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	92	O	or
15	94	98	O	SNRIs
16	100	102	O	are
17	104	117	O	coadministered
18	119	122	O	with
19	124	131	U-DYN	warfarin
D/19:1:1 D/19:6:1

Sertraline Hydrochloride	1542	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	14
Patients receiving warfarin therapy should be carefully monitored when sertraline hydrochloride is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	O	should
6	43	44	O	be
7	46	54	O	carefully
8	56	64	U-TRI	monitored
9	66	69	O	when
10	71	94	O	XXXXXXXX
11	96	97	O	is
12	99	107	O	initiated
13	109	110	O	or
14	112	123	O	discontinued
NULL

Sertraline Hydrochloride	1543	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	22
Electroconvulsive Therapy-There are no clinical studies establishing the risks or benefits of the combined use of electroconvulsive therapy (ECT) and sertraline.
1	0	16	O	Electroconvulsive
2	18	24	O	Therapy
3	26	30	O	There
4	32	34	O	are
5	36	37	O	no
6	39	46	O	clinical
7	48	54	O	studies
8	56	67	O	establishing
9	69	71	O	the
10	73	77	O	risks
11	79	80	O	or
12	82	89	O	benefits
13	91	92	O	of
14	94	96	O	the
15	98	105	O	combined
16	107	109	O	use
17	111	112	O	of
18	114	130	O	electroconvulsive
19	132	138	O	therapy
20	141	143	O	ECT
21	146	148	O	and
22	150	159	O	XXXXXXXX
NULL

Sertraline Hydrochloride	1544	34073-7	c25f968b-7037-4f60-9a02-2189769b0cbf	29
Alcohol-Although sertraline did not potentiate the cognitive and psychomotor effects of alcohol in experiments with normal subjects, the concomitant use of sertraline and alcohol is not recommended.
1	0	6	O	Alcohol
2	8	15	O	Although
3	17	26	O	XXXXXXXX
4	28	30	O	did
5	32	34	O	not
6	36	45	O	potentiate
7	47	49	O	the
8	51	59	O	cognitive
9	61	63	O	and
10	65	75	O	psychomotor
11	77	83	O	effects
12	85	86	O	of
13	88	94	O	alcohol
14	96	97	O	in
15	99	109	O	experiments
16	111	114	O	with
17	116	121	O	normal
18	123	130	O	subjects
19	131	131	O	,
20	133	135	O	the
21	137	147	O	concomitant
22	149	151	O	use
23	153	154	O	of
24	156	165	O	XXXXXXXX
25	167	169	O	and
26	171	177	O	alcohol
27	179	180	O	is
28	182	184	O	not
29	186	196	O	recommended
NULL

Sertraline Hydrochloride	1545	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	21
The mechanism of action of sertraline is presumed to be linked to its inhibition of CNS neuronal uptake of serotonin (5HT).
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	39	O	is
8	41	48	O	presumed
9	50	51	O	to
10	53	54	O	be
11	56	61	O	linked
12	63	64	O	to
13	66	68	O	its
14	70	79	O	inhibition
15	81	82	O	of
16	84	86	O	CNS
17	88	95	O	neuronal
18	97	102	O	uptake
19	104	105	O	of
20	107	115	O	serotonin
21	118	120	O	5HT
NULL

Sertraline Hydrochloride	1546	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	19
Studies at clinically relevant doses in man have demonstrated that sertraline blocks the uptake of serotonin into human platelets.
1	0	6	O	Studies
2	8	9	O	at
3	11	20	O	clinically
4	22	29	O	relevant
5	31	35	O	doses
6	37	38	O	in
7	40	42	O	man
8	44	47	O	have
9	49	60	O	demonstrated
10	62	65	O	that
11	67	76	O	XXXXXXXX
12	78	83	O	blocks
13	85	87	O	the
14	89	94	O	uptake
15	96	97	O	of
16	99	107	O	serotonin
17	109	112	O	into
18	114	118	O	human
19	120	128	O	platelets
NULL

Sertraline Hydrochloride	1547	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	31
In vitro studies in animals also suggest that sertraline is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	18	O	in
5	20	26	O	animals
6	28	31	O	also
7	33	39	O	suggest
8	41	44	O	that
9	46	55	O	XXXXXXXX
10	57	58	O	is
11	60	60	O	a
12	62	67	O	potent
13	69	71	O	and
14	73	81	O	selective
15	83	91	O	inhibitor
16	93	94	O	of
17	96	103	O	neuronal
18	105	113	O	serotonin
19	115	122	O	reuptake
20	124	126	O	and
21	128	130	O	has
22	132	135	O	only
23	137	140	O	very
24	142	145	O	weak
25	147	153	O	effects
26	155	156	O	on
27	158	171	O	norepinephrine
28	173	175	O	and
29	177	184	O	dopamine
30	186	193	O	neuronal
31	195	202	O	reuptake
NULL

Sertraline Hydrochloride	1548	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	60
In vitro studies have shown that sertraline has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	20	O	have
5	22	26	O	shown
6	28	31	O	that
7	33	42	O	XXXXXXXX
8	44	46	O	has
9	48	49	O	no
10	51	61	O	significant
11	63	70	O	affinity
12	72	74	O	for
13	76	85	O	adrenergic
14	88	93	O	alpha1
15	94	94	O	,
16	96	101	O	alpha2
17	102	102	O	,
18	104	107	O	beta
19	109	109	O	,
20	111	121	O	cholinergic
21	122	122	O	,
22	124	127	O	GABA
23	128	128	O	,
24	130	141	O	dopaminergic
25	142	142	O	,
26	144	156	O	histaminergic
27	157	157	O	,
28	159	170	O	serotonergic
29	173	177	O	5HT1A
30	178	178	O	,
31	180	184	O	5HT1B
32	185	185	O	,
33	187	190	O	5HT2
34	192	192	O	,
35	194	195	O	or
36	197	210	O	benzodiazepine
37	212	220	O	receptors
38	223	232	O	antagonism
39	234	235	O	of
40	237	240	O	such
41	242	250	O	receptors
42	252	254	O	has
43	256	259	O	been
44	261	272	O	hypothesized
45	274	275	O	to
46	277	278	O	be
47	280	289	O	associated
48	291	294	O	with
49	296	302	O	various
50	304	318	O	anticholinergic
51	319	319	O	,
52	321	328	O	sedative
53	329	329	O	,
54	331	333	O	and
55	335	348	O	cardiovascular
56	350	356	O	effects
57	358	360	O	for
58	362	366	O	other
59	368	379	O	psychotropic
60	381	385	O	drugs
NULL

Sertraline Hydrochloride	1549	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	31
The chronic administration of sertraline was found in animals to down regulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder.
1	0	2	O	The
2	4	10	O	chronic
3	12	25	O	administration
4	27	28	O	of
5	30	39	O	XXXXXXXX
6	41	43	O	was
7	45	49	O	found
8	51	52	O	in
9	54	60	O	animals
10	62	63	O	to
11	65	68	O	down
12	70	77	O	regulate
13	79	83	O	brain
14	85	98	O	norepinephrine
15	100	108	O	receptors
16	109	109	O	,
17	111	112	O	as
18	114	116	O	has
19	118	121	O	been
20	123	130	O	observed
21	132	135	O	with
22	137	141	O	other
23	143	147	O	drugs
24	149	157	O	effective
25	159	160	O	in
26	162	164	O	the
27	166	174	O	treatment
28	176	177	O	of
29	179	183	O	major
30	185	194	O	depressive
31	196	203	O	disorder
NULL

Sertraline Hydrochloride	1550	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	6
Sertraline does not inhibit monoamine oxidase.
1	0	9	O	XXXXXXXX
2	11	14	O	does
3	16	18	O	not
4	20	26	O	inhibit
5	28	36	O	monoamine
6	38	44	O	oxidase
NULL

Sertraline Hydrochloride	1551	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	37
Systemic Bioavailability-In man, following oral once-daily dosing over the range of 50 to 200 mg for 14 days, mean peak plasma concentrations (Cmax) of sertraline occurred between 4.5 to 8.4 hours post-dosing.
1	0	7	O	Systemic
2	9	23	O	Bioavailability
3	25	26	O	In
4	28	30	O	man
5	31	31	O	,
6	33	41	O	following
7	43	46	O	oral
8	48	51	O	once
9	53	57	O	daily
10	59	64	O	dosing
11	66	69	O	over
12	71	73	O	the
13	75	79	O	range
14	81	82	O	of
15	84	85	O	50
16	87	88	O	to
17	90	92	O	200
18	94	95	O	mg
19	97	99	O	for
20	101	102	O	14
21	104	107	O	days
22	108	108	O	,
23	110	113	O	mean
24	115	118	O	peak
25	120	125	O	plasma
26	127	140	O	concentrations
27	143	146	O	Cmax
28	149	150	O	of
29	152	161	O	XXXXXXXX
30	163	170	O	occurred
31	172	178	O	between
32	180	182	O	4.5
33	184	185	O	to
34	187	189	O	8.4
35	191	195	O	hours
36	197	200	O	post
37	202	207	O	dosing
NULL

Sertraline Hydrochloride	1552	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	13
The average terminal elimination half-life of plasma sertraline is about 26 hours.
1	0	2	O	The
2	4	10	O	average
3	12	19	O	terminal
4	21	31	O	elimination
5	33	36	O	half
6	38	41	O	life
7	43	44	O	of
8	46	51	O	plasma
9	53	62	O	XXXXXXXX
10	64	65	O	is
11	67	71	O	about
12	73	74	O	26
13	76	80	O	hours
NULL

Sertraline Hydrochloride	1553	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	22
Based on this pharmacokinetic parameter, steady-state sertraline plasma levels should be achieved after approximately one week of once-daily dosing.
1	0	4	O	Based
2	6	7	O	on
3	9	12	O	this
4	14	28	O	pharmacokinetic
5	30	38	O	parameter
6	39	39	O	,
7	41	46	O	steady
8	48	52	O	state
9	54	63	O	XXXXXXXX
10	65	70	O	plasma
11	72	77	O	levels
12	79	84	O	should
13	86	87	O	be
14	89	96	O	achieved
15	98	102	O	after
16	104	116	O	approximately
17	118	120	O	one
18	122	125	O	week
19	127	128	O	of
20	130	133	O	once
21	135	139	O	daily
22	141	146	O	dosing
NULL

Sertraline Hydrochloride	1554	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	38
Linear dose-proportional pharmacokinetics were demonstrated in a single dose study in which the Cmax and area under the plasma concentration time curve (AUC) of sertraline were proportional to dose over a range of 50 to 200 mg.
1	0	5	O	Linear
2	7	10	O	dose
3	12	23	O	proportional
4	25	40	O	pharmacokinetics
5	42	45	O	were
6	47	58	O	demonstrated
7	60	61	O	in
8	63	63	O	a
9	65	70	O	single
10	72	75	O	dose
11	77	81	O	study
12	83	84	O	in
13	86	90	O	which
14	92	94	O	the
15	96	99	O	Cmax
16	101	103	O	and
17	105	108	O	area
18	110	114	O	under
19	116	118	O	the
20	120	125	O	plasma
21	127	139	O	concentration
22	141	144	O	time
23	146	150	O	curve
24	153	155	O	AUC
25	158	159	O	of
26	161	170	O	XXXXXXXX
27	172	175	O	were
28	177	188	O	proportional
29	190	191	O	to
30	193	196	O	dose
31	198	201	O	over
32	203	203	O	a
33	205	209	O	range
34	211	212	O	of
35	214	215	O	50
36	217	218	O	to
37	220	222	O	200
38	224	225	O	mg
NULL

Sertraline Hydrochloride	1555	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	35
Consistent with the terminal elimination half-life, there is an approximately two-fold accumulation, compared to a single dose, of sertraline with repeated dosing over a 50 to 200 mg dose range.
1	0	9	O	Consistent
2	11	14	O	with
3	16	18	O	the
4	20	27	O	terminal
5	29	39	O	elimination
6	41	44	O	half
7	46	49	O	life
8	50	50	O	,
9	52	56	O	there
10	58	59	O	is
11	61	62	O	an
12	64	76	O	approximately
13	78	80	O	two
14	82	85	O	fold
15	87	98	O	accumulation
16	99	99	O	,
17	101	108	O	compared
18	110	111	O	to
19	113	113	O	a
20	115	120	O	single
21	122	125	O	dose
22	126	126	O	,
23	128	129	O	of
24	131	140	O	XXXXXXXX
25	142	145	O	with
26	147	154	O	repeated
27	156	161	O	dosing
28	163	166	O	over
29	168	168	O	a
30	170	171	O	50
31	173	174	O	to
32	176	178	O	200
33	180	181	O	mg
34	183	186	O	dose
35	188	192	O	range
NULL

Sertraline Hydrochloride	1556	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	16
The single dose bioavailability of sertraline tablets is approximately equal to an equivalent dose of solution.
1	0	2	O	The
2	4	9	O	single
3	11	14	O	dose
4	16	30	O	bioavailability
5	32	33	O	of
6	35	44	O	XXXXXXXX
7	46	52	O	tablets
8	54	55	O	is
9	57	69	O	approximately
10	71	75	O	equal
11	77	78	O	to
12	80	81	O	an
13	83	92	O	equivalent
14	94	97	O	dose
15	99	100	O	of
16	102	109	O	solution
NULL

Sertraline Hydrochloride	1557	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	45
In a relative bioavailability study comparing the pharmacokinetics of 100 mg sertraline as the oral solution to a 100 mg sertraline tablet in 16 healthy adults, the solution to tablet ratio of geometric mean AUC and Cmax values were 114.8% and 120.6%, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	relative
4	14	28	O	bioavailability
5	30	34	O	study
6	36	44	O	comparing
7	46	48	O	the
8	50	65	O	pharmacokinetics
9	67	68	O	of
10	70	72	O	100
11	74	75	O	mg
12	77	86	O	XXXXXXXX
13	88	89	O	as
14	91	93	O	the
15	95	98	O	oral
16	100	107	O	solution
17	109	110	O	to
18	112	112	O	a
19	114	116	O	100
20	118	119	O	mg
21	121	130	O	XXXXXXXX
22	132	137	O	tablet
23	139	140	O	in
24	142	143	O	16
25	145	151	O	healthy
26	153	158	O	adults
27	159	159	O	,
28	161	163	O	the
29	165	172	O	solution
30	174	175	O	to
31	177	182	O	tablet
32	184	188	O	ratio
33	190	191	O	of
34	193	201	O	geometric
35	203	206	O	mean
36	208	210	O	AUC
37	212	214	O	and
38	216	219	O	Cmax
39	221	226	O	values
40	228	231	O	were
41	233	238	O	114.8%
42	240	242	O	and
43	244	249	O	120.6%
44	250	250	O	,
45	252	263	O	respectively
NULL

Sertraline Hydrochloride	1558	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	26
90% confidence intervals (CI) were within the range of 80 to 125% with the exception of the upper 90% CI limit for Cmax which was 126.5%.
1	0	2	O	90%
2	4	13	O	confidence
3	15	23	O	intervals
4	26	27	O	CI
5	30	33	O	were
6	35	40	O	within
7	42	44	O	the
8	46	50	O	range
9	52	53	O	of
10	55	56	O	80
11	58	59	O	to
12	61	64	O	125%
13	66	69	O	with
14	71	73	O	the
15	75	83	O	exception
16	85	86	O	of
17	88	90	O	the
18	92	96	O	upper
19	98	100	O	90%
20	102	103	O	CI
21	105	109	O	limit
22	111	113	O	for
23	115	118	O	Cmax
24	120	124	O	which
25	126	128	O	was
26	130	135	O	126.5%
NULL

Sertraline Hydrochloride	1559	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	26
The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	18	O	food
5	20	21	O	on
6	23	25	O	the
7	27	41	O	bioavailability
8	43	44	O	of
9	46	48	O	the
10	50	59	O	XXXXXXXX
11	61	66	O	tablet
12	68	70	O	and
13	72	75	O	oral
14	77	87	O	concentrate
15	89	92	O	were
16	94	100	O	studied
17	102	103	O	in
18	105	112	O	subjects
19	114	125	O	administered
20	127	127	O	a
21	129	134	O	single
22	136	139	O	dose
23	141	144	O	with
24	146	148	O	and
25	150	156	O	without
26	158	161	O	food
NULL

Sertraline Hydrochloride	1560	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	39
For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours.
1	0	2	O	For
2	4	6	O	the
3	8	13	O	tablet
4	14	14	O	,
5	16	18	O	AUC
6	20	22	O	was
7	24	31	O	slightly
8	33	41	O	increased
9	43	46	O	when
10	48	51	O	drug
11	53	55	O	was
12	57	68	O	administered
13	70	73	O	with
14	75	78	U-KIN	food
15	80	82	O	but
16	84	86	O	the
17	88	91	O	Cmax
18	93	95	O	was
19	97	99	O	25%
20	101	107	O	greater
21	108	108	O	,
22	110	114	O	while
23	116	118	O	the
24	120	123	O	time
25	125	126	O	to
26	128	132	O	reach
27	134	137	O	peak
28	139	144	O	plasma
29	146	158	O	concentration
30	161	164	O	Tmax
31	167	175	O	decreased
32	177	180	O	from
33	182	182	O	8
34	184	188	O	hours
35	190	193	O	post
36	195	200	O	dosing
37	202	203	O	to
38	205	207	O	5.5
39	209	213	O	hours
K/14:C54602

Sertraline Hydrochloride	1561	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	17
For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7 hours with food.
1	0	2	O	For
2	4	6	O	the
3	8	11	O	oral
4	13	23	O	concentrate
5	24	24	O	,
6	26	29	O	Tmax
7	31	33	O	was
8	35	42	O	slightly
9	44	52	O	prolonged
10	54	57	O	from
11	59	61	O	5.9
12	63	67	O	hours
13	69	70	O	to
14	72	72	O	7
15	74	78	O	hours
16	80	83	O	with
17	85	88	U-KIN	food
K/17:C54604

Sertraline Hydrochloride	1562	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	7
Metabolism-Sertraline undergoes extensive first pass metabolism.
1	0	9	O	Metabolism
2	11	20	O	XXXXXXXX
3	22	30	O	undergoes
4	32	40	O	extensive
5	42	46	O	first
6	48	51	O	pass
7	53	62	O	metabolism
NULL

Sertraline Hydrochloride	1563	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	11
The principal initial pathway of metabolism for sertraline is N-demethylation.
1	0	2	O	The
2	4	12	O	principal
3	14	20	O	initial
4	22	28	O	pathway
5	30	31	O	of
6	33	42	O	metabolism
7	44	46	O	for
8	48	57	O	XXXXXXXX
9	59	60	O	is
10	62	62	O	N
11	64	76	O	demethylation
NULL

Sertraline Hydrochloride	1564	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	15
N-desmethylsertraline has a plasma terminal elimination half-life of 62 to 104 hours.
1	0	0	O	N
2	2	10	O	desmethyl
3	11	20	O	XXXXXXXX
4	22	24	O	has
5	26	26	O	a
6	28	33	O	plasma
7	35	42	O	terminal
8	44	54	O	elimination
9	56	59	O	half
10	61	64	O	life
11	66	67	O	of
12	69	70	O	62
13	72	73	O	to
14	75	77	O	104
15	79	83	O	hours
NULL

Sertraline Hydrochloride	1565	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	21
Both in vitro biochemical and in vivo pharmacological testing have shown N-desmethylsertraline to be substantially less active than sertraline.
1	0	3	O	Both
2	5	6	O	in
3	8	12	O	vitro
4	14	24	O	biochemical
5	26	28	O	and
6	30	31	O	in
7	33	36	O	vivo
8	38	52	O	pharmacological
9	54	60	O	testing
10	62	65	O	have
11	67	71	O	shown
12	73	73	O	N
13	75	83	O	desmethyl
14	84	93	O	XXXXXXXX
15	95	96	O	to
16	98	99	O	be
17	101	113	O	substantially
18	115	118	O	less
19	120	125	O	active
20	127	130	O	than
21	132	141	O	XXXXXXXX
NULL

Sertraline Hydrochloride	1566	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	18
Both sertraline and N-desmethylsertraline undergo oxidative deamination and subsequent reduction, hydroxylation, and glucuronide conjugation.
1	0	3	O	Both
2	5	14	O	XXXXXXXX
3	16	18	O	and
4	20	20	O	N
5	22	30	O	desmethyl
6	31	40	O	XXXXXXXX
7	42	48	O	undergo
8	50	58	O	oxidative
9	60	70	O	deamination
10	72	74	O	and
11	76	85	O	subsequent
12	87	95	O	reduction
13	96	96	O	,
14	98	110	O	hydroxylation
15	111	111	O	,
16	113	115	O	and
17	117	127	O	glucuronide
18	129	139	O	conjugation
NULL

Sertraline Hydrochloride	1567	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	22
In a study of radiolabeled sertraline involving two healthy male subjects, sertraline accounted for less than 5% of the plasma radioactivity.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	25	O	radiolabeled
6	27	36	O	XXXXXXXX
7	38	46	O	involving
8	48	50	O	two
9	52	58	O	healthy
10	60	63	O	male
11	65	72	O	subjects
12	73	73	O	,
13	75	84	O	XXXXXXXX
14	86	94	O	accounted
15	96	98	O	for
16	100	103	O	less
17	105	108	O	than
18	110	111	O	5%
19	113	114	O	of
20	116	118	O	the
21	120	125	O	plasma
22	127	139	O	radioactivity
NULL

Sertraline Hydrochloride	1568	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	15
About 40 to 45% of the administered radioactivity was recovered in urine in 9 days.
1	0	4	O	About
2	6	7	O	40
3	9	10	O	to
4	12	14	O	45%
5	16	17	O	of
6	19	21	O	the
7	23	34	O	administered
8	36	48	O	radioactivity
9	50	52	O	was
10	54	62	O	recovered
11	64	65	O	in
12	67	71	O	urine
13	73	74	O	in
14	76	76	O	9
15	78	81	O	days
NULL

Sertraline Hydrochloride	1569	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	8
Unchanged sertraline was not detectable in the urine.
1	0	8	O	Unchanged
2	10	19	O	XXXXXXXX
3	21	23	O	was
4	25	27	O	not
5	29	38	O	detectable
6	40	41	O	in
7	43	45	O	the
8	47	51	O	urine
NULL

Sertraline Hydrochloride	1570	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	25
For the same period, about 40 to 45% of the administered radioactivity was accounted for in feces, including 12 to 14% unchanged sertraline.
1	0	2	O	For
2	4	6	O	the
3	8	11	O	same
4	13	18	O	period
5	19	19	O	,
6	21	25	O	about
7	27	28	O	40
8	30	31	O	to
9	33	35	O	45%
10	37	38	O	of
11	40	42	O	the
12	44	55	O	administered
13	57	69	O	radioactivity
14	71	73	O	was
15	75	83	O	accounted
16	85	87	O	for
17	89	90	O	in
18	92	96	O	feces
19	97	97	O	,
20	99	107	O	including
21	109	110	O	12
22	112	113	O	to
23	115	117	O	14%
24	119	127	O	unchanged
25	129	138	O	XXXXXXXX
NULL

Sertraline Hydrochloride	1571	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	38
Desmethylsertraline exhibits time-related, dose dependent increases in AUC (0 to 24 hour), Cmax and Cmin, with about a 5 to 9 fold increase in these pharmacokinetic parameters between day 1 and day 14.
1	0	8	O	Desmethyl
2	9	18	O	XXXXXXXX
3	20	27	O	exhibits
4	29	32	O	time
5	34	40	O	related
6	41	41	O	,
7	43	46	O	dose
8	48	56	O	dependent
9	58	66	O	increases
10	68	69	O	in
11	71	73	O	AUC
12	76	76	O	0
13	78	79	O	to
14	81	82	O	24
15	84	87	O	hour
16	89	89	O	,
17	91	94	O	Cmax
18	96	98	O	and
19	100	103	O	Cmin
20	104	104	O	,
21	106	109	O	with
22	111	115	O	about
23	117	117	O	a
24	119	119	O	5
25	121	122	O	to
26	124	124	O	9
27	126	129	O	fold
28	131	138	O	increase
29	140	141	O	in
30	143	147	O	these
31	149	163	O	pharmacokinetic
32	165	174	O	parameters
33	176	182	O	between
34	184	186	O	day
35	188	188	O	1
36	190	192	O	and
37	194	196	O	day
38	198	199	O	14
NULL

Sertraline Hydrochloride	1572	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	32
Protein Binding- In vitro protein binding studies performed with radiolabeled 3H-sertraline showed that sertraline is highly bound to serum proteins (98%) in the range of 20 to 500 ng/mL.
1	0	6	O	Protein
2	8	14	O	Binding
3	17	18	O	In
4	20	24	O	vitro
5	26	32	O	protein
6	34	40	O	binding
7	42	48	O	studies
8	50	58	O	performed
9	60	63	O	with
10	65	76	O	radiolabeled
11	78	79	O	3H
12	81	90	O	XXXXXXXX
13	92	97	O	showed
14	99	102	O	that
15	104	113	O	XXXXXXXX
16	115	116	O	is
17	118	123	O	highly
18	125	129	O	bound
19	131	132	O	to
20	134	138	O	serum
21	140	147	O	proteins
22	150	152	O	98%
23	155	156	O	in
24	158	160	O	the
25	162	166	O	range
26	168	169	O	of
27	171	172	O	20
28	174	175	O	to
29	177	179	O	500
30	181	182	O	ng
31	183	183	O	/
32	184	185	O	mL
NULL

Sertraline Hydrochloride	1573	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	40
However, at up to 300 and 200 ng/mL concentrations, respectively, sertraline and N-desmethylsertraline did not alter the plasma protein binding of two other highly protein bound drugs, viz., warfarin and propranolol.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	at
4	12	13	O	up
5	15	16	O	to
6	18	20	O	300
7	22	24	O	and
8	26	28	O	200
9	30	31	O	ng
10	32	32	O	/
11	33	34	O	mL
12	36	49	O	concentrations
13	50	50	O	,
14	52	63	O	respectively
15	64	64	O	,
16	66	75	O	XXXXXXXX
17	77	79	O	and
18	81	81	O	N
19	83	91	O	desmethyl
20	92	101	O	XXXXXXXX
21	103	105	O	did
22	107	109	O	not
23	111	115	O	alter
24	117	119	O	the
25	121	126	O	plasma
26	128	134	O	protein
27	136	142	O	binding
28	144	145	O	of
29	147	149	O	two
30	151	155	O	other
31	157	162	O	highly
32	164	170	O	protein
33	172	176	O	bound
34	178	182	O	drugs
35	183	183	O	,
36	185	187	O	viz
37	189	189	O	,
38	191	198	O	warfarin
39	200	202	O	and
40	204	214	O	propranolol
NULL

Sertraline Hydrochloride	1574	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	40
Pediatric Pharmacokinetics-Sertraline pharmacokinetics were evaluated in a group of 61 pediatric patients (29 aged 6 to 12 years, 32 aged 13 to 17 years) with a DSM-III-R diagnosis of major depressive disorder or obsessive-compulsive disorder.
1	0	8	O	Pediatric
2	10	25	O	Pharmacokinetics
3	27	36	O	XXXXXXXX
4	38	53	O	pharmacokinetics
5	55	58	O	were
6	60	68	O	evaluated
7	70	71	O	in
8	73	73	O	a
9	75	79	O	group
10	81	82	O	of
11	84	85	O	61
12	87	95	O	pediatric
13	97	104	O	patients
14	107	108	O	29
15	110	113	O	aged
16	115	115	O	6
17	117	118	O	to
18	120	121	O	12
19	123	127	O	years
20	128	128	O	,
21	130	131	O	32
22	133	136	O	aged
23	138	139	O	13
24	141	142	O	to
25	144	145	O	17
26	147	151	O	years
27	154	157	O	with
28	159	159	O	a
29	161	163	O	DSM
30	165	167	O	III
31	169	169	O	R
32	171	179	O	diagnosis
33	181	182	O	of
34	184	188	O	major
35	190	199	O	depressive
36	201	208	O	disorder
37	210	211	O	or
38	213	221	O	obsessive
39	223	232	O	compulsive
40	234	241	O	disorder
NULL

Sertraline Hydrochloride	1575	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	12
Patients included both males (N = 28) and females (N = 33).
1	0	7	O	Patients
2	9	16	O	included
3	18	21	O	both
4	23	27	O	males
5	30	30	O	N
6	32	32	O	=
7	34	35	O	28
8	38	40	O	and
9	42	48	O	females
10	51	51	O	N
11	53	53	O	=
12	55	56	O	33
NULL

Sertraline Hydrochloride	1576	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	28
During 42 days of chronic sertraline dosing, sertraline was titrated up to 200 mg/day and maintained at that dose for a minimum of 11 days.
1	0	5	O	During
2	7	8	O	42
3	10	13	O	days
4	15	16	O	of
5	18	24	O	chronic
6	26	35	O	XXXXXXXX
7	37	42	O	dosing
8	43	43	O	,
9	45	54	O	XXXXXXXX
10	56	58	O	was
11	60	67	O	titrated
12	69	70	O	up
13	72	73	O	to
14	75	77	O	200
15	79	80	O	mg
16	81	81	O	/
17	82	84	O	day
18	86	88	O	and
19	90	99	O	maintained
20	101	102	O	at
21	104	107	O	that
22	109	112	O	dose
23	114	116	O	for
24	118	118	O	a
25	120	126	O	minimum
26	128	129	O	of
27	131	132	O	11
28	134	137	O	days
NULL

Sertraline Hydrochloride	1577	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	49
On the final day of sertraline 200 mg/day, the 6 to 12 year old group exhibited a mean sertraline AUC (0 to 24 hr) of 3107 ng-hr/mL, mean Cmax of 165 ng/mL, and mean half-life of 26.2 hr.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	final
4	13	15	O	day
5	17	18	O	of
6	20	29	O	XXXXXXXX
7	31	33	O	200
8	35	36	O	mg
9	37	37	O	/
10	38	40	O	day
11	41	41	O	,
12	43	45	O	the
13	47	47	O	6
14	49	50	O	to
15	52	53	O	12
16	55	58	O	year
17	60	62	O	old
18	64	68	O	group
19	70	78	O	exhibited
20	80	80	O	a
21	82	85	O	mean
22	87	96	O	XXXXXXXX
23	98	100	O	AUC
24	103	103	O	0
25	105	106	O	to
26	108	109	O	24
27	111	112	O	hr
28	115	116	O	of
29	118	121	O	3107
30	123	124	O	ng
31	126	127	O	hr
32	128	128	O	/
33	129	130	O	mL
34	131	131	O	,
35	133	136	O	mean
36	138	141	O	Cmax
37	143	144	O	of
38	146	148	O	165
39	150	151	O	ng
40	152	152	O	/
41	153	154	O	mL
42	155	155	O	,
43	157	159	O	and
44	161	164	O	mean
45	166	169	O	half
46	171	174	O	life
47	176	177	O	of
48	179	182	O	26.2
49	184	185	O	hr
NULL

Sertraline Hydrochloride	1578	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	38
The 13 to 17 year old group exhibited a mean sertraline AUC (0 to 24 hr) of 2296 ng-hr/mL, mean Cmax of 123 ng/mL, and mean half-life of 27.8 hr.
1	0	2	O	The
2	4	5	O	13
3	7	8	O	to
4	10	11	O	17
5	13	16	O	year
6	18	20	O	old
7	22	26	O	group
8	28	36	O	exhibited
9	38	38	O	a
10	40	43	O	mean
11	45	54	O	XXXXXXXX
12	56	58	O	AUC
13	61	61	O	0
14	63	64	O	to
15	66	67	O	24
16	69	70	O	hr
17	73	74	O	of
18	76	79	O	2296
19	81	82	O	ng
20	84	85	O	hr
21	86	86	O	/
22	87	88	O	mL
23	89	89	O	,
24	91	94	O	mean
25	96	99	O	Cmax
26	101	102	O	of
27	104	106	O	123
28	108	109	O	ng
29	110	110	O	/
30	111	112	O	mL
31	113	113	O	,
32	115	117	O	and
33	119	122	O	mean
34	124	127	O	half
35	129	132	O	life
36	134	135	O	of
37	137	140	O	27.8
38	142	143	O	hr
NULL

Sertraline Hydrochloride	1579	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	20
Higher plasma levels in the 6 to 12 year old group were largely attributable to patients with lower body weights.
1	0	5	O	Higher
2	7	12	O	plasma
3	14	19	O	levels
4	21	22	O	in
5	24	26	O	the
6	28	28	O	6
7	30	31	O	to
8	33	34	O	12
9	36	39	O	year
10	41	43	O	old
11	45	49	O	group
12	51	54	O	were
13	56	62	O	largely
14	64	75	O	attributable
15	77	78	O	to
16	80	87	O	patients
17	89	92	O	with
18	94	98	O	lower
19	100	103	O	body
20	105	111	O	weights
NULL

Sertraline Hydrochloride	1580	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	6
No gender associated differences were observed.
1	0	1	O	No
2	3	8	O	gender
3	10	19	O	associated
4	21	31	O	differences
5	33	36	O	were
6	38	45	O	observed
NULL

Sertraline Hydrochloride	1581	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	63
By comparison, a group of 22 separately studied adults between 18 and 45 years of age (11 male, 11 female) received 30 days of 200 mg/day sertraline and exhibited a mean sertraline AUC (0 to 24 hr) of 2570 ng-hr/mL, mean Cmax of 142 ng/mL, and mean half-life of 27.2 hr.
1	0	1	O	By
2	3	12	O	comparison
3	13	13	O	,
4	15	15	O	a
5	17	21	O	group
6	23	24	O	of
7	26	27	O	22
8	29	38	O	separately
9	40	46	O	studied
10	48	53	O	adults
11	55	61	O	between
12	63	64	O	18
13	66	68	O	and
14	70	71	O	45
15	73	77	O	years
16	79	80	O	of
17	82	84	O	age
18	87	88	O	11
19	90	93	O	male
20	94	94	O	,
21	96	97	O	11
22	99	104	O	female
23	107	114	O	received
24	116	117	O	30
25	119	122	O	days
26	124	125	O	of
27	127	129	O	200
28	131	132	O	mg
29	133	133	O	/
30	134	136	O	day
31	138	147	O	XXXXXXXX
32	149	151	O	and
33	153	161	O	exhibited
34	163	163	O	a
35	165	168	O	mean
36	170	179	O	XXXXXXXX
37	181	183	O	AUC
38	186	186	O	0
39	188	189	O	to
40	191	192	O	24
41	194	195	O	hr
42	198	199	O	of
43	201	204	O	2570
44	206	207	O	ng
45	209	210	O	hr
46	211	211	O	/
47	212	213	O	mL
48	214	214	O	,
49	216	219	O	mean
50	221	224	O	Cmax
51	226	227	O	of
52	229	231	O	142
53	233	234	O	ng
54	235	235	O	/
55	236	237	O	mL
56	238	238	O	,
57	240	242	O	and
58	244	247	O	mean
59	249	252	O	half
60	254	257	O	life
61	259	260	O	of
62	262	265	O	27.2
63	267	268	O	hr
NULL

Sertraline Hydrochloride	1582	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	38
Relative to the adults, both the 6 to 12 year olds and the 13 to 17 year olds showed about 22% lower AUC (0 to 24 hr) and Cmax values when plasma concentration was adjusted for weight.
1	0	7	O	Relative
2	9	10	O	to
3	12	14	O	the
4	16	21	O	adults
5	22	22	O	,
6	24	27	O	both
7	29	31	O	the
8	33	33	O	6
9	35	36	O	to
10	38	39	O	12
11	41	44	O	year
12	46	49	O	olds
13	51	53	O	and
14	55	57	O	the
15	59	60	O	13
16	62	63	O	to
17	65	66	O	17
18	68	71	O	year
19	73	76	O	olds
20	78	83	O	showed
21	85	89	O	about
22	91	93	O	22%
23	95	99	O	lower
24	101	103	O	AUC
25	106	106	O	0
26	108	109	O	to
27	111	112	O	24
28	114	115	O	hr
29	118	120	O	and
30	122	125	O	Cmax
31	127	132	O	values
32	134	137	O	when
33	139	144	O	plasma
34	146	158	O	concentration
35	160	162	O	was
36	164	171	O	adjusted
37	173	175	O	for
38	177	182	O	weight
NULL

Sertraline Hydrochloride	1583	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	14
These data suggest that pediatric patients metabolize sertraline with slightly greater efficiency than adults.
1	0	4	O	These
2	6	9	O	data
3	11	17	O	suggest
4	19	22	O	that
5	24	32	O	pediatric
6	34	41	O	patients
7	43	52	O	metabolize
8	54	63	O	XXXXXXXX
9	65	68	O	with
10	70	77	O	slightly
11	79	85	O	greater
12	87	96	O	efficiency
13	98	101	O	than
14	103	108	O	adults
NULL

Sertraline Hydrochloride	1584	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	29
Nevertheless, lower doses may be advisable for pediatric patients given their lower body weights, especially in very young patients, in order to avoid excessive plasma levels.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	18	O	lower
4	20	24	O	doses
5	26	28	O	may
6	30	31	O	be
7	33	41	O	advisable
8	43	45	O	for
9	47	55	O	pediatric
10	57	64	O	patients
11	66	70	O	given
12	72	76	O	their
13	78	82	O	lower
14	84	87	O	body
15	89	95	O	weights
16	96	96	O	,
17	98	107	O	especially
18	109	110	O	in
19	112	115	O	very
20	117	121	O	young
21	123	130	O	patients
22	131	131	O	,
23	133	134	O	in
24	136	140	O	order
25	142	143	O	to
26	145	149	O	avoid
27	151	159	O	excessive
28	161	166	O	plasma
29	168	173	O	levels
NULL

Sertraline Hydrochloride	1585	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	44
Age-Sertraline plasma clearance in a group of 16 (8 male, 8 female) elderly patients treated for 14 days at a dose of 100 mg/day was approximately 40% lower than in a similarly studied group of younger (25 to 32 y.o.)
1	0	2	O	Age
2	4	13	O	XXXXXXXX
3	15	20	O	plasma
4	22	30	O	clearance
5	32	33	O	in
6	35	35	O	a
7	37	41	O	group
8	43	44	O	of
9	46	47	O	16
10	50	50	O	8
11	52	55	O	male
12	56	56	O	,
13	58	58	O	8
14	60	65	O	female
15	68	74	O	elderly
16	76	83	O	patients
17	85	91	O	treated
18	93	95	O	for
19	97	98	O	14
20	100	103	O	days
21	105	106	O	at
22	108	108	O	a
23	110	113	O	dose
24	115	116	O	of
25	118	120	O	100
26	122	123	O	mg
27	124	124	O	/
28	125	127	O	day
29	129	131	O	was
30	133	145	O	approximately
31	147	149	O	40%
32	151	155	O	lower
33	157	160	O	than
34	162	163	O	in
35	165	165	O	a
36	167	175	O	similarly
37	177	183	O	studied
38	185	189	O	group
39	191	192	O	of
40	194	200	O	younger
41	203	204	O	25
42	206	207	O	to
43	209	210	O	32
44	212	214	O	y.o
NULL

Sertraline Hydrochloride	1586	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	16
Steady-state, therefore, should be achieved after 2 to 3 weeks in older patients.
1	0	5	O	Steady
2	7	11	O	state
3	12	12	O	,
4	14	22	O	therefore
5	23	23	O	,
6	25	30	O	should
7	32	33	O	be
8	35	42	O	achieved
9	44	48	O	after
10	50	50	O	2
11	52	53	O	to
12	55	55	O	3
13	57	61	O	weeks
14	63	64	O	in
15	66	70	O	older
16	72	79	O	patients
NULL

Sertraline Hydrochloride	1587	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	19
The same study showed a decreased clearance of desmethylsertraline in older males, but not in older females.
1	0	2	O	The
2	4	7	O	same
3	9	13	O	study
4	15	20	O	showed
5	22	22	O	a
6	24	32	O	decreased
7	34	42	O	clearance
8	44	45	O	of
9	47	55	O	desmethyl
10	56	65	O	XXXXXXXX
11	67	68	O	in
12	70	74	O	older
13	76	80	O	males
14	81	81	O	,
15	83	85	O	but
16	87	89	O	not
17	91	92	O	in
18	94	98	O	older
19	100	106	O	females
NULL

Sertraline Hydrochloride	1588	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	21
Liver Disease-As might be predicted from its primary site of metabolism, liver impairment can affect the elimination of sertraline.
1	0	4	O	Liver
2	6	12	O	Disease
3	14	15	O	As
4	17	21	O	might
5	23	24	O	be
6	26	34	O	predicted
7	36	39	O	from
8	41	43	O	its
9	45	51	O	primary
10	53	56	O	site
11	58	59	O	of
12	61	70	O	metabolism
13	71	71	O	,
14	73	77	O	liver
15	79	88	O	impairment
16	90	92	O	can
17	94	99	O	affect
18	101	103	O	the
19	105	115	O	elimination
20	117	118	O	of
21	120	129	O	XXXXXXXX
NULL

Sertraline Hydrochloride	1589	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	68
In patients with chronic mild liver impairment (N = 10, 8 patients with Child-Pugh scores of 5 to 6 and 2 patients with Child-Pugh scores of 7 to 8) who received 50 mg sertraline per day maintained for 21 days, sertraline clearance was reduced, resulting in approximately 3-fold greater exposure compared to age-matched volunteers with no hepatic impairment (N = 10).
1	0	1	O	In
2	3	10	O	patients
3	12	15	O	with
4	17	23	O	chronic
5	25	28	O	mild
6	30	34	O	liver
7	36	45	O	impairment
8	48	48	O	N
9	50	50	O	=
10	52	53	O	10
11	54	54	O	,
12	56	56	O	8
13	58	65	O	patients
14	67	70	O	with
15	72	76	O	Child
16	78	81	O	Pugh
17	83	88	O	scores
18	90	91	O	of
19	93	93	O	5
20	95	96	O	to
21	98	98	O	6
22	100	102	O	and
23	104	104	O	2
24	106	113	O	patients
25	115	118	O	with
26	120	124	O	Child
27	126	129	O	Pugh
28	131	136	O	scores
29	138	139	O	of
30	141	141	O	7
31	143	144	O	to
32	146	146	O	8
33	149	151	O	who
34	153	160	O	received
35	162	163	O	50
36	165	166	O	mg
37	168	177	O	XXXXXXXX
38	179	181	O	per
39	183	185	O	day
40	187	196	O	maintained
41	198	200	O	for
42	202	203	O	21
43	205	208	O	days
44	209	209	O	,
45	211	220	O	XXXXXXXX
46	222	230	O	clearance
47	232	234	O	was
48	236	242	O	reduced
49	243	243	O	,
50	245	253	O	resulting
51	255	256	O	in
52	258	270	O	approximately
53	272	272	O	3
54	274	277	O	fold
55	279	285	O	greater
56	287	294	O	exposure
57	296	303	O	compared
58	305	306	O	to
59	308	310	O	age
60	312	318	O	matched
61	320	329	O	volunteers
62	331	334	O	with
63	336	337	O	no
64	339	345	O	hepatic
65	347	356	O	impairment
66	359	359	O	N
67	361	361	O	=
68	363	364	O	10
NULL

Sertraline Hydrochloride	1590	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	19
The exposure to desmethylsertraline was approximately 2-fold greater compared to age-matched volunteers with no hepatic impairment.
1	0	2	O	The
2	4	11	O	exposure
3	13	14	O	to
4	16	24	O	desmethyl
5	25	34	O	XXXXXXXX
6	36	38	O	was
7	40	52	O	approximately
8	54	54	O	2
9	56	59	O	fold
10	61	67	O	greater
11	69	76	O	compared
12	78	79	O	to
13	81	83	O	age
14	85	91	O	matched
15	93	102	O	volunteers
16	104	107	O	with
17	109	110	O	no
18	112	118	O	hepatic
19	120	129	O	impairment
NULL

Sertraline Hydrochloride	1591	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	14
There were no significant differences in plasma protein binding observed between the two groups.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	24	O	significant
5	26	36	O	differences
6	38	39	O	in
7	41	46	O	plasma
8	48	54	O	protein
9	56	62	O	binding
10	64	71	O	observed
11	73	79	O	between
12	81	83	O	the
13	85	87	O	two
14	89	94	O	groups
NULL

Sertraline Hydrochloride	1592	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	16
The effects of sertraline in patients with moderate and severe hepatic impairment have not been studied.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	24	O	XXXXXXXX
5	26	27	O	in
6	29	36	O	patients
7	38	41	O	with
8	43	50	O	moderate
9	52	54	O	and
10	56	61	O	severe
11	63	69	O	hepatic
12	71	80	O	impairment
13	82	85	O	have
14	87	89	O	not
15	91	94	O	been
16	96	102	O	studied
NULL

Sertraline Hydrochloride	1593	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	18
The results suggest that the use of sertraline in patients with liver disease must be approached with caution.
1	0	2	O	The
2	4	10	O	results
3	12	18	O	suggest
4	20	23	O	that
5	25	27	O	the
6	29	31	O	use
7	33	34	O	of
8	36	45	O	XXXXXXXX
9	47	48	O	in
10	50	57	O	patients
11	59	62	O	with
12	64	68	O	liver
13	70	76	O	disease
14	78	81	O	must
15	83	84	O	be
16	86	95	O	approached
17	97	100	O	with
18	102	108	O	caution
NULL

Sertraline Hydrochloride	1594	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	19
If sertraline is administered to patients with liver impairment, a lower or less frequent dose should be used.
1	0	1	O	If
2	3	12	O	XXXXXXXX
3	14	15	O	is
4	17	28	O	administered
5	30	31	O	to
6	33	40	O	patients
7	42	45	O	with
8	47	51	O	liver
9	53	62	O	impairment
10	63	63	O	,
11	65	65	O	a
12	67	71	O	lower
13	73	74	O	or
14	76	79	O	less
15	81	88	O	frequent
16	90	93	O	dose
17	95	100	O	should
18	102	103	O	be
19	105	108	O	used
NULL

Sertraline Hydrochloride	1595	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	19
Renal Disease-Sertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination.
1	0	4	O	Renal
2	6	12	O	Disease
3	14	23	O	XXXXXXXX
4	25	26	O	is
5	28	38	O	extensively
6	40	50	O	metabolized
7	52	54	O	and
8	56	64	O	excretion
9	66	67	O	of
10	69	77	O	unchanged
11	79	82	O	drug
12	84	85	O	in
13	87	91	O	urine
14	93	94	O	is
15	96	96	O	a
16	98	102	O	minor
17	104	108	O	route
18	110	111	O	of
19	113	123	O	elimination
NULL

Sertraline Hydrochloride	1596	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	68
In volunteers with mild to moderate (CLcr = 30 to 60 mL/min), moderate to severe (CLcr = 10 to 29 mL/min) or severe (receiving hemodialysis) renal impairment (N = 10 each group), the pharmacokinetics and protein binding of 200 mg sertraline per day maintained for 21 days were not altered compared to age-matched volunteers (N = 12) with no renal impairment.
1	0	1	O	In
2	3	12	O	volunteers
3	14	17	O	with
4	19	22	O	mild
5	24	25	O	to
6	27	34	O	moderate
7	37	40	O	CLcr
8	42	42	O	=
9	44	45	O	30
10	47	48	O	to
11	50	51	O	60
12	53	54	O	mL
13	55	55	O	/
14	56	58	O	min
15	60	60	O	,
16	62	69	O	moderate
17	71	72	O	to
18	74	79	O	severe
19	82	85	O	CLcr
20	87	87	O	=
21	89	90	O	10
22	92	93	O	to
23	95	96	O	29
24	98	99	O	mL
25	100	100	O	/
26	101	103	O	min
27	106	107	O	or
28	109	114	O	severe
29	117	125	O	receiving
30	127	138	O	hemodialysis
31	141	145	O	renal
32	147	156	O	impairment
33	159	159	O	N
34	161	161	O	=
35	163	164	O	10
36	166	169	O	each
37	171	175	O	group
38	177	177	O	,
39	179	181	O	the
40	183	198	O	pharmacokinetics
41	200	202	O	and
42	204	210	O	protein
43	212	218	O	binding
44	220	221	O	of
45	223	225	O	200
46	227	228	O	mg
47	230	239	O	XXXXXXXX
48	241	243	O	per
49	245	247	O	day
50	249	258	O	maintained
51	260	262	O	for
52	264	265	O	21
53	267	270	O	days
54	272	275	O	were
55	277	279	O	not
56	281	287	O	altered
57	289	296	O	compared
58	298	299	O	to
59	301	303	O	age
60	305	311	O	matched
61	313	322	O	volunteers
62	325	325	O	N
63	327	327	O	=
64	329	330	O	12
65	333	336	O	with
66	338	339	O	no
67	341	345	O	renal
68	347	356	O	impairment
NULL

Sertraline Hydrochloride	1597	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	12
Thus sertraline multiple dose pharmacokinetics appear to be unaffected by renal impairment.
1	0	3	O	Thus
2	5	14	O	XXXXXXXX
3	16	23	O	multiple
4	25	28	O	dose
5	30	45	O	pharmacokinetics
6	47	52	O	appear
7	54	55	O	to
8	57	58	O	be
9	60	69	O	unaffected
10	71	72	O	by
11	74	78	O	renal
12	80	89	O	impairment
NULL

Sertraline Hydrochloride	1598	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	34
Clinical Trials Major Depressive Disorder-The efficacy of sertraline as a treatment for major depressive disorder was established in two placebo-controlled studies in adult outpatients meeting DSM-III criteria for major depressive disorder.
1	0	7	O	Clinical
2	9	14	O	Trials
3	16	20	O	Major
4	22	31	O	Depressive
5	33	40	O	Disorder
6	42	44	O	The
7	46	53	O	efficacy
8	55	56	O	of
9	58	67	O	XXXXXXXX
10	69	70	O	as
11	72	72	O	a
12	74	82	O	treatment
13	84	86	O	for
14	88	92	O	major
15	94	103	O	depressive
16	105	112	O	disorder
17	114	116	O	was
18	118	128	O	established
19	130	131	O	in
20	133	135	O	two
21	137	143	O	placebo
22	145	154	O	controlled
23	156	162	O	studies
24	164	165	O	in
25	167	171	O	adult
26	173	183	O	outpatients
27	185	191	O	meeting
28	193	195	O	DSM
29	197	199	O	III
30	201	208	O	criteria
31	210	212	O	for
32	214	218	O	major
33	220	229	O	depressive
34	231	238	O	disorder
NULL

Sertraline Hydrochloride	1599	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	32
Study 1 was an 8-week study with flexible dosing of sertraline hydrochloride in a range of 50 to 200 mg/day; the mean dose for completers was 145 mg/day.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	13	O	an
5	15	15	O	8
6	17	20	O	week
7	22	26	O	study
8	28	31	O	with
9	33	40	O	flexible
10	42	47	O	dosing
11	49	50	O	of
12	52	75	O	XXXXXXXX
13	77	78	O	in
14	80	80	O	a
15	82	86	O	range
16	88	89	O	of
17	91	92	O	50
18	94	95	O	to
19	97	99	O	200
20	101	102	O	mg
21	103	103	O	/
22	104	106	O	day
23	109	111	O	the
24	113	116	O	mean
25	118	121	O	dose
26	123	125	O	for
27	127	136	O	completers
28	138	140	O	was
29	142	144	O	145
30	146	147	O	mg
31	148	148	O	/
32	149	151	O	day
NULL

Sertraline Hydrochloride	1600	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Study 2 was a 6-week fixed-dose study, including sertraline hydrochloride doses of 50, 100, and 200 mg/day.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	14	O	6
6	16	19	O	week
7	21	25	O	fixed
8	27	30	O	dose
9	32	36	O	study
10	37	37	O	,
11	39	47	O	including
12	49	72	O	XXXXXXXX
13	74	78	O	doses
14	80	81	O	of
15	83	84	O	50
16	85	85	O	,
17	87	89	O	100
18	90	90	O	,
19	92	94	O	and
20	96	98	O	200
21	100	101	O	mg
22	102	102	O	/
23	103	105	O	day
NULL

Sertraline Hydrochloride	1601	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	26
Overall, these studies demonstrated sertraline hydrochloride to be superior to placebo on the Hamilton Depression Rating Scale and the Clinical Global Impression Severity and Improvement scales.
1	0	6	O	Overall
2	7	7	O	,
3	9	13	O	these
4	15	21	O	studies
5	23	34	O	demonstrated
6	36	59	O	XXXXXXXX
7	61	62	O	to
8	64	65	O	be
9	67	74	O	superior
10	76	77	O	to
11	79	85	O	placebo
12	87	88	O	on
13	90	92	O	the
14	94	101	O	Hamilton
15	103	112	O	Depression
16	114	119	O	Rating
17	121	125	O	Scale
18	127	129	O	and
19	131	133	O	the
20	135	142	O	Clinical
21	144	149	O	Global
22	151	160	O	Impression
23	162	169	O	Severity
24	171	173	O	and
25	175	185	O	Improvement
26	187	192	O	scales
NULL

Sertraline Hydrochloride	1602	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	13
Study 2 was not readily interpretable regarding a dose response relationship for effectiveness.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	14	O	not
5	16	22	O	readily
6	24	36	O	interpretable
7	38	46	O	regarding
8	48	48	O	a
9	50	53	O	dose
10	55	62	O	response
11	64	75	O	relationship
12	77	79	O	for
13	81	93	O	effectiveness
NULL

Sertraline Hydrochloride	1603	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	27
Study 3 involved depressed outpatients who had responded by the end of an initial 8-week open treatment phase on sertraline hydrochloride 50 to 200 mg/day.
1	0	4	O	Study
2	6	6	O	3
3	8	15	O	involved
4	17	25	O	depressed
5	27	37	O	outpatients
6	39	41	O	who
7	43	45	O	had
8	47	55	O	responded
9	57	58	O	by
10	60	62	O	the
11	64	66	O	end
12	68	69	O	of
13	71	72	O	an
14	74	80	O	initial
15	82	82	O	8
16	84	87	O	week
17	89	92	O	open
18	94	102	O	treatment
19	104	108	O	phase
20	110	111	O	on
21	113	136	O	XXXXXXXX
22	138	139	O	50
23	141	142	O	to
24	144	146	O	200
25	148	149	O	mg
26	150	150	O	/
27	151	153	O	day
NULL

Sertraline Hydrochloride	1604	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	24
These patients (N = 295) were randomized to continuation for 44 weeks on double-blind sertraline hydrochloride 50 to 200 mg/day or placebo.
1	0	4	O	These
2	6	13	O	patients
3	16	16	O	N
4	18	18	O	=
5	20	22	O	295
6	25	28	O	were
7	30	39	O	randomized
8	41	42	O	to
9	44	55	O	continuation
10	57	59	O	for
11	61	62	O	44
12	64	68	O	weeks
13	70	71	O	on
14	73	78	O	double
15	80	84	O	blind
16	86	109	O	XXXXXXXX
17	111	112	O	50
18	114	115	O	to
19	117	119	O	200
20	121	122	O	mg
21	123	123	O	/
22	124	126	O	day
23	128	129	O	or
24	131	137	O	placebo
NULL

Sertraline Hydrochloride	1605	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	17
A statistically significantly lower relapse rate was observed for patients taking sertraline hydrochloride compared to those on placebo.
1	0	0	O	A
2	2	14	O	statistically
3	16	28	O	significantly
4	30	34	O	lower
5	36	42	O	relapse
6	44	47	O	rate
7	49	51	O	was
8	53	60	O	observed
9	62	64	O	for
10	66	73	O	patients
11	75	80	O	taking
12	82	105	O	XXXXXXXX
13	107	114	O	compared
14	116	117	O	to
15	119	123	O	those
16	125	126	O	on
17	128	134	O	placebo
NULL

Sertraline Hydrochloride	1606	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
The mean dose for completers was 70 mg/day.
1	0	2	O	The
2	4	7	O	mean
3	9	12	O	dose
4	14	16	O	for
5	18	27	O	completers
6	29	31	O	was
7	33	34	O	70
8	36	37	O	mg
9	38	38	O	/
10	39	41	O	day
NULL

Sertraline Hydrochloride	1607	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	17
Analyses for gender effects on outcome did not suggest any differential responsiveness on the basis of sex.
1	0	7	O	Analyses
2	9	11	O	for
3	13	18	O	gender
4	20	26	O	effects
5	28	29	O	on
6	31	37	O	outcome
7	39	41	O	did
8	43	45	O	not
9	47	53	O	suggest
10	55	57	O	any
11	59	70	O	differential
12	72	85	O	responsiveness
13	87	88	O	on
14	90	92	O	the
15	94	98	O	basis
16	100	101	O	of
17	103	105	O	sex
NULL

Sertraline Hydrochloride	1608	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	28
Obsessive-Compulsive Disorder (OCD)-The effectiveness of sertraline in the treatment of OCD was demonstrated in three multicenter placebo-controlled studies of adult outpatients (Studies 1 to 3).
1	0	8	O	Obsessive
2	10	19	O	Compulsive
3	21	28	O	Disorder
4	31	33	O	OCD
5	36	38	O	The
6	40	52	O	effectiveness
7	54	55	O	of
8	57	66	O	XXXXXXXX
9	68	69	O	in
10	71	73	O	the
11	75	83	O	treatment
12	85	86	O	of
13	88	90	O	OCD
14	92	94	O	was
15	96	107	O	demonstrated
16	109	110	O	in
17	112	116	O	three
18	118	128	O	multicenter
19	130	136	O	placebo
20	138	147	O	controlled
21	149	155	O	studies
22	157	158	O	of
23	160	164	O	adult
24	166	176	O	outpatients
25	179	185	O	Studies
26	187	187	O	1
27	189	190	O	to
28	192	192	O	3
NULL

Sertraline Hydrochloride	1609	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	34
Patients in all studies had moderate to severe OCD (DSM-III or DSM-III-R) with mean baseline ratings on the Yale-Brown Obsessive-Compulsive Scale (YBOCS) total score ranging from 23 to 25.
1	0	7	O	Patients
2	9	10	O	in
3	12	14	O	all
4	16	22	O	studies
5	24	26	O	had
6	28	35	O	moderate
7	37	38	O	to
8	40	45	O	severe
9	47	49	O	OCD
10	52	54	O	DSM
11	56	58	O	III
12	60	61	O	or
13	63	65	O	DSM
14	67	69	O	III
15	71	71	O	R
16	74	77	O	with
17	79	82	O	mean
18	84	91	O	baseline
19	93	99	O	ratings
20	101	102	O	on
21	104	106	O	the
22	108	111	O	Yale
23	113	117	O	Brown
24	119	127	O	Obsessive
25	129	138	O	Compulsive
26	140	144	O	Scale
27	147	151	O	YBOCS
28	154	158	O	total
29	160	164	O	score
30	166	172	O	ranging
31	174	177	O	from
32	179	180	O	23
33	182	183	O	to
34	185	186	O	25
NULL

Sertraline Hydrochloride	1610	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	32
Study 1 was an 8-week study with flexible dosing of sertraline hydrochloride in a range of 50 to 200 mg/day; the mean dose for completers was 186 mg/day.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	13	O	an
5	15	15	O	8
6	17	20	O	week
7	22	26	O	study
8	28	31	O	with
9	33	40	O	flexible
10	42	47	O	dosing
11	49	50	O	of
12	52	75	O	XXXXXXXX
13	77	78	O	in
14	80	80	O	a
15	82	86	O	range
16	88	89	O	of
17	91	92	O	50
18	94	95	O	to
19	97	99	O	200
20	101	102	O	mg
21	103	103	O	/
22	104	106	O	day
23	109	111	O	the
24	113	116	O	mean
25	118	121	O	dose
26	123	125	O	for
27	127	136	O	completers
28	138	140	O	was
29	142	144	O	186
30	146	147	O	mg
31	148	148	O	/
32	149	151	O	day
NULL

Sertraline Hydrochloride	1611	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	31
Patients receiving sertraline hydrochloride experienced a mean reduction of approximately 4 points on the YBOCS total score which was significantly greater than the mean reduction of 2 points in placebo-treated patients.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	42	O	XXXXXXXX
4	44	54	O	experienced
5	56	56	O	a
6	58	61	O	mean
7	63	71	O	reduction
8	73	74	O	of
9	76	88	O	approximately
10	90	90	O	4
11	92	97	O	points
12	99	100	O	on
13	102	104	O	the
14	106	110	O	YBOCS
15	112	116	O	total
16	118	122	O	score
17	124	128	O	which
18	130	132	O	was
19	134	146	O	significantly
20	148	154	O	greater
21	156	159	O	than
22	161	163	O	the
23	165	168	O	mean
24	170	178	O	reduction
25	180	181	O	of
26	183	183	O	2
27	185	190	O	points
28	192	193	O	in
29	195	201	O	placebo
30	203	209	O	treated
31	211	218	O	patients
NULL

Sertraline Hydrochloride	1612	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Study 2 was a 12-week fixed-dose study, including sertraline hydrochloride doses of 50, 100, and 200 mg/day.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	26	O	fixed
8	28	31	O	dose
9	33	37	O	study
10	38	38	O	,
11	40	48	O	including
12	50	73	O	XXXXXXXX
13	75	79	O	doses
14	81	82	O	of
15	84	85	O	50
16	86	86	O	,
17	88	90	O	100
18	91	91	O	,
19	93	95	O	and
20	97	99	O	200
21	101	102	O	mg
22	103	103	O	/
23	104	106	O	day
NULL

Sertraline Hydrochloride	1613	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	37
Patients receiving sertraline hydrochloride doses of 50 and 200 mg/day experienced mean reductions of approximately 6 points on the YBOCS total score which were significantly greater than the approximately 3 point reduction in placebo-treated patients.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	42	O	XXXXXXXX
4	44	48	O	doses
5	50	51	O	of
6	53	54	O	50
7	56	58	O	and
8	60	62	O	200
9	64	65	O	mg
10	66	66	O	/
11	67	69	O	day
12	71	81	O	experienced
13	83	86	O	mean
14	88	97	O	reductions
15	99	100	O	of
16	102	114	O	approximately
17	116	116	O	6
18	118	123	O	points
19	125	126	O	on
20	128	130	O	the
21	132	136	O	YBOCS
22	138	142	O	total
23	144	148	O	score
24	150	154	O	which
25	156	159	O	were
26	161	173	O	significantly
27	175	181	O	greater
28	183	186	O	than
29	188	190	O	the
30	192	204	O	approximately
31	206	206	O	3
32	208	212	O	point
33	214	222	O	reduction
34	224	225	O	in
35	227	233	O	placebo
36	235	241	O	treated
37	243	250	O	patients
NULL

Sertraline Hydrochloride	1614	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	32
Study 3 was a 12-week study with flexible dosing of sertraline hydrochloride in a range of 50 to 200 mg/day; the mean dose for completers was 185 mg/day.
1	0	4	O	Study
2	6	6	O	3
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	26	O	study
8	28	31	O	with
9	33	40	O	flexible
10	42	47	O	dosing
11	49	50	O	of
12	52	75	O	XXXXXXXX
13	77	78	O	in
14	80	80	O	a
15	82	86	O	range
16	88	89	O	of
17	91	92	O	50
18	94	95	O	to
19	97	99	O	200
20	101	102	O	mg
21	103	103	O	/
22	104	106	O	day
23	109	111	O	the
24	113	116	O	mean
25	118	121	O	dose
26	123	125	O	for
27	127	136	O	completers
28	138	140	O	was
29	142	144	O	185
30	146	147	O	mg
31	148	148	O	/
32	149	151	O	day
NULL

Sertraline Hydrochloride	1615	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	32
Patients receiving sertraline hydrochloride experienced a mean reduction of approximately 7 points on the YBOCS total score which was significantly greater than the mean reduction of approximately 4 points in placebo-treated patients.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	42	O	XXXXXXXX
4	44	54	O	experienced
5	56	56	O	a
6	58	61	O	mean
7	63	71	O	reduction
8	73	74	O	of
9	76	88	O	approximately
10	90	90	O	7
11	92	97	O	points
12	99	100	O	on
13	102	104	O	the
14	106	110	O	YBOCS
15	112	116	O	total
16	118	122	O	score
17	124	128	O	which
18	130	132	O	was
19	134	146	O	significantly
20	148	154	O	greater
21	156	159	O	than
22	161	163	O	the
23	165	168	O	mean
24	170	178	O	reduction
25	180	181	O	of
26	183	195	O	approximately
27	197	197	O	4
28	199	204	O	points
29	206	207	O	in
30	209	215	O	placebo
31	217	223	O	treated
32	225	232	O	patients
NULL

Sertraline Hydrochloride	1616	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	21
Analyses for age and gender effects on outcome did not suggest any differential responsiveness on the basis of age or sex.
1	0	7	O	Analyses
2	9	11	O	for
3	13	15	O	age
4	17	19	O	and
5	21	26	O	gender
6	28	34	O	effects
7	36	37	O	on
8	39	45	O	outcome
9	47	49	O	did
10	51	53	O	not
11	55	61	O	suggest
12	63	65	O	any
13	67	78	O	differential
14	80	93	O	responsiveness
15	95	96	O	on
16	98	100	O	the
17	102	106	O	basis
18	108	109	O	of
19	111	113	O	age
20	115	116	O	or
21	118	120	O	sex
NULL

Sertraline Hydrochloride	1617	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	38
The effectiveness of sertraline hydrochloride for the treatment of OCD was also demonstrated in a 12-week, multicenter, placebo-controlled, parallel group study in a pediatric outpatient population (children and adolescents, ages 6 to 17).
1	0	2	O	The
2	4	16	O	effectiveness
3	18	19	O	of
4	21	44	O	XXXXXXXX
5	46	48	O	for
6	50	52	O	the
7	54	62	O	treatment
8	64	65	O	of
9	67	69	O	OCD
10	71	73	O	was
11	75	78	O	also
12	80	91	O	demonstrated
13	93	94	O	in
14	96	96	O	a
15	98	99	O	12
16	101	104	O	week
17	105	105	O	,
18	107	117	O	multicenter
19	118	118	O	,
20	120	126	O	placebo
21	128	137	O	controlled
22	138	138	O	,
23	140	147	O	parallel
24	149	153	O	group
25	155	159	O	study
26	161	162	O	in
27	164	164	O	a
28	166	174	O	pediatric
29	176	185	O	outpatient
30	187	196	O	population
31	199	206	O	children
32	208	210	O	and
33	212	222	O	adolescents
34	223	223	O	,
35	225	228	O	ages
36	230	230	O	6
37	232	233	O	to
38	235	236	O	17
NULL

Sertraline Hydrochloride	1618	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	54
Patients receiving sertraline in this study were initiated at doses of either 25 mg/day (children, ages 6 to 12) or 50 mg/day (adolescents, ages 13 to 17), and then titrated over the next four weeks to a maximum dose of 200 mg/day, as tolerated.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	28	O	XXXXXXXX
4	30	31	O	in
5	33	36	O	this
6	38	42	O	study
7	44	47	O	were
8	49	57	O	initiated
9	59	60	O	at
10	62	66	O	doses
11	68	69	O	of
12	71	76	O	either
13	78	79	O	25
14	81	82	O	mg
15	83	83	O	/
16	84	86	O	day
17	89	96	O	children
18	97	97	O	,
19	99	102	O	ages
20	104	104	O	6
21	106	107	O	to
22	109	110	O	12
23	113	114	O	or
24	116	117	O	50
25	119	120	O	mg
26	121	121	O	/
27	122	124	O	day
28	127	137	O	adolescents
29	138	138	O	,
30	140	143	O	ages
31	145	146	O	13
32	148	149	O	to
33	151	152	O	17
34	154	154	O	,
35	156	158	O	and
36	160	163	O	then
37	165	172	O	titrated
38	174	177	O	over
39	179	181	O	the
40	183	186	O	next
41	188	191	O	four
42	193	197	O	weeks
43	199	200	O	to
44	202	202	O	a
45	204	210	O	maximum
46	212	215	O	dose
47	217	218	O	of
48	220	222	O	200
49	224	225	O	mg
50	226	226	O	/
51	227	229	O	day
52	230	230	O	,
53	232	233	O	as
54	235	243	O	tolerated
NULL

Sertraline Hydrochloride	1619	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
The mean dose for completers was 178 mg/day.
1	0	2	O	The
2	4	7	O	mean
3	9	12	O	dose
4	14	16	O	for
5	18	27	O	completers
6	29	31	O	was
7	33	35	O	178
8	37	38	O	mg
9	39	39	O	/
10	40	42	O	day
NULL

Sertraline Hydrochloride	1620	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
Dosing was once a day in the morning or evening.
1	0	5	O	Dosing
2	7	9	O	was
3	11	14	O	once
4	16	16	O	a
5	18	20	O	day
6	22	23	O	in
7	25	27	O	the
8	29	35	O	morning
9	37	38	O	or
10	40	46	O	evening
NULL

Sertraline Hydrochloride	1621	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	29
Patients in this study had moderate to severe OCD (DSM-III-R) with mean baseline ratings on the Children's Yale-Brown Obsessive-Compulsive Scale (CYBOCS) total score of 22.
1	0	7	O	Patients
2	9	10	O	in
3	12	15	O	this
4	17	21	O	study
5	23	25	O	had
6	27	34	O	moderate
7	36	37	O	to
8	39	44	O	severe
9	46	48	O	OCD
10	51	53	O	DSM
11	55	57	O	III
12	59	59	O	R
13	62	65	O	with
14	67	70	O	mean
15	72	79	O	baseline
16	81	87	O	ratings
17	89	90	O	on
18	92	94	O	the
19	96	105	O	Children's
20	107	110	O	Yale
21	112	116	O	Brown
22	118	126	O	Obsessive
23	128	137	O	Compulsive
24	139	143	O	Scale
25	146	151	O	CYBOCS
26	154	158	O	total
27	160	164	O	score
28	166	167	O	of
29	169	170	O	22
NULL

Sertraline Hydrochloride	1622	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	28
Patients receiving sertraline experienced a mean reduction of approximately 7 units on the CYBOCS total score which was significantly greater than the 3 unit reduction for placebo patients.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	28	O	XXXXXXXX
4	30	40	O	experienced
5	42	42	O	a
6	44	47	O	mean
7	49	57	O	reduction
8	59	60	O	of
9	62	74	O	approximately
10	76	76	O	7
11	78	82	O	units
12	84	85	O	on
13	87	89	O	the
14	91	96	O	CYBOCS
15	98	102	O	total
16	104	108	O	score
17	110	114	O	which
18	116	118	O	was
19	120	132	O	significantly
20	134	140	O	greater
21	142	145	O	than
22	147	149	O	the
23	151	151	O	3
24	153	156	O	unit
25	158	166	O	reduction
26	168	170	O	for
27	172	178	O	placebo
28	180	187	O	patients
NULL

Sertraline Hydrochloride	1624	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	62
In a longer-term study, patients meeting DSM-III-R criteria for OCD who had responded during a 52-week single-blind trial on sertraline 50 to 200 mg/day (n = 224) were randomized to continuation of sertraline or to substitution of placebo for up to 28 weeks of observation for discontinuation due to relapse or insufficient clinical response.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	study
6	22	22	O	,
7	24	31	O	patients
8	33	39	O	meeting
9	41	43	O	DSM
10	45	47	O	III
11	49	49	O	R
12	51	58	O	criteria
13	60	62	O	for
14	64	66	O	OCD
15	68	70	O	who
16	72	74	O	had
17	76	84	O	responded
18	86	91	O	during
19	93	93	O	a
20	95	96	O	52
21	98	101	O	week
22	103	108	O	single
23	110	114	O	blind
24	116	120	O	trial
25	122	123	O	on
26	125	134	O	XXXXXXXX
27	136	137	O	50
28	139	140	O	to
29	142	144	O	200
30	146	147	O	mg
31	148	148	O	/
32	149	151	O	day
33	154	154	O	n
34	156	156	O	=
35	158	160	O	224
36	163	166	O	were
37	168	177	O	randomized
38	179	180	O	to
39	182	193	O	continuation
40	195	196	O	of
41	198	207	O	XXXXXXXX
42	209	210	O	or
43	212	213	O	to
44	215	226	O	substitution
45	228	229	O	of
46	231	237	O	placebo
47	239	241	O	for
48	243	244	O	up
49	246	247	O	to
50	249	250	O	28
51	252	256	O	weeks
52	258	259	O	of
53	261	271	O	observation
54	273	275	O	for
55	277	291	O	discontinuation
56	293	295	O	due
57	297	298	O	to
58	300	306	O	relapse
59	308	309	O	or
60	311	322	O	insufficient
61	324	331	O	clinical
62	333	340	O	response
NULL

Sertraline Hydrochloride	1625	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	38
Response during the single-blind phase was defined as a decrease in the YBOCS score of > 25% compared to baseline and a CGI-I of 1 (very much improved), 2 (much improved) or 3 (minimally improved).
1	0	7	O	Response
2	9	14	O	during
3	16	18	O	the
4	20	25	O	single
5	27	31	O	blind
6	33	37	O	phase
7	39	41	O	was
8	43	49	O	defined
9	51	52	O	as
10	54	54	O	a
11	56	63	O	decrease
12	65	66	O	in
13	68	70	O	the
14	72	76	O	YBOCS
15	78	82	O	score
16	84	85	O	of
17	87	87	O	>
18	89	91	O	25%
19	93	100	O	compared
20	102	103	O	to
21	105	112	O	baseline
22	114	116	O	and
23	118	118	O	a
24	120	122	O	CGI
25	124	124	O	I
26	126	127	O	of
27	129	129	O	1
28	132	135	O	very
29	137	140	O	much
30	142	149	O	improved
31	151	151	O	,
32	153	153	O	2
33	156	159	O	much
34	161	168	O	improved
35	171	172	O	or
36	174	174	O	3
37	177	185	O	minimally
38	187	194	O	improved
NULL

Sertraline Hydrochloride	1626	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	73
Relapse during the double-blind phase was defined as the following conditions being met (on three consecutive visits for 1 and 2, and for visit 3 for condition 3): (1) YBOCS score increased by > 5 points, to a minimum of 20, relative to baseline; (2) CGI-I increased by > one point; and (3) worsening of the patient's condition in the investigator's judgment, to justify alternative treatment.
1	0	6	O	Relapse
2	8	13	O	during
3	15	17	O	the
4	19	24	O	double
5	26	30	O	blind
6	32	36	O	phase
7	38	40	O	was
8	42	48	O	defined
9	50	51	O	as
10	53	55	O	the
11	57	65	O	following
12	67	76	O	conditions
13	78	82	O	being
14	84	86	O	met
15	89	90	O	on
16	92	96	O	three
17	98	108	O	consecutive
18	110	115	O	visits
19	117	119	O	for
20	121	121	O	1
21	123	125	O	and
22	127	127	O	2
23	128	128	O	,
24	130	132	O	and
25	134	136	O	for
26	138	142	O	visit
27	144	144	O	3
28	146	148	O	for
29	150	158	O	condition
30	160	160	O	3
31	162	162	O	:
32	165	165	O	1
33	168	172	O	YBOCS
34	174	178	O	score
35	180	188	O	increased
36	190	191	O	by
37	193	193	O	>
38	195	195	O	5
39	197	202	O	points
40	203	203	O	,
41	205	206	O	to
42	208	208	O	a
43	210	216	O	minimum
44	218	219	O	of
45	221	222	O	20
46	223	223	O	,
47	225	232	O	relative
48	234	235	O	to
49	237	244	O	baseline
50	248	248	O	2
51	251	253	O	CGI
52	255	255	O	I
53	257	265	O	increased
54	267	268	O	by
55	270	270	O	>
56	272	274	O	one
57	276	280	O	point
58	283	285	O	and
59	288	288	O	3
60	291	299	O	worsening
61	301	302	O	of
62	304	306	O	the
63	308	316	O	patient's
64	318	326	O	condition
65	328	329	O	in
66	331	333	O	the
67	335	348	O	investigator's
68	350	357	O	judgment
69	358	358	O	,
70	360	361	O	to
71	363	369	O	justify
72	371	381	O	alternative
73	383	391	O	treatment
NULL

Sertraline Hydrochloride	1627	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	21
Insufficient clinical response indicated a worsening of the patient's condition that resulted in study discontinuation, as assessed by the investigator.
1	0	11	O	Insufficient
2	13	20	O	clinical
3	22	29	O	response
4	31	39	O	indicated
5	41	41	O	a
6	43	51	O	worsening
7	53	54	O	of
8	56	58	O	the
9	60	68	O	patient's
10	70	78	O	condition
11	80	83	O	that
12	85	92	O	resulted
13	94	95	O	in
14	97	101	O	study
15	103	117	O	discontinuation
16	118	118	O	,
17	120	121	O	as
18	123	130	O	assessed
19	132	133	O	by
20	135	137	O	the
21	139	150	O	investigator
NULL

Sertraline Hydrochloride	1628	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	29
Patients receiving continued sertraline hydrochloride treatment experienced a significantly lower rate of discontinuation due to relapse or insufficient clinical response over the subsequent 28 weeks compared to those receiving placebo.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	27	O	continued
4	29	52	O	XXXXXXXX
5	54	62	O	treatment
6	64	74	O	experienced
7	76	76	O	a
8	78	90	O	significantly
9	92	96	O	lower
10	98	101	O	rate
11	103	104	O	of
12	106	120	O	discontinuation
13	122	124	O	due
14	126	127	O	to
15	129	135	O	relapse
16	137	138	O	or
17	140	151	O	insufficient
18	153	160	O	clinical
19	162	169	O	response
20	171	174	O	over
21	176	178	O	the
22	180	189	O	subsequent
23	191	192	O	28
24	194	198	O	weeks
25	200	207	O	compared
26	209	210	O	to
27	212	216	O	those
28	218	226	O	receiving
29	228	234	O	placebo
NULL

Sertraline Hydrochloride	1629	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	9
This pattern was demonstrated in male and female subjects.
1	0	3	O	This
2	5	11	O	pattern
3	13	15	O	was
4	17	28	O	demonstrated
5	30	31	O	in
6	33	36	O	male
7	38	40	O	and
8	42	47	O	female
9	49	56	O	subjects
NULL

Sertraline Hydrochloride	1630	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	45
Panic Disorder-The effectiveness of sertraline in the treatment of panic disorder was demonstrated in three double-blind, placebo-controlled studies (Studies 1 to 3) of adult outpatients who had a primary diagnosis of panic disorder (DSM-III-R), with or without agoraphobia.
1	0	4	O	Panic
2	6	13	O	Disorder
3	15	17	O	The
4	19	31	O	effectiveness
5	33	34	O	of
6	36	45	O	XXXXXXXX
7	47	48	O	in
8	50	52	O	the
9	54	62	O	treatment
10	64	65	O	of
11	67	71	O	panic
12	73	80	O	disorder
13	82	84	O	was
14	86	97	O	demonstrated
15	99	100	O	in
16	102	106	O	three
17	108	113	O	double
18	115	119	O	blind
19	120	120	O	,
20	122	128	O	placebo
21	130	139	O	controlled
22	141	147	O	studies
23	150	156	O	Studies
24	158	158	O	1
25	160	161	O	to
26	163	163	O	3
27	166	167	O	of
28	169	173	O	adult
29	175	185	O	outpatients
30	187	189	O	who
31	191	193	O	had
32	195	195	O	a
33	197	203	O	primary
34	205	213	O	diagnosis
35	215	216	O	of
36	218	222	O	panic
37	224	231	O	disorder
38	234	236	O	DSM
39	238	240	O	III
40	242	242	O	R
41	244	244	O	,
42	246	249	O	with
43	251	252	O	or
44	254	260	O	without
45	262	272	O	agoraphobia
NULL

Sertraline Hydrochloride	1631	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
Studies 1 and 2 were 10-week flexible dose studies.
1	0	6	O	Studies
2	8	8	O	1
3	10	12	O	and
4	14	14	O	2
5	16	19	O	were
6	21	22	O	10
7	24	27	O	week
8	29	36	O	flexible
9	38	41	O	dose
10	43	49	O	studies
NULL

Sertraline Hydrochloride	1632	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	36
Sertraline hydrochloride was initiated at 25 mg/day for the first week, and then patients were dosed in a range of 50 to 200 mg/day on the basis of clinical response and toleration.
1	0	23	O	XXXXXXXX
2	25	27	O	was
3	29	37	O	initiated
4	39	40	O	at
5	42	43	O	25
6	45	46	O	mg
7	47	47	O	/
8	48	50	O	day
9	52	54	O	for
10	56	58	O	the
11	60	64	O	first
12	66	69	O	week
13	70	70	O	,
14	72	74	O	and
15	76	79	O	then
16	81	88	O	patients
17	90	93	O	were
18	95	99	O	dosed
19	101	102	O	in
20	104	104	O	a
21	106	110	O	range
22	112	113	O	of
23	115	116	O	50
24	118	119	O	to
25	121	123	O	200
26	125	126	O	mg
27	127	127	O	/
28	128	130	O	day
29	132	133	O	on
30	135	137	O	the
31	139	143	O	basis
32	145	146	O	of
33	148	155	O	clinical
34	157	164	O	response
35	166	168	O	and
36	170	179	O	toleration
NULL

Sertraline Hydrochloride	1633	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	27
The mean sertraline hydrochloride doses for completers to 10 weeks were 131 mg/day and 144 mg/day, respectively, for Studies 1 and 2.
1	0	2	O	The
2	4	7	O	mean
3	9	32	O	XXXXXXXX
4	34	38	O	doses
5	40	42	O	for
6	44	53	O	completers
7	55	56	O	to
8	58	59	O	10
9	61	65	O	weeks
10	67	70	O	were
11	72	74	O	131
12	76	77	O	mg
13	78	78	O	/
14	79	81	O	day
15	83	85	O	and
16	87	89	O	144
17	91	92	O	mg
18	93	93	O	/
19	94	96	O	day
20	97	97	O	,
21	99	110	O	respectively
22	111	111	O	,
23	113	115	O	for
24	117	123	O	Studies
25	125	125	O	1
26	127	129	O	and
27	131	131	O	2
NULL

Sertraline Hydrochloride	1634	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	35
In these studies, sertraline hydrochloride was shown to be significantly more effective than placebo on change from baseline in panic attack frequency and on the Clinical Global Impression Severity of Illness and Global Improvement scores.
1	0	1	O	In
2	3	7	O	these
3	9	15	O	studies
4	16	16	O	,
5	18	41	O	XXXXXXXX
6	43	45	O	was
7	47	51	O	shown
8	53	54	O	to
9	56	57	O	be
10	59	71	O	significantly
11	73	76	O	more
12	78	86	O	effective
13	88	91	O	than
14	93	99	O	placebo
15	101	102	O	on
16	104	109	O	change
17	111	114	O	from
18	116	123	O	baseline
19	125	126	O	in
20	128	132	O	panic
21	134	139	O	attack
22	141	149	O	frequency
23	151	153	O	and
24	155	156	O	on
25	158	160	O	the
26	162	169	O	Clinical
27	171	176	O	Global
28	178	187	O	Impression
29	189	196	O	Severity
30	198	199	O	of
31	201	207	O	Illness
32	209	211	O	and
33	213	218	O	Global
34	220	230	O	Improvement
35	232	237	O	scores
NULL

Sertraline Hydrochloride	1635	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	27
The difference between sertraline hydrochloride and placebo in reduction from baseline in the number of full panic attacks was approximately 2 panic attacks per week in both studies.
1	0	2	O	The
2	4	13	O	difference
3	15	21	O	between
4	23	46	O	XXXXXXXX
5	48	50	O	and
6	52	58	O	placebo
7	60	61	O	in
8	63	71	O	reduction
9	73	76	O	from
10	78	85	O	baseline
11	87	88	O	in
12	90	92	O	the
13	94	99	O	number
14	101	102	O	of
15	104	107	O	full
16	109	113	O	panic
17	115	121	O	attacks
18	123	125	O	was
19	127	139	O	approximately
20	141	141	O	2
21	143	147	O	panic
22	149	155	O	attacks
23	157	159	O	per
24	161	164	O	week
25	166	167	O	in
26	169	172	O	both
27	174	180	O	studies
NULL

Sertraline Hydrochloride	1636	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Study 3 was a 12-week fixed-dose study, including sertraline hydrochloride doses of 50, 100, and 200 mg/day.
1	0	4	O	Study
2	6	6	O	3
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	22	26	O	fixed
8	28	31	O	dose
9	33	37	O	study
10	38	38	O	,
11	40	48	O	including
12	50	73	O	XXXXXXXX
13	75	79	O	doses
14	81	82	O	of
15	84	85	O	50
16	86	86	O	,
17	88	90	O	100
18	91	91	O	,
19	93	95	O	and
20	97	99	O	200
21	101	102	O	mg
22	103	103	O	/
23	104	106	O	day
NULL

Sertraline Hydrochloride	1637	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	16
Patients receiving sertraline hydrochloride experienced a significantly greater reduction in panic attack frequency than patients receiving placebo.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	42	O	XXXXXXXX
4	44	54	O	experienced
5	56	56	O	a
6	58	70	O	significantly
7	72	78	O	greater
8	80	88	O	reduction
9	90	91	O	in
10	93	97	O	panic
11	99	104	O	attack
12	106	114	O	frequency
13	116	119	O	than
14	121	128	O	patients
15	130	138	O	receiving
16	140	146	O	placebo
NULL

Sertraline Hydrochloride	1638	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	13
Study 3 was not readily interpretable regarding a dose response relationship for effectiveness.
1	0	4	O	Study
2	6	6	O	3
3	8	10	O	was
4	12	14	O	not
5	16	22	O	readily
6	24	36	O	interpretable
7	38	46	O	regarding
8	48	48	O	a
9	50	53	O	dose
10	55	62	O	response
11	64	75	O	relationship
12	77	79	O	for
13	81	93	O	effectiveness
NULL

Sertraline Hydrochloride	1639	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Subgroup analyses did not indicate that there were any differences in treatment outcomes as a function of age, race, or gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	20	O	did
4	22	24	O	not
5	26	33	O	indicate
6	35	38	O	that
7	40	44	O	there
8	46	49	O	were
9	51	53	O	any
10	55	65	O	differences
11	67	68	O	in
12	70	78	O	treatment
13	80	87	O	outcomes
14	89	90	O	as
15	92	92	O	a
16	94	101	O	function
17	103	104	O	of
18	106	108	O	age
19	109	109	O	,
20	111	114	O	race
21	115	115	O	,
22	117	118	O	or
23	120	125	O	gender
NULL

Sertraline Hydrochloride	1640	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	59
In a longer-term study, patients meeting DSM-III-R criteria for Panic Disorder who had responded during a 52-week open trial on Sertraline hydrochloride 50-200 mg/day (n=183) were randomized to continuation of Sertraline hydrochloride or to substitution of placebo for up to 28 weeks of observation for discontinuation due to relapse or insufficient clinical response.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	study
6	22	22	O	,
7	24	31	O	patients
8	33	39	O	meeting
9	41	43	O	DSM
10	45	47	O	III
11	49	49	O	R
12	51	58	O	criteria
13	60	62	O	for
14	64	68	O	Panic
15	70	77	O	Disorder
16	79	81	O	who
17	83	85	O	had
18	87	95	O	responded
19	97	102	O	during
20	104	104	O	a
21	106	107	O	52
22	109	112	O	week
23	114	117	O	open
24	119	123	O	trial
25	125	126	O	on
26	128	151	O	XXXXXXXX
27	153	154	O	50
28	156	158	O	200
29	160	161	O	mg
30	162	162	O	/
31	163	165	O	day
32	168	172	O	n=183
33	175	178	O	were
34	180	189	O	randomized
35	191	192	O	to
36	194	205	O	continuation
37	207	208	O	of
38	210	233	O	XXXXXXXX
39	235	236	O	or
40	238	239	O	to
41	241	252	O	substitution
42	254	255	O	of
43	257	263	O	placebo
44	265	267	O	for
45	269	270	O	up
46	272	273	O	to
47	275	276	O	28
48	278	282	O	weeks
49	284	285	O	of
50	287	297	O	observation
51	299	301	O	for
52	303	317	O	discontinuation
53	319	321	O	due
54	323	324	O	to
55	326	332	O	relapse
56	334	335	O	or
57	337	348	O	insufficient
58	350	357	O	clinical
59	359	366	O	response
NULL

Sertraline Hydrochloride	1641	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	20
Response during the open phase was defined as a CGI-I score of 1(very much improved) or 2 (much improved).
1	0	7	O	Response
2	9	14	O	during
3	16	18	O	the
4	20	23	O	open
5	25	29	O	phase
6	31	33	O	was
7	35	41	O	defined
8	43	44	O	as
9	46	46	O	a
10	48	50	O	CGI
11	52	52	O	I
12	54	58	O	score
13	60	61	O	of
14	63	68	O	1(very
15	70	73	O	much
16	75	82	O	improved
17	85	86	O	or
18	88	88	O	2
19	91	94	O	much
20	96	103	O	improved
NULL

Sertraline Hydrochloride	1642	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	42
Relapse during the double-blind phase was defined as the following conditions being met on three consecutive visits: (1) CGI-I > 3; (2) meets DSM-III-R criteria for Panic Disorder; (3) number of panic attacks greater than at baseline.
1	0	6	O	Relapse
2	8	13	O	during
3	15	17	O	the
4	19	24	O	double
5	26	30	O	blind
6	32	36	O	phase
7	38	40	O	was
8	42	48	O	defined
9	50	51	O	as
10	53	55	O	the
11	57	65	O	following
12	67	76	O	conditions
13	78	82	O	being
14	84	86	O	met
15	88	89	O	on
16	91	95	O	three
17	97	107	O	consecutive
18	109	114	O	visits
19	115	115	O	:
20	118	118	O	1
21	121	123	O	CGI
22	125	125	O	I
23	127	127	O	>
24	129	129	O	3
25	133	133	O	2
26	136	140	O	meets
27	142	144	O	DSM
28	146	148	O	III
29	150	150	O	R
30	152	159	O	criteria
31	161	163	O	for
32	165	169	O	Panic
33	171	178	O	Disorder
34	182	182	O	3
35	185	190	O	number
36	192	193	O	of
37	195	199	O	panic
38	201	207	O	attacks
39	209	215	O	greater
40	217	220	O	than
41	222	223	O	at
42	225	232	O	baseline
NULL

Sertraline Hydrochloride	1646	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	36
Posttraumatic Stress Disorder (PTSD)-The effectiveness of sertraline in the treatment of PTSD was established in two multicenter placebo-controlled studies (Studies 1 to 2) of adult outpatients who met DSM-III-R criteria for PTSD.
1	0	12	O	Posttraumatic
2	14	19	O	Stress
3	21	28	O	Disorder
4	31	34	O	PTSD
5	37	39	O	The
6	41	53	O	effectiveness
7	55	56	O	of
8	58	67	O	XXXXXXXX
9	69	70	O	in
10	72	74	O	the
11	76	84	O	treatment
12	86	87	O	of
13	89	92	O	PTSD
14	94	96	O	was
15	98	108	O	established
16	110	111	O	in
17	113	115	O	two
18	117	127	O	multicenter
19	129	135	O	placebo
20	137	146	O	controlled
21	148	154	O	studies
22	157	163	O	Studies
23	165	165	O	1
24	167	168	O	to
25	170	170	O	2
26	173	174	O	of
27	176	180	O	adult
28	182	192	O	outpatients
29	194	196	O	who
30	198	200	O	met
31	202	204	O	DSM
32	206	208	O	III
33	210	210	O	R
34	212	219	O	criteria
35	221	223	O	for
36	225	228	O	PTSD
NULL

Sertraline Hydrochloride	1647	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	30
The mean duration of PTSD for these patients was 12 years (Studies 1 and 2 combined) and 44% of patients (169 of the 385 patients treated) had secondary depressive disorder.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	duration
4	18	19	O	of
5	21	24	O	PTSD
6	26	28	O	for
7	30	34	O	these
8	36	43	O	patients
9	45	47	O	was
10	49	50	O	12
11	52	56	O	years
12	59	65	O	Studies
13	67	67	O	1
14	69	71	O	and
15	73	73	O	2
16	75	82	O	combined
17	85	87	O	and
18	89	91	O	44%
19	93	94	O	of
20	96	103	O	patients
21	106	108	O	169
22	110	111	O	of
23	113	115	O	the
24	117	119	O	385
25	121	128	O	patients
26	130	136	O	treated
27	139	141	O	had
28	143	151	O	secondary
29	153	162	O	depressive
30	164	171	O	disorder
NULL

Sertraline Hydrochloride	1648	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
Studies 1 and 2 were 12-week flexible dose studies.
1	0	6	O	Studies
2	8	8	O	1
3	10	12	O	and
4	14	14	O	2
5	16	19	O	were
6	21	22	O	12
7	24	27	O	week
8	29	36	O	flexible
9	38	41	O	dose
10	43	49	O	studies
NULL

Sertraline Hydrochloride	1649	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	36
Sertraline hydrochloride was initiated at 25 mg/day for the first week, and patients were then dosed in the range of 50 to 200 mg/day on the basis of clinical response and toleration.
1	0	23	O	XXXXXXXX
2	25	27	O	was
3	29	37	O	initiated
4	39	40	O	at
5	42	43	O	25
6	45	46	O	mg
7	47	47	O	/
8	48	50	O	day
9	52	54	O	for
10	56	58	O	the
11	60	64	O	first
12	66	69	O	week
13	70	70	O	,
14	72	74	O	and
15	76	83	O	patients
16	85	88	O	were
17	90	93	O	then
18	95	99	O	dosed
19	101	102	O	in
20	104	106	O	the
21	108	112	O	range
22	114	115	O	of
23	117	118	O	50
24	120	121	O	to
25	123	125	O	200
26	127	128	O	mg
27	129	129	O	/
28	130	132	O	day
29	134	135	O	on
30	137	139	O	the
31	141	145	O	basis
32	147	148	O	of
33	150	157	O	clinical
34	159	166	O	response
35	168	170	O	and
36	172	181	O	toleration
NULL

Sertraline Hydrochloride	1650	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
The mean sertraline hydrochloride dose for completers was 146 mg/day and 151 mg/day, respectively for Studies 1 and 2.
1	0	2	O	The
2	4	7	O	mean
3	9	32	O	XXXXXXXX
4	34	37	O	dose
5	39	41	O	for
6	43	52	O	completers
7	54	56	O	was
8	58	60	O	146
9	62	63	O	mg
10	64	64	O	/
11	65	67	O	day
12	69	71	O	and
13	73	75	O	151
14	77	78	O	mg
15	79	79	O	/
16	80	82	O	day
17	83	83	O	,
18	85	96	O	respectively
19	98	100	O	for
20	102	108	O	Studies
21	110	110	O	1
22	112	114	O	and
23	116	116	O	2
NULL

Sertraline Hydrochloride	1651	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	55
Study outcome was assessed by the Clinician-Administered PTSD Scale Part 2 (CAPS) which is a multi-item instrument that measures the three PTSD diagnostic symptom clusters of reexperiencing/intrusion, avoidance/numbing, and hyperarousal as well as the patient-rated Impact of Event Scale (IES) which measures intrusion and avoidance symptoms.
1	0	4	O	Study
2	6	12	O	outcome
3	14	16	O	was
4	18	25	O	assessed
5	27	28	O	by
6	30	32	O	the
7	34	42	O	Clinician
8	44	55	O	Administered
9	57	60	O	PTSD
10	62	66	O	Scale
11	68	71	O	Part
12	73	73	O	2
13	76	79	O	CAPS
14	82	86	O	which
15	88	89	O	is
16	91	91	O	a
17	93	97	O	multi
18	99	102	O	item
19	104	113	O	instrument
20	115	118	O	that
21	120	127	O	measures
22	129	131	O	the
23	133	137	O	three
24	139	142	O	PTSD
25	144	153	O	diagnostic
26	155	161	O	symptom
27	163	170	O	clusters
28	172	173	O	of
29	175	188	O	reexperiencing
30	189	189	O	/
31	190	198	O	intrusion
32	199	199	O	,
33	201	209	O	avoidance
34	210	210	O	/
35	211	217	O	numbing
36	218	218	O	,
37	220	222	O	and
38	224	235	O	hyperarousal
39	237	238	O	as
40	240	243	O	well
41	245	246	O	as
42	248	250	O	the
43	252	258	O	patient
44	260	264	O	rated
45	266	271	O	Impact
46	273	274	O	of
47	276	280	O	Event
48	282	286	O	Scale
49	289	291	O	IES
50	294	298	O	which
51	300	307	O	measures
52	309	317	O	intrusion
53	319	321	O	and
54	323	331	O	avoidance
55	333	340	O	symptoms
NULL

Sertraline Hydrochloride	1652	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	35
Sertraline hydrochloride was shown to be significantly more effective than placebo on change from baseline to endpoint on the CAPS, IES and on the Clinical Global Impressions (CGI) Severity of Illness and Global Improvement scores.
1	0	23	O	XXXXXXXX
2	25	27	O	was
3	29	33	O	shown
4	35	36	O	to
5	38	39	O	be
6	41	53	O	significantly
7	55	58	O	more
8	60	68	O	effective
9	70	73	O	than
10	75	81	O	placebo
11	83	84	O	on
12	86	91	O	change
13	93	96	O	from
14	98	105	O	baseline
15	107	108	O	to
16	110	117	O	endpoint
17	119	120	O	on
18	122	124	O	the
19	126	129	O	CAPS
20	130	130	O	,
21	132	134	O	IES
22	136	138	O	and
23	140	141	O	on
24	143	145	O	the
25	147	154	O	Clinical
26	156	161	O	Global
27	163	173	O	Impressions
28	176	178	O	CGI
29	181	188	O	Severity
30	190	191	O	of
31	193	199	O	Illness
32	201	203	O	and
33	205	210	O	Global
34	212	222	O	Improvement
35	224	229	O	scores
NULL

Sertraline Hydrochloride	1653	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	26
In two additional placebo-controlled PTSD trials, the difference in response to treatment between patients receiving sertraline hydrochloride and patients receiving placebo was not statistically significant.
1	0	1	O	In
2	3	5	O	two
3	7	16	O	additional
4	18	24	O	placebo
5	26	35	O	controlled
6	37	40	O	PTSD
7	42	47	O	trials
8	48	48	O	,
9	50	52	O	the
10	54	63	O	difference
11	65	66	O	in
12	68	75	O	response
13	77	78	O	to
14	80	88	O	treatment
15	90	96	O	between
16	98	105	O	patients
17	107	115	O	receiving
18	117	140	O	XXXXXXXX
19	142	144	O	and
20	146	153	O	patients
21	155	163	O	receiving
22	165	171	O	placebo
23	173	175	O	was
24	177	179	O	not
25	181	193	O	statistically
26	195	205	O	significant
NULL

Sertraline Hydrochloride	1654	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	30
One of these additional studies was conducted in patients similar to those recruited for Studies 1 and 2, while the second additional study was conducted in predominantly male veterans.
1	0	2	O	One
2	4	5	O	of
3	7	11	O	these
4	13	22	O	additional
5	24	30	O	studies
6	32	34	O	was
7	36	44	O	conducted
8	46	47	O	in
9	49	56	O	patients
10	58	64	O	similar
11	66	67	O	to
12	69	73	O	those
13	75	83	O	recruited
14	85	87	O	for
15	89	95	O	Studies
16	97	97	O	1
17	99	101	O	and
18	103	103	O	2
19	104	104	O	,
20	106	110	O	while
21	112	114	O	the
22	116	121	O	second
23	123	132	O	additional
24	134	138	O	study
25	140	142	O	was
26	144	152	O	conducted
27	154	155	O	in
28	157	169	O	predominantly
29	171	174	O	male
30	176	183	O	veterans
NULL

Sertraline Hydrochloride	1655	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	44
As PTSD is a more common disorder in women than men, the majority (76%) of patients in these trials were women (152 and 139 women on sertraline and placebo versus 39 and 55 men on sertraline and placebo; Studies 1 and 2 combined).
1	0	1	O	As
2	3	6	O	PTSD
3	8	9	O	is
4	11	11	O	a
5	13	16	O	more
6	18	23	O	common
7	25	32	O	disorder
8	34	35	O	in
9	37	41	O	women
10	43	46	O	than
11	48	50	O	men
12	51	51	O	,
13	53	55	O	the
14	57	64	O	majority
15	67	69	O	76%
16	72	73	O	of
17	75	82	O	patients
18	84	85	O	in
19	87	91	O	these
20	93	98	O	trials
21	100	103	O	were
22	105	109	O	women
23	112	114	O	152
24	116	118	O	and
25	120	122	O	139
26	124	128	O	women
27	130	131	O	on
28	133	142	O	XXXXXXXX
29	144	146	O	and
30	148	154	O	placebo
31	156	161	O	versus
32	163	164	O	39
33	166	168	O	and
34	170	171	O	55
35	173	175	O	men
36	177	178	O	on
37	180	189	O	XXXXXXXX
38	191	193	O	and
39	195	201	O	placebo
40	204	210	O	Studies
41	212	212	O	1
42	214	216	O	and
43	218	218	O	2
44	220	227	O	combined
NULL

Sertraline Hydrochloride	1656	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	46
Post hoc exploratory analyses revealed a significant difference between sertraline and placebo on the CAPS, IES and CGI in women, regardless of baseline diagnosis of comorbid major depressive disorder, but essentially no effect in the relatively smaller number of men in these studies.
1	0	3	O	Post
2	5	7	O	hoc
3	9	19	O	exploratory
4	21	28	O	analyses
5	30	37	O	revealed
6	39	39	O	a
7	41	51	O	significant
8	53	62	O	difference
9	64	70	O	between
10	72	81	O	XXXXXXXX
11	83	85	O	and
12	87	93	O	placebo
13	95	96	O	on
14	98	100	O	the
15	102	105	O	CAPS
16	106	106	O	,
17	108	110	O	IES
18	112	114	O	and
19	116	118	O	CGI
20	120	121	O	in
21	123	127	O	women
22	128	128	O	,
23	130	139	O	regardless
24	141	142	O	of
25	144	151	O	baseline
26	153	161	O	diagnosis
27	163	164	O	of
28	166	173	O	comorbid
29	175	179	O	major
30	181	190	O	depressive
31	192	199	O	disorder
32	200	200	O	,
33	202	204	O	but
34	206	216	O	essentially
35	218	219	O	no
36	221	226	O	effect
37	228	229	O	in
38	231	233	O	the
39	235	244	O	relatively
40	246	252	O	smaller
41	254	259	O	number
42	261	262	O	of
43	264	266	O	men
44	268	269	O	in
45	271	275	O	these
46	277	283	O	studies
NULL

Sertraline Hydrochloride	1657	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	13
The clinical significance of this apparent gender interaction is unknown at this time.
1	0	2	O	The
2	4	11	O	clinical
3	13	24	O	significance
4	26	27	O	of
5	29	32	O	this
6	34	41	O	apparent
7	43	48	O	gender
8	50	60	O	interaction
9	62	63	O	is
10	65	71	O	unknown
11	73	74	O	at
12	76	79	O	this
13	81	84	O	time
NULL

Sertraline Hydrochloride	1658	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	14
There was insufficient information to determine the effect of race or age on outcome.
1	0	4	O	There
2	6	8	O	was
3	10	21	O	insufficient
4	23	33	O	information
5	35	36	O	to
6	38	46	O	determine
7	48	50	O	the
8	52	57	O	effect
9	59	60	O	of
10	62	65	O	race
11	67	68	O	or
12	70	72	O	age
13	74	75	O	on
14	77	83	O	outcome
NULL

Sertraline Hydrochloride	1659	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	52
In a longer-term study, patients meeting DSM-III-R criteria for PTSD who had responded during a 24-week open trial on sertraline hydrochloride 50 to 200 mg/day (N=96) were randomized to continuation of sertraline hydrochloride or to substitution of placebo for up to 28 weeks of observation for relapse.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	study
6	22	22	O	,
7	24	31	O	patients
8	33	39	O	meeting
9	41	43	O	DSM
10	45	47	O	III
11	49	49	O	R
12	51	58	O	criteria
13	60	62	O	for
14	64	67	O	PTSD
15	69	71	O	who
16	73	75	O	had
17	77	85	O	responded
18	87	92	O	during
19	94	94	O	a
20	96	97	O	24
21	99	102	O	week
22	104	107	O	open
23	109	113	O	trial
24	115	116	O	on
25	118	141	O	XXXXXXXX
26	143	144	O	50
27	146	147	O	to
28	149	151	O	200
29	153	154	O	mg
30	155	155	O	/
31	156	158	O	day
32	161	164	O	N=96
33	167	170	O	were
34	172	181	O	randomized
35	183	184	O	to
36	186	197	O	continuation
37	199	200	O	of
38	202	225	O	XXXXXXXX
39	227	228	O	or
40	230	231	O	to
41	233	244	O	substitution
42	246	247	O	of
43	249	255	O	placebo
44	257	259	O	for
45	261	262	O	up
46	264	265	O	to
47	267	268	O	28
48	270	274	O	weeks
49	276	277	O	of
50	279	289	O	observation
51	291	293	O	for
52	295	301	O	relapse
NULL

Sertraline Hydrochloride	1660	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	35
Response during the open phase was defined as a CGI-I of 1 (very much improved) or 2 (much improved), and a decrease in the CAPS-2 score of > 30% compared to baseline.
1	0	7	O	Response
2	9	14	O	during
3	16	18	O	the
4	20	23	O	open
5	25	29	O	phase
6	31	33	O	was
7	35	41	O	defined
8	43	44	O	as
9	46	46	O	a
10	48	50	O	CGI
11	52	52	O	I
12	54	55	O	of
13	57	57	O	1
14	60	63	O	very
15	65	68	O	much
16	70	77	O	improved
17	80	81	O	or
18	83	83	O	2
19	86	89	O	much
20	91	98	O	improved
21	100	100	O	,
22	102	104	O	and
23	106	106	O	a
24	108	115	O	decrease
25	117	118	O	in
26	120	122	O	the
27	124	127	O	CAPS
28	129	129	O	2
29	131	135	O	score
30	137	138	O	of
31	140	140	O	>
32	142	144	O	30%
33	146	153	O	compared
34	155	156	O	to
35	158	165	O	baseline
NULL

Sertraline Hydrochloride	1661	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	51
Relapse during the double-blind phase was defined as the following conditions being met on two consecutive visits: (1) CGI-I > 3; (2) CAPS-2 score increased by > 30% and by > 15 points relative to baseline; and (3) worsening of the patient's condition in the investigator's judgment.
1	0	6	O	Relapse
2	8	13	O	during
3	15	17	O	the
4	19	24	O	double
5	26	30	O	blind
6	32	36	O	phase
7	38	40	O	was
8	42	48	O	defined
9	50	51	O	as
10	53	55	O	the
11	57	65	O	following
12	67	76	O	conditions
13	78	82	O	being
14	84	86	O	met
15	88	89	O	on
16	91	93	O	two
17	95	105	O	consecutive
18	107	112	O	visits
19	113	113	O	:
20	116	116	O	1
21	119	121	O	CGI
22	123	123	O	I
23	125	125	O	>
24	127	127	O	3
25	131	131	O	2
26	134	137	O	CAPS
27	139	139	O	2
28	141	145	O	score
29	147	155	O	increased
30	157	158	O	by
31	160	160	O	>
32	162	164	O	30%
33	166	168	O	and
34	170	171	O	by
35	173	173	O	>
36	175	176	O	15
37	178	183	O	points
38	185	192	O	relative
39	194	195	O	to
40	197	204	O	baseline
41	207	209	O	and
42	212	212	O	3
43	215	223	O	worsening
44	225	226	O	of
45	228	230	O	the
46	232	240	O	patient's
47	242	250	O	condition
48	252	253	O	in
49	255	257	O	the
50	259	272	O	investigator's
51	274	281	O	judgment
NULL

Sertraline Hydrochloride	1662	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	20
Patients receiving continued sertraline hydrochloride treatment experienced significantly lower relapse rates over the subsequent 28 weeks compared to those receiving placebo.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	27	O	continued
4	29	52	O	XXXXXXXX
5	54	62	O	treatment
6	64	74	O	experienced
7	76	88	O	significantly
8	90	94	O	lower
9	96	102	O	relapse
10	104	108	O	rates
11	110	113	O	over
12	115	117	O	the
13	119	128	O	subsequent
14	130	131	O	28
15	133	137	O	weeks
16	139	146	O	compared
17	148	149	O	to
18	151	155	O	those
19	157	165	O	receiving
20	167	173	O	placebo
NULL

Sertraline Hydrochloride	1664	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	37
Premenstrual Dysphoric Disorder (PMDD) - The effectiveness of sertraline hydrochloride for the treatment of PMDD was established in two double-blind, parallel group, placebo-controlled flexible dose trials (Studies 1 and 2) conducted over 3 menstrual cycles.
1	0	11	O	Premenstrual
2	13	21	O	Dysphoric
3	23	30	O	Disorder
4	33	36	O	PMDD
5	41	43	O	The
6	45	57	O	effectiveness
7	59	60	O	of
8	62	85	O	XXXXXXXX
9	87	89	O	for
10	91	93	O	the
11	95	103	O	treatment
12	105	106	O	of
13	108	111	O	PMDD
14	113	115	O	was
15	117	127	O	established
16	129	130	O	in
17	132	134	O	two
18	136	141	O	double
19	143	147	O	blind
20	148	148	O	,
21	150	157	O	parallel
22	159	163	O	group
23	164	164	O	,
24	166	172	O	placebo
25	174	183	O	controlled
26	185	192	O	flexible
27	194	197	O	dose
28	199	204	O	trials
29	207	213	O	Studies
30	215	215	O	1
31	217	219	O	and
32	221	221	O	2
33	224	232	O	conducted
34	234	237	O	over
35	239	239	O	3
36	241	249	O	menstrual
37	251	256	O	cycles
NULL

Sertraline Hydrochloride	1665	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	31
Patients in Study 1 met DSM-III-R criteria for Late Luteal Phase Dysphoric Disorder (LLPDD), the clinical entity now referred to as Premenstrual Dysphoric Disorder (PMDD) in DSM-IV.
1	0	7	O	Patients
2	9	10	O	in
3	12	16	O	Study
4	18	18	O	1
5	20	22	O	met
6	24	26	O	DSM
7	28	30	O	III
8	32	32	O	R
9	34	41	O	criteria
10	43	45	O	for
11	47	50	O	Late
12	52	57	O	Luteal
13	59	63	O	Phase
14	65	73	O	Dysphoric
15	75	82	O	Disorder
16	85	89	O	LLPDD
17	91	91	O	,
18	93	95	O	the
19	97	104	O	clinical
20	106	111	O	entity
21	113	115	O	now
22	117	124	O	referred
23	126	127	O	to
24	129	130	O	as
25	132	143	O	Premenstrual
26	145	153	O	Dysphoric
27	155	162	O	Disorder
28	165	168	O	PMDD
29	171	172	O	in
30	174	176	O	DSM
31	178	179	O	IV
NULL

Sertraline Hydrochloride	1666	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
Patients in Study 2 met DSM-IV criteria for PMDD.
1	0	7	O	Patients
2	9	10	O	in
3	12	16	O	Study
4	18	18	O	2
5	20	22	O	met
6	24	26	O	DSM
7	28	29	O	IV
8	31	38	O	criteria
9	40	42	O	for
10	44	47	O	PMDD
NULL

Sertraline Hydrochloride	1667	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	26
Study 1 utilized daily dosing throughout the study, while Study 2 utilized luteal phase dosing for the 2 weeks prior to the onset of menses.
1	0	4	O	Study
2	6	6	O	1
3	8	15	O	utilized
4	17	21	O	daily
5	23	28	O	dosing
6	30	39	O	throughout
7	41	43	O	the
8	45	49	O	study
9	50	50	O	,
10	52	56	O	while
11	58	62	O	Study
12	64	64	O	2
13	66	73	O	utilized
14	75	80	O	luteal
15	82	86	O	phase
16	88	93	O	dosing
17	95	97	O	for
18	99	101	O	the
19	103	103	O	2
20	105	109	O	weeks
21	111	115	O	prior
22	117	118	O	to
23	120	122	O	the
24	124	128	O	onset
25	130	131	O	of
26	133	138	O	menses
NULL

Sertraline Hydrochloride	1668	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	16
The mean duration of PMDD symptoms for these patients was approximately 10.5 years in both studies.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	duration
4	18	19	O	of
5	21	24	O	PMDD
6	26	33	O	symptoms
7	35	37	O	for
8	39	43	O	these
9	45	52	O	patients
10	54	56	O	was
11	58	70	O	approximately
12	72	75	O	10.5
13	77	81	O	years
14	83	84	O	in
15	86	89	O	both
16	91	97	O	studies
NULL

Sertraline Hydrochloride	1669	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	27
Patients on oral contraceptives were excluded from these trials; therefore, the efficacy of sertraline in combination with oral contraceptives for the treatment of PMDD is unknown.
1	0	7	O	Patients
2	9	10	O	on
3	12	15	O	oral
4	17	30	O	contraceptives
5	32	35	O	were
6	37	44	O	excluded
7	46	49	O	from
8	51	55	O	these
9	57	62	O	trials
10	65	73	O	therefore
11	74	74	O	,
12	76	78	O	the
13	80	87	O	efficacy
14	89	90	O	of
15	92	101	O	XXXXXXXX
16	103	104	O	in
17	106	116	O	combination
18	118	121	O	with
19	123	126	O	oral
20	128	141	O	contraceptives
21	143	145	O	for
22	147	149	O	the
23	151	159	O	treatment
24	161	162	O	of
25	164	167	O	PMDD
26	169	170	O	is
27	172	178	O	unknown
NULL

Sertraline Hydrochloride	1670	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	43
Efficacy was assessed with the Daily Record of Severity of Problems (DRSP), a patient-rated instrument that mirrors the diagnostic criteria for PMDD as identified in the DSM-IV, and includes assessments for mood, physical symptoms, and other symptoms.
1	0	7	O	Efficacy
2	9	11	O	was
3	13	20	O	assessed
4	22	25	O	with
5	27	29	O	the
6	31	35	O	Daily
7	37	42	O	Record
8	44	45	O	of
9	47	54	O	Severity
10	56	57	O	of
11	59	66	O	Problems
12	69	72	O	DRSP
13	74	74	O	,
14	76	76	O	a
15	78	84	O	patient
16	86	90	O	rated
17	92	101	O	instrument
18	103	106	O	that
19	108	114	O	mirrors
20	116	118	O	the
21	120	129	O	diagnostic
22	131	138	O	criteria
23	140	142	O	for
24	144	147	O	PMDD
25	149	150	O	as
26	152	161	O	identified
27	163	164	O	in
28	166	168	O	the
29	170	172	O	DSM
30	174	175	O	IV
31	176	176	O	,
32	178	180	O	and
33	182	189	O	includes
34	191	201	O	assessments
35	203	205	O	for
36	207	210	O	mood
37	211	211	O	,
38	213	220	O	physical
39	222	229	O	symptoms
40	230	230	O	,
41	232	234	O	and
42	236	240	O	other
43	242	249	O	symptoms
NULL

Sertraline Hydrochloride	1671	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	27
Other efficacy assessments included the Hamilton Depression Rating Scale (HAMD-17), and the Clinical Global Impression Severity of Illness (CGI-S) and Improvement (CGI-I) scores.
1	0	4	O	Other
2	6	13	O	efficacy
3	15	25	O	assessments
4	27	34	O	included
5	36	38	O	the
6	40	47	O	Hamilton
7	49	58	O	Depression
8	60	65	O	Rating
9	67	71	O	Scale
10	74	77	O	HAMD
11	79	80	O	17
12	82	82	O	,
13	84	86	O	and
14	88	90	O	the
15	92	99	O	Clinical
16	101	106	O	Global
17	108	117	O	Impression
18	119	126	O	Severity
19	128	129	O	of
20	131	137	O	Illness
21	140	142	O	CGI
22	144	144	O	S
23	147	149	O	and
24	151	161	O	Improvement
25	164	166	O	CGI
26	168	168	O	I
27	171	176	O	scores
NULL

Sertraline Hydrochloride	1672	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	26
In Study 1, involving n = 251 randomized patients; sertraline hydrochloride treatment was initiated at 50 mg/day and administered daily throughout the menstrual cycle.
1	0	1	O	In
2	3	7	O	Study
3	9	9	O	1
4	10	10	O	,
5	12	20	O	involving
6	22	22	O	n
7	24	24	O	=
8	26	28	O	251
9	30	39	O	randomized
10	41	48	O	patients
11	51	74	O	XXXXXXXX
12	76	84	O	treatment
13	86	88	O	was
14	90	98	O	initiated
15	100	101	O	at
16	103	104	O	50
17	106	107	O	mg
18	108	108	O	/
19	109	111	O	day
20	113	115	O	and
21	117	128	O	administered
22	130	134	O	daily
23	136	145	O	throughout
24	147	149	O	the
25	151	159	O	menstrual
26	161	165	O	cycle
NULL

Sertraline Hydrochloride	1673	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	25
In subsequent cycles, patients were dosed in the range of 50 to 150 mg/day on the basis of clinical response and toleration.
1	0	1	O	In
2	3	12	O	subsequent
3	14	19	O	cycles
4	20	20	O	,
5	22	29	O	patients
6	31	34	O	were
7	36	40	O	dosed
8	42	43	O	in
9	45	47	O	the
10	49	53	O	range
11	55	56	O	of
12	58	59	O	50
13	61	62	O	to
14	64	66	O	150
15	68	69	O	mg
16	70	70	O	/
17	71	73	O	day
18	75	76	O	on
19	78	80	O	the
20	82	86	O	basis
21	88	89	O	of
22	91	98	O	clinical
23	100	107	O	response
24	109	111	O	and
25	113	122	O	toleration
NULL

Sertraline Hydrochloride	1674	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	10
The mean dose for completers was 102 mg/day.
1	0	2	O	The
2	4	7	O	mean
3	9	12	O	dose
4	14	16	O	for
5	18	27	O	completers
6	29	31	O	was
7	33	35	O	102
8	37	38	O	mg
9	39	39	O	/
10	40	42	O	day
NULL

Sertraline Hydrochloride	1675	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	46
Sertraline hydrochloride administered daily throughout the menstrual cycle was significantly more effective than placebo on change from baseline to endpoint on the DRSP total score, the HAMD-17 total score, and the CGI-S score, as well as the CGI-I score at endpoint.
1	0	23	O	XXXXXXXX
2	25	36	O	administered
3	38	42	O	daily
4	44	53	O	throughout
5	55	57	O	the
6	59	67	O	menstrual
7	69	73	O	cycle
8	75	77	O	was
9	79	91	O	significantly
10	93	96	O	more
11	98	106	O	effective
12	108	111	O	than
13	113	119	O	placebo
14	121	122	O	on
15	124	129	O	change
16	131	134	O	from
17	136	143	O	baseline
18	145	146	O	to
19	148	155	O	endpoint
20	157	158	O	on
21	160	162	O	the
22	164	167	O	DRSP
23	169	173	O	total
24	175	179	O	score
25	180	180	O	,
26	182	184	O	the
27	186	189	O	HAMD
28	191	192	O	17
29	194	198	O	total
30	200	204	O	score
31	205	205	O	,
32	207	209	O	and
33	211	213	O	the
34	215	217	O	CGI
35	219	219	O	S
36	221	225	O	score
37	226	226	O	,
38	228	229	O	as
39	231	234	O	well
40	236	237	O	as
41	239	241	O	the
42	243	245	O	CGI
43	247	247	O	I
44	249	253	O	score
45	255	256	O	at
46	258	265	O	endpoint
NULL

Sertraline Hydrochloride	1676	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	40
In Study 2, involving n = 281 randomized patients, sertraline hydrochloride treatment was initiated at 50 mg/day in the late luteal phase (last 2 weeks) of each menstrual cycle and then discontinued at the onset of menses.
1	0	1	O	In
2	3	7	O	Study
3	9	9	O	2
4	10	10	O	,
5	12	20	O	involving
6	22	22	O	n
7	24	24	O	=
8	26	28	O	281
9	30	39	O	randomized
10	41	48	O	patients
11	49	49	O	,
12	51	74	O	XXXXXXXX
13	76	84	O	treatment
14	86	88	O	was
15	90	98	O	initiated
16	100	101	O	at
17	103	104	O	50
18	106	107	O	mg
19	108	108	O	/
20	109	111	O	day
21	113	114	O	in
22	116	118	O	the
23	120	123	O	late
24	125	130	O	luteal
25	132	136	O	phase
26	139	142	O	last
27	144	144	O	2
28	146	150	O	weeks
29	153	154	O	of
30	156	159	O	each
31	161	169	O	menstrual
32	171	175	O	cycle
33	177	179	O	and
34	181	184	O	then
35	186	197	O	discontinued
36	199	200	O	at
37	202	204	O	the
38	206	210	O	onset
39	212	213	O	of
40	215	220	O	menses
NULL

Sertraline Hydrochloride	1677	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	33
In subsequent cycles, patients were dosed in the range of 50 to 100 mg/day in the luteal phase of each cycle, on the basis of clinical response and toleration.
1	0	1	O	In
2	3	12	O	subsequent
3	14	19	O	cycles
4	20	20	O	,
5	22	29	O	patients
6	31	34	O	were
7	36	40	O	dosed
8	42	43	O	in
9	45	47	O	the
10	49	53	O	range
11	55	56	O	of
12	58	59	O	50
13	61	62	O	to
14	64	66	O	100
15	68	69	O	mg
16	70	70	O	/
17	71	73	O	day
18	75	76	O	in
19	78	80	O	the
20	82	87	O	luteal
21	89	93	O	phase
22	95	96	O	of
23	98	101	O	each
24	103	107	O	cycle
25	108	108	O	,
26	110	111	O	on
27	113	115	O	the
28	117	121	O	basis
29	123	124	O	of
30	126	133	O	clinical
31	135	142	O	response
32	144	146	O	and
33	148	157	O	toleration
NULL

Sertraline Hydrochloride	1678	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	34
Patients who were titrated to 100 mg/day received 50 mg/day for the first 3 days of the cycle, then 100 mg/day for the remainder of the cycle.
1	0	7	O	Patients
2	9	11	O	who
3	13	16	O	were
4	18	25	O	titrated
5	27	28	O	to
6	30	32	O	100
7	34	35	O	mg
8	36	36	O	/
9	37	39	O	day
10	41	48	O	received
11	50	51	O	50
12	53	54	O	mg
13	55	55	O	/
14	56	58	O	day
15	60	62	O	for
16	64	66	O	the
17	68	72	O	first
18	74	74	O	3
19	76	79	O	days
20	81	82	O	of
21	84	86	O	the
22	88	92	O	cycle
23	93	93	O	,
24	95	98	O	then
25	100	102	O	100
26	104	105	O	mg
27	106	106	O	/
28	107	109	O	day
29	111	113	O	for
30	115	117	O	the
31	119	127	O	remainder
32	129	130	O	of
33	132	134	O	the
34	136	140	O	cycle
NULL

Sertraline Hydrochloride	1679	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	11
The mean sertraline hydrochloride dose for completers was 74 mg/day.
1	0	2	O	The
2	4	7	O	mean
3	9	32	O	XXXXXXXX
4	34	37	O	dose
5	39	41	O	for
6	43	52	O	completers
7	54	56	O	was
8	58	59	O	74
9	61	62	O	mg
10	63	63	O	/
11	64	66	O	day
NULL

Sertraline Hydrochloride	1680	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	43
Sertraline hydrochloride administered in the late luteal phase of the menstrual cycle was significantly more effective than placebo on change from baseline to endpoint on the DRSP total score and the CGI-S score, as well as the CGI-I score at endpoint.
1	0	23	O	XXXXXXXX
2	25	36	O	administered
3	38	39	O	in
4	41	43	O	the
5	45	48	O	late
6	50	55	O	luteal
7	57	61	O	phase
8	63	64	O	of
9	66	68	O	the
10	70	78	O	menstrual
11	80	84	O	cycle
12	86	88	O	was
13	90	102	O	significantly
14	104	107	O	more
15	109	117	O	effective
16	119	122	O	than
17	124	130	O	placebo
18	132	133	O	on
19	135	140	O	change
20	142	145	O	from
21	147	154	O	baseline
22	156	157	O	to
23	159	166	O	endpoint
24	168	169	O	on
25	171	173	O	the
26	175	178	O	DRSP
27	180	184	O	total
28	186	190	O	score
29	192	194	O	and
30	196	198	O	the
31	200	202	O	CGI
32	204	204	O	S
33	206	210	O	score
34	211	211	O	,
35	213	214	O	as
36	216	219	O	well
37	221	222	O	as
38	224	226	O	the
39	228	230	O	CGI
40	232	232	O	I
41	234	238	O	score
42	240	241	O	at
43	243	250	O	endpoint
NULL

Sertraline Hydrochloride	1681	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	17
There was insufficient information to determine the effect of race or age on outcome in these studies.
1	0	4	O	There
2	6	8	O	was
3	10	21	O	insufficient
4	23	33	O	information
5	35	36	O	to
6	38	46	O	determine
7	48	50	O	the
8	52	57	O	effect
9	59	60	O	of
10	62	65	O	race
11	67	68	O	or
12	70	72	O	age
13	74	75	O	on
14	77	83	O	outcome
15	85	86	O	in
16	88	92	O	these
17	94	100	O	studies
NULL

Sertraline Hydrochloride	1682	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	43
Social Anxiety Disorder - The effectiveness of sertraline hydrochloride in the treatment of social anxiety disorder (also known as social phobia) was established in two multicenter placebo-controlled studies (Study 1 and 2) of adult outpatients who met DSM-IV criteria for social anxiety disorder.
1	0	5	O	Social
2	7	13	O	Anxiety
3	15	22	O	Disorder
4	26	28	O	The
5	30	42	O	effectiveness
6	44	45	O	of
7	47	70	O	XXXXXXXX
8	72	73	O	in
9	75	77	O	the
10	79	87	O	treatment
11	89	90	O	of
12	92	97	O	social
13	99	105	O	anxiety
14	107	114	O	disorder
15	117	120	O	also
16	122	126	O	known
17	128	129	O	as
18	131	136	O	social
19	138	143	O	phobia
20	146	148	O	was
21	150	160	O	established
22	162	163	O	in
23	165	167	O	two
24	169	179	O	multicenter
25	181	187	O	placebo
26	189	198	O	controlled
27	200	206	O	studies
28	209	213	O	Study
29	215	215	O	1
30	217	219	O	and
31	221	221	O	2
32	224	225	O	of
33	227	231	O	adult
34	233	243	O	outpatients
35	245	247	O	who
36	249	251	O	met
37	253	255	O	DSM
38	257	258	O	IV
39	260	267	O	criteria
40	269	271	O	for
41	273	278	O	social
42	280	286	O	anxiety
43	288	295	O	disorder
NULL

Sertraline Hydrochloride	1683	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	37
Study 1 was a 12-week, multicenter, flexible dose study comparing sertraline hydrochloride (50 to 200 mg/day) to placebo, in which sertraline hydrochloride was initiated at 25 mg/day for the first week.
1	0	4	O	Study
2	6	6	O	1
3	8	10	O	was
4	12	12	O	a
5	14	15	O	12
6	17	20	O	week
7	21	21	O	,
8	23	33	O	multicenter
9	34	34	O	,
10	36	43	O	flexible
11	45	48	O	dose
12	50	54	O	study
13	56	64	O	comparing
14	66	89	O	XXXXXXXX
15	92	93	O	50
16	95	96	O	to
17	98	100	O	200
18	102	103	O	mg
19	104	104	O	/
20	105	107	O	day
21	110	111	O	to
22	113	119	O	placebo
23	120	120	O	,
24	122	123	O	in
25	125	129	O	which
26	131	154	O	XXXXXXXX
27	156	158	O	was
28	160	168	O	initiated
29	170	171	O	at
30	173	174	O	25
31	176	177	O	mg
32	178	178	O	/
33	179	181	O	day
34	183	185	O	for
35	187	189	O	the
36	191	195	O	first
37	197	200	O	week
NULL

Sertraline Hydrochloride	1684	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	61
Study outcome was assessed by (a) the Liebowitz Social Anxiety Scale (LSAS), a 24-item clinician administered instrument that measures fear, anxiety and avoidance of social and performance situations, and by (b) the proportion of responders as defined by the Clinical Global Impression of Improvement (CGI-I) criterion of CGI-I < 2 (very much or much improved).
1	0	4	O	Study
2	6	12	O	outcome
3	14	16	O	was
4	18	25	O	assessed
5	27	28	O	by
6	31	31	O	a
7	34	36	O	the
8	38	46	O	Liebowitz
9	48	53	O	Social
10	55	61	O	Anxiety
11	63	67	O	Scale
12	70	73	O	LSAS
13	75	75	O	,
14	77	77	O	a
15	79	80	O	24
16	82	85	O	item
17	87	95	O	clinician
18	97	108	O	administered
19	110	119	O	instrument
20	121	124	O	that
21	126	133	O	measures
22	135	138	O	fear
23	139	139	O	,
24	141	147	O	anxiety
25	149	151	O	and
26	153	161	O	avoidance
27	163	164	O	of
28	166	171	O	social
29	173	175	O	and
30	177	187	O	performance
31	189	198	O	situations
32	199	199	O	,
33	201	203	O	and
34	205	206	O	by
35	209	209	O	b
36	212	214	O	the
37	216	225	O	proportion
38	227	228	O	of
39	230	239	O	responders
40	241	242	O	as
41	244	250	O	defined
42	252	253	O	by
43	255	257	O	the
44	259	266	O	Clinical
45	268	273	O	Global
46	275	284	O	Impression
47	286	287	O	of
48	289	299	O	Improvement
49	302	304	O	CGI
50	306	306	O	I
51	309	317	O	criterion
52	319	320	O	of
53	322	324	O	CGI
54	326	326	O	I
55	328	328	O	<
56	330	330	O	2
57	333	336	O	very
58	338	341	O	much
59	343	344	O	or
60	346	349	O	much
61	351	358	O	improved
NULL

Sertraline Hydrochloride	1685	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	18
Sertraline hydrochloride was statistically significantly more effective than placebo as measured by the LSAS and the percentage of responders.
1	0	23	O	XXXXXXXX
2	25	27	O	was
3	29	41	O	statistically
4	43	55	O	significantly
5	57	60	O	more
6	62	70	O	effective
7	72	75	O	than
8	77	83	O	placebo
9	85	86	O	as
10	88	95	O	measured
11	97	98	O	by
12	100	102	O	the
13	104	107	O	LSAS
14	109	111	O	and
15	113	115	O	the
16	117	126	O	percentage
17	128	129	O	of
18	131	140	O	responders
NULL

Sertraline Hydrochloride	1686	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Study 2 was a 20-week, multicenter, flexible dose study that compared sertraline hydrochloride (50 to 200 mg/day) to placebo.
1	0	4	O	Study
2	6	6	O	2
3	8	10	O	was
4	12	12	O	a
5	14	15	O	20
6	17	20	O	week
7	21	21	O	,
8	23	33	O	multicenter
9	34	34	O	,
10	36	43	O	flexible
11	45	48	O	dose
12	50	54	O	study
13	56	59	O	that
14	61	68	O	compared
15	70	93	O	XXXXXXXX
16	96	97	O	50
17	99	100	O	to
18	102	104	O	200
19	106	107	O	mg
20	108	108	O	/
21	109	111	O	day
22	114	115	O	to
23	117	123	O	placebo
NULL

Sertraline Hydrochloride	1687	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	73
Study outcome was assessed by the (a) Duke Brief Social Phobia Scale (BSPS), a multi-item clinician-rated instrument that measures fear, avoidance and physiologic response to social or performance situations, (b) the Marks Fear Questionnaire Social Phobia Subscale (FQ-SPS), a 5-item patient-rated instrument that measures change in the severity of phobic avoidance and distress, and (c) the CGI-I responder criterion of < 2.
1	0	4	O	Study
2	6	12	O	outcome
3	14	16	O	was
4	18	25	O	assessed
5	27	28	O	by
6	30	32	O	the
7	35	35	O	a
8	38	41	O	Duke
9	43	47	O	Brief
10	49	54	O	Social
11	56	61	O	Phobia
12	63	67	O	Scale
13	70	73	O	BSPS
14	75	75	O	,
15	77	77	O	a
16	79	83	O	multi
17	85	88	O	item
18	90	98	O	clinician
19	100	104	O	rated
20	106	115	O	instrument
21	117	120	O	that
22	122	129	O	measures
23	131	134	O	fear
24	135	135	O	,
25	137	145	O	avoidance
26	147	149	O	and
27	151	161	O	physiologic
28	163	170	O	response
29	172	173	O	to
30	175	180	O	social
31	182	183	O	or
32	185	195	O	performance
33	197	206	O	situations
34	207	207	O	,
35	210	210	O	b
36	213	215	O	the
37	217	221	O	Marks
38	223	226	O	Fear
39	228	240	O	Questionnaire
40	242	247	O	Social
41	249	254	O	Phobia
42	256	263	O	Subscale
43	266	267	O	FQ
44	269	271	O	SPS
45	273	273	O	,
46	275	275	O	a
47	277	277	O	5
48	279	282	O	item
49	284	290	O	patient
50	292	296	O	rated
51	298	307	O	instrument
52	309	312	O	that
53	314	321	O	measures
54	323	328	O	change
55	330	331	O	in
56	333	335	O	the
57	337	344	O	severity
58	346	347	O	of
59	349	354	O	phobic
60	356	364	O	avoidance
61	366	368	O	and
62	370	377	O	distress
63	378	378	O	,
64	380	382	O	and
65	385	385	O	c
66	388	390	O	the
67	392	394	O	CGI
68	396	396	O	I
69	398	406	O	responder
70	408	416	O	criterion
71	418	419	O	of
72	421	421	O	<
73	423	423	O	2
NULL

Sertraline Hydrochloride	1688	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	50
Sertraline hydrochloride was shown to be statistically significantly more effective than placebo as measured by the BSPS total score and fear, avoidance and physiologic factor scores, as well as the FQ-SPS total score, and to have significantly more responders than placebo as defined by the CGI-I.
1	0	23	O	XXXXXXXX
2	25	27	O	was
3	29	33	O	shown
4	35	36	O	to
5	38	39	O	be
6	41	53	O	statistically
7	55	67	O	significantly
8	69	72	O	more
9	74	82	O	effective
10	84	87	O	than
11	89	95	O	placebo
12	97	98	O	as
13	100	107	O	measured
14	109	110	O	by
15	112	114	O	the
16	116	119	O	BSPS
17	121	125	O	total
18	127	131	O	score
19	133	135	O	and
20	137	140	O	fear
21	141	141	O	,
22	143	151	O	avoidance
23	153	155	O	and
24	157	167	O	physiologic
25	169	174	O	factor
26	176	181	O	scores
27	182	182	O	,
28	184	185	O	as
29	187	190	O	well
30	192	193	O	as
31	195	197	O	the
32	199	200	O	FQ
33	202	204	O	SPS
34	206	210	O	total
35	212	216	O	score
36	217	217	O	,
37	219	221	O	and
38	223	224	O	to
39	226	229	O	have
40	231	243	O	significantly
41	245	248	O	more
42	250	259	O	responders
43	261	264	O	than
44	266	272	O	placebo
45	274	275	O	as
46	277	283	O	defined
47	285	286	O	by
48	288	290	O	the
49	292	294	O	CGI
50	296	296	O	I
NULL

Sertraline Hydrochloride	1689	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	14
Subgroup analyses did not suggest differences in treatment outcome on the basis of gender.
1	0	7	O	Subgroup
2	9	16	O	analyses
3	18	20	O	did
4	22	24	O	not
5	26	32	O	suggest
6	34	44	O	differences
7	46	47	O	in
8	49	57	O	treatment
9	59	65	O	outcome
10	67	68	O	on
11	70	72	O	the
12	74	78	O	basis
13	80	81	O	of
14	83	88	O	gender
NULL

Sertraline Hydrochloride	1691	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	63
In a longer-term study, patients meeting DSM-IV criteria for social anxiety disorder who had responded while assigned to sertraline hydrochloride (CGI-I of 1 or 2) during a 20-week placebo-controlled trial on sertraline hydrochloride 50 to 200 mg/day were randomized to continuation of sertraline hydrochloride or to substitution of placebo for up to 24 weeks of observation for relapse.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	longer
4	12	15	O	term
5	17	21	O	study
6	22	22	O	,
7	24	31	O	patients
8	33	39	O	meeting
9	41	43	O	DSM
10	45	46	O	IV
11	48	55	O	criteria
12	57	59	O	for
13	61	66	O	social
14	68	74	O	anxiety
15	76	83	O	disorder
16	85	87	O	who
17	89	91	O	had
18	93	101	O	responded
19	103	107	O	while
20	109	116	O	assigned
21	118	119	O	to
22	121	144	O	XXXXXXXX
23	147	149	O	CGI
24	151	151	O	I
25	153	154	O	of
26	156	156	O	1
27	158	159	O	or
28	161	161	O	2
29	164	169	O	during
30	171	171	O	a
31	173	174	O	20
32	176	179	O	week
33	181	187	O	placebo
34	189	198	O	controlled
35	200	204	O	trial
36	206	207	O	on
37	209	232	O	XXXXXXXX
38	234	235	O	50
39	237	238	O	to
40	240	242	O	200
41	244	245	O	mg
42	246	246	O	/
43	247	249	O	day
44	251	254	O	were
45	256	265	O	randomized
46	267	268	O	to
47	270	281	O	continuation
48	283	284	O	of
49	286	309	O	XXXXXXXX
50	311	312	O	or
51	314	315	O	to
52	317	328	O	substitution
53	330	331	O	of
54	333	339	O	placebo
55	341	343	O	for
56	345	346	O	up
57	348	349	O	to
58	351	352	O	24
59	354	358	O	weeks
60	360	361	O	of
61	363	373	O	observation
62	375	377	O	for
63	379	385	O	relapse
NULL

Sertraline Hydrochloride	1692	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	30
Relapse was defined as > 2 point increase in the Clinical Global Impression - Severity of Illness (CGI-S) score compared to baseline or study discontinuation due to lack of efficacy.
1	0	6	O	Relapse
2	8	10	O	was
3	12	18	O	defined
4	20	21	O	as
5	23	23	O	>
6	25	25	O	2
7	27	31	O	point
8	33	40	O	increase
9	42	43	O	in
10	45	47	O	the
11	49	56	O	Clinical
12	58	63	O	Global
13	65	74	O	Impression
14	78	85	O	Severity
15	87	88	O	of
16	90	96	O	Illness
17	99	101	O	CGI
18	103	103	O	S
19	106	110	O	score
20	112	119	O	compared
21	121	122	O	to
22	124	131	O	baseline
23	133	134	O	or
24	136	140	O	study
25	142	156	O	discontinuation
26	158	160	O	due
27	162	163	O	to
28	165	168	O	lack
29	170	171	O	of
30	173	180	O	efficacy
NULL

Sertraline Hydrochloride	1693	34090-1	c25f968b-7037-4f60-9a02-2189769b0cbf	23
Patients receiving sertraline hydrochloride continuation treatment experienced a statistically significantly lower relapse rate over this 24-week study than patients randomized to placebo substitution.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	42	O	XXXXXXXX
4	44	55	O	continuation
5	57	65	O	treatment
6	67	77	O	experienced
7	79	79	O	a
8	81	93	O	statistically
9	95	107	O	significantly
10	109	113	O	lower
11	115	121	O	relapse
12	123	126	O	rate
13	128	131	O	over
14	133	136	O	this
15	138	139	O	24
16	141	144	O	week
17	146	150	O	study
18	152	155	O	than
19	157	164	O	patients
20	166	175	O	randomized
21	177	178	O	to
22	180	186	O	placebo
23	188	199	O	substitution
NULL

Temazepam	1694	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	35
In a single and multiple dose absorption, distribution, metabolism, and excretion (ADME) study, using 3H labeled drug, temazepam was well absorbed and found to have minimal (8%) first pass metabolism.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	14	O	and
5	16	23	O	multiple
6	25	28	O	dose
7	30	39	O	absorption
8	40	40	O	,
9	42	53	O	distribution
10	54	54	O	,
11	56	65	O	metabolism
12	66	66	O	,
13	68	70	O	and
14	72	80	O	excretion
15	83	86	O	ADME
16	89	93	O	study
17	94	94	O	,
18	96	100	O	using
19	102	103	O	3H
20	105	111	O	labeled
21	113	116	O	drug
22	117	117	O	,
23	119	127	O	XXXXXXXX
24	129	131	O	was
25	133	136	O	well
26	138	145	O	absorbed
27	147	149	O	and
28	151	155	O	found
29	157	158	O	to
30	160	163	O	have
31	165	171	O	minimal
32	174	175	O	8%
33	178	182	O	first
34	184	187	O	pass
35	189	198	O	metabolism
NULL

Temazepam	1695	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	18
There were no active metabolites formed and the only significant metabolite present in blood was the O-conjugate.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	19	O	active
5	21	31	O	metabolites
6	33	38	O	formed
7	40	42	O	and
8	44	46	O	the
9	48	51	O	only
10	53	63	O	significant
11	65	74	O	metabolite
12	76	82	O	present
13	84	85	O	in
14	87	91	O	blood
15	93	95	O	was
16	97	99	O	the
17	101	101	O	O
18	103	111	O	conjugate
NULL

Temazepam	1696	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	9
The unchanged drug was 96% bound to plasma proteins.
1	0	2	O	The
2	4	12	O	unchanged
3	14	17	O	drug
4	19	21	O	was
5	23	25	O	96%
6	27	31	O	bound
7	33	34	O	to
8	36	41	O	plasma
9	43	50	O	proteins
NULL

Temazepam	1697	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	44
The blood level decline of the parent drug was biphasic with the short half-life ranging from 0.4 to 0.6 hours and the terminal half-life from 3.5 to 18.4 hours (mean 8.8 hours), depending on the study population and method of determination.
1	0	2	O	The
2	4	8	O	blood
3	10	14	O	level
4	16	22	O	decline
5	24	25	O	of
6	27	29	O	the
7	31	36	O	parent
8	38	41	O	drug
9	43	45	O	was
10	47	54	O	biphasic
11	56	59	O	with
12	61	63	O	the
13	65	69	O	short
14	71	74	O	half
15	76	79	O	life
16	81	87	O	ranging
17	89	92	O	from
18	94	96	O	0.4
19	98	99	O	to
20	101	103	O	0.6
21	105	109	O	hours
22	111	113	O	and
23	115	117	O	the
24	119	126	O	terminal
25	128	131	O	half
26	133	136	O	life
27	138	141	O	from
28	143	145	O	3.5
29	147	148	O	to
30	150	153	O	18.4
31	155	159	O	hours
32	162	165	O	mean
33	167	169	O	8.8
34	171	175	O	hours
35	177	177	O	,
36	179	187	O	depending
37	189	190	O	on
38	192	194	O	the
39	196	200	O	study
40	202	211	O	population
41	213	215	O	and
42	217	222	O	method
43	224	225	O	of
44	227	239	O	determination
NULL

Temazepam	1698	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	20
Metabolites were formed with a half-life of 10 hours and excreted with a half-life of approximately 2 hours.
1	0	10	O	Metabolites
2	12	15	O	were
3	17	22	O	formed
4	24	27	O	with
5	29	29	O	a
6	31	34	O	half
7	36	39	O	life
8	41	42	O	of
9	44	45	O	10
10	47	51	O	hours
11	53	55	O	and
12	57	64	O	excreted
13	66	69	O	with
14	71	71	O	a
15	73	76	O	half
16	78	81	O	life
17	83	84	O	of
18	86	98	O	approximately
19	100	100	O	2
20	102	106	O	hours
NULL

Temazepam	1699	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	17
Thus, formation of the major metabolite is the rate limiting step in the biodisposition of temazepam.
1	0	3	O	Thus
2	4	4	O	,
3	6	14	O	formation
4	16	17	O	of
5	19	21	O	the
6	23	27	O	major
7	29	38	O	metabolite
8	40	41	O	is
9	43	45	O	the
10	47	50	O	rate
11	52	59	O	limiting
12	61	64	O	step
13	66	67	O	in
14	69	71	O	the
15	73	86	O	biodisposition
16	88	89	O	of
17	91	99	O	XXXXXXXX
NULL

Temazepam	1700	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	26
A dose proportional relationship has been established for the area under the plasma concentration/time curve over the 15 mg to 30 mg dose range.
1	0	0	O	A
2	2	5	O	dose
3	7	18	O	proportional
4	20	31	O	relationship
5	33	35	O	has
6	37	40	O	been
7	42	52	O	established
8	54	56	O	for
9	58	60	O	the
10	62	65	O	area
11	67	71	O	under
12	73	75	O	the
13	77	82	O	plasma
14	84	96	O	concentration
15	97	97	O	/
16	98	101	O	time
17	103	107	O	curve
18	109	112	O	over
19	114	116	O	the
20	118	119	O	15
21	121	122	O	mg
22	124	125	O	to
23	127	128	O	30
24	130	131	O	mg
25	133	136	O	dose
26	138	142	O	range
NULL

Temazepam	1701	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	19
Temazepam was completely metabolized through conjugation prior to excretion; 80% to 90% of the dose appeared in the urine.
1	0	8	O	XXXXXXXX
2	10	12	O	was
3	14	23	O	completely
4	25	35	O	metabolized
5	37	43	O	through
6	45	55	O	conjugation
7	57	61	O	prior
8	63	64	O	to
9	66	74	O	excretion
10	77	79	O	80%
11	81	82	O	to
12	84	86	O	90%
13	88	89	O	of
14	91	93	O	the
15	95	98	O	dose
16	100	107	O	appeared
17	109	110	O	in
18	112	114	O	the
19	116	120	O	urine
NULL

Temazepam	1702	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	22
The major metabolite was the O-conjugate of temazepam (90%); the O-conjugate of N-desmethyl temazepam was a minor metabolite (7%).
1	0	2	O	The
2	4	8	O	major
3	10	19	O	metabolite
4	21	23	O	was
5	25	27	O	the
6	29	29	O	O
7	31	39	O	conjugate
8	41	42	O	of
9	44	52	O	XXXXXXXX
10	55	57	O	90%
11	61	63	O	the
12	65	65	O	O
13	67	75	O	conjugate
14	77	78	O	of
15	80	80	O	N
16	82	90	O	desmethyl
17	92	100	O	XXXXXXXX
18	102	104	O	was
19	106	106	O	a
20	108	112	O	minor
21	114	123	O	metabolite
22	126	127	O	7%
NULL

Temazepam	1703	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	48
Following ingestion of a 30 mg temazepam capsule, measurable plasma concentrations were achieved 10 to 20 minutes after dosing with peak plasma levels ranging from 666 to 982 ng/mL (mean 865 ng/mL) occurring approximately 1.2 to 1.6 hours (mean 1.5 hours) after dosing.
1	0	8	O	Following
2	10	18	O	ingestion
3	20	21	O	of
4	23	23	O	a
5	25	26	O	30
6	28	29	O	mg
7	31	39	O	XXXXXXXX
8	41	47	O	capsule
9	48	48	O	,
10	50	59	O	measurable
11	61	66	O	plasma
12	68	81	O	concentrations
13	83	86	O	were
14	88	95	O	achieved
15	97	98	O	10
16	100	101	O	to
17	103	104	O	20
18	106	112	O	minutes
19	114	118	O	after
20	120	125	O	dosing
21	127	130	O	with
22	132	135	O	peak
23	137	142	O	plasma
24	144	149	O	levels
25	151	157	O	ranging
26	159	162	O	from
27	164	166	O	666
28	168	169	O	to
29	171	173	O	982
30	175	176	O	ng
31	177	177	O	/
32	178	179	O	mL
33	182	185	O	mean
34	187	189	O	865
35	191	192	O	ng
36	193	193	O	/
37	194	195	O	mL
38	198	206	O	occurring
39	208	220	O	approximately
40	222	224	O	1.2
41	226	227	O	to
42	229	231	O	1.6
43	233	237	O	hours
44	240	243	O	mean
45	245	247	O	1.5
46	249	253	O	hours
47	256	260	O	after
48	262	267	O	dosing
NULL

Temazepam	1704	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	43
In a 7-day study, in which subjects were given a 30 mg capsule of a marketed bioequivalent temazepam product one hour before retiring, steady-state (as measured by the attainment of maximal trough concentrations) was achieved by the third dose.
1	0	1	O	In
2	3	3	O	a
3	5	5	O	7
4	7	9	O	day
5	11	15	O	study
6	16	16	O	,
7	18	19	O	in
8	21	25	O	which
9	27	34	O	subjects
10	36	39	O	were
11	41	45	O	given
12	47	47	O	a
13	49	50	O	30
14	52	53	O	mg
15	55	61	O	capsule
16	63	64	O	of
17	66	66	O	a
18	68	75	O	marketed
19	77	89	O	bioequivalent
20	91	99	O	XXXXXXXX
21	101	107	O	product
22	109	111	O	one
23	113	116	O	hour
24	118	123	O	before
25	125	132	O	retiring
26	133	133	O	,
27	135	140	O	steady
28	142	146	O	state
29	149	150	O	as
30	152	159	O	measured
31	161	162	O	by
32	164	166	O	the
33	168	177	O	attainment
34	179	180	O	of
35	182	188	O	maximal
36	190	195	O	trough
37	197	210	O	concentrations
38	213	215	O	was
39	217	224	O	achieved
40	226	227	O	by
41	229	231	O	the
42	233	237	O	third
43	239	242	O	dose
NULL

Temazepam	1705	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	32
Mean plasma levels of temazepam (for days 2 to 7) were 260 * 210 ng/mL at 9 hours and 75 * 80 ng/mL at 24 hours after dosing.
1	0	3	O	Mean
2	5	10	O	plasma
3	12	17	O	levels
4	19	20	O	of
5	22	30	O	XXXXXXXX
6	33	35	O	for
7	37	40	O	days
8	42	42	O	2
9	44	45	O	to
10	47	47	O	7
11	50	53	O	were
12	55	57	O	260
13	59	59	O	*
14	61	63	O	210
15	65	66	O	ng
16	67	67	O	/
17	68	69	O	mL
18	71	72	O	at
19	74	74	O	9
20	76	80	O	hours
21	82	84	O	and
22	86	87	O	75
23	89	89	O	*
24	91	92	O	80
25	94	95	O	ng
26	96	96	O	/
27	97	98	O	mL
28	100	101	O	at
29	103	104	O	24
30	106	110	O	hours
31	112	116	O	after
32	118	123	O	dosing
NULL

Temazepam	1706	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	28
A slight trend toward declining 24 hour plasma levels was seen after day 4 in the study, however, the 24 hour plasma levels were quite variable.
1	0	0	O	A
2	2	7	O	slight
3	9	13	O	trend
4	15	20	O	toward
5	22	30	O	declining
6	32	33	O	24
7	35	38	O	hour
8	40	45	O	plasma
9	47	52	O	levels
10	54	56	O	was
11	58	61	O	seen
12	63	67	O	after
13	69	71	O	day
14	73	73	O	4
15	75	76	O	in
16	78	80	O	the
17	82	86	O	study
18	87	87	O	,
19	89	95	O	however
20	96	96	O	,
21	98	100	O	the
22	102	103	O	24
23	105	108	O	hour
24	110	115	O	plasma
25	117	122	O	levels
26	124	127	O	were
27	129	133	O	quite
28	135	142	O	variable
NULL

Temazepam	1707	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	22
At a dose of 30 mg once a day for 8 weeks, no evidence of enzyme induction was found in man.
1	0	1	O	At
2	3	3	O	a
3	5	8	O	dose
4	10	11	O	of
5	13	14	O	30
6	16	17	O	mg
7	19	22	O	once
8	24	24	O	a
9	26	28	O	day
10	30	32	O	for
11	34	34	O	8
12	36	40	O	weeks
13	41	41	O	,
14	43	44	O	no
15	46	53	O	evidence
16	55	56	O	of
17	58	63	O	enzyme
18	65	73	O	induction
19	75	77	O	was
20	79	83	O	found
21	85	86	O	in
22	88	90	O	man
NULL

Temazepam	1708	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	43
The type and duration of hypnotic effects and the profile of unwanted effects during administration of benzodiazepine hypnotics may be influenced by the biologic half-life of the administered drug and for some hypnotics, the half-life of any active metabolites formed.
1	0	2	O	The
2	4	7	O	type
3	9	11	O	and
4	13	20	O	duration
5	22	23	O	of
6	25	32	O	hypnotic
7	34	40	O	effects
8	42	44	O	and
9	46	48	O	the
10	50	56	O	profile
11	58	59	O	of
12	61	68	O	unwanted
13	70	76	O	effects
14	78	83	O	during
15	85	98	O	administration
16	100	101	O	of
17	103	116	O	benzodiazepine
18	118	126	O	hypnotics
19	128	130	O	may
20	132	133	O	be
21	135	144	O	influenced
22	146	147	O	by
23	149	151	O	the
24	153	160	O	biologic
25	162	165	O	half
26	167	170	O	life
27	172	173	O	of
28	175	177	O	the
29	179	190	O	administered
30	192	195	O	drug
31	197	199	O	and
32	201	203	O	for
33	205	208	O	some
34	210	218	O	hypnotics
35	219	219	O	,
36	221	223	O	the
37	225	228	O	half
38	230	233	O	life
39	235	236	O	of
40	238	240	O	any
41	242	247	O	active
42	249	259	O	metabolites
43	261	266	O	formed
NULL

Temazepam	1709	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	18
Benzodiazepine hypnotics have a spectrum of half-lives from short (< 4 hours) to long (> 20 hours).
1	0	13	O	Benzodiazepine
2	15	23	O	hypnotics
3	25	28	O	have
4	30	30	O	a
5	32	39	O	spectrum
6	41	42	O	of
7	44	47	O	half
8	49	53	O	lives
9	55	58	O	from
10	60	64	O	short
11	67	67	O	<
12	69	69	O	4
13	71	75	O	hours
14	78	79	O	to
15	81	84	O	long
16	87	87	O	>
17	89	90	O	20
18	92	96	O	hours
NULL

Temazepam	1710	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	49
When half-lives are long, drug (and for some drugs their active metabolites) may accumulate during periods of nightly administration and be associated with impairments of cognitive and/or motor performance during waking hours; the possibility of interaction with other psychoactive drugs or alcohol will be enhanced.
1	0	3	O	When
2	5	8	O	half
3	10	14	O	lives
4	16	18	O	are
5	20	23	O	long
6	24	24	O	,
7	26	29	O	drug
8	32	34	O	and
9	36	38	O	for
10	40	43	O	some
11	45	49	O	drugs
12	51	55	O	their
13	57	62	O	active
14	64	74	O	metabolites
15	77	79	O	may
16	81	90	O	accumulate
17	92	97	O	during
18	99	105	O	periods
19	107	108	O	of
20	110	116	O	nightly
21	118	131	O	administration
22	133	135	O	and
23	137	138	O	be
24	140	149	O	associated
25	151	154	O	with
26	156	166	O	impairments
27	168	169	O	of
28	171	179	O	cognitive
29	181	183	O	and
30	184	184	O	/
31	185	186	O	or
32	188	192	O	motor
33	194	204	O	performance
34	206	211	O	during
35	213	218	O	waking
36	220	224	O	hours
37	227	229	O	the
38	231	241	O	possibility
39	243	244	O	of
40	246	256	O	interaction
41	258	261	O	with
42	263	267	O	other
43	269	280	O	psychoactive
44	282	286	O	drugs
45	288	289	O	or
46	291	297	O	alcohol
47	299	302	O	will
48	304	305	O	be
49	307	314	O	enhanced
NULL

Temazepam	1711	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	44
In contrast, if half-lives are shorter, drug (and, where appropriate, its active metabolites) will be cleared before the next dose is ingested, and carry over effects related to excessive sedation or CNS depression should be minimal or absent.
1	0	1	O	In
2	3	10	O	contrast
3	11	11	O	,
4	13	14	O	if
5	16	19	O	half
6	21	25	O	lives
7	27	29	O	are
8	31	37	O	shorter
9	38	38	O	,
10	40	43	O	drug
11	46	48	O	and
12	49	49	O	,
13	51	55	O	where
14	57	67	O	appropriate
15	68	68	O	,
16	70	72	O	its
17	74	79	O	active
18	81	91	O	metabolites
19	94	97	O	will
20	99	100	O	be
21	102	108	O	cleared
22	110	115	O	before
23	117	119	O	the
24	121	124	O	next
25	126	129	O	dose
26	131	132	O	is
27	134	141	O	ingested
28	142	142	O	,
29	144	146	O	and
30	148	152	O	carry
31	154	157	O	over
32	159	165	O	effects
33	167	173	O	related
34	175	176	O	to
35	178	186	O	excessive
36	188	195	O	sedation
37	197	198	O	or
38	200	202	O	CNS
39	204	213	O	depression
40	215	220	O	should
41	222	223	O	be
42	225	231	O	minimal
43	233	234	O	or
44	236	241	O	absent
NULL

Temazepam	1712	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	22
However, during nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of benzodiazepine hypnotics may develop.
1	0	6	O	However
2	7	7	O	,
3	9	14	O	during
4	16	22	O	nightly
5	24	26	O	use
6	28	30	O	for
7	32	33	O	an
8	35	42	O	extended
9	44	49	O	period
10	50	50	O	,
11	52	66	O	pharmacodynamic
12	68	76	O	tolerance
13	78	79	O	or
14	81	90	O	adaptation
15	92	93	O	to
16	95	98	O	some
17	100	106	O	effects
18	108	109	O	of
19	111	124	O	benzodiazepine
20	126	134	O	hypnotics
21	136	138	O	may
22	140	146	O	develop
NULL

Temazepam	1713	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	49
If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug, or, if appropriate, its active metabolites (i.e., in relationship to the receptor site) may occur at some point in the interval between each night's use.
1	0	1	O	If
2	3	5	O	the
3	7	10	O	drug
4	12	14	O	has
5	16	16	O	a
6	18	22	O	short
7	24	34	O	elimination
8	36	39	O	half
9	41	44	O	life
10	45	45	O	,
11	47	48	O	it
12	50	51	O	is
13	53	60	O	possible
14	62	65	O	that
15	67	67	O	a
16	69	76	O	relative
17	78	87	O	deficiency
18	89	90	O	of
19	92	94	O	the
20	96	99	O	drug
21	100	100	O	,
22	102	103	O	or
23	104	104	O	,
24	106	107	O	if
25	109	119	O	appropriate
26	120	120	O	,
27	122	124	O	its
28	126	131	O	active
29	133	143	O	metabolites
30	146	148	O	i.e
31	150	150	O	,
32	152	153	O	in
33	155	166	O	relationship
34	168	169	O	to
35	171	173	O	the
36	175	182	O	receptor
37	184	187	O	site
38	190	192	O	may
39	194	198	O	occur
40	200	201	O	at
41	203	206	O	some
42	208	212	O	point
43	214	215	O	in
44	217	219	O	the
45	221	228	O	interval
46	230	236	O	between
47	238	241	O	each
48	243	249	O	night's
49	251	253	O	use
NULL

Temazepam	1714	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	46
This sequence of events may account for two clinical findings reported to occur after several weeks of nightly use of rapidly eliminated benzodiazepine hypnotics, namely, increased wakefulness during the last third of the night, and the appearance of increased signs of daytime anxiety.
1	0	3	O	This
2	5	12	O	sequence
3	14	15	O	of
4	17	22	O	events
5	24	26	O	may
6	28	34	O	account
7	36	38	O	for
8	40	42	O	two
9	44	51	O	clinical
10	53	60	O	findings
11	62	69	O	reported
12	71	72	O	to
13	74	78	O	occur
14	80	84	O	after
15	86	92	O	several
16	94	98	O	weeks
17	100	101	O	of
18	103	109	O	nightly
19	111	113	O	use
20	115	116	O	of
21	118	124	O	rapidly
22	126	135	O	eliminated
23	137	150	O	benzodiazepine
24	152	160	O	hypnotics
25	161	161	O	,
26	163	168	O	namely
27	169	169	O	,
28	171	179	O	increased
29	181	191	O	wakefulness
30	193	198	O	during
31	200	202	O	the
32	204	207	O	last
33	209	213	O	third
34	215	216	O	of
35	218	220	O	the
36	222	226	O	night
37	227	227	O	,
38	229	231	O	and
39	233	235	O	the
40	237	246	O	appearance
41	248	249	O	of
42	251	259	O	increased
43	261	265	O	signs
44	267	268	O	of
45	270	276	O	daytime
46	278	284	O	anxiety
NULL

Temazepam	1715	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	7
Temazepam improved sleep parameters in clinical studies.
1	0	8	O	XXXXXXXX
2	10	17	O	improved
3	19	23	O	sleep
4	25	34	O	parameters
5	36	37	O	in
6	39	46	O	clinical
7	48	54	O	studies
NULL

Temazepam	1716	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	7
Residual medication effects ("hangover") were essentially absent.
1	0	7	O	Residual
2	9	18	O	medication
3	20	26	O	effects
4	29	38	O	"hangover"
5	41	44	O	were
6	46	56	O	essentially
7	58	63	O	absent
NULL

Temazepam	1717	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	15
Early morning awakening, a particular problem in the geriatric patient, was significantly reduced.
1	0	4	O	Early
2	6	12	O	morning
3	14	22	O	awakening
4	23	23	O	,
5	25	25	O	a
6	27	36	O	particular
7	38	44	O	problem
8	46	47	O	in
9	49	51	O	the
10	53	61	O	geriatric
11	63	69	O	patient
12	70	70	O	,
13	72	74	O	was
14	76	88	O	significantly
15	90	96	O	reduced
NULL

Temazepam	1718	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	35
Patients with chronic insomnia were evaluated in 2-week, placebo controlled sleep laboratory studies with temazepam at doses of 7.5 mg, 15 mg and 30 mg, given 30 minutes prior to bedtime.
1	0	7	O	Patients
2	9	12	O	with
3	14	20	O	chronic
4	22	29	O	insomnia
5	31	34	O	were
6	36	44	O	evaluated
7	46	47	O	in
8	49	49	O	2
9	51	54	O	week
10	55	55	O	,
11	57	63	O	placebo
12	65	74	O	controlled
13	76	80	O	sleep
14	82	91	O	laboratory
15	93	99	O	studies
16	101	104	O	with
17	106	114	O	XXXXXXXX
18	116	117	O	at
19	119	123	O	doses
20	125	126	O	of
21	128	130	O	7.5
22	132	133	O	mg
23	134	134	O	,
24	136	137	O	15
25	139	140	O	mg
26	142	144	O	and
27	146	147	O	30
28	149	150	O	mg
29	151	151	O	,
30	153	157	O	given
31	159	160	O	30
32	162	168	O	minutes
33	170	174	O	prior
34	176	177	O	to
35	179	185	O	bedtime
NULL

Temazepam	1719	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	44
There was a linear dose-response improvement in total sleep time and sleep latency, with significant drug-placebo differences at 2 weeks occurring only for total sleep time at the two higher doses, and for sleep latency only at the highest dose.
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	17	O	linear
5	19	22	O	dose
6	24	31	O	response
7	33	43	O	improvement
8	45	46	O	in
9	48	52	O	total
10	54	58	O	sleep
11	60	63	O	time
12	65	67	O	and
13	69	73	O	sleep
14	75	81	O	latency
15	82	82	O	,
16	84	87	O	with
17	89	99	O	significant
18	101	104	O	drug
19	106	112	O	placebo
20	114	124	O	differences
21	126	127	O	at
22	129	129	O	2
23	131	135	O	weeks
24	137	145	O	occurring
25	147	150	O	only
26	152	154	O	for
27	156	160	O	total
28	162	166	O	sleep
29	168	171	O	time
30	173	174	O	at
31	176	178	O	the
32	180	182	O	two
33	184	189	O	higher
34	191	195	O	doses
35	196	196	O	,
36	198	200	O	and
37	202	204	O	for
38	206	210	O	sleep
39	212	218	O	latency
40	220	223	O	only
41	225	226	O	at
42	228	230	O	the
43	232	238	O	highest
44	240	243	O	dose
NULL

Temazepam	1720	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	17
In these sleep laboratory studies, REM sleep was essentially unchanged and slow wave sleep was decreased.
1	0	1	O	In
2	3	7	O	these
3	9	13	O	sleep
4	15	24	O	laboratory
5	26	32	O	studies
6	33	33	O	,
7	35	37	O	REM
8	39	43	O	sleep
9	45	47	O	was
10	49	59	O	essentially
11	61	69	O	unchanged
12	71	73	O	and
13	75	78	O	slow
14	80	83	O	wave
15	85	89	O	sleep
16	91	93	O	was
17	95	103	O	decreased
NULL

Temazepam	1721	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	36
No measurable effects on daytime alertness or performance occurred following temazepam treatment or during the withdrawal period, even though a transient sleep disturbance in some sleep parameters was observed following withdrawal of the higher doses.
1	0	1	O	No
2	3	12	O	measurable
3	14	20	O	effects
4	22	23	O	on
5	25	31	O	daytime
6	33	41	O	alertness
7	43	44	O	or
8	46	56	O	performance
9	58	65	O	occurred
10	67	75	O	following
11	77	85	O	XXXXXXXX
12	87	95	O	treatment
13	97	98	O	or
14	100	105	O	during
15	107	109	O	the
16	111	120	O	withdrawal
17	122	127	O	period
18	128	128	O	,
19	130	133	O	even
20	135	140	O	though
21	142	142	O	a
22	144	152	O	transient
23	154	158	O	sleep
24	160	170	O	disturbance
25	172	173	O	in
26	175	178	O	some
27	180	184	O	sleep
28	186	195	O	parameters
29	197	199	O	was
30	201	208	O	observed
31	210	218	O	following
32	220	229	O	withdrawal
33	231	232	O	of
34	234	236	O	the
35	238	243	O	higher
36	245	249	O	doses
NULL

Temazepam	1722	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	23
There was no evidence of tolerance development in the sleep laboratory parameters when patients were given temazepam nightly for at least 2 weeks.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	of
6	25	33	O	tolerance
7	35	45	O	development
8	47	48	O	in
9	50	52	O	the
10	54	58	O	sleep
11	60	69	O	laboratory
12	71	80	O	parameters
13	82	85	O	when
14	87	94	O	patients
15	96	99	O	were
16	101	105	O	given
17	107	115	O	XXXXXXXX
18	117	123	O	nightly
19	125	127	O	for
20	129	130	O	at
21	132	136	O	least
22	138	138	O	2
23	140	144	O	weeks
NULL

Temazepam	1723	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	48
In addition, normal subjects with transient insomnia associated with first night adaptation to the sleep laboratory were evaluated in 24-hour, placebo controlled sleep laboratory studies with temazepam at doses of 7.5 mg, 15 mg and 30 mg, given 30 minutes prior to bedtime.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	18	O	normal
5	20	27	O	subjects
6	29	32	O	with
7	34	42	O	transient
8	44	51	O	insomnia
9	53	62	O	associated
10	64	67	O	with
11	69	73	O	first
12	75	79	O	night
13	81	90	O	adaptation
14	92	93	O	to
15	95	97	O	the
16	99	103	O	sleep
17	105	114	O	laboratory
18	116	119	O	were
19	121	129	O	evaluated
20	131	132	O	in
21	134	135	O	24
22	137	140	O	hour
23	141	141	O	,
24	143	149	O	placebo
25	151	160	O	controlled
26	162	166	O	sleep
27	168	177	O	laboratory
28	179	185	O	studies
29	187	190	O	with
30	192	200	O	XXXXXXXX
31	202	203	O	at
32	205	209	O	doses
33	211	212	O	of
34	214	216	O	7.5
35	218	219	O	mg
36	220	220	O	,
37	222	223	O	15
38	225	226	O	mg
39	228	230	O	and
40	232	233	O	30
41	235	236	O	mg
42	237	237	O	,
43	239	243	O	given
44	245	246	O	30
45	248	254	O	minutes
46	256	260	O	prior
47	262	263	O	to
48	265	271	O	bedtime
NULL

Temazepam	1724	34090-1	a4ee3907-45d4-41b9-af8a-39a9966cd533	52
There was a linear dose-response improvement in total sleep time, sleep latency and number of awakenings, with significant drug-placebo differences occurring for sleep latency at all doses, for total sleep time at the two higher doses and for number of awakenings only at the 30 mg dose.
1	0	4	O	There
2	6	8	O	was
3	10	10	O	a
4	12	17	O	linear
5	19	22	O	dose
6	24	31	O	response
7	33	43	O	improvement
8	45	46	O	in
9	48	52	O	total
10	54	58	O	sleep
11	60	63	O	time
12	64	64	O	,
13	66	70	O	sleep
14	72	78	O	latency
15	80	82	O	and
16	84	89	O	number
17	91	92	O	of
18	94	103	O	awakenings
19	104	104	O	,
20	106	109	O	with
21	111	121	O	significant
22	123	126	O	drug
23	128	134	O	placebo
24	136	146	O	differences
25	148	156	O	occurring
26	158	160	O	for
27	162	166	O	sleep
28	168	174	O	latency
29	176	177	O	at
30	179	181	O	all
31	183	187	O	doses
32	188	188	O	,
33	190	192	O	for
34	194	198	O	total
35	200	204	O	sleep
36	206	209	O	time
37	211	212	O	at
38	214	216	O	the
39	218	220	O	two
40	222	227	O	higher
41	229	233	O	doses
42	235	237	O	and
43	239	241	O	for
44	243	248	O	number
45	250	251	O	of
46	253	262	O	awakenings
47	264	267	O	only
48	269	270	O	at
49	272	274	O	the
50	276	277	O	30
51	279	280	O	mg
52	282	285	O	dose
NULL

Thioridazine Hydrochloride	1725	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	38
Reduced cytochrome P450 2D6 isozyme activity, drugs which inhibit this isozyme (e.g., fluoxetine and paroxetine), and certain other drugs (e.g., fluvoxamine, propranolol, and pindolol) appear to appreciably inhibit the metabolism of thioridazine.
1	0	6	O	Reduced
2	8	17	O	cytochrome
3	19	22	O	P450
4	24	26	O	2D6
5	28	34	O	isozyme
6	36	43	O	activity
7	44	44	O	,
8	46	50	O	drugs
9	52	56	O	which
10	58	64	O	inhibit
11	66	69	O	this
12	71	77	O	isozyme
13	80	82	O	e.g
14	84	84	O	,
15	86	95	U-KIN	fluoxetine
16	97	99	O	and
17	101	110	U-KIN	paroxetine
18	112	112	O	,
19	114	116	O	and
20	118	124	O	certain
21	126	130	O	other
22	132	136	O	drugs
23	139	141	O	e.g
24	143	143	O	,
25	145	155	U-KIN	fluvoxamine
26	156	156	O	,
27	158	168	U-KIN	propranolol
28	169	169	O	,
29	171	173	O	and
30	175	182	U-KIN	pindolol
31	185	190	O	appear
32	192	193	O	to
33	195	205	O	appreciably
34	207	213	B-TRI	inhibit
35	215	217	I-TRI	the
36	219	228	L-TRI	metabolism
37	230	231	O	of
38	233	244	O	XXXXXXXX
K/15:C54355 K/17:C54355 K/25:C54355 K/27:C54355 K/30:C54355

Thioridazine Hydrochloride	1726	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	41
The resulting elevated levels of thioridazine would be expected to augment the prolongation of the QTc interval associated with thioridazine and may increase the risk of serious, potentially fatal, cardiac arrhythmias, such as Torsades de pointes type arrhythmias.
1	0	2	O	The
2	4	12	O	resulting
3	14	21	O	elevated
4	23	28	O	levels
5	30	31	O	of
6	33	44	O	XXXXXXXX
7	46	50	O	would
8	52	53	O	be
9	55	62	O	expected
10	64	65	O	to
11	67	73	O	augment
12	75	77	O	the
13	79	90	O	prolongation
14	92	93	O	of
15	95	97	O	the
16	99	101	O	QTc
17	103	110	O	interval
18	112	121	O	associated
19	123	126	O	with
20	128	139	O	XXXXXXXX
21	141	143	O	and
22	145	147	O	may
23	149	156	O	increase
24	158	160	O	the
25	162	165	O	risk
26	167	168	O	of
27	170	176	O	serious
28	177	177	O	,
29	179	189	O	potentially
30	191	195	O	fatal
31	196	196	O	,
32	198	204	O	cardiac
33	206	216	O	arrhythmias
34	217	217	O	,
35	219	222	O	such
36	224	225	O	as
37	227	234	O	Torsades
38	236	237	O	de
39	239	245	O	pointes
40	247	250	O	type
41	252	262	O	arrhythmias
NULL

Thioridazine Hydrochloride	1727	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	22
Such an increased risk may result also from the additive effect of coadministering thioridazine with other agents that prolong the QTc interval.
1	0	3	O	Such
2	5	6	O	an
3	8	16	O	increased
4	18	21	O	risk
5	23	25	O	may
6	27	32	O	result
7	34	37	O	also
8	39	42	O	from
9	44	46	O	the
10	48	55	O	additive
11	57	62	O	effect
12	64	65	O	of
13	67	81	O	coadministering
14	83	94	O	XXXXXXXX
15	96	99	O	with
16	101	105	O	other
17	107	112	B-DYN	agents
18	114	117	I-DYN	that
19	119	125	I-DYN	prolong
20	127	129	I-DYN	the
21	131	133	I-DYN	QTc
22	135	142	L-DYN	interval
NULL

Thioridazine Hydrochloride	1728	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	39
Therefore, thioridazine is contraindicated with these drugs as well as in patients, comprising about 7% of the normal population, who are known to have a genetic defect leading to reduced levels of activity of P450 2D6.
1	0	8	O	Therefore
2	9	9	O	,
3	11	22	O	XXXXXXXX
4	24	25	O	is
5	27	41	O	contraindicated
6	43	46	O	with
7	48	52	O	these
8	54	58	O	drugs
9	60	61	O	as
10	63	66	O	well
11	68	69	O	as
12	71	72	O	in
13	74	81	O	patients
14	82	82	O	,
15	84	93	O	comprising
16	95	99	O	about
17	101	102	O	7%
18	104	105	O	of
19	107	109	O	the
20	111	116	O	normal
21	118	127	O	population
22	128	128	O	,
23	130	132	O	who
24	134	136	O	are
25	138	142	O	known
26	144	145	O	to
27	147	150	O	have
28	152	152	O	a
29	154	160	O	genetic
30	162	167	O	defect
31	169	175	O	leading
32	177	178	O	to
33	180	186	O	reduced
34	188	193	O	levels
35	195	196	O	of
36	198	205	O	activity
37	207	208	O	of
38	210	213	O	P450
39	215	217	O	2D6
NULL

Thioridazine Hydrochloride	1729	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	50
In a study of 19 healthy male subjects, which included 6 slow and 13 rapid hydroxylators of debrisoquin, a single 25 mg oral dose of thioridazine produced a 2.4-fold higher Cmax and a 4.5-fold higher AUC for thioridazine in the slow hydroxylators compared to rapid hydroxylators.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	15	O	19
6	17	23	O	healthy
7	25	28	O	male
8	30	37	O	subjects
9	38	38	O	,
10	40	44	O	which
11	46	53	O	included
12	55	55	O	6
13	57	60	O	slow
14	62	64	O	and
15	66	67	O	13
16	69	73	O	rapid
17	75	87	O	hydroxylators
18	89	90	O	of
19	92	102	O	debrisoquin
20	103	103	O	,
21	105	105	O	a
22	107	112	O	single
23	114	115	O	25
24	117	118	O	mg
25	120	123	O	oral
26	125	128	O	dose
27	130	131	O	of
28	133	144	O	XXXXXXXX
29	146	153	O	produced
30	155	155	O	a
31	157	159	O	2.4
32	161	164	O	fold
33	166	171	O	higher
34	173	176	O	Cmax
35	178	180	O	and
36	182	182	O	a
37	184	186	O	4.5
38	188	191	O	fold
39	193	198	O	higher
40	200	202	O	AUC
41	204	206	O	for
42	208	219	O	XXXXXXXX
43	221	222	O	in
44	224	226	O	the
45	228	231	O	slow
46	233	245	O	hydroxylators
47	247	254	O	compared
48	256	257	O	to
49	259	263	O	rapid
50	265	277	O	hydroxylators
NULL

Thioridazine Hydrochloride	1730	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	18
The rate of debrisoquin hydroxylation is felt to depend on the level of cytochrome P450 2D6 isozyme activity.
1	0	2	O	The
2	4	7	O	rate
3	9	10	O	of
4	12	22	O	debrisoquin
5	24	36	O	hydroxylation
6	38	39	O	is
7	41	44	O	felt
8	46	47	O	to
9	49	54	O	depend
10	56	57	O	on
11	59	61	O	the
12	63	67	O	level
13	69	70	O	of
14	72	81	O	cytochrome
15	83	86	O	P450
16	88	90	O	2D6
17	92	98	O	isozyme
18	100	107	O	activity
NULL

Thioridazine Hydrochloride	1731	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	28
Thus, this study suggests that drugs that inhibit P450 2D6 or the presence of reduced activity levels of this isozyme will produce elevated plasma levels of thioridazine.
1	0	3	O	Thus
2	4	4	O	,
3	6	9	O	this
4	11	15	O	study
5	17	24	O	suggests
6	26	29	O	that
7	31	35	B-KIN	drugs
8	37	40	I-KIN	that
9	42	48	I-KIN	inhibit
10	50	53	I-KIN	P450
11	55	57	L-KIN	2D6
12	59	60	O	or
13	62	64	O	the
14	66	73	O	presence
15	75	76	O	of
16	78	84	O	reduced
17	86	93	O	activity
18	95	100	O	levels
19	102	103	O	of
20	105	108	O	this
21	110	116	O	isozyme
22	118	121	O	will
23	123	129	O	produce
24	131	138	B-TRI	elevated
25	140	145	I-TRI	plasma
26	147	152	L-TRI	levels
27	154	155	O	of
28	157	168	O	XXXXXXXX
K/7:C54355

Thioridazine Hydrochloride	1732	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	45
Therefore, the coadministration of drugs that inhibit P450 2D6 with thioridazine and the use of thioridazine in patients known to have reduced activity of P450 2D6 are contraindicated. for one week) on thioridazine steady-state concentration was evaluated in ten male inpatients with schizophrenia.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	30	O	coadministration
5	32	33	O	of
6	35	39	B-UNK	drugs
7	41	44	I-UNK	that
8	46	52	I-UNK	inhibit
9	54	57	I-UNK	P450
10	59	61	L-UNK	2D6
11	63	66	O	with
12	68	79	O	XXXXXXXX
13	81	83	O	and
14	85	87	O	the
15	89	91	O	use
16	93	94	O	of
17	96	107	O	XXXXXXXX
18	109	110	O	in
19	112	119	O	patients
20	121	125	O	known
21	127	128	O	to
22	130	133	O	have
23	135	141	O	reduced
24	143	150	O	activity
25	152	153	O	of
26	155	158	O	P450
27	160	162	O	2D6
28	164	166	O	are
29	168	182	U-TRI	contraindicated
30	185	187	O	for
31	189	191	O	one
32	193	196	O	week
33	199	200	O	on
34	202	213	O	XXXXXXXX
35	215	220	O	steady
36	222	226	O	state
37	228	240	O	concentration
38	242	244	O	was
39	246	254	O	evaluated
40	256	257	O	in
41	259	261	O	ten
42	263	266	O	male
43	268	277	O	inpatients
44	279	282	O	with
45	284	296	O	schizophrenia
NULL

Thioridazine Hydrochloride	1733	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	20
Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.
1	0	13	O	Concentrations
2	15	16	O	of
3	18	29	O	XXXXXXXX
4	31	33	O	and
5	35	37	O	its
6	39	41	O	two
7	43	48	O	active
8	50	60	O	metabolites
9	61	61	O	,
10	63	74	O	mesoridazine
11	76	78	O	and
12	80	92	O	sulforidazine
13	93	93	O	,
14	95	103	O	increased
15	105	105	O	3
16	107	110	O	fold
17	112	120	O	following
18	122	137	O	coadministration
19	139	140	O	of
20	142	152	U-KIN	fluvoxamine
K/20:C54355

Thioridazine Hydrochloride	1734	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	7
Fluvoxamine and thioridazine should not be coadministered.
1	0	10	U-UNK	Fluvoxamine
2	12	14	O	and
3	16	27	O	XXXXXXXX
4	29	34	B-TRI	should
5	36	38	I-TRI	not
6	40	41	I-TRI	be
7	43	56	L-TRI	coadministered
NULL

Thioridazine Hydrochloride	1735	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	31
Concurrent administration of propranolol (100 to 800 mg daily) has been reported to produce increases in plasma levels of thioridazine (approximately 50% to 400%) and its metabolites (approximately 80% to 300%).
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	39	U-KIN	propranolol
5	42	44	O	100
6	46	47	O	to
7	49	51	O	800
8	53	54	O	mg
9	56	60	O	daily
10	63	65	O	has
11	67	70	O	been
12	72	79	O	reported
13	81	82	O	to
14	84	90	O	produce
15	92	100	B-TRI	increases
16	102	103	I-TRI	in
17	105	110	I-TRI	plasma
18	112	117	L-TRI	levels
19	119	120	O	of
20	122	133	O	XXXXXXXX
21	136	148	O	approximately
22	150	152	O	50%
23	154	155	O	to
24	157	160	O	400%
25	163	165	O	and
26	167	169	O	its
27	171	181	O	metabolites
28	184	196	O	approximately
29	198	200	O	80%
30	202	203	O	to
31	205	208	O	300%
K/4:C54355

Thioridazine Hydrochloride	1736	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	7
Propranolol and thioridazine should not be coadministered.
1	0	10	U-UNK	Propranolol
2	12	14	O	and
3	16	27	O	XXXXXXXX
4	29	34	B-TRI	should
5	36	38	I-TRI	not
6	40	41	I-TRI	be
7	43	56	L-TRI	coadministered
NULL

Thioridazine Hydrochloride	1737	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	35
Concurrent administration of pindolol and thioridazine have resulted in moderate, dose related increases in the serum levels of thioridazine and two of its metabolites, as well as higher than expected serum pindolol levels.
1	0	9	O	Concurrent
2	11	24	O	administration
3	26	27	O	of
4	29	36	U-KIN	pindolol
5	38	40	O	and
6	42	53	O	XXXXXXXX
7	55	58	O	have
8	60	67	O	resulted
9	69	70	O	in
10	72	79	O	moderate
11	80	80	O	,
12	82	85	O	dose
13	87	93	O	related
14	95	103	O	increases
15	105	106	O	in
16	108	110	O	the
17	112	116	O	serum
18	118	123	O	levels
19	125	126	O	of
20	128	139	O	XXXXXXXX
21	141	143	O	and
22	145	147	O	two
23	149	150	O	of
24	152	154	O	its
25	156	166	O	metabolites
26	167	167	O	,
27	169	170	O	as
28	172	175	O	well
29	177	178	O	as
30	180	185	O	higher
31	187	190	O	than
32	192	199	O	expected
33	201	205	O	serum
34	207	214	O	pindolol
35	216	221	O	levels
K/4:C54357

Thioridazine Hydrochloride	1738	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	7
Pindolol and thioridazine should not be coadministered.
1	0	7	U-UNK	Pindolol
2	9	11	O	and
3	13	24	O	XXXXXXXX
4	26	31	B-TRI	should
5	33	35	I-TRI	not
6	37	38	I-TRI	be
7	40	53	L-TRI	coadministered
NULL

Thioridazine Hydrochloride	1739	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	17
There are no studies of the coadministration of thioridazine and other drugs that prolong the QTc interval.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	19	O	studies
5	21	22	O	of
6	24	26	O	the
7	28	43	O	coadministration
8	45	46	O	of
9	48	59	O	XXXXXXXX
10	61	63	O	and
11	65	69	O	other
12	71	75	O	drugs
13	77	80	O	that
14	82	88	O	prolong
15	90	92	O	the
16	94	96	O	QTc
17	98	105	O	interval
NULL

Thioridazine Hydrochloride	1740	34073-7	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	24
However, it is expected that such coadministration would produce additive prolongation of the QTc interval and, thus, such use is contraindicated.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	13	O	is
5	15	22	O	expected
6	24	27	O	that
7	29	32	O	such
8	34	49	O	coadministration
9	51	55	O	would
10	57	63	O	produce
11	65	72	O	additive
12	74	85	O	prolongation
13	87	88	O	of
14	90	92	O	the
15	94	96	O	QTc
16	98	105	O	interval
17	107	109	O	and
18	110	110	O	,
19	112	115	O	thus
20	116	116	O	,
21	118	121	O	such
22	123	125	O	use
23	127	128	O	is
24	130	144	O	contraindicated
NULL

Thioridazine Hydrochloride	1741	34090-1	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	21
The basic pharmacological activity of thioridazine is similar to that of other phenothiazines, but is associated with minimal extrapyramidal stimulation.
1	0	2	O	The
2	4	8	O	basic
3	10	24	O	pharmacological
4	26	33	O	activity
5	35	36	O	of
6	38	49	O	XXXXXXXX
7	51	52	O	is
8	54	60	O	similar
9	62	63	O	to
10	65	68	O	that
11	70	71	O	of
12	73	77	O	other
13	79	92	O	phenothiazines
14	93	93	O	,
15	95	97	O	but
16	99	100	O	is
17	102	111	O	associated
18	113	116	O	with
19	118	124	O	minimal
20	126	139	O	extrapyramidal
21	141	151	O	stimulation
NULL

Thioridazine Hydrochloride	1742	34090-1	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	16
However, thioridazine has been shown to prolong the QTc interval in a dose dependent fashion.
1	0	6	O	However
2	7	7	O	,
3	9	20	O	XXXXXXXX
4	22	24	O	has
5	26	29	O	been
6	31	35	O	shown
7	37	38	O	to
8	40	46	O	prolong
9	48	50	O	the
10	52	54	O	QTc
11	56	63	O	interval
12	65	66	O	in
13	68	68	O	a
14	70	73	O	dose
15	75	83	O	dependent
16	85	91	O	fashion
NULL

Thioridazine Hydrochloride	1743	34090-1	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	22
This effect may increase the risk of serious, potentially fatal, ventricular arrhythmias, such as Torsades de pointes type arrhythmias.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	may
4	16	23	O	increase
5	25	27	O	the
6	29	32	O	risk
7	34	35	O	of
8	37	43	O	serious
9	44	44	O	,
10	46	56	O	potentially
11	58	62	O	fatal
12	63	63	O	,
13	65	75	O	ventricular
14	77	87	O	arrhythmias
15	88	88	O	,
16	90	93	O	such
17	95	96	O	as
18	98	105	O	Torsades
19	107	108	O	de
20	110	116	O	pointes
21	118	121	O	type
22	123	133	O	arrhythmias
NULL

Thioridazine Hydrochloride	1744	34090-1	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	23
Due to this risk, thioridazine is indicated only for schizophrenic patients who have not been responsive to or cannot tolerate other antipsychotic agents.
1	0	2	O	Due
2	4	5	O	to
3	7	10	O	this
4	12	15	O	risk
5	16	16	O	,
6	18	29	O	XXXXXXXX
7	31	32	O	is
8	34	42	O	indicated
9	44	47	O	only
10	49	51	O	for
11	53	65	O	schizophrenic
12	67	74	O	patients
13	76	78	O	who
14	80	83	O	have
15	85	87	O	not
16	89	92	O	been
17	94	103	O	responsive
18	105	106	O	to
19	108	109	O	or
20	111	116	O	cannot
21	118	125	O	tolerate
22	127	131	O	other
23	133	152	O	GGGGGGGG
NULL

Thioridazine Hydrochloride	1745	34090-1	9c4bedb4-2d59-4fcd-aad7-fce988cd96d8	30
However, the prescriber should be aware that thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	22	O	prescriber
5	24	29	O	should
6	31	32	O	be
7	34	38	O	aware
8	40	43	O	that
9	45	56	O	XXXXXXXX
10	58	60	O	has
11	62	64	O	not
12	66	69	O	been
13	71	84	O	systematically
14	86	94	O	evaluated
15	96	97	O	in
16	99	108	O	controlled
17	110	115	O	trials
18	117	118	O	in
19	120	128	O	treatment
20	130	139	O	refractory
21	141	153	O	schizophrenic
22	155	162	O	patients
23	164	166	O	and
24	168	170	O	its
25	172	179	O	efficacy
26	181	182	O	in
27	184	187	O	such
28	189	196	O	patients
29	198	199	O	is
30	201	207	O	unknown
NULL

Thiothixene	3064	34073-7	827cf470-485d-4925-85f2-8933a6dea830	19
Hepatic microsomal enzyme inducing agents, such as carbamazepine, were found to significantly increase the clearance of thiothixene.
1	0	6	B-KIN	Hepatic
2	8	17	I-KIN	microsomal
3	19	24	I-KIN	enzyme
4	26	33	I-KIN	inducing
5	35	40	L-KIN	agents
6	41	41	O	,
7	43	46	O	such
8	48	49	O	as
9	51	63	U-KIN	carbamazepine
10	64	64	O	,
11	66	69	O	were
12	71	75	O	found
13	77	78	O	to
14	80	92	O	significantly
15	94	101	B-TRI	increase
16	103	105	I-TRI	the
17	107	115	L-TRI	clearance
18	117	118	O	of
19	120	130	O	XXXXXXXX
K/1:C54356 K/9:C54356

Thiothixene	3065	34073-7	827cf470-485d-4925-85f2-8933a6dea830	13
Patients receiving these drugs should be observed for signs of reduced thiothixene effectiveness4,5.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	23	O	these
4	25	29	O	drugs
5	31	36	O	should
6	38	39	O	be
7	41	48	O	observed
8	50	52	O	for
9	54	58	O	signs
10	60	61	O	of
11	63	69	O	reduced
12	71	81	O	XXXXXXXX
13	83	98	O	effectiveness4,5
NULL

Thiothixene	3066	34073-7	827cf470-485d-4925-85f2-8933a6dea830	31
Due to a possible additive effect with hypotensive agents, patients receiving these drugs should be observed closely for signs of excessive hypotension when thiothixene is added to their drug regimen6.
1	0	2	O	Due
2	4	5	O	to
3	7	7	O	a
4	9	16	O	possible
5	18	25	O	additive
6	27	32	O	effect
7	34	37	O	with
8	39	49	O	hypotensive
9	51	56	O	agents
10	57	57	O	,
11	59	66	O	patients
12	68	76	O	receiving
13	78	82	O	these
14	84	88	O	drugs
15	90	95	O	should
16	97	98	O	be
17	100	107	O	observed
18	109	115	O	closely
19	117	119	O	for
20	121	125	O	signs
21	127	128	O	of
22	130	138	O	excessive
23	140	150	O	hypotension
24	152	155	O	when
25	157	167	O	XXXXXXXX
26	169	170	O	is
27	172	176	O	added
28	178	179	O	to
29	181	185	O	their
30	187	190	O	drug
31	192	199	O	regimen6
NULL

Thiothixene	3067	34090-1	827cf470-485d-4925-85f2-8933a6dea830	8
Thiothixene is an antipsychotic of the thioxanthene series.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	16	O	an
4	18	30	O	antipsychotic
5	32	33	O	of
6	35	37	O	the
7	39	50	O	thioxanthene
8	52	57	O	series
NULL

Thiothixene	3068	34090-1	827cf470-485d-4925-85f2-8933a6dea830	19
Thiothixene possesses certain chemical and pharmacological similarities to the piperazine phenothiazines and differences from the aliphatic group of phenothiazines.
1	0	10	O	XXXXXXXX
2	12	20	O	possesses
3	22	28	O	certain
4	30	37	O	chemical
5	39	41	O	and
6	43	57	O	pharmacological
7	59	70	O	similarities
8	72	73	O	to
9	75	77	O	the
10	79	88	O	piperazine
11	90	103	O	phenothiazines
12	105	107	O	and
13	109	119	O	differences
14	121	124	O	from
15	126	128	O	the
16	130	138	O	aliphatic
17	140	144	O	group
18	146	147	O	of
19	149	162	O	phenothiazines
NULL

Venlafaxine Hydrochloride	5770	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	28
Serotonergic Drugs (e.g., MAOIs, triptans, SSRIs, other SNRIs, linezolid, lithium, tramadol, or St. John's wort): Potential for serotonin syndrome.
1	0	11	B-DYN	Serotonergic
2	13	17	L-DYN	Drugs
3	20	22	O	e.g
4	24	24	O	,
5	26	30	U-DYN	MAOIs
6	31	31	O	,
7	33	40	U-DYN	triptans
8	41	41	O	,
9	43	47	U-DYN	SSRIs
10	48	48	O	,
11	50	54	O	other
12	56	60	U-DYN	SNRIs
13	61	61	O	,
14	63	71	U-DYN	linezolid
15	72	72	O	,
16	74	80	U-DYN	lithium
17	81	81	O	,
18	83	90	U-DYN	tramadol
19	91	91	O	,
20	93	94	O	or
21	96	97	B-DYN	St
22	100	105	I-DYN	John's
23	107	110	L-DYN	wort
24	112	112	O	:
25	114	122	O	Potential
26	124	126	O	for
27	128	136	B-EFF	serotonin
28	138	145	L-EFF	syndrome
D/1:27:1 D/12:27:1 D/14:27:1 D/16:27:1 D/18:27:1 D/21:27:1 D/5:27:1 D/7:27:1 D/9:27:1

Venlafaxine Hydrochloride	5771	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	10
Careful patient observation is advised (4.2, 5.2, 7.3).
1	0	6	O	Careful
2	8	14	O	patient
3	16	26	O	observation
4	28	29	O	is
5	31	37	O	advised
6	40	42	O	4.2
7	43	43	O	,
8	45	47	O	5.2
9	48	48	O	,
10	50	52	O	7.3
NULL

Venlafaxine Hydrochloride	5772	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	17
The risk of using venlafaxine in combination with other CNS-active drugs has not been systematically evaluated.
1	0	2	O	The
2	4	7	O	risk
3	9	10	O	of
4	12	16	O	using
5	18	28	O	XXXXXXXX
6	30	31	O	in
7	33	43	O	combination
8	45	48	O	with
9	50	54	O	other
10	56	58	O	CNS
11	60	65	O	active
12	67	71	O	drugs
13	73	75	O	has
14	77	79	O	not
15	81	84	O	been
16	86	99	O	systematically
17	101	109	O	evaluated
NULL

Venlafaxine Hydrochloride	5773	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	18
Consequently, caution is advised when venlafaxine hydrochloride extended-release is taken in combination with other CNS-active drugs.
1	0	11	O	Consequently
2	12	12	O	,
3	14	20	U-TRI	caution
4	22	23	O	is
5	25	31	O	advised
6	33	36	O	when
7	38	62	O	XXXXXXXX
8	64	71	O	extended
9	73	79	O	release
10	81	82	O	is
11	84	88	O	taken
12	90	91	O	in
13	93	103	O	combination
14	105	108	O	with
15	110	114	O	other
16	116	118	B-UNK	CNS
17	120	125	I-UNK	active
18	127	131	L-UNK	drugs
NULL

Venlafaxine Hydrochloride	5774	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	54
Adverse reactions, some of which were serious, have been reported in patients who have recently been discontinued from an MAOI and started on antidepressants with pharmacological properties similar to venlafaxine hydrochloride extended-release (SNRIs or SSRIs), or who have recently had SNRI or SSRI therapy discontinued prior to initiation of an MAOI.
1	0	6	B-TRI	Adverse
2	8	16	L-TRI	reactions
3	17	17	O	,
4	19	22	O	some
5	24	25	O	of
6	27	31	O	which
7	33	36	O	were
8	38	44	O	serious
9	45	45	O	,
10	47	50	O	have
11	52	55	O	been
12	57	64	O	reported
13	66	67	O	in
14	69	76	O	patients
15	78	80	O	who
16	82	85	O	have
17	87	94	O	recently
18	96	99	O	been
19	101	112	O	discontinued
20	114	117	O	from
21	119	120	O	an
22	122	125	U-UNK	MAOI
23	127	129	O	and
24	131	137	O	started
25	139	140	O	on
26	142	156	O	GGGGGGGG
27	158	161	O	with
28	163	177	O	pharmacological
29	179	188	O	properties
30	190	196	O	similar
31	198	199	O	to
32	201	225	O	XXXXXXXX
33	227	234	O	extended
34	236	242	O	release
35	245	249	O	SNRIs
36	251	252	O	or
37	254	258	O	SSRIs
38	260	260	O	,
39	262	263	O	or
40	265	267	O	who
41	269	272	O	have
42	274	281	O	recently
43	283	285	O	had
44	287	290	O	SNRI
45	292	293	O	or
46	295	298	O	SSRI
47	300	306	O	therapy
48	308	319	O	discontinued
49	321	325	O	prior
50	327	328	O	to
51	330	339	O	initiation
52	341	342	O	of
53	344	345	O	an
54	347	350	O	MAOI
NULL

Venlafaxine Hydrochloride	5775	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	65
Based on the mechanism of action of venlafaxine hydrochloride extended-release and the potential for serotonin syndrome, caution is advised when venlafaxine hydrochloride extended-release is coadministered with other drugs that may affect the serotonergic neurotransmitter systems, such as triptans, SSRIs, other SNRIs, linezolid (an antibiotic which is a reversible non-selective MAOI), lithium, tramadol, or St. John's wort.
1	0	4	O	Based
2	6	7	O	on
3	9	11	O	the
4	13	21	O	mechanism
5	23	24	O	of
6	26	31	O	action
7	33	34	O	of
8	36	60	O	XXXXXXXX
9	62	69	O	extended
10	71	77	O	release
11	79	81	O	and
12	83	85	O	the
13	87	95	O	potential
14	97	99	O	for
15	101	109	B-EFF	serotonin
16	111	118	L-EFF	syndrome
17	119	119	O	,
18	121	127	O	caution
19	129	130	O	is
20	132	138	O	advised
21	140	143	O	when
22	145	169	O	XXXXXXXX
23	171	178	O	extended
24	180	186	O	release
25	188	189	O	is
26	191	204	O	coadministered
27	206	209	O	with
28	211	215	O	other
29	217	221	B-DYN	drugs
30	223	226	I-DYN	that
31	228	230	I-DYN	may
32	232	237	I-DYN	affect
33	239	241	I-DYN	the
34	243	254	I-DYN	serotonergic
35	256	271	I-DYN	neurotransmitter
36	273	279	L-DYN	systems
37	280	280	O	,
38	282	285	O	such
39	287	288	O	as
40	290	297	U-DYN	triptans
41	298	298	O	,
42	300	304	U-DYN	SSRIs
43	305	305	O	,
44	307	311	O	other
45	313	317	U-DYN	SNRIs
46	318	318	O	,
47	320	328	U-DYN	linezolid
48	331	332	O	an
49	334	343	O	antibiotic
50	345	349	O	which
51	351	352	O	is
52	354	354	O	a
53	356	365	O	reversible
54	367	369	O	non
55	371	379	O	selective
56	381	384	O	MAOI
57	386	386	O	,
58	388	394	U-DYN	lithium
59	395	395	O	,
60	397	404	U-DYN	tramadol
61	405	405	O	,
62	407	408	O	or
63	410	411	B-DYN	St
64	414	419	I-DYN	John's
65	421	424	L-DYN	wort
D/29:15:1 D/40:15:1 D/42:15:1 D/45:15:1 D/47:15:1 D/58:15:1 D/60:15:1 D/63:15:1

Venlafaxine Hydrochloride	5776	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	29
If concomitant treatment with venlafaxine hydrochloride extended-release and these drugs is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
1	0	1	O	If
2	3	13	O	concomitant
3	15	23	O	treatment
4	25	28	O	with
5	30	54	O	XXXXXXXX
6	56	63	O	extended
7	65	71	O	release
8	73	75	O	and
9	77	81	O	these
10	83	87	O	drugs
11	89	90	O	is
12	92	101	O	clinically
13	103	111	O	warranted
14	112	112	O	,
15	114	120	O	careful
16	122	132	O	observation
17	134	135	O	of
18	137	139	O	the
19	141	147	O	patient
20	149	150	O	is
21	152	158	O	advised
22	159	159	O	,
23	161	172	O	particularly
24	174	179	O	during
25	181	189	O	treatment
26	191	200	O	initiation
27	202	204	O	and
28	206	209	O	dose
29	211	219	O	increases
NULL

Venlafaxine Hydrochloride	5777	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	13
The concomitant use of venlafaxine hydrochloride extended-release with tryptophan supplements is not recommended.
1	0	2	O	The
2	4	14	O	concomitant
3	16	18	O	use
4	20	21	O	of
5	23	47	O	XXXXXXXX
6	49	56	O	extended
7	58	64	O	release
8	66	69	O	with
9	71	80	B-UNK	tryptophan
10	82	92	L-UNK	supplements
11	94	95	O	is
12	97	99	B-TRI	not
13	101	111	L-TRI	recommended
NULL

Venlafaxine Hydrochloride	5778	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	10
Serotonin release by platelets plays an important role in hemostasis.
1	0	8	O	Serotonin
2	10	16	O	release
3	18	19	O	by
4	21	29	O	platelets
5	31	35	O	plays
6	37	38	O	an
7	40	48	O	important
8	50	53	O	role
9	55	56	O	in
10	58	67	O	hemostasis
NULL

Venlafaxine Hydrochloride	5779	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	33
The use of psychotropic drugs that interfere with serotonin reuptake is associated with the occurrence of upper gastrointestinal bleeding and concurrent use of an NSAID or aspirin may potentiate this risk of bleeding.
1	0	2	O	The
2	4	6	O	use
3	8	9	O	of
4	11	22	O	psychotropic
5	24	28	O	drugs
6	30	33	O	that
7	35	43	O	interfere
8	45	48	O	with
9	50	58	O	serotonin
10	60	67	O	reuptake
11	69	70	O	is
12	72	81	O	associated
13	83	86	O	with
14	88	90	O	the
15	92	101	O	occurrence
16	103	104	O	of
17	106	110	O	upper
18	112	127	O	gastrointestinal
19	129	136	U-EFF	bleeding
20	138	140	O	and
21	142	151	O	concurrent
22	153	155	O	use
23	157	158	O	of
24	160	161	O	an
25	163	167	U-DYN	NSAID
26	169	170	O	or
27	172	178	U-DYN	aspirin
28	180	182	O	may
29	184	193	O	potentiate
30	195	198	O	this
31	200	203	O	risk
32	205	206	O	of
33	208	215	O	bleeding
D/25:19:1 D/27:19:1

Venlafaxine Hydrochloride	5780	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	19
Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs and SNRIs are coadministered with warfarin.
1	0	6	B-EFF	Altered
2	8	20	I-EFF	anticoagulant
3	22	28	L-EFF	effects
4	29	29	O	,
5	31	39	O	including
6	41	49	B-EFF	increased
7	51	58	L-EFF	bleeding
8	59	59	O	,
9	61	64	O	have
10	66	69	O	been
11	71	78	O	reported
12	80	83	O	when
13	85	89	O	SSRIs
14	91	93	O	and
15	95	99	O	SNRIs
16	101	103	O	are
17	105	118	O	coadministered
18	120	123	O	with
19	125	132	U-DYN	warfarin
D/19:1:1 D/19:6:1

Venlafaxine Hydrochloride	5781	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	16
Patients receiving warfarin therapy should be carefully monitored when venlafaxine hydrochloride extended-release is initiated or discontinued.
1	0	7	O	Patients
2	9	17	O	receiving
3	19	26	U-UNK	warfarin
4	28	34	O	therapy
5	36	41	B-TRI	should
6	43	44	I-TRI	be
7	46	54	I-TRI	carefully
8	56	64	L-TRI	monitored
9	66	69	O	when
10	71	95	O	XXXXXXXX
11	97	104	O	extended
12	106	112	O	release
13	114	115	O	is
14	117	125	O	initiated
15	127	128	O	or
16	130	141	O	discontinued
NULL

Venlafaxine Hydrochloride	5782	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	21
The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established.
1	0	2	O	The
2	4	9	O	safety
3	11	13	O	and
4	15	22	O	efficacy
5	24	25	O	of
6	27	37	O	XXXXXXXX
7	39	45	O	therapy
8	47	48	O	in
9	50	60	O	combination
10	62	65	O	with
11	67	72	B-UNK	weight
12	74	77	I-UNK	loss
13	79	84	L-UNK	agents
14	85	85	O	,
15	87	95	O	including
16	97	107	U-UNK	phentermine
17	108	108	O	,
18	110	113	O	have
19	115	117	O	not
20	119	122	O	been
21	124	134	O	established
NULL

Venlafaxine Hydrochloride	5783	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	12
Coadministration of venlafaxine hydrochloride extended-release and weight loss agents is not recommended.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	44	O	XXXXXXXX
4	46	53	O	extended
5	55	61	O	release
6	63	65	O	and
7	67	72	B-UNK	weight
8	74	77	I-UNK	loss
9	79	84	L-UNK	agents
10	86	87	O	is
11	89	91	B-TRI	not
12	93	103	L-TRI	recommended
NULL

Venlafaxine Hydrochloride	5784	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	16
Venlafaxine hydrochloride extended-release is not indicated for weight loss alone or in combination with other products.
1	0	24	O	XXXXXXXX
2	26	33	O	extended
3	35	41	O	release
4	43	44	O	is
5	46	48	O	not
6	50	58	O	indicated
7	60	62	O	for
8	64	69	O	weight
9	71	74	O	loss
10	76	80	O	alone
11	82	83	O	or
12	85	86	O	in
13	88	98	O	combination
14	100	103	O	with
15	105	109	O	other
16	111	118	O	products
NULL

Venlafaxine Hydrochloride	5785	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	19
Figure 1: Effect of interacting drugs on the pharmacokinetics of venlafaxine and active metabolite O-desmethylvenlafaxine (ODV).
1	0	5	O	Figure
2	7	7	O	1
3	8	8	O	:
4	10	15	O	Effect
5	17	18	O	of
6	20	30	O	interacting
7	32	36	O	drugs
8	38	39	O	on
9	41	43	O	the
10	45	60	O	pharmacokinetics
11	62	63	O	of
12	65	75	O	XXXXXXXX
13	77	79	O	and
14	81	86	O	active
15	88	97	O	metabolite
16	99	99	O	O
17	101	109	O	desmethyl
18	110	120	O	XXXXXXXX
19	123	125	O	ODV
NULL

Venlafaxine Hydrochloride	5786	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	59
Abbreviations: ODV, O-desmethylvenlafaxine; AUC, area under the curve; Cmax, peak plasma concentrations; EM's, extensive metabolizers; PM's, poor metabolizers * No dose adjustment on co-administration with CYP2D6 inhibitors (Fig 3 and Metabolism Section 12.3) Figure 1 Figure 2: Effect of venlafaxine on the pharmacokinetics interacting drugs and their active metabolites.
1	0	12	O	Abbreviations
2	13	13	O	:
3	15	17	O	ODV
4	18	18	O	,
5	20	20	O	O
6	22	30	O	desmethyl
7	31	41	O	XXXXXXXX
8	44	46	O	AUC
9	47	47	O	,
10	49	52	O	area
11	54	58	O	under
12	60	62	O	the
13	64	68	O	curve
14	71	74	O	Cmax
15	75	75	O	,
16	77	80	O	peak
17	82	87	O	plasma
18	89	102	O	concentrations
19	105	108	O	EM's
20	109	109	O	,
21	111	119	O	extensive
22	121	132	O	metabolizers
23	135	138	O	PM's
24	139	139	O	,
25	141	144	O	poor
26	146	157	O	metabolizers
27	159	159	O	*
28	161	162	O	No
29	164	167	O	dose
30	169	178	O	adjustment
31	180	181	O	on
32	183	184	O	co
33	186	199	O	administration
34	201	204	O	with
35	206	211	O	CYP2D6
36	213	222	O	inhibitors
37	225	227	O	Fig
38	229	229	O	3
39	231	233	O	and
40	235	244	O	Metabolism
41	246	252	O	Section
42	254	257	O	12.3
43	260	265	O	Figure
44	267	267	O	1
45	269	274	O	Figure
46	276	276	O	2
47	277	277	O	:
48	279	284	O	Effect
49	286	287	O	of
50	289	299	O	XXXXXXXX
51	301	302	O	on
52	304	306	O	the
53	308	323	O	pharmacokinetics
54	325	335	O	interacting
55	337	341	O	drugs
56	343	345	O	and
57	347	351	O	their
58	353	358	O	active
59	360	370	O	metabolites
NULL

Venlafaxine Hydrochloride	5787	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	54
Abbreviations: AUC, area under the curve; Cmax, peak plasma concentrations; OH, hydroxyl * Data for 2-OH desipramine were not plotted to enhance clarity; the fold change and 90% CI for Cmax and AUC of 2-OH desipramine were 6.6 (5.5, 7.9) and 4.4 (3.8, 5.0), respectively.
1	0	12	O	Abbreviations
2	13	13	O	:
3	15	17	O	AUC
4	18	18	O	,
5	20	23	O	area
6	25	29	O	under
7	31	33	O	the
8	35	39	O	curve
9	42	45	O	Cmax
10	46	46	O	,
11	48	51	O	peak
12	53	58	O	plasma
13	60	73	O	concentrations
14	76	77	O	OH
15	78	78	O	,
16	80	87	O	hydroxyl
17	89	89	O	*
18	91	94	O	Data
19	96	98	O	for
20	100	100	O	2
21	102	103	O	OH
22	105	115	O	desipramine
23	117	120	O	were
24	122	124	O	not
25	126	132	O	plotted
26	134	135	O	to
27	137	143	O	enhance
28	145	151	O	clarity
29	154	156	O	the
30	158	161	O	fold
31	163	168	O	change
32	170	172	O	and
33	174	176	O	90%
34	178	179	O	CI
35	181	183	O	for
36	185	188	O	Cmax
37	190	192	O	and
38	194	196	O	AUC
39	198	199	O	of
40	201	201	O	2
41	203	204	O	OH
42	206	216	O	desipramine
43	218	221	O	were
44	223	225	O	6.6
45	228	230	O	5.5
46	231	231	O	,
47	233	235	O	7.9
48	238	240	O	and
49	242	244	O	4.4
50	247	249	O	3.8
51	250	250	O	,
52	252	254	O	5.0
53	256	256	O	,
54	258	269	O	respectively
NULL

Venlafaxine Hydrochloride	5788	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	32
Note: *: Administration of venlafaxine in a stable regimen did not exaggerate the psychomotor and psychometric effects induced by ethanol in these same subjects when they were not receiving venlafaxine.
1	0	3	O	Note
2	4	4	O	:
3	6	6	O	*
4	7	7	O	:
5	9	22	O	Administration
6	24	25	O	of
7	27	37	O	XXXXXXXX
8	39	40	O	in
9	42	42	O	a
10	44	49	O	stable
11	51	57	O	regimen
12	59	61	O	did
13	63	65	O	not
14	67	76	O	exaggerate
15	78	80	O	the
16	82	92	O	psychomotor
17	94	96	O	and
18	98	109	O	psychometric
19	111	117	O	effects
20	119	125	O	induced
21	127	128	O	by
22	130	136	O	ethanol
23	138	139	O	in
24	141	145	O	these
25	147	150	O	same
26	152	159	O	subjects
27	161	164	O	when
28	166	169	O	they
29	171	174	O	were
30	176	178	O	not
31	180	188	O	receiving
32	190	200	O	XXXXXXXX
NULL

Venlafaxine Hydrochloride	5789	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	20
Figure 2 False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine.
1	0	5	O	Figure
2	7	7	O	2
3	9	13	O	False
4	15	22	O	positive
5	24	28	O	urine
6	30	40	O	immunoassay
7	42	50	O	screening
8	52	56	O	tests
9	58	60	O	for
10	62	74	O	phencyclidine
11	77	79	O	PCP
12	82	84	O	and
13	86	96	O	amphetamine
14	98	101	O	have
15	103	106	O	been
16	108	115	O	reported
17	117	118	O	in
18	120	127	O	patients
19	129	134	O	taking
20	136	146	O	XXXXXXXX
NULL

Venlafaxine Hydrochloride	5790	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	11
This is due to lack of specificity of the screening tests.
1	0	3	O	This
2	5	6	O	is
3	8	10	O	due
4	12	13	O	to
5	15	18	O	lack
6	20	21	O	of
7	23	33	O	specificity
8	35	36	O	of
9	38	40	O	the
10	42	50	O	screening
11	52	56	O	tests
NULL

Venlafaxine Hydrochloride	5791	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	15
False positive test results may be expected for several days following discontinuation of venlafaxine therapy.
1	0	4	O	False
2	6	13	O	positive
3	15	18	O	test
4	20	26	O	results
5	28	30	O	may
6	32	33	O	be
7	35	42	O	expected
8	44	46	O	for
9	48	54	O	several
10	56	59	O	days
11	61	69	O	following
12	71	85	O	discontinuation
13	87	88	O	of
14	90	100	O	XXXXXXXX
15	102	108	O	therapy
NULL

Venlafaxine Hydrochloride	5792	34073-7	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	18
Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.
1	0	11	O	Confirmatory
2	13	17	O	tests
3	18	18	O	,
4	20	23	O	such
5	25	26	O	as
6	28	30	O	gas
7	32	45	O	chromatography
8	46	46	O	/
9	47	50	O	mass
10	52	63	O	spectrometry
11	64	64	O	,
12	66	69	O	will
13	71	81	O	distinguish
14	83	93	O	XXXXXXXX
15	95	98	O	from
16	100	102	O	PCP
17	104	106	O	and
18	108	118	O	amphetamine
NULL

Venlafaxine Hydrochloride	5793	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	38
The exact mechanism of the antidepressant action of venlafaxine in humans is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of their reuptake.
1	0	2	O	The
2	4	8	O	exact
3	10	18	O	mechanism
4	20	21	O	of
5	23	25	O	the
6	27	40	O	antidepressant
7	42	47	O	action
8	49	50	O	of
9	52	62	O	XXXXXXXX
10	64	65	O	in
11	67	72	O	humans
12	74	75	O	is
13	77	83	O	unknown
14	84	84	O	,
15	86	88	O	but
16	90	91	O	is
17	93	99	O	thought
18	101	102	O	to
19	104	105	O	be
20	107	113	O	related
21	115	116	O	to
22	118	120	O	the
23	122	133	O	potentiation
24	135	136	O	of
25	138	146	O	serotonin
26	148	150	O	and
27	152	165	O	norepinephrine
28	167	168	O	in
29	170	172	O	the
30	174	180	O	central
31	182	188	O	nervous
32	190	195	O	system
33	196	196	O	,
34	198	204	O	through
35	206	215	O	inhibition
36	217	218	O	of
37	220	224	O	their
38	226	233	O	reuptake
NULL

Venlafaxine Hydrochloride	5794	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	31
Non- clinical studies have demonstrated that venlafaxine and its active metabolite, ODV, are potent and selective inhibitors of neuronal serotonin and norepinephrine reuptake and weak inhibitors of dopamine reuptake.
1	0	2	O	Non
2	5	12	O	clinical
3	14	20	O	studies
4	22	25	O	have
5	27	38	O	demonstrated
6	40	43	O	that
7	45	55	O	XXXXXXXX
8	57	59	O	and
9	61	63	O	its
10	65	70	O	active
11	72	81	O	metabolite
12	82	82	O	,
13	84	86	O	ODV
14	87	87	O	,
15	89	91	O	are
16	93	98	O	potent
17	100	102	O	and
18	104	112	O	selective
19	114	123	O	inhibitors
20	125	126	O	of
21	128	135	O	neuronal
22	137	145	O	serotonin
23	147	149	O	and
24	151	164	O	norepinephrine
25	166	173	O	reuptake
26	175	177	O	and
27	179	182	O	weak
28	184	193	O	inhibitors
29	195	196	O	of
30	198	205	O	dopamine
31	207	214	O	reuptake
NULL

Venlafaxine Hydrochloride	5795	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	20
Venlafaxine and ODV have no significant affinity for muscarinic-cholinergic, H1-histaminergic, or A1-adrenergic receptors in vitro.
1	0	10	O	XXXXXXXX
2	12	14	O	and
3	16	18	O	ODV
4	20	23	O	have
5	25	26	O	no
6	28	38	O	significant
7	40	47	O	affinity
8	49	51	O	for
9	53	62	O	muscarinic
10	64	74	O	cholinergic
11	75	75	O	,
12	77	78	O	H1
13	80	92	O	histaminergic
14	93	93	O	,
15	95	96	O	or
16	98	99	O	A1
17	101	110	O	adrenergic
18	112	120	O	receptors
19	122	123	O	in
20	125	129	O	vitro
NULL

Venlafaxine Hydrochloride	5796	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	25
Pharmacologic activity at these receptors is hypothesized to be associated with the various anticholinergic, sedative, and cardiovascular effects seen with other psychotropic drugs.
1	0	12	O	Pharmacologic
2	14	21	O	activity
3	23	24	O	at
4	26	30	O	these
5	32	40	O	receptors
6	42	43	O	is
7	45	56	O	hypothesized
8	58	59	O	to
9	61	62	O	be
10	64	73	O	associated
11	75	78	O	with
12	80	82	O	the
13	84	90	O	various
14	92	106	O	anticholinergic
15	107	107	O	,
16	109	116	O	sedative
17	117	117	O	,
18	119	121	O	and
19	123	136	O	cardiovascular
20	138	144	O	effects
21	146	149	O	seen
22	151	154	O	with
23	156	160	O	other
24	162	173	O	psychotropic
25	175	179	O	drugs
NULL

Venlafaxine Hydrochloride	5797	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	11
Venlafaxine and ODV do not possess monoamine oxidase (MAO) inhibitory activity.
1	0	10	O	XXXXXXXX
2	12	14	O	and
3	16	18	O	ODV
4	20	21	O	do
5	23	25	O	not
6	27	33	O	possess
7	35	43	O	monoamine
8	45	51	O	oxidase
9	54	56	O	MAO
10	59	68	O	inhibitory
11	70	77	O	activity
NULL

Venlafaxine Hydrochloride	5798	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	34
Cardiac Electrophysiology The effect of venlafaxine on the QT interval was evaluated in a randomized, double-blind, placebo- and positive-controlled three-period crossover thorough QT study in 54 healthy adult subjects.
1	0	6	O	Cardiac
2	8	24	O	Electrophysiology
3	26	28	O	The
4	30	35	O	effect
5	37	38	O	of
6	40	50	O	XXXXXXXX
7	52	53	O	on
8	55	57	O	the
9	59	60	O	QT
10	62	69	O	interval
11	71	73	O	was
12	75	83	O	evaluated
13	85	86	O	in
14	88	88	O	a
15	90	99	O	randomized
16	100	100	O	,
17	102	107	O	double
18	109	113	O	blind
19	114	114	O	,
20	116	122	O	placebo
21	125	127	O	and
22	129	136	O	positive
23	138	147	O	controlled
24	149	153	O	three
25	155	160	O	period
26	162	170	O	crossover
27	172	179	O	thorough
28	181	182	O	QT
29	184	188	O	study
30	190	191	O	in
31	193	194	O	54
32	196	202	O	healthy
33	204	208	O	adult
34	210	217	O	subjects
NULL

Venlafaxine Hydrochloride	5799	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	11
No significant QT prolongation effect of venlafaxine 450 mg was detected.
1	0	1	O	No
2	3	13	O	significant
3	15	16	O	QT
4	18	29	O	prolongation
5	31	36	O	effect
6	38	39	O	of
7	41	51	O	XXXXXXXX
8	53	55	O	450
9	57	58	O	mg
10	60	62	O	was
11	64	71	O	detected
NULL

Venlafaxine Hydrochloride	5800	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	19
Steady-state concentrations of venlafaxine and ODV in plasma are attained within 3 days of oral multiple-dose therapy.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	29	O	of
5	31	41	O	XXXXXXXX
6	43	45	O	and
7	47	49	O	ODV
8	51	52	O	in
9	54	59	O	plasma
10	61	63	O	are
11	65	72	O	attained
12	74	79	O	within
13	81	81	O	3
14	83	86	O	days
15	88	89	O	of
16	91	94	O	oral
17	96	103	O	multiple
18	105	108	O	dose
19	110	116	O	therapy
NULL

Venlafaxine Hydrochloride	5801	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	17
Venlafaxine and ODV exhibited linear kinetics over the dose range of 75 to 450 mg per day.
1	0	10	O	XXXXXXXX
2	12	14	O	and
3	16	18	O	ODV
4	20	28	O	exhibited
5	30	35	O	linear
6	37	44	O	kinetics
7	46	49	O	over
8	51	53	O	the
9	55	58	O	dose
10	60	64	O	range
11	66	67	O	of
12	69	70	O	75
13	72	73	O	to
14	75	77	O	450
15	79	80	O	mg
16	82	84	O	per
17	86	88	O	day
NULL

Venlafaxine Hydrochloride	5802	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	47
Mean*SD steady-state plasma clearance of venlafaxine and ODV is 1.3*0.6 and 0.4*0.2 L/h/kg, respectively; apparent elimination half-life is 5*2 and 11*2 hours, respectively; and apparent (steady-state) volume of distribution is 7.5*3.7 and 5.7*1.8 L/kg, respectively.
1	0	6	O	Mean*SD
2	8	13	O	steady
3	15	19	O	state
4	21	26	O	plasma
5	28	36	O	clearance
6	38	39	O	of
7	41	51	O	XXXXXXXX
8	53	55	O	and
9	57	59	O	ODV
10	61	62	O	is
11	64	70	O	1.3*0.6
12	72	74	O	and
13	76	82	O	0.4*0.2
14	84	84	O	L
15	85	85	O	/
16	86	86	O	h
17	87	87	O	/
18	88	89	O	kg
19	90	90	O	,
20	92	103	O	respectively
21	106	113	O	apparent
22	115	125	O	elimination
23	127	130	O	half
24	132	135	O	life
25	137	138	O	is
26	140	142	O	5*2
27	144	146	O	and
28	148	151	O	11*2
29	153	157	O	hours
30	158	158	O	,
31	160	171	O	respectively
32	174	176	O	and
33	178	185	O	apparent
34	188	193	O	steady
35	195	199	O	state
36	202	207	O	volume
37	209	210	O	of
38	212	223	O	distribution
39	225	226	O	is
40	228	234	O	7.5*3.7
41	236	238	O	and
42	240	246	O	5.7*1.8
43	248	248	O	L
44	249	249	O	/
45	250	251	O	kg
46	252	252	O	,
47	254	265	O	respectively
NULL

Venlafaxine Hydrochloride	5803	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	17
Venlafaxine and ODV are minimally bound at therapeutic concentrations to plasma proteins (27% and 30%, respectively).
1	0	10	O	XXXXXXXX
2	12	14	O	and
3	16	18	O	ODV
4	20	22	O	are
5	24	32	O	minimally
6	34	38	O	bound
7	40	41	O	at
8	43	53	O	therapeutic
9	55	68	O	concentrations
10	70	71	O	to
11	73	78	O	plasma
12	80	87	O	proteins
13	90	92	O	27%
14	94	96	O	and
15	98	100	O	30%
16	101	101	O	,
17	103	114	O	respectively
NULL

Venlafaxine Hydrochloride	5804	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	13
Absorption and Distribution Venlafaxine is well absorbed and extensively metabolized in the liver.
1	0	9	O	Absorption
2	11	13	O	and
3	15	26	O	Distribution
4	28	38	O	XXXXXXXX
5	40	41	O	is
6	43	46	O	well
7	48	55	O	absorbed
8	57	59	O	and
9	61	71	O	extensively
10	73	83	O	metabolized
11	85	86	O	in
12	88	90	O	the
13	92	96	O	liver
NULL

Venlafaxine Hydrochloride	5805	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	20
On the basis of mass balance studies, at least 92% of a single oral dose of venlafaxine is absorbed.
1	0	1	O	On
2	3	5	O	the
3	7	11	O	basis
4	13	14	O	of
5	16	19	O	mass
6	21	27	O	balance
7	29	35	O	studies
8	36	36	O	,
9	38	39	O	at
10	41	45	O	least
11	47	49	O	92%
12	51	52	O	of
13	54	54	O	a
14	56	61	O	single
15	63	66	O	oral
16	68	71	O	dose
17	73	74	O	of
18	76	86	O	XXXXXXXX
19	88	89	O	is
20	91	98	O	absorbed
NULL

Venlafaxine Hydrochloride	5806	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	8
The absolute bioavailability of venlafaxine is approximately 45%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	42	O	XXXXXXXX
6	44	45	O	is
7	47	59	O	approximately
8	61	63	O	45%
NULL

Venlafaxine Hydrochloride	5807	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	28
Administration of venlafaxine hydrochloride extended-release (150 mg once daily) generally resulted in lower Cmax and later Tmax values than for venlafaxine hydrochloride immediate-release administered twice daily (Table 16).
1	0	13	O	Administration
2	15	16	O	of
3	18	42	O	XXXXXXXX
4	44	51	O	extended
5	53	59	O	release
6	62	64	O	150
7	66	67	O	mg
8	69	72	O	once
9	74	78	O	daily
10	81	89	O	generally
11	91	98	O	resulted
12	100	101	O	in
13	103	107	O	lower
14	109	112	O	Cmax
15	114	116	O	and
16	118	122	O	later
17	124	127	O	Tmax
18	129	134	O	values
19	136	139	O	than
20	141	143	O	for
21	145	169	O	XXXXXXXX
22	171	179	O	immediate
23	181	187	O	release
24	189	200	O	administered
25	202	206	O	twice
26	208	212	O	daily
27	215	219	O	Table
28	221	222	O	16
NULL

Venlafaxine Hydrochloride	5808	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	49
When equal daily doses of venlafaxine were administered as either an immediate-release tablet or the extended-release capsule, the exposure to both venlafaxine and ODV was similar for the two treatments, and the fluctuation in plasma concentrations was slightly lower with the venlafaxine hydrochloride extended-release capsule.
1	0	3	O	When
2	5	9	O	equal
3	11	15	O	daily
4	17	21	O	doses
5	23	24	O	of
6	26	36	O	XXXXXXXX
7	38	41	O	were
8	43	54	O	administered
9	56	57	O	as
10	59	64	O	either
11	66	67	O	an
12	69	77	O	immediate
13	79	85	O	release
14	87	92	O	tablet
15	94	95	O	or
16	97	99	O	the
17	101	108	O	extended
18	110	116	O	release
19	118	124	O	capsule
20	125	125	O	,
21	127	129	O	the
22	131	138	O	exposure
23	140	141	O	to
24	143	146	O	both
25	148	158	O	XXXXXXXX
26	160	162	O	and
27	164	166	O	ODV
28	168	170	O	was
29	172	178	O	similar
30	180	182	O	for
31	184	186	O	the
32	188	190	O	two
33	192	201	O	treatments
34	202	202	O	,
35	204	206	O	and
36	208	210	O	the
37	212	222	O	fluctuation
38	224	225	O	in
39	227	232	O	plasma
40	234	247	O	concentrations
41	249	251	O	was
42	253	260	O	slightly
43	262	266	O	lower
44	268	271	O	with
45	273	275	O	the
46	277	301	O	XXXXXXXX
47	303	310	O	extended
48	312	318	O	release
49	320	326	O	capsule
NULL

Venlafaxine Hydrochloride	5809	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	24
Therefore, venlafaxine hydrochloride extended-release provides a slower rate of absorption, but the same extent of absorption compared with the immediate-release tablet.
1	0	8	O	Therefore
2	9	9	O	,
3	11	35	O	XXXXXXXX
4	37	44	O	extended
5	46	52	O	release
6	54	61	O	provides
7	63	63	O	a
8	65	70	O	slower
9	72	75	O	rate
10	77	78	O	of
11	80	89	O	absorption
12	90	90	O	,
13	92	94	O	but
14	96	98	O	the
15	100	103	O	same
16	105	110	O	extent
17	112	113	O	of
18	115	124	O	absorption
19	126	133	O	compared
20	135	138	O	with
21	140	142	O	the
22	144	152	O	immediate
23	154	160	O	release
24	162	167	O	tablet
NULL

Venlafaxine Hydrochloride	5810	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	74
Table 16: Comparison of Cmax and Tmax Values for Venlafaxine and ODV Following Oral Administration of Venlafaxine hydrochloride Extended-Release and Venlafaxine hydrochloride Immediate-Release) Venlafaxine ODV Cmax (ng/mL) Tmax (h) Cmax (ng/mL) Tmax (h) Venlafaxine hydrochloride Extended-Release (150 mg once daily) 150 5.5 260 9 Venlafaxine hydrochloride Immediate-Release (75 mg twice daily) 225 2 290 3 Food did not affect the bioavailability of venlafaxine or its active metabolite, ODV.
1	0	4	O	Table
2	6	7	O	16
3	8	8	O	:
4	10	19	O	Comparison
5	21	22	O	of
6	24	27	O	Cmax
7	29	31	O	and
8	33	36	O	Tmax
9	38	43	O	Values
10	45	47	O	for
11	49	59	O	XXXXXXXX
12	61	63	O	and
13	65	67	O	ODV
14	69	77	O	Following
15	79	82	O	Oral
16	84	97	O	Administration
17	99	100	O	of
18	102	126	O	XXXXXXXX
19	128	135	O	Extended
20	137	143	O	Release
21	145	147	O	and
22	149	173	O	XXXXXXXX
23	175	183	O	Immediate
24	185	191	O	Release
25	194	204	O	XXXXXXXX
26	206	208	O	ODV
27	210	213	O	Cmax
28	216	217	O	ng
29	218	218	O	/
30	219	220	O	mL
31	223	226	O	Tmax
32	229	229	O	h
33	232	235	O	Cmax
34	238	239	O	ng
35	240	240	O	/
36	241	242	O	mL
37	245	248	O	Tmax
38	251	251	O	h
39	254	278	O	XXXXXXXX
40	280	287	O	Extended
41	289	295	O	Release
42	298	300	O	150
43	302	303	O	mg
44	305	308	O	once
45	310	314	O	daily
46	317	319	O	150
47	321	323	O	5.5
48	325	327	O	260
49	329	329	O	9
50	331	355	O	XXXXXXXX
51	357	365	O	Immediate
52	367	373	O	Release
53	376	377	O	75
54	379	380	O	mg
55	382	386	O	twice
56	388	392	O	daily
57	395	397	O	225
58	399	399	O	2
59	401	403	O	290
60	405	405	O	3
61	407	410	O	Food
62	412	414	O	did
63	416	418	O	not
64	420	425	O	affect
65	427	429	O	the
66	431	445	O	bioavailability
67	447	448	O	of
68	450	460	O	XXXXXXXX
69	462	463	O	or
70	465	467	O	its
71	469	474	O	active
72	476	485	O	metabolite
73	486	486	O	,
74	488	490	O	ODV
NULL

Venlafaxine Hydrochloride	5811	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	23
Time of administration (AM versus PM) did not affect the pharmacokinetics of venlafaxine and ODV from the 75 mg venlafaxine hydrochloride extended-release capsule.
1	0	3	O	Time
2	5	6	O	of
3	8	21	O	administration
4	24	25	O	AM
5	27	32	O	versus
6	34	35	O	PM
7	38	40	O	did
8	42	44	O	not
9	46	51	O	affect
10	53	55	O	the
11	57	72	O	pharmacokinetics
12	74	75	O	of
13	77	87	O	XXXXXXXX
14	89	91	O	and
15	93	95	O	ODV
16	97	100	O	from
17	102	104	O	the
18	106	107	O	75
19	109	110	O	mg
20	112	136	O	XXXXXXXX
21	138	145	O	extended
22	147	153	O	release
23	155	161	O	capsule
NULL

Venlafaxine Hydrochloride	5812	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	36
Venlafaxine is not highly bound to plasma proteins; therefore, administration of venlafaxine hydrochloride extended-release to a patient taking another drug that is highly protein-bound should not cause increased free concentrations of the other drug.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	17	O	not
4	19	24	O	highly
5	26	30	O	bound
6	32	33	O	to
7	35	40	O	plasma
8	42	49	O	proteins
9	52	60	O	therefore
10	61	61	O	,
11	63	76	O	administration
12	78	79	O	of
13	81	105	O	XXXXXXXX
14	107	114	O	extended
15	116	122	O	release
16	124	125	O	to
17	127	127	O	a
18	129	135	O	patient
19	137	142	O	taking
20	144	150	O	another
21	152	155	O	drug
22	157	160	O	that
23	162	163	O	is
24	165	170	O	highly
25	172	178	O	protein
26	180	184	O	bound
27	186	191	O	should
28	193	195	O	not
29	197	201	O	cause
30	203	211	O	increased
31	213	216	O	free
32	218	231	O	concentrations
33	233	234	O	of
34	236	238	O	the
35	240	244	O	other
36	246	249	O	drug
NULL

Venlafaxine Hydrochloride	5813	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	34
Metabolism and Elimination Following absorption, venlafaxine undergoes extensive presystemic metabolism in the liver, primarily to ODV, but also to N-desmethylvenlafaxine, N,O-didesmethylvenlafaxine, and other minor metabolites.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	27	35	O	Following
5	37	46	O	absorption
6	47	47	O	,
7	49	59	O	XXXXXXXX
8	61	69	O	undergoes
9	71	79	O	extensive
10	81	91	O	presystemic
11	93	102	O	metabolism
12	104	105	O	in
13	107	109	O	the
14	111	115	O	liver
15	116	116	O	,
16	118	126	O	primarily
17	128	129	O	to
18	131	133	O	ODV
19	134	134	O	,
20	136	138	O	but
21	140	143	O	also
22	145	146	O	to
23	148	148	O	N
24	150	158	O	desmethyl
25	159	169	O	XXXXXXXX
26	170	170	O	,
27	172	174	O	N,O
28	176	186	O	didesmethyl
29	187	197	O	XXXXXXXX
30	198	198	O	,
31	200	202	O	and
32	204	208	O	other
33	210	214	O	minor
34	216	226	O	metabolites
NULL

Venlafaxine Hydrochloride	5814	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	49
In vitro studies indicate that the formation of ODV is catalyzed by CYP2D6; this has been confirmed in a clinical study showing that patients with low CYP2D6 levels (poor metabolizers) had increased levels of venlafaxine and reduced levels of ODV compared to people with normal CYP2D6 levels (extensive metabolizers).
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	24	O	indicate
5	26	29	O	that
6	31	33	O	the
7	35	43	O	formation
8	45	46	O	of
9	48	50	O	ODV
10	52	53	O	is
11	55	63	O	catalyzed
12	65	66	O	by
13	68	73	O	CYP2D6
14	76	79	O	this
15	81	83	O	has
16	85	88	O	been
17	90	98	O	confirmed
18	100	101	O	in
19	103	103	O	a
20	105	112	O	clinical
21	114	118	O	study
22	120	126	O	showing
23	128	131	O	that
24	133	140	O	patients
25	142	145	O	with
26	147	149	O	low
27	151	156	O	CYP2D6
28	158	163	O	levels
29	166	169	O	poor
30	171	182	O	metabolizers
31	185	187	O	had
32	189	197	O	increased
33	199	204	O	levels
34	206	207	O	of
35	209	219	O	XXXXXXXX
36	221	223	O	and
37	225	231	O	reduced
38	233	238	O	levels
39	240	241	O	of
40	243	245	O	ODV
41	247	254	O	compared
42	256	257	O	to
43	259	264	O	people
44	266	269	O	with
45	271	276	O	normal
46	278	283	O	CYP2D6
47	285	290	O	levels
48	293	301	O	extensive
49	303	314	O	metabolizers
NULL

Venlafaxine Hydrochloride	5815	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	33
Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%).
1	0	12	O	Approximately
2	14	16	O	87%
3	18	19	O	of
4	21	21	O	a
5	23	33	O	XXXXXXXX
6	35	38	O	dose
7	40	41	O	is
8	43	51	O	recovered
9	53	54	O	in
10	56	58	O	the
11	60	64	O	urine
12	66	71	O	within
13	73	74	O	48
14	76	80	O	hours
15	82	83	O	as
16	85	93	O	unchanged
17	95	105	O	XXXXXXXX
18	108	109	O	5%
19	111	111	O	,
20	113	124	O	unconjugated
21	126	128	O	ODV
22	131	133	O	29%
23	135	135	O	,
24	137	146	O	conjugated
25	148	150	O	ODV
26	153	155	O	26%
27	157	157	O	,
28	159	160	O	or
29	162	166	O	other
30	168	172	O	minor
31	174	181	O	inactive
32	183	193	O	metabolites
33	196	198	O	27%
NULL

Venlafaxine Hydrochloride	5816	34090-1	4c401522-0108-49cb-8a41-fb5ad4dd0fb1	14
Renal elimination of venlafaxine and its metabolites is thus the primary route of excretion.
1	0	4	O	Renal
2	6	16	O	elimination
3	18	19	O	of
4	21	31	O	XXXXXXXX
5	33	35	O	and
6	37	39	O	its
7	41	51	O	metabolites
8	53	54	O	is
9	56	59	O	thus
10	61	63	O	the
11	65	71	O	primary
12	73	77	O	route
13	79	80	O	of
14	82	90	O	excretion
NULL

WELLBUTRIN	3846	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	40
*CYP2B6 inducers: Dose increase may be necessary if coadministered with CYP2B6 inducers (e.g., ritonavir, lopinavir, efavirenz, carbamazepine, phenobarbital, and phenytoin) based on clinical exposure, but should not exceed the maximum recommended dose.
1	0	6	O	CYP2B6
2	8	15	U-KIN	inducers
3	16	16	O	:
4	18	21	B-TRI	Dose
5	23	30	L-TRI	increase
6	32	34	O	may
7	36	37	O	be
8	39	47	O	necessary
9	49	50	O	if
10	52	65	O	coadministered
11	67	70	O	with
12	72	77	O	CYP2B6
13	79	86	O	inducers
14	89	91	O	e.g
15	93	93	O	,
16	95	103	U-KIN	ritonavir
17	104	104	O	,
18	106	114	U-KIN	lopinavir
19	115	115	O	,
20	117	125	U-KIN	efavirenz
21	126	126	O	,
22	128	140	U-KIN	carbamazepine
23	141	141	O	,
24	143	155	U-KIN	phenobarbital
25	156	156	O	,
26	158	160	O	and
27	162	170	U-KIN	phenytoin
28	173	177	O	based
29	179	180	O	on
30	182	189	O	clinical
31	191	198	O	exposure
32	199	199	O	,
33	201	203	O	but
34	205	210	O	should
35	212	214	O	not
36	216	221	O	exceed
37	223	225	O	the
38	227	233	O	maximum
39	235	245	O	recommended
40	247	250	O	dose
K/16:C54356 K/18:C54356 K/2:C54356 K/20:C54356 K/22:C54356 K/24:C54356 K/27:C54356

WELLBUTRIN	3847	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	55
*Drugs metabolized by CYP2D6: Bupropion inhibits CYP2D6 and can increase concentrations of: antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide).
1	0	5	O	Drugs
2	7	17	B-KIN	metabolized
3	19	20	I-KIN	by
4	22	27	L-KIN	CYP2D6
5	28	28	O	:
6	30	38	O	XXXXXXXX
7	40	47	O	inhibits
8	49	54	O	CYP2D6
9	56	58	O	and
10	60	62	O	can
11	64	71	B-TRI	increase
12	73	86	L-TRI	concentrations
13	88	89	O	of
14	90	90	O	:
15	92	106	U-KIN	antidepressants
16	109	111	O	e.g
17	113	113	O	,
18	115	125	U-KIN	venlafaxine
19	126	126	O	,
20	128	140	U-KIN	nortriptyline
21	141	141	O	,
22	143	152	U-KIN	imipramine
23	153	153	O	,
24	155	165	U-KIN	desipramine
25	166	166	O	,
26	168	177	U-KIN	paroxetine
27	178	178	O	,
28	180	189	U-KIN	fluoxetine
29	190	190	O	,
30	192	201	U-KIN	sertraline
31	203	203	O	,
32	205	218	U-KIN	antipsychotics
33	221	223	O	e.g
34	225	225	O	,
35	227	237	U-KIN	haloperidol
36	238	238	O	,
37	240	250	U-KIN	risperidone
38	251	251	O	,
39	253	264	U-KIN	thioridazine
40	266	266	O	,
41	268	271	B-KIN	beta
42	273	280	L-KIN	blockers
43	283	285	O	e.g
44	287	287	O	,
45	289	298	U-KIN	metoprolol
46	300	300	O	,
47	302	304	O	and
48	306	309	B-KIN	Type
49	311	312	I-KIN	1C
50	314	328	L-KIN	antiarrhythmics
51	331	333	O	e.g
52	335	335	O	,
53	337	347	U-KIN	propafenone
54	348	348	O	,
55	350	359	U-KIN	flecainide
K/15:C54357 K/18:C54357 K/2:C54357 K/20:C54357 K/22:C54357 K/24:C54357 K/26:C54357 K/28:C54357 K/30:C54357 K/32:C54357 K/35:C54357 K/37:C54357 K/39:C54357 K/41:C54357 K/45:C54357 K/48:C54357 K/53:C54357 K/55:C54357

WELLBUTRIN	3848	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	7
Consider dose reduction when using with bupropion.
1	0	7	O	Consider
2	9	12	O	dose
3	14	22	O	reduction
4	24	27	O	when
5	29	33	O	using
6	35	38	O	with
7	40	48	O	XXXXXXXX
NULL

WELLBUTRIN	3849	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	11
*Drugs that lower seizure threshold: Dose WELLBUTRIN XL with caution.
1	0	5	O	Drugs
2	7	10	B-UNK	that
3	12	16	I-UNK	lower
4	18	24	I-UNK	seizure
5	26	34	L-UNK	threshold
6	35	35	O	:
7	37	40	O	Dose
8	42	51	O	XXXXXXXX
9	53	54	O	XL
10	56	59	O	with
11	61	67	U-TRI	caution
NULL

WELLBUTRIN	3850	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
*Dopaminergic Drugs (levodopa and amantadine): CNS toxicity can occur when used concomitantly with WELLBUTRIN XL.
1	0	12	O	Dopaminergic
2	14	18	U-DYN	Drugs
3	21	28	U-DYN	levodopa
4	30	32	O	and
5	34	43	U-DYN	amantadine
6	45	45	O	:
7	47	49	B-EFF	CNS
8	51	58	L-EFF	toxicity
9	60	62	O	can
10	64	68	O	occur
11	70	73	O	when
12	75	78	O	used
13	80	92	O	concomitantly
14	94	97	O	with
15	99	108	O	XXXXXXXX
16	110	111	O	XL
D/2:7:1 D/3:7:1 D/5:7:1

WELLBUTRIN	3851	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	15
*MAOIs: Increased risk of hypertensive reactions can occur when used concomitantly with WELLBUTRIN XL.
1	0	5	O	MAOIs
2	6	6	O	:
3	8	16	O	Increased
4	18	21	O	risk
5	23	24	O	of
6	26	37	B-EFF	hypertensive
7	39	47	L-EFF	reactions
8	49	51	O	can
9	53	57	O	occur
10	59	62	O	when
11	64	67	O	used
12	69	81	O	concomitantly
13	83	86	O	with
14	88	97	O	XXXXXXXX
15	99	100	O	XL
NULL

WELLBUTRIN	3852	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
*Drug laboratory test interactions: WELLBUTRIN XL can cause false-positive urine test results for amphetamines.
1	0	4	O	Drug
2	6	15	O	laboratory
3	17	20	O	test
4	22	33	O	interactions
5	34	34	O	:
6	36	45	O	XXXXXXXX
7	47	48	O	XL
8	50	52	O	can
9	54	58	O	cause
10	60	64	O	false
11	66	73	O	positive
12	75	79	O	urine
13	81	84	O	test
14	86	92	O	results
15	94	96	O	for
16	98	109	O	amphetamines
NULL

WELLBUTRIN	3853	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	9
Bupropion is primarily metabolized to hydroxybupropion by CYP2B6.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	21	O	primarily
4	23	33	O	metabolized
5	35	36	O	to
6	38	44	O	hydroxy
7	45	53	O	XXXXXXXX
8	55	56	O	by
9	58	63	O	CYP2B6
NULL

WELLBUTRIN	3854	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	20
Therefore, the potential exists for drug interactions between WELLBUTRIN XL and drugs that are inhibitors or inducers of CYP2B6.
1	0	8	O	Therefore
2	9	9	O	,
3	11	13	O	the
4	15	23	O	potential
5	25	30	O	exists
6	32	34	O	for
7	36	39	B-TRI	drug
8	41	52	L-TRI	interactions
9	54	60	O	between
10	62	71	O	XXXXXXXX
11	73	74	O	XL
12	76	78	O	and
13	80	84	O	drugs
14	86	89	O	that
15	91	93	O	are
16	95	104	O	inhibitors
17	106	107	O	or
18	109	116	B-UNK	inducers
19	118	119	I-UNK	of
20	121	126	L-UNK	CYP2B6
NULL

WELLBUTRIN	3855	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	21
Inhibitors of CYP2B6 Ticlopidine and Clopidogrel: Concomitant treatment with these drugs can increase bupropion exposures but decrease hydroxybupropion exposure.
1	0	9	B-KIN	Inhibitors
2	11	12	I-KIN	of
3	14	19	L-KIN	CYP2B6
4	21	31	U-KIN	Ticlopidine
5	33	35	O	and
6	37	47	U-KIN	Clopidogrel
7	48	48	O	:
8	50	60	O	Concomitant
9	62	70	O	treatment
10	72	75	O	with
11	77	81	O	these
12	83	87	O	drugs
13	89	91	O	can
14	93	100	B-TRI	increase
15	102	110	I-TRI	XXXXXXXX
16	112	120	L-TRI	exposures
17	122	124	O	but
18	126	133	O	decrease
19	135	141	O	hydroxy
20	142	150	O	XXXXXXXX
21	152	159	O	exposure
K/1:C54355 K/4:C54355 K/6:C54355

WELLBUTRIN	3856	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	23
Based on clinical response, dosage adjustment of WELLBUTRIN XL may be necessary when coadministered with CYP2B6 inhibitors (e.g., ticlopidine or clopidogrel).
1	0	4	O	Based
2	6	7	O	on
3	9	16	O	clinical
4	18	25	O	response
5	26	26	O	,
6	28	33	B-TRI	dosage
7	35	44	L-TRI	adjustment
8	46	47	O	of
9	49	58	O	XXXXXXXX
10	60	61	O	XL
11	63	65	O	may
12	67	68	O	be
13	70	78	O	necessary
14	80	83	O	when
15	85	98	O	coadministered
16	100	103	O	with
17	105	110	B-UNK	CYP2B6
18	112	121	L-UNK	inhibitors
19	124	126	O	e.g
20	128	128	O	,
21	130	140	U-UNK	ticlopidine
22	142	143	O	or
23	145	155	U-UNK	clopidogrel
NULL

WELLBUTRIN	3857	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	22
Inducers of CYP2B6 Ritonavir, Lopinavir, and Efavirenz: Concomitant treatment with these drugs can decrease bupropion and hydroxybupropion exposure.
1	0	7	B-KIN	Inducers
2	9	10	I-KIN	of
3	12	17	L-KIN	CYP2B6
4	19	27	U-KIN	Ritonavir
5	28	28	O	,
6	30	38	U-KIN	Lopinavir
7	39	39	O	,
8	41	43	O	and
9	45	53	U-KIN	Efavirenz
10	54	54	O	:
11	56	66	O	Concomitant
12	68	76	O	treatment
13	78	81	O	with
14	83	87	O	these
15	89	93	O	drugs
16	95	97	O	can
17	99	106	O	decrease
18	108	116	O	XXXXXXXX
19	118	120	O	and
20	122	128	O	hydroxy
21	129	137	O	XXXXXXXX
22	139	146	O	exposure
K/1:C54356 K/4:C54356 K/6:C54356 K/9:C54356

WELLBUTRIN	3858	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	25
Dosage increase of WELLBUTRIN XL may be necessary when coadministered with ritonavir, lopinavir, or efavirenz but should not exceed the maximum recommended dose.
1	0	5	B-TRI	Dosage
2	7	14	L-TRI	increase
3	16	17	O	of
4	19	28	O	XXXXXXXX
5	30	31	O	XL
6	33	35	O	may
7	37	38	O	be
8	40	48	O	necessary
9	50	53	O	when
10	55	68	O	coadministered
11	70	73	O	with
12	75	83	U-KIN	ritonavir
13	84	84	O	,
14	86	94	U-KIN	lopinavir
15	95	95	O	,
16	97	98	O	or
17	100	108	U-KIN	efavirenz
18	110	112	O	but
19	114	119	O	should
20	121	123	O	not
21	125	130	O	exceed
22	132	134	O	the
23	136	142	O	maximum
24	144	154	O	recommended
25	156	159	O	dose
K/12:C54356 K/14:C54356 K/17:C54356

WELLBUTRIN	3859	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	23
Carbamazepine, Phenobarbital, Phenytoin: While not systemically studied, these drugs may induce metabolism of bupropion and may decrease bupropion exposure.
1	0	12	U-KIN	Carbamazepine
2	13	13	O	,
3	15	27	U-KIN	Phenobarbital
4	28	28	O	,
5	30	38	U-KIN	Phenytoin
6	39	39	O	:
7	41	45	O	While
8	47	49	O	not
9	51	62	O	systemically
10	64	70	O	studied
11	71	71	O	,
12	73	77	O	these
13	79	83	O	drugs
14	85	87	O	may
15	89	94	B-TRI	induce
16	96	105	L-TRI	metabolism
17	107	108	O	of
18	110	118	O	XXXXXXXX
19	120	122	O	and
20	124	126	O	may
21	128	135	O	decrease
22	137	145	O	XXXXXXXX
23	147	154	O	exposure
K/1:C54356 K/3:C54356 K/5:C54356

WELLBUTRIN	3860	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	30
If bupropion is used concomitantly with a CYP inducer, it may be necessary to increase the dose of bupropion, but the maximum recommended dose should not be exceeded.
1	0	1	O	If
2	3	11	O	XXXXXXXX
3	13	14	O	is
4	16	19	O	used
5	21	33	O	concomitantly
6	35	38	O	with
7	40	40	O	a
8	42	44	B-KIN	CYP
9	46	52	L-KIN	inducer
10	53	53	O	,
11	55	56	O	it
12	58	60	O	may
13	62	63	O	be
14	65	73	O	necessary
15	75	76	O	to
16	78	85	B-TRI	increase
17	87	89	I-TRI	the
18	91	94	L-TRI	dose
19	96	97	O	of
20	99	107	O	XXXXXXXX
21	108	108	O	,
22	110	112	O	but
23	114	116	O	the
24	118	124	O	maximum
25	126	136	O	recommended
26	138	141	O	dose
27	143	148	O	should
28	150	152	O	not
29	154	155	O	be
30	157	164	O	exceeded
K/8:C54356

WELLBUTRIN	3861	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	19
Drugs Metabolized by CYP2D6 Bupropion and its metabolites (erythrohydrobupropion, threohydrobupropion, hydroxybupropion) are CYP2D6 inhibitors.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	26	O	CYP2D6
5	28	36	O	XXXXXXXX
6	38	40	O	and
7	42	44	O	its
8	46	56	O	metabolites
9	59	70	O	erythrohydro
10	71	79	O	XXXXXXXX
11	80	80	O	,
12	82	91	O	threohydro
13	92	100	O	XXXXXXXX
14	101	101	O	,
15	103	109	O	hydroxy
16	110	118	O	XXXXXXXX
17	121	123	O	are
18	125	130	O	CYP2D6
19	132	141	O	inhibitors
NULL

WELLBUTRIN	3862	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	24
Therefore, coadministration of WELLBUTRIN XL with drugs that are metabolized by CYP2D6 can increase the exposures of drugs that are substrates of CYP2D6.
1	0	8	O	Therefore
2	9	9	O	,
3	11	26	O	coadministration
4	28	29	O	of
5	31	40	O	XXXXXXXX
6	42	43	O	XL
7	45	48	O	with
8	50	54	B-KIN	drugs
9	56	59	I-KIN	that
10	61	63	I-KIN	are
11	65	75	I-KIN	metabolized
12	77	78	I-KIN	by
13	80	85	L-KIN	CYP2D6
14	87	89	O	can
15	91	98	B-TRI	increase
16	100	102	I-TRI	the
17	104	112	L-TRI	exposures
18	114	115	O	of
19	117	121	O	drugs
20	123	126	O	that
21	128	130	O	are
22	132	141	B-KIN	substrates
23	143	144	I-KIN	of
24	146	151	L-KIN	CYP2D6
K/22:C54357 K/8:C54357

WELLBUTRIN	3863	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	41
Such drugs include antidepressants (e.g., venlafaxine, nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, and sertraline), antipsychotics (e.g. haloperidol, risperidone, and thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g.
1	0	3	O	Such
2	5	9	O	drugs
3	11	17	O	include
4	19	33	O	antidepressants
5	36	38	O	e.g
6	40	40	O	,
7	42	52	O	venlafaxine
8	53	53	O	,
9	55	67	O	nortriptyline
10	68	68	O	,
11	70	79	O	imipramine
12	80	80	O	,
13	82	92	O	desipramine
14	93	93	O	,
15	95	104	O	paroxetine
16	105	105	O	,
17	107	116	O	fluoxetine
18	117	117	O	,
19	119	121	O	and
20	123	132	O	sertraline
21	134	134	O	,
22	136	149	O	antipsychotics
23	152	154	O	e.g
24	157	167	O	haloperidol
25	168	168	O	,
26	170	180	O	risperidone
27	181	181	O	,
28	183	185	O	and
29	187	198	O	thioridazine
30	200	200	O	,
31	202	205	O	beta
32	207	214	O	blockers
33	217	219	O	e.g
34	221	221	O	,
35	223	232	O	metoprolol
36	234	234	O	,
37	236	238	O	and
38	240	243	O	Type
39	245	246	O	1C
40	248	262	O	antiarrhythmics
41	265	267	O	e.g
NULL

WELLBUTRIN	3864	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	28
When used concomitantly with WELLBUTRIN XL, it may be necessary to decrease the dose of these CYP2D6 substrates, particularly for drugs with a narrow therapeutic index.
1	0	3	O	When
2	5	8	O	used
3	10	22	O	concomitantly
4	24	27	O	with
5	29	38	O	XXXXXXXX
6	40	41	O	XL
7	42	42	O	,
8	44	45	O	it
9	47	49	O	may
10	51	52	O	be
11	54	62	O	necessary
12	64	65	O	to
13	67	74	B-TRI	decrease
14	76	78	I-TRI	the
15	80	83	L-TRI	dose
16	85	86	O	of
17	88	92	O	these
18	94	99	B-KIN	CYP2D6
19	101	110	L-KIN	substrates
20	111	111	O	,
21	113	124	O	particularly
22	126	128	O	for
23	130	134	O	drugs
24	136	139	O	with
25	141	141	O	a
26	143	148	O	narrow
27	150	160	O	therapeutic
28	162	166	O	index
K/18:C54357

WELLBUTRIN	3865	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	29
Drugs that require metabolic activation by CYP2D6 to be effective (e.g., tamoxifen), theoretically could have reduced efficacy when administered concomitantly with inhibitors of CYP2D6 such as bupropion.
1	0	4	B-DYN	Drugs
2	6	9	I-DYN	that
3	11	17	I-DYN	require
4	19	27	I-DYN	metabolic
5	29	38	I-DYN	activation
6	40	41	I-DYN	by
7	43	48	I-DYN	CYP2D6
8	50	51	I-DYN	to
9	53	54	I-DYN	be
10	56	64	L-DYN	effective
11	67	69	O	e.g
12	71	71	O	,
13	73	81	U-DYN	tamoxifen
14	83	83	O	,
15	85	97	O	theoretically
16	99	103	O	could
17	105	108	O	have
18	110	116	O	reduced
19	118	125	O	efficacy
20	127	130	O	when
21	132	143	O	administered
22	145	157	O	concomitantly
23	159	162	O	with
24	164	173	O	inhibitors
25	175	176	O	of
26	178	183	O	CYP2D6
27	185	188	O	such
28	190	191	O	as
29	193	201	O	XXXXXXXX
NULL

WELLBUTRIN	3866	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
Patients treated concomitantly with WELLBUTRIN XL and such drugs may require increased doses of the drug.
1	0	7	O	Patients
2	9	15	O	treated
3	17	29	O	concomitantly
4	31	34	O	with
5	36	45	O	XXXXXXXX
6	47	48	O	XL
7	50	52	O	and
8	54	57	O	such
9	59	63	O	drugs
10	65	67	O	may
11	69	75	O	require
12	77	85	O	increased
13	87	91	O	doses
14	93	94	O	of
15	96	98	O	the
16	100	103	O	drug
NULL

WELLBUTRIN	3867	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	30
Use extreme caution when coadministering WELLBUTRIN XL with other drugs that lower the seizure threshold (e.g., other bupropion products, antipsychotics, antidepressants, theophylline, or systemic corticosteroids).
1	0	2	B-TRI	Use
2	4	10	I-TRI	extreme
3	12	18	L-TRI	caution
4	20	23	O	when
5	25	39	O	coadministering
6	41	50	O	XXXXXXXX
7	52	53	O	XL
8	55	58	O	with
9	60	64	O	other
10	66	70	B-UNK	drugs
11	72	75	I-UNK	that
12	77	81	I-UNK	lower
13	83	85	I-UNK	the
14	87	93	I-UNK	seizure
15	95	103	L-UNK	threshold
16	106	108	O	e.g
17	110	110	O	,
18	112	116	O	other
19	118	126	B-UNK	XXXXXXXX
20	128	135	L-UNK	products
21	136	136	O	,
22	138	151	U-UNK	antipsychotics
23	152	152	O	,
24	154	168	U-UNK	antidepressants
25	169	169	O	,
26	171	182	U-UNK	theophylline
27	183	183	O	,
28	185	186	O	or
29	188	195	B-UNK	systemic
30	197	211	L-UNK	corticosteroids
NULL

WELLBUTRIN	3868	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	12
Use low initial doses of WELLBUTRIN XL and increase the dose gradually.
1	0	2	O	Use
2	4	6	O	low
3	8	14	O	initial
4	16	20	O	doses
5	22	23	O	of
6	25	34	O	XXXXXXXX
7	36	37	O	XL
8	39	41	O	and
9	43	50	O	increase
10	52	54	O	the
11	56	59	O	dose
12	61	69	O	gradually
NULL

WELLBUTRIN	3869	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	10
Bupropion, levodopa, and amantadine have dopamine agonist effects.
1	0	8	O	XXXXXXXX
2	9	9	O	,
3	11	18	O	levodopa
4	19	19	O	,
5	21	23	O	and
6	25	34	O	amantadine
7	36	39	O	have
8	41	48	O	dopamine
9	50	56	O	agonist
10	58	64	O	effects
NULL

WELLBUTRIN	3870	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	13
CNS toxicity has been reported when bupropion was coadministered with levodopa or amantadine.
1	0	2	B-EFF	CNS
2	4	11	L-EFF	toxicity
3	13	15	O	has
4	17	20	O	been
5	22	29	O	reported
6	31	34	O	when
7	36	44	O	XXXXXXXX
8	46	48	O	was
9	50	63	O	coadministered
10	65	68	O	with
11	70	77	U-DYN	levodopa
12	79	80	O	or
13	82	91	U-DYN	amantadine
D/11:1:1 D/13:1:1

WELLBUTRIN	3871	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	19
Adverse reactions have included restlessness, agitation, tremor, ataxia, gait disturbance, vertigo, and dizziness.
1	0	6	O	Adverse
2	8	16	O	reactions
3	18	21	O	have
4	23	30	O	included
5	32	43	O	restlessness
6	44	44	O	,
7	46	54	O	agitation
8	55	55	O	,
9	57	62	O	tremor
10	63	63	O	,
11	65	70	O	ataxia
12	71	71	O	,
13	73	76	O	gait
14	78	88	O	disturbance
15	89	89	O	,
16	91	97	O	vertigo
17	98	98	O	,
18	100	102	O	and
19	104	112	O	dizziness
NULL

WELLBUTRIN	3872	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	12
It is presumed that the toxicity results from cumulative dopamine agonist effects.
1	0	1	O	It
2	3	4	O	is
3	6	13	O	presumed
4	15	18	O	that
5	20	22	O	the
6	24	31	O	toxicity
7	33	39	O	results
8	41	44	O	from
9	46	55	O	cumulative
10	57	64	O	dopamine
11	66	72	O	agonist
12	74	80	O	effects
NULL

WELLBUTRIN	3873	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	10
Use caution when administering WELLBUTRIN XL concomitantly with these drugs.
1	0	2	O	Use
2	4	10	O	caution
3	12	15	O	when
4	17	29	O	administering
5	31	40	O	XXXXXXXX
6	42	43	O	XL
7	45	57	O	concomitantly
8	59	62	O	with
9	64	68	O	these
10	70	74	O	drugs
NULL

WELLBUTRIN	3874	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	28
In postmarketing experience, there have been rare reports of adverse neuropsychiatric events or reduced alcohol tolerance in patients who were drinking alcohol during treatment with WELLBUTRIN XL.
1	0	1	O	In
2	3	15	O	postmarketing
3	17	26	O	experience
4	27	27	O	,
5	29	33	O	there
6	35	38	O	have
7	40	43	O	been
8	45	48	O	rare
9	50	56	O	reports
10	58	59	O	of
11	61	67	B-EFF	adverse
12	69	84	I-EFF	neuropsychiatric
13	86	91	L-EFF	events
14	93	94	O	or
15	96	102	B-EFF	reduced
16	104	110	I-EFF	alcohol
17	112	120	L-EFF	tolerance
18	122	123	O	in
19	125	132	O	patients
20	134	136	O	who
21	138	141	O	were
22	143	150	O	drinking
23	152	158	O	alcohol
24	160	165	O	during
25	167	175	O	treatment
26	177	180	O	with
27	182	191	O	XXXXXXXX
28	193	194	O	XL
NULL

WELLBUTRIN	3875	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	14
The consumption of alcohol during treatment with WELLBUTRIN XL should be minimized or avoided.
1	0	2	O	The
2	4	14	O	consumption
3	16	17	O	of
4	19	25	U-UNK	alcohol
5	27	32	O	during
6	34	42	O	treatment
7	44	47	O	with
8	49	58	O	XXXXXXXX
9	60	61	O	XL
10	63	68	B-TRI	should
11	70	71	I-TRI	be
12	73	81	I-TRI	minimized
13	83	84	I-TRI	or
14	86	92	L-TRI	avoided
NULL

WELLBUTRIN	3876	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	8
Bupropion inhibits the reuptake of dopamine and norepinephrine.
1	0	8	O	XXXXXXXX
2	10	17	O	inhibits
3	19	21	O	the
4	23	30	O	reuptake
5	32	33	O	of
6	35	42	O	dopamine
7	44	46	O	and
8	48	61	O	norepinephrine
NULL

WELLBUTRIN	3877	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	24
Concomitant use of MAOIs and bupropion is contraindicated because there is an increased risk of hypertensive reactions if bupropion is used concomitantly with MAOIs.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	23	U-DYN	MAOIs
5	25	27	O	and
6	29	37	O	XXXXXXXX
7	39	40	O	is
8	42	56	O	contraindicated
9	58	64	O	because
10	66	70	O	there
11	72	73	O	is
12	75	76	O	an
13	78	86	O	increased
14	88	91	O	risk
15	93	94	O	of
16	96	107	B-EFF	hypertensive
17	109	117	L-EFF	reactions
18	119	120	O	if
19	122	130	O	XXXXXXXX
20	132	133	O	is
21	135	138	O	used
22	140	152	O	concomitantly
23	154	157	O	with
24	159	163	O	MAOIs
D/4:16:1

WELLBUTRIN	3878	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
Studies in animals demonstrate that the acute toxicity of bupropion is enhanced by the MAO inhibitor phenelzine.
1	0	6	O	Studies
2	8	9	O	in
3	11	17	O	animals
4	19	29	O	demonstrate
5	31	34	O	that
6	36	38	O	the
7	40	44	B-EFF	acute
8	46	53	I-EFF	toxicity
9	55	56	I-EFF	of
10	58	66	I-EFF	XXXXXXXX
11	68	69	I-EFF	is
12	71	78	L-EFF	enhanced
13	80	81	O	by
14	83	85	O	the
15	87	89	O	MAO
16	91	99	O	inhibitor
17	101	110	U-DYN	phenelzine
D/17:7:1

WELLBUTRIN	3879	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	22
At least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of treatment with WELLBUTRIN XL.
1	0	1	O	At
2	3	7	O	least
3	9	10	O	14
4	12	15	O	days
5	17	22	O	should
6	24	29	O	elapse
7	31	37	O	between
8	39	53	O	discontinuation
9	55	56	O	of
10	58	59	O	an
11	61	64	U-UNK	MAOI
12	66	73	O	intended
13	75	76	O	to
14	78	82	O	treat
15	84	93	O	depression
16	95	97	O	and
17	99	108	O	initiation
18	110	111	O	of
19	113	121	O	treatment
20	123	126	O	with
21	128	137	O	XXXXXXXX
22	139	140	O	XL
NULL

WELLBUTRIN	3880	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	18
Conversely, at least 14 days should be allowed after stopping WELLBUTRIN XL before starting an MAOI antidepressant.
1	0	9	O	Conversely
2	10	10	O	,
3	12	13	O	at
4	15	19	O	least
5	21	22	O	14
6	24	27	O	days
7	29	34	O	should
8	36	37	O	be
9	39	45	O	allowed
10	47	51	O	after
11	53	60	O	stopping
12	62	71	O	XXXXXXXX
13	73	74	O	XL
14	76	81	O	before
15	83	90	O	starting
16	92	93	O	an
17	95	98	U-UNK	MAOI
18	100	113	O	antidepressant
NULL

WELLBUTRIN	3881	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	15
False-positive urine immunoassay screening tests for amphetamines have been reported in patients taking bupropion.
1	0	4	O	False
2	6	13	O	positive
3	15	19	O	urine
4	21	31	O	immunoassay
5	33	41	O	screening
6	43	47	O	tests
7	49	51	O	for
8	53	64	O	amphetamines
9	66	69	O	have
10	71	74	O	been
11	76	83	O	reported
12	85	86	O	in
13	88	95	O	patients
14	97	102	O	taking
15	104	112	O	XXXXXXXX
NULL

WELLBUTRIN	3882	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	11
This is due to lack of specificity of some screening tests.
1	0	3	O	This
2	5	6	O	is
3	8	10	O	due
4	12	13	O	to
5	15	18	O	lack
6	20	21	O	of
7	23	33	O	specificity
8	35	36	O	of
9	38	41	O	some
10	43	51	O	screening
11	53	57	O	tests
NULL

WELLBUTRIN	3883	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	12
False-positive test results may result even following discontinuation of bupropion therapy.
1	0	4	O	False
2	6	13	O	positive
3	15	18	O	test
4	20	26	O	results
5	28	30	O	may
6	32	37	O	result
7	39	42	O	even
8	44	52	O	following
9	54	68	O	discontinuation
10	70	71	O	of
11	73	81	O	XXXXXXXX
12	83	89	O	therapy
NULL

WELLBUTRIN	3884	34073-7	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish bupropion from amphetamines.
1	0	11	O	Confirmatory
2	13	17	O	tests
3	18	18	O	,
4	20	23	O	such
5	25	26	O	as
6	28	30	O	gas
7	32	45	O	chromatography
8	46	46	O	/
9	47	50	O	mass
10	52	63	O	spectrometry
11	64	64	O	,
12	66	69	O	will
13	71	81	O	distinguish
14	83	91	O	XXXXXXXX
15	93	96	O	from
16	98	109	O	amphetamines
NULL

WELLBUTRIN	3885	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
The mechanism of action of bupropion is unknown, as is the case with other antidepressants.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	35	O	XXXXXXXX
7	37	38	O	is
8	40	46	O	unknown
9	47	47	O	,
10	49	50	O	as
11	52	53	O	is
12	55	57	O	the
13	59	62	O	case
14	64	67	O	with
15	69	73	O	other
16	75	89	O	antidepressants
NULL

WELLBUTRIN	3886	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
However, it is presumed that this action is mediated by noradrenergic and/or dopaminergic mechanisms.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	13	O	is
5	15	22	O	presumed
6	24	27	O	that
7	29	32	O	this
8	34	39	O	action
9	41	42	O	is
10	44	51	O	mediated
11	53	54	O	by
12	56	68	O	noradrenergic
13	70	72	O	and
14	73	73	O	/
15	74	75	O	or
16	77	88	O	dopaminergic
17	90	99	O	mechanisms
NULL

WELLBUTRIN	3887	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	25
Bupropion is a relatively weak inhibitor of the neuronal uptake of norepinephrine and dopamine and does not inhibit monoamine oxidase or the reuptake of serotonin.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	13	O	a
4	15	24	O	relatively
5	26	29	O	weak
6	31	39	O	inhibitor
7	41	42	O	of
8	44	46	O	the
9	48	55	O	neuronal
10	57	62	O	uptake
11	64	65	O	of
12	67	80	O	norepinephrine
13	82	84	O	and
14	86	93	O	dopamine
15	95	97	O	and
16	99	102	O	does
17	104	106	O	not
18	108	114	O	inhibit
19	116	124	O	monoamine
20	126	132	O	oxidase
21	134	135	O	or
22	137	139	O	the
23	141	148	O	reuptake
24	150	151	O	of
25	153	161	O	serotonin
NULL

WELLBUTRIN	3888	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	13
The pharmacologic activity and pharmacokinetics of the individual enantiomers have not been studied.
1	0	2	O	The
2	4	16	O	pharmacologic
3	18	25	O	activity
4	27	29	O	and
5	31	46	O	pharmacokinetics
6	48	49	O	of
7	51	53	O	the
8	55	64	O	individual
9	66	76	O	enantiomers
10	78	81	O	have
11	83	85	O	not
12	87	90	O	been
13	92	98	O	studied
NULL

WELLBUTRIN	3889	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
Following chronic dosing, the mean steady-state plasma concentration of bupropion was reached within 8 days.
1	0	8	O	Following
2	10	16	O	chronic
3	18	23	O	dosing
4	24	24	O	,
5	26	28	O	the
6	30	33	O	mean
7	35	40	O	steady
8	42	46	O	state
9	48	53	O	plasma
10	55	67	O	concentration
11	69	70	O	of
12	72	80	O	XXXXXXXX
13	82	84	O	was
14	86	92	O	reached
15	94	99	O	within
16	101	101	O	8
17	103	106	O	days
NULL

WELLBUTRIN	3890	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	11
The mean elimination half-life (+SD) of bupropion 21 (*9) hours.
1	0	2	O	The
2	4	7	O	mean
3	9	19	O	elimination
4	21	24	O	half
5	26	29	O	life
6	32	34	O	+SD
7	37	38	O	of
8	40	48	O	XXXXXXXX
9	50	51	O	21
10	54	55	O	9
11	58	62	O	hours
NULL

WELLBUTRIN	3891	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	56
In a study comparing 14-day dosing with WELLBUTRIN XL, 300 mg once-daily to the immediate-release formulation of bupropion at 100 mg 3 times daily, equivalence was demonstrated for peak plasma concentration and area under the curve for bupropion and the three metabolites (hydroxybupropion, threohydrobupropion, and erythrohydrobupropion).
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	19	O	comparing
5	21	22	O	14
6	24	26	O	day
7	28	33	O	dosing
8	35	38	O	with
9	40	49	O	XXXXXXXX
10	51	52	O	XL
11	53	53	O	,
12	55	57	O	300
13	59	60	O	mg
14	62	65	O	once
15	67	71	O	daily
16	73	74	O	to
17	76	78	O	the
18	80	88	O	immediate
19	90	96	O	release
20	98	108	O	formulation
21	110	111	O	of
22	113	121	O	XXXXXXXX
23	123	124	O	at
24	126	128	O	100
25	130	131	O	mg
26	133	133	O	3
27	135	139	O	times
28	141	145	O	daily
29	146	146	O	,
30	148	158	O	equivalence
31	160	162	O	was
32	164	175	O	demonstrated
33	177	179	O	for
34	181	184	O	peak
35	186	191	O	plasma
36	193	205	O	concentration
37	207	209	O	and
38	211	214	O	area
39	216	220	O	under
40	222	224	O	the
41	226	230	O	curve
42	232	234	O	for
43	236	244	O	XXXXXXXX
44	246	248	O	and
45	250	252	O	the
46	254	258	O	three
47	260	270	O	metabolites
48	273	279	O	hydroxy
49	280	288	O	XXXXXXXX
50	289	289	O	,
51	291	300	O	threohydro
52	301	309	O	XXXXXXXX
53	310	310	O	,
54	312	314	O	and
55	316	327	O	erythrohydro
56	328	336	O	XXXXXXXX
NULL

WELLBUTRIN	3892	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	48
Additionally, in a study comparing 14-day dosing with WELLBUTRIN XL 300 mg once daily to the sustained-release formulation of bupropion at 150 mg 2 times daily, equivalence was demonstrated for peak plasma concentration and area under the curve for bupropion and the three metabolites.
1	0	11	O	Additionally
2	12	12	O	,
3	14	15	O	in
4	17	17	O	a
5	19	23	O	study
6	25	33	O	comparing
7	35	36	O	14
8	38	40	O	day
9	42	47	O	dosing
10	49	52	O	with
11	54	63	O	XXXXXXXX
12	65	66	O	XL
13	68	70	O	300
14	72	73	O	mg
15	75	78	O	once
16	80	84	O	daily
17	86	87	O	to
18	89	91	O	the
19	93	101	O	sustained
20	103	109	O	release
21	111	121	O	formulation
22	123	124	O	of
23	126	134	O	XXXXXXXX
24	136	137	O	at
25	139	141	O	150
26	143	144	O	mg
27	146	146	O	2
28	148	152	O	times
29	154	158	O	daily
30	159	159	O	,
31	161	171	O	equivalence
32	173	175	O	was
33	177	188	O	demonstrated
34	190	192	O	for
35	194	197	O	peak
36	199	204	O	plasma
37	206	218	O	concentration
38	220	222	O	and
39	224	227	O	area
40	229	233	O	under
41	235	237	O	the
42	239	243	O	curve
43	245	247	O	for
44	249	257	O	XXXXXXXX
45	259	261	O	and
46	263	265	O	the
47	267	271	O	three
48	273	283	O	metabolites
NULL

WELLBUTRIN	3893	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	26
Absorption Following single oral administration of WELLBUTRIN XL tablets to healthy volunteers, the median time to peak plasma concentrations for bupropion was approximately 5 hours.
1	0	9	O	Absorption
2	11	19	O	Following
3	21	26	O	single
4	28	31	O	oral
5	33	46	O	administration
6	48	49	O	of
7	51	60	O	XXXXXXXX
8	62	63	O	XL
9	65	71	O	tablets
10	73	74	O	to
11	76	82	O	healthy
12	84	93	O	volunteers
13	94	94	O	,
14	96	98	O	the
15	100	105	O	median
16	107	110	O	time
17	112	113	O	to
18	115	118	O	peak
19	120	125	O	plasma
20	127	140	O	concentrations
21	142	144	O	for
22	146	154	O	XXXXXXXX
23	156	158	O	was
24	160	172	O	approximately
25	174	174	O	5
26	176	180	O	hours
NULL

WELLBUTRIN	3894	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
The presence of food did not affect the peak concentration or area under the curve of bupropion.
1	0	2	O	The
2	4	11	O	presence
3	13	14	O	of
4	16	19	O	food
5	21	23	O	did
6	25	27	O	not
7	29	34	O	affect
8	36	38	O	the
9	40	43	O	peak
10	45	57	O	concentration
11	59	60	O	or
12	62	65	O	area
13	67	71	O	under
14	73	75	O	the
15	77	81	O	curve
16	83	84	O	of
17	86	94	O	XXXXXXXX
NULL

WELLBUTRIN	3895	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	22
Distribution In vitro tests show that bupropion is 84% bound to human plasma proteins at concentrations up to 200 mcg/mL.
1	0	11	O	Distribution
2	13	14	O	In
3	16	20	O	vitro
4	22	26	O	tests
5	28	31	O	show
6	33	36	O	that
7	38	46	O	XXXXXXXX
8	48	49	O	is
9	51	53	O	84%
10	55	59	O	bound
11	61	62	O	to
12	64	68	O	human
13	70	75	O	plasma
14	77	84	O	proteins
15	86	87	O	at
16	89	102	O	concentrations
17	104	105	O	up
18	107	108	O	to
19	110	112	O	200
20	114	116	O	mcg
21	117	117	O	/
22	118	119	O	mL
NULL

WELLBUTRIN	3896	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	34
The extent of protein binding of the hydroxybupropion metabolite is similar to that for bupropion, whereas the extent of protein binding of the threohydrobupropion metabolite is about half that of bupropion.
1	0	2	O	The
2	4	9	O	extent
3	11	12	O	of
4	14	20	O	protein
5	22	28	O	binding
6	30	31	O	of
7	33	35	O	the
8	37	43	O	hydroxy
9	44	52	O	XXXXXXXX
10	54	63	O	metabolite
11	65	66	O	is
12	68	74	O	similar
13	76	77	O	to
14	79	82	O	that
15	84	86	O	for
16	88	96	O	XXXXXXXX
17	97	97	O	,
18	99	105	O	whereas
19	107	109	O	the
20	111	116	O	extent
21	118	119	O	of
22	121	127	O	protein
23	129	135	O	binding
24	137	138	O	of
25	140	142	O	the
26	144	153	O	threohydro
27	154	162	O	XXXXXXXX
28	164	173	O	metabolite
29	175	176	O	is
30	178	182	O	about
31	184	187	O	half
32	189	192	O	that
33	194	195	O	of
34	197	205	O	XXXXXXXX
NULL

WELLBUTRIN	3897	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	7
Metabolism Bupropion is extensively metabolized in humans.
1	0	9	O	Metabolism
2	11	19	O	XXXXXXXX
3	21	22	O	is
4	24	34	O	extensively
5	36	46	O	metabolized
6	48	49	O	in
7	51	56	O	humans
NULL

WELLBUTRIN	3898	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	41
Three metabolites are active: hydroxybupropion, which is formed via hydroxylation of the tert-butyl group of bupropion, and the amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, which are formed via reduction of the carbonyl group.
1	0	4	O	Three
2	6	16	O	metabolites
3	18	20	O	are
4	22	27	O	active
5	28	28	O	:
6	30	36	O	hydroxy
7	37	45	O	XXXXXXXX
8	46	46	O	,
9	48	52	O	which
10	54	55	O	is
11	57	62	O	formed
12	64	66	O	via
13	68	80	O	hydroxylation
14	82	83	O	of
15	85	87	O	the
16	89	92	O	tert
17	94	98	O	butyl
18	100	104	O	group
19	106	107	O	of
20	109	117	O	XXXXXXXX
21	118	118	O	,
22	120	122	O	and
23	124	126	O	the
24	128	132	O	amino
25	134	140	O	alcohol
26	142	148	O	isomers
27	150	159	O	threohydro
28	160	168	O	XXXXXXXX
29	170	172	O	and
30	174	185	O	erythrohydro
31	186	194	O	XXXXXXXX
32	195	195	O	,
33	197	201	O	which
34	203	205	O	are
35	207	212	O	formed
36	214	216	O	via
37	218	226	O	reduction
38	228	229	O	of
39	231	233	O	the
40	235	242	O	carbonyl
41	244	248	O	group
NULL

WELLBUTRIN	3899	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	31
In vitro findings suggest that CYP2B6 is the principal isoenzyme involved in the formation of hydroxybupropion, while cytochrome P450 enzymes are not involved in the formation of threohydrobupropion.
1	0	1	O	In
2	3	7	O	vitro
3	9	16	O	findings
4	18	24	O	suggest
5	26	29	O	that
6	31	36	O	CYP2B6
7	38	39	O	is
8	41	43	O	the
9	45	53	O	principal
10	55	63	O	isoenzyme
11	65	72	O	involved
12	74	75	O	in
13	77	79	O	the
14	81	89	O	formation
15	91	92	O	of
16	94	100	O	hydroxy
17	101	109	O	XXXXXXXX
18	110	110	O	,
19	112	116	O	while
20	118	127	O	cytochrome
21	129	132	O	P450
22	134	140	O	enzymes
23	142	144	O	are
24	146	148	O	not
25	150	157	O	involved
26	159	160	O	in
27	162	164	O	the
28	166	174	O	formation
29	176	177	O	of
30	179	188	O	threohydro
31	189	197	O	XXXXXXXX
NULL

WELLBUTRIN	3900	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	28
Oxidation of the bupropion side chain results in the formation of a glycine conjugate of meta-chlorobenzoic acid, which is then excreted as the major urinary metabolite.
1	0	8	O	Oxidation
2	10	11	O	of
3	13	15	O	the
4	17	25	O	XXXXXXXX
5	27	30	O	side
6	32	36	O	chain
7	38	44	O	results
8	46	47	O	in
9	49	51	O	the
10	53	61	O	formation
11	63	64	O	of
12	66	66	O	a
13	68	74	O	glycine
14	76	84	O	conjugate
15	86	87	O	of
16	89	92	O	meta
17	94	106	O	chlorobenzoic
18	108	111	O	acid
19	112	112	O	,
20	114	118	O	which
21	120	121	O	is
22	123	126	O	then
23	128	135	O	excreted
24	137	138	O	as
25	140	142	O	the
26	144	148	O	major
27	150	156	O	urinary
28	158	167	O	metabolite
NULL

WELLBUTRIN	3901	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	15
The potency and toxicity of the metabolites relative to bupropion have not been fully characterized.
1	0	2	O	The
2	4	10	O	potency
3	12	14	O	and
4	16	23	O	toxicity
5	25	26	O	of
6	28	30	O	the
7	32	42	O	metabolites
8	44	51	O	relative
9	53	54	O	to
10	56	64	O	XXXXXXXX
11	66	69	O	have
12	71	73	O	not
13	75	78	O	been
14	80	84	O	fully
15	86	98	O	characterized
NULL

WELLBUTRIN	3902	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	37
However, it has been demonstrated in an antidepressant screening test in mice that hydroxybupropion is one half as potent as bupropion, while threohydrobupropion and erythrohydrobupropion are 5-fold less potent than bupropion.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	32	O	demonstrated
7	34	35	O	in
8	37	38	O	an
9	40	53	O	antidepressant
10	55	63	O	screening
11	65	68	O	test
12	70	71	O	in
13	73	76	O	mice
14	78	81	O	that
15	83	89	O	hydroxy
16	90	98	O	XXXXXXXX
17	100	101	O	is
18	103	105	O	one
19	107	110	O	half
20	112	113	O	as
21	115	120	O	potent
22	122	123	O	as
23	125	133	O	XXXXXXXX
24	134	134	O	,
25	136	140	O	while
26	142	151	O	threohydro
27	152	160	O	XXXXXXXX
28	162	164	O	and
29	166	177	O	erythrohydro
30	178	186	O	XXXXXXXX
31	188	190	O	are
32	192	192	O	5
33	194	197	O	fold
34	199	202	O	less
35	204	209	O	potent
36	211	214	O	than
37	216	224	O	XXXXXXXX
NULL

WELLBUTRIN	3903	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	23
This may be of clinical importance, because the plasma concentrations of the metabolites are as high or higher than those of bupropion.
1	0	3	O	This
2	5	7	O	may
3	9	10	O	be
4	12	13	O	of
5	15	22	O	clinical
6	24	33	O	importance
7	34	34	O	,
8	36	42	O	because
9	44	46	O	the
10	48	53	O	plasma
11	55	68	O	concentrations
12	70	71	O	of
13	73	75	O	the
14	77	87	O	metabolites
15	89	91	O	are
16	93	94	O	as
17	96	99	O	high
18	101	102	O	or
19	104	109	O	higher
20	111	114	O	than
21	116	120	O	those
22	122	123	O	of
23	125	133	O	XXXXXXXX
NULL

WELLBUTRIN	3904	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	33
At steady state, peak plasma concentration of hydroxybupropion occurred approximately 7 hours after administration of WELLBUTRIN XL, and it was approximately 7 times the peak level of the parent drug.
1	0	1	O	At
2	3	8	O	steady
3	10	14	O	state
4	15	15	O	,
5	17	20	O	peak
6	22	27	O	plasma
7	29	41	O	concentration
8	43	44	O	of
9	46	52	O	hydroxy
10	53	61	O	XXXXXXXX
11	63	70	O	occurred
12	72	84	O	approximately
13	86	86	O	7
14	88	92	O	hours
15	94	98	O	after
16	100	113	O	administration
17	115	116	O	of
18	118	127	O	XXXXXXXX
19	129	130	O	XL
20	131	131	O	,
21	133	135	O	and
22	137	138	O	it
23	140	142	O	was
24	144	156	O	approximately
25	158	158	O	7
26	160	164	O	times
27	166	168	O	the
28	170	173	O	peak
29	175	179	O	level
30	181	182	O	of
31	184	186	O	the
32	188	193	O	parent
33	195	198	O	drug
NULL

WELLBUTRIN	3905	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	26
The elimination half-life of hydroxybupropion is approximately 20 (*5) hours, and its AUC at steady state is about 13 times that of bupropion.
1	0	2	O	The
2	4	14	O	elimination
3	16	19	O	half
4	21	24	O	life
5	26	27	O	of
6	29	35	O	hydroxy
7	36	44	O	XXXXXXXX
8	46	47	O	is
9	49	61	O	approximately
10	63	64	O	20
11	67	68	O	5
12	71	75	O	hours
13	76	76	O	,
14	78	80	O	and
15	82	84	O	its
16	86	88	O	AUC
17	90	91	O	at
18	93	98	O	steady
19	100	104	O	state
20	106	107	O	is
21	109	113	O	about
22	115	116	O	13
23	118	122	O	times
24	124	127	O	that
25	129	130	O	of
26	132	140	O	XXXXXXXX
NULL

WELLBUTRIN	3906	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	20
The times to peak concentrations for the erythrohydrobupropion and threohydrobupropion metabolites are similar to that of hydroxybupropion.
1	0	2	O	The
2	4	8	O	times
3	10	11	O	to
4	13	16	O	peak
5	18	31	O	concentrations
6	33	35	O	for
7	37	39	O	the
8	41	52	O	erythrohydro
9	53	61	O	XXXXXXXX
10	63	65	O	and
11	67	76	O	threohydro
12	77	85	O	XXXXXXXX
13	87	97	O	metabolites
14	99	101	O	are
15	103	109	O	similar
16	111	112	O	to
17	114	117	O	that
18	119	120	O	of
19	122	128	O	hydroxy
20	129	137	O	XXXXXXXX
NULL

WELLBUTRIN	3907	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	38
However, the elimination half-lives of erythrohydrobupropion and threohydrobupropion are longer, approximately 33 (*10) and 37 (*13) hours, respectively and steady-state AUCs were 1.4 and 7 times that of bupropion, respectively.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	23	O	elimination
5	25	28	O	half
6	30	34	O	lives
7	36	37	O	of
8	39	50	O	erythrohydro
9	51	59	O	XXXXXXXX
10	61	63	O	and
11	65	74	O	threohydro
12	75	83	O	XXXXXXXX
13	85	87	O	are
14	89	94	O	longer
15	95	95	O	,
16	97	109	O	approximately
17	111	112	O	33
18	115	117	O	10
19	120	122	O	and
20	124	125	O	37
21	128	130	O	13
22	133	137	O	hours
23	138	138	O	,
24	140	151	O	respectively
25	153	155	O	and
26	157	162	O	steady
27	164	168	O	state
28	170	173	O	AUCs
29	175	178	O	were
30	180	182	O	1.4
31	184	186	O	and
32	188	188	O	7
33	190	194	O	times
34	196	199	O	that
35	201	202	O	of
36	204	212	O	XXXXXXXX
37	213	213	O	,
38	215	226	O	respectively
NULL

WELLBUTRIN	3908	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
Bupropion and its metabolites exhibit linear kinetics following chronic administration of 300 to 450 mg/day.
1	0	8	O	XXXXXXXX
2	10	12	O	and
3	14	16	O	its
4	18	28	O	metabolites
5	30	36	O	exhibit
6	38	43	O	linear
7	45	52	O	kinetics
8	54	62	O	following
9	64	70	O	chronic
10	72	85	O	administration
11	87	88	O	of
12	90	92	O	300
13	94	95	O	to
14	97	99	O	450
15	101	102	O	mg
16	103	103	O	/
17	104	106	O	day
NULL

WELLBUTRIN	3909	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	29
Elimination Following oral administration of 200 mg of 14C-bupropion in humans, 87% and 10% of the radioactive dose were recovered in the urine and feces, respectively.
1	0	10	O	Elimination
2	12	20	O	Following
3	22	25	O	oral
4	27	40	O	administration
5	42	43	O	of
6	45	47	O	200
7	49	50	O	mg
8	52	53	O	of
9	55	57	O	14C
10	59	67	O	XXXXXXXX
11	69	70	O	in
12	72	77	O	humans
13	78	78	O	,
14	80	82	O	87%
15	84	86	O	and
16	88	90	O	10%
17	92	93	O	of
18	95	97	O	the
19	99	109	O	radioactive
20	111	114	O	dose
21	116	119	O	were
22	121	129	O	recovered
23	131	132	O	in
24	134	136	O	the
25	138	142	O	urine
26	144	146	O	and
27	148	152	O	feces
28	153	153	O	,
29	155	166	O	respectively
NULL

WELLBUTRIN	3910	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	11
Only 0.5% of the oral dose was excreted as unchanged bupropion.
1	0	3	O	Only
2	5	8	O	0.5%
3	10	11	O	of
4	13	15	O	the
5	17	20	O	oral
6	22	25	O	dose
7	27	29	O	was
8	31	38	O	excreted
9	40	41	O	as
10	43	51	O	unchanged
11	53	61	O	XXXXXXXX
NULL

WELLBUTRIN	3911	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	44
Population Subgroups: Factors or conditions altering metabolic capacity (e.g., liver disease, congestive heart failure [CHF], age, concomitant medications, etc.) or elimination may be expected to influence the degree and extent of accumulation of the active metabolites of bupropion.
1	0	9	O	Population
2	11	19	O	Subgroups
3	20	20	O	:
4	22	28	O	Factors
5	30	31	O	or
6	33	42	O	conditions
7	44	51	O	altering
8	53	61	O	metabolic
9	63	70	O	capacity
10	73	75	O	e.g
11	77	77	O	,
12	79	83	O	liver
13	85	91	O	disease
14	92	92	O	,
15	94	103	O	congestive
16	105	109	O	heart
17	111	117	O	failure
18	120	122	O	CHF
19	124	124	O	,
20	126	128	O	age
21	129	129	O	,
22	131	141	O	concomitant
23	143	153	O	medications
24	154	154	O	,
25	156	158	O	etc
26	162	163	O	or
27	165	175	O	elimination
28	177	179	O	may
29	181	182	O	be
30	184	191	O	expected
31	193	194	O	to
32	196	204	O	influence
33	206	208	O	the
34	210	215	O	degree
35	217	219	O	and
36	221	226	O	extent
37	228	229	O	of
38	231	242	O	accumulation
39	244	245	O	of
40	247	249	O	the
41	251	256	O	active
42	258	268	O	metabolites
43	270	271	O	of
44	273	281	O	XXXXXXXX
NULL

WELLBUTRIN	3912	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	40
The elimination of the major metabolites of bupropion may be affected by reduced renal or hepatic function, because they are moderately polar compounds and are likely to undergo further metabolism or conjugation in the liver prior to urinary excretion.
1	0	2	O	The
2	4	14	O	elimination
3	16	17	O	of
4	19	21	O	the
5	23	27	O	major
6	29	39	O	metabolites
7	41	42	O	of
8	44	52	O	XXXXXXXX
9	54	56	O	may
10	58	59	O	be
11	61	68	O	affected
12	70	71	O	by
13	73	79	O	reduced
14	81	85	O	renal
15	87	88	O	or
16	90	96	O	hepatic
17	98	105	O	function
18	106	106	O	,
19	108	114	O	because
20	116	119	O	they
21	121	123	O	are
22	125	134	O	moderately
23	136	140	O	polar
24	142	150	O	compounds
25	152	154	O	and
26	156	158	O	are
27	160	165	O	likely
28	167	168	O	to
29	170	176	O	undergo
30	178	184	O	further
31	186	195	O	metabolism
32	197	198	O	or
33	200	210	O	conjugation
34	212	213	O	in
35	215	217	O	the
36	219	223	O	liver
37	225	229	O	prior
38	231	232	O	to
39	234	240	O	urinary
40	242	250	O	excretion
NULL

WELLBUTRIN	3913	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
Renal Impairment There is limited information on the pharmacokinetics of bupropion in patients with renal impairment.
1	0	4	O	Renal
2	6	15	O	Impairment
3	17	21	O	There
4	23	24	O	is
5	26	32	O	limited
6	34	44	O	information
7	46	47	O	on
8	49	51	O	the
9	53	68	O	pharmacokinetics
10	70	71	O	of
11	73	81	O	XXXXXXXX
12	83	84	O	in
13	86	93	O	patients
14	95	98	O	with
15	100	104	O	renal
16	106	115	O	impairment
NULL

WELLBUTRIN	3914	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	57
An inter-trial comparison between normal subjects and patients with end-stage renal failure demonstrated that the parent drug Cmax and AUC values were comparable in the 2 groups, whereas the hydroxybupropion and threohydrobupropion metabolites had a 2.3- and 2.8-fold increase, respectively, in AUC for subjects with end-stage renal failure.
1	0	1	O	An
2	3	7	O	inter
3	9	13	O	trial
4	15	24	O	comparison
5	26	32	O	between
6	34	39	O	normal
7	41	48	O	subjects
8	50	52	O	and
9	54	61	O	patients
10	63	66	O	with
11	68	70	O	end
12	72	76	O	stage
13	78	82	O	renal
14	84	90	O	failure
15	92	103	O	demonstrated
16	105	108	O	that
17	110	112	O	the
18	114	119	O	parent
19	121	124	O	drug
20	126	129	O	Cmax
21	131	133	O	and
22	135	137	O	AUC
23	139	144	O	values
24	146	149	O	were
25	151	160	O	comparable
26	162	163	O	in
27	165	167	O	the
28	169	169	O	2
29	171	176	O	groups
30	177	177	O	,
31	179	185	O	whereas
32	187	189	O	the
33	191	197	O	hydroxy
34	198	206	O	XXXXXXXX
35	208	210	O	and
36	212	221	O	threohydro
37	222	230	O	XXXXXXXX
38	232	242	O	metabolites
39	244	246	O	had
40	248	248	O	a
41	250	252	O	2.3
42	255	257	O	and
43	259	261	O	2.8
44	263	266	O	fold
45	268	275	O	increase
46	276	276	O	,
47	278	289	O	respectively
48	290	290	O	,
49	292	293	O	in
50	295	297	O	AUC
51	299	301	O	for
52	303	310	O	subjects
53	312	315	O	with
54	317	319	O	end
55	321	325	O	stage
56	327	331	O	renal
57	333	339	O	failure
NULL

WELLBUTRIN	3915	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	69
A second study, comparing normal subjects and subjects with moderate-to-severe renal impairment (GFR 30.9 * 10.8 mL/min) showed that after a single 150 mg dose of sustained-release bupropion, exposure to bupropion was approximately 2-fold higher in subjects with impaired renal function, while levels of the hydroxybupropion and threo/erythrohydrobupropion (combined) metabolites were similar in the 2 groups.
1	0	0	O	A
2	2	7	O	second
3	9	13	O	study
4	14	14	O	,
5	16	24	O	comparing
6	26	31	O	normal
7	33	40	O	subjects
8	42	44	O	and
9	46	53	O	subjects
10	55	58	O	with
11	60	67	O	moderate
12	69	70	O	to
13	72	77	O	severe
14	79	83	O	renal
15	85	94	O	impairment
16	97	99	O	GFR
17	101	104	O	30.9
18	106	106	O	*
19	108	111	O	10.8
20	113	114	O	mL
21	115	115	O	/
22	116	118	O	min
23	121	126	O	showed
24	128	131	O	that
25	133	137	O	after
26	139	139	O	a
27	141	146	O	single
28	148	150	O	150
29	152	153	O	mg
30	155	158	O	dose
31	160	161	O	of
32	163	171	O	sustained
33	173	179	O	release
34	181	189	O	XXXXXXXX
35	190	190	O	,
36	192	199	O	exposure
37	201	202	O	to
38	204	212	O	XXXXXXXX
39	214	216	O	was
40	218	230	O	approximately
41	232	232	O	2
42	234	237	O	fold
43	239	244	O	higher
44	246	247	O	in
45	249	256	O	subjects
46	258	261	O	with
47	263	270	O	impaired
48	272	276	O	renal
49	278	285	O	function
50	286	286	O	,
51	288	292	O	while
52	294	299	O	levels
53	301	302	O	of
54	304	306	O	the
55	308	314	O	hydroxy
56	315	323	O	XXXXXXXX
57	325	327	O	and
58	329	333	O	threo
59	334	334	O	/
60	335	346	O	erythrohydro
61	347	355	O	XXXXXXXX
62	358	365	O	combined
63	368	378	O	metabolites
64	380	383	O	were
65	385	391	O	similar
66	393	394	O	in
67	396	398	O	the
68	400	400	O	2
69	402	407	O	groups
NULL

WELLBUTRIN	3916	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	21
Bupropion is extensively metabolized in the liver to active metabolites, which are further metabolized and subsequently excreted by the kidneys.
1	0	8	O	XXXXXXXX
2	10	11	O	is
3	13	23	O	extensively
4	25	35	O	metabolized
5	37	38	O	in
6	40	42	O	the
7	44	48	O	liver
8	50	51	O	to
9	53	58	O	active
10	60	70	O	metabolites
11	71	71	O	,
12	73	77	O	which
13	79	81	O	are
14	83	89	O	further
15	91	101	O	metabolized
16	103	105	O	and
17	107	118	O	subsequently
18	120	127	O	excreted
19	129	130	O	by
20	132	134	O	the
21	136	142	O	kidneys
NULL

WELLBUTRIN	3917	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	15
The elimination of the major metabolites of bupropion may be reduced by impaired renal function.
1	0	2	O	The
2	4	14	O	elimination
3	16	17	O	of
4	19	21	O	the
5	23	27	O	major
6	29	39	O	metabolites
7	41	42	O	of
8	44	52	O	XXXXXXXX
9	54	56	O	may
10	58	59	O	be
11	61	67	O	reduced
12	69	70	O	by
13	72	79	O	impaired
14	81	85	O	renal
15	87	94	O	function
NULL

WELLBUTRIN	3918	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	24
WELLBUTRIN XL should be used with caution in patients with renal impairment, and a reduced frequency and/or dose should be considered.
1	0	9	O	XXXXXXXX
2	11	12	O	XL
3	14	19	O	should
4	21	22	O	be
5	24	27	O	used
6	29	32	O	with
7	34	40	O	caution
8	42	43	O	in
9	45	52	O	patients
10	54	57	O	with
11	59	63	O	renal
12	65	74	O	impairment
13	75	75	O	,
14	77	79	O	and
15	81	81	O	a
16	83	89	O	reduced
17	91	99	O	frequency
18	101	103	O	and
19	104	104	O	/
20	105	106	O	or
21	108	111	O	dose
22	113	118	O	should
23	120	121	O	be
24	123	132	O	considered
NULL

WELLBUTRIN	3919	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	36
Hepatic Impairment The effect of hepatic impairment on the pharmacokinetics of bupropion was characterized in 2 single-dose trials, one in subjects with alcoholic liver disease and one in subjects with mild to severe cirrhosis.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	19	21	O	The
4	23	28	O	effect
5	30	31	O	of
6	33	39	O	hepatic
7	41	50	O	impairment
8	52	53	O	on
9	55	57	O	the
10	59	74	O	pharmacokinetics
11	76	77	O	of
12	79	87	O	XXXXXXXX
13	89	91	O	was
14	93	105	O	characterized
15	107	108	O	in
16	110	110	O	2
17	112	117	O	single
18	119	122	O	dose
19	124	129	O	trials
20	130	130	O	,
21	132	134	O	one
22	136	137	O	in
23	139	146	O	subjects
24	148	151	O	with
25	153	161	O	alcoholic
26	163	167	O	liver
27	169	175	O	disease
28	177	179	O	and
29	181	183	O	one
30	185	186	O	in
31	188	195	O	subjects
32	197	200	O	with
33	202	205	O	mild
34	207	208	O	to
35	210	215	O	severe
36	217	225	O	cirrhosis
NULL

WELLBUTRIN	3920	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	33
The first trial demonstrated that the half-life of hydroxybupropion was significantly longer in 8 subjects with alcoholic liver disease than in 8 healthy volunteers (32*14 hours versus 21*5 hours, respectively).
1	0	2	O	The
2	4	8	O	first
3	10	14	O	trial
4	16	27	O	demonstrated
5	29	32	O	that
6	34	36	O	the
7	38	41	O	half
8	43	46	O	life
9	48	49	O	of
10	51	57	O	hydroxy
11	58	66	O	XXXXXXXX
12	68	70	O	was
13	72	84	O	significantly
14	86	91	O	longer
15	93	94	O	in
16	96	96	O	8
17	98	105	O	subjects
18	107	110	O	with
19	112	120	O	alcoholic
20	122	126	O	liver
21	128	134	O	disease
22	136	139	O	than
23	141	142	O	in
24	144	144	O	8
25	146	152	O	healthy
26	154	163	O	volunteers
27	166	170	O	32*14
28	172	176	O	hours
29	178	183	O	versus
30	185	188	O	21*5
31	190	194	O	hours
32	195	195	O	,
33	197	208	O	respectively
NULL

WELLBUTRIN	3921	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	30
Although not statistically significant, the AUCs for bupropion and hydroxybupropion were more variable and tended to be greater (by 53% to 57%) in patients with alcoholic liver disease.
1	0	7	O	Although
2	9	11	O	not
3	13	25	O	statistically
4	27	37	O	significant
5	38	38	O	,
6	40	42	O	the
7	44	47	O	AUCs
8	49	51	O	for
9	53	61	O	XXXXXXXX
10	63	65	O	and
11	67	73	O	hydroxy
12	74	82	O	XXXXXXXX
13	84	87	O	were
14	89	92	O	more
15	94	101	O	variable
16	103	105	O	and
17	107	112	O	tended
18	114	115	O	to
19	117	118	O	be
20	120	126	O	greater
21	129	130	O	by
22	132	134	O	53%
23	136	137	O	to
24	139	141	O	57%
25	144	145	O	in
26	147	154	O	patients
27	156	159	O	with
28	161	169	O	alcoholic
29	171	175	O	liver
30	177	183	O	disease
NULL

WELLBUTRIN	3922	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
The differences in half-life for bupropion and the other metabolites in the 2 groups were minimal.
1	0	2	O	The
2	4	14	O	differences
3	16	17	O	in
4	19	22	O	half
5	24	27	O	life
6	29	31	O	for
7	33	41	O	XXXXXXXX
8	43	45	O	and
9	47	49	O	the
10	51	55	O	other
11	57	67	O	metabolites
12	69	70	O	in
13	72	74	O	the
14	76	76	O	2
15	78	83	O	groups
16	85	88	O	were
17	90	96	O	minimal
NULL

WELLBUTRIN	3923	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	31
The second trial demonstrated no statistically significant differences in the pharmacokinetics of bupropion and its active metabolites in 9 subjects with mild to moderate hepatic cirrhosis compared to 8 healthy volunteers.
1	0	2	O	The
2	4	9	O	second
3	11	15	O	trial
4	17	28	O	demonstrated
5	30	31	O	no
6	33	45	O	statistically
7	47	57	O	significant
8	59	69	O	differences
9	71	72	O	in
10	74	76	O	the
11	78	93	O	pharmacokinetics
12	95	96	O	of
13	98	106	O	XXXXXXXX
14	108	110	O	and
15	112	114	O	its
16	116	121	O	active
17	123	133	O	metabolites
18	135	136	O	in
19	138	138	O	9
20	140	147	O	subjects
21	149	152	O	with
22	154	157	O	mild
23	159	160	O	to
24	162	169	O	moderate
25	171	177	O	hepatic
26	179	187	O	cirrhosis
27	189	196	O	compared
28	198	199	O	to
29	201	201	O	8
30	203	209	O	healthy
31	211	220	O	volunteers
NULL

WELLBUTRIN	3924	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	33
However, more variability was observed in some of the pharmacokinetic parameters for bupropion (AUC, Cmax, and Tmax) and its active metabolites (t%) in subjects with mild to moderate hepatic cirrhosis.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	more
4	14	24	O	variability
5	26	28	O	was
6	30	37	O	observed
7	39	40	O	in
8	42	45	O	some
9	47	48	O	of
10	50	52	O	the
11	54	68	O	pharmacokinetic
12	70	79	O	parameters
13	81	83	O	for
14	85	93	O	XXXXXXXX
15	96	98	O	AUC
16	99	99	O	,
17	101	104	O	Cmax
18	105	105	O	,
19	107	109	O	and
20	111	114	O	Tmax
21	117	119	O	and
22	121	123	O	its
23	125	130	O	active
24	132	142	O	metabolites
25	145	146	O	t%
26	149	150	O	in
27	152	159	O	subjects
28	161	164	O	with
29	166	169	O	mild
30	171	172	O	to
31	174	181	O	moderate
32	183	189	O	hepatic
33	191	199	O	cirrhosis
NULL

WELLBUTRIN	3925	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	61
In addition, in patients with severe hepatic cirrhosis, the bupropion Cmax and AUC were substantially increased (mean difference: by approximately 70% and 3-fold, respectively) and more variable when compared to values in healthy volunteers; the mean bupropion half-life was also longer (29 hours in patients with severe hepatic cirrhosis vs. 19 hours in healthy subjects).
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	in
5	16	23	O	patients
6	25	28	O	with
7	30	35	O	severe
8	37	43	O	hepatic
9	45	53	O	cirrhosis
10	54	54	O	,
11	56	58	O	the
12	60	68	O	XXXXXXXX
13	70	73	O	Cmax
14	75	77	O	and
15	79	81	O	AUC
16	83	86	O	were
17	88	100	O	substantially
18	102	110	O	increased
19	113	116	O	mean
20	118	127	O	difference
21	128	128	O	:
22	130	131	O	by
23	133	145	O	approximately
24	147	149	O	70%
25	151	153	O	and
26	155	155	O	3
27	157	160	O	fold
28	161	161	O	,
29	163	174	O	respectively
30	177	179	O	and
31	181	184	O	more
32	186	193	O	variable
33	195	198	O	when
34	200	207	O	compared
35	209	210	O	to
36	212	217	O	values
37	219	220	O	in
38	222	228	O	healthy
39	230	239	O	volunteers
40	242	244	O	the
41	246	249	O	mean
42	251	259	O	XXXXXXXX
43	261	264	O	half
44	266	269	O	life
45	271	273	O	was
46	275	278	O	also
47	280	285	O	longer
48	288	289	O	29
49	291	295	O	hours
50	297	298	O	in
51	300	307	O	patients
52	309	312	O	with
53	314	319	O	severe
54	321	327	O	hepatic
55	329	337	O	cirrhosis
56	339	340	O	vs
57	343	344	O	19
58	346	350	O	hours
59	352	353	O	in
60	355	361	O	healthy
61	363	370	O	subjects
NULL

WELLBUTRIN	3926	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	13
For the metabolite hydroxybupropion, the mean Cmax was approximately 69% lower.
1	0	2	O	For
2	4	6	O	the
3	8	17	O	metabolite
4	19	25	O	hydroxy
5	26	34	O	XXXXXXXX
6	35	35	O	,
7	37	39	O	the
8	41	44	O	mean
9	46	49	O	Cmax
10	51	53	O	was
11	55	67	O	approximately
12	69	71	O	69%
13	73	77	O	lower
NULL

WELLBUTRIN	3927	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	19
For the combined amino-alcohol isomers threohydrobupropion and erythrohydrobupropion, the mean Cmax was approximately 31% lower.
1	0	2	O	For
2	4	6	O	the
3	8	15	O	combined
4	17	21	O	amino
5	23	29	O	alcohol
6	31	37	O	isomers
7	39	48	O	threohydro
8	49	57	O	XXXXXXXX
9	59	61	O	and
10	63	74	O	erythrohydro
11	75	83	O	XXXXXXXX
12	84	84	O	,
13	86	88	O	the
14	90	93	O	mean
15	95	98	O	Cmax
16	100	102	O	was
17	104	116	O	approximately
18	118	120	O	31%
19	122	126	O	lower
NULL

WELLBUTRIN	3928	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	20
The mean AUC increased by about 1%-fold for hydroxybupropion and about 2%-fold for threo/erythrohydrobupropion.
1	0	2	O	The
2	4	7	O	mean
3	9	11	O	AUC
4	13	21	O	increased
5	23	24	O	by
6	26	30	O	about
7	32	33	O	1%
8	35	38	O	fold
9	40	42	O	for
10	44	50	O	hydroxy
11	51	59	O	XXXXXXXX
12	61	63	O	and
13	65	69	O	about
14	71	72	O	2%
15	74	77	O	fold
16	79	81	O	for
17	83	87	O	threo
18	88	88	O	/
19	89	100	O	erythrohydro
20	101	109	O	XXXXXXXX
NULL

WELLBUTRIN	3929	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	20
The median Tmax was observed 19 hours later for hydroxybupropion and 31 hours later for threo/erythrohydrobupropion.
1	0	2	O	The
2	4	9	O	median
3	11	14	O	Tmax
4	16	18	O	was
5	20	27	O	observed
6	29	30	O	19
7	32	36	O	hours
8	38	42	O	later
9	44	46	O	for
10	48	54	O	hydroxy
11	55	63	O	XXXXXXXX
12	65	67	O	and
13	69	70	O	31
14	72	76	O	hours
15	78	82	O	later
16	84	86	O	for
17	88	92	O	threo
18	93	93	O	/
19	94	105	O	erythrohydro
20	106	114	O	XXXXXXXX
NULL

WELLBUTRIN	3930	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	31
The mean half-lives for hydroxybupropion and threo/erythrohydrobupropion were increased 5- and 2-fold, respectively, in patients with severe hepatic cirrhosis compared to healthy volunteers.
1	0	2	O	The
2	4	7	O	mean
3	9	12	O	half
4	14	18	O	lives
5	20	22	O	for
6	24	30	O	hydroxy
7	31	39	O	XXXXXXXX
8	41	43	O	and
9	45	49	O	threo
10	50	50	O	/
11	51	62	O	erythrohydro
12	63	71	O	XXXXXXXX
13	73	76	O	were
14	78	86	O	increased
15	88	88	O	5
16	91	93	O	and
17	95	95	O	2
18	97	100	O	fold
19	101	101	O	,
20	103	114	O	respectively
21	115	115	O	,
22	117	118	O	in
23	120	127	O	patients
24	129	132	O	with
25	134	139	O	severe
26	141	147	O	hepatic
27	149	157	O	cirrhosis
28	159	166	O	compared
29	168	169	O	to
30	171	177	O	healthy
31	179	188	O	volunteers
NULL

WELLBUTRIN	3931	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	47
Left Ventricular Dysfunction During a chronic dosing study with bupropion in 14 depressed patients with left ventricular dysfunction (history of CHF or an enlarged heart on x-ray), there was no apparent effect on the pharmacokinetics of bupropion or its metabolites, compared to healthy volunteers.
1	0	3	O	Left
2	5	15	O	Ventricular
3	17	27	O	Dysfunction
4	29	34	O	During
5	36	36	O	a
6	38	44	O	chronic
7	46	51	O	dosing
8	53	57	O	study
9	59	62	O	with
10	64	72	O	XXXXXXXX
11	74	75	O	in
12	77	78	O	14
13	80	88	O	depressed
14	90	97	O	patients
15	99	102	O	with
16	104	107	O	left
17	109	119	O	ventricular
18	121	131	O	dysfunction
19	134	140	O	history
20	142	143	O	of
21	145	147	O	CHF
22	149	150	O	or
23	152	153	O	an
24	155	162	O	enlarged
25	164	168	O	heart
26	170	171	O	on
27	173	173	O	x
28	175	177	O	ray
29	179	179	O	,
30	181	185	O	there
31	187	189	O	was
32	191	192	O	no
33	194	201	O	apparent
34	203	208	O	effect
35	210	211	O	on
36	213	215	O	the
37	217	232	O	pharmacokinetics
38	234	235	O	of
39	237	245	O	XXXXXXXX
40	247	248	O	or
41	250	252	O	its
42	254	264	O	metabolites
43	265	265	O	,
44	267	274	O	compared
45	276	277	O	to
46	279	285	O	healthy
47	287	296	O	volunteers
NULL

WELLBUTRIN	3932	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	69
Age: The effects of age on the pharmacokinetics of bupropion and its metabolites have not been fully characterized, but an exploration of steady-state bupropion concentrations from several depression efficacy studies involving patients dosed in a range of 300 to 750 mg/day, on a 3-times-a-day schedule, revealed no relationship between age (18 to 83 years) and plasma concentration of bupropion.
1	0	2	O	Age
2	3	3	O	:
3	5	7	O	The
4	9	15	O	effects
5	17	18	O	of
6	20	22	O	age
7	24	25	O	on
8	27	29	O	the
9	31	46	O	pharmacokinetics
10	48	49	O	of
11	51	59	O	XXXXXXXX
12	61	63	O	and
13	65	67	O	its
14	69	79	O	metabolites
15	81	84	O	have
16	86	88	O	not
17	90	93	O	been
18	95	99	O	fully
19	101	113	O	characterized
20	114	114	O	,
21	116	118	O	but
22	120	121	O	an
23	123	133	O	exploration
24	135	136	O	of
25	138	143	O	steady
26	145	149	O	state
27	151	159	O	XXXXXXXX
28	161	174	O	concentrations
29	176	179	O	from
30	181	187	O	several
31	189	198	O	depression
32	200	207	O	efficacy
33	209	215	O	studies
34	217	225	O	involving
35	227	234	O	patients
36	236	240	O	dosed
37	242	243	O	in
38	245	245	O	a
39	247	251	O	range
40	253	254	O	of
41	256	258	O	300
42	260	261	O	to
43	263	265	O	750
44	267	268	O	mg
45	269	269	O	/
46	270	272	O	day
47	273	273	O	,
48	275	276	O	on
49	278	278	O	a
50	280	280	O	3
51	282	286	O	times
52	288	288	O	a
53	290	292	O	day
54	294	301	O	schedule
55	302	302	O	,
56	304	311	O	revealed
57	313	314	O	no
58	316	327	O	relationship
59	329	335	O	between
60	337	339	O	age
61	342	343	O	18
62	345	346	O	to
63	348	349	O	83
64	351	355	O	years
65	358	360	O	and
66	362	367	O	plasma
67	369	381	O	concentration
68	383	384	O	of
69	386	394	O	XXXXXXXX
NULL

WELLBUTRIN	3933	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	24
A single-dose pharmacokinetic study demonstrated that the disposition of bupropion and its metabolites in elderly subjects was similar to that in younger subjects.
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	28	O	pharmacokinetic
5	30	34	O	study
6	36	47	O	demonstrated
7	49	52	O	that
8	54	56	O	the
9	58	68	O	disposition
10	70	71	O	of
11	73	81	O	XXXXXXXX
12	83	85	O	and
13	87	89	O	its
14	91	101	O	metabolites
15	103	104	O	in
16	106	112	O	elderly
17	114	121	O	subjects
18	123	125	O	was
19	127	133	O	similar
20	135	136	O	to
21	138	141	O	that
22	143	144	O	in
23	146	152	O	younger
24	154	161	O	subjects
NULL

WELLBUTRIN	3934	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	38
These data suggest that there is no prominent effect of age on bupropion concentration; however, another single- and multiple-dose pharmacokinetic study suggested that the elderly are at increased risk for accumulation of bupropion and its metabolites.
1	0	4	O	These
2	6	9	O	data
3	11	17	O	suggest
4	19	22	O	that
5	24	28	O	there
6	30	31	O	is
7	33	34	O	no
8	36	44	O	prominent
9	46	51	O	effect
10	53	54	O	of
11	56	58	O	age
12	60	61	O	on
13	63	71	O	XXXXXXXX
14	73	85	O	concentration
15	88	94	O	however
16	95	95	O	,
17	97	103	O	another
18	105	110	O	single
19	113	115	O	and
20	117	124	O	multiple
21	126	129	O	dose
22	131	145	O	pharmacokinetic
23	147	151	O	study
24	153	161	O	suggested
25	163	166	O	that
26	168	170	O	the
27	172	178	O	elderly
28	180	182	O	are
29	184	185	O	at
30	187	195	O	increased
31	197	200	O	risk
32	202	204	O	for
33	206	217	O	accumulation
34	219	220	O	of
35	222	230	O	XXXXXXXX
36	232	234	O	and
37	236	238	O	its
38	240	250	O	metabolites
NULL

WELLBUTRIN	3935	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	25
Gender A single-dose study involving 12 healthy male and 12 healthy female volunteers revealed no sex-related differences in the pharmacokinetic parameters of bupropion.
1	0	5	O	Gender
2	7	7	O	A
3	9	14	O	single
4	16	19	O	dose
5	21	25	O	study
6	27	35	O	involving
7	37	38	O	12
8	40	46	O	healthy
9	48	51	O	male
10	53	55	O	and
11	57	58	O	12
12	60	66	O	healthy
13	68	73	O	female
14	75	84	O	volunteers
15	86	93	O	revealed
16	95	96	O	no
17	98	100	O	sex
18	102	108	O	related
19	110	120	O	differences
20	122	123	O	in
21	125	127	O	the
22	129	143	O	pharmacokinetic
23	145	154	O	parameters
24	156	157	O	of
25	159	167	O	XXXXXXXX
NULL

WELLBUTRIN	3936	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	30
In addition, pooled analysis of bupropion pharmacokinetic data from 90 healthy male and 90 healthy female volunteers revealed no sex-related differences in the peak plasma concentrations of bupropion.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	18	O	pooled
5	20	27	O	analysis
6	29	30	O	of
7	32	40	O	XXXXXXXX
8	42	56	O	pharmacokinetic
9	58	61	O	data
10	63	66	O	from
11	68	69	O	90
12	71	77	O	healthy
13	79	82	O	male
14	84	86	O	and
15	88	89	O	90
16	91	97	O	healthy
17	99	104	O	female
18	106	115	O	volunteers
19	117	124	O	revealed
20	126	127	O	no
21	129	131	O	sex
22	133	139	O	related
23	141	151	O	differences
24	153	154	O	in
25	156	158	O	the
26	160	163	O	peak
27	165	170	O	plasma
28	172	185	O	concentrations
29	187	188	O	of
30	190	198	O	XXXXXXXX
NULL

WELLBUTRIN	3937	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
The mean systemic exposure (AUC) was approximately 13% higher in male volunteers compared to female volunteers.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	systemic
4	18	25	O	exposure
5	28	30	O	AUC
6	33	35	O	was
7	37	49	O	approximately
8	51	53	O	13%
9	55	60	O	higher
10	62	63	O	in
11	65	68	O	male
12	70	79	O	volunteers
13	81	88	O	compared
14	90	91	O	to
15	93	98	O	female
16	100	109	O	volunteers
NULL

WELLBUTRIN	3938	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	30
Smokers The effects of cigarette smoking on the pharmacokinetics of bupropion hydrochloride were studied in 34 healthy male and female volunteers; 17 were chronic cigarette smokers and 17 were nonsmokers.
1	0	6	O	Smokers
2	8	10	O	The
3	12	18	O	effects
4	20	21	O	of
5	23	31	O	cigarette
6	33	39	O	smoking
7	41	42	O	on
8	44	46	O	the
9	48	63	O	pharmacokinetics
10	65	66	O	of
11	68	76	O	XXXXXXXX
12	78	90	O	hydrochloride
13	92	95	O	were
14	97	103	O	studied
15	105	106	O	in
16	108	109	O	34
17	111	117	O	healthy
18	119	122	O	male
19	124	126	O	and
20	128	133	O	female
21	135	144	O	volunteers
22	147	148	O	17
23	150	153	O	were
24	155	161	O	chronic
25	163	171	O	cigarette
26	173	179	O	smokers
27	181	183	O	and
28	185	186	O	17
29	188	191	O	were
30	193	202	O	nonsmokers
NULL

WELLBUTRIN	3939	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	40
Following oral administration of a single 150 mg dose of bupropion, there was no statistically significant difference in Cmax, half-life, Tmax, AUC, or clearance of bupropion or its active metabolites between smokers and nonsmokers.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	33	O	a
6	35	40	O	single
7	42	44	O	150
8	46	47	O	mg
9	49	52	O	dose
10	54	55	O	of
11	57	65	O	XXXXXXXX
12	66	66	O	,
13	68	72	O	there
14	74	76	O	was
15	78	79	O	no
16	81	93	O	statistically
17	95	105	O	significant
18	107	116	O	difference
19	118	119	O	in
20	121	124	O	Cmax
21	125	125	O	,
22	127	130	O	half
23	132	135	O	life
24	136	136	O	,
25	138	141	O	Tmax
26	142	142	O	,
27	144	146	O	AUC
28	147	147	O	,
29	149	150	O	or
30	152	160	O	clearance
31	162	163	O	of
32	165	173	O	XXXXXXXX
33	175	176	O	or
34	178	180	O	its
35	182	187	O	active
36	189	199	O	metabolites
37	201	207	O	between
38	209	215	O	smokers
39	217	219	O	and
40	221	230	O	nonsmokers
NULL

WELLBUTRIN	3940	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	24
Drug Interactions Potential for Other Drugs to Affect WELLBUTRIN XL In vitro studies indicate that bupropion is primarily metabolized to hydroxybupropion by CYP2B6.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	26	O	Potential
4	28	30	O	for
5	32	36	O	Other
6	38	42	O	Drugs
7	44	45	O	to
8	47	52	O	Affect
9	54	63	O	XXXXXXXX
10	65	66	O	XL
11	68	69	O	In
12	71	75	O	vitro
13	77	83	O	studies
14	85	92	O	indicate
15	94	97	O	that
16	99	107	O	XXXXXXXX
17	109	110	O	is
18	112	120	O	primarily
19	122	132	O	metabolized
20	134	135	O	to
21	137	143	O	hydroxy
22	144	152	O	XXXXXXXX
23	154	155	O	by
24	157	162	O	CYP2B6
NULL

WELLBUTRIN	3942	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	23
In addition, in vitro studies suggest that paroxetine, sertraline, norfluoxetine, fluvoxamine, and nelfinavir inhibit the hydroxylation of bupropion.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	14	O	in
5	16	20	O	vitro
6	22	28	O	studies
7	30	36	O	suggest
8	38	41	O	that
9	43	52	U-DYN	paroxetine
10	53	53	O	,
11	55	64	U-DYN	sertraline
12	65	65	O	,
13	67	79	U-DYN	norfluoxetine
14	80	80	O	,
15	82	92	U-DYN	fluvoxamine
16	93	93	O	,
17	95	97	O	and
18	99	108	U-DYN	nelfinavir
19	110	116	B-EFF	inhibit
20	118	120	I-EFF	the
21	122	134	I-EFF	hydroxylation
22	136	137	I-EFF	of
23	139	147	L-EFF	XXXXXXXX
D/11:19:1 D/13:19:1 D/15:19:1 D/18:19:1 D/9:19:1

WELLBUTRIN	3943	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	48
Inhibitors of CYP2B6 Ticlopidine, Clopidogrel: In a study in healthy male volunteers, clopidogrel 75 mg once daily or ticlopidine 250 mg twice daily increased exposures (Cmax and AUC) of bupropion by 40% and 60% for clopidogrel, by 38% and 85% for ticlopidine, respectively.
1	0	9	B-KIN	Inhibitors
2	11	12	I-KIN	of
3	14	19	L-KIN	CYP2B6
4	21	31	O	Ticlopidine
5	32	32	O	,
6	34	44	O	Clopidogrel
7	45	45	O	:
8	47	48	O	In
9	50	50	O	a
10	52	56	O	study
11	58	59	O	in
12	61	67	O	healthy
13	69	72	O	male
14	74	83	O	volunteers
15	84	84	O	,
16	86	96	U-KIN	clopidogrel
17	98	99	O	75
18	101	102	O	mg
19	104	107	O	once
20	109	113	O	daily
21	115	116	O	or
22	118	128	U-KIN	ticlopidine
23	130	132	O	250
24	134	135	O	mg
25	137	141	O	twice
26	143	147	O	daily
27	149	157	B-TRI	increased
28	159	167	L-TRI	exposures
29	170	173	O	Cmax
30	175	177	O	and
31	179	181	O	AUC
32	184	185	O	of
33	187	195	O	XXXXXXXX
34	197	198	O	by
35	200	202	O	40%
36	204	206	O	and
37	208	210	O	60%
38	212	214	O	for
39	216	226	O	clopidogrel
40	227	227	O	,
41	229	230	O	by
42	232	234	O	38%
43	236	238	O	and
44	240	242	O	85%
45	244	246	O	for
46	248	258	O	ticlopidine
47	259	259	O	,
48	261	272	O	respectively
K/1:C54602 K/16:C54605 K/22:C54602

WELLBUTRIN	3944	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	7
The exposures of hydroxybupropion were decreased.
1	0	2	O	The
2	4	12	O	exposures
3	14	15	O	of
4	17	23	O	hydroxy
5	24	32	O	XXXXXXXX
6	34	37	O	were
7	39	47	O	decreased
NULL

WELLBUTRIN	3945	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	35
Prasugrel: In healthy subjects, prasugrel increased bupropion Cmax and AUC values by 14% and 18%, respectively, and decreased Cmax and AUC values of hydroxybupropion by 32% and 24%, respectively.
1	0	8	O	Prasugrel
2	9	9	O	:
3	11	12	O	In
4	14	20	O	healthy
5	22	29	O	subjects
6	30	30	O	,
7	32	40	U-KIN	prasugrel
8	42	50	B-TRI	increased
9	52	60	I-TRI	XXXXXXXX
10	62	65	L-TRI	Cmax
11	67	69	O	and
12	71	73	O	AUC
13	75	80	O	values
14	82	83	O	by
15	85	87	O	14%
16	89	91	O	and
17	93	95	O	18%
18	96	96	O	,
19	98	109	O	respectively
20	110	110	O	,
21	112	114	O	and
22	116	124	O	decreased
23	126	129	O	Cmax
24	131	133	O	and
25	135	137	O	AUC
26	139	144	O	values
27	146	147	O	of
28	149	155	O	hydroxy
29	156	164	O	XXXXXXXX
30	166	167	O	by
31	169	171	O	32%
32	173	175	O	and
33	177	179	O	24%
34	180	180	O	,
35	182	193	O	respectively
K/7:C54605

WELLBUTRIN	3946	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	31
Cimetidine: Following oral administration of bupropion 300 mg with and without cimetidine 800 mg in 24 healthy young male volunteers, the pharmacokinetics of bupropion and hydroxybupropion were unaffected.
1	0	9	O	Cimetidine
2	10	10	O	:
3	12	20	O	Following
4	22	25	O	oral
5	27	40	O	administration
6	42	43	O	of
7	45	53	O	XXXXXXXX
8	55	57	O	300
9	59	60	O	mg
10	62	65	O	with
11	67	69	O	and
12	71	77	O	without
13	79	88	O	cimetidine
14	90	92	O	800
15	94	95	O	mg
16	97	98	O	in
17	100	101	O	24
18	103	109	O	healthy
19	111	115	O	young
20	117	120	O	male
21	122	131	O	volunteers
22	132	132	O	,
23	134	136	O	the
24	138	153	O	pharmacokinetics
25	155	156	O	of
26	158	166	O	XXXXXXXX
27	168	170	O	and
28	172	178	O	hydroxy
29	179	187	O	XXXXXXXX
30	189	192	O	were
31	194	203	O	unaffected
NULL

WELLBUTRIN	3947	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	26
However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of threohydrobupropion and erythrohydrobupropion.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	there
4	15	18	O	were
5	20	22	O	16%
6	24	26	O	and
7	28	30	O	32%
8	32	40	O	increases
9	42	43	O	in
10	45	47	O	the
11	49	51	O	AUC
12	53	55	O	and
13	57	60	O	Cmax
14	61	61	O	,
15	63	74	O	respectively
16	75	75	O	,
17	77	78	O	of
18	80	82	O	the
19	84	91	O	combined
20	93	100	O	moieties
21	102	103	O	of
22	105	114	O	threohydro
23	115	123	O	XXXXXXXX
24	125	127	O	and
25	129	140	O	erythrohydro
26	141	149	O	XXXXXXXX
NULL

WELLBUTRIN	3948	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	14
Citalopram: Citalopram did not affect the pharmacokinetics of bupropion and its three metabolites.
1	0	9	O	Citalopram
2	10	10	O	:
3	12	21	O	Citalopram
4	23	25	O	did
5	27	29	O	not
6	31	36	O	affect
7	38	40	O	the
8	42	57	O	pharmacokinetics
9	59	60	O	of
10	62	70	O	XXXXXXXX
11	72	74	O	and
12	76	78	O	its
13	80	84	O	three
14	86	96	O	metabolites
NULL

WELLBUTRIN	3949	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	31
Inducers of CYP2B6 Ritonavir and Lopinavir: In a healthy volunteer study, ritonavir 100 mg twice daily reduced the AUC and Cmax of bupropion by 22% and 21%, respectively.
1	0	7	O	Inducers
2	9	10	O	of
3	12	17	O	CYP2B6
4	19	27	O	Ritonavir
5	29	31	O	and
6	33	41	O	Lopinavir
7	42	42	O	:
8	44	45	O	In
9	47	47	O	a
10	49	55	O	healthy
11	57	65	O	volunteer
12	67	71	O	study
13	72	72	O	,
14	74	82	U-KIN	ritonavir
15	84	86	O	100
16	88	89	O	mg
17	91	95	O	twice
18	97	101	O	daily
19	103	109	B-TRI	reduced
20	111	113	I-TRI	the
21	115	117	L-TRI	AUC
22	119	121	O	and
23	123	126	O	Cmax
24	128	129	O	of
25	131	139	O	XXXXXXXX
26	141	142	O	by
27	144	146	O	22%
28	148	150	O	and
29	152	154	O	21%
30	155	155	O	,
31	157	168	O	respectively
K/14:C54606

WELLBUTRIN	3950	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	26
The exposure of the hydroxybupropion metabolite was decreased by 23%, the threohydrobupropion decreased by 38%, and the erythrohydrobupropion decreased by 48%.
1	0	2	O	The
2	4	11	O	exposure
3	13	14	O	of
4	16	18	O	the
5	20	26	O	hydroxy
6	27	35	O	XXXXXXXX
7	37	46	O	metabolite
8	48	50	O	was
9	52	60	O	decreased
10	62	63	O	by
11	65	67	O	23%
12	68	68	O	,
13	70	72	O	the
14	74	83	O	threohydro
15	84	92	O	XXXXXXXX
16	94	102	O	decreased
17	104	105	O	by
18	107	109	O	38%
19	110	110	O	,
20	112	114	O	and
21	116	118	O	the
22	120	131	O	erythrohydro
23	132	140	O	XXXXXXXX
24	142	150	O	decreased
25	152	153	O	by
26	155	157	O	48%
NULL

WELLBUTRIN	3951	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	25
In a second healthy volunteer study, ritonavir 600 mg twice daily decreased the AUC and Cmax of bupropion by 66% and 62%, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	second
4	12	18	O	healthy
5	20	28	O	volunteer
6	30	34	O	study
7	35	35	O	,
8	37	45	U-KIN	ritonavir
9	47	49	O	600
10	51	52	O	mg
11	54	58	O	twice
12	60	64	O	daily
13	66	74	B-TRI	decreased
14	76	78	I-TRI	the
15	80	82	L-TRI	AUC
16	84	86	O	and
17	88	91	O	Cmax
18	93	94	O	of
19	96	104	O	XXXXXXXX
20	106	107	O	by
21	109	111	O	66%
22	113	115	O	and
23	117	119	O	62%
24	120	120	O	,
25	122	133	O	respectively
K/8:C54606

WELLBUTRIN	3952	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	26
The exposure of the hydroxybupropion metabolite was decreased by 78%, the threohydrobupropion decreased by 50%, and the erythrohydrobupropion decreased by 68%.
1	0	2	O	The
2	4	11	O	exposure
3	13	14	O	of
4	16	18	O	the
5	20	26	O	hydroxy
6	27	35	O	XXXXXXXX
7	37	46	O	metabolite
8	48	50	O	was
9	52	60	O	decreased
10	62	63	O	by
11	65	67	O	78%
12	68	68	O	,
13	70	72	O	the
14	74	83	O	threohydro
15	84	92	O	XXXXXXXX
16	94	102	O	decreased
17	104	105	O	by
18	107	109	O	50%
19	110	110	O	,
20	112	114	O	and
21	116	118	O	the
22	120	131	O	erythrohydro
23	132	140	O	XXXXXXXX
24	142	150	O	decreased
25	152	153	O	by
26	155	157	O	68%
NULL

WELLBUTRIN	3953	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	22
In another healthy volunteer study, lopinavir 400 mg/ritonavir 100 mg twice daily decreased bupropion AUC and Cmax by 57%.
1	0	1	O	In
2	3	9	O	another
3	11	17	O	healthy
4	19	27	O	volunteer
5	29	33	O	study
6	34	34	O	,
7	36	44	U-KIN	lopinavir
8	46	48	O	400
9	50	51	O	mg
10	52	52	O	/
11	53	61	U-KIN	ritonavir
12	63	65	O	100
13	67	68	O	mg
14	70	74	O	twice
15	76	80	O	daily
16	82	90	B-TRI	decreased
17	92	100	I-TRI	XXXXXXXX
18	102	104	L-TRI	AUC
19	106	108	O	and
20	110	113	O	Cmax
21	115	116	O	by
22	118	120	O	57%
K/11:C54606 K/7:C54606

WELLBUTRIN	3954	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	16
The AUC and Cmax of hydroxybupropion metabolite were decreased by 50% and 31%, respectively.
1	0	2	O	The
2	4	6	O	AUC
3	8	10	O	and
4	12	15	O	Cmax
5	17	18	O	of
6	20	26	O	hydroxy
7	27	35	O	XXXXXXXX
8	37	46	O	metabolite
9	48	51	O	were
10	53	61	O	decreased
11	63	64	O	by
12	66	68	O	50%
13	70	72	O	and
14	74	76	O	31%
15	77	77	O	,
16	79	90	O	respectively
NULL

WELLBUTRIN	3955	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	31
Efavirenz: In a study of healthy volunteers, efavirenz 600 mg once daily for 2 weeks reduced the AUC and Cmax of bupropion by approximately 55% and 34%, respectively.
1	0	8	O	Efavirenz
2	9	9	O	:
3	11	12	O	In
4	14	14	O	a
5	16	20	O	study
6	22	23	O	of
7	25	31	O	healthy
8	33	42	O	volunteers
9	43	43	O	,
10	45	53	U-KIN	efavirenz
11	55	57	O	600
12	59	60	O	mg
13	62	65	O	once
14	67	71	O	daily
15	73	75	O	for
16	77	77	O	2
17	79	83	O	weeks
18	85	91	B-TRI	reduced
19	93	95	I-TRI	the
20	97	99	L-TRI	AUC
21	101	103	O	and
22	105	108	O	Cmax
23	110	111	O	of
24	113	121	O	XXXXXXXX
25	123	124	O	by
26	126	138	O	approximately
27	140	142	O	55%
28	144	146	O	and
29	148	150	O	34%
30	151	151	O	,
31	153	164	O	respectively
K/10:C54606

WELLBUTRIN	3956	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
The AUC of hydroxybupropion was unchanged, whereas Cmax of hydroxybupropion was increased by 50%.
1	0	2	O	The
2	4	6	O	AUC
3	8	9	O	of
4	11	17	O	hydroxy
5	18	26	O	XXXXXXXX
6	28	30	O	was
7	32	40	O	unchanged
8	41	41	O	,
9	43	49	O	whereas
10	51	54	O	Cmax
11	56	57	O	of
12	59	65	O	hydroxy
13	66	74	O	XXXXXXXX
14	76	78	O	was
15	80	88	O	increased
16	90	91	O	by
17	93	95	O	50%
NULL

WELLBUTRIN	3957	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	19
Carbamazepine, Phenobarbital, Phenytoin: While not systematically studied, these drugs may induce the metabolism of bupropion.
1	0	12	U-KIN	Carbamazepine
2	13	13	O	,
3	15	27	U-KIN	Phenobarbital
4	28	28	O	,
5	30	38	U-KIN	Phenytoin
6	39	39	O	:
7	41	45	O	While
8	47	49	O	not
9	51	64	O	systematically
10	66	72	O	studied
11	73	73	O	,
12	75	79	O	these
13	81	85	O	drugs
14	87	89	O	may
15	91	96	B-TRI	induce
16	98	100	I-TRI	the
17	102	111	L-TRI	metabolism
18	113	114	O	of
19	116	124	O	XXXXXXXX
K/1:C54356 K/3:C54356 K/5:C54356

WELLBUTRIN	3958	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	23
Potential for WELLBUTRIN XL to Affect Other Drugs Animal data indicated that bupropion may be an inducer of drug-metabolizing enzymes in humans.
1	0	8	O	Potential
2	10	12	O	for
3	14	23	O	XXXXXXXX
4	25	26	O	XL
5	28	29	O	to
6	31	36	O	Affect
7	38	42	O	Other
8	44	48	O	Drugs
9	50	55	O	Animal
10	57	60	O	data
11	62	70	O	indicated
12	72	75	O	that
13	77	85	O	XXXXXXXX
14	87	89	O	may
15	91	92	O	be
16	94	95	O	an
17	97	103	O	inducer
18	105	106	O	of
19	108	111	O	drug
20	113	124	O	metabolizing
21	126	132	O	enzymes
22	134	135	O	in
23	137	142	O	humans
NULL

WELLBUTRIN	3959	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	33
In a study of 8 healthy male volunteers, following a 14-day administration of bupropion 100 mg three times per day, there was no evidence of induction of its own metabolism.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	study
4	11	12	O	of
5	14	14	O	8
6	16	22	O	healthy
7	24	27	O	male
8	29	38	O	volunteers
9	39	39	O	,
10	41	49	O	following
11	51	51	O	a
12	53	54	O	14
13	56	58	O	day
14	60	73	O	administration
15	75	76	O	of
16	78	86	O	XXXXXXXX
17	88	90	O	100
18	92	93	O	mg
19	95	99	O	three
20	101	105	O	times
21	107	109	O	per
22	111	113	O	day
23	114	114	O	,
24	116	120	O	there
25	122	124	O	was
26	126	127	O	no
27	129	136	O	evidence
28	138	139	O	of
29	141	149	O	induction
30	151	152	O	of
31	154	156	O	its
32	158	160	O	own
33	162	171	O	metabolism
NULL

WELLBUTRIN	3960	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	17
Nevertheless, there may be the potential for clinically important alterations of blood levels of coadministered drugs.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	18	O	there
4	20	22	O	may
5	24	25	O	be
6	27	29	O	the
7	31	39	O	potential
8	41	43	O	for
9	45	54	O	clinically
10	56	64	O	important
11	66	76	O	alterations
12	78	79	O	of
13	81	85	O	blood
14	87	92	O	levels
15	94	95	O	of
16	97	110	O	coadministered
17	112	116	O	drugs
NULL

WELLBUTRIN	3961	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	14
Drugs Metabolized by CYP2D6 In vitro, bupropion and hydroxybupropion are CYP2D6 inhibitors.
1	0	4	O	Drugs
2	6	16	O	Metabolized
3	18	19	O	by
4	21	26	O	CYP2D6
5	28	29	O	In
6	31	35	O	vitro
7	36	36	O	,
8	38	46	O	XXXXXXXX
9	48	50	O	and
10	52	58	O	hydroxy
11	59	67	O	XXXXXXXX
12	69	71	O	are
13	73	78	O	CYP2D6
14	80	89	O	inhibitors
NULL

WELLBUTRIN	3962	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	62
In a clinical study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of CYP2D6, bupropion given as 150 mg twice daily followed by a single dose of 50 mg desipramine increased the Cmax, AUC, and T1/2 of desipramine by an average of approximately 2-, 5-, and 2-fold, respectively.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	study
5	20	21	O	of
6	23	24	O	15
7	26	29	O	male
8	31	38	O	subjects
9	41	44	O	ages
10	46	47	O	19
11	49	50	O	to
12	52	53	O	35
13	55	59	O	years
14	62	64	O	who
15	66	69	O	were
16	71	79	O	extensive
17	81	92	O	metabolizers
18	94	95	O	of
19	97	102	O	CYP2D6
20	103	103	O	,
21	105	113	O	XXXXXXXX
22	115	119	O	given
23	121	122	O	as
24	124	126	O	150
25	128	129	O	mg
26	131	135	O	twice
27	137	141	O	daily
28	143	150	O	followed
29	152	153	O	by
30	155	155	O	a
31	157	162	O	single
32	164	167	O	dose
33	169	170	O	of
34	172	173	O	50
35	175	176	O	mg
36	178	188	U-KIN	desipramine
37	190	198	B-TRI	increased
38	200	202	I-TRI	the
39	204	207	L-TRI	Cmax
40	208	208	O	,
41	210	212	O	AUC
42	213	213	O	,
43	215	217	O	and
44	219	220	O	T1
45	221	221	O	/
46	222	222	O	2
47	224	225	O	of
48	227	237	O	desipramine
49	239	240	O	by
50	242	243	O	an
51	245	251	O	average
52	253	254	O	of
53	256	268	O	approximately
54	270	270	O	2
55	272	272	O	,
56	274	274	O	5
57	276	276	O	,
58	278	280	O	and
59	282	282	O	2
60	284	287	O	fold
61	288	288	O	,
62	290	301	O	respectively
K/36:C54611

WELLBUTRIN	3963	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	15
The effect was present for at least 7 days after the last dose of bupropion.
1	0	2	O	The
2	4	9	O	effect
3	11	13	O	was
4	15	21	O	present
5	23	25	O	for
6	27	28	O	at
7	30	34	O	least
8	36	36	O	7
9	38	41	O	days
10	43	47	O	after
11	49	51	O	the
12	53	56	O	last
13	58	61	O	dose
14	63	64	O	of
15	66	74	O	XXXXXXXX
NULL

WELLBUTRIN	3964	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	15
Concomitant use of bupropion with other drugs metabolized by CYP2D6 has not been formally studied.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	27	O	XXXXXXXX
5	29	32	O	with
6	34	38	O	other
7	40	44	O	drugs
8	46	56	O	metabolized
9	58	59	O	by
10	61	66	O	CYP2D6
11	68	70	O	has
12	72	74	O	not
13	76	79	O	been
14	81	88	O	formally
15	90	96	O	studied
NULL

WELLBUTRIN	3965	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	28
Citalopram: Although citalopram is not primarily metabolized by CYP2D6, in one study bupropion increased the Cmax and AUC of citalopram by 30% and 40%, respectively.
1	0	9	O	Citalopram
2	10	10	O	:
3	12	19	O	Although
4	21	30	U-KIN	citalopram
5	32	33	O	is
6	35	37	O	not
7	39	47	O	primarily
8	49	59	O	metabolized
9	61	62	O	by
10	64	69	O	CYP2D6
11	70	70	O	,
12	72	73	O	in
13	75	77	O	one
14	79	83	O	study
15	85	93	O	XXXXXXXX
16	95	103	B-TRI	increased
17	105	107	I-TRI	the
18	109	112	L-TRI	Cmax
19	114	116	O	and
20	118	120	O	AUC
21	122	123	O	of
22	125	134	O	citalopram
23	136	137	O	by
24	139	141	O	30%
25	143	145	O	and
26	147	149	O	40%
27	150	150	O	,
28	152	163	O	respectively
K/4:C54613

WELLBUTRIN	3966	34090-1	a435da9d-f6e8-4ddc-897d-8cd2bf777b21	23
Lamotrigine: Multiple oral doses of bupropion had no statistically significant effects on the single-dose pharmacokinetics of lamotrigine in 12 healthy volunteers.
1	0	10	O	Lamotrigine
2	11	11	O	:
3	13	20	O	Multiple
4	22	25	O	oral
5	27	31	O	doses
6	33	34	O	of
7	36	44	O	XXXXXXXX
8	46	48	O	had
9	50	51	O	no
10	53	65	O	statistically
11	67	77	O	significant
12	79	85	O	effects
13	87	88	O	on
14	90	92	O	the
15	94	99	O	single
16	101	104	O	dose
17	106	121	O	pharmacokinetics
18	123	124	O	of
19	126	136	O	lamotrigine
20	138	139	O	in
21	141	142	O	12
22	144	150	O	healthy
23	152	161	O	volunteers
NULL

ZALEPLON	6344	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	18
As with all drugs, the potential exists for interaction with other drugs by a variety of mechanisms.
1	0	1	O	As
2	3	6	O	with
3	8	10	O	all
4	12	16	O	drugs
5	17	17	O	,
6	19	21	O	the
7	23	31	O	potential
8	33	38	O	exists
9	40	42	O	for
10	44	54	O	interaction
11	56	59	O	with
12	61	65	O	other
13	67	71	O	drugs
14	73	74	O	by
15	76	76	O	a
16	78	84	O	variety
17	86	87	O	of
18	89	98	O	mechanisms
NULL

ZALEPLON	6345	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	59
CNS-Active Drugs Ethanol: Zaleplon 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.
1	0	2	O	CNS
2	4	9	O	Active
3	11	15	O	Drugs
4	17	23	O	Ethanol
5	24	24	O	:
6	26	33	O	XXXXXXXX
7	35	36	O	10
8	38	39	O	mg
9	41	51	O	potentiated
10	53	55	O	the
11	57	59	B-EFF	CNS
12	61	69	I-EFF	impairing
13	71	77	L-EFF	effects
14	79	80	O	of
15	82	88	U-DYN	ethanol
16	90	93	O	0.75
17	95	95	O	g
18	96	96	O	/
19	97	98	O	kg
20	100	101	O	on
21	103	109	O	balance
22	111	117	O	testing
23	119	121	O	and
24	123	130	O	reaction
25	132	135	O	time
26	137	139	O	for
27	141	141	O	1
28	143	146	O	hour
29	148	152	O	after
30	154	160	O	ethanol
31	162	175	O	administration
32	177	179	O	and
33	181	182	O	on
34	184	186	O	the
35	188	192	O	digit
36	194	199	O	symbol
37	201	212	O	substitution
38	214	217	O	test
39	220	223	O	DSST
40	225	225	O	,
41	227	232	O	symbol
42	234	240	O	copying
43	242	245	O	test
44	246	246	O	,
45	248	250	O	and
46	252	254	O	the
47	256	266	O	variability
48	268	276	O	component
49	278	279	O	of
50	281	283	O	the
51	285	291	O	divided
52	293	301	O	attention
53	303	306	O	test
54	308	310	O	for
55	312	314	O	2.5
56	316	320	O	hours
57	322	326	O	after
58	328	334	O	ethanol
59	336	349	O	administration
D/15:11:1

ZALEPLON	6346	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	16
The potentiation resulted from a CNS pharmacodynamic interaction; zaleplon did not affect the pharmacokinetics of ethanol.
1	0	2	O	The
2	4	15	O	potentiation
3	17	24	O	resulted
4	26	29	O	from
5	31	31	O	a
6	33	35	O	CNS
7	37	51	O	pharmacodynamic
8	53	63	O	interaction
9	66	73	O	XXXXXXXX
10	75	77	O	did
11	79	81	O	not
12	83	88	O	affect
13	90	92	O	the
14	94	109	O	pharmacokinetics
15	111	112	O	of
16	114	120	O	ethanol
NULL

ZALEPLON	6347	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	31
Imipramine: Coadministration of single doses of Zaleplon 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
1	0	9	O	Imipramine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	37	O	single
6	39	43	O	doses
7	45	46	O	of
8	48	55	O	XXXXXXXX
9	57	58	O	20
10	60	61	O	mg
11	63	65	O	and
12	67	76	U-DYN	imipramine
13	78	79	O	75
14	81	82	O	mg
15	84	91	O	produced
16	93	100	O	additive
17	102	108	O	effects
18	110	111	O	on
19	113	121	B-EFF	decreased
20	123	131	L-EFF	alertness
21	133	135	O	and
22	137	144	B-EFF	impaired
23	146	156	I-EFF	psychomotor
24	158	168	L-EFF	performance
25	170	172	O	for
26	174	174	O	2
27	176	177	O	to
28	179	179	O	4
29	181	185	O	hours
30	187	191	O	after
31	193	206	O	administration
D/12:19:1 D/12:22:1

ZALEPLON	6348	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	13
The interaction was pharmacodynamic with no alteration of the pharmacokinetics of either drug.
1	0	2	O	The
2	4	14	O	interaction
3	16	18	O	was
4	20	34	O	pharmacodynamic
5	36	39	O	with
6	41	42	O	no
7	44	53	O	alteration
8	55	56	O	of
9	58	60	O	the
10	62	77	O	pharmacokinetics
11	79	80	O	of
12	82	87	O	either
13	89	92	O	drug
NULL

ZALEPLON	6349	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	27
Paroxetine: Coadministration of a single dose of Zaleplon 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.
1	0	9	O	Paroxetine
2	10	10	O	:
3	12	27	O	Coadministration
4	29	30	O	of
5	32	32	O	a
6	34	39	O	single
7	41	44	O	dose
8	46	47	O	of
9	49	56	O	XXXXXXXX
10	58	59	O	20
11	61	62	O	mg
12	64	66	O	and
13	68	77	O	paroxetine
14	79	80	O	20
15	82	83	O	mg
16	85	89	O	daily
17	91	93	O	for
18	95	95	O	7
19	97	100	O	days
20	102	104	O	did
21	106	108	O	not
22	110	116	O	produce
23	118	120	O	any
24	122	132	O	interaction
25	134	135	O	on
26	137	147	O	psychomotor
27	149	159	O	performance
NULL

ZALEPLON	6350	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	23
Additionally, paroxetine did not alter the pharmacokinetics of Zaleplon, reflecting the absence of a role of CYP2D6 in zaleplon's metabolism.
1	0	11	O	Additionally
2	12	12	O	,
3	14	23	O	paroxetine
4	25	27	O	did
5	29	31	O	not
6	33	37	O	alter
7	39	41	O	the
8	43	58	O	pharmacokinetics
9	60	61	O	of
10	63	70	O	XXXXXXXX
11	71	71	O	,
12	73	82	O	reflecting
13	84	86	O	the
14	88	94	O	absence
15	96	97	O	of
16	99	99	O	a
17	101	104	O	role
18	106	107	O	of
19	109	114	O	CYP2D6
20	116	117	O	in
21	119	126	O	XXXXXXXX
22	127	128	O	's
23	130	139	O	metabolism
NULL

ZALEPLON	6351	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	31
Thioridazine: Coadministration of single doses of Zaleplon 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.
1	0	11	O	Thioridazine
2	12	12	O	:
3	14	29	O	Coadministration
4	31	32	O	of
5	34	39	O	single
6	41	45	O	doses
7	47	48	O	of
8	50	57	O	XXXXXXXX
9	59	60	O	20
10	62	63	O	mg
11	65	67	O	and
12	69	80	U-DYN	thioridazine
13	82	83	O	50
14	85	86	O	mg
15	88	95	O	produced
16	97	104	O	additive
17	106	112	O	effects
18	114	115	O	on
19	117	125	B-EFF	decreased
20	127	135	L-EFF	alertness
21	137	139	O	and
22	141	148	B-EFF	impaired
23	150	160	I-EFF	psychomotor
24	162	172	L-EFF	performance
25	174	176	O	for
26	178	178	O	2
27	180	181	O	to
28	183	183	O	4
29	185	189	O	hours
30	191	195	O	after
31	197	210	O	administration
D/12:19:1 D/12:22:1

ZALEPLON	6353	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	36
Venlafaxine: Coadministration of a single dose of zaleplon 10 mg and multiple doses of venlafaxine ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either zaleplon or venlafaxine.
1	0	10	O	Venlafaxine
2	11	11	O	:
3	13	28	O	Coadministration
4	30	31	O	of
5	33	33	O	a
6	35	40	O	single
7	42	45	O	dose
8	47	48	O	of
9	50	57	O	XXXXXXXX
10	59	60	O	10
11	62	63	O	mg
12	65	67	O	and
13	69	76	O	multiple
14	78	82	O	doses
15	84	85	O	of
16	87	97	O	venlafaxine
17	99	100	O	ER
18	103	110	O	extended
19	112	118	O	release
20	121	123	O	150
21	125	126	O	mg
22	128	130	O	did
23	132	134	O	not
24	136	141	O	result
25	143	144	O	in
26	146	148	O	any
27	150	160	O	significant
28	162	168	O	changes
29	170	171	O	in
30	173	175	O	the
31	177	192	O	pharmacokinetics
32	194	195	O	of
33	197	202	O	either
34	204	211	O	XXXXXXXX
35	213	214	O	or
36	216	226	O	venlafaxine
NULL

ZALEPLON	6354	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	18
In addition, there was no pharmacodynamic interaction as a result of coadministration of zaleplon and venlafaxine ER.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	17	O	there
5	19	21	O	was
6	23	24	O	no
7	26	40	O	pharmacodynamic
8	42	52	O	interaction
9	54	55	O	as
10	57	57	O	a
11	59	64	O	result
12	66	67	O	of
13	69	84	O	coadministration
14	86	87	O	of
15	89	96	O	XXXXXXXX
16	98	100	O	and
17	102	112	O	venlafaxine
18	114	115	O	ER
NULL

ZALEPLON	6355	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	41
Promethazine: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.
1	0	11	O	Promethazine
2	12	12	O	:
3	14	29	O	Coadministration
4	31	32	O	of
5	34	34	O	a
6	36	41	O	single
7	43	46	O	dose
8	48	49	O	of
9	51	58	O	XXXXXXXX
10	60	62	O	and
11	64	75	U-KIN	promethazine
12	78	79	O	10
13	81	83	O	and
14	85	86	O	25
15	88	89	O	mg
16	90	90	O	,
17	92	103	O	respectively
18	106	113	O	resulted
19	115	116	O	in
20	118	118	O	a
21	120	122	O	15%
22	124	131	B-TRI	decrease
23	133	134	I-TRI	in
24	136	142	I-TRI	maximal
25	144	149	I-TRI	plasma
26	151	164	L-TRI	concentrations
27	166	167	O	of
28	169	176	O	XXXXXXXX
29	177	177	O	,
30	179	181	O	but
31	183	184	O	no
32	186	191	O	change
33	193	194	O	in
34	196	198	O	the
35	200	203	O	area
36	205	209	O	under
37	211	213	O	the
38	215	220	O	plasma
39	222	234	O	concentration
40	236	239	O	time
41	241	245	O	curve
K/11:C54606

ZALEPLON	6356	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	14
However, the pharmacodynamics of coadministration of zaleplon and promethazine have not been evaluated.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	28	O	pharmacodynamics
5	30	31	O	of
6	33	48	O	coadministration
7	50	51	O	of
8	53	60	O	XXXXXXXX
9	62	64	O	and
10	66	77	O	promethazine
11	79	82	O	have
12	84	86	O	not
13	88	91	O	been
14	93	101	O	evaluated
NULL

ZALEPLON	6357	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	10
Caution should be exercised when these 2 agents are coadministered.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	26	O	exercised
5	28	31	O	when
6	33	37	O	these
7	39	39	O	2
8	41	46	O	agents
9	48	50	O	are
10	52	65	O	coadministered
NULL

ZALEPLON	6358	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	15
Drugs That Induce CYP3A4 Rifampin: CYP3A4 is ordinarily a minor metabolizing enzyme of zaleplon.
1	0	4	O	Drugs
2	6	9	O	That
3	11	16	O	Induce
4	18	23	O	CYP3A4
5	25	32	O	Rifampin
6	33	33	O	:
7	35	40	O	CYP3A4
8	42	43	O	is
9	45	54	O	ordinarily
10	56	56	O	a
11	58	62	O	minor
12	64	75	O	metabolizing
13	77	82	O	enzyme
14	84	85	O	of
15	87	94	O	XXXXXXXX
NULL

ZALEPLON	6359	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	31
Multiple-dose administration of the potent CYP3A4 inducer rifampin (600 mg every 24 hours, q24h, for 14 days), however, reduced zaleplon Cmax and AUC by approximately 80%.
1	0	7	O	Multiple
2	9	12	O	dose
3	14	27	O	administration
4	29	30	O	of
5	32	34	O	the
6	36	41	O	potent
7	43	48	O	CYP3A4
8	50	56	O	inducer
9	58	65	U-KIN	rifampin
10	68	70	O	600
11	72	73	O	mg
12	75	79	O	every
13	81	82	O	24
14	84	88	O	hours
15	89	89	O	,
16	91	94	O	q24h
17	95	95	O	,
18	97	99	O	for
19	101	102	O	14
20	104	107	O	days
21	109	109	O	,
22	111	117	O	however
23	118	118	O	,
24	120	126	B-TRI	reduced
25	128	135	I-TRI	XXXXXXXX
26	137	140	L-TRI	Cmax
27	142	144	O	and
28	146	148	O	AUC
29	150	151	O	by
30	153	165	O	approximately
31	167	169	O	80%
K/9:C54606

ZALEPLON	6360	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	23
The coadministration of a potent CYP3A4 enzyme inducer, although not posing a safety concern, thus could lead to ineffectiveness of zaleplon.
1	0	2	O	The
2	4	19	O	coadministration
3	21	22	O	of
4	24	24	O	a
5	26	31	B-DYN	potent
6	33	38	I-DYN	CYP3A4
7	40	45	I-DYN	enzyme
8	47	53	L-DYN	inducer
9	54	54	O	,
10	56	63	O	although
11	65	67	O	not
12	69	74	O	posing
13	76	76	O	a
14	78	83	O	safety
15	85	91	O	concern
16	92	92	O	,
17	94	97	O	thus
18	99	103	O	could
19	105	108	O	lead
20	110	111	O	to
21	113	127	B-EFF	ineffectiveness
22	129	130	I-EFF	of
23	132	139	L-EFF	XXXXXXXX
D/5:21:1

ZALEPLON	6361	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	25
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and phenobarbital.
1	0	1	O	An
2	3	13	O	alternative
3	15	17	O	non
4	19	24	O	CYP3A4
5	26	34	O	substrate
6	36	43	O	hypnotic
7	45	49	O	agent
8	51	53	O	may
9	55	56	O	be
10	58	67	O	considered
11	69	70	O	in
12	72	79	O	patients
13	81	86	O	taking
14	88	93	B-UNK	CYP3A4
15	95	102	L-UNK	inducers
16	104	107	O	such
17	109	110	O	as
18	112	119	U-UNK	rifampin
19	120	120	O	,
20	122	130	U-UNK	phenytoin
21	131	131	O	,
22	133	145	U-UNK	carbamazepine
23	146	146	O	,
24	148	150	O	and
25	152	164	U-UNK	phenobarbital
NULL

ZALEPLON	6362	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	53
Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of zaleplon because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, 5-oxo-desethylzaleplon and 5-oxo-desethylzaleplon glucuronide, account for only 9% of the urinary recovery of a zaleplon dose.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	24	O	CYP3A4
5	26	31	O	CYP3A4
6	33	34	O	is
7	36	36	O	a
8	38	42	O	minor
9	44	52	O	metabolic
10	54	60	O	pathway
11	62	64	O	for
12	66	68	O	the
13	70	80	O	elimination
14	82	83	O	of
15	85	92	O	XXXXXXXX
16	94	100	O	because
17	102	104	O	the
18	106	108	O	sum
19	110	111	O	of
20	113	120	O	desethyl
21	121	128	O	XXXXXXXX
22	131	136	O	formed
23	138	140	O	via
24	142	147	O	CYP3A4
25	149	150	O	in
26	152	156	O	vitro
27	159	161	O	and
28	163	165	O	its
29	167	177	O	metabolites
30	178	178	O	,
31	180	180	O	5
32	182	184	O	oxo
33	186	193	O	desethyl
34	194	201	O	XXXXXXXX
35	203	205	O	and
36	207	207	O	5
37	209	211	O	oxo
38	213	220	O	desethyl
39	221	228	O	XXXXXXXX
40	230	240	O	glucuronide
41	241	241	O	,
42	243	249	O	account
43	251	253	O	for
44	255	258	O	only
45	260	261	O	9%
46	263	264	O	of
47	266	268	O	the
48	270	276	O	urinary
49	278	285	O	recovery
50	287	288	O	of
51	290	290	O	a
52	292	299	O	XXXXXXXX
53	301	304	O	dose
NULL

ZALEPLON	6363	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	48
Coadministration of single, oral doses of zaleplon with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor, produced a 34% increase in zaleplon's maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.
1	0	15	O	Coadministration
2	17	18	O	of
3	20	25	O	single
4	26	26	O	,
5	28	31	O	oral
6	33	37	O	doses
7	39	40	O	of
8	42	49	O	XXXXXXXX
9	51	54	O	with
10	56	67	U-KIN	erythromycin
11	70	71	O	10
12	73	74	O	mg
13	76	78	O	and
14	80	82	O	800
15	84	85	O	mg
16	86	86	O	,
17	88	99	O	respectively
18	101	101	O	,
19	103	103	O	a
20	105	110	O	strong
21	111	111	O	,
22	113	121	O	selective
23	123	128	O	CYP3A4
24	130	138	O	inhibitor
25	139	139	O	,
26	141	148	O	produced
27	150	150	O	a
28	152	154	O	34%
29	156	163	O	increase
30	165	166	O	in
31	168	175	O	XXXXXXXX
32	176	177	O	's
33	179	185	O	maximal
34	187	192	O	plasma
35	194	207	O	concentrations
36	209	211	O	and
37	213	213	O	a
38	215	217	O	20%
39	219	226	B-TRI	increase
40	228	229	I-TRI	in
41	231	233	I-TRI	the
42	235	238	I-TRI	area
43	240	244	I-TRI	under
44	246	248	I-TRI	the
45	250	255	I-TRI	plasma
46	257	269	I-TRI	concentration
47	271	274	I-TRI	time
48	276	280	L-TRI	curve
K/10:C54605

ZALEPLON	6364	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	11
The magnitude of interaction with multiple doses of erythromycin is unknown.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	27	O	interaction
5	29	32	O	with
6	34	41	O	multiple
7	43	47	O	doses
8	49	50	O	of
9	52	63	O	erythromycin
10	65	66	O	is
11	68	74	O	unknown
NULL

ZALEPLON	6365	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	18
Other strong selective CYP3A4 inhibitors such as ketoconazole can also be expected to increase the exposure of zaleplon.
1	0	4	O	Other
2	6	11	B-KIN	strong
3	13	21	I-KIN	selective
4	23	28	I-KIN	CYP3A4
5	30	39	L-KIN	inhibitors
6	41	44	O	such
7	46	47	O	as
8	49	60	U-KIN	ketoconazole
9	62	64	O	can
10	66	69	O	also
11	71	72	O	be
12	74	81	O	expected
13	83	84	O	to
14	86	93	B-TRI	increase
15	95	97	I-TRI	the
16	99	106	L-TRI	exposure
17	108	109	O	of
18	111	118	O	XXXXXXXX
K/2:C54355 K/8:C54355

ZALEPLON	6366	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	10
A routine dosage adjustment of zaleplon is not considered necessary.
1	0	0	O	A
2	2	8	O	routine
3	10	15	O	dosage
4	17	26	O	adjustment
5	28	29	O	of
6	31	38	O	XXXXXXXX
7	40	41	O	is
8	43	45	O	not
9	47	56	O	considered
10	58	66	O	necessary
NULL

ZALEPLON	6367	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	20
Drugs That Inhibit Aldehyde Oxidase The aldehyde oxidase enzyme system is less well studied than the cytochrome P450 enzyme system.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	26	O	Aldehyde
5	28	34	O	Oxidase
6	36	38	O	The
7	40	47	O	aldehyde
8	49	55	O	oxidase
9	57	62	O	enzyme
10	64	69	O	system
11	71	72	O	is
12	74	77	O	less
13	79	82	O	well
14	84	90	O	studied
15	92	95	O	than
16	97	99	O	the
17	101	110	O	cytochrome
18	112	115	O	P450
19	117	122	O	enzyme
20	124	129	O	system
NULL

ZALEPLON	6368	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	27
Diphenhydramine: Diphenhydramine is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.
1	0	14	O	Diphenhydramine
2	15	15	O	:
3	17	31	O	Diphenhydramine
4	33	34	O	is
5	36	43	O	reported
6	45	46	O	to
7	48	49	O	be
8	51	51	O	a
9	53	56	O	weak
10	58	66	O	inhibitor
11	68	69	O	of
12	71	78	O	aldehyde
13	80	86	O	oxidase
14	88	89	O	in
15	91	93	O	rat
16	95	99	O	liver
17	100	100	O	,
18	102	104	O	but
19	106	108	O	its
20	110	119	O	inhibitory
21	121	127	O	effects
22	129	130	O	in
23	132	136	O	human
24	138	142	O	liver
25	144	146	O	are
26	148	150	O	not
27	152	156	O	known
NULL

ZALEPLON	6369	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	26
There is no pharmacokinetic interaction between zaleplon and diphenhydramine following the administration of a single dose (10 mg and 50 mg, respectively) of each drug.
1	0	4	O	There
2	6	7	O	is
3	9	10	O	no
4	12	26	O	pharmacokinetic
5	28	38	O	interaction
6	40	46	O	between
7	48	55	O	XXXXXXXX
8	57	59	O	and
9	61	75	O	diphenhydramine
10	77	85	O	following
11	87	89	O	the
12	91	104	O	administration
13	106	107	O	of
14	109	109	O	a
15	111	116	O	single
16	118	121	O	dose
17	124	125	O	10
18	127	128	O	mg
19	130	132	O	and
20	134	135	O	50
21	137	138	O	mg
22	139	139	O	,
23	141	152	O	respectively
24	155	156	O	of
25	158	161	O	each
26	163	166	O	drug
NULL

ZALEPLON	6370	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	17
However, because both of these compounds have CNS effects, an additive pharmacodynamic effect is possible.
1	0	6	O	However
2	7	7	O	,
3	9	15	O	because
4	17	20	O	both
5	22	23	O	of
6	25	29	O	these
7	31	39	O	compounds
8	41	44	O	have
9	46	48	O	CNS
10	50	56	O	effects
11	57	57	O	,
12	59	60	O	an
13	62	69	O	additive
14	71	85	O	pharmacodynamic
15	87	92	O	effect
16	94	95	O	is
17	97	104	O	possible
NULL

ZALEPLON	6371	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	37
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.
1	0	4	O	Drugs
2	6	9	O	That
3	11	17	O	Inhibit
4	19	22	O	Both
5	24	31	O	Aldehyde
6	33	39	O	Oxidase
7	41	43	O	and
8	45	50	O	CYP3A4
9	52	61	U-KIN	Cimetidine
10	62	62	O	:
11	64	73	O	Cimetidine
12	75	82	O	inhibits
13	84	87	O	both
14	89	96	O	aldehyde
15	98	104	O	oxidase
16	107	108	O	in
17	110	114	O	vitro
18	117	119	O	and
19	121	126	O	CYP3A4
20	129	130	O	in
21	132	136	O	vitro
22	138	140	O	and
23	142	143	O	in
24	145	148	O	vivo
25	150	150	O	,
26	152	154	O	the
27	156	162	O	primary
28	164	166	O	and
29	168	176	O	secondary
30	178	184	O	enzymes
31	185	185	O	,
32	187	198	O	respectively
33	199	199	O	,
34	201	211	O	responsible
35	213	215	O	for
36	217	224	O	XXXXXXXX
37	226	235	O	metabolism
K/9:C54355

ZALEPLON	6372	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	22
Concomitant administration of Zaleplon (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.
1	0	10	O	Concomitant
2	12	25	O	administration
3	27	28	O	of
4	30	37	O	XXXXXXXX
5	40	41	O	10
6	43	44	O	mg
7	47	49	O	and
8	51	60	U-KIN	cimetidine
9	63	65	O	800
10	67	68	O	mg
11	71	78	O	produced
12	80	81	O	an
13	83	85	O	85%
14	87	94	O	increase
15	96	97	O	in
16	99	101	O	the
17	103	106	O	mean
18	108	111	O	Cmax
19	113	115	O	and
20	117	119	O	AUC
21	121	122	O	of
22	124	131	O	XXXXXXXX
K/8:C54605

ZALEPLON	6373	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	18
An initial dose of 5 mg should be given to patients who are concomitantly being treated with cimetidine.
1	0	1	O	An
2	3	9	O	initial
3	11	14	O	dose
4	16	17	O	of
5	19	19	O	5
6	21	22	O	mg
7	24	29	O	should
8	31	32	O	be
9	34	38	O	given
10	40	41	O	to
11	43	50	O	patients
12	52	54	O	who
13	56	58	O	are
14	60	72	O	concomitantly
15	74	78	O	being
16	80	86	O	treated
17	88	91	O	with
18	93	102	U-UNK	cimetidine
NULL

ZALEPLON	6374	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	34
Drugs Highly Bound to Plasma Protein Zaleplon is not highly bound to plasma proteins (fraction bound 60%*15%); therefore, the disposition of zaleplon is not expected to be sensitive to alterations in protein binding.
1	0	4	O	Drugs
2	6	11	O	Highly
3	13	17	O	Bound
4	19	20	O	to
5	22	27	O	Plasma
6	29	35	O	Protein
7	37	44	O	XXXXXXXX
8	46	47	O	is
9	49	51	O	not
10	53	58	O	highly
11	60	64	O	bound
12	66	67	O	to
13	69	74	O	plasma
14	76	83	O	proteins
15	86	93	O	fraction
16	95	99	O	bound
17	101	107	O	60%*15%
18	111	119	O	therefore
19	120	120	O	,
20	122	124	O	the
21	126	136	O	disposition
22	138	139	O	of
23	141	148	O	XXXXXXXX
24	150	151	O	is
25	153	155	O	not
26	157	164	O	expected
27	166	167	O	to
28	169	170	O	be
29	172	180	O	sensitive
30	182	183	O	to
31	185	195	O	alterations
32	197	198	O	in
33	200	206	O	protein
34	208	214	O	binding
NULL

ZALEPLON	6375	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	29
In addition, administration of Zaleplon to a patient taking another drug that is highly protein bound should not cause transient increase in free concentrations of the other drug.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	26	O	administration
5	28	29	O	of
6	31	38	O	XXXXXXXX
7	40	41	O	to
8	43	43	O	a
9	45	51	O	patient
10	53	58	O	taking
11	60	66	O	another
12	68	71	O	drug
13	73	76	O	that
14	78	79	O	is
15	81	86	O	highly
16	88	94	O	protein
17	96	100	O	bound
18	102	107	O	should
19	109	111	O	not
20	113	117	O	cause
21	119	127	O	transient
22	129	136	O	increase
23	138	139	O	in
24	141	144	O	free
25	146	159	O	concentrations
26	161	162	O	of
27	164	166	O	the
28	168	172	O	other
29	174	177	O	drug
NULL

ZALEPLON	6376	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	27
Drugs with a Narrow Therapeutic Index Digoxin: Zaleplon (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).
1	0	4	O	Drugs
2	6	9	O	with
3	11	11	O	a
4	13	18	O	Narrow
5	20	30	O	Therapeutic
6	32	36	O	Index
7	38	44	O	Digoxin
8	45	45	O	:
9	47	54	O	XXXXXXXX
10	57	58	O	10
11	60	61	O	mg
12	64	66	O	did
13	68	70	O	not
14	72	77	O	affect
15	79	81	O	the
16	83	97	O	pharmacokinetic
17	99	100	O	or
18	102	116	O	pharmacodynamic
19	118	124	O	profile
20	126	127	O	of
21	129	135	O	digoxin
22	138	142	O	0.375
23	144	145	O	mg
24	147	150	O	q24h
25	152	154	O	for
26	156	156	O	8
27	158	161	O	days
NULL

ZALEPLON	6377	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	38
Warfarin: Multiple oral doses of Zaleplon (20 mg q24h for 13 days) did not affect the pharmacokinetics of warfarin (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of warfarin.
1	0	7	O	Warfarin
2	8	8	O	:
3	10	17	O	Multiple
4	19	22	O	oral
5	24	28	O	doses
6	30	31	O	of
7	33	40	O	XXXXXXXX
8	43	44	O	20
9	46	47	O	mg
10	49	52	O	q24h
11	54	56	O	for
12	58	59	O	13
13	61	64	O	days
14	67	69	O	did
15	71	73	O	not
16	75	80	O	affect
17	82	84	O	the
18	86	101	O	pharmacokinetics
19	103	104	O	of
20	106	113	O	warfarin
21	116	117	O	R+
22	121	122	O	or
23	125	125	O	S
24	129	139	O	enantiomers
25	141	142	O	or
26	144	146	O	the
27	148	163	O	pharmacodynamics
28	166	176	O	prothrombin
29	178	181	O	time
30	184	192	O	following
31	194	194	O	a
32	196	201	O	single
33	203	204	O	25
34	206	207	O	mg
35	209	212	O	oral
36	214	217	O	dose
37	219	220	O	of
38	222	229	O	warfarin
NULL

ZALEPLON	6378	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	25
Drugs That Alter Renal Excretion Ibuprofen: Ibuprofen is known to affect renal function and, consequently, alter the renal excretion of other drugs.
1	0	4	O	Drugs
2	6	9	O	That
3	11	15	O	Alter
4	17	21	O	Renal
5	23	31	O	Excretion
6	33	41	O	Ibuprofen
7	42	42	O	:
8	44	52	O	Ibuprofen
9	54	55	O	is
10	57	61	O	known
11	63	64	O	to
12	66	71	O	affect
13	73	77	O	renal
14	79	86	O	function
15	88	90	O	and
16	91	91	O	,
17	93	104	O	consequently
18	105	105	O	,
19	107	111	O	alter
20	113	115	O	the
21	117	121	O	renal
22	123	131	O	excretion
23	133	134	O	of
24	136	140	O	other
25	142	146	O	drugs
NULL

ZALEPLON	6379	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	24
There was no apparent pharmacokinetic interaction between zaleplon and ibuprofen following single dose administration (10 mg and 600 mg, respectively) of each drug.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	apparent
5	22	36	O	pharmacokinetic
6	38	48	O	interaction
7	50	56	O	between
8	58	65	O	XXXXXXXX
9	67	69	O	and
10	71	79	O	ibuprofen
11	81	89	O	following
12	91	96	O	single
13	98	101	O	dose
14	103	116	O	administration
15	119	120	O	10
16	122	123	O	mg
17	125	127	O	and
18	129	131	O	600
19	133	134	O	mg
20	135	135	O	,
21	137	148	O	respectively
22	151	152	O	of
23	154	157	O	each
24	159	162	O	drug
NULL

ZALEPLON	6380	34073-7	2f44db39-e1d9-451e-ba31-e4b10366a430	23
This was expected because zaleplon is primarily metabolized and renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose.
1	0	3	O	This
2	5	7	O	was
3	9	16	O	expected
4	18	24	O	because
5	26	33	O	XXXXXXXX
6	35	36	O	is
7	38	46	O	primarily
8	48	58	O	metabolized
9	60	62	O	and
10	64	68	O	renal
11	70	78	O	excretion
12	80	81	O	of
13	83	91	O	unchanged
14	93	100	O	XXXXXXXX
15	102	109	O	accounts
16	111	113	O	for
17	115	118	O	less
18	120	123	O	than
19	125	126	O	1%
20	128	129	O	of
21	131	133	O	the
22	135	146	O	administered
23	148	151	O	dose
NULL

ZALEPLON	6381	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	41
Pharmacodynamics and Mechanism of Action While Zaleplon is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties, it interacts with the gamma-aminobutyric acid-benzodiazepine (GABA-BZ) receptor complex.
1	0	15	O	Pharmacodynamics
2	17	19	O	and
3	21	29	O	Mechanism
4	31	32	O	of
5	34	39	O	Action
6	41	45	O	While
7	47	54	O	XXXXXXXX
8	56	57	O	is
9	59	59	O	a
10	61	68	O	hypnotic
11	70	74	O	agent
12	76	79	O	with
13	81	81	O	a
14	83	90	O	chemical
15	92	100	O	structure
16	102	110	O	unrelated
17	112	113	O	to
18	115	129	O	benzodiazepines
19	130	130	O	,
20	132	143	O	barbiturates
21	144	144	O	,
22	146	147	O	or
23	149	153	O	other
24	155	159	O	drugs
25	161	164	O	with
26	166	170	O	known
27	172	179	O	hypnotic
28	181	190	O	properties
29	191	191	O	,
30	193	194	O	it
31	196	204	O	interacts
32	206	209	O	with
33	211	213	O	the
34	215	219	O	gamma
35	221	232	O	aminobutyric
36	234	237	O	acid
37	239	252	O	benzodiazepine
38	255	258	O	GABA
39	260	261	O	BZ
40	264	271	O	receptor
41	273	279	O	complex
NULL

ZALEPLON	6382	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	40
Subunit modulation of the GABA-BZ receptor chloride channel macromolecular complex is hypothesized to be responsible for some of the pharmacological properties of benzodiazepines, which include sedative, anxiolytic, muscle relaxant, and anticonvulsive effects in animal models.
1	0	6	O	Subunit
2	8	17	O	modulation
3	19	20	O	of
4	22	24	O	the
5	26	29	O	GABA
6	31	32	O	BZ
7	34	41	O	receptor
8	43	50	O	chloride
9	52	58	O	channel
10	60	73	O	macromolecular
11	75	81	O	complex
12	83	84	O	is
13	86	97	O	hypothesized
14	99	100	O	to
15	102	103	O	be
16	105	115	O	responsible
17	117	119	O	for
18	121	124	O	some
19	126	127	O	of
20	129	131	O	the
21	133	147	O	pharmacological
22	149	158	O	properties
23	160	161	O	of
24	163	177	O	benzodiazepines
25	178	178	O	,
26	180	184	O	which
27	186	192	O	include
28	194	201	O	sedative
29	202	202	O	,
30	204	213	O	anxiolytic
31	214	214	O	,
32	216	221	O	muscle
33	223	230	O	relaxant
34	231	231	O	,
35	233	235	O	and
36	237	250	O	anticonvulsive
37	252	258	O	effects
38	260	261	O	in
39	263	268	O	animal
40	270	275	O	models
NULL

ZALEPLON	6383	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	37
Other nonclinical studies have also shown that zaleplon binds selectively to the brain omega-1 receptor situated on the alpha subunit of the GABAA/chloride ion channel receptor complex and potentiates t-butyl-bicyclophosphorothionate (TBPS) binding.
1	0	4	O	Other
2	6	16	O	nonclinical
3	18	24	O	studies
4	26	29	O	have
5	31	34	O	also
6	36	40	O	shown
7	42	45	O	that
8	47	54	O	XXXXXXXX
9	56	60	O	binds
10	62	72	O	selectively
11	74	75	O	to
12	77	79	O	the
13	81	85	O	brain
14	87	91	O	omega
15	93	93	O	1
16	95	102	O	receptor
17	104	111	O	situated
18	113	114	O	on
19	116	118	O	the
20	120	124	O	alpha
21	126	132	O	subunit
22	134	135	O	of
23	137	139	O	the
24	141	145	O	GABAA
25	146	146	O	/
26	147	154	O	chloride
27	156	158	O	ion
28	160	166	O	channel
29	168	175	O	receptor
30	177	183	O	complex
31	185	187	O	and
32	189	199	O	potentiates
33	201	201	O	t
34	203	207	O	butyl
35	209	232	O	bicyclophosphorothionate
36	235	238	O	TBPS
37	241	247	O	binding
NULL

ZALEPLON	6384	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	36
Studies of binding of zaleplon to recombinant GABAA receptors (A1B1G2 [omega-1] and A2B1G2 [omega-2]) have shown that zaleplon has a low affinity for these receptors, with preferential binding to the omega-1 receptor.
1	0	6	O	Studies
2	8	9	O	of
3	11	17	O	binding
4	19	20	O	of
5	22	29	O	XXXXXXXX
6	31	32	O	to
7	34	44	O	recombinant
8	46	50	O	GABAA
9	52	60	O	receptors
10	63	68	O	A1B1G2
11	71	75	O	omega
12	77	77	O	1
13	80	82	O	and
14	84	89	O	A2B1G2
15	92	96	O	omega
16	98	98	O	2
17	102	105	O	have
18	107	111	O	shown
19	113	116	O	that
20	118	125	O	XXXXXXXX
21	127	129	O	has
22	131	131	O	a
23	133	135	O	low
24	137	144	O	affinity
25	146	148	O	for
26	150	154	O	these
27	156	164	O	receptors
28	165	165	O	,
29	167	170	O	with
30	172	183	O	preferential
31	185	191	O	binding
32	193	194	O	to
33	196	198	O	the
34	200	204	O	omega
35	206	206	O	1
36	208	215	O	receptor
NULL

ZALEPLON	6385	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	29
Pharmacokinetics The pharmacokinetics of zaleplon have been investigated in more than 500 healthy subjects (young and elderly), nursing mothers, and patients with hepatic disease or renal disease.
1	0	15	O	Pharmacokinetics
2	17	19	O	The
3	21	36	O	pharmacokinetics
4	38	39	O	of
5	41	48	O	XXXXXXXX
6	50	53	O	have
7	55	58	O	been
8	60	71	O	investigated
9	73	74	O	in
10	76	79	O	more
11	81	84	O	than
12	86	88	O	500
13	90	96	O	healthy
14	98	105	O	subjects
15	108	112	O	young
16	114	116	O	and
17	118	124	O	elderly
18	126	126	O	,
19	128	134	O	nursing
20	136	142	O	mothers
21	143	143	O	,
22	145	147	O	and
23	149	156	O	patients
24	158	161	O	with
25	163	169	O	hepatic
26	171	177	O	disease
27	179	180	O	or
28	182	186	O	renal
29	188	194	O	disease
NULL

ZALEPLON	6386	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	31
In healthy subjects, the pharmacokinetic profile has been examined after single doses of up to 60 mg and once-daily administration at 15 mg and 30 mg for 10 days.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	19	19	O	,
5	21	23	O	the
6	25	39	O	pharmacokinetic
7	41	47	O	profile
8	49	51	O	has
9	53	56	O	been
10	58	65	O	examined
11	67	71	O	after
12	73	78	O	single
13	80	84	O	doses
14	86	87	O	of
15	89	90	O	up
16	92	93	O	to
17	95	96	O	60
18	98	99	O	mg
19	101	103	O	and
20	105	108	O	once
21	110	114	O	daily
22	116	129	O	administration
23	131	132	O	at
24	134	135	O	15
25	137	138	O	mg
26	140	142	O	and
27	144	145	O	30
28	147	148	O	mg
29	150	152	O	for
30	154	155	O	10
31	157	160	O	days
NULL

ZALEPLON	6387	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	29
Zaleplon was rapidly absorbed with a time to peak concentration (tmax) of approximately 1 hour and a terminal-phase elimination half-life (t1/2) of approximately 1 hour.
1	0	7	O	XXXXXXXX
2	9	11	O	was
3	13	19	O	rapidly
4	21	28	O	absorbed
5	30	33	O	with
6	35	35	O	a
7	37	40	O	time
8	42	43	O	to
9	45	48	O	peak
10	50	62	O	concentration
11	65	68	O	tmax
12	71	72	O	of
13	74	86	O	approximately
14	88	88	O	1
15	90	93	O	hour
16	95	97	O	and
17	99	99	O	a
18	101	108	O	terminal
19	110	114	O	phase
20	116	126	O	elimination
21	128	131	O	half
22	133	136	O	life
23	139	140	O	t1
24	141	141	O	/
25	142	142	O	2
26	145	146	O	of
27	148	160	O	approximately
28	162	162	O	1
29	164	167	O	hour
NULL

ZALEPLON	6388	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	18
Zaleplon does not accumulate with once-daily administration and its pharmacokinetics are dose proportional in the therapeutic range.
1	0	7	O	XXXXXXXX
2	9	12	O	does
3	14	16	O	not
4	18	27	O	accumulate
5	29	32	O	with
6	34	37	O	once
7	39	43	O	daily
8	45	58	O	administration
9	60	62	O	and
10	64	66	O	its
11	68	83	O	pharmacokinetics
12	85	87	O	are
13	89	92	O	dose
14	94	105	O	proportional
15	107	108	O	in
16	110	112	O	the
17	114	124	O	therapeutic
18	126	130	O	range
NULL

ZALEPLON	6389	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	11
Absorption Zaleplon is rapidly and almost completely absorbed following oral administration.
1	0	9	O	Absorption
2	11	18	O	XXXXXXXX
3	20	21	O	is
4	23	29	O	rapidly
5	31	33	O	and
6	35	40	O	almost
7	42	51	O	completely
8	53	60	O	absorbed
9	62	70	O	following
10	72	75	O	oral
11	77	90	O	administration
NULL

ZALEPLON	6390	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	12
Peak plasma concentrations are attained within approximately 1 hour after oral administration.
1	0	3	O	Peak
2	5	10	O	plasma
3	12	25	O	concentrations
4	27	29	O	are
5	31	38	O	attained
6	40	45	O	within
7	47	59	O	approximately
8	61	61	O	1
9	63	66	O	hour
10	68	72	O	after
11	74	77	O	oral
12	79	92	O	administration
NULL

ZALEPLON	6391	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	18
Although zaleplon is well absorbed, its absolute bioavailability is approximately 30% because it undergoes significant presystemic metabolism.
1	0	7	O	Although
2	9	16	O	XXXXXXXX
3	18	19	O	is
4	21	24	O	well
5	26	33	O	absorbed
6	34	34	O	,
7	36	38	O	its
8	40	47	O	absolute
9	49	63	O	bioavailability
10	65	66	O	is
11	68	80	O	approximately
12	82	84	O	30%
13	86	92	O	because
14	94	95	O	it
15	97	105	O	undergoes
16	107	117	O	significant
17	119	129	O	presystemic
18	131	140	O	metabolism
NULL

ZALEPLON	6392	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
Distribution Zaleplon is a lipophilic compound with a volume of distribution of approximately 1.4 L/kg following intravenous (IV) administration, indicating substantial distribution into extravascular tissues.
1	0	11	O	Distribution
2	13	20	O	XXXXXXXX
3	22	23	O	is
4	25	25	O	a
5	27	36	O	lipophilic
6	38	45	O	compound
7	47	50	O	with
8	52	52	O	a
9	54	59	O	volume
10	61	62	O	of
11	64	75	O	distribution
12	77	78	O	of
13	80	92	O	approximately
14	94	96	O	1.4
15	98	98	O	L
16	99	99	O	/
17	100	101	O	kg
18	103	111	O	following
19	113	123	O	intravenous
20	126	127	O	IV
21	130	143	O	administration
22	144	144	O	,
23	146	155	O	indicating
24	157	167	O	substantial
25	169	180	O	distribution
26	182	185	O	into
27	187	199	O	extravascular
28	201	207	O	tissues
NULL

ZALEPLON	6393	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
The in vitro plasma protein binding is approximately 60%*15% and is independent of zaleplon concentration over the range of 10 ng/mL to 1000 ng/mL.
1	0	2	O	The
2	4	5	O	in
3	7	11	O	vitro
4	13	18	O	plasma
5	20	26	O	protein
6	28	34	O	binding
7	36	37	O	is
8	39	51	O	approximately
9	53	59	O	60%*15%
10	61	63	O	and
11	65	66	O	is
12	68	78	O	independent
13	80	81	O	of
14	83	90	O	XXXXXXXX
15	92	104	O	concentration
16	106	109	O	over
17	111	113	O	the
18	115	119	O	range
19	121	122	O	of
20	124	125	O	10
21	127	128	O	ng
22	129	129	O	/
23	130	131	O	mL
24	133	134	O	to
25	136	139	O	1000
26	141	142	O	ng
27	143	143	O	/
28	144	145	O	mL
NULL

ZALEPLON	6394	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	14
This suggests that zaleplon disposition should not be sensitive to alterations in protein binding.
1	0	3	O	This
2	5	12	O	suggests
3	14	17	O	that
4	19	26	O	XXXXXXXX
5	28	38	O	disposition
6	40	45	O	should
7	47	49	O	not
8	51	52	O	be
9	54	62	O	sensitive
10	64	65	O	to
11	67	77	O	alterations
12	79	80	O	in
13	82	88	O	protein
14	90	96	O	binding
NULL

ZALEPLON	6395	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
The blood to plasma ratio for zaleplon is approximately 1, indicating that zaleplon is uniformly distributed throughout the blood with no extensive distribution into red blood cells.
1	0	2	O	The
2	4	8	O	blood
3	10	11	O	to
4	13	18	O	plasma
5	20	24	O	ratio
6	26	28	O	for
7	30	37	O	XXXXXXXX
8	39	40	O	is
9	42	54	O	approximately
10	56	56	O	1
11	57	57	O	,
12	59	68	O	indicating
13	70	73	O	that
14	75	82	O	XXXXXXXX
15	84	85	O	is
16	87	95	O	uniformly
17	97	107	O	distributed
18	109	118	O	throughout
19	120	122	O	the
20	124	128	O	blood
21	130	133	O	with
22	135	136	O	no
23	138	146	O	extensive
24	148	159	O	distribution
25	161	164	O	into
26	166	168	O	red
27	170	174	O	blood
28	176	180	O	cells
NULL

ZALEPLON	6396	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	21
Metabolism After oral administration, zaleplon is extensively metabolized, with less than 1% of the dose excreted unchanged in urine.
1	0	9	O	Metabolism
2	11	15	O	After
3	17	20	O	oral
4	22	35	O	administration
5	36	36	O	,
6	38	45	O	XXXXXXXX
7	47	48	O	is
8	50	60	O	extensively
9	62	72	O	metabolized
10	73	73	O	,
11	75	78	O	with
12	80	83	O	less
13	85	88	O	than
14	90	91	O	1%
15	93	94	O	of
16	96	98	O	the
17	100	103	O	dose
18	105	112	O	excreted
19	114	122	O	unchanged
20	124	125	O	in
21	127	131	O	urine
NULL

ZALEPLON	6397	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	12
Zaleplon is primarily metabolized by aldehyde oxidase to form 5-oxo-zaleplon.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	20	O	primarily
4	22	32	O	metabolized
5	34	35	O	by
6	37	44	O	aldehyde
7	46	52	O	oxidase
8	54	55	O	to
9	57	60	O	form
10	62	62	O	5
11	64	66	O	oxo
12	68	75	O	XXXXXXXX
NULL

ZALEPLON	6398	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	32
Zaleplon is metabolized to a lesser extent by cytochrome P450 (CYP) 3A4 to form desethyl zaleplon, which is quickly converted, presumably by aldehyde oxidase, to 5-oxo-desethylzaleplon.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	22	O	metabolized
4	24	25	O	to
5	27	27	O	a
6	29	34	O	lesser
7	36	41	O	extent
8	43	44	O	by
9	46	55	O	cytochrome
10	57	60	O	P450
11	63	65	O	CYP
12	68	70	O	3A4
13	72	73	O	to
14	75	78	O	form
15	80	87	O	desethyl
16	89	96	O	XXXXXXXX
17	97	97	O	,
18	99	103	O	which
19	105	106	O	is
20	108	114	O	quickly
21	116	124	O	converted
22	125	125	O	,
23	127	136	O	presumably
24	138	139	O	by
25	141	148	O	aldehyde
26	150	156	O	oxidase
27	157	157	O	,
28	159	160	O	to
29	162	162	O	5
30	164	166	O	oxo
31	168	175	O	desethyl
32	176	183	O	XXXXXXXX
NULL

ZALEPLON	6399	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	12
These oxidative metabolites are then converted to glucuronides and eliminated in urine.
1	0	4	O	These
2	6	14	O	oxidative
3	16	26	O	metabolites
4	28	30	O	are
5	32	35	O	then
6	37	45	O	converted
7	47	48	O	to
8	50	61	O	glucuronides
9	63	65	O	and
10	67	76	O	eliminated
11	78	79	O	in
12	81	85	O	urine
NULL

ZALEPLON	6400	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	8
All of zaleplon's metabolites are pharmacologically inactive.
1	0	2	O	All
2	4	5	O	of
3	7	14	O	XXXXXXXX
4	15	16	O	's
5	18	28	O	metabolites
6	30	32	O	are
7	34	50	O	pharmacologically
8	52	59	O	inactive
NULL

ZALEPLON	6401	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	22
Elimination After either oral or IV administration, zaleplon is rapidly eliminated with a mean t1/2 of approximately 1 hour.
1	0	10	O	Elimination
2	12	16	O	After
3	18	23	O	either
4	25	28	O	oral
5	30	31	O	or
6	33	34	O	IV
7	36	49	O	administration
8	50	50	O	,
9	52	59	O	XXXXXXXX
10	61	62	O	is
11	64	70	O	rapidly
12	72	81	O	eliminated
13	83	86	O	with
14	88	88	O	a
15	90	93	O	mean
16	95	96	O	t1
17	97	97	O	/
18	98	98	O	2
19	100	101	O	of
20	103	115	O	approximately
21	117	117	O	1
22	119	122	O	hour
NULL

ZALEPLON	6402	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	29
The oral-dose plasma clearance of zaleplon is about 3 L/h/kg and the IV zaleplon plasma clearance is approximately 1 L/h/kg.
1	0	2	O	The
2	4	7	O	oral
3	9	12	O	dose
4	14	19	O	plasma
5	21	29	O	clearance
6	31	32	O	of
7	34	41	O	XXXXXXXX
8	43	44	O	is
9	46	50	O	about
10	52	52	O	3
11	54	54	O	L
12	55	55	O	/
13	56	56	O	h
14	57	57	O	/
15	58	59	O	kg
16	61	63	O	and
17	65	67	O	the
18	69	70	O	IV
19	72	79	O	XXXXXXXX
20	81	86	O	plasma
21	88	96	O	clearance
22	98	99	O	is
23	101	113	O	approximately
24	115	115	O	1
25	117	117	O	L
26	118	118	O	/
27	119	119	O	h
28	120	120	O	/
29	121	122	O	kg
NULL

ZALEPLON	6403	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	33
Assuming normal hepatic blood flow and negligible renal clearance of zaleplon, the estimated hepatic extraction ratio of zaleplon is approximately 0.7, indicating that zaleplon is subject to high first-pass metabolism.
1	0	7	O	Assuming
2	9	14	O	normal
3	16	22	O	hepatic
4	24	28	O	blood
5	30	33	O	flow
6	35	37	O	and
7	39	48	O	negligible
8	50	54	O	renal
9	56	64	O	clearance
10	66	67	O	of
11	69	76	O	XXXXXXXX
12	77	77	O	,
13	79	81	O	the
14	83	91	O	estimated
15	93	99	O	hepatic
16	101	110	O	extraction
17	112	116	O	ratio
18	118	119	O	of
19	121	128	O	XXXXXXXX
20	130	131	O	is
21	133	145	O	approximately
22	147	149	O	0.7
23	150	150	O	,
24	152	161	O	indicating
25	163	166	O	that
26	168	175	O	XXXXXXXX
27	177	178	O	is
28	180	186	O	subject
29	188	189	O	to
30	191	194	O	high
31	196	200	O	first
32	202	205	O	pass
33	207	216	O	metabolism
NULL

ZALEPLON	6404	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	36
After administration of a radio labeled dose of zaleplon, 70% of the administered dose is recovered in urine within 48 hours (71% recovered within 6 days), almost all as zaleplon metabolites and their glucuronides.
1	0	4	O	After
2	6	19	O	administration
3	21	22	O	of
4	24	24	O	a
5	26	30	O	radio
6	32	38	O	labeled
7	40	43	O	dose
8	45	46	O	of
9	48	55	O	XXXXXXXX
10	56	56	O	,
11	58	60	O	70%
12	62	63	O	of
13	65	67	O	the
14	69	80	O	administered
15	82	85	O	dose
16	87	88	O	is
17	90	98	O	recovered
18	100	101	O	in
19	103	107	O	urine
20	109	114	O	within
21	116	117	O	48
22	119	123	O	hours
23	126	128	O	71%
24	130	138	O	recovered
25	140	145	O	within
26	147	147	O	6
27	149	152	O	days
28	154	154	O	,
29	156	161	O	almost
30	163	165	O	all
31	167	168	O	as
32	170	177	O	XXXXXXXX
33	179	189	O	metabolites
34	191	193	O	and
35	195	199	O	their
36	201	212	O	glucuronides
NULL

ZALEPLON	6405	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	16
An additional 17% is recovered in feces within 6 days, most as 5-oxo-zaleplon.
1	0	1	O	An
2	3	12	O	additional
3	14	16	O	17%
4	18	19	O	is
5	21	29	O	recovered
6	31	32	O	in
7	34	38	O	feces
8	40	45	O	within
9	47	47	O	6
10	49	52	O	days
11	53	53	O	,
12	55	58	O	most
13	60	61	O	as
14	63	63	O	5
15	65	67	O	oxo
16	69	76	O	XXXXXXXX
NULL

ZALEPLON	6406	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	35
Effect of Food In healthy adults a high-fat/heavy meal prolonged the absorption of zaleplon compared to the fasted state, delaying tmax by approximately 2 hours and reducing Cmax by approximately 35%.
1	0	5	O	Effect
2	7	8	O	of
3	10	13	U-KIN	Food
4	15	16	O	In
5	18	24	O	healthy
6	26	31	O	adults
7	33	33	O	a
8	35	38	B-KIN	high
9	40	42	I-KIN	fat
10	43	43	I-KIN	/
11	44	48	I-KIN	heavy
12	50	53	L-KIN	meal
13	55	63	B-TRI	prolonged
14	65	67	I-TRI	the
15	69	78	L-TRI	absorption
16	80	81	O	of
17	83	90	O	XXXXXXXX
18	92	99	O	compared
19	101	102	O	to
20	104	106	O	the
21	108	113	O	fasted
22	115	119	O	state
23	120	120	O	,
24	122	129	B-TRI	delaying
25	131	134	L-TRI	tmax
26	136	137	O	by
27	139	151	O	approximately
28	153	153	O	2
29	155	159	O	hours
30	161	163	O	and
31	165	172	B-TRI	reducing
32	174	177	L-TRI	Cmax
33	179	180	O	by
34	182	194	O	approximately
35	196	198	O	35%
K/3:C54604 K/8:C54356

ZALEPLON	6407	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	10
Zaleplon AUC and elimination half-life were not significantly affected.
1	0	7	O	XXXXXXXX
2	9	11	O	AUC
3	13	15	O	and
4	17	27	O	elimination
5	29	32	O	half
6	34	37	O	life
7	39	42	O	were
8	44	46	O	not
9	48	60	O	significantly
10	62	69	O	affected
NULL

ZALEPLON	6408	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
These results suggest that the effects of Zaleplon on sleep onset may be reduced if it is taken with or immediately after a high-fat/heavy meal.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	27	29	O	the
6	31	37	O	effects
7	39	40	O	of
8	42	49	O	XXXXXXXX
9	51	52	O	on
10	54	58	O	sleep
11	60	64	O	onset
12	66	68	O	may
13	70	71	O	be
14	73	79	O	reduced
15	81	82	O	if
16	84	85	O	it
17	87	88	O	is
18	90	94	O	taken
19	96	99	O	with
20	101	102	O	or
21	104	114	O	immediately
22	116	120	O	after
23	122	122	O	a
24	124	127	B-DYN	high
25	129	131	I-DYN	fat
26	132	132	I-DYN	/
27	133	137	I-DYN	heavy
28	139	142	L-DYN	meal
NULL

ZALEPLON	6409	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	27
Special Populations Age: The pharmacokinetics of Zaleplon have been investigated in three studies with elderly men and women ranging in age from 65 to 85 years.
1	0	6	O	Special
2	8	18	O	Populations
3	20	22	O	Age
4	23	23	O	:
5	25	27	O	The
6	29	44	O	pharmacokinetics
7	46	47	O	of
8	49	56	O	XXXXXXXX
9	58	61	O	have
10	63	66	O	been
11	68	79	O	investigated
12	81	82	O	in
13	84	88	O	three
14	90	96	O	studies
15	98	101	O	with
16	103	109	O	elderly
17	111	113	O	men
18	115	117	O	and
19	119	123	O	women
20	125	131	O	ranging
21	133	134	O	in
22	136	138	O	age
23	140	143	O	from
24	145	146	O	65
25	148	149	O	to
26	151	152	O	85
27	154	158	O	years
NULL

ZALEPLON	6410	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	26
The pharmacokinetics of Zaleplon in elderly subjects, including those over 75 years of age, are not significantly different from those in young healthy subjects.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	22	O	of
4	24	31	O	XXXXXXXX
5	33	34	O	in
6	36	42	O	elderly
7	44	51	O	subjects
8	52	52	O	,
9	54	62	O	including
10	64	68	O	those
11	70	73	O	over
12	75	76	O	75
13	78	82	O	years
14	84	85	O	of
15	87	89	O	age
16	90	90	O	,
17	92	94	O	are
18	96	98	O	not
19	100	112	O	significantly
20	114	122	O	different
21	124	127	O	from
22	129	133	O	those
23	135	136	O	in
24	138	142	O	young
25	144	150	O	healthy
26	152	159	O	subjects
NULL

ZALEPLON	6411	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	16
Gender: There is no significant difference in the pharmacokinetics of Zaleplon in men and women.
1	0	5	O	Gender
2	6	6	O	:
3	8	12	O	There
4	14	15	O	is
5	17	18	O	no
6	20	30	O	significant
7	32	41	O	difference
8	43	44	O	in
9	46	48	O	the
10	50	65	O	pharmacokinetics
11	67	68	O	of
12	70	77	O	XXXXXXXX
13	79	80	O	in
14	82	84	O	men
15	86	88	O	and
16	90	94	O	women
NULL

ZALEPLON	6412	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	17
Race: The pharmacokinetics of zaleplon have been studied in Japanese subjects as representative of Asian populations.
1	0	3	O	Race
2	4	4	O	:
3	6	8	O	The
4	10	25	O	pharmacokinetics
5	27	28	O	of
6	30	37	O	XXXXXXXX
7	39	42	O	have
8	44	47	O	been
9	49	55	O	studied
10	57	58	O	in
11	60	67	O	Japanese
12	69	76	O	subjects
13	78	79	O	as
14	81	94	O	representative
15	96	97	O	of
16	99	103	O	Asian
17	105	115	O	populations
NULL

ZALEPLON	6413	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	14
For this group, Cmax and AUC were increased 37% and 64%, respectively.
1	0	2	O	For
2	4	7	O	this
3	9	13	O	group
4	14	14	O	,
5	16	19	O	Cmax
6	21	23	O	and
7	25	27	O	AUC
8	29	32	O	were
9	34	42	O	increased
10	44	46	O	37%
11	48	50	O	and
12	52	54	O	64%
13	55	55	O	,
14	57	68	O	respectively
NULL

ZALEPLON	6414	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	32
This finding can likely be attributed to differences in body weight, or alternatively, may represent differences in enzyme activities resulting from differences in diet, environment, or other factors.
1	0	3	O	This
2	5	11	O	finding
3	13	15	O	can
4	17	22	O	likely
5	24	25	O	be
6	27	36	O	attributed
7	38	39	O	to
8	41	51	O	differences
9	53	54	O	in
10	56	59	O	body
11	61	66	O	weight
12	67	67	O	,
13	69	70	O	or
14	72	84	O	alternatively
15	85	85	O	,
16	87	89	O	may
17	91	99	O	represent
18	101	111	O	differences
19	113	114	O	in
20	116	121	O	enzyme
21	123	132	O	activities
22	134	142	O	resulting
23	144	147	O	from
24	149	159	O	differences
25	161	162	O	in
26	164	167	O	diet
27	168	168	O	,
28	170	180	O	environment
29	181	181	O	,
30	183	184	O	or
31	186	190	O	other
32	192	198	O	factors
NULL

ZALEPLON	6415	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	16
The effects of race on pharmacokinetic characteristics in other ethnic groups have not been well characterized.
1	0	2	O	The
2	4	10	O	effects
3	12	13	O	of
4	15	18	O	race
5	20	21	O	on
6	23	37	O	pharmacokinetic
7	39	53	O	characteristics
8	55	56	O	in
9	58	62	O	other
10	64	69	O	ethnic
11	71	76	O	groups
12	78	81	O	have
13	83	85	O	not
14	87	90	O	been
15	92	95	O	well
16	97	109	O	characterized
NULL

ZALEPLON	6416	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	15
Hepatic impairment: Zaleplon is metabolized primarily by the liver and undergoes significant presystemic metabolism.
1	0	6	O	Hepatic
2	8	17	O	impairment
3	18	18	O	:
4	20	27	O	XXXXXXXX
5	29	30	O	is
6	32	42	O	metabolized
7	44	52	O	primarily
8	54	55	O	by
9	57	59	O	the
10	61	65	O	liver
11	67	69	O	and
12	71	79	O	undergoes
13	81	91	O	significant
14	93	103	O	presystemic
15	105	114	O	metabolism
NULL

ZALEPLON	6417	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	51
Consequently, the oral clearance of zaleplon was reduced by 70% and 87% in compensated and decompensated cirrhotic patients, respectively, leading to marked increases in mean Cmax and AUC (up to 4-fold and 7-fold in compensated and decompensated patients, respectively), in comparison with healthy subjects.
1	0	11	O	Consequently
2	12	12	O	,
3	14	16	O	the
4	18	21	O	oral
5	23	31	O	clearance
6	33	34	O	of
7	36	43	O	XXXXXXXX
8	45	47	O	was
9	49	55	O	reduced
10	57	58	O	by
11	60	62	O	70%
12	64	66	O	and
13	68	70	O	87%
14	72	73	O	in
15	75	85	O	compensated
16	87	89	O	and
17	91	103	O	decompensated
18	105	113	O	cirrhotic
19	115	122	O	patients
20	123	123	O	,
21	125	136	O	respectively
22	137	137	O	,
23	139	145	O	leading
24	147	148	O	to
25	150	155	O	marked
26	157	165	O	increases
27	167	168	O	in
28	170	173	O	mean
29	175	178	O	Cmax
30	180	182	O	and
31	184	186	O	AUC
32	189	190	O	up
33	192	193	O	to
34	195	195	O	4
35	197	200	O	fold
36	202	204	O	and
37	206	206	O	7
38	208	211	O	fold
39	213	214	O	in
40	216	226	O	compensated
41	228	230	O	and
42	232	244	O	decompensated
43	246	253	O	patients
44	254	254	O	,
45	256	267	O	respectively
46	269	269	O	,
47	271	272	O	in
48	274	283	O	comparison
49	285	288	O	with
50	290	296	O	healthy
51	298	305	O	subjects
NULL

ZALEPLON	6418	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	16
The dose of Zaleplon should therefore be reduced in patients with mild to moderate hepatic impairment.
1	0	2	O	The
2	4	7	O	dose
3	9	10	O	of
4	12	19	O	XXXXXXXX
5	21	26	O	should
6	28	36	O	therefore
7	38	39	O	be
8	41	47	O	reduced
9	49	50	O	in
10	52	59	O	patients
11	61	64	O	with
12	66	69	O	mild
13	71	72	O	to
14	74	81	O	moderate
15	83	89	O	hepatic
16	91	100	O	impairment
NULL

ZALEPLON	6419	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	12
Zaleplon is not recommended for use in patients with severe hepatic impairment.
1	0	7	O	XXXXXXXX
2	9	10	O	is
3	12	14	O	not
4	16	26	O	recommended
5	28	30	O	for
6	32	34	O	use
7	36	37	O	in
8	39	46	O	patients
9	48	51	O	with
10	53	58	O	severe
11	60	66	O	hepatic
12	68	77	O	impairment
NULL

ZALEPLON	6420	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	31
Renal impairment: Because renal excretion of unchanged zaleplon accounts for less than 1% of the administered dose, the pharmacokinetics of zaleplon are not altered in patients with renal insufficiency.
1	0	4	O	Renal
2	6	15	O	impairment
3	16	16	O	:
4	18	24	O	Because
5	26	30	O	renal
6	32	40	O	excretion
7	42	43	O	of
8	45	53	O	unchanged
9	55	62	O	XXXXXXXX
10	64	71	O	accounts
11	73	75	O	for
12	77	80	O	less
13	82	85	O	than
14	87	88	O	1%
15	90	91	O	of
16	93	95	O	the
17	97	108	O	administered
18	110	113	O	dose
19	114	114	O	,
20	116	118	O	the
21	120	135	O	pharmacokinetics
22	137	138	O	of
23	140	147	O	XXXXXXXX
24	149	151	O	are
25	153	155	O	not
26	157	163	O	altered
27	165	166	O	in
28	168	175	O	patients
29	177	180	O	with
30	182	186	O	renal
31	188	200	O	insufficiency
NULL

ZALEPLON	6421	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	13
No dose adjustment is necessary in patients with mild to moderate renal impairment.
1	0	1	O	No
2	3	6	O	dose
3	8	17	O	adjustment
4	19	20	O	is
5	22	30	O	necessary
6	32	33	O	in
7	35	42	O	patients
8	44	47	O	with
9	49	52	O	mild
10	54	55	O	to
11	57	64	O	moderate
12	66	70	O	renal
13	72	81	O	impairment
NULL

ZALEPLON	6422	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	12
Zaleplon has not been adequately studied in patients with severe renal impairment.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	15	O	not
4	17	20	O	been
5	22	31	O	adequately
6	33	39	O	studied
7	41	42	O	in
8	44	51	O	patients
9	53	56	O	with
10	58	63	O	severe
11	65	69	O	renal
12	71	80	O	impairment
NULL

ZALEPLON	6423	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	44
Drug-Drug Interactions Because zaleplon is primarily metabolized by aldehyde oxidase, and to a lesser extent by CYP3A4, inhibitors of these enzymes might be expected to decrease zaleplon's clearance and inducers of these enzymes might be expected to increase its clearance.
1	0	3	O	Drug
2	5	8	O	Drug
3	10	21	O	Interactions
4	23	29	O	Because
5	31	38	O	XXXXXXXX
6	40	41	O	is
7	43	51	O	primarily
8	53	63	O	metabolized
9	65	66	O	by
10	68	75	O	aldehyde
11	77	83	O	oxidase
12	84	84	O	,
13	86	88	O	and
14	90	91	O	to
15	93	93	O	a
16	95	100	O	lesser
17	102	107	O	extent
18	109	110	O	by
19	112	117	O	CYP3A4
20	118	118	O	,
21	120	129	O	inhibitors
22	131	132	O	of
23	134	138	O	these
24	140	146	O	enzymes
25	148	152	O	might
26	154	155	O	be
27	157	164	O	expected
28	166	167	O	to
29	169	176	B-TRI	decrease
30	178	185	I-TRI	XXXXXXXX
31	186	187	I-TRI	's
32	189	197	L-TRI	clearance
33	199	201	O	and
34	203	210	O	inducers
35	212	213	O	of
36	215	219	O	these
37	221	227	O	enzymes
38	229	233	O	might
39	235	236	O	be
40	238	245	O	expected
41	247	248	O	to
42	250	257	O	increase
43	259	261	O	its
44	263	271	O	clearance
NULL

ZALEPLON	6424	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	31
Zaleplon has been shown to have minimal effects on the kinetics of warfarin (both R- and S-forms), imipramine, ethanol, ibuprofen, diphenhydramine, thioridazine, and digoxin.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	16	O	been
4	18	22	O	shown
5	24	25	O	to
6	27	30	O	have
7	32	38	O	minimal
8	40	46	O	effects
9	48	49	O	on
10	51	53	O	the
11	55	62	O	kinetics
12	64	65	O	of
13	67	74	O	warfarin
14	77	80	O	both
15	82	82	O	R
16	85	87	O	and
17	89	89	O	S
18	91	95	O	forms
19	97	97	O	,
20	99	108	O	imipramine
21	109	109	O	,
22	111	117	O	ethanol
23	118	118	O	,
24	120	128	O	ibuprofen
25	129	129	O	,
26	131	145	O	diphenhydramine
27	146	146	O	,
28	148	159	O	thioridazine
29	160	160	O	,
30	162	164	O	and
31	166	172	O	digoxin
NULL

ZALEPLON	6425	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	21
However, the effects of zaleplon on inhibition of enzymes involved in the metabolism of other drugs have not been studied.
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	19	O	effects
5	21	22	O	of
6	24	31	O	XXXXXXXX
7	33	34	O	on
8	36	45	O	inhibition
9	47	48	O	of
10	50	56	O	enzymes
11	58	65	O	involved
12	67	68	O	in
13	70	72	O	the
14	74	83	O	metabolism
15	85	86	O	of
16	88	92	O	other
17	94	98	O	drugs
18	100	103	O	have
19	105	107	O	not
20	109	112	O	been
21	114	120	O	studied
NULL

ZALEPLON	6427	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	40
Clinical Trials Controlled Trials Supporting Effectiveness Zaleplon (typically administered in doses of 5 mg, 10 mg, or 20 mg) has been studied in patients with chronic insomnia (n = 3,435) in 12 placebo- and active-drug-controlled trials.
1	0	7	O	Clinical
2	9	14	O	Trials
3	16	25	O	Controlled
4	27	32	O	Trials
5	34	43	O	Supporting
6	45	57	O	Effectiveness
7	59	66	O	XXXXXXXX
8	69	77	O	typically
9	79	90	O	administered
10	92	93	O	in
11	95	99	O	doses
12	101	102	O	of
13	104	104	O	5
14	106	107	O	mg
15	108	108	O	,
16	110	111	O	10
17	113	114	O	mg
18	115	115	O	,
19	117	118	O	or
20	120	121	O	20
21	123	124	O	mg
22	127	129	O	has
23	131	134	O	been
24	136	142	O	studied
25	144	145	O	in
26	147	154	O	patients
27	156	159	O	with
28	161	167	O	chronic
29	169	176	O	insomnia
30	179	179	O	n
31	181	181	O	=
32	183	187	O	3,435
33	190	191	O	in
34	193	194	O	12
35	196	202	O	placebo
36	205	207	O	and
37	209	214	O	active
38	216	219	O	drug
39	221	230	O	controlled
40	232	237	O	trials
NULL

ZALEPLON	6428	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	9
Three of the trials were in elderly patients (n=1,019).
1	0	4	O	Three
2	6	7	O	of
3	9	11	O	the
4	13	18	O	trials
5	20	23	O	were
6	25	26	O	in
7	28	34	O	elderly
8	36	43	O	patients
9	46	52	O	n=1,019
NULL

ZALEPLON	6429	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	9
It has also been studied in transient insomnia (n=264).
1	0	1	O	It
2	3	5	O	has
3	7	10	O	also
4	12	15	O	been
5	17	23	O	studied
6	25	26	O	in
7	28	36	O	transient
8	38	45	O	insomnia
9	48	52	O	n=264
NULL

ZALEPLON	6430	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	36
Because of its very short half-life, studies focused on decreasing sleep latency, with less attention to duration of sleep and number of awakenings, for which consistent differences from placebo were not demonstrated.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	18	O	very
5	20	24	O	short
6	26	29	O	half
7	31	34	O	life
8	35	35	O	,
9	37	43	O	studies
10	45	51	O	focused
11	53	54	O	on
12	56	65	O	decreasing
13	67	71	O	sleep
14	73	79	O	latency
15	80	80	O	,
16	82	85	O	with
17	87	90	O	less
18	92	100	O	attention
19	102	103	O	to
20	105	112	O	duration
21	114	115	O	of
22	117	121	O	sleep
23	123	125	O	and
24	127	132	O	number
25	134	135	O	of
26	137	146	O	awakenings
27	147	147	O	,
28	149	151	O	for
29	153	157	O	which
30	159	168	O	consistent
31	170	180	O	differences
32	182	185	O	from
33	187	193	O	placebo
34	195	198	O	were
35	200	202	O	not
36	204	215	O	demonstrated
NULL

ZALEPLON	6431	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	23
Studies were also carried out to examine the time course of effects on memory and psychomotor function, and to examine withdrawal phenomena.
1	0	6	O	Studies
2	8	11	O	were
3	13	16	O	also
4	18	24	O	carried
5	26	28	O	out
6	30	31	O	to
7	33	39	O	examine
8	41	43	O	the
9	45	48	O	time
10	50	55	O	course
11	57	58	O	of
12	60	66	O	effects
13	68	69	O	on
14	71	76	O	memory
15	78	80	O	and
16	82	92	O	psychomotor
17	94	101	O	function
18	102	102	O	,
19	104	106	O	and
20	108	109	O	to
21	111	117	O	examine
22	119	128	O	withdrawal
23	130	138	O	phenomena
NULL

ZALEPLON	6432	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	40
Transient Insomnia Normal adults experiencing transient insomnia during the first night in a sleep laboratory were evaluated in a double-blind, parallel-group trial comparing the effects of two doses of Zaleplon (5 mg and 10 mg) with placebo.
1	0	8	O	Transient
2	10	17	O	Insomnia
3	19	24	O	Normal
4	26	31	O	adults
5	33	44	O	experiencing
6	46	54	O	transient
7	56	63	O	insomnia
8	65	70	O	during
9	72	74	O	the
10	76	80	O	first
11	82	86	O	night
12	88	89	O	in
13	91	91	O	a
14	93	97	O	sleep
15	99	108	O	laboratory
16	110	113	O	were
17	115	123	O	evaluated
18	125	126	O	in
19	128	128	O	a
20	130	135	O	double
21	137	141	O	blind
22	142	142	O	,
23	144	151	O	parallel
24	153	157	O	group
25	159	163	O	trial
26	165	173	O	comparing
27	175	177	O	the
28	179	185	O	effects
29	187	188	O	of
30	190	192	O	two
31	194	198	O	doses
32	200	201	O	of
33	203	210	O	XXXXXXXX
34	213	213	O	5
35	215	216	O	mg
36	218	220	O	and
37	222	223	O	10
38	225	226	O	mg
39	229	232	O	with
40	234	240	O	placebo
NULL

ZALEPLON	6433	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	30
Zaleplon 10 mg, but not 5 mg, was superior to placebo in decreasing latency to persistent sleep (LPS), a polysomnographic measure of time to onset of sleep.
1	0	7	O	XXXXXXXX
2	9	10	O	10
3	12	13	O	mg
4	14	14	O	,
5	16	18	O	but
6	20	22	O	not
7	24	24	O	5
8	26	27	O	mg
9	28	28	O	,
10	30	32	O	was
11	34	41	O	superior
12	43	44	O	to
13	46	52	O	placebo
14	54	55	O	in
15	57	66	O	decreasing
16	68	74	O	latency
17	76	77	O	to
18	79	88	O	persistent
19	90	94	O	sleep
20	97	99	O	LPS
21	101	101	O	,
22	103	103	O	a
23	105	120	O	polysomnographic
24	122	128	O	measure
25	130	131	O	of
26	133	136	O	time
27	138	139	O	to
28	141	145	O	onset
29	147	148	O	of
30	150	154	O	sleep
NULL

ZALEPLON	6434	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	68
Chronic Insomnia Non-elderly patients: Adult outpatients with chronic insomnia were evaluated in three double-blind, parallel-group outpatient studies, one of 2 weeks duration and two of 4 weeks duration, that compared the effects of Zaleplon at doses of 5 mg (in two studies), 10 mg, and 20 mg with placebo on a subjective measure of time to sleep onset (TSO).
1	0	6	O	Chronic
2	8	15	O	Insomnia
3	17	19	O	Non
4	21	27	O	elderly
5	29	36	O	patients
6	37	37	O	:
7	39	43	O	Adult
8	45	55	O	outpatients
9	57	60	O	with
10	62	68	O	chronic
11	70	77	O	insomnia
12	79	82	O	were
13	84	92	O	evaluated
14	94	95	O	in
15	97	101	O	three
16	103	108	O	double
17	110	114	O	blind
18	115	115	O	,
19	117	124	O	parallel
20	126	130	O	group
21	132	141	O	outpatient
22	143	149	O	studies
23	150	150	O	,
24	152	154	O	one
25	156	157	O	of
26	159	159	O	2
27	161	165	O	weeks
28	167	174	O	duration
29	176	178	O	and
30	180	182	O	two
31	184	185	O	of
32	187	187	O	4
33	189	193	O	weeks
34	195	202	O	duration
35	203	203	O	,
36	205	208	O	that
37	210	217	O	compared
38	219	221	O	the
39	223	229	O	effects
40	231	232	O	of
41	234	241	O	XXXXXXXX
42	243	244	O	at
43	246	250	O	doses
44	252	253	O	of
45	255	255	O	5
46	257	258	O	mg
47	261	262	O	in
48	264	266	O	two
49	268	274	O	studies
50	276	276	O	,
51	278	279	O	10
52	281	282	O	mg
53	283	283	O	,
54	285	287	O	and
55	289	290	O	20
56	292	293	O	mg
57	295	298	O	with
58	300	306	O	placebo
59	308	309	O	on
60	311	311	O	a
61	313	322	O	subjective
62	324	330	O	measure
63	332	333	O	of
64	335	338	O	time
65	340	341	O	to
66	343	347	O	sleep
67	349	353	O	onset
68	356	358	O	TSO
NULL

ZALEPLON	6435	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	23
Zaleplon 10 mg and 20 mg were consistently superior to placebo for TSO, generally for the full duration of all three studies.
1	0	7	O	XXXXXXXX
2	9	10	O	10
3	12	13	O	mg
4	15	17	O	and
5	19	20	O	20
6	22	23	O	mg
7	25	28	O	were
8	30	41	O	consistently
9	43	50	O	superior
10	52	53	O	to
11	55	61	O	placebo
12	63	65	O	for
13	67	69	O	TSO
14	70	70	O	,
15	72	80	O	generally
16	82	84	O	for
17	86	88	O	the
18	90	93	O	full
19	95	102	O	duration
20	104	105	O	of
21	107	109	O	all
22	111	115	O	three
23	117	123	O	studies
NULL

ZALEPLON	6436	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	18
Although both doses were effective, the effect was greater and more consistent for the 20-mg dose.
1	0	7	O	Although
2	9	12	O	both
3	14	18	O	doses
4	20	23	O	were
5	25	33	O	effective
6	34	34	O	,
7	36	38	O	the
8	40	45	O	effect
9	47	49	O	was
10	51	57	O	greater
11	59	61	O	and
12	63	66	O	more
13	68	77	O	consistent
14	79	81	O	for
15	83	85	O	the
16	87	88	O	20
17	90	91	O	mg
18	93	96	O	dose
NULL

ZALEPLON	6437	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	17
The 5-mg dose was less consistently effective than were the 10-mg and 20-mg doses.
1	0	2	O	The
2	4	4	O	5
3	6	7	O	mg
4	9	12	O	dose
5	14	16	O	was
6	18	21	O	less
7	23	34	O	consistently
8	36	44	O	effective
9	46	49	O	than
10	51	54	O	were
11	56	58	O	the
12	60	61	O	10
13	63	64	O	mg
14	66	68	O	and
15	70	71	O	20
16	73	74	O	mg
17	76	80	O	doses
NULL

ZALEPLON	6438	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	26
Sleep latency with Zaleplon 10 mg and 20 mg was on the order of 10-20 minutes (15%-30%) less than with placebo in these studies.
1	0	4	O	Sleep
2	6	12	O	latency
3	14	17	O	with
4	19	26	O	XXXXXXXX
5	28	29	O	10
6	31	32	O	mg
7	34	36	O	and
8	38	39	O	20
9	41	42	O	mg
10	44	46	O	was
11	48	49	O	on
12	51	53	O	the
13	55	59	O	order
14	61	62	O	of
15	64	65	O	10
16	67	68	O	20
17	70	76	O	minutes
18	79	81	O	15%
19	83	85	O	30%
20	88	91	O	less
21	93	96	O	than
22	98	101	O	with
23	103	109	O	placebo
24	111	112	O	in
25	114	118	O	these
26	120	126	O	studies
NULL

ZALEPLON	6439	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	29
Adult outpatients with chronic insomnia were evaluated in six double-blind, parallel-group sleep laboratory studies that varied in duration from a single night up to 35 nights.
1	0	4	O	Adult
2	6	16	O	outpatients
3	18	21	O	with
4	23	29	O	chronic
5	31	38	O	insomnia
6	40	43	O	were
7	45	53	O	evaluated
8	55	56	O	in
9	58	60	O	six
10	62	67	O	double
11	69	73	O	blind
12	74	74	O	,
13	76	83	O	parallel
14	85	89	O	group
15	91	95	O	sleep
16	97	106	O	laboratory
17	108	114	O	studies
18	116	119	O	that
19	121	126	O	varied
20	128	129	O	in
21	131	138	O	duration
22	140	143	O	from
23	145	145	O	a
24	147	152	O	single
25	154	158	O	night
26	160	161	O	up
27	163	164	O	to
28	166	167	O	35
29	169	174	O	nights
NULL

ZALEPLON	6440	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	26
Overall, these studies demonstrated a superiority of Zaleplon 10 mg and 20 mg over placebo in reducing LPS on the first 2 nights of treatment.
1	0	6	O	Overall
2	7	7	O	,
3	9	13	O	these
4	15	21	O	studies
5	23	34	O	demonstrated
6	36	36	O	a
7	38	48	O	superiority
8	50	51	O	of
9	53	60	O	XXXXXXXX
10	62	63	O	10
11	65	66	O	mg
12	68	70	O	and
13	72	73	O	20
14	75	76	O	mg
15	78	81	O	over
16	83	89	O	placebo
17	91	92	O	in
18	94	101	O	reducing
19	103	105	O	LPS
20	107	108	O	on
21	110	112	O	the
22	114	118	O	first
23	120	120	O	2
24	122	127	O	nights
25	129	130	O	of
26	132	140	O	treatment
NULL

ZALEPLON	6441	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	48
At later time points in 5-, 14-, and 28-night studies, a reduction in LPS from baseline was observed for all treatment groups, including the placebo group, and thus, a significant difference between Zaleplon and placebo was not seen beyond 2 nights.
1	0	1	O	At
2	3	7	O	later
3	9	12	O	time
4	14	19	O	points
5	21	22	O	in
6	24	24	O	5
7	26	26	O	,
8	28	29	O	14
9	31	31	O	,
10	33	35	O	and
11	37	38	O	28
12	40	44	O	night
13	46	52	O	studies
14	53	53	O	,
15	55	55	O	a
16	57	65	O	reduction
17	67	68	O	in
18	70	72	O	LPS
19	74	77	O	from
20	79	86	O	baseline
21	88	90	O	was
22	92	99	O	observed
23	101	103	O	for
24	105	107	O	all
25	109	117	O	treatment
26	119	124	O	groups
27	125	125	O	,
28	127	135	O	including
29	137	139	O	the
30	141	147	O	placebo
31	149	153	O	group
32	154	154	O	,
33	156	158	O	and
34	160	163	O	thus
35	164	164	O	,
36	166	166	O	a
37	168	178	O	significant
38	180	189	O	difference
39	191	197	O	between
40	199	206	O	XXXXXXXX
41	208	210	O	and
42	212	218	O	placebo
43	220	222	O	was
44	224	226	O	not
45	228	231	O	seen
46	233	238	O	beyond
47	240	240	O	2
48	242	247	O	nights
NULL

ZALEPLON	6442	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
In a 35-night study, Zaleplon 10 mg was significantly more effective than placebo in reducing LPS at the primary efficacy endpoint on nights 29 and 30.
1	0	1	O	In
2	3	3	O	a
3	5	6	O	35
4	8	12	O	night
5	14	18	O	study
6	19	19	O	,
7	21	28	O	XXXXXXXX
8	30	31	O	10
9	33	34	O	mg
10	36	38	O	was
11	40	52	O	significantly
12	54	57	O	more
13	59	67	O	effective
14	69	72	O	than
15	74	80	O	placebo
16	82	83	O	in
17	85	92	O	reducing
18	94	96	O	LPS
19	98	99	O	at
20	101	103	O	the
21	105	111	O	primary
22	113	120	O	efficacy
23	122	129	O	endpoint
24	131	132	O	on
25	134	139	O	nights
26	141	142	O	29
27	144	146	O	and
28	148	149	O	30
NULL

ZALEPLON	6443	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	45
Elderly patients: Elderly outpatients with chronic insomnia were evaluated in two 2-week, double-blind, parallel-group outpatient studies that compared the effects of Zaleplon 5 mg and 10 mg with placebo on a subjective measure of time to sleep onset (TSO).
1	0	6	O	Elderly
2	8	15	O	patients
3	16	16	O	:
4	18	24	O	Elderly
5	26	36	O	outpatients
6	38	41	O	with
7	43	49	O	chronic
8	51	58	O	insomnia
9	60	63	O	were
10	65	73	O	evaluated
11	75	76	O	in
12	78	80	O	two
13	82	82	O	2
14	84	87	O	week
15	88	88	O	,
16	90	95	O	double
17	97	101	O	blind
18	102	102	O	,
19	104	111	O	parallel
20	113	117	O	group
21	119	128	O	outpatient
22	130	136	O	studies
23	138	141	O	that
24	143	150	O	compared
25	152	154	O	the
26	156	162	O	effects
27	164	165	O	of
28	167	174	O	XXXXXXXX
29	176	176	O	5
30	178	179	O	mg
31	181	183	O	and
32	185	186	O	10
33	188	189	O	mg
34	191	194	O	with
35	196	202	O	placebo
36	204	205	O	on
37	207	207	O	a
38	209	218	O	subjective
39	220	226	O	measure
40	228	229	O	of
41	231	234	O	time
42	236	237	O	to
43	239	243	O	sleep
44	245	249	O	onset
45	252	254	O	TSO
NULL

ZALEPLON	6444	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	32
Zaleplon at both doses was superior to placebo on TSO, generally for the full duration of both studies, with an effect size generally similar to that seen in younger persons.
1	0	7	O	XXXXXXXX
2	9	10	O	at
3	12	15	O	both
4	17	21	O	doses
5	23	25	O	was
6	27	34	O	superior
7	36	37	O	to
8	39	45	O	placebo
9	47	48	O	on
10	50	52	O	TSO
11	53	53	O	,
12	55	63	O	generally
13	65	67	O	for
14	69	71	O	the
15	73	76	O	full
16	78	85	O	duration
17	87	88	O	of
18	90	93	O	both
19	95	101	O	studies
20	102	102	O	,
21	104	107	O	with
22	109	110	O	an
23	112	117	O	effect
24	119	122	O	size
25	124	132	O	generally
26	134	140	O	similar
27	142	143	O	to
28	145	148	O	that
29	150	153	O	seen
30	155	156	O	in
31	158	164	O	younger
32	166	172	O	persons
NULL

ZALEPLON	6445	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	13
The 10-mg dose tended to have a greater effect in reducing TSO.
1	0	2	O	The
2	4	5	O	10
3	7	8	O	mg
4	10	13	O	dose
5	15	20	O	tended
6	22	23	O	to
7	25	28	O	have
8	30	30	O	a
9	32	38	O	greater
10	40	45	O	effect
11	47	48	O	in
12	50	57	O	reducing
13	59	61	O	TSO
NULL

ZALEPLON	6446	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	23
Elderly outpatients with chronic insomnia were also evaluated in a 2-night sleep laboratory study involving doses of 5 mg and 10 mg.
1	0	6	O	Elderly
2	8	18	O	outpatients
3	20	23	O	with
4	25	31	O	chronic
5	33	40	O	insomnia
6	42	45	O	were
7	47	50	O	also
8	52	60	O	evaluated
9	62	63	O	in
10	65	65	O	a
11	67	67	O	2
12	69	73	O	night
13	75	79	O	sleep
14	81	90	O	laboratory
15	92	96	O	study
16	98	106	O	involving
17	108	112	O	doses
18	114	115	O	of
19	117	117	O	5
20	119	120	O	mg
21	122	124	O	and
22	126	127	O	10
23	129	130	O	mg
NULL

ZALEPLON	6447	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	20
Both 5-mg and 10-mg doses of Zaleplon were superior to placebo in reducing latency to persistent sleep (LPS).
1	0	3	O	Both
2	5	5	O	5
3	7	8	O	mg
4	10	12	O	and
5	14	15	O	10
6	17	18	O	mg
7	20	24	O	doses
8	26	27	O	of
9	29	36	O	XXXXXXXX
10	38	41	O	were
11	43	50	O	superior
12	52	53	O	to
13	55	61	O	placebo
14	63	64	O	in
15	66	73	O	reducing
16	75	81	O	latency
17	83	84	O	to
18	86	95	O	persistent
19	97	101	O	sleep
20	104	106	O	LPS
NULL

ZALEPLON	6448	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	40
Generally in these studies, there was a slight increase in sleep duration, compared to baseline, for all treatment groups, including placebo, and thus, a significant difference from placebo on sleep duration was not demonstrated.
1	0	8	O	Generally
2	10	11	O	in
3	13	17	O	these
4	19	25	O	studies
5	26	26	O	,
6	28	32	O	there
7	34	36	O	was
8	38	38	O	a
9	40	45	O	slight
10	47	54	O	increase
11	56	57	O	in
12	59	63	O	sleep
13	65	72	O	duration
14	73	73	O	,
15	75	82	O	compared
16	84	85	O	to
17	87	94	O	baseline
18	95	95	O	,
19	97	99	O	for
20	101	103	O	all
21	105	113	O	treatment
22	115	120	O	groups
23	121	121	O	,
24	123	131	O	including
25	133	139	O	placebo
26	140	140	O	,
27	142	144	O	and
28	146	149	O	thus
29	150	150	O	,
30	152	152	O	a
31	154	164	O	significant
32	166	175	O	difference
33	177	180	O	from
34	182	188	O	placebo
35	190	191	O	on
36	193	197	O	sleep
37	199	206	O	duration
38	208	210	O	was
39	212	214	O	not
40	216	227	O	demonstrated
NULL

ZALEPLON	6449	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	96
Studies Pertinent to Safety Concerns for Sedative/Hypnotic Drugs Memory Impairment Studies involving the exposure of normal subjects to single fixed doses of Zaleplon (10 mg or 20 mg) with structured assessments of short-term memory at fixed times after dosing (eg, 1, 2, 3, 4, 5, 8, and 10 hours) generally revealed the expected impairment of short-term memory at 1 hour, the time of peak exposure to zaleplon, for both doses, with a tendency for the effect to be greater after 20 mg.
1	0	6	O	Studies
2	8	16	O	Pertinent
3	18	19	O	to
4	21	26	O	Safety
5	28	35	O	Concerns
6	37	39	O	for
7	41	48	O	Sedative
8	49	49	O	/
9	50	57	O	Hypnotic
10	59	63	O	Drugs
11	65	70	O	Memory
12	72	81	O	Impairment
13	83	89	O	Studies
14	91	99	O	involving
15	101	103	O	the
16	105	112	O	exposure
17	114	115	O	of
18	117	122	O	normal
19	124	131	O	subjects
20	133	134	O	to
21	136	141	O	single
22	143	147	O	fixed
23	149	153	O	doses
24	155	156	O	of
25	158	165	O	XXXXXXXX
26	168	169	O	10
27	171	172	O	mg
28	174	175	O	or
29	177	178	O	20
30	180	181	O	mg
31	184	187	O	with
32	189	198	O	structured
33	200	210	O	assessments
34	212	213	O	of
35	215	219	O	short
36	221	224	O	term
37	226	231	O	memory
38	233	234	O	at
39	236	240	O	fixed
40	242	246	O	times
41	248	252	O	after
42	254	259	O	dosing
43	262	263	O	eg
44	264	264	O	,
45	266	266	O	1
46	267	267	O	,
47	269	269	O	2
48	270	270	O	,
49	272	272	O	3
50	273	273	O	,
51	275	275	O	4
52	276	276	O	,
53	278	278	O	5
54	279	279	O	,
55	281	281	O	8
56	282	282	O	,
57	284	286	O	and
58	288	289	O	10
59	291	295	O	hours
60	298	306	O	generally
61	308	315	O	revealed
62	317	319	O	the
63	321	328	O	expected
64	330	339	O	impairment
65	341	342	O	of
66	344	348	O	short
67	350	353	O	term
68	355	360	O	memory
69	362	363	O	at
70	365	365	O	1
71	367	370	O	hour
72	371	371	O	,
73	373	375	O	the
74	377	380	O	time
75	382	383	O	of
76	385	388	O	peak
77	390	397	O	exposure
78	399	400	O	to
79	402	409	O	XXXXXXXX
80	410	410	O	,
81	412	414	O	for
82	416	419	O	both
83	421	425	O	doses
84	426	426	O	,
85	428	431	O	with
86	433	433	O	a
87	435	442	O	tendency
88	444	446	O	for
89	448	450	O	the
90	452	457	O	effect
91	459	460	O	to
92	462	463	O	be
93	465	471	O	greater
94	473	477	O	after
95	479	480	O	20
96	482	483	O	mg
NULL

ZALEPLON	6450	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	35
Consistent with the rapid clearance of zaleplon, memory impairment was no longer present as early as 2 hours post dosing in one study, and in none of the studies after 3-4 hours.
1	0	9	O	Consistent
2	11	14	O	with
3	16	18	O	the
4	20	24	O	rapid
5	26	34	O	clearance
6	36	37	O	of
7	39	46	O	XXXXXXXX
8	47	47	O	,
9	49	54	O	memory
10	56	65	O	impairment
11	67	69	O	was
12	71	72	O	no
13	74	79	O	longer
14	81	87	O	present
15	89	90	O	as
16	92	96	O	early
17	98	99	O	as
18	101	101	O	2
19	103	107	O	hours
20	109	112	O	post
21	114	119	O	dosing
22	121	122	O	in
23	124	126	O	one
24	128	132	O	study
25	133	133	O	,
26	135	137	O	and
27	139	140	O	in
28	142	145	O	none
29	147	148	O	of
30	150	152	O	the
31	154	160	O	studies
32	162	166	O	after
33	168	168	O	3
34	170	170	O	4
35	172	176	O	hours
NULL

ZALEPLON	6451	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	38
Nevertheless, spontaneous reporting of adverse events in larger premarketing clinical trials revealed a difference between Zaleplon and placebo in the risk of next-day amnesia (3% vs 1%), and an apparent dose-dependency for this event.
1	0	11	O	Nevertheless
2	12	12	O	,
3	14	24	O	spontaneous
4	26	34	O	reporting
5	36	37	O	of
6	39	45	O	adverse
7	47	52	O	events
8	54	55	O	in
9	57	62	O	larger
10	64	75	O	premarketing
11	77	84	O	clinical
12	86	91	O	trials
13	93	100	O	revealed
14	102	102	O	a
15	104	113	O	difference
16	115	121	O	between
17	123	130	O	XXXXXXXX
18	132	134	O	and
19	136	142	O	placebo
20	144	145	O	in
21	147	149	O	the
22	151	154	O	risk
23	156	157	O	of
24	159	162	O	next
25	164	166	O	day
26	168	174	O	amnesia
27	177	178	O	3%
28	180	181	O	vs
29	183	184	O	1%
30	186	186	O	,
31	188	190	O	and
32	192	193	O	an
33	195	202	O	apparent
34	204	207	O	dose
35	209	218	O	dependency
36	220	222	O	for
37	224	227	O	this
38	229	233	O	event
NULL

ZALEPLON	6452	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	86
Sedative/Psychomotor Effects Studies involving the exposure of normal subjects to single fixed doses of Zaleplon (10 mg or 20 mg) with structured assessments of sedation and psychomotor function (eg, reaction time and subjective ratings of alertness) at fixed times after dosing (eg, 1, 2, 3, 4, 5, 8, and 10 hours) generally revealed the expected sedation and impairment of psychomotor function at 1 hour, the time of peak exposure to zaleplon, for both doses.
1	0	7	O	Sedative
2	8	8	O	/
3	9	19	O	Psychomotor
4	21	27	O	Effects
5	29	35	O	Studies
6	37	45	O	involving
7	47	49	O	the
8	51	58	O	exposure
9	60	61	O	of
10	63	68	O	normal
11	70	77	O	subjects
12	79	80	O	to
13	82	87	O	single
14	89	93	O	fixed
15	95	99	O	doses
16	101	102	O	of
17	104	111	O	XXXXXXXX
18	114	115	O	10
19	117	118	O	mg
20	120	121	O	or
21	123	124	O	20
22	126	127	O	mg
23	130	133	O	with
24	135	144	O	structured
25	146	156	O	assessments
26	158	159	O	of
27	161	168	O	sedation
28	170	172	O	and
29	174	184	O	psychomotor
30	186	193	O	function
31	196	197	O	eg
32	198	198	O	,
33	200	207	O	reaction
34	209	212	O	time
35	214	216	O	and
36	218	227	O	subjective
37	229	235	O	ratings
38	237	238	O	of
39	240	248	O	alertness
40	251	252	O	at
41	254	258	O	fixed
42	260	264	O	times
43	266	270	O	after
44	272	277	O	dosing
45	280	281	O	eg
46	282	282	O	,
47	284	284	O	1
48	285	285	O	,
49	287	287	O	2
50	288	288	O	,
51	290	290	O	3
52	291	291	O	,
53	293	293	O	4
54	294	294	O	,
55	296	296	O	5
56	297	297	O	,
57	299	299	O	8
58	300	300	O	,
59	302	304	O	and
60	306	307	O	10
61	309	313	O	hours
62	316	324	O	generally
63	326	333	O	revealed
64	335	337	O	the
65	339	346	O	expected
66	348	355	O	sedation
67	357	359	O	and
68	361	370	O	impairment
69	372	373	O	of
70	375	385	O	psychomotor
71	387	394	O	function
72	396	397	O	at
73	399	399	O	1
74	401	404	O	hour
75	405	405	O	,
76	407	409	O	the
77	411	414	O	time
78	416	417	O	of
79	419	422	O	peak
80	424	431	O	exposure
81	433	434	O	to
82	436	443	O	XXXXXXXX
83	444	444	O	,
84	446	448	O	for
85	450	453	O	both
86	455	459	O	doses
NULL

ZALEPLON	6453	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	37
Consistent with the rapid clearance of zaleplon, impairment of psychomotor function was no longer present as early as 2 hours post dosing in one study, and in none of the studies after 3-4 hours.
1	0	9	O	Consistent
2	11	14	O	with
3	16	18	O	the
4	20	24	O	rapid
5	26	34	O	clearance
6	36	37	O	of
7	39	46	O	XXXXXXXX
8	47	47	O	,
9	49	58	O	impairment
10	60	61	O	of
11	63	73	O	psychomotor
12	75	82	O	function
13	84	86	O	was
14	88	89	O	no
15	91	96	O	longer
16	98	104	O	present
17	106	107	O	as
18	109	113	O	early
19	115	116	O	as
20	118	118	O	2
21	120	124	O	hours
22	126	129	O	post
23	131	136	O	dosing
24	138	139	O	in
25	141	143	O	one
26	145	149	O	study
27	150	150	O	,
28	152	154	O	and
29	156	157	O	in
30	159	162	O	none
31	164	165	O	of
32	167	169	O	the
33	171	177	O	studies
34	179	183	O	after
35	185	185	O	3
36	187	187	O	4
37	189	193	O	hours
NULL

ZALEPLON	6454	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	26
Spontaneous reporting of adverse events in larger premarketing clinical trials did not suggest a difference between Zaleplon and placebo in the risk of next-day somnolence.
1	0	10	O	Spontaneous
2	12	20	O	reporting
3	22	23	O	of
4	25	31	O	adverse
5	33	38	O	events
6	40	41	O	in
7	43	48	O	larger
8	50	61	O	premarketing
9	63	70	O	clinical
10	72	77	O	trials
11	79	81	O	did
12	83	85	O	not
13	87	93	O	suggest
14	95	95	O	a
15	97	106	O	difference
16	108	114	O	between
17	116	123	O	XXXXXXXX
18	125	127	O	and
19	129	135	O	placebo
20	137	138	O	in
21	140	142	O	the
22	144	147	O	risk
23	149	150	O	of
24	152	155	O	next
25	157	159	O	day
26	161	170	O	somnolence
NULL

ZALEPLON	6455	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	24
Withdrawal-Emergent Anxiety and Insomnia During nightly use for an extended period, pharmacodynamic tolerance or adaptation to some effects of hypnotics may develop.
1	0	9	O	Withdrawal
2	11	18	O	Emergent
3	20	26	O	Anxiety
4	28	30	O	and
5	32	39	O	Insomnia
6	41	46	O	During
7	48	54	O	nightly
8	56	58	O	use
9	60	62	O	for
10	64	65	O	an
11	67	74	O	extended
12	76	81	O	period
13	82	82	O	,
14	84	98	O	pharmacodynamic
15	100	108	O	tolerance
16	110	111	O	or
17	113	122	O	adaptation
18	124	125	O	to
19	127	130	O	some
20	132	138	O	effects
21	140	141	O	of
22	143	151	O	hypnotics
23	153	155	O	may
24	157	163	O	develop
NULL

ZALEPLON	6456	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	44
If the drug has a short elimination half-life, it is possible that a relative deficiency of the drug or its active metabolites (ie, in relationship to the receptor site) may occur at some point in the interval between each night's use.
1	0	1	O	If
2	3	5	O	the
3	7	10	O	drug
4	12	14	O	has
5	16	16	O	a
6	18	22	O	short
7	24	34	O	elimination
8	36	39	O	half
9	41	44	O	life
10	45	45	O	,
11	47	48	O	it
12	50	51	O	is
13	53	60	O	possible
14	62	65	O	that
15	67	67	O	a
16	69	76	O	relative
17	78	87	O	deficiency
18	89	90	O	of
19	92	94	O	the
20	96	99	O	drug
21	101	102	O	or
22	104	106	O	its
23	108	113	O	active
24	115	125	O	metabolites
25	128	129	O	ie
26	130	130	O	,
27	132	133	O	in
28	135	146	O	relationship
29	148	149	O	to
30	151	153	O	the
31	155	162	O	receptor
32	164	167	O	site
33	170	172	O	may
34	174	178	O	occur
35	180	181	O	at
36	183	186	O	some
37	188	192	O	point
38	194	195	O	in
39	197	199	O	the
40	201	208	O	interval
41	210	216	O	between
42	218	221	O	each
43	223	229	O	night's
44	231	233	O	use
NULL

ZALEPLON	6457	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	46
This sequence of events is believed to be responsible for two clinical findings reported to occur after several weeks of nightly use of other rapidly eliminated hypnotics: increased wakefulness during the last quarter of the night and the appearance of increased signs of daytime anxiety.
1	0	3	O	This
2	5	12	O	sequence
3	14	15	O	of
4	17	22	O	events
5	24	25	O	is
6	27	34	O	believed
7	36	37	O	to
8	39	40	O	be
9	42	52	O	responsible
10	54	56	O	for
11	58	60	O	two
12	62	69	O	clinical
13	71	78	O	findings
14	80	87	O	reported
15	89	90	O	to
16	92	96	O	occur
17	98	102	O	after
18	104	110	O	several
19	112	116	O	weeks
20	118	119	O	of
21	121	127	O	nightly
22	129	131	O	use
23	133	134	O	of
24	136	140	O	other
25	142	148	O	rapidly
26	150	159	O	eliminated
27	161	169	O	hypnotics
28	170	170	O	:
29	172	180	O	increased
30	182	192	O	wakefulness
31	194	199	O	during
32	201	203	O	the
33	205	208	O	last
34	210	216	O	quarter
35	218	219	O	of
36	221	223	O	the
37	225	229	O	night
38	231	233	O	and
39	235	237	O	the
40	239	248	O	appearance
41	250	251	O	of
42	253	261	O	increased
43	263	267	O	signs
44	269	270	O	of
45	272	278	O	daytime
46	280	286	O	anxiety
NULL

ZALEPLON	6458	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	10
Zaleplon has a short half-life and no active metabolites.
1	0	7	O	XXXXXXXX
2	9	11	O	has
3	13	13	O	a
4	15	19	O	short
5	21	24	O	half
6	26	29	O	life
7	31	33	O	and
8	35	36	O	no
9	38	43	O	active
10	45	55	O	metabolites
NULL

ZALEPLON	6459	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	38
At the primary efficacy endpoint (nights 29 and 30) in a 35-night sleep laboratory study, polysomnographic recordings showed that wakefulness was not significantly longer with Zaleplon than with placebo during the last quarter of the night.
1	0	1	O	At
2	3	5	O	the
3	7	13	O	primary
4	15	22	O	efficacy
5	24	31	O	endpoint
6	34	39	O	nights
7	41	42	O	29
8	44	46	O	and
9	48	49	O	30
10	52	53	O	in
11	55	55	O	a
12	57	58	O	35
13	60	64	O	night
14	66	70	O	sleep
15	72	81	O	laboratory
16	83	87	O	study
17	88	88	O	,
18	90	105	O	polysomnographic
19	107	116	O	recordings
20	118	123	O	showed
21	125	128	O	that
22	130	140	O	wakefulness
23	142	144	O	was
24	146	148	O	not
25	150	162	O	significantly
26	164	169	O	longer
27	171	174	O	with
28	176	183	O	XXXXXXXX
29	185	188	O	than
30	190	193	O	with
31	195	201	O	placebo
32	203	208	O	during
33	210	212	O	the
34	214	217	O	last
35	219	225	O	quarter
36	227	228	O	of
37	230	232	O	the
38	234	238	O	night
NULL

ZALEPLON	6460	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	15
No increase in the signs of daytime anxiety was observed in clinical trials with Zaleplon.
1	0	1	O	No
2	3	10	O	increase
3	12	13	O	in
4	15	17	O	the
5	19	23	O	signs
6	25	26	O	of
7	28	34	O	daytime
8	36	42	O	anxiety
9	44	46	O	was
10	48	55	O	observed
11	57	58	O	in
12	60	67	O	clinical
13	69	74	O	trials
14	76	79	O	with
15	81	88	O	XXXXXXXX
NULL

ZALEPLON	6461	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	44
In two sleep laboratory studies involving 14- and 28-nightly doses of Zaleplon (5 mg and 10 mg in one study and 10 mg and 20 mg in the second) and structured assessments of daytime anxiety, no increases in daytime anxiety were detected.
1	0	1	O	In
2	3	5	O	two
3	7	11	O	sleep
4	13	22	O	laboratory
5	24	30	O	studies
6	32	40	O	involving
7	42	43	O	14
8	46	48	O	and
9	50	51	O	28
10	53	59	O	nightly
11	61	65	O	doses
12	67	68	O	of
13	70	77	O	XXXXXXXX
14	80	80	O	5
15	82	83	O	mg
16	85	87	O	and
17	89	90	O	10
18	92	93	O	mg
19	95	96	O	in
20	98	100	O	one
21	102	106	O	study
22	108	110	O	and
23	112	113	O	10
24	115	116	O	mg
25	118	120	O	and
26	122	123	O	20
27	125	126	O	mg
28	128	129	O	in
29	131	133	O	the
30	135	140	O	second
31	143	145	O	and
32	147	156	O	structured
33	158	168	O	assessments
34	170	171	O	of
35	173	179	O	daytime
36	181	187	O	anxiety
37	188	188	O	,
38	190	191	O	no
39	193	201	O	increases
40	203	204	O	in
41	206	212	O	daytime
42	214	220	O	anxiety
43	222	225	O	were
44	227	234	O	detected
NULL

ZALEPLON	6462	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
Similarly, in a pooled analysis (all the parallel-group, placebo-controlled studies) of spontaneously reported daytime anxiety, no difference was observed between Zaleplon and placebo.
1	0	8	O	Similarly
2	9	9	O	,
3	11	12	O	in
4	14	14	O	a
5	16	21	O	pooled
6	23	30	O	analysis
7	33	35	O	all
8	37	39	O	the
9	41	48	O	parallel
10	50	54	O	group
11	55	55	O	,
12	57	63	O	placebo
13	65	74	O	controlled
14	76	82	O	studies
15	85	86	O	of
16	88	100	O	spontaneously
17	102	109	O	reported
18	111	117	O	daytime
19	119	125	O	anxiety
20	126	126	O	,
21	128	129	O	no
22	131	140	O	difference
23	142	144	O	was
24	146	153	O	observed
25	155	161	O	between
26	163	170	O	XXXXXXXX
27	172	174	O	and
28	176	182	O	placebo
NULL

ZALEPLON	6463	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	39
Rebound insomnia, defined as a dose-dependent temporary worsening in sleep parameters (latency, total sleep time, and number of awakenings) compared to baseline following discontinuation of treatment, is observed with short- and intermediate-acting hypnotics.
1	0	6	O	Rebound
2	8	15	O	insomnia
3	16	16	O	,
4	18	24	O	defined
5	26	27	O	as
6	29	29	O	a
7	31	34	O	dose
8	36	44	O	dependent
9	46	54	O	temporary
10	56	64	O	worsening
11	66	67	O	in
12	69	73	O	sleep
13	75	84	O	parameters
14	87	93	O	latency
15	94	94	O	,
16	96	100	O	total
17	102	106	O	sleep
18	108	111	O	time
19	112	112	O	,
20	114	116	O	and
21	118	123	O	number
22	125	126	O	of
23	128	137	O	awakenings
24	140	147	O	compared
25	149	150	O	to
26	152	159	O	baseline
27	161	169	O	following
28	171	185	O	discontinuation
29	187	188	O	of
30	190	198	O	treatment
31	199	199	O	,
32	201	202	O	is
33	204	211	O	observed
34	213	216	O	with
35	218	222	O	short
36	225	227	O	and
37	229	240	O	intermediate
38	242	247	O	acting
39	249	257	O	hypnotics
NULL

ZALEPLON	6464	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	42
Rebound insomnia following discontinuation of Zaleplon relative to baseline was examined at both nights 1 and 2 following discontinuation in three sleep laboratory studies (14, 28, and 35 nights) and five outpatient studies utilizing patient diaries (14 and 28 nights).
1	0	6	O	Rebound
2	8	15	O	insomnia
3	17	25	O	following
4	27	41	O	discontinuation
5	43	44	O	of
6	46	53	O	XXXXXXXX
7	55	62	O	relative
8	64	65	O	to
9	67	74	O	baseline
10	76	78	O	was
11	80	87	O	examined
12	89	90	O	at
13	92	95	O	both
14	97	102	O	nights
15	104	104	O	1
16	106	108	O	and
17	110	110	O	2
18	112	120	O	following
19	122	136	O	discontinuation
20	138	139	O	in
21	141	145	O	three
22	147	151	O	sleep
23	153	162	O	laboratory
24	164	170	O	studies
25	173	174	O	14
26	175	175	O	,
27	177	178	O	28
28	179	179	O	,
29	181	183	O	and
30	185	186	O	35
31	188	193	O	nights
32	196	198	O	and
33	200	203	O	five
34	205	214	O	outpatient
35	216	222	O	studies
36	224	232	O	utilizing
37	234	240	O	patient
38	242	248	O	diaries
39	251	252	O	14
40	254	256	O	and
41	258	259	O	28
42	261	266	O	nights
NULL

ZALEPLON	6465	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	12
Overall, the data suggest that rebound insomnia may be dose dependent.
1	0	6	O	Overall
2	7	7	O	,
3	9	11	O	the
4	13	16	O	data
5	18	24	O	suggest
6	26	29	O	that
7	31	37	O	rebound
8	39	46	O	insomnia
9	48	50	O	may
10	52	53	O	be
11	55	58	O	dose
12	60	68	O	dependent
NULL

ZALEPLON	6466	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
At 20 mg, there appeared to be both objective (polysomnographic) and subjective (diary) evidence of rebound insomnia on the first night after discontinuation of treatment with Zaleplon.
1	0	1	O	At
2	3	4	O	20
3	6	7	O	mg
4	8	8	O	,
5	10	14	O	there
6	16	23	O	appeared
7	25	26	O	to
8	28	29	O	be
9	31	34	O	both
10	36	44	O	objective
11	47	62	O	polysomnographic
12	65	67	O	and
13	69	78	O	subjective
14	81	85	O	diary
15	88	95	O	evidence
16	97	98	O	of
17	100	106	O	rebound
18	108	115	O	insomnia
19	117	118	O	on
20	120	122	O	the
21	124	128	O	first
22	130	134	O	night
23	136	140	O	after
24	142	156	O	discontinuation
25	158	159	O	of
26	161	169	O	treatment
27	171	174	O	with
28	176	183	O	XXXXXXXX
NULL

ZALEPLON	6467	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	28
At 5 mg and 10 mg, there was no objective and minimal subjective evidence of rebound insomnia on the first night after discontinuation of treatment with Zaleplon.
1	0	1	O	At
2	3	3	O	5
3	5	6	O	mg
4	8	10	O	and
5	12	13	O	10
6	15	16	O	mg
7	17	17	O	,
8	19	23	O	there
9	25	27	O	was
10	29	30	O	no
11	32	40	O	objective
12	42	44	O	and
13	46	52	O	minimal
14	54	63	O	subjective
15	65	72	O	evidence
16	74	75	O	of
17	77	83	O	rebound
18	85	92	O	insomnia
19	94	95	O	on
20	97	99	O	the
21	101	105	O	first
22	107	111	O	night
23	113	117	O	after
24	119	133	O	discontinuation
25	135	136	O	of
26	138	146	O	treatment
27	148	151	O	with
28	153	160	O	XXXXXXXX
NULL

ZALEPLON	6468	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	16
At all doses, the rebound effect appeared to resolve by the second night following withdrawal.
1	0	1	O	At
2	3	5	O	all
3	7	11	O	doses
4	12	12	O	,
5	14	16	O	the
6	18	24	O	rebound
7	26	31	O	effect
8	33	40	O	appeared
9	42	43	O	to
10	45	51	O	resolve
11	53	54	O	by
12	56	58	O	the
13	60	65	O	second
14	67	71	O	night
15	73	81	O	following
16	83	92	O	withdrawal
NULL

ZALEPLON	6469	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	34
In the 35-night study, there was a worsening in sleep on the first night off for both the 10-mg and 20-mg groups compared to placebo, but not to baseline.
1	0	1	O	In
2	3	5	O	the
3	7	8	O	35
4	10	14	O	night
5	16	20	O	study
6	21	21	O	,
7	23	27	O	there
8	29	31	O	was
9	33	33	O	a
10	35	43	O	worsening
11	45	46	O	in
12	48	52	O	sleep
13	54	55	O	on
14	57	59	O	the
15	61	65	O	first
16	67	71	O	night
17	73	75	O	off
18	77	79	O	for
19	81	84	O	both
20	86	88	O	the
21	90	91	O	10
22	93	94	O	mg
23	96	98	O	and
24	100	101	O	20
25	103	104	O	mg
26	106	111	O	groups
27	113	120	O	compared
28	122	123	O	to
29	125	131	O	placebo
30	132	132	O	,
31	134	136	O	but
32	138	140	O	not
33	142	143	O	to
34	145	152	O	baseline
NULL

ZALEPLON	6470	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	31
This discontinuation-emergent effect was mild, had the characteristics of the return of the symptoms of chronic insomnia, and appeared to resolve by the second night after zaleplon discontinuation.
1	0	3	O	This
2	5	19	O	discontinuation
3	21	28	O	emergent
4	30	35	O	effect
5	37	39	O	was
6	41	44	O	mild
7	45	45	O	,
8	47	49	O	had
9	51	53	O	the
10	55	69	O	characteristics
11	71	72	O	of
12	74	76	O	the
13	78	83	O	return
14	85	86	O	of
15	88	90	O	the
16	92	99	O	symptoms
17	101	102	O	of
18	104	110	O	chronic
19	112	119	O	insomnia
20	120	120	O	,
21	122	124	O	and
22	126	133	O	appeared
23	135	136	O	to
24	138	144	O	resolve
25	146	147	O	by
26	149	151	O	the
27	153	158	O	second
28	160	164	O	night
29	166	170	O	after
30	172	179	O	XXXXXXXX
31	181	195	O	discontinuation
NULL

ZALEPLON	6471	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	42
Other Withdrawal-Emergent Phenomena The potential for other withdrawal phenomena was also assessed in 14- to 28-night studies, including both the sleep laboratory studies and the outpatient studies, and in open-label studies of 6- and 12-month durations.
1	0	4	O	Other
2	6	15	O	Withdrawal
3	17	24	O	Emergent
4	26	34	O	Phenomena
5	36	38	O	The
6	40	48	O	potential
7	50	52	O	for
8	54	58	O	other
9	60	69	O	withdrawal
10	71	79	O	phenomena
11	81	83	O	was
12	85	88	O	also
13	90	97	O	assessed
14	99	100	O	in
15	102	103	O	14
16	106	107	O	to
17	109	110	O	28
18	112	116	O	night
19	118	124	O	studies
20	125	125	O	,
21	127	135	O	including
22	137	140	O	both
23	142	144	O	the
24	146	150	O	sleep
25	152	161	O	laboratory
26	163	169	O	studies
27	171	173	O	and
28	175	177	O	the
29	179	188	O	outpatient
30	190	196	O	studies
31	197	197	O	,
32	199	201	O	and
33	203	204	O	in
34	206	209	O	open
35	211	215	O	label
36	217	223	O	studies
37	225	226	O	of
38	228	228	O	6
39	231	233	O	and
40	235	236	O	12
41	238	242	O	month
42	244	252	O	durations
NULL

ZALEPLON	6472	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	25
The Benzodiazepine Withdrawal Symptom Questionnaire was used in several of these studies, both at baseline and then during days 1 and 2 following discontinuation.
1	0	2	O	The
2	4	17	O	Benzodiazepine
3	19	28	O	Withdrawal
4	30	36	O	Symptom
5	38	50	O	Questionnaire
6	52	54	O	was
7	56	59	O	used
8	61	62	O	in
9	64	70	O	several
10	72	73	O	of
11	75	79	O	these
12	81	87	O	studies
13	88	88	O	,
14	90	93	O	both
15	95	96	O	at
16	98	105	O	baseline
17	107	109	O	and
18	111	114	O	then
19	116	121	O	during
20	123	126	O	days
21	128	128	O	1
22	130	132	O	and
23	134	134	O	2
24	136	144	O	following
25	146	160	O	discontinuation
NULL

ZALEPLON	6473	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	15
Withdrawal was operationally defined as the emergence of 3 or more new symptoms after discontinuation.
1	0	9	O	Withdrawal
2	11	13	O	was
3	15	27	O	operationally
4	29	35	O	defined
5	37	38	O	as
6	40	42	O	the
7	44	52	O	emergence
8	54	55	O	of
9	57	57	O	3
10	59	60	O	or
11	62	65	O	more
12	67	69	O	new
13	71	78	O	symptoms
14	80	84	O	after
15	86	100	O	discontinuation
NULL

ZALEPLON	6474	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	35
Zaleplon was not distinguishable from placebo at doses of 5 mg, 10 mg, or 20 mg on this measure, nor was Zaleplon distinguishable from placebo on spontaneously reported withdrawal-emergent adverse events.
1	0	7	O	XXXXXXXX
2	9	11	O	was
3	13	15	O	not
4	17	31	O	distinguishable
5	33	36	O	from
6	38	44	O	placebo
7	46	47	O	at
8	49	53	O	doses
9	55	56	O	of
10	58	58	O	5
11	60	61	O	mg
12	62	62	O	,
13	64	65	O	10
14	67	68	O	mg
15	69	69	O	,
16	71	72	O	or
17	74	75	O	20
18	77	78	O	mg
19	80	81	O	on
20	83	86	O	this
21	88	94	O	measure
22	95	95	O	,
23	97	99	O	nor
24	101	103	O	was
25	105	112	O	XXXXXXXX
26	114	128	O	distinguishable
27	130	133	O	from
28	135	141	O	placebo
29	143	144	O	on
30	146	158	O	spontaneously
31	160	167	O	reported
32	169	178	O	withdrawal
33	180	187	O	emergent
34	189	195	O	adverse
35	197	202	O	events
NULL

ZALEPLON	6475	34090-1	2f44db39-e1d9-451e-ba31-e4b10366a430	22
There were no instances of withdrawal delirium, withdrawal associated hallucinations, or any other manifestations of severe sedative/hypnotic withdrawal.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	22	O	instances
5	24	25	O	of
6	27	36	O	withdrawal
7	38	45	O	delirium
8	46	46	O	,
9	48	57	O	withdrawal
10	59	68	O	associated
11	70	83	O	hallucinations
12	84	84	O	,
13	86	87	O	or
14	89	91	O	any
15	93	97	O	other
16	99	112	O	manifestations
17	114	115	O	of
18	117	122	O	severe
19	124	131	O	sedative
20	132	132	O	/
21	133	140	O	hypnotic
22	142	151	O	withdrawal
NULL

Ziprasidone	4566	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	15
Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels).
1	0	3	O	Drug
2	5	8	O	drug
3	10	21	O	interactions
4	23	25	O	can
5	27	28	O	be
6	30	44	O	pharmacodynamic
7	47	54	O	combined
8	56	68	O	pharmacologic
9	70	76	O	effects
10	79	80	O	or
11	82	96	O	pharmacokinetic
12	99	108	O	alteration
13	110	111	O	of
14	113	118	O	plasma
15	120	125	O	levels
NULL

Ziprasidone	4567	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	16
The risks of using ziprasidone in combination with other drugs have been evaluated as described below.
1	0	2	O	The
2	4	8	O	risks
3	10	11	O	of
4	13	17	O	using
5	19	29	O	XXXXXXXX
6	31	32	O	in
7	34	44	O	combination
8	46	49	O	with
9	51	55	O	other
10	57	61	O	drugs
11	63	66	O	have
12	68	71	O	been
13	73	81	O	evaluated
14	83	84	O	as
15	86	94	O	described
16	96	100	O	below
NULL

Ziprasidone	4568	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	9
All interactions studies have been conducted with oral ziprasidone.
1	0	2	O	All
2	4	15	O	interactions
3	17	23	O	studies
4	25	28	O	have
5	30	33	O	been
6	35	43	O	conducted
7	45	48	O	with
8	50	53	O	oral
9	55	65	O	XXXXXXXX
NULL

Ziprasidone	4569	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	37
Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated: Approximately two-thirds of ziprasidone is metabolized via a combination of chemical reduction by glutathione and enzymatic reduction by aldehyde oxidase.
1	0	4	O	Based
2	6	9	O	upon
3	11	13	O	the
4	15	29	O	pharmacodynamic
5	31	33	O	and
6	35	49	O	pharmacokinetic
7	51	57	O	profile
8	59	60	O	of
9	62	72	O	XXXXXXXX
10	73	73	O	,
11	75	82	O	possible
12	84	95	O	interactions
13	97	101	O	could
14	103	104	O	be
15	106	116	O	anticipated
16	117	117	O	:
17	119	131	O	Approximately
18	133	135	O	two
19	137	142	O	thirds
20	144	145	O	of
21	147	157	O	XXXXXXXX
22	159	160	O	is
23	162	172	O	metabolized
24	174	176	O	via
25	178	178	O	a
26	180	190	O	combination
27	192	193	O	of
28	195	202	O	chemical
29	204	212	O	reduction
30	214	215	O	by
31	217	227	O	glutathione
32	229	231	O	and
33	233	241	O	enzymatic
34	243	251	O	reduction
35	253	254	O	by
36	256	263	O	aldehyde
37	265	271	O	oxidase
NULL

Ziprasidone	4570	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
There are no known clinically relevant inhibitors or inducers of aldehyde oxidase.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	17	O	known
5	19	28	O	clinically
6	30	37	O	relevant
7	39	48	O	inhibitors
8	50	51	O	or
9	53	60	O	inducers
10	62	63	O	of
11	65	72	O	aldehyde
12	74	80	O	oxidase
NULL

Ziprasidone	4571	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	15
Less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation.
1	0	3	O	Less
2	5	8	O	than
3	10	12	O	one
4	14	18	O	third
5	20	21	O	of
6	23	33	O	XXXXXXXX
7	35	43	O	metabolic
8	45	53	O	clearance
9	55	56	O	is
10	58	65	O	mediated
11	67	68	O	by
12	70	79	O	cytochrome
13	81	84	O	P450
14	86	94	O	catalyzed
15	96	104	O	oxidation
NULL

Ziprasidone	4572	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	44
An in vitro enzyme inhibition study utilizing human liver microsomes showed that ziprasidone had little inhibitory effect on CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4, and thus would not likely interfere with the metabolism of drugs primarily metabolized by these enzymes.
1	0	1	O	An
2	3	4	O	in
3	6	10	O	vitro
4	12	17	O	enzyme
5	19	28	O	inhibition
6	30	34	O	study
7	36	44	O	utilizing
8	46	50	O	human
9	52	56	O	liver
10	58	67	O	microsomes
11	69	74	O	showed
12	76	79	O	that
13	81	91	O	XXXXXXXX
14	93	95	O	had
15	97	102	O	little
16	104	113	O	inhibitory
17	115	120	O	effect
18	122	123	O	on
19	125	130	O	CYP1A2
20	131	131	O	,
21	133	138	O	CYP2C9
22	139	139	O	,
23	141	147	O	CYP2C19
24	148	148	O	,
25	150	155	O	CYP2D6
26	157	159	O	and
27	161	166	O	CYP3A4
28	167	167	O	,
29	169	171	O	and
30	173	176	O	thus
31	178	182	O	would
32	184	186	O	not
33	188	193	O	likely
34	195	203	O	interfere
35	205	208	O	with
36	210	212	O	the
37	214	223	O	metabolism
38	225	226	O	of
39	228	232	O	drugs
40	234	242	O	primarily
41	244	254	O	metabolized
42	256	257	O	by
43	259	263	O	these
44	265	271	O	enzymes
NULL

Ziprasidone	4573	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
There is little potential for drug interactions with ziprasidone due to displacement.
1	0	4	O	There
2	6	7	O	is
3	9	14	O	little
4	16	24	O	potential
5	26	28	O	for
6	30	33	O	drug
7	35	46	O	interactions
8	48	51	O	with
9	53	63	O	XXXXXXXX
10	65	67	O	due
11	69	70	O	to
12	72	83	O	displacement
NULL

Ziprasidone	4574	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	13
Ziprasidone should not be used with any drug that prolongs the QT interval.
1	0	10	O	XXXXXXXX
2	12	17	B-TRI	should
3	19	21	I-TRI	not
4	23	24	I-TRI	be
5	26	29	L-TRI	used
6	31	34	O	with
7	36	38	O	any
8	40	43	B-UNK	drug
9	45	48	I-UNK	that
10	50	57	I-UNK	prolongs
11	59	61	I-UNK	the
12	63	64	I-UNK	QT
13	66	73	L-UNK	interval
NULL

Ziprasidone	4575	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	23
Given the primary CNS effects of ziprasidone, caution should be used when it is taken in combination with other centrally acting drugs.
1	0	4	O	Given
2	6	8	O	the
3	10	16	O	primary
4	18	20	O	CNS
5	22	28	O	effects
6	30	31	O	of
7	33	43	O	XXXXXXXX
8	44	44	O	,
9	46	52	U-TRI	caution
10	54	59	O	should
11	61	62	O	be
12	64	67	O	used
13	69	72	O	when
14	74	75	O	it
15	77	78	O	is
16	80	84	O	taken
17	86	87	O	in
18	89	99	O	combination
19	101	104	O	with
20	106	110	O	other
21	112	120	B-UNK	centrally
22	122	127	I-UNK	acting
23	129	133	L-UNK	drugs
NULL

Ziprasidone	4576	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	17
Because of its potential for inducing hypotension, ziprasidone may enhance the effects of certain antihypertensive agents.
1	0	6	O	Because
2	8	9	O	of
3	11	13	O	its
4	15	23	O	potential
5	25	27	O	for
6	29	36	O	inducing
7	38	48	U-EFF	hypotension
8	49	49	O	,
9	51	61	O	XXXXXXXX
10	63	65	O	may
11	67	73	B-EFF	enhance
12	75	77	I-EFF	the
13	79	85	I-EFF	effects
14	87	88	I-EFF	of
15	90	96	I-EFF	certain
16	98	113	I-EFF	antihypertensive
17	115	120	L-EFF	agents
NULL

Ziprasidone	4577	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	10
Ziprasidone may antagonize the effects of levodopa and dopamine agonists.
1	0	10	O	XXXXXXXX
2	12	14	O	may
3	16	25	B-EFF	antagonize
4	27	29	I-EFF	the
5	31	37	I-EFF	effects
6	39	40	I-EFF	of
7	42	49	I-EFF	levodopa
8	51	53	I-EFF	and
9	55	62	I-EFF	dopamine
10	64	71	L-EFF	agonists
NULL

Ziprasidone	4578	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	28
Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg twice daily for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone.
1	0	12	U-KIN	Carbamazepine
2	14	26	O	Carbamazepine
3	28	29	O	is
4	31	32	O	an
5	34	40	O	inducer
6	42	43	O	of
7	45	50	O	CYP3A4
8	53	66	O	administration
9	68	69	O	of
10	71	73	O	200
11	75	76	O	mg
12	78	82	O	twice
13	84	88	O	daily
14	90	92	O	for
15	94	95	O	21
16	97	100	O	days
17	102	109	O	resulted
18	111	112	O	in
19	114	114	O	a
20	116	123	O	decrease
21	125	126	O	of
22	128	140	O	approximately
23	142	144	O	35%
24	146	147	O	in
25	149	151	O	the
26	153	155	O	AUC
27	157	158	O	of
28	160	170	O	XXXXXXXX
K/1:C54609

Ziprasidone	4579	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
This effect may be greater when higher doses of carbamazepine are administered.
1	0	3	O	This
2	5	10	O	effect
3	12	14	O	may
4	16	17	O	be
5	19	25	O	greater
6	27	30	O	when
7	32	37	O	higher
8	39	43	O	doses
9	45	46	O	of
10	48	60	O	carbamazepine
11	62	64	O	are
12	66	77	O	administered
NULL

Ziprasidone	4580	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	31
Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and Cmax of ziprasidone by about 35-40%.
1	0	11	U-KIN	Ketoconazole
2	13	24	O	Ketoconazole
3	25	25	O	,
4	27	27	O	a
5	29	34	O	potent
6	36	44	O	inhibitor
7	46	47	O	of
8	49	54	O	CYP3A4
9	55	55	O	,
10	57	58	O	at
11	60	60	O	a
12	62	65	O	dose
13	67	68	O	of
14	70	72	O	400
15	74	75	O	mg
16	77	78	O	QD
17	80	82	O	for
18	84	84	O	5
19	86	89	O	days
20	90	90	O	,
21	92	100	B-TRI	increased
22	102	104	I-TRI	the
23	106	108	L-TRI	AUC
24	110	112	O	and
25	114	117	O	Cmax
26	119	120	O	of
27	122	132	O	XXXXXXXX
28	134	135	O	by
29	137	141	O	about
30	143	144	O	35
31	146	148	O	40%
K/1:C54602

Ziprasidone	4581	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	11
Other inhibitors of CYP3A4 would be expected to have similar effects.
1	0	4	O	Other
2	6	15	O	inhibitors
3	17	18	O	of
4	20	25	O	CYP3A4
5	27	31	O	would
6	33	34	O	be
7	36	43	O	expected
8	45	46	O	to
9	48	51	O	have
10	53	59	O	similar
11	61	67	O	effects
NULL

Ziprasidone	4582	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	17
Cimetidine Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.
1	0	9	O	Cimetidine
2	11	20	O	Cimetidine
3	22	23	O	at
4	25	25	O	a
5	27	30	O	dose
6	32	33	O	of
7	35	37	O	800
8	39	40	O	mg
9	42	43	O	QD
10	45	47	O	for
11	49	49	O	2
12	51	54	O	days
13	56	58	O	did
14	60	62	O	not
15	64	69	O	affect
16	71	81	O	XXXXXXXX
17	83	98	O	pharmacokinetics
NULL

Ziprasidone	4583	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	18
Antacid The co-administration of 30 mL of Maalox* with ziprasidone did not affect the pharmacokinetics of ziprasidone.
1	0	6	O	Antacid
2	8	10	O	The
3	12	13	O	co
4	15	28	O	administration
5	30	31	O	of
6	33	34	O	30
7	36	37	O	mL
8	39	40	O	of
9	42	48	O	Maalox*
10	50	53	O	with
11	55	65	O	XXXXXXXX
12	67	69	O	did
13	71	73	O	not
14	75	80	O	affect
15	82	84	O	the
16	86	101	O	pharmacokinetics
17	103	104	O	of
18	106	116	O	XXXXXXXX
NULL

Ziprasidone	4584	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	36
Ziprasidone at a dose of 40 mg twice daily administered concomitantly with lithium at a dose of 450 mg twice daily for 7 days did not affect the steady-state level or renal clearance of lithium.
1	0	10	O	XXXXXXXX
2	12	13	O	at
3	15	15	O	a
4	17	20	O	dose
5	22	23	O	of
6	25	26	O	40
7	28	29	O	mg
8	31	35	O	twice
9	37	41	O	daily
10	43	54	O	administered
11	56	68	O	concomitantly
12	70	73	O	with
13	75	81	O	lithium
14	83	84	O	at
15	86	86	O	a
16	88	91	O	dose
17	93	94	O	of
18	96	98	O	450
19	100	101	O	mg
20	103	107	O	twice
21	109	113	O	daily
22	115	117	O	for
23	119	119	O	7
24	121	124	O	days
25	126	128	O	did
26	130	132	O	not
27	134	139	O	affect
28	141	143	O	the
29	145	150	O	steady
30	152	156	O	state
31	158	162	O	level
32	164	165	O	or
33	167	171	O	renal
34	173	181	O	clearance
35	183	184	O	of
36	186	192	O	lithium
NULL

Ziprasidone	4585	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	19
Ziprasidone dosed adjunctively to lithium in a maintenance trial of bipolar patients did not affect mean therapeutic lithium levels.
1	0	10	O	XXXXXXXX
2	12	16	O	dosed
3	18	29	O	adjunctively
4	31	32	O	to
5	34	40	O	lithium
6	42	43	O	in
7	45	45	O	a
8	47	57	O	maintenance
9	59	63	O	trial
10	65	66	O	of
11	68	74	O	bipolar
12	76	83	O	patients
13	85	87	O	did
14	89	91	O	not
15	93	98	O	affect
16	100	103	O	mean
17	105	115	O	therapeutic
18	117	123	O	lithium
19	125	130	O	levels
NULL

Ziprasidone	4586	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	17
In vivo studies have revealed no effect of ziprasidone on the pharmacokinetics of estrogen or progesterone components.
1	0	1	O	In
2	3	6	O	vivo
3	8	14	O	studies
4	16	19	O	have
5	21	28	O	revealed
6	30	31	O	no
7	33	38	O	effect
8	40	41	O	of
9	43	53	O	XXXXXXXX
10	55	56	O	on
11	58	60	O	the
12	62	77	O	pharmacokinetics
13	79	80	O	of
14	82	89	O	estrogen
15	91	92	O	or
16	94	105	O	progesterone
17	107	116	O	components
NULL

Ziprasidone	4587	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	28
Ziprasidone at a dose of 20 mg twice daily did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinyl estradiol (0.03 mg) and levonorgestrel (0.15 mg).
1	0	10	O	XXXXXXXX
2	12	13	O	at
3	15	15	O	a
4	17	20	O	dose
5	22	23	O	of
6	25	26	O	20
7	28	29	O	mg
8	31	35	O	twice
9	37	41	O	daily
10	43	45	O	did
11	47	49	O	not
12	51	56	O	affect
13	58	60	O	the
14	62	77	O	pharmacokinetics
15	79	80	O	of
16	82	94	O	concomitantly
17	96	107	O	administered
18	109	112	O	oral
19	114	127	O	contraceptives
20	128	128	O	,
21	130	136	O	ethinyl
22	138	146	O	estradiol
23	149	152	O	0.03
24	154	155	O	mg
25	158	160	O	and
26	162	175	O	levonorgestrel
27	178	181	O	0.15
28	183	184	O	mg
NULL

Ziprasidone	4588	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	34
Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan.
1	0	9	O	Consistent
2	11	14	O	with
3	16	17	O	in
4	19	23	O	vitro
5	25	31	O	results
6	32	32	O	,
7	34	34	O	a
8	36	40	O	study
9	42	43	O	in
10	45	50	O	normal
11	52	58	O	healthy
12	60	69	O	volunteers
13	71	76	O	showed
14	78	81	O	that
15	83	93	O	XXXXXXXX
16	95	97	O	did
17	99	101	O	not
18	103	107	O	alter
19	109	111	O	the
20	113	122	O	metabolism
21	124	125	O	of
22	127	142	O	dextromethorphan
23	143	143	O	,
24	145	145	O	a
25	147	152	O	CYP2D6
26	154	158	O	model
27	160	168	O	substrate
28	169	169	O	,
29	171	172	O	to
30	174	176	O	its
31	178	182	O	major
32	184	193	O	metabolite
33	194	194	O	,
34	196	206	O	dextrorphan
NULL

Ziprasidone	4589	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	13
There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	25	O	statistically
5	27	37	O	significant
6	39	44	O	change
7	46	47	O	in
8	49	51	O	the
9	53	59	O	urinary
10	61	76	O	dextromethorphan
11	77	77	O	/
12	78	88	O	dextrorphan
13	90	94	O	ratio
NULL

Ziprasidone	4590	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	21
A pharmacokinetic interaction of ziprasidone with valproate is unlikely due to the lack of common metabolic pathways for the two drugs.
1	0	0	O	A
2	2	16	O	pharmacokinetic
3	18	28	O	interaction
4	30	31	O	of
5	33	43	O	XXXXXXXX
6	45	48	O	with
7	50	58	O	valproate
8	60	61	O	is
9	63	70	O	unlikely
10	72	74	O	due
11	76	77	O	to
12	79	81	O	the
13	83	86	O	lack
14	88	89	O	of
15	91	96	O	common
16	98	106	O	metabolic
17	108	115	O	pathways
18	117	119	O	for
19	121	123	O	the
20	125	127	O	two
21	129	133	O	drugs
NULL

Ziprasidone	4591	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	19
Ziprasidone dosed adjunctively to valproate in a maintenance trial of bipolar patients did not affect mean therapeutic valproate levels.
1	0	10	O	XXXXXXXX
2	12	16	O	dosed
3	18	29	O	adjunctively
4	31	32	O	to
5	34	42	O	valproate
6	44	45	O	in
7	47	47	O	a
8	49	59	O	maintenance
9	61	65	O	trial
10	67	68	O	of
11	70	76	O	bipolar
12	78	85	O	patients
13	87	89	O	did
14	91	93	O	not
15	95	100	O	affect
16	102	105	O	mean
17	107	117	O	therapeutic
18	119	127	O	valproate
19	129	134	O	levels
NULL

Ziprasidone	4592	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	28
Population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.
1	0	9	O	Population
2	11	25	O	pharmacokinetic
3	27	34	O	analysis
4	36	37	O	of
5	39	51	O	schizophrenic
6	53	60	O	patients
7	62	69	O	enrolled
8	71	72	O	in
9	74	83	O	controlled
10	85	92	O	clinical
11	94	99	O	trials
12	101	103	O	has
13	105	107	O	not
14	109	116	O	revealed
15	118	125	O	evidence
16	127	128	O	of
17	130	132	O	any
18	134	143	O	clinically
19	145	155	O	significant
20	157	171	O	pharmacokinetic
21	173	184	O	interactions
22	186	189	O	with
23	191	201	O	benztropine
24	202	202	O	,
25	204	214	O	propranolol
26	215	215	O	,
27	217	218	O	or
28	220	228	O	lorazepam
NULL

Ziprasidone	4593	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	14
The absolute bioavailability of a 20 mg dose under fed conditions is approximately 60%.
1	0	2	O	The
2	4	11	O	absolute
3	13	27	O	bioavailability
4	29	30	O	of
5	32	32	O	a
6	34	35	O	20
7	37	38	O	mg
8	40	43	O	dose
9	45	49	O	under
10	51	53	O	fed
11	55	64	O	conditions
12	66	67	O	is
13	69	81	O	approximately
14	83	85	O	60%
NULL

Ziprasidone	4594	34073-7	036db1f2-52b3-42a0-acf9-817b7ba8c724	15
The absorption of ziprasidone is increased up to two-fold in the presence of food.
1	0	2	O	The
2	4	13	O	absorption
3	15	16	O	of
4	18	28	O	XXXXXXXX
5	30	31	O	is
6	33	41	O	increased
7	43	44	O	up
8	46	47	O	to
9	49	51	O	two
10	53	56	O	fold
11	58	59	O	in
12	61	63	O	the
13	65	72	O	presence
14	74	75	O	of
15	77	80	U-KIN	food
K/15:C54355

Ziprasidone	4595	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	18
The mechanism of action of ziprasidone, as with other drugs having efficacy in schizophrenia, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	37	O	XXXXXXXX
7	38	38	O	,
8	40	41	O	as
9	43	46	O	with
10	48	52	O	other
11	54	58	O	drugs
12	60	65	O	having
13	67	74	O	efficacy
14	76	77	O	in
15	79	91	O	schizophrenia
16	92	92	O	,
17	94	95	O	is
18	97	103	O	unknown
NULL

Ziprasidone	4596	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	30
However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine type 2 (D 2) and serotonin type 2 (5HT 2) antagonism.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	28	O	proposed
7	30	33	O	that
8	35	38	O	this
9	40	45	O	drug's
10	47	54	O	efficacy
11	56	57	O	in
12	59	71	O	schizophrenia
13	73	74	O	is
14	76	83	O	mediated
15	85	91	O	through
16	93	93	O	a
17	95	105	O	combination
18	107	108	O	of
19	110	117	O	dopamine
20	119	122	O	type
21	124	124	O	2
22	127	127	O	D
23	129	129	O	2
24	132	134	O	and
25	136	144	O	serotonin
26	146	149	O	type
27	151	151	O	2
28	154	156	O	5HT
29	158	158	O	2
30	161	170	O	antagonism
NULL

Ziprasidone	4597	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	21
As with other drugs having efficacy in bipolar disorder, the mechanism of action of ziprasidone in bipolar disorder is unknown.
1	0	1	O	As
2	3	6	O	with
3	8	12	O	other
4	14	18	O	drugs
5	20	25	O	having
6	27	34	O	efficacy
7	36	37	O	in
8	39	45	O	bipolar
9	47	54	O	disorder
10	55	55	O	,
11	57	59	O	the
12	61	69	O	mechanism
13	71	72	O	of
14	74	79	O	action
15	81	82	O	of
16	84	94	O	XXXXXXXX
17	96	97	O	in
18	99	105	O	bipolar
19	107	114	O	disorder
20	116	117	O	is
21	119	125	O	unknown
NULL

Ziprasidone	4598	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	59
Ziprasidone exhibited high in vitro binding affinity for the dopamine D2 and D3, the serotonin 5HT2A, 5HT2C, 5HT1A, 5HT1D, and A1-adrenergic receptors (Ki s of 4.8, 7.2, 0.4, 1.3, 3.4, 2, and 10 nM, respectively), and moderate affinity for the histamine H1 receptor (Ki=47 nM).
1	0	10	O	XXXXXXXX
2	12	20	O	exhibited
3	22	25	O	high
4	27	28	O	in
5	30	34	O	vitro
6	36	42	O	binding
7	44	51	O	affinity
8	53	55	O	for
9	57	59	O	the
10	61	68	O	dopamine
11	70	71	O	D2
12	73	75	O	and
13	77	78	O	D3
14	79	79	O	,
15	81	83	O	the
16	85	93	O	serotonin
17	95	99	O	5HT2A
18	100	100	O	,
19	102	106	O	5HT2C
20	107	107	O	,
21	109	113	O	5HT1A
22	114	114	O	,
23	116	120	O	5HT1D
24	121	121	O	,
25	123	125	O	and
26	127	128	O	A1
27	130	139	O	adrenergic
28	141	149	O	receptors
29	152	153	O	Ki
30	155	155	O	s
31	157	158	O	of
32	160	162	O	4.8
33	163	163	O	,
34	165	167	O	7.2
35	168	168	O	,
36	170	172	O	0.4
37	173	173	O	,
38	175	177	O	1.3
39	178	178	O	,
40	180	182	O	3.4
41	183	183	O	,
42	185	185	O	2
43	186	186	O	,
44	188	190	O	and
45	192	193	O	10
46	195	196	O	nM
47	197	197	O	,
48	199	210	O	respectively
49	212	212	O	,
50	214	216	O	and
51	218	225	O	moderate
52	227	234	O	affinity
53	236	238	O	for
54	240	242	O	the
55	244	252	O	histamine
56	254	255	O	H1
57	257	264	O	receptor
58	267	271	O	Ki=47
59	273	274	O	nM
NULL

Ziprasidone	4599	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	27
Ziprasidone functioned as an antagonist at the D 2, 5HT 2A, and 5HT 1D receptors, and as an agonist at the 5HT 1A receptor.
1	0	10	O	XXXXXXXX
2	12	21	O	functioned
3	23	24	O	as
4	26	27	O	an
5	29	38	O	antagonist
6	40	41	O	at
7	43	45	O	the
8	47	47	O	D
9	49	49	O	2
10	50	50	O	,
11	52	54	O	5HT
12	56	57	O	2A
13	58	58	O	,
14	60	62	O	and
15	64	66	O	5HT
16	68	69	O	1D
17	71	79	O	receptors
18	80	80	O	,
19	82	84	O	and
20	86	87	O	as
21	89	90	O	an
22	92	98	O	agonist
23	100	101	O	at
24	103	105	O	the
25	107	109	O	5HT
26	111	112	O	1A
27	114	121	O	receptor
NULL

Ziprasidone	4600	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	8
Ziprasidone inhibited synaptic reuptake of serotonin and norepinephrine.
1	0	10	O	XXXXXXXX
2	12	20	O	inhibited
3	22	29	O	synaptic
4	31	38	O	reuptake
5	40	41	O	of
6	43	51	O	serotonin
7	53	55	O	and
8	57	70	O	norepinephrine
NULL

Ziprasidone	4601	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	21
No appreciable affinity was exhibited for other receptor/binding sites tested, including the cholinergic muscarinic receptor (IC50 >1 uM).
1	0	1	O	No
2	3	13	O	appreciable
3	15	22	O	affinity
4	24	26	O	was
5	28	36	O	exhibited
6	38	40	O	for
7	42	46	O	other
8	48	55	O	receptor
9	56	56	O	/
10	57	63	O	binding
11	65	69	O	sites
12	71	76	O	tested
13	77	77	O	,
14	79	87	O	including
15	89	91	O	the
16	93	103	O	cholinergic
17	105	114	O	muscarinic
18	116	123	O	receptor
19	126	129	O	IC50
20	131	132	O	>1
21	134	135	O	uM
NULL

Ziprasidone	4602	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	25
Antagonism at receptors other than dopamine and 5HT 2 with similar receptor affinities may explain some of the other therapeutic and side effects of ziprasidone.
1	0	9	O	Antagonism
2	11	12	O	at
3	14	22	O	receptors
4	24	28	O	other
5	30	33	O	than
6	35	42	O	dopamine
7	44	46	O	and
8	48	50	O	5HT
9	52	52	O	2
10	54	57	O	with
11	59	65	O	similar
12	67	74	O	receptor
13	76	85	O	affinities
14	87	89	O	may
15	91	97	O	explain
16	99	102	O	some
17	104	105	O	of
18	107	109	O	the
19	111	115	O	other
20	117	127	O	therapeutic
21	129	131	O	and
22	133	136	O	side
23	138	144	O	effects
24	146	147	O	of
25	149	159	O	XXXXXXXX
NULL

Ziprasidone	4603	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	16
Ziprasidone's antagonism of histamine H 1 receptors may explain the somnolence observed with this drug.
1	0	10	O	XXXXXXXX
2	11	12	O	's
3	14	23	O	antagonism
4	25	26	O	of
5	28	36	O	histamine
6	38	38	O	H
7	40	40	O	1
8	42	50	O	receptors
9	52	54	O	may
10	56	62	O	explain
11	64	66	O	the
12	68	77	O	somnolence
13	79	86	O	observed
14	88	91	O	with
15	93	96	O	this
16	98	101	O	drug
NULL

Ziprasidone	4604	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	16
Ziprasidone's antagonism of A1-adrenergic receptors may explain the orthostatic hypotension observed with this drug.
1	0	10	O	XXXXXXXX
2	11	12	O	's
3	14	23	O	antagonism
4	25	26	O	of
5	28	29	O	A1
6	31	40	O	adrenergic
7	42	50	O	receptors
8	52	54	O	may
9	56	62	O	explain
10	64	66	O	the
11	68	78	O	orthostatic
12	80	90	O	hypotension
13	92	99	O	observed
14	101	104	O	with
15	106	109	O	this
16	111	114	O	drug
NULL

Ziprasidone	4605	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
Oral Pharmacokinetics Ziprasidone's activity is primarily due to the parent drug.
1	0	3	O	Oral
2	5	20	O	Pharmacokinetics
3	22	32	O	XXXXXXXX
4	33	34	O	's
5	36	43	O	activity
6	45	46	O	is
7	48	56	O	primarily
8	58	60	O	due
9	62	63	O	to
10	65	67	O	the
11	69	74	O	parent
12	76	79	O	drug
NULL

Ziprasidone	4606	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	24
The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing.
1	0	2	O	The
2	4	11	O	multiple
3	13	16	O	dose
4	18	33	O	pharmacokinetics
5	35	36	O	of
6	38	48	O	XXXXXXXX
7	50	52	O	are
8	54	57	O	dose
9	59	70	O	proportional
10	72	77	O	within
11	79	81	O	the
12	83	90	O	proposed
13	92	99	O	clinical
14	101	104	O	dose
15	106	110	O	range
16	111	111	O	,
17	113	115	O	and
18	117	127	O	XXXXXXXX
19	129	140	O	accumulation
20	142	143	O	is
21	145	155	O	predictable
22	157	160	O	with
23	162	169	O	multiple
24	171	176	O	dosing
NULL

Ziprasidone	4607	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	24
Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.
1	0	10	O	Elimination
2	12	13	O	of
3	15	25	O	XXXXXXXX
4	27	28	O	is
5	30	35	O	mainly
6	37	39	O	via
7	41	47	O	hepatic
8	49	58	O	metabolism
9	60	63	O	with
10	65	65	O	a
11	67	70	O	mean
12	72	79	O	terminal
13	81	84	O	half
14	86	89	O	life
15	91	92	O	of
16	94	98	O	about
17	100	100	O	7
18	102	106	O	hours
19	108	113	O	within
20	115	117	O	the
21	119	126	O	proposed
22	128	135	O	clinical
23	137	140	O	dose
24	142	146	O	range
NULL

Ziprasidone	4608	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
Steady-state concentrations are achieved within one to three days of dosing.
1	0	5	O	Steady
2	7	11	O	state
3	13	26	O	concentrations
4	28	30	O	are
5	32	39	O	achieved
6	41	46	O	within
7	48	50	O	one
8	52	53	O	to
9	55	59	O	three
10	61	64	O	days
11	66	67	O	of
12	69	74	O	dosing
NULL

Ziprasidone	4609	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
The mean apparent systemic clearance is 7.5 mL/min/kg.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	apparent
4	18	25	O	systemic
5	27	35	O	clearance
6	37	38	O	is
7	40	42	O	7.5
8	44	45	O	mL
9	46	46	O	/
10	47	49	O	min
11	50	50	O	/
12	51	52	O	kg
NULL

Ziprasidone	4610	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	15
Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	22	O	unlikely
4	24	25	O	to
5	27	35	O	interfere
6	37	40	O	with
7	42	44	O	the
8	46	55	O	metabolism
9	57	58	O	of
10	60	64	O	drugs
11	66	76	O	metabolized
12	78	79	O	by
13	81	90	O	cytochrome
14	92	95	O	P450
15	97	103	O	enzymes
NULL

Ziprasidone	4611	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	19
Absorption: Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours.
1	0	9	O	Absorption
2	10	10	O	:
3	12	22	O	XXXXXXXX
4	24	25	O	is
5	27	30	O	well
6	32	39	O	absorbed
7	41	45	O	after
8	47	50	O	oral
9	52	65	O	administration
10	66	66	O	,
11	68	75	O	reaching
12	77	80	O	peak
13	82	87	O	plasma
14	89	102	O	concentrations
15	104	105	O	in
16	107	107	O	6
17	109	110	O	to
18	112	112	O	8
19	114	118	O	hours
NULL

Ziprasidone	4614	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	15
Distribution: Ziprasidone has a mean apparent volume of distribution of 1.5 L/kg.
1	0	11	O	Distribution
2	12	12	O	:
3	14	24	O	XXXXXXXX
4	26	28	O	has
5	30	30	O	a
6	32	35	O	mean
7	37	44	O	apparent
8	46	51	O	volume
9	53	54	O	of
10	56	67	O	distribution
11	69	70	O	of
12	72	74	O	1.5
13	76	76	O	L
14	77	77	O	/
15	78	79	O	kg
NULL

Ziprasidone	4615	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	18
It is greater than 99% bound to plasma proteins, binding primarily to albumin and A1-acid glycoprotein.
1	0	1	O	It
2	3	4	O	is
3	6	12	O	greater
4	14	17	O	than
5	19	21	O	99%
6	23	27	O	bound
7	29	30	O	to
8	32	37	O	plasma
9	39	46	O	proteins
10	47	47	O	,
11	49	55	O	binding
12	57	65	O	primarily
13	67	68	O	to
14	70	76	O	albumin
15	78	80	O	and
16	82	83	O	A1
17	85	88	O	acid
18	90	101	O	glycoprotein
NULL

Ziprasidone	4616	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	34
The in vitro plasma protein binding of ziprasidone was not altered by warfarin or propranolol, two highly protein-bound drugs, nor did ziprasidone alter the binding of these drugs in human plasma.
1	0	2	O	The
2	4	5	O	in
3	7	11	O	vitro
4	13	18	O	plasma
5	20	26	O	protein
6	28	34	O	binding
7	36	37	O	of
8	39	49	O	XXXXXXXX
9	51	53	O	was
10	55	57	O	not
11	59	65	O	altered
12	67	68	O	by
13	70	77	O	warfarin
14	79	80	O	or
15	82	92	O	propranolol
16	93	93	O	,
17	95	97	O	two
18	99	104	O	highly
19	106	112	O	protein
20	114	118	O	bound
21	120	124	O	drugs
22	125	125	O	,
23	127	129	O	nor
24	131	133	O	did
25	135	145	O	XXXXXXXX
26	147	151	O	alter
27	153	155	O	the
28	157	163	O	binding
29	165	166	O	of
30	168	172	O	these
31	174	178	O	drugs
32	180	181	O	in
33	183	187	O	human
34	189	194	O	plasma
NULL

Ziprasidone	4617	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	14
Thus, the potential for drug interactions with ziprasidone due to displacement is minimal.
1	0	3	O	Thus
2	4	4	O	,
3	6	8	O	the
4	10	18	O	potential
5	20	22	O	for
6	24	27	O	drug
7	29	40	O	interactions
8	42	45	O	with
9	47	57	O	XXXXXXXX
10	59	61	O	due
11	63	64	O	to
12	66	77	O	displacement
13	79	80	O	is
14	82	88	O	minimal
NULL

Ziprasidone	4618	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	27
Metabolism and Elimination: Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (<1%) or feces (<4%) as unchanged drug.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	26	26	O	:
5	28	38	O	XXXXXXXX
6	40	41	O	is
7	43	53	O	extensively
8	55	65	O	metabolized
9	67	71	O	after
10	73	76	O	oral
11	78	91	O	administration
12	93	96	O	with
13	98	101	O	only
14	103	103	O	a
15	105	109	O	small
16	111	116	O	amount
17	118	125	O	excreted
18	127	128	O	in
19	130	132	O	the
20	134	138	O	urine
21	141	143	O	<1%
22	146	147	O	or
23	149	153	O	feces
24	156	158	O	<4%
25	161	162	O	as
26	164	172	O	unchanged
27	174	177	O	drug
NULL

Ziprasidone	4619	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	29
Ziprasidone is primarily cleared via three metabolic routes to yield four major circulating metabolites, benzisothiazole (BITP) sulphoxide, BITP-sulphone, ziprasidone sulphoxide, and S-methyldihydroziprasidone.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	23	O	primarily
4	25	31	O	cleared
5	33	35	O	via
6	37	41	O	three
7	43	51	O	metabolic
8	53	58	O	routes
9	60	61	O	to
10	63	67	O	yield
11	69	72	O	four
12	74	78	O	major
13	80	90	O	circulating
14	92	102	O	metabolites
15	103	103	O	,
16	105	119	O	benzisothiazole
17	122	125	O	BITP
18	128	137	O	sulphoxide
19	138	138	O	,
20	140	143	O	BITP
21	145	152	O	sulphone
22	153	153	O	,
23	155	165	O	XXXXXXXX
24	167	176	O	sulphoxide
25	177	177	O	,
26	179	181	O	and
27	183	183	O	S
28	185	197	O	methyldihydro
29	198	208	O	XXXXXXXX
NULL

Ziprasidone	4620	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	19
Approximately 20% of the dose is excreted in the urine, with approximately 66% being eliminated in the feces.
1	0	12	O	Approximately
2	14	16	O	20%
3	18	19	O	of
4	21	23	O	the
5	25	28	O	dose
6	30	31	O	is
7	33	40	O	excreted
8	42	43	O	in
9	45	47	O	the
10	49	53	O	urine
11	54	54	O	,
12	56	59	O	with
13	61	73	O	approximately
14	75	77	O	66%
15	79	83	O	being
16	85	94	O	eliminated
17	96	97	O	in
18	99	101	O	the
19	103	107	O	feces
NULL

Ziprasidone	4621	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	12
Unchanged ziprasidone represents about 44% of total drug-related material in serum.
1	0	8	O	Unchanged
2	10	20	O	XXXXXXXX
3	22	31	O	represents
4	33	37	O	about
5	39	41	O	44%
6	43	44	O	of
7	46	50	O	total
8	52	55	O	drug
9	57	63	O	related
10	65	72	O	material
11	74	75	O	in
12	77	81	O	serum
NULL

Ziprasidone	4622	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	18
In vitro studies using human liver subcellular fractions indicate that S-methyldihydroziprasidone is generated in two steps.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	21	O	using
5	23	27	O	human
6	29	33	O	liver
7	35	45	O	subcellular
8	47	55	O	fractions
9	57	64	O	indicate
10	66	69	O	that
11	71	71	O	S
12	73	85	O	methyldihydro
13	86	96	O	XXXXXXXX
14	98	99	O	is
15	101	109	O	generated
16	111	112	O	in
17	114	116	O	two
18	118	122	O	steps
NULL

Ziprasidone	4623	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	33
These studies indicate that the reduction reaction is mediated primarily by chemical reduction by glutathione as well as by enzymatic reduction by aldehyde oxidase and the subsequent methylation is mediated by thiol methyltransferase.
1	0	4	O	These
2	6	12	O	studies
3	14	21	O	indicate
4	23	26	O	that
5	28	30	O	the
6	32	40	O	reduction
7	42	49	O	reaction
8	51	52	O	is
9	54	61	O	mediated
10	63	71	O	primarily
11	73	74	O	by
12	76	83	O	chemical
13	85	93	O	reduction
14	95	96	O	by
15	98	108	O	glutathione
16	110	111	O	as
17	113	116	O	well
18	118	119	O	as
19	121	122	O	by
20	124	132	O	enzymatic
21	134	142	O	reduction
22	144	145	O	by
23	147	154	O	aldehyde
24	156	162	O	oxidase
25	164	166	O	and
26	168	170	O	the
27	172	181	O	subsequent
28	183	193	O	methylation
29	195	196	O	is
30	198	205	O	mediated
31	207	208	O	by
32	210	214	O	thiol
33	216	232	O	methyltransferase
NULL

Ziprasidone	4624	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	24
In vitro studies using human liver microsomes and recombinant enzymes indicate that CYP3A4 is the major CYP contributing to the oxidative metabolism of ziprasidone.
1	0	1	O	In
2	3	7	O	vitro
3	9	15	O	studies
4	17	21	O	using
5	23	27	O	human
6	29	33	O	liver
7	35	44	O	microsomes
8	46	48	O	and
9	50	60	O	recombinant
10	62	68	O	enzymes
11	70	77	O	indicate
12	79	82	O	that
13	84	89	O	CYP3A4
14	91	92	O	is
15	94	96	O	the
16	98	102	O	major
17	104	106	O	CYP
18	108	119	O	contributing
19	121	122	O	to
20	124	126	O	the
21	128	136	O	oxidative
22	138	147	O	metabolism
23	149	150	O	of
24	152	162	O	XXXXXXXX
NULL

Ziprasidone	4625	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	8
CYP1A2 may contribute to a much lesser extent.
1	0	5	O	CYP1A2
2	7	9	O	may
3	11	20	O	contribute
4	22	23	O	to
5	25	25	O	a
6	27	30	O	much
7	32	37	O	lesser
8	39	44	O	extent
NULL

Ziprasidone	4626	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	30
Based on in vivo abundance of excretory metabolites, less than one-third of ziprasidone metabolic clearance is mediated by cytochrome P450 catalyzed oxidation and approximately two-thirds via reduction.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	15	O	vivo
5	17	25	O	abundance
6	27	28	O	of
7	30	38	O	excretory
8	40	50	O	metabolites
9	51	51	O	,
10	53	56	O	less
11	58	61	O	than
12	63	65	O	one
13	67	71	O	third
14	73	74	O	of
15	76	86	O	XXXXXXXX
16	88	96	O	metabolic
17	98	106	O	clearance
18	108	109	O	is
19	111	118	O	mediated
20	120	121	O	by
21	123	132	O	cytochrome
22	134	137	O	P450
23	139	147	O	catalyzed
24	149	157	O	oxidation
25	159	161	O	and
26	163	175	O	approximately
27	177	179	O	two
28	181	186	O	thirds
29	188	190	O	via
30	192	200	O	reduction
NULL

Ziprasidone	4628	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	13
Intramuscular Pharmacokinetics Systemic Bioavailability: The bioavailability of ziprasidone administered intramuscularly is 100%.
1	0	12	O	Intramuscular
2	14	29	O	Pharmacokinetics
3	31	38	O	Systemic
4	40	54	O	Bioavailability
5	55	55	O	:
6	57	59	O	The
7	61	75	O	bioavailability
8	77	78	O	of
9	80	90	O	XXXXXXXX
10	92	103	O	administered
11	105	119	O	intramuscularly
12	121	122	O	is
13	124	127	O	100%
NULL

Ziprasidone	4629	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	32
After intramuscular administration of single doses, peak serum concentrations typically occur at approximately 60 minutes post-dose or earlier and the mean half-life (T%) ranges from two to five hours.
1	0	4	O	After
2	6	18	O	intramuscular
3	20	33	O	administration
4	35	36	O	of
5	38	43	O	single
6	45	49	O	doses
7	50	50	O	,
8	52	55	O	peak
9	57	61	O	serum
10	63	76	O	concentrations
11	78	86	O	typically
12	88	92	O	occur
13	94	95	O	at
14	97	109	O	approximately
15	111	112	O	60
16	114	120	O	minutes
17	122	125	O	post
18	127	130	O	dose
19	132	133	O	or
20	135	141	O	earlier
21	143	145	O	and
22	147	149	O	the
23	151	154	O	mean
24	156	159	O	half
25	161	164	O	life
26	167	168	O	T%
27	171	176	O	ranges
28	178	181	O	from
29	183	185	O	two
30	187	188	O	to
31	190	193	O	five
32	195	199	O	hours
NULL

Ziprasidone	4630	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	19
Exposure increases in a dose-related manner and following three days of intramuscular dosing, little accumulation is observed.
1	0	7	O	Exposure
2	9	17	O	increases
3	19	20	O	in
4	22	22	O	a
5	24	27	O	dose
6	29	35	O	related
7	37	42	O	manner
8	44	46	O	and
9	48	56	O	following
10	58	62	O	three
11	64	67	O	days
12	69	70	O	of
13	72	84	O	intramuscular
14	86	91	O	dosing
15	92	92	O	,
16	94	99	O	little
17	101	112	O	accumulation
18	114	115	O	is
19	117	124	O	observed
NULL

Ziprasidone	4631	34090-1	036db1f2-52b3-42a0-acf9-817b7ba8c724	32
Metabolism and Elimination: Although the metabolism and elimination of IM ziprasidone have not been systematically evaluated, the intramuscular route of administration would not be expected to alter the metabolic pathways.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	26	26	O	:
5	28	35	O	Although
6	37	39	O	the
7	41	50	O	metabolism
8	52	54	O	and
9	56	66	O	elimination
10	68	69	O	of
11	71	72	O	IM
12	74	84	O	XXXXXXXX
13	86	89	O	have
14	91	93	O	not
15	95	98	O	been
16	100	113	O	systematically
17	115	123	O	evaluated
18	124	124	O	,
19	126	128	O	the
20	130	142	O	intramuscular
21	144	148	O	route
22	150	151	O	of
23	153	166	O	administration
24	168	172	O	would
25	174	176	O	not
26	178	179	O	be
27	181	188	O	expected
28	190	191	O	to
29	193	197	O	alter
30	199	201	O	the
31	203	211	O	metabolic
32	213	220	O	pathways
NULL

Zolpidem	5655	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	60
CNS depressants, including alcohol: Possible adverse additive CNS-depressant effects (5.1, 7.1) Imipramine: Decreased alertness observed (7.1) Chlorpromazine: Impaired alertness and psychomotor performance observed (7.1) Rifampin: Combination use may decrease effect (7.2) Ketoconazole: Combination use may increase effect (7.2) Co-administration of zolpidem with other CNS depressants increases the risk of CNS depression.
1	0	2	B-DYN	CNS
2	4	14	L-DYN	depressants
3	15	15	O	,
4	17	25	O	including
5	27	33	U-DYN	alcohol
6	34	34	O	:
7	36	43	O	Possible
8	45	51	B-EFF	adverse
9	53	60	I-EFF	additive
10	62	64	I-EFF	CNS
11	66	75	I-EFF	depressant
12	77	83	L-EFF	effects
13	86	88	O	5.1
14	89	89	O	,
15	91	93	O	7.1
16	96	105	U-DYN	Imipramine
17	106	106	O	:
18	108	116	B-EFF	Decreased
19	118	126	L-EFF	alertness
20	128	135	O	observed
21	138	140	O	7.1
22	143	156	U-DYN	Chlorpromazine
23	157	157	O	:
24	159	166	B-EFF	Impaired
25	168	176	L-EFF	alertness
26	178	180	O	and
27	182	192	O	psychomotor
28	194	204	O	performance
29	206	213	O	observed
30	216	218	O	7.1
31	221	228	U-DYN	Rifampin
32	229	229	O	:
33	231	241	O	Combination
34	243	245	O	use
35	247	249	O	may
36	251	258	B-EFF	decrease
37	260	265	L-EFF	effect
38	268	270	O	7.2
39	273	284	U-DYN	Ketoconazole
40	285	285	O	:
41	287	297	O	Combination
42	299	301	O	use
43	303	305	O	may
44	307	314	B-EFF	increase
45	316	321	L-EFF	effect
46	324	326	O	7.2
47	329	330	O	Co
48	332	345	O	administration
49	347	348	O	of
50	350	357	O	XXXXXXXX
51	359	362	O	with
52	364	368	O	other
53	370	372	O	CNS
54	374	384	O	depressants
55	386	394	O	increases
56	396	398	O	the
57	400	403	O	risk
58	405	406	O	of
59	408	410	B-EFF	CNS
60	412	421	L-EFF	depression
D/1:18:0 D/1:24:0 D/1:36:0 D/1:44:0 D/1:59:1 D/1:8:1 D/16:18:1 D/16:24:0 D/16:36:0 D/16:44:0 D/16:59:0 D/16:8:0 D/22:18:0 D/22:24:1 D/22:36:0 D/22:44:0 D/22:59:0 D/22:8:0 D/31:18:0 D/31:24:0 D/31:36:1 D/31:44:0 D/31:59:0 D/31:8:0 D/39:18:0 D/39:24:0 D/39:36:0 D/39:44:1 D/39:59:0 D/39:8:0 D/5:18:0 D/5:24:0 D/5:36:0 D/5:44:0 D/5:59:0 D/5:8:1

Zolpidem	5656	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	18
Concomitant use of zolpidem with these drugs may increase drowsiness and psychomotor impairment, including impaired driving ability.
1	0	10	O	Concomitant
2	12	14	O	use
3	16	17	O	of
4	19	26	O	XXXXXXXX
5	28	31	O	with
6	33	37	O	these
7	39	43	O	drugs
8	45	47	O	may
9	49	56	O	increase
10	58	67	O	drowsiness
11	69	71	O	and
12	73	83	O	psychomotor
13	85	94	O	impairment
14	95	95	O	,
15	97	105	O	including
16	107	114	O	impaired
17	116	122	O	driving
18	124	130	O	ability
NULL

Zolpidem	5657	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	16
Zolpidem tartrate was evaluated in healthy volunteers in single-dose interaction studies for several CNS drugs.
1	0	7	O	XXXXXXXX
2	9	16	O	tartrate
3	18	20	O	was
4	22	30	O	evaluated
5	32	33	O	in
6	35	41	O	healthy
7	43	52	O	volunteers
8	54	55	O	in
9	57	62	O	single
10	64	67	O	dose
11	69	79	O	interaction
12	81	87	O	studies
13	89	91	O	for
14	93	99	O	several
15	101	103	O	CNS
16	105	109	O	drugs
NULL

Zolpidem	5658	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	32
Imipramine, Chlorpromazine Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness.
1	0	9	U-DYN	Imipramine
2	10	10	O	,
3	12	25	O	Chlorpromazine
4	27	36	O	Imipramine
5	38	39	O	in
6	41	51	O	combination
7	53	56	O	with
8	58	65	O	XXXXXXXX
9	67	74	O	produced
10	76	77	O	no
11	79	93	O	pharmacokinetic
12	95	105	O	interaction
13	107	111	O	other
14	113	116	O	than
15	118	118	O	a
16	120	122	O	20%
17	124	131	B-TRI	decrease
18	133	134	I-TRI	in
19	136	139	I-TRI	peak
20	141	146	L-TRI	levels
21	148	149	O	of
22	151	160	O	imipramine
23	161	161	O	,
24	163	165	O	but
25	167	171	O	there
26	173	175	O	was
27	177	178	O	an
28	180	187	B-EFF	additive
29	189	194	I-EFF	effect
30	196	197	I-EFF	of
31	199	207	I-EFF	decreased
32	209	217	L-EFF	alertness
D/1:28:1

Zolpidem	5659	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	24
Similarly, chlorpromazine in combination with zolpidem produced no pharmacokinetic interaction, but there was an additive effect of decreased alertness and psychomotor performance.
1	0	8	O	Similarly
2	9	9	O	,
3	11	24	U-DYN	chlorpromazine
4	26	27	O	in
5	29	39	O	combination
6	41	44	O	with
7	46	53	O	XXXXXXXX
8	55	62	O	produced
9	64	65	O	no
10	67	81	O	pharmacokinetic
11	83	93	O	interaction
12	94	94	O	,
13	96	98	O	but
14	100	104	O	there
15	106	108	O	was
16	110	111	O	an
17	113	120	O	additive
18	122	127	O	effect
19	129	130	O	of
20	132	140	B-EFF	decreased
21	142	150	L-EFF	alertness
22	152	154	O	and
23	156	166	O	psychomotor
24	168	178	O	performance
D/3:20:1

Zolpidem	5660	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	19
Haloperidol A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem.
1	0	10	O	Haloperidol
2	12	12	O	A
3	14	18	O	study
4	20	28	O	involving
5	30	40	O	haloperidol
6	42	44	O	and
7	46	53	O	XXXXXXXX
8	55	62	O	revealed
9	64	65	O	no
10	67	72	O	effect
11	74	75	O	of
12	77	87	O	haloperidol
13	89	90	O	on
14	92	94	O	the
15	96	111	O	pharmacokinetics
16	113	114	O	or
17	116	131	O	pharmacodynamics
18	133	134	O	of
19	136	143	O	XXXXXXXX
NULL

Zolpidem	5661	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	21
The lack of a drug interaction following single-dose administration does not predict the absence of an effect following chronic administration.
1	0	2	O	The
2	4	7	O	lack
3	9	10	O	of
4	12	12	O	a
5	14	17	O	drug
6	19	29	O	interaction
7	31	39	O	following
8	41	46	O	single
9	48	51	O	dose
10	53	66	O	administration
11	68	71	O	does
12	73	75	O	not
13	77	83	O	predict
14	85	87	O	the
15	89	95	O	absence
16	97	98	O	of
17	100	101	O	an
18	103	108	O	effect
19	110	118	O	following
20	120	126	O	chronic
21	128	141	O	administration
NULL

Zolpidem	5662	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	15
Alcohol An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated.
1	0	6	O	Alcohol
2	8	9	O	An
3	11	18	B-EFF	additive
4	20	26	I-EFF	adverse
5	28	33	I-EFF	effect
6	35	36	I-EFF	on
7	38	48	I-EFF	psychomotor
8	50	60	L-EFF	performance
9	62	68	O	between
10	70	76	U-DYN	alcohol
11	78	80	O	and
12	82	85	O	oral
13	87	94	O	XXXXXXXX
14	96	98	O	was
15	100	111	O	demonstrated
D/10:3:1

Zolpidem	5663	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	11
Sertraline Concomitant administration of zolpidem and sertraline increases exposure to zolpidem.
1	0	9	O	Sertraline
2	11	21	O	Concomitant
3	23	36	O	administration
4	38	39	O	of
5	41	48	O	XXXXXXXX
6	50	52	O	and
7	54	63	U-KIN	sertraline
8	65	73	B-TRI	increases
9	75	82	L-TRI	exposure
10	84	85	O	to
11	87	94	O	XXXXXXXX
K/7:C54355

Zolpidem	5664	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	19
Fluoxetine After multiple doses of zolpidem tartrate and fluoxetine an increase in the zolpidem half-life (17%) was observed.
1	0	9	O	Fluoxetine
2	11	15	O	After
3	17	24	O	multiple
4	26	30	O	doses
5	32	33	O	of
6	35	42	O	XXXXXXXX
7	44	51	O	tartrate
8	53	55	O	and
9	57	66	U-KIN	fluoxetine
10	68	69	O	an
11	71	78	O	increase
12	80	81	O	in
13	83	85	O	the
14	87	94	O	XXXXXXXX
15	96	99	O	half
16	101	104	O	life
17	107	109	O	17%
18	112	114	O	was
19	116	123	O	observed
K/9:C54603

Zolpidem	5665	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	11
There was no evidence of an additive effect in psychomotor performance.
1	0	4	O	There
2	6	8	O	was
3	10	11	O	no
4	13	20	O	evidence
5	22	23	O	of
6	25	26	O	an
7	28	35	O	additive
8	37	42	O	effect
9	44	45	O	in
10	47	57	O	psychomotor
11	59	69	O	performance
NULL

Zolpidem	5666	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	13
Some compounds known to induce or inhibit CYP3A may affect exposure to zolpidem.
1	0	3	O	Some
2	5	13	B-UNK	compounds
3	15	19	I-UNK	known
4	21	22	I-UNK	to
5	24	29	I-UNK	induce
6	31	32	I-UNK	or
7	34	40	I-UNK	inhibit
8	42	46	L-UNK	CYP3A
9	48	50	O	may
10	52	57	B-TRI	affect
11	59	66	L-TRI	exposure
12	68	69	O	to
13	71	78	O	XXXXXXXX
NULL

Zolpidem	5667	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	19
The effect of drugs that induce or inhibit other P450 enzymes on the exposure to zolpidem is not known.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	18	O	drugs
5	20	23	O	that
6	25	30	O	induce
7	32	33	O	or
8	35	41	O	inhibit
9	43	47	O	other
10	49	52	O	P450
11	54	60	O	enzymes
12	62	63	O	on
13	65	67	O	the
14	69	76	O	exposure
15	78	79	O	to
16	81	88	O	XXXXXXXX
17	90	91	O	is
18	93	95	O	not
19	97	101	O	known
NULL

Zolpidem	5668	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	20
CYP3A4 Inducers Rifampin Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem.
1	0	5	B-DYN	CYP3A4
2	7	14	L-DYN	Inducers
3	16	23	U-DYN	Rifampin
4	25	32	O	Rifampin
5	33	33	O	,
6	35	35	O	a
7	37	42	B-DYN	CYP3A4
8	44	50	L-DYN	inducer
9	51	51	O	,
10	53	65	O	significantly
11	67	73	B-TRI	reduced
12	75	77	I-TRI	the
13	79	86	L-TRI	exposure
14	88	89	O	to
15	91	93	O	and
16	95	97	O	the
17	99	113	O	pharmacodynamic
18	115	121	O	effects
19	123	124	O	of
20	126	133	O	XXXXXXXX
NULL

Zolpidem	5669	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	17
Use of Rifampin in combination with zolpidem may decrease the efficacy of zolpidem and is not recommended.
1	0	2	O	Use
2	4	5	O	of
3	7	14	U-DYN	Rifampin
4	16	17	O	in
5	19	29	O	combination
6	31	34	O	with
7	36	43	O	XXXXXXXX
8	45	47	O	may
9	49	56	B-EFF	decrease
10	58	60	I-EFF	the
11	62	69	I-EFF	efficacy
12	71	72	I-EFF	of
13	74	81	L-EFF	XXXXXXXX
14	83	85	O	and
15	87	88	O	is
16	90	92	O	not
17	94	104	O	recommended
D/3:9:1

Zolpidem	5670	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	27
St. John's wort Use of St. John's wort, a CYP3A4 inducer, in combination with zolpidem may decrease blood levels of zolpidem and is not recommended.
1	0	1	B-KIN	St
2	4	9	I-KIN	John's
3	11	14	L-KIN	wort
4	16	18	O	Use
5	20	21	O	of
6	23	24	O	St
7	27	32	O	John's
8	34	37	O	wort
9	38	38	O	,
10	40	40	O	a
11	42	47	B-KIN	CYP3A4
12	49	55	L-KIN	inducer
13	56	56	O	,
14	58	59	O	in
15	61	71	O	combination
16	73	76	O	with
17	78	85	O	XXXXXXXX
18	87	89	O	may
19	91	98	B-TRI	decrease
20	100	104	I-TRI	blood
21	106	111	L-TRI	levels
22	113	114	O	of
23	116	123	O	XXXXXXXX
24	125	127	O	and
25	129	130	O	is
26	132	134	O	not
27	136	146	O	recommended
K/1:C54356 K/11:C54356

Zolpidem	5671	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	19
CYP3A4 Inhibitors Ketoconazole Ketoconazole, a potent CYP3A4 inhibitor, increased the exposure to and pharmacodynamic effects of zolpidem.
1	0	5	B-DYN	CYP3A4
2	7	16	L-DYN	Inhibitors
3	18	29	U-DYN	Ketoconazole
4	31	42	O	Ketoconazole
5	43	43	O	,
6	45	45	O	a
7	47	52	B-DYN	potent
8	54	59	I-DYN	CYP3A4
9	61	69	L-DYN	inhibitor
10	70	70	O	,
11	72	80	B-TRI	increased
12	82	84	I-TRI	the
13	86	93	L-TRI	exposure
14	95	96	O	to
15	98	100	O	and
16	102	116	O	pharmacodynamic
17	118	124	O	effects
18	126	127	O	of
19	129	136	O	XXXXXXXX
NULL

Zolpidem	5672	34073-7	d76d5540-7bae-4719-8166-f2a9106338df	21
Consideration should be given to using a lower dose of zolpidem when a potent CYP3A4 inhibitor and zolpidem are given together.
1	0	12	O	Consideration
2	14	19	O	should
3	21	22	O	be
4	24	28	O	given
5	30	31	O	to
6	33	37	O	using
7	39	39	O	a
8	41	45	B-TRI	lower
9	47	50	L-TRI	dose
10	52	53	O	of
11	55	62	O	XXXXXXXX
12	64	67	O	when
13	69	69	O	a
14	71	76	B-KIN	potent
15	78	83	I-KIN	CYP3A4
16	85	93	L-KIN	inhibitor
17	95	97	O	and
18	99	106	O	XXXXXXXX
19	108	110	O	are
20	112	116	O	given
21	118	125	O	together
K/14:C54355

Zolpidem	5673	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	30
Zolpidem, the active moiety of zolpidem tartrate, is a hypnotic agent with a chemical structure unrelated to benzodiazepines, barbiturates, or other drugs with known hypnotic properties.
1	0	7	O	XXXXXXXX
2	8	8	O	,
3	10	12	O	the
4	14	19	O	active
5	21	26	O	moiety
6	28	29	O	of
7	31	38	O	XXXXXXXX
8	40	47	O	tartrate
9	48	48	O	,
10	50	51	O	is
11	53	53	O	a
12	55	62	O	hypnotic
13	64	68	O	agent
14	70	73	O	with
15	75	75	O	a
16	77	84	O	chemical
17	86	94	O	structure
18	96	104	O	unrelated
19	106	107	O	to
20	109	123	O	benzodiazepines
21	124	124	O	,
22	126	137	O	barbiturates
23	138	138	O	,
24	140	141	O	or
25	143	147	O	other
26	149	153	O	drugs
27	155	158	O	with
28	160	164	O	known
29	166	173	O	hypnotic
30	175	184	O	properties
NULL

Zolpidem	5674	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	18
It interacts with a GABA-BZ receptor complex and shares some of the pharmacological properties of the benzodiazepines.
1	0	1	O	It
2	3	11	O	interacts
3	13	16	O	with
4	18	18	O	a
5	20	23	O	GABA
6	25	26	O	BZ
7	28	35	O	receptor
8	37	43	O	complex
9	45	47	O	and
10	49	54	O	shares
11	56	59	O	some
12	61	62	O	of
13	64	66	O	the
14	68	82	O	pharmacological
15	84	93	O	properties
16	95	96	O	of
17	98	100	O	the
18	102	116	O	benzodiazepines
NULL

Zolpidem	5675	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	37
In contrast to the benzodiazepines, which non-selectively bind to and activate all BZ receptor subtypes, zolpidem in vitro binds the BZ1 receptor preferentially with a high affinity ratio of the A1/A5 subunits.
1	0	1	O	In
2	3	10	O	contrast
3	12	13	O	to
4	15	17	O	the
5	19	33	O	benzodiazepines
6	34	34	O	,
7	36	40	O	which
8	42	44	O	non
9	46	56	O	selectively
10	58	61	O	bind
11	63	64	O	to
12	66	68	O	and
13	70	77	O	activate
14	79	81	O	all
15	83	84	O	BZ
16	86	93	O	receptor
17	95	102	O	subtypes
18	103	103	O	,
19	105	112	O	XXXXXXXX
20	114	115	O	in
21	117	121	O	vitro
22	123	127	O	binds
23	129	131	O	the
24	133	135	O	BZ1
25	137	144	O	receptor
26	146	159	O	preferentially
27	161	164	O	with
28	166	166	O	a
29	168	171	O	high
30	173	180	O	affinity
31	182	186	O	ratio
32	188	189	O	of
33	191	193	O	the
34	195	196	O	A1
35	197	197	O	/
36	198	199	O	A5
37	201	208	O	subunits
NULL

Zolpidem	5676	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	49
This selective binding of zolpidem on the BZ1 receptor is not absolute, but it may explain the relative absence of myorelaxant and anticonvulsant effects in animal studies as well as the preservation of deep sleep (stages 3 and 4) in human studies of zolpidem tartrate at hypnotic doses.
1	0	3	O	This
2	5	13	O	selective
3	15	21	O	binding
4	23	24	O	of
5	26	33	O	XXXXXXXX
6	35	36	O	on
7	38	40	O	the
8	42	44	O	BZ1
9	46	53	O	receptor
10	55	56	O	is
11	58	60	O	not
12	62	69	O	absolute
13	70	70	O	,
14	72	74	O	but
15	76	77	O	it
16	79	81	O	may
17	83	89	O	explain
18	91	93	O	the
19	95	102	O	relative
20	104	110	O	absence
21	112	113	O	of
22	115	125	O	myorelaxant
23	127	129	O	and
24	131	144	O	anticonvulsant
25	146	152	O	effects
26	154	155	O	in
27	157	162	O	animal
28	164	170	O	studies
29	172	173	O	as
30	175	178	O	well
31	180	181	O	as
32	183	185	O	the
33	187	198	O	preservation
34	200	201	O	of
35	203	206	O	deep
36	208	212	O	sleep
37	215	220	O	stages
38	222	222	O	3
39	224	226	O	and
40	228	228	O	4
41	231	232	O	in
42	234	238	O	human
43	240	246	O	studies
44	248	249	O	of
45	251	258	O	XXXXXXXX
46	260	267	O	tartrate
47	269	270	O	at
48	272	279	O	hypnotic
49	281	285	O	doses
NULL

Zolpidem	5677	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	26
The pharmacokinetic profile of AMBIEN is characterized by rapid absorption from the gastrointestinal tract and a short elimination half-life (T1/ 2) in healthy subjects.
1	0	2	O	The
2	4	18	O	pharmacokinetic
3	20	26	O	profile
4	28	29	O	of
5	31	36	O	AMBIEN
6	38	39	O	is
7	41	53	O	characterized
8	55	56	O	by
9	58	62	O	rapid
10	64	73	O	absorption
11	75	78	O	from
12	80	82	O	the
13	84	99	O	gastrointestinal
14	101	105	O	tract
15	107	109	O	and
16	111	111	O	a
17	113	117	O	short
18	119	129	O	elimination
19	131	134	O	half
20	136	139	O	life
21	142	143	O	T1
22	144	144	O	/
23	146	146	O	2
24	149	150	O	in
25	152	158	O	healthy
26	160	167	O	subjects
NULL

Zolpidem	5678	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	57
In a single-dose crossover study in 45 healthy subjects administered 5 and 10 mg zolpidem tartrate tablets, the mean peak concentrations (Cma x) were 59 (range: 29 to 113) and 121 (range: 58 to 272) ng/mL, respectively, occurring at a mean time (Tma x) of 1.6 hours for both.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	single
4	12	15	O	dose
5	17	25	O	crossover
6	27	31	O	study
7	33	34	O	in
8	36	37	O	45
9	39	45	O	healthy
10	47	54	O	subjects
11	56	67	O	administered
12	69	69	O	5
13	71	73	O	and
14	75	76	O	10
15	78	79	O	mg
16	81	88	O	XXXXXXXX
17	90	97	O	tartrate
18	99	105	O	tablets
19	106	106	O	,
20	108	110	O	the
21	112	115	O	mean
22	117	120	O	peak
23	122	135	O	concentrations
24	138	140	O	Cma
25	142	142	O	x
26	145	148	O	were
27	150	151	O	59
28	154	158	O	range
29	159	159	O	:
30	161	162	O	29
31	164	165	O	to
32	167	169	O	113
33	172	174	O	and
34	176	178	O	121
35	181	185	O	range
36	186	186	O	:
37	188	189	O	58
38	191	192	O	to
39	194	196	O	272
40	199	200	O	ng
41	201	201	O	/
42	202	203	O	mL
43	204	204	O	,
44	206	217	O	respectively
45	218	218	O	,
46	220	228	O	occurring
47	230	231	O	at
48	233	233	O	a
49	235	238	O	mean
50	240	243	O	time
51	246	248	O	Tma
52	250	250	O	x
53	253	254	O	of
54	256	258	O	1.6
55	260	264	O	hours
56	266	268	O	for
57	270	273	O	both
NULL

Zolpidem	5679	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	31
The mean AMBIEN elimination half-life was 2.6 (range: 1.4 to 4.5) and 2.5 (range: 1.4 to 3.8) hours, for the 5 and 10 mg tablets, respectively.
1	0	2	O	The
2	4	7	O	mean
3	9	14	O	AMBIEN
4	16	26	O	elimination
5	28	31	O	half
6	33	36	O	life
7	38	40	O	was
8	42	44	O	2.6
9	47	51	O	range
10	52	52	O	:
11	54	56	O	1.4
12	58	59	O	to
13	61	63	O	4.5
14	66	68	O	and
15	70	72	O	2.5
16	75	79	O	range
17	80	80	O	:
18	82	84	O	1.4
19	86	87	O	to
20	89	91	O	3.8
21	94	98	O	hours
22	99	99	O	,
23	101	103	O	for
24	105	107	O	the
25	109	109	O	5
26	111	113	O	and
27	115	116	O	10
28	118	119	O	mg
29	121	127	O	tablets
30	128	128	O	,
31	130	141	O	respectively
NULL

Zolpidem	5680	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	13
AMBIEN is converted to inactive metabolites that are eliminated primarily by renal excretion.
1	0	5	O	AMBIEN
2	7	8	O	is
3	10	18	O	converted
4	20	21	O	to
5	23	30	O	inactive
6	32	42	O	metabolites
7	44	47	O	that
8	49	51	O	are
9	53	62	O	eliminated
10	64	72	O	primarily
11	74	75	O	by
12	77	81	O	renal
13	83	91	O	excretion
NULL

Zolpidem	5681	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	37
AMBIEN demonstrated linear kinetics in the dose range of 5 to 20 mg. Total protein binding was found to be 92.5 * 0.1% and remained constant, independent of concentration between 40 and 790 ng/mL.
1	0	5	O	AMBIEN
2	7	18	O	demonstrated
3	20	25	O	linear
4	27	34	O	kinetics
5	36	37	O	in
6	39	41	O	the
7	43	46	O	dose
8	48	52	O	range
9	54	55	O	of
10	57	57	O	5
11	59	60	O	to
12	62	63	O	20
13	65	66	O	mg
14	69	73	O	Total
15	75	81	O	protein
16	83	89	O	binding
17	91	93	O	was
18	95	99	O	found
19	101	102	O	to
20	104	105	O	be
21	107	110	O	92.5
22	112	112	O	*
23	114	117	O	0.1%
24	119	121	O	and
25	123	130	O	remained
26	132	139	O	constant
27	140	140	O	,
28	142	152	O	independent
29	154	155	O	of
30	157	169	O	concentration
31	171	177	O	between
32	179	180	O	40
33	182	184	O	and
34	186	188	O	790
35	190	191	O	ng
36	192	192	O	/
37	193	194	O	mL
NULL

Zolpidem	5682	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	19
Zolpidem did not accumulate in young adults following nightly dosing with 20 mg zolpidem tartrate tablets for 2 weeks.
1	0	7	O	XXXXXXXX
2	9	11	O	did
3	13	15	O	not
4	17	26	O	accumulate
5	28	29	O	in
6	31	35	O	young
7	37	42	O	adults
8	44	52	O	following
9	54	60	O	nightly
10	62	67	O	dosing
11	69	72	O	with
12	74	75	O	20
13	77	78	O	mg
14	80	87	O	XXXXXXXX
15	89	96	O	tartrate
16	98	104	O	tablets
17	106	108	O	for
18	110	110	O	2
19	112	116	O	weeks
NULL

Zolpidem	5683	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	26
A food-effect study in 30 healthy male subjects compared the pharmacokinetics of AMBIEN 10 mg when administered while fasting or 20 minutes after a meal.
1	0	0	O	A
2	2	5	O	food
3	7	12	O	effect
4	14	18	O	study
5	20	21	O	in
6	23	24	O	30
7	26	32	O	healthy
8	34	37	O	male
9	39	46	O	subjects
10	48	55	O	compared
11	57	59	O	the
12	61	76	O	pharmacokinetics
13	78	79	O	of
14	81	86	O	AMBIEN
15	88	89	O	10
16	91	92	O	mg
17	94	97	O	when
18	99	110	O	administered
19	112	116	O	while
20	118	124	O	fasting
21	126	127	O	or
22	129	130	O	20
23	132	138	O	minutes
24	140	144	O	after
25	146	146	O	a
26	148	151	O	meal
NULL

Zolpidem	5684	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	31
Results demonstrated that with food, mean AUC and Cmax were decreased by 15% and 25%, respectively, while mean Tmax was prolonged by 60% (from 1.4 to 2.2 hr).
1	0	6	O	Results
2	8	19	O	demonstrated
3	21	24	O	that
4	26	29	O	with
5	31	34	U-KIN	food
6	35	35	O	,
7	37	40	O	mean
8	42	44	O	AUC
9	46	48	O	and
10	50	53	O	Cmax
11	55	58	O	were
12	60	68	O	decreased
13	70	71	O	by
14	73	75	O	15%
15	77	79	O	and
16	81	83	O	25%
17	84	84	O	,
18	86	97	O	respectively
19	98	98	O	,
20	100	104	O	while
21	106	109	O	mean
22	111	114	O	Tmax
23	116	118	O	was
24	120	128	O	prolonged
25	130	131	O	by
26	133	135	O	60%
27	138	141	O	from
28	143	145	O	1.4
29	147	148	O	to
30	150	152	O	2.2
31	154	155	O	hr
K/5:C54606

Zolpidem	5685	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	21
These results suggest that, for faster sleep onset, AMBIEN should not be administered with or immediately after a meal.
1	0	4	O	These
2	6	12	O	results
3	14	20	O	suggest
4	22	25	O	that
5	26	26	O	,
6	28	30	O	for
7	32	37	O	faster
8	39	43	O	sleep
9	45	49	O	onset
10	50	50	O	,
11	52	57	O	AMBIEN
12	59	64	O	should
13	66	68	O	not
14	70	71	O	be
15	73	84	O	administered
16	86	89	O	with
17	91	92	O	or
18	94	104	O	immediately
19	106	110	O	after
20	112	112	O	a
21	114	117	O	meal
NULL

Zolpidem	5686	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	16
Special Populations Elderly: In the elderly, the dose for AMBIEN should be 5 mg.
1	0	6	O	Special
2	8	18	O	Populations
3	20	26	O	Elderly
4	27	27	O	:
5	29	30	O	In
6	32	34	O	the
7	36	42	O	elderly
8	43	43	O	,
9	45	47	O	the
10	49	52	O	dose
11	54	56	O	for
12	58	63	O	AMBIEN
13	65	70	O	should
14	72	73	O	be
15	75	75	O	5
16	77	78	O	mg
NULL

Zolpidem	5687	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	29
This recommendation is based on several studies in which the mean Cmax, T1/2, and AUC were significantly increased when compared to results in young adults.
1	0	3	O	This
2	5	18	O	recommendation
3	20	21	O	is
4	23	27	O	based
5	29	30	O	on
6	32	38	O	several
7	40	46	O	studies
8	48	49	O	in
9	51	55	O	which
10	57	59	O	the
11	61	64	O	mean
12	66	69	O	Cmax
13	70	70	O	,
14	72	73	O	T1
15	74	74	O	/
16	75	75	O	2
17	76	76	O	,
18	78	80	O	and
19	82	84	O	AUC
20	86	89	O	were
21	91	103	O	significantly
22	105	113	O	increased
23	115	118	O	when
24	120	127	O	compared
25	129	130	O	to
26	132	138	O	results
27	140	141	O	in
28	143	147	O	young
29	149	154	O	adults
NULL

Zolpidem	5688	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	66
In one study of eight elderly subjects (> 70 years), the means for Cmax, T1/2, and AUC significantly increased by 50% (255 vs. 384 ng/mL), 32% (2.2 vs. 2.9 hr), and 64% (955 vs. 1,562 ng*hr/mL), respectively, as compared to younger adults (20 to 40 years) following a single 20 mg oral dose.
1	0	1	O	In
2	3	5	O	one
3	7	11	O	study
4	13	14	O	of
5	16	20	O	eight
6	22	28	O	elderly
7	30	37	O	subjects
8	40	40	O	>
9	42	43	O	70
10	45	49	O	years
11	51	51	O	,
12	53	55	O	the
13	57	61	O	means
14	63	65	O	for
15	67	70	O	Cmax
16	71	71	O	,
17	73	74	O	T1
18	75	75	O	/
19	76	76	O	2
20	77	77	O	,
21	79	81	O	and
22	83	85	O	AUC
23	87	99	O	significantly
24	101	109	O	increased
25	111	112	O	by
26	114	116	O	50%
27	119	121	O	255
28	123	124	O	vs
29	127	129	O	384
30	131	132	O	ng
31	133	133	O	/
32	134	135	O	mL
33	137	137	O	,
34	139	141	O	32%
35	144	146	O	2.2
36	148	149	O	vs
37	152	154	O	2.9
38	156	157	O	hr
39	159	159	O	,
40	161	163	O	and
41	165	167	O	64%
42	170	172	O	955
43	174	175	O	vs
44	178	182	O	1,562
45	184	188	O	ng*hr
46	189	189	O	/
47	190	191	O	mL
48	193	193	O	,
49	195	206	O	respectively
50	207	207	O	,
51	209	210	O	as
52	212	219	O	compared
53	221	222	O	to
54	224	230	O	younger
55	232	237	O	adults
56	240	241	O	20
57	243	244	O	to
58	246	247	O	40
59	249	253	O	years
60	256	264	O	following
61	266	266	O	a
62	268	273	O	single
63	275	276	O	20
64	278	279	O	mg
65	281	284	O	oral
66	286	289	O	dose
NULL

Zolpidem	5689	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	17
AMBIEN did not accumulate in elderly subjects following nightly oral dosing of 10 mg for 1 week.
1	0	5	O	AMBIEN
2	7	9	O	did
3	11	13	O	not
4	15	24	O	accumulate
5	26	27	O	in
6	29	35	O	elderly
7	37	44	O	subjects
8	46	54	O	following
9	56	62	O	nightly
10	64	67	O	oral
11	69	74	O	dosing
12	76	77	O	of
13	79	80	O	10
14	82	83	O	mg
15	85	87	O	for
16	89	89	O	1
17	91	94	O	week
NULL

Zolpidem	5690	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	21
Hepatic Impairment: The pharmacokinetics of AMBIEN in eight patients with chronic hepatic insufficiency were compared to results in healthy subjects.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	18	18	O	:
4	20	22	O	The
5	24	39	O	pharmacokinetics
6	41	42	O	of
7	44	49	O	AMBIEN
8	51	52	O	in
9	54	58	O	eight
10	60	67	O	patients
11	69	72	O	with
12	74	80	O	chronic
13	82	88	O	hepatic
14	90	102	O	insufficiency
15	104	107	O	were
16	109	116	O	compared
17	118	119	O	to
18	121	127	O	results
19	129	130	O	in
20	132	138	O	healthy
21	140	147	O	subjects
NULL

Zolpidem	5691	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	43
Following a single 20 mg oral zolpidem tartrate dose, mean Cmax and AUC were found to be two times (250 vs. 499 ng/mL) and five times (788 vs. 4,203 ng*hr/mL) higher, respectively, in hepatically -compromised patients.
1	0	8	O	Following
2	10	10	O	a
3	12	17	O	single
4	19	20	O	20
5	22	23	O	mg
6	25	28	O	oral
7	30	37	O	XXXXXXXX
8	39	46	O	tartrate
9	48	51	O	dose
10	52	52	O	,
11	54	57	O	mean
12	59	62	O	Cmax
13	64	66	O	and
14	68	70	O	AUC
15	72	75	O	were
16	77	81	O	found
17	83	84	O	to
18	86	87	O	be
19	89	91	O	two
20	93	97	O	times
21	100	102	O	250
22	104	105	O	vs
23	108	110	O	499
24	112	113	O	ng
25	114	114	O	/
26	115	116	O	mL
27	119	121	O	and
28	123	126	O	five
29	128	132	O	times
30	135	137	O	788
31	139	140	O	vs
32	143	147	O	4,203
33	149	153	O	ng*hr
34	154	154	O	/
35	155	156	O	mL
36	159	164	O	higher
37	165	165	O	,
38	167	178	O	respectively
39	179	179	O	,
40	181	182	O	in
41	184	194	O	hepatically
42	197	207	O	compromised
43	209	216	O	patients
NULL

Zolpidem	5692	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	33
The mean half-life in cirrhotic patients of 9.9 hr (range: 4.1 to 25.8 hr) was greater than that observed in normal subjects of 2.2 hr (range: 1.6 to 2.4 hr).
1	0	2	O	The
2	4	7	O	mean
3	9	12	O	half
4	14	17	O	life
5	19	20	O	in
6	22	30	O	cirrhotic
7	32	39	O	patients
8	41	42	O	of
9	44	46	O	9.9
10	48	49	O	hr
11	52	56	O	range
12	57	57	O	:
13	59	61	O	4.1
14	63	64	O	to
15	66	69	O	25.8
16	71	72	O	hr
17	75	77	O	was
18	79	85	O	greater
19	87	90	O	than
20	92	95	O	that
21	97	104	O	observed
22	106	107	O	in
23	109	114	O	normal
24	116	123	O	subjects
25	125	126	O	of
26	128	130	O	2.2
27	132	133	O	hr
28	136	140	O	range
29	141	141	O	:
30	143	145	O	1.6
31	147	148	O	to
32	150	152	O	2.4
33	154	155	O	hr
NULL

Zolpidem	5693	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	50
Renal Impairment: The pharmacokinetics of zolpidem tartrate were studied in 11 patients with end-stage renal failure (mean ClCr = 6.5 * 1.5 mL/min) undergoing hemodialysis three times a week, who were dosed with zolpidem tartrate 10 mg orally each day for 14 or 21 days.
1	0	4	O	Renal
2	6	15	O	Impairment
3	16	16	O	:
4	18	20	O	The
5	22	37	O	pharmacokinetics
6	39	40	O	of
7	42	49	O	XXXXXXXX
8	51	58	O	tartrate
9	60	63	O	were
10	65	71	O	studied
11	73	74	O	in
12	76	77	O	11
13	79	86	O	patients
14	88	91	O	with
15	93	95	O	end
16	97	101	O	stage
17	103	107	O	renal
18	109	115	O	failure
19	118	121	O	mean
20	123	126	O	ClCr
21	128	128	O	=
22	130	132	O	6.5
23	134	134	O	*
24	136	138	O	1.5
25	140	141	O	mL
26	142	142	O	/
27	143	145	O	min
28	148	157	O	undergoing
29	159	170	O	hemodialysis
30	172	176	O	three
31	178	182	O	times
32	184	184	O	a
33	186	189	O	week
34	190	190	O	,
35	192	194	O	who
36	196	199	O	were
37	201	205	O	dosed
38	207	210	O	with
39	212	219	O	XXXXXXXX
40	221	228	O	tartrate
41	230	231	O	10
42	233	234	O	mg
43	236	241	O	orally
44	243	246	O	each
45	248	250	O	day
46	252	254	O	for
47	256	257	O	14
48	259	260	O	or
49	262	263	O	21
50	265	268	O	days
NULL

Zolpidem	5694	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	31
No statistically significant differences were observed for Cmax, Tmax, half-life, and AUC between the first and last day of drug administration when baseline concentration adjustments were made.
1	0	1	O	No
2	3	15	O	statistically
3	17	27	O	significant
4	29	39	O	differences
5	41	44	O	were
6	46	53	O	observed
7	55	57	O	for
8	59	62	O	Cmax
9	63	63	O	,
10	65	68	O	Tmax
11	69	69	O	,
12	71	74	O	half
13	76	79	O	life
14	80	80	O	,
15	82	84	O	and
16	86	88	O	AUC
17	90	96	O	between
18	98	100	O	the
19	102	106	O	first
20	108	110	O	and
21	112	115	O	last
22	117	119	O	day
23	121	122	O	of
24	124	127	O	drug
25	129	142	O	administration
26	144	147	O	when
27	149	156	O	baseline
28	158	170	O	concentration
29	172	182	O	adjustments
30	184	187	O	were
31	189	192	O	made
NULL

Zolpidem	5695	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	11
No accumulation of unchanged drug appeared after 14 or 21 days.
1	0	1	O	No
2	3	14	O	accumulation
3	16	17	O	of
4	19	27	O	unchanged
5	29	32	O	drug
6	34	41	O	appeared
7	43	47	O	after
8	49	50	O	14
9	52	53	O	or
10	55	56	O	21
11	58	61	O	days
NULL

Zolpidem	5696	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	10
Zolpidem pharmacokinetics were not significantly different in renally impaired patients.
1	0	7	O	XXXXXXXX
2	9	24	O	pharmacokinetics
3	26	29	O	were
4	31	33	O	not
5	35	47	O	significantly
6	49	57	O	different
7	59	60	O	in
8	62	68	O	renally
9	70	77	O	impaired
10	79	86	O	patients
NULL

Zolpidem	5697	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	11
No dosage adjustment is necessary in patients with compromised renal function.
1	0	1	O	No
2	3	8	O	dosage
3	10	19	O	adjustment
4	21	22	O	is
5	24	32	O	necessary
6	34	35	O	in
7	37	44	O	patients
8	46	49	O	with
9	51	61	O	compromised
10	63	67	O	renal
11	69	76	O	function
NULL

Zolpidem	5698	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	18
Drug Interactions CNS-depressants Co-administration of zolpidem with other CNS depressants increases the risk of CNS depression.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	20	O	CNS
4	22	32	O	depressants
5	34	35	O	Co
6	37	50	O	administration
7	52	53	O	of
8	55	62	O	XXXXXXXX
9	64	67	O	with
10	69	73	O	other
11	75	77	B-DYN	CNS
12	79	89	L-DYN	depressants
13	91	99	O	increases
14	101	103	O	the
15	105	108	O	risk
16	110	111	O	of
17	113	115	B-EFF	CNS
18	117	126	L-EFF	depression
D/11:17:1

Zolpidem	5700	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	29
Imipramine in combination with zolpidem produced no pharmacokinetic interaction other than a 20% decrease in peak levels of imipramine, but there was an additive effect of decreased alertness.
1	0	9	O	Imipramine
2	11	12	O	in
3	14	24	O	combination
4	26	29	O	with
5	31	38	O	XXXXXXXX
6	40	47	O	produced
7	49	50	O	no
8	52	66	O	pharmacokinetic
9	68	78	O	interaction
10	80	84	O	other
11	86	89	O	than
12	91	91	O	a
13	93	95	O	20%
14	97	104	B-TRI	decrease
15	106	107	I-TRI	in
16	109	112	I-TRI	peak
17	114	119	L-TRI	levels
18	121	122	O	of
19	124	133	U-DYN	imipramine
20	134	134	O	,
21	136	138	O	but
22	140	144	O	there
23	146	148	O	was
24	150	151	O	an
25	153	160	B-EFF	additive
26	162	167	I-EFF	effect
27	169	170	I-EFF	of
28	172	180	I-EFF	decreased
29	182	190	L-EFF	alertness
D/19:25:1

Zolpidem	5702	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	18
A study involving haloperidol and zolpidem revealed no effect of haloperidol on the pharmacokinetics or pharmacodynamics of zolpidem.
1	0	0	O	A
2	2	6	O	study
3	8	16	O	involving
4	18	28	O	haloperidol
5	30	32	O	and
6	34	41	O	XXXXXXXX
7	43	50	O	revealed
8	52	53	O	no
9	55	60	O	effect
10	62	63	O	of
11	65	75	O	haloperidol
12	77	78	O	on
13	80	82	O	the
14	84	99	O	pharmacokinetics
15	101	102	O	or
16	104	119	O	pharmacodynamics
17	121	122	O	of
18	124	131	O	XXXXXXXX
NULL

Zolpidem	5704	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	14
An additive adverse effect on psychomotor performance between alcohol and oral zolpidem was demonstrated.
1	0	1	O	An
2	3	10	B-EFF	additive
3	12	18	I-EFF	adverse
4	20	25	I-EFF	effect
5	27	28	I-EFF	on
6	30	40	I-EFF	psychomotor
7	42	52	L-EFF	performance
8	54	60	O	between
9	62	68	U-DYN	alcohol
10	70	72	O	and
11	74	77	O	oral
12	79	86	O	XXXXXXXX
13	88	90	O	was
14	92	103	O	demonstrated
D/9:2:1

Zolpidem	5705	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	46
Following five consecutive nightly doses at bedtime of oral zolpidem tartrate 10 mg in the presence of sertraline 50 mg (17 consecutive daily doses, at 7:00 am, in healthy female volunteers), zolpidem Cmax was significantly higher (43%) and Tmax was significantly decreased (-53%).
1	0	8	O	Following
2	10	13	O	five
3	15	25	O	consecutive
4	27	33	O	nightly
5	35	39	O	doses
6	41	42	O	at
7	44	50	O	bedtime
8	52	53	O	of
9	55	58	O	oral
10	60	67	O	XXXXXXXX
11	69	76	O	tartrate
12	78	79	O	10
13	81	82	O	mg
14	84	85	O	in
15	87	89	O	the
16	91	98	O	presence
17	100	101	O	of
18	103	112	U-KIN	sertraline
19	114	115	O	50
20	117	118	O	mg
21	121	122	O	17
22	124	134	O	consecutive
23	136	140	O	daily
24	142	146	O	doses
25	147	147	O	,
26	149	150	O	at
27	152	155	O	7:00
28	157	158	O	am
29	159	159	O	,
30	161	162	O	in
31	164	170	O	healthy
32	172	177	O	female
33	179	188	O	volunteers
34	190	190	O	,
35	192	199	O	XXXXXXXX
36	201	204	O	Cmax
37	206	208	O	was
38	210	222	O	significantly
39	224	229	O	higher
40	232	234	O	43%
41	237	239	O	and
42	241	244	O	Tmax
43	246	248	O	was
44	250	262	O	significantly
45	264	272	O	decreased
46	276	278	O	53%
K/18:C54608

Zolpidem	5706	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	10
Pharmacokinetics of sertraline and N-desmethylsertraline were unaffected by zolpidem.
1	0	15	O	Pharmacokinetics
2	17	18	O	of
3	20	29	O	sertraline
4	31	33	O	and
5	35	35	O	N
6	37	55	O	desmethylsertraline
7	57	60	O	were
8	62	71	O	unaffected
9	73	74	O	by
10	76	83	O	XXXXXXXX
NULL

Zolpidem	5707	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	31
A single-dose interaction study with zolpidem tartrate 10 mg and fluoxetine 20 mg at steady-state levels in male volunteers did not demonstrate any clinically significant pharmacokinetic or pharmacodynamic interactions.
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	24	O	interaction
5	26	30	O	study
6	32	35	O	with
7	37	44	O	XXXXXXXX
8	46	53	O	tartrate
9	55	56	O	10
10	58	59	O	mg
11	61	63	O	and
12	65	74	O	fluoxetine
13	76	77	O	20
14	79	80	O	mg
15	82	83	O	at
16	85	90	O	steady
17	92	96	O	state
18	98	103	O	levels
19	105	106	O	in
20	108	111	O	male
21	113	122	O	volunteers
22	124	126	O	did
23	128	130	O	not
24	132	142	O	demonstrate
25	144	146	O	any
26	148	157	O	clinically
27	159	169	O	significant
28	171	185	O	pharmacokinetic
29	187	188	O	or
30	190	204	O	pharmacodynamic
31	206	217	O	interactions
NULL

Zolpidem	5708	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	30
When multiple doses of zolpidem and fluoxetine were given at steady state and the concentrations evaluated in healthy females, an increase in the zolpidem half-life (17%) was observed.
1	0	3	O	When
2	5	12	O	multiple
3	14	18	O	doses
4	20	21	O	of
5	23	30	O	XXXXXXXX
6	32	34	O	and
7	36	45	U-KIN	fluoxetine
8	47	50	O	were
9	52	56	O	given
10	58	59	O	at
11	61	66	O	steady
12	68	72	O	state
13	74	76	O	and
14	78	80	O	the
15	82	95	O	concentrations
16	97	105	O	evaluated
17	107	108	O	in
18	110	116	O	healthy
19	118	124	O	females
20	125	125	O	,
21	127	128	O	an
22	130	137	O	increase
23	139	140	O	in
24	142	144	O	the
25	146	153	O	XXXXXXXX
26	155	158	O	half
27	160	163	O	life
28	166	168	O	17%
29	171	173	O	was
30	175	182	O	observed
K/7:C54603

Zolpidem	5710	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	19
Drugs that Affect Drug Metabolism via Cytochrome P450 Some compounds known to inhibit CYP3A may increase exposure to zolpidem.
1	0	4	O	Drugs
2	6	9	O	that
3	11	16	O	Affect
4	18	21	O	Drug
5	23	32	O	Metabolism
6	34	36	O	via
7	38	47	O	Cytochrome
8	49	52	O	P450
9	54	57	O	Some
10	59	67	B-KIN	compounds
11	69	73	I-KIN	known
12	75	76	I-KIN	to
13	78	84	I-KIN	inhibit
14	86	90	L-KIN	CYP3A
15	92	94	O	may
16	96	103	B-TRI	increase
17	105	112	L-TRI	exposure
18	114	115	O	to
19	117	124	O	XXXXXXXX
K/10:C54355

Zolpidem	5711	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	15
The effect of inhibitors of other P450 enzymes on the pharmacokinetics of zolpidem is unknown.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	23	O	inhibitors
5	25	26	O	of
6	28	32	O	other
7	34	37	O	P450
8	39	45	O	enzymes
9	47	48	O	on
10	50	52	O	the
11	54	69	O	pharmacokinetics
12	71	72	O	of
13	74	81	O	XXXXXXXX
14	83	84	O	is
15	86	92	O	unknown
NULL

Zolpidem	5712	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	32
A single-dose interaction study with zolpidem tartrate 10 mg and itraconazole 200 mg at steady-state levels in male volunteers resulted in a 34% increase in AUC0-* of zolpidem tartrate.
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	24	O	interaction
5	26	30	O	study
6	32	35	O	with
7	37	44	O	XXXXXXXX
8	46	53	O	tartrate
9	55	56	O	10
10	58	59	O	mg
11	61	63	O	and
12	65	76	U-KIN	itraconazole
13	78	80	O	200
14	82	83	O	mg
15	85	86	O	at
16	88	93	O	steady
17	95	99	O	state
18	101	106	O	levels
19	108	109	O	in
20	111	114	O	male
21	116	125	O	volunteers
22	127	134	O	resulted
23	136	137	O	in
24	139	139	O	a
25	141	143	O	34%
26	145	152	B-TRI	increase
27	154	155	L-TRI	in
28	157	160	O	AUC0
29	162	162	O	*
30	164	165	O	of
31	167	174	O	XXXXXXXX
32	176	183	O	tartrate
K/12:C54605

Zolpidem	5713	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	18
There were no pharmacodynamic effects of zolpidem detected on subjective drowsiness, postural sway, or psychomotor performance.
1	0	4	O	There
2	6	9	O	were
3	11	12	O	no
4	14	28	O	pharmacodynamic
5	30	36	O	effects
6	38	39	O	of
7	41	48	O	XXXXXXXX
8	50	57	O	detected
9	59	60	O	on
10	62	71	O	subjective
11	73	82	O	drowsiness
12	83	83	O	,
13	85	92	O	postural
14	94	97	O	sway
15	98	98	O	,
16	100	101	O	or
17	103	113	O	psychomotor
18	115	125	O	performance
NULL

Zolpidem	5714	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	51
A single-dose interaction study with zolpidem tartrate 10 mg and rifampin 600 mg at steady-state levels in female subjects showed significant reductions of the AUC (-73%), Cmax (-58%), and T1/2 (-36 %) of zolpidem together with significant reductions in the pharmacodynamic effects of zolpidem tartrate.
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	24	O	interaction
5	26	30	O	study
6	32	35	O	with
7	37	44	O	XXXXXXXX
8	46	53	O	tartrate
9	55	56	O	10
10	58	59	O	mg
11	61	63	O	and
12	65	72	U-DYN	rifampin
13	74	76	O	600
14	78	79	O	mg
15	81	82	O	at
16	84	89	O	steady
17	91	95	O	state
18	97	102	O	levels
19	104	105	O	in
20	107	112	O	female
21	114	121	O	subjects
22	123	128	O	showed
23	130	140	O	significant
24	142	151	B-TRI	reductions
25	153	154	I-TRI	of
26	156	158	I-TRI	the
27	160	162	L-TRI	AUC
28	166	168	O	73%
29	170	170	O	,
30	172	175	O	Cmax
31	179	181	O	58%
32	183	183	O	,
33	185	187	O	and
34	189	190	O	T1
35	191	191	O	/
36	192	192	O	2
37	196	197	O	36
38	199	199	O	%
39	202	203	O	of
40	205	212	O	XXXXXXXX
41	214	221	O	together
42	223	226	O	with
43	228	238	O	significant
44	240	249	B-EFF	reductions
45	251	252	I-EFF	in
46	254	256	I-EFF	the
47	258	272	I-EFF	pharmacodynamic
48	274	280	I-EFF	effects
49	282	283	I-EFF	of
50	285	292	I-EFF	XXXXXXXX
51	294	301	L-EFF	tartrate
D/12:44:1

Zolpidem	5715	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	17
Rifampin, a CYP3A4 inducer, significantly reduced the exposure to and the pharmacodynamic effects of zolpidem.
1	0	7	U-DYN	Rifampin
2	8	8	O	,
3	10	10	O	a
4	12	17	O	CYP3A4
5	19	25	O	inducer
6	26	26	O	,
7	28	40	O	significantly
8	42	48	B-TRI	reduced
9	50	52	I-TRI	the
10	54	61	L-TRI	exposure
11	63	64	O	to
12	66	68	O	and
13	70	72	O	the
14	74	88	O	pharmacodynamic
15	90	96	O	effects
16	98	99	O	of
17	101	108	O	XXXXXXXX
NULL

Zolpidem	5716	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	18
Similarly, St. John's wort, a CYP3A4 inducer, may also decrease the blood levels of zolpidem.
1	0	8	O	Similarly
2	9	9	O	,
3	11	12	B-KIN	St
4	15	20	I-KIN	John's
5	22	25	L-KIN	wort
6	26	26	O	,
7	28	28	O	a
8	30	35	B-KIN	CYP3A4
9	37	43	L-KIN	inducer
10	44	44	O	,
11	46	48	O	may
12	50	53	O	also
13	55	62	B-TRI	decrease
14	64	66	I-TRI	the
15	68	72	I-TRI	blood
16	74	79	L-TRI	levels
17	81	82	O	of
18	84	91	O	XXXXXXXX
K/3:C54356 K/8:C54356

Zolpidem	5717	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	61
A single-dose interaction study with zolpidem tartrate 5 mg and ketoconazole, a potent CYP3A4 inhibitor, given as 200 mg twice daily for 2 days increased Cmax of zolpidem (30%) and the total AUC of zolpidem (70%) compared to zolpidem alone and prolonged the elimination half-life (30 %) along with an increase in the pharmacodynamic effects of zolpidem.
1	0	0	O	A
2	2	7	O	single
3	9	12	O	dose
4	14	24	O	interaction
5	26	30	O	study
6	32	35	O	with
7	37	44	O	XXXXXXXX
8	46	53	O	tartrate
9	55	55	O	5
10	57	58	O	mg
11	60	62	O	and
12	64	75	U-DYN	ketoconazole
13	76	76	O	,
14	78	78	O	a
15	80	85	O	potent
16	87	92	O	CYP3A4
17	94	102	O	inhibitor
18	103	103	O	,
19	105	109	O	given
20	111	112	O	as
21	114	116	O	200
22	118	119	O	mg
23	121	125	O	twice
24	127	131	O	daily
25	133	135	O	for
26	137	137	O	2
27	139	142	O	days
28	144	152	B-TRI	increased
29	154	157	L-TRI	Cmax
30	159	160	O	of
31	162	169	O	XXXXXXXX
32	172	174	O	30%
33	177	179	O	and
34	181	183	O	the
35	185	189	O	total
36	191	193	O	AUC
37	195	196	O	of
38	198	205	O	XXXXXXXX
39	208	210	O	70%
40	213	220	O	compared
41	222	223	O	to
42	225	232	O	XXXXXXXX
43	234	238	O	alone
44	240	242	O	and
45	244	252	O	prolonged
46	254	256	O	the
47	258	268	O	elimination
48	270	273	O	half
49	275	278	O	life
50	281	282	O	30
51	284	284	O	%
52	287	291	O	along
53	293	296	O	with
54	298	299	O	an
55	301	308	B-EFF	increase
56	310	311	I-EFF	in
57	313	315	I-EFF	the
58	317	331	I-EFF	pharmacodynamic
59	333	339	I-EFF	effects
60	341	342	I-EFF	of
61	344	351	L-EFF	XXXXXXXX
D/12:55:1

Zolpidem	5718	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	47
Additionally, fluvoxamine (a strong inhibitor of CYP1A2 and a weak inhibitor of CYP3A4 and CYP2C9) and ciprofloxacin (a strong inhibitor of CYP1A2 and a moderate inhibitor of CYP3A4) are also likely to inhibit zolpidem's metabolic pathways, potentially leading to an increase in zolpidem exposure.
1	0	11	O	Additionally
2	12	12	O	,
3	14	24	U-KIN	fluvoxamine
4	27	27	O	a
5	29	34	B-KIN	strong
6	36	44	I-KIN	inhibitor
7	46	47	I-KIN	of
8	49	54	L-KIN	CYP1A2
9	56	58	O	and
10	60	60	O	a
11	62	65	B-KIN	weak
12	67	75	I-KIN	inhibitor
13	77	78	I-KIN	of
14	80	85	L-KIN	CYP3A4
15	87	89	O	and
16	91	96	O	CYP2C9
17	99	101	O	and
18	103	115	U-KIN	ciprofloxacin
19	118	118	O	a
20	120	125	O	strong
21	127	135	O	inhibitor
22	137	138	O	of
23	140	145	O	CYP1A2
24	147	149	O	and
25	151	151	O	a
26	153	160	B-KIN	moderate
27	162	170	I-KIN	inhibitor
28	172	173	I-KIN	of
29	175	180	L-KIN	CYP3A4
30	183	185	O	are
31	187	190	O	also
32	192	197	O	likely
33	199	200	O	to
34	202	208	O	inhibit
35	210	217	O	XXXXXXXX
36	218	219	O	's
37	221	229	O	metabolic
38	231	238	O	pathways
39	239	239	O	,
40	241	251	O	potentially
41	253	259	O	leading
42	261	262	O	to
43	264	265	O	an
44	267	274	O	increase
45	276	277	O	in
46	279	286	O	XXXXXXXX
47	288	295	O	exposure
K/11:C54355 K/18:C54355 K/26:C54355 K/3:C54355 K/5:C54355

Zolpidem	5719	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	33
Other Drugs with No Interactions with Zolpidem A study involving cimetidine/zolpidem tartrate and ranitidine/zolpidem tartrate combinations revealed no effect of either drug on the pharmacokinetics or pharmacodynamics of zolpidem.
1	0	4	O	Other
2	6	10	O	Drugs
3	12	15	O	with
4	17	18	O	No
5	20	31	O	Interactions
6	33	36	O	with
7	38	45	O	XXXXXXXX
8	47	47	O	A
9	49	53	O	study
10	55	63	O	involving
11	65	74	O	cimetidine
12	75	75	O	/
13	76	83	O	XXXXXXXX
14	85	92	O	tartrate
15	94	96	O	and
16	98	107	O	ranitidine
17	108	108	O	/
18	109	116	O	XXXXXXXX
19	118	125	O	tartrate
20	127	138	O	combinations
21	140	147	O	revealed
22	149	150	O	no
23	152	157	O	effect
24	159	160	O	of
25	162	167	O	either
26	169	172	O	drug
27	174	175	O	on
28	177	179	O	the
29	181	196	O	pharmacokinetics
30	198	199	O	or
31	201	216	O	pharmacodynamics
32	218	219	O	of
33	221	228	O	XXXXXXXX
NULL

Zolpidem	5720	34090-1	d76d5540-7bae-4719-8166-f2a9106338df	21
Zolpidem tartrate had no effect on digoxin pharmacokinetics and did not affect prothrombin time when given with warfarin in healthy subjects.
1	0	7	O	XXXXXXXX
2	9	16	O	tartrate
3	18	20	O	had
4	22	23	O	no
5	25	30	O	effect
6	32	33	O	on
7	35	41	O	digoxin
8	43	58	O	pharmacokinetics
9	60	62	O	and
10	64	66	O	did
11	68	70	O	not
12	72	77	O	affect
13	79	89	O	prothrombin
14	91	94	O	time
15	96	99	O	when
16	101	105	O	given
17	107	110	O	with
18	112	119	O	warfarin
19	121	122	O	in
20	124	130	O	healthy
21	132	139	O	subjects
NULL

Zyprexa	1297	34073-7	d5051fbc-846b-4946-82df-341fb1216341	18
The risks of using olanzapine in combination with other drugs have not been extensively evaluated in systematic studies.
1	0	2	O	The
2	4	8	O	risks
3	10	11	O	of
4	13	17	O	using
5	19	28	O	XXXXXXXX
6	30	31	O	in
7	33	43	O	combination
8	45	48	O	with
9	50	54	O	other
10	56	60	O	drugs
11	62	65	O	have
12	67	69	O	not
13	71	74	O	been
14	76	86	O	extensively
15	88	96	O	evaluated
16	98	99	O	in
17	101	110	O	systematic
18	112	118	O	studies
NULL

Zyprexa	1298	34073-7	d5051fbc-846b-4946-82df-341fb1216341	6
Diazepam: May potentiate orthostatic hypotension.
1	0	7	U-DYN	Diazepam
2	8	8	O	:
3	10	12	O	May
4	14	23	O	potentiate
5	25	35	B-EFF	orthostatic
6	37	47	L-EFF	hypotension
D/1:5:1

Zyprexa	1299	34073-7	d5051fbc-846b-4946-82df-341fb1216341	6
Alcohol: May potentiate orthostatic hypotension.
1	0	6	U-DYN	Alcohol
2	7	7	O	:
3	9	11	O	May
4	13	22	O	potentiate
5	24	34	B-EFF	orthostatic
6	36	46	L-EFF	hypotension
D/1:5:1

Zyprexa	1300	34073-7	d5051fbc-846b-4946-82df-341fb1216341	6
Carbamazepine: Increased clearance of olanzapine.
1	0	12	U-KIN	Carbamazepine
2	13	13	O	:
3	15	23	B-TRI	Increased
4	25	33	L-TRI	clearance
5	35	36	O	of
6	38	47	O	XXXXXXXX
K/1:C54356

Zyprexa	1301	34073-7	d5051fbc-846b-4946-82df-341fb1216341	6
Fluvoxamine: May increase olanzapine levels.
1	0	10	U-KIN	Fluvoxamine
2	11	11	O	:
3	13	15	O	May
4	17	24	B-TRI	increase
5	26	35	I-TRI	XXXXXXXX
6	37	42	L-TRI	levels
K/1:C54355

Zyprexa	1302	34073-7	d5051fbc-846b-4946-82df-341fb1216341	19
ZYPREXA and Fluoxetine in Combination: Also refer to the Drug Interactions section of the package insert for Symbyax.
1	0	6	O	XXXXXXXX
2	8	10	O	and
3	12	21	U-UNK	Fluoxetine
4	23	24	O	in
5	26	36	O	Combination
6	37	37	O	:
7	39	42	O	Also
8	44	48	O	refer
9	50	51	O	to
10	53	55	O	the
11	57	60	B-TRI	Drug
12	62	73	L-TRI	Interactions
13	75	81	O	section
14	83	84	O	of
15	86	88	O	the
16	90	96	O	package
17	98	103	O	insert
18	105	107	O	for
19	109	115	O	Symbyax
NULL

Zyprexa	1303	34073-7	d5051fbc-846b-4946-82df-341fb1216341	19
CNS Acting Drugs: Caution should be used when taken in combination with other centrally acting drugs and alcohol.
1	0	2	O	CNS
2	4	9	O	Acting
3	11	15	O	Drugs
4	16	16	O	:
5	18	24	U-TRI	Caution
6	26	31	O	should
7	33	34	O	be
8	36	39	O	used
9	41	44	O	when
10	46	50	O	taken
11	52	53	O	in
12	55	65	O	combination
13	67	70	O	with
14	72	76	O	other
15	78	86	B-UNK	centrally
16	88	93	I-UNK	acting
17	95	99	L-UNK	drugs
18	101	103	O	and
19	105	111	U-UNK	alcohol
NULL

Zyprexa	1304	34073-7	d5051fbc-846b-4946-82df-341fb1216341	6
Antihypertensive Agents: Enhanced antihypertensive effect.
1	0	15	B-DYN	Antihypertensive
2	17	22	L-DYN	Agents
3	23	23	O	:
4	25	32	B-EFF	Enhanced
5	34	49	I-EFF	antihypertensive
6	51	56	L-EFF	effect
D/1:4:1

Zyprexa	1305	34073-7	d5051fbc-846b-4946-82df-341fb1216341	11
Levodopa and Dopamine Agonists: May antagonize levodopa/dopamine agonists.
1	0	7	O	Levodopa
2	9	11	O	and
3	13	20	O	Dopamine
4	22	29	O	Agonists
5	30	30	O	:
6	32	34	O	May
7	36	45	B-EFF	antagonize
8	47	54	L-EFF	levodopa
9	55	55	B-DYN	/
10	56	63	I-DYN	dopamine
11	65	72	L-DYN	agonists
D/9:7:0

Zyprexa	1306	34073-7	d5051fbc-846b-4946-82df-341fb1216341	8
Lorazepam (IM): Increased somnolence with IM olanzapine.
1	0	8	U-DYN	Lorazepam
2	11	12	O	IM
3	14	14	O	:
4	16	24	B-EFF	Increased
5	26	35	L-EFF	somnolence
6	37	40	O	with
7	42	43	O	IM
8	45	54	O	XXXXXXXX
D/1:4:1

Zyprexa	1307	34073-7	d5051fbc-846b-4946-82df-341fb1216341	28
Other Concomitant Drug Therapy: When using olanzapine in combination with lithium or valproate, refer to the Drug Interactions sections of the package insert for those products.
1	0	4	O	Other
2	6	16	O	Concomitant
3	18	21	O	Drug
4	23	29	O	Therapy
5	30	30	O	:
6	32	35	O	When
7	37	41	O	using
8	43	52	O	XXXXXXXX
9	54	55	O	in
10	57	67	O	combination
11	69	72	O	with
12	74	80	U-UNK	lithium
13	82	83	O	or
14	85	93	U-UNK	valproate
15	94	94	O	,
16	96	100	O	refer
17	102	103	O	to
18	105	107	O	the
19	109	112	B-TRI	Drug
20	114	125	L-TRI	Interactions
21	127	134	O	sections
22	136	137	O	of
23	139	141	O	the
24	143	149	O	package
25	151	156	O	insert
26	158	160	O	for
27	162	166	O	those
28	168	175	O	products
NULL

Zyprexa	1308	34073-7	d5051fbc-846b-4946-82df-341fb1216341	15
Diazepam - The co-administration of diazepam with olanzapine potentiated the orthostatic hypotension observed with olanzapine.
1	0	7	O	Diazepam
2	11	13	O	The
3	15	16	O	co
4	18	31	O	administration
5	33	34	O	of
6	36	43	U-DYN	diazepam
7	45	48	O	with
8	50	59	O	XXXXXXXX
9	61	71	O	potentiated
10	73	75	O	the
11	77	87	B-EFF	orthostatic
12	89	99	L-EFF	hypotension
13	101	108	O	observed
14	110	113	O	with
15	115	124	O	XXXXXXXX
D/6:11:1

Zyprexa	1309	34073-7	d5051fbc-846b-4946-82df-341fb1216341	22
Cimetidine and Antacids - Single doses of cimetidine (800mg) or aluminum- and magnesium-containing antacids did not affect the oral bioavailability of olanzapine.
1	0	9	O	Cimetidine
2	11	13	O	and
3	15	22	O	Antacids
4	26	31	O	Single
5	33	37	O	doses
6	39	40	O	of
7	42	51	O	cimetidine
8	54	58	O	800mg
9	61	62	O	or
10	64	71	O	aluminum
11	74	76	O	and
12	78	86	O	magnesium
13	88	97	O	containing
14	99	106	O	antacids
15	108	110	O	did
16	112	114	O	not
17	116	121	O	affect
18	123	125	O	the
19	127	130	O	oral
20	132	146	O	bioavailability
21	148	149	O	of
22	151	160	O	XXXXXXXX
NULL

Zyprexa	1310	34073-7	d5051fbc-846b-4946-82df-341fb1216341	16
Inducers of CYP1A2 - Carbamazepine therapy (200mgbid) causes an approximately 50% increase in the clearance of olanzapine.
1	0	7	O	Inducers
2	9	10	O	of
3	12	17	O	CYP1A2
4	21	33	U-KIN	Carbamazepine
5	35	41	O	therapy
6	44	51	O	200mgbid
7	54	59	O	causes
8	61	62	O	an
9	64	76	O	approximately
10	78	80	O	50%
11	82	89	O	increase
12	91	92	O	in
13	94	96	O	the
14	98	106	O	clearance
15	108	109	O	of
16	111	120	O	XXXXXXXX
K/4:C54356

Zyprexa	1311	34073-7	d5051fbc-846b-4946-82df-341fb1216341	17
This increase is likely due to the fact that carbamazepine is a potent inducer of CYP1A2 activity.
1	0	3	O	This
2	5	12	O	increase
3	14	15	O	is
4	17	22	O	likely
5	24	26	O	due
6	28	29	O	to
7	31	33	O	the
8	35	38	O	fact
9	40	43	O	that
10	45	57	O	carbamazepine
11	59	60	O	is
12	62	62	O	a
13	64	69	O	potent
14	71	77	O	inducer
15	79	80	O	of
16	82	87	O	CYP1A2
17	89	96	O	activity
NULL

Zyprexa	1312	34073-7	d5051fbc-846b-4946-82df-341fb1216341	14
Higher daily doses of carbamazepine may cause an even greater increase in olanzapine clearance.
1	0	5	O	Higher
2	7	11	O	daily
3	13	17	O	doses
4	19	20	O	of
5	22	34	U-KIN	carbamazepine
6	36	38	O	may
7	40	44	O	cause
8	46	47	O	an
9	49	52	O	even
10	54	60	O	greater
11	62	69	O	increase
12	71	72	O	in
13	74	83	O	XXXXXXXX
14	85	93	O	clearance
K/5:C54356

Zyprexa	1313	34073-7	d5051fbc-846b-4946-82df-341fb1216341	15
Alcohol - Ethanol (45mg/70kg single dose) did not have an effect on olanzapine pharmacokinetics.
1	0	6	O	Alcohol
2	10	16	O	Ethanol
3	19	22	O	45mg
4	23	23	O	/
5	24	27	O	70kg
6	29	34	O	single
7	36	39	O	dose
8	42	44	O	did
9	46	48	O	not
10	50	53	O	have
11	55	56	O	an
12	58	63	O	effect
13	65	66	O	on
14	68	77	O	XXXXXXXX
15	79	94	O	pharmacokinetics
NULL

Zyprexa	1314	34073-7	d5051fbc-846b-4946-82df-341fb1216341	17
The co-administration of alcohol (i.e., ethanol) with olanzapine potentiated the orthostatic hypotension observed with olanzapine.
1	0	2	O	The
2	4	5	O	co
3	7	20	O	administration
4	22	23	O	of
5	25	31	U-DYN	alcohol
6	34	36	O	i.e
7	38	38	O	,
8	40	46	U-DYN	ethanol
9	49	52	O	with
10	54	63	O	XXXXXXXX
11	65	75	O	potentiated
12	77	79	O	the
13	81	91	B-EFF	orthostatic
14	93	103	L-EFF	hypotension
15	105	112	O	observed
16	114	117	O	with
17	119	128	O	XXXXXXXX
D/5:13:1 D/8:13:1

Zyprexa	1315	34073-7	d5051fbc-846b-4946-82df-341fb1216341	16
Inhibitors of CYP1A2 Fluvoxamine: Fluvoxamine, a CYP1A2 inhibitor, decreases the clearance of olanzapine.
1	0	9	B-KIN	Inhibitors
2	11	12	I-KIN	of
3	14	19	L-KIN	CYP1A2
4	21	31	U-KIN	Fluvoxamine
5	32	32	O	:
6	34	44	O	Fluvoxamine
7	45	45	O	,
8	47	47	O	a
9	49	54	O	CYP1A2
10	56	64	O	inhibitor
11	65	65	O	,
12	67	75	B-TRI	decreases
13	77	79	I-TRI	the
14	81	89	L-TRI	clearance
15	91	92	O	of
16	94	103	O	XXXXXXXX
K/1:C54355 K/4:C54355

Zyprexa	1316	34073-7	d5051fbc-846b-4946-82df-341fb1216341	21
This results in a mean increase in olanzapine Cmax following fluvoxamine of 54% in female nonsmokers and 77% in male smokers.
1	0	3	O	This
2	5	11	O	results
3	13	14	O	in
4	16	16	O	a
5	18	21	O	mean
6	23	30	O	increase
7	32	33	O	in
8	35	44	O	XXXXXXXX
9	46	49	O	Cmax
10	51	59	O	following
11	61	71	U-KIN	fluvoxamine
12	73	74	O	of
13	76	78	O	54%
14	80	81	O	in
15	83	88	O	female
16	90	99	O	nonsmokers
17	101	103	O	and
18	105	107	O	77%
19	109	110	O	in
20	112	115	O	male
21	117	123	O	smokers
K/11:C54602

Zyprexa	1317	34073-7	d5051fbc-846b-4946-82df-341fb1216341	12
The mean increase in olanzapine AUC is 52% and 108%, respectively.
1	0	2	O	The
2	4	7	O	mean
3	9	16	O	increase
4	18	19	O	in
5	21	30	O	XXXXXXXX
6	32	34	O	AUC
7	36	37	O	is
8	39	41	O	52%
9	43	45	O	and
10	47	50	O	108%
11	51	51	O	,
12	53	64	O	respectively
NULL

Zyprexa	1318	34073-7	d5051fbc-846b-4946-82df-341fb1216341	14
Lower doses of olanzapine should be considered in patients receiving concomitant treatment with fluvoxamine.
1	0	4	B-TRI	Lower
2	6	10	L-TRI	doses
3	12	13	O	of
4	15	24	O	XXXXXXXX
5	26	31	O	should
6	33	34	O	be
7	36	45	O	considered
8	47	48	O	in
9	50	57	O	patients
10	59	67	O	receiving
11	69	79	O	concomitant
12	81	89	O	treatment
13	91	94	O	with
14	96	106	U-KIN	fluvoxamine
K/14:C54355

Zyprexa	1319	34073-7	d5051fbc-846b-4946-82df-341fb1216341	37
Inhibitors of CYP2D6 Fluoxetine: Fluoxetine (60mg single dose or 60mg daily dose for 8 days) causes a small (mean 16%) increase in the maximum concentration of olanzapine and a small (mean 16%) decrease in olanzapine clearance.
1	0	9	O	Inhibitors
2	11	12	O	of
3	14	19	O	CYP2D6
4	21	30	U-KIN	Fluoxetine
5	31	31	O	:
6	33	42	O	Fluoxetine
7	45	48	O	60mg
8	50	55	O	single
9	57	60	O	dose
10	62	63	O	or
11	65	68	O	60mg
12	70	74	O	daily
13	76	79	O	dose
14	81	83	O	for
15	85	85	O	8
16	87	90	O	days
17	93	98	O	causes
18	100	100	O	a
19	102	106	O	small
20	109	112	O	mean
21	114	116	O	16%
22	119	126	B-TRI	increase
23	128	129	I-TRI	in
24	131	133	I-TRI	the
25	135	141	I-TRI	maximum
26	143	155	L-TRI	concentration
27	157	158	O	of
28	160	169	O	XXXXXXXX
29	171	173	O	and
30	175	175	O	a
31	177	181	O	small
32	184	187	O	mean
33	189	191	O	16%
34	194	201	O	decrease
35	203	204	O	in
36	206	215	O	XXXXXXXX
37	217	225	O	clearance
K/4:C54355

Zyprexa	1320	34073-7	d5051fbc-846b-4946-82df-341fb1216341	27
The magnitude of the impact of this factor is small in comparison to the overall variability between individuals, and therefore dose modification is not routinely recommended.
1	0	2	O	The
2	4	12	O	magnitude
3	14	15	O	of
4	17	19	O	the
5	21	26	O	impact
6	28	29	O	of
7	31	34	O	this
8	36	41	O	factor
9	43	44	O	is
10	46	50	O	small
11	52	53	O	in
12	55	64	O	comparison
13	66	67	O	to
14	69	71	O	the
15	73	79	O	overall
16	81	91	O	variability
17	93	99	O	between
18	101	111	O	individuals
19	112	112	O	,
20	114	116	O	and
21	118	126	O	therefore
22	128	131	O	dose
23	133	144	O	modification
24	146	147	O	is
25	149	151	O	not
26	153	161	O	routinely
27	163	173	O	recommended
NULL

Zyprexa	1321	34073-7	d5051fbc-846b-4946-82df-341fb1216341	21
When using ZYPREXA and fluoxetine in combination, also refer to the Drug Interactions section of the package insert for Symbyax.
1	0	3	O	When
2	5	9	O	using
3	11	17	O	XXXXXXXX
4	19	21	O	and
5	23	32	U-UNK	fluoxetine
6	34	35	O	in
7	37	47	O	combination
8	48	48	O	,
9	50	53	O	also
10	55	59	O	refer
11	61	62	O	to
12	64	66	O	the
13	68	71	B-TRI	Drug
14	73	84	L-TRI	Interactions
15	86	92	O	section
16	94	95	O	of
17	97	99	O	the
18	101	107	O	package
19	109	114	O	insert
20	116	118	O	for
21	120	126	O	Symbyax
NULL

Zyprexa	1322	34073-7	d5051fbc-846b-4946-82df-341fb1216341	10
Warfarin - Warfarin (20mg single dose) did not affect olanzapine pharmacokinetics.
1	0	7	O	Warfarin
2	11	18	O	Warfarin
3	21	24	O	20mg
4	26	31	O	single
5	33	36	O	dose
6	39	41	O	did
7	43	45	O	not
8	47	52	O	affect
9	54	63	O	XXXXXXXX
10	65	80	O	pharmacokinetics
NULL

Zyprexa	1323	34073-7	d5051fbc-846b-4946-82df-341fb1216341	16
Inducers of CYP1A2 or Glucuronyl Transferase - Omeprazole and rifampin may cause an increase in olanzapine clearance.
1	0	7	O	Inducers
2	9	10	O	of
3	12	17	O	CYP1A2
4	19	20	O	or
5	22	31	O	Glucuronyl
6	33	43	O	Transferase
7	47	56	U-KIN	Omeprazole
8	58	60	O	and
9	62	69	U-KIN	rifampin
10	71	73	O	may
11	75	79	O	cause
12	81	82	O	an
13	84	91	O	increase
14	93	94	O	in
15	96	105	O	XXXXXXXX
16	107	115	O	clearance
K/7:C54356 K/9:C54356

Zyprexa	1324	34073-7	d5051fbc-846b-4946-82df-341fb1216341	18
Charcoal - The administration of activated charcoal (1g) reduced the Cmax and AUC of oral olanzapine by about 60%.
1	0	7	O	Charcoal
2	11	13	O	The
3	15	28	O	administration
4	30	31	O	of
5	33	41	B-KIN	activated
6	43	50	L-KIN	charcoal
7	53	54	O	1g
8	57	63	B-TRI	reduced
9	65	67	I-TRI	the
10	69	72	L-TRI	Cmax
11	74	76	O	and
12	78	80	O	AUC
13	82	83	O	of
14	85	88	O	oral
15	90	99	O	XXXXXXXX
16	101	102	O	by
17	104	108	O	about
18	110	112	O	60%
K/5:C54609

Zyprexa	1325	34073-7	d5051fbc-846b-4946-82df-341fb1216341	24
As peak olanzapine levels are not typically obtained until about 6 hours after dosing, charcoal may be a useful treatment for olanzapine overdose.
1	0	1	O	As
2	3	6	O	peak
3	8	17	O	XXXXXXXX
4	19	24	O	levels
5	26	28	O	are
6	30	32	O	not
7	34	42	O	typically
8	44	51	O	obtained
9	53	57	O	until
10	59	63	O	about
11	65	65	O	6
12	67	71	O	hours
13	73	77	O	after
14	79	84	O	dosing
15	85	85	O	,
16	87	94	O	charcoal
17	96	98	O	may
18	100	101	O	be
19	103	103	O	a
20	105	110	O	useful
21	112	120	O	treatment
22	122	124	O	for
23	126	135	O	XXXXXXXX
24	137	144	O	overdose
NULL

Zyprexa	1326	34073-7	d5051fbc-846b-4946-82df-341fb1216341	28
CNS Acting Drugs - Given the primary CNS effects of olanzapine, caution should be used when olanzapine is taken in combination with other centrally acting drugs and alcohol.
1	0	2	O	CNS
2	4	9	O	Acting
3	11	15	O	Drugs
4	19	23	O	Given
5	25	27	O	the
6	29	35	O	primary
7	37	39	O	CNS
8	41	47	O	effects
9	49	50	O	of
10	52	61	O	XXXXXXXX
11	62	62	O	,
12	64	70	U-TRI	caution
13	72	77	O	should
14	79	80	O	be
15	82	85	O	used
16	87	90	O	when
17	92	101	O	XXXXXXXX
18	103	104	O	is
19	106	110	O	taken
20	112	113	O	in
21	115	125	O	combination
22	127	130	O	with
23	132	136	O	other
24	138	146	B-UNK	centrally
25	148	153	I-UNK	acting
26	155	159	L-UNK	drugs
27	161	163	O	and
28	165	171	U-UNK	alcohol
NULL

Zyprexa	1327	34073-7	d5051fbc-846b-4946-82df-341fb1216341	20
Antihypertensive Agents - Olanzapine, because of its potential for inducing hypotension, may enhance the effects of certain antihypertensive agents.
1	0	15	O	Antihypertensive
2	17	22	O	Agents
3	26	35	O	XXXXXXXX
4	36	36	O	,
5	38	44	O	because
6	46	47	O	of
7	49	51	O	its
8	53	61	O	potential
9	63	65	O	for
10	67	74	O	inducing
11	76	86	O	hypotension
12	87	87	O	,
13	89	91	O	may
14	93	99	B-EFF	enhance
15	101	103	I-EFF	the
16	105	111	I-EFF	effects
17	113	114	I-EFF	of
18	116	122	I-EFF	certain
19	124	139	I-EFF	antihypertensive
20	141	146	L-EFF	agents
NULL

Zyprexa	1328	34073-7	d5051fbc-846b-4946-82df-341fb1216341	14
Levodopa and Dopamine Agonists - Olanzapine may antagonize the effects of levodopa and dopamine agonists.
1	0	7	O	Levodopa
2	9	11	O	and
3	13	20	O	Dopamine
4	22	29	O	Agonists
5	33	42	O	XXXXXXXX
6	44	46	O	may
7	48	57	B-EFF	antagonize
8	59	61	I-EFF	the
9	63	69	I-EFF	effects
10	71	72	I-EFF	of
11	74	81	L-EFF	levodopa
12	83	85	O	and
13	87	94	B-DYN	dopamine
14	96	103	L-DYN	agonists
D/13:7:0

Zyprexa	1329	34073-7	d5051fbc-846b-4946-82df-341fb1216341	30
Lorazepam (IM) - Administration of intramuscular lorazepam (2mg) 1 hour after intramuscular olanzapine for injection (5mg) did not significantly affect the pharmacokinetics of olanzapine, unconjugated lorazepam, or total lorazepam.
1	0	8	O	Lorazepam
2	11	12	O	IM
3	17	30	O	Administration
4	32	33	O	of
5	35	47	O	intramuscular
6	49	57	O	lorazepam
7	60	62	O	2mg
8	65	65	O	1
9	67	70	O	hour
10	72	76	O	after
11	78	90	O	intramuscular
12	92	101	O	XXXXXXXX
13	103	105	O	for
14	107	115	O	injection
15	118	120	O	5mg
16	123	125	O	did
17	127	129	O	not
18	131	143	O	significantly
19	145	150	O	affect
20	152	154	O	the
21	156	171	O	pharmacokinetics
22	173	174	O	of
23	176	185	O	XXXXXXXX
24	186	186	O	,
25	188	199	O	unconjugated
26	201	209	O	lorazepam
27	210	210	O	,
28	212	213	O	or
29	215	219	O	total
30	221	229	O	lorazepam
NULL

Zyprexa	1330	34073-7	d5051fbc-846b-4946-82df-341fb1216341	22
However, this co-administration of intramuscular lorazepam and intramuscular olanzapine for injection added to the somnolence observed with either drug alone.
1	0	6	O	However
2	7	7	O	,
3	9	12	O	this
4	14	15	O	co
5	17	30	O	administration
6	32	33	O	of
7	35	47	O	intramuscular
8	49	57	U-DYN	lorazepam
9	59	61	O	and
10	63	75	O	intramuscular
11	77	86	O	XXXXXXXX
12	88	90	O	for
13	92	100	O	injection
14	102	106	B-EFF	added
15	108	109	I-EFF	to
16	111	113	I-EFF	the
17	115	124	L-EFF	somnolence
18	126	133	O	observed
19	135	138	O	with
20	140	145	O	either
21	147	150	O	drug
22	152	156	O	alone
D/8:14:1

Zyprexa	1331	34073-7	d5051fbc-846b-4946-82df-341fb1216341	16
Lithium - Multiple doses of olanzapine (10mg for 8 days) did not influence the kinetics of lithium.
1	0	6	O	Lithium
2	10	17	O	Multiple
3	19	23	O	doses
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	40	43	O	10mg
7	45	47	O	for
8	49	49	O	8
9	51	54	O	days
10	57	59	O	did
11	61	63	O	not
12	65	73	O	influence
13	75	77	O	the
14	79	86	O	kinetics
15	88	89	O	of
16	91	97	O	lithium
NULL

Zyprexa	1332	34073-7	d5051fbc-846b-4946-82df-341fb1216341	12
Therefore, concomitant olanzapine administration does not require dosage adjustment of lithium.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	concomitant
4	23	32	O	XXXXXXXX
5	34	47	O	administration
6	49	52	O	does
7	54	56	O	not
8	58	64	O	require
9	66	71	O	dosage
10	73	82	O	adjustment
11	84	85	O	of
12	87	93	O	lithium
NULL

Zyprexa	1333	34073-7	d5051fbc-846b-4946-82df-341fb1216341	17
Valproate - Olanzapine (10mg daily for 2 weeks) did not affect the steady state plasma concentrations of valproate.
1	0	8	O	Valproate
2	12	21	O	XXXXXXXX
3	24	27	O	10mg
4	29	33	O	daily
5	35	37	O	for
6	39	39	O	2
7	41	45	O	weeks
8	48	50	O	did
9	52	54	O	not
10	56	61	O	affect
11	63	65	O	the
12	67	72	O	steady
13	74	78	O	state
14	80	85	O	plasma
15	87	100	O	concentrations
16	102	103	O	of
17	105	113	O	valproate
NULL

Zyprexa	1334	34073-7	d5051fbc-846b-4946-82df-341fb1216341	12
Therefore, concomitant olanzapine administration does not require dosage adjustment of valproate.
1	0	8	O	Therefore
2	9	9	O	,
3	11	21	O	concomitant
4	23	32	O	XXXXXXXX
5	34	47	O	administration
6	49	52	O	does
7	54	56	O	not
8	58	64	O	require
9	66	71	O	dosage
10	73	82	O	adjustment
11	84	85	O	of
12	87	95	O	valproate
NULL

Zyprexa	1335	34073-7	d5051fbc-846b-4946-82df-341fb1216341	31
Effect of Olanzapine on Drug Metabolizing Enzymes - Invitro studies utilizing human liver microsomes suggest that olanzapine has little potential to inhibit CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
1	0	5	O	Effect
2	7	8	O	of
3	10	19	O	XXXXXXXX
4	21	22	O	on
5	24	27	O	Drug
6	29	40	O	Metabolizing
7	42	48	O	Enzymes
8	52	58	O	Invitro
9	60	66	O	studies
10	68	76	O	utilizing
11	78	82	O	human
12	84	88	O	liver
13	90	99	O	microsomes
14	101	107	O	suggest
15	109	112	O	that
16	114	123	O	XXXXXXXX
17	125	127	O	has
18	129	134	O	little
19	136	144	O	potential
20	146	147	O	to
21	149	155	O	inhibit
22	157	162	O	CYP1A2
23	163	163	O	,
24	165	170	O	CYP2C9
25	171	171	O	,
26	173	179	O	CYP2C19
27	180	180	O	,
28	182	187	O	CYP2D6
29	188	188	O	,
30	190	192	O	and
31	194	198	O	CYP3A
NULL

Zyprexa	1336	34073-7	d5051fbc-846b-4946-82df-341fb1216341	15
Thus, olanzapine is unlikely to cause clinically important drug interactions mediated by these enzymes.
1	0	3	O	Thus
2	4	4	O	,
3	6	15	O	XXXXXXXX
4	17	18	O	is
5	20	27	O	unlikely
6	29	30	O	to
7	32	36	O	cause
8	38	47	O	clinically
9	49	57	O	important
10	59	62	O	drug
11	64	75	O	interactions
12	77	84	O	mediated
13	86	87	O	by
14	89	93	O	these
15	95	101	O	enzymes
NULL

Zyprexa	1337	34073-7	d5051fbc-846b-4946-82df-341fb1216341	17
Imipramine - Single doses of olanzapine did not affect the pharmacokinetics of imipramine or its active metabolite desipramine.
1	0	9	O	Imipramine
2	13	18	O	Single
3	20	24	O	doses
4	26	27	O	of
5	29	38	O	XXXXXXXX
6	40	42	O	did
7	44	46	O	not
8	48	53	O	affect
9	55	57	O	the
10	59	74	O	pharmacokinetics
11	76	77	O	of
12	79	88	O	imipramine
13	90	91	O	or
14	93	95	O	its
15	97	102	O	active
16	104	113	O	metabolite
17	115	125	O	desipramine
NULL

Zyprexa	1338	34073-7	d5051fbc-846b-4946-82df-341fb1216341	12
Warfarin - Single doses of olanzapine did not affect the pharmacokinetics of warfarin.
1	0	7	O	Warfarin
2	11	16	O	Single
3	18	22	O	doses
4	24	25	O	of
5	27	36	O	XXXXXXXX
6	38	40	O	did
7	42	44	O	not
8	46	51	O	affect
9	53	55	O	the
10	57	72	O	pharmacokinetics
11	74	75	O	of
12	77	84	O	warfarin
NULL

Zyprexa	1339	34073-7	d5051fbc-846b-4946-82df-341fb1216341	15
Diazepam - Olanzapine did not influence the pharmacokinetics of diazepam or its active metabolite N-desmethyldiazepam.
1	0	7	O	Diazepam
2	11	20	O	XXXXXXXX
3	22	24	O	did
4	26	28	O	not
5	30	38	O	influence
6	40	42	O	the
7	44	59	O	pharmacokinetics
8	61	62	O	of
9	64	71	O	diazepam
10	73	74	O	or
11	76	78	O	its
12	80	85	O	active
13	87	96	O	metabolite
14	98	98	O	N
15	100	116	O	desmethyldiazepam
NULL

Zyprexa	1340	34073-7	d5051fbc-846b-4946-82df-341fb1216341	17
However, diazepam co-administered with olanzapine increased the orthostatic hypotension observed with either drug given alone.
1	0	6	O	However
2	7	7	O	,
3	9	16	U-DYN	diazepam
4	18	19	O	co
5	21	32	O	administered
6	34	37	O	with
7	39	48	O	XXXXXXXX
8	50	58	B-EFF	increased
9	60	62	I-EFF	the
10	64	74	I-EFF	orthostatic
11	76	86	L-EFF	hypotension
12	88	95	O	observed
13	97	100	O	with
14	102	107	O	either
15	109	112	O	drug
16	114	118	O	given
17	120	124	O	alone
D/3:8:1

Zyprexa	1341	34073-7	d5051fbc-846b-4946-82df-341fb1216341	12
Alcohol - Multiple doses of olanzapine did not influence the kinetics of ethanol.
1	0	6	O	Alcohol
2	10	17	O	Multiple
3	19	23	O	doses
4	25	26	O	of
5	28	37	O	XXXXXXXX
6	39	41	O	did
7	43	45	O	not
8	47	55	O	influence
9	57	59	O	the
10	61	68	O	kinetics
11	70	71	O	of
12	73	79	O	ethanol
NULL

Zyprexa	1342	34073-7	d5051fbc-846b-4946-82df-341fb1216341	12
Biperiden - Multiple doses of olanzapine did not influence the kinetics of biperiden.
1	0	8	O	Biperiden
2	12	19	O	Multiple
3	21	25	O	doses
4	27	28	O	of
5	30	39	O	XXXXXXXX
6	41	43	O	did
7	45	47	O	not
8	49	57	O	influence
9	59	61	O	the
10	63	70	O	kinetics
11	72	73	O	of
12	75	83	O	biperiden
NULL

Zyprexa	1343	34073-7	d5051fbc-846b-4946-82df-341fb1216341	15
Theophylline - Multiple doses of olanzapine did not affect the pharmacokinetics of theophylline or its metabolites.
1	0	11	O	Theophylline
2	15	22	O	Multiple
3	24	28	O	doses
4	30	31	O	of
5	33	42	O	XXXXXXXX
6	44	46	O	did
7	48	50	O	not
8	52	57	O	affect
9	59	61	O	the
10	63	78	O	pharmacokinetics
11	80	81	O	of
12	83	94	O	theophylline
13	96	97	O	or
14	99	101	O	its
15	103	113	O	metabolites
NULL

Zyprexa	1344	34090-1	d5051fbc-846b-4946-82df-341fb1216341	18
The mechanism of action of olanzapine, as with other drugs having efficacy in schizophrenia, is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	37	37	O	,
8	39	40	O	as
9	42	45	O	with
10	47	51	O	other
11	53	57	O	drugs
12	59	64	O	having
13	66	73	O	efficacy
14	75	76	O	in
15	78	90	O	schizophrenia
16	91	91	O	,
17	93	94	O	is
18	96	102	O	unknown
NULL

Zyprexa	1345	34090-1	d5051fbc-846b-4946-82df-341fb1216341	23
However, it has been proposed that this drug's efficacy in schizophrenia is mediated through a combination of dopamine and serotonin type2(5HT2) antagonism.
1	0	6	O	However
2	7	7	O	,
3	9	10	O	it
4	12	14	O	has
5	16	19	O	been
6	21	28	O	proposed
7	30	33	O	that
8	35	38	O	this
9	40	45	O	drug's
10	47	54	O	efficacy
11	56	57	O	in
12	59	71	O	schizophrenia
13	73	74	O	is
14	76	83	O	mediated
15	85	91	O	through
16	93	93	O	a
17	95	105	O	combination
18	107	108	O	of
19	110	117	O	dopamine
20	119	121	O	and
21	123	131	O	serotonin
22	133	142	O	type2(5HT2
23	145	154	O	antagonism
NULL

Zyprexa	1346	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
The mechanism of action of olanzapine in the treatment of acute manic or mixed episodes associated with bipolarI disorder is unknown.
1	0	2	O	The
2	4	12	O	mechanism
3	14	15	O	of
4	17	22	O	action
5	24	25	O	of
6	27	36	O	XXXXXXXX
7	38	39	O	in
8	41	43	O	the
9	45	53	O	treatment
10	55	56	O	of
11	58	62	O	acute
12	64	68	O	manic
13	70	71	O	or
14	73	77	O	mixed
15	79	86	O	episodes
16	88	97	O	associated
17	99	102	O	with
18	104	111	O	bipolarI
19	113	120	O	disorder
20	122	123	O	is
21	125	131	O	unknown
NULL

Zyprexa	1347	34090-1	d5051fbc-846b-4946-82df-341fb1216341	36
Olanzapine binds with high affinity to the following receptors: serotonin5HT2A/2C, 5HT6 (Ki=4, 11, and 5nM, respectively), dopamineD1-4 (Ki=11-31nM), histamineH1 (Ki=7nM), and adrenergicA1 receptors (Ki=19nM).
1	0	9	O	XXXXXXXX
2	11	15	O	binds
3	17	20	O	with
4	22	25	O	high
5	27	34	O	affinity
6	36	37	O	to
7	39	41	O	the
8	43	51	O	following
9	53	61	O	receptors
10	62	62	O	:
11	64	77	O	serotonin5HT2A
12	78	78	O	/
13	79	80	O	2C
14	81	81	O	,
15	83	86	O	5HT6
16	89	92	O	Ki=4
17	93	93	O	,
18	95	96	O	11
19	97	97	O	,
20	99	101	O	and
21	103	105	O	5nM
22	106	106	O	,
23	108	119	O	respectively
24	121	121	O	,
25	123	132	O	dopamineD1
26	134	134	O	4
27	137	141	O	Ki=11
28	143	146	O	31nM
29	148	148	O	,
30	150	160	O	histamineH1
31	163	168	O	Ki=7nM
32	170	170	O	,
33	172	174	O	and
34	176	187	O	adrenergicA1
35	189	197	O	receptors
36	200	206	O	Ki=19nM
NULL

Zyprexa	1348	34090-1	d5051fbc-846b-4946-82df-341fb1216341	26
Olanzapine is an antagonist with moderate affinity binding for serotonin5HT3 (Ki=57nM) and muscarinicM1-5 (Ki=73, 96, 132, 32, and 48nM, respectively).
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	15	O	an
4	17	26	O	antagonist
5	28	31	O	with
6	33	40	O	moderate
7	42	49	O	affinity
8	51	57	O	binding
9	59	61	O	for
10	63	75	O	serotonin5HT3
11	78	84	O	Ki=57nM
12	87	89	O	and
13	91	102	O	muscarinicM1
14	104	104	O	5
15	107	111	O	Ki=73
16	112	112	O	,
17	114	115	O	96
18	116	116	O	,
19	118	120	O	132
20	121	121	O	,
21	123	124	O	32
22	125	125	O	,
23	127	129	O	and
24	131	134	O	48nM
25	135	135	O	,
26	137	148	O	respectively
NULL

Zyprexa	1349	34090-1	d5051fbc-846b-4946-82df-341fb1216341	13
Olanzapine binds weakly to GABAA, BZD, and B-adrenergic receptors (Ki>10MM).
1	0	9	O	XXXXXXXX
2	11	15	O	binds
3	17	22	O	weakly
4	24	25	O	to
5	27	31	O	GABAA
6	32	32	O	,
7	34	36	O	BZD
8	37	37	O	,
9	39	41	O	and
10	43	43	O	B
11	45	54	O	adrenergic
12	56	64	O	receptors
13	67	73	O	Ki>10MM
NULL

Zyprexa	1350	34090-1	d5051fbc-846b-4946-82df-341fb1216341	20
Antagonism at receptors other than dopamine and 5HT2 may explain some of the other therapeutic and side effects of olanzapine.
1	0	9	O	Antagonism
2	11	12	O	at
3	14	22	O	receptors
4	24	28	O	other
5	30	33	O	than
6	35	42	O	dopamine
7	44	46	O	and
8	48	51	O	5HT2
9	53	55	O	may
10	57	63	O	explain
11	65	68	O	some
12	70	71	O	of
13	73	75	O	the
14	77	81	O	other
15	83	93	O	therapeutic
16	95	97	O	and
17	99	102	O	side
18	104	110	O	effects
19	112	113	O	of
20	115	124	O	XXXXXXXX
NULL

Zyprexa	1351	34090-1	d5051fbc-846b-4946-82df-341fb1216341	13
Olanzapine's antagonism of muscarinicM1-5 receptors may explain its anticholinergic-like effects.
1	0	9	O	XXXXXXXX
2	10	11	O	's
3	13	22	O	antagonism
4	24	25	O	of
5	27	38	O	muscarinicM1
6	40	40	O	5
7	42	50	O	receptors
8	52	54	O	may
9	56	62	O	explain
10	64	66	O	its
11	68	82	O	anticholinergic
12	84	87	O	like
13	89	95	O	effects
NULL

Zyprexa	1352	34090-1	d5051fbc-846b-4946-82df-341fb1216341	14
Olanzapine's antagonism of histamineH1 receptors may explain the somnolence observed with this drug.
1	0	9	O	XXXXXXXX
2	10	11	O	's
3	13	22	O	antagonism
4	24	25	O	of
5	27	37	O	histamineH1
6	39	47	O	receptors
7	49	51	O	may
8	53	59	O	explain
9	61	63	O	the
10	65	74	O	somnolence
11	76	83	O	observed
12	85	88	O	with
13	90	93	O	this
14	95	98	O	drug
NULL

Zyprexa	1353	34090-1	d5051fbc-846b-4946-82df-341fb1216341	15
Olanzapine's antagonism of adrenergicA1 receptors may explain the orthostatic hypotension observed with this drug.
1	0	9	O	XXXXXXXX
2	10	11	O	's
3	13	22	O	antagonism
4	24	25	O	of
5	27	38	O	adrenergicA1
6	40	48	O	receptors
7	50	52	O	may
8	54	60	O	explain
9	62	64	O	the
10	66	76	O	orthostatic
11	78	88	O	hypotension
12	90	97	O	observed
13	99	102	O	with
14	104	107	O	this
15	109	112	O	drug
NULL

Zyprexa	1354	34090-1	d5051fbc-846b-4946-82df-341fb1216341	20
Oral Administration, Monotherapy - Olanzapine is well absorbed and reaches peak concentrations in approximately 6 hours following an oral dose.
1	0	3	O	Oral
2	5	18	O	Administration
3	19	19	O	,
4	21	31	O	Monotherapy
5	35	44	O	XXXXXXXX
6	46	47	O	is
7	49	52	O	well
8	54	61	O	absorbed
9	63	65	O	and
10	67	73	O	reaches
11	75	78	O	peak
12	80	93	O	concentrations
13	95	96	O	in
14	98	110	O	approximately
15	112	112	O	6
16	114	118	O	hours
17	120	128	O	following
18	130	131	O	an
19	133	136	O	oral
20	138	141	O	dose
NULL

Zyprexa	1355	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation.
1	0	1	O	It
2	3	4	O	is
3	6	15	O	eliminated
4	17	27	O	extensively
5	29	30	O	by
6	32	36	O	first
7	38	41	O	pass
8	43	52	O	metabolism
9	53	53	O	,
10	55	58	O	with
11	60	72	O	approximately
12	74	76	O	40%
13	78	79	O	of
14	81	83	O	the
15	85	88	O	dose
16	90	100	O	metabolized
17	102	107	O	before
18	109	116	O	reaching
19	118	120	O	the
20	122	129	O	systemic
21	131	141	O	circulation
NULL

Zyprexa	1356	34090-1	d5051fbc-846b-4946-82df-341fb1216341	11
Food does not affect the rate or extent of olanzapine absorption.
1	0	3	O	Food
2	5	8	O	does
3	10	12	O	not
4	14	19	O	affect
5	21	23	O	the
6	25	28	O	rate
7	30	31	O	or
8	33	38	O	extent
9	40	41	O	of
10	43	52	O	XXXXXXXX
11	54	63	O	absorption
NULL

Zyprexa	1357	34090-1	d5051fbc-846b-4946-82df-341fb1216341	19
Pharmacokinetic studies showed that ZYPREXA tablets and ZYPREXA ZYDIS (olanzapine orally disintegrating tablets) dosage forms of olanzapine are bioequivalent.
1	0	14	O	Pharmacokinetic
2	16	22	O	studies
3	24	29	O	showed
4	31	34	O	that
5	36	42	O	XXXXXXXX
6	44	50	O	tablets
7	52	54	O	and
8	56	62	O	XXXXXXXX
9	64	68	O	ZYDIS
10	71	80	O	XXXXXXXX
11	82	87	O	orally
12	89	102	O	disintegrating
13	104	110	O	tablets
14	113	118	O	dosage
15	120	124	O	forms
16	126	127	O	of
17	129	138	O	XXXXXXXX
18	140	142	O	are
19	144	156	O	bioequivalent
NULL

Zyprexa	1358	34090-1	d5051fbc-846b-4946-82df-341fb1216341	9
Olanzapine displays linear kinetics over the clinical dosing range.
1	0	9	O	XXXXXXXX
2	11	18	O	displays
3	20	25	O	linear
4	27	34	O	kinetics
5	36	39	O	over
6	41	43	O	the
7	45	52	O	clinical
8	54	59	O	dosing
9	61	65	O	range
NULL

Zyprexa	1359	34090-1	d5051fbc-846b-4946-82df-341fb1216341	37
Its half-life ranges from 21 to 54 hours (5th to 95th percentile; mean of 30hr), and apparent plasma clearance ranges from 12 to 47L/hr (5th to 95th percentile; mean of 25L/hr).
1	0	2	O	Its
2	4	7	O	half
3	9	12	O	life
4	14	19	O	ranges
5	21	24	O	from
6	26	27	O	21
7	29	30	O	to
8	32	33	O	54
9	35	39	O	hours
10	42	44	O	5th
11	46	47	O	to
12	49	52	O	95th
13	54	63	O	percentile
14	66	69	O	mean
15	71	72	O	of
16	74	77	O	30hr
17	79	79	O	,
18	81	83	O	and
19	85	92	O	apparent
20	94	99	O	plasma
21	101	109	O	clearance
22	111	116	O	ranges
23	118	121	O	from
24	123	124	O	12
25	126	127	O	to
26	129	131	O	47L
27	132	132	O	/
28	133	134	O	hr
29	137	139	O	5th
30	141	142	O	to
31	144	147	O	95th
32	149	158	O	percentile
33	161	164	O	mean
34	166	167	O	of
35	169	171	O	25L
36	172	172	O	/
37	173	174	O	hr
NULL

Zyprexa	1360	34090-1	d5051fbc-846b-4946-82df-341fb1216341	23
Administration of olanzapine once daily leads to steady-state concentrations in about 1 week that are approximately twice the concentrations after single doses.
1	0	13	O	Administration
2	15	16	O	of
3	18	27	O	XXXXXXXX
4	29	32	O	once
5	34	38	O	daily
6	40	44	O	leads
7	46	47	O	to
8	49	54	O	steady
9	56	60	O	state
10	62	75	O	concentrations
11	77	78	O	in
12	80	84	O	about
13	86	86	O	1
14	88	91	O	week
15	93	96	O	that
16	98	100	O	are
17	102	114	O	approximately
18	116	120	O	twice
19	122	124	O	the
20	126	139	O	concentrations
21	141	145	O	after
22	147	152	O	single
23	154	158	O	doses
NULL

Zyprexa	1361	34090-1	d5051fbc-846b-4946-82df-341fb1216341	25
Plasma concentrations, half-life, and clearance of olanzapine may vary between individuals on the basis of smoking status, gender, and age.
1	0	5	O	Plasma
2	7	20	O	concentrations
3	21	21	O	,
4	23	26	O	half
5	28	31	O	life
6	32	32	O	,
7	34	36	O	and
8	38	46	O	clearance
9	48	49	O	of
10	51	60	O	XXXXXXXX
11	62	64	O	may
12	66	69	O	vary
13	71	77	O	between
14	79	89	O	individuals
15	91	92	O	on
16	94	96	O	the
17	98	102	O	basis
18	104	105	O	of
19	107	113	O	smoking
20	115	120	O	status
21	121	121	O	,
22	123	128	O	gender
23	129	129	O	,
24	131	133	O	and
25	135	137	O	age
NULL

Zyprexa	1362	34090-1	d5051fbc-846b-4946-82df-341fb1216341	42
Olanzapine is extensively distributed throughout the body, with a volume of distribution of approximately 1000L. It is 93% bound to plasma proteins over the concentration range of 7 to 1100ng/mL, binding primarily to albumin and A1-acid glycoprotein.
1	0	9	O	XXXXXXXX
2	11	12	O	is
3	14	24	O	extensively
4	26	36	O	distributed
5	38	47	O	throughout
6	49	51	O	the
7	53	56	O	body
8	57	57	O	,
9	59	62	O	with
10	64	64	O	a
11	66	71	O	volume
12	73	74	O	of
13	76	87	O	distribution
14	89	90	O	of
15	92	104	O	approximately
16	106	110	O	1000L
17	113	114	O	It
18	116	117	O	is
19	119	121	O	93%
20	123	127	O	bound
21	129	130	O	to
22	132	137	O	plasma
23	139	146	O	proteins
24	148	151	O	over
25	153	155	O	the
26	157	169	O	concentration
27	171	175	O	range
28	177	178	O	of
29	180	180	O	7
30	182	183	O	to
31	185	190	O	1100ng
32	191	191	O	/
33	192	193	O	mL
34	194	194	O	,
35	196	202	O	binding
36	204	212	O	primarily
37	214	215	O	to
38	217	223	O	albumin
39	225	227	O	and
40	229	230	O	A1
41	232	235	O	acid
42	237	248	O	glycoprotein
NULL

Zyprexa	1363	34090-1	d5051fbc-846b-4946-82df-341fb1216341	33
Metabolism and Elimination - Following a single oral dose of 14Clabeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.
1	0	9	O	Metabolism
2	11	13	O	and
3	15	25	O	Elimination
4	29	37	O	Following
5	39	39	O	a
6	41	46	O	single
7	48	51	O	oral
8	53	56	O	dose
9	58	59	O	of
10	61	70	O	14Clabeled
11	72	81	O	XXXXXXXX
12	82	82	O	,
13	84	85	O	7%
14	87	88	O	of
15	90	92	O	the
16	94	97	O	dose
17	99	100	O	of
18	102	111	O	XXXXXXXX
19	113	115	O	was
20	117	125	O	recovered
21	127	128	O	in
22	130	132	O	the
23	134	138	O	urine
24	140	141	O	as
25	143	151	O	unchanged
26	153	156	O	drug
27	157	157	O	,
28	159	168	O	indicating
29	170	173	O	that
30	175	184	O	XXXXXXXX
31	186	187	O	is
32	189	194	O	highly
33	196	206	O	metabolized
NULL

Zyprexa	1364	34090-1	d5051fbc-846b-4946-82df-341fb1216341	16
Approximately 57% and 30% of the dose was recovered in the urine and feces, respectively.
1	0	12	O	Approximately
2	14	16	O	57%
3	18	20	O	and
4	22	24	O	30%
5	26	27	O	of
6	29	31	O	the
7	33	36	O	dose
8	38	40	O	was
9	42	50	O	recovered
10	52	53	O	in
11	55	57	O	the
12	59	63	O	urine
13	65	67	O	and
14	69	73	O	feces
15	74	74	O	,
16	76	87	O	respectively
NULL

Zyprexa	1365	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
In the plasma, olanzapine accounted for only 12% of the AUC for total radioactivity, indicating significant exposure to metabolites.
1	0	1	O	In
2	3	5	O	the
3	7	12	O	plasma
4	13	13	O	,
5	15	24	O	XXXXXXXX
6	26	34	O	accounted
7	36	38	O	for
8	40	43	O	only
9	45	47	O	12%
10	49	50	O	of
11	52	54	O	the
12	56	58	O	AUC
13	60	62	O	for
14	64	68	O	total
15	70	82	O	radioactivity
16	83	83	O	,
17	85	94	O	indicating
18	96	106	O	significant
19	108	115	O	exposure
20	117	118	O	to
21	120	130	O	metabolites
NULL

Zyprexa	1366	34090-1	d5051fbc-846b-4946-82df-341fb1216341	43
After multiple dosing, the major circulating metabolites were the 10-N-glucuronide, present at steady state at 44% of the concentration of olanzapine, and 4'-N-desmethyl olanzapine, present at steady state at 31% of the concentration of olanzapine.
1	0	4	O	After
2	6	13	O	multiple
3	15	20	O	dosing
4	21	21	O	,
5	23	25	O	the
6	27	31	O	major
7	33	43	O	circulating
8	45	55	O	metabolites
9	57	60	O	were
10	62	64	O	the
11	66	67	O	10
12	69	69	O	N
13	71	81	O	glucuronide
14	82	82	O	,
15	84	90	O	present
16	92	93	O	at
17	95	100	O	steady
18	102	106	O	state
19	108	109	O	at
20	111	113	O	44%
21	115	116	O	of
22	118	120	O	the
23	122	134	O	concentration
24	136	137	O	of
25	139	148	O	XXXXXXXX
26	149	149	O	,
27	151	153	O	and
28	155	156	O	4'
29	158	158	O	N
30	160	168	O	desmethyl
31	170	179	O	XXXXXXXX
32	180	180	O	,
33	182	188	O	present
34	190	191	O	at
35	193	198	O	steady
36	200	204	O	state
37	206	207	O	at
38	209	211	O	31%
39	213	214	O	of
40	216	218	O	the
41	220	232	O	concentration
42	234	235	O	of
43	237	246	O	XXXXXXXX
NULL

Zyprexa	1367	34090-1	d5051fbc-846b-4946-82df-341fb1216341	9
Both metabolites lack pharmacological activity at the concentrations observed.
1	0	3	O	Both
2	5	15	O	metabolites
3	17	20	O	lack
4	22	36	O	pharmacological
5	38	45	O	activity
6	47	48	O	at
7	50	52	O	the
8	54	67	O	concentrations
9	69	76	O	observed
NULL

Zyprexa	1368	34090-1	d5051fbc-846b-4946-82df-341fb1216341	13
Direct glucuronidation and cytochromeP450(CYP) mediated oxidation are the primary metabolic pathways for olanzapine.
1	0	5	O	Direct
2	7	21	O	glucuronidation
3	23	25	O	and
4	27	44	O	cytochromeP450(CYP
5	47	54	O	mediated
6	56	64	O	oxidation
7	66	68	O	are
8	70	72	O	the
9	74	80	O	primary
10	82	90	O	metabolic
11	92	99	O	pathways
12	101	103	O	for
13	105	114	O	XXXXXXXX
NULL

Zyprexa	1369	34090-1	d5051fbc-846b-4946-82df-341fb1216341	19
Invitro studies suggest that CYPs1A2 and 2D6, and the flavin-containing monooxygenase system are involved in olanzapine oxidation.
1	0	6	O	Invitro
2	8	14	O	studies
3	16	22	O	suggest
4	24	27	O	that
5	29	35	O	CYPs1A2
6	37	39	O	and
7	41	43	O	2D6
8	44	44	O	,
9	46	48	O	and
10	50	52	O	the
11	54	59	O	flavin
12	61	70	O	containing
13	72	84	O	monooxygenase
14	86	91	O	system
15	93	95	O	are
16	97	104	O	involved
17	106	107	O	in
18	109	118	O	XXXXXXXX
19	120	128	O	oxidation
NULL

Zyprexa	1370	34090-1	d5051fbc-846b-4946-82df-341fb1216341	28
CYP2D6 mediated oxidation appears to be a minor metabolic pathway invivo, because the clearance of olanzapine is not reduced in subjects who are deficient in this enzyme.
1	0	5	O	CYP2D6
2	7	14	O	mediated
3	16	24	O	oxidation
4	26	32	O	appears
5	34	35	O	to
6	37	38	O	be
7	40	40	O	a
8	42	46	O	minor
9	48	56	O	metabolic
10	58	64	O	pathway
11	66	71	O	invivo
12	72	72	O	,
13	74	80	O	because
14	82	84	O	the
15	86	94	O	clearance
16	96	97	O	of
17	99	108	O	XXXXXXXX
18	110	111	O	is
19	113	115	O	not
20	117	123	O	reduced
21	125	126	O	in
22	128	135	O	subjects
23	137	139	O	who
24	141	143	O	are
25	145	153	O	deficient
26	155	156	O	in
27	158	161	O	this
28	163	168	O	enzyme
NULL

Zyprexa	1371	34090-1	d5051fbc-846b-4946-82df-341fb1216341	18
Intramuscular Administration - ZYPREXA IntraMuscular results in rapid absorption with peak plasma concentrations occurring within 15 to 45 minutes.
1	0	12	O	Intramuscular
2	14	27	O	Administration
3	31	37	O	XXXXXXXX
4	39	51	O	IntraMuscular
5	53	59	O	results
6	61	62	O	in
7	64	68	O	rapid
8	70	79	O	absorption
9	81	84	O	with
10	86	89	O	peak
11	91	96	O	plasma
12	98	111	O	concentrations
13	113	121	O	occurring
14	123	128	O	within
15	130	131	O	15
16	133	134	O	to
17	136	137	O	45
18	139	145	O	minutes
NULL

Zyprexa	1372	34090-1	d5051fbc-846b-4946-82df-341fb1216341	43
Based upon a pharmacokinetic study in healthy volunteers, a 5mg dose of intramuscular olanzapine for injection produces, on average, a maximum plasma concentration approximately 5 times higher than the maximum plasma concentration produced by a 5mg dose of oral olanzapine.
1	0	4	O	Based
2	6	9	O	upon
3	11	11	O	a
4	13	27	O	pharmacokinetic
5	29	33	O	study
6	35	36	O	in
7	38	44	O	healthy
8	46	55	O	volunteers
9	56	56	O	,
10	58	58	O	a
11	60	62	O	5mg
12	64	67	O	dose
13	69	70	O	of
14	72	84	O	intramuscular
15	86	95	O	XXXXXXXX
16	97	99	O	for
17	101	109	O	injection
18	111	118	O	produces
19	119	119	O	,
20	121	122	O	on
21	124	130	O	average
22	131	131	O	,
23	133	133	O	a
24	135	141	O	maximum
25	143	148	O	plasma
26	150	162	O	concentration
27	164	176	O	approximately
28	178	178	O	5
29	180	184	O	times
30	186	191	O	higher
31	193	196	O	than
32	198	200	O	the
33	202	208	O	maximum
34	210	215	O	plasma
35	217	229	O	concentration
36	231	238	O	produced
37	240	241	O	by
38	243	243	O	a
39	245	247	O	5mg
40	249	252	O	dose
41	254	255	O	of
42	257	260	O	oral
43	262	271	O	XXXXXXXX
NULL

Zyprexa	1373	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
Area under the curve achieved after an intramuscular dose is similar to that achieved after oral administration of the same dose.
1	0	3	O	Area
2	5	9	O	under
3	11	13	O	the
4	15	19	O	curve
5	21	28	O	achieved
6	30	34	O	after
7	36	37	O	an
8	39	51	O	intramuscular
9	53	56	O	dose
10	58	59	O	is
11	61	67	O	similar
12	69	70	O	to
13	72	75	O	that
14	77	84	O	achieved
15	86	90	O	after
16	92	95	O	oral
17	97	110	O	administration
18	112	113	O	of
19	115	117	O	the
20	119	122	O	same
21	124	127	O	dose
NULL

Zyprexa	1374	34090-1	d5051fbc-846b-4946-82df-341fb1216341	15
The half-life observed after intramuscular administration is similar to that observed after oral dosing.
1	0	2	O	The
2	4	7	O	half
3	9	12	O	life
4	14	21	O	observed
5	23	27	O	after
6	29	41	O	intramuscular
7	43	56	O	administration
8	58	59	O	is
9	61	67	O	similar
10	69	70	O	to
11	72	75	O	that
12	77	84	O	observed
13	86	90	O	after
14	92	95	O	oral
15	97	102	O	dosing
NULL

Zyprexa	1375	34090-1	d5051fbc-846b-4946-82df-341fb1216341	9
The pharmacokinetics are linear over the clinical dosing range.
1	0	2	O	The
2	4	19	O	pharmacokinetics
3	21	23	O	are
4	25	30	O	linear
5	32	35	O	over
6	37	39	O	the
7	41	48	O	clinical
8	50	55	O	dosing
9	57	61	O	range
NULL

Zyprexa	1376	34090-1	d5051fbc-846b-4946-82df-341fb1216341	14
Metabolic profiles after intramuscular administration are qualitatively similar to metabolic profiles after oral administration.
1	0	8	O	Metabolic
2	10	17	O	profiles
3	19	23	O	after
4	25	37	O	intramuscular
5	39	52	O	administration
6	54	56	O	are
7	58	70	O	qualitatively
8	72	78	O	similar
9	80	81	O	to
10	83	91	O	metabolic
11	93	100	O	profiles
12	102	106	O	after
13	108	111	O	oral
14	113	126	O	administration
NULL

Zyprexa	1377	34090-1	d5051fbc-846b-4946-82df-341fb1216341	36
Specific Populations Renal Impairment - Because olanzapine is highly metabolized before excretion and only 7% of the drug is excreted unchanged, renal dysfunction alone is unlikely to have a major impact on the pharmacokinetics of olanzapine.
1	0	7	O	Specific
2	9	19	O	Populations
3	21	25	O	Renal
4	27	36	O	Impairment
5	40	46	O	Because
6	48	57	O	XXXXXXXX
7	59	60	O	is
8	62	67	O	highly
9	69	79	O	metabolized
10	81	86	O	before
11	88	96	O	excretion
12	98	100	O	and
13	102	105	O	only
14	107	108	O	7%
15	110	111	O	of
16	113	115	O	the
17	117	120	O	drug
18	122	123	O	is
19	125	132	O	excreted
20	134	142	O	unchanged
21	143	143	O	,
22	145	149	O	renal
23	151	161	O	dysfunction
24	163	167	O	alone
25	169	170	O	is
26	172	179	O	unlikely
27	181	182	O	to
28	184	187	O	have
29	189	189	O	a
30	191	195	O	major
31	197	202	O	impact
32	204	205	O	on
33	207	209	O	the
34	211	226	O	pharmacokinetics
35	228	229	O	of
36	231	240	O	XXXXXXXX
NULL

Zyprexa	1378	34090-1	d5051fbc-846b-4946-82df-341fb1216341	31
The pharmacokinetic characteristics of olanzapine were similar in patients with severe renal impairment and normal subjects, indicating that dosage adjustment based upon the degree of renal impairment is not required.
1	0	2	O	The
2	4	18	O	pharmacokinetic
3	20	34	O	characteristics
4	36	37	O	of
5	39	48	O	XXXXXXXX
6	50	53	O	were
7	55	61	O	similar
8	63	64	O	in
9	66	73	O	patients
10	75	78	O	with
11	80	85	O	severe
12	87	91	O	renal
13	93	102	O	impairment
14	104	106	O	and
15	108	113	O	normal
16	115	122	O	subjects
17	123	123	O	,
18	125	134	O	indicating
19	136	139	O	that
20	141	146	O	dosage
21	148	157	O	adjustment
22	159	163	O	based
23	165	168	O	upon
24	170	172	O	the
25	174	179	O	degree
26	181	182	O	of
27	184	188	O	renal
28	190	199	O	impairment
29	201	202	O	is
30	204	206	O	not
31	208	215	O	required
NULL

Zyprexa	1379	34090-1	d5051fbc-846b-4946-82df-341fb1216341	9
In addition, olanzapine is not removed by dialysis.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	22	O	XXXXXXXX
5	24	25	O	is
6	27	29	O	not
7	31	37	O	removed
8	39	40	O	by
9	42	49	O	dialysis
NULL

Zyprexa	1380	34090-1	d5051fbc-846b-4946-82df-341fb1216341	12
The effect of renal impairment on metabolite elimination has not been studied.
1	0	2	O	The
2	4	9	O	effect
3	11	12	O	of
4	14	18	O	renal
5	20	29	O	impairment
6	31	32	O	on
7	34	43	O	metabolite
8	45	55	O	elimination
9	57	59	O	has
10	61	63	O	not
11	65	68	O	been
12	70	76	O	studied
NULL

Zyprexa	1381	34090-1	d5051fbc-846b-4946-82df-341fb1216341	46
Hepatic Impairment - Although the presence of hepatic impairment may be expected to reduce the clearance of olanzapine, a study of the effect of impaired liver function in subjects (n=6) with clinically significant (Childs Pugh ClassificationA andB) cirrhosis revealed little effect on the pharmacokinetics of olanzapine.
1	0	6	O	Hepatic
2	8	17	O	Impairment
3	21	28	O	Although
4	30	32	O	the
5	34	41	O	presence
6	43	44	O	of
7	46	52	O	hepatic
8	54	63	O	impairment
9	65	67	O	may
10	69	70	O	be
11	72	79	O	expected
12	81	82	O	to
13	84	89	O	reduce
14	91	93	O	the
15	95	103	O	clearance
16	105	106	O	of
17	108	117	O	XXXXXXXX
18	118	118	O	,
19	120	120	O	a
20	122	126	O	study
21	128	129	O	of
22	131	133	O	the
23	135	140	O	effect
24	142	143	O	of
25	145	152	O	impaired
26	154	158	O	liver
27	160	167	O	function
28	169	170	O	in
29	172	179	O	subjects
30	182	184	O	n=6
31	187	190	O	with
32	192	201	O	clinically
33	203	213	O	significant
34	216	221	O	Childs
35	223	226	O	Pugh
36	228	242	O	ClassificationA
37	244	247	O	andB
38	250	258	O	cirrhosis
39	260	267	O	revealed
40	269	274	O	little
41	276	281	O	effect
42	283	284	O	on
43	286	288	O	the
44	290	305	O	pharmacokinetics
45	307	308	O	of
46	310	319	O	XXXXXXXX
NULL

Zyprexa	1382	34090-1	d5051fbc-846b-4946-82df-341fb1216341	31
Geriatric - In a study involving 24 healthy subjects, the mean elimination half-life of olanzapine was about 1.5 times greater in elderly (>65 years) than in nonelderly subjects (<65 years).
1	0	8	O	Geriatric
2	12	13	O	In
3	15	15	O	a
4	17	21	O	study
5	23	31	O	involving
6	33	34	O	24
7	36	42	O	healthy
8	44	51	O	subjects
9	52	52	O	,
10	54	56	O	the
11	58	61	O	mean
12	63	73	O	elimination
13	75	78	O	half
14	80	83	O	life
15	85	86	O	of
16	88	97	O	XXXXXXXX
17	99	101	O	was
18	103	107	O	about
19	109	111	O	1.5
20	113	117	O	times
21	119	125	O	greater
22	127	128	O	in
23	130	136	O	elderly
24	139	141	O	>65
25	143	147	O	years
26	150	153	O	than
27	155	156	O	in
28	158	167	O	nonelderly
29	169	176	O	subjects
30	179	181	O	<65
31	183	187	O	years
NULL

Zyprexa	1383	34090-1	d5051fbc-846b-4946-82df-341fb1216341	26
Caution should be used in dosing the elderly, especially if there are other factors that might additively influence drug metabolism and/or pharmacodynamic sensitivity.
1	0	6	O	Caution
2	8	13	O	should
3	15	16	O	be
4	18	21	O	used
5	23	24	O	in
6	26	31	O	dosing
7	33	35	O	the
8	37	43	O	elderly
9	44	44	O	,
10	46	55	O	especially
11	57	58	O	if
12	60	64	O	there
13	66	68	O	are
14	70	74	O	other
15	76	82	O	factors
16	84	87	O	that
17	89	93	O	might
18	95	104	O	additively
19	106	114	O	influence
20	116	119	O	drug
21	121	130	O	metabolism
22	132	134	O	and
23	135	135	O	/
24	136	137	O	or
25	139	153	O	pharmacodynamic
26	155	165	O	sensitivity
NULL

Zyprexa	1384	34090-1	d5051fbc-846b-4946-82df-341fb1216341	13
Gender - Clearance of olanzapine is approximately 30% lower in women than in men.
1	0	5	O	Gender
2	9	17	O	Clearance
3	19	20	O	of
4	22	31	O	XXXXXXXX
5	33	34	O	is
6	36	48	O	approximately
7	50	52	O	30%
8	54	58	O	lower
9	60	61	O	in
10	63	67	O	women
11	69	72	O	than
12	74	75	O	in
13	77	79	O	men
NULL

Zyprexa	1385	34090-1	d5051fbc-846b-4946-82df-341fb1216341	17
There were, however, no apparent differences between men and women in effectiveness or adverse effects.
1	0	4	O	There
2	6	9	O	were
3	10	10	O	,
4	12	18	O	however
5	19	19	O	,
6	21	22	O	no
7	24	31	O	apparent
8	33	43	O	differences
9	45	51	O	between
10	53	55	O	men
11	57	59	O	and
12	61	65	O	women
13	67	68	O	in
14	70	82	O	effectiveness
15	84	85	O	or
16	87	93	O	adverse
17	95	101	O	effects
NULL

Zyprexa	1386	34090-1	d5051fbc-846b-4946-82df-341fb1216341	9
Dosage modifications based on gender should not be needed.
1	0	5	O	Dosage
2	7	19	O	modifications
3	21	25	O	based
4	27	28	O	on
5	30	35	O	gender
6	37	42	O	should
7	44	46	O	not
8	48	49	O	be
9	51	56	O	needed
NULL

Zyprexa	1387	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
Smoking Status - Olanzapine clearance is about 40% higher in smokers than in nonsmokers, although dosage modifications are not routinely recommended.
1	0	6	O	Smoking
2	8	13	O	Status
3	17	26	O	XXXXXXXX
4	28	36	O	clearance
5	38	39	O	is
6	41	45	O	about
7	47	49	O	40%
8	51	56	O	higher
9	58	59	O	in
10	61	67	O	smokers
11	69	72	O	than
12	74	75	O	in
13	77	86	O	nonsmokers
14	87	87	O	,
15	89	96	O	although
16	98	103	O	dosage
17	105	117	O	modifications
18	119	121	O	are
19	123	125	O	not
20	127	135	O	routinely
21	137	147	O	recommended
NULL

Zyprexa	1388	34090-1	d5051fbc-846b-4946-82df-341fb1216341	23
Race - Invivo studies have shown that exposures are similar among Japanese, Chinese and Caucasians, especially after normalization for body weight differences.
1	0	3	O	Race
2	7	12	O	Invivo
3	14	20	O	studies
4	22	25	O	have
5	27	31	O	shown
6	33	36	O	that
7	38	46	O	exposures
8	48	50	O	are
9	52	58	O	similar
10	60	64	O	among
11	66	73	O	Japanese
12	74	74	O	,
13	76	82	O	Chinese
14	84	86	O	and
15	88	97	O	Caucasians
16	98	98	O	,
17	100	109	O	especially
18	111	115	O	after
19	117	129	O	normalization
20	131	133	O	for
21	135	138	O	body
22	140	145	O	weight
23	147	157	O	differences
NULL

Zyprexa	1389	34090-1	d5051fbc-846b-4946-82df-341fb1216341	10
Dosage modifications for race are, therefore, not recommended.
1	0	5	O	Dosage
2	7	19	O	modifications
3	21	23	O	for
4	25	28	O	race
5	30	32	O	are
6	33	33	O	,
7	35	43	O	therefore
8	44	44	O	,
9	46	48	O	not
10	50	60	O	recommended
NULL

Zyprexa	1390	34090-1	d5051fbc-846b-4946-82df-341fb1216341	20
Combined Effects - The combined effects of age, smoking, and gender could lead to substantial pharmacokinetic differences in populations.
1	0	7	O	Combined
2	9	15	O	Effects
3	19	21	O	The
4	23	30	O	combined
5	32	38	O	effects
6	40	41	O	of
7	43	45	O	age
8	46	46	O	,
9	48	54	O	smoking
10	55	55	O	,
11	57	59	O	and
12	61	66	O	gender
13	68	72	O	could
14	74	77	O	lead
15	79	80	O	to
16	82	92	O	substantial
17	94	108	O	pharmacokinetic
18	110	120	O	differences
19	122	123	O	in
20	125	135	O	populations
NULL

Zyprexa	1391	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
The clearance in young smoking males, for example, may be 3 times higher than that in elderly nonsmoking females.
1	0	2	O	The
2	4	12	O	clearance
3	14	15	O	in
4	17	21	O	young
5	23	29	O	smoking
6	31	35	O	males
7	36	36	O	,
8	38	40	O	for
9	42	48	O	example
10	49	49	O	,
11	51	53	O	may
12	55	56	O	be
13	58	58	O	3
14	60	64	O	times
15	66	71	O	higher
16	73	76	O	than
17	78	81	O	that
18	83	84	O	in
19	86	92	O	elderly
20	94	103	O	nonsmoking
21	105	111	O	females
NULL

Zyprexa	1392	34090-1	d5051fbc-846b-4946-82df-341fb1216341	21
Dosing modification may be necessary in patients who exhibit a combination of factors that may result in slower metabolism of olanzapine.
1	0	5	O	Dosing
2	7	18	O	modification
3	20	22	O	may
4	24	25	O	be
5	27	35	O	necessary
6	37	38	O	in
7	40	47	O	patients
8	49	51	O	who
9	53	59	O	exhibit
10	61	61	O	a
11	63	73	O	combination
12	75	76	O	of
13	78	84	O	factors
14	86	89	O	that
15	91	93	O	may
16	95	100	O	result
17	102	103	O	in
18	105	110	O	slower
19	112	121	O	metabolism
20	123	124	O	of
21	126	135	O	XXXXXXXX
NULL

Zyprexa	1393	34090-1	d5051fbc-846b-4946-82df-341fb1216341	34
Adolescents (ages 13 to 17 years) - In clinical studies, most adolescents were nonsmokers and this population had a lower average body weight, which resulted in higher average olanzapine exposure compared to adults.
1	0	10	O	Adolescents
2	13	16	O	ages
3	18	19	O	13
4	21	22	O	to
5	24	25	O	17
6	27	31	O	years
7	36	37	O	In
8	39	46	O	clinical
9	48	54	O	studies
10	55	55	O	,
11	57	60	O	most
12	62	72	O	adolescents
13	74	77	O	were
14	79	88	O	nonsmokers
15	90	92	O	and
16	94	97	O	this
17	99	108	O	population
18	110	112	O	had
19	114	114	O	a
20	116	120	O	lower
21	122	128	O	average
22	130	133	O	body
23	135	140	O	weight
24	141	141	O	,
25	143	147	O	which
26	149	156	O	resulted
27	158	159	O	in
28	161	166	O	higher
29	168	174	O	average
30	176	185	O	XXXXXXXX
31	187	194	O	exposure
32	196	203	O	compared
33	205	206	O	to
34	208	213	O	adults
NULL

Zytiga	2091	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	11
CYP3A4 Inducers: Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment.
1	0	5	O	CYP3A4
2	7	14	O	Inducers
3	15	15	O	:
4	17	21	U-TRI	Avoid
5	23	33	O	concomitant
6	35	40	B-UNK	strong
7	42	47	I-UNK	CYP3A4
8	49	56	L-UNK	inducers
9	58	63	O	during
10	65	70	O	XXXXXXXX
11	72	80	O	treatment
NULL

Zytiga	2092	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	15
If a strong CYP3A4 inducer must be co-administered, increase the ZYTIGA dosing frequency.
1	0	1	O	If
2	3	3	O	a
3	5	10	B-KIN	strong
4	12	17	I-KIN	CYP3A4
5	19	25	L-KIN	inducer
6	27	30	O	must
7	32	33	O	be
8	35	36	O	co
9	38	49	O	administered
10	50	50	O	,
11	52	59	O	increase
12	61	63	O	the
13	65	70	O	XXXXXXXX
14	72	77	O	dosing
15	79	87	O	frequency
K/3:C54356

Zytiga	2093	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	17
CYP2D6 Substrates: Avoid co-administration of ZYTIGA with CYP2D6 substrates that have a narrow therapeutic index.
1	0	5	O	CYP2D6
2	7	16	O	Substrates
3	17	17	O	:
4	19	23	U-TRI	Avoid
5	25	26	O	co
6	28	41	O	administration
7	43	44	O	of
8	46	51	O	XXXXXXXX
9	53	56	O	with
10	58	63	B-UNK	CYP2D6
11	65	74	I-UNK	substrates
12	76	79	I-UNK	that
13	81	84	I-UNK	have
14	86	86	I-UNK	a
15	88	93	I-UNK	narrow
16	95	105	I-UNK	therapeutic
17	107	111	L-UNK	index
NULL

Zytiga	2094	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	20
If an alternative treatment cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate.
1	0	1	O	If
2	3	4	O	an
3	6	16	O	alternative
4	18	26	O	treatment
5	28	33	O	cannot
6	35	36	O	be
7	38	41	O	used
8	42	42	O	,
9	44	51	O	exercise
10	53	59	O	caution
11	61	63	O	and
12	65	72	O	consider
13	74	74	O	a
14	76	79	B-TRI	dose
15	81	89	I-TRI	reduction
16	91	92	I-TRI	of
17	94	96	I-TRI	the
18	98	108	L-TRI	concomitant
19	110	115	B-KIN	CYP2D6
20	117	125	L-KIN	substrate
K/19:C54357

Zytiga	2095	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	12
Based on in vitro data, ZYTIGA is a substrate of CYP3A4.
1	0	4	O	Based
2	6	7	O	on
3	9	10	O	in
4	12	16	O	vitro
5	18	21	O	data
6	22	22	O	,
7	24	29	O	XXXXXXXX
8	31	32	O	is
9	34	34	O	a
10	36	44	O	substrate
11	46	47	O	of
12	49	54	O	CYP3A4
NULL

Zytiga	2096	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	23
In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%.
1	0	1	O	In
2	3	3	O	a
3	5	13	O	dedicated
4	15	18	O	drug
5	20	30	O	interaction
6	32	36	O	trial
7	37	37	O	,
8	39	40	O	co
9	42	55	O	administration
10	57	58	O	of
11	60	67	U-KIN	rifampin
12	68	68	O	,
13	70	70	O	a
14	72	77	B-KIN	strong
15	79	84	I-KIN	CYP3A4
16	86	92	L-KIN	inducer
17	93	93	O	,
18	95	103	B-TRI	decreased
19	105	112	L-TRI	exposure
20	114	115	O	of
21	117	127	O	XXXXXXXX
22	129	130	O	by
23	132	134	O	55%
K/11:C54356 K/14:C54356

Zytiga	2097	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	8
Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment.
1	0	4	U-TRI	Avoid
2	6	16	O	concomitant
3	18	23	B-UNK	strong
4	25	30	I-UNK	CYP3A4
5	32	39	L-UNK	inducers
6	41	46	O	during
7	48	53	O	XXXXXXXX
8	55	63	O	treatment
NULL

Zytiga	2099	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	28
In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone.
1	0	1	O	In
2	3	3	O	a
3	5	13	O	dedicated
4	15	18	O	drug
5	20	30	O	interaction
6	32	36	O	trial
7	37	37	O	,
8	39	40	O	co
9	42	55	O	administration
10	57	58	O	of
11	60	71	O	ketoconazole
12	72	72	O	,
13	74	74	O	a
14	76	81	O	strong
15	83	91	O	inhibitor
16	93	94	O	of
17	96	101	O	CYP3A4
18	102	102	O	,
19	104	106	O	had
20	108	109	O	no
21	111	120	O	clinically
22	122	131	O	meaningful
23	133	138	O	effect
24	140	141	O	on
25	143	145	O	the
26	147	162	O	pharmacokinetics
27	164	165	O	of
28	167	177	O	XXXXXXXX
NULL

Zytiga	2100	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	13
ZYTIGA is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8.
1	0	5	O	XXXXXXXX
2	7	8	O	is
3	10	11	O	an
4	13	21	O	inhibitor
5	23	24	O	of
6	26	28	O	the
7	30	36	O	hepatic
8	38	41	O	drug
9	43	54	O	metabolizing
10	56	62	O	enzymes
11	64	69	O	CYP2D6
12	71	73	O	and
13	75	80	O	CYP2C8
NULL

Zytiga	2101	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	41
In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	CYP2D6
4	12	15	O	drug
5	17	20	O	drug
6	22	32	O	interaction
7	34	38	O	trial
8	39	39	O	,
9	41	43	O	the
10	45	48	O	Cmax
11	50	52	O	and
12	54	56	O	AUC
13	58	59	O	of
14	61	76	U-KIN	dextromethorphan
15	79	84	B-KIN	CYP2D6
16	86	94	L-KIN	substrate
17	97	100	O	were
18	102	110	O	increased
19	112	114	O	2.8
20	117	119	O	and
21	121	123	O	2.9
22	125	128	O	fold
23	129	129	O	,
24	131	142	O	respectively
25	143	143	O	,
26	145	148	O	when
27	150	165	O	dextromethorphan
28	167	169	O	was
29	171	175	O	given
30	177	180	O	with
31	182	192	O	XXXXXXXX
32	194	200	O	acetate
33	202	206	O	1,000
34	208	209	O	mg
35	211	215	O	daily
36	217	219	O	and
37	221	230	O	prednisone
38	232	232	O	5
39	234	235	O	mg
40	237	241	O	twice
41	243	247	O	daily
K/14:C54610 K/15:C54613

Zytiga	2102	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	18
Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine).
1	0	4	U-TRI	Avoid
2	6	7	O	co
3	9	22	O	administration
4	24	25	O	of
5	27	37	O	XXXXXXXX
6	39	45	O	acetate
7	47	50	O	with
8	52	61	B-UNK	substrates
9	63	64	I-UNK	of
10	66	71	I-UNK	CYP2D6
11	73	76	I-UNK	with
12	78	78	I-UNK	a
13	80	85	I-UNK	narrow
14	87	97	I-UNK	therapeutic
15	99	103	L-UNK	index
16	106	108	O	e.g
17	110	110	O	,
18	112	123	U-UNK	thioridazine
NULL

Zytiga	2103	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	17
If alternative treatments cannot be used, consider a dose reduction of the concomitant CYP2D6 substrate drug.
1	0	1	O	If
2	3	13	O	alternative
3	15	24	O	treatments
4	26	31	O	cannot
5	33	34	O	be
6	36	39	O	used
7	40	40	O	,
8	42	49	O	consider
9	51	51	O	a
10	53	56	B-TRI	dose
11	58	66	L-TRI	reduction
12	68	69	O	of
13	71	73	O	the
14	75	85	O	concomitant
15	87	92	B-KIN	CYP2D6
16	94	102	L-KIN	substrate
17	104	107	O	drug
K/15:C54357

Zytiga	2104	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	35
In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	CYP2C8
4	12	15	O	drug
5	17	20	O	drug
6	22	32	O	interaction
7	34	38	O	trial
8	40	41	O	in
9	43	49	O	healthy
10	51	58	O	subjects
11	59	59	O	,
12	61	63	O	the
13	65	67	O	AUC
14	69	70	O	of
15	72	83	U-KIN	pioglitazone
16	86	91	B-KIN	CYP2C8
17	93	101	L-KIN	substrate
18	104	106	O	was
19	108	116	O	increased
20	118	119	O	by
21	121	123	O	46%
22	125	128	O	when
23	130	141	O	pioglitazone
24	143	145	O	was
25	147	151	O	given
26	153	160	O	together
27	162	165	O	with
28	167	167	O	a
29	169	174	O	single
30	176	179	O	dose
31	181	182	O	of
32	184	188	O	1,000
33	190	191	O	mg
34	193	203	O	XXXXXXXX
35	205	211	O	acetate
K/15:C54613 K/16:C54613

Zytiga	2105	34073-7	4e338e89-3cf2-48eb-b6e2-a06c608c6513	26
Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA.
1	0	8	O	Therefore
2	9	9	O	,
3	11	18	O	patients
4	20	25	B-TRI	should
5	27	28	I-TRI	be
6	30	38	L-TRI	monitored
7	40	46	O	closely
8	48	50	O	for
9	52	56	O	signs
10	58	59	O	of
11	61	68	O	toxicity
12	70	76	O	related
13	78	79	O	to
14	81	81	O	a
15	83	88	B-UNK	CYP2C8
16	90	98	I-UNK	substrate
17	100	103	I-UNK	with
18	105	105	I-UNK	a
19	107	112	I-UNK	narrow
20	114	124	I-UNK	therapeutic
21	126	130	L-UNK	index
22	132	133	O	if
23	135	138	O	used
24	140	152	O	concomitantly
25	154	157	O	with
26	159	164	O	XXXXXXXX
NULL

Zytiga	2106	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	24
Abiraterone acetate (ZYTIGA) is converted in vivo to abiraterone, an androgen biosynthesis inhibitor, that inhibits 17 A-hydroxylase/C17,20-lyase (CYP17).
1	0	10	O	XXXXXXXX
2	12	18	O	acetate
3	21	26	O	XXXXXXXX
4	29	30	O	is
5	32	40	O	converted
6	42	43	O	in
7	45	48	O	vivo
8	50	51	O	to
9	53	63	O	XXXXXXXX
10	64	64	O	,
11	66	67	O	an
12	69	76	O	androgen
13	78	89	O	biosynthesis
14	91	99	O	inhibitor
15	100	100	O	,
16	102	105	O	that
17	107	114	O	inhibits
18	116	117	O	17
19	119	119	O	A
20	121	131	O	hydroxylase
21	132	132	O	/
22	133	138	O	C17,20
23	140	144	O	lyase
24	147	151	O	CYP17
NULL

Zytiga	2107	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	19
This enzyme is expressed in testicular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.
1	0	3	O	This
2	5	10	O	enzyme
3	12	13	O	is
4	15	23	O	expressed
5	25	26	O	in
6	28	37	O	testicular
7	38	38	O	,
8	40	46	O	adrenal
9	47	47	O	,
10	49	51	O	and
11	53	61	O	prostatic
12	63	67	O	tumor
13	69	75	O	tissues
14	77	79	O	and
15	81	82	O	is
16	84	91	O	required
17	93	95	O	for
18	97	104	O	androgen
19	106	117	O	biosynthesis
NULL

Zytiga	2108	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	41
CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone and progesterone to their 17A-hydroxy derivatives by 17A-hydroxylase activity and 2) the subsequent formation of dehydroepiandrosterone (DHEA) and androstenedione, respectively, by C17, 20 lyase activity.
1	0	4	O	CYP17
2	6	14	O	catalyzes
3	16	18	O	two
4	20	29	O	sequential
5	31	39	O	reactions
6	40	40	O	:
7	42	42	O	1
8	45	47	O	the
9	49	58	O	conversion
10	60	61	O	of
11	63	74	O	pregnenolone
12	76	78	O	and
13	80	91	O	progesterone
14	93	94	O	to
15	96	100	O	their
16	102	104	O	17A
17	106	112	O	hydroxy
18	114	124	O	derivatives
19	126	127	O	by
20	129	131	O	17A
21	133	143	O	hydroxylase
22	145	152	O	activity
23	154	156	O	and
24	158	158	O	2
25	161	163	O	the
26	165	174	O	subsequent
27	176	184	O	formation
28	186	187	O	of
29	189	210	O	dehydroepiandrosterone
30	213	216	O	DHEA
31	219	221	O	and
32	223	237	O	androstenedione
33	238	238	O	,
34	240	251	O	respectively
35	252	252	O	,
36	254	255	O	by
37	257	259	O	C17
38	260	260	O	,
39	262	263	O	20
40	265	269	O	lyase
41	271	278	O	activity
NULL

Zytiga	2109	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	10
DHEA and androstenedione are androgens and are precursors of testosterone.
1	0	3	O	DHEA
2	5	7	O	and
3	9	23	O	androstenedione
4	25	27	O	are
5	29	37	O	androgens
6	39	41	O	and
7	43	45	O	are
8	47	56	O	precursors
9	58	59	O	of
10	61	72	O	testosterone
NULL

Zytiga	2110	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	15
Inhibition of CYP17 by abiraterone can also result in increased mineralocorticoid production by the adrenals.
1	0	9	O	Inhibition
2	11	12	O	of
3	14	18	O	CYP17
4	20	21	O	by
5	23	33	O	XXXXXXXX
6	35	37	O	can
7	39	42	O	also
8	44	49	O	result
9	51	52	O	in
10	54	62	O	increased
11	64	80	O	mineralocorticoid
12	82	91	O	production
13	93	94	O	by
14	96	98	O	the
15	100	107	O	adrenals
NULL

Zytiga	2111	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	11
Androgen sensitive prostatic carcinoma responds to treatment that decreases androgen levels.
1	0	7	O	Androgen
2	9	17	O	sensitive
3	19	27	O	prostatic
4	29	37	O	carcinoma
5	39	46	O	responds
6	48	49	O	to
7	51	59	O	treatment
8	61	64	O	that
9	66	74	O	decreases
10	76	83	O	androgen
11	85	90	O	levels
NULL

Zytiga	2112	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	32
Androgen deprivation therapies, such as treatment with GnRH agonists or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumor.
1	0	7	O	Androgen
2	9	19	O	deprivation
3	21	29	O	therapies
4	30	30	O	,
5	32	35	O	such
6	37	38	O	as
7	40	48	O	treatment
8	50	53	O	with
9	55	58	O	GnRH
10	60	67	O	agonists
11	69	70	O	or
12	72	82	O	orchiectomy
13	83	83	O	,
14	85	92	O	decrease
15	94	101	O	androgen
16	103	112	O	production
17	114	115	O	in
18	117	119	O	the
19	121	126	O	testes
20	128	130	O	but
21	132	133	O	do
22	135	137	O	not
23	139	144	O	affect
24	146	153	O	androgen
25	155	164	O	production
26	166	167	O	by
27	169	171	O	the
28	173	180	O	adrenals
29	182	183	O	or
30	185	186	O	in
31	188	190	O	the
32	192	196	O	tumor
NULL

Zytiga	2113	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	15
ZYTIGA decreased serum testosterone and other androgens in patients in the placebo-controlled clinical trial.
1	0	5	O	XXXXXXXX
2	7	15	O	decreased
3	17	21	O	serum
4	23	34	O	testosterone
5	36	38	O	and
6	40	44	O	other
7	46	54	O	androgens
8	56	57	O	in
9	59	66	O	patients
10	68	69	O	in
11	71	73	O	the
12	75	81	O	placebo
13	83	92	O	controlled
14	94	101	O	clinical
15	103	107	O	trial
NULL

Zytiga	2114	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	14
It is not necessary to monitor the effect of ZYTIGA on serum testosterone levels.
1	0	1	O	It
2	3	4	O	is
3	6	8	O	not
4	10	18	O	necessary
5	20	21	O	to
6	23	29	O	monitor
7	31	33	O	the
8	35	40	O	effect
9	42	43	O	of
10	45	50	O	XXXXXXXX
11	52	53	O	on
12	55	59	O	serum
13	61	72	O	testosterone
14	74	79	O	levels
NULL

Zytiga	2115	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	24
Changes in serum prostate specific antigen (PSA) levels may be observed but have not been shown to correlate with clinical benefit in individual patients.
1	0	6	O	Changes
2	8	9	O	in
3	11	15	O	serum
4	17	24	O	prostate
5	26	33	O	specific
6	35	41	O	antigen
7	44	46	O	PSA
8	49	54	O	levels
9	56	58	O	may
10	60	61	O	be
11	63	70	O	observed
12	72	74	O	but
13	76	79	O	have
14	81	83	O	not
15	85	88	O	been
16	90	94	O	shown
17	96	97	O	to
18	99	107	O	correlate
19	109	112	O	with
20	114	121	O	clinical
21	123	129	O	benefit
22	131	132	O	in
23	134	143	O	individual
24	145	152	O	patients
NULL

Zytiga	2116	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	25
Following administration of abiraterone acetate, the pharmacokinetics of abiraterone and abiraterone acetate have been studied in healthy subjects and in patients with metastatic CRPC.
1	0	8	O	Following
2	10	23	O	administration
3	25	26	O	of
4	28	38	O	XXXXXXXX
5	40	46	O	acetate
6	47	47	O	,
7	49	51	O	the
8	53	68	O	pharmacokinetics
9	70	71	O	of
10	73	83	O	XXXXXXXX
11	85	87	O	and
12	89	99	O	XXXXXXXX
13	101	107	O	acetate
14	109	112	O	have
15	114	117	O	been
16	119	125	O	studied
17	127	128	O	in
18	130	136	O	healthy
19	138	145	O	subjects
20	147	149	O	and
21	151	152	O	in
22	154	161	O	patients
23	163	166	O	with
24	168	177	O	metastatic
25	179	182	O	CRPC
NULL

Zytiga	2117	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	9
In vivo, abiraterone acetate is converted to abiraterone.
1	0	1	O	In
2	3	6	O	vivo
3	7	7	O	,
4	9	19	O	XXXXXXXX
5	21	27	O	acetate
6	29	30	O	is
7	32	40	O	converted
8	42	43	O	to
9	45	55	O	XXXXXXXX
NULL

Zytiga	2118	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	22
In clinical studies, abiraterone acetate plasma concentrations were below detectable levels (<0.2 ng/mL) in >99% of the analyzed samples.
1	0	1	O	In
2	3	10	O	clinical
3	12	18	O	studies
4	19	19	O	,
5	21	31	O	XXXXXXXX
6	33	39	O	acetate
7	41	46	O	plasma
8	48	61	O	concentrations
9	63	66	O	were
10	68	72	O	below
11	74	83	O	detectable
12	85	90	O	levels
13	93	96	O	<0.2
14	98	99	O	ng
15	100	100	O	/
16	101	102	O	mL
17	105	106	O	in
18	108	111	O	>99%
19	113	114	O	of
20	116	118	O	the
21	120	127	O	analyzed
22	129	135	O	samples
NULL

Zytiga	2119	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	25
Absorption Following oral administration of abiraterone acetate to patients with metastatic CRPC, the median time to reach maximum plasma abiraterone concentrations is 2 hours.
1	0	9	O	Absorption
2	11	19	O	Following
3	21	24	O	oral
4	26	39	O	administration
5	41	42	O	of
6	44	54	O	XXXXXXXX
7	56	62	O	acetate
8	64	65	O	to
9	67	74	O	patients
10	76	79	O	with
11	81	90	O	metastatic
12	92	95	O	CRPC
13	96	96	O	,
14	98	100	O	the
15	102	107	O	median
16	109	112	O	time
17	114	115	O	to
18	117	121	O	reach
19	123	129	O	maximum
20	131	136	O	plasma
21	138	148	O	XXXXXXXX
22	150	163	O	concentrations
23	165	166	O	is
24	168	168	O	2
25	170	174	O	hours
NULL

Zytiga	2120	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	27
Abiraterone accumulation is observed at steady-state, with a 2-fold higher exposure (steady-state AUC) compared to a single 1,000 mg dose of abiraterone acetate.
1	0	10	O	XXXXXXXX
2	12	23	O	accumulation
3	25	26	O	is
4	28	35	O	observed
5	37	38	O	at
6	40	45	O	steady
7	47	51	O	state
8	52	52	O	,
9	54	57	O	with
10	59	59	O	a
11	61	61	O	2
12	63	66	O	fold
13	68	73	O	higher
14	75	82	O	exposure
15	85	90	O	steady
16	92	96	O	state
17	98	100	O	AUC
18	103	110	O	compared
19	112	113	O	to
20	115	115	O	a
21	117	122	O	single
22	124	128	O	1,000
23	130	131	O	mg
24	133	136	O	dose
25	138	139	O	of
26	141	151	O	XXXXXXXX
27	153	159	O	acetate
NULL

Zytiga	2121	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	38
At the dose of 1,000 mg daily in patients with metastatic CRPC, steady-state values (mean * SD) of Cmax were 226 * 178 ng/mL and of AUC were 993 * 639 ng.hr/mL.
1	0	1	O	At
2	3	5	O	the
3	7	10	O	dose
4	12	13	O	of
5	15	19	O	1,000
6	21	22	O	mg
7	24	28	O	daily
8	30	31	O	in
9	33	40	O	patients
10	42	45	O	with
11	47	56	O	metastatic
12	58	61	O	CRPC
13	62	62	O	,
14	64	69	O	steady
15	71	75	O	state
16	77	82	O	values
17	85	88	O	mean
18	90	90	O	*
19	92	93	O	SD
20	96	97	O	of
21	99	102	O	Cmax
22	104	107	O	were
23	109	111	O	226
24	113	113	O	*
25	115	117	O	178
26	119	120	O	ng
27	121	121	O	/
28	122	123	O	mL
29	125	127	O	and
30	129	130	O	of
31	132	134	O	AUC
32	136	139	O	were
33	141	143	O	993
34	145	145	O	*
35	147	149	O	639
36	151	155	O	ng.hr
37	156	156	O	/
38	157	158	O	mL
NULL

Zytiga	2122	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	18
No major deviation from dose proportionality was observed in the dose range of 250 mg to 1,000 mg.
1	0	1	O	No
2	3	7	O	major
3	9	17	O	deviation
4	19	22	O	from
5	24	27	O	dose
6	29	43	O	proportionality
7	45	47	O	was
8	49	56	O	observed
9	58	59	O	in
10	61	63	O	the
11	65	68	O	dose
12	70	74	O	range
13	76	77	O	of
14	79	81	O	250
15	83	84	O	mg
16	86	87	O	to
17	89	93	O	1,000
18	95	96	O	mg
NULL

Zytiga	2123	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	24
However, the exposure was not significantly increased when the dose was doubled from 1,000 to 2,000 mg (8% increase in the mean AUC).
1	0	6	O	However
2	7	7	O	,
3	9	11	O	the
4	13	20	O	exposure
5	22	24	O	was
6	26	28	O	not
7	30	42	O	significantly
8	44	52	O	increased
9	54	57	O	when
10	59	61	O	the
11	63	66	O	dose
12	68	70	O	was
13	72	78	O	doubled
14	80	83	O	from
15	85	89	O	1,000
16	91	92	O	to
17	94	98	O	2,000
18	100	101	O	mg
19	104	105	O	8%
20	107	114	O	increase
21	116	117	O	in
22	119	121	O	the
23	123	126	O	mean
24	128	130	O	AUC
NULL

Zytiga	2124	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	13
Systemic exposure of abiraterone is increased when abiraterone acetate is administered with food.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	of
4	21	31	O	XXXXXXXX
5	33	34	O	is
6	36	44	O	increased
7	46	49	O	when
8	51	61	O	XXXXXXXX
9	63	69	O	acetate
10	71	72	O	is
11	74	85	O	administered
12	87	90	O	with
13	92	95	U-KIN	food
K/13:C54355

Zytiga	2125	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	70
In healthy subjects abiraterone Cmax and AUC0-* were approximately 7- and 5-fold higher, respectively, when a single dose of abiraterone acetate was administered with a low-fat meal (7% fat, 300 calories) and approximately 17- and 10-fold higher, respectively, when a single dose of abiraterone acetate was administered with a high-fat (57% fat, 825 calories) meal compared to overnight fasting.
1	0	1	O	In
2	3	9	O	healthy
3	11	18	O	subjects
4	20	30	O	XXXXXXXX
5	32	35	O	Cmax
6	37	39	O	and
7	41	44	O	AUC0
8	46	46	O	*
9	48	51	O	were
10	53	65	O	approximately
11	67	67	O	7
12	70	72	O	and
13	74	74	O	5
14	76	79	O	fold
15	81	86	O	higher
16	87	87	O	,
17	89	100	O	respectively
18	101	101	O	,
19	103	106	O	when
20	108	108	O	a
21	110	115	O	single
22	117	120	O	dose
23	122	123	O	of
24	125	135	O	XXXXXXXX
25	137	143	O	acetate
26	145	147	O	was
27	149	160	O	administered
28	162	165	O	with
29	167	167	O	a
30	169	171	B-KIN	low
31	173	175	I-KIN	fat
32	177	180	L-KIN	meal
33	183	184	O	7%
34	186	188	O	fat
35	189	189	O	,
36	191	193	O	300
37	195	202	O	calories
38	205	207	O	and
39	209	221	O	approximately
40	223	224	O	17
41	227	229	O	and
42	231	232	O	10
43	234	237	O	fold
44	239	244	O	higher
45	245	245	O	,
46	247	258	O	respectively
47	259	259	O	,
48	261	264	O	when
49	266	266	O	a
50	268	273	O	single
51	275	278	O	dose
52	280	281	O	of
53	283	293	O	XXXXXXXX
54	295	301	O	acetate
55	303	305	O	was
56	307	318	O	administered
57	320	323	O	with
58	325	325	O	a
59	327	330	O	high
60	332	334	O	fat
61	337	339	O	57%
62	341	343	O	fat
63	344	344	O	,
64	346	348	O	825
65	350	357	O	calories
66	360	363	O	meal
67	365	372	O	compared
68	374	375	O	to
69	377	385	O	overnight
70	387	393	O	fasting
K/30:C54605

Zytiga	2126	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	43
Abiraterone AUC0-* was approximately 7-fold or 1.6-fold higher, respectively, when a single dose of abiraterone acetate was administered 2 hours after or 1 hour before a medium fat meal (25% fat, 491 calories) compared to overnight fasting.
1	0	10	O	XXXXXXXX
2	12	15	O	AUC0
3	17	17	O	*
4	19	21	O	was
5	23	35	O	approximately
6	37	37	O	7
7	39	42	O	fold
8	44	45	O	or
9	47	49	O	1.6
10	51	54	O	fold
11	56	61	O	higher
12	62	62	O	,
13	64	75	O	respectively
14	76	76	O	,
15	78	81	O	when
16	83	83	O	a
17	85	90	O	single
18	92	95	O	dose
19	97	98	O	of
20	100	110	O	XXXXXXXX
21	112	118	O	acetate
22	120	122	O	was
23	124	135	O	administered
24	137	137	O	2
25	139	143	O	hours
26	145	149	O	after
27	151	152	O	or
28	154	154	O	1
29	156	159	O	hour
30	161	166	O	before
31	168	168	O	a
32	170	175	B-KIN	medium
33	177	179	I-KIN	fat
34	181	184	L-KIN	meal
35	187	189	O	25%
36	191	193	O	fat
37	194	194	O	,
38	196	198	O	491
39	200	207	O	calories
40	210	217	O	compared
41	219	220	O	to
42	222	230	O	overnight
43	232	238	O	fasting
K/32:C54605

Zytiga	2127	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	66
Systemic exposures of abiraterone in patients with metastatic CRPC, after repeated dosing of abiraterone acetate were similar when abiraterone acetate was taken with low-fat meals for 7 days and increased approximately 2-fold when taken with high-fat meals for 7 days compared to when taken at least 2 hours after a meal and at least 1 hour before a meal for 7 days.
1	0	7	O	Systemic
2	9	17	O	exposures
3	19	20	O	of
4	22	32	O	XXXXXXXX
5	34	35	O	in
6	37	44	O	patients
7	46	49	O	with
8	51	60	O	metastatic
9	62	65	O	CRPC
10	66	66	O	,
11	68	72	O	after
12	74	81	O	repeated
13	83	88	O	dosing
14	90	91	O	of
15	93	103	O	XXXXXXXX
16	105	111	O	acetate
17	113	116	O	were
18	118	124	O	similar
19	126	129	O	when
20	131	141	O	XXXXXXXX
21	143	149	O	acetate
22	151	153	O	was
23	155	159	O	taken
24	161	164	O	with
25	166	168	O	low
26	170	172	O	fat
27	174	178	O	meals
28	180	182	O	for
29	184	184	O	7
30	186	189	O	days
31	191	193	O	and
32	195	203	O	increased
33	205	217	O	approximately
34	219	219	O	2
35	221	224	O	fold
36	226	229	O	when
37	231	235	O	taken
38	237	240	O	with
39	242	245	B-KIN	high
40	247	249	I-KIN	fat
41	251	255	L-KIN	meals
42	257	259	O	for
43	261	261	O	7
44	263	266	O	days
45	268	275	O	compared
46	277	278	O	to
47	280	283	O	when
48	285	289	O	taken
49	291	292	O	at
50	294	298	O	least
51	300	300	O	2
52	302	306	O	hours
53	308	312	O	after
54	314	314	O	a
55	316	319	O	meal
56	321	323	O	and
57	325	326	O	at
58	328	332	O	least
59	334	334	O	1
60	336	339	O	hour
61	341	346	O	before
62	348	348	O	a
63	350	353	O	meal
64	355	357	O	for
65	359	359	O	7
66	361	364	O	days
K/39:C54355

Zytiga	2128	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	27
Given the normal variation in the content and composition of meals, taking ZYTIGA with meals has the potential to result in increased and highly variable exposures.
1	0	4	O	Given
2	6	8	O	the
3	10	15	O	normal
4	17	25	O	variation
5	27	28	O	in
6	30	32	O	the
7	34	40	O	content
8	42	44	O	and
9	46	56	O	composition
10	58	59	O	of
11	61	65	U-KIN	meals
12	66	66	O	,
13	68	73	O	taking
14	75	80	O	XXXXXXXX
15	82	85	O	with
16	87	91	O	meals
17	93	95	O	has
18	97	99	O	the
19	101	109	O	potential
20	111	112	O	to
21	114	119	O	result
22	121	122	O	in
23	124	132	O	increased
24	134	136	O	and
25	138	143	O	highly
26	145	152	O	variable
27	154	162	O	exposures
K/11:C54355

Zytiga	2129	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	21
Therefore, ZYTIGA must be taken on an empty stomach, either one hour before or two hours after a meal.
1	0	8	O	Therefore
2	9	9	O	,
3	11	16	O	XXXXXXXX
4	18	21	O	must
5	23	24	O	be
6	26	30	O	taken
7	32	33	O	on
8	35	36	O	an
9	38	42	O	empty
10	44	50	O	stomach
11	51	51	O	,
12	53	58	O	either
13	60	62	O	one
14	64	67	O	hour
15	69	74	O	before
16	76	77	O	or
17	79	81	O	two
18	83	87	O	hours
19	89	93	O	after
20	95	95	O	a
21	97	100	O	meal
NULL

Zytiga	2130	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	8
The tablets should be swallowed whole with water.
1	0	2	O	The
2	4	10	O	tablets
3	12	17	O	should
4	19	20	O	be
5	22	30	O	swallowed
6	32	36	O	whole
7	38	41	O	with
8	43	47	O	water
NULL

Zytiga	2131	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	21
Distribution and Protein Binding Abiraterone is highly bound (>99%) to the human plasma proteins, albumin and alpha-1 acid glycoprotein.
1	0	11	O	Distribution
2	13	15	O	and
3	17	23	O	Protein
4	25	31	O	Binding
5	33	43	O	XXXXXXXX
6	45	46	O	is
7	48	53	O	highly
8	55	59	O	bound
9	62	65	O	>99%
10	68	69	O	to
11	71	73	O	the
12	75	79	O	human
13	81	86	O	plasma
14	88	95	O	proteins
15	96	96	O	,
16	98	104	O	albumin
17	106	108	O	and
18	110	114	O	alpha
19	116	116	O	1
20	118	121	O	acid
21	123	134	O	glycoprotein
NULL

Zytiga	2132	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	47
The apparent steady-state volume of distribution (mean * SD) is 19,669 * 13,358 L. In vitro studies show that at clinically relevant concentrations, abiraterone acetate and abiraterone are not substrates of P-glycoprotein (P-gp) and that abiraterone acetate is an inhibitor of P-gp.
1	0	2	O	The
2	4	11	O	apparent
3	13	18	O	steady
4	20	24	O	state
5	26	31	O	volume
6	33	34	O	of
7	36	47	O	distribution
8	50	53	O	mean
9	55	55	O	*
10	57	58	O	SD
11	61	62	O	is
12	64	69	O	19,669
13	71	71	O	*
14	73	78	O	13,358
15	80	80	O	L
16	83	84	O	In
17	86	90	O	vitro
18	92	98	O	studies
19	100	103	O	show
20	105	108	O	that
21	110	111	O	at
22	113	122	O	clinically
23	124	131	O	relevant
24	133	146	O	concentrations
25	147	147	O	,
26	149	159	O	XXXXXXXX
27	161	167	O	acetate
28	169	171	O	and
29	173	183	O	XXXXXXXX
30	185	187	O	are
31	189	191	O	not
32	193	202	O	substrates
33	204	205	O	of
34	207	207	O	P
35	209	220	O	glycoprotein
36	223	223	O	P
37	225	226	O	gp
38	229	231	O	and
39	233	236	O	that
40	238	248	O	XXXXXXXX
41	250	256	O	acetate
42	258	259	O	is
43	261	262	O	an
44	264	272	O	inhibitor
45	274	275	O	of
46	277	277	O	P
47	279	280	O	gp
NULL

Zytiga	2133	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	19
Metabolism Following oral administration of 14C-abiraterone acetate as capsules, abiraterone acetate is hydrolyzed to abiraterone (active metabolite).
1	0	9	O	Metabolism
2	11	19	O	Following
3	21	24	O	oral
4	26	39	O	administration
5	41	42	O	of
6	44	46	O	14C
7	48	58	O	XXXXXXXX
8	60	66	O	acetate
9	68	69	O	as
10	71	78	O	capsules
11	79	79	O	,
12	81	91	O	XXXXXXXX
13	93	99	O	acetate
14	101	102	O	is
15	104	113	O	hydrolyzed
16	115	116	O	to
17	118	128	O	XXXXXXXX
18	131	136	O	active
19	138	147	O	metabolite
NULL

Zytiga	2134	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	18
The conversion is likely through esterase activity (the esterases have not been identified) and is not CYP mediated.
1	0	2	O	The
2	4	13	O	conversion
3	15	16	O	is
4	18	23	O	likely
5	25	31	O	through
6	33	40	O	esterase
7	42	49	O	activity
8	52	54	O	the
9	56	64	O	esterases
10	66	69	O	have
11	71	73	O	not
12	75	78	O	been
13	80	89	O	identified
14	92	94	O	and
15	96	97	O	is
16	99	101	O	not
17	103	105	O	CYP
18	107	114	O	mediated
NULL

Zytiga	2135	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	29
The two main circulating metabolites of abiraterone in human plasma are abiraterone sulphate (inactive) and N-oxide abiraterone sulphate (inactive), which account for about 43% of exposure each.
1	0	2	O	The
2	4	6	O	two
3	8	11	O	main
4	13	23	O	circulating
5	25	35	O	metabolites
6	37	38	O	of
7	40	50	O	XXXXXXXX
8	52	53	O	in
9	55	59	O	human
10	61	66	O	plasma
11	68	70	O	are
12	72	82	O	XXXXXXXX
13	84	91	O	sulphate
14	94	101	O	inactive
15	104	106	O	and
16	108	108	O	N
17	110	114	O	oxide
18	116	126	O	XXXXXXXX
19	128	135	O	sulphate
20	138	145	O	inactive
21	147	147	O	,
22	149	153	O	which
23	155	161	O	account
24	163	165	O	for
25	167	171	O	about
26	173	175	O	43%
27	177	178	O	of
28	180	187	O	exposure
29	189	192	O	each
NULL

Zytiga	2136	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	25
CYP3A4 and SULT2A1 are the enzymes involved in the formation of N-oxide abiraterone sulphate and SULT2A1 is involved in the formation of abiraterone sulphate.
1	0	5	O	CYP3A4
2	7	9	O	and
3	11	17	O	SULT2A1
4	19	21	O	are
5	23	25	O	the
6	27	33	O	enzymes
7	35	42	O	involved
8	44	45	O	in
9	47	49	O	the
10	51	59	O	formation
11	61	62	O	of
12	64	64	O	N
13	66	70	O	oxide
14	72	82	O	XXXXXXXX
15	84	91	O	sulphate
16	93	95	O	and
17	97	103	O	SULT2A1
18	105	106	O	is
19	108	115	O	involved
20	117	118	O	in
21	120	122	O	the
22	124	132	O	formation
23	134	135	O	of
24	137	147	O	XXXXXXXX
25	149	156	O	sulphate
NULL

Zytiga	2137	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	24
Excretion In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean * SD) is 12 * 5 hours.
1	0	8	O	Excretion
2	10	11	O	In
3	13	20	O	patients
4	22	25	O	with
5	27	36	O	metastatic
6	38	41	O	CRPC
7	42	42	O	,
8	44	46	O	the
9	48	51	O	mean
10	53	60	O	terminal
11	62	65	O	half
12	67	70	O	life
13	72	73	O	of
14	75	85	O	XXXXXXXX
15	87	88	O	in
16	90	95	O	plasma
17	98	101	O	mean
18	103	103	O	*
19	105	106	O	SD
20	109	110	O	is
21	112	113	O	12
22	115	115	O	*
23	117	117	O	5
24	119	123	O	hours
NULL

Zytiga	2138	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	23
Following oral administration of 14C-abiraterone acetate, approximately 88% of the radioactive dose is recovered in feces and approximately 5% in urine.
1	0	8	O	Following
2	10	13	O	oral
3	15	28	O	administration
4	30	31	O	of
5	33	35	O	14C
6	37	47	O	XXXXXXXX
7	49	55	O	acetate
8	56	56	O	,
9	58	70	O	approximately
10	72	74	O	88%
11	76	77	O	of
12	79	81	O	the
13	83	93	O	radioactive
14	95	98	O	dose
15	100	101	O	is
16	103	111	O	recovered
17	113	114	O	in
18	116	120	O	feces
19	122	124	O	and
20	126	138	O	approximately
21	140	141	O	5%
22	143	144	O	in
23	146	150	O	urine
NULL

Zytiga	2139	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	22
The major compounds present in feces are unchanged abiraterone acetate and abiraterone (approximately 55% and 22% of the administered dose, respectively).
1	0	2	O	The
2	4	8	O	major
3	10	18	O	compounds
4	20	26	O	present
5	28	29	O	in
6	31	35	O	feces
7	37	39	O	are
8	41	49	O	unchanged
9	51	61	O	XXXXXXXX
10	63	69	O	acetate
11	71	73	O	and
12	75	85	O	XXXXXXXX
13	88	100	O	approximately
14	102	104	O	55%
15	106	108	O	and
16	110	112	O	22%
17	114	115	O	of
18	117	119	O	the
19	121	132	O	administered
20	134	137	O	dose
21	138	138	O	,
22	140	151	O	respectively
NULL

Zytiga	2140	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	39
Patients with Hepatic Impairment The pharmacokinetics of abiraterone was examined in subjects with baseline mild (N=8) or moderate (N=8) hepatic impairment (Child-Pugh Class A and B, respectively) and in 8 healthy control subjects with normal hepatic function.
1	0	7	O	Patients
2	9	12	O	with
3	14	20	O	Hepatic
4	22	31	O	Impairment
5	33	35	O	The
6	37	52	O	pharmacokinetics
7	54	55	O	of
8	57	67	O	XXXXXXXX
9	69	71	O	was
10	73	80	O	examined
11	82	83	O	in
12	85	92	O	subjects
13	94	97	O	with
14	99	106	O	baseline
15	108	111	O	mild
16	114	116	O	N=8
17	119	120	O	or
18	122	129	O	moderate
19	132	134	O	N=8
20	137	143	O	hepatic
21	145	154	O	impairment
22	157	161	O	Child
23	163	166	O	Pugh
24	168	172	O	Class
25	174	174	O	A
26	176	178	O	and
27	180	180	O	B
28	181	181	O	,
29	183	194	O	respectively
30	197	199	O	and
31	201	202	O	in
32	204	204	O	8
33	206	212	O	healthy
34	214	220	O	control
35	222	229	O	subjects
36	231	234	O	with
37	236	241	O	normal
38	243	249	O	hepatic
39	251	258	O	function
NULL

Zytiga	2141	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	33
Systemic exposure to abiraterone after a single oral 1,000 mg dose given under fasting conditions increased approximately 1.1-fold and 3.6-fold in subjects with mild and moderate baseline hepatic impairment, respectively.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	to
4	21	31	O	XXXXXXXX
5	33	37	O	after
6	39	39	O	a
7	41	46	O	single
8	48	51	O	oral
9	53	57	O	1,000
10	59	60	O	mg
11	62	65	O	dose
12	67	71	O	given
13	73	77	O	under
14	79	85	O	fasting
15	87	96	O	conditions
16	98	106	O	increased
17	108	120	O	approximately
18	122	124	O	1.1
19	126	129	O	fold
20	131	133	O	and
21	135	137	O	3.6
22	139	142	O	fold
23	144	145	O	in
24	147	154	O	subjects
25	156	159	O	with
26	161	164	O	mild
27	166	168	O	and
28	170	177	O	moderate
29	179	186	O	baseline
30	188	194	O	hepatic
31	196	205	O	impairment
32	206	206	O	,
33	208	219	O	respectively
NULL

Zytiga	2142	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	29
The mean half-life of abiraterone is prolonged to approximately 18 hours in subjects with mild hepatic impairment and to approximately 19 hours in subjects with moderate hepatic impairment.
1	0	2	O	The
2	4	7	O	mean
3	9	12	O	half
4	14	17	O	life
5	19	20	O	of
6	22	32	O	XXXXXXXX
7	34	35	O	is
8	37	45	O	prolonged
9	47	48	O	to
10	50	62	O	approximately
11	64	65	O	18
12	67	71	O	hours
13	73	74	O	in
14	76	83	O	subjects
15	85	88	O	with
16	90	93	O	mild
17	95	101	O	hepatic
18	103	112	O	impairment
19	114	116	O	and
20	118	119	O	to
21	121	133	O	approximately
22	135	136	O	19
23	138	142	O	hours
24	144	145	O	in
25	147	154	O	subjects
26	156	159	O	with
27	161	168	O	moderate
28	170	176	O	hepatic
29	178	187	O	impairment
NULL

Zytiga	2143	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	32
In another trial, the pharmacokinetics of abiraterone were examined in subjects with baseline severe (N=8) hepatic impairment (Child-Pugh Class C) and in 8 healthy control subjects with normal hepatic function.
1	0	1	O	In
2	3	9	O	another
3	11	15	O	trial
4	16	16	O	,
5	18	20	O	the
6	22	37	O	pharmacokinetics
7	39	40	O	of
8	42	52	O	XXXXXXXX
9	54	57	O	were
10	59	66	O	examined
11	68	69	O	in
12	71	78	O	subjects
13	80	83	O	with
14	85	92	O	baseline
15	94	99	O	severe
16	102	104	O	N=8
17	107	113	O	hepatic
18	115	124	O	impairment
19	127	131	O	Child
20	133	136	O	Pugh
21	138	142	O	Class
22	144	144	O	C
23	147	149	O	and
24	151	152	O	in
25	154	154	O	8
26	156	162	O	healthy
27	164	170	O	control
28	172	179	O	subjects
29	181	184	O	with
30	186	191	O	normal
31	193	199	O	hepatic
32	201	208	O	function
NULL

Zytiga	2144	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	25
The systemic exposure (AUC) of abiraterone increased by approximately 7-fold in subjects with severe baseline hepatic impairment compared to subjects with normal hepatic function.
1	0	2	O	The
2	4	11	O	systemic
3	13	20	O	exposure
4	23	25	O	AUC
5	28	29	O	of
6	31	41	O	XXXXXXXX
7	43	51	O	increased
8	53	54	O	by
9	56	68	O	approximately
10	70	70	O	7
11	72	75	O	fold
12	77	78	O	in
13	80	87	O	subjects
14	89	92	O	with
15	94	99	O	severe
16	101	108	O	baseline
17	110	116	O	hepatic
18	118	127	O	impairment
19	129	136	O	compared
20	138	139	O	to
21	141	148	O	subjects
22	150	153	O	with
23	155	160	O	normal
24	162	168	O	hepatic
25	170	177	O	function
NULL

Zytiga	2145	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	45
In addition, the mean protein binding was found to be lower in the severe hepatic impairment group compared to the normal hepatic function group, which resulted in a two-fold increase in the fraction of free drug in patients with severe hepatic impairment.
1	0	1	O	In
2	3	10	O	addition
3	11	11	O	,
4	13	15	O	the
5	17	20	O	mean
6	22	28	O	protein
7	30	36	O	binding
8	38	40	O	was
9	42	46	O	found
10	48	49	O	to
11	51	52	O	be
12	54	58	O	lower
13	60	61	O	in
14	63	65	O	the
15	67	72	O	severe
16	74	80	O	hepatic
17	82	91	O	impairment
18	93	97	O	group
19	99	106	O	compared
20	108	109	O	to
21	111	113	O	the
22	115	120	O	normal
23	122	128	O	hepatic
24	130	137	O	function
25	139	143	O	group
26	144	144	O	,
27	146	150	O	which
28	152	159	O	resulted
29	161	162	O	in
30	164	164	O	a
31	166	168	O	two
32	170	173	O	fold
33	175	182	O	increase
34	184	185	O	in
35	187	189	O	the
36	191	198	O	fraction
37	200	201	O	of
38	203	206	O	free
39	208	211	O	drug
40	213	214	O	in
41	216	223	O	patients
42	225	228	O	with
43	230	235	O	severe
44	237	243	O	hepatic
45	245	254	O	impairment
NULL

Zytiga	2146	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	34
Patients with Renal Impairment The pharmacokinetics of abiraterone were examined in patients with end-stage renal disease (ESRD) on a stable hemodialysis schedule (N=8) and in matched control subjects with normal renal function (N=8).
1	0	7	O	Patients
2	9	12	O	with
3	14	18	O	Renal
4	20	29	O	Impairment
5	31	33	O	The
6	35	50	O	pharmacokinetics
7	52	53	O	of
8	55	65	O	XXXXXXXX
9	67	70	O	were
10	72	79	O	examined
11	81	82	O	in
12	84	91	O	patients
13	93	96	O	with
14	98	100	O	end
15	102	106	O	stage
16	108	112	O	renal
17	114	120	O	disease
18	123	126	O	ESRD
19	129	130	O	on
20	132	132	O	a
21	134	139	O	stable
22	141	152	O	hemodialysis
23	154	161	O	schedule
24	164	166	O	N=8
25	169	171	O	and
26	173	174	O	in
27	176	182	O	matched
28	184	190	O	control
29	192	199	O	subjects
30	201	204	O	with
31	206	211	O	normal
32	213	217	O	renal
33	219	226	O	function
34	229	231	O	N=8
NULL

Zytiga	2147	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	37
In the ESRD cohort of the trial, a single 1,000 mg ZYTIGA dose was given under fasting conditions 1 hour after dialysis, and samples for pharmacokinetic analysis were collected up to 96 hours post dose.
1	0	1	O	In
2	3	5	O	the
3	7	10	O	ESRD
4	12	17	O	cohort
5	19	20	O	of
6	22	24	O	the
7	26	30	O	trial
8	31	31	O	,
9	33	33	O	a
10	35	40	O	single
11	42	46	O	1,000
12	48	49	O	mg
13	51	56	O	XXXXXXXX
14	58	61	O	dose
15	63	65	O	was
16	67	71	O	given
17	73	77	O	under
18	79	85	O	fasting
19	87	96	O	conditions
20	98	98	O	1
21	100	103	O	hour
22	105	109	O	after
23	111	118	O	dialysis
24	119	119	O	,
25	121	123	O	and
26	125	131	O	samples
27	133	135	O	for
28	137	151	O	pharmacokinetic
29	153	160	O	analysis
30	162	165	O	were
31	167	175	O	collected
32	177	178	O	up
33	180	181	O	to
34	183	184	O	96
35	186	190	O	hours
36	192	195	O	post
37	197	200	O	dose
NULL

Zytiga	2148	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	31
Systemic exposure to abiraterone after a single oral 1,000 mg dose did not increase in subjects with end-stage renal disease on dialysis, compared to subjects with normal renal function.
1	0	7	O	Systemic
2	9	16	O	exposure
3	18	19	O	to
4	21	31	O	XXXXXXXX
5	33	37	O	after
6	39	39	O	a
7	41	46	O	single
8	48	51	O	oral
9	53	57	O	1,000
10	59	60	O	mg
11	62	65	O	dose
12	67	69	O	did
13	71	73	O	not
14	75	82	O	increase
15	84	85	O	in
16	87	94	O	subjects
17	96	99	O	with
18	101	103	O	end
19	105	109	O	stage
20	111	115	O	renal
21	117	123	O	disease
22	125	126	O	on
23	128	135	O	dialysis
24	136	136	O	,
25	138	145	O	compared
26	147	148	O	to
27	150	157	O	subjects
28	159	162	O	with
29	164	169	O	normal
30	171	175	O	renal
31	177	184	O	function
NULL

Zytiga	2149	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	34
Drug Interactions In vitro studies with human hepatic microsomes showed that abiraterone has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.
1	0	3	O	Drug
2	5	16	O	Interactions
3	18	19	O	In
4	21	25	O	vitro
5	27	33	O	studies
6	35	38	O	with
7	40	44	O	human
8	46	52	O	hepatic
9	54	63	O	microsomes
10	65	70	O	showed
11	72	75	O	that
12	77	87	O	XXXXXXXX
13	89	91	O	has
14	93	95	O	the
15	97	105	O	potential
16	107	108	O	to
17	110	116	O	inhibit
18	118	123	O	CYP1A2
19	124	124	O	,
20	126	131	O	CYP2D6
21	132	132	O	,
22	134	139	O	CYP2C8
23	141	143	O	and
24	145	146	O	to
25	148	148	O	a
26	150	155	O	lesser
27	157	162	O	extent
28	164	169	O	CYP2C9
29	170	170	O	,
30	172	178	O	CYP2C19
31	180	182	O	and
32	184	189	O	CYP3A4
33	190	190	O	/
34	191	191	O	5
NULL

Zytiga	2150	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	43
In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily).
1	0	1	O	In
2	3	4	O	an
3	6	7	O	in
4	9	12	O	vivo
5	14	17	O	drug
6	19	22	O	drug
7	24	34	O	interaction
8	36	40	O	trial
9	41	41	O	,
10	43	45	O	the
11	47	50	O	Cmax
12	52	54	O	and
13	56	58	O	AUC
14	60	61	O	of
15	63	78	U-KIN	dextromethorphan
16	81	86	O	CYP2D6
17	88	96	O	substrate
18	99	102	O	were
19	104	112	O	increased
20	114	116	O	2.8
21	119	121	O	and
22	123	125	O	2.9
23	127	130	O	fold
24	131	131	O	,
25	133	144	O	respectively
26	146	149	O	when
27	151	166	O	dextromethorphan
28	168	169	O	30
29	171	172	O	mg
30	174	176	O	was
31	178	182	O	given
32	184	187	O	with
33	189	199	O	XXXXXXXX
34	201	207	O	acetate
35	209	213	O	1,000
36	215	216	O	mg
37	218	222	O	daily
38	225	228	O	plus
39	230	239	O	prednisone
40	241	241	O	5
41	243	244	O	mg
42	246	250	O	twice
43	252	256	O	daily
K/15:C54610

Zytiga	2151	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	15
The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold.
1	0	2	O	The
2	4	6	O	AUC
3	8	10	O	for
4	12	22	U-KIN	dextrorphan
5	23	23	O	,
6	25	27	O	the
7	29	34	O	active
8	36	45	O	metabolite
9	47	48	O	of
10	50	65	O	dextromethorphan
11	66	66	O	,
12	68	76	O	increased
13	78	90	O	approximately
14	92	94	O	1.3
15	96	99	O	fold
K/4:C54613

Zytiga	2152	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	41
In a clinical study to determine the effects of abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily) on a single 100 mg dose of the CYP1A2 substrate theophylline, no increase in systemic exposure of theophylline was observed.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	18	O	study
5	20	21	O	to
6	23	31	O	determine
7	33	35	O	the
8	37	43	O	effects
9	45	46	O	of
10	48	58	O	XXXXXXXX
11	60	66	O	acetate
12	68	72	O	1,000
13	74	75	O	mg
14	77	81	O	daily
15	84	87	O	plus
16	89	98	O	prednisone
17	100	100	O	5
18	102	103	O	mg
19	105	109	O	twice
20	111	115	O	daily
21	118	119	O	on
22	121	121	O	a
23	123	128	O	single
24	130	132	O	100
25	134	135	O	mg
26	137	140	O	dose
27	142	143	O	of
28	145	147	O	the
29	149	154	O	CYP1A2
30	156	164	O	substrate
31	166	177	O	theophylline
32	178	178	O	,
33	180	181	O	no
34	183	190	O	increase
35	192	193	O	in
36	195	202	O	systemic
37	204	211	O	exposure
38	213	214	O	of
39	216	227	O	theophylline
40	229	231	O	was
41	233	240	O	observed
NULL

Zytiga	2153	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	9
Abiraterone is a substrate of CYP3A4, in vitro.
1	0	10	O	XXXXXXXX
2	12	13	O	is
3	15	15	O	a
4	17	25	O	substrate
5	27	28	O	of
6	30	35	O	CYP3A4
7	36	36	O	,
8	38	39	O	in
9	41	45	O	vitro
NULL

Zytiga	2154	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	44
In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4 inducer (rifampin, 600 mg daily for 6 days) followed by a single dose of abiraterone acetate 1,000 mg, the mean plasma AUC* of abiraterone was decreased by 55%.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	clinical
4	14	28	O	pharmacokinetic
5	30	40	O	interaction
6	42	46	O	study
7	48	49	O	of
8	51	57	O	healthy
9	59	66	O	subjects
10	68	77	O	pretreated
11	79	82	O	with
12	84	84	O	a
13	86	91	O	strong
14	93	98	O	CYP3A4
15	100	106	O	inducer
16	109	116	U-KIN	rifampin
17	117	117	O	,
18	119	121	O	600
19	123	124	O	mg
20	126	130	O	daily
21	132	134	O	for
22	136	136	O	6
23	138	141	O	days
24	144	151	O	followed
25	153	154	O	by
26	156	156	O	a
27	158	163	O	single
28	165	168	O	dose
29	170	171	O	of
30	173	183	O	XXXXXXXX
31	185	191	O	acetate
32	193	197	O	1,000
33	199	200	O	mg
34	201	201	O	,
35	203	205	O	the
36	207	210	O	mean
37	212	217	O	plasma
38	219	222	O	AUC*
39	224	225	O	of
40	227	237	O	XXXXXXXX
41	239	241	O	was
42	243	251	O	decreased
43	253	254	O	by
44	256	258	O	55%
K/16:C54609

Zytiga	2155	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	32
In a separate clinical pharmacokinetic interaction study of healthy subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone.
1	0	1	O	In
2	3	3	O	a
3	5	12	O	separate
4	14	21	O	clinical
5	23	37	O	pharmacokinetic
6	39	49	O	interaction
7	51	55	O	study
8	57	58	O	of
9	60	66	O	healthy
10	68	75	O	subjects
11	76	76	O	,
12	78	79	O	co
13	81	94	O	administration
14	96	97	O	of
15	99	110	O	ketoconazole
16	111	111	O	,
17	113	113	O	a
18	115	120	O	strong
19	122	130	O	inhibitor
20	132	133	O	of
21	135	140	O	CYP3A4
22	141	141	O	,
23	143	145	O	had
24	147	148	O	no
25	150	159	O	clinically
26	161	170	O	meaningful
27	172	177	O	effect
28	179	180	O	on
29	182	184	O	the
30	186	201	O	pharmacokinetics
31	203	204	O	of
32	206	216	O	XXXXXXXX
NULL

Zytiga	2156	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	33
In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate.
1	0	1	O	In
2	3	3	O	a
3	5	10	O	CYP2C8
4	12	15	O	drug
5	17	20	O	drug
6	22	32	O	interaction
7	34	38	O	trial
8	40	41	O	in
9	43	49	O	healthy
10	51	58	O	subjects
11	59	59	O	,
12	61	63	O	the
13	65	67	O	AUC
14	69	70	O	of
15	72	83	U-KIN	pioglitazone
16	85	87	O	was
17	89	97	O	increased
18	99	100	O	by
19	102	104	O	46%
20	106	109	O	when
21	111	122	O	pioglitazone
22	124	126	O	was
23	128	132	O	given
24	134	141	O	together
25	143	146	O	with
26	148	148	O	a
27	150	155	O	single
28	157	160	O	dose
29	162	163	O	of
30	165	169	O	1,000
31	171	172	O	mg
32	174	184	O	XXXXXXXX
33	186	192	O	acetate
K/15:C54613

Zytiga	2157	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	17
In vitro, abiraterone and its major metabolites were shown to inhibit the hepatic uptake transporter OATP1B1.
1	0	1	O	In
2	3	7	O	vitro
3	8	8	O	,
4	10	20	O	XXXXXXXX
5	22	24	O	and
6	26	28	O	its
7	30	34	O	major
8	36	46	O	metabolites
9	48	51	O	were
10	53	57	O	shown
11	59	60	O	to
12	62	68	O	inhibit
13	70	72	O	the
14	74	80	O	hepatic
15	82	87	O	uptake
16	89	99	O	transporter
17	101	107	O	OATP1B1
NULL

Zytiga	2158	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	11
There are no clinical data available to confirm transporter based interaction.
1	0	4	O	There
2	6	8	O	are
3	10	11	O	no
4	13	20	O	clinical
5	22	25	O	data
6	27	35	O	available
7	37	38	O	to
8	40	46	O	confirm
9	48	58	O	transporter
10	60	64	O	based
11	66	76	O	interaction
NULL

Zytiga	2159	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	48
In a multi-center, open-label, single-arm trial, 33 patients with metastatic CRPC received ZYTIGA orally at a dose of 1,000 mg once daily at least 1 hour before or 2 hours after a meal in combination with prednisone 5 mg orally twice daily.
1	0	1	O	In
2	3	3	O	a
3	5	9	O	multi
4	11	16	O	center
5	17	17	O	,
6	19	22	O	open
7	24	28	O	label
8	29	29	O	,
9	31	36	O	single
10	38	40	O	arm
11	42	46	O	trial
12	47	47	O	,
13	49	50	O	33
14	52	59	O	patients
15	61	64	O	with
16	66	75	O	metastatic
17	77	80	O	CRPC
18	82	89	O	received
19	91	96	O	XXXXXXXX
20	98	103	O	orally
21	105	106	O	at
22	108	108	O	a
23	110	113	O	dose
24	115	116	O	of
25	118	122	O	1,000
26	124	125	O	mg
27	127	130	O	once
28	132	136	O	daily
29	138	139	O	at
30	141	145	O	least
31	147	147	O	1
32	149	152	O	hour
33	154	159	O	before
34	161	162	O	or
35	164	164	O	2
36	166	170	O	hours
37	172	176	O	after
38	178	178	O	a
39	180	183	O	meal
40	185	186	O	in
41	188	198	O	combination
42	200	203	O	with
43	205	214	O	prednisone
44	216	216	O	5
45	218	219	O	mg
46	221	226	O	orally
47	228	232	O	twice
48	234	238	O	daily
NULL

Zytiga	2160	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	21
Assessments up to Cycle 2 Day 2 showed no large changes in the QTc interval (i.e., >20 ms) from baseline.
1	0	10	O	Assessments
2	12	13	O	up
3	15	16	O	to
4	18	22	O	Cycle
5	24	24	O	2
6	26	28	O	Day
7	30	30	O	2
8	32	37	O	showed
9	39	40	O	no
10	42	46	O	large
11	48	54	O	changes
12	56	57	O	in
13	59	61	O	the
14	63	65	O	QTc
15	67	74	O	interval
16	77	79	O	i.e
17	81	81	O	,
18	83	85	O	>20
19	87	88	O	ms
20	91	94	O	from
21	96	103	O	baseline
NULL

Zytiga	2161	34090-1	4e338e89-3cf2-48eb-b6e2-a06c608c6513	24
However, small increases in the QTc interval (i.e., <10 ms) due to abiraterone acetate cannot be excluded due to study design limitations.
1	0	6	O	However
2	7	7	O	,
3	9	13	O	small
4	15	23	O	increases
5	25	26	O	in
6	28	30	O	the
7	32	34	O	QTc
8	36	43	O	interval
9	46	48	O	i.e
10	50	50	O	,
11	52	54	O	<10
12	56	57	O	ms
13	60	62	O	due
14	64	65	O	to
15	67	77	O	XXXXXXXX
16	79	85	O	acetate
17	87	92	O	cannot
18	94	95	O	be
19	97	104	O	excluded
20	106	108	O	due
21	110	111	O	to
22	113	117	O	study
23	119	124	O	design
24	126	136	O	limitations
NULL

